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Meeting Profile
For thirty-four years, the mission of the 
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has been to provide state-of-the-art 
information on breast cancer research. 
The symposium aims to achieve a 
balance of clinical, translational, and 
basic research, providing a forum 
for interaction, communication, and 
education for a broad spectrum of 
researchers, health professionals, and 
those with a special interest in breast 
cancer.
In 2007, the Cancer Therapy & Re-
search Center (CTRC) at UT Health 
Science Center San Antonio and the 
American Association for Cancer 
Research (AACR) announced a col-
laboration for the future of the San 
Antonio Breast Cancer Symposium. 
The symposium has been renamed 
the CTRC-AACR San Antonio Breast 
Cancer Symposium. Complementing 
the clinical strengths of the highly 
regarded annual San Antonio Breast 
Cancer Symposium, the AACR’s sci-
entific prestige in basic, translational, 
and clinical cancer research will create 
a unique and comprehensive scientific 
meeting that will advance breast can-
cer research for the benefit of patients. 
In 2005, Baylor College of Medicine be-
came a joint sponsor of the symposium 
and will remain a part the CTRC-AACR 
collaboration.
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December 9–13, 2014
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tueSDay, DeCember 6, 2011
12:00 pm–7:30 pm
regiStration 
bridge hall
Pre-registered attendees can obtain materials. Those who have not yet 
registered may do so.
2:00 pm–7:30 pm 
eDuCational SeSSionS  
ballrooms a & b and exhibit hall D
Supported by an educational grant from  
Susan G. Komen for the Cure®
An update on advances in the technologies available for translational 
research. Sessions are to provide people with a better understanding of 
the talks they hear using the techniques described. They also provide 
researchers with a guide to the techniques they should be considering 
for their studies.
2:00 pm–3:30 pm  
treatment of metastatic breast Cancer – breast Cancer as a 
Chronic Disease  
ballroom a
Moderator:  Kathleen Pritchard, MD, FRCPC
University of Toronto
Toronto, CANADA
er positive
Kathleen Pritchard, MD, FRCPC
University of Toronto
Toronto, CANADA 
triple negative breast cancer
Vered Stearns, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns 
Hopkins 
Baltimore, MD 
her2 positive
Ian E. Krop, MD, PhD 
Dana-Farber Cancer Institute
Boston, MA
  mouse models of pi3k-Dependent and basal-like breast 
Cancer 
ballroom b
  Moderator: Carlos L. Arteaga, MD 
  Vanderbilt-Ingram Cancer Center 
  Vanderbilt University 
  Nashville, TN
pi3k mouse models of breast cancer 
Ramon E. Parsons, MD, PhD
Institute for Cancer Genetics
Columbia University 
New York, NY 
mouse models of basel-like breast cancer 
Jos Jonkers, PhD
Netherlands Cancer Institute 
Amsterdam, NETHERLANDS
patient-derived xenograft models for preclinical breast 
cancer research: not just “basal” anymore
Michael T. Lewis, PhD
Baylor College of Medicine 
Houston, TX
4:00 pm–5:30 pm  
Controversies in early breast Cancer 
exhibit hall D
Moderator: Peter M. Ravdin, MD, PhD 
UT Health Science Center San Antonio 
San Antonio, TX
Controversies in early breast cancer: Small tumors
Peter M. Ravdin, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX 
Chemotherapy benefit in er positive breast cancer – mixed 
messages
Kathy Albain, MD, FACP 
Loyola University Chicago Stritch School of Medicine
Maywood, IL 
adjuvant therapy in patients with a borderline her-2 status
Angelo Di Leo, MD, PhD
Hospital of Prato
Prato, ITALY
  new technologies in biomarker Discovery for  
 the Clinician 
 ballroom a 
 Moderator: Trey Westbrook, PhD 
  Baylor College of Medicine
  Houston, TX
metabolomics as a tool to study cancer progression
Arun Sreekumar, PhD
Baylor College of Medicine
Houston, TX
proteomics
Gordon Mills, MD, PhD 
UT MD Anderson Cancer Center 
Houston, TX
the potential of epigenetic therapy in breast cancer
Stephen Baylin, MD
Johns Hopkins University 
Baltimore, MD 
  breast Cancer trials in Developing Countries -   
 opportunities and Challenges 
 ballroom b 
 Moderator: Ismail Jatoi, MD, PhD, FACS 
  UT Health Science Center San Antonio 
  San Antonio, TX
Challenges in the design and implementation of breast 
cancer clinical trials in developing countries 
Sudeep Gupta, MD, DM
Tata Memorial Hospital
Mumbai, INDIA
practicality, promise and pitfalls in industry-sponsored 
trials (in developing countries) 
Sandra J. Horning, MD
Genentech, Inc.
South San Francisco, CA
2011 CtrC-aaCr  
San antonio breaSt CanCer 
SympoSium
program SCheDule
room locations
Exhibit Halls A, B, C & D: Street Level
Ballrooms A & B: Street Level
Bridge Hall: Street Level
(at preSS time)
Refer to www.sabcs.org for the most current information.
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novel approach to breast cancer in low income countries
David J. Kerr, CBE, MA, MD, DSc FRCP (Glas & Lon), FRCGP (Hon), 
FMedSci
University of Oxford
Oxford, UNITED KINGDOM
6:00 pm–7:30 pm  
Challenges in the Care of Special populations with breast 
Cancer 
exhibit hall D 
Moderator: Mothaffar Rimawi, MD 
Baylor College of Medicine 
Houston, TX 
oncofertility: translation in multidimensions 
Teresa K. Woodruff, PhD
Northwestern University
Chicago, IL
treatment of young women with breast cancer 
Ann H. Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
treatment of older women with breast cancer 
Arti Hurria, MD
City of Hope
Duarte, CA
  What makes a good target? 
  ballroom a 
 Moderator: Mark D. Pegram, MD 
  Miller School of Medicine of University of Miami 
  Miami, FL 
target, identification and drug discovery: What is 
druggable? 
Stephen W. Fesik, PhD
Vanderbilt University Medical Center 
Nashville, TN
Clinical validation of new therapeutic targets in breast 
cancer
Mark D. Pegram, MD
Miller School of Medicine of University of Miami 
Miami, FL
Study design considerations in the development of drugs 
and the diagnostic tests that can guide their use 
Steve Shak, MD
Genomic Health, Inc.
Hillsborough, CA 
  reconstruction 
 ballroom b 
 Moderator: Richard L. Crownover, MD, PhD 
  Cancer Therapy and Research Center at
  UT Health Science Center San Antonio 
  San Antonio, TX
breast reconstruction with implants and post-mastectomy 
irradiation: algorithms and outcomes 
Peter G. Cordeiro, MD, FACS
Memorial Sloan-Kettering Cancer Center
New York, NY
Strange bedfellows: radiation therapy and breast 
reconstruction 
Richard C. Zellars, MD 
Johns Hopkins University 
Baltimore, MD
measuring outcomes in breast reconstruction: the patient 
perspective 
Andrea L. Pusic, MD, MHS, FRCSC
Memorial Sloan-Kettering Cancer Center 
New York, NY
WeDneSDay,  DeCember 7, 2011
7:00 am–5:15 pm 
 regiStration 
 bridge hall 
6:45 am–8:15 am 
Career Development Forum: a netWorking SeSSion For 
young inveStigatorS  
ballroom b
Networking and career development opportunities for early career 
scientists. The session is open to early-career scientists, defined as 
graduate students, postdoctoral or clinical fellows, or medical students 
and residents, who are registered attendees of the SABCS. Space in the 
workshop is limited to 200 participants; registrations will be accepted on 
a first-come, first-served basis and is free of charge. 
Discussion topics at press time 
(Program subject to change)
  1. Balancing Research and Clinical Practice
      Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA
  2. Balancing Research and Clinical Practice
      Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA
  3. Careers in Industry
      Malte Peters, Novartis, Basel, Switzerland
  4. Careers in Industry
      Steven Shak, Genomic Health, Inc., Redwood City, CA
  5. Careers in Translational Research
      Rachel Schiff, Baylor College of Medicine, Houston, TX
  6. Grant Writing – Clinical/Translational
      Lisa A. Carey, University of North Carolina Lineberger  
      Comprehensive Cancer Center, Chapel Hill, NC
  7. Grant Writing – Basic/Translational
      Joan S. Brugge, Harvard Medical School, Boston, MA
  8. How to Become a Clinical Trialist
      Hope S. Rugo, UCSF Helen Diller Family Comprehensive  
      Cancer Center, San Francisco, CA
  9. How to Get the Most Out of your Fellowship Years –  
      Translational
      Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA
10. How to Get the Most Out of your Fellowship Years –   
      Clinical
      Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA
11. How to Get the Most Out of your Predoctoral Experience
      Rong Li, University of Texas Health Science Center, San  
      Antonio, TX
12. Leadership Skills
      Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center,    
      Nashville, TN
13. Making the Transition from Fellowship to Faculty
      Pepper Jo Schedin, University of Colorado, Aurora, CO
14. Making the Transition to Independence
      Valerie M. Weaver, University of California San Francisco     
      Medical Center, San Francisco, CA
15. Making the Transition to Independence
      Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA
16. Mentoring and Supervising
      Douglas Yee, University of Minnesota Masonic Cancer        
      Center, Minneapolis, MN
17. Negotiating a Job Offer
      Matthew J. Ellis, Washington University Siteman Cancer  
      Center, St. Louis, MO
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18. Setting Up and Managing a Laboratory
      Charles Perou, University of North Carolina, Chapel Hill, NC
19. Tenure and Promotion
      Suzanne A.W. Fuqua, Baylor College of Medicine Cancer  
      Center, Houston, TX 
8:30 am–8:45 am  
opening remarkS  
exhibit hall D
8:45 am–9:15 am
plenary leCture 1  
exhibit hall D
 endocrine therapy for breast Cancer: looking into the Future
Eric P. Winer, MD
Dana-Farber Cancer Institute 
Boston, MA
9:15 am–11:30 am 
general SeSSion 1 
exhibit hall D
Moderator: Kathy D. Miller, MD
Indiana University School of Medicine
Indianapolis, IN
9:15  S1-1. a phase iii randomized trial of anastrozole versus 
anastrozole and fulvestrant as first-line therapy for 
postmenopausal women with metastatic breast cancer: SWog 
S0226
Mehta RS, Barlow WE, Albain KS, Vandenberg T, Dakhil SR, Tirumali NR, 
Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. University 
of California at Irvine, Chao Family CCC, Orange, CA; SWOG, Seattle, 
WA; Loyola University Chicago Stritch School of Medicine, Maywood, IL; 
London Regional Cancer Program, London, ON, Canada; Wichita CCOP, 
Wichita, KS; NW Permanente, Portland, OR; University of Michigan, 
Michigan; Seattle Cancer Care Alliance, Seattle, WA; Arizona Cancer 
Center, Tucson, AZ; University of Texas/MD Anderson Cancer Center, 
Houston, TX.
9:30  S1-2. long-term follow-up in abCSg-12: Significantly improved 
overall survival with adjuvant zoledronic acid in premenopausal 
patients with endocrine-receptor–positive early breast cancer
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky 
P, Jakesz R, Singer C, Eidtmann H, Fesl C, Eiermann W, Marth C, Greil 
R. Medical University of Vienna, Vienna, Austria; Paracelsus Medical 
University Salzburg, Salzburg, Austria; Medical University of Graz, Graz, 
Austria; University of Schleswig-Holstein, Kiel, Germany; Austrian Breast 
and Colorectal Cancer Study Group, Vienna, Austria; Red Cross Women’s 
Hospital, Munich, Germany; Medical University of Innsbruck, Innsbruck, 
Austria.
9:45  S1-3. long-term survival outcomes among postmenopausal 
women with hormone receptor-positive early breast cancer 
receiving adjuvant letrozole and zoledronic acid: 5-year follow-up 
of Zo-FaSt
de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin 
N, Modi A, Coleman R. Royal Melbourne Hospital, Victoria, Australia; 
University Hospital of South Manchester NHS Foundation Trust, 
Manchester, United Kingdom; University Frauenklinik, Kiel, Germany; 
UZ Gasthuisberg, Leuven, Belgium; German Breast Group, Frankfurt, 
Germany; Novartis Oncology, East Hanover, NJ; University of Sheffield, 
Sheffield, United Kingdom.
10:00  Discussion
James N. Ingle, MD, Mayo Clinic College of Medicine, Rochester, MN
10:15  S1-4. retrospective analysis of study egF30008 by mass-
spectrometry based serum assay (veriStrat®)
Roder J, Roder H, Hunsucker S, Grigorieva J, Ellis C, Florance A, Gagnon 
R, O’Rourke L, Johnston S. Biodesix Inc., Aurora, CO; GlaxoSmithKline, 
Collegeville, PA; Royal Marsden Hospital, London, United Kingdom.
10:30  S1-5. modulation of cancer and stem cell biomarkers by the notch 
inhibitor mk-0752 added to endocrine therapy for early stage er+ 
breast cancer
Albain KS, Czerlanis C, Zlobin A, Covington KR, Rajan P, Godellas C, Bova 
D, Lo SS, Robinson P, Sarker S, Gaynor ER, Cooper R, Aranha G, Czaplicki K, 
Busby B, Rizzo P, Demuth T, Stiff P, Fuqua SAW, Miele L.  Loyola University 
Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Baylor Breast 
Center, Houston, TX; Merck Oncology, North Wales, PA; University of 
Mississippi Cancer Institute, Jackson, MS.
10:45  S1-6. Characterization of breast cancer distant metastasis based 
on outcome over time using a gene expression profiling approach 
and identification of pathway activities of late relapse
Saghatchian M, Mittempergher L, Michiels S, Casinius S, Glas A, Lazar 
V, Roepman P, Dessen P, Benz S, Piccart M, Delaloge S, van’t Veer L. 
Institut Gustave Roussy, Villejuif, France; Netherlands Cancer Institute, 
Amsterdam, Netherlands; Institut Jules Bordet, Belgium; Agendia; UCSF; 
UCSC.
11:00  S1-7. molecular tumor characteristics influence adjuvant 
endocrine treatment outcome
Bianchini G, Pusztai L, Iwamoto T, Kelly CM, Zambetti M, Fasolo A, Del 
Conte G, Santarpia L, Symmans WF, Gianni L. San Raffaele Cancer Center, 
Milan, Italy; University of Texas, MD Anderson Cancer Center, Houston, 
TX; Mater Misericordiae University Hospital, Dublin, Ireland; Hospital of 
Prato and Istituto Toscana Tumori, Prato, Italy.
11:15  S1-8. molecular signaling distinguishes early er positive breast 
cancer recurrences despite adjuvant tamoxifen
Liu MC, Dixon JM, Xuan JJ, Riggins RB, Chen L, Wang C, Cho Y, Zhu Y, 
Jin L, Zwart A, Wang M, Klimach UM, Wang YJ, Renshaw L, Larionov A, 
Miller W, Clarke R. Georgetown University Lombardi Comprehensive 
Cancer Center, Washington, DC; Western General Hospital, University of 
Edinburgh, Edinburgh, Scotland, United Kingdom; Virginia Polytechnic 
Institute and State University, Arlington, VA.
11:30 am–12:00 pm 
aaCr DiStinguiSheD leCtureShip in breaSt CanCer 
reSearCh  
exhibit hall D 
protective adaptive responses to breast Cancer therapies 
Joan S. Brugge, PhD
Harvard Medical School
Boston, MA
12:00 pm–1:35 pm  
lunCh
12:15 pm–1:15 pm 
proDuCt theatre 
exhibit hall C – exhibit area
 updates in breast Cancer in Diagnostic testing
Sponsored by Clarient, A GE Healthcare Company
12:30 pm–1:35 pm 
CliniCal SCienCe Forum 
medical economics - the Cost of Care  
ballroom a
Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
the cost of cancer care: how much do we spend and how can 
we spend it better?  
Elena Elkin, PhD
Memorial Sloan-Kettering Cancer Center 
New York, NY 
health care reform and cost control:  practical and ethical 
considerations for cancer care providers
Michael Hassett, MD, MPH 
Dana-Farber Cancer Institute 
Boston, MA
CTRC-AACR San Antonio Breast Cancer Symposium
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panel Discussion
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA 
Michael Hassett, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Elena Elkin, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY
12:30 pm–1:35 pm 
baSiC SCienCe Forum 
breast Cancer initiation 
ballroom b
Moderator: Yi Li, PhD, MS 
Baylor College of Medicine
Houston, TX
p53, stem cells, and breast cancer  
Geoffrey M. Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA
Stem and progenitor cells and breast cancer heterogeneity
Matthew Smalley, PhD
Breakthrough Breast Cancer Centre
Institute of Cancer Research 
London, UNITED KINGDOM
1:45 pm–2:15 pm 
SpeCial report 
breast Cancer and the environment: a life Course approach - 
report release from an iom Committee 
exhibit hall D
Moderator: Amelie G. Ramirez, Dr. PH, MPH 
UT Health Science Center San Antonio 
San Antonio, TX 
  Irva Hertz-Picciotto, PhD, MPH
  University of California, Davis
  Davis, CA
  and
  Robert A. Hiatt, MD, PhD
  University of California, San Francisco
  San Francisco, CA 
2:00 pm–3:00 pm 
proDuCt theatre 
exhibit hall C – exhibit area
 a unique treatment option for Chemotherapy induced nausea & 
vomiting
Sponsored by Prostrakan, Inc.
2:15 pm–4:00 pm  
general SeSSion 2 
exhibit hall D
Moderator: Julie R. Gralow, MD
University of Washington
Seattle, WA 
2:15  S2-1. partial breast brachytherapy is associated with inferior 
effectiveness and increased toxicity compared with whole breast 
irradiation in older patients
Smith GL, Xu Y, Buchholz TA, Giordano SH, Smith BD. University of Texas 
M.D. Anderson Cancer Center, Houston, TX.
2:30  S2-2. luminal a subtype predicts radiation response in patients 
with t1n0 breast cancer enrolled in a randomized trial of 
tamoxifen with or without breast radiation
Fyles A, McCready D, Pintilie M, Shi W, Done S, Miller N, Olivotto I, Weir 
L, Liu F-F. Princess Margaret Hospital, Toronto, Canada; British Columbia 
Cancer Agency, Vancouver, Canada.
2:45  S2-3. nSabp protocol b-34: a clinical trial comparing adjuvant 
clodronate vs. placebo in early stage breast cancer patients 
receiving systemic chemotherapy and/or tamoxifen or no therapy 
— final analysis
Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson 
CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow 
JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, 
Mamounas EP, Wolmark N. National Surgical Adjuvant Breast and Bowel 
Project (NSABP); Tom Baker Cancer Centre; University of Pittsburgh 
Graduate School of Public Health; University of Pittsburgh Cancer 
Institute School of Medicine; Kaiser Permanente, Northern California; 
University of Alabama at Birmingham/ECOG; Cross Cancer Institute; 
British Columbia Cancer Agency; University of Pittsburgh/Magee 
Women’s Hospital; Cancer Center of Kansas; Stroger Hospital Cook 
County MBCCOP; San Juan MBCCOP; University of Washington/SWOG; 
Centre Hospitalier de l’Université de Montréal; Mayo Clinic Jacksonville/
NCCTG; Allegheny General Hospital; Washington Cancer Institute, 
Washington Hospital Center; Aultman Health Foundation.
3:00  S2-4. gain (german adjuvant intergroup node positive) study: a 
phase-iii multicenter trial to compare dose dense, dose intense 
etC (iddetC) vs. eC-tX and ibandronate vs. observation in patients 
with node-positive primary breast cancer – 1st interim efficacy 
analysis
Möbus V, Thomssen C, Harbeck N, Untch M, Jackisch C, Diel IJ, Elling 
D, Conrad B, Schneeweiss A, Kreienberg R, Huober J, Müller V, Lück 
H-J, Bauerfeind I, Loibl S, Nekljudova V, von Minckwitz G. Städtische 
Kliniken Frankfurt-Höchst, Frankfurt; Klinik und Poliklinik für Gynäkologie, 
Universität Halle-Wittenberg, Halle; Brustzentrum, Universitätsklinikum, 
Köln; Helios-Klinikum Berlin-Buch, Berlin; Städtische Kliniken Offenbach, 
Offenbach; Schwerpunktpraxis Gynäkologische Onkologie, Mannheim; 
SANA Klinikum, Berlin; Elisabeth-Krankenhaus, Kassel; Universitäts-
Frauenklinik, Heidelberg; Universitäts-Frauenklinik, Ulm; Universitäts-
Frauenklinik, Tübingen; University Medical Center, Hamburg-Eppendorf; 
Gynäkologisch-onkologische Praxis, Hannover; Frauenklinik, Landshut; 
German Breast Group, Neu-Isenburg.
3:15  S2-5. an anti-her3 antibody that stabilizes the inactive 
conformation inhibits both her2 and ligand driven tumor growth
Garner AP, Bialucha CU, Chen D, Elis W, Kunz C, Li S, Murtie J, Saxena 
P, Sineshchekova O, Sprague E, Ettenberg S. Novartis Institutes for 
Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; 
Sanofi-Aventis, Cambridge, MA.
3:30  S2-6. erbb3 expression is required for maintenance of normal and 
transformed luminal breast epithelial cells
Cook RS, Balko JM, Rinehart C, Miller TW, Polyak K, Prat A, Perou CM, 
Arteaga CL. Vanderbilt University; UNC Lineberger Comprehensive 
Cancer Center; Dana Farber Cancer Institute.
3:45  S2-7 mechanisms of action and biological significance of her2 
mutations in her2-overexpressing breast cancer
Boulbes DR, Jin Q, Arold ST, Ladbury JE, Yu D, Esteva FJ. University of 
Texas - MD Anderson Cancer Center, Houston, TX; Myriad Genetics, Salt 
Lake City, UT.
4:00 pm–5:00 pm 
SuSan g. komen For the Cure® brinker aWarDS For 
SCientiFiC DiStinCtion leCtureS  
exhibit hall D
 The Basic Science award is presented to a researcher who has 
added substantively to our understanding of the basic biology of, or 
development of, methodologies that further our ability to unravel the 
genetic and molecular basis of breast cancer. This year the award is 
being presented to:
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Carlos L. Arteaga, MD
Vanderbilt-Ingram Cancer Center
Vanderbilt University
Nashville, TN
oncogenes & er: a convenient marriage for hormone-dependent 
breast cancer
The Clinical Research award is presented to a clinician who has 
significantly furthered the identification of new prevention, detection or 
treatment approaches for breast cancer and its translation into clinical 
care. This year the award is being presented to:
Armando E. Giuliano, MD, FACS, FRCSEd
Cedars-Sinai Medical Center
Saul and Joyce Brandman Breast Center
Los Angeles, CA
Changes in the management of the axilla in breast cancer
5:00 pm–7:00 pm  
poSter SeSSion 1 & reCeption 
exhibit halls a-b
tumor Cell biology: immunology and preclinical immunotherapy
p1-01-01  a rat monoclonal antibody against bone Sialoprotein ii 
is active in preventing and treating tumor growth and 
osteolytic lesions in nude rats induced by mDa-mb-231 
breast Cancer Cells
Berger MR, Zepp M, Armbruster FP. DKFZ, Heidelberg, Germany; 
Immundiagnostik Comp., Bensheim, Germany. 
p1-01-02  t Cell is a key player in the establishment of Cancer associated 
pre-metastatic bone Disease
Bonomo A, Monteiro AC, Leal AC, Alves AP, Frusciante T, Braun S, 
Azevedo RB. Instituto Nacional de Cancer, Rio de Janeiro, Brazil; 
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 
Universidade de Brasilia, Brasilia, Brazil. 
p1-01-03  the Cytotoxicity of Select neutrophils in Cancer patients and 
the role of Chemokines in inducing neutrophil Cytotoxicity
Comen E, Granot Z, Norton L, Benezra R. Memorial Sloan-Kettering 
Cancer Center, New York, NY. 
p1-01-04  immunological effects of bisphosphonates on γδt Cells in 
breast Cancer
Sugie T, Tanaka Y, Toi M, Minato N. Graduate School of Medicine, 
Kyoto University, Kyoto, Japan. 
p1-01-05  Conditioning by the tumor environment turns invariant 
natural killer t Cells into negative regulators of anti-tumor 
immunity elicited by treatment
Pilones KA, Demaria S. NYU School of Medicine, New York, NY. 
p1-01-06  mechanisms of tumor immune escape in triplenegative 
breast Cancers (tnbC) with and without mutated brCa 1
Segerer SE, Kapp M, Hahne JC, Dietl J, Engel JB. Medical University of 
Würzburg, Würzburg, Germany. 
p1-01-07  erbb-2 peptide vaccination Suppresses Spontaneous 
tumorigenesis and tumor Stem Cell expansion in mmtv-pyvt 
transgenic mouse
Park KH, Gil Ey, Choi YJ, Kim ST, Cho K, Seo JH, Lee ES, Kim IS, Disis 
ML. Korea University College of Medicine, Seoul, Korea; Korea 
University College of Medicine; University of Washington, Seattle, 
WA. 
p1-01-08  expression of interleukin-15 (il-15) and the il-15 receptor in 
human breast Cancer
Sanders AJ, Ye L, Wei XQ, Mansel RE, Jiang WG. Cardiff University 
School of Medicine, Cardiff, Wales, United Kingdom; Cardiff 
University, Cardiff, Wales, United Kingdom. 
p1-01-09  a Focused immune response targeting the homotypic 
binding Domain of the Carcinoembryonic antigen blocks the 
establishment of tumor Foci in vivo
Gariepy J, Abdul-Wahid A. University of Toronto, Toronto, ON, 
Canada; Sunnybrook Research Institute, Toronto, ON, Canada. 
p1-01-10  immune Suppression of regulatory t Cells and m2 
macrophage in breast Cancer patients
Imoto S, Sakemura N, Kamma H, Nakatsura T. School of Medicine, 
Kyorin University, Mitaka, Japan; Research Center Organization, 
National Cancer Center Hospital East, Kashiwa, Japan. 
p1-01-11  CD4+CD25highCD127low/- regulatory t Cells have 
immunosuppressive Function in patients with breast Cancer
Sakemura N, Nakatsugawa M, Ito H, Isaka H, Imi K, Tazaki E, 
Miyamoto K, Wada N, Imoto S, Nakatsura T. Graduate School of 
Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer 
Research Center Hospital East, Kashiwa Chiba, Japan. 
p1-01-12  mesoporous Silicon particles for the presentation of tumor 
antigens and adjuvant for anti-Cancer immunity
Meraz IM, Melendez B, Gu J, Serda RE. Methodist Hospital Research 
Institute, Houston, TX. 
p1-01-13  prognostic impact of CD8 in node-negative breast Cancer
Schmidt M, Chen Z, Hellwig B, Böhm D, Lebrecht A, Gebhard S, 
Gehrmann M, Koelbl H, Hengstler JG. University Hospital, Mainz, 
Germany; Technical University, Dortmund, Germany; Bayer GmBH, 
Leverkusen, Germany. 
p1-01-14  gene expression of immune mediators within nipple aspirate 
Fluid and Ductal lavage from normal and Cancerous breasts
Love SM, Ruffell B, Nguyen T, Mills D, Coussens LM. Dr. Susan Love 
Research Foundation, Santa Monica, CA; University of California-San 
Francisco, San Francisco, CA. 
p1-01-15  Do Serum Cytokines predict breast Cancer behavior?
Lush E, Dedert E, Daup M, Dhabhar F, Spiegel D, Tillie J, McMasters 
K, Sephton SE, Chagpar A. University of Louisville; Duke University 
Medical Center; Veterans Affairs Medical Center; Stanford University 
School of Medicine; James Graham Brown Cancer Center; University 
of Louisville School of Medicine; Yale School of Medicine. 
p1-01-16  Detecting a breast Carcinoma-Deriving b-Cell response: an 
immunoproteomics biomarker approach
Keller K, Boehm DU, Grus FH, Koelbl H. University Medical Center 
Mainz, Germany.
tumor Cell biology: epithelial-mesenchymal transition
p1-02-01  c-jun n-terminal kinase 1 (jnk1) inhibits tumor growth and 
metastasis by Downregulating epithelial to mesenchymal 
transition (emt) and Stem Cell-related genes
Ebelt ND, Van Den Berg CL. The University of Texas, Austin, TX. 
p1-02-02  Zoledronic acid reverses the epithelial-mesenchymal 
transition While inhibiting the tumor initiating Cell 
population of highly tumorigenic breast Cancer Cell lines
Schech AJ, Gilani RA, Kazi AA, Brodie AH. University of Maryland, 
Baltimore, Baltimore, MD. 
p1-02-03  the reciprocal roles of e-Cadherin and Zeb1 Demonstrate the 
mesenchymal-epithelial transition as a primary Characteristic 
of inflammatory breast Cancer
Chu K, Boley KM, Luo AZ, Ye Z, Wright MC, Freiter EM, Robertson FM. 
The University of Texas MD Anderson Cancer Center, Houston, TX. 
p1-02-04  estrogen receptor beta inhibits breast Cancer emt by 
regulating the expression of mir-200
Thomas C, Gayani R, Nikolos F, Hao R, Katchy A, McCollum C, 
Williams C, Bondesson M, Krishnamurthy S, Esteva F, Gustafsson 
J-A. University of Houston; University of Texas MD Anderson Cancer 
Center. 
CTRC-AACR San Antonio Breast Cancer Symposium
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p1-02-05  invasive lobular Carcinoma - a luminal breast Cancer 
histotype enriched for epithelial-to-mesenchymal transition 
Features
Metzger O, Singhal SK, Michiels S, Ignatiadis M, Bertucci F, Galant 
C, Larsimont D, Salgado R, Veys I, Fumagalli D, Saini KS, Piccart M, 
Sotiriou C. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, 
Belgium; Institut Paoli-Calmettes, Marseille, France; Cliniques 
Universitaires Saint Luc, Brussels, Belgium. 
p1-02-06  Silencing of igF-1r has paradoxical effects in triple negative 
breast Cancer phenotypes
Taliaferro-Smith LD, Oberlick EM, Liu T, Eggers C, Kline ER, Nagaraju 
GPC, Marcus A, O’Regan R. Winship Cancer Institute at Emory 
University, Atlanta, GA; Grady Memorial Hospital, Atlanta, GA. 
p1-02-07  epithelial-mesenchymal transition Correlated with Serum 
Cytokine profiling in breast Cancer patients
Giordano A, Cohen EN, Anfossi S, Gao H, Lee B-N, Mego M, Sanda 
T, Valero V, Alvarez RH, Cristofanilli M, De Placido S, Hortobagyi 
GN, Woodward W, Ueno NT, Reuben JM. The University of Texas 
MD Anderson Cancer Center, Houston, TX; University Federico II 
of Naples, Naples, Italy; Fox Chase Cancer Center, Philadelphia, PA; 
National Cancer Institute, Bratislava, Slovakia (Slovak Republic). 
p1-02-08  modulation of emt by targeting e-Cadherin restores 
radiation Sensitivity in human breast Cancer Cells
Munshi A, Yuan Y, Liu J, Meyn RE. University of Oklahoma Health 
Sciences Center, Oklahoma City, OK; Baylor College of Medicine, 
Houston, TX; The University of Texas M.D. Anderson Cancer Center, 
Houston, TX. 
p1-02-09  epigenetics-regulated micrornas related with epithelial-
mesenchymal transition of breast Cancer Cells
Sato F, Ito T, Tsuchiya S, Kawaguchi-Sakita N, Shimizu K, Tsujimoto G, 
Toi M. Graduate School of Medicine, Kyoto University, Kyoto, Japan; 
Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, 
Japan. 
p1-02-10  vimentin expression; as a prognostic Factor and a possible 
molecular target of triple negative breast Cancer
Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Akiyoshi S, Saeki 
H, Oki E, Ohga T, Kakeji Y, Maehara Y. Kyushu University, Fukuoka, 
Japan. 
p1-02-11  the bCl2 antagonist of Death, baD is Down-regulated in 
breast Cancer and inhibits Cancer Cell invasion
Cekanova M, Fernando R, Wimalasena J. University of Tennessee, 
Knoxville, TN; NIH, NCI, Bethesda, MD.
p1-02-12  p120ctn is a key effector of ras-pkCε-mediated oncogenic 
signaling
Dann SG, Miranda M, Shi C, Upeslacis E, Rosfjord E, Wu J, Golas J, Jin 
G, Klippel A.  Pfizer, Pearl River, New York.
tumor Cell biology: microenvironment – Stromal-epithelial interactions
p1-03-01  eCm Stiffness and breast tumor histology and treatment 
phenotype
Acerbi I, Au A, Chen Y-y, Park C, Hwang S, Weaver V. Center for 
Bioengineering and Tissue Regeneration, University of California, 
San Francisco, San Francisco, CA; Carol Buck Breast Cancer Center, 
University of California San Francisco, San Francisco, CA; University of 
California San Francisco, San Francisco, CA; Institute of Regeneration 
Medicine, University of California San Francisco, San Francisco, CA; 
University of California at San Francisco, San Francisco, CA. 
p1-03-02  the norton-Simon hypothesis and Cancer Stem Cells: how 
Cancer Stem Cells may explain the effectiveness of Dose-
Dense Chemotherapy
Landis MD, Dobrolecki LE, Wong H, Lai Q, Vahdat LT, Chang JC. The 
Methodist Hospital Research Institute, Houston, TX; Weill Cornell 
Medical College, New York, NY. 
p1-03-03  adaptive exploitation of Stromal Cell metabolism by tumor 
Cells
Patel B, Rattigan Y, Ackerstaff E, Koutcher J, Sukenick G, Glod J, 
Banerjee D. Cancer Institute of New Jersey - University of Medicine 
and Dentistry of New Jersey; Johns Hopkins University; Memorial 
Sloan-Kettering Cancer Center. 
p1-03-04  in-vitro Characterization of a breast Cancer microenvironment 
with epithelial-to-mesenchymal transition (emt) 
Characteristics
Casbas-Hernandez P, Roman-Perez E, Mani SA, Troester MA. School 
of Medicine, UNC, Chapel Hill, NC; Gillings School of Public Health, 
UNC, Chapel Hill, NC; UNC Hospitals, Chapel Hill, NC; University of 
Texas MD Anderson Cancer Center, Houston, TX. 
p1-03-05  Fibrocystic Changes have Different age-Dependent patterns 
in benign, in Situ, and invasive breast Cancer patients
Bekhash A, Kovatich AJ, Chen Y, Hooke JA, Kvecher L, Mural RJ, 
Shriver CD, Hu H. Windber Research Institute, Windber, PA; Walter 
Reed Army Medical Center, Washington, DC; MDR Global Systems 
LLC, Windber, PA. 
p1-03-06  Fibroadenomatoid Changes have a higher occurrence rate in 
middle-aged benign breast Disease patients with the trend 
retained in Cancer patients
Bekhash A, Hooke JA, Chen Y, Kovatich AJ, Kvecher L, Mural RJ, 
Shriver CD, Hu H. Windber Research Institute, Windber, PA; Walter 
Reed Medical Center, Washington, DC; MDR Global Systems LLC, 
Windber, PA. 
p1-03-07  Subtype-Specific gene expression Signatures in peritumoral 
non-neoplastic breast tissue
Williams T, Roman-Perez E, Rein JL, Amos KD, Troester MA. University 
of North Carolina-Chapel Hill, Chapel Hill, NC. 
p1-03-08  adipose tissue in breast Cancer: not an idle bystander but an 
active participant in breast Cancer progression
Lapeire LD, Hendrix A, Lambein K, Braems G, Valet P, Van den 
Broecke R, Bracke M, Cocquyt V, Denys H, De Wever O. Ghent 
University Hospital, Ghent, Belgium; INSERM U1048, Toulouse, 
France. 
p1-03-09  Significance of Fap, Sma and CD31 expression in the Stroma 
of breast Cancer
Tchou J, Satija C, Zhang P, Bi Y, Davuluri R, Chen H, Majumdar R, 
Mies C, Herlyn M, Pure E. Perleman School of Medicine at University 
of Pennsylvania, Philadelphia, PA; Perleman School of Medicine at 
University of Pennsylvania; Wistar Institute, Philadelphia. 
p1-03-10  S100a7 enhances breast tumor progression and metastasis 
through activation of pro-metastatic and inflammatory 
pathways
Ganju RK, Nasser MW, Qamri Z, Deol YS, Schwendener RA, Leone 
G, Wolf R, Yuspa S.  The Ohio State University Medical Center, 
Columbus, OH; University of Zurich, Zurich, Switzerland; Ludwig 
Maximilan University, Munich, Germany; National Institutes of Health, 
Bethesda, MD. 
tumor Cell biology: Stem/progenitor Cells
p1-04-01  the mechanism of anti-breast Cancer tiCs effect of pyrvinium 
pamoate is through Wnt/beta-Catenin Signaling
Xu W, Debeb B, de Lacerda A, Li L, Larson R, Reuben J, Ueno N, 
Woodward W. UT MD Anderson Cancer Center, Houston, TX. 
p1-04-02  in vitro Qualification and Quantification of murine mammary 
Stem/progenitor Cells
Dong Q, Wang D, Bandyopadhyay A, Liu Z, Yu L, Gao H, Moncada 
K, Huang C, Walter CA, Sun L-Z. University of Texas Health Science 
Center, San Antonio, TX; Wenzhou Medical College, Wenzhou, 
Zhejiang, China. 
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p1-04-03  the effect of Survivin Downregulation on radiosensitization 
of breast Cancer Cell lines grown under adherent and Stem 
Cell promoting Culture Conditions
Debeb BG, Larson R, Xu W, Lacerda L, Reuben JM, Buchholz TA, Ueno 
NT, Woodward WA. Morgan Welch Inflammatory Breast Cancer 
Clinic and Research Group, The University of Texas M.D. Anderson 
Cancer Center, Houston, TX. 
p1-04-04  Focal adhesion kinase plays a major role in the regulation of 
human Ductal Carcinoma in Situ (DCiS) Stem Cell activity
Williams KE, Bundred NJ, Farnie G. University of Manchester, 
Paterson Institute for Cancer Research, Manchester, United Kingdom; 
University Hospital of South Manchester, Manchester, United 
Kingdom. 
p1-04-05  t-Dm1 and pertuzumab as new tools for her2 Specific 
antibody-therapy against breast Cancer Stem Cells in her2-
positive mammary Carcinoma
Honig A, Diessner J, Dietl J, Wischhusen J. University of Wuerzburg, 
Wuerzburg, Germany. 
p1-04-06  ionizing radiation reprograms non-tumorigenic Cancer Cells 
into Cancer Stem Cells
Chann L, Vlashi E, Lorenza DD, Dekmezian C, Pajonk F. University of 
California, Los Angeles, CA. 
p1-04-07  poly (aDp-ribose) polymerase-1 (parp-1) is overexpressed in 
human breast Cancer Stem Cells: results from a proteomic-
based approach
Gilabert M, Ginestier C, Audebert S, Pophillat M, Toiron Y, Birnbaum 
D, Borg J-P, Charafe-Jauffret E, Gonçalves A. Institut Paoli-Calmettes, 
Marseille, France; U891 INSERM, Marseille, France; Université de la 
Méditerranée, Marseille, France; Centre d’Immunologie Marseille-
Luminy, Marseille, France. 
p1-04-08  Distribution of alDh1 positive Stem Cells in benign mammary 
tissue from Women with and without breast Cancer
Isfoss BL, Holmqvist B, Alm P, Olsson H.  Telemark Hospital, Skien, 
Norway; Lund University, Lund, Sweden.
p1-04-09   biphasic effects of Docetaxel and hedgehog Signaling 
antagonists on breast Cancer tumor-initiating Cells in vivo
Zhang X, Moraes RC, Landis MM, Wu M-F, Hilsenbeck SG, Cairo MM, 
Toftgar R, Chang JC, Lewis MT.  Baylor College of Medicine, Houston, 
TX; Karolinska Institutet, Novum, Sweden. 
tumor Cell biology: epigenetics
p1-05-01  pelp1 oncogenic Functions involve regulation of histone 
arginine methylation
Mann M, Cortez V, Yang BW, Tekmal RR, Vadlamudi RK. University 
of Texas Health Science Center at San Antonio, San Antonio, TX; 
University of Southern California, Los Angeles, CA. 
p1-05-02  epigenetic regulation by alcohol reactivates estrogen 
receptor alpha in estrogen receptor alpha-negative Cells
Wong AW, Nunez N. University of Texas at Austin, Austin, TX. 
p1-05-03  relationship between polycomb repressive Complex 
eZh2/CbX7, large non-Coding rna anril and Stem Cells 
biomarkers in triple negative breast Carcinomas: important 
role in Carcinogenesis through an epigenetic Silencing 
process and new Clues for targeted therapies
Meseure D, Vacher S, Trassard M, Drak-Alsibai K, Le Scodan R, Le 
Ray C, Regnier C, Lidereau R, Bieche I. Institut Curie Hôpital Rene 
Huguenin, St Cloud, France. 
p1-05-04 Distinct patterns of promoter Cpg island methylation of 
breast Cancer Subtype are associated with Different Stem Cell 
phenotype
Park SY, Kwon HJ, Choi Y, Lee HE, Kim S-W, Kim JH, Kim IA, Jung 
N, Cho N-Y, Kang GH. Seoul National University Bundang Hospital; 
Seoul National University Hospital; Cancer Research Institute, Seoul 
National University. 
p1-05-05  prognostic utility of histone modifier gene expression profiles 
in human breast Cancer
Patani N, Jiang WG, Newbold RF, Mokbel K. The London Breast 
Institute, The Princess Grace Hospital, London, United Kingdom; 
University Department of Surgery, Cardiff University School of 
Medicine, Cardiff, United Kingdom; Brunel Institute of Cancer 
Genetics and Pharmacogenomics, Brunel University, London, United 
Kingdom. 
p1-05-06  hypermethilation 14-3-3- Sigma promoter as a biomarker to 
Screening for metastasis and potencial prognostic Factor in 
breast Cancer patients
Martinez-Galan J, Torres-Torres B, González-Vicente A, Ruiz-
Vozmediano J, Delgado-Pérez JR. Hospital Universitario Virgen de 
las Nieves, Granada, Spain; Centro de Investigaciones Biomédicas, 
Granada, Spain. 
prognosis/response predictions: response predictions – i
p1-06-01  Withdrawn
p1-06-02  Correlation between gene variants in Cyp19 (aromatase) and 
tCl1a with Disease and tolerability endpoints in the ataC 
trial
Rae JM, Sestak I, Henry NL, Drury S, Hayes DF, Thibert JN, Lopez-
Knowles E, Salter J, Pineda S, Cuzick J, Dowsett M. University of 
Michigan, Ann Arbor, MI; Queen Mary University, London, United 
Kingdom; Royal Marsden Hospital, London, United Kingdom; 
Breakthrough Breast Cancer Research Centre, London, United 
Kingdom. 
p1-06-03  predictive value of her2, topoisomerase-ii (topo-ii) and 
tissue inhibitor of metalloproteinases (timp-1) for efficacy 
of taxane-based Chemotherapy in intermediate risk breast 
Cancer - results from the eC-Doc trial
Gluz O, Erber R, Kates R, Kreipe H, Bartels A, Liedtke C, Pelz E, Huober 
J, Kuhn W, Nitz U, Hartmann A, Harbeck N, Brünner N. West German 
Study Group, Moenchengladbach, Germany; University Hospital 
Erlangen, Erlangen, Germany; Medizinische Hochschule Hannover, 
Hannover, Germany; University Copenhagen, Copenhagen, 
Denmark; University Hospital Muenster, Muenster, Germany; 
Pathology Practice, Viersen, Germany; University Hospital Tuebingen, 
Tuenbingen, Germany; Kantnonhospital St. Gallen, St. Gallen, 
Switzerland; University Hospital Bonn, Bonn, Germany; University 
Hospital Cologne, Cologne, Germany. 
p1-06-04  pam50 proliferation index predicts response to Weekly 
adjuvant paclitaxel in node-positive operable breast Cancer
Martín M, Rodríguez-Lescure á, Stijleman IJ, Munárriz B, Ruíz-Borrego 
M, Davis C, Crespo C, Rodríguez CA, Ebbert MTW, álvarez I, Furió V, 
Bastien RRL, García AM, Cheang MC, Palacios J, Ellis MJC, Carrasco 
E, Casas MI, Caballero R, Perou CM, Bernard PS. Hospital General 
Universitario Gregorio Marañon, Madrid, Spain; Hospital Universitario 
de Elche, Elche, Spain; University of Utah Health Sciences Center/
Huntsman Cancer Institute, Salt Lake City, UT; Hospital Universitario 
La Fe, Valencia, Spain; Hospital Universitario Virgen del Rocío, Sevilla, 
Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital 
Clínico Universitario de Salamanca, Salamanca, Spain; The ARUP 
Institute for Clinical and Experimental Pathology, Salt Lake City, 
UT; Hospital de Donostia, San Sebastián, Spain; Hospital Clínico 
Universitario San Carlos, Madrid, Spain; University of North Carolina 
at Chapel Hill; Washington University in St Louis, St Louis; Spanish 
Breast Cancer Research Group, GEICAM, San Sebastián de los Reyes, 
Madrid, Spain. 
p1-06-05  Withdrawn
p1-06-06  the importance of CXCl10 and CXCr3-a in breast Cancer
Hilborn E, Sivik T, Kot A, Fornander T, Skoog L, Nordenskjöld B, Stål O, 
Jansson A. Faculty of Health Sciences, Linköping, Sweden; Karolinska 
Institutet. 
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p1-06-07  timp-1 in Combination with her2 and top2a for prediction 
of benefit from adjuvant anthracyclines in high risk breast 
Cancer patients
Hertel PB, Tu D, Ejlertsen B, Jensen M-B, Balslev E, Jiang S, O’Malley 
FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO. 
Faculty of Life Sciences, Univ of Copenhagen, Copenhagen, 
Denmark; National Cancer Institute of Canada, Kingston, ON, Canada; 
Rigshospitalet, Copenhagen, Denmark; Danish Breast Cancer 
Cooperative Group, Copenhagen, Denmark; Herlev Hospital, Herlev, 
Copenhagen, Denmark; Mount Sinai Hospital, Toronto, ON, Canada; 
University of Toronto, Toronto, ON, Canada; University of British 
Columbia Vancouver, Vancouver, BC, Canada. 
p1-06-08  effect of treatment emergent Symptoms on relapse Free 
Survival: nCiC Ctg ma.12 a randomized placebo-Controlled 
trial of tamoxifen after adjuvant Chemotherapy in pre-
menopausal Women in early breast Cancer
Chapman J-AW, Shepherd LE, Le Maitre A, Pritchard KI, Graham 
BC, Gelmon KA, Bramwell VH. NCIC Clinical Trials Group, Queen’s 
University, Kingston, ON, Canada; University of Toronto, Toronto, ON, 
Canada; BCCA - Vancouver Cancer Centre, Vancouver, BC, Canada; 
Tom Baker Cancer Centre, Calgary, AB, Canada. 
p1-06-09  patient-Specific integrative pathway analysis using 
paraDigm identifies key activities in i-Spy 1 breast Cancer 
patients (Calgb 150007/150012; aCrin 6657)
Wolf DM, Yau C, Benz S, Vaske C, Stuart J, Roy R, Olshen A, Boudreau 
A, Haussler D, Gray J, Spellman P, Davis S, Hylton N, Van ‘t Veer L, 
Esserman L. University of California, San Francisco; University of 
California, Santa Cruz; Oregon Health & Science University; I-SPY 1 
Trial Investigators. 
p1-06-10  lobular breast Cancer and naC: Combined results from the 
nki and i-Spy 1 trial
Mukhtar RA, Lips E, Wesseling J, Livasy C, Yau C, Berry D, van’t Veer 
L, Carey LA, Esserman LJ, Rodenhuis S, I-SPY Investigators, Hwang 
ES. UCSF; Netherlands Cancer Institute; University of North Carolina, 
Chapel Hill; MD Anderson. 
p1-06-11  Comparison of Community and Central her2 assessment on 
outcome of neoadjuvant Chemotherapy in the i-Spy trial
DeMichele A, Yau C, Zhu J, Wuhfkuhle J, Lenburg M, Buxton 
M, Davis S, Mies C, Livasy C, Chin K, Gray J, Carey L, Esserman L, 
Petricoin E. Abramson Cancer Center, University of Pennsylvania, 
Philadelphia, PA; University of California, San Francisco, CA; George 
Mason University, Fairfax, VA; University of California, Santa Cruz, CA; 
Carolina HealthCare System, Charlotte, NC; Oregon Health Sciences 
University, Portland, OR; The University of North Carolina at Chapel 
Hill, Chapel Hill, NC; University of Pennsylvania, Philadelphia, PA. 
p1-06-12  Circulating tumor Cells (CtC) monitoring during phase ii Study 
with lapatinib (l) and Capecitabine (C) in patients with brain 
metastases from her2-positive (+) metastatic breast Cancer 
(mbC) before Whole brain radiotherapy (Wbr): lanDSCape 
Study
Pierga J-Y, Cropet C, Tresca P, Dalenc F, Romieu G, Campone M, 
Mahier Aït-Oukhatar C, Le Rhun E, Gonçalves A, Leheurteur M, 
Domont J, Gutierrez M, Curé H, Ferrero J-M, Labbe-Devilliers C, 
Bidard F-C, Bachelot T. Institut Curie & Universite Paris Descartes, 
Paris, France; Centre Léon Bérard, Lyon, France; Institut Claudius 
Regaud, Toulouse, France; Centre Val d’Aurelle, Montpellier, France; 
Institut de Cancérologie de l’Ouest, Nantes, France; R&D Unicancer, 
Paris, France; Centre Oscar Lambret, Lille, France; Institut Paoli 
Calmettes, Marseille, France; Centre Henri Becquerel, Rouen, France; 
Institut Gustave Roussy, Villejuif, France; Institut Curie - Hôpital René 
Huguenin, Saint-Cloud, France; Institut Jean Godinot, Reims, France; 
Centre Antoine Lacassagne, Nice, France. 
p1-06-13  an amplicon-Driven aromatase inhibitor response (aDair) 
Signature provides an orthogonal risk Classifier for er+ 
breast Cancer
Luo J, Chang L-W, Van Tine BA, Tao Y, Hoog J, Giuntoli T, Davies 
SR, Snider J, Leung S, DeSchryver K, Allred C, Vickery T, Alldredge 
P, Mardis E, Nielsen TO, Parker JS, Prat A, Perou CM, Ellis MJ. 
Washington University in St. Louis, St. Louis, MO; Washington 
University in St. Louis, St. Louis, MO; University of British Columbia, 
Vancouver, BC, Canada; University of North Carolina, Chapel Hill, NC. 
p1-06-14  topoisomerase ii alpha (top2a) protein expression is a 
predictor for response to anthracycline-based Chemotherapy 
(atC-Ct): is it Due to gene amplification, her2-
Coamplification or a Summation of pathways leading to this 
highly proliferative phenotype?
Abdel-Fatah TMA, Lambros MB, Vatcheva R, Ball G, Dickinson PD, 
Moseley P, Green AR, Ellis IO, Reis-Filho JS, Chan S. Nottingham 
University City Hospital, NHS Trust, Nottingham, Nottinghamshire, 
United Kingdom; The Institute of Cancer Research, London, United 
Kingdom; School of Molecular Medical Science, Nottingham 
University, Nottingham; Nottingham Trent University, Nottingham. 
p1-06-15  a genomic predictor Developed from breast Cancer Cell 
lines predicts both Disease-Free Survival and overall Survival 
in breast Cancer patients treated with Doxorubicin and 
Cyclophosphamide: a Collaborative project of the nSabp and 
precision therapeutics
Shen K, Tang G, Kim C, Pogue-Geile K, Anderson SJ, Constantino JP, 
Bear HD, Song N, Tian C, Gabrin MJ, Zhang Y, Geyer, Jr CE, Wolmark 
N. Precision Therapeutics, Inc., Pittsburgh, PA; National Surgical 
Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of 
Pittsburgh Graduate School of Public Health, Pittsburgh, PA; Virginia 
Commonwealth University, Richmond, VA; Allegheny General 
Hospital, Pittsburgh, PA. 
p1-06-16  brCa2 mutation Carriers respond poorly to Conventional 
anthracylins/taxanes-based neo-adjuvant Chemotherapy
Raphael J, Caron O, Rimareix F, Spielmann M, Al Ghuzlan A, Mathieu 
M-C, Delaloge S. Institut Gustave Roussy, Villejuif, France. 
p1-06-17  a new pathological response index (pri) for neoadjuvant 
Chemotherapy accurately predicts Clinical outcomes of 
locally advanced breast Cancers (lapbC)
Abde-Fatah TMA, Mosley P, Lee A, Balls G, Ellis IO, Chan S. 
Nottingham University City Hospital, Nottingham, Nottinghamshire, 
United Kingdom; Nottingham University, Nottingham, United 
Kingdom; The Institute of Cancer Research, London; Nottingham 
Trent University. 
p1-06-18  loss of e-Cadherin expression in Clinical breast Cancer is 
associated with an adverse outcome on tamoxifen
Hiscox S, Rakha E, Smith C, Farrow L, Gandahara S, Green A, Ellis I, 
Barrett-Lee P, Nicholson RI, Gee J. Cardiff University, Cardiff, Wales, 
United Kingdom; Nottingham University Hospital, Nottingham, 
United Kingdom; Velindre Hospital, Cardiff, Wales, United Kingdom. 
p1-06-19  absence or low levels of c-junnh
2
 - terminal protein kinase 
(jnk) mitogen activated protein kinase (mapk) is related to a 
luminal b Subtype and an impaired Survival in patients with 
an er positive breast Cancer treated with adjuvant tamoxifen
Linderholm BK, Sanchez-Chavez B, Hellborg H, Johansson UM, 
Lewensohn R, Viktorsson K, Kanter L. Institution of Oncology, 
Sahlgrenska University Hospital, Gothenburg, Sweden; Institution of 
Oncology and Pathology, Karolinska Institute, Stockholm, Sweden; 
Institution of Pathology, Herlev, Denmark. 
p1-06-20  response to neo-adjuvant Chemotherapy and outcomes for 
i-Spy 1 patients Stratified by the 70-gene prognosis Signature 
(mammaprint) and molecular Subtyping (blueprint)
Gluck S, de Snoo F, Tian S, Glas A, van ‘t Veer L. Miller School of 
Medicine, University of Miami, Miami, FL; Agendia, Amsterdam, 
Netherlands; HDFC Cancer Center, UCSF, San Francisco, CA. 
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prognosis/response predictions: biomarkers – methods
p1-07-01  Comparison of Four her2 testing methods in the Detection 
of her2-positive breast Cancer: results from the Finher Study 
Cohort
Huang W, Wirtz R, Weidler J, Lie Y, Sherwood T, Leinonen M, Bono P, 
Isola J, Kellokumpu-Lehtinen P-L, Joensuu H. Monogram Biosciences 
Inc., So. San Francisco, CA; STRATIFYER Molecular Pathology GmbH, 
Cologne, Germany; Pharma, Turku, Finland; Helsinki University 
Central Hospital, Helsinki, Finland; Institute of Medical Technology, 
University of Tampere and Tampere University Hospital, Tampere, 
Finland; Tampere University Hospital, Tampere, Finland. 
p1-07-02  Discordance between Central and local laboratory her2 
testing from a large her2-negative population in virgo, a 
metastatic breast Cancer registry
Vogel CL, Bloom K, Burris H, Gralow JR, Mayer M, Pegram M, Rugo 
HS, Swain SM, Yardley DA, Chau M, Lalla D, Brammer MG, Kaufman 
PA. Sylvester Comprehensive Center at Deerfield, Miller School of 
Medicine, University of Miami, Miami, FL; Clarient, Inc., Aliso Viejo, 
CA; Sarah Cannon Research Institute, Nashville, TN; Tennessee 
Oncology, PLLC, Nashville, TN; University of Washington Medical 
Oncology, Seattle Cancer Care Alliance, Seattle, WA; Patient 
Advocate, New York, NY; University of California San Francisco 
Comprehensive Cancer Center, San Francisco, CA; Washington 
Cancer Institute, Washington Hospital Center, Washington, DC; 
Genentech, Inc., South San Francisco, CA; Norris Cotton Cancer 
Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
p1-07-03  preanalytical variables affect protein expression in Formalin 
Fixed paraffin embedded tissue - assessment of intrinsic 
Controls to Define tissue Quality for immunohistochemical 
analysis
Neumeister VM, Lostritto K, Siddiqui S, Anagnostou V, 
Vassilakopoulou M, Zarrella EA, Molinaro AM, Hicks DG, Rimm DL. 
Yale University School of Medicine, New Haven, CT; Rochester 
University, School of Medicine, Rochester, NY. 
p1-07-04  gene expression module biomarkers to Stratify multiple 
Clinical and therapeutic endpoints for universal breast Cancer 
Companion Diagnostic
Rhodes D, Tomlins S, Williams P, Sadis S, Wyngaard P, Oades 
K, Chattopadhyay S, Wang Y, Monforte J, Lee B-I. University of 
Michigan, Ann Arbor, MI; Compendia Bioscience, Inc., Ann Arbor, MI; 
AltheaDx, San Diego, CA. 
p1-07-05  her2 Status resolution in FiSh and ihC “Double equivocal” 
breast Carcinomas by Quantitative real-time pCr
Portier BP, Wang Z, Downs-Kelly E, Budd GT, Lanigan C, Tubbs RR. 
Cleveland Clinic, Cleveland, OH; Taussig Cancer Center, Cleveland 
Clinic, Cleveland, OH. 
p1-07-06  high Concordance of protein (by ihC), gene (by FiSh; her-2 
only) and microarray readout (by targetprint) of er/pr/her2: 
results from the minDaCt trial
Viale G, Bogaerts J, van’t Veer L, Rutgers E, Piccart M, de Snoo F, 
Engelen K, Russo L, Dell’Orto P, Glas A, Cardoso F, on behalf of the 
TRANSBIG Consortium & the MINDACT Investigators. European 
Institute of Oncology, Milan, Italy; European Organisation of Research 
and Treatment of Cancer, Brussels, Belgium; Netherlands Cancer 
Institute, Amsterdam, Netherlands; Institute Jules Bordet, Brussels, 
Belgium; AgendiaNV, Amsterdam, Netherlands; Champalimaud 
Cancer Center, Lisboa, Portugal. 
p1-07-07  assessing two methods of meta-analysis in Studies of patients 
with breast Cancer: individual patient Data-based (ipD) versus 
literature based abstracted Data (aD) in 5 meta-analyses 
including over 28,000 patients. are there results Differences 
of Concern?
Gralla RJ, Bria E, Raftopoulos H, Sperduti I, Giannarelli D, Cognetti 
F. Hofstra North Shore - LIJ School of Medicine, Lake Success, NY; 
Regina Elena National Cancer Institute, Rome, Italy. 
p1-06-21  relationship between body mass index and preoperative 
treatment response to aromatase inhibitor exemestane in 
postmenopausal patients with primary breast Cancer
Takada M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, 
Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Ueno T, Sasano 
H, Toi M. Graduate School of Medicine, Kyoto University, Japan; 
Saitama Medical University, International Medical Center, Japan; 
Osaka National Hospital, Japan; Tokyo Metropolitan Cancer and 
Infectious Diseases Center, Komagome Hospital, Japan; Niigata 
Cancer Center Hospital, Japan; Saitama Cancer Center, Japan; 
Kumamoto University, Japan; National Kyushu Cancer Center, Japan; 
Nagoya City University Hospital, Japan; Hiroshima City Asa Hospital, 
Japan; National Shikoku Cancer Center, Japan; Aichi Cancer Center 
Hospital, Japan; Tohoku University Hospital and School of Medicine, 
Japan. 
p1-06-22 identification of biomarkers in breast Cancer for prediction of 
response to parp inhibitor olaparib
Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Jakkula LR, 
Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Gray JW, 
Spellman PT, van ‘t Veer L. Lawrence Berkeley National Laboratory, 
Berkeley, CA; University of California San Francisco, San Francisco, CA; 
The Institute of Cancer Research, London, United Kingdom; Oregon 
Health & Science University, Portland, OR. 
p1-06-23  Changes in gene expression after one Dose of trastuzumab 
(t) in her2+ breast Cancer Cell lines predict novel pathways 
of response in her2 positive early Stage breast Cancer
Sprecher E, Lezon-Geyda K, Sarkar S, Bossuyt V, Narayaan M, Kumar 
A, Krop I, Winer E, Tuck D, Kleinstein S, Harris L. Yale University, New 
Haven, CT; Yale University; Beckman Coulter; Stony Brook University 
Hospital, Stony Brook, NY; Dana-Farber Cancer Institute, Boston, MA. 
p1-06-24  nuclear localization of Stat5a predicts response to 
antiestrogen therapy and prognosis of Clinical breast Cancer 
outcome
Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot 
E, Freydin B, Yang N, Tran TH, Rosenberg AL, Hooke JA, Kovatich 
AJ, Shriver CD, Rimm DL, Magliocco AM, Hyslop T, Rui H. Thomas 
Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, 
Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, 
DC; MDR Global Systems, LLC, Windber, PA; Yale University School of 
Medicine, New Haven, CT. 
p1-06-25  Changes in FDg pet Suv Correlates with ki-67 Following 2 
Weeks of aromatase inhibitor therapy in er+ early Stage 
breast Cancer, a pilot imaging Study
Gadi VK, Kurland BF, Specht JM, Rodler E, Korde LA, Peterson 
LM, Schubert EK, Chai X, Mankoff DA, Linden HM. University of 
Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, 
Seattle, WA. 
p1-06-26  the endopredict Score is a response predictor for 
neoadjuvant Chemotherapy in er-positive, her2-negative 
breast Cancer
Brase JC, Gehrmann MC, Petry C, Weber KE, Schmidt M, Kölbl H, 
Brauch H, Schwab M, Müller V, Jänicke F, Rody A, Kaufmann M, 
Filipits M, Gnant M, Denkert C, Loibl S, von Minckwitz G, Kronenwett 
R. Sividon Diagnostics, Cologne, Germany; Bayer Technology Services 
GmbH, Leverkusen, Germany; University of Mainz, Germany; Dr. 
Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart 
and University Tübingen, Germany; University Medical Center 
Hamburg-Eppendorf, Germany; J.W. Goethe University, Frankfurt, 
Germany; Medical University of Vienna, Austria; Charité - University 
of Berlin, Germany; German Breast Group, Neu-Isenburg, Germany. 
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p1-07-08  pCr genomic grade in breast Cancer: a new tool for Daily 
practice
Laïos I, Carpentier S, Veys I, Spinette S, Salgado R, Craciun L, Fasolo V, 
Volpe A, Girardi H, Catteau A, Peyro-Saint-Paul H, Piccart M, Sotiriou 
C, Larsimont D. Institut Jules Bordet, Brussels, Belgium; Université 
Libre de Bruxelles, Brussels, Belgium; IPSOGEN, Marseille. 
p1-07-09  estrogen receptor (er) mrna and er-related gene 
expression in breast Cancers that are 1%-10% er-positive by 
immunohistochemistry
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, 
Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi GN, Hatzis 
C, Symmans WF, Pusztai L. The University of Texas MD Anderson 
Cancer Center, TX; Okayama University, Okayama, Japan; Nuvera 
Biosciences Inc, MA. 
p1-07-10  validation of a Diagnostic molecular Signature (eht Dx14) on 
Fine-needle aspirate Samples from breast tumors
Delaloge S, André F, Fehlbaum P, Sol O, Vielh P. Institut Gustave 
Roussy, Villejuif, France; Exonhit, Paris, France. 
p1-07-11  Consistency and Control in Clinical assay technology over 
time: the oncotype DX recurrence Score and assessment of 
Single gene expression levels
Baehner FL, Butler SM, Anderson JM, Ballard J, Tan V, Shak S. 
Genomic Health, Inc., Redwood City, CA; UCSF, San Francisco, CA. 
p1-07-12  assessment of real World her2 Status by 
immunohistochemistry (ihC) and Fluorescence in Situ 
hybridization (FiSh) in breast Cancers: Comparison with 
hermark®, a validated Quantitative measure of her2 protein 
expression
Huang W, Paquet A, Sivaraman S, Pesano R, Goodman L, Sherwood 
T, Lie Y, Hickey J, Walworth C, Haddad M, Anderson S, Bates M, 
Weidler J. Monogram Biosciences Inc., South San Francisco, CA; 
Incyte Corporation, Wilmington, DE; Quest Diagnostics Nichols 
Institute, San Juan Capistrano, CA; Affymetrix, Santa Clara, CA; Gilead 
Sciences, Inc, Foster City, CA; Cepheid, Sunnyvale, CA. 
p1-07-13  efficiency of a laboratory Developed her2 FiSh test on 
Circulating tumor Cells
Mayer JA, Pham T, Wong KL, Scoggin J, Sales EV, Clarin T, Pircher TJ, 
Mikolajczyk SD, Cotter PD, Bischoff FZ. Biocept Inc, San Diego, CA. 
p1-07-14  Quantum Dot-labelled antibodies to assess her2 expression 
in breast Cancer
Zona S, Blackburn E, Hojjatoleslami AS, Brown IR, Gullick WJ. 
University of Kent, Canterbury, Kent, United Kingdom. 
p1-07-15  the reliability of ki-67 expression assessment using Core 
needle biopsy and Surgical Specimens of invasive breast 
Cancer: Can ki-67 Change predict benefits of preoperative 
endocrine therapy?
Mizuno Y, Takayanagi H, Sato K. Tokyo-West Tokushukai Hospitl, 
Akishima-city, Tokyo, Japan. 
p1-07-16  number needed to Count: a novel model for ki67 assessment 
in breast Cancer
Bendahl P-O, Romero Q, Grabau D, Borgquist S. Institution of 
Clinical Sciences, Lund University, Sweden; Institution of Laboratory 
Sciences, Lund University, Sweden. 
p1-07-17  multiplex plasma biomarkers associated with bone metastasis 
from breast Cancer
Leitzel K, Ali S, Bisen A, Lomakin A, Simonyan V, Lipton A. Penn State 
Hershey Medical Center, Hershey, PA; Lebanon VA Medical Center, 
Lebanon, PA ; Massachusetts Institute of Technology, Cambridge, 
MA; BioCompanion LLC, Rockville, MD. 
p1-07-18  expanding an online tool for genome-Wide validation of 
Survival-associated biomarkers in breast and ovarian Cancer 
using microarray Data of 3,862 patients
Gyorffy B, Lanczky A, Szallasi Z. Semmelweis University, Budapest, 
Hungary; Harvard Medical School, Boston. 
p1-07-19  analysis of her2-Status in breast Cancer by mass 
Spectrometry in archival, Formalin-Fixed tissues
Sanders M, Sprung R, Ham A, Sanchez V, Manning S, Arteaga C, 
Liebler D. Vanderbilt University Medical Center, Nashville, TN. 
p1-07-20  Consistent high False negative rate of her2 qrt-pCr of 
oncotype DX® in Comparison to aSCo/Cap recommended 
Combined ihC/FiSh method
Dabbs DJ, Bhargava R. Magee-Women’s Hospital of UPMC, 
Pittsburgh, PA. 
p1-07-21  analysis of molecular markers by immunohistochemistry 
(ihC) method on Formalin Fixed paraffin embedded (FFpe) 
tissues Could predict Shorter recurrence Free Survival (rFS) 
and overall Survival (oS) among patients Who have received 
adjuvant Chemotherapy for early breast Cancer
Moe M, Gee J, Finlay P, Mansel R, Adams R. Singleton Hospital, 
Swansea, United Kingdom; Velindre Hospital and Cardiff University, 
Cardiff, United Kingdom; Cardiff University, Cardiff, United Kingdom. 
p1-07-22  a venezuelan Study of breast Cancer estrogen receptor, 
progesterone receptor and her2 receptor expression by the 
Standard method, immunohistochemistry (ihC), Compared to 
a new method, Quantitative reverse transcription polymerase 
Chain reaction (rt-pCr)
Marin C-EM, Ramirez AC, Baehner FL, Yoshizawa C, Acosta MM. 
Fundacion BADAN, Caracas, Miranda, Venezuela; Genomic Health, 
Redwood City, CA. 
p1-07-23  absolute Quantification of estrogen receptor alpha in breast 
Cancer
Britton D, Scott G, Russell C, Held J, Ward M, Benz C, Pike I. Proteome 
Sciences Plc, London, United Kingdom; Buck Institute, Novato, CA. 
p1-07-24  Quantitative and immunohistochemical Detection of breast 
Cancer Cells in blood Samples
Andergassen U, Zebisch M, Kölbl AC, Schindlbeck C, Jäger B, Hepp P, 
Janni W, Jeschke U, Friese K, Rack BJ. Ludwig-Maximilians-University 
Muenchen, Munich, Bayern, Germany; Heinrich-Heine-University 
Düsseldorf, Duesseldorf, NRW, Germany; Klinikum Traunstein, 
Traunstein, Bayern, Germany. 
epidemiology, risk, and prevention: epidemiology –  
population Studies
p1-08-01  Survival in metastatic breast Cancer (mbC): no evidence 
for improved Survival Following Distant recurrence after 
adjuvant Chemotherapy
Tevaarwerk AJ, Gray R, Schneider BP, Smith ML, Wagner LI, Miller KD, 
Sparano JA. University of Wisconsin-Carbone Cancer Center; Indiana 
University-Simon Cancer Center; Northwestern University, Chicago, 
IL; Dana-Farber Cancer Institute; Research Advocacy Network; Albert 
Einstein University-Montefiore Medical Center. 
p1-08-02  pre-Diagnosis body mass index and breast Cancer prognosis 
and Survival: report from the after breast Cancer pooling 
project
Kwan ML, Chen WY, Weltzien E, Beasley JM, Lu W, Nechuta SJ, 
Quesenberry CP, Pierce JP, Shu XO, Caan BJ. Kaiser Permanente 
Division of Research; Brigham and Women’s Hospital and Harvard 
Medical School; Fred Hutchinson Cancer Research Center; Shanghai 
Institute of Preventive Medicine; Vanderbilt University; University of 
California, San Diego. 
p1-08-03  huge improvement in relapse-Free breast Cancer Survival 
over the last 25 years
Geurts SME, van Dijck JAAM, de Vegt F, Paquay Y, Siesling S, 
Verbeek ALM, Tjan-Heijnen VCG. Radboud University Nijmegen 
Medical Centre, Nijmegen, Netherlands; Hospital Bernhoven, Oss, 
Netherlands; Comprehensive Cancer Centre, Netherlands; Maastricht 
University Medical Centre, Maastricht, Netherlands. 
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p1-08-04  obesity, adjuvant therapy, and Survival outcomes in early-
Stage breast Cancer
Jiralerspong S, Wang T, Rimawi MF, Nangia JR, Schiff R, Giordano SH, 
Pollak MN, Chenault CC, Osborne CK, Hilsenbeck SG. Baylor College 
of Medicine, Houston, TX; M.D. Anderson Cancer Center, Houston, 
TX; McGill University, Montreal, Canada. 
p1-08-05  age and Survival in Women with early Stage breast Cancer: an 
analysis Controlling for tumor Subtype
Partridge AH, Hughes ME, Ottesen R, Wong Y-N, Edge SB, Theriault 
RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. Dana-
Farber Cancer Institute, Boston, MA; City of Hope, Duarte, CA; Fox 
Chase Cancer Center, Philadelphia, PA; Roswell Park Cancer Institute, 
Buffalo, NY; University of Texas MD Anderson Cancer Center, 
Houston, TX; Stanford Cancer Center, Palo Alto, CA; Brigham and 
Women’s Hospital, Boston, MA. 
p1-08-06  breast Cancer among patients with Diabetes, obesity and 
abnormal blood lipids - a population-based register Study in 
Sweden
Olsson H, Attner B, Landin Olsson M, Lithman T, Noreen D. Clinical 
Sciences, Lund University, Lund, Sweden. 
p1-08-07  Survival in uS Women Following an indication of metastatic 
breast Cancer Diagnosis and Chemotherapy initiation: a Seer-
medicare analysis
Rugo H, Taylor D, Sanon M, Clements K, Balu S, Faria C, Teitelbaum A. 
University of California San Francisco; OptumInsight; Eisai Inc. 
p1-08-08  higher prediagnostic Serum 25-hydroxyvitamin is associated 
with Substantially lower incidence of breast Cancer: 
prospective Study
Mohr SB, Gorham ED, Garland CF, Grant WB, Baggerly L. University 
of California San Diego, La Jolla, CA; Sunlight and Nutrition Research 
Center, San Francisco, CA; GrassrootsHealth, San Diego, CA. 
p1-08-09  increased mortality in Swedish Women Diagnosed with breast 
Cancer during and Shortly after pregnancy
Lambe M, Johansson ALV, Andersson TM-L, Cnattingius S, Hsieh C-C. 
Karolinska Institutet, Stockholm, Sweden; University of Massachusetts 
Medical School, Worcester; Regional Oncologic Center, Uppsala, 
Sweden. 
p1-08-10  invasive lobular breast Cancer - no increased risk of 
Contralateral Disease
Langlands F, Horgan K, Kearins O, Burns R, Dodwell D. The General 
Infirmary at Leeds, Leeds, United Kingdom; The University of 
Birmingham, Birmingham, United Kingdom; Level 6, Bexley Wing 
(Institute of Oncology), Leeds, United Kingdom; St James University 
Hospital, Leeds, United Kingdom. 
p1-08-11  Differences in recurrence Dynamics between lobular and 
Ductal invasive breast Cancer
Siesling S, Kwast ABG, Grandjean I, Ho V, van der Sangen MJC, 
Menke-Pluymers MBE, Tjan-Heijnen VCG. Comprehensive Cancer 
Centre the Netherlands, Utrecht, Netherlands; Catharina Hospital, 
Eindhoven, Netherlands; Erasmus Medical Centre, Rotterdam, 
Netherlands; Maastricht University Medical Centre, Maastricht, 
Netherlands. 
p1-08-12  hormonal therapy Compliance and mortality in metastatic 
breast Cancer
Barron TI, Kennedy MJ, Sharp L, Bennett K. Trinity College, University 
of Dublin, Dublin, Ireland; St James’s Hospital and Trinity College 
Dublin, Dublin, Ireland; National Cancer Registry Ireland, Cork, 
Ireland. 
p1-08-13  Determinants of risk, Characteristics and prognosis of breast 
Cancer occurring after hodgkin lymphoma
Rapiti E, Veit-Rubin N, Usel M, Benhamou S, Vlastos G, Vinh Hung 
V, Bouchardy C. University of Geneva, Geneva, Switzerland; Geneva 
University Hospitals, Geneva, Switzerland; INSERM, Paris, France. 
p1-08-14  arsenic methylation is associated with breast Cancer risk in 
northern mexico
López-Carrillo L, Hernández-Ramírez U, Torres-Sánchez L, Gandolfi 
JA, Ornelas-Aguirre JM, Cebrián ME. Mexico National Institute of 
Public Health, Cuernavaca, Morelos, Mexico; University of Arizona, 
Tucson, AZ; Hospital de Especialidades. Instituto Mexicano del 
Seguro Socia, Cd. Obregón, Sonora, Mexico; Centro de Investigación 
y Estudios Avanzados (Cinvestav), Mexico, DF, Mexico. 
p1-08-15  pattern of Cardiac monitoring and risk of trastuzumab 
associated-Cardiac Dysfunction in a Clinical practice: a 
population based Study
Lee-Ying R, Ubhi C, Roberts S, Lim H, Bhatt H, Gesy K, Ahmed S. 
University of Saskatchewan, Saskatoon, SK, Canada; University of 
Saskatchewan; Saskatchewan Cancer Agency. 
p1-08-16  benign breast Disease (bbD) and breast Cancer in african 
american Women
Fehmi RA, Cote M, Ruterbusch J, Alosh B, Bandyopadhyay S, Albashiti 
B, Frost MH, Hartmann LC, Visscher DW. Wayne State University/
Karmanos Cancer Institute/DMC, Detroit, MI; Wayne State University/
Karmanos Cancer Institute, Detroit, MI; Mayo Clinic Cancer Center, 
Rochester, MN. 
p1-08-17  pregnancy-associated breast Cancer Does not have a Worse 
outcome in the 4912 Women with breast Cancer of the 
amaZona project
Liedke PER, Szymonifka J, Simon SD, Barrios CH, Bines J, Finkelstein D, 
Goss PE. Massachusetts General Hospital, Boston, MA; Universidade 
Federal de São Paulo (UNIFESP), São Paulo, Brazil; Pontifícia 
Universidade Católica do RS (PUCRS), Porto Alegre, Rio Grande do 
Sul, Brazil; Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil; 
Brazilian Breast Cancer Study Group (GBECAM), São Paulo, Brazil. 
p1-08-18  aspirin exposure and nodal Status at Diagnosis in Women 
with Stage i-iii breast Cancer
Barron TI, Sharp L, Bennett K, Visvanathan K. Trinity College, 
University of Dublin, Dublin, Ireland; National Cancer Registry Ireland, 
Cork, Ireland; Johns Hopkins School of Public Health, Baltimore, MD. 
p1-08-19  Withdrawn
p1-08-20  parity interferes with the effect of age at Diagnosis on the 
Frequency breast Cancers are triple-negative
Vannevel V, Brouckaert O, Leunen K, Amant F, Berteloot P, 
Dieudonne A-S, Laenen A, Wildiers H, Paridaens R, Van Limbergen 
E, Weltens C, Moerman P, Smeets A, Lambrechts D, Christiaens M-R, 
Vergote I, Neven P. UZ Leuven, Belgium. 
p1-08-21  Demographic and Clinical Characteristics of metastatic breast 
Cancer patients and biomarker-based prevalence in the uk, 
germany, France, Spain and italy (eu-5)
Ganguli A, DeKoven M, Bonthapally V, Lee WC, Ray S. Abbott 
Laboratories, Abbott Park, IL; IMS Consulting Group, Alexandria, VA. 
p1-08-22  treatment patterns and Clinical outcomes in elderly patients 
with her2-positive metastatic breast Cancer from the 
registher observational Study
Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Ulcickas 
Yood M, Feng S, Wang LI, Brammer MG, Yardley DA. Norris Cotton 
Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, 
NH; University of Pittsburgh Cancer Center, Pittsburgh, PA; Patient 
Advocate, New York, NY; University of California San Francisco 
Comprehensive Cancer Center, San Francisco, CA; University of 
Southern California/Norris Comprehensive Cancer Center, Los 
Angeles, CA; EpiSource, LLC, Boston, MA; Boston University School 
of Medicine, Boston, MA; Genentech, Inc., South San Francisco, CA; 
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, 
PLLC, Nashville, TN. 
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p1-08-23  Characteristics of De novo Stage iv breast Cancer presentation 
and Comparison with Stage iv Disease relapse after adjuvant 
therapy
Chen L, Yalamanchi S, Waynick C, Romond E, Stevens M, Pasley G, 
Huller K, Weiss H, Massarweh S. University of Kentucky and Markey 
Cancer Center, Lexington, KY. 
p1-08-24  Clinical and pathologic Characteristics of Diabetic breast 
Cancer patients in a tertiary Care Safety net hospital
Loch MM, Eapen A, Ross AA, Rosenberg C, Blanchard RA. Boston 
University Medical Center, Boston, MA; Boston University, Boston, 
MA. 
p1-08-25  breast Cancer burden, risks and outcomes in latin america
Justo NA, Wilking NE, Jönsson B. OptumInsight, Stockholm, Sweden; 
Karolinska Institutet, Stockholm, Sweden; Stockholm School of 
Economics, Stockholm, Sweden. 
p1-08-26  assessment of the impact of ineffective treatments on 
metastatic breast cancer - a uS managed care perspective
Montero AJ, Eapen S, Gorin B, Waryas CM, Adler P.  Sylvester 
Comprehensive Cancer Center, University of Miami, Miami, Florida; 
Analysis Group, Inc, Boston, MA; Veridex, LLC, Raritan, NJ. 
p1-08-27  assessment of the economic burden of metastatic breast 
cancer - a uS managed care perspective
Montero AJ, Eapen S, Gorin B, Waryas CM, Adler P.  Sylvester 
Comprehensive Cancer Center, University of Miami, Miami, Florida; 
Analysis Group, Inc, Boston, MA; Veridex, LLC, Raritan, NJ.
p1-08-28  Differences in long-term survival for hispanic and non-
hispanic white women with breast cancer
Baumgartner KB, Pinkston CM, Denkhoff SR, Baumgartner RN.  
School of Public Health & Information Sciences, University of 
Louisville, Louisville, KY. 
epidemiology, risk, and prevention: epidemiology – genetic and 
molecular
p1-09-01  effect of obesity on gene expression in invasive breast tumors
Ellsworth RE, Croft DT, Ellsworth DL, Shriver CD. Henry M. Jackson 
Foundation, Windber, PA; Windber Research Institute, Windber, PA; 
Walter Reed Army Medical Center, Washington, DC. 
p1-09-02  hDl-Cholesterol and low-penetrance gene Cyp17 rs2486758 
influence Daily estrogen levels. the ebba-i Study
Iversen A, Thune I, McTiernan A, Makar KW, Wilsgaard T, Ellison PT, 
Jasienska G, Flote V, Poole E, Furberg A-S. University of Tromsø, 
Tromsø, Norway; Oslo University Hospital, Oslo, Norway; Fred 
Hutchinson Cancer Research Center, Seattle, WA; Harvard University, 
Cambridge, MA; Medical College, Krakow, Poland; Channing 
Laboratory, Boston, MA; University Hospital of North Norway, 
Tromsø, Norway. 
p1-09-03  prevalence of germline tp53 mutations in young Women with 
her2-positive breast Cancer
Dick MG, Masciari S, Miron A, Miron P, Foley K, Gelman R, Dillon 
DA, Richardson AL, Verselis SJ, Lypas G, Krop IE, Garber JE. Dana 
Farber Cancer Institute, Boston, MA; Brigham and Women’s Hospital, 
Boston, MA. 
p1-09-04  a genetic predictor for breast Cancer risk in a japanese 
population
Sueta A, Ito H, Iwata H, Hosono S, Watanabe M, Iwase H, Tajima 
K, Tanaka H, Matsuo K. Aichi Cancer Center Research, Nagoya, 
Japan; Kumamoto University Graduate School of Medical Science, 
Kumamoto, Japan; Aichi Cancer Center Central Hospital, Nagoya, 
Japan; Nagoya University Graduate School of Medicine, Nagoya, 
Japan. 
p1-09-05  a 3’utr Functional variant in brCa1: a predictor of poor 
outcome in breast Cancer
Dorairaj JJ, Miller N, Newell J, Kerin MJ, Weidhaas JB. National 
University of Ireland, Galway, Ireland; Yale University, New Haven, CT. 
p1-09-06  Single nucleotide polymorphisms in the brmS1 and Sipa1 
metastasis Suppressor genes as prognostic markers in breast 
Cancer patients
Roberts MR, Hong C-C, Edge SB, Yao S, Nesline M, Ambrosone CB. 
Roswell Park Cancer Institute, Buffalo, NY. 
p1-09-07  Contribution of tp53 p.r337h mutation to breast Cancer 
incidence in brazil
Giacomazzi J, Toledo de Bueno Osorio CA, Koehler-Santos P, 
Graudenz MS, Marthel-Planche G, Achatz MIW, Soares FA, Goldim JR, 
Caleffi M, Hainaut P, Camey SA, Ashton-Prolla P. Hospital de Clinicas 
de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Hospital 
do Câncer AC Camargo, São Paulo, Brazil; International Agency for 
Research on Cancer (IARC), Lyon, Rhone, France; Hospital Moinhos 
de Vento, Porto Alegre, Rio Grande do Sul, Brazil; Universidade 
Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do 
Sul, Brazil. 
p1-09-08  association of hypoxia-inducible Factor-1 with breast Cancer 
risk: a meta-analysis of published Studies
Yin W, Liu G, Lu J, Shen Z, Shao Z. Fudan University Shanghai Cancer, 
Shanghai, China. 
p1-09-09  Fetal microchimerism and in Situ breast Cancer
Eun JK, Gadi VK. University of Washington, Seattle, WA; Fred 
Hutchinson Cancer Research Center, Seattle, WA. 
psychosocial, Quality of life, and educational aspects: Cost-effectiveness
p1-10-01  utility of routine Cardiac ejection Fraction (CeF) measurement 
prior to anthracycline-based Chemotherapy (abC): a Study of 
466 patients with early-Stage her2-negative invasive breast 
Cancer
Policepatil SM, Go RS, De Maiffe BM, Gundrum JD, McHugh VL. 
Gundersen Lutheran Medical Foundation, La Crosse, WI; Gundersen 
Lutheran Medical Centre, La Crosse, WI; Gundersen Lutheran Medical 
System, La Crosse, WI. 
p1-10-02  burden of brain metastases in her2-positive breast Cancer: 
healthcare use and Costs from a French observational 
retrospective multicenter Study
Baffert S, Cottu PH, Kirova Y, Bachelot T, Le Rhun E, Mercier F, Levy 
C, Gutierrez M, Madrange N, Moldovan C, Guiu S, Serin D, Cotte FE, 
Benjamin L, Simondi C, Maillard C, Laulhere-Vigneau S, Durand-
Zaleski I. Institut Curie, Paris, France; Centre Léon Bérard, Lyon, 
France; Centre Oscar Lambret, Lille, France; Stat Process, Port Mort, 
France; Centre François Baclesse, Caen, France; Institut Curie, Saint-
Cloud, France; Institut Bergonié, Bordeaux, France; Centre Henri 
Becquerel, Rouen, France; Centre GF Leclerc, Dijon, France; Institut 
Sainte Catherine, Avignon, France; GlaxoSmithKline, Marly Le Roi, 
France; Ceri Medical, Garches, France; CHU Henri Mondor, Créteil, 
France. 
p1-10-03  Colony Stimulating Factor use with taxane-based therapy 
for metastatic breast Cancer: Claims analysis of prophylaxis, 
treatment, and Costs
Force RW, Pugmire BA, Culbertson VL. ImproveRX, LLC, Pocatello, ID; 
Idaho State University, Pocatello, ID. 
p1-10-04  Cost-utility of the 21-gene breast Cancer assay (oncotype 
DX®) in the irish healthcare Setting
Lacey L, Chien R, Hornberger J. Lacey Solutions Ltd, South Strand, 
Skerries, County Dublin, Ireland; Cedar Associates LLC, Menlo Park, 
CA; Columbia University, New York, NY; Stanford University, Stanford, 
CA. 
p1-10-05  is the 21-gene breast Cancer test (oncotype DX®) Cost-
effective?
Pronzato P, Plun-Favreau J. Istituto Naz.le Ricerca Cancro, Genova, 
Italy; Genomic Health International Sàrl, Geneva, Switzerland. 
p1-10-06  economic analysis of Chemotherapy Costs for adjuvant 
therapy in breast Cancer in France
Chereau E, Vataire A-L, Laas E, Genin A-S, Aballéa S, Rouzier R. Tenon 
- APHP, Paris, France; Creativ-Ceutical, Paris, France. 
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p1-10-07  Comparing breast Cancer Screening guidelines: a Stage-
Survival-Cost model in a public hospital
Friedman DT, Raskind-Hood C, Adams K, Becker E, Habtes I, D’Orsi C, 
Gundry K, Birdsong G, Gabram-Mendola S. Emory University, Atlanta, 
GA. 
psychosocial, Quality of life, and educational aspects: Disparities and 
barriers to Care
p1-11-01  Strong Socioeconomic Disparities in breast Cancer Quality of 
Care in Switzerland
Rapiti E, Blanc A, Benhamou S, Schubert H, Vlastos G, Schaffar R, 
Bouchardy C. University of Geneva, Geneva, Switzerland; INSERM, 
Paris, France; Geneva University Hospitals, Geneva, Switzerland. 
p1-11-02  racial/ethnic Differences in adjuvant trastuzumab 
receipt for Women with breast Cancer within the national 
Comprehensive Cancer network
Freedman RA, Hughes ME, Ottesen RA, He Y, Weeks JC, Wong Y-N, 
Theriault RL, Keating NL. Dana-Farber Cancer Institute, Boston, 
MA; City of Hope, Duarte, CA; Harvard Medical School, Boston, 
MA; Fox Chase Cancer Center, Philadelphia, PA; University of Texas 
MD Anderson Cancer Center, Houston, TX; Brigham and Women’s 
Hospital, Boston, MA. 
p1-11-03  breast Conserving Surgery or mastectomy - an urban bias? 
a rural Surgical patient population and Factors that lend to 
therapeutic Decisions in breast Cancer
Wooldridge RD, Borgstrom DC. Bassett Medical Center, 
Cooperstown, NY. 
p1-11-04  breast Cancer treatment resources and guideline-Concordant 
treatment in appalachia
Yao N, Hillemeier MM, Anderson RT, Matthews SA. Penn State, 
University Park, PA; Penn State, Hershey, PA. 
p1-11-05  investigation of epidemiological Factors as barriers to 
indicated radiation therapy in post-mastectomy breast 
Cancer patients in South Carolina
Rhome RM, Wahlquist A, Garrett-Mayer E, Harper J. Medical 
University of South Carolina, Charleston, SC. 
p1-11-06  barriers to enrollment in Cancer therapeutic Clinical trials: a 
Comprehensive Cancer Center experience
Bourdeanu L, Niland J, Stiller T, Swain-Cabriales S, Somlo G. City of 
Hope Medical Center, Duarte, CA. 
p1-11-07  impact of reduction in Cost-Sharing on Screening 
mammography utilization among rural u.S. Women
Peppercorn J, Wheeler SB, Yu M, Antetomaso J, Baxter P, Villagra 
VG, Jung S-H, Lyman GH. Duke Cancer Institute; University of North 
Carolina School of Public Health; Duke Department of Biostatistics 
and Bioinformatics; National Rural Electric Cooperatice Association. 
p1-11-08  breast Cancer Screening resources and Stage at Diagnosis in 
appalachia: a geospatial perspective
Yao N, Hillemeier MM, Anderson RT. Penn State, University Park, PA; 
Penn State, Hershey, PA. 
p1-11-09  effects of a multidisciplinary breast Cancer Clinic in an 
appalachian based medical Center
Ingham JA, Cremeans DK, Daugherty SL, Myhand RC, Sever WE. 
Adena Health System, Comprehensive Breast Care Program, 
Chillicothe, OH. 
p1-11-10  Quality of breast Cancer Care in a boston area patient 
navigator program
Raj A, Ko N, Battaglia T, Moy B. Massachusetts General Hospital, 
Boston, MA; Boston Medical Center, Boston, MA. 
p1-11-11  Wait times for breast Cancer Care in manitoba 2009-2010. 
time to Face the Challenge
Carpenter-Kellett T, Nashed M. CancerCare Manitoba, Winnipeg, MB, 
Canada. 
p1-11-12  patterns of Care of newly Diagnosed patients with breast 
Cancer in mexico
Chavarri-Guerra Y, Liedke PER, Symecko H, Hammond EE, Higgins MJ, 
Finkelstein D, Goss PE. Massachusetts General Hospital, Boston, MA. 
p1-11-13  improvement in the Quality of Care for patients with locally 
advanced breast Cancer through implementation of an 
integrated electronic Care pathway
Hogeveen S, Han D, George RL, Sweet-Goldstein M, Dinniwell RE, 
Muradali D, Brezden CB, Haq R, Simmons CE. St. Michael’s Hospital; 
Princess Maragaret Hospital. 
p1-11-14  gender and Sexual orientation of Clients Who Were linked 
to breast Cancer Screening Services through outreach and 
education Supported by the avon breast health outreach 
program
Opdyke KM, Pagaduan MG, Gates-Ferris K, Ricci CA, Hurlbert M. 
Cicatelli Associates Inc., New York, NY; Avon Foundation for Women, 
New York, NY. 
treatment – therapeutic Strategies: her2-targeted therapy
p1-12-01  pregnancy during and Following adjuvant trastuzumab in 
patients with her2-positive breast Cancer: an analysis from 
the hera trial (big 01-01)
Azim, Jr HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, 
Gresko E, Procter M, Piccart-Gebhart M. Institut Jules Bordet, Brussels, 
Belgium; German Breast Group, Frankfurt, Germany; F. Hoffmann-
La Roche, Basel, Switzerland; Frontier Science, Kincraig, United 
Kingdom. 
p1-12-02  patient-reported outcomes (pros) from a randomized phase 
ii Study (tDm4450g/bo21976) of trastuzumab emtansine 
(t-Dm1) vs trastuzumab plus Docetaxel (ht) in previously 
untreated her2-positive metastatic breast Cancer (mbC)
Bianchi GV, Kocsis J, Dirix L, Torigoe Y, Lalla D, Tong YB, Guardino 
AE, Hurvitz SA. Fondazione IRCCS Istituto Nazionale Tumori, Milan, 
Italy; Semmelweis University Budapest, Budapest; Sint-Augustinus, 
Antwerp; Genentech; UCLA/Translational Oncology Research 
International. 
p1-12-03  Combined targeting of the pi3k pathway and her2 
overcomes acquired and De novo trastuzumab resistance
O’Brien NA, McDonald K, Von Euw E, Conklin D, Kalous O, Di Tomaso 
E, Finn RS, Slamon DJ. University of California at Los Angeles, Los 
Angeles, CA; Novartis-Oncology, Cambrige, MA. 
p1-12-04  ebp50 - a novel biomarker for resistance to endocrine and 
her2-targeted therapies in breast Cancer
Gu G, Covington KR, Fernandez NM, Ando’ S, Fuqua SAW. Baylor 
College of Medicine, Houston, TX; University of Calabria, Arcavacata 
di Rende, Cosenza, Italy. 
p1-12-05  Complete pathological response of Ductal Carcinoma in Situ 
after treatment with neoadjuvant herceptin
Chalmers CR, Mallon EA, Touqan N, Horgan KJ, MacPherson I, 
Doughty JC. The Western Infirmary, Glasgow, Scotland, United 
Kingdom; Leeds General Infirmary, Leeds, Yorkshire, United Kingdom. 
p1-12-06  the role of mapk and pi3k/akt/mtor Signaling in innate 
lapatinib resistance
McDermott M, O’Brien N, McDonald K, Crown J, O’Donovan N, 
Slamon D. Dublin City University, Glasnevin, Dublin 9, Ireland; 
University of California Los Angeles, Los Angeles, CA; St. Vincents 
University Hospital, Elm Park, Dublin 4, Ireland. 
p1-12-07  pharmacokinetics (pk) of trastuzumab emtansine and 
paclitaxel or Docetaxel in patients with her2-positive mbC 
previously treated with a trastuzumab-Containing regimen
Lu D, Modi S, Elias AD, Agarwal P, Yi J-H, Guardino AE, Althaus BL, 
Girish S. Genentech, South San Francisco, CA; Memorial Sloan-
Kettering Cancer Center, New York, NY; University of Colorado, 
Aurora, CO. 
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p1-12-08  induction of adhesion molecules on target Cells maximizes 
antibody-Dependent Cell-mediated Cytotoxicity of anti-her2 
therapeutic antibody with high Fucose glycan
Jia X, Wong P-Y, Gazzano-Santoro H. Genentech Inc., South San 
Francisco, CA. 
p1-12-09  Safety and efficacy of neratinib in Combination with 
Capecitabine in patients with erbb2-positive breast Cancer
Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Kiger C, 
Germa C, Wang K, Kim S-B. Breast Cancer Unit, Vall d’Hebron University 
Hospital, Barcelona, Spain; Hospital Clinico San Carlos, Madrid, Spain; 
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 
China; Horizon Oncology Center, Lafayette, IN; Florida Hospital Cancer 
Institute, Orlando, FL; Washington University School of Medicine, St. 
Louis, MO; Pfizer Global Research and Development, Paris, France; 
Pfizer Inc, Pearl River, NY; Asan Medical Center, Seoul, Korea. 
p1-12-10  phase ii Study evaluating lapatinib (l) in Combination 
with albumin bound paclitaxel (ab-pac) in Women Who 
have received 0-1 Chemotherapy regimen for her2 
overexpressing (her2+) metastatic breast Cancer (mbC)
Yardley DA, Hart L, Bosserman L, Saleh MN, Waterhouse DM, 
Richards P, Hagan MK, DeSilvio ML, Mahoney JM, Nagarwala Y. 
Sarah Cannon Research Institute; Tennessee Oncology, PLLC; 
Florida Cancer Specialists; Willshire Oncology Medical Group; 
Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; 
Virginia Cancer Care; Oncology & Hematology Associates of SW; 
GlaxoSmithKline, Collegeville, PA. 
p1-12-11  neoadjuvant Chemotherapy-trastuzumab versus 
neoadjuvant Chemotherapy Followed by post-operative 
trastuzumab: a multicentre Study
Palmieri C, Yan K, Owadally W, Shah D, Gojis O, North B, Riddle P, 
Ahmad R, Lewanski C, Coombes RC, Cleator S, Howell S, Beresford 
M. Imperial College Healthcare NHD Trut, London, United Kingdom; 
Bristol Haematology and Oncology Centre, Bristol, United Kingdom; 
Third Faculty of Medicine, Charles University, Prague, Czech Republic; 
Imperial College London, London, United Kingdom; The Christie NHS 
Foundation Trust, Manchester, United Kingdom. 
p1-12-12  evaluation of ile655val her2 polymorphism associated with 
Cardiac toxicity Following the administration of trastuzumab 
in Women with non-metastatic breast Cancer
Diorio C, Lemieux J, Côté M-A, Provencher L, Nadeau-Larochelle C, 
Jacob S, Demers é, Tremblay-Lemay R, Saint-Pierre C, Beauchemin 
M, Barabé F, Laflamme C. Centre de Recherche FRSQ du CHA 
Universitaire de Québec, Quebec City, QC, Canada; Hôpital du Saint-
Sacrement, Quebec City, QC, Canada; Université Laval, Quebec City, 
QC, Canada; Centre Hospitalié de l’Université Laval, Quebec City, QC, 
Canada; Centre Hospitalier Affilie Universitaire de Quebec, Quebec 
City, QC, Canada. 
p1-12-13  Comparative pharmacokinetics (pk) of trastuzumab 
emtansine (t-Dm1) in patients Who have or Who have not 
received prior treatment for human epidermal growth Factor 
2 (her2)-positive metastatic breast Cancer (mbC)
Wang B, Conte P, Casanova LA, Vinholes JJdF, Saad OM, Yi J-H, 
Gupta M, Song C, Olsen SR, Perez EA, Girish S. Genentech, South San 
Francisco, CA; University of Modena and Reggio Emilia, Modena, 
Italy; Instituto Oncológico Miraflores, Lima, Peru; CliniOnco, Porto 
Alegre, Brazil; Mayo CLinic, Jacksonville, FL. 
p1-12-14  genetic ablation or pharmacological inhibition of autophagy 
Suppresses intrinsic resistance of breast Cancer to her2-
targeted therapies
Cufí S, Oliveras-Ferraros C, Vazquez-Martin A, Sauri-Nadal T, Del Barco 
S, Martin-Castillo B, Lopez-Bonet E, Menendez JA. Catalan Institute 
of Oncology, Girona, Catalonia, Spain; Girona Biomedical Research 
Institute (IDIBGi), Girona, Catalonia, Spain; University Hospital of 
Girona Dr. Josep Trueta, Girona, Catalonia, Spain. 
p1-12-15  adjuvant trastuzumab effect on her2-positive breast 
Cancers according to hormonal receptor (hr) Status: 
Crosstalk between er and egFr/her2 pathway may prevent 
trastuzumab from improving outcomes in her2-positive and 
hr-positive breast Cancers
Park YH, Cho EY, Lee JE, Nam SJ, Yang JH, Ahn JS, Im Y-H. Samsung 
Medical Center. 
p1-12-16  her-2 testing and treatment - is age a Factor?
Singh JK, Ewing K, Howell S, Howe M, Cramer A, Bundred NJ. 
School of Cancer and Enabling Sciences, University of Manchester, 
Paterson Institute for Cancer Research, Manchester, United Kingdom; 
University Hospital of South Manchester, Wythenshawe Hospital, 
Manchester, United Kingdom; The Christie NHS Foundation Trust, 
Manchester, United Kingdom. 
p1-12-17  Fluorescent in Situ hybridization evaluation of her2 Status in 
tumors with Chromosome 17 polysomy
Pietri E, Medri L, Farolfi A, Sarti S, Maltoni R, Cecconetto L, Ibrahim T, 
Paioli A, Serra L, Amadori D, Rocca A. Istituto Scientifico Romagnolo 
per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; 
Morgagni-Pierantoni Hospital, Forlì, (FC), Italy. 
p1-12-18  Change in her2 Status in her2 positive operable breast 
Cancer patients treated with neoadjuvant Chemotherapy with 
or without anti-her2 therapy: analysis of two Consecutive 
Cohorts
Barbieri E, Piacentini F, Dieci MV, Ficarra G, Bettelli S, Conte P, 
Guarneri V. Modena University Hospital, Modena, Italy. 
p1-12-19  phase i Study of Single agent trastuzumab emtansine in 
japanese patients with human epidermal growth Factor 
receptor2 (her2)-positive metastatic breast Cancer (jo22591)
Aogi K, Ando M, Iwata H, Hara F, Matsubara M, Fujiwara Y. National 
Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 
Japan; National Cancer Center Central Hospital, Chuo-ku, Tokyo, 
Japan; Chuo Hospital Aichi Cancer Center, Nagoya, Aichi, Japan; 
Chugai Pharmaceutical Co. Ltd, Chuo-ku, Tokyo, Japan. 
p1-12-20  the Safety and tolerability of vorinostat in Combination with 
lapatinib in advanced Solid tumors
Chumsri S, Tait NS, Medeiros MM, Bauer KS, Betts K-MT, Lewis JC, Bao 
T, Feigenberg SJ, Kesmodel SB, Stearns V, Edelman MJ, Sausville EA, 
Tkaczuk KHR. University of Maryland Greenebaum Cancer Center, 
Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at 
Johns Hopkins, Baltimore, MD; University of Maryland, Baltimore, MD. 
p1-12-21  adjuvant trastuzumab treatment without adjuvant 
Chemotherapy in early breast Cancer
Dall P, Koch T, Lenzen G, Kuhn T, Hielscher C, Reichert D, Maasberg 
M, Ehscheidt P, Eustermann H, Fischer G. Städt. Klinikum, Lüneburg, 
Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, 
Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, 
Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, 
Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; 
Landkreis Mittweida Khs., Mittweida, Germany. 
p1-12-22  impact on Survival of the level of her2/neu gene 
amplification in patients with her2-positive (her2+) 
advanced breast Cancer (advbrCa) treated with  
trastuzumab (h)
Gullo G, Bettio D, Zuradelli M, Masci G, Giordano L, Bareggi C, Salvini 
P, Runza L, Santoro A. St Vincent’s University Hospital, Dublin, 
Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas 
Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda 
Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas 
Gavazzeni, Bergamo, Italy. 
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p1-12-23 her4 Coexpression is associated with improved recurrence 
Free Survival in her2-positive, herceptin treated patients
Brockhoff G, Machleidt A, Piendl G, Seegers S, Sassen A, Diermeier-
Daucher S, Buchholz S, Ortmann O. University Medical Center 
Regensburg, Regensburg, Bavaria, Germany. 
p1-12-24  adherence and persistence with lapatinib in Women with 
metastatic breast Cancer Who Were previously treated with 
trastuzumab
Delea TE, Kartashov A, Sharma PP. Policy Analysis Inc. (PAI), Brookline, 
MA; GlaxoSmithKline, Philadelphia, PA. 
p1-12-25  evaluation of pten, egFr and ki67 expression as predictors 
of response to a trastuzumab-Containing neoadjuvant 
Chemotherapy regimen in a her-2 over-expressing locally 
advanced breast Cancer (labC) trial
Ho J, Turashvili G, Hayes M, Gelmon KA, Ellard SL, Macpherson N, 
Pansegrau G, Chia SK. British Columbia Cancer Agency, Vancouver, 
BC, Canada; British Columbia Cancer Research Centre, Vancouver, 
BC, Canada; British Columbia Cancer Agency, Kelowna, BC, Canada; 
British Columbia Cancer Agency, Victoria, BC, Canada; British 
Columbia Cancer Agency, Surrey, BC, Canada. 
p1-12-26  global patterns of Care for her2/neu overexpressing breast 
Cancer
Y. Chavarri-Guerra, P. Liedke, H. Symecko, B. Moy, M. Higgins, J. St. 
Louis, D. Finkelstein, P. Goss. Massachusetts General Hospital - Avon 
International Breast Cancer Program, Boston, MA. 
treatment – therapeutic Strategies: immunotherapy
p1-13-01  an update of a phase ii trial of the her2 peptide ae37 vaccine 
in breast Cancer patients to prevent recurrence
Hale DF, Perez S, Sears AK, Clifton GT, Vreeland TJ, Holmes JP, 
Ardavanis A, Pistamaltzian N, Rellias G, Ponniah S, Papamichail M, 
Peoples GE, Mittendorf EA. Brooke Army Medical Center, Ft. Sam 
Houston, TX; Saint Savas Cancer Hospital, Athens, Greece; Naval 
Medical Center San Diego, San Diego, CA; Uniformed Services 
University of the Health Sciences, USMCI, Bethesda, MD; UT M.D. 
Anderson Cancer Center, Houston, TX. 
p1-13-02  long-term Clinical benefit of adjuvant breast Cancer vaccine: 
5 year efficacy of e75 with multiple booster inoculations
Vreeland TJ, Clifton GT, Sears AK, Hale DF, Patil R, Clive KS, Holmes JP, 
Mittendorf EA, Ponniah S, Peoples GE. Brooke Army Medical Center, 
Ft. Sam Houston, TX; Windber Medical Center, Windber, Pa; Naval 
Medical Center San Diego, San Diego, CA; UT M.D. Anderson Cancer 
Center, Houston, TX; Uniformed Services University of the Health 
Sciences, USMCI, Bethesda, MD. 
p1-13-03  Zoledronic acid induces an immune response in breast Cancer 
patients through Stimulation of Central memory and effector 
memory gamma/delta t-Cells
Hamilton EP, Hobeika AC, Lyerly HK, Owzar K, Rocha G, Kimmick 
GG, Marcom PK, Peppercorn JM, Morse MA, Blackwell KL. Duke 
University, Durham, NC. 
p1-13-04  phase ii Study of topical imiquimod and abraxane for 
treatment of breast Cancer Cutaneous metastases
Salazar LG, Lu H, Gray H, Higgins D, Childs J, Yushe D, Slota M, Parker 
S, Disis ML. University of Washington, Seattle, WA. 
treatment – therapeutic Strategies: antiangiogenic therapy
p1-14-01  randomized phase ii trial of Weekly vs. q 2-Weekly vs. q 
3-Weekly nanoparticle albumin-bound paclitaxel with 
bevacizumab as First-line therapy for metastatic breast 
Cancer
Seidman AD, Conlin AK, Bach A, Forero-Torres A, Wright G, Hackney 
MH, Clawson A, Schofield D, Iglesias J, Hudis CA. Memorial Sloan-
Kettering Cancer Center, New York, NY; Providence Cancer Center, 
Portland, OR; University of Alabama - Birmingham, Birmingham, 
AL; Florida Cancer Institute, Hudson, FL; Virginia Commonwealth 
University, Richmond, VA; Celgene Corporation, Summit, NJ. 
p1-14-02  Correlation of Circulating tumor Cells (CtC) and Circulating 
endothelial Cells (CeC) with pathological Complete response 
(pCr) during neoadjuvant Chemotherapy (Ct) Combined with 
bevacizumab in her2 negative inflammatory breast Cancer 
(ibC): ancillary Study of phase ii trial beverly 1
Pierga J-Y, Bidard F-C, Andre F, Petit T, Dalenc F, Delozier T, Romieu 
G, Bonneterre J, Ferrero J-M, Kerbrat P, Lemonnier J, Viens P. Institut 
Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre 
Paul Strauss, Strasbourg, France; Centre Claudius Regaud, Toulouse, 
France; Centre François Baclesse, Caen, France; Centre Val d’Aurelle, 
Montpellier, France; Centre Oscar Lambret, Lille, France; Centre 
Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, 
France; Unicancer, Paris, France; Centre Paoli Calmettes, Marseille, 
France. 
p1-14-03  avaluZ Study: First line with bevacizumab in Combination 
with paclitaxel (p) and gemcitabine (g) in patients with her-2 
negative recurrent or metastatic bC: pFS analysis
Salvador J, Ciruelos E, Codes de Villena M, Jaen A, Gil M, Galan A, 
Murias A, Jara C, de la Haba J, Baena JM, Villanueva MJ, Bayo J, 
Blancas I, Gonzalez E, Perez D, Mel JR, Manso L. Hospital U. de Valme, 
Sevilla, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen 
Macarena, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; ICO, Bellvitge, 
Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Insular de 
Gran Canaria, Gran Canaria, Spain; Fundacion Hospital de Alcorcon, 
Alcorcon, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital Puerta 
del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Juan 
Ramón Jimenez, Huelva, Spain; Hospital San Cecilio, Granada, Spain; 
Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, 
Marbella, Spain; Hospital Lucus Augusti, Lugo, Spain. 
p1-14-04  prolonged (≥1 year) exposure to First-line bevacizumab 
Combined with paclitaxel in patients with her2-negative 
metastatic breast Cancer treated in a routine oncology 
practice Study
Kuemmel S, Schneeweiss A, Foerster FG, Geberth M, Tesch H, 
Klare P, Schumacher C, Hollburg W, Soeling U, Schmidt M. Kliniken 
Essen-Mitte, Essen, Germany; National Center for Tumor Diseases, 
Heidelberg, Germany; University of Applied Sciences Zwickau, 
Zwickau, Germany; SPGO-Mannheim, Mannheim, Germany; 
Oncological Practice Bethanien, Frankfurt, Germany; Oncology 
Practice Krebsheilkunde für Frauen, Berlin, Germany; St. Elisabeth-
Hospital, Köln, Germany; HOPA (Hämatologisch-Onkologische Praxis 
Altona) im Struenseehaus, Hamburg, Germany; Practice, Kassel, 
Germany; University Hospital Mainz, Mainz, Germany. 
p1-14-05  Surgical Complications from the geparQuinto trial of patients 
receiving preoperative bevacizumab
Eidtmann H, Kittel K, Rezai M, Tesch H, Ulmer HU, Stirnberg S, Belau 
A, Mau C, Stickeler E, Schrader I, Fasching P, Salat CT, Abdallah 
A, Holms F, Schwedler K, Nekljudova V, Loibl S, von Minckwitz G. 
Universitätsklinikum, Kiel; Praxisklinik, Berlin; Luisenkrankenhaus, 
Düsseldorf; Onkologische Gemeinschaftspraxis am Bethanien-
Krankenhaus, Frankfurt; Städtisches Klinikum, Karlsruhe; Frauenklinik, 
Rheinfelden; Universitätsklinikum, Greifswald; Helios Klinikum 
Berlin Buch, Berlin; Universitätsklinikum, Freiburg; Henrietten 
Stiftung, Hannover; Universitätsklinikum, Erlangen; Hämatologisch-
Onkologische Schwerpunktpraxis, München; Evangelisches 
Krankenhaus, Gelsenkirchen; St. Barbara-Klinik, Heessen; 
Universitätsklinikum, Frankfurt; German Breast Group, Neu-Isenburg. 
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treatment – therapeutic Strategies: alternative therapies
p1-15-01  oral Fluoropyrimidine (uFt and S-1) may augment the efficacy 
of aromatase inhibitor via the Down-regulation of estrogen 
receptor in estrogen-responsive breast Cancer Xenografts
Nukatsuka M, Saito H, Nakagawa F, Abe M, Uchida J, Shibata J, 
Matsuo K-i, Noguchi S, Kiniwa M. Taiho Pharmaceutical Co., Ltd., 
Tokushima-shi, Tokushima, Japan; Taiho Pharmaceutical Co., Ltd., 
Tsukuba-shi, Ibaragi, Japan; Osaka University Medical School, Osaka, 
Japan. 
p1-15-02 nanoparticles overcome the Decreased responsiveness 
of breast Cancer Cells to a Chemotherapeutic Drug in the 
presence of adipocytes
DeAngel RE, Sandoval MA, Lansakara-P DSS, Dunlap SM, Hursting SD, 
Cui Z. The University of Texas at Austin, Austin, TX; UT-MD Anderson 
Cancer Center, Smithville, TX. 
p1-15-03  multistage vectored nanotherapeutics for breast Cancer 
metastasis
Shen H. The Methodist Hospital Research Institute, Houston, TX. 
treatments – advanced Disease: advanced therapy - endocrine
p1-16-01  a randomized, Double-blinded, Controlled Study of 
exemestane vs. anastrozole for the First-line treatment of 
postmenopausal japanese Women with hormone receptor 
positive advanced breast Cancer
Masuda N, Iwata H, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, 
Nishizawa Y, Saeki T, Noguchi S. NHO Osaka National Hospital, Osaka, 
Japan; Aichi Cancer Center Hospital, Aichi, Japan; Kyushu Cancer 
Center, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Nagoya 
Medical Center, Aichi, Japan; Shikoku Cancer Center, Ehime, Japan; 
Pfizer Japan Inc, Japan; Saitama Medical University International 
Medical Center, Saitama, Japan; Osaka University, Osaka, Japan. 
treatments – advanced Disease: advanced therapy - targeted
p1-17-01 Figitumumab plus exemestane versus exemestane as First-
line treatment of postmenopausal hormone receptor-
positive advanced breast Cancer: a randomized, open-label 
phase ii trial
Ryan PD, Neven P, Blackwell KL, Dirix LY, Barrios CH, Miller, Jr WH, 
Fein LE, Fenton D, Benner RJ, Meech SJ, Paccagnella L, Sleight B, Yee 
D, Goss PE. Fox Chase Cancer Center, Philadelphia, PA; Universitair 
Ziekenhuis Leuven, Leuven, Belgium; Duke University Medical 
Centre, Durham, NC; Sint-Augustinus, Oncologisch Centrum, 
Antwerp, Belgium; PUCRS School of Medicine, Porto Alegre, Brazil; 
Lady Davis Institute for Medical Research, Jewish General Hospital, 
Segal Cancer Center, McGill University, Montreal, Canada; Centro 
Oncológico Rosario, Santa Fé, Argentina; Cross Cancer Institute, 
Edmonton, Canada; Pfizer Inc., Groton, CT; University of Minnesota, 
Minneapolis, MN; Massachusetts General Hospital Cancer Center, 
Boston, MA. 
p1-17-02  a phase 1/2 Study of Sar245408 (S08) in Combination with 
trastuzumab (t) or paclitaxel (p) and t in patients with her2+ 
metastatic breast Cancer (mbC) Who progressed on a previous 
t-based regimen
Tolaney S, Burris H, Gartner E, Mayer I, Saura C, Maurer M, DeCillis A, 
Ruiz-Soto R, Lager J, Winer E, Krop I. Dana Farber Cancer Institute, 
Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne 
State University/Karmanos Cancer Institute Hematology/Oncology, 
Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall 
d’Hebron University Hospital, Barcelona, Spain; Columbia University 
Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, 
Cambridge, MA. 
p1-17-03  Withdrawn
p1-17-04  phase i Study of parp inhibitor abt-888 (veliparib) in 
Combination with Cisplatin and vinorelbine for patients 
with advanced triple negative breast Cancer and/or brCa-
mutation associated breast Cancer
Rodler ET, Specht JM, Gadi VK, Kurland BF, Griffin MJ, Hammond JJ, 
Gralow JR. University of Washington/Seattle Cancer Care Alliance, 
Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. 
p1-17-05  preliminary results of a randomized phase 2 Study of pD 
0332991, a Cyclin-Dependent kinase (CDk) 4/6 inhibitor, 
in Combination with letrozole for First-line treatment of 
patients (pts) with post-menopausal, er+, her2-negative 
(her2-) advanced breast Cancer
Finn RS, Crown JP, Boer K, Lang I, Parikh RJ, Patel R, Schmidt M, 
Hagenstad C, Lim H, Pinter T, Amadori D, Chan D, Dichmann RA, 
Walshe J, Breazna A, Kim ST, Randolph S, Slamon DJ. University 
of California at Los Angeles, Los Angeles, CA; Irish Cooperative 
Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, 
Budapest, Hungary; National Institute of Oncology, Budapest, 
Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; 
Comprehensive Blood and Cancer Center, Bakersfield, CA; University 
Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology 
Associates, Lawrenceville, GA; British Columbia Cancer Agency, 
Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, 
Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura 
dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, 
Redondo Beach, CA; Central Coast Medical Oncology Corporation, 
Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New 
York, NY. 
p1-17-06  a phase ii trial of the CDk 4/6 inhibitor pD0332991 in Women 
with advanced breast Cancer
DeMichele A, Clark A, Randolph S, Christensen J, Gallagher M, Lal P, 
Feldman M, Zhang P, Perini R, Velders L, Domchek S, Kaplan-Tweed 
C, Gogineni K, Keefe S, Fox K, O’Dwyer P. University of Pennsylvania, 
Philadelphia, PA; Pfizer, New York, NY. 
p1-17-07  phase ii trial of raD001 plus Carboplatin in patients with 
triple-negative metastatic breast Cancer
Singh JC, Stein S, Volm M, Smith J, Novik Y, Speyer J, Adams S, 
Meyers M, Muggia F, Schneider R, Formenti S, Omene C, Choi H, 
Davis S, Goldberg J, Tiersten A. New York University Hospital Center, 
New York, NY. 
p1-17-08  a phase ii trial of ganetespib: efficacy and Safety in patients 
(pts) with metastatic breast Cancer (mbC)
Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Drullinsky P, Sugarman 
S, Wasserheit-Leiblich C, Moynahan ME, D’Andrea G, Haque S, Patil 
S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S. Memorial Sloan-
Kettering Cancer Center, New York, NY; Synta Pharmaceuticals Corp., 
Lexington, MA. 
p1-17-09  a phase 1/2 Dose-escalation Study of Sar245408 (S08) or 
Sar245409 (S09) in Combination with letrozole (l) in Subjects 
with hormone receptor-positive and her2-negative (hr+/
her2-) breast Cancer (bC) refractory to a nonsteroidal 
aromatase inhibitor (ai)
Baselga J, Tolaney S, Hart L, Gomez P, Gartner E, DeCillis A, Ruiz-Soto 
R, Lager J, Burris H. Massachusetts General Hospital, Boston, MA; 
Dana Farber Cancer Insitute, Boston, MA; Florida Cancer Specialists 
Drug Development Unit, Ft Myers, FL; HU Vall d’Hebron Oncology 
Service, Barcelona, Spain; Wayne State University/Karmanos Cancer 
Institute Hematology/Oncology, Detroit, MI; Exelixis, San Francisco, 
CA; Sanofi, Cambridge, MA; Sarah Canon Research Center, Nashville, 
TN. 
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p1-17-10  Cabozantinib (Xl184) in patients with metastatic breast 
Cancer: results from a phase 2 randomized Discontinuation 
trial
Tolaney SM, Nechushtan H, Berger R, Kurzrock R, Ron IG, Schöffski 
P, Awada A, Yasenchak CA, Burris HA, Ramies DA, Shen X, Winer 
EP. Dana Farber Cancer Institute, Boston, MA; Hadassah Ein-Kerem 
Medical Centre, Jerusalem, Israel; The Chaim Sheba Medical Center, 
Tel Hashomer, Israel; MD Anderson Cancer Center, Houston, TX; 
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; Universitaire 
Ziekenhuis Gasthuisberg, Leuven, Flemish Brabant, Belgium; Institut 
Jules Bordet, Brussels, Belgium; Northwest Cancer Specialists, P.C., 
Tualatin, OR; Sarah Cannon Research Institute, Nashville, TN; Exelixis, 
Inc., South San Francisco, CA. 
treatments – advanced Disease: advanced therapy  – other
p1-18-01  Z-aCt1: Zometa Combined with Standard therapy in 
patients with metastatic breast Cancer Further Decreases the 
proportion of patients with CtC Counts of 5 or above
Brufsky A, Beck J, Dakhil S, Hallmeyer S, Tezcan H, Yardley D, Tran 
D, Warsi G, Culver K. McGee Women’s Hospital of University of 
Pittsburgh Medical Center, Pittsburgh, PA; Highlands Oncology 
Goup, Fayettesville, AR; Cancer Center of Kansas, Wichita, KS; 
Oncology Specialist, SC, Park Ridge, IL; Kootenai Cancer Center, Post 
Falls, ID; Sarah Cannon Research Institute, Nashville, TN; Tennessee 
Oncology, PLLC, Nashville, TN; Novartis Pharmaceuticals Corporation, 
East Hanover, NJ. 
p1-18-02  Descriptive analysis of the management of breast 
Cancer patients with a Solitary lesion Diagnosed with 
18-Fluorodeoxyglucose positron emission tomography/
Computed tomography Scan
Redana S, De Carolis V, Racca M, Zago G, Varetto T, Montemurro F, 
Aglietta M, Evangelista L. Fondazione Piemontese per l’Oncologia - 
IRCC, Candiolo, TO, Italy; Istituto Oncologico Veneto - IOV, Padova, 
PD, Italy. 
5:00 pm–7:00 pm  
poSter DiSCuSSion i: enDoCrine reSiStanCe  
ballroom a
Viewing 5:00 pm 
Discussion 5:30 pm
Discussant: Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX
pD01-01  randomized phase ii trial of Fulvestrant with or without 
Dasatinib in postmenopausal patients with hormone 
receptor-positive metastatic breast Cancer previously treated 
with an aromatase inhibitor
Wright GL, Blum J, Krekow LK, McIntyre KJ, Wilks ST, Rabe AC, Vukelja 
SJ, Andersen JC, Wang Y, Asmar L, O’Shaughnessy J. US Oncology, 
The Woodlands, TX; Florida Cancer Institute-New-Hope, Hudson, FL; 
Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX; Texas 
Oncology-Breast Cancer Institute of North Houston, Bedford, TX; 
Texas Oncology-Dallas Presbyterian Hospital, Dallas, TX; Cancer Care 
Centers of South Texas, San Antonio, TX; Kansas City Cancer Center, 
Overland Park, KS; Texas Oncology, Tyler, TX; Northwest Cancer 
Specialists, Portland, OR. 
pD01-02  randomized phase ii Study of Dasatinib vs placebo in addition 
to exemestane in advanced er/pr-positive breast Cancer 
[bmS Ca180-261 Study]
Llombart A, Ravaioli A, Strauss L, Sy O, Abrahao F, Geese WJ, 
Lortholary A, Rea D, Ro J-S, Sohn J, Kim S-B, Curigliano G. Hospital 
Universitari Arnau De Vilanova, Lleida, Spain; Ospedale degli Infermi 
di Rimini, Rimini, Italy; Bristol-Myers Squibb, Wallingford, CT; Centre 
Catherine De Sienne, Nantes, France; City Hospital, Birmingham, 
United Kingdom; National Cancer Center, Gyeonggi-Do, Korea; 
Yonsei Cancer Center, Seoul, Korea; Asan Medical Center, Seoul, 
Korea; Instituto Europeo di Oncologia, Milano, Italy. 
pD01-03  Src is a potential therapeutic target in endocrine resistant 
breast Cancer exhibiting low estrogen receptor (er)-
mediated transactivation
Guest SK, Pancholi S, Patani N, Dowsett M, Johnston SR, Martin 
L-A. Institute of Cancer Research, London, United Kingdom; Royal 
Marsden Hospital, London, United Kingdom. 
pD01-04  entinostat, a novel histone Deacetylase inhibitor, added to 
exemestane improves pFS in advanced breast Cancer in a 
randomized, phase ii, Double-blind Study
Yardley DA, Ismail-Khan RR, Klein PM. Sarah Cannon Research 
Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; H. 
Lee Moffitt Cancer Center, Tampa, FL; PMK Consulting, San Francisco, 
CA. 
pD01-05  histone Deacetylase inhibitor lbh589 (panobinostat) 
Suppresses the activated-nFκb pathway in acquired 
aromatase inhibitor resistant breast Cancer Cells
Kubo M, Kanaya N, Liu Z, Chen S. Beckman Research Institute of the 
City of Hope, Duarte, CA. 
pD01-06  endoxifen exhibits potent anti-tumor activity and regulates 
Different genes than tamoxifen in an aromatase expressing 
mCF7 model resistant to letrozole
Goetz M, Hou X, Suman V, Reinicke K, Kuffel M, Haluska, Jr P, Oberg 
A, Grill D, Reid J, Brodie A, Ingle J, Ames M. Mayo Clinic, Rochester, 
MN; University of Maryland, Baltimore, MD. 
pD01-07  ar overexpression and aromatase inhibitor resistance in 
breast Cancer
Rechoum Y, Iacopetta D, Barone I, Ando’ S, Morales SF, Weigel NL, 
Fuqua SAW. Baylor College of Medicine, Houston, TX; University of 
Calabria, Calabria, Italy. 
pD01-08  heterogeneity of lapatinib responses in hCC1954 her2-
overexpressing breast Cancer Cells revealed by Single-Cell 
automated microscopy
Hardeman KN, Tyson D, Quaranta V. Vanderbilt University School of 
Medicine, Nashville, TN. 
pD01-09  identifying novel mechanisms of resistance to lapatinib 
in erbb2+ breast Cancer Cells through Whole genome 
mutational analysis
Jegg A, Ward TM, Iorns E, Gallas M, Aparicio SA, Pegram MD. Braman 
Family Breast Cancer Institute, Sylvester Comprehensive Cancer 
Center, University of Miami Miller School of Medicine, Miami, FL; 
UBC/BC Cancer Agency, Vancouver, Canada.
5:00 pm–7:00 pm
poSter DiSCuSSion ii: loCal therapy 
ballroom b
Viewing 5:00 pm 
Discussion 5:30 pm
Co-Discussant: Richard Crownover, MD, PhD
UT Health Science Center
San Antonio, TX
&
Co-Discussant: Ismail Jatoi, MD, PhD, FACS
UT Health Science Center
San Antonio, TX
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pD02-01  impact of Contralateral prophylactic mastectomy on Surgical 
outcomes
Stover AC, Warren Peled A, Foster RD, Esserman LJ, Alvarado MD, 
Ewing CA, Hwang ES. University of California San Francisco, San 
Francisco, CA. 
pD02-02  a Decision analysis of Contralateral prophylactic mastectomy 
in Women undergoing treatment for Sporadic unilateral 
breast Cancer
Lester-Coll NH, Lee JM, Gogineni K, Hwang W-T, Schwartz JS, 
Prosnitz RG. University of Pennsylvania Perelman School of Medicine, 
Philadelphia, PA; Massachusetts General Hospital, Boston, MA; 
Abramson Cancer Center, University of Pennsylvania Perelman 
School of Medicine, Philadelphia, PA. 
pD02-03  the effect of breast Conservation therapy vs mastectomy on 
Symptoms, physical impairments, and Function
Kesarwala AH, Pfalzer LA, O’Meara WP, Stout NL. National Cancer 
Institute, Bethesda, MD; University of Michigan - Flint, Flint, MI; 
National Naval Medical Center, Bethesda, MD. 
pD02-04  a randomized, prospective, multicenter Study of the impact 
of intraoperative margin assessment with adjunctive use of 
marginprobe vs. Standard of Care
Schnabel F, Tafra L, The MarginProbe Study Group. NYU Langone 
Medical Center, New York, NY; The AAMC Breast Center, Annapolis, 
MD; Dune Medical Devices. 
pD02-05  mri phenotype and tumor Subtype affect breast Conservation 
eligibility and mri accuracy in the i-Spy 1 trial
Mukhtar RA, Hylton N, Rosen M, The I-SPY 1 Trial Investigators, ACRIN 
6657 Investigators, Esserman LJ. UCSF; University of Pennsylvania; 
I-SPY 1 Trial; ACRIN 6657. 
pD02-06  outcomes after total-Skin Sparing mastectomy and 
immediate reconstruction in 657 breasts
Warren Peled A, Stover AC, Foster RD, Alvarado MD, Ewing CA, 
Hwang ES, Esserman LJ. University of California, San Francisco. 
pD02-07  models predicting non-Sentinel node involvement in breast 
Cancer also predict for regional recurrence if the axilla is not 
treated
Pepels M, Vestjens H, de Boer M, Bult P, van Dijck J, Mencke M, 
van Diest P, Borm G, Tjan V. Maastricht University Medical Centre; 
Radboud University Nijmegen Medical Centre; Erasmus Medical 
Centre Rotterdam; University Medical Centre Utrecht. 
pD02-08  validation over time of a nomogram predicting the Sentinel 
node positivity in early breast Carcinoma according to the 
molecular Subtypes Classification
Ngô C, De Rycke Y, Mouttet D, Reyal F, Fourchotte V, Hugonnet F, 
Falcou M-C, Bidard F-C, Vincent-Salomon A, Fourquet A, Sigal-Zafrani 
B, Alran S. Institut Curie, Paris, France. 
pD02-09  rtog 9804: a prospective randomized trial for “good risk” 
Ductal Carcinoma in Situ (DCiS), Comparing radiation (rt) to 
observation (obS)
McCormick B, Winter K, Hudis C, Kuerer H, Rakovitch E, Smith B, 
Shah A, Germain I, Hartford A, Rashtian A, Walker E, Yuen A, Strom E, 
Kerlin K, Vallow L, Small W, Pu A, Wilcox J, White J. Memorial Sloan 
Kettering Cancer Center; RTOG Statistical Center; University of Texas 
MD Anderson Cancer Center; Toronto-Sunnybrook Regional Cancer 
Centre; Massachusetts General Hospital; York Cancer Center, York, 
PA; L Hotel-Dieu de Quebec; Dartmouth Hitchcock Medical Center; 
University of Southern California-Los Angeles; Henry Ford Hospital; 
Reading Hospital and Medical Center-PA; Southeast Cancer Control 
Consortium CCOP; Mayo Clinic Jacksonville; Northwestern University 
Feinberg School of Medicine; Radiological Associates of Sacramento; 
US Oncology, Greenville, SC; Medical College of Wisconsin. 
5:00 pm–7:00 pm  
poSter SeSSion ongoing trialS 1 
exhibit hall b
bone
ot1-01-01  prospective Clinical trial evaluating efficacy of Zoledronic 
acid (Za) prophylaxis for prevention of aromatase inhibitor 
associated musculoskeletal Symptoms: Zap-aimSS trial
Bardia A, Blackford A, Jeter S, Tarpinian K, Fetting JF, Miller R, Slater 
S, Henry NL, Giles J, Stearns V. Johns Hopkins Kimmel Cancer Center, 
Baltimore, MD; University of Michigan, Ann Arbor, MI; Columbia 
University, New York City, NY. 
ot1-01-02  a multicentre Study assessing 12-Weekly intravenous 
bisphosphonate therapy in Women with low risk bone 
metastases from breast Cancer - the triumph trial
Bouganim N, Hilton J, Vandermeer L, Hopkins S, Spencer P, Robbins 
D, Amir E, Dent S, Milano C, Ooi D, Dranitsaris G, Clemons M. The 
Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess 
Margaret Hospital, Toronto, ON, Canada; The Ottawa Hospital, 
Ottawa, ON, Canada. 
ot1-01-03  a phase 3 randomized, Double-blind, placebo-Controlled 
multicenter Study Comparing Denosumab with placebo as 
adjuvant treatment for Women with early-Stage breast 
Cancer Who are at high risk of Disease recurrence (D-Care)
Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martín M, Braun 
A, Ke C, Maniar T, Braun S, Dansey R, Coleman RE. Massachusetts 
General Hospital Cancer Center, Boston, MA; PUCRS School of 
Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, 
Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital 
Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; 
Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, 
Sheffield, United Kingdom. 
ot1-01-04 neo-ZotaC: a phase iii randomized trial with neoadjuvant 
Chemotherapy (taC) with or without Zoledronic acid for 
patients with her2-negative large resectable or locally 
advanced breast Cancer
van de Ven S, Nortier JWR, Liefers GJ, ten Tije A, Kessels L, van 
Laarhoven HWM, van Warmerdam LJC, Vriens B, van den Bosch J, 
van Meershoek-Klein Kranenbarg E, van Leeuwen E, Kroep JR. Leiden 
University Medical Center, Leiden, Netherlands; Amphia Hospital, 
Breda, Netherlands; Deventer Hospital, Deventer, Netherlands; 
University Medical Center St. Radboud Nijmegen, Nijmegen, 
Netherlands; Catharina Hospital, Eindhoven, Netherlands; Academic 
Hospital Maastricht, Maastricht, Netherlands; Albert Schweitzer 
Hospital, Dordrecht, Netherlands; BOOG Study Center, Amsterdam, 
Netherlands. 
her2
ot1-02-01  phase ii neoadjuvant trial of anthracycline based regimens 
Followed by a Combination with nanoparticle almumin-
bound paclitaxel and trastuzumab in patients with operable 
t2-3,n0-1,her2 positive breast Cancer
Iwamoto M, Takahashi Y, Kimura K, Tanaka S, Uchiyama K. 
OsakaMedical College, Osaka, Japan. 
ot1-02-02  halt mbC: her2 Suppression with the addition of lapatinib 
to trastuzumab in her2-positive metastatic breast Cancer 
(lpt112515)
Lin N, Danso M, David A, Muscato J, Ellis C, DeSilvio M, Garofalo 
A, Nagarwala Y, Winer E. Dana-Farber Cancer Institute; Virginia 
Oncology Associates; Augusta Oncology Associates; Missouri Cancer 
Associates; GlaxoSmithKline. 
21s
December 6-10, 2011
www.aacrjournals.org
Program Schedule
Cancer Res; 71(24 Suppl.) December 15, 2011
ot1-02-03  egF114299: Safety and efficacy of an aromatase inhibitor (ai) 
in Combination with lapatinib (l), trastuzumab (t) or both for 
the treatment of hormone receptor-positive (hr+), her2+ 
metastatic breast Cancer (mbC)
Johnston S, Leigh M, Florance A, Wroblewski S, Gradishar W. Royal 
Marsden NHS Foundation Trust & Institute of Cancer Research; 
GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Research Triangle 
Park, NC; Northwestern University. 
ot1-02-04  adjuvant pertuzumab and herceptin in initial therapy of 
breast Cancer: aphinity (big 4-11/bo25126/toC4939g)
von Minckwitz G, Baselga J, Bradbury I, de Azambuja E, Scullion 
MJ, Ross G, Saini KS, Piccart-Gebhart M. German Breast Group, 
Neu-Isenburg, Germany; Massachusetts General Hospital, Boston; 
Frontier Science and Technology Research Foundation, Scotland; 
BrEAST Data Center, Jules Bordet Institute, Brussels, Belgium; Roche, 
Welwyn Garden City, United Kingdom; Breast International Group 
Headquarters, Brussels, Belgium; Breast International Group, Brussels, 
Belgium. 
ot1-02-05  a phase iii Clinical trial Comparing trastuzumab given 
Concurrently with radiation therapy to radiation therapy 
(rt) alone for Women with her2-positive DCiS resected by 
lumpectomy: nSabp b-43
Julian TB, Anderson SJ, Cobleigh MA, Siziopikou KP, Arthur DW, 
Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Chu L, Leasure NC, 
Atkins JN, Polikoff J, Seay TE, McCaskill-Stevens W, Rabinovitch 
R, Wolmark N. National Surgical Breast & Bowel Project (NSABP, 
Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA; University 
of Pittsburgh Graduate School of Public Health and NSABP 
Biostatistical Center, Pittsburgh, PA; Rush University Medical Center, 
Chicago, IL; Northwestern University Feinberg School of Medicine, 
Chicago, IL; Virginia Commonwealth University, Richmond, VA; 
Aultman Health Foundation, Canton, OH; Colorado Cancer Research 
Program, Denver, CO; Iowa Oncology Research Association, Des 
Moines, IA; Florida Cancer Specialists, Sarasota, FL; Reading Regional 
Cancer Center, West Reading, PA; SCCC-CCOP, Goldsboro, NC; Kaiser 
Permanente Southern California, San Diego, CA; Atlanta Regional 
Community Clinical Oncology Program, Atlanta, GA; National Cancer 
Institute, Rockville, MD; University of Colorado, Aurora, CO. 
ot1-02-06  DeteCt iii - a multicenter, randomized, phase iii Study to 
Compare Standard therapy alone versus Standard therapy 
plus lapatinib in patients with initially her2-negative 
metastatic breast Cancer and her2-positive Circulating tumor 
Cells
Melcher CA, Janni W, Ortmann U, Jäger B, Rack B, Müller V, 
Schneeweiss A, Pantel K, Solomayer E-F, Fehm T. University Hospital 
Duesseldorf, Duesseldorf, Germany; University Hospital Munich, 
Munich, Germany; National Center for Tumor Diseases Heidelberg, 
Heidelberg, Germany; University Hospital Hamburg, Hamburg, 
Germany; University Hospital Homburg, Homburg/Saar, Germany; 
University Hospital Tuebingen, Tuebingen, Germany; University 
Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany. 
ot1-02-07  nSabp b-47: a randomized phase iii trial of adjuvant therapy 
Comparing Chemotherapy alone (Six Cycles of Docetaxel 
plus Cyclophosphamide or Four Cycles of Doxorubicin 
plus Cyclophosphamide Followed by Weekly paclitaxel) to 
Chemotherapy plus trastuzumab in Women with node-
positive or high-risk node-negative her2-low invasive breast 
Cancer
Fehrenbacher L, Jeong J-H, Rastogi P, Geyer CE, Paik S, Ganz PA, Land 
SR, Costantino JP, Swain SM, Mamounas EP, Wolmark N. National 
Surgical Adjuvant Breast and Bowel Project (NSABP) Operations 
and Biostatistical Centers; Kaiser Permanente, Northern California; 
University of Pittsburgh Graduate School of Public Health; University 
of Pittsburgh Cancer Institute, University of Pittsburgh School of 
Medicine; Allegheny General Hospital; Jonsson Comprehensive 
Cancer Center at UCLA; Washington Cancer Institute, Washington 
Hospital Center; Aultman Health Foundation. 
ot1-02-08  the perSephone trial: Duration of trastuzumab with 
Chemotherapy in Women with her2 positive early breast 
Cancer. Changing the randomisation point to address 
potential barriers to recruitment
Earl HM, Loi S, Vallier A-L, Hiller L, Ogburn-Storey E, Higgins H, Dunn 
J. Addenbrooke’s Hospital, Cambridge, United Kingdom; University 
of Warwick, Coventry, United Kingdom. 
ot1-02-09  a phase ii randomized trial of lapatinib with either 
vinorelbine or Capecitabine as First- and Second-line therapy 
for her2-overexpressing metastatic breast Cancer
Janni W, Pikiel J, Sarosiek T, Karaszewska B, Papadimitriou CA, 
Schwedler K, Alavarez Gallego J, Caruso M, Herve RA, Lau MR, 
Williams LS, Briggs K, Sapunar FJ. Heinrich-Heine-Universität; 
Wojewódzkie Centrum Onkologii; Centrum Medyczne Ostrobramska; 
Przychodnia Lekarska KOMED; Alexandra Hospital; Johann-Wolfgang-
Goethe-Universität; Hospital Provinval de Zamora; Humanitas Centro 
Catanese di Oncologia; Centre Médical Clarval; GlaxoSmithKline. 
OT1-02-10  Phase I-II Study of HER2 Vaccination with Poly(I) • Poly(C
12
u) 
(ampligen®) as an adjuvant in optimally treated breast 
Cancer patients
Higgins DM, Childs J, Parker S, Guthrie KA, Disis ML, Salazar LG. 
University of Washington, Seattle, WA; Fred Hutchinson Cancer 
Research Center, Seattle, WA. 
ot1-02-11  mother: a registry Developed for Women with breast Cancer 
Who have received trastuzumab within 6 months prior to 
Conception or during pregnancy
Brown VD, Andrews EB, Wang LI, Chu LK, Trudeau C, Keppler-Noreuil 
KM. Kendle International, Wilmington, NC; RTI International, Research 
Triangle Park, NC; Genentech, South San Francisco, CA; Univ. of Iowa 
Hospital and Clinics, Iowa City, IA. 
ot1-02-12  early Detection of Cardiotoxicity by advanced Cardiac imaging 
and a novel biomarker in breast Cancer patients undergoing 
Chemotherapy
Marfatia R, Inyangetor D, Decena K, Kumar S, Alluri N, Yang C, Hager 
D, Fellows D, Runowicz CR, Kaloudis E, Liang BT, Tannenbaum S, 
Avelar E. University of Connecticut Health Center, Farmington, CT. 
ot1-02-13  Cardiac biomarkers on trastuzumab (Cabot trial): Determining 
the Cardiac biomarker profile in breast Cancer patients 
receiving adjuvant trastuzumab therapy
Kumar VNC, Kavsak P, Rask S, Mukherjee SD, Ellis P, Dhesy-Thind B. 
Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Juravinski 
Hospital, Hamilton, ON, Canada; Juravinski Cancer Centre, Hamilton, 
ON, Canada. 
prognostic and predictive markers
ot1-03-01  a randomized phase iii Clinical trial of Standard adjuvant 
endocrine therapy +/- Chemotherapy in patients (pts) with 
1-3 positive nodes, hormone receptor (hr)-positive and 
her2-negative breast Cancer with recurrence Score (rS) of 25 
or less: SWog S1007
Gonzalez-Angulo AM, Barlow WE, Gralow JR, Meric-Bernstam F, 
Hayes DF, Moinpour CM, Ramsey SD, Schott AF, Sparks DB, Albain KS, 
Hortobagyi GN. MD Anderson Cancer Center, Houston, TX; Cancer 
Research And Biostatistics, Seattle, WA; Seattle Cancer Care Alliance/
University of Washington, Seattle, WA; University of Michigan, 
Ann Arbor, MI; Fred Hutchinson Cancer Research Ctr, Seattle, 
WA; University of Michigan and SWOG, Ann Arbor, MI; SWOG, 
San Antonio, TX; Loyola Univ Chicago Stritch School of Medicine, 
Maywood, IL. 
ot1-03-02  SaFir01: a molecular Screening trial for metastatic breast 
Cancer patients
Andre F, Peletekian C, Jimenez M, Ferrero, Delaloge S, Roman Roman 
S, Dessen P, Bonnefoi H. Gustave Roussy Institute; Unicancer; Curie 
Institute; Bergonie Institute; Centre antoine lacassagne, Nice, France. 
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ot1-03-03  effect of tamoxifen therapy on inhibition of tumor 
Suppressor p53 by estrogen receptor
Kulkarni S, Fetterly GJ, Morrison CD, Adjei AA, Andrews C, Edge 
SP, Mukhopadhyay UK, Swetzig WM, Das GM. Roswell Park Cancer 
Institute, Buffalo, NY.
7:30 pm–9:30 pm
open Satellite event 
marriott rivercenter, grand ballroom
Second Opinion-An Interactive Case-Based Symposium on the 
management of Patients with Early and Advanced Breast Cancer
Website: http://www.researchtopractice.com/Meetings/SA2011 
 thurSDay, DeCember 8, 2011
6:45 am–5:15 pm 
regiStration  
bridge hall 
7:00 am–9:00 am 
poSter SeSSion 2 & Continental breakFaSt   
exhibit halls a-b
tumor Cell biology: tumor progression, invasion, and metastasis 
p2-01-01  Withdrawn 
p2-01-02  pharmacological inhibition of rankl attenuates mammary 
tumor Development and lung metastases in the mmtv-neu 
transgenic Spontaneous tumor model
Branstetter D, Jacob A, Soriano R, Allred S, Jones J, Miller R, Dougall 
WC. Amgen, Inc., Seattle, WA. 
p2-01-03  insulin-like growth Factor i (igF) induced metastasis 
Signature Correlates with poor prognosis and Decreased 
Distant metastasis-Free Survival in human breast Cancer
Sachdev D, Sarver AL. University of Minnesota, Minneapolis, MN. 
p2-01-04  the post-partum Diagnosis of pregnancy associated breast 
Cancer Confers an increased risk for metastasis without 
increased incidence of poorer prognosis biologic Subtype
Borges VF, Callihan ES, Jindal S, Lyons T, Manthey E, Gao D, Schedin 
PJ. University of Colorado Anschutz Medical Campus, Aurora, CO; 
Colorado School of Public Health, Aurora, CO; University of Colorado 
School of Medicine, Aurora, CO. 
p2-01-05  integrin αvβ6 mediates her2-Driven invasion in breast Cancer
Moore KM, Hart IR, Jones LJ, Marshall JF. Barts Cancer Institute - a 
CR-UK Centre of Excellence, Queen Mary University of London, 
London, Greater London, United Kingdom. 
p2-01-06  nSaiD analgesic ketorolac used perioperatively may Suppress 
early breast Cancer relapse: Something for nothing in breast 
Cancer?
Retsky MW, Rogers RA, Demicheli R, Hrushesky WJM, Gukas 
ID, Vaidya JS, Baum M, Forget P, De Kock M. Harvard School of 
Public Health, Boston, MA; Istituto Nazionale Tumori, Milano, Italy; 
University of South Carolina, Columbia, SC; James Paget University 
Hospital, Great Yarmouth, United Kingdom; Royal Free and UCL 
Medical School, London, United Kingdom; Cliniques Universitaires 
Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium. 
p2-01-07  proto-oncogene pelp1 promotes metastasis through mir-200 
Dependent pathway
Saha Roy S, Rao M, Sun L, Tekmal RR, Vadlamudi RK. UTHSCSA, San 
Antonio, TX. 
p2-01-08  Withdrawn 
p2-01-09  gene expression alterations in the lymph node 
microenvironment in response to Successful metastatic 
Colonization
Ellsworth RE, Valente AL, Kane JL, Ellsworth DL, Shriver CD. Henry 
M. Jackson Foundation, Windber, PA; Windber Research Institute, 
Windber, PA; Walter Reed Army Medical Center, Washington, DC. 
p2-01-10  blockage of autocrine tgF-b Signaling reduces 
tumorigenecity and lung metastasis in a murine breast 
Cancer Cell line, nmumg-St
Liu Z, Robert NW, Wang L, Bandyopadhyay A, Sun L-Z. University of 
Texas Health Science Center at San Antonio, San Antonio, TX; First 
Affiliated Hospital of Nanjing Medical University, Nanjing, JiangSu, 
China. 
p2-01-11  Fish oil targets mir-21 to increase pten expression for 
inhibition of bone metastatic CSF-1 in breast Cancer Cells
Mandal CC, Ghosh-Choudhury T, Ghosh Choudhury G, Ghosh-
Choudhury N. University of Texas Health Science Center at San 
Antonio, San Antonio, TX; Baylor College of Medicine, Houston, TX. 
p2-01-12  Determining the molecular Signature that Drives breast 
Cancer-induced brain metastasis in a mouse Xenograft model
Mukhopadhyay KD, Elkahloun AG, Yoon K, Cornell JE, Yu L, Liu Z, 
Sun L-Z. UT Health Science Center, San Antonio, TX; National Human 
Genome Research Institute- NIH, Bethesda, MD. 
p2-01-13  impact of erlotinib on mSC-mediated tiC expansion and emt
Lacerda L, Solley T, Debeb B, Xu W, Krisnamurthy S, Ueno N, Reuben 
J, Klopp A, Woodward W. UT MD Anderson Cancer Center, Houston, 
TX. 
p2-01-14  high level of CD44 expression and Soluble CD44 Secretion 
mediate trastuzumab resistance in her2 positive breast 
Cancer
Jin Q, Baek JM, Boulbes DR, Esteva FJ. MD Anderson Cancer Center, 
Houston, TX. 
p2-01-15  rt-pCr gene profiling for the prediction of bone metastases in 
primary breast Cancer
Ibrahim T, Mercatali L, Ricci R, Scarpi E, Liverani C, Serra L, Guerra D, 
Ciani S, Amadori D. Istituto Scientifico Romagnolo per lo Studio e la 
Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; I.R.S.T., Meldola, (FC), 
Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy. 
p2-01-16  Dissecting the Cellular mechanism of induction and 
Sustenance of Dormancy by rho gtpases in breast Cancer
Chatterjee M, van Golen KL. University of Delaware, Newark, DE. 
p2-01-17  l1-Cam promotes adhesion of breast Cancer Cells to the 
endothelium
Milde-Langosch K, Dippel V, Schröder C, Wicklein D, Hein S, Jänicke 
F, Müller V, Schumacher U. University Medical Center Hamburg-
Eppendorf, Hamburg, Germany. 
p2-01-18  Cancer Stem-like Cells in breast Cancer progression
Valejo FAM, Andrade JM, Sicchieri RD, Antonio HMR, Marana HRC, 
Mouro LR, Oliveira TMG, Benevides L, Silva JS, Muglia VF, Tiezzi DG. 
Faculdade de Medicina de Ribeirão Preto - University of São Paulo, 
Ribeirão preto, SP, Brazil. 
p2-01-19  expression of receptor like protein tyrosine phosphatases mu 
(ptprm) in breast Cancer and the biological effects of ptprm 
on breast Cancer Cells
Sun P-H, Ye L, Mansel RE, Jiang WG. Cardiff University School of 
Medicine, Cardiff, Wales, United Kingdom. 
p2-01-20  reduced plakoglobin expression increases the metastatic 
potential of breast Cancer Cells
Ottewell PD, Whitworth J, Cross SS, Nutter FH, Holen I. University of 
Sheffield, Sheffield, Yorkshire, United Kingdom. 
p2-01-21  the biological influence of brain Derived neurotrophic Factor 
(bDnF) on the aggressiveness of human breast Cancer Cells
Yang MX, Martin TA, Jiang WG. Capital Medical University, Beijing, 
China; Cardiff University School of Medicine, Cardiff, United Kingdom. 
p2-01-22  Characterization of Four er-negative breast primary tumor 
Dissociated Cultures as a model for the in vitro and in vivo 
Study of tumorigenesis, metastasis and angiogenesis
Drews-Elger K, Brinkman JA, Dean SJ, El-Ashry D. University of Miami, 
Miller School of Medicine, Miami, FL. 
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p2-01-23  Seprase promotes the growth and impairs the migratory 
ability of breast Cancer Cells
Jia J, Martin TA, Jiang WG. Peking University, Beijing, China; Cardiff 
University School of Medicine, Cardiff, United Kingdom. 
p2-01-24  triple-negative breast Cancer emerges from the luminal 
progenitor Compartment
Nogi H, Kamio M, Kato K, Kawaase K, Toriumi Y, Takeyama H, Uchida 
K. The Jikei University School of Medicine, Tokyo, Japan. 
p2-01-25  truncated p110 erbb2 (CtF611) increases migration and 
invasion of breast epithelial Cells by inhibiting Stat5b 
activation
Ward TM, Iorns E, Hoe N, Kim P, Singh S, Ernani V, Liu X, Jegg A-M, 
Gallas M, Lippman ME, Pegram MD. University of Miami Miller School 
of Medicine, Miami, FL; Prometheus Laboratories, San Diego, CA. 
p2-01-26  timpv: a novel downstream transcriptional target gene that 
underpins CD146-suppressed breast tumor invasion
Ouhtit A, Abdelmageed Z, Fernando A, Gaur RL, Raj MHG. College 
of Medicine & Health Sciences, Sultan Qaboos University, Muscat, 
Oman; Louisiana State University Health Sciences Center; Stanley S 
Scott Cancer Center, New Orleans, LA. 
p2-01-27  Withdrawn 
tumor Cell biology: oncogenes/tumor Suppressor genes
p2-02-01  a novel inflammatory breast Cancer-Specific oncogene, 
tazarotene-induced gene 1, promotes tumorigenicity and 
invasiveness through the receptor tyrosine kinase axl
Wang X, Saso H, Iwamoto T, Pusztai L, Gong Y, Woodward WA, 
Reuben JM, Hortobagyi GN, Ueno NT. Morgan Welch Inflammatory 
Breast Cancer Clinic; The University of Texas MD Anderson Cancer 
Center, Houston, TX; University of Texas MD Anderson Cancer 
Center, Houston, TX. 
p2-02-02  mutation of the apC tumor Suppressor Stimulates breast 
Cancer Cell proliferation through hyperactivation of Fak/Src/
jnk Signaling
Prosperi JR, Yang FF, Goss KH. University of Chicago, Chicago, IL. 
p2-02-03  map3k3, amplified in human breast Cancer, promotes breast 
tumor progression and Defines poor prognosis
Dong J. Baylor College of Medicine, Houston, TX. 
p2-02-04  novel Functions of vps34 in non-transformed epithelial Cells: 
regulation of Cell proliferation and tumorigenesis
Su H, Xu T, Ganapathy S, Yuan Z-M. UTHSCSA, San Antonio, TX. 
p2-02-05  molecular mechanism for Src homology phosphotyrosyl 
phosphatase 2 regulation of Cell motility and migration
Hartman ZR, Agazie YM. West Virginia University School of Medicine, 
Morgantown, WV. 
p2-02-06  inhibition of CDk4 phosphorylation of Smad3 Decreases 
Cyclin D overexpressing breast Cancer Cell proliferation and 
migration
Tarasewicz E, Hardy A, Straehla J, Foucar C, Zelivianski S, Jeruss J. 
Northwestern University Feinberg School of Medicine, Chicago, IL. 
p2-02-07  regulation of mtor Signaling by proto-oncogene pelp1
Gonugunta VK, Cortez V, Rethman C, Nair BC, Sareddy GR, Vadlamudi 
RK. UTHSCSA, San Antonio, TX. 
p2-02-08  int6 regulates both proteasomal Degradation and translation 
initiation and is Critical for proper Formation of acini by 
human mammary epithelium
Suo J, Snider SJ, Lloyd RE, Chang EC. BCM. 
p2-02-09  tp53 mutation patterns in breast Cancer Subgroups
Dumay A, Feugeas J-P, Wittmer E, Lehmann-Che J, Bertheau P, Espié 
M, de Cremoux P, André F, Sotiriou C, Pusztai L, de Thé H. Hôpital 
Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; 
Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer 
Center, Houston. 
p2-02-10  Differential targeting of the rb-pathway to expand the 
therapeutic index in the treatment of triple negative breast 
Cancer
Knudsen ES, Dean J, Thangavel C, Ertel A, Witkiewicz AK, McClendon 
AK.  Thomas Jefferson University, Philadelphia, PA.
tumor Cell biology: growth Factors
p2-03-01  genetic reduction of Circulating insulin-like growth Factor 
(igF)-1 Differentially impacts the effects of Diet-induced 
obesity and Calorie restriction on mammary tumor 
progression
Ford NA, Nunez NP, Perkins SN, Hursting SD. University of Texas at 
Austin, Austin, TX; National Cancer Institution, Rockville, MD. 
p2-03-02  an igF1r antibody Does not inhibit growth of tamoxifen 
resistant mCF-7 Cells
Fagan DH, Yee D. University of Minnesota, Minneapolis, MN. 
p2-03-03  an insulin-like growth Factor i (igF-i)-induced gene, Solute 
Carrier Family 7 member 11 (SlC7a11)/xCt, mediates igF-i-
induced biological behaviors in breast Cancer Cells
Yang Y, Becker MA, Yee D. University of Minnesota, Minneapolis, MN. 
p2-03-04  novel pathways underlying the initiation and transition of 
DCiS to iDC of her2-overexpressing breast Cancer model
Pradeep CR, Koestler W, Lauriola M, Nair H, Rao R, Mills GB, Yarden 
Y. MD Anderson Cancer Centre, Houston, TX; Weizmann Institute 
of Science, Rehovot, Israel; Southwest National Primate Research 
Center, San Antonio, TX; University of Texas Health Science Center 
San Antonio, San Antonio, TX. 
p2-03-05  attenuation of tgF-beta Signaling Suppresses premature 
Senescence in a p21-Dependent manner and promotes 
oncogenic ras-mediated metastatic transformation in htert-
immortalized basal-like human mammary epithelial Cells
Lin S, Yang J, Elkahloun AG, Bandyopadhyay A, Wang L, Cornell JE, 
Yeh I-T, Agyin JK, Sun L-Z. University of Texas Health Science Center, 
San Antonio, TX; NHGRI-NIH, Bethesda, MD. 
p2-03-06  endothelin-1/endothelin a receptor Signalling in breast 
Cancer
Tamkus D, Leece C, Gallo K, Madhukar BV, Dimitrov N. Michigan State 
University (MSU). 
tumor Cell biology: apoptosis and Senescence
p2-04-01  extracellular pai-1 - t-pa - igFbp3 Cascade mediates 
Chemotherapy-induced Senescence of breast Cancer Cells
Shiio Y, Elzi DJ, Song M, Hakala K, Weintraub ST. The University of 
Texas Health Science Center, San Antonio, TX. 
p2-04-02  identification of a novel glycosyltransferase-like gene as an 
autophagic inducer in human mammary Carcinoma Cells via 
Down regulation of bCl-2
Shastri BG, Jung Y, Steiner M, Perry JK, Lobie PE, Liu D-X. Liggins 
Institute, Auckland, New Zealand; Cancer Science Institute of 
Singapore, Singapore, Singapore. 
tumor Cell biology: angiogenesis
p2-05-01  acquired tamoxifen resistance promotes angiogenic 
responses in er+ breast Cancer Cells
Hayes E, Smith C, Nicholson RI, Gee J, Hiscox S. Cardiff University, 
Wales, United Kingdom. 
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p2-05-02  pgC1, peroxisome proliferator activated receptor-gamma 
(ppar-gamma) Coactivator-1, is necessary in ppar-gamma 
modulated angiogenesis
Jiang WG, Li X, Mansel RE. Cardiff University School of Medicine, 
Cardiff, Wales, United Kingdom. 
p2-05-03  is breast Cancer tryptase a novel anti-angiogenetic molecular 
target?
Ranieri G, Gadaleta-Caldarola G, Misino A, Patruno R, Goffredo V, Di 
Lecce V, Vinciarelli G, Valerio P, Zito A, Gadaleta CD. National Cancer 
Institute “G. Paolo II”, Bari, Italy; Di Venere Hospital, Bari, Italy. 
p2-05-04  mapping the Specific gene Families activated in the 
lymphangiogenesis and vasculogenic mimicry exhibited by 
inflammatory breast Cancer
Liu H, Luo AZ, Mu Z, Chu K, Ye Z, Alpaugh RK, Fernandez S, Boley 
KM, Jin J, Wright MC, Cristofanilli M, Robertson FM. The University of 
Texas, MD Anderson Cancer Center, Houston, TX; Fox Chase Cancer 
Center, Philadelphia, PA. 
p2-05-05  receptor-like protein tyrosine phosphatase kappa (ptprk) 
and its biological role in angiogenesis
Sun P-H, Ye L, Mason MD, Jiang WG. Cardiff University School of 
Medicine, Cardiff, United Kingdom. 
p2-05-06  role of repulsive guidance molecule b (rgmb) in hgF 
mediated angiogenesis
Sanders AJ, Ye L, Mason MD, Jiang WG. Cardiff University School of 
Medicine, Cardiff, United Kingdom. 
p2-05-07  Combined antiangiogenic and anti-estrogen therapy in 
breast Cancer. molecular mechanisms involved
de la Haba J, Berciano M, Cañabate M, Porras I, Valverde A, Cañas A, 
Rodriguez A, Aranda E. Hospital Universitario Reina Sofia, Institute 
for Biomedical Research Maimonides IMIBIC, Cordoba, CO, Spain; 
Hospital General Universitario, Ciudad Real, CR, Spain. 
p2-05-08  expression of ve-Statin/egfl7 in breast Cancer
Lauridant-Philippin G, Baranzelli M-C, Fournier C, Samson C, Soncin F, 
Bonneterre J. Centre Oscar Lambret, Lille, France; Institut de Biologie 
de Lille - CNRS UMR 8161, Lille, France; Université Lille Nord de 
France, Lille, France. 
p2-05-09  Secondary inflammatory breast Cancer: a possible model for 
post-Surgical Dissemination of Cancer
Hashmi S, Zolfaghari L, Levine PH. George Washington University, 
Washington, DC. 
p2-05-10  brain-Derived neurotrophic Factor, bDnF, and its biological 
impact on vascular endothelial Cells
Jiang WG, Ye L, Yang X, Mansel RE. Cardiff University School of 
Medicine, Cardiff, Wales, United Kingdom; Capital Medical University, 
Beijing, China. 
tumor Cell biology: genetics – Somatic Changes
p2-06-01  genomic instability in breast Cancers from atomic bomb 
Survivors: an analysis of microarray-Comparative genomic 
hybridization with old archival tissues
Oikawa M, Yoshiura K-i, Kondo H, Miura S, Kurashige T, Nagayasu 
T, Yano H, Nakashima M. Atomic Bomb Disease Institute, Nagasaki 
University Graduate School of Biomedical Sciences, Nagasaki, 
Japan; Nagasaki University Graduate School of Biomedical Sciences, 
Nagasaki, Japan. 
p2-06-02  FoXo3a genotype predicts age of breast Cancer onset and 
Correlates with lymph node involvement
Brouwers B, Lambrechts D, Hatse S, Dieudonné A-S, Remmerie 
C, Neven P, Smeets A, Paridaens R, Wildiers H. Universitaire 
Ziekenhuizen Leuven, Leuven, Belgium; Katholieke Universiteit 
Leuven, Leuven, Belgium. 
p2-06-03  Differential expression of breast Cancer-associated genes 
between Stage- and age-matched tumor Specimens from 
african- and Caucasian-american Women Diagnosed with 
breast Cancer
Grizzle WE, Steg AD, He Q, Steciuk MR, Byan-Parker S, Johnson MR, 
Grunda JM. University of Alabama at Birmingham, Birmingham, AL; 
Tuskegee University, Tuskegee, AL. 
p2-06-04  phosphatidylinositol-3-kinase pathway mutations are 
Common in breast Columnar Cell lesions
Troxell ML, Brunner AL, Montgomery K, Zhu SX, Neff T, Warrick A, 
Beadling C, Corless CL, West RB. Oregon Health & Science University, 
Portland, OR; Stanford University, Stanford, CA. 
tumor Cell biology: genetics – germline Changes
p2-07-01  Copy number variants in early-onset-breast Cancer
Ludwig S, Ivanovich J, Graubert TA, Goodfellow PJ. Washington 
University in St.Louis, SOM, St. Louis, MO. 
p2-07-02  germline genetic variants Disturbing the let-7/lin28 Double-
negative Feedback loop alter breast Cancer Susceptibility
Yu K-D, Shao Z-M, Chen A-X. Fudan University Shanghai Cancer 
Center, Shanghai, China. 
p2-07-03  Collective evidence Suggests neutrality for brCa1 v1687i, a 
novel Sequence variant in the Conserved thv motif of the 
First brCt repeat
Cortesi L, De Nicolo A, Medici V, Marino M, Turchetti D, Pradella LM, 
Rossi G, Parisini E, Federico M. University of Modena and Reggio 
Emilia, Modena, Italy; Dana-Farber Cancer Institute, Boston, MA; 
Harvard Medical School, Boston, MA; University of Bologna, Bologna, 
Italy; Italian Institute of Technology, Milan, Italy. 
Detection and Diagnosis – imaging and Screening: breast imaging – mri
p2-08-01  impact of aromatase inhibitors on background parenchymal 
enhancement and amount of Fibroglandular tissue on breast 
mri
Goldfarb SB, King V, Sung J, Pike M, Nulsen B, Jozefara J, Hudis C, 
Morris E, Dickler M. Memorial Sloan-Kettering Cancer Center, New 
York, NY. 
p2-08-02  magnetic resonance imaging as a predictor of pathologic 
response in patients treated with neoadjuvant Systemic 
treatment for operable breast Cancer (tbCrC 017)
De Los Santos J, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, 
Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. 
University of Alabama at Birmingham, Birmingham, AL; University 
of North Carolina Chapel Hill, Chapel Hill, NC; Dana-Farber Cancer 
Institute, Boston, MA; Duke University Medical Center, Durham, NC; 
Memorial Sloan Kettering Cancer Center, New York, NY; University 
of Pittsburgh Medical Center, Pittsburgh, PA; MD Anderson Cancer 
Center, Houston, TX; Vanderbilt University, Nashville, TN; University 
of Chicago, Chicago, IL; University of California at San Francisco, San 
Francisco, CA. 
p2-08-03  Quantitative mri for noninvasive prediction of prognostic 
markers in breast Cancer
Parsian S, Sun R, Kurland BF, Rahbar H, Allison KH, Specht JM, 
DeMartini WB, Lehman CD, Partridge SC. University of Washington, 
Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. 
p2-08-04  Computer-Derived breast mri Features have Complementary 
value for preoperative Selection of Systemic Drug therapy in 
node-negative Stage-i/ii breast Cancer patients
Gilhuijs KGA, Pengel KE, Dmitriev I, Paape A, Rutgers EEJt, 
Wesseling J, Loo CE. The University Medical Center Utrecht, 
Utrecht, Netherlands; The Netherlands Cancer Insitute/Antoni van 
Leeuwenhoek Hospital, Amsterdam, Netherlands. 
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p2-08-05  use of Dynamic Contrast-enhanced mr imaging to predict 
pathological response in primary breast Cancer
Boni V, Pina LJ, Hernando B, Lopez-Vega JM, Calvo EG, Plazaola A, 
Morales S, Anton A, Sanchez-Gomez RM, Alvarez I, Illarramendi JJ, 
De Juan A, Martinez P, Llombart A, La Huerta A, Dominguez I, Garcia-
Velloso MJ, Garcia-Gonzalez M, Lao Romera J, Puertolas T, Scherer S, 
Sabariz L, Garcia-Foncillas J. Clinic University of Navarra, Pamplona, 
Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de 
Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital 
Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San 
Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; 
Roche Madrid. 
p2-08-06  improved Spatial resolution Diffusion-Weighted imaging for 
Characterizing tumors and treatment response in patients 
with invasive breast Cancer
Wilmes LJ, McLaughlin R, Sinha S, Singer L, Proctor E, Wisner D, 
Newitt DN, Shankaranarayanan A, Joe BN, Hylton NM. University of 
California San Francisco, San Francisco, CA; GE Healthcare, Menlo 
Park, CA. 
p2-08-07  ex-vivo high resolution mri of Sentinel lymph nodes 
Following Subcutaneous injection of Superparamagnetic iron 
oxide nanoparticles
Douek M, ter Beek O, Johnson L, Pankhurst Q, Parikh J, Schaeffter T, 
Purushotham A, Charles-Eduards G. King’s College London, London, 
United Kingdom; The Royal Institution of Great Britain, London, 
United Kingdom; Guy’s & St Thomas’ Hospitals, London, United 
Kingdom. 
p2-08-08  benefit of preoperative breast mri in patients with newly 
Diagnosed breast Cancer
Miesbauer M, Sheu H, Schoissengeier A, Kirchweger B, Waldenberger 
P. St. Vincent Hospital, Linz, Austria. 
p2-08-09  the impact of preoperative breast mri in newly Diagnosed 
breast Cancer. a prospective Study of treatment outcome 
in patients Selected for breast-Conserving Surgery in a 
norwegian multidisciplinary breast Cancer Clinic
Rabben T, Rodegerdts E, Bachmann H, Funder V. Department of 
Surgery, Nordland Hospital, Bodø, Norway; Department of Radiology, 
Nordland Hospital, Bodø, Norway; Faculty of Health Sciences, 
University of Tromsø, Tromsø, Norway. 
p2-08-10  Withdrawn
p2-08-11  Correlation of mammography, ultrasound and mri in patients 
with nipple Discharge
Deshmane VH, Mulani S, Lodh N, Pungavkar S, Bhaduri A, Deshpande 
R, Madiwale C. P.D. Hinduja National Hospital, Mumbai, Maharashtra, 
India; Nanavati Hospital, Mumbai, Maharashtra, India. 
p2-08-12  additional lesion Found in preoperative breast mri; is routine 
use justified?
Kim J, You J, Shin H, Ahn S, Moon H-G, Cho N, Moon W-K, Han W, 
Noh D. Seoul National University Hospital, Seoul, Korea. 
p2-08-13  Does routine use of preoperative magnetic resonance 
imaging (mri) in breast Cancer influence the outcome?
Große R, Kantelhardt EJ, Steer S, Spinda AK, Vetter M, Ruschke K, 
Thomssen C. Martin-Luther-University Halle-Wittenberg, Halle 
(Saale), Germany. 
Detection and Diagnosis – imaging and Screening: molecular, Functional, 
and novel imaging
p2-09-01  First-in-human Whole-body her2-receptor mapping using 
affibody molecular imaging
Sandberg D, Wennborg A, Feldwisch J, Sörensen J, Garske U, 
Carlsson J, Lindman H. Uppsala University, Uppsala, Sweden; 
Affibody AB, Stockholm, Gunnar Asplunds Allé 24, Sweden. 
p2-09-02  predicting response to bevacizumab in primary breast Cancer 
using 18F-Fluorothymidina (Flt) and 18F-misonidazole 
(miSo) positron emission/Computed tomography (pet/Ct) as 
imaging biomarkers
Dominguez I, Boni V, Garcia-Velloso MJ, Lopez-Vega JM, Martinez 
P, Plazaola A, Llombart A, Anton A, Galve E, Alvarez IM, Hernando B, 
Sanchez-Gomez R, Illarramendi JJ, Morales S, De Juan A, Richter JA, 
Lahuerta A, Garcia-Gonzalez M, Lao Romera J, Puertolas T, Scherer 
S, Sabariz L, Garcia-Foncillas J. Clinic University of Navarra; Hospital 
Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital 
Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil 
de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; 
Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche 
Madrid. 
p2-09-03  breast Cancer Detection using a novel Functional imaging 
Device equipped with multiparametric Computer analysis
Sella T, Sklair-Levy M, Maya C, Rozin M, Tanir A, Maira S, Libson E, 
Izhaky D. Hadassah Hebrew University Medical Center, Jerusalem, 
Israel; Chaim Sheba Medical Center, Tel Hashomer, Israel; Rabin 
Medical Center, Petach Tikva, Israel; Assuta Medical Center, Tel-Aviv, 
Israel; Kaplan Medical Center, Rehovot, Israel; Meir Medical Center, 
Kfar Sava, Israel; Real Imaging Ltd., Airport City, Israel. 
p2-09-04  near infra red Quantum Dots as novel probes for Sentinel 
lymph node biopsy
Rizvi SB, Yang SY, Bala R, Shirin G, Seifalian AM, Keshtgar M. 
University College London, London, Hampstead, United Kingdom. 
p2-09-05  molecular imaging of hedgehog induced epithelial-Stromal 
interactions
Woodward W, Sims-Mourtada J, Yang DJ, Tworowska I, Larson R, 
Smith D, Mourtada F. RadioMedix, Inc, Houston, TX; The University of 
Texas M.D. Anderson Cancer Center, Houston, TX. 
p2-09-06  relevance of breast Cancer Subtypes in response monitoring 
with 18F-FDg pet/Ct during neoadjuvant Chemotherapy
Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters 
M-J, Gilhuijs KG, Rutgers EJ, Valdés Olmos RA. Netherlands Cancer 
Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, 
Netherlands. 
p2-09-07  metabolic response by FDg-pet in patients (pts) receiving 
trastuzumab (t) and lapatinib (l) for her2+ metastatic breast 
Cancer (mbC): Correlative analysis of tbCrC 003
Yap JT, Locascio T, Najita JS, Mayer IA, Hobday TJ, Falkson CI, Dees 
EC, Gelman RS, Rimawi MF, Nanda R, Berkowitz J, Franchetti Y, Wolff 
AC, Winer EP, Lin NU, Van den Abbeele AD. Dana-Farber Cancer 
Institute, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, 
TN; Mayo Clinic, Rochester, MN; University of Alabama, Birmingham, 
AL; University of North Carolina at Chapel Hill, Chapel Hill, NC; Baylor 
College of Medicine, Houston, TX; University of Chicago, Chicago, IL; 
Johns Hopkins Kimmel Cancer Center, Baltimore, MD. 
p2-09-08  FDg-pet in the Staging of the axilla in Women with breast 
Cancer treated with primary Chemotherapy
Lao Romera J, Puértolas Hernandez T, Alvarez Alejandro M, Godoy 
Molias A, Hernandez Garcia A, Millastre Bocos E, Garcia Mur C, Ubieto 
Laguarda MA, Artal Cortes A, Anton Torres A. Hospital Universitario 
Miguel Servet, Zaragoza, Spain; Clinica Quirón, Zaragoza, Spain. 
p2-09-09  Dynamic FDg pet and DCe-mri to assess tumor metabolism 
and blood Flow in response to neoadjuvant Sunitinib and 
paclitaxel Followed by aC + g-CSF in patients with locally-
advanced (labC) and/or inflammatory breast Cancer (ibC)
Specht JM, Kurland BF, Dunnwald LK, Doot RK, Eun JK, Schubert 
EK, Partridge SC, Ellis GK, Gadi VK, Gralow JR, Linden HM, Rodler ET, 
Mankoff DA. University of Washington, Seattle, WA; Fred Hutchinson 
Cancer Research Center, Seattle, WA; Seattle Cancer Care Alliance, 
Seattle, WA. 
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p2-09-10  giant or Windmill? 18F-FDg-pet/Ct Semi-Quantitative 
parameters and biological prognostic parameters in Women 
with breast Cancer treated with neoadjuvant Chemotherapy: 
a multicentric Study in la mancha
Muñoz-Sánchez MdM, García-Vicente A, Ortega-Ruipérez C, Palomar-
Muñoz A, Molina-Garrido MJ, Olaverri-Hernández A, Santiago-Crespo 
JA, Martín-Ordóñez F, Val-Pérez E, Cordero-García JM, Chacón JI, 
Fernández-Aramburu A, Espinosa J, Viana A, Soriano-Castrejón 
A. Hospital General Virgen de la Luz, Cuenca, Spain; Hospital 
General Universitario de Ciudad Real, Ciudad Real, Spain; Complejo 
Hospitalario de Toledo, Toledo, Spain; Complejo Hospitalario 
Universitario de Alabacete, Albacete, Spain; Hospital General Ntra Sª 
del Prado, Talavera, Toledo, Spain. 
p2-09-11  role of 18FDg-pet/Ct in the Staging of large primary 
operable breast Cancer
Groheux D, Giacchetti S, Hamy A-S, Vercellino L, Delord M, Berenger 
N, Toubert M-E, Misset J-L, Hindié E, Espié M. Saint-Louis Hospital, 
Paris, France; IUH, University of Paris VII, Paris, France. 
p2-09-12  high resolution Diffusion mri Characterizes tumor Stromal 
boundaries
McLaughlin RL, Newitt DC, Wilmes LJ, Sinha S, Wisner DJ, Hylton NM. 
UC Berkeley and UCSF, Berkeley and San Francisco, CA; UCSF, San 
Francisco, CA. 
p2-09-13  the value of FDg pet/Ct in Screening Detected breast Cancer 
patients
Koo HR, Moon WK, Cho N, Chang JM, Kang KW, Yi A. Seoul National 
University Hospital, Seoul, Korea. 
p2-09-14  evaluation of angiogenesis using Synchrotron radiation in 
Xenograft mouse models of breast Cancer
Gu S-m, Zhang X, Li R-m, Jin W, Shen Z-z, Shao Z-m, Xu X-m, Wu 
J. Cancer Hospital/Institute, Fudan University, Shanghai, China; 
Shanghai Jiao Tong University, Shanghai, China. 
p2-09-15  Functional measurements of tumor response during 
neoadjuvant Chemotherapy infusion and early during 
treatment using Diffuse optical Spectroscopic imaging
Roblyer D, Ueda S, Cerussi AE, Durkin A, Leproux A, Santoro Y, Xu 
S, Mehta R, Hsiang D, Butler J, Tromberg B. University of California, 
Irvine, CA; University of California, Irvine, Orange, CA. 
Detection and Diagnosis – imaging and Screening:  
breast imaging – other methods
p2-10-01  extracellular matrix Stiffness and mammographic Density in 
the human breast
Acerbi I, Au A, Chen Y-y, Hwang S, Weaver V. Center for 
Bioengineering and Tissue Regeneration, University of California San 
Francisco, San Francisco, CA; University of California San Francisco, 
San Francisco, CA; Eli and Edythe Broad Center of Regeneration 
Medicine and Stem Cell Research and Helen Diller Family 
Comprehensive Cancer Center, UCSF, San Francisco, CA. 
p2-10-02  assessment of tumor response to neoadjuvant 
Chemotherapy using ultrasound-guided near infrared light
Zhu Q, DeFusco P, Tannenbaum S, Ricci A, Cronin E, Hegde P, Kane 
M, Tavakoli B, Xu Y. University of Connecticut, Storrs, CT; Hartford 
Hospital, Hartford, CT; University of Connecticut Health Center, 
Farmington, CT. 
p2-10-03  non-invasive in vivo Characterization of Cancer-Cell 
proliferation & angiogenesis in Cancer-Cell-Surrounding 
Stromal microenvironment in-vivo using Diffuse optical 
tomography
Chung SH, Feldman M, Choe R, Martinez D, Yodh AG. University 
of Pennsylvania; Hospital of the University of Pennsylvania; The 
Children’s Hospital of Philadelphia; University of Rochester. 
p2-10-04  3D mapping of total Choline in human breast Cancer using 
high-Speed mr Spectroscopic imaging at 3t: a Feasibility 
Study
Posse S, Royce M, Dayao ZR, Zhang T, Zhao C, Sillerud L, Lopez S, 
Casey L, Eberhardt SC, Lomo L, Lee S-J, Rosenberg R, Rajput A, Bolan 
P. University of New Mexico School of Medicine, Albuquerque, NM; 
University of New Mexico Cancer Center, Albuquerque, NM; New 
Mexico Cancer Center, Albuquerque, NM; University of Minnesota, 
Minneapolis, MN. 
p2-10-05  Cryo-microcomputed tomography (Ct) with Synchrotron 
radiation: visualization of human breast Cancer tissue and 
Comparison with their histopathologic Findings
Jeong Y-J, Jeong H-Y, Bong J-G, Park S-H, Kim H-T, Kim J-K, Huang 
J-Y. Daegu Catholic University Medical Center, Daegu, Republic 
of Korea; Pohang University of Science and Technology, Pohang, 
Republic of Korea. 
p2-10-06  prospective ultrasonographic prediction of Sentinel 
lymph node metastasis by real-time virtual Sonography 
Constructed with three-Dimensional Computed tomography-
lymphography in breast Cancer patients
Yamamoto S, Maeda N, Yoshimura K, Oka M. Yamaguchi University 
Graduate School of Medicine, Ube, Yamaguchi, Japan. 
p2-10-07  triple-negative breast Cancer may have ultrasonographic 
Features mimicking nonmalignant lesions
Wojcinski S, Farrokh A, Schmidt J, Hillemanns P, Degenhardt F. 
Franziskus Hospital, Bielefeld, Germany; Hannover Medical School, 
Hannover, Germany. 
p2-10-08  electrical impedance imaging Characteristics of nodular and 
edematous-infiltrative Forms of breast Cancer
Korotkova M, Karpov A, Bulatov A, Frizyuk A. Clinical Hospital 9, 
Yaroslavl, Russian Federation. 
p2-10-09 Detecting breast Cancer with Dynamic Diffuse optical 
tomographic imaging
Flexman ML, Kim HK, Lim E, Desperito E, Barbour RL, Hershman DL, 
Hielscher AH. Columbia University, New York, NY; State University of 
New York, Brooklyn, NY. 
p2-10-10  a precision Comparison of breast ultrasound images between 
Different time phases by imaging Fusion technique using 
magnetic position tracking System
Nakano S, Fujii K, Yorozuya K, Yoshida M, Fukutomi T, Arai O, Mitake 
T. Aichi Medical University, Nagakute, Aichi-gun, Japan; Hitachi 
Medical Corporation. 
prognosis/response predictions: prognostic Factors and biomarkers – 
preclinical
p2-11-01  validation of predictive Dna Damage response (DDr) assay in 
luminal b and basal-like breast Cancers
Rodriguez AA, Mao Y, Zhao H, Wong S, Chang JC. The Methodist 
Research Institute, Houston, TX. 
p2-11-02  brain-Derived neurotrophic Factor expression is associated 
with poor prognosis in human breast Cancer
Patani N, Jiang WG, Mokbel K. The London Breast Institute, The 
Princess Grace Hospital, London, United Kingdom; University 
Department of Surgery, Cardiff University School of Medicine, 
Cardiff, United Kingdom; Brunel Institute of Cancer Genetics and 
Pharmacogenomics, Brunel University, London, United Kingdom. 
p2-11-03  high expression of CX3Cl1 by tumor Cells Correlates with 
a good prognosis and increased infiltrating CD8+ t Cells, 
natural killer Cells, and Dendritic Cells in breast Carcinoma
Lee JS, Park MH, Yoon JH. Chonnam National University Medical 
School, Gwangju, Republic of Korea. 
p2-11-04  tmepai is a Feedback regulator of tgF-β Signaling during 
breast Cancer progression
Singha PK, Pandeswara S, De La Chapa JJ, Venkatachalam MA, 
Saikumar P. UT Health Science Center at San Antonio, San Antonio, 
TX. 
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p2-11-05  Stromal matrix metalloproteinase-14 expression Correlates 
with the grade and biological behavior of mammary phyllodes 
tumors
Lee JS, Park MH, Yoon JH. Chonnam National University Medical 
School, Gwangju, Republic of Korea. 
p2-11-06  pten loss in asian triple negative breast Cancer is a Frequent 
event associated with basal markers, tumour grade and 
younger age of onset
Dean S, Rhodes A, Holly J, Perks C, Looi L-AM, Mun KS, Taib NA, 
Yip CH. University of the West of England, Bristol, United Kingdom; 
University of Bristol, Bristol, United Kingdom; University of Malaya, 
Kuala Lumpur, Malaysia. 
p2-11-07  expression of Selected predictive markers in african american 
Women with atypical hyperplasia of the breast
Bandyopadhyay S, Cote M, Visscher DW, Ruterbusch J, Albashiti B, 
Alosh B, Frost MH, Hartmann LC, Fehmi RA. Wayne State University/
KCI/DMC, Detroit, MI; Wayne State University/KCI, Detroit, MI; Mayo 
Clinic Cancer Center, Rochester, MN. 
p2-11-08  Clinical value of Combination assay for Quantitative 
Determination of Cancer biomarkers C2p and upa/pai-1 for 
Disease recurrence prediction of early breast Cancer patients
Schmitt M, Kiechle M, Schwarz-Boeger U, Langer R, Nakayama S, 
Matsushima T, Ishihara H. Technical University of Munich, Munich, 
Germany; Sysmex Corporation, Kobe, Japan. 
p2-11-09  egFr overexpression in triple negative breast Cancer (tnbC) 
and its association with the prognosis
Liu W, Zhang L, Ma K, Han B, Li S, Xu G, Fan Z, Liu N, Shi A. The First 
Hospital of Jilin University, Changchun, JILin, China; The 208 Hospital 
of People’s Liberation Army, Changchun, JILin, China; The Central 
Hospital of Siping, Siping, JILin, China; The Second Hospital of Jilin 
University, Changchun, JILin, China. 
p2-11-10  low toll-like receptor 9 expression is required for the 
aggressive behavior of triple negative breast Cancer Cells in 
hypoxia
Selander KS, Tuomela J, Sandholm J, Karihtala P, Pressey C, Ilvesaro 
J, Vuopala K, Kauppila JH, Kauppila S, Harris KW, Graves D, Jukkola-
Vuorinen A. University of Alabama at Birmingham, Birmingham, AL; 
Oulu University Hospital, Oulu, Finland; University of Oulu, Oulu, 
Finland. 
p2-11-11  igFbp ratio Confers resistance to igF targeting and Correlates 
with increased invasion and poor outcome in breast tumors
Becker MA, Hou X, Harrington SC, Carboni JM, Gottardis MM, Haluska 
P. Mayo Clinic, Rochester, MN; Bristol Myers Squibb Pharmaceutical 
Research Institute, Princeton, NJ. 
prognosis/response predictions: prognostic Factors and biomarkers – 
Clinical – i
p2-12-01  immunohistochemical (ihC) bag1 expression improves the 
estimation of residual risk (rr) by ihC4 in postmenopausal 
patients treated with anastrozole or tamoxifen: a transataC 
Study
Dowsett M, Afentakis M, Pineda S, Salter J, Howell A, Buzdar 
A, Forbes JF, Cuzick J. Royal Marsden Hospital, London, United 
Kingdom; Wolfson Institute of Preventive Medicine, London, 
United Kingdom; Christie Hospital, Manchester, United Kingdom; 
MD Anderson Cancer Center, Houston; University of Newcastle, 
Newcastle, Australia. 
p2-12-02  Correlation between bmi and Clinical outcome of patients 
with early Stage her2+ breast Cancer from the n9831 Clinical 
trial
Crozier JA, Moreno-Aspitia A, Ballman KV, Martino S, Kutteh LA, 
Davidson NE, Kaufman PA, Perez EA. Mayo Clinic, Jacksonville, 
FL; Mayo Clinic, Rochester, MN; The Angeles Clinic and Research 
Institute, Santa Monica, CA; Oncology Associates at Mercy Medical 
Center, Cedar Rapids, IA; University of Pittsburgh Cancer Institute, 
Pittsburgh, PA; Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
p2-12-03  a prospective Study of the prognostic implications of being a 
brCa1 Carrier for young onset breast Cancer patients
Eccles DM, Dent L, Gerty SM, Altman D, Copson ER, Simmonds 
PD, Durcan L, Ward D. University of Southampton, Southampton, 
Hampshire, United Kingdom; Oxford University, Oxford, United 
Kingdom; Southamtpon University Hospitals NHS Trust, 
Southampton, Hampshire, United Kingdom; Salisbury District 
Hospital, Salisbury, Witshire, United Kingdom. 
p2-12-04  raCgap1 mrna assay outperforms ki-67 as a proliferation 
marker in the Finher Study Cohort
Wirtz RM, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen P-L, 
Kataja V, Turpeenniemi-Hujanen T, Jyrkkiö S, Huang W, Eidt S, 
Joensuu H. STRATIFYER Molecular Pathology GmbH, Cologne, 
Germany; Pharma, Finland; Helsinki University Central Hospital and 
University of Helsinki, Finland; University of Tampere and Tampere 
University Hospital, Finland; Tampere University Hospital, Finland; 
Kuopio University Hospital, Finland; Oulu University Hospital, Finland; 
Turku University Hospital, Finland; Monogram Biosciences, Inc.; 
Institute of Pathology at the St-Elisabeth-Hospital, Germany. 
p2-12-05  Correlation between Quantitative her2 protein expression 
and risk of brain metastases in her2-positive advanced breast 
Cancer patients receiving trastuzumab-Containing therapy
Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, 
Haddad M, Paquet A, Lie Y, Czartoryska-Arlukowicz B, Wysocki 
P, Jankowski T, Radecka B, Foszczynska-Kloda M, Litwiniuk M, 
Debska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J. Military 
Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, 
Gdansk, Poland; Monogram Biosciences, South San Francisco, 
CA; International Drug Development Institute, Louvain-la-Neuve, 
Belgium; Bialystok Oncology Center, Bialystok, Poland; Great Poland 
Cancer Center, Poznan, Poland; Lublin Oncology Center, Lublin, 
Poland; Opole Oncology Center, Opole, Poland; West Pomeranian 
Oncology Center, Szczecin, Poland; Poznan University of Medical 
Sciences, Poznan, Poland; Regional Cancer Center, Lódz, Poland; 
Cepheid, Sunnyvale, CA. 
p2-12-06  nomogram to predict Subsequent bone metastasis in patients 
with non metastatic breast Carcinomas
Lousquy R, Delpech Y, Rouzier R, Gligorov J, Hsu L, Barranger E, 
Pusztai L, Uzan S, Hortobagyi GN, Coutant C, Ibrahim NK. Lariboisiere 
Hospital, AP-HP, Paris, France, Metropolitan; Tenon Hospital, AP-HP, 
Paris, France, Metropolitan; The University of Texas M.D. Anderson 
Cancer Center, Houston, TX; Georges Francois Leclerc Cancer Center, 
Dijon, France, Metropolitan. 
p2-12-07  pooled analysis of outcomes of t1a/bn0, her2-amplified 
breast Cancer
Amir E, Seruga B, Ocana A, Carlsson L, Bedard P. Princess Margaret 
Hospital, Toronto, Canada; Institute of Oncology Ljubljana, Ljubljana, 
Slovenia; Albacete University Hospital, Albacete, Spain. 
p2-12-08  bcl-2 as a prognostic marker in breast Cancer patients 
receiving endocrine therapy
Larsen MS, Bjerre KD, Laenkholm A-V, Giobbie-Hurder A, Ejlertsen 
B, Lykkesfeldt AE, Rasmussen BB. Herlev Hospital, Herlev, Denmark; 
Rigshospitalet, Copenhagen, Denmark; Dana-Farber Cancer 
Institute, Boston, MA; Danish Cancer Society, Inst of Cancer Biology, 
Copenhagen, Denmark. 
p2-12-09  prediction of risk of recurrence (rrr) after 5-years of Follow-
up by ki-67 and ihC4: a transataC Study
Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Buzdar A, Forbes 
JF, Dowsett M. Queen Mary University of London, London, United 
Kingdom; Royal Marsden Hospital and Breakthrough Breast Cancer 
Centre, London, United Kingdom; Christie Hospital, Manchester, 
United Kingdom; University of Texas, Texas; University of Newcastle, 
Newcastle, NSW, Australia. 
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p2-12-10  low tCr Diversity (Divpenia) is a prognosis Factor of overall 
Survival in metastatic breast Cancer
Manuel M, Tredan O, Bachelot T, Parmentier G, Courtier A, Rabeony 
T, Chabaud S, Mouret J-F, Grives A, Perez S, Clapisson G, Blay J-Y, 
Caux C, Pasqual N, Menetrier-Caux C. CRCL UMR INSERM 1052 CNRS 
5286, Centre Léon Bérard, Lyon, France; ImmunID Technologies, 
Grenoble, France; Centre Léon Bérard, Lyon, France. 
p2-12-11  Clinical relevance of a il-8/b-Cell gene Signature identified 
from triple negative breast Cancer (tnbC) in intrinsic breast 
Cancer Subtypes
Rody A, Holtrich U, Ruckhaeberle E, Radosa J, Juhasz-Boess I, 
Solomayer EF, Kaufmann M, Karn T. Saarland University, Homburg, 
Germany; Goethe-University, Frankfurt, Germany. 
p2-12-12  prognostic utility of breast Cancer index for late relapse in 
patients with early Stage breast Cancer
Schnabel CA, Zhang Y, Kesty NC, Erlander MG. bioTheranostics, Inc, 
San Diego, CA. 
p2-12-13  topoisomerase 2 alpha (top2a) rna expression provides 
prognostic information in hormone receptor positive breast 
Cancer that is Complementary to a Simulated algorithm for 
recurrence Score
Sparano JA, Goldstein LJ, Davidson NE, Sledge, Jr GW, Gray R. Albert 
Einstein College of Medicine, Montefiore Medical Center, Bronx, NY; 
Fox Chase Cancer Center, Philadelphia, PA; University of Pittsburgh, 
Pittsburgh, PA; Indiana University, Indianapolis, IN; Eastern 
Cooperative Oncology Group, Brookline, MA. 
p2-12-14  prognostic value of her2 positivity and negative hormonal 
Status in patients with Small tumor (<1cm) and node-
negative breast Cancer
Meattini I, Livi L, Saieva C, Agresti B, Scotti V, Nori J, Sanchez LJ, 
Vezzosi V, Bianchi S, Cataliotti L, Biti G. Florence University, Florence, 
Italy; Cancer Prevention and Research Institute, Florence, Italy. 
p2-12-15  gainS: a breast Cancer prognostic index utilizing lymph node 
ratio
Dorairaj JJ, Wall D, Newell J, Blamey RW, Sweeney KJ, Ball G, 
Kerin MJ. National University of Ireland, Galway, Ireland; Breast 
Institute, Nottingham City Hospital, Nottingham, United Kingdom; 
Nottingham Trent University, Nottingham, United Kingdom. 
p2-12-16  her2 expression is the major risk Factor for recurrence in 
pt1a-b,n0 breast Cancer: a French regional population-based 
Study of 671 patients
Rouanet P, Daures JP, Roger P, Mathieu A, Romieu G, Cretin J, 
Barneon G, Granier M, Maran-Gonzalez A, Thibault S, Boissiere 
F, Bibeau F. Val d’Aurelle Cancer Institute, Montpellier, France; 
Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, 
France; ONCO LR Regional Network, Montpellier, France. 
p2-12-17  prospective evaluation of the Conversion rate of her2, er and 
pr between primary tumors and Corresponding metastases. 
Converther/geiCam 2009-03 Study
Martinez de Dueñas E, Lluch A, Guerrero A, Chacon JI, Perez R, 
Antolin S, Blancas I, Ferrer-Lozano J, Burgues O, Lopez A, Gonzalez-
Angulo AM. Hospital Provincial de Castellon, Castellon, Spain; 
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto 
Valenciano de Oncologia, Valencia, Spain; Hospital Virgen de la Salud 
de Toledo, Toledo, Spain; Hospital Universitario Quiron, Madrid, 
Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, 
Spain; Hospital Clinico San Cecilio de Granada, Granada, Spain; MD 
Anderson Cancer Center, Houston, TX. 
p2-12-18  a prognostic model based on node Status, Cathpesin-D and 
ki-67 predict the outcome of patients Failing to achieve 
pathological Complete response after anthracycline-based 
neoadjuvant Chemotherapy for breast Cancer
Chen S, Chen C, Yu K, Shao Z. Shanghai Cancer Hospital, Fudan 
University, Shanghai, China. 
p2-12-19  nomogram to predict recurrence and to avoid unnecessary 
adjuvant Chemotherapy based on ki67 index and er Status 
in hormone receptor (hr)-positive breast Cancers with low 
number of nodal metastases (≤3) (nCt01273415)
Park YH, Im S-A, Cho EY, Ahn JH, Kim S, Keam B, Han W, Park IA, 
Noh D-Y, Lee JE, Nam SJ, Yang JH, Ahn JS, Im Y-H. Samsung Medical 
Center; Seoul National University College of Medicine. 
p2-12-20  adjuvant! online is overoptimistic in predicting Survival of 
asian breast Cancer patients
Bhoo Pathy N, Yip CH, Hartman M, Saxena N, Taib NA, Bulgiba AM, 
van der Graaf Y, Verkooijen HM. University of Malaya; University 
Medical Center Utrecht; Ministry of Health Malaysia; National 
University of Singapore; Karolinska Institutet. 
p2-12-21  impact of recent parity on histopathological tumor Features 
and outcome of young Women with breast Cancer
Nagatsuma AK, Shimizu C, Tsuda H, Saji S, Hojo T, Sugano K, Fujiwara 
Y. National Cancer Center Hospital; Saitama Medical University 
International Medical Center; Tochigi Cancer Center Research 
Institute. 
p2-12-22  a prognostic index Composed of progesterone receptor 
Status, tumour Size and S-phase Fraction, predicts Survival in 
node-negative breast Cancer patients in a large multicentre 
prospective Cohort Study
Klintman M, Nilsson F, Bendahl P-O, Fernö M, Liljegren G, Emdin S, 
Malmström P. Clinical Sciences, Lund University and Skane University 
Hospital, Lund, Sweden; University of Umeå and Umeå University 
Hospital, Umeå, Sweden; örebo University Hospital, örebro, Sweden. 
p2-12-23  how Should We assess tumour Size (t Stage) in patients with 
multicentric/multifocal breast Cancer? results from the nCiC 
Ctg ma.5 randomized trial of CeF vs. CmF in pre-menopausal 
Women with node positive breast Cancer
Bouganim N, Dong B, Hilton JF, Chapman J-AW, Arnaout A, O’Malley 
F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan 
T, Pritchard KI, Shepherd L, Clemons M. The Ottawa Cancer Center, 
Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; 
The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-
University of Toronto, Toronto, ON, Canada; Vancouver Hospital and 
Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency- 
University of British Columbia, Vancouver, BC, Canada; Juravinski 
Cancer Center-McMaster University, Hamilton, ON, Canada; Tom 
Baker Cancer Center-University of Calgary, Calgary, AB, Canada; 
Odette Cancer Center-University of Toronto, Toronto, ON, Canada. 
p2-12-24  resumption or persistence of menstruation after Cytotoxic 
Chemotherapy is a poor prognostic Factor for Disease Free 
Survival in premenopausal patients with early breast Cancer
Park IH, Han H-S, Lee KS, Kang HS, Lee S, Kim SW, Jung SY, Shin KH, 
Ro J. National Cancer Center, Goyang, Korea; Chungbuk National 
University, Korea. 
p2-12-25  blinded multi-Site validation of a pathology-based prognostic 
marker profile for operable hormone receptor-positive breast 
Cancer
Linke SP, Bremer TM, Man AK, Bloom KJ, Lawton TJ. Prediction 
Sciences, La Jolla, CA; Clarient, Inc., Aliso Viejo, CA; Seattle Breast 
Pathology Consultants, Seattle, WA. 
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p2-12-26  impact of the recurrence Score on adjuvant Decision-
making in er-positive early breast Cancer - results of a large 
prospective multicentre Decision impact Study in node 
negative and node positive Disease
Rezai M, Eiermann W, Kümmel S, Kühn T, Warm M, Friedrichs K, 
Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, Jackisch C, 
Witzel I, Eidtmann H, Kaufmann M, Blohmer JU. Luisenkrankenhaus, 
Düsseldorf, Germany; Rotkreuzklinikum, München, Germany; 
Kliniken Essen-Mitte, Essen, Germany; Klinikum Esslingen, Esslingen, 
Germany; Krankenhaus Holweide, Köln, Germany; Brustzentrum, 
Hamburg, Germany; Universitätsklinikum, Heidelberg, Germany; 
Universitätsklinikum, Rostock, Germany; Universitätsklinikum, 
Magdeburg, Germany; Eilenriedeklinik, Hannover, Germany; 
Klinikum Offenbach, Offenbach, Germany; Universitätsklinikum 
Eppendorf, Hamburg, Germany; Universitätsklinikum, Kiel, Germany; 
Univesitätsklinikum, Frankfurt, Germany; Sankt Gertrauden-
Krankenhaus, Berlin, Germany. 
p2-12-27  Simply adding together the Diameters of tumor Foci in 
patients with multicentric or multifocal Disease Does not add 
any additional prognostic information: an analysis from nCiC 
Ctg ma.12 randomized placebo-Controlled trial of tamoxifen 
after adjuvant Chemotherapy in pre-menopausal Women with 
early breast Cancer
Hilton JF, Dong B, Bouganim N, Chapman J-AW, Arnaout A, O’Malley 
F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan 
T, Pritchard KI, Shepherd L, Clemons M. Queens University, Kingston, 
ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, 
ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, 
Canada; Vancouver Hospital and Health Sciences Centre, University 
of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, 
University of British Columbia, Vancouver, BC, Canada; Juravinski 
Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom 
Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; 
Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. 
p2-12-28  Studies of a malignancy-associated protein, osteopontin, in 
nCiC Ctg ma.14, a randomized trial of tamoxifen versus 
Combined tamoxifen and octreotide lar in adjuvant 
treatment of Women with early breast Cancer
Bramwell VH, Tuck AB, Chapman J-A, Anborgh PH, Postenka CO, 
Shepherd L, Pritchard KI, Han L, Wilson C, Pollak M, Chambers AF. 
Tom Baker Cancer Centre, Calgary, AB, Canada; London Regional 
Cancer Program, London, ON, Canada; NCIC Clinical Trials Group, 
Kingston, ON, Canada. 
p2-12-30  pre-operative haematological markers and prognosis in early 
breast Cancer
Cordiner RL, Mansell J, Obondo C, Angerson WJ, Lannigan A, 
McMillan D, Wilson CR, Doughty JC. Western Infirmary, Glasgow, 
United Kingdom; Wishaw General Hospital, Wishaw, United 
Kingdom. 
p2-12-31  moderate immunohistochemical expression of her2 (2+) 
without her2 gene-amplification is a negative prognostic 
Factor in early breast Cancer
Rossi V, Sarotto I, Maggiorotto F, Tomasi Cont N, Redana S, Aglietta 
M, Ponzone R, Montemurro F. Institute for Cancer Research and 
Treatment IRCC, Candiolo, Turin, Italy. 
p2-12-32  association between progranulin (gp88) expression and 
recurrence risk for breast Cancer patients with estrogen 
receptor positive invasive Ductal Carcinoma
Serrero G, Hawkins DM, Ioffe O, Bejarano P, Phillips JT, Head JF, Elliott 
RL, Godwin AK, Weaver J, Yue B.  A&G Pharmaceutical Inc, Columbia, 
MD; University of Minnesota, Minneapolis, MN; University of 
Maryland, Baltimore, MD; University of Miami, Miami, FL; EEH Breast 
Cancer Research and Treatment Center, Baton Rouge, LA; University 
of Kansas Medical Center, Kansas City, KS; Fox Chase Cancer Center, 
Philadelphia, PA. 
p2-12-33  Withdrawn 
epidemiology, risk, and prevention: Familial breast Cancer – genetic 
testing
p2-13-01  gene profiling of Whole blood may identify patients with 
brCa mutations
Mina LA, Gokmen-Polar Y, Goswami C, Storniolo AM, Li L, Badve S, 
Sledge GW. Indiana University School of Medicine, Indianapolis, IN. 
p2-13-02  parent of origin of brCa mutation may Determine age at 
breast Cancer Diagnosis
Shapira I, Budman DR, Akerman M, Weiselberg L, Vinciguerra V, 
D’Olimpio J, Devoe C, Cheng K, Donahue L, John V, Cohen S. Hofstra 
North Shore LIJ School of Medicine, Lake Success, NY; Feistein 
Institute for Medical Research, Manhasset, NY. 
p2-13-03  Comparative assessment of 636 Women at risk for hereditary 
breast Cancer within 3 public hospitals: the Consortium of 
underserved brCa testers
Beattie MS, Ganschow P, Gabram-Mendola S, Wilson A, Joseph G, 
Lee R, Loranger K, Stanislaw C, Seelaus C, Farrell R, Trim L, DelPozo 
S, Luce J. University of California, San Francisco, CA; San Francisco 
General Hospital, San Francisco, CA; Stroger Hospital of Cook County, 
Chicago, IL; Rush University Medical Center, Chicago, IL; Emory 
University, Atlanta, GA; Grady Memorial Hospital, Atlanta, GA. 
p2-13-04  testing Women with invasive lobular breast Cancer for brCa 
mutations
Turco DL, Elsayegh N, Litton J, Hortobagyi GN, Arun B. M.D. Anderson 
Cancer Center, Houston, TX. 
p2-13-05  breast Cancer, brCa mutations and attitudes regarding 
pregnancy and preimplantation genetic Diagnosis
Litton JK, Etzel CJ, Jackson MA, Muse KI, Turco D, Schover LR, 
Theriault RL, Mattair D, Lu KH, Hortobagyi GN, Arun BK. The 
University of Texas MD Anderson Cancer Center, Houston, TX. 
p2-13-06  Withdrawn 
p2-13-07  prevalence of germline brCa1 and brCa2 Deleterious 
mutations in brazilian patients with high-risk of breast and 
ovarian Cancer
Diz MDPE, Escobar KA, Guindalini RSC, Pasini FS, Snitkoviski IML, 
Maistro S, Hoff PMG, Federico MHH. Instituto do Cancer do Estado de 
Sao Paulo, Sao Paulo, Brazil; Faculdade de Medicina da Universidade 
de Sao Paulo, Sao Paulo, Brazil. 
p2-13-08  a retrospective Study on Surveillance behaviour and 
prophylaxis after genetic testing for hereditary breast and 
ovarian Cancer among high-risk Chinese Females
Kwong A, Chu ATW. The University of Hong Kong, Hong Kong; The 
Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong. 
p2-13-09  First Statewide experience with telephone Delivery of Cancer 
genetic Counseling
Pruski-Clark J, Trivedi A, Kelle S, Rebecca S. Informed Medical 
Decisions, Inc., St. Petersburg, FL. 
p2-13-10  Detection, visualization and high resolution physical 
mapping of large rearrangements by molecular Combing in 
the hereditary breast Cancer genes brCa1 and brCa2
Ceppi M, Roleau E, Cheeseman K, Thomas A, Briaux A, Lefol C, 
Walrafen P, Bensimon A, Lidereau R, Conseiller E. Genomic Vision, 
Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, 
France. 
p2-13-11  Follow up of brCa1/2 Carriers: the Spectrum of Cancer 
Diagnoses in healthy at risk individuals (htr), and in Cancer 
Survivors (CS)
Clara AI, Costa CS, Silva J, Marques JC, Moura C, André S, Luís A, 
Bento S, Opinião A, Rodrigues P, Machado P, Fragoso S, Santos S, Vaz 
F. Instituto Português de Oncologia, Lisbon, Portugal. 
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p2-13-12  the impact of a directive counseling procedure in families 
with a brCa1/2 gene mutation: uptake of predictive genetic 
testing and general outcome
Sermijn E, Teugels E, Fontaine C, Vanhoeij M, Cosyns S, Goossens M, 
De Roo V, Pauwels I, Bonduelle M, De Greve J.  UZ Brussel, Brussels, 
Belgium. 
epidemiology, risk, and prevention: ethnic/racial aspects
p2-14-01  race, response to Chemotherapy, and outcome within 
Clinical breast Cancer Subtypes
Tichy JR, Deal AM, Anders CK, Carey LA. UNC, Chapel Hill, NC. 
p2-14-02  nCiC Ctg ma.27: Clinical tolerability and overall Survival of 
racial and ethnic minority Women on aromatase inhibitor 
therapy
Moy B, Shepherd LE, Chapman J-AW, Le Maitre A, Gelmon KA, Elliott 
C, Ingle JN, Goss PE. Massachusetts General Hospital, Boston, MA; 
National Cancer Institute of Canada Clinical Trials Group, Kingston, 
ON, Canada; British Columbia Cancer Agency, Vancouver, BC, 
Canada; Mayo Clinic, Rochester, MN. 
p2-14-03  a Comparison of biologic Differences in tumors in a matched 
Cohort of hispanic and Caucasian Women with early-Stage 
breast Cancer using the 21-gene recurrence Score assay
Lim EA, Hershman DL, Greenlee H, Crew KD, Maurer MA, Hibshoosh 
H, Kalinsky K. Columbia University Medical Center, New York, NY; 
Mailman School of Public Health, New York, NY. 
p2-14-04  the influence of Demographic, psychosocial and emotional 
barriers to Screening for Colorectal and ovarian Cancer among 
latina breast Cancer Survivors
Ramirez AG, Holden AE, San Miguel SL, Gallion KJ. UT Health Science 
Center at San Antonio, San Antonio, TX. 
p2-14-05  racial Differences in the use of adjuvant Chemotherapy for 
breast Cancer in a large urban integrated health System
Simon MS, Lamerato L, Krajenta R, Booza J, Ruterbusch J, Kunz S, 
Schwartz K. Karmanos Cancer Institute at Wayne State University, 
Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State 
University, Detroit, MI. 
p2-14-06  Clinical and pathologic Characteristics of haitian breast Cancer 
patients in a tertiary Care Safety net hospital
Loch MM, Ross AA, Rosenberg C, Blanchard RA. Boston University 
Medical Center, Boston, MA; Boston University, Boston, MA. 
p2-14-07  ethnic Differences in breast Cancer molecular Subtypes and 
Survival outcomes in a multi-ethnic Singaporean population
Yap Y-S, Lo S-K, Ng RCH, Dent R, Ramya G, Chen WJJ, Ho G-H, 
Chua E-T, Tan P-H, Wong N-S. National Cancer Centre Singapore, 
Singapore, Singapore; Singapore General Hospital, Outram Road, 
Singapore, Singapore. 
p2-14-08  hormone receptor Status and breast Cancer Survival among 
hispanic and non-hispanic White Women over 10 years of 
Follow-up
Denkhoff SR, Baumgartner KB, Yang D, Pinkston CM, Baumgartner 
RN. University of Louisville, Louisville, KY. 
p2-14-09  Comparison between Spanish and peruvian patients with 
early breast Cancer
Castaneda CA, Gomez HL, Vallejos C, Cortes-Funes H, Castellano D, 
Andrés E, Cruz W, Ciruelos EM. Instituto Nacional de Enfermedades 
Neoplásicas, Lima, Peru; Hospital Universitario 12 de Octubre, 
Madrid, Spain. 
p2-14-10  are there variations in invasive tumour Characteristics 
between Different ethnic groups?
Hariri B, Lo M, Gandamihardja T, Lewis J, Hogben K. Imperial College 
Healthcare NHS Trust, Charing Cross Hospital, London, United 
Kingdom. 
treatment – local: Surgery
p2-15-01  Surgical patterns of Care after magnetic resonance imaging in 
the academic Setting in patients with operable breast Cancer 
treated with neoadjuvant Systemic therapy: a Secondary 
analysis of tbCrC 017
De Los Santos J, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, 
Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. 
University of Alabama at Birmingham, Birmingham, AL; University 
of North Carolina Chapel Hill, Chapel Hill, NC; Dana-Farber Cancer 
Institute, Boston, MA; Duke University Medical Center, Durham, NC; 
Memorial Sloan Kettering Cancer Center, New York, NY; University 
of Pittsburgh Medical Center, Pittsburgh, PA; MD Anderson Cancer 
Center, Houston, TX; Vanderbilt University, Nashville, TN; University 
of Chicago, Chicago, IL; University of California at San Francisco, San 
Francisco, CA. 
p2-15-02  are We performing more mastectomies on Women Diagnosed 
with invasive breast Cancer?
Lo MCI, Hariri B, Gandamihardja T, Lewis J, Hogben K. Imperial 
College Healthcare NHS Trust, Charing Cross Hospital, London, 
United Kingdom. 
p2-15-03  nipple-Sparing mastectomy for breast Cancer in japanese 
experience: an assessment from long Follow-up Data of 
Complication and Cancer Control in 806 patients
Sakurai T, Sakurai T, Umemura T, Jinta E, Suzuma T, Yoshimura G. 
Wakayama Medical University Kihoku Hospital, Ito, Wakayama, 
Japan; Sakurai Breast Clinic, Wakayama, Japan; Kiwa Hospital, Japan; 
Kushimoto Arida Hospital, Japan; Kishiwada Shimin Hospital, Japan. 
p2-15-04  Clinical Significance of resection with Curative intent for 
isolated pulmonary metastases from breast Cancer. multi-
institutional Study in japan
Sato N, Ohsumi S, Iwase T, Inaji H, Mizutani M, Nishimura R, Mukai 
H. Niigata Cancer Center Hospital, Niigata, Japan; National Hospital 
Organization Shikoku Cancer Center, Matsuyama, Japan; Cancer 
Institute Hospital, Tokyo, Japan; Osaka Medical Center for Cancer 
and Cardiovascular Diseases, Osaka, Japan; National Hospital 
Organization Osaka National Hospital, Osaka, Japan; Kumamoto City 
Hospital, Kumamoto, Japan; National Cancer Center Hospital East, 
Kashiwa, Japan. 
p2-15-05  excision of the primary tumour in patients with metastatic 
breast Cancer - Will e2108 provide the Definitive answer?
Samiee S, Berardi P, Bouganim N, Vandermeer L, Arnaout A, Mirsky 
D, Dent S, Caudrelier J-M, Chasen M, Clemons M. Ottawa General 
Cancer Centre, Ottawa, ON, Canada. 
p2-15-06  breast Cancer liver metastases - possibilities and limits of 
Surgical treatment
Narsanska A, Treskova I, Treska V, Skalicky T, Sutnar A. University 
Hospital and Medical Faculty Pilsen, Charles University Prague, Pilsen, 
Czech Republic. 
p2-15-07  the need for additional Surgeries to adequately excise 
early breast Cancers may have a negative impact on local 
recurrence
Warburton R, Alriyees L, Wang DY, Wong SL, Leong W. University 
Health Network, University of Toronto, Toronto, ON, Canada. 
p2-15-08  new trends for Surgical treatment of large breast tumors
Zucca Matthes AG, Vieira RAC, Kerr LM, Matthes ACS, Folgueira 
MAAK, Uemura G. Barretos’Cancer Hospital, Barretos, SP, Brazil; 
School of Medicine of Botucatu - UNESP, Botucatu, SP, Brazil; USP, 
Sao Paulo, SP, Brazil; University Barão de Mauá, Ribeirão Preto, SP, 
Brazil. 
p2-15-09  prospective randomized Comparison of Conventional 
instruments and the harmonic Focus® Device in breast-
Conserving therapy for primary breast Cancer
Böhm D, Kubitza A, Lebrecht A, Schmidt M, Kölbl H. University 
Medical Centre, Mainz, Germany. 
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p2-15-10  Do patients with incurable advanced breast tumor and 
Distant metastasis Derive any benefit from primary tumor 
resection?
Takahashi M, Shibasaki S, Jotoku H, Watanabe K-i. Hokkaido Cancer 
Center, Sapporo, Hokkaido, Japan. 
p2-15-11  outcomes of Corrective procedure with vicryl mesh as an 
oncoplastic Surgery of the breast
Lim YA, Lee YO, Kim JH, Kim HS, Kang HJ, Kim LS. Hallym Sacred 
Heart Hospital, College of Medicine, Hallym University, Anyang, 
Gyeonggi-do, Korea. 
p2-15-12  management Strategy of early-Stage breast Cancer patients: 
With or without axillary lymph node Dissection
Yamamoto D, Tanaka K, Tsubota Y, Yosida H, Kanemastu S. Kansai 
Medical University, Hirakata, Japan; Ribon-Roze Tanaka Kanji Clinic, 
Osaka, Japan. 
p2-15-13  oncologic and Cosmetic outcome in breast Cancer patients 
Who underwent “moving Window” operation
Ohno Y, Noguchi M, Nakano Y, Noguchi M, Kosaka T. Kanazawa 
Medical University, Japan. 
treatment – local: reconstruction
p2-16-01  a multi-Centre prospective Cohort Study evaluating health 
related Quality of life after types of immediate latissimus 
Dorsi (lD) breast reconstruction
Winters ZE, Haviland J, Reece-Smith A, Betambeau N, Choudhry K, 
Chaudhry A, Mills J, Benson J, Galea M, MacMannus P, Nicholson S, 
Weiler-Mithoff E, Rayter Z, Thomson HJ. University Hospitals Bristol 
NHS Foundation Trust, Bristol, Avon, South West, United Kingdom; 
Clinical Trials & Statistics Unit, The Institute of Cancer Research, 
Sutton, London, Sutton Surrey, United Kingdom; Cambridge 
University Hospitals NHS Foundation Trust, Cambridge, East Anglia, 
United Kingdom; Western General NHS Foundation Trust Swindon, 
Swindon, South West, United Kingdom; Hull and East Yorkshire 
Hospitals NHS Trust, Hull, East Yorkshire, United Kingdom; York 
Hospitals NHS Trust, York, East Yorkshire, United Kingdom; NHS 
Greater Glasgow and Clyde, Canniesburn, Glasgow, Scotland, United 
Kingdom. 
p2-16-02  how Well Do medical oncologists and plastic Surgeons 
Communicate about their patients?
Milucky JL, Deal A, Wu R, McNally RS, Anders C, Lee C. University of 
North Carolina at Chapel Hill, Chapel Hill, NC. 
p2-16-03  outcomes of nipple-Sparing mastectomy (nSm) and 
immediate reconstruction
Chidester JR, Olson JR, Poruk KE, Marengo JJ, Matsen CB, Neumayer 
L, Agarwal J. Loma Linda University Medical Center, Loma Linda, CA; 
University of Utah School of Medicine, Salt Lake City, UT. 
p2-16-04  abdominal Wall Stability and Flap Complications are 
unaltered Following Deep inferior epigastric perforator (Diep) 
Flap breast reconstruction Despite increasing body mass 
index: analysis of 418 patients and 639 Flaps
Ochoa O, Chrysopoulo M, Nastala C, Ledoux P, Pisano S. Plastics 
Reconstructive and Microsurgical Associates of South Texas, San 
Antonio, TX. 
p2-16-05  Delay of adjuvant Chemotherapy after elective mastectomy 
and immediate reconstruction in breast Conservation 
Candidates: a matched-pair analysis
Barry PN, Riley EC, Pan J, Crew JB, Lee K, Jain D, Kruse B, Quillo AR, 
Rai S, Dragun AE. James Graham Brown Cancer Center, University of 
Louisville School of Medicine, Louisville, KY. 
p2-16-06  a Systematic review of Standardised Clinical outcomes 
and patient reported outcome measures (promS) in breast 
reconstruction
Winters ZE, Chaudhry A, Benson JR. University Hospitals Bristol NHS 
Foundation Trust, Bristol, South West, United Kingdom; Cambridge 
University Hospitals NHS Foundation Trust, Cambridge, East Anglia, 
United Kingdom. 
p2-16-07  a randomised Controlled trial to evaluate the role of tisseel, 
a Fibrin Sealant on Seroma Formation in latissimus dorsi 
breast reconstruction
Winters ZE, Llewellyn-Bennett R, English R, Turner J, Rayter Z, 
Greenwood R. University Hospitals Bristol NHS Foundation Trust, 
Bristol, South West, United Kingdom. 
p2-16-08  expander-implant-reconstruction - aesthetic outcome and 
patients’ Satisfaction in a 10-year-period
Kern PA, Zarth F, Rainer K, Scherag AS, Mahdi R. Breast Center 
Düsseldorf Louis Hospital, Düsseldorf, North Rhine Westfalia, 
Germany; University Clinic of Essen, Essen, North Rhine Westfalia, 
Germany; University of Duisburg-Essen, Essen, Germany. 
p2-16-09  nipple-areolar Sparing mastectomy: utility of the lateral 
inframammary incision in immediate implant-based 
reconstructions
Guth AA, Blechman K, Levovitz C, Small K, Axelrod D, Karp N, Choi M. 
NYU-Langone Medical Center, New York, NY. 
p2-16-10  practice variations in post-mastectomy breast reconstruction: 
What are the roles of Clinical Factors, access barriers, and 
Delayed reconstruction?
Cox D, Milucky J, Dominik R, Lee C. University of North Carolina at 
Chapel Hill, Chapel Hill, NC. 
p2-16-11  role of proper patient Counselling in Combination with effect 
of Socioeconomic Deprivation on the rate of immediate 
breast reconstruction after mastectomy
Chakrabarti M, Fitzgerald C, Obondo C, Weiler-Mithoff E, Doughty 
J, Romics, Jr L. Victoria Infirmary Glasgow; Glasgow Royal Infirmary; 
Western Infirmary Glasgow. 
p2-16-12  Skin reducing nipple Sparing mastectomy - a treatment 
option for patients with Significant ptosis or macromastia
Ott Young A, Alizadeh K, Hodyl C, Pronovost M, Davenport T. Yale 
New Haven Health System, Fairfield, CT; Long Island Plastic Surgical 
Group, Garden City, NY; South Nassau Communities Hospital, 
Oceanside, NY. 
p2-16-13  life after mastectomy without breast reconstruction - are the 
needs of Caribbean Women Different?
Morton-Gittens J, Ali R, Affan AM, Bovell P, Rampaul R. National 
Radiotherapy Centre, St James, Trinidad and Tobago. 
p2-16-14  Skin Sparing mastectomy and immediate latissimus Dorsi 
Flap reconstruction: patient reported outcome and Factors 
affecting the highest patient Satisfaction
Kim Z, Kang S-G, Lee J, Kim SY, Lim CW, Lee MH. Soonchunhyang 
University Hospital, Seoul, Korea. 
p2-16-15  oncological Safety and Survival rate according to 
reconstructive Surgery in advanced breast Cancer after 
neoadjuvant Chemotherapy
Kim WW, Lee JJ, Nam KH, Jung JH, Chae YS, Yang JD, Lee YH, Park 
HY. Kyungpook National University; Hyosung Hospital. 
p2-16-16 nipple Sparing mastectomy and immediate breast 
reconstruction: Critical appraisal of Five year, Single Centre 
outcomes
Westbroek D, Karat I, Min-Hui H, Gukas I, Daoud R, Laidlaw IJ. Frimley 
Park Hospital, Portsmouth Road, Frimley, Surrey, United Kingdom. 
treatment – adjuvant: adjuvant endocrine therapy
p2-17-01  influence of Delayed Zoledronic acid initiation on Disease-
Free Survival in postmenopausal Women with endocrine 
receptor-positive early breast Cancer receiving adjuvant 
letrozole: exploratory analyses from the Zo-FaSt trial
Coleman R, De Boer R, Eidtmann H, Neven P, von Minckwitz G, 
Martin N, Modi A, Bundred N. University of Sheffield, Sheffield, 
United Kingdom; Royal Melbourne Hospital, Victoria, Australia; 
University Frauenklinik, Kiel, Germany; UZ Gasthuisberg, Leuven, 
Belgium; German Breast Group, Frankfurt, Germany; Novartis 
Oncology, East Hanover, NJ; University Hospital of South Manchester 
NHS Foundation Trust, Manchester, United Kingdom. 
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p2-17-02 increased progression Free and overall Survival in breast 
Cancer patients with menopausal Symptoms or arthralgia/
myalgia during adjuvant treatment with exemestane or 
tamoxifen - results of the german team trial
Hadji P, Kieback DG, Hasenburg A, Tams J, Ziller M. Phillipps 
University, Marburg, Germany; Elblandkliniken, Meissen, Germany; 
University Hospital Freiburg, Freiburg, Germany; ICRC-Weyer GmbH, 
Berlin, Germany. 
p2-17-03  incomplete uptake and Diminished adherence to endocrine 
therapy in Women with hormone receptor positive breast 
Cancer 4 years from Diagnosis: an australian Cohort Study
Bell RJ, Fradkin P, Schwarz M, Davis SR. Monash University, 
Melbourne, VIC, Australia; Alfred Health, Melbourne, VIC, Australia. 
p2-17-04  induction of tamoxifen metabolism by rifampicin: a Worrying 
Drug-Drug interaction
Binkhorst L, Loos WJ, de Jongh FE, Hamberg P, Ghobadi 
Moghaddam-Helmantel IM, Jager A, Seynaeve C, Verweij J, van 
Gelder T, Mathijssen RH. Erasmus University Medical Center, 
Rotterdam, Netherlands; Erasmus University Medical Center - Daniel 
den Hoed Cancer Center, Rotterdam, Netherlands; Ikazia Hospital, 
Rotterdam, Netherlands; Sint Franciscus Gasthuis, Rotterdam, 
Netherlands. 
p2-17-05  antiprogestin proellex Suppresses proliferation of aromatase 
overexpressing and letrozole resistant t47D breast Cancer 
Cells
Gupta A, Mehta R, Alimirah F, Murillo G, Peng X, Wiehle R, Mehta 
R. IIT Research Institute, Chicago, IL; Repros Therapeutics, The 
Woodlands, TX. 
p2-17-06  patterns of bone Density evaluation in a Community 
population treated with aromatase inhibitors
Ligibel JA, O’Malley AJ, Fisher M, Daniel GW, Winer EP, Keating NL. 
Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, 
Boston, MA; HealthCore. 
p2-17-07  Construction of a predictive model of probability of ovarian 
Function recovery in a Series of premenopausal breast Cancer 
patients with Chemotherapy-induced amenorrhea Switched 
to an aromatase inhibitor (ai) after adjuvant tamoxifen
Perez-Fidalgo JA, Bermejo B, Pons V, Guzman C, Bosch A, Lluch 
A. Hospital Clínico Universitario, Valencia, Spain; Pfizer Spain, 
Alcobendas (Madrid), Spain.  
p2-17-08  prospective Study of aromatase inhibitor induced bone loss 
and lipid levels in early postmenopausal (pm) hormone 
receptor positive (hr+) breast Cancer (bC) patients treated 
with adjuvant letrozole extended beyond 5 years (yrs)
Fontaine C, Hanssens S, Van den Berge D, Decoster L, Schallier D, 
Declippeleir D, Van Hoeij M, Sacre R, Degrève J. UZ Brussel, Jette, 
Brussel, Belgium. 
p2-17-09  a prospective assessment of loss of grip Strength by baseline 
bmi in breast Cancer patients receiving adjuvant aromatase 
inhibitors or tamoxifen
Lintermans A, Dieudonné A-S, Vanderhaegen J, Henry NL, Laenen A, 
Wildiers H, Paridaens R, Christiaens M-R, Smeets A, Leunen K, Amant 
F, Vergote I, Neven P. University Hospitals Leuven, Leuven, Belgium; 
University of Michigan Comprehensive Cancer Center, MI; Katholieke 
Universiteit Leuven, Leuven, Belgium. 
treatment – adjuvant: adjuvant therapy – targeted
p2-18-01  the magnitude of trastuzumab benefit in her2-positive 
(her2+) lobular breast Carcinoma (bC): results of a hera trial 
Sub-group analysis
Metzger O, Procter M, de Azambuja E, Viale G, Leyland-Jones B, 
Dowsett M, Gelber R, Gresko E, Loi S, Sotiriou C, Piccart M. Institut 
Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; 
Frontier Science (Scotland) Ltd, Kincraig, Kingussie, United Kingdom; 
European Institute of Oncology, Milan, Italy; Emory University, 
Atlanta; Royal Marsden Hospital and Institute of Cancer Research, 
London, United Kingdom; Dana-Farber Cancer Institute, Boston; 
Roche, Basel, Switzerland. 
p2-18-02  Cardiac outcomes of patients on adjuvant Weekly paclitaxel 
(t) and trastuzumab (h) for node negative, her2 positive 
breast Cancer (bCa)
Dang C, Tolaney S, Najita J, Gelman R, Yardley D, Marcom K, Albain 
K, Rugo H, Miller K, Ellis M, Shapira I, Wolff A, Carey L, Vahdat L, 
Burdette-Radoux S, Budd T, Krop I, Burstein H, Hudis C, Winer E. 
Memorial Sloan-Kettering Cancer Center; Dana-Farber Cancer 
Institute; Tennessee Oncology and Sarah Cannon Research Institute; 
Duke University; Loyola University Medical Center; Univerity of 
California-San Francisco Comprehensive Cancer Center; Indiana 
University; Washington University; North Shore-Long Island Jewish 
Medical Center; Johns Hopkins University; University of North 
Carolina; Weill Cornell Medical College; University of Vermont; 
Cleveland Clinic Taussig Cancer Institute Case. 
p2-18-03  Systemic adjuvant treatment of t1a and t1b n0m0 her2+ 
breast Carcinomas; an aerio/uniCanCer Study
Peron J, Vano Y, Frenel J-S, Wassermann J, Albiges L, Rodrigues 
MJ, Cottu PH. Centre Léon Bérard, Lyon, France; Centre Antoine 
Lacassagne, Nice; Institut de Cancerologie de l’Ouest, Centre René 
Gauducheau, Nantes; Institut Curie, Centre René Huguenin, Saint-
Cloud; Institut Gustave Roussy, Villejuif; Institut Curie, Paris. 
p2-18-04  pilot evaluation of bevacizumab (bev) in Combination 
with Docetaxel (t) and Cyclophosphamide (C) as adjuvant 
treatment (adjrx) for patients (pts) with early Stage (eS) 
breast Cancer (brCa)
Gullo G, Kennedy J, Breathnach O, McCaffrey J, Keane M, Martin 
M, Gupta R, Leonard G, Tryfonopoulos D, O’Shea T, Crown J. Irish 
Cooperative Oncology Research Group, Dublin, Ireland. 
p2-18-05  Cardiotoxicity risks of adjuvant trastuzumab in asian breast 
Cancer patients
Shih V, Chan A, Sim MH, Teo C, Chen W, Wong ZW. National Cancer 
Centre, Singapore; National University of Singapore, Singapore. 
p2-18-06  Conventional trastuzumab is an antagonist of natural killer 
Cells: making the Case for Fucose-Depleted trastuzumab
Listinsky JJ, Siegal GP, Listinsky CM. University of Alabama at 
Birmingham, Birmingham, AL; Case Western Reserve University, 
Cleveland, OH. 
treatment – adjuvant: adjuvant therapy – other
p2-19-01  impact of Zoledronic acid on Fractures, bone mineral Density 
and bone remodeling in the aZure trial (big 01-04)
Coleman R, Woodward E, Turner L, Marshall H, Collinson M, Dodwell 
D, Davies C, Bell R, Cameron D, Brown J. University of Sheffield, 
Sheffield, United Kingdom; University of Leeds, Leeds, United 
Kingdom; Andrew Love Cancer Centre, Geelong, Victoria, Australia; 
Western General Hospital, Edinburgh, United Kingdom. 
p2-19-02  multidisciplinary treatment of pregnancy-associated breast 
Cancer
Meisel JL, Economy KE, Zabicki-Calvillo K, Gelber S, Kereakoglow S, 
Winer EP, Partridge AH, Mayer EL. Brigham and Women’s Hospital, 
Boston, MA; Dana-Farber Cancer Institute, Boston, MA. 
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p2-19-03  influence of Zoledronic acid on bmD in premenopausal 
Women with breast Cancer and neoadjuvant or adjuvant 
Chemotherapy and/or endocrine treatment - the probone 
Studies
Hadji P, Kauka A, Bauer T, Kalder M, Albert U, Birkholz K, Baier M, 
Muth M, Ziller M. Philipps-University of Marburg, Marburg, Germany; 
Novartis Pharma GmbH, Nuernberg, Germany. 
p2-19-04  Changes in adjuvant treatment of early breast Cancer in italy 
between 2000 and 2008. the nemeSi Study versus the nora 
Study
Mustacchi G, Cazzaniga ME, Pronzato P, Clavarezza M, Del Mastro L, 
Venturini M, Amadori D, Bidoli P, Boni C, Caruso M, Riccardi F, Dondi 
D. Università, Trieste, Italy; Ospedale San Gerardo, Monza, Italy; IRCCS 
Istituto Nazionale Ricerca sul Cancro, Genova, Italy; Ospedale Sacro 
Cuore Don Calabria, Negrar (VR), Italy; I.R.S.T., Meldola (Forlì), Italy; 
Azienda Ospedaliera S Maria Nuova, Reggio Emilia, Italy; Centro 
Oncologico Catanese, Humanitas, Catania, Italy; Ospedale Cardarelli, 
Napoli, Italy; Sanofi Aventis, Milano, Italy.
7:00 am–9:00 am 
poSter DiSCuSSion iii: genomiCS  
ballroom a
Viewing 7:00 am
Discussion 7:45 am
Discussant: Laura J. van’t Veer, PhD
University of California San Francisco
San Francisco, CA
pD03-01  an integrated analysis of three Distinct ibC/nibC affymetrix 
gene expression Data Sets Further unveils the molecular 
biology of ibC
Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A, Birnbaum 
D, Robertson FM, van Dam PA, Woodward WA, Viens P, Dirix LY, 
Reuben JM, Iwamoto T, Cristofanilli M, Bertucci F. Oncology Center 
- GH Sint-Augustinus, Wilrijk, Antwerp, Belgium; The University 
of Texas MD Anderson Cancer Center, Houston, TX; Institut 
Paoli-Calmettes (IPC), Marseille, France; World IBC Consortium; 
Contributed Equally. 
pD03-02  prognostic and predictive predictors for triple negative breast 
Cancer
Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Schmidt M, Müller V, 
Gätje R, Hanker L, Ahr A, Holtrich U, Rody A, Kaufmann M. Goethe 
University, Frankfurt, Hessen, Germany; University of Texas M.D. 
Anderson Cancer Center, Houston, TX; University of Münster; 
University of Mainz; University Hospital Hamburg-Eppendorf; 
Saarland-University. 
pD03-03  identification of transcription Factors Critical for the growth 
of basal breast Cancer
Shepherd JH, Mazumdar A, Tsimelzon A, Hilsenbeck SG, Brown PH. 
Baylor College of Medicine, Houston, TX; The University of Texas MD 
Anderson Cancer Center, Houston, TX. 
pD03-04  Superpathway analyses of luminal and basaloid breast 
Cancers from the Cancer genome atlas (tCga) program
Yau C, Benz S, Sanborn JZ, Stuart J, Haussler D, Benz C. Buck Institute 
for Research on Aging, Novato, CA; UC Santa Cruz, Santa Cruz, CA. 
pD03-05  Withdrawn
pD03-06  basal-like breast tumors are associated with Frequent micro 
genomic aberrations in important Cancer genes
Chao H-H, He X, Perou CM. University of North Carolina - Chapel Hill, 
Chapel Hill, NC. 
pD03-07  breast Cancer heterogeneity and treatment resistance: Clues 
from metaplastic tumors
Felding-Habermann B, O’Sullivan DM, Lorger M, MacDermed D, 
Fernandez-Santidrian A, Steele JB, Telli ML, Jeffrey SS, Murray S, 
Torkamani A, Cunliffe H, Vaughn SV. The Scripps Research Institute, 
La Jolla, CA; Scripps Clinic, La Jolla, CA; Stanford University, Stanford, 
CA; Translational Genomics Research Institute, Phoenix, AZ. 
pD03-08  brCa1-like triple negative tumors: Clinicopathological 
variables and Chemosensitivity to alkylating agents
Wesseling J, Lips EH, Oonk AMM, Smits RM, van Rijn CCM, Mulder 
L, Laddach N, Savola SS, Wessels LFA, Nederlof PM, Rodenhuis S, 
Imholz ALT. Netherlands Cancer Institute-Antoni van Leeuwenhoek 
Hospital, Amsterdam, Netherlands; Deventer Hospital, Deventer, 
Netherlands; MRC-Holland, Amsterdam, Netherlands. 
pD03-09  breast Cancer recurrence risk probed by Whole transcriptome 
next generation Sequencing in 136 patients
Baker J, Liu M-L, Crager M, Stephans J, Pho M, Jeong J, Scott A, 
Ambannavar R, Morlan J, Pelham R, Qu K, Mena RR, Esteban J, Collin 
F, Sinicropi D. Genomic Health Inc., Redwood City, CA; Providence St. 
Joseph Medical Center, Burbank, CA. 
pD03-10  gene modules and response to neoadjuvant Chemotherapy 
in breast Cancer: a meta-analysis
Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, 
Loi S, Andre F, Piccart M, Michiels S, Sotiriou C. Institut Jules Bordet, 
Brussels, Belgium; Harvard School of Public Health, Boston; Université 
Paris XI, Paris, France.
7:00 am–9:00 am  
poSter DiSCuSSion iv: SurvivorShip   
ballroom b
Viewing 7:00 am
Discussion 7:45 am
Discussant: Dawn Hershman, MD, MS
Columbia University Medical Center
New York, NY
pD04-01  predictors of recovery of ovarian Function during aromatase 
inhibitor (ai) therapy
Henry NL, Banerjee M, Hayden J, Yakim E, Schott AF, Stearns V, 
Partridge AH, Hayes DF. University of Michigan Medical School, Ann 
Arbor, MI; Johns Hopkins School of Medicine; Dana Farber Cancer 
Institute. 
pD04-02  recovery of ovarian Function in breast Cancer patients with 
Chemotherapy-induced amenorrhea receiving anastrozole in 
the Dutch Data Study
Tjan-Heijnen VC, Smorenburg CH, de Graaf H, Erdkamp F, Honkoop 
A, Wals J, van Gastel S, van der Sangen M, Seynaeve C, Nortier 
JW, Borm G. Maastricht University Medical Centre, Netherlands; 
Medical Centre Alkmaar, Netherlands; Medical Centre Leeuwarden, 
Netherlands; Orbis Medical Centre, Netherlands; Isala Clinics, 
Netherlands; Atrium Medical Centre, Netherlands; Comprehensive 
Cancer Centre Netherlands Nijmegen, Netherlands; Catharina-
Hospital, Netherlands; Erasmus University Medical Centre, 
Netherlands; Leiden University Medical Centre, Netherlands; 
Radboud University Nijmegen Medical Centre, Netherlands. 
pD04-03  Sexual Dysfunction in premenopausal Women with breast 
Cancer: prevalence and Severity
Goldfarb SB, Dickler M, Patil S, Jia R, Sit L, Damast S, Carter J, Kaplan 
J, Hudis C, Basch E. Memorial Sloan-Kettering Cancer Center, New 
York, NY. 
pD04-04  Sexual Dysfunction in Women with early Stage breast Cancer 
on endocrine therapy: encouraging results from a prospective 
Study
Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler 
SZ, Song X, Graham N, Dent S. The Ottawa Hospital Cancer Centre, 
Ottawa, ON, Canada; Carleton University, Ottawa, ON, Canada. 
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pD04-05  body image issues in young breast Cancer patients: the 
impact of Chemotherapy, hormone treatment, and Surgery
Rosenberg SM, Tamimi RM, Gelber S, Kereakoglow S, Borges V, Come 
S, Schapira L, Winer E, Partridge A. Harvard School of Public Health, 
Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of 
Colorado Cancer Center, Denver, CO; Beth Israel Deaconess Medical 
Center, Boston, MA; Massachusetts General Hospital, Boston, MA. 
pD04-06  a randomised Controlled trial of Quality of life and Fatigue 
after Support group intervention in primary breast Cancer 
patients
Granstam Björneklett H, Lindemalm C, Ojutkangas M-L, Berglund 
A, Letocha H, Strang P, Bergkvist L. Centre for Clinical Research, 
Västerås, Sweden; Cancer Centre Karolinska, Solna, Sweden; Centre 
for Clinical Research, Central Hospital, Västerås, Sweden; Karolinska 
Institute, SSH, Stockholm, Sweden; Karolinska Institute, Stockholm, 
Sweden. 
pD04-07  Cognitive Function and reproductive hormones in Women 
receiving anastrozole
Bender CM, Sereika SM, Ryan CM, Berga SL. University of Pittsburgh, 
Pittsburgh, PA; Emory University, Atlanta, GA. 
pD04-08  altered neurocognitive responses prior to adjuvant therapy 
for breast Cancer: a Functional mri analysis of the impact of 
Worry and Fatigue
Cimprich B, Hayes DF, Askren MK, Jung MS, Berman MG, Therrien 
B, Reuter-Lorenz PA, Zhang M, Peltier S, Noll DC. University of 
Michigan, Ann Arbor, MI. 
pD04-09  Self-reported Cognitive attributes and Fatigue improve 
over long-term Follow-up in breast Cancer Survivors; Some 
Cognitive attributes are Worse in breast Cancer Survivors 
than in non-Cancer Controls
Hsu T, Ennis M, Hood N, Goodwin PJ. University of Toronto, Toronto, 
ON, Canada; Applied Statistician, Markham, ON, Canada; Mount Sinai 
Hospital, Toronto, ON, Canada; Mount Sinai and Princess Margaret 
Hospitals, Samuel Lunenfeld Research Institue, University of Toronto, 
Toronto, ON, Canada.
9:00 am–9:30 am 
plenary leCture 2 
exhibit hall D 
 macrophages as novel targets for therapy in breast Cancer
Lisa M. Coussens, PhD
University of California San Francisco
San Francisco, CA
9:30 am–11:15 am 
general SeSSion 3 
exhibit hall D
Moderator: Jose Baselga, MD, PhD 
Massachusetts General Hospital
Boston, MA 
9:30  S3-1. update of international breast Cancer Study group trial 
23-01 to compare axillary dissection versus no axillary dissection 
in patients with clinically node negative breast cancer and 
micrometastases in the sentinel node
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, 
Chifu C, Sargenti M, Intra M, Gentilini O, Massarut S, Garbay J-R, Zgajnar 
J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Price KN, Goldhirsch 
A, Gelber RD, Veronesi U. International Breast Cancer Study Group Trial 
23-01 Investigators.
9:45  S3-2. neoadjuvant chemotherapy adapted by interim response 
improves overall survival of primary breast cancer patients – 
results of the gepartrio trial
von Minckwitz G, Blohmer JU, Costa S, Denkert C, Eidtmann H, Eiermann 
W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, 
Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl 
S. German Breast Group, Neu-Isenburg; St. Gertrauden Krankenhaus, 
Berlin; Universitäts-Frauenklinik, Magdeburg; Charité, Berlin; Universitäts-
Frauenklinik, Kiel; Frauenklinik vom Roten Kreuz, München; Universitäts-
Frauenklinik, Rostock; Henrietten-Stiftung, Hannover; Brustzentrum 
Kantonsspital St. Gallen / Universitäts-Frauenklinik Tübingen; 
Frauenklinik, Klinikum, Offenbach; Universitäts-Frauenklinik, Frankfurt; 
Klinikum Essen Mitte, Essen; Universitäts-Frauenklinik Rechts der Isar, 
München; Universitäts-Frauenklinik, Heidelberg; Frauenklinik, Berlin; 
Brustzentrum SRH Waldkliniken, Gera.
10:00  S3-3. association of pten loss and pik3Ca mutations on outcome 
in her2+ metastatic breast cancer patients treated with first-line 
lapatinib plus paclitaxel or paclitaxel alone
Xu B-h, Guan Z-z, Shen Z-z, Tong Z-s, Jiang Z-f, Yang J-I, DeSilvio 
M, Leigh M, Ellis C. Cancer Hospital, CAMS & PUMC; Sun Yat-Sen 
Medical University Cancer Center; Shanghai Cancer Center, Fudan 
University; Tianjin Medical University Cancer Institute and Hospital; 
Hospital Affiliated to Military Medical Science; Beijing 301 PLA Hospital; 
GlaxoSmithKline.
10:15  S3-4. er downregulation with fulvestrant in combination with 
pan-pi3k inhibitor bkm120 synergizes against er+/pi3k-mutant 
breast cancer xenografts in vivo
Miller TW, Fox EM, Balko JM, Meszoely IM, Sanders ME, Kuba MG, 
Wagle N, Garraway LA, Maira S-M, Arteaga CL. Vanderbilt University, 
Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for 
Biomedical Research, Basel, Switzerland.
10:30  S3-5. next generation sequencing reveals co-activating events in 
the mapk and p13k/akt pathways in metastatic triple negative 
breast cancers
O’Shaughnessy J, Craig DW, Kiefer J, Sinari S, Moses TM, Wong S, Aldrich 
J, Christoforides A, Dinh J, Itzatt T, Blum J, Kurdoglu A, Salhia B, Baker A, 
Siddiqui A, Hoang L, Billings P, Trent JM, Mousses S, Von Hoff D, Carpten 
JD. Baylor Sammons Cancer Center, Dallas, TX; Translational Genomics 
Research Institute, Phoenix, AZ; Life Technologies, Carlsbad, CA; US 
Oncology, The Woodlands, TX.
10:45  S3-6. neoadjuvant chemotherapy of paclitaxel with or without 
rad001: results of the non-responder part of the geparQuinto 
study (gbg 44)
Huober J, Hanusch C, Fasching PA, Rezai M, Eidtmann H, Kittel K, 
Schwedler K, Tesch H, Höß C, Mau C, Khandan F, Krabisch P, Loibl S, 
Nekljudova V, Untch M, von Minckwitz G. Kantonsspital St. Gallen/
Universitäts-Frauenklinik Tübingen; Frauenklinik vom Roten Kreuz, 
München; Universitäts-Frauenklinik, Erlangen.
11:00  S3-7. everolimus for postmenopausal women with advanced 
breast cancer: updated results of the bolero-2 phase iii trial 
Hortobagyi GN, Piccart M, Rugo H, Burris H, Campone M, Noguchi S, 
Gnant M, Pritchard KI, Vittori L, Mukhopadhyay P, Sahmoud T, Lebwohl D, 
Baselga J.  The University of Texas, MD Anderson Cancer Center, Houston, 
TX; Jules Bordet Institute (Institut Jules Bordet), Brussels, Belgium; 
University of California, San Francisco Helen Diller Family Comprehensive 
Cancer Center, UCSF, San Francisco, CA; Sarah Cannon Research Institute, 
Nashville, TN; Institut de Cancérologie de l’Ouest - René Gauducheau, 
Centre de Recherche en Cancérologie, Nantes Saint Herblain, France ; 
Osaka University, Department of Breast and Endocrine Surgery, Osaka, 
Japan;  Comprehensive Cancer Center, Medical University of Vienna, 
Vienna, Austria; Sunnybrook Odette Cancer Centre and the University 
of Toronto, Toronto, Canada; Novartis Pharma AG, Basel, Switzerland; 
Novartis Pharmaceuticals Corporation, East Hanover, NJ; Massachusetts 
General Hospital Cancer Center and Harvard Medical School, Boston, MA.
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11:15 am–12:00 pm 
William l. mCguire memorial leCture  
exhibit hall D 
Sponsored by Cancer Therapy & Research Center
 translating genomic insights into improved breast cancer 
management
Joe Gray, PhD
Oregon Health & Science University
Portland, OR
12:00 pm–1:35 pm 
lunCh
12:15 pm–1:15 pm 
proDuCt theatre 
exhibit hall C – exhibit area
 abraxane
Sponsored by Celgene Corporation
12:30 pm–1:35 pm 
CaSe DiSCuSSion 1 
ballroom a
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Panelists:
John Benson, MD 
Cambridge University
Cambridge, UNITED KINGDOM
Lisa Carey, MD
University of North Carolina
Chapel Hill, NC
Daniel Hayes, MD
University of Michigan
Ann Arbor, MI
Wendy Woodward, MD
MD Anderson Cancer Center
Houston, TX
Kay Wissmann
IL Deadline Action Network (NBCC)
Carbondale, IL
12:30 pm–1:35 pm 
baSiC SCienCe Forum 
ballroom b
 estrogen receptor
Moderator: Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX 
  Steroid receptor cistromics
Myles Brown, MD
Dana-Farber Cancer Institute
Boston, MA
  nuclear receptor coactivators: physiology and disease
Bert W. O’Malley, MD
Baylor College of Medicine
Houston, TX
1:45 pm–3:15 pm 
mini-SympoSium 1 
ballroom b
 tumor heterogeneity and metastasis
Moderator: Rachel Schiff, PhD 
Baylor College of Medicine
Houston, TX
  imaging cancer invasion and experimental therapy response: 
how to overcome resistance niches
Peter Friedl, MD, PhD
Radboud University Nijmegen
HB Nijmegen, NETHERLANDS
  tumor-entrained neutrophils inhibit breast cancer metastasis 
seeding in the lung 
Robert Benezra, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY
  tumor heterogeneity and metastasis 
Matthew J. Ellis, MB, BChir, PhD
Washington University School of Medicine
St. Louis, MO
1:45 pm–3:15 pm 
mini-SympoSium 2 
exhibit hall D
 environmental exposures, epigenetics and epidemiology
Moderator: Cheryl Lyn Walker, PhD 
UT MD Anderson Cancer Center 
Houston, TX
  epidemiology of preeclampsia and other early exposures on 
breast cancer risk
Michele R. Forman, PhD
UT Austin
Austin, TX
  environ exposures, epigenetics & epidemiology influence of 
environmental factors on pubertal maturation and breast 
cancer etiology 
Robert A. Hiatt, MD, PhD
University of California, San Francisco
San Francisco, CA
  breast cancer and the environment: Developmental 
reprogramming of cancer susceptibility by early life 
environmental exposures 
Cheryl Lyn Walker, PhD
UT MD Anderson Cancer Center
Houston, TX
3:15 pm–5:15 pm 
general SeSSion 4 
exhibit hall D
Moderator: Emiel JT Rutgers, MD, PhD 
Netherlands Cancer Institute 
Amsterdam, NETHERLANDS
3:15  S4-1. overdiagnosis in breast cancer screening: methodological 
considerations of current estimates
Smith RA, Duffy SW. American Cancer Society, Atlanta, GA; Queen Mary 
University of London, London, United Kingdom.
3:30  S4-2. the risk of contralateral breast cancer in brCa1/2 carriers 
compared to non-brCa1/2 carriers in an unselected cohort
van den Broek AJ, Schmidt MK, Tollenaar RAEM, van ‘t Veer LJ, van 
Leeuwen FE. Netherlands Cancer Institute, Amsterdam, Netherlands; 
Leiden University Medical Center, Leiden, Netherlands.
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3:45  S4-3. prospective comparison of risk assessment tools in early 
breast cancer (recurrence score, upa/pai-1, central grade, and 
luminal subtypes): Final correlation analysis from the phase iii 
WSg-plan b trial
Gluz O, Kreipe H, Degenhardt T, Kates R, Christgen M, Liedtke C, Shak 
S, Clemens M, Markmann S, Uleer C, Augustin D, Thomssen C, Nitz U, 
Harbeck N. West German Study Group, Moenchengladbach, Germany; 
Medizinische Hochschule, Hannover, Germany; University of Muenster, 
Muenster, Germany; Genomic Health Inc, Redwood City; Klinikum 
Mutterhaus, Trier, Germany; Klinikum Suedstadt, Rostock, Germany; 
Gynecology Practice, Hildesheim, Germany; Klinikum Deggendorf; 
Deggendorf, Germany, University of Halle/Saale, Halle/Saale, Germany; 
Bethesda Clinics, Moenchengladbach, Germany; University of Cologne, 
Cologne, Germany.
4:00  S4-4. Clarifying the risk of breast cancer in women with atypical 
breast lesions
Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EMH, 
Polufriaginof F, Parmigiani G, Garber JE, Smith BL, Gadd MA, Specht 
MC, Guidi AJ, Roche CA, Hughes KS. Massachusetts General Hospital, 
Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley 
Hospital, Newton, MA; Wayne State University, Detroit, MI.
4:15  S4-5. Comparison of pam50 risk of recurrence (ror) score with 
oncotypeDx and ihC4 for predicting residual risk of rFS and 
distant rFS after endocrine therapy: a transataC study
Dowsett M, Lopez-Knowles E, Sidhu K, Pineda S, Cowens JW, Ferree S, 
Storhoff J, Schaper C, Cuzick J. Royal Marsden Hospital and Breakthrough 
Breast Cancer Centre, London, United Kingdom; Wolfson Institute of 
Preventive Medicine, London, United Kingdom; Nanostring Technologies, 
Seattle, WA.
4:30  S4-6. a quantitative multigene rt-pCr assay for predicting 
recurrence risk after surgical excision alone without irradiation for 
ductal carcinoma in situ (DCiS): a prospective validation study of 
the DCiS score from eCog e5194
Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, 
Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood 
W. Albert Einstein Medical Center, Philadelphia, PA; Eastern Cooperative 
Oncology Group, Boston, MA; Genomic Health, Inc., Redwood City, 
CA; Indiana University, Indianapolis, IN; The Hope Center, Cartersville, 
GA; University of Pittsburgh, Pittsburgh, PA; Mayo Clinic Jacksonville, 
Jacksonville, FL; Mayo Clinic Rochester, Rochester, MN; Albert Einstein 
College of Medicine Bronx, NY; Emory University, Atlanta, GA.
4:45  S4-7. results of a randomized, double-blind, multicenter, placebo-
controlled study of adjuvant lapatinib in women with early-stage 
erbb2-overexpressing breast cancer
Goss P, Smith I, O’Shaugnessy J, Ejlertsen B, Kaufmann M, Boyle F, 
Buzdar A, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, 
Pritchard K, Aktan G, Rappold E, Williams L, Finkelstein D.  Massachusetts 
Gen Hosp, Boston MA; Royal Marsden Hosp, London, UK; Baylor 
Sammons Cancer Ctr, Dallas TX; Rigshospitalet, Copenhagen, Denmark; 
JW Goethe-Universität, Frankfurt, Germany; Royal North Shore Hosp, 
Sydney, Australia; UT MD Anderson Cancer Ctr, Houston TX; Centre GF 
Leclerc, Dijon, France; Northwestern Univ, Chicago IL; Hosp Universitario 
San Carlos, Madrid, Spain; Jules Bordet Inst, Brussels, Belgium; Toronto-
Sunnybrook Regional Cancer Ctr, Toronto, Ontario; GlaxoSmithKline, 
Collegeville PA and Uxbridge, UK.
5:00  S4-8. First results of averel, a randomized phase iii trial to 
evaluate bevacizumab (bev) in combination with trastuzumab (h) 
+ docetaxel (DoC) as first-line therapy for her2-positive locally 
recurrent/metastatic breast cancer (lr/mbC) 
Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot X, 
Smirnova I, Moliterni A, Andre F, Chan A, Lipatov O, Chan S, Wardley W, 
Greil R, Provencher L, Moore N, Prot S, Semiglazov V. Osp San Raffaele, 
Milan, Italy; Ctr Régionale de Lutte contre le Cancer, Montpellier, France; 
NN Blokhin Oncol Res Ctr, Moscow, Russian Federation; Fundação Pio XII 
Hosp de Cancer, Barretos, Brazil; Univ Hosp, Udine, Italy; Univ Hosp Jean 
Minjoz, Besançon, France; Med Rad Sci Ctr, Obinsk, Russian Federation; 
Istituto Nazionale Tumori, Milan, Italy; Inst Gustave Roussy, Villejuif, 
France; Mount Hosp, Perth, Australia; Republican Clin Oncol Dispensary, 
Ufa, Russian Federation; Nottingham Univ Hospitals, Nottingham, UK; 
The Christie, Manchester, UK; III. Med Universitätsklinik, Salzburg, Austria; 
CHA-Hôpital du Saint-Sacrement, Québec, Canada; F Hoffman-LaRoche, 
Basel, Switzerland; NN Petrov Res Inst of Oncol, St Petersburg, Russian 
Federation.
5:15 pm–7:00 pm 
poSter SeSSion 3 & reCeption 
exhibit halls a-b
tumor Cell biology: novel/emerging therapeutic targets
p3-01-01  geminin overexpression prevents the Completion of 
topoisomerase iiα Chromosome Decatenation leading to 
aneuploidy in human mammary epithelial Cells
ElShamy WM, Gardner L, Malik R, Shimizu Y, Mullins N. University of 
Mississippi Medical Center, Jackson, MS. 
p3-01-02  eC 304: a novel progesterone receptor (pr) antagonist 
inhibits transcription and induces Cell Cycle arrest in t47D 
breast Cancer Cells
Bhaskaran SS, Kesavaram N, Nickisch KJ, VandeBerg JL, Nair HB. Texas 
Biomedical Research Institute, San Antonio, TX; Evestra, Inc., San 
Antonio, TX. 
p3-01-03  the hominoid-Specific gene Shon is oncogenic in human 
mammary Carcinoma
Jung Y, Shastri BG, Kong X-J, Zhu T, Perry JK, Lobie PE, Liu D-X. Liggins 
Institute, Auckland, AKL, New Zealand; Hefei National Laboratory for 
Physical Sciences, Hefei, Anhui, China; Cancer Science Institute of 
Singapore, Singapore, Singapore. 
p3-01-04  Differential impact of gefitinib and plX4720 on proliferation 
of mCF10a and isogenic lines as measured with a metastasis 
expression Score
Christopherson C, Rigby S, Chang M, Foster R, Wang A, Sninsky J, 
Kwok S, Torrance C. Celera, Alameda, CA; Horizon Discovery Ltd, 
Cambridge, United Kingdom. 
p3-01-05  Wnt Signaling: a new target for treatment and prevention of 
endocrine resistant breast Cancer?
Micallef RA, Smith C, Barrow D, Nicholson RI, Gee JMW, Barratt-Lee 
PJ, Hiscox SE. Cardiff University, Cardiff, Wales, United Kingdom; 
Velindre NHS Trust, Cardiff, Wales, United Kingdom. 
p3-01-06  nF-κb inhibition promotes radiosensitivity of breast 
Cancer Cells in three-Dimensional Culture through abating 
β1-integrin expression
Ahmed KM, Zhang H, Park CC. Ernest Orlando Lawrence Berkeley 
National Laboratory, Berkeley, CA. 
p3-01-07  a murine Xenograft model for the Study of Ciclooxygenase-2 
expression and Function in human breast Cancer
Solano AR, Orlando UD, Garona J, Ripoli GV, Duarte AB, Maloberti PM, 
Avagnina MA, Alonso DF, Gomez DE, Podesta EJ. School of Medicine 
University of Buenos Aires, Buenos Aires, Argentina; University 
of Quilmes, Quilmes, Buenos Aires, Argentina; Center of Medical 
Education and Clinical Investigation Norberto Quirno, Buenos Aires, 
Argentina. 
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p3-01-08  in vitro and in vivo antitumor activity of the aurora and 
angiogenic kinase inhibitor enmD-2076 in triple-negative 
breast Cancer models
Diamond JR, Eckhardt SG, Tan AC, Selby HM, Newton TP, Pitts TM, 
Bray MR, Fletcher GC, Tentler JJ. University of Colorado Cancer 
Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada. 
p3-01-09  oncogenic activation of hSF1 enables the malignant 
progression of breast Carcinoma
Mendillo ML, Santagata S, Koeva M, Fraenkel E, Ince TA, Whitesell L, 
Lindquist S. Whitehead Institute for Biomedical Research, Cambridge, 
MA; Brigham and Women’s Hospital, Boston, Boston, MA; 
Massachusetts Institute of Technology, Cambridge, MA; University of 
Miami Miller School of Medicine, Miami, FL; Howard Hughes Medical 
Institute, Cambridge, MA. 
p3-01-10  Dmba-breast Cancer in Diet induced obesity (Dio) and lean 
mice is related to leptin Signaling
Gillespie C, Penichet MG, Colbert LS, McGlothen T, Guo S, Zhou W, 
Gonzalez-Perez RR. Morehouse School of Medicine, Atlanta, GA; 
Shenyang Medical College, Liaoning Pro, P.R., China. 
p3-01-11  increased gene Copy number of c-kit and vegFr2 at 4q12 in 
primary breast Cancer is related to an aggressive phenotype 
and impaired prognosis
Rydén L, Johansson I, Ebbesson A, Grabau D, Wigerup C, Aaltonen 
KE, Hedenfalk I. Clinical Science Lund, Lund, Sweden. 
p3-01-12  prognostic impact of rank, rankl and opg gene expression 
in er positive primary breast Cancer
Ruckhaeberle E, Mueller V, Schmidt M, Saenger N, Hanker L, Gaetje 
R, Ahr A, Holtrich U, Karn T, Rody A, Kaufmann M. Department 
of Gynecological Oncology, Frankfurt, Germany; Department of 
Obstetrics and Gynecology, Hamburg, Germany; Department 
of Obstetrics and Gynecology, Mainz, Germany; Department of 
Obstetrics and Gynecology, Homburg/Saar, Germany. 
p3-01-13 leptin modulates the response to tamoxifen treatment in 
er-positive breast Cancer Cell lines
Yom CK, Han W, Kim S-W, Kim DW, Kang E, Noh D-Y. Seoul National 
University Bundang Hospital, Seoul National University College of 
Medicine, Seongnam, Korea; Seoul National University College of 
Medicine, Seoul, Korea. 
p3-01-14  rank and rank ligand (rankl) expression in invasive breast 
Carcinoma and human breast Cancer Cell lines
Jacob A, Branstetter D, Rohrbach K, Winters A, Erwert R, Allred S, 
Jones J, Miller R, Tometsko M, Blake M, Dougall WC. Amgen Inc., 
Seattle, WA; Amgen Inc., Thousand Oaks, CA. 
p3-01-15  the role of Src homology phosphotyrosyl phosphatase-2 in 
basal-type/triple-negative breast Cancer - implications for 
targeted therapy
Agazie YM, Matalka F, Hartman ZR. West Virginia University School of 
Medicine, Morgantown, WV. 
p3-01-16  expression of basal markers in Correlation with pten and 
brCa 1 in triple negative breast Carcinomas (tn) treated with 
Chemotherapy versus parp inhibitors
Chivukula M, Carter G, Puhalla S. Magee Women’s Hospital of 
Pittsburgh, Pittsburgh, PA; Magee Women’s Hospital of UPMC, 
Pittsburgh, PA. 
p3-01-17  Cadherin-11 as a therapeutic target in poor prognosis breast 
cancers
Assefnia S, Guidry Auvil JM, Dakshanamurthy S, Hampel C, Brown 
M, Anastadiadis P, Brenner M, Byers SW.  Lombardi Comprehensive 
Cancer Research Center, Georgetown University Medical Center, 
Washington, DC; Mayo Clinic, Jacksonville, FL; Brigham and Women’s 
Hospital, Harvard University, Boston, MA.
p3-01-18  amplification of anaplastic lymphoma kinase (alk) as a 
common genetic alteration in inflammatory breast Cancer
Robertson FM, Petricoin EF, Chu K, Mu Z, Jin J, Circo R, Fernandez 
SV, Alpaugh RK, Zook M, Sun G, Wulfkuhle J, Liotta LA, Ye Z, 
Krishnamurthy S, Luo AZ, Lui H, Wright MC, Woodward WA, Barsky 
SH, Cristofanilli M.  The University of Texas MD Anderson Cancer 
Center, Houston, TX; George Mason University, Manassas, VA; Fox 
Chase Cancer Center, Philadelphia, PA; The University of Nevada 
School of Medicine and Nevada Cancer Institute, Reno and Las 
Vegas, NV.
p3-01-19  pegph20 depletion of pericellular hyaluronan sensitizes high 
hyaluronan-producing tumor cells in antibody-dependent 
cell-mediated cytotoxicity
Shepard HM, Singha NC, Jiang P, Zimmerman S, Connor R, Frost GI.  
Halozyment Therapeutic Inc., San Diego, CA.
tumor Cell biology: new agents and mechanisms
p3-02-01  a novel bispecific, hexavalent, antibody (hexab) inhibits 
anchorage-independent growth and reduces invasiveness of 
triple-negative breast Cancer Cell lines in vitro
Goldenberg DM, Wang Y, Trisal P, Cardillo TM, Rossi EA, Chang C-H. 
Garden State Cancer Center, Center for Molecular Medicine and 
Immunology, Morris Plains, NJ; Immunomedics, Inc., Morris Plains, 
NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ. 
p3-02-02  novel ranpirnase-based immunornases Display potent 
Cytotoxicity in Diverse human breast Cancer Cell lines
Goldenberg DM, Liu D, Wang Y, Rossi EA, Chang C-H. Garden State 
Cancer Center, Center for Molecular Medicine and Immunology, 
Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ; IBC 
Pharmaceuticals, Inc., Morris Plains, NJ. 
tumor Cell biology: micrornas
p3-03-01  low expression of microrna-210 is an independent good 
prognostic Factor in japanese triple-negative breast Cancer 
patients
Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, 
Takahashi S, Iwase H, Fujii Y, Yamashita H. Nagoya City University 
Graduate School of Medical Sciences, Nagoya, Aichi, Japan; 
Kumamoto University Graduate School of Medical Sciences, 
Kumamoto, Japan. 
p3-03-02  higher expression levels of Circulating mir-21, mir-19a and 
mir-10b are associated with high risk Features in breast 
Cancer
Anfossi S, Giordano A, Cohen EN, Gao H, Cristofanilli M, Valero V, 
Alvarez RH, Hortobagyi GN, Woodward W, Ueno NT, Lee B-N, Reuben 
JM. The University of Texas MD Anderson Cancer Center, Houston, 
TX; Fox Chase Cancer Center, Philadelphia, PA. 
p3-03-03  Congruence between patterns of microrna expression and 
histologic grading of invasive breast Carcinomas
Ellsworth DL, Croft DT, Field LA, Deyarmin B, Kane J, Ellsworth RE, 
Hooke JA, Shriver CD. Windber Research Institute, Windber, PA; 
Henry M Jackson Foundation, Rockville, MD; Walter Reed Army 
Medical Center, Washington, DC. 
p3-03-04  targeted modulation of her receptor Signaling in breast 
Cancer using mir-21
Aubele M, Ludyga N, Braselmann H, Atkinson MJ, Auer G, Anastasov 
N. Helmholtz Zentrum München, German Research Center for 
Environmental Health, Neuherberg, Germany; Karolinska Institute 
and Hospital, Stockholm, Sweden. 
p3-03-05  identification of mirnas and their associated target genes 
involved in endocrine resistance in breast Cancer
Healy NA, Creighton CJ, Fu X, Tsimelzon A, Hilsenbeck SG, Miller N, 
Kerin MJ, Osborne CK, Schiff R. Baylor College of Medicine, Houston, 
TX; National University of Ireland, Galway, Ireland. 
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p3-03-06  regulation of microrna expression by autocrine human 
growth hormone in breast Cancer Cells
Pertziger M, Shastri BG, Liu D-X, Zhu T, Lobie PE, Perry JK. University 
of Auckland, Auckland, New Zealand; University of Science and 
Technology of China, Hefei, Anhui, China; National University of 
Singapore, Singapore. 
p3-03-07  a novel approach integrating microrna and mrna 
Signatures of hmapk Signaling is highly predictive of 
er- Status and outcome in breast Cancer - role of hmapk 
micrornas in repression of er and p27
Miller P, Clarke J, Koru-Sengul T, Brinkman J, El-Ashry D. University of 
Miami, Miami, FL. 
p3-03-08  micrornas in mammary Stem-like Cells and triple-negative 
breast Cancer; Conserved Functions and treatment potential
Williams C, Aydogdu E, Katchy A, Lin C-Y, Haldosen L-A, Helguero L. 
University of Houston, Houston, TX; Karolinska Institute, Stockholm, 
Sweden; University of Aveiro, Aveiro, Portugal. 
p3-03-09  mir-944 is down-regulated in her2 positive breast 
cancer tumors: identification of putative mrna targets by 
transcriptome analysis
Fonseca MA, Romero SL, Hidalgo A, Rodriguez S, Bautista V, Marchat 
LA, Perez-Plasencia C, Arechaga E, Lopez-Camarillo C.  Universidad 
Autonoma de la Ciudad de Mexico, Mexico, DF, Mexico; Instituto 
Nacional de Medicina Genomica, Mexico, DF, Mexico; Instituto de 
Enfermedades de la mama FUCAM, Mexico, DF, Mexico; Escuela 
Nacional de Medicina y Homeopatia del IPN, Mexico, DF, Mexico; 
Instituto Nacional de Cancerologia, Mexico, DF, Mexico. 
tumor Cell biology: molecular profiles
p3-04-01  molecular Characterization of african breast Cancer; results 
from a large tissue microarray Study
Shaaban A, Hatfield A, Omoniyi Esan GO, Komolafe AO, Daramola 
A, Pathak D, D’Cruz N, Alizadeh Y, Lewis P, Titloye NA. St James’s 
Institute of Oncology, Leeds, United Kingdom; Obafemi Awolowo 
Teaching Hospital Comples, Ile-Ife, Nigeria; Swansea School of 
Medicine, Swansea, United Kingdom; College of Medicine University 
of Lagos/ Lagos University Teaching Hospital, Lagos, Nigeria. 
p3-04-02  bevacizumab treatment alters intrinsic Subtypes in a vegF-
reinforced Xenograft model of er-positive breast Cancer
Gökmen-Polar Y, Toroni RA, Goswami C, Sanders KL, Sirimalle U, 
Mehta R, Li L, Ivan M, Badve S, Sledge GW. Indiana University School 
of Medicine, Indianapolis, IN. 
p3-04-03  identification of hormone-responsive genes as biomarkers for 
menstrual Cycle phases and menopausal Status
Wang J, Lee O, Heinz R, Ivancic D, Scholtens D, Chatterton RT, Khan 
SA. Northwestern University, Chicago, IL. 
p3-04-04  patterns of Distant metastasis according to the molecular 
Subtypes of breast Cancer; results of 529 breast Cancer 
patients
Hwang MJ, Seo YJ, Lee JH, Son GT, Choi JE, Bae YK, Kang SH, Lee SJ. 
Yeungnam University College of Medicine, Daegu, Republic of Korea. 
p3-04-05  expression profiles of rank and rankl mrna and protein in 
the mammary gland of Female Cynomolgus monkeys after 
long-term treatment with Different menopausal hormone 
therapies
Branstetter D, Wood CE, Rohrbach K, Borgerink H, Dougall WC. 
Amgen Inc., Seattle, CA; Wake Forest School of Medicine, Winston-
Salem, NC. 
p3-04-06  Comparison of mammaprint, blueprint, and targetprint with 
Clinical parameters in patients with breast Cancer: Findings 
from a prospective united States Cohort
Nguyen B, Sinha R, Kerlin D, Barone J, Garcia A, Yao K, Rivera E, 
Stork-Sloots L, Deck K. Long Beach Memorial Health Care, Long 
Beach, CA; Rockwood Clinic, Spokane, WA; John Muir, Walnut Creek, 
CA; Comprehensive Breast Care of San Diego and Sharp Memorial 
Hospital, San Diego, CA; University of Southern California, Los 
Angeles, CA; North Shore University Health System, Chicago, IL; The 
Methodist Hospital/Weill Cornell University, Houston, TX; Agendia 
Inc, Irvine, CA; Saddleback Memorial Medical Center, Laguna Hills, 
CA. 
p3-04-07  physiological Concentrations of genistein and 17β-estradiol 
inhibit mDa-mb-231 breast Cancer Cell proliferation by 
increasing bax/bcl2 ratio and Decreasing perk1/2 expression
Rajah TT, Peine KJ, Du N, Serret CA. DePaul University, Chicago, IL. 
p3-04-08  increased cellular expression activity of minimal residual 
disease in breast cancer after surgery
Pachmann K, Carl S, Camara O.  Friedrich Schiller University Jena, 
Jena, Germany. 
tumor Cell biology: tumor heterogeneity/molecular Subclassification
p3-05-01  gene profiling of histopathologically Characterized apocrine 
breast Cancers
Feugeas J-P, Dumay A, Lehmann-Che J, de Cremoux P, Delord M, 
Soulier J, Hamy A-S, Espié M, André F, Marty M, Sotiriou C, Piccart-
Gebhart M, Pusztai L, Bertheau P, de Thé H. Hopital Saint-Louis, Paris, 
France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, 
Bruxelles, France; MD Anderson Cancer Center, Houston. 
p3-05-02  Subtype-Specific Co-occurrence of atypical hyperplasia and in 
Situ Carcinoma with invasive breast Cancers
Kovatich AJ, Kvecher L, Chen Y, Bekhash A, Hooke JA, Shriver CD, 
Mural RJ, Hu H. Windber Research Institute, Windber, PA; Walter 
Reed Army Medical Center, Washington, DC; MDR Global Systems 
LLC, Windber, PA. 
p3-05-03  transcriptomic validation of molecular Classification of 
invasive Ductal Carcinoma based on immunohistochemical 
markers and grade
Rigaill G, Richardson M, Gravier E, Yann M, Gentien D, Caly M, 
Fourquet A, Alran S, Sastre X, Dubois T, Vincent-Salomon A. Institut 
Curie, Paris, France. 
p3-05-04  Changes in recurrence risk of breast Cancer intrisic Subtypes 
over time
Ribelles N, Perez-Villa L, Pajares B, Jerez JM, Vicioso L, Jimenez B, de 
Luque V, Franco L, Alvarez M, Perez-Rivas LG, Sanchez-Muñoz A, 
Gallego E, Marquez A, Hierro I, Alba E. Hospital Universitario Virgen 
de la Victoria, Malaga, Spain; Universidad de Malaga, Malaga, Spain. 
p3-05-05  Cyclin D1 gene amplification is rarely heterogeneous in 
breast Cancer
Burandt E, Grünert M, Choschzick M, Müller V, Bokemeyer C, Simon 
R, Sauter G, Lebeau A, Jänicke F, Wilczak W. University Medical 
Center Hamburg-Eppendorf, Hamburg, Germany. 
p3-05-06  progression of breast Cancer molecular Subtypes through 
Different Clinical Stages
Ciruelos EM, Castaneda CA, Andrés E, Gomez HL, Castellano D, 
Mendiola C, Manso L, Ghanem I, Farfan C, Cortes-Funes H. Hospital 
Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de 
Enfermedades Neoplásicas, Lima, Peru. 
p3-05-07  genetic heterogeneity of amplification Status in breast 
invasive Carcinoma with 2+ her2 immunostaining: What Can 
We learn?
Valent A, Delaloge S, Ferchiou M, Bernheim A, Mathieu M-C. Institut 
Gustave Roussy, Villejuif, France, Metropolitan. 
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p3-05-08  hormone receptor heterogeneity in Ductal intraepithelial 
neoplasia (Ductal Carcinoma in Situ) of the breast
Sowden M, Flynn C, Bossuyt V, Lannin D, Chagpar AB. Yale University 
School of Medicine, New Haven, CT. 
p3-05-09  Comparison of Clinical Features and patterns of recurrence 
in triple negative breast Cancers in relation to other breast 
Cancers
Tosello de Oliveira C, Barbosa EM, Costa de Andrade J, Lyra EC, 
Felzener MC, Krutman Zveibil D, Grosso SHG, Sampaio Goes de 
Oliveira R, Sampaio Góes JC. Instituto Brasileiro de Controle do 
Cancer, Sao Paulo, Brazil. 
p3-05-10  Standardized Quantitative methods for investigating the 
intratumor heterogeneity of her2 in FFpe breast Cancer 
Specimens utilizing the vectra System, inForm and aQua 
technology
Hoyt CC, Gustavson MD, Davis WL, Lane KA, Scott CG, Graves, Jr LL. 
Caliper Life Sciences, Hopkinton, MA; HistoRx, Branford, CT. 
tumor Cell biology: genomics
p3-06-01  next generation rna Sequencing reveals Changes in gene 
expression and alternative Splicing upon brief exposure to 
therapy in early breast Cancer
Varadan V, Kamalakaran S, Janevski A, Banerjee N, Lezon-Geyda K, 
Bossuyt V, Flowers D, Sikov W, Abu-Khalaf M, Rizack T, Dimitrova N, 
Harris LN. Philips Research North America, Briarcliff Manor, NY; Yale 
University School of Medicine, New Haven, CT; Brown University 
School of Medicine, Providence, RI. 
p3-06-02 identification of redundant, tumor Subtype Specific Fusion 
transcripts in primary breast tumors
Thompson EA, Asmann YW, Necela BM, Andorfer CA, Cunliffe HE, 
Hossain A, Getz JE, Hostetter G, Schroth GP, Perez EA. Mayo Clinic, 
Jacksonville, FL; Mayo Clinic, Rochester, MN; TGen, Scottsdale, AZ; 
Illumina, Inc., Hayward, CA. 
p3-06-03  hypodiploidy, 1pter loss and inactive X Chromosome 
retention are associated with brCa1 Somatic or germline 
inactivation in basal-like breast Carcinomas: proposal for a 
new brCaness genomic Signature
Manié E, Popova T, Vincent-Salomon A, Dubois T, Delattre O, Sastre-
Garau X, Stoppa-Lyonnet D, Stern M-H. Institut Curie, Paris, France; 
INSERM, Paris, France; Université Paris-Descartes, Paris, France. 
p3-06-04  Sno/mirna expression via next generation Sequencing: 
variation in patients before and after treatment
Banerjee N, Kamalakaran S, Varadan V, Janevski A, Lezon-Geyda 
K, Bossuyt V, Flowers D, Sikov W, Abu-Khalaf M, Rizack T, Harris L, 
Dimitrova N. Philips Research North America, Briarcliff Manor, NY; 
Yale University School of Medicine, New Haven, CT; Brown University 
School of Medicine, Providence, RI. 
p3-06-05  Comparison of oncotype DX® recurrence Scores between 
Surgical and Core biopsy Specimens in breast Cancer patients
Stull TS, Goodwin MC, Anderson JM, Baehner FL, Sing AP, Yoshizawa 
CN, Barrio AV, Frazier TG. The Bryn Mawr Hospital, Bryn Mawr, PA; 
Genomic Health, Inc, Redwood City, CA. 
p3-06-06  Comparison of gene expression profiles of lymph node 
positive and lymph node negative er positive breast tumors 
in pre- and postmenopausal Women
Rapuri PB, Brilhart G, Deyarmin B, Kvecher L, Hu H, Hooke JA, Shriver 
CD, Mural RJ. Windber Research Institute, Windber, PA; Walter Reed 
Medical Center, Washington, DC. 
p3-06-07  integrated genomic and pathway analysis reveals key 
pathways across breast Subtypes
Benz S, Sanborn JZ, Vaske C. Five3 Genomics, LLC, Santa Cruz, CA. 
p3-06-08  SCan-b: an accelerated translational pipeline from profile to 
prognosis and prediction for individual breast Cancer patients
Loman N, Saal LH, Häkkinen J, Vallon-Christersson J, Ringnér M, 
Hegardt C, Jönsson G, Gruvberger-Saal SK, Kvist A, Reuterswärd C, 
Schulz R, Karlsson A, Jönsson M, Grabau D, Manjer J, Carlson J, Malina 
J, Larsson C, Rydén L, Borg å. Lund University, Lund, Sweden; Skåne 
University Hospital, Lund, Sweden; Skåne University Hospital, Malmö, 
Sweden. 
Detection and Diagnosis: axillary Staging and Sentinel nodes
p3-07-01  are the Findings of aSoCog Z0011 applicable to District 
general hospital breast unit - and how Should they Change 
our practice?
Olsen SB, Amr B, Omar A, Smith J, Thomson S, Monib S, Lai LM. West 
Hertfordshire NHS Trust, St Albans, Hertfordshire, United Kingdom. 
p3-07-02  prediction of non-Sentinel lymph node Status in breast 
Cancer patients with a micrometastatic Sentinel lymph node 
Determined by the one Step nucleic acid amplification 
(oSna) assay
Di Filippo F, Casini B, Gallo E, Terrenato I, Botti C, Mottolese M, 
Pescarmona E, Marandino F, Buglioni S. Regina Elena National Cancer 
Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy. 
p3-07-03  one-Step nucleic acid amplification (oSna) for the Diagnosis 
of Sentinel lymph nodes of breast Cancer - results of the 
China multicenter Study CbCSg-001c
Wang YS, Ouyang T, Wu J, Liu YH, Cao XC. Shandong Cancer Hospital 
& Institute, Jinan, Shandong, China; Beijing University Cancer 
Hospital, Beijing, China; Fudan University Cancer Hospital, Shanghai, 
China; Guangdong General Hospital, Guangzhou, Guangdong, China; 
Tianjin Midical University Cancer Hospital, Tianjin, China. 
p3-07-04  Does omission of axillary Dissection after a positive Sentinel 
node biopsy influence indication to adjuvant Chemotherapy 
in operable breast Cancer patients?
Montemurro F, Maggiorotto F, Valabrega G, Kubatzki F, Rossi V, 
Marocco F, Magistris A, Gatti M, Sarotto I, Aglietta M, Ponzone R. 
Fondazione del Piemonte per l’Oncologia/IRCC, Candiolo, Torino, 
Italy. 
p3-07-05  nomogram incorporating Sln metastasis Size provides the 
most accurate prediction of non-Sln involvement in breast 
Cancer patients
Gainer SM, Mittendorf EA, Hunt KK, Bassett RL, Yi M, Meric-Bernstam 
F, Ross MI, Babiera GV, Kuerer HM, Caudle AS, Hwang RF. UT-M.D. 
Anderson Cancer Center, Houston, TX. 
p3-07-06  prognostic utility of upfront nodal Staging prior to 
neoadjuvant Chemotherapy: the uab experience
Keene KS, De Los Santos JF, Krontiras H, Hinton B, Meredith R, 
Li Y, Carpenter JT, Bland K, Forero A. University of Alabama at 
Birmingham, Birmingham, AL. 
p3-07-07  effect of Sentinel lymph node biopsy without axillary lymph 
node Dissection on overall Survival in patients with t1 or t2 
node-positive breast Cancer: a report from the korean breast 
Cancer Society
Park HS, Chae BJ, Song BJ, Jung SS, KBCS Investigators. The Catholic 
University of Korea College of Medicine, Seoul, Korea; Korean Breast 
Cancer Society. 
p3-07-08  accurate Staging of axillary lymph nodes from breast Cancer 
patients using a novel molecular method
Osako T, Iwase T, Kimura K, Yamashita K, Horii R, Akiyama F. Cancer 
Institute Hospital of Japanese Foundation for Cancer Research, Koto-
ku, Tokyo, Japan. 
p3-07-09  prediction of additional nodal metastasis in breast Cancer 
patients with a positive Sentinel node biopsy: a new 
nomogram including her2 Status
Ngô C, De Rycke Y, Castellier C, Fourchotte V, Hugonnet F, Hajage 
D, Reyal F, Vincent-Salomon A, Pierga J-Y, Kirova Y, Sastre-Garau X, 
Alran S. Institut Curie, Paris, France. 
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p3-07-10  Sentinel lymph node navigation Surgery using Combination 
of indocyanine green Fluorescence and blue Dye for breast 
Cancer patients
Takahashi M, Hayashida T, Jinno H, Kitagawa Y. Keio University 
School of Medicine, Tokyo, Shinjuku, Japan. 
p3-07-11  multicenter Comparative Study between one-Step nucleic 
acid amplification (oSna) Whole node assay and Standard 
Frozen Section histology: intraoperative molecular assay for 
Sentinel lymph node metastases in early breast Cancer Can 
avoid a Second Surgery
Espinosa-Bravo M, Ramos T, Aizpurua Gomez M, Sao Avilés A, Peg 
Carmara V, Sancho M, Gónzalez-Orus JM, Xercavins Montosa J, 
Ramos M, Rubio IT. Hospital Universitario Vall d´Hebron, Barcelona, 
Spain; Hospital Universitario de Salamanca, Salamanca, Spain. 
p3-07-12  value of preoperative ultrasound-guided axillary lymph 
node biopsy for preventing Futile Sentinel node procedures in 
breast Cancer: a Systematic review and meta-analysis
Diepstraten SC, Sever AR, Buckens CF, Veldhuis WB, van den Bosch 
MA, Mali WP, Verkooijen HM. University Medical Center Utrecht, 
Netherlands; Maidstone Hospital, United Kingdom. 
p3-07-13  validation and Comparison of models to predict nonsentinel 
lymph node metastasis in Chinese breast Cancer patients with 
positive Sentinel lymph nodes
Chen K, Jia W, Zeng Y, Fan M, Su F, Li S. Sun Yat-sen Memorial 
Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. 
p3-07-14  Sensory Disturbance of the ipsilateral upper arm after breast 
Cancer Surgery with Sentinel node biopsy alone Compared 
with axillary Dissection - a prospective Study
Ohsumi S, Kiyoto S, Takahashi M, Hara F, Takabatake D, Takashima 
S, Aogi K, Shimozuma K. NHO Shikoku Cancer Center, Matsuyama, 
Ehime, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan. 
p3-07-15  Sequential peri-areolar and peri-tumoural SpeCt/Ct 
lymphoscintigraphy has identified high rates of Discordance 
in both axillary and internal mammary Sentinel lymph node 
mapping
Noushi F, Spillane A, Gebski V, Snook K, Gillet D, Cooper R, Allwright 
S, Uren R. Sydney University, Sydney, New South Wales, Australia; 
Mater Hospital, Crows Nest, New South Wales, Australia. 
p3-07-16  the efficacy of arm node preserving Surgery using axillary 
reverse mapping for preventing lymphedema in patients 
with breast Cancer
Seo YJ, Hwang MJ, Lee JH, Son GT, Choi JE, Bae YK, Kang SH, Lee SJ. 
Yeungnam University College of Medicine, Daegu, Republic of Korea. 
p3-07-17  optimal number of Sentinel lymph nodes that Could avoid 
Completion of axillary lymph node Dissection in operable 
breast Cancer
Salmon RJ, de Ricke Y, Falcou MC. Institut Curie, Paris, France. 
p3-07-18  Withdrawn
p3-07-19  long-term outcome of internal mammary lymph node 
Detected by lymphoscintigraphy in early breast Cancer
Koo MY, Lee JE, Nam SJ, Yang J-H, Lee SK, Kim S, Choi M-Y, Cho DH, 
Kim J, Lee J, Jung SP. Samsung Medical Center, Seoul, Korea. 
p3-07-20  an independent assessment of Seven nomograms for 
predicting the probability of additional axillary nodal 
metastasis after positive Sentinel lymph node biopsy in a 
Cohort of british breast Cancer population
Nadeem RM, Gudur LD, Saidan ZA. Lancashire Teaching Hospitals 
NHS Foundation Trust, Chorley, United Kingdom. 
p3-07-21  Sentinel lymph node metastasis are more likely to 
Develop in triple positive breast Cancer patients without 
Compromising Disease Free Survival
Rubio IT, Espinosa-Bravo M, Cebrecos I, Sao A, Peg V, Di Cosimo S, 
Cortes J, Xercavins J. Hospital Universitario Vall d´Hebron, Barcelona, 
Spain. 
p3-07-22  Combined approach for Staging the axilla in breast Cancer 
patients with Clinically (-)nodes versus Sentinel node biopsy 
alone
Patel RK, Krol VV, Cibull ML, McGrath PC, Fjällskog M-L, Pirruccello 
EA, Szabunio AL, Samayoa LM. University of Kentucky, Lexington, KY; 
Uppsala University, Uppsala, Sweden; VAMC, Lexington, KY. 
p3-07-23  intraoperative molecular analysis of Sentinel lymph nodes 
in breast Cancer using one Step nucleic acid amplification 
(oSna)
Chaudhry A, Massey E, Jenkins M, Calder C, Winters ZE, Rayter Z. 
Bristol Royal Infirmary, Bristol. 
p3-07-24  accuracy and Cost effectiveness of Frozen Section 
examination of the Sentinel lymph node (Sln) in Ductal 
Carcinoma in Situ (DCiS) of breast
Ballehaninna UK, Santoro E, Schaefer SS, Blackwood MM, 
Chamberlain RS. Saint Barnabas Medical Center, Livingston, NJ; 
Maimonides Medical Center, Brooklyn, NY; Saint George’s University 
School of Medicine, West Indies, Grenada; University of Medicine and 
Dentistry of New Jersey, Newark, NJ. 
p3-07-25  Sentinel lymph node mapping in breast Cancer after primary 
Chemotherapy
Bonardi S, Andreis D, Allevi G, Aguggini S, Milani M, Generali 
D, Bersiga A, Brizzi MP, Dogliotti L, Berruti A, Bottini A. Azienda 
Ospedaliera Istituti Ospitalieri, Cremona, Italy; Azienda Ospedaliera 
Universitaria San Luigi di Orbassano, Università di Torino, Orbassano, 
Torino, Italy. 
p3-07-26 how generalizable is the patient population enrolled in 
aCoSog Z11?
Lannin DR, Killelea BK, Grube BJ, Horowitz N, Chagpar AB. Yale 
University School of Medicine, New Haven, CT. 
p3-07-27  roCk ii expression Can be a potential marker of non-Sentinel 
lymph node metastasis in breast Cancer patients with 
Sentinel lymph node involvement
Shigematsu H, Taguchi K, Shiotani S, Kawaguchi H, Nishiyama K, 
Ohno S, Okada M. Hiroshima University Hospital, Hiroshima, Japan; 
National Kyushu Cancer Center, Fukuoka, Japan. 
p3-07-28  one Step nucleic acid amplification (oSna) for intraoperative 
molecular Detection of lymph node metastases and micro-
metastases in breast Cancer
Babar MM, Madani R, Jackson P, Irvine T, Layer G, Kissin M. Royal 
Surrey County Hospital, Guildford, SU, United Kingdom; University of 
Surrey, Guildford, SU, United Kingdom. 
p3-07-29  validating the lymph node ratio as a prognostic indicator 
among South east asian breast Cancer patients
Saxena N, Hartman M, Bhoo Pathy N, Aziz R, Siew EL, Lee SC, Yip 
CH, Verkooijen HM. National University of Singapore, Singapore, 
Singapore; Faculty of Medicine, University of Malaya, Kuala Lumpur, 
Malaysia; University Medical Center Utrecht, Utrecht, Netherlands; 
National University Cancer Institute, National University Health 
Systems, Singapore, Singapore. 
p3-07-30  applying the Findings of the Z11 trial to a uk practice
Chalmers CR, Mallon EA, Stallard S, Doughty JC, Wilson CR. Western 
Infirmary, Glasgow, Scotland, United Kingdom. 
p3-07-31  intra-operative assessment of Sentinel lymph nodes in breast 
Cancer with touch imprint Cytology (tiC) in 460 Consecutive 
patients
Iqbal M, Shetty G, Randhawa S, Sandhu F, Chachlani N, Simon 
J, Harries S, Jones L, Clarke D. Warwick Hospital, Warwick, West 
Midlands, United Kingdom. 
p3-07-32  the role of axillary ultrasound in the Detection of metastases 
from primary breast Cancers
Yamashita M, Little E, Fraley J, Hovanessian-Larsen L, Sener SF. Keck 
School of Medicine, University of Southern California, Los Angeles, 
CA. 
41s
December 6-10, 2011
www.aacrjournals.org
Program Schedule
Cancer Res; 71(24 Suppl.) December 15, 2011
p3-07-33  are Single node metastases more Common in patients with 
breast Cancer in the Sentinel node era?
Shetty G, Randhawa S, Mohammed I, Harries S, Jones L, Clarke D. 
Warwick Hospital, Warwick, Westmidlands, United Kingdom. 
p3-07-34  occult metastasis in Sentinel node: Should this affect the 
Clinical Decision making? a Systematic review and meta-
analysis
Valachis A, Nearchou A, Polyzos NP, Lind P, Berqvist J. 
Mälarsjukhuset, Eskilstuna, Sweden; Universitair Ziekenhuis Brussel, 
Brussels, Belgium; Karolinska Institutet, Stockholm, Sweden. 
p3-07-35  validation of online Calculators to predict non-Sentinel 
lymph node Status in Sentinel lymph node-positive breast 
Cancer patients
Tanaka S, Sato N, Fujioka H, Takahashi Y, Kimura K, Iwamoto M. 
Osaka Medical College, Takatsuki, Osaka, Japan. 
p3-07-36  predicting Sentinel lymph node metastasis of a Chinese 
breast Cancer population: assessment of an existing 
nomogram and a new predictive nomogram
Chen J-y, Chen J-j, Yang B-l, Liu Z-b, Huang X-y, Liu G-y, Han Q-x, 
Yang W-t, Shen Z-z, Shao Z-m, Wu J. Fudan University Shanghai 
Cancer Center, Shanghai, China. 
p3-07-37  Clinical Characteristics and treatment of brazilian Women 
with breast Cancer at public and private institutions
Hegg R, Mattar A, Gebrim LH, Emerenciano K, Pinotti M, Perdicaris M, 
van Eyll B, Franke F, Pinczowski H, Freitas, Jr R, Jendiroba D, Borges G, 
Queiroz G, Nascimento YV, Gampel O, Mathias C, Budel V, Strepassos 
E, Delgado G. Perola Byington Hospital, Sao Paulo, SP, Brazil; Liga 
Norte Riograndense; EGIMAJAP; Instituto Santista de Oncologia; 
Instituto do Cancer Arnaldo Vieira de Carvalho; Hospital de Caridade 
de Ijui; Faculdade de Medicina do ABC; Hospital das Clinicas de 
Goiania; Centro Goiano de Oncologia; Clinica de Neoplasias Litoral; 
Hospital Araujo Jorge; Cepon; Hospital do Servidor Publico do Estado 
de Sao Paulo; Nucleo de Oncologia da Bahia; Unoversidade Federal 
do Parana; Hospital Sao Rafael; Hospital Santa Lucinda. 
p3-07-38  Selective omission of blue Dye in patients undergoing 
Sentinel lymph node biopsy for breast Cancer
Waters JL, Iqbal M, Jones L, Harries S, Clarke D. Warwick Hospital, 
South West Warwickshire Foundation Trust, Warwick, West Midlands, 
United Kingdom. 
p3-07-39  Where to look for Sentinel lymph node in breast Cancer
Düran A. Klinikum Bayreuth GmbH, Bayreuth, Bayern, Germany. 
p3-07-40 impact of the Sentinel lymph node procedure on the 
Detection of positive lymph nodes in breast Cancer
Smeets A, Yoshihara E, Laenen A, Wildiers H, Reynders A, Soens 
J, Paridaens R, Van Ongeval C, Floris G, Moerman P, Neven P, 
Christiaens M-R. University Hospitals Leuven, Leuven, Belgium; 
Katholieke Universiteit Leuven, Leuven, Belgium. 
p3-07-41  Sentinel lymph node biopsy is a reliable method for lymph 
node evaluation in neoadjuvant Chemotherapy treated 
breast Cancer patients
Kaplan R, Qiu Q, Monni S, Swistel A, Shin S. The New York-
Presbyterian Hospital-Weill Cornell Medical Center, New York, NY. 
p3-07-42  lymphovascular invasion best Correlates with presence of 
nodal metastasis in Sentinel lymph node biopsy
Absar MS, Adelekan MO, Patel E, Cotterill S. North Manchester 
General Hospital, Manchester, United Kingdom; University of 
Manchester, Manchester, United Kingdom. 
p3-07-43  the impact of timing in Sentinel lymph node biopsy in 
primary breast Cancer
Güth U, Schmid SM, Myrick ME, Obermann EC, Viehl CT, Rochlitz C, 
Forrer F. University Hospital Basel, Basel, Switzerland. 
p3-07-44  Feasibility of axillary reverse mapping during Sentinel lymph 
node biopsy in breast Cancer
Noguchi M, Ohno Y, Nakano Y, Noguchi M, Kosaka T. Kanazawa 
Medical University, Kahoku, Ishikawa, Japan. 
p3-07-45  role of SpeCt-Ct in Detecting Sentinel lymph nodes in 
patients with ipsilateral breast Cancer recurrence and 
previous axillary lymph node Dissection
Cordoba O, Perez-Ceresuela F, Roca I, Mendoza C, Cortadellas T, 
Espinosa-Bravo M, Rodriguez J, Peg V, Rubio IT, Xercavins J. Hospital 
Universitari Vall d’Hebron, Barcelona, Spain; Universitat Autònoma de 
Barcelona, Barcelona, Spain. 
p3-07-46  accuracy of Spio-enhanced mr imaging alone for the 
Diagnosis of Sentinel node metastases in patients with breast 
Cancer
Motomura K, Nakahara S, Ishitobi M, Komoike Y, Koyama H, Inaji 
H, Horinouchi T, Nakanishi K. Osaka Medical Center for Cancer and 
Cardiovascular Diseases, Osaka, Japan. 
p3-07-47  validated nomogram to predict Sentinel lymph node 
positivity in breast Cancer patients
Kaplan R, Qiu Q, Monni S, D’Alfonso T, Shin SJ. The New York-
Presbyterian Hospital - Weill Cornell Medical College, New York, NY. 
p3-07-48  axillary imaging with Dynamic mri Following Subcutaneous 
injection of Superparamagnetic iron oxide nanoparticles
Douek M, Johnson L, Parikh J, Charles-Eduards G, Hall-Craggs M. 
King’s College London, London, United Kingdom; Guy’ and St 
Thomas’ Hospitals, London, United Kingdom; University College 
Hospital, London, United Kingdom. 
p3-07-49  microinvasive breast Carcinoma: evaluation of status axillary is 
necessary?
Gioia SM, Marinho FM, Esteves JM, Carmo PA, Magalhaes LM, Vignal 
GM, Felicio FL.  Brazilian National Cancer Institute, Rio de Janeiro, Rio 
de Janeiro, Brazil. 
epidemiology, risk, and prevention: prevention – behavioral interventions
p3-08-01  effects of an integrated yoga program on mood States, 
Distress, Quality of life, Diurnal Cortisol rhythms and natural 
killer Cell Counts in metastatic breast Cancer Survivors
Gopinath SK, Rao RM, Sanjeevarao VH, Diwakar RB, Basavalingaiah 
AS, Patil S, Raghuram N, Ramarao N, Usharani RM. HCG - BIO Super 
Speciality Centre, Bangalore, Karnataka, India; Swami Vivekananda 
Yoga Anusandhana Samsthana, Bangalore, Karnataka, India. 
p3-08-02  evaluating the impact of educational material on anastrozole 
treatment adherence - the Final results of the artemiS Study
Nogaret J-M, Coibion M, Neven P, Soepenberg O, Graas M-PP, 
Deschamp V, Vanlerberghe T. Jules Bordet Institute, Brussels, 
Belgium; CHC St-Vincent, Rocourt, Belgium; University Hospital 
Leuven, Leuven, Belgium; MariaZiekenhuis, Noord-Limburg, Belgium; 
CHC Saint-Joseph, Liège, Belgium; AstraZeneca Benelux, Brussels, 
Belgium. 
p3-08-03  exercise increases Soluble vascular endothelial growth Factor 
receptor-1 (sFlt-1) in the Circulation of adult Women
Makey K, Patterson SG, Robinson J, Loftin M, Waddell DE, Miele L, 
Chinchar E, Huang M, Smith AD, Weber M, Gu J-W. University of 
Mississippi Medical Center, Jackson, MS; University of Mississippi, 
Oxford, MS. 
p3-08-04  “how important is this for me?” - the role of necessity beliefs 
as Determinants of breast Cancer prevention intentions 
among high-risk Women
Verma S, Paquet L, Stacey D, Davis I, Bedard M, Lowry S, Ianni L. 
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Carleton 
University, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, 
Canada. 
p3-08-05  internet-assisted weight loss for overweight/obese women at 
high risk for breast cancer
Cadmus-Bertram LA, Wang JB, Pierce JP, Patterson RE, Newman VA, 
Ojeda-Fournier H, Barbara PA.  University of California, San Diego, La 
Jolla, CA. 
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epidemiology, risk, and prevention: prevention – nutritional Studies
p3-09-01  Change in Carbohydrate intake and breast Cancer prognosis
Emond JA, Patterson RE, Pierce JP. UCSD Moores Cancer Center, La 
Jolla, CA; San Diego State University, San Diego, CA. 
p3-09-02  intermittent Dietary Carbohydrate restriction enables Weight 
loss and reduces breast Cancer risk biomarkers
Harvie M, Wright C, Pegington M, Mitchell E, Evans DG, Jebb S, Clarke 
R, Goodacre R, Dunn W, Mattson M, Howell A. University Hospital 
of South Manchester, Manchester, United Kingdom; MRC Human 
Nutrition Research Group, Cambridge, United Kingdom; University 
of Manchester, Manchester, United Kingdom; National Institute of 
Aging, Baltimore. 
p3-09-03  long-Chain polyunsaturated Fatty acid intake and its 
relationship to long-Chain polyunsaturated Fatty acids in 
Serum, red blood Cells and breast tissue
Harvey KE, Li S, Carlson SE, Sullivan DK, Klemp JR, Kimler BF, Fabian 
CJ. University of Kansas Medical Center, Kansas City, KS. 
p3-09-04  Comparative preventive efficacy of aqueous extracts from 
lycium barbarum bark and Fruit on estrogen receptor 
positive human mammary Carcinoma mCF-7 Cells
Telang NT, Li G, Sepkovic DW, Bradlow LH, Wong GGY, Telang NT. 
Palindrome Liaisons, Montvale, NJ; American Institute for Chinese 
Medicine, New York, NY; Hackensack University Medical Center, 
Hackensack, NJ. 
p3-09-05  understanding the role of estrogen in Sex Differences in 
adipocyte biology for Cancer prevention
Stubbins RE, Holcomb VB, Hong J, Nunez NP. The University of Texas 
at Austin, Austin, TX. 
p3-09-06  Changes of Serum vitamin D according to the breast Cancer 
treatment
Kim HJ, Yi OV, Koh BS, Yu JH, Lee JW, Son BH, Ahn SH. Asan Medical 
Center, Seoul, Korea. 
epidemiology, risk, and prevention: prevention – preclinical Studies and 
model Systems
p3-10-01  alternative Dosing regimens with the egFr inhibitors 
(gefitinib and lapatinib) in mammary Cancer models: 
prevention and therapeutic efficacy
Lubet RA, Bode AM, Szabo E, Grubbs CJ. National Cancer Institute, 
Bethesda, MD; Hormel Institute, Austin, MN; University of Alabama at 
Birmingham, Birmingham, AL. 
p3-10-02  gene expression Changes in methylnitrosourea (mnu)-
induced er+ mammary Cancers Following Short-term 
treatment of rats with the aromatase inhibitor vorozole
Lubet RA, Grubbs CJ, Bode A, You M, Lu Y. National Cancer Institute, 
Bethesda, MD; University of Alabama at Birmingham, Birmingham, 
AL; Hormel Institute, Austin, MN; Medical College of Wisconsin, 
Milwaukee, WI. 
p3-10-03  bardoxolone (5meCDDo) inhibits Cancer initiation but 
promotes progression in rodent models of breast Cancer. 
What Does it mean for the antioxidant response element 
(are) as a primary prevention target?
Lubet RA, Townsend R, Vedell P, Steele VE, Grubbs CJ. National 
Cancer Institute, Bethesda, MD; Washington University School of 
Medicine, Saint Louis, MO; Medical College of Wisconsin, Milwaukee, 
WI; University of Alabama at Birmingham, Birmingham, AL. 
p3-10-04  halting early breast Cancer progression with omega-3 ethyl 
esters: altering tumor microenvironment in 21t Series Cell 
lines
Chen CH, Rhodes ME, Fabian C, Hursting SD, deGraffenried LA. 
University of Texas at Austin, Austin, TX; University of Kansas Cancer 
Center, Kansas City, KS. 
epidemiology, risk, and prevention: prevention – Clinical trials
p3-11-01  effects of exemestane therapy on the lipid profile of 
postmenopausal Women with an elevated risk of Developing 
invasive breast Cancer
Gatti M, Venzon D, Zujewski J, Korde L, Isaacs C, Cohen P, Warren 
R, Gallagher A, Eng-Wong J. Georgetown University Hospital, 
Washington, DC; National Cancer Institute, National Institutes 
of Health, Bethesda, MD; University of Washington, Seattle, WA; 
Lombardi Comprehensive Cancer Center, Georgetown University 
Hospital, Washington, DC. 
p3-11-02  Changing paradigms for breast Cancer Chemoprevention?
Chlebowski RT. Los Angeles Biomedical Research Institute @ Harbor-
UCLA Medical Center, Torrance, CA. 
p3-11-03  a phase i trial of D-limonene in newly Diagnosed breast 
Cancer patients: a Chemoprevention Study
Lang JE, Miller JA, Nokes BT, LeBeau LG, Delbridge M, Chow H-HS. 
Arizona Cancer Center, University of Arizona, Tucson, AZ. 
p3-11-04  a randomized phase ii biomarker Study of atorvastatin in 
premenopausal Women at increased risk for breast Cancer
Wood ME, Kingsley F, Ellerton JA, Atkins JN, Grubs SS, Muss HB, 
Garber JE. University of Vermont, Burlington, VT; Cancer Consultants, 
Las Vegas, NV; Southeastern Medical Center, Winston-Salem, NC; 
Medical Oncology Hematology Consultants, Newark, DE; University 
of North Carolina Lineberger Comprehensive Cancer Center, Chapel 
Hill, NC; Dana-Farber Cancer Institute, Boston, MA. 
p3-11-05  an efficient resource to accelerate research into the Cause 
and prevention of breast Cancer: the love/avon army of 
Women
Love SM. Dr. Susan Love Research Foundation, Santa Monica, CA. 
p3-11-06  a pilot Study of rpFna in overweight and obese 
postmenopausal Women
Korde LA, Grieco VS, Imayama I, Kumai C, Mason C, Duggan CR, 
Wang C-Y, McTiernan A. University of Washington, Seattle, WA; Fred 
Hutchinson Cancer Research Center, Seattle, WA. 
p3-11-07  mammary gland biopsy to examine Surrogate endpoint 
biomarkers of preventive agent efficacy
Heckman-Stoddard B, Lubet RA, Bode AM, Grubbs CJ. National 
Cancer Institute, Bethesda, MD; University of Minnesota, Austin, MN; 
University of AL at Birmingham, Birmingham, AL. 
treatment – local: breast Conservation
p3-12-01  roll trial - radio-guided occult lesion localization versus 
Wire guided localization in breast Conserving Surgery for 
non-palpable breast Cancer: a multicenter randomized 
Controlled trial
Postma EL, Verkooijen HM, van Esser SE, Hobbelink MG, van der 
Schelling GP, Koelemij R, Witkamp AJ, Contant CM, van Diest PJ, 
Borel Rinkes IH, van den Bosch MA, Mali WP, van Hillegersberg 
R. UMC Utrecht, Utrecht, Netherlands; St. Antonius Ziekenhuis, 
Nieuwegein, Netherlands; Amphia Hospital, Breda, Netherlands; 
Maasstad Hospital, Rotterdam, Netherlands. 
p3-12-02  intra-operative margin assessment of Diffuse Disease with 
marginprobe™ as an adjunct to Standard of Care, results from 
a randomized prospective multi Center Study
Boolbol SK, Cocilovo C, Tafra L. Beth Israel Medical Center, New York, 
NY; Inova, Alexandria, VA; Anne Arundel Health System, Annapolis, 
MD. 
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p3-12-03  a prognostic index of ipsilateral breast tumor recurrence 
in patients treated with breast-Conserving Surgery after 
preoperative Chemotherapy: validation of m.D. anderson 
prognostic index
Ohno S, Ohsumi S, Inaji H, Akiyama F, Akashi-Tanaka S, Sato N, 
Takahashi K, Oura S. National Kyushu Cancer Center, Fukuoka, Japan; 
National Shikoku Cancer Center, Matsuyama, Ehime, Japan; Osaka 
Medical Center for Cancer and Cardiovasucular Disease, Osaka, 
Japan; The Cancer Institute of the Japanese Foundation for Cancer 
Research, Tokyo, Tokyo, Japan; National Cancer Center Hospital, 
Tokyo, Tokyo, Japan; Niigata Cancer Center Hospital, Niigata, Japan; 
Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan; Wakayama 
Medical University, Wakayama, Japan. 
p3-12-04  involved anterior margins after breast Conserving Surgery: is 
re-excision required?
Mullen R, Macaskill EJ, Khalil A, Elseedawy E, Brown DC, Lee AC, 
Purdie C, Jordan L, Thompson AM. Ninewells Hospital, Dundee, 
United Kingdom; Perth Royal Infirmary, Perth, United Kingdom. 
p3-12-05  breast Cancer recurrence: 2nd Conservative treatment versus 
mastectomy
Michel V, Houvenaeghel G, Bannier M, Tallet A, Minsat M, Lambaudie 
E, Salem N, Butarelli M, Resbeut M. Paoli Calmettes Cancer Institute, 
Marseille, France. 
treatment – local: radiotherapy
p3-13-01  boost radiation therapy not of value in reducing ibtr of 
invasive or noninvasive breast Cancers for patients with DCiS: 
results from the nSabp b-24 trial
Julian TB, Vicini FA, Costantino JP, Arthur DW, Kidwell KM, Land 
SR, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast 
& Bowel Project, Pittsburgh, PA; Allegheny General Hospital, 
Pittsburgh, PA; Beaumont Health System, Royal Oak, MI; Virginia 
Commonwealth University, Richmond, VA; Graduate School of Public 
Health, University of Pittsburgh, Pittsburgh, PA; Aultman Health 
Foundation, Canton, OH. 
p3-13-02  the impact of lymph node Status on Clinical outcomes 
Following accelerated partial breast irradiation
Shah C, Wilkinson JB, Wallace M, Vicini F. William Beaumont Hospital, 
Royal Oak, MI. 
p3-13-03  long-term Symptoms after radiotherapy of Supraclavicular 
lymph nodes in breast Cancer patients
Lundstedt D, Gustafsson M, Steineck G, Alsadius D, Sundberg A, 
Wilderäng U, Holmberg E, Johansson K-A, Karlsson P. Institute of 
Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 
Gothenburg, Sweden; Institute of Clinical Sciences, Gothenburg, 
Sweden; Karolinska Institute, Stockholm, Sweden. 
p3-13-04  Functional and Cosmetic outcomes Following post-
mastectomy irradiation with tissue expander/implant 
reconstruction
Baschnagel A, Shah C, Wilkinson JB, Dekhne N, Margolis J, Arthur 
DW, Vicini F. William Beaumont Hospital, Royal Oak, MI; VCU Massey 
Cancer Center, Richmond, VA. 
p3-13-05  analysis of heart Dose-volume parameters and Cardiac events 
among node positive breast Cancer (npbC) patients treated 
with three-Dimensional Conformal radiation therapy (3D-
Crt)
Bradley J, Prior P, Sparks I, Xiang Q, Santana-Davila R, Walker A, 
Wilson JF, Li XA, White J. Medical College of Wisconsin, Milwaukee, 
WI. 
p3-13-06  Cardiovascular magentic resonance imaging and radiation-
induced heart Disease Following radiotherapy for breast 
Cancer
Cutter D, Ferreira V, Basagiannis C, Becher HHH, Correa C, Darby S, 
Francis J, Karamitos T, Lavery B, McGale P, Neubauer S, Newton J, 
Rahimi K, Taylor C. University of Oxford, Oxford, United Kingdom; 
Oxford Cancer Centre, Oxford, United Kingdom. 
p3-13-07  the targit-a trial update Confirms no increase in local 
recurrence
Vaidya JS, Baum M, Wenz F, Bulsara M, Tobias J, Alvarodo M, 
Saunders C, Williams N, Joseph D, on Behalf of the TARGIT Trialists 
Group. University College London, London, United Kingdom; 
University of Heidelberg, Mannheim, United Kingdom; University 
of Notre Dame, Fremantle, United Kingdom; University College 
Hospital and Whittington Hospital, London, United Kingdom; School 
of Surgery, University of Western Australia, London (All), United 
Kingdom; University of San Francisco, London (All), United Kingdom; 
Sir Charles Gairdener Hospital, London (All), United Kingdom. 
p3-13-08  Survival analysis and recurrence patterns in locally advanced 
breast Cancer Following neoadjuvant Chemotherapy and 
preoperative Concurrent Chemo radiotherapy
Shaw RJ, Lara F, Robles CD, Vilar D. Instituto Nacional de 
Cancerologia, Mexico City, Mexico. 
p3-13-09  impact of estrogen receptor negativity on Clinical outcomes 
Following accelerated partial breast irradiation
Wilkinson JB, Baschnagel A, Shah C, Amin M, Nadeau L, Mitchell CK, 
Wallace MF, Chen PY, Grills IS, Martinez AA, Vicini FA. Beaumont 
Cancer Institute, Oakland University William Beaumont School of 
Medicine, Royal Oak, MI. 
p3-13-10  Does lapatinip increase pulmonary toxicity When 
Concurrently used with radiation therapy? an experimental 
Study with Wistar-albino rats
Senel Bese N, Yetmen O, Guzel E, Karaca C, Coban I, Elicin O, Suzer O. 
I.U Cerrahpasa Medical Faculty, Istanbul, Turkey. 
p3-13-11  Survival benefit associated with post-mastectomy radiation 
for node-positive, intermediate-risk breast Cancer patients: 
results of a Study from the Seer registry Data
Horowitz DP, Ng J, Burri RJ. Columbia University Medical Center-New 
York Presbyterian Hosptial, New York, NY. 
p3-13-12  electrons for intraoperative breast radiotherapy in Selected 
patients: long-term results of the montpellier phase ii trial
Lemanski C, Dubois JB, Gutowski M, Gourgou S, Ailleres N, Azria D. 
CRLC Val d’Aurelle, Montpellier, France. 
treatment – therapeutic Strategies: neoadjuvant Chemotherapy
p3-14-01  panitumumab in Combination with FeC 100 (5-Fluorouracile, 
epirubicin, Cyclophosphamide) Followed by Docetaxel (t) in 
patients with operable, triple negative breast Cancer (tnbC): 
Final results of a multicentre neoadjuvant pilot phase ii Study
Nabholtz J-M, Weber B, Gligorov J, Mouret-Reynier M-A, Tredan 
O, Vanlemmens L, Petit T, Mayer F, Van Praagh-Doreau I, 
Dubray-Longeras P, Nayl B, Ferriere J-P, Jouannaud C, Devaud 
H, Tubiana-Mathieu N, Abrial C, Kwiatkowski F, Planchat E, 
Chalabi N, Penault-Llorca F, Chollet P. Jean Perrin Comprehensive 
Cancer Centre, Clermont-Ferrand, France, Metropolitan; Alexis 
Vautrin Comprehensive Cancer Centre, Vandoeuvre les Nancy, 
France, Metropolitan; Tenon University Hospital, Paris, France, 
Metropolitan; Leon Berard Comprehensive Cancer Centre, Lyon, 
France, Metropolitan; Oscar Lambret Comprehensive Cancer 
Centre, Lille, France, Metropolitan; Paul Strauss Comprehensive 
Cancer Centre, Strasbourg, France, Metropolitan; Georges François 
Leclerc Comprehensive Cancer Centre, Dijon, France, Metropolitan; 
Jean Godinot Comprehensive Cancer Institute, Reims, France, 
Metropolitan; Limoges University Hospital, Limoges, France, 
Metropolitan. 
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p3-14-02  Sequential versus upfront intensified neoadjuvant 
Chemotherapy in patients with large resectable or locally 
advanced breast Cancer (intenS), toxicity results from a 
phase iii Study of the Dutch breast Cancer trialists’ group 
(boog)
Vriens BE, Van de Vijver KK, Boetes C, van Gastel SM, Wals J, 
Smilde TJ, van Warmerdam LJ, van Laarhoven HW, van Spronsen 
DJ, Borm GF, Tjan-Heijnen VC. Maastricht University Medical 
Centre, Maastricht, Netherlands; Comprehensive Cancer Centre 
the Netherlands, Nijmegen, Netherlands; Atrium Medical Centre, 
Heerlen, Netherlands; Jeroen Bosch Hospital, ‘s Hertogenbosch, 
Netherlands; Catharina-Hospital, Eindhoven, Netherlands; Radboud 
University Nijmegen Medical Centre, Nijmegen, Netherlands; 
Canisius-Wilhelmina Hospital, Nijmegen, Netherlands. 
p3-14-03  abCb1 Single nucleotide polymorphismas a possible 
prognostic Factor in breast Cancer patients receiving 
Docetaxel and Doxorubicin neoadjuvant Chemotherapy on 
Systemic treatment
Kim H-J, Lee K-H, Im S-A, Jang IJ, Yi SJ, Keam B, Kim YJ, Han S-W, 
Oh D-Y, Kim JH, Cho N, Chie EK, Han W, Moon WK, Kim T-Y, Noh 
D-Y, Park IA, Bang Y-J, Ha SW. Seoul National University College of 
Medicine, Seoul, Korea; Cancer Research Institute; Seoul National 
University Bundang Hospital, Seongnam, Korea. 
p3-14-04  assessment of genomic prognostic Signatures as predictors of 
response to neoadjuvant Chemotherapy in patients with early 
Stage breast Cancer
Culakova E, Poniewierski MS, Huang M, Kuderer NM, Ginsburg 
GS, Barry W, Marcom PK, Ready N, Abernethy A, Lyman GH. Duke 
University, Durham, NC. 
p3-14-05  evaluation of residual Cancer burden index (rCbi) as a 
predictor of Disease Free Survival in a non-Selected Cohort of 
breast Cancer patients treated in the neoadjuvant Setting
Perez-Fidalgo J-A, Martinez M, Ferrer J, Pons V, Burgues O, Bermejo 
B, Furriol J, Eroles P, Lluch A. Hospital Clinico Universitario, Valencia, 
Spain. 
p3-14-06  Combined use of 18F-FDg pet/Ct and mri to monitor breast 
Cancer response during neoadjuvant Chemotherapy
Pengel KE, Koolen BB, Vogel W, Valdes Olmos R, Wesseling J, 
Vrancken Peeters M-J, Loo CE, Gilhuijs KG. Netherlands Cancer 
Institute, Amsterdam, Netherlands; Netherlands Cancer Institute, 
Amsterdam; University Medical Centre Utrecht, Utrecht, Netherlands. 
p3-14-07  relative risk of recurrence (rr) over time in er positive and 
negative t4 breast Cancer patients achieving less than pCr 
(<pCr) after primary Chemotherapy: a reversal trend of 
recurrence beyond 60 months after Diagnosis
Ionta MT, Atzori F, Pusceddu V, Notari F, Valle E, Guerzoni D, Chiappe 
A, Marongiu M, Minerba L, Massidda B. University Hospital, Cagliari, 
Italy; Hospital of Oncology Businco, Cagliari, Italy. 
p3-14-08  a phase ii Study of gemcitabine and Carboplatin (gC) plus 
iniparib (bSi-201) as neoadjuvant therapy for triple-negative 
and brCa1/2 mutation-associated breast Cancer
Telli ML, Kurian AW, Jensen KC, Vinayak S, Flaherty P, Lipson JA, 
Wapnir I, Daniel B, Carlson RW, Mills MA, Chang P-J, Schackmann 
E, Rocha C, Sherman B, Blackwood-Chirchir A, Bradley C, Ford 
JM. Stanford University, Stanford, CA; BiPar Sciences, South San 
Francisco, CA. 
p3-14-09  a phase ii preoperative Study of Dasatinib, a multi-targeted 
tyrosine kinase inhibitor, in locally advanced “triple-
negative” breast Cancer patients
Rimawi MF, Rodriguez AA, Yang WT, Gonzalez-Angulo AM, Nangia 
JR, Wang T, Speers C, Mills G, Hilsenbeck SG, Brown PH, Chang JC. 
Baylor College of Medicine, Houston, TX; The Methodist Hospital, 
Houston, TX; M.D. Anderson Cancer Center, Houston, TX. 
p3-14-10  early predictive value of non-responder to Docetaxel in 
neoadjuvant Chemotherapy in breast Cancer using 18F- FDg-
pet
Hirakata T, Fujisawa T, Yanagita Y, Horikoshi H, Oya N, Akiyoshi 
T, Kinoshita T, Kuwano H. Gunma Prefectural Cancer Center, Ota, 
Gunma, Japan; Tsurugaya Hospital, Isesaki, Gunma, Japan; Graduate 
School of Medicine, Gunma University, Maebashi, Gunma, Japan. 
p3-14-11 Comparison of two nomograms to predict pathologic 
Complete response to neoadjuvant Chemotherapy - evidence 
that her2 positive tumors need Specific predictors
Rouzier R, Frati A, Coutant C, Bezu C, Antoine M, Uzan S, Chopier J, 
Chereau E, Gligorov J. Tenon - APHP, Paris, France. 
p3-14-12  local Control of primary breast Cancer treated with radical 
radiotherapy alone after neoadjuvant Chemotherapy
Makris A, Li SP, Ravichandran D, Ostler PJ, Pittam M. Mount Vernon 
Cancer Centre, Northwood, Middlesex, United Kingdom; Luton and 
Dunstable, Luton, United Kingdom. 
p3-14-13  a prospective open-label randomized phase ii neoadjuvant 
Study of non-pegylated liposomal Doxorubicin (myoCet®) 
plus Cyclophosphamide and trastuzumab versus 
Conventional Doxorubicin plus Cyclophosphamide alone, 
each Followed by Docetaxel and trastuzumab, in her2-
positive breast Cancer patients
Llombart-Cussac A, Pernas-Simon S, Rezai M, Hauschild M, Venturini 
M, Machiels J-P, Paepke S, Luporsi E, Kasiborski F, Kayitalire L. 
Hospital Arnau de Vilanova, Lleida, Spain; L’Hospitalet de Llobregat, 
Barcelona, Spain; Luisenkrankenhaus Düsseldorf, Düsseldorf, 
Germany; Ospedale Sacro Cuore, Negrar (Verona), Italy; Cliniques 
Universitaires St-Luc, Université Catholique de Louvain, Brussels, 
Belgium; Technischen Universität München, München, Germany; 
Centre Alexis Vautrin, Vandoeuvre-Les-Nancy, France; Cephalon, 
Maisons-Alfort, France; Frauenklinik und Brustzentrum Rheinfelden, 
Rheinfelden, Germany. 
p3-14-14  increased prevalence of low vitamin D level in breast Cancer 
patients during neoadjuvant Chemotherapy
Jacot W, Pouderoux S, Thezenas S, Chapelle A, Romieu G, Lamy P-J. 
CRLC Val d’Aurelle, Montpellier, France. 
p3-14-15  non-randomized, open label phase ii trial evaluating the 
Safety and efficacy of taxotere (t) Followed by myocet (m) 
+ Cyclophosphamide (C) as First-line treatment for her2-
negative breast Cancer (bC)
García-Mata J, Calvo L, López R, Ramos M, Castellanos J, Heras L. 
Complexo Hospitalario de Ourense, Ourense, Spain; Complexo 
Hospitalario Universitario A Coruña, A Coruña, A Coruña, Spain; 
Hospital Clínico de Santiago, Santiago de Compostela, A Coruña, 
Spain; Centro Oncológico de Galicia, A Coruña, A Coruña, Spain; 
Complexo Hospitalario Universitario Xeral Cíes, Vigo, Pontevedra, 
Spain; Hospital Sociosanitari de l’Hospitalet, Barcelona, Spain. 
p3-14-16  molecular phenotype and the use of her-2 targeted agents 
influence the accuracy of breast mri after neoadjuvant 
Chemotherapy
Moon H-G, Han W, Noh D-Y, Ahn S, Kim J, Shin H, Min J. Seoul 
National University College of Medicine; Dankuk University Hospital. 
p3-14-17  paclitaxel, Carboplatin, and trastuzumab in a neoadjuvant 
regimen for her2-positive breast Cancer: the train Study
Sonke GS, Mandjes IA, Holtkamp M, Schot M, Oosterkamp 
HM, Wesseling J, Vrancken Peeters M-J, Rodenhuis S, Linn SC. 
Netherlands Cancer Institute, Amsterdam, Netherlands. 
p3-14-18  primary tumor response to neoadjuvant Chemotherapy is 
Significantly associated with nodal pathological Complete 
response in breast Cancer patients with Cytologically proven 
axillary node metastasis
Hwang H, Park S, Lee JS, Kim S-I, Park B-W. Yonsei University College 
of Medicine, Seoul, Korea. 
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p3-14-19  impact of Chemotherapy-induced amenorrhea on response 
to neoadjuvant Chemotherapy in breast Cancer
Ahn SK, Moon HG, Kim JS, You JM, Shin Hc, Han W, Noh D-y. Seoul 
National University Hospital. 
p3-14-20  Concomitant taxane-anthracyclin regimen for neoadjuvant 
Chemotherapy of primary breast Cancer: experience from a 
Cohort of 223 patients treated in a Single institution
Coquan E, Guizard A-V, Heutte N, Bor C, Allouache D, Delcambre C, 
Switsers O, Guilloit J-M, Leiber N, Delozier T, Levy C. François Baclesse 
Cancer Center, Caen, France. 
p3-14-21  neoadjuvant therapy response, Subtype and brCa Status in 
an underserved population
Tripathy D, Ahmed S, Bahl P, Wang Y, Ji L, Ricker C, Weng Grumley J, 
Liu SV, Sener SF, Klipfel N, Kaur C. University of Southern California, 
Los Angeles, CA. 
p3-14-22  response to neoadjuvant Chemotherapy in elderly patients 
with locally advanced breast Cancer
Vanderhaegen J, Wildiers H, Christiaens M-R, Smeets A, Leunen K, 
Neven P, Vergote I, Vanlimbergen E, Weltens C, Janssen H, Moerman 
P, Brouckaert O, Brouwers B, Paridaens R. University Hospital 
Gasthuisberg, Leuven, Belgium. 
p3-14-23  response to neoadjuvant Chemotherapy and Survival in 
japanese patients with triple-negative breast Cancer
Ohtani S, Kochi M, Ito M, Takada S, Matsuura H, Higaki K. Hiroshima 
City Hospital, Hiroshima, Japan. 
p3-14-24  a phase ii trial of tS-1 and Docetaxel Followed by 5-Fu/
epirubicin/Cyclophosphamide (FeC) as preoperative 
treatment in Women with Stage ii/iii breast Cancer
Hayashida T, Jinno H, Sakata M, Takahashi M, Kitagawa Y. Keio 
University, School of Medicine, Tokyo, Japan. 
p3-14-25  neoadjuvant trastuzumab and paclitaxel Combination 
induces a high rate of pathological Complete responses in 
locally advanced breast Cancer by exploiting host antitumor 
immunity
Dolcetti R, Crivellari D, Muraro E, Martorelli D, Miolo G, Lombardi 
D, Massarut S, Perin T, Talamini R, Turchet E, Comaro E, Carbone 
A, Veronesi A. Centro di Riferimento Oncologico, IRCCS; National 
Cancer Institute, Aviano (PN), Italy. 
p3-14-26  the effect of biologic Subtype in patients treated with 
neoadjuvant Chemotherapy: a uab experience
Keene KS, De Los Santos JF, Meredith R, Hinton B, Li Y, Krontiras 
H, Bland K, Carpenter JT, Forero A. University of Alabama at 
Birmingham, Birmingham, AL. 
p3-14-27  pegylated liposomal Doxorubicin (plD) as primary treatment 
in estrogen receptor (er) and her2 poor breast Cancer and 
risk of Developing Cardiotoxicity or elderly patients (pt). 
results from the phase ii CapriCe Study
Gil MJ, Bellet MC, Llombart, Ojeda B, Manso L, Mesia C, Morales 
S, García-Martinez H, Martínez N, Melé M, Fernández-Ortega A, 
Baselga J. Institut Català dáOncologia, LáHospitalet, Barcelona; H. 
Vall dáHebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant 
Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, 
Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain. 
p3-14-28  anZ 0502 neogem: a phase ii trial evaluating the efficacy 
and Safety of epirubicin and Cyclophosphamide Followed by 
Docetaxel with gemcitabine (+ trastuzumab if her2 positive) 
as neoadjuvant Chemotherapy for Women with large 
operable or locally advanced breast Carcinoma
McCarthy N, Boyle F, Bull J, Leong E, Simpson A, Kannourakis 
G, Gebski V, Forbes JF, Wilcken N, Lindsay DF, Badger HD. Royal 
Brisbane and Women’s Hospital, Brisbane, Queensland, Australia; 
The Mater Hospital, Sydney, New South Wales, Australia; Wellington 
Hospital, Wellington, New Zealand; Ballarat Oncology and 
Haematology Service, Ballarat, Victoria, Australia; NHMRC Clinical 
Trials Centre, Sydney, New South Wales, Australia; University of 
Newcastle, Newcastle, New South Wales, Australia; Calvary Mater 
Newcastle, Newcastle, New South Wales, Australia; Westmead 
Hospital, Sydney, New South Wales, Australia; Australian New 
Zealand Breast Cancer Trials Group, Newcastle, New South Wales, 
Australia. 
p3-14-29  neoadjuvant Sunitinib administered with Weekly paclitaxel/
Carboplatin in patients with locally advanced triple-negative 
breast Cancer: a Sarah Cannon research institute phase i/ii 
trial
Yardley DA, Peacock NW, Peyton J, Shipley DL, Spigel S, Barton J, 
Shih KC, Raefsky E, Liggett W, Burris III HA, Hainsworth JD. Sarah 
Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, 
Nashville, TN. 
p3-14-30  Concurrent Celecoxib with FeC Followed by Docetaxel Shows 
good responses and prognosis in a neoadjuvant breast 
Cancer Study
Chow LWC, Tung SY, Ng T-Y, Oh D-Y, Im S-A, Lee M-H, Yip AYS, Toi 
M, Glück S. Organisation for Oncology and Translational Research, 
Hong Kong; UNIMED Medical Institute, Hong Kong; Tuen Mun 
Hospital, Hong Kong; Seoul National University Hospital, Seoul, 
Korea; Soonchunhyang University Hospital, Seoul, Korea; Kyoto 
University, Kyoto, Japan; University of Miami Leonard M. Miller 
School of Medicine, Miami, FL. 
p3-14-31 preoperative Chemotherapy and bevacizumab for locally 
advanced her-2 negative breast Cancer Followed by 
prolonged postoperative bevacizumab for those with less 
than Complete pathologic response
Carpenter JT, Forero A, Falkson CI, Nabell LM, De Los Santos JF, 
Krontiras H, Bland KI, Li Y. University of Alabama at Birmingham, 
Birmingham, AL. 
treatment – therapeutic Strategies: neoadjuvant endocrine therapy
p3-15-01  an interim efficacy analysis of neoadjuvant letrozole in the 
new primary endocrine-therapy origination Study (neoS/n-
SaS bC06): a randomized Study of adjuvant endocrine 
therapy with or without Chemotherapy for postmenopausal 
breast Cancer patients Who responded to neoadjuvant 
letrozole
Iwata H, Yamaguchi T, Masuda N, Toyama T, Kashiwaba M, 
Yamamoto Y, Taira N, Saji S, Ohashi Y. Aichi Cancer Center, Nagoya, 
Japan; Tohoku University Graduate School of Medicine, Sendai, 
Japan; NHO Osaka National Hospital, Osaka, Japan; Nagoya City 
University Hospital, Nagoya, Japan; Iwate Medical University, 
Morioka, Japan; Kumamoto University Hospital, Kumamoto, Japan; 
Okayama University Hospital, Okayama, Japan; Saitama Medical 
University International Medical Center, Hidaka, Japan; The University 
of Tokyo, Tokyo, Japan. 
p3-15-02  the Change of bone turnover markers during neoadjuvant 
anastrozole versus exemestane: a randomized Single-Center 
Study
Jinno H, Shimada K, Takahashi M, Hayashida T, Hirose S, Ikeda T, 
Kitagawa Y. Keio University School of Medicine, Shinjuku, Tokyo, 
Japan; Teikyo University School of Medicine, Itabashi, Tokyo, Japan. 
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treatment – therapeutic Strategies: new Drugs and treatment Strategies
p3-16-01  Safety profile and Clinical activity of Single-agent bkm120, a 
pan-Class i pi3k inhibitor, for the treatment of patients with 
metastatic breast Carcinoma
Rodon J, Bendell JC, Abdul Razak AR, Homji N, Trandafir L, Quadt 
C, Graña-Suárez B, Siu LL, Di Tomaso E, Demanse D, Massacesi C, 
Hirawat S, Burris III HA, Baselga J. Vall d’Hebron University Hospital, 
Barcelona, Spain; Sarah Cannon Research Institute, Nashville, 
TN; Princess Margaret Hospital, Toronto, ON, Canada; Novartis 
Pharmaceuticals, Florham Park, NJ; Novartis Oncology, Paris, France; 
Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for 
BioMedical Research Inc, Cambridge, MA; Massuchusetts, Boston, 
MA. 
p3-16-02  targeting tumor initiating Cells with sirna/nanotherapy in 
triple negative breast Cancer
Granados-Principal S, Deng X, Liu D, Chang JC, Shen H, Dave B. 
The Methodist Research Institute, Houston, TX; Baylor College of 
Medicine, Houston, TX. 
p3-16-03  enhancing anti-igF Directed therapeutics by Co-targeting 
autophagy
Oh AS, LaPara K, Yee D. University of Minnesota, Minneapolis, MN. 
p3-16-04  a novel monoclonal antibody to Secreted Frizzled related 
protein 2 inhibits triple negative breast Carcinoma growth 
rate in vivo
Klauber-DeMore N, Fontenot E, Mumper R, Ma P, Rossi E, 
Siamakpour-Reihani S, Bone B, Hilliard E, Ketelsen D, Santos C, 
Patterson C. University of North Carolina at Chapel Hill, Chapel Hill, 
NC. 
p3-16-05  a phase ii trial expansion Cohort of the parp inhibitor 
veliparib (abt888) and temozolomide in brCa1/2 associated 
metastatic breast Cancer
Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Habin K, Qian J, 
Giranda V, Shepherd S, Garber JE, Ellisen LW, Winer EP, Goss PE. 
Massachusetts General Hospital Cancer Center, Boston, MA; Dana 
Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical 
Center, Boston, MA; Harvard Medical School, Boston, MA; Abbott 
Laboratories, Abbott Park, IL. 
p3-16-06  phase ii trial of tS-1 in Combination with oxaliplatin (SoX) 
in patients with metastatic breast Cancer (mbC) previously 
treated with anthracycline and taxane Chemotherapy 
[torCh] [korean Cancer Study group (kCSg) br07-03]
Im S-A, Oh D-Y, Lee KS, Ahn J-H, Shon J, Ahn JS, Kim JH, Han SW, 
Lee MH, Lee KE, Lee K, Kim HJ, Keam B, Kim S-Y, Kim SB, Im YH, Ro J, 
Park H-S. Seoul National University Hospital, Seoul, Republic of Korea; 
National Cancer Center, Republic of Korea; Asan Medical Center, 
Seoul, Republic of Korea; Yonsei University College of Medicine, 
Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic 
of Korea; Seoul National University Bundang Hospital, Seongnam, 
Republic of Korea; Inha University Hospital, Incheon, Republic of 
Korea; Ewha Womans University Medical Center, Seoul, Republic of 
Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic 
of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; 
Soon Chun Hyang University Hospital, Seoul, Republic of Korea. 
p3-16-07  effect of Denosumab treatment for patients with breast 
Cancer and bone metastases: results from the open-label 
extension treatment phase
Stopeck AT, Lipton A, Martín M, Body J-J, Paterson A, Steger GG, 
Tonkin K, De Boer RH, Fujiwara Y, Yardley D, Jassem J, Takano T, 
Solal-Celigny P, Fan M, Braun A. Arizona Cancer Center, University of 
Arizona, Tucson, AZ; Penn State Milton S. Hershey Medical Center, 
Hershey, PA; Hospital General Universitario Gregorio Marañón, 
Madrid, Spain; CHU Brugmann, Université Libre de Bruxelles, 
Brussels, Belgium; Tom Baker Cancer Centre, Calgary, AB, Canada; 
Medical University of Vienna, Vienna, Austria; Cross Cancer Institute, 
Edmonton, AB, Canada; Royal Melbourne and Western Hospitals, 
Melbourne, Australia; National Cancer Center Hospital, Tokyo, Japan; 
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, 
PLLC, Nashville, TN; Akademickie Centrum Kliniczne Szpital Akademii 
Medycznej w Gdansku, Gdansk, Poland; Toranomon Hospital, Tokyo, 
Japan; Clinique Victor Hugo, Centre Jean Bernard, Le Mans, France; 
Amgen, Inc., Thousand Oaks, CA. 
p3-16-08  a phase 2, randomized open-label Study of iniparib, 
administered either Weekly or twice-Weekly in Combination 
with gemcitabine plus Carboplatin in patients with mtnbC
Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov 
J, Jäger A, Gianni L, Lindeman G, Pham N, Su Y, Gao G, Mery-
Mignard D, Paridaens R, Verweij J. Institut Curie, Paris, Cedex 05, 
France; Université de Bordeaux, Bordeaux, INSERM, France; Hospital 
Clínico Universitario Virgen de la Victoria, Málaga, Spain; Institut 
Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles, 
Brussells, Belgium; Centre Georges François Leclerc, Dijon, France; 
University Hospital Jean Minjoz, Besançon, France; University Paris VI, 
Paris, France; Erasmus University Medical Center, Daniel den Hoed 
Cancer Center, Rotterdam, Netherlands; hSR - San Raffaele, Milan, 
Italy; The Royal Melbourne Hospital and The Walter and Eliza Hall 
Institute of Medical Research, Melbourne, Victoria, Australia; Sanofi, 
Vitry, Paris, France; Sanofi, Great Valley, PA; Sanofi, Cambridge, MA; 
University Hospital Gasthuisberg, Catholic University of Leuven, 
Leuven, Belgium; Erasmus University Medical Center, Rotterdam, 
Netherlands. 
p3-16-09  endoxifen, a newly Developed breast Cancer Drug, has 
anabolic actions on the mouse Skeleton
Hawse JR, Cicek M, Subramaniam M, Pitel KS, Peters KD, Grygo SB, 
Wu X, Evans GL, Iwaniec UT, Turner RT, Ingle JN, Goetz MP, Spelsberg 
TC. Mayo Clinic; Oregon State University. 
p3-16-10  the efficacy of Zoledronic acid in breast Cancer adjuvant 
therapy: a meta-analysis of randomized Controlled trials
Lu J, Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z. Fudan 
University Shanghai Cancer Center, Shanghai, China; Shanghai 
Medical College, Fudan University, Shanghai, China. 
p3-16-11  prospective evaluation of radiation pneumonitis in 
neoadjuvant Concurrent Docetaxel and radiation therapy for 
locally advanced breast Cancer
Louie AV, Rodrigues G, Sathya A, Perera F, Ong M, D’Souza D, 
Chambers AF, Brackstone M. London Regional Cancer Program, 
London, ON, Canada. 
p3-16-13  Cardiac Safety of non-pegylated liposomal Doxorubicin and 
Docetaxel as 1st line treatment in metastatic her2 negative 
breast Cancer (myotax Study)
van Warmerdam L, Schiphorst P, Nieboer P, Dercksen M, de Jongh 
F, Schmidt R. Catharina-Ziekenhuis, Eindhoven, Netherlands; 
Streekziekenhuis Koningin Beatrix, Winterswijk, Netherlands; 
Wilhelmina Ziekenhuis, Assen, Netherlands; Maxima MC, Eindhoven, 
Netherlands; Ikazia Ziekenhuis, Rotterdam, Netherlands; Foundation 
BO3, Steenderen, Netherlands. 
p3-16-14  effect of tg02, a multikinase inhibitor, on triple negative 
breast Cancer Cells
Pandiella A, Ortiz-Ruiz MJ, Burrows F, Ocaña A, Esparis-Ogando A. 
Cancer Research Center, Salamanca, Spain; Hospital Universitario, 
Albacete, Spain; Tragara Pharmaceuticals, San Diego, CA. 
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p3-16-15  phase i Study with biomarker evaluation of neoadjuvant 
Sunitinib in Combination with exemestane in post-menopausal 
Women with hormone-Sensitive, her-2 negative primary 
breast Cancer
Morales S, Gil M, Llombart A, Garcia M, Urruticoechea A, Pernas 
S. University Hospital Arnau de Vilanova, Lleida, Cataluña, Spain; 
University Hospital ICO-Duran i Reynals, Barcelona, Cataluña, Spain. 
p3-16-16  overcoming egFr resistance using Dasatinib in Combination 
with Cetuximab and Cisplatin in triple negative breast Cancer 
Cell lines
Kim EMH, Gartner E, Choi L, Boerner J. Wayne State University, 
Karmanos Cancer Center, Detroit, MI. 
p3-16-17  the identification of novel microtubule Stabilizing 
taccalonolides
Risinger AL, Li J, Peng J, Chen Z, Mooberry SL. University of Texas 
Health Science Center, San Antonio, TX; Shanghai Institute of Materia 
Medica, Shanghai, China. 
p3-16-18  phase 2, open-label Study of eZn-2208 (peg-Sn38) in patients 
with previously treated metastatic breast Cancer  
O’Shaughnessy JA, Osborne CRC, Steinberg MA, Holmes FA, Kim HS, 
Kocs DM, Richards PD, Vukelja SJ, Berkowitz N, Buchbinder A.  Texas 
Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX; 
Virginia Oncology Associates, Norfolk, VA; Texas Oncology - Houston 
Memorial City, Houston, TX; Rocky Mountain Cancer Centers, Denver, 
CO; Texas Oncology - Austin Midtown, Austin, TX; Oncology & 
Hematology Associates of Southwest Virginia, Inc., D.B.A. Blue Ridge 
Cancer Care, Salem, VA; Tyler Cancer Center, Tyler, TX; US Oncology; 
Enzon Pharmaceuticals, Inc., Piscataway, NJ.
treatment – therapeutic Strategies: novel Drugs and targeted agents
p3-17-01  apoe and its receptors (lrp8, vlDlr) Function as growth 
Signals for triple-negative breast Cancer and represent a 
novel therapeutic target
Shiang C, Qi Y, Wang B, Broom B, Pusztai L. UT M.D. Anderson Cancer 
Center. 
p3-17-02  targeting the autophagy pathway for Drug resistance of 
breast tumor-initiating Cells
Zhao H, Li F, Cui K, Sheng J, Landis M, Chang J, Wong S, Dave B. 
The Methodist Hospital Research Institute, Weill Medical College, 
Cornell University, Houston, TX; The Methodist Hospital, Weill Medical 
College, Cornell University, Houston, TX. 
p3-17-03  aDam17: a novel therapeutic target for treatment of triple 
negative breast Cancer
McGowan PM, Mullooly M, Sukor S, Madden S, McDermott E, Pierce 
A, Crown J, O’Donovan N, Duffy MJ. St. Vincent’s University Hospital, 
Dublin, Ireland; University College Dublin Dublin, Dublin, Ireland; 
Dublin City University, Dublin, Ireland; Molecular Therapeutics Cancer 
Ireland, Dublin, Ireland. 
p3-17-04  CXCr1/2 regulates human breast Cancer Stem Cell activity via 
egFr/her2-Dependent and -independent pathway
Singh JK, Farnie G, Clarke RB, Bundred NJ. School of Cancer and 
Enabling Sciences, University of Manchester, Paterson Institute for 
Cancer Research, Manchester, United Kingdom; Univeristity Hospital 
of South Manchester, Wythenshawe Hospital, Manchester, United 
Kingdom. 
p3-17-05  beyond her2 and hormonal agents: the heat Shock protein 90 
inhibitor ganetespib as a potential new breast Cancer therapy
Friedland JC, Sang J, Modi S, Bradley R, El-Hariry I, Wada Y, Proia DA. 
Synta Pharmaceuticals, Lexington, MA; Memorial Sloan-Kettering 
Cancer Center, New York, NY. 
p3-17-06  Final results of a Controlled, randomized 3-arm phase ii trial 
of endotag™-1, a Cationic liposomal Formulation of paclitaxel 
targeting tumor endothelial Cells, in advanced triple-
negative breast Cancer (tnbC)
Awada A, Bondarenko IN, Tarasova O, Bonneterre J, Nowara E, Ferrero 
JM, Bakshi AV, Weidenthaler H, Wilke C, Piccart MJ. Institut Jules 
Bordet, Brussels, Belgium; Dnepropetrovsk State Medical Academy, 
Dnepropetrovsk, Ukraine; Academy of Medical Sciences of Ukraine, 
Kharkov, Ukraine; Centre Oscar Lambret, Lille, France; Instytut im. 
M.Sklodowskiej-Curie, Gliwice, Poland; Centre Antoine Lacassagne, 
Nice, France; Kaushalya Medical Foundation, Thane, India; Medigene 
AG, Martinsried, Germany. 
p3-17-07  egCg, a green tea antioxidant Suppresses breast tumor 
angiogenesis and growth via inhibiting the activation of hiF-
1α and nFΚb, and vegF expression
Makey KL, Tucker KB, Chinchar E, Miele L, Pei I, Thomas EY, Gu J-W. 
University of Mississippi Medical Center, Jackson, MS. 
p3-17-08  macroautophagy protects breast Cancer mCF-7 Cells from 
tam-induced apoptosis via mitogen-activated protein kinase 
(mapk) pathway
Hou YF, Ma XY, Liu Z, Yu SJ, Shao ZM. Cancer Institute, Shanghai, 
China. 
p3-17-09  neutralizing the prolactin receptor with therapeutic antibody 
lFa102: a novel approach for the treatment of breast Cancer
Damiano JS, Wasserman E, Rendahl K, Jeffry U, Rediske J, Kakar S, 
Gardner H, Abraham J. Novartis Institutes for BioMedical Research, 
Emeryville, CA; Novartis Pharmaceuticals, Florham Park, NJ; Novartis 
Institutes for BioMedical Research, Cambridge, MA. 
p3-17-10  epCam as a target for Chemical antibodies in metastatic 
breast Cancer
Shigdar SL, Duan W. Deakin University, Geelong, Victoria, Australia. 
p3-17-11  Dovitinib (tki258), a Dual inhibitor of FgFr and vegFr, induces 
tumor growth Suppression in Xenograft models of primary 
human breast Cancer
Shi MM, Linnartz R, Versace R, Graus Porta D, Kay A, Dugan M. 
Novartis Oncology, East Hanover, NJ; Novartis Institutes for 
BioMedical Research, Basel, Switzerland. 
p3-17-12  regulation of tubulin detyrosination-a cancer cell specific anti-
microtubule strategy for breast cancer treatment
Byers SW, Sung Y-MS, Hall MD, Sahab ZJ.  Georgetown-Lombardi 
Comprehensive Cancer, Washington, DC. 
p3-17-13  romidepsin inhibits growth and metastasis and is synergistic 
with paclitaxel in pre-clinical models of inflammatory breast 
cancer
Robertson FM, Chu K, Mu Z, Boley KM, Green TL, Moraes R, Zhang 
X, Alpaugh RK, Bagsby A, Ye Z, Wright MC, Liu H, Luo AZ, Barsky SH, 
Heise C, Cristofanilli M.  The University of Texas MD Anderson Cancer 
Center, Houston, TX, ; Fox Chase Cancer Center, Philadelphia, PA; 
University of Nevada School of Medicine and Nevada Cancer Center, 
Reno and Las Vegas, NV; Celgene Corporation, San Francisco, CA. 
treatment – therapeutic Strategies: Signal transduction inhibitors
p3-18-01  cmet inhibitor and the inhibition of growth of breast Cancer 
Cells in bone marrow matrix environment
Ye L, Mason MD, Bramble P, Jiang WG. Cardiff University School 
of Medicine, Cardiff, Wales, United Kingdom; Astra-Zeneca 
Pharmaceuticals, Surry, United Kingdom. 
p3-18-02  a Combination of pathway-targeted inhibitor with Dna-repair 
inhibitor: preclinical efficacy of Zactima and olaparib in triple 
negative Subset of breast Cancer
Dey N, Wu H, Sun Y, De P, Leyland-Jones B. Emory University, Atlanta, 
GA. 
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p3-18-03  in vitro potency of mtor kinase (tor1/tor2) inhibitor, ink128 
in er+ and her2 overexpressing breast Cancer Cells
De P, Sun Y, Dey N, Leyland-Jones B. Emory University, Atlanta, GA. 
p3-18-04  pathway guided Selection of targeted inhibitors for breast 
Cancer treatment
von Ahsen O, Kim P, Langley E, Hazra S, Lee T, Leesman G, Schneider 
C, Singh S, Krahn T. Bayer Healthcare, Berlin, Germany; Prometheus 
Inc., San Diego, CA. 
p3-18-05  triple-negative breast Cancer: Stem Cells, Cancer and new 
treatment Strategy
Yin S, Xu L, Reddy KB. Wayne State University School of Medicine, 
Detroit, MI. 
p3-18-06  aeZS-131 - a highly Selective erk-inhibitor: Characterization 
and preclinical testing in triple negative breast Cancer (tnbC)
Engel JB, Seipelt I, Hönig A, Hahne JC, Teifel M. Medical University of 
Würzburg, Würzburg, Germany; Æterna Zentaris GmbH, Frankfurt, 
Germany.
p3-18-07  multiplex rtk inhibitor Screening utilizing a plate-based 
immunoassay with near-infrared Detection
Finkel DJ, James AE, Felix RA, Wegner GJ. R&D Systems Inc., 
Minneapolis, MN; Tocris Bioscience, Bristol, United Kingdom.
5:15 pm–7:00 pm 
poSter DiSCuSSion v: her2  
ballroom a 
Viewing 5:15 pm 
Discussion 5:30 pm
Discussant: Michael F. Press, MD, PhD
USC/ Norris Comprehensive Cancer Center
Los Angeles, CA 
pD05-01  trans-Cher-lob: a biomarker analysis of the randomized 
phase ii Study of neoadjuvant Chemotherapy plus 
trastuzumab, lapatinib or Combined trastuzumab and 
lapatinib in her2 positive operable breast Cancer
Guarneri V, Frassoldati A, Ficarra G, Maiorana A, Bettelli S, Bottini A, 
Cagossi K, Bisagni G, Ravaioli A, Amadori D, Musolino A, Cavanna 
L, Orlando L, Giardina G, Piacentini F, Bagnalasta M, Conte P. 
Modena University Hospital, Modena, Italy; Medical Oncology, 
Ferrara University Hospital; Modena University Hospital; Istituti 
Ospitalieri, Cremona; Ramazzini Hospital, Carpi; Arcispedale Santa 
Maria Nuova, Reggio Emilia; Ospedale Infermi, Rimini; Istituto 
Scientifico Romagnolo per lo Studio e la Cura dei Tumori,Meldola 
(FC); Parma University Hospital; Hospital of Piacenza; Ospedale 
di Circolo e Fondazione Macchi, Varese; Perrino Hospital, Brindisi; 
GlaxoSmithKline, Verona. 
pD05-02  effect of her2/topoisomerase ii alpha (top2a) gene Status 
or protein expression and Chromosome 17 (Cep17) polysomy 
on the outcome of breast Cancer patients treated with 
anthracycline-Containing Dose-Dense Sequential adjuvant 
Chemotherapy with or without paclitaxel - a pooled analysis 
of two hellenic Cooperative oncology group (heCog) phase iii 
trials
Dafni U, Bobos M, Tsolaki E, Batistatou A, Koletsa F, Televantou D, 
Gogas H, Linardou H, Pectasides D, Kalogeras KT, Galani E, Koutras A, 
Papadimitriou CA, Fountzilas G. Hellenic Cooperative Oncology Group 
(HeCOG), Athens, Greece. 
pD05-03  impact of Quantitative measurement of her2, her3, her4, 
egFr, er and pten protein expression on benefit to adjuvant 
trastuzumab in early-Stage her2+ breast Cancer patients in 
nCCtg n9831
Perez EA, Ballman KV, Reinholz MM, Dueck AC, Cheng H, Jenkins RB, 
McCullough AE, Chen B, Davidson NE, Martino S, Kaufman PA, Kutteh 
LA, Sledge GW, Geiger XJ, Ingle JN, Tenner KS, Harris LN, Gralow JR, 
Rimm DL. Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; 
Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, 
Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, 
CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology 
Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University 
Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New 
Haven, CT; Seattle Cancer Care Alliance, Seattle, WA. 
pD05-04  Quantitative measurement of antigen Degradation in nCCtg 
n9831 tissue microarrays
Cheng H, Rimm DL, Reinholz MM, Lingle WL, Ballman KV, Dueck AC, 
Chen B, McCullough AE, Jenkins RB, Perez EA. Yale University School 
of Medicine, New Haven, CT; Mayo Clinic, Rochester, MN; Mayo Clinic, 
Scottsdale, AZ; Mayo Clinic, Jacksonville, FL. 
pD05-05  meta analysis of Discordant her2 Status in matched primary 
and metastatic breast Cancer
Richter S, Zee A. Princess Margaret Hospital; University of Western 
Ontario. 
pD05-06  Determination of her2 Status with analysis of plasma Dna by 
Digital pCr in patients with metastatic breast Cancer
Graeser MK, Gevensleben H, Smith IE, Ashworth A, Turner NC. 
Institute of Cancer Research, London, United Kingdom; Royal 
Marsden Hospital, London, United Kingdom. 
pD05-07  prospective validation and Characterization of her2 positive 
Circulating tumor Cells in patients with her2 negative 
metastatic breast Cancer
Olson EM, Flores LM, Najita JS, Curley C, Jeong J, Murray K, Savoie JJ, 
Winer EP, Krop IE. Dana-Farber Cancer Institute, Boston, MA.
5:15 pm–7:00 pm 
poSter DiSCuSSion vi: CoSt eFFeCtiveneSS/utiliZation 
ballroom b
Viewing 5:15 pm 
Discussion 5:30 pm
Discussant: Thomas J. Smith, MD, FACP
Johns Hopkins
Baltimore, MD 
pD06-01  molecular Classification with 21 gene assay (oncotypeDx) 
in 196,967 er positive patients Shows high Frequency of 
low recurrence Score (lrS) in both node positive (n+) and 
negative (n-) breast Cancer (brCa) Cohorts. Cost and guideline 
implications
Ragaz J, Wilson KS, Wong H, Muraca G, Hryniuk W, Bajdik C. University 
of British Columbia, Vancouver, BC, Canada; Care Path Inc., Toronto, 
ON, Canada. 
pD06-02  Cost-effectiveness evaluation of the oncotype DX® breast 
Cancer assay in Clinical practice in the uk
Holt SDH, Bennett H, Bertelli G, Valentine WJ, Phillips CJ. Prince Philip 
Hospital, Llanelli, United Kingdom; Cardiff Research Consortium, 
Cardiff, United Kingdom; Singleton Hospital, Swansea, United 
Kingdom; Ossian Health Economics and Communications, Basel, 
Switzerland; Swansea University, Swansea, United Kingdom. 
pD06-03  Cost effectiveness analysis of brCa1/2 genetic testing
Li Q, Holland M, Huston A, Noyes K. University of Rochester School of 
Medicine, Rochester, NY. 
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pD06-04  uptake and economic impact of First-Cycle Colony Stimulating 
Factor use during the adjuvant treatment of breast Cancer
Hershman DL, Wilde ET, Wright JD, Buono DL, Kalinsky K, Malin J, Tsai 
WY, Neugut AI. Columbia University, New York, NY; Mailman School 
of Public Health, New York, NY; Greater Los Angeles VA Healthcare 
System, Los Angeles, CA. 
pD06-05  primary and Secondary pegfilgrastim utilization in adjuvant 
Chemotherapy for breast Cancer in the Community
Patt DA, Espirito JL, Turnwald B, Hoverman JR, Neubauer MA, 
Busby LT, Brooks BD, Kolodziej MA, Anderson RW, Beveridge RA, on 
Behalf of US Oncology Pathways Task Force and Clinical Content 
Development Team. Texas Oncology, TX; US Oncology, TX; Kansas 
City Cancer Center, KS; Rocky Mountain Cancer Center, CO; New York 
Oncology Hematology, NY. 
pD06-06  is adjuvant trastuzumab economically justified in her-2/neu 
positive t1bno breast Cancer?
Skedgel C, Rayson D, Younis T. Capital Health, Halifax, NS, Canada. 
pD06-07  Compliance and arthralgias in Clinical therapy (CompaCt): 
assessment of the incidence and Severity of arthralgia, 
treatment Costs and Compliance within the First year of 
adjuvant anastrozole therapy
Hadji P, Blettner M, Bolten WW, Harbeck N, Hindenburg H-J, 
Jackisch C, König K, Lueck H-J, Rief W, Zaun S, Klein P, Kreienberg 
R. Phillips-University, Marburg, Germany; Institute for Medical 
Biometry and Epidemiology, Mainz, Germany; Klaus-Miehlke-
Klinik for Rheumatology, Wiesbaden, Germany; Breast Center, 
Women’s University Hospital, Cologne, Germany; Berufsverband 
Niedergelassener Gynäkologischer Onkologen e.V., Berlin, Germany; 
Klinikum Offenbach, Germany; Berufsverband der Frauenärzte 
e.V., Germany; Gyn. Oncological Practice, Hannover, Germany; 
AstraZeneca, Germany; DSH Statistics, Germany; University Womens’ 
Hospital, Ulm, Germany. 
pD06-08  projecting the impact of adopting trial results
Esserman LJ, Mohan AJ, Park C, Berry DA, Ozanne E, Alvarado MD. 
UCSF; M.D. Anderson. 
pD06-09 early predictors of prolonged unemployment after a Diagnosis 
of breast Cancer
Blinder V, Patil S, Eberle C, Maly RC. Memorial Sloan-Kettering Cancer 
Center, New York, NY; University of California, Los Angeles, CA. 
pD06-10  breast Cancer patient Distress associated with Difficulties 
navigating the Costs associated with Care: results from a 
national education program
Ahmed I, Gubin A, Champion L, Harvey A, Amsellem M. The Cancer 
Support Community.
5:15 pm–7:00 pm 
poSter SeSSion ongoing trialS 2 
exhibit hall b
Chemotherapy
ot2-01-01  international breast Cancer Study group (ibCSg) trial 22-00: 
low-Dose Cytotoxics as maintenance “anti-angiogenesis 
treatment” Following adjuvant induction Chemotherapy for 
patients with er-negative and pgr-negative breast Cancer
Colleoni M. International Breast Cancer Study Group. 
ot2-01-02  First-line bevacizumab in Combination with Capecitabine or 
paclitaxel for her2-negative locally recurrent or metastatic 
breast Cancer (lr/mbC): a randomized phase iii trial
Beslija, Brodowicz, Greil, Inbar MJI, Kahán, Kaufman, Lang, Steger, 
Stemmer, Zielinski, Zvirbule, The CECOG TURANDOT Trialists. Institute 
of Oncology, Sarajevo, Bosnia and Herzegovina; Medical University 
of Vienna, Vienna, Austria; University Hospital Salzburg, Salzburg, 
Austria; Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel; University 
of Szeged, Szeged, Hungary; Sheba Medical Center, Tel Hashomer, 
Israel; National Institute of Oncology, Budapest, Hungary; Rabin 
Medical Center, Petah Tikva, Israel; Riga Eastern Clinical University 
Hospital, Riga, Latvia. 
ot2-01-03  eribulin in Women with locally advanced breast Cancer 
Who Do not achieve pathologic Complete response (pCr) 
Following neoadjuvant Chemotherapy: a Sarah Cannon 
research institute phase ii trial
Yardley DA, Peacock NW, Hainsworth JD, Burris III HA. Sarah Cannon 
Research Institute, Nashville, TN; Tennessee Oncology, PLLC, 
Nashville, TN. 
ot2-01-04  Cardiac Safety of anthracycline-Containing adjuvant 
Chemotherapy of early breast Cancer: oSCar/abC ongoing, 
observational, multicentric Study
Ricevuto E, Cocciolone V, Zilli M, Scognamiglio MT, Pistilli B, Di 
Menna G, Mancini M, Cannita K, Adinolfi MI, Ferrandina MG, Pancotti 
A, Recchia F, Latini L, Ficorella C, Iacobelli S. San Salvatore Hospital, 
University of L’Aquila, L’Aquila, Italy; SS. Annunziata Hospital 
and G. Bernabeo Hospital, University G. D’Annunzio, Chieti, Italy; 
Ospedale Civile of Macerata, Macerata, Italy; F. Renzetti Hospital, 
Lanciano, Chieti, Italy; Catholic University of the Sacred Heart, Rome, 
Campobasso, Italy; Mazzini Hospital, Teramo, Italy; Ospedale Civile of 
Avezzano, Avezzano, L’AquILa, Italy. 
endocrine therapy
ot2-02-01  the Sole trial: international breast Cancer Study group (ibCSg 
35-07) and breast international group (big 1-07) Study of 
letrozole extension
Colleoni M. SOLE Collaborative Group and International Breast Cancer 
Study Group. 
Diagnosis and biomarkers
ot2-03-01  incidence of mastalgia as a presenting Complaint in iranian 
population with regard to age, bmi, education, residency 
(City or rural), State of marriage and Compare with Western 
Countries
Razavi S. Private Breast Clinic, Esfahan, Islamic Republic of Iran. 
ot2-03-02  prospective neo-adjuvant registry trial linking mammaprint, 
Subtyping and treatment response: neoadjuvant breast 
registry - Symphony trial (nbrSt)
Whitworth P, Beitsch P, Gittleman M, Akbari S. Nashville Breast 
Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast Care 
Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA. 
ot2-03-03  Spectroscopic Feature of breast Cancer
Ogura H, Yamashita D, Nasu H, Hosokawa Y, Koizumi K, Yamaki E, 
Yoshimoto K, Suzuki T, Ueda Y, Oda M, Yamashita Y, Sakahara H. 
Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, 
Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan. 
ot2-03-04  a trial model for the Future in the Search for personalised 
medicine - the uk poetiC and ephoS-b perioperative trials 
experience
Bliss JM, Robison LE, Webster-Smith MF, Emson MA, Kilburn LS, 
Smith IE, Robertson J, Dowsett M, Bundred NJ, Cameron DA, Vidya 
R, Horgan K, Evans AA, Kokan JS, Pinhel I, A’Hern R, on Behalf 
of the POETIC & EPHOS-B Trialists. Institute of Cancer Research, 
Sutton, London, United Kingdom; Royal Marsden Hospital, London, 
United Kingdom; Nottingham University Hospitals, Nottingham, 
United Kingdom; Royal Marsden Hospital and Breakthrough Breast 
Cancer Centre, London, United Kingdom; Wythenshawe Hospital, 
Manchester, United Kingdom; Western General Hospital, Edinburgh, 
United Kingdom; Stafford Hospital, Stafford, United Kingdom; Leeds 
General Infirmary, Leeds, United Kingdom; Poole Hospital, Poole, 
United Kingdom; Macclesfield District General Hospital, Macclesfield, 
United Kingdom. 
ot2-03-05  evaluation of the prevalence and prognostic Significance 
of vegF
165b
 in breast Cancer patients Compared to healthy 
Women
Guenthner-Biller MM, Rademacher A, Mayr D, Engelstädter V, Friese 
K, Jeschke U, Rack B. Ludwig-Maximilians-University, Munich, Bavaria, 
Germany. 
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ot2-03-06  aCrin 6698 mr imaging biomarkers for assessment of breast 
Cancer response to neoadjuvant Chemotherapy: a Sub-Study 
of the i-Spy 2 trial (investigation of Serial Studies to predict 
your therapeutic response with imaging and molecular 
analysis)
Hylton NM, Partridge SC, Rosen M, Kim E, L’Heureux DZ, Esseman 
L. University of California at San Francisco, San Francisco, CA; 
University of Washington, Seattle, WA; Hospital of the University 
of Pennsylvania, Philadelphia, PA; Brown University, Providence, RI; 
American College of Radiology Imaging Network, Philadelphia, PA. 
ot2-03-07  Withdrawn 
prevention
ot2-04-01  a randomized phase ii trial of vitamin D vs placebo in 
premenopausal Women: Calgb 70806
Wood ME, Kingsley F, Ambaye AB, Yee L, Jung S-H, Marshall JR, 
Paskett E. University of Vermont, Burlington, VT; Ohio State University; 
Roswell Park Cancer Institute; Duke University. 
ot2-04-02  metformin for breast Cancer prevention: a pilot Study
Ledgerwood MM, Ojeda-Fournier H, Patterson R, Hasteh F, Andre MP, 
Cadmus L, Blair S. University of California, San Diego, CA. 
ot2-04-03  uptake of a randomized breast Cancer prevention trial 
Comparing letrozole to placebo in brCa1/2 mutations Carriers: 
the FnClCC onCo-03/liber trial
Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker JP, Chabbert 
Buffet N, Lemonnier J, Roca L, Mijonnet S, Baudry K, Martin AL. 
University Hospital CHU Arnaud de Villeneuve, Montpellier, France; 
Centre Léon Bérard, Lyon and Université de Lyon 1; CNRS; UMR 5558, 
Villeurbanne, France; Centre Francois Baclesse, Caen, France; Institut 
Gustave Roussy, Villejuif; Centre Paul Strauss, Strasbourg; AP HP 
Hôpital Tenon; Fédération Nationale Française des Centres de Lutte 
Contre le Cancer. 
imaging
ot2-05-01  an open-label positron emission tomography Study to 
investigate and Quantify brain and tumor penetration 
of Carbon-11-labeled lapatinib in patients with her2-
overexpressing advanced or metastatic breast Cancer
Coombes RC, Reise JA, Lau MR, Carme SC, Searle GE, Huiban M, 
Burgess P, Noibi S, Koch K, Sapunar F, Saleem A. Imperial College; 
GlaxoSmithKline Oncology; GlaxoSmithKline Clincial Imaging Centre. 
ot2-05-02  aCrin 6691 monitoring and predicting breast Cancer 
neoadjuvant Chemotherapy response using Diffuse optical 
Spectroscopic imaging (DoSi)
Tromberg BJ, L’Heureux DZ, Mankoff DA, Zhang Z, Cerussi A, Mehta R, 
Carpenter PM, Butler JA, Hylton NM, Kaufman P, Pogue BW, Paulsen 
K, Yodh AG, Boas D, Isakoff S. University of California, Irvine, CA; 
American College of Radiology Imaging Network, Philadelphia, PA; 
University of Washington, Seattle, WA; Brown University, Providence, 
RI; University of California at San Fransisco, San Fransisco, CA; 
Dartmouth University, Lebanon, NH; University of Pennsylvania, 
Philadelphia, PA; Massachusetts General Hospital, Charlestown, MA; 
Massachusetts General Hospital, Boston, MA. 
ot2-05-03  aCrin 6688 phase ii Study of Fluorine-18 3’-Deoxy-3’ 
Fluorothymidine (Flt) in invasive breast Cancer
Jolles PJ, Kostakoglu L, Bear HD, Idowu MO, Kurdziel K, Shankar 
L, Mankoff DA, Duan F, L’Heureux DZ. Virginia Commonwealth 
University, Richmond, VA; Mount Sinai School of Medicine, New 
York, NY; National Cancer Institute, Bethesda, MD; University of 
Washington, Seattle, WA; Brown University, Providence, RI; American 
College of Radiology Imaging Network, Philadelphia, PA. 
ot2-05-04  aCrin pa 4006: Comparison of Full-Field Digital 
mammography with Digital breast tomosynthesis image 
acquisition in relation to Screening Call-back rate
Conant EF, Maidment A, Copit D, Olson CB, Heckel ML, Gatsonis C. 
Hospital of the University of Pennsylvania, Philadelphia, PA; Albert 
Einstein Medical Center, Philadelphia, PA; American College of 
Radiology Imaging Network, Philadelphia, PA; Brown University, 
Providence, RI. 
ot2-05-05  phase i/ii Study of adoptive t Cell therapy Following in vivo 
priming with a her2 peptide-based vaccine in patients with 
Stage iv breast Cancer
Parker SL, Higgins DM, Childs JS, Dang Y, Guthrie KA, Disis ML, Salazar 
LG, Coveler A. University of Washington, Seattle, WA; Fred Hutchinson 
Cancer Research Center, Seattle, WA. 
ot2-05-06  aCoSog Z11101/aCrin 6694: effect of preoperative breast mri 
on Surgical outcomes, Costs and Quality of life of Women with 
breast Cancer
Bedrosian I, Suman VJ, Yao K, Shih Y-CT, Yen TWF, Comstock C, 
Newstead G, Birdwell R, Kim E, L’Heureux DZ, Gatsonis C. MD 
Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; 
University of Chicago, Evanston, IL; University of Chicago, Chicago, 
IL; Medical College of Wisconsin, Milwaukee, WI; Memorial Sloan-
Kettering Cancer Center, New York City, NY; Harvard Medical School, 
Boston, MA; Brown University, Providence, RI; American College of 
Radiology Imaging Network, Philadelphia, PA. 
radiotherapy
ot2-06-01  a phase iii randomized multicentric French Study to evaluate 
the impact of a localized 16-gy boost after Conservative 
Surgery and a 50-gy Whole-breast irradiation in breast Ductal 
Carcinoma in Situ (the bonbiS trial)
Azria D, Cowen D, De La Lande B, Bourgier C, Latorzeff I, Leblanc-
Onfroy M, Douadi-Gaci Z, Pradier O, Peignaux K, Levy C, Ellis S, 
Lecouillard I, Racadot S, Bontemps P, Benyoucef A, Lagarde P, 
Laharie-Mineur H, Cretin J, Marchal C, Serin D, Lemanski C. CRLC 
Val d’Aurelle, Montpellier, France; AP-HM, Marseille, France; Centre 
Rene Huguenin, Saint Cloud, France; IGR, Villejuif, France; Groupe 
ONCORAD, Toulouse, France; Centre Rene Gauducheau, Nantes, 
France; Centre Catherine de Sienne, Nantes, France; CHU Brest, Brest, 
France; CRLC G-F Leclerc, Dijon, France; CRLC François Baclesse, Caen, 
France; Centre Catalan d’Oncologie, Perpignan, France; CRLC Eugene 
Marquis, Rennes, France; Centre Leon Berard, Lyon, France; CHU 
Besancon, Besancon, France; Centre Henri Becquerel, Rouen, France; 
Institut Bergonie, Bordeaux, France; Clinique Tivoli, Bordeaux, France; 
Clinique Valdegour, Nimes, France; Centre Alexis Vautrin, Vandoeuvre 
les Nancy, France; Institut Sainte Catherine, Avignon, France. 
ot2-06-02  a randomized phase iii Study of Conventional Whole breast 
irradiation (Wbi) vs partial breast irradiation (pbi) for Women 
with Stage 0, 1, or 2 breast Cancer: nSabp b-39/rtog 0413
Julian TB, Costantino JP, Vicini FA, White JR, Cecchini RS, Winter KA, 
Arthur DW, Kuske R, Rabinovitch R, Parda DS, Mamounas EP, Curran, 
Jr WJ, Wolmark N. National Surgical Adjuvant Breast & Bowel Project 
(NSABP), Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA; 
NSABP Biostatistical Center, Pittsburgh, PA; University of Pittsburgh 
Graduate School of Public Health, Pittsburgh, PA; Beaumont Health 
System, Royal Oak, MI; Radiation Therapy Oncology Group (RTOG), 
Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; 
Virginia Commonwealth University, Richmond, VA; Arizona Breast 
Cancer Specialists, Scottsdale, AZ; University of Colorado Denver, 
Aurora, CO; Aultman Health Foundation, Canton, OH; Emory 
University, Atlanta, GA. 
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Side-effect Control
ot2-07-01  pasireotide long acting release (lar) in breast Cancer patients 
to prevent lymphocele after mastectomy and axillary node 
Dissection: a randomized, multicenter, phase ii Study
Chereau E, Uzan C, Bezu C, Mazouni C, Ballester M, Gouy S, Rimareix 
F, Garbay J-R, Daraï E, Uzan S, Coutant C, Rouzier R. Tenon - APHP, 
Paris, France; Institut Gustave Roussy, Villejuif, France. 
ot2-07-02  SWog S0927: a randomized Double blind placebo-Controlled 
trial of omega-3-Fatty acid for the Control of aromatase 
inhibitor (ai)-induced musculoskeletal pain in Women with 
early Stage breast Cancer
Hershman DL, Unger JM, Crew KD, Moinpour CM, Minasian LM, 
Hansen L, Lew DL, Kaberle K, Wade JL, Meyskens FL. Columbia 
University, New York, NY; SWOG, Seattle, WA; National Cancer 
Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, Portland, 
OR; SWOG, San Antonio, TX; Cancer Care Specialists of Illinois, 
Decatur, IL; University of California, Irvine, Orange County, CA. 
7:30 pm–9:30 pm
open Satellite event 
marriott rivercenter, grand ballroom
Targeting breast Cancer Molecular Phenotypes: A Dialogue Between 
Community and Academic Oncologists
WEBSITE: http://primeoncology.org/sanantoniosymposium2011
FriDay, DeCember 9, 2011
6:45 am–5:15 pm 
regiStration  
bridge hall
7:00 am–9:00 am 
poSter SeSSion 4 & Continental breakFaSt 
exhibit halls a-b
tumor Cell biology: endocrine therapy and resistance
p4-01-01  preclinical and Clinical Studies of estrogen Deprivation Support 
the pDgF/abl pathway as a novel therapeutic target for 
overcoming resistance
Weigel MT, Banerjee S, A’Hern R, Arnedos M, Ghazoui Z, Dunbier AK, 
Dowsett M, Martin L-A. Institute of Cancer Research, London, United 
Kingdom; Royal Marsden Hospital, London, United Kingdom. 
p4-01-02  endocrine resistance: mechanism, tumorigenic Capacities, and 
new therapeutic Strategies
Morrison GD, Fu X, Ithimakin S, Rimawi MF, Wicha MS, Osborne 
CK, Schiff R. Baylor College of Medicine, Houston, TX; University of 
Michigan, Ann Arbor, MI. 
p4-01-03  establishment and Characterization of an endocrine resistance 
model in vitro and in vivo by inducible pten knockdown
Fu X, Shea M, Biswal NC, Mitchell T, Giuliano M, Healy NA, Meerbrey 
KL, Joshi A, Westbrook T, Hilsenbeck SG, Osborne CK, Schiff R. Baylor 
College of Medicine, Houston, TX; National University of Ireland, 
Galway, Ireland. 
p4-01-04  effects of Cyp2D6 phenotype and Drug adherence on 
tamoxifen metabolite levels
Sousa BA, Nasim S, Cole DE, Wong BY, Hill K, Pritchard KI, Trudeau 
M, Verma S, Dent RA, Petrella T, Gandhi S, Ueng S, Vandenberghe 
U, Romaschin A, Warner E. Sunnybrook Health Sciences Odette 
Cancer Centre, Toronto, ON, Canada; Li Ka Shing Research Institute, 
Biochemistry, Toronto, ON, Canada. 
p4-01-05  the multikinase inhibitor Sorafenib Can overcome 
antiestrogen resistance in patients with progressive 
metastatic estrogen receptor (er) positive breast Cancer
Moss J, Black EP, Wang C, Li L, Sloan S, Lye A, Romond E, Weiss H, 
Massarweh S. University of Kentucky and Markey Cancer Center, 
Lexington, KY. 
p4-01-06  global Characterization of the SrC-1 transcriptome identifies 
Disintegrin C as an er-independent mediator of endocrine 
resistant breast Cancer
Bolger JC, McCartan DP, McIlroy M, Byrne C, Fagan A, Xu J, O’Gaora 
P, Hill ADK, Young LS. Royal College of Surgeons in Ireland, Dublin, 
Ireland; University College Dublin, Dublin, Ireland; Dan L. Duncan 
Cancer Center, Baylor College of Medicine, Houston, TX. 
p4-01-07  Combining hedgehog inhibitor, gDC-0449 with tamoxifen 
overcomes tamoxifen-resistance in in-vitro and in-vivo 
Studies of estrogen-receptor positive breast Cancer
Majumder S, Lu Y, Teng K-y, Kaffenberger T, Zhang X, Nuovo G, 
Love RR, Ramaswamy B. The Ohio State University, Columbus, OH; 
International Breast Cancer Research Foundation, Madison, WI. 
p4-01-08  the role of Ser991 pelp1 phosphorylation in therapy 
resistance and metastasis of breast Cancer
Sareddy GR, Nair BC, Krishnan SR, Gonugunta VK, Vadlamudi RK. 
UTHSCSA, San Antonio, TX. 
p4-01-09  reduced Cyba expression leads to the Development of 
Fulvestrant resistance in a breast Cancer Cell line
Skerry BJO, Ramsahoye BH. The University of Edinburgh, Edinburgh, 
United Kingdom. 
p4-01-10  the role of the Steroid receptor Coactivator SrC1 and its 
Functional partner hoXC11 in the Development of endocrine 
resistant breast Cancer
Walsh CA, McCartan D, Hill ADK, Young LS. Royal College of Surgeons 
in Ireland, Dublin, Ireland. 
p4-01-11  autocrine human growth hormone (hgh) reduces the 
Sensitivity of breast Cancer Cells to treatment with tamoxifen 
and Fulvestrant
Perry JK, Chen H, Bougen NM, Liu D-X, Lobie PE. University of 
Auckland, Auckland, New Zealand; National University of Singapore, 
Singapore. 
p4-01-12  the unfolded protein response (upr) and pro-Survival 
autophagy Contributes to antiestrogen resistance in breast 
Cancer
Clarke R, Shajahan AN, Cook KL, Hickman FE, Facey CO. Georgetown 
University, Lombardi Comprehensive Cancer Center, Washington, DC. 
p4-01-13  biology of aggressiveness and tamoxifen resistance in 
hormone receptor-positive very young age breast Cancer
Han W, Ro J, Jung S. Seoul National University Hospital, Seoul, Korea; 
National Cancer Center, Goyang, Kyungi, Korea. 
p4-01-14  Fulvestrant regulates epidermal growth Factor (egF) ligands 
and induces egF receptor activation in mCF-7 breast Cancer 
Cells
Zhang X, Diaz MR, Yee D. University of Minnesota, Minneapolis, MN. 
p4-01-15  alteration of y-box binding protein-1 expression modifies the 
response to endocrine therapy in estrogen receptor positive 
breast Cancer
Ito T, Kamijo S, Izumi H, Kohno K, Ito K-i. Shinshu University School of 
Medicine, Matsumoto, Nagano, Japan; University of Occupational & 
Environmental Health, Kitakyushu, Fukuoka, Japan. 
p4-01-16  the influence of Cyp2D6 genetic polymorphisms on variability 
of tamoxifen metabolism in the lebanese breast Cancer 
population
Tfayli A, Zgheib N, Holail J, Habbal M-Z, Halawi R, El-Saghir N, Salem 
Z. American University of Beirut, Beirut, Lebanon. 
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p4-01-17  timp-1 over-expression Confers resistance of mCF-7 breast 
Cancer Cells to Fulvestrant
Bjerre CA, Vinther L, Belling K, Schrohl Rasmussen A-S, Li J, Lin X, 
Han Z, Wang J, Bolund L, Jensen V, Nielsen BS, Soekilde R, Gupta 
R, Lademann U, Brünner N, Stenvang J. Faculty of Life Sciences, 
University of Copenhagen, Copenhagen, Denmark; Technical 
University of Denmark, Lyngby, Denmark; Aarhus University, Aarhus, 
Denmark; BGI-Shenzhen, Shenzhen, China; Exiqon A/S, Vedbeak, 
Denmark. 
p4-01-18  ap-1 blockade potentiates the anti-tumor effect of endocrine 
treatment and reverts the resistant phenotype in hormone 
receptor-positive breast Cancer
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien 
M, Hilsenbeck SG, Healy N, Mazumdar A, Trivedi MV, Jeselsohn R, 
He HH, Fu X, Gutierrez C, Brown M, Brown PH, Osborne CK, Schiff R. 
Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; 
The University of Texas M.D. Anderson Cancer Center, Houston, TX; 
Dana-Farber Cancer Institute and Harvard Medical School, Boston, 
MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess 
Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, 
NH; UH College of Pharmacy, Houston, TX. 
p4-01-19  SrC-1 expression is a prognostic Factor of breast Cancer-
Specific and Disease-Free Survival in inflammatory breast 
Cancer
Arias-Pulido H, Ahmed RD, Chaher N, Vargas J, Joste N, Lomo L, 
Qualls C, Azziez S, Terki N, Bouzid K, Prossnitz E, Royce M. University of 
New Mexico, Albuquerque, NM; Centre Pierre et Marie Curie, Algiers, 
Algeria. 
p4-01-20  Specific anti-proliferative profile of endoxifen for mCF-7 Cell 
Compared to 4-oh tamoxifen
Saji S, Hirose M, Hayashi S-i, Kuroi K. Saitama Medical University, IMC, 
Saitama, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, 
Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; 
Kyoto University, Graduate School of Medicine, Kyoto, Japan. 
p4-01-21  an estrogen-inducible transcription Factor FoXp1 promotes 
estrogen-Dependent Cell proliferation of breast Cancer Cells 
and is associated with 5-year Disease-Free Survival in patients 
with tamoxifen-treated breast Cancer
Shigekawa T, Ijichi N, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi 
K, Tsuda H, Osaki A, Saeki T, Inoue S. Tokyo Metropolitan Cancer and 
Infectious Disease Center, Komagome Hospital; Research Center for 
Genomic Medicine, Saitama Medical University; International Medical 
Center, Saitama Medical University; National Cancer Center Hospital; 
National Shikoku Cancer Center; Graduate School of Medicine, The 
University of Tokyo. 
p4-01-22  Cyclin D1 and its prognostic value in planning of endocrine 
therapy for Women of postmenopausal age with breast 
Cancer
Skvortsov V, Manikhas A, Manikhas G, Oganesyan A, Raskin G. City 
Clinical Oncology Dispensary, St. Petersburg, Russian Federation; 
Pavlov State Medical University of St. Petersburg, St. Petersburg, 
Russian Federation. 
tumor Cell biology: hormonal Factors and receptors
p4-02-01  bis(2-ethylhexyl) phthalate: a potential endocrine Disruptor 
Confer letrozole insensitivity and induction of aromatase 
activity in breast Cancer Cells
Nair HB, Bhaskaran SS, Krishnegowda NK, Tekmal RR, VandeBerg JL. 
Texas Biomedical Research Institute, San Antonio, TX; University of 
Texas Health Science Center, San Antonio, TX. 
p4-02-02  the natural Fetal estrogen estetrol (e4), Causes anti-estrogenic 
effects in Women with endocrine-responsive positive early 
breast Cancer
Singer CF, Natter C, Steurer S, Rudas M, Moinfar F, Appels NRCA, 
Visser M, Kubista E, Bennink C. Medical University of Vienna, Wien; 
Medical University of Graz, Wien; Pantarheie Bioscience. 
p4-02-03  biological Functions of estrogen receptor-beta and its variants 
in breast Cancer
Hawse JR, Wu X, Cicek M, Subramaniam M, Negron V, Lingle WL, 
Goetz MP, Spelsberg TC, Ingle JN. Mayo Clinic. 
p4-02-04  androgen receptor (ar) expression in a Cohort of patients 
(pts) with triple negative breast Cancer (tnbC)
Gucalp A, Gupta G, Patil S, Wen YH, Akram M, Brogi E, Powell SN, Ho 
AY, Hudis CA, Traina TA. Memorial Sloan-Kettering Cancer Center, 
New York, NY. 
p4-02-05  the regulation of artemin Signalling by igF-1 in mammary 
Carcinoma Cells
Yip C, Liu D, Lobie PE, Perry JK. University of Auckland, Auckland, New 
Zealand; National University of Singapore, Singapore. 
p4-02-06  progesterone receptor expression predicts poor outcome 
in estrogen receptor positive, lymph node negative breast 
Cancer - a population based Study
Purdie CA, Quinlan P, Jordan LB, Ashfield A, Baker L, Dewar JA, 
Thompson AM. Ninewells Hospital & Medical School, Dundee, United 
Kingdom; University of Dundee, Dundee, United Kingdom. 
p4-02-07  influence of the progesterone receptor on the prognosis of 
breast Cancer in interaction with other prognostic Factors
Salmen JC, Fasching PA, Hepp P, Jueckstock J, Haeberle L, Mohrmann 
S, Beckmann MW, Hartmann A, Wachter DL, Friese K, Janni W, Rack B. 
Frauenklinik der Heinrich-Heine-Universitaet, Duesseldorf, Germany; 
University of California at Los Angeles, Los Angeles; LMU Muenchen, 
Frauenklinik Innenstadt Maistrasse 11, Muenchen, Germany; 
Frauenklinik des Universitaetsklinikums Erlangen, Erlangen, Germany; 
Universitaetsklinikum Erlangen, Erlangen, Germany. 
p4-02-08  obesity-induced aromatase expression in the breast 
microenvironment promotes estrogen receptor activity 
independent of Circulating estradiol levels
Bowers LW, Brenner AJ, Li R, Tekmal RR, deGraffenried LA. The 
University of Texas at Austin, Austin, TX; The University of Texas 
Health Science Center at San Antonio, San Antonio, TX. 
p4-02-09  estrogen-related receptor α mediates insulin-like growth 
Factor-i Dependent migration in breast Cancer Cells
Fettig-Anderson LM, Oh AS, Yee D. University of Minnesota, 
Minneapolis, MN. 
p4-02-10  the relationship between estrogen receptor gene 
polymorphism and mammographic Density in postmenopausal 
Women
Baldisserotto FDG, Elias S, Silva IDCG, Nazario ACP. Universidade 
Federal de Sao Paulo - UNIFESP-EPM, Sao Paulo, SP, Brazil. 
p4-02-11  insulin-like growth Factor i promotes estrogen receptor 
positive breast Cancer Cell proliferation, in part, through 
Cyp1a1 Signaling
Rodriguez M, Becker M, Yee D, Potter D. University of Minnesota, 
Minneapolis, MN. 
p4-02-12  plasma estradiol levels and Degree of estrogen receptor 
positivity by image analysis in a large Cohort of breast Cancer 
Cases: results from the nurses’ health Study
Collins LC, Frieling GW, Ahern TP, Hu R, Hankinson SE, Tamimi RM. 
Beth Israel Deaconess Medical Center, Boston; Harvard Medical 
School, Boston; Channing Laboratory, Brigham and Women’s 
Hospital, Boston; Harvard School of Public Health, Boston. 
tumor Cell biology: animal models
p4-03-01  Stat5 regulates the pi3-kinase/akt1 pathway during mammary 
gland Development and promotes neoplastic transformation 
in a mouse model for Cowden Syndrome
Schmidt JW, Sakamoto K, Creamer BA, Leone G, Wagner K-U. 
University of Nebraska Medical Center, Omaha, NE; Ohio State 
University, Columbus, OH. 
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p4-03-02  high Fat Diet-induced postmenopausal obesity promotes 
tumor angiogenesis and breast Cancer progression in age-
relevant ovariectomized mice
Gu J-W, Young E, Patterson SG, Makey KL, Huang M, Tucker KB, 
Chinchar E, Miele L. University of Mississippi Medical Center, Jackson, 
MS. 
p4-03-03  therapeutic Sensitivities of mouse models of human breast 
Cancer
Usary JE, Darr DB, Zhao W, Balletta LD, Aparicio AP, Karginova OA, 
Jordan JL, Perou CM. University of North Carolina, Chapel Hill, NC. 
p4-03-04  identification of molecular targets for Cancer-initiating Cells 
using a triple-negative breast Cancer mouse model
Kai K, Iwamoto T, Pusztai L, Hortobagyi GN, Saya H, Ueno NT. The 
University of Texas MD Anderson Cancer Center, Houston, TX; 
Institute for Advanced Medical Research, Shinjuku-ku, Tokyo, Japan. 
p4-03-05  Development of an inducible estrogen receptor Co-activator 
pelp1 mammary tumor model
Cortez VA, Newallo D, Chodosh LA, Tekmal RR, Vadlamudi RK. 
The University of Texas Health Science Center at San Antonio, 
San Antonio, TX; University of Pennsylvania School of Medicine, 
Pennsylvania, PA. 
p4-03-06  Development and Comparative Characterization of metastasis 
in newly Developed pre-Clinical models of inflammatory breast 
Cancer
Chu K, Mu Z, Alpaugh KR, Fernandez S, Freiter EM, Wu H, Zook MB, 
Barsky SH, Cristofanilli M, Robertson FM. The University of Texas MD 
Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, 
Philadelphia, PA; University of Nevada School of Medicine, Reno, NV; 
Nevada Cancer Institute, Las Vegas, NV. 
tumor Cell biology: mammary Development and Differentiation
p4-04-01  identification of a unique mammary Cell type expressing 
mesenchymal markers, but Capable of multilineage epithelial 
Differentiation
Landua JD, Lewis MT. Baylor College of Medicine, Houston, TX. 
p4-04-02  Smoothened Function as a g-protein Coupled receptor in 
mammary epithelial Cells
Villanueva H, Visbal AP, Birnbaumer L, Plummer NW, Lewis MT. Baylor 
College of Medicine, Houston, TX; National Institute of Environmental 
Health Sciences, Research Triangle Park, NC. 
tumor Cell biology: metabolism and breast Cancer
p4-05-01  rab25 alters Cellular energetics and growth Signaling during 
breast oncogenesis
Mitra S, Cheng KW, Dennison JB, Mills GB. MD Anderson Cancer 
Center, Houston, TX. 
p4-05-02  early Developmental exposures to a high Carbohydrate/high 
Fat Diet affect glucose metabolism and mammary Cancer 
Susceptibility
Berton TR, Lambertz I, Tian J, Johanning G, Conti C, Fuchs-Young R. 
UT MD Anderson Cancer Center, Smithville, TX; UT MD Anderson 
Cancer Center, Bastrop, TX. 
p4-05-03  mechanism underlying metabolic heterogeneity in breast 
Cancer Subtypes
Molina JR, Dennison JB, Zhang F, Mills GB. MD Anderson Cancer 
Center, Houston, TX. 
p4-05-04  arachidonic acid-induced elevated expression of 
5-lipoxygenase is linked to metastatic migration of breast 
Cancer Cells
Roy D, De Chatterjee A, Pal R, Roychowdhury S, Das S. University of 
Texas at El Paso, El Paso, TX. 
p4-05-05 imaging mass Spectrometry based lipid metabolites analysis 
for breast Cancer
Ide Y, Nishio T, Hosokawa Y, Matsunuma R, Koizumi K, Ogura H, Shiiya 
N, Setou M. Hamamatsu University School of Medicine, Hamamatsu, 
Japan. 
p4-05-06 Systemic Cholesterol promotes breast tumor aggressiveness
Santos CR, Almeida JM, Dias S.  Portuguese Institute of Oncology, 
Lisbon, Lisbon, Portugal.
p4-05-07 insulin-like growth factor 1 induces a rewiring of the aerobic 
glycolysis pathway in breast cancer
Pinto DM, Murphy JP, Chisholm KA, Druker A.  National Research 
Council of Canada, Halifax, Nova Scotia, Canada; Harvard University, 
Boston, Massachusetts, United States; Queen Elizabeth II Health 
Sciences Centre, Halifax, Nova Scotia, Canada.
p4-05-08 metabolomic profiling of breast Cancer Delineates Clinical and 
race-Specific Subtypes and associated bioprocesses
Putluri N, Dorsey T, Golfmann L, Nanda S, Putluri V, Wallace T, Mathe 
E, Zhang X, Terunuma A, Michailidis G, Lewis M, Schiff R, Ambs S, 
Sreekumar A.  Baylor College of Medicine, Houston, TX; National 
Cancer Institute, Bethesda, Maryland; University of Michigan, Ann 
Arbor, MI.
tumor Cell biology: micrometastases
p4-06-01  Withdrawn
p4-06-02  microscopic Disease in blood and bone marrow predicts 
Survival in early Stage breast Cancer
Lucci A, Krishnamurthy S, Lodhi A, Bhattacharyya A, Hall C, Anderson 
A, Bedrosian I, Singh B, Kuerer H. University of Texas MD Anderson 
Cancer Center, Houston, TX. 
p4-06-03  multiplex gene expression of Disseminated tumor Cells in 
the bone marrow of breast Cancer patients identifies novel 
therapeutic targets
Aft R, Mudalagiriyappa C, Pillai S, Fleming T, Watson M. Washington 
University, St. Louis, MO. 
p4-06-04  Detection of her2 gene amplification in Circulating tumor 
Cells and Disseminated tumor Cells by Fluorescence in Situ 
hybridization using oncoCee™
Krishnamurthy S, Bischoff FZ, Mayer JA, Wong K, Pham T, Kuerer HM, 
Lodhi AK, Bhattacharyya A, Hall CS, Lucci A. University of Texas M.D. 
Anderson Cancer Center, Houston, TX; Biocept Laboratories, San 
Diego, CA. 
p4-06-05  prognostic impact of Disseminated and Circulating tumor Cells 
in patients treated for locally advanced breast Cancer
Mathiesen RR, Nesland JM, Renolen A, Løkkevik E, Anker G, østenstad 
B, Lundgren S, Riisberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume 
B. Oslo University Hospital The Radium Hospital, Oslo, Norway; Oslo 
University Hospital, Oslo, Norway; University of Bergen, Bergen, 
Norway; Haukeland University Hospital, Bergen, Norway; St. Olavs 
University Hospital, Trondheim, Norway; Norwegian University of 
Science and Technology, Trondheim, Norway; University Hospital 
of Northern Norway and Institute of Clinical Medicine, University of 
Tromsø, Tromsø, Norway; Stavanger University Hospital, Stavanger, 
Norway; Oslo University Hospital, The Radium Hospital, Oslo, Norway; 
University of Oslo, Oslo, Norway. 
p4-06-06  morphological Categories of iCC-Detected Ck+ Cells in bone 
marrow have Different prognostic impact in breast Cancer
Borgen E, Synnestvedt M, Schirmer CB, Schlichting E, Nesland JM, 
Naume B. The Radium Hospital, Oslo University Hospital, Oslo, 
Norway; The Radium Hospital, Oslo University Hospital, Oslo, Norway; 
Ullevål Hospital, Oslo University Hospital, Oslo, Norway; University of 
Oslo, Oslo, Norway. 
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Detection and Diagnosis – pathology: Circulating tumor Cells
p4-07-01  Circulating tumor Cells, Disease recurrence and Survival in 
newly Diagnosed breast Cancer
Franken B, de Groot MR, Terstappen LWMM, Mastboom WJB, Van der 
Palen J, Tibbe AGJ. Medisch Spectrum Twente, Enschede, Overijssel, 
Netherlands; University of Twente, Enschede, Overijssel, Netherlands. 
p4-07-02  Detection, enrichment, Characterization and propagation 
of Circulating tumour Cells from patients with advanced 
metastatic breast Cancer
Mihalcioiu C, Lian J, Bertos N, Omeroglu A, Sebag M, DiBattista J, 
Li J, Chughtai N, Park M, Kremer R. Royal Victoria Hospital/McGill 
University, Montreal, QC, Canada; McGill University, Montreal, QC, 
Canada. 
p4-07-03  identification of triple-negative primary breast Cancer 
Xenograft models with high numbers of Circulating and 
Disseminated tumor Cells
Giuliano M, Christiny PI, Zhang X, Mao S, Contreras A, Lewis MT, 
Rimawi MF, Osborne CK, Schiff R, Trivedi MV. Baylor College of 
Medicine, Houston, TX; UH College of Pharmacy, Houston, TX. 
p4-07-04  nomogram including Circulating tumor Cells (CtC) Count 
before and during Chemotherapy for individual Survival 
prediction of metastatic breast Cancer patients
Bidard F-C, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, 
Wolp-Diniz R, Dieras V, Mathiot C, Asselain B, Pierga J-Y. Institut Curie, 
Paris, France; Centre Leon Berard, Lyon, France; Institut Gustave 
Roussy, Villejuif, France; Institut de Cancérologie de l’Ouest, Nantes, 
France. 
p4-07-05  Comparison of pik3Ca hot Spot mutations in the primary 
tumor or metastases with pik3Ca mutations or pik3Ca over-
expression in Circulating tumor Cells of metastatic breast 
Cancer patients under Sequential palliative therapy
Aktas B, Kasimir-Bauer S, Kasper S, Derks C, Kimmig R, Schuler M, 
Tewes M. West German Cancer Center, University Hospital Essen, 
University of Duisburg-Essen, Essen, Germany. 
p4-07-06  Correlation of two analytical methods for Circulating tumor 
Cells in peripheral blood of patients with primary breast Cancer
Jaeger BAS, Rack B, Jueckstock J, Salmen J, Ortmann U, Lorenz 
R, Rezai M, Beck T, Schneeweiss A, Zwingers T, Beckmann MW, 
Friese K, Janni W. Klinikum der Ludwig-Maximilians-Universitaet - 
Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, 
Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-Hecker-Wesche, 
Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; 
RoMed Klinikum Rosenheim, Rosenheim, Germany; University 
Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, 
Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany. 
p4-07-07  Circulating tumor Cells predict Survival in non-metastatic 
breast Cancer
Lucci A, Krishnamurthy S, Bhattacharyya A, Lodhi A, Hall C, Singh B, 
Anderson A, Bedrosian I, Kuerer H. University of Texas MD Anderson 
Cancer Center, Houston, TX. 
p4-07-08  Subsets and molecular Signatures of Circulating tumor Cells in 
breast Cancer brain metastasis
Marchetti D, Zhang L, Wetzel M, Zaidi T, Ridgway L, Schoeber W, He 
W, Groves MD, Katz RL. Baylor College of Medicine, Houston, TX; MD 
Anderson Cancer Center, Houston, TX. 
p4-07-09  automated Quantitative assessment of her2 expression of 
Circulating tumor Cells (CtC) in metastatic breast Cancer (iC 
2006-04 Study)
Bidard F-C, Ligthart ST, Decraene C, Bachelot T, Delaloge S, Brain 
E, Campone M, Pierga J-Y, Terstappen LWMM. Institut Curie, Paris, 
France; University of Twente, Enschede, Netherlands; Centre Leon 
Berard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Institut 
de Cancérologie de l’Ouest, Nantes, France. 
p4-07-10  Circulating tumor Cells in newly Diagnosed inflammatory 
breast Cancer
Mego M, Giordano A, De Giorgi U, Hsu L, Lucci A, Dawood S, 
Woodward WA, Ueno NT, Valero V, Andreopoulou E, Hortobagyi GN, 
Reuben JM, Cristofanilli M. Comenius University, School of Medicine, 
Bratislava, Slovakia (Slovak Republic); UT MD Anderson Cancer Center, 
Houston, TX; Fox Chase Cancer Center, Philadelphia. 
p4-07-11  Circulating tumor Cells after neoadjuvant therapy predict 
outcome in Stage i to iii breast Cancer
Gainer S, Krishnamurthy S, Bhattacharyya A, Lodhi A, Hall C, Kuerer H, 
Bedrosian I, Anderson A, Singh B, Lucci A. The University of Texas MD 
Anderson Cancer Center, Houston, TX. 
p4-07-12  identification of p53 mutation in Whole genome Dna from 
Single Circulating tumor Cells (CtCs) and primary breast 
Cancers (bC) from patients (pts) with metastatic breast Cancer 
(mbC)
Yang L, Wang Y, Chu P, Liu Q, Hsieh B, Liu X, Yen Y, Bruce R, Somlo G. 
City of Hope; Palo Alto Research Center. 
p4-07-13  prognostic impact of Circulating tumor Cells assessed with the 
Cell Search assay and adna test breast in metastatic breast 
Cancer patients - the DeteCt Study
Mueller V, Riethdorf S, Rack B, Wolfgang J, Fasching PA, Solomayer E, 
Aktas B, Kasimir-Bauer S, Mury D, Pantel K, Fehm T. University Medical 
Center Hamburg-Eppendorf; LMU Munich; University Medical Center 
Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen 
Nuremberg, Erlangen; University Medical Center Homburg/Saar; 
University Medical Center Essen; University Medical Center Tübingen, 
All Authors on Behalf of the DETECT Study Group. 
p4-07-14  Circulating tumor Cells (CtCs) Detection and her2 profiling by 
CellSearch® in non-metastatic breast Cancer: an international 
ring Study to assess inter-reader variability
Ignatiadis M, Pierga J-Y, Campion M, Fehm T, Payne R, Rack B, 
Mavroudis D, Riethdorf S, Rothe F, Bessi S, Aura CM, Sandri MT, 
Borgen E, Kraan J, Terstappen LWMM, Piccart M, Sotiriou C, Michiels 
S, Pantel K. Institut Jules Bordet, Brussels, Belgium; Institut Curie, 
Paris, France; Mayo Clinic, Rochester; Universitaets-Frauenklinik, 
Tubingen, Germany; Hammersmith Hospital, Imperial College, 
London, United Kingdom; Ludwig-Maximilians-Universitat, Munchen, 
Germany; University of Crete, Crete, Greece; University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany; Hospital of Prato, Prato, 
Italy; Vall d’Hebron, Barcelona, Spain; European Institute of Oncology, 
Milan, Italy; Oslo University Hospital, Oslo, Norway; Erasmus Medical 
Center, Rotterdam, Netherlands; University of Twente, Twente, 
Netherlands. 
p4-07-15  insulin-like growth Factor receptor i (igFir) expression in 
Circulating tumor Cells (CtCs) of patients with early and 
metastatic breast Cancer (bC)
Spiliotaki M, Markomanolaki H, Kokotsaki M, Kallergi G, Mavroudis 
D, Georgoulias V, Agelaki S. School of Medicine, University of Crete, 
Heraklion, Crete, Greece; University General Hospital of Heraklion, 
Heraklion, Crete, Greece. 
p4-07-16  Development of Circulating tumor Cell-endocrine therapy 
index in metastatic breast Cancer patients
Paoletti C, Connelly MC, Chianese DA, Brown ME, Muñiz MC, Rae 
JM, Thomas DG, Hayes DF. University of Michigan Comphrehensive 
Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon 
Valley, PA. 
p4-07-17  isolation of highly pure Circulating tumor Cells (CtCs) from 
metastatic breast Cancer (mbC) patients for gene expression 
analysis
Magbanua MJ, Hauranieh L, Pendyala P, Sosa E, Scott J, Rugo H, Park 
J. University of California, San Francisco, CA. 
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p4-07-18  prospective assessment of Circulating tumor Cells and Serum 
markers for pFS prediction in metastatic breast Cancer
Bidard F-C, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, 
Cottu P, Beuzeboc P, Mathiot C, Pierga J-Y. Institut Curie, Paris, France; 
Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, 
France; Centre René Gauducheau, Nantes, France. 
p4-07-19  bone marrow involvement is associated with high numbers 
of Circulating tumor Cells in peripheral blood of metastatic 
breast Cancer patients
Grisanti S, Consoli F, Almici C, Bertagna F, Verardi R, Ungari M, 
Amoroso V, Pedersini R, Vassalli L, Montani E, Simoncini EL. Spedali 
Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy. 
p4-07-20  apoptosis in Circulating tumor Cells (CtCs) of early and 
metastatic breast Cancer patients
Kallergi G, Konstantinidis G, Papadaki M, Agelaki S, Mavroudis D, 
Stournaras C, Georgoulias V. School of Medicine, University of Crete, 
Heraklion, Crete, Greece; University General Hospital of Heraklion, 
Heraklion, Crete, Greece. 
p4-07-21  a Comparison of two methods for the Detection of Circulating 
tumor Cells (CtCs) in patients (pts) with early and metastatic 
breast Cancer (bC): rt-pCr for Cytokeratin (Ck) -19 mrna 
versus the CellSearch System
Politaki E, Agelaki S, Apostolaki S, Perraki M, Hatzidaki D, Lianidou ES, 
Mavroudis D, Georgoulias V. University General Hospital of Heraklion, 
Heraklion, Crete, Greece; University of Athens, Athens, Greece. 
Detection and Diagnosis – pathology: Circulating markers
p4-08-01  predictive value of her2 Serum levels in patients treated 
with lapatinib or trastuzumab - a translational project in the 
neoadjuvant “geparquinto” trial
Witzel ID, Loibl S, von Minckwitz G, Abdallah A, Kühn T, Overkamp 
F, Fehm T, Schrader I, Uleer C, Kohls A, Stirnberg S, zu Eulenburg C, 
Untch M, Müller V. University Medical Center Hamburg-Eppendorf, 
Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; 
Helios Klinikum Berlin Buch, Berlin, Germany; University Medical 
Center Tübingen, Tübingen, Germany; Hospital Gelsenkirchen, 
Gelsenkirchen, Germany; Hospital Esslingen, Esslingen, Germany; 
Oncologianova, Recklinghausen, Germany; Gynäko-Onkologische 
Praxis Hannover, Hannover, Germany; Gynäkologische 
Gemeinschaftspraxis, Hildesheim, Germany; Ev. Krankenhaus, 
Ludwigsfelde-Teltow, Germany; Frauenklinik Rheinfelden, 
Rheinfelden, Germany. 
p4-08-02  estradiol (e2) mediated Secretion of vascular endothelial 
growth Factor (vegF) and Stimulation of t-regulatory Cells 
(t-regs): their role for the Worse prognosis of breast Cancer 
(bC) in premenopause
Recchia F, Candeloro G, Desideri G, Necozione S, Recchia COC, Rea S. 
Civilian Hospital, Avezzano, AQ, Italy; University, L’Aquila, AQ, Italy. 
p4-08-03  Serum autoantibodies to breast Cancer associated antigens 
reflect tumor biology: an opportunity for early Detection & 
prevention?
Eiermann W, Jackson L, Murray A, Chapman CJ, Peek LJ, 
Widschwendter P, Allen J, Graham H, Robertson JF. Fauenklinik vom 
Roten, Munich, Germany; University of Nottingham, Nottingham, 
United Kingdom; Oncimmune Ltd, Nottingham, United Kingdom; 
Oncimmune LLC, De Soto, KS. 
p4-08-04  preoperative thrombin pathway activation identifies node 
positive patients in early breast Cancer
Shaker H, Kirwan C, Landberg G, Bundred NJ. University Hospital of 
South Manchester, Manchester, United Kingdom; Paterson Institute 
for Cancer Research, Manchester, United Kingdom. 
p4-08-05  Diagnostic Significance of exosomal mirnas in the plasma of 
breast Cancer patients
Kwong A, Ng EKO, Leung CPH, Chan V, Li R, Wong CLP, Ma ESK. 
The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong 
Sanatorium & Hospital, Hong Kong. 
prognosis/response predictions: prognostic Factors and biomarkers – 
Clinical – ii
p4-09-01  identification of poor prognosis t1t2n0 luminal erbb2-ve 
breast Carcinomas
Vincent-Salomon A, Benhamo V, Gravier E, Rigaill G, Robin S, 
Savignoni A, Mariani O, Pierron G, Gentien D, Reyal F, Cottu P, 
Fourquet A, Sastre X, Asselain B, Delattre O. Institut Curie, Paris, 
France. 
p4-09-02  g protein-Coupled estrogen receptor 1 positively Correlates 
with estrogen receptor α expression and increased Distant 
Disease-Free Survival of breast Cancer patients
Leeb-Lundberg FLM, Sjöström M, Broselid S, Jirström K, Belting M, 
Olde B, Lövgren K, Malmström P, Bendahl P-O, Hartman L, Fernö M. 
Lund University, Lund, Sweden. 
p4-09-03  Clinical Significance of her2+ and triple-negative Status in 
patients with tumor Size ≤ 1 cm and node negative breast 
Cancer
Shao T, Boolbol SK, Boachie-Adjei K, Klein P. Beth Israel Medical 
Center, Continuum Cancer Centers of New York, New York, NY. 
p4-09-04  Do Decreased Cep17 Signals indicate the presence of 
“monosomy” in breast Cancer? a Study of her2 gene Status 
and her2 immunohistochemistry
Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Duesterhoeft SM, 
Kussick SL, Gown AM. PhenoPath Laboratories, Seattle, WA. 
p4-09-05  Ca15-3 adds prognostic information in “luminal” type breast 
Cancer - a Single Center experience evaluating 700 patients 
with a median Follow-up of 5 years
Thomssen C, Kantelhardt EJ, Vetter M, Steer S, Ruider T, Holzhausen 
H-J, Strauß H-G, Große R, GYN/OB, Halle (Saale), Germany; Inst. of 
Pathology, Halle (Saale), Germany. 
p4-09-06  the prognostic value of tumour-Stroma ratio in triple 
negative breast Cancer
Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven 
EA. Hospital Group Twente, Almelo, Netherlands; Pathology 
Laboratory East Netherlands, Enschede, Netherlands; Medical 
Spectrum Twente, Enschede, Netherlands; Hospital Group Twente, 
Hengelo, Netherlands. 
p4-09-07  breast Cancer outcome by Combined immunohistochemical 
er/pr/her2 receptor phenotype
Brouckaert O, Laenen A, Reynders A, Vanderhaegen J, Amant F, 
Leunen K, Smeets A, Berteloot P, Van Limbergen E, Weltens C, 
Moerman P, Paridaens R, Wildiers H, Vergote I, Christiaens M-R, 
Neven P. Uz Leuven, Leuven, Vlaams Brabant, Belgium; Interuniversity 
Centre for Biostatistics and Statistical Bioinformatics, Hasselt, Limburg, 
Belgium. 
p4-09-08  Secretory leukocyte protease inhibitor as a Differential 
Diagnostic biomarker of tumor emboli in inflammatory breast 
Cancer
Robertson FM, Ye Z, Chu K, Luo AZ, Wright MC, Jin J, Barsky SH, 
Cristofanilli M, Krishnamurthy S. The University of Texas MD Anderson 
Cancer Center, Houston, TX; University of Nevada School of Medicine, 
Reno, NV; Nevada Cancer Institute, Las Vegas, NV; Fox Chase Cancer 
Center, Philadelphia, PA. 
p4-09-09  expression of c-met and phospho c-met in breast Cancers by 
Subtype and its impact on Survival outcomes
Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, 
Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, 
Gonzalez-Angulo AM. MD Anderson Cancer Center, Houston, TX. 
p4-09-10  assessment of Circulating immune parameters in patients with 
metastatic breast Cancer improves Survival prediction
Tredan O, Manuel M, Chabaud S, Biota C, Bachelot T, Clapisson G, 
Bajard A, Blay J-Y, Caux C, Menetrier-Caux C. Centre Leon Berard, 
Lyon, France. 
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p4-09-11 kinesin Family member 2C (kiF2C) is a new Surrogate 
prognostic marker in breast Cancer (bC)
Abdel-Fatah TMA, Green AR, Lemetre C, Moseley P, Chan S, Ellis IO, 
Balls G. Nottingham University City Hospital NHS Trust, Nottingham, 
United Kingdom; Nottingham University, Nottingham, United 
Kingdom; Nottingham Trent University, Nottingham, United 
Kingdom. 
p4-09-12  Clinical validation of immunohistochemical Signature 
predictive of patients’ 8 year outcome in node negative breast 
Carcinomas
Charpin C, Tavassoli F, Giusiano S, Secq V, Villeret J, Garcia S, Lavaut 
M-N, Bonnier P, Birnbaum D, Iovanna J. INSERM U624 - Hopital Nord, 
Marseille, France; Yale University School of Medicine, New Haven; 
INSERM UMR 891, Marseille, France. 
p4-09-13  external validation of adjuvant! online breast Cancer 
prognosis tool. improvement is Still needed
Hajage D, De Rycke Y, Bollet M, Savignoni A, Caly M, Pierga J-Y, 
Horlings HM, Van de Vijver MJ, Vincent-Salomon A, Sigal B, Senechal 
C, Asselain B, Sastre X, Reyal F. Institut Curie, Paris, France; Academic 
Medical Center, Amsterdam, Netherlands. 
p4-09-14  Differential expression of the akt1 isoform in mammary Ductal 
Carcinoma
Sanders AJ, Mansel RE, Jiang WG. Cardiff University School of 
Medicine, Cardiff, United Kingdom. 
p4-09-15  Clinical and pathological predictors of outcome among 
patients with triple negative breast Cancer
Pearlstone DB, Gray M, Garofalo RM, Trapani M, Nyirenda T, 
Hazelwood VA. Hackensack University Medical Center, Hackensack, 
NJ; Stevens Institute of Technology, Hoboken, NJ; John Theurer 
Cancer Center, Hackensack, NJ. 
p4-09-16  Factors affecting the Development of axillary lymph node 
metastases in t1a-t1b breast Cancers
Khair TA, Boolbol SK, Boachi-Adjei K, Klein P. Beth Israel Medical 
Center, Continuum Cancer Centers of New York, New York, NY. 
p4-09-17  leptin and adiponectin expression in breast Cancer
Jeong Y-J, Jeong H-Y, Bong J-G, Park S-H, Choi J-H, Oh H-K. School 
of Medicine, Catholic University of Daegu, Daegu, Korea; College of 
Pharmacy, Kyung Hee University, Seoul, Korea. 
p4-09-18  australian Decision impact Study: the impact of oncotype 
DX recurrence Score (rS) on adjuvant treatment Decisions 
in hormone receptor positive (hr+), node negative (n0) and 
node positive (n+) early Stage breast Cancer (eSbC) in the 
multidisciplinary Clinic (mDC)
de Boer RH, Baker C, Speakman D, Mann B. Royal Melbourne Hospital, 
Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, 
Australia; Peter MacCallum Cancer Institute, Melbourne, Victoria, 
Australia; Royal Melbourne and Royal Women’s Hospital, Melbourne, 
Victoria, Australia. 
p4-09-19  pCna+ tumor associated macrophages are associated with 
m1 and m2 gene expression, and Confer poor prognosis in the 
absence of anti-tumor immune environment
Mukhtar R, Wolf D, Tandon V, Zhu J, Lenburg M, van’t Veer L, 
Campbell MJ, I-SPY Trial Investigators, Esserman LJ. UCSF; Boston 
University. 
p4-09-20  expression profile of interleukin 17b and the receptor il-17br 
in Clinical breast Cancer
Sanders AJ, Mansel RE, Mason MD, Jiang WG. Cardiff University 
School of Medicine, Cardiff, United Kingdom. 
p4-09-21  a novel prognostic marker for triple-negative breast Cancers
Wallon UM, Sabol JL, Zemba-Palko V, Carp NZ, Ciocca RM, 
Wojciechowski BS, Prendergast GC. Lankenau Institute for Medical 
Research, Wynnewood, PA; Lankenau Medical Center, Wynnewood, 
PA. 
p4-09-22  multicenter Quality assurance profile review of lobular breast 
Carcinomas versus the 21 gene recurrence Score: assessment 
of Clinical relevance
Dabbs DJ, Hicks D, Tubbs R, Bhargava R, Brufsky A. University of 
Pittsburgh Medical Center, Pittsburgh, PA; University of Rochester 
Medical Center, Rochester, NY; Cleveland Clinic, Cleveland, OH. 
p4-09-23  monitoring autophosphorylation of mammalian target of 
rapamycin (mtor) for histoprognostic grading of invasive 
breast Cancer: impact on the reclassification of patients with 
grade 2 tumors using the nottingham grading System
Sauri-Nadal T, Del Barco S, Vazquez-Martin A, Oliveras-Ferraros C, Cufí 
S, Martin-Castillo B, Lopez-Bonet E, Menendez JA. Catalan Institute 
of Oncology, Girona, Catalonia, Spain; Dr. Josep Trueta University 
Hospital, Girona, Catalonia, Spain. 
p4-09-24  Correlation of aurora Family member expression with Clinical 
breast Cancer prognosis
Annakesavan A, Sanders AJ, Harding KG, Jiang WG. School of 
Medicine, Cardiff University, Cardiff, Wales, United Kingdom. 
p4-09-25  impact of body mass index (bmi) for Clinical outcomes in 
japanese breast Cancer patients
Gondou N, Fujita T, Sawaki M, Hattori M, Kondou N, Horio A, Adati E, 
Usio A, Sueta A, Iwata H. Aichi Cancer Hospital; Aichi Cancer Center 
Research Institute. 
p4-09-26  prognostic Significance of tissue inhibitor of 
metalloproteinase-1 (timp-1) in breast Cancer
Dechaphunkul A, Phukaoloun M, Kanjanapradit K, Graham K, Ghosh 
S, Santos C, Mackey JR. Cross Cancer Institute, University of Alberta, 
Edmonton, AB, Canada; Faculty of Medicine, Prince of Songkla 
University, Hat Yai, Songkhla, Thailand. 
p4-09-27  Can We predict the benefit of the 70-gene Signature in the 
Choice of adjuvant Systemic treatment for er positive, 
her2 negative tumors in Daily practice? a Single institution 
experience
Torrisi R, Garcia-Etienne CA, Losurdo A, Morenghi E, Di Tommaso 
L, Gatzemeier W, Sagona A, Rossetti C, Eboli M, Rubino A, Barbieri 
E, Andreoli C, Orefice S, Gandini C, Masci G, Santoro A, Tinterri C. 
Humanitas Cancer Center, Milan, Italy. 
p4-09-28  Comparison of oncotype DX (oDX) and mammostrat (mS) risk 
estimations and Correlations with histologic tumor Features in 
low grade, er-positive invasive breast Carcinoma (bC)
Acs G, Kiluk J, Loftus L, Laronga C. Moffitt Cancer Center, Tampa, 
FL; Women’s Pathology Consultants, Ruffolo Hooper & Associates, 
Tampa, FL. 
p4-09-29  a nomogram to predict prognosis in node-negative breast 
Carcinoma
Mazouni C, Spyratos F, Romain S, Fina F, Bonnier P, Ouafik L, Martin 
P-M. APHM, Marseille, France; Institut Curie - Hôpital René Huguenin, 
Paris, France. 
p4-09-30  relationship between Dna ploidy, biomarker expression and 
molecular Subtypes of invasive breast Cancer
Sarode VR, Rahardja D, Morrison DH, Peng Y, Rao R, Euhus D. 
University of Texas Southwestern Medical Center, Dallas, TX. 
p4-09-31  Withdrawn
p4-09-32  Withdrawn
p4-09-33  the prognostic Significance of metaplastic Carcinoma of the 
breast - a Comprehensive Comparison Study with Common 
breast Cancers
Lai H-W, Kuo S-J, Chen D-R, Chen S-T. Changhua Christian Hospital, 
Changhua, Taiwan. 
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p4-09-34  luminal infiltrating lobular Carcinoma of the breast: Clinical 
and prognostic Features
Valdiviezo NI, Vega E, Castañeda C, Flores C, Mendiola CD, Manso 
LM, Dorta M, De Velasco GA, Cortés-Funés H, Ghanem I, Ciruelos EM. 
Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional 
de Enfermedades Neoplasicas, Lima, Peru. 
p4-09-35  Co-expression of ki-67 is Critical for outcome of 
Cyclooxygenase-2 positive breast Cancer
Park S, Koo JS, Lee JS, Hwang H, Ko S, Kim SI, Park B-W. Yonsei 
University College of Medicine, Seoul, Korea. 
epidemiology, risk, and prevention: risk Factors and modeling
p4-10-01  tumor markers predicting recurrence type after a primary 
Ductal Carcinoma in Situ
Zhou W, Johansson C, Jirström K, Ringberg A, Blomqvist C, Amini 
R-M, Fjällskog M-L, Wärnberg F. Uppsala University Hospital, Uppsala, 
Sweden; Malmö University Hospital, Malmö, Sweden; Lund University, 
Lund, Sweden; Helsinki University Central Hospital, Helsinki, Finland; 
Uppsala University, Uppsala, Sweden. 
p4-10-02  a meta-analysis of the association of blood levels of 
vitamin-D and the risk of breast Cancer
Amir E, Carlsson L, Seruga B, Ocana A, Goodwin PJ. Princess Margaret 
Hospital, Toronto, Canada; Institute of Oncology Ljubljana, Ljubljana, 
Slovenia; Albacete University Hospital, Albacete, Spain; Mount Sinai 
Hospital, Toronto, Canada. 
p4-10-03  association between bmi, physical activity and breast Cancer 
histologic types
Nyante SJ, Dallal CM, Gierach GL, Sherman ME, Park Y, Hollenbeck 
AR, Brinton LA. National Cancer Institute, Rockville, MD; AARP, 
Washington, DC. 
p4-10-04  automated breast Cancer risk assessment: identifying high 
risk Women in the primary Care Setting
Ozanne E, Omer Z, Carlson K. University of California, San Francisco; 
Massachusetts General Hospital. 
p4-10-05  improved breast Cancer risk assessment in biopsied Women 
using the polyfactorial model oncovue®
Jupe ER, Pugh TW, Knowlton NS, DeFreese DC. InterGenetics 
Incorporated, Oklahoma City, OK; NSK Statistical Solutions,LLC, 
Choctaw, OK. 
p4-10-06  evaluation of brCapro risk assessment model in patients with 
Ductal Carcinoma in Situ
Muse KI, Elsayegh N, Gutierrez-Barrera AM, Kuerer H, Valero V, 
Litton JK, Hortobagyi GN, Arun BK. UT MD Anderson Cancer Center, 
Houston, TX. 
p4-10-07  Clinico-pathologic Features of breast Cancer patients with 
primary metastatic Disease versus localized Disease: a 
multicenter Study
Barinoff J, Hils R, Bender A, Gross J, Kurz C, Tauchert S, Mann E, 
Schwidde I, Ipsen B, Sawitzki K, Heitz F, Harter P, Traut A, du Bois 
A. Kliniken Essen Mitte, Essen, Germany; Dr.-Horst-Schmidt-Klinik, 
Wiesbaden, Germany; Asklepios Klinik, Lich, Germany; Sankt 
Gertrauden-Krankenhaus, Berlin-Wilmersdorf, Germany; Klinikum 
Esslingen, Esslingen am Neckar, Germany; Caritsklinik St. Theresia, 
Saarbrücken, Germany; Universitätsklinikum Gießen und Marburg, 
Standort Marburg, Marburg, Germany; Klinikum Frankfurt Höchst, 
Frankfurt am Main, Germany; Evangelisches Krankenhaus Wesel, 
Wesel, Germany. 
p4-10-08  risk Factor profiles of Women with DCiS and invasive Ductal 
breast Cancers
Schnabel F, Chun Kim J, Billig J, Cimeno A, Mehta P, Guth A, 
Hochman T, Shapiro R, Hiotis K, Siegel B, Axelrod D. NYU Cancer 
Institute, NYU Langone Medical Center, New York, NY; NYU Langone 
Medical Center, New York, NY. 
p4-10-09  hormone replacement therapy: a benign breast Disease’s 
risk?
Hamy AS, Gronier H, Porcher R, Giacchetti S, Cuvier C, De 
Roquancourt A, Espie M. Saint Louis Hospital, AP HP, Faculté Paris VII, 
Paris, France. 
p4-10-10  breast Cancer risk Factors among asian versus Caucasian 
Women with brCa1/2 mutations
de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, 
McPherson LA, Sharma B, Kardashian A, Schackmann EA, Kingham KE, 
Mills MA, West DW, Ford JM, Kurian AW. Stanford University School of 
Medicine, Stanford, CA; University of Hong Kong Li Ka Shing Faculty 
of Medicine, Hong Kong, China. 
p4-10-11  genetic and environmental predictors, endogenous hormones 
and growth Factors and risk of estrogen receptor-positive 
breast Cancer in japanese Women
Yoshimoto N, Nishiyama T, Toyama T, Takahashi S, Shiraki N, Sugiura 
H, Endo Y, Iwasa M, Fujii Y, Yamashita H. Nagoya City University 
Graduate School of Medical Sciences, Nagoya, Aichi, Japan. 
epidemiology, risk, and prevention: epidemiology, risk, and prevention – 
other
p4-11-01  bilateral oophorectomy is associated with a higher prevalence 
of arthritis and lower bone mineral Density in Women 40 
years and older
McCarthy AM, Visvanathan K. Johns Hopkins Bloomberg School 
of Public Health, Baltimore, MD; Johns Hopkins Sidney Kimmel 
Comprehensive Cancer Center, Baltimore, MD. 
p4-11-02  insulin-like growth Factor-1 (igF-1), insulin-like growth Factor 
binding protein-3 (igFbp-3) and lobule type among Women in 
the nurses’ health Study ii (nhS ii)
Collins LC, Rice MS, Shen D, Connolly JL, Schnitt SJ, Tamimi RM. 
Beth Israel Deaconess Medical Center and Harvard Medical School; 
Brigham and Women’s Hospital and Harvard School of Public Health, 
Boston. 
p4-11-03  prognosis of pregnancy-associated breast Cancer: a meta-
analysis involving 39,415 patients
Azim, Jr HA, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis 
N, Peccatori FA. Institut Jules Bordet, Brussels, Belgium; European 
Institute of Oncology, Milan, Italy; University of Ioannina, Ioannina, 
Greece. 
p4-11-04  risk of primary (pbC) and Contralateral breast Cancer (CbC) 
after ovarian Cancer (oC) in brCa1 and brCa2 mutation 
Carriers; implications for Surveillance and risk reducing 
mastectomy
Seynaeve C, Vencken P, Hooning M, Menke-Pluymers M, Heemskerk-
Gerritsen A, Van Doorn L, Collee M, Jager A, Van Montfort K, Burger C, 
Kriege M. Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, 
Netherlands. 
p4-11-05  association between bisphosphonate use in metastatic breast 
Cancer (mbC) and overall Survival
Mathew A, Mathew IE, Rosenzweig MQ, Brufsky AM. University of 
Pittsburgh Medical Center; University of Pittsburgh Cancer Institute; 
Magee-Womens Hospital. 
p4-11-06  uptake of Selective estrogen receptor modulators and other 
breast Cancer prevention Strategies among high-risk Women 
Seen in a breast Center
Reimers LL, Campbell J, Hershman D, Greenlee H, Terry MB, Maurer 
M, Kalinsky K, Jayasena R, Sandoval R, Alvarez M, Crew KD. Columbia 
University Mailman School of Public Health, New York, NY; Columbia 
University College of Physicians and Surgeons, New York, NY; 
Columbia University, New York, NY. 
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p4-11-07  Feasibility and acceptability of offering breast Cancer risk 
estimation in the Context of the uk national health Service 
breast Cancer Screening programme: a new paradigm for 
Cancer prevention
Evans DGR, Astley S, Stavrinos P, Sahin S, Ingham S, McBurney H, 
Eckersley B, Wilson M, Beetles U, Harvie M, Warren R, Sergeant 
J, Hufton A, Warwick J, Newman W, Buchan I, Cuzick J, Howell 
A. University Hospital of South Manchester, Manchester, United 
Kingdom; University of Manchester, Manchester, United Kingdom; 
Central Manchester Foundation Trust, Manchester, United Kingdom; 
Queen Mary University London, London, United Kingdom. 
p4-11-08  Changes in the Distribution of loco-regional and Distant 
breast Cancer recurrences over the last 20 years: implications 
for patient Care and Future research
Bouganim N, Clemons M, Amir E. The Ottawa Hospital Cancer 
Center, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, 
Canada. 
p4-11-09  polymorphisms related to Steroid hormone Concentrations in 
nipple aspirate Fluid (naF)
Lee O, Chatterton RT, Shidfar A, Wang J, Khan SA, Scholtens D. 
Northwestern University, Chicago, IL. 
p4-11-10  perceptions, knowledge and Satisfaction with Contralateral 
prophylactic mastectomy among young Women with breast 
Cancer
Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan 
S, Morrow M, Schapira L, Come S, Winer E, Partridge AH. Dana- Farber 
Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, 
MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Beth 
Isreal Deaconess Medical Center, Boston, MA. 
p4-11-11  thyroid Disease is associated with breast Cancer: a meta-
analysis
Hardefeldt PJ, Eslick GD, Edirimanne S. The University of Sydney, 
Sydney, NSW, Australia; Nepean Hospital, Penrith, NSW, Australia. 
p4-11-12  molecular phenotype of breast Cancers in a large Cohort of 
young Women according to time interval Since pregnancy
Collins LC, Gelber S, Marotti JD, Cole K, Kereakoglow S, Ruddy KJ, 
Brachtel EF, Schapira L, Come SE, Borges VF, Schedin PJ, Warner E, 
Winer E, Partridge A. Beth Israel Deaconess Medical Center, Boston; 
Harvard Medical School, Boston; Dana Farber Cancer Institute, 
Boston; Dartmouth-Hitchcock Medical Center, Lebanon, Hanover, 
NH; Brigham and Women’s Hospital, Boston; Massachusetts General 
Hospital, Boston; University of Colorado Cancer Center, Colarado; 
Sunnybrook Odette Cancer Centre, Toronto. 
p4-11-13  influence of two years of exemestane on bone mineral Density 
in postmenopausal Women at increased risk of Developing 
breast Cancer; a Companion Study to the nCiC Ctg map.3 trial
Goss PE, Richardson H, Ingle JN, Chlebowski RT, Fabian CJ, Garber 
JE, Sarto GE, Hiltz A, Tu D, Cheung AM. Massachusetts General 
Hospital Cancer Center, Boston, MA; Queen’s University, Kingston, 
ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical 
Research Institute, Torrance, CA; University of Kansas Medical Center, 
Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for 
Women’s Health and Health Research, Madison, WI; General Hospital, 
Toronto, ON, Canada. 
p4-11-14  number needed to treat (nnt) as a measure of incremental 
Drug benefit: Denosumab vs. Zoledronic acid for the 
prevention of Skeletal related events (Sres) in advanced 
breast Cancer
Dranitsaris G, Kaura S. Augmentium Pharma Consulting, Toronto, 
Canada; Novartis Pharmaceuticals, NJ. 
p4-11-15 increased propability of triple negative breast Cancer (tnbC) 
in premenopausal patients after exogenous hormonal intake 
(ehi)
Pistamaltzian NF, Tzavara C, Papadimitriou C, Gyftaki R, Tryfonopoulos 
D, Panopoulos C, Tsoukalas N, Koumakis G, Demiri S, Koufopoulos N, 
Misitzis Y, Apostolikas N, Efremidis A. Agios Savvas Cancer Hospital of 
Athens, Athens, Greece; University of Athens, Athens, Greece. 
p4-11-16  Withdrawn
p4-11-17  noninferiority (ni) phase iii trials in advanced breast Cancer 
(abC) over 12 years
Saad ED, Militao MS. Dendrix Research, Sao Paulo, Brazil. 
p4-11-18  mammographic Surveillance in atypical hyperplasia of the 
breast and Subsequent Development of Cancer. a need for 
long term Follow up
Koron R, Sridharan U, Mitchell G, Holcombe C. Royal Liverpool and 
Broadgreen University Hospital Trust, Liverpool, Merseyside, United 
Kingdom. 
p4-11-19  healthcare resource utilization among breast Cancer 
patients with bone metastases and Skeletal-related events: a 
population-based Cohort Study in Denmark (1997 - 2009)
Yong M, Christiansen CF, Gammelager H, Sværke C, Chia V, Atchison 
C, Fryzek J. Amgen Inc, Thousand Oaks, CA; Aarhus University 
Hospital, Aarhus, Denmark; Exponent, Alexandria, VA. 
p4-11-20  observational Study of body Weight Changes and metabolic 
Syndrome in breast Cancer patients receiving adjuvant 
therapy: Characteristics of Dietary pattern in korean breast 
Cancer patients
Park JH, Kim S, Kim Y, Kim YJ, Lee K-W, Kim S-W, Kim I, Park SY, Park 
YJ, Choi SH, Kim JH. Seoul National University Bundang Hospital, 
Seongnam. 
p4-11-21  a retrospective analysis of Women at increased lifetime risk 
for breast Cancer: referral patterns to Subspecialty providers, 
recommendations and outcomes
Ehsani S, Tevaarwerk A, Wilke L, Neuman H, Beckman C, Becker J, 
Stettner A, Strigel R, Szalkucki L, Burkard M, Wisinski KB. University of 
Wisconsin Carbone Cancer Center, Madison, WI. 
p4-11-22  Familial history of Cancer among breast Cancer Women under 
36 yr. in rio De janeiro, brazil
Koifman S, Ortega GPJ, Koifman RJ. National School of Public Health, 
Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil. 
p4-11-23  lifelong exposure to isoflavones results in a reduced 
responsivity of the mammary gland towards estradiol
Diel P, Vollmer G, Hertrampf T, Moller FJ, Kulling S, Molzberger A.  
German Sports University, Cologne, Germany; Technical University 
Dresden, Dresden, Germany; Max Rubner-Institut, Karlsruhe, 
Germany. 
psychosocial, Quality of life, and educational aspects: Survivorship 
research
p4-12-01  the breast-activity and healthy eating after Diagnosis 
(b-aheaD) Study - a randomised Comparison of Weight 
Control programmes during adjuvant treatment
Harvie M, Pegington M, Bundred N, Campbell A, Wolstenholme J, 
Adams J, Speed S, Morris J, Howell A. Univeristy Hospital of South 
Manchester, Manchester, United Kingdom; University of Dundee, 
United Kingdom; University of Oxford, United Kingdom; University 
of Manchester, United Kingdom; University Hospital of South 
Manchester, United Kingdom. 
p4-12-02  the association of anastrozole adherence and Cognitive 
Function in breast Cancer
Sereika SM, Dunbar-Jacob JM, Ryan CM, Adam B, Bender CM. 
University of Pittsburgh, Pittsburgh, PA; University of Pittsburgh 
Medical Center, Pittsburgh, PA. 
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p4-12-03  post-Diagnosis Weight gain in breast Cancer Survivors: When 
Should We intervene?
Bradshaw PT, Cleveland RJ, Stevens J, Rosamond W, Abrahamson PE, 
Teitelbaum SL, Neugut AI, Gammon MD. University of North Carolina 
at Chapel Hill, Chapel Hill, NC; Mount Sinai School of Medicine, New 
York, NY; Columbia University, New York, NY. 
p4-12-04  Withdrawn
p4-12-05  impact of the lifestyle intervention Study in adjuvant 
treatment of early breast Cancer (liSa) Weight loss 
intervention upon physical activity
Ligibel JA, Segal R, Pond G, Dion M-J, Pritchard KI, Levine M, Goodwin 
PJ. Dana-Farber Cancer Institute, Boston, MA; University of Ottawa, 
Ottawa, ON; McMaster University, Hamilton, ON; University of 
Toronto, Toronto, ON. 
p4-12-06  risk Factors for relative Weight gain >10% in breast Cancer 
Survivors: Findings from the Su.vi.maX Cohort
Zelek L, Czernichow S, Galan P, Hercberg S. Assistance Publique 
Hôpitaux de Paris, CHU Avicenne, Bobigny, France; INSERM/ U1125 
INRA/CNAM/Université Paris 13, Bobigny, France. 
p4-12-07  outcomes of a behavioral Weight Control intervention among 
rural breast Cancer Survivors
Befort CA, Klemp JR, Austin HL, Krigel S, Sullivan DK, Schmitz KH, Perri 
MG, Fabian CJ. University of Kansas Medical Center; University of 
Pennsylvania; University of Florida. 
p4-12-08  Five year preliminary outcomes of a prospective Surveillance 
model to reduce upper extremity morbidity related to breast 
Cancer treatment
Stout NL, Pfalzer L, Levy E, McGarvey C, Gerber L, Springer B, Soballe 
P. National Naval Medical Center; University of Michigan- Flint; 
National Institutes of Health; CLM Consulting; George Mason 
University; Office of the Surgeon General; Naval Hospital San Diego. 
p4-12-09  Withdrawn
p4-12-10  a prospective Study of physical activity patterns and Changes 
in breast Cancer patients during active breast Cancer 
treatment
Kim I-R, Choi E-K, Nam S-J, Lee J, Lee S-K, Yang J, Noh DY, Han W, 
Cho J. Samsung Comprehensive Cancer Center, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 
SurgerySamsung Medical Center, Sungkyunkwan University School 
of Medicine, Seoul, Korea; Konkuk University Medical Center, Konkuk 
University School of Medicine, Seoul, Korea; Seoul National University 
Hospital, Seoul National University School of Medicine, Seoul, Korea; 
Johns Hopkins Bloomberg School of Public Health, Baltimore; 
Behavior and Society, Johns Hopkins Bloomberg School of Public 
Health, Baltimore. 
p4-12-11  myelodysplastic Syndrome post primary breast Cancer 
treatment: Cases from a Community Cancer Center: 1990-2010
Kaplan HG, Malmgren JA, Atwood MK. Swedish Cancer Institute, 
Seattle, WA; HealthStat Consulting, Inc., Seattle, WA. 
p4-12-12  patient-, illness-, and/or treatment-related baseline predictors 
of nonadherence to oral hormonal therapy
Wickersham KE, Sereika SM, Bender CM. University of Pittsburgh, 
Pittsburgh, PA. 
p4-12-13  a multi-Center randomized Controlled Double blind 
trial assessing the effect of acupuncture in reducing 
musculoskeletal Symptoms in breast Cancer patients taking 
aromatase inhibitors: First interim analysis
Bao T, Tarpinian K, Medeiros M, Gould J, Jeter S, Cai L, Tait N, Shetty 
J, Lewis J, Gitten L, Betts K, Hoffman A, Feigenberg S, Chumsri S, 
Armstronge DK, Bardia A, Tan M, Stebbing J, Folkerd E, Dowsett M, 
Singh H, Tkaczuk K, Stearns V. University of Maryland Greenebaum 
Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel 
Comprehensive Cancer Center, Baltimore, MD; Hammersmith 
Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; 
The Royal Marsden NHS Foundation Trust, London, United Kingdom. 
p4-12-14  pilot Study utilizing Fluorine-18 Fluorodeoxyglucose (F-18 
FDg) positron emission tomography-Computed tomography 
Scan (pet-Ct Scan) to investigate brain metabolic Changes 
during treatment in Women with breast Cancer
Virani S, Lagos R, Hobbs G, Marano G, Nagaiah G, Abraham J. West 
Virginia University, Morgantown, WV. 
p4-12-15  Cancer Survivor Care: an evaluation of a group visit model of 
Care for breast Cancer Survivors at Duke Cancer Center
Trotter KJ, Schneider S.  Duke University Medical Center, Durham, NC; 
Duke University, Duraham, NC.
psychosocial, Quality of life, and educational aspects: palliation and pain 
management
p4-13-01  pain Severity and analgesic use associated with Skeletal-
related events in patients with advanced breast Cancer and 
bone metastases
Fallowfield L, Cleeland CS, Body J-J, Stopeck A, von Moos R, Patrick 
DL, Clemons M, Tonkin K, Masuda N, Lipton A, De Boer R, Salvagni 
S, Tosello Oliveira C, Ying W, Braun A, Cong Z. Cancer Research 
UK, University of Sussex, Brighton, United Kingdom; University of 
Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, 
Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, 
Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, 
Switzerland; University of Washington, Seattle, WA; The Ottawa 
Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, 
Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn 
State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne 
Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, 
Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; 
Amgen Inc., Thousand Oaks, CA. 
p4-13-02  hospice utilization and end of life Care in metastatic breast 
Cancer patients at a Comprehensive Cancer Center
O’Connor TL, Ngamphaiboon N, Morris J, Callinan NK, Milch RA, Kerr 
CH, Watroba N, Edge SB. Roswell Park Cancer Institute, Buffalo, NY; 
The Buffalo Center for Hospice and Palliative Care, Cheektowaga, NY. 
p4-13-03  retrospective analysis of palonosetron Compared with older 
5-ht3 receptor antagonists (ondansetron, Dolasetron, and 
granisetron) in preventing anthracycline-induced nausea and 
vomiting in breast Cancer patients from Four phase 3 trials
Rugo HS, Schwartzberg L, Morrow GR, Barbour SY, Ballinari G, Thorn 
MD, Cox D. UCSF Helen Diller Family Comprehensive Cancer Center; 
West Clinic; University of Rochester, School of Medicine and Dentistry; 
Duke University Medical Center; Helsinn Healthcare SA; Statistical 
Resources, Inc; Eisai, Inc. 
psychosocial, Quality of life, and educational aspects: Quality of life – 
Supportive Care
p4-14-01  Weight-adjusted Change of unilateral arm volumes for 
Quantification of lymphedema after bilateral breast Surgery
Miller CL, Specht MC, Ancukiewicz M, Skolny MN, O’Toole J, Taghian 
AG. Massachusetts General Hospital, Boston, MA. 
p4-14-02  risk Factors for early lymphoedema Do not predict late 
Development of lymphoedema
Kilbreath SL, Beith J, Refshauge KM, Lee M-J, Ward LC. University 
of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, 
Camperdown, NSW, Australia; University of Queensland, St Lucia, 
QLD, Australia. 
p4-14-03  Support groups in breast Cancer: an evidence based 
assessment of 1606 patients with Concerning topics for 
Support group Discussion and presentation
Gralla RJ, Morse KD, Rittenberg CN, Petersen JA, Rosen LM, Lesser M. 
Hofstra North Shore - LIJ School of Medicine, New York, NY; Nexcura, 
Seattle, WA; Feinstein Institute for Medical Research, Manhasset, NY. 
p4-14-04  tolerance of Docetaxel: is obesity a risk Factor for toxicity? a 
pilot Study
Parent D, Rallet A, Jovenin N, Yazbek G, Cure H, Rey J-B. Institut Jean 
Godinot, Reims, France. 
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p4-16-05  a randomized phase 2 Study of a loading Dose of 
ibandronate in patients with bone metastases from breast 
Cancer
Ritchie DM, Bray C, Canney P. Beatson West of Scotland Cancer 
Centre, Glasgow, United Kingdom. 
p4-16-06  expression patterns of receptor activator of nuclear Factor-κb 
(rank) and Src in a Series of primary breast tumors (bt) and 
bone metastases (bm) in patients (pts) with metastatic breast 
Cancer (mbC)
Gucalp A, Comen E, Redana S, Evangelista L, Giri DD, Zhang XH, 
Patil S, Akram M, Norton L, Hudis CA, Fornier MN. Memorial Sloan-
Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, 
New York, NY; Piemontese per l’Oncologia - Institute for Cancer 
Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto 
(IOV - IRCCS), Padua, Italy. 
p4-16-07  breast Cancer bone metastasis prevalence and Survival 
outcomes: a Quantitative review of the literature
Mitchell ME, Taylor A, Lowe KA, Langeberg W, Alexander D, Kelsh M, 
Body J-J. Exponent; Amgen; CHU Brugmann. 
p4-16-08  pilot randomized trial of De-escalated (q12 Weekly) versus 
Standard (q3-4 Weekly) intravenous bisphosphonates in 
Women with low-risk bone metastases from breast Cancer
Amir E, Freedman O, Carlsson L, Usmani T, Lee E, Dranitsaris G, 
Clemons M. Princess Margaret Hospital and The University of 
Toronto, Canada; The Ottawa Hospital Cancer Centre and The 
University of Ottawa, Canada. 
p4-16-09  health resource utilization (hru) associated with Skeletal-
related events (Sres) in advanced breast Cancer patients with 
bone metastases: results from a prospective multinational 
observational Study
Lüftner D, Lorusso V, Duran I, Hechmati G, Garzon-Rodriguez 
C, Ashcroft J, Bahl A, Ghelani P, Wei R, Thomas E, Hoefeler H. 
Universitätsmedizin Berlin, Berlin, Germany; Oncology Institute 
ASL, Leece, Italy; Centro Integral Oncologico Clara Campal (CIOCC), 
Madrid, Spain; Amgen (Europe) GmbH, Zug, Switzerland; Instituto 
Catalán Oncología ICO-IDIBELL, Barcelona, Spain; Pinderfields 
General Hospital, Wakefield, United Kingdom; University Hospitals 
Bristol, Bristol, United Kingdom; Ovatech Solutions, London, United 
Kingdom; Amgen Inc., So. San Francisco, CA; Forschungszentrum 
Ruhr, Witten, Germany. 
treatment – types and Sites of breast Cancer: brain metastases
p4-17-01  trastuzumab Does not increase the incidence of Central 
nervous System (CnS) relapses in her2-positive early breast 
Cancer: the hera trial experience
Pestalozzi B, Holmes E, Metzger O, de Azambuja E, Hogge L, Scullion 
M, Gelber R, Piccart-Gebhart M, Cameron D. HERA Study Team. 
p4-17-02  Whole-brain radiation therapy plus Concomitant 
temozolomide for the treatment of brain metastases from 
breast Cancer: a randomized prospective multicenter phase ii 
Study
Kirova YM, Hajage D, Gerber S, Le Scodan R, Pierga J-Y, Bourgier 
C, Campana F, Asselain B, Fourquet A, Levy C. Institut Curie, Paris, 
France; Institut Gustave Roussy, Villejuif, France; Centre François 
Baclesse, France. 
p4-17-03  incidence rate of asymptomatic brain metastases in 
patients with her2+ metastatic breast Cancer Screened for 
egF111438/Cerebel Study
Pivot X, Hackmann J, Manikhas A, Moore Y, Parikh R, Kothari D, 
Joshi A, Aktan G, Coleman R. University Hospital of Besancon; 
Marien-Hospital; St Petersburg City Clinical Oncology Dispensary; 
GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Uxbridge, United 
Kingdom; Weston Park Hospital. 
p4-14-05  Chemotherapy-induced alopecia, body image and 
psychological Distress in Women with breast Cancer: a 
prospective Study
Choi E-K, Kim I-R, Nam S-J, Lee J, Yang J, Lee S-K, Noh D-Y, Han W, 
Cho J. Samsung Comprehensive Cancer Center, Samsung Medical 
Center, Sungkyunkwan University School of Medicine; Johns Hopkins 
Bloomberg School of Public Health; Samsung Medical Center, 
Sungkyunkwan University School of Medicine; Konkuk University 
Medical Center, Konkuk University School of Medicine; Seoul National 
University Hospital, Seoul National University School of Medicine. 
psychosocial, Quality of life, and educational aspects: psychological 
aspects
p4-15-01  high prevalence of prospective memory (pm) impairment in 
early breast Cancer (ebC) Survivors within 1 year of adjuvant 
Chemotherapy Completion: novel Findings Concerning post 
Chemotherapy Cognitive effects
Paquet L, Verma S, Collins B, Song X, Wheatley-Price P, Hopkins S, 
Segal R, Dent S, Mirsky D, Goel R, Young V, Clemons M, Keller O, 
Chinneck A, Young R, Bedard M. Carleton University, Ottawa, ON, 
Canada; The Ottawa Hospital Cancer Center, Ottawa, ON, Canada; The 
Ottawa Hospital, Ottawa, ON, Canada. 
p4-15-02  Clinical and epidemiological Correlates of elevated Distress 
thermometer Scores in breast Cancer patients
Powers K, Pappas L, Buchmann L, Anderson L, Gauchay L, Rich A, 
Agarwal J. University of Utah, Salt Lake City, UT; Huntsman Cancer 
Institute, Salt Lake City, UT. 
p4-15-03  patient-provider Communication and patient informational 
needs for breast reconstruction post-mastectomy: results 
from a national Survey
Ahmed I, Gubin A, Champion L, Harvey A, Amsellem M. The Cancer 
Support Community. 
treatment – types and Sites of breast Cancer: bone metastases
p4-16-01  proteomic analysis of patient plasma identifies parathyroid 
hormone related protein (pthrp12-48) as a potential 
biomarker of breast Cancer bone metastasis
Washam CL, Byrum SD, Leitzel K, Suhail AM, Lipton A, Suva LJ. 
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for 
Medical Sciences, Little Rock, AR; Penn State Hershey Cancer Institute, 
Penn State Hershey Medical Center, Hershey, PA; Lebanon VA 
Medical Center, Lebanon, PA. 
p4-16-02  problems with identifying bone metastasis-Specific genes 
without Considering biological Differences between 
er-positive and er-negative breast Cancers
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Nakamura S, 
Hortobagyi GN, Pusztai L, Symmans F, Ueno NT. The University of 
Texas MD Anderson Cancer Center, Houston, TX; Hospital of Prato 
and Instituto Toscano Tumori, Prato, Italy; Showa University School of 
Medicine, Tokyo, Japan. 
p4-16-03  proof of the anti-tumour effect of Zoledronic acid (Za) in 
naive bone-only metastatic and locally advanced breast 
Cancer: results from the biological Window therapy
Foroni C, Andreis D, Maldotti M, Cappelletti MR, Generali DG. Istituti 
Ospitalieri di Cremona, Cremona, Italy. 
p4-16-04  an open-label, phase iia, non-randomized Study of 
radium-223 in breast Cancer patients with bone Dominant 
Disease no longer Considered Suitable for endocrine therapy
Coleman R, Flamen P, Naume B, Jerusalem G, Garcia C, Piccart M, 
O’Bryan-Tear CG, Aksnes A-K. Weston Park Hospital, Sheffield, United 
Kingdom; Institut Jules Bordet, Brussels, Belgium; Oslo University 
Hospital, Oslo, Norway; CHU Sart Tilman, B35, Liege, Belgium; Algeta 
ASA, Oslo, Norway; Bayer Healthcare Pharmaceuticals, Montville, NJ. 
61s
December 6-10, 2011
www.aacrjournals.org
Program Schedule
Cancer Res; 71(24 Suppl.) December 15, 2011
p4-18-03  basal-like phenotype of brCa associated Ductal Carcinoma 
in-Situ
Kristjansdottir K, Laprise J, Scalia-Wilbur J, Simon R, Steinhoff M, 
Legare R. Women and Infants Hospital of RI, Providence, RI. 
p4-18-04  hypofractionated radiotherapy for breast Ductal Carcinoma in 
Situ
Hathout L, Fortin B, Vulpe H, Hijal T, Bahig H, Dubé P, Yassa M. 
Hôpital Maisonneuve-Rosemont, Centre Affilié à l’Université de 
Montréal, Montreal, QC, Canada; McGill University Health Centre, The 
Montreal General Hospital, Montreal, QC, Canada. 
p4-18-05  Ductal Carcinoma in Situ with microinvasion: Clinical and 
pathological Characteristics, treatments and outcomes
Gandy C, Modesto-Nauleau A, Mery E, Filleron T, Charitansky H, 
Roche H, de Lafontan B. Institut Claudius Regaud, Toulouse, France. 
p4-18-06  relationship between pathological Features, her2 protein 
expression, and her2 and Cep17 Copy numbers in DCiS
Lambein K, Van Bockstal M, Praet M, Denys H, Braems G, Nuyts 
A, Cocquyt V, Pauwels P, Van Den Broecke R, Libbrecht L. Ghent 
University Hospital, Ghent, Belgium; Ghent University, Ghent, 
Belgium. 
treatment – types and Sites of breast Cancer:  
male breast Cancer
p4-19-01  male breast Cancer according to tumor Subtype and race: a 
California Cancer registry (CCr)-population based Study
Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Hortobagyi GN, 
Giordano SH. The University of Texas, MD Anderson Cancer Center; 
Cancer Prevention Institute of California. 
p4-19-02  a population-based Study of Contemporary Systemic therapy 
for male breast Cancer
Bradley KL, Villa D, Speers CH, Woods R, Tyldesley S. British Columbia 
Cancer Agency, Vancouver, BC, Canada. 
p4-19-03  physical and psychological Sequelae of breast Cancer in men
Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow 
S, Winer EP, Partridge AH. Dana-Farber Cancer Institute, Boston, 
MA; M.D. Anderson Cancer Center, Houston, TX; Memorial Sloan 
Kettering Cancer Center, New York, NY. 
p4-19-04  evaluation of histopathological parameters in male breast 
Cancer reveals Differences Compared with Female breast 
Cancer
Nilsson C, Johansson I, Ahlin C, Thorstenson S, Bergkvist L, Amin 
R-M, Holmqvist M, Hedenfalk I, Fjällskog M-L. Central Hospital of 
Västerås, Västerås, Sweden; Uppsala University, Uppsala, Sweden; 
Lund University, Lund, Sweden; örebro University Hospital, örebro, 
Sweden; Linköping University Hospital, Linköping, Sweden; Uppsala, 
Sweden. 
p4-19-05  a population-based Study of guideline-based brCa Screening 
in male breast Carcinoma
Bradley KL, Nuk JE, Chia SK, Villa D, Speers CH, Woods R, Young S, 
Tyldesley S. British Columbia Cancer Agency, Vancouver, BC, Canada. 
p4-19-06  ghrelin expression is associated with Favorable outcome in 
male breast Cancer
Grönberg M, Nilsson C, Johansson I, Hedenfalk I, Janson ET, Fjällskog 
M-L. Dept. of Medical Sciences, Section of Endocrine Oncology, 
Uppsala, Sweden; Dept. of Oncology, Radiology and Clinical 
Immunology, Uppsala, Sweden; Dept. of Oncology, Clinical Sciences, 
Lund, Sweden; Center for Clinical Research, Västerås, Sweden. 
p4-17-04  pharmacokinetic Disposition of pegylated liposomal 
Doxorubicin Compared with non-liposomal Doxorubicin in an 
intracranial breast Cancer murine model
Anders CK, Adamo B, Walsh MD, Karginova O, Darr D, Deal AM, 
Santos C, Bash R, Hanna SK, Carey LA, Miller CR, Sharpless N, 
Zamboni WC. University of North Carolina at Chapel Hill (UNC), 
Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, 
Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel 
Hill, NC; University of Messina, Messina, Italy. 
p4-17-05  brain metastasis Free Survival (bmFS) Differs between breast 
Cancer Subtypes
Bartsch R, Berghoff A, Bago-Horvath Z, DeVries C, Dubsky P, 
Pluschnig U, Rudas M, Rottenfusser A, Fitzal F, Dieckmann K, Mader 
RM, Gnant M, Zielinski CC, Steger GG. Medical University of Vienna, 
Vienna, Austria. 
p4-17-06  prognostic role of triple negative Subtype in breast Cancer 
patients with brain metastases
Mathew A, Mathew IE, Rosenzweig MQ, Brufsky AM. University of 
Pittsburgh Medical Center; University of Pittsburgh Cancer Institute; 
Magee-Womens Hospital. 
p4-17-07  the Shifting landscape of metastatic breast Cancer to the CnS
Quigley MR, Fukui O, Chew B, Bhatia S, Karlovits S. Allegheny General 
Hospital, Pittsburgh, PA. 
p4-17-08  is Cranial magnetic resonance imaging (mri) necessary 
for Staging of asymptomatic her2-positive breast Cancer 
patients?
Kaplan MA, Inal A, Kucukoner M, Urakci Z, Isikdogan A. Dicle 
University, Diyarbakir, Turkey. 
p4-17-09  Comparative performances of prognostic indexes for breast 
Cancer patients presenting with brain metastases
Braccini A-L, Azria D, Thezenas S, Ferrero J-M, Romieu G, Jacot W. 
CRLC Val d’Aurelle Paul Lamarque, Montpellier, France; Antoine 
Lacassagne Cancer Center, Nice, France. 
p4-17-10  insights into mechanisms involved in the accumulation of 
nanovectors within the breast Cancer brain metastasis
Yokoi K, Xuewu L, Alexander JF, Fidler IJ, Mauro F, Biana G. The 
Methodist Hospital Research Institute, Houston, TX; M D Anderson 
Cancer Center, Houston, TX. 
p4-17-11  Central nervous System involvement and Clinical outcome, 
review of 135 patients, 9-year Follow up
Watanabe J, Ogiya A, Tadokoro Y, Tanaka K, Takahashi K, Uematsu T, 
Mitsuya K. Shizuoka Cancer Center, Shizuoka, Japan; Shizuoka Cancer 
Center. 
p4-17-12  analysis of predictive and prognostic Factors for metastatic 
breast Cancer patients with brain metastasis treated by Whole 
brain radiotherapy
Park IH, Lee KS, Shin KH, Ro J. National Cancer Center, Goyang, Korea. 
treatment – types and Sites of breast Cancer: DCiS/lCiS
p4-18-01  prognostic role of tumor and Stromal p16/ink4a in Ductal 
Carcinoma in Situ (DCiS)
Linke SP, Bremer TM, Wärnberg F, Zhou W, Goldstein L, Jirström, 
Amini. Prelude Corporation, Laguna Hills, CA; Uppsala University 
Hospital, Uppsala, Sweden; PhenoPath Laboratories, Seattle, WA; 
Lund University, Lund, Sweden. 
p4-18-02  Sentinel node biopsy in extensive Ductal Carcinoma in Situ 
(DCiS) Diagnosed by vacuum-assisted macrobiopsy (vamb) 
and treated by mastectomy: results of the French prospective 
trial Cinnamome
Tunon-de-lara C, Giard S, Baron M, Le-Bouedec G, Garbay J-R, 
Blanchot J, Mollard J, Charitansky H, Martin-Françoise S, Michy 
T, Fondrinier E, Butarelli M, Loustalot C, Raout I, Macgrogan G. 
Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, 
France. 
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pD07-01  Sequential treatment with epirubicin/Cyclophosphamide, 
Followed by Docetaxel vs. FeC120 in the adjuvant treatment 
of breast Cancer patients with extensive lymph node 
involvement: Final Survival analysis of the german aDebar 
phase iii Study
Janni WJ, Harbeck N, Sommer H, Rack B, Salmen J, Augustin D, 
Simon W, Jueckstock J, Wischnik A, Anneke K, Melcher C, Friese 
K, Kiechle M. Heinrich-Heine-University, Duesseldorf, Germany; 
University Cologne, Cologne, Germany; Ludwig-Maximilians-
University, Munich, Germany; Mammazentrum Ostbayern, 
Deggendorf, Germany; Robert-Bosch-Krankenhaus, Stuttgart, 
Germany; Zentalklinikum, Augsburg, Germany; Technische 
Universität, Munich, Germany. 
pD07-02  Docetaxel is Superior to paclitaxel given every three Weeks 
in post operative patients with node-positive breast Cancer: 
results of the Final analyses of the nSaS-bC (national Surgical 
adjuvant Study of breast Cancer) 02 trial from japan
Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata 
H, Mukai H, Uemura Y, Ohashi Y. Hamamatsu Oncology Center, 
Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, Japan; 
Saitama Cancer Center, Inachou-Omuro, Japan; NHO Osaka National 
Hospital, Osaka, Japan; Shikoku Cancer Center, Matsuyama, Japan; 
Kyushu Cancer Center, Fukuoka, Japan; Aichi Cancer Center, Nagoya, 
Japan; National Cancer Center, Kashiwa, Japan; University of Tokyo, 
Tokyo, Japan. 
pD07-03  phase ii trial of adjuvant tC (Docetaxel/Cyclophosphamide) 
plus trastuzumab (her tC) in her2-positive early Stage breast 
Cancer patients
Jones S, Collea R, Paul D, Oratz R, Sedlacek S, Favret AM, Gore, Jr 
II, Lindquist DL, Holmes FA, Allison MAK, Steinberg MS, Stokoe C, 
Portillo RM, Crockett M, Wang Y, Asmar L, Robert N, O’Shaughnessy 
J. US Oncology, The Woodlands, TX; Baylor Sammons Cancer Center, 
Dallas, TX; New York Oncology Hematology, Albany, NY; Rocky 
Mountain Cancer Center, Denver, CO; Physician, New York, NY; 
Virginia Cancer Specialists, PC, Fairfax, VA; Birmingham Hematology 
and Oncology, Birmingham, AL; Arizona Oncology Associates, 
Sedona, AZ; Texas Oncology, Houston, TX; Comprehensive Cancer 
Center, Henderson, NV; Virginia Oncology Associates, Virginia Beach, 
VA; Texas Oncology, Plano, TX; Texas Oncology, El Paso, TX. 
pD07-04  lapatinib vs trastuzumab in Combination with Standard 
eC-D Chemotherapy in the neaodjuvant treatment of 
her2+ patients. results from the geiCam 2006-14 phase ii 
randomized trial
Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez P, 
Ramos M, Rojo F, Burgués O, Porras I, Tibau A, Carrasco E, Cámara 
MC, Lluch A. Hospital Virgen de la Victoria, Malaga, Spain; Hospital 
del Mar, Barcelona, Spain; Hospital Universitario Reina Sofía, Córdoba, 
Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Complejo 
Hospitalario Universitario de A Coruña, A Coruña, Spain; Hospital 
General de Jaén, Jaén, Spain; Centro Oncológico de Galicia, A 
Coruña, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital 
Clínico Universitario de Valencia, Valencia, Spain; GEICAM (Spanish 
Breast Cancer Research Group), San Sebastián de los Reyes, Madrid, 
Spain. 
treatment – types and Sites of breast Cancer: inflammatory breast Cancer
p4-20-01  multicentric phase ii paCS 09/beverly1 trial: First efficacy and 
Safety results of neoadjuvant Chemotherapy Combined with 
bevacizumab in her2-negative patients with non-metastatic 
inflammatory breast Cancer
Viens P, Petit T, Dalenc F, Pierga JY, Delozier T, Romieu G, Bonneterre 
J, Ferrero J-M, Kerbrat P, Mouret-Reynier M-A, Bachelot T, Soulie P, 
Lerebours F, Eymard J-C, Deblock M, Lortholary A, Hardy-Bessard 
A-C, Boher J-M, Asselain B, Charafe-Jauffret E, Lemonnier J, Martin 
A-L, Andre F. Institut Paoli Calmettes, Marseille, France; Centre Paul 
Strauss, Strasbourg, France; Institut Claudius Regaud, Toulouse, 
France; Institut Curie, Paris, France; Centre François Baclesse, Caen, 
France; Centre Val d’Aurelle, Montpellier, France; Centre Oscar 
Lambret, Lille, France; Centre Antoine Lacassagne, Nice, France; 
Centre Eugène Marquis, Rennes, France; Centre Jean Perrin, 
Clermont-Ferrand, France; Centre Leon Berard, Lyon, France; Centre 
Paul Papin, Angers, France; Institut Curie, Saint Cloud, France; Institut 
Jean Godinot, Reims, France; Centre Alexis Vautrin, Nancy, France; 
Centre Catherine de Sienne, Nantes, France; Clinique Armoricaine, 
Saint Brieuc, France; R&D Unicancer, Paris, France; Institut Gustave 
Roussy, Villejuif, France. 
p4-20-02  inflammatory breast Cancer (ibC) in the national 
Comprehensive Cancer network (nCCn): the Disease, the 
recurrence pattern and the outcome
Lubbe W, Li T, Hughes M, Ottesen R, Cristofanilli M, Weeks J, Wong 
Y-N. Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer 
Institute, Boston, MA; City of Hope Cancer Center, Duarte, CA. 
p4-20-03  t-Cell Cytokine production related to progression of breast 
Cancer patients
Cohen EN, Gao H, Lee B-N, Giordano A, Tin S, Anfossi S, Parker CA, 
Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, 
Ueno NT, Reuben JM. The University of Texas MD Anderson Cancer 
Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; 
The University of Texas Graduate School of Biomedical Sciences at 
Houston, Houston, TX. 
p4-20-04  Cytokine Synthesis by activated Dendritic Cells in relation to 
Disease progression in inflammatory breast Cancer (ibC)
Gao H, Cohen EN, Lee B-N, Giordano A, Tin S, Anfossi S, Parker CA, 
Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, 
Ueno NT, Reuben JM. The University of Texas MD Anderson Cancer 
Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA. 
p4-20-05  inflammatory breast Cancer: Comparison of epidemiology, 
biology, and prognosis between japan and the united States, 
a hospital-based Study
Yamauchi H, Natori A, Hayashi N, Soejima K, Takahashi O, Fukui T, 
Nakamura S, Cristofanilli M, Ueno N. St. Luke’s International Hospital, 
Chuo-ku, Tokyo, Japan; Showa University, Shinagawa-ku, Tokyo, 
Japan; Fox Chase Cancer Center, Philadelphia, PA; The University of 
Texas M.D. Anderson Cancer Center, Houston, TX.
7:00 am–9:00 am 
poSter DiSCuSSion vii: What’S neW in Chemotherapy 
trialS? 
ballroom a
Viewing 7:00 am 
Discussion 7:45 am
Discussant: Clifford Hudis, MD
Memorial Sloan-Kettering Cancer Center
New York, NY 
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pD07-08  the effect on Surgical Complications of bevacizumab added to 
neoadjuvant Chemotherapy: nSabp protocol b-40
Bear HD, Tang G, Rastogi P, Geyer CE, André R, Atkins JN, Baez-Diaz 
L, Brufsky AM, Mehta RS, Fehrenbacher L, Pajon ER, Senecal FM, 
Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain 
SM, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast 
and Bowel Project (NSABP); Virginia Commonwealth University, 
Massey Cancer Center; University of Pittsburgh Graduate School 
of Public Health; University of Pittsburgh Cancer Institute School 
of Medicine; Allegheny General Hospital; Centre Hospitalier de 
l’Université de Montréal; Southeast Cancer Control Consortium 
CCOP; San Juan MBCCOP; University of Pittsburgh/Magee Women’s 
Hospital; University of California at Irvine, School of Medicine, Chao 
Family Comprehensive Cancer Center; Kaiser Permanente, Northern 
California; CCOP, Colorado Cancer Research Program; CCOP, North-
West Medical Specialties; Kansas City Clinical Oncology Program; 
Jewish General Hospital, McGill University; Genesys Regional Medical 
Center; Dayton CCOP; Washington Cancer Institute, Washington 
Hospital Center; Aultman Health Foundation.
7:00 am–9:00 am 
poSter DiSCuSSion viii: targeting triple negativeS anD 
Stem CellS  
ballroom b
Viewing 7:00 am 
Discussion 7:45 am
Discussant: Geoffrey Lindeman, MD, PhD
Walter and Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA 
pD08-01  jnk2 regulates mammary lineage Differentiation in tumors 
and normal glands through notch1 and p53
Cantrell MA, Ebelt ND, Van Den Berg CL. University of Texas at Austin, 
Austin, TX. 
pD08-02  targeting bCl-2 expressing breast tumors with bh3-mimetics 
- a new Class of Drugs in breast Cancer?
Lindeman GJ, Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, 
Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, 
Strasser A, Huang DCS, Visvader JE. The Walter and Eliza Hall Institute 
of Medical Research, Parkville, VIC, Australia; The Royal Melbourne 
Hospital, Parkville, VIC, Australia; The University of Melbourne, 
Parkville, VIC, Australia; Peter MacCallum Cancer Centre, East 
Melbourne, VIC, Australia; Ospitalieri di Cremona, Cremona, Italy. 
pD08-03  inhibition of mek/erk- and jnk-Dependent expression of 
interleukin-6 and interleukin-8 targets basal-like breast 
Cancer Stem Cells
Balko JM, Cook RS, Kuba MG, Miller TW, Bhola NE, Sanders ME, 
Meszoely IM, Dowsett M, Gomez H, Arteaga CL. Vanderbilt University, 
Nashville, TN; Royal Marsden Hospital, United Kingdom; Instituto 
Nacional de Enfermedades Neoplásicas, Lima, Peru. 
pD08-04  inhibition of the tgFβ/tgFβr2 pathway prevents enrichment 
of Drug-resistant breast Cancer Stem Cells by anti-Cancer 
Chemotherapy
Bhola N, Arteaga C. Vanderbilt University Medical Center, Nashville, 
TN. 
pD08-05  Stat3 Signaling in human breast Cancer Stem Cells
Wei W, Zhang M, Tweardy D, Rosen J, Lewis M. Baylor College of 
Medicine. 
pD08-06  erk2 promotes Stem Cell-like Characteristics in triple-
negative breast Cancer
Bartholomeusz C, Saso H, Dadbin A, Kazuharu K, Hortobagyi GN. The 
University of Texas MD Anderson Cancer Center, Houston, TX. 
pD07-05  local recurrence risk in 6377 patients with early breast 
Cancer receiving neoadjuvant anthracycline-taxane +/- 
trastuzumab Containing Chemotherapy
von Minckwitz G, Kaufmann M, Kümmel S, Fasching PA, Eiermann 
W, Blohmer JU, Costa S, Hilfrich J, Jackisch C, Gerber B, Barinoff J, 
Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, 
Mehta K, Loibl S, Untch M. German Breast Group, Neu-Isenburg; 
Universitäts-Frauenklinik, Frankfurt; Universitäts-Frauenklinik, 
Essen; University Hospital Erlangen, Erlangen; Klinikum zum Roten 
Kreuz, München; St. Gertrauden Krankenhaus, Berlin; Universitäts-
Frauenklinik, Magdeburg; Henrietten-Stiftung, Hannover; Städtische 
Kliniken, Offenbach; Universitäts-Frauenklinik, Rostock; Horst Schmidt 
Klinik Wiesbaden; Universitäts-Frauenklinik, Tübingen; University of 
California, Los Angeles; Hämato-Onkologische Praxis, Wuppertal; 
Universitäts-Frauenklinik, Freiburg; Universitäts-Frauenklinik, Köln; 
Helios-Klinikum Berlin-Buch, Berlin. 
pD07-06  adjuvant Chemotherapy with or without Darbepoetin alpha 
in node-positive breast Cancer: Survival and Quality of life 
analysis from the prospective randomized WSg ara plus trial
Nitz U, Gluz O, Oberhoff C, Reimer T, Schumacher C, Hackmann J, 
Warm M, Uleer C, Runde V, Kuemmel S, Zuna I, Harbeck N. West 
German Study Group, Moenchengladbach, Germany; Bethesda 
Hospital, Moenchengladbach, Germany; Bethesda Hospital, 
Wuppertal, Germany; University Hospital Essen, Essen, Germany; 
Catholical Hospital Essen North, Essen, Germany; University Hospital 
Suedstadt, Rostock, Germany; St. Elisabeth Hospital, Cologne, 
Germany; Marien-Hospital Witten, Witten, Germany; University 
Hospital Cologne, Cologne, Germany; Krankenhaus Koeln-Holweide, 
Cologne, Germany; Gynecological Practice, Hildesheim, Germany; 
Wilhelm-Anton-Hospital Goch, Goch, Germany; Hospital Essen-Mitte, 
Essen, Germany. 
pD07-07 Combination of paclitaxel and bevacizumab without or with 
Capecitabine as First-line treatment of her2-negative locally 
recurrent or metastatic breast Cancer (lr/mbC): First results 
from a randomized, multicenter, open-label, phase ii Study 
of the Dutch breast Cancer trialists’ group (boog)
Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos 
MMEM, Linn SC, van den Bosch J, Nortier JWR, Braun JJ, de Graaf 
H, Portielje JEA, Los M, Gooyer DD, van Tinteren H, Boven E. VU 
University Medical Center, Amsterdam, Netherlands; Comprehensive 
Cancer Centre the Netherlands, Netherlands; Isala Clinics, Zwolle, 
Netherlands; Erasmus Medical Center-Daniel den Hoed Cancer 
Center, Rotterdam, Netherlands; Tergooi Hospitals, Hilversum, 
Netherlands; Reinier de Graaf Hospital, Delft, Netherlands; The 
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 
Amsterdam, Netherlands; Albert Schweitzer Hospital, Dordrecht, 
Netherlands; Leiden University Medical Center, Leiden, Netherlands; 
Vlietland Hospital, Schiedam, Netherlands; Medical Center 
Leeuwarden, Leeuwarden, Netherlands; Haga Hospital, The Hague, 
Netherlands; St. Antonius Hospital, Nieuwegein, Netherlands; 
Franciscus Hospital, Roosendaal, Netherlands. 
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10:00  S5-3. basement membrane localized tumor cells are protected 
from her2-targeted therapy in vivo
Zoeller JJ, Bronson RT, Gilmer TM, Selfors LM, Lu Y, Mills GB, Brugge JS. 
Harvard Medical School, Boston, MA; GlaxoSmithKline, Research Triangle 
Park, NC; UT MD Anderson Cancer Center, Houston, TX.
10:15  S5-4. pCr as a surrogate in her2-positive patients treated with 
trastuzumab
Loibl S, von Minckwitz G, Blohmer JU, Costa S, Eidtmann H, Fasching 
PA, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, 
Konecny G, Denkert C, Nekljudova V, Mehta K, Untch M. German Breast 
Group, Neu-Isenburg; St. Gertrauden Krankenhaus, Berlin; Universitäts-
Frauenklinik, Magdeburg; Universitätsklinikum, Kiel; University Hospital, 
Erlangen; Universitäts-Frauenklinik, Rostock; Klinikum zum Roten Kreuz, 
München; Henrietten-Stiftung, Hannover; Universitäts-Frauenklinik, 
Tübingen; Städtische Kliniken, Offenbach; Universitäts-Frauenklinik, 
Frankfurt; University of California, Los Angeles; Charité, Berlin; Helios 
Klinikum Berlin-Buch, Berlin.
10:30  S5-5. a phase iii, randomized, double-blind, placebo-controlled 
registration trial to evaluate the efficacy and safety of pertuzumab 
+ trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel 
in patients with previously untreated her2-positive metastatic 
breast cancer (Cleopatra)
Baselga J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Cortés 
J, Knott A, Clark E, Ross GA, Swain SM. Massachusetts General Hospital 
Cancer Center, Boston, MA; Asan Medical Center, University of Ulsan, 
College of Medicine, Seoul, Korea; Seoul National University College 
of Medicine, Seoul, Korea; Hospital Pérola Byington, São Paulo, Brazil; 
Samsung Medical Center, Sungkyunkwan University School of Medicine, 
Seoul, Korea; Lenigrad Regional Oncology Dispensary, St. Petersburg, 
Russian Federation; CPMEC-Mastology Unit of Conceição Hospital, 
Porto Alegre, Brazil; Vall d’Hebron University Hospital, Barcelona, Spain; 
Roche Products Limited, Welwyn, United Kingdom; Washington Cancer 
Institute, Washington Hospital Center, Washington, DC.
10:45  S5-6. neoadjuvant pertuzumab and trastuzumab concurrent or 
sequential with an anthracycline-containing or concurrent with an 
anthracycline-free standard regimen: a randomized phase ii study 
(tryphaena)
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, 
Seo J-H, Tsai Y-F, Ackrill A, Ross G, Cortés J. National Center for Tumor 
Diseases, University Hospital, Heidelberg, Germany; British Columbia 
Cancer Agency - Vancouver Centre, University of British Columbia, 
Vancouver, Canada; Royal Bournemouth Hospital, Bournemouth 
University, Bournemouth, United Kingdom; Auckland City Hospital, 
Auckland, New Zealand; Cancer Institute “I. Chiricuta”, Cluj-Napoca, 
Romania; Hospital Pérola Byington, São Paulo, Brazil; Breast-Center, 
Zürich, Switzerland; Korea University Guro Hospital, Guro, Korea; Taipei 
Veterans General Hospital, Taipei, Taiwan; Roche Products Limited, 
Welwyn, United Kingdom; Vall d’Hebron University Hospital, Barcelona, 
Spain.
11:00  S5-7. a phase 2, randomized, open-label, study of neratinib (hki-
272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of 
her2+ locally advanced or metastatic breast cancer
Martin M, Bonneterre J, Geyer, Jr CE, Ito Y, Ro J, Lang I, Kim S-B, Germa C, 
Vermette J, Vo Van ML, Wang K, Wang K, Awada A. Hospital Universitario 
Gregorio Marañón, Madrid, Spain; Centre Oscar Lambret, Lille, France; 
Allegheny Cancer Center, Pittsburgh, PA; The Cancer Institute Hospital 
of JFCR, Tokyo, Japan; National Cancer Center, Goyang, Korea; National 
Institute of Oncology, Budapest, Hungary; Asan Medical Center, Seoul, 
Korea; Pfizer Global Research and Development, Paris, France; Pfizer 
Inc, Collegeville, PA; Bristol Meyers Squibb, Princeton, NJ; Jules Bordet 
Institute, Brussels, Belgium.
11:15  Discussion
C. Kent Osborne, Baylor College of Medicine, Houston, TX 
pD08-07  Wound-healing Drainage Fluids promote triple negative 
breast Cancer progression
Campiglio M, Sasso M, Bianchi F, Plantamura I, Iorio M, De Cecco L, 
Giustarini E, Agresti R, Ghirelli C, Cremona M, Tripodo C, Tagliabue E. 
Fondazione IRCCS-Istituto Nazionale Tumori, Milan, Italy; University 
of Palermo, Palermo, Italy. 
pD08-08  preclinical efficacy of the Combination of met and Src Family 
kinase inhibitors in triple-negative breast Cancer
Gartner EM, Kim EMH, Choi L, Boerner J. Karmanos Cancer Center at 
Wayne State University, Detroit, MI. 
pD08-09  ptpn12 gene expression Signature in triple negative breast 
Cancer Cohort
Ghazalpour A, Bender RP, McGinniss MJ, Ashfaq R. Caris Life Sciences, 
Phoenix, AZ. 
pD08-10  high Frequency of triple negative mammary Carcinomas in 
the Dog as model of human breast Cancer
Nguyen F, Abadie J, Loussouarn D, Ibisch C, Rieder N, Campion L, 
Belousov A, Bemelmans I, Hanzenne C, Campone M. Ecole Nationale 
Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche 
Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de 
Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie 
de l’Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), 
France.
pD08-11  targeting porcupine, a Critical node for Wnt Signalling in 
Cancer
Liu J, Pan S, Sun F, Kasibhatla S, Schuller A, Li A, Li C, Cui X, Wang 
T, Villarroel M, Mclaughlin M, Sellers W, Boral A, Harris J. Genomics 
Institute of the Novartis Research Foundation, San Diego, CA; 
Novartis Institutes For BioMedical Research, Cambridge, MA. 
9:00 am–9:30 am 
plenary leCture 3 
exhibit hall D
 advances in axillary Surgery: Sentinel nodes and beyond 
Barbara L. Smith, MD, PhD
Massachusetts General Hospital 
Boston, MA 
9:30 am–11:30 am 
general SeSSion 5 
exhibit hall D
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX 
9:30  S5-1. neoadjuvant pertuzumab and trastuzumab: biomarker 
analyses of a 4-arm randomized phase ii study (neoSphere) in 
patients with her2-positive breast cancer
Gianni L, Bianchini G, Kiermaier A, Bianchi G, Im Y-H, Pienkowski T, 
Roman L, Liu M-C, Tseng L-M, Ratnayake J, Szado T, Ross GA, Valagussa P. 
Oncologia Medica, San Raffaele Cancer Center, Milan, Italy; Roche, Basel, 
Switzerland; Oncologia Medica 1, Fondazione IRCCS Instituto Nazionale 
Tumori, Milan, Italy; Samsung Medical Center, Seoul, Korea; Centrum 
Onkologii, Warsaw, Poland; Leningrad Regional Oncology Dispensary, 
St Petersburg, Russian Federation; Koo Foundation Sun Yat-Sen Cancer 
Center, Taipei, Taiwan; Taipei-Veterans General Hospital, National 
Yang-Ming University, Tiapei, Taiwan; Roche Products Limited, Welwyn, 
United Kingdom; Genentech, South San Francisco, CA; Fondazioine 
Michelangelo, Milan, Italy.
9:45  S5-2. pam50 her2-enriched subtype enriches for tumor response 
to neoadjuvant anthracyclines/taxane and trastuzumab/taxane 
containing regimens in her2-positive breast cancer
Cheang MCU, Prat A, Fan C, Perou CM. Lineberger Comprehensive 
Cancer Center, Chapel Hill, NC.
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1:45 pm–3:15 pm 
mini-SympoSium 3 
ballroom b
 metabolism in breast Cancer - metabolomics 
Moderator: Michael Pollak, MD
McGill University
Montreal, CANADA
  adiposity, metabolism, and risk of breast cancer  
Susan E. Hankinson, ScD
Harvard Medical School
Boston, MA
  hiF-1, metabolism, and metastasis
Gregg L. Semenza, MD, PhD
The Johns Hopkins University School of Medicine 
Baltimore, MD
  energy metabolism in breast cancer: translational science 
insights relevant to effects of diet, exercise, and metformin on 
risk and prognosis
Michael Pollak, MD
McGill University
Montreal, CANADA
1:45 pm–3:15 pm 
mini-SympoSium 4 
exhibit hall D
 the role and promise of neoadjuvant therapy in breast Cancer  
Moderator: Lisa A. Carey, MD, ScM
University of North Carolina
Chapel Hill, NC
  the neoadjuvant setting, her2-driven and triple negative 
breast cancer  
Lisa A. Carey, MD, ScM
University of North Carolina
Chapel Hill, NC
  preoperative endocrine therapy: new approaches
Ian Smith, MD
Royal Marsden Hospital 
London, UNITED KINGDOM
  interface with radiation oncology
Thomas A. Buchholz , MD
UT MD Anderson Cancer Center
Houston, TX
  neoadjuvant trials as a discovery tool
Carlos L. Arteaga, MD
Vanderbilt-Ingram Cancer Center
Vanderbilt University 
Nashville, TN
3:15 pm–5:00 pm 
general SeSSion 6 
exhibit hall D
Moderator: Pamela Goodwin, MD 
Mount Sinai Hospital 
Toronto, CANADA
11:30 am–12:00 pm  
aaCr outStanDing inveStigator aWarD For breaSt 
CanCer reSearCh, FunDing by SuSan g. komen For the 
Cure®  
exhibit hall D
 alteration and inhibition of pten in breast Cancer
Ramon E. Parsons, MD, PhD
Columbia University
New York, NY
12:00 pm–1:35 pm 
lunCh
12:15 pm–1:15 pm 
proDuCt theatre 
exhibit hall C – exhibit area
 abraxane
Sponsored by Celgene Corporation
12:30 pm–1:35 pm 
CaSe DiSCuSSion 2 
ballroom a
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Panelists:
Kimberly Blackwell, MD
Duke University
Durham, NC
Jennifer Bellon, MD
Dana-Farber Cancer Institute
Boston, MA
Ismail Jatoi, MD
UT Health Science Center
San Antonio, TX
Martine Piccart, MD, PhD
Institut Jules Bordet
Brussels, BELGIUM
Vernal Branch
Virginia Breast Cancer Foundation
Richmond VA
12:30 pm–1:35 pm 
baSiC SCienCe Forum  
ballroom b
 tumor microenvironment
Moderator: Rong Li, PhD 
UT Health Science Center San Antonio
San Antonio, TX
  extrinsic and intrinsic Force regulation of breast Cancer 
progression and treatment
Valerie M. Weaver, PhD
University of California San Francisco
San Francisco, CA 
  CoX-2 dependent collagen fibrillogenesis drives metastasis in 
the postpartum involuting mammary gland
Pepper J. Schedin, PhD
University of Colorado Denver
Aurora, CO 
CTRC-AACR San Antonio Breast Cancer Symposium
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p5-01-02  Wnt5a is a prognostic biomarker in estrogen receptor-positive 
premenopausal breast Cancer
Sand-Dejmek JT, Ehrnstrom R, Andersson T, Ryden L. Clinical 
Sciences, Skåne University Hospital, Lund University, Malmoe, 
Sweden; Laboratory Medicine, Skåne University Hospital, Lund 
University, Malmoe, Sweden. 
p5-01-03  Correlation between aromatase expression in metastatic and 
primary breast Cancer
Ribeiro JM, Luis IV, Correia L, Casimiro S, Fernandes A, Quintela 
A, Mestan J, Ramos M, Costa L. Hospital de Santa Maria, Lisbon, 
Portugal; University of Lisbon, Lisbon; Hospital de Santa Maria, 
Lisbon; Novartis Pharma. 
p5-01-04  FoXp3 positive regulatory t lymphocytes and epithelial 
FoXp3 expression in Synchronous normal, Ductal Carcinoma 
in Situ and invasive Cancer of the breast
Lal A, Chan L, DeVries S, Chin K, Benz CC, Chen Y-Y, Hwang S, 
Waldman FM. UCSF, SF, CA. 
p5-01-05  activating mutations in pik3Ca or akt1 in the i-Spy 1 trial 
(Calgb 150007/150012; aCrin 6657)
Boudreau A, Yau C, Petrillo L, Stemke-Hale K, Mills GB, Gray JW, 
Wolf DM, van ‘t Veer LJ, The I-SPY 1 TRIAL Investigators, Esserman 
LJ. University of California, San Francisco; University of Texas MD 
Anderson Cancer Center; Oregon Health & Science University. 
p5-01-06  gene Copy number and expression of tymp and tymS are 
predictive of outcome in breast Cancer patients treated with 
Capecitabine
Audet RM, Changyu S, Duchnowska R, Adamowicz K, Zok J, 
Rogowski W, Litwiniuk M, Debska S, Jaworska M, Foszczynska-Kloda 
M, Kulma-Kreft M, Zabkowska K, Jassem J, Edgerton S, Vang Nielsen 
K, Thor A, Chang J, Miller K, Sledge GW, Leyland-Jones B. V M Institut 
of Research, Montreal, QC, Canada; Medical University of Gdansk, 
Gdansk, Poland; Indiana University School of Medicine, Indianapolis, 
IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory 
University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; 
DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, 
Houston, TX; Military Institute of Medicine, Warsaw; Regional 
Oncology Center, Olsztyn; Poznan University of Medical Sciences; 
Regional Cancer Center, Lodz, MD; District Hospital, Wroc³aw, MD; 
West Pomeranian Oncology Center, Szczecin; Gdynia Oncology 
Center. 
p5-01-07  identification of SorbS2 as a Candidate marker to predict 
metastatic relapse in breast Cancer
Alsafadi S, Scott V, Pautier P, Goubar A, Lazar V, Dessen P, Lacroix L, 
Duvillard P, Morice P, André F, Delaloge S. Gustave Roussy Cancer 
Institute, Villejuif, France. 
p5-01-08  immunocytochemistry Staining of estrogen receptor in 
Circulating tumor Cells as Compared to primary tumor
Mayer JA, Pham T, Wong KL, Bischoff FZ. Biocept Inc, San Diego, CA. 
p5-01-09  Differences in Serum estradiol and prolactin Concentrations in 
Women Who yield nipple aspiration Fluid and those Who Do 
not
Khan SA, Fought AJ, Scholtens DM, McGathey C, Heinz RE, 
Chatterton RT. Northwestern University, Feinberg School of 
Medicine, Chicago, IL. 
p5-01-10  a potential new marker for, and Facilitator of, hormone 
independence
Monaco ME, Wu X, Lee P. NYU School of Medicine, New York, NY; VA 
NY Harbor Healthcare System, New York, NY. 
p5-01-11  Small node-negative (t1b-cn0) invasive hormone receptor 
(hr)-positive breast Cancers: is there a population Which 
might have benefit from adjuvant Chemotherapy?
Park YH, Cho EY, Lee JE, Nam SJ, Yang JH, Ahn JS, Im Y-H. Samsung 
Medical Center. 
3:15  S6-1. menopause-specific and health-related qualities of 
life among post-menopausal women taking exemestane for 
prevention of breast cancer: results from the nCiC Ctg map.3 
placebo-controlled randomized controlled trial
Maunsell E, Richardson H, Ingle JN, Ales-Martinez JE, Chlebowski RT, 
Fabian CJ, Sarto GE, Garber JE, Pujol P, Hiltz A, Tu D, Goss PE. Université 
Laval, Quebec City, QC, Canada; Queen’s University, Kingston, ON, 
Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, 
Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University 
of Kansas Medical Center, Westwood, KS; Center for Women’s Health and 
Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; 
CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts 
General Hospital Cancer Center, Boston, MA.
3:30  S6-2. patient-reported predictors of early treatment 
discontinuation: nCiC jma.27/e1Z03 quality of life study of 
postmenopausal women with primary breast cancer randomized 
to exemestane or anastrozole
Wagner LI, Zhao F, Chapman J-AW, Cella D, Shepherd LE, Sledge GW, 
Goss PE. Northwestern University Feinberg School of Medicine, Chicago, 
IL; Dana-Farber Cancer Institute, Boston, MA; NCIC Clinical Trials Group, 
Queen’s University, Kingston, ON, Canada; Indiana University Simon 
Cancer Center, Indianapolis, IN; Massachusetts General Hospital, Boston, 
MA.
3:45 Discussion
Patricia A. Ganz, MD
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA 
4:00  S6-3. influence of hospital factors, physician factors and type 
of health insurance on receipt of immediate postmastectomy 
reconstruction in young women with breast cancer
Hershman DL, Neugut AI, Richards CA, Kalinsky K, Charles AS, Wright 
JD. Columbia University, New York, NY; Mailman School of Public Health, 
New York, NY.
4:15 S6-4. protein kinase mutation patterns in human breast cancer
Pusztai L, Qi Y, Shi W, Liu C-G, Wang B, Liu X, Booser D, Esteva FJ, 
Symmans F, Hortobagyi GN. UT MD Anderson Cancer Center, Houston, 
TX.
4:30 S6-5. obesity drives epithelial-to-mesenchymal transition and 
tumor progression in a novel claudin-low mammary cancer model
Dunlap SM, Chiao LJ, Nogueria L, Usary J, Perou CM, Varticovski L, 
Hursting SD. University of Texas, Austin, TX; University of North Carolina, 
Chapel Hill, NC; National Cancer Institute, Bethesda, MD; University of 
Texas M.D. Anderson Cancer Center, Smithville, TX
4:45  S6-6. expression of key estrogen-regulated genes differ 
substantially across the menstrual cycle in er+ breast tumours
Haynes BP, Viale B, A’Hern R, Smith IE, Dowsett M, Galimberti V, 
Rotmensz N, Gibelli B. Royal Marsden Hospital, London, United Kingdom; 
Institute of Cancer Research, Sutton, Surrey, United Kingdom; European 
Institute of Oncology, Milan, Italy.
5:00 pm–7:00 pm 
poSter SeSSion 5 & reCeption  
exhibit halls a-b
tumor Cell biology: biomarkers
p5-01-01  identification, validation and assessment of transcriptional 
relevance of a pDgFr-activation Signature in (inflammatory) 
breast Cancer
Van Laere SJ, Van Golen KL, Joglekar M, Ueno NT, Finetti P, Van 
Dam PA, Viens P, Birnbaum D, Bertucci F, Vermeulen PB, Dirix LY. 
Oncology Center - GH Sint-Augustinus, Wilrijk, Antwerp, Belgium; 
University of Delaware, Newark, DE; The University of Texas MD 
Anderson Cancer Center, Houston, TX; Institut Paoli-Calmettes (IPC), 
Marseille, France; World IBC Consortium; Contributed Equally. 
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p5-02-03  lipid raft Disruption by Docosahexaenoic acid induces 
apoptosis in transformed human mammary luminal 
epithelial Cells harboring her-2 overexpression
Ravacci GR, Tharcisio, Junior T, Logullo AF, Torrinhas RS, Brentani 
MM, Waitzberg DL. Medical School, University of São Paulo, São 
Paulo, Brazil; UNIFESP University, São Paulo, Brazil. 
p5-02-04  Disruption of endothelial Cells barrier integrity by invasive 
breast Cancer Cells
Haidari M, Zhang W, Chen Z, Mortazavi A, Dixon R. Texas Heart 
Institute, Houston, TX; The University of Texas Health Science Center 
at Houston, Houston, TX. 
p5-02-05  real-time Subcellular imaging of breast Cancer Cell 
attachment in blood vessels using gFp-labeled paxillin in 
live mice
Suetsugu A, Digman M, Gratton E, Moriwaki H, Saji S, Bouvet M, 
Hoffman RM. AntiCancer Inc., San Diego, CA; University of California 
San Diego, San Diego, CA; Gifu University Graduate School of 
Medicine, Gifu, Japan; University of California Irvine, Irvine, CA. 
tumor Cell biology: Cell Cycle regulation
p5-03-01  Cytoplasmic Cyclin e and p-CDk2 expression in triple negative 
breast Carcinomas measured by immunohistochemistry 
Correlates with poor outcome
Biernacka A, Karakas C, Wingate H, Bondy M, Sahin A, Hunt K, 
Khandan K. MD Anderson Cancer Center, Houston, TX. 
p5-03-02  aurora a is Closely linked to an aggressive phenotype of 
breast Cancer
Yamamoto Y, Ibusuki M, Murakami K, Iwase H. Kumamoto University, 
Graduate School of Medical Sciences, Kumamoto, Japan. 
p5-03-03  identification of new Substrates for breast tumor Specific 
low-molecular-Weight Cyclin e Cyclin-Dependent-kinase 2
Akli S, Duong M, Keyomarsi K. M. D. Anderson Cancer Center, 
University of Texas, Houston, TX. 
p5-03-04  Circadian modulation of estrogen receptor alpha promoter 
activity
Villa LM, Santos CS, Cousins S, Finkielstein CV. Virginia Polytechnic 
Institute and State University, Blacksburg, VA. 
tumor Cell biology: Systems biology of breast Cancer
p5-04-01  bp1, a homeotic transcription Factor, indirectly upregulates 
er-alpha in er positive Cell lines
Berg PE, Awate S, Kirolikar SP. The George Washington University, 
Washington, DC. 
p5-04-02  tnbl: an integrated knowledge Space of triple-negative and 
basal-like breast Cancers
Zhu J. OmicsHealth LLC, Morris Plains, NJ. 
p5-04-03  personalized Cancer treatment Selection using Computational 
Signaling pathway models
Verhaegh W, Hatzis P, Clevers H, van de Stolpe A. Philips Research, 
Eindhoven, Netherlands; Hubrecht Institute, Utrecht, Netherlands. 
tumor Cell biology: etiology/Carcinogenesis
p5-05-01  vitamin D Status in newly Diagnosed breast Cancer patients 
inversely Correlates with tumor Size and moderately 
Correlates with outcome
Hatse S, Lambrechts D, Verstuyf M, Smeets A, Brouwers B, Vandorpe 
T, Brouckaert O, Peuteman G, Laenen A, Kriebitzsch C, Dieudonné 
A-S, Paridaens R, Neven P, Christiaens M-T, Bouillon R, Wildiers H. 
Cathologic University of Leuven, Belgium; Catholic University of 
Leuven, Belgium; University Hospitals Leuven, Belgium. 
p5-05-02  phenotypic plasticity in the normal breast
Sauder CAM, Koziel JE, Choi M, Fox MJ, Badve S, Blosser RJ, 
Mathieson T, Rufenbarger CA, Henry JE, Storniolo AMV, Herbert B-S, 
Clare SE. Indiana University School of Medicine, Indianapolis, IN; 
Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer 
Center, Indianapolis, IN; The Catherine Peachy Fund, Inc., Warsaw, IN. 
p5-01-12  identification of an atm activation Subtype in pten mutant 
breast tumours
McCabe N, Walker SM, Goffard N, Wikstrom K, Greenan C, Delaney T, 
McCarthy M, McDyer F, Hill L, Deharo S, Proutski V, Keating K, Mullan 
P, Harkin DP, Kennedy RD. Almac Diagnostics, Craigavon, United 
Kingdom; Queens University Belfast, Belfast, United Kingdom. 
p5-01-13  high levels of nuclear heat Shock Factor 1 (hSF1) are 
associated with poor prognosis in breast Cancer: results from 
the nurses’ health Study
Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, 
Schnitt SJ, Whitesell L, Lindquist S, Tamimi RM, Ince TA. Brigham 
and Women’s Hospital, Boston, MA; Harvard School of Public Health, 
Boston, MA; Dana Farber Cancer Center, Boston, MA; Whitehead 
Institute for Biomedical Sciences, Cambridge, MA; Beth Israel 
Deaconess Medical Center, Boston, MA; University of Miami Miller 
School of Medicine, Miami, FL. 
p5-01-14  phosphoproteomic analysis of timp-1 overexpressing mCF-7 
human breast Cancer Cells reveals increased expression and 
phosphorylation of topoisomerase proteins
Fogh L, Hekmat O, Munk S, Jensen NF, Brünner N, Stenvang J, 
Lademann U, Olsen JV. Faculty of Life Sciences, University of 
Copenhagen, Copenhagen, Denmark; Faculty of Health Science, 
Copenhagen University, Copenhagen, Denmark. 
p5-01-15  the Functional role of the estrogen-regulated gene greb1: 
Characterization of a novel greb1 knockout mouse model
Hnatyszyn HJ, Rodriguez C, Herbert L, Olson R, Lippman ME. 
University of Miami, Miami, FL. 
p5-01-16  the Detection of Circulating Ck19 mrna-positive Cells in 
the blood and the mitotic index of the primary tumor have 
independent prognostic value in early breast Cancer
Tryfonidis K, Perraki M, Apostolaki S, Kafousi M, Agelaki S, 
Georgoulias V, Stathopoulos EN, Mavroudis D. University General 
Hospital of Heraklion, Heraklion, Crete, Greece; School of Medicine, 
University of Crete, Heraklion, Crete, Greece. 
p5-01-17  her2 amplification in primary tumor: a potential marker for 
presence of Circulating tumor Cells in inflammatory breast 
Cancer patients?
Bhattacharyya A, Krishnamurthy S, Lodhi A, Hall C, Anderson A, 
Jackson S, Ueno N, Bedrosian I, Kuerer H, Lucci A. University of Texas 
MD Anderson Cancer Center, Houston, TX. 
p5-01-18  identification of pax6 as a human breast Cancer-testis 
antigen
Yang M, Wang Y. The First Hospital of Jilin University, Changchun, 
JILin, China; Jilin University, Changchun, JILin, China. 
p5-01-19  endothelin-1 expression in breast Cancer tissue, Surrounding 
Stroma, Correlation with tumor microvessel Density and 
Clinical outcome
Tamkus D, Wiese D, Sikorskii A, Chivu S, Peddi P, Chitneni S. Michigan 
State University (MSU); McLaren Regional Medical Center (MRMC). 
tumor Cell biology: Cellular mechanisms
p5-02-01  erbb4 ectodomain as a biomarker and a potential therapeutic 
target for breast Cancer
Hollmen M, Liu P, Wildiers H, Reinvall I, Vandorpe T, Smeets A, 
Deraedt K, Vahlberg T, Joensuu H, Leahy D, Schoffski P, Elenius K. 
University of Turku, Turku, Finland; Johns Hopkins University School 
of Medicine, Turku, Finland; University Hospitals Leuven, Belgium; 
University of Turku, Finland; Helsinki University Hospital, Helsinki, 
Finland. 
p5-02-02  Divergent effects of Zoledronate and Denosumab on Cellular 
interactions between osteoblasts and breast Cancer Cells
Kaiser T, Teufel I, Wallwiener D, Klein G, Fehm T. Medical University 
Hospital of Tuebingen, Tuebingen, Germany; Center for Medical 
Research, University of Tuebingen, Tuebingen, Germany. 
CTRC-AACR San Antonio Breast Cancer Symposium
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p5-06-07  the mechanisms of autophagy involved in the effects of 
everolimus (raD001) on overcoming multidrug resistance of 
breast Cancer Cell line mCF-7/aDr
Liu Z-B, Hou YF, Xu W-H, Ling H, Shao Z-M. Breast Cancer Institute, 
Shanghai, China. 
p5-06-08  mesenchymal Stem Cells and Carcinoma-associated 
Fibroblasts Sensitize breast Cancer Cells in 3D Cultures to 
kinase inhibitors
Dittmer J, Dittmer A, Oerlecke I, Leyh B, Martens JWM, Thomssen C. 
Clinic for Gynecology University Halle, Germany; Erasmus University 
Medical Center. 
p5-06-09  acquired Sensitivity to trail mediated apoptosis in lapatinib 
resistant Skbr3 Cells
Eustace AJ, Browne BC, McDermott M, Gallagher C, Watson W, 
Crown J, O’Donovan N. Dublin City University, Dublin, Ireland; 
University College Dublin, Dublin, Ireland; St. Vincents University 
Hospital, Dublin, Ireland. 
p5-06-10  leptin Signaling impacts notch and Wnt Crosstalk in breast 
Cancer
McGlothen TZ, Gillespie C, Colbert L, Blaylock-Hogans D. Morehouse 
School of Medicine, Atlanta, GA; Spelman College, Atlanta, GA. 
p5-06-11  Quercetin-3-methyl ether inhibits lapatinib-Sensitive and 
lapatinib-resistant breast Cancer Cell growth by inducing 
g2/m arrest and apoptosis
Bode AM, Li J, Zhu F, Normanno NE, Ericson ME, Lubet RA. University 
of Minnesota, Austin, MN; INT-Fondazione Pascale, Naples, Italy; 
University of Minnesota, Minneapolis, MN; National Cancer Institute, 
Rockville, MD. 
tumor Cell biology: tumor Cell and molecular biology – other
p5-07-01  novel alternative Splice variants of her2 in invasive breast 
Cancer
Assam EE, Rhodes A, Ladomery M, Harries L, Sohail M. University of 
the West of England, Bristol, Gloucestershire, United Kingdom; Royal 
Devon and Exeter NHS Foundation Trust Hospital, Exeter, Devon, 
United Kingdom; United Hospitals Bristol Foundation Trust, Bristol, 
Gloucestershire, United Kingdom. 
p5-07-02  Could the Combination of CoX-2 inhibitor and Calcitriol be a 
new Chemopreventive approach to Decrease the incidence of 
breast Cancer?
Thill M, Cordes T, Fischer D, Hoellen F, Friedrich M, Diedrich K, 
Dittmer C. University Hospital Schleswig-Holstein, Campus Luebeck, 
Luebeck, Germany; Helios Klinikum Krefeld, Krefeld, Germany. 
p5-07-03  modulation of autophagic activity by extracellular ph
Xu T, Su H, Ganapathy S, Yuan Z-M. University of Texas Health 
Science Center at San Antonio, San Antonio, TX. 
p5-07-04  is α-l-Fucose overexpressed on Cells of aggressive human 
breast Cancers?
Listinsky JJ, Siegal GP, Listinsky CM. University of Alabama at 
Birmingham, Birmingham, AL; Case Western Reserve University, 
Cleveland, OH. 
p5-07-05  hypoxic mammary epithelial Cells in three-Dimensional 
Culture Develop a Cancer-like phenotype
Vaapil M, Helczynska K, Påhlman S, Jögi A. Lund University, Sweden. 
p5-07-06  effect of angiotensin-(1-7) and angiotensin ii on t47D breast 
Cancer Cells in the proliferation and camp production
Correa-Noronha SSAA, Noronha SMR, Alecrim C, Shimuta SI, Nakaie 
CR, Gebrim LH, Nazario ACP, Silva IDCG. UNIFESP, São Paulo, SP, 
Brazil. 
p5-07-07  Follistatin Suppresses in vitro growth of breast Cancer Cells 
and its reduced expression in breast Cancer associated with 
poor Differentiation and prognosis
Ye L, Mansel RE, Jiang WG. Cardiff University School of Medicine, 
Cardiff, United Kingdom. 
p5-05-03  the effect of breastfeeding on molecular Characteristics of 
invasive breast Cancer
Ellsworth RE, Valente AL, Kane JL, Shriver CD. Henry M. Jackson 
Foundation, Windber, PA; Windber Research Institute, Windber, PA; 
Walter Reed Army Medical Center, Washington, DC. 
p5-05-04  tamoxifen-induced apoptosis is Compromised by bisphenol-a 
and methylparaben exposure
Goodson III WH, Luciani MG, Sayeed A, Jaffee I, Moore II DH, 
Dairkee SH. California Pacific Medical Center Research Institute, San 
Francisco, CA; Kimmel Cancer Center, San Francisco, CA; California 
Pacific Medical Center, San Francisco, CA; University of California, San 
Francisco, CA. 
p5-05-05 human papiloma virus identification in intraductal papilloma 
and breast Cancer using broad-Spectrum primers
Balci FL, Bender O, Coskun F, Duzgun AP, Saylam B, Yuney E, Rota S, 
Fidan I, Feldman S, Soran A. Numune Training and Research Hospital, 
Ankara, Turkey; Okmeydani Training and Research Hospital, Istanbul, 
Turkey; Gazi University School of Medicine, Turkey; Columbia 
University College of Physicians and Surgeons, New York; University 
of Pittsburgh, Magee-Womens Hospital, Pittsburgh. 
p5-05-06 Dysregulation in the transport of iron and haem is implicated 
in the aetiopathogenesis of breast Cancer
Roe T, Hoar F, Tselepis C. University of Birmingham, Birmingham, 
United Kingdom; City Hospital, Birmingham, United Kingdom. 
p5-05-07  the msp1 polymorphism of Cytochrome p-450 Cyp1a1 in 
asymptomatic Women with breast Cysts
Fenile R, Nazario A, Facina G.  Federal University of Sao Paulo, Sao 
Paulo, SP, Brazil.
tumor Cell biology: Drug resistance
p5-06-01  gene expression analysis of resistance to bevacizumab in a 
vegF-reinforced Xenograft model of er-positive breast Cancer
Gökmen-Polar Y, Toroni RA, Goswami C, Sanders KL, Mehta R, 
Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW. 
Indiana University School of Medicine, Indianapolis, IN; University of 
Medicine and Pharmac, La Jolla, CA. 
p5-06-02  response and acquired resistance of brCa1-Deficient triple-
negative breast Cancer Xenografts to alkylators or parp 
inhibitors
ter Brugge P, van der Burg E, Kristel P, Boon U, Moutinho Freixas 
C, Esteller M, Hogervorst F, Gevensleben H, Turner N, Wesseling J, 
Jonkers J. Netherlands Cancer Institute, Amsterdam, Netherlands; 
Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; 
Gene function, Breakthrough breast cancer research centre, London, 
UK. 
p5-06-03  gene expression associated with breast Cancer primary and 
Secondary resistance to neoadjuvant Chemotherapy
Fujiki FK, Katayama MLH, Brentani H, Carraro DM, Abreu APS, 
Barros Filho MC, Oliveira CT, Caldeira JRF, Góes JCS, Brentani MM, 
Folgueira MAK. Faculdade de Medicina da Universidade de Sao 
Paulo, Sao Paulo, Brazil; Faculdade de Medicina da USP, Sao Paulo, 
Brazil; Hospital do Cancer A.C. Camargo, Sao Paulo, Brazil; Instituto 
Brasileiro de Controle do Cancer, Sao Paulo, Brazil; Hospital do 
Câncer A.C. Camargo, Sao Paulo, Brazil; Hospital Amaral Carvalho, 
Jau, Sao Paulo, Brazil. 
p5-06-04  mechanisms of acquired resistance to insulin-like growth 
Factor 1 receptor inhibitor in mCF-7 breast Cancer Cell line
Ekyalongo RC, Mukohara T, Kataoka Y, Kiyota N, Fujiwara Y, Minami 
H. Kobe University Graduate School of Medicine, Kobe, Japan; Kobe 
University Hospital Cancer Center, Kobe, Japan. 
p5-06-05  Withdrawn 
p5-06-06  the rna binding protein FuS is a potential marker for breast 
Cancer progression and therapy response
Brooke GN, Bevan CL, Rudraraju B, Palmieri C. Imperial College 
London, London, United Kingdom. 
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p5-09-06  breast cancer detection through metabolic fingerprint in 
blood
Baeten K, De Jonge E, Smeets A, Van Limbergen E, Christiaens 
M-R, Adriaensens P, Stinissen P, Wildiers H.  Hasselt University, 
Diepenbeek, Limburg, Belgium; Multipdisciplinary Breast Centre, 
Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium; Multidisciplinary 
Breast Centre, University Hospitals Leuven, Leuven, Vlaams-Brabant, 
Belgium.
Detection and Diagnosis: imaging and Screening: radiology – tumor 
monitoring
p5-10-01  metabolic pharmacodynamic effect evidenced by 18FDg-pet 
as a tool for early prediction of iniparib efficacy in metastatic 
triple negative breast Cancer (mtnbC): a proof of Concept 
Study
Kerrou K, Gligorov J. Eastern Paris University Hospitals, APHP Tenon, 
Paris, France; Eastern Paris University Hospitals, APHP Tenon - APREC, 
Paris, France. 
p5-10-02  relevance of magnetic resonance imaging to predict Disease-
Free Survival after neoadjuvant Chemotherapy of breast 
Cancer
Loo CE, Vrancken Peeters M-JTFD, Wesseling J, Gilhuijs KGA. NKI-AVL 
(Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital), 
Amsterdam, Netherlands; University Medical Centre Utrecht, Utrecht, 
Netherlands; NKI-AVL, Amsterdam, Netherlands. 
Detection and Diagnosis – pathology: Diagnostic pathology
p5-11-01  the accuracy of preoperative ultrasonography guided 
vacuum-assisted breast biopsy in Determining histological 
type, er Status, pgr Status, her2 Status and ki67 level in 
invasive breast Cancer
Fujita T, Sawaki M, Hattori M, Kondo N, Horio A, Ushio A, Gondo N, 
Adachi E, Iwata H. Aichi Cancer Center Hospital, Nagoya, Japan. 
p5-11-02  prediction of results of mammaprint’s 70 gene Signatures by 
Conventional histopathological and biological approaches in 
patients with breast Cancer
Moinfar F, Luschin-Ebengreuth G, Tsybrovskyy O, Regitnig P, 
Mannweiler S, Ratschek M, Bjelic-Radisic V, Pristauz-Telsnigg G, Bader 
A, Seitz G. Medical University of Graz; Sozialstiftung Bamberg. 
p5-11-03  real-time imaging of human breast tissue with reflectance 
Confocal microscopy: Correlation with routine pathology
Fogarty SP, Shiffert MT, Berezowski K, Hartmann D, Cabrera MC, 
Sidawy MK, Furth PA, Liu MC. Georgetown University, Washington, 
DC. 
p5-11-04  Withdrawn 
p5-11-05  measurement of neoadjuvant Chemotherapy tumor response 
in locally advanced breast Cancer by three methodologies. 
Correlation with overall Survival
Garcia-Saenz JA, Romero A, Lopez Garcia-Asenjo JA, Roman JM, 
Moreno A, Fuentes M, Furio V, Pelayo A, Diaz-Rubio E, Caldes 
T, Martin M. Hospital Clinico San Carlos, Madrid, Spain; Hospital 
Principe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital 
Gregorio Marañon, Madrid, Spain. 
p5-11-06  immunohistochemistry Discordance between primary and 
recurrent tumors in breat Cancer. analysis of potential 
influence of technique bias by Comparing test-results under 
two Different Conditions
Perez-Fidalgo J-A, Ferrer J, Bosch A, Burgués O, Martinez M, Eroles P, 
Bermejo B, Pons V, Lluch A. Hospital Clinico Universitario, Valencia, 
Spain. 
p5-11-07  receptor Concordance in triple-negative breast Cancer (tnbC) 
recurrences
Killian ME, De Los Santos JF, Forero-Torres A, Krontiras H. University 
of Alabama at Birmingham, Birmingham, AL. 
p5-07-08  pomegranate extract targets mirna-27a and mirna-155 in 
the reduction of inflammation and cell growth in er+ breast 
cancer in vitro and vivo
Mertens-Talcott SU, Banerjee N, Safe S, Talcott S.  Texas A&M 
University, College Station, Texas; Texas A&M Health Science Center, 
College Station, Texas.
Detection and Diagnosis – imaging and Screening: breast imaging – 
mammography
p5-08-01  Quantitative analysis of Strain ratio of microcalcification 
lesions with Surgical Specimen mammography
Hung S-H, Chen R-C, Wu Y-T, Chen T, Lin C-H. Taipei City Hospital, 
Taiwan; National Yang- Ming University, Taiwan. 
p5-08-02  mammographic breast texture predicts benign biopsy results 
and Composition
Duewer FW, Kerlikowske K, Tlsty T, Fan B, Parvin B, Ma L, Shepherd J. 
UCSF, San Francisco, CA; LBNL, Berkeley, CA. 
p5-08-03  how reader’s training, Software, and image Formats impact 
percent Dense area measures
Fan B, Duewer F, Wu F, Kerlikowske K, Vachon C, Shepherd JA. 
University of California San Francisco, San Francisco, CA; Mayo Clinic 
College of Medicine, Rochester, MN. 
p5-08-04  mammographic microcalcifications and breast Cancer 
tumorigenesis: a radiologic-pathologic analysis
Naseem M, Murray J, Hilton JF, Han D, Hogeveen S, Heersink 
RL, Muradali D, Simmons C, Bell D, Haq R, Brezden-Masley C. St. 
Michael’s Hospital, Toronto, Canada; University of Toronto, Toronto, 
Canada. 
p5-08-05 Withdrawn
p5-08-06  Comparison of mammographic Density between Ductal 
Carcinoma in Situ and benign breast Disease
Cho JY, Shin EJ, Lee JW, Kim HJ, Koh BS, Yu JH, Son BH, Ahn SH, Shin 
HJ. Asan Medical Center, Seoul, Korea.   
Detection and Diagnosis – imaging and Screening: Screening
p5-09-01  breast Cancer annual Screening program núcleo mama porto 
alegre (nmpoa): imaging results after Seven years
Caleffi M, Amaral C, Zignani J, Graudenz M, Duarte Filho D. Hospital 
Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil. 
p5-09-02  reducing excess biopsies: improving Screening through risk 
Stratification and new thresholds for intervention
Kim DN, Kim J-H, Flowers CI, Elias S, Moore DH, Esserman LJ. Athena 
Breast Health Network, San Francisco, CA; Moffitt Cancer Center, 
Tampa, FL; University Medical Center Utrecht, Utrecht, Netherlands; 
University of California, San Francisco, CA. 
p5-09-03  health literacy affects use of Screening mammography in an 
underinsured population
Komenaka IK, Nodora J, Hsu C-H, Machado L, Klemens AE, Zenuk 
R, Bouton ME, Martinez ME, Weiss BD. Maricopa Medical Center, 
Phoenix, AZ; University of Arizona, Tucson, AZ. 
p5-09-04  predictors of malignancy and Surgical outcomes Following 
indeterminate Core needle biopsy in the british breast 
Screening programme
Gillespie HS, Lowry K, Somerville J, McIntosh SA. University of 
Aberdeen, Foresterhill, Aberdeen, Aberdeenshire, Scotland, United 
Kingdom; Belfast City Hospital, Belfast, County Down, United 
Kingdom. 
p5-09-05  non-palpable lesions Findings in a breast Cancer 
opportunistic Screening in South brazil
Rockenbach R, Rombaldi RL, Caleffi M. HospitaL Geral, Caxias do Sul, 
Rio Grande do Sul, Brazil; Hospital Moinhos de Vento, Porto Alegre, 
Rio Grande do Sul, Brazil. 
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p5-11-17  evaluating tumor heterogeneity in immunohistochemistry 
Stained breast Cancer tissue
Potts SJ, Landis N, Eberhard DA, Schmechel SC, Young D, Lange 
H. Flagship Biosciences, Flagstaff, AZ; University of North Carolina, 
Chapel Hill, NC; University of Minnesota, Minneapolis, MN. 
Detection and Diagnosis – pathology:  Detection and Diagnosis – other
p5-12-01  aromatase inhibitor Specific metastasis is Driven by the 
Steroid receptor Coactivator SrC-1
Theissen SM, McBryan J, Byrne C, Hughes E, Cocchiglia S, Hill AD, 
Young LS. Royal College of Surgeons in Ireland, Dublin 2, Ireland. 
p5-12-02  vacuum assisted biopsies of Ductal Carcinoma in Situ and 
Concordance with post-operative histology: implications for 
the low risk DCiS trial
Soumian S, Down SK, Roked F, Chaudhri S, Francis A. Queen 
Elizabeth Hospital, University Hospitals Birmingham, Birmingham, 
England, United Kingdom. 
p5-12-03  an innovative Quantification method for tamoxifen and three 
metabolites in Formalin-Fixed paraffin-embedded tissues by 
liquid Chromatography and tandem mass Spectrometry
Magliocco AM, Ng ES, Kangarloo B, Konno M, Paterson A. Tom Baker 
Cancer Centre, Calgary, AB, Canada; University of Calgary, Calgary, 
AB, Canada. 
p5-12-04  genetic linkage between acquired and primary lymphedema 
evaluated through Whole exome Sequencing and nir 
Fluorescence lymphatic imaging
Sevick-Muraca EM, Gonzalez-Garay ML, Fife CE, Guilliod R, Hall O, 
Marshall MV, Rasmussen JC, Aldrich MB, Darne C, Zhu B, Tan I-C, 
Caskey CT. University of Texas Health Science Center, Houston, TX; 
Memorial Hermann Hospital, Houston, TX. 
p5-12-05  (in-)efficiencies in the preoperative imaging evaluation of the 
medicare breast Cancer patient
Bleicher RJ, Ruth K, Sigurdson ER, Evers K, Wong Y-N, Boraas M, 
Egleston BL. Fox Chase Cancer Center, Philadelphia, PA. 
p5-12-06  gastrointestinal metastatis of invasive lobular breast 
carcinoma: brazilian Cancer institute review from march 2004 
to april 2009
De Mello Goncalves Pinheiro LM, Cardozo FP, Nagime M, Esteves JM, 
De Lima CFF, Carmo PA.  Brazilian National Cancer Institute, Rio de 
Janeiro, Rio de Janeiro, Brazil.
p5-12-07  physicians’ call to use mammary ductoscopy in patients 
without spontaneous nipple discharge
Xu Z, Dou T-H, Wu S, Xing H, Song C, Dou C.  Norman Bethune 
Medical School,Jilin University, Changchun, Jilin Province, China; 
Dehui County Hospital, Dehui, Jilin Province, China; Indiana 
University, Indianapolis, IN; Georgia University System/Georgia 
Gwinnett College, Lawrenceville, GA. 
prognosis/response predictions: response predictions – ii
p5-13-01  Survival outcome with bevacizumab: activation of the 
phosphatidylinositol-3 kinase (pi3k) pathway Due to pik3Ca 
mutations or pten loss makes a Difference
Vidal M, Di Cosimo S, Torrejon D, Saura C, Gómez-Pardo P, Pérez-
Garcia J, Muñoz-Couselo E, Bellet M, Sanchez-Olle G, De Mattos-
Arruda L, Oliveira M, Tabernero J, Baselga J, Cortes J. Vall d’Hebron 
Institute of Oncology, Vall d’Hebron University Hospital, Universitat 
Autònoma de Barcelona, Barcelona, Spain; Massachusetts General 
Hospital Cancer Center. Harvard Medical School, Boston. 
p5-13-02  prediction of Dasatinib Sensitivity of breast Cancer based on a 
novel tyrosine kinase-activity profiling assay
Kawai M, Torikoshi Y, Notoya M, Gohda K, Ueno NT, Ishihara H. 
Sysmex Corporation, Kobe, Hyogo, Japan; The University of Texas MD 
Anderson Cancer Center, Houston, TX. 
p5-11-08  high Concordance of 5 her2 in Situ hybridization methods 
with abbott FiSh
Boers JE, Netjes C, Meeuwissen HC, Prinsen C, Bart J, van der Logt 
EMJ, Schuuring E. Isala Klinieken, Zwolle, Netherlands; University 
Medical Center, Groningen, Netherlands. 
p5-11-09  high Concordance for microarray based Determination of er, 
pr and her2 receptor Status and local ihC/FiSh assessment 
Worldwide in 749 patients
Wesseling J, Cusumano G, Tinterri C, Sapino A, Zanconati F, Lutke-
Holzik M, Nguygen B, Deck K, Querzoli P, Perin T, Giardina C, Seitz 
G, Guinebretiere J, Barone J, Watanabe T. Netherlands Cancer 
Institute, Amsterdam, Netherlands; CHC, Liege, Belgium; Instituto 
Clinico Humanitas, IRCCS, Rozzano, Italy; Universita di Torino, Torino, 
Italy; Università di Trieste, Trieste, Italy; Medisch Spectrum Twente, 
Enschede, Netherlands; Locg Beach Memorial Health Care, Loch 
Beach, CA; Saddleback Memorial Medical Center, Laguna Hills, CA; 
Instituto di Patologia, Universita di Ferrara, Ferrara, Italy; Centro 
di Riferimento Oncologico, Aviano, Italy; Instituto di Anatomia 
Patologica, Iniverstita degli Studi di Bari, Bari, Italy; Klinikum 
Bamberg, Bamberg, Germany; Centre Rene Huguenin, Saint-Cloud, 
France; Comprehensive Breast Care and Sharp Memorial Hospital, 
San Diego, CA; Hamamatsu Oncology Center, Hamamatsu, Japan. 
p5-11-10  reproducibility and robustness of the FDa approved inForm 
her2 Dual iSh Dna probe Cocktail assay
Loftin IR, McElhinny AS, Miller R, Garcia C, Bai I, Ranger-Moore J, 
Ostrem J, Padilla M, Grogan T. Ventana Medical Systems, Inc., Tucson, 
AZ. 
p5-11-11  automated Quantification methods improve the accuracy of 
pr as an independent prognostic Factor in tamoxifen treated 
breast Cancer patients
Klimowicz AC, Kornaga EN, Yau A, Pohorelic BK, Petrillo SK, Konno 
M, Magliocco AM. Tom Baker Cancer Centre, Calgary, AB, Canada; 
University of Calgary, Calgary, AB, Canada. 
p5-11-12  Correlation of ki67 expression between initial biopsy and 
Surgical Specimen in untreated breast Cancer patients. Does 
menstrual Cycle matter?
Torrejón D, Rubio I, Sanchez-Olle G, Peg V, Sansano I, Jimenez 
J, Gomez P, De la Peña L, Di Cosimo S. Vall d’Hebron University 
Hospital, Barcelona, Spain; Solti Breast Cancer Research Group. 
p5-11-13  rates of upgrade to malignancy for 271 Cases of atypical 
Columnar Cell hyperplasia Diagnosed by breast Core biopsy
Peres A, Barranger E, Becette V, Boudinet A, Guinebretiere J-M, 
Cherel P. Lariboisiere Hospital, Paris, France; Institut Curie, Saint-
Cloud, France. 
p5-11-14  Flat epithelial atypia of the breast: a Single institution 
experience
Joh JE, Acs G, Kiluk JV, Laronga C, Khakpour N, Lee MC. H. Lee Moffitt 
Cancer Center & Research Institute, Tampa, FL. 
p5-11-15  Should her-2 Score 0/1+ breast Cancer Cases be retested by 
in-Situ hybridisation? results of a multicenter retesting Study
Reiner-Concin AM, Lax S, Regitnig P, Kronberger C, Jasarevic Z, 
Bogner S. Danube Hospital, Vienna, Austria; General Hospital Graz 
West, Graz, Austria; Medical University Graz, Graz, Austria; LKH 
Salzburg, Salzburg, Austria; LHK Feldkirch, Feldkirch, Austria; LKH 
Linz, Linz, Austria. 
p5-11-16  CD44 and CD24 expression in Ductal invasive breast 
Carcinomas, Classified by molecular Subtypes and its 
association with prognostic Factors
Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Soares FA, Maciel 
MdS, Brentani MM. Hospital AC Camargo, São Paulo, Brazil; 
Universidade Federal de São Paulo, São Paulo, Brazil; Faculdade de 
Medicina da Universidade de São Paulo, São Paulo, Brazil; Hospital 
A.C. Camargo, São Paulo, Brazil. 
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p5-13-10  Discordance of estrogen receptor and her-2/neu Status Can 
be Seen between First and Subsequently biopsied metastatic 
lesions in breast Cancer
Lower EE, Kennedy D. Oncology Hematology Care, Cincinnati, OH. 
p5-13-11  pten and tau-protein expression: predictive value of poor 
response to trastuzumab plus paclitaxel in patients with 
her2-positive breast Cancer
Koo DH, Ahn J-H, Yoon DH, Kim S-B, Lee HJ, Kong KY, Son BH, Ahn 
SH, Jung KH. Asan Medical Center, University of Ulsan College of 
Medicine, Seoul, Korea. 
p5-13-12  Can the ki67 proliferation index predict the oncotype DX 
recurrence Score in lymph node negative, er positive breast 
Cancer?
Prendergast A, Martin K, Doolan P, Clarke C, Clynes M, Evoy D, 
McDermott E, Crown J, Kennedy S. Dublin City University, Dublin, 
Ireland; Conway Institute of Biomolecular and Biomedical Research, 
University College Dublin, Dublin, Ireland; St. Vincent’s University 
Hospital, Dublin, Ireland. 
p5-13-13  the role of topoisomerase iiα in predicting Sensitivity to 
anthracyclines in breast Cancer patients: a meta-analysis of 
published literatures
Lu J, Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z. Shanghai 
Cancer Center, Fudan University, Shanghai, China; Shanghai Medical 
College, Fudan University, Shanghai, China. 
p5-13-14  Drug-metabolizing enzyme polymorphisms and Clinical 
outcome of anthracycline-based Chemotherapy in Chinese 
han breast Cancer patients
Tang J, Zhao J, Wu J, Ji M, Zhong S. Jiangsu Cancer Hospital, Nanjing, 
Jiangsu, China. 
p5-13-15  proteomic identification of predictive biomarkers of 
resistance to neoadjuvant Chemotherapy in luminal breast 
Cancer: a possible role for 14-3-3 and biD?
Hodgkinson VC, ELFadl D, Agarwal V, Garimella V, Drew PJ, Lind 
MJ, Cawkwell L. University of Hull, Hull, United Kingdom; Castle 
Hill Hospital, Hull, United Kingdom; Hull York Medical School, Hull, 
United Kingdom. 
p5-13-16  reduction in pet uptake-value is an early predictor for 
response to neoadjuvant therapy including anthracycline 
and taxane in Stage ii-iiia breast
Lao Romera J, Puértolas Hernandez T, Godoy Molias A, Alvarez 
Alejandro M, Madani Perez J, Garcia Mur C, Ubieto MA, Cebollero 
de Miguel A, Artal Cortes A, Anton Torres A. Hospital Universitario 
Miguel Servet, Zaragoza, Spain; Clinica Quirón, Zaragoza, Spain. 
p5-13-17  multigene Signature assays in patients with early-Stage 
breast Cancer (eSbC) receiving neoadjuvant Chemotherapy: 
an nCi-Funded Systematic review and evidence Summary of 
predictive performance
Lyman GH, Culakova E, Poniewierski MS, Huang M, Barry W, Ginsburg 
G, Abernethy A, Marcom PK, Ready N, Kuderer NM. Duke University 
School of Medicine, Durham, NC; Duke University, Durham, NC. 
p5-13-18  a Study of the usefulness of tumor markers Ca 15-3 and tpS 
in monitoring of Different Subgroups of metastatic breast 
Cancer
Lindman H, Al-Musawi S, Nilsson G, Yachnin J. Uppsala University, 
Uppsala, Sweden. 
p5-13-19  borderline estrogen and progesterone receptor expression 
and efficacy of anti-estrogen therapy analyzed by 
Subpopulation treatment effect pattern plot analysis
Luoh S-W, Ramsey B, Park B, Keenan E. Oregon Health and Science 
University, Portland, OR; Portland Veterans Administration Medical 
Center, Portland, OR. 
p5-13-03  Correlation of Clinical and molecular Findings with pathologic 
response to preoperative lapatinib and trastuzumab, 
Separately or in Combination, prior to neoadjuvant 
Chemotherapy for her2 positive breast Cancer
Holmes FA, Espina V, Liotta LA, Chang JC, Nagarwala YX, Danso 
M, McIntyre K, Osborne CR, Krekow LK, Gagnon RC, Mahoney 
JM, O’Shaughnessy JA. US Oncology, The Woodlands, TX; Texas 
Oncology, Houston, TX; George Mason University, Manassas, VA; 
The Methodist Hospital, Houston, TX; GlaxoSmithKline Oncology, 
Collegeville, PA; Virginia Oncology Associates, Virginia Beach, VA; 
Texas Oncology Austin, Austin, TX; Baylor Sammons Cancer Center, 
Dallas, TX; Texas Oncology, Bedford, TX; Texas Oncology, Dallas, TX. 
p5-13-04  Changes in phosphorylation Status at vegFr2 and basal 
tumor hypoxic volume assessed by misonidazol (miSo) 
positron emission tomography (pet/Ct) as potential 
biomarkers for predicting response to bevacizumab in breast 
Cancer
Garcia-Foncilla J, Garcia-Velloso MJ, Dominguez I, Morales S, 
Hernando B, Sanchez R, Alvarez I, Anton A, Illarramendi JJ, De Juan A, 
Martinez P, Lahuerta A, Llombart A, Garcia-Gonzalez M, Lao Romera 
J, Purtolas T, Scherer S, Sabariz L, Lopez-Vega JM, Galve E, Plazaola A, 
Boni V. Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; 
Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital 
Miguel Servet; josejuan.illarr@terra.es; Hospital Marques de Valdecilla; 
Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid. 
p5-13-05  non-invasive in vivo 1h magnetic resonance Spectroscopy 
(mrS) monitoring of breast tumor response to igF1r 
targeted therapy
Sachdev D, Lin JE, Lunzer C, Marjanska M, Garwood M, Yee D. 
University of Minnesota, Minneapolis, MN. 
p5-13-06  lipidomic profile predicts pathologic Complete response to 
neoadjuvant Weekly paclitaxel treatment
Facina G, Calux NMCT, Silva MFR, Bonetti TCS, Nazario ACP, Silva 
IDCG. Federal University of Sao Paulo, Sao Paulo, Brazil. 
p5-13-07  met and hepatocyte growth Factor (hgF) increased gene 
Copy number is associated to trastuzumab Failure in her2 
positive metastatic breast Cancer (mbC)
Minuti G, Duchnowska R, Jassem J, Roncalli M, O’Brien T, Fabi 
A, Landi L, Di Marsico R, Biernat W, Czartoryska-Arlukowicz B, 
Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczynska-Kloda M, 
Tempinska-Szalach A, Rossi E, Varella-Garcia M, Cappuzzo F. Istituto 
Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military 
Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, 
Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, 
Italy; Laboratory of Molecular Pathology, University of Colorado 
Cancer Center, Denver, CO; National Cancer Institute Regina Elena, 
Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; 
Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, 
Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria 
Oncology Center, Olsztyn, Poland; West Pomeranian Oncology 
Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA 
Interuniversity Consortium, Bologna, Italy. 
p5-13-08  breast Cancer index predicts likelihood of breast Conservation 
Surgery after neoadjuvant Chemotherapy
Mazouni C, Mathieu M-C, Kesty NC, Zhang Y, Scott V, Schnabel CA, 
Erlander MG, Delaloge S, Andre F. Institut Gustave Roussy, Villejuif, 
France; bioTheranostics, Inc, San Diego, CA. 
p5-13-09  Correlation of oncotype DX recurrence Scores with 
pathologic response Following neoadjuvant ixabepilone and 
Cyclophosphamide in patients with her2-negative breast 
Cancer: a Sarah Cannon research institute phase ii trial
Yardley DA, Peacock NW, Hendricks C, Huh SY, Ketchum S, Chao C, 
Yoshizawa C, Burris III HA, Hainsworth JD. Sarah Cannon Research 
Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; 
Center for Cancer and Blood Disorders, Bethesda, MD; Providence 
Medical Group, Terre Haute, IN; Mercy Hospital, Portland, ME; 
Genomic Health, Redwood City, CA. 
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p5-14-05  anti-müllerian hormone (amh) levels in premenopausal 
breast Cancer patients treated with adjuvant Chemotherapy - 
a translational research project of the SuCCeSS Study
Neugebauer JK, Rack BK, Kupka M, Dinkel C, Schneeweiss A, 
Schrader I, Tesch H, Rezai M, Söling U, Friese K, Beckmann MW, 
Janni W, Müller V. Ludwig-Maximilians-Universität, Munich, 
Germany; University Hospital Heidelberg, Heidelberg, Germany; 
Henriettenstiftung Hannover, Hannover, Germany; Fachpraxis für 
Onkologie, Frankfurt, Germany; Luisenkrankenhaus Duesseldorf, 
Duesseldorf, Germany; Gemeinschaftspraxis Siehl&Söling, Kassel, 
Germany; University Hospital Erlangen, Erlangen, Germany; Heinrich-
Heine-Universität, Duesseldorf, Germany; University Medical Center, 
Hamburg-Eppendorf, Germany. 
p5-14-06  interaction between Stoma and tumor Characteristics as a 
new prognostic and predictive marker in breast Carcinomas
Tagliabue E, Sandri M, Casalini P, Aiello P, Pupa SM, Orlandi R, Balsari 
A, Triulzi T. Fondazione IRCCS- Istituto Nazionale dei Tumori, Milan, 
Italy; University of Milan, Milan, Italy. 
p5-14-07  Withdrawn
p5-14-08  impact of progesterone receptor Semiquantitative 
immunohistochemical result on oncotype DX® recurrence 
Score: a Quality assurance Study of 1078 Cases
Bhargava R, Dabbs DJ. Magee-Womens Hospital of UPMC, 
Pittsburgh, PA. 
p5-14-09  Withdrawn
p5-14-10  ethnic Differences in the association between tumor Size and 
lymph node Status among breast Cancer patients in South 
east asia
Saxena N, Verkooijen HM, Bhoo Pathy N, Siew EL, Iau P, Lee SC, 
Yip CH, Hartman M. National University of Singapore, Singapore, 
Singapore; University Medical Center Utrecht, Utrecht, Netherlands; 
Julius Center University of Malaya, Kuala Lumpur, Malaysia; National 
University Cancer Institute, National University Health Systems, 
Singapore, Singapore; Faculty of Medicine, University of Malaya 
Medical Center, Kuala Lumpur, Malaysia. 
p5-14-11  elevated Serum Ferritin predicts reduced progression-Free 
and overall Survival in trastuzumab-treated metastatic breast 
Cancer
Alkhateeb AA, Connor J, Leitzel K, Ali S, Campbell-Baird C, Evans M, 
Koestler W, Fuchs E-M, Lipton A. The Pennsylvania State University 
Hershey Medical Center, Hershey, PA; Lebanon VA Medical Center, 
Lebanon, PA; Medical University of Vienna, Vienna, Austria. 
p5-14-12  bayesian belief network mortality analysis of a breast Cancer 
registry Data Set
Eberhardt JS, Hyslop T, Hu H, Rui H. DecisionQ Corporation, 
Washington, DC; Thomas Jefferson University, Philadelphia, PA; 
Windber Research Institute, Windber, PA. 
p5-14-13  Favorable prognosis in patients with t1a,b node-negative 
triple negative breast Cancers treated with multimodality 
therapy
Ho AY, Gupta G, Perez CA, King TA, Patil SM, Rogers KH, Brogi E, 
Morrow M, Hudis C, Traina T, McCormick B, Powell SN, Robson ME. 
Memorial Sloan Kettering Cancer Center, New York, NY. 
p5-14-14  the presence of a Fibrotic Focus adds Significant prognostic 
information to the prognostic 76-gene relapse Score in 
lymph node negative breast Cancer
Van den Eynden GG, Van Laere SJ, Smid M, Martens JW, Foekens 
JA, Vermeulen PB, Dirix LY. Augustinus Hospital, Antwerp, Belgium; 
Erasmus Medical Center Rotterdam, Rotterdam, Netherlands. 
p5-13-20  top2a amplification have associated with response to 
anthracycline-based preoperative Chemotherapy in primary 
breast Cancer
Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Zhao L. Cancer Hospital, 
Chinese Academy of Medical Science, Beijing, China. 
p5-13-21  japanese patients with Discordance in estrogen receptor 
between primary breast Cancer and recurrent tumor have a 
poorer outcome
Tanaka K, Kawaguchi H, Kuba S, Koga C, Nishimura S, Yoshiyama 
T, Ishida M, Nakamura Y, Ohno S. National Kyushu Cancer Center, 
Fukuoka, Japan. 
p5-13-22  gene expression profiles predict pathological Complete 
response to Standard neoadjuvant Fluorouracil, Doxorubicin, 
and Cyclophosphamide and paclitaxel with or without 
trastuzumab in early breast Cancer
Tamura K. National Cancer Center Hospital, Tokyo, Japan. 
p5-13-23  individualized treatment Strategies for her2-negative breast 
Cancer Subtypes
Ishikawa T, Shimizu D, Yamada A, Sasaki T, Morita S, Tanabe M, 
Kawachi K, Nozawa A, Chishima T, Kimura M, Ichikawa Y, Endo I. 
Yokohama City University Medical Center, Yokohama, Kanagawa, 
Japan; Yokohama City University, Yokohama, Kanagawa, Japan. 
p5-13-24  a predictive model of early Systemic Disease relapse after 
Standard adjuvant therapy for breast Cancer
Chen L, Hodskins J, Chokshi S, Croley J, Stevens M, Pasley G, Huller K, 
Reynolds J, Weiss H, Massarweh S. University of Kentucky and Markey 
Cancer Center, Lexington, KY. 
prognosis/response predictions: prognostic and predictive Factors – other
p5-14-01  Differences in efficacy by assessment method: nCiC Ctg 
adjuvant breast Cancer trials ma.5, ma.12, ma.14, ma.21, 
ma.27 meta-analysis
Dong B, Chapman J-AW, Yerushalmi R, Goss PE, Pollak MN, Burnell 
MJ, Bramwell VH, Levine MN, Pritchard KI, Whelan TJ, Ingle JN, 
Parulekar W, Shepherd LE, Gelmon KA. NCIC Clinical Trials Group, 
Queen’s University, Kingston, ON, Canada; Vancouver Cancer Centre-
BCCA, Vancouver, BC, Canada; Harvard Medical School, Boston, MA; 
McGill University, Montreal, QC, Canada; Atlantic Health Sciences 
Corporation, Saint John, NB, Canada; Alberta Cancer Board, Calgary, 
AB, Canada; McMaster University, Hamilton, ON, Canada; University 
of Toronto, Toronto, ON, Canada; Mayo Clinic, Rochester, MN. 
p5-14-02  Clinicopathologic and prognostic Difference of Screen 
Detected breast Cancer Compared with Symptomatic breast 
Cancer
Kim J, Lee SK, Kim S, Koo MY, Choi M-Y, Cho DH, Bae SY, Lee J, Jung 
SP, Lee JE, Yang J-H, Nam SJ. Samsung Medical Center, Seoul, Korea; 
Konkuk University Medical Center, Seoul, Korea. 
p5-14-03  genomic Comparison of paired primary breast Carcinomas and 
macrometastatic lymph node metastases using Quantitative 
rt-pCr by oncotype DX: assessment of the recurrence Score 
and Quantitative Single genes
Boolbol SK, Kirstein L, Harshan M, Klein P, Cohen J-M, Chadha M, 
Baehner FL, Malamud SC. Beth Israel Medical Center, New York, NY; 
Genomic Health Inc., Redwood City, CA. 
p5-14-04  rank expression in primary tumor tissue at the time of 
Diagnosis Correlates with risk of Subsequent bone metastases 
in the i-Spy 1 trial (Calgb 150007/150012; aCrin 6657)
Li J, Moore D, Yau C, Campbell M, Park J, I-SPY-1 TRIAL Investigator, 
Rugo HS. University of California, San Francisco, CA; Cancer and 
Developmental Therapeutics Program, Buck Institute for Age 
Research, Novato, CA. 
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p5-14-23  Clinical outcomes of Different Subtypes Detected by 
immunohistochemistry of early invasive breast Cancers in a 
monoinstitutional Series
Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, 
Aldovini D, Dipasquale M, Galligioni E. S Chiara Hospital, Trento; FBK, 
Trento; S. Chiara Hospital, Trento. 
p5-14-24  the long term prognostic impact of real-time Quantitative 
rt-pCr Detection of Cytokeratin 19 mrna in preoperative 
bone marrow aspirates of early breast Cancer patients
Punie K, Wynendaele W, Clement P, Paridaens R, Christiaens M-R, 
Jacobs B, Wildiers H. University Hospitals Gasthuisberg, Leuven, 
Belgium; Catholic University Leuven, Leuven, Belgium. 
p5-14-25  Disease presentation, treatment, and outcome in young and 
elderly Women with breast Cancer
Yu E, Yu D, Godette K, Mister D, Torres M. Emory University, Atlanta, 
GA. 
p5-14-26  results from a prospective Clinical Study on the impact of 
oncotype DX on adjuvant treatment Decision making in a 
Cohort of 142 uk patients
Holt S, Bertelli G, Brinkworth E, Durrani S, Jones S, Khawaja S, 
Laggner U, Moe M, Pudney D, Pitcher S, Rolles M, Sharaiha Y, Whelan 
S. Prince Philip Hospital, Llanelli, Carmarthenshire, United Kingdom; 
Singleton Hospital, Swansea, West Glamorgan, United Kingdom; 
Bronglais Hospital, Aberystwyth, Ceredigion, United Kingdom. 
p5-14-27  prognostic Factors of node-negative, high risk and 1-3 
positive lymph nodes breast Cancer by intrinsic Subtype in 
patients with adjuvant Chemotherapy
Kojima Y, Hashimoto K, Harano K, Shimizu C, Yunokawa M, Yonemori 
K, Tamura K, Katsumata N, Ando M, Kinoshita T, Fujiwara Y. National 
Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuo-Ku, Japan.
p5-14-28  large weight loss is associated with a higher risk of mortality 
in breast cancer survivors with comorbid conditions
Caan B, Shu X-O, Chen W, Pierce J, Kwan M, Kroenke C, Patterson R, 
Nechuta S.  Division of Research, Kaiser Permanente, Oakland, CA; 
Vanderbilt University, Nashville, TN; Harvard Medical School, Boston, 
MA; University of California, San Diego, San Diego, CA.
psychosocial, Quality of life, and educational aspects: Doctor-patient 
Communication
p5-15-01  Words matter: influence of DCiS Diagnosis terminology on 
patient treatment Decisions
Omer Z, Hwang ES, Esserman LJ, Ozanne EM. University of California, 
San Francisco; Massachusetts General Hospital. 
p5-15-02  patients’ views about how oncologists Should explain 
prognosis in advanced Cancer
Kiely BE, McCaughan G, Christodoulou S, Tattersall MHN, Beale 
P, Grimison P, Stockler MR. University of Sydney, Sydney, NSW, 
Australia; Royal Prince Alfred and Concord Hospitals, Sydney, NSW, 
Australia. 
p5-15-03  Development of a patient Decision aid for Women 70 years 
and older with Stage i, hormonally Sensitive, breast Cancer 
Considering adjuvant treatment post-lumpectomy
Szumacher E, Wong J, D’Alimonte L, Angus J, Paszat L, Metcalfe K, 
Whelan T, Llewellyn-Thomas H. Odette Cancer Centre, Sunnybrook 
Health Sciences Centre, Toronto, ON, Canada; University of Toronto, 
Toronto, ON, Canada; Education Independent Consultant, Toronto, 
ON; Juravinski Cancer Centre, Hamilton, ON, Canada; Women’s 
College Research Institute, Toronto, ON, Canada; Dartmouth Medical 
School, Lebanon, NH. 
p5-15-04  Withdrawn 
p5-14-15  prognostic impact of Chemotherapy-induced amenorrhea 
(Cia) in premenopausal breast Cancer: a meta-analysis of 
published literatures
Lu J, Zhou Q, Yin W. Fudan University Shanghai Cancer Center, 
Shanghai, China. 
p5-14-16  molecular Classification in primary breast Cancer and 
Corresponding lymph node metastasis Show impaired 
prognostic profile in the metastatic node
Falck A-K, Ferno M, Bendahl P-O, Rydén L. Clinical Sciences, Lund, 
Sweden. 
p5-14-17  Stage iv at presentation - are her2 positive tumors 
overrepresented?
Woods R, Yerushalmi R, Speers C, Tydesley S, Gelmon K. BC Cancer 
Agency, Vancouver, BC, Canada. 
p5-14-18  today’s estrogen receptor positive/her-2-neu receptor 
negative breast Cancer patients Do Significantly better than 
yesterday’s estrogen receptor positive breast Cancer patients
Madsen EV, Elias SG, Gobardhan PD, van Oort PM, van der 
Ent FW, Nieweg OE, Valdés Olmos RA, Smidt M, van Dalen 
T. Diakonessenhuis Utrecht, Utrecht, Netherlands; University 
Medical Centre Utrecht, Utrecht, Netherlands; The Netherlands 
Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, 
Netherlands; Maastricht University Medical Centre, Maastricht, 
Netherlands; Orbis Medical Centre, Sittard, Netherlands. 
p5-14-19  ipsilateral breast tumor recurrence prediction with Web-
based normogram in korea
Jung S, Lee SK, Kim S, Koo MY, Choi M-Y, Bae SY, Cho DH, Lee 
J, Kim JK, Yang J-H, Lee JE, Nam SJ. Amsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, Korea; Konkuk 
University Medical Center, Seoul, Korea. 
p5-14-20  neoadjuvant Chemotherapy (nCt) in 466 patients for 
operable breast Cancer: the prognostic value of Sbr grade 
variation
Abrial C, Mouret-Reynier M-A, Wang-Lopez Q, Durando X, Thivat E, 
Raoelfils I, Gimbergues P, Van Praagh-Doreau I, Nabholtz J-M, Chollet 
P, Penault-Llorca F. Jean Perrin Comprehensive Cancer Centre, 
Clermont-Ferrand, France, Metropolitan. 
p5-14-21  predicting the Status of the axillary lymph nodes in 1300 
Consecutive patients with early breast Cancer treated in a 
Single institution
Yoshihara E, Smeets A, Laenen A, Reynders A, Wildiers H, Soens 
J, Paridaens R, Van Ongeval C, Floris G, Moerman P, Neven P, 
Christiaens M-R. Catholic University of Leuven, Leuven, Belgium; 
University Hospitals Leuven, Leuven, Belgium. 
p5-14-22  prospective observational Study to Describe the 
Clinicopathological and biological Characteristics and the 
management of metastatic breast Cancer patients Who 
experienced Complete or partial remission or Disease 
Stabilization during at least 3 years
Zamora P, Pérez-Carrión R, Manso L, Crespo C, Mendiola C, Alvarez-
López I, Margeli M, Bayo-Calero JL, González-Farre X, Santaballa 
A, Ciruelos EM, Afonso R, Lao J, Catalán G, álvarez-Gallego JV, 
Miramón-López J, Salvador-Bofill FJ, Ruiz-Borrego M. Hospital La 
Paz, Madrid, Spain; Hospital Quirón, Madrid, Spain; Hospital 12 de 
Octubre, Madrid, Spain; Hospital Ramón y Cajal, Madrid, Spain; 
Hospital Donostia, San Sebastián, Spain; Hospital Germans Trias 
i Pujol, Badalona, Spain; Hospital Juan Ramón Jiménez, Huelva, 
Spain; Hospital Clinic de Barcelona, Barcelona, Spain; Hospital La Fe, 
Valencia, Spain; Hospital Nuestra Señora de la Candelaria, Santa Cruz 
de Tenerife, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital 
Son Llàtzer, Mallorca, Spain; Complejo Hospitalario de Zamora, 
Zamora, Spain; Hospital Serranía de Ronda, Ronda, Spain; Hospital 
Virgen de Valme, Sevilla, Spain; Hospital Virgen del Rocío, Sevilla, 
Spain. 
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p5-17-05  24 months Follow-up results from paCt (patient’s anastrozole 
Compliance to therapy programme), a non-interventional 
Study evaluating the influence of a Standardized information 
Service on Compliance in postmenopausal Women with early 
breast Cancer
Lueck H-J, Hadji P, Harbeck N, Jackisch C, Blettner M, Zaun S, 
Windemuth-Kieselbach C, Beck T, Köhler U, Schmitt D, Kreienberg 
R. Gyn-Oncological Practice, Hannover, Germany; Phillips-University, 
Marburg, Germany; Breast Center, University of Cologne, Cologne, 
Germany; City Womens Hospital Offenbach, Offenbach, Germany; 
Institute of Medical Biostatistics, University, Mainz, Germany; 
AstraZeneca Germany, Wedel, Germany; Alcedis GmbH, Germany; 
Hospital Rosenheim, Rosenheim, Germany; Hospital St. Georg, 
Leipzig, Germany; Consulting Doctor-Patient Communication, 
Radolfzell, Germany; University Womens’ Hospital, Ulm, Germany. 
p5-17-06  pilot Study of a Questionnaire to assess impact of a breast 
Cancer Diagnosis in young Women on their relationship with 
their mothers
Ali A, Fergus K, Wright F, Pritchard K, Kiss A, Warner E. Sunnybrook 
Health Sciences Centre, Toronto, ON, Canada. 
p5-17-07  her2+ metastatic breast Cancer patient experiences on 
treatment in the biologic era: Findings from a Community 
Web-based Survey
Mayer M, Doan JF, Lang K, Hurvitz SA, Lalla D, Woodward RM, 
Brammer MG, Menzin J, Tripathy D. AdvancedBC.org; Genentech, 
Inc., South San Francisco, CA; Boston Health Economics, Waltham, 
MA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; 
USC/Norris Comprehensive Cancer Center, Los Angeles, CA. 
p5-17-08  the value of progression-Free Survival from the patient 
perspective: an online Survey of Women with metastatic 
breast Cancer in the united States
Hurvitz SA, Mathias SD, Doan JF, Crosby RD. UCLA School of 
Medicine/Translational Oncology Research International, Los 
Angeles, CA; Health Outcomes Solutions, Winter Park, FL; Genentech, 
Inc., South San Francisco, CA. 
treatment – Chemotherapy: adjuvant Chemotherapy
p5-18-01  no effect of adjuvant Chemotherapy in postmenopausal 
patients with invasive lobular (mixed) breast Cancer
Truin W, Voogd A, Vreugdenhil G, Van der Heiden-van der Loo 
M, Siesling S, Roumen R. Maxima Medical Centre, Veldhoven, 
Netherlands; Maastricht University, Maastricht, Netherlands; 
Comprehensive Cancer Centre, Utrecht, Netherlands; Comprehensive 
Cancer Centre, Enschede, Netherlands. 
p5-18-02  a population level assessment of emergency room visits 
and hospitalizations for Women undergoing adjuvant 
Chemotherapy for early breast Cancer
Enright KA, Trudeau M, Yun L, Grunfeld E, Krzyzanowska M. Peel 
Regional Cancer Centre, Credit Valley Hospital, Mississauga, ON, 
Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; 
Institute for Clinical Evaluative Science, Toronto, ON, Canada; 
University of Toronto, Toronto, ON, Canada; Cancer Care Ontario, 
Toronto, ON, Canada; Princess Margaret Hospital, Toronto, ON, 
Canada. 
p5-15-05  impact of breast Specialized physician Consultation on 
Surgical Decision making for breast Cancer and Decision 
Conflict in Women with hereditary breast Cancer risk
Boughey JC, Hoskin TL, Williams CI, Hartmann LC, Allers TM, Degnim 
AC, Frost M. Mayo Clinic, Rochester, MN. 
psychosocial, Quality of life, and educational aspects: education
p5-16-01  are We going to be able to train Future Surgeons how to 
perform axillary lymph node Dissection?
Betambeau N, Chan C. Cheltenham General Hospital, Cheltenham, 
Gloucestershire, United Kingdom. 
p5-16-02  the impact of educational materials on Compliance and 
persistence with adjuvant aromatase inhibitors: 2 year 
Follow-up and Final results from the CariatiDe Study
Neven P, Markopoulos C, Tanner MME, Marty ME, Kreienberg R, 
Atkins L, Franquet AA, Serin D, Gulcelik MA, Deschamp V. University 
Hospitals Leuven, Leuven, Belgium; Medical School University of 
Athens, Athens, Greece; Tampere University Hospital, Tampere, 
Finland; Saint Louis University Hospital, Paris, France; University of 
Ulm, Ulm, Bade-Wurttemberg, Germany; University College London, 
London, United Kingdom; IDDI (International Drug Development 
Institute), Louvain-la-Neuve (Ottignies), Belgium; Institut St. 
Catherine, Avignon, France; Ankara Oncology Hospital, Ankara, 
Turkey; AstraZeneca, Brussels, Belgium. 
p5-16-03  the breast Cancer novela, Se valiente…Son tus Senos, an 
innovative tool to educate latina Women about breast 
Cancer
Febus-Sampayo I, Mota R, Yaker A. SHARE: Self-Help for Women with 
Breast or Ovarian Cancer, New York, NY. 
psychosocial, Quality of life, and educational aspects: other
p5-17-01  evaluation of psychosocial Distress in main Care-givers 
of patients with metastatic breast Cancer Who receive 
treatment in a Community based oncology group practice
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, 
Mergenthaler U, Thomalla J, van Roye C, Köppler H. Hematology/
Oncology Group Practice, Koblenz, Germany; Institute for Health 
Care Research in Oncology, Koblenz, Germany 
p5-17-02  associations between breast Cancer patients’ Satisfaction with 
nursing Staff and hospital Characteristics, results of a german 
multicenter Study
Wuerstlein R, Kowalski C, Diener S, Krebs S, Pfaff H, Harbeck N. 
University Hospital Cologne, CIO, Köln, Germany. 
p5-17-03  the association between breast Cancer related 
lymphedema’s risk Factors and likelihood of edema 
progression
Skolny MN, Miller CL, O’Toole J, Sadek B, Ancukiewicz M, Taghain AG. 
Massachusetts General Hospital, Boston, MA. 
p5-17-04  association between breast Cancer and osteoporosis among 
Women 85 years or older
Okanami Y, Honma N, Arai T, Sawabe M, Maeda I, Takagi M, Younes 
M, Takubo K. St. Marianna University School of Medicine, Kawasaki, 
Kanagawa, Japan; Tokyo Metropolitan Institute of Gerontology; 
Baylor College of Medicine. 
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p5-18-09  the incidence of Febrile neutropenia in the First Course of 
adjuvant Chemotherapy with Docetaxel/Cyclophosphamide 
with or without pegfilgrastim
Jones S, Paul D, Sedlacek S, Vukelja S, Wilks ST, Stokoe C, Osborne 
CR, Krekow L, McIntyre K, Holmes FA, Guerra LG, Zhan F, Asmar 
L, O’Shaughnessy J, Blum JL. US Oncology, The Woodlands, TX; 
Baylor-Sammons Cancer Center, Baylor University, Dallas, TX; Rocky 
Mountain Cancer Center, Denver, CO; Texas Oncology-Tyler, Tyler, 
TX; Cancer Care Centers of South Texas, San Antonio, TX; Texas 
Oncology, Plano, TX; Breast Cancer Center of North Texas, Bedford, 
TX; Texas Oncology-Dallas Presbyterian Hospital, Dallas, TX; Texas 
Oncology-Houston Memorial City, Houston, TX. 
p5-18-10  utilisation of primary and Secondary g-CSF prophylaxis 
enables optimal Dose Delivery of Standard adjuvant 
Chemotherapy in early breast Cancer: results of 1655 patients 
from a Single institution
Chan A, McGregor S. Mount Hospital, Perth, WA, Australia. 
p5-18-11  incidence of Chemotherapy Dose reductions and Dose Delays, 
and reduced Chemotherapy Dose intensity in early Stage 
breast Cancer
Weycker D, Edelsberg J, Kartashov A, Barron R, Lyman G. Policy 
Analysis Inc. (PAI), Brookline, MA; Amgen Inc., Thousand Oaks, CA; 
Duke University, Durham, NC. 
p5-18-12  perception, practice and toxicity of adjuvant treatment of 
her2+ breast Cancer in Wisconsin
Rocque GB, Onitilo AA, Engel JM, Pettke EN, Boshoven AM, Zhang 
S, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk AJ, Burkard ME. 
University of Wisconsin Carbone Cancer Center, Madison, WI; The 
Marshfield Clinic, Weston, WI; University of Wisconsin School of 
Medicine and Public Health, Madison, WI. 
p5-18-13  adjuvant Chemotherapy with vinorelbine+5Fu or 
Capecitabine in poor responders to neoadjuvant eC- 
Docetaxel Chemotherapy (naC) for locally advanced breast 
Cancers
Giacchetti SSG, Hajage DDH, Pierga J-YJYP, Delaloge SSD, Brain 
EEB, Tembo OOT, Sigal BBS, Mathieu M-CMCM, Bertheau PPB, 
Guinebretiere J-MJMG, Asselain BBA, Marty MMM. Hôpital Saint 
Louis, Paris, France; Institut Curie, Paris, France; Institut Gustave 
Roussy, Villejuif, France. 
treatment – Chemotherapy: Chemotherapy in advanced Disease
p5-19-01  Final results of a three-arm randomised phase ii Study of 
oral vinorelbine plus Capecitabine versus oral vinorelbine 
and Capecitabine in Sequence versus Docetaxel plus 
Capecitabine in patients with metastatic breast Cancer 
previously treated with anthracyclines
Campone M, Dobrovolskaya N, Tjulandin S, Chen S-C, Fourie S, Mefti 
F, Konstantinova M, Lefresne F, Meheust N, Jassem J. Institut de 
Cancérologie de l’Ouest/René Gauducheau, Saint Herblain, Nantes 
Cedex, France; Russian Research Center of Roentgenoradiology, 
Moscow, Russian Federation; Russian Oncological Research Center, 
Moscow, Russian Federation; Chang Gung Memorial Hospital, Taipei, 
Taiwan; Wilmed Park Oncology, Klerksdorp, South Africa; Centre 
René Huguenin, Saint-Cloud, France; Moscow Regional Oncology 
Dispensary, Moscow, Russian Federation; Institut de Recherche Pierre 
Fabre, Boulogne, France; Medical University of Gdansk, Gdansk, 
Poland. 
p5-18-03  First interim toxicity analysis of the randomized phase iii 
WSg plan b trial Comparing 4xeC-4xDoc versus 6xtC in breast 
Cancer patients with her2 negative breast Cancer (bC)
Nitz U, Gluz O, Krepe H, Liedtke B, Aktas B, Henschen S, Pollmanns 
A, Krabisch P, Zuna I, Shak S, Thomsseen C, Harbeck N. West 
German Study Group, Moenchengladbach, Germany; Breast Centre 
Niederrhein/Bethesda Hospital, Moenchengladbach, Germany; 
Bethesda Hospital, Wuppertal, Germany; Medizinishce Hochschule, 
Hannover, Germany; Evangelical Hospital, Bergisch Gladbach, 
Germany; University Hospital, Essen, Germany; Johanniter Hospital, 
Stendal, Germany; Evangelical Hospital, Oberhausen, Germany; 
City Hospital Chemnitz, Chemnitz, Germany; Genomic Health Inc, 
Redwood City, Germany; University Hospital Halle/Saale, Halle/Saale, 
Germany; University Hospital Cologne, Cologne, Germany. 
p5-18-04  Safety profile of ixabepilone as adjuvant treatment for poor 
prognosis early breast Cancer: First results of the unicancer-
paCS 08 trial
Campone M, Spielmann M, Wildiers H, Cottu P, Kerbrat P, Levy 
C, Mayer F, Bachelot T, Winston T, Eymard J-C, Uwer L, Machiels 
J-P, Verhoeven D, Jaubert D, Facchini T, Orfeuvre H, Canon J-L, 
Asselain B, Roca L, Lacroix Triki M, Martin AL, Roche H. Centre René 
Gauducheau, Nantes, France; Institut Gustave Roussy, Villejuif, 
France; Katholike Universiteit, Leuven, Belgium; Institut Curie, Paris, 
France; Centre Eugène Marquis, Rennes, France; Centre François 
Baclesse, Caen, France; Centre Georges-François Leclerc, Dijon, 
France; Centre Léon Bérard, Lyon, France; Mayo Clinic Florida, 
Jacksonville; Institut Jean Godinot, Reims, France; Centre Alexis 
Vautrin, Nancy, France; UCL Cliniques Universitaires SAINT-LUC, 
Bruxelles, Belgium; AZ Klina Oncology, Brasschaat, Belgium; Clinique 
Tivoli, Bordeaux, France; Polyclinique de Courlancy, Reims, France; 
Centre Hospitalier de Fleyriat, Bourg en Bresse, France; Grand Hopital 
de Charleroi, Charleroi, Belgium; Centre Val d’Aurelle, Montpellier, 
France; Institut Claudius Regaud, Toulouse, France; R&D Unicancer, 
Paris, France. 
p5-18-05  incidence of Febrile neutropenia in patients treated with 
Docetaxel and Cyclophosphamide (tC) for adjuvant breast 
Cancer
Yee J, Chan J, Fehrenbacher L, Fredriks D, Chen D, Wong W, Colley 
D. Kaiser Permanente, Northern California; Kaiser Permanente, 
Northwest. 
p5-18-06 taxanes and Cyclophosphamide are equally effective in breast 
Cancer: a meta-analysis of ten phase iii trials in early and 
advanced Disease
Vriens BE, Lobbezoo DJ, Voogd AC, Veeck J, Tjan-Heijnen VC. 
Maastricht University Medical Centre, Maastricht, Netherlands; 
Maxima Medical Centre, Eindhoven, Netherlands. 
p5-18-07  presence of Disseminated tumor Cells after adjuvant 
Chemotherapy in breast Cancer and Disseminated tumor Cells 
monitoring during Secondary adjuvant treatment
Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg 
T, Kersten C, Mjaaland I, Vindi L, Schirmer CB, Nesland JM, Naume B. 
Oslo University Hospital, The Radium Hospital, Oslo, Norway; Oslo 
University Hospital, Ullevål, Oslo, Norway; Hospital Innlandet, Gjøvik, 
Norway; University Hospital Northern Norway, Tromsø, Norway; 
Sørlandet Hospital Kristiansand, Kristiansand, Norway; Stavanger 
University Hospital, Stavanger, Norway; ålesund Hospital, ålesund, 
Norway; University of Oslo, Norway. 
p5-18-08  a Comparative effectiveness analysis of trastuzumab 
persistence between two adjuvant breast Cancer treatment 
regimens among uS health plan enrollees
Lalla D, Pelletier EM, Goodman S, Brammer M, Schabert VF. 
Genentech Inc., South San Francisco, CA; IMS Consulting Group, 
Watertown, MA; IMS Consulting Group, Woodland Hills, CA. 
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p5-19-09  phase ii trial of ixabepilone plus Carboplatin in patients with 
metastatic breast Cancer: the eClipSe Study
Osborne C, Challagalla JD, Fanning SR, Eisenbeis CF, Holmes FA, 
Monaghan GG, Neubauer MA, Rabe AC, Raja V, Robbins GJ, Taboada 
C, Vukelja SJ, Wilks ST, Wang Y, Brown J-A, Asmar L, O’Shaughnessy 
J. US Oncology, The Woodlands, TX; Baylor-Sammons Cancer Center, 
Dallas, TX; Texas Oncology, Witchita Falls, KS; Cancer Centers of 
The Carolinas, Greenville, SC; Cancer Centers of North Carolina, 
Raleigh, NC; Texas Oncology-Houston Memorial City, Houston, TX; 
Kansas City Cancer Center, Kansas City, MO; Kansas City Cancer 
Center-Southwest, Overland Park, KS; Kansas City Cancer Center, 
Kansas City, KS; Florida Cancer Institute-New Hope, New Port Richey, 
FL; Texas Oncology-Methodist Charlton Cancer Center, Dallas, TX; 
Texas Oncology-Tyler, Tyler, TX; Cancer Centers of South Texas, San 
Antonio, TX. 
p5-19-10  Correlation of response of Weekly paclitaxel and paraplatin 
as First line treatment of metastatic breast Cancer with p53 
Status
El-Sadda W, Magdy M, Abdel-Halim I, Abdel-Wahab A. Mansoura 
University Hospital, Mansoura, Egypt. 
p5-19-11  tesetaxel, an oral taxane, as First-line therapy for Women 
with metastatic breast Cancer
Schwartzberg L, Rubin P, Patnaik A, Itri L, Olson AL, Seidman AD. 
The West Clinic, Memphis, TN; The Moses H. Cone Regional Cancer 
Center, Greensboro, NC; START Center - South Texas Accelerated 
Research Therapeutics, San Antonio, TX; Genta Incorporated, 
Berkeley Heights, NJ; Memorial Sloan-Kettering Cancer Center, New 
York, NY. 
p5-19-12 integration of Capecitabine monotherapy with Capecitabine 
Combination therapy in metastatic breast Cancer patients: 
First report on Safety and efficacy of Single agent 
Capecitabine maintenance Study
Xu B, Wang J, Yuan P, Ma F, Li Q, Zhang P, Fan Y, Li Q. Cancer 
Hospital Chinese Academy of Medical Sciences, Beijing, China. 
p5-19-13  a randomized phase ii trial of First-line metastatic breast 
Cancer (mbC) patients: Sub-Set analysis of albumin-bound 
paclitaxel (ab-pac) given Weekly at 150 mg/m2
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas 
GM, Clawson A, Bhar P. Northwestern University Feinberg School of 
Medicine, Chicago, IL; Leningrad Regional Oncology Center, Russian 
Federation; Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, 
Russian Federation; City Oncology Hospital, Russian Federation; St. 
Petersburg City Oncology Center, St. Petersburg, Russian Federation; 
Celgene Corporation, Summit, NJ. 
p5-19-14  platinum-based Chemotherapy in triple-negative breast 
Cancer
Villarreal-Garza C, Bouganim N, Khalaf D, Clemons M, Kassam F, 
Enright K, Verma S, Myers J, Dent R. Sunnybrook Odette Cancer 
Centre, Toronto, ON, Canada; The Ottawa Hospital Cancer Centre, 
Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, 
Canada; Credit Valley Hospital, Mississauga, ON, Canada. 
treatment – Chemotherapy: toxicities and management
p5-20-01  patient valuation of reduced risk of Side effects during 
treatment for metastatic breast Cancer
Lalla D, McLaughlin T, Brammer M, Bramley T, Bare A, Carlton R. 
Genentech Inc., S San Francisco, CA; Xcenda, Palm Harbor, FL. 
p5-20-02  n-terminal pro-brain b-type natriuretic peptide (nt-pro-bnp) 
before and during treatment with trastuzumab allows early 
Detection of Cardiotoxicity in breast Cancer patients
Blancas I, Carrillo J, Legerén M, Delgado M, Jurado JM, Zarcos I, 
Villaescusa A, Gómez FJ, Moreno E, García-Puche JL. Hospital Clínico 
San Cecilio, Granada, Spain; University of Granada, Granada, Spain. 
p5-19-02  Comparison of the incidence of peripheral neuropathy with 
eribulin mesylate versus ixabepilone in metastatic breast 
Cancer patients: a randomized phase ii Study
Vahdat L, Gopalakrishna P, Garcia AA, Vogel C, Pellegrino C, 
Lindquist, Iannotti N. Weill Cornell Medical College, New York, NY; 
Eisai, Inc., Woodcliff Lake, NJ; University of Southern California Keck 
School of Medicine, Los Angeles, CA; Sylvester Comprehensive 
Cancer Center, University of Miami, Miller School of Medicine, 
Deerfield Beach, FL; Montefiore Medical Center, New York, NY; 
Hematology-Oncology Associates of the Treasure Coast, Port Saint 
Lucie, FL; US Oncology, Sedona, AZ. 
p5-19-03  albumin-bound paclitaxel (ab-pac) versus Docetaxel for First-
line treatment of metastatic breast Cancer (mbC): overall 
Survival and Safety analysis of a randomized phase ii trial
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, 
Clawson A, Bhar P. Northwestern University, Chicago, IL; Leningrad 
Regional Oncology Center, Russian Federation; Yaroslavl Regional 
Clinical Oncology Hospital, Yaroslavl, Russian Federation; City 
Oncology Hospital, Moscow, Russian Federation; St. Petersburg 
Oncology Center, St. Petersburg, Russian Federation; Celgene 
Corporation, Summit, NJ. 
p5-19-04  results of a randomized phase ii Study Demonstrate benefit 
of platinum-based regimen in the First-line treatment of 
triple negative breast Cancer (tnbC)
Fan Y, Xu BH, Yuan P, Wang JY, Ma F, Ding XY, Zhang P, Li Q, Cai RG. 
Cancer Institute & Hospital, Chinese Academy of Medical Sciences & 
Peking Union Medical College, Beijing, China. 
p5-19-05  age-related Changes in the pharmacokinetics (pk), response, 
and toxicity of Weekly nab-paclitaxel in patients with 
metastatic breast Cancer (mbC)
Hurria A, Synold T, Blanchard S, Wong C, Mortimer J, Luu T, Chung C, 
Ramani R, Katheria V, Hansen K, Jayani R, Brown J, Williams B, Rotter 
A, Somlo G. City of Hope, Duarte, CA. 
p5-19-06  highly effective of gemcitabine and Cisplatin (gp) as First-
line Combination therapy in patients with triple-negative 
metastatic breast Cancer: Final report of a phase ii trial
Wang Z, Hu X, Wang B, Wang L, Zhang J, Wang H, Liu G, Hu Z, Wu 
J, Shao Z. Cancer Hospital of Fudan University, Shanghai Medical 
College, Shanghai, China. 
p5-19-07  the effects of abCC2 and SlCo1b3 Single nucleotide 
polymorphisms on Docetaxel-induced leukopenia in breast 
Cancer patients
Chen J, Wu LJ, Shen P, Yu LF, Huang S. The First Affiliated 
Hospital,College of Medicine, Zhejiang University, Hangzhou, 
Zhejiang, China. 
p5-19-08  pooled analysis of individual patient Data from Capecitabine 
monotherapy Clinical trials in anthracycline-/taxane-
pretreated locally advanced or metastatic breast Cancer (la/
mbC)
Blum JL, Barrios CH, Feldman N, Verma S, McKenna E, Lee S, Scotto 
N, Gralow J. Baylor Sammons Cancer Center, Texas Oncology, US 
Oncology, Dallas, TX; PUCRS School of Medicine, Porto Alegre, 
Brazil; Olive View-UCLA Medical Center, Sylmar, CA; Sunnybrook 
Oddette Cancer Centre, University of Toronto, Toronto, ON, Canada; 
Hoffmann-La Roche Inc., San Francisco, CA; F. Hoffmann-La Roche 
Ltd, Basel, Switzerland; University of Washington, Seattle, WA. 
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treatment – trial resources etc.: Clinical trials Design and management
p5-22-01  Feasibility and patient Safety of Serial biopsies (bx) in 
metastatic her2-positive breast Cancer (bC) to evaluate 
alterations in molecular biomarkers (bm): preliminary results 
of Shersig (Study of her2 Signature in metastatic breast 
Cancer) a prospective phase ii Study
Chan A, Chan S, Price D, Bergh J, Lluch A, Redfern A, Chirgwin J, 
Lidbrink E, Dhadda A, Lopéz-Vega J, Lindman H, Beith J, Baron-
Hay S, Kiermaier A, Herbst F, Ellis I. Mount Medical Centre, Perth, 
Australia; Nottingham City Hospital, Nottingham, United Kingdom; 
Karolinska Institutet and University Hospital, Stockholm, Sweden; 
Hospital Clínico Universitario de Valencia, Valencia, Spain; Royal 
Perth Hospital, Perth, Australia; Eastern Health Melbourne, Australia; 
Scarborough Hospital, Scarborough, United Kingdom; Hospital 
Universitario Marques de Valdecilla, Santander, Spain; Uppsala 
University Hospital, Uppsala, Sweden; Royal Prince Alfred Hospital, 
Camperdown, Australia; Royal North Shore Hospital, St Leonards, 
Australia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Nottingham 
University Hospitals, Nottingham, United Kingdom. 
treatment – other
p5-23-01  the impact of primary tumor resection on the Survival of 
patients with Stage iv breast Cancer according to molecular 
Subtype
Ahn Sk, Moon H-G, Kim JS, You Jm, Shin Hc, Han W, Noh D-y. Seoul 
National University Hospital. 
p5-23-02  Clinicopathological Features of young patients age <35 years 
with breast Cancer in japan
Kataoka A, Tokunaga E, Masuda N, Shien T, Ohno S, Kinoshita T, 
Shimizu C. Breast Surgery Clinic, Minato-ku, Tokyo, Japan; Kyushu 
University Hospital, Fukuoka City, Fukuoka, Japan; National Hospital 
Organization Osaka National Hospital, Osaka City, Osaka, Japan; 
Okayama University Hospital, Okayama City, Okayama, Japan; 
National Hospital Organization Kyushu Cancer Center, Fukuoka City, 
Fukuoka, Japan; National Cancer Center Hospital, Chuo-ku, Tokyo, 
Japan; The Japanese Breast Cancer Society (JBCS) Study Group on 
Breast Cancer in Young Women. 
p5-23-03  breast Cancer in elderly treatment algorithm - a new 
approach to optimize the management of breast Cancer in 
older patients
Tahir M, Pretorius R, Robinson T, Walker R, Stotter A. University 
Hospitals of Leicester NHS Trust, Leicester, United Kingdom. 
p5-23-04  gonadotrophin-releasing hormone analogues for ovarian 
Function preservation in Women with premenopausal breast 
Cancer undergoing adjuvant Chemotherapy: a Systematic 
review and meta-analysis
Cruz MRS, Motta E, Silva EMK, Bernardo SG, Atallah AN. Hospital Sao 
Jose, Sao Paulo, Brazil; Universidade Federal de Sao Paulo, Sao Paulo, 
Brazil. 
p5-23-05  Withdrawn 
p5-23-06  monitoring of Quality indicators Should lead to Quality 
measures. a Dynamic Clinical pathway for the treatment of 
patients with early breast Cancer is a tool for better Cancer 
Care: implementation and prospective analysis between 
2002-2010
van Dam PA, Verheyden G, Trinh BX, VanderMussele H, Wuyts H, 
Verkinderen L, Hauspy J, Vermeulen P, Dirix LY. Sint Augustinus 
Hospital, Wilrijk, Antwerp, Belgium. 
p5-23-07  treatment Strategy of locally advanced breast Cancer in Sub 
group (t3n1m0, t4bn1m0) in Developing Countries
Gupta AK, Kaushal M. Mahatma Gandhi Memorial Medical College 
and Maharaja Yashwantrao Hospital, Indore, Madhya Pradesh, India.
p5-20-03  personalizing Supportive Care: a Clinical prediction model for 
neutropenic Complications in patients with early-Stage breast 
Cancer (eSbC) receiving intermediate risk Chemotherapy
Kuderer NM, Culakova E, Poniewierski MS, Crawford J, Dale D, Lyman 
GH. Duke University, Durham, NC; University of Washington, Seattle, 
WA. 
p5-20-04  is primary prophylaxis with g-CSF indicated for adjuvant tC 
or FeC-D Chemotherapy? a Systematic review and meta-
analyses
Younis T, Rayson D, Thompson K. Dalhousie University at the Queen 
Elizabeth II Health Sciences Centre, Halifax, NS, Canada. 
p5-20-05  peripheral blood transcriptomics and Doxorubicin 
Cardiotoxicity
Todorova VK, Beggs ML, Dhakal IB, Hennings LJ, Makhoul I, Klimberg 
VS. University of Arkansas for Medical Sciences, Little Rock, AR. 
p5-20-06  Survival in Women with breast Cancer Who used or Did not 
use Scalp Cooling in the neoadjuvant/adjuvant Setting
Lemieux J, Perron L, Provencher L, Brisson J, Amireault C, Blanchette 
C, Maunsell E. Centre de Recherche FRSQ du CHA Universitaire de 
Québec, Quebec City, QC, Canada; Hôpital du Saint-Sacrement, 
Quebec City, QC, Canada; Université Laval, Quebec City, QC, Canada; 
Institut Nationale de Santé Publique, Quebec City, QC, Canada; 
Université de Montréal, Montreal, QC, Canada. 
p5-20-07  estimation of Febrile neutropenia in Women receiving 
Docetaxel plus Cyclophosphamide as adjuvant therapy for 
early Stage breast Cancer: a retrospective analysis
Bordoni RE, Haislip ST, Gilmore JW, Sharpe J, Abella E, Choi MR. 
Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, 
CA. 
p5-20-08  multicenter results of Scalp Cooling to prevent 
Chemotherapy-induced alopecia in 1500 breast Cancer 
patients
van den Hurk C, Peerbooms M, Komen M, Nortier H, Breed W. 
Comprehensive Cancer Centre South (IKZ), Eindhoven, Netherlands; 
Medical Centre Alkmaar, Alkmaar, Netherlands; Leiden University 
Medical Centre, Leiden, Netherlands. 
treatment – trial resources etc.: tissue and Data banks
p5-21-01  a renewable tissue resource of phenotypically Stable human 
breast Cancer Xenografts for preclinical Studies
Zhang X, Dobrolecki LE, Lai Q, Landis MD, Wong H, Tsimelzon A, 
Claerhout S, Contreras A, Gutierrez C, Huang J, Wu M-F, Pavlick AC, 
Froehlich AM, Hilsenbeck SG, Mills GB, Wiechmann L, Petrovic I, 
Rimawi MF, Schiff R, Chang JC, Lewis MT. Baylor College of Medicine, 
Houston, TX; The University of Texas MD Anderson Cancer Center, 
Houston, TX. 
p5-21-02  the Susan g. komen for the Cure® tissue bank at the iu Simon 
Cancer Center: the Source for normal breast tissue and 
biospecimens
Clare SE, Mathieson T, Henry JE, Zhang H, Way ES, Ridley KE, Badve 
S, Herbert B-S, Rufenbarger CA, Storniolo AMV. Indiana University 
School of Medicine, Indianapolis, IN. 
p5-21-03  the breast Cancer Campaign tissue bank
Jones L, Chelala C, Ellis I, Ekbote U, Green A, Hanby A, Jordan L, 
Purdie C, Quinlan P, Speirs V. Barts Cancer Institute, London, United 
Kingdom; University of Nottingham, Nottingham, United Kingdom; 
University of Leeds, Leeds, United Kingdom; University of Dundee, 
Dundee, United Kingdom. 
p5-21-04  patient attitudes towards undergoing additional breast 
biopsy for research purposes
Naim FM, Ballinger R, McLauchlan R, Hadjiminas DJ, Hogben K, 
Palmieri C, Cleator SJ. Royal Free Hospital, Royal Free Hampstead 
NHS Trust, London, United Kingdom; Brighton and Sussex Medical 
School, Brighton, United Kingdom; Charing Cross Hospital, Imperial 
NHS Healthcare Trust, London, United Kingdom. 
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5:00 pm–7:00 pm 
poSter DiSCuSSion X: tumor SuppreSSorS/Dna repair 
ballroom b
Viewing 5:00 pm 
Discussion 5:30 pm
Discussant: Nicholas Turner, MD
Royal Marsden Hospital
London, UNITED KINGDOM
pD10-01  prevalence of Dysfunctional Fanconi anemia (Fa) Dna repair 
pathway in breast Cancer
Ramaswamy B, Srividya V, Mullins D, Carothers S, Young G, Wenrui 
D, Zhao W, Lustberg M, Leon M, Weslowski R, Layman R, Mrozek E, 
Shapiro CL, Villalona-Calero M. The Ohio State University, Columbus, 
OH. 
pD10-02  Sporadic breast Cancers Show Defects in the brCa1-brCa2 
pathway of homologous recombination in all biomarker-
Defined Sub-types of breast Cancer
Powell SN, Mutter RW, Delsite R, Bindra R, King T, Giri D, Park J. 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
pD10-03  Withdrawn
pD10-04  exploration of the relationship between loss of pten and 
brCa1 expression in triple negative breast Carcinoma
Jones N, Velasco V, Reault M, Dapremont V, Rouault A, Bonnet F, 
Longy M, MacGrogan G, Sevenet N. Institut Bergonié, Bordeaux, 
France. 
pD10-05  identification of novel brCa1 transcriptional targets that 
promote the Survival of brCa1-mutated estrogen receptor-α 
negative (er-ve) breast tumours
Lamers E, Haddock P, Cochrane DJ, Gorski JJ, Blayney J, McDyer FA, 
Mulligan JM, Mullan PB, Couch FJ, Kennedy RD, Harkin PD, Quinn JE. 
Queen’s University of Belfast, Belfast, Antrim, United Kingdom; Almac 
Ltd., Cragaivon, United Kingdom; Mayo Clinic College of Medicine, 
Rochester, MN. 
pD10-06  loss of the retinoblastoma tumor Suppressor (rb) in triple 
negative breast Cancer is associated with a Favorable 
prognosis
Witkiewicz AK, Kline J, Mitchell E, Ertel A, Knudsen ES. Thomas 
Jefferson University, Philadelphia, PA; Kimmel Cancer Center, 
Philadelphia, PA. 
pD10-07  microrna profiles of breast tumors identifies the mir 17-92 
Cluster as a group of potentially essential oncomirs in triple-
negative breast Cancer
Son BH, Birkbak NJ, Tian R, Iglehart D, Wang ZC, Richardson AL. 
Dana-Farber Cancer Institute, Boston, MA; Asan Medical Center, 
Seoul, Korea; Technical University of Denmark, Lyngby, Denmark; 
Brigham and Women’s Hospital, Harvard Medical School, Boston, 
MA.
5:00 pm–7:00 pm 
poSter SeSSion ongoing trialS 3 
exhibit hall b
new agents
ot3-01-01  randomized phase ii Study of Fulvestrant versus Fulvestrant 
plus bortezomib in postmenopausal Women with estrogen 
receptor (er) positive, aromatase-inhibitor (ai) resistant 
metastatic breast Cancer (mbC): new york Cancer Consortium 
trial p8457
Adelson KB, Raptis G, Sparano J, Germain D. Mount Sinai School of 
Medicine, New York, NY; Albert Einstein Cancer Center, Bronx, NY. 
p5-23-08  minimally invasive treatment of elderly breast cancer patients 
using preferential radiofrequency ablation
Schassburger K-U, Lofgren L, Leifland K, Thorneman K, Wiksell 
H.  Karolinska Institutet, Stockholm, Sweden; Capio S:t Gorans 
Hospital, Stockholm, Sweden; Unilabs AB, Capio S:t Gorans Hospital, 
Stockholm, Sweden.
5:00 pm–7:00 pm 
poSter DiSCuSSion iX: pi3k/mtor  
ballroom a
Viewing 5:00 pm 
Discussion 5:30 pm
Discussant: Ana-Maria Gonzalez-Angulo, MD, MSC
UT MD Anderson Cancer Center
Houston, TX 
pD09-01  target-based therapeutic matching in early-phase Clinical 
trials in patients with advanced breast Cancer and pik3Ca 
mutations
Janku F, Moulder SL, Wheler JJ, Stepanek V, Falchook GS, Naing A, 
Hong DS, Fu S, Piha-Paul SA, Luthra R, Tsimberidou AM, Kurzrock R. 
The University of Texas MD Anderson Cancer Center, Houston, TX. 
pD09-02  Withdrawn
pD09-03  phase i/ii Study of bkm120 in Combination with trastuzumab 
in patients with her2 overexpressing metastatic breast 
Cancer resistant to trastuzumab-Containing therapy
Saura C, Bendell J, Jerusalem G, Graña-Suárez B, Su S, Ru Q, De 
Buck S, Devisme C, Bosch A, Urruticoechea A, Beck JT, DiTomaso E, 
Rouyrre N, Sternberg DW, Massacesi C, Hirawat S, Dirix L, Baselga 
J. Hospital Vall d’Hebron, Barcelona, Spain; Sarah Cannon Research 
Institute, Nashville, TN; C.H.U. Sart-Tilman, Liege, Belgium; Novartis 
Pharmaceuticals, Florham Park, NJ; Novartis Pharma AG, Basel, 
Switzerland; Hospital Clínico Universitario de Valencia, Valencia, 
Spain; Catalan Institute of Oncology, Barcelona, Spain; Highlands 
Oncology Group, Fayetteville, AZ; Novartis Institutes for BioMedical 
Research, Cambridge, MA; Novartis Oncology, Paris, France; 
Oncologisch Centrum AZ-St. Augustinus Oncology, Wilrijk, Belgium; 
Massachusetts General Hospital, Boston, MA. 
pD09-04  a phase ib, open-label, Dose-escalation Study of the Safety 
and pharmacology of the pi3-kinase inhibitor gDC-0941 in 
Combination with paclitaxel and bevacizumab in patients with 
locally recurrent or metastatic breast Cancer
Schöffski P, De Benedictis E, Gendreau S, Gianni L, Krop IE, Levy G, 
Ware J, Wildiers H, Winer EP. Catholic University, Leuven, Belgium; 
Istituto Nazionale dei Tumori, Milan, Italy; Genentech Inc., South San 
Francisco, CA; Dana-Farber Cancer Institute, Boston, MA. 
pD09-05  Su2C phase ib Study of pan-pi3k inhibitor bkm120 plus 
aromatase inhibitor letrozole in er+/her2- metastatic breast 
Cancer (mbC)
Mayer IA, Balko JM, Kuba MG, Sanders ME, Yap J, Li Y, Winer E, 
Arteaga CL. Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana 
Farber Cancer Institute, Boston, MA; MD Anderson Cancer Center, 
Houston, TX. 
pD09-06  phase ii trial of raD001 (everolimus), an mtor inhibitor, 
with Weekly Cisplatin and paclitaxel in patients with her2-
negative metastatic breast Cancer (mbC)
Mayer IA, Means-Powell J, Abramson VG, Shyr Y, Balko JM, Kuba 
MG, Gharavi HM, Schlabach L, Arteaga CL, Pietenpol JA. Vanderbilt-
Ingram Cancer Center, Nashville, TN; Vanderbilt-Ingram Cancer 
Center Affiliated Network (VICCAN). 
pD09-08  Combined inhibition of mtorC1 with temsirolimus and her2 
with neratinib: a phase i/ii Study in patients with metastatic 
her2-amplified or triple-negative breast Cancer
Gajria D, King T, Pannu H, Sakr R, Seidman AD, Modi S, Dickler 
M, Drullinsky P, Syldor A, Sujata P, Majid M, Norton L, Rosen N, 
Chandarlapaty S. Memorial Sloan-Kettering Cancer Center, New York, 
NY. 
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ot3-01-11  a randomized, phase ii multicenter, Double-blind, placebo-
Controlled trial evaluating metmab and/or bevacizumab 
in Combination with Weekly paclitaxel in patients with 
metastatic triple-negative breast Cancer
Daniel BR, Campone M, Dieras V, Ervin T, Yu W, Paton VE, Xia Q, 
Peterson A. Chattanooga Oncology Hematology Associates - SCRI, 
Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, 
France; Institute Curie, Paris, France; Florida Cancer Specialists, 
Englewood, FL; Genentech Inc., South San Francisco, CA. 
ot3-01-12  Withdrawn
ot3-01-13  phase one trial of Combined temsirolimus, erlotinib, and 
Cisplatin in advanced Solid tumors
Maurer M, Kalinsky K, Crew K, Jayasena R, Forman J, Lau Y-K, Shaw J, 
Parsons R, Hershman D. Columbia University, New York, NY. 
ot3-01-14  n0937: phase ii trial of brostallicin and Cisplatin in patients 
with metastatic triple negative breast Cancer
Moreno-Aspitia A, Rowland KM, Liu H, Hillman DW, Stella PJ, Perez 
EA. Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Carle 
Cancer Center, Urbana, IL; St. Joseph Mercy Cancer Center, Ypsilanti, 
MI. 
ot3-01-15  phase iii trial evaluating the addition of bevacizumab to 
endocrine therapy as First-line treatment for advanced 
breast Cancer: the lea Study
De la Haba-Rodriguez JR, von Minckwitz G, Martín M, Morales S, 
Crespo C, Guerrero A, Anton-Torres A, Gil M, Muñoz M, Carrasco E, 
Rodríguez-Martin C, Porras I, Aktas B, Schoenegg W, Tio J, Mehta 
K, Loibl S, on Behalf of GEICAM and GBG. University Reina Sofia 
Hospital, Córdoba, Spain; German Breast Group, Neu-Isenberg, 
Germany; Universitario Gregorio Marañón, Spain; Hospital Ararnu de 
Vilanova de Lleida, Spain; Hospital Universitario Ramón y Cajal, Spain; 
Instituto Valenciano de Oncologia, Spain; Miguel Servet University 
Hospital, Spain; Institut Catala d’Oncologia, Spain; Provincial Hospital 
Clinic, Barcelona, Spain; GEICAM Headquarters, Madrid, Spain; 
University Hospital, Essen, Germany; Praxis Dr Schnoenegg, Berlin, 
Germany; Universitaetsklinikum Muenster, Germany. 
ot3-01-16 a phase 2 Study of ridaforolimus (riDa) and Dalotuzumab 
(Dalo) in estrogen receptor positive (er+) breast Cancer
Lu BD, Blum JL, Cortes J, Rugo HS, Swanton C, Eaton L, Song Y, 
Zhang T, Ebbinghaus SW, Baselga J. Merck Research Laboratories, 
Kenilworth, NJ; Texas Oncology, US Oncology, Dallas, TX; Vall 
D’Hebron University Hospital, Barcelona, Spain; UCSF Hellen Diller 
Family Comprehensive Cancer Center, San Francisco, CA; The 
Royal Marsend Hospital, Sutton, United Kingdom; Merck Research 
Laboratories, North Wales, PA; Merck Research Laboratories, Boston, 
MA; Massachusetts General Hospital, Boston, MA. 
ot3-01-17  randomized, Double-blind, placebo-Controlled phase ii 
trial of low-Dose metronomic Cyclophosphamide alone or 
in Combination with veliparib (abt-888) in Chemotherapy-
resistant er and/or pr-positive, her2/neu-negative 
metastatic breast Cancer: new york Cancer Consortium trial 
p8853
Andreopoulou E, Chen AP, Zujewski JA, Kalinsky K, Vahdat L, Raptis 
G, Hershman D, Novic Y, Muggia F, Sparano J. Albert Einstein College 
of Medicine/Montefiore Medical Center, Bronx, NY; National Cancer 
Institute, Bethesda, MD; Columbia University Medical Center, New 
York, NY; Weill Cornell Medical College, New York, NY; Mount Sinai 
School of Medicine, New York, NY; New York University Langone 
Medical Center, New York, NY. 
ot3-01-18  Combination immunotherapy with trastuzumab and the her2 
vaccine e75 in low and intermediate her2-expressing breast 
Cancer patients to prevent recurrence
Sears AK, Clifton GT, Vreeland TJ, Hale DF, Ponniah S, Mittendorf 
EA, Peoples GE. Brooke Army Medical Center, Ft. Sam Houston, 
TX; Uniformed Services University of the Health Sciences, USMCI, 
Bethesda, MD; UT M.D. Anderson Cancer Center, Houston, TX. 
ot3-01-02  imatinib mesylate in Combination with vinorelbine for 
patients with metastatic breast Cancer - an ongoing phase i/ii 
Clinical trial
Mundhenke C, Schem C, Bauerschlag DO, Weigel MT, Hilpert F, 
Eidtmann H, Tiemann K, Muth M, May C, Hanson S, Jonat W, Maass 
N. Kiel University, Kiel, SH, Germany; RWTH Aachen, Aachen, NRW, 
Germany; Novartis Pharma, Nuremberg, Bavaria, Germany; Institut 
fuer Haematopathologie Hamburg, Hamburg, HH, Germany. 
ot3-01-03  pre-Surgical evaluation of the akt inhibitor mk-2206 in 
patients with operable invasive breast Cancer: new york 
Cancer Consortium trial p8740
Kalinsky K, Sparano JA, Kim M, Crew KD, Maurer MA, Taback B, 
Feldman SM, Hibshoosh H, Wiechmann LS, Adelson KB, Hershman 
DL. Columbia University Medical Center, New York, NY; Albert 
Einstein College of Medicine, New York, NY; Mount Sinai School of 
Medicine, New York, NY. 
ot3-01-04  tania: a randomized phase iii trial evaluating Continued 
and reintroduced bevacizumab (bev) in patients previously 
treated with 1st-line bev for locally recurrent/metastatic 
breast Cancer (lr/mbC)
von Minckwitz G, Cortés J, Gligorov J, Marschner NW, Puglisi F, 
Vrdoljak E, Duenne A-A, Zielinski C. German Breast Group, GBG 
Forschungs GmbH, Neu-Isenburg, Germany; Vall d’Hebron University 
Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; 
Outpatient Cancer Centre, Freiburg, Germany; University Hospital of 
Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La 
Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, 
Austria. 
ot3-01-05  parp inhibition after preoperative Chemotherapy in patients 
with triple-negative breast Cancer (tnbC) or known brCa 1/2 
mutations: hoosier oncology group bre09-146
Miller KD, Perkins SM, Badve SS, Sledge GW, Schneider BP. Indiana 
University Melvin and Bren Simon Cancer Center. 
ot3-01-06  a phase 2 Study investigating the Safety, efficacy and 
Surrogate biomarkers of response of 5-azacitidine (5-aZa) 
and entinostat (mS-275) in patients with advanced breast 
Cancer
Connolly RM, Jankowitz RC, Andreopoulou E, Allred JB, Jeter SC, 
Zorzi J, Adam BM, Espinoza-Delgado I, Baylin SB, Zahnow CA, Ahuja 
N, Davidson NE, Stearns V. Sidney Kimmel Comprehensive Cancer 
Center at Johns Hopkins University, Baltimore, MD; University of 
Pittsburgh Cancer Institute, Pittsburgh, PA; Albert Einstein College 
of Medicine, Montefiore Medical Center, New York, NY; Mayo Clinic, 
Rochester, MN; National Cancer Institute, Bethesda, MD. 
ot3-01-07  the beaCon Study (breast Cancer outcomes with nktr-
102): a phase 3 open-label, randomized, multicenter Study 
of nktr-102 versus treatment of physician’s Choice (tpC) 
in patients (pts) with locally recurrent or metastatic breast 
Cancer (mbC) previously treated with an anthracycline, a 
taxane, and Capecitabine (atC)
Awada A, Leung ACF, Zhao C, Hannah AL, Perez EA. Universite Libre 
de Bruxelles, Brussels, Belgium; Nektar Therapeutics, San Francisco, 
CA; Mayo Clinic, Jacksonville, FL. 
ot3-01-08  phase ii Study of S-1 Combined with Cisplatin in the First-line 
treatment of triple negative breast Cancer
Fan Y, Xu BH. Cancer Hospital & Institute,Chinese Academy of 
Medical Sciences & Peking Union Medical College, Beijing, China. 
ot3-01-09  phase 3 trial Comparing Capecitabine in Combination with 
Sorafenib or placebo for treatment of locally advanced or 
metastatic her2-negative breast Cancer (reSilienCe)
Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar 
WJ. Massachusetts General Hospital Cancer Center; West Clinic; 
Bayer HealthCare Pharmaceuticals; Feinberg School of Medicine, 
Northwestern University. 
ot3-01-10  Withdrawn
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genome Data for the masses: presentation of tCga and igC breast 
tumor Data  
Moderator: Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC
and
Michael Stratton, FRCPath, FMCDSCI, FRS
The Wellcome Trust Sanger Institute
Hinxton, Cambridge, UNITED KINGDOM
  tCga breast cancer sequencing: results and interpretation
Elaine R. Mardis, PhD
Washington University
St. Louis, MO 
  Diverse patterns of mutation in breast cancer genomes
Michael Stratton, FRCPath, FMCDSCI, FRS
The Wellcome Trust Sanger Institute
Hinxton, Cambridge, UNITED KINGDOM
  integrative genomic analyses of breast cancer from the 
Cancer genome atlas (tCga)
Chad J. Creighton, PhD
Baylor College of Medicine
Houston, TX
  epigenomic data analysis of tCga breast cancer samples
Peter W. Laird, PhD
USC Epigenome Center
Los Angeles, CA
  the Dna copy number landscapes and genomic architecture: 
relevance for progression and outcome
Anne-Lise Børresen-Dale, PhD, MD (h.c.)
Oslo University Hospital
Oslo, NORWAY
  genomic analyzes for pathway characterization
David Haussler, PhD
University of California, Santa Cruz
Santa Cruz, CA 
10:00 am–12:00 pm 
the year in revieW 
exhibit hall D
 Moderator: C. Kent Osborne, MD  
Baylor College of Medicine  
Houston, TX  
 advances in basic breast cancer research
Kornelia Polyak, MD, PhD 
Dana-Farber Cancer Institute
Boston, MA
 translational breast cancer research
Andrea Richardson, MD, PhD
Dana-Farber Cancer Institute
Boston, MA 
 early breast cancer
Nancy E. Davidson, MD
University of Pittsburgh Cancer Institute 
Pittsburgh, PA 
 Challenges and success: treatment of metastatic breast cancer 
2011
Hope S. Rugo, MD
University of California, San Francisco 
San Francisco, CA
12:00 pm 
aDjournment 
ot3-01-19  phase ii Study of topical imiquimod and Weekly abraxane for 
the treatment of breast Cancer Cutaneous metastases
Higgins DM, Childs J, Parker S, Disis ML, Salazar LG. University of 
Washington, Seattle, WA. 
other
ot3-02-01  a 1-year prospective longitudinal Study of the role of 
psychosocial Factors in adherence to adjuvant endocrine 
therapy in early breast Cancer
Song X, Verma S, Dent S, Clemons M, Graham N, Bedard M, Paquet 
L. The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Carleton 
University, Ottawa, ON, Canada. 
ot3-02-02  yoga Compared to exercise as a therapeutic intervention 
during (neo)adjuvant Chemotherapy in Women with Stage 
i-iii breast Cancer
Wiedemann F, Büssing A, Halle M, Kiechle M, Kohls N, Ostermann T, 
Sattler D, Ettl J. Technische Universität München, Munich, Germany; 
Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie 
Arabella, Munich, Germany; Ludwig-Maximilians-Universität 
München, Bad Tölz, Germany. 
ot3-02-03  patient empowerment by group medical Consultations in 
the Follow-up of breast Cancer Survivors and Surveillance of 
Women with a brCa mutation
van Laarhoven HWM, Prins JB, Schlooz MS, Besselink, Bögemann L, 
van Koolwijk MPA, Hoogerbrugge N, Visser A. Radboud University 
Nijmegen Medical Centre, Nijmegen, Netherlands. 
ot3-02-04  tbCrC 012: abCDe, a phase ii randomized Study of adjuvant 
bevacizumab, metronomic Chemotherapy (Cm), Diet and 
exercise after preoperative Chemotherapy for breast Cancer
Mayer EL, Ligibel JA, Burstein HJ, Peppercorn JM, Miller KD, Carey LA, 
Dickler MN, Mayer IA, Forero A, Eng-Wong J, Pletcher PJ, Ryabin N, 
Gelman R, Wolff AC, Winer EP. Dana-Farber Cancer Institute, Boston, 
MA; Duke University Medical Center, Durham, NC; Indiana University 
Melvin and Bren Simon Cancer Center, Indianapolis, IN; University of 
North Carolina at Chapel Hill, Durham, NC; Memorial Sloan-Kettering 
Cancer Center, New York, NY; Vanderbilt University, Nashville, TN; 
University of Alabama, Birmingham, AL; Georgetown University 
Lombardi Comprehensive Cancer Center, Washington, DC; Hoosier 
Oncology Group, Indianapolis, IN; Johns Hopkins Kimmel Cancer 
Center, Baltimore, MD.
7:30 pm–10:00 pm
open Satellite event 
marriott rivercenter, grand ballroom
Clinical Applications for Preventing and Managing Skeletal-Related 
Events in Breast Cancer: A Current Perspective
Website: http://www.clinicaloptions.com/Oncology/Live%20Events/
Satellite%20Symposium/Bone%20Health%20Symposium.aspx
SaturDay, DeCember 10, 2011
7:00 am–9:00 am 
regiStration  
bridge hall
7:00 am 
Continental breakFaSt  
exhibit hall C
8:00 am–10:00 am 
SpeCial report 
exhibit hall D
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ES1-3
Treatment of Metastatic Breast Cancer – Breast Cancer as a 
Chronic Disease: Triple Negative Breast Cancer.
Stearns V. Sidney Kimmel Comprehensive Cancer Center, Baltimore, 
MD
Carcinomas of the breast that do not express the estrogen or 
progesterone receptors (ER/PR) and are not associated with over-
expression or amplification of HER2/neu have been designated 
triple negative breast cancer. These tumors represent approximately 
15-20% of all breast cancers, but are more prevalent in younger 
women, in African Americans, and in BRCA1 mutation carriers. 
Molecular profiling data suggest that many of triple negative tumors, 
but not all, are basal-like. The basal-like tumors are more likely to 
be resistant to standard therapies resulting in disease recurrence 
and poor prognosis. It is likely that triple negative breast cancer 
will be further sub classified to several additional distinct subtypes. 
Regardless of additional sub classification of the entity, the only 
treatment currently available for women with triple negative breast 
cancer is chemotherapy-based. In this symposium, I will review 
current molecular classification, prognosis and predictive markers, 
treatment options, emerging approaches, and clinical trials.
ES2-2
Mouse Models of Basal-Like Breast Cancer.
Jonkers J. Netherlands Cancer Institute, Amsterdam, Netherlands
Mouse models of human cancer provide powerful in vivo tools 
to study the mechanisms underlying drug response and acquired 
resistance. Once these processes are understood in sufficient detail 
it may be possible to design (combination) therapies that not only 
cause complete remissions but also eliminate remnant cells that might 
elicit recurrent disease.
Women carrying germline mutations in BRCA1 are strongly 
predisposed to developing basal-like breast cancers, which frequently 
contain TP53 mutations. To study the role of BRCA1 loss-of-function 
in development of basal-like breast cancer, we and others have 
established human tumor xenograft models for basal-like-breast 
cancer as well as genetically engineered mouse models (GEMMs) 
for BRCA1-mutated basal-like breast cancer based on tissue-specific 
deletion of p53 and Brca1 [1]. The mammary tumors that arise in 
these mouse models show strong similarity to basal-like breast 
cancer with respect to expression of basal cell markers, high tumor 
grade, and lack of expression of hormone receptors and HER2 [2]. 
In addition, the BRCA1-mutated basal-like tumors in our mouse 
models are characterized by a high degree of genomic instability and 
hypersensitivity to DNA-damaging agents due to loss of homology-
directed double-strand break (DSB) repair [3].
We have successfully used the xenograft models and GEMMs of 
BRCA1-deficient basal-like breast cancer for preclinical evaluation 
of therapy response and elucidation of mechanisms of acquired drug 
resistance. BRCA-deficient mammary tumors are highly sensitive 
to PARP inhibitors and platinum drugs, but none of these drugs is 
capable of causing tumor eradication and all tumors grow back after 
drug treatment. Using functional genetic screens and mouse genetics, 
we found that therapy response and resistance is affected by several 
factors, including drug efflux transporter activity [3,4], type of 
BRCA1 founder mutation and 53BP1 status [5].
The lack of tumor eradication prompted us to look for additional 
drugs targeting BRCA-deficient tumors. Using a cell-based screening 
approach, we found that bifunctional alkylators such as nimustine 
may cause durable complete remission of BRCA-deficient mouse 
mammary tumors [6], suggesting that BRCA-mutated hereditary 
breast cancers and BRCA-like sporadic tumors may be eradicated by 
dose-intensive treatment with bifunctional alkylators. In support of 
this notion, patients with breast cancers that display a BRCA1-like 
profile of genomic aberrations show a high complete remission rate 
and long progression-free survival after treatment with high-dose 
alkylating chemotherapy [7].
References
1. Drost and Jonkers (2009). Br J Cancer 101:1651-1657.
2. Liu et al. (2007). Proc Natl Acad Sci USA 104:12111-12116.
3. Rottenberg et al. (2007). Proc Natl Acad Sci USA 104:12117-12122.
4. Rottenberg et al. (2008). Proc Natl Acad Sci USA 105:17079-17084.
5. Bouwman et al. (2010). Nat Struct Mol Biol 17: 688-695.
6. Evers et al. (2010). Clin Cancer Res 16: 99-108.
7. Vollebergh M, et al. (2011). Ann Oncol 22: 1561-1570
ES2-3
Patient-Derived Xenograft Models for Preclinical Breast Cancer 
Research: Not Just “Basal” Anymore.
Lewis MT. Baylor College of Medicine, Houston, TX
Translational breast cancer research is hampered by difficulties in 
obtaining and studying primary human breast tissue, and by the lack 
of in vivo preclinical models that reflect the range of patient tumor 
biology accurately. In an effort to overcome these limitations, several 
groups have recently succeeded in propagating patient-derived breast 
cancer xenografts representing multiple breast cancer subtypes, 
including estrogen and progesterone receptor positive, and HER2 
positive tumors. In our laboratory, we have developed a diverse set 
of human breast tumors grown as xenografts in the mammary fat pad 
of SCID/Beige and NOD/SCID/IL2g-receptor null (NSG) mice, two 
relatively new immunocompromised mouse models, under various 
transplant conditions. In all cases, xenograft lines were established 
directly from breast cancer patient samples, without intervening 
culture in vitro, using the epithelium-free mammary fat pad as the 
transplantation site. Of the conditions tested, xenograft take rate 
was highest in the presence of a low-dose estradiol pellet without 
exogenous human fibroblasts. Thirty five stably transplantable 
xenograft lines representing 27 patients were established, using 
pre-treatment, mid-treatment, and/or post-treatment samples. Most 
patients yielding xenografts were “triple-negative” (ER-PR-HER2-) 
(n=21). However, we were able to establish lines from three ER-
PR-HER2+ patients, one ER+PR+HER2-, one ER+PR-HER2-, and 
one “triple-positive” (ER+PR+HER2+) patients. Serially passaged 
xenografts show phenotypic consistency with the tumor of origin at 
the histopathology level, and remarkable stability across multiple 
transplant generations at both the genomic, transcriptomic, and 
proteomic levels. Of 27 lines evaluated fully, thirteen xenografts 
showed metastasis to the mouse lung. These models, in conjunction 
with others like them, thus serve as renewable, quality-controlled 
tissue resources, and are proving useful for preclinical evaluation of 
experimental therapeutics.
ES3-3
Adjuvant Therapy in Patients with a Borderline HER-2 Status.
Oakman C, Migliaccio I, Santarpia L, Di Leo A. Hospital of Prato, 
Istituto Toscano Tumori, Prato, Italy
Adjuvant trastuzumab is indicated in individuals with early breast 
cancer which has HER2 gene amplification and/or HER2 protein 
overexpression. In the pivotal phase III adjuvant trials which tested 
the addition of trastuzumab to chemotherapy, positive HER2 status 
was defined as strong and complete cell membrane staining by 
immunohistochemistry (IHC) of >10% of invasive tumor cells or gene 
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amplification determined by fluorescence in-situ hybridisation (FISH) 
ratio of HER2 gene copy number to chromosome 17 centromeres 
(CEP17) of >2.0.
The decision to use trastuzumab is based on a binary categorization 
of HER2 as positive or negative. As such, the definition of HER2 
positivity is critical, as it dictates who will or will not receive 
potentially efficacious treatment. The challenge in creating guidelines 
for anti-HER2 treatment is that an HER2 result is described as positive 
or negative, but HER2 exists as a continuum of gene copy number 
and protein expression.
A source of uncertainty in the management of patients is the 
discordance between the diagnostic thresholds for HER2 adopted in 
the adjuvant trastuzumab trials and those specified in the subsequently 
published American Society of Clinical Oncology and the College 
of American Pathologists (ASCO-CAP) guidelines. According to 
ASCO-CAP, HER2 positivity is defined by uniform intense and 
complete membrane staining by IHC in ≥30% of cells or HER2/
CEP17 FISH ratio≥2.2. The definition is stricter than thresholds 
applied in the adjuvant trials, identifying a narrower population as 
HER2 positive.
A further source of uncertainty is discordance between IHC and 
FISH. There is generally high concordance between the two methods, 
as increased HER2 protein is generally attributable to HER2 
amplification. Discordant results may occur if one assay is correct 
and the other is incorrect, due to pre-analytic, analytic, and/or post-
analytic error. True discordance may be attributable to intra-tumoral 
heterogeneity or polysomy chromosome 17. Within a tumor, HER2 
amplification and/or overexpression may be detected in discrete 
focal HER2 amplified clones (FHAC) or in individual cells diffusely 
scattered on a dominant background of HER2 negative/equivocal 
expression. FHAC have been reported in association with discordance 
between IHC and FISH. Cells with polysomy chromosome 17 have 
extra copies of the HER2 gene. In such cases, tumors may be IHC 
positive although the HER2:CEP17 FISH ratio is not elevated. 
Notably, available data are inconsistent and uncertainty remains as 
to whether polysomy 17 without HER2 amplification is associated 
with protein overexpression
During this session, clinical situations with borderline HER2-status 
will be presented and discussed. Biological heterogeneity within 
the same tumor, polysomy chromosome 17, and moderate HER2 
positivity may contribute to determination of an uncertain HER2 
status, making unclear the benefit of adjuvant trastuzumab in these 
cases. Clinical considerations highlighting pros/cons of adjuvant 
trastuzumab in these cases, as well as updated biological information 
and clinical perspectives, will be presented.
ES5-1
Breast Cancer Trials in Developing Countries – Opportunities 
and Challenges.
Gupta S, Badwe RA, Mittra I, Nag S, Dawood S, Munshi A. Tata 
Memorial Hospital, Mumbai, Maharashtra, India; Jehangir Hospital, 
Pune, India; Dubai Hospital, Dubai, United Arab Emirates
Breast cancer (BC) incidence is low, but increasing in the urban areas 
of many developing countries (DC) because of adoption of western 
lifestyle, including reproductive and fertility patterns. Because of 
large populations in DC, the absolute number of BC patients is 
high. Distinctive features of BC in DC include younger median age 
(population pyramid effect), advanced stage at presentation, absence 
of screen detected cancers, higher fraction of triple negative and 
lower fraction of hormone responsive tumors and higher mortality/
incidence ratio.
Several common themes emerge when considering the design/
implementation of BC trials in DC:
1. Many DC have established population-based cancer registration 
process with good quality data on BC incidence. However data on 
patterns of care and long term outcome is sparse. This affects the 
accuracy of baseline assumptions while designing BC trials.
2. There is lack of unique identification numbers for citizens with 
linked national health/death registers in DC that creates difficulties 
in follow-up. Ensuring adequate follow-up in BC trials requires 
special efforts in DC.
3. There is deficient cooperative group trials culture in most DC with 
consequent inefficient recruitment, retention and follow-up in clinical 
trials, despite large absolute numbers of BC patients. Investment in 
creating such a culture is likely to be very productive in the long term.
4. Healthcare community, civil society and governments in DC are 
insufficiently sensitized to the importance of clinical trials as drivers 
of improvement in health delivery, in addition to providing solutions 
for topical problems in BC. Sustained effort in this area is likely to 
result in better acceptance of clinical trials.
5. There are cultural differences with western countries (paternalistic 
healthcare systems with passive acceptance of healthcare by 
consumers) that makes informed consent (IC) process difficult. The 
complexity of IC documents prepared by western researchers in 
collaborative projects, coupled with the desire for literal translation 
into local languages, makes the IC process daunting, even for 
experienced researchers.
6. Regulatory and ethical oversight of BC trials in DC is variable, 
ranging from sophisticated to rudimentary. Several tertiary care 
academic centers have well organized institutional review boards 
that ensure proper conduct of BC trials. Approval of international 
collaborative projects, especially those that involve transfer of 
biological material for translational science, is difficult in many 
countries.
7. Since BC patients in DC receive fewer lines of therapy as a routine 
standard, there are opportunities to research new interventions in less 
heavily treated patients.
8. There is opportunity to research technology that has not yet been 
widely adopted in DC (such as sentinel lymph node technique versus 
other forms of reduced axillary surgery, newer radiation delivery 
techniques) in randomized trials.
9. Testing neoadjuvant therapies in large tumors is very feasible in 
DC beacuse of large numbers.
There are other research opportunities in DC that can be themes of 
collaborative research with developed countries. Simplicity of design 
and ease of implementation will facilitate such collaborations. These 
will be discussed in the final presentation.
ES5-3
Novel Approaches to Breast Cancer Management in Low-Income 
Countries.
Kerr DJ. Africa-Oxford Cancer Consortium
There is clear evidence that the global burden of cancer is increasingly 
affecting low and middle – income countries, effectively those 
nations who have least health infrastructure to deal with complex 
diseases like cancer. A new approach to cancer therapy is required 
that combines efficacy, reduced side effects, cost-effectiveness 
with a delivery mechanism that does not rely on access to distant 
and expensive regional cancer centres. To this end we propose to 
develop a combination oral chemotherapy formulation which is 
likely to offer a clinically useful advantage to patients suffering from 
breast cancer For almost half a century, systemic therapy of cancer 
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has been dominated by the use of cytotoxic chemotherapeutics. 
Most of these drugs are DNA damaging agents or microtubule 
inhibitors that are designed to inhibit or kill rapidly dividing cells, 
often administered in single doses or short courses of therapy at the 
highest doses possible, with prolonged breaks (generally of 2–3 weeks 
in duration) between successive cycles of therapy. A reappraisal 
of the optimal way of administering chemotherapy is underway. 
Instead of using short bursts of toxic chemotherapy interspersed 
with long breaks to allow recovery from the harmful side effects, 
there is now a shift in thinking towards the view that more chronic 
or decelerated schedules of drug administration using much smaller 
individual doses than the MTD may be more effective — not only 
in terms of reducing certain toxicities, but perhaps also improving 
anti-tumour efficacy with an additional anti-endothelial cell effect, 
so-called ‘metronomic’ chemotherapy.We propose development of 
a flat dose, combination, oral chemotherapy formulation which will 
contain the following classes of antineoplastic agents, which have 
been shown to have activity in breast cancer. Fluoropyrimidines eg 
Capecitabine  ; Alkylating Agents eg Cyclophosphamide ; Antiemetics 
eg Metoclopramide; administered continuously at doses inducing 
Grade 1 toxicity.
The drug doses will be carefully selected to provide moderately 
effective cancer control with reduced toxicity profiles. The clinical 
development pathway will be conducted in India and SubSaharan 
Africa with a view to providing a managed package of care which will 
allow delivery of the MetroPill to women with breast cancer in rural 
and minor urban settings rather than the regional cancer centres. We 
will train a cohort of district general hospital doctors/nurses to monitor 
and deliver the MetroPill,  supported by a teaching package app and 
mobile phone technology to provide symptom support for patients. 
A phase 1 feasibility and pharmacokinetic study will be performed in 
20-30 patients followed by single arm Phase 2 studies(n=40 patients) 
in breast cancer patients, which will report response rates, progression 
free survival and quality of life as a prelude to phase 3 trials.  We 
believe that this is the sort of lateral approach we must consider if 
we are to take elements of cancer therapy to those regions which lie 
beyond the shadow of conventional cancer centres.
ES6-1
Oncofertility: Translation in Multiple Dimensions.
Woodruff TK. Northwestern University
Cancer is now a disease with a variety of treatment options, which are 
leading to longer and more productive lives by survivors. Globally, 
there are 10 million people diagnosed with cancer.  10% of these 
newly diagnosed men and women are under the age of 45 years old. 
Infertility can be a consequence of many of the more aggressive 
chemo- and radiation therapies that prolong and save lives.  The ability 
to easily preserve sperm prior to cancer treatment provides hope at 
the time of diagnosis and families later in life for male survivors.  A 
notable example is Tour de France winner Lance Armstrong who 
has three children conceived using sperm frozen days before he 
underwent the massive chemo- and radiation therapy that saved his 
life. Unlike sperm, the female germ cell, the oocyte or egg must be 
retrieved surgically.  Moreover, the vast majority of collected oocytes 
will be immature and cannot be used immediately by a woman who 
is ready to start a family.  The overall hypothesis of the program is 
that effective fertility-extending options can be provided to young 
women undergoing life-preserving cancer treatment. The purpose of 
our work is to bring physicians, medical ethicists, social scientists 
and basic scientists together to develop new strategies for fertility 
preservation for female cancer survivors under the new discipline of 
oncofertility.   At the basic science level, complex issues of ovarian 
function and preservation must be addressed including the problem 
of follicle growth and development in vitro. Our investigative 
group has developed a 3-dimensional system that supports follicle 
development, largely, we believe, because the links between the 
oocyte and its surrounding cells are maintained.   The goal of our 
program and the broader Oncofertility Consortium is to explore and 
expand the reproductive options available to young people facing a 
fertility-threatening but life-preserving cancer treatment.
This work is supported by NIH/NICHD Structure-Function 
Relationships in Reproductive Science, U54 HD041857; and, the 
Oncofertility Consortium, UL1DE019587 and RL1HD05829  http://
oncofertility.northwestern.edu/
ES6-3
Breast Cancer in the Older Adult.
Hurria A. City of Hope Comprehensive Cancer Center, Duarte, CA
Breast cancer is a disease associated with aging. In the US, the median 
age of breast cancer diagnosis and death is 61 years and 68 years, 
respectively. The number of older adults in the US is rising, and the 
number of individuals age 65 and older is expected to double by the 
year 2030. This demographic shift will lead to an increase in the 
number of individuals diagnosed with breast cancer. It is estimated 
that from 2010 to 2030 there will be a 57% growth in the number of 
new cases of breast cancer in patients age 65 and older.1 A challenge 
in caring for older adults with breast cancer is that they have been 
historically underrepresented in clinical trials that set the standard 
for breast cancer care.2 However, a growing body of evidence-based 
literature can be utilized to inform and optimize the care of the older 
adults with breast cancer. This presentation will focus on the treatment 
of early stage breast cancer in older adults, including the risks and 
benefits of local and systemic therapies, as well as survivorship issues.
Recently reported phase III studies have led to advances in the 
treatment of older adults with breast cancer. A phase III randomized 
study evaluated the role of radiation therapy following lumpectomy 
in patients age 70 and older with stage I hormone receptor (HR) 
positive breast cancer who received treatment with tamoxifen. Receipt 
of radiation therapy was associated with a decrease in the risk of 
locoregional recurrence; however, there was no difference in overall 
survival. The study results underscore the importance of competing 
comorbidity as a cause of death in older adults with early stage breast 
cancer.3 The role of axillary lymph node dissection was evaluated 
in a randomized study of women over age 60 with node-negative, 
HR positive breast cancer who received treatment with tamoxifen. 
Patients were randomized to breast surgery and axillary dissection, 
or breast surgery alone. There was no difference between disease-free 
and overall survival in the 2 study arms.4 A phase III randomized 
study evaluated the efficacy of standard adjuvant IV chemotherapy 
(doxorubicin and cyclophosphamide [AC] or cyclophosphamide, 
methotrexate, and 5-fluorouracil [CMF]) versus oral chemotherapy 
(capecitabine) in patients age 65 and older with stage I-III breast 
cancer. Those patients who received standard chemotherapy showed 
improvement in progression-free and overall survival compared with 
patients who received capecitabine. This study demonstrates that IV 
polychemotherapy regimens remain the standard of care for older 
adults who are prescribed adjuvant chemotherapy.5
These phase III studies advance our understanding in the care of 
older adults with breast cancer. Furthermore, they demonstrate 
the feasibility and importance of accruing older adults to phase III 
trials, which will improve our evidence-based care of this growing 
population.
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ES8-1
Breast Reconstruction with Implants and Post-Mastectomy 
Irradiation: Algorithm and Outcomes.
Cordeiro PG. Memorial Sloan-Kettering Cancer Center, New York, 
NY
Breast reconstruction in the face of radiotherapy proposes a unique set 
of challenges to the plastic surgeon and often alters the algorithm of 
the reconstruction. The impact of radiation changes on the alloplastic 
breast reconstruction is unpredictable. The author will review current 
approaches to reconstruction of the patient if they are to undergo 
post-mastectomy radiation. The algorithm for reconstruction and 
outcomes after radiation will be presented.
ES8-3
Measuring Outcomes in Breast Reconstruction: The Patient 
Perspective.
Pusic A. Memorial Sloan-Kettering Cancer Center, New York, NY
In breast reconstruction, understanding patients’ perceptions of 
surgical results is of primary importance. As new reconstructive 
techniques continue to advance, surgeons and patients require high 
quality information on key outcomes such as patient satisfaction and 
quality of life. The need for meaningful data is further accentuated by 
concerns over healthcare expenditures and the increasing involvement 
of patients in their own surgical decision-making.
Patient-reported outcome (PRO) measures are questionnaires 
specifically designed to quantify aspects of outcome such as patient 
satisfaction and health-related quality of life. When developed 
and validated according to internationally recognized standards, 
PRO measures can provide reliable and valid assessment of patient 
outcomes. Traditionally, PRO measures were used in clinical research 
alone; however, advances in psychometric methods have now 
facilitated the development of a new generation of PRO measures 
that are also useful in clinical care.
This presentation will provide an overview of PRO research in 
breast reconstruction. The BREAST-Q, a new PRO measure for 
breast surgery patients, will be highlighted. Physicians will gain the 
necessary critical appraisal skills to interpret and apply evidence from 
PRO studies in their own clinical practice. Approaches to routine use 
of PRO measures in clinical care will also be described.
DL1-1
Adaptive Resistance to Targeted Therapies.
Brugge JS, Muranen T, Zoeller J, Worster D, Iwanicki M, Selfors L, 
Mills G. Harvard Medical School, Boston, MA; MD Anderson Cancer 
Center, Houston, TX
While therapies that target specific molecular alterations in human 
tumors are showing significant efficacy in the clinic, drug resistance 
remains a major obstacle. Studies from our laboratory and others 
have provided evidence that PI3K- and HER2- targeted therapies 
induce a program of molecular responses to drug treatment that 
significantly contributes to drug resistance. Interestingly, we have 
found that resistance in vitro and in mouse models is significantly 
enriched in cells attached to basement membrane. This resistance 
correlates with specific upregulation of the adaptive response in the 
matrix-attached cells. Importantly, inhibition of key components 
of the adaptive response, like BCL-2, abrogates the drug-induced 
adaptive resistance. We propose a model in which matrix-protection 
from targeted therapies allows survival of a subpopulation of tumor 
cells associated with matrix/basement membrane which expand  and 
lead to more stable drug resistance.
PL1-1
How To Use Endocrine Therapy for Breast Cancer: Beyond the 
Basics.
Winer EP. Dana-Farber Cancer Institute
Over two thirds of all breast cancers are hormone receptor positive. 
The majority of these tumors have some degree of sensitivity to 
endocrine treatments.  The approach to endocrine therapy has 
become more complex over the past decade, and there are more 
treatment choices than before.  Not only are there choices about which 
endocrine therapy to use, but also important decisions about how long 
to continue treatment and how to sequence agents.    It has become 
clear that the benefits and risks of endocrine therapy vary both from 
tumor to tumor and from person to person.  The landscape will soon 
become even more complicated as targeted therapies are combined 
with endocrine therapy to prevent or reverse drug resistance.  This 
lecture will focus on a number of key issues:  1) Can we improve 
upon a 5 year course of tamoxifen in premenopausal women?  2) 
Given the high risk of late recurrence in many patients with hormone 
receptor positive disease, which patients will benefit from extended 
adjuvant therapy and what should this therapy be?  3)  Is the use of 
an aromatase inhibitor alone in postmenopausal women sufficient 
therapy for all breast cancer patients and how should we select 
individuals who should be considered for other approaches?  4) In 
2011, are there patients with hormone receptor positive disease who 
should not receive adjuvant endocrine therapy?  5) What approaches 
can be used to circumvent resistance to hormonal therapy, and how 
quickly will they be incorporated into clinical practice?  The talk will 
address the dilemmas that are most vexing for clinicians and have 
immediate relevance for clinical practice.
BS1-1
Stem Cells, Cancer, and Cancer Stem Cells.
Wahl GM. Salk Institute for Biological Studies
Significant advances in breast cancer prevention and treatment have 
come from strategies based on knowledge of mammary cell biology 
and the unique molecular fingerprints of individual tumors.
The work I will present concerns the contribution of stem-like cells we 
and others have found in many breast cancers.  It has been proposed 
that such cells may mediate cancer initiation, perpetuation, and 
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generation of tumor heterogeneity, drug resistance and metastasis. 
The problem of  “intratumoral heterogeneity” is very important 
to understand, for it provides a plausible mechanism of resistance 
to targeted therapies and can contribute to metastasis, two critical 
problems to solve to increase survival and improve cure rates of 
breast cancer patients.
Cancer has been called a caricature of embryogenesis. However, 
we are not aware of studies to determine whether mammary stem 
cells arise during mammogenesis, or whether they are only found 
in the adult.  If such cells do arise during development, do they 
exhibit similarities to the stem-like cells detected in breast cancers? 
We explored these questions by isolating stem cells from mice, and 
then studying archival tumor microarrays and human cell lines. 
We dissected each stage of mouse mammogenesis and determined 
that fetal mammary stem cells (fMaSC) are not measurable by 
transplantation analyses early in development.  However, they 
increase in abundance dramatically in late development, at the time 
when the rudiment invades through the mesenchyme into the adjacent 
fat pad. The cell surface properties of these cells enabled us to purify 
them extensively, and determine the genes they express, as well as 
those expressed in the stroma with which they associate.  We found 
that the fMaSCs have many similarities to aggressive breast cancers, 
including an impressive enrichment for the fMaSC gene expression 
program in basal-like breast cancers.  Interestingly, the associated 
fetal stromal (fSTR) cells have similarities to what have been termed 
“Cancer Stem Cells”, and we found the fSTR signature enriched 
in the rather rare Claudin-low and metaplastic breast cancers.  We 
have also identified growth regulatory pathways that may provide 
therapeutic targets for breast cancers exhibiting an fMaSC-like gene 
expression signature.
Our studies establish significant links between the molecular 
pathways present in both the stem cell containing and the stromal 
associated compartments of the embryo.  How stem-like cells 
arise in breast cancer, however, still remains an open question.  An 
intriguing possibility is suggested by our observation that breast 
cancers encoding mutant p53 genes are also highly enriched for 
stem-like gene expression signatures.  We propose that just as p53 
deficiency increases the frequency of somatic cell reprogramming, 
p53 deficiency in breast cancer may enable cancer cells to revert to 
an embryonic stem-cell state that offers advantages for cancer cell 
survival, proliferation, and ability to invade adjacent tissue.
Funding: This work was funded by grants from the Breast Cancer 
Research Program of the Department of Defense, the Breast Cancer 
Research Foundation, Susan G. Komen for the Cure, and the G. 
Harold and Leila Y. Mathers Charitable Foundation.
BS1-2
Stem and Progenitor Cells and the Origins of Breast Cancer 
Heterogeneity.
Smalley MJ, Molyneux G, Melchor L. The Institute of Cancer 
Research, London, United Kingdom
Breast cancer heterogeneity results from different genetic lesions 
occurring in different stem or progenitor cells of origin. We previously 
demonstrated that deletion of the Brca1 tumour suppressor in basal 
stem cells or luminal estrogen receptor negative progenitors in 
the mouse mammary epithelium resulted in very different tumour 
phenotypes. Remarkably, the progenitor origin tumours most closely 
resembled human BRCA1 tumours. Having examined what occurs 
when the same genetic lesion is made is different cells of origin, we 
are now examining the results of making different lesions in the same 
cell. We have knocked out different combinations of Brca2, Pten 
and p53 in the luminal progenitors and carried out a comparative 
analysis of the resulting tumours. Confirming the hypothesis that 
tumour heterogeneity is dependent on both genetic lesion and cell 
of origin, widely differing tumour phenotypes were generated. 
Remarkably, one gene combination generated tumours in which the 
same cells expressed both basal and luminal cell lineage terminal 
differentiation markers. These results have important implications 
for our understanding of the origins of tumour cellular heterogeneity.
SR1-1
Breast Cancer and the Environment: A Life Course Approach – 
Report Release from an IOM Committee.
Hertz-Picciotto I. University of California, Davis
In response to a request from Susan G. Komen for the Cure®, an 
Institute of Medicine (IOM) committee was convened to review and 
assess the strength of the science base regarding the relationship 
between breast cancer and the environment. As part of their charge, 
the committee members reviewed the evidentiary standards for 
identifying and measuring cancer risk factors and the methodological 
challenges involved in conducting research on breast cancer and the 
environment. They also considered the potential interaction between 
genetic and environmental risk factors. The committee’s report notes 
evidence-based actions that women could take to reduce their risk of 
breast cancer and offers recommendations for future research on breast 
cancer and the environment. The results of this IOM committee’s 
work will be presented.
SR1-2
Breast Cancer and the Environment: A Life Course Approach – 
Report Release from an IOM Committee.
Hiatt RA. University of California, San Francisco, San Francisco, CA
In response to a request from Susan G. Komen for the Cure®, an 
Institute of Medicine (IOM) committee was convened to review and 
assess the strength of the science base regarding the relationship 
between breast cancer and the environment. As part of their charge, 
the committee members reviewed the evidentiary standards for 
identifying and measuring cancer risk factors and the methodological 
challenges involved in conducting research on breast cancer and the 
environment. They also considered the potential interaction between 
genetic and environmental risk factors. The committee’s report notes 
evidence-based actions that women could take to reduce their risk of 
breast cancer and offers recommendations for future research on breast 
cancer and the environment. The results of this IOM committee’s 
work will be presented.
BS2-2
Nuclear Receptor Coactivators: Physiology and Disease.
O’Malley BW. Baylor College of Medicine, Houston, TX
Nuclear receptors control gene expression by recruiting transcriptional 
coactivators (or corepressors). The coactivators are ‘master regulators’ 
that activate genes to control physiologies such as reproduction, 
growth and metabolism. Consequently, they are major players in 
the development of many inherited and acquired endocrine-related 
pathologies such as fertility/endometriosis, cancers, and disorders of 
carbohydrate, lipid and protein metabolism. The coactivator proteins 
provide important insights to polygenic diseases and represent a new 
class of drug targets for therapeutic interventions.
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MS1-1
Imaging Cancer Invasion In Vivo: Mechanisms and Implications 
for Therapy.
Friedl P. Radboud University Nijmegen
The tumor microenvironment contributes to cancer invasion, growth 
and survival and thereby impacts tumor responses to therapy. 
Using infrared-excited multiphoton microscopy in orthotopic 
fibrosarcoma and melanoma xenografts, we here identify a novel 
radio- and chemoresistance niche consisting of invading tumor cell 
strands consisting of several hundred connected cells located within 
collagen-rich stroma nearby blood and lymph vessels. Despite 
normoxia, perivascular invasion strands were resistant to high-dose 
hypofractionated irradiation which otherwise was sufficient to induce 
regression of the tumor main mass. This invasion-associated chemo- 
and radioresistance was sensitive to the simultaneous inhibition of b1 
and b3 integrins by RNA interference or combined anti-b1/aV integrin 
antibody treatment leading to proliferation arrest, anoikis induction 
and subtotal to complete regression of both tumor lesion and invasion 
strands. Thus, collective invasion is an important invasion mode in 
solid tumors into a microenvironmentally priviledged perivascular 
survival niche which conveys radioresistance by integrin-dependent 
signals.
MS1-2
Tumor Entrained Neutrophils Inhibit Seeding in the Pre-
Metastatic Lung.
Granot Z, Heneke E, Comen EA, King TA, Norton L, Benezra R. 
Memorial Sloan-Kettering Cancer Center
Primary tumors have been shown to prepare distal organs for later 
colonization of  metastatic cells by stimulating organ-specific 
infiltration of bone marrow derived cells. We have recently 
demonstrated that neutrophils are mobilized by the primary tumor 
and accumulate in the lung prior to the arrival of metastatic cells 
in mouse models of breast cancer. Tumor-entrained neutrophils 
(TENs) inhibit metastatic seeding in the lungs by generating H2O2 
and tumor secreted CCL2 is both required and sufficient for optimal 
anti-metastatic entrainment of G-CSF-mobilized neutrophils. TENs 
are present in the peripheral blood of breast cancer patients prior to 
surgical resection but not in healthy individuals. Thus, while tumor-
secreted factors contribute to tumor progression at the primary site, 
they concomitantly induce a neutrophil-mediated inhibitory process 
at the metastatic site.
MS1-3
Tumor Heterogeneity and Metastasis.
Ellis MJ, Perou C, Carey L, Mardis E. Washington University School 
of Medicine, St Louis, MO; UNC, Chapel Hill, NC
Massively parallel sequencing using Next Gen sequencing 
approaches have opened a new window into our understanding of 
the molecular architecture of breast cancer. A significant advantage 
of these technologies are that they are digital in nature because the 
measurement technology begins with single DNA molecules attached 
to a substrate. As a result, not only do these technologies provide an 
efficient means to identify somatic mutations, information is also 
provided on the frequency with which any given mutation is observed 
within the population of DNA molecules in the sample under analysis.
The first and most striking feature of Next Gen analysis of breast 
cancer is the large numbers of somatic mutations that have been 
identified. Genome wide, thousands of mutations can be present in 
a single tumor. While this finding generates immense complexity 
from the perspective of defining biological drivers versus passengers, 
it does open up a new opportunity to study variations in mutation 
frequency. In a perfectly monoclonal tumor with a diploid genome 
and no contaminating normal cell DNA the mutation frequencies 
generated by digital sequencing will be 50% for a heterozygous 
mutation or 100% for homozygous mutations. Very few breast 
cancers subjected to whole genome sequencing exhibit this pattern, 
rather mutations occur with a wide variation of frequencies from the 
detection limit, around 5%, through to 100%. Furthermore mutation 
frequency clustering often occurs, a phenomenon best explained by 
the presence of a repertoire of mutations present in a founder clone 
that are present in all tumors, combined with additional less common 
mutations that represent a subdominant or minority population of cells 
that have arisen through additional clonal outgrowth.
In a multi-clonal model one of the most critical questions is “which 
clone determines the prognosis?”. One way to begin to answer this 
question is to sequence tumors before and after therapy and to compare 
primary tumors versus metastases. In our initial experience of a patient 
with a basal-like breast cancer in which a whole cancer genome was 
generated from her primary, her subsequent brain metastasis and a 
mouse xenograft generated from the breast primary, there was clear 
evidence of a shift in mutation frequency primary to metastasis, 
suggesting the brain metastasis arose from a minor sub-clone. The 
mutational profile of the xenograft more closely resembled the 
metastasis rather than the primary, suggesting the grafting process 
captured the metastatic clone (1).
In this invited lecture we will present an extension of our sequencing 
experiences with further human progenitor-mouse xenograft 
comparisons, comparisons between human primaries and paired 
metastases and also examples of ER+ breast cancer genomes 
obtained before and after neoadjuvant endocrine therapy. In all these 
experiments multiclonality appears to be the rule rather than the 
exception. The clinical and biological implications of these findings 
will be discussed.
1. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. 
Genome remodelling in a basal-like breast cancer metastasis and 
xenograft. Nature. 2010;464(7291):999-1005. PMCID: 2872544.
MS2-1
Early Life Exposures and Breast Cancer Risk: Preeclampsia 
and Puberty.
Forman MR. UT MD Anderson Cancer Center
Women diagnosed with preeclampsia (PE)  in pregnancy have a 
12-72% reduced risk of breast cancer compared to women with a 
normotensive pregnancy while her daughter from the index pregnancy 
also has a lower breast cancer risk than normotensive (NT) daughters. 
Why is this so?  The preeclamptic (PE) pregnancy is highly androgenic 
with low levels of estrogens and insulin-like growth factor -1 levels. 
We followed a cohort of offspring of preeclamptic pregnancies 
and of normotensive pregnancies from birth through 12.8 years to 
examine whether daughters of the PE pregnancy would delay breast 
development, have lower estrogens and IGF-1 levels in puberty 
compared to their normotensive offspring and also compared factors 
influencing age at onset of puberty in the PE and NT girls.   In young 
pubertal aged girls of 10 years, high dehydroepiandosterone- sulfate 
levels (DHEAS) but low testosterone levels may reflect the in utero 
exposures of the PE compared to the NT offspring. By 13 years, PE 
daughters had a 20% lower risk of breast development (OR= 0.80 95% 
CI 0.70-1.00). In an examination of the role of early life exposures on 
age at onset of puberty, we report that age of greatest weight gain in 
infancy is earlier for the NT (3-6 months) than the PE (6-12 months) 
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and that age of greatest weight gain in infancy is associated with the 
odds of age at onset of puberty.  Our findings and those of others in 
early life exposures and breast cancer risk provide clues to tailoring 
the effect of early exposures by maternal morbidity in pregnancy.
MS2-2
Environmental Exposures, Epigenetics, and Epidemiology: 
Influence of Environmental Factors on Pubertal Maturation and 
Breast Cancer Etiology.
Hiatt RA. University of California, San Francisco, San Francisco, CA
Although much of breast cancer etiology can be explained on the 
basis of reproductive and family histories, there remains concern 
among both the public and scientific communities about the possible 
role of environmental factors.  Several well-established observations 
suggest a role of external environmental factors including the 
5-fold international differences in incidence rates and the rapid 
inter-generational increases in incidence with migration from low 
to high incidence countries. Although epidemiologic studies in 
adult populations have generally failed to discover a strong role 
for environmental factors in breast cancer etiology, emerging data 
suggests that relevant exposures may have effects in early life during 
so-called “windows of susceptibility” and be missed by attempted 
measurement in adulthood.  Exposures to ionizing radiation and 
to diethylstilbestrol during pubertal development and in utero, 
respectively, are two examples. Recently, more attention has been 
directed to other environmental exposures, especially endocrine 
disrupting chemicals (EDCs) during early development and the 
pubertal period in particular. Many EDCs can now be measured in 
biospecimens from young prepubertal girls and in pregnant women, 
and animal studies suggest that some of these may cause changes in 
reproductive systems.
Early menarche is a well-established risk factor for breast cancer and 
increases risk approximately 2-fold compared to later menarche. The 
average age at menarche has also dramatically decreased in developed 
countries over the last 100 years, likely as the result of environmental 
factors including diet. However, the relevant exposures and their 
mode and timing of action are not well understood. An on-going 
epidemiologic cohort study of 1239 pre-pubertal girls from diverse 
race/ethnic and socioeconomic backgrounds has documented still 
earlier ages of pubertal onset and is offering insights into the potential 
role of EDCs and other chemicals, diet, physical activity, psychosocial 
and genetic factors on pubertal onset, the age of menarche and other 
markers of early development. This research on early environmental 
exposures in humans is proving both exciting and challenging and 
requires consideration of the complex nature of  breast cancer etiology.
MS2-3
Breast Cancer and the Environment: Developmental 
Reprogramming of Cancer Susceptibility by Early Life 
Environmental Exposures.
Walker CL. Texas A&M Institute for Biosciences and Technology, 
Houston, TX
In the last two decades it has become appreciated that adverse 
environmental exposures early in life can have a profound impact on 
susceptibility to adult diseases such as obesity, cardiovascular disease, 
diabetes, metabolic syndrome and cancer.  The “developmental 
origins of health and disease” or DOHaD hypothesis, posits that 
environmental exposures during key periods of tissue development 
and organogenesis can “reprogram” the cell’s epigenome in a way that 
increases susceptibility to disease later in life.  It is now clear that even 
brief environmental exposures can reprogram developing tissues and 
profoundly increase risk of developing cancer in adulthood decades 
after the exposures occurred.  This developmental reprogramming 
has been best appreciated in the context of early life exposures to 
environmental agents such as xenoestrogens that mimic steroid 
hormones, with such exposures dramatically increasing susceptibility 
to hormone-dependent tumors of the breast and reproductive 
tract later in life.  Recent advances in the field of environmental 
epigenomics have provided data that epigenetic alterations in both 
DNA methylation and histone methyl marks are induced during 
developmental reprogramming. In some tissues, xenoestrogens induce 
these epigenetic alterations via activation of non-genomic signaling, 
providing a direct link between xenoestrogen exposure and disruption 
of the cell’s epigenetic machinery.  For example, xenoestrogen-
induced activation of non-genomic PI3K/AKT signaling has been 
shown to target the histone methyltransferase EZH2, modulating 
the activity of this epigenetic “writer” and disrupting the proper 
“installation” of epigenetic histone methyl marks during development. 
Understanding the nature of the epigenetic reprogramming induced 
by early life exposures to xenoestrogens (and other environmental 
agents) has important implications for our understanding of breast 
cancer susceptibility across the life-course and for identifying 
effective strategies to prevent this disease.
PL2-1
Macrophages as Novel Targets for Therapy in Breast Cancer.
Coussens LM. University of California San Francisco
While BC has not historically been linked to underlying inflammation 
or infection, it exhibits tumor-associated inflammation marked by 
infiltration of innate and adaptive immune cells into developing 
tumors. In BC, macrophages are one of the most abundant innate 
immune cells present. BC-associated macrophages are regulated in 
part by colony stimulating factor 1 (CSF1), a key cytokine involved 
in monocyte/macrophage maturation, recruitment and activation, and 
its cognate receptor CSF1R. Macrophage presence in BC correlates 
with increased CSF1, increased vascular density, and worse clinical 
outcome. We reported that CD4+ T cells promote invasion and 
metastasis of mammary adenocarcinomas by directly regulating 
macrophage phenotype that in turn fosters invasive tumor growth, 
presence of circulating tumor cells and pulmonary metastasis. This 
preclinical data implied that women with BC heavily infiltrated by 
macrophages would have a worse clinical outcome as compared 
to tumors not heavily infiltrated with macrophages. We evaluated 
survival outcomes in 698 women with invasive BC treated with 
surgery alone and found that recurrence-free survival could be 
stratified based upon macrophage and T cell infiltration. Thus, we 
investigated CSF1 and CSF1R antagonists, in combination with 
standard-of-care chemotherapy (CTX) in mouse models of mammary 
carcinogenesis. We found that when macrophage infiltration 
in mammary adenocarcinomas was blocked, paclitaxel (PTX) 
chemosensitivity was increased, accompanied by development of 
productive anti-tumor immune responses and CD8+ cytotoxic T 
cell (CTL) infiltration. The combined effects of these changes were 
reduced primary tumor growth, 85% reduction in metastases and 
increased survival. In collaboration with clinical colleagues, we are 
currently evaluating the clinical benefit of macrophage modulation 
in preclinical models of BC to facilitate biomarker identification, 
and inform clinical trials of CTX in combination with macrophage-
antagonists. Based on our preliminary data, we hypothesize that 
components of macrophage responses in BC can be identified to serve 
as biomarkers for risk stratification. And, that these components can be 
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effectively targeted for therapeutic intervention, resulting in reduced 
late-stage BC development and metastasis when combined with CTX.
LMC acknowledges generous support from the NIH/NCI 
(R01CA130980, R01CA13256, R01CA140943, R01CA15531), 
the Department of Defense (W81XWH-09-1-0342, W81XWH-10-
BCRP-EOHS-EXP) and the Susan G Komen Foundation (KG111084)
BS3-1
Extrinsic and Intrinsic Force Regulation of Breast Cancer 
Progression and Treatment.
Weaver VMM. University of California San Francisco, San Francisco, 
CA
Breast tissue development and homeostasis are tightly regulated by 
mechanical cues. Alterations in tensional homeostasis characterize 
breast cancer. The challenge is to clarify how chemical and mechanical 
cue collaborate to regulate breast tissue function and to determine 
when and how these forces regulate breast cancer behavior. The 
Weaver group has been studying how cells in the breast sense 
and transduce mechanical cues to regulate their behavior and how 
altered mechanical force compromises breast tissue homeostasis to 
drive cancer (Dufort et al., Nature Mol Biol Rev 2011). Our work 
focuses on clarifying the role of force in normal breast behavior and 
in breast cancer initiation, transformation, metastasis and treatment 
response. We showed that extracellular matrix (ECM) stiffness, 
which is tightly controlled through matrix concentration, topology 
and posttranslational modifications, is a critical isometric force that 
modulates mammary gland morphogenesis and tumorigenesis. We 
demonstrated that the ECM associated with the mammary epithelium 
progressively stiffens as the tissue transforms and that breast cancer 
subtype is characterized by increasing ECM stiffness. Thus, normal 
human breast tissue is quite soft, the ECM associated with fibrocystic 
lesions is twice as stiff, ER/PR+ve invasive breast cancers are 4 fold 
stiffer and triple negative breast lesions are the stiffest (6-10 times 
stiffer). We showed that a stiffened ECM modifies breast tissue 
behavior by promoting the assembly of integrin focal adhesions which 
potentiate growth factor receptor signaling and induce cytoskeletal 
remodeling and actomyosin contractility (Paszek et al., Cancer Cell 
2005; Paszek et al., PLOS Computational 2009). We determined 
that ECM stiffness also potentiates the tumor promoting effect of 
oncogenes such as Ras, EGFR and ErbB2 by increasing the activity of 
ERK, wnt and PI3 kinase and inducing tissue fibrosis. Inducing ECM 
stiffness promotes the malignant transformation of pre malignant 
oncogenically-primed mammary epithelial cells, whereas inhibiting 
ECM stiffening prevents breast tissue fibrosis and tumor progression 
and metastasis (Levental et al., CELL 2009). Importantly, the tissues 
response to force also depends upon the cellular mechanoresponsive 
machinery and we determined that oncogenic transformation 
and elevated chemokine and cytokine signaling induces aberrant 
force sensing and elevated breast tumor tension. Most notably we 
demonstrated that oncogenic signaling through Ras signaling to 
ERK induces ECM remodeling and stiffening which are required 
to stimulate wnt thereby driving tumor cell invasion to induce an 
epithelial to mesenchymal like transition that potentiates breast tumor 
aggression and metastasis. More recently we found that ECM stiffness 
dictates the efficacy of treatment response - with high ECM stiffness 
potentiating chemo, immune and radiation-induced tumor regression 
and apoptosis. The clinical relevance of these findings are now being 
investigated with collaborators at UCSF and Duke. (supported by 
DOD BCRP W81XWH-05-1-0330 and NCI U54CA143836-01, R01 
CA138818-01A1, U01 CA151925-01, RO1 CA085492, and R01 
CA140663-01A2 to VMW, NIH grant 1U01ES009458-01 to ZW and 
NCI SPORE P50 CA058207 to VMW, CP, & SH).
BS3-2
Mammary Stroma as an NSAID Target; Implications for 
Pregnancy-Associated Breast Cancer.
Schedin PJ, Lyons TR, O’Brien J, Callihan E, Russell T, Martinson 
H, Tan A-C, Hansen K, Keely PJ, Borges V. University of Colorado 
Denver Anschutz Medical Campus, Auroroa, CO; University of 
Wisconsin, Madison, WI
Utilizing a young women’s breast cancer cohort from the University 
of Colorado Cancer Center, we show that women diagnosed as late 
as five-ten years postpartum have worse prognosis than nulliparous 
women or women diagnosed during pregnancy, and represent ~50% 
of all young women’s breast cancer patients. We propose that breast 
involution following pregnancy accounts for this poor prognosis. 
Characterization of involution identifies tissue remodeling programs 
that share similarities with microenvironments known to promote 
metastasis. Using SHG imaging, we find fibrillar collagen bundles 
with radially-aligned fibers similar to those observed in invasive 
tumors deposited in the involuting gland. By immunohistochemistry 
and FACS we find macrophages with an M2-polarization-like profile 
similar to tumor-associated macrophages at abundant levels during 
involution. In three independent mouse models for post-partum 
breast cancer, we isolate postpartum mammary gland involution as 
a driving force for cancer progression. Mammary tumors arising in 
the mouse involuting microenvironment express COX-2 and isolated 
tumor cells are motile and invasive in a collagen-1/COX-2 dependent 
manner. Targeting involution-macrophages as likely mediators of 
tumor promotion was accomplished using a previously described 
mouse transgenic model. Macrophage depletion during involution 
had catastrophic effects on normal mammary gland involution. 
Conversely, inhibition of COX-2 with celecoxib, aspirin or ibuprofen 
did not interfere with postpartum lobular regression. COX-2 inhibition 
did decrease tumor growth, local tumor cell dispersion and lung 
metastasis. NSAID treatment also suppressed collagen and tenascin-C 
deposition in the involuting microenvironment, suggesting that 
modulation of extracellular matrix proteins may be a novel mechanism 
by which NSAIDs exhibit chemopreventive activity. Our studies 
indicate two distinct roles for COX-2 in the postpartum setting. 
COX-2 activity within the tumor cell is required for invasiveness 
and COX-2 activity in the host promotes collagen fibrillogenesis.
Several correlative observations implicate the collagen/COX-2 
pathway in postpartum breast cancer in women: involuting breast 
tissue has increased collagen with radially aligned fibers, analysis of 
11 publically available microarray data sets shows high COL1A and 
COX-2 independently correlate with decreased relapse free-survival 
in young breast cancer patients, and COX-2 protein is observed in 
DCIS lesions in postpartum cases at higher levels than nulliparous 
cases.
In summary, our studies suggest further research into COX-2 inhibitor 
use might provide a novel strategy to improve the prognosis of young 
women should they be diagnosed with postpartum breast cancer. The 
question of whether an NSAID based intervention study could be 
aimed at recently pregnant women at high risk for breast cancer also 
remains to be determined, but is an extremely desirable objective 
given that the ~ 6 million pregnancies in the US per year.
Supported by grants from DoD Synergistic Idea Awards BC060531 
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MS3-2
HIF-1, Metabolism, and Breast Cancer Metastasis.
Luo W, Zhang H, Wong CC-L, Gilkes DM, Hu H, Semenza GL. The 
Johns Hopkins University School of Medicine, Baltimore, MD; 
University of Science and Technology of China, Hefei, Anhui, China
Increased glucose uptake and metabolism is a universal characteristic 
of advanced solid cancers. There are two well-established 
mechanisms underlying the reprogramming of tumor metabolism. 
First, intratumoral hypoxia induces the activity of the transcriptional 
activator hypoxia-inducible factor 1 (HIF-1) by inhibiting the O2-
dependent prolyl and asparaginyl hydroxylases that inhibit HIF-1a 
stability and transactivation, respectively. Second, genetic alterations 
increase the activity of HIF-1, thereby increasing the expression 
of glucose transporters (GLUT1, GLUT3), glycolytic enzymes 
(ALDOA, ENO1, HK2, LDHA, PKM2), pH regulators (CAR9, 
NHE1, MCT4), and proteins that inhibit mitochondrial metabolism 
(BNIP3, PDK1). Metabolites, such as the glycolytic end-product 
lactate, also induce HIF-1 activity, thereby providing a signal to further 
increase glycolytic metabolism. Recently, we have identified a novel 
feed-forward mechanism by which glycolytic enzyme expression 
leads to increased HIF-1 transcriptional activity. Pyruvate kinase 
isoforms PKM1 and PKM2 are alternatively spliced products of the 
PKM2 gene. PKM2, but not PKM1, alters glucose metabolism in 
cancer cells and contributes to tumorigenesis by mechanisms that are 
not explained by its known biochemical activity. We show that PKM2 
gene transcription is activated by HIF-1. PKM2 interacts directly 
with the HIF-1a subunit and promotes transactivation of HIF-1 target 
genes by enhancing HIF-1 binding and p300 recruitment to hypoxia 
response elements, whereas PKM1 fails to regulate HIF-1 activity. 
Interaction of PKM2 with prolyl hydroxylase 3 (PHD3) enhances 
PKM2 binding to HIF-1a and PKM2 coactivator function. Mass 
spectrometry and anti-hydroxyproline antibody assays demonstrate 
PKM2 hydroxylation on proline-403/408. PHD3 knockdown inhibits 
PKM2 coactivator function, reduces glucose uptake and lactate 
production, and increases O2 consumption in cancer cells. Thus, 
PKM2 participates in a positive feedback loop that promotes HIF-1 
transactivation and reprograms glucose metabolism in cancer cells (1).
HIF-1 also plays critical roles in breast cancer metastasis. HIF-1 
controls metastatic niche formation by activating transcription of 
genes encoding lysyl oxidase (LOX) and LOX-like proteins 2 and 
4, which remodel collagen in the lungs, thereby recruiting bone 
marrow-derived cells that establish a microenvironment suitable 
for colonization by breast cancer cells (2). HIF-1 also promotes 
the extravasation of circulating breast cancer cells in the lungs by 
activating transcription of the genes encoding L1CAM, which encodes 
a cell adhesion molecule that promotes the interaction of breast cancer 
cells with vascular endothelial cells (ECs), and angiopoietin-like 4, 
which encodes a secreted factor that inhibits EC-EC interaction (3). 
Inhibition of HIF-1 activity by genetic or pharmacologic strategies 
dramatically inhibits the metastasis of breast cancer cells to the lungs 
in orthotopic mouse models (2, 3).
(1) Luo W. et al. Cell 2011;145:732.
(2) Wong CC et al. Proc Natl Acad Sci USA 2011 Sept 12. 
doi:10.1073/pnas.1113483108.
(3) Zhang H. et al. Oncogene 2011 Aug 22. doi: 10.1038/onc.2011.365.
MS3-3
Energy Metabolism in Breast Cancer: Translational Science 
Insights Relevant to Effects of Diet, Exercise, and Metformin on 
Risk and Prognosis.
Pollak M. McGill University and Jewish General Hospital
Energy metabolism is relevant to breast cancer at both the cellular and 
whole organism levels. Whole organism energy balance determines 
body mass, which has been associated with variations in both breast 
cancer risk and prognosis. Experimentally, breast carcinogenesis 
is facilitated by excess caloric intake and inhibited by caloric 
restriction. The simplistic notion that excess food intake provides 
additional energy to breast epithelial cells at risk for transformation 
or to breast cancers, leading to aggressive behavior, is not supported 
by experimental data. Rather, variations in energy balance have 
important influences on the hormonal and cytokine environment of 
the patient, and these influence carcinogenesis and tumor behaviour. 
Experimental models provide evidence that one such mediating 
hormone is insulin. Most breast cancers have insulin receptors. 
When mice with breast cancer are experimentally manipulated to 
have insulin deficiency (type I) diabetes, tumor growth rate is slowed 
(despite hyperglycemia). Conversley, when mice are provided with a 
“junk food” diet, insulin levels rise, tumor insulin receptor activation 
increases, and tumors grow more quickly. However, when breast 
cancers evolve to have activating muations in signalling networks 
downstream of insulin receptors, they become more aggressive and 
unresponsive to variations in energy intake and insulin no longer 
influences their behavior.
There is retrospective pharmacoepidemiologic evidence for a 
substantial ( ~50%) reduction in breast cancer risk in type II 
(hyperinsulinemic) diabetic patients prescribed metformin. This has 
contributed to current interest in the hypothesis that metformin has 
uses in cancer prevention or treatment. Metformin acts to reduce 
cellular ATP production by inhibiting mitochondrial respiratory 
complex I. This results in activation of AMPK. In liver, this results 
in reduced gluconeogenesis, which reduces the hyperglycemia 
and hyperinsulinemia of type II diabetes. This systemic effect 
may reduce proliferation of the subset of neoplasms that are 
growth stimulated by insulin, but does not operate in the absence 
of baseline hyperinsulinemia. Other mechanisms of metformin 
action involve direct effects on at-risk or transformed cells. These 
mechanisms require adequate levels of the drug in the relevant cells, 
but metformin doses used in diabetes treatment may not achieve 
optimum concentrations in cancers, particularly those that lack the 
active transport molecules responsible for cellular metformin uptake. 
Overall, laboratory studies suggest that any benefits of metformin 
will not be homogeneous among a population of at-risk women in a 
prevention context, nor among breast cancer patients in a treatment 
context. The validation of candidate predictive biomarkers for 
metformin benefit, together with more detailed pharmokinetic data, 
may allow for optimized clinical trial design. Further research is 
also required to clarify if metformin should best be evaluated as a 
single agent or in combinations. Thus, metformin and derivatives 
can be regarded as lead compounds for optimization, and this line 
of research may lead to novel metabolic approaches to breat cancer 
prevention and treatment.
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MS4-1
The Neoadjuvant Setting, HER2-Driven and Triple Negative 
Breast Cancer.
Carey LA. University of North Carolina
The benefits of neoadjuvant therapy include: tumor cytoreduction, 
minimizing surgical resection volume, conversion to breast 
conservation, and the opportunity to test new drugs and regimens 
because response in the breast is a surrogate for long-term survival. 
Off-trial, neoadjuvant regimens should mimic adjuvant regimens in 
drug, dose, and schedule; “tailored” approaches or treatment to best 
response have not been adequately studied. In HER2+ and triple 
negative (ER-, PR-, and HER2-negative, TNBC) BrCa, the backbone 
of neoadjuvant treatment is chemotherapy, with HER2-targeting 
added to the former. In hormone receptor-positive, HER2-negative 
BrCa, randomized clinical trials suggest similar efficacy of endocrine 
therapy and chemotherapy in response, however pathologic complete 
response (pCR) is rare.
HER2-targeting with the anti-HER2 antibody trastuzumab (H) added 
to chemotherapy for HER2+ BrCa augments pCR, with 1 year of H 
completed adjuvantly. Off-trial options include AC-docetaxel (D) + H, 
AC-paclitaxel (T) + H, and D + carboplatin + H (DCH). It is likely that 
small, node-negative HER2+ BrCa are overtreated by these regimens; 
a challenge is to develop less chemotherapy-intensive regimens for 
the lower-risk setting. Several studies have examined other HER2-
targeted drugs. In NeoALTTO, HER2+ patients received either TH, 
T + HER1/HER2 inhibitor lapatinib (TL), or the combination THL. 
pCR was lower (and toxicity higher) in TL; THL had the highest 
pCR rate (47%). GeparQuinto compared EC-DH to EC-DL and also 
found lower pCR rate and higher toxicity in the L-containing arm. 
NeoSPHERE examined the anti-HER2 heterodimerization domain 
antibody pertuzumab (P), pCR rates were higher with combination 
DHP (46%) vs. DH (29%) and DP (24%). The all-biologic HP arm 
had a 17% pCR rate. In TBCRC006, HL alone resulted in a 28% 
pCR rate. These studies support combination HER2-targeting-based 
regimens in adjuvant trials.
TNBC lacks the known targetable molecules, ER, PR, or HER2, 
leaving chemotherapy the mainstay of treatment. Early TNBC is 
sensitive to conventional agents, and possesses one of the highest pCR 
rates to neoadjuvant anthracycline/taxane-based chemotherapy. The 
use of DNA-damaging drugs in TNBC is based on the association 
of Basal-like BrCa with BRCA1 germline mutations. Neoadjuvant 
studies are small and heterogeneous but supportive of a high pCR 
rate (>70%) to platinums in known carriers, however studies of 
sporadic TNBC are less clear. CALGB 40603, an ongoing randomized 
phase II study of taxane with or without carboplatin and with and 
without the antiVEGF antibody bevacizumab (B), will provide direct 
evidence. Although lacking known targeted therapy, subset analysis 
of the HER2-negative component of GeparQuinto suggested that 
TNBC had higher pCR rates with EC-D + B (45%) compared with 
chemotherapy alone (36%). The biology and identification of novel 
targets in TNBC as well as optimization of the chemotherapy remain 
subjects of intense study.
Neoadjuvant therapy is an excellent approach for patients with clinical 
stage II-III in whom the nature of systemic therapy is clear. It also 
provides a rich laboratory for drugs, regimens, and the identification 
of predictive markers and subtype biology in a timely and efficient 
manner.
MS4-2
Preoperative Endocrine Therapy: New Approaches.
Smith I. The Royal Marsden Hospital, London, United Kingdom
Modern neoadjuvant endocrine therapy trials comparing aromatase 
inhibitors (AIs) with tamoxifen have shown that neoadjuvant AIs 
can downstage cancers and avoid mastectomy in around 50% of post 
menopausal women with large ER positive tumours, and are superior 
to tamoxifen in this respect.
The future potential of preoperative endocrine therapy is in the use 
of molecular biomarkers after starting treatment to predict outcome. 
This approach was pioneered in the IMPACT trial which showed 
that the reduction in tumour proliferation as measured by the 
biomarker KI67 comparing neoadjuvant anastrozole v tamoxifen v. 
the combination. was significantly greater for anastrozole than for the 
other 2 arms, predicting the same long-term outcome benefit in the 
equivalent adjuvant ATAC trial. The change in Ki67 with treatment 
could be used to predict potential benefit with other novel endocrine 
therapy approaches. Recently a similar neoadjuvant trial comparing 
anastrozole v letrozole v exemestane has shown no significant 
difference in Ki67 suppression between arms, predicting no long-term 
difference in clinical outcome with these agents.
Around 15% of patients with good initial tumour Ki67 suppression 
after 2 weeks of preoperative endocrine therapy show recovery of 
Ki67 by 12 weeks, providing early biomarker evidence of treatment 
resistance. Clinical outcome in these patients appears correspondingly 
worse. This provides an opportunity for biomarker led studies of 
agents targeting both innate and acquired resistance to endocrine 
therapy, defined by 2 week and 12 week Ki67 levels.. One such 
preoperative endocrine therapy trial with Ki67 as primary endpoint 
has already been carried out: patients were started on 2 weeks of 
preoperative anastrozole and then randomised to the addition or 
not of the tyrosine kinase inhibitor, gefitinib (IRESSA). This novel 
pre-operative endocrine therapy approach also allows the study of 
changes in other biomarkers and in gene expression as a means of 
elucidating underlying mechanisms of resistance
Finally the clinical potential of Ki67 after 2 weeks preoperative AI 
treatment is further demonstrated by the observation that higher 2 
week values of Ki67 after treatment in the IMPACT trial predicted 
for a significantly worse recurrence-free survival. This raises the 
intriguing possibility that patients with ER positive breast cancer, 
including small cancers, could be treated with 2 weeks pre-operative 
endocrine therapy before surgery and Ki67 levels at surgery be used to 
predict long-term outcome for the individual patient and in particular 
to identify those patients with a good prognosis who would not require 
chemotherapy. This hypothesis is being tested in the UK POETIC 
(Peri-Operative Endocrine Therapy for Individualised Care) trial 
which has so far accrued around 2,000 patients out of an overall target 
of 4,000. A similar approach in which Ki67, pathologic stage and ER 
at the end of a course of neoadjuvant endocrine therapy are combined 
to produce a Preoperative Endocrine Prognostic Index (PEPI) is being 
used to identify patients with such a low risk of relapse that adjuvant 
chemotherapy may not be necessary.
MS4-3
Radiation for Patients Treated with Neoadjuvant Chemotherapy.
Buchholz TA. UT MD Anderson Cancer Center
The increased use of neoadjuvant systemic therapy for patients with 
stage II or stage III breast cancer has raised a number of important 
questions concerning local-regional treatments, particularly within the 
field of radiation oncology. Historically, the indications for radiation 
use after mastectomy and treatment of regional lymph node fields were 
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determined on the basis of pathological extent of disease. It is clear 
that neoadjuvant systemic treatments changes the pathological extent 
of disease in most cases. Additional data are needed to determine how 
the degree of disease response should guide radiation oncologists 
to the tailor treatment approaches. Specifically, there is potential 
for minimizing local-regional treatments in those with favorable 
responses and intensifying therapy for those with unfavorable 
responses. One surgical success in de-intensification of local treatment 
has been the ability to safely treat with breast conservative therapy 
for selected patients with advanced primary tumors that respond 
favorably to neoadjuvant chemotherapy. It may also be possible to 
limit radiation treatments for selected patients with favorable disease 
response. Specifically, data from M. D. Anderson and the NSABP 
suggest that patients with clinical stage II breast cancer who have 
negative axillary lymph nodes after neoadjuvant chemotherapy have 
low rates of recurrence after mastectomy and low rates of regional 
lymph node recurrences. (1-4) This may permit a more selective 
approach to using radiation after mastectomy or regional lymph node 
radiation for patients with stage II disease. In contrast, data suggest 
that patients who present with clinical stage III disease maintain high 
rates of local-regional recurrence independent of treatment response 
and therefore all such patients are recommended to postmastectomy 
and regional lymph node irradiation.(1,3)
Patients with a poor response to neoadjuvant chemotherapy 
unfortunately remain a therapeutic challenge. In addition to high 
persistent rates of distant metastases, these patients have clinically 
relevant rates of local-regional recurrence despite mastectomy and 
high dose postmastectomy radiation. For such patients, new protocols 
are needed to evaluated novel systemic approaches and radiation 
sensitizer strategies.
1. Buchholz TA, et al. Predictors of local-regional recurrence after 
neoadjuvant chemotherapy and mastectomy without radiation. J Clin 
Oncol. Jan 1 2002;20(1):17-23.
2. Garg AK, et al. T3 disease at presentation or pathologic involvement 
of four or more lymph nodes predict for locoregional recurrence in 
stage II breast cancer treated with neoadjuvant chemotherapy and 
mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. May 
1 2004;59(1):138-145.
3. McGuire SE, et al. Postmastectomy radiation improves the 
outcome of patients with locally advanced breast cancer who achieve 
a pathologic complete response to neoadjuvant chemotherapy. Int J 
Radiat Oncol Biol Phys. Apr 5 2007.
4. Mamounas E, et al. Predictors of locoregional failure (LRF) in 
patients receiving neoadjuvant chemotherapy (NC): Results from 
combined analysis of NSABP B-18 and NSABP B-27. Abstracts 
from the ASCO 2010 Breast Cancer Symposium
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PL3-1
Advances in Axillary Surgery: Sentinel Nodes and beyond.
Smith BL. Massachusetts General Hospital
Axillary node status is one of the strongest prognostic factors in 
breast cancer patients. The presence of tumor in axillary nodes, and 
number of positive nodes, predicts risk of metastatic disease and 
long term survival.
In the past, axillary dissection provided both accurate evaluation of 
nodal status and excellent local control. However, complications of 
axillary dissection, including lymphedema, pain, and impaired arm 
function, have led to keen interest in alternatives to axillary dissection 
for local control and assessment of prognosis.
Sentinel node biopsy provides a low-morbidity alternative to 
axillary dissection for patients with clinically negative nodes. It was 
recognized that breast lymphatics converge in the axilla, delivering 
fluid, travelling tumor cells and dye particles to a small number of 
“sentinel” nodes. Sentinel node biopsy techniques take advantage 
of this lymphatic anatomy using dye injection intraoperatively to 
permit identification and removal of only the most important axillary 
nodes – those most likely to contain metastases. A negative sentinel 
node provides accurate staging and reliably predicts a low axillary 
recurrence rate, eliminating the need for dissection. Sentinel node 
mapping also allows study of the relationship between the size of a 
nodal metastasis and impact on prognosis. Sentinel node mapping 
techniques, morbidity, and data on the reliability of sentinel node 
biopsy will be reviewed.
40-50% of patients with a positive sentinel node will have additional 
positive axillary nodes, indicating a need for additional axillary 
treatment for local control. Completion axillary dissection was 
initially used for local control and prognostic assessment in patients 
with a positive sentinel node. Recently, the ACOSOG Z0011 trial 
showed that patients with 1 or 2 positive sentinel nodes who receive 
standard whole breast irradiation without further axillary surgery 
have equivalent local control as patients having completion axillary 
dissection. Axillary recurrence rates in the Z0011 trial were <1% at 
6.3 years follow-up in both the radiation alone and dissection arms.
Changing axillary management algorithms resulting from these data 
will be discussed. Sentinel node biopsy can now replace axillary 
dissection for patients with negative nodes undergoing either 
lumpectomy or mastectomy. Sentinel node biopsy can also replace 
dissection for lumpectomy patients with 1-2 positive sentinel nodes 
where data on the precise number of additional positive axillary nodes 
is not needed for treatment decisions. At present, axillary dissection is 
still recommended for patients with palpable axillary nodes, 3 or more 
positive sentinel nodes, gross extranodal tumor, and positive sentinel 
nodes after neoadjuvant therapy, or for positive nodes in patients 
undergoing mastectomy. Trials of radiation instead of dissection in 
such patients are likely.
Management of the axilla will evolve further as options for assessment 
of tumor and host factors increase. Gene expression profiling may 
prove more important than primary tumor size and node status for 
predicting prognosis and guiding therapy – an approach already used 
in estrogen receptor positive tumors. Future options for incorporating 
axillary node status with tumor and host factors in breast cancer 
management will be considered.
SR2-1
The Genomic Mutation Landscape of Breast Cancer: A TCGA 
Report.
Mardis ER. Washington University
An important goal, that of characterizing the breadth and complexity 
of mutations in breast cancer, is being approached by The Cancer 
Genome Atlas in its next-generation sequencing and analysis of 
the exome and whole genome content of breast cancer samples.  At 
present, we have produced, analyzed, and validated mutations by 
exome capture of matched tumor and normal genomic DNA across 
all breast cancer subtypes, using over 500 samples as our primary 
discovery set. The resulting information has been further analyzed 
by integration with other data types being generated in the project, 
including RNA-seq, methylation and SNP array data. We have further 
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initiated a study using whole genome sequencing of 21 basal subtype 
cases.  My presentation will provide an overview of the methods 
of data generation, analysis and integration.  I will further provide 
information about our discoveries to-date and future plans.
SR2-3
Integrative Genomic Analyses of Breast Cancer from The Cancer 
Genome Atlas (TCGA).
Creighton C. Baylor College of Medicine
Cancer is a disease characterized by genetic aberrations, which lead 
to widespread deregulation of cell signaling and gene transcription. 
Over ten years ago, gene transcription profiling of human cancers 
was found to distinguish distinct intrinsic molecular subtypes of the 
disease (luminal A/B, HER2, basal, normal-like). TCGA is a large-
scale collaborative effort which seeks to comprehensively catalogue 
the molecular aberrations in various cancers, including breast cancer, 
at levels of somatic mutation, copy alteration, DNA promoter 
methylation, protein signaling, and gene and miRNA transcription. 
Having all of these molecular data on the same set of ~500 human 
breast tumors, allows us to construct a more complete molecular 
portrait of the intrinsic subtypes, along with their candidate molecular 
drivers. Among other things, integrative analysis of the p53 and PI3K 
pathways in breast cancer reveal differences in pathway alteration 
and pathway activity among the subtypes.
SR2-5
The DNA Copy Number Landscapes and Genomic Architecture; 
Relevance for Progression and Outcome.
Børresen-Dale A-L. Norwegian Radium Hospital, Oslo University 
Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, 
Oslo, Norway
Patterns of genomic aberrations have been defined that underlie 
specific expression subgroups of breast cancer (BC) that may infer 
paths of tumor progression and shed light on mechanisms involved. 
Classifications built on levels of genomic distortion have been shown 
to have prognostic value. We recently developed two platform-
independent algorithms to explore genomic architectural distortion 
using aCGH data to measure whole-arm gains and losses [whole arm 
aberration index (WAAI)] and complex rearrangements [complex 
arm aberration index (CAAI)]. By applying CAAI and WAAI to 
data from 595 BC patients, we were able to separate the cases into 
eight subgroups with different distributions of genomic distortion. 
Within each subgroup data from expression analyses, sequencing 
and ploidy indicated that progression occurs along separate paths 
into more complex genotypes. Histological grade had prognostic 
impact only in the luminal-related groups, whereas the complexity 
identified by CAAI had an overall independent prognostic power. The 
results emphasized the relation among structural genomic alterations, 
molecular subtype, and clinical behavior and showed that objective 
score of genomic complexity (CAAI) is an independent prognostic 
marker. The CAAI algorithm calculates complexity scores per 
chromosome arm and is based on relatively large genomic stretches, in 
megabase order of magnitude. We have further developed this method 
to calculate probe-focused complexity scores per sample, a continuous 
complexity index (CCI), that increases the resolution significantly 
by calculating complexity scores for every genomic locus. CCI was 
calculated based on data derived from aCGH analyses of a set of 
394 invasive ductal BCs. This approach enabled us to identify novel 
regions frequently subjected to high levels distortion and furthermore, 
to pinpoint regions with increased complexity which was associated 
with more aggressive disease. A total of 25 recurrent regions with 
high level complexity were identified. Regional complexities on 
chromosome arms 8p, 11q and 17q were each associated with clinical 
parameters associated with aggressive disease. Complexity patterns 
were different between tumors of different gene expression subtypes. 
Multivariate Cox analysis revealed that regional complexity on 
17q21.32-q21.33 was significantly associated with shorter survival, 
independent of established clinical variables. The new algorithm 
developed represents a novel tool that can be utilized to identify 
smaller genomic regions of importance as well the genes therein that 
could be further explored.
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SR2-6
Genome Data for the Masses: Presentation of TCGA and IGC 
Breast Tumor Data.
Haussler D. Howard Hughes Medical Institute
Large-scale cancer genomics projects will sequence tens of 
thousands of tumors in the next few years, along with matched 
normal tissue samples. Among these are The Cancer Genome Atlas 
(TCGA), Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET), and the International Cancer Genomics 
Consortium (ICGC). TCGA alone plans to analyze 500 clinically 
characterized samples from each of 20 different cancer types, 
detecting frequently mutated genes, common copy number variants, 
rearrangements, altered gene expression, and methylation changes. 
These data will provide an exceptional resource for identifying new 
diagnostic targets and predictors of response.
As a data analysis center and the primary sequence database for 
TCGA, we have built on technology developed for the UCSC 
Genome Browser  to develop a cancer genome analysis pipeline 
and a cancer genomics browser (genome-cancer.ucsc.edu). These 
interpret cancer genomics data to aid in the identification of new 
targets. We reconstruct changes in tumor genomes and their expressed 
transcripts from tumor sequencing data (DNA, RNA, methylation) 
and use an approach based on factor graphs, called PARADIGM, 
to map multiple data types into a single coherent pathway model 
that includes thousands of genes and interactions for higher-level 
interpretation. By transforming raw genomic data to pathway activity 
levels, PARADIGM provides a comprehensible window into the data 
that can be coupled to predictors of response to improve accuracy. 
This paves the way to form hypotheses that clinical investigators can 
test in cell-line models and later explore in clinical trials.
Today’s concurrent cancer genomic projects provide an exceptional 
opportunity to study the molecular nature of cancer on an enormous 
scale never before possible. A cancer genomics data repository that 
hosts multiple large projects and makes them accessible through a 
general cancer genomics browser (with effective data access control) 
will leverage each study and enable cross-tumor cancer research.

www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 201195s
December 6-10, 2011 Abstracts: General Session 1
S1-1
A Phase III Randomized Trial of Anastrozole Versus Anastrozole 
and Fulvestrant as First-Line Therapy for Postmenopausal 
Women with Metastatic Breast Cancer: SWOG S0226.
Mehta RS, Barlow WE, Albain KS, Vandenberg T, Dakhil SR, Tirumali 
NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. 
University of California at Irvine, Chao Family CCC, Orange, CA; 
SWOG, Seattle, WA; Loyola University Chicago Stritch School of 
Medicine, Maywood, IL; London Regional Cancer Program, London, 
ON, Canada; Wichita CCOP, Wichita, KS; NW Permanente, Portland, 
OR; University of Michigan, Michigan; Seattle Cancer Care Alliance, 
Seattle, WA; Arizona Cancer Center, Tucson, AZ; Univerity of Texas/
MD Anderson Cancer Center, Houston, TX
Background: Anastrozole inhibits the aromatase enzyme-induced 
estrogen synthesis, and fulvestrant down-regulates estrogen receptors 
in hormone receptor-positive breast cancer. We hypothesized that the 
simultaneous disruption of the ligand-receptor axis with concurrent 
use of these agents may be potentially additive or synergistic in first-
line therapy of hormone receptor-positive metastatic breast cancer in 
postmenopausal women.
Materials and Methods: A total of 707 patients were randomized 
to either 1 mg anastrozole P.O. daily (Arm 1) or to the combination 
of anastrozole and fulvestrant (Arm 2). Fulvestrant was given as an 
intramuscular injection as follows: loading dose of 500 mg on day 0, 
followed by 250 mg on days 14, 28 and 250 mg maintenance monthly 
thereafter. The primary endpoint was progression-free survival 
(PFS), with a power of 90% and one-sided alpha of 0.025 to detect 
an expected median PFS of 10 months in Arm 1 versus 13 months in 
Arm 2. Randomization was stratified by adjuvant tamoxifen use with 
the possibility of differential benefit of fulvestrant in the two strata. 
Patients were encouraged to crossover to fulvestrant after progression 
on the anastrozole alone arm (40% did), if they were not candidates 
for immediate chemotherapy. Analysis of survival was by 2-sided 
stratified log-rank tests and Cox regression using intent-to-treat. 
Two interim analyses were performed with the final analysis using a 
2-sided p-value of 0.04.
Results: There were 548 events (287 and 261 by arms, respectively) 
among 694 eligible patients (345 and 349, respectively). Overall, 
median PFS was 13.5 months for anastrozole and 15.0 months for 
the combination of fulvestrant and anastrozole (log-rank p=0.0145; 
HR=0.81 (95% CI 0.68-0.96). In a subset analysis of tamoxifen-naive 
women (60%, n=414), median PFS was 12.6 months and 17.0 months 
for Arms 1 and 2, respectively (log-rank p=0.0069; HR=0.74 (95% 
CI 0.60-0.92)), and 14.1 months and 13.5 months for Arms 1 and 2, 
respectively, in the 40% of tamoxifen-pretreated women (log-rank p 
= 0.56; HR=0.93 (95% CI 0.71-1.20)). A trend for improved overall 
survival (OS) in the combination arm was seen (median OS was 42 
and 48.6 months based on 152 and 137 deaths respectively, log-rank p 
= 0.094; HR=0.82 (95% CI 0.65-1.03)). On the combination arm, three 
treatment-related deaths occurred: due to pulmonary embolism (2) 
or cerebrovascular ischemia (1); one Grade 4 thrombosis/embolism 
and one Grade 4 neutropenia and lymphopenia were reported. On 
the anastrozole arm, four patients experienced Grade 4 toxicities: 
thrombosis/embolism, arthralgia, thrombocytopenia, and dyspnea. 
In general, Grade 3 or higher toxicity was rare (12.7% vs. 14.5% for 
Arms 1 and 2, respectively) and did not differ significantly.
Discussion: The combination of anastrozole and fulvestrant was 
associated with improved PFS compared to anastrozole alone as 
well as a trend in OS despite substantial crossover, thus offering a 
new standard in the first-line treatment of hormone receptor-positive 
breast cancer in postmenopausal women, specifically in tamoxifen-
naive patients. ClinicalTrials.gov:NCT00075764. Funding: NIH/NCI 
CA32102, CA38926 and AstraZeneca.
S1-2
Long-Term Follow-Up in ABCSG-12: Significantly Improved 
Overall Survival with Adjuvant Zoledronic Acid in Premenopausal 
Patients with Endocrine-Receptor–Positive Early Breast Cancer.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky 
P, Jakesz R, Singer C, Eidtmann H, Fesl C, Eiermann W, Marth C, 
Greil R. Medical University of Vienna, Vienna, Austria; Paracelsus 
Medical University Salzburg, Salzburg, Austria; Medical University 
of Graz, Graz, Austria; University of Schleswig-Holstein, Kiel, 
Germany; Austrian Breast and Colorectal Cancer Study Group, 
Vienna, Austria; Red Cross Women’s Hospital, Munich, Germany; 
Medical University of Innsbruck, Innsbruck, Austria
Background: We have previously reported significantly improved 
disease-free survival (DFS) in premenopausal patients with endocrine-
responsive early breast cancer receiving adjuvant zoledronic acid 
(ZOL) in ABCSG-12 (Gnant M, et al. NEJM. 2009;360:679-91). 
Other trials, such as ZO-FAST and the postmenopausal (>5 yr) subset 
analysis of AZURE, have demonstrated similar anticancer effects 
with ZOL. Now with >6 yr of follow-up in ABCSG-12, we report 
an overall survival (OS) benefit and preplanned subgroup analyses 
that more precisely define interactions between the ZOL benefit and 
patient/tumor characteristics.
Methods: Premenopausal women with endocrine-receptor–positive 
early stage breast cancer (N = 1,803) were randomized to ovarian 
function suppression with goserelin (3.6 mg q28d) and tamoxifen 
(TAM; 20 mg/d) or anastrozole (ANA; 1 mg/d) ± ZOL (4 mg q6mo) 
for 3 yr. Endpoints included DFS and OS, both analyzed using log-
rank test and Cox models.
Results: At median follow-up of 76 mo, patients receiving ZOL had 
a significant 27% reduction in the risk of DFS events (HR = 0.73; 
Cox P = .022) and a significant 41% reduction in the risk of death 
(HR = 0.59; Cox P = .027) vs no ZOL. Multivariate analyses showed 
a strong interaction between ZOL and patient age, but did not show 
any interactions between ZOL and ANA/TAM or any classic tumor 
parameter (eg, T, N, grade, ER). Among patients > 40 yr of age (n = 
1,390) with presumed complete ovarian blockade, ZOL significantly 
reduced the risk of DFS events by 34% (HR = 0.66; Cox P = .014) 
and the risk of death by 49% (HR = 0.51; Cox P = .020); however, 
there were no significant DFS or OS benefits in patients <40 yr of 
age. Currently, all patients have completed 3 yr of ZOL and are in 
the follow-up phase with no reported cases of osteonecrosis of the 
jaw or renal failure. Additional analyses at a median follow-up of 
approximately 84 mo are planned for late 2011 and will be presented, 
providing additional insights into disease recurrence patterns with 
and without ZOL.
Conclusions: Long-term follow-up of ABCSG-12 (76 months) 
confirms and extends previous results seen at 48 mo and 62 mo 
follow-up, and suggests that anticancer benefits of adjuvant ZOL 
result in highly significant DFS and OS benefits mainly in patients 
with a low-estrogen environment (ie, ovarian suppression and age 
>40 yr). These results are consistent with the significant DFS and 
OS improvements seen in the postmenopausal (>5 yr) cohort of the 
AZURE trial, and suggest that both estrogen deprivation and reduction 
of bone-turnover–derived growth factors in the bone marrow 
microenvironment are needed for sufficient suppression of dormant 
micrometastases. Taken together with the previously demonstrated 
bone-protective effects of ZOL, these DFS and OS benefits strongly 
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suggest that adding ZOL to adjuvant endocrine therapy should be 
considered for premenopausal women with endocrine-receptor–
positive early breast cancer.
S1-3
Long-Term Survival Outcomes among Postmenopausal Women 
with Hormone Receptor-Positive Early Breast Cancer Receiving 
Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of 
ZO-FAST.
de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, 
Martin N, Modi A, Coleman R. Royal Melbourne Hospital, Victoria, 
Australia; University Hospital of South Manchester NHS Foundation 
Trust, Manchester, United Kingdom; University Frauenklinik, Kiel, 
Germany; UZ Gasthuisberg, Leuven, Belgium; German Breast 
Group, Frankfurt, Germany; Novartis Oncology, East Hanover, NJ; 
University of Sheffield, Sheffield, United Kingdom
Introduction: Recent clinical trials suggest potential anticancer 
activity for bisphosphonates combined with adjuvant endocrine 
therapy in patients with hormone receptor-positive (HR+) early breast 
cancer (EBC). Data from the interim analysis of AZURE suggest 
that the benefits of adding zoledronic acid (ZOL) may be greatest 
in patients with low estrogen levels (Coleman RE, et al. SABCS 
2010). In ZO-FAST, we have previously demonstrated that adding 
ZOL to adjuvant therapy significantly improved bone mineral density 
(BMD) and prolonged disease-free survival (DFS) vs delayed ZOL 
(de Boer R, et al. SABCS 2010). We report here the effect of time 
since menopause at breast cancer diagnosis (ie, baseline menopausal 
status) on DFS benefits with ZOL.
Methods: Postmenopausal women with HR+ EBC receiving letrozole 
(LET; 2.5 mg qd × 5 yr) with a BMD T-score ≥–2 (N=1065) were 
randomized to ZOL (4 mg q6mo): immediate (IMZOL) or delayed 
(DZOL; initiated for postbaseline T-score <–2 or nontraumatic/
asymptomatic fracture). Patients were followed for disease recurrence 
and overall survival (OS) for 5 years. Patients were eligible for the 
study if they had established menopause at the time of diagnosis, 
or if they became menopausal because of chemotherapy or ovarian 
suppression (ie, recently postmenopausal). The effect of baseline 
menopausal status on DFS was examined in Cox regression analyses.
Results: At 60 months’ follow-up in the overall population (N=1065), 
IMZOL significantly reduced the risk of a DFS event by 34% vs 
DZOL (hazard ratio [HR]=0.66; 95% confidence interval [CI], 
0.44-0.97; P=.034). In exploratory analyses of women who were 
postmenopausal for >5 years or >60 years old at study entry (n=670), 
IMZOL improved DFS (HR=0.63; 95% CI, 0.39-1.01; P=.052) and 
significantly prolonged OS (HR=0.50; 95% CI, 0.27-0.92; P=.022) 
vs DZOL. Additional subgroup analyses including patterns of breast 
cancer recurrence will be presented. During 5 years of treatment, 
osteonecrosis of the jaw (ONJ) was reported in 4/669 patients (0.6%) 
who received ZOL, and there was no increase in renal adverse events 
(AEs) in the ZOL-treated patients. Overall, AEs were consistent with 
the known safety profiles of both study drugs.
Conclusions: Long-term follow-up in ZO-FAST confirms the overall 
survival benefits of adding ZOL (4 mg q6mo) to adjuvant LET 
therapy for EBC. However, subset analyses suggest that women with 
established postmenopausal status may benefit from ZOL therapy 
more than others. These results are consistent with observations in 
the AZURE trial, and support potentially greater ZOL benefits in a 
low-estrogen environment. Additional studies are needed to fully 
define the patient populations most likely to benefit from adjuvant 
ZOL in this setting.
S1-4
Retrospective Analysis of Study EGF30008 by Mass-Spectrometry 
Based Serum Assay (VeriStrat®).
Roder J, Roder H, Hunsucker S, Grigorieva J, Ellis C, Florance 
A, Gagnon R, O’Rourke L, Johnston S. Biodesix Inc., Aurora, CO; 
GlaxoSmithKline, Collegeville, PA; Royal Marsden Hospital, London, 
United Kingdom
Background: In EGF30008 the addition of lapatinib (La) to first-line 
treatment with letrozole (Le) significantly improved progression-free 
survival (PFS) in patients (pts) with hormone receptor positive (HR+), 
HER2 positive (HER2+) metastatic breast cancer (hazard ratio (HR) 
= 0.71; p=0.019), but not in HR+, HER2 negative (HER2-) pts. This 
study assessed the ability of VeriStrat (VS), a mass-spectrometry 
blood-based pretreatment assay correlating with clinical outcome 
from EGFR-TKI therapy, to stratify pt outcome in EGF30008. The 
VS assay assigns VS Good (Good), VS Poor (Poor), or Indeterminate 
labels to a serum sample based on a specific 8-peak signature in the 
mass-spectra (Taguchi F et al., JNCI 2007).
Methods: Blinded to clinical data, pretreatment serum was analyzed 
using standard VS procedurei. Statistical analyses were performed 
using Mantel-Haenszel and Cox proportional hazards methods; 
correlations were evaluated using Fisher’s exact and c2 tests.
Results: Of the 1286 pts randomized (HER2+=219; HER2-=952; 
HER2 unknown=115), 1163 pts had serum available; a VS label was 
assigned to 1046 pts (961 Good; 80 Poor; 5 Indeterminate); 117 were 
not evaluable (hemolyzed). In the overall population there was no 
significant difference in PFS between Good and Poor groups within 
the Le+La arm (p=0.53). In contrast, PFS of the Good group was 
longer than that of the Poor group within the Le only arm (HR=0.36, 
p<0.001) and comparable with that of Good pts within the Le+La 
arm (median PFS 10.8 mo vs 11.0 mo). An interaction test showed 
significantly different HRs for PFS in Good vs Poor between treatment 
arms (p=0.002).
In the HER2+ population both Good (n=169) and Poor (n=13) groups 
received significant PFS benefit from addition of La to Le: in Good 
HR=0.71, p=0.046, medians 3.0 mo (Le) vs 8.0 mo (Le+La); in Poor 
HR=0.17, p=0.02, medians 2.3 mo (Le) vs 8.6 mo (Le+La).
In the HER2- population median PFS for the Poor group (n=58) 
increased from 3.1 to 11.0 mo (HR=0.57, p=0.068) with addition of 
La to Le, whereas the Good group (n=702) received no significant 
benefit, median 13.6 mo on Le and 13.8 mo on Le+La (PFS HR= 
0.85, p=0.09).
In multivariate analysis VS remained independently significant and 
predictive of differential treatment effect in the overall population. 
No significant correlation of VS classification with HER2 status 
(p=0.35) or prior adjuvant hormonal therapy (p=0.33) was found. 
VeriStrat was also not significantly correlated with baseline HER2 
ECD levels (low <15 ng/ml vs. high ≥15 ng/ml), p = 0.23, or ER 
expression (H-score:lower quartile:<160 vs. rest), p=0.18.
Conclusions:
In the overall population VeriStrat predicted PFS in Le alone but not in 
the Le+La combination, with a significant differential treatment effect. 
VeriStrat identified a subset of pts with inferior PFS on Le therapy. 
Adding La to Le improved outcome in HER2+ pts, and interestingly 
suggested an improvement in the VS Poor subset of HER2- pts. 
HER2- VS Good pts do not gain benefit with the addition of La. No 
correlation between VS and investigated predictors of benefit from 
the addition of La to Le in HER2- pts was observed. If these results 
can be validated in a prospective study, the addition of La to Le may 
be a potential treatment option for HER2- HR+ VS poor pts.
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S1-5
Modulation of Cancer and Stem Cell Biomarkers by the Notch 
Inhibitor MK-0752 Added to Endocrine Therapy for Early Stage 
ER+ Breast Cancer.
Albain KS, Czerlanis C, Zlobin A, Covington KR, Rajan P, Godellas 
C, Bova D, Lo SS, Robinson P, Sarker S, Gaynor ER, Cooper R, 
Aranha G, Czaplicki K, Busby B, Rizzo P, Demuth T, Stiff P, Fuqua 
SAW, Miele L. Loyola University Chicago Cardinal Bernardin 
Cancer Center, Maywood, IL; Baylor Breast Center, Houston, TX; 
Merck Oncology, North Wales, PA; University of Mississippi Cancer 
Institute, Jackson, MS
Background: New strategies to enhance endocrine therapy (ET) 
efficacy and/or overcome resistance by targeting key survival 
pathways are needed. Preclinical data indicate that unwanted effects 
of ET include reactivation of the Notch pathway, critical for breast 
tumor initiating (stem) cells. Notch inhibition with gamma secretase 
inhibitors (GSI) enhances tamoxifen (tam) efficacy in xenografts, 
but impact of GSI+ET in human breast cancer (BC) is unknown. Our 
objective was to add short exposure of the GSI MK-0752 to ongoing 
tam or letrozole (let) in the presurgical window to assess feasibility, 
safety and biomarker/pathway impact in a 20-patient (pt) pilot study 
(ClinTrials.gov NCT00756717). We previously evaluated several 
biomarkers in the first cohort, which showed promise with Notch 
and proliferation inhibition. We present new results adding the final 
cohort, plus additional biomarkers and microarray analyses.
Methods: Pts with early stage ER+ BC received 25 days (d) of ET. 
MK-0752 was added d15 (350 mg PO 3d on, 4d off, 3d on) with 
definitive surgery d25. Core biopsies were done at baseline, d14 
and d25, with qRT-PCR for Notch-related and other genes critical 
to stem cell renewal/proliferation. Gene expression levels after GSI 
(d25) vs ET alone (d14) were analyzed and d25 changes in all pts 
combined for each gene were compared. Microarray expression 
estimates and modeling were performed using dCHip and Red-R, 
implementing gene-wise comparisons using Limma. Probes were 
defined as significantly regulated by paired t tests if p ≤ 0.001 for the 
comparisons of baseline to tam/let and tam/let to tam/let+GSI. Data 
were exploratory so all probe data were included in the modeling, 
and no corrections for multiple comparisons were used. Differentially 
expressed genes were submitted to DAVID for pathway analysis.
Results: Of 22 pts accrued, 20 (11 tam, 9 let) were evaluable, 
meeting accrual goals (2 withdrew before MK-0752); 19 completed 
therapy to date. Toxicity was minimal. Significant (p<.05) changes 
in mRNA levels after GSI+ET vs end of ET in 17 pts (3 in progress) 
were down-regulation of Notch4 in 13; Ki67, 13; Notch1, 12; 
RUNX1 (stem cell transcription factor), 13; ADAM19 (disintegrin/
metalloproteinase), 12; MMP7 (Wnt target), 11; CCND1 (cyclin D1), 
10; and up-regulation of NOXA (pro-apoptotic BH3-only gene), 13. 
Microarray analyses (10 completed, remainder underway) found 
significant numbers of GSI-regulated genes that were independent 
of tam/let. Of 4036 genes increased by GSI, 2777 were unchanged 
by tam/let; of 3978 genes decreased by GSI, 1017 were not impacted 
by tam/let. For example, of genes regulated by GSI alone, there was 
modulation of important cancer pathways: Wnt5a, FGFs, FGFR, IGF-
1R were decreased; Fas and caspases were increased. These changes 
in gene expression are being compared with ET resistance profiles.
Conclusions: Short exposure of MK-0752 added to ET was feasible, 
well tolerated, and resulted in significant biomarker response in all 
tumors. MK-0752 favorably modulated proliferation, apoptosis, 
stem cell and metastasis-related targets, and impacted critical cancer 
pathways. This suggests potential roles for MK-0752 in optimizing 
endocrine therapy and overcoming endocrine resistance.
S1-6
Characterization of Breast Cancer Distant Metastasis Based on 
Outcome over Time Using a Gene Expression Profiling Approach 
and Identification of Pathway Activities of Late Relapse.
Saghatchian M, Mittempergher L, Michiels S, Casinius S, Glas A, 
Lazar V, Roepman P, Dessen P, Benz S, Piccart M, Delaloge S, van’t 
Veer L. Institut Gustave Roussy, Villejuif, France; Netherlands Cancer 
Institute., Amsterdam, Netherlands; Institut Jules Bordet, Belgium; 
Agendia; UCSF; UCSC
Background
Previous reports have described the use of microarrays to assess 
the molecular classification of human breast cancers and defined 
new subgroups based on gene expression that are relevant to patient 
management through their ability to predict metastatic relapse and 
survival relapse . However, different mechanisms may be associated 
with the development of early and late distant metastases. With the 
hypothesis that tumors may lead to early or distant metastases based 
on their intrinsic biological initial features, we aimed at defining 
molecular profiles for several subgroups of patients based on their 
outcome over time.
Material and methods
Breast primary tumors were selected from retrospective series of 
patients with frozen material available. These series include patients 
of all ages, LN- and LN+; Estrogen or Progesteron-receptor positive, 
Her2-negative, no adjuvant treatment, with a follow-up of more than 
10 years (y) for the control group or distant metastatic relapse as 
first event (DM) for the study group (n=144). Patients tumors were 
classified in 4 groups: no relapse at 10 y (M0), DM before 3 y (M0-3, 
n=30), DM between 3 and 7 y (M3-7), DM after 7 y (M7+).
Samples were collected in 2 different institutions (NKI series for 
identifying the signature and IGR series for validation).
Gene expression analysis of breast tumor samples was performed 
using custom-made Agilent 44K high-density microarrays and 
hybridized against the Mammaprint® reference pool (MRP). Tumors 
were also assessed for their Mammaprint® status, wound-healing 
signature status and their intrinsic subtypes based on the Blueprint® 
signature. Moreover, we identified the pathway-level activities of the 
patient groups using PARADIGM.
Results and Discussion
For the NKI series, A subset of 144 samples was included based on 
the selection criteria : 57 M0, 31 M0-3, 25 M3-7, 31 M7+.
None of the 3 previously mentioned signatures correctly identified 
M0 vs. M7+ patients.
In order to identify a predictive signature of late relapse (after 7y) 
we considered M0 and M7+ MammaPrint-Low Risk patients and we 
split them in a training (n=41) and in a test (n=23) sets.
A 73-gene signature was able to classify M7+ patients with 75% of 
sensitivity and 66% of specificity on the test set. DM after 7yr showed 
significant activation of pathway related to inflammatory response 
and angiogenesis.
Detailed results and validation results on the independent IGR series 
will be presented at the meeting.
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S1-7
Molecular Tumor Characteristics Influence Adjuvant Endocrine 
Treatment Outcome.
Bianchini G, Pusztai L, Iwamoto T, Kelly CM, Zambetti M, Fasolo 
A, Del Conte G, Santarpia L, Symmans WF, Gianni L. San Raffaele 
Cancer Center, Milan, Italy; University of Texas, MD Anderson 
Cancer Center, Houston; Mater Misericordiae University Hospital, 
Dublin, Ireland; Hospital of Prato and Istituto Toscana Tumori, 
Prato, Italy
Background
Used upfront or after 2 to 3 years (yrs) of tamoxifen (TAM) or as 
extended treatment after 5 yrs of TAM, aromatase inhibitors (AIs) are 
associated with less recurrences than with 5 yrs of TAM. However, up 
front AIs were not superior to TAM→AI sequence in node negative 
(N-) tumors (TEAM study, SABCS 2009; BIG1-98 trial, NEJM 
2009). The observation is consistent with the hypothesis that early 
relapses may be more frequently due to intrinsic endocrine resistance 
irrespective of the use of TAM or AIs whereas late relapses depend 
on acquired resistance.
Methods
Affymetrix HGU133A-based gene expression profiles from two 
adjuvant datasets (n=556) of patients treated with 5 yrs TAM were 
evaluated and included 285 N-, 247 N+ and 24 Nx estrogen receptor-
positive cases. A proliferation score based on the expression of 12 
mitotic kinases (MKS) (Bianchini, Cancer Res 2010) and a 4-gene 
estrogen-related score (ERS) adopted from the Oncotype DX 
Recurrence Score were assessed. Median cut-off points were used 
for both biomarkers. Pattern of relapse according to marker status 
were evaluated in three distinct time cohorts (0-2.5 yrs, 2.5-5 yrs, 
5-10 yrs). Outcome was assessed according to distant relapse rates.
Results
A violation of the proportional hazards assumption was found for 
both scores indicating time-dependent effects. The table shows distant 
relapse rates according to biomarker group within each time cohort.
  Time cohort
  0-2.5 yrs 2.5-5 yrs 5-10 yrs
Biomarkers group No. pts % Relapse p % Relapse p % Relapse p
lowMKS/highERS 162 1.3 0.111 2.7 0.039 4.4 0.006
lowMKS/lowERS 116 4.4  8.7  17.4  
highMKS/highERS 116 1.8 <0.001 13.1 0.634 27.1 <0.001
highMKS/lowERS 162 15.8  15.8  6.0  
Among low proliferation tumors (lowMKS), the highERS group had 
low and steadily increasing recurrence rates, while the lowERS group 
showed a higher risk of relapse that increased continuously over the 
time. Among the highly proliferative tumors (highMKS), the high 
endocrine-sensitive group (highERS) had a lower risk of relapse 
within the 0-2.5 yrs compared to lowERS cancers. The difference is 
not persisting at the longer follow up of 2.5-5 yrs, and at 5-10 yrs the 
highERS group has higher risk of relapse. The pattern of relapse was 
similar for N- and N+ cancers. However, in the 0-2.5 yrs interval all 
recurrences occurred in the highMKS/lowERS among N- cancers, 
while only 57% of recurrences did occur in N+ cases in the same 
biomarkers group (p=0.012).
Discussion
Highly proliferative, high endocrine-sensitive (highERS) cancers are 
at the greatest risk of late relapse and extended endocrine therapy 
beyond 5 yrs may be useful. Low proliferation, low ERS cancers 
also remain at substantial risk for late recurrences. Between 0 to 2.5 
yrs all recurrences in N- tumors and close to 60% in N+ were in high 
proliferative/low endocrine-sensitive tumors. This difference could 
explain the beneficial trend for up-front AIs vs. sequential TAM→AIs 
in the N+, but not in N- subgroups of the TEAM and BIG1-98 trials. 
It also is consistent with the hypothesis that the highly proliferative 
low ERS group includes tumors intrinsically resistant to both AIs and 
TAM. Risk stratification by these two simple metrics may improve 
the readout of future adjuvant clinical trials with endocrine drugs, 
and may influence their design.
S1-8
Molecular Signaling Distinguishes Early ER Positive Breast 
Cancer Recurrences Despite Adjuvant Tamoxifen.
Liu MC, Dixon JM, Xuan JJ, Riggins RB, Chen L, Wang C, Cho Y, 
Zhu Y, Jin L, Zwart A, Wang M, Klimach UM, Wang YJ, Renshaw L, 
Larionov A, Miller WR, Clarke R. Georgetown University Lombardi 
Comprehensive Cancer Center, Washington, DC; Western General 
Hospital, University of Edinburgh, Edinburgh, Scotland, United 
Kingdom; Virginia Polytechnic Institute and State University, 
Arlington, VA
Background: Unlike recurrences with other therapies, ER+ breast 
cancers (BC) can recur >10 yrs after an apparent successful period 
of adjuvant endocrine therapy. The molecular basis for this pattern 
of resistance is unresolved. We addressed the hypothesis that early 
recurrences during tamoxifen (TAM) treatment exhibit different 
biological characteristics than those that recur years later by assessing 
for variation in their respective transcriptomes.
Methods: Appropriate tumors were identified from a set (BC030280) 
of snap-frozen tumor biopsies collected in Edinburgh from subjects 
with stage I-III BC before starting TAM (no chemotherapy); all had 
>10 yrs follow-up. Using rigorous standard operating procedures, high 
quality total RNA was extracted from samples with >50% malignant 
epithelium and arrayed on Affymetrix U133 Plus 2.0 GeneChips. 
Raw data were normalized using PLIER and analyzed with an 
adapted validated training and internal cross-validation workflow 
to avoid gene selection bias. A published dataset (Loi) was used for 
independent classifier validation that best fit our criteria for sample 
size, treatment (TAM only), data quality, and recurrence distribution. 
Early (E) vs late (L) recurrences were defined as distant relapse <3 vs 
>10 yrs from diagnosis. To explore putative mechanistic associations 
driving the transcriptome differences, a novel computational 
procedure was developed to integrate gene expression data with 
protein-protein interaction (PPI) data and create a statistical network 
model of the signaling. Metropolis sampling, a Markov Chain Monte 
Carlo method that can be implemented as a modified random walk 
procedure, identified ER network topology represented by the genes 
(nodes) and their predicted interconnections (edges).
Results: A support vector machine with recursive feature elimination 
was used for the binary classification tasks on the BC030280 dataset. 
The optimized classifier for E vs L recurrence was independently 
tested on the Loi dataset with high levels of accuracy, specificity, 
and sensitivity.
 E vs L (n) accuracy specificity sensitivity AUC PPV; NPV HR; p
BC030280 24 vs 15 0.90 0.95 0.81 0.87 0.91; 0.81 3.45; <0.0001
Loi 12 vs 19 0.77 0.83 0.74 0.81 0.88; 0.67 3.11; 0.0004
Classifier validation is supported by the respective survival curves 
(not shown). Gene set enrichment analysis reveals the top PPIs are 
primarily related to apoptosis (23/50; p=2.9e-13) and proliferation 
(14/50; p=6.8e-5). Substantial overlap of the network features and 
topology was seen between datasets. Specifically, increased relative 
expression of ESR1, ESR2, EGFR, BCL2, and AR was seen in L vs 
E recurrent tumors, and increased expression of CALM1, CALM2, 
CALM3, SRC, CDK1, and MAPK1 was seen in E vs L recurrent 
tumors. Several hubs (nodes with >5 edges) independently predicted 
for recurrence in additional public datasets of ER+ BC.
Discussion: Our work provides clear evidence that robust molecular 
differences exist between ER+ BC that recur early vs. much later 
despite adjuvant TAM. Exploiting these differences will improve 
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our understanding of involved signaling pathways, allow for the 
reliable prediction of early treatment failure, and guide use of novel 
therapeutics specifically directed at preventing E vs L recurrences 
on endocrine therapy.
S2-1
Partial Breast Brachytherapy Is Associated with Inferior 
Effectiveness and Increased Toxicity Compared with Whole 
Breast Irradiation in Older Patients.
Smith GL, Xu Y, Buchholz TA, Giordano SH, Smith BD. University 
of Texas M.D. Anderson Cancer Center, Houston, TX
Background: Accelerated partial breast brachytherapy (APBI-
brachy) is an increasingly popular radiation treatment for older 
patients diagnosed with early stage breast cancer. Despite growing 
utilization, there is a lack of population-based cohort studies as well 
as randomized phase III data to compare its effectiveness and toxicity 
profile with standard whole breast irradiation (WBI). The purpose 
of this study was to provide the first nationally comprehensive 
comparison of effectiveness and toxicity outcomes in older Medicare 
patients treated with APBI-brachy versus WBI.
Methods: Medicare billing claims identified beneficiaries age>66 
with incident invasive breast cancers diagnosed between 2000 and 
2007 and treated with conservative surgery followed by APBI-brachy 
alone versus WBI. Cumulative incidence of subsequent mastectomy 
(a validated surrogate for local failure) was compared between 
the two treatment groups using the log-rank test. Adjusted risk of 
subsequent mastectomy was determined using a multivariate Cox 
proportional hazards model including demographic, socioeconomic, 
and clinical covariates. Risks of acute complications (hospitalization 
or infection within 120 days of radiation), were compared using the 
chi-square test. Adjusted odds of acute complications were determined 
using multivariate logistic models including covariates. Cumulative 
incidences of long-term toxicities (rib fracture, fat necrosis, breast 
pain, and pneumonitis) were compared using the log-rank test.
Results: In 130,535 women, use of APBI-brachy increased over 
time from <1% of patients treated in 2000 to 13% of patients in 
2007 (P<0.001 for trend). Patients treated with APBI-brachy were 
less likely to have axillary lymph node involvement or to have 
received chemotherapy, and were more likely to be older, White, 
and have comorbid illness. At 5 years, the cumulative incidence 
of subsequent mastectomy was significantly higher in patients 
treated with APBI-brachy (4.0% in APBI-brachy vs. 2.2% in WBI, 
P<0.001). On multivariate analysis, there was a two-fold increased 
risk for subsequent mastectomy in patients treated with APBI-brachy 
(HR= 2.14; 95% CI 1.83-2.52, P<0.001). APBI-brachy was also 
associated with more acute complications, including a higher risk 
of hospitalization (9.6% vs. 5.7%; P<0.001) (Adjusted OR= 1.71; 
1.58-1.86); and infection (8.1% vs. 4.5%; P<0.001) (Adjusted OR= 
1.85; 1.69-2.02; P<0.001). APBI-brachy was also associated with 
higher 5-year cumulative incidence of rib fracture (4.2% vs. 3.6% in 
WBI), fat necrosis (9.1% vs. 3.7%), and breast pain (14.9% vs. 11.7%) 
(P<0.001 for all comparisons), but a lower incidence of pneumonitis 
(0.1% vs. 0.8%, P<0.001).
Discussion: APBI-brachy was associated with inferior effectiveness 
as well as increased acute and late toxicities compared with WBI in 
this cohort of older breast cancer patients. These data underscore the 
importance of awaiting mature results of randomized trials designed to 
prospectively compare these treatments before employing widespread 
adoption of APBI-brachy as an alternative to WBI in select patients.
S2-2
Luminal A Subtype Predicts Radiation Response in Patients with 
T1N0 Breast Cancer Enrolled in a Randomized Trial of Tamoxifen 
with or without Breast Radiation.
Fyles A, McCready D, Pintilie M, Shi W, Done S, Miller N, Olivotto 
I, Weir L, Liu F-F. Princess Margaret Hospital, Toronto, Canada; 
British Columbia Cancer Agency, Vancouver, Canada
Objectives
To determine the predictive effect of molecular subtyping using the 
six biomarker immunohistochemical panel in predicting ipsilateral 
breast relapse (IBR) in women age 50 and older with T1 and T2 node 
negative breast cancer in a randomized trial of tamoxifen (Tam) +/- 
whole breast radiation (WBRT).
Methods
Between December 1992 and June 2000, 769 women were 
randomized to WBRT and Tamoxifen (Tam, n=386) 20 mg daily for 
5 years or Tam alone (n=383). Median age was 68 years, 639 (83%) 
had pT1 tumors. Intrinsic molecular subtype was determined using 
semi-quantitative analysis of ER, PR, Ki-67, HER2, EGFR and 
cytokeratin (CK) 5/6 on tissue microarrays constructed from tumor 
blocks from 172 of 345 available tumors. Patients were classified 
into the following categories: luminal A, luminal B, luminal-HER2, 
HER2 enriched, basal-like, or triple-negative phenotype-nonbasal. 
Median follow-up was 10 years.
Results
IBR at 10 years was 13.8% with Tam compared to 5.0% with Tam/
WBRT (p<0.0001). Tumour size (HR 1.54, p=0.001), ER positive 
(HR 0.35, p=0.006), age (HR 0.96, p=0.014), and treatment with 
Tam/WBRT (HR 0.28, p<0.0001) were significant factors for IBR.
Luminal A tumors (ER or PR positive, HER2 negative, Ki-67<14%, 
n=95) had the lowest rate of IBR, 6.9% at 10 years with Tam alone 
and 4.5% with Tam/WBRT, p=0.4). In women aged 60 and over with 
Luminal A subtype IBR was 5.4% with Tam alone and 6% with Tam/
WBRT (n=74, p=0.8). Luminal B (ER or PR positive, HER2 negative, 
Ki67>14%, n=53) had an IBR of 23.8% with Tam alone and 0% with 
Tam/WBRT, p=0.012). Luminal HER2 (ER or PR positive, HER2 
positive, n=10) and HER2-enriched (ER and PR negative, HER2 
positive, n=14) demonstrated the highest risk of IBR.
Conclusions
Six marker IHC subtype appears to be predictive for radiation 
response in women over 50 with T1/2 node-negative breast cancer. 
Luminal A subtype demonstrated a low risk of breast relapse with 
Tam alone, particularly in women age 60 and older. These results 
require validation in additional specimens and clinical trials, but 
this subgroup represents a significant proportion of women (74/172 
or 43%), who may be spared the inconvenience and side effects of 
breast radiation. In contrast, breast RT is beneficial in women with 
higher risk subtypes (Luminal B, HER2 enriched, basal). Limitations 
of this analysis include the relatively small numbers of patients and 
the low event rate in smaller subgroups.
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NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant 
Clodronate vs. Placebo in Early Stage Breast Cancer Patients 
Receiving Systemic Chemotherapy and/or Tamoxifen or No 
Therapy – Final Analysis.
Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, 
Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, 
Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer 
CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N. National 
Surgical Adjuvant Breast and Bowel Project (NSABP); Tom Baker 
Cancer Centre; University of Pittsburgh Graduate School of Public 
Health; University of Pittsburgh Cancer Institute School of Medicine; 
Kaiser Permanente, Northern California; University of Alabama 
at Birmingham/ECOG; Cross Cancer Institute; British Columbia 
Cancer Agency; University of Pittsburg/Magee Women’s Hospital; 
Cancer Center of Kansas; Stroger Hospital Cook County MBCCOP; 
San Juan MBCCOP; University of Washington/SWOG; Centre 
Hospitalier de l’Université de Montréal; Mayo Clinic Jacksonville/
NCCTG; Allegheny General Hospital; Washington Cancer Institute, 
Washington Hospital Center; Aultman Health Foundation
Bisphosphonates reduce the incidence of skeletal-related events 
(fractures, pain, hypercalcemia) in patients (pts) with bone metastases 
from breast cancer. By inhibiting osteoclast function and subsequent 
bone turnover they may inhibit the growth of bone (and other) 
metastases. Their role in preventing or delaying the development of 
bone (or other) metastases in pts with early breast cancer is uncertain. 
Three previous trials of oral clodronate have given mixed results. 
The largest trial (placebo-controlled) and a smaller open-label trial 
suggested that oral clodronate benefitted pts with improved bone 
metastases-free survival (BMFS) and overall survival (OS), but a 
third open-label study showed no benefit with an apparent detrimental 
effect on survival. Studies of IV zoledronate in open-label trials in 
early breast cancer have also shown mixed results: the AZURE trial 
in pts with node positive breast cancer showed no benefit in disease-
free survival (DFS) or OS with a possible effect in pts aged over 60. 
The ABCSG-12 trial in GnRH (plus tamoxifen or anastrozole) treated 
women with early breast cancer showed a small DFS benefit for those 
receiving IV zoledronate but no BMFS or OS benefit.
Methods: B-34 is a prospective, randomized, double-blind, phase III 
clinical trial in pts with stage 1, 2 or 3 breast cancer assessing oral 
clodronate 1600mg daily for 3 years compared to placebo given alone 
or in addition to adjuvant chemo- or hormone therapy. Stratification is 
by age (<50, +50), number of positive nodes (0, 1-3, 4+) and ER/PR 
status. The primary end-point is DFS. Secondary endpoints are the 
incidence of skeletal metastases, OS, relapse-free survival, incidence 
of non-skeletal metastases, and incidence of skeletal morbid events.
Results: 3323 patients were accrued – 1662 in Group A and 1661 in 
Group B. As of March 31, 2011, 54 pts were declared ineligible: 23 
in Group A and 31 in Group B. The average time on study is 101.3 
months. Patient characteristics were evenly distributed throughout 
both groups. Approximately 75% of pts in each group had negative 
axillary lymph nodes and some 78% in each group were ER and/or 
PR positive. About 64% of pts were age 50 or over. Oral clodronate 
was generally tolerable, toxicities observed being mainly due to 
the concomitant systemic chemotherapy. One pt in Group A had a 
1 mm area of osteonecrosis on the palatal taurus. Compliance, as 
expected with trials of oral medications, has been a problem. 1910 
pts completed 3 years of therapy. Event rates were slower than 
anticipated. This final analysis assesses a total of 598 events in the 
two arms.
Conclusions: This trial is the largest placebo-controlled study of 
an oral bisphosphonate in patients with early breast cancer and will 
provide further information on the role of bisphosphonates in breast 
cancer management.
Supported for NSABP by NCI U10CA12027, -37377, 69651, 69974; 
and Bayer Schering Pharma Oy; for ECOG by U10CA021115; for 
NCCTG by U10CA25224; for SWOG by U10CA38926.
S2-4
GAIN (German Adjuvant Intergroup Node Positive) Study: A 
Phase-III Multicenter Trial To Compare Dose Dense, Dose Intense 
ETC (iddETC) vs. EC-TX and Ibandronate vs. Observation in 
Patients with Node-Positive Primary Breast Cancer – 1st Interim 
EFFICACY Analysis.
Möbus V, Diel IJ, Harbeck N, Elling D, Jackisch C, Thomssen C, 
Untch M, Conrad B, Schneeweiss A, Kreienberg R, Huober J, Müller 
V, Lück H-J, Bauerfeind I, Loibl S, Nekljudova V, von Minckwitz G, 
on Behalf of the GBG / AGO-B / NOGGO Study Groups. Städtische 
Kliniken Frankfurt-Höchst, Frankfurt; Klinik und Poliklinik für 
Gynäkologie, Universität Halle-Wittenberg, Halle; Brustzentrum, 
Universitätsklinikum, Köln; Helios-Klinikum Berlin-Buch, Berlin; 
Städtische Kliniken Offenbach, Offenbach; Schwerpunktpraxis 
Gynäkologische Onkologie, Mannheim; SANA Klinikum, Berlin; 
Elisabeth-Krankenhaus, Kassel; Universitäts-Frauenklinik, 
Heidelberg; Universitäts-Frauenklinik, Ulm; Universitäts-
Frauenklinik, Tübingen; University Medical Center, Hamburg-
Eppendorf; Gynäkologisch-onkologische Praxis, Hannover; 
Frauenklinik, Landshut; German Breast Group, Neu-Isenburg
Background: We previously showed that intense dose-dense (idd) 
epirubicin (E), paclitaxel (T), cyclophosphamide (C) results in a 
superior DFS and OS compared to conventionally dosed EC-T in 
pts with primary breast cancer (PBC) and ≥4 involved lymph nodes 
(LN) (Möbus et al JCO 2010). In the GAIN study, the intense dose-
dense strategy has been further investigated as  well as the adjuvant 
application of ibandronate (I). We here report on the planned interim 
efficacy analysis after 50% (N>401) of the required events have 
occurred.
Methods: A prospective, multi-center, controlled, non-blinded, 
randomized phase III trial investigating ETC (E: 150 mg/m², T:225 
mg/m², C:2500-2000 mg/m², i.v. day 1, q15 for 3 cycles each: A1); 
or EC→TX (E: 112.5 mg/m² + C: 600 mg/m², i.v. day 1, q 15 for 4 
cycles →T: 67.5 mg/m² i.v. day 1, q 8 for 10 weeks + X: 2000 mg/m² 
p. o. day 1-14, q 22 for 4 cycles: A2). Pts were further randomized 
in a 2:1 ratio to receive ibandronate: 50 mg/day p.o.for 2 years (B1) 
or observation (B2). Pts received a primary prophylaxis with either 
epoetin β or darbepoetin α and pegfilgrastim during ETC or EC. After 
recruitment of 1500 pts prophylactic ciprofloxacin was implemented 
and the dose of C was reduced to 2000 mg/m².
Eligibility: Females ≥18 and <65 years, histologically confirmed LN 
positive uni- or bilateral PBC; adequate surgery, ≥1 pos.LN; ECOG 
≤2; written informed consent.
Primary objective:compare DFS A1 vs. A2 and B1 vs.B2. Secondary 
objectives: OS, safety, incidence of secondary primaries, and EFS in 
subgroups of hormone sensitivity and number of pos. LN between 
arms; assessment of compliance; determine prognostic factors.
3000 pts with 801 events were needed to show an increase of 5-year 
DFS from 75% to 79% for pts receiving EC→TX and 728 events to 
show an increase of 5-year DFS from 75% to 79.5% for pts receiving 
I, assuming a drop-out rate of 5%, α=0.05 (two-sided)and 1-ß =80%. 
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An interim analysis for both primary objectives was planned after 50% 
of the expected events occurred. Safety results have been reported 
previously (Möbus et al. SABCS 2009).
Results: 3023 patients were randomized between 06/2004 and 
08/2008.1512 received ETC and 1511 EC→TX. 29pts never started 
therapy, 14 in ETC, 15 in EC→TX. Median follow-up is 38.7 months. 
Median age was 50 years; pN1 (37.7%), pN2 (35.4%); pN3 (26.9%); 
77.4% had ductal invasive carcinoma, 46.6% were grade 3; 76.7% 
had hormone receptor-positive tumors, 22% were HER2-positive. 
405 events have occurred by 12.05.2011.380pts relapsed and 25pts.
died w/o relapse. The interim futility boundary for chemotherapy 
was not crossed. For the ibandronate question the futility boundary 
was reached. There was no difference in DFS and OS between the 
patients with and without ibandronate (DFS log-rank p=0.593; HR 
1.059; 95%CI 0.861-1.301; OS log-rank p=0.801 HR 0.961; 95% 
CI 0.705-1.31).
Conclusion: The GAIN study demonstrated that adjuvant ibandronate 
does neither improve DFS nor OS in primary node positive breast 
cancer after treatment with dose-intensified chemotherapy.
S2-5
An Anti-HER3 Antibody That Stabilizes the Inactive Conformation 
Inhibits Both HER2 and Ligand Driven Tumor Growth.
Garner AP, Bialucha CU, Chen D, Elis W, Kunz C, Li S, Murtie 
J, Saxena P, Sineshchekova O, Sprague E, Ettenberg S. Novartis 
Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, 
Munich, Germany; Sanofi-Aventis, Cambridge, MA
Background: HER3 (ErbB3) is a member of the ErbB family of 
receptor tyrosine kinases (RTK). In normal physiology, ligands 
(e.g. neuregulin) activate HER3 by promoting dimerization with 
other RTK’s such as HER2 (ErbB2). Inappropriate HER2/ HER3 
dimerization as a result of HER2 over-expression in cancer results 
in HER3 mediated activation of the oncogenic PI3K pathway. The 
HER2- targeted antibody trastuzumab inefficiently inhibits HER2 
mediated HER3 activation allowing persistent HER3 signaling that is 
speculated to limit clinical responses. Consequently, combination of 
a HER3- targeted agent with trastuzumab may be of clinical benefit. 
Furthermore, ectopic HER3 activation has recently been implicated 
in the relief of a feedback loop induced by PI3K inhibitors that may 
perhaps limit their efficacy in HER2 driven tumors. Since HER3 
activation in HER2 driven cancers occurs in a ligand- independent 
manner, antibodies that primarily inhibit ligand- induced HER3 
activation are largely inactive in HER2 driven xenograft models.
Results: H3F15, a high affinity (26pM) HER3- targeted fully human 
IgG1 antibody was selected from the Human Combinatorial Antibody 
Library (HuCAL) using phage display technology. In a broad range 
of HER2 amplified breast and gastric cell lines, H3F15 displayed 
potent inhibition (IC50 <1nM) of HER3/ AKT phosphorylation 
and proliferation. Interestingly, H3F15 also effectively inhibited 
neuregulin stimulated HER3 phosphorylation and downstream 
signaling in MCF7 cells indicating that H3F15 inhibits multiple 
modes of HER3 activation. Determining the H3F15/ HER3 crystal 
structure revealed that H3F15 binds a novel conformational epitope 
that traps HER3 in the inactive conformation thus preventing its 
activation by either HER2 or neuregulin. In vivo testing of H3F15 
using xenograft tumor models driven by either HER2 (BT474) or 
HER3 ligands (BxPC3) confirmed that single agent H3F15 (20mg/ 
kg) significantly inhibited tumor growth (83 and 77% inhibition 
respectively). Furthermore, combinations of H3F15 with either 
trastuzumab or PI3K- targeted agents were synergistic in a panel 
of HER2 driven cell lines whilst the in vivo combination of H3F15 
(20mg/kg) with trastuzumab (1mg/kg) was sufficient to induce tumor 
regression.
Discussion: H3F15 is a HER3- targeted antagonist IgG1 that stabilizes 
the inactive form of HER3. This novel mechanism of action enables 
H3F15 to uniquely inhibit both ligand-induced and HER2-mediated 
activation of HER3. Thus H3F15 is the first HER3 antibody to display 
single-agent efficacy in both HER2 and ligand driven xenograft 
models whilst also inducing tumor regressions in combination with 
trastuzumab. Based on preclinical data, combining H3F15 with either 
trastuzumab or PI3K- targeted agents fully inhibits the HER2/ HER3 
signaling pathway, which may lead to greater and more sustained 
clinical efficacy in HER2 driven cancers.
S2-6
ErbB3 Expression Is Required for Maintenance of Normal and 
Transformed Luminal Breast Epithelial Cells.
Cook RS, Balko JM, Rinehart C, Miller TW, Polyak K, Prat A, 
Perou CM, Arteaga CL. Vanderbilt University; UNC Lineberger 
Comprehensive Cancer Center; Dana Farber Cancer Institute
The ErbB receptor tyrosine kinase family regulates breast 
development and cancer. ErbB2/HER2 expression correlates with 
HER2-enriched breast cancers, while epidermal growth factor 
receptor (EGFR) expression often correlates with triple negative 
breast cancers. Less is known regarding ErbB3, which harbors only 
weak kinase activity, but strongly activates phosphatidylinositol-3 
kinase (PI3K)/Akt signaling upon heterodimerization with EGFR 
or ErbB2. We report herein that ERBB3 mRNA expression strongly 
correlates with Luminal A/B breast cancers, which express lower 
levels of EGFR and ErbB2. Mammary-specific loss of ErbB3 in 
mice reduced Akt phosphorylation and caused cell death in the 
luminal epithelium. A decreased luminal population in ErbB3-
deficient epithelium correlated with expansion of the mammary 
stem/progenitor fraction. In normal breast samples, ERBB3 mRNA 
expression was highest in mature/progenitor luminal populations, 
and lowest in the stem/basal population. Loss of ErbB3 shifted gene 
expression in mammary epithelial cells to resemble a mammary 
stem cell signature. The genes most greatly impacted by ErbB3 loss 
produced a signature that correlated with decreased overall survival in 
tamoxifen-treated patients. Knock-down of ErbB3 in human luminal 
breast cancer cells caused decreased cell growth under conditions 
of estrogen deprivation, decreased expression of the gene encoding 
aromatase, and impaired expression of estrogen receptor-induced 
genes, including those that encode progesterone receptor and TFF1. 
Treatment of MCF7 luminal breast cancer xenografts with AMG-888, 
a humanized monoclonal antibody directed against ErbB3, decreased 
tumor growth. Combination of AMG-888 with the estrogen receptor 
inhibitor fulvestrant caused MCF7 tumor regression. Taken together, 
these results suggest that ErbB3 is required to sustain normal and 
transformed luminal epithelial cells of the breast, and suggest that 
targeting ErbB3 may improve the clinical outcome of breast cancers 
treated with endocrine therapy.
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S2-7
Mechanisms of Action and Biological Significance of HER2 
Mutations in HER2-Overexpressing Breast Cancer.
Boulbes DR, Jin Q, Arold ST, Ladbury JE, Yu D, Esteva FJ. University 
of Texas - MDAnderson Cancer Center, Houston, TX; University of 
Texas - MD Anderson Cancer Center, Houston, TX
Background: Trastuzumab is the most successful HER2-directed 
therapy in patients with early-stage and advanced HER2 positive 
breast cancer. Although trastuzumab improves survival in the 
adjuvant setting, 15-20% of the patients develop metastasis. Lapatinib 
is currently the only tyrosine kinase inhibitor approved for the 
treatment of patients with metastatic breast cancer after trastuzumab 
progression. However, progression eventually occurs and the disease 
remains incurable for the majority of patients. Recently, somatic 
mutations in the HER2 kinase domain have been reported in lung 
adenocarcinomas which result in constitutive phosphorylation of 
HER2, EGFR and cellular substrates. Activation of these receptors 
and pathways in lung cancer was associated with tumor progression 
and trastuzumab resistance, but tumors remained sensitive to a 
tyrosine kinase inhibitor. Because there are many different types of 
breast cancer that respond differently to treatments, more approaches 
are needed to predict which patients will most likely respond to a 
given therapy.
Material and Methods: Using gene sequencing on 78 HER2 positive 
breast tumors, our laboratory identified 4 novel missense variants 
in the kinase domain of HER2. None of the patients whose tumors 
carried one of these mutations achieved objective response to 
trastuzumab. Mutants were created using directed mutagenesis, 
inserted in a lentiviral expression plasmid and stably expressed in 
different breast cancer or non-tumorigenic cell lines. An ATP-based 
assay was used for cell survival studies. Migration studies were 
performed using Boyden-chambers coated with Matrigel. Anchorage-
independent colony formation was assessed in soft-agar. Signaling 
pathways and phosphorylation status were analyzed by Western 
blot. Localization results were obtained by immunofluorescence and 
confocal microscopy followed by deconvolution analysis.
Results: Two of the mutants were dramatically under-phosphorylated 
and presented an altered cellular localization revealed by 
immunofluorescence studies in both cell lines and patient surgical 
samples. Also, cells expressing HER2 mutants showed an increased 
ability to invade Matrigel and migrate and to form colonies in 
soft-agar, suggesting the induction of a more aggressive behavior. 
In particular, one of the mutations was strongly associated with 
resistance to lapatinib treatment in cell survival and soft-agar assays, 
and higher doses of lapatinib were necessary to inhibit the ERK and 
AKT pathways. Computational analysis revealed that the mechanism 
of lapatinib resistance could be explained by a sterical obstruction 
of the ATP-binding pocket of the protein kinase domain that would 
impede the binding of lapatinib.
Conclusion: HER2 mutations confer a more aggressive phenotype. A 
specific mutation directly interacts with Lapatinib binding to HER2 
and predicts resistance to Lapatinib in HER2-overexpressing breast 
cancer cells. Further characterization of novel HER2 mutations may 
have a direct implication in the development of novel markers for 
early diagnostics, patient selection and characterization of more 
appropriate and personalized treatment.
S3-1
Update of International Breast Cancer Study Group Trial 23-01 
To Compare Axillary Dissection Versus No Axillary Dissection 
in Patients with Clinically Node Negative Breast Cancer and 
Micrometastases in the Sentinel Node.
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, 
Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Massarut S, 
Garbay J-R, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert 
M, Price KN, Goldhirsch A, Gelber RD, Veronesi U. International 
Breast Cancer Study Group Trial 23-01 Investigators
Introduction and Study Design
For patients (pts) with a metastatic sentinel node (SN), axillary 
dissection is standard treatment to achieve optimal locoregional 
control. However, for many pts the SN is the only positive node and 
for pts with minimal SN involvement, axillary dissection (AD) may 
be overtreatment. IBCSG Trial 23-01 was designed to determine 
whether AD is necessary in pts with minimal SN involvement (defined 
as one or more micrometastatic (≤2 mm) SNs) and tumor ≤5 cm. 
Consenting eligible pts were first registered; those with the requisite 
SN involvement were randomized to AD (group A) vs. no further 
axillary surgery (group B). The primary endpoint was disease-free 
survival (DFS). Secondary endpoints included overall survival (OS) 
and systemic disease-free survival (SDFS). The trial started in April 
2001 and closed in February 2010. The accrual target was 1,960 pts 
to provide 90% power to detect non-equivalence if 5-year DFS was 
64% for group B and 70% in group A. At closure 6,681 pts had been 
registered, with 934 randomized from 27 centers. The primary reasons 
for early closure were that projected time to complete accrual was 
too long, and the aggregate event rate at 30 months median follow 
up was much lower than anticipated.
Baseline Characteristics and Treatment
Mean patient age at entry was 54 years (range 26-81). More 
postmenopausal (56%) than premenopausal pts (44%) were 
randomized. Sixty-seven percent of pts had tumor <2 cm, while 
7% had tumor ≥3 cm; 26% had grade 3 disease. Tumors were 
estrogen-receptor positive in 89% of pts, and progesterone-receptor 
positive in 75%. In the involved sentinel node(s), 67% of pts had 
≤1.0 mm micrometastasis, 29% had 1.1-2.0 mm micrometastasis, 
2% had metastasis >2.0 mm, and 2% were unknown. Most (96%) 
pts underwent lymphoscintigraphy, and 1 or 2 sentinel nodes were 
found in about 85%. A previous excision biopsy was performed in 
16%. Conservative surgery was definitive treatment in 75%; the others 
received mastectomy. Adjuvant radiotherapy was performed in 89% 
of group A and 92% of group B.
Outcomes
On 25 May 2011, median follow was 49 months. There were 88 DFS 
events. Sites of first DFS event were breast cancer-related in 66 pts 
[local (8), contralateral breast (10), regional (6), and distant (42)], and 
non-breast cancer-related in 22 [second malignancies (17) and deaths 
without prior cancer event (5)]. Four-year DFS (± standard error) 
was 91% (±1.4%). Four-year competing risk cumulative incidences 
were 7.3% (±1.0%) for breast cancer events and 2.0% (±0.5%) for 
non-breast cancer events. With 101 DFS events, the trial is estimated 
to have 90% power to detect non-equivalence if 5-year DFS is 87% 
for group B compared with 92% for group A.
Conclusion
In this trial, restricted to clinically N0 with microscopic SN 
involvement, breast cancer recurrence and relapse rates are very low 
at a median follow-up of 4 years. The first comparison of outcomes 
between the two arms will be presented after a median follow-up of 
5 years, when number of DFS events is anticipated to exceed 100.
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S3-2
Neoadjuvant Chemotherapy Adapted by Interim Response 
Improves Overall Survival of Primary Breast Cancer Patients – 
Results of the GeparTrio Trial.
von Minckwitz G, Blohmer JU, Costa S, Denkert C, Eidtmann H, 
Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch 
C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, 
Zahm DM, Mehta K, Loibl S. German Breast Group, Neu-Isenburg; 
St. Gertrauden Krankenhaus, Berlin; Universitäts-Frauenklinik, 
Magdeburg; Charité, Berlin; Universitäts-Frauenklinik, Kiel; 
Frauenklinik vom Roten Kreuz, München; Universitäts-Frauenklinik, 
Rostock; Henrietten-Stiftung, Hannover; Brustzentrum Kantonsspital 
St. Gallen / Universitäts-Frauenklinik Tübingen; Frauenklinik, 
Klinikum, Offenbach; Universitäts-Frauenklinik, Frankfurt; Klinikum 
Essen Mitte, Essen; Universitäts-Frauenklinik Rechts der Isar, 
München; Universitäts-Frauenklinik, Heidelberg; Frauenklinik, 
Berlin; Brustzentrum SRH Waldkliniken, Gera
Background:
The GeparTrio phase III trial investigated the concept of interim 
response-adapted neoadjuvant chemotherapy. Patients with an 
early response after 2 cycles chemotherapy were considered highly 
chemo-sensitive and randomized to additional 2 chemotherapy cycles 
compared to standard treatment. Patients with no early response were 
considered less chemo-sensitive and randomized to continue with a 
non-cross-resistant chemotherapy or with standard chemotherapy. 
Pathological complete response (pCR) rates were different between 
responders and non-responders but not between the randomized arms 
(von Minckwitz G, et al JNCI 2008+2008; Huober et al. BCRT 2010). 
We report here on the results of the secondary endpoints: disease-free 
(DFS) and overall survival (OS).
Patients and Methods:
2072 patients with operable or locally advanced breast cancer were 
treated with 2 cycles TAC (docetaxel, doxorubicin cyclophosphamide) 
before interim response assessment. Responders were randomized to 
additional TACx4 (N=704) or TACx6 (N=686) and non-responders 
to TACx4 (N=321) or NXx4 (vinorelbine, capecitabine) (N=301). 
None of the HER2+ patients received Trastuzumab. Endocrine 
treatment was given postoperatively to ER+ and/or PgR+ patients. 
We observed 480 recurrences and 302 deaths during median 62 
months of follow up.
Results:
Patients receiving the experimental treatments (TACx8 or TACx2-
NXx4) showed a longer DFS (HR 0.71; 95%CI 0.60-0.86, p<0.001) 
and longer OS (HR 0.79; 95%CI 0.63–0.99, p=0.048) compared to 
patients receiving standard TACx6 treatment. Treatment effects on 
DFS were restricted to patients with luminal A (p=0.003), luminal 
B (HER2-) (p=0.006) and luminal B(HER2+) (p=0.04) tumors. 
Experimental treatments did not improve outcome in HER2+(non-
luminal) (p=1.0) and triple-negative (p=0.5) tumors. Responders 
showed a significant longer DFS (HR 0.79; 95%CI 0.62-0.97), 
p=0.026) and a trend towards a longer OS (HR 0.76; 95%CI 0.57–
1.01, p=0.061) if they were treated with TACx8 compared to TACx6. 
Non-responders showed a longer DFS (HR 0.6; 95%CI 0.43–0.82, 
p=0.001) but not OS (HR 0.85; 95%CI 0.57–1.27, p=0.4) when 
treated with TACx2-NXx4 compared to TACx6. Results according 
to phenotypes of responders and non-responders were comparable 
to the overall comparison. In general, patients with a pCR showed 
a better DFS if they had triple-negative (p<0.0001), HER2+(non-
luminal) (p<0.0001) or luminal B(HER2-) (p=0.004), but not if they 
had luminal A (p=0.66) or luminal B (HER2+) (0.67) disease.
Conclusion: 
Adapting neoadjuvant chemotherapy according to interim response 
leads to better DFS and OS and represents therefore a unique 
advantage over adjuvant treatment. The investigated strategies to 
improve standard chemotherapy were most effective in the luminal 
A and B phenotypes. These phenotypes are usually considered less 
chemo-sensitive and pCR is not a prognostic factor. This might explain 
why the observed survival advantages could not be predicted by pCR.
S3-3
Association of PTEN Loss and PIK3CA Mutations on Outcome 
in HER2+ Metastatic Breast Cancer Patients Treated with First-
Line Lapatinib Plus Paclitaxel or Paclitaxel Alone.
Xu B, Guan Z-Z, Shen Z-Z, Tong Z-S, Jiang Z-F, Yang J-l, DeSilvio 
M, Leigh M, Ellis C. Cancer Hospital, CAMS & PUMC; Sun Yat-Sen 
Medical University Cancer Center; Shanghai Cancer Center, Fudan 
University; Tianjin Medical University Cancer Institute and Hospital; 
Hospital Affiliated to Military Medical Science; Beijing 301 PLA 
Hospital; GlaxoSmithKline
Background
Identifying molecular determinants underpinning response and 
resistance to anti-cancer therapies is essential to selecting optimal 
treatment for patients (pts). The PI3K pathway is frequently 
deregulated in cancer. In preclinical models deregulated PI3K 
has been shown to enhance the survival of breast cancer cells and 
confer resistance to chemotherapy and HER2-directed agents. This 
exploratory study evaluated the impact PIK3CA mutations and PTEN 
loss had on the efficacy of paclitaxel alone (P) and in combination with 
lapatinib (L+P) in HER2-positive metastatic breast cancer (MBC) pts 
enrolled in study EGF104535, results of which demonstrated that pts 
treated with the combination of L+P derived an absolute improvement 
in median overall survival (OS) of 7.3.months (median OS=27.8 
months in L+P compared with 20.5 months in P).
Method
Baseline tissue from primary breast tumor or metastatic site was 
obtained in the form of formalin-fixed, paraffin-embedded material. 
Of the total study population (n=444), 389 pts had tissue available 
for biomarker analyses, 277 of whom provided written informed 
consent for optional tumor genetics (i.e., PIK3CA analysis). PTEN 
was evaluated on whole sections by immunohistochemistry (rabbit 
monoclonal antibody); pathology review and image analysis were 
performed, producing an ordinal score and optical density (OD). 
Qiagen/DxS assay was used in assessing PIK3CA mutation status. 
Logistic regression and Cox-proportional hazard models were used 
in analyses of biomarkers with efficacy endpoints.
Results
Evaluable results for PTEN and PIK3CA were available for 91% 
(354/389) and 62% (171/274) of pts, respectively. In the overall 
population, 24% (65/274) had tumors harboring PIK3CA mutations 
(E542K, E545K/D, H1047R); 13% (49/389) had absence of PTEN 
expression. Survival outcome appeared to be independent of PTEN 
expression (P >0.2). PIK3CA mutations were significantly associated 
with worse OS (HR=1.88; 95% CI=1.26, 2.80; P=0.002). PFS was 
significantly improved in pts treated with L+P compared with P in 
both PTEN strata (loss/expression; P<0.001). In pts stratified by 
PIK3CA status, treatment with L+P reduced the risk of progression 
compared with P in the wildtype strata (N=106; HR=0.43; 95% CI= 
0.28, 0.65; P<0.0001); in the mutation strata, PFS was not significantly 
reduced with the addition of L (N=65; HR=0.70; 95% CI= 0.42, 
1.17; P=0.179).
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Conclusions
In this exploratory study, PTEN was not prognostic whereas PIK3CA 
mutations appear to be an adverse prognostic feature in HER2+ 
MBC. PTEN expression may not be predictive as both strata derived 
significant benefit with L+P treatment. PFS benefit from L+P was 
significant in pts with PIK3CA wildtype tumors whereas the PFS 
benefit was not significant in the PIK3CA mutation strata. Additional 
analyses are ongoing and will be presented.
S3-4
ER Downregulation with Fulvestrant in Combination with pan-
PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant 
Breast Cancer Xenografts In Vivo.
Miller TW, Fox EM, Balko JM, Meszoely IM, Sanders ME, Kuba 
MG, Wagle N, Garraway LA, Maira S-M, Arteaga CL. Vanderbilt 
University, Nashville, TN; Dana-Farber Cancer Institute, Boston, 
MA; Novartis Inst. for Biomedical Research, Basel, Switzerland
ER+ breast cancers typically respond to aromatase inhibitors (AIs), 
but a significant fraction exhibit de novo or acquired resistance. To 
discover mechanisms of resistance to AIs, we maintained four ER+, 
hormone-dependent human breast cancer cell lines in hormone-
depleted conditions for several months until estrogen-independent 
populations emerged (termed long-term estrogen-deprived, LTED). 
A siRNA kinome screen identified 42 kinases that suppressed 
hormone-independent MCF-7/LTED cell growth ≥33% (p<0.05). 
Pathway analysis revealed phosphatidylinositol 3-kinase (PI3K) as 
a central hub which integrates signaling from, or emits signaling 
to many of these 42 kinases. Further, treatment with the PI3K/
mTOR dual inhibitor BEZ235 or the pan-PI3K inhibitor BKM120 
suppressed LTED cell growth, and prevented the emergence of 
hormone-independent cells.
Activating mutations in PIK3CA, the gene encoding the p110a 
catalytic subunit of PI3K, are present in about 35% of ER+ breast 
cancers. We investigated whether PIK3CA mutations modify the 
tumor response to estrogen deprivation with letrozole in a pre-surgical 
clinical trial (NCT00651976). Twenty-one patients with stage I-II 
operable ER+/HER2- breast cancer were treated with letrozole for 
10-21 days up to 24 h prior to surgery. Core tumor biopsies were 
obtained before treatment and at the time of surgical resection. Ki67 
immunohistochemistry (IHC) was scored in pre- and post-letrozole 
specimens. The change in natural log of the Ki67 score between pre- 
and post-treatment samples was stratified by PIK3CA mutant vs. wild-
type (WT) status. PIK3CA-mutant tumors exhibited a statistically 
lower reduction in Ki67 score compared to tumors with WT PIK3CA 
(p=0.03). These findings suggest that mutational activation of PI3K 
attenuates the response to estrogen deprivation.
In some LTED cell lines, downregulation of ER with fulvestrant or 
siRNA inhibited estrogen-independent growth, suggesting that the 
unliganded ER can maintain proliferation of cells adapted to estrogen 
deprivation. Prior work suggested that PI3K-ER crosstalk promotes 
resistance to estrogen deprivation. However, inhibition of PI3K/
AKT/TORC1 signaling did not alter ERS167 phosphorylation in 
LTED cells, and ER downregulation with fulvestrant did not inhibit 
PI3K/AKT, suggesting that PI3K and ER modulate non-overlapping 
pathways in cells adapted to estrogen deprivation. Treatment with 
BKM120 synergized with fulvestrant to inhibit the growth of 6/8 ER+ 
breast cancer cell lines in estrogen-depleted conditions. Treatment 
with single-agent fulvestrant or BKM120 in athymic mice devoid 
of estrogen supplementation partially inhibited the growth of ER+/
PI3K-mutant MCF-7 xenografts, while the combination induced near-
complete tumor regression. IHC analysis showed increased cleaved 
caspase-3+ cells in BKM120-treated tumors and decreased Ki67+ 
cells in fulvestrant-treated tumors, implying that the combination 
induced tumor regression by both inhibition of tumor cell proliferation 
and induction of apoptosis. These data suggest that upon progression 
on an aromatase inhibitor, patients with ER+/PI3K-mutant breast 
cancer would benefit from a combination of an ER downregulator 
and a PI3K pathway inhibitor.
S3-5
Next Generation Sequencing Reveals Co-Activating Events in the 
MAPK and P13K/AKT Pathways in Metastatic Triple Negative 
Breast Cancers.
O’Shaughnessy J, Craig DW, Kiefer J, Sinari S, Moses TM, Wong 
S, Aldrich J, Christoforides A, Dinh J, Itzatt T, Blum J, Kurdoglu A, 
Salhia B, Baker A, Siddiqui A, Hoang L, Billings P, Trent JM, Mousses 
S, Von Hoff D, Carpten JD. Baylor Sammons Cancer Center, Dallas, 
TX; Translational Genomics Research Institute, Phoenix, AZ; Life 
Technologies, Carlsbad, CA; US Oncology, The Woodlands, TX
INTRODUCTION: The clinical application of next generation 
sequencing to comprehensively characterize groups of driving 
mutations in individual metastatic triple negative breast cancer 
(mTNBC) genomes has the potential to reveal therapeutically relevant 
pathway dependencies. Towards this end, we harvested tissue from 
14 patients with mTNBC and are conducting deep whole genome and 
transcriptome sequencing for each case to identify mutations that can 
guide therapeutic targeting within available phase I/II clinical trials.
METHODS: Metastatic tumor tissue was harvested from 14 
mTNBC patients, and 7 samples have undergone total genome and 
transcriptome sequencing with the others currently underway. We are 
utilizing the Life Technologies SOLiD® system to sequence germline 
and tumor DNA to sufficient depth to identify somatic genome 
alterations including point mutations, indels, and structural events 
including translocations. Furthermore, RNA-seq is being performed 
on these tumors, along with a series of age- and ethnicity-matched 
normal breast controls to perform deep differential expression 
analysis, isoform expression analysis, and fusion transcript detection. 
Our team of genome scientists and clinical oncologists are evaluating 
the sequencing findings and are prioritizing the investigational 
therapeutic options for each patient.
RESULTS: Our whole genome and transcriptome sequencing study 
has revealed numerous known and novel mutations in mTNBC. 
However, all patients’ cancers analyzed to date had alterations that 
would activate the MAPK pathway, but through various mechanisms 
in different patients. These include BRAF amplification and 
overexpression, NF1 homozygous deletion, and consistent IQGAP3 
overexpression. Furthermore, all patients’ cancers also harbor 
mutations that would activate the PI3K/AKT pathway including PTEN 
homozygous deletion or down-regulation, consistent INPP4B down-
regulation, FBXW7 homozygous deletion, and ERAS overexpression. 
Moreover, although we and others show ERBB4 down-regulation 
in breast tumors, we are the first to report unique somatic genomic 
events that significantly alter the ERBB4 locus leading to its loss in the 
majority (5/7) of our patients’ tumors. Importantly, we are beginning 
to use these insights to prioritize therapeutic targeting and have 
observed that one chemotherapy-refractory mTNBC patient, with 
a high-level BRAF amplification/overexpression along with down-
regulation of PTEN and INPP4B, had a major response to combined 
mek plus akt inhibitors on a phase I study.
CONCLUSIONS: Comprehensive genomic and transcriptomic 
interrogation of mTNBCs has revealed events supporting co-
activation of the MAPK and PI3K/AKT pathways in all the tumors 
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albeit by different mutational mechanisms and supports potential 
effectiveness of combination therapy in the treatment of mTNBC. 
We plan to treat these patients with combined mek plus akt inhibitors 
on a new phase I study beginning in August 2011 to determine the 
effectiveness of co-inhibition of these pathways based on this frequent 
genomic context.
S3-6
Neoadjuvant Chemotherapy of Paclitaxel with or without Rad001: 
Results of the Non-Responder Part of the GEPARQUINTO Study 
(GBG 44).
Huober J, Hanusch C, Fasching PA, Rezai M, Eidtmann H, Kittel 
K, Schwedler K, Tesch H, Höß C, Mau C, Khandan F, Krabisch P, 
Loibl S, Nekljudova V, Untch M, von Minckwitz G. Kantonsspital St. 
Gallen/Universitäts-Frauenklinik Tübingen; Frauenklinik vom Roten 
Kreuz, München; Universitäts-Frauenklinik, Erlangen
Background:
The oral signal transduction inhibitor everolimus (RAD001 = R), 
binds selectively to mTOR (mammalian target of rapamycin), an 
intracellular protein kinase implicated in the control of cellular 
proliferation of activated T-lymphocytes and neoplastic cells. Phase 
II data suggested that R can enhance the clinical efficacy of endocrine 
treatment in the metastatic and neoadjuvant setting.
The GeparQuinto phase III study had 3 settings (HER2-positive: 
trastuzumab vs lapatinib; HER2-negative: +/- bevacizumab (Bev); 
HER2-negative non-responder: +/- R). Primary aim of the last setting 
was to improve pathological complete response (pCR) for patients 
with HER2-negative breast cancer not responding to 4x epirubicin/
cyclophosphamide (EC) +/- Bev by adding R to weekly paclitaxel 
as neoadjuvant chemotherapy.
Patients and Methods:
Patients with untreated HER2-negative breast cancer were eligible if 
their tumors were stage cT3/4a-d; or estrogen (ER) and progesterone 
(PgR) receptor-negative; or ER/PgR-positive tumors with clinically 
N+ (for cT2) or pNSLN+ (for cT1). Only patients without response 
(<50% tumor reduction) to 4x EC+/-Bev were eligible and were 
randomized to receive further paclitaxel (Pac: 80 mg/m² q1w x12) 
chemotherapy with or without R. Treatment with R started 21 to 35 
days after the last application of EC with a dose escalation from 2.5 
mg every 2nd day to 5 mg every day over 14 days and maintained 
at 5 mg/day for additional 10 weeks. Dose of R could be decreased 
to 2.5 mg/day in case of toxicity. Treatment with Pac started within 
7-14 days after the start of R. pCR was defined as no invasive and 
no non-invasive tumor residuals in breast and nodes. We assumed a 
pCR rate of 5% for Pac based on the GeparDuo study and expected 
a pCR of 12.1% for Pac+R (odds ratio 2.62). A two-sided Pearson’s 
C² with a=0.05 and b=0.20 calculated a sample size of 566 P. One 
interim futility analysis after 1/3 of patients completed therapy was 
planned. Randomisation was stratified by participating center, ER/
PgR status, extend of disease (T4 or N3 vs. T1-3 and N0-2) and pre-
treatment with Bev or not.
Results:
Between 11/07 and 15/06/11 402 P were randomized to Pac (N=201) 
and Pac+R (N=201). Median age was 51.0 and 50.0 [-R / +R] years. 
Median clinical tumor size was 40 / 40 mm; 62% / 55% had cT2, 
18% / 20% cT3, and 16.7% / 16.7% cT4a-d tumors; 88% / 89% had 
non-lobular; 35% / 33% grade 3; 55% / 57% node-positive; and 29% 
/ 27% ER and PgR-negative (triple-negative) disease.
The futility interim analysis was performed in 02/10, futility boundary 
was not reached and the trial was continued. After the other 2 settings 
completed accrual in 06/10, recruitment to the 3rd setting dropped such 
that it appeared not possible to recruit the full number of patients.. 
The trial will therefore close recruitment on June, 30th 2011 with an 
estimated statistical power of 65%. Results on histological response 
and surgical outcome will be reported.
Conclusion: 
This will be the first report on efficacy data of neoadjuvant R + Pac 
for patients with early breast cancer. The results of the GeparQuinto 
study will have to be set into context with the results from the Bolero 
studies in metastatic disease.
S3-7
Everolimus for Postmenopausal Women with Advanced Breast 
Cancer: Updated Results of the BOLERO-2 Phase III Trial.
Hortobagyi GN, Piccart M, Rugo H, Burris H, Campone M, Noguchi 
S, Gnant M, Pritchard KI, Vittori L, Mukhopadhyay P, Sahmoud T, 
Lebwohl D, Baselga J. The University of Texas, MD Anderson Cancer 
Center, Houston, TX; Jules Bordet Institute (Institut Jules Bordet), 
Brussels, Belgium; University of California, San Francisco Helen 
Diller Family Comprehensive Cancer Center, UCSF, San Francisco, 
CA; Sarah Cannon Research Institute, Nashville, TN; Institut de 
Cancérologie de l’Ouest - René Gauducheau, Centre de Recherche 
en Cancérologie, Nantes Saint Herblain, France; Osaka University, 
Osaka, Japan; Comprehensive Cancer Center, Medical University 
of Vienna, Vienna, Austria; Sunnybrook Odette Cancer Centre and 
the University of Toronto, Toronto, Canada; Novartis Pharma AG, 
Basel, Switzerland; Novartis Pharmaceuticals Corporation, East 
Hanover, NJ; Massachusetts General Hospital Cancer Center and 
Harvard Medical School, Boston, MA
Background: The mTOR pathway is constitutively activated in 
hormone-resistant advanced breast cancer (ABC). In phase II trials, 
everolimus (EVE) showed promising efficacy both as monotherapy 
and in combination with endocrine therapy in patients with estrogen 
receptor–positive (ER+) ABC. This double-blind, placebo-controlled, 
phase III study evaluated EVE plus exemestane (EXE) in patients 
with ER+ ABC refractory to letrozole or anastrozole.
Patients and Methods: Eligible patients were randomized (2:1) to 
EXE (25 mg/day) with EVE (10 mg/day) or with matching placebo. 
The primary endpoint was progression-free survival (PFS). Secondary 
endpoints included overall survival, response rate, quality of life 
(QoL), and safety.
Results: 724 patients were randomized (485: EVE+EXE; 239: EXE). 
Baseline characteristics were well balanced; median age was 62 years, 
56% had visceral involvement, and 84% had documented benefit from 
previous endocrine therapy, which included letrozole or anastrozole 
(100%), tamoxifen (48%), fulvestrant (16%), and chemotherapy for 
advanced disease (25%). This analysis is based on 457 events and 
median follow-up of 12.5 months. PFS by investigator assessment 
showed a hazard ratio (HR) of 0.44 (95% CI: 0.36-0.53) and a median 
duration of 7.4 (EVE+EXE) vs 3.2 months (EXE) (P<1 × 10-16) 
and 12-month estimate of 31% vs 10%. PFS by central assessment 
showed an HR of 0.36 (95% CI: 0.28-0.45) and a median duration of 
11.0 (EVE+EXE) vs 4.1 months (EXE) (P<1 × 10-16) and 12-month 
estimate of 48% vs 18%. Response rates and clinical benefit rate were 
also higher for EVE+EXE (12.0% vs 1.3% and 50.5% vs 25.5%). A 
total of 138 patients died; 17.3% in the EVE+EXE arm and 22.6% 
in the EXE arm.  
The most common grade 3/4 adverse events were stomatitis (8% vs 
1%), anemia (7% vs 1%), hyperglycemia (5% vs < 1%), dyspnea (4% 
vs 1%), and fatigue (4% vs 1%) for the EVE+EXE and EXE groups, 
respectively. Grade 3 pneumonitis was observed in patients receiving 
EVE (3% vs 0%). No difference in time to deterioration of QoL was 
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observed. EVE increased EXE steady-state Cmin and Cmax levels by 
45% and 64%, respectively, with no difference in estradiol levels. 
Serum markers of bone resorption and bone formation increased in 
the EXE arm and generally decreased in the EVE+EXE arm.
Conclusion: The addition of EVE to EXE is associated with 
significant and sustained prolongation of PFS. Adverse events were 
higher in the combination arm but manageable by dose interruption 
and/or reduction and did not affect QoL. EVE in combination with 
an aromatase inhibitor is a promising therapeutic option for women 
with hormone receptor–positive advanced breast cancer.
S4-1
Overdiagnosis in Breast Cancer Screening: Methodological 
Considerations of Current Estimates.
Smith RA, Duffy SW. American Cancer Society, Atlanta, GA; Queen 
Mary University of London, London, United Kingdom
Background
A harm that has received considerable attention in breast cancer 
screening is overdiagnosis, i.e., the detection through screening 
of breast cancer that is non-progressive. Since there is no way to 
distinguish a truly non-progressive tumor from one that is progressive, 
overdiagnosis is a statistical phenomenon that is estimated as the 
difference between observed and expected incidence rates. However, 
there is no agreement on the true rate of overdiagnosis in breast 
cancer screening. Estimates vary widely, with the highest estimates 
reported in the scientific literature having received significant 
media attention under the premise that a signifiant fraction of newly 
diagnosed breast cancers are non-progressive and thus overtreated. 
We examined the range of overdiagnosis estimates in the context of 
factors that influence observed and expected breast cancer incidence 
rates over time.
Methods
Only studies that compared incidence rates of invasive breast cancer, 
or invasive breast cancer and ductal carcinoma in situ (DCIS), in a 
group invited or exposed to mammography compared with a group 
not invited or not exposed to mammography were included in our 
analysis. Studies were evaluated based on whether or not they adjusted 
for contemporaneous trends in the underlying incidence of disease, 
which may differ in different age groups, and age-specific effect on 
incidence rates due to lead time.
Results
We identified 17 studies (Table 1) that attempted to estimate 
overdiagnosis of breast cancer resulting from mammography 
screening. The main determinant of high estimated rates of 
overdiagnosis was a failure to adjust for lead time. The highest 
rate of overdiagnosis (33%) occurred in the one study that did not 
correct for either lead time or confounders. Studies that only partially 
corrected for lead time and confounding also had high estimates of 
overdiagnosis (mean = 30%), whereas studies that corrected for both 
lead time and confounders had the lowest estimate of overdiagnosis 
(mean =5%).
Conclusion
The possibility that some breast cancers detected by mammography 
are indolent and not life threatening within the patient’s natural life 
is real. However, it is clear from our analysis that the wide range of 
estimates of overdiagnosis are due to whether or not studies have 
adjusted for factors in and outside of screening programs known to 
influence incidence rates over time. Our findings suggest that the true 
rate of overdiagnosis associated with breast cancer screening, to the 
extent that it exits at all, is small.
S4-2
The Risk of Contralateral Breast Cancer in BRCA1/2 Carriers 
Compared to Non-BRCA1/2 Carriers in an Unselected Cohort.
van den Broek AJ, Schmidt MK, Tollenaar RAEM, van ‘t Veer LJ, van 
Leeuwen FE. Netherlands Cancer Institute, Amsterdam, Netherlands; 
Leiden University Medical Center, Leiden, Netherlands
Background: Women who survived their first breast cancer have a 
higher risk to develop a new primary tumor in the contralateral breast 
than the risk of women in the general population to develop a first 
breast cancer. Especially women who carry a germline mutation in 
either the BRCA1 or the BRCA2 gene face a high lifetime risk of 
developing a synchronous or metachronous bilateral breast cancer. It 
is important to provide precise risk estimates of contralateral breast 
cancer and identify factors which predict the risk of CBC in this group 
of high risk women. To answer these questions, we looked at the effect 
of BRCA1/2-carriership and its interaction with other factors on the 
risk to develop a CBC in an unselected cohort of breast cancer patients.
Materials and methods: We collected clinico-pathological, treatment 
and follow-up data for 4856 patients with unilateral, invasive breast 
cancer, diagnosed under the age of 50, between 1970 and 2003, in 
ten different hospitals throughout The Netherlands. Germline DNA 
was isolated from formalin-fixed paraffin-embedded tissue and 
patients were tested for the most prevalent pathogenic BRCA1 and 
BRCA2 mutations in The Netherlands. DNA and clinical data were 
coded before the analyses. All second primary breast tumors in the 
contralateral breast diagnosed more than 3 months after the diagnosis 
of the first breast cancer were considered as events. Preliminary results 
from life-table analysis and Cox Proportional Hazard models adjusted 
for age at diagnosis are shown here. Further statistical analyses will 
include competing risk analysis.
Results: In 4856 patients genotyped for BRCA1/2 mutations, 206 
(4.2%) carriers were identified. During a median follow-up of 9.8 
years (range 0-38), 9% of the patients developed a CBC, resulting in 
a cumulative 15-year risk for CBC of 10.4% (95% CI = 9.25-11.7) 
for non-carriers and 35.4% (95% CI = 25.9-46.9) for carriers of a 
BRCA1 or BRCA2 mutation (HR = 4.04 (95% CI = 2.88-5.68)). 
Patients carrying a BRCA1/2 mutation who were diagnosed under 
the age of 40 with their first breast cancer experienced a cumulative 
15-year risk for CBC of 52.4 % (95% CI = 36.4-70.3) versus 21.3 % 
(95% CI = 12.0-36.0) in those over the age of 40 (HR = 0.30 (95% CI 
= 0.14-0.65)). Furthermore, BRCA1/2 mutation carriers with a triple 
negative first tumor had a cumulative risk for CBC of 43.6 (95% CI = 
25.1-67.7), in contrast, BRCA1/2 mutation carriers with a non-triple 
negative first tumor had a cumulative risk for CBC of 13.4 % (95% 
CI = 4.21-38.4) (HR = 0.24 (95% CI = 0.07-0.86)). Age at diagnosis 
and triple negative status were not found to be predictors of the risk 
of CBC in non-carriers (HR = 0.81 (95% CI = 0.53-1.24) and HR = 
1.49 (95% CI = 0.91-2.41) respectively).
Discussion: In this study we identified subgroups of patients with a 
high risk to develop a CBC after their first breast cancer. Guidelines 
about treatment decisions and screening for follow-up should take into 
account these high risk subgroups to provide even better information 
and counseling for BRCA1/2 mutation carriers.
On behalf of more than 20 involved authors of the BOSOM study from 
10 different hospitals and institutions throughout The Netherlands.
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S4-3
Prospective Comparison of Risk Assessment Tools in Early Breast 
Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and 
Luminal Subtypes): Final Correlation Analysis from the Phase 
III WSG-Plan B Trial.
Gluz O, Kreipe H, Degenhardt T, Kates R, Christgen M, Liedtke C, 
Shak S, Clemens M, Markmann S, Uleer C, Augustin D, Thomssen C, 
Nitz U, Harbeck N. West German Study Group, Moenchengladbach, 
Germany; Medizinische Hochschule, Hannover, Germany; University 
of Muenster, Muenster, Germany; Genomic Health Inc, Redwood 
City; Klinikum Mutterhaus, Trier, Germany; Klinikum Suedstadt, 
Rostock, Germany; Gynecology Practice, Hildesheim, Germany; 
Klinikum Deggendorf, Deggendorf, Germany; University of Halle/
Saale, Halle/Saale, Germany; Bethesda Clinics, Moenchengladbach, 
Germany; University of Cologne, Cologne, Germany
Background: Both the Recurrence Score® (RS) multi-gene assay 
and invasion factors uPA/PAI-1 are recommended by guidelines 
(ASCO, AGO) for decision support regarding adjuvant chemotherapy 
(cht) in patients with early breast cancer (BC). In the EC-DOC trial, 
we previously suggested central grade 3 and high Ki-67 levels as 
independent predictive markers for enhanced benefit of taxane-based 
cht in intermediate risk BC. Here, we present the final WSG-Plan B 
trial correlation analysis of these risk assessment tools.
Methods: Plan B trial (evaluating anthracyline-free adjuvant cht, 
6xTC, vs. 4xEC-4xDOC in HER2-negative BC; n=2,448 to be 
randomized for chemotherapy). RS has been used as the selection 
criterion for cht vs. endocrine therapy alone in HR+ BC (if RS<11 
in pN0 or pN1) since an amendment in August 2009. uPA/PAI-1 (by 
ELISA) is obtained as an optional risk factor. Evaluation of central 
grade and luminal B subtype (using 14% or 20% Ki-67 cut-offs) are 
performed by the independent trial pathologist in all HR+ tumors.
Results: From April 2009 to June 2011, 3037 patients have been 
recruited and 2290 randomized. The study will be completed by 
August 2011. Data on RS are available in 2361 patients with HR+ 
tumors: RS is distributed as follows: 0-11 (18%), 12-25 (61%), >25 
(21%). In 257 patients with 0-3 involved LN, cht was omitted based 
on RS results (12.3% of patients after amendment).
By the last interim analysis in February 2011, data on central grade 
are available in 1509 patients and Ki-67 in 592 patients. An only 
moderate positive correlation was observed between Ki-67 and RS 
(Spearman’s coefficient rs=0.336; p<0.001) as continuous variables 
and between RS and central grade (rs=0.498, p<0.001). High RS is 
predictive of high grade G3 (66% of RS25 high risk and 74% of RS30 
high risk are G3), but 30-33% of tumors were assessed as G3 within 
the low-risk RS11-18 group and 14%-40% of G3 tumors were classified 
as low-risk RS11-18. When considered as risk categories, there was 
only a weak concordance between RS and uPA/PAI-1, using either 
standard RS (18; 30) or PlanB cut-offs (low risk <11 RS), with 67% 
of patients having high uPA/PAI-1 within the low/intermediate-RS 
subgroups. High-risk RS is predictive of high-risk by uPA/PAI-1, 
poor grade and luminal B subtype. However, the converse is not true, 
since clinically relevant proportions (between 33-66%) of patients 
identified by uPA/PAI-1 or Ki-67 as being at high-risk had low or 
intermediate RS. Final correlation analyses in all Plan B patients with 
HR+ tumors (n>2.500) will be presented at the meeting. Discussion: 
For the first time, risk groups according to RS, Ki-67 and uPA/PAI-1 
have been prospectively compared within a phase III trial setting both 
in N0 and N+ early BC. These data show high-risk status according 
to RS is predictive of high risk by uPA/PAI-1, high grade by central 
pathology and luminal B subtype, but not converse. In the low and 
intermediate risk RS groups, there are still patients considered high-
risk according to uPA/PAI-1, Ki-67 or central grade. Further follow-up 
of the WSG-Plan B trial will clarify the clinical significance of these 
findings regarding patient outcomes.
S4-4
Clarifying the Risk of Breast Cancer in Women with Atypical 
Breast Lesions.
Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EMH, 
Polufriaginof F, Parmigiani G, Garber JE, Smith BL, Gadd MA, 
Specht MC, Guidi AJ, Roche CA, Hughes KS. Massachusetts General 
Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; 
Newton-Wellesley Hospital, Newton, MA; Wayne State University, 
Detroit, MI
Background: Women diagnosed with atypical ductal hyperplasia 
(ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ 
(LCIS), and borderline ADH/DCIS are at increased risk for breast 
cancer, but the precise degree of risk varies widely in the literature. 
Information from prior studies is limited by grouping ADH and ALH 
together and by small cohort sizes.
Objectives: To identify women with a pathologic diagnosis of ADH, 
ALH, LCIS, and borderline ADH/DCIS using Natural Language 
Processing. To evaluate breast cancer risk based on atypia type.
Methods: Using Natural Language Processing, we reviewed all 
electronically available pathology reports from Massachusetts 
General Hospital, Brigham and Women’s Hospital, and Newton-
Wellesley Hospital (members of Partners HealthCare System) from 
1987-2010. We identified all women with a diagnosis of ADH, 
ALH, LCIS, and borderline ADH/DCIS with no prior or concurrent 
diagnosis of breast cancer. We determined the incidence of subsequent 
invasive and noninvasive breast cancer, the side of cancer diagnosis 
compared to original atypia side, and the time to cancer diagnosis 
for each atypia type.
Results: We reviewed 76,333 path reports in 42,950 unique 
individuals and identified 3049 women who were diagnosed with 
atypical breast lesions over this 14-year period; 1233 (40.4%) had 
ADH, 851 (27.9%) had ALH, 595 (19.5%) had LCIS, and 370 (12.1%) 
had borderline ADH/DCIS. The mean age for atypia diagnosis was 
51 years (range: 18-93). At a mean follow-up of 66 months, cancer 
occurred in 7.0% of women with ADH, 11.3% of women with ALH, 
11.1% of women with LCIS, and 8.4% of women with borderline 
ADH/DCIS. The median time to breast cancer diagnosis was 48 
months with ADH, 50 months with ALH, 47 months with LCIS, and 
60 months with borderline ADH/DCIS. Significantly more ipsilateral 
cancers developed than contralateral cancers for all types of atypia 
combined (p=0.027).
Atypia Type
5-Year  
Cancer  
Risk
10-Year  
Cancer  
Risk
Number of Cancers
Percent of  
Ipsilateral  
Cancer
Percent of  
Contralateral  
Cancer
Percent of  
Bilateral  
Cancer
ADH (n=1233) 4.7% 14.5% From ADH (n=86) 57.0% 40.7% 1.2%
ALH (n=851) 9.5% 20.3% From ALH (n=96) 55.2% 42.7% 1.0%
LCIS (n=595) 9.1% 16.4% From LCIS (n=66) 56.1% 40.9% 3.0%
Borderline  
(n=370)
6.9% 14.2% From Borderline  
(n=31)
54.8% 41.9% 3.2%
Table 1: Estimated 5 and 10-year breast cancer risks and laterality of cancer based on type of atypia. 
The development of invasive versus noninvasive breast cancer was 
not significantly affected by atypia type. Subsequent cancers were 
DCIS in 121 patients (43.4%) and invasive in 158 patients (56.6%). 
Kaplan Meier curves for time to cancer diagnosis based on atypia 
type were created. The curves for ADH and borderline ADH/DCIS 
were similar and significantly different than the curves for ALH and 
LCIS (p<0.001). The estimated 5 and 10-year breast cancer risks for 
each atypia type are presented in Table 1.
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Conclusion: A diagnosis of ADH, ALH, LCIS, or borderline ADH/
DCIS increases a woman’s risk of invasive and noninvasive breast 
cancer in either breast. The breast cancer risk at 5 and 10 years is 
significantly higher in those with ALH or LCIS compared to those 
with ADH or borderline ADH/DCIS, but there is little difference 
in risk between ADH and borderline ADH/DCIS or between LCIS 
and ALH.
S4-5
Comparison of PAM50 Risk of Recurrence (ROR) Score with 
OncotypeDx and IHC4 for Predicting Residual Risk of RFS and 
Distant-(D)RFS after Endocrine Therapy: A TransATAC Study.
Dowsett M, Lopez-Knowles E, Sidhu K, Pineda S, Cowens JW, 
Ferree S, Storhoff J, Schaper C, Cuzick J. Royal Marsden Hospital 
and Breakthrough Breast Cancer Centre, London, United Kingdom; 
Wolfson Institute of Preventive Medicine, London, United Kingdom; 
Nanostring Technologies, Seattle, WA
Aim: To assess the performance of the risk of recurrence (ROR) 
score in predicting RFS and DRFS for postmenopausal patients with 
primary ER+ breast cancer treated with anastrozole or tamoxifen and 
compare this with the performance of Oncotype Dx and IHC4 for 
both N0 and N+ patients.
Background: OncotypeDx Recurrence Score (RS) is used to assess RR 
after endocrine therapy in primary ER+ breast cancer and is valid for 
both tamoxifen and anastrozole (Dowsett ref). IHC4 is a 4-panel set 
of IHC markers (ER, PgR, HER2, Ki67) that was shown to provide 
as much prognostic accuracy as RS in the translational arm of the 
ATAC trial (TransATAC) of anastrozole versus tamoxifen alone or 
combined and subsequently independently validated (Cuzick et al, 
JCO, 2011, in press). PAM50 is 50-gene test that has been optimised 
to separate intrinsic disease subtypes and is used to generate a ROR 
score. Good correlation has been shown between the ROR and RS but 
no large scale comparisons of their ability to predict clinical outcome 
have been conducted.
Methods: PAM50 analysis was conducted using NanoString 
technology on 125 ng RNA extracted from all 1026 samples from 
the TransATAC study that had at least 500ng RNA available. Nodal 
status was known on 986: N+, 271; N-neg 715. ROR scores were 
calculated and their relationship with RFS and DRFS assessed in 
both the N-neg and N+ categories. The prognostic value of ROR 
when added to standard clinical variables was assessed using the 
likelihood ratio chi-square. Finally, the relative accuracy of prognosis 
in this patient population using ROR, RS and IHC4 was evaluated 
by comparing the C-index for each test.
Results: Results are currently being derived and will be presented 
in full.
Discussion: This is the first large-scale clinical comparison of 2 
prominent multi-gene predictors for use in FFPE material. The 
results will be instrumental in defining the preferred method for 
use in assessing residual risk of recurrence in patients treated with 
endocrine therapy.
S4-6
A Quantitative Multigene RT-PCR Assay for Predicting 
Recurrence Risk after Surgical Excision Alone without 
Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective 
Validation Study of the DCIS Score from ECOG E5194.
Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak 
S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, 
Wood W. Albert Einstein Medical Center, Philadelphia, PA; Eastern 
Cooperative Oncology Group, Boston, MA; Genomic Health, Inc., 
Redwood City, CA; Indiana University, Indianapolis, IN; The Hope 
Center, Cartersville, GA; University of Pittsburgh, Pittsburgh, PA; 
Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Rochester, 
Rochester, MN; Albert Einstein College of Medicine, Bronx, NY; 
Emory University, Atlanta, GA
Background: We have previously reported the results of surgical 
excision without irradiation for selected patients with DCIS in ECOG 
E5194, where the 5-year rates of local recurrence varied with age, 
grade, and lesion size (Hughes et al. J Clin Oncol 27:5319, 2009). 
New methods are needed to provide more accurate and reproducible 
assessment of recurrence risk.
Methods: ECOG E5194 included 670 eligible patients with DCIS 
treated with surgical excision (≥ 3 mm negative margins) without 
irradiation, 228 of whom received tamoxifen. Patients had low or 
intermediate grade DCIS ≤ 2.5 cm, or high grade DCIS ≤ 1 cm. The 
Oncotype DX® assay was performed by quantitative RT-PCR using 
formalin fixed paraffin embedded tumor specimens from 327 patients 
(49% of the parent study). Recurrence Score® (RS) was calculated 
using the published algorithm. A new, prespecified DCIS Score™ was 
designed to predict recurrence using an optimized gene expression 
algorithm. The primary objective was to determine whether there was 
a significant association between the risk of an ipsilateral breast event 
(IBE) and the continuous DCIS Score in Cox models. 46 patients had 
an IBE (defined as ipsilateral local recurrence of DCIS [n=20] or 
invasive cancer [n=26]). Median follow-up was 8.8 years.
Results: The 10-year IBE rates were 15.4% for low/intermediate 
grade DCIS and 15.1% for high-grade DCIS (as determined by 
central pathology review), and for invasive IBE, 5.6% and 9.8%, 
respectively. Comparison between local and expert grading showed 
substantial disagreement. Continuous DCIS Score was significantly 
associated with IBE (HR 2.34 per 50 units; 95% CI 1.15, 4.59; p=0.02) 
when adjusted for tamoxifen use (prespecified primary analysis) and 
with invasive IBE (HR 3.73; CI 1.34, 9.82; p=0.01). DCIS Score 
was significantly associated with outcome when evaluated by the 
prespecified risk groups (see Table). Similar results were observed 
with and without adjustment for tamoxifen use or for negative margin 
width. Features associated with IBE in multivariate models included 
menopausal status (HR 0.49; 95% CI 0.27, 0.90; p=0.02), tumor size 
(HR 1.52 per 5 mm; 95% CI 1.11, 2.01; p=0.01), and continuous 
DCIS Score (HR 2.41; 95% CI 1.15, 4.89; p=0.02). The standard 
RS, which is calculated using thresholding of many genes unlike the 
DCIS Score, was not associated with IBE or invasive IBE (p > 0.6).
Conclusions: We have prospectively validated a multigene assay that 
quantifies recurrence risk and complements traditional clinical and 
pathologic factors in selected patients with DCIS treated with surgical 
excision without irradiation. The DCIS Score provides a new clinical 
tool for individualized selection of treatment for patients with DCIS.
10-Year Outcomes with the New DCIS Score.
  10-Year Kaplan-Meier Rate (95% CI)
DCIS Score Risk Group No. (%)
Ipsilateral Breast Event  
(Invasive or DCIS)
Invasive Ipsilateral Breast Event
Low (<39) 246 (75%) 12.0% (8.1%, 17.6%) 5.1% (2.8%, 9.5%)
Intermediate (39-54) 45 (14%) 24.5% (13.8%, 41.1%) 8.9% (2.9%, 25.8%)
High (≥55) 36 (11%) 27.3% (15.2%, 45.9%) 19.1% (9.0%, 37.7%)
Log rank p-value  .02 .01
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S4-7
Results of a Randomized, Double-Blind, Multicenter, Placebo-
Controlled Study of Adjuvant Lapatinib in Women with Early-
Stage ErbB2-Overexpressing Breast Cancer. 
Goss P, Smith I, O’Shaugnessy J, Ejlertsen B, Kaufmann M, Boyle 
F, Buzdar A, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-
Gebhart M, Pritchard K, Aktan G, Rappold E, Williams L, Finkelstein 
D. Massachusetts Gen Hosp, Boston, MA; Royal Marsden Hosp, 
London, United Kingdom; Baylor Sammons Cancer Ctr, Dallas, 
TX; Rigshospitalet, Copenhagen, Denmark; JW Goethe-Universität, 
Frankfurt, Germany; Royal North Shore Hosp, Sydney, Australia; UT 
MD Anderson Cancer Ctr, Houston, TX; Centre GF Leclerc, Dijon, 
France; Northwestern Univ, Chicago, IL; Hosp Universitario San 
Carlos, Madrid, Spain; Jules Bordet Inst, Brussels, Belgium; Toronto-
Sunnybrook Regional Cancer Ctr, Toronto, ON; GlaxoSmithKline, 
Collegeville, PA and Uxbridge, United Kingdom
Late-breaking – abstract will be available at the meeting.
S4-8
First Results of AVEREL, a Randomized Phase III Trial To 
Evaluate Bevacizumab (BEV) in Combination with Trastuzumab 
(H) + Docetaxel (DOC) as First-Line Therapy for HER2-Positive 
Locally Recurrent/Metastatic Breast Cancer (LR/mBC).
Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot 
X, Smirnova I, Moliterni A, Andre F, Chan A, Lipatov O, Chan S, 
Wardley A, Greil R, Provencher L, Moore N, Prot S, Semiglazov 
V. Ospedale San Raffaele, Milan, Italy; Centre Régionale de Lutte 
Contre le Cancer, Val d'Aurelle, Montpellier, France; N. N. Blokhin 
Russian Oncology Research Center, Moscow, Russian Federation; 
Fundação Pio XII- Hospital de Cåncer de Barretos, Barretos, Brazil; 
University Hospital of Udine, Udine, Italy; University Hospital Jean 
Minjoz, Besancxon, France; Medical Radiological Science Center, 
Obninsk, Russian Federation; Fondazione IRCCS, Istituto Nazionale 
Tumori, Milan, Italy; Gustave Roussy Institute, Villejuif, France; 
Mount Hospital, Perth, Australia; Republican Clinical Oncology 
Dispensary, Ufa, Russian Federation; Nottingham University 
Hospitals NHS Trust, Nottingham, United Kingdom; The Christie, 
Manchester, United Kingdom; III. Medizinische Universitätsklinik 
Salzburg, Salzburg, Austria; CHA-Hôpital du Saint-Sacrement, QC, 
Canada; F. Hoffmann-La Roche Ltd, Basel, Switzerland; N. N. Petrov 
Research Institute of Oncology, St Petersburg, Russian Federation
Background: H + taxane is an established and effective first-line 
treatment for HER2-positive LR/mBC. Preclinical data provide the 
rationale for combining BEV and H in HER2-positive LR/mBC but 
clinical data in this setting are limited to single-arm phase II studies. 
AVEREL is the first randomized trial of BEV in HER2-positive LR/
mBC.
Methods: Eligible patients had measurable or evaluable HER2-
positive LR/mBC (centrally confirmed IHC 3+ or FISH/CISH 
+), ECOG performance status 0/1, and had received no prior 
chemotherapy for advanced disease. Prior adjuvant H/taxanes were 
permitted unless disease had recurred <6/<12 months after the last 
dose, respectively. Patients with CNS metastases were excluded. 
Patients were stratified according to adjuvant H, prior (neo)adjuvant 
taxane (further stratified by time to relapse since last dose of [neo]
adjuvant chemotherapy/no chemotherapy), hormone receptor status, 
and measurable disease, and were randomized to receive either H (8 
mg/kg → 6 mg/kg q3w) + DOC (100 mg/m2 q3w) or H + DOC + BEV 
(15 mg/kg q3w). H and BEV were given until disease progression; 
DOC was given for a planned minimum of 6 cycles unless progression 
or unacceptable toxicity mandated earlier discontinuation. The 
primary endpoint was progression-free survival (PFS). Additional 
endpoints included overall survival (OS), overall response rate (ORR; 
assessed by RECIST 1.0), duration of response, time to treatment 
failure, safety (NCI CTCAE v3.0 adverse events [AEs] and AEs of 
special interest for BEV), quality of life (FACT-B), and translational 
research. The primary analysis of PFS was prespecified after 310 
investigator-assessed PFS events. The statistical design provided 
90% power to detect a PFS hazard ratio (HR) of 0.69 (median PFS 
11→16 months) with a=0.05.
Results: Between Sep 2006 and Feb 2010, 424 patients were enrolled 
from 60 centers; 421 received treatment. Baseline characteristics were 
generally well balanced in the H + DOC and H + DOC + BEV arms: 
median age 55 and 53 years, respectively; visceral metastases 71% 
and 77%; prior adjuvant H 12% and 13%; disease-free interval <12 
months 43% in both arms; measurable disease 85% in both arms. 
Median follow-up was 26 months in both arms. Efficacy results are 
summarized in the table.
Endpoint H + DOC H + DOC + BEV
PFS (n=208) (n=216)
Investigator assessed   
Events, n (%) 154 (74) 153 (71)
HR, unstratified analysis (95% CI) 0.82 (0.65-1.02)
p-valuea 0.0775
Median, months (95% CI) 13.7 (11.4-16.3) 16.5 (14.1-19.1)
HR, stratified analysis (95% CI) 0.76 (0.60-0.96)
IRC assessed (stratified, censored for non-protocol therapy)   
Events, n (%) 114 (55) 111 (51)
HR (95% CI) 0.72 (0.54-0.94)
p-value 0.0162
Median, months (95% CI) 13.9 (11.2-16.7) 16.8 (14.1-19.5)
ORR (n=176) (n=183)
Investigator assessed, % 69.9 74.3
p-value 0.3492
IRC assessed, % 65.9 76.5
p-value 0.0265
aBoundary for significance p=0.0445; IRC = Independent Review Committee
No new safety signals were observed. The following grade ≥3 AEs 
were more common in the BEV-containing arm than the H + DOC 
arm: congestive heart failure (5.1% vs 2.9%, respectively); febrile 
neutropenia (11.6% vs 8.7%); hypertension (11.6% vs 0.5%). Grade 
5 AEs occurred in 1.4% of the H + DOC + BEV arm vs 1.9% of the 
H + DOC arm.
Conclusions: The addition of BEV to H + DOC improved PFS 
without reaching statistical significance according to investigator 
assessment (unstratified HR 0.82; 95% CI 0.65-1.02). The 
improvement as assessed by Independent Review Committee was 
statistically significant. Evaluation of biomarkers is ongoing to try to 
identify those patients who may benefit from first-line BEV-containing 
therapy for HER2-positive LR/mBC.
S5-1
Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker 
Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in 
Patients (pts) with HER2-Positive Breast Cancer (BC).
Gianni L, Bianchini G, Kiermaier A, Bianchi G, Im Y-H, Pienkowski 
T, Roman L, Liu M-C, Tseng L-M, Ratnayake J, Szado T, Ross GA, 
Valagussa P. Oncologia Medica, San Raffaele Cancer Center, Milan, 
Italy; Roche, Basel, Switzerland; Oncologia Medica 1, Fondazione 
IRCCS Instituto Nazionale Tumori, Milan, Italy; Samsung Medical 
Center, Seoul, Korea; Centrum Onkologii, Warsaw, Poland; 
Leningrad Regional Oncology Dispensary, St Petersburg, Russian 
Federation; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, 
Taiwan; Taipei-Veterans General Hospital, National Yang-Ming 
University, Taipei, Taiwan; Roche Products Limited, Welwyn, 
United Kingdom; Genentech, South San Francisco; Fondazione 
Michelangelo, Milan, Italy
Background: NeoSphere showed that P with H and docetaxel (T) 
had a significantly higher pCR rate (45.8%) compared with TH 
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(29%) or other P combinations (HP, TP) (Gianni, SABCS 2010). 
HER2+/ER+ and HER2+/ER– BC have different patterns of gene 
expression, and treatment response seems to be driven by different 
biologic pathways (Bianchini, ASCO 2011). This effect was also seen 
in NeoSphere. A broad panel of biomarkers (BMs) was assessed in 
tumor specimens and in sera to characterize the molecular profile of 
the ITT population and to explore BMs with different treatments and 
in different subsets of pts.
Methods: Core biopsies and sera from 387/417 pts collected at 
baseline were available for BM analyses. HER2, all its truncated 
forms, HER3, IGF1R, PTEN, and pAKT were assessed by IHC and 
a modified H-score was derived per each marker. HER1, HER2, 
HER3, amphiregulin (AREG) and betacellulin mRNA expression 
in tumor tissue was assessed by qRT-PCR. C-myc was assessed by 
FISH. Mutational analyses of 8 hot spots within PIK3CA on tumor 
DNA was done via TaqMan-PCR. ELISA was used to detect HER2 
extracellular domain (ECD), AREG, EGF, and TGFa in serum. 
Treatment interaction test was performed to test for association 
between BMs and pCR. In the analysis, median values were used as 
cutoffs, except for PTEN, PIK3CA mutation, and c-myc amplification, 
where cutoffs were applied following a biologic rationale.
Results: In the overall population, high HER2 membrane protein 
expression measured by modified H-score was associated with a 
significantly higher pCR rate in the THP arm (p=0.001), with a large 
benefit from combination of P with TH (OR=3.74, CI 80%, 2.21- 6.34; 
p=0.0009). The cutoff derived from NeoSphere has no immediate 
clinical applicability. A decreased likelihood of pCR was detected 
for pts with PI3K mutations in all 4 arms in a preliminary analysis 
limited to about 70% of cases. A final analysis will be presented. 
A significantly different distribution of BM expression in the ER+ 
vs ER- subgroups was found for 10 of 16 BMs (FDR<0.05). Low 
levels of IGF1R were found to be associated with higher pCR with 
combination of P with TH in the ER- (OR=4.40, CI 80%, 2.17-8.9; 
p=0.006) but not ER+ subgroup. High HER2 mRNA expression was 
associated with higher pCR rate in the HP arm in ER- (p=0.021) but 
not ER+ (p=0.74) tumors. Data on the full BM analysis including 
those on the ratio between HER2 ECD and intracellular domain (p95) 
will be presented. The levels measured for AREG and betacellulin 
were generally very low (less than the limits of variability for these 
assays), hence further analysis was not felt meaningful.
Summary: The level of HER2 membrane protein expression was 
associated with increased benefit from combination of P with TH. 
The PI3K mutational status appears to have a relevant role in defining 
the likelihood of response with all treatments. The different treatment 
effects according to ER status are reflected in a different molecular 
BM profile in ER+ vs ER- tumors, with the IGF1R membrane score 
being correlated with ER- tumors.
S5-2
PAM50 HER2-Enriched Subtype Enriches for Tumor Response 
to Neoadjuvant Anthracyclines/Taxane and Trastuzumab/Taxane 
Containing Regimens in HER2-Positive Breast Cancer.
Cheang MCU, Prat A, Fan C, Perou CM. Lineberger Comprehensive 
Cancer Center, Chapel Hill, NC
Background: Patients with clinically HER2-positive (clinHer2+) 
tumors often receive trastuzumab in combination with chemotherapy 
as their standard of care. This study sought to determine the 
predictive value of the HER2-enriched (HER2-E) molecular subtype 
for sensitivity to neoadjuvant anthracycline/taxane containing 
chemotherapy and a trastuzumab plus taxane-based regimen within 
clinHer2+ disease.
Materials and methods: Gene expression data on pre-treatment 
fresh-frozen tumor tissues were collected from a combined cohort 
of MDACC/I-SPY trial (GSE25055/65), and the XeNA trial 
(GSE22358). Patients from MDACC/I-SPY were treated with 
doxorubicin/cyclophosphamide (AC) or 5-fluorouracil/epirubicin or 
doxorubicin/C (FEC or FAC) sequentially with paclitaxel. All patients 
from XeNA received capecitabine /docetaxel (and trastuzumab if 
clinHer2+). Intrinsic subtypes were determined using PAM50. Chi-
square test and multivariable logistic regression analysis were used 
to test significance of association between subtype and pathological 
complete response (pCR or residual cancer burden [RCB] 0/1) and 
residual disease (RD or RCB2/3) adjusted with pre-treatment tumor 
size. Kaplan Meier was used for distant relapse-free survival (DRFS) 
estimates.
Results: For the MDACC/I-SPY cohort (n=595), pCR rates for 
intrinsic subtypes were 3% (5/168) for LumA, 16% (14/90) for LumB, 
33% (23/69) for HER2-E and 37% (76/208) for Basal-like. Tumors 
achieving RCB0/1 were significantly associated with better DFRS 
compared to those tumors with RCB 2/3, even within each intrinsic 
subtype. The 5-year DFRS for HER2-E with RCB0/1 and RCB2/3 
was 100% and 31% (p=0.007), respectively. ClinHer2+ status was 
also significantly associated with pCR (34% vs. 19%, p=0.016). 
Strikingly, among the clinHer2+ tumors (n=47), 75% (12/16) of the 
responders were classified as HER2-E (Table 1A) and those tumors 
that were clinHer2+/HER2-E had 6 times odds to achieve pCR when 
compared to clinHer2+/non-HER2-E. In the XeNA trial (n=122), 
the HER2-E subtype was significantly associated with response, 
composing 85% (7/8) of the clinHer2+ who achieved a pCR. Finally, 
clinHer2+/HER2-E tumors were 34 times more likely to achieve pCR 
than clinHer2+/non-HER2-E tumors (Table1B).
Frequencies of pCR among subtypes in clinHer2+ tumors, subset by studies.
(A) PAM50 within clinHer2+ tumors in MDACC/
ISPY
RD pCR Total
LumA 6(100%) 0 6
LumB 6(86%) 1(14%) 7
HER2-E 14(55%) 12(45%) 26
Basal-like 5(63%) 3(37%) 8
Total 31(66%) 16(34%) 47
Odds Ratio for HER2E vs. Non-Her2-E to pCR 6(95% CI 1-33), p=0.03
(B) PAM50 within clinHer2+ tumors in XeNA RD pCR Total
LumA 1(50%) 1(50%) 2
LumB 7(100%) 0 7
HER2-E 5(42%) 7(58%) 12
Basal-like 3(100%) 0 3
Total 16(67%) 8(33%) 24
Odds Ratio for HER2-E vs. non-HER2-E to pCR 34(95% CI 2-604), p=0.016
Conclusion: The sensitivity of clinHer2+ tumors to neoadjuvant 
anthracycline/taxane-based regimens, and trastuzumab-based 
chemotherapy is mainly contained within tumors of the HER2-E 
subtype. Given that this molecular subtype cannot simply be 
recapitulated using clinical ER and HER2 status, our results highlight 
the importance of identifying patients with HER2-E tumors as this 
appears to greatly enrich for responsiveness and treatment benefit.
S5-3
Basement Membrane Localized Tumor Cells Are Protected from 
HER2-Targeted Therapy In Vivo.
Zoeller JJ, Bronson RT, Gilmer TM, Selfors LM, Lu Y, Mills GB, 
Brugge JS. Harvard Medical School, Boston, MA; GlaxoSmithKline, 
Research Triangle Park, NC; UT MD Anderson Cancer Center, 
Houston, TX
Drug resistance compromises the efficacy of HER2-targeted therapy. 
Results from our laboratory, and previous reports from others, indicate 
that tumor cell attachment to basement membrane (BM) and other 
extracellular matrix (ECM) proteins may confer drug resistance. 
We have discovered a differential drug response between the outer, 
matrix-attached cells and inner matrix-deprived cells comprising 
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3-dimensional (3D) tumor spheroids grown in reconstituted basement 
membrane (T. Muranen and J. Brugge, unpublished data). The outer 
matrix-attached cells are resistant to multiple drug therapies. To 
address whether these observations are relevant in vivo, we utilized 
a previously described model of human-in-mouse HER2-positive 
ductal carcinoma in situ (DCIS), which involves the intraductal 
transplantation of human HER2-positive SUM225 tumor cells 
directly into the ductal network of the mouse mammary gland. The 
intraductal tumors generated are histologically indistinguishable 
from human DCIS lesions and recapitulate the architecture of the 3D 
tumor spheroids. The tumors are characterized by organized nests of 
noninvasive cells confined within a BM surrounded by ECM. These 
features permit a direct assessment of differential drug response 
within the tumor. We focused on the tumor cell response to short-
term lapatinib monotherapy in vivo. A close examination of the tumor 
architecture revealed that cells closest to the basement membrane, 
and nearest to the vasculature, display a striking insensitivity to 
lapatinib whereas the remainder of the tumor undergoes extensive 
cell death in response to treatment. Further characterization also 
revealed that cells closest to the basement membrane largely maintain 
proliferative capacity despite an overall significant reduction in the 
total Ki67-positive cell population. These results provide in vivo 
evidence that basement membrane-attached tumor cells are protected 
from lapatinib. We confirmed that these cells maintain HER2 status 
and also observed an overall reduction in pHER2, pAKT and pERK 
throughout the tumor suggestive of adaptive response mechanisms, 
which support the proliferation and survival of these cell populations 
despite inhibition of the HER2 pathway. To further explore potential 
mechanisms of the adaptive response, we performed reverse phase 
protein array (RPPA) analysis on protein lysates prepared from tumor 
biopsy fragments following lapatinib monotherapy. RPPA profile 
analysis revealed an adaptive response composed of upregulation of 
multiple RTKs (HER2, IGFI-R) and altered apoptotic protein levels 
(Bcl-2, Bim, Bcl-xL) in addition to activation of AKT/S6K and ERK/
p38 pathway components. These observations suggest that basement 
membrane-attached tumor cells may escape from lapatinib response 
via compensatory activation of these survival mechanisms. Each 
of these components will serve as targets for designing combined 
therapeutic approaches capable of targeting the protected basement 
membrane-attached tumor cells. Our results suggest that resistant 
populations may be a source of residual disease post-therapy, 
therefore identifying and characterizing these cells will be crucial to 
the prevention of disease recurrence in the clinic.
S5-4
pCR as a Surrogate in HER2-Positive Patients Treated with 
Trastuzumab.
Loibl S, von Minckwitz G, Blohmer JU, Costa SD, Eidtmann H, 
Fasching PA, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch 
C, Kaufmann M, Konecny G, Denkert C, Nekljudova V, Mehta K, 
Untch M. German Breast Group, Neu-Isenburg; St. Gertrauden 
Krankenhaus, Berlin; Universitäts-Frauenklinik, Magdeburg; 
Universitätsklinikum, Kiel; University Hospital, Erlangen; 
Universitäts-Frauenklinik, Rostock; Klinikum zum Roten Kreuz, 
München; Henrietten-Stiftung, Hannover; Universitäts-Frauenklinik, 
Tübingen; Städtische Kliniken, Offenbach; Universitäts-Frauenklinik, 
Frankfurt; University of California, Los Angeles; Charité, Berlin; 
Helios Klinikum Berlin-Buch, Berlin
Background: Patients with HER2-positive metastatic disease used to 
show a more unfavorable prognosis compared to patients with HER2-
negative tumors. With the introduction of trastuzumab, patients with 
HER2-positive metastatic breast cancer show an improved survival 
compared to patients with HER2-negative tumors (Dawood et al. 
2010). So far it has not been shown, if such a switch in prognosis is 
also achieved in early breast cancer.
Methods: 6377 patients from 7 neoadjuvant German studies with 
operable or locally advanced, non-metastatic breast cancer were 
analyzed (for details see von Minckwitz G et al, BCRT 2010). In 
earlier studies patients (pts) with HER2-positive disease did not 
receive trastuzumab. Trastuzumab was given in 2 trials parallel to 
chemotherapy for 12-36 weeks and completed after surgery for up 
to one year of treatment. All patients with endocrine responsive 
disease received adjuvant endocrine therapy according to institutional 
standard. We compared the overall and disease free survival in three 
subgroups, HER2-negative patients, HER2-positive w/o trastuzumab 
and HER2-positive patients with trastuzumab according to pCR 
defined as ypT0, ypN0.
Results: 6377 patients were evaluable. During a median follow up of 
46.3 (0-127) months and observation of 22.869 patient years, 1466 
(23%) relapses and 775 (12.2%) deaths were observed. 3060 had 
HER2-negative disease, 665 patients had HER2-positive disease w/o 
trastuzumab and 662 patients with HER2-positive disease received 
trastuzumab. No data on HER2 status were available in 1990 (31.2%) 
patients as measurement of HER2 was only implemented in the 
study procedures since 2001.Median age of patients at time of study 
entry was 50.1 (21-81) years. Median tumor size was 4.0 (range 1.2 
– 33.0) cm. Overall 15% (955) of patients had a pCR. The pCR rate 
in HER2-positive pts was 24% in those with trastuzumab and 15.8% 
in those without. There was no difference in overall DFS in the three 
groups achieving a pCR (log rank p=0.251). There was a strong trend 
towards a better OS in pCR HER2+pts being treated with trastuzumab 
(overall log rank p= 0.067). Cox regression analysis revealed HER2 
positive patients with trastuzumab had a better OS than HER2-positive 
pts w/o trastuzumab (HR: 7.44; 95%CI [0.92-60.1; p=0.06) and 
HER2negative pts (HR: 3.86; 95% CI [0.5-29.41], p=0.19).
However, for non-pCR pts, DFS was significantly inferior for pts 
treated with trastuzumab compared to patients without trastuzumab 
(HR: 0.81, 95% CI [0.63-1.04), p=0.102 ) or pts with HER2-negative 
tumors (HR: 0.75; 95% CI [0.61-0.92] p=0.006.)(overall log-rank 
p=0.022). However, OS was not significantly different between the 
three groups of non-pCR pts.
Conclusion: Patients with HER2-positive primary breast cancer 
treated with trastuzumab achieve a higher pCR rate. This higher 
absolute number of pCRs in trastuzumab-treated patients lead to a 
DFS at least as good as that of HER2-positive not trastuzumab treated 
and HER2-negative patients and OS even tended to be superior to 
the other two groups. This supports that pCR can be considered as a 
surrogate marker in HER2-positive disease. However, HER2-positive, 
trastuzumab-treated patients without a pCR are at high risk of relapse 
and are at high medical need for new treatment options.
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S5-5
A Phase III, Randomized, Double-Blind, Placebo-Controlled 
Registration Trial To Evaluate the Efficacy and Safety of 
Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + 
Trastuzumab + Docetaxel in Patients with Previously Untreated 
HER2-Positive Metastatic Breast Cancer (CLEOPATRA).
Baselga J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini 
JL, Cortés J, Knott A, Clark E, Ross GA, Swain SM. Massachusetts 
General Hospital Cancer Center, Boston, MA; Asan Medical Center, 
University of Ulsan, College of Medicine, Seoul, Korea; Seoul 
National University College of Medicine, Seoul, Korea; Hospital 
Pérola Byington, São Paulo, Brazil; Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, Korea; 
Leningrad Regional Oncology Dispensary, St Petersburg, Russian 
Federation; CPMEC-Mastology Unit of Conceição Hospital, Porto 
Alegre, Brazil; Vall d’Hebron University Hospital, Barcelona, Spain; 
Roche Products Limited, Welwyn, United Kingdom; Washington 
Cancer Institute, Washington Hospital Center, Washington, DC
Background: Pertuzumab (P) is a fully humanized investigational 
monoclonal antibody that binds to human epidermal growth factor 
receptor 2 (HER2), preventing dimerization of HER2 with other HER 
family members and inducing antibody-dependent cell-mediated 
cytotoxicity. Its mechanisms of action are complementary to those 
of the anti-HER2 antibody trastuzumab (H) and the two antibodies 
combined have superior activity compared with either antibody alone 
in preclinical and clinical studies. In patients with advanced disease, 
P in combination with H has been shown to be active in patients 
whose disease has progressed while on H therapy (Baselga et al. J 
Clin Oncol 2010). Furthermore, P has been shown to improve the 
activity of H and docetaxel (T) in a randomized neoadjuvant study 
(Gianni et al. SABCS 2010, S3-2). No increase in overall toxicity 
and, in particular, no increase in cardiac events was observed with 
the addition of P to H and HT regimens.
Methods: In this double-blind Phase III study patients with centrally 
confirmed HER2-positive metastatic or locally recurrent, unresectable 
breast cancer were randomized to receive either placebo+H+T or 
P+H+T. Patients could have received one prior hormonal treatment 
for metastatic breast cancer and/or prior systemic neoadjuvant or 
adjuvant therapy including prior H and T. Patients had to have a 
baseline left ventricular ejection fraction ≥50% and no history of 
declines to <50% during or after prior H therapy.
Study medication was as follows: P 840 mg loading dose followed by 
420 mg q3w; H 8 mg/kg loading dose followed by 6 mg/kg q3w; T 
75 mg/m2 q3w (with subsequent dose escalation to 100 mg/m2 if 75 
mg/m2 was well tolerated). Patients were recommended to receive at 
least 6 cycles of T. In the case of chemotherapy discontinuation due 
to cumulative toxicity, antibody therapy was continued until disease 
progression, unacceptable toxicity, or withdrawal of consent.
Patients were stratified according to region and prior treatment status 
(adjuvant therapy or de novo metastatic breast cancer).
The primary endpoint for the study was progression-free survival 
(PFS) as determined by independent review. The primary analysis 
was planned to take place when approximately 381 independently 
confirmed PFS events had occurred. This would provide 80% power 
to detect a 33% improvement in PFS (HR=0.75) at the two-sided 
significance level of 5%. Secondary endpoints included overall 
survival, investigator-determined PFS, overall response rate, duration 
of response, safety, and quality of life.
Patient safety was monitored throughout the study by an independent 
data monitoring committee and a cardiac review committee.
This study is registered at ClinicalTrials.gov: NCT00567190.
Results: 808 patients were recruited between February 2008 and 
July 2010. The required number of PFS events for analysis of the 
primary endpoint has been reached and independent assessment 
PFS is currently being performed. Results of the primary analysis of 
efficacy and safety will be presented.
S5-6
Neoadjuvant Pertuzumab and Trastuzumab Concurrent or 
Sequential with an Anthracycline-Containing or Concurrent with 
an Anthracycline-Free Standard Regimen: A Randomized Phase 
II Study (TRYPHAENA).
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch 
C, Seo J-H, Tsai Y-F, Ackrill A, Ross G, Cortés J. National Center 
for Tumor Diseases, University Hospital, Heidelberg, Germany; 
British Columbia Cancer Agency - Vancouver Centre, University of 
British Columbia, Vancouver, Canada; Royal Bournemouth Hospital, 
Bournemouth University, Bournemouth, United Kingdom; Regional 
Cancer and Blood Centre, Auckland City Hospital, Auckland, New 
Zealand; Cancer Institute “I. Chiricuta”, Cluj-Napoca, Romania; 
Hospital Pérola Byington, São Paulo, Brazil; Breast-Center, Zürich, 
Switzerland; Department of Internal Medicine, Korea University Guro 
Hospital, Guro, Korea; Taipei Veterans General Hospital, Department 
of Surgery, Taipei, Taiwan; Roche Products Limited, Welwyn, United 
Kingdom; Vall d’Hebron University Hospital, Barcelona, Spain
Background: Pertuzumab (P) is a fully humanized investigational 
monoclonal antibody that binds to human epidermal growth factor 
receptor 2 (HER2), preventing homo- and heterodimerization of HER2 
and other HER family members and inducing antibody-dependent 
cell-mediated cytotoxicity. The NeoSphere study demonstrated 
significantly increased antitumor activity in the neoadjuvant setting 
for the combination of P and trastuzumab (H) plus docetaxel (T) 
compared with HT alone (Gianni et al. SABCS 2010), consistent 
with the hypothesis of complementary mechanisms of action of P 
and H. No increase in cardiac risk was observed with the addition 
of P to H and HT regimens. Anthracyclines have an important role 
in the treatment of breast cancer and may be especially efficacious 
in HER2-positive disease. In the TRYPHAENA study, P and H 
are being administered either sequentially or concurrently with an 
anthracycline-containing or concurrently with an anthracycline-free 
standard regimen in order to establish the tolerability profile of these 
regimens for testing in the adjuvant setting.
Methods: Patients with centrally confirmed stage II or III (including 
locally advanced and inflammatory disease) HER2-positive breast 
cancer (defined as centrally confirmed HER2 IHC 3+ or FISH/CISH+) 
were randomized to receive:
  Neoadjuvant therapy q3w x 6 cycles  Surgery 
 Adjuvant therapy  
H q3w x 17/20cycles 
 Arm A  Concurrent (n=75)
5-fluorouracil, epirubicin, 
cyclophosphamide (FEC)+HP x 3, 
followed by THP x 3
→ H x 17
 Arm B  Sequential (n=75) FEC x 3, followed by THP x 3 → H x 20
 Arm C  Anthracycline-free  
(n=75)
Carboplatin+THP x 6 → H x 17
Study medication: P 840 mg loading dose and 420 mg maintenance; 
H 8 mg/kg loading dose and 6 mg/kg maintenance; T was given at 
75 mg/m2 with dose escalation to 100 mg/m2 if the starting dose was 
well tolerated (no dose escalation in Arm C); FEC (5-fluorouracil 500 
mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 600 mg/m2) 
and carboplatin AUC 6. All treatments were given intravenously q3w.
The study is ongoing. All patients will receive H for 1 year. The 
primary endpoint is assessment of the safety and tolerability of 
neoadjuvant treatment. During neoadjuvant treatment, left ventricular 
ejection fraction is assessed at Cycles 2, 4, and 6 by echocardiogram 
or multiple-gated acquisition. Safety data are supervised by a data 
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and safety monitoring board. The key secondary endpoint is the 
rate of pathological complete response (pCR) defined as absence of 
invasive disease in the breast at surgery. Tissue specimens at baseline 
and post-surgery were required for all patients.
This study is registered at ClinicalTrials.gov: NCT00976989.
Results: 225 patients have been recruited. No arm has required 
modification due to safety concerns or to excessive incidence of 
disease progression. Analysis of the study results is anticipated in Q3 
2011. Safety/tolerability and efficacy (pCR) data will be presented.
S5-7
A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-
272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment 
of HER2+ Locally Advanced or Metastatic Breast Cancer.
Martin M, Bonneterre J, Geyer, Jr CE, Ito Y, Ro J, Lang I, Kim 
S-B, Germa C, Vermette J, Vo Van ML, Wang K, Wang K, Awada A. 
Hospital Universitario Gregorio Marañón, Madrid, Spain; Centre 
Oscar Lambret, Lille, France; Allegheny Cancer Center, Pittsburgh, 
PA; The Cancer Institute Hospital of JFCR, Tokyo, Japan; National 
Cancer Center, Goyang, Korea; National Institute of Oncology, 
Budapest, Hungary; Asan Medical Center, Seoul, Korea; Pfizer 
Global Research and Development, Paris, France; Pfizer Inc, 
Collegeville, PA; Bristol Meyers Squibb, Princeton, NJ; Jules Bordet 
Institute, Brussels, Belgium
Background: Neratinib (N), an irreversible pan-tyrosine kinase 
inhibitor (TKI), with activity against HER1, -2 and -4, has shown 
antitumor activity in patients (pts) with HER2+ breast cancer 
(BC). Lapatinib (L), a reversible HER1 and -2 TKI is approved in 
combination with capecitabine (C) for treatment of pts with HER2+ 
advanced or metastatic BC who had prior therapy.
Materials and Methods: This phase 2, randomized, open-label 
study evaluated safety and efficacy of N 240 mg/day vs L 1,250 
mg/day plus C 2,000 mg/m2/day (14 days/21 day cycle) in pts 
with HER2+ locally advanced or metastatic BC. Eligible pts had: 
≤2 prior trastuzumab regimens, prior taxane treatment, and no 
prior anthracycline treatment with cumulative dose >400 mg/m2 
doxorubicin, >800 mg/m2 epirubicin, or >equivalent dose of other 
anthracycline. Primary endpoint was progression-free survival (PFS; 
investigator-assessed); secondary endpoints included safety, overall 
survival (OS), objective response rate (ORR), and clinical benefit 
rate (CBR; % pts with complete response, partial response, or stable 
disease ≥24 wks). Tumor assessments were every 6 wks for the first 
48 wks, then every 12 wks until progressive disease (PD; RECIST 
1.0) or initiation of new anticancer therapy.
Results: Overall, 117 pts were randomized to N and 116 to L plus 
C (LC). Mean age (SD; range) was 53.9 y (10.3; 28-79); 60% 
were White, 34% Asian, and 6% other. Prior treatments included: 
trastuzumab (229 pts: 168 metastatic or locally advanced, 51 adjuvant, 
10 neoadjuvant), taxanes (230 pts), and anthracycline (156 pts). 
Median treatment duration (range) was 126.5 days (1-636) for N and 
201 days (13-622) for LC. Median relative dose intensity (actual/
expected exposure) for N was 100%. As of data cutoff, 84% had 
discontinued treatment; 65% from PD (N 63%, LC 67%), 9% for 
adverse events (AEs; N 7%, LC 11%). In the ITT cohort, for N and 
LC, respectively, median PFS (95% CI) was 4.5 mo (3.1-5.7) and 6.8 
mo (5.9-8.2; P = 0.091; hazard ratio = 1.3 [95% CI, 1.0-1.8]); median 
OS (95% CI) was 19.4 mo (19.4-22.2; 41 deaths) and 19.0 mo (16.9-
NA; 35 deaths; P = 0.180); ORR (95% CI) was 29% (21-38) and 41% 
(32-50; P = 0.067); CBR (95% CI) was 44% (35-54) and 64% (54-
73; P = 0.003). Most common drug-related treatment-emergent AEs 
(TEAEs; any grade) were diarrhea (N 84%, LC 67%), nausea (34%, 
38%), palmar-plantar erythrodysesthesia (PPE; 5%, 63%), and rash 
(18%, 34%); for grade ≥3, diarrhea (28%, 10%) and PPE (0, 14%). 
Dose reductions/discontinuations from diarrhea occurred in 13/3 pts 
on N, and 15/7 pts on LC. Study deaths for N and LC, respectively, 
included: 36 pts (31%) and 32 pts (28%) from PD; 5 pts (4%) and 3 
pts (3%) from AEs unrelated to study drug.
Discussion: In this setting of pts less heavily pre-treated than in the 
pivotal LC trial, single agent N demonstrated high anti-tumor activity 
(ORR 29%), confirming results from prior N phase 2 trials. N alone 
did not appear to be as effective as LC. No unexpected TEAEs were 
observed; N was well tolerated in pts with HER2+ locally advanced 
or metastatic BC; while diarrhea was more frequent on N than LC, it 
was manageable with antidiarrheals and did not lead to more treatment 
discontinuations.
S6-1
Menopause-Specific and Health-Related Qualities of Life among 
Post-Menopausal Women Taking Exemestane for Prevention of 
Breast Cancer: Results from the NCIC CTG MAP.3 Placebo-
Controlled Randomized Controlled Trial.
Maunsell E, Richardson H, Ingle JN, Ales-Martinez JE, Chlebowski 
RT, Fabian CJ, Sarto GE, Garber JE, Pujol P, Hiltz A, Tu D, Goss 
PE. Université Laval, Quebec City, QC, Canada; Queen’s University, 
Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital 
Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research 
Institute, Torrance, CA; University of Kansas Medical Center, 
Westwood, KS; Center for Women’s Health and Health Research, 
Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-
Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts 
General Hospital Cancer Center, Boston, MA
Background: Exemestane, a steroidal aromatase inhibitor, reduced 
the incidence of invasive breast cancers by 65% among 4560 post-
menopausal randomized to exemestane or placebo for 5 years on 
MAP.3. Differences in quality of life (QOL) were judged to be 
minimal, but only summary information was reported. Purpose: 
To provide more detailed information about effects of exemestane 
on menopause-specific and health-related qualities of life. Method: 
Participation in quality of life assessment was an eligibility criterion. 
Menopause-specific and health-related qualities of life were assessed 
using the MENQOL (4 scales; physical, vasomotor, psychosocial, 
sexual) and SF-36 (8 scales; physical health, role function – physical, 
bodily pain, general health, vitality, social function, role function 
– emotional, mental health, and 2 summary scales) instruments, 
respectively at baseline, 6 months and then yearly after randomization. 
Compliance with QOL questionnaire completion at each follow-up 
visit ranged from 93-98%, and did not differ by group. Change scores 
for each MENQOL and SF-36 scale, calculated for each assessment 
time relative to baseline, were compared using the Wilcoxon Rank-
Sum test. Summary scores were used to summarize the QOL scores 
observed at each time point for each SF-36 dimension and overall 
mental (MCS) and physical component summaries (PCS) and 
MENQOL domains. Clinically important worsening of MENQOL 
change scores was defined as an increase of ≥0.5/8 points. SF-36 
change scores were considered worsened if scores decreased by 
≥ 5 points from baseline. Results: Both groups were balanced on 
scores for MENQOL and SF-36 at baseline. Median follow-up 
was 35 months and the proportion of women who stopped study 
medication early for toxicity reasons was 15% in the exemestane 
arm and 11% in the placebo arm. There was a statistically significant 
difference in change scores for vasomotor symptoms among women 
on exemestane during the first 4 years (p-values <0.01), compared to 
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placebo. However, no between-group differences in vasomotor change 
met the criterion for clinical importance. Women on exemestane 
had statistically poorer sexual functioning (mean change = -0.02, 
SD=1.37) compared to placebo (mean change = -0.12, SD=1.32) 
during the first 6 months on study (p-value = 0.03) but the differences 
were not statistically significant thereafter or clinically important at 
any time. Among the 8 SF-36 scales, only bodily pain was statistically 
different between exemestane and placebo for the first 24 months on 
study medication (p-value <0.01), but no between-group difference 
in change scores exceeded 5 points. Overall SF-36 PCS and MCS 
assessing changes in overall physical and mental health-related QOL 
did not differ significantly by group at any assessment. Conclusion: 
Our assessment that early differences in vasomotor symptoms and 
pain were probably not clinically important is supported by the 
observation of no between-group differences when overall physical 
and mental health-related QOL changes were compared. Exemestane 
does not appear to have a major negative impact on the quality of 
life among these women.
S6-2
Patient-Reported Predictors of Early Treatment Discontinuation: 
NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal 
Women with Primary Breast Cancer Randomized to Exemestane 
or Anastrozole.
Wagner LI, Zhao F, Chapman J-AW, Cella D, Shepherd LE, 
Sledge GW, Goss PE. Northwestern University Feinberg School of 
Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; 
NCIC Clinical Trials Group, Queen’s University, Kingston, ON, 
Canada; Indiana University Simon Cancer Center, Indianapolis, IN; 
Massachusetts General Hospital, Boston, MA
Background: Patient-reported outcomes (PRO) assess symptom 
burden and health-related quality of life (HRQL) more accurately 
than clinical report. We previously found that treatment-emergent 
adverse events (CTCAE V3.0) did not impact efficacy in the main 
NCIC MA.27 trial, although many women discontinued treatment 
early. The purpose of this substudy was to obtain PROs in MA.27/
E1Z03 participants to evaluate treatment-related side effects and 
HRQL between exemestane and anastrozole and to identify predictors 
of treatment discontinuation.
Methods: The Eastern Cooperative Oncology Group trial (E1Z03) 
assessed PROs in a sample of MA.27 patients (N=686; 99.3% 
participation rate). Participants completed the 56-item Functional 
Assessment of Cancer Therapy–Endocrine Symptoms (FACT-ES) 
pre-treatment and at months 3, 6, 12 and 24 to assess breast-cancer 
specific concerns, side effects of hormonal treatments and HRQL. 
We used 1) Wilcoxon rank sum test to compare treatment-related 
symptoms and HRQL between trial arms; 2) linear mixed effect 
models to test differences in changes of treatment-related symptoms 
and HRQL between trial arms; 3) linear regression to examine the 
effects of symptoms on HRQL and 4) adjusted Cox regression to 
assess predictors of treatment duration.
Results: Participants included 371 women randomized to anastrozole 
and 315 randomized to exemestane. Demographic and disease 
characteristics were balanced between trial arms. Participants were 
a mean age of 65.6 yrs (SD=9.2), White (95.9%), ECOG PS of 0 
(87.2%), stage T1 (75.5%) or T2 (22.7%), and stage N0 (73.9%) or 
N1 (16.3%). Prior treatments included partial mastectomy (65.7%), 
chemotherapy (27.8%) and radiotherapy (51.7%). Treatment-related 
symptoms measured by 23 items from the FACT-ES did not differ 
between treatment arms at months 3, 6, 12 and 24 and the timeline 
change of treatment-related symptoms was similar between treatment 
arms (p = ns). HRQL was significantly impacted by decreased 
libido, weight gain, feeling bloated, breast sensitivity, mood swings, 
irritability, join pain, nausea and bother by treatment side effects (p < 
0.001). 248 participants were off-treatment by 4.1 yrs. A Cox model 
adjusted for other symptoms, demographic and disease characteristics 
indicated the hazard of discontinuing treatment early increased by 
29% when the severity of being bothered by side effects at baseline 
increased by 1 point (HR=1.29, 95% CI:1.09-1.54). At baseline, 
patients with prior treatments or taking more medicines reported more 
bother by side effects (p < 0.001). Increased joint pain in the first 3 
months after treatment was also associated with increased hazard of 
discontinuing treatment early (HR=1.13, 95% CI: 1.01-1.28).
Conclusions: PRO assessment indicated comparable symptom 
burden and HRQL among postmenopausal women randomized to 
anastrozole or exemestane, with increasing symptom burden over 
time negatively affecting HRQL. Patients who 1) initiate an aromatase 
inhibitor (AI) with bother by side effects from prior treatment and 
concomitant medications and 2) experience increased joint pain during 
the first 3 months of AI therapy are at risk for early discontinuation 
of AI therapy.
S6-3
Influence of Hospital Factors, Physician Factors and Type of 
Health Insurance on Receipt of Immediate Postmastectomy 
Reconstruction in Young Women with Breast Cancer.
Hershman DL, Neugut AI, Richards CA, Kalinsky K, Charles AS, 
Wright JD. Columbia University, New York, NY; Mailman School of 
Public Health, New York, NY
Objective
For women with breast cancer who choose mastectomy, breast 
reconstruction is known to offer a cosmetic and psychological 
advantage. Despite this, only a minority of patients undergo post 
mastectomy reconstruction. Little is known about factors that 
influence reconstruction in younger women who undergo mastectomy. 
We evaluated the association of demographic, hospital, physician and 
insurance factors with receipt of immediate breast reconstruction.
Methods
We used the Perspective database to identify women who underwent 
a mastectomy for breast cancer from 2000-2010. Perspective is 
a voluntary, fee-supported database that samples more than 500 
acute-care hospitals throughout the United States that contribute 
data on inpatient hospital admissions. ICD-9 procedure codes were 
used to identify women who underwent reconstruction at the time 
of mastectomy. Differences in reconstruction rates over time were 
examined by age, race, and type of insurance (commercial, Medicaid, 
Medicare and self-pay). Logistic regression analysis was used to 
determine factors predictive of immediate breast reconstruction after 
mastectomy. Additional analyses were done on the population of 
younger women (<50 years of age).
Results
We identified 106,988 women with breast cancer who underwent 
mastectomy, and of these, 24,150 (22.6%) underwent immediate 
reconstruction. From 2000 to 2010,, reconstruction rates increased 
from 15% to 33.3%, increasing the most for women with commercial 
insurance (25.3% to 54.6%) and women under the age of 50 (29% 
to 60%); for women under the age of 50 with commercial insurance 
the rate in 2010 was 67.5%. Multivariable analysis found that 
reconstruction was significantly less likely with increasing age, black 
race (OR=0.66), rural hospital location (OR=0.48), non-teaching 
hospital (OR=0.82) and >2 co-morbid conditions (OR=0.72). Odds 
of reconstruction increased with commercial (OR=3.0) and public 
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(OR=1.6) insurance (compared to self-pay), bilateral mastectomies 
(OR=2.5), being single (OR=1.09) and increased hospital volume 
(OR=1.94). No association was found with breast surgeon volume. 
Similar associations were seen in the subgroup of women <50 years 
of age. Prolonged length of stay was greater for women undergoing 
reconstruction (29.2% vs. 18.5%, p<0.0001); however, in-hospital 
complication rates were similar at 5.6% and 5.3%, respectively.
Conclusion
Despite its benefits, less than one-third of all women, and half of 
women under the age of 50, received post mastectomy reconstruction 
in 2010. Insurance status was one of the largest predictors of 
immediate reconstruction, and its influence has increased over time. 
Public policy should ensure that access to reconstructive surgery is 
available to all women, regardless of insurance type.
S6-4
Protein Kinase Mutation Patterns in Human Breast Cancer.
Pusztai L, Qi Y, Shi W, Liu C-G, Wang B, Liu X, Booser D, Esteva 
FJ, Symmans F, Hortobagyi GN. UT MD Anderson Cancer Center, 
Houston, TX
Background: We performed next generation targeted sequencing of 
all known human protein kinases (n=530 genes) and 56 additional 
cancer related genes (BRCA1,2, p53, PTEN, etc..) in 112 samples to 
assess the kinase mutation landscape of breast cancer. Gene expression 
profiling was also performed on RNA from each specimen and DNA 
copy number variations were assessed in a subset of 59 cases using 
array CGH. The three types of genomic data were mapped to canonical 
biological pathways to identify frequently genomically disturbed 
pathways in these cancers. Methods: DNA and RNA extracted from 
fine needle biopsies of 92 breast cancers were analyzed, 20 samples 
were sequenced in duplicates or triplicates to assess technical variation 
of the results. Targeted sequencing was performed with Agilent 
SureSelect Human Kinome kit and the SOLiD sequencing platform. 
Gene expression profiling and array CGH were performed with 
Affymetrix U133A chips and Agilent 244K CGH array. Sequence data 
was mapped to hg19, functional impact scores were calculated with 
SWIFT, canonical pathways were obtained from the Broad Institute. 
Results: 0.1% of the entire genome was sequenced and >80% of target 
base pairs had > 20-fold coverage. The mean number of single nucleic 
acid variants (SNV) and indels per sample were 1043 (range: 493-
1583, about 60% homozygous) and 159 (range: 75-269) respectively, 
97% of SNVs and 78% of indels were already represented in dbSNP 
or COSMIC data bases. About 20% of SNVs were predicted to alter 
kinase or other biological function. The mean number of functionally 
high impact SNVs was 28 per sample (range 11-47). In addition to 
known p53 and PI3K mutations we detected frequent mutations in 
BRCA1 (20%) and observed several predicted high impact SNVs 
in HER2 (20%) as well as in many MAPK family enzymes. Not 
all SNVs were distributed equally across disease subsets, SNVs 
in ULK4, BMP2K, PALB2, ALPK3 were more frequent in triple 
negative cancers (TNBC) whereas SNVs in EPHA2 was more 
common in ER+ cancers. Among TNBC, those with residual cancer 
after neo-adjuvant chemotherapy (n=22) had significantly higher rates 
of SNVs in HUNK, TRPM7, NEK1 and HER3 compared to cases 
with pathologic complete response (n=25). When high impact SNVs, 
DNA copy number alterations and gene over-expression (relative to 
normal breast n=45) observed in individual cases were mapped to 
biological pathways a complex network of anomalies emerged for 
each case. Conclusion: We observed several known mutations in 
cancer genes and also detected many SNVs in important regulatory 
genes that were previously described as functional, germ-line variants 
with experimentally validated or suspected impact on protein function. 
Individual cancers have unique combinations of these events. This 
suggest that cancers arise in the context of complex genomic “germ 
line noise” which may determine which types of somatic events can 
or cannot “drive” individual cancers. The data also suggest therapeutic 
hypotheses about what biological pathways should be targeted in 
individuals and in subsets of cancers.
S6-5
Obesity Drives Epithelial-to-Mesenchymal Transition and Tumor 
Progression in a Novel Claudin-Low Mammary Cancer Model.
Dunlap SM, Chiao LJ, Nogueria L, Usary J, Perou CM, Varticovski 
L, Hursting SD. University of Texas, Austin, TX; University of North 
Carolina, Chapel Hill, NC; National Cancer Institute, Bethesda, MD; 
University of Texas M.D. Anderson Cancer Center, Smithville, TX
Background: Epidemiological evidence suggests a potential role 
of obesity in regulating clinical subtype, differentiation status, and 
prognosis of breast cancer. Specifically, an elevated waist-hip ratio 
is associated with increased risk and progression of basal-like breast 
cancer, an aggressive form characterized by heterogeneous tumors 
typically enriched in a putative tumor initiating cell (TIC) population. 
However, the exact mechanism of obesity-driven tumor progression 
remains unknown. Therefore, we hypothesized that obesity regulates 
a plastic population of multipotent malignant cells.
Materials, Methods, and Results: To test this hypothesis, we generated 
and characterized two distinct murine mammary tumor cell lines 
derived from MMTV-Wnt-1 transgenic mice, designated M-Wnt and 
E-Wnt. M-Wnt cells displayed a mesenchymal morphology while 
E-Wnt cells had an epithelial morphology. M-Wnt cells harbored 
a large CD44+/CD24- putative TIC population (62% +/- 7.8), had 
significant mammosphere forming capacity (>30% of cells form 
mammospheres, p<0.0001), and increased ALDH activity (7% are 
ALDH+, p=0.0004). M-Wnt cells have increased migration (scratch 
assay) and invasion in vitro (226-fold higher after 30h, p<0.0001). As 
few as 50 unsorted M-Wnt cells, injected into C57BL/6 mice were 
capable of forming a tumor. Microarray analysis revealed that M-Wnt 
cells display gene expression profiles virtually identical to human 
Claudin-low breast tumors, while E-Wnt cells clustered with basal-
like tumors. EMT and stem cell gene expression patterns of M-Wnt 
cells were maintained in vivo, including decreased E-cadherin and 
increased N-cadherin, fibronectin, vimentin, SNAIL, TWIST, SLUG, 
FOXC2, and TGF-b (p<0.05 for all). Using these cell lines in vivo, 
we tested the hypothesis that energy balance modulation, through 
diet-induced obesity (DIO) and calorie restriction (CR), regulates 
the TIC population. We found that M-Wnt tumors, transplanted into 
ovariecomized syngeneic female C57BL/6 mice, grew at significantly 
different growth rates depending on the diet treatment (DIO > Control, 
p=0.011; CR < Control, p=0.012), while E-Wnt tumors were only 
affected by CR (CR < Control p=0.001; no difference between DIO 
and Control tumors). DIO enhanced M-Wnt tumor progression, 
adipocyte infiltration, and central necrosis and drove EMT (decreased 
E-Cadherin and increased fibronectin and N-Cadherin expression) 
through modulation of key TIC associated genes, including increased 
TGF-b, SNAIL, FOXC2, and Oct4 (p<0.05 for all).
Discussion: In conclusion, we found that the mesenchymal M-Wnt 
cell line is highly responsive to changes in dietary energy balance 
status relative to the E-Wnt differentiated epithelial cell line, which 
demonstrates that clinical subtypes of breast cancer are differentially 
regulated by energy balance modulation. Additionally, our data 
demonstrates, for the first time, that energy balance modulation (ie, CR 
and obesity) directly regulates EMT, in response to local upregulation 
of TGF-b signaling.
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S6-6
Expression of Key Estrogen-Regulated Genes (ERGs) Differ 
Substantially across the Menstrual Cycle in ER+ Breast Tumours.
Haynes BP, Viale B, A’Hern R, Smith IE, Dowsett M, Galimberti V, 
Rotmensz N, Gibelli B. Royal Marsden Hospital, London, United 
Kingdom; Institute of Cancer Research, Sutton, Surrey, United 
Kingdom; European Institute of Oncology, Milan, Italy
Aim: To determine whether there are substantial changes in the 
expression of ERGs in estrogen receptor positive (ER+) breast cancer 
through the menstrual cycle.
Background: Plasma levels of estradiol (E2) vary from c.100pM to 
c.1000pM and progesterone levels from <3nM to >50nM through 
the menstrual cycle. The changes in E2 are proportionally similar to 
those that occur in postmenopausal women treated with an aromatase 
inhibitor which lead to profound changes in the expression of ERGs. 
However, there are only inconsistent data on whether the cyclical 
changes in hormone levels during the menstrual cycle affect gene 
expression in ER+ tumours.
Methods; 173 paraffin-embedded ER+ breast carcinomas were 
analysed from premenopausal patients in which day of menstrual 
cycle and hormonal data were recorded at the time of surgery1 
enabling accurate definition of the timing of the ovarian cycle. The 
patients were ascribed to one of 3 pre-defined time windows of the 
menstrual cycle: window 1: days 27-35 + 1-6 (low circulating E2 and 
progesterone); window 2: days 7-16 (high E2 and low progesterone); 
window 3: days 17-26 (moderate E2 and high progesterone). RNA 
was extracted (RecoverAll; Ambion) and QPCR used to measure 
expression of ESR1, 4 ERGs (TFF1, PGR, GREB1 and PDZK1)2 
and 3 housekeeping genes.
Results: ESR1 expression did not differ significantly across the 
menstrual cycle but there was strong evidence of differences in the 
ERGs (Kruskal-Wallis; p=0.0015 to 0.093). Gene expression levels 
of the 4 ERGs were 51-109% higher in window 2 than window 1 
(see table) and this was significant for PGR, GREB1 and TFF1 and 
approached significance for PDZK1. The expression of all the ERGs 
was lower (14-59%) in window 3 compared to window 2 (significant 
for TFF1). PGR and GREB1 expression was significantly higher (30-
40%) in window 3 compared to window 1.
 % difference in median expression for ER+ tumours (Mann-Whitney p)
 PGR GREB1 TFF1 PDZK1 AvERG
Difference:  
window  
1 and 2
+109.5  
(p=0.0041)
+51.4  
(p=0.0006)
+88.8  
(p=0.037)
+97.5  
(p=0.092)
+63.2  
(p=0.0002)
Difference:  
window  
2 and 3
-33.1 (p>0.20) -13.9 (p>0.20) -52.4 (p=0.028) -58.8 (p=0.061) -30.5 (p=0.007)
Difference:  
window  
1 and 3
+40.2 (p=0.049) +30.4 (p=0.021) -10.1 (p>0.20) -18.5 (p>0.20) +13.4 (p=0.17)
The average expression of these 4 ERGs gives the AvERG, a 
previously defined index of estrogen responsiveness2. This showed 
similar changes to the individual ERGs but the reduced variability 
of the AvERG led to even greater statistical significance. A control 
set of ER- tumours (n=83) showed very low expression of the ERGs 
and no cyclical changes.
Discussion: These data reveal significant changes in breast tumour 
biology across the menstrual cycle. As these changes are likely to 
occur only in tumours that are estrogen-dependent their measurement 
may potentially be developed as a test of a tumour’s likely response 
to estrogen deprivation. Several ERGs are present in currently used 
molecular profiling tests; variable expression of these markers 
through the menstrual cycle may affect the interpretation of the tests. 
Proliferation-related genes are currently being assessed to determine 
if their expression varies in a similar way.
1. Zurrida et al., Crit Rev Oncol Hem 2001, 38; 223-30
2. Dunbier et al., JCO 2010, 28; 1161-7
PD01-01
Randomized Phase II Trial of Fulvestrant with or without 
Dasatinib in Postmenopausal Patients with Hormone Receptor-
Positive Metastatic Breast Cancer Previously Treated with an 
Aromatase Inhibitor.
Wright GL, Blum J, Krekow LK, McIntyre KJ, Wilks ST, Rabe AC, 
Vukelja SJ, Andersen JC, Wang Y, Asmar L, O’Shaughnessy J. US 
Oncology, The Woodlands, TX; Florida Cancer Institute-New-Hope, 
Hudson, FL; Texas Oncology, Baylor-Sammons Cancer Center, 
Dallas, TX; Texas Oncology-Breast Cancer Institute of North 
Houston, Bedford, TX; Texas Oncology-Dallas Presbyterian Hospital, 
Dallas, TX; Cancer Care Centers of South Texas, San Antonio, TX; 
Kansas City Cancer Center, Overland Park, KS; Texas Oncology, 
Tyler, TX; Northwest Cancer Specialists, Portland, OR
Introduction: Fulvestrant is an effective endocrine therapy in patients 
with ER+ metastatic breast cancer (MBC) that has become resistant 
to non-steroidal aromatase inhibitors (NSAI). Dasatinib is a potent, 
broad spectrum ATP-competitive inhibitor of SRC tyrosine kinase 
activity that can lead to endocrine therapy resistance and late bone 
metastases. Dasatinib inhibits proliferation of cancer cell lines that 
express activated SRC. Inhibition of SRC signaling may overcome the 
endocrine resistance of HR+ MBC. We sought to determine whether 
addition of dasatinib to fulvestrant would increase progression-free 
survival (PFS) over fulvestrant alone in MBC.
Methods: This is a randomized phase II study including patients with 
evaluable or measurable ER+ MBC whose disease had progressed 
while on adjuvant or metastatic NSAI. Patients were stratified to ≤ 2 
yrs vs > 2 yrs from initial breast cancer diagnosis to first diagnosis of 
metastatic disease and randomly assigned 1:1 to Arm 1 (loading dose 
of fulvestrant 500 mg followed by 250 mg IM and dasatinib 100 mg 
PO QD) or Arm 2 (single-agent fulvestrant 250 mg IM). Following 
FDA approval in 2010 of the 500 mg dose, a loading dose (500 mg) 
of fulvestrant on Day 1 was followed by 500 mg on Day 15 of Cycle 
1 and on Day 1 of each subsequent cycle (n=40 patients received the 
higher dose). Arm 2 patients who progressed while on fulvestrant 
could cross over to receive fulvestrant plus dasatinib. The primary 
objective was median PFS. Secondary objectives included overall 
survival (OS), overall response rate (ORR), and safety.
Results: The study included 99 patients, 50 in Arm 1 (combination) 
and 49 in Arm 2 (fulvestrant alone). Results for Arm 1 and Arm 2, 
respectively, were: median PFS 6.0 and 5.3 months; median OS 
17.0 and 21.7 months; and clinical benefit rates (CBR) (PR+SD ≥6 
months) were 14 (28.0%, 95%CI=16.2%-42.5%) and 16 (32.7%, 
95%CI=19.9%-47.5%) months. In Arm 1 and Arm 2, 24% and 8% 
developed grade 1/2 pleural effusion; 34% and 10% developed 
grade 1/2 diarrhea, 40% and 6% developed grade 1/2 nausea, and 
30% and 18% developed grade 1/2 fatigue. Six patients on Arm 1 
stopped dasatinib due to AEs, mainly pleural effusion and dyspnea. 
Eighteen (37%) Arm 2 patients crossed over to receive combined 
fulvestrant/dasatinib at disease progression on fulvestrant. Median 
PFS for crossover patients was 3.8 months, with the longest duration 
of treatment being 12 and 15 months in 2 patients.
Conclusions: The addition of dasatinib to fulvestrant in ER+ 
postmenopausal MBC patients whose disease had progressed through 
an NSAI did not improve PFS, CBR, or OS. The combination 
of fulvestrant and dasatinib in patients with ER+ MBC was well 
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tolerated. Formalin-fixed paraffin-embedded archival BC tissue is 
being analyzed for SRC-related signature to determine whether a 
subset of patients benefit from dasatinib.
PD01-02
Randomized Phase II Study of Dasatinib vs Placebo in Addition 
to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS 
CA180-261 Study].
Llombart A, Ravaioli A, Strauss L, Sy O, Abrahao F, Geese WJ, 
Lortholary A, Rea D, Ro J-S, Sohn J, Kim S-B, Curigliano G. Hospital 
Universitari Arnau De Vilanova, Lleida, Spain; Ospedale degli 
Infermi di Rimini, Rimini, Italy; Bristol-Myers Squibb, Wallingford, 
CT; Centre Catherine De Sienne, Nantes, France; City Hospital, 
Birmingham, United Kingdom; National Cancer Center, Gyeonggi-
Do, Korea; Yonsei Cancer Center, Seoul, Korea; Asan Medical Center, 
Seoul, Korea; Instituto Europeo di Oncologia, Milano, Italy
Background: Src-family kinases (SFKs) are involved in estrogen 
receptor (ER) and progesterone receptor (PgR) signaling pathways, in 
resistance to hormonal therapy, and in osteoclast function. Dasatinib 
is a potent oral inhibitor of SFKs and other kinases, but single-agent 
activity in advanced breast cancer (ABC) is limited. Biomarkers 
may identify patient subsets with increased benefit. In this Phase II 
study, the combination of dasatinib with exemestane was evaluated in 
patients (pts) with ER+ and/or PgR+ ABC resistant to a nonsteroidal 
aromatase inhibitor (NSAI).
Methods: In a randomized double-blind Phase II trial (CA180-261), 
157 patients (pts) with ECOG performance status of 0-1, measurable 
or evaluable disease, and progression (PD) during, or within 1 year 
after adjuvant, treatment with an NSAI were stratified by symptomatic 
bone metastasis (SBM) and other factors, and assigned 1:1 to receive 
dasatinib (100 mg daily) or matched placebo in combination with 
exemestane (25 mg daily). Progression-free survival (PFS) was the 
primary endpoint and clinical benefit (CBR; partial response+stable 
disease ≥24 wks) the key secondary endpoint. The study was designed 
for 80% power to detect a hazard ratio (HR) of 0.67 between arms, 
corresponding to median PFS increase from 4 to 6 months using 
1-sided a=0.1. Archival tumor samples for biomarker analysis were 
collected. Patient-reported pain score and a measure of bone lysis 
(urinary N-telopeptide, uNTX) were collected serially in pts with 
SBM.
Results: Planned analysis was performed after 119 events (PD or 
death) were recorded, at which time 129 pts had discontinued study 
treatment. Overall PFS comparison was non-significant (HR=0.86; 
1-sided p=0.148), with median PFS of 16 weeks (95% CI 12, 18) in 
the placebo arm and 18 weeks (95% CI 15,24) in the dasatinib arm. 
Estimated free-from-progression rate at 24 weeks was 33% in placebo 
and 43% in the dasatinib arm. Pts with SBM, 40% of study population, 
had improved PFS on the dasatinib arm (HR=0.68, 1-sided p=0.094). 
Preliminary CBR at this analysis (31 of 38 censored pts continue on 
study) was higher in the dasatinib arm. Expected dasatinib-related 
toxicities were observed, including pleural effusion [23% (5% Gr≥3) 
in dasatinib vs 1% (0 Gr≥3) in placebo] and diarrhea [25% (1% 
Gr≥3) vs 1% (0 Gr≥3)]. Musculoskeletal adverse events (AEs) were 
comparable between arms, but fatigue or asthenia [37% (4% Gr≥3) 
vs 20% (0 Gr≥3)], skin AEs [28% (1% Gr≥3) vs 11% (0 Gr≥3)] and 
headache [22% (3% Gr≥3) vs 9% (0 Gr≥3)] were more common in 
dasatinib arm. Dose interruption or reduction was more frequent for 
dasatinib compared to placebo. Biomarker analyses are in progress.
Conclusion: PFS difference (HR=0.82) was not significant in overall 
study population, but higher CBR in the dasatinib arm and higher PFS 
in pts with SBM (HR=0.68) suggests that dasatinib has efficacy in a 
subset. The safety profile was consistent with dasatinib experience; 
AEs, including pleural effusion and diarrhea, were more common with 
dasatinib as compared with placebo. Updated efficacy and biomarker 
analyses will be presented.
PD01-03
Src Is a Potential Therapeutic Target in Endocrine Resistant 
Breast Cancer Exhibiting Low Estrogen Receptor (ER)-Mediated 
Transactivation.
Guest SK, Pancholi S, Patani N, Dowsett M, Johnston SR, Martin 
L-A. Institute of Cancer Research, London, United Kingdom; Royal 
Marsden Hospital, London, United Kingdom
Aim: Identification of the mechanisms governing sensitivity to 
dasatinib in endocrine resistant breast cancer.
Background: Despite the effectiveness of endocrine therapies over 
40% of women relapse. To identify the molecular mechanisms 
associated with resistance to estrogen-deprivation on an aromatase 
inhibitor, we previously assessed changes in gene expression during 
adaptation to long-term culture of MCF7 human breast cancer (BC) 
cells in the absence of estradiol (E2) (LTED). Analyses of canonical 
signaling pathways highlighted FAK as one of the major pathways 
up regulated at the point of resistance and src as a dominant gene in 
this pathway. Src phosphorylates a plethora of proteins including ER. 
Surprisingly dasatinib a pan src inhibitor enhanced proliferation of 
MCF7 cells in the absence of E2 and had limited anti-proliferative 
effect in the LTED model. In contrast tamoxifen resistant MCF7 cells 
(TAMR) were exquisitely sensitive to dasantinib [1].
Methods: Proliferation was assessed using Titre Glo™. ER-mediated 
transcription was measured with an estrogen-response element linked 
luciferase reporter construct. Protein expression was determined by 
immunoblotting. Confocal microscopy was used to determine cellular 
localization of ER.
Results: Dasatinib decreased proliferation of the TAMR (IC50 
0.05nM) and resensitized them to tamoxifen but had no effect on 
the wild-type (wt)-MCF7 or LTED cells. Previously a relationship 
between BC subtype and sensitivity to dasatinib was reported with 
basal and post-EMT BC cell lines showing the highest sensitivity, 
which associated with high caveolin (CAV) expression [2]. In ovarian 
cancer expression of CAV and urinokinase plasminogen activator 
(uPA) also predicted sensitivity to dasatinib [3]. TAMR cells had a 
2-fold increase in CAV-1 and 7-fold increase in uPA compared to wt 
cells. Comparison of LTED and TAMR showed that the TAMR whilst 
continuing to express high levels of ER, had a 10-fold lower level of 
ER-transactivation compared to wt-MCF7 and did not express PGR. 
In contrast the LTED showed a 7-fold increase in ER-transactivation 
compared to wt cells in the absence of E2. Strong evidence suggests 
ER in the TAMR cells acts via a non-genomic mechanism with ER 
expressed throughout the cell rather than being restricted to the 
nucleus. This implies the TAMR have an impeded luminal phenotype 
in relation to ER-genomic function. Dasatinib reduced the expression 
of ER in the TAMR and resulted in nuclear shuttling of ER whilst 
having no effect on the wt. BT474 (ER+/HER2 amplified) showed a 
similar distribution of ER to the TAMR cells but were far less sensitive 
to the antiproliferative effect of dasatinib. Of note the TAMR have 
increased phosphorylation of HER2 but no amplification.
Conclusion: These data suggest src has differential effects in these 
endocrine resistant cell lines. The anti-proliferative effect of dasatinib 
was more pronounced in the endocrine resistant cell line with low ER 
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genomic activity. Src inhibition warrants further clinical evaluation 
as a therapeutic target in endocrine resistant breast cancer.
1. S.K. Guest, Ann Oncol 2011, 22 (Supp 2):ii29–ii36.
2. Finn RS, Br Can Res Treat. 2007, 105(3):319-26.
3. Konecny GE, BJC. 2009,101(10):1699-70.
PD01-04
Entinostat, a Novel Histone Deacetylase Inhibitor, Added to 
Exemestane Improves PFS in Advanced Breast Cancer in a 
Randomized, Phase II, Double-Blind Study.
Yardley DA, Ismail-Khan RR, Klein PM. Sarah Cannon Research 
Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; 
H. Lee Moffitt Cancer Center, Tampa, FL; PMK Consulting, San 
Francisco, CA
Background: Entinostat is a novel, oral, class I-selective histone 
deacetylase inhibitor (HDACi) that has been shown pre-clinically to 
inhibit mechanisms of aromatase inhibitor (AI) resistance through 
epigenetically driven down-regulation of activated growth factor 
signaling pathways and normalization of estrogen receptor levels. 
This provided a strong rationale for the entinostat breast cancer 
(BC) program, which was designed to evaluate entinostat’s ability to 
increase and/or restore sensitivity to treatment with an AI. Methods: 
Postmenopausal women with ER+ advanced BC who had ≤ 1 prior 
chemotherapy and had progressed on a non-steroidal AI were 
randomized 1:1 to exemestane 25 mg daily + entinostat 5 mg or 
placebo weekly. Progression free survival (PFS) was the primary 
endpoint; objective response rate and clinical benefit rate were 
secondary endpoints and overall survival (OS) was an exploratory 
endpoint. Prospectively defined subsets of interest included patients 
with “AI-sensitive and AI-resistant disease”. AI-sensitive was defined 
as having had a PR, CR or SD for ≥6 months (mos) in the metastatic 
setting or having completed and remained disease free for ≥12 
months post adjuvant therapy. All others were considered AI-resistant. 
Treatment continued until disease progression or unacceptable 
toxicity. Response assessments were performed every 8 weeks. 
Results: 130 women were enrolled (64 exemestane+entinostat [E+E]; 
66 exemestane+placebo [E+P]. All but 1 patient had Stage IV disease. 
82% had measurable disease, of which 60% had visceral involvement. 
42% had 1 prior line of hormonal therapy; 58% had >1. Analysis of 
the intent-to-treat (ITT) population showed significantly (defined 
prospectively as p<0.10) longer PFS with E+E than with E+P (median 
4.28 vs 2.27 mos, respectively; hazard ratio [HR] = 0.73; p=0.06) (CI 
0.49, 1.09). While not powered, results for pre-defined subsets were 
consistent with improved PFS in the E+E arm. Interestingly, the subset 
of patients identified as AI-resistant, demonstrated a HR of 0.61 (CI 
0.30, 1.25) (median 3.72 vs. 1.78 mos). While OS is still early, at 18 
mos median follow-up at time of abstract submission, the E+E arm 
demonstrated a median OS of 26.94 mos compared to the E+P arm 
of 20.33 mos (HR = 0.56) (CI 0.31, 1.02). Entinostat combined with 
exemestane was well tolerated. The most frequent adverse events 
(AEs) were fatigue, gastrointestinal disturbances, and hematologic 
abnormalities. AEs with a ≥ 20% higher incidence with E+E than 
E+P were fatigue (46% vs 26%) and uncomplicated neutropenia 
(25% vs 0%). Serious AE rate was similar for both arms (13% vs 
12%). Conclusions: Adding entinostat to exemestane resulted in 
improved PFS, the study’s primary endpoint. At a median follow-
up of 18 mos, the exploratory endpoint of OS was also increased in 
the E+E arm. Importantly for a phase II study, the PFS benefit in all 
subsets evaluated was consistent with the overall improvement seen 
in the ITT. These data demonstrate that the addition of entinostat to 
AI therapy may prolong the duration of AI therapy, thereby delaying 
the initiation of subsequent therapies such as chemotherapy, a goal 
for many breast cancer patients. A phase III study is planned.
PD01-05
Histone Deacetylase Inhibitor LBH589 (Panobinostat) Suppresses 
the Activated-NFkB Pathway in Acquired Aromatase Inhibitor 
Resistant Breast Cancer Cells.
Kubo M, Kanaya N, Liu Z, Chen S. Beckman Research Institute of 
the City of Hope, Duarte, CA
Background: Aromatase inhibitors (AIs) are effective in treating 
postmenopausal patients with estrogen receptor (ER)-positive breast 
cancer. However, resistance to endocrine therapies remains a major 
problem in the management of ER-positive breast cancer. Recently, 
histone deacetylase inhibitors (HDACis) show promise as cancer 
therapeutics, but the full scope of their utility remains unknown.
Experimental Design: In order to search for critical genes in 
developing resistance to AI, a microarray study was performed on 
AI resistant cells derived from MCF-7aro cells that overexpress 
aromatase and on AI resistant tumors from our mouse experiments. 
Moreover, using MCF-7aro cells that are resistant to anastrozole 
(Ana-R), letrozole (Let-R), and exemestane (Exe-R), as well as 
LTEDaro, we evaluated the significance of NFkB1 and several 
regulatory genes in AI resistance, and the anti-NFkB1 activity of 
HDACi LBH589 in vitro and in vivo.
Results: Significant changes (Fold change cutoff > 1.5, false discovery 
rate < 0.05) in the expression levels of 22 genes among three networks 
were identified from microarray analysis of our in vitro and in vivo 
models of acquired AI resistance. NFkB1 is a key player in one of 
three networks, including 11 genes, and is functionally up-regulated in 
all AI resistant cells. NFkB1 knockdown suppresses the proliferation 
of AI resistant cells more than that of MCF-7aro cells. Moreover, 
AI resistant cell lines are highly sensitive to LBH589 treatment and 
apoptosis is induced in these cell lines. LBH589 suppressed NFkB1 
as demonstrated at both the mRNA and protein levels in LTEDaro 
and other AI resistant cell lines. Furthermore, the LBH589 treatment 
abrogated tumor growth in mice, and was associated with significant 
decreased levels of NFkB1 in tumors.
Conclusions: Our findings provide new insights into how the NFkB1-
mediated networks play roles in AI resistance, and strongly support 
that LBH589 offers a novel therapeutic strategy for patients with AI 
resistant breast cancer.
PD01-06
Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates 
Different Genes Than Tamoxifen in an Aromatase Expressing 
MCF7 Model Resistant to Letrozole.
Goetz M, Hou X, Suman V, Reinicke K, Kuffel M, Haluska, Jr P, Oberg 
A, Grill D, Reid J, Brodie A, Ingle J, Ames M. Mayo Clinic, Rochester, 
MN; University of Maryland, Baltimore, MD
Background: First in human studies of Z-endoxifen hydrochloride (E), 
the active metabolite of tamoxifen (T), are underway in metastatic 
breast cancer (BC). Previous data have demonstrated the superiority 
of aromatase inhibitors (AI’s) over T in estrogen receptor (ER) + 
BC. Using an in vivo aromatase expressing model (MCF7/AC1), we 
compared the antitumor activity of E with T and Letrozole (L), as 
well as the antitumor activity and global gene expression changes of 
E with T in an L-resistant model.
Methods: MCF7/AC1 tumors were stimulated with androstenedione. 
Once tumor size reached 300 mm3, mice (30/group) were randomly 
assigned to one of five treatment groups: control (daily, po), T (500 
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µg/day, sc), endoxifen 25 mg/kg/day p.o.(LDE) endoxifen 75 mg/kg/
day p.o. (HDE) or letrozole, 10 µg/day s.c for 4 weeks. Tumors were 
harvested from control, T, and E groups while the L group continued 
treatment until the development of resistance defined as an increase 
in tumor volume of at least 300% from day 1. Mice with L-resistant 
tumors were randomly assigned to T (n=4) or E (n=5) for 4 weeks and 
then sacrificed. Gene expression in L-resistant tumors was quantified 
using Affymetrix U133+2 and changes in gene expression profiles 
[comparing T and E with L-resistant (n=3)] were analyzed. Genes 
identified as significantly different were confirmed by real-time RT-
PCR assays.
Results: At the 4 week time point, both doses of E and L resulted in 
greater anti-tumor activity than control (Wilcoxon rank sum test: all 
p < 0.0001); however, tumor burden did not differ between T and 
control (p=0.095). HDE resulted in significantly less tumor burden 
than T (p=0.002) but was similar to L. In mice that continued on L, 
resistance developed at 24 weeks in 9/25 mice. These mice were 
randomly assigned to either T (n=4) or E (n=5) for 4 weeks. Tumor 
volume (expressed as a % of its size prior to randomization) was 
significantly different comparing E (73.3%; range: 69.3 to 80.75%) 
versus T (148.39%; range: 114.07 to 165.99%) (Wilcoxon rank sum 
test p=0.016). Compared to control, microarray studies identified 
1518 unique probe sets regulated by E (p<0.001) compared to 441 for 
T including estrogen-regulated genes such as progesterone receptor 
(PGR) and amphiregulin (AREG) that were significantly down-
regulated in the E group [PGR (-6.2 fold, p=0.000008) and AREG 
(-3.2 fold, p=.0006) but unchanged or up-regulated in the T group 
(PGR unchanged and AREG +9.2 fold p=0.00002). These findings 
were confirmed by RT-PCR.
Conclusions: Using the MCF7/AC1 model previously used to show 
the superiority of AI’s over T, HDE demonstrated similar antitumor 
activity to L and was superior to T. In cells resistant to L, E was 
superior to T and gene expression changes demonstrate that E down-
regulates while T activates estrogen regulated genes. These findings 
support the ongoing development of E for the treatment of ER+ BC.
PD01-07
AR Overexpression and Aromatase Inhibitor Resistance in Breast 
Cancer.
Rechoum Y, Iacopetta D, Barone I, Ando’ S, Morales SF, Weigel NL, 
Fuqua SAW. Baylor College of Medicine, Houston, TX; University 
of Calabria, Calabria, Italy
Background: Aromatase inhibitors (AIs) have emerged as the therapy 
of choice for the treatment of estrogen receptor alpha (ERa)-positive 
breast cancer. However, many patients develop resistance to AI 
treatment. Although the involvement of the ERa in AI resistance is 
well established, the role of the androgen receptor (AR) is not known. 
It has been estimated that about 60%-70% of ERa-positive breast 
cancer co-express the AR, and that AR agonists can either inhibit 
or stimulate breast cancer cell proliferation. Thus it is important to 
determine if there are biomarkers predicting AR’s effects in breast 
tumors. We have previously shown a role for AR-overexpression in 
tamoxifen resistance in ERa-positive MCF-7 breast cancer cells; here 
we hypothesized that AR overexpression might similarly be involved 
in resistance to the AI anastrazole (Anas).
Materials and Methods: Stable transfection of MCF-7 cells was 
performed to generate cell lines that express the aromatase gene 
(MCF-7 BK Arom) and then co-transfected with an AR expression 
vector (MCF-7 AR Arom). Aromatase and AR expression levels 
were evaluated by western blot analysis, and the enzyme activity 
was evaluated using aromatase activity assays. Proliferation was 
tested using anchorage independent soft agar assays and MTT in the 
presence of the androgen substrate androstenedione (AD), or AD 
plus Anas. ERa and AR transcriptional activities were tested with 
ERE-luciferase reporter assays. Localization of ERa and AR within 
the cells was visualized using immunofluorescence microscopy.
Results: ERa-positive MCF-7 cells were stably transfected with 
either aromatase, or aromatase plus AR. MCF-7 aromatase clones 
overexpressing AR were resistant to the growth inhibitory effects 
of Anas when stimulated with the androgen AD. Resistance was not 
mediated through changes in aromatase expression or activity. The 
growth of several of the AR Arom-overexpressing cells was stimulated 
with treatment of Anas alone, suggesting that Anas was acting as an 
agonist. As expected, AD treatment stimulated ERa transcriptional 
activity, but Anas was unable to block AD-stimulated activity in 
AR Arom-overexpressing cells using ERE-Luciferase reporter 
assay. Anas was able to enhance AR and ERa colocalization in AR-
overxpressing cells. Resistance was not associated with activation 
of known mechanisms of resistance, such as HER2, IGF-1R, or 
MAPK. However AR-overexpressing cells had higher constitutive 
phosphorylation of Akt. Accordingly, resistance to Anas was blocked 
using an Akt1/2 inhibitor.
Conclusion: Using a model of ERa-positive breast cancer cells 
expressing exogenous aromatase and AR, we have demonstrated that 
AR overexpression confers resistance to the AI Anas. These results 
suggest that in patients recurring on hormonal therapy whose tumors 
express elevated levels of AR, targeted therapy to Akt might restore 
hormone sensitivity.
PD01-08
Heterogeneity of Lapatinib Responses in HCC1954 HER2-
Overexpressing Breast Cancer Cells Revealed by Single-Cell 
Automated Microscopy.
Hardeman KN, Tyson D, Quaranta V. Vanderbilt University School 
of Medicine, Nashville, TN
In breast cancer, 20-30% of patients present with HER2 overexpression, 
making them potential candidates for targeted HER2 therapies such as 
lapatinib. Lapatinib is a dual, intracellular tyrosine kinase inhibitor of 
HER2 & EGFR and is standard care for metastatic breast cancer. Drug 
resistance to this type of therapy is a major cause of death in cancer 
patients. Intra-tumor heterogeneity with respect to drug response can 
be a driving force for relapse and/or drug resistance. In current drug 
response end-point assays (IC50), information on heterogeneity is lost 
because cell differences are averaged out over the whole population. 
To produce a more realistic appreciation of drug response variability 
within a tumor, our lab has developed an extension of high content 
automated microscopy, called Extended Time Resolved Automated 
Microscopy (ETRAM). ETRAM entails the visual tracking of 
single cells with fine temporal & spatial resolution, allowing for 
the calculation of proliferation, death, and quiescence rates from 
image stacks and movies. HER2+ breast cancer HCC1954 cells were 
fluorescently labeled w/ a nuclear tag (H2BmRFP) and treated w/ 
lapatinib in a dose-dependent manner, from 2000 nM to 0 nM (DMSO 
control). Using the ETRAM method we followed nearly 1000 single 
cells/treatment condition over 72 hours, acquiring images every 10-
12 minutes. Unexpectedly, we discovered that small but significant 
subpopulations of HCC1954 cells are unaffected by high lapatinib 
concentrations (2000 nM) and continue to divide. Furthermore, a 
substantial subpopulation responds to high lapatinib by entering 
quiescence, not apoptosis. Since HCC1954 cells have a previously 
reported lapatinib IC50 of 300 nM, our data demonstrate a need to 
further investigate these subpopulations of cells in order to determine 
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their contribution to the IC50. Image stacks are being further analyzed 
to extract cellular metrics of division, quiescence and death rates in 
the presence of lapatinib. We are also investigating single cells by 
immunofluorescence of signaling molecules in the HER2 pathway, 
along with downstream targets such as PI3K, mTOR/AKT, SHC, 
and RAF1, to assess molecular differences regarding dividing and 
quiescent subpopulations in lapatinib, versus lapatinib-sensitive cells 
that apoptose. Our ETRAM-based single cell analyses may stimulate 
a re-interpretation of lapatinib responses in HER2-overexpressing 
breast cancer, and hopefully point to improved strategies of lapatinib 
treatment.
PD01-09
Identifying Novel Mechanisms of Resistance to Lapatinib in 
ERBB2+ Breast Cancer Cells through Whole Genome Mutational 
Analysis.
Jegg A, Ward TM, Iorns E, Gallas M, Aparicio SA, Pegram MD. 
Braman Family Breast Cancer Institute, Sylvester Comprehensive 
Cancer Center, University of Miami Miller School of Medicine, 
Miami, FL; UBC/BC Cancer Agency, Vancouver, Canada
Background: Overexpression of the epidermal growth factor 
receptor ERBB2 (HER2) is found in 20% of human breast cancers. 
Therapies targeting ERBB2 including trastuzumab and lapatinib 
have significantly improved the outlook for women with ERBB2+ 
breast cancer. However, resistance to these agents occurs frequently 
and remains a significant clinical problem. In the case of lapatinib 
resistance, the mechanism(s) of resistance remain poorly understood, 
since the current proposed rationale thought to limit lapatinib’s 
anti-tumor effects has been difficult to reconcile with clinical data. 
Therefore, we hypothesize that novel mechanisms of resistance could 
be identified by mapping genomic variations in ERBB2+ cells with 
acquired resistance to lapatinib. The identification of such mutations 
may provide insights into mechanisms of resistance and may indicate 
therapeutic strategies to overcome lapatinib resistance in ERBB2+ 
breast cancer.
Material and Methods: SKBR3 breast cancer cells resistant to 
lapatinib were generated through serial passage by exposure of 
drug sensitive parental SKBR3 cells to increasing concentrations 
of lapatinib up to the peak plasma concentration observed in human 
subjects (2.6 uM (SK-lapR)). Multiple signaling pathways in 
lapatinib sensitive and resistant cells were interrogated by Reverse 
Phase Protein Array (RPPA) and western blot analysis. To identify 
genome wide somatic mutations, the Exome of lapatinib resistant and 
sensitive SKBR3 cells was sequenced utilizing next generation deep 
sequencing. Following exclusion of germline variants, the acquired 
gene mutations in lapatinib resistant SKBR3 cells were confirmed by 
DNA re-sequencing of PCR amplified DNA segments.
Results and Discussion: Analysis of activated signaling pathways 
in lapatinib resistant and sensitive SKBR3 cells did not confirm any 
of the previously proposed mechanisms of resistance. In particular, 
these cells show no activation of AKT or alternative receptor 
tyrosine kinases such as IGF-IR, ERBB3 or c-Met. However they 
exhibit sustained activation of mTORC1 and ERK1/2, as well as 
phosphorylation of STAT3, STAT5, rpS6 and CREB. Initial sequence 
analysis of exome and transcriptome reveals the presence of 76 single 
nucleotide variants/Indels differing between sensitive and resistant 
cells with 34/76 validated as true mutations present in the genome 
of lapatinib resistant SKBR3 cells, including mutations in LATS2, 
MAP3K5, SMAD3 and PDGFRA. This is the first exome sequence 
analysis to be reported which defines a drug resistant phenotype in 
ERBB2+ breast cancer. Ongoing work includes investigation of 
mutations as drug resistance mediators and analysis of copy number 
variations and gene fusions/translocations to systematically search 
for molecular alterations, with the goal of providing a rationale for 
the design of new combination therapies aimed at lapatinib resistance 
for ERBB2+ breast cancer.
PD02-01
Impact of Contralateral Prophylactic Mastectomy on Surgical 
Outcomes.
Stover AC, Warren Peled A, Foster RD, Esserman LJ, Alvarado MD, 
Ewing CA, Hwang ES. University of California San Francisco, San 
Francisco, CA
Background: Among women with unilateral cancer, rates of 
contralateral prophylactic mastectomy (CPM) are continuing to 
increase. However, little is known about whether rates and types 
of complications differ between patients undergoing unilateral 
mastectomy or bilateral mastectomy, limiting the surgical outcomes 
evidence that can be presented in pre-surgical decision making for 
women considering CPM. This study was undertaken to determine 
whether surgical complications are increased in women undergoing 
CPM compared to those without CPM.
Methods: Between the years 2005-2010, all patients at UCSF 
undergoing mastectomy with immediate reconstruction were 
entered into a prospective database. This database was queried for 
patients with unilateral cancer who had mastectomy and immediate 
reconstruction with or without CPM. Surgical outcomes, including 
implant loss, admission for IV antibiotics, and return to OR were 
evaluated and compared between patients who did and did not undergo 
CPM. Patients with bilateral cancer or bilateral prophylactic surgery 
were excluded; analyses were limited to patients with a minimum of 
1 year follow-up.
Results: 468 patients were identified who met study criteria, totaling 
667 breasts. Mean follow-up time was 22 months (range 12 – 69 
months). 269 of the 468 (57.5%) patients had unilateral mastectomy 
only, while 199 of 468 (42.5%) patients also had CPM. There were 
no differences in tumor grade, stage, follow-up time, smoking history, 
or radiation (prior or post-surgery) between the two groups. The only 
significant differences between the unilateral and bilateral groups were 
median age at diagnosis (50.7 vs. 45.9 respectively; p < .0001) and 
receipt of neoadjuvant chemotherapy (34.7% vs. 41.3% respectively; 
p < .01). Surgical outcomes were compared between groups. The 
overall rate of major complications differed significantly due to an 
increased rate of infectious complications and unplanned return to 
surgery in the CPM group (Table 1). Nevertheless, this did not result 
in a higher implant loss rate in the CPM group.
Table 1. Complication rates in patients with and without CPM
Type of Surgery Major Complication1 Implant Loss2 IV antibiotics1
Unplanned 
Return  
to OR1
Unilateral 72/269 (26.77%) 30/269 (11.15%) 34/269 (12.64%) 63/269 (23.42%)
Bilateral 81/199 (40.7%) 31/199 (15.58%) 43/199 (21.61%) 71/199 (35.68%)
All patients 153/468 (32.69%) 61/468 (13.03%) 77/468 (16.45%) 134/468 (28.63%)
1p < .01; 2not significant
In patients undergoing bilateral mastectomy, overall complication 
rates were comparable between the index breast and the CPM breast; 
however, there was a higher implant loss rate in the index breast 
(22/177 vs. 11/188; p=0.05).
Conclusions: While CPM is an increasingly common procedure, 
it is associated with an increased risk of major post-operative 
surgical complications. In this cohort, patients undergoing bilateral 
mastectomy for unilateral cancer had higher rates of overall 
complications, greater use of IV antibiotics, and more frequent return 
to the operating room. Since the majority of CPM cases are not at 
sufficiently high risk for a second breast cancer to meet clinical criteria 
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for prophylactic surgery, guidelines and clinical recommendations 
should consider these increased complication rates when counseling 
women contemplating CPM.
PD02-02
A Decision Analysis of Contralateral Prophylactic Mastectomy 
in Women Undergoing Treatment for Sporadic Unilateral Breast 
Cancer.
Lester-Coll NH, Lee JM, Gogineni K, Hwang W-T, Schwartz JS, 
Prosnitz RG. University of Pennsylvania Perelman School of 
Medicine, Philadelphia, PA; Massachusetts General Hospital, Boston, 
MA; Abramson Cancer Center, University of Pennsylvania Perelman 
School of Medicine, Philadelphia, PA
Background:
The intent of contralateral prophylactic mastectomy (CPM) is to 
improve survival after a diagnosis of unilateral breast cancer by 
reducing the risk of contralateral breast cancer (CBC). CPM rates 
are rising among women with sporadic breast cancer, despite limited 
evidence that its benefits outweigh its harms. Although CPM is 
highly effective in reducing a woman’s risk of CBC, the competing 
mortality risk from a patient’s index breast cancer may offset its 
benefits. Furthermore, any examination of CPM needs to consider 
quality of life effects.
Methods:
We developed a Markov decision analytic model to estimate the effect 
of CPM in women with newly diagnosed unilateral breast cancer. 
The primary outcomes examined were gains in life expectancy (LE) 
and quality-adjusted life expectancy (QALE) for CPM compared 
with no CPM in 18 hypothetical cohorts of 45-year old women. 
Data from the British Columbia Cancer Agency (BCCA) was used 
to generate AJCC stage and molecular subtype-specific estimates 
of the risk of developing distant metastases from an index breast 
cancer. A correction factor was applied to account for the omission 
of relevant systemic therapy (including trastuzamab) in some women 
in the BCCA cohort. Additional model parameters, including utilities 
(quality of life weights) for breast cancer and CPM health states, 
were identified from the published medical literature. LE and QALE 
estimates were not discounted in the base case. Univariate sensitivity 
analysis was used to examine the impact of plausible variation in the 
key model parameters on model results.
Results:
CPM improved LE in all cohorts (range: 0.06 - 0.54 years, Table 1). 
AJCC stage had more effect on LE than molecular subtype (stage I 
mean, 0.43 years, stage III mean, 0.11 years). However, after adjusting 
for quality of life, a strategy of no CPM was favored in all cohorts. 
Univariate sensitivity analysis demonstrated that the only model 
parameter that influenced the outcome of QALE was the utility for 
health after CPM. In the base case the utility after CPM was 0.81 
(compared to 0.85 for No CPM). The preferred strategy did not 
change from No CPM to CPM unless the utility after CPM exceeded 
0.83. Model results were otherwise stable across the ranges of the 
key parameters examined, including the risk of distant metastases 
resulting from a patient’s index breast cancer by stage and subtype, 
duration of survival with metastatic breast cancer, and the risk of CBC.
Conclusions:
The primary drivers of survival after unilateral breast cancer are 
stage at diagnosis and molecular subtype. Our model demonstrates 
that CPM confers modest additional LE gains, even in women with 
early-stage, favorable-subtype breast cancer. Furthermore, this modest 
benefit is negated if one assumes a small reduction in quality of life 
due to CPM. The decision to pursue CPM as part of treatment of 
unilateral breast cancer should include consideration of both patient 
specific breast cancer characteristics and individual preferences.
Table 1: Gains in LE Associated with CPM in years
Molecular Subtype AJCC I AJCC II AJCC III
Luminal A 0.49 0.38 0.18
Luminal B 0.37 0.22 0.09
HER2 0.54 0.25 0.14
Luminal/HER2 0.42 0.26 0.14
Basal-like 0.37 0.14 0.04
Triple Negative Non-Basal 0.41 0.23 0.06
PD02-03
The Effect of Breast Conservation Therapy vs Mastectomy on 
Symptoms, Physical Impairments, and Function.
Kesarwala AH, Pfalzer LA, O’Meara WP, Stout NL. National Cancer 
Institute, Bethesda, MD; University of Michigan - Flint, Flint, MI; 
National Naval Medical Center, Bethesda, MD
Background: Early-stage breast cancer (BC) patients choose between 
breast conservation therapy (BCT) and mastectomy based on 
comparable recurrence rates and overall survival. In the absence of 
mortality benefit, consideration of anticipated functional impairments 
could guide decision making. Although BCT offers less extensive 
surgery, the administration of radiation therapy (RT) may adversely 
impact upper extremity (UE) function. The purpose of this analysis 
is to investigate the effect of BCT vs modified radical mastectomy 
(MRM) without RT on functional impairments among BC survivors.
Materials and Methods: 196 women diagnosed with BC between 2001-
05 were enrolled and treated in a prospective surveillance physical 
therapy program. 115 received either BCT, including lumpectomy 
and whole breast RT, or MRM without RT and were analyzed for 
this report. Participants’ UE range of motion (ROM), strength, and 
limb volume were assessed pre-operatively and at 1, 3, 6, 9, and 12+ 
months post-operatively by a physical therapist. Limb volume was 
assessed using infrared optoelectronic perometry. At 12+ months, 
overall health status, UE symptoms and function, and physical activity 
levels were reported using standardized questionnaires. Analysis 
of variance estimated differences in impairments and self-reported 
symptoms and function. One-way ANOVA analysis was used to 
determine significance between groups (p ≤ 0.05).
Results: 65 women (57.5%) received BCT and 50 women (42.5%) 
received MRM. No significant differences in age, BMI, stage, ER/
PR status, and number of dissected lymph nodes were found between 
groups. At 1 month post-operatively, shoulder internal rotation 
(p=0.03), abduction (p=0.01), and flexion (p=0.004) were worse in 
post-MRM patients, with a trend towards worse external rotation 
(p=0.06). A higher rate of axillary cording was seen in patients 
post-MRM (p=0.02). By 12+ months post-operatively, there were 
no differences in any of the shoulder ROM variables. BCT patients 
reported, however, greater weakness (p=0.03) and diminished ability 
to perform heavy household tasks (p=0.03). There was no significant 
difference between BCT vs. MRM in rates of early lymphedema (40% 
vs 38%) or seroma (14% vs 22%).
Conclusion: Functional impairments represent an important category 
of morbidity for BC survivors and should be considered in pre-
treatment decision making. Post-operative RT as part of BCT may not 
contribute significantly to impairment over the first year of treatment. 
The presence of self-reported weakness and difficulty performing 
heavy household tasks at 12+ months suggest possible future 
functional deficits, especially considering the potentially progressive 
nature of RT-associated tissue changes. Additional research is needed 
to assess longer-term changes and the impact of RT in the context of 
aggregate effects of other BC treatment modalities.
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PD02-04
A Randomized, Prospective, Multicenter Study of the Impact 
of Intraoperative Margin Assessment with Adjunctive Use of 
MarginProbe vs. Standard of Care.
Schnabel F, Tafra L, The MarginProbe Study Group. NYU Langone 
Medical Center, New York, NY; The AAMC Breast Center, Annapolis, 
MD; Dune Medical Devices
Background: The current practice of breast conserving surgery (BCS) 
involves intraoperative margin assessment according to the surgeon’s 
gross assessment and judgment. The failure of this intraoperative 
assessment has been associated with a 20-30% reoperation rate to 
assure negative margins. MarginProbe (Dune Medical Devices) was 
developed to provide real-time assessment of lumpectomy specimens 
to evaluate for the presence of disease at the surgical margins. A 
21-center international pivotal study was conducted to determine 
if adjunctive use of MarginProbe can enable surgeons to identify 
positive margins intraoperatively, resulting in fewer patients who are 
candidates for re-excision procedures.
Methods: 664 women with non-palpable lesions undergoing 
lumpectomy for DCIS and invasive cancer were enrolled and 596 
randomized (1:1) in the operating room following standard of care 
(SOC) lumpectomy. In the device arm, MarginProbe was used 
to assess all surfaces of the lumpectomy specimen and positive 
readings required additional resections. All specimens were inked 
in the operating room by the surgeon. All specimens were examined 
to verify excision of the target lesion intraoperatively. Pathologists 
were blinded to study arm. Additional surgeries to re-excise involved 
margins were performed per each individual site criteria. Patients 
were followed for 2 months following surgery; additional procedures 
were documented. Safety was assessed by reports of adverse events.
Results: No safety concerns were raised. Of the 298 patients in each 
arm, 55% (163/298) patients in the device arm (D) and 49% (147/298) 
in the control arm (C) had at least one positive margin on the main 
lumpectomy specimen (≤ 1mm). Surgeons’ ability to identify and 
resect all positive margins per patient was significantly improved 
with device use (D: 72% (117/163), C: 22% (33/147); p < 0.0001). 
Following lumpectomy, the number of patients having positive 
margins due to failed intraoperative assessment (excluding skin or 
fascia) was reduced by 57% in the device arm (D: 42/298(14%), C: 
98/298(32.8%), p<0.0001), leading to a 50% reduction in re-excisions 
for this group (D: 31/298 (10.4%), C: 62/298 (20.8%); p=0.001). 
There was no significant difference in tissue volume removed (D: 
93cc, C: 85cc; 25cc non-inferiority delta, p <0.0001). Normalized to 
baseline breast size, tissue volume in the device arm was non-inferior 
to the control arm (D: 15.1%, C: 12.5%, 5% non-inferiority delta, p 
<0.0001). For patients having at least one positive margin prior to 
intraoperative assessment, there was a trend in the device arm towards 
smaller average tissue volume resected to achieve clear margins (D: 
99cc, C: 108cc; p=0.6).
Conclusions: Adjunctive use of MarginProbe during BCS significantly 
improved surgical outcomes by improving surgeons’ ability to identify 
and immediately resect positive margins, reducing the number of 
patients requiring re-excision. Overall tissue volume removed was 
not statistically different in the two arms. Patients in the device arm 
who had positive margins prior to intraoperative assessment had less 
average tissue volume removed and required fewer re-excisions to 
achieve appropriate margins.
PD02-05
MRI Phenotype and Tumor Subtype Affect Breast Conservation 
Eligibility and MRI Accuracy in the I-SPY 1 Trial.
Mukhtar RA, Hylton N, Rosen M, The I-SPY 1 Trial Investigators, 
ACRIN 6657 Investigators, Esserman LJ. UCSF; University of 
Pennsylvania; I-SPY 1 Trial; ACRIN 6657
Background
Neoadjuvant chemotherapy (NAC) in breast cancer allows assessment 
of response to treatment and increases eligibility for breast 
conservation treatment (BCT). We previously reported that MRI 
tumor phenotype (based on loss of containment) predicted response 
to NAC and ability to achieve BCT. Since tumor subtype can affect 
MRI features, we sought to validate whether MRI phenotype and/or 
tumor subtype affected BCT eligibility in a prospective trial, I-SPY 
(CALGB 150007/ACRIN 6657). We also investigated the accuracy of 
post-NAC MRI in determining BCT eligibility, and the distribution of 
tumor subtypes within MRI phenotypes with the goal of identifying 
clinically useful factors associated with successful BCT.
Methods
We analyzed I-SPY 1 Trial data, a multi-center, prospective NAC trial 
with serial MRIs. Phenotypes 1 and 2 were well defined masses, while 
3, 4, and 5 were more diffuse. Subjects were considered truly eligible 
for BCT if tumor diameter on surgical pathology was ≤ 4 cm (based 
on NSABP B-06 trial criteria). Post-NAC MRI and surgical pathology 
were considered discrepant if longest tumor diameter differed by > 2 
cm. Categorical variables were compared using the chi-squared test.
Results
Of the 221 subjects, 198 had pre and post-NAC MRIs, and surgical 
pathology available. Of these, 174 had a tumor diameter > 4 cm 
prior to NAC, and were considered initially ineligible for BCT. After 
NAC, 141 (81%) patients became BCT eligible based on having <4 
cm of residual tumor. In contrast, 46 (26%) had pathologic complete 
response (pCR, no invasive tumor). The rate of becoming BCT eligible 
differed by hormone receptor (HR)/Her2 status (p = 0.005) and MRI 
phenotype (p = 0.037), with higher rates of eligibility in Her2+ and 
triple negative tumors, and the well defined MRI phenotypes. Overall, 
75 (38%) patients had a size discrepancy between tumor diameter 
on post-NAC MRI and size on surgical pathology. Subjects with 
diffuse MRI phenotypes had more size discrepancy than phenotypes 
1 and 2 (p = 0.001). Subjects with HR+/Her2- tumors also had more 
size discrepancy than other subtypes (p = 0.004). The more diffuse 
MRI phenotypes were more commonly HR+/Her2- tumors, and less 
commonly HR-/Her2- (p = 0.006). There was no difference in actual 
receipt of BCT by HR/Her2 status. However, patients with a well-
defined MRI phenotype were significantly more likely to actually 
receive BCT than those with a diffuse MRI phenotype (47% versus 
27%, p = 0.023).
Conclusions
Patients with well defined patterns on MRI and with Her2+ or 
triple negative disease were more likely to become eligible for BCT 
after NAC. The same factors that predict pCR also predict BCT 
eligibility, but far more patients achieve BCT eligibility than pCR. 
MRI after NAC was less accurate in the diffuse phenotypes, which 
could reflect increased difficulty in measuring tumor size in this 
setting. Tumor phenotype and subtype can help predict likelihood of 
achieving eligibility for BCT, and can be useful in setting appropriate 
expectations for women at the start of NAC.
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PD02-06
Outcomes after Total-Skin Sparing Mastectomy and Immediate 
Reconstruction in 657 Breasts.
Warren Peled A, Stover AC, Foster RD, Alvarado MD, Ewing CA, 
Hwang ES, Esserman LJ. University of California, San Francisco
INTRODUCTION: Total skin-sparing mastectomy (TSSM) is 
increasingly offered to women for both therapeutic and prophylactic 
indications. When combined with immediate breast reconstruction, 
patients can achieve excellent aesthetic results and high satisfaction. 
However, the oncologic safety of the procedure remains controversial. 
Further, the technique can be associated with higher rates of post-
operative ischemic complications. We conducted this study to 
determine oncologic and ischemic outcomes in a large cohort of 
patients undergoing TSSM and immediate reconstruction.
METHODS: Patient and tumor characteristics and treatment details 
were collected in a prospectively maintained database. All patients 
undergoing TSSM and immediate breast reconstruction at our 
institution from 2001 to 2010 were included in the analysis. The 
development of any post-operative complications or local or distant 
recurrence was determined.
RESULTS: TSSM with immediate reconstruction was performed 
in 428 patients for a total of 657 breasts. Mean patient age was 
46.9 years. 210 patients (49%) had neoadjuvant chemotherapy for 
locally advanced disease. 114 patients (26.7%) had post-mastectomy 
radiation therapy. 54% of patients had bilateral mastectomies. 
Prophylactic mastectomies (either unilateral or bilateral) accounted 
for 244 (37.1%) of cases, which included bilateral mastectomies in 15 
patients (30 cases) who were known BRCA-1 or -2 mutation carriers. 
Expander-implant reconstruction was performed in 80% of the cases, 
while the rest of the cases involved autologous reconstruction (15.3%) 
or immediate implant placement (4.7%). On pathologic examination, 
nipple tissue from 11 breasts (1.7%) contained in situ cancer and from 
9 breasts (1.4%) contained invasive cancer; re-excision was performed 
in 7 of these cases, the nipple-areolar complex was removed entirely 
in 9 cases, and radiation therapy was given without further excision 
in the rest of cases. Ischemic or necrotic post-operative complications 
included 13 cases (1.9%) of partial nipple loss, 10 cases (1.5%) of 
complete nipple loss, and 78 cases (11.8%) of skin flap necrosis or 
incisional dehiscence. At a median follow-up of 23 months (range 
3-116 months), 5 patients (1.2%) had developed a local recurrence 
alone, 10 patients (2.4%) had developed a distant recurrence alone, 
and 6 patients (1.4%) had developed both loco-regional recurrence 
and distant metastases. In the subset of patients with at least 3 years’ 
follow-up, rates of local and of distant recurrence were 1.7% at a 
median of 45 months follow-up. None of the patients who underwent 
bilateral prophylactic mastectomy for BRCA-1 or -2 mutations 
developed subsequent breast cancers.
CONCLUSIONS: In this large, high-risk cohort, TSSM was 
associated with low rates of nipple involvement and loco-regional 
recurrence. Ischemic complications, although uncommon, often 
resulted in nipple loss. These short-term outcomes are encouraging, 
although longer follow-up will be important for confirmation of long-
term oncologic safety. Serial improvements in surgical technique can 
improve selection criteria and reduce post-operative complication 
rates.
PD02-07
Models Predicting Non-Sentinel Node Involvement in Breast 
Cancer Also Predict for Regional Recurrence If the Axilla Is 
Not Treated.
Pepels M, Vestjens H, de Boer M, Bult P, van Dijck J, Mencke M, 
van Diest P, Borm G, Tjan V. Maastricht University Medical Centre; 
Radboud University Nijmegen Medical Centre; Erasmus Medical 
Centre Rotterdam; University Medical Centre Utrecht
Background 
Series on breast cancer patients with sentinel node (SN) isolated 
tumor cells or micrometastases show low recurrence rates in the 
presence of SN isolated tumor cells, and varying recurrence rates in 
the presence of SN micrometastases. Non-SN prediction models are 
frequently used as a decision aid to identify patients that may not 
need axillary treatment, but this still needs to be validated in respect 
to regional recurrence.
Patients and Methods 
We followed a cohort of 486 patients in the MIRROR-study of 
whom none received axillary treatment with favorable primary tumor 
characteristics and pN0(i+)(sn) or pN1(mi)(sn) for a median of 5 
years. The patients were categorized into low or high-risk subgroups 
based on several published non-SN prediction models (cut-off levels 
between models varied from 3 to 10%), i.e. the Tenon Scoring system, 
MSKCC nomogram, Stanford nomogram and a Dutch model (Bolster 
et al.). The primary endpoint was 5-year regional recurrence-free 
survival.
Results
The overall 5-year regional recurrence rate was 3.0% (+/- 0.1%). 
Using the Tenon scoring system, we identified 438 patients with a 
low risk score of 3.5 or lower with a 5-year regional recurrence rate of 
2.3% (+/- 0.8%), compared to a recurrence rate of 10.1% (+/- 0.4%) 
in 48 patients with a score above 3.5. For the MSKCC nomogram a 
low risk score of 0.10 or lower identified 300 patients with a 5-year 
recurrence rate of 2.8% (+/- 1.1%), and a score above 0.10 identified 
166 patients with a recurrence rate of 3.4% (+/- 1.5%) (20 patients not 
assessable). By the Stanford nomogram a low risk cutoff level of 10% 
identified 21 patients without recurrence, whereas 465 patients had 
a 3.2% (+/-0.9%) recurrence rate. Using a Dutch model, a low risk 
cutoff score of 20 discriminated between 384 patients with a 5-year 
recurrence rate of 2.2% (+/- 0.8%) and 102 patients with a recurrence 
rate of 6.3% (+/- 2.9%). Further analyses with different cut-off values 
and subgroups will be presented at the conference.
Conclusion 
Using several published non-SN prediction models for predicting 
regional recurrence, the Tenon scoring system outperformed the other 
models in that it identified the largest subgroup of patients with a low 
recurrence rate. We would recommend axillary treatment in patients 
classified as high risk according to the Tenon score.
Funding: Netherlands Organization for Health Research and 
Development (ZonMw 945-06-509).
PD02-08
Validation over Time of a Nomogram Predicting the Sentinel Node 
Positivity in Early Breast Carcinoma According to the Molecular 
Subtypes Classification.
Ngô C, De Rycke Y, Mouttet D, Reyal F, Fourchotte V, Hugonnet F, 
Falcou M-C, Bidard F-C, Vincent-Salomon A, Fourquet A, Sigal-
Zafrani B, Alran S. Institut Curie, Paris, France
Background: The molecular subtypes of breast cancer have different 
axillary status. A new nomogram including the interaction covariate 
between estrogen receptor (ER) and HER2 status has been recently 
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published (Reyal et al. PLOSone, may 2011) and allows to identify 
before surgery the patients with a high risk of positive sentinel lymph 
node (SLN). The purpose of our study was to validate this model on 
an independent population.
Patients and methods: We studied 755 consecutive patients 
treated for operable breast cancer with sentinel node biopsies in 
2009, from the Institut Curie breast cancer prospective database. 
Baseline characteristics were compared between our population and 
the population used to build the model, using Chi-square test for 
categorical variables and Kruskal-Wallis test for continuous variables. 
The multivariate model, including age, tumor size, lymphovascular 
invasion and interaction covariate between ER and HER2 status, 
was used to calculate the theoretical risk of positive sentinel lymph 
node (SLN) for all patients. The performance of the model on our 
population was then evaluated in terms of discrimination (area under 
the curve AUC) and of calibration (Hosmer-Lemeshow HL test).
Results: Characteristics of our population were significantly 
different from the training population for the following variables: 
tumor size (median 12mm [1-60] versus 13mm [1-100] p=0.005), 
lymphovascular invasion (18.6% versus 23.7% p=0.006), positive 
ER (91.4% versus 87% p=0.002) and age as followed: 56.7% of 
patients < 60 versus 63.1%, 17.5% of patients between 60 and 65 
versus 14.1% and 25.8% of patients above 65 versus 22.8% p=0.01. 
The nomogram showed similar results in our population than in the 
training population in terms of discrimination (AUC= 0.72 [0.68-0.76] 
versus 0.73 [0.7-0.75] and calibration (HL p= 0.4 versus p=0.35).
Conclusions: Despite significant differences between the two 
populations concerning variables which are part of the nomogram, 
the model was validated in our population. Our study shows that this 
nomogram is efficient and robust over time to predict the likelihood 
of positive SLN according to molecular subtypes defined by surrogate 
markers ER and HER2 determined by immunohistochemistry in 
clinical practice.
PD02-09
Withdrawn by Author
PD03-01
An Integrated Analysis of Three Distinct IBC/nIBC Affymetrix 
Gene Expression Data Sets Further Unveils the Molecular Biology 
of IBC.
Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A, Birnbaum 
D, Robertson FM, van Dam PA, Woodward WA, Viens P, Dirix LY, 
Reuben JM, Iwamoto T, Cristofanilli M, Bertucci F. Oncology Center 
- GH Sint-Augustinus, Wilrijk, Antwerp, Belgium; The University 
of Texas MD Anderson Cancer Center, Houston, TX; Institut 
Paoli-Calmettes (IPC), Marseille, France; World IBC Consortium; 
Contributed Equally
Introduction. Several studies have applied gene expression profiling 
to inflammatory breast cancer (IBC). Most of these studies were 
underpowered. Here, we present an integrated analysis of 3 distinct 
gene expression data sets of IBC and non-IBC (nIBC) samples to 
further uncover the IBC-specific molecular biology with enhanced 
statistical power.
Materials & Methods. Three Affymetrix gene expression data sets 
were combined, resulting in a series of 137 IBC and 252 nIBC 
samples. IBC was diagnosed clinically. Each sample was classified 
according to several published gene signatures. Transcriptional 
heterogeneity was investigated using hierarchical clustering, 
coupled with silhouette score analysis. IBC-specific, molecular 
subtype-independent differences in gene expression were identified 
using linear regression modeling. Differentially expressed genes 
were translated into pathways using Ingenuity Pathway Analysis. 
Cox regression analysis was used to identify variables influencing 
distant metastasis-free survival (DMFS) in IBC. Finally, we focussed 
on the molecular aspects of pathological response to neodjuvant 
chemotherapy in patients with IBC.
Results. In our series of IBC samples, 4 robust sample clusters were 
identified. These sample clusters were mainly associated with the 
different molecular subtypes (P<0.0001), all of which were identified 
in IBC with a similar prevalence in nIBC, except for the Luminal A 
subtype (9% vs. 40%; P<0.0001) and the ErbB2+ subtype (23% vs. 
8%; P=0.0002). A total of 632 genes were differentially expressed. 
Analysis of this gene list identified an IBC-repressed network centered 
on TGFb. Activated TGFb-profiles and SMAD-profiles in the nIBC 
samples corroborated these findings. Consistent with published poor 
prognosis signatures, current survival analysis indicated that the 
molecular subtypes are significantly associated with prognosis in IBC. 
Surprisingly, in IBC, the Luminal A samples exhibited the shortest 
DMFS-interval (HR=4.02; P<0.05). Comparison of responders and 
non-responders to neoadjuvant chemotherapy suggests a prominent 
role for inflammation/immunity-related processes in determining the 
efficacy of neoadjuvant chemotherapy in IBC.
Conclusions. IBC, like nIBC, is transcriptionally heterogeneous 
as exemplified by the identification of 4 robust sample clusters in 
the present series. This observation is further corroborated by the 
identification of all known molecular subtypes in IBC, albeit with 
a different distribution pattern characterized by a low frequency of 
Luminal A samples. Nevertheless, this phenotype is clinically relevant, 
as demonstrated by the poor prognosis profile. Our observations can 
be explained by the IBC-specific repression of TGFb, which is a key 
molecule of epithelial-to-mesenchymal transition and is also known 
to prevent ER-expressing cells from proliferating. Finally, as in nIBC, 
inflammation- and immunity-related processes are important aspects 
of response to neoadjuvant chemotherapy in IBC.
PD03-02
Prognostic and Predictive Predictors for Triple Negative Breast 
Cancer.
Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Schmidt M, Müller V, 
Gätje R, Hanker L, Ahr A, Holtrich U, Rody A, Kaufmann M. Goethe 
University, Frankfurt, Hessen, Germany; University of Texas M.D. 
Anderson Cancer Center, Houston, TX; University of Münster; 
University of Mainz; University Hospital Hamburg-Eppendorf; 
Saarland-University
Background: Both the prognosis and the therapeutic options in triple 
negative breast cancer (TNBC) are rather limited. Current prognostic 
gene expression profiles for breast cancer mainly reflect proliferation 
status and are most useful in ER-positive cancers. The identification 
of prognostic gene signatures from TNBC cohorts in previous studies 
was hindered due to relatively small sample sizes.
Materials and Methods: All currently available TNBC gene expression 
datasets generated on Affymetrix U133 gene chips were assembled. 
To minimize inter-laboratory variation we analyzed only highly 
comparable arrays and data set-biased genes were filtered. Supervised 
analysis was applied to identify a prognostic signature from a finding 
cohort of 394 TNBC and validation was performed in an independent 
cohort of 261 TNBC. The genes from the prognostic predictor were 
analyzed for their correlation to known molecular phenotypes among 
TNBC.
Results: Two supervised prognostic signatures consisting of 264 
and 26 probesets, respectively, were obtained when applying 
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different cutoffs for false discovery rates of 25% and < 3.5% in 
the finding cohort. In multivariate analysis in the independent 
validation cohort hazard ratios of 4.03 (95% CI 1.71-9.48; P=0.001) 
and 4.08 (95% CI 1.79-9.28; P=0.001), respectively, were obtained 
for the two signatures. When compared to 16 metagenes for 
previously described molecular phenotypes in TNBC the prognostic 
signatures displayed highest correlation to metagenes for IL-8/
inflammation, VEGF/angiogenesis, and Histones. A subset of genes 
in the 264-probeset signature was inversely associated with a poor 
prognosis (29/264=11.0%). Most of these “good prognosis” genes 
are correlated with immune cell metagenes (21/29=72.4%). In 
contrast both identified supervised prognostic signatures did not 
correlate to previously published prognostic signatures (recurrence 
score, genomic grade index, Amsterdam signature, wound response 
signature, 7-gene immune response module, stroma derived 
prognostic predictor, and a medullary like signature). Regarding the 
response of TNBC to neoadjuvant chemotherapy the predictive value 
of the B-cell metagene was superior to the 264- and 26-probeset 
signatures. However combination of the B-cell metagene and the 
signatures increased the AUC in ROC-analysis from 0.606 to 0.656.
Conclusions: The use datasets consisting only of TNBC allows 
identification supervised prognostic signatures for TNBC which are 
unrelated to previously known prognostic signatures.
PD03-03
Identification of Transcription Factors Critical for the Growth 
of Basal Breast Cancer.
Shepherd JH, Mazumdar A, Tsimelzon A, Hilsenbeck SG, Brown PH. 
Baylor College of Medicine, Houston, TX; The University of Texas 
MD Anderson Cancer Center, Houston, TX
Background: Basal breast cancers are aggressive, poor prognosis 
tumors that occur commonly in young women and in African 
American women. Profiling of breast tumor mRNA has demonstrated 
that there are differences in gene expression between the basal and 
luminal subtypes of breast cancer. In this study, we identified response 
elements in the genes that define basal breast cancers, and identified 
transcription factors that are critical for the growth of basal breast 
cancer cells.
Materials and Methods: We performed promoter analysis using 4 
published microarray studies (PMID: 12829800; PMID: 19435916; 
PMID: 17157792; PMID: 11562467) to select genes that are highly 
expressed in basal tumors compared to luminal tumors. For this 
analysis we selected 61 genes highly expressed in a set of basal 
tumors in any of the 4 microarray studies. We next used the online 
tool, CORE_TF, along with the MATCH algorithm minimizing for 
the sum of false positives and false negatives to identify binding 
motifs within the promoter (defined from -1 kb to the first exon) of 
each gene. The frequency of binding motif occurrence for these 61 
basal genes was compared to the frequency within the promoters 
of 3000 randomly selected genes. Significance was tested using 
an exact binomial test with a cutoff of p<0.05. RNA expression of 
motif-identified transcription factors was then analyzed in-silico 
using all 10 datasets in Oncomine™ that contained annotation for 
triple-negative status. Expression in triple negative samples was 
compared to expression in non-triple-negative samples with a cutoff of 
p <0.05 . We next performed siRNA knockdown studies to determine 
whether the identified TFs regulate basal breast cancer growth. Basal 
and luminal cells transfected with control and specific siRNAs were 
grown in triplicate and mean cell counts at day 6 were compared.
Results: Promoter analysis identified 24 binding motifs that were 
over-represented in basal breast tumor genes compared to a random 
set of 3000 genes. TransFac analysis indicated that 47 transcription 
factors bind the 24 identified motifs. Oncomine analysis showed 
that 8 of the 47 transcription factors were significantly more highly 
expressed in basal as compared to non-basal tumors. Identified 
transcription factors include FOXC1, FOXM1, CDC5L, E2F3, CEBP 
and NF-Y. siRNA to FOXM1 in 2 basal breast cell lines reduced 
growth by >70% after 6 days, whereas, in the luminal cell line MCF7, 
growth was reduced by 15%.
Discussion: This study identified transcription factors that are highly 
expressed in basal breast tumors (as compared to non-basal breast 
tumors). siRNA knockdown studies showed that FOXM1 is critical for 
basal breast cancer cell growth. These results suggest that transcription 
factors highly expressed in basal breast cancers may be novel targets 
for the treatment of this disease.
These studies were supported by a Promise grant from the Susan G. 
Komen for the Cure (PB, SGH), and by the Norman E. Brinker Award 
for Research Excellence (PB).
PD03-04
SuperPathway Analyses of Luminal and Basaloid Breast Cancers 
from the Cancer Genome Atlas (TCGA) Program.
Yau C, Benz S, Sanborn JZ, Stuart J, Haussler D, Benz C. Buck 
Institute for Research on Aging, Novato, CA; UC Santa Cruz, Santa 
Cruz, CA
The biological and clinical heterogeneity of breast cancer is clearly 
evident by its different intrinsic transcriptome subtypes. With 
exception of the HER2 subtype, pathways and signaling networks 
driving and distinguishing the other major breast cancer subtypes 
(basaloid, luminal-A, luminal-B) remain largely undefined. As of April 
2011, >300 TCGA breast cancer samples have been characterized by 
both genomic copy number analysis and mRNA expression profiling 
(44% luminal-A, 26% luminal-B, 16% basaloid). As well, overall 
survival (OS) data are presently available on 104 luminal-A and 52 
luminal-B cases, showing significantly poorer outcome for the latter of 
these hormonally driven subtypes (log rank p<0.05). Since the poorer 
outcome of luminal-B breast cancers may be due to their harboring 
more TP53 gene mutations (~34%), we used a gene expression 
signature reported for TP53 mutated estrogen receptor-positive (ER+) 
breast cancers (Coutant et al., 2011), and confirmed that the TCGA 
luminal-B cases significantly overexpress this signature relative to 
luminal-A breast cases in which TP53 mutations are uncommon 
(6%). Curiously, within each luminal subtype, while this signature 
correlated with TP53 mutations it did not correlate with TP53 loss of 
heterozygosity (LOH), which was also higher in luminal-B (~30%) 
relative to luminal-A (~10%) cases. We used the network analysis 
tool PARADIGM (Vaske et al., Bioinformatics 26, i247-245) to 
integrate both DNA copy number and transcriptome data and infer 
pathway activity and interaction differences between luminal-A and 
luminal-B cases, and between the luminal and basaloid subtypes. 
This tool merges features derived from curated signal transduction, 
transcriptional and metabolic pathways into a Superimposed Pathway 
(SuperPathway) containing ~3.1K unique activities, 1820 of which 
revealed significant differences among the breast cancer subtypes 
(Kruskal-Wallis test, Benjamin Hochberg FDR-corrected p <0.05). 
From the significant pathway activities differentiating basaloid from 
luminal-A (1399) or luminal-B (1122) subtypes, assessed using 
two independent approaches (functional enrichment/EASE scores, 
subnetwork analysis and hub interconnectivity >10 edges), higher 
FOXA1 (ER signaling) and lower HIF1A/ARNT transcription factor 
hub activities emerged as shared luminal differences relative to 
basaloid breast cancers. Of the 433 significant activities differentiating 
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luminal-A from luminal-B subtypes, MYC/MAX, FOXM1, and 
MYB emerged as more active hubs in luminal-B, with normal TP53 
function as a more active hub in luminal-A breast cancers. In sum, 
these TCGA analyses offer further insights into the signaling pathways 
differentiating basaloid from luminal breast cancers, and reveal major 
transcription factor hubs distinguishing the two common hormone 
dependent subtypes, luminal-A and luminal-B breast cancers. These 
findings suggest that SuperPathway analyses may inform therapeutic 
target opportunities and promote clinical development of breast cancer 
subtype specific treatment regimens.
PD03-05
Withdrawn by Author
PD03-06
Basal-Like Breast Tumors Are Associated with Frequent Micro 
Genomic Aberrations in Important Cancer Genes.
Chao H-H, He X, Perou CM. University of North Carolina - Chapel 
Hill, Chapel Hill, NC
Background: The basal-like subtype has been shown to have increased 
genomic instability relative to other breast cancer subtypes and this 
may reflect processes involved in the pathogenesis of this disease. 
Basal-like tumor specific regions of aberration have previously been 
identified by large-scale genomic analyses in terms of cytobands 
and specific genes such as RAD17, RAD50 and chr 10p. There is, 
however, some evidence that these subtype associated genomic events 
extend to smaller scale genomic aberrations as well. A previous study 
(Saal et al, 2008) described one such event in the Basal-like SUM149 
breast cancer cell, which contains a small amplification in exon 2 of 
the PTEN gene. We suspect that primary breast tumors may harbor 
similar events, and that these events may have previously been 
undetectable using the current generation of whole genome copy 
number arrays. In this study, we sought to identify small regions of 
genomic change that might contribute to the tumor development of 
primary breast tumor by high density, gene centric CGH arrays on 
both cell lines and primary tumors and then validate the presence of 
these regions using mRNA-seq.
Methods: A custom Agilent tiling array for CGH (244,000 probes 
at a 200bp tiling resolution) was created to identify small regions 
of genomic change, and was focused on previously identified basal-
specific regions and genes. One important application of this array is to 
refine common regions of DNA copy number variations in basal-like 
breast tumors and discover small-scale genomic changes unable to be 
detected by lower-resolution genome wide arrays. Tumor genomic 
DNA from 100 patients and 10 breast cancer cell lines was labeled and 
hybridized to these arrays. Log intensity ratio plots were generated for 
each sample for each gene (128 different genes tested) and analyzed 
for copy number changes. mRNA-seq was also performed on a subset 
of these samples (14 tumors, 4 cell lines).
Results: We confirmed the presence of the PTEN micro-amplification 
in SUM149 and by using mRNA-seq, also showed that this resulted in 
loss of expression of all exons downstream of this event. In addition 
to large-scale amplifications and deletions, our data also showed that 
primary tumor breast cancer genomes frequently contain areas of 
small-scale copy number gains and losses, termed microevents. The 
genomic landscape of the basal-like subtype also exhibited many of 
these microevents, as basal-like tumors have the highest incidence 
of these events. Conversely, Luminal A tumors, the subtype with the 
most stable genome, exhibited the lowest numbers of microevents 
and lowest numbers of gross copy number aberrations. Our results 
also indicated that RB1 and PTEN, two genes known to be involved 
in basal-like breast tumor formation, showed a particularly high 
incidence of these microevents. These microevents may alter 
expression of the involved gene as well, as suggested by data from 
microarray and mRNA-seq studies.
Conclusion: Using a high probe density, gene-centric aCGH 
microarray, we present evidence of small-scale genomic aberrations 
that may contribute to gene inactivation, and thus, genomic instability 
and tumor formation through a mechanism not detected using 
conventional copy number analyses.
PD03-07
Breast Cancer Heterogeneity and Treatment Resistance: Clues 
from Metaplastic Tumors.
Felding-Habermann B, O’Sullivan DM, Lorger M, MacDermed D, 
Fernandez-Santidrian A, Steele JB, Telli ML, Jeffrey SS, Murray S, 
Torkamani A, Cunliffe H, Vaughn SV. The Scripps Research Institute, 
La Jolla, CA; Scripps Clinic, La Jolla, CA; Stanford University, 
Stanford, CA; Translational Genomics Research Institute, Phoenix, 
AZ
At late stage, nearly all breast cancers are heterogeneous and refractory 
to treatment, like metaplastic breast cancer is at an early stage. These 
rare carcinomas are highly aggressive and de-differentiated. They are 
enriched for mesenchymal and stem cell features and essentially fail 
current therapies. As metaplastic tumors provide a time-compressed 
picture of breast cancer progression early on, understanding these 
tumors will yield insight into mechanisms that drive breast cancer 
into advanced stages and treatment resistance.
To investigate a genetic basis for heterogeneity in metaplastic breast 
cancer, we established a progression model comprising three cell lines. 
The cell lines were derived from a primary tumor, a local recurrence 
and a pleural effusion of a 40-year old patient. The primary tumor was 
a stage III invasive metaplastic, triple negative, inflammatory breast 
cancer, resected after neoadjuvant chemotherapy (capecitabine and 
taxotere, then adriamycin and one cycle of bevacizumab). The local 
recurrence, biopsied seven months post mastectomy, developed after 
the patient received adjuvant carboplatin and gemcitabine for 3 cycles 
and then radiation to the chest wall. At this time, the patient had lung 
metastases and was treated with taxol and bevacizumab yielding a 
mixed response. Local invasive growth continued and a malignant 
pleural effusion developed four months later. Analyzing the genetic 
and molecular characteristics of this progression model in vitro, its 
tumorigenicity and metastasis in vivo, and interrogating lead findings 
in a growing collection of metaplastic tumors helps us to dissect the 
genetic heterogeneity in breast cancer, and potentially to identify the 
cell types that drive disease progression and treatment resistance.
Our gene expression analyses and genomic evaluations identified 
epithelial to mesenchymal transition (EMT) as a key characteristic 
in the progression and treatment resistance of this cancer. Major 
changes in cytoskeletal genes, chemokines and their receptors, 
amplification of drug transporter proteins, metalloproteinases and 
matrix proteins seen with increasing motility and invasiveness along 
with recruitment of host inflammatory responses in the in vivo model, 
loss of chromosomal regions harboring known and putative tumor 
suppressors, and deletions of genes encoding proteins for metabolic 
inactivation of sex hormones in the breast tissue, along with specific 
loss of clusters of desmosomal genes are guiding our understanding 
of metaplastic breast cancer progression. The results provide insight 
into the development, the extremely invasive nature, and treatment 
resistance of these tumors. Our collaborative network of clinicians, 
pathologists, translational genomic researchers and bioinformatics 
specialists will enable us to identify and prioritize genetic events as 
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disease drivers, prognostic biomarkers of disease progression, and 
determinants of treatment resistance. Our goal is to identify molecular 
and functional targets for effective therapy and evaluate them in the 
clinic. Lessons learned from metaplastic breast cancer will improve 
our understanding of breast cancer progression in general, and could 
translate into effective treatments for advanced breast cancer where 
current standard of care is failing.
PD03-08
BRCA1-Like Triple Negative Tumors: Clinicopathological 
Variables and Chemosensitivity to Alkylating Agents.
Wesseling J, Lips EH, Oonk AMM, Smits RM, van Rijn CCM, Mulder 
L, Laddach N, Savola SS, Wessels LFA, Nederlof PM, Rodenhuis S, 
Imholz ALT. Netherlands Cancer Institute-Antoni van Leeuwenhoek 
Hospital, Amsterdam, Netherlands; Deventer Hospital, Deventer, 
Netherlands; MRC-Holland, Amsterdam, Netherlands
Background
Our group has previously employed array Comparative Genomic 
Hybridization (aCGH) to assess the genomic patterns of BRCA1-
mutated breast cancers. It is reasonable to assume that this pattern 
indicates ‘BRCAness’ and thus serves as a marker for homologous 
recombination deficiency. This BRCA1-like aCGH profile is also 
present in about half of all triple negative sporadic breast cancers 
and has been shown to be predictive for benefit from intensive 
chemotherapy with DNA crosslinking agents. To study BRCA1-like 
tumors and conventional dose chemotherapy sensitivity in more 
detail, we compared clinical factors and survival rates in a uniform 
cohort of triple negative breast tumors treated with alkylating agents.
Patients and methods
103 patients with triple negative tumors received conventional dose 
adjuvant chemotherapy with doxorubicin/cyclophosphamide. DNA 
was extracted from tumor samples and BRCA1-like profiles were 
assessed. Tumors were classified as BRCA1-like or non-BRCA1-like. 
Standard clinical and histopathological factors were determined and 
compared between both groups. Relapse free survival (RFS), disease 
specific survival (DSS) and overall survival (OS) after diagnosis 
were compared between BRCA1-like and non-BRCA1-like tumors.
Results
66 tumors (65%) had a BRCA1-like profile, while 35 tumors (35%) 
did not show such a profile. Patients with BRCA1-like tumors tended 
to be younger and had more often node-negative disease compared 
to the patients with non-BRCA1-like tumors (p=0.058 and p=0.034, 
respectively). There was no significant difference in survival between 
BRCA1-like and non BRCA1-like patients after treatment with 
alkylating agents: the median RFS was 121 vs. 109 months, median 
DSS was 129 vs. 114 months and OS was 127 vs. 110 months, for 
BRCA1-like versus non-BRCA1-like tumors. T-stage was the only 
variable significantly associated with survival.
Conclusion
BRCA1-like tumors occurred in younger patients and were more 
often node negative, which are features shared with tumors in 
BRCA1-mutation carriers. We did not observe a difference in survival 
between BRCA1-like and non-BRCA1-like triple negative breast 
cancers after treatment with conventional dose chemotherapy with 
alkylating agents. These results confirm our previous findings that 
BRCA1-like tumors have similar sensitivity to anthracycline-based 
adjuvant chemotherapy as other triple-negative tumors. It will be 
important to establish whether BRCA1-like tumors also share the 
exquisite sensitivity of BRCA-mutated tumors to PARP-inhibitors.
PD03-09
Breast Cancer Recurrence Risk Probed by Whole Transcriptome 
Next Generation Sequencing in 136 Patients.
Baker J, Liu M-L, Crager M, Stephans J, Pho M, Jeong J, Scott 
A, Ambannavar R, Morlan J, Pelham R, Qu K, Mena RR, Esteban 
J, Collin F, Sinicropi D. Genomic Health Inc., Redwood City, CA; 
Providence St. Joseph Medical Center, Burbank, CA
Background: RNA biomarkers discovered by RT-PCR-based gene 
expression profiling of archival formalin-fixed paraffin-embedded 
(FFPE) tissue are the basis for very precise and sensitive clinical 
diagnostic tests, such as the 21 gene Oncotype DX® breast cancer 
assay. Both inherent limits of technical scalability and the small 
amounts of patient FFPE RNA available place practical constraints 
on the number of transcripts that can be interrogated by RT-PCR. 
We developed new methods for RNA profiling through massively 
parallel “next generation” sequencing (RNA-Seq) of archival 
FFPE specimens. We report here the technical performance of this 
methodology and compare the results to RT-PCR results obtained in 
one of the studies that were carried out to develop the 21 gene assay.
Methods: RNA was extracted in 2002 from 136 invasive breast tumors 
that were formalin-fixed and paraffin-embedded between 1990 and 
1997. RNA-Seq was carried out using minor modifications to methods 
we have reported previously (Sinicropi et al., Advances in Genome 
Biology and Technology Conference, p. 170, 2010 and p. 198, 2011). 
Briefly, 0.1 mg of total RNA was selectively depleted of ribosomal 
RNA and sequencing libraries were prepared using a modification 
of the ScriptSeq™ kit from Epicentre. The libraries were sequenced 
on an Illumina HiSeq 2000 instrument with multiplexing of two 
libraries per lane for 50 cycles in one direction. The resulting FASTQ 
sequences were mapped to version hg19 of the human genome using 
the Illumina CASAVA pipeline. The total number of sequences (reads) 
that uniquely mapped to all exons of each RefSeq entry was used for 
quantification of expression levels.
Results: On average, there were 43 million reads per sample (range 
31 – 58 million; SD=4.6 million) of which 69% uniquely mapped 
to the human genome. Ribosomal RNA was effectively removed 
and accounted for <0.3% of total counts. Significant coverage of a 
high proportion of the human genome was obtained, with 40% of 
RefSeq transcripts represented by a median of more than 100 reads. 
Using Cox proportional hazards analysis to evaluate the association 
of quantitative gene expression with breast cancer recurrence, the 
standardized hazard ratios and p-values for the 21 Oncotype DX 
genes determined by RNA-Seq were comparable to those originally 
obtained using RT-PCR. Moreover, whole transcriptome RNA-Seq 
identified more than 1800 new coding, intronic, and intergenic 
transcripts that strongly associated with breast cancer recurrence risk 
(at a false discovery rate <10%) and revealed heretofore unappreciated 
co-expressed gene networks. Summary: New methodology has been 
developed for application of next generation sequencing-based whole 
transcriptome profiling to small amounts of archival FFPE tissue. This 
technology has sensitivity and selectivity comparable to RT-PCR, can 
provide a vast increase in the number of interrogated transcripts, can 
reveal new biological relationships, and has excellent performance 
suitable for the discovery of RNA biomarkers.
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PD03-10
Gene Modules and Response to Neoadjuvant Chemotherapy in 
Breast Cancer: A Meta-Analysis.
Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello 
C, Loi S, Andre F, Piccart M, Michiels S, Sotiriou C. Institut Jules 
Bordet, Brussels, Belgium; Harvard School of Public Health, Boston; 
Université Paris XI, Paris, France
Background: We and others have shown that high expression of 
proliferation and immune related genes are associated with pathological 
complete response (pCR) after neoadjuvant chemotherapy in breast 
cancer (BC). Here, we performed a meta-analysis to validate these 
findings and to interrogate the association between pCR and several 
other gene expression modules beyond standard clinico-pathological 
characteristics in BC subtypes.
Methods: We searched for publicly available gene expression studies 
evaluating anthracycline ± taxane-based neoadjuvant chemotherapy. 
We identified 7 studies with complete genomic and clinico-
pathological data including pCR totaling 788 patients. Relapse-free 
survival (RFS) data were available for 427 patients. We used gene 
expression data generated from pretreatment biopsies and computed 
17 gene modules corresponding to proliferation-driven signatures, 
immune response, stroma activation, phosphatase and tensin homolog 
(PTEN) loss, chromosomal instability, and several other oncogenic 
pathways. We calculated odds ratios (OR) for pCR for one-unit 
increases in scaled modules, all adjusting for pretreatment clinico-
pathological characteristics. Moreover, we tested for interactions 
between gene modules and ER or HER2 status for their association 
with pCR after adjusting for clinicopathological characteristics. We 
used the false discovery rate (FDR) to adjust for multiple testing.
Results: We observed pCR in 178(22.6%) of 788 patients: 112(30.1%) 
of 372 with ER-/HER2- BC, 41(36%) of 113 with HER2+ BC, 
and 25(8.2%) of 303 with ER+/HER2- BC. High values of the 
proliferation-driven modules were associated with increased pCR 
rates in ER-/HER2- (e.g. Gene70 OR=2.34, 95%CI 1.22-4.59, 
p=0.01, FDR=0.10) and ER+/HER2- (e.g. Gene70 OR=3.26, CI 
1.13-9.60, p=0.03, FDR=0.16), but not in the HER2+ subtype (e.g. 
Gene70 OR=0.82, CI 0.23-2.67, p=0.74, FDR=0.86). There was 
a trend for interaction between proliferation-driven modules (e.g. 
Gene70) and HER2 status (p=0.08, FDR=0.23). Interestingly, we 
demonstrated a strong association between high values of immune 
module and increased pCR rates in the HER2+ (OR=6.58, CI 2.20-
23.40, p<0.01, FDR=0.03) and ER-/HER2- (OR=1.75, CI 1.12-2.76, 
p=0.02, FDR=0.10) but not in the ER+/HER2- subtype (OR=1.50, 
CI 0.63-3.42, p=0.35, FDR=0.49). Moreover, high values of AKT 
activation module were associated with decreased pCR rates in 
HER2+ (OR=0.38, CI 0.14-0.98, p=0.05, FDR=0.29) but not in 
the ER-/HER2- (OR=0.87, CI 0.56-1.37, p=0.56, FDR=0.68) or 
ER+/HER2- (OR=1.81, CI 0.65-5.30, p=0.27, FDR=0.47) subtype. 
Interactions between immune module and HER2 status and between 
AKT module and HER2 status were nominally significant (p=0.04 and 
p=0.05, respectively), but came with an FDR of 0.23. Of interest after 
a median follow-up of 3.47 years, (95% CI 3.18-3.70 years) patients 
with pCR had significantly longer RFS irrespective of BC subtypes 
(HR=0.20, 95% CI 0.08 to 0.50, p<0.001).
Conclusion: Different biological processes namely proliferation, 
immune response and AKT activation are associated with pCR 
in different BC subtypes. Our results suggest that new drugs that 
modulate immune responses in ER-/HER2- and HER2+ BC and target 
AKT activation in HER2+ BC might be evaluated in these subtypes.
PD04-01
Predictors of Recovery of Ovarian Function during Aromatase 
Inhibitor (AI) Therapy.
Henry NL, Banerjee M, Hayden J, Yakim E, Schott AF, Stearns V, 
Partridge AH, Hayes DF. University of Michigan Medical School, 
Ann Arbor, MI; Johns Hopkins School of Medicine; Dana Farber 
Cancer Institute
Background: AIs may cause a paradoxical rise in estrogen levels due 
to re-activation of ovarian function in women with chemotherapy-
induced ovarian failure (CIOF). Therefore, identification of residual 
ovarian estradiol production is critical if such women are treated 
with adjuvant AI therapy rather than tamoxifen. We performed a 
prospective registry trial to identify predictors of recovery of ovarian 
function during AI therapy.
Methods: Women with hormone receptor (HR) positive breast cancer 
who were pre- or peri-menopausal at diagnosis and who remained 
amenorrheic for ≥8 weeks after cyclophosphamide-containing 
adjuvant chemotherapy were enrolled in a multi-institutional, open-
label clinical trial of anastrozole (1 mg/day). Following confirmation 
that serum estradiol (E2) levels were <20 pg/ml using an ultrasensitive 
E2 assay (Quest Diagnostics), subjects initiated anastrozole. Serum 
E2 was assessed biweekly for 12 wks, then less frequently, for 72 
wks. Multivariable logistic regression was used to evaluate clinical 
predictors (age at AI initiation OR chemotherapy, menopausal status 
at chemotherapy, body mass index (BMI), baseline E2) of recovery 
of ovarian function defined as elevated serum E2 levels or return of 
menses.
Results: Sixty-nine women were enrolled; current status is given in 
Table 1.
Current status of enrolled subjects
Postmenopausal E2 levels ≥ 48 wks 15
Elevated E2 levels during AI therapy 19
Vaginal bleeding without elevated E2 levels 2
Discontinued AI: toxicity 10
Discontinued AI: subject or physician preference 8
On study <48 weeks 6
Screen failures (elevated E2 prior to AI therapy) 7
Withdrew prior to initiation of AI therapy 2
Median age at initiation of chemotherapy was 47.2 yrs (range 37-
55), median time since chemotherapy was 0.8 yrs (range 0.3-6.4), 
and median age at enrollment was 49.8 yrs (range 40-58). Thirty-six 
had received tamoxifen. We observed elevated E2 concentrations or 
return of menses during AI therapy in 21 subjects after a median 2.0 
mo (range 0.6-17); for that cohort, median age at chemotherapy was 
43.8 yrs (range 37-51) and median age at AI initiation was 45.8 yrs 
(range 40-56). In contrast, for the 15 subjects who had postmenopausal 
E2 levels for at least 48 wks, median age at chemotherapy was 
49.2 yrs (range 44-52) and median age at AI initiation was 50.7 
yrs (range 44-55). Age at chemotherapy (p=0.0006) and age at AI 
initiation (p=0.001) were statistically significant different between 
the 2 cohorts. On multivariable analysis, age at chemotherapy and 
age at AI initiation remained significant when each was adjusted 
for menopausal status, BMI, and baseline E2 (odds ratio (OR) 1.64, 
p=0.0102 and OR 1.47, p=0.015, respectively).
Conclusions: A significant proportion of women who develop CIOF 
recover ovarian function during AI therapy. Although recovery is 
usually rapid, it can occur at least one year following initiation of 
AI therapy. Younger age was the strongest predictor of recovery of 
ovarian function, although 2 of 21 women who developed elevated 
E2 levels or return of menses were older than 50 yrs at the time of 
chemotherapy. Tamoxifen remains the standard of care for women 
with CIOF; if use of an AI is necessary, patients should be monitored 
frequently with high-quality E2 assays for recurrent ovarian function.
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PD04-02
Recovery of Ovarian Function in Breast Cancer Patients with 
Chemotherapy-Induced Amenorrhea Receiving Anastrozole in 
the Dutch DATA Study.
Tjan-Heijnen VC, Smorenburg CH, de Graaf H, Erdkamp F, Honkoop 
A, Wals J, van Gastel S, van der Sangen M, Seynaeve C, Nortier 
JW, Borm G. Maastricht University Medical Centre, Netherlands; 
Medical Centre Alkmaar, Netherlands; Medical Centre Leeuwarden, 
Netherlands; Orbis Medical Centre, Netherlands; Isala Clinics, 
Netherlands; Atrium Medical Centre, Netherlands; Comprehensive 
Cancer Centre Netherlands Nijmegen, Netherlands; Catharina-
Hospital, Netherlands; Erasmus University Medical Centre, 
Netherlands; Leiden University Medical Centre, Netherlands; 
Radboud University Nijmegen Medical Centre, Netherlands
Background: In early stage hormone receptor positive breast cancer, 
aromatase inhibitors (AIs) are established as adjuvant therapy for 
postmenopausal women. In daily practice AIs are also offered to 
patients with chemotherapy-induced amenorrhea (CIA). The impact 
of AIs on estrogen (E2) levels in these patients has not extensively 
been studied, although this could be very relevant for the efficacy and 
safety of the adjuvant hormonal treatment. The Dutch phase III DATA 
study is assessing the impact on disease-free survival of 3 vs. 6 years 
of anastrozole after 2-3 years of tamoxifen (N=1900 patients in total), 
and has included both postmenopausal patients and patients with CIA. 
The current analysis reports on the hormonal data in the CIA group.
Patients and methods: We identified patients from the DATA study 
< 55 years of age at randomization who had received adjuvant 
chemotherapy and developed CIA, and excluded patients with 
ovariectomy or use of LHRH agonist. Patients were considered as 
having CIA if they were in amenorrhea since 3 months before start 
of chemotherapy up to 6 months after start of chemotherapy, and did 
not resume menses during tamoxifen therapy. Patients were eligible 
if postmenopausal E2 levels were confirmed within the last three 
months before randomization. Plasma FSH and E2 levels were serially 
determined at 6-month intervals.
Results: A total of 285 patients with CIA were identified in the 
DATA study. Median age was 50.8 years (range 35.9 – 54.9). Results 
on E2 and FSH levels are presented in the Table. During treatment 
with anastrazole, FSH levels tended to increase over time and E2 
levels didn’t decline. Of note, FSH increased in nearly all patients 
with significantly elevated (premenopausal) E2 levels, in contrast 
to the pattern seen in spontaneous recovery of ovarian function. 
During follow-up, 4 patients had vaginal bleeding, 2 of them having 
postmenopausal E2 levels. In 8 (2.8%) patients E2 levels became > 
200 pmol/l (considered premenopausal) after 12-30 months use of 
AI. Using a more strict cutoff value of E2 (> 100 pmol/l), 62 (21.8%) 
patients had elevated levels of E2 during AI treatment. With 70 
pmol/l as cutoff value, 117 (41.0%) patients had at some point during 
treatment an increased E2 level. Updated and detailed analyses will 
be presented at the meeting.
 No.  patients
E2 median  
(pmol/l)
E2 range  
(pmol/l)
No. pts with  
E2 ≥200  
pmol/l
No. pts  
with E2 
≥100 pmol/l
FSH median  
(U/l)
FSH range 
(U/l)
Baseline 285 57 0-192   30 1-78
T= 6 months 161 44 0-190 0 26 59 2-170
T=12 months 121 44 0-700 3 14 61 2-170
T=18 months 112 44 11-463 2 12 65 1-170
T=24 months 81 44 18-390 2 7 64 6-170
T=30 months 62 40 12-219 1 3 61 5-170
Conclusion: In this first series of a large number of CIA patients 
with available data on E2 and FSH levels during anastrozole therapy, 
we observed high E2 levels in a substantial number of patients. The 
combination of increased E2 and FSH levels may indicate continuous 
stimulation of remaining ovarian follicles. The efficacy of AIs in 
women with CIA without strict E2 monitoring and adequate treatment 
modification in the presence of increasing E2 can be questioned. 
Further data hereon are warranted.
Supported by: AstraZeneca NL and the Dutch Breast Cancer Trialists’ 
Group (BOOG).
PD04-03
Sexual Dysfunction in Premenopausal Women with Breast 
Cancer: Prevalence and Severity.
Goldfarb SB, Dickler M, Patil S, Jia R, Sit L, Damast S, Carter J, 
Kaplan J, Hudis C, Basch E. Memorial Sloan-Kettering Cancer 
Center, New York, NY
Background: Sexual dysfunction is reported after chemotherapy 
and endocrine therapies. However, the prevalence and severity of 
sexual dysfunction in premenopausal women undergoing therapy for 
both local and metastatic disease is not well defined. This study was 
performed in order to understand the impact of contemporary breast 
cancer treatment on the prevalence and severity of sexual health in 
premenopausal women.
Methods: We developed a survey that includes a previously validated 
questionnaire, the Female Sexual Function Index (FSFI), as well as 
an established measure of health-related quality of life (the EuroQol 
EQ-5D), and disease-specific items to characterize sexual dysfunction 
and its causes based on literature review and expert consultations. 
Anonymous administration of the surveys was conducted in outpatient 
clinic waiting areas of the Breast Cancer Center at Memorial Sloan-
Kettering Cancer Center (MSKCC), under an IRB waiver of consent.
Results: 372 consecutively approached premenopausal women with 
breast cancer of any stage, undergoing treatment were each queried 
once. The mean age was 47. 87% reported current or past hormonal 
treatment, and 86% reported current or past chemotherapy (76% 
adjuvant; 24% for metastatic disease). Sexual dysfunction attributed 
to breast cancer or its treatment, defined as an FSFI score <26, was 
reported by 75% of respondents with a mean score of 16.3. Among 
these women, 79% of patients considered their sexual symptoms 
to be bothersome, with 51% noting moderate or severe levels of 
bother (score >=5/10). In a multivariate analysis, metastatic disease, 
development of amenorrhea from cancer treatment, antidepressant 
use and poorer overall health were each significantly associated 
with worse FSFI scores. Lower FSFI scores were also significantly 
associated with worse health-related quality of life.
Conclusion: Sexual dysfunction is prevalent in premenopausal 
women treated for breast cancer and should be discussed with 
patients as a potential adverse effect of therapy. Assessment of sexual 
symptoms throughout treatment and beyond may facilitate the use 
of potential interventions such as lubricants, dilators, treatment 
modification and counseling.
PD04-04
Sexual Dysfunction in Women with Early Stage Breast Cancer 
on Endocrine Therapy: Encouraging Results from a Prospective 
Study.
Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, 
Gertler SZ, Song X, Graham N, Dent S. The Ottawa Hospital Cancer 
Centre, Ottawa, ON, Canada; Carleton University, Ottawa, ON, 
Canada
Background: While the side effects of endocrine therapy (ET) for 
early stage breast cancer (EBC) have been extensively studied, the 
link between ET and sexual dysfunction (SD) remains a contentious 
issue. Most studies have focused on documenting only the presence 
of problems in specific domains of endocrine symptoms (ES) (e.g. 
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hot flushes, vaginal dryness) and sexual functioning (SF) (interest, 
satisfaction, arousal, lubrication) without also taking sexual distress 
into account. To our knowledge, there have been no prospective 
longitudinal studies evaluating SF and SD before the onset of ET 
and after treatment initiation. We report the initial 6 month results of 
this study of SD in women initiating ET for EBC.
Methods: Hormone receptor positive EBC post-menopausal women 
were approached for a larger study of SF aimed at comparing the 
prevalence of SD across endocrine agents (tamoxifen vs aromatase 
inhibitor) and at evaluating the impact of anxious predisposition 
and ES on SD. Here we report on changes in ES, SF and SD after 6 
months of ET. SF was evaluated with the Female Sexual Function 
Index (FSFI) while sexual distress was assessed with the Female 
Sexual Distress Scale. ES were measured with FACT-B ES subscale. 
Participants completed questionnaires prior to initiation (T0) of ET 
and at 6 months (T1). SD was assessed using the APA classification.
Results: Between January 2009 and May 2011, 118 EBC patients 
entered the study and 83 have completed both assessments (mean 
age 62; 30% received chemotherapy). Over time, the levels of ES 
increased (p <0.001). Despite the worsening of ES at T1, no decline 
in SF was observed, this for each FSFI domain (desire, arousal, 
lubrication, discomfort during intercourse and satisfaction). There 
was no change in the percentage of women reporting 1 or more sexual 
problems over time (85% vs 87%, ns) nor in the percentage who were 
sexually distressed (32% vs 34%, ns). The prevalence of SD did not 
increase after 6 months of ET (T0=28% vs T1=33%, ns). There were 
no differences in the percentage of women who worsened (i.e., no 
SD at T0 but SD at T1, 12%) and those who improved (SD at T0 
but no SD at T1, 7%) over time (McNemar X2, p >.5) Importantly, 
women classified as experiencing SD at T0 were more likely to also 
experience SD at T1 (OR=4.5, 95% CI=2.162 to 9.366) than women 
who had no SD at T0.
Discussion: This is the first prospective case cohort study evaluating 
ES, SF and SD in women with EBC on ET. The good news for women 
is that although ES increased during ET (p < 0.001), this did not have 
a negative impact on sexual problems (85% vs 87%, ns) or SD (32% 
vs 34%, ns). This is encouraging news but longer follow-up of these 
women will provide further insight into the impact of ET on ES and 
SD over time (> 6 months). The impact of specific types of ET on ES, 
and SD will also be evaluated. Of interest, the high uptake and high 
completion rate (>80%) of questionnaires, indicate this is a matter of 
relevance and importance to women taking adjuvant ET and merits 
acknowledgement and sensitive discussion.
PD04-05
Body Image Issues in Young Breast Cancer Patients: The Impact 
of Chemotherapy, Hormone Treatment, and Surgery.
Rosenberg SM, Tamimi RM, Gelber S, Kereakoglow S, Borges V, 
Come S, Schapira L, Winer E, Partridge A. Harvard School of Public 
Health, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; 
University of Colorado Cancer Center, Denver, CO; Beth Israel 
Deaconess Medical Center, Boston, MA; Massachusetts General 
Hospital, Boston, MA
Background: While there is evidence that younger women with 
breast cancer are more likely to experience compromised quality 
of life compared to older women, few studies have prospectively 
explored the impact of treatment, including surgery, chemotherapy, 
and hormone therapy, on body image, in particular, in very young 
women (≤40 years old). This analysis examined treatment-associated 
differences in self-reported body image among a large cohort of 
young women diagnosed with breast cancer. Methods: 431 women 
enrolled in an ongoing multi-center prospective cohort study with 
Stage 0-Stage III breast cancer were included in this analysis. Body 
image was measured at baseline (1-12 months following diagnosis) 
using three items from the Cancer Rehabilitation Evaluation System 
(CARES) survey. CARES scores range from 0-4, with higher scores 
indicative of greater image concerns. Mean differences in CARES 
scores between treatment groups (chemotherapy within the last month 
vs. none; hormone therapy vs. none; lumpectomy vs. mastectomy 
alone vs. mastectomy + reconstruction) were estimated using 
T-tests and one-way ANOVA. To control for concurrent treatment, 
stage, and time since diagnosis, multiple linear regression models 
were fit and least squares means estimated and compared between 
treatment groups. Multiple comparisons were adjusted for using 
the Bonferroni correction. Results: Median age at diagnosis was 37 
(range: 17-40) and median time from diagnosis to study enrollment 
was 5 months (range: 1-12 months). In the unadjusted analysis, 
there were no significant differences in scores between women who 
had received chemotherapy within the last month and those who 
did not (p=0.80), while women who reported hormone treatment 
had higher mean CARES scores compared to women who did not 
(p=0.04). Among women who had undergone surgery (n=370), 
women who had lumpectomies had a mean CARES score of 0.95, 
which was significantly lower (p<.0001) compared to both women 
who had undergone mastectomy alone (CARES: 1.89) and women 
who reported mastectomy + reconstruction (CARES: 1.53). After 
adjusting for concurrent treatment (including radiation), time since 
diagnosis, and stage of disease, only differences between surgical 
groups remained significant (p<.0001), with mean scores among 
women who had either undergone mastectomy alone (CARES: 2.02) 
or together with reconstruction (CARES: 1.58) higher compared 
to those who had a breast conserving procedure (CARES: 0.92) 
Conclusion: To the best of our knowledge, this is the largest analysis 
of treatment-related body image issues in young women with breast 
cancer. Treatment with chemotherapy and hormonal therapy did not 
appear to affect short-term body image. However, women who had 
a breast conserving procedure had the fewest body image concerns 
as measured by the CARES, while women undergoing more radical 
surgery appear to be at increased risk for low perceived body image 
though this may be mitigated to a degree by reconstruction. Further 
analyses will explore whether differences between surgical groups 
persist over time as well as examine the trajectory of change over 
the course of follow-up.
PD04-06
A Randomised Controlled Trial of Quality of Life and Fatigue 
after Support Group Intervention in Primary Breast Cancer 
Patients.
Granstam Björneklett H, Lindemalm C, Ojutkangas M-L, Berglund 
A, Letocha H, Strang P, Bergkvist L. Centre for Clinical Research, 
Västerås, Sweden; Cancer Centre Karolinska, Solna, Sweden; 
Centre for Clinical Research, Central Hospital, Västerås, Sweden; 
Karolinska Institute, SSH, Stockholm, Sweden; Karolinska Institute, 
Stockholm, Sweden
Background: When diagnosed with breast cancer, most women’s 
lives change as well as their perspectives on and appreciation of life. 
The aim of the present study was to evaluate whether psychosocial 
support intervention could influence health- related quality of life 
and fatigue during the first year after diagnosis.
Material and Methods: Of 382 patients with newly diagnosed breast 
cancer, 191 + 191 patients were randomized to an intervention group 
or to a routine control group respectively.
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The intervention group received support intervention that lasted 
one week on a residential basis, followed by four days of follow-up 
two months later. The support intervention included informative-
educational parts, relaxation training, mental visualisation and non-
verbal communication. Health-related quality of life was measured 
using the EORTC-QLQ 30 and QLQ-BR23 questionnaires and fatigue 
with the Norwegian version of the Fatigue scale at baseline, 2, 6 and 
12 months after intervention.
Result: There were a time-dependant improvement in both functional 
and symptom scales between baseline and 12 months as measured 
by the EORTC QLQ 30 and BR 23 questionnaires and there was a 
decrease in fatigue between baseline and after 2 months with further 
improvement up to 12 months in both groups but there were no 
differences between the intervention and control groups at any point 
in time.
Conclusion: Health related Quality of Life improves and symptoms 
of fatigue decreases over time, but we could not see any additional 
effect from the rehabilitation program in this setting.
Key words: Support intervention, breast cancer, health- related 
quality of life, fatigue, EORTC-QLQ 30 and BR 23, the Norwegian 
version of the fatigue scale.
PD04-07
Cognitive Function and Reproductive Hormones in Women 
Receiving Anastrozole.
Bender CM, Sereika SM, Ryan CM, Berga SL. University of 
Pittsburgh, Pittsburgh, PA; Emory University, Atlanta, GA
Background: The effects of adjuvant hormonal therapy on hormone 
levels may contribute to deterioration in cognitive function 
experienced by women with breast cancer. Estrogen receptors are 
present throughout the central nervous system. Estrogen binding 
increases ChAT, synaptogenesis and dendritic spine density in the 
hippocampus and hypothalamus and decreases monoamine oxidase 
activity. Aromatase inhibitors, such as anastrozole, interrupt estrogen 
biosynthesis resulting in profound estrogen reductions. We studied 
whether changes in reproductive hormone levels mediate changes in 
cognitive function in 3 cohorts of postmenopausal women; women 
with breast cancer who receive chemotherapy+anastrozole (CA; 
n=41) or anastrozole only (AO; n=50)] and age and education matched 
healthy women (n=44).
Methods: We assessed cognitive function and reproductive hormones 
(E2, LH, FSH) before therapy and at 6, 12 and 18 months post-therapy 
initiation. A battery of neuropsychological measures was used to 
assess multiple cognitive domains. Using mixed effects modeling, we 
analyzed changes in hormone levels from pretreatment to 6, 12 and 
18 months post-therapy initiation and then explored intercorrelations 
between changes in hormone levels and cognitive function at all 
timepoints.
Results: Women were an average 59.3 years of age with an average 
14.9 years of education. No significant group-by-time effects were 
found for LH. However, we found significant group by time effects 
for E2 when comparing CA with controls (p=.0002) and AO with 
controls (p<.0001) and for FSH when comparing AO with controls 
(p=.03). We found that E2 declined from pretreatment in the breast 
cancer groups as follows; CA [E2 declined from pretreatment to 
immediately post-chemotherapy (p = .09), and at 6 (p=.0002) and 
12 (p=.014) months post anastrozole initiation, and AO [E2 declined 
from pretreatment to 6 (p<.0001), 12 (p=.004) and 18 (p<.0001) 
months post-anastrozole initiation]. We also found increases in FSH 
in the AO group from pretreatment to 6 (p=.002) and 12 (p=.05) 
months. No significant within-group changes for E2, FSH, or LH 
were observed for controls.
For the full sample, the intercorrelations revealed that reductions 
in E2 were related to poorer psychomotor efficiency from baseline 
to 18 months post-baseline (rs=.358, p=.02). For the AO group, 
reductions in E2 were related to poorer executive function (r=.600, 
p= 002) from 6 to 12 months post-anastrozole initiation and poorer 
psychomotor efficiency (r=.453, p=.07) from pretreatment to 18 
months post-anastrozole initiation. For the CA group, reductions in 
E2 were marginally significantly related to poorer attention (r=.307, 
p=.08) from pretreatment to post-chemotherapy; and to poorer 
executive function from pretreatment to 6 months (r=.446, p=.06) and 
12 months (r=.651, p=.03) post-anastrozole initiation. No significant 
relationships between changes in E2 levels and cognitive function 
were found in the controls.
Conclusions: Reductions in E2 may be related to cognitive 
deterioration in women with breast cancer. Further examination of 
these relationships is needed to confirm the results and determine 
whether these relationships persist through the remainder and after 
the conclusion of therapy.
PD04-08
Altered Neurocognitive Responses Prior to Adjuvant Therapy 
for Breast Cancer: A Functional MRI Analysis of the Impact of 
Worry and Fatigue.
Cimprich B, Hayes DF, Askren MK, Jung MS, Berman MG, Therrien 
B, Reuter-Lorenz PA, Zhang M, Peltier S, Noll DC. University of 
Michigan, Ann Arbor, MI
Background: The underlying brain mechanisms of altered cognitive 
function associated with adjuvant chemotherapy for breast cancer, 
commonly designated “chemobrain”, have yet to be determined. 
Recent research indicates that compromised cognitive function 
may already exist prior to treatment, adding to the complexity of 
determining the true impact of adjuvant chemotherapy on brain 
function. We examined whether two common symptoms associated 
with breast cancer diagnosis, worry and fatigue, might influence 
neurocognitive responses during functional magnetic resonance 
imaging (fMRI) before adjuvant therapy.
Methods: Seventy five women (29 -75 years) awaiting either adjuvant 
chemotherapy (n=25) or radiation therapy (n=25) for localized breast 
cancer and age-matched controls without breast cancer (n=25) were 
enrolled. Participants performed a verbal working memory task 
(VWMT) with varying levels of demand for cognitive control during 
fMRI scanning and provided self-reports of worry and fatigue after 
scanning. Imaging data were analyzed using the general linear model 
implemented in SPM5; comparative statistics were used to determine 
group differences in self-report and behavioral measures.
Results: In general, the pre-chemotherapy group showed compromised 
cognitive functioning relative to the other groups. Specifically, they 
reported higher worry than the pre-radiation therapy (p=.036) 
and control (p=.047) groups. The pre-chemotherapy group also 
identified greater fatigue than controls (p=.04); the pre-radiation 
group reported a fatigue level between the other two groups. In the 
VWMT, the pre-chemotherapy group was less accurate than controls 
(p=.05), while the mean accuracy for the pre-radiation group again 
fell between these two groups. fMRI results showed that the control 
group selectively increased recruitment of executive control brain 
regions including the left inferior frontal gyrus (LIFG) and the 
anterior cingulate cortex (ACC) in response to high vs. low demand 
conditions. However, recruitment of LIGF and ACC by the control 
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group was greater than that by both the pre-chemotherapy (p=.01 and 
p=.003 respectively) and the pre-radiation groups (p=.027 and p=.02 
respectively). Overall, higher fatigue was correlated with failure to 
increase recruitment of the LIFG and ACC in high vs. low demand 
conditions (p=.002 and p=.078 respectively). Greater worry was 
correlated with failure to suppress task-irrelevant activation of default 
network regions, particularly the posterior cingulate cortex, in high 
vs. low demand conditions, and with lower accuracy in the VWMT 
(p=.01). Thus, fatigue and worry made independent contributions 
to altered neurocognitive responses prior to any adjuvant treatment.
Discussion: These findings suggest that women awaiting adjuvant 
chemotherapy are vulnerable to compromised cognitive functioning, 
specifically in the domains of attention and working memory, related 
to higher worry and fatigue. Worry and fatigue may contribute to 
the cognitive impact often attributed to adjuvant chemotherapy. 
Therapeutic interventions to counteract worry and fatigue hold 
potential for optimizing cognitive function prior to adjuvant treatment 
for breast cancer.
PD04-09
Self-Reported Cognitive Attributes and Fatigue Improve over 
Long-Term Follow-Up in Breast Cancer Survivors; Some 
Cognitive Attributes Are Worse in Breast Cancer Survivors Than 
in Non-Cancer Controls.
Hsu T, Ennis M, Hood N, Goodwin PJ. University of Toronto, Toronto, 
ON, Canada; Applied Statistician, Markham, ON, Canada; Mount 
Sinai Hospital, Toronto, ON, Canada; Mount Sinai and Princess 
Margaret Hospitals, Samuel Lunenfeld Research Institue, University 
of Toronto, Toronto, ON, Canada
Background: Cognitive deficits and fatigue have been reported 
in breast cancer (BC) patients undergoing a variety of treatments, 
including chemotherapy; in some studies these concerns persist after 
completion of treatment. We examined these factors over time (median 
11 yrs) in a longitudinal study of BC patients and compared the status 
of long-term BC survivors to non-BC controls.
Methods: 535 T1-3, N0-1, M0 BC patients were enrolled 1989-96; 
260 women survived without metastases to participate in long-term 
follow-up (LTFU) measurements in 2006-8. 161 controls without 
BC were enrolled 2007-8. Questionnaires examined a range of QOL 
attributes; here we focus on items related to cognition and fatigue 
including: EORTC QLQ C30 (cognitive functioning, fatigue), 
Profile of Mood States (POMS - confusion/bewilderment, fatigue/
inertia, vigor/activity), Fatigue Symptom Inventory (FSI - average 
fatigue past week, total disruption index), Everyday Problems (EDP 
- forgetfulness, difficulty concentrating, easily distracted). 166 of the 
BC patients had also completed EORTC and POMS at diagnosis and 1 
year, and change in items on these questionnaires was calculated. Age 
and income adjusted differences between BC (LTFU) and controls 
were analyzed. Clinical significance was defined as ≥5% of the scale 
range or an effect size of ≥0.2 and statistical significance as P≤ 0.05.
Results: BC cases were older than controls (62.3 vs 59.1 yr), had 
lower education (24.6 vs 10.2% high school only) and family 
income (38.2 vs 19.8% < $60,000 annually) (all P<0.01). Cognitive 
attributes: BC patients showed clinically and statistically significant 
improvements between diagnosis and LTFU on POMS confusion/
bewilderment but not EORTC cognitive functioning. Comparing 
BC (LTFU) to controls, in multivariate analyses adjusted for age 
and income, EORTC cognitive functioning (81.5 vs 87.4) and EDP 
forgetfulness (0.9 vs 0.6) were clinically and statistically significantly 
worse in BC patients than controls. In contrast, POMS confusion/
bewilderment, EDP difficulty concentrating and EDP easily distracted 
scores were similar in BC patients at LTFU and controls. Fatigue: BC 
patients showed clinically and statistically significant improvements 
between diagnosis and LTFU on EORTC fatigue, POMS fatigue/
inertia and POMS vigor/activity. After adjustment for age and income 
there were no clinically and statistically significant differences 
between BC (LTFU) and controls on any fatigue items.
Conclusions: Fatigue items, as well as some cognitive items, 
improved over time in BC patients and scores were comparable 
to scores in non-BC controls at LTFU. However, scores on some 
cognitive items were worse in LTFU BC patients than in non-BC 
controls raising concerns that BC diagnosis and treatment may be 
associated with long-term adverse effects on some aspects of self-
reported cognitive attributes.
(Funded by The Breast Cancer Research Foundation)
PD05-01
Trans-CHER-Lob: A Biomarker Analysis of the Randomized 
Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, 
Lapatinib or Combined Trastuzumab and Lapatinib in HER2 
Positive Operable Breast Cancer.
Guarneri V, Frassoldati A, Ficarra G, Maiorana A, Bettelli S, 
Bottini A, Cagossi K, Bisagni G, Ravaioli A, Amadori D, Musolino 
A, Cavanna L, Orlando L, Giardina G, Piacentini F, Bagnalasta 
M, Conte P. Modena University Hospital, Modena, Italy; Medical 
Oncology, Ferrara University Hospital; Modena University Hospital; 
Istituti Ospitalieri, Cremona; Ramazzini Hospital, Carpi; Arcispedale 
Santa Maria Nuova, Reggio Emilia; Ospedale Infermi, Rimini; Istituto 
Scientifico Romagnolo per lo Studio e la Cura dei Tumori,Meldola 
(FC); Parma University Hospital; Hospital of Piacenza; Ospedale 
di Circolo e Fondazione Macchi, Varese; Perrino Hospital, Brindisi; 
GlaxoSmithKline, Verona
Introduction: The CHER-Lob study is a randomized phase II trial 
of preoperative sequential taxanes-anthracyclines in combination 
with trastuzumab, lapatinib, or combined trastuzumab and lapatinib 
in HER2 positive, stage II-IIIA breast cancer patients. A translational 
program to evaluate predictors of response as well as treatment effects 
on tissue biomarkers was pre-planned.
Methods: The CHER-Lob translational program includes the central 
evaluation of HER2, p95HER2, PTEN, pAKT, Ki67 on pre and 
post-therapy samples. All these biomarkers have been evaluated 
by immunohistochemistry. FISH analysis was performed in case of 
HER2 IHC 2+, and in all the discordant cases between central and 
local laboratories. Biomarkers change from baseline to surgery has 
been evaluated with the Wilcoxon signed-ranks matched-pair test.
Results: 121 patients have been randomized. The pathologic complete 
response rate (breast and axillary lymphnodes) was 26% in Arm 
A (chemotherapy + trastuzumab), 28% in arm B (chemotherapy 
+ lapatinib) and 44% in arm C (chemotherapy + trastuzumab 
and lapatinib). The concordance between central and local HER2 
assessment on pre-treatment biopsy was 97%.
The mean (min;max) PTEN expression pre- and post-therapy were 
66% (0;100) and 68.4% (0;100) respectively.
The mean (min;max) pAKT expression pre- and post-therapy were 
23.3% (0;100) and 8.8% (0;90) respectively. A significant decrease 
was observed in the overall samples (p=0.01). When analyzing 
the lapatinib alone arm, the difference was no longer significant 
(p=0.06), while it maintained significance when evaluating the two 
trastuzumab containing arms (p=0.0013). The mean (min;max) ki67 
expression pre- and post-therapy were 29.5% (4;90) and 16.6% (1;50) 
respectively. A significant decrease was observed when looking at the 
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whole population (p<0.0001). A significantly higher ki67 inhibition 
was observed in the dual vs single anti-Her2 therapy (p= 0.003).
Conclusions: The central HER2 retesting showed a high concordance 
with local laboratories. Treatment induced a suppression in pAKT 
expression, that was higher in patients receiving trastuzumab. The dual 
anti-HER2 blockade induced a higher KI67 inhibition as compared 
to single anti-Her2 blockade. The evaluation of the predictive 
and prognostic role of these biomarkers is ongoing. Supported by 
GlaxoSmithKline
PD05-02
Effect of HER2/Topoisomerase II alpha (TOP2A) Gene Status or 
Protein Expression and Chromosome 17 (CEP17) Polysomy on the 
Outcome of Breast Cancer Patients Treated with Anthracycline-
Containing Dose-Dense Sequential Adjuvant Chemotherapy 
with or without Paclitaxel – A Pooled Analysis of Two Hellenic 
Cooperative Oncology Group (HeCOG) Phase III Trials.
Dafni U, Bobos M, Tsolaki E, Batistatou A, Koletsa F, Televantou 
D, Gogas H, Linardou H, Pectasides D, Kalogeras KT, Galani E, 
Koutras A, Papadimitriou CA, Fountzilas G. Hellenic Cooperative 
Oncology Group (HeCOG), Athens, Greece
Background: The HER2 gene has been established as a valid 
biomarker in the treatment of breast cancer patients with trastuzumab 
and probably with other agents, such as paclitaxel or anthracyclines. 
The TOP2A gene has been associated with response to anthracyclines. 
The relationship of HER2/TOP2A gene status in the presence of 
CEP17 polysomy with patients’ outcome following adjuvant treatment 
with anthracyclines with or without paclitaxel is not established.
Patients and methods: Formalin-fixed paraffin-embedded (FFPE) 
tumor tissue blocks from 1,033 patients (61.5% of 1,681 randomized 
patients) with high-risk operable breast cancer enrolled in two 
sequential phase III trials1,2 were assessed in a central laboratory 
for HER2/TOP2A gene amplification and CEP17 polysomy 
by fluorescence in situ hybridization (FISH) and tumors were 
categorized according to the 2007 American Society of Clinical 
Oncology/College of American Pathologists guidelines. HER2 and 
TOP2A amplification was defined as a gene/CEP17 ratio of >=2.2 
and >=2.0, respectively or a gene copy number of >6. Additionally 
HER2, TOP2A, ER/PgR, Ki67, CK5 and EGFR protein expression 
were assessed by immunohistochemistry (IHC) and all patients were 
classified according to their IHC phenotype. Treatment consisted 
of epirubicin-based dose-dense sequential adjuvant chemotherapy 
followed by hormonal therapy and radiation, as indicated.
Results: Disease-free survival (DFS) and overall survival (OS) did 
not differ significantly between treatment groups. Median follow-
up was 92 months, while 5-year DFS (OS) rates were 74% (88%), 
69% (81%) and 75% (86%) for the E-T-CMF, E-CMF and ET-CMF 
groups, respectively. HER2 amplification was found in 24.1% of 
the patients and TOP2A amplification in 10.3%. In total, 46.7% of 
HER2 amplified tumors demonstrated TOP2A co-amplification. The 
median (range) of HER2, TOP2A and CEP17 copy numbers was 2.55 
(0.70-45.15), 2.2 (0.50-26.15) and 2.05 (0.45-26.55), respectively. 
21% of the tumors were considered to be polysomic (32.5% of those 
with HER2 amplification). Adjusting for treatment groups in the Cox 
model, TOP2A amplification, CEP17 polysomy and HER2/TOP2A 
co-amplification were not associated with either relapse or death. 
Treatment with paclitaxel was associated with improved survival 
in the HER2-amplified subgroup (HR=0.493, interaction p=0.036; 
adjusting for clinicopathological prognostic factors: HR=0.553, 
interaction p=0.054), an association that was not apparent for DFS.
Conclusions: HER2 amplification was predictive for OS benefit from 
adjuvant treatment with paclitaxel in patients treated with epirubicin-
based dose-dense sequential adjuvant chemotherapy, but not for 
DFS. TOP2A amplification, CEP17 polysomy and HER2/TOP2A 
co-amplification were not associated with outcome.
1. Ann Oncol 16:1762-71, 2005; 2. Ann Oncol 19:853-60, 2008.
PD05-03
Impact of Quantitative Measurement of HER2, HER3, HER4, 
EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant 
Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in 
NCCTG N9831.
Perez EA, Ballman KV, Reinholz MM, Dueck AC, Cheng H, Jenkins 
RB, McCullough AE, Chen B, Davidson NE, Martino S, Kaufman 
PA, Kutteh LA, Sledge GW, Geiger XJ, Ingle JN, Tenner KS, Harris 
LN, Gralow JR, Rimm DL. Mayo Clinic, Jacksonville, FL; Mayo 
Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University 
of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and 
Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical 
Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar 
Rapids, IA; Indiana University Medical Center Cancer Pavillion, 
Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer 
Care Alliance, Seattle, WA
Background: Prediction of benefit from trastuzumab in patients (pts) 
with HER2+ breast cancer remains an important goal. We sought to 
investigate the predictive value of quantitative measurement of HER2, 
HER3, HER4, EGFR, ER and PTEN protein expression on the benefit 
of trastuzumab in the phase III HER2+ adjuvant N9831 study for pts 
randomized to chemotherapy alone (Arm A) or chemotherapy with 
sequential (Arm B) or concurrent trastuzumab (Arm C).
Methods: For each marker, we evaluated quantitative expression, 
relationship with demographic data, and association with disease-free 
survival (DFS) of pts. Freshly cut tissue microarray slides with up 
to three-fold redundancy per specimen from the N9831 cohort were 
treated identically using the AQUA (Camp, et al; Nat Med 2002, 
JCO 2008) method of quantitative immunofluorescence for each 
marker. HER2 was tested with CB11 (mouse monoclonal, Biocare, 
Inc.) and preliminary results were available for 698 of nearly 1400 
pt specimens to be tested. The minimum value per pt was used in 
statistical analysis. Specimens were classified with high versus low 
expression based on a median value cutpoint for each marker. Median 
follow-up was 7.0 yrs.
Results: Quantitative HER2 was compared with centrally performed 
HER2 testing by IHC and FISH. Median quantitative HER2 via 
AQUA was 10,017 units for the HER2 IHC 3+ group (n=607) versus 
1058, 831, and 970 for the HER2 IHC 2+ (n=68), 1+ (n=11), and 
0 (n=11) groups, respectively. The Spearman correlation between 
quantitative HER2 and FISH HER2/CEP17 ratio was 0.32 (p<0.001). 
High quantitative HER2 was associated with lower percentage of 
hormone receptor positivity (48% vs 59%, chi-sq p=0.003) but not 
associated with age, race, nodal positivity, tumor histology, grade, 
or size. High HER2 did not impact DFS in any arm of the study (See 
Table). Data for additional HER2 testing, HER3, HER4, EGFR, ER 
and PTEN are in process and will be ready by September, 2011.
Conclusions: Similar to results based on standard HER2 testing by 
IHC and FISH in N9831, quantitative HER2 did not impact benefit 
from adjuvant trastuzumab. Results for additional markers will be 
presented. Our complete quantitative results for a second epitope on 
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HER2, HER3, HER4, ER and EGFR will be the first report of these 
markers in a large patient cohort in the adjuvant setting.
Disease Free Survival
Arm HER2 N #Events HR 95% CI p-value 5yr DFS
A Low 108 77    73.8
 High 121 89 0.92 0.55-1.54 0.75 76.8
B Low 107 30    76.7
 High 142 26 0.63 0.36-1.10 0.10 83.7
C Low 105 22    87.5
 High 115 21 0.92 0.50-1.69 0.79 85.1
PD05-04
Quantitative Measurement of Antigen Degradation in NCCTG 
N9831 Tissue Microarrays.
Cheng H, Rimm DL, Reinholz MM, Lingle WL, Ballman KV, Dueck 
AC, Chen B, McCullough AE, Jenkins RB, Perez EA. Yale University 
School of Medicine, New Haven, CT; Mayo Clinic, Rochester, MN; 
Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Jacksonville, FL
Background: Unstained recuts from formalin-fixed paraffin-
embedded tissues are commonly collected for cooperative group 
studies. There is concern among pathologists that improper storage 
conditions can lead to antigen degradation. In an effort to quantify 
this effect, we compared the expression of HER1 and HER2 on two 
sets of identical cohort tissue microarrays (TMAs) from the N9831 
HER2+ adjuvant phase III trial (NCT00005970; www.clinicaltrials.
gov); one freshly cut set (cut April 18, 2011) and a second set stored at 
4 degrees for over two years (cut between Nov, 2007 and Jan, 2008).
Methods: The two sets of TMA slides containing 1580 tumor 
samples from the N9831 cohort were treated identically using the 
AQUA method of quantitative immunofluorescence. HER1 was 
tested with D38B1 (rabbit monoclonal, Cell Signaling Technology, 
Inc.) and HER2 with CB11 (mouse monoclonal, Biocare, Inc.) on 
tumors from 695 patients (712 specimens) in the fresh TMAs and 
779 patients (800 specimens) in the old TMAs in up to three-fold 
redundancy per specimen.
Results: Frequency distributions of the expression of HER2 
revealed bimodality in the fresh TMAs compared to an attenuated 
distribution of the old cases. The average score of the entire cohort 
was significantly lower in old TMAs compared to fresh cuts (paired 
t-test, p<0.0001). Linear regression of the average HER2 scores from 
new TMAs versus the average scores from old TMAs showed a slope 
term of 0.52, which is statistically significantly different from the 
hypothetical value of 1 (p<0.0001). Regressions between any two 
fresh slides showed slopes close to 1.0. Similar results were seen 
for HER1, but fewer positive cases made the changes less dramatic.
Conclusions: The storage condition of tissue slides is a critical pre-
analytical variable that can dramatically lower the score of HER1 and 
HER2, artificially. Thus, studies done on inadequately stored slides, 
either whole sections or TMAs, must be interpreted with caution. 
Tissue collection and analysis of biomarkers for cooperative group 
studies should not include unstained recuts, but rather, entire blocks 
or large cores from tissue blocks.
PD05-05
Meta Analysis of Discordant HER2 Status in Matched Primary 
and Metastatic Breast Cancer.
Richter S, Zandvakili A. Princess Margaret Hospital; University of 
Western Ontario
Background: The status of HER2 amplification in breast cancer 
is an important prognostic and predictive indicator. Only those 
tumors exhibiting HER2 overamplification are candidates for HER2 
targeted therapy. It remains controversial how accurately HER2 
status of primary tumors reflects HER2 status in distant metastases. 
Discordance between primary and metastatic tumors can impact 
significantly on patient management and suitability for HER2 targeted 
therapies in the setting of recurrent distant disease.
Methods: A literature search of the PubMed database was performed 
to identify all primary studies comparing HER2 status in matched 
primary and distant metastatic tumors between January 2005 and 
February 2011. Review and data extraction was performed by two 
independent reviewers. Eligible studies evaluated HER2 status by 
current ASCO guidelines. Studies comparing paired primary and 
axillary lymph nodes or synchronous primaries and metastases were 
excluded. Weighted pooled estimates were calculated.
Results: The original search strategy retrieved 1703 studies for which 
there were 62 eligible studies for full evaluation. Metastatic sites 
included bone, brain, lung and liver. Traztuzumab was received in 
three studies. Weighted summary estimate for negative to positive 
discordance was 23% (95% CI, 16.0-28%). Positive to negative 
discordance had a weighted summary estimate of 4% (95% CI, 
0.0-6%).
Discussion: Meta analysis of studies adhering to ASCO guidelines 
for HER2 status determination revealed a significant rate of change 
to HER2 positive metastatic disease in HER2 unamplified primary 
breast cancers. This data suggests that nearly one quarter of patients 
may be denied the benefit of HER2 targeted therapy if HER2 primary 
status alone is used a the sole measure in determining therapeutic 
options upon distant recurrence.
PD05-06
Determination of HER2 Status with Analysis of Plasma DNA by 
Digital PCR in Patients with Metastatic Breast Cancer.
Graeser MK, Gevensleben H, Smith IE, Ashworth A, Turner NC. 
Institute of Cancer Research, London, United Kingdom; Royal 
Marsden Hospital, London, United Kingdom
Background. A small proportion of originally HER2 negative primary 
breast cancers relapse with HER2 amplified disease. Identification of 
these cancers is important as these patients may benefit from HER2 
targeting therapies. A proportion of free plasma DNA originates 
from the cancer, and accurate determination of HER2 copy number 
in plasma DNA has the potential to non-invasively determine HER2 
status in patients with metastatic breast cancer. Digital PCR can 
differentiate small increases in DNA concentration with a much 
higher degree of accuracy than conventional quantitative PCR, and 
here we assess the potential of plasma DNA digital PCR to determine 
HER2 status.
Methods. We examined a cohort of 44 patients with metastatic breast 
cancer treated at the Royal Marsden Hospital who had received a 
median of 1.5 prior courses of chemotherapy for recurrent disease; 
34 patients had ER positive and 9 HER2 positive (all 3+ positive 
HercepTest) disease as determined on biopsy of recurrent disease 
in 16 patients and original primary cancer in 28 patients. Following 
informed consent, plasma samples were taken, free plasma DNA was 
extracted and concentration determined with LINE1 quantitative PCR. 
We designed a custom HER2 copy number TaqMan MBG-probe 
(Applied Biosystems) and two chromosome 17 peri-centromeric 
control probes TUFMP1 and UBBP4, avoiding known SNPs and 
regions of normal copy number variation. Digital PCR was performed 
in 384 well format on a 7900HT Fast RT-PCR system, with copy 
number ratio determined using the Poisson distribution.
Results. HER2 Digital PCR assay was initially tested on DNA from 
9 HER2 amplified cell lines. HER2/UPPB4 ratio was increased in 
9/9 HER2 amplified cell lines, and HER2/TUFMP1 in 7/9 due to co-
amplification of the 17q peri-centromeric DNA in 2 cell lines. Dilution 
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experiments with SKBR3 DNA in non-amplified DNA demonstrated 
sensitivity down to ~1% levels. We selected HER2/UBBP4 digital 
PCR for examination of patient samples. Plasma DNA Digital PCR 
HER2/UBBP4 ratios differed substantially between HER2 non-
amplified (mean 1.047, SD 0.149, median 1.046, range 0.70-1.264), 
and HER2 amplified cancers (median 2.231, range 1.138-7.89, 
p<0.001). Digital PCR HER2 ratios had a high diagnostic accuracy 
with ROC curve AUC 0.967 (95% CI 0.585-0.997). With a threshold 
Digital PCR HER2 ratio of 1.3 the test had 100% specificity and 89% 
sensitivity, with negative predictive value 97%. The single miscalled 
HER2 amplified patient had a low tumour burden. Results of a test 
set using sequential probability ratio test analysis will be presented 
at the conference.
Conclusions: Plasma DNA Digital PCR accurately determined HER2 
status in patients with metastatic breast cancer. Analyses of plasma 
DNA have the potential to replace biopsy sampling of metastatic 
disease to guided targeted therapy.
PD05-07
Prospective Validation and Characterization of HER2 Positive 
Circulating Tumor Cells in Patients with HER2 Negative 
Metastatic Breast Cancer.
Olson EM, Flores LM, Najita JS, Curley C, Jeong J, Murray K, Savoie 
JJ, Winer EP, Krop IE. Dana-Farber Cancer Institute, Boston, MA
Background: Circulating tumor cells (CTCs) with evidence of 
HER2 amplification can occur in patients (pts) with clinically HER2 
negative metastatic breast cancer. While these findings potentially 
have profound implications for CTCs as a biomarker for treatment, 
prospective validation and characterization of this subgroup is 
necessary.
Methods: We created a prospective cohort of pts with metastatic 
breast cancer that were HER2 negative by IHC and/or FISH on 
all available primary and metastatic biopsies. Blood samples were 
collected at study entry and then again at ≥ 3 weeks if available. 
CTCs were enumerated by a modification of the Veridex CellSearch 
Profile kit. FISH was performed on each CTC sample and reported as 
positive if the HER2/CEP17 ratio was ≥ 2.0. Analyses are descriptive.
Results: 66 pts were consented for study and this report includes the 
65 pts with detectable CTCs. Median number of CTCs was 226 (range 
112 to > 3000). At initial testing, 23 pts (35%) had HER2 positive 
CTCs, median HER2:CEP17 ratio of 3.4. 50% (11 of 22) of the pts 
with lobular or ductal/lobular histology had HER2 amplified CTCs, 
compared to only 27% (10 of 36) of patients with ductal histology. 
Women with ER positive disease had HER2 positive CTCs in 40% 
of cases (20 of 49) compared to 19% of ER negative pts (3 of 16). 
To assess concordance of HER2 amplification of CTCs over time, 
34 pts consented to be retested at a median 5.9 weeks after initial 
screening (range 3.3 - 17 weeks) and all but 1 had detectable CTCs. 
Baseline characteristics of these 34 pts were similar to the original 
population, with HER2 amplified CTCs detected in 35% (12 of 34) 
pts at initial screening. HER2 positive CTCs were concordant at 
time of retesting in 83% (10 of 12) pts; the 2 women with discordant 
CTCs were receiving HER2 directed therapy. Of the pts with HER2 
negative CTCs at initial screening, 81% (17 of 21) continued to have 
HER2 negative CTCs at time of retesting.
Conclusion: We observed a higher prevalence of HER2 positive CTCs 
among pts with ER positive disease and evidence of lobular histology. 
The presence of HER2 positive CTCs is concordant over time in the 
majority of pts. The functional significance of HER2 positive CTCs 
in patients with clinically HER2 negative breast cancer will be tested 
in a prospective study with HER2-directed therapy.
PD06-01
Molecular Classification with 21 Gene Assay (Oncotype DX®) 
Shows in 196,967 ER Positive Patients High Frequency of Low 
Recurrence Score [LRS] in Both Node Positive (N+) and Negative 
(N-) Breast Cancer (BrCa) Cohorts. Definition of Chemoresistance 
Based on LRS with Cost and Guideline Implications.
Ragaz J, Wilson KS, Wong H, Muraca G, Hryniuk W, Bajdik C. 
University of British Columbia, Vancouver, BC, Canada; British 
Columbia Cancer Agency, Vancouver, BC, Canada; CarePath, Inc., 
University of Toronto
BACKGROUND
Key retrospective analyses have shown no benefit from adjuvant CT 
[CT] in ER+, N-ve and N+ve BrCa pts with LRS by Oncotype DX 
assay. (For N-ve, hazards [RR] = 1.31, 95% C.I.: 0.46, 3.78 (Paik 
et.al., 2006); for N+ve, RR=1.01, 95% C.I.: 0.54, 1.93 (Albain et.al. 
2009)]. LRS (RS<18) can therefore be equated to CT resistance 
(CTRES).
OBJECTIVES
1. To determine the frequency of CTRES determined by Oncotype DX 
in the Genomic Health database of ER+, N-ve and N+ve pts.
2. To estimate the net cost savings resulting from avoidance of CT 
for CTRES pts, based on universal Oncotype DX testing in ER+ pts 
being considered for CT.
METHODOLOGY
STEP 1
Oncotype DX results were analyzed according to nodal status in the 
196,967 ER+ tumor samples for CT candidates submitted to Genomic 
Health between Jan 2007 – Apr 2011.
STEP 2
We then calculated the $ cost saved, result of Oncotype DX, 
assuming:
i. of new BrCa pts, 42% could be candidates Oncotype DX and CT 
(ER+, high risk N-ve; and all ER+ N+ve)
ii. either 50% or 100% CT avoidance – according to oncology practice 
- among LRS cases, estimating the CT cost/pt = $15,000 US; and 
Oncotype DX cost/pt = $4,000 US.
RESULTS - STEP 1
LRS based on Oncotype DX was more prevalent in N+ pts (chi sq p <0.0001)
RS N - N +
Category # % # %
Low (RS<18) 99,259 54% 8,170 59%
Int (RS 18-30) 61,898 34% 4,440 32%
High (RS≥31) 21,867 12% 1,333 9%
TOTAL 183,024  13,943  
RESULTS - STEP 2
CT Cost [in millions, USD] / 1,000 newly diagnosed cases who are CT and Oncotype DX 
candidates, of whom 50% [conservative estimates] will have LRS
$COST No test 50% of LRS avoid CT 100% of LRS avoid CT
CT 15 11.25 7.5
21 gene assay 0 4 4
Health system cost 15 15.25 11.75
Cost Savings $ 0 +0.25 mil -3.5 mil
Total cost savings / year / U.S.   -$330.75 mil
Thus, in USA, with 225,000 new BrCa pts / year, and 94 500 [42%] 
candidates for Oncotype DX, over 47,250 pts will have LRS, with 
overall savings of $330.8 mil /year with 100% CT avoidance. In 
Canada, with 25,000 estimated new BrCa pts/year, corresponding 
savings will be $46.2 mil / year.
CONCLUSIONS:
1. Low RS status, presently the most reliable CTRES biomarker, is 
expressed with higher frequency among N+ve (59%) vs N-ve (54%) 
ER+ breast cancer pts.
2. If all eligible cases had the Oncotype DX test, and all with LRS 
would avoid CT, close to 50,000 pts in USA, and over 5,200 in 
Canada will be spared ineffective CT and associated toxicity / year, 
with hundreds of million dollars saved each year.
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3. On principles of ethics and economy, these data suggest that until 
new research refines the molecular classification of BrCa for higher 
efficacy, and with lower cost and more practical access:
a. universal OncotypeDx testing for pts should be performed for all 
ER+ breast cancer pts candidates for CT;
b. management guidelines should be changed to avoid CT in all LRS 
pts, irrespective of nodal status;
c. until prospective randomized trials confirm CT benefit among LRS 
pts, its use should be considered investigational.
PD06-02
Cost-Effectiveness Evaluation of the Oncotype DX® Breast 
Cancer Assay in Clinical Practice in the UK.
Holt SDH, Bennett H, Bertelli G, Valentine WJ, Phillips CJ. Prince 
Philip Hospital, Llanelli, United Kingdom; Cardiff Research 
Consortium, Cardiff, United Kingdom; Singleton Hospital, Swansea, 
United Kingdom; Ossian Health Economics and Communications, 
Basel, Switzerland; Swansea University, Swansea, United Kingdom
Objective: Optimizing therapeutic regimens for breast cancer patients 
has an important role to play in improving outcomes and planning 
the best use of National Health Service resources. Oncotype DX® 
testing has been shown to provide clinically valuable information 
in addition to traditional measurements (such as tumor size, tumor 
grade and lymph node status) to support chemotherapy treatment 
decision making in women with estrogen receptor positive (ER+), 
node-negative and up to 3 node-positive breast cancer. The aim of 
this study was to evaluate the cost-effectiveness of Oncotype DX 
testing to support adjuvant therapy decision making versus current 
clinical practice in the treatment of patients with ER+, early-stage 
breast cancer in the UK.
Methods: A Markov model was developed to make long-term 
projections of distant recurrence, survival, quality-adjusted life 
expectancy and direct medical costs for patients with ER+, node-
negative or micrometastatic (pN1mic) early-stage breast cancer. 
Scenarios using conventional diagnostic procedures (including 
Adjuvant! Online and the Nottingham Prognostic Index) or Oncotype 
DX testing to inform treatment recommendations for adjuvant therapy 
were modeled. The model relied on data from an ongoing study in 
Wales for treatment recommendations (with and without Oncotype 
DX), landmark Oncotype DX studies for the risk of recurrence, 
and UK-specific life tables for mortality. Costs were derived from 
published UK sources and expressed in 2010 Pounds Sterling (GBP). 
Future costs and clinical benefits were discounted at 3.5% annually. 
Probabilistic and deterministic sensitivity analyses were performed.
Results: Oncotype DX was projected to increase mean life expectancy 
by 0.16 years and mean quality adjusted life expectancy by 0.14 
quality-adjusted life years (QALYs) compared with current clinical 
practice over a 30-year time horizon (see table). Clinical benefits 
were driven by optimized allocation of adjuvant chemotherapy in 
the Oncotype DX group. Direct medical costs were estimated to be 
higher with Oncotype DX testing, leading to an incremental cost-
effectiveness ratio (ICER) of approximately GBP 6,232 per QALY 
gained for Oncotype DX versus current clinical practice in the UK. 
Sensitivity analysis showed that the cost-effectiveness of Oncotype 
DX testing was most sensitive to variations in patient age and net 
changes in chemotherapy for low risk patients.
Long-term clinical and cost outcomes with Oncotype DX testing versus current clinical practice
 Current clinical practice Oncotype DX testing Difference
Life expectancy (years) 14.73 14.89 0.16
Quality-adjusted life expectancy 
(QALYs)
11.39 11.54 0.14
Cost (GBP) 11,847.24 12,734.93 887.69
ICER (GBP per QALY gained) 6,231.91
Values shown are per patient. 
Conclusions: Reallocation of adjuvant chemotherapy based on 
Oncotype DX test results was associated with improvements in 
survival and quality-adjusted life expectancy in this modeling 
analysis. At a willingness to pay threshold of GBP 20,000 per 
QALY (commonly quoted as representing good value for money in 
the UK), probabilistic sensitivity analysis showed that there was a 
99.6% probability that Oncotype DX would be cost-effective versus 
current clinical practice.
PD06-03
Cost Effectiveness Analysis of BRCA1/2 Genetic Testing.
Li Q, Holland M, Huston A, Noyes K. University of Rochester School 
of Medicine, Rochester, NY
Background: Family history of breast and/or ovarian cancer is 
associated with an increased risk to carry a BRCA1 or BRCA2 gene 
mutationmutations which significantly increase a woman’s risk to 
develop breast and/or ovarian cancer. This study examines whether 
BRCA1/2 genetic testing (intervention) remains cost-effective 
compared to no genetic testing strategy (control) from the societal 
and private payer perspectives given updates in healthcare practice, 
policy and clinical specificity of testing in the last 10 years.
Data and method: We updated a previous published semi-Markov 
model (Holland et al., Value in Health, 2009. 12(2): p. 207) to include 
new information about associated costs and treatment strategies and 
test specificity. The target population is 35 year old asymptomatic 
US women with an elevated risk of BRCA1/2 genetic mutation. The 
estimates of probability (prevalence, risk, preference and mortality), 
cost, and utility are derived from published reports and BRCA1/2 
test technical documentation. We conducted the basecase cost-
utility analysis and a series of sensitivity analyses by varying pretest 
probability of BRCA1/2 mutation, clinical sensitivity of BRCA1/2 
testing, initial utility after BC diagnosis and patient preference in 
the first year after mastectomy, cost of BRCA1/2 testing, and out-
of-pocket costs.
Results: From the societal perspective, the “no test” strategy was 
estimated to cost $162K and resulted in 20.2 QALY gain over a 
patient’s lifetime. The “test” strategy was estimated to cost $172K 
and result in 20.5 QALY gain, resulting in the incremental cost 
effectiveness ratio (ICER) of $30.6K/QALY. From a private payer 
perspective, the ICER was $36.8K/QALY. By conducting sensitivity 
analyses, we concluded that the model was robust to variation in the 
model parameters. Within the ranges of most variable estimates, the 
test strategy was more cost effective compared to the no-test strategy. 
The initial utility after BC diagnosis (basecase value 0.75) does not 
impact the choice of preferred strategy (testing is always preferred). 
Based on the probability of mutation for women with family history 
(basecase value 8.7%), testing is preferred if probability is greater 
than 3.1%, while no testing is preferred for values <3.1%. Only if cost 
of genetic testing is greater than $8,948 testing would it no longer be 
cost effective, which is however far beyond even the upper bound 
of cost estimate ($4,500). As long as the sensitivity of BRCA testing 
remains greater than 80% and initial utility after mastectomy <0.9, 
the testing is preferred over no testing.
Discussion: The strategy of BRCA1/2 testing of women at high risk 
for BRCA1/2 mutations and treatment of BRCA1/2 positive women is 
cost-effective compared to “no genetic testing” strategy. Cost of the 
actual test is not a barrier to its cost-effectiveness. Despite adding MRI 
to breast cancer surveillance in high risk population and increases in 
healthcare costs, BRCA1/2 testing remains cost-effective from both 
the societal and from a private payer perspectives for an unaffected 
population with BRCA1/2 prevalence of greater than 3%.
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PD06-04
Uptake and Economic Impact of First-Cycle Colony Stimulating 
Factor Use during the Adjuvant Treatment of Breast Cancer.
Hershman DL, Wilde ET, Wright JD, Buono DL, Kalinsky K, Malin 
J, Tsai WY, Neugut AI. Columbia University, New York, NY; Mailman 
School of Public Health, New York, NY; Greater Los Angeles VA 
Healthcare System, Los Angeles, CA
Background: In 2002, pegfilgrastim was approved by the FDA 
and the benefits of dose-dense breast cancer(BC) chemotherapy 
were reported. A meta-analysis revealed these benefits were limited 
to hormone receptor negative tumors (20% risk reduction), where 
hormone receptor positive cancers had a minimal 2% risk reduction. 
We examined first-cycle growth factor use(FC-CSF) before and after 
2002 and estimated US expenditures for dose-dense chemotherapy 
by hormone receptor status.
Methods: We identified subjects in SEER-Medicare>65 years oldwith 
stage I-III BC between 1998 and 2005who had>1 chemotherapy claim 
within one year of diagnosis. We classified those with an average cycle 
length <21 days as having had dose-dense therapy. The associations 
of patient, tumor, and physician-related factors with receipt of any 
CSF and FC-CSF use were analyzed using GEE. Costs and event-free 
life-years saved were estimated for patients by HR status.
Results: Among the 11,143 patients identified, 5,356(48.1%) hada 
CSF claim during therapy and 2095(18.8%) had FC-CSF. CSF use 
increased from 25.4% to 70.9%, FC-CSF increased from 6.4% to 
46.9% and pegfilgrastim increased from 5% to 85%. During this 
time receipt of the combination of an anthracycline and a taxane 
increased from 12% to 47%. In a multivariable analysis, any CSF 
use was associated with age, treatment by an oncologist, and 
chemotherapy type; and negatively associated with black/Hispanic 
race, rural residence and shorter chemotherapy duration. FC-CSF 
use was associated also with higher SES. For hormone receptor 
negative patients, the cost per event-free life year saved was $5,512, 
with annual costs of $19.5 million. For hormone receptor positive 
patients, however, there was no savings in life years (and therefore 
no relevant cost per event-free life year saved) with annual costs of 
$38.8 million for those over 65. The annual costs were estimated at 
$86.1 million for the hormone receptor positive patient population 
incorporating all ages.
Conclusions: Our study demonstrated a widespread increase in 
the use of CSF’s and specifically first cycle pegfilgrastim in elderly 
women receiving adjuvant chemotherapy for breast cancer. This 
4-fold increase came shortly after published reports of the benefits 
of dose-dense therapy. While this approach is very cost-effective in 
women with hormone receptor negative tumors, it has come at great 
financial cost in women with hormone receptor positive tumors who 
are less likely to have a meaningful benefit. In order to reduce the 
total costs of cancer-care, efforts should be made to ensure that these 
treatments are reserved for only those who benefit substantially from 
their use.
PD06-05
Primary and Secondary Pegfilgrastim Utilization in Adjuvant 
Chemotherapy for Breast Cancer in the Community.
Patt DA, Espirito JL, Turnwald B, Hoverman JR, Neubauer MA, 
Busby LT, Brooks BD, Kolodziej MA, Anderson RW, Beveridge RA, 
On Behalf of US Oncology Pathways Task Force and Clinical Content 
Development Team. Texas Oncology, TX; US Oncology, TX; Kansas 
City Cancer Center, KS; Rocky Mountain Cancer Center, CO; New 
York Oncology Hematology, NY
Background
Various factors are taken into consideration in the selection of 
adjuvant breast cancer (BC) chemotherapy (CT) regimens for patients. 
Choice of CT, schedule, duration, and supportive care affects costs 
and toxicity. Understanding clinical practice utilization patterns are 
important when making cost estimates of adjuvant therapy. Because 
pegfilgrastim is a large driver of cost it is important to understand 
the utilization characteristics. We aimed to characterize primary 
and secondary pegfilgrastim use during neoadjuvant/adjuvant (N/
Ad) chemotherapy by regimen type. While initial data suggests the 
incidence of febrile neutropenia (FN) is low among some docetaxel 
containing regimens, we wanted to further characterize pegfilgrastim 
utilization, as previous utilization studies suggested it was higher 
than expected.
Methods 
Using the US Oncology iKnowMed™ EHR database, we 
retrospectively identified female BC patients (pts) diagnosed with 
stage I-III BC, between 7/2006 and 11/2010. Secondary diagnoses 
were excluded. Pts were characterized by age, ER and HER2 status, 
tumor size, grade, and nodes. CT utilization was determined by the 
number of pts assigned an N/Ad line of therapy (LOT) during the 
study period. Regimens were categorized by CT title and drugs. 
Clinical trial pts were included. Pegfilgrastim utilization was 
characterized if administered within 6 months of being assigned to 
an N/Ad CT regimen, and was captured as primary prophylaxis if 
the first dose was administered ≤5 days of C1D1 of a regimen, and 
secondary prophylaxis if >5days.
Results
General chemotherapy and pegfilgrastim utilization characteristics 
were previously reported. This report captures primary vs. secondary 
pegfilgrastim use. During the time period, 40,881 BC pts were 
identified. Of these, 15,328 pts (37%) were assigned an N/Ad CT 
regimen and 72% (11, 022 pts) received pegfilgrastim at any time 
within 6 months of their N/Ad regimen. Docetaxel containing 
regimens (TC, TAC, TCH) and dose-dense regimens accounted for 
the majority of all pegfilgrastim use. Pegfilgrastim utilization with the 
TC regimen was 70%, and represented 25% of all N/Ad pegfilgrastim 
utilization. The vast majority of utilization for TC and TCH was 
primary prophylaxis as detailed below:
Regimen Primary utilization % of total
Secondary 
utilization % of total None % of total Grand Total
TC 2089 53% 637 16% 1183 30% 3909
TCH 795 53% 302 20% 398 27% 1495
Conclusions
While primary prophylaxis in regimens like dose-dense AC and TAC 
are expected, the primary utilization of pegfilgrastim in TC and TCH 
is higher than expected based on published clinical trial experience. 
The incidence of FN has been reported at 5% in the clinical trial by 
Jones et al with TC, however subsequent reports suggest the incidence 
of FN may be higher than expected. Our results demonstrate high 
primary prophylaxis utilization adoption in clinical practice. With the 
availability of generic docetaxel, commonly used drugs in adjuvant 
BC except trastuzumab have generic equivalents. Pegfilgrastim will 
be the largest cost driver in women receiving adjuvant chemotherapy 
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and should be considered among cost estimates. This study may 
underestimate utilization of pegfilgrastim if it was administered 
outside of the cancer center.
PD06-06
Is Adjuvant Trastuzumab Economically Justified in Her-2/neu 
Positive T1bNO Breast Cancer?
Skedgel C, Rayson D, Younis T. Capital Health, Halifax, NS, Canada
Background: A number of clinical trials and cost-utility analyses of 
adjuvant trastuzumab (aTZ) for Her-2/neu positive breast cancer 
suggest favourable efficacy and safety along with acceptable cost-
effectiveness. These evaluations, however, were based on patient 
cohorts with moderate-to-high risk disease, including node positive 
or high risk node negative disease with tumor sizes greater than 1cm 
(≥T1cN0). The role of aTZ for patients with lower risk disease, such 
as T1bN0, remains unclear in light of the varying 10-year relapse 
risks (10-30%) reported to date.
Objective: To estimate the cost-utility of chemotherapy plus aTZ 
versus chemotherapy alone in Her-2/neu positive breast cancer 
patients with lower recurrence risk in terms of cost per quality-
adjusted life year (QALY) gained.
Methods: A state-transition economic model was developed to 
estimate the incremental costs and quality-adjusted life year 
(QALY) gains associated with a strategy of chemotherapy plus aTZ 
relative to chemotherapy alone over a 25-year analysis horizon. 
The model consisted of four broad health states, stratified with 
or without cardiotoxicity: 1) disease-free, 2) local recurrence, 3) 
distant recurrence and 4) death. Given the variability in reported risk 
estimates for T1bN0 disease, a range of 10-year baseline recurrence 
risks (10-30%) in the absence of chemotherapy or aTZ was examined. 
The clinical benefit of chemotherapy was assumed to differ according 
to age (<50 vs. ≥50 years). The hazard ratio of recurrence with aTZ 
(HR=0.64) and the rate of associated adverse cardiac events were 
derived primarily from the HERA clinical trial. Utility weights and 
the costs of local and distant cancer recurrence were derived from the 
literature, while the costs of adjuvant and palliative TZ were derived 
from our previous work. The model took a direct payer perspective, 
with costs reported in 2011 Canadian dollars (CDN$). Costs and 
QALYs were both discounted by 3% annually. The reference analysis 
assumed 3 years of clinical benefit from chemptherapy and aTZ. A 
series of one-way sensitivity analyses tested the impact of longer 
benefit as well as the impacts of measuring outcomes in terms life 
years rather than QALYs, a lifetime analysis horizon and different 
HRs.
Results: The reference analysis observed that the cost per QALY 
gained was greater than CDN$100,000 across the entire range of 
recurrence risks tested. One-way sensitivity analyses observed that 
considering life years rather than QALYs, a lifetime analysis horizon, 
extending the duration of benefit to 5 years or improving the HR to 
0.54 each did little to improve the overall economic favorability of 
aTZ, even at the higher range of recurrence risk.
Conclusions: The cost-utility of adjuvant trastuzumab appears 
unfavourable in Her-2/neu positive breast cancers with a baseline 
10-year relapse risk of less than 30% without treatments, such as in 
T1bN0 disease. Specific estimates of cost-utility await more precise 
estimates of the recurrence risk in patients with T1bN0 disease.
PD06-07
COMPliance and Arthralgias in Clinical Therapy (COMPACT): 
Assessment of the Incidence and Severity of Arthralgia, Treatment 
Costs and Compliance within the First Year of Adjuvant 
Anastrozole Therapy.
Hadji P, Blettner M, Bolten WW, Harbeck N, Hindenburg H-J, 
Jackisch C, König K, Lueck H-J, Rief W, Zaun S, Klein P, Kreienberg 
R. Phillips-University, Marburg, Germany; Institute for Medical 
Biometry and Epidemiology, Mainz, Germany; Klaus-Miehlke-
Klinik for Rheumatology, Wiesbaden, Germany; Breast Center, 
Women’s University Hospital, Cologne, Germany; Berufsverband 
Niedergelassener Gynäkologischer Onkologen e.V., Berlin, Germany; 
Klinikum Offenbach, Germany; Berufsverband der Frauenärzte 
e.V., Germany; Gyn. Oncological Practice, Hannover, Germany; 
AstraZeneca, Germany; DSH Statistics, Germany; University 
Womens’ Hospital, Ulm, Germany
Introduction: Aromatase inhibitors (AI) are well established as 
adjuvant endocrine treatment for postmenopausal (PMP) women with 
HR+ early breast cancer (EBC). However, according to retrospective 
data, compliance to adjuvant endocrine therapy for EBC may drop to 
below 70% after one year and to as low as 50% by year 4. In clinical 
trials, AI are significantly more frequently associated with arthralgia 
than tamoxifen. Yet, prospective real world data on the effects of 
AI-associated arthralgia on patient compliance, patient outcomes as 
well as treatment costs of arthralgia are lacking.
Methods: COMPACT is an open, prospective, non-interventional 
study assessing the incidence and severity of arthralgia, treatment 
costs, and compliance within the first year of adjuvant anastrozole 
therapy in PMP women with HR+ EBC. The study is sponsored 
by AstraZeneca Germany and supported by three major German 
health insurance funds [GWQ ServicePlus AG, DAK, TK]. Patients 
on adjuvant treatment for 3-6 months were enrolled at 620 breast 
centres and practices throughout Germany and stratified by, a) 
initial adjuvant anastrozole therapy or, b) switch from tamoxifen to 
anastrozole. All patients receive regular standardized information 
about EBC from baseline to week 20 to support treatment compliance. 
Data on patient demographics, occurrence of and treatment of 
arthralgia, and quality of life will be collected at baseline, 3, 6 and 
9 months. Primary endpoints are scaled data on arthralgia, assessed 
with a visual analogous scale (VAS) via patient questionnaire, and 
compliance to anastrozole in both strata, assessed by patient and 
investigator questionnaire. Secondary endpoints include the incidence 
of arthralgia, treatment costs, reasons for non-compliance, and the 
influence of arthralgia on clinical outcome. For a subgroup of patients 
data on arthralgia treatment and compliance will be validated with 
corresponding data of the participating health insurance funds.
Results: Between April 2009 and February 2011, 2313 patients were 
recruited, 2007 receiving upfront anastrozole and 306 patients on 
switch therapy. Preliminary baseline data for 2313 patients show the 
following patient characteristics: mean age 64.5 years, mean BMI 
27.7. Only 16.8% of patients had received hormone replacement 
therapy prior to their cancer. 41.5 % of patients had concomitant 
symptoms relating to skeleton or musculature, and 11.9% stated 
arthralgias existing prior to anastrozole treatment. 13.1% reported a 
worsening of pre-existing arthralgias or new arthralgia after starting 
on anastrozole treatment.
Conclusion: COMPACT aims to provide valid real world data on 
the incidence and severity of AI-associated arthralgia, treatment 
modalities and treatment costs. Our results will help to understand 
and better counsel patients about AI-associated arthralgia to improve 
adherence to AI-treatment, breast cancer outcomes, and therapy costs.
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PD06-08
Projecting the Impact of Adopting Trial Results
Esserman LJ, Mohan AJ, Park C, Berry DA, Ozanne E, Alvarado 
MD. UCSF; M.D. Anderson
Background: There is often a substantial delay between the 
presentation of clinical trial results and change in practice. Reasons 
for slow adoption include the disruption of practice routines, doubt 
about the validity of results, financial disincentive, and resistance to 
change. We propose a decision-making process to inform adoption 
that considers three factors: likelihood the trial’s conclusions will not 
change with longer follow up, and consequences of early and late 
adoption. We apply this framework to the published 4-year results 
of the international TARGIT-A trial, which compares intraoperative 
radiation therapy (IORT) to external beam radiation therapy (EBRT).
Methods: To find whether the trial results will remain robust, we 
reviewed the TARGIT-A trial’s annual hazards for local recurrence 
(LR). We then reviewed 5-10 year LR rates from recent clinical trials 
with similar patient populations undergoing RT, no RT or partial breast 
RT. To assess the impact of an early change in practice, a Markov 
model was used to evaluate life expectancy, quality adjusted life 
years (QALYs), and cost. Sensitivity analysis estimated the impact of 
varying the LR rate 1-20x the TARGIT-A 4 year results. To estimate 
the impact of late adoption,  we generated the expected number of 
N0, grades 1 & 2, ductal cancers in postmenopausal women (>50 
yrs) from SEER and US Census Bureau data. Using Medicare rates, 
costs of EBRT vs. IORT were compared and potential savings to the 
health care system calculated.
Results: The TARGIT-A peak hazard for LR for IORT and EBRT 
occurred at 3 years. In the START and ATAC trials, the peak local 
recurrence Kaplan Meier estimates are between 2 and 3 years. In 
other trials (ATAC, and in the 2005 RT Lancet overview) there is no 
second peak of recurrence, making it unlikely that longer follow up 
will change the conclusion of the TARGIT-A results. The LRR in 
similar trials have dropped steadily over time for post menopausal, 
stage I patients with or without RT. Impact of early adoption: If 
treatment were adopted early, the impact on life expectancy and 
QALYs would be minimal unless IORT LR rate exceeds 20% over a 
10 year period of time. Impact of late adoption: In the US, 45% of new 
breast cancer cases fit the described population. EBRT costs $6,400 
more than IORT per patient on average. If adoption were delayed 
5 years to allow the trial results to mature, 70,136 patients per year 
are expected to receive EBRT resulting in a societal burden of >$2.2 
billion barring the capital investment required for new technology. 
This also assumes that patients have equal utility for a single dose of 
IORT as they do for 3-6 weeks of postoperative radiation therapy. If 
IORT utility is higher than that of EBRT, then the IORT strategy is 
both more effective and less costly.
Conclusion: The process of modeling the impact of both early and late 
adoption when considering the stability of trial results can serve as a 
tool to evaluate whether to change practice. This analysis was tested 
on the results of the TARGIT-A trial, and demonstrated that prompt 
adoption of the IORT intervention would cause minimal harm, provide 
an improved quality of life, and offer significant societal savings.
PD06-09
Early Predictors of Prolonged Unemployment after a Diagnosis 
of Breast Cancer.
Blinder V, Patil S, Eberle C, Maly RC. Memorial Sloan-Kettering 
Cancer Center, New York, NY; University of California, Los Angeles, 
CA
Introduction: Low-income women may be more vulnerable to job 
loss and prolonged work absence after a diagnosis of breast cancer 
than their higher-income counterparts. This can have important 
adverse financial consequences on breast cancer survivors. The 
identification of early risk factors for long-term unemployment 
could inform interventions to help patients avoid this outcome. 
Methods: A consecutive sample of 921 low-income, underinsured or 
uninsured, English and/or Spanish-speaking women treated for breast 
cancer through the California Breast and Cervical Cancer Treatment 
Program was recruited and surveyed 6 months after a diagnosis of 
breast cancer. Participants completed follow-up telephone surveys at 
18, 36, and 60 months post-diagnosis; 539 remained in the cohort at 
60 months. This analysis includes only the 315 (58%) women who 
were employed before diagnosis. Our primary study outcome was 
prolonged unemployment, defined as being unemployed at every 
survey. Baseline characteristics (measured in the 6-month survey) 
were compared between women with prolonged unemployment and 
those who were working 60 months after diagnosis. Results: The 
median age of the study sample was 50, and 98% had a baseline 
annual household income < $40,000. Eighty-five of 315 (27%) women 
who were employed before diagnosis had prolonged unemployment 
after diagnosis. In contrast, 168 (53%) were working at 60 months. 
Baseline predictors of prolonged unemployment after diagnosis 
include lower household income (p=0.003), inadequacy of financial 
resources to cover needs (40% vs. 23%, for inadequate vs. adequate, 
p=0.006), lower education (43%, 30%, and 23% among those who 
did not complete high school, had a high school diploma, and had a 
college diploma, respectively, p=0.04), higher comorbidity burden 
(p=0.006), higher cancer stage at diagnosis (p=0.001), and receipt 
of chemotherapy (p=0.008). Variables found not to be associated 
with prolonged unemployment include age, ethnicity, acculturation, 
marital status, children in the home, social support, job type, type 
of breast surgery, type of axillary surgery, endocrine therapy, and 
radiation therapy. In a multivariable analysis that included ethnicity, 
education, income, chemotherapy, and comorbidity, the latter three 
variables remained statistically significant predictors of prolonged 
unemployment, but education and ethnicity were not significantly 
associated with the outcome. Discussion: More than a quarter of 
women treated for breast cancer never returned to work during the 
five years after their diagnosis. In this low-income sample, those with 
the lowest income appeared to be especially vulnerable to prolonged 
unemployment, even when controlling for education. It is possible that 
the income provided by a low-paying job provides a marginal benefit, 
if any, over disability income, and additional research is needed to 
better understand this relationship and its financial and psychosocial 
consequences. Clinical variables also were important predictors of 
prolonged unemployment. Women with a higher comorbidity burden 
and those treated with chemotherapy appear to be most vulnerable to 
prolonged unemployment. This may have clinical implications for 
informed decision-making between oncologists and their patients.
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PD06-10
Breast Cancer Patient Distress Associated with Difficulties 
Navigating the Costs Associated with Care: Results from a 
National Education Program.
Ahmed I, Gubin A, Champion L, Harvey A, Amsellem M. The Cancer 
Support Community
Compounding the stressors related with a diagnosis of breast cancer 
can be the associated direct and indirect costs of cancer care. To 
address this need, the Cancer Support Community (CSC) in 2009 
developed an evidence-based, professionally-led national education 
workshop for cancer patients and caregivers entitled Frankly Speaking 
About Cancer: Coping with the Cost of Care. As part of this workshop, 
participants completed a survey describing their experiences 
coping with the cost of cancer care. To date, responses from 465 
participants (representing 46 workshops) have been analyzed. Of 
those participants, 105 are women diagnosed with breast cancer.
Though workshop participants were affected by a wide variety of 
cancer diagnoses, half of those with cancer attending the workshop 
(50%) were affected by breast cancer. No significant differences 
between breast cancer patients and individuals with other cancers were 
found. Analyses are based on responses from breast cancer patients 
only. Participants’ pre-workshop rating of their understanding about 
the financial aspects of their breast cancer care was low (m =2.8, 
s.d.=1.0) and was significantly less than their level of knowledge 
post-workshop (m =4.1, s.d.=0.7, p <.05).
Most attendees (72.8%) reported experiencing some degree of 
emotional distress from trying to manage cancer care costs, and nearly 
one-third of attendees (30.1%) reported significant distress. Most 
(64.8%) reported that their healthcare team did not discuss financial 
aspects of care with them. Of attendees whose team did discuss it 
with them, typically it was a social worker, physician, or nurse. Of 
those who had this discussion, only 34% reported that this information 
was actually useful to them. Not surprisingly then, attendees reported 
they have looked elsewhere for information about managing the costs 
of care, such as patient support organizations (40.2%), the Internet 
(43.5%), and other patients (41.3%).
A positive to arise from the workshop is that most participants 
(69.9%) reported the intention to discuss financial aspects of their 
care with their healthcare team based on what they had learned from 
the workshop. Intention to have this discussion with their healthcare 
team was both positively correlated with having experienced 
emotional distress about the cost of their care (r =.29, p <.05) as well 
as negatively correlated with their level of pre-workshop knowledge 
about financial issues in breast cancer care (r =-.28, p <.05).Taken 
together, these data highlight significant obstacles that individuals 
face in receiving meaningful information relevant to managing the 
costs associated with cancer care.
PD07-01
Sequential Treatment with Epirubicin/Cyclophosphamide, 
Followed by Docetaxel vs. FEC120 in the Adjuvant Treatment of 
Breast Cancer Patients with Extensive Lymph Node Involvement: 
Final Survival Analysis of the German ADEBAR Phase III Study.
Janni WJ, Harbeck N, Sommer H, Rack B, Salmen J, Augustin D, 
Simon W, Jueckstock J, Wischnik A, Anneke K, Melcher C, Friese 
K, Kiechle M. Heinrich-Heine-University, Duesseldorf, Germany; 
University Cologne, Cologne, Germany; Ludwig-Maximilians-
University, Munich, Germany; Mammazentrum Ostbayern, 
Deggendorf, Germany; Robert-Bosch-Krankenhaus, Stuttgart, 
Germany; Zentalklinikum, Augsburg, Germany; Technische 
Universität, Munich, Germany
Background: Based on meta-analytic evidence, taxane containing 
adjuvant chemotherapy has been established as standard treatment 
in node-positive breast cancer. However, in the MA-21 study, 
adriamycin-cyclophosphamide, followed by paclitaxel (AC-P) was 
significantly inferior to the gold standard of anthracycline treatment, 
FEC120 (Burnell, SABCS 2006). We prospectively compared a 
sequential epirubicin-docetaxel chemotherapy regimen to FEC120.
Patients and Methods:
The ADEBAR study was a multicenter phase III trial (n=1502) to 
evaluate whether breast cancer (BC) pts with > 3 axillary lymph node 
metastases benefit from a sequential anthracycline-docetaxel regimen 
(E90C–D: 4 cycles epirubicin [E] 90 mg/m2 plus cyclophosphamide 
[C] 600 mg/m2 q21 days followed by 4 cycles docetaxel [D] 100mg/
m2 q21 days) compared to dose-intensive anthracycline-containing 
polychemotherapy (FE120C: 6 cycles E 60 mg/m² d 1+8, 5-FU 
500mg/m² d 1+8 and C 75 mg/m² d 1-14, q4 weeks). The median 
follow-up time will be 60 months.
Results:
Treatment was stopped prematurely in 3.7% of the pts in the 
E90C–D arm and in 8.0% in the FE120C arm due to toxicity 
(p=0.0009). Antibiotic treatment was given in 10.4% (E90C–D) 
vs. 19.7% (FE120C), G-CSF support in 39.2% vs 61.4 % and 
erythropoietin stimulation in 8.7% vs. 20.0%, respectively 
(p<0.0001). Haematological toxicity (leucopenia, neutropenic 
fever, thrombocytopenia, anemia) was significantly higher in the 
FE120C-arm.
Mature final 5-year-survival data will be presented at the SABCS 
meeting 2011.
Conclusion:
Different toxicity profiles given, hematological toxicity in the FE120C 
group was more severe than in the E90C–D. Mature survival data 
will be discussed in this context.
PD07-02
Docetaxel Is Superior to Paclitaxel Given Every Three Weeks 
in Post Operative Patients with Node-Positive Breast Cancer: 
Results of the Final Analyses of the NSAS-BC (National Surgical 
Adjuvant Study of Breast Cancer) 02 Trial from Japan.
Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata 
H, Mukai H, Uemura Y, Ohashi Y. Hamamatsu Oncology Center, 
Hamamatsu, Japan; Kitasato University Hospital, Sagamihara, 
Japan; Saitama Cancer Center, Inachou-Omuro, Japan; NHO 
Osaka National Hospital, Osaka, Japan; Shikoku Cancer Center, 
Matsuyama, Japan; Kyushu Cancer Center, Fukuoka, Japan; Aichi 
Cancer Center, Nagoya, Japan; National Cancer Center, Kashiwa, 
Japan; University of Tokyo, Tokyo, Japan
 Background: Four cycles of doxorubicin plus cyclophosphamide 
(4-AC) followed by four cycles of a taxane is widely used for 
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postoperative chemotherapy in breast cancer (BC). Concern about 
relatively rare, but life-threatening toxicity of anthracyclines such 
as heart failure and secondary leukemia has promoted research to 
seek anthracycline-free regimens. Since 1990’s when taxanes were 
introduced, docetaxel (DTX) is used interchangeably with paclitaxel 
(PTX) for the treatment of BC, but they may differ more than initially 
anticipated. We conducted this trial to test two hypotheses: (1) Eight 
cycles of a taxane is not inferior to 4-AC followed by four cycles of 
a taxane; (2) one taxane is superior to the other.
 Methods: Eligibility included a diagnosis of clinical stage I-IIIA 
and axillary node-positive BC, an age younger than 71 years and 
with performance status of 0 to 1. Patients were randomly assigned 
to receive either one of the following regimens;
 ACP: 4-AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/
m2 q3w  x 4) followed by 4-PTX (175 mg/m2 q3w  x 4)
 ACD: 4-AC followed by 4-DTX (75 mg/m2 q3w  x 4)
 8-PTX: PTX (175 mg/m2 q3w  x 8)
 8-DTX: DTX (75 mg/m2 q3w  x 8)
Comparisons included PTX vs. DTX (ACP + 8-PTX vs. ACD + 
8-DTX) and +AC vs. -AC (ACP + ACD vs. 8-PTX + 8-DTX). The 
primary endpoint was disease-free survival (DFS), and the secondary 
endpoints include overall survival (OS). The trial was powered to 
prove the non-inferiority of +AC to -AC (threshold hazard ratio 1.32) 
in terms of DFS. DFS was also compared between PTX and DTX to 
determine any superiority.
 Results: A total of 1,060 eligible patients were accrued at 84 centers 
between December 2001 and April 2006. There were 348 DFS events 
and 166 deaths after a median followup of 72.2 months. DTX was 
superior to PTX in terms of both DFS (Hazard ratio(HR) 0.76; 95% 
Confidence Interval(CI) 0.62-0.95, p=0.012) and OS (HR 0.72;95%CI 
0.53-0.97, p=0.033). -AC was not inferior to +AC with respect to 
DFS (HR: 1.21, 90% CI 1.01-1.44). Among the four arms, 8-PTX 
alone resulted in poorer DFS (compared with ACP, HR 1.42 95%CI 
1.07-1.89).
Comparison of Disease Free Survival in four arms
 ACP ACD 8-PTX 8-DTX
Hazard Ratio 1 0.93 1.42 0.91
95% Confidence Interval - 0.68-1.26 1.07-1.89 0.67-1.24
 p value - 0.62 0.016 0.56
Nausea and vomiting were more frequent with +AC than -AC. Edema 
and febrile neutropenia were more frequent with DTX than PTX. The 
incidence of sensory neuropathy was higher with PTX than DTX and 
it lasted for more than one year of the end of PTX treatment.
 Conclusions:  When AC, PTX and DTX were given every three 
weeks, both DFS and OS were better in the arms including DTX than 
in those including PTX. AC followed by a taxane can be replaced 
by 8-DTX.
PD07-03
Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) 
Plus Trastuzumab (HER TC) in HER2-Positive Early Stage 
Breast Cancer Patients.
Jones S, Collea R, Paul D, Oratz R, Sedlacek S, Favret AM, Gore, Jr 
II, Lindquist DL, Holmes FA, Allison MAK, Steinberg MS, Stokoe C, 
Portillo RM, Crockett M, Wang Y, Asmar L, Robert N, O’Shaughnessy 
J. US Oncology, The Woodlands, TX; Baylor Sammons Cancer 
Center, Dallas, TX; New York Oncology Hematology, Albany, 
NY; Rocky Moutain Cancer Center, Denver, CO; Physician, 
New York, NY; Virginia Cancer Specialists, PC, Fairfax, VA; 
Birmingham Hematology and Oncology, Birmingham, AL; Arizona 
Oncology Associates, Sedona, AZ; Texas Oncology, Houston, TX; 
Comprehensive Cancer Center, Henderson, NV; Virginia Oncology 
Associates, Virginia Beach, VA; Texas Oncology, Plano, TX; Texas 
Oncology, El Paso, TX
Introduction: TC is an effective adjuvant chemotherapy regimen in 
early stage breast cancer (ESBC) patients. Jones et al (J Clin Oncol 
2009 Mar 10;27(3):1177-1183) demonstrated a significantly superior 
5-year DFS and OS for TC compared to AC. Because TC was superior 
to AC in a subset analysis of HER2+ breast cancer treated without 
trastuzumab, we tested TC in combination with 1 year of trastuzumab 
in lower risk HER2+ ESBC, predominately node negative disease.
Methods: This was an open-label, phase II study of TC+H in HER2+ 
patients based on HER2 overexpression determined at the local level. 
Tissue was collected for central review of HER2 and TOP2A status. 
There was no lower limit of tumor size for lymph node negative 
cancers. Every 21 days, patients received docetaxel (T) 75mg/m2 IV, 
plus cyclophosphamide (C) 600mg/m2 IV, plus weekly trastuzumab 
(H) 4mg/kg IV (loading dose) and 2mg/kg IV thereafter for a total of 
4 cycles. After 4 cycles of TC+H, patients continued on H for a total 
of 1 year. Appropriate patients received radiotherapy. Cardiotoxicity 
(decreased left ventricular ejection faction) was assessed by MUGA 
or ECHO at baseline, at completion of TC+H, and then at 3-month 
intervals until completion of trastuzumab treatment. The primary 
endpoint was DFS at 2 years with continued follow-up for 3 years. 
Secondary endpoints were OS and safety.
Results: 486 patients received treatment, and 397(82%) completed 
a full year of H. Median age was 55 years(range: 24-75.8), ECOG 
PS 0=426(87.7%) and 1=60(12.3%); 280(57.6%) were Stage 1, 
200(41.2%) were Stage II, and 6(1.2%) were Stage III. Disease-free 
survival and OS at 2 and 3 years are listed in the table below according 
to various features.
Table 1
No. Patients DFS 2-Yr % DFS 3-Yr % OS 2-Yr % OS 3-Yr %
486 safety population 98 96 99 99
101 node positive 96 92 100 98
385 node negative 98 97 99 99
106 <1.1 cm tumor size 99 99 100 100
221 1.1-2.0 cm tumor size 98 96 100 100
159 >2.0 cm tumor size 95 94 99 97
The most common Grade 3/4 toxicities were neutropenia (47.1%) 
and febrile neutropenia (6.2%). There were 5 deaths: 1 due to PD, 1 
aspiration, and 1 respiratory distress syndrome (possibly related to 
treatment), 1 cardiopulmonary arrest, and 1 unknown. There were 13 
cases of recurrent breast cancer (local 5, or local/distant 8). Cardiac 
dysfunction occurred in 28(5.8%) patients, with 12(2.5%) being 
Grade 1, 14(2.9%) Grade 2, and 2(0.4%) grades 3/4. Sixteen patients 
had to stop H due to cardiac dysfunction with H. Central assessment 
of TOP2A status was performed by FISH in 90% of cases: TOP2A-
amplified (42%), deleted (27%), and normal (31%). However TOP2A 
status had no effect on outcome.
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Conclusions: 1) The HER TC regimen was evaluated in 486 patients 
with HER2 overexpressed ESBC and found to be effective at the 
primary endpoint of 2 years.
2) Efficacy was demonstrated in node negative cancer including 94 
cancers <1 cm.
3) Toxicity was acceptable with a low rate of cardiac dysfunction, 
mainly reversible. 4) The HER TC regimen is an option for patients 
with lower risk HER2 overexpressing ESBC.
PD07-04
Lapatinib vs Trastuzumab in Combination with Standard EC-D 
Chemotherapy in the Neaodjuvant Treatment of HER2+ Patients. 
Results from the GEICAM 2006-14 Phase II Randomized Trial.
Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez 
P, Ramos M, Rojo F, Burgués O, Porras I, Tibau A, Carrasco E, 
Cámara MC, Lluch A. Hospital Virgen de la Victoria, Malaga, Spain; 
Hospital del Mar, Barcelona, Spain; Hospital Universitario Reina 
Sofía, Córdoba, Spain; Hospital Santa Creu i Sant Pau, Barcelona, 
Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, 
Spain; Hospital General de Jaén, Jaén, Spain; Centro Oncológico 
de Galicia, A Coruña, Spain; Fundación Jiménez Díaz, Madrid, 
Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; 
GEICAM (Spanish Breast Cancer Research Group), San Sebastián 
de los Reyes, Madrid, Spain
Background: The addition of trastuzumab (T) to neoadjuvant 
chemotherapy increases pCR rate in patients with HER2 + breast 
cancer. Lapatinib (L) in combination with chemotherapy is also 
an active drug in breast cancer patients. This study investigates the 
efficacy of trastuzumab or lapatinib added to chemotherapy in the 
neoadjuvant setting.
Methods: Patients (Pt) with tumors greater than 2 cm (or less with 
positive axilla) and HER2+ (Herceptest 3+ or 2+ with FISH+) 
that have not received any prior treatment for breast cancer were 
recruited. Pts were randomized to receive epirubicin 90 mg/m2 plus 
cyclophosphamide 600 mg/m2 x 4 cycles (cy) followed by docetaxel 
100 mg/m2 (with growth colony stimulating factor support) plus either 
T 8 mg/kg loading dose and then 6 mg/Kg intravenous (EC-DT) or 
L 1250 mg orally (EC-DL). Patients were stratified according to 
tumor size (T1-2 vs T3-4), and estrogen receptor status (positive vs 
negative). The primary end-point was pathological complete response 
(pCR) in the breast measured by Miller and Payne criteria. Secondary 
end-points were clinical response (by imaging test), toxicity and 
correlation between pCR and tumor biomarkers.
Results: From February-09 to October-10, 102 pts were randomized 
(50 EC-DT, 52 EC-DL). Pts characteristics were well balanced 
between arms. Median age was 48 years (30-79), 56% of pts were 
premenopausal, 7% grade I, 45% grade III. 14/59/12/15% were 
T1/T2/T3/T4 and 69% N+. 58% were estrogen receptor positive 
and 44% progesterone receptor positive. Three patients were FISH 
negative after central assessment and were not considered evaluable 
for efficacy. pCR rate in the breast was 52% (95% CI: 38-66) for 
EC-DT and 25% (95% CI: 13.5-37.5) for EC-DL (p-value=0.0065). 
pCR---pN0 was 48% (95% CI: 34–62) for EC-DT and 24% (95% 
CI: 12 – 35) for EC-DL (p-value=0.01). Clinical response was 77% 
with EC-DT and 65% with EC-DL (p-value=0.176). Grade III-IV 
toxicity was similar between arms except for diarrhea that was more 
frequent in EC-DL 14% than in EC-DT 2% (p-value=0.03); more 
patients discontinue treatment due to toxicity with EC-DL (1 vs 6; 
p-value=0.055).
Conclusions: Our study shows that EC-DT was more efficacious 
and less toxic than EC-DL in the neoadjuvant treatment of HER2+ 
pts. Biomarker profiling in the tumors, including activation levels of 
tyrosine-kinase receptors, signaling pathways and surrogate markers 
(proliferation and apoptosis) is ongoing; their correlation with pCR 
will be presented at the meeting.
PD07-05
Local Recurrence Risk in 6377 Patients with Early Breast Cancer 
Receiving Neoadjuvant Anthracycline-Taxane +/- Trastuzumab 
Containing Chemotherapy.
von Minckwitz G, Kaufmann M, Kümmel S, Fasching PA, Eiermann 
W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, Barinoff 
J, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, 
Mehta K, Loibl S, Untch M. German Breast Group, Neu-Isenburg; 
Universitäts-Frauenklinik, Frankfurt; Universitäts-Frauenklinik, 
Essen; University Hospital Erlangen, Erlangen; Klinikum zum Roten 
Kreuz, München; St. Gertrauden Krankenhaus, Berlin; Universitäts-
Frauenklinik, Magdeburg; Henrietten-Stiftung, Hannover; Städtische 
Kliniken, Offenbach; Universitäts-Frauenklinik, Rostock; Horst 
Schmidt Klinik Wiesbaden; Universitäts-Frauenklinik, Tübingen; 
University of California, Los Angeles; Hämato-Onkologische Praxis, 
Wuppertal; Universitäts-Frauenklinik, Freiburg; Universitäts-
Frauenklinik, Köln; Helios-Klinikum Berlin-Buch, Berlin
Background: Locoregional recurrence (LRR; defined according 
to Hudis C, JCO 2007) risk after neoadjuvant systemic treatment 
is considered as a possible hazard of this treatment approach. 
However, few data exist on the incidence and risk factors for LRR 
after anthracycline-taxane+/-trastuzumab (AT+/-H) containing 
neoadjuvant treatment. We analyzed individual data of 7 prospective 
neoadjuvant trials conducted by the German Breast Group and the 
AGO Breast Group.
Patients (Pts) and methods: 6377 Pts with operable or locally 
advanced, non-metastatic breast cancer were analyzed (for details 
see von Minckwitz G et al, BCRT 2010). Postsurgical radiotherapy 
was indicated after breast conservation for all patients and after 
mastectomy for patients with cT3/4 or cN+ disease. Endocrine 
treatment was given to ER- and/or PgR-positive patients. 485 LRR 
were observed during a median follow up of 46.2 (0-127) months.
Results: LRR was similar for patients treated by tumorectomy (7.2% 
of N=1123), segmentectomy (6.8% of N=1121), quadrantectomy 
(7% of 557), or breast conservation (BCT) (not otherwise specified) 
(7.7% of N=819), but higher in patients treated by mastectomy 
(ME) (12.1% of N=1670) (p<0.001). Rate of breast conservation 
decreased by increasing initial tumor size (cT1(N=198): 77.7%, 
cT2(N=3675): 78.1%, cT3(N=795): 49.4%, cT4a-c(N=348): 35.9%, 
cT4d(N=235):19.1%). LRR in patients treated by BCT or ME were 
9.1% vs 9.1% for cT1 (p=0.9); 6.9% vs. 9.8% for cT2 (p=0.001); 
9.7% vs 14.2% for cT3 (p=0.04); 3.2% vs. 11.7% for cT4a-c 
(p=0.004; and 22.2% vs 18.9% for cT4d (p=0.4). LRR increased 
with surgical yT-stage from 4.7% for ypT0 (N=990), 11.8% for 
ypTis (N=340), 9.1% for ypT1 (N=1555), 8.2% for ypT2 (N=926), 
13.8% for ypT3 (N=232), 20% ypT4a-c (N=80), to 31.2% for ypT4d 
(N=16) (p<0.001). Comparable results were obtained for cN and 
ypN stages. Patients with a pathological complete response (pCR = 
ypT0 ypN0) showed a lower LRR of 3.7% compared to patients not 
achieving a pCR (3.7% vs 9.9% (HR 0.36 p<0.001). Patients with 
a pCR showed low LRR in all intrinsic subtypes except Luminal B/
HER2+ -like tumors (Luminal A-like tumors (N=105; 3.8%), Luminal 
B/HER2- -like (N=40; 0%), Luminal B/Her2+ -like (N=124; 8.1%), 
HER2+(non-luminal)-like (N=158; 1.9%), triple-negative (N=276; 
2.5%) (p=0.016). Patients without a pCR showed an excessive LRR 
for HER2+(non-luminal) and triple-negative tumors (Luminal A-like 
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tumors (N=1498; 5.1%), Luminal B/HER2- -like (N=304; 11.9%), 
Luminal B/HER2+ -like (N=602; 8.5%), HER2+(non-luminal)-like 
(N=367; 18%) and triple-negative (N=276; 17.8%) (p<0.001). cT, cN, 
ypN, intrinsic subtype, but not ypT stage and type of surgery were 
independent predictors of LRR for patients without pCR in a Cox 
regression model. None of these factors except Luminal B/HER2+ 
(p=0.012) were significant in patients with pCR.
Conclusions: LRR in this large pooled analysis after AT+/-H 
containing neoadjuvant treatment appears to be low, especially in all 
patients with a pCR except Luminal B/HER2+ disease. In patients 
without a pCR low cT, cN, ypN and Luminal tumor type predict a 
low LRR. Other stages and subtypes without pCR should be carefully 
followed up irrespective of type of surgery.
PD07-06
Adjuvant Chemotherapy with or without Darbepoetin alpha 
in Node-Positive Breast Cancer: Survival and Quality of Life 
Analysis from the Prospective Randomized WSG ARA Plus Trial.
Nitz U, Gluz O, Oberhoff C, Reimer T, Schumacher C, Hackmann J, 
Warm M, Uleer C, Runde V, Kuemmel S, Zuna I, Harbeck N. West 
German Study Group, Moenchengladbach, Germany; Bethesda 
Hospital, Moenchengladbach, Germany; Bethesda Hospital, 
Wuppertal, Germany; University Hospital Essen, Essen, Germany; 
Catholical Hospital Essen North, Essen, Germany; University 
Hospital Suedstadt, Rostock, Germany; St. Elisabeth Hospital, 
Cologne, Germany; Marien-Hospital Witten, Witten, Germany; 
University Hospital Cologne, Cologne, Germany; Krankenhaus 
Koeln-Holweide, Cologne, Germany; Gynecological Practice, 
Hildesheim, Germany; Wilhelm-Anton-Hospital Goch, Goch, 
Germany; Hospital Essen-Mitte, Essen, Germany
Background: Darbepoetin alpha (ARA) is currently used to reduce 
chemotherapy-associated anemia (CAA) rates in various solid tumors. 
A possible negative impact of ARA on patient survival has been 
suggested in some clinical trials. The objective of the prospective 
randomized phase III ARA Plus trial is to compare the survival effect 
of darbepoetin alpha use (ARA+/ARA-) in combination with modern 
standard adjuvant chemotherapy targeting guideline-recommended 
Hb-levels in high-risk breast cancer (BC).
Methods: ARA Plus compared 6 cycles T75A50C500 q3w or 6 cycles 
F500E100C500 q3w (at discretion of each center) in patients with 
node positive BC (aged 18-65 years). Patients were randomized to 
darbepoetin (ARA+) 500 µg q3w until completion of radiotherapy 
or to standard supportive care (ARA-). ARA was started at Hb-levels 
<13 g/dL (amendment 01/2008: Hb <12 g/dL) and stopped at >14 g/
dL (>12 g/dL). Primary endpoint is event-free survival (EFS: relapses, 
death without disease evidence, second malignancy). Overall survival 
(OS), toxicity, Hb-levels and quality of life are secondary endpoints. 
Survival analysis was planned after 7 years of study duration. EFS was 
tested using c2-test (a=0.05) with a statistical power of b=80% and 
log-rank test. Quality of life was measured using FACT questionnaires 
at beginning of therapy, mid, end of therapy, and at 1 year afterwards.
Results: 1234 pts (616 ARA+/618 ARA-) from 70 centres in 
Germany were randomized between 01/04 and 06/08. 1198 intent to 
treat patients (ITT) were analysed (1096 TAC; 102 CEF). Baseline 
characteristics were well balanced in ARA+ and ARA- arms: median 
age 53/53 years; tumor size 2.4/2.4cm; number of + LN 3/3; HR+ 
80%/ 83.5%, G3 40.7%/36.7%. Toxicity data have been reported 
earlier (SABCS 2008).
At median follow up of 40 months, 168 events (81 ARA+, 83 ARA-) 
and 134 relapses (65 ARA+, 69 ARA-) were reported. There was no 
significant difference in 3-year EFS between ARA+ and ARA- arms 
(89.2% vs. 87.6%, p=0.97, c2-test). 37 deaths were reported in the 
ARA- and 36 in the ARA+ arm. 3-year OS was 95.4% and 95.1% 
for ARA+ and ARA-, respectively (p=0.85). Only nodal involvement 
(>4 vs. 1-3), negative HR, tumor size >2 cm and G3 were significant 
survival predictors by multivariate analysis. Unplanned retrospective 
analysis revealed better EFS for ARA+ vs. ARA- in HR- (p=0.05), 
and no difference in HR+ group (p=0.6). In ARA+ patients, Hb-levels 
were stable over the whole treatment period with rare overstimulation. 
In ARA- patients, Hb-levels decreased during therapy (median of 
all cycles ARA+/ARA-: 12.5/11.6 g/dL). There was no correlation 
between mean Hb-levels and survival in either study arm.
There were no significant differences in mean FACT scores changes 
(general, anemia, cognitive) from begin to end of therapy in either 
study arm. More detailed analyses are ongoing.
Conclusions: To date, the WSG ARA plus trial is the only 
prospectively randomized trial in early high-risk BC exclusively 
focusing on the impact of adjuvant ARA on patient outcome. 
Supportive administration of ARA appears to be safe and to have no 
significant survival effect when used in combination with TAC or 
CEF according to current guidelines.
PD07-07
Combination of Paclitaxel and Bevacizumab without or with 
Capecitabine as First-Line Treatment of HER2-Negative Locally 
Recurrent or Metastatic Breast Cancer (LR/MBC): First Results 
from a Randomized, Multicenter, Open-Label, Phase II Study of 
the Dutch Breast Cancer Trialists’ Group (BOOG).
Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos 
MMEM, Linn SC, van den Bosch J, Nortier JWR, Braun JJ, de Graaf 
H, Portielje JEA, Los M, Gooyer DD, van Tinteren H, Boven E. VU 
University Medical Center, Amsterdam, Netherlands; Comprehensive 
Cancer Centre the Netherlands, Netherlands; Isala Clinics, Zwolle, 
Netherlands; Erasmus Medical Center-Daniel den Hoed Cancer 
Center, Rotterdam, Netherlands; Tergooi Hospitals, Hilversum, 
Netherlands; Reinier de Graaf Hospital, Delft, Netherlands; The 
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 
Amsterdam, Netherlands; Albert Schweitzer Hospital, Dordrecht, 
Netherlands; Leiden University Medical Center, Leiden, Netherlands; 
Vlietland Hospital, Schiedam, Netherlands; Medical Center 
Leeuwarden, Leeuwarden, Netherlands; Haga Hospital, The Hague, 
Netherlands; St. Antonius Hospital, Nieuwegein, Netherlands; 
Franciscus Hospital, Roosendaal, Netherlands
Background: First-line treatment of HER2-negative LR/MBC with 
paclitaxel (T) and bevacizumab (A) has demonstrated improved 
progression-free survival (PFS) and overall response rate (ORR) when 
compared with T alone (E2100). We determined whether addition of 
capecitabine (X) to AT is safe and would be better effective than AT 
in women with HER2-negative LR/MBC.
Methods: Eligibility criteria were age ≥18 & ≤75 years, measurable 
or non-measurable HER2-negative LR/MBC, ECOG PS 0–1 and no 
prior chemotherapy for LR/MBC. Patients were randomized in 1:1 
ratio to receive AT (4-week cycle of T 90 mg/m2 on days 1, 8, 15 and 
A 10 mg/kg on days 1, 15 for 6 cycles, followed by A 15 mg/kg on 
day 1 given 3-weekly for subsequent cycles) or ATX (3-week cycle of 
T 90 mg/m2 on days 1, 8, A 15 mg/kg on day 1 and X 825 mg/m2 bid 
on days 1–14 for 8 cycles, followed by A 15 mg/kg on day 1 and X 
825 mg/m2 bid on days 1–14 given 3-weekly for subsequent cycles). 
Treatment was discontinued at disease progression, unmanageable 
toxicity or withdrawal of consent. The primary endpoint was PFS. 
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Secondary endpoints were overall survival, ORR, duration of response 
and toxicity. Efficacy was evaluated according to RECIST 1.0 and 
toxicity was assessed according to NCI CTCAE 3.0.
Results: From June 2007 till December 2010, 312 patients were 
recruited at 36 sites. The median age was 56 years (range 32–76). 
Among all patients, 52% had ECOG 0, 85% were hormone-receptor 
positive, 86% had measurable disease and 8% had bone-only 
metastases. These factors were well balanced between both arms. 
A total of 48% and 33% of patients, respectively, received prior 
hormonal therapy or radiotherapy for LR/MBC. At the data cut-off 
of 1st June 2011, the median follow-up duration was 23 months. 311 
patients received at least one cycle of treatment and were evaluable 
for safety. The median number of treatment cycles in AT was 9 and 
in ATX was 11 (both 33 weeks). An ORR of ≥40% was reached in 
patients with measurable disease in both groups. The incidence of 
serious adverse events (SAEs) was 47% and 40% for AT and ATX, 
respectively, while that of treatment-related SAEs was 12% and 19%, 
respectively. Treatment-related deaths were 2% for AT and 2% for 
ATX. The overall rate of AEs grade 3 or 4 was similar in both arms 
as shown in Table 1, except for hand-foot syndrome grade 3 and 
neutropenia grade 3 in ATX . In addition, 6 patients with pulmonary 
embolism were reported in ATX.
Most common grade 3 or 4 treatment-related AEs in all cycles
 AT (N = 156) ATX (N = 154)
Side-effects Grade 3 (%) Grade 4 (%) Grade 3 (%) Grade 4 (%)
Fatigue 4 0 7 0
Leucopenia 7.1 1.3 6.5 1.3
Neutropenia 10 1.9 16 3.2
Peripheral neuropathy 7.1 0 5.9 0
Hypertension 10 0 13 0
Proteinuria 3.2 0 3.9 0
Hemorrhage 0 0.6 0 0
Thrombotic event 0.6 0 3.2 0.6
Pulmonary embolism 0 0 0 3.9
Hand-foot syndrome 0 0 31 0
Conclusions:
ATX was well tolerable, although more patients experienced hand-
foot syndrome grade 3 and thromboembolic events than patients 
treated with AT. The efficacy data will be presented at the meeting.
Support: This study was supported by Roche.
PD07-08
The Effect on Surgical Complications of Bevacizumab Added to 
Neoadjuvant Chemotherapy: NSABP Protocol B-40.
Bear HD, Tang G, Rastogi P, Geyer CE, André R, Atkins JN, Baez-
Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Pajon ER, Senecal 
FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, 
Swain SM, Mamounas EP, Wolmark N. National Surgical Adjuvant 
Breast and Bowel Project (NSABP); Virginia Commonwealth 
University, Massey Cancer Center; University of Pittsburgh Graduate 
School of Public Health; University of Pittsburgh Cancer Institute 
School of Medicine; Allegheny General Hospital; Centre Hospitalier 
de l’Université de Montréal; Southeast Cancer Control Consortium 
CCOP; San Juan MBCCOP; University of Pittsburg/Magee Women’s 
Hospital; University of California at Irvine, School of Medicine, Chao 
Family Comprehensive Cancer Center; Kaiser Permanente, Northern 
California; CCOP, Colorado Cancer Research Program; CCOP, 
North-West Medical Specialties; Kansas City Clinical Oncology 
Program; Jewish General Hospital, McGill University; Genesys 
Regional Medical Center; Dayton CCOP; Washington Cancer 
Institute, Washington Hospital Center; Aultman Health Foundation
The NSABP trial B-40 was designed to determine whether adding 
capecitabine or gemcitabine to docetaxel followed by AC would 
increase the pathologic complete response (pCR) rates in patients 
with operable HER2-negative breast cancer and to determine whether 
the addition of bevacizumab to three docetaxel-based regimens 
followed by AC would increase pCR rates. Secondary endpoints 
include the percentage of surgical complications after mastectomy, 
lumpectomy, and axillary staging procedures in the patients who 
received chemotherapy versus those who received chemotherapy 
and bevacizumab.
Methods: Women with HER2-negative operable breast cancer 
received one of the following docetaxel-based regimens with or 
without bevacizumab (15mg/kg) every 3 weeks for four cycles: 
docetaxel 100 mg/m2 IV; docetaxel 75 mg/m2 and capecitabine 
825 mg/m2 po BID days 1-14; and docetaxel 75 mg/m2 day 1 and 
gemcitabine 1000 mg/m2 IV days 1 and 8. These regimens were 
followed by preoperative standard AC on day 1 every 21 days for four 
cycles with or without bevacizumab 15 mg/kg given with the initial 2 
cycles of AC. Treatment groups randomized to receive bevacizumab 
resumed postoperative bevacizumab 15 mg/kg IV every 3 weeks for 
an additional 10 doses. Assessment of surgical complications was 
performed from the date of surgery through 24 months following 
study entry.
Results: Planned analysis for surgical complications will be 
conducted in October 2011 and will be presented along with breast 
reconstruction data.
Funded by NCI PHS grants U10-CA-37377, U10-CA-69974, U10-
CA-12027, U10-CA-69651, and U10-CA-52667, with additional 
support from F. Hoffmann La-Roche, Ltd., Genentech, USA, and 
Eli Lilly and Company.
PD08-01
JNK2 Regulates Mammary Lineage Differentiation in Tumors 
and Normal Glands through Notch1 and p53.
Cantrell MA, Ebelt ND, Van Den Berg CL. University of Texas at 
Austin, Austin, TX
The classification of patient tumors by clinical subtype has gained 
wide acceptance due to the implications for prognosis and treatment. 
However, recent studies have cast doubt on previously advocated 
normal mammary origins of these subtypes. Thus, the link between 
the normal mammary gland and mammary tumors is more complex 
than expected. C-Jun N-Terminal Kinase-2 (JNK2) is a protein that is 
involved in numerous developmental processes and our previous work 
has shown it to be important for DNA damage response in mammary 
tumors. In attempt to gain insight into the link between mammary 
development and tumorigenesis, we compared normal mammary 
glands of JNK2 knockout (jnk2ko) mice to jnk2ko mammary tumors 
expressing or lacking wildtype p53 (p53ko). These studies showed 
that jnk2ko glands possess 35% fewer basal cells (p=0.0078) with 
a corresponding increase in luminal epithelial cell populations 
(p=0.100). This luminal response is corroborated by in vitro 3D 
assays of primary mammary epithelial cells (MECs) where luminal 
cell differentiation is normalized by inhibition of Notch signaling. 
Expression notch-1, a well-known regulator of MEC differentiation, 
is increased jnk2ko mammary glands. Increased expression of the 
Notch-1 target gene, hes-1, was also seen (p=0.005). Histology 
revealed that increased expression of active Notch-1 is localized to 
the mammary stem cell niche, the terminal end bud. Similar to the 
normal gland, jnk2ko mammary tumors possessing wildtype p53 
exhibit decreased proportions of basal cells (p=0.0002) and increased 
proportions of luminal cells (p=0.0411) relative to wildtype. Jnk2ko 
cell lines derived from these tumors show decreased expression of 
notch-1 (p=0.0018) and hes-1 (p=0.0602) following introduction of 
JNK2. Luciferase assays comparing activity of the notch-1 promoter 
to a notch-1 promoter with mutated p53 response elements revealed 
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a dependence of increased notch-1 promoter activity in jnk2ko cells 
on the p53 response element. P53ko tumor cells, by contrast, do not 
exhibit alterations in notch-1 promoter activity in the absence of 
p53 response elements, regardless of JNK2 status. QPCR showed 
that loss of JNK2 in normal mammary glands and tumors causes 
increased p53 expression—thus providing a potential mechanism. In 
support that Notch upregulation in the absence of JNK2 is dependent 
upon p53, normal glands lacking p53 show no differences in lineage 
differentiation. P53ko tumors also show no differences in basal 
lineage differentiation, however, increases in luminal differentiation 
are maintained in the absence of JNK2. Consistent with increased 
luminal differentiation, jnk2ko caused decreased expression of 
markers involved in the epithelial to mesenchymal transition 
phenotype. This data suggests that JNK2 is important not only for 
lineage differentiation in normal mammary glands, but in mammary 
tumors and that the effect is dependent on both Notch1 and p53.
PD08-02
Targeting BCL-2 Expressing Breast Tumors with BH3-Mimetics 
– A New Class of Drugs in Breast Cancer?
Lindeman GJ, Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa 
F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth 
GK, Strasser A, Huang DCS, Visvader JE. The Walter and Eliza Hall 
Institute of Medical Research, Parkville, VIC, Australia; The Royal 
Melbourne Hospital, Parkville, VIC, Australia; The University of 
Melbourne, Parkville, VIC, Australia; Peter MacCallum Cancer 
Centre, East Melbourne, VIC, Australia; Ospitalieri di Cremona, 
Cremona, Italy
Background: Impairment of apoptosis is a hallmark of cancer and can 
result in resistance to chemotherapy. Tumor resistance to apoptosis 
is frequently acquired through deregulated expression of BCL-2 
family members or inactivation of the p53 tumor suppressor pathway. 
Over-expression of the pro-survival protein BCL-2 is common in 
breast cancer (where it is readily detected by immunostaining), and 
has been shown to be an important prognostic marker. A potential 
role for BCL-2 as a therapeutic target in breast cancer, however, 
has not been explored. Recently, small molecules termed ‘BH3-
mimetics’ have been developed that mimic the action of pro-apoptotic 
BH3-only proteins. These bind and neutralize pro-survival proteins 
including BCL-2. Here we have derived a panel of primary breast 
tumor xenografts (that include basal-like breast tumors) to study the 
efficacy of the BH3-mimetic ABT-737 combined with docetaxel in 
targeting BCL-2-positive breast cancer.
Methods and Results: We first studied the expression of BCL-2, 
pro-survival family members BCL-XL and MCL-1, and the pro-
apoptotic protein BIM in tissue microarrays of 197 primary breast 
tumors, which were subtyped on the basis of ER, PR, HER2, CK5/6 
and EGFR expression. BCL-2 was overexpressed in luminal (83.3%), 
HER2-positive (50.0%), basal-like (18.5%) and ‘marker-null’ (41.4%) 
breast cancers. BCL-2-positive tumors generally co-expressed BCL-
XL (96.2%), MCL-1 (94.7%) and BIM (93.5%).
To determine whether the BH3-mimetic ABT-737 (which neutralizes 
BCL-2, BCL-XL and BCL-W) was effective in targeting BCL-2-
expressing breast tumors, we generated a panel of 28 primary breast 
tumor xenografts in immunocompromised NOG mice. Five xenograft 
lines (838T, 24T, 315T, 13T and 806T) were selected for further 
analysis. Four were basal-like, and one (315T) was a luminal B tumor, 
as determined by gene profiling. Mice bearing tumor xenografts were 
treated with ABT-737 (50 mg/kg i.p. d1-10), docetaxel (10 mg/kg 
i.p. d1) or a combination in q21d cycles. Tumor response and overall 
survival were significantly improved by combination therapy, but only 
for tumors that expressed elevated levels of BCL-2. Treatment with 
ABT-737 alone was ineffective, suggesting that ABT-737 sensitized 
tumors to docetaxel. Combination therapy was accompanied by a 
marked increase in apoptosis and dissociation of BIM from BCL-2, 
indicating that a perturbation of BIM complexes may contribute to 
the activation of the apoptotic cascade. Notably, ABT-737 appeared 
effective in targeting BCL-2-expressing basal-like tumor xenografts 
(838T and 24T) harboring p53 mutations.
Discussion: Primary breast tumor xenograft models that recapitulate 
the phenotype of the primary tumor have been developed as useful 
‘proof-of-principle’, pre-clinical models. Here we provide the first 
in vivo evidence that BH3-mimetics can be used to sensitize primary 
BCL-2-expressing breast tumors to taxane chemotherapy. Our results 
suggest that elevated BCL-2 expression constitutes a predictive 
response marker in breast cancer. These findings provide a rationale 
for the development of clinical protocols using the oral analogue 
ABT-263 (navitoclax) as an adjunct to taxane chemotherapy in BCL-
2-expressing basal-like and luminal breast cancer.
PD08-03
Inhibition of MEK/ERK- and JNK-Dependent Expression of 
Interleukin-6 and Interleukin-8 Targets Basal-Like Breast Cancer 
Stem Cells.
Balko JM, Cook RS, Kuba MG, Miller TW, Bhola NE, Sanders 
ME, Meszoely IM, Dowsett M, Gomez H, Arteaga CL. Vanderbilt 
University, Nashville, TN; Royal Marsden Hospital, United Kingdom; 
Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
Background: Neoadjuvant chemotherapy (NAC) induces a 
pathological complete response in approximately 30% of triple-
negative or basal-like breast cancers (BLBC). However, patients 
with residual disease often recur after surgery, presumably due 
to persistent drug-resistant subpopulations with cancer stem cell 
(CSC)-like properties. Thus, elimination of this CSC compartment in 
BLBC has the potential to improve survival by reducing post-surgical 
metastatic recurrences.
Methods: We sampled 49 post-NAC breast cancer samples including 
22 BLBCs and quantified RNA for 355 cancer-related transcripts using 
Nanostring technology. Transcripts associated with a high Ki67 in the 
residual disease (a biomarker of early recurrence) were identified and 
bioinformatically examined for an association with drug resistance 
and a CSC phenotype. Loss of DUSP4, a negative feedback regulator 
of ERK1/2 and JNK1/2, was highly associated with a high post-NAC 
Ki67. We examined the role of loss of DUSP4 in promoting a drug-
resistant, CSC phenotype.
Results: Low DUSP4 expression in post-NAC tumors was 
associated with high ERK1/2 activation and BLBC gene expression. 
siRNA knockdown of DUSP4 enhanced resistance to anti-cancer 
chemotherapy (docetaxel, camptothecin). Alternatively, forced 
DUSP4 expression in breast cancer cell lines abrogated the 
activation of transcription factors downstream of ERK and JNK 
and sensitized cells to docetaxel-induced apoptosis. In highly 
metastastic BLBC cell lines, MEK inhibition with AZD6244 and 
JNK inhibition with SP600125 significantly reduced mammosphere 
formation and self-renewal. Inhibition of JNK and MEK reduced 
IL6 and IL8 expression, two cytokines known to expand the CSC 
compartment. Reconstitution of exogenous IL6 and IL8 after MEK 
inhibition restored mammosphere formation potential. Chromatin 
immunoprecipitation demonstrated that the oncogenic transcription 
factor ETS-1, an ERK1/2 substrate, binds the IL8 promoter in 
a MEK1/2-dependent manner. We are currently confirming the 
association of DUSP4 loss with Ki67, ERK activation, and IL6/IL8 
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expression in a cohort of 113 post-NAC triple negative breast cancers.
Conclusions: Our data demonstrate that loss of DUSP4 in BLBC 
promotes ERK and JNK activation by impairing negative feedback 
of these pathways. Activation of ERK and JNK drives expression of 
IL6 and IL8 expression, possibly through ETS-1 activation. Thus, 
targeting these signaling pathways may eliminate residual cancer 
stem cells after neoadjuvant chemotherapy and improve cure rates 
in BLBC.
PD08-04
Inhibition of the TGFb/TGFbR2 Pathway Prevents Enrichment 
of Drug-Resistant Breast Cancer Stem Cells by Anti-Cancer 
Chemotherapy.
Bhola N, Arteaga C. Vanderbilt University Medical Center, Nashville, 
TN
Triple-negative breast cancer (TNBC) is the most virulent form of 
breast cancer and is associated with a worse prognosis compared 
to hormone receptor- and HER2-positive tumors. The standard 
treatment of TNBC is cytotoxic chemotherapy. TNBC patients tend 
to display a good initial response to chemotherapy; however, they 
exhibit higher recurrence rates and overall poor long term survival. 
Reasons for this high metastatic recurrence rate and mortality are 
believed to be the existence of a chemo-resistant tumor-initiating 
population called cancer stem cells (CSCs). CSCs are defined as cells 
with the ability to self-renew, differentiate into non-tumorigenic cells, 
and initiate tumors in vivo. CSCs isolated from breast cancer tissue 
display increased transforming growth factor (TGF) b and TGFb 
type II receptor (TGFbR2) mRNA expression compared to the non-
CSC population. Furthermore, breast CSCs exhibit characteristics 
of an epithelial to mesenchymal transition (EMT), a process driven 
by the TGFb signaling and associated with metastatic progression. 
Therefore, we hypothesize that inhibiting the TGFb/TGFbR2 
pathway can abrogate the breast CSC population and sensitize 
TNBC to chemotherapy, thus reducing metastatic recurrences 
and tumor progression. 
To address this hypothesis, we used the TNBC cell lines SUM159 
and BT549. We examined the effect of TGFb1, the TGFb receptor 
I/II kinase inhibitor LY2157299, the TGFbRII receptor and TGFb1 
neutralizing antibodies TR1, and LY2424087 and paclitaxel on 
the CSC population of these cell lines by 1) flow cytometric 
analysis of stem cell markers (ALDH, CD44, and PROCR); and 
2) mammosphere formation assays. In both cell lines, LY2157299, 
LY2424087, and TR1 abrogated TGFb-mediated CSC enrichment and 
mammosphere formation (p≤0.01). Treatment with paclitaxel resulted 
in an enrichment of CSCs as measured by FACS and mammosphere 
formation (p≤0.005) both in vitro and in SUM159 xenografts 
established in athymic mice. Further, treatment with paclitaxel 
upregulated TGFbR2 and TGFb1 mRNAs and phosphorylated 
SMAD2 levels in CSCs sorted from post-therapy SUM159 xenografts. 
RNAi-mediated knockdown of TGFbR2 in BT549 cells decreased 
mammosphere formation but did not affect the proportion of CSCs 
analyzed by FACS (p≤0.005 and p=0.03, respectively). TGFbR2 
and SMAD4 siRNA decreased the CD44hi/CD24lo population in 
both cell lines. SMAD4 siRNA also decreased CSCs, mammosphere 
formation, and viability in SUM159, BT549, and MDA-231 basal-
like and HCC1954 (HER2+) cells. SMAD4 knockdown resulted in a 
significant decrease in the CSC-associated genes interleukin-8 (IL-8) 
and Nanog. Finally, a combination of either LY2157299 or SMAD4 
siRNA with paclitaxel decreased both stem cell marker expression, 
IL-8 and mammosphere formation compared to each treatment alone 
(p≤0.006).
These findings suggest that autocrine TGFb signaling plays a 
maintenance role in breast CSCs viability. Second, blockade of the 
TGFb/TGFbR2 pathway with genetic or pharmacological inhibitors 
can ameliorate or prevent the enrichment of drug-resistant CSCs 
by anti-cancer chemotherapy. These studies provide a rationale for 
studies of chemotherapy ± TGFb inhibitors in patients with TNBC 
using stem cell markers as surrogates of clinical response.
PD08-05
Stat3 Signaling in Human Breast Cancer Stem Cells.
Wei W, Zhang M, Tweardy D, Rosen J, Lewis M. Baylor College of 
Medicine
Recent data suggest the existence of a unique subset of breast cancer 
cells capable of initiating tumor growth and giving rise to all other 
cells characteristic of a given tumor. These cells have been termed 
“cancer stem cells” or “tumor-initiating cells”. Breast cancer stem 
cells appear to be resistant to chemo- and radiotherapies and may be 
responsible for recurrence and metastasis in breast cancer patients. 
Identifying the cellular signaling pathways responsible for breast 
cancer stem cell maintenance and self-renewal represents a critical 
hurdle for developing effective therapeutics.
The Stat3 pathway is a critical regulator of the function of normal 
stem cells, and shows altered expression in human breast cancers [4]. 
Moreover, IL-6, the Stat3 signaling agonist, is required for breast 
cancer stem cell function in human breast cancer cell lines. All these 
suggest an important role of Stat3 signaling in breast cancer stem 
cells. However, due to lack of method for pathway-activity-based 
live cell separation, whether Stat3 functions in the cancer stem cells 
themselves or whether it may function in surrounding niche cells 
remain unknown. We have constructed a lentiviral fluorescent reporter 
for Stat3 signaling which contains four copies of M67 Stat3 binding 
sites upstream of enhanced Green Fluorescent Protein. This reporter 
system enables FACS-sorting of cells with active Stat3 signaling and 
in vivo/in situ localization of Stat3 responsive cells. In addition, C188-
9, the first Stat3 specific competitive inhibitor, has been developed 
in our collaborator’s lab, which provides us an advanced tool in 
studying Stat3 function.
We hypothesize that Stat3 signaling is preferentially active in stem-
like subpopulation and depend on non-stem cancer cells to maintain 
its activation. Three aims to test this hypothesis include: 1. To test 
whether cancer cells with activated Stat3 signaling are enriched for 
breast cancer stem cells or whether they may serve as niche cells. 
2. To test whether small molecule antagonists of Stat3 signaling can 
inhibit cancer stem cell function. 3. To identify novel targets of Stat3 
signaling that may serve as indicators of responsiveness to Stat3 
antagonist or predict treatment response.
So far, our GFP reporters for Stat3 signaling effectively report Stat3 
activity in both patient xenografts and human breast cancer cell lines 
in vivo and in vitro, which enables effective separation of Stat3+/
Stat3- cells for functional Study. MDA231 and SUM159 tumors with 
reporters have been established. Tumor cells will be sorted according 
to Stat3 activity and perform limiting dilution and MSFE assays. 
Tumors with reporters will also be treated by C188-9, Chemo, or in 
combination to study synergistic effect of Stat3 inhibitors on tumor 
growth. Preliminary data based on inhibitor and limiting dilution 
studies suggested that Stat3 signaling is required for stem cell 
function. However, neither Stat3+ nor Stat3- cells are self-sufficient 
in performing these functions, indicating communications between 
subpopulations.
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PD08-06
ERK2 Promotes Stem Cell-Like Characteristics in Triple-
Negative Breast Cancer.
Bartholomeusz C, Saso H, Dadbin A, Kazuharu K, Hortobagyi GN. 
The University of Texas MD Anderson Cancer Center, Houston, TX
Background: Triple-negative breast cancer (TNBC) is resistant to 
targeted therapies such as hormonal therapy and HER2-targeted 
therapies. Thus, no specific targeted therapy is currently available 
for TNBC. ERK2, a component of the MAPK pathway, plays an 
important role in epithelial-mesenchymal transition (EMT) in MCF-
7-10A, a nontransformed human mammary epithelial cell line and is 
required for full acquisition of stem cell-like characteristics. Inhibition 
of ERK2 dramatically reduces cell growth, whereas inhibition of 
ERK1 significantly facilitates proliferation. ERK1 mutant mice have 
a strikingly milder phenotype than ERK2 mutant mice, which die 
early in development. In addition, we have shown that the upstream 
target of ERK, MEK, may be a target for treating TNBC with the 
MEK inhibitor selumetinib. Our reverse-phase protein array analysis 
showed that of patients with TNBC, those with ERK2-overexpressing 
tumors were at higher risk of death than those with low-ERK2-
expressing tumors. Therefore, we hypothesized that ERK2 promotes 
the tumorigenesis and metastasis of TNBC. We sought to determine 
the role of ERK2 in the tumorigenic and metastatic activities in 
TNBC and whether ERK2 is required for acquisition of stem cell-like 
characteristics in TNBC.
Methods: We studied the role of ERK1 and ERK2 in the TNBC cell 
line SUM-149. We used shRNA to specifically knockdown ERK1 
and ERK2 (shERK1 and shERK2) and examined whether knocking 
down ERK1 and ERK2 correlated with EMT regulation, migration, 
and tumorigenicity in TNBC cells.
Results: Compared with parental SUM-149 cells, stable clones that 
constitutively expressed shERK1 or shERK2 showed no difference in 
growth rate. However, knocking down ERK2 significantly inhibited 
migration and the acquisition of stem cell-like characteristics (CD44+/
CD24-) in SUM-149 cells in vitro. In addition, knockdown of ERK2 
also inhibited anchorage-independent growth, an indicator of in 
vivo tumorigenicity, whereas knockdown of ERK1 did not inhibit 
anchorage-independent growth. However, inhibition of ERK1 or 
ERK2 in 2D or 3D cell culture did not correlate with changes in 
epithelial and mesenchymal markers by western blot analysis.
Conclusion: Our data demonstrate that ERK2 may promote the 
tumorigenesis of TNBC via enriching cancer stem cells. Our long-
term goal is to develop ERK-targeted therapy for TNBC.
PD08-07
Wound-Healing Drainage Fluids Promote Triple Negative Breast 
Cancer Progression.
Campiglio M, Sasso M, Bianchi F, Plantamura I, Iorio M, De Cecco 
L, Giustarini E, Agresti R, Ghirelli C, Cremona M, Tripodo C, 
Tagliabue E. Fondazione IRCCS-Istituto Nazionale Tumori, Milan, 
Italy; University of Palermo, Palermo, Italy
Triple negative breast cancers (TNBC) account for 15% of breast 
cancers. TNBCs carry a high risk of recurrence and deaths, due to 
the high rate of local and systemic relapse in these patients and no 
therapeutic options except chemotherapy are currently available. 
The TNBC pattern of recurrence present a distant recurrence peak at 
approximately 3 years and then declines rapidly thereafter, whereas 
in all non-TNBC types the recurrence risk seems to be constant over 
time. TNBC relapse risk is comparable to that of HER2-positive 
tumors subtype, in which growth-factors released during the healing 
process accelerate the early recurrences in HER2-positive patients. 
Thus, we speculate that also TNBC early relapse may depend on 
their capability to respond to wound-healing stimulation. To this 
aim, TNBC were treated with drainages to identify which receptors/
pathways can be activated and play a driving role in TNBC 
progression. A pilot reverse phase protein microarray (RPMA) 
experiment on MDA-MB-231 TN cells drainage-fluids stimulated 
revealed a specific activation of PDGFR and VEGFR and their 
downstream pathways, whereas no significant changes were observed 
in other receptors, such as EGFR, IRS, Met and ERB3. The type of 
activated receptors suggested the involvement of endothelial receptors 
upon drainages stimulation and, indeed TNBC cell lines expressed 
endothelial molecules, such as CD34, CD31, CD146. Beside the 
proved role of some of these receptors in cellular proliferation, the 
TNBC endothelial-like phenotype prompt us to analyzed TNBC 
cell lines capability to form vascular-like channels when seeded on 
matrigel. Drainages were able to accelerate the formation of vascular 
channels in TNBC cell lines and, moreover to consistently increase 
proliferation of TNBC cells compared to non-TNBC cells. To prove 
whether receptors found activated by drainages play a key role in 
TNBC progression, we targeted PDGFR, VEGFR and other receptors 
possibly involved in angiogenesis and vasculogenic mimicry with 
sunitinib (targeting PDGFR, VEGFR, FGF and c-kit), anti-bFGF 
antibody (Ab)(targeting the ligand bFGF) and bevacizumab (targeting 
the VEGF) in TNBC cells drainage-stimulated in vitro. Sunitinib and 
anti-bFGF Ab halved the proliferation of TNBC cell lines and reduced 
of almost 60% the formation of vascular-like channels in TNBC 
cells, whereas bevacizumab modestly affect proliferation but not 
vasculogenic properties. Notably, sunitinib and anti-bFGF Ab strongly 
inhibited MDA-MB-231 and MDA-MB-468 xenografts tumor growth 
(sunitinib: 80%, and 70% Growth Index (GI), respectively; anti-bFGF 
Ab 70% and 60% GI, respectively) whereas bevacizumab determined 
no more than 30% decrease of tumor volume. Unfortunately, all these 
drugs did not efficiently control the development of lung metastases, 
that indeed significant increased compared to their control, possibly 
through induction of hypoxia processes. In conclusion, wound 
healing promotes TNBC progression by sustaining proliferation 
and vasculogenesis. The use of sunitinib and anti-bFGF antibody 
strongly inhibited tumor growth in mice models, but significantly 
increased lung metastases suggesting a combined use of these drugs 
with molecules able to interfere with hypoxia pathway.
PD08-08
Preclinical Efficacy of the Combination of Met and Src Family 
Kinase Inhibitors in Triple-Negative Breast Cancer.
Gartner EM, Kim EMH, Choi L, Boerner J. Karmanos Cancer Center 
at Wayne State University, Detroit, MI
Background: Epidermal growth factor receptor (EGFR), although 
overexpressed in almost 60% of all triple-negative breast cancers, has 
yet to be identified as an effective therapeutic target for the treatment 
of the disease. We have previously shown in cell culture models of 
triple-negative breast cancer that primary resistance to EGFR tyrosine 
kinase inhibitors through ligand-independent phosphorylation can 
be overcome by co-inhibiting EGFR with either Met or Src family 
kinases (SFKs). We also demonstrated that inhibiting Met kinase 
activity reduced EGFR and c-Src phosphorylation and inhibiting 
SFK reduced EGFR phosphorylation. Taken together, these data 
suggest that EGFR, Met and SFKs regulate the activity of each other 
through transphosphorylation. This process of transphosphorylation, 
or crosstalk, allows for the continued activation of key signaling 
proteins required for proliferation and transformation. Here we 
demonstrate that inhibiting both Met and SFKs decreases cell viability 
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and eliminates the need for inhibition of EGFR tyrosine kinase 
activity, as the autophosphorylation sites of EGFR were lost with 
the combination treatment.
Methods: Seven triple-negative (SUM102, SUM149, SUM229, 
SUM1315, BT20, BT549, MDA-MB-231), two HER2+ (SUM190 
and SKBr3), and two ER/PR+ (MCF7 and T47D) breast cancer cell 
lines were used to test the efficacy of the combination of Met and SFK 
inhibitors, Arq-197 and dasatinib, respectively. Cell viability after drug 
treatment was assessed by MTT assays. IC50 values were calculated 
and drug synergy calculations were performed. Transphosphorylation 
was measured by immunoblotting using phospho-specific antibodies. 
Apoptosis was characterized by immunoblotting.
Results: All seven triple-negative breast cancer cell lines demonstrated 
decreased cell viability with the combination of Arq-197 and dasatinib 
when compared with either drug alone. In contrast, none of the HER2+ 
or ER/PR+ breast cancer cell lines had any additional loss of viability 
with the combination treatment. We found that the interactions 
between Arq-197 and dasatinib were synergistic in several of the 
breast cancer cell lines. Specifically, in one such cell line (BT20), the 
combinatorial index values were less than 1.0. Interestingly, in this cell 
line, the tyrosine phosphorylation levels on residues 1068 and 992 of 
EGFR were significantly altered with the combination treatment and 
activation of apoptotic proteins, including PARP, occurred.
Conclusions: These data demonstrate that two tyrosine kinases, known 
to be downstream of EGFR activation, interact to promote resistance 
to EGFR inhibitors. However, inhibiting both Met and SFKs was 
sufficient to decrease cell viability and stimulate apoptosis in triple-
negative breast cancer cells. Further studies to validate the relevance 
of these findings are ongoing.
PD08-09
PTPN12 Gene Expression Signature in Triple Negative Breast 
Cancer Cohort.
Ghazalpour A, Bender RP, McGinniss MJ, Ashfaq R. Caris Life 
Sciences, Phoenix, AZ
PTPN12 tyrosine phosphatase may play a role in tumor development/
progression in triple negative breast cancer patients (TNP). The 
effects of PTPN12 appear to be mediated through several tyrosine 
kinase receptors including EGFR, HER2, and PDGFR-beta. We 
investigated the variability associated with PTPN12 transcript in 
the microarray gene expression data obtained from 105 TNP as 
determined by IHC for ER and PR and IHC and FISH for HER2 during 
our clinical molecular profiling on solid tumors. The mRNA levels 
of PTPN12 in our cohort was highly variable suggesting a complex 
genetic regulation of PTPN12 transcription in TNP patients. The 
highly variable nature of PTPN12 mRNA levels lead us to perform a 
correlation-based analysis of the transcriptome in TNP samples to gain 
insight into pathways and cellular processes associated with PTPN12 
variation. Specifically, we quantile-normalized and performed two-
dimensional hierarchical clustering of the 1000 top correlated genes 
with PTPN12 expression across the 105 TNP samples. We identified 
seven distinct gene clusters and three distinct patient subpopulations. 
The three distinct subtypes of TNP were comprised of low expressing 
PTPN12 (median log2 expression of 12.3), medium expressing 
PTPN12 (median log2 expression of 13.1), and high expressing 
PTPN12 (median log2 expression of 13.4). From the 7 gene clusters 
identified, 6 were positively correlated and one cluster (cluster 3) 
was negatively correlated with PTPN12 expression. Upon examining 
the genes within each cluster, we found that all contain unique set of 
genes related to cell proliferation, cell death, cell motility, cell cycle 
regulation and other cancer related pathways. From the 7 clusters, 
clusters 1, 6 and 7 had the highest fraction of such genes. The gene 
expression pattern and the gene content of these three clusters is as 
follows: Cluster 1 (208 genes) were genes that were highly expressed 
in all three TNP groups and the expression of the genes was highest in 
high PTPN12 expressing patients. Functional classification of genes 
by the DAVID bioinformatics tool at NCBI showed several genes 
related to cancer, including 19 MAP kinase signaling genes, and 
15 genes involved in regulation of apoptosis. Cluster 6 (150 genes) 
contained genes showing very low expression in low-expressing 
TNPs, moderately expressed in medium expressing TNPs, and highly 
expressed in high-expressing TNPs. Cluster 6 had the highest fraction 
of cancer related genes including 7 mitosis and cell cycle check point 
genes, 6 cytoskeletal genes, 4 phosphatases and 6 kinases including 
KRAS, 4 DNA repair genes, 8 signal transduction genes, 3 positive 
regulator of apoptosis, and 22 genes involved in regulation of gene 
expression. Cluster 7 (166 genes) contained genes that were expressed 
at low level throughout the three TNP groups but the severity of 
under-expression was higher in TNP patients with low PTPN12 
expression. In cluster 7 there were 5 genes belonging to the EGFR 
and FGF signaling pathways, and 6 genes involved in mitosis. It is 
worth noting that EGFR pathway has been postulated to crosstalk 
with PTPN12 protein. All together our results provide support for 
the involvement of PTPN12 in cancer development and highlights a 
promising therapeutic target for TNP patients.
PD08-10
High Frequency of Triple Negative Mammary Carcinomas in the 
Dog as Model of Human Breast Cancer.
Nguyen F, Abadie J, Loussouarn D, Ibisch C, Rieder N, Campion L, 
Belousov A, Bemelmans I, Hanzenne C, Campone M. Ecole Nationale 
Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche 
Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de 
Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie 
de l’Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), 
France
Background Information: Relevant animal models of human breast 
cancer are currently lacking, especially regarding the triple-negative 
breast cancer (TNBC) subtype, for which efficient therapies are 
needed. Recent studies indicate that spontaneous canine mammary 
carcinomas (CMCs) (which are common in France due to absence of 
early neutering) resemble human breast cancers, by pathology, tumor 
genetics, and biological behavior. However, the current molecular 
classification of human breast cancer has not been evaluated in 
canine samples yet.
Objective: To establish the prognostic value of the human 
immunophenotypic classification in dogs To evaluate CMCs as a 
model of human breast cancer including TNBC.
Methods: 350 CMCs treated by surgery alone were obtained from 
the Nantes Atlantic College of Veterinary Medicine, Food Science 
and Engineering (France) from 2005 to 2008. Recorded clinical data 
included breed, neutering, age at diagnosis, presence of metastases, 
cause and time to death. Histological records included the subtype 
of carcinoma, Elston & Ellis grade, presence of emboli and lymph 
node metastasis. By immunohistochemistry (IHC) using ER, PR, Her2 
(Herceptest and Pathway® Her2), CK5/6, EGF-R and KI67, CMCs 
were classified into the subtypes of human breast cancer according 
to Nielsen et al. IHC analyses were independently reviewed by four 
pathologists.
Results: The preliminary data in this abstract are based on 200 cases. 
The mean age at diagnosis was 10.8±2.1 years. 72,7% of dogs were 
intact female (27,3% of late neutering). 41% of dogs died due to 
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cancer progression (metastasis rate of 30%). The most common 
histologic subtype was simple tubulopapillary CMC (53%), then 
solid CMC (32%). The most common grades were grade II (49%) 
and III (43%). 53% of the tumours showed lymphatic emboli. 4 
immunophenotypes were defined: luminal A (11.9%), luminal B 
(5.1%), basal-like (59.3%) and non basal-like (23.7%) triple negative 
CMCs. 8.8% of the CMCs were scored Her2 2+ but none were 
considered Her2-overexpressing as defined by a 3+ score, despite 
appropriate staining with the two well established methods. Predictive 
factors for specific survival were: dog weight (p=0.01), histologic 
subtype (p=0.001), presence of emboli (p<0.0001) or lymph node 
metastasis (p=0.02), Ki67 index (p=0.03). Triple-negative carcinomas 
showed a significantly shorter specific survival (median=224 days) 
when compared to luminal A CMCs (median=641 days) (Mann-
Whitney, p=0.016).
Conclusion: The molecular classification of human breast cancer 
identifies 4 subtypes of invasive CMCs with different prognoses. 
In dogs, a low rate of luminal tumors are observed, and no Her2-
overexpressing tumors are found (defined by a score of 3+ by Her2 
immunohistochemistry). 83% of CMCs were of the triple-negative 
subtype, associated with a shorter survival, as reported in human 
breast cancer. Infiltrative mammary cancer in dogs could be an 
interesting model for preclinical investigations. Final data based on 
350 animals will be presented at the meeting.
PD08-11
Targeting Porcupine, a Critical Node for Wnt Signalling in 
Cancer.
Liu J, Pan S, Sun F, Kasibhatla S, Schuller A, Li A, Li C, Cui X, 
Wang T, Villarroel M, Mclaughlin M, Sellers W, Boral A, Harris J. 
Genomics Institute of the Novartis Research Foundation, San Diego, 
CA; Novartis Institutes For BioMedical Research, Cambridge, MA
Wnt ligands were first discovered based upon their transforming 
activity in the setting of mouse mammary tumor virus (MMTV) 
induced mammary carcinogenesis. Wnt signalling is required for 
normal development of the mammary gland and dysregulated Wnt 
signalling is implicated in cancers of the breast and colon among 
others. Furthermore, lobular breast cancer commonly shows reduced 
expression of E-cadherin that can lead to release of membrane-bound 
b-catenin into the cytoplasm and potentially increase Wnt signalling in 
the presence of Wnt ligand. To date, however, low-molecular weight 
therapeutic inhibitors of the Wnt pathway have not been developed.
We set out to discover key points of intervention in the Wnt pathway 
and to develop low molecular weight inhibitors against such nodes. 
To this end, a cellular high-throughput screen for small molecule 
inhibitors of the Wnt pathway was performed. In this assay, cells 
secreting Wnt3a were co-cultured with cells harboring a luciferase 
reporter driven by the Wnt/beta-catenin responsive elements. Potent 
and specific Wnt pathway inhibitors were identified from this screen. 
To discern the mechanism of action of these compounds, a lead 
inhibitor was radiolabeled and used to probe protein targets in a 
radioligand binding assay. From these assays a candidate target of 
the inhibitor was identified as Porcupine. Porcupine is a membrane 
bound O-acyltransferase enzyme that is required for and dedicated 
to palmitoylating Wnt ligands, a necessary step in the process of 
Wnt ligand secretion. Inhibition of Porcupine blocks Wnt dependent 
activities, including LRP6 phosphorylation and the expression of 
Wnt target genes, such as Axin2, which in turn reduces the growth 
of cancer cells dependent on autocrine or paracrine Wnt signaling.
A selective and orally bioavailable Porcupine inhibitor (NVP-
LGK974) that inhibits the Wnt pathway in vitro and in vivo was 
developed through medicinal chemistry optimization. In preclinical 
evaluation, the compound robustly suppressed Wnt pathway signaling 
in vivo resulting in tumor regression in a murine breast cancer model 
driven by MMTV-Wnt1. In addition, this inhibitor attenuated tumor 
growth as a single agent and induced tumor regression in combination 
with Taxol in a human primary breast tumor model.
Wnt signalling is also important for the maintenance and homeostasis 
of normal tissues including gastrointestinal tissue. However, 
preclinical rodent efficacy models of cancer demonstrate that 
intermittent pharmacological inhibition of Porcupine can be effective 
against the tumor and mostly spare the normal gastrointestinal tissue, 
with an acceptable therapeutic window.
A Phase I dose escalation study of NVP-LGK974 in patients 
with melanoma and lobular breast cancer to evaluate the safety, 
tolerability, PK, and PD properties is expected to begin this year.
PD09-01
Target-Based Therapeutic Matching in Early-Phase Clinical 
Trials in Patients with Advanced Breast Cancer and PIK3CA 
Mutations.
Janku F, Moulder SL, Wheler JJ, Stepanek V, Falchook GS, Naing A, 
Hong DS, Fu S, Piha-Paul SA, Luthra R, Tsimberidou AM, Kurzrock 
R. The University of Texas MD Anderson Cancer Center, Houston, TX
Background: Therapeutic matching based on underlying molecular 
abnormalities showed promising results in early-phase clinical trials. 
PIK3CA mutations may predict response to therapies with PI3K/
AKT/mTOR inhibitors.
Methods: Tumors from patients with breast cancer referred to 
the Clinical Center for Targeted Therapy (Phase I Program) were 
analyzed for PIK3CA mutations. Patients with PIK3CA mutations 
were treated, whenever feasible, with agents targeting the PI3K/
AKT/mTOR pathway.
Results: Of 54 patients analyzed, 15 (28%) had PIK3CA mutations. 
PIK3CA mutations were found in 5/9 (56%) metaplastic, 3/8 (38%) 
HER2-positive, 7/29 (24%) hormone receptor-positive, and 0/8 (0%) 
triple negative (excluding metaplastic) breast cancers (P=0.07). Of the 
15 patients with PIK3CA mutations, 12 (80%) were treated in clinical 
trials containing a PI3K/AKT/mTOR pathway inhibitor (median age, 
54; median number of prior therapies, 3). Of these 12 patients, 3 (25%, 
95% CI 0.09-0.53) had stable disease for more than 6 months (SD>6 
months; n=1) or a partial response (PR; n=2). Breast cancer patients 
without PIK3CA mutations treated on the same protocols had a rate 
of SD>6 months/PR of 8% (1/12; 95% CI 0.01-0.35, p=0.6). Of the 
4 patients with a H1047R mutation treated with agents targeting 
the PI3K/AKT/mTOR pathway, 3 (75%) had SD>6 months (n=1) 
or a PR (n=2) compared to 0 of 8 patients (0%) with other PIK3CA 
mutations (P=0.045). Patients with H1047R mutations had a median 
progression-free survival (PFS) of 8.5 months compared to 2 months 
in patients with other PIK3CA mutations (p=0.13).
Conclusion: Heavily pretreated patients with PIK3CA-mutant 
advanced breast cancer had a SD>6 months/PR rate of 25% on 
protocols incorporating PI3K/AKT/mTOR. Patients with mutation 
H1047R had significantly longer SD>6 months/PR rate compared 
to those with other PIK3CA mutations. Our observations suggest 
that screening for PIK3CA mutations is warranted in larger numbers 
of patients with advanced breast cancer when treatment with PI3K/
AKT/mTOR pathway inhibitors is planned.
PD09-02
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PD09-03
Phase I/II Study of BKM120 in Combination with Trastuzumab 
in Patients with HER2 Overexpressing Metastatic Breast Cancer 
Resistant to Trastuzumab-Containing Therapy.
Saura C, Bendell J, Jerusalem G, Graña-Suárez B, Su S, Ru Q, De 
Buck S, Devisme C, Bosch A, Urruticoechea A, Beck JT, DiTomaso E, 
Rouyrre N, Sternberg DW, Massacesi C, Hirawat S, Dirix L, Baselga 
J. Hospital Vall d’Hebron, Barcelona, Spain; Sarah Cannon Research 
Institute, Nashville, TN; C.H.U. Sart-Tilman, Liege, Belgium; 
Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharma 
AG, Basel, Switzerland; Hospital Clínico Universitario de Valencia, 
Valencia, Spain; Catalan Institute of Oncology, Barcelona, Spain; 
Highlands Oncology Group, Fayetteville, AZ; Novartis Institutes for 
BioMedical Research, Cambridge, MA; Novartis Oncology, Paris, 
France; Oncologisch Centrum AZ-St. Augustinus Oncology, Wilrijk, 
Belgium; Massachusetts General Hospital, Boston, MA
Introduct ion :  HER2 ampl i f ica t ion  can  ac t iva te  the 
phosphatidylinositol-3-kinase (PI3K) pathway in breast cancer. 
Furthermore, trastuzumab (T) resistance can be associated with 
loss/deregulation of PTEN, which also causes activation of PI3K 
pathway signaling. BKM120, a potent orally bioavailable pan-class 
I PI3K inhibitor, could reverse resistance to T in vitro. Furthermore, 
administration of BKM120 with T demonstrated synergistic activity 
in preclinical models. The potential for combining BKM120 with T 
in heavily pretreated HER2+ metastatic breast cancer (MBC) patients 
(pts) will be determined in this study to substantiate the hypothesis 
for future development.
Methods: HER2+ MBC pts resistant to T-containing therapy 
(progression on or within 4 weeks since last T administration) received 
treatment in the dose-escalation portion of this multicenter trial. Prior 
anti-HER2-directed therapies were allowed. The primary objective 
was to determine the maximum tolerated dose (MTD) of BKM120 in 
combination with the standard dose of weekly T. A Bayesian logistic 
regression model with overdose control guided the dose escalation.
Results: Seventeen pts with MBC have been enrolled: 5 at 50 mg/day 
and 12 at 100 mg/day dose of BKM120. Escalation was conducted 
up to the MTD level of single agent BKM120, 100 mg/day. Patient 
characteristics: median age 46 years (range 34–70); most pts were 
heavily pretreated (reported range of prior chemotherapy lines 1–4). 
In preliminary results (cut-off date 1st June 2011), 7 pts discontinued 
treatment. BKM120 in combination with T showed a mean peak drug 
concentration and half-life similar to single-agent BKM120. T trough 
levels remained above the single agent efficacy threshold. Only one 
dose-limiting toxicity (G3 asthenia) was reported at the BKM120 
dose of 100 mg/day. The MTD was determined to be 100 mg/day. 
Reported G3 adverse events were asthenia, altered mood, rash, GGT 
increase, hypokalemia, and hypersensitivity in 1pt each. No G4 
toxicity has been observed so far. With regards to activity, 2 partial 
responses (1 confirmed) and 3 occurrences of disease stabilization 
have been observed.
Conclusions: BKM120 in combination with T in heavily pretreated 
HER2+ MBC pts with T-resistance has an acceptable safety profile 
and has shown encouraging preliminary activity. The Phase II portion 
of the study is ongoing. An updated analysis of efficacy, the potential 
correlation with PI3K pathway alteration status overlaying HER2 
activation, and pharmacodynamics study will be presented.
PD09-04
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety 
and Pharmacology of the PI3-Kinase Inhibitor GDC-0941 in 
Combination with Paclitaxel and Bevacizumab in Patients with 
Locally Recurrent or Metastatic Breast Cancer.
Schöffski P, De Benedictis E, Gendreau S, Gianni L, Krop IE, Levy G, 
Ware J, Wildiers H, Winer EP. Catholic University, Leuven, Belgium; 
Istituto Nazionale dei Tumori, Milan, Italy; Genentech Inc., South San 
Francisco, CA; Dana-Farber Cancer Institute, Boston, MA
Background: GDC-0941 is a potent and selective oral pan-inhibitor 
of class I PI3K isoforms that demonstrates single-agent activity in 
xenograft models1,2,3. Increased phosphorylation of AKT has been 
observed in breast cancer (BC) cell lines treated with paclitaxel in 
vitro, suggesting dependence on the PI3K pathway for survival in 
response to chemotherapy treatment. GDC-0941 increases the anti-
tumor activity of taxanes, associated with increased apoptotic cell 
death, in multiple BC xenograft models2.
Material and Methods: Patients (pts) with HER2-negative locally 
recurrent or metastatic BC (MBC) that received no more than 2 prior 
anti-cancer therapies for MBC (prior paclitaxel and/or bevacizumab 
permitted) were enrolled in a Phase Ib study (GDC4629g) of paclitaxel 
and GDC-0941 with and without bevacizumab using a 3+3 dose 
escalation design to evaluate the safety, tolerability, and PK and 
determine the MTD of the combination. Paclitaxel was given at 90 mg/
m2 on Days 1, 8 and 15 and bevacizumab, if applicable, at 10 mg/kg 
on Days 1 and 15 every 28 days. Two dosing schedules of GDC-0941 
were examined: GDC-0941 given once-daily on Days 1-21 (“21+7” 
schedule) or given for 5 consecutive days followed by a 2-day drug 
holiday (“5+2” schedule, implemented to potentially to improve the 
efficacy and safety of the combination treatment).
Results: We report data from 5 cohorts (25 pts). Sixteen of the 25 
pts (64%) are hormone-receptor positive and 12 of 25 patients (48%) 
received prior treatment with a taxane, (all but one in the neo-adjuvant 
or adjuvant setting) and only one patient received prior treatment with 
bevacizumab. Pts in Cohort 1 received GDC-0941 60 mg given 21+7 
with paclitaxel in Cycle 1; they were allowed to receive bevacizumab 
starting in Cycle 2. One DLT of Grade 3 subclavian vein thrombosis 
(in a pt with an indwelling catheter) was observed at this dose level. 
The cohort was expanded without any additional DLTs. In Cohorts 2 
and 3, GDC-0941 was given 21+7 at 60 mg and 100 mg, respectively, 
with paclitaxel and bevacizumab starting in Cycle 1. In Cohort 4, 
GDC-0941 was given 5+2 at 165 mg with paclitaxel only. Cohort 5, 
with 250 mg GDC-0941 given 5+2 with paclitaxel only, is currently 
under evaluation. The most common drug-related AEs in 22 treated 
patients are in Table 1. Preliminary PK for GDC-0941, paclitaxel and 
6-hydroxypaclitaxel were similar to historical profiles from previous 
studies of these molecules. One CR and 9 PRs (ORR 46%) have been 
observed to date.
Table 1: Drug-Related AEs Observed in >10% of Pts
Preferred Term All Grades Grade 3/4
Diarrhea 63 5
Alopecia 59 -
Neutropenia 59 36
Peripheral neuropathy* 55 9
Nausea 50 0
Nail Disorders 41 14
Rash 32 0
Epistaxis 27 0
Hypertension 18 5
Anemia 16 0
Dyspnea 14 5
Headache 14 0
*includes term of peripheral sensory neuropathy 
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Conclusions: GDC-0941 given 5+2 at doses up to 165 mg QD in 
combination with paclitaxel is well tolerated and dose escalation 
continues with encouraging clinical activity. Updated safety, PK and 
efficacy data will be presented.
1Junttila et al, Cancer Cell 2009
2Yao et al., CCR 2009
3O’Brien et al., CCR 2010
PD09-05
SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus 
Aromatase Inhibitor Letrozole in ER+/HER2- Metastatic Breast 
Cancer (MBC).
Mayer IA, Balko JM, Kuba MG, Sanders ME, Yap J, Li Y, Winer 
E, Arteaga CL. Vanderbilt-Ingram Cancer Center, Nashville, TN; 
Dana Farber Cancer Institute, Boston, MA; MD Anderson Cancer 
Center, Houston, TX
Background: Experimental evidence and clinical data suggest that 
PIK3CA mutations (present in approximately 35% of ER+ cancers) 
are associated with de novo or acquired resistance to antiestrogen 
therapy. Considering that most breast cancers resistant to antiestrogen 
therapy retain ER and estrogen sensitivity, treatment of ER+ breast 
cancers with single-agent PI3K-targeted therapy may be insufficient 
to inhibit tumor growth.
Materials and Methods: To evaluate safety/tolerability, we initiated 
a phase Ib clinical trial of letrozole with the pan-PI3K inhibitor 
BKM120 (Novartis) in post-menopausal patients with ER+/HER2– 
MBC. Letrozole (2.5 mg/d) and BKM120 (100 mg/d) were given on 
a 28-day cycle. When necessary, BKM120 was reduced to 80 and 
60 mg/day. Treatment was continued until unacceptable toxicity or 
progression of disease. Disease was assessed every 2 months. FDG-
PET imaging was performed at 2 weeks to identify changes indicative 
of pharmacodynamic modulation of PI3K/AKT.
Results: Twenty patients have been accrued; all but 2 patients had 
previously progressed on an aromatase inhibitor (AI) in the metastatic 
setting. Median age was 56 years; 85% of patients had metastatic 
bone disease, 70%, visceral metastases. Twelve patients are still on 
treatment, 2 of these are currently on BKM120 80 mg/day. Three 
patients discontinued treatment within 2 months of initiation due to 
grade 3 transaminitis, grade 2 irritability, and grade 2 hyperglycemia, 
despite dose reductions and/or optimal treatment. Most common 
toxicities are summarized in the table below. Transaminase elevation 
was the only DLT at 100 mg/d BKM120. Of the 12 evaluable patients 
that completed at least 8 weeks of treatment, 1 had a partial response, 
7 had stable disease, and 4 had disease progression (RECIST). So far 
3 patients have been on treatment for >4 months. Over 50% of patients 
had >25% reduction in their peak SUV at the 2-week FDG-PET scan.
Percentage of patients with most common related adverse effects (CTCAE.4)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Total
Hyperglycemia 30 10 10 0 50
Nausea 35 10 0 0 45
Fatigue 25 15 5 0 45
Transaminase elevation 20 10 15 0 45
Alkaline phosphatase elevation 15 5 0 0 20
Diarrhea 30 5 0 0 35
Anxiety 20 0 5 0 25
Irritability 5 10 0 0 15
Depression 10 25 5 0 40
Rash 20 0 5 0 25
Discussion: The letrozole + BKM120 combination is active in 
patients with ER+/HER2– MBC refractory to previous therapy 
with an AI. At this time, all patients’ primary diagnostic tumor 
biopsies and/or metastatic biopsies are being analyzed for the 
presence of PIK3CA, AKT1, or PTEN mutations and PTEN loss 
(immunohistochemistry). FDG-PET imaging at 2 weeks appears to 
be a useful pharmacodynamic biomarker of PI3K pathway inhibition. 
Correlation of mutational analysis with clinical benefit will be 
presented at the meeting. Despite an overall safe side effect profile, 
an alternative administration schedule of BKM120 with letrozole is 
planned to enhance tolerability of the combination.
PD09-06
Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with 
Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative 
Metastatic Breast Cancer (MBC).
Mayer IA, Means-Powell J, Abramson VG, Shyr Y, Balko JM, 
Kuba MG, Gharavi HM, Schlabach L, Arteaga CL, Pietenpol JA. 
Vanderbilt-Ingram Cancer Center, Nashville, TN; Vanderbilt-Ingram 
Cancer Center Affiliated Network (VICCAN)
Background: In basal-like breast cancers, drugs that either negatively 
modulate p63 and/or activate p73, such as cisplatin and paclitaxel, 
promote p73-dependent apoptosis. Further, the serine threonine kinase 
mTOR negatively regulates p73. Inhibition of mTOR with RAD001 
upregulates p73, and results in p73-mediated apoptosis. Therefore, 
we conducted a phase II trial in patients with HER2-negative MBC to 
explore safety, tolerability and anti-tumor activity of the combination 
of paclitaxel, cisplatin and RAD001.
Materials and Methods: We initiated an open-label, phase II multi-
institutional study of weekly cisplatin (25 mg/m2), paclitaxel (80 mg/
m2) and daily RAD001 (5 mg), given on a 28-day cycle. Treatment 
was continued until unacceptable toxicity or progression of disease. 
All toxicities were documented using the NCICTCv.4. Disease was 
assessed every 2 months.
Results: A total of 55 patients were enrolled. Median age was 55 years; 
62% of patients had prior chemotherapy with a median of 3 previous 
regimens in the metastatic setting. Sixty-three percent of patients had 
triple-negative disease, 81% patients had visceral disease, and 35% 
had bone metastases. Twenty-one patients are still on study. The most 
common toxicities are summarized in the table below. Neutropenia 
was the main cause for dose reductions, mainly after cycle 3. Only 1 
patient developed febrile neutropenia. Of the 44 patients assessed for 
best response (RECIST) thus far, 11 had partial response, 21 stable 
disease, 9 disease progression, and 3 were not evaluable. Thirty 
eight patients have discontinued treatment so far; 30 due to disease 
progression, 5 due to toxicity, and 3 withdrew consent. Current median 
time to progression on the evaluable patients is 6 months.
Percentage of patients with most common related adverse effects (CTCAE.4)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Total
Anemia 21 38 13 0 72
Neutropenia 1 19 21 3 44
Thrombocytopenia 38 17 1 0 56
Transaminase elevation 17 5 1 0 23
Nausea 34 5 1 0 40
Diarrhea 15 1 0 0 16
Stomatitis 11 3 0 0 14
Hypercholesterolemia 17 5 0 0 23
Neuropathy 13 13 1 0 27
Fatigue 15 25 1 0 41
Discussion: The combination of RAD001, cisplatin and paclitaxel 
was overall very well tolerated despite cumulative pancytopenia. 
Significant antitumor activity in this heavily pre-treated patient 
population was seen. All patients’ primary diagnostic and/or 
metastatic tumor biopsies are currently being analyzed for the 
presence of PIK3CA and AKT1 mutations, and immunohistochemical 
expression of p53, p63, p73, and PTEN. Microarrays are being 
generated to determine whether time to progression is superior in 
patients with basal-like breast cancers. Microarrays will be mined 
to identify a pretreatment profile that mirrors a low p63/high p73 
gene expression signature. Correlation of mutational analysis and 
gene signatures with clinical benefit will be presented at the meeting
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PD09-08
Combined Inhibition of mTORC1 with Temsirolimus and HER2 
with Neratinib: A Phase I/II Study in Patients with Metastatic 
HER2-Amplified or Triple-Negative Breast Cancer.
Gajria D, King T, Pannu H, Sakr R, Seidman AD, Modi S, Dickler 
M, Drullinsky P, Syldor A, Sujata P, Majid M, Norton L, Rosen N, 
Chandarlapaty S. Memorial Sloan-Kettering Cancer Center, New 
York, NY
Background: Hyperactivation of the PI3K-AKT-mTOR pathway 
is a postulated mechanism of resistance to anti-HER2 therapies and 
has also been described in triple-negative breast tumors. In HER2-
amplified (HER2+) laboratory models, inhibition of this pathway 
induces activation of upstream receptor tyrosine kinases such as 
HER3. In triple-negative breast cancer (TN), HER1 overexpression 
has been identified and models show sensitivity to combined HER1 
and mTOR inhibition. We hypothesize that dual inhibition of the 
PI3K pathway, HER1/2, and induced HER3 may be highly effective 
in patients with HER2+ or TN breast cancer (BC). This phase I/II 
trial is designed to determine the tolerability and possible efficacy 
of the mTOR inhibitor temsirolimus (T) plus the HER1/2 inhibitor 
neratinib (N) in patients with trastuzumab-refractory, HER2+ or TN 
BC. We will also explore mutational activation of the PI3K pathway 
in trastuzumab-refractory tumors as it relates to response to the T-N 
combination.
Methods: The phase I dose-escalation study evaluated T (flat dose IV 
weekly) plus N (240 mg oral daily) in patients with metastatic HER2+ 
or TN BC. Cycle length was 4 weeks. Phase I end points included 
definition of maximum tolerated dose (MTD) and response rate (RR) 
per RECIST. The phase II study has a Simon two-stage design and 
evaluates the HER2+ and TN patients separately. Phase II endpoints 
include progression free survival and duration of response. Response 
was evaluated radiographically every 8 weeks, toxicity assessed 
every 2 weeks. All patients underwent biopsy of metastatic disease 
for biomarker assessment. Activating mutations in PIK3CA were 
assayed using the Sequenom MassARRAY system. Expression of 
PTEN was assessed by immunohistochemistry utilizing a published 
scoring system.
Results: The phase I study enrolled 8 HER2+ patients who received 
a median of 5 (1-13) cycles of therapy. All patients had received 
trastuzumab and a median of 5.5 (2-12) prior lines of therapy. Frequent 
treatment-related grade 2 events were: hyperglycemia (4/8), elevated 
CPK (3/8), diarrhea (2/8), and rash (2/8). Grade 3 diarrhea was the 
dose-limiting toxicity. Other grade 3 toxicity was hyperglycemia (1/8); 
hematologic toxicities were not observed. The MTD of temsirolimus 
with neratinib is 8 mg IV weekly. Six patients treated at MTD were 
evaluable for response; 4 patients had PR, 1 had SD for a RR of 67%. 
PI3K pathway activation, through PIK3CA mutational activation or 
PTEN loss, was identified in 4/6 tumors analyzed and did not preclude 
response to temsirolimus and neratinib. Updated results reflecting the 
phase II patients will be reported.
Conclusions: Temsirolimus plus neratinib is active in trastuzumab-
refractory HER2+ patients. The phase II study is ongoing and 
additional efficacy and safety data in both HER2-amplified and 
triple-negative breast cancer patients will be presented.
PD10-01
Prevalence of Dysfunctional Fanconi Anemia (FA) DNA Repair 
Pathway in Breast Cancer.
Ramaswamy B, Srividya V, Mullins DA, Carothers S, Young G, Wenrui 
D, Zhao W, Lustberg M, Leon M, Weslowski R, Layman R, Mrozek 
E, Shapiro CL, Villalona-Calero M. The Ohio State University, 
Columbus, OH; The Ohio State University
Purpose: BRCA1/2 deficient breast tumors are highly sensitive 
to poly- ADP-ribose polymerase inhibitors (PARPi). The Fanconi 
Anemia (FA) associated gene products along with BRCA 1/2 
function in a common pathway that regulates the cellular response 
to DNA damage, suggesting that tumors with dysfunction of any 
of the components of FA network would be susceptible to PARPi. 
Understanding the prevalence of such defects in breast tumors using 
reproducible methodology will help us target these tumors with novel 
agents and potentially improve outcomes. Hence we sought to assess 
the prevalence of FA pathway defect in breast tumors by the absence 
of nuclear FANCD2 (a pivotal protein in the FA/BRCA pathway which 
is monoubiquitylated in the nucleus in response to DNA damage) 
repair foci using a novel immunofluorescence method and correlate 
this with known molecular markers of breast cancer.
Methods: Using primary tumors obtained from the ongoing PARPi 
clinical trials (NCT01017640 and NCT01251874) and tumor bank, we 
evaluated 102 breast tumors for the somatic functionality of the FA 
pathway (FANCD2 foci formation) by the FA Triple Stain Immuno-
Fluorescence (FATSI) test performed in a CLIA-certified laboratory 
using paraffin embedded tissues. The tissue sections are incubated 
with a primary antibody cocktail of rabbit polyclonal FANCD2 
antibody and a monoclonal anti-Ki67 mouse antibody, followed by 
co-incubation with a secondary antibody (FITC conjugated to anti-
rabbit IgG and Alexafluor 594 donkey anti-mouse), mounted on glass 
slides in a DAPI containing embedding medium and evaluated by a 
fluorescence microscope. Absence of nuclear FANCD2 formation in 
100 proliferating tumor cells was considered positive for FA defect. 
Hormone receptor (HR) and Her2 status was compared between the 
groups using Fisher’s exact test.
Results: A total of 102 primary breast tumors were analyzed for 
FANCD2 by FATSI test of which 62 were triple negative (TN), 37 
were HR positive and 3 were Her2 positive. Of these, 29 tumors (28%) 
were positive for FA defect with no significant differences among the 
molecular subtypes (26% in TN vs 32% in HR + vs 33% in Her2+).
Table 1
Factor FA defect = no FA defect = yes p-value
ER Positive 20 (64.5%) 11 (35.5%) 0.34
PR Positive 20 (74.1%) 7 (25.9%) 0.81
HER2 3+ 2 (66.7%) 1 (33.3%) 1.0
TN 46 (74.2%) 16 (25.8%) 0.51
Conclusions: We report a novel methodology to efficiently screen 
archival FFPE tumors for somatic functional defect of FA DNA 
repair pathway and demonstrated a high prevalence (one-third) in 
breast tumors irrespective of molecular subtype. We are currently 
conducting clinical trials with PARPi including patients with tumors 
that test positive for FA defect to demonstrate if such tumors are 
sensitive to PARPi.
PD10-02
Sporadic Breast Cancers Show Defects in the BRCA1-BRCA2 
Pathway of Homologous Recombination in All Biomarker-Defined 
Sub-Types of Breast Cancer.
Powell SN, Mutter RW, Delsite R, Bindra R, King T, Giri D, Park J. 
Memorial Sloan-Kettering Cancer Center, New York, NY
Background: Mutation carriers of BRCA1 and BRCA2 are well 
known to develop early onset breast cancer, with loss of the second 
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allele occurring in the development of the tumor. However, by array 
comparative genomic hybridization (aCGH) studies, some sporadic 
breast cancers have a similar “genetic landscape” as BRCA-mutation 
carriers, showing large losses and gains across the genome. We have 
now identified that DNA repair defects involving the BRCA1-BRCA2 
pathway can occur in the absence of mutations in either gene and in 
the absence of a deficiency in either protein.
Methods: Fresh human breast cancer samples were irradiated, 
ex-vivo, to look for the ability to assemble RAD51 protein macro-
complexes or foci. Primary breast cancer specimens were obtained 
from consented patients with non-metastatic, invasive carcinomas 
following lumpectomy or mastectomy, without neoadjuvant cytotoxic 
or hormonal therapy. A single cell suspension was prepared from 
the tumor, with one half irradiated to 10Gy and the other half mock-
treated. After 4h, cells were mounted, fixed on slides, and stained 
with anti-Rad51, anti-BRCA1, and anti-gH2AX antibodies. At least 
200 nuclei were examined and scored using confocal microscopy. A 
failure to induce RAD51 nuclear foci by 2-fold after ionizing radiation 
was designated as defective in homologous recombination (HR).
Results: For the 71 patient samples analyzed, we have 14 triple-
negative tumors, of which 6 are HR-defective (42.8%); for Her2-
amplified tumors, we have 6/19 (31.6%) that are HR-defective and 
for ER+ tumors 6/38 (15.8%). The overall incidence of HR-defective 
tumors is 18/71 (25.3%), which is substantially higher than we would 
have expected.
Incidence of BRCA-HR pathway defects by Biomarker Group
 DNA Repair Status  
Breast Ca Type HR-defective HR-proficient %
ER+ 6 32 16
Her2-amp 6 13 32
Triple-Negative 6 8 43
Known mutation carriers were not included in the study, since these 
samples are BRCA-HR-defective in all cases we have tested. For 
the more recently acquired samples, we have undertaken additional 
tests to characterize the tumors: short-term growth assays in response 
to mitomycinC to validate that HR-defective tumors are indeed 
sensitive to cross-linking agents; and, a pilot analysis to study aCGH 
patterns in HR-defective tumors. The latter studies have compared 
6 repair-deficient and 6 repair-proficient tumors using unsupervised 
cluster analysis of large block deletions or large block copy number 
increase, which clearly reveal that large block alterations are linked 
to repair-deficient tumors.
Conclusions: There is a significant incidence of BRCA-HR defective 
sporadic breast cancers, as determined by RAD51 function in response 
to ionizing radiation plus genetic landscape alterations using aCGH. 
The pool of breast cancers that are susceptible to repair targeting 
strategies is larger than expected and is not readily defined by 
conventional diagnostic biomarker classification. These findings may 
account for the failure of the recent phase III study of the addition 
of iniparib to carboplatin and gemcitabine in triple-negative cancer 
as only a minority of the tumors will be susceptible to this targeting 
strategy.
PD10-03
Withdrawn by Author
PD10-04
Exploration of the Relationship between Loss of PTEN and 
BRCA1 Expression in Triple Negative Breast Carcinoma.
Jones N, Velasco V, Reault M, Dapremont V, Gastaldello B, Rouault 
A, Bonnet F, Debled M, Tunon de Lara C, Longy M, MacGrogan G, 
Sevenet N. Institut Bergonié, Bordeaux, France
Based on the mechanism of action of PARP inhibitors, BRCAness 
breast and ovarian cancers could be defined as the optimal group of 
tumours to target with such drugs. As the BRCAness phenotype is not 
fully defined at present, a surrogate phenotype of triple negative breast 
cancer (TNBC) has been proposed. Results of recent clinical trials 
involving PARP inhibitors in the context of TNBC do not demonstrate 
a significant improvement in overall survival or progression free 
survival, partly due to the inaccurate selection of certain tumours. 
Data from cell culture studies suggests that loss of PTEN expression 
could be a marker of PARP inhibitor sensitivity.
Materials and Methods
A retrospective study of 160 TNBC resected at Institut Bergonie 
between 1989 and 2010 was undertaken. Inclusion criteria were: ER 
& PR immunohistochemcial (IHC) negativity (<10% tumour cells 
positive), non-amplification of HER2 (IHC score 0, 1, or 2 with 
negative FISH analysis) and an invasive ductal carcinoma resected 
before chemotherapy. For some familial cases, germline BRCA1 
mutation screening had been performed in a diagnostic setting and 
was accompanied by genetic counselling. PTEN IHC, point mutation 
and gross rearrangement screening, along with BRCA1 expression and 
promoter methylation analysis (through real-time PCR and bisulfite 
treatment, respectively) and 53BP1 IHC were undertaken on this 
series of TNBC.
Results
Twenty percent of sporadic and familial TNBC demonstrated 
reduced BRCA1 expression with a greater than 7 fold reduction in 
expression. Almost half of tumours demonstrated a complete loss 
of PTEN expression as assessed by IHC, with a deleterious PTEN 
point mutation identified in 5% of cases. Although a slight correlation 
is observed between the complete loss of PTEN and a reduction in 
BRCA1 expression, a complete overlap of these two alterations was 
not observed; tumours with reduced BRCA1 expression do not always 
demonstrate complete negativity on PTEN IHC and certain tumours 
displaying complete negativity on PTEN IHC do not show a reduction 
in BRCA1 expression. Full immunohistochemical characterization of 
the tumour series (ER, PR, HER2, AR, CK5/6 & EGFR) together with 
the results of PTEN, BRCA1 and 53BP1 analyses will be presented.
Conclusion
These results suggest that at present, loss of PTEN expression is 
not a suitable surrogate marker for tumours with reduced BRCA1 
expression. This should be borne in mind for ancillary studies of 
clinical trials involving PARP inhibitors in the treatment of breast 
tumours and further investigation is warranted.
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PD10-05
Identification of Novel BRCA1 Transcriptional Targets That 
Promote the Survival of BRCA1-Mutated Estrogen Receptor-a 
Negative (ER-ve) Breast Tumours.
Lamers E, Haddock P, Cochrane DJ, Gorski JJ, Blayney J, McDyer 
FA, Mulligan JM, Mullan PB, Couch FJ, Kennedy RD, Harkin PD, 
Quinn JE. Queen’s University of Belfast, Belfast, Antrim, United 
Kingdom; Almac Ltd., Cragaivon, United Kingdom; Mayo Clinic 
College of Medicine, Rochester, MN
Background
The BRCA1 tumour suppressor gene is mutated in the germline 
of women who are predisposed to developing breast cancer. Gene 
expression profiling has identified at least five different breast 
cancer subtypes with BRCA- mutated breast tumours clustering 
with triple negative breast cancers. The majority of BRCA1-mutated 
breast tumours are characterised as being negative for the estrogen 
receptor-a (ER-a), however, the underlying molecular biology of 
these tumours has not yet been fully determined. The aim of this 
study is to identify and characterise novel proliferation-associated 
BRCA1 target genes that are activated in BRCA1 mutated estrogen 
receptor negative (ER-ve) breast tumours.
Methods
Gene expression profiling and data analysis was performed on a cohort 
of 46 FFPE (Formalin Fixed Paraffin Embedded) derived BRCA1 
mutated (ER-ve) breast tumours and matched sporadic controls using 
the Almac Diagnostics Breast DSA research tool. Profiling was also 
performed on a panel of 15 breast cancer cell lines. Bioinformatics 
analysis was performed using Oncomine, DAVID and Metacore. High 
throughput siRNA screens using HiPerFect were performed on the 
Qiagen Flexiplate siRNA. Validation of gene targets was performed 
by qRT-PCR and ChIP assay. Clonogenic assays were performed 
to independently validate the effect of selected target genes on cell 
survival.
Results
A list of differentially expressed transcripts was derived from the 
comparison of 23 (ER-ve) BRCA1 mutated breast tumours and 23 
matched sporadic controls. A genome-wide ChIP-Chip promoter 
analysis was also performed in MCF7 breast cancer cells. By 
overlapping these two datasets, a list of tumour derived BRCA1 
promoter bound target genes was identified. Functional analysis of 
this gene list has identified the main pathways and processes that are 
deregulated in BRCA1 mutated (ER-ve) breast cancer including: 
(1) immune response (2) induction of the epithelial to mesenchymal 
transition (EMT) (3) cell cycle regulation and (4) apoptosis and 
survival. Hierarchical clustering of these 46 breast tumours and 15 
breast cancer cell lines was performed and the BRCA1 mutated (ER-
ve) breast cancer cell lines (MDA436 and SUM149) were identified as 
those that best reflect the biology BRCA1 mutated (ER-ve) tumours. 
High throughput siRNA screening in these cell lines has identified 
a set of transcripts that when inhibited have a negative impact on 
cellular proliferation. Independent validation by qRT-PCR, ChIP 
assay, western blotting and clonogenic assays have confirmed HE4 
(WFDC2) as a novel BRCA1 target gene that provides a growth 
advantage in BRCA1 mutated (ER-ve) breast cancer cells.
Conclusions
Gene expression profiling of an extensive cohort of BRCA1 mutated 
(ER-ve) breast tumours and matched sporadic controls has identified 
a profile of BRCA1 mutated (ER-ve) breast cancer. This list has 
been further refined to generate a list of BRCA1 promoter bound 
transcriptional target genes. High throughout siRNA screening has 
revealed a panel of genes that are implicated in the proliferation of 
BRCA1 mutated (ER-ve) breast cancer. HE4 has been identified as a 
novel BRCA1 transcriptional target gene that promotes the survival 
of BRCA1 mutated (ER-ve) breast tumours.
PD10-06
Loss of the Retinoblastoma Tumor Suppressor (RB) in Triple 
Negative Breast Cancer Is Associated with a Favorable Prognosis.
Witkiewicz AK, Kline J, Mitchell E, Ertel A, Knudsen ES. Thomas 
Jefferson University, Philadelphia, PA; Kimmel Cancer Center, 
Philadelphia, PA
Introduction
The retinoblastoma tumor suppressor gene (RB), initially identified in 
the pediatric tumor retinoblastoma, has been shown to be functionally 
inactivated in a variety of other tumor types. RB functions as a key 
regulator of cell cycle progression and modulates the response to a 
variety of physiological and clinically relevant stresses. In breast 
cancer, loss of RB has been shown to have prognostic significance 
and influence therapeutic response; however, a comprehensive 
analyses of RB in triple negative breast cancer (TNBC) has not been 
performed. Although TNBC represents only 15-20% of breast cancers 
it accounts for approximately half of breast cancer deaths. A subset 
of patients with TNBC will have a dramatic and durable response to 
standard chemotherapy. However, currently there are no markers that 
identify this patient subset. Since RB loss impinges on the response 
to chemotherapy, the goal of this study was to investigate the impact 
of RB-status on clinical management of TNBC.
Material and Methods
A cohort of 220 patients diagnosed and treated at Thomas Jefferson 
University Hospital was included in the study. RB-status was 
evaluated by immunohistochmistry (IHC) using 3 markers: p16ink4a 
(MTM Laboratories, Cat #: 9518,1:50 dilution ), Ki67 (AbCam, Cat 
#: ab16667, 1:600 dilution) and RB (Thermoscientific, Cat #: MS-
107-B, 1:50 dilution) through automated image analysis (Aperio). 
Cases were considered negative for RB when no neoplastic cell 
nuclei demonstrated labeling in sections in which stromal cells 
and endothelial cells stained; Ki67 and p16ink4 were scored using 
established published criteria. Gene expression profiling was 
performed on 12 cases (6 RB positive and 6 RB negative by IHC) 
and RB pathway status in these samples was evaluated using an RB-
loss signature developed by our group. Parallel analyses of TNBC 
expression data sets were also employed to define the relationship of 
the RB pathway with clinical outcome. Overall survival was analyzed 
using LogRank test and Cox proportional hazard model. Data were 
analyzed in SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
176 patients had samples that could be scored for RB, p16ink4 
and Ki67 expression. 46% (71/176) showed RB loss. RB loss was 
associated with high p16ink4a expression and high Ki67 proliferation 
index in 93% (66/71) of samples and correlated with RB loss signature 
in all but one sample. RB loss and high p16ink4 expression was 
associated with a longer overall survival in this cohort (p=0.003). In 
contrast, patients with TNBC showing RB positivity and high p16ink4 
had the worse survival (median survival 4 months, 10 year survival 
23%). These findings were consistent with gene expression profiling 
data that indicate specific loss of RB function in TNBC is associated 
with improved response to chemotherapy and improved survival.
Conclusion
RB loss appears to be a predictor of a favorable clinical outcome in 
TNBC treated with conventional adjuvant chemotherapy.
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PD10-07
microRNA Profiles of Breast Tumors Identifies the miR 17-92 
Cluster as a Group of Potentially Essential Oncomirs in Triple-
Negative Breast Cancer.
Son BH, Birkbak NJ, Tian R, Iglehart D, Wang ZC, Richardson AL. 
Dana-Farber Cancer Institute, Boston, MA; Asan Medical Center, 
Seoul, Korea; Technical University of Denmark, Lyngby, Denmark; 
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Introduction: MicroRNAs (miRNAs) are a class of short non-coding 
RNAs of about 20-24 nucleotides that act post-transcriptionally 
to modulate gene expression by sequence-specific base-pairing 
with target mRNAs. While the function of human miRNA remains 
largely unknown, certain miRNAs have previously been implicated 
in cancer development and progression. In this study, we investigate 
the expression of 734 miRNAs across a cohort of 7 normal breast 
samples and 104 breast cancer tumors including 70 ER-/PR-/HER2- 
(triple negative, TN), 15 ER+/PR+, and 19 HER2+.
Methods: We used the novel Nanostring technology to quantify the 
expression of 734 miRNAs. Unsupervised hierarchical clustering 
was performed using miRNAs that were detected as expressed in at 
least one sample. A two-sided Wilcoxon rank sum test was used to 
identify miRNAs with a significantly differential expression between 
two sets of samples.
Results: In agreement with previously published results, we found 
that tumor samples clustered into the luminal and TN subtypes using 
unsupervised hierarchical clustering on the expressed miRNAs. 
Interestingly, microRNA expression was similar between HER2 
amplified ER+ and HER2 amplified ER-, suggesting a common 
luminal origin. When we specifically compared luminal (ER+ or 
HER2+) to TNBC, we found that 50 miRNAs showed significant 
differential expression. In particular, the miR-17-92 cluster(1) 
was expressed at significantly higher levels in TN tumors. Within 
the luminal tumors the miR-17-92 cluster was strongly correlated 
with proliferation and grade; although miR17-92 was expressed 
at high level, there was no correlation with proliferation in the TN 
tumors. miR17-92, which inhibits translation of E2F1(1), is in a 
regulatory network with myc and E2F to control the balance between 
proliferation and apoptosis(2). The absence of correlation between 
miR17-92 and proliferation in the TN tumors suggests disruption 
of this regulatory network. Indeed, we found a positive correlation 
between expression of miR17-92 and p16 and inverse correlation 
with RB across the tumor set. The high p16/low RB expression in 
TN tumors is consistent with disruption of the RB pathway (3) and 
suggest these TN tumors may depend on miR17-92 to down-modulate 
expression of E2F1 which would otherwise induce apoptosis.
Conclusions: Our results show that miRNA expression in breast 
cancer tumors differs depending on subtype. We also find evidence 
to suggest subtype-specific miRNA regulation of proliferation and 
a particular dependency of TN tumors on the miR17-92 cluster for 
survival.
References:
1. Novotny et al. Translational repression of E2F1 mRNA in 
carcinoma in situ and normal testis correlates with expression of the 
miR-17-92 cluster. Cell Death Differ. 2007.
2. Aguda et. al. MicroRNA regulation of a cancer network: 
Consequences of the feedback loops involving miR-17-92, E2F, and 
Myc. PNAS 2009.
3. Subhawong et. al. Most basal-like breast carcinomas demonstrate 
the same Rb-/p16+ immunophenotype as the HPV-related poorly 
differentiated squamous cell carcinomas which they resemble 
morphologically. Am J Surg Pathol. 2009.
P1-01-01
A Rat Monoclonal Antibody Against Bone Sialoprotein II Is Active 
in Preventing and Treating Tumor Growth and Osteolytic Lesions 
in Nude Rats Induced by MDA-MB-231 Breast Cancer Cells.
Berger MR, Zepp M, Armbruster FP. DKFZ, Heidelberg, Germany; 
Immundiagnostik Comp., Bensheim, Germany
The SIBLING protein bone sialoprotein II (BSPII) has been found 
implicated in lytic skeletal metastasis. Previous experiments 
had shown that targeting BSPII by a polyclonal IgY antibody or 
knock down of the gene’s transcript are instrumental in inhibiting 
experimental lytic skeletal metastasis. The aim of this study was 
to investigate the preventive and therapeutic effects of a new rat 
monoclonal anti BSPII antibody against tumor growth and osteolytic 
activity of MDA-MB-231 breast cancer cells growing in nude rats.
In the preventive arm of this study, rats were pre-treated with the 
antibody (0 and 10 mg/kg) starting one week before tumor inoculation. 
In parallel, MDA-MB-231luc cells were incubated with the antibody 
for one week (0 and 0.5 mg/ml). Following inoculation of 1x105 
MDA-MB-231luc breast cancer cells into the femoral artery of 6 male 
nude rats, respectively, lesions were expected to develop only in the 
tibia, femur or fibula of the respective hind leg. Their appearance and 
development were monitored for six weeks by light emission, caused 
by luciferase mediated metabolism of luciferin. Photon emission was 
recorded at regular intervals by a Xenogen IVIS 100 imaging system.
In the treatment arm of this study, the antibody administration (10 
mg/kg/week) started when tumor bearing rats had shown stable tumor 
growth. Experimental groups of rats received the first treatment either 
at four (late onset; n = 8) or at two (early onset; n = 6) weeks after 
tumor cell implantation. Tumor bearing animals were (sham-) treated 
and followed for up to 8 weeks.
All 6 control rats of the preventive arm showed steady tumor growth. 
In variance, the rats receiving MDA-MB-231luc cells that had been 
pre-exposed to the antibody and those rats, which had been pre-treated 
with the antibody showed clearly reduced light emission as indicator 
of reduced tumor growth. At 6 weeks after tumor cell inoculation, 
only 1 of 6 rats was positive for light emission in the group receiving 
pre-exposed tumor cells (p<0.01), 3 of 6 rats were positive in the 
group receiving pre-treatment with the antibody (p<0.05), and 1 of 
6 rats was positive in the group receiving both, pre-exposed tumor 
cells as well as pre-treatment with the antibody (p<0.01).
In the treatment arm, all but one untreated tumor bearing rats showed 
rapid tumor growth accompanied with lytic destruction of femur 
and tibia of the respective hind leg (18/19; tumor take rate 95%). 
In contrast, rats treated with the anti-BSP antibody did not show a 
significant increase in light emission nor a clinical deterioration. In 
fact, 6 of 8 rats receiving the late onset therapy didn’t show any light 
emission after 4 to 6 weeks (p = 0.01 versus control) as well as 4 of 
6 rats receiving the early onset therapy with the antibody (p < 0.05). 
Radiological and histological examination confirmed that animals 
without light emission were free of tumor growth, corresponding to 
a complete remission.
In conclusion, the rat monoclonal antibody directed against BSP II 
is a powerful tool in treating experimental skeletal metastasis and 
warrants further development.
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T Cell Is a Key Player in the Establishment of Cancer Associated 
Pre-Metastatic Bone Disease.
Bonomo A, Monteiro AC, Leal AC, Alves AP, Frusciante T, Braun S, 
Azevedo RB. Instituto Nacional de Cancer, Rio de Janeiro, Brazil; 
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 
Universidade de Brasilia, Brasilia, Brazil
Syngeneic mouse models of malignant diseases have the important 
advantage of allowing studies to be carried out in immunocompetent 
animals. In this work, the 4T1(metastatic) and 67NR (non-metastatic) 
sibling cell lines of mammary mouse carcinomas, syngeneic to 
BALB/c mouse were used to study tumor specific immune response 
and its impact on bone disease.
By day 11 after tumor injection, in the absence of metastasis, pro-
osteoclastogenic cytokines IL17F, TNFa, IL-1b and RANKL were 
present in the BM of 4T1+ mice in contrast to the virtual absence of 
these in the BM of 67NR+ animals.
More important, imaging studies (histomorphometry and microCT) 
showed that trabecular bone mass is close to maximum loss (around 
50%) already by day 11, in the absence of metastasis. These results 
support the possibility of T cell involvement in pre-metastatic lesion.
Indeed, in vitro, BM T cells from 4T1+ mice, but not from 67NR+, 
could induce OC differentiation in response to tumor antigens 
ascertained by TRAP enzymatic activity, morphology and osteolytic 
disk assay. In vivo transfer experiments showed that T cells from 
4T1+ mice (Day 11), when transferred into nude mice produce 3 times 
more IL17F and 4 times more RANKL than donor 67NR+ T cells. 
Moreover, trabecular bone at day 14 after transfer of 4T1+T cells 
was already 30% that of normal nude mice in contrast to 100% from 
67NR+ T cells. Of note is the fact that these activities are achieved 
in the absence of the metastatic 4T1 tumor in the nude host, but 
challenged with either 67NR or protein antigen extract.
To address the role of T cell derived IL17F and RANKL , T cells from 
4T1 bearing mice (day 11) were silenced with shRNA specific for 
each of these cytokines and transferred into nude mice. Animals were 
challenged with soluble tumor antigen. Silencing IL17F had no effect 
over bone loss. However, RANKL silencing completely inhibited 
osteolytic lesions. Together, these results indicate that RANKL in 
T cells mediate the osteolytic lesions and that cancer induced bone 
disease can be metastasis independent.
Since osteolytic lesions are believed to be important to feed the tumor 
with growth factors in a vicious cycle established in the metastatic 
niche, we asked if T cells could be preparing the pre-metastatic niche. 
When 4T1 cells are injected into athymic nude mice, bone metastasis 
is not observed up to day 24, while by day 20 it is already present 
in euthymic BALB/c animals, indicating that T cells are critical to 
prepare the seeding soil for tumor cells within the bone. We are 
currently investigating the role of T cells in the establishment of 
metastasis at later time points as well as in the primary tumor growth.
Our results strongly suggest that tumor cells, according to its 
metastatic activity, can modulate T cell activity systemically. 
Moreover, and not less important, we show that cancer induced 
bone disease starts before metastatic colonization and is mediated by 
RANKL expressed in tumor specific T cells. We propose that this is 
the very first step on the establishment of the “vicious cycle” which 
will allow tumor growth.
We believe this work can open new avenues on the prognostic 
evaluation and treatment of women with breast cancer.
P1-01-03
The Cytotoxicity of Select Neutrophils in Cancer Patients and 
the Role of Chemokines in Inducing Neutrophil Cytotoxicity.
Comen E, Granot Z, Norton L, Benezra R. Memorial Sloan-Kettering 
Cancer Center, New York, NY; Memorial Sloan-Kettering Institute, 
New York, NY
Background: Using murine mammary tumor models, recent research 
conducted by our laboratory at the Sloan-Kettering Institute indicates 
that select neutrophils are mobilized by a primary breast tumor and 
uniquely have the capacity to inhibit metastatic seeding in the lung 
(Granot Z et al. unpublished). We sought to evaluate the cytotoxic 
role of select neutrophils in the peripheral blood of breast cancer 
patients as contrasted with those from women without breast cancer 
and women with DCIS . In addition, we sought to determine whether 
the addition of select chemokines to neutrophils from a DCIS patient 
could induce cytotoxicity.
Methods: Neutrophils were purified from the blood of 21 newly 
diagnosed pre-operative breast cancer patients without evidence of 
metastatic disease, 9 healthy female volunteers with no history of any 
cancer, and 3 patients with newly diagnosed DCIS. Cytotoxicity was 
evaluated by incubating isolated neutrophils with luciferase labeled 
MDA-MB-231 cells. Luciferase activity, as a reflection of % cell 
kill, was measured using a Bio-Tek microplate luminescence reader. 
Neutrophils from a DCIS patient with low cytotoxicity were then 
co-cultured with various CC chemokines (CCl2, CCL3 and CCL5) or 
CXCL chemokines (CXCL1, CXCL12, and CXCL16) at 100ng/ml.
Results: Significant cytotoxicity was notably observed when MDA-
MB-231 cells were co-cultured with neutrophils purified from patients 
with invasive tumors. Pre-operative breast cancer patients (n=21) had 
a cell kill range of 0-30% (mean = 12.1%), whereas healthy subjects 
(n=9) had a cell kill range of 0.2-8% (mean = 2.6%), p<0.004. DCIS 
patients (N=3) had a cell kill range of 3-4% (mean = 2.7). The addition 
of select chemokines to neutrophils from a DCIS patient with low 
cytotoxicity (3.2%) resulted in significant increases in cytotoxicity. 
Table 1 indicates the relative cytotoxicity percentages from the 
addition of each chemokine.
Conclusions: To date, this preliminary work is the first to demonstrate 
the cytotoxic role of select neutrophils in the peripheral blood of breast 
cancer patients as contrasted with those from women without breast 
cancer. We further demonstrate the novel induction of neutrophil 
cytotoxicity by select chemokines. Further studies are needed to 
evaluate the prognostic and therapeutic role of cytotoxic neutrophils 
as well as the role of chemokines in neutrophil cytotoxicity.
Table 1: Induction of neutrophil cytotoxicity by select chemokines
 No chemokines added CCL2 CCL5 Mip1a CXCL1 CXCL12 CXCL16
Cytotoxicity 3.2% 20% 29% 37% 10% 49% 31%
P1-01-04
Immunological Effects of Bisphosphonates on gdT Cells in Breast 
Cancer.
Sugie T, Tanaka Y, Toi M, Minato N. Graduate School of Medicine, 
Kyoto University, Kyoto, Japan
Background: Human gdT cells play an important role in the first-line 
of defence. Accumulating data demonstrate that gd T cells recognize 
nonpeptide antigens such as IPP and HMBPP and activated gdT 
cells have potent cytotoxic activity against tumor cells. Nitrogen-
containing bisphosphonates like zoledronic acid inhibit farnesyl 
diphosphate synthetase, resulting in the accumulation of upstream 
metabolites such as IPP. Previous studies on the adoptive transfer of 
ex-vivo amplified gd T cells demonstrated the safety and feasibility 
of gdT cell–based immunotherapy for metastatic cancer. According 
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to ABCSG-12 clinical trial, zoldedoric acid improved DFS of patients 
with early–stage breast cancer under adjuvant endocrine therapy. 
Whereas a precise mechanism remained unclear, it is likely that gdT 
cells are involved in this anti-tumor effect in breast cancer.
Materials and Methods: Peripheral blood mononuclear cells derived 
from 63 (54 untreated non-metastatic and 9 metastatic) patients with 
breast cancer were examined for the baseline population of gdT cells 
and their proliferative responses to zoledronic acid in vitro. Tumor-
infiltrating lymphocytes were isolated from 20 tumor biopsies and 2 
pleural effusions. Peripheral blood gdT cells were stimulated with 5 
mM zoledronic acid and cultured in the presence of 100 IU/ml IL-2 for 
10 days. Amplified gd T cells were analyzed for cytokine production 
and cytotoxic activity.
Results: The proportion of gd (TCRVd2 -bearing) T cells among 
peripheral blood CD3+ cells was 4.2 ± 5.0%. Although it was 
equivalent to the previously reported value of 4.3 ± 2.2% in healthy 
volunteers, 14% (9/63) of patients exhibited an increase in the number 
of peripheral blood gdT cells at baseline. The level of TCRVd2 T cells 
with potent anti-tumor activity was significantly higher than that 
of TCRVd1 T cells (4.2± 5.0% vs. 1.5 ± 1.8%, p<0.001), whereas 
they were present in tumor-infiltrating cells at essentially the same 
levels (4.4± 9.6% vs. 3.7 ± 9.7%, p=0.434). Percentage of TCR Vd2+ 
CD3+cells among amplified gd T cells in vitro and cytokine (IFN-g 
and TNF-a) production by them were significantly proportional to 
the initial level of TCRVd2+/CD3+ ratio in peripheral blood. Upon 
treatment with zoledronic acid, breast cancer cell lines became 
susceptible to gd T cells.
Conclusions: gd (TCR Vd2-bearing ) T cells increased in some 
patients with breast cancer and the TCRVd2+/CD3+ ratio at baseline 
was correlated with the efficiency of proliferation and cytotoxic 
activity when treated with zoledronic acid. Zoledronic acid efficiently 
sensitized breast tumor cells to be lyzed by gd T cells. The present 
results suggest that gd T cells stimulated with zoledronic acid can be 
utilized for immunotherapy against breast cancer.
P1-01-05
Conditioning by the Tumor Environment Turns Invariant Natural 
Killer T Cells into Negative Regulators of Anti-Tumor Immunity 
Elicited by Treatment.
Pilones KA, Demaria S. NYU School of Medicine, New York, NY
Background: Local suppression in the tumor microenvironment 
remains an important obstacle to success of immune-based therapy. 
We have previously shown in the 4T1 model of metastatic breast 
cancer that combination radiotherapy (RT) to the primary tumor and 
CTLA-4 blockade can elicit a robust anti-tumor effector response that 
can inhibit metastases and prolong survival. However, complete cure 
and long-term memory was seen in only a small fraction of mice, 
prompting us to investigate new ways to improve the response elicited 
by treatment. iNKT cells are known to be powerful regulators of 
tumor immunity as a result of their ability to rapidly secrete a broad 
range of cytokines, but the mechanisms regulating their switch from 
a stimulatory to a regulatory role remain poorly defined. We have 
previously shown that iNKT cells negatively regulate the response to 
treatment with RT and CTLA-4 blockade in 4T1 tumor-bearing mice 
(Clin Cancer Res 15:597, 2009). Here, we test the novel hypothesis 
that conditioning of iNKT cells to perform this regulatory role occurs 
within the tumor microenvironment. Specifically, we address whether 
4T1 tumor cells, directly or indirectly, promote iNKT cell regulatory 
phenotype. Methods: For in vitro experiments, 4T1 tumor or LPS-
matured bone marrow-derived dendritic cells (BMDC) were loaded 
with a-galactosylceramide and used to stimulate the NKT DN32.D3 
hybridoma cells. In some wells, BMDCs were supplemented with 4T1 
conditioned media or loaded with tumor lysates from 4T1 cells. For in 
vivo experiments, wild-type and iNKT-deficient mice were inoculated 
s.c with 4T1 cells for enumeration of DCs on immunostained sections. 
Phenotypic profile of DCs within tumor and draining lymph nodes 
were assessed by flow cytometry. Results: 4T1 cells are positive for 
CD1d by real-time RT-PCR; surface CD1d were barely detectable 
by flow cytometry but sufficient to induce activation of DN32.D3 
cells when irradiated 4T1 cells were loaded with a-GalCer. BMDC 
supplemented with conditioned media from untreated or irradiated 
4T1 cells, or loaded with tumor lysates from irradiated 4T1 cells 
were also able to activate DN32.D3 cells, and this effect was partially 
inhibited by blocking CD1d mAb (1B1) in a dose-dependent manner. 
In vivo, we found that iNKT-deficient mice showed significantly 
(p=0.04) higher densities of tumor infiltrating DCs than wild type 
mice. Moreover, DC in tumor and tumor-draining lymph nodes 
expressed markers of maturation in the absence but not presence of 
iNKT cells. Conclusion: Results indicate that a 4T1 derived factor, 
possibly a lipid antigen that can be presented directly by tumor cells 
themselves or indirectly by BMDCs induces activation of iNKT 
cells in vitro. In vivo, data suggests that iNKT cells downregulate 
the response to treatment by controlling the population of DC present 
in the tumor and draining lymph nodes. Since DC are essential for 
cross-presentation of the tumor antigens released by RT-induced cell 
death, reduced DC numbers may impair the activation of anti-tumor 
T cells. Supported by DOD Postdoctoral Award W81XWH-10-1-
P1-01-06
Mechanisms of Tumor Immune Escape in Triplenegative Breast 
Cancers (TNBC) with and without Mutated BRCA 1.
Segerer SE, Kapp M, Hahne JC, Dietl J, Engel JB. Medical University 
of Würzburg, Würzburg, Germany
Background
Triplenegative breast cancer (TNBC) is associated with a dismal 
prognosis, although these tumors are chemosensitive. This 
phenomenon could be at least in part due to tumor immune escape. 
The current study investigates the host’s immune response to TNBC 
cells and explores the presence of immunesuppressive factors, such 
as pAKT-expression and infiltration with FoxP3 positive regulatory 
T-cells (Tregs), in human TNBC samples.
Material and Methods
NK-cell induced lysis of tumor cells was evaluated in human breast 
cancer cell lines MCF-7 (ER/PR pos.), HCC 1937 (triplenegative, 
BRCA 1 mutated) and HCC 1806 (triplenegative). Expression of pAKT 
and infiltration with Tregs was determined by immunehistochemistry 
and evaluated semiquantatitavely (0 no expression- 3 strong 
expression). Control groups consisted of: Fibroadenoma (N=6), 
prohpyhlactic mastectomy (BRCA 1 mutated, N=3), ER/PR + breast 
cancer (N=13). They were compared with triplenegative breast 
cancers: N = 9 BRCA wildtype and N = 6 BRCA 1 mutated.
Results
At an effector target/target-ratio of 10/1 NK-cell induced lysis in HCC 
1937 and HCC 1806 was 2.27 and 4.45 increased, respectively, as 
compared to MCF 7 cells. No infiltration with Tregs was detected in 
fibroadenoma and prophylactic mastectomy samples. Infiltration with 
FoxP3-positive Tregs was 0.92 +/- 0.75 in ER/PR + breast cancers and 
2.66 +/-0.5 (p<0.05) in TNBC and 2.16 +/-0.98 (p<0.05) in TNBC 
with BRCA mutation, respectively. Expression of pAKT was 1.45 
+/- 1.29 in ER/PR + breast cancers and 1.77 +/-1.20 in TNBC and 
2.66 +/-0.51 (p<0.05) TNBC/ with BRCA mutation.
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Discussion
TNBC cells stimulated the NK-cell response to a stronger extent 
than did ER-positive MCF 7 cells mirrored by a more pronounced 
NK-cell- induced lysis. Thus, the observed stronger infiltration 
with FoxP3-positive Tregs in TNBC tumor samples could reflect a 
compensatory mechanism to suppress the host’s immune response. 
In other tumor entities, such as ovarian cancer infiltration with 
Tregs is associated with a worse overall survival (1). Thus, the 
significantly increased infiltration with Tregs, could suggest that the 
worse prognosis of TNBC is due to tumor immune escape and further 
investigation of immunemodulatory therapeutic strategies in TNBC 
could prove fruitful.
(1) Specific recruitment of regulatory T cells in ovarian carcinoma 
fosters immune privilege and predicts reduced survival.
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, 
Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, 
Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis 
ML, Knutson KL, Chen L, Zou W.
Nat Med. 2004 Sep;10(9):942-9.
P1-01-07
ErbB-2 Peptide Vaccination Suppresses Spontaneous 
Tumorigenesis and Tumor Stem Cell Expansion in MMTV-PyVT 
Transgenic Mouse.
Park KH, Gil EY, Choi YJ, Kim ST, Cho KR, Seo JH, Lee ES, Kim IS, 
Disis ML. Korea University College of Medicine, Seoul, Korea; Korea 
University College of Medicine; University of Washington, Seattle, WA
Immunization targeting ErbB-2 could have considerable therapeutic 
potential by controlling growth and metastasis of highly aggressive 
tumor cells in the earlier preclinical and clinical studies. Just a few 
studies have examined preventive potential of ErbB-2 vaccines 
in preclinical studies. However, animal model systems used in 
the previous studies were tumor transplantation or neu-transgenic 
mouse, which were not relevant to human HER-2 positive breast 
tumorigenesis. In this study, active immunotherapy against tumor 
antigen ErbB-2/neu for primary prevention of breast cancer was 
tested using FVB/N-Tg (MMTV-PyVT) transgenic mice model. 
Mice were grouped to receive either ErbB-2 peptide vaccine, 
immune adjuvant only, tetanus toxoid, or PBS every 2 weeks for 3 
times and monthly thereafter. The MMTV-PyVT transgenic mice 
in control groups (PBS, immune adjuvant only, or tetanus toxoid 
peptide) developed spontaneous mammary adenocarcinomas in 12 
to 15 weeks, but vaccination against ErbB-2 strongly suppressed 
tumor formation by 30 weeks of observation. Further pathologic 
examination showed complete prevention of tumorigenesis was 
observed in ErbB-2 vaccinated mice, whereas the mice in control 
groups developed highly aggressive ErbB-2 overexpressing tumors 
similar to human breast cancer. The tumor protective effect of peptide 
vaccination was associated with induction of ErbB-2-specific humoral 
immune responses as well as T cell responses. Additionally, role of 
signal through ErbB-2 pathway and the relationship with stemness 
of cancer cells were determined by Aldefluor assay, mammosphere 
formation assay using Mouse mammary carcinoma (MMC) cells 
in vitro, and level of nestin expression determined by Western blot 
analysis. Further analysis of mammosphere formation capacity 
of MMC cells using immune sera showed that sera from ErbB2 
vaccinated mice had a significant inhibitory effect on mammosphere 
formation in ErbB-2 overexpressing MMC cells. These results 
suggest that ErbB-2 targeting by cancer vaccination might be useful 
adjuvant to standard therapy, helping to prevent relapse in patients 
with ErbB-2-overexpressing tumors by suppressing stem/progenitor 
cell population.
P1-01-08
Expression of Interleukin-15 (IL-15) and the IL-15 Receptor in 
Human Breast Cancer.
Sanders AJ, Ye L, Wei XQ, Mansel RE, Jiang WG. Cardiff University 
School of Medicine, Cardiff, Wales, United Kingdom; Cardiff 
University, Cardiff, Wales, United Kingdom
Introduction: Interleukin-15 (IL15) is a cytokine that influences 
activation and proliferation of T-lymphocytes. IL-15 is produced 
in the body leukocytes such as phagocytes and in many ways has 
similar immunoregulatory functions to IL-2 including stimulation of 
NK cells and CD8(+) T cells. It has been suggested that IL-15 may 
increase the immunity to cancer cells and cancer cell’s response to 
therapeutic agents. IL-15 has also been shown to be able to inhibit 
tumour growth in vivo. However, the expression profile of IL-15 and 
IL-15 receptor (IL-15) in solid tumours including human breast cancer 
is not clear. The present study investigated the expression profile of 
both IL-15 and IL-15R in human breast cancer and deduced a clinical 
and pathological relevance with breast cancer.
Methods: Immunohistochemical methods were used to detect IL-15 
and IL-15RA in mammary tissues. IL-15 and IL-15RA transcripts 
were analysed using real-time quantitative PCR method. Levels of 
IL-15 and IL-15RA were compared in normal and tumour tissues as 
well as against tumour staging, nodal status, disease progression and 
clinical outcome after a 10-year followup.
Results: Both IL-15 and IL-15RA were detectable in mammary 
tissues and were seen in both epithelial cells and infiltrating cells. 
Node positive tumours had low levels of IL-15 compared with node 
negative tumours (21.7±10 vs 103±46, respectively). Late stage 
tumour also had lower levels of IL-15 (95±43, 31±15, 3.7±2 and 
1.3±1.15 for stage I, II, III and IV tumours respectively. p=0.036 and 
p=0.032, stage-II and Stage-III vs stage-I). Patients with metastatic 
disease (10.3±3) and patients died of breast cancer related conditions 
(8.5±6) had markedly low levels of IL-15 when compared with those 
who were disease free (54.7±25). The disease free survival time for 
patients with low levels IL-15 was 126 (114-138, 95%CI) months, 
compared with 139 (131-148) months for those with high levels of 
IL-15. Despite the reduced expression of IL-15 in aggressive tumours, 
expression of IL-15 receptor, IL-15RA, did not display a significant 
change and failed to showed a link with nodal status, tumour staging 
and clinical outcome.
Conclusions: Interleukin-15, an immuoregulatory cytokine, has an 
aberrant expression in human breast cancer. Low levels of IL-15, but 
not IL-15 receptor, is associated with the aggressiveness and disease 
progression of breast cancer. Together with reported effect of IL-15 
on NK cells and other anti-tumour lymphocytes, IL-15 appears to be 
a useful therapeutic option.
P1-01-09
A Focused Immune Response Targeting the Homotypic 
Binding Domain of the Carcinoembryonic Antigen Blocks the 
Establishment of Tumor Foci In Vivo.
Gariepy J, Abdul-Wahid A. University of Toronto, Toronto, ON, 
Canada; Sunnybrook Research Institute, Toronto, ON, Canada
Background: The carcinoembryonic antigen (CEA) is over-expressed 
in ~56% of breast cancer biopsies but is absent on normal breast 
tissues. Clinically, high preoperative serum concentrations of CEA in 
breast cancer patients correlate with metastasis, treatment failure and 
poor overall prognosis. More importantly, the homotypic cell adhesion 
functions of CEA have been associated with cancer progression and 
tumor metastasis. One approach to prevent the establishment of CEA-
dependent metastatic foci in breast cancer patients would thus be to 
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interfere with the cell adhesion functions of this cell surface antigen. 
We hypothesize that vaccinating CEA-expressing transgenic (CEA.
Tg) mice with a recombinant, altered-self form of the Ig V-like N 
domain of CEA, involved in homotypic interactions, should result in 
a focused immune response able to block the CEA-mediated adhesion 
of murine carcinoma cells expressing CEA (MC38.CEA) and the 
establishment of metastatic foci in this transgenic mouse model.
Material and Methods: A recombinant form of the CEA N domain 
was expressed in E.coli, purified and shown in cell-based assays to 
bind to the A3 domain of human CEA and to block cell adhesion in 
CEA-expressing tumor cell lines. CEA-expressing transgenic mice 
were vaccinated i.p. with the recombinant CEA N domain protein and 
poly I:C. Resulting serum Ig [IgG1 and IgG2a] as well as cytokine 
expression levels [IFN-g, IL-4 and IL10 responses] were measured 
by ELISA and ELISPOT assays. The CEA-expressing MC38 murine 
tumor cells were implanted s.c. into CEA.Tg mice [hind leg; primary 
site model; tumor growth within 7 days] or administered i.v. to 
generate lung tumor metastases within 60 days or injected i.p. to 
generate peritoneal tumor nodules within 35 days in unvaccinated 
animals.
Results: The recombinant folded, deglycosylated N domain of human 
CEA is perceived as an altered self-antigen by CEA.Tg mice when 
administered i.p. with poly I:C acting as an adjuvant. The vaccinated 
mice develop strong IgG1 and IgG2a responses able to kill CEA-
expressing human breast cancer cell lines [MCF-7 and MDA-MB231] 
in vitro by both Antibody-Dependent Cellular Cytotoxicity (ADCC) 
and Complement-Dependent Cytotoxicity (CDC) mechanisms. The 
sera of such animals also inhibited cell-cell aggregation mediated 
by CEA expression. Vaccination of CEA.tg mice following the 
establishment of CEA-expressing MC38 murine hind leg tumor mass 
resulted in a significant delay in tumor growth. More importantly, 
animals pre-vaccinated with the recombinant CEA N domain did not 
display lung or peritoneal tumor foci following the i.v. or i.p. injection 
of CEA-expressing murine tumor cells.
Discussion: A simple vaccination protocol using a recombinant form 
of the N domain of CEA as an immunogen is sufficient to engender an 
immune response that can block the development of CEA-expressing 
tumor foci in the lungs and peritoneal cavity of CEA.tg mice and 
destroys human breast cancer cells expressing CEA. These results 
suggest that mounting a focused antibody response to the N domain 
of CEA may represent a simple therapeutic strategy to control the 
establishment of metastatic foci in breast cancer patients expression 
high levels of the antigen CEA.
P1-01-10
Immune Suppression of Regulatory T Cells and M2 Macrophage 
in Breast Cancer Patients.
Imoto S, Sakemura N, Kamma H, Nakatsura T. School of Medicine, 
Kyorin University, Mitaka, Japan; Research Center Organization, 
National Cancer Center Hospital East, Kashiwa, Japan
Background: Recent multi-disciplinary treatments of breast cancer 
(BC) could decrease the mortality rate, but successful immune therapy 
remains uncertain. To explore new strategy of immune therapy of 
BC, we are investigating about host-tumor immune response in 
BC patients. Materials and methods: Tumor tissue specimens and 
peripheral blood mononuclear cells (PBMC) were obtained from early 
and advanced BC patients. PBMC were also collected from healthy 
volunteers. Regulatory T (Treg) cells were examined by counting 
CD4+CD25highCD127low/-cells in PBMC with flow cytometry 
analysis. Immunohistochemical evaluation of tumor specimens was 
performed with monoclonal antibodies of HLA-ABC and DR, CD56, 
CD68, CD83, and CD163. The number of stained cells was analyzed 
using a semiquantitative ordinal scale ranging from 0 to 3 (0, +/-, 
++, +++). Results: HLA-ABC and DR were stained negative in 44% 
and 82% of 50 BC cases. When host-tumor immune response were 
compared between 38 early BC cases and 12 advanced BC cases, 
numbers of CD68-positive cells significantly increased in peripheral 
tumor tissues of advanced BC cases than in those of early BC cases 
(92% versus 53%). CD163-positive tumor cells were also detected 
more frequently in advanced BC cases than in early BC cases (75% 
versus 16%). There were no significant differences of distribution of 
CD4, CD8, CD56, and CD83-positive cells in early and advanced BC 
cases. Treg cells in PBMC significantly increased in percentage of 
the population in 37 BC patients than in 21 healthy volunteers (4.2% 
versus 2.5% of CD4-positive cells at mean value). Interestingly, Treg 
cells decreased in percentage of the population in 36 postoperative 
BC patients. Conclusions: Our results suggest that Treg cells render 
BC patients under immune suppression and M2 macrophage plays 
an important role of tumor progression. Targeted therapy against M2 
macrophage may be a promising strategy of breast cancer.
P1-01-11
C D 4 +C D 2 5 h i g hC D 1 2 7 l o w / -  R e g u l a t o r y  T C e l l s  H a v e 
Immunosuppressive Function in Patients with Breast Cancer.
Sakemura N, Nakatsugawa M, Ito H, Isaka H, Imi K, Tazaki E, 
Miyamoto K, Wada N, Imoto S, Nakatsura T. Graduate School of 
Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer 
Research Center Hospital East, Kashiwa Chiba, Japan
CD4+CD25highFoxp3+ regulatory T cells play a central role in 
self-tolerance and suppress antitumor immune response. Recent 
studies have shown that low levels of the IL-7 receptor (CD127) are 
expressed on CD4+CD25highFoxp3+ regulatory T cells surfaces and 
the expression of CD127 is inversely correlated with the suppressive 
function of CD4+CD25high regulatory T cells. We evaluated the 
frequency of CD4+CD25highCD127low/- T cells in peripheral blood 
lymphocytes of 72 breast cancer patients and 21 healthy volunteers. 
The expression of Foxp3 mRNA was inversely correlated with 
the CD127 expression and correlated with CD25 expression. The 
frequency of CD4+CD25highCD127low/- T cells in breast cancer patients 
was significantly higher than that of healthy volunteers (p=0.0045). 
CD4+CD25highCD127low/- T cells were increased in hormone receptor 
negative patients and HER2 positive patients, but no statistical 
significant was observed in stage progression. In addition, the 
frequency of CD4+CD25highCD127low/- T cells decreased after curative 
resection in breast cancer patients (p=0.005). CD4+CD25highCD127low/- 
T cells also suppress proliferation of autologous CD4+CD25- helper 
T cells and CD8+ cytotoxic T cells in CFSE-based cell proliferation 
assay. These findings suggest that CD4+CD25highCD127low/- T cells 
a useful marker for regulatory T cells in breast cancer. Circulative 
peripheral regulatory T cells may participate in immune tolerance to 
breast carcinoma.
P1-01-12
Mesoporous Silicon Particles for the Presentation of Tumor 
Antigens and Adjuvant for Anti-Cancer Immunity.
Meraz IM, Melendez B, Gu J, Serda RE. Methodist Hospital Research 
Institute, Houston, TX
Custom-made vaccines based on personalized tumor antigens are 
realistic options for secondary therapy, with the patient’s excised 
tumor providing antigens. Overlap in the personalized repertoire of 
tumor antigens among patients also provides insight into targets for 
preventative cancer vaccines. Nanotechnology provides carriers for 
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shielded delivery of antigens and presentation of immunostimulatory 
molecules. Rapid uptake of particles by phagocytic immune cells 
and migration to lymphatic tissue for antigen presentation provides 
opportunities to elicit tumor specific immune responses. Dendritic 
cells (DC) are the master antigen presenting cells (APC) for efficient 
processing and presentation of antigens. We have tested the ability of 
mesoporous silicon particles (pSi) to function as substrates for DC 
and to activate cells via engagement of surface toll-like receptors 
(TLR). pSi particles, surface labeled with lipopolysaccharide (LPS) 
or monophosphoryl lipid (MPL), were presented to bone marrow-
derived DC. This resulted in rapid uptake of particles, with an 
enormous capacity for number of particles internalized per cell. 
Confocal microscopy studies supported higher uptake of LPS and 
MPL conjugated as compared to unlabeled pSi. pSi particle uptake 
into DC was also supported by electron microscopy imaging. TLR 
ligands induced morphological changes in GM-CSF stimulated cells 
consistent with maturation towards a DC phenotype. As expected, 
LPS conjugation to particles resulted in significant toxicity. MPL 
conjugated pSi showed little or no toxicity to DC and showed 
improved particle uptake into DC with morphological changes 
consistent with maturation towards a mature DC phenotype.The 
impact of cytokine cocktail on DC maturation and its impact on 
particle uptake were also examined. Flow cytometry analysis 
supported greater uptake of pSi by DC stimulated with GM-CSF 
and IL-4 compared to GM-CSF alone, with reduced uptake in the 
presence of TNF-alpha. Consistent with findings reported by others, 
addition of TNF-alpha to the cell media also resulted in higher levels 
of expression of costimulatory molecules by DC, compared to cells 
stimulated with GM-CSF alone. Thus immature DC are better able 
to internalize particle-based vaccines, with cytokine or TLR-driven 
maturation enhancing expression of costimulatory molecules for more 
effective antigen presentation.
P1-01-13
Prognostic Impact of CD8 in Node-Negative Breast Cancer.
Schmidt M, Chen Z, Hellwig B, Böhm D, Lebrecht A, Gebhard S, 
Gehrmann M, Koelbl H, Hengstler JG. University Hospital, Mainz, 
Germany; Technical University, Dortmund, Germany; Bayer GmBH, 
Leverkusen, Germany
Background: Infiltration of cytotoxic T lymphocytes (CTL) is a 
common feature in breast cancer. We examined the prognostic impact 
of CD8 positive CTL in formalin-fixed-paraffin-embedded (FFPE) 
tissue using immunohistochemistry (IHC) in node-negative breast 
cancer and validated our findings in previously published cohorts 
using RNA expression.
Methods: CD8 was evaluated in FFPE tissue of 339 medically 
untreated node-negative breast cancer patients utilizing IHC. Results 
were validated utilizing microarray based gene-expression data of 
four cohorts of medically untreated node-negative breast cancer 
patients (n=824). Impact of CD8 on metastasis-free survival (MFS) 
was analyzed with univariate and multivariate Cox regression. 
Meta-analysis of previously published cohorts was performed using 
a random effects model. Prognostic significance was examined in 
the whole cohort and in different molecular subtypes (ER+/HER2-, 
ER-/HER2-, HER2). Correlation between RNA expression and IHC 
was analyzed according to Spearman.
Results: Immunohistochemical detection of CD8+ CTL was 
associated with MFS in univariate (hazard ratio [HR] 0.76, 95% 
confidence interval [95% CI] 0.59-0.98, P=0.037) as well as in 
multivatiate analysis (HR 0.61, 95% CI 0.46-0.81, P=0.001). Protein 
levels of CD8 had a good correlation with RNA expression (r=0.488). 
Higher RNA expression of CD8 was related to better MFS in a meta-
analysis of the whole cohort (HR 0.74, 95% CI 0.60-0.90, P=0.0023). 
However, prognostic significance was confined to ER+/HER2- (HR 
0.71, 95% CI 0.51-0.99, P=0.0201) and HER2+ (HR 0.60, 95% CI 
0.38-0.97, P=0.037) but not to ER-/HER2- molecular subtypes (HR 
0.77, 95% CI 0.52-1.14, P=0.1965).
Conclusion: CD8 positive CTL have independent prognostic 
significance in node-negative breast cancer.
P1-01-14
Gene Expression of Immune Mediators within Nipple Aspirate 
Fluid and Ductal Lavage from Normal and Cancerous Breasts.
Love SM, Ruffell B, Nguyen T, Mills D, Coussens LM. Dr. Susan Love 
Research Foundation, Santa Monica, CA; University of California-
San Francisco, San Francisco, CA
The majority of breast cancers are thought to initiate in the lining of the 
6 to 8 ducts that exit the nipple. Evidence suggests that the presence 
of nipple aspirate fluid (NAF), and in particular NAF containing 
atypical epithelial cells, in the ducts is predictive of future breast 
cancer risk. Although NAF fluid and cells may be representative 
of a preneoplastic state, use of NAF has not proven to represent a 
robust indicator for future malignancy. Chronic infiltration of tissues 
by immune cells predisposes them to future malignancy. Since 
macrophages can represent up to half of the total cells recovered 
from NAF, and their presence within malignant breast tumors has 
predictive value in terms of survival, we hypothesized that changes 
in the inflammatory microenvironment of breast ducts may foster 
future malignancy and/or provide an early indicator of future 
neoplasia. To test this hypothesis, we conducted an exploratory study 
to investigate gene expression in NAF and ductal lavage fluid. We 
first used real-time PCR to quantitatively measure mRNA expression 
of select genes within the cellular milieu of NAF to determine if 
that microenvironment correlated with a tumor-promoting state. 
Expression of multiple genes was observed in 15 samples collected 
from healthy volunteers, with robust expression of myeloid-associated 
genes including CD14, CD68, CCL3, CSF1 and IL1B observed in 
the majority of samples. To determine whether similar inflammatory 
microenvironments were found within each duct, and whether they 
were comparable to those in NAF-containing ducts, ductal lavage 
(DL) samples were obtained from 4 different ducts at the same time 
as NAF collection. Out of 7 volunteers, 4 provided samples allowing 
comparison between NAF and DL, and between multiple ducts. 
Analysis of gene expression from these healthy volunteers indicated 
that gene expression differed between NAF samples and each DL 
sample. More importantly, unique gene expression was found for 
each duct sampled, indicating that the immune microenvironment 
within each duct is distinct from other ducts within the same breast. 
In order to identify a potential inflammatory gene signature, we then 
obtained NAF samples from patients with breast cancer that had not 
received neoadjuvant chemotherapy prior to surgery, from both the 
cancerous and contralateral breasts. With 4 patients analyzed, no 
consistent expression difference has thus far been observed, indicating 
either that the relevant genes have not been identified, or that analysis 
of inflammatory genes within NAF may not be a predictive method 
with which to evaluate risk of future malignancy in women that 
produce NAF. A larger study is warranted to further investigate the 
significance of inflammatory gene expression in breast ductal fluid.
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P1-01-15
Do Serum Cytokines Predict Breast Cancer Behavior?
Lush E, Dedert E, Daup M, Dhabhar F, Spiegel D, Tillie J, McMasters 
K, Sephton SE, Chagpar A. University of Louisville; Duke University 
Medical Center; Veterans Affairs Medical Center; Stanford University 
School of Medicine; James Graham Brown Cancer Center; University 
of Louisville School of Medicine; Yale School of Medicine
Introduction: The role of inflammation in breast cancer development 
and progression is poorly understood. The potential for serum 
cytokines to predict breast cancer behavior is an intriguing hypothesis, 
and data to date, has been conflicting. We sought to determine if serum 
inflammatory cytokines could predict clinicopathologic factors in 
breast cancer patients.
Methods: Fifty-seven women with newly diagnosed breast cancer 
(stage 0-4) were accrued to this IRB-approved study. Serum cytokine 
levels were obtained in 50 of these women; this was the cohort of 
interest. All patients underwent surgical therapy, and log serum 
cytokine levels were correlated to final pathologic results.
Results: The median patient age was 51 (range; 21-79) with a median 
tumor size was 19.5 mm (range; 2.3-95.0 mm). A variety of cytokines 
were evaluated. None were found to correlate with tumor size, lymph 
node status, presence of metastases, tumor grade, or lymphovascular 
invasion (all p’s > .05). While most of the cytokines evaluated did not 
correlate with hormone receptor status, a significant correlation was 
seen between serum IFN-gamma and estrogen receptor (p = .011) 
and progesterone receptor (p = .013) status. No correlation was seen 
with her-2-neu status (p > .05).
Conclusions: Serum cytokine levels do not seem to correlate 
with tumor size, lymph node status or grade. However, the strong 
correlation between IFN-gamma serum levels and hormone receptor 
status is hypothesis-generating and requires further study.
P1-01-16
Detecting a Breast Carcinoma-Deriving B-Cell Response: An 
Immunoproteomics Biomarker Approach.
Keller K, Boehm DU, Grus FH, Koelbl H. University Medical Center 
Mainz, Germany
Background:
Noninvasive biomarkers for the early detection of breast cancer are 
crucial due to the fact that the relapse risk of breast cancer is rising 
with the time point of its detection. Currently, none of the reported 
molecular biomarkers is established for the clinical use as a diagnostic 
tool. Previous proteomics-based studies showed the immunogenicity 
of breast carcinoma and the following B-cell mediated immune 
response. As a result, several autoantibodies against tumor proteins 
were detected in the sera of breast cancer patients. However, these 
putative biomarkers are still lacking of clinically reliable specificity 
and sensitivity, even of better discrimination of cancer patients when 
combining different biomarkers. The search for a new antibody 
biomarker signature remains very important as a potential cancer 
detection tool. For further investigations we analyzed the antibody 
pattern in serum samples of diseased patients and healthy controls 
after incubation with whole protein extract from a native carcinoma 
and identified the putative tumor-specific immunoreactive antigens.
Materials and methods:
For our de novo profiling of tumor antigens we used a protein extract 
from a primary invasive ductal carcinoma. Sera from 20 women, of 
which 19 were diagnosed with breast carcinoma and one with DCIS 
(CA), and 20 sera from age-matched healthy donors (CTRL) were 
obtained and pooled separately. For an optimal separation of tumor 
antigens a two-dimensional sodium dodecylsulfate gel electrophoresis 
(2D SDS-PAGE) was applied. Following immunoblots with each 
serum pool were performed and the immunospecific reactions 
visualized with a horseradish peroxidase-conjugated anti-IgG 
antibody. The relevant tumor antigens were identified via Matrix-
Assisted Laser Desorption Ionization Time of Flight Mass 
Spectrometry (MALDI TOF-TOF MS).
Results:
After the incubation of each serum pool with tumor antigens 
we obtained different extensive antibody profiles, whereas the 
visualized immunoreactive components varied in the signal intensity. 
We identified over 10 tumor antigens which reacted with the 
corresponding autoantibodies in CA or CTRL approach, showing 
again the complexity of immune response. Besides of already 
described breast carcinoma related antigens like alpha enolase, 
which showed immune reaction also with the healthy serum pool, 
we identified several potential antigens of interest like peroxiredoxin 
6 which showed a strong immune response only after the incubation 
with cancer sera.
Discussion:
In our study we visualized a complex immune response pattern 
showing the autoantibody profiles in cancer and healthy sera against 
tumor-deriving antigens. Also some of identified breast carcinoma 
antigens were already described; other novel breast carcinoma-related 
antigens were detected too. Our next step in the intriguing search 
for cancer antibody biomarkers is the individual screening of sera to 
confirm the specificity of the tumor-deriving B-cell responses and the 
validation of these results by using an independent study population.
P1-02-01
c-Jun N-Terminal Kinase 1 (JNK1) Inhibits Tumor Growth 
and Metastasis by Downregulating Epithelial to Mesenchymal 
Transition (EMT) and Stem Cell-Related Genes.
Ebelt ND, Van Den Berg CL. The University of Texas, Austin, TX
Murine and human mammary cancers often show dysregulation of 
important signaling pathways including the canonical Wingless-
iNTegrated (Wnt) and avian ERythroBlastosis oncogene B 
(ErbB) pathways. Transgenic expression of Wnt ligands causes 
transformation of normal mammary cells in mice, and Wnt10b is 
frequently upregulated in human breast cancers. Overexpression of 
ErbB ligands and amplification of receptors have also been implicated 
in human breast cancer. JNK1 is a tumor suppressor in the skin and 
intestinal epithelium, and JNKs are known to integrate ErbB and Wnt 
pathways as well as others to control cell growth and differentiation. 
In a murine mammary cancer model where 4T1.2 cells were injected 
into the mammary gland, reducing JNK1 levels by expressing shRNA 
(shJNK1) resulted in increased tumor growth and lung metastasis 
compared to mice injected with control vector- (pSM2) expressing 
cells. A microarray analysis comparing gene expression between 
shJNK1 and control tumors revealed 2 and 2.5-fold increases in 
the ErbB pathway genes Nrg3 and ETV5, 2-fold increases in the 
Wnt genes Bcl-9 and Wnt10a, and a 1.6-fold increase in the EMT 
gene Twist1. RT-PCR analysis of in vitro grown 4T1.2 cell lines 
transfected with shJNK1 confirmed increased expression of Bcl-9 
and ETV5, as well as the ETV5 target Cox-2. ErbB2 protein was also 
overexpressed. The shJNK1 cells showed upregulation of pERK in 
response to Heregulin1 (an Erbb2/3 ligand) and Fibroblast Growth 
Factor (FGF) 1, which further amplifies canonical Wnt signaling. In 
a p53-/- tumor model, ETV5, Bcl-9, and Cox-2 were still upregulated 
in jnk1-/-compared to wildtype tumor cells, indicating this effect is 
p53-independent. In the normal mammary gland, a 4-fold increase 
in ETV5 and a 5-fold increase in Twist1 were found in jnk1-/- mice 
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compared to wildtype, further indicating that this effect is dependent 
on JNK1 alone. The ErbB and Wnt pathways are known to upregulate 
EMT and stem-cell related genes, however, the involvement of JNK1 
in these effects is a novel hypothesis. Thus far, our data suggest that 
JNK1 deficiency targets these oncogenic pathways to contribute to 
a more aggressive tumor phenotype due to heightened EMT and 
“stem-cellness”. Further studies using cell sorting and differentiation 
assays will determine whether normal jnk1-/- glands contain a higher 
fraction of stem cells than wildtype glands. Inhibition of EMT genes 
and/or ETV5 in the p53-/-;jnk1-/- cancer cells will determine whether 
the tumor growth or metastasis phenotypes are dependent on these 
genes. EMT and stem-cell genes are frequently expressed in human 
breast cancer subtypes that exhibit low survival rates, and EMT is 
known to be linked to increased metastasis. Some of these sub-types, 
such as claudin-low tumors, currently have no molecularly-targeted 
treatments, therefore it is important to determine what proteins 
critically contribute to these phenotypes so that efficient and effective 
treatments can be developed.
P1-02-02
Zoledronic Acid Reverses the Epithelial-Mesenchymal Transition 
While Inhibiting the Tumor Initiating Cell Population of Highly 
Tumorigenic Breast Cancer Cell Lines.
Schech AJ, Gilani RA, Kazi AA, Brodie AH. University of Maryland, 
Baltimore, Baltimore, MD
Breast cancer remains the second leading cause of cancer related 
death amongst women in the United States. This is largely due to 
metastasis of cancer cells from the primary tumor to other parts of 
the body, and to the putative cancer stem cell population. Both are 
driven by the epithelial-mesenchymal transition (EMT), a cellular 
process whereby cancer cells of epithelial origin lose their epithelial 
characteristics and acquire a mesenchymal phenotype. Cells which 
undergo EMT tend to be motile and invasive, and therefore can 
metastasize to other parts of the body. EMT has also been implicated in 
the generation of cells expressing the cancer stem cell phenotype. As 
metastatic disease and the cancer stem cell are difficult to eliminate, 
more effective therapy is required. Zoledronic acid, originally 
indicated for use in the treatment of osteoporosis, has been reported 
to inhibit the growth of breast cancer cells. The mechanism of this 
effect however has yet to be determined. In preliminary data studies, 
treatment with zoledronic acid was found to reduce activation of 
nuclear factor kappa-b, an established regulator of EMT. These 
findings suggest that treatment with zoledronic acid may reverse 
EMT in breast cancer cells, driving them to express a more epithelial 
phenotype. To test this hypothesis, the highly metastatic, triple 
negative breast cancer cell lines MDA-MB-231 and Hs578t, which 
largely express mesenchymal proteins, were used to measure cell 
viability and changes in protein and mRNA expression following 
treatment with zoledronic acid. Dose response analysis for inhibition 
of cell viability showed an IC50 of approximately 2µM in the Hs578t 
and 6 µM in the MDA-MB-231 cell line. Zoledronic acid treated 
cells displayed a decreased mesenchymal phenotype, as evidenced 
by reduced expression of mesenchymal markers N-cadherin (75% 
reduction, p<0.076; 65% reduction, p<0.005) and TWIST (67% 
reduction, p<0.08; 64% reduction, p<0.009) in MDA-MB-231 and 
Hs578t cells, respectively. This was accompanied by a subsequent 
increase in epithelial phenotype as evidenced by increased expression 
of epithelial marker E-cadherin (223% increase, p<0.006) in MDA-
MB-231 cells. To further elucidate the effects on the mesenchymal 
and epithelial phenotypes of these cells, surface expression of CD24 
and CD44 was measured by flow cytometry. While vehicle treated 
samples of both cell lines stained positive for CD44 and negative 
for CD24, zoledronic acid treatment decreased CD44 expression. As 
both increased the ratio of surface expression of CD44high/CD24low 
and mammosphere formation are characteristics of the breast cancer 
stem cell, effects of zoledronic acid on this subpopulation in Hs578t 
cells were determined. Cells pretreated with zoledronic acid were 
seeded under mammosphere conditions and allowed to propagate 
for 7 days. Zoledronic acid treated cells formed significantly fewer 
mammospheres (86% reduction, p<0.041), while the ones that formed 
were smaller in size. These findings suggest that zoledronic acid is 
able to reverse the epithelial mesenchymal transition, which may 
reduce the tumor initiating capacity of highly metastatic cells.
P1-02-03
The Reciprocal Roles of E-Cadherin and ZEB1 Demonstrate the 
Mesenchymal-Epithelial Transition as a Primary Characteristic 
of Inflammatory Breast Cancer.
Chu K, Boley KM, Luo AZ, Ye Z, Wright MC, Freiter EM, Robertson 
FM. The University of Texas MD Anderson Cancer Center, Houston, 
TX
Background: Inflammatory breast cancer (IBC) is a rare but very 
aggressive form of breast cancer. IBC is characterized by nests 
of tightly aggregated cells, defined as tumor emboli, that exhibit 
characteristics of cancer stem cells (CSCs). IBC tumor emboli 
express E-cadherin which is required to maintain their integrity 
and our recent evidence demonstrates that expression of E-cadherin 
by tumor emboli is associated with lack of ZEB1 expression, a 
transcriptional repressor of E-cadherin. This is at odds with the current 
hypothesis that metastatic progression is associated with the process 
of epithelial mesenchymal transition (EMT), with loss of E-cadherin 
and gain of transcription factors including ZEB1, acquisition of CSC 
characteristics and enhanced invasive capabilities.
Materials and Methods: shRNA knockdown and over-expression 
methods, real time PCR arrays, western blotting, and in vitro assays to 
evaluate proliferation, invasion, growth in soft agar and clonogenicity 
and in vivo animal studies were used.
Results: Expression of E-cadherin was reduced by shRNA and ZEB1 
was expressed in SUM149 IBC tumor cells. Numerous EMT-related 
genes were upregulated with loss of E-cadherin and gain of ZEB1, 
including N-cadherin and vimentin. However, there were marginal 
differences in the in vitro parameters of proliferation, Matrigel 
invasion and anchorage independent growth in soft agar between 
SUM149-shECad or SUM149-ZEB1 clones and their respective 
vector control cells. The loss of E-cadherin and gain of ZEB1 altered 
the morphology of SUM149 cells when cultured under low adherence 
conditions permissive for the enrichment of CSC, exhibiting a 
reversion in grape-like morphology to more well defined spheres, 
which was accompanied by increased clonogenicity in both SUM149-
shECad and SUM149-ZEB1 cells. The loss of E-cadherin and the 
gain of ZEB1 significantly inhibited tumor growth of cells injected 
in the mammary fat pad of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice. 
Tumor volume at 56 days for E-cadherin vector control cells was 
771.9 mm3 +/- 185.6 compared to shECadherin tumors, which was 
13.6 mm3 +/- 7.2. Tumor volume of ZEB1 vector control tumors was 
346.1 mm3 +/- 96 compared to volume of ZEB1 expressing tumors, 
which was 21.5 mm3 +/- 7.2.Conclusions: E-cadherin with lack of 
ZEB1 expression in IBC is consistent with a mesenchymal-epithelial 
transition (MET), consistent with the retention of the epithelial 
phenotype while maintaining a program of rapid metastasis and 
colonization of lymph nodes and distant organ sites. Furthermore, 
we demonstrate that the E-cadherin-ZEB1 axis is critical for the in 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011163s
December 6-10, 2011 Abstracts: Poster Session 1
vivo growth of IBC tumor cells. Although SUM149 cells are fully 
capable of undergoing an EMT process, which is under negative 
regulation by E-cadherin, the process of EMT does not drive in vivo 
tumor growth in IBC.
P1-02-04
Estrogen Receptor beta Inhibits Breast Cancer EMT by 
Regulating the Expression of miR-200.
Thomas C, Gayani R, Nikolos F, Hao R, Katchy A, McCollum C, 
Williams C, Bondesson M, Krishnamurthy S, Esteva F, Gustafsson 
J-A. University of Houston; University of Texas MD Anderson 
Cancer Center
Estrogen receptor beta (ERb) mediates the effects of estrogens in a 
variety of human tissues and regulates cellular processes involved in 
initiation and progression of breast cancer such as cell proliferation 
and migration. Clinical studies produced contradictory data regarding 
the role for ERb in prognosis of metastatic breast cancer and the 
molecular mechanism through which ERb influences cell migration 
and invasion has not been fully elucidated. Here we show that 
induction of ERb expression inhibits epithelial to mesenchymal 
transition (EMT) in metastatic breast cancer cells. This correlates with 
an ERb-mediated induction in the expression of the epithelial marker 
E-cadherin and downregulation of its transcriptional repressors ZEB1 
and SIP1. ERb alters the expression of ZEB1 and SIP1 by inducing the 
expression of the miR-200a, miR200b and miR-429. Downregulation 
of these miRNAs in ERb-expressing cells resulted in decreased cell-
cell contact and decline of E-cadherin levels. In addition, ERb was 
found to inhibit the invasiveness of metastatic breast cancer cells in 
a zebrafish xenotransplantation model. We are now examining breast 
cancer specimens derived from ductal carcinomas and metaplastic 
breast cancers to see whether ERb levels decline in the mesenchymal 
regions and ERb expression is correlated with epithelial markers. 
These data propose a crucial role for ERb in the regulation of EMT 
and in prognosis of invasive and metastatic breast cancer.
P1-02-05
Invasive Lobular Carcinoma – A Luminal Breast Cancer 
Histotype Enriched for Epithelial-to-Mesenchymal Transition 
Features.
Metzger O, Singhal SK, Michiels S, Ignatiadis M, Bertucci F, Galant 
C, Larsimont D, Salgado R, Veys I, Fumagalli D, Saini KS, Piccart 
M, Sotiriou C. Institut Jules Bordet, Université Libre de Bruxelles, 
Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; 
Cliniques Universitaires Saint Luc, Brussels, Belgium
Background: Invasive lobular carcinoma (ILC) represent the second 
most common breast cancer (BC) histotype, but little information 
is available about its molecular features. We sought to perform a 
comprehensive molecular classification of ILC and to investigate the 
molecular features that can differentiate ILC from invasive ductal 
carcinoma (IDC).
Methods: A consecutive series of 174 ILC tumors from three different 
centers with mininum 5-year follow-up was selected. Gene expression 
data were generated using Affymetrix U133 Plus 2.0 arrays. Data 
were analyzed by using frozen robust multiarray analysis (Matthew 
et al. 2009). ILC tumors were classified into BC molecular subtypes 
using the PAM50 classifier. Invasive Disease Free Survival (IDFS) 
was defined as the interval between the date of surgery and the date 
of any invasive recurrence or death. Multivariate analyses for 10-y 
IDFS containing classical clinico-pathologic characteristics were 
performed for different gene signatures, which were scaled so that 
2.5 and 97.5% percentiles equal -1 and 1. A cohort of 90 IDC tumor 
samples, normalised with the same method, was used to compare 
expression data between ILC and IDC.
Results: ILCs were mainly characterized as luminal A (LA: 76%, 
n=133) and luminal B (LB:; 20%, n=34) followed by a minority of 
HER2-positive (2%, n=3), basal (1%, n=2) and normal-like (1%, n=2) 
based on Perou’s classification. LB had inferior 10-y IDFS than LA 
in univariate cox regression analysis (HR = 1.99, 95% CI, 1.08-3.67, 
p=0.026). The EMT gene module was significantly higher expressed 
in ILC as compared to IDC (p < 0.001). Adjusted hazard ratios (HR) 
for different gene modules investigated are detailed in the table below.
Table 1. Adjusted (HR) for a one-unit change in a gene module for 10-y IDFS in 174 ILC tumors in 
17 multivariate models
Gene Signatures HR 95% CI P values FDR
GGI (Sotiriou JNCI 2006) 2.3 1.28-4.13 0.005 0.08
GENE70 (Van’t Veer Nature 2002) 2.1 1.11-3.92 0.022 0.16
CIN70 (Carter Nat Genetics 2006) 2.2 1.17-3.97 0.013 0.13
Immune response (Teschendorff Gen Biol. 2007) 0.6 0.35-1.14 0.128 0.41
STAT1(Desmedt CCR 2007) 0.9 0.47-1.59 0.632 0.81
RAS (Bild Nature 2006) 1.4 0.83-2.51 0.195 0.47
MAPK (Creighton Cancer Res 2006) 2.2 0.86-5.71 0.100 0.36
PTEN (Saal PNAS 2007) 1.7 0.93-3.23 0.084 0.36
AKT mTor (Majumder Nat Med 2004) 1.4 0.65-2.98 0.389 0.79
PIK3CA (Loi PNAS2010) 1.2 0.66-2.29 0.520 0.79
IGF1 (Creighton JCO 2008) 3.7 1.61-8.31 0.002 0.06
SRC (Bild Nature 2006) 0.6 0.33-1.20 0.157 0.41
MYC (Bild Nature 2006) 0.7 0.31-1.70 0.454 0.79
E2F3 (Bild Nature 2006) 1.8 0.83-3.71 0.143 0.41
Beta Catenin (Bild Nature 2006) 1.2 0.59-2.35 0.653 0.81
EMT (Taube PNAS 2011) 1.1 0.59-2.14 0.724 0.81
Stroma (Lim Nat Med 2009) 0.9 0.45-1.69 0.691 0.81
FDR, false discovery rate 
Conclusions: ILC is mainly composed of luminal tumors and a 
minority of HER2-positive tumors. Similarly to IDC, proliferation 
remains a statistically significant prognostic factor for ILC. ILC 
tumors were enriched with an EMT phenotype, which is not observed 
among IDC luminals. Of interest IGF signaling, which is known to be 
associated with poor prognosis in ER-positive BC, added prognostic 
value in this population which may open new therapeutics avenues 
for ILC.
P1-02-06
Silencing of IGF-1R Has Paradoxical Effects in Triple Negative 
Breast Cancer Phenotypes.
Taliaferro-Smith LD, Oberlick EM, Liu T, Eggers C, Kline ER, 
Nagaraju GPC, Marcus A, O’Regan R. Winship Cancer Institute at 
Emory University, Atlanta, GA; Grady Memorial Hospital, Atlanta, 
GA
Background: Triple negative (TN) breast cancers are a heterogeneous 
group of breast cancers with a poor prognosis in part due to a lack of 
effective targeted agents. Insulin-like growth factor-1 receptor (IGF-
1R) has been shown to play a role in breast cancer cell proliferation, 
adhesion, invasion, and migration and is overexpressed in more than 
a third of TN breast tumors. We hypothesized that IGF-1R could be 
a therapeutic target for a subset of TN breast cancers. Methods: We 
evaluated the effects of IGF-1R silencing on the metastatic properties 
of TN breast cancer cells by knock down in two morphologically 
distinct TN breast cancer cell lines using shRNA lentiviral techniques. 
Reverse-transcription polymerase chain reaction (RT-PCR) and 
immunoblotting were used to detect mRNA and protein expression 
levels, respectively, of IGF-1R signaling molecules. Anchorage-
dependent growth and Matrigel chamber assays were performed 
to assess the effects of IGF-1R silencing on colony formation and 
invasion of TN breast cancer cells, respectively; wound-healing 
and spheroid migration were also performed to assess the effects 
of IGF-1R inhibition on TN breast cancer cell motility. Results: 
Stably transfected mesenchymal MDA-MB-231 TN cells showed 
effective downregulation of IGF-1R protein expression, which 
resulted in mesenchymal-to-epithelial transition (MET), confirmed by 
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upregulation of the epithelial marker E-cadherin and downregulation 
of the mesenchymal marker vimentin. Importantly, this MET resulted 
in reduced colony formation (p<0.0042) and cell motility and 
dramatically reduced invasion (p<0.0001). Conversely, silencing of 
IGF-1R in epithelial MDA-MB-468 TN cells induced epithelial-to-
mesenchymal transition (EMT), confirmed by downregulation of 
E-cadherin and upregulation of vimentin expression, with resultant 
increased colony formation (p<0.006), cell motility, and invasion 
(p<0.0001). Conclusion: Collectively, these results demonstrate 
a paradoxical effect of targeting IGF-1R in TN breast cancers 
of mesenchymal and epithelial origin. Targeting IGF-1R in TN 
breast cancers with a mesenchymal phenotype decreases invasion 
and metastatic potential. In contrast, targeting IGF-1R in TN 
breast cancers with an epithelial phenotype could have potentially 
detrimental effects. Our data suggest that IGF-1R inhibition should 
be explored as a therapeutic modality in TN breast cancers with a 
mesenchymal phenotype.
P1-02-07
Epithelial-Mesenchymal Transition Correlated with Serum 
Cytokine Profiling in Breast Cancer Patients.
Giordano A, Cohen EN, Anfossi S, Gao H, Lee B-N, Mego M, Sanda 
T, Valero V, Alvarez RH, Cristofanilli M, De Placido S, Hortobagyi 
GN, Woodward W, Ueno NT, Reuben JM. The University of Texas 
MD Anderson Cancer Center, Houston, TX; University Federico II 
of Naples, Naples, Italy; Fox Chase Cancer Center, Philadelphia, 
PA; National Cancer Institute, Bratislava, Slovakia (Slovak Republic)
Background: Inflammation contributes to the increased invasiveness 
and poor prognosis in breast cancer (BC) patients. Specifically, the 
expression of the proinflammatory cytokines interleukin-6 (IL-
6), tumor necrosis factor alpha (TNFa) and interleukin-1 (IL-1) 
have all been linked to increased invasiveness and poor prognosis. 
Interestingly, the increased invasiveness was associated with an 
increase in the acquisition of markers of epithelial-mesenchymal 
transition (EMT). Therefore, we determined whether the levels of 
circulating proinflammatory cytokines (IL-1, IL-6, TNFa) and anti-
inflammatory cytokines (IL10) were correlated with the induction 
of EMT transcription factors (TFs), Snail1, Zeb1, Twist1, in breast 
cancer patients.
Materials and Methods: From two laboratory-based ongoing studies 
at the MD Anderson Cancer Center, 41 BC patients were assessed 
for EMT-TFs in circulating CD45-ve cells (EMT-CTCs) and for 
serum proinflammatory cytokines before starting any treatment. 32 
of 41 patients assessed for EMT had metastatic BC. EMT-CTCs were 
detected by qRT-PCR for the EMT-TFs Snail1, Zeb1 and Twist1 
(Mego 2011; PMID 21387303) and serum cytokines were measured 
by Luminex bead array assay (MILLIPLEX™ MAP Human Cytokine/
Chemokine Panel). Cytokine serum concentrations were compared 
with the median cytokine levels of healthy donors (HD). We examined 
the association of serum cytokines above the median HD levels and 
the presence of EMT-CTCs by non-parametric Mann-Whitney test 
with a statistical significance for p<.05.
Results: Of the 41 patients assessed for both serum cytokines and 
EMT-CTCs, 14 (34%) were positive for at least one EMT-TF, 
including 3 of 9 (33%) patients with no-metastatic BC and 11 of 32 
(34%) patients with metastatic BC. We found that serum levels of 
IL1a, IL2, TGFa, and TNFb in patients that were above the median 
levels of HD sera were higher in patients with EMT-CTCs in the 
blood (higher IL1a concentration in patients with over expression of 
Snail1, Zeb1, and Twist1; IL2 with Zeb1; TGFa with Snail1; TNFb 
with Zeb1, and Twist1). Further, the higher ratio of proinflammatory/
anti-inflammatory cytokines, was associated with the presence of at 
least one EMT-TF, e.g., IL8/IL10 (p=.005) and TNFa/IL10 (p=.037).
Discussion: Patients with proinflammatory cytokine (IL1a, IL2, 
TGFa, and TNFb) levels above the median levels of HD or who had 
a predominantly proinflammatory cytokine profile were more likely to 
have at least one EMT-TF in their blood. These data are consistent with 
the hypothesis that proinflammatory cytokines promote EMT, which 
may be involved in tumor aggressiveness and disease progression.
P1-02-08
Modulation of EMT by Targeting E-Cadherin Restores Radiation 
Sensitivity in Human Breast Cancer Cells.
Munshi A, Yuan Y, Liu J, Meyn RE. University of Oklahoma Health 
Sciences Center, Oklahoma City, OK; Baylor College of Medicine, 
Houston, TX; The University of Texas M.D. Anderson Cancer Center, 
Houston, TX
E-cadherin is the major adhesion protein associated with epithelial 
cells and loss of its expression is diagnostic of the epithelial to 
mesenchymal transition (EMT). Findings from our laboratory, suggest 
that EMT, detected as the loss of E-cadherin expression, may regulate 
tumor cell radiosensitivity, i.e. cells that have undergone EMT are 
relatively radioresistant compared to the lines that have retained the 
epithelial phenotype, which typically are relatively radiosensitive. 
To definitively test this hypothesis we compared expression levels of 
E-cadherin and other EMT related markers in ER-a negative (MDA-
MB-231 and Hs578t) and ER-a positive (MCF-7) human breast 
cancer cells. We observed that many ER-a negative lines, were also 
E-cadherin negative, and the ER-a positive lines were positive for 
E-cadherin expression. Clonogenic cell survival assays showed that 
the cell lines expressing estrogen receptor (MCF-7) and had high 
expression of E-cadherin, were also more sensitive to increasing 
doses of radiation. Treatment of MCF-7 cells with 100nM siRNA to 
E-cadherin for 72 hrs made the cells more resistant to radiation with 
the surviving fraction changing from 42.3% in control cells to 56.4% 
in siRNA treated cells. In contrast, ER negative cells (MDA-MB-231 
and Hs578t) had no detectable expression of E-cadherin and were 
more radioresistant. We transfected MDA-MB-231 and Hs578t cells 
with a CDH1-expression vector and isolated stable clones, which were 
then tested for radiosensitivity. Cells transfected with the backbone 
vector (pCMV) served as controls. Restoring E-cadherin expression 
radiosensitized both, MDA-MB-231 and Hs578t cells, compared to 
the control vector cell line, suggesting that restoration of E-cadherin 
expression in mesenchymal-like cells produces a radiosensitizing 
effect. These observations suggest that ER-a signaling might regulate 
E-cadherin and implied that this regulation might influence EMT 
and radioresistance. Overall, our results suggest that the EMT status 
of breast cancer cells governs their response to radiation. A detailed 
investigation of the mechanism is ongoing.
P1-02-09
Epigenetics-Regulated microRNAs Related with Epithelial-
Mesenchymal Transition of Breast Cancer Cells.
Sato F, Ito T, Tsuchiya S, Kawaguchi-Sakita N, Shimizu K, Tsujimoto 
G, Toi M. Graduate School of Medicine, Kyoto University, Kyoto, 
Japan; Graduate School of Pharmaceutical Sciences, Kyoto 
University, Kyoto, Japan
Background: Epithelial-mesenchymal transition (EMT) is a program 
in which biological cells change morphologically and functionally 
from an epithelial phenotype to a mesenchymal phenotype. The EMT 
is involved in the process of cancer metastasis. On the other hand, 
accumulated evidence showed epigenetics and microRNA plays 
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important roles in breast cancer. However, to date, biological networks 
between epigenetics and microRNAs regarding EMT remains largely 
unclear. Thus, the aim of this study is to identify epigenetics-regulated 
microRNAs related with EMT of breast cancer.
Materials / Methods and Results: MicroRNA expression profiles of 
11 breast cancer cell lines (8 epithelial-phenotype (E-type) cells and 3 
mesenchymal-phenotype (M-type) cells) were obtained by microarray 
method. Unsupervised clustering analysis showed that E- and M-type 
breast cancer cells had different microRNA expression profiles. On 
the other hand, we obtained a genomewide methylation status of 
these breast cancer cell lines by a MeDIP-seq method. An integrated 
in silico analysis identified microRNAs which microRNA and DNA 
methylation were inversely correlated. All of miR-200b/a/429 cluster 
members were listed in top5 differentially expressed miRs between E- 
and M-type cells, and also in top 5 epigenetics-regulated microRNAs. 
In the further study, we focused upon the miR-200b/a/429 cluster. 
A COBRA assay revealed that promoter regions of miR-200b/a/429 
cluster in M-type breast cancer cells were more frequently methylated 
than that in E-type cells (65.1% vs 6.8%, p<0.0001, respectively). The 
methylation levels were inversely associated with miR-200b/a/429 
cluster expression (Taqman assay, p<0.01). In addition, demethylating 
treatment using 5-aza-dC unmasked miR-200b/a/429 expression in 
M-typed breast cancer cell lines. Taken together, the finding indicated 
that the expression of miR-200b/a/429 cluster is epigenetically 
regulated. Next, we investigated an effect of the miR-200b/a/429 
cluster upon cell motility as a function of the EMT. A transfection 
of exogenous miR-200b/429 inhibited 24% of cell migration ability 
(Transwell assay). Utilizing microRNA target prediction algorithm, 
we identified fibronectin as a target gene of miR-200b/429. Utilizing 
several prediction algorithms for microRNA target genes, we 
identified fibronectin as a target gene of miR-200b/429. A luciferase-
based reporter assay demonstrated that miR-200b/429 were directly 
associated with fibronectin-3’UTR and repressed 21% (p<0.0001) of 
the reporter gene expression post-transcriptionally.
Conclusion: The promoter hypermethylation of miR-200b cluster is 
associated with epithelial-mesenchymal transition, and stimulates 
cell motility by upregulating fibronectin expression in mesenchymal-
phenotype breast cancer cells.
P1-02-10
Vimentin Expression; as a Prognostic Factor and a Possible 
Molecular Target of Triple Negative Breast Cancer.
Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Akiyoshi S, Saeki 
H, Oki E, Ohga T, Kakeji Y, Maehara Y. Kyushu University, Fukuoka, 
Japan
BACKGROUND: Triple negative breast cancer (TNBC), characterized 
by absence of estrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor 2 (HER2), is typically 
associated with aggressive tumor phenotype and poor prognosis. 
TNBC is also considered highly heterogeneous disease. Since TNBC 
lacks efficient therapeutic target, it is generally treated with non-
specific cytotoxic agents. A better understanding of molecular and 
histopathological features of TNBC is of great importance, in order 
to develop a new therapeutic strategy and to improve the prognosis 
of TNBC. TNBC has many similarities with basal-like breast cancer 
(BLBC), and is also associated with stemness and BRCAness. In 
addition, recent studies suggest links between TNBC and epithelial-
mesenchymal transition (EMT). To identify prognostic biomarkers 
and novel therapeutic targets, we investigated the expression of the 
factors associated with EMT in TNBC.
MATERIALS and METHODS: Sporadic invasive breast cancer 
specimens were obtained from 659 Japanese patients who underwent 
surgery in our department between 1994 and 2010, and 90(14%) 
cases were diagnosed as TNBC. The E-cadherin and vimentin mRNA 
expression was evaluated by quantitative RT-PCR. The E-cadherin, 
vimentin, CK5/6 and epidermal growth factor receptor(EGFR) protein 
expression was assessed by immunohistochemistry. In this study, we 
defined TNBC with positive expression of CK5/6 and/ or EGFR as 
BLBC, and TNBC with low expression of E-cadherin and positive 
expression of vimentin as EMT-type.
RESULTS: Compared with non-TNBC cases, E-cadherin mRNA 
expression was significantly lower in TNBC cases (p=0.0012). 
Immunohistochemically, E-cadherin expression was significantly 
lower (p=0.0001) and vimentin expression was significantly higher 
(p=0.0049) in TNBC cases. Vimentin expression was associated with 
younger age (<50 years old, p=0.021), high nuclear grade (p=0.017) 
and high Ki67 expression (p<.001) in TNBC. Among the patients 
with TNBC, vimentin expression was significantly associated with 
poor prognosis, in terms of disease free survival (p=0.0059) and 
overall survival (p=0.013). Multivariate analysis showed that vimentin 
expression was an independent prognostic factor for both disease free 
survival (p=0.017) and overall survival (p=0.012). Among TNBC 
cases, 52(63%) cases were BLBCs and 15(18%) cases were EMT-
type. Among BLBC patients, vimentin expression was also associated 
with significantly shorter disease free survival (p=0.0085) and overall 
survival (p=0.0057). The patients with both BLBC and EMT-type 
features showed especially poor prognosis(P=0.05).
CONCLUSION: These findings suggest that elevated expression of 
vimentin attributes to the aggressive phenotype in TNBC patients. 
Vimentin expression might be useful as a molecular marker for 
prognosis of TNBC, and vimentin may represent a novel therapeutic 
target of TNBC.
P1-02-11
The BCL2 Antagonist of Death, BAD Is Down-Regulated in Breast 
Cancer and Inhibits Cancer Cell Invasion.
Cekanova M, Fernando R, Wimalasena J. University of Tennessee, 
Knoxville, TN; NIH, NCI, Bethesda, MD
Background
Recent clinical evidence suggest that expression of BCL2 and its 
antagonist BAD are good prognosticators for survival in breast cancer 
patients. BAD protein was previously shown by us to inhibit cyclin 
D1 expression and cJun activation, both may enhance invasiveness 
of tumor cells(Fernando et al JBC 07). However, the role of BAD and 
other BCL2 family proteins in invasion/metastasis of breast cancer 
is poorly characterized.
Methods
By immunohistochemistry nuclear and cytoplasmic staining of several 
proteins including BAD in normal epithelial was compared to that 
of cancer cells in human specimens . Western blotting and ELISA 
methods were used to compare BAD overexpressing MCF7 breast 
cancer cells with control cells for the expression of variety of signaling 
molecules, proteins that take part in metastasis and invasion and 
ability of cells to invade was measured. PCR was used to measure m 
RNA levels and reporter constructs utilized for transcriptional factor 
activity studies.
Results
Grade II breast cancer specimens express less total and phosphorylated 
forms of BAD in nuclei and cytoplasm compared to normals. BAD 
expression decreased Sp1, b-catenin and STAT proteins, which may 
increase cyclin D1 in vitro. BAD inhibited activation of the CRE and 
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res; 71(24 Suppl.) December 15, 2011 Cancer Research166s
AP1 elements, and phosphorylation of BAD on S112 and S136 is 
required for this activity. BAD inhibited the Ras/MEK/ERK pathway 
and JNK ,which may underlie inactivation of c Jun. BAD, like BCL2, 
may decrease metastasis,therefore, ability of BAD to modulate the 
expression of metastasis related proteins were measured and MMP10, 
VEGF, SNAIL, CXCR4, E-cadherin, and TlMP2 were regulated by 
BAD with a concomitant reduction in cell invasion.
Conclusion
Higher expression of BAD in breast cancer and a role in metastasis 
and proliferation suggests that BAD is valuable prognostic marker 
in breast cancer and a multi functional protein. Further given the 
overwhelming clinical evidence that BCL2 prolongs survival, a 
reevaluation of the role of BCL2 family proteins in metastasis is 
urgently required.
P1-03-01
ECM Stiffness and Breast Tumor Histology and Treatment 
Phenotype.
Acerbi I, Au A, Chen Y-Y, Park C, Hwang S, Weaver V. Center for 
Bioengineering and Tissue Regeneration, University of California, 
San Francisco, San Francisco, CA; Carol Buck Breast Cancer 
Center, University of California San Francisco, San Francisco, CA; 
University of California San Francisco, San Francisco, CA; Institute 
of Regeneration Medicine, University of California San Francisco, 
San Francisco, CA; University of California at San Francisco, San 
Francisco, CA
Currently, the extent of local surgery and radiation for breast cancer 
is not guided by biological or anatomical principles, and the optimal 
volume of treatment is not defined. Local tumor progression is 
strongly influenced by a dynamic interplay between the genetically-
modified epithelium and the associated cellular and non-cellular 
stroma (Butcher, 2009; Levental, 2009). The extracellular matrix 
(ECM) is modified in breast tumors and data indicate that the ECM 
stiffens progressively as mammary tumors evolve and enhancing 
ECM stiffness promotes mammary tumorigenesis while inhibiting 
ECM stiffening reduces tumor progression. However, the degree 
and extent of local stromal changes, and their clinical impact in 
breast cancer evolution and treatment remain unclear. This has led 
us to predict that the desmoplastic stroma surrounding breast tumors 
reflects tumor phenotype and behavior and can be characterized by 
biophysical metrics of the ECM stroma and molecular signatures of 
the breast epithelium. Accordingly, we hypothesize that these features 
may be integrated into a stromal phenotype that can be developed as a 
predictive tool. To test this concept we used a rigorous biomechanical 
and biochemical analysis of mastectomy specimens from women with 
various stages and histology phenotypes of treated and non-treated 
breast cancer to explore the relationship between ECM stiffness, 
mechanotransduction and tumor behavior. The goal of the study 
was to characterize stromal changes as a function of tumor stage 
and histology phenotype as well as before and after chemotherapy 
by measuring biophysical and topological features of the ECM and 
biochemical and molecular signatures of the mammary epithelium. 
The objective was to determine if there is a significant association 
with tumor histology phenotype that could be integrated to generate a 
stromal phenotype. Egan sections of were acquired from breast tissue 
containing benign and invasive ER positive and negative carcinoma 
and from treated and non-treated patients. All tissues were subjected 
to IHC histological and mechanosignaling analysis (H&E; 397FAK; 
Lysyl Oxidase; phosphomyosin) and biomechanical assessment (Atomic 
Force Microscopy; Structured Illumination Polarized Imaging; Two 
Photon Imaging). Preliminary data were consistent with prior in vitro 
and in vivo studies and showed that there was a significant increase in 
ECM stiffness as the tissues transitioned from normal to an invasive 
lesion with the highest stiffness being located at the tumor edge (~2-
4 folds greater). Intriguingly, we observed that ER negative tumors 
were substantially stiffer than ER positive tumors (50% increase in 
upper 10-percentile) and that there were tracks of ECM stiffness 
that correlated with orientated parallel collagen fibers and ECM 
birefringence. Moreover, we quantified a significant decrease in ECM 
stiffness following treatment (40% lower) with the most striking 
reduction in ECM tension being noted in ER negative patient tissues 
who demonstrated the most robust response. This study should lead 
to a deeper understanding of the nature of breast cancer stroma and 
its role in tumor phenotype and response to therapy.
Supported by : NCI SPORE P50 CA058207 to VMW, CP, & SH; 
U01 ES019458-02 to ZW; NCI R01 CA138818-01A1 to VMW; & 
U54 CA143836-01 to VMW & JL.
P1-03-02
The Norton-Simon Hypothesis and Cancer Stem Cells: How 
Cancer Stem Cells May Explain the Effectiveness of Dose-Dense 
Chemotherapy.
Landis MD, Dobrolecki LE, Wong H, Lai Q, Vahdat LT, Chang JC. The 
Methodist Hospital Research Institute, Houston, TX; Weill Cornell 
Medical College, New York, NY
Background: Systemic therapies are effective initially in controlling 
and reversing tumor growth; however, residual cancers will invariably 
re-grow despite this initial response. We have published data from 
paired human breast cancer samples that standard therapy every 
three weeks kills dividing daughter cells but not tumor-initiating 
cells (TICs), so that samples obtained after therapy are enriched for 
CD44+/CD24-/low putative “tumor-initiating” or “cancer stem” cells, 
indicating that standard treatment regimens are missing the critical 
targets, TICs. Interestingly, we have recent data in human breast 
tumors that indicate that TICs may in fact be chemosensitive initially, 
with a decrease in TICs observed within two days of chemotherapy, 
but shortly thereafter, TICS are actually induced by chemotherapy. 
Materials and Methods: To evaluate TICs response to chemotherapy, 
mice with human breast tumor xenograft lines BCM-2665a and 
BCM-2147 were treated with vehicle, 10-, or 33-mg/kg docetaxel, 
and then tumors were collected for TIC assays and molecular analysis 
at both 48 and 72h after treatment. Using Affymetrix gene expression 
microarrays and reverse phase protein array (RPPA) analysis with 
119 different validated antibodies, we identified pathways involved 
in regulation of TICs. Results: According to flow cytometric analysis 
for TIC markers and mammosphere (MS) formation efficiency, 
BCM-2665 TICs were reduced by docetaxel treatment compared to 
vehicle-treated at 48h post 10 mg/kg docetaxel (4-fold decrease) and 
48 and 72h post 33 mg/kg docetaxel compared to control (14- and 
2-fold decrease, respectively). Although the BCM-2147 TICs did 
not significantly decrease at any time points or doses tested, they 
were clearly induced at 72h post-treatment compared to control. 
Additionally, BCM-2665 TICs were increased within 72h post 10 
mg/kg docetaxel, indicating that these time points are ideal for 
defining the mechanisms responsible for induction of TICs. Ingenuity 
Pathway Analysis of Affymetrix microarray data for both BCM-
2665 and BCM-2147 revealed induction of inflammatory pathways, 
suggesting leukocyte infiltration associated with induction of TICs. 
Furthermore, RPPA analysis confirmed gene expression changes 
from the microarray data, and implicated apoptosis and inflammatory 
pathways. Sixteen of 28 proteins significantly changed with activation 
of CSC are involved in development of leukocytes. Discussion: These 
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findings are consistent with the Norton-Simon Hypothesis in that 
chemotherapy regimens given more frequently may in fact eliminate 
TICs, thereby explaining the proven increased effectiveness of dose-
dense chemotherapy. Based on when TICs became chemoresistant, 
we are comparing dose-dense treatment (4 mg/kg docetaxel every 3 
days) to a traditional single dose of 32 mg/kg, in an effort to eliminate 
the tumor cells that cause tumor recurrence. Furthermore, our analysis 
of gene expression at both the RNA and protein level implicated the 
immune cells as TICs inducers. Since our immunocompromised mice 
lack T- and B- cells but have active macrophages, macrophages are 
indicated as inducers of TICs. We are focusing our current efforts 
at identifying how immune cells activate TICs and thus enhance 
tumorigenesis.
P1-03-03
Adaptive Exploitation of Stromal Cell Metabolism by Tumor 
Cells.
Patel B, Rattigan Y, Ackerstaff E, Koutcher J, Sukenick G, Glod J, 
Banerjee D. Cancer Institute of New Jersey - University of Medicine 
and Dentistry of New Jersey; Johns Hopkins University; Memorial 
Sloan-Kettering Cancer Center
Tumor cells secrete cytokines to recruit and activate stromal cells 
in the tumor milieu leading to reciprocal paracrine support of tumor 
growth by stroma-derived growth factors. This is an important means 
by which tumors adapt their microenvironment to facilitate their 
growth. Indeed, breast cancer development and metastatic progression 
is highly dependent on stromal support, particularly from carcinoma 
associated fibroblasts (CAFs). As a result of aerobic glycolysis, 
tumor cells produce and secrete high levels of lactate, thought to be 
a toxic byproduct that needs to be extruded into the tumor milieu. 
Using CAFs generated by prolonged exposure to tumor conditioned 
medium, we have investigated the role that lactate may play in CAF-
mediated support of tumor growth. In addition to extruding lactate 
as a byproduct of glycolysis, we suggest that tumor cells secrete it 
to recruit and subsequently exploit stromal cells to recycle lactate 
into utilizable metabolites, such as pyruvate, to fulfill metabolic 
demands of tumor cells. Our hypothesis is that lactate secreted by 
tumor cells is taken up by stromal cells and converted to metabolites 
critical for tumor growth and progression. Our studies indicate that 
(i) MDA-MB-231 breast cancer cells secrete significantly higher 
levels of lactate (3-fold more) under hypoxia, and that (ii) lactate 
recruits mesenchymal stem cells, the precursors of CAFs, towards 
tumor cells by activating signaling pathways to enhance migration. 
Lactate is transported by a family of proteins termed monocarboxylate 
transporters (MCTs); cells take up lactate via MCT1 and efflux it via 
MCT4. Expectedly, MDA-MB-231 breast carcinoma cells display 
low expression of MCT1 while exhibiting high expression of MCT4. 
However, CAFs show high expression of MCT1 while displaying 
low expression of MCT4, indicating that lactate extruded by the 
tumor cells is taken up by stromal cells. Our investigation further 
revealed that expression of lactate dehydrogenase B and pyruvate 
dehydrogenase are induced upon lactate exposure in CAFs, supporting 
the contention that the lactate taken up by stromal cells is metabolized. 
This implies that CAFs may be less glycolytic than MDA-MB-231s. 
Indeed the expression of pyruvate kinase isoform 2 (PKM2), which 
positively correlates with glycolysis, is greater in MDA-MMB-231s 
than in CAFs, while CAFs express significantly more PKM1, the 
isoform that correlates with a more oxidative metabolic state. Finally, 
13C NMR spectroscopic analyses indicate that 13C-lactate is indeed 
metabolized via the TCA cycle in stromal cells, further supporting our 
hypothesis. Thus, stromal fibroblasts in the tumor microenvironment 
have the capacity to take up tumor-secreted lactate and use it as an 
energy source. To our knowledge this is the first in vitro model system 
demonstrating tumor/stroma metabolic coupling by which tumor cells 
exploit stromal cells.
A better understanding of the molecular mechanisms governing 
metabolic cooperation within the tumor milieu will potentially identify 
new targets for therapeutic intervention.
P1-03-04
In-Vitro Characterization of a Breast Cancer Microenvironment 
with Epithel ia l - to-Mesenchymal  Transi t ion (EMT) 
Characteristics.
Casbas-Hernandez P, Roman-Perez E, Mani SA, Troester MA. School 
of Medicine, UNC, Chapel Hill, NC; Gillings School of Public Health, 
UNC, Chapel Hill, NC; UNC Hospitals, Chapel Hill, NC; University 
of Texas MD Anderson Cancer Center, Houston, TX
Non-neoplastic tissues adjacent to tumor is known to influence 
the progression of the disease. We and others found that there are 
two types of microenvironment, one of these highly expresses 
genes associated with epithelial-to-mesenchymal transition (EMT). 
Tumor adjacent microenvironment (TAME) with wound responses 
have been observed in >90% of tumor-adjacent tissues, but 
EMT- characteristics seems to be less common and are observed 
in less than half of all patients. Our data suggest that the patients 
with EMT-TAME have worse breast cancer outcome, particularly 
among estrogen receptor positive patients. Thus, understanding 
the molecular cross talk between tumor cells and adjacent cells 
located in the TAME with EMT properties may identify targetable 
pathways that play a important role in breast cancer progression. 
Toward this end, we developed an in-vitro model system that can be 
used to probe paracrine signaling between cancer cells and adjacent 
cells undergoing EMT. We hypothesized that the presence of EMT 
signals in the TAME will alter the gene expression and phenotype of 
epithelial cells. We further hypothesized that the interactions between 
cancer cells and their TAME would be subtype dependent. Using cell 
line models of luminal and basal-like breast cancer, we performed 
cocultures with cancer cells and cell line models of EMT. The latter 
cell lines were HMLE cells transduced with either Snail or Twist, 
representing an intermediate state between an epithelial and a fully 
mesenchymal phenotype. This coculture system allows the study of 
heterotypic interactions between cancers and TAME cells with EMT 
characteristics. Gene expression, proliferation, migration, anchorage 
independent growth and cytokine production of different breast 
cancer and non-neoplastic cell lines were evaluated. We observed 
that coculture with models of EMT microenvironments altered the 
behavior of epithelial cells and that the gene expression changes 
were relevant to in-vivo in public datasets, showing correlations 
with both subtype and outcome. Cocultured cells acquired more 
migratory behavior and reduced expression of cellular adhesion genes, 
while simultaneously increasing anchorage independent growth and 
production of cytokines such as IL-6 and IL-8. Furthermore, we 
observed different response by luminal and basal-like breast cancer 
cells to the coculture condition, suggesting that the tumor-TAME 
interactions occur in a tumor subtype dependent fashion. These results 
reiterate the importance of the surrounding environment on cancer 
cell phenotypes and document that paracrine interactions with cells 
undergoing EMT may increase the aggressiveness of some cancers. 
Identification of specific signaling pathways that define interactions 
between specific breast cancer subtypes and their microenvironments 
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will lead to new insights regarding tumor biology and identify 
potential pathway-specific biomarkers and/or targets for prognosis 
and treatment of breast cancer.
P1-03-05
Fibrocystic Changes Have Different Age-Dependent Patterns in 
Benign, In Situ, and Invasive Breast Cancer Patients.
Bekhash A, Kovatich AJ, Chen Y, Hooke JA, Kvecher L, Mural RJ, 
Shriver CD, Hu H. Windber Research Institute, Windber, PA; Walter 
Reed Army Medical Center, Washington, DC; MDR Global Systems 
LLC, Windber, PA
Background: Fibrocystic changes (FCCs) have been known to 
develop in the aging process. Breast cancers in younger and elderly 
women are known to have different characteristics. Less is known 
about alterations in the microenvironment for disease development in 
middle-aged women who undergo menopausal changes. The Walter 
Reed Army Medical Center, through the Clinical Breast Care Project, 
has enrolled over 2000 subjects undergoing a biopsy; all the pathology 
was reviewed by a single pathologist. These subjects provide an 
opportunity to study the age-dependent pattern of FCC across benign, 
in situ (IS) and invasive breast carcinoma (IBC) patient populations.
Methods: Subjects were enrolled following IRB-approved protocols. 
A total of 2060 subjects were identified for this study, including 
1226 benign/atypical, 193 IS, and 641 IBC patients. Patients were 
divided into three age groups: <=45 years, 46-65 years, and >=66 
years. Chi-Square test in the SAS was used for statistical analysis 
across the age groups for the occurrence of FCCs. For IS and IBC 
patients, additional analysis was performed on high grade (grade 3) 
and non-high grade (grades 1 and 2 combined) cancers. For IS, grade 
analysis was performed on ductal carcinoma (DCIS).
Results: As shown in the Table, FCC occurrence rate is significantly 
lower in younger patients in the benign population. In the IBC 
population, this rate is significantly higher in middle-aged patients. 
This higher rate is significant in the non-high grade patients but 
disappears in the high grade patients. In the IS population, the same 
trend exists that the FCC rate is higher in middle-aged patients. 
This trend is retained in non-high grade DCIS but again lost in high 
grade DCIS.
Occurrence rate of fibrocystic changes in different patient populations across the three age groups
Pathology/Group <46 y; %, (n) 46-65 y; %, (n) >65 y; %, (n) p
Benign 39.5%, (676) 53.5%, (413) 52.6%, (137) <.0001
     
Invasive 56.1%, (132) 66.0%, (309) 55.5%, (200) 0.028
Non-high Grade 54.0%, (76) 73.2%, (194) 61.4%, (145) 0.005
High Grade 63.8%, (30) 56.8%, (95) 45.2%, (42) 0.201
     
In Situ 72.7%, (33) 79.2%, (101) 64.4%, (59) 0.122
Non-high Grade 66.7%, (15) 82.6%, (46) 66.7%, (36) 0.201
High Grade 72.7%, (11) 66.7%, (21) 60%, (15) 0.792
Discussion: The observation that FCC increases with age in the 
benign population, but is bell-shaped in IBC and IS populations, 
supports a hypothesis that physiological changes in the middle-aged 
women may alter the microenvironment for disease development. 
The observation that the bell-shaped pattern is due to non-high grade 
DCIS but not due to high-grade DCIS suggests that changes in the 
microenvironment contribute to breast disease development.
P1-03-06
Fibroadenomatoid Changes Have a Higher Occurrence Rate 
in Middle-Aged Benign Breast Disease Patients with the Trend 
Retained in Cancer Patients.
Bekhash A, Hooke JA, Chen Y, Kovatich AJ, Kvecher L, Mural RJ, 
Shriver CD, Hu H. Windber Research Institute, Windber, PA; Walter 
Reed Medical Center, Washington, DC; MDR Global Systems LLC, 
Windber, PA
Background: Fibroadenoma (FA) is a common benign breast lesion 
known to have a high incidence rate in younger women. There are 
controversial reports whether FA elevates the risk of developing 
breast cancers. In clinical practice, FA may be surgically removed 
due to multiple reasons making it complicated to study its impact on 
the development of breast cancers that have a higher incidence rate 
in older women. Fibroadenomatoid change (FAC), also known as 
fibroadenomatous hyperplasia, is an uncommon lesion with histologic 
features similar to that of FA but lacking well-defined borders and 
usually discovered incidentally on breast biopsy specimens. FAC 
is not surgically targeted. The Walter Reed Army Medical Center, 
through the Clinical Breast Care Project, has enrolled over 2000 
subjects undergoing a biopsy; all the pathology was reviewed by a 
single pathologist. These subjects provide an opportunity to study 
the age-dependent pattern of FAC in different patient populations.
Methods: Subjects were enrolled following IRB-approved protocols 
with data collected through two comprehensive questionnaires, a 
Core Questionnaire and a Pathology Checklist. A total of 1964 female 
subjects were identified for this study, including 1135 benign/atypical, 
192 in situ, and 637 invasive cancer patients. Patients were divided 
into three age groups: <=45 years, 46-65 years, and >=66 years. Chi-
Square test in the SAS was used for statistical analysis.
Results: As shown in the table, FA occurrence rate decreases 
significantly with increasing age in benign disease patients. FAC, 
on the other hand, shows a significantly higher occurrence rate in 
middle-aged patients with benign findings, and this trend is retained 
in the invasive or in situ cancer populations. FAC rate is also 
significantly higher in patients with cancer (invasive, or invasive and 
in situ combined) compared to benign patients in each age group with 
p-values ranging from 0.0001 to 0.019 (not shown).
Occurrence rate of fibroadenoma and fibroadnomatoid change in different patient populations 
across the three age groups
Pathology/Group <46 y; %, (n) 46-65 y; %,(n) >65 y; %,(n) P
Fibroadenoma     
Benign 40.0%, (630) 14.6%, (384) 10.7%, (121) <.0001
In Situ 6.3%, (32) 7.9%, (101) 11.9%, (59) 0.594
Invasive 6.1%, (131) 7.5%, (307) 3.0%, (199) 0.108
     
Fibroadenomatoid Change     
Benign 4.3%, (630) 7.6%, (384) 3.3%, (121) 0.046
In Situ 6.3%, (32) 18.8%, (101) 13.6%, (59) 0.207
Invasive 13.0%, (131) 15.6%, (307) 10.6%, (199) 0.258
Discussion: Our preliminary results suggest that FAC occurs more 
often in middle-aged patients. It’s significantly lower occurrence in 
patients with benign findings may be partially explained by the fact 
that breast cancer patients undergo more extensive surgeries, thus 
providing more breast tissue for pathologic evaluation. Otherwise, 
the increased FAC rate may suggest its role as a risk factor for cancer 
development. Since FAC may be considered a miniature FA that is not 
surgically targeted, it may be used as a window for the study of FA on 
its impact in cancer development. Further study needs to be performed 
to explain why FA and FAC have different age-dependent patterns 
and whether FA or FAC is a risk factor for breast cancer development.
P1-03-07
Subtype-Specific Gene Expression Signatures in Peritumoral 
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Non-Neoplastic Breast Tissue.
Williams T, Roman-Perez E, Rein JL, Amos KD, Troester MA. 
University of North Carolina-Chapel Hill, Chapel Hill, NC
Tumors and histologically normal-tissue adjacent to cancer share many 
biological features with healing wounds. We previously described that 
the majority of cancer-adjacent normal (CN) tissues show activation 
of wound response gene expression signatures. However, CN tissue 
also shows considerable heterogeneity across patients. Therefore, to 
characterize interindividual variation in CN tissues, we performed 
unsupervised clustering on gene expression data from women with 
invasive breast cancer or ductal carcinoma in situ of the breast. Two 
distinct classes of CN tissue were identified, one of which showed 
gene expression consistent with epithelial-to-mesenchymal transition 
(EMT), a process that is well known to be activated in healing wounds. 
Activation of this signature was present in ~40% of cancer-adjacent 
normal specimens and it was also correlated with poor outcome among 
ER-positive patients. We next hypothesized that gene expression 
changes in cancer-adjacent normal tissue would be associated with 
breast cancer subtype and/or estrogen receptor status. To test this, we 
performed supervised analysis to identify subtype-associated gene 
expression profiles in CN. We observed that more aggressive tumor 
subtypes had distinct gene expression profiles in the adjacent normal 
tissue in supervised analysis. Specifically, Basal-like and luminal 
B tumors were characterized by reduced expression of claudins 
and cell adhesion genes, while also exhibiting higher expression of 
transcription factors associated with migration. These characteristic 
changes were validated in independent datasets by evaluating the 
ability of these signatures to predict subtype. It is possible to predict 
tumor subtype using just adjacent normal gene expression. Thus, 
our findings show that cancer-adjacent tissue may have value in 
identifying tumor subtype for cases where tumors are too small to 
allow genomic analyses. Furthermore, genomic field effects may have 
clinical implications if, as our data suggests, subtypes with higher 
local recurrence rates (e.g. basal-like and luminal B breast cancers) 
have widespread genomic alterations, even in non-neoplastic tissue. 
Widespread genomic changes may indicate a need for mastectomy 
rather than breast conserving therapy. Ongoing work is (1) assessing 
these signatures in association with relapse outcomes in the Polish 
Women’s Breast Cancer Study, where more than 10 years of follow 
up data have been accrued on more than 200 patients, and (2) using 
co-culture models systems to study paracrine communication between 
breast cancer cells and stroma according to breast cancer subtypes.
P1-03-08
Adipose Tissue in Breast Cancer: Not an Idle Bystander but an 
Active Participant in Breast Cancer Progression.
Lapeire LD, Hendrix A, Lambein K, Braems G, Valet P, Van den 
Broecke R, Bracke M, Cocquyt V, Denys H, De Wever O. Ghent 
University Hospital, Ghent, Belgium; INSERM U1048, Toulouse, 
France
Background:
Adipose tissue is a dynamic organ that secretes a plethora of molecules 
called adipokines. In breast cancer we find a unique situation were 
genetically changed cells (the cancer cells) are in close contact 
with adipocytes. Moreover, obesity is a known negative prognostic 
marker for postmenopausal breast cancer patients. We hypothesize 
that adipocyte-derived factors influence breast cancer progression.
Materials and methods:
Adipose tissue was collected from breast cancer patients undergoing 
a mastectomy. After macroscopic removal of blood vessels and 
connective tissue, the adipose tissue was carefully cut into 2-3mm3 
pieces and were incubated in specific adipose-tissue culture medium. 
After 24h, the medium was collected and the quality was checked by 
determining the concentration of total proteins, leptin, adiponectin, 
TNFalpha and triglycerides. This conditioned medium of adipose 
tissue (CM AT) was used for in vitro experimentation with MCF-7 
breast cancer cells.
Results:
Effect of AT on morphology and aggregation: when MCF-7 cells are 
grown in a culture flask, they tend to form round compact islands. 
Under influence of CM AT, the islands form sharp edges, the cells 
in an island can be counted individually and they show scattering. 
Importantly, despite the major changes in cellular morphology, CM 
AT removal rescued the compact island formation of MCF-7 cells. 
In the slow aggregation assay, cells treated with CM AT (and a 
subtherapeutic concentration of a neutralizing E-cadherin antibody) 
lost the ability to form compact aggregates. Furthermore, MCF-7 
spheroids placed inside adipose tissue showed massive reorganization 
into an irregularly shaped mass.
Effect of AT on proliferation: starting from an equal number of cells 
and counting them every 2 days, it became clear that MCF-7 cells 
with CM AT had a higher rate of proliferation than MCF-7 cells in 
control medium. This stimulation of proliferation was confirmed by 
cell cycle analysis which revealed a doubling of cells in the G2/M 
phase, and western blot which showed an upregulation of cyclin A 
and cyclin E, both positive regulators of the cell cycle.
Effect of AT on invasion: a 24h collagen type I invasion assay revealed 
invasive characteristics of MCF-7 cells treated with CM AT while 
MCF-7 cells in control conditions are round and non-invasive. In 
contrast, a transwell collagen test over 14 days was not able to show 
MCF-7 cells invading the collagen gel under influence of CM AT. 
However, the growth pattern of MCF-7 cells on the collagen gel 
was clearly disorganised when compared with the control situation.
Conclusion:
These findings suggest that adipose tissue-derived factors exert 
a dramatic selective force on patterning, invasion and growth of 
MCF-7 breast cancer cells. Unraveling the mechanism behind these 
observations may provide vital information regarding the link between 
obesity and poor prognosis in postmenopausal breast cancer.
P1-03-09
Significance of FAP, SMA and CD31 Expression in the Stroma 
of Breast Cancer.
Tchou J, Satija C, Zhang P, Bi Y, Davuluri R, Chen H, Majumdar R, 
Mies C, Herlyn M, Pure E. Perleman School of Medicine at University 
of Pennsylvania, Philadelphia, PA; Perleman School of Medicine at 
University of Pennsylvania; Wistar Institute, Philadelphia
Breast cancer stroma heterogeneity has been demonstrated in various 
gene expression profile analyses. Whether there is any association 
between stroma heterogeneity and the molecular phenotype of 
breast cancer has yet to be established. Therefore, we performed 
immunohistochemical analyses (IHC) to evaluate the expression of the 
following stromal cell markers (fibroblast activation protein (FAP), 
smooth muscle actin (SMA), and CD31, an endothelial cell marker) in 
tumor tissues from a contemporary cohort of 52 patients comprising 
of all four molecular subtypes (luminal A (n=25); luminal B (n=2); 
Her2-neu (+) (n=5); and basal (n=20)). We hypothesize that stroma 
heterogeneity as reflected by the proportion of stromal cells staining 
(+) for FAP and SMA may correlate with their molecular epithelial 
phenotype. Furthermore, studying the distribution of these stromal 
cell markers in IHC sections may evaluate their spatial relationship 
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with tumor cells, immune cells, and tumor microvasculature which 
may have strategic significance within the tumor/microenvironment.
Clinical characteristics of study cohort and stromal cell marker distribution in breast cancer tissue 
stratified by molecular subtypes
  Luminal A 
(n=25)
Luminal B 
(n=2)
Her2-neu 
(n=5)
Basal (n=20) p-value
Age of 
diagnosis (years) 56.4 ± 17.4 58.0 ± 7.1 51.2 ± 17.4 50.5 ± 15.3 0.5959
Tumor size (cm) 3.2 ± 1.6 2.3 ± 0.3 8.1 ± 6.8 3.5 ± 1.7 0.0007
Tumor grade mean mBR score 6.8 ± 1.3 7.5 ± 0.7 7.3 ± 1.5 8.4 ± 0.8 0.0008
No. positive 
nodes  4.2 ± 5.3 4.0 ± 1.5 2.5 ± 3.8 2.6 ± 5.5 0.5945
Fibroblast 
activation 
protein
mean % stromal 
cells (+) 86.2 ± 12.7 50.0 ± 0.0 92.0 ± 8.4 84.4 ± 14.8 0.69
 mean intensity (range1-3) 2.25 ± 0.5 2.0 ± 0.0 2.0 ± 0.0 2.4 ± 0.5 0.43
 index (% stromal cells x intensity) 186.8 ± 54.1 100.0 ± 0.0 184.0 ± 16.7 210.6 ± 66.8 0.12
Smooth 
muscle actin
mean % stromal 
cells (+) 30.4 ± 33.1 5.0 ± 0.0 52.0 ± 17.9 24.3 ± 27.7 0.48
 mean intensity (range 1-3) 1.4 ± 0.9 1.0 ± 0.0 1.8 ± 0.4 1.3 ± 0.8 0.77
Microvessel 
density
Mean no. CD31 
(+) lumen forming 
microvessels per 20x 
magnification
20.8 ± 8.4 27.0 ± 2.8 28.3 ± 5.5 25.2 ± 11.0 0.07
As shown in Table 1, FAP is a more robust stromal cell marker 
staining 85±14% of stromal cells compared to SMA which stains 
only 28±29% of stromal cells (p<0.05). However, the distribution of 
FAP, SMA and microvessel density appears to be similar in all four 
subtypes. Multivariate analyses to correlate molecular subtype, tumor 
grade, tumor size, the no. of (+) nodes, and age with the % stromal 
cells staining (+) for FAP, SMA and CD31 yielded a significant 
correlation between the intensity of FAP(+) cells with tumor size, 
tumor grade, and the no. of positive nodes (p=0.00134, 0.0044, and 
0.01141 respectively). We conclude that 1) stroma heterogeneity 
on IHC does not differ significantly across molecular subtypes; 2) 
FAP is a robust stromal cell marker; and 3) a higher FAP expression 
intensity on IHC may correlate with poor prognosis. Recent reports 
on the role of FAP in promoting tumor growth plus the abundance 
of FAP expression in breast cancer stroma underscore a significant 
role of FAP in breast cancer.
P1-04-01
The Mechanism of Anti-Breast Cancer TICs Effect of Pyrvinium 
Pamoate Is through WNT/beta-Catenin Signaling.
Xu W, Debeb B, de Lacerda A, Li L, Larson R, Reuben J, Ueno N, 
Woodward W. UT MD Anderson Cancer Center, Houston, TX
We have previously shown that pyrvinium pamoate can decrease 
breast cancer TICs in vitro and shrink the tumor size in vivo. 
Although pyrvinium pamoate has been shown to target beta-catenin 
through activating CK-1alpha in a vitro model, the mechanism of 
its anti-breast cancer TICs effect is unknown. Herein, we use a 
constitutively active WNT/beta-catenin signaling construct EBETAP 
(ref) to determine if the anti-breast TIC effect of pyrvinium pamoate 
is through WNT/beta-catenin signaling. . Using aldefluor expression 
and mammosphere formation efficiency as TIC surrogate assays, we 
found that TICs of SUM-159 transfected with EBETAP construct are 
resistant to pyrvinium pamoate treatment compared to control cells. 
Moreover, microarray analysis reveals a series of genes and signaling 
downstream of WNT-catenin were down-regulated in SUM-159 cells 
treated with pyrvinium pamoate. In summary, mechanism of anti-
breast cancer TICs effect of pyrvinium pamoate is through WNT/
beta-catenin signaling.
P1-04-02
In Vitro Qualification and Quantification of Murine Mammary 
Stem/Progenitor Cells.
Dong Q, Wang D, Bandyopadhyay A, Liu Z, Yu L, Gao H, Moncada 
K, Huang C, Walter CA, Sun L-Z. University of Texas Health Science 
Center, San Antonio, TX; Wenzhou Medical College, Wenzhou, 
Zhejiang, China
Increasing evidence suggest that tumors with a cell origin of more 
basal or stem-like sources are often highly metastatic and associated 
with poor prognosis. Identification of the cell of origin thus has 
important implications for development of new preventive and 
therapeutic approaches. To identifying the cells of origin of various 
breast cancers, understanding the normal cellular hierarchy within 
the breast tissue is an important prerequisite. However, current 
understanding of normal mammary stem/progenitor cell is limited 
due to the lack of a robust in vitro assay. The newly developed cell 
surface markers (CD24+CD49fhi) can only be used for low percent of 
enrichment. The only gold standard assay for functional evaluation of 
stem cell property is the in vivo transplantation of cleared mammary 
fat pad assay, yet this assay is expensive, time consuming, and 
requires highly trained skills, and thus cannot be used routinely for 
experiments. The goal of our study is thus to develop a robust in vitro 
assay to qualify and quantify murine mammary stem/progenitor cells. 
Our rationale lies on our recent findings of in vitro study of different 
fractions of murine stem/progenitor cells. When we use isolated 
primary epithelial cells for in vitro mammosphere formation, we 
found that stem cell enriched fraction and progenitor cell enriched 
fraction both formed very small mammospheres (≤ 50 µm) and 
these spheres appear to be of clonal origin (one cell gives rise to one 
sphere). When we plated these small spheres into 3D extracellular 
matrix for colony formation, however, they gave rise to two distinct 
structures: stem-enriched fraction generated predominately solid 
structure while progenitor-enriched fraction is dominated by hollow 
structures. Previous studies have linked the solid structure to the basal/
myoepithelial lineage and the hollow structure to the luminal lineage. 
We thus suspected that the small mammospheres derived from the 
stem or progenitor enriched fractions could be originated from single 
stem or progenitor cell, and the number of spheres could indicate 
the number of original stem/progenitor cells within these enriched 
fractions. Subsequent in vivo transplantation with single sphere or 
single solid structure cultured in 3D extracellular matrix derived from 
green fluorescent protein transgenic mice proved that single sphere or 
3D solid structure can repopulate the gland-free mammary fat pad. To 
conclude, the in vitro mammosphere formation in combination with 
subsequent differentiation in 3D extracellular matrix can be used as 
a robust in vitro assay for qualification and quantification of murine 
mammary stem/progenitor cells. This in vitro assay will greatly 
facilitate our understanding of genes regulate stem cell self-renewal, 
proliferation, differentiation as well as mechanisms keeping them at 
quiescent state within the niche.
P1-04-03
The Effect of Survivin Downregulation on Radiosensitization of 
Breast Cancer Cell Lines Grown under Adherent and Stem Cell 
Promoting Culture Conditions.
Debeb BG, Larson R, Xu W, Lacerda L, Reuben JM, Buchholz TA, 
Ueno NT, Woodward WA. Morgan Welch Inflammatory Breast Cancer 
Clinic and Research Group, The University of Texas M.D. Anderson 
Cancer Center, Houston, TX
Survivin, the smallest member of the inhibitor of apoptosis protein 
(IAP) family, is a bifunctional protein that has been implicated in both 
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control of cell division and inhibition of apoptosis. Survivin has been 
shown to be involved in radiation resistance of various cancer types 
and its expression is increased by sublethal doses of irradiation in both 
differentiated and cancer stem cell (CSC) population. However, it is 
unknown whether suppression of survivin radiosensitizes the CSC 
population or diminishes its self renewal ability. Herein, we cloned 
the survivin dominant-negative mutant lacking a phosphorylation site 
(T34A) (Mesri et al., 2001 JCI) into the lentiviral LeGo vectors and 
assessed mammosphere formation and radiosensitization in MCF7, 
SUM149 and SUM159 cell lines grown under adherent or stem cell 
promoting conditions. We found an induction of survivin by western 
blotting in the dominant negative mutant (T34A)-transfected cell 
lines. Moreover, we observed a higher than two-fold increase in the 
Sub-G1 population as well as an increased Caspase 3 activity in the 
T34A-transfected SUM149 and SUM159 cells compared to control 
cells indicating an anti-apoptotic function of survivin. We also found 
that T34A-transfected cells showed a 1.5 to 2-fold decrease in the 
number of mammospheres compared to the control-transfected cells. 
Furthermore, T34A-transfected cells showed radiosensitization in 
adherent cells from SUM149 and SUM159 cells but no effect was 
observed in MCF7 cells. However, no radiosensitization was observed 
in stem cell promoting culture conditions with increasing doses of 
radiation in all tested cell lines. This indicates that the widely used 
standard clonogenic assays do not optimally select anti-CSC agents 
and that targeted therapies should be specifically tested for their 
activity against the CSC population. Further functional endpoint 
studies will be conducted to validate the in vitro findings.
P1-04-04
Focal Adhesion Kinase Plays a Major Role in the Regulation of 
Human Ductal Carcinoma In Situ (DCIS) Stem Cell Activity.
Williams KE, Bundred NJ, Farnie G. University of Manchester, 
Paterson Institute for Cancer Research, Manchester, United 
Kingdom; University Hospital of South Manchester, Manchester, 
United Kingdom
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase that 
has been implicated in the regulation of normal mammary stem cells 
and cancer stem cells (CSCs) within mouse models. FAK is frequently 
overexpressed in human breast cancers but its role in human CSCs is 
not known. We aimed to investigate the role of FAK in human ductal 
carcinoma in situ (DCIS) stem cells (SCs).
We have used PF573228 to inhibit FAK activity in SUM225 (HER2-
overexpressing) and MCF10DCIS.com (HER2-normal) DCIS cell 
lines. PF573228 inhibits the autophosphorylation of FAK at tyrosine 
397 causing inactivation. Western blot analysis confirmed PF573228 
(0.1-5µM) caused a dose dependent inhibition of FAK activity in 
both cell lines.
The in vitro mammosphere colony assay was used to measure CSC 
activity in both DCIS cell lines and primary DCIS samples (n=5) 
(LREC#01/012). Mammosphere-forming efficiency (MFE) was 
calculated as percentage colony formation (>60mm) in the presence 
or absence of PF573228 (0.1-5mM).
MFE was reduced in both the SUM225 cell line (p=0.02) and in 
the MCF10DCIS.com cell line (p=0.04) by PF573228 at a dose 
concentration of ≥0.1mM (see Table 1). PF573228 (1mM) also reduced 
mammosphere formation in human primary DCIS cells (n=5) by 
18.1±5.75% when compared to control (p=0.03).
Table One Shows the Primary Generation Mammosphere Forming Efficiency (MFE) in the DCIS 
cell lines.
 Dose Concentration of PF573228 (mM)
Cell Line 0 0.1 0.5 1.0 5.0
SUM225 2.26±0.11 1.92±0.06a 1.46±0.06c 1.33±0.03c 0.98±0.05c
MCF10DCIS.com 1.23±0.09 1.04±0.1b 0.71±0.06c 0.60±0.06c 0.39±0.03c
(a) p=0.02 (b) p=0.04 and (c) p= <0.0001 compared to control, Mann Whitney U, 2-tailed test.
To measure the effect of PF573228 on DCIS SC self-renewal capacity 
we performed secondary generation mammosphere colony assays. 
Primary generation mammospheres that had been treated with 
PF573228 (0.1-5µM) were dissociated into a single cell suspension 
and reseeded out into mammosphere culture conditions with no 
additional PF573228. The mammosphere regeneration ratio (MRR) 
was calculated as the proportion of secondary mammospheres formed 
relative to the number of primary mammospheres.
MRR was reduced in both the SUM225 (p=0.005) and MCF10DCIS.
com (p=0.001) cell lines after treatment with ≥0.5mM or ≥1.0mM 
PF573228 respectively (see Table 2). Preliminary data in human 
primary DCIS cells (n=1) also shows a reduction in MRR, from 
0.56 to 0.14 with 0.5mM PF573228. These results suggest that CSC 
self-renewal capacity is reduced by FAK inhibition.
Table Two Shows the Secondary Generation Mammosphere Regeneration Ratio (MRR) in the 
DCIS cell lines.
 Dose Concentration of PF573228 (mM) in primary culture only
Cell Line 0 0.1 0.5 1.0 5.0
SUM225 0.71±0.05 0.46±0.11 0.30±0.02d 0.28±0.04e 0.31±0.13f
MCF10DCIS.com 0.84±0.04 0.79±0.01 0.61±0.10 0.44±0.04g 0.48±0.01g
(d) p=0.005, (e) p=0.004, (f) p=0.003 and (g) p= 0.001 compared to control, unpaired, 2-tailed t-test.
We conclude that FAK signalling is important in human DCIS 
SC activity measured by mammosphere growth and regeneration. 
Targeting FAK in the treatment of DCIS may reduce disease 
recurrence and improve patient outcome.
P1-04-05
T-DM1 and Pertuzumab as New Tools for HER2 Specific 
Antibody-Therapy Against Breast Cancer Stem Cells in HER2-
Positive Mammary Carcinoma.
Honig A, Diessner J, Dietl J, Wischhusen J. Universitty of Wuerzburg, 
Wuerzburg, Germany
Trastuzumab (Herceptin®) has significantly improved the overall 
survival of patients with HER2-positive breast cancer. The efficacy 
of this treatment depends significantly on antibody-dependent cell 
mediated cytotoxicity (ADCC). However, while trastuzumab can 
direct NK cells towards tumor cells and thereby promote tumor cell 
lysis, spheroid-forming tumor-initiating cells are largely spared. 
Consequently, populations of surviving cells showed greatly enhanced 
clonogenicity in vitro and tumorigenicity in vivo. Low HER2 levels 
and reduced expression of activating NK cell ligands provide likely 
explanations for the escape of these cells from HER2-directed 
NK cell-dependent therapies. Moreover, recent data show that 
unproductive interactions between immune cells and cancer cells 
can induce a process called “epithelial-to-mesenchymal transition” 
(EMT) which enables previously differentiated cancer cells to acquire 
stem cell-like properties as evidenced by a CD44highCD24low breast 
cancer stem cell signature and aldehyde dehydrogenase positivity. 
We thus investigated whether new HER2-specific antibodies could 
enhance NK-cell mediated target cell lysis or inhibit the induction 
of tumor stem cells.
The antibody pertuzumab also binds to the HER2-receptor. It 
inhibits homo- and heterodimerization of the HER2 receptor with 
other member of the HER family, in particular the dimerization of 
HER2/HER3 receptors. We were able to show that the combination 
of trastuzumab and pertuzumab leads to increased antibody-binding 
on breast cancer cells and breast cancer stem cells, resulting in 
enhanced ADCC. This correlates with the clinically observed synergy 
between trastuzumab and pertuzumab as observed for example in the 
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res; 71(24 Suppl.) December 15, 2011 Cancer Research172s
Neosphere trial, a neoadjuvant study for HER2-positive breast cancer.
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate 
which combines trastuzumab with the tubulin inhibitor maytansine. 
Interestingly, treatment with T-DM1 largely prevented the NK cell-
dependent induction of the EMT markers Twist and Snail and the 
characteristic downregulation of E-cadherin. Thus, T-DM1 apparently 
interferes with EMT and may hence prevent the re-induction of 
the stem cell phenotype. In line with the presumed effect against 
cancer stem cells, T-DM1 significantly attenuated the clonogenic 
potential of FACS-sorted trastuzumab-unresponsive cancer stem 
cells. Accordingly, our data show that these new therapeutics may be 
more effective against cancer stem cells and thereby promise a more 
sustained treatment of HER2-positive breast cancer.
P1-04-06
Ionizing Radiation Reprograms Non-Tumorigenic Cancer Cells 
into Cancer Stem Cells.
Chann L, Vlashi E, Lorenza DD, Dekmezian C, Pajonk F. University 
of California, Los Angeles, CA
Breast cancers are thought to be organized hierarchically with a small 
number of breast cancer stem cells (BCSCs) able to re-grow a tumor 
while their progeny lack this feature. BCSCs in breast cancer have 
been found to be relatively resistant to radiation and several groups 
reported enrichment for BCSCs when breast cancers are subjected to 
classical anticancer treatment. Differentiation of BCSCs is thought 
to be unidirectional but an alternative model assumes that stemness 
can be obtained by clonal evolution.
In this study, we quantified the number of BCSCs surviving after 
radiation treatment. We compared the number of surviving BCSCs to 
the expected number and found an increase in BCSCs after irradiation 
that could not be explained by current models. We propose that 
radiation induces a BCSC phenotype in previously non-BCSCs and 
show that this transition is Notch-dependent and coincided with up-
regulation of the transcription factors Oct4, Sox-2, Nanog, and Klf4.
P1-04-07
Poly (ADP-Ribose) Polymerase-1 (PARP-1) Is Overexpressed in 
Human Breast Cancer Stem Cells: Results from a Proteomic-
Based Approach.
Gilabert M, Ginestier C, Audebert S, Pophillat M, Toiron Y, 
Birnbaum D, Borg J-P, Charafe-Jauffret E, Gonçalves A. Institut 
Paoli-Calmettes, Marseille, France; U891 INSERM, Marseille, 
France; Université de la Méditerranée, Marseille, France; Centre 
d’Immunologie Marseille-Luminy, Marseille, France
Introduction: Cancer stem cells (CSC) have been increasingly 
recognized as playing a major role in various fields of breast tumor 
biology including carcinogeneis, metastasis and resistance to 
cytotoxic drugs and radiotherapy. Identification of protein biomarkers 
associated with breast CSC may help understanding CSC biology as 
well as identifying novel diagnostics and specific therapeutic targets. 
2-D Fluorescence Difference Gel Electrophoresis (2-D DIGE) is a 
method that labels protein samples with fluorescent dyes before 2-D 
electrophoresis, enabling accurate analysis of differences in protein 
abundance between samples.
Methods: Using flow cytometry-based ALDEFLUOR assay (ALD), 
we isolated CSC-enriched (ALD-positive) and non CSC-enriched 
(ALD-negative) cell populations of MDA-MB-453, a human breast 
cancer cell line. Total proteins were extracted from both fractions 
using urea-based buffer and subjected to 2D-DIGE. Differentially 
expressed spots were excised, proteins were gel-extracted, digested 
and identified using MALDI-TOF MS (Ultraflex, Brucker Daltonics, 
Billerica, USA)
Results: 2D-DIGE revealed differential expression of various protein 
spots between ALD-positive and ALD-negative MDA-MB-453 cells. 
MALDI-TOF MS analysis allowed identification of 11 differentially 
expressed proteins, among which 7 were down-regulated and 4 were 
up-regulated in ALD-positive MDA-MB-453 cells, including Poly 
(ADP-ribose) polymerase-1 (PARP-1). Overexpression of PARP-1 
in MDA-MB-453 cells was further confirmed by western blot using 
specific monoclonal antibody and such an observation was extended 
to 4 additional human breast cancer cell lines including HCC1937, 
MDA-MB-436, SUM149 and SUM159. These 5 human breast cancer 
cells were found to display a limited short-term sensitivity (within the 
micromolar range) to olaparib, a specific PARP-1 inhibitor. However, 
a negative correlation was found between the level of overexpression 
and the ability of olaparib to inhibit the growth of ALD-positive cells.
Conclusion: A proteomic-based approach revealed that PARP-1 was 
up-regulated in ALD-positive, CSC-enriched from various human 
breast cancer cell lines. Such an overexpression may contribute to 
clinical resistance to PARP-inhibitors.
P1-04-08
Distribution of ALDH1 Positive Stem Cells in Benign Mammary 
Tissue from Women with and without Breast Cancer.
Isfoss BL, Holmqvist B, Alm P, Olsson H. Telemark Hospital, Skien, 
Norway; Lund University, Lund, Sweden
Background and Aims. ALDH1 in female breast tissue has been 
linked to stem cells, but little is known about the benign cellular 
organisation in situ. We investigated the distibution of ALDH1 
immunoreactive (ALDH1+) cells in histomorphologically benign 
breast tissue from 28 women with or without breast cancer.
Methods and Results. ALDH1+ cells were detected in benign tissue 
of women age 20 - 72, located most commonly within the luminal 
and intermediate ductular levels and in the stroma. ALDH1+ cell 
populations and Ki-67+ cell populations were present in separate 
ductules, both cell types rarely showing epithelial differentiation. 
ALDH1+ cells were non-reactive to Ki-67 and oestrogen receptor. 
Stromal round/oval ALDH1+ non-leukocyte cells in both age groups 
expressed contractile protein. There was a lower concentration of 
luminal and intermediate ductular ALDH1+ cells in post-menopausal 
women than pre-menopausal women, lower in cancer than non-cancer 
patients, and higher in women on exogenous hormones.
Conclusions. The study provides further evidence for the stem 
cell character of ALDH1+ cells, here in benign breast tissue of 
cancer and non-cancer women throughout non-lactating adult life, 
and contributes evidence of benign stromal ALDH1+ cells. The 
distribution of ductular ALDH1+ stem cells appears to be influenced 
by hormonal status.
P1-04-09
Biphasic Effects of Docetaxel and Hedgehog Signaling Antagonists 
on Breast Cancer Tumor-Initiating Cells In Vivo.
Zhang X, Moraes RC, Landis MM, Wu M-F, Hilsenbeck SG, Cairo 
MM, Toftgar R, Chang JC, Lewis MT. Baylor College of Medicine, 
Houston, TX; Karolinska Institutet, Novum, Sweden
Recent data suggest the existence of a subset of breast cancer cells 
variously termed cancer stem cells, tumor-initiating, or tumor-
propagating cells, that are capable of self-renewal and of regenerating 
tumors upon transplantation that are biologically consistent with 
the tumor of origin. These cells appear to be intrinsically resistant 
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to systemic chemo- and radiation therapies and may therefore be 
responsible for treatment resistance, and disease recurrence.
Several signal transduction networks have been implicated in normal 
and malignant stem cell self-renewal. These include those of the 
Hedgehog, Notch, Wnt, EGF, FGF families of ligands. Antagonists of 
these networks have become attractive targeted therapeutic agents. In 
this study, we evaluated two different Hedgehog signaling antagonists, 
one targeting Smoothened (the main membrane effector of activated 
signaling) and one targeting GLI1/2 (the two transcription factors 
mediating ligand response), for their ability to shrink patient-derived 
xenograft tumors and to affect the number or function of breast 
tumor-initiating cells in vivo. Both antagonists showed little effect 
as single agents, but could augment tumor shrinkage by docetaxel. 
However, these effects were only observed in those models showing 
evidence of canonical SMO/GLI-mediated signaling. In dilutional 
transplantation assays, both SMO or GLI targeted agents have a 
biphasic effect on the behavior of the tumor-initiating population 
such that large cell numbers yielded few tumors while intermediate 
cell numbers yielded tumors at a comparable rate as controls. These 
data suggest that combination therapy alters the functional state of 
stem cells in the context of larger cell numbers rather than targeting 
the tumor-initiating cell directly. These data therefore have significant 
relevance for the interpretation of ongoing clinical trials of hedgehog 
signaling inhibitors in solid tumors, including breast cancer.
P1-05-01
PELP1 Oncogenic Functions Involve Regulation of Histone 
Arginine Methylation.
Mann M, Cortez V, Yang BW, Tekmal RR, Vadlamudi RK. University 
of Texas Health Science Center at San Antonio, San Antonio, TX; 
University of Southern California, Los Angeles, CA
BACKGROUND: Cancer is caused by abnormalities of the genome 
and epigenome including the frequently occurring epigenetic 
changes of histone modifications. Specifically, estrogen-induced 
breast carcinogenesis is characterized by alterations in histone 
modifications. Reader proteins that recognize these modifications 
facilitate modulation of genes and their resulting biological actions. 
In addition to regulation by several coregulators, estrogen receptor 
alpha (ER) transcriptional activation or repression depends on the 
modulation of histone methylation at target promoters. The ER 
coregulator PELP1 plays an important role in ER signaling, is a 
proto-oncogene with aberrant expression in hormone- related cancers 
and a prognostic indicator of decreased survival in breast cancer 
patients. The molecular mechanisms by which PELP1 promotes 
oncogenesis remain unknown; however, previous studies from our 
lab have shown that PELP1 has the potential to function as a reader 
of chromatin modifications.
MATERIALS AND METHODS: A histone peptide array (Active 
Motif) that contains 384 unique combinations of histone modifications 
was used to explore the PELP1 epigenetic interactome using the 
manufacturer’s protocol. Purified full length and various deletions 
of epitope tagged PELP1 were used for the screening. Using MCF7 
and ZR75 model cells with stable expression of PELP1 or PELP1 
shRNA, we examined the significance and role of PELP1 on the 
histone arginine methylation using ERE reporter gene assays, confocal 
microscopy and ChIP assays. Pre-clinical nude mice based models 
were used to validate the PELP1 effects on arginine methylation in 
vivo and PELP1-siRNA liposomes were used to downregulate PELP1 
expression in vivo. IHC studies were performed to examine the status 
of histone arginine methylation in murine breast tumors.
RESULTS: Our results show that PELP1 uniquely recognizes 
histones modified by arginine dimethylation, arginine citrullination 
and lysine dimethylation. Phosphorylation of residues adjacent to a 
methyl modification affects the ability of PELP1 to recognize histone 
methylation. Using various deletions of PELP1 peptides, we have 
found that PELP1 acts as a module for recognition of a specific histone 
modification through the carboxyl-terminal glutamic acid rich region. 
Reporter gene assays showed that PELP1 functionally interacts with 
arginine methyltransferases including CARM1 and PRMT6, both 
shown to be dysregulated in human cancers, and synergistically 
enhances ER-transactivation. Chromatin immunoprecipitation assays 
revealed that PELP1 has the potential to alter histone H3 arginine 
methylation status at ER target gene promoters. PELP1 knockdown 
via PELP1-sRNA liposomes using xenograft based assays resulted 
in decreased arginine dimethylation with concomitant reduction in 
tumor volume.
Conclusions: Our findings suggest that PELP1 is a reader of 
histone methyl modifications and deregulation of PELP1 may have 
implications on tumor proliferation via epigenetic alterations at ER 
target promoters. Targeting these epigenetic alterations through 
inhibition of PELP1 and the arginine methyltransferases could be 
a promising cancer therapeutic. This study was funded by CPRIT 
pre-doctoral fellowship grant and Komen KG090447.
P1-05-02
Epigenetic Regulation by Alcohol Reactivates Estrogen Receptor 
alpha in Estrogen Receptor alpha-Negative Cells.
Wong AW, Nunez N. University of Texas at Austin, Austin, TX
Introduction: Alcohol consumption is an established risk factor for 
breast cancer development and contributes to mammary tumorigenesis 
through the regulation of estrogen receptor alpha (ERa) expression. 
Previously, we reported that alcohol consumption in the MMTV-
neu ERa-negative mouse model of human breast cancer resulted 
in significantly increased ERa expression compared to non-alcohol 
consuming mice. Thus, our results indicated that alcohol consumption 
led to reexpression of ERa in an ERa-negative mouse model. Several 
lines of evidence suggest that ERa expression in ERa-negative cancer 
cells is inhibited through epigenetic mechanisms. In this study, we 
examine the role of alcohol on ERa reactivation through changes 
in histone modifications, DNA methylation, and recruitment of 
transcriptional regulation complexes on the ERa promoter, in vitro.
Methods: ERa-negative MDA-MB-231 human breast cancer cells 
were treated with 0.1%, 0.2% and 0.5% v/v ethanol in culture media 
for 24 h. Chromatin immunoprecipitation (ChIP) assays were used to 
examine the enrichment of active and inactive markers of chromatin 
on the ERa promoter following alcohol treatment. DNA methylation 
at three ERa promoter CpG dinucleotide sites was assessed following 
alcohol treatment using methyl-sensitive restriction enzyme 
(MSRE)-qPCR. ChIP assays are used to determine the binding of the 
transcriptional regulation complexes, pRb2/p130-E2F4/5-HDAC1-
SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-
DNMT1, to the ERa promoter following alcohol treatment. MCF-7 
human breast cancer cells served as an ERa-positive control.
Results: We report that histone modifications were affected by 
alcohol treatment in a dose-dependent manner. Enrichment levels of 
all five chromatin markers tested, which includes markers of active 
and inactive transcription, were significantly altered as a result of 
alcohol treatment (p<0.05). We also found significantly decreased 
DNA methylation at three ERa promoter CpG sites as a result of 
alcohol treatment (p<0.05). Experiments testing the recruitment of the 
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transcriptional regulation complexes, pRb2/p130-E2F4/5-HDAC1-
SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-
DNMT1, are currently ongoing.
Discussion: ERa expression has been linked to mammary 
carcinogenesis and clinical outcome in breast cancer patients. 
However, approximately one out of three breast cancers lack ERa 
expression at the time of diagnosis and many breast cancers lose 
ERa expression during the course of tumor progression. Thus, 
understanding the regulation of ERa expression in breast cancer cells 
is critical and results from this study will facilitate the development 
of novel therapeutic strategies and treatment options for hormone-
resistant breast cancer.
P1-05-03
Relationship between Polycomb Repressive Complex EZH2/
CBX7, Large Non-Coding RNA ANRIL and Stem Cells 
Biomarkers in Triple Negative Breast Carcinomas: Important 
Role in Carcinogenesis through an Epigenetic Silencing Process 
and New Clues for Targeted Therapies.
Meseure D, Vacher S, Trassard M, Drak-Alsibai K, Le Scodan R, Le 
Ray C, Regnier C, Lidereau R, Bieche I. Institut Curie Hôpital Rene 
Huguenin, St Cloud, France
Background: Epigenetic deregulation and carcinogenesis are 
intimately connected and gene silencing is a major consequence 
of epigenetic modifications. Polycomb group proteins (PcG) 
play important roles by inhibiting chromatin remodeling and 
transcription, silencing tumor suppressor genes, regulating stem 
cells and interconnecting with Wnt/beta-catenin, TGF-beta and 
Sonic-Hedgehog pathways. EZH2 is a transcriptional repressor and 
acts mainly as an oncogenic silencer gene involved in cell cycle 
regulation. Large non coding RNA are major regulators of oncogenic 
and oncosuppressive pathways at epigenetic, transcriptional and 
post-transcriptional levels. Recent studies have showed that (i) 
EZH2 overexpression is associated with cancer progression and 
aquisition of stem cell properties and (ii) disruption of ANRIL/
CBX7 interactions repress the INK4b/ARF/INK4a locus. The aim 
of the study was to analyze PRC complexes, large non-coding RNA 
ANRIL and downstream signaling targets in triple negative breast 
carcinomas (TNC).
Design: By using real time quantitative RT-PCR in a series of 
432 invasive breast ductal carcinomas (IDC), we quantified gene 
expression levels of the large non coding RNA ANRIL, PcG (EZH2, 
CBX7, SUZ12), stem cells markers (ALDH1, CD133, ASCL1) and 
oncosuppressor genes (p15, p16 and p19). Immunohistochemistry 
(IHC) was performed using EZH2, CBX7, ALDH1 and b-catenin 
Abs. We compared mRNA expression levels and IHC intensity score 
in TNC with non TNC and normal breast parenchyma.
Results: EZH2 overexpression was respectively found by RT-PCR 
and IHC in the TNC subgroup of IDC. We observed variable mRNA 
expression levels of SUZ12, CBX7, ANRIL, ALDH1, CD133, ASCL1, 
p15, p16, and p19. IHC showed EZH2 and CBX7 nuclear staining. 
Mutual positive correlations were found between EZH2, CBX7, 
ALDH1, ASCL1 and CCND1 (p<10-5). Conclusion: Polycomb 
EZH2/CBX7 and the large non coding RNA ANRIL are epigenetic 
transcriptional repressors overexpressed in the TNC subgroup of IDC. 
Their implication in the process of gene silencing (p16, p15, p19), 
activation of oncogenic pathways (Wnt, TGFb) and tumor stem cells 
self-renewal may explain several hallmarks of TNC and open new 
avenues to target this aggressive subgroup.
P1-05-04
Distinct Patterns of Promoter CpG Island Methylation of 
Breast Cancer Subtype Are Associated with Different Stem Cell 
Phenotype.
Park SY, Kwon HJ, Choi Y, Lee HE, Kim S-W, Kim JH, Kim IA, Jung 
N, Cho N-Y, Kang GH. Seoul National University Bundang Hospital; 
Seoul National University Hospital; Cancer Research Institute, Seoul 
National University
Background: Although DNA methylation profiles in breast cancer 
have been connected to breast cancer molecular subtype, there have 
been no studies of the association of DNA methylation with stem cell 
phenotype. This study was designed to evaluate promoter CpG islands 
methylation of 15 genes with regard to breast cancer subtype and to 
investigate whether the patterns of CpG island methylation in each 
subtype are associated with cancer stem cell phenotype represented 
by CD44+/CD24- or ALDH1 expression.
Methods: We performed MethyLight analysis for the methylation 
status of 15 promoter CpG island loci involved in breast cancer 
progression (APC, DLEC1, GRIN2B, GSTP1, HOXA1, HOXA10, 
IGF2, MT1G, RARB, RASSF1A, RUNX3, SCGB3A1, SFRP1, SFRP4, 
and TMEFF2) and determined cancer stem cell phenotype by CD44/
CD24 and ALDH1 immunohistochmeistry in 36 luminal A, 33 luminal 
B, 30 luminal-HER2, 40 HER2 enriched, and 40 basal-like subtypes 
of breast cancer.
Results: The number of CpG island loci methylated was significantly 
different among subtypes and it was highest in luminal-HER2 
subtype and lowest in basal-like subtype. Methylation frequencies 
and levels in 12 out of the 15 genes were significantly different 
among all subtypes and basal-like subtype showed significantly 
lower methylation frequencies and levels in nine genes, compared to 
luminal A, luminal B, HER2 enriched, and luminal-HER2 subtypes. 
CD44+/CD24- or ALDH1+ putative stem cell populations were most 
enriched in basal-like subtype. The methylation of promoter CpG 
islands was significantly lower in CD44+/CD24-cell (+) tumors, 
compared to CD44+/CD24-cell (-) tumors, even within the basal-like 
subtype. ALDH1 (+) tumors also had significantly lower methylation, 
compared to ALDH1 (-) tumors.
Conclusions: Our findings showed that promoter CpG island 
methylation was significantly different according to breast cancer 
subtype and stem cell phenotype of tumor, suggesting that breast 
cancers have different methylation patterns according to molecular 
subtypes and it is associated with stem cell phenotypes of the tumor.
P1-05-05
Prognostic Utility of Histone Modifier Gene Expression Profiles 
in Human Breast Cancer.
Patani N, Jiang WG, Newbold RF, Mokbel K. The London Breast 
Institute, The Princess Grace Hospital, London, United Kingdom; 
University Department of Surgery, Cardiff University School of 
Medicine, Cardiff, United Kingdom; Brunel Institute of Cancer 
Genetics and Pharmacogenomics, Brunel University, London, United 
Kingdom
Background: Gene expression is stringently controlled under 
physiological conditions by epigenetic mechanisms, including the 
specific methylation of cytosine residues within CpG dinucleotides 
and orchestrated adjustments in the histone dependent organisation of 
chromatin. The organisation of DNA within the chromatin template 
depends upon highly conserved histone proteins, the properties of 
which continue to exceed the simplistic packaging role originally 
assigned to them. Histone modifier enzymes impart a dynamic histone 
code and specific permutations have significant implications for 
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chromatin topology and the functional configuration of promoters. 
This study follows our initial report describing potential tumour 
suppressor function associated with the histone methyltransferase 
SETD2 in human breast cancer. The objective was to evaluate the 
expression profiles of sixteen additional histone modifier genes in 
women with primary operable breast cancer within a well annotated 
cohort with extended follow-up.
Methods: Primary breast cancer tissues (n=127) and adjacent benign/
normal tissues (n=33) underwent RNA extraction and reverse 
transcription. The transcript levels of histone modifier genes were 
evaluated using real-time quantitative PCR, these included: histone 
acetyltransferases (CREBBP), Class 1 (HDAC1 and HDAC2), 
II (HDAC5) and III (SIRT1) histone deacetylases and histone 
methyltransferases (SUV39H1 and SUV39H2) amongst others. 
Transcript levels were analysed against a range of clinico-pathological 
variables, including: tumour size, grade, nodal involvement, 
histological subtype, receptor status, TNM stage, Nottingham 
Prognostic Index, disease free and overall survival over a 10 year 
follow-up period.
Results: Transcript levels of the histone modifier genes in breast 
cancer tissues differed significantly from non-malignant samples 
(HDAC5, HDAC1, KDM4A and KDM6A). Amongst breast cancers, 
significant differences in transcript levels were associated with 
established pathological parameters and prognostic indices: tumour 
grade (KAT5, HDAC1, KDM4A, SUV39H1 and KDM6A), receptor 
status (KAT5, SMYD3 and KDM1A), histological type (KAT5, 
KDM5C, MYST1, KDM4A and MLL), TNM stage (SUV39H1, 
KAT2B, KDM1A, KDM4A, KDM5C, MYST1, HDAC5 and KAT5), 
Nottingham Prognostic Index (KDM5C, MLL, MYST1 and SMYD3), 
disease free survival (SUV39H1, SMYD3, HDAC5, KDM6A, 
HDAC1, KDM1A, KDM4A, MYST1, KDM5C, KAT5 and MLL) 
and overall survival (MYST1). Interestingly, significant correlations 
were also identified between the differential expression profiles of 
particular histone modifying genes.
Conclusion: The expression profiles of histone modifier genes 
differ significantly between breast cancer tissues and normal/
benign samples. Particular expression profiles in breast cancer are 
significantly associated with established pathological parameters, 
prognostic indices, disease free and overall survival. The biological 
significance and clinical relevance of altered expression of specific 
histone modifier genes and particular permutations of misexpression 
remain to be fully elucidated and further study is warranted. 
Epigenetic signatures derived from histone modifier genes may offer 
utility as biomarkers and histone modifier enzymes have potential for 
targeted therapeutic strategies.
P1-05-06
Hypermethilation 14-3-3- Sigma Promoter as a Biomarker to 
Screening for Metastasis and Potencial Prognostic Factor in 
Breast Cancer Patients.
Martinez-Galan J, Torres-Torres B, González-Vicente A, Ruiz-
Vozmediano J, Delgado-Pérez JR. Hospital Universitario Virgen de 
las Nieves, Granada, Spain; Centro de Investigaciones Biomédicas, 
Granada, Spain
Background: 14-3-3sigma is an epithelial marker whose expression 
is induced by DNA damage through a p53-dependent pathway. 
14-3-3sigma functions sequesters cyclin B1-CDC2 complexes 
outside the nucleus and thereby contributes to a G2 arrest. Epigenetic 
silencing by CpG methylation, p53 inactivation, and proteasome-
dependent proteolysis leads to loss of 14-3-3sigma and is often 
observed in precancerous lesions and likely to be causally linked to 
the onset of cancer
Objetive: To correlation methylation levels of promoter 14-3-3 
sigma with association prognostic factors in breast cancer and their 
correlation with phenotype luminal.
Material and Methods: This is a prospective study we quantified 
methylation levels of promoter 14-3-3 sigma gene in 107 women 
with breast cancer and 108 control subjects by Real Time QMS-PCR 
SYBR green (methylation-specific PCR) and analyzed association 
with prognostics factor in breast cancer.
Results: Median age was 58 years (32-88); 69% were postmenopausal 
women. Nodal involvement N0; 63%,N1;30%,N2;7%), 
tumor size (T1;58%,T2;35%,T3;4%,T4;4%) and grade G1; 
20%,G2;37%,G3;30%). Significant differences between breast 
cancer patients (pts) and healthy controls in relative serum levels 
of methylated gene promoters 14-3-3s (p=0.0047) were detected.
Presence of methylated 14-3-3-s in serum of breast cancer patients 
was associated with T3-4 stage (OMS) (p<0.05) and nodal positive 
status (p< 0.05). With a median follow up 6 years we saw more 
probability of developing distance metastasis in patients with 
methylation 14-3-3 sigma (p>0.05).
Conclusions: Hypermethylation of the 14-3-3 sigma promoter is an 
early and frequent event in breast neoplastic transformation, leading 
to the suggestion that silencing of 14-3-3 sigma may be an important 
event in tumor progression and particularly in breast carcinogenesis. 
This study identifies the presence of variations in global levels 
of methylation promoters genes in patients breast cancer with 
different phenotype classes and shows that these differences have 
clinical significance. Perhaps in the detection of CpG methylation 
of 14-3-3sigma may be used for diagnostic and prognostic purposes.
P1-06-01
Withdrawn by Author
P1-06-02
Correlation between Gene Variants in CYP19 (Aromatase) and 
TCL1A with Disease and Tolerability Endpoints in the ATAC 
Trial.
Rae JM, Sestak I, Henry NL, Drury S, Hayes DF, Thibert JN, Lopez-
Knowles E, Salter J, Pineda S, Cuzick J, Dowsett M. University of 
Michigan, Ann Arbor, MI; Queen Mary University, London, United 
Kingdom; Royal Marsden Hospital, London, United Kingdom; 
Breakthrough Breast Cancer Research Centre, London, United 
Kingdom
Aim: To assess whether candidate polymorphisms in CYP19 
(aromatase) and TCL1A were associated with recurrence, 
musculoskeletal symptoms (MSKs) or hot-flushes in primary estrogen 
receptor-positive breast cancer in postmenopausal women treated 
with tamoxifen or anastrozole.
Background. Recently, variants rs10459592 and rs4775936 in CYP19 
(aromatase) have been reported to be associated with aromatase 
inhibitor (AI) response in patients with metastatic breast cancer 
(Park, et al, CCP, 2011) and variants in CYP19 and at the 3’ end of 
TCL1A (rs11849538) with AI-induced arthralgia (Ingle, et al, JCO, 
2010). These findings require validation before clinical application. 
The ATAC trial was a prospective randomized double-blind placebo-
controlled trial that compared the adjuvant use of anastrozole versus 
tamoxifen for 5 years. The trial’s detailed efficacy and safety data, 
long term (10-year) follow-up and high event rate make it an ideal 
setting for pharmacogenetic single nucleotide polymorphism (SNP) 
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validation studies. Here we report our findings testing for correlations 
with 3 SNPs in CYP19 and TCL1A with clinical outcomes including 
any disease recurrence, distant recurrence, MSKs, and hot-flushes.
Methods: Genotypes were determined using ABI Taqman assays 
without knowledge of the patient’s treatment assignment or outcomes. 
Hazard ratios (HR) and corresponding 95% confidence intervals (CI) 
were estimated by the proportional hazards regression model and were 
adjusted for: age, tumor size, grade, and nodal status (for survival 
analyses) and age, hormone replacement therapy, body mass index, 
and smoking (for toxicity analyses).
Results: 807 patients were genotyped for CYP19 SNPs rs10459592 
and rs4775936 and 842 for TCL1A SNP rs11849538. The rs10459592 
genotype frequencies were 16.6% Wt/Wt, 51.5% Wt/Vt, and 32% Vt/
Vt. There was a trend towards decreased recurrence in Vt/Vt and Vt/
Wt compared to Wt/Wt (HR=0.77 [0.50-1.22] and 0.68 [0.42-1.09], 
p[trend]=0.1), similar for both anastrozole- and tamoxifen-treated 
patients and also similar for distant recurrence. For the same SNP, 
there was a trend toward more MSKs in Vt/Vt and Vt/Wt compared 
to Wt/Wt (HR=1.22 [0.80-1.88] and 1.47 [0.94-2.30], p[trend]=0.08), 
primarily due to the effect in the tamoxifen cohort (HR=1.88 [0.89-
3.99], p[trend]=0.1). The rs4775936 genotype frequencies were 
26.0% Wt/Wt, 52.1% Wt/Vt and 21.9% Vt/Vt. Trends in the same 
direction as those for rs10459592 were found with rs4775936, albeit 
less significant. The TCL1A genotype frequencies were 77.5% Wt/Wt, 
20% Wt/Vt and 2.5% Vt/Vt. No association was observed between 
TCL1A genotypes and recurrences or MSKs, however, the small 
number of Vt/Vt patients on tamoxifen had greater incidence of hot 
flushes (HR=1.99 [0.9-3.91], p=0.09).
Conclusion: These data do not support an association between the 
TCL1A 3’ variant and AI-induced MSKs independent of severity. 
Our data do support the CYP19 SNP rs10459592 and the loosely 
linked rs4775936, which previously were associated with letrozole 
efficacy, as probably being associated with better disease outcome 
on anastrozole and tamoxifen and with worse drug side effects. The 
degree of association requires definition in further data sets.
P1-06-03
Predictive Value of HER2, Topoisomerase-II (Topo-II) and 
Tissue Inhibitor of Metalloproteinases (TIMP-1) for Efficacy 
of Taxane-Based Chemotherapy in Intermediate Risk Breast 
Cancer – Results from the EC-Doc Trial.
Gluz O, Erber R, Kates R, Kreipe H, Bartels A, Liedtke C, Pelz 
E, Huober J, Kuhn W, Nitz U, Hartmann A, Harbeck N, Brünner 
N. West German Study Group, Moenchengladbach, Germany; 
University Hospital Erlangen, Erlangen, Germany; Medizinische 
Hochschule Hannover, Hannover, Germany; University Copenhagen, 
Copenhagen, Denmark; University Hospital Muenster, Muenster, 
Germany; Pathology Practice, Viersen, Germany; Unniversity 
Hospital Tuebingen, Tuenbingen, Germany; Kantnonhospital St. 
Gallen, St. Gallen, Switzerland; University Hospital Bonn, Bonn, 
Germany; University Hospital Cologne, Cologne, Germany
Background:
Despite extensive research, there is still no consensus on optimal 
predictors for use of taxane-based chemotherapy (cht) in early breast 
cancer. Some studies have revealed HER2 as a significant predictive 
marker for efficacy of taxanes and anthracyclines. TIMP-1 and 
Topo-II are reported to be predictive for anthracycline efficacy. In 
our previous reports, both Ki-67>20% and central G3 status emerged 
as significant predictors for taxane benefit. We have now compared 
HER2 and Topo-II (as protein expression and gene amplification) 
and TIMP-1 immunoreactivity as well as factor combinations (HT 
(HER2/TIMP-1) and 2T (Topo-II/TIMP-1) regarding their predictive 
value for benefit from taxane-based cht..
Methods: The EC-Doc trial randomized 1950 patients with 1-3 
positive LN to 6x CEF/CMF vs. 4xEC-4xDoc. Significantly better 
DFS and OS favoring EC-Doc have been previously reported (Nitz 
et al., SABCS 2008). Protein expression and gene amplification 
data as well central histology/grade were available for 772 patients. 
Survival analysis was performed using Cox proportional hazards and 
Kaplan-Meier statistics. Analysis of HER2 survival impact status was 
prospectively planned.
Results: The entire and the investigated study populations did not 
differ regarding baseline characteristics. After median follow up of 
64 months, both DFS (5y 90% vs. 80%, p=0.006) and OS (5y 95% 
vs. 92%, p=0.022) rates significantly favored EC-Doc vs. CEF in 
this cohort as well. HER2 over-expression (3+ and/or FISH>2.0) 
was reported in 158 tumors (20%), Topo-II aberration (deletion or 
amplification) was reported in 78 (49.4%) HER2+ and in 83 (13.6%) 
HER2-negative tumors; 496 tumors were classified as TIMP-1 
immunoreactive (65.2%). None of these factors were significantly 
prognostic for EFS in this collective. Regarding DFS, EC-Doc was 
strongly superior to FEC in HER2+ tumors (HR=0.29, 95%CI: 0.12-
0.7, p=0.006) but not in HER2- tumors (p=0.18). In Topo-II aberrated 
tumors, the benefit of EC-Doc was remarkably strong (HR=0.28, 95% 
CI: 0.11-0.69, p=0.006), whereas the benefit was not significant in 
Topo-II normal tumors (p=0.16), which comprise more than ¾ of 
the total. In contrast, Topo-II protein overexpression (>10%) was not 
associated with a stronger benefit in either subgroup. The superiority 
of EC-Doc to FEC was significant in the larger group of TIMP-1 
immunoreactive tumors (HR=0.57, p=0.025) but not in TIMP-1 
negative tumors (p=0.14), similar behavior was seen in “HT” and “2T” 
subgroups (significance with HR about 0.5 in the “+” subgroups).
In a multivariate model for DFS including age, tumor size, Ki-67, 
central grade, HR, HER2, TOPO_II aberration, TIMP-1 status, 
therapy and interactions of all these factors with therapy arm, the only 
significant therapy interaction was that of (high) Ki-67 (HR=0.76, 
95% CI: 0.59-0.98, p=0.03); significant main effects in this model 
were age, central grade, and Ki-67.
Conclusions: These data suggest predictive significance for Topo-
II aberration, TIMP immunoreactivity and HER2 over-expression 
as well as a multivariate predictive significance of high Ki-67 for 
enhanced benefit of taxane-based cht.
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P1-06-04
PAM50 Proliferation Index Predicts Response to Weekly 
Adjuvant Paclitaxel in Node-Positive Operable Breast Cancer.
Martín M, Rodríguez-Lescure Á, Stijleman IJ, Munárriz B, Ruíz-
Borrego M, Davis C, Crespo C, Rodríguez CA, Ebbert MTW, Álvarez I, 
Furió V, Bastien RRL, García AM, Cheang MC, Palacios J, Ellis MJC, 
Carrasco E, Casas MI, Caballero R, Perou CM, Bernard PS. Hospital 
General Universitario Gregorio Marañon, Madrid, Spain; Hospital 
Universitario de Elche, Elche, Spain; University of Utah Health 
Sciences Center/Huntsman Cancer Institute, Salt Lake City, UT; 
Hospital Universitario La Fe, Valencia, Spain; Hospital Universitario 
Virgen del Rocío, Sevilla, Spain; Hospital Universitario Ramón y 
Cajal, Madrid, Spain; Hospital Clínico Universitario de Salamanca, 
Salamanca, Spain; The ARUP Institute for Clinical and Experimental 
Pathology, Salt Lake City, UT; Hospital de Donostia, San Sebastián, 
Spain; Hospital Clínico Universitario San Carlos, Madrid, Spain; 
University of North Carolina at Chapel Hill; Washington University in 
St Louis, St Louis; Spanish Breast Cancer Research Group, GEICAM, 
San Sebastián de los Reyes, Madrid, Spain
BACKGROUND
Predictive factors of survival benefit from taxane over non-taxane 
based adjuvant chemotherapy regimens are needed. Recent studies 
have suggested that “intrinsic” breast cancer subtypes may differ 
in their responsiveness to specific chemotherapeutics. Tumor 
samples from GEICAM 9906 study (Randomized Phase 3 Trial of 
Fluorouracil, Epirubicin, and Cyclophosphamide Alone [FEC] or 
FEC Followed by Paclitaxel [FEC-P] for Early Breast Cancer, JNCI 
100:805, 2008) were gene expression profiled using the RT-qPCR 
PAM50 clinical test in order to identify potential predictive markers 
of taxane clinical benefit.
METHODS
793 formalin-fixed paraffin-embedded tumors were studied and 
classified into intrinsic subtypes (Luminal A & B, HER2-enriched, 
Basal-like, and Normal) using the PAM50 test. The assay also 
provided gene expression scores for the standard protein biomarkers 
usually measured by immunohistochemistry (ESR1/ER, PGR/
PR, and ERBB2/HER2) and a meta-gene score for proliferation 
(proliferation signature) and for a luminal gene signature. Intrinsic 
subtypes, individual genes, or meta-genes were correlated with 
disease-free survival (DFS). Multivariable Cox regression analyses 
were performed to determine the significance of the interaction 
between treatment and intrinsic subtypes, single genes and meta-
genes, adjusting for standard clinicopathological factors.
RESULTS
A 8.7 years follow-up update of GEICAM 9906 trial confirmed 
a statistically significant advantage of FEC-P over FEC in terms 
of DFS (p=0.016) and OS (p=0.013). Exploratory analyses for 
prognostic factors showed that treatment arm (p=0.016), tumor size 
(p<0.0001), type of surgery (p=0.003), tumor grade (p=0.001), nodal 
status (p<0.0001), intrinsic subtypes (p<0.0001), ERBB2 (p=0.031), 
PGR (p<0.0001), Luminal meta-gene (p=0.006) and Proliferation 
meta-gene (p<0.0001) were associated with DFS. A Cox multivariate 
analysis using the backward and forward method showed that only 
the treatment arm (P=0.052), tumor size (p=0.0003), nodal status 
(p=0.001), intrinsic subtypes (p=0.045) and Proliferation (p=0.008) 
were prognostic for DFS.
Concerning predictive factors, exploratory analyses were performed 
and interaction tests were calculated. Theses analyses showed that 
FEC-P was superior to FEC in low PGR expression (HR= 0.68, 
p=0.034) and not in high PGR group (HR=0.83, p=0.245); interaction 
test p=0.358. Similarly, FEC-P was superior in low ERBB2 expression 
(HR=0.67; p=0.005) and not in the high ERBB2 group (HR=0.92, 
P=0.707); interaction test p=0.256. Interestingly, superiority of FEC-P 
was observed for the low Proliferation Signature group (HR=0.58, 
p= 0.006) in contrast to the high proliferation group (HR=0.93, 
p=0.633); the interaction test showed an almost statistical significant 
difference (p=0.069). The FEC-P arm showed improved outcome in 
all genomic intrinsic subtypes, although no subtype alone reached 
statistical significance.
CONCLUSION
Our study suggests that the PAM50 proliferation signature could be 
predictive of benefit for adding weekly paclitaxel to the adjuvant 
chemotherapy FEC regimen. These results need further validation 
in an independent study.
The last two authors of this abstract have contributed equally to 
this study.
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The Importance of CXCL10 and CXCR3-A in Breast Cancer.
Hilborn E, Sivik T, Kot A, Fornander T, Skoog L, Nordenskjöld B, 
Stål O, Jansson A. Faculty of Health Sciences, Linköping, Sweden; 
Karolinska Institutet
Background: CXCL10 is a chemokine with chemo attractant 
properties which signals through G protein-coupled receptor CXCR3. 
At least two reported isoforms exists; CXCR3-A and CXCR3-B. 
CXCL10 is involved in the recruitment of leucocytes, immune 
modulation and angiogenesis. In animal models CXCL10 inhibits 
tumour growth, metastase formation and inhibits angiogenesis. The 
receptors have opposite features; CXCR3-A mediates proliferative 
or anti-apoptotic response and CXCR3-B mediates growth inhibition 
and apoptosis in response to ligand binding. The aim of this study 
was to investigate the role of CXCL10 and CXCR3-A as prognostic 
or tamoxifen treatment predictive factors in breast cancer.
Material and Methods: A randomized tamoxifen trial comprising 
1,780 breast cancer patients was conducted in Stockholm, Sweden, 
1976-1990. All patients had lymph node negative primary breast 
cancer and were postmenopausal at the time of diagnosis. The 
patients were randomized to tamoxifen or no endocrine treatment. 
We analyzed the protein expression of CXCL10 and the receptor 
CXCR3A with immunohistochemistry using tissue microarrays, 
which were constructed from paraffin blocks originating from 912 
patients. CXCL10 and CXCR3A could be scored in 793 (87%) and 
735 (81%), respectively.
Results: High expression of CXCL10 was associated with significant 
benefit of tamoxifen treatment concerning local recurrence and 
breast cancer survival (P=0.02 and P=0.008). For patients with high 
CXCL10 expression, tamoxifen decreased the risk concerning local 
recurrence (rate ratio (RR) = 0.56, 95% C.I. 0.33-0.97, P=0.0029) 
and breast cancer survival (RR 0.6 95% C.I. 0.39-0.97, P=0.023).
High expression of CXCR3-A was associated with significant benefit 
of tamoxifen treatment concerning total recurrence and breast cancer 
survival (P=0.00001 and P=0.004, respectively). For patients with 
high CXCR3-A expression, tamoxifen decreased the risk of total 
recurrence (RR 0.54 95% C.I. 0.35-0.83, P=0.005) and breast cancer 
survival (RR 0.49 95% C.I. 0.35-0.69, P=0.00003). On the opposite, in 
the cohort of patients with no endocrine treatment and high CXCR3-A 
expression, there was an increased risk of total recurrence (P=0.003). 
(RR 2.07 95% C.I. 1.18-3.61, P=0.011).
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Conclusions: This study indicates that high expression of CXCL10 
can be used as predictive markers for tamoxifen treatment. Further, 
high expression of CXCR3-A is related to bad prognosis and predicts 
tamoxifen treatment in breast cancer patients. This needs to be further 
evaluated.
P1-06-07
TIMP-1 in Combination with HER2 and TOP2A for Prediction 
of Benefit from Adjuvant Anthracyclines in High Risk Breast 
Cancer Patients.
Hertel PB, Tu D, Ejlertsen B, Jensen M-B, Balslev E, Jiang S, 
O’Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner 
N, Nielsen TO. Faculty of Life Sciences, Univ of Copenhagen, 
Copenhagen, Denmark; National Cancer Institute of Canada, 
Kingston, ON, Canada; Rigshospitalet, Copenhagen, Denmark; 
Danish Breast Cancer Cooperative Group, Copenhagen, Denmark; 
Herlev Hospital, Herlev, Copenhagen, Denmark; Mount Sinai 
Hospital, Toronto, ON, Canada; University of Toronto, Toronto, 
ON, Canada; University of British Columbia Vancouver, Vancouver, 
BC, Canada
Purpose: HER2 amplification, TOP2A aberrations and absence of 
TIMP-1 (Tissue Inhibitor of Metalloproteinase-1) expression in 
breast carcinomas have been associated with incremental benefit from 
anthracycline-containing adjuvant chemotherapy in several reports. 
In the DBCG 89D trial, we demonstrated that the predictive value of 
these markers improved when they were combined in a profile and 
the present study was undertaken to validate these findings in NCIC 
CTG MA.5, a similar but independent clinical trial.
Design: TIMP-1 was examined by immunohistochemistry in archival 
tumor tissue from 403 of 716 premenopausal high-risk patients with 
known HER2 and TOP2A status who were randomized to CEF or 
CMF in the MA.5 trial. Patients were classified according to 2 pre-
defined marker profiles – the HT profile (HER2, TIMP-1) and the 2T 
profile (TOP2A, TIMP-1) and the statistical analyses were performed 
as closely as possible to the analytical approach used previously in 
the MA.5 trial and when analysing the biomarker profiles in the 
DBCG 89D trial.
Results: 98 (24%) patients had no TIMP-1 staining of tumor cells, 
27% were HER2 amplified, and 18% were TOP2A aberrant. 44% 
of patients were classified as HT responsive (HER2-positive and/or 
TIMP-1 negative) and 37% as 2T responsive (TOP2A aberrant and/
or TIMP-1 negative). There was no heterogeneity in treatment effect 
of CEF versus CMF according to TIMP-1. In HT responsive patients, 
CEF was superior to CMF with improved RFS (adjusted HR, 0.64; 
95% CI, 0.42 to 0.98) and a borderline-significant improvement 
in OS (adjusted HR, 0.66; 95% CI, 0.42 to 1.04). A significant HT 
profile versus treatment interaction was detected for OS (P=0.03). In 
2T responsive patients, CEF was superior to CMF with borderline 
significant improvement in RFS (adjusted HR, 0.67; 95% CI, 0.43 
to 1.03), and with improvement in OS (adjusted HR, 0.58; 95% CI, 
0.36 to 0.93). A significant 2T profile versus treatment interaction 
was detected for OS (P=0.01).
Conclusion: In the MA.5 trial, we have validated the HT and 2T 
profiles as predictors of incremental benefit from anthracycline-
containing chemotherapy. The proportion of patients categorized as 
anthracycline responsive increases from 18-27% using individual 
markers to 37-44% when combining TIMP-1 with either HER2 or 
TOP2A. Patients with responsive profiles had a 34-42% relative 
reduction in mortality when treated with CEF. In contrast, patients 
with non-responsive profiles (56-63% of patients) had no incremental 
benefit from CEF compared with CMF. All 3 biomarkers are easily 
applied in the pathology lab and as such could be used in daily clinical 
practice to select patients for anthracycline or non-anthracycline 
containing adjuvant chemotherapy.
P1-06-08
Effect of Treatment Emergent Symptoms on Relapse Free 
Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled 
Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-
Menopausal Women in Early Breast Cancer.
Chapman J-AW, Shepherd LE, Le Maitre A, Pritchard KI, Graham 
BC, Gelmon KA, Bramwell VH. NCIC Clinical Trials Group, Queen’s 
University, Kingston, ON, Canada; University of Toronto, Toronto, 
ON, Canada; BCCA - Vancouver Cancer Centre, Vancouver, BC, 
Canada; Tom Baker Cancer Centre, Calgary, AB, Canada
Background: Evidence from the ATAC trial that vasomotor or joint 
symptomatology by 3 months is associated with reduced recurrence 
after 3 months led to an interest in examining this phenomenon in 
other aromatase inhibitor trials. We examined here whether there is 
such an association in the context of a placebo-controlled tamoxifen 
therapy trial.
Methods: NCIC CTG MA.12 is a randomized placebo-controlled trial 
of tamoxifen (TAM) after adjuvant chemotherapy for pre-menopausal 
women with early breast cancer. Eligible patients were included if 
they received some protocol therapy, were alive and disease-free at 
3 months: 1.) without prior grade 3/4 vasomotor or joint symptoms 
(N=293; only 3 patients had prior grade 1/2 vasomotor or joint 
symptoms); separately, 2.) all patients with/without prior vasomotor 
or joint symptoms (N=631). Vasomotor symptom at 3 months was 
adverse reporting of any grade of hot flashes and/or sweating , while 
joint symptom was any adverse event reporting of pain –joint, pain 
–muscle, pain –bone, arthritis, joint –function, or musculoskeletal –
other. Exact Fisher tests were used to examine associations between 
baseline patient and tumour characteristics, treatment arm, and the 
development of symptomatology. Univariate testing of effect of 
symptomatology on relapse-free survival (RFS) was with a stratified 
Cox model, and multivariate was with stratified step-wise forward 
Cox modeling.
Results: MA.12 accrued 672 patients, and the median follow-up for this 
investigation was 9.7 years. Excluding patients with prior vasomotor 
or joint symptoms, 27.3% of 293 patients reported vasomotor or joint 
symptoms by three months, all of which was vasomotor. Meanwhile, 
20.8% of all 631 patients had symptomatology by 3 months: 19.2% 
reported vasomotor alone, 1.1% joint alone, and 0.5% both. With no 
prior symptoms, 23.4% on placebo (P) and 31.7% on TAM developed 
symptomatology; age was the only baseline factor with significant 
differences at 3 months (p=0.01), with under 40 years 18% of women 
on TAM and 8% on P, and 50 or older, 21% on TAM and 14% on P 
being symptomatic. For all patients, 20.1% on P and 21.4% on TAM 
reported symptomatology by 3 months, and there was weak evidence 
that those >50 on TAM had more symptoms (p=0.06). Vasomotor and 
joint symptoms did not exhibit significant univariate or multivariate 
effects on RFS (without prior symptoms, respectively, p=0.98 and 
p=0.90; for all patients, p=0.99 and p=0.93).
Discussion: We did not observe any association of vasomotor or 
joint symptoms by 3 months and relapse-free survival after 3 months 
in the MA.12 placebo-controlled trial of tamoxifen therapy in pre-
menopausal women. This mirrors the results we observed in our 
MA.27 trial of exemestane versus anastrozole in postmenopausal 
women, and points to the simple metric of early symptomatology 
not being a universal predictor of reduced relapse.
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Patient-Specific Integrative Pathway Analysis Using PARADIGM 
Identifies Key Activities in I-SPY 1 Breast Cancer Patients 
(CALGB 150007/150012; ACRIN 6657).
Wolf DM, Yau C, Benz S, Vaske C, Stuart J, Roy R, Olshen A, Boudreau 
A, Haussler D, Gray J, Spellman P, Davis S, Hylton N, Van ‘t Veer L, 
Esserman L. University of California, San Francisco; University of 
California, Santa Cruz; Oregon Health & Science University; I-SPY 
1 Trial Investigators
Background: A major challenge in interpreting high-throughput 
multianalyte genomic data sets such as those produced by the ISPY 
clinical trials is data integration and interpretation within the context 
of biologically relevant pathways. To address this need, the data 
analysis tool PARADIGM (PAthway Recognition Algorithm using 
Data Integration on Genomic Models) was developed to infer the 
activities of genetic pathways by integrating any number of functional 
genomic data sets for a given patient sample into a pathway activity 
profile.
Methods: We used PARADIGM to integrate gene expression (Agilent 
44K) and DNA copy number data (AFFY 22K and 330K MIP) 
from 133 ISPY-1 patients into pathway component activity levels 
for approximately 1400 curated signal transduction, transcriptional 
and metabolic pathways superimposed onto a single non-redundant 
‘SuperPathway’. These pathway activities then become the substrate 
for statistical analyses to identify pathways characterizing different 
breast cancer subtypes, as well as those associated with recurrence 
and response to neoadjuvant chemotherapy within breast cancer 
subgroups. To identify subtype-specific pathway activities, we used 
ANOVA for initial feature filtering followed by Tukey analysis with 
Benjamini Hochberg multiple testing correction. For other binary 
outcome comparisons we used Mann-Whitney (2-sample Wilcoxon) 
analysis. PARADIGM results were corroborated with pathway 
enrichment analysis and filtered for significance.
Results: In agreement with breast cancer cell line and other prior 
studies, basal-like and triple negative cancers are dominated by 
upregulation of the FOXM1 and MYC/Max subnetworks and 
downregulation of the FOXA1/ER signal transduction pathway, 
the converse of the activity pattern seen in luminal breast cancers. 
These and other subtype associations pass stringent multiple testing 
corrected significance tests. Though an association study of recurrence 
over the entire patient cohort mostly yields pathways characteristic 
of basal-like tumors, alternative pathway associations emerge when 
subtypes are analyzed individually for outcome and significance 
tests are relaxed to include features that pass un-corrected Wilcoxon 
significance tests and also generate highly significant pathway 
enrichment scores. Subtype-specific drivers of recurrence and 
chemo-resistance supported by this level of evidence include ALK1/2 
(TGFB-BMP) and p53 effector signaling for basals and Syndecan-1 
and c-MYC for luminals. Chemo-sensitivity pathways, assessed by 
association with pCR and RCB1, appear to be subtype-specific as well, 
with HDAC class 1 signaling, LRP6-Wnt, and IRE1alpha chaperones 
dominating basal-like cancers and c-MYB activity dominating Her2+ 
cancers, whereas chemo-sensitivity of HR+Her2- cancers though 
rare appears to be driven by the DNA damage axis (BRCA/BARD1).
Conclusion: These and other similar analyses suggest that patients 
with TN or basal-like disease might benefit from the addition of ALK1 
pathway inhibitors to treatment, whereas high risk HR+ patients might 
benefit from Syndecan-1 inhibitors. C-MYC/MAX inhibitors might 
benefit all high risk patients.
P1-06-10
Lobular Breast Cancer and NAC: Combined Results from the 
NKI and I-SPY 1 Trial.
Mukhtar RA, Lips E, Wesseling J, Livasy C, Yau C, Berry D, van’t 
Veer L, Carey LA, Esserman LJ, Rodenhuis S, I-SPY Investigators, 
Hwang ES. UCSF; Netherlands Cancer Institute; University of North 
Caroline, Chapel Hill; MD Anderson
Background
The benefits of neoadjuvant chemotherapy (NAC) in breast cancer 
are twofold: allowing breast conservation surgery, and assessment 
of response. Having pathologic complete response (pCR) predicts 
improved outcomes. Many have suggested that invasive lobular 
cancers (ILC) do not respond to NAC as well as invasive ductal 
cancers (IDC), and recommend against offering NAC in such cases. 
We previously investigated differences in the response to NAC in ILC 
and IDC in the I-SPY 1 Trial, and now present findings from a joint 
analysis with the Netherlands Cancer Institute (NKI).
Methods
We combined datasets comprising 676 patients (221 from I-SPY, 
455 from NKI) enrolled in NAC trials. Eligible patients had palpable 
tumors ≥ 3 cm, and underwent serial biopsies, microarray analysis 
(Agilent 44K for I-SPY and Illumina 6v3 for NKI), and MRI imaging. 
ILC versus IDC histology was assigned by pathologic appearance, and 
ILCs were tested for e-cadherin expression and centrally reviewed by 
a breast pathologist at each site. We performed multivariate logistic 
regression analyses to assess differences in pCR. We compared 
intrinsic subtypes, prognostic gene signature expression, and MRI 
phenotypes.
Results 
There were 75 ILC and 601 IDC cases. ILCs had lower risk features 
and were more likely hormone receptor + (Table 1) but there was 
substantial heterogeneity and many ILC had high risk features. There 
were fewer T2 (33% versus 48%) but more T3 tumors (59% versus 
37%) among the ILCs. Nearly 10% of ILC cases had the basal intrinsic 
molecular subtype; 22% expressed the activated wound healing 
signature, and 56% had a high risk 70-gene prognostic signature. 
While pCR rate was lower in ILCs, adjustment for low risk features 
showed lobular histology was not an independent predictor of pCR. 
ILC was less likely to present as a solid mass. 85% of ILC were 
e-cadherin negative.
Characteristics of ILC versus IDC
 Overall ILC IDC pvalue
PathCR    0.008
 152 (22.7%) 8 (10.7%) 144 (24.2%)  
     
Grade 3    <0.001
 214 (43.9%) 2 (3.9%) 212 (48.6%)  
     
Marker subtypes    <0.001
HR+/Her2- 331 (49.3%) 59 (78.7%) 272 (45.6%)  
HR+/Her2+ 92 (13.7%) 10 (13.3%) 82 (13.7%)  
HR-/Her2+ 82 (12.2%) 3 (4%) 79 (13.3%)  
HR-/Her2- 166 (24.7%) 3 (4%) 163 (27.4%)  
     
Intrinsic Subtypes    <0.001
Lum A 131 (31.6%) 29 (70.7%) 102 (27.4%)  
Lum B 82 (19.8%) 2 (4.9%) 80 (21.5%)  
Her 2 66 (15.9%) 2 (4.9%) 64 (17%)  
Basal 101 (24.4%) 4 (9.8%) 97 (26%)  
Normal 34 (8.2%) 4 (9.8%) 30 (8%)  
     
Wound healing sig activated    <0.001
 250 (60.4%) 9 (22%) 241 (64.6%)  
     
HIgh risk 70 gene sig    <0.001
 359 (86.7%) 23 (56%) 336 (90%)  
     
MRI Pattern    <0.001
Mass 179 (41.5%) 6 (13%) 173 (44.9%)  
Multinodular 127 (29.5%) 26 (56.5%) 101 (26.3%)  
Diffuse 125 (29%) 14 (30.4%) 111 (28.8%)  
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Conclusions
This combined analysis suggests that the decreased response to NAC 
in ILC is due to the association between ILC and low risk features. 
ILC in a clinically high risk setting has a higher proportion of high 
risk biology in spite of lobular histology. Lobular histology alone 
should not be used to exclude patients from NAC trials or treatment.
P1-06-11
Comparison of Community and Central Her2 Assessment on 
Outcome of Neoadjuvant Chemotherapy in the I-SPY Trial.
DeMichele A, Yau C, Zhu J, Wuhfkuhle J, Lenburg M, Buxton M, 
Davis S, Mies C, Livasy C, Chin K, Gray J, Carey L, Esserman L, 
Petricoin E. Abramson Cancer Center, University of Pennsylvania, 
Philadelphia, PA; University of California, San Francisco, CA; 
George Mason University, Fairfax, VA; University of California, 
Santa Cruz, CA; Carolina HealthCare System, Charlotte, NC; Oregon 
Health Sciences University, Portland, OR; The University of North 
Carolina at Chapel Hill, Chapel Hill, NC; University of Pennsylvania, 
Philadelphia, PA
Background: Her-2/neu overexpression, by immunohistochemistry 
(IHC) or fluorescence in-situ hybridization (FISH), is highly 
correlated with response to trastuzumab and these are currently the 
gold-standard, FDA-cleared testing methods for assigning treatment 
to Her-2-directed therapies. However, substantial variability has 
been documented between community and central laboratory IHC 
and FISH testing. Biologically, Her-2 overexpression may reflect 
increased gene copy number, gene expression and/or protein 
production, and these can be measured by other platforms, including 
comparative genomic hybridization (CGH), expression arrays and 
quantitative protein assays, respectively. We sought to determine 
the degree to which community IHC/FISH results differed from 
centrally-assessed IHC, FISH, and other assessment platforms within 
the I-SPY Trial and whether response to neoadjuvant chemotherapy 
(NAC) differed by platform.
Methods: The I-SPY Trial enrolled 237 women 2002-06 with 
invasive breast tumors at least 3 cm in clinical/radiographic size 
who subsequently underwent anthracycline/taxane NAC, serial 
core biopsies and imaging. Pathologic complete response (pCR) 
was determined at time of surgery and 3-year follow up has been 
reached. Trastuzumab was given to Her2+ patients at physician 
discretion, based upon community IHC/FISH results, and became 
more widespread after 2005. Central I-SPY laboratories determined 
Her2 copy number by MIP array, gene expression by Affymetrix 
and Agilent arrays, and Her2 protein by reverse-phase protein array 
(RPMA). Unsupervised clustering algorithms were used to evaluate 
expression patterns. Composite variables were constructed for DNA, 
RNA and protein positivity as well as for community and central 
IHC/FISH. Platforms were compared and Kaplan-Meier curves were 
constructed to compare outcomes by platform.
Results: 222 women were evaluable, though not all patients had 
results for all platforms. Community composite IHC/FISH was 
positive in 64/214 (30%) but only 41 of these (64%) were confirmed 
by central IHC/FISH and 4 additional cases were centrally positive 
despite negative community testing. Concordance was high among 
centrally-assessed Her2 platforms, but was lower between community 
IHC/protein and central RNA (90%), DNA (91%) and protein (91%). 
Among patients receiving trastuzumab (n=36), the pCR rate was 
~50% regardless of Her2-assessment platform; in contrast, those 
not receiving trastuzumab had pCR rates below 30%. Among the 
64 patients deemed Her2+ by community IHC/FISH, 30 (48%) had 
pCR and 15 (25%) have had distant relapse. Five distant relapses 
have occurred despite pCR; all received trastuzumab, all were Her2 
positive by multiple central platforms and 3/5 were ER-positive. Sites 
of distant relapse included brain, bone and viscera; only 1 of 5 had 
isolated brain relapse.
Conclusions: Community IHC/FISH testing for Her2 expression in 
the I-SPY Trial overcalled Her2 positivity compared to central testing 
while central results were highly concordant among DNA, RNA 
and protein platforms. Despite the high rate of community “false 
positives”, relapse after pCR occurred only in central Her2 “true 
positives,” exclusively among those receiving trastuzumab, and was 
rarely isolated to CNS sanctuary sites.
P1-06-12
Circulating Tumor Cells (CTC) Monitoring during Phase II Study 
with Lapatinib (L) and Capecitabine (C) in Patients with Brain 
Metastases from HER2-Positive (+) Metastatic Breast Cancer 
(MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE 
Study.
Pierga J-Y, Cropet C, Tresca P, Dalenc F, Romieu G, Campone M, 
Mahier Aït-Oukhatar C, Le Rhun E, Gonçalves A, Leheurteur M, 
Domont J, Gutierrez M, Curé H, Ferrero J-M, Labbe-Devilliers C, 
Bidard F-C, Bachelot T. Institut Curie & Universite Paris Descartes, 
Paris, France; Centre Léon Bérard, Lyon, France; Institut Claudius 
Regaud, Toulouse, France; Centre Val d’Aurelle, Montpellier, 
France; Institut de Cancérologie de l’Ouest, Nantes, France; R&D 
Unicancer, Paris, France; Centre Oscar Lambret, Lille, France; 
Institut Paoli Calmettes, Marseille, France; Centre Henri Becquerel, 
Rouen, France; Institut Gustave Roussy, Villejuif, France; Institut 
Curie - Hôpital René Huguenin, Saint-Cloud, France; Institut Jean 
Godinot, Reims, France; Centre Antoine Lacassagne, Nice, France
Background: Decrease of CTC level during treatment in MBC has 
been reported as an independent prognostic and predictive factor of 
patients’ outcome. Monitoring CTC in addition to clinical response 
criteria is currently evaluated in early clinical trials in various cancer 
types. We sought to evaluate the clinical interest of peripheral blood 
CTC for patients included in the LANDSCAPE study which assessed 
the efficacy of upfront systemic treatment with L+C for newly 
diagnosed brain metastasis.
Methods: This analysis is a preplanned secondary endpoint of 
the LANDSCAPE study. Eligible pts had HER2+ MBC with BM 
not previously treated with WBR, C or L. Pts received L1250 mg/
day and C2000 mg/m2/day, days 1-14, every 21 days. The primary 
endpoint was a centrally assessed CNS objective response (CNS-
OR) defined as a ≥50% volumetric reduction of CNS lesions in the 
absence of increasing steroid use, progressive neurologic symptoms or 
progressive extra-CNS disease. CTC were detected in 7.5 ml of blood 
using the CellSearchSystem™, combining EpCAM immunomagnetic 
selection (IMS) followed by anti-cytokeratin (A45B/B3) fluorescently 
staining for CTC at baseline and at day (D) 21, before cycle 2.
Results: From 04 /2009 to 08/2010, 45 pts were enrolled, 41 were 
evaluable for CTC at baseline and 38 at D21. Median age was 56 
(range 35 to 79). PS was >1 only in 2 pts. At baseline, 20/41 (48.8%) 
pts had ≥ 1CTC and 9 (22%) ≥ 5CTC (range 1-301, median 3). CTC 
were detected in pts with (18/37) or without disease outside SNC 
(2/6) (p=0.63). At a median follow-up of 10 months (range 2.9-
16.5), median TTP was 6.0 months [95% CI 4.9; 7.4] vs. 4.3 [2.8; 
5.9] months for pts without and with CTC at baseline respectively 
(p=0.14). After 21 days of treatment, a disappearance of CTC was 
observed in 11pts (31%). At D21, only 7 (18.4%) pts had ≥ 1CTC 
and 3 (8%) ≥ 5 CTC (p=0.006, D21 vs. baseline). In 43 evaluable 
pts, CNS-OR rate was 67% (95%CI 51-81), with a median time 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011181s
December 6-10, 2011 Abstracts: Poster Session 1
from inclusion to response of 1.8 month. Absence of CTC was not 
correlated with CNS-OR rate at baseline (17/21 (81%) vs. 11/19 
(58%), NS). Strikingly, remaining positivity for CTC at D 21 (≥ 
1CTC) was correlated with a poor response rate in CNS: 2/6 (33.3%) 
vs. 25/31 (80.6%) in pts with 0 CTC, p=0.03.
Conclusions: Early decrease (at D 21) in CTC level is correlated with 
a high response rate in newly diagnosed BM to L + C and underlines 
the predictive value of this blood marker in MBC pts even for brain 
metastasis. Longer follow-up is needed to assess its prognostic value 
under antiHER2 targeted therapy.
P1-06-13
An Amplicon-Driven Aromatase Inhibitor Response (ADAIR) 
Signature Provides an Orthogonal Risk Classifier for ER+ Breast 
Cancer.
Luo J, Chang L-W, Van Tine BA, Tao Y, Hoog J, Giuntoli T, Davies 
SR, Snider J, Leung S, DeSchryver K, Allred C, Vickery T, Alldredge 
P, Mardis E, Nielsen TO, Parker JS, Prat A, Perou CM, Ellis MJ. 
Washington Univeristy in St. Louis, St. Louis, MO; Washington 
University in St. Louis, St. Louis, MO; University of British Columbia, 
Vancouver, BC, Canada; University of North Carolina, Chapel Hill, 
NC
Background: Many gene signatures have been proposed to predict 
outcomes for estrogen receptor positive (ER+) breast cancer; most are 
solely based on mRNA expression data without integration of genomic 
aberrations that are the primary drivers of disease. We coupled gene 
expression and copy number variation data to improve the current 
generation of prognostic algorithms.
Methods: mRNA expression based discovery was conducted in 
167 patients with low (<10%) or high (>10%) levels of Ki67 after 
neoadjuvant aromatase inhibition. Genes that were significant 
in SAM analysis (q ≤0.05) were used if significantly correlated 
(P≤0.05) with copy number gains detected by aCGH. Interrogation 
for association with relapse-free survival (RFS) (P≤0.05) in a large 
public microarray dataset produced an Amplicon-Driven Aromatase 
Inhibitor Response (ADAIR) signature. Each gene was subject to 
rigorous independent validation in public microarray datasets and by 
NanoString on archival tumor RNA accrued from patients treated with 
adjuvant tamoxifen (UBC-TAM) that were previously profiled for 
PAM50 subtyping and risk of relapse (ROR) analysis. To determine 
underlying biology, pathway and transcriptional factor (TF) network 
analyses were conducted.
Results: A 54-gene ADAIR signature of 27 FR(favorable response) 
and 27 UR(unfavorable response) genes was chosen based on 
statistical and genomic information. 80% of the ADAIR genes were 
univariately prognostic for RFS in UBC-TAM. The multigene-based 
ADAIR risk classifier of endocrine sensitive, intermediate and 
insensitive categories were prognostic for relapse in the combined 
public data (p=2.72e-08) and UBC-TAM (p=1.51e-08). Multivariable 
survival analysis showed that ADAIR was independently prognostic 
from standard clinical variables. The ADAIR risk classifier was highly 
concordant with the PAM50-gene based intrinsic subtype and ROR 
using subtype information (ROR-S) in all datasets in the analysis 
(for ROR-S, p=3.50E-44 in combined public data and p=2.16E-47 
in UBC-TAM). ADAIR significantly stratified the patients in the 
medium ROR subtype risk group (p= 0.007 in public cohort, p=0.005 
in TAM), suggesting clinical utility. Pathway analysis indicated that 
the FR gene signature was enriched for cell survival genes, while 
UR genes were largely cell cycle related. Two major TFs, E2F1 
and GABPB1 were predicted to regulate 22 and 13 signature genes. 
Amplification/overexpression of E2F1 regulated genes characterizes 
the UR signature. In contrast, the FR signature downregulates the 
transcriptional repressor GABPB1, resulting in upregulated NFKB1 
possibly mediating a survival response.
Conclusions: These data suggest that current gene expression 
signatures can be improved upon through the inclusion of genes 
whose over-expression is linked to the gene copy number gains typical 
of the ER+ breast cancer genome. Functionally, tumors sensitive 
to estrogen deprivation are associated with genes that promote cell 
survival, whereas resistant tumors are associated with genes that drive 
estrogen independent cell cycle progression. This study underscores 
the profound differences in the transcriptome of estrogen-dependent 
and independent breast cancer beyond the patterns identified by the 
established classifiers.
P1-06-14
Topoisomerase II alpha (Top2a) Protein Expression Is a Predictor 
for Response to Anthracycline-Based Chemotherapy (ATC-CT): 
Is It Due to Gene Amplification, HER2-Coamplification or a 
Summation of Pathways Leading to This Highly Proliferative 
Phenotype?
Abdel-Fatah TMA, Lambros MB, Vatcheva R, Ball G, Dickinson PD, 
Moseley P, Green AR, Ellis IO, Reis-Filho JS, Chan S. Nottingham 
University City Hospital, NHS Trust, Nottingham, Nottinghamshire, 
United Kingdom; The Institute of Cancer Research, London, United 
Kingdom; School of Molecular Medical Science, Nottingham 
University., Nottingham; Nottingham Trent University, Nottingham
Background: The evaluation of Top2a protein may be clinically more 
useful than gene alterations as a predictive marker for ATC-CT. In this 
study we assessed the association between gene copy number, gene 
and protein expressions of both TOP2A and HER2, and their effect on 
clinicopathological outcomes and management of breast cancer (BC).
Methods: 1- To study the response to anthracycline based 
chemotherapy (ATC-CT):
The associations between clinical outcomes and both gene copy 
number changes (using in-situ hybridization; CISH) and protein 
expression (using immunohistochemistry) were studied in the 
neoadjuvant and adjuvant settings: a) 250 locally advanced primary 
BC treated with Neoadjuvant ATC-CT with or without Taxane 
followed by surgery (S) + radiotherapy (RT); pathological complete 
response (pCR) was used as the primary end point (PEP), b) 245 BC 
in which all patients were treated with S + RT followed by Adjuvant 
ATC-CT; progression free survival (PFS) was used as PEP ii) 145 
primary BC overexpressing HER-2 treated with S+ RT followed by 
sequential adjuvant ATC-CT+ trastuzumab; PFS was used as PEP.
2- To study the clinic-pathological association of TOP2A alterations, 
we evaluated TOP2A alterations detected by CISH and IHC in 
unselected series of 1650 consecutive cases of primary BC who 
treated with S + RT and received adjuvant CMF and/or endocrine 
therapies according to Nottingham prognostic index and ER status.
3- To study in details the molecular alterations of TOP2A/HER2, 
in 171 unselected series of primary BC, we evaluated a) gene copy 
number changes using both high resolution oligo array CGH and 
CISH, b) mRNA expression using Agilent gene expression array and 
c) protein expression using IHC. We analysed 48,000 gene transcripts 
using Artificial Neural Networks (ANN) and pathway analysis to 
identify genes and biological pathways that related to TOP2A gene 
alterations.
Results: 
1) In the ATC-CT neoadjuvant series, the pCR rate was 32/115 
(28%) in tumours expressing high levels of Topo2A, compared to 
5/74 (7%) in tumours expressing low levels of Topo2A (p<0.0001). 
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In multivariate analysis, Top2A overexpression was an independent 
predictor for pCR (HR 5.1, CI 95%; 1.4-18.4, p<0.001).
2) TOP2A overexpression was strongly associated with mitotic index, 
histological grade, KIF2C, loss of p53 function and the absence of 
both BRCA1 and ATM inactivation (p<0.0001).
3) ANN and pathway analysis revealed that TOP2A-strongly 
correlated genes are involved in: mitotic cell cycle regulation 
especially M phase and cell division (AURKB, KIF2C, BRIC5, 
ASPM, CCNA2, BUB1, FBXO5, PTTG1, CDCA5, CDCA3 
CDCA8), Kinesin and microtubules regulator genes (KIF2C, KIF11, 
KIF14, KIF20A, KIF23, and KIFC1), and metastases (BRIC5, 
BUB1B, CCNA2, CCNE, PRRG1, PRM2, STMN1). 
Conclusions: Top2A protein expression is an independent predictor 
for pCR after ATC-CT treatment. The high response rate of top2A 
protein overexpression supports the theory that Top2a protein is a 
direct target of ATC-CT in these highly proliferative tumour cells. 
Furthermore, evaluation of Top2A protein may lead to a clinically 
useful test.
P1-06-15
A Genomic Predictor Developed from Breast Cancer Cell Lines 
Predicts Both Disease-Free Survival and Overall Survival 
in Breast Cancer Patients Treated with Doxorubicin and 
Cyclophosphamide: A Collaborative Project of the NSABP and 
Precision Therapeutics.
Shen K, Tang G, Kim C, Pogue-Geile K, Anderson SJ, Constantino 
JP, Bear HD, Song N, Tian C, Gabrin MJ, Zhang Y, Geyer, Jr 
CE, Wolmark N. Precision Therapeutics, Inc., Pittsburgh, PA; 
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, 
PA; University of Pittsburgh Graduate School of Public Health, 
Pittsburgh, PA; Virginia Commonwealth University, Richmond, VA; 
Allegheny General Hospital, Pittsburgh, PA
Background: A cell line-derived multigene predictor of tumor 
response to doxorubicin + cyclophosphamide (MGP-AC) has been 
shown to predict the pathological complete response (pCR) in breast 
cancer patients from the National Surgical Adjuvant Breast and Bowel 
Project (NSABP) Protocol B-27. However, a cell line-derived MPG 
for doxorubicin + cyclophosphamide + docetaxel (MGP-ACT) was 
not predictive in patients from B-27. The purpose of this study was 
to further assess the performance of these predictors on disease-
free survival (DFS) and overall survival (OS) in the same patient 
populations.
Methods: NSABP B-27 was a 3-arm trial of 2411 early-stage breast 
cancer patients randomized to receive 4 cycles of preoperative 
doxorubicin+cyclophosphamide (AC) or 4 cycles of AC followed 
by 4 cycles of docetaxel either pre-op (AC+T) or post-op (AC→T). 
MGPs for AC and ACT were developed based on the in vitro assay and 
microarray genomic profiles of 40 breast cancer cell lines. A higher 
MGP score indicates lower chemoresponse sensitivity.
Results: 322 patients with available microarray data were included 
for this analysis (103 treated with AC, 102 with AC+T, and 117 with 
AC→T). For patients treated with AC, a higher MGP-AC score was 
significantly associated with increased risk of disease progression 
(standardized hazard ratio [HR] [SD set to 1]=1.48, 95% confidence 
interval [CI]=1.02-2.15, p=0.043) or death (standardized HR=1.66, 
95% CI=1.06-2.62, p=0.028) after adjusting for clinical covariates 
(ER status, clinical tumor size, lymph node status, and age). The 
addition of MGP-AC to the clinical model improves the accuracy in 
predicting five-year DFS: the area under the ROC curve improved 
from 63% to 72%. For patients treated with AC+T or AC→T, MGP-
ACT was not predictive of either DFS (standardized HR=1.03, 
95% CI=0.78-1.37, p=0.818) or OS (standardized HR=1.05, 95% 
CI=0.73-1.51, p=0.8).
Conclusions: A cell line-derived MGP for AC that was predictive 
of pCR was also predictive of DFS and OS in breast cancer patients 
treated with neoadjuvant AC. The MGP for ACT, which was not 
predictive for pCR, was not predictive of either DFS or OS in patients 
who received docetaxel after AC.
The B-27 study was funded by NCI PHS grants U10-CA-37377, U10-
CA-69974, U10-CA-12027, U10-CA-69651, and U24-CA-114732, 
and received additional support from sanofi-aventis.
P1-06-16
BRCA2 Mutation Carriers Respond Poorly to Conventional 
Anthracylins/Taxanes-Based Neo-Adjuvant Chemotherapy.
Raphael J, Caron O, Rimareix F, Spielmann M, Al Ghuzlan A, Mathieu 
M-C, Delaloge S. Institut Gustave Roussy, Villejuif, France
Background: BRCA2 carriers typically develop luminal B-type breast 
cancers. Their exact sensitivity to conventional chemotherapy remains 
unclear. Promising drugs such as parp inhibitors are currently being 
developed in this indication. We attempted to evaluate pathological 
response rates of BRCA2 carriers in current the routine setting.
Patients and methods: we screened our database of all patients seen 
at our genetic clinic over the past 15 years who were completely 
tested for BRCA1 and BRCA2 mutation and had received primary 
anthracyclines/taxanes-based chemotherapy (6-8 cycles) for invasive 
breast cancer as primary care. The pathological responses of pts who 
tested positive for BRCA2 were compared to those of BRCA1 and 
BRCA2-negative patients who had been diagnosed with luminal 
breast cancer (ER-positive, Her2-negative).
Results: Among 155 BRCA2-carriers and 503 wild-type patients, 
24 BRCA2 pts and 58 pts with luminal B-type breast cancer have 
received primary standard anthracyclin/taxane-based chemotherapy. 
Median age was 38 for both populations. Median tumor size was 
45 and 40 mm respectively among carriers and WT pts. 60% of 
BRCA2 and 100% of WT luminal B pts had ER-positive disease. A 
pathological complete response occurred in 18% of BRCA2 carriers 
and of 39% of luminal B Wt-pts. 65% of BRCA2 and 51% of WT-pts 
pts remained node-positive.
Conclusion: Deleterious germline mutations of BRCA2 are associated 
with a low probability of complete pathological response and a high 
risk of axillary invasion after conventional primary chemotherapy. 
Alternative treatments are highly expected.
P1-06-17
A New Pathological Response Index (PRI) for Neoadjuvant 
Chemotherapy Accurately Predicts Clinical Outcomes of Locally 
Advanced Breast Cancers (LAPBC).
Abde-Fatah TMA, Mosley P, Lee A, Balls G, Ellis IO, Chan S. 
Nottingham University City Hospital, Nottingham, Nottinghamshire, 
United Kingdom; Nottingham University, Nottingham, United 
Kingdom; The Institute of Cancer Research, London; Nottingham 
Trent University
Pathological complete response (pCR) after neoadjuvant chemotherapy 
predicts overall survival that is independent of treatment regimen. 
However; pCR is not a perfect surrogate for overall survival, given 
that a significant number of patients who did not achieve pCR also 
have a good prognosis and a small number of patients with pCR 
still develop recurrences. Furthermore, residual cancer cells after 
neoadjuvant therapy includes a wide range of responses from near 
pCR to complete resistance.
In this study we performed a comprehensive pathological assessment 
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for 245 surgical specimens of LAPBC, treated at a single institution, 
removed after receiving neoadjuvant anthracycline combination 
chemotherapy only (n=152) or with Taxane (n=93) with median 
follow up 42 months. Progression free survival (PFS) was used as the 
study endpoint. For comparison, residual cancer burden (RCB) was 
calculated using web calculator at www.mdanderson,org/breast_BCR.
A multivariate Cox regression model revealed that size of the residual 
invasive carcinoma (OR; 3.2, CI 95%; 1.6-6.1, p=0.001), presence 
of lympho-vascular invasion (OR; 2.4, CI 95%; 1.3-4.3, p=0.004), 
absence of any pathological evidence of response at the site of the 
primary tumour or axillary lymph nodes after CT (OR; 3.2, CI 95%; 
2.2-8.0, p=0.00001), and presence of at least one apical lymph node 
metastases (OR; 4.2, CI 95%; 1.5-6.8, p=0.003) at surgery were 
significantly associated with shorter PFS. These results were used to 
develop a pathological response index (PRI) from which 5 prognostic 
subgroups with distinct clinical outcomes were identified.
Patients with PRI-PG1 (n=110; 49%) had a good clinical outcomes 
in both ER+ (3-year PFS; 91%) and ER- tumours (3-year PFS; 84%). 
Moreover, patients with PRI-PGI who did not show pCR (n=69) had 
equivalent overall and PFS as those with PRI-PG1 who achieved 
pCR (n=41); p=NS. Patients with PRI-PG2-5, had a 5 fold increase 
in the risk of progression compared to those with PRI-PG1 (HR; 5.2, 
CI 95%; 2.9-9.6, p≤0.0001). ER+ patients with PRI-PG3-5 (25% of 
ER+ cases) had shorter 3-year PFS 30%) compared to those ER+ 
with PRI PG1-2 (91%) despite treatment with adjuvant hormonal 
therapy (HR=6.5, CI 95%; 2.8-14.7, p<0.0001). Similarly, HER2 
positive patients with PRI- PG3-5 (20% of HER2+ patients) showed 
very rapid progression within < 3 years (PFS; 10 %) vs. those with 
PRI-PG1-2 (PFS; 82%) despite trastuzumab treatment (HR=8.4; CI 
95%; 2.8-25.0, p<0.0001).
In conclusion, a pathological response index including size of 
residual tumour, post chemotherapy lymph node pathological stage, 
lympho-vascular invasion and any evidence of fibrotic/response 
reaction following neoadjuvant chemotherapy may accurately predict 
the chance of disease progression, identify a greater proportion of 
patients (>twice as many as pCR) who could potentially benefit from 
the neoadjuvant chemotherapy and may be able to spared further 
adjuvant therapy. Furthermore this new PRI may help to improve 
the sensitivity of pathological response as a study end-point for 
predicting tumours response to a given neoadjuvant regimen and 
enable biological markers to be studied in a good prognostic group 
in additional to pCR.
P1-06-18
Loss of E-Cadherin Expression in Clinical Breast Cancer Is 
Associated with an Adverse Outcome on Tamoxifen.
Hiscox S, Rakha E, Smith C, Farrow L, Gandahara S, Green A, Ellis I, 
Barrett-Lee P, Nicholson RI, Gee J. Cardiff University, Cardiff, Wales, 
United Kingdom; Nottingham University Hospital, Nottingham, 
United Kingdom; Velindre Hospital, Cardiff, Wales, United Kingdom
Background: Despite the benefits provided by tamoxifen, not all ER+ 
patients respond to endocrine therapy and a substantial number of 
patients who initially respond ultimately relapse whilst on therapy, 
with endocrine resistance associating with poorer survival. The ability 
to identify biomarkers predictive of outcome on endocrine treatment 
would enable more effective stratification of patients most likely to 
benefit from such measures. Previously, we reported that tamoxifen 
is able to promote the development of a highly aggressive phenotype 
in ER+, HER2- endocrine-sensitive breast cancer cells in vitro that 
have been depleted of the intercellular adhesion molecule, E-cadherin. 
Here we have investigated the clinical relevance of these observations 
by examining the association between E-cadherin protein expression 
and clinical outcome in a series of primary early stage (Stage I-IIIA) 
invasive ductal carcinomas of the breast.
Material and Methods: A series of 794 ER+ breast cancer tissues 
of known E-cadherin immunohistochemical status (Rakha EA et al 
(2005) Histopathol 46(6)) were available for this study and comprised 
both patients who had received tamoxifen for 5 years (n=345) or who 
had had no endocrine treatment (n=449). E-cadherin was further 
assessed in a group of ER-negative, tamoxifen-treated primary breast 
cancers (n=93) as an internal control. The median E-cadherin H-score 
staining was 120 (range 0 to 300).
Results: Kaplain-Meier survival analysis revealed a significant 
association between reduced E-cadherin expression (< median) and 
overall survival (OS) in the tamoxifen-treated group at 20 years 
(p=0.04; Hazard Ratio [HR]=1.51, 95% CI:1.01-2.26) however 
this relationship was much stronger at 5 years (p=0.02; HR=2.00, 
95% CI:1.10-3.65). In the ER+, tamoxifen-untreated tumours, a 
relationship was observed at 60 months only. Reduced E-cadherin also 
correlated with metastasis (regional and distant, p=0.01; HR=1.90, 
95%CI:1-12-3.24) but only within the tamoxifen-treated group and 
only within the first 5-years, reflecting the time during which patients 
would have received tamoxifen. In the ER-, tamoxifen-treated cohort, 
no adverse impact of reduced E cadherin on these parameters was 
observed. Subgroup analysis of tamoxifen-treated patients revealed 
that the association between E-cadherin loss and adverse outcome 
was apparent in both HER2+ (n=39) and HER2- (n=302) cohorts. 
However, the association was more significant within the HER2+ 
group (p=0.02 for OS; HR=3.45, 95% CI:1.08-11.07) (p=0.03 for 
regional and distant metastasis; HR=2.78, 95%CI:1.02-7.57). These 
data support our in vitro observations that suppression of E-cadherin 
within in ER+, HER2+ breast cancer cell lines results in a significant 
gain in migration and invasion in response to tamoxifen.
Discussion: These results are supportive of our hypothesis that low 
or absent E-cadherin expression in ER+, ductal breast cancer treated 
with tamoxifen predicts poor survival, particularly within the ER+, 
HER2+ phenotype. Of note, the presence of tamoxifen appears to be 
required for this event, suggesting that there is a patient cohort where 
other systemic endocrine therapy should be considered. E-cadherin 
represents a biomarker able to discriminate such cases.
P1-06-19
Absence or Low Levels of c-JunNH2 – Terminal Protein Kinase 
(JNK) Mitogen Activated Protein Kinase (MAPK) Is Related to 
a Luminal B Subtype and an Impaired Survival in Patients with 
an ER Positive Breast Cancer Treated with Adjuvant Tamoxifen.
Linderholm BK, Sanchez-Chavez B, Hellborg H, Johansson UM, 
Lewensohn R, Viktorsson K, Kanter L. Institution of Oncology, 
Sahlgrenska University Hospital, Gothenburg, Sweden; Institution of 
Oncology and Pathology, Karolinska Institute, Stockholm, Sweden; 
Institution of Pathology, Herlev, Denmark
Background: Resistance to endocrine therapy is a clinical problem 
and is not explained by lack or loss of the oestrogen receptor (ER). Up-
regulation of several receptor tyrosine kinases have been correlated 
to diminished effect of endocrine treatment. More contradictory are 
the role of downstream mitogen activated protein kinases (MAPK’s). 
Patients and Methods: We performed a tissue micro array (TMA’s) 
on patients that originate from an earlier presented population of 404 
patients with a steroid receptor positive BC subjected to tamoxifen 
as only adjuvant systemic treatment. Material from 120 patients was 
available for the TMA. JNK, p38 and ERK was determined by use 
of immunohistochemistry and scored 0, +1, +2, +3. Patients were 
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grouped into two categories for statistical analyses. Results: Absence 
or low JNK was statistically significantly correlated with HER2+ 
(p=0.018), a Luminal B like subtype (ER+, high proliferation and/or 
HER2+) (p=0.007), shorter relapse-free (p= 0.0494) and breast cancer 
corrected survival (p=0.0458). High ERK was more frequent among 
node-negative patients (p=0.00469) and more frequent in relapse-free 
patients; RFS (p= 0.225); BCCS (p= 0.0705). High expression of p38 
was associated with p38 previously determined by ELISA (p=0.085) 
and HER2+ (p=0.094), however not reaching statistical significance. 
High p38 was related to increased relapses within the first years but the 
difference vanished with longer follow-up time; RFS (p=0.486) and 
BCCS (p= 0.589). JNK remained as an independent marker of RFS 
in a Cox proportional multivariate analysis (HR=2.19; 95%CI=1.14-
11.41; p=0.029), together with nodal status (HR=3.6; 95%CI=1.44-
8.81; p=0.006) and histological grade (HR=3.1; 95%CI=1.29-7.56; 
p=0.011). Discussion: Our data on ERK and p38 is concordant with 
results from previous published studies. Two studies have shown ERK 
expression, determined by IHC to be correlated with “good prognosis 
features” as smaller tumour size, absence of nodal metastasis, lower 
proliferation and a favourable outcome after adjuvant tamoxifen 
(Svensson et. al. 2005, Bergqvist et. al. 2006). Higher p38 determined 
by use of an ELISA has been suggested as a marker of early relapses 
i.e. intrinsic resistance, although methodological problems must 
be taken into account (Linderholm et. al. 2011). By use of IHC we 
could confirm that patients with higher expression of p38 actually 
had significantly more relapses within early follow-up. JNK was the 
MAPK with the most pronounced effect on survival. Absent or low 
expression was significantly correlated with an impaired survival 
in both uni- and multivariate analyses, a finding to our very best 
knowledge not described before. Low JNK was actually found more 
frequently in patients with a HER2 positive or Luminal B like BC 
(ER+, high proliferation rate or HER2+). Conclusions: Our results 
suggest that MAPK’s can be evaluated by IHC on TMA’s. Absence/
low JNK was significantly correlated with an impaired survival and 
a Luminal B like subtype. Confirming studies in large preferable 
randomised patient populations are warranted.
P1-06-20
Response to Neo-Adjuvant Chemotherapy and Outcomes for 
I-SPY 1 Patients Stratified by the 70-Gene Prognosis Signature 
(MammaPrint) and Molecular Subtyping (BluePrint).
Gluck S, de Snoo F, Tian S, Glas A, van ‘t Veer L. Miller School of 
Medicine, University of Miami, Miami, FL; Agendia, Amsterdam, 
Netherlands; HDFC Cancer Center, UCSF, San Francisco, CA
Background
Classification of breast cancers into molecular subtypes may be 
important for the proper selection of therapy for patients as tumors 
with seemingly similar biology can have strikingly different clinical 
outcomes. We analyzed response to neo-adjuvant chemotherapy as a 
function of molecular sub-types and show patient survival from the 
multi-center neo adjuvant trial, I-SPY I (CALGB 150007/150012; 
ACRIN 6657). Previous analyses had shown that breast cancer 
subtypes as identified by immunohistochemistry or molecular 
analyses, have distinct clinical outcome (Esserman, ASCO 2009). 
Here, we analyze how the 70-gene signature (MammaPrint) together 
with an 80-gene molecular subtyping profile (BluePrint=Basal-type, 
Luminal-type, ERBB2-type; de Snoo, ASCO, 2010 and manuscript 
under review) can sub-classify patients.
Materials
This study was carried out on genomics data of core needle biopsies 
from 149 out of 221 patients enrolled in the I-SPY I trial, a multi-
center trial designed to identify predictive markers of pathological 
complete response (pCR) and disease-free survival (DFS) in women 
with locally advanced breast cancer (3 cm or greater). All women 
received neoadjuvant Doxorubicin & Cytoxan followed by paclitaxel 
chemotherapy. The 70-gene and the subtyping signatures, Basal, 
Luminal and ERBB2-type were determined on 44K Agilent arrays 
available through the I-SPY 1 data portal (Esserman, ASCO, 2009 
and manuscript under review).
Results
The 70-gene signature classified 9% of patients (13/149) as Low 
Risk, of whom one patient was ERBB2-type, and the other 12 
were Luminal-type. None of these patients experienced a pCR. The 
remaining 136 were classified as 70-gene High Risk (91%), of whom 
47% were classified as Luminal-type with a pCR rate of 13%, 41% 
were Basal-type with a pCR rate of 34%, and 12% were ERBB2-type 
with a pCR rate of 56%.
Patients with BluePrint Basal-type tumors had a 5-year DFS of 61%; 
ERBB2-type had a 5-year DFS of 78%; 70-gene High Risk/Luminal-
type had a 5-year DFS of 73% and 70-gene Low Risk/Luminal-type 
showed 5-year DFS of 100%.
The molecular subtype classification shows significant association 
to clinically assessed receptor status. However, clinically assessed 
HER2+ patients were distributed across all molecular subtypes, where 
ER+HER+ are predominantly classified as Luminal-type.
Conclusion
This study was performed with the I-SPY I dataset, which provides a 
platform to compare, contrast & combine marker signatures to tailor 
therapy. We show how combining BluePrint, with MammaPrint risk-
classification can detect specific groups of patients who are at high 
risk of recurrence and who would have a higher likelihood to benefit 
from chemotherapy. Furthermore, MammaPrint Low Risk patients do 
not benefit from neo-adjuvant therapy, though have excellent survival 
rates, suggesting that the Low Risk Luminal-type patients could be 
managed conservatively.
P1-06-21
Relationship between Body Mass Index and Preoperative 
Treatment Response to Aromatase Inhibitor Exemestane in 
Postmenopausal Patients with Primary Breast Cancer.
Takada M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto 
Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Ueno T, 
Sasano H, Toi M. Graduate School of Medicine, Kyoto University, 
Japan; Saitama Medical University, International Medical Center, 
Japan; Osaka National Hospital, Japan; Tokyo Metropolitan Cancer 
and Infectious Diseases Center, Komagome Hospital, Japan; Niigata 
Cancer Center Hospital, Japan; Saitama Cancer Center, Japan; 
Kumamoto University, Japan; National Kyushu Cancer Center, 
Japan; Nagoya City University Hospital, Japan; Hiroshima City 
Asa Hospital, Japan; National Shikoku Cancer Center, Japan; Aichi 
Cancer Center Hospital, Japan; Tohoku University Hospital and 
School of Medicine, Japan
Background:
Some studies have shown that high body mass index (BMI) is 
associated with inferior outcome after adjuvant therapy with non-
steroidal aromatase inhibitor, anastrozole in breast cancer patients. We 
aimed to investigate predictive effect of BMI on clinical response to 
neoadjuvant therapy with steroidal aromatase inhibitor, exemestane 
in postmenopausal patients with primary breast cancer.
Patients and methods:
The study group consisted of 109 patients from the JFMC 34-0601 
neoadjuvant endocrine therapy trial in which postmenopausal patients 
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with estrogen receptor (ER)-positive primary breast cancer were 
administered exemestane (25 mg/day) for 24 weeks before surgery. 
Patients were categorized into three groups according to BMI: low 
(BMI < 22 kg/m2), intermediate (22 ≤ BMI < 25 kg/m2) and high 
(BMI ≥ 25 kg/m2). Statistical analyses were performed to explore the 
predictive effect of BMI on clinical response using a multivariable 
logistic regression model.
Results:
Higher BMI correlated with positive progesterone receptor status (p < 
0.01) and low Ki-67 index (p = 0.03). Objective response rates (ORR) 
were 21.7% in low BMI, 56.0% in intermediate BMI and 60.6% in 
high BMI, respectively (p = 0.01). In a multivariate analysis, only 
low BMI was an independent negative predictor of clinical response.
Conclusion:
Low BMI was associated with a decreased ORR to neoadjuvant 
endocrine therapy with exemestane. Our results may suggest that the 
predictive effect of BMI varies according to the type of aromatase 
inhibitor and objective outcome.
P1-06-22
Identification of Biomarkers in Breast Cancer for Prediction of 
Response to PARP Inhibitor Olaparib.
Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Jakkula 
LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, 
Gray JW, Spellman PT, van ‘t Veer L. Lawrence Berkeley National 
Laboratory, Berkeley, CA; University of California San Francisco, 
San Francisco, CA; The Institute of Cancer Research, London, United 
Kingdom; Oregon Health & Science University, Portland, OR
Background: Poly (ADP-ribose) polymerase (PARP) is an enzyme 
involved in DNA repair. PARP inhibitors operate on the principle of 
synthetic lethality in conjunction with DNA damaging agents, and are 
likely to be useful for treatment of BRCA-mutated cancers and triple 
negative breast cancers exhibiting ‘BRCA-ness’ or other signs of DNA 
repair deficiency. Multiple PARP inhibitors have been developed, such 
as Olaparib (AstraZeneca), BSI-201 (Sanofi-Aventis) and ABT-888 
(Abbott Laboratories). Though some clinical trials have shown drugs 
in this class to be promising, not all results have been positive. As 
PARP inhibitors differ in mechanism of action, dosing interval and 
toxicities, trial results seem to depend on the specific combination 
of PARP inhibitor and patient population. To understand why some 
studies succeeded and others failed and to guide new clinical trials in 
patient selection, there is an urgent need for biomarker identification, 
both for PARP inhibitors in general and for the specific idiosyncratic 
mechanisms of each drug.
Material and Methods: Thirty-three in vitro breast cancer cell lines 
were administered the PARP inhibitor Olaparib, with sensitivity 
to the compound summarized as the dose necessary to kill 50% of 
each culture. mRNA expression (Affymetrix U133A, Exon 1.0ST 
array) and transcriptome sequence (Illumina GAII) were available 
for 22/33 cell lines, among which 9 were sensitive and 13 resistant. 
To obtain robust predictive markers that are minimally dependent 
on the specific PARP inhibitor and expression platform, a bottom-up 
approach was opted for, restricted to genes in the major DNA repair 
pathways. Logistic regression with forward selection was used to 
determine the most important markers, further reduced based on 
consistency across platforms. The weighted voting algorithm was 
used to build the final predictor. Eight U133A data sets with number 
of tumor samples varying from 61 to 289 were subsequently used to 
verify prevalence and to identify the subpopulations that are likely 
to respond according to the predictor. To verify cross-platform 
generalizability, the signature was additionally tested in 430 TCGA 
samples with custom Agilent 244K gene expression.
Results: For the development of a genomic signature that might 
work for multiple PARP inhibitors and expression platforms, prior 
knowledge of DNA repair pathways was incorporated and stringent 
criteria for marker inclusion were applied using three different 
platforms. Eight genes fulfilled the criteria, of which 5 were resistance 
markers and 3 sensitivity markers. When testing the 8-gene signature 
in eight U133A data sets, 40-48% of patients were predicted to be 
responsive to Olaparib. In addition, well-known markers (ER, PR, 
ERBB2, KRT5/17) were examined in patients expressing the 8-gene 
sensitivity signature. A higher percentage of these patients were 
ERBB2-negative and did overexpress KRT5/17, indicative for the 
basal subtype. Prevalence and relationship with these markers were 
confirmed in 430 samples on a distinct platform (Agilent).
Conclusion: Cell line exposure to Olaparib has yielded an 8-gene 
predictor of sensitivity. This signature was observed in a substantial 
fraction of primary breast tumors predicted to benefit from Olaparib.
P1-06-23
Changes in Gene Expression after One Dose of Trastuzumab (T) 
in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of 
Response in HER2 Positive Early Stage Breast Cancer.
Sprecher E, Lezon-Geyda K, Sarkar S, Bossuyt V, Narayaan M, Kumar 
A, Krop I, Winer E, Tuck D, Kleinstein S, Harris L. Yale University, 
New Haven, CT; Yale University; Beckman Coulter; Stony Brook 
University Hospital, Stony Brook, NY; Dana-Farber Cancer Institute, 
Boston, MA
Introduction: Trastuzumab is a targeted therapy against the HER2 
cell surface receptor and has greatly improved prognosis for HER2+ 
breast cancer patients. Despite decades of research, the mechanism 
of action of T remains unclear and mechanisms of resistance have 
not been adequately defined. We sought to determine if models of 
response and resistance in vitro could identify biomarkers in vivo in 
HER2+ early breast cancer.
Methods: BT474 and UACC812 cell lines were treated with 10ug/
ml T for 0 and 24 hours. Fresh tumor core biopsies were taken at a 
2 week timepoint after a single dose of T (8mg/m2) from 80 HER2-
overexpressing, early breast cancer patients enrolled on a clinical 
trial of T>T+C. Nucleic acids were extracted using Qiagen AllPrep 
and were analyzed with Illumina HT12v3 Beadchip arrays. All arrays 
were processed at the Yale Center for Genome Analysis (West Haven, 
CT). Clinical response at surgery was defined as pathologic complete 
response (pCR), objective response (CR+PR=OR) and non-response 
(SD+PD=NOR) by RECIST criteria. Gene expression was analyzed 
in Bioconductor using LIMMA analysis. Pathway analysis was 
performed using the DAVID bioinformatics resource.
Results: We identified gene expression signatures of T response and 
resistance in HER2+ breast cancer cell lines across 24-hour exposure 
to trastuzumab. 180-genes changed significantly in a T-sensitive 
HER2+ cell line (BT474) and 58 genes changed significantly across 
treatment in a T-resistant HER2+ cell line (UACC812). We applied 
these signatures to gene expression profiles from early stage HER2+ 
breast tumors treated with a single dose of T. The BT474 T-responsive 
signature was enriched among the changes in expression across 
treatment for responsive patients. The expression change for the 
BT474 signature genes was also able to partially cluster responsive 
and resistant breast tumors by outcome. A subset of the UACC812 
T-resistance signature was also enriched in the differential between 
responsive and resistant tumors prior to T treatment.
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Pathway analysis based on the direction of change of genes in pCR and 
sensitive (BT474) cell lines found gland development/differentiation 
(enrichment score=4.5), DNA synthesis (ES=4.0) , chaperone 
(ES=2.8) and transcriptional machinery (ES=2.2) to be coordinately 
downregulated in both sensitive cell lines and tumors. This suggests 
that the downregulation of differentiation pathways seen in our ‘pCR 
signature’ (Harris etal: AACR 2011) is not an epiphenomenon of 
cell loss. There were no significant pathways upregulated in both 
sensitive tumors and cell lines, however discordant genes were 
enriched in chromatin regulation pathways (ES=4.1). Of note, our 
previous findings of amplicon gene downregulation in pCR tumors, 
yet upregulation in cell lines points to a novel mechanism of chromatin 
modulation heretofor undiscovered in response to T.
Conclusions: These results demonstrate the value of iterative study 
of in vitro and in vivo response mechanisms in HER2 cell lines and 
tumors, and the importance of brief exposure studies in understanding 
the mechanism of response to T, and other targeted therapies.
P1-06-24
Nuclear Localization of Stat5a Predicts Response to Antiestrogen 
Therapy and Prognosis of Clinical Breast Cancer Outcome.
Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, 
Pequignot E, Freydin B, Yang N, Tran TH, Rosenberg AL, Hooke 
JA, Kovatich AJ, Shriver CD, Rimm DL, Magliocco AM, Hyslop T, 
Rui H. Thomas Jefferson University, Philadelphia, PA; Tom Baker 
Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical 
Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; 
Yale University School of Medicine, New Haven, CT
Nuclear-localized and tyrosine-phosphorylated Stat5 has been 
reported as a favorable prognostic marker and predictor of response 
to antiestrogen therapy in breast cancer. Phospho-Stat5 antibodies 
do not distinguish between phosphorylated Stat5a and the closely 
related Stat5b, but Stat5a is considered more critical for normal 
mammary development than Stat5b. The purpose of this study was 
to determine whether levels of nuclear-localized Stat5a protein 
(Nuc-Stat5a) were prognostic of clinical outcome or predictive 
of antiestrogen response. Stat5a was detected by traditional 
diaminobenzidine-chromogen immunohistochemistry (IHC) and 
pathologist scoring or by quantitative immunofluorescence in five 
archival cohorts of breast cancer. Levels of nuclear-localized Stat5a 
(Nuc-Stat5a) were evaluated by pathologist scoring of whole tissue 
sections detected by IHC or automated quantitative analysis (AQUA) 
of immunofluorescently-labeled tissue microarrays. Levels of Nuc-
Stat5a were reduced in invasive breast cancer tissues and lymph 
node metastases compared to normal tissue and ductal carcinoma 
in situ when quantified by AQUA (Material I; n=180). Tissues from 
patients not treated with adjuvant therapy or treated with antiestrogen 
monotherapy were analyzed according to Nuc-Stat5a status for breast 
cancer-specific survival (CSS) and time to recurrence (TTR) using 
univariate and multivariate statistical models, adjusting for clinical 
features including tumor grade, size, lymph node and ER, PR and 
Her2 status. In two prognostic cohorts of node-negative breast cancer 
patients, low expression of Nuc-Stat5a, detected by standard IHC 
(Material II; n=223) or quantitative analysis (Material III; n=198), was 
prognostic of poor breast cancer outcome as measured by univariate 
and multivariate CSS (Material II/III) and TTR (Material II). CSS and 
TTR analysis of two independent materials of tumors from patients 
treated with antiestrogen monotherapy and analyzed by standard IHC 
(Material IV; n=73) or quantitative immunofluorescence (Material V; 
n=97) indicated that patients whose tumors expressed low levels of 
Nuc-Stat5a were at a greater than 4-fold risk of antiestrogen therapy 
failure when adjusted for hormone receptor status and clinical features 
(multivariate CSS: Material IV HR=4.3 (1.2,15.6), p=0.03; Material 
V HR=5.0 (1.87,13.06), p=0.001). In conclusion, loss of Nuc-Stat5a 
is a promising independent marker of poor breast cancer prognosis 
in node-negative, non-adjuvant treated breast cancer patients. 
Additionally, Nuc-Stat5a may be a useful clinical tool to predict 
tumor response to antiestrogen therapy.
P1-06-25
Changes in FDG PET SUV Correlates with Ki-67 Following 2 
Weeks of Aromatase Inhibitor Therapy in ER+ Early Stage Breast 
Cancer, a Pilot Imaging Study.
Gadi VK, Kurland BF, Specht JM, Rodler E, Korde LA, Peterson 
LM, Schubert EK, Chai X, Mankoff DA, Linden HM. University of 
Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, 
Seattle, WA
Background: In estrogen receptor positive (ER+) tumors, a low 
proliferative index (Ki-67) two weeks into endocrine therapy predicts 
response. FDG PET non-invasively measures tumor sites in vivo. The 
pre-operative window is an opportunity to assess impact of systemic 
therapies. We tested associations between FDG PET standardized 
uptake value (SUV) and Ki-67 after two weeks of aromatase inhibitor 
(AI) therapy in newly diagnosed, postmenopausal women.
Methods: Postmenopausal patients with clinical stage I-II ER+ 
HER2– primary tumors underwent a 9-35 day “run-in” of AI 
monotherapy prior to definitive surgery. FDG PET was performed 
before AI therapy, and 1-5 days before surgery. Ki-67 was measured 
in baseline core biopsy and surgical specimens.
Results: To date, 18 patients (median age 59) have been enrolled of 
whom 14 patients have undergone serial FDG PET imaging with 12 
completed assessment of Ki-67 in surgical samples including one 
who had no residual invasive carcinoma. The majority harbored 
ductal carcinomas (n=16) with 10/18 having histologic grade ≥ 2. 
The median number of days exposed to AI was 18 (range, 9-35). 
Baseline SUV ranged from 1.8 to 10.9 (median 2.5), and post run-in 
SUV (7-34 days later) ranged from 1.0 to 10.7 (median 2.5). A median 
14% decrease in SUV was observed between paired FDG PET studies 
(range, 44% decline to 13% increase). Five of 12 patients’ index 
lesion FDG SUV declined by 20% or more; all also had Ki-67 ≤5% 
at surgery. An additional 5 patients with Ki-67 ≤5% at surgery had 
percentage change in FDG PET SUV of 0% to 17% decline. Results 
will be updated as accrual is ongoing.
Conclusions: Substantial changes in FDG PET SUV in the breast 
tumor were appreciated early in AI therapy. SUV declined or was 
stable in all but one patient of 14, and all patients with ≥ 20% decrease 
in SUV had a low (≤5%) Ki-67 at surgery. Serial PET is a promising 
measure of early response to therapy. 
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P1-06-26
The EndoPredict Score Is a Response Predictor for Neoadjuvant 
Chemotherapy in ER-Positive, HER2-Negative Breast Cancer.
Brase JC, Gehrmann MC, Petry C, Weber KE, Schmidt M, Kölbl 
H, Brauch H, Schwab M, Müller V, Jänicke F, Rody A, Kaufmann 
M, Filipits M, Gnant M, Denkert C, Loibl S, von Minckwitz G, 
Kronenwett R. Sividon Diagnostics, Cologne, Germany; Bayer 
Technology Services GmbH, Leverkusen, Germany; University of 
Mainz, Germany; Dr. Margarete Fischer-Bosch Institute of Clinical 
Pharmacology Stuttgart and University Tübingen, Germany; 
University Medical Center Hamburg-Eppendorf, Germany; J.W. 
Goethe University, Frankfurt, Germany; Medical University of 
Vienna, Austria; Charité - University of Berlin, Germany; German 
Breast Group, Neu-Isenburg, Germany
Background:
The EndoPredict (EP) score is a multigene classifier to predict the 
likelihood of distant recurrence in ER-positive, HER2-negative 
breast cancer patients treated with adjuvant endocrine therapy. Two 
large randomized phase III trials involving endocrine therapy only 
(n > 1700) demonstrated additional prognostic information of the EP 
score independent from clinicopathological parameters by classifying 
49% as low risk. However, the predictive role of the EP is not clear. 
Therefore, we examined whether the EP Score also predicts sensitivity 
towards neoadjuvant chemotherapy in ER-positive, HER2-negative 
breast cancer patients.
Methods:
Four publicly available gene expression data sets (Affymetrix HG-
U133A) were retrieved from the gene expression omnibus (GEO) 
data repository. All analyzed breast cancer patients were treated 
with anthracycline or taxane/anthracycline-based neoadjuvant 
chemotherapy. Microarray cel files were MAS5 normalized with a 
global scaling procedure and a target intensity of 500. The analysis 
was restricted to ER-positive, HER2-negative breast cancer patients 
according to pre-specified cut-off levels for the respective ESR1/
ERBB2 Affymetrix probesets. The EP score was calculated and 
patients were classified as having low or high risk according to the 
pre-specified validated cut-off value. Pathological complete response 
(pCR) - defined as no residual invasive cancer in the breast or lymph 
nodes - was used as the primary endpoint for the assessment of 
treatment response.
Results:
The EP Score was examined in 221 ER-positive, HER2-negative 
breast cancer patients treated with neoadjuvant therapy. Among the 
221 patients, 61 tumors (27.6 %) were classified as EP-low-risk, 
whereas 160 tumors (72.4%) were EP-high-risk. Only one of the EP-
low-risk tumors achieved a pCR after neoadjuvant therapy, whereas 24 
of the 25 pCR events were classified as EP high risk. The sensitivity 
of the EP score was 96% and the negative predictive value 98% with 
an area under the receiver operating characteristic curve of 0.73.
Conclusions:
The EP Score is a predictor of chemosensitivity in the neoadjuvant 
setting. The test correctly identified all but one of the patients 
achieving a pCR suggesting that the benefit of cytotoxic chemotherapy 
is limited to the EP high risk group.
P1-07-01
Comparison of Four HER2 Testing Methods in the Detection of 
HER2-Positive Breast Cancer: Results from the FinHer Study 
Cohort.
Huang W, Wirtz R, Weidler J, Lie Y, Sherwood T, Leinonen M, 
Bono P, Isola J, Kellokumpu-Lehtinen P-L, Joensuu H. Monogram 
Biosciences Inc., So. San Francisco, CA; STRATIFYER Molecular 
Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; 
Helsinki University Central Hospital, Helsinki, Finland; Institute of 
Medical Technology, University of Tampere and Tampere University 
Hospital, Tampere, Finland; Tampere University Hospital, Tampere, 
Finland
Background: Accurate assessment of the HER2 status is essential for 
identifying patients who may benefit from HER2 targeted therapy. 
The current methods, immunohistochemistry (IHC) and in situ 
hybridization (ISH), determine HER2 status semi-quantitatively as 
positive (+), equivocal (+/-) and negative (-) with predefined cutoff 
values. Recent studies have suggested that current HER2 cutoffs may 
not be optimal for all clinical settings of HER2 targeted therapy. In a 
small subset of adjuvant NCCTG N9831 patients confirmed as HER2-
normal by round-robin review of HER2 testing, trastuzumab benefit 
was observed (Perez et al, SABCS 2010). Quantification of HER2 
as continuous variable may enable a more accurate optimization of 
HER2 cutoffs for various HER2 targeted therapies. In this study, we 
measured continuous HER2 protein expression by the HERmark™ 
assay and continuous mRNA expression by quantitative real time 
polymerase chain reaction (qPCR), and compared these results with 
central IHC and central chromogenic in situ hybridization (CISH) 
results of FinHer.
Methods: Total HER2 protein expression (H2T) was quantified 
using the HERmark assay as previously described (Huang et al. Am 
J Clin Pathol 2010;134:303). HER2 mRNA expression (H2N) was 
measured by qPCR as previously published (Noske et al. Br Cancer 
Res Treat 2011;126:109). The results of H2T and H2N as continuous 
variables and as predefined categories were compared with central 
CISH results from FinHer (Joensuu et al, N Engl J Med 2006;354), 
and central IHC retesting.
Results: H2T in 899 evaluable samples described a continuum of 
0.4 to 721.2 (relative HERmark unit); while H2N in 915 evaluable 
samples showed a continuum of 31.4 to 42.8 (delta-Ct). Significant 
correlation between H2T and H2N as continuous variable was found 
(R2= 0.56, P< .0001). Paired method comparison was performed for 
samples with valid results in any two of the four testing methods. 
Overall concordance of H2T and H2N with predefined categories 
(+, +/-, -) was 81%, and concordance of (+) and (-) subsets was 
95% when (+/-) cases (H2T 11%; H2N 6%) were excluded. Overall 
concordance of central IHC and H2T categories (+, +/-, -) was 75%, 
and concordance of (+) and (-) subsets was 96% when (+/-) cases 
(IHC 16%; H2T 11%) were excluded. Overall concordance of IHC 
and H2N categories (+, +/-, -) was 84%, and concordance of (+) and 
(-) subsets was 99% when (+/-) cases (IHC 16%; H2N 6%) were 
excluded. Concordance of central CISH (+, -) with H2T and H2N 
categories (+, -) was 89% and 91%, respectively, when (+/-) cases 
were excluded from H2T (13%) and H2N (8%), respectively.
Conclusions: All four methods identified HER2-positive breast 
cancers. The discordance rate between the methods tested was 
approximately 10 to 20% despite careful delineation of cancerous 
tissue in the sample and analysis of adjacent tumor sections. No 
combination of assays could be identified with concordance rate 
>95% when the equivocal subsets were included in comparisons. 
Exclusion of the equivocal subsets (about 10% of samples) yielded 
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high concordance rates of approximately 95% or higher. H2T and H2N 
showed comparable continuous distribution patterns and significant 
concordance with standard HER2 status by central IHC and CISH.
P1-07-02
Discordance between Central and Local Laboratory HER2 
Testing from a Large HER2-Negative Population in VIRGO, a 
Metastatic Breast Cancer Registry.
Vogel CL, Bloom K, Burris H, Gralow JR, Mayer M, Pegram M, 
Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Brammer MG, 
Kaufman PA. Sylvester Comprehensive Center at Deerfield, Miller 
School of Medicine, University of Miami, Miami, FL; Clarient, Inc., 
Aliso Viejo, CA; Sarah Cannon Research Institute, Nashville, TN; 
Tennessee Oncology, PLLC, Nashville, TN; University of Washington 
Medical Oncology, Seattle Cancer Care Alliance, Seattle, WA; Patient 
Advocate, New York, NY; University of California San Francisco 
Comprehensive Cancer Center, San Francisco, CA; Washington 
Cancer Institute, Washington Hospital Center, Washington, DC; 
Genentech, Inc., South San Francisco, CA; Norris Cotton Cancer 
Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background: HER2 overexpression is associated with unfavorable 
prognosis and is reported in 18–25% of breast cancers (BC). HER2 
testing is often performed using immunohistochemistry (IHC) or 
fluorescence in situ hybridization (FISH). Because of the significant 
benefit of HER2-directed therapies, it is critical to accurately identify 
women whose tumors are HER2+. Reports have noted discordance 
between HER2+ test results from local vs. large reference labs in 
patients with HER2+ BC evaluated for trastuzumab-based clinical 
studies. There are little published data on central testing of BC found 
to be negative locally.
Patients and Methods: VIRGO is an observational cohort of 
N=1,287 women with primarily HER2-negative metastatic BC. An 
optional tissue collection substudy was conducted, and 776 patient 
samples were received and centrally retested. Central testing was 
performed at 2 reference labs and tumors were deemed HER2+ if 
IHC 3+ and/or FISH positive (HER2:CEP17 ratio ≥2.0). Tumors 
with unknown/missing local HER2 status (n=68) were excluded 
from primary analyses. Number of patients potentially affected based 
on BC incidences from the American Cancer Society (ACS) 2011 
estimates and the World Health Organization (WHO) 2008 report 
were calculated. Testing on the remainder of the HER2-negative 
cohort is in process.
Results: Central retesting has been performed on tumor samples 
from n=373 patients to date: HER2-negative locally evaluable 
tumors (n=301), n=4 HER2-negative locally with no evaluable 
tumor, and HER2 unknown (n=68). A total of 301 unique patient 
samples were included in the primary analysis. Of these, 15 (4.98% 
[95% CI (2.7%, 7.9%)] were found to be HER2+ by central testing 
(Table). Based on sensitivity analyses assuming all 68 tumors with 
unknown HER2 status to be negative locally, 4.07%(15 /369) would 
be centrally HER2+.
Table. Local testing vs. central testing findings and resulting discordance
 Central testing
Local testing Negative Positive Total Discordance Patients impacted annually
 (n) (n) (n) (%) 95%CI US/worldwide
Negative 286 15 301 4.98 [2.7, 7.9] 9,305/55,342
Unknown (HER2 status 
not recorded) 68 0 68 N/A N/A
Total 345 15 369 4.07 7,444/44,274
Of the 15 HER2+ tumors, 4 tumors tested positive centrally by both 
IHC and FISH; 6 IHC positive/FISH negative; and 5 FISH positive/
IHC negative. 14/15 tumors were tested locally by only one testing 
methodology, and 11/15 were determined to be HER2+ centrally 
based on the testing methodology not performed locally. Investigators 
for all 15 patients have been notified of central HER2 testing results.
Conclusion: Based on ACS estimates of 232,620 new cases of 
invasive BC diagnosed in the US in 2011 (assuming 80% testing 
HER2-negative); a discordance rate of 4-5% equates to 7,444 – 9,305 
patients’ tumors diagnosed as HER2+ by central testing. Based on 
WHO global BC incidence estimates, 44,274 – 55,342 patients could 
be impacted worldwide as reported in this study. Inaccurate HER2 
testing has significant clinical impact, both in denying appropriate 
treatment or leading to inappropriate use of HER2-targeted therapies. 
This study suggests testing by both IHC and FISH may be of benefit 
to accurately identify HER2 status, consistent with the Herceptin® 
USPI.
P1-07-03
Preanalytical Variables Affect Protein Expression in Formalin 
Fixed Paraffin Embedded Tissue – Assessment of Intrinsic 
Controls To Define Tissue Quality for Immunohistochemical 
Analysis.
Neumeister VM, Lostritto K, Siddiqui S, Anagnostou V, Vassilakopoulou 
M, Zarrella EA, Molinaro AM, Hicks DG, Rimm DL. Yale University 
School of Medicine, New Haven, CT; Rochester University, School 
of Medicine, Rochester, NY
Background:. Recently it has been shown that biospecimen handling 
and pre-analytical variables can dramatically affect biomarker assays 
of protein expression in tumor tissue. Phospho-proteins and even 
labile unmodified proteins have been suggested to show significant 
loss of expression due to prolonged time to formalin fixation. Here 
we assess 4 clinically relevant proteins (ER, PR, HER2 and Ki67) 
and 20 other proteins for changes as a function to the key preanalytic 
variables of ischemic time. The ultimate goal of our effort is to find 
a method to monitor the degradative effect of these variables by 
construction of a Tissue Quality Index (TQI).
Materials and Methods: Two different breast cancer cohorts were 
used in order to analyze the biomarkers and their change according 
to time to formalin fixation. The first cohort consists of 93 breast 
cancer specimens in 2 fold redundancy on a TMA with cell lines and 
controls. The time to formalin fixation for each breast cancer specimen 
was recorded and ranges from 25 to 415 minutes. The second cohort 
consists of 25 matched pairs of breast cancer biopsies and resections. 
The time to formalin fixation for the biopsies is minimal while the 
time to fixation for the resections, though not recorded, averages 
between 1 and 3 hours. Protein expression was measured using the 
AQUA method of quantitative immunofluorescence.
Results: ER alpha, PR, HER2 and Ki67 were each analyzed on the 
time to fixation array with 2 different antibodies commonly used in 
the clinical setting. Correlation of AQUA scores of these markers 
with time to formalin fixation revealed a trend towards loss of protein 
expression as a linear function of time to fixation without reaching 
statistical significance. Analysis of these 4 proteins on the matched 
pairs of biopsies and resections showed that tumor heterogeneity 
predominated over the effects of ischemic time.
Toward identification of markers for a TQI, 20 biomarkers were 
analyzed on the time to fixation array. Both HIF1alpha and AKAP13 
show a significant increase as a function of time to fixation, whereas 
pMAPK, histone 4 and pTyrosine 4G10 revealed a significant loss 
of expression. These trends were confirmed in the matched pair 
validation set with the execption of histone 4. A TQI is being built 
from these variables.
Conclusions: Ischemic time is a critical pre-analytical variable that 
impacts measurement of protein expression in tumor tissue. The 4 
standard markers used clinically in breast cancer appear to show only 
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moderate effects that appear less critical to measurement accuracy 
than the issue of tumor heterogeneity. We identified 4 proteins which 
show a significant change with increasing time to formalin fixation 
and should allow construction of a TQI for assessment of pre-analytic 
antigenic degradation.
P1-07-04
Gene Expression Module Biomarkers To Stratify Multiple 
Clinical and Therapeutic Endpoints for Universal Breast Cancer 
Companion Diagnostic.
Rhodes D, Tomlins S, Williams P, Sadis S, Wyngaard P, Oades 
K, Chattopadhyay S, Wang Y, Monforte J, Lee B-I. University of 
Michigan, Ann Arbor, MI; Compendia Bioscience, Inc., Ann Arbor, 
MI; AltheaDx, San Diego, CA
Gene expression patterns are increasingly capable of stratifying 
patients based on prognosis and response to therapy. Given the limited 
availability of sample tissue, however, it is not feasible to run many 
tests, suggesting the need for a universal companion diagnostic assay 
that is informative with respect to multiple clinical and therapeutic 
endpoints. Key challenges are identification of appropriate gene 
expression biomarkers, translation of biomarkers to clinical assays, 
and development of reliable gene expression profiling of formalin-
fixed clinical specimens. Here, we describe a meta-analysis approach 
that identifies novel biomarker modules that results in multiple clinical 
and therapeutic read-outs.
A co-expression meta-analysis of 5,339 breast tumors from 56 
microarray datasets identified highly co-expressed sets of genes 
(modules) across multiple datasets. These module based biomarkers 
were tested for their ability to associate with prognostic and predictive 
targets in published datasets. In addition, each module was reduced 
from 10 – 1,000 genes to the top performing 2-3 genes based on the 
degree of co-expression across the meta-analysis and validation by 
quantitative PCR in an independent panel of FFPE tumor samples.
This study demonstrates that a single 96 gene qPCR test utilizing 
multiple module biomarkers is not only capable of stratifying patients 
by standard histopathological parameters (ER, PR and Her2), but 
also stratifies by other diverse elements of the disease (cell lineage, 
dysregulated core biological functions, factors of cell growth, 
underlying genomic aberrations and the tumor microenvironment). 
Taken together, these biological variables represent the major 
biological diversity present within the breast cancer population. A 
series of retrospective analyses demonstrated that different single 
module and combinations of modules were capable of predicting a 
variety of clinical endpoints, including 5-year survival, neoadjuvant 
chemotherapy response in ER- patients and targeted therapy response 
in model systems.The molecular heterogeneity of breast cancer can 
be summarized by discrete gene expression modules that individually 
represent distinct biological pathways, and that collectively can be 
represented by as few as 96 genes. These breast cancer modules, 
together with outlier genes, allow for summation of the entire 
transcriptional program and provide a universal assay with broad 
application to companion diagnostics development.
P1-07-05
HER2 Status Resolution in FISH and IHC “Double Equivocal” 
Breast Carcinomas by Quantitative Real-Time PCR.
Portier BP, Wang Z, Downs-Kelly E, Budd GT, Lanigan C, Tubbs RR. 
Cleveland Clinic, Cleveland, OH; Taussig Cancer Center, Cleveland 
Clinic, Cleveland, OH
Background:
Clinical testing for HER2 amplification/over-expression is performed 
by immunohistochemistry (IHC) and/or fluorescence in situ 
hybridization (FISH) as outlined by the ASCO/CAP guidelines. 
Although these guidelines standardize testing and reporting, in a 
subset of patients, HER2 is equivocal by both IHC and FISH (“Double 
Equivocal”). These double equivocal patients represent a clinically 
problematic sub-group that currently lack standardized management 
guidelines. In this study, we utilize Quantitative Real-Time PCR 
(Q-RT-PCR) to resolve HER2 status in invasive breast cancer cases 
that could not be resolved via IHC and FISH testing.
Material and Methods:
FISH for HER2 was performed on 2259 invasive breast carcinomas 
from 1/2008 to 12/2010. In accordance with ASCO/CAP, all equivocal 
HER2 FISH cases were reflex tested by IHC. In double equivocal 
cases, RNA extraction was performed following macro-dissection 
using High Pure RNA Paraffin Kit (Roche Applied Biosciences, 
Indianapolis, IN). Q-RT-PCR was carried out using TaqMan® RNA-
to-CT™ 1-Step Kit with primers and probes for HER2, B2M, and 
GAPDH (Applied Biosystems, Foster City, CA). Q-RT-PCR results 
were expressed as the relative quantification of HER2 vs. two control 
genes, all normalized against calibrator RNA from the MCF7 cell 
line. Cut off for Q-RT-PCR HER2 overexpression was set using ROC 
curve analysis (MedCalc, Belgium).
Results:
In our cohort of 2259 patients, 124 (5.5%) had an equivocal HER2 
result by primary FISH testing. Reflex HER2 testing by IHC was 
unable to resolve the HER2 status in 35 (1.5%) patients. Detection 
of HER2 overexpression by Q-RT-PCR was validated using 50 
FISH confirmed amplified and 50 non-amplified cases. Q-RT-PCR 
performed on these 2 control populations generated two non-
overlapping populations and ROC curve analysis using a cut off value 
of 7.0 showed 100% sensitivity and specificity in detection of HER2 
overexpression. Application of Q-RT-PCR in the double equivocal 
sub-group resulted in resolution of HER2 status in all cases, 8 HER2 
positive (test value ranging from 7.12 – 15.37) and 14 HER2 negative 
(test value ranging from 1.05 – 6.92).
Conclusion:
Application of Q-RT-PCR for HER2 represents a viable approach 
to resolve HER2 status in cases that fail classification by both FISH 
and IHC. Q-RT-PCR combines the precision and high sensitivity 
of real-time PCR with the morphological specificity of histological 
evaluation and ultimately allows definitive HER2 classification at 
the time of initial diagnosis. This knowledge of HER2 status at the 
time of diagnosis allows for comprehensive neoadjuvant treatment 
although, additional studies correlating response to anti-HER2 therapy 
and HER2 status by Q-RT-PCR are warranted.
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P1-07-06
High Concordance of Protein (by IHC), Gene (by FISH; HER-2 
Only) and Microarray Readout (by TargetPrint) of ER/PR/HER2: 
Results from the MINDACT Trial.
Viale G, Bogaerts J, van’t Veer L, Rutgers E, Piccart M, de Snoo F, 
Engelen K, Russo L, Dell’Orto P, Glas A, Cardoso F, On Behalf of 
the TRANSBIG Consortium & the MINDACT Investigators. European 
Institute of Oncology, Milan, Italy; European Organisation of 
Research and Treatment of Cancer, Brussels, Belgium; Netherlands 
Cancer Institute, Amsterdam, Netherlands; Institute Jules 
Bordet, Brussels, Belgium; AgendiaNV, Amsterdam, Netherlands; 
Champalimaud Cancer Center, Lisboa, Portugal
Background
Previously, the micro-array readout of ER, PR and HER2 by 
TargetPrint was shown to be strongly correlated with high quality 
immunohistochemistry (IHC)/FISH assessment, especially for ER and 
HER2. Concordance rates were 93% (k=0.79) for ER; 83% (k=0.65) 
for PR and 96% for HER2 (k=0.88) in 636 patients (Roepman et al., 
Clin Cancer Res, 2009).
This study analysis was undertaken to further determine the 
correlation of microarray readout with IHC/FISH assessment both 
locally and centrally determined in the 1st 800 pts enrolled in the 
MINDACT trial. This work is essential to determine the quality of 
biological data in the two risk assessment methods used in MINDACT 
based upon which adjuvant chemotherapy decision is made, in order 
to exclude bias.
Methods
ER/PR/HER2 IHC assessment was performed on the 1st 800 primary 
breast cancers (BC) of pts enrolled in the MINDACT study. The 
assessment was performed locally at each center (n=800) and by 
central review at the laboratory of the European Institute of Oncology 
(n=626). A tumor was classified positive for ER and PR when 1 % of 
tumor cells showed positive staining. HER2 IHC status was scored 
as 0, 1+, 2+ or 3+; a score of 3+ was considered positive. In 2+ cases 
FISH was performed to assess final HER2 status. Gene expression 
data for ER, PR and HER2 were obtained by TargetPrint stratified 
as receptor positive or negative using previously determined and 
validated thresholds for ER, PR and HER2 mRNA levels (n=800).
Results
Comparison of local assessment (IHC & FISH for HER2) with central 
review indicated highly similar results for receptor readout with a 
concordance of 98% (k=0.90) for ER; and 96% for HER2 (k=0.80) 
and slightly lower for PR (90% (k=0.72)).
Comparison of central assessment (IHC & FISH for HER2) with 
micro array readout by TargetPrint indicated highly similar results 
for receptor readout with a concordance of 97% (k=0.88) for ER and 
95% for HER2 (k=0.76). For PR the concordance was lower but still 
quite acceptable (85% (k=0.62)).
Conclusion
Local and centrally assessed ER, PR and HER2 status in the first 
800 MINDACT patient samples indicate a high level of quality for 
pathology in the local participating hospitals. These results exclude 
any bias induced by a lower quality of “traditional” pathology results 
as compared to the centrally assessed MammaPrint, both used for risk 
assessment and adjuvant chemotherapy decision in the MINDACT 
trial. The microarray-based assessment of ER, PR and HER2 gives 
results comparable to IHC & FISH and provides an objective and 
quantitative assessment of tumor receptor status. These results 
indicate that TargetPrint can serve as a second pathology assessment 
for locally assessed parameters, especially since TargetPrint is part 
of a multi-profile platform for breast cancer treatment management.
This work was funded by the Breast Cancer Research Foundation 
and the EU Framework Program VI.
P1-07-07
Assessing Two Methods of Meta-Analysis in Studies of Patients 
with Breast Cancer: Individual Patient Data-Based (IPD) Versus 
Literature Based Abstracted Data (AD) in 5 Meta-Analyses 
Including over 28,000 Patients. Are There Results Differences 
of Concern?
Gralla RJ, Bria E, Raftopoulos H, Sperduti I, Giannarelli D, Cognetti 
F. Hofstra North Shore - LIJ School of Medicine, Lake Success, NY; 
Regina Elena National Cancer Institute, Rome, Italy
Background: Meta-analyses are widely used to provide high level 
evidence to resolve controversies. Differences of opinion continue 
concerning the two most frequently used methods (IPD and AD) and 
their roles in providing reliable recommendations for Evidence-Based 
Medicine. Some regard the IDP method as being more accurate, yet 
it is time-consuming, expensive, and can be troubled by getting data 
from all investigators. We tested whether overall conclusions would 
differ between the two methods when using the same studies for 
comparison. To overcome limitations related to simple correlation 
analysis, and: 1) to weigh the agreement between these 2 approaches 
(Bland-Altman [BA], Lancet 1986), and 2) to evaluate the eventual 
predictive role of the data coming from AD over IPD, an analysis 
with multiple methods was performed.
Methods: 5 meta-analyses in breast cancer examining 9 outcomes 
which had been subjected to IPD meta-analysis were selected. 
Literature-based AD meta-analyses were then conducted. Hazard 
Ratios (HR) and Risk Ratios (RRs) with 95% confidence intervals 
(CI) were extracted or derived from original meta-analyses. At least 
90% of patients’ reports were required for the IDP analysis. Methods 
agreement was analyzed according to the BA method, as difference 
or ratios, and a comparison with the Variance-Ratio test (F-test), 
and the Concordance Correlation Coefficient (CCC) was done. 
Correlations between IPD/AD-ratios were estimated using a linear 
regression model with Pearson (r) and R2 coefficients (parametric) 
and Spearman’s Rho/Kendall’s Tau coefficient (non-parametric), to 
derive a predictive estimation on IPD when adopting AD. MedCalc® 
Software was used.
Results: 9 outcomes in 5 meta-analyses (28,358 patients) were 
analyzed, as seen in the table.
Table 1.
Setting Outcome Patients [AD/IPD] HRs/RRs [AD] HRs/RRs [IPD]
Breast [Adj. ANA] DFS 3672 / 4006 0.708 0.71
Breast [Adv. TAX] PFS 2805 / 3034 0.984 0.94
Breast [Adv. TAX] OS 2805 / 3034 0.987 0.95
Breast [Adj. AIs] DFS 11163 / 9856 0.86 0.769
Breast [Adj. AIs] OS 11163 / 9856 0.95 0.94
Breast [Adj. AIs-Switch] DFS 8794 / 9015 0.80 0.711
Breast [Adj. AIs-Switch] OS 8794 / 9015 0.80 0.79
Breast [Adv. BEVA] OS 2695 / 2447 0.95 0.97
Breast [Adv. BEVA] PFS 2695 / 2447 0.68 0.998
Graphical comparison between the deviation from the ‘line of 
identity’ identified with the B-A method did not show meaningful 
differences between AD and IPD (mean difference -0.01535, 95% 
CI -0.0315, 0.0008; mean ratio 0.9816, 95% CI 0.9625, 1.0008). No 
significant difference in the Variance (F-test 1.01, p=0.98), and a 
high concordance (CCC 0.9775, 95% CI 0.91, 0.99) were found. A 
highly significant correlation by both parametric and non-parametric 
tests allowed derivation of a linear regression equation able to predict 
estimation IPD results from AD data; R2 0.97, p<0.001.
Conclusions: When analyzing the results of studies (AD) or patient 
results from those same studies (IDP) we found: 1) No significant or 
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meaningful differences between the 2 meta-analysis methods; and 
2) Data from the AD analyses are able to predict those from IPD, 
without significant risk of overestimation.
P1-07-08
PCR Genomic Grade in Breast Cancer: A New Tool for Daily 
Practice.
Laïos I, Carpentier S, Veys I, Spinette S, Salgado R, Craciun L, Fasolo 
V, Volpe A, Girardi H, Catteau A, Peyro-Saint-Paul H, Piccart M, 
Sotiriou C, Larsimont D. Institut Jules Bordet, Brussels, Belgium; 
Université Libre de Bruxelles, Brussels, Belgium; IPSOGEN, 
Marseille
Background: Genomic grade (GG) is a 97-gene signature which 
improves the accuracy and prognostic value of histological grade 
(HG) in invasive breast cancer (IBC) (Sotiriou JNCI 2006). It is 
particularly useful in stratifying HG2 tumors into GG-1 (low grade) 
and GG-3 (high grade) tumors. In order to extend the applicability 
of GG on routinely-used formalin-fixed-paraffin-embedded (FFPE) 
samples, the original microarray MapQuant Dx® signature was 
converted into a RQ-PCR assay (PCR-GG). The study aimed at 
validating the grading classification performance of the newly 
developed PCR-GG test.
Methods: Subsets of genes derived from the original GG were 
selected by testing their grading classification and prognostic 
performances using different classifiers on 15 independent public 
microarray data sets. 25 most-performing genes were quantified by 
RQ-PCR using a TaqMan assay on a training set consisting of 91 
early IBC cases graded acc. to the Elston-Ellis recommendations, 
and classification performance of various combinations assessed. 
Analytical performance of the final reduced signature was assessed 
on 4 samples (5 RNA extractions and 3 RQ-PCR per sample) and 
used to define a 95% CI around the GG-1/GG-3 cut-off. Cases with a 
PCR-GG score falling into the 95% CI were considered “Equivocal” 
(Eq). Concordance with the MapQuant Dx® GG was assessed on 44 
paired FFPE/frozen samples of the training set. Grade classification 
performance of the PCR-GG test was evaluated on an independent 
validation set of 396 FFPE samples retrieved from the Department 
of Pathology (2004 to 2010) of Institut Jules Bordet (Brussels, Be). 
FFPE samples from early invasive, N0, ER+, HER2-, ductal or lobular 
BC containing ≥30% inv. tumor cells were selected. Classification 
performance was evaluated on the whole cohort and by histological 
subtype.
Results: The PCR-GG signature is based on the expression of 6 
reporter and 3 reference genes. Most of the genes are overexpressed 
in grade 3 tumors and are associated with proliferation. The 9-gene 
PCR-GG showed a high concordance with the original GG microarray 
test (95%). 388 eligible cases were available for validation. 336 
samples contained ≥30% inv. tumor cells and 322 were successfully 
amplified, corresponding to a 96% technical success rate. The HG1, 
HG2 and HG3 distribution in the validation cohort were 27%, 55% 
and 18% resp. PCR-GG reclassified 84% of all tumors (Table 1) with 
an overall concordance of 90% (92% HG1/GG-1 concordance and 
88% HG3/GG-3). 82% of HG2 tumors were reclassified into 74% 
GG-1 and 26 % GG-3. Overall concordance was 91% in the Ductal 
subset (comprising 84% of all cases) and 89% in the Lobular subset.
Conclusion: The newly developed PCR-GG test composed of 9 genes 
can be performed on FFPE samples. It is highly concordant with 
HG and recapitulates the classification performance of the original 
97-gene microarray GG test with 84% reclassified tumors. Further 
validation is planned on the BIG 1-98 cohort. Applicability of GGI 
on FFPE samples will open its use in routine clinical practice.
9-gene PCR-GG grading classification performance
 HG1 HG2 HG3 TOTAL
GG-1 71 107 6 184 (57%)
Eq 9 31 12 52 (16%)
GG-3 6 38 42 86 (27%)
 86 (27%) 176 (55%) 60 (18%) 322
P1-07-09
Estrogen Receptor (ER) mRNA and ER-Related Gene 
Expression in Breast Cancers That Are 1%-10% ER-Positive by 
Immunohistochemistry.
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, 
Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi GN, Hatzis 
C, Symmans WF, Pusztai L. The University of Texas MD Anderson 
Cancer Center, TX; Okayama University, Okayama, Japan; Nuvera 
Biosciences Inc, MA
Purpose: Our goal was to examine whether borderline estrogen 
receptor (ER)-positive cancers, defined as 1-10% positivity by 
immunohistochemistry (IHC), show the same global gene expression 
pattern and high ESR1 mRNA expression as ER-positive cancers or 
are more similar to ER-negative cancers.
Patients and methods: ER status was determined by IHC in 465 
primary breast cancers and with Affymetrix U133A gene chip (ESR1 
mRNA gene expression: Probe set = 205225_at). We compared 
expressions of ESR1 mRNA and a 106-probe set ER-associated 
gene signature score between ER-negative (n=183), 1-9% (n=25), 
exactly 10% (n=6), and > 10% ER-positive (n=251) cancers. We 
also assessed the molecular class of the borderline ER-positive cases 
using the PAM-50 classifier.
Results: Among the 1-9%, 10% and > 10% IHC positive cases, 24%, 
67% and 92% were also ER-positive by ESR1 mRNA expression. The 
average ESR1 expression was significantly higher in the > 10% IHC-
positive cohorts compared to the 1-9% or completely negative cases 
but in these latter two cohorts ER expression was similarly low. The 
average ER gene signature scores were similar for the ER-negative 
and 1-9% IHC-positive cases, but significantly lower than in > 10% 
ER-positive cases. None of the 1-9% ER-positive cases were classified 
as Luminal A, 2 were Luminal B and 12 were Basal-like. Among the 
10% ER-positive cases, 2 were Luminal A and 1 was Luminal B.
Conclusion: Overall, 24% of the 1-9% and 67% of the 10% ER-
positive cancers show ESR1 mRNA levels and gene signatures that are 
consistent with ER-positive, potentially endocrine sensitive tumors.
P1-07-10
Validation of a Diagnostic Molecular Signature (EHT Dx14) on 
Fine-Needle Aspirate Samples from Breast Tumors.
Delaloge S, André F, Fehlbaum P, Sol O, Vielh P. Institut Gustave 
Roussy, Villejuif, France; Exonhit, Paris, France
Background: A 1228-probeset molecular classifier (EHT Dx14) able 
to discriminate benign breast lesions from breast adenocarcinoma 
with a 96% performance was previously identified in a panel of 71 
fine-needle aspirate (FNA) samples of nodular breast lesions collected 
at Institut Gustave Roussy (IGR). The microarray which enabled the 
signature identification was based on the genomewide RNA analysis 
using the ExonHit’s SpliceArray™ technology. The objective of 
the current study was to validate the performance of the EHT Dx14 
molecular classifier on an independent cohort of FNA samples stored 
at the Centre de Ressources Biologiques at IGR.
Patients and methods: The samples were collected from women 
undergoing investigations for suspicious nodular breast lesions 
classified BIRAD ACR 4 or 5 on mammogram and/or ultrasonography. 
The morphological cytological analysis of FNA samples classified the 
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lesions as either benign, malignant or indeterminate. All samples were 
associated with a definite clinico-pathological diagnosis of the breast 
lesions. The first part of the study aims at confirming the sensitivity, 
specificity and overall performance of EHT Dx14 among lesions 
clearly classified by morphological cytology. The second part aims 
at establishing its performance among lesions with indeterminate 
cytological results.
Results: In the first part of the study, the EHT Dx14 transcriptomic 
signature was applied on a set of 94 FNA consecutive samples 
categorized as benign (n=47) or adenocarcinoma (n=47) on 
cytology. The benign/malignant status of the lesions was confirmed 
by subsequent investigations or follow-up. Results of EHT DX-
14 assessment of the samples were respectively 97.9% (95%CI : 
[88.7%-99.9%]) for sensitivity and 91.5% (95%CI : [79.6%-97.6%]) 
for specificity. Results on indeterminate FNA samples are being 
investigated in the second part of the study.
Conclusion: This study did confirm the high performance of EHT 
Dx14 signature in identifying malignant from benign breast lesions 
in clinically suspect lesions . EHT Dx14 may provide adequate 
biological diagnosis in the absence of capability of morphological 
evaluation.
P1-07-11
Consistency and Control in Clinical Assay Technology over Time: 
The Oncotype DX Recurrence Score and Assessment of Single 
Gene Expression Levels.
Baehner FL, Butler SM, Anderson JM, Ballard J, Tan V, Shak S. 
Genomic Health, Inc., Redwood City, CA; UCSF, San Francisco, CA
Background: ASCO® and CAP have recently highlighted the 
importance of consistency and control in clinical assay technology. 
To date the Oncotype DX® Recurrence Score® (RS) has been ordered 
to assist in individualized treatment decision making in over 200,000 
estrogen receptor positive, early stage breast cancer patients. The 
assay quantifies gene expression using RT-PCR from fixed paraffin 
embedded tissue (FPET) and employs a large number of controls and 
calibrators to enhance precision and reproducibility. Over 6 years of 
data on the assay presents an opportunity to explore consistency over 
time in the RS and quantitative single gene levels (ER, PR, HER2).
Methods: All tumors successfully analyzed in the Genomic Health 
Laboratory from 1/1/05-3/31/11 were included. Descriptive statistics 
for the RS, the average reference gene expression level, and expression 
levels for quantitative single genes were obtained for each calendar 
year. This was done for the entire data set as well as for subgroups 
defined by histological tumor type. The associations by year between 
HER2 and GRB7, ER and HER2, and ER and PR expression levels 
were explored including scatterplots and summary statistics.
Results: There were a total of 207,691 breast cancer cases, and the 
number in each calendar year increased over time as shown in the 
Table. In general the median age increased slightly over time, as did 
the proportion of patients in the low RS Risk Group. There was no 
systematic change over time in the average reference gene expression 
level, or in the expression levels for the individual genes ER, PR or 
HER2 during the period from 2008 to 2011 when individual gene 
testing was provided as part of the Oncotype DX assay report. The 
relationships between HER2 and GRB7, ER and HER2, and ER and 
PR remained consistent over time.
Conclusions: Active monitoring of the Oncotype DX assay as 
mandated by ASCO/CAP shows a high degree of consistency in 
results for both the multigene Recurrence Score and the quantitative 
single gene results. These results and the approaches used for 
monitoring consistency are relevant to other institutions in their efforts 
to maintain and improve assay quality control.
Table. Percent of Patients in each Recurrence Score Risk Group and Median Values for Age, 
Reference Gene Average Expression, and Expression Levels for Quantitative ER, PR and HER2
Year 2005 2006 2007 2008 2009 2010 2011
N 7123 14853 24504 39694 49224 56499 15794
Age 55 56 57 58 59 60 60
Reference Gene Avg 28.0 27.8 28.0 28.2 28.4 28.2 28.1
Recurrence Score        
% Low (<39) 50 49 52 54 56 56 53
% Int (39-54) 36 38 37 33 32 32 35
% High (≥55) 14 13 11 13 12 12 12
ER* n/a n/a n/a 9.9 10.0 10.0 9.9
PR* n/a n/a n/a 7.5 7.5 7.5 7.4
HER2* n/a n/a n/a 9.1 9.1 9.1 8.9
*Single gene reporting initiated in 2008
P1-07-12
Assessment of Real World HER2 Status by Immunohistochemistry 
(IHC) and Fluorescence In Situ Hybridization (FISH) in Breast 
Cancers: Comparison with HERmark®, a Validated Quantitative 
Measure of HER2 Protein Expression.
Huang W, Paquet A, Sivaraman S, Pesano R, Goodman L, Sherwood 
T, Lie Y, Hickey J, Walworth C, Haddad M, Anderson S, Bates M, 
Weidler J. Monogram Biosciences Inc., South San Francisco, CA; 
Incyte Corporation, Wilmington, DE; Quest Diagnostics Nichols 
Institute, San Juan Capistrano, CA; Affymetrix, Santa Clara, CA; 
Gilead Sciences, Inc, Foster City, CA; Cepheid, Sunnyvale, CA
Background: Accurate assessment of the HER2 status is critical in 
determining appropriate therapy for patients with invasive breast 
cancer. ASCO/CAP HER2 testing guidelines caution that up to 20% 
of routine HER2 testing by IHC/FISH may be unreliable (Wolff et 
al. JCO 2007;25:118). The HERmark assay is a novel quantitative 
HER2 protein measurement for determining HER2 status in breast 
cancer. Central HER2 testing showed high concordance (96-98%) 
with HERmark for positive and negative categories when equivocal 
subsets were excluded (Huang et al. Am J Clin Pathol 2010;134:303; 
Joensuu et al, 2008 SABCS, abstract 2071). In this study, we examined 
concordance between HERmark and routine HER2 testing by IHC and 
FISH from “real world” formalin-fixed, paraffin-embedded (FFPE) 
breast cancers submitted commercially for HERmark testing.
Methods: 717 HERmark results on FFPE breast cancers tested 
from 2008 to 2010 and corresponding HER2 IHC/FISH results were 
reviewed. The IHC and FISH results, per pathology reports submitted 
at the time of HERmark testing, were compared to HERmark 
categorical (negative, equivocal, positive) results.
Results: 590 (419) samples had IHC (FISH) and HERmark results 
available. Of these cases, 92% (94%) were either negative or 
equivocal by IHC (FISH). The HERmark testing reported 33% 
HERmark negative, 33% HERmark equivocal and 34% HERmark 
positive. Comparisons of HER2 status by IHC and FISH vs. HERmark 
are detailed in Table 1.
Table 1: Comparison of HERmark with HER2 IHC and FISH.
 IHC 0, 1+ IHC 2+ IHC 3+ FISH < 1.8 1.8 < FISH ≤ 2.2 FISH > 2.2
HERmark 
negative 143 (46%) 44 (19%) 6 (13%) 73 (31%) 33 (21%) 5 (19%)
HERmark 
equivocal 109 (35%) 75 (32%) 10 (21%) 82 (35%) 51 (33%) 12 (46%)
HERmark 
positive 59 (19%) 113 (49%) 31 (66%) 82 (35%) 72 (46%) 9 (35%)
Total 311 232 47 237 156 26
19% of cases classified as IHC 0 or 1+ were positive by HERmark; 
35% classified as FISH negative were HERmark positive. Of the 
158 triple negative cases by IHC/FISH (ER, PR and HER2 negative, 
data not shown), 38 (24%) were reclassified as HER2 positive by 
HERmark.
Conclusions: Higher than expected discordance between HER2 IHC/
FISH and the HERmark assay was observed in this study compared 
with central HER2 testing of prior study cohorts. Selection bias may 
have impacted these results as ≥ 92% of cases submitted for HERmark 
testing were either equivocal or negative by routine HER2 IHC/FISH. 
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Central HER2 FISH retesting of these samples will be performed and 
compared with HERmark results to further evaluate the discordance 
observed in this analysis.
P1-07-13
Efficiency of a Laboratory Developed HER2 FISH Test on 
Circulating Tumor Cells.
Mayer JA, Pham T, Wong KL, Scoggin J, Sales EV, Clarin T, Pircher 
TJ, Mikolajczyk SD, Cotter PD, Bischoff FZ. Biocept Inc, San Diego, 
CA
INTRODUCTION: Most circulating tumor cell (CTC) platforms rely 
on EpCAM for capture and cytokeratin (CK) for detection. However, 
an important population of cells that are CK-negative (i.e. cells with 
epithelial-mesenchymal transition (EMT) phenotype) will be missed. 
We report a new strategy to efficiently isolate a more heterogeneous 
population of CTCs using an antibody cocktail.
METHODS: In the first prospective study, blood (20 mL) was 
collected from 89 patients diagnosed with various late stage 
metastatic/recurrent cancers (breast, CRC, lung, prostate) following 
IRB approval. PBMCs were incubated with either EpCAM alone 
or a mixture of 10 capture antibodies to target both epithelial 
and mesenchymal cells. CTCs were subsequently captured in the 
OncoCEE™ channels and detected with cytokeratin (CK) and CD45. 
A second prospective IRB approved study involving 54 patients 
diagnosed with late stage metastatic/recurrent breast cancer was 
performed using similar detection strategies (CK cocktail mixture 
and anti-CD45) with the addition of HER2 FISH to determine 
amplification status among captured CK+/CD45- and CK-/CD45- 
cells.
RESULTS: In the first study, overall detection of CK+ cells was 83% 
with EpCAM alone and 93% with antibody cocktail. In addition, a 
median of 0.4 CK+ cells/mL and 1.0 CK+ cells/mL was observed 
using EpCAM and antibody cocktail, respectively. In the second study, 
CK+/CD45- cells were detected in 43 of 54 cases (80%). Among the 
43 cases in which CK+/CD45- cells were detected, high concordance 
(93%) in HER2 status between primary tumor and CTCs was observed 
with HER2 amplification noted in both CK+/CD45- (50%) and CK-/
CD45- (50%) cells.
CONCLUSIONS: We have developed a novel and robust method for 
CTC enumeration that utilizes a cocktail of antibodies for the detection 
of a heterogeneous (CK+ and CK-) population of CTCs. Our findings 
suggest an important population of CK- cells is being missed by 
current stain criteria in breast cancer patients. Data also demonstrate 
that recovery of CTCs from peripheral blood using the OncoCEE™ 
platform is efficient and suitable for FISH-based laboratory testing.
P1-07-14
Quantum Dot-Labelled Antibodies To Assess HER2 Expression 
in Breast Cancer.
Zona S, Blackburn E, Hojjatoleslami AS, Brown IR, Gullick WJ. 
University of Kent, Canterbury, Kent, United Kingdom
Background: The Human Epidermal Growth Factor Receptor 2 
(HER2) is overexpressed in 18-20% of breast cancers. Herceptin is 
an effective drug for the treatment of breast cancers expressing high 
levels of HER2. It is well known that there is a correlation between 
levels of HER2 expression and response to Herceptin. However a 
proportion of patients selected for Herceptin treatment do not respond 
to the drug. The accuracy of the assessment of HER2 levels in breast 
cancer is therefore important to predict patients’ response to Herceptin 
therapy. The current techniques in clinical use for the assessment 
of HER2 are immunohistochemistry (IHC) and fluorescence in situ 
hybridization (FISH); however both IHC and FISH have several 
limitations which may result in patient misclassification. A more 
accurate technique, which can quantify HER2 levels more precisely, 
could help to improve clinical diagnosis, prediction of prognosis and 
allow more accurate select individual patients for particular drug 
therapies.
Materials and Methods: We employed QDs labelled antibodies, laser 
scanning confocal microscopy and image segmentation techniques 
to quantify HER2 expression in cases of formalin fixed paraffin 
embedded breast cancers. Quantum dots (QDs) are a new class of 
fluorochromes made of semiconductor nanocrystal which have several 
useful properties for quantitative image analysis. In order to validate 
the system we used a breast cancer HER2-IHC control tissue array 
with negative, low, moderate and strong expressing cases, and a tissue 
microarray containing 60 samples of formalin fixed paraffin embedded 
breast cancer sections, previously examined by IHC and scored semi-
quantitatively (0-3+). We then applied this system to quantify HER2 
expression a tissue microarray containing 150 primary breast cancers 
scored as 3+ by IHC from patients treated with Herceptin.
Results: We first demonstrated that the QD system could reliably 
detect HER2 expression in IHC 3+ cases. A comparison of 
immunofluorescent staining with conventional immunohistochemistry 
showed that QDs give more linear and scalable measurements of 
receptor levels. We also quantified HER2 within a set of 150 breast 
cancers scored as 3+ by IHC, and we found that HER2 is expressed 
at very different levels, ranging over fifty fold between individual 
(IHC3+) cases. We currently are evaluating the correlation between 
HER2 receptor levels, measured by QDs, and patient’s response to 
Herceptin.
Conclusion: QDs and image analysis can produce a more precise 
measurement of HER2 levels of expression than IHC. This should help 
to improve clinical diagnosis, prognosis, identify specific treatments 
for individual patients and reduce costs associated with Herceptin 
treatment. This technology may be applied to study other members 
of the EGF family in breast cancers or more widely as a quantitative 
measurement of biomarkers in tumours.
P1-07-15
The Reliability of Ki-67 Expression Assessment Using Core 
Needle Biopsy and Surgical Specimens of Invasive Breast Cancer: 
Can Ki-67 Change Predict Benefits of Preoperative Endocrine 
Therapy?
Mizuno Y, Takayanagi H, Sato K. Tokyo-West Tokushukai Hospitl, 
Akishima-City, Tokyo, Japan
Background: The use of Ki-67 change as a predictive marker 
in breast cancer has been widely investigated in patients treated 
with preoperative endocrine therapy. It has been assumed that Ki-
67 expression determined using core needle biopsy and surgical 
specimens of invasive breast cancer is concordant. Many studies 
have suggested the concordance of the results obtained using core 
needle biopsy and surgical specimens for expression of the estrogen 
receptor (ER), progesterone receptor (PgR), and human epidermal 
growth factor receptor type2 (HER2) status in early-stage breast 
cancer. However, there was few study to compare Ki-67 expression 
in the core needle biopsy and surgical specimens. We conducted a 
retrospective study of Ki-67 expression assessment between the two 
types of specimens to answer this question.
Methods: A total of 269 patients underwent primary operations 
for early-stage breast cancer at Tokyo-West Tokushukai Hospital 
from August 2008 to May 2011. Among these patients, 169 patients 
who received core needle biopsy prior to operation were enrolled. 
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Patients with ductal carcinoma in situ and those with neoadjuvant 
chemotherapy were excluded. A cutoff value of 20% was used for 
Ki-67–positive criteria. We also examined ER, PgR, and HER2 
expression and compared it with Ki-67 expression. Statistical 
significance for concordance rates between the two types of specimens 
was evaluated by Wilcoxon t-test. To evaluate the consequence of 
formalin and genetic heterogeneity, parameters such as operative 
method and tumor size were analyzed by c2 analysis.
Results: The concordance rate between the two types of specimens 
for Ki-67 expression was 76%, and this was significantly lower 
than that for ER expression, which was 96%. The concordance rates 
for PgR and HER2 expression were 88% and 91%, respectively, 
and they were not significantly different from the rate for Ki-67 
expression. 45 patients(34.6%) had received mastectomy in the 
Ki-67 concordant group, and 14 patients(34.1%) in the discordant 
group. 55 patients(42.0%) showed T2~ tumor size in the concordant 
group, 13 patients(31.7%) in the discordant group. No significant 
differences of parameters such as operative method (mastectomy vs 
breast conserving surgery) and tumor size (T1 vs T2~) were observed 
between the two patient groups.
Conclusion: The reliability of Ki-67 concordance rate assessment 
using core needle biopsy specimens was significantly lower than 
that of ER expression. A standard pathological assessment of Ki-
67 expression might be needed for the possible use of Ki-67 as a 
predictive marker for preoperative endocrine therapy.
P1-07-16
Number Needed To Count: A Novel Model for Ki67 Assessment 
in Breast Cancer.
Bendahl P-O, Romero Q, Grabau D, Borgquist S. Institution of 
Clinical Sciences, Lund University, Sweden; Institution of Laboratory 
Sciences, Lund University, Sweden
Background:
Tumor proliferation assessed by Ki67 is frequently used as a 
prognostic and above all treatment predictive marker i breast cancer 
where a decrease in Ki67 expression, following neo-adjuvant therapy, 
may be interpreted as a reliable treatment effect. Previous studies have 
indicated that the optimal number of tumor cells needed to count may 
vary from case to case. The standard error of the estimated proportion 
will decrease with increasing number of tumor cells counted (n), 
but a dilution bias will affect the estimate in cases with few tumor 
cells within a hotspot area. Hence, a large n is appropriate in Ki67-
homogeneous hotspot areas and inappropriate, at least for small 
hotspots, in case of heterogeneity. Further, a chosen cut-off value has 
implications for the choice of n. A low n may be sufficient for extreme 
proportions, but the closer the true unknown proportion is to the cut-
off, the larger n will be required. The lack of consensus concerning 
Ki67 assessment may jeopardize the comparison of research results. 
Hence, a standardized counting model is warranted.
Material and Methods:
Exact two-sided confidence intervals for proportions based on the 
binomial distribution were used to derive rejection regions for 
sequential testing of the null hypothesis that the fraction of Ki67-
positive cells is equal to the chosen cut-off (20% in this study). A lower 
limit of 50 counted tumor cells to get a reasonably stable estimate 
and an upper limit of 400 tumor cells to prevent extreme dilution bias 
for small hotspots, were applied. Briefly, the counting strategy can 
be explained as follows: Locate a hotspot and count 50 tumor cells. 
If the Ki67 estimate belongs to the upper or lower rejection region, 
stop counting. If not, count another 10 tumor cells and perform a 
new hypothesis test. Proceed until either the null hypothesis has been 
rejected or the upper limit of 400 has been reached. Simulation was 
used to determine that a nominal significance level of a=0.01 for 
each test will keep the overall probability of falsely rejecting the null 
hypothesis fixed at 0.05. The novel counting strategy was compared 
to static counting of 200 tumor cells using 100 Ki67-stained breast 
cancer samples.
Results:
The median number of tumor cells needed to count to determine 
Ki67-status was 100 and the average 175. The rejection region was 
reached immediately after 50 tumor cells counted for 32 samples with 
Ki67-levels far from the cut-off, whereas counting 400 tumor cells 
was insufficient for classification in another 18 samples. In samples 
classified as highly proliferative (>20%), the mean Ki67-estimate 
was 49% using the counting model compared to 42% using a fixed 
denominator of 200 tumor cells. The largest absolute difference 
between the two estimates for these 32 samples was 23% - from 42% 
(model) to 19% (static), thus more than a factor two and a dilution 
effect leading to changed Ki67-status.
Conclusions:
Estimation of the fraction of Ki67-positive tumor cells using a fixed 
denominator may be inadequate – especially for small hotspots. We 
hereby propose a strategy for tumor cell count optimization that 
hopefully will contribute to standardization of the counting practice 
for tumor proliferation assessed by Ki67.
P1-07-17
Multiplex Plasma Biomarkers Associated with Bone Metastasis 
from Breast Cancer.
Leitzel K, Ali S, Bisen A, Lomakin A, Simonyan V, Lipton A. Penn State 
Hershey Medical Center, Hershey, PA; Lebanon VA Medical Center, 
Lebanon, PA; Massachusetts Institute of Technology, Cambridge, 
MA; BioCompanion LLC, Rockville, MD
Background: Over two-thirds of breast cancer patients who relapse 
will develop bone metastasis, and there are currently no effective 
biomarkers to predict for this event. Multiplex immunoassay 
technology for 60 bone metastasis-associated biomarkers was 
conducted on pretreatment plasma from 40 patients enrolled in a 
2nd-line phase III hormone therapy trial of metastatic breast cancer, 
to discover effective circulating biomarkers predictive of bone 
metastasis.
Methods: Pretreatment EDTA plasma from 20 patients with 
bone metastasis, and 20 patients with non-bone metastasis from 
the letrozole-megace 2nd-line phase III hormone therapy trial of 
metastatic breast cancer was evaluated using Searchlight multiplex 
immunoassay technology (Aushon Biosciences, Billerica, MA) on 
60 biomarkers custom-selected for known association with bone 
metastasis. Multiplex data analysis for maximal discrimination of 
bone metastasis vs. no bone metastasis cohorts was performed by 
two independent statisticians: one evaluated the predictive capacity 
of individual biomarkers as well as two-marker combinations 
constructed by Monte Carlo optimization using Metropolis algorithm 
(MMC), and the other used a machine learning technique called hybrid 
bootstrapped RLDA +PCA (regularized linear discriminant analysis 
with principal component analysis, with dimensionality reduction 
used in the bootstrapping procedure).
Results: One of the 60 analytes (IL-17) was undetectable at the 1.6 
pg/ml lower limit of detection, and was not included in the multiplex 
statistical analyses. Of the remaining 59 analytes, MMC multiplex 
analysis yielded 9 biomarkers that predicted for bone metastasis, 
whereas RLDA + PCA multiplex analysis yielded 20 predictive 
biomarkers. Common to both analyses, which were limited in this 
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small 40 patient study, were 5 biomarkers, with varying functions 
including growth factors, cytokines, inflammatory factors, protease 
inhibitors, and cell adhesion molecules.
Conclusions: Multiplex analysis of 60 biomarkers custom-selected 
for known association with breast cancer metastasis to bone yielded 
5 pretreatment plasma biomarkers classified as predictive of bone 
metastasis by 2 different multiplex statistical analysis methods. 
Evaluation of these biomarkers is now warranted in a larger validation 
cohort of breast cancer patients with and without bone metastasis.
P1-07-18
Expanding an Online Tool for Genome-Wide Validation of 
Survival-Associated Biomarkers in Breast and Ovarian Cancer 
Using Microarray Data of 3,862 Patients.
Gyorffy B, Lanczky A, Szallasi Z. Semmelweis University, Budapest, 
Hungary; Harvard Medical School, Boston
The pre-clinical validation of prognostic gene candidates in large 
independent patient cohorts is a pre-requisite for the development 
of robust biomarkers. We earlier implemented an online tool to 
assess the prognostic or predictive value of the expression levels of 
all microarray quantified genes in breast cancer patients. In present 
study, we further expanded our database, added additional analytical 
options and implemented the tool for ovarian cancer patients.
The database was set up using gene expression data and survival 
information of breast and ovarian cancer patients downloaded 
from GEO and TCGA (Affymetrix HGU133A, HGU133A 2.0 and 
HGU133+2 microarrays). After quality control and normalization 
only probes present on all three Affymetrix platforms were retained 
(n=22,277). Patients can be stratified into the various robust subtypes 
either by histology or by various gene expression profiling based 
methods. To analyze the prognostic value of the selected gene in the 
various cohorts the patients are divided into two groups according 
to the median expression of the gene. A Kaplan-Meier survival plot 
is generated and significance is computed.
All together 2,472 breast cancer patients and 1,390 ovarian cancer 
patients were entered into the database. These groups can be compared 
using relapse free survival (n=2,414 in breast cancer and 1,090 in 
ovarian cancer) or overall survival (n=463 and n=1,290). Follow-up 
threshold has been implemented to exclude long-term effects. The 
combination of several probe sets can be employed to assess the 
mean of their expression as a multigene predictor of survival and 
therapy efficiency.
In summary, we expanded our global online biomarker validation 
platform to mine all available microarray data to assess the prognostic 
power of 22,277 genes in 2,472 breast and 1,390 ovarian cancer 
patients. The tool can be accessed online at: www.kmplot.com/breast 
and www.kmplot.com/dev/ovar.
P1-07-19
Analysis of HER2-Status in Breast Cancer by Mass Spectrometry 
in Archival, Formalin-Fixed Tissues.
Sanders M, Sprung R, Ham A, Sanchez V, Manning S, Arteaga C, 
Liebler D. Vanderbilt University Medical Center, Nashville, TN
HER2 (ERBB2) is overexpressed in about 25% of breast cancers 
and predicts clinical benefit from trastuzumab, as well as response to 
anthracycline-based chemotherapy. Fluorescence in situ hybridization 
(FISH) to detect HER2 gene copy number and immunohistochemistry 
(IHC) to detect HER2 protein levels are approved by the FDA to 
identify HER2-positive (H2) tumors. However, the 2007 ASCO/CAP 
report concluded that approximately 20% of HER2 testing may be 
inaccurate. Further, the available data did not clearly demonstrate clear 
superiority of either IHC or FISH as a predictor of benefit from anti-
HER2 therapy. Discordance between these methods is as high as 5%. 
Thus, novel complementary quantitative methods for interrogating 
HER2 expression in tumors are needed.
Targeted protein analysis by multiple reaction monitoring mass 
spectrometry (MRM-MS) offers a powerful approach to configure 
assays for specific proteins without using antibodies. Our studies 
using this platform have demonstrated applicability to formalin-fixed, 
paraffin-embedded (FFPE) specimens. In the current studies, we used 
this approach to measure signals from two tryptic peptides specific 
to HER2, one each from the extracellular and intracellular domains, 
selected from among 28 candidates based on their signal intensity 
and sharpness of their chromatographic profiles. Preliminary studies 
with a HER2-overexpressing BT474 xenograft in mice demonstrated 
quantitation and detected previously reported HER2 ectodomain 
shedding. Subsequent analysis of FFPE tissue from five H2 and 
five triple-negative (TN) tumors yielded measurement of at least 1 
femptomole of receptor for H2 tumors and less than 0.2 femptomole 
of receptor for TN tumors per microgram of digest analyzed. If we 
assume 200 picograms of protein per cell, the results suggest 110,00 to 
468,000 receptors per cell in the H2 tumors and only 2,000 to 14,000 
receptors per cell in the TN tumors. Despite significant biological 
variability in receptor levels measured among the specimens of each 
type, a clear separation of the H2 and TN tumors was achieved based 
on the peptide quantitation. This preliminary study demonstrates the 
potential of MRM-MS in FFPE tissue to provide an alternate approach 
to IHC-based protein analysis. MRM-MS offers the potential for more, 
accurate and robust HER2 quantification in clinical breast cancer 
tissues. The next phase of this work will encompass a larger sample 
set, including tumors with equivocal and negative FISH and/or IHC 
test results. Correlation with response to anti-Her2 therapy will be 
performed in samples with available follow-up data.
P1-07-20
Consistent High False Negative Rate of HER2 qRT-PCR of 
Oncotype DX® in Comparison to ASCO/CAP Recommended 
Combined IHC/FISH Method.
Dabbs DJ, Bhargava R. Magee-Women’s Hospital of UPMC, 
Pittsburgh, PA
Background
In our prior multi-institutional study of 843 cases we have shown 
a high false negative rate for HER2 testing by the oncotype DX® 
RT-PCR method, (ODX) compared to our combined FISH and IHC 
approach [J Clin Oncol 29: 2011 (suppl; abstr 603)]. This study is part 
of an ongoing quality assurance study, comparing HER2 test results 
by FISH/IHC and the ODX.
Methods
From July 2010 till April, 2011, all patients who had either positive or 
equivocal HER2 results (on core biopsy) at Magee-Womens Hospital 
(MWH) by combined IHC/FISH, and who also had the ODX ordered 
(on resection specimen) by an oncologist, were reviewed for positive 
concordance of HER2 results. All tissues were fixed and FISH/IHC 
was reported according to ASCO/CAP HER2 guidelines. The core 
biopsy HER2 positive results were also confirmed positive on the 
same tissue block that was tested by ODX.
Results
Of the total 234 cases, there were 21 cases that were either classified as 
positive (n=8) or equivocal (n=13) by combined IHC/FISH approach 
at MWH. Of the 8 MWH+ cases, 4 showed 3+ IHC score and these 
were also positive by ODX. The remainder 4 MWH+ cases were 
IHC 2+, and unequivocally amplified by FISH. These 4 cases were 
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either equivocal (2 cases) or negative (2 cases) by ODX. Thirteen 
cases reported as equivocal by MWH FISH, were all reported as 
negative by ODX. Of the 213 MWH negative cases, 212 were also 
negative by ODX (percent negative agreement of >99%) and one 
case was called equivocal. If all equivocal cases are excluded, then 
percent positive agreement (PPA) between IHC/FISH and ODX is 
67% (4/6). If “equivocal” cases are considered as “negative”, then 
PPA is 50% (4/8). If “equivocal” cases are considered as “positive”, 
then PPA is only 29% (6/21).
Conclusions
(1) Similar to our prior study [J Clin Oncol 29: 2011 (suppl; abstr 
603)], there is a consistent poor percent positive agreement for 
HER2 testing between FDA cleared FISH/IHC methods and ODX, 
and these results cast serious doubt on the robustness/reliability of 
ODX results for HER2. (2) There should be serious concern raised 
over the reliability of the other multivariate index platform results of 
ODX, and likely, the ODX recurrence score for an individual patient, 
as this sensitivity data suggests inadequate tissue microdissection, or 
issues with the ODX test platform. (3) Clinicians need to be aware that 
HER2 results of ODX are not reliable for patients who are equivocal 
or amplified by FDA approved methods, and only FDA approved 
methods should guide treatment decisions.
P1-07-21
Analysis of Molecular Markers by Immunohistochemistry 
(IHC) Method on Formalin Fixed Paraffin Embedded (FFPE) 
Tissues Could Predict Shorter Recurrence Free Survival (RFS) 
and Overall Survival (OS) among Patients Who Have Received 
Adjuvant Chemotherapy for Early Breast Cancer.
Moe M, Gee J, Finlay P, Mansel R, Adams R. Singleton Hospital, 
Swansea, United Kingdom; Velindre Hospital and Cardiff University, 
Cardiff, United Kingdom; Cardiff University, Cardiff, United Kingdom
Background: Various molecular markers assessed by IHC (ER, PR, 
HER2) and gene expression profiling (e.g. Oncotype Dx) have been 
developed as prognostic and predictive tools for breast cancer. Gene 
profiling is said to be superior to IHC but at a considerable cost with 
limited availability. IHC is relatively inexpensive and more readily 
available. If early breast cancer patients who are going to relapse 
within 5 years of curative surgery despite adjuvant chemotherapy 
could be identified by IHC on FFPE tissue alternative adjuvant 
therapies could be explored. In this context, here we evaluate IHC 
for expression of a panel of molecular markers implicated in: growth 
signalling pathways (ER, PR, HER2, EGFR, CD71, Ki67, MCM2), 
cell survival (Bcl-2, Bag 1), angiogenesis (PDGFRa) and cell cycle 
progression (Aurora A, MCM2). Of note, this study includes markers 
of breast cancer molecular subtype (ER, PR, HER2, Ki67, EGFR, 
also CK5/6) and several proteins encoded by genes in the Oncotype 
Dx test (ER, PR, HER2, Ki 67, Bcl2, Bag1 and CD68).
Materials and Method: 72 cases (R) relapsing within 5 years of 
curative surgery, 72 controls (C), relapse free > 5 years were identified 
from the hospital records. All patients had adjuvant chemotherapy. 
Controls were matched to cases by Adjuvant! recurrence risk 
(ARR). Optimised IHC was performed on FFPE TMA slides using a 
Ventana autostainer. Protein expression was evaluated on digitalised 
images (Mirax scanner). Survival analysis by molecular markers 
expression and also 5 molecular subtypes, Luminal A (LA = ER/
PR+, HER2-, Ki67-), Luminal B (LB = ER/PR+, HER2/Ki67+), 
HER2 enriched (H = ER-, PR-, HER2+), Core Basal (CB = ER-, 
PR-, HER2-, CK5/6/EGFR+) and 5-negative (5N = negative for 
ER,PR,HER2,EGFR,CK5/6)], were performed. SPSS 16v. was used 
for statistical analysis.
Findings: All but four cases had died at the time of analysis. Four 
controls developed relapse at 83.8, 90.6, 107.7, 127.6 months 
respectively. Two controls died from non-breast cancer causes. 
Median (m) follow-up for the controls group ( ie. mOS)was 104.9 mo 
(72.8 - 164.4). For cases, mRFS and mOS were 23.2 (4.5 - 59.9) and 
39.7(8.1 - 129). mRFS and mOS for IHC molecular subtypes were: 
Subtype LA = not yet & not yet; LB = 58.1 & 86.1; CB = 15.4 & 30.4; 
H = 28 & 55.9; 5N = 19.9 & 26 (p < 0.0001 & <0.0001 by Log rank 
test). Better RFS and OS were found for positive Bcl2 (p = 0.036 & 
0.058) and MCM2 (p = 0.022 & 0.048), negative Aurora A (p = 0.01 
& 0.001) and PDGFRa (p = 0.07 & 0.086) expressions. For this study 
cohort there was no correlation between ARR and survival outcome 
or molecular subtypes. Result of ongoing multivariate analysis and 
correlation between survival and CD68, CD71 and Bag 1 expressions 
will be presented in the conference.
Discussion: Subtypes CB & 5N, negative Bcl-2 & MCM2, positive 
Aurora A & PDGFRa expression as measured by IHC were predictive 
of poor RFS and OS. While these findings need to be verified in 
an independent cohort, IHC profiles nevertheless have potential to 
stratify different risk groups for clinical trials and effective adjuvant 
treatments.
P1-07-22
A Venezuelan Study of Breast Cancer Estrogen Receptor, 
Progesterone Receptor and HER2 Receptor Expression by the 
Standard Method, Immunohistochemistry (IHC), Compared to 
a New Method, Quantitative Reverse Transcription Polymerase 
Chain Reaction (RT-PCR).
Marin C-EM, Ramirez AC, Baehner FL, Yoshizawa C, Acosta MM. 
Fundacion BADAN, Caracas, Miranda, Venezuela; Genomic Health, 
Redwood City, CA
Background: Assessment of ER, PR and HER2 is of significant 
importance in breast cancer diagnosis and treatment. We have 
performed the first large assessment of central IHC for ER, PR and 
HER2 by a South American (Caracas, Venezuela) Central Lab to 
Central Lab RT-PCR by Oncotype DX®.
Design: Breast cancer specimens from the Fundación BADAN were 
evaluated by IHC for ER (clone 1D5), PR (clone 636) using 1% 
staining for positivity using ASCO/CAP guidelines and HER2 (clone 
A0485) using ASCO/CAP guidelines of 3+ in ≥30%. Standardized 
quantitative RT-PCR analysis for ER and PR used Oncotype DX 
with the pre-defined cutoffs of 6.5 units and 5.5 units for positivity, 
respectively. For HER2 the standard pre-defined cutoffs were used: 
positive ≥11.5 units, equivocal >10.7-<11.5 units, and negative 
≤10.7 units. For HER2 concordance analysis the equivocal range 
was excluded from both assays according to ASCO/CAP Guidelines 
(Wolff et al, 2006). For all quantitative RT-PCR assessments the 
reference normalized expression measurements ranged from 0 to 15, 
where each 1-unit increase reflects about a 2-fold increase in RNA.
Result: Evaluable data was obtained in 96 pts for ER, 95 pts for PR 
(1 patient assessment unavailable) and 89 pts for HER2 (7 patient 
assessments unavailable). Two-by-two tables (below) compare IHC 
versus RT-PCR for ER, PR and HER2. The overall concordance for 
ER between IHC and RT-PCR was 94% (Kappa 0.467; 95% CI 0.107, 
0.828); for PR between IHC and RT-PCR was 92% (Kappa 0.668; 
95% CI 0.457, 0.878); and for HER2 between IHC and RT-PCR was 
97% (Kappa = 0.649; 95% CI 0.280, 1.000). Three IHC 2+ cases and 
4 equivocal cases by Oncotype DX were excluded from Concordance 
and Kappa statistics.
Conclusion: RT-PCR by Oncotype DX for ER, PR and HER2 status 
is useful for active monitoring of IHC assays as mandated by ASCO/
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CAP guidelines. There is a high degree of overall concordance 
between central IHC performed in South America (Caracas, 
Venezuela) and central RT-PCR for ER, PR and HER2 status.
Concordance for IHC versus RT-PCR for ER, PR and HER2
ER ODx - ODx + All
ER IHC - 3 4 7
ER IHC + 2 87 89
All 5 91 96
    
PR ODx - ODx + All
PR IHC - 10 1 11
PR IHC + 7 77 84
All 17 78 95
    
HER2 ODx - ODx + All
HER2 IHC 0, 1+ 83 1 84
HER2 IHC 3+ 2 3 5
All 85 4 89
HER2 Excludes Equivocal Cases per ASCO/CAP guidelines
P1-07-23
Absolute Quantification of Estrogen Receptor alpha in Breast 
Cancer.
Britton D, Scott G, Russell C, Held J, Ward M, Benz C, Pike I. 
Proteome Sciences Plc, London, United Kingdom; Buck Institute, 
Novato, CA
Estrogen receptor alpha (ER) is the first biomarker to have been 
clinically validated as a predictor of cancer therapy response. 
Measurements of tumor ER expression were based on radiolabeled 
ligand binding to receptor present in tumor lysates. Despite substantial 
tissue requirement, lack of specificity for ER isoforms (alpha versus 
beta) or receptor integrity, quantitative determination of tumor ER 
content (fmol/mg total protein) was possible. Introduction of anti-ER 
antibodies later permitted immunohistochemical (lHC) evaluation of 
ER expression. IHC determination of ER status in newly diagnosed 
breast cancer is now a standard of care. While these IHC assays 
have been shown to be as predictive of endocrine responsiveness 
as ligand binding assays, they remain semi-quantitative at best 
reporting tumor ER status either categorically (e.g. + or -) or as a 
numeric score which is subjective and lacks a linear relationship 
with endocrine responsiveness. Thus the lack of precision for 
quantifying ER as a predictive biomarker is one of the most important 
unresolved issues in breast cancer. We are working to develop a 
proteomic liquid chromatography-mass spectrometry (LC-MS) assay 
to help resolve this issue. Samples included recombinant ER (rER), 
immunoprecipitated (IP) rER, and IP ER from MCF7 cells. ER was 
digested with trypsin, lyophilised and solubilised in 5 femto-mol/
microliter (100 ml) heavy peptide internal standard mix. ER peptides 
were resolved by LC (100 ml/minute) and detected by selected reaction 
monitoring MS. The area under the total ion chromatogram for each 
peptide were used to quantify the amount of analyte present in each 
sample as a single point reference to the signal of the heavy peptide 
spike. An 11 point calibration curve (0.1-1000 fmol on column (o/c)) 
of light peptides with each point in the curve spiked with 100 fmol 
heavy peptide was also produced to determine assay characteristics 
such as limits of detection (LOD), limits of quantification (LOQ), 
linearity, accuracy and precision. Three ER peptides were selected 
for quantification as they gave the greatest LOD, LOQ, linearity as 
well as reasonable intra- and inter-assay precision following multiple 
digestions of rER (intra = 3 digestions in 1 day; inter = 9 digestions 
over 3 weeks).
 LOD  
(fmol o/c)
LOQ  
(fmol o/c)
R2 Intra cv % Inter cv %
YYITGEAEGFPATV 0.70 2.32 0.9999 8 18
EAGPPAFYRPNSDNRR 0.19 0.63 0.9904 27 28
GGASVEETDQSHLATAGSTSSHSLQK 1.35 4.49 0.9996 6 13
Following IP of ER from four replicate MCF7 cell lysates (1mg/
ml total protein) and measurement of ion intensities of the three ER 
peptides the mean concentration of ER was calculated to be 52 fmol 
(S.D of 7.5 fmol; n=4) per mg of total cell lysate after normalising 
for IP efficiency. We continue to develop the method to improve 
sensitivity and normalise for variability in IP and digestion. With the 
inclusion of reference peptides to known ER phosphorylation sites we 
are also in the process of quantifying ER phosphorylation. We aim to 
accurately determine ER concentration and phosphorylation status 
in tumor lysates and assess how these correlate with responsiveness 
to antiestrogen therapies.
P1-07-24
Quantitative and Immunohistochemical Detection of Breast 
Cancer Cells in Blood Samples.
Andergassen U, Zebisch M, Kölbl AC, Schindlbeck C, Jäger B, Hepp 
P, Janni W, Jeschke U, Friese K, Rack BJ. Ludwig-Maximilians-
University Muenchen, Munich, Bayern, Germany; Heinrich-Heine-
University Düsseldorf, Duesseldorf, NRW, Germany; Klinikum 
Traunstein, Traunstein, Bayern, Germany
Background
Disseminated tumor cells (DTCs) in bone marrow and circulating 
tumor cells (CTCs) in blood are found in patients with epithelial 
carcinomas (breast cancer) and are often correlated with poor 
prognosis of the disease. In current models circulating tumor 
cells (CTCs) dissolved from the primary tumor are thought to be 
responsible for the occurrence of metastases. However, the detection 
of CTCs is still a technical challenge. In this study, two methods for 
tumor cell detection of patients’ samples are presented (Real-Time-
PCR and immunohisto-chemical staining). Both are simple and known 
methods with a high sensitivity and a spread marker panel.
Materials and Methods
For the implementation of both methods, different breast cancer 
cell lines have been used (Cama-1, MCF-7; ZR-75-1). For Real-
Time-PCR, blood samples of a healthy donors were spiked with 
different cell counts (0, 10, 100, 1000, 10.000 and 100.000) per ml 
blood sample. Total RNA was isolated from the samples, reversely 
transcribed into cDNA and used for TaqMan Real-Time-PCR reaction 
with probes against CK8, 18 and 19, while 18S was used as reference. 
Relative Quantification Curves were drawn by Microsoft™ Excel®.
For immunohistochemical staining, cytospins were prepared from 
spiked blood samples, fixed with acetone, air dried and stained 
with antibodies against Her2- and Thomsen-Friedenreich-Antigen 
(CD176). In a second staining step fluorescently labelled secondary 
antibodies were applied. Nuclei were counterstained with DAPI, TF-
Antigen was stained by Cy2 and Her2-Antigen by Cy3. The staining 
was controlled and documented by an epifluorescence microscope.
Results
The curve of Relative Quantification for MCF-7 and ZR-75-1 cells 
shows an increasing slope starting from 1000 cells. For the Cama-1 
cell line this trend is already seen from 10-100 cells. In ZR-75-1 all 
three genes analysed reveal this trend, whereas in Cama-1 and MCF-7 
cells a strong increase in Relative Quantification is especially seen 
for CK8 and 18. In the immunohistochemical staining, the cells were 
considered as tumour cells if they showed staining with the antibody-
combinations used. Stained cells were counted and recovery rates 
were determined. For ZR-75-1, 17 of 30 cells which were spiked in 
the blood samples were recovered. For MCF-7, 18 cells were found 
in average, and for Cama-1 23 cells were located per slide. The 
recovery rates calculated from these numbers are 56,6% and 60,0% 
for ZR-75-1 and MCF-7, for Cama-1 the recovery rate reaches 76,6%.
Conclusion It seems that Cama-1 cells are a better model than MCF-7 
and ZR-75-1 for Real-Time PCR quantification of mamma carcinoma 
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tumor cells in blood samples. MCF-7 and ZR-75-1 cells tend to 
react more likely immunologically with blood cells of the donor 
(agglutination between blood cells and cancer cells). The Cama-1 
cell line shows also advantages in the detection of tumor cells using 
immunohistochemical staining. Therefore it will be necessary to test 
both methods on patient samples to proof their benefit.
P1-08-01
Survival in Metastatic Breast Cancer (MBC): No Evidence for 
Improved Survival Following Distant Recurrence after Adjuvant 
Chemotherapy.
Tevaarwerk AJ, Gray R, Schneider BP, Smith ML, Wagner LI, Miller 
KD, Sparano JA. University of Wisconsin-Carbone Cancer Center; 
Indiana University-Simon Cancer Center; Northwestern University, 
Chicago, IL; Dana-Farber Cancer Institute; Research Advocacy 
Network; Albert Einstein University-Montefiore Medical Center
Population-based studies have suggested improved survival for 
patients diagnosed with MBC in recent years, presumably due to the 
availability of new and more effective therapies (Chia et al. Cancer 
2007; Dawood et al. JCO, 2008). The objective of this analysis was 
to determine if survival improved for patients who participated in 
Eastern Cooperative Oncology Group (ECOG) adjuvant trials and 
later developed MBC.
Methods: Adjuvant trials coordinated by the ECOG that accrued 
patients between 1978 and 2002 were reviewed (n=12), which 
included followup until 2010. Cytotoxic and biologic agents approved 
for MBC during this time included paclitaxel (1994), capecitabine 
and trastuzumab (1998), docetaxel and gemcitabine (2004), lapatinib 
and ixabepilone (2007), and bevacizumab (2008). Survival following 
distant recurrence was estimated for 4 time periods ranging from 
6-10 years, and adjusted for baseline covariates in a Cox proportional 
hazards model. Because distant relapse free interval (DRFI) was the 
covariate most strongly associated with survival after recurrence, and 
the potential for “gap time” bias this could introduce, logrank tests for 
other covariates and estimates of effects were computed stratified on 
DRFI (0-3, >3-6, > 6 years). HER2 status was not routinely available 
and thus not included.
Results:  The 12 trials included 14,752 patients (93% received 
adjuvant chemotherapy); 3711 (25.2%) developed distant recurrence. 
Median survival after distant recurrence was 20 months; the estimated 
5 and 10-year survival rates were 16.3% and 6.1%, respectively. 
Median survival by time period is shown in the table, stratified 
by DRFI. Median survival did not significantly change over time 
by DRFI (≤3 years, p=0.15; >3 yr, p=0.57). In a Cox proportional 
hazards model, factors associated with inferior survival after adjusting 
for other covariates included shorter DRFI (<3 years vs. 3-6 years 
- hazard ratio [HR] 1.60, p<0.001, and > 6 vs. < 3 years - HR 2.23, 
p <0.001), ER-negative disease (HR 1.30, p<0.001), PR-negative 
disease (HR 1.36, P<0.0001), number of positive axillary nodes at 
diagnosis (1-3 vs. 0 nodes - HR 1.28, 4-9 vs. 0 nodes - HR 1.51, > 
9 vs. 0 nodes - HR 1.51, p<0.0001), and black vs. white race (HR 
1.29, p=0.0003), but not age at recurrence (p=0.07). When the year 
of recurrence was added to the Cox proportional hazards model 
using the intervals shown in the table below, it was not significantly 
associated with survival. Results were similar when 1978-2010 was 
assessed by 5-6 year intervals.
Conclusions:  In contrast to reports from population-based studies, 
we do not observe any improvement in survival over time for patients 
who develop distant recurrence after adjuvant chemotherapy. There 
remains a critical unmet need for new therapies for MBC, especially 
for those who recur after adjuvant chemotherapy.
Table 1. Survival by year of recurrence with MBC
Year of Diagnosis with MBC DRFI>3 years DRFI>3 years Logrank P value
1978-86 13 mo 34 mo <0.0001
1987-94 13 mo 33 mo <0.0001
1995-2004 14 mo 31 mo <0.0001
2005-10 -- 32 mo --
 p=0.15 p= 0.57  
P1-08-02
Pre-Diagnosis Body Mass Index and Breast Cancer Prognosis and 
Survival: Report from the after Breast Cancer Pooling Project.
Kwan ML, Chen WY, Weltzien E, Beasley JM, Lu W, Nechuta SJ, 
Quesenberry CP, Pierce JP, Shu XO, Caan BJ. Kaiser Permanente 
Division of Research; Brigham and Women’s Hospital and Harvard 
Medical School; Fred Hutchinson Cancer Research Center; Shanghai 
Institute of Preventive Medicine; Vanderbilt University; University 
of California, San Diego
Background: A large body of evidence dating back over 30 years 
suggests that obese women have poorer survival after a breast cancer 
(BC) diagnosis compared to non-obese women. Despite most studies 
supporting an association of elevated risk of overall mortality with 
obesity, the relationship of obesity with risk of BC recurrence, BC 
mortality and non-BC mortality remains unclear. Furthermore, reports 
suggest that the association of BMI with BC outcomes may be U or J 
shaped, prompting the necessity of examining underweight and more 
severely obese women as independent groups. We conducted a pooled 
investigation of pre-diagnosis BMI and BC recurrence and survival 
using data from the After Breast Cancer Pooling Project (ABCPP).
Materials and Methods: The ABCPP includes 14,950 BC survivors 
from four prospective cohorts (three US and one Shanghai, China) 
diagnosed from 1990-2006 with invasive primary AJCC Stage 
I-III BC at ages 20-83 years. A random effects meta-analysis was 
conducted to assess heterogeneity across studies and poolability of 
data. Delayed entry Cox proportional hazards models were used to 
estimate hazard ratios (HR) and 95% confidence intervals (CI) for 
the associations of pre-diagnosis BMI (underweight <18.5 kg/m2, 
normal 18.5-<25 kg/m2, overweight 25-<30 kg/m2, obese ≥30 kg/
m2) with BC recurrence, BC death, non-BC death, and overall death, 
adjusted for age at diagnosis, stage, race/ethnicity, menopausal status, 
hormone receptor status, number of positive lymph nodes, treatment, 
smoking history, and comorbidity (diabetes, hypertension, and/or 
CVD). Subgroup analyses further divided the obesity group into obese 
(30-<35 kg/m2), severely obese (35-<40 kg/m2), and morbidly obese 
(≥40 kg/m2) categories.
Results: No heterogeneity in effect estimates by study was found. 2104 
deaths (1416 BC-related) and 2320 recurrences were observed after a 
mean (SD) of 7.66 (3.95) years of follow-up. Both underweight and 
obese women had a statistically significant increased risk of overall 
death compared to normal-weight women (underweight HR=1.69; 
95% CI: 1.25, 2.28 and obese HR=1.22; 95% CI: 1.08, 1.38; p for non-
linear association<0.01). Similar associations were found for non-BC 
death. Obese but not underweight was associated with increased risk 
of BC death (HR=1.17; 95% CI: 1.01, 1.36) and recurrence (HR=1.11; 
95% CI: 0.98, 1.26). When examining finer obesity categories, the 
morbidly obese women had the greatest risk for all outcomes (overall 
death HR=1.90; 95% CI: 1.48, 2.45; non-BC death HR= 3.27; 95% 
CI: 2.25, 4.77; BC death HR = 1.47; 95% CI: 1.05, 2.06; recurrence 
HR = 1.27; 95% CI: 0.95, 1.71). No effect modification was observed 
by menopausal status, hormone receptor status, chemotherapy, and 
smoking. In all analyses, overweight women had similar risk of 
outcomes compared to normal-weight women.
Discussion: In this large pooling study of nearly 15,000 BC survivors, 
we found that the association between BMI and BC outcomes, 
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specifically overall death and non-BC death, was U shaped with 
both underweight and obese women at greatest risk. Morbidly obese 
women were at even greater risk compared to other obesity groups. 
Maintaining a healthy weight throughout adult life may be beneficial 
for BC prognosis and survival.
P1-08-03
Huge Improvement in Relapse-Free Breast Cancer Survival over 
the Last 25 Years.
Geurts SME, van Dijck JAAM, de Vegt F, Paquay Y, Siesling S, 
Verbeek ALM, Tjan-Heijnen VCG. Radboud University Nijmegen 
Medical Centre, Nijmegen, Netherlands; Hospital Bernhoven, 
Oss, Netherlands; Comprehensive Cancer Centre, Netherlands; 
Maastricht University Medical Centre, Maastricht, Netherlands
Introduction The purpose of this study was to evaluate the dwindling 
risk of relapse in breast cancer patients treated with curative intent 
since the 1970s.
Patients and methods 8570 women diagnosed with invasive breast 
cancer in 2003 or 2004 were compared with 307 consecutively 
diagnosed patients with invasive breast cancer between 1972 and 
1986 in the Netherlands. Five-year overall survival and 5-year risk of 
relapse, i.e. second primary breast cancer, locoregional recurrence or 
distant metastasis, were calculated using the Kaplan-Meier method. 
Multivariable Cox-proportional hazards modelling was applied to 
correct the period-specific risk of relapse for tumour size, lymph 
node involvement and age at diagnosis.
Results Median (range) age at diagnosis was 52 years (27-82 years) 
in 1972-1986 and 58 years (20-96 years) in 2003-2004. Patients 
diagnosed in 1972-1986 had a larger tumour size and similar nodal 
involvement as compared to patients diagnosed in 2003-2004. In 
2003-2004 more women were treated with breast conserving surgery, 
chemotherapy, and hormonal therapy as compared to 1972-1986. The 
5-year overall survival rate increased from 71% (95% CI: 65% - 76%) 
in the period 1972-1986 to 85% (95% CI: 84% – 85%) in the years 
2003-2004. Five-year risk of any relapse decreased from 37% to 16% 
across the calendar years (table 1). This decrease was observed for 
the risk of locoregional recurrence and the risk of distant metastasis 
(table 1). Risk of second primary breast cancer was similar for both 
periods of diagnosis (table 1). After adjustment for tumour size, nodal 
status and age at diagnosis the decrease in risk of relapse remained 
significant for patients diagnosed in 2003-2004 compared to 1972-
1986 (HR= 0.5, 95% CI: 0.4 - 0.6).
Conclusion Over the last decades, the risk of breast cancer relapse 
has tremendously decreased, also after adjustment for tumour stage 
and age at diagnosis. The improved prognosis can be explained 
by the more often administered and intensified systemic treatment 
procedures and, further, by an earlier detection. The similar nodal 
stage probably resulted from stage migration caused by a more 
thoroughly performed lymph node staging in 2003-2004 compared 
to 1972-1986.
TABLE 1 Five-year risk of relapse by site of recurrence and period of diagnosis
 1972-1986 2003-2004
 n=279 n=8415
First site of relapse No. events 5-year risk (95% CI) No. events 5-year risk (95% CI)
Relapse 99 0.37 (0.31-0.42) 1277 0.16 (0.15-0.17)
Second primary tumor 7 0.03 (0.01-0.05) 186 0.02 (0.02-0.03)
Local or regional recurrence 44 0.18 (0.13-0.23) 285 0.04 (0.03-0.04)
Distant metastases 70 0.34 (0.29-0.40) 938 0.12 (0.11-0.13)
P1-08-04
Obesity, Adjuvant Therapy, and Survival Outcomes in Early-
Stage Breast Cancer.
Jiralerspong S, Wang T, Rimawi MF, Nangia JR, Schiff R, Giordano 
SH, Pollak MN, Chenault CC, Osborne CK, Hilsenbeck SG. Baylor 
College of Medicine, Houston, TX; M.D. Anderson Cancer Center, 
Houston, TX; McGill University, Montreal, Canada
BACKGROUND: Obesity has risen to epidemic proportions and is 
associated with worse breast cancer (BC) prognosis in most studies. 
However, the effects of obesity according to adjuvant therapy 
choice are largely unknown. To address this issue, we examined the 
relationship between body mass index (BMI), adjuvant therapy, and 
survival outcomes in a large cohort of early-stage BC patients.
METHODS: We retrospectively studied patients from the Baylor 
Breast Center Tumor Bank treated from 1970-1995. Patients were 
divided into 3 BMI classes: normal/underweight (N, BMI<25), 
overweight (Ov, BMI 25-30), obese (Ob, BMI≥30); and 4 treatment 
groups: no adjuvant therapy, chemotherapy (mainly CMF), endocrine 
therapy (mainly tamoxifen), both chemo- and endocrine therapy. 
Time-to-recurrence (TTR), disease-free survival (DFS) and overall 
survival (OS) were estimated by the Kaplan-Meier method and 
compared among groups via the log-rank test. Multivariate analysis 
was conducted via Cox proportional hazards models.
RESULTS: There were 4,368 patients. Median age was 58. 74% 
were postmenopausal. 72% had stage I-II disease, 28% stage III. 
76% were estrogen receptor (ER)-positive, 24% ER-negative. 
Patients distributed into BMI classes as follows: N 48%, Ov 30%, 
Ob 22%. Higher BMI was associated with postmenopausal status 
and increasing age, tumor size, positive lymph nodes, and stage, 
as well as a higher likelihood of receiving treatment. Median 
follow-up was 5 years. Kaplan-Meier analysis showed that TTR 
was significantly shorter in the Ov and Ob groups as compared to 
the N group (p=0.019), due to distant (p=0.001) rather than local 
(p=0.970) recurrences. DFS was also significantly worse in the Ov 
and Ob groups (p=0.002), as was OS (p=0.001). The Table shows the 
hazard ratios for the various survival outcomes after adjustment for 
age, tumor size, nodal status, and treatment groups. For all patients, 
TTR, DFS, and OS were significantly worse in the Ob vs. N groups. 
TTR and DFS were significantly worse in the chemo treated Ob vs. 
N groups. DFS and OS were significantly better in the endo treated 
Ov vs. N groups.
DISCUSSION: In this large cohort of BC patients, survival outcomes 
(TTR, DFS, OS) were significantly worse in the obese group. This 
remained true after adjustment for multiple factors. Obesity was 
associated with worse survival outcomes in the chemo treated (CMF) 
group. Overweight was associated with better survival outcomes in 
the endo treated (tamoxifen) group. These results confirm and extend 
the results of previous studies. Further studies to discover the reasons 
for these differences in outcomes are underway.
Summary of hazard ratios by BMI categories and treatment groups
 TTR DFS OS
BMI category All patients   
Ov 1.001 (0.872-1.149) 0.990 (0.887-1.105) 0.972 (0.863-1.095)
Ob 1.156 (0.999-1.339) 1.133 (1.006-1.276) 1.180 (1.040-1.340)
 Untreated   
Ov 0.981 (0.799-1.204) 1.012 (0.869-1.180) 1.042 (0.884-1.227)
Ob 1.179 (0.944-1.472) 1.106 (0.929-1.317) 1.097 (0.909-1.322)
 Chemo   
Ov 1.155 (0.877-1.520) 1.109 (0.868-1.417) 1.026 (0.784-1.343)
Ob 1.380 (1.041-1.830) 1.295 (1.004-1.671) 1.283 (0.970-1.696)
 Endo   
Ov 0.724 (0.488-1.074) 0.631 (0.464-0.857) 0.590 (0.425-0.820)
Ob 0.871 (0.576-1.318) 0.886 (0.653-1.202) 0.997 (0.725-1.370)
 Both   
Ov 1.035 (0.724-1.479) 1.120 (0.828-1.513) 1.101 (0.791-1.533)
Ob 0.952 (0.645-1.405) 1.096 (0.798-1.505) 1.317 (0.942-1.841)
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Age and Survival in Women with Early Stage Breast Cancer: An 
Analysis Controlling for Tumor Subtype.
Partridge AH, Hughes ME, Ottesen R, Wong Y-N, Edge SB, Theriault 
RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. Dana-
Farber Cancer Institute, Boston, MA; City of Hope, Duarte, CA; 
Fox Chase Cancer Center, Philadelphia, PA; Roswell Park Cancer 
Institute, Buffalo, NY; University of Texas MD Anderson Cancer 
Center, Houston, TX; Stanford Cancer Center, Palo Alto, CA; Brigham 
and Women’s Hospital, Boston, MA
Background: Previous research has suggested that young age at 
diagnosis is an independent risk factor for breast cancer recurrence 
and death in women with early stage breast cancer. However, young 
women are more likely to have aggressive subtypes of breast cancer. 
No prior studies have adequately controlled for tumor phenotype, 
including HER-2/neu (HER2) status, in particular. Recent evidence 
has suggested that the prognostic effect of young age varies by tumor 
subtype.
Methods: We examined data from women with newly diagnosed 
Stage 1-3 breast cancer presenting to one of 8 NCCN centers between 
January 2000 and December 2007. Multivariate Cox proportional 
hazards models were used to assess the relationship between age 
and breast cancer specific survival, controlling for known prognostic 
factors and treatment. In addition, we conducted stratified analyses 
by estrogen receptor (ER) and HER2 status.
Results: 19,633 women with Stage 1-3 breast cancer eligible for 
analysis including 2,177 (11%) who were age 40 years or younger 
at diagnosis. Younger women were more likely to be non-white or 
Hispanic, more educated, employed, and to have higher stage, high 
grade, ER-negative, progesterone receptor (PR) negative, and HER2-
positive disease, and treated with chemotherapy and trastuzumab 
(all variables P< 0.0001 by Chi-Square test). 5-year survival among 
younger women was 94.1 (95% Confidence Interval [CI] 92.9-95.3) 
and 96.3 (95% CI 95.9-96.6) for older women. In a multivariate 
Cox proportional hazards model controlling for sociodemographic, 
disease, and treatment characteristics, women age < 40 or younger at 
diagnosis had increased mortality compared to older women (Hazard 
Ratio [HR] 1.26, 95% CI 1.02-1.56). In stratified analyses, age 40 
or less was associated with increased mortality among women with 
ER-positive disease (HR 1.44, 95% CI 1.01-2.05), but was not among 
those with ER-negative disease (HR 1.15, 95% CI 0.85-1.55). Younger 
age was associated with a statistically significant increase in mortality 
among women with HER2-negative disease (HR 1.29, 95% CI 1.00-
1.68), but this difference did not reach statistical significance among 
those with HER2-positive disease (HR 1.30, 95% CI 0.82-2.09).
Conclusions: The effect of age on short-term survival of women 
with early breast cancer appears to vary by breast cancer subtype, 
particularly ER status. Further research to elucidate differences in 
breast cancer biology and efficacy of therapy within tumor types by 
age is warranted.
P1-08-06
Breast Cancer among Patients with Diabetes, Obesity and 
Abnormal Blood Lipids – A Population-Based Register Study 
in Sweden.
Olsson H, Attner B, Landin Olsson M, Lithman T, Noreen D. Clinical 
Sciences, Lund University, Lund, Sweden
Objective: To study how the incidence of breast cancer is related to 
diabetes, obesity or abnormal blood lipids.
Methods: Diagnosis of diabetes, obesity or abnormal blood lipids 
was studied 0-10 years prior to the diagnosis of cancer in 2724 cases 
of cancer and in 20542 controls matched regarding age, sex and 
domicile in a population based material. Diagnoses were obtained 
by using out and inpatient population based registries. Also the use 
of glargine and metformin was studied in relation to cancer risk in 
diabetic patients using the national pharmacy prescription registry. 
Conditional logistic regression was used for the analyses.
Results: Diabetes was significantly more common prior to diagnosis 
in patients with breast cancer with diabetes diagnosed 0-4 years 
prior to the cancer diagnosis. The findings remained after adjusting 
for obesity and high blood lipids. Obesity was significantly more 
common in patients with breast cancer above the age of 60 years in 
those where obesity was diagnosed close to the diagnosis of cancer. 
High blood lipids were significantly less common in patients with 
breast cancer close to diagnosis.
Glargine use was associated with a doubled risk 2.88 (1.15-6.64) 
and metformin use with a lower risk of cancer in diabetic patients 
0.92 (0.82-1.09).
 Diabetes Obesity* Blood lipids
Breast cancer A 1.18 (0.99-1.40 0.70 (0.46-1.08) 0.79 (0.62-1.00)
Breast cancer B 1.37 (1.10-1.71) 0.79 (0.52-1.19) 0.73 (0.56-0.95)
Breast cancer C 1.11 (0.88-1.40) 0.78 (0.45-1.36 ) 1.02 (0.72-1.45)
A=univariate analysis for the time interval 90-1460 days prior to the diagnosis of the patient. 
B=multivariate analysis for the time interval 90-1460 days prior to the diagnosis of the patient 
C=multivariate analysis for the time interval 1461-3650 days prior to the diagnosis of the patient 
*Above 60 years obesity and breast cancer 1.55 (0.96-2.50) and below 60 years 0.59 (0.29-1.21)
Conclusions: Within 4 years of diagnosis diabetes, obesity after age 
60 and low blood lipids are associated with breast cancer. Glargine 
use seems to increase overall cancer risk.
P1-08-07
Survival in US Women Following an Indication of Metastatic 
Breast Cancer Diagnosis and Chemotherapy Initiation: A SEER-
Medicare Analysis.
Rugo H, Taylor D, Sanon M, Clements K, Balu S, Faria C, Teitelbaum 
A. University of California San Francisco; OptumInsight; Eisai Inc.
Objective: Use SEER-Medicare data to identify US women with 
metastatic breast cancer (MBC) treated (tx) with chemotherapy (CTX) 
and evaluate survival.
Methods: Key inclusion criteria were women diagnosed (dx) with 
breast cancer (BC) in 2001-2005 with 1) Medicare enrollment 12 mo 
prior to dx through follow-up (2008) or death; 2) an indication of tx 
with CTX at any time after initial BC diagnosis (any stage). Dx of 
MBC between 2001-2006. MBC dx date was defined as the initial 
BC dx date if the patient had “distant” disease at entry into SEER or 
the date of first appearance of secondary malignancy in claims data 
(ICD9 codes 197.0-198.1, 198.3-198.7, 198.82-198.89) during follow 
up, at least 2 mo after initial dx. CTX date was defined as the date 
of first receipt of a CTX agent commonly used to treat BC after the 
MBC date. Data on oral medications (e.g., most hormone therapies, 
capecitabine) were not available. Kaplan-Meier survival analyses 
were performed to describe survival after MBC dx (patients were 
censored at end of follow-up). Survival was assessed both from the 
date of MBC and receipt of first intravenous (IV) chemo. Subgroup 
analyses were performed based on age, type of MBC dx and estrogen 
receptor (ER) status.
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Results: Patient demographics and survival are shown in the table.
Median survival by patient characteristics
 From MBC date From first IV chemo date
 Months N Months N
Overall Survival (OS) 21.6 5805 16.1 4235
     
OS by Age (years)     
≤ 64 22.2 594 19.3 441
65 - 74 25.4 2519 18.5 1972
75 - 84 19.6 2293 14.1 1614
≥ 85 15.1 399 11.2 208
     
OS by type of MBC dx     
At first diagnosis 37.9 468 37.9 417
During follow-up 21.3 5337 15.6 3818
     
OS by ER status     
ER+ 27.3 1760 18.7 1223
ER- 12.7 932 12.5 692
Unknown 21.8 3133 16.2 2320
Conclusions: Despite recent advances in treatment options, median 
survival following a dx of MBC is less than two years, and is 
approximately 16 months after start of IV CTX. Survival is shorter 
for patients who develop MBC after an initial breast cancer dx 
compared to those with MBC at diagnosis, and for those with ER-
negative tumors. In order to improve clinical outcomes, it is critical 
to pursue a better understanding of tumor biology and appropriate 
use of new agents.
P1-08-08
Higher Prediagnostic Serum 25-Hydroxyvitamin Is Associated 
with Substantially Lower Incidence of Breast Cancer: Prospective 
Study.
Mohr SB, Gorham ED, Garland CF, Grant WB, Baggerly L. 
University of California San Diego, La Jolla, CA; Sunlight and 
Nutrition Research Center, San Francisco, CA; GrassrootsHealth, 
San Diego, CA
Background: Recent studies have found lower risk of breast cancer 
in women with higher serum concentrations of 25-hydroxyvitamin 
D (25[OH]D), with few exceptions. To help resolve remaining 
differences, a nested case-control study was conducted.
Material and Methods: Serum was provided by the Department of 
Defense Serum Repository for 600 new cases of breast cancer and 
600 controls individually matched on age ±6 months; date blood was 
drawn ±2 days; and active-duty status; and were analyzed for 25(OH)
D by a chemiluminescent assay. Mean age was 40 years (SD ±7 years, 
range 20-56 years). The individuals were 55% white, 33% African-
American, and 11% other races. Mean serum 25(OH)D concentrations 
by quintile, from lowest to highest, were 11, 18, 24, 30 and 42 ng/
ml. Dividing points were <15, 15-21, 22-27, 28-35, and >35 ng/ml.
Results: Race-adjusted odds ratios for breast cancer, from lowest 
to highest quintile of serum 25(OH)D, were 1.0 (reference), 0.58, 
0.78, and 0.52 (ptrend < 0.05). The difference between risk of breast 
cancer in the lowest and highest 25(OH)D quintiles was significant 
(p < 0.05). The association of low serum 25(OH)D with high risk 
of breast cancer was strongest for serum drawn during the 3 month 
period preceding diagnosis of breast cancer, and in white women. 
There was a strong linear inverse relationship between serum 25(OH)
D and risk of breast cancer in this group. A similar trend was present 
for overall data including all intervals and races, but was weaker and 
not as clearly linear.
Discussion: Consistent with most previous research, women whose 
serum 25(OH)D concentration was high (42 ng/ml) had approximately 
half the risk of breast cancer as those whose serum 25(OH)D was 
low (11 ng/ml). The trend was similar after adjustment for race. The 
favorable association of serum 25(OH)D with risk of breast cancer 
apparently was strongest during the final few doublings of the tumor 
mass preceding diagnosis in this population. (An alternative, far less 
likely, interpretation, is that the tumor mass might adversely influence 
25(OH)D concentration). A serum 25(OH)D concentration of 42 ng/
ml can be achieved with vitamin D3 intake of 4000 IU/day. This is the 
safe daily upper level intake of the National Academy of Sciences-
Institute of Medicine (NAS-IOM December 2010 monograph). 
While further research would be beneficial, such intake should 
be recommended as a useful tool for prevention of breast cancer. 
Serum 25(OH)D should be monitored on a routine basis, when 
feasible, to ensure that at least 40 ng/ml is maintained throughout the 
year, and 150 ng/ml is not exceeded. This hygienic measure could 
prevent approximately 50% of breast cancer in the US. (The views 
expressed in this abstract are those of the authors and do not represent 
positions of the Department of the Navy, Department of the Army, 
the Department of Defense or the US Government.)
P1-08-09
Increased Mortality in Swedish Women Diagnosed with Breast 
Cancer during and Shortly after Pregnancy.
Johansson ALV, Andersson TM-L, Cnattingius S, Hsieh C-C, 
Lambe M. Karolinska Institutet, Stockholm, Sweden; University 
of Massachusetts Medical School, Worcester; Regional Oncologic 
Center, Uppsala, Sweden
Background: The incidence of pregnancy-associated breast cancer 
(PABC), i.e. breast cancer diagnosed during pregnancy or within 
two years after delivery, is increasing in Sweden. Results from 
epidemiological studies suggest that women with PABC have worse 
prognosis than women of same age and no recent birth. We studied 
the mortality in women with PABC, compared to women with a 
diagnosis of breast cancer not close to pregnancy, and in relation 
to when the PABC diagnosis occurred (during pregnancy, different 
postpartum periods). We also studied whether mortality varied over 
time since diagnosis.
Materials and Methods: We used data from the Swedish National 
Cancer Register to identify all women diagnosed with breast cancer 
between ages 15-44 years during 1963-2002 (n=15,729). The 
study cohort was linked to the Multi-Generation Register to obtain 
information on childbirths and when they occurred. We estimated 
mortality rates among women with and without PABC, and subdivided 
by time of detection among PABC patients (PABC during pregnancy, 
or during months 1-3, 4-6, 7-12, 13-18, 19-24 after delivery). Hazard 
ratios (HR) with 95% confidence intervals (CI) were estimated using 
the novel method of flexible parametric survival models. These 
models use splines to model the baseline hazard rate, and are able to 
pick up more subtle time-dependent effects than the more commonly 
used piecewise splitting of the timescale (for example in Poisson 
regression).
Results: Women with PABC had higher mortality than women 
diagnosed at the same age and calendar period and with no recent 
birth. In women with PABC (n=1,110), 46% died during follow-up, 
compared to 34% of the non-PABC patients (n=14,611). The mortality 
in both groups peaked at around two years after diagnosis, with the 
highest peak occurring in women diagnosed 4-6 months after delivery 
(HR=3.8, 95% CI 2.4-5.9). Also, among women diagnosed during 
pregnancy the mortality was higher compared to women diagnosed 
further away from delivery. An increased mortality among women 
with PABC remained up to 10 years after diagnosis.
Discussion: Women with PABC had a poorer prognosis compared to 
women with breast cancer and no recent birth. The worse prognosis 
may be due to diagnostic delays or tumour promoting hormonal 
boosts or changes in the tumour micro-environment post-partum. 
Taken together, our findings indicate that women with PABC represent 
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a high-risk group of young breast cancer patients that may require 
special management. Also, by applying novel statistical methods 
we were able to detect time dependent effects in that the elevated 
mortality associated with PABC varied by timing of diagnosis and 
time since diagnosis.
P1-08-10
Invasive Lobular Breast Cancer – No Increased Risk of 
Contralateral Disease.
Langlands F, Horgan K, Kearins O, Burns R, Dodwell D. The 
General Infirmary at Leeds, Leeds, United Kingdom; The University 
of Birmingham, Birmingham, United Kingdom; Level 6, Bexley Wing 
(Institute of Oncology), Leeds, United Kingdom; St James University 
Hospital, Leeds, United Kingdom
Background: Invasive lobular carcinoma (ILC) is the second 
most common type of breast cancer accounting for up to 14% of 
invasive breast cancers. Worldwide the incidence of breast cancer 
is increasing each year. Large population based studies using the 
Surveillance, Epidemiology, and End results (SEER) data have 
shown that the incidence of ILC has increased from 1977 to 1995. 
ILC has historically been thought to be associated with an increased 
risk of developing contralateral breast cancer and this belief may, in 
part, be responsible for the increasing trend towards contralateral 
prophylactic mastectomy.
Methods: All female patients diagnosed with breast cancer during 
the time period 1998-2003 were identified from two large cancer 
registries, Northern and Yorkshire Cancer Registry and Information 
Service (NYCRIS) and West Midlands Cancer Intelligence Unit 
(WMCIU). All patients diagnosed with either Infiltrating duct(adeno)
carcinoma, microinvasive ductal carcinoma, infiltrating ductular 
carcinoma (all classified as ‘ductal’) or lobular (adeno)carcinoma 
were included. Patients with a mixed type of breast cancer were 
excluded from the analysis. Follow-up was complete until October 
2010. Data were compiled for diagnosed contralateral breast cancer 
of any histological type.
Results: Of the 32,735 patients with invasive ductal cancer 898 
(2.74%) developed a contralateral breast cancer. In comparison 166 
(3.1%) of 5397 patients with lobular cancer developed a contralateral 
breast cancer. The median time to first contralateral event was 
equivalent for both morphologies (ductal 40 months and lobular 39 
months).
Conclusion: This study suggests that there is no increased risk for 
developing a contralateral breast cancer in patients diagnosed with 
an invasive lobular breast cancer.
P1-08-11
Differences in Recurrence Dynamics between Lobular and Ductal 
Invasive Breast Cancer.
Siesling S, Kwast ABG, Grandjean I, Ho V, van der Sangen MJC, 
Menke-Pluymers MBE, Tjan-Heijnen VCG. Comprehensive Cancer 
Centre the Netherlands, Utrecht, Netherlands; Catharina Hospital, 
Eindhoven, Netherlands; Erasmus Medical Centre, Rotterdam, 
Netherlands; Maastricht University Medical Centre, Maastricht, 
Netherlands
Introduction: Many studies investigated disease free survival 
after breast cancer treatment. A few studies focused on patterns 
of recurrence risk over time. However, they ignored the impact of 
histology. This study aimed to determine differences in recurrence 
dynamics on population-based data between patients with a ductal 
breast cancer (DBC) and lobular breast cancer (LBC).
Methods: All surgically treated women diagnosed in 2003-2004 
with invasive DBC or LBC, with no distant metastases or second 
primary breast cancer were selected from the Netherlands Cancer 
Registry. The recurrence patterns were studied using the life-table 
method to estimate the hazard rate for the first recurrence with the 
worst prognosis (locoregional (LRR) or distant metastases), that 
is, the conditional probability of manifesting recurrence in a time 
interval, given that the patient is clinically free of any recurrence at 
the beginning of the interval. The wilcoxon test was used to determine 
differences in recurrence patterns between DBC and LBC.
Results: Of 16,231 women identified, 87% had DBC and 13% 
LBC. LRR was found in 4% of the DBC and in 3% of the LBC 
patients, whereas metastases were found in 11% and 10% of patients, 
respectively. Notably, in DBC patients a peak in recurrence rate was 
seen between 1-2 years after diagnosis, both for LRR and distant 
metastases. On the other hand, in LBC patients the recurrence pattern 
did not show major peaks: after 2 years the curve revealed an almost 
steady level for LRR and distant metastases. This recurrence pattern 
was significantly different (P=<0.001). Moreover, the influence of age, 
stage and treatment on recurrence differed between DBC and LBC. 
We also noticed a difference in localization of metastasis.
Conclusion: Our study showed an overall equal number of 
recurrences after DBC and LBC, but with a totally different recurrence 
pattern, which could have implications on follow-up of the patients.
P1-08-12
Hormonal Therapy Compliance and Mortality in Metastatic 
Breast Cancer.
Barron TI, Kennedy MJ, Sharp L, Bennett K. Trinity College, 
University of Dublin, Dublin, Ireland; St James’s Hospital and Trinity 
College Dublin, Dublin, Ireland; National Cancer Registry Ireland, 
Cork, Ireland
Methods: A retrospective analysis was conducted using linked 
pharmacy claims and cancer registry data from the population-based 
National Cancer Registry Ireland (NCRI). Women with stage IV 
breast cancer at initial diagnosis (2004-2006), who received HTx as 
1st line treatment for ≥90 days were identified (tamoxifen, toremifene, 
fulvestrant, anastrozole, letrozole, exemestane). Compliance was 
calculated over the time that patients remained on HTx i.e. from the 
date of treatment initiation to the earliest of either HTx discontinuation 
or end of follow up (31/12/07, 3 years or death). Patients discontinuing 
HTx were assigned their compliance rate at this time for the remainder 
of follow-up. In the primary analysis Cox proportional hazard models 
with late entry at 90 days post HTx initiation and time varying 
compliance (defined dichotomously as: low < 80%, high ≥ 80%), were 
used to estimate hazard ratios (HR) and 95% confidence intervals (CI) 
for all-cause and breast cancer specific mortality. Secondary analyses 
of (a) time to treatment discontinuation and (b) compliance in the first 
90 days of treatment were conducted. All models were adjusted for 
age, tumor grade, number/site of metastases, estrogen, progesterone 
and human epidermal growth factor 2 receptor status.
Results: 359 women with stage IV breast cancer at diagnosis were 
identified. Of these, 151 received HTx as 1st line treatment. Median 
HTx compliance was 84.8%, (range 19.4%-100%; interquartile range 
75.5%–100%). Demographic, tumor and treatment characteristics 
were similar between low (n=51) and high (n=100) compliance 
groups. The number and distribution of metastatic sites at diagnosis 
was also similar (low/high compliance: bone only 70.6%/70.0%, lung 
only 17.6%/18.0%, liver only 11.8%/14.0%, brain only 0.0%/0.0%, 
other 13.7%/17.0%, multiple sites 15.7%/18.0%). Compliance 
rates for both compliance groups increased marginally over time. 
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Unadjusted all-cause mortality rates were 143 and 359 deaths/1000 
woman years for low and high compliance respectively. Low 
compliance was associated with a 90% increased risk of all-cause (HR 
1.90; 95%CI 1.06, 3.41) and breast cancer specific (HR 1.91; 95%CI 
1.03, 3.55) mortality. In the secondary analyses low compliance was 
associated with a shorter time to HTx discontinuation (HR 1.97; 
95%CI 1.01, 3.84). Low compliance within the first 90 days of 
treatment was associated with non-significantly increased mortality 
(all-cause HR 1.57; 95%CI 0.88, 2.80; breast cancer specific HR 
1.58; 95%CI 0.85, 2.93).
Discussion: This study demonstrates, for the first time to our 
knowledge, a significant association between low HTx compliance 
and increased mortality in patients with MBC. In addition, the 
observed association between compliance and treatment duration 
is consistent with a reduced time to disease progression in low 
compliance patients. The findings do not appear to be related to either 
the burden of metastatic disease at diagnosis or to increasing disease 
severity causing lower compliance over time. These results suggest 
that the development and evaluation of effective interventions to 
support HTx compliance in patients with MBC is warranted.
P1-08-13
Determinants of Risk, Characteristics and Prognosis of Breast 
Cancer Occurring after Hodgkin Lymphoma.
Rapiti E, Veit-Rubin N, Usel M, Benhamou S, Vlastos G, Vinh Hung 
V, Bouchardy C. University of Geneva, Geneva, Switzerland; Geneva 
University Hospitals, Geneva, Switzerland; INSERM, Paris, France
Background
Several studies have evaluated the excess of breast cancer (BC) 
risk after Hodgkin lymphoma (HL) but none has reported of all the 
aspects of BC occurring after HL including determinants of risk, 
comparison with other BC profile, treatment and outcome. This is 
the aim of our study.
Patients and Methods
We used data from the Surveillance, Epidemiology and End Results 
(SEER) Programme of the National Cancer Institute. To assess the risk 
and determinants of BC after HL we included all 9’620 women with 
first primary HL diagnosed between 1973 and 2007 and calculated 
age and period standardized incidence ratio (SIR) of BC as compared 
with general population. We also compared tumour characteristics and 
treatment between BC after HL (n= 316) vs. all other first primary BC 
occurring during the same period (n=450’413) by logistic regression. 
Finally, we compared breast cancer specific mortality between the 
two groups by Cox model.
Results
Overall, HL patients had an increased risk of developing BC (SIR: 
2.4, 95% confidence interval [CI]: 2.2-2.7); the risk decreased with 
increasing age at HL, and disappeared when HL occurred after 50 
years. BC risk was the same among those treated with or without 
radiotherapy until 15 years after HL and then an excess appeared in 
the irradiated group and persisted over 30 years after diagnosis of 
HL. Compared with other BC, BC after HL occurred at younger age 
(Adjusted odds ratio [OR] for age 40-59 vs. < 40 years 0.25, 95%CI: 
0.20-0.33), was diagnosed at an early stage (OR for regional extension 
vs. localized 0.63, 95% CI: 0.42-0.89), expressed less frequently 
hormone receptors (OR for negative vs. positive status: 1.34, 95%CI: 
0.99-1.81), was located more frequently in external quadrants (OR 
for internal vs. external: 0.61, 95%CI: 0.42-0.89), and received less 
frequently radiotherapy (OR for use vs. non use: 0.30, 95%CI: 0.22-
042). The last two results were limited to patients who had received 
radiotherapy for HL. BC after HL presented higher breast cancer 
mortality (Hazard ratio: 1.36, 95%CI: 1.05-1.76) after adjustment 
for patients, tumour and treatment characteristics.
Conclusion
This study provides valuable results on various aspects of BC 
occurring after HL. In particular, we found earlier stage at diagnosis 
of BC probably linked to higher surveillance, more aggressive 
tumours probably due to iatrogenic effect of HL treatment, more 
frequent occurrence in outer quadrants less protected during mantel 
radiation. Also, this study confirms the poorer prognostic of those 
BC not explained by differences in patient, tumour or treatment 
characteristics.
P1-08-14
Arsenic Methylation Is Associated with Breast Cancer Risk in 
Northern Mexico.
López-Carrillo L, Hernández-Ramírez U, Torres-Sánchez L, Gandolfi 
JA, Ornelas-Aguirre JM, Cebrián ME. Mexico National Institute of 
Public Health, Cuernavaca, Morelos, Mexico; University of Arizona, 
Tucson, AZ; Hospital de Especialidades. Instituto Mexicano del 
Seguro Socia, Cd. Obregón, Sonora, Mexico; Centro de Investigación 
y Estudios Avanzados (Cinvestav), Mexico, DF, Mexico
Background: Arsenic (iAs) exposure has been associated with several 
types of cancer. However, most studies to date have not yet implicated 
iAs as a cofactor for breast cancer (BC). BC incidence and mortality 
are 3-fold higher in Northern Mexico (NM) than in the rest of the 
country. iAs levels in drinking water are a source of concern since 
they have been above international standards. We hypothesized that 
iAs exposure and individual Arsenic-methylation ability are potential 
cofactors for BC risk.
Material and Methods: We investigated 840 BC incident cases and 
973 controls from a population-based case-control study performed in 
NM. Women were directly interviewed about dietary and reproductive 
BC covariables. iAs metabolites in urine were determined by HPLC/
ICP-MS. Methylation capacity was assessed by calculating the 
percentage of iAs species and primary [MMA(V)/(As(III)+As(V)] 
(PMI) and secondary [DMA(V)/MMA(V)] methylation indexes 
(SMI).
Results: The range of total urinary Arsenic was 0.4-303.9 ug/L. 
Most women (91%) had values above 50 ugAs/L. %MMA(V) was 
significantly higher in BC cases while %DMA(V) was significantly 
lower. PMI was positively associated with BC (OR T3vsT1=1.47; 
CI95=1.17-1.84; p for trend=0.001), while SMI was negatively 
associated (OR T3vsT1=0.54; CI95=0.42-0.68; p for trend<0.001).
Discussion: As exposure may pose a risk for BC, particularly in 
women with higher capacity to methylate iAs to MMA(V) and lower 
capacity to further methylate MMA(V) to DMA(V). This is consistent 
with studies indicating that the proportion of MMA(V) in urine 
was positively associated whereas that of DMA(V) was inversely 
associated with the risk of skin, bladder and lung cancer. Further 
research is needed about the temporal relationships between disease 
and methylation capacity and the presence of potential association 
modifiers, including environmental and genetic factors involved in 
one carbon metabolism.
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Pattern of Cardiac Monitoring and Risk of Trastuzumab 
Associated-Cardiac Dysfunction in a Clinical Practice: A 
Population Based Study.
Lee-Ying R, Ubhi C, Roberts S, Lim H, Bhatt H, Gesy K, Ahmed S. 
University of Saskatchewan, Saskatoon, SK, Canada; University of 
Saskatchewan; Saskatchewan Cancer Agency
Background: Adjuvant trastuzumab therapy (ATT) in women with 
early-stage HER2+ breast cancer has been associated with significant 
reduction in the disease recurrence and mortality. Cardiac dysfunction 
(CD) is a known serious adverse effect of ATT. Although periodic 
cardiac monitoring is recommended during ATT, little is known about 
pattern of cardiac monitoring and incidence of CD in a clinical setting. 
The study aimed to determine extent of cardiac monitoring and rate 
of CD during ATT and to identify factors correlated with CD.
Methods: Medical records of women with localized HER+ breast 
cancer diagnosed between the years 2005-2007 in the province of 
Saskatchewan was reviewed. Women with advanced or recurrent 
disease or if they were treated in the setting of an adjuvant trastuzumab 
trial were excluded. A logistic regression analysis was performed to 
determine various clinical variables correlated with CD.
Results: A total 116 eligible women with median age of 54 yrs (range: 
27-74) and median BMI of 27 (range: 44-17) were indentified. 40% 
had a cardiac risk factor & 30% were premenopausal. 51% had 
node positive & 53% had ER or PR+ breast cancer. 92% received 
anthracycline-based chemotherapy and 23% received sequential ATT. 
Of 62 patients with ER/PR+ breast cancer, 61% received adjuvant 
aromatase inhibitors. Baseline cardiac assessment was performed in 
93% women. 98% women underwent periodic cardiac monitoring 
during ATT, 55% had monitoring performed at the interval of 3-4 
months & 82% women had monitoring performed at the interval of 
3-6 months. Mean baseline cardiac ejection fraction (EF%) prior to 
the commencement of chemotherapy and ATT were 65% & 63.9% 
respectively (p=NS). CD was observed in 32 (28%) women and 
only 4% were symptomatic. Trastuzumab was interrupted in 34%, 
and was discontinued in 20% women. Of 32 women with CD, 59% 
were referred to a cardiologist and 53% were treated with medication. 
CD was reversible in 84% cases. On multivariate analysis adjuvant 
aromatase inhibitor therapy was significantly correlated with cardiac 
dysfunction (Odd ratio 6.9 [95% CI: 1.4-33.0]). During the follow up 
period 18% women developed recurrent disease and 16% were died. 
Conclusions: Our results confirm high compliance with cardiac 
monitoring, though not as frequently as recommended in the 
clinical trial setting. Overall the rate of symptomatic decline in 
cardiac function was similar to the rate reported in the clinical trials, 
however, a relatively higher incidence of asymptomatic decline in the 
left ventricle EF% was noted. Among various variables examined, 
adjuvant aromatase inhibitor therapy was associated with an increased 
risk of CD.
P1-08-16
Benign Breast Disease (BBD) and Breast Cancer in African 
American Women.
Fehmi RA, Cote M, Ruterbusch J, Alosh B, Bandyopadhyay S, 
Albashiti B, Frost MH, Hartmann LC, Visscher DW. Wayne State 
University/Karmanos Cancer Institute/DMC, Detroit, MI; Wayne 
State University/Karmanos Cancer Institute, Detroit, MI; Mayo Clinic 
Cancer Center, Rochester, MN
African American (AA) women have higher mortality rates from 
breast cancer (BrCa) and are diagnosed at younger ages than their 
Caucasian counterparts. Women who have had a benign breast biopsy 
are at increased risk of the disease, although less is known about the 
risk of BrCa associated with benign breast disease in AA women. 
We examined 1428 breast biopsies from AA women which occurred 
from 1997-2000 and assessed various pathologic markers including: 
apocrine metaplasia, ductal hyperplasia including atypia, evidence 
of cysts, duct ectasia, fibrosis, intra-ductal papilloma, sclerosing 
adenosis, columnar alteration, and involution (atrophy). These women 
were followed for later BrCa through the Metropolitan Detroit Cancer 
Surveillance System, part of the Surveillance, Epidemiology and 
End Results (SEER) program through 2008. Women who developed 
BrCa were compared to those in the cohort who did not, and to other 
AA women with BrCa in the SEER registry. AA women in our study 
were also compared to Caucasian women in the Mayo Clinic cohort. 
Differences in variables were assessed by chi-squared tests and 95% 
confidence intervals. Of the 1428 biopsies, 52 (3.6%) subsequent 
incident breast cancers were reported in SEER. The mean age at 
diagnosis was 59, and the mean time from biopsy to BrCa diagnosis 
was 6.1 years. Individuals with atypical ductal hyperplasia at biopsy 
(n=37, 2.6%) were more likely to develop breast cancer (n=7, 13.5%, 
p<0.01). No other pathologic variables were associated with increased 
risk. Women in our cohort with breast cancer did not differ from AA in 
the SEER database with respect to age at diagnosis, stage at diagnosis, 
or receptor positivity. Compared to the Caucasian women in the Mayo 
Clinic BBD cohort, AA women in our study were younger at biopsy 
(p<0.01), but had similar percentages of involution and atypia (p=0.50 
and 0.15, respectively). Our preliminary findings among a relatively 
small group of AA women with prior benign breast biopsies and 
incident breast cancers suggest that results from the Mayo Cohort 
study are likely to apply to AA populations.
P1-08-17
Pregnancy-Associated Breast Cancer Does Not Have a Worse 
Outcome in the 4912 Women with Breast Cancer of the 
AMAZONA Project.
Liedke PER, Szymonifka J, Simon SD, Barrios CH, Bines J, 
Finkelstein D, Goss PE. Massachusetts General Hospital, Boston, 
MA; Universidade Federal de São Paulo (UNIFESP), São Paulo, 
Brazil; Pontifícia Universidade Católica do RS (PUCRS), Porto 
Alegre, Rio Grande do Sul, Brazil; Instituto Nacional do Câncer 
(INCA), Rio de Janeiro, Brazil; Brazilian Breast Cancer Study Group 
(GBECAM), São Paulo, Brazil
Introduction: Pregnancy traditionally is considered a protective factor 
for breast cancer. Recent data suggests that pregnancy-associated 
breast cancer (PABC), a distinct biologic variant possibly related to 
breast involution, can occur up to 10 years post-partum and may carry 
a worse prognosis than that of age matched sporadic or nulliparous 
breast cancer. The Amazona project is a retrospective cohort of 4,912 
Brazilian women with breast cancer that has previously reported on 
worse outcomes of patients according to type of institution where 
treatment was received (San Antonio 2009 abstr. 3082). We have 
assessed the outcomes of PABC in the Amazona cohort.
Objectives: 1- To identify whether women who were diagnosed with 
breast cancer up to 10 years after their first pregnancy had worse 
disease free survival (DFS) and overall survival (OS) than nulliparous 
women (NW); 2- to assess if age at first pregnancy is related to age of 
breast cancer diagnosis and worse DFS or OS; 3- to assess whether 
number of pregnancies is associated with worse DFS or OS; 4- to 
assess whether time from first pregnancy to diagnosis or age of first 
pregnancy are associated with histological grade, clinical stage or 
tumor expression of ER, PR, and HER2.
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Methods: We analyzed 4836 women for whom parous history was 
available, in respect to DFS, OS, tumor clinical stage, histological 
grade, expression of ER, PR and HER2, according to age of first 
pregnancy, diagnosis up to 5 and 10 years after first pregnancy, and 
number of pregnancies, using NW as controls. Analysis of DFS and 
OS was done by Cox regression modeling adjusted for institution 
type, stage, ER, PR, HER2 and grade.
Results: Our cohort had 1996 nulliparous women and 2840 parous 
women. The median follow up was 28 months and there were 318 
deaths and 735 recurrences. We did not find any correlation between 
PABC with DFS (5 year interval HR 1.15, 95%CI 0.43-3.07; 10 year 
interval HR 1.01, 95%CI 0.57-1.81) or OS (5 year interval HR 1.88, 
95%CI 0.6-5.94; 10 year interval HR 0.5, 95%CI 0.73-3.09), nor was 
there a correlation between age at first pregnancy with age of breast 
cancer diagnosis. We also did not see any difference between age of 
first pregnancy and DFS or OS.
Women with 3 or more pregnancies had worse OS (HR 0.71, 95%CI 
0.54-0.93) but not worse DFS (HR 0.93, 95%CI 0.76-1.13).Tumors 
diagnosed within 5 or 10 years from first pregnancy did not differ by 
grade, ER, PR, HER2, and clinical stage from those of NW. Women 
who had their first pregnancy after age 20 tended to have more ER 
positive (OR 1.99, 95%CI 1.49-2.65), PR positive (OR 1.40, 95%CI 
1.06-1.87), and HER2 positive (OR 1.85, 95%CI 1.22-2.79) tumors 
than NW.
Conclusions: In this large cohort of breast cancer patients from the 
diverse geographic and socioeconomic spectrum of Brazil we did not 
find any association between PABC or age of first pregnancy to DFS 
or OS. The association with worse OS but not DFS for women with 
3 or more pregnancies might be due to confounding factors. PABC 
was not associated with worse clinical prognostic factors. Women 
who had their first pregnancy after age 20 were more likely to have 
ER+, PR+ and HER2 + tumors than nulliparous patients.
P1-08-18
Aspirin Exposure and Nodal Status at Diagnosis in Women with 
Stage I-III Breast Cancer.
Barron TI, Sharp L, Bennett K, Visvanathan K. Trinity College, 
University of Dublin, Dublin, Ireland; National Cancer Registry 
Ireland, Cork, Ireland; Johns Hopkins Scchool of Public Health, 
Baltimore, MD
Background: The recent Nurses’ Health Study reported an association 
between aspirin use and a reduction in breast cancer (BC) recurrence 
and BC-specific mortality. It has been suggested based on preclinical 
data that these effects may be due to the inhibition of tumor invasion 
and metastasis by aspirin. To test this hypothesis we examined the 
association between aspirin exposure prior to BC diagnosis and nodal 
involvement at diagnosis.
Methods: A retrospective analysis was conducted using linked 
pharmacy claims and cancer registry data from the National Cancer 
Registry Ireland. Women with an incident diagnosis of stage I-III 
BC between 2001-2006 and no prior invasive cancer were included. 
Women with a prescription for aspirin at any time in the year prior to 
diagnosis were defined as exposed. Multivariate logistic regression 
was used to estimate odds ratios (OR) and 95% confidence intervals 
(CI) for (a) N0 disease; (b) N1 disease (c) N1/2/3 disease at diagnosis 
in aspirin exposed (overall exposure & exposure quartiles by duration 
of use) versus unexposed women. All analyses were adjusted for age, 
tumor size/grade, ER, PR and HER2 receptor status. Analyses were 
repeated including women with stage IV BC at diagnosis. Survival 
analyses are ongoing.
Results: 4212 women with stage I-III BC at diagnosis were identified. 
1086 (25.8%) had a supply of aspirin available to them in the year 
prior to diagnosis (median dose 75mg, interquartile range 75mg, 
75mg). Women taking aspirin were older than those who did not 
(74.3 yrs/64.4 yrs p<0.05). There was no difference in tumor sizes, 
grade, ER, PR or HER2 receptor status between exposed and 
unexposed women. In the multivariate logistic regression analysis 
aspirin exposure was associated with significantly increased odds of 
an N0 tumor (Table 1; OR 1.27 95%CI 1.09, 1.48) and significantly 
decreased odds of an N1 or N1/2/3 tumor. Additionally, women taking 
aspirin for >95% of the year prior to diagnosis had the highest odds 
of an N0 tumor (Table1; OR 1.50 95%CI 1.14, 1.97 ). There was no 
difference in the odds of an N0 tumor for women taking aspirin for 
<40% of the prior year (OR 1.01 95%CI 0.78, 1.31). Inclusion of stage 
IV BC (n=789) in the analysis did not significantly alter these results.
Adjusted Odds Ratios (95%CI) for Nodal Involvement at Diagnosis in Aspirin Exposed Versus 
Unexposed Women with Stage I-III Breast Cancer
 Aspirin Exposure Duration In Year Prior to Diagnosis
 All Q1: >0%-40% Q2: >40%-80% Q3: >80%-95% Q4: >95%-100%
N0 1.27 (1.09, 1.48) 1.01 (0.78, 1.31) 1.18 (0.90, 1.55) 1.48 (1.13, 1.95) 1.50 (1.14, 1.97)
N1 0.75 (0.64, 0.89) 0.96 (0.73, 1.26) 0.70 (0.52, 0.95) 0.65 (0.49, 0.88) 0.69 (0.52, 0.94)
N1/2/3 0.72 (0.61, 0.85) 0.89 (0.68, 1.18) 0.70 (0.52, 0.93) 0.62 (0.47, 0.83) 0.67 (0.51, 0.90)
Adjusted for age, tumor size/grade ER, PR, HER2.
Discussion: This study demonstrates a significant association 
between aspirin use in the year prior to BC diagnosis and the 
degree of nodal involvement at diagnosis. Furthermore there was 
a clear dose-response relationship between increasing duration of 
exposure and nodal status. These associations are unlikely to be due 
to confounding by healthy user/adherer behaviors as tumor sizes did 
not vary significantly between unexposed and exposed women, or 
across quartiles of exposure duration.
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P1-08-20
Parity Interferes with the Effect of Age at Diagnosis on the 
Frequency Breast Cancers Are Triple-Negative.
Vannevel V, Brouckaert O, Leunen K, Amant F, Berteloot P, Dieudonne 
A-S, Laenen A, Wildiers H, Paridaens R, Van Limbergen E, Weltens 
C, Moerman P, Smeets A, Lambrechts D, Christiaens M-R, Vergote 
I, Neven P. UZ Leuven, Belgium
Background
Epidemiologic studies show an age related decrease in the frequency 
that breast cancers are triple negative (TN) (estrogen receptor, 
progesterone receptor and HER-2 negative). Parity increases the risk 
of TN breast cancer as a previous full-term pregnancy mainly protects 
against ER+ breast cancer. It is unknown whether this protective 
affect appears at all ages of breast cancer diagnosis. We study the 
frequency of triple negative breast cancers by parity and age at breast 
cancer diagnosis.
Methods
We performed a retrospective case-case analysis including 1583 
consecutive female patients with primary diagnosis of invasive breast 
cancer, < 51 years at diagnosis. We compared the frequency of TN 
tumors between parous (N = 1271) and nulliparous (N = 312) women 
in three age categories (21 to 30 yrs, 31 to 40 yrs and 41 to 50 yrs). 
For statistical analysis we used a logistic regression model.
Results
We confirmed a decrease of TN breast cancer with age (p < 0.0001). 
This decrease is stronger pronounced in the nulliparous group. Parity 
favors TN tumors only in women > 40 years at breast cancer diagnosis.
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Proportion breast cancers are TN by parity and age at diagnosis
PARA 0 N = 312 TN (14.1 %) PARA > 0 N = 1271 TN (15.0 %)
21-30 yrs N = 24 37.5 % 21-30 yrs N = 20 25.0 %
31-40 yrs N = 95 18.9 % 31-40 yrs N = 263 20.5 %
41-50 yrs N = 193 8.8 % 41-50 yrs N = 988 13.4 %
Discussion
Although several other factors may affect the frequency breast cancers 
are TN, age at breast cancer diagnosis interacts with the effect of a 
previous pregnancy on the frequency breast cancers are TN. Breast 
cancers in young women (< age 40) may have been initiated long 
before pregnancy can induce a protective effect against ER-positive 
cases. The international BCAC has recently accepted to validate our 
UZ Leuven findings.
P1-08-21
Demographic and Clinical Characteristics of Metastatic Breast 
Cancer Patients and Biomarker-Based Prevalence in the UK, 
Germany, France, Spain and Italy (EU-5).
Ganguli A, DeKoven M, Bonthapally V, Lee WC, Ray S. Abbott 
Laboratories, Abbott Park, IL; IMS Consulting Group, Alexandria, VA
Background: Much peer-reviewed literature focuses on metastatic 
breast cancer (mBC) treatment regimens. However, research around 
mBC patients’ demographic/clinical characteristics across Europe is 
limited. This study compared such mBC characteristics as well as 
biomarker-based prevalence across the EU-5.
Methods: IMS LifeLink™ Oncology Analyzer (OA) database, 
based upon practicing oncologist surveys, was used to identify mBC 
patients aged ≥18 between 01/2005-06/2010. The study investigated 
the distribution of mBC population based on age, biomarker, co-
morbidities and stage at diagnosis. This study also estimated the 
proportion of patients, and sites of metastasis, by lines of drug 
therapies (LOT).
Results: A total of 186,640 mBC patients were identified - Germany 
(30.2%), France (22.4%), UK (21.2%), Italy (17.7%) and Spain 
(8.4%). The majority of patients were aged 61-70yrs (24%-32%), 
except in Spain (22.3% aged 71-80yrs). Proportion of mBC patients 
with ≥1 co-morbid condition were highest in Germany (36.3%), 
followed by Spain (32.8%), UK (31.5%), Italy (27.6%) and France 
(20.1%), with diabetes (12.9-23.9%) and cardiac dysfunction (5.2-
21.7%) being most prevalent. The distribution of mBC patients by 
biomarker status was 53.9% HER-/HR+, 17.8% HER+/HR+, 11.1% 
HER+/HR- and 17.2% triple negative, and was similar amongst the 
EU5 countries. The top three metastatic sites were bone (54.4%), 
lung (36.0%) and liver (32.7%), with proportion of bone metastasis 
increasing from 1st LOT (38.1%) to 4th LOT (69.6%). Almost 50% 
of the mBC patients were diagnosed at Stage IV, 14% at Stage III, 
26% at Stage II and 6% at Stage I. Of all mBC patients, 93% received 
1st LOT, 31% received 2nd LOT, 27% received 3rd LOT and 6.8% 
received 4thLOT.
Conclusion: In the EU-5, mBC patients were primarily elderly 
and HER-/HR+. The burden of bone metastasis was higher in later 
LOTs. Following the 1st LOT, fewer patients moved to subsequent 
treatments. Additional research on EU-5 clinical practice patterns 
is warranted.
P1-08-22
Treatment Patterns and Clinical Outcomes in Elderly Patients 
with HER2-Positive Metastatic Breast Cancer from the registHER 
Observational Study.
Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Ulcickas 
Yood M, Feng S, Wang LI, Brammer MG, Yardley DA. Norris Cotton 
Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, 
NH; University of Pittsburgh Cancer Center, Pittsburgh, PA; Patient 
Advocate, New York, NY; University of California San Francisco 
Comprehensive Cancer Center, San Francisco, CA; University of 
Southern California/Norris Comprehensive Cancer Center, Los 
Angeles, CA; EpiSource, LLC, Boston, MA; Boston University School 
of Medicine, Boston, MA; Genentech, Inc., South San Francisco, CA; 
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, 
PLLC, Nashville, TN
Background: Data are lacking regarding treatment patterns and 
outcomes in elderly patients (pts) with HER2-positive (HER2+) 
metastatic breast cancer (MBC).
Methods: registHER is a large, observational cohort of pts with 
HER2+ MBC diagnosed within 6 months of enrollment. Pts 
(N=1,001) were followed until death, disenrollment, or June 2009 
(median follow-up 27 months). In these analyses, pts were stratified 
into three groups based on age at MBC diagnosis: younger (<65 
years), older (65-74 years), elderly (≥75 years). For Progression 
Free Survival (PFS) and Overall Survival (OS) analyses of 1st-line 
trastuzumab (T) vs. no T, older and elderly pts were combined due to 
small number of events in elderly. Hierarchical multivariate analyses 
were adjusted for baseline characteristics and treatments.
Results: ER/PR status was similar across age groups (Table 1). Elderly 
pts with HER2+ MBC had higher rates of underlying cardiovascular 
disease (CVD) than younger or older pts. In pts receiving T-based 
1st-line treatment, elderly pts were less likely to receive chemotherapy 
(C), and more likely to receive T alone or combined with hormone 
therapy (HT). Central nervous system (CNS) events decreased 
with increasing age. In T-treated pts, incidence of left ventricular 
dysfunction (grade ≥3) was higher in elderly pts (3/63 [4.8%]) than 
in younger (21/746 [2.8%]) or older pts (2/134 [1.5%]). Across age 
groups, unadjusted median PFS (months) was significantly higher 
for pts treated with T in 1st-line than those who were not (<65 years 
T: 11.0; <65 years no T: 3.4; ≥65 years T: 11.7; ≥65 years no T: 4.8). 
In pts <65 years, unadjusted median OS (months) was significantly 
higher in T-treated pts; in pts ≥65 years, median OS was similar (<65 
years T: 40.4, <65 years no T: 25.9; ≥65 years T: 31.2, ≥65 years 
no T: 28.5). In multivariate analyses, T in 1st-line was associated 
with significant improvement in PFS across age (Table 2). In OS, 
significant improvement was observed for pts <65 years; results were 
suggestive for pts ≥65 years.
Conclusions: Elderly pts (≥75 years) with HER2+ MBC in registHER 
had higher rates of underlying CVD than younger counterparts and 
received less aggressive treatment, including less 1st-line T. These 
population-based, real-world data suggest improved PFS with T as 
1st-line therapy across all age groups.
Table 1. Clinical characteristics of younger (<65 years), older (65-74 years) and elderly (≥75 
years) pts
 Age at MBC (years)
Parameter (%) <65 65-74 ≥75
 (n=792) (n=144) (n=65)
ER/PR status    
ER+ or PR+ 53.8 49.3 50.8
ER- & PR- 43.1 43.8 46.2
Unknown 3.2 6.9 3.1
Underlying CVD at baseline 12.6 29.2 46.2
T-based 1st-line regimens (n=668) (n=117) (n=50)
C only 67.1 70.1 60.0
HT only 5.4 4.3 18.0
C & HT 21.6 13.7 8.0
T alone 6.0 12.0 14.0
Any CNS event 39.9 31.9 18.5
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Table 2. Multivariate* results for PFS and OS in younger (<65 years) and combined older and 
elderly (≤65 years) pts (T in 1st-line vs. no T in 1st-line)
PFS Hazard Ratio 95% CI P-value
<65 years 0.40 0.32, 0.49 <.01
≥65 years 0.52 0.36, 0.76 <.01
OS
<65 years 0.59 0.46, 0.77 <.01
≥65 years 0.75 0.47, 1.19 0.22
*Adjusted for race, ECOG performance status, serum albumin, ER/PR status, #metastatic sites, 
stage, underlying CVD, non-cardiac comorbidities, 1st-line C, HT 
P1-08-23
Characteristics of De Novo Stage IV Breast Cancer Presentation 
and Comparison with Stage IV Disease Relapse after Adjuvant 
Therapy.
Chen L, Yalamanchi S, Waynick C, Romond E, Stevens M, Pasley G, 
Huller K, Weiss H, Massarweh S. University of Kentucky and Markey 
Cancer Center, Lexington, KY
Background: We hypothesized that patients diagnosed with stage IV 
breast cancer at presentation may have different disease characteristics 
than patients who develop relapsed stage IV disease after adjuvant 
therapy. To examine potential differences, we analyzed a prospectively 
collected data set for patients diagnosed at the Markey Cancer Center 
starting from the beginning of 2007 to date.
Methods: Out of 1089 patients, we identified 76 patients (7%) who 
presented with de novo stage IV disease and 40 patients (4%) who 
experienced systemic disease relapse after initial adjuvant therapy. We 
compared key variables between the two groups including patient age, 
tumor size, grade, estrogen receptor (ER) status, progesterone receptor 
(PgR) status, HER2, and sites of metastatic disease involvement. 
Statistical significance was determined using the Chi-square test, 
Fisher’s exact test, two-sample t-test, or Wilcoxon’s rank sum test 
as appropriate.
Results: Patients with de novo stage IV breast cancer were more 
likely to be older (median age 58.5 years, Range 28-88) than women 
with relapsed stage IV breast cancer (median age 53 years, Range 
28-77), and this difference was statistically significant (p = 0.039). As 
compared to the group with relapsed disease, breast cancer presenting 
with de novo stage IV disease was more likely to be Grade 1/2 (43% 
vs. 18.4%, p=0.032), ER positive (69.7% vs. 47.5%, p= 0.019), and 
PgR positive (56.6% vs. 32.5%, p= 0.0136). Interestingly, de novo 
stage IV breast cancer was more likely to be HER2 positive than in 
patients with relapsed disease (27.54% vs. 10.26%, p=0.035). When 
available patient data prior to 2007 was included in the analysis, 
we observed no significant difference in the frequency of HER2 
expression between the de novo and relapsed groups (27.4% vs. 
19.4%, p= 0.26). In comparing sites of metastatic disease involvement, 
the de novo stage IV patient group was more likely to have bone 
metastasis than the relapsed disease patient group (68.4% vs. 35%, 
p = 0.0006). There were no significant differences in the frequency 
of other metastatic sites involved, including brain, liver, and lung.
Conclusions: In this breast cancer patient cohort, there was a 
relatively high percentage of women presenting with stage IV disease, 
likely reflecting the underserved nature of this patient population. 
Women with de novo stage IV breast cancer were more likely to be 
older, have ER/PgR positive disease, and have bone metastasis as the 
primary site of involvement. These characteristics may reflect delay in 
initial presentation rather than a biologically more aggressive disease 
phenotype. The higher relative frequency of HER2 positive cancer 
in the de novo stage IV patient group is likely related to the impact 
of adjuvant trastuzumab use on reducing the risk of relapse in HER2 
positive breast cancer.
P1-08-24
Clinical and Pathologic Characteristics of Diabetic Breast Cancer 
Patients in a Tertiary Care Safety Net Hospital.
Loch MM, Eapen A, Ross AA, Rosenberg C, Blanchard RA. Boston 
University Medical Center, Boston, MA; Boston University, Boston, 
MA
Background: Recent studies have indicated an increased risk of 
breast cancer in women with diabetes, and an increase in disease 
specific mortality in patients with diabetes and breast cancer. Clinical 
and pathologic features of diabetic women with breast cancer have 
not been described. We examine tumor characteristics in diabetic 
women in our ethnically diverse tertiary care hospital that may help 
explain the increased mortality seen in diabetic women diagnosed 
with breast cancer.
Methods: We expanded a pre-existing database to include all women 
diagnosed with breast cancer from 1998-2011. From the electronic 
medical record we documented age, body mass index (BMI), place of 
birth, self-identified race/ethnicity, date of diagnosis, T, N, M stage, 
grade, ER, PR, HER2 expression, presence of diabetes (DM) or 
thyroid disease at diagnosis, recurrence and treatment data including 
neoadjuvant, surgical, adjuvant and radiation therapy and adequacy 
of treatment. We determined associations using contingency tables 
and multivariate logistic regression.
Results: 480 cases were identified. Patients were racially diverse: 
35% white [W], 41% black [B], 14% Hispanic and 10% other. 23% 
had DM, 47% were obese (body mass index [BMI] >30). Age in 
DM vs. non-DM were 63.327 vs. 57.729 (p= < 0.0001) and BMI in 
DM vs. non-DM were 32.749 vs. 29.433 (p<0.001). When exploring 
odds ratios (OR) of different tumor subtypes, none were statistically 
significant when controlling for age and BMI. The OR calculated were 
as follows: Triple negative 1.00 (confidence interval [CI]: 0.6-1.666, 
p = 0.9996), ER+ 1.063 (CI: 0.68-1.662, p=0.7877), PR+ 1.005 (CI: 
0.67-1.506, p=0.9811), HER2+ 1.011 (CI: 0.578-1.768, p= 0.8535), 
recurrence: 1.090 (CI: 0.634-1.873, p= 0.7558). There were no 
significant interactions with DM and T, N stage when controlling for 
age and BMI. T stage: p=0.6962, N stage : p=0.7349 and recurrence 
p=0.5469 on recurrence controlling for age, BMI and grade: p=0.5462. 
There was no significant association between grade in DM vs. no 
DM with rates of grade in DM as follows: grade 1: 10.81%, grade 
2: 49.55%, grade 3: 39.64% and in non-DM grade 1: 13.55%, grade 
2: 45.8% and grade 3: 40.65%. Mean score difference p=0.7588.
Conclusions: We did not find significant differences in our DM women 
compared with non-DM women when evaluating tumor subtype, T 
stage, N stage, grade or recurrence. In our patient population these 
factors do not play a role in the increased cause specific mortality in 
DM patients with breast cancer. Other factors must play a role in this 
and should be explored further.
P1-08-25
Breast Cancer Burden, Risks and Outcomes in Latin America.
Justo NA, Wilking NE, Jönsson B. OptumInsight, Stockholm, Sweden; 
Karolinska Institutet, Stockholm, Sweden; Stockholm School of 
Economics, Stockholm, Sweden
BACKGROUND: Breast cancer (BC) burden and care vary 
substantially across Latin America (LA). Aim: Provide an overview 
of the epidemiology, outcomes and countries’ risk profiles in LA to 
identify opportunities for improvement.
METHODS: Review of literature (PubMed, LILACS, SCIELO), 
public databases (Globocan 2002 & 2008, CEPALSTAT, DIRAC, 
PAHO, WHOSYS, etc) and conference presentations (ASCO, 
ISPOR). Local experts & patient organizations were surveyed. Current 
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BC epidemiology in LAC, future trends, countries’ risk profiles 
and outcomes (such as mortality-to-incidence ratios - MIRs) were 
analyzed and compared (Sweden as benchmark).
RESULTS: BC annual incidence (114,900 cases) & mortality (37,000 
deaths) are the highest of all cancers in LA and twice as many deaths 
are expected by 2030. Countries more advanced in the demographic 
transition, like Uruguay and Argentina, present much higher incidence 
and mortality but also better outcomes as observed in their MIRs. 
In LA women are diagnosed younger and at a more advanced stage, 
especially in countries with poor outcomes, such as Ecuador, Mexico 
or Peru. The imbalanced progress since 2002 seems to widen the 
gap in BC outcomes, but countries like Costa Rica are catching up.
BC epidemiology and outcomes
 Incidence ASR 2008
Mortality 
ASR 2008
Mean age @ 
diagnosis
Stage (% I 
+ II)
MIR 2002 MIR 2008 Change (%)
Argentina 74 20 60  0,29 0,27 -8
Brazil 42 12 56 63 0,31 0,29 -5
Chile 40 11 58 70 0,30 0,27 -8
Colombia 31 10 57 61 0,41 0,32 -22
Costa Rica 43 12 58  0,44 0,28 -35
Ecuador 31 10 56  0,41 0,33 -21
Mexico 27 10 53 62 0,40 0,37 -7
Pamama 29 12 57  0,41 0,40 -4
Peru 34 11 54 51 0,40 0,32 -20
Uruguay 91 24 61 82 0,29 0,27 -8
Venezuela 43 14 55  0,39 0,32 -17
Sweden 79 14 63 92 0,20 0,19 -5
Age is the main risk factor; while the association of education and 
wealth with BC occurrence is less significant. Reproductive and 
lifestyle-related risk factors, proven at a patient level, were not 
significant at a country-aggregate level and the specialized literature 
indicates that the evidence on associations between BC and diet is 
inconclusive.
Correlation between BC incidence and risk factors
Risk factor Correlation Coefficient P-value
Births women under 30 -0,485 0,131
Age at childbearing 0,378 0,252
Fertility rate -0,309 0,355
Overweight & obesity (fem) 0,219 0,518
Alcohol consumption (fem) 0,112 0,791
GDP per Capita 0,688 0,019
Education (fem) 0,679 0,031
Mean Age (fem) 0,846 0,001
DISCUSSION: LA’s considerable variation embedded within per-
countries’ averages may be masking underlying causality. Though, it 
can be inferred that there is no one-suit-all prevention campaign and 
policies aimed at reducing the risk of developing BC will succeed 
as long as they are properly targeted and tailored for different needs. 
Early diagnosis and population-wide access to treatment following 
evidence-based best practices remain unresolved matters that endow 
many of these countries with the opportunity to substantially improve 
the care for their women.
P1-09-01
Effect of Obesity on Gene Expression in Invasive Breast Tumors.
Ellsworth RE, Croft DT, Ellsworth DL, Shriver CD. Henry M. Jackson 
Foundation, Windber, PA; Windber Research Institute, Windber, PA; 
Walter Reed Army Medical Center, Washington, DC
Background: Obesity is a risk factor for breast cancer in 
postmenopausal women and weight gain after diagnosis is associated 
with decreased survival and less favorable clinical characteristics such 
as greater tumor burden, higher grade, and poor prognosis, regardless 
of menopausal status. Despite the negative impact of obesity on 
clinical outcome, molecular mechanisms influencing breast cancer 
prognosis remain elusive.
Methods: Postmenopausal women with invasive breast cancer (n=20) 
in the Clinical Breast Care Project who were obese at diagnosis 
(BMI ≥30) were matched by age, stage, ER status, HER2 status, 
and tumor grade to women who maintained a healthy weight (BMI 
= 18.5-24.9). Sections of pure invasive carcinoma were obtained by 
laser microdissection from flash-frozen or OCT embedded sections. 
Gene expression data using U133 2.0 microarrays was generated 
to compare genome-wide patterns of expression in breast tumors 
between obese and normal-weight patients. Data were analyzed using 
Partek Genomics Suite.
Results: Principal Component Analysis accurately clustered the 
specimens into two groups, healthy weight or obese. Using a 
false-discovery rate (FDR) p-value <0.05 with a minimum 2.0-fold 
change of expression, 119 probes from 106 genes were differentially 
expressed, with 35 genes expressed at significantly higher levels and 
71 at significantly lower levels in tumors from obese women compared 
to those from healthy-weight patients. Hierarchical clustering using 
these 119 probes reliably partitioned all samples as healthy-weight 
or obese. Genes differentially expressed include lower expression of 
several members of the histone cluster 1 family, APOD and IGF1, and 
higher expression of FABP7, members of the major histocompatibility 
complex and LTF in tumors from obese women.
Conclusions: Invasive breast tumors from obese women are 
genetically different from those of healthy-weight women. Altered 
gene expression may affect tumor cell proliferation and survival, 
contributing to aggressive phenotypes and altered immune response. 
These underlying molecular differences may contribute to the less 
favorable prognosis observed in obese women with breast cancer.
P1-09-02
HDL-Cholesterol and Low-Penetrance Gene CYP17 rs2486758 
Influence Daily Estrogen Levels. The EBBA-I Study.
Iversen A, Thune I, McTiernan A, Makar KW, Wilsgaard T, Ellison 
PT, Jasienska G, Flote V, Poole E, Furberg A-S. University of 
Tromsø, Tromsø, Norway; Oslo University Hospital, Oslo, Norway; 
Fred Hutchinson Cancer Research Center, Seattle, WA; Harvard 
University, Cambridge, MA; Medical College, Krakow, Poland; 
Channing Laboratory, Boston, MA; University Hospital of North 
Norway, Tromsø, Norway
Objectives: The low-penetrance gene CYP17 encodes cytochrome 
P450 enzymes, catalysts in the endogenous estrogen biosynthesis. 
Low levels of high-density lipoprotein cholesterol (HDL-C) have been 
associated with increased estrogen level1, increased breast cancer risk 
and poor breast cancer prognosis2. However, the relationship between 
CYP17 and metabolic profile including HDL-C levels, and estradiol 
levels remains unclear. Thus, we hypothesize that gene-environment 
interactions between eight SNPs on CYP17 and metabolic profile 
including HDL-cholesterol, may influence the levels of biologically 
active 17b-estradiol of importance of breast cancer development.
Material and methods: The Norwegian Energy Balance and Breast 
cancer Aspects Study (EBBA-I) includes 203 healthy women (25-
35 years) that underwent clinical examinations, blood sampling for 
metabolic profiling in serum and DNA extraction from whole blood, 
and daily saliva sampling throughout an entire menstrual cycle. Daily 
salivary levels of 17b-estradiol were measured by radioimmunoassay 
at the Reproductive Ecology Laboratory, Harvard University, USA. 
Tagging SNPs (rs1004467, rs743575, rs4919687, rs3781286, 
rs3824755, rs10786712, rs743572, rs2486758) representing CYP17 
variability in the Caucasian population were selected using MAF 
> 5 % and r2 = 0.80. The polymorphisms were genotyped at the 
Molecular Epidemiology Laboratory, Fred Hutchinson Cancer 
Research Center, USA. A clustered metabolic risk score was defined 
based on WHO criteria for the metabolic syndrome. Multivariable 
linear and generalized estimating equation regression models were 
used to study the associations.
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Result: Women with at least one variant allele of the CYP17 
rs2486758 combined with the highest metabolic risk score (i.e. 
upper tertile), had 53% higher levels of daily salivary 17b-estradiol 
throughout the entire menstrual cycle compared with all other women 
(P < 0.001). Among women in the upper tertile of metabolic risk 
score, those with the variant allele had 43 % higher levels of daily 
salivary 17b-estradiol (P =0.002). Similarly, the combination of 
having the variant allele and serum total cholesterol/HDL-C ratio 
in the upper tertile was associated with 43% higher levels of daily 
salivary 17b-estradiol, compared with all other women (P= 0.005), 
and 34% higher levels of daily salivary 17b-estradiol, compared 
with the women with common allele in the upper tertile (P= 0.038).
Conclusion: Our results suggest that a polymorphism in CYP17 
(rs2486758) may represent a strong genetic predisposition to 
increased endogenous estrogen levels in women with an unfavourable 
metabolic profile and a high total cholesterol/HDL-C ratio. Thus, 
total cholesterol/HDL-C ratio may be a clinical biomarker for breast 
cancer development in these subsets of women.
References
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P1-09-03
Prevalence of Germline TP53 Mutations in Young Women with 
HER2-Positive Breast Cancer.
Dick MG, Masciari S, Miron A, Miron P, Foley K, Gelman R, Dillon 
DA, Richardson AL, Verselis SJ, Lypas G, Krop IE, Garber JE. 
Dana Farber Cancer Institute, Boston, MA; Brigham and Women’s 
Hospital, Boston, MA
Background: Li Fraumeni syndrome is a rare inherited cancer 
susceptibility condition associated with germline mutations in the 
TP53 gene, in which breast cancer (BC) is the most frequent tumor. 
The prevalence of TP53 mutations in population-based series of 
very young onset BC (<30 years at diagnosis) ranges from <1% to 
approximately 7%1-4. Recent data show that BC in patients carrying a 
germline TP53 mutation are commonly HER2 amplified (63-83%)5-7. 
In this study, we assessed the prevalence of germline TP53 mutations 
in women with HER2 positive BC diagnosed age < 50 years.
Material & Methods: We identified 347 women with invasive 
HER2 positive BC diagnosed at age < 50 years using the Clinical 
Operations and Research Information System (CORIS) at the Dana 
Farber Cancer Institute. Information on age at diagnosis, histology, 
hormone receptor and HER2 status as well as personal and family 
cancer history was confirmed from medical records. 129 patients were 
excluded for various reasons, including a cancer diagnosis prior to the 
BC and a documented BRCA1/2 mutation. A combination of Exon 
Grouping Analysis (EGAN) and Sanger sequencing for detection 
of TP53 mutations in exons 2-11 including surrounding intronic 
sequence was performed on 218 germline DNA samples. Multiplex 
Ligation-dependent Probe Amplification (MLPA) analysis for the 
detection of TP53 deletions or duplications is ongoing.
Results: A germline TP53 mutation was identified in 4 women 
diagnosed at age < 50 years (1.8%, 95%CI 0.5-4.6). At BC diagnosis, 
they were 23, 32, 44 and 50 years. Two BC were ER+/PR+, HER2+ 
and 2 were ER-/PR-, HER2+. Estimate of prevalence of germline 
TP53 mutations by age at BC diagnosis are: age < 35, 2/41 (4.9%, 
95%CI 0.6-16.6), and age < 45 3/168 (1.8%, 95%CI 0.4-5.1). Among 
the women with germline TP53 mutations, 2 met the Chompret 
criteria8 and none the classic LFS criteria.
Discussion: TP53 mutations were identified in a cohort of women 
with HER2+ BC at young age. As expected, the frequency is higher in 
younger women, but mutations were seen in all age groups that were 
evaluated. None of these women met classic LFS criteria by family 
history. Consideration of TP53 testing should be given to women 
diagnosed below age 35 who are negative for BRCA1/2 mutations 
regardless of family history. Analysis of other series will be helpful in 
reaching more stable estimates of the prevalence of mutation carriers 
among patients with HER2+ BC at young age.
1. Sidransky D et al. Cancer Res. 1992; 52:2984-2986.
2. Borresen AL et al. Cancer Res.1992; 52:3234-3236.
3. Lalloo F et al. Lancet 2003; 361:1101–02
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P1-09-04
A Genetic Predictor for Breast Cancer Risk in a Japanese 
Population.
Sueta A, Ito H, Iwata H, Hosono S, Watanabe M, Iwase H, Tajima 
K, Tanaka H, Matsuo K. Aichi Cancer Center Research, Nagoya, 
Japan; Kumamoto University Graduate School of Medical Science, 
Kumamoto, Japan; Aichi Cancer Center Central Hospital, Nagoya, 
Japan; Nagoya University Graduate School of Medicine, Nagoya, 
Japan
Objective Genome-wide association studies (GWASs) have identified 
genetic variants associated with breast cancer. Most GWASs to data 
were conducted in women with European background and the extent 
to which these variants contribute as predictors of breast cancer among 
Japanese population is unknown.
Methods We analyzed 24 genetic variants that have been identified 
in previous GWASs and conducted a case-control study with 697 
cases and age- and menopausal status- matched 1394 controls in 
the framework of the Hospital-based Epidemiologic Study at Aichi 
Cancer Center (HERPACC). All subjects were asked to provide 
information on lifestyle factors and blood samples for genetic studies. 
We fit conditional regression models with genetic variants and 
conventional risk factors including age, age at menarche, menopausal 
status, current body-mass-index, age at first live birth, regular 
exercise, family history of breast cancer, and referral pattern to our 
hospital. In addition, we created a polygenetic risk score, using the 
single nucleotide polymorphisms (SNPs) with statistically significant 
association with the breast cancer risk to measure the cumulative 
effect of multiple genetic risk variants. Furthermore, we evaluated the 
prediction model that included conventional risk factors by comparing 
with and without the genetic risk score, using c statistic.
Results Eleven SNPs (FGFR2-rs2981579, rs2981578, rs1219648, 
rs2420946, rs2981582, TOX3/TNRC9-rs8051542, rs3803662, 
LOC643714-rs4784227, C6orf97-rs2046210, 8q24-rs13281615, 
SLC4A7-rs4973768) revealed significant associations with breast 
cancer risk (each P < 0.05 in either per allele, dominant, or recessive 
model). A dose-dependent association was observed between the risk 
of breast cancer and the genetic risk score, which is an aggregate 
measure of the alleles in 7 selected variants; rs2981579, rs3803662, 
rs2046210, rs13281615, rs4973768, rs3817198 and rs10931936. 
Compared to women with scores of 3 or less, odds ratios (ORs) for 
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women with scores of 4-5, 6-7, 8-9 and 10 or more were 1.33 (95% 
confidence interval, 1.00 - 1.80), 1.71 (1.26 - 2.30), 3.01 (1.97 - 4.58) 
and 8.69 (2.74 - 27.5), respectively (Ptrend < 0.001). The ORs for 
premenopausal women with the corresponding risk scores were 1.71 
(1.12 - 2.63), 1.79 (1.15 - 2.78), 3.70 (1.98 - 6.93), and 14.0 (3.30 - 
59.5), respectively, and those for postmenopausal women with the 
corresponding risk scores were 1.09 (0.72 - 1.66), 1.71 (1.12 - 2.61), 
2.60 (1.44 - 4.71), 3.75 (0.57 - 24.4), respectively, compared to those 
with scores of 3 or less (each Ptrend < 0.001). The c statistic for a model 
including the genetic risk score in addition to the conventional risk 
factors was 0.633, whereas 0.602 without it (P < 0.001). Population-
attributable fraction of the risk score was 33.8%.
Conclusion we identified a genetic predictor of breast cancer in a 
Japanese population. A risk model including genetic risk score may 
be useful to distinguish women at high-risk of breast cancer from 
those at low-risk, particularly in the context of targeted prevention.
P1-09-05
A 3’UTR Functional Variant in BRCA1: A Predictor of Poor 
Outcome in Breast Cancer.
Dorairaj JJ, Miller N, Newell J, Kerin MJ, Weidhaas JB. National 
University of Ireland, Galway, Ireland; Yale University, New Haven, 
CT
Background: MicroRNAs (miRNAs) are class of gene regulators 
which exert their effects through binding with partial complementarity 
to sequences in the 3’untranslated region (3’UTR) of the target 
mRNA. Single nucleotide polymorphisms (SNPs) in the 3’UTR of 
target mRNA have the potential to disrupt or create new illegitimate 
miRNA targets and have been associated with cancer predisposition 
as well as tumor biology. An association between rs8176318 and 
risk for familial breast and ovarian cancer as well as risk for triple 
negative breast cancer in African American women has previously 
been established. We aimed to evaluate the phenotypic effect of 
rs8176318 in a west of Ireland breast cancer cohort, and also its role 
as a biomarker of prognosis.
Methods: DNA from 727 unselected breast cancer cases and 
387 controls were extracted from whole blood and genotyped for 
rs8176318 in the 3’UTR of the BRCA1 oncogene. The association 
with disease specific parameters and outcome were evaluated.
Results: Overall, there was a significant difference in the distribution 
of the three genotypes between cases and controls (p=0.035). The 
dominant variant model was predictive of breast cancer (OR=1.4, 
95% CI 1.1-1.8). Fifty-two percent of breast cancer cases had the 
variant, with similar prevalence between subtypes: Luminal A (279 
[54%] of 519 cases), Luminal B (37 [43%] of 85 cases), HER2 (21 
[53%] of 40 cases) and triple negative breast cancer (41 [49%] of 83 
cases). Comparing the prevalence of the variant within respective 
subtypes with controls however, Luminal A breast cancer was most 
strongly associated with rs8176318 (OR=1.5, 95%CI 1.1-1.9). The 
variant was not significantly associated with disease free survival 
(DFS) in all cancer cases (Log-rank test=0.084). However, rs8176318 
was predictive of a poorer DFS (Log-rank test=0.041) in Luminal 
A patients with a 10-year DFS of 54% (95% CI 0.4-0.7) and 77% 
(95%CI 0.7-0.9) for the variant versus the non-variant, respectively. 
In addition, patients with Stage IV disease had a 6-fold increased 
risk of carrying the variant (p = 0.035), with 17 (73%) of 23 patients 
with metastasis at presentation positive for the variant compared to 
324 (50%) of 642 patients without metastasis (p=0.034). Luminal 
A patients with Stage IV disease had a 13-fold risk of carrying the 
variant (p=0.043) in regression analysis, controlling for all other 
clinicopathological variables. Similarly, the variant was associated 
with distant metastasis in Luminal A patients, with 11 (92%) of 12 
patients with metastasis positive for the variant compared to 242 
(52%) of 463 patients without metastasis (p=0.028).
Conclusion: These findings suggest that rs8176318, a variant in the 
3’UTR of BRCA1, is a genetic marker for modest breast cancer risk 
but aggressive tumor biology in breast cancer, and highlights the 
need for further clinical and biological evaluation of such markers.
P1-09-06
Single Nucleotide Polymorphisms in the BRMS1 and SIPA1 
Metastasis Suppressor Genes as Prognostic Markers in Breast 
Cancer Patients.
Roberts MR, Hong C-C, Edge SB, Yao S, Nesline M, Ambrosone CB. 
Roswell Park Cancer Institute, Buffalo, NY
Introduction: Single nucleotide polymorphisms (SNPs) in the 
metastasis suppressors BRMS1 and SIPA1 may affect metastatic 
efficiency. BRMS1 affects apoptosis, colonization, cell adhesion, and 
invasive potential. Loss of BRMS1 expression has been correlated 
with younger age at diagnosis and reduced survival time in patients 
with progesterone-receptor (PR) negative, HER2-positive tumors. 
SIPA1 affects extracellular matrix gene expression and cell adhesion, 
and while SNPs have been associated with node positive, estrogen-
receptor (ER)/PR negative tumors, evidence for a relationship with 
survival has been conflicting. Identifying SNPs that affect risk of 
recurrence and survival may improve the ascertainment of patients 
who require aggressive adjuvant therapy following a diagnosis of 
breast cancer. We evaluated associations between seven BRMS1 and 
SIPA1 SNPs and recurrence and survival in patients with primary 
breast cancer.
Methods: We identified 1,015 incident breast cancer patients who 
received surgery at Roswell Park Cancer Institute (RPCI) and 
participated in the DataBank and BioRepository (DBBR) resource. 
Participants completed an epidemiologic questionnaire and provided 
a blood sample prior to surgery or other treatment. Clinical and 
pathologic data were linked to de-identified participant data in the 
DBBR database. SNPs in BRMS1 (rs11537993, rs3116068, and 
rs1052566) and SIPA1 (rs75894763, rs746429, rs3741378, and 
rs2306364) were genotyped by RPCI’s Genomics facility using 
Sequenom® iPLEX Gold and Taqman® real-time PCR assays. Cox 
proportional hazards regression was used to estimate hazard ratios 
and 95% confidence intervals.
Results: The median follow-up time was 33 months, and 49 deaths 
and 42 recurrences occurred. Tumors were more likely to be larger, 
node positive, ER/PR negative, and high grade among patients who 
experienced a recurrence or death. Recurrence was less likely in older 
patients and those with higher body mass index, although the latter 
association was nonsignificant (p=0.06). Patients with at least one 
variant allele of the BRMS1 rs3116068 genotype experienced shorter 
overall survival compared to patients with the homozygous common 
genotype (HR=2.05, 95% CI 1.15-3.63, rs3116068 AG+AA compared 
to GG). The remaining SNPs were not associated with overall 
survival, and none of the SNPs were associated with recurrence.
Conclusions: In our data, the variant allele of rs3116068 was more 
common among women whose breast cancer was node negative and 
HER2-positive, compared to those with the common rs3116068 allele. 
The rs3116068 variant allele is also associated with poorer survival. 
While our findings do not support a role for common SNPs in the 
SIPA1 gene in breast cancer prognosis, BRMS1 rs3116068 may be a 
useful prognostic biomarker. Future goals are to examine additional 
SNPs in BRMS1 and other metastasis-related genes in a larger, racially 
diverse population.
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P1-09-07
Contribution of TP53 p.R337H Mutation to Breast Cancer 
Incidence in Brazil.
Giacomazzi J, Toledo de Bueno Osorio CA, Koehler-Santos P, 
Graudenz MS, Marthel-Planche G, Achatz MIW, Soares FA, Goldim 
JR, Caleffi M, Hainaut P, Camey SA, Ashton-Prolla P. Hospital de 
Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; 
Hospital do Câncer AC Camargo, São Paulo, Brazil; International 
Agency for Research on Cancer (IARC), Lyon, Rhone, France; 
Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil; 
Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 
Rio Grande do Sul, Brazil
Background: The exact contribution of TP53 germline mutations, 
associated with Li Fraumeni Syndrome - LFS, to the overall 
burden of cancer is still only partially known. Studies in Southern 
and Southeastern Brazil have shown that a particular mutant, 
TP53 p.R337H, has incomplete penetrance and may be present 
in a significant number of subjects (estimated frequency at the 
populational level of 1:300 individuals). In an exploratory approach, 
the aim of this study is to assess the prevalence of the TP53 p.R337H 
mutation in women with breast cancer diagnosed before 46 and after 
55 years of age, unselected for family history of cancer and resident 
in Southern and Southeastern Brazil.
Methods: Formalin-fixed paraffin-embedded (FFPE) non-tumoral 
tissue of 521 women diagnosed with breast cancer between 2000 and 
2010 in two pathology laboratories were obtained retrospectively and 
consecutively, and analyzed after anonimization. Genomic DNA was 
isolated with the QIAamp DNA Tissue Kit and genotyping performed 
by allelic discrimination using a TaqMan assay. Confirmation of all 
mutation-positive and a sample of mutation-negative cases was done 
by TP53 exon 10 sequencing.
Results: Analysis of the first 299 cases identified the TP53 p.R337H 
mutation in the germline of 15 (5,0%) cases: 13/142 (9,2%) before 46 
years and 2/157 (1,3%) diagnosed after 55 years. The p53 expression 
pattern assessed by immunohistochemistry in the breast tumors was 
not different between p.R337H mutation carriers and non-carriers.
Conclusion: Preliminary analysis in a sample of women with 
breast cancer in Southern Brazil indicates that the germline TP53 
p.R337H founder mutation is present in a high proportion of cases, 
especially those diagnosed at a young age. Germline TP53 mutations 
are considered rare, occurring in about 1:5000 individuals of the 
general population. The occurrence of this founder mutation at such 
a high frequency in a particular geographic region has important 
implications for disease management and cancer risk counseling 
for these patients and families. This mutation likely contributes to 
a significant proportion of the health burden associated with breast 
cancer in Southern Brazil.
P1-09-08
Association of Hypoxia-Inducible Factor-1 with Breast Cancer 
Risk: A Meta-Analysis of Published Studies.
Yin W, Liu G, Lu J, Shen Z, Shao Z. Fudan University Shanghai 
Cancer, Shanghai, China
Background: Hypoxia-inducible factor-1 (HIF-1) plays an important 
role in the development and progression of breast cancer. However, 
conflicting results have been yielded for the association between 
HIF-1 polymorphisms and breast cancer risk. Therefore, we carried 
out a meta-analysis to assess the association of HIF-1 1772 C/T and 
1790 G/A polymorphisms with breast cancer.
Material and methods: Computerized and manual searches were 
performed to identify eligible studies comparing allelic and 
genotypic frequency between cases and controls in breast cancer. 
Odds ratios (ORs) were used to estimate the association between 
HIF-1 polymorphisms and breast cancer risk. The fixed-effects or 
random-effects model was used to combine data. Subgroup analyses 
by ethnicity were also performed.
Results: This meta-analysis for 1772 C/T polymorphism included 
1934 breast cancer cases and 1848 controls, and for 1790 G/A 
polymorphism included 602 breast cancer cases and 479 controls. 
We found that 1772C/T polymorphism increased the risk of breast 
cancer in the recessive model (OR = 2.273, 95% CI: 1.061-4.872, P 
= 0.035), whereas similar effect failed to be observed in the dominant 
model (OR = 1.075, 95% CI: 0.717-1.613, P = 0.725). There was a 
significant increase in breast cancer risk among Asian women (OR = 
4.162, 95% CI: 1.508-11.484, P = 0.006) but not Turkish patients in 
the recessive model. For the 1790G/A polymorphism, we found that 
it had no exact effect on the decreased risk of breast cancer in both 
recessive and dominant model.
Discussion: This meta-analysis indicates that the polymorphism of 
HIF-1 1772C/T rather than 1790G/A polymorphism might be one 
of the high risk factors for breast cancer. The effect of the 1772C/T 
polymorphism on breast cancer risk is completely generated by the 
Asian women.
P1-09-09
Fetal Microchimerism and In Situ Breast Cancer.
Eun JK, Gadi VK. University of Washington, Seattle, WA; Fred 
Hutchinson Cancer Research Center, Seattle, WA
Background: Haploidentical fetal cells acquired and maintained by 
a woman in her blood and tissues long after pregnancy completion, 
also known as fetal microchimerism, is inversely associated with 
invasive breast cancer. Furthermore, in healthy women, absence of 
fetal microchimerism serves as a risk factor for development of future 
breast cancer (J Clin Oncol 29: 2011 suppl; abstr 1574). Here, we test 
the hypothesis that failure to maintain fetal microchimerism following 
pregnancy is also associated with in situ breast cancer.
Methods: Buffy coat specimens were obtained from the Roswell 
Park Cancer Institute Data Bank and BioRepository from parous 
patients with in situ breast cancer and parous control volunteers with 
no prior history of cancer. Using quantitative PCR, DNA extracts 
from peripheral blood buffy coat specimens were tested by a single 
female operator blinded to case:control status for the presence (and 
concentrations) of Y chromosome sequence DYS14, a marker of male 
fetal microchimerism.
Results: In this interim analysis, 83% (34/41) of healthy control 
women and 55% (29/53) in situ breast cancer patients tested positively 
for the presence of DYS14. The unadjusted odds ratio was 0.25 
(95%-CI of 0.08-0.72; p=0.008). Median concentrations were also 
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greater in healthy women compared to women with in situ cancer, 
0.15 versus 0.02 fetal cell equivalents per 10^5 proband genomes, 
respectively (p=0.004).
Summary: Preliminary results suggest that the associations of fetal 
microchimerism and in situ breast cancer are similar in magnitude 
and direction to that observed for invasive disease. The natural 
history of in situ breast cancer is for a large portion of patients to 
develop invasive disease in 8-10 years absent of comprehensive 
locoregional control; results here point to a failure to maintain or 
loss of haploidentical fetal cells well before development of invasive 
disease. Final results from the entire cohort planned (n=200) with 
adjustment for anthropometric, reproductive, and cancer specific 
factors will be presented at the meeting.
P1-10-01
Utility of Routine Cardiac Ejection Fraction (CEF) Measurement 
Prior to Anthracycline-Based Chemotherapy (ABC): A Study of 
466 Patients with Early-Stage Her2-Negative Invasive Breast 
Cancer.
Policepatil SM, Go RS, De Maiffe BM, Gundrum JD, McHugh VL. 
Gundersen Lutheran Medical Foundation, La Crosse, WI; Gundersen 
Lutheran Medical Centre, La Crosse, WI; Gundersen Lutheran 
Medical System, La Crosse, WI
Background: Despite the lack of evidence to support its utility, 
routine CEF measurement prior to ABC is a common practice in 
the community, required in most US clinical trials, endorsed by the 
American Heart Association and American College of Cardiology, and 
appears on Food Drug Administration-approved labeling guidelines.
Objectives: We determined the frequency of the following 
events in newly diagnosed invasive breast cancer patients: a) 
CEF measurement prior to ABC; b) asymptomatic left ventricular 
dysfunction; c) modification in initial treatment strategy as a result 
of CEF measurement; d) development of congestive heart failure 
(CHF) after ABC.
Methods: From our cancer registry, we obtained a list of all female 
patients with newly diagnosed stage I-III breast cancer who were 
treated with chemotherapy as part of initial therapy at our institution 
in 2000-2010 (N=562). We excluded those with prior CHF, ABC, 
and those who had Her2-positive disease (n=66). CEF <50% was 
considered low. CHF risk factors including coronary heart disease, 
cigarette smoking, hypertension, obesity, and diabetes mellitus were 
collected.
Results: We included 496 patients with the following stage 
distribution: I (22%), II (54%), and III (24%). The mean age was 53 
years (SD+11; range 25-88). In 30 (7%) patients, ABC was considered 
inappropriate by the physician provider due to poor performance 
status, co-morbidities, and physician or patient preference. Of the 
466 patients considered for ABC, CEF was measured in 241 (52%) 
patients before chemotherapy. In the latter group, only 1 (0.4%) 
patient was found to have asymptomatic left ventricular dysfunction 
with CEF of 48%. Among patients considered for ABC, 10 (2%) did 
not receive ABC for the following reasons: low or borderline CEF 
(2), patient preference (3), co-morbidities (2), and randomization to 
non-ABC in clinical trials (3). After a mean follow up 57 months 
(SD+34), only 3 of 456 (0.7%) patients who received ABC developed 
CHF. Two had normal CEF prior to treatment while the other did not 
have CEF measured. The practice of CEF measurement prior to ABC 
varied among physician providers, ranging from 23% to 67% (mean/
SD 47%+15%). Those who had CEF measured before chemotherapy 
were older (55 vs. 50 years; P <0.001) and had more CHF risk factors 
(1.3 vs. 0.9; P <0.001).
Conclusions: At our institution, routine CEF measurement prior 
to ABC as initial therapy for early-stage Her2-negative invasive 
breast cancer patients is a common though not uniform practice. 
Asymptomatic left ventricular dysfunction is rarely detected and 
generally mild. Our findings do not support the utility of routine 
CEF measurement in this population and challenge current practice 
and guidelines. Potential cost implications to our health care system 
can be substantial.
P1-10-02
Burden of Brain Metastases in HER2-Positive Breast Cancer: 
Healthcare Use and Costs from a French Observational 
Retrospective Multicenter Study.
Baffert S, Cottu PH, Kirova Y, Bachelot T, Le Rhun E, Mercier F, 
Levy C, Gutierrez M, Madrange N, Moldovan C, Guiu S, Serin D, 
Cotte FE, Benjamin L, Simondi C, Maillard C, Laulhere-Vigneau S, 
Durand-Zaleski I. Institut Curie, Paris, France; Centre Léon Bérard, 
Lyon, France; Centre Oscar Lambret, Lille, France; Stat Process, 
Port Mort, France; Centre François Baclesse, Caen, France; Institut 
Curie, Saint-Cloud, France; Institut Bergonié, Bordeaux, France; 
Centre Henri Becquerel, Rouen, France; Centre GF Leclerc, Dijon, 
France; Institut Sainte Catherine, Avignon, France; GlaxoSmithKline, 
Marly Le Roi, France; Ceri Medical, Garches, France; CHU Henri 
Mondor, Créteil, France
Background
HER2+ status is associated with poor prognosis and a high incidence 
of brain metastases (BM) in breast cancer (BC). Addition of HER2-
targeted therapies to conventional chemotherapy has significantly 
improved survival in HER2+ patients (pts). Management of BM 
implies a multidisciplinary therapeutic approach involving medical 
oncology, radiation oncology and neurosurgery teams. Nevertheless 
available data evaluating health resources use and associated costs 
are limited. Our objective was to describe treatment patterns and 
healthcare costs associated with HER2+ BMBC patients.
Patients and methods 
An observational retrospective study was conducted on 207 HER2+ 
BC pts, newly diagnosed with BM as first site of relapse or as 
secondary metastases between January 2006 and December 2008. Pts 
were recruited in 10 hospitals, all funded by a prospective payment 
system based on Diagnosis Related Groups (DRG). Individual data 
concerning initial diagnosis, distant and BM relapses, treatments, 
complications and hospitalization stays were collected during a 2 
year - follow-up. DRGs 2007 official tariffs (per-case payment basis) 
and 2007 expensive innovative drugs tariffs (drugs paid to hospitals 
by Health Insurance in addition to per-case payments) were used to 
estimate direct medical costs from the Health Insurance perspective. 
Survival was estimated using Kaplan Meier method. In the presence 
of cost-censored data, a partitioned estimator was used to adjust 
censoring costs (Bang and Tsiatis, Biometrics, 2002).
Results
91.8% (190/207) of BMBC pts received radiation therapy, 84.5% 
(175/207) received chemotherapy including HER2 targeted treatments 
and 12.6% (26/207) were treated by neurosurgery. 72.5% (150/207) 
of pts were hospitalized at least once during the follow-up period. Pts 
had on average 2.90 hospital stays (range 1-8). The median duration of 
stay was 9 days (1-221). Complications leading to re-hospitalization 
were recorded in 45.9% (95/207) of pts. The median overall survival 
from the diagnosis of BM was 13 m. Hospital healthcare costs were 
concentrated on the 6 first months following BM diagnosis. Mean 
cost of BMBC management was 18,480€/patient within the 6 first 
months and decreased to 16,306€ from 7-12 months, 15,844€ from 
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13-18 months, and 15,225€ from 19-24 months. The proportion of 
costs attributed to inpatient hospitalizations stay (treatments and 
complications) was similar to the one attributed to drugs whatever 
the period of follow-up. Pts with BM as first site of relapse consumed 
more healthcare resources compared to pts with secondary BM 
(38,813€/pt vs 32,253€/pt after one year of follow-up, respectively).
Conclusions
Healthcare resources spending is mainly concentrated at the beginning 
of metastatic disease management, especially for patients with BM 
as first site of relapse. These results illustrate the use of expensive 
treatments in the first months following BM diagnosis. Individual 
data derived from this observational study allowed us to gather more 
specifically treatment patterns for HER2+ BMBC in order to estimate 
the costs more accurately.
P1-10-03
Colony Stimulating Factor Use with Taxane-Based Therapy 
for Metastatic Breast Cancer: Claims Analysis of Prophylaxis, 
Treatment, and Costs.
Force RW, Pugmire BA, Culbertson VL. ImproveRX, LLC, Pocatello, 
ID; Idaho State University, Pocatello, ID
Background: The taxanes (paclitaxel, docetaxel, and albumin-
bound paclitaxel) are used in women with metastatic breast cancer 
(MBC). Clinical trials indicate that these drugs may differ in their 
toxicity profiles, including rates of neutropenia and need for colony 
stimulating factor (CSF) supportive therapy. Utilizing medical claims 
data, we evaluated prophylactic and treatment-related CSF use among 
women receive taxane-based chemotherapy regimens.
Objective: To determine if differences exist in rates of CSF use for 
prophylaxis, treatment and associated costs in women receiving 
taxane-based chemotherapy for MBC.
Methods: Women with MBC were identified with ICD-9-CM codes 
and by their prior use of adjuvant chemo regimens. Paid medical 
claims (source: Ingenix Consulting) from May 1, 2006 to April 30, 
2009 were analyzed. Study groups were defined according to the first 
taxane administered. CSF utilization was classified as prophylaxis 
(0-5 days post-taxane administration), treatment (6-21 days post-
taxane,) or non-taxane associated use (>21 days post-taxane). 
Comparisons were made between the taxane groups. All CSF costs 
were captured from date of first taxane to end of taxane therapy 
+21 days and categorized as above. Patients censored if ≥35 days 
elapsed with no taxane therapy. Two-stage regression analyses were 
performed. Control variables included age, Romano comorbidity 
score, and use of prior and other concurrent chemotherapy.
Results: 4,503 women (mean age: 53 +/- 10 years) with MBC were 
identified: 2,599 in the docetaxel group; 1,643 received paclitaxel; 
and 261 received nab-paclitaxel. More patients receiving docetaxel 
received any CSF (75.6%) than either paclitaxel (49.8%) or albumin-
bound paclitaxel (36.8% P<0.05 for each comparison). For docetaxel 
70.5% of women received prophylactic CSF, whereas the rates were 
47.0% for paclitaxel and 33.0 for albumin-bound paclitaxel (P<0.05). 
The rate of women receiving CSF in the albumin-bound paclitaxel 
group was not different than the other groups. Daily per-patient CSF 
expenditures during taxane therapy were $176.81 (95% CI, $168.20-
$185.52 ) for docetaxel, $127.71(95% CI, $113.62-$142.60) for 
paclitaxel, and 46.24 (95% CI, $29.37-$67.25 ) for albumin-bound 
paclitaxel.
Conclusions: Compared with docetaxel and paclitaxel, patients 
receiving albumin-bound paclitaxel had significantly lower 
prophylactic CSF use, yet did not experience any difference in 
treatment-related use. Daily per-patient CSF expenditures for 
albumin-bound paclitaxel were significantly lower than the other 
two taxanes.
P1-10-04
Cost-Utility of the 21-Gene Breast Cancer Assay (Oncotype DX®) 
in the Irish Healthcare Setting.
Lacey L, Chien R, Hornberger J. Lacey Solutions Ltd, South Strand, 
Skerries, County Dublin, Ireland; Cedar Associates LLC, Menlo 
Park, CA; Columbia University, New York, NY; Stanford University, 
Stanford, CA
Objective: The Oncotype DX® Breast Cancer Test is a validated 
21-gene assay that predicts the likelihood of benefit from adjuvant 
chemotherapy in early-stage, node-negative and up to 3-node-positive, 
ER+ breast cancer as well as the likelihood of distant recurrence 
at 10-years. Study objective was to investigate the cost-utility 
(incremental cost per QALY gained) of using Oncotype DX® in early 
stage, node-negative, ER+ breast cancer patients, from the perspective 
of the Irish Healthcare system.
Methods: A cost-utility analysis was performed over the lifetime of the 
patient using a state transition model (Markov), which simulated the 
costs and quality-adjusted survival associated with and without the use 
of Oncotype DX® to inform adjuvant chemotherapy decisions. The 
model included 3 health states: no recurrence, recurrence and death. 
Transition probabilities between health states, utility scores associated 
with each of the health state, patient cohort characteristics and impact 
of Oncotype DX® on chemotherapy decisions data were derived from 
published sources. Direct medical costs associated with chemotherapy 
were collected from a representative panel of 5 hospitals in Ireland. 
Costs and outcomes were discounted at 4% per annum and the analysis 
was conducted over 30 years (lifetime horizon). Probabilistic and 
one-way sensitivity analyses were conducted.
Results: Costs associated with adjuvant chemotherapy (4 cycles of 
TC) included the following costs: drug (€1,002); administration and 
monitoring (€1,646); adverse event prevention (€3,561) and adverse 
event management (€756). The average total cost of chemotherapy 
across hospitals therefore summed up to €6,965. The base case 
incremental cost per QALY gained with ODX testing was estimated 
to be €9,462. There was a 74% chance for ODX to be cost-effective 
at a willingness to pay threshold of €20,000.
Conclusions: Using Oncotype DX® as a decision tool to inform 
adjuvant chemotherapy in node-negative, ER+ breast cancer patients, 
is likely to be cost-effective in the Irish healthcare setting. This 
estimate is probably conservative as the cost and disutility associated 
with long-term impact of chemotherapy related adverse events (i.e. 
such as cardiotoxicity, secondary leukaemia and potential cognitive 
impairment) have not been considered.
P1-10-05
Is the 21-Gene Breast Cancer Test (Oncotype DX®) Cost-
Effective?
Pronzato P, Plun-Favreau J. Istituto Naz.le Ricerca Cancro, Genova, 
Italy; Genomic Health International Sàrl, Geneva, Switzerland
Background: The Oncotype DX® Breast Cancer Test is a validated 21-
gene assay that predicts 10 year risk of recurrence and the likelihood 
of benefit from adjuvant chemotherapy in early-stage, node-negative 
ER+ breast cancer. The cost-effectiveness of using Oncotype DX® 
has been published in several countries but to date, there hasn’t been 
any review of these studies.
Materials and methods: The electronic database Pubmed and a 
selection of congress databases were searched using combinations 
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of search terms designed to identify publications describing cost-
effectiveness analyses of Oncotype DX®in early stage breast cancer 
patients. Searches were limited to those published in the English 
language between January 2001 and April 2011. All records were 
screened for inclusion in the review. The methodological quality of 
selected publications was assessed using the 35 items methodological 
checklist from Drummond et al (1996).
Results: Five published health economics analyses and 3 abstracts 
(two posters and an oral presentation) were identified. The studies 
were carried out in several countries (US (2), Canada (2), Japan, 
Israel, Singapore and Hungary and have used a Markov modelling 
approach based on data from a large multicentre trial (e.g. NSABP 
B-20) to make estimates of long-term outcomes, and assess the 
cost-effectiveness of using the Oncotype DX® recurrence score in 
patients classified as having a high or low risk of distant recurrence 
using other methods of assessment. All studies were carried out in 
the perspective of the healthcare payer, and therefore did not consider 
broader costs to the patients and the society. Study comparators, costs, 
characteristics of the population receiving the test and impact of using 
the Oncotype DX® results on treatment decisions were adapted to each 
individual country clinical practice explaining the large range of cost-
effectiveness results from these studies. In the US, using Oncotype 
DX® was shown to be cost-saving when in one of the Canadian studies, 
it was likely to be cost-effective (incremental cost-effectiveness ratio 
of $64,063 per QALY gained). Consistently across all five studies, use 
of Oncotype DX® was projected to improve survival (where reported), 
quality-adjusted life expectancy and to reduce chemotherapy costs 
versus comparators. When looking at the methodological quality of 
studies, they generally scored well with positive responses to 24 or 
more of the 35 questions on reporting. The exception was the Lyman 
et al. (US) paper where only 17 positive responses were recorded. 
The two posters, as expected scored lower than the full scale articles 
with positive responses of 15 and 18 out of 35 items.
Conclusions: Published literature to date is of good methodological 
quality and consistently supports the cost-effectiveness of using 
Oncotype DX® in the various settings. Further analyses should be 
carried on to assess the budget impact of funding Oncotype DX®and 
to include a broader perspective of the costs.
P1-10-06
Economic Analysis of Chemotherapy Costs for Adjuvant Therapy 
in Breast Cancer in France.
Chereau E, Vataire A-L, Laas E, Genin A-S, Aballéa S, Rouzier R. 
Tenon - APHP, Paris, France; Creativ-Ceutical, Paris, France
Background: Total costs of adjuvant chemotherapy can be estimated 
using different perspectives. To date, only few studies are available 
in France and only few of these studies have incorporated all the 
relevant cost items. Indeed the total cost of adjuvant chemotherapy 
for breast cancer should include not only the drug costs and their 
administration but also supportive care, transportation and part of the 
work absenteeism, because all these costs are borne by the French 
social security. The study objective was to estimate the total costs of 
adjuvant chemotherapy in France using two different perspectives: 
the French social security and society.
Methods: We conducted a retrospective study to calculate the total cost 
of first line adjuvant chemotherapy for breast cancer in France. We 
developed an electronic CRF to collect clinical data, chemotherapy 
drug details, side effects and personal data such as the type of 
transportation from home to hospital for chemotherapy treatments 
and duration of work absenteeism. We added the cost of medical 
consultations, radiology and biology. We also calculated the exact 
cost of paramedical time and material. All data were collected after 
patient’s acceptance from clinical records and by phone. Medical 
resource data were collected from patients’ files for which data were 
recorded in February 2010 in Tenon hospital (Paris). Unit costs were 
collected from the French medical insurance database, and other 
public sources such as national statistics and the technical agency 
for hospitalization information.
Results: We collected data from 30 patients who had adjuvant 
chemotherapy for breast cancer. Median age was 57.7 years and 37.9% 
of patients had a regular work. Using the social security perspective, 
the mean cost (+/- SD) for pre chemotherapy exams and management 
(biology, oncologist consultation, implantable port system) was €320 
+/-€32. For each chemotherapy cycle, the costs of chemotherapy 
drugs, preventive medications and chemotherapy administration 
were €1267 +/- €1424. The cost of chemotherapy adverse events was 
€405 +/- €829 and €39 +/- €28 for usual monitoring of chemotherapy 
(biology tests and medical consultations). Transportation costs were 
estimated at €11 +/- €12 and sick leave payments at €445 +/- €521. The 
mean total cost per cycle was €1806 +/- €1226 per chemotherapy cycle 
and €12724 +/- €8426 for the whole adjuvant chemotherapy regimen. 
Using a broader societal perspective, the total cost of chemotherapy 
was €14668 +/- €9707 per patient, as it included the full cost of lost 
productivity due to work absenteeism.
Conclusion: We reported the first cost analysis of adjuvant 
chemotherapy for breast cancer in France using two different 
perspectives (the French social security and the society). Using 
the social security perspective, chemotherapy drugs and their 
administration accounted for 70% of the total cost of chemotherapy 
against 60% when using the societal perspective.
P1-10-07
Comparing Breast Cancer Screening Guidelines: A Stage-
Survival-Cost Model in a Public Hospital.
Friedman DT, Raskind-Hood C, Adams K, Becker E, Habtes I, D’Orsi 
C, Gundry K, Birdsong G, Gabram-Mendola S. Emory University, 
Atlanta, GA
Background: Despite advances in diagnosis and treatment of breast 
cancer in the United States, racial disparities in survival persist. 
Female breast cancer represented the costliest cancer site in 2010 
with further increases projected to 2020. Mammography screening 
guidelines reflect the inherent difficulty in reconciling mortality 
reduction with potential harms to patients and cost-effectiveness 
concerns. Controversy still surrounds the 2009 updated USPSTF 
recommendations, as critics and advocates alike evaluate lives saved, 
costs, and how best to compare screening strategies. This study 
simulates USPSTF and ACS guidelines’ effects on stage, 5-year 
survival, and cost of treatment vs. usual practice in women treated 
in an urban public hospital.
Methods: Charts of 84 patients diagnosed with Stage I-III breast 
cancer in 2008 were reviewed. Published tumor doubling times guided 
a retrospective model to predict size at diagnosis by simulated ACS or 
USPSTF guidelines. AJCC-7 stages were then assigned to produce 3 
distributions: 1) actual stage; 2) stage under ACS; and 3) stage under 
USPSTF. Survival estimates by stage and year from diagnosis were 
drawn from NCDB statistics and applied to each stage distribution, 
yielding average predicted survival for the actual and hypothetical 
scenarios. Finally, treatment costs for women continuously enrolled 
in Medicaid for 18 months were calculated from merged claims and 
registry data and similarly applied.
Results: Study patients averaged 55 years; 85% were African 
American. Forty-nine percent were covered by Medicaid and 23% 
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by Medicare. Comparing actual and predicted stages at diagnosis 
showed significant shifts in stage distribution between all three 
scenarios (Table 1).
Actual and predicted stages at diagnosis
 Guidelines Chi Square (All p<0.0001)
Stages Actual (at diagnosis): % total (n)
ACS-predicted: 
% total (n)
USPSTF-predicted: 
% total (n)  
I 37% (31) 46% (39) 14% (12) Actual vs. ACS, c² = 132.02
II 46% (39) 43% (36) 73% (61) Actual vs. USPSTF, c² = 103.17
III 13% (11) 4% (3) 6%(5) ACS vs. USPSTF, c² = 149.61
Missing 4% (3) 7% (6) 7% (6)  
ACS guidelines predicted higher survival (87.5% at 5 years) than 
actual (85.5%; p<0.01) or USPSTF (84.6%; p<0.0001), while no 
significant difference was revealed between actual and USPSTF. 
ACS guidelines also predicted lower costs of treatment relative to 
USPSTF and actual, while USPSTF guidelines were more expensive 
than actual (Table 2).
Average net cost per patient across screening scenarios
Scenario comparison Breast procs/dx All claims
USPSTF vs. actual + $3,338* + $3,762*
ACS vs. actual - $3,809* - $4,507*
ACS vs. USPSTF - $7,147** - $8,270**
*p<0.01; **p<0.001 
Discussion: To our knowledge, no studies have compared the impact 
of alternative screening guidelines on outcomes in a predominantly 
African-American, public hospital population. These data support 
continued use of and adherence to ACS screening recommendations 
for inner city patients to achieve the best survival and the lowest 
cost. Given the likelihood of patients to be uninsured or covered by 
federal programs, this study carries implications for public policy 
and patient education, especially in low-resource programs caring 
for underserved patients.
P1-11-01
Strong Socioeconomic Disparities in Breast Cancer Quality of 
Care in Switzerland.
Rapiti E, Blanc A, Benhamou S, Schubert H, Vlastos G, Schaffar R, 
Bouchardy C. University of Geneva, Geneva, Switzerland; INSERM, 
Paris, France; Geneva University Hospitals, Geneva, Switzerland
Background
Despite substantial research on socioeconomic disparities in breast 
cancer prognosis, important gaps remain concerning the causes of 
over mortality among socially deprived patients. In this population-
based study, we identify disparities by socioeconomic status (SES) 
in diagnosis assessment and management of breast cancer in Geneva, 
Switzerland, where the average income and the health care system 
cost are among the highest in the world.
Methods
We included in the study all 1110 women reported with invasive breast 
cancer at the Geneva Cancer Registry between 2003 and 2005. SES 
was regrouped in three levels: low (manual employees, skilled and 
unskilled workers), middle (nonmanual employees and administrative 
staff) and high (professionals, executive administrators, entrepreneurs) 
based on the patient’s last occupation or, if unemployed, that of the 
spouse. We compared patients, tumour, treatment characteristics, 
surgeon caseload and delay of diagnosis as well as some of the 
management quality indicators established by the European School 
of Mastology among SES classes by heterogeneity tests. To assess 
the independent effect of each factor we used multivariate logistic 
regression, comparing women of high vs. low SES.
Results
Compared with patients of high SES, low SES patients were older, 
more often born outside Switzerland and treated in the public system. 
Low SES women had less often screen detected cancers (29% vs. 
41%; OR multi-adjusted for breast self-examination vs. mammography: 1.7, 
95%CI: 1.1-2.6, p=0.020), and less frequently magnetic resonance 
imaging to assess tumour size/focality (4% vs. 15%; OR multi-adjusted 
for breast MRI vs. ultrasound: 0.2, 95%CI: 0.1-0.5, p=0.001). They 
had more often a delay longer than 4 weeks between diagnosis and 
treatment (53.8% vs. 32.7%; OR multi-adjusted for 4 weeks and more vs. 
less: 2.6, 95%CI: 1.7-4.1, p<0.000). Also, women of low SES were 
more frequently operated by surgeons with a lower caseload (<5 new 
breast cancer operations per year) (55% vs. 30%; OR multi-adjusted for 
surgeon’s caseload of 5-15 vs. <5: 0.4, 95%CI: 0.1-0.9, p=0.020), had 
more often positive surgical margins (11.4% vs. 5.4%; OR multi-adjusted 
for negative vs. positive margins: 0.4, 95% CI 0.2-1.0, p=0.057) and 
lower access to anti-aromatase treatments (29.6% vs. 43.6%). In 
particular, the probability to receive anastrozole vs. tamoxifen was 
70% lower (OR multi-adjusted for anastrozole vs. tamoxifen: 0.3, 95%CI: 
0.2-0.6, p<0.000).
Conclusions
This study shows strong SES differences all along the continuum of 
breast cancer management, even in the highly medicalized county of 
Geneva. Only by improving the quality of care provided to women of 
low SES we will be able to prevent the excess breast cancer mortality 
observed among these women.
P1-11-02
Racial/Ethnic Differences in Adjuvant Trastuzumab Receipt for 
Women with Breast Cancer within the National Comprehensive 
Cancer Network.
Freedman RA, Hughes ME, Ottesen RA, He Y, Weeks JC, Wong Y-N, 
Theriault RL, Keating NL. Dana-Farber Cancer Institute, Boston, 
MA; City of Hope, Duarte, CA; Harvard Medical School, Boston, 
MA; Fox Chase Cancer Center, Philadelphia, PA; University of Texas 
MD Anderson Cancer Center, Houston, TX; Brigham and Women’s 
Hospital, Boston, MA
Background
Racial/ethnic disparities in breast cancer care are well documented. 
Although adjuvant trastuzumab has been shown to improve disease 
outcomes for women with Human Epidermal Growth Factor Receptor 
2 (HER2)-positive cancers, the ‘real world’ utilization and toxicity 
of adjuvant trastuzumab are unknown. Because therapy involves 
one year of treatment and the costs of treatment are high, a risk for 
treatment disparity exists. We examined differences in receipt and 
completion of adjuvant trastuzumab by race/ethnicity, education, 
employment, and insurance for women diagnosed with HER2-positive 
breast cancer.
Methods
Using the National Comprehensive Cancer Network (NCCN) Breast 
Cancer Outcomes Database, we identified 1,146 women with stage 
I-III HER-2 positive breast cancer who presented to participating 
NCCN institutions during 2005-2008. In multivariable logistic 
analyses, we assessed the effect of race/ethnicity on the likelihood of 
trastuzumab therapy, and among women who initiated trastuzumab, 
the likelihood of completing ≥ 270 days of therapy, adjusting for 
center, diagnosis year, age, insurance, comorbidity, education, 
employment, and tumor characteristics. We also examined reasons 
for discontinuation of therapy among those who stopped treatment 
prematurely.
Results
Among patients eligible for this analysis, 75% women were 
Caucasian, 9% were African-American, and 9% were Hispanic. Most 
women had managed care insurance (71%) and were employed/
student (52%). About one-third (36%) had a college degree and 39% 
had a high school education or less. Overall, most women (82%) 
received neo/adjuvant trastuzumab and there were no racial/ethnic 
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differences in receipt of therapy (adjusted odds ratio [OR] 1.11, 95% 
confidence interval [CI] .72-1.71 for African-American and OR 1.39, 
95% CI .76-2.54 for Hispanic, versus Caucasian women). Among the 
769 women who initiated neo/adjuvant trastuzumab and had ≥ 365 
days of follow-up, 84% completed ≥ 270 days of trastuzumab. Rates 
of completion were lower for African-American (72%) and Hispanic 
(82%) women than Caucasian women (85%). In adjusted analyses, 
African-American women but not Hispanic women had lower odds of 
completing therapy compared with Caucasian women (OR .45, 95% 
CI .29-.70, p=0.0003). Indemnity insurance (versus managed care) 
was associated with lower odds of trastuzumab completion, as was 
having a high school education or less (versus college education). 
Among the 123 women who did not complete trastuzumab, 26% 
stopped early for toxicity, and this occurred more frequently for 
African-American women than Caucasian women (50% vs. 21%), but 
small sample precluded a meaningful test for statistical significance.
Conclusion
Compared with Caucasian women, African-American women 
had similar rates of initiation of adjuvant trastuzumab but much 
lower rates of completion that were not explained by differences 
in education, employment, or insurance. Because of the significant 
benefits conferred by adjuvant trastuzumab therapy for HER2-positive 
breast cancer, interventions to assure completion of therapy could lead 
to improved outcomes. Further exploration of racial differences in 
toxicity and tolerance of therapy are also warranted.
P1-11-03
Breast Conserving Surgery or Mastectomy – An Urban Bias? 
A Rural Surgical Patient Population and Factors That Lend to 
Therapeutic Decisions in Breast Cancer.
Wooldridge RD, Borgstrom DC. Bassett Medical Center, Cooperstown, 
NY
Introduction: For women with early stage breast cancer, it is accepted 
that BCS followed by radiation therapy yields equivalent results to 
mastectomy. Over the past 20 years, rates of women choosing BCS 
have increased. However, the national mastectomy rate remains 
high. Multiple influential factors have been investigated in efforts 
to define those that aid in surgical decision making, including age, 
race, education concerning surgical options, and the influence of their 
surgeon and discussion regarding surgical options. Our study centered 
on our rural breast cancer population, anticipating that a woman’s 
surgical choice might be affected by unique rural factors not present 
in an urban setting. Methods: Stage 0-II breast cancer patients were 
identified using the Tumor Registry for 1/2000 through 12/2008. 
Patients were divided into two groups based on surgical procedure, 
BCS or mastectomy, and mailed a survey. Questions included basic 
demographics in addition to concerns of recurrence, driving distance 
to the nearest radiation center, potential need for another operation, 
influence by educational materials or family members, discussion of 
options with their surgeon, as well as if they sought a second opinion. 
Responses were assigned values using a Likert scale. Univariate 
analyses were performed to detect relationships between surgery 
choice and survey variables. Those variables found to be significant 
at the univariate level were entered into a multivariate logistic 
regression model predicting the probability of mastectomy versus 
BCS. Results: An overall response rate of 83.1% was achieved, with 
a total of 283 completed surveys. The mean age at the time of surgery 
was 61.1 years (SD 9.3), which was not statistically significant. The 
univariate analyses detected four statistically significant variables 
related to surgical choice – the worry about recurrence (91.6% 
mastectomy patients, 55.4% BCS patients: p-value <0.0001) , a 
faster return to “normal life” (51.7% mastectomy patients, 69.9% 
of BSC patients: p-value 0.039), avoiding another operation (68.9% 
mastectomy patients, 45.2% BCS patients: p-value 0.012), and having 
obtained a second opinion (30.5% of mastectomy patients, 16.7% 
BCS patients: p-value 0.036). There was no difference in surgical 
choice when comparing for age, level of education, distance from 
a radiation center, or concerns about driving in inclement weather. 
The resulting multivariate logistic regression model showed the 
strongest independent predictor of surgical choice to be worry about 
breast cancer recurrence, with a p-value of 0.0005 and an odds ratio 
of 6.1 (95% CI 2.2-16.7). The desire for a faster return to a normal 
life was also significantly predictive in this model. Regarding the 
patient’s impression of the discussion with their surgeon about their 
surgical options, 95.2% of mastectomy patients and 89.2% BCS 
patients stated that their surgeon discussed both as surgical choices. 
Conclusions: Anticipated rural-unique factors were not related to 
surgical decision making in our population of early stage breast 
cancer patients. Concern about breast cancer recurrence was the most 
strongly associated factor in the choice of mastectomy over BCS.
P1-11-04
Breast Cancer Treatment Resources and Guideline-Concordant 
Treatment in Appalachia.
Yao N, Hillemeier MM, Anderson RT, Matthews SA. Penn State, 
University Park, PA; Penn State, Hershey, PA
Background: Appalachia has poorer cancer outcomes, but little 
research has been done regarding availability of cancer care resources 
in this region and how resource availability may relate to cancer 
outcomes. This study 1) examines associations between radiation 
therapy resources and receipt of radiotherapy after BCS in counties 
within Kentucky - a SEER state; and 2) describes spatial patterning 
of breast cancer treatment resources in all 13 Appalachian states.
Methods: For the Kentucky analyses, county-level data from the Area 
Resource File and SEER registry are analyzed. Bivariate analyses 
and spatial lag regression using a 6-nearest neighboring counties 
matrix are conducted. The sample includes stage I or II primary 
breast cancer patients age 18+ years diagnosed in Kentucky during 
2000-2007. The dependent variable is the county-level percentage 
of patients received BCS without radiation; independent variables 
include density of radiation therapy providers and facilities and other 
socioeconomic covariates. For the analyses of entire Appalachian 
region, descriptive analyses and exploratory spatial data analysis 
are conducted including 420 Appalachian counties and 644 non-
Appalachian counties in 13 states.
Results: In Kentucky 16.44% of 17,227 early stage breast cancer 
patients received BCS without radiation therapy (21.08% in 
Appalachia versus 14.80% in non-Appalachia, p<0.001). Appalachian 
Kentucky had significantly fewer radiation oncologists and radiation 
therapy facilities per capita than non-Appalachian Kentucky. The 
number of radiation therapy facilities per capita is negatively 
associated with rates of BCS without radiation when controlling for 
covariates. Analysis of 13 Appalachian states shows that Appalachian 
counties, especially in the Central and Southern regions, had 
significant fewer physicians per capita in Surgery, Anesthesia, Clinical 
Pathology, and Radiation Oncology. Clustering of scarce breast cancer 
care resources was observed in Central Appalachia.
Conclusions: Appalachian counties, especially in central Appalachia, 
have fewer breast cancer treatment resources than non-Appalachian 
counties, and resource availability is associated with cancer health 
disparities.
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Table 1. Spatial Lag Regression Analysis Modeling Variables Predicting for County-Level Rates of 
Omitting Radiation Therapy After Breast Conserving Surgery
Variables Coefficient (Std. Error)
Number of counties used 120
Spatially lagged Rate of BCS without Radiation 0.65*** (0.08)
Intercept 55.31** (20.26)
Appalachian designation 6.12** (2.31)
Number of radiation oncologists per 100,000 residents 1.21 (0.84)
Number of radiation therapy facilities per 100,000 residents -4.59** (1.40)
% of white population -0.37* (0.17)
Poverty rates 0.47 (0.32)
% of uninsured population -1.52** (0.56)
Medicare HMO penetration rate -0.29 (0.17)
% of women older than 45 -0.07 (0.32)
% counties without radiotherapy facility in its own county or neighboring 
counties 0.83 (1.90)
% counties without radiation oncologists in its county or neighboring 
counties 0.21 (1.93)
% counties not on interstate highway -1.23 (1.56)
Log likelihood -409.52
AIC 845.039
Notes: * p<.05, ** p<.01, *** p<.001 
P1-11-05
Investigation of Epidemiological Factors as Barriers to Indicated 
Radiation Therapy in Post-Mastectomy Breast Cancer Patients 
in South Carolina.
Rhome RM, Wahlquist A, Garrett-Mayer E, Harper J. Medical 
University of South Carolina, Charleston, SC
Purpose: Post-mastectomy radiation therapy (PMRT) has been shown 
to provide improved locoregional control and overall survival in 
intermediate and high-risk breast cancer patients1,2. To investigate the 
frequency of utilization and potential barriers to receipt of adjuvant 
PMRT in South Carolina, an analysis of the S.C. Cancer Registry 
(SCCR) database was undertaken.
Methods: Epidemiological factors such as age, race, and geographic 
distance from a radiation therapy facility were analyzed as potential 
predictors of whether patients received the indicated radiotherapy. 
Post-mastectomy breast cancer patients (n=1080) recorded in the 
SCCR from 2006-2008 were stratified as low (Tis/T1, N0) (43%), 
intermediate (T1/T2, N1) (27%), or high (T3/T4, N2/N3) (30%) risk. 
Logistic regression models were used to predict receipt of adjuvant 
radiotherapy based on factors such as race, age, and geographical 
distance from radiation treatment facility.
Results: Adjuvant PMRT was received in 4% (19/469) of low 
risk patients, 23% (67/288) of intermediate risk patients, and 44% 
(141/323) of high risk patients. In both intermediate and high risk 
groups, older patients were less likely to receive PMRT. The odds of 
receiving PMRT decreased by 3% (OR= 1.03; 95% CI: 1.01-1.05; 
p=0.01) and 2% (OR=1.02; 95% CI: 1.002-1.035; p=0.03) per year in 
the intermediate and high risk groups, respectively. Race and distance 
from treatment facility were not predictive of receipt of PMRT in 
high risk patients.
Conclusion: Utilization of adjuvant PMRT in intermediate and 
high risk breast cancer patients in South Carolina is low, despite the 
evidence that it confers a survival benefit in both premenopausal 
and postmenopausal women. Of the patient-related factors analyzed, 
only age predicted lower odds of receiving radiotherapy in both the 
intermediate and high risk group. In high risk patients of advanced 
age (>70), breast cancer continues to be a major cause of mortality 
which can be improved by radiotherapy3. Future educational efforts 
should focus on addressing patient and physician bias against 
radiotherapy based on patient age. Further study is needed to identify 
socio-economic-, physician- and health system- related factors that 
maybe impacting the underutilization of PMRT in South Carolina.
References:
1. Overgaard, M, PS Hansen, et al. 1997. Postoperative radiotherapy 
in high-risk premenopausal women with breast cancer who receive 
adjuvant chemotherapy. NEJM, 337:14, pg 949-955.
2. Overgaard M, Jensen M-J, Overgaard J, et al. 1999. Postoperative 
radiotherapy in high-risk postmenopausal breast-cancer patients given 
adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 
82c randomised trial. Lancet. 353: 1641-1648.
3. Smith, BD, BG Haffty, A Hurria, DH Galusha, and CP Gross. 2006. 
Postmastectomy radiation and survival in older women with breast 
cancer. JCO, 24:30, pg 4901-4907.
P1-11-06
Barriers to Enrollment in Cancer Therapeutic Clinical Trials: A 
Comprehensive Cancer Center Experience.
Bourdeanu L, Niland J, Stiller T, Swain-Cabriales S, Somlo G. City 
of Hope Medical Center, Duarte, CA
PURPOSE: Well-conducted cancer therapeutic clinical trials are 
essential for improving patient outcomes. Unfortunately, less than 
5% of new cancer patients participate in clinical trials on average 
nationwide. Failure to recruit eligible patients represents a major 
impediment to the success of clinical trials. Barriers to patient accrual 
in cancer clinical trials must be identified and overcome to increase 
patient participation.
MATERIALS AND METHODS: A retrospective analysis of 418 
patients with a diagnosis of breast cancer seen at City of Hope Medical 
Center in 2009 was performed. Along with descriptive analysis of 
patient demographic data, logistic regression analyses were performed 
to evaluate predictors of enrollment.
RESULTS: Of the 418 new breast cancer patients in 2009, we 
determined that 138 (33%) were eligible for available therapeutic 
clinical trials at City of Hope. At the initial visits, physicians did 
not consider clinical trials in 32% (44/138) of these patients. Of 
the 138 eligible patients, 58% (80/138) of patients participated in 
clinical trials. The remainder (58/138, 42%) either declined trial 
participation despite meeting eligibility criteria (14/58, 24%), or 
were not considered for clinical trials by their respective physician 
(44/58, 76%). By logistic regression analysis, patients with Stages II 
and III disease were significantly more likely to enroll in clinical trials 
compared to those with stage 0 or I (OR=2.89, 95% CI, 1.17-7.12, P 
= .02; OR=9.17, 95% Cl, 2.65-31.76, P=0.0005;, respectively). Age, 
preferred language, marital status, family history of breast cancer, 
and race were not found to be significant predictors of enrollment in 
therapeutic clinical trials.
CONCLUSION: While enrollment of eligible breast cancer patients 
onto therapeutic clinical trials at City of Hope is high (58%), overall 
the proportion going onto clinical trials remains low (80/418, 19%), 
though higher than national averages. We found that the majority of 
patients did not enroll due to lack of availability of a suitable trial, 
ineligibility, or lack of offering of trial enrollment by the treating 
MD. Barriers to cancer clinical trial accrual should be prospectively 
identified and addressed in future studies, with the hope of leading 
to more vigorous enrollment.
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Impact of Reduction in Cost-Sharing on Screening Mammography 
Utilization among Rural U.S. Women.
Peppercorn J, Wheeler SB, Yu M, Antetomaso J, Baxter P, Villagra 
VG, Jung S-H, Lyman GH. Duke Cancer Institute; University of North 
Carolina School of Public Health; Duke Department of Biostatistics 
and Bioinformatics; National Rural Electric Cooperatice Association
Background: Early detection of breast cancer through mammography 
screening leads to earlier stage at diagnosis and improved survival. For 
reasons that are poorly understood, in recent years the rate of screening 
has demonstrated periods of decline, and screening has proved to be 
less common in rural compared to urban areas of the U.S. In 2006, 
the National Rural Electric Cooperative Association (NRECA) which 
provides health care to over 100,000 electrical workers and their 
families in primarily rural areas of the U.S. eliminated copayments 
for screening mammography in an effort to boost screening rates. 
We conducted a population based analysis of screening utilization 
to determine the impact of this policy initiative.
Methods: Using the NRECA insurance database, all women aged 
40 to 64 with no prior history of breast cancer or DCIS (based on 
ICD-9 codes) were identified and we evaluated claims data on annual 
screening mammography utilization (SMU) between 1999 and 2009 
stratified by age group in 5 year intervals. Changes in SMU over time 
were assessed focusing on the periods before and after the policy 
change in January 2006. We also evaluated diagnosis of breast cancer 
and receipt of mastectomy and chemotherapy as a potential proxy 
for more advanced disease at diagnosis. Descriptive statistics were 
estimated and the mammography rate was fitted on years using the 
identity link (proc genmod in SAS). In order to test the impact of 
the 2006 change in cost-sharing on the trend in mammography rate, 
we introduced change point terms in slope and intercept to the linear 
model. Chi-squared test for 2x2 tables was used to compare SMU 
rates between two consecutive years for each age group. All p-values 
are two-sided.
Results: During this period, a mean of 20,825 women aged 40 to 
64 each year received health insurance through NRECA. SMU 
increased from 38.1% in 1999 to 49.5% in 2009. Analyzing SMU 
before and after the change in cost sharing policy demonstrates a 
significant change in the rate of screening at the 2006 intercept (p = 
0.0275) although the slope of year to year change in screening rate 
did not change. In stratified analysis there was a significant change 
in SMU between 2005 and 2006 for all age groups. In the 4 years 
prior to the NRECA change in policy, 554 women were diagnosed 
with breast cancer and 40 underwent mastectomy and chemotherapy. 
In comparison, from 2006 to 2009, only 20 women out of 540 with 
newly diagnosed breast cancer underwent such therapy (7.2% prior 
to policy change vs. 3.7% following, P = 0.01).
Conclusion: The impact of health plan benefits changes can be 
evaluated among a primarily rural population of women aged 40 to 
64 using the novel NRECA database. Annual SMU remained low, 
but improved following elimination in copayments suggesting that 
financial barriers impact screening. Multiple factors may explain 
changes in SMU and treatment intensity over time. However, cost-
sharing for high value health care services may have unintended 
negative consequences. Further evaluation of this database is 
planned to evaluate biannual screening rates, correlation with 
sociodemographic factors, impact of recent controversy over 
screening guidelines and additional barriers to screening utilization 
in this rural population.
P1-11-08
Breast Cancer Screening Resources and Stage at Diagnosis in 
Appalachia: A Geospatial Perspective.
Yao N, Hillemeier MM, Anderson RT. Penn State, University Park, 
PA; Penn State, Hershey, PA
Background: National Cancer Institute has designated Appalachia 
as a priority area characterized by significant disparities in cancer 
outcomes. However, little research focuses on the availability of 
cancer care resources in this region and how resource availability may 
relate to cancer outcomes. This paper will describe the distribution 
of breast cancer screening resources in Appalachia and examine the 
relationship between the screening resources and breast cancer stage 
at diagnosis at the population level.
Method: Percentages of early stage breast cancer incidence are 
computed based on the county-level data from the four Appalachian 
state cancer registry data from 2000 to 2008. Per capita breast cancer 
screening providers or facilities are computed for these Appalachian 
states. Descriptive analysis, exploratory spatial data analysis, and 
spatial regression were conducted.
Results: Appalachian counties had significantly fewer primary 
physicians, OB/GYN specialists, and diagnostic radiologists per 
capita than non-Appalachian counties. Spatial analysis demonstrates 
moderate clustering of scarce breast cancer screening resource 
and low percentage of early stage breast cancer incidence in West 
Virginia and Appalachian Kentucky. Those diagnosed at early stages 
were 67.92% of Appalachian vs. 68.34% of non-Appalachian breast 
cancer patients. The number of diagnostic radiologists per capita 
is significantly associated with the percentage of early stage breast 
cancer incidence when controlling for covariates such as county level 
poverty rates, uninsurance rate, percentage of adults with college 
degree, and per capita primary care resources.
Conclusions: Fewer diagnostic radiologists in West Virginia and 
Appalachia Kentucky are associated with lower percentage of early 
stage breast cancer incidence in the Central Appalachia region. Public 
health intervention could include policies and regulations to improve 
breast cancer screening resources in this region.
Table 1. Regression Analysis Modeling Variables Predicting for Percentage of Early State Breast 
Cancer Incidence at County Level
Variables Coefficient (Std. Error)
Number of counties used 330
Intercept 66.24 (6.26)
Appalachian designation 0.30 (0.33)
Number of primary physicians per 100,000 residents -0.02 (0.01)
Number of OB/GYN per 100,000 residents 0.00 (0.02)
Number of diagnostic radiologists per 100,000 residents 0.12* (0.06)
Number of hospitals with mammography service per 100,000 residents -0.01 (0.02)
Percentage of white population 0.04 (0.06)
Poverty rates -0.20 (0.13)
Percentage of uninsured population -0.09 (0.21)
Percentage of adults with college degree 0.09 (0.06)
Adjusted R-square 0.1415
Notes: * p<.05
P1-11-09
Effects of a Multidisciplinary Breast Cancer Clinic in an 
Appalachian Based Medical Center.
Ingham JA, Cremeans DK, Daugherty SL, Myhand RC, Sever 
WE. Adena Health System, Comprehensive Breast Care Program, 
Chillicothe, OH
Background: Adena Health System is a not for profit 250 bed 
institution that provides health care for a 13 county region in southeast, 
Appalachia Ohio. Access to health care in rural setting is an ongoing 
challenge. Several barriers to health care access affect this region. 
Socioeconomic burden and lack of higher education are two of the 
most dominant barriers. The age-adjusted beast cancer rates are 5.3% 
higher in the Appalachian region and the stage at presentation is more 
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advanced. In December of 2009, we held our first Multidisciplinary 
Breast Cancer Clinic (MDBCC). The goal of the MDBCC is to 
facilitate prompt diagnosis and effective treatment. The MDBCC 
is staffed by a team of physicians consisting of surgeons, medical 
oncologists, and radiation oncologists. The team meets with the patient 
in a one on one setting. That same day the patients are discussed by 
the team with input from pathology and radiology in order to tailor 
a treatment plan specifically for each patient. After the conference, 
the recommendations are discussed with the patient before treatment 
is initiated.
Material and Methods: In a retrospective review, we evaluated the 
effect of a MDBCC on days to diagnosis, days from diagnosis to 
treatment, percentage of patients receiving neoadjuvant chemotherapy, 
and stage at diagnosis. Since December 2009, there have been over 
90 breast cancer patients evaluated in the MDBCC. We randomly 
selected 60 breast cancer patients treated prior to MDBCC between 
2008-09 and 66 patients evaluated at the MDBCC between December 
2009-2011 from the tumor registry database.
Results: The average number of days to diagnosis pre-MDBCC 
was 15.5 days as compared to 4 days post-MDBCC. In 2008-09, 
the average days to treatment (pathology result to a-port placement, 
surgery or chemotherapy) was 18 days as compared to 12 days 
post-MDBCC. The percentage of patients receiving neoadjuvant 
chemotherapy has not changed significantly, however, there is an 
upward trend approaching statistical significance (10% per-MDBCC 
vs. 12% post-MDBCC). The stage at presentation has not changed 
significantly since the start of the MDBCC.
Discussion: The development of the MDBCC has proven to be a 
successful team oriented approach to breast cancer diagnosis and 
treatment. Time to diagnosis and initiation of treatment has improved. 
Providing patients with access to multiple specialists and forming a 
treatment plan the same day improves quality of care and lessens 
economic burden. The MDBCC is clearly feasible and particularly 
suited to the rural hospital setting. System wide, we hope to see a 
decrease in the stage at presentation and are confident based upon 
our current data that this in a realistic goal.
P1-11-10
Quality of Breast Cancer Care in a Boston Area Patient Navigator 
Program.
Raj A, Ko N, Battaglia T, Moy B. Massachusetts General Hospital, 
Boston, MA; Boston Medical Center, Boston, MA
Background: Elimination of disparities is critically important for 
lessening the burden of cancer. Patient navigator programs (PNPs) 
assist with all aspects of care, including access, cancer prevention, 
screening, post-diagnosis care, and survivorship care. Little is 
known about the effect of PNPs on patient care and outcomes 
following the diagnosis of breast cancer (BC). We examined quality 
measures (QMs) of breast cancer care among women participating 
in the Massachusetts General Hospital Avon Breast Care Patient 
Navigator Program (MABCP), which provides patient navigation 
services to disadvantaged minority communities in the greater 
Boston area. Methods: Women diagnosed with BC who participated 
in the MABCP from 2001 to 2011 were followed to determine the 
proportion whose care was concordant with American Society of 
Clinical Oncology/National Comprehensive Cancer Network (ASCO/
NCCN) QMs. QMs included 1) hormonal therapy (HT) within 1 year 
of diagnosis for HR+ tumors > 1 cm; 2)chemotherapy within 120 
days of diagnosis of HR- >1cm tumors for women <70 years; and 3) 
post-lumpectomy radiation therapy (XRT). Descriptive statistics were 
used to report characteristics of MABCP patients. Results: Of the 
186 MABCP patients diagnosed with BC, some treatment data was 
available on 158 (85%) and race/stage information was available on 
149 (80%) [Table 1]. Among the MABCP patients, concordant care 
was received by 70/74 (95%) for the HT QM, 15/17 (88%) for the 
chemotherapy QM, and 65/71 (92%) for the XRT QM. In comparison, 
available benchmark concordance rates of BC patients treated at 8 
NCCN centers from 2003-6 are: 340/382 (89%) for the HT QM, 
156/179 (87%) for the chemotherapy QM, and 141/148 (95%) for the 
XRT QM. Conclusions: Overall, breast cancer care in the MABCP 
PNP is concordant with published ASCO/NCCN quality measures. At 
present, the sample is insufficient to compare concordance rates with 
NCCN patients but preliminarily, it appears that the quality of care 
is comparable. Future research should include prospective analyses 
of quality metrics to assess the process and outcomes of patient 
navigation in diverse settings, compared with control populations.
Race and Stage of Massachusetts General Hospital Avon Breast Care Patient Navigator Program
 Race/Ethnicity  DCIS  Stage 1  Stage 2  Stage 3  Stage 4  Race # (%) 
White 16 18 17 5 3 59 (40%)
Black 5 7 8 9 1 30 (20%)
Hispanic 16 19 11 3 3 52 (35%)
Asian/ME 0 4 2 2 0 8 (5%)
Total (%) 37 (24.8%) 48 (32.2%) 38 (25.5%) 19 (12.8%) 7 (4.7%) 149
P1-11-11
Wait Times for Breast Cancer Care in Manitoba 2009-2010. Time 
To Face the Challenge.
Carpenter-Kellett T, Nashed M. CancerCare Manitoba, Winnipeg, 
MB, Canada
Background: Wait times for patients with breast cancer to receive 
oncological treatment vary significantly. In Manitoba, the radiation 
treatment wait times improved in the year 2005 compared to 2001. 
However, other parts of the patient’s journey have lengthened and 
negated the reduction seen in radiation treatment wait times.
Aims: To examine the overall time from disease suspicion to treatment 
of breast cancer patients from June 2009 to June 2010 and to compare 
to the previously published wait times.
Methods: This population-based retrospective study looked at 
representative samples of women newly diagnosed with breast cancer. 
Patients were followed from the time of first presentation, either to 
their family physician or after a suspicious screening mammogram, 
to the time adjuvant treatment was started. Each patient’s journey 
was subdivided into different chronological stages. The data was 
compared to the wait times reported in 2005.
Results: 363 patients’ data was collected and analyzed. The median 
elapsed time in days for each phase of the journey was calculated. 
Total wait times from suspicion to diagnosis were also calculated. 
The wait times of most stages of the patients’ journey have worsened 
when compared to 2005. .However, there was some improvement in 
the diagnostic part of the journey. Delays to surgery and pathology 
have contributed to lengthening of the total journey. There was also 
a systematic and repetitive administration delay at each transition. 
Screen-detected cases had a shorter journey than those who presented 
through a family physician.
Conclusions: In spite of improvements achieved in the wait times at 
some stages of the journey, the total length of the patient journey has 
not been shortened. This represents not only individual team failures 
but also a built in complexity in the health system. In order to achieve 
a meaningful cut in wait times for breast cancer patients, the entire 
trajectory of care needs to be addressed.
CTRC-AACR San Antonio Breast Cancer Symposium
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P1-11-12
Patterns of Care of Newly Diagnosed Patients with Breast Cancer 
in Mexico.
Chavarri-Guerra Y, Liedke PER, Symecko H, Hammond EE, Higgins 
MJ, Finkelstein D, Goss PE. Massachusetts General Hospital, 
Boston, MA
Background: Breast cancer is the most common form of cancer and the 
leading cause of cancer death in women worldwide. More than 55% 
of breast cancer deaths occur in low and middle income countries. 
Although incidence rates for breast cancer are lower in developing 
countries, mortality rates are higher. This phenomenon has been 
attributed to limited access to care for breast cancer patients, including 
screening and early diagnosis as well as primary surgical, radiation 
and systemic therapies. Similar to trends in other poor and middle 
income countries, breast cancer mortality in Mexico is rising. The goal 
of this survey of physicians caring for patients with breast cancer in 
Mexico is to obtain information about current treatment patterns of 
newly diagnosed patients and to describe their clinical characteristics.
Methods: A web-based closed survey has been sent to 854 physicians 
providing care to newly diagnosed breast cancer patients across 
Mexico, including medical oncologists and breast cancer surgeons. 
The survey instrument contains 35 questions assessing demographic 
data, access to diagnosis and treatment in a variety of clinical 
patient scenarios. The responses will be anonymous and entered 
automatically into a secure database for analysis. Fisher exact test will 
be used for the frequency analysis. Chi-squared statistics and Kendall 
correlation will be used for nominal and ordinal variables respectively.
Results: The results will be presented at the 2011 San Antonio Breast 
Cancer Symposium.
Conclusions: The results of this survey will highlight potential 
disparities in care received by breast cancer patients across the 
full geographic and socioeconomic spectrum of Mexico in order 
to highlight the need for uniform, quality based approaches for the 
diagnosis and treatment of breast cancer patients in Mexico, and 
will serve as an example of how one middle income country faces 
challenges and unmet medical needs regarding access to care of 
women with breast cancer.
P1-11-13
Improvement in the Quality of Care for Patients with Locally 
Advanced Breast Cancer through Implementation of an 
Integrated Electronic Care Pathway.
Hogeveen S, Han D, George RL, Sweet-Goldstein M, Dinniwell RE, 
Muradali D, Brezden CB, Haq R, Simmons CE. St. Michael’s Hospital; 
Princess Maragaret Hospital
Background: Locally advanced breast cancer (LABC) refers to the 
most advanced stage of non-metastatic tumours with an incidence 
of approximately 10% in newly diagnosed breast cancers. Currently, 
for optimal care, patients with LABC require a multidisciplinary 
approach including coordinated planning with medical, surgical 
and radiation oncologists. Many barriers may exist in co-ordinating 
timely management of these patients. Care pathways are important 
tools to streamline care and data collection and feedback allows for 
quality improvement in clinical practice. We created an interactive 
electronic care pathway and self populating quality assurance database 
at St. Michael’s Hospital (SMH) to facilitate multidisciplinary teams 
to track LABC patient histories and patient treatments in order to 
coordinate therapy effectively and expedite care (LABC E-PATH).
Methods: This is an observational before-and-after cohort study of 
patients with LABC with a retrospective review pre-implementation 
and prospective collection of clinical data post-implementation. The 
completeness of workup and the timeliness of treatment pre- and 
post-implementation were assessed.
Results: With the implementation of the LABC E-PATH in May 
2010, the time between the referral of an LABC patient to a medical 
oncologist and consultation has decreased from 7 days (range 0 to 493) 
pre-implementation to 2 days (range 0 to 29) post-implementation. 
The time between referral to medical oncologist and the start of 
their chemotherapy treatment decreased significantly from a median 
of 19 days to 8 days (pre-implementation: range = 0 to 493, post-
implementation: range = 0 to 128) (p=0.0028). All pre-treatment 
staging was completed faster post-implementation of the LABC 
e-path than pre-implementation, expediting time to initiation of 
chemotherapy. The number of referrals for LABC to the SMH 
program increased from < 1 patient per month to 4 patients per month 
post-implementation.
Conclusions: The LABC E-PATH has achieved its goal of expediting 
care and overcoming barriers to timely treatment in this patient 
population. It has also ensured timely and appropriate resource 
allocation. This unique system may also be applied to other disease 
sites where coordination of a multi-disciplinary team is critical for 
appropriate patient management.
P1-11-14
Gender and Sexual Orientation of Clients Who Were Linked 
to Breast Cancer Screening Services through Outreach and 
Education Supported by the Avon Breast Health Outreach 
Program.
Opdyke KM, Pagaduan MG, Gates-Ferris K, Ricci CA, Hurlbert 
M. Cicatelli Associates Inc., New York, NY; Avon Foundation for 
Women, New York, NY
Background: Lesbian, gay, bisexual, and transgender (LGBT) 
individuals experience health disparities in breast cancer screening 
related to multiple socioeconomic factors, including stigma and 
discrimination. Since 2001, the Avon Breast Health Outreach Program 
(Avon BHOP) has granted almost $60 million to 240+ organizations 
to promote breast cancer screening. Avon BHOP beneficiaries 
collect a standardized set of de-identified, self-reported client level 
health and demographic data to ensure that programs reach their 
target population. Prior to 2011, no data on client gender or sexual 
orientation were collected.
Methods: From 2009-2010, the Avon BHOP conducted a review 
of the standard confidential client intake form (CIF), last revised in 
2006. Based on stakeholder input, including the Avon Foundation 
for Women and Avon BHOP beneficiaries, the CIF was updated 
in 2011 to incorporate variables for gender and sexual orientation. 
Proposed revisions were presented to current beneficiaries in June 
2010 for feedback. Although the CIF has historically included 
many sensitive elements such as race/ethnicity and income, several 
programs expressed concern that clients or program staff would be 
uncomfortable addressing questions on gender and sexual orientation 
in particular. In response, the Avon BHOP Coordinating Center 
provided standard language that programs could use to help ease the 
concerns of staff and clients that incorporated three key messages: 
1) the same form is used for all clients and programs funded by the 
Avon BHOP to help ensure funds are reaching clients in need; 2) all 
responses are kept confidential; and 3) clients may skip any question 
they are not comfortable answering.
Results: Preliminary CIF data for January-March 2011 were analyzed 
for 20,672 clients from 109 programs. Overall, 96.6% (n=19,966) 
indicated female gender; 0.5% (n=101) self-reported gender as 
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follows: 75 male, 8 transgender, 12 “other”, and 6 “unknown”; and 
2.9% (n=605) did not respond to this question. For sexual orientation, 
77.7% (n=16,067) of clients selected “heterosexual”. Of the remaining 
22.3% (n=4,606), 175 (0.8%) selected “lesbian, gay or bisexual”, 
431 (2.1%) selected “other”, 1045 (5.1%) selected “unknown”, and 
2,954 (14.3%) did not respond to this question. By program, the non-
response rate ranged from 0% to 40.2% for gender, and from 0% to 
81.9% for sexual orientation.
Discussion: Avon BHOP programs were able to collect sensitive 
information on client gender and sexual orientation during the first 
three months during which this information was requested. Despite 
concerns expressed among staff, overall response rates were high and 
rates of “unknown” (which may indicate that a staff person did not 
ask a client to complete the question) were low. Beneficiaries receive 
a quarterly summary of their own CIF data, which allows program 
staff to review client responses and ensure that client needs are met 
in a culturally sensitive manner. The Avon BHOP is committed to 
supporting diversity among funded programs; requesting data on 
client gender and sexual orientation may help improve services for 
LGBT clients by giving them a voice and reducing stigma.
P1-12-01
Pregnancy during and Following Adjuvant Trastuzumab in 
Patients with HER2-Positive Breast Cancer: An Analysis from 
the HERA Trial (BIG 01-01).
Azim, Jr HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant 
F, Gresko E, Procter M, Piccart-Gebhart M. Institut Jules Bordet, 
Brussels, Belgium; German Breast Group, Frankfurt, Germany; F. 
Hoffmann-La Roche, Basel, Switzerland; Frontier Science, Kincraig, 
United Kingdom
Background: 1-year of adjuvant trastuzumab (T) is the standard 
of care in managing patients (pts) with early HER2-positive breast 
cancer (BC). As T is not known to alter fertility, pts with childbearing 
potential could become pregnant during or following treatment with 
T. Cases of oligohydramnios, some associated with fatal pulmonary 
hypoplasia of the fetus have been reported in women receiving T 
during pregnancy (preg). Here we report the outcome of preg in all 
pts enrolled in the HERA trial.
Methods: Pregnancies in the HERA trial are reported on a distinct 
“pregnancy form” for up to 10 years following T completion. The form 
includes information on approximate date of conception, preg course 
& outcome, fetal measurements at birth, and congenital anomalies. 
Any missing data were retrieved from the study site, if available. For 
this analysis, pts were grouped into 3 groups: 1) preg during and up 
to 3 months after T, 2) preg > 3 months of last T dose, and 3) preg 
with no prior exposure to T.
Results: By March 2010, 70 preg were reported in 58 out of 5102 pts 
randomized. Five, 30 and 7 completed preg were reported in groups 
1, 2 & 3 respectively.
Table 1
 Group1 (Preg on T) Group2 (Preg after T)
Group3 
(Preg with no 
exposure to T)
N.pts (n.preg) 16 (16) 31 (43)* 11 (11)
Missing preg info 0 3 1
N.completed preg 5 (31%) 30 (69%) 7 (63%)
Live Birth 5 (100%) 33 (100%)** 7 (100%)
Mean gestational week at delivery 40 (n=5) 38 (n=22) 39 (n=6)
Mean Apgar score at 10 min 10 (n=3) 9.5 (n=18) 9 (n=6)
Mean fetal weight in gm 3485 (n=4) 3123 (n=25) 3431 (n=7)
Mean fetal length in cm 50 (n=3) 52 (n=18) 50 (n=5)
* 3 pts got preg on and after T ** 3 twin deliveries
As per protocol, all pts on T were required to use adequate 
contraceptive measures, yet 16 pts became pregnant during the course 
of T and up to 3 months thereafter. The percentage of completed preg 
was lowest in group 1, with 4 spontaneous and 7 induced abortions. In 
group 2, preg occurred at a mean of 29 months following completion 
of T, with 6 spontaneous and 4 induced abortions. In group 3, abortion 
was induced in 3 pts and no spontaneous abortions reported. Across 
all 3 groups, all but 1 spontaneous abortion occurred during the 
1st trimester. Two congenital anomalies were reported; a Down’s 
syndrome in a 43 year old pt >5 years after completing T for which 
abortion was induced, and one with partial fusion of the 2nd and 3rd 
toe born to a pt in group 3.
Conclusions: Unintentional exposure to T during preg may be 
associated with spontaneous abortion, yet the numbers remain low 
to draw firm conclusions (spontaneous abortion rate in general 
population is up to 20%). No oligohydramnios or anomalies were 
observed in group 1. While an increased risk of oligohydramnios 
has been reported when T is administered after the 1st trimester, T 
administered to Cynomolgus monkeys during organogenesis did 
not cause fetal harm (Pentsuk et al; 2009). Nevertheless, women of 
childbearing potential should be advised to use effective contraception 
during and up to 6 months after treatment with T. On the other hand, 
prior exposure to T did not appear to affect the preg course or outcome. 
We are planning to collect information from the other T adjuvant trials 
to confirm our findings.
P1-12-02
Patient-Reported Outcomes (PROs) from a Randomized Phase 
II Study (TDM4450g/BO21976) of Trastuzumab Emtansine 
(T-DM1) vs Trastuzumab Plus Docetaxel (HT) in Previously 
Untreated HER2-Positive Metastatic Breast Cancer (MBC).
Bianchi GV, Kocsis J, Dirix L, Torigoe Y, Lalla D, Tong YB, Guardino 
AE, Hurvitz SA. Fondazione IRCCS Istituto Nazionale Tumori, Milan, 
Italy; Semmelweis University Budapest, Budapest; Sint-Augustinus, 
Antwerp; Genentech; UCLA/Translational Oncology Research 
International
Background
T-DM1 is an antibody-drug conjugate in development for HER2-
positive cancer. As a single-agent, it has demonstrated promising 
efficacy and safety when administered after multiple lines of HER2-
directed therapy. In the current study, we compared the safety and 
efficacy of T-DM1 to standard first-line treatment for HER2-positive 
MBC. This abstract highlights the PRO results in the context of 
efficacy and safety.
Methods
Patients with HER2-positive MBC and no prior MBC therapy were 
randomized 1:1 to T-DM1 3.6 mg/kg IV q3w or H 6 mg/kg IV (8 
mg/kg in cycle 1) + T 75 or 100 mg/m2 IV q3w. Primary objectives 
were investigator-assessed progression free survival (PFS) and safety. 
Key secondary end points included objective response rate and the 
FACT-B Trial Outcome Index (TOI). Patients completed the FACT-B 
on day 1 of each treatment cycle. The FACT-B TOI, the primary 
PRO end point, comprises a subset of the FACT-B and provides a 
summary measure of physical and functional well being and breast 
cancer specific symptoms. Time to FACT-B TOI worsening (ie, ≥5 
point decrease in TOI) was assessed with Kaplan-Meier methods and 
a Cox model. A repeated measures mixed effects (RMME) model 
was used to evaluate potential treatment effects on TOI across cycles. 
Preliminary PRO results based on a data cutoff of November 15, 2010, 
are included here; final data will be presented.
Results
A total of 137 patients were randomized (67 T-DM1, 70 HT). Baseline 
patient and disease characteristics were similar in each arm. Patients 
treated with T-DM1 had longer PFS (14.2 vs 9.2 months, HR=0.59, 
P= 0.035) with less toxicity (eg, 46.4% grade 3/4 adverse events 
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with T-DM1 vs 89.4% with HT) than those treated with HT. ORR 
was similar in both arms (64.2% T-DM1, 58.0% HT). A total of 
132 patients (65 T-DM1, 67 HT) were evaluable for PRO analyses 
with a high compliance rate. In a preliminary analysis, FACT-B TOI 
worsening was significantly delayed in the T-DM1 arm compared 
with the control arm (7.5 vs 3.5 months, HR=0.58, P=0.022). The 
RMME model showed a mean difference of 3.65 in FACT-B TOI 
scores (P=0.023), mainly driven by physical well being (PWB) 
scores (mean difference 2.28, P=0.002), favoring T-DM1. In addition, 
5 of 7 PWB items showed significantly better mean scores in the 
T-DM1 arm: “lack of energy” (P=0.011), “trouble meeting needs of 
family” (P=0.025), “bothered by side effects” (P<0.001), “feeling 
ill” (P=0.016) and “forced to spend time in bed” (P=0.015); the 2 
remaining items, “nausea” and “pain,” showed numerically better 
mean scores with T-DM1.
Conclusions
Compared to HT, T-DM1 as first-line treatment of HER2-positive 
MBC conferred longer PFS and a more favorable toxicity profile. The 
PRO data suggest that T-DM1 is also associated with meaningfully 
improved tolerability relative to HT, contributing to an overall clinical 
benefit and better health-related quality of life. Thus, T-DM1 may 
improve the standard of care for patients with previously untreated 
HER2-positive MBC.
P1-12-03
Combined Targeting of the PI3K Pathway and HER2 Overcomes 
Acquired and De Novo Trastuzumab Resistance.
O’Brien NA, McDonald K, Von Euw E, Conklin D, Kalous O, Di 
Tomaso E, Finn RS, Slamon DJ. University of California at Los 
Angeles, Los Angeles, CA; Novartis-Oncology, Cambrige, MA
Background: Although trastuzumab and lapatinib provide clinical 
benefit for women with HER2-positive breast cancer, both de novo 
and acquired resistance to these agents exist. There is increasing 
evidence to suggest that aberrant activity of the PI3K/AKT/mTOR 
signaling pathway is one of the key mechanisms responsible for 
resistance. Thus, pharmacologically targeting the PI3K pathway 
is a rational approach for overcoming resistance to HER2-targeted 
therapy. However, specifically targeting individual elements of the 
PI3K pathway may result in feedback activation or in activation 
of compensatory pathways, whereas targeting the pathway at 
multiple points may be more effective in permanently shutting down 
proliferation and inducing cell death.
Materials and Methods: In this study we evaluated the activity of 
three small molecule tyrosine kinase inhibitors that target specific 
critical portions of the PI3K pathway; BKM120 (pan-PI3K), 
RAD001 (mTORC1 specific) and BEZ235 (dual PI3K & mTOR) 
both individually and in combination with trastuzumab in a panel of 
HER2-amplified breast cancer cell lines that have previously been 
characterized for trastuzumab response/resistance.
Results: In the trastuzumab sensitive BT-474 and SKBR3 cell lines, 72 
hours of trastuzumab treatment efficiently inhibited cell proliferation 
and deactivated AKT (S473 & Th308), PS6K and ERK signaling. In 
contrast, in the trastuzumab-resistant MDA453 and SUM225 cell 
lines, as well as the BT-474 cells conditioned to acquire trastuzumab 
resistance (BT-TR), trastuzumab treatment did not inhibit pAKT, 
pS6K and pERK levels. RAD001 had significant antiproliferative 
activity in both trastuzumab sensitive and resistant cell lines and 
resulted in rapid down regulation of pPS6K (mTOR) activity (15 
min). However, this deactivation was followed by a reactivation of 
AKT and ERK signaling (24 to 72 hours). BKM120 also demonstrated 
anti-proliferative activity independent of trastuzumab sensitivity. 
Specifically targeting PI3K with BKM120 directly decreased pAKT/
pS6K/pERK signaling and feedback activation was less pronounced 
than that observed with RAD001. Of the three molecules tested, 
BEZ235 was the most efficacious in the cell line panel (all IC50gs 
< 20 nM). BEZ235 rapidly (15 min) decreased pAKT/pS6K/pERK 
signaling in both trastuzumab sensitive and resistant cells lines and 
this inhibition was maintained at 72 hours. Thus, BEZ235 is effective 
in shutting down PI3K feedback activation and efficiently shuts 
down PI3K signaling in trastuzumab resistant HER2-amplified breast 
cancer cell lines. The combined treatment of trastuzumab and each 
of the PI3K/mTOR targeting agents resulted in greater inhibition of 
proliferation and induction of cell death in the HER2-amplified cell 
lines than each agent used alone. No increase in activity was observed 
in the HER2-normal control cell lines, MCF-7 and KPL-1.
Discussion: Together, these data indicate that targeting the PI3K/AKT/
mTOR pathway either alone or in combination with trastuzumab is 
effective in overcoming trastuzumab resistance. These findings are 
currently being validated in in vivo models of trastuzumab resistance.
P1-12-04
EBP50 – A Novel Biomarker for Resistance to Endocrine and 
HER2-Targeted Therapies in Breast Cancer.
Gu G, Covington KR, Fernandez NM, Ando’ S, Fuqua SAW. 
Baylor College of Medicine, Houston, TX; University of Calabria, 
Arcavacata di Rende, Cosenza, Italy
Background: Therapeutic strategies directed at inhibiting the action 
of ERa using antiestrogens, such as tamoxifen (Tam), or inhibiting 
HER2 signalling using a monoclonal antibody-Trastuzumab (Tras) 
are the standard therapies offered to women with ERa or ERa/
HER2-positive cancer. However, not all patients respond to these 
targeted therapies, and a large number of patients who do respond 
will eventually develop disease progression or recurrence while on 
therapy. EBP50 functions as a molecular scaffold to coordinate a 
diverse range of regulatory processes and a number of studies suggest 
a role for EBP50 in cancer progression.
Material and Methods: Microarray profiling was used to identify 
genes associated with response to tamoxifen in primary as compared 
to metastatic breast tumor recurrences. Stable transfection of 
EBP50 shRNA was performed in ZR75B and BT-474 cells. Cell 
response to Tam and/or Tras was evaluated using soft agar and 
MTT growth assays. The molecular signaling pathways affected 
by EBP50 knockdown were explored using immunoblot, and 
immunoprecipitation. Cellular localization was determined using 
confocal microscopy. Mammosphere potential was used to evaluate 
the stem cell renewal capacity in BT-474 cells.
Results: The mean levels of EBP50 were reduced in the tamoxifen-
resistant, metastatic breast tumors compared to tamoxifen-sensitive 
tumors. Knockdown of EBP50 levels decreased Tam sensitivity 
in ZR75B cells. Thus reduction in EBP50 levels analygous to that 
discovered in resistant patients, conferred resistance to the growth 
inhibitory effects of Tam. Cells with knockdown of EBP50 (shEBP50 
cells) showed higher levels of phosphorylated HER2, EGFR and 
HER3, as well as their downstream signalling pathways. PI3K and 
AKT inhibitors were able to restore Tam sensitivity in shEBP50 
cells. After long term treatment of ZR75-B cells with Tam resulted 
in decreased endogenous levels of EBP50, suggesting that only cells 
evolving with lower EBP50 levels were able to survive Tam treatment. 
Similarly, knockdown EBP50 in ERa/HER2 positive BT-474 cells 
significantly increased phosphorylated HER2 and these cells were 
resistant not only to Tam, but also to Tras treatment. BT-474 cells 
acquired Tras resistance concomittant with decreased EBP50 levels 
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in a dose-dependent manner respective to parental cells. Interestingly, 
shEBP50 cells demonstrated an enhanced capacity to form 
mammospheres compared to vector control cells. We demonstrate that 
EBP50 is able to bind HER2 using immunoprecipitation, suggesting 
that EBP50 interacts directly with HER2. Confocal microscope 
analysis demonstrated the colocalization of these two proteins. 
Inhibitors to c-Src, PI3K, AKT and EGFR were used in combination 
with Tras; shEBP50 cells were sensitive to both PI3K and AKT 
inhibitors, and EGFR inhibitors were able to restore Tras sensitivity.
Discussion: Our data suggest that EBP50 is a novel negative 
regulator of HER2 signaling, and its loss conferred resistance to 
both Tam and Tras. EBP50 loss might function to stabilize HER2, 
and enhance dimerization with EGFR and HER3. We hypothesize 
that EBP50 levels might be a new predictive biomarker for targeted 
therapy; patients with low EBP50 levels might best be treated with a 
combination of therapies including PI3K/AKT inhibitors.
P1-12-05
Complete Pathological Response of Ductal Carcinoma In Situ 
after Treatment with Neoadjuvant Herceptin.
Chalmers CR, Mallon EA, Touqan N, Horgan KJ, MacPherson I, 
Doughty JC. The Western Infirmary, Glasgow, Scotland, United 
Kingdom; Leeds General Infirmary, Leeds, Yorkshire, United 
Kingdom
Introduction: The introduction of neo-adjuvant herceptin has led to 
pathological complete response rates of up to 60% in patients with 
breast cancer. The traditional (NSABP) definition of pathological 
complete response includes cases demonstrating residual DCIS and 
little is known about the effects of neo-adjuvant herceptin in this 
situation. Current evidence suggests that DCIS is chemo-resistant, 
but it has also been shown that DCIS is more likely to be HER-2 
positive than primary cancer.
Results: We describe six patients who received neo-adjuvant 
chemotherapy and herceptin for biopsy-proven, node-positive, large 
breast cancers either with an extensive component of concomitant 
DCIS or a separate DCIS focus. Neo-adjuvant treatment did not 
result in any changes in the pattern of mammographic calcification 
seen pre-operatively (Figure 1 a-c), however histopathology of all 
six specimens showed ductal spaces containing macrophages and 
calcification but no residual lining epithelium, features consistent with 
pathological complete response of the DCIS component (Figure 1d).
Figure 1: Pathologically complete response of DCIS after neo-
adjuvant treatment with herceptin. (a) Pre-treatment mammogram (b) 
Post neo-adjuvant chemotherapy and herceptin mammogram showing 
resolution of the mass effect of the primary cancer and unchanged 
residual mammographic calcification associated with the extensive 
DCIS component (c) Wire-localised specimen demonstrating excision 
of calcification (d) Histopathology of the same specimen showing 
calcium-filled ducts and no residual lining epithelium.
Discussion: In conclusion, neo-adjuvant herceptin is associated with 
complete pathological response of both breast cancer and DCIS. 
The presence of unchanged persistent mammographic calcification 
in known regions of DCIS after treatment complicates any role of 
mammographic surveillance in this group and raises the question 
of optimal surgical management in the future management of these 
individuals.
P1-12-06
The Role of MAPK and PI3K/AKT/mTOR Signaling in Innate 
Lapatinib Resistance.
McDermott M, O’Brien N, McDonald K, Crown J, O’Donovan N, 
Slamon D. Dublin City University, Glasnevin, Dublin 9, Ireland; 
University of California Los Angeles, Los Angeles, CA; St. Vincents 
University Hospital, Elm Park, Dublin 4, Ireland
Background:
Lapatinib is a tyrosine kinase inhibitor which blocks downstream 
MAPK and P13K/AKT/mTOR proliferation and survival signaling 
pathways in HER2 positive breast cancer cell lines, tumor xenografts 
and HER2 positive breast cancer patients. However, pre-clinical 
and clinical studies have shown that not all HER2 positive patients 
respond to lapatinib and thus innate resistance to lapatinib exists. 
The identification of biomarkers of lapatinib response is therefore 
critical and would enable individual therapeutic decisions to be 
based on tumor biology rather than basic histopathology data alone. 
The aim of this study was to examine the role of MAPK and PI3K/
AKT/mTOR signaling in a panel of lapatinib sensitive and resistant 
HER2-amplified breast cancer cell lines to identify pharmacodynamic 
markers of response to lapatinib treatment.
Methods:
Dose response curves were generated to determine sensitivity to 
lapatinib in a panel of 17 HER2-amplified breast cancer cell lines. 
Total and phosphorylated levels of HER2, HER3, EGFR, AKT, 
ERK, S6K and eEF2 were determined following 24 hours lapatinib 
treatment in each of the cell lines.
Results:
Twelve of the cell lines were sensitive to lapatinib with IC50g < 1 mM 
while 5 of the cell lines were innately resistant to lapatinib with IC50g 
> 1 mM. Levels of pHER2 and pHER3 were decreased in response to 
lapatinib in all cell lines independent of sensitivity to lapatinib. This 
suggests that inhibition of HER2/HER3 activation is not indicative 
of response to lapatinib treatment. There was also no correlation 
between the levels of HER2, HER3, and EGFR and sensitivity to 
lapatinib in the cell line panel.
In lapatinib sensitive cell lines, lapatinib decreased PI3K (pAKT), 
mTOR (pS6K) and MAPK (pERK) signaling and increased peEF2 
levels. In contrast the levels of pAKT, pS6K, peEF2 and pERK were 
maintained following lapatinib treatment in lapatinib resistant cells. 
The continued activation of these proteins in the presence of lapatinib 
suggests a possible feedback mechanism that warrants further 
investigation. These data confirm that maintained signaling through 
either the P13K/AKT/mTOR pathway or the MAPK pathways in the 
presence of lapatinib can be an early pharmacodynamic biomarker 
of response.
Conclusions:
Maintenance of pAKT, pS6K, peEF2 and pERK levels, in response 
to lapatinib treatment correlates with lapatinib resistance. These 
data suggest that alterations in the P13K/AKT/mTOR and MAPK 
pathways play an important role in innate lapatinib resistance and 
pharmacologically targeting these pathways is a rational therapeutic 
approach for overcoming innate lapatinib resistance.
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P1-12-07
Pharmacokinetics (PK) of Trastuzumab Emtansine and Paclitaxel 
or Docetaxel in Patients with HER2-Positive MBC Previously 
Treated with a Trastuzumab-Containing Regimen.
Lu D, Modi S, Elias AD, Agarwal P, Yi J-H, Guardino AE, Althaus 
BL, Girish S. Genentech, South San Francisco, CA; Memorial Sloan-
Kettering Cancer Center, New York, NY; University of Colorado, 
Aurora, CO
Background
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate 
composed of trastuzumab, DM1 (a potent cytotoxic tubulin 
polymerization inhibitor), and the stable MCC linker. Based on in 
vitro and preclinical data suggesting synergy in tumor cell cytotoxicity 
with T-DM1 + taxanes, these combinations are being tested in phase 
Ib studies. The assessment of risk for PK-based drug interaction 
(PK-DI) with these combinations is important. T-DM1 is expected 
to undergo proteolytic degradation with no significant involvement 
of cytochrome P450 isoenzymes (CYPs), and DM1 is metabolized 
mainly by CYP3A4 (and to a lesser extent by CYP3A5). Paclitaxel 
(P) and docetaxel (D) are metabolized primarily by CYP2C8 and 
CYP3A4, respectively. None of these drugs inhibits or induces CYPs 
at clinically relevant concentrations. Since DM1 and D are both 
metabolized by CYP3A4, PK-DI may occur. This is less likely with 
DM1 and P since they are primarily metabolized by different CYPs.
Methods
The tolerability, PK, and dose-limiting toxicities of T-DM1 + P or D 
were investigated in 2 studies (TDM4652g and BP22572) of patients 
with HER2-positive MBC previously treated with a trastuzumab-
containing regimen. For PK-DI analysis, both studies used a staggered 
dosing design in the first cycle, with same-day dosing in subsequent 
cycles. Study BP22572 was later amended to give both drugs on the 
same day in all cycles. Either P (65 mg/m2, n=11; 80 mg/m2, n=6) 
or D (60 mg/m2, n=12; 75 mg/m2, n=6) was combined with T-DM1 
at various doses (2 mg/kg or 2.4 mg/kg q3w or 1.2 mg/kg qw for 
TDM4652g; 2.4 mg/kg or 3.6 mg/kg q3w for BP22572). PK of 
T-DM1, total trastuzumab (conjugated + unconjugated trastuzumab), 
DM1, P, and D were evaluated and compared with historical single-
agent data and across cycles within the study, using population 
analysis and/or noncompartmental analysis (NCA), as data allowed. 
Preliminary safety and efficacy data for the historical T-DM1 single-
agent studies were reported previously (Krop JCO 2010; Burris JCO 
2010; Krop ESMO 2010).
Results
The PK of P and D were similar from cycle 1 to cycle 2 for maximum 
concentration (Cmax), area under the concentration-time curve, half-
life, clearance (CL) and steady-state volume of distribution, and 
were also similar to historical single-agent data. The Cmax of DM1 
was <8 ng/mL in both studies, and the average Cmax values were 
similar to historical single-agent data. T-DM1 PK parameters for the 
combination studies are within the range of historical single-agent data 
(Table). Data from additional patients and doses in the combination 
studies will be presented.
Bayesian post hoc PK parameters for T-DM1
Data source Patients, n CL (L/day), median [range] V1b (L), median [range]
BP22572 (T-DM1 + D) 18 0.542 [0.413–0.671] 2.41 [1.98–3.03]
TDM4652g (T-DM1 + P) 17 0.768 [0.526–1.16] 3.15 [2.18–4.07]
Historical data (T-DM1)a 268 0.699 [0.296–1.28] 3.27 [1.90–5.21]
aIncludes patients from studies TDM3569g, TDM4258g and TDM4374g with PK samples (n=273); 
5 patients receiving 0.3, 0.6, and 1.2 mg/kg q3w were excluded due to non-linear PK at these low 
doses. bCentral volume of distribution.
Conclusion
The risk of clinically relevant PK-DI between T-DM1 and P or D 
appears to be low.
P1-12-08
Induction of Adhesion Molecules on Target Cells Maximizes 
Antibody-Dependent Cell-Mediated Cytotoxicity of Anti-Her2 
Therapeutic Antibody with High Fucose Glycan.
Jia X, Wong P-Y, Gazzano-Santoro H. Genentech Inc., South San 
Francisco, CA
Background: Antibody-dependent cell-mediated cytotoxicity 
(ADCC) is one pivotal effector function of certain therapeutic 
antibodies. ADCC is the lysis of antibody-coated target cells by 
effector cells expressing Fc receptors (FcR) that recognize the 
fragment crystallizable (Fc) region of the bound antibody. Higher 
fucosylated terminal glycan on Fc results in significantly lower 
ADCC activity because core fucose sterically hinders the binding of 
Fc region to FcR on effector cells. The role of adhesion molecules 
in ADCC is unclear but it has been reported that adhesion molecules 
help better orientation of effector cells (natural killer cells) toward 
adhesion molecule-coated beads. We hypothesize that a preferable 
association of effector cells and target cells mediated by adhesion 
molecules may compensate ADCC loss due to the steric hindrance 
of high core fucose on Fc. Recombinant humanized monoclonal anti-
Her2 antibodies (anti-Her2 rhuMAb) at various fucosylation levels 
have been used in this study to evaluate the role of adhesion molecules 
in ADCC of antibodies with high fucose glycan.
Materials and Methods: Natural killer (NK) cell line transfected 
with FcR were used as effector cells. Her2-expressing breast cancer 
cell lines BT-474 and SK-BR3 were used as target cells. Adhesion 
molecules were induced in target cells by incubation with 50ng/ml 
of recombinant human tumor necrosis factor (TNFa) for 1-2 days. 
Anti-Her2 rhuMAbs with different Fc fucosylation (G0-F from <1% 
to >2%) were added in the co-culture of effector cells and target cells. 
ADCC activities were quantitated by target cells lysis assessment 
using Europium-TDA release assay.
Results: Untreated BT-474 or SK-BR3 target cells had very little 
adhesion molecule expression. A high fucosylated anti-Her2 rhuMAb 
induced 52% of target cell lysis, which represented two-thirds of 
cell lysis by a low fucosylated Ab. Increment of E:T ratio could not 
maximize ADCC activities. With TNFa treatment, target cell lysis 
was increased from 52% to 100% by high fucose rhuMAb. This 
enhancement of ADCC activities is probably due to the expression of 
adhesion molecules such as ICAM-1 and VCAM-1, which was shown 
to be up-regulated by 100-fold on target cells in the presence of TNFa. 
Our data suggested that ADCC activities in Her2-expressing breast 
cancer cell lines were HER2-specific, anti-HER2 rhuMAb-dependent 
and adhesion molecules were indispensible for the enhanced ADCC 
activities.
Discussion: rhuMAbs produced in Chinese hamster ovary (CHO) 
cell lines may contain various Fc fucosylation, hence various ADCC 
activities. Although up-regulation of adhesion molecules alone cannot 
lyse target cells directly, our data suggested maximized ADCC 
activities by rhuMAbs with high Fc fucosylation level could be 
achieved by induction of adhesion molecule expression on target cells.
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Safety and Efficacy of Neratinib in Combination with Capecitabine 
in Patients with ErbB2-Positive Breast Cancer.
Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Kiger 
C, Germa C, Wang K, Kim S-B. Breast Cancer Unit, Vall d’Hebron 
University Hospital, Barcelona, Spain; Hospital Clinico San Carlos, 
Madrid, Spain; Cancer Hospital, Chinese Academy of Medical 
Sciences, Beijing, China; Horizon Oncology Center, Lafayette, 
IN; Florida Hospital Cancer Institute, Orlando, FL; Washington 
University School of Medicine, St. Louis, MO; Pfizer Global Research 
and Development, Paris, France; Pfizer Inc, Pearl River, NY; Asan 
Medical Center, Seoul, Korea
Background: Neratinib (HKI-272) is an irreversible pan-ErbB 
receptor tyrosine kinase inhibitor that has shown antitumor activity 
in patients with ErbB2+ breast cancer. Capecitabine has demonstrated 
efficacy and tolerability in combination with lapatinib, a reversible 
dual ErbB1/ErbB2 kinase inhibitor, in patients with ErbB2+ advanced 
breast cancer. The current study evaluated the safety and clinical 
activity of neratinib in combination with capecitabine.
Methods: In part 1 of this open-label, phase 1/2 study, the maximum 
tolerated dose (MTD) of neratinib in combination with capecitabine 
was determined in adults with advanced solid tumors. Part 2 of the 
study further evaluated the safety and clinical activity of neratinib plus 
capecitabine at the MTD in adults with confirmed ErbB2+ metastatic 
or locally advanced breast cancer (ECOG Performance Status of 
0-2). Eligible patients had received prior taxane treatment and ≥1 
prior trastuzumab-containing regimen for ≥6 weeks for metastatic or 
locally advanced disease. The primary endpoint of part 2 was objective 
response rate (ORR); tumor responses were assessed by investigators 
using modified RECIST version 1.0 guidelines every 6 weeks.
Results: In part 1 (n = 33), the MTD was determined to be neratinib 
240 mg/day plus capecitabine 750 mg/m2 twice daily on Days 1 
to 14 of each 21-day cycle. In part 2, as of April 2011, 72 female 
patients (median age of 52 years [range, 33-79 years]) with ErbB2+ 
breast cancer were enrolled and treated at the MTD; 7 patients had 
prior lapatinib exposure and all had prior trastuzumab and taxane 
exposure. As of the snapshot date, 56% of patients at the MTD 
were still participating in the study. The most common drug-related 
adverse events (AEs) in part 2 were diarrhea (89%), palmar-plantar 
erythrodysesthesia (57%), nausea (33%), vomiting (26%), and 
decreased appetite (22%). Grade 3/4 drug-related AEs in ≥5% of 
patients were diarrhea (25%) and palmar-plantar erythrodysesthesia 
(13%). Eight patients withdrew from part 2 due to AEs, including 
4 who withdrew due to diarrhea. Dose interruptions of neratinib 
and capecitabine, respectively, due to AEs were required by 19 and 
29 patients; dose reductions due to AEs were required by 8 and 
22 patients. As of June 2010 (interim analysis), 22 patients were 
evaluable for efficacy in part 2 of the study. Of these 22 patients, 
11 achieved a partial response for an ORR of 50%. An additional 2 
patients maintained stable disease for ≥24 weeks, resulting in a clinical 
benefit rate of 59%, and 8 patients had stable disease for <24 weeks. 
One patient had progressive disease without achieving a response or 
stable disease. Updated efficacy data will be presented.
Conclusions: The results of this study indicate that neratinib 
combined with capecitabine is tolerable and has promising antitumor 
activity in patients with ErbB2+ metastatic or locally advanced breast 
cancer pretreated with trastuzumab. This study supports further 
evaluation of this combination in ErbB2+ breast cancer.
P1-12-10
Phase II Study Evaluating Lapatinib (L) in Combination with 
Albumin Bound Paclitaxel (ab-Pac) in Women Who Have 
Received 0-1 Chemotherapy Regimen for HER2 Overexpressing 
(HER2+) Metastatic Breast Cancer (MBC).
Yardley DA, Hart L, Bosserman L, Saleh MN, Waterhouse DM, 
Richards P, Hagan MK, DeSilvio ML, Mahoney JM, Nagarwala 
Y. Sarah Cannon Research Institute; Tennessee Oncology, PLLC; 
Florida Cancer Specialists; Willshire Oncology Medical Group; 
Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; 
Virginia Cancer Care; Oncology & Hematology Associates of SW; 
GlaxoSmithKline, Collegeville, PA
Background: L, a dual kinase inhibitor of epidermal growth factor 
receptor (EGFR) and the human epidermal growth factor receptor-2 
(HER2), approved for the treatment of HER2+ MBC in combination 
with capecitabine following progression after trastuzumab, 
anthracycline, and taxane. L in combination with chemotherapy has 
significantly improved progression free survival in patients (pts) with 
HER2+ MBC. Ab-Pac is a cremophor free, albumin-bound paclitaxel 
approved for use in pts with MBC demonstrating superior efficacy 
and safety when compared to other taxanes.
Methods: Phase II study (LPT111111) evaluated the efficacy and 
safety of L in combination with ab-Pac in 60 pts with histologically 
confirmed stage IV HER2+ (IHC 3+/FISH+) invasive MBC. Pts 
received 0-1 prior chemotherapeutic regimen in the metastatic setting 
and no prior treatment with L. Prior taxane therapy permitted provided 
this was > 12 months prior to study entry, LVEF>50%, peripheral 
neuropathy < 2, prior CNS mets permitted, and prior endocrine 
therapy permitted. Pts received ab-Pac (125 mg/m2 IV on Days 1, 
8, 15, q28 days) plus L (1250 mg daily). Planned safety analysis 
of the first 5 pts prompted a protocol amendment with a 20% dose 
reduction for both agents due to Grade (G) 3 neutropenia and diarrhea. 
Subsequent pts received ab-Pac (100 mg/m2 IV on Day 1, 8, 15, 
q28 days) in combination with L (1000 mg daily). Pts with SD or a 
response continued L alone until progression. Response assessments 
performed every 2 cycles. The primary endpoint was overall response 
rate (ORR) and secondary endpoints were progression-free survival 
(PFS), time to response, duration of response and overall survival 
(OS).
Results: Here we present the final analysis of all subjects receiving 
at least 6 months of protocol therapy. Median age is 56 years; 45 
pts (75%) received treatment as 1st line therapy and 15 (25%) as 
2nd line; 57% hormone receptor positive and 43% negative; 42% 
received trastuzumab and 40% received a taxane in either (neo) 
adjuvant or metastatic setting. After a median of 5.6 months, 7% pts 
had a complete response, 47% a partial response and 17% had stable 
disease, the ORR was 53% [95% CI: 41% to 66%]. The median time 
to response was 7.8 wks [95% CI: 7.4 to 8.1] with a median duration 
of response of 48.7 wks [95% CI: 31.7 to 57.1]. The median PFS was 
39.7 wks [95% CI: 34.1 to 63.9]. Duration of exposure to ab-Pac; 
48% received less than 6 cycles, 30% received 6 cycles and 22% 
received greater than 6 cycles. Table 1 shows the most common G 
≥2 treatment-related toxicities.
Table 1
 Grade 2 (%) Grade 3 (%) Grade 4 (%)
Diarrhea 23 20 4
Fatigue 10 8 2
Nausea 22 2 2
Rash 18 3 0
Neutropenia 10 22 0
Two fatal adverse events; one pt with a h/o arrhythmia experienced 
sudden death of presumed cardiac origin and the other subject with 
h/o COPD, hypertension and uncontrolled diabetes experienced acute 
renal failure. No G 3/4 elevation in LFTs observed.
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Conclusions: L 1000 mg with ab-Pac 100 mg/m2 IV on Day 1, 8, 
15, q28 day is feasible with manageable and predictable toxicity. 
The ORR of 53% compares favorably with other HER2 based 
combinations in this setting and warrants further exploration.
P1-12-11
Neoadjuvant Chemotherapy-Trastuzumab Versus Neoadjuvant 
Chemotherapy Followed by Post-Operative Trastuzumab: A 
Multicentre Study.
Palmieri C, Yan K, Owadally W, Shah D, Gojis O, North B, Riddle P, 
Ahmad R, Lewanski C, Coombes RC, Cleator S, Howell S, Beresford 
M. Imperial College Healthcare NHD Trut, London, United Kingdom; 
Bristol Haematology and Oncology Centre, Bristol, United Kingdom; 
Third Faculty of Medicine, Charles University, Prague, Czech 
Republic; Imperial College London, London, United Kingdom; The 
Christie NHS Foundation Trust, Manchester, United Kingdom
Background:The addition of neoadjuvant trastuzumab (NAT) to 
neoadjuvant chemotherapy (NCT) has been shown to increase the 
rate of breast preservation and pathological complete response 
(pCR) compared to neoadjuvant chemotherapy alone (NCT). 
Furthermore, pCR following NCT-NAT is higher and pCR in this 
setting has been associated with improved disease free survival 
(DFS) compared to NCT alone group. No study has yet investigated 
the effect of NCT-NAT versus NCT followed by surgery followed 
by adjuvant trastuzumab (AT) on disease free survival and overall 
survival. Methods: All cases of invasive breast cancer diagnosed 
at Imperial College Healthcare NHS Trust, Christie Hospital and 
University Hospitals Bristol NHS Foundation Trust between 2006-
2010 were reviewed and all early HER2 positive breast cancers 
receiving neoadjuvant treatment were identified, and case notes 
reviewed. Histopathological details, neoadjuvant treatment and where 
trastuzumab was initiated were recorded. pCR rate was documented 
and an efficacy analysis performed, disease free survival (DFS) and 
overall survival (OS) for the whole cohort, and for cases treated with 
NCT-NAT versus NCT alone followed by surgery and AT.Results: 
Between 2006-2010 122 invasive HER2 positive invasive breast 
cancers were treated in the neoadjuvant setting at the 3 centres. Of 
these 58% (71) received NCT alone and 42% (51) were treated with 
NCT-NAT. The median follow up for whole group was 26 months 
(range 4.9-70.4), 30.5 months (range 10.5-70.4) for NCT group and 
20.1 months (range 4.9-59) for NCT-NAT group. 19 (27%) relapse/
death events in NCT group compared to 7 (14%) in NCT-NAT group 
have occurred. For the whole cohort DFS at 3 years was 74.6% (95% 
CI; 69.5-79.7%), for those receiving NCT-NAT versus NCT alone, 
DFS was 75.7% (95% CI 85.4-66) versus 74% (95% CI 80.1-67.9) 
respectively. The OS at 3 years for whole group was 81.4% (95% CI 
76-79.7%), for those receiving NAT versus NCT alone it was 81.6% 
(95% CI 71.2-92%) versus 81.2% (95% CI 74.9-87.5). The overall 
pCR rate was 26% (31/121), majority of pCR were in NAT group 
(61%). pCR occurred in 37% and 15% of patients receiving NCT-
NAT and NCT respectively. 3 year DFS for those attaining a pCR 
was 92.3% (95% CI 87-97.5%) versus without pCR 70.9% (95% 
CI 65.1-76.7%). The 3 year OS was 85.7% (95% CI 72.5-98.9) for 
patients with a pCR compared to 80.7% (95% CI 74.9-86.5%) for 
those without PCR. Full details of the histopathological features, 
neoadjuvant therapy toxicity will be presented. Additional cases 
are being added and an up dated efficacy analysis will be presented. 
Conclusion:Patients treated with NAT upfront have a lower number 
of events. Currently, no difference is seen in DFS and OS for NAT 
versus NCT. However, pCR is higher with NAT and those with a pCR 
have a longer DFS and OS.
P1-12-12
Evaluation of Ile655Val HER2 Polymorphism Associated with 
Cardiac Toxicity Following the Administration of Trastuzumab 
in Women with Non-Metastatic Breast Cancer.
Diorio C, Lemieux J, Côté M-A, Provencher L, Nadeau-Larochelle C, 
Jacob S, Demers É, Tremblay-Lemay R, Saint-Pierre C, Beauchemin 
M, Barabé F, Laflamme C. Centre de Recherche FRSQ du CHA 
Universitaire de Québec, Quebec City, QC, Canada; Hôpital du 
Saint-Sacrement, Quebec City, QC, Canada; Université Laval, 
Quebec City, QC, Canada; Centre Hospitalié de l’Université Laval, 
Quebec City, QC, Canada; Centre Hospitalier Affilie Universitaire 
de Quebec, Quebec City, QC, Canada
Background: Trastuzumab is well tolerated without major side effects 
except for cardiac toxicity. Although a number of clinical parameters 
have been associated with trastuzumab-associated cardiac toxicity 
(TACT), there is some indication that genetic variation of the HER2 
gene may be associated with TACT in a population of metastatic 
breast cancer patients. However, this finding needs confirmation and 
we looked at a population of non-metastatic breast cancer.
Purpose: This study aimed to evaluate the association between 
cardiac toxicity and HER2 [Ile655Val] polymorphism in non-
metastatic breast cancer patients treated with trastuzumab.
Method: The Ile655Val HER2 polymorphism was assessed in 41 
women using TaqMan technology. For this study, the genotyping was 
performed using DNA extracted from normal breast tissue located 
at more than 1 cm of any other lesions. Charts review was used to 
collect information on TACT which was defined as a decrease in the 
left ventricular ejection fraction (LVEF) of ≥15% or ≥10% with a 
resulting LVEF < 50% or any follow-up LVEF of < 45%. The Fisher 
exact test was used to evaluate the association between cardiac toxicity 
and HER2 polymorphism.
Results: No deviation from the Hardy-Weinberg equilibrium has been 
observed for the allele and genotype frequencies. The distribution 
of HER2 polymorphism was 10 Ile/Val (24%) and 31 Ile/Ile (76%). 
In this population, 22% (9/41) developed a cardiac toxicity. The 
Val655Ile genotype was associated with cardiac toxicity (0.03). In 
this preliminary study, 50% (5/10) of Ile/Val carriers compared to 
13% (4/31) of Ile/Ile carriers showed TACT.
Conclusion: HER2 Ile655Val polymorphism may be an efficient 
marker of TACT considering this tendency with this small cohort 
of patients. Larger sample is needed to strengthen this conclusion, 
since this result may influence on prescribing decision for adjuvant 
chemotherapy and anti-HER2 therapy in HER2 positive patients.
P1-12-13
Comparative Pharmacokinetics (PK) of Trastuzumab Emtansine 
(T-DM1) in Patients Who Have or Who Have Not Received Prior 
Treatment for Human Epidermal Growth Factor 2 (HER2)-
Positive Metastatic Breast Cancer (MBC).
Wang B, Conte P, Casanova LA, da Fonseca Vinholes JJ, Saad OM, 
Yi J-H, Gupta M, Song C, Olsen SR, Perez EA, Girish S. Genentech, 
South San Francisco, CA; University of Modena and Reggio 
Emilia, Modena, Italy; Instituto Oncológico Miraflores, Lima, Peru; 
CliniOnco, Porto Alegre, Brazil; Mayo CLinic, Jacksonville, FL
Background
T-DM1, an antibody-drug conjugate composed of trastuzumab, a 
stable linker, and the cytotoxic agent DM1, is in development for 
the treatment of HER2-positive cancers. Single-agent T-DM1 3.6 
mg/kg every 3 weeks (q3w) has demonstrated clinical activity in 
2 phase II studies (TDM4258g and TDM4374g) in patients with 
pretreated HER2-positive MBC. The efficacy and safety of T-DM1 
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vs trastuzumab + docetaxel was investigated in patients with no 
prior MBC treatment in the randomized phase II study TDM4450g/
BO21976. Here we report the PK of T-DM1 from that study and 
compare these data with those from studies that enrolled pretreated 
patients.
Methods
In all 3 studies, PK parameters, including maximum concentration 
(Cmax), area under the concentration-time curve (AUC), terminal 
half-life (t½), steady-state volume of distribution (Vss), and clearance 
(CL) were estimated by noncompartmental analysis (NCA) for serum 
T-DM1, serum total trastuzumab (conjugated and unconjugated), 
and plasma DM1. The effects of baseline trastuzumab and HER2 
extracellular domain (ECD) concentration on T-DM1 exposure were 
explored and the relationship between T-DM1 exposure and clinical 
response (objective response rate [ORR] and progression-free survival 
[PFS]) was modeled.
Results
T-DM1 PK from evaluable patients enrolled in 3 studies are shown in 
Table 1. No significant correlations were observed between efficacy 
(as measured by ORR) and T-DM1 exposure (AUC, Cmax) after 
administration of T-DM1 to pretreated patients; efficacy-exposure 
analyses (ORR and PFS) for previously untreated patients will be 
presented. Patients with measurable concentrations of trastuzumab 
at baseline had a greater AUC during cycle 1; however, this did not 
impact ORR. Baseline circulating HER2 ECD concentrations also 
had no effect on ORR for pretreated patients. The impact of baseline 
trastuzumab and HER2 ECD concentrations on ORR and PFS in 
previously untreated patients will be presented.
PK of T-DM1 3.6 mg/kg q3w in 3 phase II studies
 Mean (SD)
 Serum total trastuzumab
Plasma  
DM1
T-DM1
Study (PK  
evaluable n;  
total N)
Cmax (mg/mL)
Cmax  
(ng/mL)
Cmax  
(mg/mL)
AUCinf  
(day • mg/
mL)
t1/2 (day) Vss (mL/kg)
CL (mL/ 
day/kg)
TDM4450g— 
no prior MBC  
treatment  
(41; 70)
81.5 (20.6) 5.08  (2.41)
84.9  
(30.6) 476 (119) 3.58 (0.666) 30.0 (8.21)
8.09  
(2.50)
TDM4258g— 
pretreateda  
(101; 112)
88.0 (30.2) 5.35  (2.03)
80.9  
(20.7) 457 (129) 3.53 (0.714) 28.4 (12.9)
8.51  
(2.69)
TDM4374g— 
pretreateda  
(105; 110)
89.9 (31.3) 5.36  (2.56)
79.5  
(21.1) 486 (141) 3.96 (0.964) 31.2 (10.9)
8.04  
(2.97)
aMedian number of non-hormonal therapies for MBC was 5 (range 1–17) in TDM4258g and 7 
(range 3–17) in TDM4374g
Conclusions
Single-agent T-DM1 has similar PK in patients who have received 
prior therapy for MBC and in those who have not. The PK of T-DM1 
was not affected by prior trastuzumab treatment or by circulating 
HER2 ECD, and no significant correlations were observed between 
efficacy (ORR) and T-DM1 exposure (AUC, Cmax) or HER2 ECD for 
pretreated patients. The relationships between efficacy and T-DM1 
exposure and HER2 ECD concentrations will be presented for patients 
without prior MBC treatment.
P1-12-14
Genetic Ablation or Pharmacological Inhibition of Autophagy 
Suppresses Intrinsic Resistance of Breast Cancer to HER2-
Targeted Therapies.
Cufí S, Oliveras-Ferraros C, Vazquez-Martin A, Sauri-Nadal T, Del 
Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA. Catalan 
Institute of Oncology, Girona, Catalonia, Spain; Girona Biomedical 
Research Institute (IDIBGi), Girona, Catalonia, Spain; University 
Hospital of Girona Dr. Josep Trueta, Girona, Catalonia, Spain
Autophagy, an evolutionary conserved catabolic process whereby 
cells generate energy and building blocks by promoting large-scale 
recycling of cytoplasmic macromolecules and organelles, represents 
a novel drug-targetable molecular mechanism underlying de novo 
(primary) refractoriness of HER2 gene-amplified breast cancer 
(BC) to HER2 inhibition. JIMT-1 cells, which were obtained from 
a HER2-positive BC patient that rapidly progressed on trastuzumab 
(Herceptin™) ab initio and that show cross-resistance to multiple 
HER1/2 inhibiting drugs including lapatinib (Tykerb™), were found 
to constitutively exhibit an enhanced autophagic vesicle content as 
assessed by immunoblotting of endogenous ATG8/LC3 lipidation 
and confocal imaging of the recruitment of ATG8/LC3 to autophagic 
vesicles. A significant decrease in the expression status of the specific 
autophagy receptor p62/SQSTM1 -a protein selectively degraded 
by autophagy- confirmed further a constitutive activation of the 
autophagic flux in trastuzumab-refractory JIMT-1 cells. When the 
Human Autophagy RT2 Profiler™ PCR Array was employed to profile 
the expression of 84 genes involved in autophagy, ATG12 was the 
most differentially up-regulated gene in JIMT-1 cells (>10-fold) as 
compared with trastuzumab-responsive SKBR3 cells. Upon collection 
of the transcriptional profile of the ATG12 gene across two sets of > 
50 widely used BC cell lines, HER2+ BC cells with well-established 
de novo resistance to trastuzumab were characterized by expressing 
significantly higher levels of ATG12. When lentiviral-delivered small 
hairpin RNA was employed to stably & specifically knock-down 
ATG12 gene, JIMT-1 ATG12-shRNA cells were more significantly 
growth-inhibited by trastuzumab (up to 5-fold) than parental JIMT-
1 cells. Moreover, the half-maximal inhibitory concentration (IC50) 
values for the small-molecule HER1/2 Tyrosine Kinase Inhibitors 
gefitinib, erlotinib and lapatinib were drastically reduced by up 
to 10 times in response to ATG12 gene silencing. Knockdown of 
autophagy-regulatory genes other than ATG12 (e.g. ATG5, ATG8/
LC3B) similarly suppressed refractoriness to trastuzumab as well as 
co-existing resistance to other HER1/2-targeted agents. Knockdown 
of autophagy-specific genes, however, did not alter basal sensitivity 
of JIMT-1 cells to multiple cytotoxics including doxorubicin, 
cisplatin, paclitaxel and vinorelbine. When lysosomal degradation was 
pharmacologically inhibited by using the antimalarial lysosomotropic 
drug chloroquine we found a massive accumulation of abnormal 
autophagolysosomes that promoted synergistic re-sensitization 
of JIMT-1 cells to the growth inhibitory and apoptotic activity of 
trastuzumab. In summary, autophagy-specific genes appear to play 
a potent protective role against HER2 inhibiting drugs currently in 
use. Given that genetic and pharmacological targeting of autophagy 
was found to be detrimental to intrinsic BC refractoriness to HER2-
targeted therapies, our current findings may provide rationale for 
novel, chloroquine-based therapeutic approaches aimed to circumvent 
primary-resistance and potentiate the efficacy of both trastuzumab and 
lapatinib in patients treated for HER2-positive BC disease.
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P1-12-15
Adjuvant Trastuzumab Effect on HER2-Positive Breast Cancers 
According to Hormonal Receptor (HR) Status: Crosstalk between 
ER and EGFR/HER2 Pathway May Prevent Trastuzumab from 
Improving Outcomes in HER2-Positive and HR-Positive Breast 
Cancers.
Park YH, Cho EY, Lee JE, Nam SJ, Yang JH, Ahn JS, Im Y-H. Samsung 
Medical Center
Background: Crosstalk between growth factor receptor, especially 
the EGFR/HER2 pathway, and ER pathways has been associated 
with endocrine resistance. Thus, combination therapy targeting both 
ER and EGFR/HER2 signaling to block the crosstalk between these 
pathways and eliminate escape routes have been proven effective in 
both preclinical and clinical models. Anti-HER2 directed therapy 
has been reported to restore hormone sensitivity in HER2-positive 
breast cancers. Adding trastuzumab to conventional treatment 
has been a standard treatment of choice in HER2-positive breast 
cancer irrespective of hormonal receptor (HR) status. The purpose 
of the study is to evaluate adding effect of 1 year of trastuzumab to 
conventional adjuvant treatment in patients with HER2-positive breast 
cancer who received surgery according to HR status.
Patients and Methods: We retrospectively analyzed the 
clinicopathologic characteristics and outcomes of 618 postoperative 
HER2-positive breast cancer patients between 2001 and 2008 at the 
Samsung Medical Center. Most of HER2-positive patients in our 
institute were treated with 1 year of trastuzumab as a part of adjuvant 
therapy since 2007 (post-trastuzumab era) compared with 2000-2006 
(pre-trastuzumab era). Clinical outcomes including recurrence-
free survival (RFS) were analyzed between pre-trastuzumab and 
post-trastuzumab era according to HR status. We performed Cox 
regression multivariate analysis for relapse using variables from 
univariate analysis by log-rank test for relapse. Clinical presentations 
and clinicopathologic characteristics were evaluated at the time of 
recurrence between both eras.
Results: The median age at diagnosis was 46 years (range, 22-79). 
During the median 60.0 months of follow-up, the 5-year recurrence 
rate was 20.2%. The 618 patients were divided into two groups 
(patients who received (n=175) and did not receive (n=443) adjuvant 
trastuzumab). Recurrence rate was much lower in post-trastuzumab era 
than in pre-trastuzumab era (13.6% vs. 32.3%, p<0.0001). Improving 
outcomes due to adding trastuzumab in patients with HER2+ve/HR-
ve patients showed significant benefit from trastuzumab throughout 
the follow-up period (p=0.004). However, this improving effect 
appeared not to be consistent with statistical significance in HER2+ve/
HR+ve patients (p=0.135). The analyses were performed according to 
quantitative ER Allred scores in HER2+ve/ER+ve patients, the effect 
of adding trastuzumab appeared to be mitigated as time over without 
any statistical significance (p=0.975). Young age (≤35) (hazard 
ratio (HR) 2.4, p<0.0001), trastuzumab use (HR 0.4, p=0.001), and 
node positivity (HR 2.8, p<0.0001) were identified as independent 
prognostic factors for recurrence in Cox-regression multivariate 
analysis. Limiting to HER2+ve/ER+ve patients, the statistical 
significances of trastuzumab use as independent factors were not 
maintained in Cox-regression models (p=0.074 for trastuzumab use).
Conclusion: Cross-talk between ER and EGFR/HER2 pathways 
may mitigate trastuzumab effect in HER2+ve/ER+ve breast cancers. 
Further study is warranted.
P1-12-16
HER-2 Testing and Treatment – Is Age a Factor?
Singh JK, Ewing K, Howell S, Howe M, Cramer A, Bundred NJ. 
School of Cancer and Enabling Sciences, University of Manchester, 
Paterson Institute for Cancer Research, Manchester, United Kingdom; 
Univeristity Hospital of South Manchester, Wythenshawe Hospital, 
Manchester, United Kingdom; The Christie NHS Foundation Trust, 
Manchester, United Kingdom
Aims:
Elderly breast cancer patients have a poorer prognosis due to late 
diagnosis and sub-optimal treatment. In the UK, HER-2 testing was 
introduced in 2005 and we sought to determine whether HER-2 
testing was performed on patients of all ages and whether HER-2 
positive patients of all ages subsequently received Herceptin, from 
implementation in 2005 until 2008.
Methods:
Review of all newly diagnosed breast cancers in women over 50 in 
our Unit between January 2005 and December 2008 was performed. 
Cases were identified from the hospital pathology electronic database. 
Patients were considered HER-2 positive if tissue sections scored 3+ 
on immunohistochemical analysis (intense membranous staining) 
or if gene amplification was detected using fluorescence in-situ 
hybridisation (FISH). Patients were eligible for treatment with 
Herceptin if the tumour exceeded 1cm in size or if they had lymph-
node positive disease, per UK guidelines. Herceptin treatment was 
determined for all patients.
Results:
In total 703 patients with a median age of 68 years (range 56 to 
98) were identified and 628 (89.3%) underwent definitive surgery 
(mastectomies: 246; wide local excisions: 382) and axillary 
surgery. In total 371 patients (52.8%) underwent HER-2 testing by 
immunohistochemistry or FISH. HER-2 tests performed by year: 
2005 (51/131; 38.9%); 2006 (59/187; 31.6%); 2007 (71/189; 37.6%) 
and 2008 (190/196; 96.9%). Fifty six patients (15.1%) were HER-2 
positive by immunohistochemistry or FISH. Median age of HER2 
positive patients was 66 years (range 57 to 98); median age of HER2 
negative patients was 68 years (range 56 to 96).
Forty four HER-2 positive patients (78.6%) were eligible for 
treatment with Herceptin; of these 28 patients (63.6%) were treated 
with Herceptin. HER2 testing, treatment with Herceptin and overall 
5-year mortality rate for patients between 50 to 69 years and patients 
aged 70 years or older is summarised in Table1.
Summary of HER-2 testing, treatment with Herceptin and overall 5-year mortality rate for patients 
aged between 50 to 69 years and patients aged 70 years or older
Age group n n tested n HER-2 positive
n eligible for 
Herceptin
n treated with 
Herceptin
Overall 5-year 
mortality rate / 
mortality rate of 
HER2 positive 
pts
50-69 434 (61.7%) 247 (56.9%) 37 (15.0%) 30 (81.1%) 24 (80.0%) 13% / 38%
≥70 269 (38.3%) 124 (46.1%) 19 (15.3%) 14 (73.7%) 4 (28.6%) 36% / 29%
n=number of patients; pt=patients; CI=confidence interval
Twenty percent of patients aged between 50 to 69 years and 71.4% 
of patients aged 70 years or older eligible for Herceptin were not 
treated. Reasons for non-treatment included: multiple co-morbidities 
(4); treatment declined by oncologists (1); no referral to oncologists 
(1); death prior to treatment (2) and unknown (8). Median follow up 
time was 43.3 months (range 0.2 to 73.8). All cause mortality was 
higher in the over 70 year old breast cancer group (Log Rank Test 
p=0.001) regardless of HER-2 status.
Conclusions:
National introduction of routine HER-2 testing for all newly 
diagnosed breast cancers led to a testing rate increase to almost 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011229s
December 6-10, 2011 Abstracts: Poster Session 1
97%. Despite this only 63.6% of HER-2 positive patients eligible 
for treatment with Herceptin received it. Patients aged 70 years or 
older were less likely to receive Herceptin due to multiple factors.
P1-12-17
Fluorescent In Situ Hybridization Evaluation of HER2 Status in 
Tumors with Chromosome 17 Polysomy.
Pietri E, Medri L, Farolfi A, Sarti S, Maltoni R, Cecconetto L, 
Ibrahim T, Paioli A, Serra L, Amadori D, Rocca A. Istituto Scientifico 
Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, 
(FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
Introduction: According to the American Society of Clinical 
Oncology-College of American Pathologists recommendations for 
HER2 testing, a positive fluorescent in situ hybridization (FISH) 
result is defined as >6 HER2 gene copies/nucleus (for test systems 
with no internal control probe [single-color]) or as HER2 gene/
chromosome 17 centromere (CEP17) ratio > 2.2 (for systems with an 
internal control probe [dual-color]). Although an increase in CEP17 
copy number (average ≥ 3.0 copies/nucleus) is commonly considered 
to represent polysomy of chromosome 17, it can also be a result of 
gains of 17q with centromere involvement, or amplification of the 
centromeric region. The classification of HER2-positive tumors 
according to the HER2/CEP17 ratio may therefore misclassify a 
fraction of truly amplified cases as polysomic. We prospectively 
evaluated tumors with chromosome 17 polysomy but no HER2 
amplification to assess HER2 status using the above two FISH 
classifications and immunohistochemistry (IHC).
Materials and methods: Tumors were tested for gene amplification 
by FISH with probes to HER2/neu and CEP17 using the PathVysion 
HER-2 DNA Probe Kit (Vysis). Classification was based on the 
HER2/CEP17 ratio (amplified when > 2.2) and average HER2 gene 
copy number/nucleus (amplified when > 6 copies). Both polysomic 
and equivocal cases (HER2/CEP17 ratio 1.8 – 2.2) were further 
studied by IHC using the HercepTest (Dako) with 0-3 scoring system 
(overexpression when 3+).
Results: From March 2010 to May 2011 we evaluated 31 primary 
breast cancers showing chromosome 17 polysomy. Median HER2/
CEP17 ratio was 1.3 (range 0.5-1.9), median HER2 copy number 
was 5.4 (range 2.6-13.8), and median CEP17 copy number was 
4.2 (range 3.2-8.0). Thirteen (42%) had an average HER2 gene 
copy number > 6/nucleus (median 6.8, range 6.1-13.8) and would 
therefore be considered as amplified if classified according to the 
absolute HER2 gene copy number. Nine (75%) of these were 3+ at 
IHC and the remaining 4 were 2+, whereas among the 18 cases with 
an average HER2 gene copy number ≤ 6/nucleus, one was 2+, ten 
were 1+, and 7 scored 0. Twenty-nine cases showed negative HER2/
CEP17 ratios (< 1.8) and three cases equivocal HER2/CEP17 ratios 
(between 1.8 and 2.2). Using HER2/CEP17 ratio as first assessment 
and IHC only in equivocal cases, only one of the 31 “polysomic” cases 
would have been classified as HER2-positive. However, 8 polysomic 
cases with HER2/CEP17 ratio < 1.8 showed 3+ immunostaining (all 
with average HER2 gene copy number > 6/nucleus), while 3 other 
cases had an average HER2 gene copy number > 6/nucleus with 2+ 
immunostaining.
Conclusions: Our results show that both FISH evaluation criteria 
and IHC can modify the percentage of polysomic tumors classified as 
HER2-positive. However, the number of gene copies/nucleus appears 
more frequently associated with 3+ IHC than the HER2/CEP17 ratio. 
The predictive impact of the former method on response to anti-HER2 
treatments warrants further investigation.
P1-12-18
Change in HER2 Status in HER2 Positive Operable Breast 
Cancer Patients Treated with Neoadjuvant Chemotherapy with 
or without Anti-HER2 Therapy: Analysis of Two Consecutive 
Cohorts.
Barbieri E, Piacentini F, Dieci MV, Ficarra G, Bettelli S, Conte P, 
Guarneri V. Modena University Hospital, Modena, Italy
Introduction: emerging literature data have shown a change of 
HER2 expression from primary tumors to metastatic deposits. Tumor 
heterogeneity, genetic drift as well as selective pressure of adjuvant 
therapy have been suggested to explain this phenomenon.
Aim of the present analysis is to evaluate the change in HER2 
expression after neoadjuvant chemotherapy with or without anti-
HER2 agents.
Methods: two consecutive cohorts of HER2+ breast cancer patients 
treated with neoadjuvant therapy were identified from a prospectively 
maintained database including 310 patients. The first cohort (A) 
includes 38 patients enrolled before 2005, treated with chemotherapy 
alone. The second cohort (B) includes 48 patients treated with 
neoadjuvant chemotherapy in combination with antiHER2 agents 
(trastuzumab or lapatinib).
HER2 expression was evaluated by IHC on pre-treatment core 
biopsy (tru-cut with 14 gauge needle) and on surgical specimen 
after neoadjuvant therapy. FISH analysis was performed on IHC 
2+ samples.
Results: The two cohorts were balanced in respect of tumor stage, 
patient age, and HR expression. In particular, a co-expression of 
HER2 and HR was observed in 60% of the patients in cohort A and 
in 70% of the patients in cohort B (p=0.2).
Patients in cohort B have a significantly higher rate of pathologic 
complete response (pCR) in comparison to cohort A (45% vs 11%, 
p=0.001). A change in HER2 expression from biopsy to post-therapy 
samples was observed in 39% of the patients in cohort A vs 12% of 
the patients in cohort B (p=0.02). No patients with pCR have recurred 
so far vs 25% of the patients with less than pCR (p=0.005). The rate 
of recurrence was significantly higher for patients experiencing a 
change in HER2 expression (50% vs 19%, p=0.018).
Conclusion: contrary to our expectations, patients not receiving anti-
HER2 therapy as part of neoadjuvant therapy were more likely to have 
a change in HER2 status vs patients receiving anti-HER2 neoadjuvant 
therapy. The change in HER2 status has a negative prognostic impact.
P1-12-19
Phase I Study of Single Agent Trastuzumab Emtansine in 
Japanese Patients with Human Epidermal Growth Factor 
Receptor2 (HER2)-Positive Metastatic Breast Cancer (JO22591).
Aogi K, Ando M, Iwata H, Hara F, Matsubara M, Fujiwara Y. National 
Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 
Japan; National Cancer Center Central Hospital, Chuo-ku, Tokyo, 
Japan; Chuo Hospital Aichi Cancer Center, Nagoya, Aichi, Japan; 
Chugai Pharmaceutical Co. Ltd, Chuo-ku, Tokyo, Japan
Background
Trastuzumab emtansine (T-DM1), first-in-class anti-HER2 antibody–
drug conjugate (ADC) is under development for the treatment of 
HER2-postive recurrent locally advanced or metastatic breast cancer 
(MBC). T-DM1 is composed of: trastuzumab; DM1, an inhibitor 
of tubulin polymerization derived from maytansine; and the stable 
MCC linker that conjugates DM1 and trastuzumab. T-DM1 has been 
evaluated at multiple dose levels in a phase I trial (TDM3569g): 
every 3 weeks (q3w) (0.3–4.8 mg/kg) and weekly (1.2–2.9 mg/kg), 
and in two subsequent phase II trials (TDM4258g and TDM4374g) 
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for patients with heavily pretreated HER2-positive MBC. T-DM1 
monotherapy (3.6 mg/kg q3w) has demonstrated robust clinical 
efficacy in these two phase II clinical studies. Dose escalation 
data from the TDM3569g provided the basis for this phase I study 
(JO22591) study, to investigate the maximal tolerated dose (MTD) 
in Japanese patients.
Methods
This Japanese Phase I study was a single-arm, dose-escalation 
study in patients with HER2-positive MBC who had received prior 
therapies that included trastuzumab . The objective of the study 
was to determine the MTD of T-DM1 during Cycle 1, using the 
continual reassessment method, among three dose cohorts when 
administered as a single agent and to investigate safety, tolerability and 
pharmacokinetics of T-DM1 in patients with HER2-positive MBC. 
Eligibility criteria were standard for this type of study. T-DM1 was 
administered every 3 weeks at a dose level of 1.8 mg/kg, 2.4 mg/kg 
or 3.6 mg/kg. Outcomes were assessed by standard solid-tumor phase 
I methods. Adverse events were reported using CTCAE version 3.0, 
and tumor response was assessed according to RECIST version 1.0.
Results
Ten patients were recruited: (1.8 mg/kg [n=1], 2.4 mg/kg [n=4], or 3.6 
mg/kg [n=5]. One patient in the 2.4 mg/kg group experienced DLTs 
(Grade 3 AST increase and ALT increase). No other adverse events 
corresponding to a DLT were observed in any other patients during 
the DLT observation period. As a result, the MTD in Japanese MBC 
patients was determined to be 3.6 mg/kg q3w.
The most frequently reported adverse events, regardless of whether 
they were related to the study drug, were nausea, fatigue, arthralgia 
and pyrexia. The main changes in laboratory test values recorded were 
platelet count decrease, AST increase and ALT increase. Efficacy was 
preliminarily assessed with tumor responses, a partial response was 
observed in two patients. Most of the AEs were mild and manageable.
There were no marked differences in any pharmacokinetic parameters 
for T-DM1, DM1 or total trastuzumab following administration of 
T-DM1 between the JO22591 study and the two Western studies 
(TDM3569g and TDM4258g), and no data obtained suggested any 
ethnic differences.
Conclusions
T-DM1 monotherapy (3.6 mg/kg every 3 weeks) was well-tolerated in 
Japanese patients. PK and safety in Japanese patients were comparable 
to PK and safety in the Western population. These results support 
further clinical studies with T-DM1 in Japanese patients.
P1-12-20
The Safety and Tolerability of Vorinostat in Combination with 
Lapatinib in Advanced Solid Tumors.
Chumsri S, Tait NS, Medeiros MM, Bauer KS, Betts K-MT, Lewis 
JC, Bao T, Feigenberg SJ, Kesmodel SB, Stearns V, Edelman MJ, 
Sausville EA, Tkaczuk KHR. University of Maryland Greenebaum 
Cancer Center, Baltimore, MD; The Sidney Kimmel Comprehensive 
Cancer Center at Johns Hopkins, Baltimore, MD; University of 
Maryland, Baltimore, MD
Background: Lapatinib has been previously shown to markedly 
decrease cancer stem cells (CSC) in HER2-positive breast cancer. In 
preclinical models, we have demonstrated that histone deacetylase 
inhibitors (HDACi) such as vorinostat can induce differentiation 
and decrease CSC. The combination of vorinostat and lapatinib is 
synergistic with a combination index of 0.32 (synergism if CI <1). 
We therefore undertook a pilot study to evaluate the combination of 
these two drugs in advanced solid tumors.
Method: Patients were eligible if they were: age ≥ 18 years with 
incurable solid tumors, ECOG PS 0-2, adequate organ function, and 
no prior exposure to HDACi. The first 3 patients received lapatinib 
at the dose of 1,250 mg continuous daily and vorinostat 300 mg 4 
days on 3 days off. The second dose level with lapatinib 1,250 mg 
continuous daily and vorinostat 400 mg 4 days on 3 days off were 
administered in 6 patients. Cycles were repeated every 21 days until 
disease progression. Echocardiogram and radiologic evaluation were 
performed every 12 weeks. During the first cycle, pharmacokinetic 
(PK) evaluation was performed on days 18 and 21.
Results: Nine consented patients (7 with metastatic breast cancer, 1 
with non-small cell lung cancer, and 1 with thyroid cancer) have been 
enrolled with the median age of 52 (range 25-66). Patients received an 
average of 6 prior treatments (range 2-10). No dose limiting toxicity or 
drug related death have been observed. Grade 1-2 toxicities including 
diarrhea, fatigue, muscle cramps and stomatitis were observed. No 
grade 3 or 4 hepatic, renal or cardiac toxicity were observed (including 
no QTc prolongation and no significant reduction in the left ventricular 
ejection fraction). Patients have received the maximum of 7 cycles 
(median 3 cycles, range 2-7). Response: as of June 2011, 2 patients 
are still on treatment. Two patients achieved stable disease (triple 
negative metastatic breast cancer and HER2-positive breast cancer), 6 
patients with progressive disease, and 1 patient is too early to evaluate 
for response. PK analysis will be presented at the time of the meeting.
Conclusions: The combination of vorinostat and lapatinib is tolerable 
and has some antitumor activity in heavily pretreated advanced solid 
tumors. A phase II study in HER2-positive metastatic breast cancer 
is underway with lapatinib 1,250 mg continuous daily and vorinostat 
400 mg 4 days on 3 days off.
P1-12-21
Adjuvant Trastuzumab Treatment without Adjuvant 
Chemotherapy in Early Breast Cancer.
Dall P, Koch T, Lenzen G, Kuhn T, Hielscher C, Reichert D, Maasberg 
M, Ehscheidt P, Eustermann H, Fischer G. Städt. Klinikum, Lüneburg, 
Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, 
Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, 
Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, 
Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; 
Landkreis Mittweida Khs., Mittweida, Germany
Background: Trastuzumab (T) is approved in most Western 
countries for the treatment of early, HER2+ breast cancer (BC) 
parallel or sequential to adjuvant chemotherapy (CT). Nevertheless, 
as in metastatic disease, the antibody seems to be used without 
chemotherapy in a selected group of HER2+ patients (pt). The purpose 
of this analysis is to characterize this subgroup as well as describe 
safety and efficacy outcome parameters in this German prospective 
observation trial.
Methods: At present, 2870 patients (pts) have been enrolled and 
documented in this ongoing non-interventional study from 270 
German centers. At data base closure for this analysis, sufficient 
documentation was available from 2422 eligible pts.
Results: The proportion of pts receiving T without preceding or 
concomitant CT (noCT) was 180/2422 (7.4 %). This subgroup was 
characterized by higher age (median 58 vs.56 in the CT group, 
p=0.0026; ≥70 years: 18%/10%), smaller primaries (pT1 49%/43%, 
p=0.11), more favorable grading (G3 45%/53%, p=0.045), a higher 
proportion of positive hormone receptor (67%/61%, p=0.096) and 
less radiotherapy (64%/79%, p<0.0001). The strong association 
to radiotherapy is probably due to the fact, that the choice of this 
additional modality reflects the overall risk assessment of the pt. 
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In contrast, there was no difference in nodal involvement (pN0: 
52%/51%; positive nodes: mean 2.5/2.4). In multivariate analysis 
(logistic regression model, not incorporating radiotherapy), hormone 
receptor status is not predictive (p=0.41), while age ≥65 (p=0.0011), 
grade 1/2 (p=0.046) and pT1 (p=0.089) independently remain at least 
borderline significant. The mean number of T administrations was 
18 and the median duration of T therapy was 12 months in the noCT 
group as well as the CT group. 57% of the noCT pts received adjuvant 
endocrine therapy. In the CT group, 81% received anthracyclines 
and 61% taxanes.
Based on a still low number of only 13 observed events in the noCT 
group, no differences in relapse-free survival could be detected 
(p=0.38). Pathological cardiac findings in the pt’s history was not 
predictive of therapy selection (6%/7%) and were also similarly 
distributed at the end of T therapy (7%/8%). Cardiac function 
disorders of CTC grade 3/4 were reported in 1% of both groups, 
across all grades slightly less frequent in the noCT group (2.8%/4.0%). 
Conclusions: A small, but distinct group of early BC pts without 
adjuvant chemotherapy receives T treatment for HER2+ disease. 
These patients are characterized by higher age and favorable primary 
tumor staging and grading, but not by cardiac comorbidities.
P1-12-22
Impact on Survival of the Level of HER2/neu Gene Amplification 
in Patients with HER2-Positive (HER2+) Advanced Breast Cancer 
(AdvBrCa) Treated with Trastuzumab (H).
Gullo G, Bettio D, Zuradelli M, Masci G, Giordano L, Bareggi C, 
Salvini P, Runza L, Santoro A. St Vincent’s University Hospital, 
Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; 
Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 
Cliniche Humanitas Gavazzeni, Bergamo, Italy
Background The level of HER2/neu (HER2) amplification, defined 
as HER2/centromeric region of chromosome 17 (CEP17) ratio at 
dual-color fluorescent in-situ hybridization (FISH) test presents 
wide variations in clinical practice but its clinical significance is 
still undefined. We designed this retrospective study to investigate 
the correlations between level of HER2 amplification in primary (T) 
and/or metastases (M) and outcome in a cohort of HER2+ AdvBrCa 
pts treated with a H-containing therapy. Methods Retrospective 
multicentric study designed according to REporting recommendations 
for tumor MARKer prognostic studies (REMARK). To be included 
pts must have all the following: metastatic or locally advanced (not 
amenable of curative surgery) BrCa, HER2+ tumour defined as score 
3+ at immunohistochemistry or FISH positive, treatment with a 
H-containing regimen (no H in neo- or adjuvant setting was allowed), 
at least one tumour sample from T and/or M available, measurable 
or evaluable disease, adequate follow up (FU) information.Outcome 
parameters included event-free survival (EFS) and overall survival 
(OS). All FISH tests were prospectively performed in a central 
laboratory of cytogenetic specifically for this study and in accordance 
with the international guidelines on FISH testing. Results Ninety-
one females were identified and 63 included in the final analysis. 
Forty-seven pts had one specimen available from T or M, 16 pts 
had two specimens from either T and a corresponding M. All M 
samples were obtained before treatment with H. Median FU time is 
19.2 months (range 1.2-94.6). In 11 out of 16 cases (69%) with two 
tumour specimens HER2/CEP17 ratio was higher in M than in T 
with a statistically significant difference in the median HER2/CEP17 
ratio between T (8.3, range: 3.1-18.4) and the corresponding M (10.9, 
range: 4.6-20.8) (p=0.004). The incremental gain in HER2/CEP17 
ratio was associated with significantly shorter OS after trastuzumab-
based therapy (p=0.023). A trend towards a correlation between 
increase in level of HER2 amplification assessed in M and shorter 
EFS and OS was observed. No statistically significant correlation 
was found between level of HER2 amplification assessed in T and 
EFS and OS. Conclusions Level of HER2 amplification reported as 
HER2/CEP17 ratio is a dynamic parameter in HER2+ AdvBrCa as it 
increases from T to the matched M in a significant proportion of pts. 
The gain in HER2 gene copies may represent a prognostic factor for 
shorter OS when pts with HER2+ AdvBrCa are treated with a H-based 
therapy. Further studies on the level of HER2 amplification in BrCa 
metastases are strongly warranted to better understand the biology 
of HER2-positive breast cancer and to better identify patients with a 
poorer prognosis after treatment with H.
P1-12-23
HER4 Coexpression Is Associated with Improved Recurrence 
Free Survival in HER2-Positive, Herceptin Treated Patients.
Brockhoff G, Machleidt A, Piendl G, Seegers S, Sassen A, Diermeier-
Daucher S, Buchholz S, Ortmann O. University Medical Center 
Regensburg, Regensburg, Bavaria, Germany
Background: Individual therapy efficiency of HER2-positive 
metastatic and pre-metastatic breast cancer patients varies 
significantly and spans from effectual responsiveness over acquired 
insensitivity to complete resistance from the outset. Thus no predictive 
information can be deduced from HER2 diagnostics so that molecular 
biomarkers indicative for sensitivity / resistance to Herceptin are 
needed to be identified. The HER2 related HER4-receptor has been 
shown to have ambivalent (pro-apoptotic or pro-proliferative) activity 
and consequently represents a prime candidate to affect HER2 activity 
under Herceptin treatment. We retrospectively analyzed potential 
her4 gene amplification and HER4 protein expression in HER2-
positive, Herceptin treated patients. Patient’s overall and recurrence 
free survival was evaluated as a function of HER2/HER4 expression.
Methods: Using dual color Fluorescence in-situ Hybridization (FISH 
probes, Zytovision, Bremerhaven, Germany) and qPCR (LC480, 
Roche, Penzberg, Germany) we quantitatively investigated primary 
breast cancer tissues from nearly 50 (FISH) and 160 (PCR) patients 
who received Herceptin treatment. We quantified the her4 gene copy 
numbers and evaluated the protein expression profile of all four known 
HER4 isotypes (JM-a/CYT1, JM-a/CYT2, JM-b/CYT1, JM-b/CYT2).
Results: FISH analysis revealed a positive and independent prognostic 
marker in Herceptin treated breast cancer patients with respect to 
overall survival. Moreover by quantitative PCR analysis we found 
a significant variability of HER4 protein expression (JM-a/CYT1 
and JM-a/CYT2; no JM-b isotypes) in HER2 positive breast cancer 
tissues, whereas HER2/HER4 positive patients show a significant 
better recurrence free survival compared to HER2 positive but HER4 
negative patients (p = 0,003).
Conclusions: HER4 has been demonstrated to potentially exert tumor 
suppressing activity and in turn to have a favourable impact on the 
course of breast cancer disease. We show here that HER4 expression 
prolongs in particular recurrence free survival of Herceptin treated 
patients which indicates a functional integration of HER4 into anti-
HER2 targeting. Complementing functional studies allowing for 
isotype specific function of HER4 will elucidate the special role of 
this receptor tyrosine kinase in the context of Herceptin treatment 
and might facilitate individualized anti-ErbB-receptor targeting with 
higher efficiency.
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P1-12-24
Adherence and Persistence with Lapatinib in Women with 
Metastatic Breast Cancer Who Were Previously Treated with 
Trastuzumab.
Delea TE, Kartashov A, Sharma PP. Policy Analysis Inc. (PAI), 
Brookline, MA; GlaxoSmithKline, Philadelphia, PA
Background. Lapatinib is an oral small molecule dual tyrosine kinase 
inhibitor that binds intracellularly to the ATP binding site of the 
EGFR and HER2 receptors. In a randomized controlled trial (RCT) 
of women with HER2+ metastatic breast cancer (MBC) previously 
treated with trastuzumab, an anthracycline, and taxanes, lapatinib 
plus capecitabine improved time to progression versus capecitabine 
monotherapy. In an RCT of postmenopausal women with HR+ MBC, 
1st-line therapy with lapatinib plus letrozole improved progression-
free survival vs. letrozole monotherapy in the primary analysis HER2+ 
population. Data on adherence and persistence with lapatinib in typical 
clinical practice are unavailable.
Methods. This was retrospective observational study of adherence 
and persistence with lapatinib in women with MBC who were 
previously treated with trastuzumab. Data were from the Thomson 
MedStat MarketScan® Commercial and Medicare health insurance 
claims databases spanning 1/2000-3/2010 and representing >90 
million covered lives. Subjects included women with ≥1 claims 
with a diagnosis of breast cancer, ≥1 claims with a diagnosis of 
distant metastases, ≥1 trastuzumab claim after first distant metastases 
diagnosis, and ≥1 lapatinib claim after first trastuzumab claim (date 
of first lapatinib claim=“index date”). Pts with <12 mos. continuous 
enrollment pre-index or <3 mos. continuous enrollment post-index 
were excluded. Measures of lapatinib adherence and persistence were 
calculated from days supplied information on pharmacy claims and 
included medication possession ratio (MPR), time to discontinuation 
(end of supply), time to first treatment interruption (gap during 
treatment of ≥30 days without supply) , and duration of continuous 
therapy (time to gap of ≥30 days without supply or end of supply).
Results. A total of 1299 pts had ≥1 claims with a diagnosis of breast 
cancer, ≥1 claims with a diagnosis of distant metastases , ≥1 claims 
for trastuzumab, and ≥1 claims for lapatinib (1106 Commercial, 93 
Medicare). Of these, 666 met all inclusion criteria (572 Commercial, 
94 Medicare). Mean (SD) age was 52 (8) years in Commercial pts and 
72 (6) years in Medicare pts. Among all pts, 73% had claims history 
of prior taxanes, 27% prior anthracylines, and 24% prior taxanes and 
prior anthracyclines. Mean (SD) initial lapatinib dosage was 1161 
(339) mg daily; 84% initiated lapatinib on 1250 mg daily. Sixty-three 
percent received index lapatinib in combination with capecitabine; 
6% in combination with an aromatase inhibitor. Median follow-up 
was 12 mos. Mean (SD) number of lapatinib claims was 7.1 (4.9). 
Mean (SD) MPR was 87% (19%); median MPR was 96%. Kaplan-
Meier estimated median time to discontinuation of lapatinib was 
7.4 months (95%CI 6.7-8.0 mos). Seventy three percent of patients 
had no treatment interruption during follow-up. Median duration of 
continuous therapy was 5.2 mos (95%CI 4.8-5.7 mos).
Conclusions. In women with MBC previously-treated with 
trastuzumab, adherence and persistence with lapatinib in typical 
clinical practice are relatively high. Further research is needed to 
identify predictors and consequences of non-adherence so that efforts 
may be targeted to enhance adherence to effective treatment.
P1-12-25
Evaluation of PTEN, EGFR and Ki67 Expression as Predictors 
of Response to a Trastuzumab-Containing Neoadjuvant 
Chemotherapy Regimen in a HER-2 Over-Expressing Locally 
Advanced Breast Cancer (LABC) Trial.
Ho J, Turashvili G, Hayes M, Gelmon KA, Ellard SL, Macpherson N, 
Pansegrau G, Chia SK. British Columbia Cancer Agency, Vancouver, 
BC, Canada; British Columbia Cancer Research Centre, Vancouver, 
BC, Canada; British Columbia Cancer Agency, Kelowna, BC, 
Canada; British Columbia Cancer Agency, Victoria, BC, Canada; 
British Columbia Cancer Agency, Surrey, BC, Canada
Background: In patients with HER-2 over-expressing breast cancer, 
predictors of trastuzumab response and resistance remain unclear 
and unvalidated. In an exploratory analysis within a phase II trial, 
we evaluated various biologic markers as predictors of response or 
resistance to a trastuzumab containing neoadjuvant chemotherapy 
regimen.
Methods: A tissue microarray (TMA) was constructed from formalin-
fixed paraffin-embedded tumor tissue samples obtained prior to 
neoadjuvant chemotherapy in 21 (from a total of 30) HER-2 positive 
stage II-III patients. Protocol treatment consisted of 4 cycles of 
5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC100) followed 
by 4 cycles of Docetaxel, Carboplatin (AUC 6) and Trastuzumab 
(TCH). Immunohistochemical (IHC) analyses of estrogen receptor 
(ER), progesterone receptor (PR), HER-2, Ki67, EGFR and PTEN 
were performed utilizing previously published protocols and cut-offs. 
HER-2 equivocal (2+) by IHC cases was confirmed by prior FISH 
analysis. Fisher’s exact test was used for statistical analysis.
Results: 21 patients had sufficient tumour for analysis. Median 
age at diagnosis was 49 years old, 67% were pre-menopausal, and 
biomarker expression was as follows: 43% ER positive, 29% PR 
positive, and 100% HER-2 positive. 14 patients (67%) had pathologic 
complete response (pCR) following the completion of neoadjuvant 
chemotherapy and trastuzumab. In general, tumour samples showed 
high Ki67 (>14%) staining (62%), low EGFR positivity (14%), 
and high PTEN expression (71%). Neither high Ki67 expression 
(p=0.65), any EGFR expression (p=0.26), nor PTEN loss (p=0.60) 
was associated with higher or lower rates of pCR respectively.
Conclusion: In our small cohort of locally advanced HER-2 over-
expressing tumours, baseline expression of Ki67, EGFR and 
PTEN were not associated with pCR to a neoadjuvant sequential 
anthracycline and taxane/trastuzumab combination regimen. 
Additional biomarkers for an activated PI3K pathway and for p95 
will be attempted.
P1-12-26
Global Patterns of Care for HER2/Neu Overexpressing Breast 
Cancer.
Chavarri-Guerra Y, Liedke P, Symecko H, Moy B, Higgins M, St. Louis 
J, Finkelstein D, Goss P, Massachusetts General Hospital - Avon 
International Breast Cancer Program, Boston, MA 
Background: Her2/neu overexpression is an independent adverse 
prognostic factor present in approximately 25% of invasive breast 
cancers. HER2-overexpressing breast cancer is particularly common 
in younger patients and therefore poses a significant public health 
burden. Anti-Her2/neu adjuvant trastuzumab significantly reduces 
the risk of recurrence as well as improves survival. In view of the 
serious potential ramifications of not receiving anti-Her2/neu therapy 
when appropriate, we undertook this international project to determine 
clinical access to Her2/neu testing and treatment patterns for women 
with HER2/neu-positive early breast cancer.
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Methods: A web-based survey was sent to 386 physicians from 33 
countries who participated in the “TEACH” trial, a double blind 
placebo-controlled phase III study of a novel anti-Her2/neu therapy, 
lapatinib, in women with primary Her2/neu-positive breast cancer. 
The survey contained 27 questions addressing physician and patient 
demographics, access to Her-2/Neu testing in everyday clinical 
practice, and anti-Her2/neu treatment options in a variety of clinical 
scenarios.
Results: One hundred and fifty one participants (39%) from 28 
countries answered the survey. Ninety eight percent of the participants 
reported having Her2/neu tumor expression routinely measured for 
clinical practice in their institutions by immunohistochemistry (83%), 
FISH (78%) and other methods (17%). Among Asian physicians, 
18% did not have routine testing available and sent primary tumors 
for central testing for TEACH eligibility. Forty eight percent of 
physicians surveyed reported instances when they had recommended 
adjuvant Her2-directed therapy to a patient who eventually did not 
receive it. The proportion of physicians from developing countries 
that reported patients not receiving therapy was higher than those 
from developed countries (68% vs. 38%, respectively). The main 
reason for not receiving trastuzumab was cost in developing countries, 
while in more developed countries patient refusal and co-morbidities 
were the main reasons.
Discussion: This survey reflects availability of HER2 breast tumor 
testing and anti-Her2/neu therapy among physicians from 28 countries 
worldwide who participated in an anti-Her2/neu therapy clinical trial 
of a free anti-Her2/neu therapy. These results indicate that a high 
proportion of women with Her2/neu-overexpressing breast cancer 
may not receive standard anti-Her2/neu adjuvant therapy especially in 
developing countries, the barrier to treatment being cost of therapy. We 
are extending our access to care survey project to a more unselected 
diverse group of physicians in developing countries.
P1-13-01
An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine 
in Breast Cancer Patients To Prevent Recurrence.
Hale DF, Perez S, Sears AK, Clifton GT, Vreeland TJ, Holmes JP, 
Ardavanis A, Pistamaltzian N, Rellias G, Ponniah S, Papamichail M, 
Peoples GE, Mittendorf EA. Brooke Army Medical Center, Ft. Sam 
Houston, TX; Saint Savas Cancer Hospital, Athens, Greece; Naval 
Medical Center San Diego, San Diego, CA; Uniformed Services 
University of the Health Sciences, USMCI, Bethesda, MD; UT M.D. 
Anderson Cancer Center, Houston, TX
Introduction
AE37 is the Ii-Key hybrid of the HER2-derived peptide AE36 
(HER2:776-790). A phase I trial administering AE37 with the 
immunoadjuvant GM-CSF demonstrated the vaccine to be safe 
and capable of stimulating CD4+helper T-cells with HER2-specific 
anti-tumor activity. Here we present an update of our prospective, 
randomized, single-blinded, phase II trial of the AE37 vaccine for 
the prevention of breast cancer recurrence in disease-free, high risk 
patients.
Methods
After completion of standard therapy, disease-free, node positive or 
high risk node negative breast cancer patients were randomized to 
receive either AE37+GM-CSF (vaccine) or GM-CSF alone (control) 
in six monthly intradermal inoculations. Patients were enrolled 
with any level of HER2 expression, (IHC 1+ 2+ or 3+). Specific 
immunologic responses to both AE36 and AE37 were evaluated in 
all patients at pre-determined intervals: before (RO), mid-series (R3), 
upon completion (R6), and at six (RC6) and 12 (RC12) months after 
completion of the vaccine series. In vitro responses were measured 
using the [3H]-thymidine incorporation assay and in vivo responses 
using delayed-type hypersensitivity (DTH) reactions. The trial’s 
primary endpoint is disease recurrence.
Results
To date, 215 patients have enrolled (vaccine=92, control=123). 99% 
of local and systemic toxicities were ≤grade 2 or less. There were 
no grade 4-5 local or systemic toxicities and no difference between 
toxicity profiles of vaccine and control groups. Vaccine patients 
exhibited a statistically significant increase from baseline in AE36 
and AE37 proliferative responses at each time point, including 
maintenance of this response up to 12 months post-vaccination 
(AE36 (cpm): R0=0, R3=1335, R6=1242, RC6=1586, RC12=1360; 
AE37: R0=0, R3=2859, R6=2300, RC6=3235, RC12=3279, p<0.001) 
while there have been no proliferative changes for control patients 
(AE36: R0=91, R3=95, R6=97, RC6=126, RC12=48; AE37: R0=291, 
R3=399, R6=319, RC6=103, RC12=0). Vaccine patients also had 
statistically significant increases in DTH reactions to both AE36 
and AE37 (AE36 (mm): R0=0, R6=15, RC6=15, RC12=15; AE37: 
R0=0, R6=24, RC6=17, RC12=20 p=<0.001) while controls had 
no response (AE36: R0, R6, RC6, RC12=0; AE37: R0, R6, RC6, 
RC12=0). With a median follow up of 17 months, breast cancer 
recurrences were reduced by 42% in vaccine patients compared 
to control patients (7.6% vs. 13.2%, p=0.15). In an analysis of 
patients with low HER2 expression (IHC 1 or 2+), vaccine patients 
experienced a 49% reduction in recurrence compared to controls 
(9.5% vs. 18.6%, p=0.16) with no reduction seen in HER2 over-
expressing patients (6.0% vs. 7.9%, p=0.49).
Conclusions
The AE37 vaccine is safe and well tolerated with only mild toxicity, 
which is attributable to the GM-CSF immunoadjuvant. The AE37 
vaccine elicits strong peptide specific in-vivo and ex-vivo immune 
responses, which are maintained for 12 months after completion 
of the vaccine series. While the number of recurrences are still 
low, the recurrence rate appears to decrease in vaccinated patients. 
Administration of the AE37 vaccine may reduce the risk of breast 
cancer recurrence with the greatest benefit in patients with low levels 
of HER2 expression.
P1-13-02
Long-Term Clinical Benefit of Adjuvant Breast Cancer Vaccine: 
5 Year Efficacy of E75 with Multiple Booster Inoculations.
Vreeland TJ, Clifton GT, Sears AK, Hale DF, Patil R, Clive KS, Holmes 
JP, Mittendorf EA, Ponniah S, Peoples GE. Brooke Army Medical 
Center, Ft. Sam Houston, TX; Windber Medical Center, Windber, Pa; 
Naval Medical Center San Diego, San Diego, CA; UT M.D. Anderson 
Cancer Center, Houston, TX; Uniformed Services University of the 
Health Sciences, USMCI, Bethesda, MD
Background: We are conducting phase I/II clinical trials vaccinating 
breast cancer patients with E75, an HLA-A2/A3 restricted HER2/neu 
(HER2) peptide mixed with GM-CSF. The vaccine has been studied 
in the adjuvant setting to prevent recurrences in clinically disease-free 
patients after completion of standard therapy. We have previously 
reported that the vaccine is safe, effectively stimulates HER2-specific 
immunity, and appears to improve disease-free survival at 24 months. 
Here, we report long-term data at a median follow-up of 60 months.
Methods: The phase I/II trials were performed as dose escalation/
schedule optimization trials enrolling node positive and high-risk, 
node-negative patients with tumors expressing any level of HER2. 
Vaccinated patients were given 4-6 monthly inoculations of E75 with 
GM-CSF immunoadjuvant. Due to waning immunity, a voluntary 
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booster program was initiated, with inoculations every 6 months 
after completion of the primary vaccine series (PVS). Patients were 
monitored for local and systemic toxicities, which were graded by the 
NCI’s Common Terminology Criteria for Adverse Events. Vaccinated 
patients and controls were followed for 60 months and recurrences 
were documented. Demographic differences were compared with the 
Fisher’s exact test and survival was analyzed by the log-rank test.
Results: 187 patients were enrolled; 108 in the vaccine group 
(VG) and 79 in the unvaccinated control group (CG). The vaccine 
and control groups were well-matched with the only statistically 
significant difference being ER-/PR- status (31.1% in VG vs 17.7% 
in CG, p=0.04). Vaccination was well tolerated with primarily grade 
1 and grade 2 toxicity in the PVS (Local Toxicity: 85% Grade 1, 15% 
Grade 2, 0% Grade 3; systemic toxicity: 71% Grade 1, 14% Grade 2, 
and 3% Grade 3). Fifty-three of the VG patients received at least one 
booster, with 34 receiving a second booster, 25 a third, 22 a fourth, 12 
a fifth, and 9 receiving at least six boosters. Booster inoculations were 
well-tolerated with only grade 1 and 2 local and systemic toxicities. 
There were delayed urticarial reactions in 7/53(13%) of the boosted 
patients occurring at a median of 9 days (5-21 days) after inoculation; 
these were grade 2 reactions and well-tolerated. After a median 
follow-up of 60 months, there has been a nonsignificant decrease 
in recurrences observed in the VG compared to the CG (10.6% vs 
20.3%, p=0.098). The hazard ratio is 0.52 in the VG. In patients with 
immunity maintained with voluntary boosters, there have been even 
fewer (3.8%) recurrences (p=0.03).
Conclusions: The E75 breast cancer vaccine is safe and well–
tolerated. With long-term follow-up at 60 months, the E75 vaccine 
continues to show a strong trend toward preventing breast cancer 
recurrence in vaccinated patients particularly in patients whose 
immunity is maintained with booster inoculations. To investigate this 
further, a phase III trial with prospective boosting is being initiated.
P1-13-03
Zoledronic Acid Induces an Immune Response in Breast Cancer 
Patients through Stimulation of Central Memory and Effector 
Memory gamma/delta T-Cells.
Hamilton EP, Hobeika AC, Lyerly HK, Owzar K, Rocha G, Kimmick 
GG, Marcom PK, Peppercorn JM, Morse MA, Blackwell KL. Duke 
University, Durham, NC
Background
Zoledronic acid (ZA) in combination with endocrine therapy (ET) and 
ovarian ablation (OA) reported a DFS advantage in premenopausal 
women with early stage breast cancer (EBC) in ABCSG-12. Emerging 
evidence from pre-clinical studies suggests that ZA increases gamma/
delta T-cells (GDT), an immune cell population with anti-tumor 
activity. This study examined immune responses to a single dose of 
ZA in patients with either EBC or metastatic breast cancer (MBC) 
through sequential measurement of T-cells and immune regulatory 
cytokines.
Methods
Women with EBC/MBC, both pre- and post-menopausal, and no 
history of immune dysregulation who were scheduled to receive their 
first-ever dose of ZA were eligible. Blood was collected for serum 
and blood mononuclear cells at Day 0 (pre-ZA), Day 1 (18-48 hours 
post-ZA), Day 7 (Day 5-8 post ZA), and Day 28 (Day 25-32 post-ZA). 
GDT populations and cytokine responses were assayed using flow 
cytometry and multi-analyte profiling beads (Luminex), respectively. 
Relative changes from baseline at days 1, 7 and 18 were quantified 
using log-ratios and analyzed using the Wilcoxon signed-rank test.
Results
24 patients were enrolled from Oct 2009 to Mar 2011. 75% of pts 
had MBC, and 25% had EBC, while 75% received ET, 17% received 
chemo (C), and 8% received other. Following ZA administration, 
a transient decrease in total GDT (CD3+/Vdelta2+) at Day 1 was 
seen (p<0.0003). This was followed by an increase in both effector 
(CD3+/Vdelta2+/CD45RA-/CD27-) (P<0.005) and central memory 
GDT (CD3+/Vdelta2+/CD45RA-/CD27+)(P<0.007) and a decrease 
in naïve GDT (CD3+/Vdelta2+/CD45RA+/CD27+) (P<0.006) at day 
7; total GDT unchanged. The change in naïve GDT and effector GDT 
appeared to persist at Day 28. IL-1RA (P<0.003), IL-12 (P<0.0005), 
MIP-1b (P<0.0005), IP-10 (P<0.00002) and MIG (P<0.00006), were 
increased at Day 1 compared to baseline. By day 28, these cytokine 
levels returned to baseline except IP-10 which appeared to remain 
elevated. In this limited patient sample, no differences were observed 
between patients with EBC vs. MBC, ET vs. C, and pre- vs. post-
menopausal.
Conclusion
ZA appears to induce a highly significant change in immune effector 
cells in both EBC and MBC patients receiving ET or C. Mobilization 
of anti-tumor T-cells with a decrease in total (non-specific) GDT 
followed by a marked increase post-ZA in specific central and effector 
memory GDT was seen at day 7. Significant increases in cytokine 
levels, like those seen in this study including those associated with 
Th1 responses or cell-mediated immunity, as well as IL-12 levels, 
have been implicated in direct anti-tumor activity. This apparent 
cytokine and cellular response to ZA could offer an important biologic 
mechanism for the anti-cancer activity reported in ABCSG-12. Further 
studies should be performed to determine which subsets of BC patients 
might achieve these described immune benefits from ZA.
P1-13-04
Phase II Study of Topical Imiquimod and Abraxane for Treatment 
of Breast Cancer Cutaneous Metastases.
Salazar LG, Lu H, Gray H, Higgins D, Childs J, Yushe D, Slota M, 
Parker S, Disis ML. University of Washington, Seattle, WA
Background: Breast cancer (BC) cutaneous lesions can present 
as local chest wall recurrence or isolated sites of metastatic 
disease. Current treatments with full thickness chest wall resection, 
radiation therapy and chemotherapy are not curative; and have 
significant morbidity and poor overall response rates. Combining 
local immunomodulation and systemic chemotherapy may be more 
effective in treating cutaneous disease. Topical imiquimod (IMQ), 
a TLR-7 agonist, has shown clinical activity against cutaneous 
metastasis. Pre-clinical studies have shown IMQ to stimulate Th1 
cytokine secretion and up-regulate immune co-stimulatory molecules 
at the tumor site; resulting in augmented tumor specific T cell 
immunity and tumor growth inhibition. Use of paclitaxel in BC, 
has demonstrated immunostimulatory effects of increased serum 
IFN-g and enhanced NK/LAK cell activity. Abraxane (albumin-
bound paclitaxel) may be used in conjunction with IMQ as steroid 
pre-treatment is not required. We hypothesize the immune effects of 
Abraxane may synergize and augment the IMQ anti-tumor effects, 
resulting in greater clinical response. A phase II single-arm study of 
chemoimmunotherapy with topical IMQ and Abraxane was initiated 
to determine its safety and therapeutic efficacy; and examine its effect 
on augmenting endogenous tumor specific immunity and inducing 
tumor molecular alterations associated with inhibition of tumor 
growth and/or common pathways of BC immune escape.
Materials and Methods: Up to 15 BC patients with cutaneous lesions 
no longer amenable to standard therapy are enrolled and receive 3 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011235s
December 6-10, 2011 Abstracts: Poster Session 1
treatment cycles. A treatment cycle consist of topical 5% IMQ to target 
lesions 4 days/week (wk.) and Abraxane 100 mg/m2 on Days 1, 8, 
15 every 28 Days. Toxicity is evaluated per CTCAE v3.0 on Days 1, 
8, 15 of each cycle and wks. 13, 16, 20, 24. Target lesion antitumor 
activity is assessed per modified WHO criteria (Complete response 
(CR); Partial response (PR); Stable disease (SD); Progressive disease 
(PD)) at baseline, wks. 4, 8, 12, 16, 20, 24. 2-mm target lesion skin 
biopsies are obtained pre-and post-treatment for histologic analysis 
and RT-PCR analysis of a 7 IFN-related gene signature associated 
with tumor inhibition. Immunity to HER2, IGFBP-2, TOPO-IIa, p53 
and serum TGF-b levels are evaluated at baseline and wks. 12, 24 
with IFN-g ELISPOT and ELISA, respectively.
Results: 10 patients have been enrolled. Median (range) values 
include: age, 54 years (48-92), time from metastatic diagnosis, 
134 months (58-728), prior chemotherapy regimens, 5 (2-10). 5/10 
patients had received prior local therapy, e.g., radiation. 5/10, 4/10, 
and 2/10 patients had triple negative, HER2+ and ER+/PR+ tumors, 
respectively. In 5 patients completing 3 treatment cycles, overall 
response rate (ORR) = 100% (3 CR, 2 PR). In the 5 patients who 
completed 1-2 treatment cycles, ORR = 80% (2 PR, 2 SD, 1 PD). 
Treatment related toxicity is primarily grade I/II neutropenia, anemia; 
grade I skin toxicity. Immunologic analyses are ongoing and will be 
presented with completed clinical data on all patients.
Conclusions: Chemoimmunotherapy with topical IMQ and Abraxane 
is well-tolerated and shows excellent clinical efficacy in treating 
metastatic cutaneous lesions in heavily pretreated BC patients.
P1-14-01
Randomized Phase II Trial of Weekly vs. q 2-Weekly vs. 
q 3-Weekly Nanoparticle Albumin-Bound Paclitaxel with 
Bevacizumab as First-Line Therapy for Metastatic Breast Cancer.
Seidman AD, Conlin AK, Bach A, Forero-Torres A, Wright G, Hackney 
MH, Clawson A, Schofield D, Iglesias J, Hudis CA. Memorial Sloan-
Kettering Cancer Center, New York, NY; Providence Cancer Center, 
Portland, OR; University of Alabama - Birmingham, Birmingham, 
AL; Florida Cancer Institute, Hudson, FL; Virginia Commonwealth 
University, Richmond, VA; Celgene Corporation, Summit, NJ
Background: Nanoparticle albumin-bound paclitaxel (nab-P) 
260 mg/m2 is superior to paclitaxel 175 mg/m2 (P) every 3 weeks 
(Gradishar et al. JCO 2005) in metastatic breast cancer (MBC), 
and weekly uninterrupted P is more effective than q3wk P in MBC 
(Seidman et al. JCO 2008). Bevacizumab (bev) nearly doubles 
response rate and time to progression (TTP) when added to P as 1st 
line therapy for MBC (Miller et al. NEJM 2007).
Methods: This open-label, phase II study randomized patients (pts) 
to nab-P at 260 mg/m2 q3wk (arm A) vs. 260 mg/m2 q 2wk with 
filgrastim (arm B) vs. 130 mg/m2 weekly uninterrupted (arm C), all 
with bev (15 mg/kg q 3 weeks arm A, 10 mg/kg q 2 weeks arms B 
and C). Patients were required to have measurable, HER2 negative 
MBC and no prior chemotherapy for MBC. The primary endpoints 
were response rate and toxicity.
Results: Of 212 pts randomized, 208 (75 arm A, 54 arm B, 79 arm C) 
were treated, with balanced demographics and baseline characteristics. 
The median age was 57 (range 29-85), 82% were postmenopausal 
and 89% had visceral disease (64% lung, 50% liver). ECOG PS 
0:60%, 1:35%, 2:5%. 62% had prior neo-adjuvant or adjuvant 
chemotherapy for early stage disease: anthracycline: 54%, taxane: 
38%. No significant differences in confirmed complete and partial 
response rates were noted (A: 40%, B: 44%, C: 46%). Median TTP 
was longer in Arm C (9.0 months) versus both arms B (6.3 months) 
and A (8.0 months), overall p=0.065. There were no differences in 
overall survival (Arm A: 21.3 months, Arm B: 19 months, Arm C: 
25.3 months). As per protocol-specified stopping rule, arm B was 
closed early due to an unacceptable safety profile with significantly 
more grade ≥ 2 fatigue (B:57%, A: 39%, C:39%, p=0.048) and bone 
pain (B:19%, A:10%, C:4%, p=0.024). Sensory neuropathy was 
common; grades 2/3/4: Arm A: 29%/32%/1%, Arm B: 15%/50%/2%, 
Arm C: 27%/43%/1%). Sensory neuropathy was commonly readily 
reversible with dose delay and reduction. Febrile neutropenia occurred 
in <2% of pts in all arms. Arm C patients experienced significantly 
less arthralgia compared with arms A and B, but dose delays were 
frequent (86% of pts) on this planned uninterrupted weekly schedule. 
Bevacizumab-related events were consistent with prior phase III trials 
of taxane/bev; there were no new safety signals.
Conclusions: Significant and similar antitumor activity was observed 
in all arms. Weekly nab-P with bev (arm C) resulted in longer TTP. 
Weekly nab-P with bev (arm C) appears to have the highest therapeutic 
index, however sensory neuropathy is limiting, suggesting that a 
3 week on/1 week off schedule could be preferable and should be 
studied comparatively.
P1-14-02
Correlation of Circulating Tumor Cells (CTC) and Circulating 
Endothelial Cells (CEC) with Pathological Complete Response 
(pCR) during Neoadjuvant Chemotherapy (CT) Combined with 
Bevacizumab in HER2 Negative Inflammatory Breast Cancer 
(IBC): Ancillary Study of Phase II Trial BEVERLY 1.
Pierga J-Y, Bidard F-C, Andre F, Petit T, Dalenc F, Delozier T, Romieu 
G, Bonneterre J, Ferrero J-M, Kerbrat P, Lemonnier J, Viens P. Institut 
Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; 
Centre Paul Strauss, Strasbourg, France; Centre Claudius Regaud, 
Toulouse, France; Centre François Baclesse, Caen, France; Centre 
Val d’Aurelle, Montpellier, France; Centre Oscar Lambret, Lille, 
France; Centre Antoine Lacassagne, Nice, France; Centre Eugène 
Marquis, Rennes, France; Unicancer, Paris, France; Centre Paoli 
Calmettes, Marseille, France
Background: Prognostic value of CTC detection in blood has 
been reported in primary breast cancer with a rate around 20% in 
the neoadjuvant setting. No correlation between CTC and pCR to 
neoadjuvant CT in operable breast cancer has been reported (Pierga 
CCR 2008, Riethdorf CCR 2010). Predictive value of CEC for 
response to anti-angiogenic agents is unclear. Methods: CTC and 
CEC were detected in 7.5 ml and 4 ml of blood respectively with 
CellSearch™ System in the neoadjuvant setting of HER2 negative 
IBC (T4d) patients (pts) enrolled in the phase II multicentre trial 
BEVERLY 1, evaluating bevacizumab (15mg/kg q3w) in combination 
with sequential neoadjuvant CT of 4 cycles of FEC followed by 4 
cycles of Docetaxel. Patients received postoperatively 10 cycles of 
bevacizumab and hormonotherapy if tumor was ER+. Results: From 
12/08 to 09/10, 101 pts were included, 96 were evaluable for pCR 
and 92 for CTC and CEC. Out of 96 pts, 51 (53%) had triple negative 
breast cancer (TNBC). At baseline, 37 pts out of 92 had ≥ 1 detectable 
CTC (40%, 95%CI 30-50%).
CTC and CEC detection during treatment
  Baseline Pre C5 Pre surgery Post surgery End of adjuvant Bev
CTC ≥1CTC 37/92 (40%) 5/82 (6%) 7/65 (11%) 2/63 (3%) 6/35 (17%)
 ≥5CTC 17/92 (18.5%) 1/82 (1%) 1/65 (1.5%) 1/63 (1.5%) 1/35 (3%)
 Range 1-559 1-6 1-5 1-2 1-212
CEC Median 12 18 125 39 22
 Range 1-696 1-505 1-635 1-1243 3-359
 +/-SD 85 68 133 170 71
At baseline, CTC level was not correlated with CEC level, neither 
with TNBC nor pCR. A drop in CTC incidence was observed from 
baseline to the 1st follow-up analysis after 4 cycles (p<0.0001). Out 
of 6 pts with detectable CTC at the end of adjuvant bevacizumab (8 
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months post surgery) none had pCR (p=0.05 Yates test). There was 
a significant increase of CEC from baseline to presurgery sample (p 
<0.001) and a decrease (p=0.04) after tumor removal and end of CT. 
A higher level of CEC (>20/4ml) before C5 could be associated with 
a higher probability of pCR (Khi2 test, p=0.003). Conclusions: We 
observed a high CTC detection rate of 40% in HER2- IBC, including 
TNBC. CEC levels increased progressively during neoadjuvant 
treatment and decreased after its interruption. Baseline CTC and CEC 
levels were not predictive of pCR. Detection of CTC at 8 months of 
follow-up was associated with the absence of response to neoadjuvant 
chemotherapy.
P1-14-03
AVALUZ Study: First Line with Bevacizumab in Combination 
with Paclitaxel (P) and Gemcitabine (G) in Patients with HER-2 
Negative Recurrent or Metastatic BC: PFS Analysis.
Salvador J, Ciruelos E, Codes de Villena M, Jaen A, Gil M, Galan 
A, Murias A, Jara C, de la Haba J, Baena JM, Villanueva MJ, Bayo 
J, Blancas I, Gonzalez E, Perez D, Mel JR, Manso L. Hospital U. 
de Valme, Sevilla, Spain; Hospital 12 de Octubre, Madrid, Spain; 
Hospital Virgen Macarena, Sevilla, Spain; Hospital de Jaen, Jaen, 
Spain; ICO, Bellvitge, Spain; Hospital de Sagunto, Sagunto, Spain; 
Hospital Insular de Gran Canaria, Gran Canaria, Spain; Fundacion 
Hospital de Alcorcon, Alcorcon, Spain; Hospital Reina Sofia, 
Cordoba, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital 
Meixoeiro, Vigo, Spain; Hospital Juan Ramón Jimenez, Huelva, 
Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las 
Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain; 
Hospital Lucus Augusti, Lugo, Spain
Background
The combination of bevacizumab (B) with taxanes, capecitabine 
or anthracyclines has shown increased PFS in pts with mBC. The 
combination with G and P has been evaluated and has demonstrated 
high response rate and good toxicity profile. The aim of this study is 
to evaluate the efficacy and toxicity profile of the combination of B 
with G and P, providing an update of PFS and the toxicity experienced 
in all patients treated.
Methods
A phase II multicenter, national, open-label study in pts diagnosed 
of recurrent or metastatic HER-2 negative BC, treated with first line 
B 10 mg/kg, P 150 mg/m2 and G 2000 mg/m2 day 1 and 15 c/28 d 
until progression disease, unacceptable toxicity or medical decision. 
This abstract evaluates efficacy by PFS as primary endpoint and as 
secondary endpoints: response rate and toxicity profile (NCI CTC 
v3.0 criteria).
Results
From January 2009 to December 2009, 82 evaluable patients were 
recruited in 23 sites. The characteristic of the all of patients included 
(90) are: median age 51.5 (26-81), ER + 68%, PR + 59%, triple 
negative pts 19%, previous chemotherapy (neoadj or adj) 64.4% 
and > 3 metastatic sites 21% of patients (19). The median cycles 
administered per pts was 7 (1-26) and the relative median dose 
intensity was 0.93 for B, 0.89 for P and 0.91 for G.
Of the 75 patients with response assessment, the overall response rate 
obtained was 72% with a clinical benefit of 89.3% (80.6-95.28%) (CR 
14.7% (11), PR 57.3% (43), SD 17.3% and PD 10.7%). Of the 82 
patients with a median follow up of 16.5 m (0.16- 26.38), preliminary 
median PFS (43% events) for these pts was 11.48 m (8.98-15.72), 
the median duration of first response (MDR) was 12.4 m (7.47-NA) 
and the median OS was 21.35 m (20.72- NA). The one year OS % 
was 84.15% (74.27 – 90.47).
Toxicity was generally manageable. Related AEs have been reported 
in 67/82 patients which were mostly mild or moderate. Safety analysis 
revealed 24 SAEs in 21 patients.
Conclusions
Bevacizumab in combination with paclitaxel and gemcitabine showed 
significant PFS compared with the published data with paclitaxel and 
gemcitabine and high clinical benefit with manageable safety profile.
P1-14-04
Prolonged (≥1 Year) Exposure to First-Line Bevacizumab 
Combined with Paclitaxel in Patients with HER2-Negative 
Metastatic Breast Cancer Treated in a Routine Oncology Practice 
Study.
Kuemmel S, Schneeweiss A, Foerster FG, Geberth M, Tesch H, 
Klare P, Schumacher C, Hollburg W, Soeling U, Schmidt M. Kliniken 
Essen-Mitte, Essen, Germany; National Center for Tumor Diseases, 
Heidelberg, Germany; University of Applied Sciences Zwickau, 
Zwickau, Germany; SPGO-Mannheim, Mannheim, Germany; 
Oncological Practice Bethanien, Frankfurt, Germany; Oncology 
Practice Krebsheilkunde für Frauen, Berlin, Germany; St. Elisabeth-
Hospital, Köln, Germany; HOPA (Hämatologisch-Onkologische 
Praxis Altona) im Struenseehaus, Hamburg, Germany; Practice, 
Kassel, Germany; University Hospital Mainz, Mainz, Germany
Background: First-line bevacizumab (BEV) combined with weekly 
paclitaxel (PAC) significantly improves progression-free survival 
(PFS) and response rate (RR) vs PAC alone in HER2-negative 
metastatic breast cancer (mBC), as shown in E2100. The benefit 
of BEV combined with other chemotherapy (CT) agents was 
demonstrated in AVADO and RIBBON-1. BEV was continued for 
≥1 year in 21% of patients in the global ATHENA safety study and 
in 42% of patients in the JO19901 single-arm Japanese study of 
BEV–PAC. We analyzed data from the subgroup of patients treated 
for ≥1 year in a German routine oncology practice study to provide 
insight into the safety and efficacy of prolonged first-line BEV–PAC.
Methods: Patients who had received no prior CT for their mBC 
received BEV–PAC per the European label. Efficacy and safety 
were documented for up to 1 year (or until progression, death, or 
BEV discontinuation if earlier) with additional long-term follow-up. 
Data from patients treated with BEV for ≥1 year were extracted for 
this analysis.
Results: By Jan 2011, data were available for 818 patients, of 
whom 157 (19%) had already received BEV for ≥1 year. Baseline 
characteristics of this subset relative to the overall population are 
summarized in the table.
Characteristic Overall population (n=818)
Subgroup treated with BEV  
for ≥1 year (n=157)
Median age, years (range) 58 (26–87) 56 (28–79)
Age ≥65 years, % 32 29
Metastatic at diagnosis, % 19 15
Disease-free interval <12 months, % 24* 14†
≥3 metastatic sites, % 33 29
Triple-negative disease, % 19 13
Prior endocrine therapy for mBC, % 22 26
Prior (neo)adjuvant chemotherapy, % 65 62
*n=556. †n=109
In 79% of those treated for ≥1 year, BEV was continued as a single 
agent after discontinuation of CT. The overall RR in patients treated 
for ≥1 year was 81% (complete response in 20%). Median PFS was 
17.9 months (events in 44% of patients) vs 9.4 months in the overall 
population (events in 68%). Overall survival data are immature, as 
81% of those treated for ≥1 year are still alive. The most common 
grade 3/4 adverse events in patients treated with BEV for ≥1 year 
were hypertension (11% of patients), pain (10%), and leukopenia 
(7%). There were no cases of gastrointestinal perforation, arterial 
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thromboembolic event, or reversible posterior leukoencephalopathy 
syndrome in those treated for ≥1 year. Analysis of adverse events 
according to time of onset is ongoing.
Conclusions: A notable proportion of patients appear to derive benefit 
from prolonged exposure to first-line BEV-containing therapy. In the 
present analysis, baseline characteristics appeared more favorable in 
the subset of patients treated for ≥1 year than in the overall population. 
Efficacy data clearly have a bias towards improved outcome in those 
able to continue BEV for ≥1 year, as these patients had sustained 
disease control for ≥1 year. However, the efficacy of prolonged 
BEV-containing therapy is of interest and suggests that some patients 
achieve sustained disease control with continued first-line BEV–PAC 
with limited side effects.
P1-14-05
Surgical Complications from the GeparQuinto Trial of Patients 
Receiving Preoperative Bevacizumab.
Eidtmann H, Kittel K, Rezai M, Tesch H, Ulmer HU, Stirnberg S, Belau 
A, Mau C, Stickeler E, Schrader I, Fasching P, Salat CT, Abdallah 
A, Holms F, Schwedler K, Nekljudova V, Loibl S, von Minckwitz G. 
Universitätsklinikum, Kiel; Praxisklinik, Berlin; Luisenkrankenhaus, 
Düsseldorf; Onkologische Gemeinschaftspraxis am Bethanien-
Krankenhaus, Frankfurt; Städtisches Klinikum, Karlsruhe; 
Frauenklinik, Rheinfelden; Universitätsklinikum, Greifswald; Helios 
Klinikum Berlin Buch, Berlin; Universitätsklinikum, Freiburg; 
Henrietten Stiftung, Hannover; Universitätsklinikum, Erlangen; 
Hämatologisch-Onkologische Schwerpunktpraxis, München; 
Evangelisches Krankenhaus, Gelsenkirchen; St. Barbara-Klinik, 
Heessen; Universitätsklinikum, Frankfurt; German Breast Group, 
Neu-Isenburg
Background: Bevacizumab has been reported to increase the risk 
of surgical complications, especially in pts treated with neoadjuvant 
chemotherapy.
Methods: In January 2010 it was decided to collect surgical 
complications prospectively on a specifically developed from. All 
patients received chemotherapy with epirubicin/cyclophosphamide 
(EC) followed by docetaxel (T) with or w/o bevacizumab. Patients 
not responding to the first 4 cycles of EC+/-B were enrolled in another 
setting. All patients receiving bevacizumab were supposed to be 
operated at 5 weeks after the last infusion of bevacizumab.
Results: Data from 699 patients have been prospectively collected, 
329 received EC-T and 370 ECB-TB. Median age was 48 years in 
both arms. Median tumor size was 30mm in the ET-C arm vs 35mm 
in the ECB-TB arm (p=0.13). Multifocal or multicentric disease 
was present in 21% in the EC-T arm vs 22.4% (p=0.74). 36% of the 
patients received a sentinel node biopsy prior to start of neoadjuvant 
chemotherapy in both groups. 68.7% of patients received breast 
conserving therapy in the EC-T arm compared to 71.1% in the ECB-
TB arm (p=0.54). The rate of pathological complete response was 
19.5% with EC-T compared to 23.2% with ECB-TB (p=0.26). The 
median time from last CHT+/- bevacizumab to surgery was 29 days in 
EC-T and 34 days in ECB-TB. Bleeding or hematoma were reported in 
6.7% of the patients treated by EC-T and 7.1% with ECB-TB (p=0.88). 
Wound infections or abscess were reported in 2.5% with EC-T and 
3.9% with ECB-TB (p=0.39). Delayed wound healing was reported 
in 3.4% with EC-T and 6.3% with ECB-TB (p=0.11). Necrosis was 
reported in 1.9% with EC-T and 2.5% with ECB-TB (p=0.80). Any 
complication was reported in 11% with EC-T compared to 15.3% 
with ECB-TB (p=0.12).
Conclusion: In general the rate of surgical complications was low. 
Patients treated with bevacizumab had a numerical increase of surgical 
complications. However, none of the differences were statistically 
significant. The intervals from last infusion to surgery as defined by 
the study protocol appear to be safe.
P1-15-01
Oral Fluoropyrimidine (UFT and S-1) May Augment the Efficacy 
of Aromatase Inhibitor Via the Down-Regulation of Estrogen 
Receptor in Estrogen-Responsive Breast Cancer Xenografts.
Nukatsuka M, Saito H, Nakagawa F, Abe M, Uchida J, Shibata J, 
Matsuo K-I, Noguchi S, Kiniwa M. Taiho Pharmaceutical Co., Ltd., 
Tokushima-shi, Tokushima, Japan; Taiho Pharmaceutical Co., Ltd., 
Tsukuba-shi, Ibaragi, Japan; Osaka University Medical School, 
Osaka, Japan
Breast cancer patients has tended to be more personalized by 
biomarkers, such as estrogen receptor (ER), HER-2 and other 
risk factors. Adjuvant endocrine therapy is recommended for all 
ER-positive breast cancer patients, and the addition of adjuvant 
chemotherapy to endocrine therapy has been shown to further improve 
the prognosis of ER-positive breast cancer patients. Addition of an 
oral fluoropyrimidine, UFT was shown to improve the outcome of 
patients with luminal A cancer. Based on these studies, the present 
preclinical study was designed to evaluate a new combination therapy 
comprised of the aromatase inhibitor anastrozole (ANA) and the oral 
fluoropyrimidines, UFT and S-1 against luminal A human breast 
cancer cell line MCF-7/Arom 14, which was stably transfected with 
the cDNA of human aromatase. MCF-7/Arom 14 cells showed a 
high aromatase activity (111.6±69.6 fmole/mg protrin/hr) in vivo. 
Testosterone failed to induce cell growth of parent MCF-7. But, 
MCF-7/Arom 14 cells were potentiated by both testosterone and E2 
in vitro, and ANA and 5-fluorouracil (5-FU) inhibited cell growth 
at concentrations of 0.005 to 10 and 0.2 to 5 mM, respectively. The 
combination of 5-FU and ANA additively inhibited cell growth. 
MCF-7/Arom 14 was implantable in vivo, but it failed to grow in 
he absence of E2 or testosterone releasing pellet (Tes-P). The growth 
of MCF-7/Arom 14 was significantly inhibited by ANA and S-1 or 
UFT alone vs Control (Tes-P alone) in vivo. The combination of 
ANA with S-1 or UFT administered using a 21-day consecutive, 
metronomic-like regimen. On day 22, relative tumor volume (RTV) 
treated by ANA and UFT or ANA and S-1 was significantly lower 
than either mono-therapy by Welch’s t-test. Based on RTV change 
the period required for the RTV to reach 3 was estimated, and its 
differences between control was designated as growth delay period 
(GDP). GDP of combination-therapy was 2 to 4 times longer than 
either mono-therapy.
Antitumor activity against MCF-7/Arom 14
Group Dose (mg/kg) RTV on day 22(mean±SD) GDP (days)
Tes-P free - 1.43±0.39 NE
Control - 6.11±0.85 0
ANA alone 3 4.59±0.49 2.4
UFT alone 20 4.71±0.67 3.0
UFT+ANA 20+3 3.83±0.53** 4.3
S-1 alone 10 3.90±0.62 5.5
S-1+ANA 10+3 3.24±0.50* 9.5
*, ** p<0.05 and 0.01, respectively (intersection-union test). n=10. 
To investigate the mechanisms by which fluoropyrimidines enhance 
the antitumor activity of ANA, the protein and mRNA expression 
levels of ER-a in tumor tissue after treatment with S-1, ANA, 
and the typical chemotherapeutic agents doxorubicin (ADM) or 
paclitaxel (TXL) were analyzed by immuno-histostain and RT-
PCR, respectively. The protein and mRNA expression of ER-a 
were markedly decreased by S-1 or S-1+ANA, but not for ADM or 
TXL. The reduced ER-a level might increase antitumor activity of 
ANA in addition to the decreased estrogen production. As activity 
of dihydropyrimidine dehydrogenase (DPD) in breast cancer is 
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higher, UFT or S-1 which is resistant against DPD would be suitable 
compared other 5-FU derivatives. Therefore, the combination of ANA 
and S-1 might yield a greater benefit than other chemotherapeutic 
agents in postmenopausal women with Luminal A breast cancer.
P1-15-02
Nanoparticles Overcome the Decreased Responsiveness of Breast 
Cancer Cells to a Chemotherapeutic Drug in the Presence of 
Adipocytes.
DeAngel RE, Sandoval MA, Lansakara-P DSS, Dunlap SM, Hursting 
SD, Cui Z. The University of Texas at Austin, Austin, TX; UT-MD 
Anderson Cancer Center, Smithville, TX
Background
Excess adipose tissue plays a role in increasing breast cancer risk 
and tumor aggressiveness. However, the role of mature adipocytes 
in tumor progression and response to therapy remains unclear. 
Despite advances in breast cancer treatment, obese patients still 
show decreased response to chemotherapy. The incorporation of 
nanoparticles (NPs) in breast cancer therapeutics represents a novel 
approach for improving therapy efficacy. NPs increase the drug 
accumulation in the tumor site resulting in increased drug disposition, 
decreased cytotoxicity and decreased adverse side effects. However, 
few studies have evaluated the response to chemotherapy-loaded-NPs 
in the context of obesity. Gemcitabine is a widely used nucleoside 
analog that inhibits DNA synthesis. Previously, we prepared a novel 
gemcitabine formulation by incorporating 4-(N)-stearoyl gemcitabine 
in solid-lipid NPs (Gem-NPs). We hypothesized that the enhancement 
of tumor growth and decreased response to therapy in the presence 
of adipocytes can be offset by treatment with Gem-NPs. To test this 
we used an in vitro model of adipocyte-conditioned media (CM) and 
investigated the effects of mature adipocytes on breast cancer cells.
Methods
Murine 3T3-L1 adipocytes were induced to differentiate; adipocyte-
CM from these cells was collected, centrifuged and used for most 
assays. Murine (M-Wnt, E-Wnt) and human (MCF-7) cancer cells 
were grown in RPMI and DMEM, respectively, supplemented with 
10% FBS and 1% penicillin/streptomycin at 37 C with 5% CO2. 
Once the cells were confluent, cells were split and then cultured 
in the presence of adipocyte-CM (1 or 10%). After gemcitabine 
and Gem-NPs (50 mM) treatment for 48 h, cell proliferation was 
measured using the commercial Calcein AM, Annexin V was used 
to assess apoptosis, and PI staining was used for cell cycle analysis. 
Invasiveness capacity was measured by culture in a Transwell system 
with a matrigel invasion assay. CM from undifferentiated 3T3-L1 
adipocytes (fibroblasts-CM) were used as a negative control.
Results
After 48 h of culture with CM, all cells (M-Wnt, E-Wnt, and MCF-
7) showed increased proliferation (p <0.05) and the invasiveness 
capacity was increased in the presence of adipocyte-CM after 20 h 
in culture. Cells cultured with adipocyte–CM were less responsive 
to treatment with gemcitabine (p < 0.01) relative to cells cultured 
with fibroblasts-CM. The apoptotic response to gemcitabine was 
decreased, and s-phase arrest was not observed in the presence of 
adipocyte-CM. However, treatment with Gem-NP overcame the 
decrease in gemcitabine responsiveness caused by adipocyte-CM, 
restoring apoptotic response and S-phase arrest.
Conclusion
Our results strongly support the role of mature adipocytes in 
promoting tumor growth and invasiveness while decreasing the 
response to a standard chemotherapy. Our findings also suggest that 
incorporating a chemotherapeutic drug into NPs can potentially 
decrease chemotherapy resistance, particularly in obese patients. 
Animal studies are underway to evaluate this response in an in vivo 
mouse model of obesity.
P1-15-03
Multistage Vectored Nanotherapeutics for Breast Cancer 
Metastasis.
Shen H. The Methodist Hospital Research Institute, Houston, TX
Significant progresses have been made on overall survival rates 
in breast cancer. The five-year survival rate of women diagnosed 
with Stage I-III breast cancer has been steadily improving decades 
over decades. These improvements in survival have primarily been 
attributed to availability of modern diagnostic tools that allow for 
early detection, and the increased use of adjuvant systemic therapies. 
However, the situation with breast cancer metastasis is discouraging, 
with only marginal improvement in some reports to no improvement 
at all in other studies in survival of the relapsed metastatic patients. 
More breast cancer patients are killed by cancer metastasis than by 
the primary cancer.
Nanotechnology has played an important role in the fight against 
breast cancer in the last decade. The first nano-liposomal formulation 
of doxorubicin (Dox), Doxil, was FDA approved in 1994, and is 
currently used to treat multiple cancer types including recurrent and 
refractory breast cancers. More nano-formulated drugs have since 
been approved. These nanotherapeutics work based on the enhanced 
permeability and retention (EPR) effect, and still cause severe 
toxicity to the body, however. To overcome these defects of the first 
generation of nanotherapeutics, we have developed a silicon-based 
multistage vector (MSV) system with the aim to specifically delivery 
drugs to cancer tissues with the least toxicity to the normal organs. 
These are particle-in-particle “Russian Doll” systems with each stage 
designed to provide transport across a set of sequential biological 
barriers, and provide associated levels of targeting specificity. We 
have demonstrated highly reproducible therapeutic efficacy with 
this system to deliver the conventional chemotherapy drugs and 
siRNA oligos.
We have generated mouse lung metastasis models with the human 
breast cancer cell line MDA-MB-231 which was engineered with a 
luciferase gene, and used multiple doxorubicin formulations to treat 
the tumor mice. These included free doxorubicin (3 mg/kg weekly), 
Doxil (6 mg/kg biweekly), a new formulation of doxorubicin in 
micelles (miDox, 6 mg/kg biweekly), and miDox in MSV (MSV/
Dox, 6 mg/kg biweekly). Tumor growth in the lung was monitored 
by bioluminescence with a Xenogen IVIS200 optical in vivo imaging 
system. As expected, treatment with free Dox caused significant 
weight loss indicating drug toxicity, most likely to the heart. Tumor 
growth in the free Dox treatment group halted initially, but resumed 
two weeks later. The tumor cells in these animals might have 
developed resistance to Dox during the treatment. Doxil treatment 
also triggered weight loss initially. This correlates with the cardiac 
side effect of the drug observed in clinic. Neither miDox or MSV/
Dox caused weight loss. Tumor growth was also inhibited in mice 
treated with both formulations. The result was much more significant 
with MSV/Dox than with miDox. No tumor cells were observed in 
the lung after a 6-week treatment with MSV/Dox, while 40% of the 
miDox-treated mice still had residue, but detectable tumor cells in 
the lung. These results indicate that we have developed a powerful 
system for tumor-specific delivery of therapeutic in the treatment of 
breast cancer metastasis.
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P1-16-01
A Randomized, Double-Blinded, Controlled Study of Exemestane 
vs. Anastrozole for the First-Line Treatment of Postmenopausal 
Japanese Women with Hormone Receptor Positive Advanced 
Breast Cancer.
Masuda N, Iwata H, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, 
Nishizawa Y, Saeki T, Noguchi S. NHO Osaka National Hospital, 
Osaka, Japan; Aichi Cancer Center Hospital, Aichi, Japan; Kyushu 
Cancer Center, Fukuoka, Japan; Sagara Hospital, Kagoshima, 
Japan; Nagoya Medical Center, Aichi, Japan; Shikoku Cancer Center, 
Ehime, Japan; Pfizer Japan Inc, Japan; Saitama Medical University 
International Medical Center, Saitama, Japan; Osaka University, 
Osaka, Japan
Background
The steroidal irreversible aromatase inhibitor (AI) exemestane (E), 
the non-steroidal reversible AI anastrozole (A) and tamoxifen (T) 
are approved for the first-line treatment of the postmenopausal 
women with hormone receptor (HR) positive advanced breast cancer 
(ABC) in Japan. Although there are some studies which compare the 
efficacy and safety of AIs and T in the first-line disease setting, the 
number of studies that compare efficacy and safety of AIs is limited. 
We conducted this multicenter, randomized, double-blinded non-
inferiority study, to evaluate the time to progression (TTP) in HR 
positive ABC randomized to therapy with E or A.
Methods
Patients (pts) who were ≥20 years [yrs], postmenopausal, ECOG 
PS ≤1 and had HR positive ABC that recurred after the adjuvant 
therapy or metastatic disease settings were eligible and randomized 
(1:1) to 25 mg/day of E or to 1 mg/day of A. Data were evaluated 
for non-inferiority of E compared to A defined as the upper limit of 
a two-sided 95% confidence interval (CI) of the hazard ratio (HR) of 
TTP being less than or equal to 1.25. The primary endpoint was TTP 
assessed by the independent radiological images review committee 
(RIRC). Secondary endpoints included TTP by investigator, time 
to treatment failure, overall survival (OS), objective response rate 
(ORR), clinical benefit rate, and safety.
Results 
A total of 298 pts from 58 sites were randomized to E (n=149; mean 
age: 63.4 yrs) or A (n=149; mean age: 64.0 yrs). The mean BMI 
for the E and A arms were 23.0 kg/m2 and 23.6 kg/m2, respectively. 
Six pts (2 pts in E arm, 4 pts in A arm) were excluded from the full 
analysis set due to lack of evaluation for anti-tumor response after 
study medication started.
Median TTP (as per RIRC) was 13.8 months (M) vs. 11.1 M for E 
vs. A, respectively (HR 1.007; 95% CI: 0.771–1.317). Median TTP 
(Investigator) was 13.8 M vs. 13.7 M for E vs. A, respectively (HR 
1.059; 95% CI: 0.816–1.374). The median OS for A treated pts was 
60.1 M, OS for E was not reached (as of data cut-off: December 8, 
2010). ORR for E was 43.9% (95% CI: 35.3–52.8) and 39.1% (95% 
CI: 30.6–48.1) for A. Other analyses, including sub-population 
analyses are ongoing.
The incidence of treatment related adverse events (AEs) in E arm 
was 71.1% (n=106) and in A arm 59.7% (n=89); the AEs were mostly 
grade 1 and 2 in 61.7% (n=92) and 53.7% (n=80) of pts respectively. 
They were expected and manageable. Treatment related SAEs were 
similar in both groups: 6 (4.0%) in E arm and 5 (3.4%) in A arm. 
The most common AEs for E were hot flushes (22.1%), arthralgias 
(16.8%), musculoskeletal stiffness (11.4%) and g-GTP increased 
(10.1%); in A arm, hot flushes (14.8%) and arthralgia (16.8%) were 
observed in >10% pts.
Conclusions
Although median TTP (RIRC) of E is slightly improved compared 
with that of A, the result of TTP did not meet the non-inferiority 
criteria. There were no significant differences found between E and 
A in ORR. Although AEs in E were numerically higher, the observed 
AE profiles were similar to those previously reported for E and A. 
This study shows that E is comparable to A in efficacy and safety.
P1-17-01
Figitumumab Plus Exemestane Versus Exemestane as First-
Line Treatment of Postmenopausal Hormone Receptor-Positive 
Advanced Breast Cancer: A Randomized, Open-Label Phase II 
Trial.
Ryan PD, Neven P, Blackwell KL, Dirix LY, Barrios CH, Miller, Jr 
WH, Fein LE, Fenton D, Benner RJ, Meech SJ, Paccagnella L, Sleight 
B, Yee D, Goss PE. Fox Chase Cancer Center, Philadelphia, PA; 
Universitair Ziekenhuis Leuven, Leuven, Belgium; Duke University 
Medical Centre, Durham, NC; Sint-Augustinus, Oncologisch 
Centrum, Antwerp, Belgium; PUCRS School of Medicine, Porto 
Alegre, Brazil; Lady Davis Institute for Medical Research, Jewish 
General Hospital, Segal Cancer Center, McGill University, Montreal, 
Canada; Centro Oncológico Rosario, Santa Fé, Argentina; Cross 
Cancer Institute, Edmonton, Canada; Pfizer Inc., Groton, CT; 
Universiy of Minnesota, Minneapolis, MN; Massachusetts General 
Hospital Cancer Center, Boston, MA
Background
Figitumumab (CP-751,871) is a fully human IgG2 monoclonal 
antibody that inhibits IGF-1R. Exemestane profoundly reduces 
estrogen production and has activity as first-line treatment in 
postmenopausal metastatic hormone receptor-positive (HR+) breast 
cancer (BC). Preclinical studies suggest cross-talk between the IGF-
1R and estrogen receptor pathways. Combining agents that inhibit 
these pathways could benefit women with advanced BC.
Methods
This was an open-label, multicenter, randomized, phase II trial of first-
line figitumumab + exemestane (Arm A) vs. exemestane alone (Arm 
B) in HR+ postmenopausal advanced BC. Eligibility included: age 
>18 yrs with Stage IIIB or IV disease; baseline ECOG PS ≤2. A high 
rate of grade [G] 3 and 4 hyperglycemia after figitumumab treatment 
prompted a protocol amendment in February 2010 requiring patients 
(pts) to have a baseline HbA1c <5.7%. Patients received exemestane 
25 mg po daily ± intravenous figitumumab 20 mg/kg every 21 days. 
The primary endpoint was progression-free survival (PFS) in pts 
with baseline HbA1c <5.7%. Secondary endpoints included clinical 
benefit rate (CBR) and safety.
Results 
Between 2007 and February 2011, 103 pts were randomized to Arm 
A and 102 to Arm B. Of these, 37 pts in Arm A and 40 pts in Arm B 
had baseline HbA1c <5.7%. These data are from an unplanned interim 
analysis which preceded premature study termination by the Sponsor 
for clinical development reasons and to expedite availability of data 
collected to date. Baseline demographics were balanced between 
arms. PFS, CBR and safety are summarized in Table 1.
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res; 71(24 Suppl.) December 15, 2011 Cancer Research240s
Table 1
 Arm A Arm B Arm A Arm B
 HbA1c <5.7% HbA1c <5.7% Overall Overall
 n=37 n=40 n=103 n=102
Median PFS, months 13.3 9.1 10.9 9.1
(Events) (18) (28) (66) (78)
 HR 0.603; 95%CI 0.332, 1.096 HR 0.867; 95%CI 0.624, 1.205
 *P=0.092 *P=0.394
CBR†, % [95% Exact CI] 65 [47.5, 79.8] 58 [40.9, 73.0] 64 [54.0, 73.3] 62 [51.6, 71.2]
 n=37 n=40 n=112‡ n=103‡
G3/4/5 AEs (all causality), % 24/0/0 25/3/3 33/7/4 20/2/3
*2-sided P-value from an unstratified log-rank test; †Complete responses + partial responses + 
[stable disease >6 months]; ‡Safety population includes the first 10 pts enrolled who were assigned 
to study drug, in error, without randomization
The majority of AEs were G1/2. In the Arm A overall population, 
the most common G3/4 events (in decreasing frequency) were 
hyperglycemia, diabetes mellitus, weight loss, isolated GGT elevation 
and fatigue. Hyperglycemia was uncommon in Arm B and in all pts 
with HbA1c <5.7%.[Table 2].
Table 2
Hyperglycemia, % G1–2 G3 G4
Arm A (n=112) 24 10 2
Arm A HbA1c <5.7% (n=37) 22 3 0
Arm B (n=103) 2 1 0
Arm B HbA1c <5.7% (n=40) 6 3 0
Conclusions
The addition of figitumumab to exemestane was tolerable but overall 
did not improve PFS compared with exemestane alone in pts eligible 
for this trial. However, a trend toward benefit with figitumumab 
combined with exemestane in pts without evidence of baseline 
metabolic syndrome (HbA1c <5.7%) was observed together with 
improved tolerability; further study with this combination may be 
warranted.
P1-17-02
A Phase 1/2 Study of SAR245408 (S08) in Combination with 
Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ 
Metastatic Breast Cancer (MBC) Who Progressed on a Previous 
T-Based Regimen.
Tolaney S, Burris H, Gartner E, Mayer I, Saura C, Maurer M, DeCillis 
A, Ruiz-Soto R, Lager J, Winer E, Krop I. Dana Farber Cancer 
Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; 
Wayne State University/Karmanos Cancer Institute Hematology/
Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, 
TN; Vall d’Hebron University Hospital, Barcelona, Spain; Columbia 
University Medical Center, New York, NY; Exelixis, San Francisco, 
CA; Sanofi, Cambridge, MA
BACKGROUND: Most HER2+ MBC patients (pts) treated with a 
combination of T+P progress within 1 year. Activation of downstream 
pathways through either deficiency in PTEN or mutations in the PI3K 
pathway has been implicated in the development of resistance to T. 
S08 is a potent, orally bioavailable, pan-PI3K inhibitor that inhibits 
phosphorylation of multiple downstream components of the PI3K/
PTEN signaling pathway and has demonstrated activity as a single 
agent and in combination with other anticancer agents (Edelman G, 
et al., ASCO 2010; Traynor AM, et al. ASCO 2010).
PATIENTS and METHODS: This ongoing, open-label multicenter 
phase 1/2 study (NCT01042925) was designed to assess safety and 
tolerability of S08 in combination with either T or T+P. Eligible 
female pts were ≥18 yrs, ECOG PS 0-2, with adequate organ and 
marrow function and had advanced or recurrent HER2+ MBC disease 
refractory to T. Pts have received, and progressed on at least 1 prior 
T-containing regimen for metastatic disease. Pts were allocated to Arm 
1 or Arm 2 and received different dose levels of S08 (starting dose 
200 mg PO, daily) in combination with either T 8/6 mg/kg IV on Day 
(D) 1 q3w (Arm 1) or T 8/6 mg/kg IV on D1 + P 80 mg/m2 on D 1, 
8, and 15 q3w (Arm 2). In phase 1, a standard ascending 3 + 3 dose 
escalation design was used in each arm to evaluate safety/tolerability 
of the combinations. Following establishment of preliminary maximal 
tolerated doses (MTDs) for each combination, subsequent pts will be 
accrued to the phase 2 portion. Approximately 25 additional pts will 
be enrolled in each arm to further evaluate the safety and estimate 
the overall response rate (ORR) in each arm.
RESULTS: As of June 1st 2011, 33 pts median age 55 yrs were 
enrolled; 18 to Arm 1 and 15 to Arm 2. Based on preliminary data of 
the study, in Arm 1, the most common treatment emergent adverse 
events (TEAEs) regardless of relationship include rash, diarrhea, 
fatigue, nausea, vomiting; in Arm 2 were neutropenia, diarrhea, 
fatigue, nausea, hyporexia, hypokalemia, peripheral neuropathy, rash 
and hyperglycemia. SAEs reported in Arm 1 (3 subjects) included Gr3 
dehydration (2 cases), Gr3 epigastric pain and Gr2 dyspnea; those 
SAEs in Arm 2 (4 subjects) included Gr4 neutropenia, Gr3 anorexia, 
Gr3 dehydration, Gr3 epigastric pain, Gr3 thromboembolism, Gr2 
nausea, Gr2 pneumonitis and Gr2 headache. A total of 4 DLTs were 
reported; 2 in Arm 1 [Gr3 skin rash (S08; 400 mg dose)] and 2 in 
Arm 2 [Gr4 neutropenia (S08; 200mg dose)] (table 1). With phase I 
nearly complete, the MTD for arm 1 is S08 300 mg PO daily and T 
8/6 mg/kg D1 q3w. The data for Arm 2 (current dose level ongoing 
at the maximum allowed per protocol) will be completed in August 
2011. Preliminary PK data did not show interactions between S08 
and either T or T+P.
Dose Escalation
Arm # Patients enrolled (n) SAR245408 dose level, mg qd DLT
1 - T 6 200 -
 6 300 -
 6 400 2 Gr 3 skin rash
2 - T + P 9 200 2 Gr 4 neutropenia
 3 300 -
 3 400 -
DISCUSSION: S08 can be combined with either T or with T+P. 
Additional safety, PK and efficacy data will be presented from phase 1.
P1-17-03
Withdrawn by Author
P1-17-04
Phase I Study of PARP Inhibitor ABT-888 (Veliparib) in 
Combination with Cisplatin and Vinorelbine for Patients with 
Advanced Triple Negative Breast Cancer and/or BRCA-Mutation 
Associated Breast Cancer.
Rodler ET, Specht JM, Gadi VK, Kurland BF, Griffin MJ, Hammond 
JJ, Gralow JR. University of Washington/Seattle Cancer Care 
Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, 
Seattle, WA
Background: Inhibitors of poly(ADP-ribose) polymerase (PARP) 
have shown preclinical and clinical activity in targeting tumors with 
pre-existing DNA repair defects, in particular BRCA1 and BRCA2 
deficient tumors. Cisplatin (CP) has demonstrated synergy with ABT-
888 (veliparib) in breast cancer xenograft models and has anti-tumor 
activity in triple negative (TN) and BRCA-1 deficient breast cancer. 
Vinorelbine (V) combined with CP has shown safety and efficacy 
in patients with pretreated metastatic breast cancer. Methods: We 
are conducting a phase I study to determine the maximum tolerated 
dose (MTD), pharmacokinetic (PK) and pharmacodynamic profiles 
(PD), and preliminary anti-tumor activity of veliparib in combination 
with CP and V in patients (pts) with metastatic breast cancer who 
are either TN or who have BRCA1 or BRCA2 mutation associated 
breast cancer. Cohorts receive escalating doses of ABT-888 orally 
BID days 1-14, CP 75 mg/m2 intravenously (IV) day 1 and V 25 
mg/m2 IV days 1,8 every 21 days, in a 3+3 design. Results: As 
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of 6/14/11, 18 eligible female pts have been enrolled. The median 
age at registration was 50 years (range 34-78 years). Sixteen pts 
received at least one prior metastatic regimen (range 0-8). Three pts 
had previously treated brain metastases. BRCA mutation status was 
as follows: BRCA1+ (3 pts); BRCA2+ (2 pts); confirmed mutation 
negative (8 pts); unknown (5 pts). Four pts received the 20 mg BID 
veliparib dose (one patient in the cohort died of progressive disease 
early in cycle 1 and was replaced), 3 received 30 mg BID, 6 received 
40 mg BID, and 5 have been enrolled at dose level 4 (60 mg BID). 
Dose limiting toxicities occurred in one patient at the 40 mg BID 
dose (grade 4 thrombocytopenia), and one patient at the 60 mg BID 
dose (grade 3 neutropenic fever). Adverse events are typical for a 
platinum-based chemotherapy regimen and include nausea, fatigue, 
thrombocytopenia, and neutropenia. MTD has not been reached. 
Of 11 pts evaluable for radiographic response to date, 6 (55%) had 
a PR (3 of whom have a BRCA mutation) and 5 (45%) had stable 
disease. Correlative studies will use immunohistochemistry and 
gene expression array to evaluate the profile of TN breast cancer 
and predictors of response to treatment. Conclusion: Veliparib in 
combination with CP and V has been generally well tolerated to date. 
Objective anti-tumor activity was seen in BRCA mutation carriers and 
in pts with sporadic TN breast cancer. PK, PD, and biomarker analysis 
is underway. Enrollment continues in the dose escalation cohorts.
P1-17-05
Preliminary Results of a Randomized Phase 2 Study of PD 
0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in 
Combination with Letrozole for First-Line Treatment of Patients 
(pts) with Post-Menopausal, ER+, HER2-Negative (HER2–) 
Advanced Breast Cancer.
Finn RS, Crown JP, Boer K, Lang I, Parikh RJ, Patel R, Schmidt M, 
Hagenstad C, Lim H, Pinter T, Amadori D, Chan D, Dichmann RA, 
Walshe J, Breazna A, Kim ST, Randolph S, Slamon DJ. University 
of California at Los Angeles, Los Angeles, CA; Irish Cooperative 
Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, 
Budapest, Hungary; National Institute of Oncology, Budapest, 
Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; 
Comprehensive Blood and Cancer Center, Bakersfield, CA; University 
Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology 
Associates, Lawrenceville, GA; British Columbia Cancer Agency, 
Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, 
Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
Tumori, Meldola, Italy; Cancer Care Associates Medical Group, 
Redondo Beach, CA; Central Coast Medical Oncology Corporation, 
Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, 
New York, NY
Background: PD 0332991 is an orally bioavailable selective inhibitor 
of CDK 4/6 and prevents cellular DNA synthesis by prohibiting 
progression of the cell cycle from G1 into the S phase. Preclinical 
evaluations suggest that reduction in CDKN2A (p16) expression 
and cyclin D1 (CCND1) overexpression confer susceptibility to PD 
0332991 (Finn 2009). In addition, PD 0332991 was synergistic in 
combination with tamoxifen in vitro in ER+ human breast cancer cell 
lines. Based on these observations, a phase 1/2 study in combination 
with letrozole as first-line therapy for advanced ER+ post-menopausal 
breast cancer was initiated. The phase 1 part of the study (completed) 
determined the recommended phase 2 dose to be PD 0332991 125 mg 
QD on Schedule 3/1 (3 weeks on treatment followed by 1-week off 
treatment) in combination with letrozole 2.5 mg QD. The combination 
was generally well tolerated and encouraging antitumor activity was 
observed. We present preliminary data from the randomized Phase 
2 portion comparing letrozole alone to letrozole plus PD 0332991. 
Methods: The Phase 2 portion of the study is designed as a two-part 
study; we present data from Part 1. In both parts, eligible patients 
are randomized 1:1 to letrozole 2.5 mg QD alone (control) or PD 
0332991 125 mg QD on schedule 3/1 and letrozole 2.5 mg QD 
(treatment, tx). Part 1enrolled post-menopausal women with ER+, 
HER2– cancer using only ER+, HER2–as a selection criteria. Part 2 
is now enrolling post-menopausal women with ER+, HER2– breast 
cancer with CCND1 amplification and/or loss of p16 by FISH (target 
N=150). The primary endpoint is progression-free survival (PFS); 
secondary endpoints include overall survival, response rate, safety, 
and correlative studies. Pts are stratified for disease site and length 
from prior adjuvant therapy. Pts continue assigned study treatment 
until disease progression, unacceptable toxicity, or consent withdrawal 
and are followed every 2 months to assess disease status. Tumor 
tissue was required for participation. Results: 66 patients have been 
randomized in Part 1. At the time of data cut-off (April 2011) median 
duration of treatment is 20 (range 4–64) wks for control and 27 (2-59) 
wks for tx. Dose reductions occurred in 9 pts on the tx arm and none 
on the control arm. There are no complete responses. The number of 
partial responses for pts with measurable disease are similar between 
arms (4/22 control vs 5/24 in tx). The number of pts with stable 
disease≥ 24 weeks was higher in the tx arm (5 vs 8). The number of 
pts with best response of progressive disease is lower in the treatment 
arm (2 vs 6). PFS data are immature. Twelve pts remain on control 
vs. 21 on tx. As in the Phase I portion of the study, the most common 
treatment-related AEs were neutropenia and leucopenia without 
febrile neutropenia. Biomarker studies for CCND1 amplification, p16 
loss, RB status, and Ki67 are ongoing. Conclusion: The combination 
of PD 0332991 and letrozole is well tolerated as first-line treatment 
of ER+, HER2– post-menopausal breast cancer. Updated efficacy 
data and biomarker data will be presented.
P1-17-06
A Phase II Trial of the CDK 4/6 Inhibitor PD0332991 in Women 
with Advanced Breast Cancer.
DeMichele A, Clark A, Randolph S, Christensen J, Gallagher M, Lal 
P, Feldman M, Zhang P, Perini R, Velders L, Domchek S, Kaplan-
Tweed C, Gogineni K, Keefe S, Fox K, O’Dwyer P. University of 
Pennsylvania, Philadelphia, PA; Pfizer, New York, NY
Background: Dysregulation of the G1/S checkpoint of the cell cycle is 
a feature of many breast cancers. PD0332991, a potent oral inhibitor 
of cyclin-dependent kinases (CDKs) 4 and 6 is well-tolerated and has 
demonstrated activity in a phase I trial in a variety of solid tumors at 
a phase II dose of 125 mg daily on a 3 week on/1 week off schedule. 
Preclinical data suggest that this agent is most active in ER+ (luminal) 
breast cancers. We are performing a phase II study of PD0332991 in 
women with advanced breast cancer, one of several parallel disease 
cohorts under study.
Methods: Patients with histologically-confirmed stage IV breast cancer 
were eligible if they had primary or metastatic tumor which stained 
positive for retinoblastoma (Rb) protein by immunohistochemistry, 
disease measureable by RECIST criteria and adequate organ function/
performance status. Treatment was initiated with PD0332991 at 
125 mg orally, days 1 – 21 of a 28-day treatment cycle. Tumor 
assessments occurred after every 2 cycles (8-week intervals). The 
primary objective was to determine the safety and response rates in 
cohorts of 15 patients per tumor type; 15 patients per arm provided 
80% power to detect a 15% (1/15) response rate per disease that would 
lead to further cohort expansion. Secondary objectives include PK, 
PD and predictive biomarker assessment.
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Results: 36 patients were screened, 32 (89%) stained positive for 
Rb, and 14 have enrolled on study. The only reported toxicites are 
neutropenia (7 patients, 4 grade 3/4), thrombocytopenia (1 patient, 
grade 1) and fatigue (1 patient, grade 2). 3 patients (23%) have 
had dose interruptions and 5 (38%) have had dose-reduction for 
neutropenia, though no episodes of febrile neutropenia have occurred. 
Among 11 patients assessable for response to date, there is 1(7%) 
partial response (PR), 6 (43%) with stable disease (SD) and 4 (29%) 
with progressive disease (PD). 3 of 6 patients with stable disease 
have received greater than 6 months of therapy, and these sustained 
responses have occurred with dosing as low as 50 mg/day. All PR/
SD have occurred in patients with ER+ tumors; all PD have been in 
patients with triple negative (ER-/PR-/Her2-) disease. The cyclin 
D1 status of all patients are being assessed. Of the 10 ER+ patients, 
3 are cyclin D1 amplified, 5 are non-amplified and 2 are pending 
assessment. 2 in 4 cyclin D1 non-amplified patients had SD, while 
2 of 2 evaluable patients with amplification had SD. PK and PD 
analyses are in progress.
Conclusions: PD 0332991 is an extremely well-tolerated, oral CDK 
4/6 inhibitor that demonstrates prolonged single-agent activity in ER+ 
breast cancer patients who have progressed on hormonal therapy. 
These data have prompted expansion of this breast cancer cohort 
to further delineate activity and translational studies examining 
predictors of response are underway.
P1-17-07
Phase II Trial of RAD001 Plus Carboplatin in Patients with 
Triple-Negative Metastatic Breast Cancer.
Singh JC, Stein S, Volm M, Smith J, Novik Y, Speyer J, Adams S, 
Meyers M, Muggia F, Schneider R, Formenti S, Omene C, Choi 
H, Davis S, Goldberg J, Tiersten A. New York University Hospital 
Center, New York, NY
Background: RAD001 is an oral mTOR inhibitor that has exhibited 
activity in breast cancer. Triple negative breast cancer cells are unable 
to repair double stranded DNA breaks and hence have sensitivity 
to platinum agents that cause interstrand cross-links. Rapamycin 
acts synergistically with platinum agents to induce apoptosis and 
inhibit proliferation in at least two different breast cancer cell lines 
(including ER/PR negative cell lines). We propose that combination 
RAD001 and carboplatin may have activity in triple-negative breast 
cancer. Methods: The primary objective of the study is to determine 
clinical benefit (complete remission (CR) + partial remission (PR) + 
stable disease (SD)) and the toxicity of this combination in women 
with triple negative metastatic breast cancer who have had 0-3 prior 
chemotherapy regimens for metastatic disease. Secondary objectives 
are to determine progression free survival as well as investigating the 
relationship between pretreatment sensitivity (biopsy at baseline) 
and clinical response (biopsy post 2 cycles) using IHC staining 
for abundance of key proteins in the Akt-mTOR pathway and their 
activity using surrogate phosphorylation site-specific antibodies (Akt 
and phospho-serine 473, phospho-threonine and phospho-threonine 
308 Akt; mTOR and phospho-serine 2448 mTOR; ribosome protein 
S6 kinase (S6K) and phospho-threonine 378 S6K; 4E-BP1 and 
phospho-serine 65 4E-BP1). Prior carboplatin is allowed. Women with 
treated brain metastasis are eligible. According to the original study 
plan, carboplatin AUC 6, was to be given intravenously every three 
weeks. Five mg of RAD001 was to be given daily with a 3 patient run-
in and then 10 mg daily if there were no dose-limiting toxicities. Due 
to a unexpected amount of thrombocytopenia with this combination 
the dose of carboplatin was first amended to AUC 5 and most recently 
to AUC 4 with 5 mg of RAD001 (and no plan to escalate to 10 mg). 
Results: Fourteen patients of a planned 25 have been recruited 
thus far. Median age is 58.5. Median number of prior regimens is 
2 (0-3). Of the 7 patients assessable for response at this time, there 
have been 2 PR’s and 5 patients with SD. One SD was achieved 
in a patient progressing on single agent carboplatin at study entry. 
Median duration of SD + PR is 28.5 weeks (5 patients have ongoing 
response ranging from 8-46.5 weeks). Five of 8 patients assessable 
for toxicity had grade 3 or 4 thrombocytopenia and 2 patients had 
grade 3 neutropenia. No cases of febrile neutropenia were observed. 
Four patients have required blood transfusion and one patient has 
required platelet transfusion. All patients have had treatment held 
and/or dose reductions secondary to hematological toxicity, however, 
since amended carboplatin dose the regimen has been very well 
tolerated with only one out of six patients) with grade 3 neutropenia 
and grade 3 thrombocytopenia. There have been no non-hematological 
grade 3 or 4 toxicities. Conclusions: Clinical benefit was observed 
in all 7 assessable patients. Dose limiting thrombocytopenia was an 
unexpected side effect requiring protocol amendment. We continue 
to accrue study subjects at the amended dosing.
P1-17-08
A Phase II Trial of Ganetespib: Efficacy and Safety in Patients 
(pts) with Metastatic Breast Cancer (MBC).
Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Drullinsky P, 
Sugarman S, Wasserheit-Leiblich C, Moynahan ME, D’Andrea G, 
Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi 
S. Memorial Sloan-Kettering Cancer Center, New York, NY; Synta 
Pharmaceuticals Corp., Lexington, MA
Background: Heat shock protein 90 (Hsp90) is a molecular chaperone 
that maintains the stability of a number of key cellular oncoproteins 
(client proteins). When Hsp90 is inhibited, its client proteins 
undergo ubiquitination and degradation. HER2 is one of the most 
sensitive client proteins of Hsp90 and we have previously shown 
that tanespimycin, a geldanamycin-based Hsp90 inhibitor, is active in 
trastuzumab-refractory HER2+ MBC, with a RR of 22% and clinical 
benefit rate of 59%. Ganetespib is a synthetic, small molecule, IV 
administered, non-geldanamycin Hsp90 inhibitor which has broader 
inhibitory effects on oncoproteins with pre-clinical antitumor activity 
in more breast cancer (BC) subtypes, including triple negative breast 
cancer (TNBC). We therefore tested ganetespib in an unselected 
cohort of patients with advanced BC.
Methods: Pts with locally advanced or MBC were treated with single 
agent ganetespib at 200mg/m2 once weekly for 3 weeks, on a 28 day 
cycle. The primary endpoint of the trial was overall response rate using 
RECIST 1.1. Pts with HER2+ BC were required to have received prior 
therapy with trastuzumab. No more than 3 lines of chemotherapy in 
the metastatic setting were permitted and there was no limit on prior 
lines of hormone therapy. Pts were evaluated for response after 2 
cycles. The trial used a Simon two-stage design requiring at least 3 
responses among the first 22 pts, to allow expansion to a total of 40 pts.
Results: A total of 14 pts have been treated thus far with a median 
age of 45.3 years (36.6 to 59.1) and the following subtypes: 8 ER+/ 
HER2+, 3 ER-/HER2+, 1 ER+/HER2- and 2 TNBC. Pts received a 
median of 1.84 cycles (0.33 to 4). The most common treatment-related 
AEs were Grade 1/2 and included the following: diarrhea (64%), 
fatigue (50%), nausea (35%), vomiting (14%), insomnia (14%) and 
hypersensitivity reactions (35%). The diarrhea had an early onset (< 24 
hrs) and lasted up to 48 hrs post-infusion and was managed with either 
Imodium or similar anti-diarrheal medication. Pts who developed a 
hypersensitivity reaction were successfully re-challenged following 
pre-medication using dexamethasone plus H1/H2 antagonists. Grade 
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3 AEs were limited to 2 pts: 1 with an asymptomatic and reversible 
elevation in serum amylase, and the other with abdominal pain and 
diarrhea requiring a dose reduction to 175mg/m2. Of the 10 pts 
evaluable for efficacy, there is 1 confirmed partial response (PR), 
1 minor response (MR) and 2 pts with stable disease (14%). The pt 
with MR had TNBC and was taken off-study due to a complicated 
pneumonia requiring hospitalization (unrelated). The remaining 3 pts 
had HER2+ BC; 2 of these 3 pts (1 PR, 1 SD) are continuing on study 
and have completed 4 cycles thus far. Updated toxicity and efficacy 
data will be presented.
Conclusions: These data show activity for single agent ganetespib 
in different subtypes of breast cancer. Ganetespib was well tolerated, 
with expected gastrointestinal toxicity that was mild in nature and 
manageable in all patients. Accrual continues and we will present 
updated data at the meeting.
P1-17-09
A Phase 1/2 Dose-Escalation Study of SAR245408 (S08) or 
SAR245409 (S09) in Combination with Letrozole (L) in Subjects 
with Hormone Receptor-Positive and HER2-Negative (HR+/
HER2-) Breast Cancer (BC) Refractory to a Nonsteroidal 
Aromatase Inhibitor (AI).
Baselga J, Tolaney S, Hart L, Gomez P, Gartner E, DeCillis A, Ruiz-
Soto R, Lager J, Burris H. Massachusetts General Hospital, Boston, 
MA; Dana Farber Cancer Insitute, Boston, MA; Florida Cancer 
Specialists Drug Development Unit, Ft Myers, FL; HU Vall d’Hebron 
Oncology Service, Barcelona, Spain; Wayne State University/
Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; 
Exelixis, San Francisco, CA; Sanofi, Cambridge, MA; Sarah Canon 
Research Center, Nashville, TN
Background: Upregulation of PI3K activity is a common molecular 
mechanism involved in resistance to AIs. S08 is a potent, orally 
bioavailable, pan-PI3K inhibitor. S09 is a potent, orally bioavailable 
inhibitor of PI3K which also possesses mTOR inhibitory activity. 
Both compounds exhibit robust PI3K and ERK pathway inhibition in 
paired human tumor biopsy samples from phase 1 studies (Edelman 
G, et al. ASCO 2010; Brana I, et al. ASCO 2010).
Methods: This ongoing, open-label, multicenter, phase 1/2 study 
(NCT01082068) was designed to evaluate the safety and tolerability 
of L in combination with either S08 (Arm 1) or S09 (Arm 2). Eligible 
female patients (pts) were ≥18 yrs, ECOG PS 0-1, with advanced or 
recurrent HR+/HER2- BC whose disease is refractory to nonsteroidal 
AIs. Phase 1 used an ascending 3+3 dose-escalation design and pts 
were accrued to each arm until no more than 1/3 pts or ≥33% of 3-6 
pts at a given dose level experienced a dose-limiting toxicity (DLT) 
during the first 28-day cycle. Pts were alternately assigned to Arm 1 or 
Arm 2 and received 2.5 mg L PO (qd ) in combination with different 
dose levels of either S08 (Arm 1; starting dose 200 mg tablets, PO, 
qd ) or S09 (Arm 2; starting dose of 30 mg capsules, PO, bid). After 
reaching a preliminary maximum tolerated dose (MTD) for each 
combination, pts will accrue to the phase 2 portion of the study. A two-
stage design will be used evaluate the phase 2 co-primary endpoints 
of ORR and PFS. Each arm will be evaluated independently and no 
formal comparisons between arms are planned.
Results: As of June 1st 2011, 17 pts were enrolled to Arm 1 (8 pts) or 
Arm 2 (9 pts). Median age was 54 yrs. Based on preliminary data , 
the adverse event profile in both arms were similar to those reported 
in the single agent phase I studies for S08 and S09 respectively. SAEs 
reported in Arm 1 (2 subjects) included 2 cases of Gr1 pneumothorax 
and 1 Gr4 pneumonitis; in Arm 2 (2 subjects) included Gr4 lumbar 
pain and Gr4 elevation of ALT and AST. No DLTs were reported in 
Arm 1 while one DLT (Gr3 skin rash) was reported in Arm 2 at a 
dose level of S09 50 mg bid (table 1). Arm 1 dosing data from S08 
400 mg qd + L 2.5 mg qd dose level (maximum dose level allowed 
per protocol) will be completed by August 2011. For Arm 2, the MTD 
was S09 50 mg bid + L 2.5 mg, qd.
Dose Escalation
Arm Patients enrolled (n) Letrozole, mg S08 or S09 dose level, mg DLT
1 S08 + L 6 2.5 200 -
 2 2.5 400 -
2 S09 + L 3 2.5 30 -
 6 2.5 50 * Gr 3 skin rash
* the single agent MTD of S09
Discussion. Both S08 and S09 can be combined with L, and maximal 
doses for both combinations were established. Additional safety, PK 
and efficacy data will be presented from phase 1.
P1-17-10
Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: 
Results from a Phase 2 Randomized Discontinuation Trial.
Tolaney SM, Nechushtan H, Berger R, Kurzrock R, Ron IG, Schöffski 
P, Awada A, Yasenchak CA, Burris HA, Ramies DA, Shen X, Winer 
EP. Dana Farber Cancer Institute, Boston, MA; Hadassah Ein-Kerem 
Medical Centre, Jerusalem, Israel; The Chaim Sheba Medical Center, 
Tel Hashomer, Israel; MD Anderson Cancer Center, Houston, TX; 
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; Universitaire 
Ziekenhuis Gasthuisberg, Leuven, Flemish Brabant, Belgium; Institut 
Jules Bordet, Brussels, Belgium; Northwest Cancer Specialists, P.C., 
Tualatin, OR; Sarah Cannon Research Institute, Nashville, TN; 
Exelixis, Inc., South San Francisco, CA
Background: Cabozantinib is an oral, potent inhibitor of MET and 
VEGFR2. MET overexpression has been observed in metastatic 
breast cancer (MBC). High levels of VEGF and its receptors are 
associated with poor prognosis in patients (pts) with breast cancer. 
Simultaneous targeting of the MET and VEGF signaling pathways 
with cabozantinib may therefore be a promising treatment strategy. 
Results of a phase 2 randomized discontinuation trial (RDT) with 
single-agent cabozantinib have demonstrated clinical activity in a 
broad range of tumor types. In addition to observed effects on soft 
tissue lesions, cabozantinib has also been associated with effects 
on bone metastases as exhibited by partial or complete bone scan 
resolution, pain relief and/or reduction of narcotic use.
Methods: MBC pts (ER [+], triple [-] or inflammatory subtype) 
with progressive and measurable disease received single-agent 
cabozantinib at 100 mg qd PO over a 12 week (wk) lead-in period. 
Up to 4 prior treatment regimens (hormonal excluded) for MBC were 
allowed. Tumor response was assessed every 6 wks per mRECIST 
1.0. Treatment beyond wk 12 was based on response: pts with partial 
response (PR) continued with open-label cabozantinib, those with 
stable disease (SD) were randomized to cabozantinib vs. placebo, 
and those with progressive disease were discontinued. The primary 
endpoint was objective response rate (ORR) in the lead-in period, 
and progression free survival in the randomized period. Post-hoc 
evaluations of bone scans were conducted.
Results: 20 MBC pts were enrolled with a median age of 55 years 
(range: 31-71).19 pts had invasive ductal carcinoma (1 pt with 
inflammatory MBC), and 1 pt had invasive lobular carcinoma. 75% 
of pts were ER/PR [+]; 15% were HER2/neu [+]. 85% of pts had 
visceral disease including 65% with liver metastases; 70% had bone 
disease. The median number of prior regimens was 3; 45% received 
prior anti-VEGF therapy. Most common related adverse events ≥ 
Grade 3 were fatigue/asthenia, 20%; and hand-foot syndrome, 20%. 
Dose reductions and permanent discontinuations for AEs occurred in 
35% and 15% of pts, respectively. Soft tissue effects: At wk 12, ORR 
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per RECIST was 10% and overall disease control rate (PR+SD) was 
45%. Notably, tumor shrinkage was observed in 15/16 pts (94%) with 
≥1 post-baseline tumor assessment. Bone effects: 2/3 pts evaluable 
by bone scan at baseline had partial resolution of lesions and one 
pt had SD on follow-up bone scans as early as Wk 6. Out of 7 pts 
receiving narcotics for bone pain, 3 pts reported improved pain and 
2 pts had decreased narcotic use, per investigator. The majority of pts 
analyzed had declines in plasma CTx, an osteoclast marker. Additional 
enrollment and further bone marker analyses are ongoing.
Conclusions: Cabozantinib exhibits clinical activity in pts with MBC 
regardless of receptor and prior treatment status as reflected by high 
rate of tumor regression and effects on bone metastases. Cabozantinib 
is generally well tolerated and the safety profile is comparable to that 
seen with other tyrosine kinase inhibitors.
P1-18-01
Z-ACT1: Zometa Combined with Standard Therapy in Patients 
with Metastatic Breast Cancer Further Decreases the Proportion 
of Patients with CTC Counts of 5 or above.
Brufsky A, Beck J, Dakhil S, Hallmeyer S, Tezcan H, Yardley D, 
Tran D, Warsi G, Culver K. McGee Women’s Hospital of University 
of Pittsburgh Medical Center, Pittsburgh, PA; Highlands Oncology 
Goup, Fayettesville, AR; Cancer Center of Kansas, Wichita, KS; 
Oncology Specialist, SC, Park Ridge, IL; Kootenai Cancer Center, 
Post Falls, ID; Sarah Cannon Research Institute, Nashville, TN; 
Tennessee Oncology, PLLC, Nashville, TN; Novartis Pharmaceuticals 
Corporation, East Hanover, NJ
Introduction: Zoledronic acid (ZOL) has been shown to reduce the 
risk of recurrence and residual tumor size in the adjuvant/neoadjuvant 
setting in patients with early/intermediate-stage breast cancer 
(BC). In addition, ZOL combined with neoadjuvant chemotherapy 
reduced numbers of disseminated-tumor cells in the bone marrow 
compared with chemotherapy alone. However, the activity of ZOL 
on disseminated- or circulating-tumor cells (CTCs) in patients with 
metastatic breast cancer (MBC) is not well defined. Cristofanilli M, 
et al (J Clin Oncol. 2005; 23: 1420-30) reported that CTCs in MBC 
are an independent predictor of overall survival (OS) and progression-
free survival (PFS). Accordingly, this study is evaluating the potential 
anticancer benefit of adding ZOL to standard therapy in patients with 
newly diagnosed MBC as assessed by the change in CTC count from 
baseline to 3-5 weeks.
Methods: Eligible patients had HER2-negative MBC, newly 
diagnosed or at first relapse after adjuvant therapy with or without 
bone metastases. In this open-label 3-arm study, patients without bone 
metastases were randomized to standard therapy + ZOL every 3-4 
weeks for the first 6 months (Arm A) or standard therapy + ZOL during 
month 6-12 after standard therapy initiation (Arm B). All patients 
with bone metastases received ZOL every 3-4 weeks (Arm C). The 
primary endpoint is PFS. Secondary endpoints include the proportion 
of patients with CTCs ≥5 or <5 per 7.5 mL of peripheral blood 3-5 
weeks after standard therapy initiation. Data were compared with 
historical controls (patients with MBC receiving first-line standard 
treatment alone; Cristofanilli M, et al. 2005). CTCs were quantified 
using CellSearch™.
Results: In Z-ACT1, 29 previously untreated MBC patients with 
bone metastases were enrolled in Arm C, all of whom had ≥1 CTC 
at study entry (range, 1-117). 53% received hormonal therapy alone, 
42% chemotherapy alone, and 5% received various combinations. In 
patients receiving standard therapy + ZOL, the percentage of patients 
with CTC ≥5 decreased from 55% to 25% at 3-5 weeks. At baseline, 
the median uNTX level was 46.5 (n = 10) in patients with < 5 CTCs 
and 57 in patients with ≥5 CTC (n = 13). At 3-5 weeks, the median 
decrease from baseline in uNTX was 74% (n = 10) in the < 5 CTC 
group and 25% (n = 5) in the ≥5 CTC group. At 3-5 weeks, the 
median uNTX levels in the <5 and ≥5 CTC groups were 12 and 22 
nmol bce/mmol, respectively. This study has now been modified to 
a 2-arm study (standard therapy +/- ZOL) in MBC patients with no 
bone metastases. CTC, uNTX, and PFS data will be presented from 
this new head-to-head analysis. Changes in CTCs out to 6 months 
and correlation with uNTX and PFS in this original bone metastasis 
cohort will also be presented.
Conclusions: This preliminary analysis suggests that the addition 
of ZOL to standard therapy in women with bone metastases from 
MBC results in a further decrease in CTC numbers at 3-5 weeks 
after initiation of therapy.
P1-18-02
Descriptive Analysis of the Management of Breast Cancer Patients 
with a Solitary Lesion Diagnosed with 18-Fluorodeoxyglucose 
Positron Emission Tomography/Computed Tomography Scan.
Redana S, De Carolis V, Racca M, Zago G, Varetto T, Montemurro F, 
Aglietta M, Evangelista L. Fondazione Piemontese per l’Oncologia 
- IRCC, Candiolo, TO, Italy; Istituto Oncologico Veneto - IOV, 
Padova, PD, Italy
Background: a small percentage of breast cancer (BC) patients (pts) 
will develop oligo-metastatic disease (OMD), often with a solitary 
lesion (SL). Growing evidences suggest a survival benefit for pts who 
undergo local treatment for SL. However, 18-fluorodeoxyglucose 
(FDG) positron emission tomography/computed tomography (PET/
CT) scan might improve the detection of truly SL, an important 
prerequisite for local treatments. We describe pattern of presentation 
and management of pts with SL diagnosed by FDG-PET/CT.
Patients and Methods: From a bi-institutional database we 
retrospectively identified 137 pts who underwent a PET/CT because 
of rising tumor markers (95, 69%) or clinical/radiological suspect of 
disease recurrence (42, 31%). Median time from surgery of primary 
tumor to metastatic progression was 48 months (range 6-216 months). 
Comparisons of categorical and continuous variables were analyzed 
by the Chi-Square test and Mann-Whitney U test. Significance was 
set at p<0.05.
Results: PET/CT was positive in 78/137 pts. In 35 pts (26%) abnormal 
PET/CT findings consisted of a single area of increased metabolic 
activity, whereas in the other 43 (31%) multiple hyper-metabolic 
lesions were found. Twenty/35 pts with single hyper-metabolic spots 
had confirmed malignant SL: 17 (49%) were BC recurrences and 3 
(9%) were new primary tumors other than BC. In the remaining 15 
pts, hyper-metabolic SL were consistent with areas of inflammation, 
past trauma, thyroid struma and physiological ovarian functioning. 
Eight pts with SL (2: liver, 3: bone, 2: soft tissues, 1: lung) underwent 
local therapy, which consisted of surgical excision ± radiation therapy 
(4 pts), percutaneous cementoplasty and radiation therapy (2 pts), 
radiation therapy alone (1 pts) and percutaneous radiofrequency 
ablation (1 pts). After local treatment 7 pts also received systemic 
therapy: chemotherapy for 3 and endocrine therapy for 4 pts. Pts 
with solitary bone lesion also received zoledronic acid. Nine pts 
received only systemic therapy (4: soft tissues, 2: bone, 2: liver, 
1: lung). Median age at the time of diagnosis of SL, histology of 
primary tumor, hormone receptor status, HER2 status, site of SL and 
prior exposure to adjuvant chemotherapy did not differ between pts 
treated with local or systemic therapy. At the time of this analysis, 
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11/17 pts with confirmed SL had progressed (5 had been treated with 
local and systemic therapy and 6 with systemic therapy alone), and 
all the pts were alive.
Discussion: Our retrospective analysis suggests that FDG-PET/CT 
is a useful tool to identify BC pts with OMD susceptible of local 
and aggressive treatment, despite the impressive number of solitary 
non-neoplastic lesions. Our numbers are too small to point out any 
benefit from the addition of local over systemic treatment, and survival 
analyses were not significant. Nevertheless, due to growing evidences 
of a benefit of aggressive treatments for SL, treatment options for pts 
with OMD cannot leave aside local treatments. However, with the 
limitation due to small numbers and retrospective design, our data 
are hypothesis generating, and should be interpreted with caution.
P2-01-01
Withdrawn by Author
P2-01-02
Pharmacological Inhibition of RANKL Attenuates Mammary 
Tumor Development and Lung Metastases in the MMTV-neu 
Transgenic Spontaneous Tumor Model.
Branstetter D, Jacob A, Soriano R, Allred S, Jones J, Miller R, Dougall 
WC. Amgen, Inc., Seattle, WA
Background: RANK and its ligand (RANKL), key factors for bone 
remodeling and metastasis, are crucial for the development of mouse 
mammary glands during pregnancy. In a mouse model of mammary 
carcinogenesis induced by the hormone medroxyprogesterone (MPA) 
and a carcinogen (DMBA), treatment with a RANKL inhibitor RANK-
Fc reduces hormone-induced mammary epithelial proliferation, 
incidence of preneoplasias, and mammary adenocarcinomas. This 
study assessed the expression of mouse RANK and RANKL in FVB 
wild-type (WT) and MMTV-neu mice and whether RANKL inhibition 
could inhibit mammary tumor formation and lung metastases in this 
model.
Materials and Methods: MMTV-neu mice were treated with the 
RANKL inhibitor RANK-Fc (10 mg/kg, 3x/week) or vehicle (muFc) 
beginning at 20 weeks. Mammary tumor formation was determined 
by palpation and confirmed by histologic examination. The presence 
of preneoplastic lesions and histotype of tumors was determined on 
H&E-stained tissues. Entire lungs from tumor-bearing MMTV-neu 
mice were step-sectioned at 75 mm and assessed histologically for 
the presence of metastases. Epithelial proliferation was measured by 
BrdU labeling of the mammary epithelium. The expression of RANK, 
RANKL, cyclin D1, progesterone receptor (PR), F4/80, FOXP3, and 
CD3 was determined by immunohistochemistry (IHC).
Results: RANK-Fc treatment of MMTV-neu mice resulted in a 
significant reduction in total number of mammary tumors and 
lung metastases quantified at necropsy but did not impact median 
time to spontaneous mammary tumor onset. RANKL inhibition 
resulted in reduced pre-neoplasias and corresponding reductions in 
proliferation and cyclin D1 within normal mammary epithelia but not 
in adenocarcinomas. Treatment of MMTV-neu mice with RANK-
Fc also reduced the incidence and number of lung metastases per 
mouse. RANK protein was detected in normal mammary epithelium, 
preneoplastic mammary intraepithelial neoplasia (MIN), the epithelial 
component of adenocarcinomas and lung metastases, and monocytic 
element adjacent to primary MMTV-neu tumors. RANKL protein 
was detected in normal mammary epithelium but not in the epithelia, 
stromal component or infiltrating cells of adenocarcinomas or lung 
metastases. Progesterone receptor expression was observed in normal 
mammary epithelium of MMTV-neu and FVB WT mice but decreased 
over time in MMTV-neu mice and was not detected in preneoplasias, 
adenocarcinomas, or lung metastases. CD3 was detected in mammary 
tumors and lung metastases but neither RANKL nor FOXP3 were 
present. Staining of lymph nodes was used as a positive control for 
RANKL and FOXP3. Expression of FOXP3 and RANKL were not 
measurably colocalized in dual staining of lymph nodes.
Discussion: RANKL is expressed in normal mammary epithelia of 
MMTV-neu mice but is not detected in any stage of atypia, including 
MIN, mammary adenocarcinoma, or lung metastases. Selective 
pharmacological inhibition of RANKL by RANK-Fc treatment 
attenuated mammary tumor development and lung metastases in the 
MMTV-neu transgenic spontaneous tumor model.
P2-01-03
Insulin-Like Growth Factor I (IGF) Induced Metastasis Signature 
Correlates with Poor Prognosis and Decreased Distant Metastasis-
Free Survival in Human Breast Cancer.
Sachdev D, Sarver AL. University of Minnesota, Minneapolis, MN
The insulin-like growth factors (IGFs) acting via the type I insulin-like 
growth factor receptor (IGF-1R) regulate tumor growth, survival and 
metastasis of multiple types of cancers. Agents targeting IGF-1R are 
currently being tested in phase II/III clinical trials in human cancers. 
We have previously reported that IGF1R can regulate metastasis 
independently of primary tumor growth in a model of high risk 
metastatic breast cancer using the triple negative MDA435/LCC6 
metastatic cancer cells, which form spontaneous lung metastases 
when injected into the mammary fat pad of mice. We have shown that 
disruption of IGF signaling either with an antibody against IGF1R, 
AVE1642, or a dominant negative IGF-1R construct, does not affect 
growth in the mammary fat pad but inhibits pulmonary metastases 
and colonization of the lungs. Regulation of such a phenotype will 
not be measured in clinical trials and these findings imply that clinical 
trials of this therapeutic strategy may need to adjust their endpoints 
for assessing benefit by taking into account that inhibition of IGF1R 
signaling may inhibit metastasis but not primary tumor growth.
Here, we sought to develop an IGF induced metastasis signature 
that may be useful in selecting patients that could benefit from 
IGF1R targeted therapy and determine if changes in expression of 
the genes in the signature can be useful in monitoring response. 
Serum starved LCC6-WT cells (with wild-type functional IGF1R) 
and LCC6-DN (cells with dominant negative IGF1R) were treated 
with IGF-I, AVE1642 (fully human antibody against IGF1R that 
inhibits metastasis but not tumor growth in the mammary fat pad), 
or AVE1642+ IGF-I for 4 and 24 hours and microarray analysis 
was performed using the U133 Plus 2.0 human arrays with 47,000 
transcripts. IGF-I regulated over 100 transcripts in LCC6-WT cells 
compared to IGF-I in LCC6-DN cells. Over 400 transcripts were 
basally differentially expressed in LCC6-WT cells compared to 
LCC6-DN cells. Array data were also analyzed to determine genes 
regulated by IGF-I signaling in LCC6-WT cells compared to untreated 
LCC6-WT cells and if disruption of signaling with AVE1642 affected 
genes whose expression was regulated by IGF-I signaling. A total of 
263 transcripts were regulated by IGF signaling in LCC6-WT cells 
compared to untreated cells and AVE1642 treatment reversed the 
regulation of all transcripts induced by IGF-I in LCC6-WT cells. 
53 of the most significantly regulated genes were used to query two 
different human breast tumor datasets to determine if genes in IGF 
signaling induced metastasis signature are associated with lymph 
node metastasis and poor prognosis in human tumors. IGF regulated 
metastasis signature genes were expressed in human tumors in the 
van’t Veer and Wang datasets. Further, IGF activated metastasis 
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signature was correlated to decreased survival and decreased distant 
metastasis free survival in breast cancer patients. Our results suggest 
that presence of IGF induced metastasis signature in patients confers 
prognostic value and identifying IGF driven metastasis signatures 
may be useful to identify and monitor patients who could benefit 
from IGF1R targeted therapy for inhibition of metastatic disease.
P2-01-04
The Post-Partum Diagnosis of Pregnancy Associated Breast 
Cancer Confers an Increased Risk for Metastasis without 
Increased Incidence of Poorer Prognosis Biologic Subtype.
Borges VF, Callihan ES, Jindal S, Lyons T, Manthey E, Gao D, Schedin 
PJ. University of Colorado Anschutz Medical Campus, Aurora, 
CO; Colorado School of Public Health, Aurora, CO; University of 
Colorado School of Medicine, Aurora, CO
Background: All women who complete a childbirth have an increased 
risk for the subsequent breast cancer regardless of age at their first 
birth. In younger women, this period truncates 10 years later and 
pregnancy then becomes protective, whereas in older mothers the 
risk persists. Moreover, breast cancers diagnosed subsequent to a 
recent childbirth have an increased risk for metastasis and death. 
However much of the existing data is confounded by inclusion of 
cases diagnosed during pregnancy. Hypothesis: Our preclinical 
models of pregnancy associated breast cancer (PABC) has identified 
the “involution hypothesis”, where the normal physiologic post-
partum breast involution is the pregnancy-related event promotional 
of breast cancer growth, invasion and metastasis. We have performed 
a retrospective cohort study, restricted to postpartum PABC and 
controls, to fully characterize post-partum PABC by biologic subtype 
and known predictors for metastasis. Also we identify if the specific 
period of post-partum PABC has a higher risk for metastasis then 
non-PABC, as predicted by our animal model studies. Methods: 
We performed a retrospective cohort of 527 cases of breast cancer 
diagnosed at age 45 or younger from 1981-2011. Pregnancy status 
was identified from medical records and defined as nulliparous 
(n=107), PABC (up to 5 years post-partum of last childbirth, n=114), 
and Later Parous (>10 years post-partum, n=239). Clinicopathologic 
characteristics were obtained from pathology records. Outcomes 
data obtained through the University of Colorado Tumor Registrar. 
Hazard ratios of risk of metastatic recurrence of nulliparous and 
PABC groups were analyzed using a Cox Proportional Hazards 
Model and time to metastatic recurrence was analyzed using 
standard Kaplan Meier curves. Results: Compared to nulliparous 
cases, PABC cases were more frequently Stage IV(11.4% v. 4.9%), 
T3 tumor size(17.3% v. 13.1%), poorly differentiated(56.6% v. 
49.0%), lobular histology(4.5% v.1.0%) , with lymphovascular 
invasion(30.4% v. 24.5%) and with involved lymphnodes(57.6% 
v. 48.6%). No differences were seen between Luminal A, Luminal 
B, Her 2 and Triple Negative subtypes. Average follow-up was 3.4 
years for nulliparous, 3.5 for PABC and 4.6 for Later Parous. Survival 
analysis revealed a cumulative 5-year metastatic recurrence free 
probability of 80.6% for nulliparous, 68.5% for PABC and 80.5% 
for Later Parous. Compared to nulliparous, PABC had greater than a 
three times higher risk for subsequent metastatic recurrence (HR 3.29, 
95% CI: 1.25-8.63). No significant difference in the risk of metastatic 
recurrence for Later Parous compared to nulliparous was observed 
(HR: 1.079, 95% CI: 0.46-2.55). Conclusion: Post-partum PABC is 
characterized by higher stage at diagnosis but without enrichment 
for poorer prognosis biologic subtypes. Post-Partum PABC has an 
increased risk for metastasis within five years of diagnosis, with 
an overall 3.29 times higher risk of a metastatic recurrence. These 
data support our hypothesis that the post-partum window, and the 
associated role of naturally occurring involution, may be promotional 
of tumor growth, invasion and metastasis as previously identified in 
our animal models.
P2-01-05
Integrin avb6 Mediates HER2-Driven Invasion in Breast Cancer.
Moore KM, Hart IR, Jones LJ, Marshall JF. Barts Cancer Institute - 
a CR-UK Centre of Excellence, Queen Mary University of London, 
London, Greater London, United Kingdom
We have shown strong expression of integrin avb6 reduces the 
5 year survival of HER2-positive breast cancers from 66% (HR 
1.84) for moderate/low avb6 expressors to 54% (HR 2.18) in cases 
with strong expression (2063 cases, unpublished). This is in direct 
comparison to HER2/avb6-double negative cases, where strong 
avb6 expression reduces survival from 86% (HR 1.00) to 77% (HR 
1.20). The biological mechanism underlying these observations was 
investigated in two isogenic breast cancer models: MCF-7/neo-1 and 
MCF-7/HER2-18 (a gift from Prof. M-C. Hung, USA) and MCF10A 
and MCF10A.CA1a.
Flow cytometry showed MCF-7/HER2-18 expressed high levels of 
both HER2 and avb6 whereas MCF-7/neo-1 expressed low levels 
of both receptors. MCF10A and MCF10A.CA1a both expressed high 
levels of avb6 whereas only MCF10A.CA1a expressed elevated 
levels of HER2. In charcoal-stripped (cs)-serum, comparing MCF-7/
neo-1 and MCF-7/HER2-18, HRGb1(1mM), which stimulates HER2/
HER3 heterodimers, increased proliferation by 50.2%±9% (P=0.048) 
and 66.2%±5.5% (P=0.003), in MCF-7/neo-1 and MCF-7/HER2-18 
cells respectively. In contrast, Herceptin reduced proliferation by 
32.3%±13.4% (P=0.003) and 15.2%±3.4% (P=0.028), respectively. 
MCF10A and MCF10A.CA1a proliferation remained unchanged 
with HRGb1 treatment and antibody-blockade of avb6 did not affect 
proliferation of any cell line. (NB, in complete serum there was no 
effect on proliferation of any of the above treatments). Invasion 
through Matrigel of MCF-7/HER2-18 was inhibited by antibody 
blockade (10mg/ml) of avb6 (mAb 10D5; 38.6%±20.8%, P=0.005) or 
HER2 (Herceptin, 10mg/ml; 40.1%±28.6%, P=0.01). The same trend 
was observed in MCF10A.CA1a invasion (83%±30.2% (P=0.025) 
with 10D5 and 80.4%±8.7% (P=0.022) with Herceptin). Combination 
of both antibodies had no additional effect.
siRNA knockdown of avb6 or HER2 in MCF-7/HER2-18 and 
MCF10A.CA1a cells also reduced invasion to a similar extent as the 
blocking antibodies. This suggests that HER2 driven breast carcinoma 
invasion is mediated by avb6. To investigate this further HER2/3 was 
stimulated with HRGb1, which consistently increased invasion by 
111.5%±35.4% (P=0.011) in MCF-7/HER2-18 cells and by 57%±34% 
(P=0.042) in MCF10A.CA1a cells; an increase that was abrogated 
by co-treatment with 10D5 or Herceptin.
To determine the mechanism through which HER2 and avb6 co-
operate we examined several signalling pathways. Analysis of total 
or activated Akt, ERKI/II, c-Jun or Src in the MCF-7 model showed 
no changes. However, elevated total and phospho-Stat3 in MCF-7/
HER2-18 were observed and siRNA knockdown, or small-molecule 
inhibition, of Stat3 suppressed invasion of MCF-7/HER2-18 cells 
(54.5%±27.3% (P=0.008) and 55.3%±33.3% (P=0.01) respectively), 
possibly suggesting that activation of Stat3 may link avb6 and 
HER2 co-operative signalling in this model. Interestingly, Akt was 
constitutively phosphorylated in MCF10A.CA1a cells and, moreover, 
10D5 reduced these levels suggesting avb6 may influence HER2 
signalling via Akt in these cells.
These data confirm HER2-driven invasion is avb6-mediated and 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011247s
December 6-10, 2011 Abstracts: Poster Session 2
provide a mechanistic explanation for our clinical observations. We 
suggest HER2 and avb6 should be considered as dual targets for 
future therapy of some breast cancers.
P2-01-06
NSAID Analgesic Ketorolac Used Perioperatively May Suppress 
Early Breast Cancer Relapse: Something for Nothing in Breast 
Cancer?
Retsky MW, Rogers RA, Demicheli R, Hrushesky WJM, Gukas ID, 
Vaidya JS, Baum M, Forget P, De Kock M. Harvard School of Public 
Health, Boston, MA; Istituto Nazionale Tumori, Milano, Italy; 
University of South Carolina, Columbia, SC; James Paget University 
Hospital, Great Yarmouth, United Kingdom; Royal Free and UCL 
Medical School, London, United Kingdom; Cliniques Universitaires 
Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium
Background: Over a decade ago, we were confronted with data that 
showed an unexpected bimodal pattern of hazard of relapse among 
early stage breast cancer patients treated by mastectomy without any 
adjuvant systemic treatment. This pattern has now been identified 
in 20 independent databases from US, Europe and Asia. There is 
an early peak of relapses at 18 months, a nadir at 50 months and 
a broad second peak extending from 60 months to over 15 years. 
Fifty to eighty percent of relapses, the proportion increasing with 
primary tumor size, reside within the first peak. This pattern was not 
explainable by accepted theories. We proposed based on computer 
simulations that the broad second peak relapses result from steady 
stochastic progressions from single dormant malignant cells to 
avascular micrometastases and then on to growing deposits. To 
explain the first peak, we had to postulate that something happened 
at about the time of surgery to provoke sudden exits from dormant 
phases to active growth and then to detection. There was a particularly 
sharp early relapse mode within 10 months for premenopausal patients 
with positive nodes that appeared to be surgery-induced angiogenesis 
of dormant avascular micrometastases. We have been able to explain 
a wide variety of breast cancer observations with this hypothesis. 
These include high effectiveness of adjuvant chemotherapy only for 
premenopausal node positive women and why early detection works 
better for women age 50-59 than for women age 40-49.
Methods and Materials: Forget et al reported data from a retrospective 
study of 327 consecutive patients comparing various perioperative 
analgesics and anesthetics in one Belgian hospital and one surgeon. 
Patients were treated with mastectomy and conventional adjuvant 
therapy. Follow-up is average 27.3 months with range 13-44 months.
Results: NSAID ketorolac, a common analgesic used in surgery, 
produced far superior disease-free survival in the first 5 years after 
surgery. The expected prominent early relapse peak is all but absent. 
These results are superior to any adjuvant therapy we have examined.
Discussion: If this observation holds up to further scrutiny, it could 
mean that the simple use of this safe and effective anti-inflammatory 
agent at surgery might eliminate early relapses. Concerning a possible 
mechanism, since ketorolac is the only anti-inflammatory agent among 
the analgesics studied, our attention is drawn to inflammation. Might 
this imply that transient systemic inflammation accompanying surgery 
is part of the metastatic tumor seeding process? Inflammation can be 
a very rapidly occurring effect since bump and redness following a 
mosquito bite occur within seconds. It is well established that many 
cancer patients have circulating cancer cells. Data show a surge in 
circulating epidermal cells after primary breast cancer surgery but that 
intriguingly occurs days later. Blood speed in capillaries is 0.03cm/
sec which would make leaky capillary venules a very efficient way 
for circulating cancer cells to enter tissue. From our simulations the 
few relapses in the ketorolac data look like the leading edge of the 
late broad peak - viewable for the first time.
P2-01-07
Proto-Oncogene PELP1 Promotes Metastasis through miR-200 
Dependent Pathway.
Saha Roy S, Rao M, Sun L, Tekmal RR, Vadlamudi RK. UTHSCSA, 
San Antonio, TX
Background: Endocrine therapy is the most important component of 
adjuvant therapy for patients with early stage estrogen receptor (ER)-
positive breast cancer. Despite positive effects of hormonal therapy, 
initial or acquired resistance to endocrine therapies frequently occurs 
and tumor recurs as advanced metastatic disease. Accumulating 
evidence suggests that ER-coregulators play an essential role in cancer 
progression and that metastatic tumors have increased expression 
of coregulators. Proline glutamic acid rich protein (PELP1) is an 
ER coregulator, its expression is upregulated during breast cancer 
progression to metastasis. PELP1 is an independent prognostic 
predictor of shorter breast cancer specific survival and its elevated 
expression positively associates with markers of poor outcome. The 
objective of this study is to examine the mechanism and significance 
of PELP1 mediated signaling in breast cancer metastasis.
Methods: To examine the significance of PELP1 in metastasis, we 
have used two ER+Ve (ZR75, MCF7) and one ER-ve MDA-MB 231 
models cell that either stably express PELP1 or PELP1 shRNA. MCF7 
and ZR75 cells were used as controls. Role of PELP1 on metastasis 
was studied using Boyden chamber, wound healing, invasion, MMP 
and reporter gene assays. Epithelial to Mesenchymal Transition 
(EMT) real time qPCR Array (Super array) was used to identify 
PELP1 target genes. Whole genome based microarray analysis 
was performed to identify PELP1 regulated microRNAs. miRNA 
mimetics and antamiRs were used to establish the mechanism. Nude 
mice based assays were performed to study the role of PELP1 on in 
vivo metastasis.
Results: Boyden chamber and wound healing assays showed PELP1 
down regulation substantially affect migration of both ER+ve and 
ER-ve cells and showed alterations in the expression of the EMT 
markers. Focused microarray studies identified PELP1 modulate 
expression of eight genes involved in the EMT (including Snail, Twist, 
ZEB1 and MMPs). In xenograft assays, overexpression of PELP1 
in non-metastatic cells increases their propensity for metastasis in 
vivo, while PELP1 knockdown in metastatic model cells decreased 
in vivo metastatic potential. Whole genome microRNA array analysis 
revealed that miR 200a and miR141 were upregulated in cells 
expressing PELP1-shRNA compared to control shRNA expressing 
cells. Accordingly, over expression of PELP1 in low metastatic model 
cells decreased expression of miR200a and miR141. Mechanistic 
studies showed PELP1 down regulate expression of metastasis 
suppressive microRNAs (miR200a and miR141) by promoting 
chromatin modifications. Ectopic expression of miR200a and miR141 
mimetic decreased PELP1 mediated metastatic functions.
Conclusions: These results suggest that PELP1 play a role in breast 
cancer metastasis by promoting cell motility/EMT by modulating 
microRNA expression and blockage of PELP1 axis has potential 
to reduce metastasis potential of breast cancer cells. Understanding 
how NR coregulator PELP1 plays a role in metastasis will be useful 
in maximizing treatment opportunities for metastatic breast cancer. 
This study is funded by DOD grant.
P2-01-08
Withdrawn by Author
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P2-01-09
Gene Expression Alterations in the Lymph Node Microenvironment 
in Response to Successful Metastatic Colonization.
Ellsworth RE, Valente AL, Kane JL, Ellsworth DL, Shriver CD. Henry 
M. Jackson Foundation, Windber, PA; Windber Research Institute, 
Windber, PA; Walter Reed Army Medical Center, Washington, DC
Background: Breast stroma is known to play an active role in 
tumorigenesis, undergoing both phenotypic and molecular changes to 
facilitate and promote tumor development and growth. The metastatic 
microenvironment also plays a role in successful colonization; 
however, the genetic changes in these secondary microenvironments 
associated with metastasis are not well described.
Methods: Women with invasive breast cancer with at least one lymph 
node with macrometastases and one lymph node with no detectable 
metastases were identified from the Clinical Breast Care Project. 
Lymph node tissue was microdissected from both the metastatic 
lymph node microenvironment and negative nodes and hybridized 
to U133A 2.0 gene expression arrays. Differential expression was 
detected using Partek® Genomics Suite™6.5 using a cutoff of 
P<0.001, >2-fold change.
Results: Nineteen genes were differentially expressed between 
negative lymph nodes and lymph node tissue microdissected from 
lymph nodes with metastatic tumors. Eleven genes, including 
EPCAM, KRT19 and MUC1 were expressed at significantly higher 
levels in lymph node tissue from metastatic lymph nodes while eight 
genes, such as CXCL2 and CXCL5, were expressed at significantly 
higher levels in negative lymph nodes. Results have been validated 
in external sample sets for AZGP1, CLEC4M, CXCL2, EPCAM, 
MUC1, PIP and TFPI.
Conclusions: Lymph node tissue differs in gene expression between 
those harboring metastatic tumors and those without metastasis. Genes 
expressed at higher levels in lymph nodes with macrometastases are 
involved in tumorigenesis, suggesting that like the breast stromal 
microenvironment, the metastatic microenvironment undergoes cross-
talk with the tumor cells. In addition, a cluster of genes involved in 
immune function are expressed at lower levels in metastatic lymph 
nodes, suggesting that suppression of proper immune response may 
be required for successful metastatic colonization.
P2-01-10
Blockage of Autocrine TGF-b Signaling Reduces Tumorigenecity 
and Lung Metastasis in a Murine Breast Cancer Cell Line, 
NMuMG-ST.
Liu Z, Robert NW, Wang L, Bandyopadhyay A, Sun L-Z. University 
of Texas Health Science Center at San Antonio, San Antonio, TX; 
First Affiliated Hospital of Nanjing Medical University, Nanjing, 
JiangSu, China
Transforming growth factor beta (TGF-b) is known to have a dualistic 
role in breast cancer cells, acting as a tumor suppressor or a tumor 
promoter. This dualistic property varies in different cells and at 
different progression stages. Studies show that autocrine TGF-b is 
necessary for the growth and survival of MDA-MB-231 cells, and 
was also known to enhance the survival of MCF-7 cells. However, 
the role of autocrine TGF-b in spontaneously transformed cells is 
still less understood. We have retrovirally transduced a dominant 
negative TGF-b Type II receptor (DN RII) into a spontaneously 
transformed murine mammary gland epithelial cell line NMuMG-
ST (DN RII cells). The expression of DN RII reduces TGF-b 
sensitivity of NMuMG-ST cells in a gene transcription assay and a 
growth inhibition assay. Interestingly, the autocrine TGF-b supports 
the survival of NMuMG-ST cells, although the exogenous TGF-b 
inhibits the growth of NMuMG-ST cells. Moreover, more apoptosis 
were observed in the DN RII cells compared to the control cells in 
both in vivo and in vitro experiment. We found that AKT and ERK 
pathway mediates autocrine TGF-b’s survival signal. Results of 
western immunoblot for several stem cell markers and mammosphere 
formation assay suggest that autocrine TGF-b signaling is essential 
for the maintenance of stem like cell subpopulation in NMuMG-
ST cells. By using immunocytostaining, we found that the DN RII 
cells expressed more E-cadherin and less Vimentin when compared 
to the control NMuMG-ST cells, which indicate that blocking 
autocrine TGF-b signaling pathway could inhibit the process of 
EMT in NMuMG-ST cells. Notably, when the cells were inoculated 
orthotopically in nude mouse mammary glands, tumors formed by 
DN RII cells grew at a similar rate as those formed by control cells, 
but caused fewer lung metastases. Our finding identified that the 
autocrine TGF-b signaling is important for the survival and metastatic 
ability of NMuMG-ST, which could provide an important foundation 
for further investigation on the role of autocrine TGF-b signaling in 
breast cancer.
P2-01-11
Fish Oil Targets miR-21 To Increase PTEN Expression for 
Inhibition of Bone Metastatic CSF-1 in Breast Cancer Cells.
Mandal CC, Ghosh-Choudhury T, Ghosh Choudhury G, Ghosh-
Choudhury N. University of Texas Health Science Center at San 
Antonio, San Antonio, TX; Baylor College of Medicine, Houston, TX
Current therapy for the breast cancer patients is aimed at treating 
the cancer mainly at the primary site with limited ability to block 
metastasis. We have recently shown that fish oil (FO) diet significantly 
prevents MDA MB-231 breast cancer cell (MDA) metastasis to 
bone in a mouse model. Colony stimulating factor-1 (CSF-1) is 
one of major osteoclastogenic cytokines responsible for osteolytic 
metastasis of breast cancer. Quantitative RT-PCR (qRT-PCR) analysis 
showed significant inhibition of CSF-1 mRNA expression in fish 
oil fed mice xenograft tumor samples and docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA), two w-3 fatty acids in fish 
oil, inhibited CSF-1 mRNA and protein expression in MDA cells. A 
positive correlation was observed between expression of CSF-1 and 
the bone metastatic potential of different breast cancer cells. We have 
demonstrated recently upregulation in PTEN expression by FO diet as 
a mechanism of breast tumor growth arrest in mice. Over expression 
of PTEN inhibited migration of MDA cells. PTEN is a negative 
regulator of PI 3 kinase/Akt signaling. We investigated the mechanism 
of CSF-1 expression by breast cancer cells. Cotransfection of the 
CSF-1 promoter-driven luciferase plasmid (CSF-1-Luc) in MDA with 
PTEN or dominant negative (DN) PI 3 kinase or DN Akt, inhibited 
the transcription of CSF-1, indicating requirement of PI 3 kinase/Akt 
signaling. Several oncogenic microRNAs including miR-21 have 
been shown to induce metastasis of cancer cells. Fish oil fed mice 
tumors and DHA- and EPA-treated MDA cells significantly blocked 
miR-21 expression in MDA. PTEN mRNA 3’UTR contains miR-21 
recognition element. Over expression of miR-21 inhibited PTEN 
3’UTR-Luc reporter activity but it was increased by downregulation 
of miR-21, indicating functional targeting of PTEN mRNA by 
miR-21 in MDA. Similarly, expression of either miR-21 or miR-21 
Sponge (plasmid-coded anti-miR-21 sequences) in MDA significantly 
suppressed or increased PTEN protein, respectively. Moreover, 
DHA-increased PTEN expression is reversed by over expression of 
miR-21 indicating a critical regulation of PTEN by miR-21. miR-
21 over expression increased migration of MDA cells and partially 
reversed DHA- or EPA-mediated inhibition of migration. Since PTEN 
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regulates expression of CSF-1, we examined the involvement of miR-
21. Expression of miR-21 enhanced while miR-21 Sponge reduced 
expression of CSF-1 mRNA and its transcription. Furthermore, DHA-
inhibited CSF-1 mRNA expression is reversed by over expression of 
miR-21. Together these results uncover a novel function of fish oil, 
which beheads miR-21 signaling to dampen expression of CSF-1 thus 
preventing osteoclastogenesis and osteolytic lesions in breast cancer.
P2-01-12
Determining the Molecular Signature That Drives Breast Cancer-
Induced Brain Metastasis in a Mouse Xenograft Model.
Mukhopadhyay KD, Elkahloun AG, Yoon K, Cornell JE, Yu L, Liu 
Z, Sun L-Z. UT Health Science Center, San Antonio, TX; National 
Human Genome Research Institute- NIH, Bethesda, MD
Breast cancer (BCa) is the most common malignant disease in women 
in U.S. and the mortality in BCa patients is due to the metastasis of the 
disease from primary site. Brain metastasis accounts for nearly 20% 
of all metastases in BCa. It is the most feared complication of BCa 
because of very few effective treatment regimens available, leading 
to lower survival rate in patients. The exact molecular mechanism 
for metastases of BCa into brain is unknown. Rodent model systems 
have been reported for brain metastasis in BCa but the current models 
for brain metastasis have limitations. Therefore, there is a need of 
efficient model system that can significantly contribute towards our 
understanding of different factors from both host and tumor leading 
to brain metastasis.
Previously we reported isolation and characterization of estrogen 
independent B6TC cells that are derived from the stable spontaneous 
fusion of MDA-MB-231/GFP/Neo and ZR-75-1/GFP/puro in mouse 
bone marrow microenvironment. This chimeric B6TC has propensity 
to metastasize to brain when inoculated through intracardiac (I.C.) 
route, and express stem cell-like features. In the present study using 
B6TC, we have developed an efficient and novel mouse model for 
studying BCa-induced brain metastasis. We have generated three cell 
lines from B6TC through three successive rounds of inoculation in 
mouse and subsequent isolation of brain metastatic cells. Each round 
of selection enhanced the brain metastatic propensity. An initial 
microarray analysis identified genes like MMP1, HB-EGF, ST3GAL1, 
PTGS2, ITGA3, and CXCR4, which showed significant up-regulation 
in B6TC compared to its parental metastatic MDA-MB-231 or non-
aggressive ZR-75-1 cells. These genes are implicated in metastasis 
regulation. A second round of RNA microarray was performed with 
three sublines of B6TC with successively enhanced brain metastatic 
propensity to identify unique potential brain metastatic genes showing 
gradual up or down-regulation over generations. From analysis of 
the gene expression profiles, apart from potent brain metastatic 
genes detected earlier, we also identified some molecular pathways, 
including TGF beta signaling pathway that are associated with 
enhanced brain metastasis. The B6TC model is novel for studying 
the molecular mechanism of brain metastasis, as in this model, apart 
from experimental metastasis in brain through I.C route, cells show 
spontaneous metastases to the brain from the primary tumor and this 
unique feature will enable us to study the mechanisms of the early 
steps of brain metastasis progression. Further analyses to find out 
common miRNAs that are over or under-expressed in the sublines 
over successive generations and determination of gene targets of 
miRNA are underway. This study will not only provide valuable 
insight into molecular mechanism of BCa-induced brain metastasis 
but also lay the foundation to identify novel prognostic and therapeutic 
markers of brain metastases, leading ultimately to the discovery 
of novel molecularly targeted drugs to prevent and eradicate BCa 
metastasis initiation, progression and recurrence.
P2-01-13
Impact of Erlotinib on MSC-Mediated TIC Expansion and EMT.
Lacerda L, Solley T, Debeb B, Xu W, Krisnamurthy S, Ueno N, 
Reuben J, Klopp A, Woodward W. UT MD ANderson Cancer Center, 
Houston, TX
Background: Recently, we have demonstrated that mesenchymal 
stem cells (MSC) and MSC secreted factors (MSC-CM) have 
a profound effect on tumor initiating cells (TIC) enriched 
mammosphere formation and latency of tumor xenografts formation 
from breast cancer cell lines. Furthermore these interactions increased 
the expression of epithelial mesenchymal transition (EMT)-associated 
proteins which are associated with tumor cell invasion and metastasis 
as well as the TIC phenotype. (Klopp, A. H. et al., 2010, PLoS One. 
5, e12180). Our data suggest that the presence of MSC in the tumor 
microenvironment may increase metastases by conferring stem 
progenitor cell biology on more differentiated non-metastatic cells. 
In addition, preliminary data suggested MSC-CM upregulated EGFR 
signaling in breast cancer cells. Therefore, we hypothesized that 
inhibiting EGFR signaling with erlotinib (tyrosin kinase inhibitor) 
can suppress MSC-mediated TIC expansion and EMT.
Methods & Results: In order to demonstrate that erlotinib inhibits 
MSC-CM promoted expansion of TIC, we cultured breast cancer 
cells lines (SUM149, SUM159, SUM190, MDA-IBC3 and MCF-
7) in anchorage independent conditions with MSC-CM and treated 
them with increasing concentrations of erlotinib. The efficiency 
of mammosphere formation was examined after 5 days. We found 
that erlotinib inhibited MSC mediated increase in mammosphere 
formation in triple negative cell lines SUM149 and SUM159, and 
HER2-positive cell lines SUM190 and MDA-IBC3, but not in ER-
positive, erlotinib resistant MCF-7 cells. Furthermore, we evaluated 
the impact of erlotinib on cell cultures grown with breast cancer 
patient-derived fluids, such as seroma and malignant pleural effusions. 
We observed that the effect of erlotinib on mammospheres formation 
was attenuated by both types of patient fluids.
Discussion: Patients with triple negative breast cancer have the 
highest rates of metastases and no available targeted therapies for 
treatment. EGFR is expressed in a significant proportion of triple 
negative breast cancers, and recent clinical and preclinical studies 
suggest that EGFR may contribute to the metastasis or aggressiveness 
of triple negative breast cancer. Here we demonstrate that host and 
environmentally-derived factors are critical for determining resistance 
to erlotinib. In vivo studies regarding the ability of erlotininb to 
prevent MSC-enhanced TIC survival and metastases are underway.
P2-01-14
High Level of CD44 Expression and Soluble CD44 Secretion 
Mediate Trastuzumab Resistance in HER2 Positive Breast 
Cancer.
Jin Q, Baek JM, Boulbes DR, Esteva FJ. MD Anderson Cancer 
Center, Houston, TX
Background: Overexpression of HER2 occurs in 15–25% of invasive 
breast cancer. Trastuzumab, a humanized monoclonal antibody 
targeting the extracellular domain of HER2, markedly improves 
disease-free and overall survival in patients with HER2-positive breast 
cancer. However, resistance to trastuzumab develops in most patients 
with HER2-overexpressing metastatic breast cancer. Breast cancer 
stem cells have been shown to express HER2, although its role in the 
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development or maintenance of stem cells is not well characterized. 
CD44 is one of the proposed markers for breast cancer stem cells. 
We investigated the role of CD44 in acquired trastuzumab resistance 
in HER2 positive breast cancer.
Methods: CD44 mRNA expression was measured by quantitative 
real-time PCR. The proportion of CD44 positive cells was measured 
by fluorescence-activated cell sorting (FACS). Soluble CD44 level 
was detected by enzyme-linked immunosorbent assay (ELISA). In 
vitro tumorigenicity was evaluated by soft agar colony formation 
assay. Cell invasion was tested by using a matrigel invasion assay. In 
vivo tumor growth was evaluated using a mammary fat pad xenograft 
mouse model.
Results: CD44 mRNA expression, CD44 positive cell population 
by FACS, and CD44 secretion were significantly increased in both 
SKBR3 derived trastuzumab resistant SKBR3 clone 3 and BT474 
derived trastuzumab resistant HR20 cells compared to parental, 
trastuzumab sensitive cells. Consistent with the increase in CD44, 
trastuzumab resistant cells showed an increase in soft agar colony 
formation and cell invasion, which were blocked by siRNA-induced 
downregulation of CD44 expression. Tumor growth and incidence 
were enhanced in mice injected with trastuzumab resistant HR20 cells 
compared to the mice injected with trastuzumab sensitive parental 
BT474 cells. Knock-down of CD44 expression by the transfection 
with CD44-specific siRNA suppressed in vivo tumor growth in the 
mice injected with trastuzumab resistant HR20 cells. Finally, we found 
high serum CD44 levels correlated with advanced tumor progression 
in HER2 positive breast cancer.
Conclusion: Our findings indicate that high levels of CD44 mediate 
trastuzumab resistance in HER2 positive breast cancer cells as well as 
tumor progression in mice. Circulating CD44 is prognostic in patients 
with HER2 positive breast cancer. CD44 may be a therapeutic target 
for HER2 positive breast cancer.
P2-01-15
RT-PCR Gene Profiling for the Prediction of Bone Metastases in 
Primary Breast Cancer.
Ibrahim T, Mercatali L, Ricci R, Scarpi E, Liverani C, Serra L, Guerra 
D, Ciani S, Amadori D. Istituto Scientifico Romagnolo per lo Studio e 
la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; I.R.S.T., Meldola, 
(FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
Background: Patients with breast cancer frequently develop bone 
metastases, which are responsible for high morbidity and mortality. 
It is known that numerous molecules are involved in the bone 
metastasization process and that only cancer cells with a specific 
molecular profile are capable of reaching and colonizing bone tissue. 
The early detection of patients with a high probability of relapsing 
to bone could be used to select candidates for tailored therapy with 
bone-specific drugs such as bisphosphonates or RANK-L inhibitors. 
The aim of the present study was to identify a pattern of tissue markers 
from primary breast cancer capable of predicting bone metastatization.
Material and methods: The expression of different markers was 
retrospectively analyzed in frozen breast cancer tissue samples from 
40 patients comprising 15 cases with no evidence of disease (NEDP), 
15 with bone metastases (BMP), and 10 with visceral metastases 
(VMP). Twelve transcripts were analyzed by Quantitative Real 
time PCR: trefoil factor 1(TFF1), DKK1, bone sialoprotein (IBSP), 
heparanase (HPSE), osteopontin (SPP1), Agr2, SPARC, CTGF, 
COMP, follistatin (FST), osteoprotegerin and RANK. The predictive 
accuracy of each marker was calculated using receiver operating 
characteristic (ROC) curves.
Results: Analysis of marker expression in the 3 different subgroups 
showed twofold higher median values of COMP and HPSE in BMP 
with respect to either NEDP or VMP (no significant difference). 
Furthermore, TFF1 median value was about sevenfold higher in BMP 
than in the other 2 subgroups (p=0.05). The area under the curve 
(AUC) was 0.73 for TFF1 and 0.62 for COMP and HPSE. Considering 
markers as dichotomous variables, TFF1 expression in BMP reached 
67% compared to 21% and 20 % in NEDP and VMP, respectively. 
In dichotomous variable analysis, the most important result was 
observed for TFF1; in particular, TFF1 positivity was observed in 
67% of cases in the BMP subgroup compared to only 21% and 20 % 
in NEDP and VMP, respectively. The combination analysis of TFF1 
and other markers showed that positivity to at least one of the three 
markers, TFF1, DKK1, or IBSP, was observed in 80% of cases for 
the BMP group, and in only in 21% and 20% of cases in NEDP and 
VMP subgroups (p=0.041). Another interesting marker was RANK: 
although sensitivity was fairly low (12%), specificity reached 100% 
in both control groups.
Conclusions: Our preliminary study identified a RT-PCR gene 
expression pattern in primary breast cancer that could predict patients 
destined to bone relapse. Such patients could consequently benefit 
from adjuvant treatment with bone-targeted therapy.
P2-01-16
Dissecting the Cellular Mechanism of Induction and Sustenance 
of Dormancy by Rho GTPases in Breast Cancer.
Chatterjee M, van Golen KL. University of Delaware, Newark, DE
Tumor dormancy has been a very real problem in breast cancer 
survivors where recurrences are common and usually fatal. Molecular 
mechanisms involved in this process are often poorly understood and 
are a hot spotin breast cancer research today.
We have found that Rho GTPases, specifically RhoC, is hyperactivated 
in low metastatic dormant breast tumor cells while RhoA is 
downregulated. We also found RhoC causes phosphorylation of c-jun 
NH2 terminal kinase (JNK) in these cells which in turn activates the 
process of autophagy, a possible mode of cell survival in dormant 
tumor cells. Modulating RhoC affected phosphorylation of JNK. 
Also, abrogating JNK by a pharmacological inhibitor SP600125 
inhibited expression of the autophagy marker LC3B-II. Autophagy 
genes like Atg 5 and Atg12 were expressed along with the autophagy 
marker LC3B-II. On inhibiting autophagy by a specific inhibitor 
3-Methyladenine (3-MA), cells did not readily undergo apoptosis but 
on stressing them doubly with LY294002, an inhibitor of Class I PI3K, 
along with 3-MA (inhibitor of Class III PI3K), significant number of 
dormant cells underwent apoptosis as observed by TUNEL staining.
We also found that p190RhoGAP was activated in these dormant cells 
which may lead to the observed downregulation of RhoA activation 
levels. Involvement of beta-1 integrin along with c-src in activation 
of RhoC was observed in these dormant cells. We are in the process 
of further elucidating these signal transduction processes that might 
be involved in cellular dormancy of breast cancer.
A better understanding of some of the cellular mechanisms of 
induction and sustenance of dormancy may aid in formulating 
therapies for annihilating these dormant tumor cells thus preventing 
the often fatal relapses in breast cancer survivors.
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P2-01-17
L1-CAM Promotes Adhesion of Breast Cancer Cells to the 
Endothelium.
Milde-Langosch K, Dippel V, Schröder C, Wicklein D, Hein S, Jänicke 
F, Müller V, Schumacher U. University Medical Center Hamburg-
Eppendorf, Hamburg, Germany
Background: Overexpression of the adhesion molecule L1-CAM (L1) 
in breast cancer is correlated with nodal involvement, high grading, 
and a shorter recurrence-free and overall survival, but the mechanism 
leading to this effect is poorly understood. L1 is also expressed in 
endothelial cells promoting the interaction between lymphatic cells 
and endothelia via homophilic L1-L1 interaction. This mechanism 
might also mediate adhesion of breast cancer cells to endothelia 
and thus promote metastasis. To examine this likely role of L1, the 
impact of L1 expression in breast cancer cells on their adherence to 
human pulmonary microvascular endothelial cells (HPMEC) was 
investigated and potential L1 ligands on these cells were identified.
Methods: MDA-MB231-Fra2 breast cancer cells expressing high 
levels of L1 were stably transfected with shRNA vectors to generate 
two clones with strong L1 downregulation (L1low clones). Adherence 
of these clones to endothelial cells was studied in dynamic cell-flow 
adhesion assays in channels seeded with HPMEC simulating in 
vivo-conditions. Rolling or adherent cells per minute were counted 
using CapImage software. For the cell-flow assay HPMEC were 
activated with TNFa. In order to identify the L1 ligand, endothelial 
cells were partly pre-incubated with blocking antibodies directed to 
the potential binding partners L1, ALCAM, ICAM-1 and E-selectin 
before interaction with tumor cells. In additional experiments, flow 
chambers were coated with recombinant L1-CAM, ICAM1, ALCAM 
or E-selectin, and the adherence of MDA-MB231 cells with high or 
low L1 expression to these proteins was investigated.
Results: Adhesion of MDA-MB231 cells to activated HPMEC was 
significantly higher in L1high cells compared to L1low clones, 
where the number of adherent cells was only 40-50% of the L1high 
control (p=0.025; p=0.035). Blocking experiments showed that the 
adherence of L1high cells could be reduced by antibodies directed 
to ALCAM (p=0.0007), but not to ICAM1. Anti-L1 antibodies had a 
significant effect only in passages of endothelial cells which showed 
L1 expression, whereas E-selectin blocking strongly diminished 
adherence of breast cancer cells irrespective of their L1 expression. 
In addition, L1low clones showed significantly lower adhesion to 
recombinant L1, ALCAM and E-selectin proteins compared to the 
parental cells.
Conclusion: Our experiments indicate that L1 expression in breast 
cancer cells leads to an increased adherence to activated endothelial 
cells via homophilic (L1-L1) or heterophilic (L1-ALCAM) 
interactions. This mechanism is a possible explanation for the 
increased metastatic potential and poor prognosis in L1-positive 
carcinomas observed in vivo. Our results suggest that this adhesion 
molecule might be a suitable target for therapeutic interventions.
P2-01-18
Cancer Stem-Like Cells in Breast Cancer Progression.
Valejo FAM, Andrade JM, Sicchieri RD, Antonio HMR, Marana 
HRC, Mouro LR, Oliveira TMG, Benevides L, Silva JS, Muglia VF, 
Tiezzi DG. Faculdade de Medicina de Ribeirão Preto - University 
of São Paulo, Ribeirão preto, SP, Brazil; Faculdade de Medicina de 
Ribeirão Preto - University of São Paulo, Ribeirao Preto, SP, Brazil
Background: increasing evidences support the presence of cancer 
stem-like cells (CSLCs) within breast carcinomas. A subset of cells 
enriched for CSLCs within the tumor can be identified by flow 
cytometry. It has been supposed that CSLC component is responsible 
for tumor resistance and metastasis. However, the analysis of such 
population has never been evaluated during breast cancer progression.
Patients and Methods: We prospectively included 98 women with 
histologically proven breast carcinomas to assess the presence of 
CSLCs within the primary tumor. According to clinical stage (CS), 
five patients were CS 0 (palpable DCIS), 16 CS I, 20 CS II and 
negative lymph nodes (IIA-), 20 CS II and positive lymph nodes 
(IIA+), 6 IIIa, 17 IIIb, 1IIIc and 2 CS IV. Additionally, ten lymph 
node metastases from IIA+ patients were analyzed. Invasive ductal 
carcinoma (IDC) was observed in 79 patients. We excluded from the 
analysis patients with non ductal histology (n= 11). The percentage 
of CD44+/CD24- (n= 79), ALDH1+ (ALDEFLUOR®) (n= 29), 
ABCG2+ (n= 44 ) and CXCR4+ (n= 46 ) cells within ESA+ cells 
was determined by flow cytometry in fresh sampled tumors. The 
mammosphere assay was studied in 14 samples. The relationship 
between cytometry analyses and clinical and pathological features 
was analyzed.
Results: The median prevalence of CD44+/CD24- cells within ESA+ 
population was 1.63% in stage 0, 2.39% in stage I, 0.42% in stage 
IIA-, 8.15% in stage IIA+, 0.52% in stage III (p=0.005). The CD44+/
CD24- cell population was analyzed in 10 lymph node metastasis 
and, the median prevalence of this population within ESA+ cells 
was 4.7%. There was no variation of median prevalence of ALDH1+, 
CXCR4+, ABCG2+ and the median number of spheres among clinical 
stages (p=0.1, p=0.8, p=0.8, p=0.8, respectively). We didn’t observe 
any association among the expression of, ABCG2+, CXCR4+ with 
histological grade and the expression of ER and PgR. The median 
percentage of CD44+/CD24- cells was higher (2.39% vs 0.41%) in 
ER positive tumors (p=0.003). The median percentage of ESA+/
CXCR4+ cells was higher (42,5% vs 9,7%) in HER2- tumors. There 
was no correlation between the studied markers and the patients’ age 
and clinical tumor diameter. The results are summarized in Table 1.
Results of association between expression cells surface markers and ALDH1 activity (Aldefluor®) 
with clinical and pathological features in invasive ductal carcinomas.
 ESA+/CD44+/CD24- ESA+/ALDH1+ ESA+/CXCR4+ ESA+/ABCG2+
CS p=0.005 p=0.15 p=0.83 p=0.88
0 1.63 6.69 47.3 69.2
I 2.39 36.4 37.2 20.4
IIA- 0.42 20.2 31.4 41.9
IIA+ 8.15 23.9 19.9 27.0
III 0.52 6.2 11.2 61.1
Grade p=0.44 p=0.78 p=0.25 p=0.99
I 1.85 26.1 36.5 35.2
II 1.02 18.6 10.9 50.7
III 1.42 14.0 29.0 50.7
ER p=0.003 p=0.4 p=0.06 p=0.6
Positive 2.39 20.2 41.8 49.5
Negative 0.41 16.7 10.9 33.1
PgR p=0.18 p=0.33 p=0.2 p=0.8
Positive 1.81 21.9 41.8 41.9
Negative 0.68 18.6 18.3 49.5
HER2 0.14 p=0.8 p=0.03 p=0.9
Positive 1.10 20.0 9.7 42.3
Negative 1.85 18.6 42.5 53.0
Discussion: We found a significant variation in CSLC population 
during breast cancer progression. Our data show a gradual increase 
in CD44+/CD24- cells within ESA+ population from stage 0 to stage 
IIA+ and a significant decrease in stage III tumors. This observation 
supports the hypothesis that a population of CSLCs could be 
associated with breast cancer progression.
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Expression of Receptor Like Protein Tyrosine Phosphatases mu 
(PTPRM) in Breast Cancer and the Biological Effects of PTPRM 
on Breast Cancer Cells.
Sun P-H, Ye L, Mansel RE, Jiang WG. Cardiff University School of 
Medicine, Cardiff, Wales, United Kingdom
Introduction:
Protein tyrosine phosphatases (PTPs) play a major role in many 
cellular functions including cell survival, proliferation, differentiation 
and motility. The receptor-like protein tyrosine phosphatase mu 
(PTPRM) has a similar structure to cell-cell adhesion molecules and 
has been shown to exhibit homophilic binding and confer cell-cell 
adhesion in cells including epithelial and cancer cells. However, the 
role played by PTPRM in breast cancer remains unclear. The present 
study investigated the expression of PTPRM in breast cancer and the 
biological impact of PTPRM on breast cancer cells.
Methods:
Expression of PTPRM protein and gene transcript was examined 
in a cohort of primary breast cancer tumours. The association of 
PTPRM transcripts level and pathological and clinical aspects was 
then analysed. Expression of PTPRM transcript in breast cancer cells 
were knocked down using a specific anti-PTPRM transgene. The 
impact of PTPRM knockdown on breast cancer was evaluated using 
a series of in vitro cell models and in vivo tumour model.
Result:
PTPRM protein was seen generally distributed in the breast tissues, 
including tumours and normal background tissues. A stronger staining 
was revealed in cytoplasm of both mammary epithelia and cancer 
cells in comparison with the surrounding stromal cells. A significantly 
decrease was seen in poorly differentiated tumours (92.5±279), and 
moderately differentiated tumours (288±110), compared with that 
of well differentiated (472±114), p=0.011 and p=0.031 respectively. 
PTPRM transcript levels were decreased in patients died from breast 
cancer. The expression of PTPRM transcripts was significantly 
associated with disease free survival. Patients with lower expression 
of PTPRM had shorter survival compared with those with high level 
of PTPRM expression (p=0.029). Knocking down PTPRM from 
breast cancer cells significantly increased cell adhesion compared 
with control cells (p<0.001). Likewise, the knockdown also marked 
increase the rate of cell migration (102.9±11.3µm for control vs 
115.3±10.5µm for PTPRM knockdown, p<0.05).
Conclusion: The expression of PTPRM transcripts is decreased in 
poorly differentiated breast tumours and is correlated with poorer 
long term survival. This is likely to be contributed to by the biological 
impact of PTPRM on the aggressiveness of breast cancer cells.
P2-01-20
Reduced Plakoglobin Expression Increases the Metastatic 
Potential of Breast Cancer Cells.
Ottewell PD, Whitworth J, Cross SS, Nutter FH, Holen I. University 
of Sheffield, Sheffield, Yorkshire, United Kingdom
The majority of deaths from breast cancer are a result of metastases, 
however, little is understood about the genetic alterations underlying 
their onset. A recent study of human breast cancer biopsies showed 
alterations of expression of 9 genes in primary tumours that had 
metastasized compared to benign tumours. Of these, plakoglobin 
was the most altered, with metastatic tumours showing a 3x decrease 
in expression compared to benign. Furthermore, expression of 
plakoglobin is reduced upon autocrine production of human growth 
hormone, which is associated with increased breast tumour cell 
invasion in vivo. Plakoglobin codes for the adhesion protein gamma-
catenin, an integral part of the cadherin-catenin complex involved in 
cell-to-cell adhesion. The aim of the current study is to investigate the 
effects of plakoglobin knockdown on cell proliferation, migration, 
adhesion and invasion in  vitro and  in vivo.
The non-metastatic human breast cancer cell lines MCF7 and T47D 
that express high levels of plakoglobin and gamma-catenin were stably 
transfected with miRNA to two different regions of the plakoglobin 
gene, or scramble vector, to produce plakoglobin knockdown and 
controls for each cell line. Plakoglobin gene expression was monitored 
by qPCR and gamma-catenin expression by Western blot. Cell 
proliferation was assessed 24, 48, 72 and 96 hours post seeding; cell 
migration and invasion were measured over 24 and 48 hours using 
scratch and modified Boyden Chamber assays. Cell-cell adhesion 
was assessed by spheroid formation in agar matrix. For in vivo 
experiments, MCF7 plakoglobin knockdown and control cells were 
inoculated into the 5th and 10th mammary fat pads of 12-week old 
female balb/c mice (n=10 per group). Tumour growth was monitored 
by caliper measurements and local invasion was investigated 6 weeks 
after tumour inoculation on histological sections. Shedding of tumour 
cells into the blood stream and evidence of metastatic bone lesions 
was monitored by flow cytometry and mCT, respectively.
Plakoglobin and gamma catenin expression were reduced by more 
than 80% in all knockdown cell lines used but were unaltered 
following transfection with the scrambled vector. Furthermore, 
knockdown of plakoglobin did not effect expression of its binding 
partner, e-cadherin. Reduced expression of  plakoglobin resulted in 
a more than 3-fold increase in MCF7 and T47D cell proliferation in 
vitro (p<0.005) and a 2-fold increase in MCF-7 proliferation in vivo 
(P<0.05), compared with control. In addition plakoglobin knockdown 
cells showed a 6 – 15 fold increase in invasion through basement 
membrane (p<0.005), a 2-fold increase in migration (p<0.005) and 
exhibited reduced cell-to-cell adhesion compared with control cells.
Data show that decreased expression of plakoglobin increases the 
early pro-metastatic behaviour of cells including increased cell 
proliferation, migration and invasion.
P2-01-21
The Biological Influence of Brain Derived Neurotrophic Factor 
(BDNF) on the Aggressiveness of Human Breast Cancer Cells.
Yang MX, Martin TA, Jiang WG. Capital Medical University, Beijing, 
China; Cardiff University School of Medicine, Cardiff, United 
Kingdom
Introduction: Brain derived neurotrophic factor (BDNF) is a member 
of the neurotrophin superfamily and has been indicated in the 
pathophysiology of the nervous system and is important in a number 
of neurological and psychological conditions. Recently, BDNF has 
also been shown to play a role in the development and progression of 
solid tumours myeloma, lung cancer and prostate cancer. It has been 
recently reported that BDNF is also aberrantly expressed in human 
breast cancer and that a raised level of BDNF is associated with poor 
clinical outcome and reduced survival. The present study aimed to 
investigate the biological role of BDNF in human breast cancer.
Materials and methods: A panel of human breast cancer cells 
were used in the present study. The expression profile of BDNF 
was evaluated using RT-PCR. We constructed a set of anti-BDNF 
transgenes which were used to transfect breast cancer cells in order 
to generate BDNF knockdown cells (MCFDBDNF). The impact of 
BDNF knockdown on growth and cellular migration were evaluated 
using standard growth assays and ECIS (electronic cell impedance 
sensing) technology.
Results: BDNF gene transcripts were successfully detected in the 
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breast cancer cell lines, MCF-7, MDA MB-231 and ZR 75-1. MCF-7 
wild type cells were subject to transfection of anti-BDNF transgenes, 
followed by the establishment of BDNF knockdown sub-lines and 
empty vector control cells (MCFpef). Loss of BDNF in breast cancer 
cells resulted in reduction of cell growth rate (growth rate in MCFDBDNF 
by day 3 1.60+/-0.11, compared with 2.06+/-0.04 in MCFpef, p=0.006). 
Using electric cell-substrate impedance sensing, it was found that 
loss of BDNF in breast cancer cells resulted in a significant increase 
in the rate of cellular attachment and migration (migration rate over 
14 h in ohms: MCFDBDNF 6310.125+/-595.183 compared with MCFpef 
5115.5 +/-422.394, p=0.0003).
Conclusion: When BDNF was stably knocked down in MCF-7 cell 
lines, the growth and proliferation were decreased. The ECIS results 
also showed that cell migration was decreased in MCF-7 cells stably 
transfected with ribozymes for BDNF compared with the vector 
control. It is concluded that BDNF, a neurotrophic growth factor 
aberrantly expressed in cancers such as breast cancer, has a profound 
impact on the cellular behaviour of breast cancer cells and that loss 
of BDNF is associated with a reduction of the aggressiveness of 
breast cancer. BDNF is therefore a potential therapeutic target in 
breast cancer and its effect in human breast cancer requires further 
investigation.
P2-01-22
Characterization of Four ER-Negative Breast Primary Tumor 
Dissociated Cultures as a Model for the In Vitro and In Vivo 
Study of Tumorigenesis, Metastasis and Angiogenesis.
Drews-Elger K, Brinkman JA, Dean SJ, El-Ashry D. University of 
Miami, Miller School of Medicine, Miami, FL
ER negative breast cancers comprise a subtype of tumors for which 
there are few therapies with successful response. Currently, the use 
of established cell lines has allowed detailed molecular and cellular 
studies on cancer mechanisms ranging form stem cells to proliferation, 
from tumorigenesis to invasion and metastases, and from tumor 
suppressors to oncogenes. But while cell lines provide a source of 
homogeneous, propagatable material, a drawback of this model is 
that most breast cancer cell lines are derived from metastatic lesions 
that may harbor additional mutations and have little resemblance with 
the primary tumor of origin. Additionally, the continuous passage of 
these cells over the last 20-plus years has given rise to well-established 
differences in growth rate, hormone receptor status, karyotype and 
clonogenicity. Our purpose here was to characterize four primary 
dissociated tumor (DT) cell cultures from ER- breast tumors, the 
establishment of which we had previously described, to determine 
if they could provide more accurate models for both in vitro and in 
vivo studies. These four DT cultures (DT16, DT22, DT25 and DT28) 
display a triple negative phenotype and were characterized by their 
genomic profile by the PAM50 predictor analysis as belonging to 
the basal (DT22, DT25 and DT28) and luminal B (DT16) subtypes. 
Of those cultures for which primary tumor sample was available, 
microarray gene expression profiling and cell line clustering analysis 
show the primary tumor and dissociated culture cluster together 
and to similar breast tumors. Interestingly, of the three basal DT 
cultures, DT22 clusters with Claudin-low tumors and cell lines. We 
have established that each of these 4 DTs are tumorigenic in the 
NOD/SCID mouse model, and are now assessing their metastatic 
potential. DT16 generated metastases in 25% of the mice (6 out 
of 24; two in liver, four in lymph node). DT22 generated highly 
vascularized tumors, which may provide a relevant model for study 
of the in vivo vascular recruitment process. In addition, we have 
analyzed and characterized the role of pivotal signaling pathways 
often deregulated in breast cancer such as EGFR, P-MAPK, PI3k/
mTOR, p53, TGFb, Hedgehog, Notch, and Wnt in both the 2D culture 
as well as in sections of xenograft samples. Given that the scope 
of primary tumor heterogeneity and consequently the early stages 
of breast tumorigenesis are under-represented by current in vitro 
models in breast cancer research, the use of these DT cell cultures 
could more accurately recapitulate the disease in both the in vitro 
and in vivo settings.
P2-01-23
Seprase Promotes the Growth and Impairs the Migratory Ability 
of Breast Cancer Cells.
Jia J, Martin TA, Jiang WG. Peking University, Beijing, China; 
Cardiff University School of Medicine, Cardiff, United Kingdom
Background: Seprase or Fibroblast Activation Protein alpha (FAP-a) 
is an integral membrane serine peptidase. It has been shown that it 
plays an important role in tumour proliferation, migration, invasion 
and angiogenesis. However, previous work has not satisfactorily 
explained both the suppression and promotion effects that have 
been observed. Furthermore, the interaction of Seprase with other 
membrane molecules or pathway had not been well investigated. This 
study aimed to investigate the role of Seprase in human breast cancer.
Methods: The full length of Seprase cDNA was isolated from 
normal human prostate tissue using RT-PCR and then cloned into an 
expression vector (pEF6-V5 His, TOPO). Following confirmation 
of successful cloning, the plasmid was transfected into the to human 
breast cancer cell lines, MCF-7 and MDA-MB-231. The function of 
Separase in these two cell lines was then analysed using cell function 
assays and ECIS, and the potential interaction with other signalling 
pathways explored.
Results: Compared with the MCF-7 wild type cells (MCF-7wt) and 
the MCF-7 cells transfected with pEF6/V5 empty vector (MCF-7pef), 
the MCF7 cells transfected with Seprase (MCF-7exp) had increased 
growth ability and impaired migratory ability. The growth rate of 
MCF-7exp cells was 1132.72% on day 5 while those of MCF-7wt and 
MCF-7pef control cells were 897.24% and 990.99% respectively 
(p=0.011 and 0.032). The resistance increase of MCF-7exp cells at 2 
hours after wounding in ECIS assays was 478.22ohms compare with 
1063.75 ohms and 1563.09 ohms in MCF-7wt and MCF-7pef control 
cells (p<0.05). In MDA-MB-231 cells, over-expression of Seprase 
resulted in impaired motility. The resistance increase of the MDA-
MB-231 wild type cells (MDA-MB-231wt), MDA-MB-231 cells 
tranfected with pEF6/V5 vector (MDA-MB-231pef), and the MDA-
MB-231 cells transfected with Seprase (MDA-MB-231exp) at 3 hours 
after wounding in ECIS assay were 216.75ohms, 216.00ohms and 
120.16ohms respectively. The growth of MDA-MB-231 cells and the 
adhesion and invasion ability of both MCF-7 cells and MDA-MB-231 
cells were not dramatically influenced with Seprase expression. An 
inhibitor to focal adhesion kinase (FAK) restored the reduced motility 
ability of both MCF-7exp cells and MDA-MB-231exp cells. However, 
inhibitors to PI3K, ERK and ROCK had no influence on it.
Conclusion: These results suggest that Seprase promotes proliferation 
but inhibits the migration of breast cancer cells by potentially 
regulating the FAK pathway.
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Triple-Negative Breast Cancer Emerges from the Luminal 
Progenitor Compartment.
Nogi H, Kamio M, Kato K, Kawaase K, Toriumi Y, Takeyama H, 
Uchida K. The Jikei University School of Medicine, Tokyo, Japan
Background: Triple-negative breast cancers (TNBC) are defined as 
tumors that lack expression of estrogen receptor (ER), progesterone 
receptor (PgR), and human epidermal growth factor receptor type 
2 (HER2). Majority of TNBC (approximately 80%) are basal-like 
breast cancers. The question of whether there is a specific, identifiable 
cell in the normal breast form which basal-like breast cancers arise 
is controversial. We evaluated the frequency and receptor status of 
ductal carcinoma in situ (DCIS) and ductal components associated 
with T1 invasive ductal carcinoma (IDC) to clarify the developmental 
pathway of TNBC.
Methods: From our institutional archives between April 2000 and 
April 2011, we retrieved 758 cases of DCIS and T1 invasive ductal 
carcinoma without prior operative treatment. Immunohistochemistry 
for ER, PgR and HER2 was performed on ductal components and 
invasive components. Statistical analysis was performed using Fisher 
Extract Test.
Results: The frequencies of triple-negative (TN) subtype at each size 
were not seen significant differences. Ductal components were seen 
in 51 (84%) TN-IDC cases. Within 51 cases, the ductal components 
were TN in 49 cases. The remaining 3 cases were positive for ER 
and PgR, but negative HER2.
Frequencies of each subtype
 TN HR+HER2- HR+HER2+ HR-HER2+ Total
DCIS 11 (7%) 115 (75%) 6 (4%) 21 (14%) 153
T1mic 2 (13%) 9 (56%) 3 (19%) 2 (13%) 16
T1a 8 (14%) 38 (68%) 2 (4%) 8 (14%) 56
T1b 8 (9%) 71 (79%) 4 (4%) 7 (8%) 90
T1c 43 (9%) 329 (60%) 36 (8%) 35 (7%) 443
HR: hormone receptor
Conclusion: The resemblance between ductal components and 
invasive components and the coincident frequency of TNBC at 
each size sustain the hypothesis that TNBC arise from the luminal 
progenitor compartment.
P2-01-25
Truncated p110 ERBB2 (CTF611) Increases Migration and 
Invasion of Breast Epithelial Cells by Inhibiting STAT5b 
Activation.
Ward TM, Iorns E, Hoe N, Kim P, Singh S, Ernani V, Liu X, Jegg 
A-M, Gallas M, Lippman ME, Pegram MD. University of Miami 
Miller School of Medicine, Miami, FL; Prometheus Laboratories, 
San Diego, CA
Background: Truncated ERBB2 receptors are present in a subset of 
human ERBB2+ amplified/ overexpressing breast tumors, and are 
associated with trastuzumab resistance, metastasis, and poor clinical 
prognosis. However, whether truncated ERBB2 receptors are drivers 
of metastasis has not been well defined. In this study, we examined 
effects of full-length (p185) and truncated (p110) ERBB2 on the 
migration and invasion of human mammary epithelial cells, including 
HMLE and MCF10A cells.
Material and Methods: Recombinant p185 and p110 ERBB2 were 
stably expressed in human mammary epithelial cells (HMLE) and 
MCF10A cells via retroviral vector. Expression of comparable 
levels of p185 and p110 in cells was confirmed by western blot. The 
phosphorylation states of downstream signaling proteins including 
STAT5 were assayed via phosphoproteomics and Collaborative 
Enzyme Enhanced Reactive (CEER™) immunoassay. The effects of 
the p110 constructs on cell migration and invasion were investigated 
by transwell assays. shRNA-encoding lentivirus was used for specific 
silencing of STAT5b in HMLE cells, and STAT5b silencing was 
confirmed at the protein level using western blot.
Results and Discussion: Expression of p110 ERBB2 increased 
cell migration (HMLE, p = 0.04; MCF10A, p< 0.01) and invasion 
(HMLE, p= 0.03) when compared to expression of p185. Furthermore, 
expression of p110 in HMLE cells was associated with reduced 
phosphorylation of STAT5b. shRNA mediated silencing of STAT5b 
was sufficient to increase the migration (p < 0.01) and invasion of 
HMLE cells, phenocopying the p110 driven effects on HMLE cells. 
In clinical studies, loss of activated STAT5 protein correlates with 
breast cancer progression and is a negative predictor of survival. By 
analyzing publicly available gene expression datasets, we found that 
STAT5b mRNA expression is also significantly decreased in breast 
cancer compared to normal breast tissues in several studies, as well 
as in ERBB2 amplified vs. nonamplified samples. To our knowledge, 
this is the first reported perturbation of STAT signaling by truncated 
ERBB2 receptor, and suggests a mechanism by which truncated 
p110 ERBB2 (CTF611) increases migration and invasion of breast 
epithelial cells. This study extends the available data regarding STAT5 
loss in breast cancer progression.
P2-01-26
TIMPv: a novel downstream transcriptional target gene that 
underpins CD146-suppressed breast tumor invasion
Ouhtit A, Abdelmageed Z, Fernando A, Gaur RL, Raj MHG. College 
of Medicine & Health Sciences, Sultan Qaboos University, Muscat, 
Oman; Louisiana State University Health Sciences Center; Stanley 
S Scott Cancer Center, New Orleans, LA, United States
Background: CD146, a marker of endothelial cells, promotes tumor 
progression of many cancers including melanoma and prostate. 
Strikingly, several lines of evidence suggest that it is a suppressor of 
breast cancer (BC) progression. Not only the ligand(s) has not been 
identified, but CD146-downstream signaling mechanisms remain 
unknown. 
Material and Methods: Here, we report the functional importance of 
CD146 and that of a novel transcriptional target of CD146-signaling, 
variant of tissue inhibitor of metalloproteinases (TIMPv) identified by 
microarray analysis, in underpinning the suppression of BC invasion, 
using novel validated Enhanced Green Fluorescent Protein (EGFP)-
inducible systems of CD146 expression both in vitro and in vivo. 
Results: In functional experiments, induction of CD146 inhibited 
BC cell migration and invasion. TIMPv was identified by expression 
profiling as a novel transcriptional target of CD146-signaling, an 
association validated by quantitative PCR and immunoblotting 
experiments in a range of breast and melanoma cancer cells. However, 
siRNA inhibition of CD146 in the SKMel-28 melanoma cell line 
increased TIMPv expression, suggesting that while TIMPv is a 
positive transcriptional target of CD146 in BC cells, it is negatively 
regulated in melanoma cells. Furthermore, the functional relevance 
of TIMPv to CD146-suppressed metastasis was demonstrated by 
selective suppression of TIMPv in CD146-expressing BC inducible 
cells using RNAi. More interestingly, induction of CD146 expression 
in vivo using mouse EGFP-inducible system of CD146 expression 
resulted in suppression of breast tumor growth.
Discussion: Our study is the first report to provide a functional 
molecular link of TIMPv to cancer via unique axis that underpin 
CD146-suppressed BC progression, thus identifying TIMPv as a 
potential target for guiding the development of novel therapeutic 
strategies for BC.
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P2-02-01
A Novel Inflammatory Breast Cancer-Specific Oncogene, 
Tazarotene-Induced Gene 1, Promotes Tumorigenicity and 
Invasiveness through the Receptor Tyrosine Kinase Axl.
Wang X, Saso H, Iwamoto T, Pusztai L, Gong Y, Woodward WA, 
Reuben JM, Hortobagyi GN, Ueno NT. Morgan Welch Inflammatory 
Breast Cancer Clinic; The University of Texas MD Anderson Cancer 
Center, Houston, TX; University of Texas MD Anderson Cancer 
Center, Houston, TX
Background: Inflammatory breast cancer (IBC) is the most lethal 
and aggressive form of breast cancer and is highly metastatic. The 
prognosis of patients with IBC is poor, and effective standard therapies 
for IBC are limited because the molecular mechanisms underlying 
the pathogenesis of IBC remain unknown. We recently found that 
tazarotene-induced gene 1 (TIG1) expression is significantly higher 
in IBC cell lines than in non-IBC cell lines. In both IBC and non-
IBC data sets, estrogen receptor-negative/HER2-negative samples 
had significantly higher expression of TIG1 than did other clinical 
subtypes (estrogen receptor-positive/HER2-negative and HER2-
positive). Therefore, we hypothesized that TIG1 plays an important 
role in the malignant process of IBC. In these studies, we determined 
the biological function of TIG1 in IBC cells and elucidated the 
molecular mechanism by which TIG1 regulates the invasiveness of 
IBC cells.
Methods: TIG1 expression in SUM149 and KPL-4 IBC cells was 
stably knocked down, and the effects of this knockdown on in vitro 
cell proliferation, migration, and invasion were analyzed. The effects 
of restoring TIG1 expression on TIG1-silencing IBC cells were 
also examined. To determine the tumorigenic activity of TIG1 in 
vivo, TIG1 stable-knockdown SUM149 cells and control shRNA-
transfected cells were implanted into the mammary fat pads of athymic 
nude mice, and tumor growth was monitored. The receptor tyrosine 
kinase Axl, a potential functional partner of TIG1, was identified using 
DNA microarray analysis. The interaction between TIG1 and Axl in 
IBC cells was examined using immunoprecipitation and confocal 
microscopy assays. The signaling pathway in IBC cells in which 
TIG1 participates was also investigated.
Results: Knockdown of TIG1 expression in IBC cells reduced their 
proliferation, migration, and invasion in vitro. Also, silencing of 
TIG1 dramatically inhibited IBC tumor growth in a xenograft model. 
Moreover, restoring TIG1 expression rescued the proliferation, 
motility, and invasiveness of TIG1-silenced IBC cells. Most 
importantly, we identified Axl as a functional partner of TIG1 by 
showing that TIG1 interacted with and stabilized Axl in IBC cells. 
TIG1 regulated the invasiveness of IBC cells through mediation of the 
Axl signaling pathway. In SUM149 cells, TIG1 depletion decreased 
Axl expression, which led to downregulation of expression of matrix 
metalloproteinase-9, a molecule required for Axl-mediated invasion, 
and inactivation of nuclear factor-kB, ultimately leading to decreased 
invasiveness of IBC cells.
Conclusion: Our results identified TIG1 as an oncogenic gene that 
contributes to the tumorigenic and metastatic properties of IBC. Our 
data also linked TIG1 with the key tumorigenic gene Axl in IBC cells. 
Further studies designed to establish TIG1 as a therapeutic target in 
the treatment of patients with IBC are under way.
P2-02-02
Mutation of the APC Tumor Suppressor Stimulates Breast 
Cancer Cell Proliferation through Hyperactivation of FAK/Src/
JNK Signaling.
Prosperi JR, Yang FF, Goss KH. University of Chicago, Chicago, IL
Background: The Adenomatous Polyposis Coli (APC) tumor 
suppressor gene is silenced by hypermethylation or mutated in as 
many as 70% of human sporadic breast cancers. In mouse models, 
germline mutation of Apc disrupts normal mammary development 
and predisposes to mammary tumor formation. In an effort to more 
accurately model human breast cancer and determine the role for APC 
inactivation in the context of other oncogenic events, our laboratory 
has recently demonstrated that APC loss promotes mammary tumor 
development in the presence of the Polyoma virus middle T antigen 
(PyMT) oncogene, and results in a tumor phenotype resembling 
human metaplastic breast cancer. In this model, Apc mutation 
significantly enhances tumor cell proliferation but does not impact 
Wnt/b-catenin signaling. Because APC loss also induces mammary 
tumor cell spreading and morphological changes, we hypothesized 
that APC may regulate proliferation via signaling by the focal 
adhesion kinase (FAK) and Src (kinases) downstream of altered 
cell-matrix interactions.
Materials and Methods: Cell lines were established from primary 
cultures of experimental (MMTV-PyMT;ApcMin/+) and control 
(MMTV-PyMT;Apc+/+) mammary tumors and maintained in RPMI 
1640 supplemented with 10% FBS and antibiotics at 37°C with 5% 
CO2. Cell proliferation was measured by incorporation of 5-bromo-2-
deoxyuridine (BrdU), and subsequent immunofluorescence (IF) with 
an anti-BrdU antibody. Western blot analysis and IF were utilized to 
quantify the expression of junctional and signaling molecules and 
determine their localization, respectively. To investigate Wnt/b-
catenin pathway activation, dual-luciferase reporter assays were 
performed using cells transfected with either Top-Flash or Fop-Flash 
reporter constructs.
Results: Cell lines isolated from mammary tumors from MMTV-
PyMT;ApcMin/+ mice had altered morphology and increased rates 
of proliferation, both of which are consistent with our previous in 
vivo findings using this mouse model. In vitro, Apc mutation was 
associated with increased phosphorylation of FAK, Src and Jun 
kinase (JNK). Activation of both Src and JNK were required for the 
enhanced proliferation in the MMTV-PyMT;ApcMin/+ cell lines. In 
contrast, we did not observe any change in the expression of Wnt/b-
catenin target genes, b-catenin subcellular localization, or b-catenin/
TCF-mediated transcriptional activity. Combined, these data suggest 
that the proliferative and morphological changes mediated by APC 
loss in the PyMT breast cancer model are dependent on enhanced 
signaling downstream of cell-matrix interactions but do not involve 
the Wnt/b-catenin pathway.
Discussion: These data indicate that APC status is an important 
determinant of breast cancer cell behavior and specifically suggest that 
integrin-mediated signaling networks, including FAK, Src and JNK, 
are hyperactivated by APC loss to promote tumor cell proliferation. 
Moreover, these preclinical model systems offer a platform for further 
dissecting the molecular mechanisms by which APC contributes to 
breast carcinogenesis as well as identifying therapeutic strategies that 
may be effective in APC-deficient breast cancers.
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P2-02-03
MAP3K3, Amplified in Human Breast Cancer, Promotes Breast 
Tumor Progression and Defines Poor Prognosis.
Dong J. Baylor College of Medicine, Houston, TX
Gene amplification in the 17q chromosomal region is observed 
frequently in breast cancers. An integrative bioinformatics analysis 
nominated MAP3K3 gene, located in 17q23, as a potential therapeutic 
target in breast cancer. This gene encodes the mitogen-activated 
protein kinase kinase kinase 3 (MEKK3), but has not yet been 
associated with cancer-causal genetic aberrations. We found that 
MAP3K3 was amplified in approximately 8-20% of breast carcinomas, 
and that its over-expression was an independent prognostic marker 
for poor outcome with respect to relapse-free and overall survival, 
especially among the estrogen receptor-positive breast cancer patients. 
shRNA-mediated knockdown of MAP3K3 expression significantly 
inhibited cell proliferation and colony formation of MAP3K3-
amplified breast cancer cell lines MCF7 and MDA-MB361, and 
promoted breast cancer cell apoptosis induced by TNFa, TRAIL, 
or a doxorubicin. In addition, ectopic expression of MAP3K3, in 
collaboration with Ras, induced colony formation in both primary 
mouse embryonic fibroblasts and immortalized mammary epithelial 
cells (MCF-10A). Together, these results suggest that MAP3K3 
is a potential biomarker indicating poor prognosis, contributes to 
resistance to therapy, and is an oncogene in breast carcinogenesis. 
Therefore, therapeutic targeting of MAP3K3 may be attractive in 
breast cancer patients with MAP3K3-amplified breast cancer.
P2-02-04
Novel Functions of vps34 in Non-Transformed Epithelial Cells: 
Regulation of Cell Proliferation and Tumorigenesis.
Su H, Xu T, Ganapathy S, Yuan Z-M. UTHSCSA, San Antonio, TX
Autophagic and endocytic pathways are tightly regulated membrane 
rearrangement processes that are crucial for homeostasis, development 
and disease. A list of proteins regulating these cellular processes 
show altered expression in cancers, suggesting derailed autophagy 
or endocytosis as an emerging feature of cancer. Class III 
phosphatidylinositol 3-kinase (PI3kinase) Vps34 regulates both 
autophagic and endocytic systems by recruiting proteins containing 
PtdIns3P binding domains. Recently, many new insights into the 
biology of class III PI3Kinase have been reported. Most of these 
studies, however, used mainly transformed cells. It is unclear whether 
class III PI3Kinase works similarly in non-transformed cells. In 
the recent study, we explored this by depleting both transformed 
and non-transformed mammary epithelial cell lines of Vps34 
using shRNA. In consistent with previous finding, vps34-depleted 
cells are defect in formation of FYVE-GFP puncta, and showed 
altered early and recycling endosome dynamics. In a shark contrast 
to transformed cells where knockdown of Vps34 was associated 
with decreased growth, Vps34 deficiency in non-transformed cells 
resulted in a marked increase in cell proliferation. The deregulated 
autophagy function found in Vps34-depleted cells appeared to be 
not involved in cell growth regulation as silence of either Atg7 
or Beclin1 expression did not affect the growth rate. On the other 
hand, reporter luciferase-based ten-pathway screens suggested an 
altered activity of the MAPK pathway. Indeed, biochemical analysis 
indicated a sustained ERK activation resulting from the impediment 
of endosome-mediated EGFR turnover in Vps34 deficient cells. A 
contribution of the endosomal pathway to Vps34-mediated regulation 
of cell proliferation was further confirmed by using Rab5 and Rab11 
mutants that deregulated early and recycling endosome, respectively. 
Importantly, inactivation of Vps34 compromised the cellular barrier 
against oncogene-mediated transformation, as demonstrated by the 
increased susceptibility of Vps34 depleted cells to Ras-induced colony 
formation in vitro and tumor development in mice. All together, our 
data uncover a novel role for the class III PI3Kinase-endosomal 
pathway in regulation of cell proliferation.
P2-02-05
Molecular Mechanism for Src Homology Phosphotyrosyl 
Phosphatase 2 Regulation of Cell Motility and Migration.
Hartman ZR, Agazie YM. West Virginia University School of Medicine, 
Morgantown, WV
Background: The Src homology phosphotyrosyl phosphatase 2 
(SHP2) acts as a transducer of mitogenic and cell survival signaling 
downstream of receptor tyrosine kinases, cytokine receptors and 
integrins. As such, SHP2 promotes cell growth, transformation, 
survival, and motility, among other processes. Recent studies suggest 
that SHP2 is overexpressed in breast cancer and is essential for the 
maintenance of the transformed phenotype both in the HER2-positive 
and the basal-type/triple-negative breast cancer (BTBC) cells.
Materials and Methods: The expression of SHP2 in BTBC cells 
was suppressed constitutively by lenti virus-mediated transduction 
of specific shRNA. Impact of SHP2 inhibition on cell migration 
was determined by the monolayer wound healing assay. The SHP2 
substrate-trapping mutant was used to identify FAK as an SHP2 
substrate. Site-directed mutagenesis, binding studies and phosphatase 
assays were employed to further characterize FAK as a bona fide 
SHP2 substrate. Immunofluorescence microscopy was conducted to 
visualize the amounts of phosphorylated FAK and its location in the 
cell after adhesion.
Results: We demonstrate that SHP2 is essential for the migration of 
BTBC cells as evidenced by loss of the enhanced migratory behavior 
upon its inhibition. Using the SHP2 substrate-trapping mutant, 
FAK was identified as a biological substrate of SHP2. Site-directed 
mutagenesis, binding studies and phosphatase assays confirmed that 
SHP2 indeed associates with and dephosphorylates FAK at the pY397 
site, a site known to promote the focal adhesion activity of FAK. 
Immunofluorescence of breast cancer cells with SHP2 inhibition were 
found to have higher levels of FAK pY397 further confirming that 
FAK is an SHP2 substrate. The increase in pY397 level correlated 
with loss of cell polarity, enhanced focal adhesion formation, and 
acquisition of non-transformed morphology.
Discussion: These results suggest that dephosphorylation of pY397 of 
FAK by SHP2 is the major mechanism by which it is able to modulate 
cancer cell migration. Together with previous findings, the current 
studies show that SHP2 is a suitable target for therapeutic intervention 
to combat breast cancer metastasis.
P2-02-06
Inhibition of CDK4 Phosphorylation of Smad3 Decreases 
Cyclin D Overexpressing Breast Cancer Cell Proliferation and 
Migration.
Tarasewicz E, Hardy A, Straehla J, Foucar C, Zelivianski S, Jeruss J. 
Northwestern University Feinberg School of Medicine, Chicago, IL
Introduction: Several aspects of breast cancer onset and disease 
progression have been linked to members of the TGFb superfamily 
and their associated downstream signaling components, the Smads. 
Alterations in Smad signaling have been directly implicated in the 
dichotomous role of TGFb in malignancy, enacting both tumor 
suppressant and tumor promoting behaviors in breast carcinogenesis. 
Our previous work characterized Smad3 as a tumor suppressor 
and found that Smad3 action is inhibited upon phosphorylation 
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by cyclin D/CDK4 in breast cancer cells. Others have shown that 
CDK phosphorylation of Smad3 can affect cell motility. Based on 
these findings, we hypothesized that activation of CDK4 leads to 
phosphorylation and inhibition of Smad3, thus releasing cell cycle 
arrest and promoting cell proliferation and metastasis.
Methods: MCF7 parental and cyclin D overexpressing cells (MCF7 
CD1) were treated with a CDK4 inhibitor alone or in combination 
with doxorubicin or paclitaxel and cell proliferation was determined 
using the MTS assay. MCF7 study cells were also transduced with 
lentiviral empty vector, wild-type (WT) Smad3, or Smad3 containing 
mutant CDK sites (T179V and 5M) resistant to inhibitory cyclin 
D/CDK phosphorylation. Stably transduced cells were plated in 
Matrigel 3-dimensional (3D) culture and treated with CDK4 inhibitor 
alone or with doxorubicin over a 12 day time course. Colony area 
was measured using MetaMorph software. Transwell migration 
and Matrigel invasion assays were used to determine the effect 
that transfection with Smad3 CDK phosphorylation site mutants or 
treatment with a CDK4 inhibitor had on highly metastatic cyclin D 
expressing MDA-MB-231 cells. Study wells were fixed/stained and 
the number of migrated or invaded cells was counted.
Results: Treatment with the CDK4 inhibitor alone resulted in a growth 
inhibitory effect on proliferation of MCF7 parental and CD1 cells. 
Treatment with the CDK4 inhibitor in combination with chemotherapy 
resulted in the greatest inhibition of cell proliferation. In 3D culture, 
colonies formed by MCF7 study cells transduced with T179V or 5M 
Smad3 mutant constructs had smaller acinar size when compared with 
vector-transduced control cells. When compared to untreated cells, the 
MCF7 CD1 cells treated with CDK4 inhibitor or chemotherapy alone 
had smaller acinar size, with greatest decrease in size observed when 
the treatments were combined. Lastly, MDA-MB-231 cells transfected 
with the 5M Smad3 mutant construct, containing mutations in all 5 
CDK phosphorylation sites, resulted in the greatest decrease in cell 
migration and invasion, when compared with cells transfected with 
both vector control or WT Smad3. Treatment of the MDA-MB-231 
cells with the CDK4 inhibitor also resulted in a significant decrease 
in cell migration and invasion.
Conclusions: Mutation of CDK phosphorylation sites in the Smad3 
construct or direct inhibition of CDK4 resulted in a decrease in breast 
cancer cell proliferation, 3D colony formation and cell migration and 
invasion. Treatment with the CDK4 inhibitor in combination with 
chemotherapy further augmented these results. Inhibition of CDK4 
and restoration of Smad3 activity may have a role in the treatment 
of breast cancers overexpressing cyclin D.
P2-02-07
Regulation of mTOR Signaling by Proto-Oncogene PELP1.
Gonugunta VK, Cortez V, Rethman C, Nair BC, Sareddy GR, 
Vadlamudi RK. UTHSCSA, San Antonio, TX
BACKGROUND: Despite positive effects of hormonal therapy, 
initial or acquired resistance to endocrine therapies frequently 
occurs. Emerging evidence suggests that ER action is complex and 
requires functional interactions with coregulators. In addition, ER also 
participates in extra-nuclear signaling events in the cytoplasm and 
growth factor cross talk with ER is implicated in the development of 
therapy resistance. The mammalian target of rapamycin (mTOR) is 
a serine/threonine kinase that plays an important role on cell growth 
and proliferation. Proline, Glutamic-acid and Leucine-rich Protein 
1 (PELP1) is an ER coregulator that functions in nuclear as well as 
extra-nuclear actions. PELP1 functions as a proto-oncogene and is 
a prognostic indicator of shorter breast cancer specific survival. The 
objective if this study is to examine whether PELP1 participates in 
ER-growth factor signaling cross talk via mTOR pathway.
METHODS: To test this hypothesis, we have used ER-positive model 
cells (MCF7, ZR75) along with PELP1 over expressing (MCF7-
PELP1, ZR75-PELP1) and PELP1 knock down cells (MCF7-PELP1 
shRNA, ZR-75-PELP1 shRNA). Estrogen and Heregulin were used 
as signal inducers. Rapamycin that inhibit mTORC1 and AZD8055, 
an inhibitor of both mTORC1 and mTORC2 activities were used as 
pharmacological inhibitors to block mTOR pathway. The affect of 
blocking mTOR axis on PELP1 mediated oncogenic functions was 
determined using ERE and E2F reporter gene assays, cell proliferation 
(MTT) and anchorage independent assays. Cell cycle progression was 
monitored by flow cytometry. PELP1 modulation of mTOR signaling 
was validated using siRNA approach in MCF7, ZR75 cells and/or by 
PELP1 overexpression in PELP1-shRNA clones and evaluated the 
role of identified components for changes in the mTOR signaling 
using Western analysis. IHC analysis of mTOR signaling components 
was performed using tissues collected from PELP1 overexpressing 
and PELP1 siRNA liposome treated tumors.
RESULTS: Over expression of PELP1 enhanced the estrogen and 
heregulin mediated cell proliferation in breast cancer cells. Knock 
down of PELP1 with siRNA significantly reduced the activation of 
mTOR signaling components (p70S6K and 4E-BP1). Accordingly, 
over expression of PELP1 in the breast cancer cells correlated with 
increased mTOR signaling. Pharmacological inhibition of mTOR 
substantially reduced PELP1 mediated ER coactivation functions 
in ERE reporter gene assays. Rapamycin (10-7M) or AZD8055 
(10-8M) abolished PELP1 mediated growth advantage in estrogen 
and heregulin stimulated breast cancer cells. Further, combinatorial 
treatment of mTOR inhibitors sensitized PELP1 overexpressing cells 
to tamoxifen therapy. IHC studies using xenograft tissues with PELP1 
overexpression or down regulation, showed correlation of PELP1 
expression with the activation of mTOR signaling components.
CONCLUSIONS: Our results suggest that PELP1 driven oncogenic 
functions involve PELP1 modulation of mTOR signaling and 
blockage of mTOR signaling render PELP1 driven tumors highly 
sensitive to therapeutic inhibition.
P2-02-08
Int6 Regulates Both Proteasomal Degradation and Translation 
Initiation and Is Critical for Proper Formation of Acini by Human 
Mammary Epithelium.
Suo J, Snider SJ, Lloyd RE, Chang EC. BCM
The mammalian INT6/EIF3E gene has been implicated in breast 
tumor formation, but its functional activities remain poorly defined. 
Consistent with the fact that Int6 is frequently down-regulated in 
human breast tumors, we found that repressing INT6 expression 
induced transformed properties in normal human mammary epithelial 
cells (MCF10A) in both 2D and 3D cultures. Int6 contains a PCI 
domain, found in several components of both the proteasome and the 
translation initiation factor eIF3, suggesting that it can functionally 
interact with both. Indeed, our data show that Int6 associates with 
proteasomes in human cells, and that INT6 knockdown prevents 
proper assembly of active proteasomes. In addition, we show that 
down-regulation of INT6 reduces translation initiation (both polysome 
formation and global protein synthesis). However, Int6 regulates 
translation selectively, reducing translation from cap-dependent and 
Bcl2- IRES reporters, but stimulating translation from the CVB3 
IRES. These data collectively suggest that Int6 controls both protein 
synthesis and protein degradation, and is thus capable of fine-tuning 
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protein levels. Abnormal levels of regulatory proteins caused by 
Int6 abnormalities may thus be responsible for disrupting normal 
morphogenesis of mammary epithelial cells and causing transformed 
phenotypes.
P2-02-09
TP53 Mutation Patterns in Breast Cancer Subgroups.
Dumay A, Feugeas J-P, Wittmer E, Lehmann-Che J, Bertheau P, 
Espié M, de Cremoux P, André F, Sotiriou C, Pusztai L, de Thé H. 
Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, 
France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson 
Cancer Center, Houston
Tumor protein 53 (TP53) is the most commonly altered gene in human 
cancers. In breast cancers, TP53 is mutated in approximately 30% 
of all cases, but this frequency fluctuates widely within the different 
molecular subclasses. Different types of mutations may be observed, 
such as substitutions (replacement of a nucleotide pair by another 
one), or complex mutations (deletions or insertions of one or more 
nucleotides). Mutation types may reflect mechanism of DNA lesion 
or DNA repair deficiencies. Furthermore, mutations can give rise 
to different effects such as truncating mutations leading to loss of 
function, or missense mutations often leading to dominant negative 
activity. Those mutation effects can be advantageous in tumorigenesis 
and thus can be subject to selective pressure.
Here we classified 572 breast tumors in three groups, according 
to microarray data: luminal, basal and molecular apocrine. TP53 
status was assessed by a yeast-based functional assay (FASAY) and 
cDNA sequencing. We then assessed whether any feature of TP53 
mutations would be preferentially associated to a specific subtype 
of breast cancer.
- In term of TP53 mutation frequencies, as expected, lowest frequency 
was observed in luminal subgroup (26%) and highest in basal (90%) 
and molecular apocrine (70%). Notably, much higher rate of TP53 
mutations occurred in luminal B subgroup (41%) than in luminal 
A one (17%), suggesting that TP53 may be an important feature in 
progression from luminal A to B.
- In term of mutations types, luminal tumors showed high frequency of 
substitutions, while molecular apocrine and basal presented increased 
rate of deletions and insertions, reflecting probably increased rate of 
DNA breaks. This suggests that same mutational events may occur 
in basal and molecular apocrine tumors.
- In term of mutation effects, we found high frequency of missense 
mutations in luminal tumors (notably AT to GC) and much higher 
rate of truncating mutations in basal tumors. These observations 
point to an existence of different selection pressure in each of them, 
such as a strong pressure for P53 mutations with potential dominant 
negative inhibition of P73/P63 (recently shown to favor invasion), in 
luminal tumors. Collectively, these results point not only to different 
mechanisms of P53 gene inactivation, but also different functional 
consequences among the different breast cancer subclasses.
P2-02-10
Differential Targeting of the RB-Pathway To Expand the 
Therapeutic Index in the Treatment of Triple Negative Breast 
Cancer.
Knudsen ES, Dean J, Thangavel C, Ertel A, Witkiewicz AK, 
McClendon AK. Thomas Jefferson University, Philadelphia, PA
Background: The retinoblastoma tumor suppressor (RB) is inactivated 
in a significant fraction of triple negative breast cancers (TNBC). RB 
loss is believed to contribute to tumor initiation and progression, and 
provocative data suggest that RB loss is associated with improved 
response to cytotoxic chemotherapy. Unfortunately, such therapies 
have significant side effects that impinge on patient quality of life. 
Here we explored the ability to specifically target RB loss in TNBC 
to expand the therapeutic index by protecting against undesired side-
effects of chemotherapy.
Experimental Design: A combination of cell culture and xenograft 
models of triple negative breast cancer were used to evaluate how RB-
status impinges on sensitivity to chemotherapy. These models were 
complemented by the analyses of clinical specimens from patients 
treated with chemotherapy. Parallel use of agents that activate RB 
function with high specificity were interrogated as potential tissue 
protectors to ameliorate side effect of chemotherapy.
Results: RB loss in preclinical models is associated with increased 
sensitivity to conventional cytotoxic chemotherapies that are 
frequently employed in the treatment of TNBC. The findings were 
recapitulated through the analyses of clinical specimens, and suggest 
that the loss of RB could be particularly useful in defining TNBC 
patients with improved response to chemotherapy. Combination 
studies of pharmacological activation of the RB pathway and cytotoxic 
chemotherapies commonly used to treat TNBC demonstrated that 
activation of RB can modulate the efficacy of cytotoxic compounds 
in the treatment of TNBC. Importantly, functional studies indicated 
that RB pathway activation limits cardiotoxicity associated with 
anthracycline based treatments and correspondingly improve cardiac 
function in animal studies.
Conclusions: Combined, these studies indicate that RB pathway 
status could be utilized in the clinic to direct combination treatments 
that would exploit the sensitivity of RB-deficient tumors to cytotoxic 
chemotherapies while simultaneously providing protection for normal 
tissues.
P2-03-01
Genetic Reduction of Circulating Insulin-Like Growth Factor 
(IGF)-1 Differentially Impacts the Effects of Diet-Induced Obesity 
and Calorie Restriction on Mammary Tumor Progression.
Ford NA, Nunez NP, Perkins SN, Hursting SD. University of Texas 
at Austin, Austin, TX; National Cancer Institution, Rockville, MD
Background: Epidemiological evidence suggests that obesity 
worsens breast cancer prognosis in pre- and postmenopausal women. 
Previously we demonstrated that diet-induced obese (DIO) mice and 
rats have higher circulating levels of IGF-1 and enhanced mammary 
tumor burden compared to normoweight controls. In contrast, we have 
found in several mouse models that a 30% calorie restricted (CR) diet 
regimen reduced serum IGF-1 levels and decreased mammary tumor 
growth. The present study investigated the effects of CR and DIO on 
mammary tumor growth in mice with normal serum levels of IGF-1 
(wild-type) or mice with reduced circulating levels of IGF-1 (LID). 
Our goal was to identify new targets and strategies (with a focus on 
the IGF-1 pathway) for breaking the obesity-breast cancer link, which 
is important given the high prevalence of obesity in the U.S., and the 
strong association between obesity and breast cancer.
Materials and Methods: Virgin female liver-specific IGF-1-deficient 
(LID) and wild-type (FVB/NCr) mice (10-12 weeks of age) were 
randomized (n=10-14 per group) to receive: control diet (modified 
AIN-76A), a 30% CR regimen, or a DIO regimen (60 kcal% fat 
diet). Mice consumed the experimental diets for 11 to 15 weeks prior 
to orthotopic injection (4th mammary fat pad) of Met-1fvb2murine 
mammary tumor cells derived from a polyoma middle-T antigen 
transgenic mouse mammary tumor. Transplanted tumors were allowed 
to grow for 4 weeks and tumor volume was measured by electronic 
calipers biweekly. Mice were then killed, serum was collected and 
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stored at -80C, and tumors were excised, weighed and either formalin-
fixed, paraffin-embedded or flash-frozen.
Results: Using the LID mouse model of IGF-1 deficiency, this 
study established that decreased circulating IGF-1 (relative to wild-
type mice) dramatically reduces Met-1fvb2 mammary tumor growth 
regardless of diet treatment (P=0.034). We also showed in LID mice 
that CR (44 +/- 15.6 mm3), relative to control diet (89 +/- 33 mm3) 
has no significant effect on Met-1fvb2 tumor growth, suggesting nearly 
all of the suppressive effects of CR on tumor growth (at least in the 
Met-1fvb2 model), can be explained by reduced systemic IGF-1. In 
contrast, while most of the DIO effect on tumor growth was ablated 
in the LID mice (332 +/- 104 mm3) vs. wild-type mice (3130 +/- 421 
mm3), tumor growth in LID/DIO mice was significantly higher than 
LID/control mice (89 +/- 33, P=0.006) despite no change in IGF-1 
levels, suggesting that a mechanism independent of IGF-1 contributes 
to some of the effects of DIO on Met-1fvb2 mammary tumor growth. 
Within LID mice, serum insulin, resistin and adiponectin were not 
modified by the CR or DIO diet.
Discussion: We conclude that components of the IGF-1 pathway 
represent promising mechanistic targets for mimicking the anti-
cancer effects of CR and breaking the obesity-breast cancer link. 
However, there are likely other mechanisms independent of IGF-1 
that contribute to the breast tumor enhancing effects of DIO and that 
need to be defined.
P2-03-02
An IGF1R Antibody Does Not Inhibit Growth of Tamoxifen 
Resistant MCF-7 Cells.
Fagan DH, Yee D. University of Minnesota, Minneapolis, MN
The role of the insulin-like growth factor (IGF) system in breast 
cancer has been well defined, and inhibitors of this pathway are 
currently in clinical trials. The majority of anti-IGF1R clinical trials 
are in estrogen receptor-positive patients who have progressed on 
prior endocrine therapy with some early reports showing no benefit 
for addition of IGF1R inhibitors to endocrine therapy. The effect in 
endocrine-resistant models, mimicking the clinical trial scenario, 
has not been adequately investigated. To examine the effectiveness 
of IGF1R inhibitors in vitro, tamoxifen-resistant (TamR) cells were 
generated by culturing MCF-7L cells in the presence of 4-hydroxy-
tamoxifen for more than 1 year. TamR cells had diminished levels of 
IGF1R with unchanged levels of insulin receptor (IR), and enhanced 
phosphorylation of Akt . Further, TamR cells failed to further respond 
to IGF-I-induced Akt activation while retaining responsiveness to 
both insulin and IGF-II. Additionally, IGF-I failed to enhance the 
proliferation and anchorage-independent growth of TamR cells; 
however, both insulin and IGF-II stimulated proliferation and 
anchorage-independent growth. An IGF1R antibody (dalotuzumab) 
was able to inhibit IGF-I-mediated Akt phosphorylation, proliferation, 
and anchorage-independent growth in parental MCF-7L cells and 
had minimal effect on insulin and IGF-II stimulation. In TamR cells, 
dalotuzumab failed to inhibit proliferation or anchorage-independent 
growth in response to either insulin or IGF-II. An IGF1R tyrosine 
kinase inhibitor, (AEW 541) with equal potency for the IGF1R and IR, 
inhibited IGF-I-, IGF-II-, and insulin-stimulated Akt phosphorylation, 
proliferation, and anchorage-independent growth in MCF-7L 
parental cells. Interestingly, AEW 541 also inhibited insulin- and 
IGF-II-stimulated Akt phosphorylation, proliferation, and anchorage-
independent growth in MCF-7L TamR cells. We conclude that 
cells selected for tamoxifen resistance in vitro have downregulated 
IGF1R making antibodies directed against this receptor ineffective. 
Preliminary studies in vivo, suggest that initial co-treatment with 
tamoxifen plus dalotuzumab was more effective than either drug 
alone. In contrast, acquired tamoxifen resistance might require dual 
inhibition of IGF1R and PI3K targets to completely suppress IGF 
system signaling as currently under study in the clinic. Alternatively, 
IGF1R tyrosine kinase inhibitors may be effective by inhibiting both 
IGF1R and IR signaling in cells selected for tamoxifen resistance.
P2-03-03
An Insulin-Like Growth Factor I (IGF-I)-Induced Gene, Solute 
Carrier Family 7 Member 11 (SLC7A11)/xCT, Mediates IGF-I-
Induced Biological Behaviors in Breast Cancer Cells.
Yang Y, Becker MA, Yee D. University of Minnesota, Minneapolis, MN
Our laboratory studied the gene expression profiles of a series of 
T47D variant cell lines with differential insulin receptor substrate 
(IRS) adaptor protein expression to develop predictive IGF-I pathway 
biomarkers. We identified an IGF-I-induced gene, SLC7A11 (or 
xCT), which is specifically regulated through IRS-1. xCT encodes the 
cystine/glutamate transporter subunit of the heterodimeric amino acid 
transport system xc- which is a major plasma membrane transporter 
for the cellular uptake of cystine in exchange for intracellular 
glutamate. xCT is involved in the regulations of proliferation, 
metastasis, and drug resistance in various cancers. However, to 
date, the linkage between xCT and the IGF-I signaling pathway has 
not been described. To study the role for xCT in mediating IGF-I-
induced biology in breast cancer cell lines, we examined xCT mRNA 
expression upon IGF-I stimulation in two breast cancer cell lines; 
the MCF-7 (IRS-1 activated) and MDA-MB-231 (IRS-2 activated) 
cells. Significant increased xCT expression was observed only in 
MCF-7 cells after IGF-I treatment. Immunoblots showed that xCT 
protein expression was elevated after IGF-I treatment and induced 
glutamate/cystine exchange in MCF-7 cells. shRNA was used to 
downregulate xCT in MCF-7 and MDA-MB-231 cells. In MCF-7, 
IGF-I-stimulated cell monolayer growth was suppressed by xCT 
shRNA or by the xCT inhibitor sulfasalazine (SASP). In MDA-
MB-231 cells, xCT downregulation did not affect IGF-mediated 
Boyden chamber migration. Thus, IGF-I induction of cellular xCT 
levels is associated with cell growth in the IRS-1 activated MCF-7 
cells, while MDA-MB-231 cells were not affected by downregulation 
of this gene. Therefore, our data imply that xCT may mediate IGF-I 
induced biological functions in breast cancer cell lines through an 
IRS-1 dependent pathway.
P2-03-04
Novel Pathways Underlying the Initiation and Transition of DCIS 
to IDC of HER2-Overexpressing Breast Cancer Model.
Pradeep CR, Koestler W, Lauriola M, Nair H, Rao R, Mills GB, Yarden 
Y. MD Anderson Cancer Centre, Houston, TX; Weizmann Institute 
of Science, Rehovot, Israel; Southwest National Primate Research 
Center, San Antonio, TX; University of Texas Health Science Center 
San Antonio, San Antonio, TX
Background: The HER2/Neu -oncogene is amplified in 20-25% 
percent of human primary breast cancers and this alteration is 
associated with disease behaviour. The HER2/neu oncogene 
encodes a receptor-like tyrosine kinase, whose overexpression in 
breast cancer predicts poor prognosis and resistance to conventional 
therapies.Whereas signalling pathways emanating from HER2 have 
been characterized, much less is known about the transcriptionally 
regulated genes controlled by HER2 that contribute to the initiation 
of Ductal Carcinoma Insitu (DCIS) and their transition to an invasive 
ductal carcinoma (IDC).
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Materials and Methods: Normal and HER2 overexpressing mammary 
epithelial cells (MCF10A) were grown in extracellular matrix to form 
3D structures, When grown in extracellular matrix as 3-dimensional 
spheroids, control cells developed a hollow lumen, but HER2-
overexpressing cells populated the lumen by evading apoptosis. 
On the next step, uopon the growth factror stimulation HER2-
overexpressing cells grown in extracellular matrix, which protruded 
invasive outgrowths. Highly variable genes were selected from the 
described phenotypes using RNA isolated from the 3D structures and 
hybridized to an Affymetrix HuGene 1.0 ST oligonucleotide array.
Results: Using microarrays we analysed transcriptional events 
responsible for the morphological changes and found several novel 
sets of genes such as integral proteins, transcription factors, matrix 
proteases, Notch genes and chemokines were highly altered in the 
HER2 overexpressing group which were not appreciated before. 
Using gene annotation we defined molecular-pathways responsible 
for the phenotypical changes. More specifically, our study proposes 
a two hit model describes the pathways involved in the initiation of 
the Ductal Carcinoma Insitu and their transition to Invasive Cancer 
underlying the HER2 transcriptional network.
Discussion: According to the proposed model, expansion of ductal 
hyperplasia is limited by intraluminal apoptosis, unless they 
overexpress HER2, which drives proliferation and forms DCIS due to 
HER2 induced Notch pathways genes. Secondly, results obtained with 
the 3D system and their reflection in clinical outcome, we propose that 
neither HER2 amplification, nor the presence of GFs, is sufficient for 
development of IDC, but their co-occurrence can instigate metastasis 
by the activation of genes of integrin-adhesion signaling. The more 
virulent scenario combines HER2 amplification with GFs, thereby 
switching a robust, auto-stimulatory program.
P2-03-05
Attenuation of TGF-beta Signaling Suppresses Premature 
Senescence in a p21-Dependent Manner and Promotes Oncogenic 
ras-Mediated Metastatic Transformation in hTERT-Immortalized 
Basal-Like Human Mammary Epithelial Cells.
Lin S, Yang J, Elkahloun AG, Bandyopadhyay A, Wang L, Cornell 
JE, Yeh I-T, Agyin JK, Sun L-Z. University of Texas Health Science 
Center, San Antonio, TX; NHGRI-NIH, Bethesda, MD
Triple negative, basal-like breast cancer is highly aggressive and has a 
poor prognosis. The molecular mechanisms that drive its progression 
are elusive and no molecular target has been identified for its prevention 
or treatment. Here, we demonstrate that triple negative human breast 
cancer cells and clinical samples show an attenuated transforming 
growth factor-beta (TGF-b) signaling. Therefore, we developed 
a series of isogenic basal-like human mammary epithelial cells 
(HMECs) with altered TGF-b sensitivity and different malignancy, 
resembling a full spectrum of basal-like breast carcinogenesis, and 
determined the molecular mechanisms that contribute to oncogene-
induced transformation of basal-like HMECs when TGF-b signaling 
is attenuated. We found that expression of a dominant-negative RII 
(DNRII) receptor of TGF-b abrogated autocrine TGF-b signaling in 
telomerase-immortalized HMECs and suppressed H-ras-V12-induced 
senescence-like growth arrest (SLGA). Furthermore, co-expression 
of DNRII and H-ras-V12 rendered HMECs to become highly 
tumorigenic and metastatic in vivo in comparison with H-ras-V12-
transformed HMECs that spontaneously escaped H-ras-V12-induced 
SLGA. By using microarray analysis, we found that p21 is the major 
player mediating Ras-induce SLGA and attenuated or loss of p21 
expression contributed to the escape from SLGA when autocrine 
TGF-b signaling is blocked in HMECs. Furthermore, knockdown of 
p21 also suppressed H-ras-V12-induced SLGA. Our results identifies 
that autocrine TGF-b signaling is an integral part of cellular anti-
transformation network by suppressing the expression of a host of 
genes including p21-regulated genes that mediate oncogene-induced 
transformation in basal-like breast cancer.
P2-03-06
Endothelin-1/Endothelin A Receptor Signalling in Breast Cancer.
Tamkus D, Leece C, Gallo K, Madhukar BV, Dimitrov N. Michigan 
State University (MSU)
Background: Endothelin-1 (ET-1) and endothelin A receptor (ETAR) 
are implicated in breast cancer growth and progression. ET-1 is 
secreted by both tumor cells and stroma (macrophages, endothelial 
cells). The purpose of this study is to evaluate ET-1/ETAR role on 
cell proliferation and its effects on EGFR signaling pathway.
Materials and Methods: Two breast cancer cell lines: MCF-7 and 
MDA-MB-231 were stimulated with ET-1. Proliferation of breast 
cancer cells was analyzed using MTT assay. Protein expression 
( EGFR, pEGFR, AKT, pAKT, ERK, pERK ) was evaluated by 
Western blot. siRNA knockdown of endothelin A receptor (ETAR) 
was performed in MCF-7 and MDA-MB-231.
Results: ET-1 stimulated proliferation in both cell lines. Interestingly, 
at higher ET-1 concentrations cell proliferation was more pronounced 
in MCF-7 when compared with MDA-MB-231. Stimulation with 
ET-1 activated EGFR and downstream signaling proteins (pAKT and 
pERK) in both cell lines. Incubation of breast cancer cells with ET-1 
for 48 hours had different effect on total EGFR level: 3 fold increase 
of total EGFR was seen in MCF-7, while no change was detected in 
MDA-MB-231. siRNA against ETAR decreased ET-1 induced cell 
proliferation and reduced total EGFR level in MCF-7.
Conclusions: These observations suggest that ET-1/ETAR plays an 
important role in survival and proliferation of breast cancer cells. 
However, those effects are diverse in different subtypes of breast 
cancer. Our results may represent an improved selective targeted 
treatment strategy, especially for estrogen receptor positive breast 
cancer.
P2-04-01
Extracellular PAI-1 – t-PA – IGFBP3 Cascade Mediates 
Chemotherapy-Induced Senescence of Breast Cancer Cells.
Shiio Y, Elzi DJ, Song M, Hakala K, Weintraub ST. The University of 
Texas Health Science Center, San Antonio, TX
Upon successful chemotherapy, cancer cells undergo either apoptosis 
or senescence. Whereas the mechanism of cancer cell apoptosis is 
relatively well understood, there is only scant knowledge on how 
chemotherapy-induced cancer senescence occurs. Here we report 
that a cascade of secreted proteins, plasminogen activator inhibitor 
1 (PAI-1) - tissue-type plasminogen activator (t-PA) – insulin-like 
growth factor-binding protein 3 (IGFBP3), mediates chemotherapy-
induced senescence of breast cancer cells.
MCF-7 breast cancer cells display robust senescence induction upon 
doxorubicin treatment and we found that the conditioned medium 
from senescent MCF-7 cells can induce senescence in non-senescent 
MCF-7 cells, which suggested the presence of secreted mediator(s) of 
senescence. To identify such mediator(s), we undertook a quantitative 
proteomic analysis of the protein secretion from senescent MCF-7 
cells and observed significantly increased levels of secreted IGFBP3. 
Increased extracellular IGFBP3 levels were also observed upon 
doxorubicin-induced senescence of ZR75-1 breast cancer cells and 
primary mammary epithelial cells. We demonstrated that IGFBP3 
induces senescence in breast cancer cells, which requires the Rb and 
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p53 pathways. Conversely, shRNA-mediated knock-down of IGFBP3 
alleviated doxorubicin-induced senescence of breast cancer cells. 
These results suggest that IGFBP3 functions as secreted mediator of 
chemotherapy-induced breast cancer senescence.
To gain insight into the regulation of IGFBP3-induced senescence, 
we undertook a proteomic screening for IGFBP3 interactor(s) in 
the secretome and identified t-PA as candidate interactor. t-PA is a 
secreted protease that is known to cleave and activate plasminogen. 
We found that t-PA cleaves IGFBP3 and abolishes IGFBP3-induced 
or doxorubicin-induced senescence of breast cancer cells. The 
protease activity of t-PA toward plasminogen is inhibited by PAI-
1 and we demonstrated that PAI-1 also protects IGFBP3 from 
cleavage by t-PA. Interestingly, PAI-1 was previously identified as 
an inducer of senescence that acts downstream of p53 (Nature Cell 
Biology 8:877-84, 2006). We showed that IGFBP3 knock-down 
by shRNAs abolishes senescence induction by PAI-1, suggesting 
that IGFBP3 is a critical downstream mediator of PAI-1-induced 
senescence. We also observed dramatically increased extracellular 
PAI-1 levels upon doxorubicin-induced senescence of breast cancer 
cells. Importantly, RNAi suppression of PAI-1 in breast cancer cells 
resulted in concomitant suppression of extracellular IGFBP3 levels 
upon doxorubicin treatment and abrogation of senescence induction. 
Taken together, these results suggest a role for extracellular PAI-
1 – t-PA – IGFBP3 cascade in mediating chemotherapy-induced 
senescence of breast cancer cells.
This study uncovered the extracellular components of senescence 
signaling for chemotherapy-treated breast cancer cells. Senescence 
mediators secreted from chemotherapy-treated breast cancer cells may 
amplify the senescence response and provide a non-cell autonomous 
tumor suppression mechanism. These extracellular senescence 
mediators could be exploited to increase the efficacy of breast cancer 
chemotherapy.
P2-04-02
Identification of a Novel Glycosyltransferase-Like Gene as an 
Autophagic Inducer in Human Mammary Carcinoma Cells Via 
Down Regulation of BCL-2.
Shastri BG, Jung Y, Steiner M, Perry JK, Lobie PE, Liu D-X. Liggins 
Institute, Auckland, New Zealand; Cancer Science Institute of 
Singapore, Singapore, Singapore
Here we report the identification of a previously undescribed 
glycosyltransferase-like gene, GLTx, and its cellular effect on 
mammary carcinoma cells. GLTx codes for a novel human protein 
which is highly conserved in primates. Data obtained from the 
mRNA expression database Oncomine, demonstrate that GLTx 
is differentially expressed in a variety of cancers including breast 
cancer. Western blot analysis of a multiple human tissue blot using 
a rabbit polyclonal antibody against GLTx demonstrated that GLTx 
was highly expressed in liver, moderately in kidney, intestine and 
stomach and undetectable in any other tissues. To functionally 
characterize GLTx, we attempted to establish stable cell lines 
with forced expression. However, forced expression of GLTx was 
completely lethal and resulted in severe cell death in the mammary 
carcinoma cell lines, MCF-7 and BT549, as well as in any other cell 
lines tested. Staining of MCF-7 cells transiently transfected with a 
GLTx expression plasmid by either Hoechst 33258 or fluorescein 
isothiocyanate-conjugated annexin V and propidium iodide confirmed 
that the observed cell death was not caused by apoptosis. Further 
investigation confirmed that GLTx expressing cells exhibited 
cytoplasmic accumulation of autophagosomes, consistent with the 
induction of autophagy, as measured by the fluorescently labelled 
autophagosome marker LC3. In addition we have shown that GLTx 
downregulated BCL-2, an inhibitor of autophagy, as measured by 
BCL-2 gene promoter luciferase activity assay and western blot assay 
following transient transfection of a GLTx expressing plasmid. Thus, 
we have demonstrated that GLTx is a novel autophagic inducer that 
causes cell death by down regulating BCL-2.
P2-05-01
Acquired Tamoxifen Resistance Promotes Angiogenic Responses 
in ER+ Breast Cancer Cells.
Hayes E, Smith C, Nicholson RI, Gee J, Hiscox S. Cardiff University, 
Wales, United Kingdom
Background: In the treatment of pre-menopausal women with 
oestrogen positive (ER+) breast cancer, tamoxifen represents a first 
line of adjuvant treatment with demonstrable benefits. Despite this, 
resistance is frequently acquired to tamoxifen with an associated poor 
prognosis. Breast cancer cell models have revealed the importance of 
growth factor signalling networks in sustaining growth of endocrine-
resistant cancers and, more recently, their ability to promote a highly 
migratory and invasive phenotype, together with the expression of 
genes with pro-angiogenic ontology. The potential of endocrine 
resistant cells to elicit angiogenic responses, however, remains 
unknown.
Materials and Methods: Real-time PCR was used to validate results 
from preliminary Affymetrix-based gene profiling of pro-angiogenic 
gene expression in endocrine-sensitive MCF7 cells and their 
tamoxifen-resistant (TamR) counterparts. The expression of pro-
angiogenic factors in conditioned media (CM) from these cells was 
assessed by ELISA. The proliferative and migratory effects of MCF7 
and TamR CM on vascular endothelial cells (HUVEC and HECV 
cells), was determined by MTS cell proliferation assay, wound closure 
assays and Matrigel tubule formation assays. Changes in endothelial 
cell migration following co-culture with endocrine-resistant cells were 
examined using Boyden-chamber chemotaxis assays. Growth factor 
signalling and migration pathway activation in endothelial cells in 
response to CM was determined by Western blotting.
Results: TamR cells were found to express high levels of HIF-1a, IL-8 
and VEGF-A at an mRNA level compared with expression in MCF7 
cells. High levels of VEGF-A protein were also confirmed in the 
conditioned media from TamR cells versus their endocrine-sensitive 
counterparts. TamR conditioned media promoted endothelial cell 
proliferation, migration and the formation of tubules to a greater extent 
than that seen in MCF7 CM treated cells. TamR conditioned media 
was found to stimulate VEGFR2 phosphorylation and downstream 
activation of MAPK in endothelial cells compared to MCF7 CM. 
Pharmacological inhibition of VEGFR2 activity in endothelial cells 
suppressed TamR-induced endothelial cell proliferation and VEGFR 
phosphorylation. Further pharmacological manipulation of erbB 
receptors and intracellular kinases in TamR cells revealed an ERGF/
Her2-Src kinase dependent mechanism of VEGF-A production in 
these cells.
Discussion: These data suggest acquired tamoxifen resistance is 
accompanied by development of an erbB receptor/Src kinase-
dependant pro-angiogenic phenotype which, if recapitulated in vivo, 
may promote tumour progression. Therapeutic targeting of erbB/Src 
axis may prove beneficial in such cases.
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P2-05-02
PGC1, Peroxisome Proliferator Activated Receptor-gamma 
(PPAR-gamma) Coactivator-1, Is Necessary in PPAR-gamma 
Modulated Angiogenesis.
Jiang WG, Li X, Mansel RE. Cardiff University School of Medicine, 
Cardiff, Wales, United Kingdom
Background. Peroxisome proliferator activated receptor- gamma 
(PPAR-gamma), a nuclear hormone receptor, has been shown to be 
an important regulator of gene expression. PPAR-gamma agonists 
have been shown to have anti-cancer properties by ways of inducing 
expression of tumour suppressor genes. It has been indicated that this 
action of PPAR-gamma is manifested by forming a complex with the 
PPAR-gamma coactivators (PGC1 &2) and in association with other 
transcription factors such as SRC-1 and CREB binding proteins. Both 
PPAR-gamma and PGC-1 have been shown to be aberrantly expressed 
in human cancer including human breast cancer (1). PPAR-gamma 
also plays a role in regulating angiogenesis and that PPAR-gamma 
agonists have been shown to have anti-angiogenic functions. In the 
present study, we investigated the role of PGC-1 in PPAR-gamma 
mediated actions on vascular endothelial cells.
Materials and methods. Mammalian expression systems for human 
full length PGC-1 ereonstructed. Anti-PGC-1 transgenes were 
constructed again using human mammalian expression vector in 
order to knock down PGC-1 transcript from the cells. Human vascular 
endothelial cell, HECV, was used in the study. Cell functions linked 
to angiogenesis including cell adhesion and cellular migration was 
evaluated using the electric cell impedance sensing method. PPAR-
gamma agonists and antagonists were used in the cell models during 
the analyses.
Results. HECV cells weakly expressed PGC-1 and PPAR-gamma. 
Using the transgenes created, sublines over-expressing PGC1 
(HECVPGC1exp) or with PGC-1 expression knockdown (HECVPGC1KD) 
were established. Loss of PGC1 showed marked increase in both 
adhesion and cellular migration, opposite was true forHECVPGC1exp 
cells. PPAR-gamma agonist, pioglitizone and ciglitizone, reduced the 
adhesion of control cells. In contrast, PPAR-gamma antagonist SR202 
exhibited a concentration dependent stimulation of both adhesion and 
migration of the control cells. Knocking down PGC1 in endothelial 
cells rendered cells lost response to SR202.
Conclusions. PGC-1 is essential in during the modulation of 
endothelial cells by PPAR-gamma. Together with the aberrant 
expression of both PPAR-gamma and PGC-1 in breast cancer, it is 
concluded that PGC-1 is a central player in PPAR-gamma mediated 
action in both cancer cells and angiogenesis.
1. Jiang WG, Douglas-Jones A, Mansel RE. Expression of 
peroxisome-proliferator activated receptor-gamma (PPARgamma) 
and the PPARgamma co-activator, PGC-1, in human breast cancer 
correlates with clinical outcomes. Int J Cancer. 2003, 106(5):752-757.
P2-05-03
Is Breast Cancer Tryptase a Novel Anti-Angiogenetic Molecular 
Target?
Ranieri G, Gadaleta-Caldarola G, Misino A, Patruno R, Goffredo V, 
Di Lecce V, Vinciarelli G, Valerio P, Zito A, Gadaleta CD. National 
Cancer Institute “G. Paolo II”, Bari, Italy; Di Venere Hospital, 
Bari, Italy
Tryptase, a serine protease stored and released from mast cells 
granules has been identified as a new non-classical angiogenetic 
factor. Tryptase is an agonist of proteinase-activated receptor-2 a G 
protein involved in cellular proliferation and angiogenesis. On the 
other hand mast cells can release tryptase following c-Kit receptor 
activation. We have evaluated the correlations among the number of 
MCs positive to tryptase (MCDPT), the number of c-Kit receptor 
expressing cells (C-KREC) and microvascular density (MVD) in a 
series of 91 primary T1-3, N0-2 M0 female breast cancer by means of 
immunohistochemistry and image analysis methods. Six-micrometers 
thick serial sections of formalin-fixed and paraffin-embedded bioptic 
tumor samples were microwaved at 500 W for 10 min. and treated 
with a 3% hydrogen peroxide solution. Sections were incubated 
with primary antibodies: anti-tryptase (AA1; Dako, Glostrup, 
Denmark), anti-c-Kit receptor (A4502; Dako, Glostrup, Denmark) 
and anti-CD34 (QB-END 10; Bio-Optica Milan, Italy). In serial 
sections MVD, MCDPT and C-KREC were counted by means of 
image analysis (Quantimet 500 Leica) at x400 microscopic fields. 
Data demonstrated a significantly (r= ranging from 0.72 to 0.91; 
p: ranging from 0.001 to 0.003 by Pearson’s analysis respectively) 
correlation between MVD, MCDPT and C-KREC to each other. 
Published in vitro data suggest that tryptase induce angiogenesis in 
vascular endothelial cells and breast cancer cells lines. According to 
these data we shown that MVD, MCDPT and C-KREC paralleled to 
each other suggesting a role in in vivo breast cancer angiogenesis. In 
this context the inhibition of c-Kit mast cells tryptase degranulation 
by several tyrosin kinase inhibitors might be evaluated in clinical 
trials. Finally available tryptase inhibitors such as gabexate mesilate 
or nafamostat mesilate might be evaluated in clinical trials as a new 
antiangiogenetic approach.
P2-05-04
Mapping the Specific Gene Families Activated in the 
Lymphangiogenesis and Vasculogenic Mimicry Exhibited by 
Inflammatory Breast Cancer.
Liu H, Luo AZ, Mu Z, Chu K, Ye Z, Alpaugh RK, Fernandez S, Boley 
KM, Jin J, Wright MC, Cristofanilli M, Robertson FM. The University 
of Texas, MD Anderson Cancer Center, Houston, TX; Fox Chase 
Cancer Center, Philadelphia, PA
Background: Inflammatory breast cancer (IBC) is the most metastatic 
variant of locally advanced breast cancer. Although IBC is diagnosed 
less commonly than other types of breast cancer, it is extremely 
aggressive, and accounts for a disproportionate number of breast 
cancer related deaths annually. IBC exhibits very specific patterns 
of lymphangiogenesis and vasculogenic mimicry, however detailed 
studies of the genes and proteins involved in these angiogenic 
processes are lacking. This study performed whole unbiased gene 
transcription studies with validation by protein arrays using all 
available pre-clinical cell lines and in vivo xenograft models of 
IBC, including a new model of IBC, FC-IBC01, which exhibits 
lymphovascular invasion, to identify the specific pathways involved 
in the distinctive angiogenesis observed in IBC.
Materials and Methods: Real-time quantitative RT-PCR, cDNA 
microarray gene profiling, immunofluorescence with confocal imaging 
and protein arrays were used to examine differential expression of 
specific angiogenic gene families including VEGFA,B,C,D, VEGF 
Receptor genes, and ANG/TIE genes linked to angiogenesis and 
lymphangiogenesis.
Results: Activity of the matrix metalloproteinase, MMP-2, is required 
for IBC tumor cells to undergo vasculogenic mimicry (VM), which 
is associated with a loss of TIMP-2, a well known inhibitor of 
angiogenesis. Therapeutics that target MMP activity can successfully 
inhibit this VM. Furthermore, pre-clinical models of IBC that form 
IBC tumor emboli exhibit lymphovascular invasion that is associated 
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with distinct patterns of expression of genes that encode for distinct 
receptor tyrosine kinases that may represent important therapeutic 
targets for IBC.
Discussion: Identification of the distinct angiogenic pathways that 
are activated in IBC provides insight into the therapeutic targets that 
may abrogate the distinct lymphovascular invasion and vasculogenic 
mimicry that are linked to the aggressive metastasis of IBC.
P2-05-05
Receptor-Like Protein Tyrosine Phosphatase Kappa (PTPRK) 
and Its Biological Role in Angiogenesis.
Sun P-H, Ye L, Mason MD, Jiang WG. Cardiff University School of 
Medicine, Cardiff, United Kingdom
Introduction:
Protein Tyrosine Phosphatases (PTPs) are known as signalling 
molecules which affect cell growth, differentiation and oncogenic 
transformation. PTPs have been indicated in tumourigenesis and 
progression of various solid tumours. PTPRK, receptor-type protein 
tyrosine phosphatase kappa, has been shown to down-regulate 
transcriptional activity of beta-catenin and impact distribution of beta-
catenin/E-cadherin complexes on cancer cell membrane. However, the 
role played by PTPRK in angiogenesis remains unknown. In present 
study, the effect of PTPRK knock-down on functions and tubule 
formation ability of HECV cells was investigated. (or In the present 
study, the effect of PTPRK on angiogenesis process was investigated.)
Methods:
anti-PTPRK ribozyme transgenes were constructed to knock-down 
PTPRK expression in vascular endothelial cells, HECV cells. The 
subsequent effect upon in vitro cell growth, adhesion, migration and 
microvascular tubule formation was examined using a variety of 
functional assays.
Result:
Knock-down PTPRK in HECV cells (HECVDPTPRK) resulted in a 
decrease of cell growth in vitro. The growth rate of HECVDPTPRK 
was 276.3±16.4, p=0.01 compared with HECVpEF (314.8±21.9) 
controls. However, knock-down of PTPRK in HECV cells increased 
cell motility. The cell migration distance of HECVDPTPRK was 
83.8±19.8mm, p=0.008 compared with HECVpEF (61.8±11.8mm) 
controls. No effect on cell adhesion by PTPRK knockdown was 
seen in HECVDPTPRK (81.2±6.6), compared with HECVpEF control 
(78.8±15.6). Furthermore, knock-down of PTPRK suppressed 
tubule formation in HECV cells, the length of total tubules (mm) in 
HECVDPTPRK was 2167.4±943.2, p<0.05 compared with HECVpEF 
(3130.6±386.9) control.
Conclusion: Knock-down of PTPRK reduced the growth and 
tubule formation abilities of vascular endothelial cells. It suggests 
that PTPRK is pivotal regulator for angiogenic process. Further 
investigations are required to identify the downstream pathways 
involved in these impacts.
P2-05-06
Role of Repulsive Guidance Molecule b (RGMb) in HGF 
Mediated Angiogenesis.
Sanders AJ, Ye L, Mason MD, Jiang WG. Cardiff University School 
of Medicine, Cardiff, United Kingdom
Introduction:
Hepatocyte Growth Factor (HGF) has been widely documented 
as playing a key role in enhancing the aggressive nature of cancer 
through its ability to promote cellular processes such as migration, 
invasion and angiogenesis. Development of a blood supply is vital 
to advanced tumour growth and increased metastatic potential. In 
the current study we identified RGMb (DRAGON), a member of 
the Repulsive Guidance Molecule family, as being upregulated by 
HGF and assessed its potential to contribute to HGF mediated pro-
angiogenic traits.
Methods:
Expression of RGMb was identified as being upregulated in human 
endothelial HECV cells following 4 hour treatment with HGF 
(40ng/ml) using micro array analysis and Q-PCR. Subsequently, the 
expression of RGMb was targeted through the transfection of HECV 
cells with a plasmid containing a ribozyme transgene specifically 
targeted to RGMb. The role of RGMb in HGF mediated cellular 
migration and tubule formation in vitro was examined.
Results:
Significant increases in RGMb expression in HECV cells were 
observed on the mirco-array following 4 hour treatment with HGF (P 
= 0.004) and this trend was also identified using Q-PCR. Transfection 
with the ribozyme transgene brought about substantial reductions in 
RGMb expression at both transcript and protein levels as assessed 
using RT-PCR, QPCR and Western blot analysis. Knockout of RGMb 
brought about a significant increase in migration rates, compared to 
HECV cells transfected with a closed pEF6 plasmid only (HECVpEF6), 
following a 90minute period (p = 0.034 at 90 minute time point vs 
pEF6 control). Treatment of HGF enhanced migration rates of HECV 
control cells with significant differences between untreated and HGF 
treated pEF6 cells obvious following 60 minutes (p < 0.05 at 60 
and 75 minutes, p = 0.002 at 90 minutes). In contrast to this, HECV 
cells transfected with the RGMb ribozyme transgene (HECVRGMbKO) 
were unaffected by HGF treatment, with no significant differences 
observed between treated or untreated HECVRGMbKO cells at any 
time points. A similar trend was observed in the angiogenic tubule 
formation assay, where treatment of HECVpEF6 cells with HGF could 
significantly enhance the levels of tubules formed (mean tubule 
perimeter, untreated 8087+/- 632 vs HGF treated 13131+/- 988, p = 
0.001). Treatment of HECVRGMbKO cells with HGF did not significantly 
enhance levels of tubule formation (mean tubule perimeter, untreated 
7523+/-2458 vs HGF treated 11050+/-1512, p = 0.21).
Conclusions:
Targeting of RGMb in endothelial cells appears to reduce their 
sensitivity to the promotional effect of HGF on cell migration and 
tubule formation, important traits in the angiogenic cascade. Our data 
suggests that RGMb may be one molecule involved in the process 
through which HGF enhances angiogenic potential and targeting 
this molecule may be a useful strategy in a number of cancer types 
to interfere with HGF promoted angiogenesis.
P2-05-07
Combined Antiangiogenic and Anti-Estrogen Therapy in Breast 
Cancer. Molecular Mechanisms Involved.
de la Haba J, Berciano M, Cañabate M, Porras I, Valverde A, Cañas A, 
Rodriguez A, Aranda E. Hospital Universitario Reina Sofia, Institute 
for Biomedical Research Maimonides IMIBIC, Cordoba, CO, Spain; 
Hospital General Universitario, Ciudad Real, CR, Spain
Background: Much is known about the mechanisms involved in 
the response to anti-hormonal treatment or those involved in the 
response to antiangiogenic therapy. It is also known the association 
between angiogenesis and hormonal status, both in physiological 
and pathological settings. However, the molecular and cellular 
mechanisms contributing to the efficacy of combined antiangiogenic-
antihormonal therapy in breast cancer are still unknown. This 
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combination is currently in clinical trials, but unfortunately there are 
scarce preclinical studies contributing to the rationale of combining 
antiangiogenic and antihormonal therapies.
Aims: To define the mechanisms involved in the response to combined 
antiangiogenic-antihormonal treatments in breast cancer cells.
Methods: Breast cancer cell lines with different estrogen dependence 
(MCF-7, BT-474, MDA-MB-231) were subjected to an estrogen 
gradient (estradiol), and treated with fulvestrant (antiestrogen), plus 
bevacizumab (anti-angiogenic). Cellular proliferation and apoptosis 
were determined using the corresponding kits. Proliferation and 
survival intracellular signaling pathways, estrogen alpha and VEGF 
receptors activation and COX-2 expression were analyzed by western-
blot using specific antibodies.
Results: In estrogen-dependent breast cancer cells (MCF-7 and 
BT-474) the pro-proliferative effect of estradiol decreased after 
bevacizumab treatment.
Table 1. Proliferation 48 hours (%) ± SD
Breast Cancer Cell Lines E E+B E+F E+F+B
MFC-7(ER+) 100±2.9 19±1.0 87,6±1.7 20.1±0.2
BT-474(ER+) 100.0 ± 16.3 36.9 ± 0.6 82.9 ± 6.2 29.2 ± 0.2
MDA-MB-231 (ER-) 100.0 ± 7.7 106.2 ± 2.4 105.1 ± 2.8 98.5 ± 3.6
a E=Estradiol 100 nM, B=Bevacizumab 200 ug/mL, F=Fulvestrant 100 nM,
Furthermore, the combination of the antiangiogenic with an 
antiestrogen enhanced this antiproliferative effect, that was also 
related to the reduction in the levels of VEGF-A in the culture medium 
and to diminished ER alpha phosphorylation. The combined treatment 
also altered the phosphorylation of Akt and Erk1/2 signaling kinases. 
Interestingly, bevacizumab treatment augmented COX-2 activity in 
MCF-7.
Conclusions: Our results suggest that in estrogen dependent breast 
cancer cells the anti-proliferative effect of bevacizumab depends 
on estradiol concentration, that in turn affects VEGF production 
levels, using a different mechanism to apoptosis. The combination 
of bevacizumab with antiestrogens enhances this antitumoral effect, 
altering intracellular signaling pathways of proliferation and survival.
P2-05-08
Expression of VE-Statin/egfl7 in Breast Cancer.
Lauridant-Philippin G, Baranzelli M-C, Fournier C, Samson C, 
Soncin F, Bonneterre J. Centre Oscar Lambret, Lille, France; Institut 
de Biologie de Lille - CNRS UMR 8161, Lille, France; Université 
Lille Nord de France, Lille, France
Patients and methods: Specimens of breast cancer (174 invasive 
and 37 in situ) were obtained from 205 patients (pts) treated in our 
institution in 2005.Their median age was 57 years (39-92). VE-statin 
expression was studied by immunohistochemistry (IHC) using anti-
hVE-statin/egfl7 (AF3638, R&D) and by RT-qPCR on formalin-fixed 
paraffin sections. 174 invasive carcinomas (141 ductular and 30 
lobular) and 37 DCIS were studied. Determination was done twice by 
two different observers. Statistics used Chi2 and Fisher’s exact tests 
for categorical data and Kruskall-Wallis test for continuous variables.
Results: Pathological characteristics of the patients with invasive 
tumors were as follows : 81% ductular, 17% lobular ; median tumor 
size 18 mm (2-100) ; SBR grade 1 in 27%, 2 in 58% and 3 in 15% of 
the tumors ; estradiol receptor (ER) + in 90%, progesterone receptor 
(PR) + in 66% ; 6,5% HER2 positive. In 105 cases there was DCIS 
together with invasive tumors. For invasive tumors and DCIS, 
progression-free survival (PFS) at 5 years were 85% and 100% and 
overall survival (OS) 96% and 95%, respectively. Characteristics of 
the DCIS were median tumor size 18 mm (2-60), ER+ in 88%, PR+ 
in 62%. IHC results were obtained in 159 invasive carcinoma and 
34 DCIS, RT-qPCR results in 96 samples. In the group of invasive 
tumors, a cytoplasmic VE-statin/egfl7 signal was obtained in 80% of 
invasive cells, more frequently than in normal glandular cells (71% 
vs 41%, p=0,003) but significantly less than in peritumoral DCIS 
(71% vs 89%, p=0,001). The signal was higher in ductular than in 
lobular carcinoma (85% vs 54%, p=0,003). In RT-qPCR analyses, 
RNA levels were higher in SBR1 grade tumors (p=0,008), in ER+ 
invasive tumors (p=0,02) and in pN- tumors (p=0,003). In the group 
of DCIS, a cytoplasmic signal was obtained in 82% of the cells. It 
was more frequently observed in tumor than in normal glandular cells 
(82% vs 52%, p=0,02). A 3+ cytoplasmic signal was more frequent 
in DCIS alone than in DCIS associated with invasive carcinoma 
(23% vs 6%, p=0,02). No prognostic significance differences were 
observed on PFS or on OS.
Discussion: This work is the first expression study of VE-statin/
egfl7 in breast cancer. The results were reproduced by two different 
observers. IHC signal was cytoplasmic and higher in DCIS than in 
invasive carcinomas. Furthermore the signal was even higher when 
there was only DCIS than when it was associated with invasive lesion. 
The signal was higher in ductular than lobular carcinoma, consistent 
with previous publications on other angiogenesis mediators. Similarly, 
the signal was higher in low SBR grade, as well in ER positive 
tumors. Phase 1 studies are ongoing in order to evaluate the effects 
of inhibition of VE-statin/egfl7.
P2-05-09
Secondary Inflammatory Breast Cancer: A Possible Model for 
Post-Surgical Dissemination of Cancer.
Hashmi S, Zolfaghari L, Levine PH. George Washington University, 
Washington, DC
Background: The phenomenon of accelerated tumor growth following 
surgery has been observed repeatedly and merits further study. 
Inflammatory breast carcinoma (IBC) is widely recognized as an 
extremely aggressive malignancy characterized by micrometastasis 
at the time of diagnosis. It is fast growing, highly angiogenic and 
angioinvasive, features that are present from its inception. The idea of 
a dormant cancer cell and awakening of metastatic disease following a 
surgical/ traumatic event may well be exemplified by secondary IBC, 
a term used to describe the IBC appearing following surgery for a non-
inflammatory primary breast carcinoma. One possible mechanism can 
be related to the stimulation of dormant micrometastasis through local 
angiogenesis occurring as part of posttraumatic healing. It is therefore 
possible that secondary IBC can be used as a model to support local 
angiogenesis as an important contributor to the development of an 
aggressive cancer.
Materials and Methods: Cases of secondary IBC were identified 
in a review of patients referred to the IBC Registry (IBCR). In this 
report we document the histories of three patients with secondary 
IBC as well as two additional patients whose disease presentation 
also supports the possible occurrence of IBC secondary to breast 
trauma. Secondary IBC cases were defined as women who had surgery 
for non-inflammatory breast cancer with recurrence at the previous 
mastectomy site manifest as skin erythema shown to be associated 
with pathologically confirmed tumor emboli in the dermal lymphatics.
Results: Two of the patients with secondary IBC developed 
pathologically confirmed dermal lymphatic invasion two and 42 
months after partial mastectomy for non-inflammatory breast cancer. 
The third had been apparently free of recurrence for seven years when 
she had reconstructive surgery, which was followed by IBC seven 
months later. Two additional cases are presented, one in which IBC 
manifested one month following ductogram procedure and had a 
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contralateral breast IBC recurrence 2 years later. The other patient 
was diagnosed with IBC one year following nipple piercing and 
ring removal.
Discussion: Recent publications have focused on the role of surgery 
in the subsequent development of metastatic breast cancer, many 
of them focusing on a hormonal mechanism triggered by removal 
of the primary tumor. We propose local angiogenesis as another 
possible mechanism for post-surgical dissemination of cancer. In 
view of the hypothesis that trauma can stimulate angiogenesis which 
can accelerate tumor growth, the documentation of IBC appearing 
at the site of a traumatic event merits consideration. Our experience 
with IBC, noted in the case reports above suggest that local trauma 
probably mediated in large part by angiogenesis can be an important 
trigger of IBC. We would therefore suggest that secondary IBC be 
considered for investigation of one possible mechanism for post-
surgical tumor dissemination.
P2-05-10
Brain-Derived Neurotrophic Factor, BDNF, and Its Biological 
Impact on Vascular Endothelial Cells.
Jiang WG, Ye L, Yang X, Mansel RE. Cardiff University School 
of Medicine, Cardiff, Wales, United Kingdom; Capital Medical 
University, Beijing, China
Background: BDNF, Brain-derived neurotrophic factor is a member 
of the neurotrophin superfamily and is a known growth factor for 
both central and peripheral nervous systems. While BDNF has been 
shown to play a role in the development of a number clinical condition 
including epilepsy, Alzheimer’s and Parkinson’s disease, it has 
recently been implicated in human cancers, primarily in neurological 
related malignancies, as well as ovarian cancer, lung cancer and 
skin malignancies. We have recently reported a pivotal relationship 
between BDNF and disease progression and clinical outcome in 
human breast cancer. Certain members of the neurotrophin family 
have also been shown to play a role in the regulation of angiogenesis. 
In the present study, we examined the impact of BDNF on the 
biological behaviour of vascular endothelia cells.
Materials and methods. Human vascular endothelial cells were used in 
the present study. A human BDNF expression plasmid was constructed 
from a cDNA library of normal tissues. Anti-BDNF transgenes were 
constructed based on the secondary structure of human BDNF and 
used to knockdown the expression of BDNF from the cells. Vascular 
endothelial cells with differential expression of BDNF were generated 
using the expression construct. Cell-matrix adhesion, cell migration 
and growth were determined.
Results. Human vascular endothelial cells (HECV) expressed 
very low levels of BDNF, traceable by PCR method. The cells 
were transfected with BDNF expression plasmid, which allowed 
establishment of BDNF over-expressing sublines , HECVBDNFexp. 
Expression of BDNF had a marked influence on matrix adhesion of 
the endothelial cells (adhesion indices for control and HECVBDNFexp 
cells being 3.3± 0.83 and 2.18± 0.94, respectively, p=0.01). It is 
interesting to note that the change of adhesion was likely to involve 
the focal adhesion (FAK) pathway as a FAK inhibitor, PF573228, had 
a profound impact on the adhesion of both control and HECVBDNFexp 
cells. Manipulation of BDNF in endothelial cells had a similar effect 
on the cellular migration, although to a lesser degree.Conclusions. 
Brain-derived neurotrophic factor, BDNF, has a profound impact on 
the biological functions of vascular endothelial cells. This may have 
implications in the angiogenic process seen in solid tumours.
P2-06-01
Genomic Instability in Breast Cancers from Atomic Bomb 
Survivors: An Analysis of Microarray-Comparative Genomic 
Hybridization with Old Archival Tissues.
Oikawa M, Yoshiura K-I, Kondo H, Miura S, Kurashige T, Nagayasu 
T, Yano H, Nakashima M. Atomic Bomb Disease Institute, Nagasaki 
University Graduate School of Biomedical Sciences, Nagasaki, 
Japan; Nagasaki University Graduate School of Biomedical Sciences, 
Nagasaki, Japan
Background: Sixty-six years after two atomic bombs (A-bombs) 
explosion on Hiroshima and Nagasaki, the incidence of breast cancer 
in A-bomb survivors still higher than that in controlled populations. 
We have reported a higher incidence of HER2 and C-MYC oncogene 
amplification in breast cancers from A-bomb survivors, which 
suggested genomic instability (GIN) induced by A-bomb radiation 
exposure might promote breast carcinogenesis in A-bomb survivors. 
The purpose of this study was to clarify the effect of A-bomb radiation 
exposure on GIN in breast cancer using microarray-comparative 
genomic hybridization (aCGH). Materials and Methods: DNA 
was extracted from the paraffin-embedded tissues of invasive ductal 
cancers from 11 survivors exposed at 1.5km from the hypocenter and 
9 calendar year-matched non-exposed patients followed by aCGH 
analysis using a high-density oligonucleotide microarray (Agilent® 
SurePrint G3 8x60k microarray). The total length of chromosomal 
aberrant region was used as an indicator of GIN, and correlation 
with clinicopathological factors were statistically tested. Results: 
The mean of the derivative log ratio spread (DLRSpread), which 
estimates the log ratio noise by calculating the spread of log ratio 
differences between consecutive probes along all chromosomes, was 
0.60 (range, 0.30 to 1.05). The concordance of aCGH results with 
FISH results for HER2 gene amplification was 90%. Samples from 
A-bomb survivors had significantly more copy number aberrations 
(CNA) than samples from control patients (P= 0.040). Samples with 
C-MYC gene amplification determined by aCGH analysis tended to 
harbor more CNA (P= 0.20), and age at the time of diagnosis tended to 
be inversely associated with the total length of chromosomal aberrant 
regions (P= 0.13). The multivariate analysis with covariance revealed 
that the status of A-bomb exposure was the only independent factor 
which was significantly associated the total length of chromosomal 
aberrant regions (P= 0.0324). Conclusions: This study suggested 
that A-bomb radiation may affect the development of chromosomal 
aberrant regions including oncogene amplification by inducing GIN 
and may be associated with a higher histological grade in breast cancer 
found in A-bomb survivors.
P2-06-02
FOXO3a Genotype Predicts Age of Breast Cancer Onset and 
Correlates with Lymph Node Involvement.
Brouwers B, Lambrechts D, Hatse S, Dieudonné A-S, Remmerie 
C, Neven P, Smeets A, Paridaens R, Wildiers H. Universitaire 
Ziekenhuizen Leuven, Leuven, Belgium; Katholieke Universiteit 
Leuven, Leuven, Belgium
Background: Ageing mechanisms and genetic traits underlying the 
aging process are intimately linked with mechanisms that protect 
against cancer. FOXO3a genotype might be an important clue in this 
regard, as single nucleotide polymorphisms in this gene have been 
related to longevity, but also to differences in cancer susceptibility. 
FOXO3a is thought to work as a cellular ‘switch’, by either promoting 
apoptosis or halting proliferation and protecting from oxidative stress. 
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We have assessed FOXO3a genotype in a cohort of breast cancer 
patients to investigate possible associations with patient and/or breast 
tumor characteristics.
Patients and methods:Eligible subjects were all early breast cancer 
patients with upfront surgery, diagnosed at our center between 2000 
till 2010, from which germline DNA (peripheral blood) was available. 
2 SNP’s in the FOXO3a gene, known to correlate with ageing or age 
associated diseases were assessed by Sequenom (rs 9400239 and rs 
6911407).
Results: 2047 patients were included in the study. Age at diagnosis 
was found to be lower for patients homozygous for the minor allele 
at position rs6911407 (genotype A/A) (median age at diagnosis 
52 years;P=0.001;95% C.I. 50.7–53.3). Patients homozygous for 
the wild type allele (genotype C/C) at this position had a median 
age at diagnosis 55.0 years;95% C.I. 54.0–56.0. After correction 
for possible confounding variables BMI at diagnosis and parity, 
the association between age at diagnosis still remained significant 
(P=0.025, N=1348). We also assessed the relationship of the specific 
genotypes with tumor characteristics. We found that rs6911407 is 
positively correlated with lymph node status. This finding remains 
significant after correction for possible confounding variables ER, 
PR, Her-2, tumor size and tumor grade (OR=1.224 for homozygous 
mutants versus wild type; P=0.014;95% C.I. 1.042–1.437).
Conclusion: In our cohort of primary breast cancers, we found that 
patients homozygous for the minor allele at position rs 6911407 in the 
FOXO3a gene, develop breast cancer at younger age, and have more 
lymph node involvement compared to patients homozygous for the 
wild type allele. SNP’s in nearly complete linkage disequilibrium with 
rs6911407 have previously been correlated with healthy longevity. 
At first sight, this seems contradictory with our current findings. 
However, our results are in accordance with the trade-off that has 
been described to exist between longevity and risk of cancer. It is 
generally assumed that FOXO3a and p53 function are oppositely 
controlled by common regulation systems, such that changes in 
FOXO activation would always be counterbalanced by an inverse 
change in p53 activation. If FOXO3a is strongly activated in order to 
protect against DNA damage (i.e. longevity function), p53-mediated 
cancer protection will concomitantly be diminished . This mechanism 
reconciles the apparent paradox between the longevity phenotype that 
has previously been linked with rs 6911407 on the one hand, and, on 
the other hand, our current findings of earlier breast cancer onset and 
increased lymph node metastasis. Further research on the function of 
FOXO3a in both aging and cancer is required to shed more light on 
the molecular mechanisms underlying these observations.
P2-06-03
Differential Expression of Breast Cancer-Associated Genes 
between Stage- and Age-Matched Tumor Specimens from 
African- and Caucasian-American Women Diagnosed with 
Breast Cancer.
Grizzle WE, Steg AD, He Q, Steciuk MR, Byan-Parker S, Johnson 
MR, Grunda JM. University of Alabama at Birmingham, Birmingham, 
AL; Tuskegee University, Tuskegee, AL
Background: Recent studies suggest that the poorer outcome of 
breast cancer patients observed in African-American women (AAW) 
may, in part, result from underlying genetic factors. The purpose of 
this study was to investigate gene expression differences between 
Caucasian-American women (CAW) and AAW that may contribute 
to this poorer prognosis.
Methods: The expression of genes involved in breast carcinoma 
prognosis, response to therapy, estrogen signaling, and tumor 
aggressiveness was assessed in age- and stage-matched CAW and 
AAW paraffin-embedded breast cancer specimens. The Wilcoxon-
Mann-Whitney Test was used to identify genes with a significant 
difference in expression between CAW and AAW. To determine 
if the differentially expressed genes could segregate between the 
CAW and AAW, we performed semi-supervised principle component 
analysis (SSPCA).
Results: Twenty genes were differentially expressed between AAW 
and CAW. SSPCA incorporating these 20 genes separated AAW and 
CAW into two distinct groups. AAW were significantly (p < 0.05) 
more likely to display aberrations in G1/S cell-cycle regulatory genes, 
decreased expression of cell-adhesion genes, and low to no expression 
of ESR1, PGR, ERBB2 and estrogen pathway targets.
Conclusions: The gene expression differences identified between 
AAW and CAW may contribute to more aggressive disease, resistance 
to therapy, enhanced metastatic potential and poor clinical outcome.
Impact: These findings support the hypothesis that breast cancer 
specimens collected from AAW display distinct genetic differences 
compared to similar tissues obtained from CAW. Additional 
population-based studies are necessary to determine if these genetic 
variations contribute to the highly aggressive and treatment-resistant 
breast cancer phenotype frequently observed in AAW.
P2-06-04
Phosphatidylinositol-3-Kinase Pathway Mutations Are Common 
in Breast Columnar Cell Lesions.
Troxell ML, Brunner AL, Montgomery K, Zhu SX, Neff T, Warrick 
A, Beadling C, Corless CL, West RB. Oregon Health & Science 
University, Portland, OR; Stanford University, Stanford, CA
The phosphatidylinositol-3-kinase pathway is one of the most 
commonly mutated in invasive breast carcinoma, with PIK3CA 
mutations present in ~25% of invasive carcinomas, and AKT1 
mutations identified in up to 5%. Several studies have demonstrated 
the same complement of mutations in ductal carcinoma in-situ (DCIS), 
as well as benign papillomas. We sought to investigate whether 
PIK3CA mutations occur in breast columnar cell lesions (CCL).
Twenty-five breast resection specimens containing CCL (including 
columnar cell change, columnar cell hyperplasia, and flat epithelial 
atypia) were identified from the files of Stanford University Pathology; 
15 of these had associated invasive carcinoma (IDC) or carcinoma 
in situ. DNA was prepared from punches of formalin-fixed paraffin-
embedded tissue blocks using standard methods. DNA extracts 
were screened for a panel of point mutations using a multiplex PCR 
panel with a mass-spectroscopy readout (Sequenom MassARRAY). 
The panel covers 321 mutations in 30 genes, including ABL, 
AKT1/2/3, BRAF, CDK4, CTNNB1, EGFR1, ERBB2, FBX4, FBXW7, 
FGFR1/2/3, FLT3, GNAQ, HRAS, JAK2, KIT, KRAS, MAPK2K1/2, 
MET, NRAS, PDGFRA, PIK3CA, PTPN11, RET, SOS1, and TP53. 
The majority of mutations were confirmed by Sanger sequencing.
PIK3CA mutations were identified in 12/25 CCL (48%); paired 
normal breast tissue was tested in 21 cases and was negative for 
mutations in all but one case. In associated DCIS, 4/8 (50%) 
harbored PIK3CA mutations, while 3/9 IDC had mutations (33%, 2 
PIK3CA, 1 AKT1). The mutation status of CCL and carcinomas was 
frequently discordant. Of 15 cases, only 6 demonstrated the same 
genotype in matched samples of CCL and carcinoma (5 wildtype, 
1 PIK3CA H1047R). Interestingly, 5 patients had mutations in CCL 
with wildtype DCIS or IDC; 2 patients had different point mutations 
in CCL and carcinoma, including one patient with discordant mutant 
DCIS and wildtype IDC. Only 3 cases had wildtype CCL and mutated 
carcinoma.
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The nearly 50% PIK3CA mutation prevalence in CCL is greater than 
reported in most studies of invasive breast cancer. Further, CCL and 
carcinoma were frequently discordant for PIK3CA/AKT1 mutation 
status; most commonly the CCL harbored a PIK3CA mutation, while 
the associated carcinoma was wildtype. Although these findings need 
validation in a larger study, they raise interesting questions as to the 
role of PIK3CA/AKT pathway in breast carcinogenesis, and as to the 
biologic/precursor potential of CCL.
P2-07-01
Copy Number Variants in Early-Onset-Breast Cancer.
Ludwig S, Ivanovich J, Graubert TA, Goodfellow PJ. Washington 
University in St.Louis, SOM, St. Louis, MO
Background: Copy number variants (CNVs) are known to contribute 
to the risk for development of immune diseases, neurological disorders 
and to a lesser extent cancer. Many CNVs do not directly involve 
gene sequences. CHL1, a cell adhesion molecule with homology to 
L1CAM, is down-regulated in a large proportion of breast cancer. A 
deletion CNV immediately 5’ of the CHL1 transcriptional start site 
has been described. The CHL1 CNV’s role in breast cancer risk has 
not previously been explored.
Material and Methods: 50 research subjects recruited to the 
Washington University/Siteman Cancer Center Young Women’s 
Breast Cancer Program (YWBCP) were selected for a CNV discovery 
study. These women were diagnosed breast cancer < age 40, tested 
negative for BRCA1/2 mutations and have a negative family 
history for breast cancer. The selection criteria enriched for de novo 
mutations. Comparative genomic hybridization (CGH) analyses 
were undertaken using the NimbleGen 2.1 million oligonucleotide 
array. DNA copy number was compared between proband and each 
of her parents to identify potential deletions or amplifications in the 
daughter relative to both parents (de novo changes). PCR was used to 
confirm a subset of the CGH-predicted differences in copy number. 
Chi-square test was used to determine statistical significances of 
CNV occurrences near the CHL1 gene between women with breast 
cancer and control cases.
Results: aCGH data analysis has been completed for 25 YWBC trios 
(patients and parents). 247 differences in copy number in the breast 
cancer cases relative to their parents were identified (1-18 putative de 
novo CNVs per case). 91% of the observed changes were deletions and 
9% were amplifications. One proband showed an 11,560 bp deletion 
5’ of the CHL1 gene that was not seen in her parents. Conventional 
PCR confirmed a homozygous deletion of a ~3 kb region in the 
patient, in the region of a known CNV with a reported frequency of 
~3%. Testing an additional 368 early-onset breast cancer cases for 
the CHL1 deletion revealed 25 additional homozygous deletions 
(6.8%). The deletion was present in 9 of 197 controls (4.5%). qPCR 
studies revealed the parents of the patient with the CHL1 deletion 
each carried a single copy of the CNV, making de novo copy number 
change in the proband very unlikely. Deletion specific assays for the 
CHL1 CNV are being used to test CNV genotypes in an extended 
case-control study.
Discussion: CHL1 expression has previously been shown to be 
down-regulated in primary breast tumors. Our preliminary analysis 
of YWBC cases and controls indicates the CHL1 regulatory region 
CNV is unlikely to be associated with risk for early-onset breast 
cancer. Additional candidate de novo copy number changes seen 
in the genomes of patients with early-onset breast cancer are being 
evaluated to determine their roles as genetic risk factors.
P2-07-02
Germline Genetic Variants Disturbing the Let-7/LIN28 Double-
Negative Feedback Loop Alter Breast Cancer Susceptibility.
Yu K-D, Shao Z-M, Chen A-X. Fudan University Shanghai Cancer 
Center, Shanghai, China
Previous studies have shown that let-7 can repress the post-
transcriptional translation of LIN28, and LIN28, in turn, could 
block the maturation of let-7, forming a double-negative feedback 
loop. In this study, we investigated the effect of germline genetic 
variants on regulation of the homeostasis of the let-7/LIN28 loop and 
breast cancer risk. We initially demonstrated that the T/C variants of 
rs3811463, a single nucleotide polymorphism (SNP) located near 
the let-7 binding site in LIN28, could lead to differential regulation 
of LIN28 by let-7. Specifically, the C allele of rs3811463 weakened 
let-7-induced repression of LIN28 mRNA, resulting in increased 
production of LIN28 protein, which could in turn downregulate 
the level of mature let-7. This effect was then validated at the 
tissue level in that the normal breast tissue of individuals with 
the rs3811463-TC genotype expressed significantly lower levels 
of let-7 and higher levels of LIN28 protein than those individuals 
with the rs3811463-TT genotype. Because previous in vitro and 
ex vivo experiments have consistently suggested that LIN28 could 
promote cellular transformation, we then systematically evaluated 
the relationship between rs3811463 as well as other common LIN28 
SNPs and the risk of breast cancer in a stepwise manner. The first 
hospital-based association study (n = 2,300) demonstrated that two 
SNPs were significantly associated with breast cancer risk, one of 
which was rs3811463, while the other was rs6697410. The C allele 
of the rs3811463 SNP corresponded to an increased risk of breast 
cancer with an odds ratio (OR) of 1.25 (P = 0.0091), which was 
successfully replicated in a second independent study (n = 1,156) 
with community-based controls. The combined P-value of the two 
studies was 8.0 × 10-5. Taken together, our study demonstrates that 
host genetic variants could disturb the regulation of the let-7/LIN28 
double-negative feedback loop and alter breast cancer risk.
P2-07-03
Collective Evidence Suggests Neutrality for BRCA1 V1687I, a 
Novel Sequence Variant in the Conserved THV Motif of the First 
BRCT Repeat.
Cortesi L, De Nicolo A, Medici V, Marino M, Turchetti D, Pradella 
LM, Rossi G, Parisini E, Federico M. University of Modena and 
Reggio Emilia, Modena, Italy; Dana-Farber Cancer Institute, Boston, 
MA; Harvard Medical School, Boston, MA; University of Bologna, 
Bologna, Italy; Italian Institute of Technology, Milan, Italy; These 
Authors Contributed Equally to This Work
Background: Unequivocal classification of BRCA1 and BRCA2 
variants of uncertain significance (VUS) with respect to their effect 
on protein function is a challenge with consequent implications for 
clinical decision-making. Currently, integration of different types of 
evidence derived from independent sources appears to be the most 
reliable approach to help define disease relevance for each single VUS.
During a routine screening for BRCA1 and BRCA2 mutations carried 
out by the Modena study group for familial breast and ovarian cancer 
we identified a novel BRCA1 sequence change (c.5178G>A) that 
causes a valine to isoleucine (V to I) substitution at position 1687. 
The sequence alteration was found in a patient diagnosed with early 
onset breast cancer and it was present neither in other breast/ovarian 
cancer families screened nor in unaffected control individuals. No co-
occurrence of the variant with any known clinically relevant BRCA1 
mutations was observed.
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The C-terminally located BRCA1 V1687I lies in the conserved THV 
motif of the first BRCT repeat. Disease-causality has previously 
been suggested for two neighbouring sequence alterations, BRCA1 
V1688del, whose repercussions on protein stability and function were 
also reported (De Nicolo et al., 2009), and BRCA1 H1686Q (Giannini 
et al, 2008). We aimed at garnering evidence that, together with 
family and genetic data, could help assess the clinical significance 
of the V1687I variant.
Methods: We employed a multimodal approach that included 
immunohistochemistry on tumor sections, in silico analyses, 
comparative structural modeling, and ascertainment of BRCT-
mediated functional associations.
Results: Whereas tumor histology, receptor and HER2/neu status were 
compatible with a BRCA1-deficient phenotype, most algorithms we 
used to assess sequence and structure variation based on evolutionary 
conservation predicted the BRCA1 V1687I variant to be benign. In 
line with this prediction, analysis of the modeled BRCA1 V1687I 
BRCT domain did not reveal any major structural changes relative 
to the wild type counterpart and suggested that BRCA1 V1687I 
leaves the local architecture and overall stability of the protein largely 
unaltered. Consistently, the BRCA1 V1687I protein was properly 
expressed and localized to the nucleus, and it was still capable of 
binding BRIP1/FANCJ, CtIP and Abraxas, three BRCT-interacting, 
DNA damage response and repair partner proteins.
Conclusions: Based on our collected evidence, the BRCA1 V1687I 
amino acid change, although occurring in an evolutionary conserved 
region, does not seem to affect the function of the correspondingly 
encoded protein, and hence it is a likely benign sequence alteration.
P2-08-01
Impact of Aromatase Inhibitors on Background Parenchymal 
Enhancement and Amount of Fibroglandular Tissue on Breast 
MRI.
Goldfarb SB, King V, Sung J, Pike M, Nulsen B, Jozefara J, Hudis 
C, Morris E, Dickler M. Memorial Sloan-Kettering Cancer Center, 
New York, NY
Background: 
On breast MRI, background parenchymal enhancement (BPE) and 
volume of fibroglandular tissue (FGT) have been shown to reflect 
a patient’s hormonal status. Tamoxifen has been shown to reduce 
mammographic breast density and may serve as an early predictor 
of response in the prevention setting (Cuzick, JNCI 2011). We have 
shown that adjuvant tamoxifen can reduce BPE in the unaffected 
breast in women with breast cancer. We hypothesize that aromatase 
inhibitor (AI) induced endocrine changes in breast tissue should 
also be evident and therefore we performed a study to evaluate 
whether adjuvant AI therapy influences BPE or amount of FGT in 
the contralateral breast.
Methods:
An electronic medical record review identified 856 postmenopausal 
women with stage I-III breast cancer who had at least two breast MRIs 
and took adjuvant AI treatment. A retrospective chart review was 
conducted to select those patients without a history of prior tamoxifen 
or raloxifene treatment who had a MRI of the contralateral breast both 
before and during 6 to 12 months of AI treatment. After exclusion of 
all irradiated breasts, 168 women were eligible. MRIs were performed 
between August 1999 and June 2010. Two radiologists who were blind 
to AI treatment status, independently rated level of BPE and amount 
of FGT using categorical scales: BPE – Minimal, Mild, Moderate, 
Marked; FGT – Fatty, Scattered, Heterogeneously Dense, Dense 
(based on proposed BIRADS criteria for BPE and on ACR criteria 
for FGT). Blinded side-by-side direct comparison evaluated whether 
there was a category change between the two MRIs. A consensus was 
reached in cases of disagreement. The Wilcoxon signed-rank test was 
used to assess changes in rating categories for BPE and FGT between 
before and during AI breast MRIs. A waiver of authorization was 
granted by the institutional review board for this study.
Results:
In this study 127/168 (76%) women were treated with anastrozole, 
33/168 (20%) with letrozole and 8/168 (5%) with exemestane. Based 
on the blinded side-by-side comparison, a category (or more) decrease 
in BPE occurred during treatment with AIs (p<0.0001). There was 
an overall shift from higher to lower degree of BPE in 35% (45/127) 
of the women taking anastrozole while a category increase occurred 
in only one woman (1%; p <0.0001). A similar result was seen in 
the women taking letrozole [45% (15/33) had a decrease versus 
3% (1/33) an increase; p=0.0003] and exemestane [25% (2/8) had a 
decrease versus 12.5% (1/8) an increase; p=0.50]. For FGT a category 
decrease occurred in 5% (6/127) of anastrozole users while no increase 
occurred [0% (0/127), p=0.016]. The respective numbers for letrozole 
were 3% (1/33) and 0% (0/33), and nobody on exemestane had a 
change in FGT.
Conclusions:
After 6 to 12 months of treatment with adjuvant AIs, there was a 
statistically significant category (or more) decrease in BPE. BPE 
is more sensitive than FGT to changes in normal breast stroma that 
occur during adjuvant treatment with AIs and BPE may be a marker 
of anti-hormonal activity in the breasts.
P2-08-02
Magnetic Resonance Imaging as a Predictor of Pathologic 
Response in Patients Treated with Neoadjuvant Systemic 
Treatment for Operable Breast Cancer (TBCRC 017).
De Los Santos J, Cantor A, Mcguire K, Golshan M, Meric-Bernstam 
F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang 
S. University of Alabama at Birmingham, Birmingham, AL; University 
of North Carolina Chapel Hill, Chapel Hill, NC; Dana-Farber Cancer 
Institute, Boston, MA; Duke University Medical Center, Durham, NC; 
Memorial Sloan Kettering Cancer Center, New York, NY; University 
of Pittsburgh Medical Center, Pittsburgh, PA; MD Anderson Cancer 
Center, Houston, TX; Vanderbilt University, Nashville, TN; University 
of Chicago, Chicago, IL; University of California at San Francisco, 
San Francisco, CA
Background: Increased pathologic complete response (pCR) rates 
observed with neoadjuvant chemotherapy for invasive breast cancer 
has prompted interest in whether patients with pCR can be identified 
preoperatively and potentially spared the morbidity of surgery. This 
multicenter retrospective study was performed to determine the 
accuracy of preoperative MRI in predicting pCR in the breast and 
whether MRI performance differs by molecular subtype, histology, 
and treatment regimen.
Methods: 770 women from 8 institutions were retrospectively 
identified as having received neoadjuvant systemic therapy 
with MRI obtained at baseline and after completion of systemic 
treatment. Tumor phenotypes were defined on the basis of estrogen 
and progesterone receptor (ER/PR or HR) and HER2 receptor 
status. Univariate and multivariate analyses of factors influencing 
radiographic complete response (rCR) and pCR were recorded, with 
rCR defined as resolution of any abnormal enhancement, mass, or 
distortion on MRI, and pCR defined as resolution of both invasive 
disease and DCIS.
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Results: rCR and pCR for the total group were 182/746 (24%) and 
179/746 (24%), respectively, with the highest rate of pCR seen 
among the triple-negative (TN; 57/155; 37%) and HR-/HER2+ 
(38/101; 38%) subtypes. Covariates significantly associated with rCR 
included T stage (p=0.0002), tumor grade (p=0.005), IHC phenotype 
(p=0.005), and chemotherapy regimen (p<0.0001). On multivariate 
analysis, only tumor phenotype was independently associated with 
likelihood of rCR, with both TN (OR = 2.00, 95% CI 1.20-3.33) and 
HR-HER2+ (OR=2.30, 95% CI 1.09 -4.83) more likely to achieve 
rCR than HR+HER- (reference group). Overall accuracy of MRI for 
prediction of pCR was 74%. Sensitivity, NPV, PPV, and accuracy 
differed significantly among tumor subtypes, with the greatest NPV 
in the HR-/HER2+ and TN subtypes (table1). Among patients with 
rCR, ER- status (OR=6.4, 95% CI 1.1 to 35.6), PR- status (OR=3.8, 
95% CI 1.2 to 11.4), and tumor grade of 3 vs 1 or 2 (OR=2.49, 95% 
CI 1.22-5.07) were independently associated with likelihood of pCR.
Discussion: MRI performance for predicting pCR in patients with 
invasive breast cancer receiving neoadjuvant systemic therapy 
differed significantly among breast cancer subtypes; however this 
difference is likely due to subtype differences in frequency of pCR 
and not to intrinsically better or worse MRI detection. The relatively 
low NPV of MRI following neoadjuvant systemic therapy does not 
support using MRI rCR alone to accurately identify those patients 
that can safely avoid surgery.
Performance of Post-treatment MRI in the Breast
Subtype Rate pCR  (%)
Sensitivity  
(%) Specificity (%) NPV (%) PPV (%)
Accuracy  
(%)
Total Group 179/746 (24) 470/567 (83) 85/179 (47) 85/182 (47) 470/564 (83) 555/746 (74)
HR+/HER2- 44/327 (13) 243/283 (86) 20/44 (45) 20/160 (33) 243/267 (91) 263/327 (80)
HR-/HER2+ 38/101 (38) 52/63 (83) 18/38 (47) 18/29 (62) 52/72 (72) 70/101 (69)
HR+/HER2+ 37/148 (25) 86/111 (77) 18/37 (49) 18/43 (42) 86/105 (82) 104/148 (70)
TN 57/155 (37) 79/98 (81) 28/57 (49) 28/47 (60) 79/108 (73) 107/155 (69)
p value* <0.0001 0.02 NS 0.014 <0.0001 0.01
*p values compare the 4 phenotypes for pCR rate and for each performance measure with breast 
MRI
P2-08-03
Quantitative MRI for Noninvasive Prediction of Prognostic 
Markers in Breast Cancer.
Parsian S, Sun R, Kurland BF, Rahbar H, Allison KH, Specht JM, 
DeMartini WB, Lehman CD, Partridge SC. University of Washington, 
Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
Background: Magnetic resonance imaging (MRI) is a valuable 
tool for assessing extent of breast cancer and monitoring treatment 
response. Quantitative measures by diffusion-weighted MRI (DWI) 
and dynamic contrast-enhanced (DCE) MRI reflect tumor cellularity 
and vascularity. Tumor grade and some histopathological markers, 
such as ER, PR, HER-2, Ki67 and P53, are prognostic factors that 
can also be associated with tumor cellularity and vascularity. DWI 
and DCE measures may therefore provide a noninvasive means for 
predicting disease prognosis and stratifying patients to appropriate 
therapies. The purpose of this study was to investigate the correlation 
between quantitative MRI features and prognostic pathological factors 
in patients with invasive breast cancer.
Methods: This IRB-approved retrospective study included patients 
with biopsy-proven invasive cancer who underwent 1.5T breast MRI 
(including DCE and DWI) from October 2005 to May 2006 prior to 
treatment. Pathology data was obtained from pre-treatment biopsy 
and intrinsic subtype classification was approximated by standard 
immunohistochemistry characteristics. After excluding cases with 
missing MRI or pathology data, the final study cohort included 41 
invasive cancers (36 ductal and 5 lobular carcinomas) in 36 patients. 
MRI measures included lesion DCE kinetic features: peak initial 
enhancement (PE), percent rapid enhancement (RE), and percent 
washout (WO), and DWI normalized apparent diffusion coefficient 
values (nADC). Associations between imaging features and pathology 
markers, cancer grades and intrinsic subtypes were evaluated by 
Mann-Whitney U test and multivariate logistic regression.
Results: Results of univariate comparisons are summarized in Table 
1. One or more DCE-MRI kinetic parameters were significantly 
predictive (p<0.05) of each of the histopathological markers with the 
exception of ER, which was marginally associated with WO (p=0.05). 
Each of the DCE kinetics parameters significantly discriminated 
grade III tumors from grades I and II and luminal A from luminal 
B and basal-like intrinsic subtypes. In multivariate regression, both 
PE and WO were significant independent predictors of tumor grade 
(p=0.0094, p=0.0005, respectively). WO and nADC were significant 
independent predictors of PR status (p=0.0054, p=0.0027), while PE 
was the only significant independent predictor of both Ki67 (p=0.014) 
and intrinsic subtype (p=0.015).
Conclusion: This preliminary study suggests that quantitative MRI 
measures are associated with prognostic tumor markers and may 
provide valuable noninvasive characterization of tumor biology. 
Larger prospective studies are needed to validate our findings.
Table 1. Imaging features versus prognostic pathological factors in 41 invasive breast tumors (p 
values given)
 n +/- PE RE WO nADC
ER 31+/ 10- 0.145 0.457 0.051 0.121
PR 25+/ 16- 0.015* 0.095 0.015* 0.028*
HER2 5+/ 36- 0.297 0.036* 0.484 0.577
Ki-67 27 high/ 14 low 0.020* 0.069 0.017* 0.891
P53 9+/ 30- 0.460 0.325 0.048* 0.841
Grade 12 I/ 14 II/ 15 III 0.004* 0.036* 0.004* 0.908
Subtype 17 Luminal A/ 15 Luminal B / 9 Basal 0.009* 0.027* 0.021* 0.096
* Significant correlation (p<0.05)
P2-08-04
Computer-Derived Breast MRI Features Have Complementary 
Value for Preoperative Selection of Systemic Drug Therapy in 
Node-Negative Stage-I/II Breast Cancer Patients.
Gilhuijs KGA, Pengel KE, Dmitriev I, Paape A, Rutgers EEJTh, 
Wesseling J, Loo CE. The University Medical Center Utrecht, 
Utrecht, Netherlands; The Netherlands Cancer Insitute/Antoni van 
Leeuwenhoek Hospital, Amsterdam, Netherlands
Background: Typical guidelines for adjuvant systemic drug therapy 
require assessment of lymph node status, tumor extent and grade. 
Increasing interest exists, however, for preoperative therapy 
(neoadjuvant drug therapy and preoperative partial breast irradiation). 
Here, representative excision specimens are not available to assess 
eligibility for systemic therapy. Moreover, tumor grade may be 
difficult to assess in core biopsies resulting in underestimation rates 
up to 40%. Contrast-enhanced MRI has been shown to correlate 
with underlying tumor biology, but it is unknown whether it can 
complement eligibility criteria for systemic drug therapy.
Purpose: To assess the complementary value of MRI to determine 
eligibility for systemic drug therapy prior to breast-conserving surgery 
in node-negative stage-I/II breast cancer patients.
Materials and methods: Patients with preoperative node-negative 
invasive breast cancer ≥1.0 cm and eligible for breast-conserving 
therapy after conventional breast imaging and MRI were consecutively 
included between February 2000 and March 2007. Informed consent 
was obtained from all patients. Eligibility to systemic therapy was 
determined on the basis of national guidelines using age, size, tumor 
grade, as well as axillary lymph node status at final pathology. Twenty 
temporal and morphological features of contrast uptake at MRI were 
automatically analyzed by a previously build CAD workstation1,2. 
Preoperative lymph node status was derived from ultrasound-
guided fine-needle aspiration. Multivariate logistic regression and 
receiver-operating characteristics (ROC) analysis was used to assess 
associations between preoperative features (age, ER status, computer-
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extracted MRI features) and eligibility to systemic therapy based on 
post-operative features (tumor size, grade, lymph node status).
Results: Three-hundred-and-eighty-six patients were included. The 
mean patient age was 58 years. The mean tumor size at pathology 
was 1.6 cm. Tumor grade was I, II and III in 128 (33%), 163 (42%), 
and 94 (24%) of tumors, respectively. Post-operative lymph node 
status was positive in 115/386 (30%) patients. In total, 262/386 
(68%) patients were eligible for systemic drug therapy based on 
post-operative pathology. Multivariate analysis of preoperatively 
available features yielded ER status, and principle components 1, 6, 8 
and 15 of the computer-extracted features. These components describe 
tumor volume and shape, heterogeneity of contrast uptake, late-
enhancement kinetics, and probability of malignancy. The resulting 
model correlated with the Adjuvant! program (R=0.55, p<0.0001). 
The area under the ROC curve was 0.82 (p<0.0001). Without the 
model, agreement between preoperative and postoperative assessment 
of eligibility to drug therapy was 232/386 (60%) at 15/124 (12%) 
overestimation rate. With the MRI model, it increased to 258/386 
(67%) (p=0.004) without increasing overestimation rate.
Conclusion: Computer-analysis of contrast-enhanced MRI has 
potential to complement preoperative selection of stage I/II node-
negative breast-cancer patients for systemic drug therapy.
Ref:
1. Gilhuijs et al., Radiology 2002; 225: 907-916
2. Deurloo et al., Radiology 2005; 234: 693-701
P2-08-05
Use of Dynamic Contrast-Enhanced MR Imaging To Predict 
Pathological Response in Primary Breast Cancer.
Boni V, Pina LJ, Hernando B, Lopez-Vega JM, Calvo EG, Plazaola 
A, Morales S, Anton A, Sanchez-Gomez RM, Alvarez I, Illarramendi 
JJ, De Juan A, Martinez P, Llombart A, La Huerta A, Dominguez I, 
Garcia-Velloso MJ, Garcia-Gonzalez M, Lao Romera J, Puertolas 
T, Scherer S, Sabariz L, Garcia-Foncillas J. Clinic University of 
Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; 
Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues 
de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel 
Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital 
de Navarra; Roche Basel; Roche Madrid
Purpose: To investigate the effect of bevacizumab infusion on 
vascular parameters assessed by dynamic contrast-enhanced magnetic 
resonance (DCE-MR) imaging and to test their association with 
pathological response in primary breast cancer.
Materials and Methods: 73 patients (median age, 47 ys; age range, 
29-70 ys) with biopsy-proven, previously untreated, primary breast 
cancer were recruited from October 2009 to November 2010 in this 
phase II, multicenter and non-randomized clinical trial. Patients (pts) 
received single infusion of bevacizumab (15 mg/ kg) (C1) 3 weeks 
prior to the beginning of neoadjuvant chemotherapy consisting in 
4 cycles of docetaxel (60 mg/mq), doxorubicin (50 mg/mq) and 
bevacizumab (15 mg/ kg) every 21 days (C2-C5) following by 
surgery. All pts underwent DCE-MR imaging before and 14-21 
days after C1. Quantitative and semiquantitative kinetic parameters 
were calculated at baseline and after C1, including the volume 
transfer constant (K(trans)), which primarily reflects the wash-in of 
the contrast agent, the backflow rate contrant (K(ep)), extracellular 
volume fraction (V(e)) and the initial area under the gadolinium 
concentration-time curve over 60 seconds (IAUGC(60)). Changes 
in the DCE-MRI kinetic parameters K(trans), K(ep), V(e) and 
IAUGC(60) were calculated and Wilcoxon test was used to assess 
significant effects induced by bevacizumab on kinetic parameters. 
Pathological response on surgical specimens after C5 was assessed 
according to Miller and Payne classification. Pts with tumor reduction 
>30% were considered as responders (G3-G4-G5) whether tumor 
reduction <30% were considered as no responders (G1-G2). DCE-
MR imaging parameters and clinical-pathological characteristics were 
correlated with pathological response using Mann-Whitney test in 
univariate and logistic regression in multivariate analyses. Receiver 
operating curves (ROC) was used to define the best cut-off of the 
parameter found associated with pathological response.
Results: DCE-MRI was performed before (n=72) and after (n=71) 
C1. K(trans), K(ep), V(e) and IAUCG(60) values were significantly 
different at the baseline and after C1 (p<0.01). Median changes were, 
respectively, -51, -101, -52.5 and -4.8. Fifty-two (74%) pts achieved 
response (G3-G4-G5) after C5 whether 18 (24%) were considered 
as no responder (G1-G2); for 3 (4%) patients Miller/Payne tumor 
evaluation was not available. At univariate analysis, negative estrogen 
receptor (ER) status and higher post-C1 K(ep) (p=.057) showed a 
trend toward an association with response. At multivariate analysis, 
only ER status remains a significant predictor of response (p= .04). 
Area under ROC curve for K(ep) was 0.65 (IC95% 0.05-0.8, p=.057).
Conclusion: Bevacizumab affects tumor vasculature, perfusion and 
permeability as showed by the significantly reduction in all kinetic 
vasculature parameters obtained in DCE-MR imaging after C1. 
However, in our population these changes were not associated with 
pathological response. On the other hand, backflow rate constant, 
K(ep), a perfusion-related parameter derived from DCE-MRI yielded 
after C1 major than 80, may be associated with higher pathological 
response with a specificity of 88% and sensitivity of 90%. Future 
studies are warranted to confirm these findings.
P2-08-06
Improved Spatial Resolution Diffusion-Weighted Imaging for 
Characterizing Tumors and Treatment Response in Patients with 
Invasive Breast Cancer.
Wilmes LJ, McLaughlin R, Sinha S, Singer L, Proctor E, Wisner D, 
Newitt DN, Shankaranarayanan A, Joe BN, Hylton NM. University 
of California San Francisco, San Francisco, CA; GE Healthcare, 
Menlo Park, CA
Background: Diffusion weighted magnetic resonance imaging (DWI) 
is a non-invasive technique that is sensitive to tissue microstructure. 
Previous studies have shown that DWI adds positive predictive value 
in diagnostic studies of breast cancer and it has been shown to predict 
tumor response to neoadjuvant chemotherapy. While DWI shows 
promise for evaluating breast cancer, the technique suffers from 
limitations. Specifically, image distortion is common with the echo 
planar sequence available for DWI on clinical scanners, and spatial 
resolution is lower than that of other MRI sequences. Our group has 
optimized a high-resolution reduced field-of-view DWI acquisition, 
originally developed for the spine by Saritas et al., for breast imaging. 
The goal of this work was to compare high resolution (hr)-DWI) to 
standard resolution (std)-DWI for characterizing breast tumors.
Methods: Patients undergoing neoadjuvant chemotherapy were 
scanned with MRI before, during and after neoadjuvant chemotherapy 
as part of IRB-approved studies at our institution. Nine women were 
scanned with both hr-DWI and std-DWI before and after one cycle 
of chemotherapy. Apparent diffusion coefficient (ADC) maps were 
calculated from hr-DWI and std-DWI data using previously described 
methods. One tumor region of interest (ROI) was defined on the hr-
DWI slice estimated to contain the largest tumor area. This tumor 
ROI was then applied to the corresponding slice and location on the 
std-DWI and hr-DWI ADC maps. Mean tumor ADC as well as 15th, 
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25th, 50th, 75th, and 90th percentile ADCs were calculated for both 
DWI acquisitions for all subjects.
Results: The mean tumor ADC values measured prior to treatment 
were similar for the hr-DWI and std-DWI acquisitions, however there 
was a significant difference between hr- and std-DWI 15th and 25th 
percentile ADC values (p= 0.0495, p=0.0717) For the early treatment 
time point, significant differences between the two DWI acquisitions 
were found for: mean tumor ADC, 15th, 25th, and 50th percentiles 
(p=0.0302, 0.0075, 0.0212, and 0.0488, respectively), with the most 
significant difference found for the lowest (15th) percentile measured. 
Tumor hr-DWI ADCs were consistently lower than std-DWI ADCs.
Discussion: These data show that although the mean ADC values 
calculated from the pre-treatment hr-DWI and std-DWI are similar, the 
lower percentile (15th, and 25th) ADC values are significantly lower 
for the hr-DWI acquisition. Our results also showed larger difference 
in lower percentile ADC values between the two sequences after 
one cycle of chemotherapy. The differences in the lower percentile 
ADC values calculated from the hr-DWI are consistent with reduced 
partial voluming between viable tumor tissue, which is characterized 
low ADC values, and normal fibroglandular tissue. This may be 
particularly important for post-treatment ADC measurements where 
tumor size may decrease, potentially making partial volume effects 
more pronounced. Continuing studies are evaluating the relationship 
between low percentile ADC values from hr-DWI and tumor stage 
and response to treatment.
P2-08-07
Ex-Vivo High Resolution MRI of Sentinel Lymph Nodes 
Following Subcutaneous Injection of Superparamagnetic Iron 
Oxide Nanoparticles.
Douek M, ter Beek O, Johnson L, Pankhurst Q, Parikh J, Schaeffter 
T, Purushotham A, Charles-Eduards G. King’s College London, 
London, United Kingdom; The Royal Institution of Great Britain, 
London, United Kingdom; Guy’s & St Thomas’ Hospitals, London, 
United Kingdom
Background: Superparamagnetic iron oxide (SPIO) enhanced 
axillary MRI is a promising novel imaging modality that could be 
used to characterize sentinel nodes non-invasively. In order to better 
characterize lymph nodes and evaluate their morphological features, 
we imaged nodes ex-vivo using high resolution MRI, following a 
pre-operative subcutaneous injection of SPIO.
Material and methods: Prior to surgery patients received a 
circumareolar injection of SPIO (Endorem, Guerbet, Paris) into the 
upper outer quadrant of the affected breast. Sentinel lymph nodes 
excised during surgery were transported to the imaging department 
fresh. Nodes were placed in glass tubes and scanned using a Bruker 
9.4T MRI system (T2 mapping: turbo spin echo, 16 equi-spaced TEs 
from 7.1 to 113.6 ms, TR = 1616 ms. T2* mapping: gradient echo, 
6 equi-spaced TEs from 3.5 to 21 ms, TR = 1000 ms, flip angle = 30 
degrees. Diffusion-weighted: spin echo, b-values 0 and 1000 s/mm2, 
TE = 18 ms, TR = 6500 ms.). Slice thickness was 1 mm with an in 
plane spatial resolution of 100µm. Image analysis was undertaken 
using Osirix (v3.8, 64-bit).
Results: A total of 40 nodes were successfully imaged, excised from 
14 patients. The internal architecture of nodes was clearly seen and in 
the 3 involved nodes, a macrometastasis was identified. Three patients 
received a 4ml injection of SPIO and 11 patients, a 2ml injection. 
More SPIO deposition was seen within nodal sinuses following 4ml 
of SPIO, but there was no significant decrease in mean T2 value. 
Four nodes were re-imaged following formalin fixation and nodal 
architecture was unchanged with a trend towards an increase in mean 
T2 values within nodes. SPIO was identified in all sentinel nodes.
Discussion: Ex-vivo MRI with subcutaneous SPIO contrast, is a useful 
method for imaging and characterization of sentinel nodes. A better 
understanding of ex-vivo features is a useful aide to understanding 
the morphological features seen following in-vivo SPIO enhanced 
axillary MRI.
P2-08-08
Benefit of Preoperative Breast MRI in Patients with Newly 
Diagnosed Breast Cancer.
Miesbauer M, Sheu H, Schoissengeier A, Kirchweger B, Waldenberger 
P. St. Vincent Hospital, Linz, Austria
Objective: The aim of our study was to evaluate the effect of 
routinely performed preoperative Breast MRI (pMRI) on the planned 
therapeutical management of all patients with newly diagnosed 
Breast cancer.
Subjects and Methods: 180 patients with newly diagnosed Breast 
Cancer between 9/2009 – 12/2010 were enrolled in this retrospective 
study performed in a certified European Breast Cancer Unit; mean 
age 60,6 years; 1,5 T MRI ( TIM-Symphony, Siemens Germany).
Results: In 53/180 (29,4%) cases the preoperative MRI changed 
the planned therapeutical management concerning surgical and 
chemotherapeutical options. In 42/180(23,3%) patients additional 
lesions were identified only by pMRI , 33/42(78,6%) have been 
malignant and 8/42(19%) were benign. The real extent of the tumor 
was detected in 43/53 (81%) cases – group A; a bilateral carcinoma 
was detected in 4/53 (7,5%) cases – group B; in 6/53 (11,5%) cases 
the malignant lesion could only be detected with preoperative MRI 
- group C; for group A the pMRI led to wider excisions with 15 
segmental -or quadrant resections and 28 mastectomies; for group 
B the pMRI resulted in 4 additional lumpectomies; for group C 
the pMRI caused 4 lumpectomies, 1 segemental resection and 2 
mastecomies . 5 of 6 patients got neoadjuvant chemotherapy only due 
to results of pMRI; in 3 of these 5 patiens breast conserving surgery 
was possible. Histology: DCIS 23/53 (43,4%), invasive cancer 23/53 
(43,4%), multicentric/multifocal malignant lesions 7/53 (13,2%). The 
sensitivity of the pMRI was not influenced by the histology of the 
lesion, the age of the patient or menopausal status. The maximum 
periode between initial presentation of the patient and breast surgery 
was 21 days.
Conclusion: In 29,4% of our patients the pMRI resulted in a significant 
change of the planned therapeutical regime. Histology of the lesion, 
patients age or menopausal status did not influence the sensitivity 
of pMRI. There was no relevant delay in the initiation of treatment. 
Therefore we recommend performing pMRI in breast cancer staging 
routinely.
P2-08-09
The Impact of Preoperative Breast MRI in Newly Diagnosed 
Breast Cancer. A Prospective Study of Treatment Outcome in 
Patients Selected for Breast-Conserving Surgery in a Norwegian 
Multidisciplinary Breast Cancer Clinic.
Rabben T, Rodegerdts E, Bachmann H, Funder V. Department 
of Surgery, Nordland Hospital, Bodø, Norway; Department of 
Radiology, Nordland Hospital, Bodø, Norway; Faculty of Health 
Sciences, University of Tromsø, Tromsø, Norway
Background: The aim of the study was to evaluate the impact of 
preoperative breast MRI on primary surgical treatment in a specialized 
multidisciplinary breast cancer clinic. The diagnostic tools routinely 
used are conventional mammography, ultrasound with core needle 
biopsy, and clinical examination including palpation of breast and 
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axillary nodes. If indicated, the examination includes ultrasound 
examination and fine needle biopsy of axillary glands. We offer all 
patients selected for breast-conserving surgery preoperative breast 
MRI.
Material and methods: We included consecutively 145 breast cancer 
lesions in 143 women (two had bilateral cancer) aged 35-75 in a 
prospective study, collecting data from January 2009 to December 
2010. The patients were all selected for breast-conserving surgery 
based on the criteria recommended by the Norwegian Breast Cancer 
Group. That is, tumor ≤ 4 cm, or acceptable tumor:breast ratio, and 
age > 35. Multifocal lesions, defined as more than one tumor > 1 cm 
apart, size of tumor > 4 cm, or a large tumor:breast ratio, extensive 
ductal carcinoma in situ (DCIS), or known genetic disposition for 
breast cancer, indicates mastectomy according to these criterias. In 
addition, when postoperative radiation therapy is contraindicated, 
mastectomy is indicated. If the patients filled the criteria for breast-
conserving surgery, they were offered preoperative breast MRI and 
included in the study. Patients who either choose mastectomy, or did 
not get a breast MRI for technical reasons, were excluded from the 
study. Two experienced breast radiologists evaluated the breast MRIs, 
and three experienced breast radiologists studied the mammographies 
and did the ultrasound examinations and biopsies. All additional MRI 
findings were examined by ultrasound-guided biopsy and given a 
histological diagnose before it influenced the surgical method.
Results: We excluded 28 patients from the study; 10 patients choose 
mastectomy, 13 patients were excluded due to problems with the MRI 
technology, and 5 patients were excluded for other reasons. Among 
the remaining 117 patients, 96 were treated by breast-conserving 
surgery, and 21 by mastectomy. The change of operative method was 
induced by the preoperative breast MRI in 16 patients, because of 
multifocality in 11 patients, and because of a more extensive tumor 
than discovered by conventional diagnostic tools, in 5 patients. 
Five patients had a secondary mastectomy, due to histopathological 
findings in the lump. In one patient preoperative MRI revealed 
cancer in the contralateral breast, and in one patient the additional 
findings on MRI resulted in preoperative systemic chemotherapy. 
The multifocality diagnosed on the preoperative MRI was confirmed 
on histopathological examination of the breast in 10/11 patients. In 
one patient who received preoperative systemic chemotherapy, the 
removed breast was without sign of malignant cells on microscopic 
examination.
Discussion: In this prospective study preoperative breast MRI give 
additional information that have impact on the primary surgical 
treatment in 16/117 or 13,7% of the patients selected for breast-
conserving surgery.
P2-08-10
Withdrawn by Author
P2-08-11
Correlation of Mammography, Ultrasound and MRI in Patients 
with Nipple Discharge.
Deshmane VH, Mulani S, Lodh N, Pungavkar S, Bhaduri A, 
Deshpande R, Madiwale C. P.D. Hinduja National Hospital, Mumbai, 
Maharashtra, India; Nanavati Hospital, Mumbai, Maharashtra, India
BACKGROUND: Breast cancer mainly originates in the epithelial 
lining of milk ducts or lobules. Once early pre-malignant or malignant 
changes occur in the ductal lining there is a long latent period before 
they manifest symptoms or are detected on imaging. Symptomatic 
nipple discharge (SND) is a common symptom noted in approximately 
5% of patients. Although, usually benign it may be the earliest sign 
of cancer. The current standard evaluation of patients with nipple 
discharge includes clinical examination (CE), mammography (MMG) 
and ultrasound (US). Contrast enhanced MRI is considered the most 
sensitive imaging modality for the breast and reports suggest it may 
be of benefit in the evaluation of nipple discharge. We have combined 
MRI with standard evaluation in an ongoing prospective study to 
determine its utility in patients with SND.
PATIENTS AND METHODS: Between July 2004 and 31st May 2011, 
75 women underwent surgery for SND. All were initially evaluated 
by CE, MMG and US following which a contrast enhanced breast 
MRI was requested. MRI was performed on a 1.5T MR unit using 
a dedicated breast coil. A STIR sequence in the coronal and sagittal 
planes along with an unenhanced fat-suppressed T1 W sequence was 
used to evaluate the ducts. The imaging findings were used to direct 
surgical excision. All specimens were oriented and evaluated by the 
pathologist by sectioning at 1 cm interval, from the ductal end to the 
periphery. The results of preoperative MMG, US and MRI findings 
were compared with pathology.
RESULTS: The incidence of cancer in this series was 29% and high 
risk lesions were noted in 43%. MMG and US were performed in 75 
patients. MRI was requested in all 75 patients but could be performed 
in 64. MRI proved to be the most sensitive technique for detection 
of an abnormality in the breast (92%) compared to MMG 25%, and 
US 63%. MMG, US and MRI were suggestive of benign change in 
64 (85%), 65 (87%) and 43 (67%) patients respectively, of which 14 
(22 %), 15 (23%) and 7 (16%) were malignant on pathology. MMG, 
US and MRI reported suspicious change in 11(15%), 10 (13%) and 
21(33%) patients respectively of which 8 (73%), 7 (70%) and 9 (43%) 
patients had cancer on pathology. MRI had the highest sensitivity 
for malignancy (54%) compared to MMG (36%) and US (32%) but 
MRI had a low specificity (74%) ( MMG 94%; US 94%). However, 
MRI had a high negative predictive value (86%) (MMG 78%; US 
73%). Of the 22 patients with cancers, 12 were deemed to be normal 
on CE, MMG and US examination. Thus standard evaluation would 
have missed 54% of the cancers detected in this series.
CONCLUSIONS: Nipple discharge is associated with significant 
incidence of cancer and high risk changes. The majority of these 
are missed on standard evaluation (CE, MMG, US). MRI is the 
most sensitive method for the detection of an abnormality in these 
patients. It defines the location and extent of the abnormality and 
can guide surgical excision. However, MRI is unable to accurately 
differentiate malignant from benign lesions. Hence, excision of an 
identified abnormality and pathological evaluation remains essential.
P2-08-12
Additional Lesion Found in Preoperative Breast MRI; Is Routine 
Use Justified?
Kim J, You J, Shin H, Ahn S, Moon H-G, Cho N, Moon W-K, Han W, 
Noh D. Seoul National University Hospital, Seoul, Korea
Preoperative breast MRI has been increasingly performed in patients 
with newly diagnosed breast cancer due to its high sensitivity in 
assessing the extent and additional malignant foci. But due to it’s 
low specificity, role of routine preoperative breast MRI has become 
an issue. In this study we aught to analyze the characteristics of the 
additional lesion found in preoperative breast MRI and to evaluate the 
clinicopathological factors in association with likelihood of having 
additional malignancy.
We retrospectively reviewed 2491 patients who undergone surgery 
due to breast cancer in Seoul National University Hospital(SNUH) 
between Jan 2006 and Dec 2010. Neoadjuvant chemotherapy cases, 
patients undergone initial sonography in other center or ones with 
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prior excision were excluded and total 1068 patients were analyzed. 
The additional lesion was defined as the lesion not found in initial 
sonography and detected in preoperative breast MRI. The pathology 
of the additional lesion was reviewed and the association between the 
clinicopathologic factors and additional malignancy were evaluated. 
Accuracy of breast MRI was estimated regarding cancer yield, 
positive predictive value(PPV).
Mean age at diagnosis was 50.9 years (21 to 85 years). Overall 
detection rate of additional lesion was 26.2%(280 out of 1068). Mean 
size of the additional lesion was 9.8mm(3-51). Additional lesions 
consist of 99(35.4% of 280) C4 or higher, 174(62.1% of 280) below 
C4, 7(2.5% of 280) C0 lesions. Among them 100 patients undergone 
onstage surgery. 5(55% of 100) lesions were in ipsilateral breast and 
45(45% of 100) in contralateral breast. Breast conserving surgery 
and mastectomy rate of the 100 onstage-operation group was 36% 
versus 64% and 64.6% versus 35.4% in total 1068 patients, showing 
no significant change of operation method of the primary cancer 
owing to additional lesion.
Among the100 patients, 54(19.3% of 280) were benign, 3(1.1% of 
280) were atypical ductal hyperplasia, 13(4.6% of 280) were in situ 
carcinoma, 19(6.8% of 280) were invasive carcinoma and 11(3.9% 
of 280) were unknown. Cancer yield was 2.99%(32 out of 1068) and 
PPV of preoperative breast MRI was 39.0%(31 out of 82).
In univariate analysis, young age and premenopausal patients showed 
to have higher rate of additional cancer found in MRI(p=0.022, 
p=0.036). Breast density, size and LN status of the primary cancer 
didn’t show significancy and neither the hormone receptor status 
with each p value 0.705, 0.381, 0.973, 0.375 respectively. Lobular 
carcinoma(ILC or mixed IDC with ILC) and low grade carcinoma 
showed significancy of having additional malignancy (p=0.019, 
0.022). In multivariate analysis age, low grade carcinoma and lobular 
carcinoma showed independent association with p value 0.014, 
0.039, 0.035 respectively(HR 0.95, 95%CI:0.94 o 0.99),(HR 0.39, 
95%CI:0.16 to 0.96),(HR 5.66, 95%CI:1.13 to 28.39).
Routine preoperative breast MRI use can result in overtreatment also 
with delay in surgical management. In our data, younger age, low 
grade carcinoma, lobular carcinoma showed independent association 
having additional malignant foci in breast MRI. With the basis of 
mammography and sonography, preoperative breast MRI should only 
be done when additional gain is considered to overcome the flaws.
P2-08-13
Does Routine Use of Preoperative Magnetic Resonance Imaging 
(MRI) in Breast Cancer Influence the Outcome?
Große R, Kantelhardt EJ, Steer S, Spinda AK, Vetter M, Ruschke 
K, Thomssen C. Martin-Luther-University Halle-Wittenberg, Halle 
(Saale), Germany
Introduction:
The role of routine preoperative breast MRI in patients diagnosed 
with breast cancer is still under discussion. In a milestone review, 
Houssami et al. (CA Cancer J Clin 2009;59;290) did not demonstrate 
an advantage with regard to DFS or OS. We reviewed our case series 
(n=793) in order to add evidence to the current discussion of whether 
or not preoperative MRI would influence the outcome.
Material and Methods:
In our database we identified four years of diagnosis (2004-07) 
in which a high percentage (72%) of patients (349 of 483) with 
histologically confirmed invasive breast cancer received preoperative 
MRI. In the following years (2008/09), MRI was still done in 31% 
of the cases (97 of 309). All pts were treated according to national 
guidelines; however, patients with additional lesions in MRI were 
subjected to an additional MRI-guided needle biopsy or additional 
wire-guided excision. The median follow-up time was 31.5 months 
(0-81). The patients were followed clinically. In most cases local 
surveillance was done by mammography.
Results:
In the total cohort, 20% of the patients had additional needle biopsies 
and/or wire-localisation due to MRI-findings. By MRI, lesions that 
subsequently led to an additional preoperative needle biopsy were 
found in 82 pts. Interestingly, only ten contralateral second cancers 
were found. In 357 pts, MRI was used as guidance during the 
operation with (n=118) or without MRI-supported wire localization 
(n=238). The percentage of additional MRI-needle biopsy or MRI-
supported localisation did not differ between invasive ductal (n=655) 
and lobular cancer (n=91): 10% versus 13% needle biopsies and 15% 
versus 20% wire localisations. The number of surgical procedures 
to achieve tumor-free margins did not differ between patients with 
or without preoperative MRI. In this series, 69 of 100 patients 
who received neoadjuvant chemotherapy, also had MRI-imaging. 
Considering the patient cohort with follow-up available (n=737), no 
significant difference of DFS probability was observed between pts 
with and without preoperative MRI.
Discussion:
This retrospective analysis did not demonstrate any advantage for 
routine preoperative MRI with regard to local treatment and DFS 
probability. The observed rate of 20% additional operative procedures 
corresponds to similar published data (16% additional multicentric or 
multifocal lesions found by MRI, Solin, Breast. 2010;19:7).
P2-09-01
First-in-Human Whole-Body HER2-Receptor Mapping Using 
Affibody Molecular Imaging.
Sandberg D, Wennborg A, Feldwisch J, Sörensen J, Garske U, 
Carlsson J, Lindman H. Uppsala University, Uppsala, Sweden; 
Affibody AB, Stockholm, Gunnar Asplunds Allé 24, Sweden
Background: ABY-025 is a member of a promising class of scaffold-
based antibody alternatives known as Affibody molecules with 
superior properties for molecular imaging compared to monoclonal 
antibodies. It is a minimal-size, high-affinity HER2 binder, non-
competitive with trastuzumab allowing imaging even during 
trastuzumab therapy. This pilot clinical study set out to establish a 
safe clinical procedure for further tests and to verify whether breast 
cancer lesions could be identified and characterized for HER2 
expression using single-photon emission computed tomography 
(SPECT) imaging.
Patients and methods: Seven patients with metastatic breast cancer, 
five with HER2 positive primary tumors and two HER2 negative 
controls were included. A standard 3-hour 18F-FDG-PET was 
performed to locate the lesions and 5 days later an injection with 111In-
labeled ABY-025 was given followed by whole body scanning at 30 
minutes with additional SPECT at 4, 24 and 48 hours. Biopsies were 
taken from amenable lesions and analyzed by immunohistochemistry 
to verify the HER2 status.
Results: Large metastases were visualized already at 30 minutes and at 
later registrations a majority of all known lesions could be identified. 
A brain metastasis showed exceptionally high HER2 signal-to-
background-ratio. Two fundamental behaviors were observed: High 
tumor to background ratio, increasing over time, was predominant in 
the HER2-positive group while the HER2-negative group generally 
presented a lower ratio. One patient in the positive group unexpectedly 
showed low tumor to background ratio similar to the negative group. 
Biopsy verified that the initially positive patient had converted to low 
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HER2 expression. All other biopsies confirmed that the metastases 
were still positive or negative in line with the subject’s primary 
lesions. None of the subjects had any adverse reactions due to the 
investigations.
Conclusion: ABY-025 can be used safely in humans with similar 
excellent whole body HER2-receptor molecular imaging capabilities 
as have already been observed in animal models. Promising 
indications of in vivo HER2-receptor status discriminatory 
capabilities were observed.
P2-09-02
Predicting Response to Bevacizumab in Primary Breast Cancer 
Using 18F-Fluorothymidina (FLT) and 18F-Misonidazole (MISO) 
Positron Emission/Computed Tomography (PET/CT) as Imaging 
Biomarkers.
Dominguez I, Boni V, Garcia-Velloso MJ, Lopez-Vega JM, Martinez P, 
Plazaola A, Llombart A, Anton A, Galve E, Alvarez IM, Hernando B, 
Sanchez-Gomez R, Illarramendi JJ, Morales S, De Juan A, Richter JA, 
Lahuerta A, Garcia-Gonzalez M, Lao Romera J, Puertolas T, Scherer 
S, Sabariz Luis, Garcia-Foncillas J. Clinic University of Navarra; 
Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; 
Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; 
Hospital Civil de Basurto; Hospital Donostia; Hospital General 
Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; 
Roche Basel; Roche Madrid
Background: To investigate the hypothesis that early changes in 
tumor proliferation and hypoxic status induced by bevacizumab 
and assessed by imaging biomarkers might predict response to 
bevacizumab therapy.
Methods: 73 chemotherapy naïve, stage II-III breast cancer (BC) 
patients (pts) were enrolled in the training set of this phase II, single-
arm, multicenter and prospective clinical trial from October 2009 until 
November 2010. Pts received single infusion of bevacizumab (15 mg/ 
kg) (C1) 3 weeks prior to the beginning of neoadjuvant chemotherapy 
(NAC) consisting in 4 cycles of docetaxel (60 mg/mq), doxorubicin 
(50 mg/mq) and bevacizumab (15 mg/ kg) every 21 days (C2-C5) 
following by surgery. Tumor proliferation and hypoxic status were 
evaluated using FLT and MISO PET/CT at baseline and 14-21 days 
after bevacizumab (C1). Standardized uptake values (SUV) for FLT 
and MISO and ratios to reference tissues, mediastinum (T/Me) or 
muscle (T/Mu), for MISO were calculated. Pathological response on 
surgical specimens was assessed according to Miller/Payne grading 
system. Pts with reduction in tumor cells >30% (G3-G4-G5) or 
<30% (G1-G2) were respectively considered as responders and no-
responders. Association between pathological response, baseline and 
changes induced by bevacizumab (C1) in imaging biomarkers was 
analyzed using Mann-Whitney test. Receiver operating characteristic 
(ROC) curve was performed to test sensitivity and specificity of the 
biomarker found associated to response. Its value as independent 
predictor was tested in multivariate analysis using logistic regression.
Results: Median baseline MISO and FLT SUV values in tumors 
were 1.2 (range 0.69-2.39) and 2.89 (range 0.97-7.18). Significant 
change after C1 was observed in FLT (2.7 vs 1.8, p<0.001) but no in 
MISO uptake. Fifty-two (74%) pts achieved response (G3-G4-G5) 
whether 18 (24%) were considered as no responder (G1-G2); for 
3 (4%) patients Miller/Payne tumor evaluation was not available. 
Response showed a trend toward an association with negative estrogen 
receptors (ER) expression (p=0.08) and triple negative tumors (11/73) 
(p=0.05). FLT SUV baseline and changes after C1 in MISO SUV, 
T/Mu and T/Me were all significantly associated with pathological 
response (p=0.057, 0.03, 0.016, 0.010). ER expression and T/Mu 
change remained significantly associated with response in multivariate 
analysis (OR=24.8, IC95% 1.8-334, p=0.01 and OR=0.95, IC 95% 
0.92-0.99, p value=0.02). Decrease in MISO T/Mu uptake >20% 
yielded a ROC curve area of 0.7 (95% CI: 0.56 - 0.85) with 94% 
sensitivity and 87% specificity. Conclusion: Bevacizumab determined 
a marked decrease in tumor proliferation. Interestingly, a decrease 
greater than 20% in tumor hypoxic status after C1 and assessed by 
MISO was found significantly associated with pathological response 
suggesting a potential value of early decrease in hypoxic tumor 
status as predictive biomarker of response. Bevacizumab, causing 
normalization of the tumor microvasculature, seems to potentiate the 
effect of cytotoxic agents on primary BC. A validation set is warranted 
to confirm these findings.
P2-09-03
Breast Cancer Detection Using a Novel Functional Imaging Device 
Equipped with Multiparametric Computer Analysis.
Sella T, Sklair-Levy M, Maya C, Rozin M, Tanir A, Maira S, Libson E, 
Izhaky D. Hadassah Hebrew University Medical Center, Jerusalem, 
Israel; Chaim Sheba Medical Center, Tel Hashomer, Israel; Rabin 
Medical Center, Petach Tikva, Israel; Assuta Medical Center, Tel-Aviv, 
Israel; Kaplan Medical Center, Rehovot, Israel; Meir Medical Center, 
Kfar Sava, Israel; Real Imaging Ltd., Airport City, Israel
Introduction: A novel prototype system performing functional 
three-dimensional (3D) infrared imaging (RUTH), coupled with 
multi-parametric computer analysis (MIRA), was evaluated for 
non-invasive breast cancer detection. The technique utilizes non-
ionizing radiation and automatically provides risk assessment based 
on parameters derived from a clinically known training set.
Materials and methods: Following IRB approval, prospective multi-
center, two-armed blinded evaluation, was performed on 102 women, 
which included 43 patients with biopsy proven breast cancer and 59 
women with a normal (BI-RADS 1) mammogram. RUTH imaging 
(Real Imaging Ltd, Israel) was acquired on a continuous temporal 
timeline for 5 minutes during which a cold-stress test was applied for 
one minute. Acquired data were analyzed using multiple computed 
algorithms (MIRA) which were combined to develop a master 
algorithm for risk assessment of breast cancer. Analysis was blinded 
to the clinical status. Results were displayed as risk assessment scale 
with 100 being suspicious for breast cancer and -100 inferring normal 
healthy breasts.
Results Thirty-nine of 43 cancers (91.7%) were identified using 
this novel technology. The sensitivity and specificity of RUTH 
coupled with MIRA for detecting breast cancer were 90.7% and 
67.8% respectively. The AUC defined by the ROC curve was 0.832. 
Twenty-seven of the 39 (70%) detected cancers were smaller than 
20mm in size.
Conclusions: This preliminary study shows adequate performance 
of the novel technology examined for detecting breast cancer. 
Performance is comparable to the reported performance of new 
adjunctive breast imaging technologies such as tomosynthesis and 
contrast-enhanced mammography, and superior to the published 
sensitivity of mammography. Our results warrant further evaluation 
of the RUTH and MIRA technologies in detecting and characterizing 
breast cancer.
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011275s
December 6-10, 2011 Abstracts: Poster Session 2
P2-09-04
Near Infra Red Quantum Dots as Novel Probes for Sentinel 
Lymph Node Biopsy.
Rizvi SB, Yang SY, Bala R, Shirin G, Seifalian AM, Keshtgar M. 
University College London, London, Hampstead, United Kingdom
Background
Sentinel Lymph Node Biopsy (SLNB) is a standard procedure in 
breast cancer surgery. The current tracers for SLNB including the 
blue dye and radiocolloid, have various limitations like anaphylactic 
reaction to the dye and exposure of radioactivity to both patients and 
staff. Quantum dots (QDs) are fluorescent nanoparticles (2-10nm 
in diameter), with unique photophysical properties like enhanced 
photostability and size tunable emission wavelengths, that can 
potentially replace the current tracers for SLNB. QDs emitting in 
the Near Infra Red (NIR) range of the electromagnetic spectrum 
can be tracked in deep tissues as biological tissues are transparent to 
NIR wavelengths (700-2000nm). We have developed Near Infra Red 
emitting Quantum Dots (NIR QDs) as alternative probes for SLNB 
and set up a live NIR imaging system to track them in deep tissues.
Materials and Methods
NIR emitting QDs based on CdTeHg were synthesized by a one 
pot aqueous method and characterized using Transmission Electron 
Microscopy (TEM), UV-Vis spectrometry and photoluminescence 
studies. 100µl of QDs (1mg/ml) were co-injected intradermally with 
blue dye into the hind legs of rat models (n=4) and compared to 
controls (n=4) which were injected with blue dye only. The procedure 
was conducted under inhalational anaesthesia using isofluorane and 
rats were monitored for hemodynamic instability for a period of 2 hrs 
after injection. QDs were tracked using a live NIR imaging system 
including an excitation light of 630nm, emission filter of 850nm and 
a Hamamatsu Orca 2 UV-Vis-NIR thermoelectrically cooled CCD 
camera.
Results
NIR QDs had a core diameter of 7nm on TEM and emitted at 
860nm upon excitation with a 630nm light source. Within 3 minutes 
of an intradermal injection QDs entered the lymphatic tracts. The 
lymphatics converged to the groin and a small surgical incision at 
this site revealed the underlying sentinel lymph node with minimal 
dissection. The rats remained hemodynamically stable throughout the 
duration of the procedure with no significant difference in comparison 
with the controls.
Conclusion
NIR emitting QDs can be used for accurate localisation of the SLN 
prior to surgical incision, making this an even more minimally 
invasive procedure and possibly an office based procedure in the 
future. The nanosize, surface chemistry and deep tissue visibility of 
these novel nanoprobes allow relentless possibilities for in vitro and 
in vivo molecular and cellular imaging. NIR QDs can be conjugated 
to biomolecules for cancer localisation, detection of micrometastasis 
and image guided targeted drug delivery of chemotherapeutic agents. 
Further studies to investigate their in vivo biodistribution are in 
progress to take this technology one step closer to clinical application.
P2-09-05
Molecular Imaging of Hedgehog Induced Epithelial-Stromal 
Interactions.
Sims-Mourtada J, Yang DJ, Tworowska I, Larson R, Smith D, 
Mourtada F, Woodward W. RadioMedix, Inc, Houston, TX; The 
University of Texas M.D. Anderson Cancer Center, Houston, TX
Introduction: Epithelial-stromal Hedghehog (HH) pathway signaling, 
originating from Sonic Hedgehog (SHH) ligand secreted by tumor 
cells, promotes breast cancer growth and metastasis. Furthermore, 
high tumor SHH expression is associated with poor prognosis in 
invasive ductal carcinoma. Studies have also shown high expression of 
Patched (PTCH) mRNA in SHH expressing tumors as well as cancer 
stem-like cells. This is in part due to a feedback loop that results in 
increased PTCH gene expression upon HH signaling. We sought to 
exploit this feedback loop by using radiolabeled derivative of SHH to 
identify tumors that have a high level of hedgehog signaling. These 
agents can potentially be used for molecular imaging of HH induced 
changes in PTCH expression originating from tumor expressed SHH.
Methods: Recombinant N-terminal SHH derivatives were 
radioiodinated with iodine-131 using the idogen method. Iodinated 
proteins were obtained with radiolabeling yields of 50-60 % and 
specific activity of 9.3E10Ci/mol. Receptor binding studies were 
performed on breast cancer cell lines with varying SHH expression. 
Studies were also conducted on cells cultured in stem cell promoting 
conditions (mammospheres), after exposure to ionizing radiation 
or treatment with the hedgehog inhibitor cyclopamine. Scatchard 
plots were generated using Graph pad software. Pilot studies were 
conducted with 131I-SHH to test the potential of imaging PTCH 
receptor expression in a rat model of breast cancer. Fisher rats bearing 
breast cancer xenografts were injected with approximately 250 
microCi of 131I-SHH. Planar scinitigraphy was conducted at 2, 4 and 
24 hours. Studies were performed with iodinated BSA as a control for 
extracellular perfusion and retention. Tissue biodistribution studies 
were also performed using this model.
Results: Receptor binding of 131I-SHH was significantly increased 
in cell lines with high endogenous HH pathway activation. Receptor 
binding was also increased after exposure to ionizing radiation 
and significantly decreased following treatment with hedgehog 
inhibitors. Scatchard analysis revealed up to a 14 fold increase in 
PTCH receptor sites in mammospheres compared to the entire breast 
cancer population. A 10-fold increase in PTCH receptor binding 
sites was also observed in cells after exposure to ionizing radiation. 
In vivo imaging and biodistribution studies revealed significant 
accumulation of 131I-SHH within tumor tissue as compared to normal 
organs. Tumor:muscle ratios were approximately 8:1 at 4 hours, while 
tumor to blood and tumor to bone were 2:1 and 5:1 respectively. 
Significant uptake was also observed in liver tissue, as a result of 
protein degradation and excretion and endogenous PTCH expression.
Conclusions: These studies show that expression of the PTCH 
receptor is increased in cells with active HH signaling and in breast 
cancer mammospheres. Our findings also show that PTCH receptor 
expression is decreased upon treatment with HH signaling inhibitors. 
Preliminary imaging studies show that 131I-SHH is capable of in vivo 
detection of breast tumors with high hedgehog signaling. Our data 
suggests that radiolabeled SHH derivatives may provide a method 
to follow epithelial-stromal HH interactions and determine response 
to SHH targeted therapies.
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P2-09-06
Relevance of Breast Cancer Subtypes in Response Monitoring 
with 18F-FDG PET/CT during Neoadjuvant Chemotherapy.
Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters 
M-JT, Gilhuijs KG, Rutgers EJ, Valdés Olmos RA. Netherlands Cancer 
Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Background – Neoadjuvant chemotherapy (NAC) is increasingly 
applied in stage II and III breast cancer. Response monitoring with 
magnetic resonance imaging (MRI) has been shown valuable, but 
knowledge of the breast cancer subtype is essential for correct 
interpretation of response assessment.(Loo et al, J Clin Oncol 
29:660-6, 2011)
The aim of the present study was to evaluate the relevance of breast 
cancer subtype for 18F-fluorodeoxyglucose (FDG) positron emission 
tomography with computed tomography (PET/CT) markers for 
monitoring of therapy response during NAC.
Methods – Evaluation included 94 women with primary stage II or 
III breast cancer and measurable (quantifiable) FDG tumor uptake. 
FDG PET/CT scans were performed before and after six weeks of 
NAC using similar prone patient positioning. FDG uptake of the 
primary tumor was quantified using maximum standardized uptake 
values (SUVmax). Tumors were divided into three subtypes using 
immunohistochemistry: human epidermal growth factor receptor 2 
(HER2) positive, estrogen receptor (ER) positive/HER2 negative and 
triple negative. Tumor response was assessed as presence of residual 
tumor in the surgery specimen (no response or partial response) or 
absence thereof (near complete or complete response). Multivariate 
regression analysis and receiver operating characteristic (ROC) 
analyses were employed to determine significant associations.
Results – A (near) complete response at pathology was observed in 16 
(73%) of 22 HER2 positive tumors, 5 (12%) of 43 ER positive/HER2 
negative tumors and 20 (69%) of 29 triple negative tumors. In the 
multivariate regression analysis for the whole group, (near) complete 
response in the surgery specimen was significantly associated with 
relative reduction of SUVmax of the tumor between both scans 
and breast cancer subtype (area under the curve of the ROC curve 
0.88 [95% confidence interval 0.81-0.95], p<0.001); no significant 
associations were found for FDG uptake at baseline and age. In a 
subgroup analysis of breast cancer subtype, a significant association 
was found between pathologic response and relative reduction of 
SUVmax for ER positive/HER2 negative and triple negative tumors 
(p=0.012 and p<0.001, respectively), but not for HER2 positive 
tumors (p=0.151).
Conclusion – Knowledge of the breast cancer subtype appears relevant 
for the assessment of response to NAC with FDG PET/CT. Response 
monitoring with FDG PET/CT may predict a pathological response 
adequately in ER positive/HER2 negative and triple negative tumors, 
but seems less accurate in HER2 positive tumors. The reasons for 
these differences need to be elucidated in further investigations.
Disclosure – This study was performed within the framework of 
CTMM, the Center for Translational Molecular Medicine (www.
ctmm.nl), project Breast CARE (grant 030-104).
P2-09-07
Metabolic Response by FDG-PET in Patients (pts) Receiving 
Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast 
Cancer (MBC): Correlative Analysis of TBCRC 003.
Yap JT, Locascio T, Najita JS, Mayer IA, Hobday TJ, Falkson CI, 
Dees EC, Gelman RS, Rimawi MF, Nanda R, Berkowitz J, Franchetti 
Y, Wolff AC, Winer EP, Lin NU, Van den Abbeele AD. Dana-Farber 
Cancer Institute, Boston, MA; Vanderbilt-Ingram Cancer Center, 
Nashville, TN; Mayo Clinic, Rochester, MN; University of Alabama, 
Birmingham, AL; University of North Carolina at Chapel Hill, Chapel 
Hill, NC; Baylor College of Medicine, Houston, TX; University 
of Chicago, Chicago, IL; Johns Hopkins Kimmel Cancer Center, 
Baltimore, MD
Background: We evaluated the safety and efficacy of L+T in pts 
with 0-2 prior lines of chemotherapy (CT) for HER2+ MBC. In the 
context of this phase II trial, we evaluated metabolic response by 
FDG-PET and explored the relationship between metabolic response 
and clinical outcomes.
Methods: Pts with measurable, HER2+ MBC were eligible. Cohort 
1: No prior T, L, or CT +T for MBC, and >1 yr from adjuvant T, if 
received. Cohort 2: 1-2 prior lines of CT for MBC, including T, or 
relapse within 1 yr of adjuvant T. Pts received L 1,000 mg QD + T (2 
mg/kg weekly or 6 mg/kg Q3W). Staging studies were done with CT 
or MRI at baseline (BL) and every 2 cycles (1 cycle=4 weeks [wks]). 
Objective response was assessed by local investigator according to 
RECIST 1.0. FDG-PET/CT was performed at BL, Wk 1, and Wk 8 
per NCI guidelines. Central quality assurance, review, and analysis 
were performed on FDG-PET studies. Up to 5 target lesions were 
identified on BL FDG-PET images based on hypermetabolic uptake. 
Percent change in the summed maximum standardized uptake value 
(SUVmax) of target lesions was calculated at Wk 1 or Wk 8, compared 
to BL. Metabolic response was assessed according to EORTC criteria 
for % change in SUVmax (progressive disease [PD]: >25% increase; 
partial response [PR]: >25% decrease; stable disease [SD]: <25% 
change). Metabolic response at Wk 1 was compared to Wk 8 as well 
as to clinical outcome, including objective response, clinical benefit, 
and progression-free survival (PFS).
Results: 87 pts were registered to the study. Of these, one pt did 
not begin protocol therapy and one pt did not have MBC on further 
testing, and are not included. 81/85 pts had FDG-PET data at Wk 1; 
75/85 had data at Wk 8. Metabolic PR at Wk 1 was observed in 28/39 
(72%) pts in Cohort 1 and 20/42 (48%) pts in Cohort 2. Metabolic 
PR at Wk 8 was observed in 27/34 (79%) pts in Cohort 1 and 18/41 
(44%) pts in Cohort 2. Wk 1 and Wk 8 metabolic responses were 
similar. In cohort 1, 18/28 (64%) pts who achieved Wk 1 metabolic 
PR had clinical benefit by RECIST. Of pts with Wk 1 metabolic 
SD, 2/9 (22%) had clinical benefit. In cohort 2, 9/20 (45%) pts who 
achieved Wk 1 metabolic PR had clinical benefit; 5/22 (23%) who 
achieved Week 1 metabolic SD had clinical benefit. Exploratory 
analysis of progression-free survival (PFS) showed that pts in Cohort 
1 who achieved Wk 1 metabolic PR experienced a median PFS of 
9.3 months ([mos]; 95% CI 5.6-22.3); for pts with metabolic SD, 
median PFS was 1.9 mos (95% CI 0.8-5.5). For pts in Cohort 2, Wk 
1 metabolic PR was associated with median PFS of 5.6 mos (95% 
CI 3.7-7.8), whereas for pts with metabolic SD, median PFS was 3.7 
mos (95% CI 1.8-5.5).
Conclusions: L+T is associated with a high rate of early and sustained 
metabolic response by FDG-PET. Exploratory analyses suggest that 
metabolic PR may be associated with clinical benefit and longer PFS.
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Cohort 1
 Best RECIST response      
Wk 1 PET response Confirmed CR/PR SD >/=24 wks
Unconfirmed  
PR SD<24 wks PD Unknown
PR (n=28) 18 0 4 2 4 0
SD (n=9) 1 1 0 2 5 0
PD (n=2) 0 0 0 0 1 1
Cohort 2
 Best RECIST  response      
Wk 1 PET response
Confirmed  
CR/PR
SD>/=24 wks Unconfirmed PR SD<24 wks PD Unknown
PR (n=20) 7 2 5 5 1 0
SD (n=22) 2 3 0 8 9 0
P2-09-08
FDG-PET in the Staging of the Axilla in Women with Breast 
Cancer Treated with Primary Chemotherapy.
Lao Romera J, Puértolas Hernandez T, Alvarez Alejandro M, Godoy 
Molias A, Hernandez Garcia A, Millastre Bocos E, Garcia Mur C, 
Ubieto Laguarda MA, Artal Cortes A, Anton Torres A. Hospital 
Universitario Miguel Servet, Zaragoza, Spain; Clinica Quirón, 
Zaragoza, Spain
Background: FDG-PET has proven to be useful during the initial 
staging of several tumor types. The aim of the present study was to 
assess the accuracy of this test in the assessment of initial axillary 
status in patients referred to treatment with induction chemotherapy.
Material and Methods: Women with stage II-IIIA (tumors measuring 
≥3cm or positive-staged axillary involvement) to be treated with 
neoadjuvant Docetaxel-Doxorubicin-Cyclophosphamide (TAC 
scheme) were included. In every patient a physical exam, MRI, 
ultrasound-guided FNAB and FDG-PET were performed prior 
starting chemotherapy. The criteria to consider the axilla to be 
initially positive were positive surgical staging or type-D pathological 
response (Miller-Payne) in the axilla. The ability of FDG-PET to 
predict pathological response in patients with breast cancer was 
assessed and compared with other routine procedures.
Results: 42 patients (p) were included. Median age was 45 years 
(30-66). 11p (26.2%) were triple-negative. 2p (4.8%) were Her-2 
+. By clinical stage, 13p (30.9%) were IIA, 17p (40.4%) IIB and 
12p (28.2%) IIIA. 41p (97.6%) underwent surgery after induction 
chemotherapy. According to surgical staging 31p (75.6%) were 
deemed to be N+ from the diagnosis (19p with pathologic N1-3a 
and 12p with type-D nodal response). PET scan positively detected 
deposits in the axilla in 26p (83.9%) of those patients compared to 
22p (70.9%) with ultrasound-FNAB, 19p (61.3%) physical exam 
and 14p (45.2%) MRI.
Conclusions: In this study FDG-PET could predict axillary 
involvement more precisely than other routine staging procedures in 
these patients submitted to be treated with induction chemotherapy.
P2-09-09
Dynamic FDG PET and DCE-MRI To Assess Tumor Metabolism 
and Blood Flow in Response to Neoadjuvant Sunitinib and 
Paclitaxel Followed by AC + G-CSF in Patients with Locally-
Advanced (LABC) and/or Inflammatory Breast Cancer (IBC).
Specht JM, Kurland BF, Dunnwald LK, Doot RK, Eun JK, Schubert 
EK, Partridge SC, Ellis GK, Gadi VK, Gralow JR, Linden HM, 
Rodler ET, Mankoff DA. University of Washington, Seattle, WA; Fred 
Hutchinson Cancer Research Center, Seattle, WA; Seattle Cancer 
Care Alliance, Seattle, WA
Background: Kinetic analysis of FDG PET and DCE-MRI can 
identify patterns of breast tumor metabolism and perfusion that predict 
pathologic response, relapse, and survival in patients (pts) receiving 
neoadjuvant chemotherapy (NC). We are enrolling pts with LABC 
or IBC on a phase II trial of neoadjuvant sunitinib and metronomic 
chemotherapy. The addition of sunitinib, a tyrosine kinase inhibitor 
of VEGFR1-3, PDGFR, c-KIT, to NC is hypothesized to increase 
rate of pathologic complete response (pCR). Assessment of FDG 
PET measures of glucose metabolism (Ki), glucose delivery (K1) 
which approximates blood flow, and MRI measures of blood flow 
and vascularity (peak enhancement (PE), signal enhancement ratio 
(SER), and volume) during NC offers the opportunity to evaluate the 
in vivo pharmacodynamics of sunitinib.
Methods: Pts with HER2-negative LABC or IBC participated in a 
companion imaging trial with [18F]-FDG PET and DCE-MRI before 
NC (T0), after a 1 wk run-in of sunitinib 25 mg po daily (T1), after 12 
wks of paclitaxel 80 mg/m2 IV Qwk and sunitinib 25 mg po daily (T2), 
and prior to breast surgery (T3) after 15 wks of doxorubicin 24 mg/m2 
IV Qwk, cyclophosphamide 60 mg/m2 po daily with G-CSF 5 mcg/
kg SC days 2-6 each wk. FDG metabolic rate (Ki), glucose delivery 
(K1), and MR indices (PE, SER, volume) were assessed. Imaging 
parameters were compared for groups defined by NC pathologic 
complete response (pCR) vs. non-pCR using a two-sample t-test.
Results: The imaging trial included 14 pts. Median age was 50 years 
(43-79). All had HER2-negative LABC (n=13, 93%) or IBC (n=1, 
7%). Most tumors were ductal (n=12, 86%) and high grade (n=9, 
64%). Seven (50%) tumors were ER negative. pCR was observed in 
4/14 (29%) pts in this cohort. Changes in Ki, K1, and MRI volume 
were observed between baseline (T0) and the sunitinib run-in (T1). 
For example, 8/14 (57%) had a decrease in K1 of ≥20%, and 3 (21%) 
had an increase of ≥20%. These 1 week changes did not predict 
subsequent response to NC. However, declines in Ki and K1 between 
baseline (T0) and following sunitinib and paclitaxel (T2) did predict 
pCR. The average change in glucose metabolism (Ki) was a 95% 
decline with pCR and a 68% decline otherwise (p= 0.007). The 
average T0-T2 K1 change was 83% decline for pts with pCR and 
47% decline otherwise (p= 0.029). In contrast to our previous studies 
in LABC pts treated with NC where decline in K1 was predictive of 
response, decline in Ki appears to be the more robust predictor of 
response in this cohort. Of 11 pts with PET scans at T2 and T3, 5 
showed marked increase (>20%) in Ki and 6 showed marked increase 
in K1 after withdrawal of sunitinib.
Conclusion: Changes in breast tumor glucose metabolism (Ki), 
glucose delivery (K1), and blood flow (MR PE, SER, volume) can 
be detected after 1 wk of sunitinib, but are not predictive of response 
to NC. In the setting of anti-vascular therapy, measures of tumor 
glucose metabolism (Ki) are predictive and perhaps, more predictive 
of outcome than measures of glucose delivery (K1) which may be 
altered by sunitinib.
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P2-09-10
Giant or Windmill? 18F-FDG-PET/CT Semi-Quantitative 
Parameters and Biological Prognostic Parameters in Women 
with Breast Cancer Treated with Neoadjuvant Chemotherapy: 
A Multicentric Study in La Mancha.
del Mar Muñoz-Sánchez M, García-Vicente A, Ortega-Ruipérez 
C, Palomar-Muñoz A, Molina-Garrido MJ, Olaverri-Hernández 
A, Santiago-Crespo JA, Martín-Ordóñez F, Val-Pérez E, Cordero-
García JM, Chacón JI, Fernández-Aramburu A, Espinosa J, Viana 
A, Soriano-Castrejón A. Hospital General Virgen de la Luz, Cuenca, 
Spain; Hospital General Universitario de Ciudad Real, Ciudad Real, 
Spain; Complejo Hospitalario de Toledo, Toledo, Spain; Complejo 
Hospitalario Universitario de Alabacete, Albacete, Spain; Hospital 
General Ntra Sª del Prado, Talavera, Toledo, Spain
Background: To analyze the possible predictive-prognostic value 
of 18F-FDG-PET/CT to evaluate response to primary preoperative 
neoadjuvant (NA) chemotherapy (CT) in women with breast cancer 
(BC) a multicenter study is being conducted in most Hospitals in 
Castilla – La Mancha (central Spain). As per protocol a PET/CT study 
has to be conducted prior to 1st cycle, after 2nd cycle and at the end of 
induction CT. We report here the initial results with the correlation 
between the PET/CT results and pathological-radiological-clinical 
findings prior to NA CT.
Aim: To analyze the correlation between 18F-FDG uptake assessed by 
PET/CT and histopathological and inmunohistochemical prognostic 
factors in BC prior to NA CT.
Material and methods: 68 women diagnosed of BC (36 with locally 
advanced BC) were prospectively evaluated. PET/CT was requested 
in the initial staging previous to NA CT. Clinical and metabolic 
stages were assessed according to TNM classification. All biological 
prognostic parameters, such as ER, PR, p53 and c-erbB-2 expression, 
proliferation rate (Ki-67), and grading (SBR) were determined from 
tissue of the primary tumour prior to NA CT. All patients underwent an 
18F-FDG PET/CT with a dual-time-point acquisition performed in the 
early phase 1 h after FDG administration (PET-1) and in the delayed 
phase 3 h after FDG administration (PET-2). Both examinations 
were evaluated qualitatively and semiquantitatively with calculation 
of SUVmax values in PET-1 (SUV-1) and in PET-2 (SUV-2) and 
the percentage variation of the standard uptake values (retention 
index) between PET-1 and PET-2. Metabolic, clinical and biological 
parameters were correlated. Student, ANOVA and Bonferroni tests 
were used to compare the means, chi-score to compare proportions 
and Pearson correlation to compare two quantitative variables.
Results: A positive relationship was found between the SUVmax, 
tumour size, clinical and metabolic stages. SUV-1 and SUV-2 values 
showed significant statistical correlation (p<0.05) with PET stage and 
tumour size assessed by PET. On the contrary, the retention index 
showed relation with clinical stage (p<0.05). About the biological 
parameters, retention index showed the best results with positive 
and significant relation (p<0.05) with histological grade, ER status, 
Ki-67 and c-erbB-2 expression. Isolated SUV values only showed 
significant relation to Ki-67 expression.
Conclusion: The retention index showed the best correlation with 
biological and clinical parameters compared to isolated SUVmax 
values. It may be useful as a predictive marker of tumor biological 
behavior. Nevertheless these are only the results of PET/CT prior 
to NA CT, with longer follow up we hopefully will be able to look 
at the correlation between PET/CT and radiological, clinical and 
pathological response after NA CT.
P2-09-11
Role of 18FDG-PET/CT in the Staging of Large Primary 
Operable Breast Cancer.
Groheux D, Giacchetti S, Hamy A-S, Vercellino L, Delord M, Berenger 
N, Toubert M-E, Misset J-L, Hindié E, Espié M. Saint-Louis Hospital, 
Paris, France; IUH, University of Paris VII, Paris, France
Background: Prospective evaluation of the role of 18FDG-PET/CT in 
patients with large primary operable breast cancer.
Material and Methods: During 56 months, consecutive patients 
with large (>2cm) breast cancer and clinical stage IIA/IIB/IIIA 
(based on clinical examination, mammography, breast MRI and 
ultrasonography) underwent 18FDG-PET/CT. The nuclear physician 
was blind to the results of any other procedure (bone scan, chest X-ray, 
liver ultrasound, or thoraco-abdominal CT scan).
Results: Out of the 131 examined patients, 36 had clinical stage IIA 
(34 T2 N0, 2 T1 N1), 48 stage IIB (20 T3 N0, 28 T2 N1), and 47 
stage IIIA (29 T3 N1, 9 T2 N2, 9 T3 N2). 18FDG-PET/CT modified 
staging for 5.6% of stage IIA patients, for 14.6% of stage IIB patients, 
and for 27.6% of stage IIIA patients. However, within stage IIIA, the 
yield was specifically high among the 18 patients with N2 disease 
(56% stage modification). When considering stage IIB and primary 
operable IIIA (T3 N1) together, the yield of 18FDG-PET/CT was 
13% (10/77); extra-axillary regional lymph nodes were detected in 
5 and distant metastases in 7 patients. In this series, 18FDG-PET/CT 
outperformed bone scan with only 1 misclassification versus 8 for 
bone scan (p=0.036).
Discussion: 18FDG-PET/CT provided useful information in 13% of 
patients with T3 N0 / T2 N1 / T3 N1 disease. The yield was more 
modest in patients with T2 N0 disease. The very high yield in the case 
of lymph nodes classified N2 demonstrates that stage IIIA comprises 
two quite distinct groups of patients.
P2-09-12
High Resolution Diffusion MRI Characterizes Tumor Stromal 
Boundaries.
McLaughlin RL, Newitt DC, Wilmes LJ, Sinha S, Wisner DJ, Hylton 
NM. UC Berkeley and UCSF, Berkeley and San Francisco, CA; 
UCSF, San Francisco, CA
Background: Studies of 3D cell cultures have shown that 
mammary epithelial cell growth and morphogenesis is regulated 
by extracellular matrix (ECM) stiffness, linking ECM stiffening 
to malignant transformation. Tumors are consistently stiffer than 
normal adjacent tissue, and matrix stiffening is caused by ECM 
cross-linking and increased deposition of collagen. Some evidence 
suggests that collagen orientation at tumor boundaries can promote 
tumor metastasis. Measuring the stiffness of the tumor boundaries 
and adjacent stromal tissue may give additional information 1) 
about tumor microenvironment and 2) to guide treatment. Diffusion-
weighted imaging (DWI) MRI measures the mobility of water in 
tissue and may be sensitive to this phenomenon.
Material and Methods: MRI data was collected on patients with 
locally advance breast cancer enrolled in an IRB-approved study at 
UCSF and signed informed consent. In addition to a standard dynamic 
contrast enhanced (DCE) MRI, a high-resolution diffusion-weighted 
image (HR DWI) was acquired with an echo planar imaging sequence 
and the following parameters: TR/TE=4000/64.8 ms, b=0,600, 
FOV=70x140mm, matrix=28x64, and voxel size=0.55x0.55x4.0mm. 
Apparent diffusion coefficient (ADC) maps were created. HR DWI 
images were segmented into tumor and non-enhancing, surrounding 
stromal tissue. A proximity mapping method was used to measure 
ADC values at the inner edge of tumor and at increasing distances 
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from the tumor boundary on HR DWI. The mean was calculated for 
the voxels in 1 mm increments, starting at 5 mm into the tumor (-5 
mm) and ending at 2.5 cm away from the tumor (25 mm).
Results: The average of the changes per 1 mm shell was largest for 
the transition of the tumor boundary (Table 1). In Table 1, the -5 to 0 
mm, 0 to 5 mm, and 5 to 25 mm columns represent inside the tumor, 
tumor boundary, and outside the tumor, respectively. In general, ADC 
values were consistently lower inside the tumor than outside. The 
greatest changes per 1 mm shell was seen in the transition from inside 
to outside tumor, although the values varied among tumor types. Each 
of the three cases analyzed had different patterns of ADC values.
Table 1: Changes in ADC values relative to tumor distance
 Average of the change in ADC per 1 mm shell for distance of:
Patient -5 mm to 0 mm 0 mm to 5 mm 5 mm to 25 mm
1 43.1 198 0.629
2 -1.12 97.5 -8.91
3 -41.8 62.3 -11.0
Discussion: These preliminary studies show that water mobility 
measurements change at the tumor boundary, with different patterns 
observed among individual patients. We are further investigating the 
influence of density and tumor margin morphology on these ADC 
measurements.
P2-09-13
The Value of FDG PET/CT in Screening Detected Breast Cancer 
Patients.
Koo HR, Moon WK, Cho N, Chang JM, Kang KW, Yi A. Seoul National 
University Hospital, Seoul, Korea
Background. To evaluate the diagnostic value of FDG PET/CT for 
initial staging of screening detected breast cancer.
Methods. Between January 2008 and June 2010, a total of 77 women 
(mean age 54 years, range 31-77 years) with screening detected 
primary breast cancer (mean invasive tumor size 1.65cm, range 
1-70mm) underwent whole body fluorine-18 fluorodeoxyglucose 
(FDG) PET/CT for initial staging and were included in this 
retrospective study. Two patients had bilateral breast cancer. The 
sensitivity of FDG PET/CT for the detection of primary tumor 
and the sensitivity, specificity, PPV and NPV for the detection of 
axillary lymph node metastases were determined. Systemic staging 
with whole body FDG PET/CT was also performed. For analysis of 
diagnostic performance of FDG PET/CT, quantitative measurement 
of the maximum standardized uptake value (SUVmax) criteria 1.0 
was used. The final histopathology following surgery served as the 
gold standard.
Results. The primary tumor was FDG PET/CT positive in 65 of 79 
lesions (82%). Depending on the tumor size, there was a variation 
in diagnostic sensitivity (63% in ≤ 1cm tumor, n=19 vs. 88% in > 
1cm tumor, n=60) and the uptake of FDG was significantly higher 
in > 1cm tumor than in ≤ 1cm tumor (mean SUVmax 2.85 vs. 1.11, 
p<0.05). The uptake of FDG was significantly higher in ductal 
carcinomas compared to lobular carcinomas (median SUVmax 
2.0, n=72 vs. 1.3, n=7, p<0.05). Of the 77 patients included in this 
study, 16 patients were found to have axillary node metastasis. The 
sensitivity, specificity, PPV and NPV of FDG PET/CT for detection 
of LN metastasis were 63% (10/16), 89% (54/61), 59% (10/17) and 
90% (54/60), respectively. FDG PET/CT showed distant uptake 
in 9 patients and 8 of 9 were false positive results. 4 lesions were 
confirmed histopathologically as benign and 4 lesions were evaluated 
with radiologic methods. One of nine was true positive result. Distant 
involvement was skeletal and visible on the conventional bone 
scintigraphy. The patient staged as cT1N3M1.
Conclusion. FDG PET/CT has limited value for the initial staging 
of screening detected breast cancer patients. Considering high 
costs, radiation exposure and false positivity, FDG PET-CT is not 
recommended for the preoperative evaluation of screening detected 
breast cancer patients.
P2-09-14
Evaluation of Angiogenesis Using Synchrotron Radiation in 
Xenograft Mouse Models of Breast Cancer.
Gu S-M, Zhang X, Li R-M, Jin W, Shen Z-Z, Shao Z-M, Xu X-M, Wu 
J. Cancer Hospital/Institute, Fudan University, Shanghai, China; 
Shanghai Jiao Tong University, Shanghai, China
Visualization of microvasculatures is an important step in 
understanding the mechanism of early vessel disorders in breast 
cancer and developing effective therapeutic strategies. However, 
quantitative evaluation of breast cancer angiogenesis using 
immunohistochemistry has been limited in generating detailed and 
reproducible data. To analyze the diversification of angiogenesis 
in the development of tumor growth and evaluate anti-vascular 
effects of Avastin, a new method of microvascular imaging was 
introduced in this paper. We used New X-ray microangiography 
and third-generation synchrotron radiation-based micro-computed 
tomography (SR micro-CT) to investigate the structures and density 
of microvessels at each stage of xenograft mouse models that were 
created by inoculation with MDA-MB-231HM cells (one breast 
cancer cell line with high metastasis potential). Barium Sulfate 
Nanoparticles, was used as a blood vessels contrast agent through left 
cardiac ventricle. Three dimensional structures of microvessels were 
displayed with a high spatial image resolution at around 20–30 µm. 
The density of microvessles was significantly reduced from the third 
week in mouse xenograft models. This observation with SR micro-CT 
was consistent with the results analyzed by immunohistochemical 
techniques. In addition, human breast cancer–bearing mice were 
treated site-specifically with humanized monoclonal antibody 
(Avastin) that targets all isoforms of VEGF-A. Tumor volume and 
the density of angiogenesis were significantly reduced in xenograft 
mouse models of breast cancer treated with avastin when compared 
with untreated mice as assessed by SR micro-CT. Specifically, the 
density of smaller vessels (di<50µm) was decreased significantly 
while the density of larger vessels was little changed in the Avastin-
treated mice. Therefore, synchrotron radiation technique is a novel 
method for investigating breast cancer angiogenesis, and this might 
be considered as an additional complementary tool for more precise 
quantification of angiogenesis.
P2-09-15
Functional Measurements of Tumor Response during Neoadjuvant 
Chemotherapy Infusion and Early during Treatment Using 
Diffuse Optical Spectroscopic Imaging.
Roblyer D, Ueda S, Cerussi AE, Durkin A, Leproux A, Santoro Y, Xu 
S, Mehta R, Hsiang D, Butler J, Tromberg B. University of California, 
Irvine, CA; University of California, Irvine, Orange, CA
Background: Non-invasive markers of neoadjuvant chemotherapy 
response early during treatment would provide physicians a valuable 
tool to make evidence-based changes to treatment strategies. In a 
retrospective study of 23 patients presented at SABCS 2011 we 
demonstrated that Diffuse Optical Spectroscopic Imaging (DOSI) 
can discriminate non-responding from responding subjects on the 
first day after the start therapy based on the presence or absence 
of an oxyhemoglobin flare. Here we present results of an ongoing 
prospective study designed to confirm the predictive nature and 
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biological origins of oxyhemoglobin flare and to determine if similar 
functional changes occur at even earlier timepoints such as during 
infusion.
Methods: DOSI was used to measure hemodynamic and metabolic 
information from tumors and surrounding normal tissue in patients 
prior to neoadjuvant chemotherapy, during chemotherapy infusion, 
and daily for the first week of treatment. DOSI uses temporally 
modulated near-infrared light to determine absolute tissue 
concentrations of oxyhemoglobin, deoxyhemoglobin, water and lipid 
content and requires no exogenous contrast agent. Measurements 
are made using a simple handheld probe placed on the skin. Blood 
samples were also collected at baseline and daily for seven days 
after the first infusion and tested for a panel inflammatory cytokines. 
Patients received paclitaxel + carboplatin + bevacizumab. Overall 
response to therapy was determined by the decrease in anatomic 
tumor size.
Results: To date three subjects have been measured, two of which 
have completed neoadjuvant chemotherapy and undergone surgery. 
One subject was a pathologic complete responder (pCR) and the 
other a non-responder (NR). In both the pCR subject and the subject 
still undergoing therapy there were significant functional changes 
measured in the tumor during infusion. A decrease in oxyhemoglobin 
and oxygen saturation occurred after paclitaxel infusion (saturation 
changes: -4.8% and -9.7% for each subject respectively), followed by 
an increase in these quantities after carboplatin infusion (saturation: 
3.8% and 5.9% respectively). In the NR subject both oxyhemoglobin 
and oxygen saturation had only small fluctuations during infusion 
(saturation: 1.1%). Oxyhemoglobin flare was also observed 24 
hours after infusion for each of the patients. Plasma levels of several 
inflammatory cytokines including G-CSF, MIP-1a, and C-reactive 
protein increased 24 hours after infusion for the first two subjects and 
subsequently decreased at 48 hours.
Discussion: We have confirmed the presence of oxyhemoglobin flare 
on day one after infusion in this small prospective patient cohort. 
Increased plasma levels of inflammatory cytokines were correlated 
in time with the presence of oxyhemoglobin flare suggesting a 
possible link between optical measurements and inflammatory 
processes induced by chemotherapy. Additionally, we report for the 
first time significant changes in tumoral oxyhemoglobin and oxygen 
saturation during chemotherapy infusion. These changes may be of 
prognostic significance. DOSI allows functional measurements of 
tumor response at timepoints unachievable with current functional 
medical imaging modalities.
P2-10-01
Extracellular Matrix Stiffness and Mammographic Density in 
the Human Breast.
Acerbi I, Au A, Chen Y-Y, Hwang S, Weaver V. Center for 
Bioengineering and Tissue Regeneration, University of California 
San Francisco, San Francisco, CA; University of California San 
Francisco, San Francisco, CA; Eli and Edythe Broad Center of 
Regeneration Medicine and Stem Cell Research and Helen Diller 
Family Comprehensive Cancer Center, UCSF, San Francisco, CA
Introduction: Mammographic density (MD) is associated with 
greater risk to malignancy. MD is also correlated to high collagen 
content in the extra cellular matrix (ECM). Data from our group and 
others have highlighted the importance of mechanical cues from the 
ECM in breast tissue homeostasis and tumor progression to invasion 
[1; 2; reviewed in 3]. Whether the stiffness of the ECM could also 
initiate breast cancer and if so how remains unknown. Because 
elevated collagen levels increases ECM stiffness, we hypothesize that 
MD increases breast cancer risk because the ECM is stiffer.
Materials and Methods: We studied breast tissues obtained through 
prophylactic mastectomy from women with low (BIRADS 1) 
versus high MD (BIRADS 4). From each surgically excised breast, 
samples of 0.5cm x 0.5cm x 1cm dimension were removed from the 
retroareolar region and from 4 peripheral quadrants. Sample sections 
were subjected to biophysical, morphological and biochemical 
analysis. Biophysical analysis included the application of Atomic 
Force Microscopy to obtain an extensive force map of distinct 
anatomical regions of the ECM associated with the intra-lobular 
and inter-lobular ECM. Topological analysis of ECM architecture 
was performed using two photons and SIM-POL imaging coupled 
with picrosirius staining, polarized light imaging and image 
quantification. Biochemical and morphological analysis consisted of 
immunohistochemistry for markers that detect mechano-signaling in 
the epithelium and stromal fibroblasts, and H&E to visualize cellular 
and ECM organization.
Results and Discussion: We found that the intra-lobular ECM 
associated with the terminal end-buds in the breast contained 
anisotropic relaxed collagen fibrils and was very compliant. By 
contrast, the inter-lobular ECM of the breast contained oriented 
collagen fibrils and was relatively stiffer. Notably, the ECM associated 
with the retroareolar region, which is typically detected as very 
dense using mammographic imaging, contained oriented collagen 
fibrils, and was significantly stiffer than the ECM associated with 
the peripheral quadrants. Intriguingly, preliminary data suggested 
that the ECM associated with the terminal end-buds in the upper 
outer quadrant showed a trend towards greater stiffness in women 
with high MD (BIRADS 4) than low MD (BIRADS 1). Although, 
it is tempting to speculate that ECM stiffness could enhance risk to 
malignancy, further sample analysis is now necessary.
Conclusions: 
· In the human breast there is anatomical heterogeneity with respect 
to ECM organization and mechanical properties.
· High MD appears to reflect elevated ECM stiffness.
· The intra-lobular ECM is considerably stiffer in the upper outer 
quadrant than in the other peripheral regions of the breast.
· Atomic Force Microscopy is a tractable method to monitor ECM 
stiffness and mechanical heterogeneity in the human breast.
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P2-10-02
Assessment of Tumor Response to Neoadjuvant Chemotherapy 
Using Ultrasound-Guided Near Infrared Light.
Zhu Q, DeFusco P, Tannenbaum S, Ricci A, Cronin E, Hegde P, Kane 
M, Tavakoli B, Xu Y. University of Connecticut, Storrs, CT; Hartford 
Hospital, Hartford, CT; University of Connecticut Health Center, 
Farmington, CT
Background: Neoadjuvant chemotherapy has been increasingly used 
in treating breast cancers. Because breast cancer is a heterogeneous 
disease,it is important to effectively monitor the tumor response to 
assist in tailoring treatments to response. In our early study, we have 
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introduced a novel ultrasound (US)-guided diffused light imaging in 
the near infrared (NIR) spectrum to monitor tumor vascular changes 
which correlated to tumor response. The objectives of this study are: 
(a) to validate the initial findings with a larger patient pool, and (b) 
to assess vascular changes at every treatment cycle and to correlate 
early vascular changes with the tumor pathological response.
Methods: 33 patients who underwent neoadjuvant treatment were 
recruited from Dec. 2007 to May 2011 and their tumor vascular 
content was assessed with a combined imager consisting of a 
commercial US system coupled to a NIR imager. Patients were imaged 
before their treatment, at the end of each treatment cycle and before 
their surgery. The co-registered US was used to localize the tumor 
and the NIR imager was used to map the tumor vascular distribution 
which was assessed based on a percentage total hemoglobin (%tHb) 
concentration normalized to the pre-treatment level. 18 patients 
were treated with AC followed byTaxol. This group of patients 
was monitored every two weeks at the end of each treatment. The 
remaining patients were on 3-week cycles of chemotherapy and 
monitored every 3 weeks. 6 patients were treated with TC without 
Adriamycin (TC), or with Adriamycin (TAC), 6 HER2 positive 
patients were treated with TC and Herceptin (TCH); and 3 patients 
were treated with AC/Bevacizumab. Pathologic response was graded 
based on Miller and Payne system as grade 1: non-responders (A); 
grades 2 and 3: partial responders (B); 4: near-complete and 5: 
complete responders (C).
Results: In the AC/Taxol group (n=18), there were 5 responders (C), 9 
partial (B) and 4 non-responders (A). The statistical significance based 
on %tHb between groups A and C was achieved at the end of cycle 5 
and the rest of the treatment cycles (p<0.05), however, the statistical 
significance between A and B was only obtained at end of cycle 5 
(p<0.05) and not maintained for cycles 6-8. The statistical significance 
between B and C was only achieved at the end the treatment (p<0.05). 
For the TC,TAC and TCH group (n=12), there were 6 responders(C) 
and 6 partial responders (B). The statistical significance between 
these two groups was achieved at the end of cycle 3 and the rest of 
the treatment cycles (p<0.05). For the 3 patients who were treated 
with AC/Bevacizumab, 2 patients achieved complete response and 
one partial with grade 2. The complete responders had more than 
50% reduction in %tHb at the end of cycles 3-4; while the partial one 
showed only 10-15% reduction during the entire treatment course.
Discussion: Our findings indicate that tumor vascular changes 
assessed by %tHb can be used to predict the tumor pathological 
response. This is a powerful tool to help predict responsiveness to 
therapy. Interestingly, dramatic and early responses were noted in 
the patients who received the biologic agents (bevacizumab and 
herceptin) and this may be very valuable in following responses 
using these agents.
P2-10-03
Non-Invasive In Vivo Characterization of Cancer-Cell 
Proliferation & Angiogenesis in Cancer-Cell-Surrounding 
Stromal Microenvironment In-Vivo Using Diffuse Optical 
Tomography.
Chung SH, Feldman M, Choe R, Martinez D, Yodh AG. University 
of Pennsylvania; Hospital of the University of Pennsylvania; The 
Children’s Hospital of Philadelphia; University of Rochester
Background: Cancer cell proliferation and stromal microenvironment 
changes have been shown to indicate tumor growth (Orimo, Weinberg 
et al., Cell, 2005, Coussens and Werb, Nature, 2002). However, most 
studies were performed using excised tissue samples or cultured 
cells. In-vivo characterization of these properties in human breast 
cancer could magnify the importance of recent findings from in-vitro 
tissues. Diffuse Optical Tomography (DOT) provides quantitative 
three-dimensional (3D) images of the physiological and pathological 
properties of breast cancer tissues in vivo. In this study, we investigate 
the relationship between DOT measured physiological parameters, 
such as hemoglobin & tissue oxygenation that differentiate malignant, 
benign and normal breast tissues (Choe, Yodh et al. JBO, 2009), and 
histologically quantified Ki67 expression in cancer cell nuclei and 
vasculature in the stromal microenvironment surrounding breast 
cancer cells.
Methods: DOT was employed to measure 20 infiltrating ductal 
carcinoma patients. DOT utilizes non-ionizing low power near 
infrared light to examine a subject laying in the prone position on a 
bed with her breasts inside a breast box. DOT quantifies oxy- and 
deoxy-hemoglobin concentration and tissue oxygenation. Cancer 
proliferation was quantified by calculating Ki67 stained nuclei percent 
and vascular area (calculated by detecting CD34 stained vascular 
structure using automated RGB based software).
Results: The ratio of Ki67 expression in cancer cells to surrounding 
normal cells was correlated with DOT-measured tumor-to-normal 
ratio of volume-averaged oxy-hemoglobin and tissue oxygen 
saturation (R=0.72, p-value: 0.0197 and R=0.68, p-value: 0.0293, 
respectively, N=10). The vascular area (µm2) the surrounding 
stroma was correlated with total hemoglobin concentration and oxy-
hemoglobin (R=0.49, p-value: 0.1238 and R=0.43, p-value: 0.1819, 
respectively, N=11). Additionally, cancer-to-normal ratio of nuclei 
compactness and cancer micro-vessel density was correlated with 
tumor-to-normal ratio of oxy-hemoglobin concentration (R=0.43, 
p-value: 0.056 and R=0.43, p-value:0.058, respectively, N=20).
Discussion: The positive correlations between Ki67 cancer-
proliferation-marker and tissue oxy-hemoglobin concentration 
indicate that DOT detects increased oxygenated environment for 
proliferating cells. The observation that nuclei compactness increases 
with oxy-hemoglobin concentration also supports the statement 
above, and, the correlation between hemoglobin concentration and 
vascular area in surrounding stroma suggests that DOT measures 
tumor growth stimulated by stromal micro-environment changes. The 
difference between the field of view needed to calculate a parameter 
value (i.e., macroscopic (cm3) for DOT and microscopic (µm3) for 
histology) likely lowers the correlation between the two technologies. 
However, the results of this study clearly suggest that DOT measures 
tumor growth due to proliferation of cancer cells and angiogenesis 
in cancer-cell-surrounding stroma. This work was supported by NIH 
and the Susan G. Komen for the Cure foundation.
P2-10-04
3D Mapping of Total Choline in Human Breast Cancer Using 
High-Speed MR Spectroscopic Imaging at 3T: A Feasibility Study.
Posse S, Royce M, Dayao ZR, Zhang T, Zhao C, Sillerud L, Lopez 
S, Casey L, Eberhardt SC, Lomo L, Lee S-J, Rosenberg R, Rajput A, 
Bolan P. University of New Mexico School of Medicine, Albuquerque, 
NM; University of New Mexico Cancer Center, Albuquerque, NM; 
New Mexico Cancer Center, Albuquerque, NM; University of 
Minnesota, Minneapolis, MN
PURPOSE: To assess the feasibility of quantitative high-speed 
MR spectroscopic imaging (MRSI) of total Choline (tCho) as an 
adjunct to dynamic-contrast enhanced (DCE) MRI to improve 
lesion characterization and monitor treatment response in patients 
undergoing neoadjuvant chemotherapy.
METHOD AND MATERIALS: Seven patients with biopsy-
confirmed, infiltrating ductal carcinoma were studied using a clinical 
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3T MR scanner (Siemens Medical Solutions, Erlangen, Germany) 
equipped with 8- and 16-channel breast array (Hologic Inc., Bedford, 
MA). Measurements were performed using PRESS prelocalized 
3D Proton-Echo-Planar-Spectroscopic-Imaging (PEPSI) using TR/
TE=2000ms/135ms, matrix size up to 32×16x8, voxel size=1cc, and 
total acquisition time of 10 minutes (including water reference scan). 
Additional data were collected at TE 60 ms to enhance sensitivity 
for detecting tCho and J-coupled resonances. TE-averaging (8 steps, 
DTE: 2.5 ms) was employed to minimize gradient sideband artifacts. 
Quantification of tCho in reference to tissue water was performed 
using spectral fitting and relaxation correction.
RESULTS: Strongly elevated tCho with maximum concentration 
ranging from 0.3 to 4.1 mmol/kg was measured in five patients 
with single and multi-centric enhancing lesions larger than 2 cc 
volume (Table 1). The measured tCho concentration in Grade 3 
tumors was higher than in lower grade untreated and treated tumors. 
Strong decreases in tCho concentration were measured in 2 patients 
undergoing neoadjuvant therapy in a follow-up scan. At short TE an 
additional resonance was detected that was elevated in enhancing 
lesions and tentatively assigned to Taurine. Two patients had lesions 
smaller than 2 cc with surgical clips in which tCho was not detectable 
due to line broadening. MRSI data sets were preferentially collected 
before contrast injection, since it increased spectral line width by 
up to 50%.
CONCLUSION: This study demonstrates feasibility of quantitatively 
mapping tCho in invasive breast carcinoma using high-speed MRSI. 
The long-term goals are to utilize high-speed MRSI as an early 
predictor of treatment failure in women undergoing neoadjuvant 
therapy (i.e. chemotherapy, endocrine therapy or biologic therapy) 
for breast cancer and to develop an improved screening protocol for 
high-risk patients.
Grant support: 1RC1EB010617-01
TABLE 1: Clinical status and tCho concentration
    MRSI scan 1 MRSI scan 2
Patient Tumor Grade - Tumor Stage
Lesion size 
[cc] -  
ER, PR & 
Her2  
Status
Neo- 
adjuvant  
Therapy
Neo- 
adjuvant 
Therapy
Max. tCho  
[mmol/kg]
Therapy  
duration
Max. tCho  
[mmol/kg]
1 2 - T4bN3cM0 5.0 - ER -/ 
PR -/Her2+
1. Taxol +  
Carbo +  
Trastuzum-ab  
2010 2.  
Herceptin +  
FEC 2010
24 weeks 0.43 NS NS
2 2 - T4dN3M0 1.8 - ER +/ 
PR +/Her2+
1. FEC 14 weeks ND NS NS
3 3 - T1N0M 5.7 - ER -/ 
PR -/Her2-
None None 1.4 NS NS
4 1 - T2N0M0 6.8 - ER +/ 
PR +/Her2-
None None 0.7 None 0.3
5 3 - T3N1M0 32 - ER -/ 
PR +/Her2-
1. Taxol 4 days 4.1 18 days 2.0
6 3 - T3N1M0 39 - ER +/ 
PR -/Her2-
1. Taxol 22 days 1.6 40 days 0.9
7 2 - T1cN0M0 1.2 - ER +/ 
PR +/Her2+
None None ND NS NS
ND: Not detected due to spectral line broadening (surgical clip). NS: Not scanned
P2-10-05
Cryo-Microcomputed Tomography (CT) with Synchrotron 
Radiation: Visualization of Human Breast Cancer Tissue and 
Comparison with Their Histopathologic Findings.
Jeong Y-J, Jeong H-Y, Bong J-G, Park S-H, Kim H-T, Kim J-K, Huang 
J-Y. Daegu Catholic University Medical Center, Daegu, Republic 
of Korea; Pohang University of Science and Technology, Pohang, 
Republic of Korea
Background: A synchrotron radiation (SR)-based X-ray source offers 
a powerful tool for diagnosis of breast disease due to the energy 
spectrum properties and the peculiar laminar beam geometry. The 
aims of this study were to estimate the visualization of the human 
breast cancer tissue with SR cryo-micro CT and to compare the results 
with histopathological examinations.
Material and Methods: The cancerous breast tissue samples were 
routinely fixed in 10% neutral buffered formalin, and each specimen 
was cut down to a cylindrical sample with 2 mm diameter and 10 mm 
height. Each breast cancer sample was rapidly frozen with dry ice, 
mounted on a computer-controlled precision stage and maintained 
at cryogenic temperature throughout data collection. Experiments 
were performed at the bending magnet beamline 7B2 of Pohang 
Light Source (PLS) in Accelerator Laboratory (PAL) which is a 
third-generation SR facility with 2.5 GeV operating energy. The 
white beam imaging system developed for synchrotron tomography 
consists of a 1 mm Si attenuator, 100 mm-thick CdWO4 scintillator 
and a full-frame charge-coulped device camera. The detector is placed 
10 mm downstream from the sample on an optical table which can 
be rotated in the fan beam about a vertical axis for tomography. For 
tomography, images were collected at 0.18° increments through 180°. 
The visual image was magnified using a 20x microscope objective 
and captured using a digital CCD camera. The spatial resolution 
determined by standard sample was about 1.5 mm. Three-dimensional 
volume images of the specimen were obtained by applying a filtered 
back-projection algorithm to the projection images using a software 
package OCTOPUS. Surface reconstruction and volume segmentation 
and rendering were performed using Amira software. After imaging 
the samples were split into several sections, processed and embedded 
in paraffin. Obtained tomography images were compared with 
corresponding histopathological findings in optical microscopy.
Results: A total of 1000 synchrotron tomography images were 
acquired from the samples and only a small number of different 
typical cases were selected for a detailed analysis. The correspondence 
between tomography images and histopathological findings were 
determined. Synchrotron tomography images yield high contrast from 
smoothly varying internal structures corresponding to information on 
actual structures seen at histopathological analysis.
Discussion: Since the projection of 3D anatomic information onto 
2D image will complicate subtle difference in X-ray transmission 
and objects at different depths will be superimposed on each other, 
the subtle difference in subject attenuation, diffraction and contrast 
may not be clearly visible or completely lost. Tomography with SR 
has superior visualization of subject contrast, together with depth 
localization, so it is useful for visualizing anatomical structures in the 
sample. In this study, the obtained SR cryo-micro CT images of human 
breast cancer tissue were comparable with standard histopathologic 
findings. The results suggest that tomography with SR has a great 
potential as a diagnostic tool and also its clinical application is 
feasible, especially in breast imaging.
P2-10-06
Prospective Ultrasonographic Prediction of Sentinel Lymph Node 
Metastasis by Real-Time Virtual Sonography Constructed with 
Three-Dimensional Computed Tomography-Lymphography in 
Breast Cancer Patients.
Yamamoto S, Maeda N, Yoshimura K, Oka M. Yamaguchi University 
Graduate School of Medicine, Ube, Yamaguchi, Japan
Background: Real-time virtual sonography (RVS) systems display 
virtual multiplanar reconstruction (MPR) images obtained from 
three-dimensional (3D) computed tomography (CT)–lymphography 
(LG), significantly improving preoperative detection of sentinel 
lymph nodes (SLNs). The purpose of this study was to prospectively 
evaluate SLN metastasis using an RVS system.
Methods: We identified SLNs in 73 clinically node-negative breast 
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cancer patients using an RVS system to display in real time a virtual 
MPR obtained from CT volume data corresponding to the same 
cross-sectional image from ultrasonography (US). CT volume data 
were obtained using our original 3DCT-LG, which accurately detects 
SLNs in breast cancer. We then prospectively attempted to predict 
metastasis to SLNs. SLN metastases were assessed by measuring 
the cortex thickness in the presence of a visible hilum. We defined 
suspected SLN metastases as SLNs with a cortex thickness of at least 
2.5 mm on the basis of our preliminary data. All patients underwent 
SLN biopsy and SLN metastases were examined pathologically with 
serial 2.0-mm-thick multiple slices.
Results: Suspected SLN metastases were identified in 24 of 73 
patients, and 13 of these 24 patients were pathologically positive. 
The remaining 49 patients displayed no suspected SLNs, and 46 of 
these 49 were pathologically negative. Sensitivity, specificity, positive 
predictive value, negative predictive value, and overall accuracy of 
measuring cortical thickness for predicting metastatic involvement 
of SLNs were 81, 81, 54, 94, and 81%, respectively.
Conclusion: If cortical thickness of the SLN is less than 2.5 mm, 
SLN metastasis is unlikely to be present. If cortical thickness of the 
SLN is at least 2.5 mm, preoperative fine-needle aspiration cytology 
may be recommended to verify the possibility of SLN metastasis.
P2-10-07
Triple-Negative Breast Cancer May Have Ultrasonographic 
Features Mimicking Nonmalignant Lesions.
Wojcinski S, Farrokh A, Schmidt J, Hillemanns P, Degenhardt F. 
Franziskus Hospital, Bielefeld, Germany; Hannover Medical School, 
Hannover, Germany
Background:
Triple-negative breast cancer (TNBC) is known to have unique 
molecular, clinical and pathologic characteristics. Histological studies 
illustrate high mitotic counts, geographic necrosis, pushing borders of 
invasion, and stromal lymphocytic response. These growth patterns 
may also affect the appearance of TNBC in ultrasound.
Our study evaluates the ultrasonographic features of TNBC according 
to the ACR BI-RADS®-US classification system and compares these 
features with non-TNBC.
Materials and methods:
Data of 385 consecutive breast cancer cases were collected from 
our hospital database. Digitally recorded ultrasound images were 
available for 292 patients. These images were interpreted according 
to the BI-RADS® system by an examiner blinded to the patients’ 
characteristics and histological results. The ultrasonographic features 
of TNBC (n=45) and non-TNBC (n=247) were compared using 
Fisher’s exact test.
Results:
TNBC was more common in younger patients and exhibited higher 
tumor grades and more advanced tumor stages.
Focusing on the ultrasound features, TNBC was more likely to exhibit 
round or oval shape (35.5% versus 25.9% in non-TNBC) and the 
margin of TNBC was more frequently described as microlobulated 
(48.9% versus 37.7% in non-TNBC) instead of angular or spiculated. 
In TNBC the echogenic halo was significantly less often observed 
(46.7% versus 64.4% in non-TNBC, p=0.0302) and we found 
less architectural distortions (65.5% versus 84.3% in non-TNBC, 
p=0.0341). Regarding the posterior acoustic features, an enhancement 
was significantly more often observed in TNBC (26.7% versus 13.0% 
in non-TNBC, p=0.0391).
Discussion:
TNBC and non-TNBC seem to have different ultrasonographic 
features. This can be explained by the unique pathologic profile of 
this breast cancer subtype. As some of the distinct ultrasound criteria 
of TNBC are associated with benign masses, TNBC may mimic 
nonmalignant lesions. Being familiar with these features can avoid 
false-negative classification of TNBC.
P2-10-08
Electrical Impedance Imaging Characteristics of Nodular and 
Edematous-Infiltrative Forms of Breast Cancer.
Korotkova M, Karpov A, Bulatov A, Frizyuk A. Clinical Hospital 9, 
Yaroslavl, Russian Federation
Introduction:
The purpose of this research is to establish diagnostic criteria of 
electrical impedance mammography, which are typical for nodular 
and diffuse forms of breast cancer.
Materials and Methods:
From 2008 to 2011, we examined 558 patients, 34 of whom had 
various forms of breast cancer (BC).
All the patients were examined with electrical impedance potential 
mammography utilizing the electrical impedance computer 
mammograph MEIK, which enables to acquire images of 3-D 
conductivity distribution layers within mamma’s tissues up to 5 cm 
depth.
Group I comprised 27 women suffering from nodular forms of BC. 
Among them 9 women without clinical signs of the disease were put 
into subgroup I&a.
19 patients having significant clinical signs, such as edema, 
inflammation and infiltration, were put into subgroup Ib.
Group II included 6 patients with diffuse BC.
102 patients without any mammary gland disease were put into the 
control group.
Both visual and quantitative assessment of electrical impedance 
mammograms (EIM) was conducted.
Result:
Distinctions of kind were revealed between EIMs of the 
abovementioned patient groups.
In case of nodular BC both general and local changes were observed 
in EIMs.
General changes include deformation of mamma’s contour, 
hyperimpedance contour and displacement of inner structures.
Local changes comprise focal changes of electrical conductivity in 
form of an- or isoimpedance areas and hyperimpedance contour on 
the border of the tumor and surrounding tissue.
In EIM mammograms of 100% patients belonging to subgroup Ia 
only local changes of electrical conductivity were detected in a form 
of animpedance area presented on several scan planes in the location 
corresponding to the tumor (electrical conductivity index >0.95), 
while there were no general changes in the image. The size of lesions 
detected in this group was less than 1 cm.
Clinical signs of the decease were always present in group Ib 
patients. EIMs of these patients revealed both general and various 
local changes.
Visual estimation of images revealed deformation of the mammary 
gland contour in 50% of the cases, subcutaneous fat infiltration - in 
61%, anatomic changes with displacement of internal structures 
in 78%, perifocal infiltration in 94%. The quantitative analysis 
established the following: mean electrical conductivity index of 
a healthy mammary gland, as a rule, exceeded the index of mean 
electrical conductivity of the affected one; and the index of the 
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res; 71(24 Suppl.) December 15, 2011 Cancer Research284s
mean electrical conductivity of a tumor exceeded the index of mean 
electrical conductivity of the affected gland almost twofold.
EIMs of 100% of the patients with diffuse (edematous-infiltrative) BC 
revealed typical general changes of electrical conductivity: electrical 
conductivity of the affected mammary gland is considerably lower 
than that of the healthy one as well as lower than that of the age 
norm. This results in the intense dark EIM and significant change of 
electrical impedance anatomy.
Conclusions:
The revealed peculiarities of the electrical impedance images 
during various forms of the infiltrating BC growth correlate with 
the pathological-physiological phases of the tumor development. 
The article is illustrated with electrical impedance mammograms 
(EIMs) and tables.
P2-10-09
Detecting Breast Cancer with Dynamic Diffuse Optical 
Tomographic Imaging.
Flexman ML, Kim HK, Lim E, Desperito E, Barbour RL, Hershman 
DL, Hielscher AH. Columbia University, New York, NY; State 
University of New York, Brooklyn, NY
Background: Over the last decade diffuse optical tomography 
(DOT) has emerged as a novel medical imaging modality. Near-
infrared light is used to non-invasively probe biological tissue, and 
three-dimensional (3D) maps of blood-dependent parameters can be 
obtained. Several studies are underway to show the clinical utility of 
DOT for imaging brain disease, joint disease, and breast cancer. Here 
we present the largest clinical study to date that uses hemodynamic 
effects caused by a simple breath hold to identify breast tumors 
using DOT.
Methods: We have designed and built a DOT breast imaging system 
that can acquire full 3D data sets within a fraction of a second. The 
system affords the ability to study fast hemodynamic effects in both 
breasts simultaneously. Using non-compressive imaging heads we 
measured the oxygenated and deoxygenated hemoglobin levels in 
the breasts of 15 patients whose mammogram showed a mass >1 cm 
(4 benign, 11 malignant) and 3 healthy controls. Data was acquired 
over the course of a 30-second breath hold and 30 seconds thereafter. 
In addition, a baseline measurement of 30 seconds prior to the 
breath hold was obtained. A multi-wavelength image reconstruction 
algorithm was used to create 3D maps of hemoglobin-dependent 
parameters (D[HbO2] and D[Hb]) in the breast every 0.58 seconds, 
over the course of the 90-second experiment. An image analysis 
algorithm identified regions of peak percentage change in [Hb] and 
[HbO2] in the breast and then computed the average hemoglobin 
levels in those regions.
Results: We observed an increase in the hemoglobin levels in all 
breasts during the breath hold. Upon resuming breathing, these 
hemoglobin levels returned to baseline. Tumor bearing breasts showed 
a statistically significant slower return to baseline than healthy breasts. 
In particular, we found that tumors can be detected by a substantially 
larger D[Hb] value as compared to normal tissue in images acquired 
15 seconds following the end of the breath hold. In 10 of 11 patients 
the malignant tumor was identified using this technique, suggesting 
sensitivity over 90%. No regions of increased D[Hb] were seen in 
the healthy breasts, or in the breasts with benign masses. The peak 
percentage change in [Hb] at the 15 second post-breath hold time 
point was 10.0 ± 6.0% (n=11) in the malignant tumors compared to 
1.4 ± 0.5% (n=3) (p=0.001) in healthy patients and 4.8 ± 1.9% in 
benign masses (n=4)(p=0.03).
Discussion: A breath hold impedes venous return to the heart, which 
causes pooling of blood in the breast. This is observed as an increase 
in [Hb] and [HbO2] using DOT. Tumor vasculature is known to be 
more disorganized, tortuous, and leakier than normal vasculature. 
Therefore, once the breath hold is released and blood is allowed to 
drain from the breast, blood accumulated in the tumor during the 
breath hold will drain more slowly than blood in healthy tissue. This 
study has shown that DOT allows us to visualize these hemodynamic 
effects and use them to detect tumors with a simple breath hold and 
compression-free imaging head. Future studies need to explore 
the detection limits and general clinical utility of this technique 
for screening, differentiating malignant from benign masses, and 
treatment monitoring.
P2-10-10
A Precision Comparison of Breast Ultrasound Images between 
Different Time Phases by Imaging Fusion Technique Using 
Magnetic Position Tracking System.
Nakano S, Fujii K, Yorozuya K, Yoshida M, Fukutomi T, Arai O, 
Mitake T. Aichi Medical University, Nagakute, Aichi-gun, Japan; 
Hitachi Medical Corporation
Purpose 
We developed a real-time virtual sonography (RVS) in which real-
time ultrasound (US) images and reconstructive virtual US images 
of the same cross-section are synchronized based on US volume data 
obtained on the same monitor using magnetic position tracking system 
(US-RVS). The purpose of this study was to evaluate the accuracy of 
US-RVS to compare breast US images between different time phases.
Materials and Methods 
Between March 2010 and April 2011, US-RVS was performed in 
108 consecutive patients with 112 target lesions for US (mean lesion 
size: 12 mm, 54 malignant and 58 benign). We used US-RVS system 
which consisted of sonography equipment, magnetic field generator, 
magnetic sensor, and workstation. To assess the accuracy of the US-
RVS, we analyzed the sonographic re-identification rate of target 
lesions in different time phases.
Results
Among the 112 target lesions, 105 (94%) lesions were re-identified 
by US-RVS. The remaining occult 7 (6%) lesions were included one 
DCIS and 6 fibrocystic changes in terms of the histological type, and 
one mass lesion and 6 nonmass like lesions in terms of morphological 
feature.US-RVS enabled us to precisely compare arbitrary cross-
sections of US images in any direction between different time phases 
independent of the operator’s skill.
Conclusion
US-RVS, which requires no contrast medium and involves no 
radiation exposure, can be a useful modality for temporally tracking 
regions of interest using US.
P2-11-01
Validation of Predictive DNA Damage Response (DDR) Assay in 
Luminal B and Basal-Like Breast Cancers.
Rodriguez AA, Mao Y, Zhao H, Wong S, Chang JC. The Methodist 
Research Institute, Houston, TX
Background: We previously published a 69-gene DDR microarray 
signature that predicted for pathologic complete response (pCR) to 
anthracycline chemotherapy in women with basal-like breast cancer 
in two clinical studies1. Here, we sought to validate this predictive 
signature in independent data sets of breast cancers, selecting for 
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basal-like and luminal B subtypes. We also customized a low density 
qRT-PCR array for use on formalin-fixed paraffin embedded tissue 
that will allow for prospective validation and clinical use.
Methods: Six independent validation sets were selected with known 
response to DNA damaging agents, containing either anthracyclines 
or cisplatin2-7. One independent data set with known response to 
the microtubulin agent docetaxel (non-DNA damaging) was used.8 
Using PAM50 genes, the tumors were first classified according to the 
molecular subtype. The predictive value of the 69-gene DDR assay 
was then correlated with known pathologic response, and the receiver 
operating curve determined.
We then performed qRT-PCR of these 69 genes with 5 controls, and 
correlated the expression of these genes with microarray RNA values 
in an additional 50 basal tumors. The data for individual genes was 
normalized, combined, and then hierarchically clustered.
Results: In the 170 basal tumors treated with DNA damaging 
agents, a high score predicted response in basal-like tumors. A, p< 
0.05. Conversely, for a non-DNA-damaging therapy, a high score 
significantly predicted for lack of response. B. In the 116 luminal B 
cancers, the DDR-assay also predicted for response to DNA damaging 
agent containing regimens with AUCs ranging from 0.67 to 0.80. C.
Prediction of DDR assay on Public Datasets
Treatment N pCR AUC 95% CI
A) Basal-like tumors - Response
Epirubicin 87 11 0.68 0.49-0.86
Cisplatin 24 12 0.79 0.60-0.97
FAC/TFAC 59 13 0.69 0.50-0.87
B) Basal-like tumors - No Response
Docetaxel/Capecitabine 35 12 0.70 0.51-0.90
C) Luminal B tumors - Response
FAC/FEC 30 7 0.80 0.59-1.00
FEC_TX 21 7 0.70 0.45-0.96
TFAC 65 6 0.67 0.42-0.91
N:number of patients, pCR: complete and near pathological response, AUC:area under the curve
Microarray of the 69 DDR gene expression values was compared 
with Ct values by q-RTPCR low density array for 50 paired samples. 
High concordance between these two platforms (48/50 samples) was 
observed.
Conclusion: We have identified a robust predictive DDR assay that 
predicts for response to the DNA damaging agents, doxorubicin, 
epirubicin, and cisplatin in multiple studies, but not for docetaxel 
therapy. Future studies are underway to test for prediction of benefit 
of PARP1 inhibitor in basal-like and luminal B breast cancer.
References:
(1) Rodriguez AA et al: Breast Can Res Treat 123:189-96 (2) Tabchy 
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P2-11-02
Brain-Derived Neurotrophic Factor Expression Is Associated 
with Poor Prognosis in Human Breast Cancer.
Patani N, Jiang WG, Mokbel K. The London Breast Institute, The 
Princess Grace Hospital, London, United Kingdom; University 
Department of Surgery, Cardiff University School of Medicine, 
Cardiff, United Kingdom; Brunel Institute of Cancer Genetics and 
Pharmacogenomics, Brunel University, London, United Kingdom
Background: Brain-derived neurotrophic factor (BDNF) belongs 
to the neurotrophin superfamily of polypeptide growth factors 
whose physiological roles primarily relate to the development and 
function of the vertebrate nervous system. However, BDNF is also 
expressed in non-neuronal tissues and has been implicated in breast 
cancer, in addition to several other human malignancies, including: 
neuroblastoma, myeloma, ovarian, lung, prostate, hepato-cellular, 
pancreatic, head and neck squamous cell carcinomas and pulmonary 
carcinoid tumours. Although increased neurotrophin and cognate 
receptor expression have been demonstrated in breast cancer, the 
emerging role of BDNF in tumour biology and its utility as a novel 
biomarker have yet to be fully elucidated. In this study, the mRNA 
and protein expression of BDNF are evaluated in women with primary 
operable breast cancer in a well annotated cohort with extended 
follow-up.
Methods: Breast cancer tissues (n=127) and normal/benign tissues 
(n=33) underwent RNA extraction and reverse transcription. Transcript 
levels of BDNF were determined using real-time quantitative PCR and 
protein expression was assessed using standardised semi-quantitative 
immuno-histochemical techniques. Expression levels in neoplastic 
tissues were compared with adjacent normal/benign samples and 
evaluated against conventional pathological parameters, including: 
tumour size, grade, nodal involvement, TNM stage, in addition to 
Nottingham Prognostic Index (NPI), disease free and overall survival 
over a 10 year follow-up period.
Results: BDNF was found to be expressed in both normal breast tissue 
and breast cancer specimens. Significantly greater BDNF expression 
was identified in neoplastic cells, compared to normal mammary 
epithelial cells, by immuno-histochemical analysis. In keeping with 
this, higher mRNA transcript levels of BDNF were also found in 
breast cancers compared to normal samples (p=0.007). Increased 
BDNF transcript levels were found to be significantly associated with 
nodal positivity (p=0.047) and increased with NPI; NPI-1 vs. NPI-2 
(p=0.009). Higher BDNF expression was significantly associated with 
local recurrence (p=0.0014), death from breast cancer (p=0.018) and 
poor prognosis overall (p=0.013), when compared to patients who 
remained disease free. Higher transcript levels were significantly 
associated with poorer overall survival (106 vs. 136 months, p=0.006) 
after a median follow up of 10 years.
Conclusion: Neurotrophins and their receptors are increasingly 
being implicated as novel mediators of carcinogenesis in neuronal 
and non-neuronal tissues. BDNF is overexpressed in breast cancer 
and significantly associated with adverse pathological parameters, 
including nodal positivity and increasing NPI. Higher BDNF 
expression was significantly associated with poorer clinical outcomes, 
including local recurrence, death, poor prognosis and reduced overall 
survival. The present study adds to the literature in support of the 
oncogenic function of BDNF in breast cancer and is the first to 
quantitatively evaluate expression in a large cohort. BDNF expression 
may offer prognostic utility as a biomarker and further mechanistic 
studies are warranted to explore the potential for targeted therapeutic 
manipulation.
P2-11-03
High Expression of CX3CL1 by Tumor Cells Correlates with a 
Good Prognosis and Increased Infiltrating CD8+ T Cells, Natural 
Killer Cells, and Dendritic Cells in Breast Carcinoma.
Lee JS, Park MH, Yoon JH. Chonnam National University Medical 
School, Gwangju, Republic of Korea
CX3CL1 is the only CX3C chemokine that can chemoattract CD8+ 
T cells, natural killer (NK) cells, and dendritic cells (DCs). Although 
studies have reported that CX3CL1 regulates the host immune 
response, the roles of the CX3CL1 in breast carcinoma remain 
unknown. We evaluated the expression CX3CL1 in 198 surgical 
specimens of breast carcinoma and analyzed any association with 
the clinicopathological factors, including CD8+ T cells, CD56+ 
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NK cells, and CD1a+ DCs, while also evaluating the impact on 
the prognosis. High CX3CL1 expression was found in 136 of 
198 (68.7%) breast carcinomas. The numbers of stromal CD8+ T 
cells, intratumoral CD1a+ DCs, and stromal CD56+ NK cells were 
significantly increased in the high CX3CL1 expression group (19.3 
± 15.2, 0.3 ± 0.9 and 1.4 ± 1.7 per field, respectively) compared with 
the low expression group (10.2 ± 13.1, 0.0 ± 0.3 and 0.7 ± 0.8 per 
field, respectively). Patients with high CX3CL1 expression had a 
significantly better prognosis for disease-free and overall survival than 
those with low expression (P = 0.002 and P = 0.000, respectively). 
In a multivariate analysis, the CX3CL1 expression was identified as 
one of the independent prognostic factors for overall survival (odds 
ratio, 2.29; P = 0.002). These data suggest that CX3CL1 expressed in 
the tumor cells appears to enhance the recruitment of CD8+ T cells, 
NK cells, and CD1a+ DCs, thereby bringing about a better prognosis 
in breast carcinoma. CX3CL1 is a new prognostic biomarker and be 
a novel candidate for development of a more effective therapeutic 
strategy for breast carcinoma.
P2-11-04
TMEPAI Is a Feedback Regulator of TGF-b Signaling during 
Breast Cancer Progression.
Singha PK, Pandeswara S, De La Chapa JJ, Venkatachalam MA, 
Saikumar P. UT Health Science Center at San Antonio, San Antonio, 
TX
Background: Despite lack of hormone receptors (ER/PR) and HER2, 
many triple negative breast cancers (TNBC) depend on transforming 
growth factor beta (TGF-b) signaling activity for late growth and 
metastasis. Thus TGF-b signaling is a major potential target to treat 
TNBC patients. However, inhibition of TGF-b signaling pathway 
carries the risk of disturbing the tumor suppressive activity of 
TGF-b in normal tissues and early cancers. Hence, present study was 
undertaken with a goal to identify suitable markers which will enable 
to develop drugs that retard only the “oncogenic activity” of TGF-b 
while preserving its growth suppressive activities.
Materials and Methods: All cell lines were cultured according 
to the recommended standard procedures. Lentiviral mediated 
expression vector was used to stably knockdown endogenous 
TMEPAI expression. DNA transfections and luciferase assays were 
performed according to vendor instructions. Cell proliferation was 
measured by quantitation of total cellular DNA. Immunoblotting 
and immunohistochemical analysis were performed using standard 
methods.
Results: Previously we have shown that Transmembrane prostate 
androgen-induced protein (TMEPAI), a TGF-b inducible gene 
has the potential to convert tumor suppressive TGF-b into a tumor 
promoter. In the present study, we show that Smad binding elements 
driven luciferase reporter activity, a measure of TGF-b signaling, 
was dramatically increased in TMEPAI knockdown cells. While 
wild type cancer cells showed transient raise in phosphorylation 
of Smad2 and Smad3 with TGF-b treatment, TMEPAI knockdown 
resulted in increased and sustained levels of phosphorylated Smad2 
and Smad3. In normal mammary epithelial cells, continuous presence 
of TGF-b blocked their growth. In contrast, breast cancer cells 
showed a biphasic growth response (moderate inhibition up to 72h 
followed by strong growth stimulation) to TGF-b, while TMEPAI-
deficiency blocked this response to TGF-b. Furthermore, exogenous 
expression of TMEPAI in normal mammary epithelial cells and 
TMEPAI-knockdown cells resulted in reduced TGF-b-dependent 
Smad activity. Additionally, we found that TMEPAI subverts tumor 
suppressive TGF-b dependent Smad signaling into tumor promotive 
non-Smad signaling through stimulation of stress activated protein 
kinases. Inhibition of stress kinases also reduced the growth of cancer 
cells similar to TMEPAI deficiency. To evaluate the translational 
importance of TMEPAI as predictive marker, immunohistochemical 
analysis on human breast cancer specimens revealed the gain of 
TMEPAI expressions in aggressive human breast tumor samples but 
not in normal human breast tissue specimens.
Conclusions: Our results show that TMEPAI, which subverts tumor 
suppressive Smad signaling, may serve as a novel prognostic and 
predictive marker for aggressive and TGF-b dependent of metastatic 
breast cancers. These studies will further provide new clues to develop 
an effective and decisive anti-TGF-b therapy against aggressive 
breast cancers without disturbing the growth suppression by TGF-b 
in normal tissues and early tumors.
P2-11-05
Stromal Matrix Metalloproteinase-14 Expression Correlates 
with the Grade and Biological Behavior of Mammary Phyllodes 
Tumors.
Lee JS, Park MH, Yoon JH. Chonnam National University Medical 
School, Gwangju, Republic of Korea
Phyllodes tumors (PTs) of the breast are rare biphasic tumors with the 
potential for invasion and metastatic spread. Matrix metalloproteases 
(MMPs) and their tissue inhibitors of metalloproteases (TIMPs) 
are involved in several key aspects of tumoral growth, invasion 
and metastasis, but little is known of their expression in PTs. The 
objective of this study was to assess the expression of MMPs and 
TIMPs in PTs and to determine their association with grade and 
clinical behavior of PTs. Eighty-two PTs (50 benign, 22 borderline, 
and 10 malignant) were studied. Automated immunohistochemical 
staining for MMP-1, -2, -7, -9, -11, -13, and -14 and TIMP-1, -2, and 
-3 was performed using tissue microarray blocks and the expression 
of MMPs and TIMPs was assessed in both the stromal components. 
There were no significant differences in the expression of stromal 
MMPs and TIMPs in the three groups of PTs, except for MMP-14. 
There was a significant increase in stromal MMP-14 expression with 
increasing PT grade (P < 0.01). The stromal MMP-14 expression in 
the borderline and malignant PTs was higher than that in benign PTs 
(P < 0.05 and P < 0.05, respectively). Furthermore, the expression 
of stromal MMP-14 was associated with a higher rate of recurrence 
(P < 0.05). Our results show for the first time that stromal MMP-14 
expression is associated with the grade and clinical behavior of PTs 
of the breast.
P2-11-06
PTEN Loss in Asian Triple Negative Breast Cancer Is a Frequent 
Event Associated with Basal Markers, Tumour Grade and 
Younger Age of Onset.
Dean S, Rhodes A, Holly J, Perks C, Looi L-M, Mun KS, Taib NA, 
Yip CH. University of the West of England, Bristol, United Kingdom; 
University of Bristol, Bristol, United Kingdom; University of Malaya, 
Kuala Lumpur, Malaysia
Triple negative (TN) breast cancers are defined by their lack 
of expression of hormone receptors and HER2 and account for 
approximately 15% of all breast cancers. They are highly aggressive 
tumors for which there is currently no effective targeted therapy. 
PTEN is a tumor suppressor gene that shows loss or mutation in 
many types of cancer. PTEN functions by deactivating Akt signaling 
so cell growth is inhibited and apoptosis is promoted. PTEN has also 
been found to have an important role in DNA repair. Cancers with 
PTEN loss have been shown to be sensitive to PARP inhibitors that 
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prevent DNA repair and result in tumor cell death. In unselected 
breast cancer cohorts with the expected frequency of HER2 and 
hormone receptor positive cases, its loss appears to be a relatively 
rare event. Insulin-like growth factor binding protein-2 (IGFBP-2) 
regulates the anti-apoptotic and mitogenic effects of insulin like 
growth factors (IGF’s) -I and –II and can also exert its own intrinsic 
effects on cell function; in vitro cell line models have shown that 
IGFBP-2 down regulates PTEN expression by interacting with the 
b-integrin receptor. The purpose of the current study was to investigate 
the extent of PTEN loss in an Asian series of TN breast cancers also 
to determine the association of PTEN loss with IGFBP2 expression 
and clinicopathological features. 122 TN breast carcinomas from the 
University of Malaya Medical Centre were immunohistochemically 
(IHC) stained for CK5/6, CK14, PTEN and IGFBP-2. The basal-like 
phenotype was defined as positivity for either one or both of CK5/6 
and CK14, in invasive tumour cells. A modified Allred scoring system 
was used to assess the IGFBP-2 staining. PTEN was assessed for loss 
in both the cytoplasm and the nuclei; the surrounding stromal tissue 
and normal ducts had to be positive for the case to be assessable. 
Expression of basal CKs were present in the majority of cases, with 
72.5% and 70.4% of TN cases staining positively for CK5/6 and 
CK14, respectively. Loss of nuclear and cytoplasmic IHC staining 
for PTEN occurred in 44.9% of TN cases. In those cases with PTEN 
loss, 88.4% were positive for CK5/6 compared to only 66% for cases 
without PTEN loss. (p=0.011). The median age of patients with tumors 
showing PTEN loss were 48 years old, compared with 56 years in 
those without PTEN loss (p=0.007). Of the cases showing PTEN loss, 
35/40 (87.5%) were Grade 3 tumors; in comparison 28/46 (60.9%) 
of tumors without PTEN loss were Grade 3 (p=0.008). With respect 
to IGFBP2, 26.5% of cases were positive using the cut-off score of 
6 or greater. However, there was no significant association between 
PTEN loss and IGFBP2 expression (p= 0.542). Complete PTEN loss 
was a frequent event in a cohort of nearly one hundred TN breast 
cancers; this was significantly associated with younger age. PTEN 
loss can be readily and reliably assessed by an optimised IHC assay 
and validated PTEN antibody. The extent of PTEN loss occurring in 
TN breast cancers may well reflect a defect in DNA double strand 
repair and therefore, along with other suitable markers, may prove to 
be a valuable assay to identify those patients with TN breast cancers 
that are most likely to respond well to PARP inhibitors.
P2-11-07
Expression of Selected Predictive Markers in African American 
Women with Atypical Hyperplasia of the Breast.
Bandyopadhyay S, Cote M, Visscher DW, Ruterbusch J, Albashiti B, 
Alosh B, Frost MH, Hartmann LC, Fehmi RA. Wayne State University/
KCI/DMC, Detroit, MI; Wayne State University/KCI, Detroit, MI; 
Mayo Clinic Cancer Center, Rochester, MN
Invasive breast carcinoma in African American (AA) women 
differs significantly from their Caucasian (CA) counterparts in its 
incidence, morphology and outcome. These tumors are more likely 
to be high grade, hormone receptor negative, present at a younger 
age and at a higher stage. Evaluation and a better understanding of 
precursor lesions may help delineate the mechanisms underlying 
the development of breast cancer in these two groups. Atypical 
hyperplasia (AH) in the breast has been associated with an increased 
risk of developing cancer (relative risk~4.0). Risk stratification of 
these women by identification of predictive biomarkers would be 
beneficial for optimal patient care. In our study we evaluated the 
expression of the following prognostic biomarkers: estrogen receptor 
(ER), Cyclooxygenase-2 (COX-2) enzyme and Ki-67 in AH in a 
cohort of AA women with benign breast biopsies.
AA women with benign breast biopsies from years 1997-2000 were 
retrieved from our departmental database. Clinical and follow up data 
was obtained from the SEER database. The hematoxylin and eosin 
(H & E) slides for these cases were reviewed by 2 pathologists, who 
were blinded to the outcome, and those with atypia were included in 
this study. Paraffin blocks were retrieved for immunohistochemical 
(IHC) analysis and standardized scoring methods applied.
A total of 1608 AA women had benign breast biopsies during the 
study period. We performed IHC analysis on 37 (2.3%) who were 
diagnosed with atypia (25 cases of atypical ductal hyperplasia (ADH) 
and 12 cases of atypical lobular hyperplasia (ALH)). Increased COX-
2 expression was seen in 19 of 28 (67.8%) cases with AH. Of these, 
13 of 19 cases (68.4%) were of ADH and 6 of 9 cases (66.7%) were 
of ALH. Twenty of 25 cases had a high expression of ER overall. Of 
these, 15 of 17 (88.2%) of the positive cases was in the ADH category 
and 3 of 7 (42.8%) was in the ALH group.
Of 32 cases, only 3 cases showed a proliferation rate of > 2% (9.4%) 
with Ki-67 IHC stain. All of these cases belonged to the ADH (21) 
category. In summary, the majority of AH cases showed increased 
COX-2 expression, although no differences were observed between 
lobular and ductal lesions. In contrast, ADH lesions appeared to 
exhibit increased reactivity for ER compared to ALH. Similarly, 
although rare, more ADH cases showed an increased proliferation 
rate compared to ALH. From our data, COX-2 and ER might be of 
prognostic significance in AA patients with AH. Larger studies with 
follow up are needed to understand this disease further.
P2-11-08
Clinical Value of Combination Assay for Quantitative 
Determination of Cancer Biomarkers C2P and uPA/PAI-1 for 
Disease Recurrence Prediction of Early Breast Cancer Patients.
Schmitt M, Kiechle M, Schwarz-Boeger U, Langer R, Nakayama S, 
Matsushima T, Ishihara H. Technical University of Munich, Munich, 
Germany; Sysmex Corporation, Kobe, Japan
[Background] C2P is an assay measuring specific activities (SA; 
kinase activity compensated by its protein expression) of cyclin-
dependent kinases CDK1 and CDK2 by examining a small piece 
of fresh-frozen tumor tissue. We reported previously that the C2P 
risk score given by CDK1SA and CDK2SA is a potent prognostic 
factor in node-negative breast cancer patients. Likewise, a uPA/PAI-
1 ELISA test (FEMTELLE®, American Diagnostica Inc. Stamford, 
CT) quantitatively determines uPA (urokinase-type plasminogen 
activator) and PAI-1 (plasminogen activator inhibitor type-1) antigen 
levels in tumor tissue extracts, to identify patients with high or low 
risk of disease recurrence of node-negative breast cancer patients. 
These cancer biomarkers are recommended by the ASCO at the 
highest level of evidence (LOE-1) for therapy decision making in 
node-negative breast cancer patients. From the biological point of 
view, the above two assays can be placed into two categories: tumor 
cell proliferation for C2P and tumor cell invasion for uPA/PAI-1. 
This fact led us to examine the concept of combination of the two 
assays to better select breast cancer patients at risk. [Results] Fifty-
nine cases of frozen primary breast cancer tissues were subjected to 
the C2P assay in a blinded manner. Twenty-one cases (40%) were 
categorized into “high risk”, 7 cases (14%) into “intermediate risk”, 
and 24 cases (46%) into “low risk”. Seven cases were judged as “not 
informative”. The uPA/PAI-1 results and clinical information (26: 
recurrent cases, 30: non-recurrent cases, 1: stage IV, 2: unknown) were 
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provided by the TUM tumor bank. uPA/PAI-1 risk categories of 36 
cases (61%) were classified “high” and 23 cases (39%) categorized 
“low”. C2P and uPA/PAI-1 showed statistically significant correlation 
to histological grading (Pearson correlation coefficient; 0.45 and 
0.40, respectively). No significant correlation was observed between 
C2P and uPA/PAI-1. By Kaplan-Meier analysis for disease-free 
survival, in cases treated with endocrine therapy only, both C2P and 
uPA/PAI-1 showed a reproducible trend to the respective claimed 
performances as prognostic factors. In the combination analysis of 
the two parameters, where low/low was judged as “low” and the 
others as “high”, 11 cases (24%) were categorized into “low” and 
34 cases (76%) into “high”. The sensitivity and negative predictive 
value for disease recurrence were 90% (19/20) and 91% (10/11), 
respectively. Strong statistical significance was observed between 
the risk categories by the log-rank test; p=0.0089, and also by Cox 
proportional hazards regression analysis; HR=9.18, p=0.032. By 
multivariate analysis, also including tumor size and nodal status, the 
CP2 uPA/PAI-1 combination evolved as a significant, statistically 
independent parameter (HR: 6.51, p<0.01). [Conclusion] In this 
investigative study, the significance of the combination concept 
was strongly suggested for early breast cancer patients treated with 
endocrine therapy only. Yet, prior to implementation in the clinical 
setting, the practical performance of the combination assay should be 
validated by investigating an independent patient cohort.
P2-11-09
EGFR Overexpression in Triple Negative Breast Cancer (TNBC) 
and Its Association with the Prognosis.
Liu W, Zhang L, Ma K, Han B, Li S, Xu G, Fan Z, Liu N, Shi A. The 
First Hospital of Jilin University, Changchun, Jilin, China; The 208 
Hospital of People’s Liberation Army, Changchun, Jilin, China; The 
Central Hospital of Siping, Siping, Jilin, China; The Second Hospital 
of Jilin University, Changchun, Jilin, China; The Siping Center 
Hospital, Siping City, Jilin Province, China
Objective: The aim of this study is to investigate EGFR expression 
in Triple Negative Breast Cancer (TNBC), and to find the relationship 
between EGFR overexpression and prognosis of TNBC, further to 
clarify the significance of EGFR in TNBC and provide valuable 
information for TNBC therapy.
Methods: 42 triple nega nd ection ssitive breast cancer patients(studying 
group) and 40 HER2(3+) breast cancer patients(controling group) 
who underwent surgery from January 2000 to December 2005 
were analyzed. 82 cases of paraffin-embedded specimens were 
detected by Immunohistochemistry(IHC), fluorescence in situ 
hybridization(FISH) and polymerase chain reaction(PCR) to 
investigate the overexpression, amplification and mutation of EGFR 
gene. The distant-free survival(DFS) and overall survival(OS) of these 
patients were used to investigate the relationship between EGFR 
overexpression and the prognosis of TNBC.
Results: 34(43.9%) EGFR overexpression was observed in all 
cases, while gene amplification was only 7(9.1%) cases. No EGFR 
gene mutation was found in all cases. Overexpression of EGFR 
occurring in 57.1% patients in TNBC group and 25.0% patients in 
HER2 group, and we didn’t found any correlation between EGFR 
overexpression and clinicopathology. 50(61.0%) patients relapsed 
(TNBC 28,HER2 22) and 27(32.9%) patients died(TNBC 18,HER2 
9) were observed during the more than 5 years follow-up. The 5-year 
DFS was 57.1% and 77.5% respectively, the 5-year OS was 71.4% 
and 87.5% in TNBC and HER2 groups. In TNBC group, the survival 
of the EGFR-overexpressing group patients was significantly lower 
than that of the non-EGFR-overexpressing group patients (p=0.018 
for DFS, p=0.026 for OS); In HER2 group, no statistical difference 
was found (p=0.079 for DFS, p=0.055 for OS).
Conclusions: This study showed that EGFR overexpression 
increased significantly in TNBC patients, which was no correlation 
with their clinico-pathological data. EGFR gene amplification was 
much less frequent than its overexpression. It suggested that EGFR 
gene amplification may not be the unique mechanism of EGFR 
overexpression in TNBC. There may be other possible mechanisms 
and pathways that cause EGFR overexpression. In addition, it may 
suggest that gefitinib therapy is useless in TNBC patients because 
we did not find any mutations in the tested exons of TNBC. EGFR 
overexpression may associate with a poor outcome of TNBC patients 
which suggest it could be a significant prognostic factor for TNBC 
patients. EGFR may play important role for molecular-targeting 
therapy of TNBC.
P2-11-10
Low Toll-Like Receptor 9 Expression Is Required for the 
Aggressive Behavior of Triple Negative Breast Cancer Cells in 
Hypoxia.
Selander KS, Tuomela J, Sandholm J, Karihtala P, Pressey C, 
Ilvesaro J, Vuopala K, Kauppila JH, Kauppila S, Harris KW, Graves 
D, Jukkola-Vuorinen A. University of Alabama at Birmingham, 
Birmingham, AL; Oulu University Hospital, Oulu, Finland; University 
of Oulu, Oulu, Finland
Toll-like receptor-9 (TLR9) is a cellular DNA-receptor and a member 
of the innate immune system which is widely expressed in breast 
cancers. Although synthetic TLR9-ligands stimulate breast cancer 
cell invasion in vitro, through down-regulation of tissue inhibitor of 
matrix metalloproteinase-3 (TIMP-3), the role of this protein in breast 
or other cancer pathophysiology is unclear. We discovered that low 
tumor TLR9 expression is associated with a significantly shortened 
breast cancer specific survival among patients with triple negative 
tumors, but not among those with ER+ tumors. We further discovered 
that hypoxia induces TLR9 expression in breast cancer cells in vitro 
and in vivo. Although the triple negative TLR9 siRNA MDA-MB-231 
breast cancer cells (with lower TLR9 expression) were less invasive 
than control siRNA cells in normoxia, these cells became highly 
aggressive in hypoxia and they formed significantly larger tumors than 
corresponding control cells in an orthotopic model in vivo. Further 
in vitro experiments revealed that the removal of TLR9 expression 
through siRNA significantly potentiated the hypoxia-induced invasive 
capacity of the triple negative MDA-MB-231 cells, but not that of the 
ER+ T47-D cells. Low TLR9 expression in hypoxia resulted also in 
complete disappearance of TIMP-3 in the MDA-MB-231 cells, but 
not in the ER+ T47-D cells. Taken together, these studies suggest that 
low TLR9 expression has different effects on the behavior of triple 
negative and ER+ breast cancer cells in hypoxia; triple negative cells 
become more invasive under these conditions, possibly through loss 
of endogenous invasion inhibitors, such as TIMP-3. Furthermore, 
these studies suggest that low TLR9 expression in triple negative 
breast cancers may serve as a novel prognostic factor and help 
characterize the group of patients that are at a high risk of relapse. 
Finally, our results suggest that any treatments or factors that lower 
TLR9 expression or induce hypoxia in residual or metastatic triple 
negative breast cancer cells, might actually induce their spread.
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P2-11-11
IGFBP Ratio Confers Resistance to IGF Targeting and Correlates 
with Increased Invasion and Poor Outcome in Breast Tumors.
Becker MA, Hou X, Harrington SC, Carboni JM, Gottardis MM, 
Haluska P. Mayo Clinic, Rochester, MN; Bristol Myers Squibb 
Pharmaceutical Research Institute, Princeton, NJ
Purpose: To assess the role of insulin-like growth factor binding 
protein 5 (IGFBP-5) as a marker of relapse and survival in breast 
cancer tumors.
Experimental Design: Targeted regulation of IGFBP-5 was identified 
in MCF-7 cells resistant (MCF-7R4) to the IGF-1R/InsR inhibitor, 
BMS-536924 and examined by comparative microarray analysis, 
western and ELISA. Protein expression of IGFBP-5 was measured 
by immunohistochemistry in a cohort of 84 breast cancer patients to 
examine correlative associations with invasive tumor fraction and 
overall survival (OS). The expression ratio of IGFBP-5/IGFBP-4 
(BPR) was determined in multiple breast tumor cohorts for univariate 
analysis.
Results: IGFBP-5 was markedly upregulated and highly localized 
to the membrane in MCF-7R4 resistant cells. When compared to 
pathologically normal reduction mammoplasty tissue, IGFBP-5 
expression levels were upregulated in both invasive and histologically 
normal adjacent breast cancer tissue. In an independent cohort of 
breast cancer patients, IGFBP-5 protein levels correlated directly 
with invasion and OS. In univariate and multivariate modeling, 
metastasis-free survival, recurrence free survival (RFS) and OS were 
significantly associated with high IGFBP-5 expression. Prognostic 
power of IGFBP-5 was further increased with the addition of IGFBP-4 
and tumors were ranked based upon IGFBP-5/IGFBP-4 expression 
ratio (BPR). Multiple breast cancer cohorts confirm that BPR (high 
vs. low) was a strong predictor of RFS and OS.
Conclusion: IGFBP-5 expression is a marker of poor outcome in 
breast cancer patients. An IGFBP-5/IGFBP-4 expression ratio may 
serve as a surrogate biomarker of IGF pathway activation and predict 
sensitivity to IGF-1R-targeted therapies.
P2-12-01
Immunohistochemical (IHC) BAG1 Expression Improves the 
Estimation of Residual Risk (RR) by IHC4 in Postmenopausal 
Patients Treated with Anastrozole or Tamoxifen: A TransATAC 
Study.
Dowsett M, Afentakis M, Pineda S, Salter J, Howell A, Buzdar A, 
Forbes JF, Cuzick J. Royal Marsden Hospital, London, United 
Kingdom; Wolfson Institute of Preventive Medicine, London, 
United Kingdom; Christie Hospital, Manchester, United Kingdom; 
MD Anderson Cancer Center, Houston; University of Newcastle, 
Newcastle, Australia
Aim: To determine whether the incorporation of BAG1 staining 
improves the estimate of RR after endocrine therapy in postmenopausal 
patients with ER+ve tumours treated with endocrine therapy.
Background: BAG1 encodes a protein (BCL2-associated athanogene 
1) that binds to BCL2 and enhances its anti-apoptotic effects. BAG1 
is included as a separate subgroup in the 21-gene OncotypeDx 
Recurrence Score (RS) that is used to assess RR after endocrine 
therapy in primary ER+ breast cancer. IHC4 is a 4-panel set of IHC 
markers (ER, PgR, HER2, Ki67) that was shown to provide as much 
prognostic accuracy as RS in the translational arm of the ATAC trial 
(TransATAC) of anastrozole versus tamoxifen alone or combined 
and subsequently independently validated (Cuzick et al, JCO, 2011, 
in press). Addition of extra markers such as BAG1 to IHC4 may 
improve the accuracy of the IHC4 and provide extra discriminatory 
power for oncologists.
Methods: Samples in triplicate TMAs from the TransATAC cohort 
were stained for BAG1 using the Genetex 3.10G3E2 antibody after 
validation using siRNA knockdown. Staining was scored separately 
as nuclear or cytoplasmic and categorized by intensity as 0, 1, 2 or 
3. BAG1 IHC values were assessed for their correlation with BAG1 
mRNA levels. The statistical analysis plan was pre-specified and 
tested possible additional information from BAG1 expression to the 
IHC4 in patients not treated with chemotherapy by change in the 
likelihood ratio chi-square (DLR-X2). Results were included only if 
there was also complete data for ER, PgR, Ki67 and HER2. Primary 
analysis was on the HER2-ve node-negative (N-neg) population; 
secondary analysis was on all N-neg patients. Follow-up was to 
10 years and the primary end-point was time to distant recurrence 
(TTDR).
Results: Data on both nuclear and cytoplasmic BAG1 as well as the 
other 4 IHC parameters was available on 961 cases of which 855 were 
HER2-ve. There was a significant correlation between cytoplasmic 
and nuclear BAG1 (p=0.23, p<0.0001) but the nuclear staining 
correlated better with mRNA levels and was therefore considered 
further. Weak but significant correlations were also seen with ER, 
PgR and tumour grade. In the univariate analysis nuclear BAG1 was 
significantly associated with worse TTDR in HER2-ve and all N-neg 
cases (X2=7.91, p=0.005 and X2=10.63, p=0.001 respectively). 
Nuclear BAG1 also contributed significantly in multivariate analyses 
in the 2 populations firstly when added to the clinical model (X2=4.99, 
p=0.02 and X2=5.93, p=0.015 respectively) and secondly when 
subtracted from clinical plus the IHC4 parameters (X2=5.55, p=0.02 
and X2=4.50, p=0.03 respectively).
Conclusions: Nuclear BAG1 expression has significant value for 
estimating RR that is independent of standard clinical and IHC 
parameters and it improves the prediction of TTDR in the TransATAC 
population beyond that with the validated IHC4 score. Unlike IHC4 
markers, BAG1 is not commonly measured in pathology work-up 
of breast cancers. The clinical utility of its addition to IHC4 will be 
tested by measuring its discrimination of high and low risk patients 
in clinical practice.
P2-12-02
Correlation between BMI and Clinical Outcome of Patients with 
Early Stage HER2+ Breast Cancer from the N9831 Clinical Trial.
Crozier JA, Moreno-Aspitia A, Ballman KV, Martino S, Kutteh LA, 
Davidson NE, Kaufman PA, Perez EA. Mayo Clinic, Jacksonville, 
FL; Mayo Clinic, Rochester, MN; The Angeles Clinic and Research 
Institute, Santa Monica, CA; Oncology Associates at Mercy Medical 
Center, Cedar Rapids, IA; University of Pittsburgh Cancer Institute, 
Pittsburgh, PA; Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background: Obesity, as defined by body mass index (BMI), has 
been associated with increased recurrence rate, shorter DFS and 
increased death rates due to breast cancer (BC). Most of the studies 
to date have examined the relationship of BMI and DFS in patients 
with hormone receptor positive disease. To our knowledge, BMI and 
its relationship with outcome in early stage HER2 positive breast 
cancer has not previously been examined. The N9831 is a large phase 
III trial testing the role of trastuzumab in the adjuvant setting of high 
risk patients with early stage HER2+ BC. We hypothesized that the 
occurrence of overweight and obesity may correlate with outcome.
Methods: This analysis presents BMI and its relation to tumor 
characteristics and DFS in patients (pts) enrolled in the N9831 clinical 
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trial. Pts were categorized as normal weight, overweight or obese 
using the WHO BMI classification parameters of < 25%, 25-29% 
and ≥ 30% respectively. For patient characteristics, patients were 
grouped into non-obese (BMI< 30) and obese (≥ 30) cohorts. DFS was 
estimated by the Kaplan-Meier method. Comparisons between arms A 
(chemotherapy alone), B (chemotherapy plus sequential trastuzumab) 
and C (chemotherapy plus concurrent trastuzumab) were performed 
using the Cox proportional hazards model, stratified by BMI.
Results: Analysis was completed on 3,017 eligible pts. Obese pts 
were more likely to be older and postmenopausal (p<0.0001 for 
both). There was no significant association between BMI and ER/PR 
status (p=0.07) or histologic tumor grade (p=0.33). Obese pts were 
found to have significantly larger tumors ≥ 2 cm (p=0.002) and more 
positive lymph nodes (p=0.02). There was no significant difference 
in DFS within each intrinsic arm (A, B and C) between the obese 
and non-obese pts at 3, 5 or 7 yrs of follow up. However, pts in the 
non-obese group had significantly improved DFS in arm B and C 
compared to arm A (p=0.001 and p<0.0001 respectively). Also obese 
pts in arm C had significantly improved DFS compared to obese pts 
in arm A (p=0.008). There was a trend of improved DFS in the obese 
group in arm B compared to arm A, but this was not statistically 
significant (p=0.09). Pts in the normal weight and overweight groups 
did significantly better in arm B (p=0.02 for both) and arm C (p=0.01 
and p=0.002 respectively) compared to arm A.
Conclusions: This analysis of data from the N9831 study confirms 
that obese pts with early stage HER2+ tumors have worse clinical 
outcome than pts with BMI < 30%. Adjuvant trastuzumab improved 
clinical outcome regardless of BMI. This study supports weight loss 
intervention for obese women with early stage HER2+ BC.
P2-12-03
A Prospective Study of the Prognostic Implications of Being a 
BRCA1 Carrier for Young Onset Breast Cancer Patients.
Eccles DM, Dent L, Gerty SM, Altman D, Copson ER, Simmonds 
PD, Durcan L, Ward D. University of Southampton, Southampton, 
Hampshire, United Kingdom; Oxford University, Oxford, United 
Kingdom; Southamtpon University Hospitals NHS Trust, Southampton, 
Hampshire, United Kingdom; Salisbury District Hospital, Salisbury, 
Witshire, United Kingdom
Background: BRCA1 gene carriers frequently develop triple negative 
breast cancer (TNBC) at young ages. Retrospective studies have 
reached conflicting conclusions about the prognostic implications of 
breast cancer diagnosed on a background of a constitutional BRCA1 
gene mutation. Many studies have the disadvantages of retrospective 
design and small numbers or both. The Prospective study of Outcomes 
in Sporadic versus Hereditary breast cancer (POSH) recruited 3024 
patients diagnosed before 41 years of age and treated for breast cancer 
in the UK between 2000 and 2007 (protocol published: Eccles et al 
BMC Cancer 2008).
Aim: To investigate the effect of family history and BRCA1 gene 
mutation status on breast cancer survival in women aged younger 
than 41 years at diagnosis.
Methods: Cases in which the primary tumour pathology report 
was not available (2.8% of total) were excluded from this analysis. 
A completed family history questionnaire was available for 2907 
cases (99% of total). The primary end point for this analysis was the 
development of distant metastases from breast cancer. All patients 
were younger than the starting age for screening in the UK except for 
known gene carriers of which there were only 8 in total, the remainder 
of identified gene carriers were tested after cancer diagnosis or as part 
of this study. Over 90% of patients received adjuvant or neoadjuvant 
chemotherapy with over 90% of these receiving an anthracycline 
based regimen. Kaplan Meier survival analysis and log rank test were 
used to assess survival differences.
Results: 2937 patients were included in the analysis. Mean and 
median age at diagnosis was 36 years and the cohort was followed 
prospectively for a mean and median follow up time of 50 months. 
Overall distant disease free survival in the whole cohort was only 75% 
at 5 years. The effect of family history on presentation was explored. 
Patients who reported a first or second degree relative with breast 
cancer presented with smaller tumours (20mm compared to 22.5mm, 
p= 0.006) but no difference in axillary nodal status (p=0.2605). 
Survival was however significantly better comparing the 499 patients 
who reported a family history of breast cancer compared with the rest 
of the cohort (p=0.0164). 539 patients had been tested for mutations in 
the BRCA1/2 genes and 176 high risk gene BRCA1/BRCA2 carriers 
were identified. We compared 118 patients with a known BRCA1 gene 
mutation (almost all diagnosed after the cancer) to the 465 patients 
with confirmed TNBC (p=0.0118). Survival was significantly better 
in the BRCA1 carriers (p=0.0118). After excluding 29 gene carriers 
whose primary tumour showed any of ER, HER2 or PR as positive, 
the same improved survival trend was seen although significant at 
the 10% level (p=0.07).
Conclusion: This prospective study indicates that BRCA1 gene 
carriers clearly do not have a worse prognosis when compared to triple 
negative breast cancers or young onset breast cancer overall and these 
early follow up data indicate an improved outlook in gene carriers.
P2-12-04
RACGAP1 mRNA Assay Outperforms Ki-67 as a Proliferation 
Marker in the FinHer Study Cohort.
Wirtz RM, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen P-L, 
Kataja V, Turpeenniemi-Hujanen T, Jyrkkiö S, Huang W, Eidt S, 
Joensuu H. STRATIFYER Molecular Pathology GmbH, Cologne, 
Germany; Pharma, Finland; Helsinki University Central Hospital 
and University of Helsinki, Finland; University of Tampere and 
Tampere University Hospital, Finland; Tampere University Hospital, 
Finland; Kuopio University Hospital, Finland; Oulu University 
Hospital, Finland; Turku University Hospital, Finland; Monogram 
Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, 
Germany
Background: Molecular subtyping of breast cancer has become an 
integral part of standard evaluation of breast cancer patients. Their 
assessment requires combining data from analyses on ER, PR, HER2 
and cell proliferation markers. However, their immunohistochemical 
(IHC) testing carries an up to 20% risk of erroneous results. Similarly, 
assessment of cell proliferation by Ki-67 staining is hampered by lack 
of standardization of laboratory methods and agreement on cut-offs. 
Here we tested the prognostic value of objective quantitation of ESR1, 
PgR, HER2 and the proliferation markers RACGAP1 using RT-qPCR 
and compared the results with local and central IHC assessments.
Methods: RNA was extracted from FFPE tumor tissue of 917 
patients who participated in the FinHer trial. ESR1, PgR, HER2 and 
RACGAP1 mRNA expression were measured using RT-qPCR. The 
molecular subtypes (luminal, HER2-enriched and triple-negative) 
were determined. Prognostic significance of proliferation markers was 
assessed using univariate and multivariate analyses. The RT-qPCR 
results were compared with local and central IHC results.
Results: HER2 mRNA showed a bimodal distribution with 197 
(21.4%) out of the 917 tumors being above the predefined cut-off 
. HER2 mRNA expression increased in parallel with HER protein 
expression. Overall concordance of HER2 mRNA testing with 
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central IHC and CISH was good, while local IHC testing suffered 
higher false positive rates. RACGAP1 mRNA expression was the 
greater the higher the histological grade. ESR1 and PgR mRNA 
correlated negatively with the histological grade (r=-0.38 and r=-0.33; 
p<0.0001), whereas HER2 and RACGAP1 mRNA were correlated 
positively (r=0.10 and r=0.49; p=0.002 and p<0.0001, respectively). 
RACGAP1 mRNA was negatively associated with ESR1 and PgR 
mRNA (r=-0.17 and r=-0.26, respectively; p<0.0001 for each). 
Molecular subtypes determined by RT-qPCR using predefined cut-off 
values were highly prognostic for overall survival (OS) (p<0.001). 
The 5-year OS rate for patients with luminal cancer was 94% and 
86% for HER2-enriched cancer and 84% for triple-negative cancer 
. In the subset of luminal tumors, high expression of RACGAP1 
identified a population of patients who were at a high risk of death 
(5-year OS 82% versus 95%; p<0.0001). In a multivariate analysis 
RACGAP1 mRNA expression, nodal status and chemotherapy type 
were independent prognostic factors, whereas IHC of ER, PgR, Ki-67 
and histological grade were not significant.
Conclusions: Molecular subtyping of breast cancer by RT-qPCR using 
RNA isolated from FFPE tissue proved successfully in this large 
patient cohort. RACGAP1 mRNA expression distinguished high and 
low risk luminal breast cancers. In a multivariate analysis mRNA-
based molecular markers outperformed the immunohistochemical 
markers ER, PgR and Ki-67. Of note, quantitative assessment of the 
proliferation marker RACGAP1 was superior to semiquantitative 
assessment of Ki-67 from routine FFPE tissues using IHC. We 
conclude that quantitative assessment of ESR1, PgR, HER2 and 
RACGAP1 mRNA by RT-qPCR is a robust and reproducible method 
to assess these key tumor biological factors from archival FFPE tumor 
tissue. RACGAP1 is novel cell proliferation marker in breast cancer 
that warrants further validation.
P2-12-05
Correlation between Quantitative HER2 Protein Expression and 
Risk of Brain Metastases in HER2-Positive Advanced Breast 
Cancer Patients Receiving Trastuzumab-Containing Therapy.
Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, 
Haddad M, Paquet A, Lie Y, Czartoryska-Arlukowicz B, Wysocki 
P, Jankowski T, Radecka B, Foszczynska-Kloda M, Litwiniuk M, 
Debska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J. Military 
Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, 
Gdansk, Poland; Monogram Biosciences, South San Francisco, 
CA; International Drug Development Institute, Louvain-la-Neuve, 
Belgium; Bialystok Oncology Center, Bialystok, Poland; Great Poland 
Cancer Center, Poznan, Poland; Lublin Oncology Center, Lublin, 
Poland; Opole Oncology Center, Opole, Poland; West Pomeranian 
Oncology Center, Szczecin, Poland; Poznan University of Medical 
Sciences, Poznan, Poland; Regional Cancer Center, Lódz, Poland; 
Cepheid, Sunnyvale, CA
Background. Patients with HER2-positive breast cancer are at 
particularly high risk for brain metastases; however, the biological 
basis is not fully understood. Within HER2-positive breast cancer 
tumors, it is possible to resolve a ~1.5-log range of HER2 protein 
expression using a novel quantitative HER2 assay (HERmark®). 
We investigated the correlation between quantitative HER2 protein 
expression in primary breast cancers and the time to brain metastases 
(TTBM) in HER2-positive advanced breast cancer patients treated 
with trastuzumab.
Methods. The study group included 142 consecutive patients who 
were administered trastuzumab-based therapy for HER2-positive 
metastatic breast cancer, defined as 3+ categorical staining by 
immunohistochemistry (IHC). HER-2/neu gene copy number was 
subsequently quantified as HER2/CEP17 ratio by central laboratory 
fluorescence in situ hybridization (FISH). HER2 protein was 
quantified as total HER2 protein expression (H2T) by the HERmark 
assay in formalin-fixed, paraffin-embedded primary tumor samples. 
HER2 variables were correlated with clinical features and TTBM 
measured from the initiation of trastuzumab-containing therapy.
Results. H2T level (continuous variable) was correlated with shorter 
TTBM (HR=2.3; p=0.013), whereas HER2 gene amplification by 
FISH (p=0.28) and continuous HER2/CEP17 ratio (p=0.25) had no 
significant prognostic impact. The correlation between continuous 
H2T level and TTBM was confirmed in a multivariate analysis 
(HR=3.2; p=0.021). Controlling for the competing risk of death from 
causes other than brain metastases, continuous H2T remained a strong 
correlate of TTBM (HR=2.7; p=0.0009). In the subset of patients that 
was centrally-determined HER2 positive by FISH (117 patients), 
above-median H2T level was significantly associated with shorter 
TTBM (HR=2.4; p=0.005), whereas this was not true for median 
FISH/CEP17 ratio (p=0.4). In a multivariate analysis of this subset, 
continuous H2T (p=0.021) and a time dependent covariate capturing 
time to non-brain metastases (p=0.0044) were prognostic for TTBM, 
whereas FISH/CEP17, ER, PgR and grade were not.
Conclusions. These data reveal a strong relationship between 
quantitative HER2 protein expression levels and the risk of 
brain relapse in HER2-positive advanced breast cancer patients. 
Consequently, quantitative assessment of HER2 protein expression 
may inform and facilitate refinements in therapeutic treatment 
strategies for selected subpopulations of patients in this group.
P2-12-06
Nomogram To Predict Subsequent Bone Metastasis in Patients 
with Non Metastatic Breast Carcinomas.
Lousquy R, Delpech Y, Rouzier R, Gligorov J, Hsu L, Barranger 
E, Pusztai L, Uzan S, Hortobagyi GN, Coutant C, Ibrahim NK. 
Lariboisiere Hospital, AP-HP, Paris, France, Metropolitan; Tenon 
Hospital, AP-HP, Paris, France, Metropolitan; The University of 
Texas M.D. Anderson Cancer Center, Houston, TX; Georges Francois 
Leclerc Cancer Center, Dijon, France, Metropolitan
Background:Bone metastasis (BM) is one of the most common 
sites of distant metastasis for breast cancer. We hypothesized that its 
occurrence can be predicted if a clinical nomogram can be developed, 
thus allowing for selection of patients at high risk for BM.
Patients and Methods: Medical records of patients with non 
metastatic breast cancer were prospectively collected for the period 
between January 1997 and February 2007 at the M.D. Anderson 
Cancer Center (Texas, USA). A multivariate logistic regression 
analysis of selected prognostic features was done. Based on Cox 
proportional hazards regression model, a nomogram to predict 
BM was constructed and validated in an independent cohort of 
579 patients with non metastatic breast cancer at time of diagnosis 
treated at the Tenon Hospital (Paris, France) between January 2003 
and December 2005.
Results: Of 4175 patients with non metastatic breast cancer, 
314 developed subsequent BM. Age, T stage, lymph node status, 
lymphovascular space invasion, breast cancer molecular subtype, 
adjuvant hormonotherapy were significantly and independently 
associated with subsequent BM. The nomogram had a concordance 
index of 0.69 (95% CI, 0.68 to 0.70) in the training set. The validation 
set showed a good discrimination with a concordance index of 0.65 
(95% CI, 0.57 to 0.72). At 3, 5 and 7 years, the nomogram was well 
calibrated.
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Conclusion:We have developed a robust tool that is able to predict 
subsequent BM in patients with non metastatic breast cancer. 
Selection of an enriched patient population at high risk for BM will 
allow to practice individualized therapeutic strategies, an adapted 
medical supervision and will facilitate the design of trials aiming at 
its prevention with the use of biphosphonate treatment.
P2-12-07
Pooled Analysis of Outcomes of T1a/bN0, HER2-Amplified 
Breast Cancer.
Amir E, Seruga B, Ocana A, Carlsson L, Bedard P. Princess Margaret 
Hospital, Toronto, Canada; Institute of Oncology Ljubljana, 
Ljubljana, Slovenia; Albacete University Hospital, Albacete, Spain
Background: Breast tumors with HER2 amplification have a worse 
prognosis than those with normal HER2 expression. This finding is 
independent of tumor size and other classical prognostic factors used 
in the adjuvant setting. The prognosis of node negative, sub-centimeter 
(T1a/bN0) tumors is usually excellent. However, little is known about 
the prognostic impact of HER2-amplification in this group. This study 
therefore, aimed to evaluate the relative and absolute prognostic 
impact of HER2-amplification in T1a/bN0 tumors.
Materials and Methods: Published data from studies assessing the 
outcomes of patients with HER2-amplified, node negative, T1a/
bN0 tumors were included in a pooled analysis. Odds ratios (OR), 
95% confidence intervals (CI) and absolute risks were computed for 
recurrence and distant recurrence at 5 years. Pooled hazard ratios 
(HR) for disease-free survival (DFS), were also assessed.
Results: A total of 3 case-control studies were included in the analysis 
and comprised 485 patients with HER2-amplified breast cancer 
(57.3% were also hormone receptor positive) and 1096 patients 
with HER2-normal disease (82.2% were hormone receptor positive). 
Among the HER2-amplified group, 4.1% received trastuzumab and 
18.6% received chemotherapy. In the HER2-normal group, 4.3% 
received chemotherapy Estimated median follow-up was 5.7 years. 
HER2-amplification was associated worse DFS (HR = 2.60, 95% CI 
1.53-4.41, p<.001) and increased odds for recurrence at 5 years (OR 
= 3.79, 95% CI 2.35-6.10, p<.001). There was a non-significant trend 
towards increased odds of distant recurrence at 5 years (OR = 2.51, 
95% CI 0.82-7.67, p=.11). Compared with HER2-normal cancers, 
those with HER2-amplification showed lower absolute probability 
of recurrence-free survival at 5 years (90.1% vs. 94.6%, p<.001) 
and distant recurrence-free survival at 5 years (95.1% vs. 97.6%, 
p<.001). Among HER2-amplified cancers, tumor size 0.6-1.0cm 
(T1b) was associated with a trend for higher odds of recurrence at 5 
years compared with those 0.5cm or smaller (T1a, pooled OR = 1.58, 
95% CI 0.96-2.60, p=.07).
Conclusions: HER2-amplification is associated with worse outcome 
in T1a/bN0 tumors. However, recurrence-free and distant recurrence-
free survival at 5 years is excellent in this group, particularly in 
those with T1a tumors. These data question the role of adjuvant 
chemotherapy and trastuzumab in these patients unless associated 
with other high risk features. A differentially lower risk for distant 
recurrence suggests the possible role for more aggressive local therapy 
such as surgery and/or radiation therapy.
P2-12-08
Bcl-2 as a Prognostic Marker in Breast Cancer Patients Receiving 
Endocrine Therapy.
Larsen MS, Bjerre KD, Laenkholm A-V, Giobbie-Hurder A, Ejlertsen 
B, Lykkesfeldt AE, Rasmussen BB. Herlev Hospital, Herlev, Denmark; 
Rigshospitalet, Copenhagen, Denmark; Dana-Farber Cancer 
Institute, Boston, MA; Danish Cancer Society, Inst of Cancer Biology, 
Copenhagen, Denmark
Background: In breast cancer patients with estrogen receptor (ER) 
positive tumors, endocrine treatment reduces recurrence. However, 
30% of patients eventually relapse in spite of therapy. Additional 
markers to identify this group of therapy resistant, prognostically 
unfavourable patients are therefore needed. The expression of 
Bcl-2 has been shown to be a prognostic factor in breast cancer 
patients regardless of ER-status, but assessment of Bcl-2 by 
immunohistochemistry (IHC) needs to be standardized since different 
scoring systems and different cut-points have been used. In a pilot 
study comprising 258 ER positive tumors from tamoxifen-treated 
patients, a simple scoring system enabled us to find suitable cut-
points, selecting patient-groups with poor prognosis. The aim of the 
current study was to validate these results in a similar population 
from a large randomised study.
Material and methods: Bcl-2 was assessed in 1082 (78%) of the 
1396 postmenopausal Danish patients who in the BIG 1-98 trial were 
randomised to 5 years of tamoxifen (N=325), letrozole (N=335) or 
a sequence of these agents (N=422). Tissue microarrays were made 
from formalin fixed paraffin embedded primary tumors. An IHC score 
for expression of cytoplasmic Bcl-2 (clone 124, Dako) was performed 
according to both the number of positive cells (0%=0, 1-10%=1, 
11-50%=2, 51-100%=3) and the intensity of the staining (weak, 
moderate, strong) as in the pilot study. The associations between 
Bcl-2 status and clinicopathological variables were assessed. The 
prognostic value of Bcl-2 according to cut-points determined in the 
pilot study was analysed by Cox proportional hazards models. The 
primary endpoint was disease free survival (DFS).
Results: Patients were divided into three subgroups according 
to predefined cut-points: Bcl-2 low (score 0 or 1 (n= 24)), Bcl-2 
intermediate (score 2 or score 3/weak or moderate (n= 216)) and Bcl-
2 high (score 3/strong (n= 842)). Bcl-2 expression was significantly 
associated with ER (P=0.0003) and progesterone receptor (PgR) 
(P<0.0001), and negatively associated with Ki-67 (P=0.0021) and 
tumor grade (P=0.005). In univariate analysis patients in the Bcl-2 low 
group had a bad prognosis compared to the Bcl-2 high group (HR=2.3; 
95% CI: 1.2 to 4.1). In the multivariable analysis including ER, PgR, 
Ki-67, positive lymph nodes, age, tumor size and histological type 
and grading, association between Bcl-2 and DFS was not statistically 
significant (P=0.35).
Discussion: We found Bcl-2 to be a prognostic factor in the univariate 
analysis (P=0.024) but not to be an independent predictor of poor 
survival of ER positive patients treated with tamoxifen and/or 
letrozole. In this population a low or absent expression of Bcl-2 
was uncommon (2.2 %), as expected since Bcl-2 is an ER regulated 
protein. The results of the pilot study could not be confirmed in 
this validation study. However, the strong positive relation to other 
prognostic factors like tumor grade and high proliferative index 
indicates that Bcl-2 could contribute to factors characterising a group 
of tumors with a bad prognosis.
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P2-12-09
Prediction of Residual Risk of Recurrence after 5 Years of 
Follow-Up by Clinicopathologic Variables and 4 IHC Markers: 
A TransATAC Study.
Sestak I, Cuzick J, Dowsett M, Salter J, Quinn E, Zabaglo L, Howell 
A, Buzdar A, Forbes J, Queen Mary University of London, London, 
United Kingdom; Royal Marsden Hospital and Breakthrough 
Breast Cancer Centre, London, United Kingdom; Christie Hospital, 
Manchester, United Kingdom; University of Texas, Texas; University 
of Newcastle, Newcastle, NSW, Australia
Background: Adjuvant endocrine therapy beyond 5 years is known to 
be of benefit to some ER+ patients but it is unclear which patients have 
sufficient residual risk (RR) to merit this. We have previously shown 
that 4 immunohistochemical markers (ER, PgR, Ki67, HER-2), both 
alone and combined into the IHC4 score (Cuzick et al, JCO 2011) are 
significantly correlated with time to recurrence (TTR) in the overall 
follow up of a cohort of 1125 patients from the monotherapy arms of 
the Arimidex, Tamoxifen, Alone or in combination (ATAC) trial. We 
have now assessed the relationship of each of these parameters and 
common clinical variables (nodal status, grade, tumour size, age and 
treatment option) for predicting outcome beyond 5 years. Material 
and Methods: We determined the univariate and multivariate 
prognostic value of clinical variables and the 4 IHC variables 
separately and as the IHC4 score for TTR separately in years 0-5 
and 5-10 of follow up for all patients, separately for anastrozole and 
tamoxifen and only in the node-negative patients. Results: Results 
in years 5-10 are summarized in the Table. Nodal status, tumour size 
and grade were at least as strong in years 5-10 as in years 0-5. Ki67 
and the overall IHC4 score were the only significant IHC biomarkers 
related to TTR univariately in this period, but both lost significance 
in a multivariate model including clinical variables. There were no 
significant interactions with treatment. Similar results were seen 
for the node-negative population. Conclusions: None of the IHC4 
markers provided significant additional prognostic information in the 
5-10 year period, but nodal status, tumour size and grade continued 
to be strong prognostic factors.
Table: Univariate and multivariate analyses of immunohistochemical 
markers and clinical variables in the 5-10 years follow-up period.
5-10y Follow up period
 Univariate  analysis   
Multivariate  
analysis  
 HR (95% CI) LR-X2(P-value)  HR (95% CI)
LR-X2*
(P-value)
Nodal status
(neg. vs. pos.) 2.95 (2.04-4.26)
30.8
(<0.0001)
Nodal status
(neg. vs. pos.) 2.23 (1.51-3.29)
16.08
(0.0001)
Tumour size
(≤2cm vs. >2cm) 3.13 (2.17-4.52)
36.23
(<0.0001)
Tumour size
(≤2cm vs. >2cm) 2.16 (1.46-3.19)
14.76
(0.0001)
Grade
(well vs. mod./poor)
3.54 (1.79-7.00) 18.97
(<0.0001)
Grade
(well vs.  
mod./poor)
2.47 (1.22-4.99) 7.88(0.005)
Clinical Score 2.51 (2.08-3.04) 71.71(<0.0001)
Clinical + IHC4
(χ2 vs. IHC4) 2.50 (2.06-3.03)
67.87
(<0.0001)
ER (H-Score/30) 0.92 (0.81-1.04) 1.65(0.2)    
PgR (%/10) 0.97 (0.92-1.02) 1.45(0.2)    
HER2 (pos vs neg) 1.09 (0.59-2.03) 0.07(0.8)    
Ki67  
(ln(1+10*Ki67(%)))
1.29 (1.09-1.54) 9.04(0.003) Ki67 1.13 (0.96-1.35)
2.18
(0.14)
IHC4 Score 1.64 (1.15-2.34) 7.00(0.008)
IHC4 + Clinical
(χ2 vs. Clinical) 1.40 (0.97-2.03)
3.15
(0.08)
* For addition to model containing all other factors (except clinical score and IHC4 score which only 
is for addition to the other score) 
P2-12-10
Low TCR Diversity (Divpenia) Is a Prognosis Factor of Overall 
Survival in Metastatic Breast Cancer.
Manuel M, Tredan O, Bachelot T, Parmentier G, Courtier A, Rabeony 
T, Chabaud S, Mouret J-F, Grives A, Perez S, Clapisson G, Blay 
J-Y, Caux C, Pasqual N, Menetrier-Caux C. CRCL UMR INSERM 
1052 CNRS 5286, Centre Léon Bérard, Lyon, France; ImmunID 
Technologies, Grenoble, France; Centre Léon Bérard, Lyon, France
Background: We already showed that lymphopenia (<1000 
lymphocytes/µl) or CD4+ T cell lymphopenia (<450/µl) detected 
before initiation of chemotherapy are prognostic factors for toxicity 
and death for metastatic breast cancer (MBC) patients. The goal of 
the present study was to identify the characteristics of the T cells in 
these lymphopenic patients. TCR diversity was investigated and tested 
as a prognostic factor for overall survival (OS).
Patients and methods: The ImmunTraCkeR® assay (ImmunID, 
Grenoble, France), which analyzes through semi quantitative 
multiplex-PCR the V-D-J combinatorial diversity of TCR-beta 
chain (TRB), was used to investigate diversity of T cell repertoire 
on cryopreserved blood samples from a retrospective cohort of MBC 
patients before chemotherapy administration (n=66). Univariate and 
multivariate analysis were performed. We then validated our score on 
a prospective cohort (n=67) using the same eligibility criteria (MBC 
patients before first line chemotherapy administration).
Results: Using a 33% cutoff for divpenia in our retrospective 
cohort (T cell diversity below 33%) (average diversity for healthy 
people is 70%), divpenia was associated with a median OS of 10 
months vs 22 months for patients with diversity >33% (logrank p 
value=0.04). The NDL® score (Numeration Diversity Lymphocytes 
representation) that combines lymphocyte numeration with TRB 
diversity, demonstrated that lympho-divpenia (T cell diversity below 
33% and lymphopenia below 1Giga/L) was associated with a poor OS 
compared to patients with either lymphocyte <1000/µL & diversity 
>33% or lymphocyte >1000/µL & diversity <33% or both lymphocyte 
>1000/µL and diversity >33% (p=0.015). In multivariate analysis, 
including performance status (PS), hemoglobin level, polynuclear 
neutrophil count (PNN), age, and liver metastasis, NDL® score 
was identified as an independent prognostic factor for OS. In our 
prospective validation cohort, NDL® score was also identified as a 
prognostic factors for OS (p=0,007), as well as lymphopenia (<1000/
µL) (p=0,0003), CD4+ lymphopenia (<450/µL) (p=0,04), menopausal 
status (p=0,02), hormonal receptor status (estrogen receptor p=0.02; 
progesterone receptor p=0.002) and lung metastasis (p=0,009). In 
multivariate analysis, hemoglobin level was the only independent 
prognostic factor in this cohort.
Conclusion: We showed that Divpenia and NDL® score are 
prognostic factors for OS in MBC patients. In order to confirm these 
results, a prospective clinical trial is ongoing on a larger cohort of 
MBC and lung cancer patients.
P2-12-11
Clinical Relevance of a IL-8/B-Cell Gene Signature Identified 
from Triple Negative Breast Cancer (TNBC) in Intrinsic Breast 
Cancer Subtypes.
Rody A, Holtrich U, Ruckhaeberle E, Radosa J, Juhasz-Boess I, 
Solomayer EF, Kaufmann M, Karn T. Saarland University, Homburg, 
Germany; Goethe-University, Frankfurt, Germany
Background
As presented recently (SABCS 2010, #S5-5) a ratio of high B-cell 
and low IL-8 metagenes using gene expression analysis identified 32 
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% of triple negative breast cancers with good prognosis and was the 
only significant predictor in multivariate analysis including routine 
clinicopathological variables.
However, the clinical relevance of this signature within the intrinsic 
breast cancer subtypes still remains unclear and is analyzed here.
Methods
Affymetrix gene expression data from n=2417 breast cancer patients 
have been assembled. We performed an unsupervised analysis to 
define metagenes that distinguish molecular subsets within TNBC 
(SABCS 2010, #S5-5) . A high expression of B- cell metagenes was 
associated with good and high expression of IL-8-related metagenes 
were associated with poor prognosis.
To identify intrinsic subtypes we used the method previously 
described by Hu et al. (2006) and the prognostic value within those 
subtypes was assessed by analyzing the event free survival of patients 
as function of high and low B-cell/IL-8 metagene ratio.
Results
Comparing ER positive with ER negative patients the B-cell/IL-8 ratio 
showed only in ER negative breast cancer a significant prognostic 
value (log rank p-value <.0001).
Within the entire cohort 37.8 % of patients could be assigend to 
luminal A, 35.2 % to luminal B, 7,4 % to erbB2 and 19.6 % to basal-
like subtypes. Event free survival of patients with good or poor B-cell/
IL-8 ratio showed only in basal-like breast cancer patients a statistical 
significant difference (p<.0001). However, we could not observe any 
difference in prognosis in luminal A and B, as well as erbB2 tumors.
No difference in the expression of the proliferation metagene was 
observed when samples of the intrinsic subtypes were stratified 
according to the prognostic predictor based on high expression of the 
B-Cell metagene and low expression of the IL-8 metagene.
Conclusion
The B-cell/IL-8 ratio is highly prognostic in basal-like/ TNBC and 
shows no association with proliferation status.
P2-12-12
Prognostic Utility of Breast Cancer Index for Late Relapse in 
Patients with Early Stage Breast Cancer.
Schnabel CA, Zhang Y, Kesty NC, Erlander MG. bioTheranostics, 
Inc, San Diego, CA
Background: Residual risk of relapse remains a substantial concern 
for breast cancer patients as greater than half of recurrences occur 
beyond the initial 5y of tamoxifen therapy. First generation multi-
gene signatures provide further prognostic information to standard 
clinical and pathological factors, however, their utility is strongest for 
predicting early relapse (≤5y post-diagnosis), and they have limited 
prognostic value for late metastatic risk. Breast Cancer Index (BCI), a 
continuous risk index based on the combination of HOXB13:IL17BR 
(H:I) and the molecular grade index (MGI), estimates the individual 
risk of recurrence in ER+, LN- breast cancer patients. In this study, 
the prognostic performance of BCI for predicting early versus late 
relapse (≤5y vs >5y post-diagnosis) was examined.
Methods: Gene expression profiling was performed on RNA extracted 
from FFPE tumor samples from untreated, postmenopausal, ER+ early 
stage breast cancer patients in the randomized Stockholm Trial. RT-
PCR assay, pre-defined BCI score, H:I and MGI cut-points, and risk 
group categorization were done as previously described (Jerevall et 
al., Br J Cancer 2011). Association of gene expression data with the 
clinical endpoint of time to distant metastasis was assessed by Kaplan- 
Meier analysis using the log rank test; time-varying coefficient Cox 
proportional models were used to estimate the time-dependent hazard 
ratios (HRs).
Results: Analyses included 274 ER+, LN- patients (51% PR+, 87% 
HER2-, 63% grade 2, 17.7 y median follow-up) who did not receive 
adjuvant tamoxifen treatment. BCI was significantly associated with 
10-year distant metastasis-free survival, with probabilities of 91% (86-
96%), 82% (74-91%), and 65% (52-80%) for the low, intermediate, 
and high-risk BCI groups, respectively (HR high versus low-risk 
group = 4.31; 95%CI, 2.23-8.33; P=0.00001). Risk stratification for 
the first 5-y post-diagnosis using time-varying coefficient Cox models 
showed both MGI and BCI were significantly prognostic with HRs of 
6.13 (95% CI: 2.11-17.8; P=0.0009) and 5.77 (95% CI: 2.16-15.39; 
P=0.0005). For prediction of late relapse in the subset of patients 
that remained distant metastasis-free for at least 5-y (N=221), MGI 
decreased in prognostic utility (HR 1.65, 0.76-3.56; P=0.2), consistent 
with other proliferation-based gene signatures. In comparison, both 
H:I and BCI were significantly associated with risk of late relapse 
[HRs 2.89 (1.31-6.36; P=0.009); 3.31(1.3-8.39); P=0.012].
 H:I MGI BCI
 High vs Low High vs Low Int vs Low High vs Low
First 5 Years 1.85 (p=0.12) 6.13 (p=0.0009) 2.55 (p=0.083) 5.77 (p=0.0005)
After 5 Years 2.89 (p=0.009) 1.65 (p=0.20) 1.60 (p=0.32) 3.31 (p=0.012)
Conclusions: This post-hoc analysis of a randomized clinical trial 
cohort demonstrates the prognostic utility of BCI to predict disease 
outcome for both early and late risk of relapse in untreated patients 
with early stage breast cancer. Given the significant need for predictors 
of late risk, the stability of BCI prognostic performance may have 
important implications for the type and duration of treatment for 
hormone-responsive breast cancer.
P2-12-13
Topoisomerase 2 alpha (TOP2A) RNA Expression Provides 
Prognostic Information in Hormone Receptor Positive Breast 
Cancer That Is Complementary to a Simulated Algorithm for 
Recurrence Score.
Sparano JA, Goldstein LJ, Davidson NE, Sledge, Jr GW, Gray R. 
Albert Einstein College of Medicine, Montefiore Medical Center, 
Bronx, NY; Fox Chase Cancer Center, Philadelphia, PA; University 
of Pittsburgh, Pittsburgh, PA; Indiana University, Indianapolis, IN; 
Eastern Cooperative Oncology Group, Brookline, MA
Background: We have previously reported that TOP2A RNA 
expression was prognostic in patients with operable estrogen receptor 
(ER) positive breast cancer treated with anthracycline containing 
adjuvant chemotherapy plus endocrine therapy in trial E2197, and 
provided complementary prognostic information in those who had 
a mid-range Recurrence Score (RS) (Sparano et al. Clin Cancer Res 
2009; 15; 7693). The purpose of this analysis was to provide additional 
evidence regarding this observation.
Methods: We evaluated TOP2A RNA expression in 4 independent 
data sets individually and in a pooled analysis including all data. We 
also used an algorithm to simulate the Oncotype DX Recurrence 
Score (SimRS). The analysis included 752 patients with early stage 
breast cancer that was ER-positive, HER2-negative defined by 
gene expression. Results are expressed as the hazard ratio (HR) for 
estimates of the effect of a one standard deviation increase in the value 
of the log gene expression (x + 1SD vs. x) as a continuous function. 
Five-year relapse free survival (RFS) rates were also evaluated for 
patients with a mid-range SimRS for high vs. low TOP2A expression 
(above vs. below the median, which was prognostic in E2197). The 
distribution of SimRS was categorized to be concordant with the 
distribution of actual RS in E2197 (47%, 34%, 19%, respectively 
for RS <18 - low, 18-30 - intermediate, ≥31 - high).
Results: The HR for models including TOP2A alone and joint models 
including TOP2A and SimRS are shown in the table.
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Dataset Adjuvant  Therapy TOP2A
TOP2A  
(+SimRS)
SimRS 
(+TOP2A)
Low vs. High  
TOP2A  
in mid-range RS
Wang (N=192; 
Lancet, 2005)
None 1.58 (p=0.001) 1.2 (p=0.21) 1.54 (p=0.0007)
87% vs 50%  
(p=0.02)
Van de Vijver 
(N=212; NEJM, 
2002)
C+/-H  
(N=110),  
H (N=20)
1.62 (p=0.0001) 1.30 (p=0.06) 1.55 (p<0.0001)
79% vs 70%  
(p=0.88)
Desmedt 
(N=124, CCR, 
2007)
None 1.83 (p=0.001) 1.63 (p=0.02) 1.23 (p=0.20)
85% vs 58%  
(p=0.03)
Loi (N=224, 
JCO 2007)
Tamoxifen 1.41(p=0.004) 1.15 (p=0.33) 1.37 (p=0.01) 87% vs 80%  
(p=0.24)
Pooled As above 1.56 (p<0.0001) 1.26 (p=0.003) 1.44 (p<0.0001) 1.82 (p=0.007)
Abbreviations: c-chemotherapy, H - hormonal therapy
TOP2A expression was significantly associated with recurrence in 
all 4 datasets when evaluated individually (HR 1.56, p<0.0001 in 
pooled analysis), and 2 of 4 datasets individually when adjusted 
for SimRS (HR 1.26, p=0.003 in pooled analysis). SimRS was 
significantly prognostic when adjusted for TOP2A individually in 3 
of 4 datasets (HR 1.44, p<0.0001 in pooled analysis). For those with 
an intermediate SimRS, five year RFS rates were significantly higher 
in 2 datasets individually for high vs. low TOP2A expression (HR 
1.82, p=0.007 in pooled analysis).
Conclusions: This analysis provides additional evidence that TOP2A 
expression provides prognostic information in patients with ER-
positive, HER2-negative disease, a population known to have low 
incidence of TOP2A gene alterations. These findings also suggest 
that TOP2A expression provides information that is complementary 
to RS, and may be useful for identifying high risk subjects who have 
a mid-range RS. These findings require prospective validation in 
other prospective or prospective-retrospective trials using the actual 
rather than simulated RS.
P2-12-14
Prognostic Value of HER2 Positivity and Negative Hormonal 
Status in Patients with Small Tumor (<1cm) and Node-Negative 
Breast Cancer.
Meattini I, Livi L, Saieva C, Agresti B, Scotti V, Nori J, Sanchez 
LJ, Vezzosi V, Bianchi S, Cataliotti L, Biti G. Florence University, 
Florence, Italy; Cancer Prevention and Research Institute, Florence, 
Italy
Introduction. Human epidermal growth factor receptor 2 (HER2) 
amplification has become the prototype biomarker to develop tailored 
biological treatment. Many studies suggested that HER2 positivity 
is an independent predictor of disease recurrence and breast cancer 
mortality. Trastuzumab has been introduced into clinical practice for 
high-risk HER2-positive patients who have completed the standard 
adjuvant treatment.
However, small (<1cm), node-negative tumors remain a subgroup of 
HER2-positive patients who are currently ineligible for trastuzumab 
treatment, as clinically they have been deemed to have no requirement 
for standard adjuvant chemotherapy.
The aim of our analysis was to evaluate the prognostic factors of 
local and distant recurrence in patients diagnosed with T1a-b, node-
negative, HER-2 positive breast cancer.
Materials and methods. A total of 704 patients were diagnosed at 
Florence University between November 1999 and December 2008 
with node-negative, invasive BC that were 1 cm or smaller. Patients 
with ductal carcinoma in situ, with recurrent BC at presentation and 
patients that received adjuvant chemotherapy were excluded from 
analysis.
Results. Mean follow-up was 4.9 years (0.5 – 10.8 years); we recorded 
a total of 19 recurrences, including 10 distant recurrences. Mean time 
to local relapse occurrence was 3.8 years (0.4 – 7.3 years); mean 
time to distant metastases diagnosis was 4.4 years (1.4 – 7.6 years).
Among all patients, the recurrence-free survival (RFS) was 93.7%. 
The only parameter that emerged as significant predictor of events 
is the age (p=0.02).
The distant recurrence-free survival (DRFS) rate was 96.5%. Patients 
who had HER2-positive BC had worse DRFS than patients who had 
HER2-negative BC (92.0% v 96.9%; p=0.045). In addition to HER2, 
also HR status was significantly associated with DRFS (p=0.026). 
Patients who had HR negative status had worse DRFS than patients 
who had HR positive status (91.4% v 97.4%; p=0.045).
Conclusions. Patients with T1a-b, node-negative, breast cancer 
have a low risk of distant and local recurrence. Women with HER2-
positive and negative hormonal status have a significant risk of distant 
recurrence and should be considered for anti-HER2 adjuvant therapy.
P2-12-15
GAINS: A Breast Cancer Prognostic Index Utilizing Lymph 
Node Ratio.
Dorairaj JJ, Wall D, Newell J, Blamey RW, Sweeney KJ, Ball G, Kerin 
MJ. National University of Ireland, Galway, Ireland; Breast Institute, 
Nottingham City Hospital, Nottingham, United Kingdom; Nottingham 
Trent University, Nottingham, United Kingdom
Introduction: Axillary lymph node status is an important predictor 
of overall survival (OS), hence its inclusion in clinical prognostic 
tools. The Nottingham Prognostic Index (NPI) which incorporates 
Lymph Node (LN) stage, tumor size and grade generates a score 
which predicts a percentage 10-year survival. Despite its status as 
a benchmark model for breast cancer prognosis, newer prognostic 
factors do exist. Lymph Node Ratio (LNR) is a superior prognostic 
indicator compared to absolute positive lymph node number, 
warranting re-evaluation of breast cancer prognostication. The 
aims of this study were threefold: identify the strength of LNR as a 
prognostic indicator compared to LN stage and NPI; establish a new 
prognostic index (Galway Index of Survival [GAINS]), taking into 
account the effect of LNR and breast cancer subtype on traditional 
clinicopathological features in breast cancer prognostication; and 
evaluate the prognostic efficacy of the new index compared to NPI.
Methods: Two cohorts were used: Galway Cohort-a prospectively 
compiled cohort of 1668 cases with histologically proven Stage 1, 
2 and 3 primary operable breast cancer treated between 1990-2010 
in a single institution; and ONCOPOOL-a retrospectively compiled 
database of 16944 cases treated across 12 European breast cancer units 
between 1990-1999. A Cox Proportional Hazards model was fitted to 
evaluate the strength of LNR compared to LN stage (within the NPI 
model) in both cohorts. The effect of clinicopathological variables on 
OS was analyzed using multivariable analysis in the Galway cohort. 
Three models were created (Model 1: Traditional prognostic variables 
excluding NPI and LNR; Model 2: Model 1 and LNR; Model 3: Model 
1 and NPI) and compared using Likelihood-ratio tests.
Variables evaluated within regression models
Model Variables
1 Age,Menopausal Status,Grade,Histological Subtype,Size,LN Stage,Metastasis,Stage,Mole
cular subtype (based on immunohistochemistry),ER/PR/HER2 status
2 Variables in Model 1 and LNR
3 Variables in Model 1 and NPI groups
Stepwise variable selection was used to identify the best model to 
create a prognostic index and performance of the two indices was 
evaluated using Receiver Operating Curves (ROC).
Results: Controlling for tumor size and histological grade, LNR 
is a stronger prognostic factor than LN Stage in both the Galway 
(b values of 1.2 and 0.3 respectively) and ONCOPOOL (b values 
of 1.3 and 0.3 respectively) cohorts, with LNR rendering LN stage 
non significant (p=0.135) in the former. In the Galway cohort, 
separate comparisons of Model 2 and 3 with Model 1 demonstrated 
that traditional clinicopathological variables in addition to LNR 
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(Model 2) best predicted OS (p=0.019). Within Model 2, LNR was 
a significant predictor of survival (p=0.014, Hazard Ratio 7.4). Age, 
LNR, stage and molecular subtype were significant prognostic factors, 
and corresponded to distinct survival patterns when included in the 
new prognostic index. GAINS performed almost identically to NPI, 
with similar areas under the curve (AUC) (GAINS AUC=0.745 
[95%CI0.67-0.82]; NPI AUC=0.742 [95%CI0.67-0.82]).
Conclusion: LNR is a better prognostic indicator compared to LN 
Stage. GAINS performs just as well as NPI as a prognostic index and 
has the potential for clinical utility given further validation.
P2-12-16
HER2 Expression Is the Major Risk Factor for Recurrence in 
pT1a-b,N0 Breast Cancer: A French Regional Population-Based 
Study of 671 Patients.
Rouanet P, Daures JP, Roger P, Mathieu A, Romieu G, Cretin J, 
Barneon G, Granier M, Maran-Gonzalez A, Thibault S, Boissiere 
F, Bibeau F. Val d’Aurelle Cancer Institute, Montpellier, France; 
Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, 
France; ONCO LR Regional Network, Montpellier, France
Background
To evaluate the prognostic impact of HER2 overexpression in patients 
with pT1a-b, node negative, breast cancers.
Patients and Methods
A population of 1127 patients whose diseases were staged as pT1a-b, 
pN0 and who were treated in the Languedoc-Roussillon (ONCO LR 
Southern French regional network) from 1999 to 2004, was identified. 
95% of patients had conservative management, no patient received 
adjuvant trastuzumab, 5% received chemotherapy and 80% anti-
estrogen endocrine therapy. HER 2 status was retrospectively assessed 
by immunohistochemistry in 671 patients (122 pT1a/549 pT1b). 
Kaplan-Meier method was used to estimate disease-free survival 
(DFS). Cox proportional hazard models were used to determine 
associations between HER2 status and disease-free survival adjusting 
on variables significantly linked to it.
Results
9-year Overall survival was 95%. HER2 overexpression (3+) was 
observed in 5.2% of the patients (n=35).
HER2 3+ category was most frequently identified in the following 
sub groups: pT1a lesion (12.3% vs 3.6%; p: 0.0001), mastectomies 
(14% vs 4.4%; p:0.023), Grade 2-3 (91% vs 50%; p<0.0001), 
estrogen receptor (ER) negative (-) tumors (57% vs 30%; p<0.0001), 
progesterone receptor (PR) – tumors (74% vs 42%; p: 0.0002). HER2 
3+ was less frequent with adjuvant hormonal treatment (43% vs 80%; 
p<0.0001). 33 relapse (5%) were observed with a median follow-up 
of 6.4 years (range, 0.3 to 9.9 years). The 5-year DFS rates were 78% 
and 95% in patients with HER2-positive and HER2-negative tumors, 
respectively (p:0.017).
According to the immunohistochemical phenotype DFS5 were 95%, 
94%, 85%, 73.6% for ER+/PR+/HER2- (n:502/75%), ER-/PR-/
HER2- (n:134/20%), ER+/PR+/HER2 3+ (n:15/2%) and ER-/PR-/
HER2 3+ tumors (n:20/3%), respectively (p:0.02).
In univariate analysis, HER2 positive tumors (p:0.017), phenotype 
classification (p:0.02) and adjuvant treatment (p:0.013) were 
significant prognostic factors. In multivariate analysis, only patients 
with HER2 3+ tumors had higher risks of recurrence (hazard ratio 
[HR], 2.41; 95% CI: [1.06-5.53]; p<0.05) than those with HER2 - 
tumors.
Discussion
Node-negative, pT1a-b, breast cancer patients overexpressing HER2 
have a significant risk of recurrence at 6 years median follow-up. In 
our series of small breast tumors, HER2 status seems to be a better 
prognostic factor than ER status. In patients with hormone receptor–
positive diseases, HER2 positivity is associated with a worse DFS 
despite an anti-estrogen treatment.
P2-12-17
Prospective Evaluation of the Conversion Rate of HER2, ER and 
PR between Primary Tumors and Corresponding Metastases. 
CONVERTHER/GEICAM 2009-03 Study.
Martinez de Dueñas E, Lluch A, Guerrero A, Chacon JI, Perez 
R, Antolin S, Blancas I, Ferrer-Lozano J, Burgues O, Lopez A, 
Gonzalez-Angulo AM. Hospital Provincial de Castellon, Castellon, 
Spain; Hospital Clinico Universitario de Valencia, Valencia, Spain; 
Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Virgen 
de la Salud de Toledo, Toledo, Spain; Hospital Universitario Quiron, 
Madrid, Spain; Complejo Hospitalario Universitario A Coruña, A 
Coruña, Spain; Hospital Clinico San Cecilio de Granada, Granada, 
Spain; MD Anderson Cancer Center, Houston, TX
Introduction: A substantial number of small studies, most 
retrospective, have shown variable degrees of discordance in HER2, 
ER and PR expression between primary and metastatic breast 
cancer. This may have prognostic and therapeutic implications. 
These discordances could be triggered by tumor somatic mutations, 
intratumoral heterogeneity, or technical issues with receptor assayes. 
In this prospective study, we centrally analyzed and determined the 
changes in receptor status between primary tumor and corresponding 
metastases.
Methods: In 32 Spanish hospitals, patients where primary tumor 
sample was available, were prospectively included prior to the biopsy 
of the presumably metastatic lesion. Determinations of ER and PR 
status (assessed by immuhistochemistry [IHC]) and HER2 status 
(IHC and FISH) were centrally and blindly performed in both primary 
tumor and metastases. Concordance rate between local laboratories 
and central laboratory receptor determinations were analyzed. We 
also determined whether the biopsy results modified the oncologist 
initial treatment strategy.
Results: A total of 236 patients were included. To today, 183 paired 
cases were centrally evaluated. Patients in first recurrence were 
65% and the mean age was 57.2 years. Biopsy samples were taken 
from locoregional recurrence (25%), liver metastases (28%), bone 
metastases (11%), lung metastases (7%) and other locations (29%). 
In 6.6% of the biopsies normal tissue, benign lesion or secondary 
malignant neoplasm were seen. The changes in HER2, ER and PR 
were 17%, 26% and 35% (local lab) and 4%, 12% and 26% (central 
lab), respectively; and were independent of treatment given or 
biopsy localization. Concordance rate in HER2, ER and PR between 
local and central determination were 83%, 92% and 78% (kappa 
index 0.58, 0.80 and 0.55), respectively. Changes in receptor status 
lead to a modification in medical management in 16% of patients.
Conclusions: A remarkable discordance in receptor status, especially 
in the hormonal receptors, was found between primary tumor and 
metastases that implies a change in medical management in 16% 
of patients. These discordances were reduced but remained after 
performing in a high-quality central laboratory, so that they could only 
be partly explained by technical discrepancies in receptor assessments.
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P2-12-18
A Prognostic Model Based on Node Status, Cathpesin-D and Ki-67 
Predict the Outcome of Patients Failing To Achieve Pathological 
Complete Response after Anthracycline-Based Neoadjuvant 
Chemotherapy for Breast Cancer.
Chen S, Chen C, Yu K, Shao Z. Shanghai Cancer Hospital, Fudan 
University, Shanghai, China
Background: Aim of this study was to evaluate factors which could 
possibly affect the outcome of patients failing to achieve pathological 
complete response (pCR) after anthracycline-based neoadjuvant 
chemotherapy (NCT) for breast cancer, and built a prognostic model 
to predict disease free survival (DFS) and overall survival (OS).
Material and Methods: We retrospectively collected data of 
199 stage II-III breast cancer patients who had failed to achieve 
pathological complete response after neoadjuvant chemotherapy in 
Shanghai Cancer Hospital. The NCT regimens were NE (navelbine 
25mg/m2, day 1, 8 and epirubicin 60mg/m2, day 1; every three weeks) 
or CEF (cyclophosphamide 600 mg/m2, day 1; epirubicin 60 mg/m2, 
day 1 and 5-fluorouracil 600 mg/m2, day 1; every three weeks) for a 
median treatment course of 3 cycles. To develop the prognostic model, 
variables at baseline(age, menopausal status, tumor size, node status, 
ER, PR, and HER-2) and at surgery(tumor size, grade, histotype, 
node status, vascular invasion, ER, PR, HER-2, Cathpesin-D, P53, 
Topo-IIa, Nm-23, Bcl-2, BAX, MDR, GSTn, PS2, P27, Cyclin D1 
and Ki-67) were investigated. Multivariate Cox regression model 
and Kaplan-Meier method was used to build the model, and show the 
discrimination of DFS and OS in different risk groups.
Results: By multivariate analysis, ≥4 lymph node metastasis (HR=1.9, 
P=0.009), Cath-D positive (HR=2.5, P=0.006), and Ki-67 index≥20% 
(HR=1.9, P=0.001) at surgery were independent predictors for lower 
DFS and OS rate among non-pCR responders. We built a prognostic 
scoring model on the basis of these variables, in which ≥4+ nodes, 
Cath-D + or Ki-67 index≥20% would contribute 1 point separately 
to the risk score. The 5-year DFS rates in low(0 point), intermediate-
low(1 point), intermediate-high(2 points) and high risk groups(3 
points) were 94%, 65%, 43%, and 28%, respectively (Log-rank teat 
p<0.001). The 5-year OS rates in these four groups were 94%, 84%, 
66% and 34%, respectively (Log-rank test p<0.001).Conclusion: 
Post-NCT node status, Cathpesin-D and Ki-67 were used to develop 
a prognostic model which could simply discriminate patients with 
poor prognosis among non-pCR responders after anthracycline-
based neoadjuvant chemotherapy, and might help to tailor further 
individualized treatment strategies.
P2-12-19
Nomogram To Predict Recurrence and To Avoid Unnecessary 
Adjuvant Chemotherapy Based on Ki67 Index and ER Status 
in Hormone Receptor (HR)-Positive Breast Cancers with Low 
Number of Nodal Metastases (≤3) (NCT01273415).
Park YH, Im S-A, Cho EY, Ahn JH, Kim S, Keam B, Han W, Park IA, 
Noh D-Y, Lee JE, Nam SJ, Yang JH, Ahn JS, Im Y-H. Samsung Medical 
Center; Seoul National University College of Medicine
Background: Hormone receptor (HR) positive breast cancers 
characterized with ER-associated genes are differentiated luminal B 
from luminal A tumors mainly by proliferation genes. According to 
NCCN guideline 2011, node positivity has been a main determinant 
to decide adjuvant chemotherapy with category 1. However, the 
experts’ panel at the St. Gallen Consensus in 2009 do not provides 
definite indications to give or withhold chemotherapy in patient 
group with intermediate criteria including low numbers (1-3, N1) 
of involved lymph nodes. Thus, in cases of limited number of nodal 
metastases, the role of biologic factors including Ki67 index needs to 
be defined. The aims of this study are to evaluate of Ki67 index as a 
useful surrogate marker to predict recurrence and to avoid unnecessary 
adjuvant chemotherapy and to develop nomogram based on Ki67 
index to determine adjuvant therapeutic options in HR-positive in 
N0 and N1 breast cancers.
Patients and Methods: We retrospectively analyzed the 
clinicopathologic characteristics and outcomes of 953 postoperative 
HR-positive N0 and N1 breast cancer patients between 2004 and 2007 
at the Samsung Medical Center. We constructed nomogram based 
on Cox regression model using independent factors demonstrated 
in multivariate analysis and validated externally in a cohort of 895 
patients treated at Seoul National University Hospital.
Results: In Cox regression multivariate analysis, ER–ve/PgR+ve and 
Ki67 index were identified as independent factors.
Multivariate Cox-regression analysis on RFS
 P value Hazard Ratio 95% CI
ER negative/PR positive 0.016 2.646 1.026-6.827
Ki67 (categotical variable) <0.0001   
0-1+ <0.0001 0.000 0.000
2+ <0.0001 0.114 0.047-0.286
3+ 0.007 0.287 0.120-0.751
4+ 0.522 0.753 0.317-1.826
RFS: Recurrenc free survival, 95% CI: 95% confidence interval
Nomogram base on Cox-regression model showed an AUC of 0.75 
(95% CI, 0.72-0.77) in the training set. The validation set showed a 
good discrimination with an AUC of 0.63 (95% CI, 0.60-0.66). We 
defined low nomogram score as less than 53, and high nomogram 
score as 53 or more from the cut-off value of the nomogrma ROC 
curve. Patients who received anthracycline-containing adjuvant 
chemotherapy with high nomogram scores showed better RFS with 
statistical significance than those who did not receive anthracycline-
containing adjuvant chemotherapy with high nomogram scores 
(p<0.0001). In contrast, the patients with low nomogram scores 
did not show any benefit from anthracycline-containing adjuvant 
chemotherapy (p=0.804). When the patients with high nomogram 
scores divided into two groups according to Allred ER scores (0-4 vs 
5-8), the patients with high ER Allred scores (5-8) and high nomogram 
scores did not show any benefit from anthracycline-containing 
chemotherapy (p=0.283). Main benefit from adjuvant chemotherapy 
is focused on the patients with low ER Allred scores (0-4) and high 
nomogram score (p=0.022).
Conclusion: Ki67 index is useful as a valuable surrogate marker 
to predict recurrence and to avoid unnecessary chemotherapy. 
Nomogram based on Ki67 index is constructed and validated to 
determine adjuvant therapeutic options in HR-positive N0 and N1 
breast cancers.
P2-12-20
Adjuvant! Online Is Overoptimistic in Predicting Survival of 
Asian Breast Cancer Patients.
Bhoo Pathy N, Yip CH, Hartman M, Saxena N, Taib NA, Bulgiba AM, 
van der Graaf Y, Verkooijen HM. University of Malaya; University 
Medical Center Utrecht; Ministry of Health Malaysia; National 
University of Singapore; Karolinska Institutet
Background: Adjuvant! Online is a free web-based tool which 
predicts 10-year breast cancer outcomes and efficacy of adjuvant 
therapy in patients with breast cancer. As its prognostic performance 
has only been validated in high income Caucasian populations, the 
model was validated in a middle income Asian setting.
Material and Methods: Within the University Malaya Hospital-
Based Breast Cancer Registry, all 631 women receiving standard 
surgery for invasive non-metastatic breast cancer between 1993 and 
2000 were identified. Calibration of Adjuvant! Online was evaluated 
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by comparing the predicted 10-year overall survival with observed 
10-year survival. Discrimination of the model was tested by receiver 
operating characteristic (ROC) analysis.
Results: For the entire cohort, Adjuvant! Online predicted 10 year 
survival (70.3%) was significantly higher than the observed 10 years 
survival (63.6 %) by a difference of 6.7% (95%CI: 3.0%- 10.4%). 
The model was especially overoptimistic in women under 40 years 
and in women of Malay ethnicity, where survival was overestimated 
by approximately 20% (95%CI: 9.8- 29.8%) and 15% (95%CI: 5.3- 
24.5%) respectively.
Calibration of Adjuvant! Online in 631 South East Asian Women with Breast Cancer
 Number (%) Overall Survival (%)
  Adjuvant!  Predicted Observed (SE)
Predicted – 
Observed (95%CI)
P value¹
All patients 631 (100) 70.3 63.6 (1.9) 6.7 (3.0 to 10.4) <0.001
Age (years)      
<40 96 (15.1) 75.6 55.8 (5.1) 19.8 (9.8 to 29.8) <0.001
40-64.9 469 (74.3) 71.9 67.3 (2.2) 4.6 (3.7 to 8.9) 0.037
≥65 67 (10.6) 51.8 49.0 (6.2) 2.8 (-9.4 to 15.0) 0.653
Ethnicity²      
Chinese 422 (67.6) 71.6 67.7 (2.3) 3.9 (-0.6 to 8.4) 0.091
Malay 106 (17.0) 71.2 56.3 (4.9) 14.9 (5.3 to 24.5) 0.003
Indian 96 (15.4) 64.9 55.5 (5.1) 9.4 (-0.6 to 19.4) 0.068
Tumor size (cm)      
<2 123 (19.5) 81.5 80.0 (3.7) 1.5 (-5.8 to 8.8) 0.686
2-5 385 (61.0) 71.4 64.2 (2.5) 7.2 (2.3 to 12.1) 0.004
>5 123 (19.5) 55.8 45.9 (4.5) 9.9 (1.1 to 18.7) 0.030
Lymph node involvement      
No 329 (52.1) 79.8 77.8 (2.3) 2.0 (-2.5 to 6.5) 0.385
Yes 302 (47.9) 60.0 48.5 (2.9) 11.5 (5.8 to 17.2) <0.001
Estrogen receptor status      
Positive 262 (41.5) 78.0 72.6 (2.8) 5.4 (-0.1 to 10.9) 0.055
Negative 212 (33.6) 61.0 51.2 (3.5) 9.8 (2.9 to 16.7) 0.006
Unknown 157 (24.9) 70.2 65.3 (3.8) 4.9 (-2.5 to 12.3) 0.199
Grade      
Low 73 (11.6) 82.6 85.9 (4.1) -3.3 (-11.3 to 4.7) 0.424
Moderate 243 (38.5) 72.5 63.3 (3.1) 9.2 (3.1 to 15.3) 0.003
High 158 (25.0) 64.2 53.8 (4.0) 10.4 (2.6 to 18.2) 0.010
Unknown 157 (24.9) 67.5 63.7 (3.9) 3.8 (-3.8 to 11.4) 0.331
Chemotherapy      
Yes 396 (62.8) 69.7 59.6 (2.5) 10.1 (5.2 to 15.0) <0.001
No 235 (37.2) 71.4 70.6 (3.0) 0.8 (-5.1 to 6.7) 0.790
Hormone therapy      
Yes 458 (72.6) 72.1 66.3 (2.2) 5.8 (1.5 to 10.1) 0.009
No 173 (27.4) 65.7 56.5 (3.8) 9.2 (1.8 to 16.6) 0.017
SE = standard error. ¹ Derived using a one-sample t- test for proportions, based on the assumption 
that the Adjuvant! Online predicted survival is the true population value. ² Excluding patients from 
other races (n=7). 
Adjuvant! Online performed fairly in terms of discrimination, with 
an area under ROC curve of 0.73 (95%CI: 0.69-0.77).
Conclusion: Even though Adjuvant! Online is capable of 
discriminating between good and poor survivors, it systematically 
overestimates survival. These findings suggest that the model requires 
adaptation prior to use in Asian settings.
P2-12-21
Impact of Recent Parity on Histopathological Tumor Features 
and Outcome of Young Women with Breast Cancer.
Nagatsuma AK, Shimizu C, Tsuda H, Saji S, Hojo T, Sugano K, 
Fujiwara Y. National Cancer Center Hospital; Saitama Medical 
University International Medical Center; Tochigi Cancer Center 
Research Institute
Background: Younger age has been associated with worse 
outcome in breast cancer patients (pts) and recent parity has been 
epidemiologically identified as worse prognostic factor among women 
with breast cancer. The objective of this study was to explore potential 
factors associated with worse prognosis in young breast cancer pts, 
and to demonstrate the impact of parity on the histopathological tumor 
feature and patient outcome.
Materials and Methods: We retrospectively analyzed 634 early 
breast cancer pts younger than 45 years old who underwent surgery 
between 2000 and 2009. For statistical analysis, Pearson’s and Fisher’s 
exact test were used. Survival analysis was performed only for pts 
diagnosed before 2006 in order to obtain a minimum follow up 5 years.
Results: 108 women were diagnosed within 5 years since last parity 
(Group A), 216 were diagnosed > 5 years since last parity (Group 
B) and 310 were nulliparous (Group C). Median age at diagnosis 
was 37 (range 26-44), 41 (range 32-44), and 38.5 (range 22-44) and 
family history (FH) of breast and/or ovarian cancer within second 
degree was found in 23, 22, and 23% of the pts in Groups A, B, 
and C, respectively. In Groups A, B and C, clinical stage was III in 
22, 10 and 12% (p= .025), ER was positive in 65, 69 and 70% (p= 
.650), PgR was positive in 64, 75 and 74% (p= .057), and HER2 was 
positive in 25, 14 and 14% (p=.017), respectively. Tumors in Group 
A had higher histological grade (grade 3: 60/44/47%, p=.019), higher 
nuclear grade (grade 3: 61/47/48%, p=.036) and more lymph vessel 
invasion (61/52/45%, p=.015) compared to those in Groups B and C, 
respectively. Median follow up time was 85.1 months (range 1.8-137.1 
months) during which there were 61 deaths. In univariate analysis, age 
and FH were not correlated with overall survival (OS). OS in Group 
A was significantly lower than in Group B (hazard ratio (HR) 3.51, 
95% confidential interval (CI) 1.80-6.84, p<.001) and in Group C (HR 
2.42, 95%CI 1.36-4.29, p=.002), while OS did not differ significantly 
between Groups B and C. In the pts without FH, the HR of cancer 
death was more pronounced in Group A than in Group B (HR 4.25, 
95%CI 1.97-9.14, p<.001) or Group C (HR 2.67, 95%CI 1.43-5.01, 
p=.002), while there was no significant difference among the groups 
in pts with FH. In multivariate analysis among the pts without FH, 
lymph vessel invasion (HR 4.51, 95%CI 1.89-10.76, p=.001), Group 
A women (HR 2.28, 95%CI 1.25-4.17, p=.007), histological grade 
3 (HR 2.72, 95%CI 1.28-5.77, p=.009), PgR negativity (HR 2.23, 
95%CI 1.19-4.18, p=.013) and clinical stage II and III (HR 2.92, 
95%CI 1.04-8.21, p=.04) were significantly associated with poor 
prognosis, adjusting for age.
Conclusion: Recent parity was associated with worse histopathological 
features in breast cancer of women younger than 45. It was also 
associated with worse outcome, especially among pts without FH. 
Recent parity seems to be a confounding factor for the worse outcome 
in young breast cancer patients, which justifies further studies to 
elucidate underlying biology.
P2-12-22
A Prognostic Index Composed of Progesterone Receptor 
Status, Tumour Size and S-phase Fraction, Predicts Survival in 
Node-Negative Breast Cancer Patients in a Large Multicentre 
Prospective Cohort Study.
Klintman M, Nilsson F, Bendahl P-O, Fernö M, Liljegren G, Emdin 
S, Malmström P. Clinical Sciences, Lund University and Skane 
University Hospital, Lund, Sweden; University of Umeå and Umeå 
University Hospital, Umeå, Sweden; Örebo University Hospital, 
Örebro, Sweden
Background: The importance of the added prognostic value of 
proliferation, either single factors such as Ki67 or flow cytometric 
S-phase fraction (SPF), or as the main common denominator in the 
majority of gene expression profiles, has been highlighted over the last 
years in node-negative breast cancer. There are however few published 
prospective studies. In an earlier retrospective study on node-negative 
breast cancer from our group, a prognostic index consisting of PR 
status, tumour size and a proliferation factor, SPF, identified one third 
of the patients as high risk, with a fourfold increased risk of distant 
recurrence. The present study was set up to validate this index in a 
large prospective multicenter cohort study with long term follow-up.
Material and Methods: 596 patients from 3 regions in Sweden 
were between 1991-1995 included in the study. Inclusion criteria 
were: 10mm≤tumour size≤50mm, node-negativity, ≥5 lymph nodes 
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removed, age <60 years, and radical surgery. Patients with bilateral 
breast cancer or previous malignancy were excluded. Prospective 
analyses of ER, PR, and flow cytometric SPF were performed. 
High- risk was defined as 2 or more of the following: 1. size >20mm 
2. PR- (in the absence of PR status, ER-) and 3. high SPF (in the 
absence of SPF, Bloom Richardson grade 3). 82% of the patients 
received no adjuvant medical treatment. Cox proportional hazards 
regression, stratified for centre, was used to model the impact of the 
index on breast cancer specific survival (BCSS). Median follow-up 
was 16 years for the 452 patients alive at last follow-up. Analyses 
were done after 5 and 10 years follow-up, during which 42 and 95 
patients, respectively, died of breast cancer.
Results: 31% of the patients were identified as high-risk. In univariate 
analysis, the index was prognostic for BCSS after 5 years (HR 5.1, 
95%CI: 2.7-9.8,) as well as 10 years (HR 2.2, 95%CI: 1.5-3.4). The 
prognostic impact remained significant after adjustment for adjuvant 
medical treatment and age. The 5- and 10-year BCSS (95%CI) was 
97% (94-98) and 87% (83-90) for low risk patients, compared with 
85% (79-89) and 76% (69-81) for high risk patients. In the group with 
no risk factors (n=218 ), no patient died of breast cancer during the 
first 5 years. Proliferation was the strongest factor for BCSS followed 
by PR and tumour size, both in uni- and multivariate analyses. In 
multivariate analysis, adjusted for adjuvant treatment and age, the 
HR for proliferation was 7.5 (95%CI: 3.2-18) after 5 years and 2.5 
(95%CI: 1.6-4.0) after 10 years.
Discussion: This large prospective multicenter cohort study validates 
the results from an earlier retrospective study, that a prognostic index 
consisting of PR status, tumour size and a proliferation factor, SPF, 
reliably identifies one third of the node-negative patients with a high 
risk of relapse. The index also identifies an extreme low risk group; 
patients with no risk factors, with 100% 5-year survival. This group 
could be spared adjuvant medical treatment, especially chemotherapy. 
Taken together, this index may be clinically helpful for prognostic 
considerations and for selection of adjuvant treatment.
P2-12-23
How Should We Assess Tumour Size (T Stage) in Patients with 
Multicentric/Multifocal Breast Cancer? Results from the NCIC 
CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal 
Women with Node Positive Breast Cancer.
Bouganim N, Dong B, Hilton JF, Chapman J-AW, Arnaout A, O’Malley 
F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan 
T, Pritchard KI, Shepherd L, Clemons M. The Ottawa Cancer Center, 
Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; 
The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-
University of Toronto, Toronto, ON, Canada; Vancouver Hospital and 
Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency- 
University of British Columbia, Vancouver, BC, Canada; Juravinski 
Cancer Center-McMaster University, Hamilton, ON, Canada; Tom 
Baker Cancer Center-University of Calgary, Calgary, AB, Canada; 
Odette Cancer Center-University of Toronto, Toronto, ON, Canada
Background: A common clinical conundrum in breast cancer 
management is whether pathologic T stage in women with 
multicentric or multifocal disease should be taken as the diameter of 
the largest focus or as the sum of all foci in the breast. Most staging 
systems, such as the American Joint Committee on Cancer (AJCC), 
simply use the largest tumour focus for staging. We examine here 
the impact of alternate methods of estimating tumour size including 
measures of total tumour size, volume and surface area.
Methods: NCIC CTG MA.5 is a randomized trial of CEF versus 
CMF in pre-menopausal women with node positive breast cancer. 
Median follow up is 10 years. Pathologically reported patient tumour 
dimensions for up to 3 foci were utilized to examine the effects of 
tumour size on Breast-Cancer-Free-Interval (BCFI). BCFI is defined 
as the time from randomization until recurrence: first local invasive 
or DCIS, regional, distant, contralateral invasive or DCIS. Tumour 
size was estimated as 1) pathologic T stage as per AJCC criteria; 2) 
largest dimension of largest tumour focus (cm); 3) sum of largest 
dimension(s) of tumour foci (cm); 4) sum of surface area(s) of tumour 
foci (cm2) , and 5) sum of volume of tumour foci (cm3). Step-wise 
forward unstratified Cox regression was used to assess the different 
effects of tumour size.
Results: This study accrued 710 patients, 37% with T1 tumours, 52% 
with T2 tumours and 9% with T3 tumours; 61% had 1 to 3 positive 
lymph nodes. 59% hormone receptor positive . Higher pathologic T 
stage (p=0.001) and greater surface area (p=0.02) were associated 
with shorter BCFI, as was lymphovascular invasion (p=0.03), and # 
of lymph nodes involved (p<0.0001). Administration of anthracycline 
therapy led to significantly longer BCFI (0.003). The sum of largest 
tumour sizes (p=0.33) and sum of tumour volume (p=0.34) were 
not significantly associated with BCFI. Additionally, when the less 
complete locally reported tumour grade data were included, higher 
tumour grade was associated with shorter BCFI (p<0.0001).
Conclusions: Consideration of multicentric and multifocal disease 
was an important adjunct to standard pathologic tumour size as was 
estimation of tumour surface area in this chemotherapy trial of node 
positive premenopausal women. However, simply adding together 
the diameters of tumours in patients with multicentric or multifocal 
disease did not add any additional prognostic information in this high 
risk patient population.
P2-12-24
Resumption or Persistence of Menstruation after Cytotoxic 
Chemotherapy Is a Poor Prognostic Factor for Disease Free 
Survival in Premenopausal Patients with Early Breast Cancer.
Park IH, Han H-S, Lee KS, Kang HS, Lee S, Kim SW, Jung SY, Shin 
KH, Ro J. National Cancer Center, Goyang, Korea; Chungbuk 
National University, Korea
Background
We investigated the relationship between resumption or persistence 
of menstruation after chemotherapy and disease free survival (DFS) 
in premenopausal patients with early breast cancer.
Patients and methods
A total of 843 patients diagnosed with a stage I to III breast cancer 
between March 2001 and December 2006 were included in this study. 
All patients received cytotoxic chemotherapy after surgery; 411 
(48.8%) with anthracycline based, 416 (49.3%) with anthracycline and 
taxane containing, and 16 (1.9%) with other regimens. We reviewed 
the medical records with a long term follow-up.
Results
The median age of patients was 41 years (range, 21-54 years) and 
the median follow-up duration was 6.2 years (range, 0.7-10.4 years).
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Table 1. Patient characteristics
Variables No. of patients (%)
Age (median yr, range) 41 (21-54)
Hormone receptor  
Positive 632 (75%)
Negative 211 (25%)
HER2 receptor  
Positive 133 (15.8%)
Negative 415 (49.2%)
Not known 295 (35%)
Stage  
I 209 (24.8%)
II 438 (52%)
III 189 (22.4%)
Not known 7 (0.8%)
Body Mass Index (BMI)  
<18.5kg/m2 37 (4.4%)
18.5-22.9kg/m2 431 (51.1%)
≥ 23kg/m2 374 (44.4%)
Missing 1 (0.1%)
Adjuvant chemotherapy  
Anthracycline based 411 (48.8%)
Taxane containing 416 (49.3%)
Others 16 (1.9%)
Adjuvant hormonal therapy 621 (73.7%)
CIA  
Present 658 (78.1%)
Absent 102 (12.1%)
Not known 83 (9.8%)
Resumption of period  
Yes 442 (52.4%)
No 401 (47.6%)
Of all, 632 (75%) patients were hormone receptor (HR) positive who 
received tamoxifen therapy upon completion of chemotherapy. The 
chemotherapy induced amenorrhea (CIA) rate was 78.1% (n=658) 
and 52.4% (n= 442) experienced the resumption of period during 
the long term follow-up. One hundred two (12.1%) patients had 
persistent menstruation without CIA. The disease free survival (DFS) 
was significantly affected by the younger age (≤ 35 years) (HR=1.58, 
[95% CI, 1.10-2.70], P=0.014), advanced stage (stage 3) (HR=4.45, 
[95% CI, 3.17-6.25], P<0.001), HR negativity (HR=2.21, [95% CI, 
1.57-3.12], P<0.001), HER2 positivity (HR=1.56, [95% CI, 1.04-
2.34], P=0.032), and the resumption or persistent period (HR=2.03, 
[95% CI, 1.42-2.91], P<0.001). HR negativity (HR=2.03, [95% CI, 
1.43-2.90], P<0.001), advanced stage (HR=4.40, [95% CI, 3.12-6.21], 
P<0.001), and the resumed or persistent period (HR=1.85, [95% CI, 
1.24-2.77], P=0.002) were remained significant factors for DFS on 
multivariate analysis.
Table 2. Analysis for disease free survival in all patients
Variable Univariate analysis  Multivariate analysis  
 HR (95% CI) P-value HR (95% CI) P-value
Age ≤ 35 years 1.58 (1.10-2.70) 0.014 1.07 (0.71-1.60) 0.752
Resumed/persistent period 2.03 (1.42-2.91) <0.001 1.85 (1.24-2.77) 0.002
Stage III vs. I/II 4.45 (3.17-6.25) <0.001 4.40 (3.12-6.21) <0.001
HR negativity 2.21 (1.57-3.12) <0.001 2.03 (1.43-2.90) <0.001
HER2 positivity 1.56 (1.04-2.34) 0.032 1.18 (0.78-1.79) 0.435
BMI <18.5kg/m2 0.66 (0.24-1.78) 0.412   
BMI ≥ 23kg/m2 1.05 (0.75-1.48) 0.767   
Conclusions
A considerable proportion of premenopausal patients treated 
by chemotherapy experienced resuming period after CIA. The 
resumption or persistence of menstruation was a poor prognostic 
factor for disease free survival in premenopausal patients with early 
breast cancer.
P2-12-25
Blinded Multi-Site Validation of a Pathology-Based Prognostic 
Marker Profile for Operable Hormone Receptor-Positive Breast 
Cancer.
Linke SP, Bremer TM, Man AK, Bloom KJ, Lawton TJ. Prediction 
Sciences, La Jolla, CA; Clarient, Inc., Aliso Viejo, CA; Seattle Breast 
Pathology Consultants, Seattle, WA
Background: We previously reported development and preliminary 
validation of a marker profile with a risk of recurrence algorithm 
for patients with operable hormone receptor (HR)-positive breast 
cancer using tissue microarrays. The profile includes ER, PR, HER2, 
EGFR, BCL2, and p53 (assessed by IHC) and MYC/8q24 (assessed 
by FISH). It also directly incorporates the standard clinicopathologic 
risk factors tumor size, tumor grade, and nodal status to the extent 
that their prognostic value is not replaced by the molecular markers. 
Here, we demonstrate validation of the profile in a blinded multi-site 
study conducted on whole sections.
Material and methods: The study was conducted in a blinded fashion 
using an independent data management firm (Synteract, Carlsbad, 
CA). Eligible patients were females diagnosed between 1985 and 1997 
with HR-positive stage I-IIIA breast cancer treated only with hormone 
therapy after definitive surgery for whom sufficient tumor samples 
were available for testing. Slides with FFPE tumor tissue sections 
and associated clinicopathologic, treatment, and outcome data were 
provided by four clinical sites through the NCI-funded Cooperative 
Breast Cancer Tissue Resource program: Fox-Chase Cancer Center 
(Philadelphia, PA) (n=106), Kaiser Permanente Northwest (Portland, 
OR) (n=165), University of Miami (FL) (n=55), and Washington 
University St. Louis (MO) (n=74). Marker assays, scoring, and 
calculation of risk scores using a predefined algorithm were conducted 
at Clarient, a CLIA-certified laboratory. The algorithm assigned a risk 
score to each patient on a scale of 0 to 10+, and a predefined threshold 
of 3.8 was used to separate patients into low and high risk groups.
Results: Complete data for all seven markers was obtained in 349 of 
the 400 patients. The algorithm defined 28% of the patients (n=99) 
as high-risk and 72% of the patients (n=250) as low-risk. The high-
risk and low-risk patient groups had 10-year distant metastasis rates 
of 34% and 9%, respectively, resulting in a hazard ratio of 4.7 (95% 
CI, 2.3-7.8, p<0.0001) through 10 years without an intermediate-risk 
group. Similar results were achieved when using disease-specific 
survival (death with evidence of breast cancer recurrence) as the 
outcome. Using a standard threshold score of 3.4, the Nottingham 
Prognostic Index (NPI) also stratified the patients (n=349) into low 
and high risk groups (p=0.03), but only 10% of the patients were in 
the low-risk category, and the profile further risk stratified patients in 
the NPI intermediate and high risk categories similar to the overall 
patient set (p<0.001). In multivariate Cox proportional hazards 
analysis with clinicopathologic factors, only the profile and tumor 
size were significant (Wald statistic p<0.001 for both).
Discussion: This blinded study, using a predefined algorithm and 
threshold, validates the prognostic and clinical utility of the multi-
marker profile to help guide the appropriate level of adjuvant treatment 
in breast cancer patients.
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P2-12-26
Impact of the Recurrence Score on Adjuvant Decision-Making in 
ER-Positive Early Breast Cancer – Results of a Large Prospective 
Multicentre Decision Impact Study in Node Negative and Node 
Positive Disease.
Rezai M, Eiermann W, Kümmel S, Kühn T, Warm M, Friedrichs K, 
Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, Jackisch C, 
Witzel I, Eidtmann H, Kaufmann M, Blohmer JU. Luisenkrankenhaus, 
Düsseldorf, Germany; Rotkreuzklinikum, München, Germany; 
Kliniken Essen-Mitte, Essen, Germany; Klinikum Esslingen, Esslingen, 
Germany; Krankenhaus Holweide, Köln, Germany; Brustzentrum, 
Hamburg, Germany; Universitätsklinikum, Heidelberg, Germany; 
Universitätsklinikum, Rostock, Germany; Universitätsklinikum, 
Magdeburg, Germany; Eilenriedeklinik, Hannover, Germany; 
Klinikum Offenbach, Offenbach, Germany; Universitätsklinikum 
Eppendorf, Hamburg, Germany; Universitätsklinikum, Kiel, 
Germany; Univesitätsklinikum, Frankfurt, Germany; Sankt 
Gertrauden-Krankenhaus, Berlin, Germany
Background: Oncotype DX® has become part of clinical routine in the 
diagnosis and decision-making progress in early breast cancer (EBC). 
Prospective data on its clinical use and impact on treatment decisions 
in ER-positive (ER+) node negative (N0) disease from various 
controlled clinical trials in different countries have been published 
recently. The Recurrence Score® (RS) has also been validated as a 
prognostic and predictive marker for patients with ER+ node positive 
(N+) disease. As of today no prospective data have been reported 
on its impact on decision making in these patients. We performed a 
large prospective study to evaluate RS-guided adjuvant therapy in 
N0 and N+ ER+ EBC.
Material and Methods: Patients (pts) with ER+, HER2-negative 
N0 and N+ (1-3 positive lymph nodes) EBC and no contraindication 
for adjuvant chemotherapy were included in the study. Physicians’ 
adjuvant treatment recommendations and their confidence in these as 
well as patients’ decisional conflicts were assessed before and after 
knowledge of the results of the test using standardized questionnaires. 
Actual treatment data were collected to perform pharmacoeconomic 
analyses. Analyses were performed on the per-protocol population 
for whom a Recurrence Score result and treatment recommendations 
pre and post-test were available.
Results: Overall 379 pts were recruited. In 11 pts Oncotype DX could 
not be performed and 2 pts dropped out leaving 366 pts in the per 
protocol population. Of these, 244 (66.7%) were N0 and 122 (33.3%) 
N+. Median age was 56 years (Range 25-85). Overall, 54.1% had 
low, 38.0% intermediate and 7.9% high RS values. For N0 disease, 
the distribution of RSs was 53.7%, 38.9%, 7.4% and for N+ disease 
54.9%, 36.9% and 9.0%, respectively.
Initial treatment recommendation changed in 33.1% of all cases; 
30.3% in N0 and 38.5% in N+ disease, and in 36.4% for pts with low, 
30.9% with intermediate and 20.7% with high RSs. In 21.6% of all 
pts a recommendation for adjuvant chemoendocrine therapy (CHT) 
was changed to endocrine therapy (HT), 10.7% of recommendations 
changed from HT to CHT. For N0 disease change rates were 18.4% 
from CHT to HT and 11.5% from HT to CHT. For N+ disease 
27.9% of recommendations changed from CHT to HT and 9.0% 
of recommendations changed from HT to CHT. In 25% of all, 22% 
of N0 and 39% of N+ pts initially recommended HT the post-RS 
recommendation changed to CHT; in 38% of all, 39% of N0 and 
37% of N+ pts initially recommended CHT the recommendation 
changed to HT.
Overall, physicians’ confidence increased in 45.1% of all (p=0.047) 
and 44.7 of N0 and 45.9% of N+ cases, respectively. There was 
a moderate decrease of the decisional conflict score in all pts and 
subgroups that reached statistical significance for all pts (p=0.029) 
and the low RS subgroup (p=0.003).
Conclusions: Results of this large prospective study show an 
impact of the RS on adjuvant treatment decision making in German 
clinical practice for patients with ER+ EBC. Recommendations were 
predominantly changed from chemoendocrine to endocrine adjuvant 
therapy resulting in a net reduction of chemotherapy usage. This effect 
was more pronounced for patients with 1-3 positive nodes.
P2-12-27
Simply Adding Together the Diameters of Tumor Foci in Patients 
with Multicentric or Multifocal Disease Does Not Add Any 
Additional Prognostic Information: An Analysis from NCIC 
CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen 
after Adjuvant Chemotherapy in Pre-Menopausal Women with 
Early Breast Cancer.
Hilton JF, Dong B, Bouganim N, Chapman J-AW, Arnaout A, O’Malley 
F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan 
T, Pritchard KI, Shepherd L, Clemons M. Queens University, Kingston, 
ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, 
ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, 
Canada; Vancouver Hospital and Health Sciences Centre, University 
of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, 
University of British Columbia, Vancouver, BC, Canada; Juravinski 
Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom 
Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; 
Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
Background: A common clinical conundrum in breast cancer 
management is whether pathologic T stage in women with 
multicentric or multifocal disease should be taken as the diameter of 
the largest focus or as the sum of all foci in the breast. Most staging 
systems, such as the American Joint Committee on Cancer (AJCC), 
simply use the largest tumor focus for staging. We examine here 
the impact of alternate methods of estimating tumour size including 
measures of total tumor size, volume and surface area.
Materials & Methods: NCIC CTG MA.12 is a randomized placebo-
controlled trial of tamoxifen after adjuvant chemotherapy for 
pre-menopausal women with early breast cancer. Median follow 
up is 9.7 years. Pathologically reported patient tumor dimensions 
for up to 3 foci were utilized to examine the effects of tumor size 
on Breast-Cancer-Free-Interval (BCFI), defined as the time from 
randomization until recurrence (defined as first local, regional, distant, 
or contralateral invasive tumor or DCIS). Tumor size was estimated 
as 1) pathologic T stage as per AJCC criteria; 2) largest dimension 
of largest tumor focus (cm); 3) sum of largest dimension(s) of tumor 
foci (cm); 4) sum of surface area(s) of tumor foci (cm2), and 5) sum 
of volume of tumor foci (cm3). Step-wise forward unstratified Cox 
regression was used to assess the different effects of tumor size.
Results: This study accrued 672 patients, 43% with T1 tumors, 51% 
with T2 tumors, and 6% with T3/T4 tumors; 25% were node negative 
and 56% had 1-3 positive lymph nodes. 75% were locally determined 
to have hormone receptor positive tumors. A higher number of 
involved lymph nodes was associated with significantly shorter BCFI 
(p<0.0001). None of pathologic T stage (p=0.14), largest dimension 
of largest tumor size (p=0.14), sum of largest dimensions of tumor 
foci (p=0.24), sum of surface area (p=0.38), and sum of volume of 
foci (p=0.51) were significantly associated with BCFI. Likewise, 
lymphovascular invasion (p=0.08), grade (p=0.14), nor administration 
of anthracycline therapy (p=0.08) were associated with BCFI.
Discussion: In the MA.12 population of pre-menopausal women 
randomized to either tamoxifen or placebo, the sole factor significantly 
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associated with BCFI was nodal status. No measure of tumor size 
in unifocal or multicentric/multifocal tumors impacted BCFI. The 
findings of this mature data set suggest that simply adding together 
the diameters of tumors in patients with multicentric or multifocal 
disease did not add any additional prognostic information.
P2-12-28
Studies of a Malignancy-Associated Protein, Osteopontin, in 
NCIC CTG MA.14, a Randomized Trial of Tamoxifen Versus 
Combined Tamoxifen and Octreotide LAR in Adjuvant Treatment 
of Women with Early Breast Cancer.
Bramwell VH, Tuck AB, Chapman J-A, Anborgh PH, Postenka CO, 
Shepherd L, Pritchard KI, Han L, Wilson C, Pollak M, Chambers AF. 
Tom Baker Cancer Centre, Calgary, AB, Canada; London Regional 
Cancer Program, London, ON, Canada; NCIC Clinical Trials Group, 
Kingston, ON, Canada
Background: We have shown, in women with metastatic breast 
cancer (BC), that high baseline plasma osteopontin (OPN) levels and 
increases over time are associated with poor survival. In primary BC, 
increased immunohistochemical (IHC) expression of OPN in tumour 
is associated with poorer survival and is elevated in lymph node 
metastases relative to primary tumour. Our current study evaluates 
tumour and baseline/serial plasma OPN levels after resection of 
primary BC.
Methods: In NCIC CTG MA.14, 667 postmenopausal women post 
surgery received 5 yrs Tamoxifen (T) +/- 2 yrs monthly Octreotide 
LAR. There were no differences in survival outcomes between arms. 
OPN was assayed by IHC in primary BC. OPN was measured in 
plasma at baseline (up to 4 mos post randomization) and serially 
in recurrent (18 mos time window) versus non-recurrent cases, by 
ELISA. Statistical Analysis: IHC and plasma OPN had Box-Cox 
variance stabilization transformations (power 0.5; logarithm). 
Descriptive characterization of both OPN measurements is provided 
for all patients, by baseline patient and tumour characteristics, and by 
recurrence status. Univariate stratified log-rank statistics and hazard 
ratios with 95% CI were generated for intention to treat (ITT), event 
free survival (EFS), relapse fee survival (RFS), overall survival, 
any bone RFS, and non-bone RFS. Stratified step-wise forward Cox 
regression was used, with factor added if p<0.05.
Results: From 667 MA.14 patients, 647 patients were assessed for 
OPN: 462 (69%) by IHC; 387 (58%) at baseline in plasma (with 2,542 
samples total from serial sampling). IHC % tumor positivity had mean 
33.9% (95% CI 30.2%-37.9%), while baseline plasma OPN was mean 
46.1 (44.6-47.6) ng/ml. In 80 women with recurrence, mean OPN 
during the recurrence window was 60.7 (52.8-69.8) ng/ml. Neither 
baseline IHC or plasma OPN levels were significantly associated 
with any of the endpoints in either univariate or multivariate 
analyses. Older age (p=0.02), greater nodal involvement (p=0.001), 
higher baseline body mass index (p<0.0001), and higher tumour 
grade (p<0.0001) were multivariately associated with shorter EFS. 
Baseline plasma OPN was not correlated with IHC OPN (Pearson 
0.02, p=0.73).
Discussion: Mean baseline OPN plasma level 46.1 ng/ml (median 
45 ng/ml) in MA.14 was similar to our previous findings in healthy 
women (median 47 ng/ml). In contrast, we previously showed that 
63% of 158 women with a new diagnosis of metastatic BC had 
elevated OPN levels with median value 177 ng/ml. Our results thus 
far suggest that tumor and plasma levels, while associated with 
prognosis in metastatic BC, may not be so in primary BC following 
surgery. However, in MA.14, the 80 women with recurrent BC had 
significantly higher mean OPN in the recurrence window, 60.7 ng/
ml, than at baseline. We will present further analyses exploring this 
finding.
P2-12-30
Pre-Operative Haematological Markers and Prognosis in Early 
Breast Cancer.
Cordiner RL, Mansell J, Obondo C, Angerson WJ, Lannigan A, 
McMillan D, Wilson CR, Doughty JC. Western Infirmary, Glasgow, 
United Kingdom; Wishaw General Hospital, Wishaw, United Kingdom
Background: Systemic inflammation may influence survival in 
women with breast cancer. Both the platelet lymphocyte ratio (PLR) 
and the neutrophil lymphocyte ratio (NLR) have been shown to be 
associated with survival in a number of solid tumours. The aim of this 
study was to assess the role of PLR and NLR in survival of women 
with early breast cancer.
Methods: Women diagnosed with early breast cancer at two centres 
between 2003 and 2006 were included. All women had measured 
white cells, neutrophils, lymphocytes and platelets. NLR and PLR 
were calculated. Cox regression survival analysis was performed 
with breast cancer specific survival used as the primary end point. 
Significant associations of NLR and PLR with pathological variables 
was assessed using the Chi squared test.
Results: 707 women were included with a median follow up of 3.7yrs. 
On univariate analysis neither NLR (HR 1.08, 95% CI 0.66-1.79) 
or PLR (HR 0.96, 95% CI 0.58-1.59) were significantly associated 
with breast cancer specific survival. An increased PLR was found to 
be associated with significantly fewer grade 1 tumours (P<0.05) but 
no other significant associations with pathology was demonstrated 
for either PLR or NLR.
Conclusions: This study would suggest that the NLR and PLR are 
not prognostic of survival in women with early breast cancer.
P2-12-31
Moderate Immunohistochemical Expression of HER2 (2+) 
without HER2 Gene-Amplification Is a Negative Prognostic 
Factor in Early Breast Cancer.
Rossi V, Sarotto I, Maggiorotto F, Tomasi Cont N, Redana S, Aglietta 
M, Ponzone R, Montemurro F. Institute for Cancer Research and 
Treatment IRCC, Candiolo, Turin, Italy
Purpose
We sought to evaluate whether moderate HER2 immunohistochemical 
(IHC) expression (2+ and no HER2/amplification) identifies early 
breast cancer (EBC) with a distinct prognostic profile.
Methods
A total of 1295 women (median age 58, range 22-94) undergoing 
surgery for EBC from Jan 1995 to Sept 2009 were retrospectively 
reviewed. All patients had undergone HER2 testing by the HercepTest 
and, when needed, by fluorescence in-situ hybridization (FISH). All 
tests were carried on at our Institutional Surgical Pathology laboratory. 
The impact of HER2 status on disease-free survival (DFS) was 
corrected for other clinical and pathological potential covariates by 
Cox Proportional Regression Analysis.
Results
A total of 494 (38%), 486 (38%), 119 (9%) and 196 (15%) of the 
patients had HER2 0+, 1+ 2+ and positive (3+ or FISH+) tumors, 
respectively. Sixty-one of 196 patients with HER2-positive EBC 
received adjuvant trastuzumab. A total of 298 DFS events occurred 
at median follow-up of 59 months (4-137 months). By using HER2 
0+ status as reference, multivariate analysis revealed that HER2 2+ 
expression was associated with a significant increase in the risk of 
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a DFS event (HR 2.303, 95% C.I. 1.501-3.533, p<0.001), whereas 
HER2 1+ was not (HR 0.976, 95% C.I. 0.698-1.365, p=0.889). We 
performed exploratory two-group comparisons by further classifying 
tumors according to hormone-receptor status (cutoff for ER and PgR 
positivity ≥10% of stained cells). Results are summarized in the table. 
HER2 2+ expression was associated with worse prognosis in both ER 
and/or PgR positive and ER/PgR negative tumors. In the latter group, 
HER2 2+ expression was associated with a particularly high rate of 
DFS events, with a 60-month projected DFS of 20%. Furthermore, 
while DFS curves plateaued at 60 months for HER2-positive tumors 
(with and without adjuvant trastuzumab) and for ER/PgR negative 
tumors with HER2 0/1+ expression, hormone receptor positive/HER2 
2+ tumors displayed a particularly high rate of late relapses (beyond 
60 months). Results did not change using a 1% cutoff to define ER 
and PgR positivity.
Conclusion
Moderate HER2 positivity (IHC 2+/FISH negative) identifies EBC 
patients at increased risk of a DFS event, regardless of hormone 
receptor status. Due to suggestions from large randomized trials that 
the benefits of trastuzumab may not be limited to HER2-positive 
tumors, patients with HER2 2+ EBC are ideal candidates for studies 
testing this hypothesis.
Multivariate Hazard Ratios, corrected by age, lymph-node status, tumor diameter, tumor grade, 
proliferation (Ki 67 index) and receipt of adjuvant chemotherapy
Comparison Number HR* 95% C.I. p
ER and/or PgR positive     
HER2 2+ vs HER2 0/1+ 92/760 1.989 1.230-3.215 0.005
ER and PgR negative     
HER2 2+ vs HER2 0/1+ 17/96 3.635 1.647-8.021 0.001
P2-12-32
Association between Progranulin (GP88) Expression and 
Recurrence Risk for Breast Cancer Patients with Estrogen 
Receptor Positive Invasive Ductal Carcinoma.
Serrero G, Hawkins DM, Ioffe O, Bejarano P, Phillips JT, Head 
JF, Elliott RL, Godwin AK, Weaver J, Yue B. A&G Pharmaceutical 
Inc, Columbia, MD; University of Minnesota, Minneapolis, MN; 
University of Maryland, Baltimore, MD; University of Miami, Miami, 
FL; EEH Breast Cancer Rsearch and Treatment Center, Baton Rouge, 
LA; University of Kansas Medical Center, Kansas City, KS; Fox Chase 
Cancer Center, Philadelphia, PA
Purpose:
GP88 (progranulin) is a critical player of breast tumorigenesis for 
estrogen receptor positive (ER+) breast cancer. Pathological studies 
showed that GP88 was expressed in invasive ductal carcinoma 
(IDC), but not in normal mammary tissue, benign lesions or lobular 
carcinoma. The present study examines GP88 prognostic significance 
in association with recurrence risk for patients with ER+ IDC.
Patients and Methods:
Two retrospective multi-site clinical studies examined GP88 
expression by immunohistochemistry (IHC) analysis in paraffin-
embedded tumor tissues in correlation with patients’ survival 
outcomes. The training study established a GP88 cut-off value 
associated with decreased disease-free (DFS) and overall (OS) 
survivals. The validation study verified the GP88 cut-off value and 
compared GP88 prognostic information with other prognostic factors 
in multivariate analysis.
Results:
GP88 expression is associated with a statistically significant 
increase in recurrence risk for ER+ IDC patients. The training study 
established that GP88 3+ score by IHC analysis was associated with 
decreased DFS (p=0.0004) and OS (p=0.0036). The independent 
validation study verified that GP88 3+ score for the high risk group 
and demonstrated that GP88 3+ score was associated with a 5.9-fold 
higher hazard of disease recurrence and a 2.5-fold higher mortality 
hazard compared to patients with tumor GP88<3+. GP88 remained 
an independent risk predictor after considering age, nodal status, 
tumor size, tumor grade, progesterone receptor expression, treatment 
and disease stage.
Conclusion:
Our training and validation studies demonstrate that the survival 
factor GP88 is a prognostic biomarker, predictive of recurrence risk 
and increased mortality for ER+ IDC patients, independent from 
other prognostic factors. These results provide support for measuring 
GP88 tissue expression for newly diagnosed early stage breast cancer 
patients.
This work was supported by grants R43CA124179, and U01CA113916 
from the National Cancer Institute, grants 07-2007-064 and 02-2010-
010 from the Avon Foundation for Women.
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P2-13-01
Gene Profiling of Whole Blood May Identify Patients with BRCA 
Mutations.
Mina LA, Gokmen-Polar Y, Goswami C, Storniolo AM, Li L, Badve S, 
Sledge GW. Indiana University School of Medicine, Indianapolis, IN
Background:The BRCA1 and the BRCA2 proteins play a role in DNA 
repair and confer genomic stability to the cell. Identifying BRCA 
mutation carriers has become an important tool for prevention as 
well as guiding therapy in cancer patients. We proposed to test the 
hypothesis that gene expression analysis of peripheral whole blood 
can reliably detect these mutations.
Materials and methods:
Following IRB approval, 10cc of blood was collected from 36 women 
(BRCA1 (n=8), BRCA2 (n=9), Hereditary breast cancer without 
BRCA (FAM) (n=7), sporadic breast cancer (SPO) (n=11)). 3 of 
BRCA1 and 5 of BRCA2 samples were from women without cancer. 
Following RNA extraction (using the method described by Beekman 
et al) and quality assessment, Illumina® Whole-Genome DASL™ 
microarray (Human Ref-8 BeadChips) analysis was performed. The 
raw data was normalized and analyzed using Partek® Genomic Suite. 
Differentially expressed genes were identified using ANOVA analysis. 
Geneset specific supervised analysis was performed to visualize the 
inherent similarities and differences in the gene expression amongst 
different groups for 1) DNA repair and 2) Immune-system-related 
genes. Ingenuity Pathway Analysis (IPA) was performed to interpret 
the data in the context of biological processes, pathways and networks.
Results:
Twenty-nine of the 87 immune-related genes were up-regulated in 
BRCA1 and BRCA2 groups compared to SPO or FAM groups; these 
included IL7R, CD53, CD2, CD48 and HLA-DRA. Twenty-five of 
the 79 DNA repair genes were up-regulated in BRCA1 and BRCA2; 
these included FANCC, RAD51L3, MSH2, MSH6 and PCNA. In 
IPA analysis, the comparison of BRCA1 vs. REST (BRCA2 + FAM 
+ SPO) showed a strong immunologic signal, with the top altered 
biological processes including “Immunologic disease”, “Infection 
mechanism”, “Immune cell trafficking” and “cell-mediated immune 
response “. The top 5 canonical pathways also reflected a similar 
pattern and included “iCOS-iCOSL Signaling in T Helper Cells”, 
“OX40 Signaling Pathway”, “Calcium-induced T Lymphocyte”, 
“Apoptosis Regulation of IL-2 Expression in Activated and Anergic 
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T Lymphocytes” and “Protein Ubiquitination Pathway”. When 
BRCA2 was compared with the REST (BRCA1 + FAM + SPO), a 
much weaker signal was noted with none of the canonical pathways 
being significantly altered. PAM analysis showed that a set of 16 
genes could differentiate the BRCA patients from the rest with an 
error rate of 5%. Further validation of this geneset is being performed.
Conclusion:
Gene profiling in whole blood may offer an easy, reliable and 
inexpensive way to identify patients with BRCA mutation. Further 
studies are currently underway to validate our results in a larger 
patient population.
P2-13-02
Parent of Origin of BRCA Mutation May Determine Age at Breast 
Cancer Diagnosis.
Shapira I, Budman DR, Akerman M, Weiselberg L, Vinciguerra V, 
D’Olimpio J, Devoe C, Cheng KL, Donahue L, John V, Cohen S. 
Hofstra North Shore LIJ School of Medicine, Lake Success, NY; 
Feistein Institute for Medical Research, Manhasset, NY
Background
Genetic diseases may display parent-of-origin effects. In such cases, 
the risk depends on the specific parent or origin allele. Imprinting 
effect is evident in autosomal dominant hereditary paraganglioma 
leads to tumors only if inherited from paternal germline. Cancer 
penetrance in mutations carriers may be determined by the parent 
origin of BRCA mutation.
Methods 
From 2007-2010 we analyzed 1889 consecutive (136 ovarian + 1753 
breast) breast (BrCa) or ovarian cancer (OvCa) patients presenting for 
treatment at our outpatient facility. In 130 patients with BRCA 1 or 2 
mutations the parent of origin for the mutation was known. Of the 130 
patients 2 had both BRCA1 and BRCA2 mutated paternally inherited 
and were excluded from this analysis. Of the breast cancer patients: 
28 patients had paternal and 29 had maternal BRCA1 mutations, 24 
had paternal and 21 had maternal BRCA 2 mutations. Of the ovarian 
cancer patients 6 had paternal and 10 had maternal BRCA1 mutations, 
7 had paternal and 3 had maternal BRCA2 mutations.
In carriers of BRCA mutations the mean age at diagnosis for ovarian 
cancer was 51 (range 21-70) and for breast cancer was 43 (range 
24-78).
Two-sample t-test was used to compare the mean age at diagnosis 
in patients with BRCA 1 or 2 mutations of paternal or maternal 
inheritance.
For breast cancer maternal allele versus paternal allele 2-sample 
t-test and p-value were compared for the age at first diagnosis. For 
breast cancer patients BRCA1 maternal inheritance (mean+SD yrs) 
45.73+11.22 versus paternal inheritance 38.04+7.14 2-sample t-test 
p-value p<0.0020. For breast cancer BRCA2 maternal inheritance 
(mean+SD yrs) 50.65+10.44 versus paternal inheritance 41.68+6.16, 
2-sample t-test p-value p<0.0008.
Results:
Significantly younger age at breast cancer diagnosis was observed 
in paternal vs. maternal inheritance of BRCA1 mutation (38 vs 46, 
respectively, p<0.0020) and BRCA2 mutation (42 vs 51 respectively, 
p<0.0008). There was no significant difference between paternal and 
maternal age of ovarian cancer diagnosis of BRCA1 (p<0.1415) or 
BRCA2 mutation (p<0.3470).
Conclusion: 
The restrospective nature of the study may introduce ascertainment 
bias. However, the breast and ovarian cancers cases in BRCA1 & 2 
carriers with maternal or paternal inheritance mirror the Mendelian 
autosomal dominant pattern in our unselected consecutive cohort of 
patients. Maternal and paternal inherited BRCA alleles may not be 
exchangeable. Women with paternally inherited mutations in BRCA 
gene mutations develop breast cancer at younger age compared with 
women who inherit the gene mutations from their mothers. In this 
small sample, clear differences at age of cancer diagnosis are apparent 
in paternal inheritance of BRCA gene mutation. If this observation 
duplicates in larger cohorts results will have important implications for 
recommendation of surgical risk reduction in BRCA mutation carriers.
P2-13-03
Comparative Assessment of 636 Women at Risk for Hereditary 
Breast Cancer within 3 Public Hospitals: The Consortium of 
Underserved BRCA Testers.
Beattie MS, Ganschow P, Gabram-Mendola S, Wilson A, Joseph 
G, Lee R, Loranger K, Stanislaw C, Seelaus C, Farrell R, Trim L, 
DelPozo S, Luce J. University of California, San Francisco, CA; San 
Francisco General Hospital, San Francisco, CA; Stroger Hospital 
of Cook County, Chicago, IL; Rush University Medical Center, 
Chicago, IL; Emory University, Atlanta, GA; Grady Memorial 
Hospital, Atlanta, GA
Background: Underserved women at risk for Hereditary Breast 
and Ovarian Cancer (HBOC) are confronted with many unique 
challenges, such as barriers to accessing appropriate genetic testing 
and counseling services and decreased resources, that place them at 
increased cancer risk. It is unclear whether these high-risk women 
are appropriately referred for genetic counseling and what their 
genetic test results demonstrate due to minimal practice-based 
evidence. To study this population, and to establish an infrastructure 
to further explore long-term outcomes, we formed the Consortium 
of Underserved BRCA testers in October 2010 from: San Francisco 
General Hospital (SF), Stroger Hospital of Cook County (Chicago), 
and Grady Memorial Hospital (Atlanta).
Methods: Using common clinical and research protocols and mixed 
methods analysis, we examined and compared referral patterns, 
demographics, and BRCA test results between sites. We used chart 
reviews and common data collection instruments to gather and pool 
data. Using descriptive and comparative statistics, we examined 
similarities and differences between Consortium sites.
Results: SF’s program began 9 years ago, Chicago’s began 6 years 
ago, and Atlanta’s began 3 years ago. Medicaid funding for BRCA 
testing has been available in SF since 2011, in Chicago since 2009, 
and is not yet available in Atlanta. P values were all <0.05 for 
comparing referral sources between sites. Each site uses unique 
referral tools and systems. For example, in SF, a family history 
screening questionnaire is administered during mammography; in 
Chicago, an extensive primary care network has been educated to 
provide appropriate referrals; in Atlanta, a pedigree assessment tool 
is employed by referring clinics.
Table 1: Referrals to Genetic Counseling and Testing in the Consortium of Underserved BRCA 
testers
Sites SF Chicago Atlanta
Number of referrals n=1341 n= 1510 n=91
Breast clinic 17% 18% 55%
GYN 6% 6% 21%
Oncology 6% 25% 19%
Primary care 20% 37% N/A
Mammography 43% N/A 5%
Family members 5% N/A 1%
Other (University, community, private, emergency 
department, and self-referrals)* 3% 14% N/A
*p < 0.05 in chi-squared analysis
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Table 2 demonstrates similar BRCA positive rates (13-18%) despite 
statistically significant differences in race/ethnicity between sites.
Table 2: Characteristics of BRCA Testers by Site
Site SF Chicago Atlanta
Number of BRCA Testers 260 375 60
African American 9% 38% 67%
Asian 21% 7% 2%
Caucasian 41% 25% 13%
Hispanic 25% 26% 5%
Mixed 1% 1% 9%
Other* 3% 3% 4%
Jewish Ancestry 20% 1% 1%
Positive Results 18% 16% 13%
Uninformative Negative Results 72% 72% 81%
Variant of Undetermined Significance 5% 8% 4%
True Negative Results 5% 4% 2%
*Includes Native American, Pacific Islander, and Middle Eastern
Conclusions: Despite differences in referral patterns and Medicaid 
funding, underserved women at all 3 public hospital sites had similar 
BRCA positive rates, which are in line with positive rates from 
University Cancer Centers. We believe this relates to the availability 
of genetic counseling services and a similar testing threshold at each 
site. The large and ethnically diverse population of this Consortium 
can serve as a valuable resource for researchers and clinicians. We 
plan to follow this cohort prospectively to study clinical outcomes 
and medical decisions after BRCA testing in underserved families 
at risk of HBOC.
P2-13-04
Testing Women with Invasive Lobular Breast Cancer for BRCA 
Mutations.
Turco DL, Elsayegh N, Litton J, Hortobagyi GN, Arun B. M.D. 
Anderson Cancer Center, Houston, TX
Background: Infiltrating lobular carcinoma (ILC) is the second most 
common type of invasive breast cancer behind infiltrating ductal 
carcinoma (IDC). ILC makes up approximately eight percent of all 
invasive lesions. In addition, the mixed ductal and lobular carcinoma 
histology makes up approximately seven percent of all invasive 
diagnoses.
There are several biologic differences that are demonstrated by ILC 
compared to other common pathologies. They are more frequently 
bilateral and multicentric. They tend to be seen in women slightly 
older than the average age of diagnosis and are usually ER positive.
It is also known that individuals with a genetic predisposition have 
an increased risk to develop breast cancers. Women with a mutation 
in their CDH1 gene have up to a 39% chance to develop ILC. The 
majority of hereditary breast cancer is caused by germ line mutations 
in the BRCA1 and BRCA2 genes. Women with a mutation in their 
BRCA1 or BRCA2 gene have up to an 87% risk to develop an invasive 
breast cancer, however, the presence of ILC in this population has not 
been well defined. Therefore, the aim of this study is to evaluate the 
rate of germline BRCA mutations in a cohort of patients both with 
pure ILC, as well as mixed ILC/IDC.
Methods: A retrospective chart review revealed one hundred and sixty 
nine women with ILC and mixed ILC/IDC who underwent genetic 
testing for mutations in the BRCA1 and BRCA2 genes through the 
Clinical Cancer Genetics Program at M. D. Anderson Cancer Center. 
Women are referred for genetic testing using referral guidelines based 
on the NCCN guidelines, this usually involves a personal history of 
early onset breast cancer and/or a family history of breast and/or 
ovarian cancer.
Results: Out of the 169 patients, 19 (11.24%) were found to have a 
germline mutation in their BRCA1 or BRCA2 gene. A significant 
majority (73.7%) of these patients were BRCA2 positive. Five 
women tested for a variant of uncertain significance. The average age 
of diagnosis for the cohort was 55.6 years (range 30-87); while the 
average age of diagnosis for a positive patient was 49.4 years (range 
30-72). Of the 62 women with pure ILC, 5 (8.06%) were positive 
for a BRCA gene mutation. Historically, out of all the patients with 
breast cancer referred and tested through the Clinical Cancer Genetics 
Program, approximately 15% test positive, and research shows that 
in the general population, 7-10% of breast cancer patients will test 
positive.
Conclusions: while the positivity rates between the cohorts are not 
statistically significant, we have shown that patients with a BRCA 
mutation can develop ILC in addition to the more commonly seen 
IDC. We suggest that patients continue to be referred for genetic 
counseling according to the NCCN guidelines, regardless of the 
pathology of their tumor.
P2-13-05
Breast Cancer, BRCA Mutations and Attitudes Regarding 
Pregnancy and Preimplantation Genetic Diagnosis.
Litton JK, Etzel CJ, Jackson MA, Muse KI, Turco D, Schover LR, 
Theriault RL, Mattair D, Lu KH, Hortobagyi GN, Arun BK. The 
University of Texas MD Anderson Cancer Center, Houston, TX
Background: Breast cancer is associated with treatment-related 
infertility and has been demonstrated to be a major concern for 
premenopausal survivors. Detection of a BRCA deleterious 
mutation may also affect attitudes regarding future childbearing. 
Preimplantation genetic diagnosis (PGD) allows women to use in 
vitro fertilization (IVF) to implant only those embryos without a 
BRCA mutation. The ability to test the fetus for BRCA mutations is 
also available through amniocentesis and chorionic villus sampling 
(CVS). The objective of this study was to evaluate attitudes about 
childbearing and fertility in women being evaluated for a BRCA 
mutation. Methods: Women with childbearing potential who were 
referred to the Clinical Cancer Genetics Clinic to be evaluated 
for a BRCA mutation were invited to participate in this survey. 
The questionnaire was administered prior to genetic counseling. A 
follow-up was administered after the BRCA results were disclosed. 
The survey queried participants regarding their attitudes on fertility, 
pregnancy as it may relate to cancer and the potential of a BRCA 
mutation. Other questions detailed attitudes regarding IVF, PGD, and 
CVS in these instances. Descriptive statistics were used. Results: One 
hundred and twenty-eight women completed pre-questionnaires and 
to date 76 have completed post results disclosure questionnaires. The 
mean age was 33 (range 21-44) with 69.5% with a diagnosis of breast 
cancer, 39.8% received chemotherapy and 60.9% already had at least 1 
biological child. A future child was desired by 45.3% although 53.1% 
worried that their children would have an increased risk of cancer. 
Regarding PGD, although only 30.9% (38/123) said that they would 
use PGD, 80.2% felt that the testing should be available to families 
with inherited cancers. Regarding fetal testing via amniocentesis or 
CVS, 29.7% would have the fetus tested and 7% would consider 
termination if a genetic mutation was identified. Additionally, 69.5% 
felt it was important to receive fertility counseling and treatment at 
the same place where they receive their cancer care. To date 8 women 
have been diagnosed with a BRCA1 mutation and 4 with a BRCA2 
mutation. When asked similar questions after their genetic results 
were disclosed, 2 women who had previously stated they would not 
use PGD changed their mind. Conclusions: Future pregnancies are 
important to many breast cancer survivors. BRCA mutation carriers 
have the option to have children without passing on their genetic 
risk for cancer. Although few would use these interventions, a large 
majority felt it was important to have information about these choices 
and to have options for fertility preservation options addressed at the 
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center where cancer care is delivered.
P2-13-06
Feasibility of Fast-Track Germline Genetic Analyses for Localized 
Breast Cancer Patients and Its Impact on Local Management.
Caron O, Guillaud-Bataille M, Bressac B, Rimareix F, Karsenti G, 
Leymarie N, Gouy S, Uzan C, Guillemeau C, Bourgier C, Heymann 
S, Frebourg T, Delaloge S. Institut Gustave Roussy, Villejuif, France; 
Centre Hospitalier Universitaire de Rouen, Rouen, France
Background : Patients with BRCA1-BRCA2 germline mutation 
who developed a first breast cancer (BC) have a high risk to develop 
a second BC, especially if aged less than 40 at first diagnosis. Thus, 
a positive BRCA test may influence the therapeutic management 
and orients towards non conservative surgery to reduce new BC 
occurrence. We set up a fast-track process to get BRCA1/2 and 
sometimes p53 mutation results within the shortest possible interval, 
in recently diagnosed BC patients whose probability to be mutation 
carriers was high (> 20%).
Methods: Between 05/02/2009 and 03/01/2011, 61 patients diagnosed 
with localized BC requesting neo-adjuvant or adjuvant chemotherapy 
and whose personal or familial history fulfilled BRCA1/2 or P53 
genetic testing criteria, were proposed genetic counselling. After 
a first multisciplinary team meeting (MT), genetic testing was 
proposed and performed according to usual genetic counselling 
rules. Psychological support was offered at every step of the process. 
Patients were informed that their test would be analysed as part of a 
fast-track process and were aware of the potential consequences of 
a positive test. Results were communicated and discussed during a 
second MT, when initial therapeutic plan was eventually changed.
Results: All women who were referred to the genetic clinic for fast-
track testing accepted the analysis. The mean age at diagnosis was 
38 (range 26-55). The whole process (from 1st genetic consultation 
till disclosure consultation) was completed in a median interval of 
99 days (range 19-245). All pts received appointment within 5 days, 
when results were available. 50% pts postponed for more than 15 
days their disclosure appointment (range 0-113 days). One patient 
(pt) declined result disclosure. 18 pts (30%) were found to be carrier 
of a deleterious mutation (13 BRCA1, 4 BRCA2, 1 p53). Variants 
of unknown significance (UV) in BRCA1 or BRCA2 genes were 
identified in another 4 patients. In 18 cases, surgery type initially 
proposed was changed because of the presence of the germline 
mutation: all pts were proposed ipsilateral mastectomy eventually 
associated to immediate reconstruction as often possible, as well as 
controlateral mastectomy. Final surgery turned to bilateral mastectomy 
in 3 patients with deleterious BRCA mutation and in one suspect UV. 
14 patients with mutation accepted the change, but four BRCA2 
and one BRCA1 mutation carriers refused mastectomy or bilateral 
mastectomy. Radiotherapy was cancelled in a p53 mutation carrier.
Conclusion: This data show that genetic testing might be considered 
as a part of therapeutic decision. Moreover, 22% (4/18) opted for 
a simultaneous controlateral prophylactic mastectomy. On the 
other hand, some women did not change their mind with mutation 
knowledge (4/18, 22%). Psychological impact of this procedure is 
currently retrospectively assessed by a self-questionnaire, fulfilled 
by mail. Analyses will be available for the meeting.
Mutation and decision making
 Nb Treatment changes between  
1st and 2nd MT
Change accepted by patient
BRCA1 mutation 13 10 9
BRCA2 mutation 4 4 0
P53 mutation 1 1 1
MT: multidisciplinary team meeting
P2-13-07
Prevalence of Germline BRCA1 and BRCA2 Deleterious 
Mutations in Brazilian Patients with High-Risk of Breast and 
Ovarian Cancer.
Diz MDPE, Escobar KA, Guindalini RSC, Pasini FS, Snitkoviski 
IML, Maistro S, Hoff PMG, Federico MHH. Instituto do Cancer do 
Estado de Sao Paulo, Sao Paulo, Brazil; Faculdade de Medicina da 
Universidade de Sao Paulo, Sao Paulo, Brazil
Background: Germline mutations in the BRCA1/2 genes account for 
the majority of hereditary breast ovarian cancer (HBOC). Distribution 
and prevalence of clinically relevant mutations in BRCA1/2 differ 
among different populations. All of the Brazilian studies published 
to date have not performed complete sequencing of both genes, 
restricting their analyses to selected exons. In addition, a highly 
heterogeneous mutation spectrum was observed. The lack of data 
concerning the prevalence and profile of BRCA1/2 deleterious 
mutation and the appropriated screening criteria for DNA sequencing 
in the Brazilian population complicates the design of screening 
strategies.
Objective: To accurately determine the contribution of BRCA1/2 
germline mutations in a well characterized sample of Brazilian breast 
and ovarian high-risk pts.
Methodology: A total of 73 unrelated pts attending a Brazilian public 
hospital from September 2005 to July 2006, with HBOC risk ≥10% 
according to Frank, Evans or BRCAPRO algorithms, underwent 
complete sequencing and MLPA analysis of BRCA1/2 genes. 
Demographic data and tumor pathological features were extracted 
from prospectively registered medical records.
Results: Mean age, median of cancer cases in families and median 
score by Frank, Evans and BRCAPRO algorithms were respectively 
48y (24-78), 4 (0-13), 11.2 (0-56,3), 13.4 (0,1-100) and 16 (2-75). A 
total of 79 unknown clinical significance mutations were identified: 
44 in BRCA1 and 35 in BRCA2. Known deleterious mutations were 
identified in 8 pts. Four in BRCA1: R71G at exon 5, 5382insC at 
exon 20 (2 patients) and R1751X at exon 20; and four in BRCA2: 
R2318X at exon 13, R3128X at exon 25, 5844del5 and 6633del5 at 
exon 11. Several polymorphisms were found in all pts. No mutation 
was detected by MLPA technique. One novel frameshift deleterious 
mutation in BRCA2: 6610insTT at exon 11 which results in a stop 
codon was detected in a breast cancer patient and in four of her 
relatives from a family with high-risk of HBOC. Taking into account 
the novel mutation, the prevalence of BRCA1/2 mutation in high-risk 
pts in our cohort is 12,3%. Pts characteristics presented in [table 1]. 
Conclusion: To the best of our knowledge, the study represents the first 
report of the complete sequencing and MLPA analysis of BRCA1/2 
genes in large Brazilian series of HBOC high-risk pts. The prevalence 
of germline mutations found in the present study was similar to the 
reported by other studies examining high-risk populations.
Characteristics of patients with BRCA1/2 deleterious mutations
Mutation
Age at BC 
diagnosis Histology HR status HER2 status BRCAPRO Frank Evans
B2; R3128X 41 IDC pos pos 0,493 26,3 22
B2; 5844del5 55 IDC pos pos 0,05 10,2 23
B2; 6610insTT 45 IDC pos ind 0,16 17,5 19
B2; R2318X 44 N/C N/C N/C 0,442 30,8 31
B2; 6633del5 42 IDC pos pos 0,903 20 32
B1; 5382insC 64 IDC neg neg 0,311 16,4 31
B1; R71G 43; 45 MC+ILC N/A N/A 0,988 39 38
B1; R1751X 40 IDC(b) N/A N/A 0,796 18,4 20
B1; 5382insC 53 IDC(b) neg neg 0,704 31,8 31,8
B1=BRCA1; B2=BRCA2; BC=breast cancer; IDC=invasive ductal carcinoma; MC=medullary 
carcinoma; ILC=invasive lobular carcinoma; HR=hormone receptor; (b)=bilateral, N/A=not 
available; N/C=never had cancer; pos=positive; neg=negative, ind=indeterminate
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P2-13-08
A Retrospective Study on Surveillance Behaviour and Prophylaxis 
after Genetic Testing for Hereditary Breast and Ovarian Cancer 
among High-Risk Chinese Females.
Kwong A, Chu ATW. The University of Hong Kong, Hong Kong; The 
Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong
Background: Research in the West has shown that the uptake rates 
of surveillance and prophylaxis may be different in BRCA mutation 
carriers and non carriers and this may vary between different 
ethnicities. To date there is limited comprehensive data available for 
the behavioural pattern of Asian cohorts. The present on-going study is 
the first to investigate the behavioural impact and medical compliance 
of Chinese high risk females who had undergone BRCA1/2 genetic 
testing up to 1.5 years after genetic testing.
Methods: 88 females with personal or family breast and/or ovarian 
cancer history who had BRCA1/2 genetic testing performed by 
the Hong Kong Hereditary Breast Cancer Family Registry were 
surveyed by a face-to-face or telephone interview. Sociodemographic 
information, genetic test results, pre-and post-testing surveillance 
practice, chemoprevention methods used and attitudes towards 
clinical management were obtained. Retrieval of medical records 
was performed using a prospective database.
Results: 39 carriers and 49 noncarriers of a BRCA 1/2 mutations 
were interviewed. 82.1% of carriers and 79.6% noncarriers had 
breast and/or ovarian cancer prior to testing. The uptake rate of breast 
surveillance by eligible carriers (85.2%) and noncarriers (71.1%) 
remained high after knowing the test results. 12.8% and 15.4% of 
the eligible carriers had prophylactic contralateral mastectomy and 
salpingo-oophorectomy respectively, while 5.1% chose to have 
both procedures within 1.5 years of knowing the genetic test result. 
Significantly more carriers (85.7%) than noncarriers (49%) underwent 
ovarian surveillance (p= 0.004). 25.6% of carriers and 26.5% of 
noncarriers with breast cancer history chose Western chemoprevention 
methods, while no carriers without breast cancer history chose such 
methods. 34.7% of carriers (30.8% of noncarriers) used Chinese 
herbal medicine as complementary prevention treatment after 
knowing the genetic test result. Clinicians’ advice was perceived as 
the major reason of choosing a particular surveillance or preventative 
strategy.
Conclusions: As population-based breast screening is unavailable in 
Hong Kong, the relatively high uptake rate of breast screening among 
noncarriers may be the result of enhancement in health-consciousness 
due to prior personal or family cancer experience. Proper education 
by clinicians is crucial to increase uptake of high risk screening. 
Traditional Chinese herbal medicine methods are commonly used as 
a form of prevention. A longitudinal prospective study will contribute 
to the understanding of attitude-change towards clinical management 
of this Chinese population who may have different cultural beliefs.
P2-13-09
First Statewide Experience with Telephone Delivery of Cancer 
Genetic Counseling.
Pruski-Clark J, Trivedi A, Kelle S, Rebecca S. Informed Medical 
Decisions, Inc., St. Petersburg, FL
Background: National guidelines and multiple professional medical 
societies recommend genetic counseling as the standard of care 
for women with a personal and/or family history suggestive of a 
hereditary cancer syndrome. In addition, the ability to provide risk 
assessment and genetic counseling is a requirement for accreditation 
of breast centers by organizations such as the National Accreditation 
Program for Breast Centers (NAPBC) and the Commission on 
Cancer. However, there is clear evidence that this standard is not 
being achieved. Many individuals are undergoing genetic testing for 
these syndromes without adequate pre- and post-test counseling and, 
on the other hand, many individuals who are appropriate for genetic 
testing are not being identified and referred for genetic counseling 
and therefore not receiving potentially life-saving genetic information 
and services. A number of factors have been identified as contributors 
to these poor public health outcomes, including a lack of available 
genetic counseling services due to a limited number of trained genetics 
professionals and their limited geographic distribution. Research 
has demonstrated the effectiveness of cancer genetic counseling 
delivered by telephone, but to date, almost no real-world experience 
has been reported. We provided statewide access to board-certified 
genetic counselors via telephone in Michigan beginning in February 
2010 and report our experience with the first 200 patients at risk for 
hereditary breast and ovarian cancer.
Materials and Methods: Baseline data were analyzed for all Michigan 
patients undergoing telephone genetic counseling through Informed 
Medical Decisions since service delivery began in February 2010. 
Variables include demographics, geographic location, personal cancer 
history, family cancer history, Gail risk and test appropriateness 
criteria.
Results: Analysis has been completed on the first 200 patients referred 
for consideration of hereditary breast and ovarian cancer. Outcomes 
include testing, results and, where applicable, reasons testing was 
not pursued, patient and provider satisfaction, as well as trends over 
time in patient volumes, providers using the service and uptake by 
geographic location.
Conclusion: Based on statewide experience in Michigan, telephone 
cancer genetic counseling is a viable method for service delivery in 
the real world. The Michigan experience can serve as a cost-effective 
model for improving genetic services in other locations with limited 
access to genetic experts.
P2-13-10
Detection, Visualization and High Resolution Physical Mapping of 
Large Rearrangements by Molecular Combing in the Hereditary 
Breast Cancer Genes BRCA1 and BRCA2.
Ceppi M, Roleau E, Cheeseman K, Thomas A, Briaux A, Lefol C, 
Walrafen P, Bensimon A, Lidereau R, Conseiller E. Genomic Vision, 
Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-
Cloud, France
The BRCA1 and BRCA2 genes are involved, with high penetrance, 
in breast and ovarian cancer susceptibility. About 2% to 4% of breast 
cancer patients with a positive family history who are negative for 
BRCA1 and BRCA2 point mutations can be expected to carry large 
genomic alterations (deletion or duplication) in one of the two genes, 
and especially BRCA1. However, large rearrangements are missed 
by direct sequencing.
Molecular Combing is a powerful FISH-based technique for direct 
visualization of single DNA molecules, allowing the entire genome to 
be examined at high resolution in a single analysis. We have developed 
a novel genetic test based on Molecular Combing. For that purpose, 
we designed specific BRCA1 and BRCA2 “Genomic Morse Codes” 
(GMC), also covering the non-coding regions and including large 
genomic portions flanking both genes. We developed a measurement 
strategy for the GMC signals, and validated our approach by blindly 
testing 10 breast cancer patients with a positive family history and 10 
control patients. Large rearrangements, corresponding to deletions and 
duplications of one or several exons and with sizes ranging from 3 kb 
to 40 kb, were detected on both genes, including the characterization 
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of 4 new mutations (for BRCA1: Del ex 3, Del ex 24 and Dup ex 3; 
for BRCA2: Dup ex 17-20). The identified mutations confirmed the 
results obtained with high-resolution zoom-in aCGH (11 k) in the 
same patients, with a resolution in the 1-2 kb range. Importantly, 
the developed GMC allowed to unambiguously localize several 
tandem repeat duplications on both genes, and to precisely map large 
rearrangements in the problematic Alu-rich 5’-region of BRCA1.
We propose the developed Molecular Combing genetic test as a 
valuable tool for the screening of tandem repeat duplications, CNVs, 
and other complex rearrangements in BRCA1 and BRCA2, such as 
translocations and inversions, to be combined in clinical settings with 
an essay that allows the detection of point mutations. We see the main 
application of the developed molecular diagnostic tool as a predictive 
genetic test. However, we envisage to extended the application of the 
developed tool as a companion diagnostic test, for instance in the 
screening of BRCA-mutated cells in the context of the development 
of PARP inhibitors. Thus, the genetic test may be applied not only to 
clinical blood samples, but also to circulating cells and heterogeneous 
cell populations, such as tumor tissues.
P2-13-11
Follow Up of BRCA1/2 Carriers: The Spectrum of Cancer 
Diagnoses in Healthy at Risk Individuals (HTR), and in Cancer 
Survivors (CS).
Clara AI, Costa CS, Silva J, Marques JC, Moura C, André S, Luís A, 
Bento S, Opinião A, Rodrigues P, Machado P, Fragoso S, Santos S, 
Vaz F. Instituto Português de Oncologia, Lisbon, Portugal
Introduction and Objective: Data from long term follow up of 
BRCA1/2 carriers is scarce and is mainly related to BRCA1 women. 
Our multidisciplinary program targets both women and men for 
counselling towards BRCA1/2 screening and inclusion in clinical 
follow up. In here we review all cancer diagnoses observed in our 
BRCA1/2 cohort during follow up.
Methods: Review of individual records of BRCA1/2 carriers 
registered from January 2000 to December 2010. Follow up was 
calculated since BRCA1/2 post-test counselling until the last visit to 
the Clinic. All new cancer diagnoses and preventive surgeries were 
registered.
Results: Two-hundred and fifty nine BRCA1/2 carriers (206 females 
and 53 males) were diagnosed with BRCA1/2 mutations (42 BRCA1 
and 217 BRCA2). Medium follow up for all population is 25 months 
(1-98). At the date of initial BRCA1/2 diagnosis 99 women and 14 
men were CS.
Female population: Eighty-eight female CS had been previously 
diagnosed with breast cancer (18 bilateral cases), 18 with ovarian 
cancer, and 1 with biliary tract cancer. Preventive surgeries in the 
CS female population were: bilateral adnexectomy (33 pts) and 
prophylactic contralateral mastectomy (10 pts). In this CS female 
population, new cancers, during follow up were: Contralateral breast 
cancer (4 cases), peritoneal cancer (2 cases in pts with previous 
prophylactic surgery) and skin non-melanoma cancers (2 cases). In 
female HTR, 23 preventive bilateral adnexectomies and 20 bilateral 
mastectomies were performed. Cancer diagnoses during follow up 
were: breast (11), peritoneum (1 in a pt with previous prophylactic 
surgery), gastric (1) and M3 leukemia (1). Global failure of 
prophylactic adnexectomy, so far (CS+HTR): 3/56 (5%).
Male population: The medium age for male CS is 73 yrs and for male 
HTR is 52 yrs. Male CS had mostly been previously diagnosed with 
BC (12; 4 bilateral) and prostate cancer (4). Other previous cancers: 
gastric (2), skin (2: 1Melanoma, 1 non-Melanoma), colorectal (1). One 
BRCA2 man with gynecomastia and prostate cancer was submitted to 
reduction mastectomy, as a preventive surgery. During follow up, we 
diagnosed second and third cancers in male CS: breast (2), prostate 
(6) and gastric (1). Only 1 male HTR was diagnosed with cancer: 
skin non-melanoma.
Conclusion: The proportion of second and third cancer diagnoses 
in the male BRCA2 CS population is higher than in the female 
BRCA1/2 CS population. Small numbers and the availability of 
preventive surgery for women influence this observation. No data 
from preventive mastectomy exists for males (we have one case). 
The low frequency of cancer in male HTR may be due to younger 
age and other unknown modifier factors. Longer follow is needed.
P2-14-01
Race, Response to Chemotherapy, and Outcome within Clinical 
Breast Cancer Subtypes.
Tichy JR, Deal AM, Anders CK, Carey LA. UNC, Chapel Hill, NC
Introduction: Racial disparity in breast cancer (BC) outcome 
has been attributed to access to care, socioeconomic factors, and 
biologic factors. In particular, the prevalence of triple negative BC is 
significantly higher among African-American (AA) women than white 
women (non-AA). However a recent population-based study suggests 
that racial disparities persist even if stratified by subtype, although it 
is possible that bias in stage at presentation may have influenced these 
results. In this study, we examined 464 women of uniform clinical 
stage II-III breast cancer, all treated with neoadjuvant chemotherapy, 
and examined pathologic complete response (pCR), recurrence-free 
survival (RFS), and overall survival (OS) to see if racial disparity 
exists within a more homogeneous stage and treatment cohort.
Methods: The UNC Neoadjuvant Breast Cancer Database is a 
prospectively maintained cohort with clinical and outcome annotation. 
We identified women diagnosed between 1991-2011 and assigned 
BC subtype by clinical assay for estrogen receptor and progesterone 
receptor (hormone receptors, HR) and HER2. Fisher’s Exact and 
Wilcoxon Rank sum tests compared characteristics between AA and 
non-AA. The Kaplan-Meier method and Log Rank test compared 
OS and RFS curves.
Results: 142 (31%) of 464 women were AA, 294 (63%) were white, 
and 28 (6%) were other races (for analysis white and “other” were 
categorized as non-AA). 191 (41%) were clinical stage II and 273 
(59%) stage III at diagnosis. Stage at diagnosis did not differ between 
AA and non-AA (p=0.07). AA were slightly older (median age 49 
v 45, p=0.01) and were more likely to be HR-/Her2- (44% v 25%, 
p=0.003). All patients received preoperative chemotherapy. AA 
received less biologic therapy such as trastuzumab or on-protocol 
bevacizumab (10% v 18%, p=0.03) and received significantly less 
endocrine therapy (46% v 59%, p=0.01) than non-AA patients. 102 
(22%) of patients had a pCR to neoadjuvant chemotherapy; pCR 
rates did not differ significantly by race (p=0.7) or within subtype 
by race (all p>0.14). At a median follow-up of 4.5 years, 121 (26%) 
of patients have died. Among HR-/HER2- (n=114) and HR-/HER2+ 
(n=47) patients, OS and RFS did not differ between AA and non-AA 
(all p>0.5). Conversely, among HR+/HER2- patients (n=159) AA 
had worse OS (p=0.01) and RFS (p= 0.03) and among HR+/HER2+ 
patients (n=53), AA had worse OS (p=0.0004) and RFS (p=0.005).
Table 1
5 yr RFS HR-/HER2- HR-/HER2+ HR+/HER2- HR+/HER2+
 n=114 n=47 n=159 n=53
AA 61% (45%-75%) 61% (26%-83%) 52% (31%-69%) 36% (11%-61%)
Non-AA 71% (57-81%) 74% (51%-88%) 76% (65%-84%) 81% (59%-92%)
p-value 0.5 0.6 0.03 0.005
Conclusion: In this cohort of clinical stage II-III BC patients, AA 
women were over 75% more likely to have triple negative BC than 
non-AA patients. Pathologic reponse to chemotherapy did not differ 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011309s
December 6-10, 2011 Abstracts: Poster Session 2
between AA and non-AA patients. Examining the entire cohort, AA 
women had worse RFS and OS, however there was no difference 
among ER-negative subtypes. The difference in RFS and OS was 
driven by worse outcome among women with ER or PR+ tumors 
(regardless of HER2). It is possible that this racial disparity in outcome 
among hormone receptor-positive BC patients reflects unknown 
biologic differences by race, or differences in access to or receipt of 
endocrine therapy.
P2-14-02
NCIC CTG MA.27: Clinical Tolerability and Overall Survival 
of Racial and Ethnic Minority Women on Aromatase Inhibitor 
Therapy.
Moy B, Shepherd LE, Chapman J-AW, Le Maitre A, Gelmon KA, Elliott 
C, Ingle JN, Goss PE. Massachusetts General Hospital, Boston, MA; 
National Cancer Institute of Canada Clinical Trials Group, Kingston, 
ON, Canada; British Columbia Cancer Agency, Vancouver, BC, 
Canada; Mayo Clinic, Rochester, MN
Background: Aromatase inhibitors (AIs) are standard adjuvant 
therapy for postmenopausal women with hormone receptor-positive 
breast cancer. We previously reported that racial/ethnic minority 
women receiving an AI in NCIC CTG MA.17 experienced fewer 
hot flashes, fatigue, and arthralgias than Caucasians (Moy B et al. 
Ann Oncol 2006;17:1637). Here we examined whether race affected 
clinical outcomes in the MA.27 AI trial comparing exemestane (E) 
with anastrozole (A). Methods: Fisher’s exact test was used to 
compare observed side effects (0 vs grades 1-5) between minority 
and Caucasian women. Adverse events (AE), including menopausal 
symptoms, were assessed according to the Common Terminology 
Criteria of the National Cancer Institute (version 3.0). ITT univariate 
test of race effects on overall survival (OS) was determined with a 
stratified log-rank test, while multivariate testing was with stratified 
Cox regression. Results: Among 7312 for whom race was known, 
distribution was: Caucasian (n=6939; 95%); black (n=235; 3%); 
Asian/Native Hawaiian/Pacific Islander (n=93); 1%; American Indian 
(n=39; 1%); and mixed race (n=6). Among women treated with E, 
minorities reported a significantly lower incidence of hot flashes (45% 
vs. 56%; p=0.003) and fatigue (34% vs. 46%; p=0.001) compared to 
Caucasians. Similarly with A, minority women reported significantly 
fewer hot flashes (47% vs. 58%; p=0.002) and lower cholesterol 
(12% vs. 18%; p=0.01); however, they reported more headaches 
than Caucasians (16% vs. 10%; p=0.01). Caucasian women were 
more likely to discontinue therapy due to AE or side effects (32% 
vs. 24%). There was a significant OS interaction (p=0.02) between 
race and treatment with minority women on E having fewer deaths 
than those on A. Caucasian women had HR of E to A of 0.98 (95% CI 
0.81-1.20), p=0.85, while minorities had HR of E to A of 0.72 (95% 
CI 0.33-1.58), p=0.41. Conclusions: Minority women tolerated AIs 
better and were also more compliant than Caucasians, supporting our 
previous findings. A significant interaction between race and type of 
AI therapy for OS was seen, favoring exemestane in minority women. 
Replication of these findings in larger cohorts is necessary. Since race/
ethnicity may serve as a surrogate for genetic differences, our findings 
suggest pharmacogenomic differences which require further research.
P2-14-03
A Comparison of Biologic Differences in Tumors in a Matched 
Cohort of Hispanic and Caucasian Women with Early-Stage 
Breast Cancer Using the 21-Gene Recurrence Score Assay.
Lim EA, Hershman DL, Greenlee H, Crew KD, Maurer MA, 
Hibshoosh H, Kalinsky K. Columbia University Medical Center, New 
York, NY; Mailman School of Public Health, New York, NY
Background: Several studies demonstrate that Hispanic women 
have a higher mortality rate and lower incidence of breast cancer 
(BC) as compared to Caucasian women. This survival pattern has 
also been observed in Hispanic women with untreated, early-stage 
BC. The Hispanic population should be considered a heterogeneous 
group, however, given the various racial and national backgrounds 
that comprise this entity. As African American (AA) similarly 
demonstrate a worse survival as compared to Caucasian women, a 
retrospective analysis of 27 tumor from AA patients (pts) showed 
a significantly higher expression of the 5 proliferation genes in the 
21-gene recurrence score (RS) assay (Oncotype Dx) as compared 
to other races, with no significant difference observed in the 21-
gene RS. The primary aim of this analysis is to investigate biologic 
differences between Hispanic women in a primarily Dominican 
Republic population, as compared to Caucasian women, as determined 
by indices in the 21-gene RS assay.
Methods: We collected data from women with early-stage breast 
cancer who underwent RS assay testing between 2005 and 2011. Pt 
charts were reviewed for ethnicity (Hispanic or other), country of 
origin, RS, 10-year risk of distant recurrence, and breast tumor ER/
PR/HER2 expression by Oncotype Dx. Hispanic pts were matched to 
Caucasians in a 1:2 fashion based on age (+/- 10 years), tumor stage, 
and presence of lymph node metastases. Prognostically important 
clinicopathologic features were collected, including lymphovascular 
invasion (LVI) and grade. Descriptive statistics were computed. 
Two Sample t-testing was used to evaluate if RS was equal across 
by ethnicity groups.
Results: Of 214 pts who underwent RS testing, 30 (13.5%) were 
Hispanic: 18 from the Dominican Republic, 5 from Puerto Rico, 
and 1 from various Central and South American populations. The 30 
Hispanic women were matched to 57 Caucasians: total population 
87 pts. The mean RS for Caucasian women was 18.3 (range: 0-54) 
and for Caucasians: 15.5 (range: 1-38). By two Sample t test, no 
statistically different differences were observed between Hispanic and 
Caucasian women in regards to the RS (p= 0.2828) or 10-year distant 
recurrence score after 5 years of anti-estrogen therapy (p=0.4218). No 
differences were observed in median ER expression (9.4% vs. 10.1%: 
Hispanic vs. Caucasian), PR (7.2% vs. 7.7%), or HER2 (9.2% vs. 
9.0%). LVI was numerically more frequently identified in Hispanic 
pts [7/30 (23.3%) vs. 8/57 (14.0%)], as were grade III tumors [7/30 
(23.3%) and 4/57 (7%)].
Conclusions: Similar to the findings with AA pts, there was no 
significant difference in RS between Hispanic and matched Caucasian 
women with early-stage BCs. A numerical trend to a higher RS was 
seen in this Hispanic population of primarily pts from the Dominican 
Republic. We will evaluate for differences in the 5 genes involved 
in proliferation (CCNB1, MKI17, MYBL2, BIRC5, AURKA). Also, 
further analyses will be conducted with additional pts to determine 
if the numeric differences in RS, LVI, and grade are observed in a 
larger cohort.
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P2-14-04
The Influence of Demographic, Psychosocial and Emotional 
Barriers to Screening for Colorectal and Ovarian Cancer among 
Latina Breast Cancer Survivors.
Ramirez AG, Holden AE, San Miguel SL, Gallion KJ. UT Health 
Science Center at San Antonio, San Antonio, TX
Background Ten percent of all new cancers are diagnosed in cancer 
survivors and second cancers are the sixth leading cause of cancer 
deaths. Breast cancer survivorship brings to the fore concern that 
survivors obtain thorough preventive health screening services. In 
two previous studies, we observed that Latina women are unable to 
comply with recommendations for breast cancer care due in part to 
psychosocial barriers including inability to understand physicians 
and fear of recommendations. Affective influences, particularly 
depression may also contribute to noncompliance via its inhibitory 
effect on vigilance. Here we test a hypothesis that similar barriers in 
addition to depression level restrict breast cancer survivor screening 
for colorectal and ovarian cancer.
Methods We conducted a cross-sectional study of 117 Latina breast 
cancer survivors using self-report data. Proportions of respondents 
compliant and noncompliant with recommended screening protocols 
were compared. Reasons were coded “yes”-”no”; depression was 
measured with the Center for Epidemiologic Studies (CESD) 
instrument dichotomized at the usual cutoff of 16 points or higher 
signifying depression. Cancer screening compliance was determined 
by published NCI guidelines. Associations were determined via chi-
squared analysis. Multivariate analysis was conducted using logistic 
regression.
Results Only 5 (4.2%) of participants were screened for both cancers, 
43 (36.8%) for either cancer, and 69 (59.0%) were screened for neither 
cancer. Reported barriers to cancer care were generally high with 
respect to screening for other cancers, but only “cannot understand 
English” (66% v 53%, p=.05) and “care is too expensive” (84% v 
71%, p=.05) were associated with lack of ovarian cancer screening 
and none were associated significantly with lack of colorectal 
screening. Thirty-two percent of the sample met CESD criteria for 
depression, nearly twice the general population rate; it is associated 
with ovarian but not colorectal screening noncompliance. Factors 
including unemployment (74% v 57%, p=.03) and no familial history 
of cancer (75% v 53%, p=.02) are related to non-compliance with 
ovarian screening, but only unmarried status is related to colorectal 
screening (54% v 20%, p=.01). Separate multiple logistic regression 
analyses confirmed the independent significant association of these 
factors with ovarian and colorectal screening compliance, indicating 
good model fit and significant proportions of variance explained by 
the models.
Discussion There are significant impediments to cancer screening 
among Latina breast cancer survivors. They derive from multiple 
domains (demographic factors, psychosocial barriers, and affective 
states). For this reason they require further research to clearly identify 
them. Moreover we must develop an equally broad-based preventive 
strategy that addresses each of these domains to promote vigilance 
and increase healthy behaviors among Latina women.
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P2-14-05
Racial Differences in the Use of Adjuvant Chemotherapy for 
Breast Cancer in a Large Urban Integrated Health System.
Simon MS, Lamerato L, Krajenta R, Booza J, Ruterbusch J, Kunz S, 
Schwartz K. Karmanos Cancer Institute at Wayne State University, 
Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State 
University, Detroit, MI
Background: Despite improvements in breast cancer treatment, there 
continues to be a gap in survival between African American (AA) and 
White women with breast cancer, which may be due at least in part to 
racial differences in the patterns of care. In order to better understand 
breast cancer survival disparities, we evaluated racial differences in 
the receipt of adjuvant chemotherapy among women treated at a large 
integrated health care system in Southeastern Michigan. Materials 
and Methods: The study population included 2,234 women (33 % 
AA) with stage I through III breast cancer treated at the Henry Ford 
Health System (HFHS) from 1996 through 2005. Linked datasets 
from the HFHS, the Metropolitan Detroit Cancer Surveillance System 
(MDCSS) and the U.S. Census Bureau were used to obtain socio-
demographic and clinical information. Co-morbidity was assessed by 
the Charlson co-morbidity index (CCI), and economic deprivation was 
categorized using a neighborhood deprivation index (DI). Results: 
AA women were significantly more likely than Whites to have larger 
tumors (40% vs. 31% > 2 cm), as well as more aggressive tumors 
(29% vs 19% estrogen and progesterone negative). AA women were 
also significantly more likely than Whites to have other co-morbid 
conditions (15 % vs. 8% with a CCI of 2+) and to reside in a more 
economically deprived area (45% vs. 5% reside in the most deprived 
area). While AA women were more likely to receive adjuvant 
chemotherapy (47% vs. 43%, p=0.0278), they were also more likely 
to have a delay in initiation of treatment (57% vs 45% delayed beyond 
60 days from diagnosis, p=0.0004). After multivariable adjustment for 
age, DI, CCI, insurance and surgery, there were no racial differences 
in treatment delay (Odds Ratio 1.20, 95% confidence interval, 0.82-
1.77). Discussion: In a large urban integrated health care system, racial 
differences in the delay in receipt of adjuvant chemotherapy for breast 
cancer can be explained by clinical and socioeconomic characteristics.
P2-14-06
Clinical and Pathologic Characteristics of Haitian Breast Cancer 
Patients in a Tertiary Care Safety Net Hospital.
Loch MM, Ross AA, Rosenberg C, Blanchard RA. Boston University 
Medical Center, Boston, MA; Boston University, Boston, MA
Background: There is limited literature regarding Haitian women and 
breast cancer. What exists is based on screening with no literature on 
clinical or pathologic subtypes of breast cancer. We examined patient 
and tumor characteristics in Haitian born women with invasive breast 
cancer in our ethnically diverse tertiary care hospital.
Methods: We expanded a pre-existing database to include all women 
diagnosed with breast cancer from 1998-2011. From the electronic 
medical record we documented age, body mass index (BMI), place of 
birth, self-identified race/ethnicity, date of diagnosis, T, N, M stage, 
grade, ER, PR, HER2 expression, recurrence and treatment data 
including neoadjuvant, surgical, adjuvant and radiation therapy and 
adequacy of treatment. We determined associations using contingency 
tables and multivariate logistic regression.
Results: 480 cases identified. Patients were racially diverse: 35% 
white (W), 41% black (B), 14% Hispanic and 10% other with 8% of 
patients self-identified as Haitian (Ha). Ha patients were younger at 
diagnosis, with mean age 55.1 vs. 59.4 overall p=0.04. Mean age W: 
62 B: 58. Mean BMI was not significant. Ha women had an odds ratio 
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(OR) of triple negative (Tneg) breast cancer: 3.078 (CI: 1.608-5.892, 
p=0.0007), B: 3.392 (CI: 2.113 - 5.441, p=<0.0001), W: 0.339 (CI: 
0.192-0.599, p=0.0002) when controlling for age and BMI. Ha OR of 
ER+: 0.459 (CI: 0.246-0.859, p=0.0149), B: 0.384 (CI: 0.257 - 0.575, 
p<0.0001), W: 0.8771 (CI: 1.525 - 3.792 p=0.0002). Ha OR of PR+: 
0.535 (CI: 0.288-0.995, p=0.0481) when controlling for age and BMI. 
Her2+ expression was not significantly different. OR of recurrence 
in Ha: 2.110 (CI: 1.068-4.171, p= 0.0317) controlling for age and 
BMI. When grade was added to the multiple regression model, the 
odds of recurrence in Ha women was no longer significant OR 1.845 
(CI: 0.923-3.690, p=0.0833); however, recurrence appeared to be 
associated with grade OR 1.858 (CI: 1.273-2.711, p=0.0013). Higher 
grade was significantly associated with Ha status, controlling for 
categorical age and BMI (mean score differences p = 0.0086). Crude 
rates of each grade in Ha women were 4% grade 1, 38% grade 2, 58% 
grade 3 and the rates in non-Ha women were 14% grade 1, 48% grade 
2, 38% grade 3. Exploring recurrence further, treatment records were 
reviewed and while a minority of patients did not receive adequate 
primary therapy, the majority of women did receive adequate therapy.
Conclusions: Ha women were younger at diagnosis, had a higher 
risk of triple negative, ER negative and PR negative tumors and had 
more grade 3 tumors when controlling for age and BMI. Rates of 
recurrence appeared higher in Ha women, but the association was no 
longer significant when controlling for grade in addition to age and 
BMI. Analysis is ongoing, and we expect to report data on survival 
and treatment adequacy when compared to other groups in our dataset.
P2-14-07
Ethnic Differences in Breast Cancer Molecular Subtypes and 
Survival Outcomes in a Multi-Ethnic Singaporean Population.
Yap Y-S, Lo S-K, Ng RCH, Dent R, Ramya G, Chen WJJ, Ho G-H, 
Chua E-T, Tan P-H, Wong N-S. National Cancer Centre Singapore, 
Singapore, Singapore; Singapore General Hospital, Outram Road, 
Singapore, Singapore
Background: Previous studies have described differences in breast 
cancer biological subtypes from various ethnic backgrounds such as 
women of African descent. Data on the heterogeneity of breast cancer 
biology among Asian ethnic groups is limited.
Objectives: The aim of this study was to evaluate the frequency of the 
different immunohistochemical (IHC) subtypes of breast carcinoma 
and clinical outcomes among Chinese, Malay and Indian patients 
(pts) at a single Singaporean institution.
Methods: Local pts of Chinese, Malay and Indian ethnicity seen at the 
National Cancer Centre Singapore (NCCS) and diagnosed with breast 
cancer from 2001 to 2004 were included in this retrospective study. 
Tumours were classified using IHC profiles as 1)”Luminal”: (ER+ 
and/or PR+, HER2-), 2) HER2 overexpressing (HER2+ regardless 
of hormone receptor status) and 3) Triple Negative (TNBC: ER, 
PR and HER2-). Data was collected on pt and tumor characteristics 
including stage, grade, body mass index (BMI), treatment received 
including chemotherapy and endocrine therapy, as well as disease-
free survival(DFS) and overall survival(OS). Statistical analysis was 
performed using PASW statistics version 18.
Results: Out of the total of 2,061 pts in this study, 86.6% were 
Chinese, 8.7% were Malays and 4.7% were Indians. Among pts with 
fully defined receptor status(n=1,427), Chinese pts were more likely 
to have “luminal” breast cancer at 57% compared with 45% among 
Malays (p=0.005) and 50% among Indians (p=0.11, ns). Malay and 
Indian pts were more likely to have TNBC compared with Chinese 
pts (25.2% and 25% versus 16.6%, p=0.0082 and 0.027 respectively). 
The frequency of HER2-overexpressing breast cancer did not differ 
significantly among the Chinese(26.6%), Malay(30.1%) and Indian 
pts(25%). A greater proportion of Malay pts presented at more 
advanced stage of 3 or 4 than Chinese and Indian pts (45.6% vs 32.1% 
and 31.5%, p<0.001 and 0.01 respectively), and were diagnosed at 
an earlier age than Chinese and Indians (48.5y vs 52.3y and 52.2y, p 
<0.001 and 0.05 respectively). The frequency of grade 3 cancers was 
higher among Malays and Indians compared with Chinese (52.3% 
and 56.3% vs 42%, p=0.007 and 0.006 respectively), and had higher 
BMI compared to Chinese pts (26.4 and 26.2 vs 22.8, p<0.001 and 
<0.001 respectively). Malay pts also had lower 5-yr DFS at 59 % and 
5-yr OS at 76% compared with 76%(p=<0.001) and 84%(p=0.04) in 
Chinese pts. Survival analyses on Indian pts were limited by the small 
numbers. Full multivariate analyses will be tabulated.
Conclusions: There are significant differences in the frequency of 
various subtypes of breast cancer among the Chinese, Malays and 
Indians in Singapore. The disparities in survival outcomes between 
the Chinese and the Malays may be related to more aggressive tumor 
biology, more advanced stage at diagnosis and host factors such as 
higher BMI. The full impact of ethnicity on breast carcinogenesis is 
still unknown but is increasingly relevant with the development of 
therapies that target specific molecular pathways.
P2-14-08
Hormone Receptor Status and Breast Cancer Survival among 
Hispanic and Non-Hispanic White Women over 10 Years of 
Follow-Up.
Denkhoff SR, Baumgartner KB, Yang D, Pinkston CM, Baumgartner 
RN. University of Louisville, Louisville, KY
Introduction: The joint presence or absence of expression of estrogen 
receptor (ER+/-), progesterone receptor (PR+/-), and Her2neu 
(Her2+/-) is now widely used to define the hormone receptor (HR) 
phenotype of breast tumors. HR phenotype influences breast cancer 
etiology, response to treatment and survival, which may vary by 
ethnic group. The triple negative phenotype (TNT: ER-/PR-/Her2-) is 
associated with the poorest survival and is more common in African 
American than white women. Few studies have assessed how HR 
status differs by Hispanic (H) versus non-Hispanic white (NHW) 
ethnicity in relation to survival.
Methods: We analyzed data from the New Mexico site of the ‘Health, 
Eating, Activity and Lifestyle’ (HEAL) study for breast cancer 
mortality over 10 years of follow-up by HR phenotype and ethnicity 
for 126 H and 408 NHW women with invasive (I-IIIA), first primary 
breast cancer. Kaplan Meier curves were used to describe differences 
in survival by ethnicity and HR phenotype (ER+/PR+/Her2+, referent; 
ER+/PR+/Her2-; ER-/PR-/Her2+; and ER-/PR-/Her2-). Hazard ratios 
were estimated using Cox regression models stratified by phenotype 
and ethnicity, adjusting for age at diagnosis, stage, and diagnosis of 
another cancer (yes/no).
Results: Kaplan Meier (KM) analysis indicated that the TNT 
phenotype was associated with poorer survival, particularly during the 
first 5 years, although the difference was not statistically significant 
after 10 years of follow-up (p=0.36). The prevalence of TNT was 
higher in H (10.3%) than NHW (6.6%) women, and H also tended to 
poorer survival than NHW women (p=0.17). In multivariate-adjusted 
models, women with a TNT phenotype had a 26% increased risk of 
death (HR=1.26 95% CI 0.62-2.6). In NHW women, the risk was 
12% (HR=1.12 95% CI 0.43-2.9). Among H women, those with a 
TNT phenotype had a 17% increased risk of death (HR=1.17 95% 
CI 0.35-3.8) while those with ER-/PR-/Her2+ had a 46% increase 
(HR= 1.46 95% CI 0.40-5.3).
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Discussion: Although this analysis is limited by small numbers, the 
results suggest that H women may have worse 10-year survival rates 
than NHW women and that women with TNT have a higher risk of 
death regardless of ethnicity. These differences in survival could be 
due to a higher rate of recurrence or issues related to treatment. This 
study suggests that there is an ethnic disparity in survival by HR 
subtypes that should be examined in a larger population based study.
P2-14-09
Comparison between Spanish and Peruvian Patients with Early 
Breast Cancer.
Castaneda CA, Gomez HL, Vallejos C, Cortes-Funes H, Castellano D, 
Andrés E, Cruz W, Ciruelos EM. Instituto Nacional de Enfermedades 
Neoplásicas, Lima, Peru; Hospital Universitario 12 de Octubre, 
Madrid, Spain
Purpose: Breast Cancer (BC) is a genetic, heterogeneous disease and 
has a remarkable variability according to racial factors. Hypothetic 
explanations for these disparities include differences in tumor 
biology. The present study was designed to compare clinical and 
pathological features between Peruvian Latinas and Spanish women 
with BC; interest of this analysis increases if we take into account the 
relationship among historic ancestries of both ethnic groups (Incas 
emporium and Spanish conquers).
Methods: Information was retrospectively reviewed from patients 
files and pathologic reports from Instituto Nacional de Enfermedades 
Neoplasicas (INEN) in Lima- Peru, and Hospital Universitario 
12 de Octubre in Madrid- Spain. In order to produce comparative 
information and avoid subjective clinical measurements we selected 
only non-metastatic and non-bilateral invasive BC cases that 
underwent surgery as initial therapy. BC cases were classified as 
molecular subtypes: Luminal A [RE+ and/ or RP+, HER2-], Lum B 
[RE+ and/ or RP+, HER2+], triple negative (TN) [RE-, RP-, HER2-] 
and HER2 [RE-, RP-, HER2+]. Variables were compared with the X2 
test and survival curves were evaluated with Kaplan-Meier method.
Results: The study included 3765 BC cases. The Spanish cohort 
involved 1539 (40.9%) women consecutively diagnosed between 
1997 and 2007 (median follow-up of 7.9 years). The Peruvian cohort 
involved 2226 (59.1%) women consecutively diagnosed between 
2000 and 2006 (median follow-up of 6.3 years).
In terms of pathological features, grade I tumors were more frequent 
in Spanish (16.2%) than Peruvian women (9.6%) (p<0.001). Higher 
rates of lobular histology were also found in Spanish (12.5%) than 
Peruvian (6.0%) women (p<0.001). Spanish cases presented at earlier 
stages when evaluated by lymph node status (N0 in 58.9% vs 47.1%) 
(p<0.001) or by tumor size (T1 in 37.9% vs 17-2%). Conservative 
surgery were more frequent among Spanish cases (50.6% vs 16.8%) 
(p<0.001). TN molecular subtype were more frequent among Peruvian 
cases (22.5% vs 12.4%) (p<0.001).
Brain (10.4% vs5.3%), and skin and subcutaneous (7.1% vs 2.4%) 
metastases were more frequently found in Peruvian patients. On the 
other hand, contralateral breast cancer was more frequent among 
Spanish patients (12.2% vs 2.8%).
And when evaluated by molecular subtypes, bone metastases in TN 
were more frequent among Spanish (25.4%) than Peruvian (18.5%) 
cases.
Table 1: Recurrence site of breast cancer in Spanish and Peruvian Triple-Negative Breast Cancer
Recurrence location Triple- Negative
 Hospital 12 de Octubre INEN
Contralateral 5 (7%) 4 (3.2%)
Locoregional 25 (35.3%) 40 (32.2%)
Lung and pleura 21 (29.6%) 33 (26.6%)
Bone 18 (25.4%) 23 (18.5%)
Disease-free survival rates at 7 years were similar between Spanish 
and Peruvian patients (80,3% vs 79,6%, p=0.197). However, overall 
survival at 7 years was better in Spanish women (90.4% vs 82.6%, 
p<0.001).
Conclusion: Epidemiologic differences in terms of histological 
features, clinical stage at diagnosis, molecular subtypes distribution, 
recurrence patterns and prognosis were found among Spanish and 
Peruvian BC patients in this retrospective analysis.
P2-14-10
Are There Variations in Invasive Tumour Characteristics between 
Different Ethnic Groups?
Hariri B, Lo M, Gandamihardja T, Lewis J, Hogben K. Imperial 
College Healthcare NHS Trust, Charing Cross Hospital, London, 
United Kingdom
Introduction
Studies have shown that ethnic minorities with breast cancer are 
more likely to present at a younger age and with more aggressive 
tumours. The aim of this study was to examine the variation in tumour 
characteristics and surgical outcomes in different ethnic groups in our 
breast unit over a 12-month period.
Methods
A retrospective study was performed on all patients with a new 
diagnosis of breast cancer, either screen-detected or symptomatic, 
between January to December 2009. Using our Trust databases, 
data on patient demographics, tumour characteristics, and ethnicity 
were collected. Where ethnicity was not documented, patients were 
contacted by telephone to complete the database. Those unable to 
be contacted were excluded from the study. Other exclusion criteria 
include those with recurrent ipsilateral breast cancer.
Results
A total of 270 patients (265 females) were included in our study, of 
which 235 (87%) had invasive cancers (ductal carcinoma, lobular 
carcinoma, tubular carcinoma, mucinous carcinoma, cribriform 
carcinoma, papillary carcinoma, sarcoma) and the remaining 35 
patients (13%) had non-invasive cancers (ductal carcinoma in-situ, 
lobular carcinoma in-situ, papilloma, columnar cell hyperplasia).
We were unable to contact 23 (8.5%) patients to ascertain their 
ethnicity, and therefore these have been excluded from our results.
 Ethnicity (n)
 White Black Asian Chinese Mixed Other
Number of patients 161 8 24 2 2 10
Mean age (years) 59 52 54 59 59 57
Age range (years) 25-86 39-69 37-75 48-68 49-67 39-67
Size of tumour
<15mm 64 3 7 2 0 4
≥15mm 76 4 15 0 2 6
Multifocal 14 0 2 0 0 0
Lymph node status
Negative 95 6 10 2 1 7
1-3 42 1 7 0 0 1
>3 13 1 3 0 1 0
Grade
1 35 1 3 0 1 0
2 97 3 16 2 1 6
3 24 3 4 0 0 3
Receptor status
ER positive 141 4 20 2 2 6
Triple negative 5 5 1 0 0 0
Surgical intervention
Wide local excision 102 6 12 1 1 6
Mastectomy 58 2 12 1 1 4
Table 1. Tumour characteristics and surgical intervention in patients with invasive breast cancer in 
2009
Conclusion
We found that the age of breast cancer presentation was lowest 
in Black and Asian patients (mean age 52 years and 54 years, 
respectively), compared to White (mean age 59 years). Furthermore, 
compared to white patients, tumours in Asian patients were larger 
(62.5% vs 47.2%), of higher grade (83.3% vs 75.2%), more likely 
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to be ER negative (16.7% vs 12.4%), and tended to be lymph node 
positive (41.7% vs 34.2%). These may explain the higher mastectomy 
rate in Asian patients (n=12, 50%).
The reason for the younger presentation age in the ethnic Asian group 
is unclear. However, it is possible that their cancer may have different 
tumour biology. Other studies have suggested reasons such as birth 
cohort effect and obesity.
Reflecting the United Kingdom’s population the majority of patients 
that present to our breast unit are White and the number of Asian 
patients remains small. An increase in the sample size may strengthen 
our results.
P2-15-01
Surgical Patterns of Care after Magnetic Resonance Imaging in 
the Academic Setting in Patients with Operable Breast Cancer 
Treated with Neoadjuvant Systemic Therapy: A Secondary 
Analysis of TBCRC 017.
De Los Santos J, Cantor A, Mcguire K, Golshan M, Meric-Bernstam 
F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang 
S. University of Alabama at Birmingham, Birmingham, AL; University 
of North Carolina Chapel Hill, Chapel Hill, NC; Dana-Farber Cancer 
Institute, Boston, MA; Duke University Medical Center, Durham, NC; 
Memorial Sloan Kettering Cancer Center, New York, NY; University 
of Pittsburgh Medical Center, Pittsburgh, PA; MD Anderson Cancer 
Center, Houston, TX; Vanderbilt University, Nashville, TN; University 
of Chicago, Chicago, IL; University of California at San Francisco, 
San Francisco, CA
Background: Neoadjuvant chemotherapy is increasingly used to 
downstage locally advanced tumors, test new regimens, and improve 
chances of breast conservation. In parallel, use of breast MRI for 
surgical planning and as a potential response biomarker has also 
increased along with an observed increase in mastectomy rates. This 
secondary analysis reports surgical patterns of care across 8 NCI 
comprehensive cancer centers in women receiving both neoadjuvant 
therapy and breast MRIs.
Methods: 770 women from 8 institutions were retrospectively 
identified as having received neoadjuvant systemic therapy with MRI 
done before and after systemic treatment. Univariate and multivariate 
analyses of covariates associated with surgical management were 
performed. Within MRI complete response or not, the Jonckheere-
Terpstra Test (JTT) was used to test for a trend in mastectomy rate 
by T stage.
Results: Surgical data was available on 763/770 patients. Table 1 lists 
MRI response by pretreatment imaging size and final breast surgery. 
Distribution of pretreatment imaging-defined T stage was as follows: 
T1 66 (8%), T2 436 (57%), T3 230 (30%), and T4 36 (5%). 347/763 
(45%) patients received breast conserving surgery and 416/763 
(55%) had a mastectomy. 58% vs 43% (p=0.0003) of those with an 
incomplete vs complete MRI response had a mastectomy, respectively. 
Univariate logistic regression analysis of covariates significantly 
associated with use of mastectomy included ER- status (p=0.01), 
incomplete MRI response (p=0.0003), higher T stage (p<0.0001), 
chemotherapy regimen (p=0.006), younger age (p<0.0001), and 
institution (p=0.002); all except chemotherapy regimen and institution 
remained independent predictors of mastectomy on multivariate 
analysis. Patients with larger baseline T stage and an incomplete 
response on MRI (P<0.001) were more likely to undergo mastectomy. 
Overall, breast conservation was low (262/495, 53%) of all T1-T2 
patients, especially in the T1 subset (26/65, 40%).
Conclusions: In a contemporary group of women treated with 
preoperative chemotherapy at NCI designated cancer centers and 
with available pre/post MRI, we observed a lower frequency of 
breast conservation as compared to historical data from prospective 
randomized trials. Larger tumor size at baseline was associated with 
higher mastectomy rates. However, even among those with a complete 
MRI response, 43% had a mastectomy. In addition to clinical response 
and MRI findings, factors not examined here (e.g., BRCA status, 
education level, and patient/provider preference) may influence the 
decision-making process and deserve further evaluation.
Pretreatment  
T stage* MRI Response
 Complete Incomplete
 Lumpectomy Mastectomy p-value Lumpectomy Mastectomy p-value
Entire Cohort 105/184 (57%) 79/184 (43%) 0.3520** 240/575 (42%) 335/575 (58%) <0.0001***
T1 9/26 (35%) 17/26 (65%)  17/39 (44%) 22/39 (56%)  
T2 73/115 (63%) 42/115 (37%)  163/315 (52%) 152/315 (48%)  
T3 21/39 (54%) 18/39 (46%)  50/188 (27%) 138/188 (73%)  
T4 2/4 (50%) 2/4 (50%)  10/31 (32%) 21/31 (68%)  
*T stage was defined by largest single dimension by imaging
**Comparing T1 vs T2 vs T3 vs T4 for rCR by JTT 
***Comparing T1 vs T2 vs T3 vs T4 for incompletes by JTT.
P2-15-02
Are We Performing More Mastectomies on Women Diagnosed 
with Invasive Breast Cancer?
Lo MCI, Hariri B, Gandamihardja T, Lewis J, Hogben K. Imperial 
College Healthcare NHS Trust, Charing Cross Hospital, London, 
United Kingdom
 Introduction 
Surgical management of breast cancer has changed over the past 
several decades; breast-conserving surgery has become widely 
accepted. Mastectomies, however, are still being performed as part 
of the management of breast cancer. The aim of this study was to 
investigate the indications for mastectomy in women with invasive 
breast cancer within our institution.
 Method 
A systematic review of all new patients with invasive breast cancer 
treated with surgical intervention at our breast unit in the years 
2000, 2005 and 2009 was performed. Using our databases, patient 
demographics, tumour characteristics and reasons for mastectomy 
were examined. Screen-detected and symptomatic patients were 
included in the study. Patients excluded were those with incomplete 
data and recurrent breast cancer.
 Results 
A total of 584 patients (F:M, 576:8); with cancer types which included 
invasive ductal carcinoma (n=501, 84%), invasive lobular carcinoma 
(n=51, 9%), invasive tubular carcinoma (n=27, 5%) and sarcomas 
(n=5, 1%) were studied.
Table 1: Type of surgery performed in patients with invasive breast cancer
 Years
 2000 2005 2009
Number of patients (n) 170 189 225
Surgical intervention n (%)
Wide local excision 33 (92) 115 (84) 52 (85) 74 (58) 71 (90) 70 (48)
Mastectomy 3 (9) 22 (16) 9 (15) 54 (42) 8 (10) 76 (52)
italic - screen-detected patients; non-italic - symptomatic patients
Table 2: Indications for mastectomy in patients with invasive breast cancer in 2009
  Screen-detected (n)  Symptomatic (n) 
 Number of patients 9 75
 Mean age (years) 59 58
 Age range (years) 51-66 25-86
 Size of invasive cancers 
<15mm 1 18
≥15mm 8 51
Other a 0 6
 Indications for mastectomy 
Multifocal lesion 5 38
Large tumour in relation to breast size 1 10
Location of tumour 0 3
Patient choice 4 13
- Family history of breast cancer 0 2
- Fear of further treatment 1 7
a Tumours with sizes not recorded 
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Conclusion 
In our institution, the majority of patients with screen-detected 
invasive breast cancer fulfilled the criteria to have breast-conserving 
surgery; mastectomy rate for screen-detected cancers remained 
stable. However, we found that in the symptomatic patient group, 
there was an increase in mastectomy rate from 16% (n=170) in 2000 
to 52% (n=225) in 2009. Despite this trend, our results were still 
in keeping with the national standard as illustrated by the National 
Cancer Intelligence Network, where they noted that in 2006, 52% 
of symptomatic patients with invasive breast cancer underwent 
mastectomy in the United Kingdom.
The reason for a higher mastectomy rate in symptomatic patients 
compared to screen-detected patients in 2009 is multifactorial. We 
found that a larger proportion of symptomatic patients presented 
with larger tumours and tumours which were multifocal in nature. 
Other factors which may have contributed included more accurate 
estimation of tumour size by imaging (e.g. MRI) and patient choice.
P2-15-03
Nipple-Sparing Mastectomy for Breast Cancer in Japanese 
Experience: An Assessment from Long Follow-Up Data of 
Complication and Cancer Control in 806 Patients.
Sakurai T, Sakurai T, Umemura T, Jinta E, Suzuma T, Yoshimura 
G. Wakayama Medical University Kihoku Hospital, Ito, Wakayama, 
Japan; Sakurai Breast Clinic, Wakayama, Japan; Kiwa Hospital, 
Japan; Kushimoto Arida Hospital, Japan; Kishiwada Shimin 
Hospital, Japan
[Introduction] Mastectomy has been conducted in general for cases 
in which breast conservation is inapplicable. Since Nipple-sparing 
Mastectomy (NSM) conserves nipple-areola, it is not only more 
advantageous in an aspect that nipple-areola reconstruction isn’t 
required in case of breast reconstruction compared with mastectomy 
but also significantly meaningful because the sensation of nipple-
areola is preserved in about 70% cases by skin flap preparation based 
on thick flap method we have adopted. On the other hand, NSM is 
controversial relating to complication of surgery and recurrence as 
well.
[Objective] We’ve made (1) review of safety in NSM surgical 
technique, (2) discussion over recurrence and prognosis comparing 
with those in mastectomy, and (3) consideration of performance in 
immediate reconstructions.
[Result] (1) Of all cases of NSM, the number of cases in stage 0, 
1, 2A, 2B, 3 and 4 was 21, 305, 239, 123, 112 and 6 respectively. 
During 104 months of follow-up period in average, total of seven 
complication cases (0.9%) were observed, including two flap necrosis 
cases and five postoperative bleeding cases, but no nipple necrosis 
case was recorded. Although nipple-areola recurrence rate (%) in 
stage 0, 1, 2A, 2B and 3A was 0, 2.9, 4.6, 2.4 and 5.3 respectively, 
prognosis of nipple-areola recurrence cases was good showing no 
difference between stages (OS: 60M; 93%, 100M; 84%). Skin flap 
recurrence rate (%) in stage 0, 1, 2A, 2B and 3 was 0, 3.2, 3.3, 4.0 
and 14.2 respectively, and prognosis of skin flap recurrence cases was 
significantly worse in stage 2B and 3 compared with that in stage 1 
and 2A (p < 0.001).
(2) We analyzed local recurrence rate, recurrent free survival and 
overall survival between 806 of NSM cases and 200 of mastectomy 
cases which had been performed during the same period, and the 
result showed no significant difference in those rates between NSM 
and mastectomy cases.
(3) Infectious complication was observed in one out of 18 immediate 
reconstruction cases using free dermal fat graft. Among 124 
immediate reconstruction cases using implant, complications were 
observed in five postoperative bleeding.
[Conclusion] NSM was excellent in cosmetic aspect showing 
equivalent results in local recurrence rate and prognosis compared 
with those in mastectomy cases. Besides, patient’s satisfaction was 
also higher in those who had had NSM alone without reconstruction. 
Our long term follow-up data shows that NSM may be considered 
as an alternative option for mastectomy in cases in which breast-
conserving surgery is inapplicable in breast cancer patients.
P2-15-04
Clinical Significance of Resection with Curative Intent for Isolated 
Pulmonary Metastases from Breast Cancer. Multi-Institutional 
Study in Japan.
Sato N, Ohsumi S, Iwase T, Inaji H, Mizutani M, Nishimura R, Mukai 
H. Niigata Cancer Center Hospital, Niigata, Japan; National Hospital 
Organization Shikoku Cancer Center, Matsuyama, Japan; Cancer 
Institute Hospital, Tokyo, Japan; Osaka Medical Center for Cancer 
and Cardiovascular Diseases, Osaka, Japan; National Hospital 
Organization Osaka National Hospital, Osaka, Japan; Kumamoto 
City Hospital, Kumamoto, Japan; National Cancer Center Hospital 
East, Kashiwa, Japan
OBJECTIVE: Although resection of isolated pulmonary metastases is 
a common treatment in other primaries such as colon cancer, the role 
of lung metastasectomy of breast cancer is still unclear. The objective 
of the present study was to investigate the clinical outcome of our 
operated patients with isolated pulmonary breast cancer metastases 
and discuss the clinical implication of resection with curative intent 
for them.
METHODS: We retrospectively analyzed 86 female patients with 
histologically proven isolated pulmonary metastases from breast 
cancer who were treated with surgery of curative intent between 
January 1980 and September 2010 at 7 Japanese hospitals. The mean 
age of them was 50 years, the median disease free interval (DFI) 
from the definitive surgery for the primary breast cancer was 4.6 
years (range: 0.5 - 20.4 years) and the median follow-up after lung 
metastasectomy was 4.1 years (range: 0.3 - 30.9 years).
RESULTS: Lung metastasectomy was performed by thoracotomy 
in 22 patients and by video-assisted thoracoscopic surgical resection 
in 64 patients. The number of metastatic foci resected was one for 
79 patients, two for 6, and unknown for 1. Lymph node resection 
was performed for 12 patients, was not done for 69, and unknown 
for 5. Five-year survival rates after lung metastasectomy were 68% 
in the patients. The main prognostic factor was the DFI. Five-year 
survival rates for patients with DFI of longer than 2 years (n = 72) 
and those with DFI of shorter than 2 years (n=14) were 74.5% and 
33.8%, respectively (p = 0.0006). Five-year survival rates after lung 
metastasectomy were 68% in patients without macroscopic residual 
pulmonary tumor after lung metastasectomy (n = 69) and 34% in 
those with macroscopic residual tumor (n = 12) (p = 0.023). Five-
year disease free survival after lung metastasectomy for patients 
without macroscopic residual tumor was 51 %. Five-year survival 
rates were 78% in patient with endocrine hormonal therapy following 
lung metastasectomy (n = 51) and 53% in those without endocrine 
hormonal therapy (n = 35) (p = 0.045). No prognostic influence could 
be demonstrated for age, number of initial axillary node metastases, 
primary tumor size.
CONCLUSION: The prognosis of the breast cancer patients with 
isolated pulmonary metastases who underwent metastasectomy with 
curative intent was good. It was affected by the biological aspects 
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of the primary tumor, “curativity” of the resection, and systemic 
treatments after lung resection. It may be expected that some of those 
patients will be cured by surgery with curative intent.
P2-15-05
Excision of the Primary Tumour in Patients with Metastatic 
Breast Cancer – Will E2108 Provide the Definitive Answer?
Samiee S, Berardi P, Bouganim N, Vandermeer L, Arnaout A, Mirsky 
D, Dent S, Caudrelier J-M, Chasen M, Clemons M. Ottawa General 
Cancer Centre, Ottawa, ON, Canada
Background: Approximately 10% of new breast cancer patients will 
present with overt synchronous metastatic disease. Controversy 
exists about the optimal local management of these patients. While 
several series suggest that removal of primary tumour is associated 
with a survival benefit, the retrospective nature of these studies raises 
considerable methodological challenges. We decided to evaluate the 
experience at our centre around the impact of surgery in patients with 
synchronous metastasis.
Method: Case records of all patients seen with primary breast 
cancer and concurrent distant metastases between 2005 to 2007 
were reviewed. Demographic and treatment data was collected. The 
study endpoints compared both overall survival and symptomatic 
local progression rates between patients who had breast surgery and 
those who did not.
RESULTS: 111 patients were identified. Median follow-up 40 
months (0.6-71 months). Patients were divided into two groups: those 
patients who underwent breast surgery (n=48; 29/48 had surgery 
immediate prior to metastatic diagnosis) and those that did not have 
surgery(n = 63). The surgical group were less likely to present with T4 
tumours (20% vs 36%), N3 nodal disease (8% vs 19%) and visceral 
metastasis (67% vs 73%)when compared with non-surgical group. 
Improved overall survival (49 months vs 33 months; p=0.01) and 
less symptomatic local progression rates ( 15% vs 43%, p < 0.001 ) 
were seen in the surgical group compared to the non-surgical group.
CONCLUSIONS: The optimal local management of patients with 
metastatic breast cancer is unknown. Despite the surgery group 
demonstrating an improved overall survival and symptomatic local 
control, this group had less aggressive disease at presentation. These 
results confirm the need for prospective randomized studies. E2108, 
an ongoing Phase III Trial, was designed to assess the effect of 
breast surgery in metastatic patients responding to first line systemic 
therapy. If excision of the primary tumour is associated with a 
survival benefit, then the pre-selected subgroup of patients that have 
responded to initial systemic therapy is the desired population to put 
this hypothesis to test.
P2-15-06
Breast Cancer Liver Metastases – Possibilities and Limits of 
Surgical Treatment.
Narsanska A, Treskova I, Treska V, Skalicky T, Sutnar A. University 
Hospital and Medical Faculty Pilsen, Charles University Prague, 
Pilsen, Czech Republic
Background: Breast cancer liver metastases (BCLM) are often 
considered as a sign of a systemic disease with little hope of 
therapeutic success. The aim of study was to assess the possibilities 
and determine the limits of the surgical treatment of BCLM.
Method: 646 patients were operated for malignant and benign lesions 
of the liver between 1999 and 2010. Liver surgery for BCLM was 
performed in 21 women of the average age of 48.5 years (33-71). The 
average time from the primary surgery for breast cancer till BCLM 
diagnosis was 4.7 years (2 months - 9 years). BCLM were solitary 
in 17 and in four cases multiple. Patient selection for liver surgery 
was based on sufficient future remnant liver volume, the absence 
of systemic non-resectable tumor dissemination and response to 
chemotherapy. The authors performed six right-sided hepatectomy, 
four segmentectomies, three left lobectomies, one metastasectomy, 
six radiofrequency ablations (RFA), one combined procedure - 
liver resection and RFA. Histological examination revealed ductal 
carcinoma in fourteen and lobular carcinoma in seven cases. All 
patients were treated with the curative adjuvant chemotherapy after 
surgery. The data were statistically evaluated by statistical software 
Statistica 9.0.
Results: 30 – days mortality rate was 0%. One patient had a 
complicated hepatectomy with iatrogenic bile duct injury. According 
to statistical analysis the probability of patients survival twelve, resp. 
thirty months after surgery was 100, resp. 66.7% and the probability 
of the tumor relapse anywhere in the body was at the same time 
intervals 0, resp. 71. 5%.
Conclusion: Liver surgery combined with the adjuvant chemotherapy 
are a therapeutic methods of choice for highly selected patients with 
metastases limited to the liver and objective response to neoadjuvant 
chemotherapy.
The study was supported by the research projects IGA MZ NS 9727 
and IGA MZ NS 102 40.
P2-15-07
The Need for Additional Surgeries to Adequately Excise 
Early Breast Cancers May Have a Negative Impact on Local 
Recurrence.
Warburton R, Alriyees L, Wang DY, Wong SL, Leong W. University 
Health Network, University of Toronto, Toronto, ON, Canada
Background: Breast conservation surgery (BCS) is considered the 
standard of care for the treatment of early stage breast cancer (ESBC, 
AJCC stage 1 and 2). 20 to 50% of patients will require further 
surgery for positive or close margins. There is recent data suggesting 
that re-operation can have a negative impact on local and distant 
recurrences. Our aim is to examine the effects of multiple surgeries 
to obtain adequate margins on breast cancer recurrence, metastatic 
disease and survival.
Methods: We reviewed a prospectively maintained breast cancer 
database at the University Health Network and included all women 
who had BCS for their first diagnosis of ESBC between January 2004 
and December 2007. Patients with neoadjuvant chemotherapy were 
excluded. We collected patient demographics, surgical pathology, 
adjuvant therapy and follow up outcome data, which included local 
recurrence, distant recurrence, cancer-specific survival and overall 
survival. Clinical and pathologic features were compared using chi-
square analyses. Patients who had one lumpectomy were compared 
to those who had multiple surgeries by using Kaplan-Meier survival 
curves and log rank test.
Results: Of a total of 744 patients (8 patients had bilateral cancer) 577 
(77.6%) had one lumpectomy only (Group 1). 167 (22.4%) patients 
required further surgery (group 2 = LR+LM+LRM): 83 (11.1%) had 
a re-excision (LR), 69 (9.3%) had mastectomy (LM) and 15 (2%) 
had a re-excision followed by a mastectomy (LRM). Thus, a total of 
85 (11.4%) patients had mastectomy to achieve adequate margins. 
All clinicopathologic factors and adjuvant systemic treatments were 
similar between the two groups except for age and use of adjuvant 
radiotherapy, which was related to that fact that many of those in 
group 2 had mastectomy. We observed a difference in disease-free 
survival favoring patients with lumpectomy only (group 1- 3.4% 
vs. group 2 - 8.1%, p= 0.01) but there was no difference in distant 
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metastasis (4.5% vs. 5.6%, p=0.56), cancer-specific survival (97.6% 
vs. 95.6%, p=0.20) and overall survival (6.9% vs 6.3%, p= 0.76) at 
a median follow up of 4.54 years.
Conclusion: Despite having similar stage, grade, receptor status and 
adjuvant systemic therapies, having multiple surgeries for primary 
breast cancer appeared to be associated with decreased disease-free 
survival but had no difference in rates of distant metastatic disease, 
cancer-specific survival and overall survival.
P2-15-08
New Trends for Surgical Treatment of Large Breast Tumors.
Zucca Matthes AG, Vieira RAC, Kerr LM, Matthes ACS, Folgueira 
MAAK, Uemura G. Barretos’Cancer Hospital, Barretos, SP, Brazil; 
School of Medicine of Botucatu - UNESP, Botucatu, SP, Brazil; USP, 
Sao Paulo, SP, Brazil; University Barão de Mauá, Ribeirão Preto, 
SP, Brazil
Introduction: The locally advanced breast cancer is still common in 
developing countries. The neoadjuvant chemotherapy (NC) allows 
converting large tumor into operable one. Oncoplastic surgery (OS) 
adds new techniques to breast conservative treatment(BCT). The 
association between NC and OS provides the resection of large 
amount of breast tissue, including skin, with satisfactory aesthetic 
results.
Objective: Evaluate the possibilities to indicate oncoplastic 
techniques to determine BCT after NC for large breast tumors.
Material and Methods: A prospective clinical trial (www.
clinicaltrials.gov; NCT00820690) study with women breast 
cancer patients, clinical stage III, no extense skin involvement, 
submitted to NC, based on four cycles of doxorubicin 60mg/m2 + 
cyclophosphamide 600 mg/m2 and 4 cycles of paclitaxel 175mg/
m2. Preoperative tattoo was realized for all patients to determine 
the clinical dimensions of the tumor. Tumor size was controlled by 
physical and radiological exams. The oncoplastic surgeries were 
offered in accordance to clinical-imaging previous to NC, final 
response to chemotherapy, tumor localization, tumor size, breast 
size, oncologic security, patient comorbidities and experience of 
the surgeon. The skin-sparing mastectomy with immediate breast 
reconstruction was also considered an oncoplastic technique. The 
surgical planning has involved the whole area previously marked 
by the tattoo regardless of tumor response. A detailed analysis of the 
pathological specimen was provided to confirm the oncologic safety of 
the treatment. All patients were followed by radiotherapy after surgery.
Results: 50 patients were enrolled. PE tumor median measurement 
was 6.5 cm (3.0 to 14.0 cm) and pathologic median tumor was 4.0 
cm (0 to 14.5cm). Pathologic response was rated as stable disease, 
progressive disease, partial response and complete response in 18%, 
10%, 68% and 4% of the cases, respectively. Pathologic responses 
were diverse and included tumor micro-fragmentation and macro-
fragmentation. PE tumor size before chemotherapy correlated best 
with MRI (ricc 0.588, p < 0.001), as well as pathologic tumor size 
measured after chemotherapy correlated best with MRI (ricc 0.738, p 
<0.001). The surgical approach allowed BCT in 34% (17) of patients. 
Skin involvement was presented in 38% of pathologic specimen 
regardless previous clinical exam noticed.
Conclusion: Oncoplastic techniques increase the rates of BCT 
for selected patients in spite of large locally advanced tumors. 
The surgical planning is fundamental to this approach. This study 
recommends the full resection of the tumoral area previous to NC, 
including marked skin, regardless the response to neoadjuvant 
treatment. Follow-up of these patients will be important for additional 
information in the future.
P2-15-09
Prospective Randomized Comparison of Conventional 
Instruments and the Harmonic Focus® Device in Breast-
Conserving Therapy for Primary Breast Cancer.
Böhm D, Kubitza A, Lebrecht A, Schmidt M, Kölbl H. University 
Medical Centre, Mainz, Germany
Background: In recent years, surgeons have utilized Harmonic 
instruments to perform breast cancer resection. Retrospective 
and prospective studies have demonstrated that the use of this 
surgical device for mastectomy and axillary dissection can reduce 
perioperative blood loss, seroma formation, and duration and 
total amount of drainage. No study has analyzed the feasibility of 
Harmonic instruments in breast-conserving surgery. We conducted a 
prospective, randomized clinical trial comparing Harmonic instrument 
and conventional surgery in the performance of breast conserving 
surgery and axillary procedures to determine differences in surgical 
procedures, postoperative outcome, and complications.
Methods: One hundred and forty seven patients with operable breast 
cancer who underwent breast-conserving surgery at a single institution 
between December 2009 and March 2011 were included in the 
analysis. Surgery was performed in 73 patients with the Harmonic 
Focus® device and in 74 with scissors and electrocautery. Charts were 
reviewed for patient demographics, histopathologic reports, surgical 
procedures, length of stay, volume and duration of postoperative 
drainage, complications such as seroma and hematoma formation, 
and postoperative pain.
Results: We found a statistically significant difference in size of 
resected breast tissue (p<0.001), postoperative serum hemoglobin 
(p=0.001), volume (p<0.001) and duration (p<0.001) of breast 
drainage, volume (p<0.001) and duration (p=0.001) of axillary 
drainage, intramammary (p=0.04) and axillary (p=0.006) seroma 
formation, subjective (p=0.012) and objective (p<0.001) postoperative 
pain, and length of hospital stay (p=0.002) in favor of the Harmonic 
surgical device.
Discussion: This is the only study comparing the Harmonic 
instrument with traditional surgery in both breast conserving surgery 
and axillary procedures. From this study, we conclude that despite 
higher costs, the Harmonic device is safe to use and provides key 
benefits in intraoperative technique, postoperative outcome, and rate 
of complications in breast cancer surgery.
P2-15-10
Do Patients with Incurable Advanced Breast Tumor and Distant 
Metastasis Derive Any Benefit from Primary Tumor Resection?
Takahashi M, Shibasaki S, Jotoku H, Watanabe K-I. Hokkaido Cancer 
Center, Sapporo, Hokkaido, Japan
Background: Metastatic breast cancer (MBC) is considered 
incurable. Surgical removal of primary tumors has not been 
established as a standard treatment for MBC because it is generally 
accepted that local therapy provides no survival advantage once 
metastases have occurred. Additionally, tumor excision may further 
stimulate metastasis.4 Therefore, primary tumor resection in patients 
with MBC is usually only applied as a palliative treatment for 
symptomatic wound complications such as bleeding, ulcer formation, 
unpleasant smell, and purulent discharge. In recent years, however, 
some retrospective studies have reported advantages of debulking 
surgery in terms of improving patient outcome. We retrospectively 
analyzed the surgical benefits and prognostic factors for patients with 
MBC who were treated at our center.
Methods: We retrospectively reviewed individual medical records 
from the Hokkaido Cancer Center. In this study, incurable advanced 
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breast cancer is defined as the presence of a tumor, larger than 5 cm, 
and shows either (invasion to chest wall or skin or is an inflammatory 
carcinoma) and at least one metastatic site, including distant lymph 
nodes, bone, or visceral organs (lung, pleura, mediastinum, liver, and 
brain) at diagnosis. Between January 2000 and June 2010, 92 women 
were diagnosed with incurable advanced breast cancer at our institute. 
The effect of surgical treatment on survival was evaluated. Patient 
demographics and tumor characteristics were also investigated.
Results: Thirty-six patients had surgery for resection of primary 
tumors. There were no substantive differences between individuals, 
or between tumor characteristics, for patients who underwent surgery 
versus patients who did not. The median survival time for surgically 
treated patients was 25.0 months versus 24.8 months for patients who 
did not undergo surgical resection (P=0.352). Only three patients 
relapsed within three months of surgery. For the remaining majority 
of patients, primary tumor resection gave some relief from the often 
severe symptoms that come from harboring a large tumor for an 
extended time. In univariate and subsequent multivariate analyses 
of predictive indicators, a diagnosis of triple-negative breast cancer 
and/or metastasis to more than three sites was significantly associated 
with a severe prognosis.
Conclusion: Primary tumor resection failed to prolong overall 
survival times in patients with incurable advanced breast cancer that 
was greater than 5 cm. However, surgery did improve the quality of 
life in patients who were expected to have a relatively long prognosis.
P2-15-11
Outcomes of Corrective Procedure with Vicryl Mesh as an 
Oncoplastic Surgery of the Breast.
Lim YA, Lee YO, Kim JH, Kim HS, Kang HJ, Kim LS. Hallym Sacred 
Heart Hospital, College of Medicine, Hallym University, Anyang, 
Gyeonggi-do, Korea
Background: Both cosmetic and oncologic outcomes are becoming 
more important for breast cancer patients. Breast-conserving surgery 
(BCS) has an acceptable cosmetic result compared with mastectomy, 
but BCS is also associated with cosmetic failure. In this study, we 
evaluated the cosmetic outcome of reconstructive surgery with the 
absorbable implant vicryl mesh after BCS compared with the outcome 
of BCS alone.
Methods: From May 2007 to December 2009, 101 patients were 
involved in this study at Hallym University Sacred Heart Hospital. We 
used absorbable implants made of folding vicryl mesh and wrapped 
them with Interceed. In 79 cases, BCS with vicryl mesh implantation 
was performed; in the other 56 cases, only BCS was performed. 
Patient satisfaction with cosmetic outcomes was evaluated. We also 
analyzed other factors that affected cosmetic outcomes, including 
patient ages, body mass indices, tumor locations, and removed 
breast tissue.
Results: In the vicryl mesh implantation group, 65 of 79 patients 
(82.3%) were satisfied; in the BCS-only group, 24 of 56 patients 
(43%) were satisfied (P < 0.05). In the vicryl mesh implantation 
group, patient ages, body mass indices, and removed breast tissue 
did not affect cosmetic outcomes. When the tumor was located in 
the upper outer quadrant, the patients were more satisfied (P < 0.05).
Conclusions: Reconstructive procedures with vicryl mesh are simple, 
safe, and less expensive than other plastic reconstruction techniques. 
This study suggests that the procedure was superior to BCS alone in 
cosmetic outcomes. We believe that the procedure could become a 
favorable technique in oncoplastic surgery.
P2-15-12
Management Strategy of Early-Stage Breast Cancer Patients: 
With or without Axillary Lymph Node Dissection.
Yamamoto D, Tanaka K, Tsubota Y, Yosida H, Kanemastu S. Kansai 
Medical University, Hirakata, Japan; Ribon-Roze Tanaka Kanji 
Clinic, Osaka, Japan
Background: The sentinel lymph node (SLN) biopsy has steadily 
replaced axillary lymph node dissection (ALND) for staging clinically 
node-negative breast cancer. However ALND remains the standard 
management of the axilla when a tumor-positive sentinel lymph 
node (SLN) is identified. The aim of this study was to evaluate the 
ALND in local, distant recurrence, and overall survival (OS) in breast 
cancer patients.
Methods: We identified 350 patients with breast cancer (clinically 
T1/T2N0M0) from the prospective database from five institutions 
from July 1999 and April 2004. All patient age ranged from 26 to 
81 (median 49) years. All patients underwent mastectomy or breast 
conserving surgery (BCT) combined with either ALND or no ALND. 
Criteria of negative ALN metastasis are that minor axis of ALN 
is under 5 mm on CT images and fat tissue in the hilum of ALN 
does not disappear on ultra-sound images. In the case that hormone 
receptor expression is positive, pt was administered for 5 years. In the 
case of T1c or T2 under 70 years old, neoadjuvant and/or adjuvant 
anthracycline-based chemotherapies were administered. After surgery, 
patients without ALND/with ALND received tangential irradiation at 
the region of breast. ALND and no ALND groups were compared for 
incidence of local, regional, distant recurrence, and overall survival.
Results: Patients with ALND (n=350) were compared with no ALND 
group (n=126). There were significant differences in primary tumor 
size, histology, nuclear grade, presence of LVI, ER/PgR/HER2 
status between the two groups. Five years OS was 97.9% in ALND 
group, it was 98.0% in no ALND group (p>0.01). Further there was 
no significant difference between two groups in local, regional, and 
distant recurrence.
Conclusions: These results indicate that ALND is omissible for 
cT1/T2N0M0 breast cancer by a combination of hormone therapy, 
neoadjuvant/adjuvant chemotherapy, and irradiation.
P2-15-13
Oncologic and Cosmetic Outcome in Breast Cancer Patients Who 
Underwent “Moving Window” Operation.
Ohno Y, Noguchi M, Nakano Y, Noguchi M, Kosaka T. Kanazawa 
Medical University, Japan
Background: An inappropriate skin incision on the breast reduces the 
cosmetic benefit of breast-conserving surgery (BCS).
Methods: To improve the cosmetic outcome, we have performed 
“Moving window” operation in which BCS can be performed via a 
periareolar incision (periareolar approach) and/or axillary incision 
(axillary approach) under direct visualization. Axillary lymph node 
dissection is also performed via an axillary incision.
Results: Periareolar approach was performed in 65 patients and 
axillary approach in 43 patients. Average operation time was 
130 minutes in periareolar approach and 131 minutes in axillary 
approach. Average blood loss was 37 mL and 50 mL, respectively. 
Postoperatively, the surgical margin of breast tissue was histologically 
confirmed to be negative in 107 (99%) of 108 patients, while two 
patients underwent reoperation because of positive surgical margin. 
Fifty-two patients (85%) in periareolar approach and 37 patients 
(86%) in axillary approach had excellent or good cosmetic results. 
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With a mean follow-up of 36 months, one patient with DCIS 
developed in-breast recurrence, while 3 patients who had neoadjuvant 
chemotherapy developed in-breast recurrence.
Conclusion: The moving window operation can improve a cosmetic 
outcome of the conserved breast without compromising the 
oncological safety.
Moreover, it can reduce operating time and blood loss when compared 
with the endoscope-assisted BCS.
P2-16-01
A Multi-Centre Prospective Cohort Study Evaluating Health 
Related Quality of Life after Types of Immediate Latissimus 
Dorsi (LD) Breast Reconstruction.
Winters ZE, Haviland J, Reece-Smith A, Betambeau N, Choudhry 
K, Chaudhry A, Mills J, Benson J, Galea M, MacMannus P, 
Nicholson S, Weiler-Mithoff E, Rayter Z, Thomson HJ. University 
Hospitals Bristol NHS Foundation Trust, Bristol, Avon, South West, 
United Kingdom; Clinical Trials & Statistics Unit, The Institute of 
Cancer Research, Sutton, London, Sutton Surrey, United Kingdom; 
Cambridge University Hospitals NHS Foundation Trust, Cambridge, 
East Anglia, United Kingdom; Western General NHS Foundation 
Trust Swindon, Swindon, South West, United Kingdom; Hull and 
East Yorkshire Hospitals NHS Trust, Hull, East Yorkshire, United 
Kingdom; York Hospitals NHS Trust, York, East Yorkshire, United 
Kingdom; NHS Greater Glasgow and Clyde, Canniesburn, Glasgow, 
Scotland, United Kingdom
Introduction: Evidence for the clinical effectiveness of breast 
reconstruction based on Patient Reported Outcome Measures 
(PROMS) is lacking. Methodology evaluating PROMS after types 
of breast reconstruction has been poor with respect to study design, 
statistics, missing data and absence of prospective documentation of 
pre-defined complication data in a systematic review of all studies 
since 19781. Furthermore, there is no reliable data on the effects of 
associated radiotherapy (RT) in this context. As a prelude to a proposed 
randomised trial in breast reconstruction, our aim was to conduct a 
‘robust’ cohort study evaluating the effects of either implant-assisted 
LD (LDI) or tissue only (ALD) LD flap reconstruction in relation 
to key determinants including clinico-pathological parameters, 
complications and treatment schedules over a 36 month period.
Methods: An MREC approved prospective longitudinal cohort 
study involving 6 centres commenced in early 2007. Serial PROMS 
using the EORTC QLQ-C30, BR-23, FACT-B, BIS and HADS, 
were completed pre-operatively and at 3, 6, 12, 24 and 36 months 
after surgery. Data up to 12 months were included in this analysis 
as data were sparse beyond this point; follow-up is ongoing. 
Demographic and clinical data were compared between the surgical 
groups. Generalised estimating equations were used to investigate 
demographic and clinical predictors of HRQL over time.
Results: A total of 189 patients (107 – ALD, 82 – LDI) were recruited, 
with a mean age of 50 years (range 22-70). Baseline questionnaires 
were completed by 149 (79%) women, with 167 (88%) available 
at 12 months. Patients in the ALD group had a higher BMI (mean 
27.3 versus 25.2 in LDI, p=0.001) and a greater likelihood of post-
mastectomy RT (52% versus 30% in LDI, p=0.004).
Only role functioning (p=0.001) and pain (p=0.003) were significantly 
adversely affected in the ALD v LDI group, with no statistically 
significant effects from PMRT on HRQL, although chemotherapy 
impaired global QoL (p<0.001) and social functioning (p=0.001), 
and increased fatigue (p=0.007). Early complications (< 3 months) 
significantly impaired HRQL in general, as did poor baseline scores 
(p<0.01 for various subscales). Significant improvements over time 
were noted for global QoL, role and social functioning, fatigue, pain 
and breast symptoms (p<0.001 for all).
Conclusion: There is increasing evidence of clinical equipoise 
between types of LD breast reconstruction and despite acknowledged 
cosmetic disadvantages the overall effects of PMRT on HRQL are 
minimal. The identification of important variables that may affect 
HRQL is crucial in all studies evaluating the effects of surgery 
on PROMS. Their integration into study results is essential for 
correct interpretation of clinically based assessments. This remains 
a challenging aspect in cohort studies, and emphasises the need for 
pragmatism in design of trials in the field.
1. Winters ZE, Benson JR, Pusic AL. Annals of Surgery 
2010;252(6):929-42
P2-16-02
How Well Do Medical Oncologists and Plastic Surgeons 
Communicate about Their Patients?
Milucky JL, Deal A, Wu R, McNally RS, Anders C, Lee C. University 
of North Carolina at Chapel Hill, Chapel Hill, NC
Background: While complications of post-mastectomy breast 
reconstruction can affect the timing of adjuvant chemotherapy, 
chemotherapy can affect the wound healing process after 
reconstruction. Due to this interdependence, adequate communication 
between medical oncologists (MO) and plastic surgeons (PS) may 
be critical to optimize patient outcomes. In this study, we sought to 
evaluate the knowledge MO and PS have of each other’s fields, the 
roles they expect of each other, and how often they communicate in 
treating breast reconstruction patients.
Methods: A cross-sectional survey was conducted in a convenience 
sample of MO who treat at least one breast cancer (BC) patient 
per month and PS who perform at least one breast reconstruction 
per year. Surveys were distributed via email, US mail, and at two 
professional meetings. The survey included knowledge questions 
about reconstruction and chemotherapy, questions about provider 
and patient responsibilities for timely chemotherapy initiation, and 
questions about communication with other specialties. Fisher’s Exact 
and Wilcoxon Rank Sum tests were used to compare differences 
between groups.
Results: 53 medical oncologists and 23 plastic surgeons completed 
surveys (51% response rate). MO and PS had similar overall 
knowledge scores (MO 59%, PS 56%, p=0.5). 23% of MO knew the 
correct treatments for breast skin necrosis, and 60% knew the correct 
treatment for seromas. 32% of PS knew the approximate duration of 
Her2-directed therapy, and 14% of PS identified the usual adjuvant 
treatment for patients who have had neoadjuvant chemotherapy. 
Providers from both specialties who primarily practice in a rural 
setting scored significantly lower on the knowledge portion of the 
survey than those practicing in an academic medical center or urban/
suburban area (51% rural versus 59%, p=0.03).
The MO and PS agreed on the MO’s degree of responsibility for 
timely chemotherapy initiation (MO mean 4.6 versus PS mean 4.4 out 
of 5, p =0.2). However, they disagreed about the PS’s responsibility 
for timely chemotherapy initiation (MO mean 3.8, PS mean 3.0 out 
of 5, p=0.01).
MO attributed low importance to a history of immediate breast 
reconstruction when planning chemotherapy treatment (mean 2.5 out 
of 10). PS placed little importance on the likelihood of post-operative 
chemotherapy when planning immediate breast reconstruction 
(mean 3.6 out of 10). Both MO and PS reported more frequent 
communication with each other about patients with complications 
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than about uncomplicated patients (mean 3.9 times over first 6 
month for complications versus mean 1.6 over first 6 months for 
uncomplicated). This translated to communicating about 2.5 times 
as often for complicated patients (p<0.001).
Conclusion: Medical oncologists and plastic surgeons have 
substantial deficits in knowledge about each other’s fields and differ 
in their opinion regarding the burden of responsibility in ensuring 
timely chemotherapy initiation. While MO and PS increase their 
communication when complications arise, these data suggest room 
for improvement in communication and understanding, which could 
improve the care of BC patients who undergo reconstruction and 
chemotherapy.
P2-16-03
Outcomes of Nipple-Sparing Mastectomy (NSM) and Immediate 
Reconstruction.
Chidester JR, Olson JR, Poruk KE, Marengo JJ, Matsen CB, 
Neumayer L, Agarwal J. Loma Linda University Medical Center, 
Loma Linda, CA; University of Utah School of Medicine, Salt Lake 
City, UT
Background: Nipple-sparing mastectomy (NSM) is the surgical 
removal of breast tissue that preserves the entire skin envelope 
including the nipple areola skin (NAS). We report our experience 
performing NSMs and immediate breast reconstruction for both high-
risk breast cancer treatment and prophylaxis over a six-year period at 
The University of Utah and Huntsman Cancer Hospital.
Methods: A retrospective chart review was performed on patients 
undergoing NSM from April 2005 – April 2011. Data collection 
included: patient demographics, oncologic details, surgical 
information (including reconstruction timing and type), and 
complications (infection, hematoma, seroma, skin necrosis, NAS 
complication, skin flap loss, premature expander exchange/removal, 
and capsular contracture).
Results: 130 patients underwent 205 NSMs. Of these, 106 (81.5%) 
patients received mastectomy treatment for cancer while 24 (18.5%) 
patients were prophylactically treated. 102 NSMs (49.8%) were on 
breasts with biopsy-proven cancer, while 103 (50.2%) NSMs were 
on breasts for prophylaxis. All patients were female with a mean 
age of 44.7 years (range, 16 – 82 years). 119 (92.2%) patients were 
Caucasian, 3 (2.3%) were Asian, and 1 (0.8%) was Hispanic. The 
mean weight was 65.2 kg (range, 42.8 – 98.8 kg) and BMI (n=106) 
was 23.7 kg/m2 (SE±0.4). 14 (10.9%) and 12 (9.3%) of the patients 
were known to have a BRCA1 and BRCA2 mutation, respectively. 
Two (1.6%) patients had a p53 mutation. 172 (83.5%) of the nipples 
were spared via an 8 cm incision lateral to the midpoint of the 
areola, while 5 (2.4%) of the incisions were made along the IMF. 
The remaining 28 (13.7%) incisions were made by other techniques. 
201 (98.0%) breasts were immediately reconstructed with tissue 
expanders (193 went on to implant reconstruction and 8 underwent 
autologous tissue reconstruction). 4 (2.0%) breasts received delayed 
reconstruction. Positive margins were found in 15 (7.3%) of 205 
breasts. 60 (58.8%) of 102 cancerous breasts that underwent NSM 
were Stage 0 – I, 35 (34.3%) were Stage II and the remaining 8 (7.8%) 
were Stage III – IV. Complications by case (Table 1) and by breast 
(Table 2) are shown below.
Table 1. Complications by case
Complication Cancer (n=106) Prophylaxis (n=24) Total p value
Infection 18 6 24 0.39
Premature Exchange/Removal 6 4 10 0.087
Hematoma 5 2 7 0.61
Seroma 10 4 14 0.29
NAS Complication 11 5 16 0.17
Skin Necrosis 15 5 20 0.53
Skin Flap Loss 4 0 4 1.00
Capsular Contracture 13 1 14 0.46
Total 82 27 109  
Table 2. Complications by breast
Complication Cancer (n=102) Prophylaxis (n=103) Total p value
Infection 11 13 24 0.83
Premature Exchange/Removal 6 4 10 0.54
Hematoma 5 2 7 0.28
Seroma 10 4 14 0.11
NAS Complication 11 5 16 0.13
Skin Necrosis 10 10 20 1.00
Skin Flap Loss 3 1 4 0.37
Capsular Contracture 13 1 14 0.0006
Total 69 40 109  
Conclusion: When comparing NSMs in both patients and individual 
breasts with cancer to patients and breasts treated for prophylaxis, 
there is no significant difference in complication rates by case or 
breast, except for the capsular contracture rate, which was significantly 
higher in breasts treated for cancer. Overall, complication rates are 
low in both cases of cancer and prophylaxis; this demonstrates that 
NSM and immediate reconstruction is a highly effective method of 
treatment for both groups.
P2-16-04
Abdominal Wall Stability and Flap Complications Are Unaltered 
Following Deep Inferior Epigastric Perforator (DIEP) Flap Breast 
Reconstruction Despite Increasing Body Mass Index: Analysis of 
418 Patients and 639 Flaps.
Ochoa O, Chrysopoulo M, Nastala C, Ledoux P, Pisano S. Plastics 
Reconstructive and Microsurgical Associates of South Texas, San 
Antonio, TX
Introduction: Promoted by reports of decreased donor-site morbidity 
compared to traditional transverse rectus abdominus (TRAM) flap 
breast reconstruction, deep inferior epigastric perforator (DIEP) flaps 
have gained significant popularity. Increasing body mass index (BMI) 
is associated with poor flap-specific and donor-site outcomes in breast 
reconstruction using traditional techniques. The current study aims at 
defining flap-specific and donor-site complications with increasing 
BMI in patients undergoing DIEP flap breast construction.
Methods: A retrospective analysis of 639 DIEP flaps on 418 
consecutive patients between Jan 2006 to March 2008 was performed. 
Patients were stratified into five groups based on BMI: normal weight 
(≤ 24.9), overweight (25-29.9), obese (30-34.9), severely obese (35-
39.9), and morbidly obese (≥ 40). Medical co-morbidities, adjuvant 
chemo-radiation therapy, timing of reconstruction, active tobacco use 
and surgical history were collected. Primary outcomes were compared 
between BMI groups.
Results: Average BMI for the entire population was 28.3 (range 
17-42). There were 100 (23.9 %) normal weight, 153 (36.6 %) 
overweight, 113 (27.0 %) obese, 45 (10.8 %) severely obese, and 
7(1.7%) morbidly obese patients with an average follow-up of 1088 
(range 720-1528) days. Increasing BMI was associated with increased 
incidence of hypertension, previous abdominal surgeries, and length 
of follow-up. Age, active tobacco use, adjuvant chemo-radiation 
therapy and timing of reconstruction were similar across all BMI 
groups. Flap complications stratified by BMI groups demonstrated 
significantly increased delayed wound healing complications in 
severely obese patients compared to lower BMI groups. Incidence of 
flap soft tissue infections, hematoma or seroma formation, fat necrosis, 
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thrombotic and overall complications including flap failure were not 
significantly different between groups. Donor-site complications 
stratified by BMI demonstrated significantly increased delayed wound 
healing and overall complications among morbidly obese patients 
compared to other groups. Incidence of donor-site infection, acute 
or subacute hematomas, seroma formation, abdominal wall bulging, 
and hernia formation were not significantly different between groups 
despite increasing BMI.
Conclusion: Increasing BMI predisposes patients to delayed 
wound healing complications in both flap and donor-site locations. 
Nevertheless, overall flap complications remain similar across all 
BMI groups. Despite increased overall donor-site complications in 
patients with increasing BMI, abdominal wall stability was maintained 
during a follow-up period approximating 3 years. Given a similar flap 
complication profile and maintenance of abdominal stability, DIEP 
flaps are recommended in patients with increased BMI.
P2-16-05
Delay of Adjuvant Chemotherapy after Elective Mastectomy and 
Immediate Reconstruction in Breast Conservation Candidates: 
A Matched-Pair Analysis.
Barry PN, Riley EC, Pan J, Crew JB, Lee K, Jain D, Kruse B, 
Quillo AR, Rai S, Dragun AE. James Graham Brown Cancer Center, 
University of Louisville School of Medicine, Louisville, KY
Background: To analyze factors that influence the timing of adjuvant 
chemotherapy in patients who are candidates for breast conservation 
therapy (BCT) but elect mastectomy with immediate reconstruction 
(M-IR).
Methods: Using data from the University of Louisville Cancer 
Registry, we identified 35 consecutively-treated patients with stage 
I or II breast cancer between 2004 and 2009 who underwent M-IR 
and adjuvant chemotherapy. These were matched for age and AJCC 
stage to 35 controls who underwent BCT and adjuvant chemotherapy. 
We examined the timing of initiation of chemotherapy from the date 
of surgery and assessed the probability of therapeutic delay using 
univariate logistic regression and McNemar’s test for matched pairs.
Results: For the 70 patients included in this study, the median age 
was 46y (range: 30-65y), and the distribution for stage I, IIA and IIB 
was 22.9%, 65.7% and 11.4%, respectively. The two groups were 
well balanced in terms of race, rural/urban status, smoking, diabetes, 
insurance coverage, and histology. The median time to initiation of 
adjuvant chemotherapy was 38 days (range: 25-103 days) for BCT 
and 55 days (range: 30-165 days) for M-IR. Patients undergoing M-IR 
were more likely to experience any delay (> 45 days; 74.3% vs. 25.7%, 
p < 0.001) and/or significant delay (>90 days; 20.0% vs. 2.9%, p < 
0.001) than those choosing BCT. On univariate logistic regression 
analysis, the extent of surgery had a major impact on the likelihood 
of any delay in chemotherapy (OR= 8.35, 95% C.I. = 2.86-24.3, p 
<0.001). None of the other aforementioned factors predicted for delay.
Conclusion: The use of elective mastectomy with immediate 
reconstruction in breast conservation candidates independently 
predicts for delay in initiation of adjuvant chemotherapy. Further study 
is needed to qualify the underlying causes of and ultimate clinical 
significance of these delays.
P2-16-06
A Systematic Review of Standardised Clinical Outcomes and 
Patient Reported Outcome Measures (PROMS) in Breast 
Reconstruction.
Winters ZE, Chaudhry A, Benson JR. University Hospitals Bristol 
NHS Foundation Trust, Bristol, South West, United Kingdom; 
Cambridge University Hospitals NHS Foundation Trust, Cambridge, 
East Anglia, United Kingdom
Introduction
Failure to prospectively define and report surgical complications across 
a range of study designs is a confounding factor that fundamentally 
compromises the interpretation of data on health-related quality of 
life (HRQL) and PROMS. The UK National Mastectomy and Breast 
Reconstruction audit on 5000 breast reconstruction patients found 
higher than expected levels of complications (including rates of 
reoperation and levels of infection). We aimed to analyze the reporting 
of complications in a systematic review of all studies evaluating 
PROMS in breast reconstruction since 19781.
Methods
Efficace criteria for HRQL methodology were used to assess the 
inclusion eligibility for each study1. Two out of 34 eligible studies 
were excluded due to overlapping patient datasets and small numbers 
(n<5) of breast reconstruction cases. Two reviewers examined 
the reporting of complications. The study designs comprised: 2 
randomised controlled trials (RCT); 10 prospective longitudinal 
studies (PLS) and 20 retrospective studies (RS). RCTs and PLS were 
evaluated for predefined complications, their grading according to 
Clavien-Dindo2 and their integration into the evaluation of PROMS 
results. RS were evaluated for the reporting of complications and 
their statistical methodology.
Results
A total of 3213 patients were included in the 32 studies. The type of 
reconstruction was only recorded in 71% of patients. The majority 
of patients in these studies underwent abdominal flap reconstruction, 
compared to implant only techniques (32%), and less than 10% 
comprising Latissimus dorsi flaps. Only 19% of studies recorded 
complications with the majority (81%) failing to report any 
complications. Only 3 studies provided details of the numbers and 
level of complications amongst a total of 44 patients (1.4% of the 
total number of patients). Reported complications were graded and 
classified either as major (requiring surgical intervention) or minor 
comprising 55% and 45%, respectively. None of the RCT or PLS 
studies defined either the type or level of complications a priori, nor 
stratified complications based on risk factors such as age, body mass 
index, smoking and diabetes.
Conclusion
There is a significant under estimation of the contribution of 
complications to HRQL and PROMS reporting. This fact diminishes 
the current evidence on the effects of breast reconstruction on 
PROMS. There should be collective efforts to improve the standards 
of documentation for clinical outcomes in breast reconstruction. This 
together with standardized reporting of PROMS will consolidate 
clinical evidence upon which decision-making and provision of 
patient information can be confidently based.
1. Winters ZE, Benson JR, Pusic AL. Annals of Surgery 
2010;252(6):929-42
2. Dindo D et al. Annals of Surgery 2004;240(2):205-213
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P2-16-07
A Randomised Controlled Trial To Evaluate the Role of Tisseel, a 
Fibrin Sealant on Seroma Formation in Latissimus dorsi Breast 
Reconstruction.
Winters ZE, Llewellyn-Bennett R, English R, Turner J, Rayter Z, 
Greenwood R. University Hospitals Bristol NHS Foundation Trust, 
Bristol, South West, United Kingdom
Introduction
Donor site seromas are common complications following Latissimus 
dorsi breast reconstructions (LDBR), as shown in the UK National 
Mastectomy and Breast Reconstruction audit. Level I clinical 
evidence following the performance of an RCT supports ‘fixation’ 
of the back skin flaps by quilting sutures1. Fibrin sealants (Tisseel) 
have been postulated to reduce seromas after simple mastectomy and 
axillary dissections2, but their role in reducing donor site seromas after 
breast reconstruction has yet to be performed in a ‘robust’ clinical 
trial. The aim of this RCT was to compare Tisseel against Control 
(no Tisseel) on the incidence of seromas after LDBR.
Methods
In an ethics approved single centre, single-blinded study comprising 
2 surgeons from 2005-2010; 106 women were randomised to either 
Control (52) or Tisseel (54) interventions after immediate or delayed 
breast reconstructions. Sixteen patient s were excluded as follows due 
to incomplete data at 3 months or re-operations of the donor site for 
complications. The types of breast reconstructions comprised implant-
assisted LD (LDI) in 45 women, 23 extended LD flaps (ELD) and 23 
ELD with implant (ELDI). Immediate breast reconstructions (n=87) 
comprised the majority compared to only 4 delayed procedures. Intra-
operative drains were placed to the breast, axilla and donor site (x two) 
as per standard practice. A 0.5% fibrinogen concentration was used 
in a hydraulic hand-held Tisseel spray application to the donor site 
chest wall over 60 seconds. Two stay sutures were pre-placed 2 cm 
adjacent to the donor wound skin edges above and below prior to the 
Tisseel application. In the control group, 2 drains only were placed. 
The primary outcome measure was the total seroma volumes from all 
the sites over 3 months. This was used for the power calculation of the 
sample size and showed a requirement for a minimum of 95 women. 
Secondary outcomes included the volumes of the donor site seromas, 
and the frequency of post-drain removal donor site aspirations of all 
symptomatic seromas by patient self-report.
Results
The effect of Tisseel glue was to reduce the mean total drain (breast, 
axilla and back) volume from 2170ml to 1919ml (P=0.05, Mann-
Whitney) within 7-10 days. The donor site seroma volumes were 
similar between the 2 groups over 3 months. The mean donor site 
total drain volumes (LD donor site drain volume and symptomatic 
donor site aspirations) were 5412ml in the Control group (840-6252), 
compared to the Tisseel group producing 4646ml (5384-738). There 
were no statistical differences between the frequencies or volumes 
of patient reported seromas aspirated post-drain removal between the 
two groups. This comprised a mean of 4 aspirations (range 0-13) in 
the Control group compared to a mean of 9 aspirations (range 0-11) 
after the use of Tisseel (P=0.548).
Conclusion
Tisseel glue may reduce the ‘early’ effect of seroma development, 
but has not shown any significant role in minimising the potential 
‘shearing’ of the donor site skin flaps causing later seroma formation. 
Current evidence recommends quilting sutures as the gold-standard 
in reducing this complication.
1. Daltrey I et. al. BJS 2006; 93(7):825-830.
2. Jain PK et. al. BJS 2004; 91:54-60.
P2-16-08
Expander-Implant-Reconstruction – Aesthetic Outcome and 
Patients’ Satisfaction in a 10-Year-Period.
Kern PA, Zarth F, Rainer K, Scherag A, Mahdi R. Breast Center 
Düsseldorf Louis Hospital, Düsseldorf, North Rhine Westfalia, 
Germany; University Clinic of Essen, Essen, North Rhine 
Westfalia, Germany; Institute for Medical Informatics, Biometry 
and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, 
Germany
Background. Breast reconstruction after mastectomy is gaining 
increasing significance avoiding the post-mastectomy-trauma and 
providing the patients with a normal body image after breast cancer 
survival. This study was conducted to investigate the patients’ 
characteristics and comorbidities in correlation with the surgical 
outcome of expander-implant-reconstruction after mastectomy. 
Patients’ satisfaction with the surgical result and self-perception as 
well as their partner interaction were also analyzed in their dependance 
of these patient-related data.
Methods. In this large retrospective cohort study 258 women were 
enrolled with expander- and/or implant-reconstruction in a single-
institution-setting of a 10-years-period (2000-2009). Patient’s 
satisfaction with the result of surgery was evaluated by questionnaires 
and interviews and patient-related data were retrieved like BMI, 
smoking, pre-existing diseases and chemo- and radiotherapy, 
the differentiation between one-stage/two-stage reconstruction, 
immediate/delayed reconstruction, antibiotics and complications 
(secondary bleeding, pain, capsular contracture, implant rotation, 
etc.). Finally, the patients’ interaction with their partners and their 
adhaerence to their decision for reconstruction was investigated.
For explorative statistical analyses we used standard univariate 
methods appropriately for the scale level of the variables (e.g. Fishers 
exact tests for n x m Tables or exact Wilcoxon Mann Whitney tests 
to compare two distributions) and applied a significance level a of 
5% to each test.
Results: BMI and patients’ satisfaction with the aesthetic result was 
inversely correlated (p=0,004) and a negative self-perception had 
a negative impact on interaction with the partner (p<0,001) after 
breast reconstruction. BMI was positively correlated with the loss of 
the implant (p=0,005). Further comorbidities led to worse patients’ 
satisfaction in rating of the aesthetic results.
Conclusion. 
Patients characteristics like obesity and other comorbidites are 
associated with lower patients’ satisfaction with the surgical outcome 
after expander-implant-breast reconstruction.
A decrease of satisfaction is detectable after expander-implant 
reconstruction within years compared to autologous reconstruction.
These results should be taken into consideration for counselling of 
patients opting for breast reconstruction after mastectomy.
This is to our knowledge the largest single-institution study evaluating 
the patients’ satisfaction with implant-reconstruction after breast 
cancer treatment and comparing the outcome with various patient 
characteristics giving a rationale for selection of the optimal 
reconstructive method.
CTRC-AACR San Antonio Breast Cancer Symposium
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P2-16-09
Nipple-Areolar Sparing Mastectomy: Utility of the Lateral 
Inframammary Incision in Immediate Implant-Based 
Reconstructions.
Guth AA, Blechman K, Levovitz C, Small K, Axelrod D, Karp N, Choi 
M. NYU-Langone Medical Center, New York, NY; NYU-Langone 
Medical Center
Purpose: Nipple and/or areola-sparing mastectomy as a therapeutic 
or prophylactic procedure for breast cancer is rapidly gaining 
popularity as the literature continues to support it safety. The lateral 
inframammary fold (IMF) approach provides adequate exposure and 
eliminates visible scars on the anterior surface of the breast, making 
this incision cosmetically superior to radial or periareolar approaches.
Methods: We reviewed 58 consecutive nipple and/or areola-sparing 
mastectomies performed through a lateral IMF incision with 
immediate implant-based reconstruction, with or without tissue 
expansion, between June 2008 and February 2011. Prior to incision, 
breasts were lightly tumesced with dilute anesthetic solution with 
epinephrine. Sharp dissection, rather than electrocautery, was used as 
much as possible to minimize thermal injury to the mastectomy flap. 
When indicated, acellular dermal matrix was placed as an inferolateral 
sling. Subsequent fat grafting to correct contour deformities was 
performed in select patients. Three-dimensional (3D) photographs 
assessed changes in volume, antero-posterior projection, and ptosis. 
Retroareolar/nipple tissue underwent routine intraoperative frozen 
section analysis in cancer cases.
Results: Mean patient age was 44 years, and mean follow-up time 
was 14 months. Depending upon the judgment of the oncologic 
surgeon, 44 (76%) mastectomies were nipple/areola-sparing, and 
14 (24%) were areola-sparing. Thirteen mastectomies (22%) were 
therapeutic, the remaining 45 mastectomies (78%) were prophylactic. 
Five of the nine sentinel lymph node biopsies (56%) were performed 
through the lateral IMF incision without the need for a counter-
incision. Acellular dermal matrix was used in 44 (76%) breasts. 
Average permanent implant volume was 313 cc (range 170 to 750 
cc), and average fat grafting volume was 90 cc (range 36 to 177 
cc). Mastectomy flap necrosis, requiring operative debridement, 
occurred in three breasts (5%). One of these breasts required a salvage 
latissimus dorsi myocutaneous flap to complete the reconstruction. 
Of the 44 nipple/areola sparing mastectomies, three (7%) required 
operative debridement and reconstruction for partial nipple necrosis. 
No statistically significant differences existed between therapeutic 
and prophylactic mastectomies for developing partial skin or 
nipple necrosis (p = 0.65). Morphologic outcomes using 3D scan 
measurements showed reconstructed breasts were larger, more 
projected, and less ptotic (196 vs. 248 cc, 80 vs. 90 mm, 146 vs. 134 
mm, p < 0.01 for each parameter).
Conclusion: Excellent results can be achieved with immediate 
implant-based reconstruction of nipple and/or areola-sparing 
mastectomy through a lateral IMF incision. NAC survival is reliable, 
and complication rates are low.
P2-16-10
Practice Variations in Post-Mastectomy Breast Reconstruction: 
What Are the Roles of Clinical Factors, Access Barriers, and 
Delayed Reconstruction?
Cox D, Milucky J, Dominik R, Lee C. University of North Carolina 
at Chapel Hill, Chapel Hill, NC
Background: Breast reconstruction rates vary widely by race, 
income, and location. Proposed explanations have included clinical 
contraindications to reconstruction, access barriers, and patient 
or surgeon preference for delayed reconstruction. We sought to 
determine whether clinical contraindications (planned radiation, 
comorbidities) or access barriers (distance to care, surgeon) were 
associated with reconstruction and to estimate the frequency of 
delayed reconstruction over time.
Methods: A retrospective cohort study was conducted among women 
treated with mastectomy for Stage 0-IIIa breast cancer between 2002 
and 2007 at one institution. Demographics, stage, comorbidities, 
adjuvant therapy plans, and treatments were obtained from the 
medical record. Multivariable modified Poisson regression analyses 
were performed, with immediate and any reconstruction (immediate 
or delayed) as outcomes. Interaction terms were added to examine 
surgeon effects. Kaplan-Meier survival analysis was performed.
Results: Among 539 women, 18.9% had a plan for chemotherapy; 
13.7% had a plan for radiation. Comorbidities were: obesity 
17.1%, diabetes 11.9%, smoking 16.3%, heart disease 5.6%, 
immunodeficiency 2.2%. Most patients (59.8%) lived within 50 
miles of the hospital. 33.8% had immediate reconstruction; 5.6% had 
delayed. Patients who had a plan for adjuvant therapy or comorbidity 
were less likely to have reconstruction. Patients who lived farther from 
the hospital were slightly more likely to have reconstruction, but this 
was not statistically significant (p<0.08). None of the associations 
varied significantly by surgeon. Few patients had reconstruction more 
than 2 years after mastectomy.
Multivariable Poisson regression analysis of factors associated with immediate or any reconstruction
Factor Immediate Reconstruction Any Reconstruction
 RR 95% CI RR 95% CI
Plan for adjuvant therapy 0.43 0.28, 0.64 0.59 0.45, 0.79
Comorbidities 0.67 0.56, 0.80 0.67 0.56, 0.79
Distance>50 miles 1.17 0.92, 1.50 1.17 0.94, 1.45
Abbreviations: RR relative risk; CI confidence interval
Conclusion: Clinical contraindications may explain some breast 
reconstruction practice variations. Few patients who defer immediate 
reconstruction, however, ever have delayed reconstruction.
P2-16-11
Role of Proper Patient Counselling in Combination with Effect 
of Socioeconomic Deprivation on the Rate of Immediate Breast 
Reconstruction after Mastectomy.
Chakrabarti M, Stallard S, Fitzgerald C, Obondo C, Weiler-Mithoff 
E, Doughty J, Romics, Jr L. Victoria Infirmary Glasgow; Glasgow 
Royal Infirmary; Western Infirmary Glasgow
Introduction: current guidelines in the United Kingdom suggest that 
the possibility of breast reconstruction should be discussed with all 
patients prior to mastectomy. However, the majority of patients are 
still treated with mastectomy alone and no reconstruction is carried 
out. It has also been suggested that women from more deprived areas 
are less likely to undergo immediate breast reconstruction (IBR). We 
investigated potential pitfalls in patient counselling and consequent 
decision making contributing to present IBR rate in combination with 
the effect of socioeconomic deprivation.
Methods: data from 89 consecutive mastectomy patients was 
prospectively collected in a single centre in Glasgow between August 
2010 and March 2011. Each patient was scored for deprivation 
based on The Scottish Index of Multiple Deprivation. The patients 
were then divided into two groups: high and low deprivation levels. 
Consultations about IR and patients’ acceptance of counselling were 
analysed. For statistical calculations Fischer’s exact test was applied.
Results: IBR was offered to 41 (46%) patients, but it was not to 42 
(47%) (6 were excluded due to incomplete data). 25 patients accepted 
IBR, and of those 24 (27%) underwent IBR. 16 of 41 patients refused 
to undergo IBR due to lack of interest (10), not feeling ready for 
it (2), preference of delayed procedure (2) and fear of delaying 
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adjuvant therapy (2). Of 42 patients whom IBR was not offered, only 
10 were documented in the notes, while there was no reference for 
discussing reconstruction in 32 (36%) cases. Reasons for not even 
discussing reconstruction were the following: age (15), co-morbidities 
(18), locally advanced cancer (2), co-morbidities with age (5), and 
locally advanced cancer with age (2). As regards to socioeconomic 
deprivation; 44 (49%) patients were from deprived areas and 39 
(44%) from affluent areas. 41 patients were offered IBR and of these 
23 (26%) were from affluent areas compared to 18 (20%). Of the 42 
patients who were not offered IR, 26 (29%) were from deprived while 
16 (18%) from affluent areas (p<0.05). Of the 44 deprived patients, 
18 were offered IBR but 26 were not. 15 of 25 patients, who accepted 
IBR, were from affluent areas. The 16 patients who refused IBR had 
equal distribution of deprivation.
Conclusions: while none of the reasons for not offering IBR represent 
absolute contraindication to IBR, decisions about refusal are based 
mostly on patients’ subjective intuitions. Further, a greater proportion 
of the patients who were not offered IBR were from more deprived 
areas, and it seems that patients from affluent areas are more likely 
to be offered IBR compared to ones from deprived areas. However, 
confounding factors such as co-morbidities may contribute to 
the above. We believe, therefore, that detailed counselling about 
reconstruction of each patient requiring mastectomy is necessary, 
which is likely to further increase IBR rate.
 High Deprivation Low Deprivation
IBR offered: 41 patients (46%) 18 (20%) 23 (26%)
IBR not offered: 42 patients (47%) 26 (29%) 16 (18%)
(Total 83, excluding 6 patients)
P2-16-12
Skin Reducing Nipple Sparing Mastectomy – A Treatment Option 
for Patients with Significant Ptosis or Macromastia.
Ott Young A, Alizadeh K, Hodyl C, Pronovost M, Davenport T. Yale 
New Haven Health System, Fairfield, CT; Long Island Plastic Surgical 
Group, Garden City, NY; South Nassau Communities Hospital, 
Oceanside, NY
Background: With new data showing the oncologic safety of nipple 
sparing mastectomy with immediate reconstruction - nipple sparing 
mastectomies are now offered to an increasing number of mastectomy 
patients. Unfortunately cosmetically acceptable reconstruction of 
nipple sparing mastectomies is technically limited to women with 
perfect breast anatomy - where the skin envelope shows no or little 
redundancy and where the nipple areolar complex is located in the 
perfect location on the breast mount. Especially in countries with a 
high incidence of obesity and associated macromastia only a small 
percentage of women fall into this category.A high percentahge of 
patients who would otherwise be good candidates for nipple sparing 
procedures are excluded based on their unfavorable breast anatomy.
We describe a surgical technique that reduces the redundant 
mastectomy skin envelope in a breast reduction pattern and places 
the native nipple areolar complex as a free skin graft into proper 
anatomical position. This technique in conjunction with implant or 
autologous reconstruction combines the benefits of shorter better 
vascularized skin flaps with the cosmetic and emotional benefits 
of preserving the nipple areolar complex even in the anatomically 
difficult cases.
Methods: To investigate the safety and efficiency of this method we 
reviewed medical records of 40 patients who underwent 60 nipple 
preserving skin reducing mastectomies over the last 4 years. All 
procedures were performed by the senior author and follow up ranged 
from 4 weeks to 50 months.
The charts were analyzed for the occurrence of complications such 
as infection, seroma, hematoma, mastectomy flap necrosis, nipple- 
areolar loss and loco regional recurrence.
All patients were asked to rate their reconstruction on a scale of 
poor- good - excellent.
Results: In 60 reconstructed breasts we encountered one case of 
seroma, four cases of limited mastectomy flap necrosis treated with 
local wound care and one case of partial areolar necrosis treated with 
local excision. No loco regional recurrences, hematomas or infections 
were encountered. Out of the group of 40 patients, 31 patients rated 
their result as excellent, 8 as good, and one as poor.
Conclusion: Our results compare favorably with data published in the 
literature. Patient satisfaction rates are high and complication rates 
are low in a patient population that historically has been a challenge 
for the breast surgeon, as well as, the plastic surgeon. The use of a 
skin reducing mastectomy in conjunction with a free nipple graft 
enables the breast surgeon to offer nipple sparing procedures for 
all patients who are good oncological candidates regardless of their 
breast anatomy.
P2-16-13
Life after Mastectomy without Breast Reconstruction – Are the 
Needs of Caribbean Women Different?
Morton-Gittens J, Ali R, Affan AM, Bovell P, Rampaul R. National 
Radiotherapy Centre, St James, Trinidad and Tobago
Aim: The standard of care in the United States and United 
Kingdom for women undergoing mastectomy is to be offered breast 
reconstruction surgery (BRS), either immediate or delayed. In 
Trinidad, for a variety of reasons, patients are not routinely offered 
this option. We undertook a study to determine the impact of breast 
surgery without reconstruction on their perception of sexuality, 
body image, relationships and quality of life. The aim is to establish 
a benchmark for the planning and incorporation of reconstructive 
options into the care pathway of patients requiring oncoplastic surgery 
in the Caribbean.
Method: A questionnaire was administered to post surgery breast 
cancer patients in a public oncology clinic in Trinidad. These patients 
had no BRS and had surgery at various institutions in Trinidad, where 
the primary surgical service was General Surgery. Data was collected 
prospectively and analysed using SPSS software.
Results: Of 130 questionnaires administered to date, 80(61.5%) of 
those collected were adequate for analysis. 46.1%(n=35) of patients 
were less than fifty years of age; 44%(n=24) were Afro-Caribbean and 
55.6% (n=30) East Indian-Caribbean; 61.1%(n=44) had mastectomies 
and 38.9%(n=28) had breast conserving surgery (BCS). Of all 
patients, 90%(n=70) felt attractive, feminine and satisfied with their 
bodies before surgery, however postoperatively, all who had BCS 
remained satisfied with their bodies but a significant proportion 
of patients in the mastectomy group were dissatisfied(p=0.006) 
and found it harder to look at themselves naked(p=0.025) and be 
seen naked by their partners (42.9%, n=15). East Indian-Caribbean 
women felt less attractive after surgery compared to Afro-Caribbean 
patients(p=0.024). Among all patients, 19.2% felt shy to go out in 
public after surgery, 28.8% left their house less and 35% (n=25) had 
fewer social interactions. When analysed by ethnicity, East Indian-
Caribbean women were more likely to avoid public events(p=0.003) 
and had fewer social interactions(p=0.028) than Afro-Caribbean 
patients. This effect persisted in mastectomy patients(p=0.007), 
especially in the East Indian-Caribbean group(p=0.0017). 69% of 
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patients were willing to undergo BRS, but it was offered to only 
32.5%(n=13) of mastectomy patients. The interest in BRS was similar 
in all races, age groups and surgery types.
Conclusion: This study explores the experiences and needs of 
Caribbean women with breast cancer in Trinidad. We found from this 
data that their needs mirror those of women in other countries where 
BRS is incorporated into the core care pathway. Our data demonstrates 
that even with ethnic differences, there is deterioration in self esteem 
and feminity with breast cancer surgery, with lasting effects. Subtle 
differences appear to be present in body image perception amongst 
East Indian-Caribbean women versus Afro-Caribbean and may be a 
useful template when assessing patient needs with a view to how we 
individualize care in the Caribbean setting. This data also emphasizes 
the potential benefit in incorporating an Oncology-Plastic Surgery 
Team approach in our setting and supports the view that providing 
BRS to patients as early as possible can help to maintain a positive 
outlook in personal and social interactions.
P2-16-14
Skin Sparing Mastectomy and Immediate Latissimus Dorsi Flap 
Reconstruction: Patient Reported Outcome and Factors Affecting 
the Highest Patient Satisfaction.
Kim Z, Kang S-G, Lee J, Kim SY, Lim CW, Lee MH. Soonchunhyang 
University Hospital, Seoul, Korea
Background: Skin sparing mastectomy (SSM) and immediate breast 
reconstruction (IBR) with latissimus dorsi (LD) flap is a tailored 
surgical procedure for breast cancer patients. In this study the 
oncologic safety, morbidities, and aesthetic results of SSM and LD 
IBR, as regards to patient satisfaction, were assessed.
Material and Methods: Between March 2000 and February 2011, 
single surgeon performed SSM and IBR for 145 patients. Eighty-five 
patients completed the patient satisfaction survey, and 65 patients 
with SSM and LD IBR were included. The patients were divided 
into 2 groups according to their degree of satisfaction, and a stratified 
analysis was performed.
Results: The mean age of the patients was 48.4 years (range, 21-74), 
and the pathologic results were infiltrating ductal carcinoma (n=48, 
73.8%), ductal carcinoma in situ (n=15, 23.1%), and others (n=2, 
3.1%). After a mean follow-up of 34 months (range, 1.6-89.9) no 
local recurrence occurred, and there were no skin necrosis or LD 
flap loss. Donor site morbidities were seroma (n=8, 12.3%), scarring 
(n=8, 12.3%), and back pain (n=6, 9.2%).
Post-operative complications and morbidities
 Group 1 (n=39) Group 2 (n=26) P-value
Hematoma 0 0  
Infection 0 0  
Skin flap complication    
Skin necrosis 0 0  
Fat necrosis 0 0  
Dnonor site complication    
Seroma 6 (15.4%) 2 (7.7%) 0.355
Marked scarring 4 (10.3%) 4 (15.4%) 0.538
Back pain 4 (10.3%) 2 (7.7%) 0.726
Group 1: poor, fair, and good patient satisfaction, Group 2: excellent patient satisfaction
Fifty patients (76.9%) were satisfied with their surgical outcomes, 
and 40% reported their degree of satisfaction as excellent. Breast 
symmetry (P<0.001), nipple cosmesis (P<0.001), surgeon assessment 
(P<0.001), observer assessment (P<0.001), and visual difference 
of bilateral breasts (P=0.021) were factors that affected the highest 
patient satisfaction.
Aesthetic results
 Group 1 (n=39) Group 2 (n=26) P-value
 mean±SD (range) / n (%) mean±SD (range) / n (%)  
Skin incision   0.241
Circum-areolar 32 (82.1) 24 (92.3)  
Circum-areolar + extension 7 (17.9) 2 (7.7)  
Contralateral procedure   0.334
No 38 (97.4) 24 (92.3)  
Yes (reduction) 1 (2.6) 2 (7.7)  
Nipple reconstruction   0.128
No 18 (46.2) 17 (65.4)  
Yes 21 (53.8) 9 (34.6)  
Dnonor site scar length, cm 17.0±2.8 (7.0-24.0) 17.2±1.8 (13.0-22.0) 0.788
Breast size symmetry 6.9±2.0 (3.0-10.0) 8.7±1.4 (5.0-10.0) <0.001
Nipple cosmesis 7.7±1.6 (3.0-10.0) 9.0±0.9 (6.0-10.0) <0.001
Surgeon assessment 6.9±2.1 (3.0-10.0) 8.8±1.3 (5.0-10.0) <0.001
Breast clinic nurse assessment 7.2±2.0 (3.0-10.0) 9.1±1.0 (6.0-10.0) <0.001
Group 1: poor, fair, and good patient satisfaction, Group 2: excellent patient satisfaction 
Conclusion: The present study demonstrated that our SSM and LD 
IBR was oncologically safe, and was associated with low morbidity 
rates. LD flap per se, without a prosthetic implant, could sufficiently 
produce a high level of patient satisfaction. Accurate surgical 
techniuqes and careful consideration for breast symmetry and nipple 
cosmesis would be the key to meet the patient’s expectations and 
enhanced quality of life.
P2-16-15
Oncological Safety and Survival Rate According to Reconstructive 
Surgery in Advanced Breast Cancer after Neoadjuvant 
Chemotherapy.
Kim WW, Lee JJ, Nam KH, Jung JH, Chae YS, Yang JD, Lee YH, Park 
HY. Kyungpook National University; Hyosung Hospital
Purpose
Oncoplastic surgery has received attention according as the incidence 
of breast cancer is rising and quality of life including cosmetic result 
after surgery is regarded as important. The aim of this study is to 
compare combined reconstructive surgery with standard surgery 
regarding to oncological safety and survival rate in advanced breast 
cancer after neoadjuvant chemotherapy (CTx).
Method
Thirty-seven patients underwent neoadjuvant CTx and surgery with 
advanced breast cancer were analyzed from September 2007 to March 
2010. Group A (n=12) received combined reconstructive surgery, 
group B (n=25) had standard surgery.
Results
There were no differences in age, size, metastatic LN, stage, ER/PR/
Her-2 status, recurrence, metastasis and death between group A and B. 
Patients with good response in neoadjuvant chemotherapy (26 cases 
(72.9%)) had CTx-operation-radiation therapy (RTx), cases with poor 
response (10 cases (27.1%)) underwent CTx-RTx-operation. There 
was significant difference in order of treatment, eight patients among 
group A(66.6%) had CTx-RTx-operation, 22 cases in group B(88.0%) 
received CTx-operation-RTx (p=0.006). Mean follow up period was 
22 months, 2 patients (5.2%) experienced local recurrences, 11 cases 
(34.3%) diagnosed with distant metastasis, and 4 patients (10.5%) 
expired with breast cancer.
Charateristics comparison between group A and B
Variables Group A (n=12) Group B (n=25) p-value
Age (year) 45.7 ± 3.2 47.2 ± 2.3 0.722
Tumor size (cm) 3.6 ± 0.9 1.9 ± 0.4 0.063
LN metastasis 5.0 ± 3.2 4.2 ± 1.3 0.786
Stage III 11 (91.7%) 22 (88.0%) 0.560
Stage IV 1 ( 8.3%) 3 (12.0%) 0.560
ER/PR (+) 5 / 6 11 / 9 1.000/0.488
Her-2 (+) 5 (41.7 %) 9 (36.0%) 0.177
CR/PR/SD/PD 2/7/1/2 5/12/5/3 0.766
Chemo - Op - RTx 5 (41.7%) 22 (88.0%) 0.006
Chemo - RTx - Op 7 (58.3%) 3 (12.0%) 0.006
Local recurrence 0 (0%) 2 (8.0%) 1.000
Distant metastasis 5 (41.6%) 7 (28.0%) 0.726
Death 3 (25.0%) 1 (4.0%) 0.091
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Conclusion
Advanced breast cancer with poorly responded in neoadjuvant CTx 
could be actively treated with sequential CTx-RTx-reconstructive 
surgery. Combined reconstructive surgery was oncologically safe 
operation in advanced breast cancer.
P2-16-16
Nipple Sparing Mastectomy and Immediate Breast Reconstruction: 
Critical Appraisal of Five Year, Single Centre Outcomes.
Westbroek D, Karat I, Min-Hui H, Gukas I, Daoud R, Laidlaw IJ. 
Frimley Park Hospital, Portsmouth Road, Frimley, Surrey, United 
Kingdom
Background :
Approximately 5,000 patients undergo breast reconstruction annually 
in the United Kingdom ( 2:1 ratio of immediate versus delayed 
respectively). Whilst skin sparing mastectomy is an accepted modality 
for local control in appropriately selected patients, nipple preservation 
remains controversial. In over 1,800 peer reviewed nipple sparing 
mastectomy (NSM) cases, the local event rate attributable to NAC 
preservation following NSM (therapeutic and prophylactic) is 0.16% 
with no evidence of deleterious impact on disease free survival.
This study aims to evaluate in a selected cohort of patients, the 
oncological safety and aesthetic outcome of nipple- sparing 
mastectomy and immediate breast reconstruction (IBR). We highlight 
the surgical technique used and propose in/exclusion criteria.
Material and Methods:
Patients were identified retrospectively from our Institution’s 
electronic patient records and WinPath™ database by searching 
clinical codes corresponding to NSM & IBR, performed by the senior 
authors (IJL and RD) between January 2004 and December 2008. 
Pre-operative selection criteria included: 100% pre-operative lesion 
characterisation; 5mm margin acceptance; submission of separate 
nipple core specimens for paraffin block histological assessment 
and re-excision of all involved/ close margins. Follow-up data was 
verified from patients’ case notes, histo- pathological review and 
standardised photographic views. Endpoints include: local recurrence 
rate, disease free survival, peri-operative NAC subcutaneous tissue 
loss and validated aesthetic outcome measures.
Results*:
84 patients underwent NSM & IBR for invasive disease. The mean 
age was 52.1 years and a median follow-up of 38 months. IBR utilised 
autologous tissue (latissimus dorsi or transverse rectus abdominus 
musculocutaneous flaps) with/ without implant prosthesis. There 
was one case of local recurrence (1.2%) in a patient who declined 
re-excision of close/involved margins and no recorded breast cancer 
related deaths. Peri-operative complication rates were within the 
national mastectomy breast reconstruction audit outcome guidelines.
Conclusion:
In this cohort of patients, nipple sparing mastectomy and immediate 
breast reconstruction achieves comparable oncological outcomes with 
excellent aesthesis relative to traditional ablative procedures for local 
control. Nipple preservation although not evaluated independently 
does enhance cosmetic outcomes.
*(Preliminary analysis)
P2-17-01
Influence of Delayed Zoledronic Acid Initiation on Disease-Free 
Survival in Postmenopausal Women with Endocrine Receptor-
Positive Early Breast Cancer Receiving Adjuvant Letrozole: 
Exploratory Analyses from the ZO-FAST Trial.
Coleman R, De Boer R, Eidtmann H, Neven P, von Minckwitz G, 
Martin N, Modi A, Bundred N. University of Sheffield, Sheffield, 
United Kingdom; Royal Melbourne Hospital, Victoria, Australia; 
University Frauenklinik, Kiel, Germany; UZ Gasthuisberg, Leuven, 
Belgium; German Breast Group, Frankfurt, Germany; Novartis 
Oncology, East Hanover, NJ; University Hospital of South Manchester 
NHS Foundation Trust, Manchester, United Kingdom
Introduction: Bisphosphonates (BPs) combined with adjuvant 
endocrine therapy have been shown to prevent aromatase inhibitor-
associated bone loss (AIBL) and improve outcomes in recent clinical 
trials in patients with hormone receptor-positive (HR+) early breast 
cancer (EBC). Accelerated bone turnover (a common phenomenon 
during AIBL) has been associated with increased risk of bone 
metastasis in EBC (Lipton A, et al. St. Gallen 2009. abs #244), but 
little is known about the effect of BPs on the disease course in women 
with EBC and progressing AIBL. We have previously demonstrated 
that adding ZOL to adjuvant therapy significantly improved bone 
mineral density (BMD) and prolonged disease-free survival (DFS) vs 
delayed ZOL (de Boer R, et al. SABCS 2010. P5-11-01). We report 
here the prognostic factors for DFS and the effect of ZOL initiation 
in the delayed ZOL (DZOL) arm of the ZO-FAST trial at 5 years’ 
median follow-up.
Methods: The ZO-FAST trial randomized postmenopausal women 
with HR+ EBC initiating letrozole (LET; 2.5 mg qd × 5 years) with 
a BMD T-score ≥ –2 (N=1,065) to immediate (IMZOL; 4 mg q 
6 months) or DZOL (initiated for post-baseline T-score < –2, or 
nontraumatic/asymptomatic fractures). The primary endpoint was 
change in BMD at 12 months; patients were followed for disease 
recurrence and overall survival for 5 years (secondary endpoints). 
Exploratory Cox regression analyses were performed to identify 
prognostic factors for DFS in the DZOL arm.
Results: At 60-months follow-up, IMZOL significantly reduced the 
risk of a DFS event by 34% vs DZOL (42 vs 62 events; ~80% distant 
recurrences and 20% local; hazard ratio [HR]=0.66; 95% confidence 
interval [CI], 0.44-0.97; P=.034) in the intent-to-treat population 
(N=1,065; n=532 IMZOL; n=533 DZOL). In exploratory analyses 
of the DZOL arm (n=535; safety population), patients who initiated 
DZOL treatment (n=144) had significantly improved DFS (10 events; 
HR=0.462; 95% CI, 0.23-0.94; P=.033) compared with DZOL arm 
patients who never initiated ZOL (53 events; n=391). Other significant 
prognostic factors for DFS events in the DZOL arm were age ≥65 
years at study entry (HR=1.949; 95% CI, 1.09-3.47; P=.024 vs age 
<65 years) and cancer T-stage ≥2 (HR=2.155; 95% CI, 1.03-4.51; 
P=.042 vs T-stage <2).
Conclusions: Exploratory analyses of the ZO-FAST database revealed 
significant DFS benefits from initiation of ZOL treatment for post-
baseline fractures or T-scores < –2, suggesting that ZOL (even if 
initiated late) can positively influence the disease course in patients 
with AIBL. Together with other studies showing DFS benefits from 
ZOL in patients with complete ovarian suppression/postmenopausal 
status (Coleman RE, et al. SABCS 2010. abs #S4-5; Gnant M, et 
al. NEJM 2009;360:679-691), these data suggest that treating (and 
ideally, preventing) AIBL may also improve DFS in patients with 
HR+ EBC.
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res; 71(24 Suppl.) December 15, 2011 Cancer Research326s
P2-17-02
Increased Progression Free and Overall Survival in Breast Cancer 
Patients with Menopausal Symptoms or Arthralgia/Myalgia 
during Adjuvant Treatment with Exemestane or Tamoxifen – 
Results of the German TEAM Trial.
Hadji P, Kieback DG, Hasenburg A, Tams J, Ziller M. Phillipps 
University, Marburg, Germany; Elblandkliniken, Meissen, Germany; 
University Hospital Freiburg, Freiburg, Germany; ICRC-Weyer 
GmbH, Berlin, Germany
Background:
Previous studies have suggested a correlation between the occurrence 
of vasomotor or joint symptoms during tamoxifen or aromatase 
inhibitor treatment and improved clinical response. We assessed if 
there was any correlation between treatment-emergent adverse events 
during exemestane or tamoxifen treatment and clinical response.
Methods:
A retrospective analysis of the German cohort of the TEAM trial was 
performed to assess progression-free survival and overall survival in 
patients with and without menopausal symptoms or arthralgia/myalgia 
during adjuvant treatment with exemestane or tamoxifen.
Results:
A total of 1502 patients were included in this analysis; 739 patients 
received tamoxifen and 763 received exemestane. Patients reporting 
menopausal symptoms and patients reporting arthralgia/myalgia 
during tamoxifen or exemestane treatment had significantly longer 
overall survival and progression-free survival. The effect on overall 
survival was irrespective of treatment. Progression-free survival 
was significantly improved in exemestane-treated patients reporting 
menopausal symptoms or those reporting arthralgia/myalgia versus 
those not reporting these adverse events. There was no significant 
difference in progression-free survival between tamoxifen-treated 
patients reporting these symptoms versus those who did not. A 
combined analysis of patients reporting either menopausal symptoms 
or arthralgia/myalgia showed that overall survival and progression-
free survival was significantly improved in patients reporting one of 
these symptoms versus those not reporting either symptom. In this 
analysis, the effect on overall survival and progression-free survival 
was irrespective of treatment.
Conclusions:
Our results suggest that the occurrence of menopausal symptoms or 
arthralgia/myalgia during treatment with tamoxifen or exemestane is 
associated with significantly improved overall survival.
P2-17-03
Incomplete Uptake and Diminished Adherence to Endocrine 
Therapy in Women with Hormone Receptor Positive Breast 
Cancer 4 Years from Diagnosis: An Australian Cohort Study.
Bell RJ, Fradkin P, Schwarz M, Davis SR. Monash University, 
Melbourne, VIC, Australia; Alfred Health, Melbourne, VIC, Australia
Background: Tamoxifen(T) and the aromatase inhibitors (AIs) are 
associated with side effects which impair adherence to therapy. Our 
aim was to investigate the uptake of, and adherence to, endocrine 
therapy (ET) in a cohort of women with invasive breast cancer (BC) 
nearly 4 years post-diagnosis.
Materials and Methods: The BUPA Health Foundation Health and 
Well being After Breast Cancer study is a prospective questionnaire-
based cohort study of 1684 women with their first episode of invasive 
BC recruited between 2004 and 2006 through the Victorian Cancer 
Registry (VCR), Australia. An enrolment questionnaire (EQ) was 
completed within 12 months of diagnosis, with questionnaires every 
12 months thereafter (FQ1-FQ3). Tumor pathology was provided by 
the VCR. FQ3 was completed on average 3.8 years from diagnosis. 
Active disease included a new primary BC, local recurrence or 
metastatic disease.
Results: Of 1684 recruits, 1370 were HR+. At diagnosis, average 
age was 58 years and 50% were stage 1. The table shows the number 
of HR+ women retained in the analysis at each questionnaire, the 
average time of each questionnaire from diagnosis and the proportions 
of women at each questionnaire on any ET on T, an AI or on no ET.
Use of ET at each questionnaire
Questionnaire (n) years from diagnosis (mean) %ET %T %AI % no ET
EQ (1370) 0.8 65% 43% 22% 35%
FQ1 (1301) 1.8 87% 52% 35% 13%
FQ2 (1237) 2.8 84% 44% 40% 16%
FQ3 (1193) 3.8 82% 41% 41% 18%
Switching of ET from T to an AI was predominantly a clinician 
decision. Cessation of T was patient initiated, mainly for vasomotor 
symptoms and vaginal bleeding. For the change from an AI to T, or 
cessation of an AI, the main reason was joint pain.
At FQ3, nearly 4 years from diagnosis, 215 (18%) women were not 
on any ET. Compared with women on ET at this time, these 215 
women were more likely to have been stage 1 (rather than > stage 
1) at diagnosis, have active disease by FQ3, be seeing an alternative 
therapist (all p<0.01) and were less likely to be seeing an oncologist 
(p<0.001).
The 215 women not on ET nearly 4 years from diagnosis consisted 
of 117 previous users and 98 never-users. Compared with the 117 
previous users, the 98 never-users were more likely to be stage 1 at 
diagnosis (p<0.01) and be less likely to see an oncologist (p<0.001). 
Compared with women on ET at FQ3, both previous- and never 
users were more likely to have active disease and see an alternative 
therapist (all p<0.01).
Discussion:
By nearly 4 years from diagnosis, an increasing proportion of women 
with HR+ BC are not on ET, despite the evidence for the benefit of 
therapy for at least 5 years. Differences between ET users and non-
users at this stage are not simply explained by previous users not 
continuing ET, with or without active disease. There is a small (8.2%) 
but important subgroup who appear to have never been on ET, which 
raises serious concerns.
P2-17-04
Induction of Tamoxifen Metabolism by Rifampicin: A Worrying 
Drug-Drug Interaction.
Binkhorst L, Loos WJ, de Jongh FE, Hamberg P, Ghobadi 
Moghaddam-Helmantel IM, Jager A, Seynaeve C, Verweij J, van 
Gelder T, Mathijssen RH. Erasmus University Medical Center, 
Rotterdam, Netherlands; Erasmus University Medical Center - Daniel 
den Hoed Cancer Center, Rotterdam, Netherlands; Ikazia Hospital, 
Rotterdam, Netherlands; Sint Franciscus Gasthuis, Rotterdam, 
Netherlands
Background: Tamoxifen (Tam) undergoes extensive biotransformation 
into several metabolites, including the highly active metabolite 
endoxifen. Differences in metabolism, influenced by both genetic 
and environmental factors, largely contribute to the inter-individual 
variability in endoxifen plasma concentrations, potentially affecting 
the efficacy of Tam. Conflicting results between CYP2D6 genotype/
phenotype and endoxifen concentrations have been observed. A 
reason for this discrepancy may be that CYP3A4 may have a more 
crucial role in the formation of endoxifen than previously thought (de 
Graan et al, JCO, in press). Hypothesizing that induction of CYP3A4 
and CYP2D6 could lead to increased endoxifen levels, a prospective 
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study was activated evaluating the effects of enzyme induction by 
rifampicin (Rif) on the plasma pharmacokinetics (PK) of Tam and 
its metabolites.
Methods: A randomized cross-over study design was used, with 
each patient serving as her own control. Breast cancer patients on 
steady state Tam therapy (20 or 40 mg once daily) were included. 
Patients underwent two periods of plasma sampling covering 24 
hrs each, once using Tam alone, and once after 15 days of oral 
Rif (600 mg daily) taken in combination with Tam. Patients were 
randomized for sampling sequence 1) Tam alone followed by Rif/
Tam versus 2) Rif/Tam followed by Tam alone. PK sampling in 
sequence 2 was performed after a 30-day wash-out period of Rif. 
Tam and its main metabolites ND-Tam, 4-OH-Tam and endoxifen 
were quantitated by a validated LC-MS/MS method. PK parameters, 
including area under the plasma-concentration time curve (AUC) and 
maximum concentration (Cmax) of all four compounds were calculated 
(WinNonLin program) and compared (with or without Rif) using a 
two-sided paired t-test. For safety reasons an interim-analysis was 
performed after 4 patients.
Results: The interim-analysis showed that concentrations of Tam 
and its metabolites were significantly decreased during Rif/Tam 
co-administration as compared to Tam administration alone (see 
table). Especially endoxifen exposure was decreased by a mean of 
69%. Based on these data it was decided to stop further enrollment 
in this study.
Conclusions: Concentrations of Tam and its main metabolites 
decreased significantly after induction by rifampicin. Potentially 
contributing factors include further metabolism of Tam-metabolites 
into other inactive metabolites or conjugates (i.e. glucuronides) or a 
decreased oral availability of Tam. Further pharmacokinetic analyses, 
including the analysis of glucuronides and other metabolites, will be 
performed to better understand the mechanism behind these findings. 
Based upon these data, combining rifampicin with Tam should be 
avoided. Similar drug-drug interactions may exist between Tam and 
other strong CYP inducers, such as St John’s wort and phenytoin.
 Tam without Rif (Mean (SD))
Tam with Rif 
(Mean (SD))  Ratio (with/without)  Sign.(P-value) 
 Tam     
Cmax 329 (161) 79.9 (61.6) 0.24 0.02
AUC 4,863 (2,653) 847 (567) 0.17 0.03
 ND-Tam     
Cmax 459 (227) 156 (110) 0.34 0.02
AUC 7,716 (4,100) 2,623 (1,802) 0.34 0.02
 4-OH-Tam     
Cmax 4.8 (1.3) 1.8 (1.1) 0.38 0.01
AUC 92 (21) 30 (15) 0.33 0.01
 Endoxifen     
Cmax 23.6 (10.0) 6.9 (2.5) 0.29 0.05
AUC 387 (133) 122 (57) 0.31 0.04
Cmax (nM); AUC  0-24  (nM*h)
P2-17-05
Antiprogestin Proellex Suppresses Proliferation of Aromatase 
Overexpressing and Letrozole Resistant T47D Breast Cancer 
Cells.
Gupta A, Mehta R, Alimirah F, Murillo G, Peng X, Wiehle R, Mehta 
R. IIT Research Institute, Chicago, IL; Repros Therapeutics, The 
Woodlands, TX
Background: Aromatase is a cytochrome P450 CYP19A1 enzyme 
responsible for the conversion of C19 androgens to C18 estrogen. 
Aromatase overexpression leads to increase in local estrogen 
concentration in post menopausal women diagnosed for breast cancer. 
Aromatase inhibitors (AI) are used as one of the first line therapies 
for the treatment of ER+PR+ breast cancers. However, many patients 
acquire resistance to AI treatment. Therefore alternative approaches are 
being sought for patients with AI resistance. Previous reports suggest 
that upregulation of progesterone receptor can lead to enhanced 
expression of EGFR/ERK/MAPK involved in acquiring resistance. 
In this study, we evaluated the effect of a selective progesterone 
receptor modulator, CDB4124 (Proellex) with low glucocorticoid 
activity on aromatase overexpressing and Letrozole resistant T47D 
cells. Methods: Aromatase overexpressing T47D (T47Darom) and 
respective control (T47Dcon) breast cancer cell lines were generated 
by stable transfection with plasmid containing CYP19A1 coding 
region, or empty vector respectively. Letrozole resistant cell line 
(T47DaromLR) was generated by incubating T47Darom for 75 
weeks in the presence of 10µM Letrozole. Cell proliferation was 
determined by MTT or Crystal violet assays. Gene expressions were 
quantitated by qRT-PCR whereas proteins were identified by western 
blot analyses, flow cytometry and immunofluorescence staining. 
Aromatase activity was determined by estradiol ELISA . The effects 
of Proellex on anchorage independent growth were measured by soft 
agar colony formation. Statistical differences between the various 
groups were determined by Student’s ‘T’ test or ANOVA followed 
by Bonferroni’s post hoc test. Results: T47Darom and T47DaromLR 
cell lines had significantly higher aromatase expression (mRNA and 
protein) and as a result exhibited increased conversion of testosterone 
to estradiol as compared to T47Dcon. Both these cell lines showed 
enhanced growth in the presence of Testosterone. In T47Darom cells 
increased PR-B and EGFR expression as compared to T47Dcon cells 
was observed . Proellex, Letrozole and other known AI (Anastrozole, 
Exemestane) inhibited testosterone induced cell proliferation and 
anchorage independent growth of T47Darom cells. The inhibition of 
cell proliferation was significantly greater when cells were treated 
with Proellex in combination to other AIs. Proellex inhibited mRNA 
and protein levels of PR-B, reduced PRB/p300 complex formation in 
the nuclei and significantly reduced EGFR expression in T47Darom 
cells. Our results in the present study indicate that antiproliferative 
effect of Proellex may be due to PR-B / EGFR modulation in ER+PR+, 
aromatase overexpressing cells. Conclusion: Overall these results 
suggest that antiprogestin, Proellex could be developed as a possible 
treatment strategy for aromatase overexpressing ER+/PR+ breast 
cancer patients as well as for AI resistant breast cancer patients.
P2-17-06
Patterns of Bone Density Evaluation in a Community Population 
Treated with Aromatase Inhibitors.
Ligibel JA, O’Malley AJ, Fisher M, Daniel GW, Winer EP, Keating 
NL. Dana-Farber Cancer Institute, Boston, MA; Harvard Medical 
School, Boston, MA; HealthCore
Aromatase inhibitors (AIs) lead to an increased risk of bone loss 
and fracture. Fracture rates in adjuvant AI studies have ranged from 
2.3% to 11%, with higher rates seen in studies with longer duration 
of AI therapy and longer follow up. The American Society of Clinical 
Oncology recommends baseline bone density testing upon initiation 
of AI therapy and repeat testing every 1-2 years while on therapy. 
There are few data regarding the incorporation of these guidelines 
into clinical practice. We sought to evaluate patterns of bone density 
testing in a community-based cohort of breast cancer patients treated 
with AIs.
Methods
We obtained encounter and pharmacy data from the HealthCore 
Integrated Research Database, a fully integrated commercial payer 
dataset including patients enrolled in WellPoint insurance plans. We 
identified 9138 women aged ≥50 years who had at least 2 diagnosis 
codes for breast cancer between 2001 and 2007 (followed through 
2008), and who filled at least 1 prescription for an AI. We identified 
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bone density testing using encounter data and used logistic regression 
to assess patient demographic and clinical characteristics associated 
with baseline bone density testing (any test from 6 months before 
through 6 months after the first prescription for AI). Among 2038 
women who continued AI therapy for ≥2 years, we used logistic 
regression to assess factors associated with receipt of any bone density 
during the 2-year period.
Results
Overall, 41.6% of women underwent baseline bone density testing. 
Rates of bone density testing increased over time, from 26.6% in 
2002 to 44.7% in 2008 (adjusted odds ratio [AOR] for 2008 vs. 
2002=2.02, 95% confidence interval [CI]=1.53-2.68). Older women 
were less likely to undergo baseline bone density testing (AOR for 
women age ≥69 vs. 51-59=0.64, 95% CI=0.56-0.72). Women taking 
proton pump inhibitors, which have been linked to bone density 
loss, were also less likely to undergo baseline bone density testing 
(AOR=0.86, 95% CI=0.73-1.00). Women living in areas of lower 
education (p<.001), and areas with a higher proportion of blacks 
(p=.02) or Hispanics (p<.001), as well as women previously treated 
with tamoxifen (p=.02), were all also less likely to undergo baseline 
bone density. Women receiving bisphosphonates in the year before 
initiation of an AI were more likely to undergo baseline bone density 
(AOR=1.33, 95% CI=1.16-1.51).
Among women on AIs for at least 2 years, 59.9% of women underwent 
a bone density within 2 years of starting treatment. In adjusted 
analyses, earlier year of AI initiation (p<.001), living in areas with 
lower education levels (p<.001), and having been previously treated 
with tamoxifen (p<.001) were all associated with a decreased 
likelihood of undergoing bone density testing.
Conclusions
Despite the increased risk of fracture in women treated with AIs and 
guidelines recommending regular bone density evaluation, 58.4% 
of women starting an AI and 40.1% of women on long-term therapy 
did not undergo bone density evaluation in this community-based 
population. Older women, who might be especially vulnerable to 
bone loss and fracture, were less likely to undergo baseline bone 
density evaluation. More attention is needed to ensure that preventable 
fractures are avoided in patients taking AIs.
P2-17-07
Construction of a Predictive Model of Probability of Ovarian 
Function Recovery in a Series of Premenopausal Breast Cancer 
Patients with Chemotherapy-Induced Amenorrhea Switched to 
an Aromatase Inhibitor (AI) after Adjuvant Tamoxifen.
Perez-Fidalgo JA, Bermejo B, Pons V, Guzman C, Bosch A, Lluch 
A. Hospital Clínico Universitario, Valencia, Spain; Pfizer Spain, 
Alcobendas (Madrid), Spain
Introduction: AI therapy is not recommended in breast cancer patients 
with conserved ovarian function as AI decreases estrogenic feedback 
leading to an increased of FSH and LH. In patients older than 40 
and with prolonged amenorrhea, switching to an AI after tamoxifen 
therapy is a controversial approach but with an adequate follow-up 
for early detection of potential menses renewal it might be feasible. 
Several factors have been identified in the literature as clinical 
defining variables of CIA while other factors have been associated 
with high probability of permanent CIA. Among clinical defining 
variables are time from last menses date (LMD) and low estradiol (E2) 
levels. Risk variables for permanent CIA are chemotherapy schedule 
administered and advanced age. We aimed to construct a predictive 
model to identify high risk of renewal of menses after switching to 
AI in premenopausal patients with CIA lasting at least 1 year.
Methods: Based on defining and prognostic variables of CIA, a 
predictive model of high probability of permanent amenorrhea was 
constructed by assigning a score as follows:
1) Time from LMD to switching date >3 years: 1 point, < 3 years: 
0 points
2) E2 levels <20 ng/ml: 1 point, >20 ng/ml or unknown: 0 points
3) Age > 45 years: 1 point, < or = 45: 0 points
4) Chemotherapy regimen administered: dose dense or high doses: 2 
points, conventional doses regimen with anthracycline and taxanes: 1 
point, conventional doses only anthracycline-based or other: 0 points.
Final score obtained from 0 to 5 points was classified in two groups: 
Low-probability of permanent amenorrhea: score 0-2, and high 
probability of permanent amenorrhea: score 3-5. To validate this 
probability model we retrospectively analysed data from a prospective 
maintained database of early breast cancer patients, clinically 
premenopausal at diagnosis that were treated in our institution 
from May 2004 to December 2009. All patients had histologically 
confirmation of hormone-sensitive breast carcinoma at stage I-III. 
Therapy included in all cases adjuvant or neoadjuvant chemotherapy 
and adjuvant tamoxifen and all patients referred a CIA lasting at 
least 1 year. Since 2006, in most patients E2 levels before switching 
were determined.
Results: Validation of probability model was performed in our series 
of 102 premenopausal patients of whom 9 recovered ovarian function 
(prevalence ratio: 0.088).
 Ovarian function recovery 
after AI
No ovarían function recovery 
after AI
Total
Score 0-2: low probability of 
permanent amenorrhea. 9 40 49
Score 3-5: high probability of 
permanent amenorrhea 0 53 53
total 9 93 102
Test sensibility of the model was 100% and specificity 56.99%. 
Positive predictive value was 18.4% and negative predictive value 
100%. Positive likelihood ratio was 2.32 and negative likelihood 
ratio was 0.
Conclusions: Our model of probability of ovarian function recovery 
is a highly sensitive test that might become a useful tool to identify 
premenopausal patients with CIA that could be safely switched to AI 
after tamoxifen. Further validation in a prospective series including 
more accurate E2 monitoring and follow-up is warranted.
P2-17-08
Prospective Study of Aromatase Inhibitor Induced Bone Loss 
and Lipid Levels in Early Postmenopausal (PM) Hormone 
Receptor Positive (HR+) Breast Cancer (BC) Patients Treated 
with Adjuvant Letrozole Extended beyond 5 Years (yrs).
Fontaine C, Hanssens S, Van Den Berge D, Decoster L, Schallier 
D, Declippeleir D, Vanhoeij M, Lamote J, Sacre R, De Grève J. 
Oncologisch Centrum, UZ Brussel, Brussel, Laarbeeklaan, Jette, 
Belgium
Introduction/Aim:
Adjuvant treatment with aromatase inhibitors (AI) is associated with 
accelerated bone loss and increase in lipid levels. The effectiveness 
and tolerance of extended treatment with AI beyond 5 years is 
currently under investigation. In the SOLE study, five years of 
continuous (C) extended letrozole is compared to interrupted therapy 
(9 months on, 3 months off letrozole) after 5 yrs of tamoxifen, AI or 
sequential hormonal therapy. We have evaluated the bone mineral 
density and lipid levels during the extended use of letrozole beyond 
5 yrs in a cohort of patients included in the SOLE study.
Patients and methods: Postmenopauzal women with HR+ BC, 
receiving extended continuous (C) or intermittent (I) letrozole for 5 
yrs after 5 yrs of tamoxifen, 5 yrs of an AI, or switch therapy within 
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the first 5 years, were included. Bone mineral density was measured 
at the lumbar spine (L2-4) and total hip BMD (g/cm2), by dual energy 
X-ray absorptiometry (DXA). The mean percentage change in BMD 
at 12, 36 and 60 months (mths) was compared between the C and I 
treatment with letrozole and with baseline values. Differences between 
the treatment groups were assessed by the independent samples T test. 
We also compared the evolution of the serum lipid levels in both arms.
Results: Thirty two patients (pts) were included with a mean age 
of 62 yrs (+/- 8.7 yrs). Thirty pts were valuable because of missing 
baseline DXA values in 2. In their first 5 years of adjuvant letrozole, 
prior to inclusion in the current study, twenty three pts had a mean 
percentage decrease of -0,76 (13,25 SD) and 7 pts who had received 
preventive zoledronate in the ZOFAST study, had a mean percentage 
increase in BMD of 4,4 (6,08 SD). 
Currently 12 pts receiving the continuous letrozole are evaluable 
after a first one year extension of adjuvant letrozole. They had a 
mean percentage increase in BMD for the lumbar spine of 1.8 (3.3 
SD), and a mean percentage increase in BMD for the hip of 0.85 
(SD 1.93). Eight pts included in the intermittent arm are evaluable. 
They experience a mean percentage decrease in BMD for the lumbar 
spine of -0.32(2.7 SD) and a mean decrease in BMD for the hip of 
-2.9(SD 3.6) The difference between the two treatment groups was 
not significant for the lumbar spine measurements (p=0.14), but it was 
significant for the hip (p=0.02). The mean fasting cholesterol levels 
at 12 months in the C arm (12pts) was 228mg/dl (24.4 SD) and in 
the I arm (11pts) was 225,5mg/dl(32,3 SD) (p=0.37).
Conclusion: This is the first prospective BMD and lipid follow-up 
study during adjuvant letrozole extended beyond 5 yrs in PM early 
breast cancer pts. After the first year of extended intake of continuous 
or intermittent letrozole a possible difference in bone mineral density 
between the two arms is emerging, but the two groups are too small 
to make final conclusions. An updated longer follow-up on more 
patients will be presented. After one year no differential effect on 
cholesterol levels has been observed.
P2-17-09
A Prospective Assessment of Loss of Grip Strength by Baseline 
BMI in Breast Cancer Patients Receiving Adjuvant Aromatase 
Inhibitors or Tamoxifen.
Lintermans A, Dieudonné A-S, Vanderhaegen J, Henry NL, Laenen 
A, Wildiers H, Paridaens R, Christiaens M-R, Smeets A, Leunen K, 
Amant F, Vergote I, Neven P. University Hospitals Leuven, Leuven, 
Belgium; University of Michigan Comphrehensive Cancer Center, 
MI; Katholieke Universiteit Leuven, Leuven, Belgium
Background The 3rd generation aromatase inhibitors (AIs) induce 
or enhance musculoskeletal problems. Underlying mechanisms are 
probably multiple, but remain unknown. We have previously reported 
that loss of grip strength together with tenosynovial abnormalities 
are more important in AI- than in tamoxifen-users (Morales et al, 
JCO 2008) and that musculoskeletal changes in AI-users are more 
pronounced in women with extremes in baseline BMI (Lintermans et 
al, Ann Oncol 2011) We here report preliminary results from a larger 
population and plan to validate findings in patients from University 
of Michigan.
Patients and methods In this prospective observational study, 
postmenopausal early breast cancer patients scheduled to start 
adjuvant hormonal therapy with any of the third generation AIs 
or tamoxifen were recruited. After providing informed consent, a 
functional assessment test of grip strength was performed with a 
modified sphygmomanometer. Re-evaluation was done after 3, 6 
and 12 months of therapy. BMI and waist to hip ratio (WHR) were 
assessed and a rheumatological questionnaire was completed at 
each visit.
Results Ninety-four (79 AI; 15 tamoxifen) of the planned 200 patients 
were included in this preliminary study. 18% of AI-users discontinued 
their treatment due to musculoskeletal symptoms compared with 
none of the tamoxifen-users. 62% of patients on AI and 35% of 
tamoxifen patients complained of new or worsened joint pain. Table 
1 shows the proportion of patients that attribute their complaints to 
their endocrine therapy. Grip strength significantly decreased over 
time (p=0.03), with patients under AI treatment having a larger loss 
of grip strength than patients under tamoxifen treatment (p=0.04). 
We confirm our previously reported results on the shape of the 
curve “BMI AI-induced loss of grip strength”. Years past menopause 
and age showed a significant effect on grip strength (p<0.001 and 
p=0.0007, respectively), whereas no significant relationship was 
found between WHR with grip strength or joint pain. Detailed results 
will be presented.
Table 1 Percentage of patients assigning their endocrine therapy as causal factor for the side effects
 Aromatase Inhibitor Tamoxifen
Joint pain 71% 17%
Joint stiffness 77% 0%
Hot flashes 85% 82%
Muscle aches 68% 7%
Numbness 62% 0%
Cognition problems 38% 38%
Sexual problems 64% 40%
Conclusion Our preliminary results confirm that a majority of patients 
treated with an AI experience musculoskeletal problems, which 
are considered due to the therapy by most patients. Grip strength 
decreased over time, with a significantly larger loss of grip strength 
in the AI-users compared with the tamoxifen-users. AI-induced loss 
of grip strength and baseline BMI showed an inverted U-shaped 
association, although differences between quartiles were small. 
Further results should be awaited as this is only a preliminary analysis.
P2-18-01
The Magnitude of Trastuzumab Benefit in HER2-Positive 
(HER2+) Lobular Breast Carcinoma (BC): Results of a HERA 
Trial Sub-Group Analysis.
Metzger O, Procter M, de Azambuja E, Viale G, Leyland-Jones B, 
Dowsett M, Gelber R, Gresko E, Loi S, Sotiriou C, Piccart M. Institut 
Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; 
Frontier Science (Scotland) Ltd, Kincraig, Kingussie, United 
Kingdom; European Institute of Oncology, Milan, Italy; Emory 
University, Atlanta; Royal Marsden Hospital and Institute of Cancer 
Research, London, United Kingdom; Dana-Farber Cancer Institute, 
Boston; Roche, Basel, Switzerland
Background: Invasive lobular carcinoma (ILC) represents the second 
most common BC subtype and is often characterized as hormone 
receptor positive and HER2-negative. However a small subset of 
ILC is found to be HER2+. Isolated case reports have demonstrated 
high responsiveness to trastuzumab in patients with advanced HER2+ 
ILC. The HERA trial compares 1 or 2 years of trastuzumab treatment 
with observation and 1 versus 2 years of trastuzumab treatment after 
standard chemotherapy in women with HER2+ breast cancer. We 
sought to evaluate the incidence of HER2+ ILC and the magnitude of 
trastuzumab benefit in HER2+ ILC in the context of the HERA trial. 
In addition, we sought to describe the pattern of hormone receptor 
positivity in the subsets of ILC and invasive ductal carcinoma (IDC)
Methods: The database used in the analysis had a clinical cut-off 
date of 9th June 2008 and 4-year median follow-up (Gianni et al., 
2011). Patients randomized to the 1-year trastuzumab and observation 
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arms were included in the present analysis. Central assessment of 
hormone receptor status was considered. Histological BC subtype 
was assessed locally.
Results: Of the 1703 women randomized to one-year of trastuzumab 
and 1698 to observation, 5.5% (n=187) and 94.5% (n=3213) were 
diagnosed as HER2+ ILC and IDC, respectively. Central hormone 
receptor status was available in 88.3% (n = 2838) of IDC and 86.1% 
(n=161) of ILC. ER and/or PR positivity was more common in ILC 
than IDC (63.4% [102/161] vs. 46.3% [1314/2838]; p<0.001). Allred 
scores for ER are shown in the table below. The DFS hazard ratios 
comparing one year of trastuzumab versus observation were 0.63 
(95% CI 0.34-1.14) for ILC and 0.77 (95% CI 0.67-0.89) for IDC. 
There was no evidence of an interaction between histological subtype 
and trastuzumab benefit (interaction [subtype lobular and subtype 
ductal and not lobular] p=0.49).
Summary of Central Assessment of Hormone Receptor Status by Type of Primary Breast Cancer
 Lobular (HER2+) Ductal (HER2+)
 N = 187 N = 3213
Hormone receptor status   
n 161 2838
Positive 102 (63.4%) 1314 (46.3%)
Negative 59 (36.6%) 1524 (53.7%)
   
Estrogen receptor status   
n 160 2835
Allred 0-2 72 (45.0%) 1777 (62.7%)
Allred 3-5 29 (18.1%) 415 (14.7%)
Allred 6-8 59 (36.9%) 643 (22.7%)
Conclusion: HER2+ ILC accounts for 5.5% of patients included in 
a large population of over 3,000 HER2+ BC. While only a limited 
number of patients with ILC was enrolled, this analysis suggests 
an increased ER positivity in ILC compared to IDC. There was 
no suggestion that patients with HER2+ ILC derived a different 
magnitude of benefit from adjuvant trastuzumab when compared to 
the HER2+ IDC cohort. The lack of central pathology review for BC 
subtype assessment is a caveat of our study. Future research in the field 
of ILC and particularly in the HER2+ subset should be encouraged.
P2-18-02
Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) 
and Trastuzumab (H) for Node Negative, HER2 Positive Breast 
Cancer (BCA).
Dang C, Tolaney S, Najita J, Gelman R, Yardley D, Marcom K, Albain 
K, Rugo H, Miller K, Ellis M, Shapira I, Wolff A, Carey L, Vahdat 
L, Burdette-Radoux S, Budd T, Krop I, Burstein H, Hudis C, Winer 
E. Memorial Sloan-Kettering Cancer Center; Dana-Farber Cancer 
Institute; Tennessee Oncology and Sarah Cannon Research Institute; 
Duke University; Loyola University Medical Center; Univerity of 
California-San Francisco Comprehensive Cancer Center; Indiana 
University; Washington University; North Shore-Long Island Jewish 
Medical Center; Johns Hopkins University; University of North 
Carolina; Weill Cornell Medical College; University of Vermont; 
Cleveland Clinic Taussig Cancer Institute Case
Background: Patients (pts) with (w/) node-negative HER2-positive 
BCA have a higher risk of recurrence than those with node-negative 
HER2-negative disease. Several randomized trials have shown the 
benefit of chemotherapy (most with an anthracycline) and trastuzumab 
(H) for pts with node-positive and high-risk node-negative BCA. 
However, the benefit of chemotherapy and H needs to be further 
explored in the node-negative group. Due to the 2-4% risk of 
symptomatic congestive heart failure (CHF) with an anthracycline-
based treatment (Rx) followed by H, we set out to conduct a study of 
a taxane-based Rx with H in a node-negative population.
Design: This is a single arm, multicenter, phase II study of paclitaxel 
(T) (80 mg/m2) and trastuzumab (H) x 12 weekly (w) (4 mg/kg load 
→2 mg/kg) → H x 52 w (2 mg/kg weekly or 6 mg/kg q 3 w). Pts 
with HER2-positive BCA (IHC 3 + or FISH amplified at > 2.0) with 
negative nodes (micrometastasis later allowed) and with a tumor 
size < 3 cm were enrolled. The primary endpoint is disease-free 
survival. Secondary endpoints include the incidence of G 3/4 left 
ventricular systolic dysfunction or congestive heart failure (CHF). 
Pts had serial left ventricular ejection fraction (LVEF) monitored at 
baseline (BSLN), and at month (mo) 3, mo 6, and mo 12 w/ a multi-
gated acquisition scan or echocardiogram. H was held for significant 
asymptomatic (Asx) LVEF ↓ (10-15% ↓ from BSLN and < lower 
limit of normal or > 16% ↓ from BSLN), and H was stopped for CHF.
Results: From 10-9-2007 to 9-3-2010, 406 pts were enrolled. The 
median (med) age was 55 years (range 23-84 years); 118/406 (29%) 
had hypertension and 30/406 (7%) had diabetes. As of 6-1-2011, 307 
are reported as off Rx of which 261 have completed protocol therapy; 
99 remain on therapy. To date, 100%, 94%, 84%, and 83% of pts had 
LVEF monitoring at BSLN, mo 3, mo 6, and mo 12. The med LVEF 
at BSLN was 65% (range 50%-81%), at mo 3 was 64% (range 45%-
81%), at mo 6 was 64% (range 45%-81%), and at mo 12 was 65% 
(range 37%-90%). Two pts had CHF; 1 pt had CHF at mo 11 (LVEF 
was 55% at BSLN and 37% w/ CHF event) and 1 pt had CHF at mo 
6 (LVEF was 66% at BSLN and 49% w/ CHF event). To date, 13 
pts had H held for significant Asx LVEF ↓; details on those who had 
appropriate LVEF recovery and had H restarted will be provided. All 
patients will have completed 12 mo of Rx by October 2011, and an 
accurate report of the incidence of CHF will be available.
Conclusion: This represents the cardiac report of pts receiving TH 
as adjuvant Rx for node-negative (micrometastasis allowed) HER2 
positive BCA. Both the CHF events and number of pts w/ H hold 
due to significant Asx ↓ LVEF appear low. Overall, the serial med 
LVEFs remain stable throughout the 12 mo of Rx. Final data on all 
406 pts will be available in December 2011.
P2-18-03
Systemic Adjuvant Treatment of T1a and T1b N0M0 HER2+ 
Breast Carcinomas; an AERIO/UNICANCER Study.
Peron J, Vano Y, Frenel J-S, Wassermann J, Albiges L, Rodrigues 
MJ, Cottu PH. Centre Léon Bérard, Lyon, France; Centre Antoine 
Lacassagne, Nice; Institut de Cancerologie de l’Ouest, Centre René 
Gauducheau, Nantes; Institut Curie, Centre René Huguenin, Saint-
Cloud; Institut Gustave Roussy, Villejuif; Institut Curie, Paris
Background:
Trials have shown benefit of adjuvant trastuzumab (TZM) for node-
positive (N+) or T1c+ HER2-positive breast carcinomas.
Methods:
Retrospective series in 6 french cancer centers from 2000 to 2010 
of T1abN0M0 HER2 positive breast carcinomas. Multifocal tumors 
were excluded.
Results:
Two hundred five N- cases were retrieved. Median size was 8 mm 
(range, 2 to 10 mm), 51 were T1a (25%), 152 tumors were T1b; 
120 tumors (59 %) exhibited significant hormonal receptors (HR) 
expression. All patients had surgery, 65 % (n= 133) had a local 
irradiation. Ninety percent of HR+ patients (108/120) received 
hormonotherapy: 77 received aromatase inhibitors (AI) upfront or 
sequential; 23 received tamoxifen (TAM) alone 13 received LHRH 
agonists alone or in combination with TAM or AI. Forty-nine percent 
(n= 101) had chemotherapy (CT) (Anthracycline alone for 41 cases, 
taxane alone for 31 cases, sequential A/T for 28 cases and concurrent 
for 1 case), associated with TZM in 90 cases. TZM was administered 
without chemotherapy in 3 cases. Decision of adjuvant CT and/or 
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TZM was associated with (all p<0.05) HR-negative status, Elston-
Ellis grade 2/3 and high mitotic index (MI) while patients with HR+/
low MI tumors were rarely treated (p<0.01). With a 41 months median 
follow-up, there was a statistically significant difference in invasive 
recurrences between TZM treated patients and others (log-rank test 
p=0.04). Twelve of the 112 patients treated without TZM (11 %) had 
a recurrent invasive disease including 6 metastatic cases and 3 fatal 
events. There was one invasive recurrence in TZM group. There 
were as much recurrences in T1a as in T1b tumors. Three of the 12 
recurrences (25%) in the group without TZM occurred in T1a cases.
Conclusion:
T1abN0M0 HER2 positive tumors have a significant risk of recurrence 
which could be avoided by adjuvant chemotherapy associated with 
TZM. Interestingly, there were no differences in the risk of recurrence 
between T1a and T1b. Adjuvant chemotherapy associated with TZM 
should not only be discussed in T1bN0 HER2-positive tumors but 
also in T1aN0 HER2-positive cases.
P2-18-04
Pilot Evaluation of Bevacizumab (Bev) in Combination with 
Docetaxel (T) and Cyclophosphamide (C) as Adjuvant Treatment 
(AdjRx) for Patients (pts) with Early Stage (ES) Breast Cancer 
(BrCa).
Gullo G, Kennedy J, Breathnach O, McCaffrey J, Keane M, Martin 
M, Gupta R, Leonard G, Tryfonopoulos D, O’Shea T, Crown J. Irish 
Cooperative Oncology Research Group, Dublin, Ireland
Background: The combination of Bev + chemotherapy (CRx) has 
been shown to produce superior response rates and progression free 
survival compared to CRx alone, providing a rationale for the study of 
Bev with AdjCRx for pts with ESBrCa. As Bev can cause hypertension 
(HTN) and may increase the risk of cardiac failure, there is a rationale 
for studying a standard non-anthracycline (Anth) AdjCRx with Bev, 
e.g. TC (docetaxel-cyclophosphamide). We performed a pilot phase 
II study to evaluate the feasibility and toxicity of TC+Bev in pts with 
ESBrCa in preparation for participation in a random assignment trial. 
We have previously reported preliminary toxicity data. Methods: 
Eligibility criteria included: ESBrCa which was HER-2 normal, 
node+ or, N- and primary tumour (T) >2 cm and receptor negative, 
or T >3 cm, normal left ventricle ejection fraction (LVEF), no active/
uncontrolled cardiovascular disease, normal organ and marrow 
function. Treatment consisted of four 3-weekly cycles of docetaxel 
75 mg/m2 together with cyclophosphamide 600 mg/m2. Patients 
commenced Bev 15 mg/kg i.v. on day 1, and then every 3 weeks to a 
total of 18 cycles of treatments. Pts were monitored clinically, with 
echocardiograms and with serial estimations of BNP and troponin. 
Results: A total of 106 female pts were accrued in 9 ICORG sites 
between 11/2008 and 7/2010. Ages ranged from 25-75 (median 52). 
On 20/06/2011, 105 pts have completed study Rx, 1 will finish 7/2011. 
A total of 36 serious adverse events (SAEs) have been reported so 
far, 33 involving hospital admission, 3 serious for other reasons. In 
25 (24%) pts study Rx was discontinued due to: HTN-9, intestinal 
perforation-2, consent withdrawl-7, infection-2, proteinuria-1, 
anaphylaxis-1, cancer relapse-1, arthralgia-1, anal fistula-1. The 
two perforations occurred at cycles 1 and 16 of Bev respectively. 
Neither pt with perforation had history of prior abdominal surgery. 
The median number of cycles achieved by the discontinued pts was 
9. HTN of any grade occurred in 49 out of 103 (48%) pts who had no 
HTN at baseline (BL) and 42 of them required Rx. Among pts who 
experienced HTN on study Rx and completed Bev, 34 (81%) were 
still on anti-hypertensive 4 weeks after last infusion of Bev. Forty-one 
(39%) pts had LVEF drop >10% from BL during study Rx. In 8 (7.5%) 
pts LVEF declined below 50%, 6 are documented to have recovered 
to normal, 2 had no further LVEF measurements (1 declined, 1 
unknown reason). No episodes of CCF were reported. Troponin 
and BNP levels were normal in all 57 pts with serial measurements. 
Fourteen pts required treatment for neutropenia-related infection or 
for abscess/fistula. Conclusions: In this study Bev overall toxicity 
in ESBC pts was similar to that reported for pts with MBC, and Bev 
discontinuation due to toxicity was relatively frequent . Although 
no pt developed CCF 7.5% of decline in LVEF<50% was observed. 
Intestinal perforation can occur in ESBC pts in absence of prior 
intestinal surgery and in the post-CRx phase of Bev. Pts receiving 
Bev with non-Anth AdjCRx require careful monitoring for toxicity.
P2-18-05
Cardiotoxicity Risks of Adjuvant Trastuzumab in Asian Breast 
Cancer Patients.
Shih V, Chan A, Sim MH, Teo C, Chen W, Wong ZW. National Cancer 
Centre, Singapore; National University of Singapore, Singapore
Background: Adjuvant trastuzumab (T)-based chemotherapy reduces 
relapse and improves overall survival in early breast cancer. However, 
T-associated cardiotoxicity potentially limits its use. Our study aims 
to report the incidence, severity and reversibility of cardiotoxicity 
amongst Asian breast cancer patients.
Methods: This is a retrospective review of patients who have received 
adjuvant T from June 2005 to March 2011 at our centre. CT was 
defined as a drop in left ventricular ejection fraction (LVEF) to less 
than 50% and / or reduction of > 10% of baseline. Cardiovascular 
(CVS) risk factors were defined as having at least one of the following 
factors: family or previous history of CAD, hypertension, diabetes 
mellitus, hyperlipidemia and smoking. One-way repeated measures 
ANOVA was used to evaluate the mean LVEF change and Chi-square 
test to evaluate the association of demographics and CT.
Results: A total of 314 female patients were reviewed. CT was 
reported in 124 (39.5%), of whom 96 had asymptomatic decline 
in LVEF and 28 were symptomatic. T was withheld (n=53) due to 
asymptomatic decline in LVEF (n=40), symptomatic heart failure 
(n=3) and both (n=10). Forty-three patients with resolution of CHF 
(n=11) or LVEF recovery (n=32) were rechallenged. Cardiotoxicity 
recurred in 14 - asymptomatic decline in LVEF (n=10), recurrent CHF 
(n=1) and both (n=3). Overall, there were no cardiac-related deaths. 
Factors that predicted for CT included low normal pre-trastuzumab 
LVEF (<60%) (p=0.01), prior anthracyclines (p=0.011), decline in 
LVEF pre-anthracycline and before T (p=0.022) and BMI > 23kg/
m2 (p=0.018). Three-monthly LVEF showed statistically significant 
decline against baseline over the time points (p=0.005). As expected, 
the decline in LVEF demonstrated significant interaction with CT 
groups and non CT group (p<0.001).
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Clinical characteristics and LVEF of patients with and without trastuzumab cardiotoxicity
Demographics / Variables
Cardiotoxicity 
(n=124), %
No Cardiotoxicity 
(n=176), %
Median Age (yrs, range) 52 (34-72) 52 (33-74)
Ethnicity (Chinese) 82.3 86.9
Body Mass Index (kg/m2) > or = 23kg/m2 52.4 38.6
Stage
I 23.4 23.3
II 47.6 44.3
III 38.2 32.4
Presence of at least one CVS Risk Factor 32.3 34.7
Anthracycline users 79.8 66.5
Taxanes users 71.8 78.4
Concurrent Radiotherapy (n=83) 73.5 (n=112) 83
Baseline LVEF > or = 60% 61.3 52.3
LVEF decline pre-anthracyclines and prior to trastuzumab 61.3 52.3
Mean LVEF (%)
Baseline 62.5 +/- 6.9 60.2 +/- 5.1
3 month 55.0 +/- 10.0 59.2 +/- 8.8
6 month 53.0 +/- 11.8 59.3 +/- 8.7
9 month 56.0 +/- 7.1 60.1 +/- 5.9
12 month 56.5 +/- 6.0 59.8 +/- 5.5
Maximum decline of LVEE, compared to baseline (%)
3 month -24 - 9
6 month -34 -15
9 month -29 -9
12 month -19 -9
Conclusions: A higher incidence of CT (39.5%) was observed 
among Asian breast cancer patients compared to previously reported 
in Caucasians (24%). Although 77.4% of patients presented with 
asymptomatic decline in LVEF, approximately one-third of patients 
experienced recurrent CT upon rechallenge.
P2-18-06
Conventional Trastuzumab Is an Antagonist of Natural Killer 
Cells: Making the Case for Fucose-Depleted Trastuzumab.
Listinsky JJ, Siegal GP, Listinsky CM. University of Alabama at 
Birmingham, Birmingham, AL; Case Western Reserve University, 
Cleveland, OH
The discovery of the HER2 receptor and later the development of 
trastuzumab (an anti-HER2 antibody) were major advances leading 
toward the treatment of a significant proportion of human breast 
cancers. Trastuzumab (Herceptin®) is a humanized monoclonal 
IgG1 whose discrete antitumor effects are exerted through the 2 main 
components of the antibody. Trastuzumab’s FAB portion binds to the 
HER2 extracellular domain, interrupting HER2 signaling. The FC 
portion then engages the activating receptor (FcgRIIIa) on an effector 
cell, usually a natural killer (NK) cell and instigates a lytic attack via 
antibody-dependent cellular cytotoxicity (ADCC).
The value of trastuzumab in breast cancer therapy is well established, 
but, there are limitations to the drug’s effectiveness. These include: 
(1) unresponsive tumors with low or equivocal HER2 expression; 
(2) de novo (primary) resistance to therapy in over 50% of patients 
with HER2-positive tumors; (3) frequent emergence of secondary 
resistance often after short exposure periods; (4) competition of 
plasma IgG proteins with antibodies for binding to the activating 
FC receptors on NK cells; and (5) the high cost of trastuzumab 
treatment, raising concerns for the economic sustainability of this 
form of therapy.
Trastuzumab and other therapeutic antibodies share a structural feature 
that is critical to their effectiveness: a specific oligosaccharide which is 
covalently linked to the FC region at asparagine 297 (Asn297) in each 
of the 2 heavy chains. This oligosaccharide, a mannosyl-chitobiose 
core, is “core-fucosylated” with a single a-L-fucose (fucose) sugar 
attached via an a(1,6) linkage. In 2002, Shields et al. developed a 
novel form of trastuzumab which lacked core fucose in the Fc region 
[J Biol Chem 2002; 277: 26733-40]. When compared to conventional 
trastuzumab, the fucose-depleted trastuzumab was 43-fold more 
potent in provoking ADCC against HER2-expressing human breast 
cancer cells in vitro. Subsequent studies with several monoclonal 
antibodies have elucidated the role of core fucose in inhibiting ADCC, 
by reducing the affinity of trastuzumab’s Fc portion for the activating 
FC receptors located on effector cells. The superior ADCC effect 
of fucose-depleted trastuzumab has now been demonstrated in vivo 
[Junttila TT et al., Cancer Res 2010; 70: 4481-4489].
We review both in vitro and in vivo evidence from multiple 
laboratories (working with trastuzumab, rituximab and other 
therapeutic antibodies) to argue that fucose-depleted trastuzumab 
offers several potential advantages over conventional trastuzumab. 
Such advantages in clinical use, we postulate, include (1) treatment of 
patients with trastuzumab-resistant tumors, (2) treatment of patients 
with equivocal or low expression of HER2, and (3) decreased cost 
of treatment.
P2-19-01
Impact of Zoledronic Acid on Fractures, Bone Mineral Density 
and Bone Remodeling in the AZURE Trial (BIG 01-04).
Coleman R, Woodward E, Turner L, Marshall H, Collinson M, 
Dodwell D, Davies C, Bell R, Cameron D, Brown J. University of 
Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, 
United Kingdom; Andrew Love Cancer Centre, Geelong, Victoria, 
Australia; Western General Hospital, Edinburgh, United Kingdom
Background: The AZURE trial was designed to determine whether 
the addition of zoledronic acid (ZOL) to standard adjuvant therapy 
improves disease free survival (DFS) in patients (pts) with stage II/
III breast cancer. Although in a recent analysis after 752 events and 
a median follow-up of 59 months no difference in overall DFS was 
seen between ZOL and control pts, significant benefits were seen in 
women >5years post menopause. Here, we report the impact of ZOL 
on fractures in the main study, and on bone mineral density (BMD) 
and bone remodeling evaluated within a sub-study.
Materials and methods: 3360 pts were randomized to receive (neo) 
adjuvant chemotherapy (CT) and/or endocrine therapy with (n=1681) 
or without (n=1678) up to 19 doses of ZOL 4mg over 5 years. Pts 
with osteoporosis and those using bisphosphonates, either at baseline 
or in the previous year, were excluded from study entry. BMD was 
assessed in 228 patients within a sub-study; 40 of these also underwent 
quantitative bone scanning (QBS), a novel imaging technique that 
yields values for 99mTc-MDP/HMDP whole skeleton plasma clearance 
(Kbone) as a surrogate for the rate of bone remodeling and enables 
assessment of specific regions of interest within the skeleton.
Results: Fractures occurred in 152 (4.5%) pts; 60 (3.6%) ZOL pts 
compared with 92 (5.5%) control (CTRL) pts (difference -1.9%; 
95%CI -3.3%, -0.5%). The difference in fracture incidence appeared 
early and persisted throughout the follow-up period. Fifty-six (86.2%) 
of the fractures in the ZOL group and 68 (61.8%) in the CTRL group 
occurred in the absence of, or prior to a DFS event. The fracture 
rates before disease recurrence were similar at 3.0% (51 pts) in the 
ZOL group and 3.4% (57 pts) in the CTRL group (difference -0.4%; 
95%CI -1.6%, 0.8%). In contrast, 2.1% (8 ZOL pts) and 9.1% (34 
CTRL pts) experienced a fracture after a DFS event (difference -6.9%; 
95% CI -10.2%, -3.7%). For pts with a DFS event, the majority of 
fractures occurred after a skeletal recurrence; 87.5% (7 of 8) ZOL 
and 88.2% (30 of 34) CTRL pts. BMD Z-scores at completion of 
protocol treatment were higher in patients treated with ZOL. Kbone was 
lower in ZOL patients (26.5 vs 29.8 ml min-1 using 99mTc-MDP and 
34.3 vs 39.3 ml min-1 with 99mTc-HMDP). Expressed as a percentage 
of whole skeleton clearance, regional values in the mandible were 
similar 1.15% (ZOL) vs. 1.22% (CTRL).
Conclusions: Adjuvant ZOL given in the schedule studied in AZURE 
reduced the fracture rate in patients who developed recurrence of 
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breast cancer. BMD was higher and the rate of bone remodeling less 
in patients treated with ZOL. Further follow-up will determine the 
duration and clinical relevance of these effects on bone health.
P2-19-02
Multidisciplinary Treatment of Pregnancy-Associated Breast 
Cancer.
Meisel JL, Economy KE, Zabicki-Calvillo K, Gelber S, Kereakoglow 
S, Winer EP, Partridge AH, Mayer EL. Brigham and Women’s 
Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
Background
Breast cancer complicates pregnancy in a significant minority of 
younger breast cancer (BC) patients (pts). Application of standard 
treatment algorithms is limited by the lack of randomized data to 
support safety and efficacy. A multidisciplinary approach attempts to 
maximize treatment efficacy for a pt while minimizing fetal toxicity. 
We sought to describe contemporary multidisciplinary BC treatment 
in an academic setting and explore early maternal and fetal outcomes.
Methods
A search of the Dana-Farber/Harvard Cancer Center clinical 
database was performed to find BC pts self-identified as pregnant at 
presentation with >2 visits at our institution. Information available 
within the database along with complementary chart review provided 
sociodemographic, disease, staging, pregnancy and treatment 
information as well as short-term maternal and fetal outcomes.
Results
55 pts diagnosed between 1996-2011 were identified. The median 
age at diagnosis was 34 years. 25.5% were stage I, 49.1% stage 
II, 20% stage III, and 5.4% stage IV. 63.6% had hormone receptor 
positive disease, 36.3% HER2 positive, and 18.1% triple negative. 
71% underwent testing for germline BRCA1/2 mutations, with 9% 
of all pts testing positive. 29% were diagnosed in the first trimester 
(T1), 29% in T2, and 42% in T3. 89% underwent ultrasound imaging 
for staging, 49% X-ray imaging, 16.3% MRI, and 0% CT. 67% 
underwent surgery during pregnancy: 43.2% mastectomy, 48.6% 
lumpectomy, and 8.1% lumpectomy with subsequent mastectomy 
during pregnancy. 18.9% underwent surgery in T1, 45.9% in T2, 
and 37.8% in T3. 27.2% underwent sentinel lymph node biopsy. 
51% received chemotherapy (C) during pregnancy: of those, 
100% received anthracycline/cyclophosphamide (2-4 cycles), 11% 
paclitaxel, and 0% trastuzumab. 28.5% received C on a dose-dense 
schedule, with 25% supported by growth factors (14.2% filgrastim, 
10.8% pegfilgrastim). 28.5% received neoadjuvant C. C was initiated 
during T1 for 0%, T2 for 64.3%, and T3 for 35.7%. Two pts terminated 
pregnancy in T1, one spontaneously miscarried at 12 weeks (wks), 
and two are currently in the third trimester of pregnancy; therefore, a 
total of 50 pts had delivered at the time of this analysis. The median 
time of delivery was 36 wks. 50% delivered prior to 37 wks and 
were considered preterm; of those, 76% were inductions or Caesarian 
sections planned to facilitate cancer therapy. Only 12% delivered prior 
to 34 wks. For the 25 infants for whom Apgar scores were available, 
76% had scores of > 8 at delivery, and 100% had scores of > 8 at 5 
minutes. For the 25 infants for whom birth weights were available, 
the median birth weight was 6lbs 1oz. Only 4 were less than 5lbs at 
the time of delivery. A total of 4 fetal abnormalities were noted: cleft 
palate (2), club foot (1), and ventricular septal defect (1).
Conclusions
Within a multidisciplinary academic center, treatment of pregnancy-
associated BC using contemporary treatment algorithms, including 
taxane chemotherapy, growth factor support, and sentinel lymph node 
biopsy, has been pursued without significant adverse effect on fetal 
outcomes when compared to other published series. A considerable 
number of preterm deliveries have been observed. Further data 
collection is ongoing for confirmation of initial observations.
P2-19-03
Influence of Zoledronic Acid on BMD in Premenopausal Women 
with Breast Cancer and Neoadjuvant or Adjuvant Chemotherapy 
and/or Endocrine Treatment – The ProBone Studies.
Hadji P, Kauka A, Bauer T, Kalder M, Albert U, Birkholz K, Baier 
M, Muth M, Ziller M. Philipps-University of Marburg, Marburg, 
Germany; Novartis Pharma GmbH, Nuernberg, Germany
Background: Based on baseline bone mineral density (BMD), 
adjuvant chemotherapy or endocrine therapy for early breast 
cancer patients can lead to substantially increased fracture risk. A 
significant decrease of BMD >10% after 2 years of chemotherapy 
(CT) and/or endocrine therapy (ET) has been reported. In recent 
studies, zoledronic acid (ZOL) produced an increase in BMD in 
premenopausal and postmenopausal patients with breast cancer 
(ABCSG-12, Z-FAST, ZO-FAST, etc). In addition, a significant 
increase in disease-free survival (DFS) with ZOL vs no ZOL was 
observed in most of these studies.
Methods: The aim of 2 single-center, placebo-controlled, randomized 
studies—Probone I and Probone II—was to investigate the effect of 
adjuvant treatment with ZOL on BMD in premenopausal women 
with early breast cancer treated with CT and/or ET. Patients with 
hormone-receptor–negative (HR–) breast cancer (Probone I) were 
treated with (neo)adjuvant CT; patients with hormone-receptor–
positive (HR+) breast cancer (Probone II) were treated with ET alone 
or in combination with (neo)adjuvant CT. Randomized patients 
received ZOL 4 mg or placebo IV every 3 months for 24 months. 
The primary objective was the change in BMD at the lumbar spine 
between baseline and month 24 (measured by dual-energy X-ray 
absorptiometry [DXA]). Secondary objectives included DFS; BMD 
at total hip, femur, and os calcis; quantitative ultrasonometry (QUS) 
at os calcis and phalanges; markers of bone turnover (C-telopeptide of 
type I collagen [CTX] and N-terminal propeptide of type I procollagen 
[P1NP]); endocrine hormones (follicle-stimulating hormone [FSH], 
estradiol, testosterone, sex hormone-binding globulin [SHBG], 
parathyroid hormone [PTH], vitamin D, anti-Müllerian hormone 
[AMH], inhibin A/B, etc); pathologic fractures; and safety and 
tolerability.
Results: 70 HR+ and 11 HR– breast cancer patients have been enrolled 
into the studies. The last patient will have been treated for 24 months 
by the end of June 2011.
Conclusions: The effects of ZOL on lumbar spine BMD at 24 months 
and secondary endpoints will be presented at the meeting.
P2-19-04
Changes in Adjuvant Treatment of Early Breast Cancer in Italy 
between 2000 and 2008. The NEMESI Study Versus the NORA 
Study.
Mustacchi G, Cazzaniga ME, Pronzato P, Clavarezza M, Del Mastro 
L, Venturini M, Amadori D, Bidoli P, Boni C, Caruso M, Riccardi F, 
Dondi D. Università, Trieste, Italy; Ospedale San Gerardo, Monza, 
Italy; IRCCS Istituto Nazionale Ricerca sul Cancro, Genova, Italy; 
Ospedale Sacro Cuore Don Calabria, Negrar (VR), Italy; I.R.S.T., 
Meldola (Forlì), Italy; Azienda Ospedaliera S Maria Nuova, Reggio 
Emilia, Italy; Centro Oncologico Catanese, Humanitas, Catania, 
Italy; Ospedale Cardarelli, Napoli, Italy; Sanofi Aventis, Milano, Italy
Background: In the early 2000s, we identified treatment patterns of 
early breast cancer (EBC) in Italy (NORA study). To ascertain whether 
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attitudes have changed, we conducted a similar study in 2008.
Patients and methods : In this retrospective study (NEMESI), we 
recorded the clinical, tumour and treatment characteristics of 1.894 
EBC patients in 63 Italian oncological centres in 2008, and compared 
the results with those of NORA, on 3.515 patients in 70 same/
similar Italian institutions, in 2000-2003. Tumor stage, surgery and 
endocrine-responsiveness are not comparable because of different 
recruitment protocols, patients charactheristics and adjuvant treatment 
strategies are perfectly comparable as a reliable picture of adjuvant 
strategies in Italy.
Results: There was no difference in age class distribution, menopausal 
status, ECOG performance status, tumor grade, ki67 and estrogen 
receptors content. HER2 status was simila but . determined in 98% of 
cases in NEMESI vs 46.2% in NORA. The overall use of endocrine 
treatment (HT) increased from 80.3% in NORA to 83.5% in NEMESI 
(p = 0.005); the overall use of chemotherapy (CHT) decreased from 
68.4% to 57.8% (p = 0.00001). HT alone increased from 31.6% to 
42.2% (P = 0.00001) and CHT alone decreased from 18.8% to 16.2% 
(p = 0.017). The use of both treatments decreased from 49.2% to 
41.6% (p = 0.00001). Trastuzumab was never given in NORA and in 
15% of cases in NEMESI (85% of all HER2 positive cases).
The choice for HT was tamoxifen for 5 years in 32.5% of cases 
in NEMESI and 86.6% in NORA (p = 0.000001), and aromatase 
inhibitors for 5 years in 55.2% vs 13.3% of cases, respectively (P 
= 0.000001). The “switch” from tamoxifen 2-3 years to aromatase 
inhibitors 2-3 years was planned in 10.1% of cases in NEMESI and 
actually done in 12.9% of cases in NORA (p = 0.001). The overall use 
of LHRH analogues was significantly higher in NEMESI vs NORA 
(26.7% vs 3.0%, p = 0.00001). CMF-like regimens decreased from 
37.0% in NORA to 9.1% (p = 0.000001). Anthracycline-containing 
regimens decreased from 52.1% in NORA to 48.8% in NEMESI; p 
= 0.0001) in favour of of regimens containing anthracyclines and 
taxanes, either in combination or sequential (0.9% in NORA vs 38.4% 
in NEMESIS, p = 0.000001). The use of taxanes alone regimens 
remained low (3.5% vs 3.7%, ns). The overall use of anthracyclines 
and taxanes increased from 53.0% to 87.5% and from 4.3% to 42.1%, 
respectively (both p =0.00001).
Conclusions:EBC treatment has changed significantly in 6 years. 
Adjuvant strategies are significantly different, with a great increase of 
aromatase inhibitors and LHRH analogues associated with tamoxifen; 
anthra-taxane combinations have also significantly increased.
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P3-01-01
Geminin Overexpression Prevents the Completion of 
Topoisomerase IIa Chromosome Decatenation Leading to 
Aneuploidy in Human Mammary Epithelial Cells.
ElShamy WM, Gardner L, Malik R, Shimizu Y, Mullins N. University 
of Mississippi Medical Center, Jackson, MS
Topoisomerase IIa (TopoIIa) cleaves DNA in a reversible manner, 
making it a valuable target for agents such as etoposide that trap the 
enzyme in a covalent bond with the DNA end it cleaves and prevents 
DNA re-ligation and triggers cell death in cancer cells. However, 
development of resistance to these agents limits their therapeutic 
use. In this study, we examined therapeutic targeting of geminin for 
improving the therapeutic potential of TopoIIa agents.
Human mammary epithelial (HME) and breast cancer cell lines 
were used. Geminin, TopoIIa, Cdc7 silencing was done using 
specific siRNAs. Transit or stable inducible overexpression of these 
proteins and CKIe were also used, as well as several pharmacological 
inhibitors that target TopoIIa, Cdc7, or CKIe. We manipulated 
HME cells expressing H2B-GFP, in order to detect chromosome 
bridges. Immunoprecipitation and direct western blot were used to 
detect interactions between these proteins and their total expression, 
respectively, whereas interactions on chromosomal arms were 
detected using the TARDIS assay. TopoIIa phosphorylation by 
Cdc7 or CKIe was done using in vitro kinase assay. The TopoGen 
decatenation kit was used to measure TopoIIa decatenation activity. 
Finally, comet assay and metaphase chromosome spread were 
used to detect chromosome breakages and changes in chromosome 
condensation or numbers, respectively.
We found that geminin and TopoIIa interact in G2/M/early G1 cells 
on chromosomes, that geminin recruits TopoIIa to chromosomal 
decatenation sites or vice versa, and that geminin silencing in 
HME cells triggers the formation of chromosome bridges through 
suppressing TopoIIa access to chromosomal arms. CKIe kinase 
phosphorylates and positively regulates TopoIIa chromosome 
localization and function. CKIe kinase overexpression or Cdc7 
kinase silencing (also phosphorylates TopoIIa in vitro), restored 
DNA decatenation and chromosome segregation in geminin-silenced 
cells before triggering cell death. In vivo, at normal concentration, 
geminin recruits the desumoylating enzymes SENP1 and SENP2 to 
desumoylate chromosomal bound TopoIIa and promote its release 
from chromosomes following completion of DNA decatenation. In 
cells overexpressing geminin, premature departure of TopoIIa from 
chromosomes is thought to be due to the fact that geminin recruits 
more of these desumoylating enzymes, or recruits them earlier, to 
chromosomal bound TopoIIa. This triggers premature release of 
TopoIIa from chromosomes, which we propose induces aneuploidy 
in HME cells, since chromosome breakages generated through were 
not sensed and/or repaired and the cell cycle was not arrested.
TopoIIa recruitment and its chromosome decatenation function 
require normal level of geminin. Geminin silencing induces a 
cytokinetic checkpoint in which Cdc7 phosphorylates TopoIIa and 
inhibits its chromosomal recruitment and decatenation function. 
Geminin overexpression prematurely desumoylates TopoIIa, 
triggering its premature departure from chromosomes and leading 
to chromosomal abnormalities and the formation of aneuploid, drug 
resistant cancer cells.We propose that therapeutic targeting of geminin 
is essential for improving the therapeutic potential of TopoIIa agents.
P3-01-02
EC 304: A Novel Progesterone Receptor (PR) Antagonist Inhibits 
Transcription and Induces Cell Cycle Arrest in T47D Breast 
Cancer Cells.
Bhaskaran SS, Kesavaram N, Nickisch KJ, VandeBerg JL, Nair HB. 
Texas Biomedical Research Institute, San Antonio, TX; Evestra, Inc., 
San Antonio, TX
Progesterone receptor (PR) is a ligand activated transcription factor 
which plays a crucial role in female reproduction. PR antagonists 
have been shown to repress estrogen dependent proliferation in the 
uterus and mammary gland. Even though PR antagonists are potent 
therapeutic candidates for breast cancer, partial agonism towards 
glucocorticoid receptor (GR) and androgen receptor (AR) lead to 
undesirable side effects. Evestra’s rational design and development 
approach in the synthesis of EC304 was aimed at minimizing 
these side effects as well as to deliver more potent and selective 
antiprogestins. We used select screen® (Invitrogen) to determine 
relative binding affinity of EC304 with AR,GR and PR. The binding 
affinity of EC304 showed strong antagonism towards PR with mild or 
negligible agonism with AR or GR. PR transactivation was inhibited 
by EC304 with IC50 of 0.04nM in the presence of progesterone (5nM). 
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EC304 showed superior cytotoxicity over known antiprogestins 
ZK230211, ORG33628, CDB2914, CDB4124 and RU486 in T47D 
cells. IC50 of EC304 was found to be 0.5nM in a 6-day cytotoxicity 
assay (MTT) in T47D cells stimulated with 1nM estrogen (E2). In a 
21-day in vitro tumorigenicity assay, EC304 inhibited 80 and 100% of 
colony formation of T47D cells in the presence of E2 at 1 and 10 nM 
respectively. Further studies revealed that EC304 induced apoptosis 
and G1-phase arrest in cell cycle progression when co-incubated with 
E2 for 24 h. Treatment with EC304 down regulated PR target genes 
and up regulated cell cycle dependent kinase (CDK) inhibitor P21 in 
vitro. Ongoing studies address whether EC304 is specifically acting 
on PR-A or PR-B isoform at gene expression, protein levels and PR 
isoform specific knockdowns in T47D and other metastatic breast 
cancer cells. Considered together, these data indicate that EC304 
might be a safer but efficacious novel antiprogestin for hormone 
sensitive postmenopausal breast cancer patients.
P3-01-03
The Hominoid-Specific Gene SHON Is Oncogenic in Human 
Mammary Carcinoma.
Jung Y, Shastri BG, Kong X-J, Zhu T, Perry JK, Lobie PE, Liu D-X. 
Liggins Institute, Auckland, AKL, New Zealand; Hefei National 
Laboratory for Physical Sciences, Hefei, Anhui, China; Cancer 
Science Institue of Singapore, Singapore, Singapore
Breast cancer is still the most common malignancy and the leading 
cause of cancer deaths in both developed and under developed 
countries. Molecular targeted therapy, in particular monoclonal 
antibody-based treatment, has emerged as a promising approach to 
treat this disease because of its high specificity and reduced toxicity. 
As a consequence, identification of novel molecular therapeutic 
targets is of crucial importance. In an effort to discover new targets 
for monoclonal antibody-based targeted therapy, we have identified 
a novel and secreted hominoid-specific molecule, SHON (secreted 
hominoid-specific oncogene), in the human mammary carcinoma 
cell line, MCF-7. Like other hominoid-specific genes, SHON has 
no known orthologs outside of the primate lineage. It is highly 
expressed in all cancer cell lines tested so far including breast, 
lung, liver, stomach, colon and prostate cancer as determined at the 
mRNA level by RT-PCR and at the protein level by western blotting. 
Forced expression of SHON in MCF-7 cells significantly increased 
cell proliferation and survival as demonstrated by 5-bromo-2’-
deoxyuridine (BrdU) incorporation and Annexin V/propidium iodide 
apoptosis assays, respectively. Forced expression of SHON also 
promoted MCF-7 cell anchorage independent growth in soft agar and 
enhanced cell migration and invasion. Moreover, forced expression 
of SHON in MCF-7 cells increased tumour volume in a xenograft 
model of human breast cancer in immunodeficient mice. Furthermore, 
depletion of endogenous SHON expression using small interfering 
RNAs, or functional inhibition using an inhibitory rabbit anti-SHON 
polyclonal antibody, decreased MCF-7 cell proliferation and survival, 
and reduced MCF-7 oncogenicity and invasiveness. Therefore, SHON 
is a novel oncogene for mammary carcinoma cells which may be 
useful as a therapeutic target for the treatment of breast cancer.
P3-01-04
Differential Impact of Gefitinib and PLX4720 on Proliferation 
of MCF10A and Isogenic Lines as Measured with a Metastasis 
Expression Score.
Christopherson C, Rigby S, Chang M, Foster R, Wang A, Sninsky J, 
Kwok S, Torrance C. Celera, Alameda, CA; Horizon Discovery Ltd, 
Cambridge, United Kingdom
Background: We previously reported that a published “Metastasis 
Score” (MS) could be used to evaluate the effects of a PI3K inhibitor 
(GDC-0941) on mutated human isogenic breast cancer cell lines. MS, 
based on the expression of 14 genes, has been shown to predict distant 
metastasis in ER(+), node (-), breast cancer. We were interested to 
determine the impact of gefitinib (EGFR inhibitor) and PLX-4720 
(selective inhibitor of BRAF V600E) on MS to assess the applicability 
of this score to a broader class of targeted agents. In addition, given 
the cross-talk between metabolism and proliferation, we also profiled 
genes involved in glycolysis, fatty acid metabolism and oxidative 
phosphorylation.
Methods: Parental MCF10A (WT for all genes) and isogenic lines 
of MCF10A harboring PI3K (H1047R), p53 null or KRAS(G12V) 
mutations were cultured overnight in DMEM:F12 media under 
identical conditions. Cells were then treated with gefitinib, PLX4720, 
or DMSO (vehicle control) and further incubated for 24hr. Expression 
analysis was performed by RT-PCR.
Results: The MS of the PI3K (H1047R) and p53 null lines was higher 
than the parental line and lower for the KRAS (G12V) line. Treatment 
of parental, PI3K and KRAS cell lines with gefitinib resulted in dose-
dependent decreases in MS, as reported for GDC-0941, with a higher 
dose required to inhibit growth of PI3K (H1047R) cells. Treatment of 
p53 null cells with gefitinib, however, had only a modest effect on MS. 
In contrast to gefitinib, MS increased with PLX-4720 treatment in all 
4 lines; the greatest increase was observed in KRAS (G12V) cells. The 
expression of metabolic genes differed significantly depending on the 
oncogenic mutation harbored by the cell line. ACTA2, ACLY, RPIA, 
KHK, GLS2 were most highly expressed in p53 null but lowest in 
KRAS (G12V), while GLUT5, PFKFB4, ENO3, SLC27A1, PGK2, 
GLUT1, TKT were expressed most highly in KRAS (G12V) but 
lowest in PI3K(H1047R). Upon treatment with gefitinib or PLX-4720, 
genes that were downregulated in the mutated lines generally showed 
a dose-dependent increase; those that were upregulated relative to the 
parental, showed a dose-dependent decrease with treatment.
Discussion: The decrease in MS of the parental, PI3K (H1047R) 
and KRAS (G12V) cell lines treated with gefitinib supports the 
impact of this EGFR inhibitor on cell proliferation. The modest 
effect on MS in p53 null cells supports the findings that sensitivity 
to gefitinib requires active p53 in order to induce apoptosis through a 
p53-dependent pathway. Increases in MS were observed in all 4 cell 
lines treated with PLX-4720, with the largest increase observed in 
KRAS (G12V). The enhanced proliferation of a BRAF WT cell line 
with a KRAS mutation is consistent with the Ras-dependent nature 
of this pathway. The metabolic genes showed diverse expression 
patterns that differed with different oncogenic mutations and likely 
reflect the multiple mechanisms controlling metabolism in cancer. An 
improved understanding of the expression of metabolic genes relative 
to proliferation in cell lines with various oncogenic mutations may 
provide additional insights into the dysregulation of these cellular 
processes and the possible role of anti-metabolite intervention.
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P3-01-05
Wnt Signaling: A New Target for Treatment and Prevention of 
Endocrine Resistant Breast Cancer?
Micallef RA, Smith C, Barrow D, Nicholson RI, Gee JMW, Barratt-Lee 
PJ, Hiscox SE. Cardiff University, Cardiff, Wales, United Kingdom; 
Velindre NHS Trust, Cardiff, Wales, United Kingdom
Background: Wnt signaling is altered in nearly half of all breast 
cancers. Both up regulation of Wnt pathway activators and down 
regulation of pathway inhibitors have been identified in breast cancer. 
Previously we have reported that activity of b-catenin is altered in 
acquired tamoxifen-resistant (TamR) breast cancer cells compared 
to endocrine–sensitive parental MCF7 cells, with an increase in 
b-catenin-mediated gene transcription. Data is lacking on the role 
of Wnt signaling in acquired endocrine resistance in breast cancer. 
Endocrine relapse predicts a poor clinical outcome and remains 
an important target for future drug development. In this study we 
investigated the role of Wnt signaling in acquired tamoxifen resistance 
and its contribution to the associated aggressive phenotype in vitro.
Materials/ Methods: We performed exploratory Affymetrix HGU-
133A gene microarray analysis of key Wnt pathway components in 
log-phase TamR vs. MCF7 cell lines, as well as comparing MCF7 
cells +/- 10 day tamoxifen exposure. This was paralleled by western 
blot (WB) analysis. Effects of Wnt signaling inhibition on growth 
and cell migration were explored using two commercially available 
inhibitors: IWP2 (inhibits Wnt production, pLRP6) and PNU74654 
(interferes with b-catenin-Tcf/Lef binding). MTT cell proliferation 
assays (6 days) and cell migration assays (24hrs) were carried out.
Results: Microarray analysis of key Wnt pathway components 
revealed up regulation of wnts 3, 4 and 6; up regulation of Wnt 
pathway activators LRP5 and LRP6; down regulation of pathway 
inhibitors (DKK1, DKK4); and down regulation of Axin1 (destruction 
complex component). Changes are >1.5-fold. WB analysis confirmed 
up regulation of total b-catenin and LRP6 in TamR versus MCF7 cells 
as well as activity of LRP6. In accordance with this, inhibition of Wnt 
signaling using IWP2 10uM or PNU74654 10uM, whilst having no 
effect on MCF7 cell proliferation, significantly suppressed the growth 
of TamR cells (p<0.001). Inhibition of Wnt signaling in TamR cells 
also suppressed cell migration (p<0.001). Gene microarray data for 
MCF7 cells treated with tamoxifen for 10 days showed up regulation 
of LRP6 and wnt4 and down regulation of LRP5, wnt6, Axin1 and 
DKK4 compared to control.
Discussion: These observations suggest that deregulated Wnt 
signaling may play a role in acquired tamoxifen resistance in breast 
cancer where it may act to promote growth and the development of 
a more aggressive phenotype. Its interaction with other pathways is 
important in the prevention of resistance with co-treatment strategies. 
Wnt1 can rescue MCF7 cells from growth suppression caused by 
4-hydroxytamoxifen. Given the early changes in the Wnt pathway in 
MCF7 cells treated with tamoxifen, further exploration in the context 
of earlier Wnt targeting alongside antihormone treatment is required. 
Monitoring of Wnt signaling within clinical samples from patients 
who have relapsed after hormone treatment is urgently warranted 
given that the Wnt inhibitors showed promise in controlling this 
state in vitro.
P3-01-06
NF-kB Inhibition Promotes Radiosensitivity of Breast Cancer 
Cells in Three-Dimensional Culture through Abating b1-Integrin 
Expression.
Ahmed KM, Zhang H, Park CC. Ernest Orlando Lawrence Berkeley 
National Laboratory, Berkeley, CA
Therapy-associated tumor resistance, giving rise to recurrence 
and mortality, is a critical issue in cancer therapy. The molecular 
mechanisms causing tumor resistnace to the therapeutic radiation 
remain elusive. Nuclear factor-KB (NF-KB), a stress-sensitive 
heterodimeric transcription factor in the regulation of the stress-
responsive genes, has been shown to initiate prosurvival signaling 
pathways. The cooperative function of NF-KB with other key stress 
elements in radioresistance remains to be elucidated. We have 
previously reported that induction of a5b1-integrin is associated 
with the enhanced cell survival of breast cancer cells after exposure 
to high dose IR (ionizing radiation). Because a typical NF-KB binding 
site was located in human b1-integrin promoter region, b1-integrin-
mediated resistance to radiation may be regulated by NF-KB. The 
aim of the present study was to reveal a connection between NF-KB 
and b1-integrin pathways in radioprotection of malignant T4-2 
mammary epithelial cells in 3D lrECM (three-dimensional laminin-
rich extracellular matrix). We show that the elevated NF-KB activity 
was correlated with enhanced clonogenic survival, and increased 
NF-KB heterodimer p50/p65 levels were associated with an increase 
in total and phosphorylated (Thr 788/789) b1-integrins. Inhibition of 
NF-KB activation significantly reduced clonogenic survival with the 
inhibition of b1-integrin. These results indicate that NF-KB-mediated 
induction of b1-integrin is associated with an increased radiation 
resistance. Treatment of T4-2 colonies, formed at day 4, with NF-
KB activation inhibitor in 3D lrECM before exposure to IR (4-Gy 
X-ray) resulted in a reduction of the size of colonies. The surviving 
colonies were associated with a decrease in proliferation and increase 
in apoptosis, indicating a decrease of resistance to IR. Together, these 
results provide the first evidence that NF-KB-mediated b1-integrin 
expression is responsible for tumor radioresistance. The NF-KB/b1-
integrin pathway may serve as an efficient drug target to re-sensitize 
radioresistant tumor cells.
P3-01-07
A Murine Xenograft Model for the Study of Ciclooxygenase-2 
Expression and Function in Human Breast Cancer.
Solano AR, Orlando UD, Garona J, Ripoli GV, Duarte AB, Maloberti 
PM, Avagnina MA, Alonso DF, Gomez DE, Podesta EJ. School of 
Medicine University of Buenos Aires, Buenos Aires, Argentina; 
University of Quilmes, Quilmes, Buenos Aires, Argentina; Center 
of Medical Education and Clinical Investigation Norberto Quirno, 
Buenos Aires, Argentina
BACKGROUND: ciclooxygenase-2 (COX-2) has been suggested 
as a necessary component of the cellular and molecular mechanisms 
behind breast cancer cell motility and invasion The potential 
therapeutic benefit of COX-2 inhibitors in a range of cancers is being 
seen as a great promise however, there have been recent concerns 
about potential cardiotoxicity. Thus, there is an urgency to develop 
new inhibitors exhibiting a better risk/benefit ratio.
Acyl-CoA synthetase 4 (ACSL4), belongs to a five-member family 
of enzymes that esterifies mainly arachidonic acid into acyl-CoA. We 
have provided first-time evidence demonstrating that, ACSL4 is the 
key enzyme that regulates the induction of COX-2, the production 
of prostaglandin E2 (PGE2) and the proliferation and metastatic 
potential of breast cancer cells. Therefore, the aim of the study was 
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the development of an in vivo model of human breast tumor xenografts 
for the study of the regulation of COX-2 expression and action.
RESULTS: stable transfection of MCF-7 cells with ACSL4 cDNA 
under the control of tetracycline (MCF-7 Tet-off-ACSL4) resulted 
in a significant increase in the expression of COX-2. The increment 
in COX-2 expression registered in MCF-7 Tet-off-ACSL4 cells is 
accompanied with an increase in the production of PGE2, and the 
proliferation and metastatic potential of cancer cells. Next, we tested 
whether the injection of MCF-7 Tet-off/ACSL4 cells into nude mice 
resulted in tumor development.
The results of those experiments demonstrate that MCF-7 Tet-off/
ACSL4 cells develop into murine mammary tumors whereas cells 
transfected with the MCF-7 Tet-off empty vector did not. Interestingly, 
treatment of nude mice with tetracycline resulted in tumor growth 
inhibition. The results show that the sole transfection of ACSL4 
results in a phenotype change that endows the cells with the capacity 
to develop into tumors when injected into nude mice. Tumor volume 
(TV) at day 70 reached 468.4± 189.3mm3. Treatment with tetracycline 
reduced TV to 189.3± 65.9mm3 (p<0.05). The growth rate between 
days 45-70 was 12.30 mm3/day. Tumors were classified as Basal-
like subtypes.
We have also observed an inhibition of proliferation and migration 
of MDA-MB-231 cell cultures when exposed to a combination of 
ACSL4 and COX-2 inhibitors. Interestingly, the compounds assayed 
markedly reduced cell proliferation and migration at concentrations 
that are less effective when used alone. These results point to an 
effect that has the advantage of exposing the cells to lower drug 
concentrations.
CONCLUSION: Based on our results, we hypothesize that ACSL4 
and COX-2 could constitute potential therapeutic targets for the 
control of tumor growth. Our animal model of mammary tumors 
constitutes a proper platform for the study of those therapies.
P3-01-08
In Vitro and In Vivo Antitumor Activity of the Aurora and 
Angiogenic Kinase Inhibitor ENMD-2076 in Triple-Negative 
Breast Cancer Models.
Diamond JR, Eckhardt SG, Tan AC, Selby HM, Newton TP, Pitts TM, 
Bray MR, Fletcher GC, Tentler JJ. University of Colorado Cancer 
Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
Background: Triple-negative breast cancer (TNBC) is an aggressive 
biologic subtype which lacks effective targeted anti-cancer agents 
and is characterized by a high mitotic index and dependence on 
angiogenesis. ENMD-2076 is a novel orally bioavailable Aurora 
and angiogenic kinase inhibitor currently in clinical development 
with favorable pharmacokinetics and a manageable toxicity profile. 
The purpose of this study was to use TNBC cell line-based in vitro 
and in vivo models to demonstrate the antitumor activity of ENMD-
2076 towards this breast cancer subtype compared to the luminal 
and HER2-amplified subtypes. Additionally, we used baseline gene 
expression profiling and pathway analysis to explore molecular 
predictors of responsiveness to ENMD-2076 in TNBC.
Methods: Twenty-five breast cancer cell lines were exposed to 
ENMD-2076 and the effects on proliferation, apoptosis, and cell 
cycle distribution were evaluated. Proliferation was assessed using 
an SRB assay, apoptosis was analyzed using a caspase 3/7 assay and 
cell cycle was measured using flow cytometry. In vitro activity of 
ENMD-2076 was confirmed in 3-D cell culture and in MDA-MB-231 
and MDA-MB-468 triple-negative breast cancer xenograft models and 
immunohistochemical analysis was performed for phosphor-histone 
H3 (pHH3). Gene array and gene set enrichment analysis (GSEA) 
was used to identify pathways differentially regulated in the sensitive 
and resistance cell lines, including within the triple-negative breast 
cancer subset.
Results: In vitro exposure to ENMD-2076 resulted in robust inhibition 
of proliferation in TNBC cell lines which was associated with a G2 
cell cycle arrest and induction of caspase-dependent apoptosis. Of the 
TNBC cell lines screened, 1 of 10 had a mean IC50 value > 5 µmol/L 
and 7 of 10 had a mean IC50 < 1 µmol/L (Fisher’s exact test, p-value = 
0.009). In comparison, only 1 luminal (ER+) and one HER2-amplified 
breast cancer cell line had an IC50 value < 1, whereas 7 and 5 resistant 
lines were luminal and HER2-amplified, respectively (Fisher’s exact 
test, p-values = 0.02 and 0.11 for ER and HER2 status, respectively). 
ENMD-2076 exhibited antitumor activity towards MDA-MD-231 
and MDA-MB-468 xenograft models of TNBC with statistically 
significant tumor growth inhibition compared to vehicle control 
(p< 0.05 and p< 0.01, respectively). A trend towards an increase in 
pHH3 staining cells in the MDA-MB-231 ENMD-2076 treated group 
compared to the vehicle control group was observed; however, this 
was not statistically significant (104.7 + 36.2 positive cells/mm2 in 
treated vs. 79.9 + 34.5 in control). Using significance of analysis of 
microarrays (SAM) analysis and GSEA, we identified Ran, a member 
of the mitotic spindle regulation pathway as upregulated in sensitive 
TNBC cell lines (p = 0.017). Interestingly, AURKA, the main target 
of ENMD-2076, is a core gene in this pathway.
Conclusions: ENMD-2076 exhibited robust anticancer activity 
towards preclinical models of TNBC, supporting future clinical 
investigations of this agent in TNBC with an emphasis on the 
continued development of biomarkers predictive of response in this 
breast cancer subset.
P3-01-09
Oncogenic Activation of HSF1 Enables the Malignant Progression 
of Breast Carcinoma.
Mendillo ML, Santagata S, Koeva M, Fraenkel E, Ince TA, Whitesell 
L, Lindquist S. Whitehead Institute for Biomedical Research, 
Cambridge, MA; Brigham and Women’s Hospital, Boston, Boston, 
MA; Massachusetts Institute of Technology, Cambridge, MA; 
University of Miami Miller School of Medicine, Miami, FL; Howard 
Hughes Medical Institute, Cambridge, MA
HSF1 is best known for its role as the master transcriptional regulator 
of the evolutionarily conserved heat-shock response. In mice, 
Hsf1 knock-outs dramatically reduce susceptibility to malignant 
transformation and tumor formation, and markedly increased survival 
in cancers driven by both oncogenic and tumor suppressor mutations. 
Likewise, RNAi-mediated knockdown markedly reduces the growth 
and survival of human cell lines established from cancers driven 
by a diversity of genetic lesions. The transcriptional network that 
HSF1 coordinates during heat-shock is known, but is unknown in 
malignancy. We compare HSF1 function in isogenic breast cancer 
cells of high and low malignant potential. HSF1 orchestrates a far-
reaching transcriptional program that is dependent on transformation 
and the degree of malignancy. The oncogenic HSF1 program differs 
markedly from the classical heat-shock response. It is enriched 
for genes involved in a myriad of cellular processes known to be 
important in malignancy, including transcription, translation, glucose 
metabolism and cellular adhesion. It includes only a particular subset 
of heat-shock protein genes, and many of these are regulated in a 
manner that differs from their regulation by heat-shock. We also 
find that HSF1 is overexpressed and activated in a large subset of all 
conventionally defined classes of breast cancer. Moreover, tumors 
with high expression of the oncogenic HSF1 transcriptional network 
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are strongly associated with poor outcome as monitored by metastasis 
and death. Our findings suggest that the oncogenic HSF1 activation 
program is rooted in fundamental aspects of tumor biology and will 
prove a powerful new tool in the clinical management of patients with 
breast cancer and, likely, other malignancies as well.
P3-01-10
DMBA-Breast Cancer in Diet Induced Obesity (DIO) and Lean 
Mice Is Related to Leptin Signaling.
Gillespie C, Penichet MG, Colbert LS, McGlothen T, Guo S, Zhou 
W, Gonzalez-Perez RR. Morehouse School of Medicine, Atlanta, GA; 
Shenyang Medical College, Liaoning Pro, P.R., China
Introduction: Leptin, the major adipokine released by adipose 
tissue, is strongly linked to obesity related-cancers. We have shown 
previously that inhibition of leptin signaling with pegylated leptin 
peptide receptor antagonist 2 (PEG-LPrA2) negatively impacted 
human xenograft and syngeneic mouse breast cancer growth as well 
as VEGF/VEGFR2 levels [1,2]. Objective: We hypothesize that leptin 
signaling is essential for 7,12-dimethylbenz[A]anthracene (DMBA)-
mammary tumor (MT) particularly in obese mice. Methods: The study 
investigated the potential of PEG-LPrA2 to prevent MT in lean and 
diet-induced-obesity (DIO)-C57BL/6J female mice treated with 1 mg/
dose/weekly for 6 weeks of DMBA. Obesity was induced by feeding 
DIO-mice (95% obese mice after 5 weeks) with high fat diet (PDI-1; 
45% Kcal from fat). Lean mice were fed a normal diet (PDI-1; 5% 
Kcal from fat). PEG-LPrA2 was administered intravenously. Lean 
and DIO-mice received either one or two PEG-LPrA2 dose/week 
(50 ml/0.1 mM) two weeks prior to DMBA to test its preventative 
potential through the end point (32 weeks). Control mice received 
saline injections. Results: Obesity was positively correlated to the 
development of DMBA-MT in mice. MTs were found in 17% of 
lean control and 69% of DIO-control mice. Notably, PEG-LPrA2 
prevented the onset of DMBA-MT in lean (one and two doses: 0% 
tumor-bearing mice) and DIO-mice (one-dose, 29% and two-dose 
0% MT). PEG-LPrA2 treatment did not alter body weight nor food 
intake in lean or DIO-mice. VEGF levels were significant higher 
(32 fold) in control DIO-mice. PEG-LPrA2 inhibition of leptin 
signaling decreased tumor levels of Notch ligands (Jagged-1 & DLL-
4), receptors (Notch 1-4) and target genes (Survivin and Hey2) and 
reduced OB-R, IL-1R tI, VEGF/VEGFR2, bcl-2, HIF-1a and NFkB 
(p50 and p105). Conclusions: Present data strongly suggest that leptin 
signaling is essential for DMBA-induced MT in the context of obesity. 
Overall, the effective chemoprevention of DMBA-MT by PEG-LPrA2 
treatment in DIO and lean mice reinforces the potential use of leptin 
signaling inhibition for breast cancer prevention. These observations 
are most significant for obese populations showing higher levels of 
leptin and incidence of breast cancer. [This work was supported in 
part by NIH/NCI1SC1CA138658-02; NIH/ARRA/3SC1CA138658-
02S1 and the Georgia Cancer Coalition Distinguished Cancer 
Scholar Award (to RRGP); CREDO (MSCR) 2R25RR017694-06A1 
to L.S.C; the Morehouse School of Medicine (MSM) MBRS RISE 
Program (NIH/NIGMS 506 GM08248) to T.Z.M; and facilities and 
support services at Morehouse School of Medicine (NIH RR03034 
and 1C06 RR18386)].
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P3-01-11
Increased Gene Copy Number of c-KIT and VEGFR2 at 4q12 in 
Primary Breast Cancer Is Related to an Aggressive Phenotype 
and Impaired Prognosis.
Rydén L, Johansson I, Ebbesson A, Grabau D, Wigerup C, Aaltonen 
KE, Hedenfalk I. Clnical Science Lund, Lund, Sweden
Introduction: Triple-negative breast cancer (TNBC) accounts for 
approximately 15% of all female breast cancer and is associated with 
aggressive clinical behaviour. No targeted treatments are available for 
TNBC. Drugs inhibiting tyrosine kinases, such as vascular endothelial 
growth factor receptor 2 (VEGFR2) and c-KIT, have however shown 
some promising results for patients with TNBC. The aim of the 
present study was to investigate whether gains and/or amplifications 
of VEGFR2 and c-KIT occur in TNBC. These genes may constitute 
novel candidate biomarkers for selecting TNBC patients for treatment 
with tyrosine kinase inhibitors.
Material & Methods: Fluorescence in situ hybridization (FISH) 
was used to quantify gene copy numbers of VEGFR2 and c-KIT in 
83 primary human breast cancers, of which 31 were classified as 
TNBC. Gains were defined as >4 gene copies in more than 40% of the 
cancer cells, while amplification was defined as gene copy/CEP ratio 
>2 in more than 10% of the cancer cells. A tumour was considered 
FISH positive for c-KIT and/or VEGFR2 if it displayed copy number 
gain and/or amplification. Immunohistochemical (IHC) staining was 
performed for assessment of c-KIT protein expression.
Results: Ten (32%) of the TNBCs were VEGFR2 FISH positive 
and nine (29%) were c-KIT FISH positive, whereas non-TNBCs 
were FISH positive for VEGFR2 and c-KIT in nine (18%) cases for 
both genes. No significant difference in frequency between TNBCs 
and non-TNBCs was found. There was a correlation between FISH 
positivity for VEGFR2 and c-KIT (c2 test, P<0.001), and VEGFR2 
and c-KIT FISH positivity correlated to ER/PgR negativity and high 
Nottingham histological grade (NHG). A significantly worse breast 
cancer specific survival (BCSS) was seen for FISH positive cases in 
the whole cohort as well as among untreated patients and non-TNBCs, 
but not among TNBC cases.
Discussion: The high correlation between VEGFR2 and c-KIT 
FISH positivity suggests that the genes are co-amplified. Increased 
copy number of both genes was related to aggressive disease and a 
worse prognosis, and thus has the potential of functioning as a novel 
predictive biomarker for selected targeted therapy particularly in the 
difficult-to-treat TNBC patient category.
P3-01-12
Prognostic Impact of RANK, RANKL and OPG Gene Expression 
in ER Positive Primary Breast Cancer.
Ruckhaeberle E, Mueller V, Schmidt M, Saenger N, Hanker L, Gaetje 
R, Ahr A, Holtrich U, Karn T, Rody A, Kaufmann M. Department 
of Gynecological Oncology, Frankfurt, Germany; Department 
of Obstetrics and Gynecology, Hamburg, Germany; Department 
of Obstetrics and Gynecology, Mainz, Germany; Department of 
Obstetrics and Gynecology, Homburg/Saar, Germany
Background: 
The cell surface receptor RANK (receptor activator of NFkB), its 
ligand (RANKL) and the decoy receptor of RANKL osteoprotegerin 
(OPG) play an important functional role in bone physiology and in 
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bone metastasis by regulating osteoclasts. Just recently it was shown 
that tumor-infiltrating lymphocytes can stimulate breast cancer 
metastases through RANK-RANKL signalling.
Material and methods: 
We analyzed gene expression of RANK, RANKL and OPG in a 
combined Affymetrix dataset of 307 ER positive breast cancers 
from our institutions which were either untreated of treated with 
chemotherapy. Kaplan Meier analysis of disease free survival and 
Cox regression analysis was applied to examine the prognostic value 
of the different markers.
Results:
We observed no significant difference in survival when samples were 
analyzed according to either RANK or RANKL mRNA expression. In 
contrast when samples were stratified in quartiles of OPG expression 
a positive linear relationship of survival with the expression of OPG 
was observed. Moreover since OPG demonstrated a bimodal type of 
expression a cutoff value can be derived from the expression data. 
Using this cutoff value a hazard ration of 2.14 (95% CI 1.27-3.61; 
P=0.004 for low OPG expression was detected. OPG expression 
correlated with lower proportion of grade 3 tumors (15.7% vs 27%; 
P=0.022) and a higher proportion of PgR positive samples (86.2% vs 
71.4%; P=0.002). No significant differences were observed for lymph 
node status, age, tumor size and HER2 status. In multivariate analysis 
only lymph node status remained significant while OPG, Ki67, age, 
grade, and PgR only displayed a trend towards significance.
Conclusion:
Expression of osteoprotegerin seems to correlate with good prognosis 
in ER postive breast cancer. These data are in line with in vitro 
studies demonstration that OPG inhibits RANKL induced migration 
of tumor cells.
P3-01-13
Leptin Modulates the Response to Tamoxifen Treatment in ER-
Positive Breast Cancer Cell Lines.
Yom CK, Han W, Kim S-W, Kim DW, Kang E, Noh D-Y. Seoul National 
University Bundang Hospital, Seoul National University College of 
Medicine, Seongnam, Korea; Seoul National University College of 
Medicine, Seoul, Korea
Obesity is known to a risk factor for breast cancer in postmenopausal 
women. Leptin is a potent adipokine which mainly produced by 
adipose tissue and leptin signaling plays a significant role in tumor 
development and invasion of breast cancer. In recent study, leptin 
induced aromatase gene expression, elevating aromatase activity 
and increasing estrogen synthesis in MCF-7 cell. Leptin was also 
able to enhance estrogen receptor a (ERa)–dependent transcription 
by decreasing ERa ubiquitination and degradation. And this imply 
that lepin may play some role on hormone resistancy of ER-positive 
breast cancer. The aims of this study is to evaluate whether leptin 
modulates the effect on tamoxifen treatment in estrogen receptor 
(ER)-positive breast cancer cell.
At first, we examined leptin and Leptin receptor(Ob-R) expression by 
western blot assay in various breast cancer cells and cell proliferation 
by cell viability assay in combination with leptin and tamoxifen under 
estradiol (E2) treatment. And we analyzed the effect of leptin on the 
response of tamoxifen treatment in ER-positive breast cancer cells 
and which result from activation of ERK1/2 and STAT3 signaling 
pathway in leptin treatment.
We used the MCF-7 (ER+/Leptin +/Ob-R+) cell and T-47D (ER+/
Leptin +/Ob-R-)cell to compare the effect of leptin according to Ob-R 
status. Leptin had the proliferative effect on MCF-7 comparing to 
control and T-47D cells. But leptin had no additional effect on both 
cells in combination with tamoxifen or E2. Interestingly, Leptin had 
an inhibitory effect on tamoxifen especially in high E2 (20 nM) setting 
in both MCF-7 and T-47D cells. In cell signaling, when leptin was 
added to combination treatment of E2 and tamoxifen, the total- and 
phospho- of ERK1/2 was more activated than combination without 
leptin in MCF-7. In case of STAT3, activation of total- and phospho-
STAT3 were relatively remarkable comparing to combination without 
leptin, when the three agents are combined to treatment in MCF-7. 
On the contrary, in T-47D cell, when leptin added to combination of 
E2 and tamoxifen, leptin relatively induced the activation of total 
ERK1/2 comparing to combination of E2 and tamoxifen without 
leptin. But this result was not shown in phospho-ERK1/2 signaling. 
In STAT3 signaling, same results was noted in T-47D.
We concluded that leptin interfere with the anti-estrogenic effects 
of tamoxifen under E2 condition both in MCF-7 and in T-47D ER-
positive breast cancer cells through activation not only Ob-R but also 
crosstalk other signaling system. These results imply that inhibition 
of leptin expect to enhance the hormone response in ER-positive 
breast cancer, and therefore, to be the promising way to overcome 
hormonal resistance.
P3-01-14
RANK and RANK Ligand (RANKL) Expression in Invasive 
Breast Carcinoma and Human Breast Cancer Cell Lines.
Jacob A, Branstetter D, Rohrbach K, Winters A, Erwert R, Allred S, 
Jones J, Miller R, Tometsko M, Blake M, Dougall WC. Amgen Inc., 
Seattle, WA; Amgen Inc., Thousand Oaks, CA
Purpose: RANK and its ligand (RANKL), key factors for bone 
remodeling and metastasis, are crucial for the development of mouse 
mammary gland during pregnancy. RANKL functions as a major 
paracrine effector of the mitogenic action of progesterone in mouse 
mammary epithelium and has a role in ovarian hormone-dependent 
expansion and regenerative potential of mammary stem cells 
(MaSC). RANKL inhibition has been shown to reduce mammary 
tumor formation and pulmonary metastases in mouse models. Many 
published expression analyses of RANK and RANKL have been 
performed using immunohistochemistry (IHC) without documented 
validation of antibody specificity. This study assessed the expression 
of human RANK and RANKL in human invasive breast carcinoma 
(IBC) and human breast cancer cell lines using specific, monoclonal 
antibodies validated and optimized for IHC or flow cytometry.
Methods: RANK and RANKL expression was analyzed in a panel 
of human breast cancer cell lines representing luminal or basal 
breast subtypes using qPCR, flow cytometry and surface receptor 
quantitation. Antibodies against human RANK (N-1H8, N-2B10; 
Amgen) and human RANKL (M366, AMG161; Amgen) were used 
for flow cytometry, surface receptor quantitation or IHC staining. 
For human IBC, the intensity of IHC staining was scored on a 
semiquantitative scale (0=absent, 1=weak, 2=moderate, 3=intense). 
Incidence was scored as a positive IHC signal (any intensity). In vitro 
responses of cell lines to RANKL were also tested.
Results: The specificity of the antibodies was substantiated by 
concordant signals observed using multiple independent analyses, 
including IHC, flow cytometry and Western blots of positive and 
negative control cells and xenograft samples. Analysis of primary 
human IBC using IHC demonstrated that 25/114 (22%) IBC 
samples expressed RANK and 18/97 IBC (19%) expressed RANKL 
protein within the tumor epithelium. RANK protein was observed 
in monocytic cells infiltrating the tumor in 87/114 (76%) and within 
normal mammary epithelium adjacent to tumors in 35/79 (44%) of 
samples. RANKL was observed in infiltrating monocytic cells within 
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the tumor in 60/115 (52%) and within normal mammary epithelium 
adjacent to tumors in 15/68 (22%) of samples. Both mRNA and 
RANK surface protein were detected in multiple breast cancer cell 
lines, including basal and luminal subtypes. Functional RANK 
expression on cell lines was confirmed in vitro by the observation 
of RANKL-dependent increases in mRNAs (e.g. MMP-9, IL-6 or 
IL-8) or proteins in conditioned media (e.g. IL-6, IL-8), despite the 
relatively low surface expression of RANK observed (range = 1240-
9120 sites/cell).
Conclusion: RANK and RANKL expression was observed in the 
epithelial carcinoma element in human IBC using IHC. RANK 
and RANKL expression was also observed in normal mammary 
epithelium and monocytic cells adjacent to breast tumors. Functional 
RANK expression was observed in human breast cancer cell lines, 
including both basal and luminal subtypes.
P3-01-15
The Role of Src Homology Phosphotyrosyl Phosphatase-2 in 
Basal-Type/Triple-Negative Breast Cancer – Implications for 
Targeted Therapy.
Agazie YM, Matalka F, Hartman ZR. West Virginia University School 
of Medicine, Morgantown, WV; West Virginia University School of 
Medicine, Morganotwn, WV
Background: Of all breast cancer subtypes, the basal-type/triple-
negative breast cancer (BTBC) has the worst clinical outcome. The 
major reasons are the highly invasive nature of the disease and the 
limited treatment options available to patients. As opposed to the 
HER2-positive and the hormone-positive breast cancers, targeted 
therapy against BTBC is unavailable. These premises underscore 
the need for discovering and characterizing drug targets in BTBC. 
In this study, we have focused on the Src homology phosphotyrosyl 
phosphatase 2 (SHP) which seems to play pivotal roles in BTBC. The 
major reason for focusing on SHP2 is that it is an essential downstream 
effector of mitogenic and cell survival signaling downstream of 
receptor tyrosine kinases such as EGFR (HER1) and IGF-1R, and 
the cytoplasmic tyrosine kinase Src, which are known to be elevated 
in BTBC.
Materials and Methods: The state of SHP2 and EGFR expression 
in BTBC tumors was determined by immunohistochemistry. The 
functional significance of SHP2 in BTBC cells was investigated 
by ablating its expression with specific shRNA and then assessing 
impact on mitogenic and cell survival signaling using immunoblotting 
with phospho-specific antibodies, effect on transformation using 
3D cultures such as growth in soft agar and matrigel, consequence 
on cell motility and invasiveness using florescent-tagged matrigel. 
Furthermore, the impact of SHP2 inhibition on tumorigenesis was 
tested by intramammary transplantation in vivo and monitoring and 
analyzing tumor growth and metastasis.
Results: We have shown that the SHP2 protein is elevated in BTBC 
tumors. More importantly, the elevated expression of SHP2 is highly 
correlated with overexpression of the EGFR (HER1), suggesting 
their potential synergistic role to promote BTBC. Inhibition of 
SHP2 in BTBC cells reversed transformation and suppressed 
proliferation, indicating their dependence on the function of SHP2. 
Moreover, inhibition of SHP2 abolished EGF-induced mitogenic 
and cell survival signaling, which is in agreement with its role in 
cell proliferation and transformation. More dramatic was that the 
invasive phenotype of BTBC cells in 3D matrigel was completely 
blocked by inhibition of SHP2, suggesting that the invasive property 
of these cells is dependent on SHP2. Even more dramatic was that the 
tumorigenic and metastatic potential of BTBC cells was abolished 
by SHP2 inhibition.
Discussion: The current study demonstrates that SHP2 plays a pivotal 
role in promoting BTBC. Given that SHP2 is a tyrosine phosphatase 
with positive signaling role, its promotion of BTBC must occurs 
through promotion of tyrosine kinase signaling. Together, our results 
provide the first glimpse on the potential of SHP2 as a drug target 
in BTBC.
P3-01-16
Expression of Basal Markers in Correlation with PTEN and 
BRCA 1 in Triple Negative Breast Carcinomas (TN) Treated with 
Chemotherapy Versus PARP Inhibitors.
Chivukula M, Carter G, Puhalla S. Magee Women’s Hospital of 
Pittsburgh, Pittsburgh, PA; Magee Women’s Hospital of UPMC, 
Pittsburgh, PA
The link between the BRCA1 tumour-suppressor gene and hereditary 
breast and ovarian cancer is established. The morphologic and 
immunohistochemical features of basal like phenotype carcinomas 
have shown to be correlated with the BRCA 1 expression. PTEN 
(phosphatase and Tensin Homolog) is a novel tumour suppressor 
gene located on chromosome 10. PTEN mutations are believed to 
exert their effects through the putative PI3K-AKT-mTOR signaling 
pathway. Lack of PTEN expression, suggests that PARP inhibitors 
may be therapeutically useful for a subset of invasive breast cancers. 
The data on PTEN status in breast carcinomas is emerging. The 
aim of our study is to assess the immunohistochemical expression 
of basal markers, PTEN and BRCA 1 in a subset of triple negative 
breast carcinomas with known BRCA status. Results : Results are 
shown in Table 1.
TABLE 1
 TN, Chemo+ (n-17) **TN, PARP + (n-6)
CK5(+) 12/17 6/6
CK 5 (-) 5/17 0/6
EGFR (+) 16/17 6/6
EGFR (-) 1/17 0/6
BRCA 1 (+) 13/17 6/6
BRCA 1 (-) 4/17 0/6
PTEN (+) 15/17 6/6
PTEN (-) 2/17 0/6
TN: triple negative; Chemo: patients who received chemotherapy; (**): Study ongoing with new 
patients; (+): Positive; (-): Negative
Conclusions: 1. Initial results from our study indicate high expression 
of PTEN is seen in TN breast carcinomas. 2. There appears to be 
decreased BRCA 1 protein expression in TN patients who tested 
positive for BRCA mutations. 3. Given the loss of PTEN in a subset 
of TN Chemo group, PARP inhibitors may be suggested to be 
therapeutically useful and needs to be evaluated further. 4. The lack 
of CK 5 basal keratin in some patients needs to be addressed further. 
The study is on going with addition of new cases. The updated data 
and preliminary data with patient responses on PARP inhibitor will 
be presented.
P3-02-01
A Novel Bispecific, Hexavalent, Antibody (HexAb) Inhibits 
Anchorage-Independent Growth and Reduces Invasiveness of 
Triple-Negative Breast Cancer Cell Lines In Vitro.
Goldenberg DM, Wang Y, Trisal P, Cardillo TM, Rossi EA, Chang 
C-H. Garden State Cancer Center, Center for Molecular Medicine 
and Immunology, Morris Plains, NJ; Immunomedics, Inc., Morris 
Plains, NJ; IBC Pharmaceuticals, Inc., Morris Plains, NJ
Background: Combination therapy using two different monoclonal 
antibodies to achieve improved efficacy without increased toxicity 
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is being pursued in various preclinical and clinical studies but, in 
principle, could be accomplished with a single bispecific antibody 
(bsAb). We note the elevated expression of the type-I insulin-like 
growth factor receptor (IGF-1R) and the trophoblast cell-surface 
marker (Trop-2) in diverse epithelial tumors, including breast cancers, 
and the increasing evidence of their correlation with poor survival. 
Therefore, we chose to explore the potential of 1R-(E1)-(E1), the 
bispecific HexAb constructed from hR1 (humanized anti-IGF-1R) and 
hRS7 (humanized anti-Trop-2) for treating breast cancers. Methods: 
1R-(E1)-(E1) was generated by the Dock-and-Lock (DNL) method to 
comprise a full IgG of hR1 linked to two stabilized dimers of hRS7 
Fab, and evaluated in three HER2-negative breast cancer cell lines: 
the non-evasive MCF-7, the moderately invasive MDA-MB-468, and 
the highly invasive MDA-MB-231. The in vitro characterizations of 
1R-(E1)-(E1) included flow cytometry to determine cell binding, soft 
agar assay to evaluate the effect on anchorage-independent growth, 
and BD matrigel chambers to assess invasion properties. Statistical 
differences (P values) between two populations were determined by 
Student’s t-test. Results: All three cell lines were found to express 
both IGF-1R and Trop-2, with MCF-7 and MDA-MB-468 notably 
higher in IGF-1R and Trop-2, respectively. As expected, 1R-(E1)-(E1) 
bound to all three cell lines. At 50 mg/mL, 1R-(E1)-(E1) reduced the 
invasion of MDA-MB-468 to less than 10% of the untreated control, 
whereas under the same conditions, MDA-MB-231 appeared to 
be resistant, while the parental antibodies showed no effects. The 
ability of 1R-(E1)-(E1) to inhibit anchorage-independent growth 
was demonstrated at 200 nM in MDA-MB-231, with a statistically 
significant difference (P< 0.041) when compared with samples treated 
with parental antibodies at the same concentrations. Cells treated with 
1R-(E1)-(E1) produced few and much smaller colonies, the largest 
size of which was less than 1/10 of the untreated cells. The parental 
hR1 alone, but not hRS7, had some effect on inhibiting the growth 
of MDA-MB-231 in soft agar, presumably resulting from the down-
regulation of IGF-1R. Conclusions: These promising results warrant 
further evaluation of 1R-(E1)-(E1) in other breast cancer cell lines, 
as well as the exploration of new bispecific HexAbs that comprise 
different antibodies capable of targeting other solid cancers.
P3-02-02
Novel Ranpirnase-Based ImmunoRNases Display Potent 
Cytotoxicity in Diverse Human Breast Cancer Cell Lines.
Goldenberg DM, Liu D, Wang Y, Rossi EA, Chang C-H. Garden State 
Cancer Center, Center for Molecular Medicine and Immunology, 
Morris Plains, NJ; Immunomedics, Inc, Morris Plains, NJ; IBC 
Pharmaceuticals, Inc., Morris Plains, NJ
Ranpirnase (Rap) is an amphibian ribonuclease originally isolated 
from the oocytes of Rana pipiens. Rap shows anti-tumor activity 
in diverse cancers and its potency can be enhanced by chemically 
linking or recombinantly fusing Rap to a tumor-targeting antibody, 
as demonstrated for CD22- or CD74-expresing hematological 
malignancies, as well as a variety of Trop-2-expressing cell lines 
derived from breast, cervical, lung, pancreatic, and prostate cancers. 
The Dock-and-Lock (DNL) platform enables the design and generation 
of targetable therapeutics that are multivalent, multispecific, and 
multifunctional. Here, we report the successful application of the DNL 
method to generate a novel class of Rap-based immunoRNases, each 
of which features a pair of dimeric Rap molecules covalently tethered 
to a select monoclonal antibody at the carboxyl termini of the heavy 
chains. Two such constructs, designated E1-Rap and 22-Rap, were 
developed with hRS7 (humanized anti-Trop-2) and epratuzumab 
(humanized anti-CD22), respectively, purified to near homogeneity, 
and evaluated in a panel of human breast cancer lines, including the 
basal-like, triple-negative subtype (MDA-MB-468, MDA-MB-231, 
BT20, HCC1806, and HCC1395), the luminal B, HER2-negative 
subtype (MCF-7), and the HER2-positive subtype (SKBR3), all 
except HCC1395 expressing high to moderate levels of Trop-2, and 
none expressing CD22. As demonstrated by flow cytometry, E1-Rap 
and hRS7 bound equivalently to MDA-MB-468, indicating the affinity 
of E1-Rap for Trop-2 is not compromised. Surprisingly, 22-Rap, but 
not epratuzumab, also bound substantially to MDA-MB-468, albeit 
to a lesser extent than E1-Rap. We thus postulate that the four highly 
basic Rap molecules in the DNL conjugate may confer a spatial 
configuration to largely enhance their interaction with negatively-
charged cell surface proteins, such as heparan sulfate proteoglycans. 
Whereas the individual DNL component (IgG or Rap) alone or in 
combination showed negligible in vitro cytotoxicity in all seven breast 
cancer cell lines examined, E1-Rap exhibited EC50 values of 1 nM 
or less in MDA-MB-468 (0.03 nM), MCF-7 (0.1 nM), BT20 (0.18 
nM), HCC1806 (0.19 nM), and SKBR3 (1.29 nM). In comparison, 
the potency of 22-Rap was at least 10-fold lower than E1-Rap in 
MDA-MB-468, BT20 and HCC1806, with an EC50 of ~2 nM. Neither 
E1-Rap nor 22-Rap was very effective in inhibiting the proliferation 
of the more aggressive MDA-MB-231, with an EC50 above 50 nM. 
In the Trop-2-negative HCC1395, the dose-response curves obtained 
for E1-Rap and 22-Rap were nearly identical (EC50 ~100 nM), as they 
should be if the cytotoxicity was mediated mainly through the Rap 
component. The results of Immunofluorescence microscopy showed 
E1-Rap was effectively internalized and localized in the cytosol. 
Thus, these ImmunoRNases are potentially new cancer therapeutics 
for breast and other solid tumors.
P3-03-01
Low Expression of microRNA-210 Is an Independent Good 
Prognostic Factor in Japanese Triple-Negative Breast Cancer 
Patients.
Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, 
Takahashi S, Iwase H, Fujii Y, Yamashita H. Nagoya City University 
Graduate School of Medical Sciences, Nagoya, Aichi, Japan; 
Kumamoto University Graduate School of Medical Sciences, 
Kumamoto, Japan
Background: microRNAs (miRNAs) have emerged as a new class 
of non-coding genes involved in regulating cell proliferation, 
differentiation, and viability. Recent studies have identified miR-210 
among a set of hypoxia-regulated miRNAs and demonstrated a direct 
regulatory role of hypoxia-inducible factor-1 alpha (HIF-1a) in its 
transcription. High expression of miR-210 has been reported to be a 
poor prognostic factor in several types of cancers including breast.
Materials and Methods: TaqMan MicroRNA assays for miR-210 
expression were performed in 219 breast cancers (58 triple-negative 
(TNBCs), and 161 ER-positive and HER2-negative). Correlations 
between miR-210 expression and clinicopathological factors were 
analyzed. The effects of several variables on survival were tested by 
Cox proportional hazards regression analysis.
Results: miR-210 expression in TNBCs was significantly higher 
than in ER-positive and HER2-negative breast cancers (p<0.001). 
Patients whose TNBCs had low miR-210 expression experienced 
significantly better disease-free and overall survival compared with 
high miR-210 expressors (p=0.02 and p=0.05, respectively). Notably, 
among 40 node-negative TNBCs, 5-year disease-free survival was 
approximately 60% in patients whose tumors had high or intermediate 
miR-210 expression (n=26), while no patients with low miR-210 
expression (n=14) suffered recurrent disease. Cox univariate and 
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multivariate analyses demonstrated that low expression of miR-210 
was an independent good prognostic factor in TNBCs.
miR-210 expression in breast cancer: Cox proportional hazards regression analysis
 univariate multivariate  
 p value p value risk ratio of recurrence (95% CI)
miR-210    
Low expression   1.0 (reference)
Intermediate or High expression 0.036 0.049 4.39 (1.00 to 19.28)
Nodal status    
Negative   1.0 (reference)
Positive 0.011 0.018 3.06 (1.20 to 7.80)
Tumor size    
≤ 2cm   1.0 (reference)
> 2 cm 0.653 0.710 1.23 (0.40 to 3.76)
Grade    
1 or 2   1.0 (reference)
3 0.557 0.280 0.59 (0.22 to 1.53)
Discussion: Although prognosis of patients with TNBCs is poor, 
those whose tumors expressed low levels of miR-210 had a more 
favorable prognosis. Thus, the degree of miR-210 expression might 
be a clinically useful prognostic factor for decision-making regarding 
treatment in the adjuvant setting, especially in node-negative TNBC 
patients.
P3-03-02
Higher Expression Levels of Circulating miR-21, miR-19a and 
miR-10b Are Associated with High Risk Features in Breast 
Cancer.
Anfossi S, Giordano A, Cohen EN, Gao H, Cristofanilli M, Valero 
V, Alvarez RH, Hortobagyi GN, Woodward W, Ueno NT, Lee B-N, 
Reuben JM. The University of Texas MD Anderson Cancer Center, 
Houston, TX; Fox Chase Cancer Center, Philadelphia, PA
Background
MicroRNAs (miRs) have oncogenic and tumor-suppressor functions. 
MiR-21, miR-19a and miR-10b are overexpressed in breast cancer and 
regulate tumor cell migration, invasion and angiogenesis. We assessed 
the levels of miR-21, -19a, and -10b in sera of breast cancer patients 
and their association with the stage, histological type, hormonal 
receptor (HR) status and HER2 amplification in the primary tumor. 
Since circulating tumor cells (CTC) detected by CellSearch® are an 
independent and strong predictor of overall survival in metastatic 
breast cancer (MBC), we assessed the relationship between circulating 
miRs and CTCs.
Methods
The study consisted of 30 healthy donors (HD) and 95 breast cancer 
(BC) patients. Patients’ sera were collected before starting a new line 
of treatment. Total RNA was isolated, reverse transcribed to cDNA 
and then subjected to qRT-PCR for the detection of miR-21, -19a, -10b 
and -192 using the TaqMan MicroRNA Assay (Applied Biosystems, 
Foster City, CA). Mir-192 was used to normalize the expression 
levels of the other miRs. Fold-changes in expression of miRs were 
calculated using the 2-DCt method, where DCt= mean CTtarget-miRNA – 
mean CTmiR-192. CTCs were enumerated using CellSearch™ (Veridex 
LLC, Warren, NJ). Mann-Whitney U test was used to determine 
differences in serum miR expression levels between patients and HD.
Results
Of the 95 BC patients, 39 were non-MBC and 56 MBC. Patients 
grouped according to the receptor expression by immunohistochemical 
staining consisted of 27 HR+HER2-, 30 HR+HER2+, 20 HR-HER2+, 
and 18 HR-HER2- triple negative BC (TNBC). MiR-21 and miR-
19a were higher in non-MBC patients than in HD (p=.001, p<.001, 
respectively). MiR-21, miR-19a and miR-10b levels were higher in 
metastatic patients than in HD (p<.001, p<.001, p=.038, respectively). 
MBC patients had a higher median level of miR-21 than that of non-
MBC patients (p=.02). Patients with (HR+HER2+, HR-HER2+, TNBC) 
had significantly higher median levels of both miR-21 (p=.018; 
p=.009; p=.045) and miR-10b (p=.011; p=.014; p=.03) compared 
with HR+HER2- BC. HER2+ patients had higher median levels of both 
miR-21 and miR-10b than those of HER2- BC (p=.033; p=.01) and 
HD (p<.001; p=.009). Further, median miR-19a expression was higher 
in IBC patients than in non-IBC patients (p=.025). Finally, patients 
with <5 CTCs had a higher median expression level of miR-10b than 
that of patients with ≥5 CTCs (p=.042).
Discussion
High expression levels of miR-21, miR-19a and miR-10b in sera are 
observed in breast cancer patients, especially with advanced disease. 
HER2+ BC patients had higher serum levels of miR-21 and miR-10b 
than HER2-. IBC patients had a higher serum level of miR-19a than 
non-IBC patients. Moreover, patients with <5 CTCs had high serum 
levels of miR-10b that can be induced by Twist1 during the epithelial-
mesenchymal transition (EMT) and, in part, explain the inability of 
CellSearch® to detect CTCs undergoing EMT.
P3-03-03
Congruence between Patterns of microRNA Expression and 
Histologic Grading of Invasive Breast Carcinomas.
Ellsworth DL, Croft DT, Field LA, Deyarmin B, Kane J, Ellsworth 
RE, Hooke JA, Shriver CD. Windber Research Institute, Windber, PA; 
Henry M Jackson Foundation, Rockville, MD; Walter Reed Army 
Medical Center, Washington, DC
Background: Histologic grading may be used as an indicator of 
prognosis in breast cancer; patients with low-grade carcinomas have 
~85% ten-year survival compared to just 45% survival in patients with 
high-grade disease. Although useful for risk stratification, assigning 
nuclear grade is subjective, and a large proportion of carcinomas 
are classified as intermediate-grade with uncertain prognosis, 
thus limiting clinical utility. MicroRNAs (miRNAs) regulate gene 
expression and serve an important role in breast cancer development. 
In this study we examined miRNA expression profiles in low-grade 
and high-grade breast carcinomas to determine if miRNA expression 
is associated with pathological classifications of tumor grade.
Methods: Breast tumors were obtained from 69 patients enrolled in 
the Clinical Breast Care Project. Samples were partitioned into low-
grade (n=30) or high-grade (n=39) categories using the Nottingham 
Histologic Score. Following laser microdissection of frozen tissue 
sections, miRNA was isolated from pure populations of breast 
tumor cells and hybridized to Affymetrix GeneChip® miRNA arrays 
containing over 800 human miRNA probes. Expression profiles were 
analyzed with Partek Genomics Suite using the miRNA Expression 
Module.
Results: We identified 30 unique miRNAs that showed differential 
expression at a False Discovery Rate (FDR) p<0.05 between low-
grade and high-grade breast carcinomas. Gene targets for these 
miRNAs function primarily in metabolism and cell communication. 
Expression of hsa-miR-18a and hsa-miR-572 was significantly 
different between histologic grades at an FDR p<1x10-8 and 
hierarchical clustering based on these miRNAs correctly classified 
97% (29/30) of low-grade and 90% (35/39) of high-grade tumors. 
miR-18a has been shown to inhibit ER signaling and promote cellular 
differentiation, while the role of miR-572 in breast carcinogenesis 
is not well known.
Conclusions: Dysregulation of miRNAs may accompany changes 
in cellular morphology typically used in histologic classification 
of breast carcinomas. Patterns of miRNA expression may improve 
reproducibility and clinical utility of tumor grading and may prove 
useful for prediction of recurrence and survival for patients with 
intermediate-grade carcinomas.
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P3-03-04
Targeted Modulation of HER Receptor Signaling in Breast 
Cancer Using miR-21.
Aubele M, Ludyga N, Braselmann H, Atkinson MJ, Auer G, Anastasov 
N. Helmholtz Zentrum München, German Research Center for 
Environmental Health, Neuherberg, Germany; Karolinska Institute 
and Hospital, Stockholm, Sweden
Introduction: MicroRNAs (miRNAs) are multifunctional nucleic 
acids that regulate the stability and translational efficiency of 
targeted messenger RNAs. Endogenously altered miRNA levels 
have been linked in breast cancer to acquired chemoresistance and 
changed radiosensitivity. Thus the modification of miRNA expression 
represents an attractive therapeutic strategy. We now show that the 
targeted inhibition of miR-21 can modify expression of the HER2 
receptor in breast cancer.
Materials and Methods: Using TaqMan-based technology the 
expression of five selected miRNAs (miR-7b, miR-10a, miR-17-5p, 
miR-125a, and miR-21) was investigated in formalin-fixed, paraffin-
embedded breast carcinoma tissues expressing different levels of 
HER2 (n=60). Possible regulation of HER2 was explored in cell 
lines using lentivirus to stably downregulate or upregulate HER2 
and miR-21 expressions. The effects were analyzed using qRT-PCR, 
Western blots, proliferation and migration assays.
Results: In tumor tissues we identified overexpression of miR-10a and 
miR-21, and underexpression of miR-17-5p and miR-125a in most of 
the tumor tissue samples. Significant associations (p≤0.05) were found 
between HER receptor expression and the expression of miR-17-5p 
and miR-125a, and miR-21 showed correlation with expression of ER 
and PR. Furthermore, analysis of miR-21 downregulation in breast 
cancer cell lines showed inhibition of cellular proliferation and HER2 
protein synthesis. Additionally, downregulation of HER2 expression 
decreased miR-21 expression and showed moderate change in cellular 
proliferation activity.
Conclusions: Based on these results we conclude that there is tight 
interplay between HER2 and miR-21 expression in breast cancer 
cells. Because miRNAs modulate gene expression we suggest that 
modulation of miR-21 has the potential to impact tumor therapy by 
interference with specific signaling pathways.
P3-03-05
Identification of miRNAs and Their Associated Target Genes 
Involved in Endocrine Resistance in Breast Cancer.
Healy NA, Creighton CJ, Fu X, Tsimelzon A, Hilsenbeck SG, Miller 
N, Kerin MJ, Osborne CK, Schiff R. Baylor College of Medicine, 
Houston, TX; National University of Ireland, Galway, Ireland
Background: Despite the widespread use of the selective estrogen 
receptor modulator tamoxifen or strategies of estrogen deprivation 
in the treatment of estrogen receptor-positive breast cancer, tumor 
resistance to endocrine therapy remains a serious clinical problem. 
MiRNAs are a class of endogenous, single stranded RNA molecules 
that play a pivotal role in the regulation of gene expression. Altered 
expression levels of these molecules have been implicated in a number 
of malignancies, including breast cancer. The aim of this study was 
to identify those miRNAs that may be associated with endocrine 
resistance and to further investigate their role in development of 
this resistance.
Methods: MCF7L breast cancer cells were cultured in regular parental 
medium (Par) or in phenol-red free, 10% charcoal-stripped FBS 
medium treated by estrogen deprivation (ED, >6months), tamoxifen 
(Tam, 10-7M, >6months), or estrogen (E2, 10-9M,>1month). Cells 
treated by long-term Tam or ED developed resistance (TamR or 
EDR) and resumed cell growth, which was confirmed by growth 
curve assay. Parallel short-term treatment (10 days) with estrogen 
deprivation or tamoxifen to represent the endocrine-sensitive phase, 
and short-term E2 treated cells as a control was also performed. A 
whole-transcriptome miRNA microarray was performed by High 
Throughput Genomics (Tucson, AZ), using cell lysates from Par, 
short-term/endocrine sensitive, E2 treated cells, TamR and EDR. 
The expression levels of several miRNAs were validated by real-time 
quantitative PCR (Q-PCR). MiRNAs dysregulated in TamR cells 
were integrated with predicted gene targets showing anti-correlated 
expression patterns across human breast tumors in The Cancer 
Genome Atlas (TCGA) datasets.
Results: The miRNA microarray identified 23 miRNAs that are 
upregulated in TamR cells (>1.7 fold change, p<0.005) compared 
to parental cells grown in the presence of E2, and 37 miRNAs that 
were downregulated (>50%, p<0.005). In addition, 6 miRNAs were 
observed to be upregulated in EDR and 3 downregulated in EDR 
compared with controls. Validation of four of these upregulated 
miRNAs within the TamR group, miR221, miR-222, miR-301b and 
miR-181c, was performed using Q-PCR. Previously identified genes 
associated with TamR were scanned for potential binding sites of 
these deregulated miRNAs using miRanda and TargetScan and many 
potential miRNA targeted genes are downregulated in TamR. Both 
miR-221 and miR-181c are predicted to target estrogen receptor gene 
(ESR1), and downregulation of this target gene was confirmed at the 
mRNA level by Q-PCR. A strong negative correlation was identified 
between ESR1 and both miR-181c and miR-221 expression levels 
in breast tumor samples, according to TCGA data. Work is ongoing 
to identify the role of miR-181c and other miRNAs in tamoxifen 
resistance, using a loss-of-function approach. Parallel miRNA 
profiling of multiple endocrine models is underway to identify 
commonly deregulated miRNAs associated with endocrine resistance.
Conclusions: This study has identified those miRNAs associated with 
endocrine resistance in breast cancer. These miRNAs may provide 
potential predictive markers of resistance to endocrine therapy and 
modulation of these may lead to increased therapeutic sensitivity.
P3-03-06
Regulation of microRNA Expression by Autocrine Human 
Growth Hormone in Breast Cancer Cells.
Pertziger M, Shastri BG, Liu D-X, Zhu T, Lobie PE, Perry JK. 
University of Auckland, Auckland, New Zealand; University of 
Science and Technology of China, Hefei, Anhui, China; National 
University of Singapore, Singapore
Introduction: MicroRNAs (miRNAs) are a class of small non-protein 
coding RNAs approximately 20-24 nucleotides in length which 
regulate the expression of genes by pairing with the 3’ untranslated 
regions of target mRNA molecules and inhibiting translation or 
promoting mRNA degradation. Mature miRNAs are processed 
from longer transcripts by the miRNA biogenesis machinery, which 
includes key enzymes Dicer, Drosha and AGO-2. Altered miRNA 
expression has been implicated in many pathologies, including 
breast cancer. In general it is the deregulated expression of individual 
miRNAs that has been implicated in breast cancer pathogenesis. 
However, global downregulation of all or the majority of miRNAs 
has also been observed and can lead to a more invasive phenotype 
and increased proliferation in various cancers. Global miRNA 
downregulation has been associated with changes in expression levels 
of proteins involved in miRNA biogenesis.
The growth hormone/insulin-like growth factor-1 axis is emerging as 
an important mediator of tumour development. Studies investigating 
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hGH expression in human breast cancer have demonstrated that 
hGH expression is positively correlated with lymph node metastasis, 
tumour stage, HER-2 status and proliferative index. In mammary 
carcinoma cells autocrine hGH promotes cell proliferation, survival, 
migration/invasion and epithelial-to-mesenchymal transition as well 
as tumour formation in a xenograft model. In the current study we 
demonstrate that autocrine hGH regulates miRNA biogenesis in 
breast cancer cells.
Methods: Forced expression of hGH was established in the mammary 
carcinoma cell lines MCF-7 and T47D by stable transfection. miRNA 
expression was determined using miRNA microarray, quantitative 
real-time PCR (qPCR) arrays and qPCR assays. The expression levels 
of genes and proteins involved in miRNA biogenesis were assessed 
using real-time qPCR assays and Western blotting.
Results: More than 90% of miRNAs assayed were downregulated 
in hGH-transfected MCF-7 and T47D cells, compared to control 
transfected cells, as demonstrated by miRNA microarray and qPCR 
array. Changes in miRNA expression determined by microarray and 
qPCR array were verified using miRNA-specific qPCR assays. In 
MCF-7 cells, autocrine hGH did not significantly affect the mRNA 
expression levels of miRNA machinery components Drosha, DGCR8, 
PACT, TARBP, EXP-5, Dicer and AGO2 when compared to control 
transfected cells. Whereas in T47D cells autocrine hGH increased 
mRNA expression of TARBP, PACT and EXP-5 by 2.0, 2.3 and 1.8 
fold respectively, compared to control transfected cells. Western blot 
analysis demonstrated that, autocrine hGH decreased protein levels 
of Dicer in MCF-7 cells, whereas Drosha and AGO2 were unchanged 
compared to control transfected cells. In T47D cells autocrine hGH 
decreased protein levels of Dicer, Drosha and AGO2 when compared 
to control transfected cells.
Conclusion: Our findings demonstrate that autocrine hGH stimulates 
global downregulation of miRNA expression in breast cancer cells. 
This may be one mechanism whereby autocrine hGH promotes 
tumour progression. Our results also indicate that autocrine hGH-
mediated global downregulation of miRNA expression may occur 
through regulation of proteins involved in the miRNA biogenesis.
P3-03-07
A Novel Approach Integrating microRNA and mRNA Signatures 
of HMAPK Signaling Is Highly Predictive of ER- Status and 
Outcome in Breast Cancer – Role of HMAPK microRNAs in 
Repression of ER and p27.
Miller P, Clarke J, Koru-Sengul T, Brinkman J, El-Ashry D. University 
of Miami, Miami, FL
Deregulation of the MAPK signaling pathway in breast cancer is 
known to facilitate the down-regulation of the estrogen receptor and to 
contribute to the aggressive nature of ER negative and triple negative 
breast cancers. We have identified a microRNA signature indicative 
of hyperactive MAPK (hMAPK) signaling, which complements a 
previously established hyperactive MAPK gene expression signature. 
We have shown that hMAPK signaling also alters the regulatory 
activity of many microRNAs, including particular microRNAs with 
established roles in the biology of breast cancer, miR-221/222 and 
miR-22. Expression correlation with both the hMAPK microRNA 
signature and hMAPK mRNA signature is significantly associated 
with ER-negative status, increased tumor grade, high proliferation 
rate, and, importantly, poor disease specific survival among breast 
cancer patients, regardless of ER status. The hMAPK microRNA 
signature contains 127 microRNAs, 47 up-regulated and 70 down-
regulated. Of note, hMAPK up-regulated microRNAs include miR-
221/222 and 22, both of which have been demonstrated to target ER 
while miR-221/222 targets the cell cycle regulatory protein p27. 
Down-regulated microRNAs include miR-375, which positively 
regulates ER expression by down-regulating expression of an ER 
repressor. miR-221/222 and miR-22 exhibit both enhanced expression 
and enhanced regulatory activity in the context of hMAPK signaling, 
indicating an important role for these microRNAs in the biology of 
hMAPK signaling in breast cancer. In addition to these microRNAs, 
an unbiased approach of determining MAPK regulated microRNAs 
targeting the 3’ UTRs of both ER and p27 will identify novel 
microRNAs involved in the MAPK regulated repression of ER and 
p27. These data not only suggest a regulatory role for microRNAs 
whose expression and biological activity are altered under conditions 
of hyperactivation of MAPK signaling in establishing and maintaining 
ER negativity and tumor aggression, but also indicate that hMAPK 
signaling may represent a novel aggressive tumor biology that is 
indicative of poor disease outcome in breast cancer.
P3-03-08
microRNAs in Mammary Stem-Like Cells and Triple-Negative 
Breast Cancer; Conserved Functions and Treatment Potential.
Williams C, Aydogdu E, Katchy A, Lin C-Y, Haldosen L-A, Helguero L. 
University of Houston, Houston, TX; Karolinska Institute, Stockholm, 
Sweden; University of Aveiro, Aveiro, Portugal
Background: Mammary stem and progenitor cells are thought to be 
precursors of different subclasses of breast cancer. Triple-negative 
breast cancer exhibit similarities to stem or progenitor-like cells. 
microRNAs (miRNAs) play pivotal roles in both stem cell biology 
and oncogenesis. Given their potential as therapeutic targets, little 
is known, however, regarding miRNAs expression and functions in 
normal and breast cancer cells. Our objective was to identify which 
miRNAs are involved in mammary stem cell maintenance and 
differentiation and study their potential roles in triple-negative breast 
cancer. We investigated their expression during induced differentiation 
of mammary stem-like cells, correlated their expression to that of 
triple-negative breast cancer cells and studied the functions of the 
most regulated and conserved candidates.
Material and Methods: Using large-scale profiling and extensive 
qPCR confirmation we defined miRNAs regulated during stem-like 
cell differentiation. We investigated their expression in different breast 
cancer cell lines, and performed functional studies using miRNA 
mimics and inhibitors in normal stem-like cells and triple-negative 
breast cancer cells.
Results: Twenty-one miRNAs were strongly regulated in repeated 
rounds of mammary cell differentiation. The majority, including 
the miR-200 family and known tumor suppressor miRNAs, was 
upregulated during differentiation. Only 4 miRNAs, including the 
oncomiR, miR-17, were upregulated in the stem cell-like stage. 
Pathway analysis indicated complex interactions between regulated 
miRNA clusters and major pathways regulated during this transition, 
including stem cell maintenance, proliferation and differentiation. 
The cell model used exhibited gene expression profiles resembling 
basal-like poor prognosis breast cancer. Morover, we present data 
of miRNAs that target the genes and networks responsible for this 
correlation. miRNAs detected in this study can also differentiate 
between human non-cancer and breast cancer cell lines, and a subclass 
of miRNAs, was specifically downregulated in a basal-like breast 
cancer cell line. The functions of five miRNAs (miR-200a, -200b, 
-146b, -148a and -206) were further investigated.
Discussion: Our findings suggest that the identified miRNAs have 
significant roles in biological pathways and networks associated with 
mammary stem/progenitor cell maintenance and triple-negative breast 
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cancer and support their further evaluation as potential prognostic 
markers and therapeutic targets in the treatment of breast cancer.
P3-04-01
Molecular Characterization of African Breast Cancer; Results 
from a Large Tissue Microarray Study.
Shaaban A, Hatfield A, Omoniyi Esan GO, Komolafe AO, Daramola 
A, Pathak D, D’Cruz N, Alizadeh Y, Lewis P, Titloye NA. St James’s 
Institute of Oncology, Leeds, United Kingdom; Obafemi Awolowo 
Teaching Hospital Comples, Ile-Ife, Nigeria; Swansea School of 
Medicine, Swansea, United Kingdom; College of Medicine University 
of Lagos/ Lagos University Teaching Hospital, Lagos, Nigeria
Introduction
Breast cancer in African women has been understudied for decades. 
Evidence derived mainly from studies on African-American women, 
supports that tumours of black women are biologically different and 
more aggressive than those occurring in the white population. Of the 
4 main taxonomic groups of breast cancer, basal tumours are more 
represented in those women. In the present state of knowledge, very 
little is known about the biology and molecular profile of breast cancer 
in Africa. The aim of this study was to test the hypothesis that the 
molecular profile of African breast cancer is distinct from its Western 
counterpart. This was achieved by collecting a large cohort of breast 
carcinomas from an indigenous African population for phenotypical 
characterization and testing for expression of potential predictive 
and prognostic markers.
Methods
Breast tumours were collected via collaboration with five centres 
in Nigeria (the most populous country in Africa) and assembled 
into tissue microarrays (TMAs). All tumours were reviewed by 
a specialist breast pathologist following the Royal College of 
Pathologists (RCPath) guidelines to confirm diagnosis, type, grade 
and nodal status. Patients age, tumour size and clinical data, where 
available, were collected from the original pathology reports and 
case notes. Representative tumour areas were selected and marked 
for TMA construction. TMA sections were stained for a range of 
markers including hormone receptors (ERa, ERb, PR, AR), cyclin 
D, HER2, Ki67, bcl2, basal (CK5/6, CK14) and luminal cytokeratins 
(CK18, 19).
Results
A total of 830 tumours were assembled into TMAs. The mean age 
at diagnosis was 47.69yrs with 58% of patients presenting under the 
age of 50. Only 8.5% of tumours were of grade 1. Most tumours 
(87%) were of ductal no special type, followed by lobular and 
metaplastic carcinomas. The majority of the tumours were ERa, PR 
and HER2 negative (77%, 80% and 81% respectively). The triple 
negative tumours were the predominant phenotype (55.6%). Luminal 
A type tumours comprised 24.3% followed by the HER2 positive 
(13.9%) and luminal B tumours (6.2%). The differences of all those 
parameters were statistically highly significant (p<0.001). Most 
tumours expressed ERß including 75% of those that were ERa/PR 
negative. A large proportion of the tumours (22%) were of the basal 
phenotype of which two thirds were also triple negative. Over half 
of the triple negative tumours were also node positive.
Hierarchal cluster analysis showed the basal tumours dendrogram to 
comprise two groups; one showing clustering of ERa/PR/HER2 and 
the second showing clustering of ERß with CK5 and CK14.
Conclusion
To our knowledge, this is largest and most comprehensive study of 
African breast cancer to date. Our data confirms the hypothesis that 
African breast cancer is biologically distinct and shows remarkable 
differences in histological type, grade, hormone receptors & HER2 
status when compared with breast cancer in white women. The early 
age at presentation, predominance of high grade and triple negative, 
but not necessarily basal phenotype, may explain the poor prognosis 
and requires tailoring treatment strategies to target this unique profile.
P3-04-02
Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-
Reinforced Xenograft Model of ER-Positive Breast Cancer.
Gökmen-Polar Y, Toroni RA, Goswami C, Sanders KL, Sirimalle 
U, Mehta R, Li L, Ivan M, Badve S, Sledge GW. Indiana University 
School of Medicine, Indianapolis, IN
Background: Anti-vascular endothelial growth factor (anti-VEGF) 
therapy improves disease-free but not overall survival in metastatic 
breast cancer. To seek further insight on resistance to anti-VEGF 
antibody bevacizumab (BEV) at the molecular level, we developed 
breast cancer xenograft models allowing comparison of tumor 
response at different time-points. Here we report the gene expression 
and miRNA analyses of response and non-response to BEV in these 
models.
Methods: MCF-7 cells transfected with control vector (ML20) or 
VEGF (MV165) were implanted into the mammary fat pads of 
athymic mice. Tumors from short-term treatment with BEV (3 
weeks; Responders to BEV, R) or long-term treatment (8 weeks; Non-
Responders, NR) or with vehicle control group (V) were subjected to 
whole-genome gene expression analysis (Human WG-6v2 Expression 
Beadchips, Illumina) and miRNA profiling (TaqMan ArrayHuman 
MicroRNA A+B Cards Set v3.0, Applied Biosystems).Validation of 
the chosen genes was performed using quantitative real-time RT-PCR 
(qRT-PCR) and Immunohistochemistry (IHC).
Results: Short-term treatment to BEV (3 weeks; 5 mg/kg, i.p./twice 
weekly) inhibited primary tumor growth significantly in MV165 
xenografts compared with vehicle control, whereas BEV treatment did 
not affect the tumor growth in the ML20 model. MV165 xenografts 
progressed after 8 weeks of BEV treatment. Gene set enrichment 
analysis (GSEA) revealed that luminal A-related gene sets were 
enriched in MV165-R compared to MV165-NR group including 
DESMEDT (ESR1), SMID_Breast_Cancer_Luminal_A_up, and 
MASSARWEH_ Tamoxifen_Resistance_ Down. Myoepithelial-
specific gene sets were upregulated in both the R and NR groups 
compared with the vehicle group. qRT-PCR analysis showed that 
estrogen receptor alpha (ESR1) representative for luminal A decreased 
significantly in the MV-165-NR group (P=0.001) compared to vehicle. 
In contrast, Cytokeratin 5 (KRT5) levels increased significantly in 
both R (P=0.02) and NR (P=0.03) groups. In addition, KRT14 was 
upregulated in R (P= 0.04) and in NR (P=0.14) group in comparison 
with the vehicle group, suggesting the upregulation of myoepithelial 
phenotype specific to BEV treated MV165 model, but not ML20 
model. Similar results were obtained by IHC. Consistent with mRNA 
changes, ESR1 regulated miRNA such as miR-107 (P=0.007) and 
miRNA important in tamoxifen resistance such as mir-451 (P= 
0.0003) were also altered in MV165-NR group compared to vehicle.
Conclusion: These results suggest that treatment with BEV may alter 
the intrinsic subtypes in the presence of VEGF expression. These data 
may help to explain the variable results to anti-VEGF therapy based 
on the duration of BEV treatment.
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P3-04-03
Identification of Hormone-Responsive Genes as Biomarkers for 
Menstrual Cycle Phases and Menopausal Status.
Wang J, Lee O, Heinz R, Ivancic D, Scholtens D, Chatterton RT, Khan 
SA. Northwestern University, Chicago, IL; Northwestern University
Background: The definition and validation of biomarkers in archived 
breast tissue samples for prognostic research is limited by the fact that 
the exact menstrual cycle phases and menopausal status at the time of 
tissue sampling is often unknown or not accurate by patient survey. 
Biomarkers that vary with menstrual cycle phases in premenopausal 
women would be difficult to standardize. There are also significant 
differences in gene expression in pre- and post-menopausal women. 
Therefore, menstrual cycle fluctuation and menopausal status need 
to be considered for all candidate biomarkers as part of the validation 
process. The aim of this study is to identify genes responsive to 
different hormones to accurately define menstrual cycle phases and 
menopausal status.
Methods: We studied gene expression profiles of 18 random fine-
needle aspirate (rFNA) samples from unaffected contralateral breast 
(8 pre-menopausal, mean age 44.5; 10 post-menopausal, mean age 
58.8) and investigated the correlation between gene expression and 
serum hormone levels of estradiol (E2), progesterone (P4) and follicle 
stimulating hormone (FSH). Genes that were highly correlated with 
the serum levels of each hormone (Pearson correlation coefficient r 
> 0.60) were considered as specific hormone-responsive genes (P < 
0.0085). The combined gene profiles of hormone-responsive genes 
were used to dissect samples in different menstrual cycle phases 
and menopausal status. Selected genes related to mammary gland 
development and hormone regulation based on gene function and 
gene network analysis were validated using qRT-PCR in 18 original 
rFNA samples and in 28 independent samples.
Results: From 35,964 genes and 12,838 undesignated transcripts, we 
identified genes/transcripts highly correlated with E2 (1091 genes), 
P4 (127 genes) or FSH (58 genes). The most significantly correlated 
genes in each group were selected to define four panels of genes: Panel 
A-21genes stimulated by E2 (r > 0.78); Panel B-22 genes stimulated 
by P4 (r > 0.75); Panel C-7 genes stimulated by FSH (r > 0.65); 
and Panel D-10 genes suppressed by FSH (r < -0.65). Hierarchical 
clustering analysis using the combination of gene panels dissected the 
samples into four clusters based on three phases of menstrual cycles 
and post-menopausal status. Specifically, high panel C and low panel 
D expression segregated post- from pre-menopausal samples. Low 
expression of panel A and B genes dissected early follicular phase 
from late follicular and luteal phases, while higher expression of 
panel B genes discriminated luteal phase from late follicular samples.
Conclusion: Our results indicate that the menstrual cycle phases 
and menopausal status determined by age, patient survey and serum 
hormone concentrations are reflected in the expression of specific gene 
sets in the normal breast. The combination of hormone-responsive 
gene panels would allow the classification of breast samples regarding 
to the menstrual phases and menopausal status at the time of sampling. 
It would also facilitate the selection and validation of breast cancer 
biomarkers that are independent of menstrual cycle fluctuation and 
menopausal variation for clinical use.
P3-04-04
Patterns of Distant Metastasis According to the Molecular 
Subtypes of Breast Cancer; Results of 529 Breast Cancer Patients.
Hwang MJ, Seo YJ, Lee JH, Son GT, Choi JE, Bae YK, Kang SH, 
Lee SJ. Yeungnam University College of Medicine, Daegu, Republic 
of Korea
Backgrounds;
Distant metastasis from breast cancer arises from various sites. But 
few studies concerning factors that can predict metastasis patterns in 
breast cancer has been reported. In this study, we analyzed the effect 
of breast cancer molecular subtypes on distant metastasis patterns and 
tried to determine factors that predict metastasis sites.
Patients and methods;
From January 1995 to January 2004 at Yeungnam university hospital, 
patients diagnosed with the primary invasive breast cancer and 
received treatments were included in this study. Patients with bilateral 
breast cancer or distant metastasis at diagnosis were excluded. After 
analyzing estrogen receptor (ER), progesterone receptor (PR), 
human epidermal growth factor 2 (HER2), epidermal growth factor 
(EGFR) and cytokeratin (CK) 5/6 status, we classified patients into 
5 categories, luminal A, luminal B, HER2-enriched, basal-like, and 
normal (triple negative nonbasal) breast cancers. Distant metastatic 
patterns of each category were analyzed.
Results;
529 patients were eligible for tissue microassay analysis and median 
follow-up period was 7.7 years. In this period, total 82 patients 
(15.5%) had locoregional relapse or distant metastasis and distant 
metastasis were identified in 54 patients (10.2%). Each distant 
metastatic rate was 10.5% (33/313) in luminal A, 8.7% (4/46) in 
luminal B, 10.2% (6/59) in HER2-enriched, 7.9% (7/89) in basal-like, 
and 18.2% (4/22) in normal subtype. Most frequent site of distant 
metastasis in all patients was bone and such result was consistent with 
Luminal A subtype. Liver metastasis was most frequent in Luminal 
B subtype, lung metastasis in HER2 enriched and normal subtype 
and brain metastasis in basal-like subtype.
Characteristics of metastasis based on sites among patient who developed distant metastasis
subtypes No. of patients bone brain liver lung & pleura distant node
  No.(%) No.(%) No.(%) No.(%) No.(%)
Luminal A 33 25(78.5) 1(3.0) 6(18.2) 13(39.4) 10(30.3)
Luminal B 4 2(50.0) 0(0.0) 4(100.0) 3(75.0) 1(25.0)
HER2 enriched 6 2(33.3) 1(16.7) 2(33.3) 5(83.3) 2(33.3)
Basal-Like 7 2(28.6) 3(42.9) 0(0.0) 3(42.9) 0(0.0)
Normal 4 0(0.0) 0(0.0) 1(25.0) 3(75.0) 1(25.0)
p-value  0.008 0.016 0.003 0.178 0.566
Conclusions;
There was a definite association between breast cancer molecular 
subtype and distant metastatic pattern. If more patients and prolonged 
follow up periods are analyzed, we would be able to determine the 
best follow up intervals, methods and treatment directions concerning 
subtypes of breast cancer.
P3-04-05
Expression Profiles of RANK and RANKL mRNA and Protein in 
the Mammary Gland of Female Cynomolgus Monkeys after Long-
Term Treatment with Different Menopausal Hormone Therapies.
Branstetter D, Wood CE, Rohrbach K, Borgerink H, Dougall WC. 
Amgen Inc., Seattle, CA; Wake Forest School of Medicine, Winston-
Salem, NC
Background: RANK and its ligand (RANKL), key factors for bone 
remodeling and metastasis, are crucial for the development of the 
mouse mammary gland during pregnancy. OPG also binds RANKL 
and inhibits RANKL action. Treatment of mice with progesterone 
increases RANKL expression in mammary epithelium. RANKL 
functions as a major paracrine effector of both progesterone-dependent 
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mitogenic action in mammary tissue, and also in ovarian hormone-
dependent expansion and regenerative potential of mammary stem 
cells. RANKL inhibition in vivo reduces progestin-induced mammary 
preneoplasias and adenocarcinomas. In postmenopausal women, 
the addition of a progestin to estrogen therapy has been associated 
with significant increases in mammary proliferation, breast density, 
and breast cancer risk and recurrence. The goal of this study was 
to characterize the expression of RANK, RANKL, and OPG in the 
mammary gland following estrogen + progestin therapy in comparison 
with estrogen-alone therapy or placebo in a postmenopausal primate 
model.
Methods: Ovariectomized female cynomolgus monkeys (Macaca 
fascicularis) were randomized into 3 treatment groups: placebo, 
oral conjugated equine estrogens at 0.625 mg/d (CEE) and CEE 
with medroxyprogesterone acetate (MPA) at 2.5 mg/d (CEE+MPA). 
Treatments were administered in the diet for 2 years. RANK, RANKL, 
and OPG mRNA were measured in mammary gland samples (n = 
28 to 31/group) using quantitative real-time reverse transcriptase 
polymerase chain reaction (qPCR). Antibodies against human RANK 
(N-2B10 and N-1H8; Amgen) and human RANKL (M366; Amgen) 
were used for immunohistochemistry (IHC) of formalin-fixed tissues 
(n = 20 to 23/group) along with an isotype control. The intensity of 
IHC staining was scored on a semiquantitative scale (0 = absent, 1 = 
weak, 2 = moderate, 3 = intense). Incidence was scored as a positive 
IHC signal (any intensity).
Results: Analysis of mRNA revealed that treatment with CEE+MPA 
resulted in a significantly greater ratio of RANKL to OPG compared 
to treatment with placebo (P < 0.01) or CEE (P < 0.05). IHC 
demonstrated RANK protein was predominately localized to basal 
cells of ducts and acinar cells, while RANKL protein was localized 
to luminal cells. RANK protein was detected in mammary glands 
of animals in all groups: placebo (74%), CEE (55%), and CEE 
+MPA (53%). RANKL protein was expressed in the animals treated 
with CEE+MPA (74%) and CEE (15%), but not in placebo-treated 
animals. Quantitative expression of specific mRNA markers for 
epithelial proliferation (MKI67) and density (KRT19) was highest for 
CEE+MPA, intermediate for CEE, and lowest for placebo.
Discussion: Key components of the RANKL/RANK pathway are 
expressed in the normal postmenopausal primate mammary gland, 
modulated by long-term estrogen+progestin exposure at clinically 
relevant doses, and associated with changes in estrogen+progestin-
driven proliferation of mammary tissue.
P3-04-06
Comparison of MammaPrint, BluePrint, and TargetPrint with 
Clinical Parameters in Patients with Breast Cancer: Findings 
from a Prospective United States Cohort.
Nguyen B, Sinha R, Kerlin D, Barone J, Garcia A, Yao K, Rivera E, 
Stork-Sloots L, Deck K. Long Beach Memorial Health Care, Long 
Beach, CA; Rockwood Clinic, Spokane, WA; John Muir, Walnut Creek, 
CA; Comprehensive Breast Care of San Diego and Sharp Memorial 
Hospital, San Diego, CA; University of Southern California, Los 
Angeles, CA; North Shore University Health System, Chicago, IL; 
The Methodist Hospital/Weill Cornell University, Houston, TX; 
Agendia Inc, Irvine, CA; Saddleback Memorial Medical Center, 
Laguna Hills, CA
Background
MammaPrint (MP) is a powerful predictor of disease outcome in early 
stage breast cancer. In addition, TargetPrint (TP), a quality approved 
microarray-based test that measures the mRNA expression level of 
ER, PR and HER2 and an 80 gene expression Molecular Subtyping 
profile BluePrint (BP) were developed. In the present study, MP, BP 
and TP were measured in a prospective U.S. breast cancer patient 
cohort.
Methods
MP results were evaluated in fresh tumor samples from 141 breast 
cancer patients (T1-4N0-2; median age 62 [35-97 yr]) collected by 
core needle biopsy or from a surgical specimen between July 2008 
and February 2011. We compared treatment advice as recommended 
by NCCN guidelines and classification according to MP. In addition, 
we compared IHC/FISH ER, PR and HER2 assessments with TP. The 
MP and BP results were used to subtype the patients into molecular 
subgroups.
Results
For the group of patients (n=69) for which NCCN recommends the 
use of a multi-gene signature for determining chemotherapy treatment 
recommendations, 50 patients were classified as High Risk and 19 
as Low Risk by MP. Comparison of TP with IHC/FISH indicated 
a concordance of 98% for ER, 91% for PR, and 94% for HER2. 
For a subgroup of 63 patients combined MP and BP results were 
available; 22 patients were Luminal-type/MP Low Risk, 31 patients 
were Luminal-type/MP High risk, 1 patient was Her2-type/MP Low 
Risk, 2 patients were Her2-type/MP High Risk and 7 patients were 
Basal-type/MP High Risk.
Conclusion
The multi-gene signature MammaPrint, as well as BluePrint and 
TargetPrint provides additional information for treatment guidance. 
By combining MammaPrint with the BluePrint molecular subtyping 
profile, specific groups of patients can be recognized that are at high 
risk of recurrence and that would possibly benefit from specific 
treatment. This study shows that TargetPrint provides high quality 
second opinion for local IHC/FISH assessment.
P3-04-07
Physiological Concentrations of Genistein and 17b-Estradiol 
Inhibit MDA-MB-231 Breast Cancer Cell Proliferation by 
Increasing Bax/Bcl2 Ratio and Decreasing pERK1/2 Expression.
Rajah TT, Peine KJ, Du N, Serret CA. DePaul University, Chicago, IL
Background: Our previous results were the first to show that 
physiological concentrations (1 µM) of genistein, a soy component, 
in the presence of 17b-estradiol (1 nM) inhibited the cell proliferation 
of MDA-MB-231 (Estrogen receptor (ER) b positive) breast cancer 
cells. These results are relevant in premenopausal women with breast 
cancer of the ERa-negative and ERb-positive type, especially given 
the increasing trends of soy intake among the US population in the past 
decade. The aim of the present study was to identify the mechanism 
by which genistein plus 17b-estradiol inhibits the cell proliferation of 
ERa-negative and ERb-positive breast cancer cells. Our hypothesis is 
that the balance of signaling actions by genistein plus 17b-estradiol 
from different signaling pathways is likely to lead to the cell’s choice 
to either proliferate or enter the apoptotic pathway. For this purpose, 
the effect of low and high concentrations of genistein (1 µM and 
100 µM) in the presence or absence of 17b-estradiol (1 nM) was 
studied on the expression of cell signaling proteins involved in cell 
proliferation, survival and apoptosis (pERK1/2, pAkt, Bax and Bcl2) 
and correlated to cell proliferation and apoptosis in MDA-MB-231 
(ERb positive and ERa negative) breast cancer cells.
Methods: Cell proliferation was determined by the MTT assay, 
apoptosis determined microscopically by the use of acridine orange 
and ethidium bromide dyes and the expression of cell signaling 
proteins by western blotting.
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Results: Our results show that 1µM genistein plus 17b-estradiol 
significantly increased apoptosis (p<0.05) as compared to the control 
(12.47% vs 5.87% respectively). Increased expression of Bax/Bcl2 
(2.5 fold) along with a decreased expression of phosphorylated 
ERK1/2 (2 fold) was observed in cells treated with 1µM genistein 
plus 17b-estradiol as compared to the control cells. Phosphorylated 
Akt did not show any differences in the treatment condition as 
compared to the control. High concentrations of genistein (100 µM) 
in the presence or absence of 17b-estradiol also increased apoptosis; 
however these changes could not be correlated to the expression of 
Bax/Bcl2, or pERK1/2.
Conclusion: In conclusion, our results show that physiological 
concentrations of genistein in the presence of 17b-estradiol inhibit cell 
growth through apoptosis via increased Bax/Bcl2 and a concomitant 
decrease in pERK1/2 expression. Our results also suggest that 
different concentrations of genistein elicit cell responses through 
different signaling mechanisms. These results are especially relevant 
to the cohort of premenopausal women with breast cancer of the ERb 
positive and ERa negative type.
P3-05-01
Gene Profiling of Histopathologically Characterized Apocrine 
Breast Cancers.
Feugeas J-P, Dumay A, Lehmann-Che J, de Cremoux P, Delord M, 
Soulier J, Hamy A-S, Espié M, André F, Marty M, Sotiriou C, Piccart-
Gebhart M, Pusztai L, Bertheau P, de Thé H. Hopital Saint-Louis, 
Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules 
Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
 Background:
Breast cancer is currently classified in 3 groups based on estrogen 
receptor alpha (ER) and human epidermal growth factor receptor 
2 (HER2/ERBB2) gene expression : one basal-like (ER-ERBB2-), 
one HER2-enriched (ERBB2+) and one luminal (ER+). Yet, in 
transcriptome-based classifications, ER-ERBB2+ group partially 
overlaps with more recently defined ER-AR+ (androgen receptor 
positive) group. This type was named molecular apocrine, in reference 
to the histopathologically characterized apocrine carcinomas (H-Apo), 
in which a marked activation of AR signaling was demonstrated with 
a distinct proteomic signature. H-Apo tumors correspond to 1% of 
invasive breast carcinomas and are clearly morphological distinct 
from other AR+ tumors. However, no specific H-Apo transcriptome 
signature has been reported for this sub-group. In an effort to better 
characterize those tumors, we have performed a meta-analysis of 
genomic data, focusing on the ER- AR+ breast subset.
 Samples and Methods:
Chips were from Affymetrix array generations HG-U133. 258 profiles 
were unpublished and 1145 were from published or in press data. 
Gene expression was carried out after GC-RMA normalization. 
Unsupervised hierarchical clustering and other statistical analysis 
were performed with R software.
 Results :
160 of the 1403 investigated tumors were ER-AR+. An unsupervised 
hierarchical clustering clearly identified a small subgroup of 14 
closely tumors expressing high transcripts levels of PIP, HPGD, 
ACSM1, AR, SDR5A1, HS3DB1. This profile was very similar to 
the proteomic signature previously described for the H-Apo tumors. 
In addition, the pathology report, although available only for 4 of 
those14 tumors, described them as typical apocrine carcinomas. 
Taken together, these data suggested that this cluster was the H-Apo 
subgroup. Unexpectedly, when using the transcriptomic PAM50 
classification, 13 were classified as Luminal and only 1 as HER2-
enriched, although the 14 tumors were all ER-negative. CGH analysis 
with Agilent 244K chips was carried out with 25 ER- AR+ tumors, 
of which 5 were H-Apo carcinomas. Importantly, those 5 H-Apo 
tumors exhibited fewer DNA lesions than the other ER-AR+ apocrine 
tumors (17% copy number alterations in H-Apo group versus 41%, 
p=0.02). More CGH data are currently under investigations and will 
be discussed.
 Discussion :
The histopathologically characterized apocrine carcinomas (H-Apo) 
display transcriptomic signs of active androgen metabolism and fewer 
DNA lesions than others molecular apocrine tumors. This could 
suggest that molecular apocrine and H-apocrine tumor derive from 
the same cell of origin, but that only H-Apo retains morphological 
apocrine features, possibly due to the presence of fewer genetic 
lesions. In any case, the prominent androgen signaling activation 
warrants functional assays of anti-androgen in these breast cancer 
subtypes.
P3-05-02
Subtype-Specific Co-Occurrence of Atypical Hyperplasia and In 
Situ Carcinoma with Invasive Breast Cancers.
Kovatich AJ, Kvecher L, Chen Y, Bekhash A, Hooke JA, Shriver CD, 
Mural RJ, Hu H. Windber Research Institute, Windber, PA; Walter 
Reed Army Medical Center, Washington, DC; MDR Global Systems 
LLC, Windber, PA
Background: Atypical ductal hyperplasia (ADH), lobular carcinoma 
in situ (LCIS), and ductal carcinoma in situ (DCIS) are considered 
risk factors for the development of invasive breast cancer (IBC). The 
co-occurrence of these lesions with IBC may provide insights into 
cancer initiation and development. IBC subtypes have distinct clinico-
pathological features. A clinically practical IHC-based subtyping 
classification has been developed based on the expression of ER, 
PR, HER2, and Ki67, defining Luminal A (LA), Luminal B (LB), 
HER2+, and Triple Negative (TN) subtypes. The Walter Reed Army 
Medical Center (WRAMC), through the Clinical Breast Care Project 
(CBCP), has enrolled over 500 IBC subjects with single pathologist 
review and central lab analysis. The co-occurrence of ADH, LCIS, 
and DCIS will be studied in relation to IBC subtypes.
Methods: Subjects were enrolled following IRB-approved protocols. 
IBC patients enrolled at WRAMC were selected and their clinical and 
pathology data were reviewed. ER and PR positivity is defined as > 
5% nuclear staining. The HER2 result is negative if the IHC=0 or 1+ 
and positive if IHC=3+. For IHC=2+, the FISH result determines the 
final HER2 status. Ki67 is considered positive if nuclear staining is 
>= 15%. For IBC subtypes, LA is ER+/HER2-/Ki67-; LB is either 
ER+/HER2-/Ki67+, or ER+/HER2+; HER2+ is ER-/PR-/HER2+; 
TN is ER-/PR-/HER2-. Statistical analysis was performed using 
SAS, and the Chi-Square test was used for categorical data analysis 
supplemented by the Fisher’s Exact test where appropriate. For age 
analysis, ANOVA was performed with Bonferroni adjustment for 
multi-pair t-test.
Results: A total of 459 IBC patients were identified and categorized 
into LA (41.6%), LB (27.7%), HER2+ (10.2%), and TN (20.5%). 
Many of the previously reported subtype-specific characteristics were 
confirmed. Age at diagnosis varied by subtype (p=0.0034) with LA 
being the oldest (Mean+SD=59.9+12.5 years) and TN the youngest 
(54+12.6 years, p=0.0048). Ethnicity distribution of African American 
(AA) relative to Caucasian American patients varied significantly in 
subtypes with AA=18% in LA, 31% in LB, 32% in Her2+, and 42% 
in TN (p=0.0008). The grade, the AJCC stage and its components T 
and N were all significantly different among the subtypes (p ranges 
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from <0.0001 to 0.0020). The grades and stages were consistently 
lowest for LA, highest for HER2+ and TN. We further found that 
the co-occurrence of ADH, DCIS, and LCIS with IBC were subtype-
specific with the following distributions: ADH—LA (25.1%), LB 
(18.9%), HER2+ (0%), and TN (6.4%) (p<0.0001, n=78); DCIS —LA 
(63.4%), LB (76.4%), HER2+ (80.9%), and TN (58.5%) (p=0.0039, 
n=311); LCIS—LA (36.7%), LB (19.7%), HER2+ (4.3%), and TN 
(6.4%) (p<0.0001, n=103).
Discussion: By including Ki67 in IHC-based IBC subtyping we 
confirmed many subtype-specific clinico-pathological characteristics 
in the CBCP WRAMC population. We further report subtype-specific 
co-occurrences of ADH, DCIS, and LCIS. These co-occurrence 
patterns may reveal distinct developmental mechanisms between the 
different subtypes of IBC.
P3-05-03
Transcriptomic Validation of Molecular Classification of Invasive 
Ductal Carcinoma Based on Immunohistochemical Markers 
and Grade.
Rigaill G, Richardson M, Gravier E, Yann M, Gentien D, Caly M, 
Fourquet A, Alran S, Sastre X, Dubois T, Vincent-Salomon A. Institut 
Curie, Paris, France
Transcriptomic analyses identified four major groups among invasive 
ductal carcinomas, associated with different clinical outcomes. Their 
definitions in practice is still matter of debate. Our aims were 1) to 
validate definitions based on immunohistochemical markers and 
grade: luminal A= ER and or PR+ve, grade I HER2-ve, luminal 
B= ER+ve and /or PR+ve , HER2+ve or grade III, HER2 enriched 
carcinomas= HER2+ve and ER-ve, basal-like/triple negative 
carcinomas= grade III, ER-ve, PR-ve, HER2-ve and expression of 
at least one of the basal-like markers (CK5/6, CK14, EGFR); 2) to 
refine this immunohistochemical definition.
142 consecutive tumors were selected in our tumour bank (42 triple-
negative and grade III; 31 HER2+ve and ER-ve; 35 luminal B ER 
or PR+ve and grade III (7 cases) or HER2+ve (28 cases); luminal 
A (34 ER+ve or PR+ve, grade I)). Transcriptomic analyses were 
performed using Affymetrix U133+2 arrays (good quality RNAs 
obtained for all frozen specimens). The molecular classes determined 
according to proposed definitions were compared to those obtained 
with unsupervised clustering analyses using datas after GC-RMA 
normalisation (with the intrinsic gene list genes and with the highest 
variance genes). Marker patterns of expression (CK 8/18, 5/6, 14, 
EGFR, BCL2 and Ki67) were analysed within each molecular class.
Based on the phenotypical definition and grade, 10 and 9% of 
cases were misclassified respectively using unsupervised clustering 
either with the intrinsic gene list or the highest variance genes. The 
misclassified tumors were luminal B HER2+ve case with low ER level 
of expression, or HER2+ve and ER-ve cases classified among the 
triple-negative group. 39 out of 42 (93%) triple negative expressed at 
least one of the basal markers. RP expression pattern differed between 
luminal A and B carcinomas. All luminal A showed at least > 15% 
of positive cells and 65% of them harboured > 50% of positive cells. 
In contrast, luminal B showed < 15% of positive cells in 70% of the 
cases. Bcl2 was negative in 40% of the luminal B cases and positive 
(> 20% stained cells) in more than 90% of the luminal A cases. CK14 
was positive (i.e. > 1% positive cell) in 65% of the triple negative 
cases, compared to CK5/6 positive in 58% of the cases. Ki67 was 
> 20% in 90% of the triple negative and in 55% of luminal B cases 
compared to less than 5% of the luminal A cases. 20 and 30% of 
HER2+ve ER-ve carcinomas expressed CK5/6 , CK14 and EGFR 
associated in more than 90% of the cases to CK8/18 positivity (> 
20% positive cells).
Identification of molecular classes of breast carcinomas was 
accurately determined by immunohistochemistry and grade. Low 
level of RP expression and BCL2 negativity were part of the 
luminal B phenotype. CK14 was more sensitive in this population 
of triple negative carcinomas to identify basal-like carcinomas. 
KI67 was highly expressed in the vast majority if not all breast 
triple negative carcinomas. HER2+ve ER-ve carcinomas can express 
basal markers but in contrast to basal-like carcinomas, associated in 
the large majority of the cases to CK8/18 expression. The accurate 
determination of molecular groups of breast carcinomas should be 
a key parameter for development of targeted therapies within each 
group.
P3-05-04
Changes in Recurrence Risk of Breast Cancer Intrisic Subtypes 
over Time.
Ribelles N, Perez-Villa L, Pajares B, Jerez JM, Vicioso L, Jimenez B, 
de Luque V, Franco L, Alvarez M, Perez-Rivas LG, Sanchez-Muñoz A, 
Gallego E, Marquez A, Hierro I, Alba E. Hospital Universitario Virgen 
de la Victoria, Malaga, Spain; Universidad de Malaga, Malaga, Spain
B a c k g r o u n d :  G e n e  e x p r e s s i o n  p r o f i l i n g  a n d  t h e i r 
immunohistochemistry-based surrogates have consistently revealed 
prognostically significant breast cancer (BC) subtypes: Luminal A 
(Lum A), Luminal B (Lum B), HER2, Basal-like (BL) and Triple 
negative phenotype-nonbasal (TNP-nb). In addition, there are clinical 
evidence that hazard of BC recurrence varies over time with two 
peaks of high risk at 18-24 and 60 months. This study compares the 
time-related patterns of recurrence within BC subtypes.
Methods: Tissue microarrays were constructed from 937 early BC 
patients diagnosed and treated at our Hospital from 1982 to 2005 with 
available archival paraffin tissue blocks. BC subtypes were defined 
using an immunopanel of estrogen receptor, progesterone receptor, 
HER2, epidermal growth factor receptor, cytokeratin 5/6 and Ki67 by 
prespecified published methods. Univariate and multivariate analysis 
(Cox regression) were performed on progression-free survival. 
Smoothed curves for hazard rates (HR) were estimated by a Kernel-
like smoothing procedure. The statistical analysis was done by using 
the R software environment.
Results: Cases were classified as follows: Lum A 46.8%, Lum B 
25.2%, HER2 11.3%, BL 11.3%, TNP-nb 5.4%. None of the patients 
were treated with adjuvant trastuzumab. With a median follow up 
of 80 months age, tumor size, nodal status and intrinsic subtypes 
were independent prognostic factors. HER2 and BL show high and 
early peak in HR curves and decreasing sharply to 36 and 48 months 
respectively. HR in Lum A, Lum B and TNP-nb exhibit a smoother 
and nearly steady curve.
HAZARD RATES FOR BC SUBTYPES RECURRENCE
 Total Lum A Lum B HER2 BL TNP-nb
Maximum HR (%) 0.6 0.3 0.7 1.6 1.0 0.7
Time of Maximum HR (months) 25 39.2 33.2 21.2 17.9 34.6
Conclusions: BC subtypes have distinct outcome but also displays 
different pattern of recurrence over time. These data might imply that 
pathways underlying early and late recurrences could be different. 
This additional information would suggest the convenience of 
considering different timings and duration of adjuvant treatments 
depending of BC subtypes, and also in the design of surveillance 
recommendations.
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P3-05-05
Cyclin D1 Gene Amplification Is Rarely Heterogeneous in Breast 
Cancer.
Burandt E, Grünert M, Choschzick M, Müller V, Bokemeyer C, Simon 
R, Sauter G, Lebeau A, Jänicke F, Wilczak W. University Medical 
Center Hamburg-Eppendorf, Hamburg, Germany
Background: Amplification of Cyclin D1 (CCND1) occurs in about 
10 - 20% of breast cancers and has been suggested to predict resistance 
to anti-hormonal therapy. As the diagnostic accuracy of predictive 
biomarkers can be substantially limited by regional expression 
differences within tumors, heterogeneity of CCND1 amplification 
was assessed in this study. To assess heterogeneity, a novel tissue 
microarray based analysis platform was developed.
Material and Methods: To comprehensively asses the three-
dimensional molecular composition of breast cancers, a “heterogeneity 
TMA” was constructed containing 8 different tissue cylinders from as 
many different cancer containing tumor blocks as possible (at least 4) 
from 147 primary breast cancers. Additional tissue samples were taken 
from 1-4 corresponding nodal metastases from 35 of these patients. 
Dual labeling fluorescence in situ hybridization (FISH) with probes 
for CCND1 and centromere 11 was applied.
Results: The analysis revealed amplification in 29 of 133 (21.8%) 
patients with interpretable FISH data. CCND1 amplification was 
more frequently seen in ductal (22 of 87; 25.29%) than in lobular 
type (5 of 32; 15.63%) (p=0.251). CCND1 amplification was also 
associated with high tumor grade with amplification rates of 1 of 18 
(5.56%) in grade 1, 15 of 72 (20.83%) in grade 2 and 12 of 40 (30%) 
in grade 3 carcinoma (p=0.075). CCND1 amplification was more 
frequently seen in ER positive cases (27 of 110; 24.55%) than in 
ER negative cases (1 of 17; 5.88%) (p=0.052). No association could 
be found between CCND1 amplification and tumor stage (p=0.445) 
and CCND1 amplification and PR status (p=0.752). Heterogeneous 
amplification status was detected in 9 of 29 (31.0%) amplified tumors, 
i.e. in 6.8% of all informative cases. Heterogeneity was successfully 
validated on large sections in all 4 heterogeneous cases with high level 
amplification. In the remaining 5 “heterogeneous cases” discordant 
results were due to variable interpretation of borderline amplification 
results with CCND1/centromer 11 ratios between 1.7 and 2.3. There 
were no discrepancies seen between primary tumors and matched 
lymph node metastases.
Discussion: The high degree of homogeneity seen for CCND1 
amplification suggests that this alteration represents an early event in 
tumor development/progression in a subset of breast cancers. CCND1 
status determined in a small biopsy will be highly representative of 
the entire tumor and will thus be appropriate for predicting treatment 
outcome.
P3-05-06
Progression of Breast Cancer Molecular Subtypes through 
Different Clinical Stages.
Ciruelos EM, Castaneda CA, Andrés E, Gomez HL, Castellano D, 
Mendiola C, Manso L, Ghanem I, Farfan C, Cortes-Funes H. Hospital 
Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de 
Enfermedades Neoplásicas, Lima, Peru
Purpose: Molecular classification of breast cancer (BC) through 
immunohistochemistry classifies patients globally in 4 subtypes with 
similar features and prognosis. The present study was designed to 
compare features of BC subtypes in early versus locally advanced 
clinical stages. A secondary objective was compare molecular 
subtypes of the primary vs recurrences.
Methods: The study included 1621 patients with non-metastatic 
invasive BC that were consecutively diagnosed at Hospital 
Universitario 12 de Octubre, Madrid, between 1997 and 2007. 
Luminal A was defined as ER+ and PR+, HER2-negative and Ki67 
< 14%. Luminal B was defined as PR-negative, HER2-positive or 
ki67≥14%. HER2 was defined as ER and PR-negative, and HER2-
positive.Triple negative (TN) were tumors with ER, PR and HER2 
-negativity. Clinicopathological characteristics and outcomes were 
retrospectively reviewed. Variables were compared with the X2 test, 
and survival curves were evaluated with Kaplan-Meier method.
Results: Most patients were diagnosed as T1 (48%) and T2 (39.7%) 
clinical stages, and classified as Luminal B (49%) and Luminal A 
(29%). GIII frequency increased from T1 to T3-4 in Luminal A 
(p=0.002), and Luminal B (p=0.051) subtypes, but not in HER2 
(p=0.867) or TN (p=0.53).
Table 1. Pathologic features of molecular subtypes through Tumor Clinical Stage.
Subtype Luminal A Luminal B HER2/ TN
Tumor (T) Clinical Stage # Pat. G III (%) 
(p=0.002)
# Pat. G III (%) 
(p= 0.051)
# Pat. G III (%) (p=0.867)/ 
(p=0.089)
T1 310 8.7 367 20.9 45/ 60 68/ 65.4
T2 127 23.8 330 47.4 66/ 121 62.9/ 74
T3-4 80 40 98 52 18/ 43 70/ 79.4
Median ER tended to decrease from T1 to T3-4 in Luminal B 
(p=0.062). Median Ki67 of T1 and T3-4 were not different in HER2 
(p=0.867) and TN (p=0.533) subtypes.
Molecular subtypes carry significant different prognosis (DFS and 
OS) in all T stages except for T1a cases. When T3-4 and T1 stages of 
the same molecular subtype were compared, a significant shorter DFS 
were found for more advanced stages in the Luminal A (p=0.0002), 
Luminal B (0.0001) and TN (0.0017), but not for HER2 (p=0.54) 
subtype. And, similar results were found for OS.
We compared molecular subtypes in the primary tumor and in the 
metastatic site in 83 cases (excluding contralateral recurrences) 
and found change of phenotype in 54% of the cases. Changes 
fromLuminal A to a more aggressive phenotype were more frequent 
than in the opposite situation (14 vs 2 cases).
Conclusion: Despite the molecular classification of early-stage 
BC that classifies patients in well-defined prognostic subgroups, 
tumors are continuously changing and tumor behavior becomes 
more aggressive through progression. Therefore, even tumors with 
favorable phenotype could loss their good prognosis in locally 
advanced stages. Obtention of tumor tissue at metastatic sites is also 
mandatory to a better selection of systemic therapies in relapsed 
patients.
P3-05-07
Genetic Heterogeneity of Amplification Status in Breast Invasive 
Carcinoma with 2+ HER2 Immunostaining: What Can We 
Learn?
Valent A, Delaloge S, Ferchiou M, Bernheim A, Mathieu M-C. Institut 
Gustave Roussy, Villejuif, France, Metropolitan
Background : The genetic heterogeneity of HER2 gene amplification 
(GA) in breast cancer has previously been described, but the clinical 
significance of this phenomenon remains unknown. We studied the 
genetic categories of a series of consecutive 2+ IHC cases over 5 years, 
with a focus on cases with HER2 GA detected in minor clone(s). We 
compared the HER2 status in primary tumors and positive axillary 
lymph nodes (ALN) when available to test the hypothesis that HER2 
amplified cells are more aggressive and metastase quicker than non 
amplified cells.
Material and methods : From January 1st. 2006 to May 30. 2011, 
4491 invasive breast carcinomas had HER2 immunohistochemical 
(IHC) and/or HER2 gene status evaluation on their tumor sample 
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in Institut Gustave Roussy. The distribution according to their IHC 
was as follows: 0 in 2915 cases (65%), 1+ in 569 cases (12.6%), 2+ 
in 536 cases (11.8%) and 3+ in 471 cases (10.6%). All 2+ samples 
were checked by Fluorescence in situ hybridization (FISH). For 
each case we analysed 100 invasive cells in 10 microscopic fields. 
Heterogeneous amplification was defined as presence of 5-50% of 
amplified cells (ratio>2,2) within the tumors otherwise classified as 
not amplified or borderline (ratio for 100 cells : <2,2 according to 
the ASCO 2007 and CAP criteria). The IHC 2+ tumors show five 
main genetic categories.
Results : FISH with HER2/cen17 probes can classify IHC 2+ tumors 
into 5 genetic categories : normal gene status (two chromosomes 
(chr) 17 and two HER2 genes) : 90 cases; chr 17 “ polysomy “/17q 
gain : 145 cases; HER2 gain : 122 cases; HER2 amplification (major 
clone) : 135 cases and chr 17 monosomy : 44 cases. We focused our 
interest to IHC 2+ cases where the major clone showed no HER2 
amplification, but minority clone (cut off 5%) showed the HER2 
amplification (ratio >2,2 or >6 HER2 copies per cell). We found 48 
such cases (10% of 2+ cases). These cases had been reported as not 
amplified (42/48) or borderline (6/48). To find out if the amplified 
cells are those which metastase, we checked 10 involved ALN: they 
all showed the similar genetic heterogeneity as a primary tumor with 
a global ratio < 2,2. Other cases with involved ALN are in ongoing 
study by FISH.
Conclusions : The genetic heterogeneity of IHC 2+ tumors is a 
common event and five different genetic categories can be detected. 
A part of the HER2 negative cases contained one or several HER2 
amplified clones. Preliminary results show a similar genetic 
heterogeneity of metastatic population. Our results on the small series 
of cases do not confirm the hypothesis that the only amplified clones 
metastase, but all clones (amplified and not amplified) has a metastatic 
capacity. A multi-center collaboration is needed to collect the high 
number of cases with heterogeneous amplification to:
1) Find out a proportion of such patients in HER2 IHC 2+ group 
(10% in our study).
2) Study a status of the gene in relapse cases.
P3-05-08
Hormone Receptor Heterogeneity in Ductal Intraepithelial 
Neoplasia (Ductal Carcinoma In Situ) of the Breast.
Sowden M, Flynn C, Bossuyt V, Lannin D, Chagpar AB. Yale 
University School of Medicine, New Haven, CT
Background
Ductal Intraepithelial Neoplasia [DIN] often shows heterogeneity 
of both morphology and nuclear grade within the same patient. It is 
unknown whether this implies heterogeneity with respect to hormone 
receptor status that may affect treatment. We sought to determine the 
rate of heterogeneity in terms of nuclear grade and receptor status 
in DIN patients.
Methods
A hospital tumor registry was queried for patients diagnosed with DIN 
between 1980 and 2010. Of the 746 patients identified, 579 (77.6%) 
had a concomitant invasive tumor. Of the remaining 167 patients, 
70 were diagnosed prior to 2007 (when ASCO-CAP guidelines for 
hormone receptor measurements were released), 2 were found to have 
lobular intraepithelial neoplasia rather than DIN, and in 11 cases, 
pathology slides were not available for review. Of the 84 remaining 
patients with DIN, 17 (20.2%) had DIN 1 alone, 19 (22.6%) had 
DIN 2 alone, and 7 (8.3%) had DIN 3 alone. 41 (48.8%) of the 
patients had more than one grade of DIN. These patients formed the 
cohort of interest. Slides were reviewed by a single pathologist who 
evaluated ER and PR positivity within the different grades of DIN 
in each patient, classifying tumors staining 1% or greater as positive. 
Statistical analyses were performed using SPSS.
Results
The median patient age was 53 years old. Of the 41 patients with 
multiple grades of DIN, 32 (78.0%) had DIN 1 and 2, 6 (14.6%) had 
DIN 2 and 3, and 3 (7.3%) had DIN 1, 2, and 3 within the same tumor. 
93.8%, 94.7% and 88.9% of DIN 1, 2 and 3 lesions respectively were 
ER-positive. A difference in hormone receptor status between different 
grades of DIN within the same tumor was noted in 12 (29.3%) of 
patients; of these 3 (10.3%) varied in ER status and 10 (34.5%) 
varied in PR status. Of the 2 patients with ER-negative DIN 1, both 
had ER-positive higher grade DIN within the same tumor. Of the 2 
patients with ER-negative DIN 2, one had ER-positive DIN 1 while 
the other had ER-negative DIN 3. Therefore, of the total 41 patients, 
40 (97.6%) had at least one component of DIN that was ER-positive, 
and evaluating more than one grade of DIN for ER allowed 75% 
of patients with at least one ER-negative component to be offered 
hormonal therapy.
Conclusions
Nearly 50% of patients with DIN will have more than one nuclear 
grade in the same tumor. These different nuclear grades vary in 
hormone receptor status in approximately 30% of patients. The 
majority of patients (97.6%) have at least one component of their 
DIN that is ER-positive. For those who have at least one component 
that is ER-negative, up to 75% may be offered hormonal therapy 
by considering other grades of DIN in treatment decision-making.
P3-05-09
Comparison of Clinical Features and Patterns of Recurrence 
in Triple Negative Breast Cancers in Relation to Other Breast 
Cancers.
Tosello de Oliveira C, Barbosa EM, Costa de Andrade J, Lyra EC, 
Felzener MC, Krutman Zveibil D, Grosso SHG, Sampaio Goes de 
Oliveira R, Sampaio Góes JC. Instituto Brasileiro de Controle do 
Cancer, Sao Paulo, Brazil
Background: Breast cancer is an heterogeneous disease that have 
several and different biological characteristics and clinical behaviours. 
Of these, triple negative breast cancer represents 10-17%.This kind 
of tumor is characterized by estrogen, progesterone and HER2 
receptor negativity and they are very aggressive, associated with poor 
prognosis, younger patients, high incidence of metastases and shorter 
relapse free survival. Triple negative breast tumours are more likely 
to experience local recurrence and distant relapse than other breast 
tumors, and require a more aggressive intervention.
PURPOSE: To compare the incidence of metastases, clinical features 
and outcome among patients with triple negative breast cancer and 
women with other types of breast cancer.
METHODS: This is a retrospective cohort analysis from 3893 
patients with invasive breast cancer, diagnosed between January 
2000 and April 2011 and attended at Brazilian Institute of Cancer 
Control ( IBCC) in Sao Paulo, Brazil. Five hundred of these tumors 
were triple negative. We made a correlation of clinical variables such 
as age, tumor stage (TNM) and analysis of last follow-ups, such as 
metastases, disease free survival, death for tumor, death for other 
reasons, lost of follow-up, hygiene and diet regime (RHD) and local 
recurrence.
Results: The median follow-up for the cohort was 4,29 years. 
The mean age at diagnosis in triple negative group was 54,8 and 
for the others group was 57,1 years. Subgroup analysis of tumor 
grade showed that the triple negative breast tumors were diagnosed 
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later (Stage II and III; p:<0,0001). There was no difference in the 
appearance of the two types of tumors, when considering diagnose 
age. The incidence of metastases, death for tumor and free survival 
in triple negative tumors, respectively; 25,6%, 13,8% and 57,2% 
(p:<0,0001) demonstrates the aggressiveness of this kind of tumor.
Characteristics of triple negative versus other breast cancers
 Other  Triple Negative   
 N 3393 N 500  
 N % N % p (Chi-square)
Average Diagnose Age 57,12  54,81   
Average Follow-up (Years) 4,29  4,28   
      
Tumor Grade      
I 667 19,65% 36 7,20%  
II 1486 43,80% 229 45,80%  
III 1067 31,45% 208 41,60%  
IV 173 5,10% 27 5,40% <0.0001
      
Diagnose Age      
20-29 25 0,74% 9 1,8¨%  
30-39 275 8,10% 42 8,40%  
40-49 768 22,63% 138 27,60%  
50-59 911 26,85% 137 27,40%  
60-69 736 21,69% 94 18,80%  
70-79 505 14,88% 63 12,60%  
80-89 155 4,57% 16 3,20%  
90-99 18 0,53% 1 0,20%  
      
Results of last Follow-up      
Metastases 682 20,10% 128 25,60%  
Disease free survival 2235 65,87% 286 57,20%  
Death for Tumor 391 11,52% 69 13,80%  
Death for other reason 67 1,97% 13 2,60%  
No Follow-up 1 0,03% 1 0,20%  
RHD 5 0,15% 1 0,20%  
Local recurrence 12 0,35% 2 0,40% <0.0001
P3-05-10
Standardized Quantitative Methods for Investigating the 
Intratumor Heterogeneity of HER2 in FFPE Breast Cancer 
Specimens Utilizing the Vectra System, inForm and AQUA 
Technology.
Hoyt CC, Gustavson MD, Davis WL, Lane KA, Scott CG, Graves, Jr 
LL. Caliper Life Sciences, Hopkinton, MA; HistoRx, Branford, CT
Background: While intratumoral heterogeneity of HER2 gene 
expression is well documented, the HER2 intratumor protein 
expression heterogeneity and its clinical relevance is largely 
unknown but generally believed to be worth of investigation to 
ascertain its impact on HER2 targeted treatment outcome. Methods 
for investigating intratumor protein expression heterogeneity 
must preserve tissue architecture yet provide quantitative protein 
measurement. Immunohistochemistry (IHC) generally lacks 
standardization and quantitative capabilities and furthermore, 
current scoring methods do not account for, or report, heterogeneity. 
Robust and automated methods for characterizing and quantfication 
of heterogeneity are needed. Material and Methods: Whole tissue 
samples stained for HER2 expression by fluorescent quantitative 
IHC methods were analyzed by digital imaging microscopy (Vectra 
system with inForm software, Caliper, Hopkinton MA) providing 
automated pattern-recognition-based selection of area of interest and 
field of view sampling strategies. Quantitative image analysis (AQUA 
technology, HistoRx, Branford, CT) for quantitative measurement 
of HER2 protein expression as well as objective, quantitative 
determination of heterogeneity were performed. Requirements for 
percent tumor sampling at high-power to capture heterogeneity 
were assessed, to support optimization of slide scanning. Results: 
Heatmap representation of HER2 expression levels, and a statistical 
heterogeneity score developed based on the Simpson’s biodiversity 
index (Simpson 1949) demonstrate visually as well as quantitatively 
HER2 heterogeneity in breast cancer tissues. Heterogeneity as a 
function of % area needed for accurate determination of whole section 
score along with confidence intervals as a function of percentage 
tumor analyzed inform appropriate sampling strategies. Conclusion: 
This study demonstrates the suitability of standardized quantitative 
methods for measuring heterogeneity and the feasibility of its use in 
investigations exploring the clinical relevance of HER2 intratumor 
heterogeneity with respect to both measurement strategies as well as 
treatment outcome. Through characterization of heterogeneous HER2 
expression in tumors and optimized measurement strategies, it should 
be possible to design optimized treatment strategy aimed at treating 
the whole tumor as a function of objective quantitative assessment 
of HER2 expression.
P3-06-01
Next Generation RNA Sequencing Reveals Changes in Gene 
Expression and Alternative Splicing upon Brief Exposure to 
Therapy in Early Breast Cancer.
Varadan V, Kamalakaran S, Janevski A, Banerjee N, Lezon-Geyda K, 
Bossuyt V, Flowers D, Sikov W, Abu-Khalaf M, Rizack T, Dimitrova 
N, Harris LN. Philips Research North America, Briarcliff Manor, 
NY; Yale University School of Medicine, New Haven, CT; Brown 
University School of Medicine, Providence, RI
Background:
The use of next generation RNA sequencing (RNA-seq) allows for the 
characterization of the transcriptome at levels of detail unachievable 
by array-based technologies. RNA-seq analysis can quantify 
expression of novel transcripts and alternatively spliced isoforms in 
addition to known genes. Alternative splicing allows for flexibility 
in production of protein isoforms and is frequently dysregulated in 
cancer. As splice variants may play a role in response to therapy 
(Solier, et al, Cancer Res., 2010), we studied differential gene and 
isoform expression in breast cancers after one dose of treatment, prior 
to a course of preoperative therapy.
Methods:
We sequenced transcriptomes of core biopsy samples from 8 
breast cancer patients enrolled in a preoperative clinical trial using 
trastuzumab (HER2 positive) or bevacizumab (HER2 negative) with 
chemotherapy. Tumor core biopsies were taken before and after 10 
days of either biologic or nab-paclitaxel treatment and stored in OCT 
compound. Total RNA was extracted, amplified and libraries were 
constructed for the 16 samples using TruSeq (Illumina). Paired-end 
sequencing was performed on the Illumina GAII platform with 
read length of 74bp. Sequence data was mapped using TopHat and 
transcript abundance in FPKM units (Fragments per kilo-base of 
mRNA per million reads) estimated for a total of 22,160 unique genes 
and 34,449 unique transcripts from RefSeq. Differential expression 
of transcripts between baseline and 10-day samples was estimated 
using t-statistics with read-counts modeled as a Poisson distribution. 
Differentially expressed transcripts were selected at a significance 
level of 0.05 after multiple testing correction.
Results:
Each sample had on average 46 million paired-end reads, of 
which on average 70% were mappable to the human reference 
genome (UCSC, hg19). A median of 138 (range 68-948) transcripts 
varied with treatment. GO analysis showed enrichment of cell-
adhesion, apoptosis, differentiation and cell proliferation pathways. 
Interestingly, the isoforms of several known cancer genes such as 
TP53 were seen in all treatment types. Certain isoforms were only 
seen to change upon brief exposure to chemotherapy such as BCL2 
whereas TNF ligand and PCDH isoforms showed significant change 
only with biologic agents.
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Conclusions:
These results suggest that recurrent changes in both canonical 
genes and splice variants occur over the course of treatment in early 
breast cancer. This underscores the value of RNA-seq to provide 
novel information that may be clinically useful. Brief exposure to 
monotherapy prior to combination treatment may provide important 
mechanistic insights and produce predictive biomarkers. Biologic 
treatments may produce unique changes that can only be discovered 
with novel next generation sequencing techniques.
P3-06-02
Identification of Redundant, Tumor Subtype Specific Fusion 
Transcripts in Primary Breast Tumors.
Thompson EA, Asmann YW, Necela BM, Andorfer CA, Cunliffe HE, 
Hossain A, Getz JE, Hostetter G, Schroth GP, Perez EA. Mayo Clinic, 
Jacksonville, FL; Mayo Clinic, Rochester, MN; TGen, Scottsdale, AZ; 
Illumina, Inc., Hayward, CA
Background: The role of fusion genes and associated fusion 
transcripts has long been recognized in hematopoietic malignancies. 
Until quite recently it has been difficult to detect such events on a 
genomic scale in solid tumors. Consequently, little is known about 
the potential role of fusion genes, transcripts, and proteins as driver 
mutations, biomarkers, or therapeutic targets in breast cancer.
Methods: We have developed a novel analytical pipeline, Snowshoes-
FTD, for detection of fusion transcripts in breast cancer cell lines and 
tumor samples (Asmann, et al. NAR 2011; May 27 ePub ahead of 
print). Preliminary analyses have been carried out with a panel of 8 
each ER+, HER2+, and triple negative (TN) primary breast tumors, 8 
primary human mammary epithelial cell (HMEC) lines from biopsy 
samples, plus 16 normal tissues from the Illumina Body Map dataset.
Results: We have identified 120 redundant, tumor-specific fusion 
transcripts, expressed in two or more tumors and in no non-
transformed samples. Sixteen of these represent intrachromosomal 
fusions and 104 arise from fusion of transcripts that map to two 
different chromosomes. Every breast tumor expressed one or more 
fusion transcripts. Twenty-nine fusion transcripts appeared to be 
tumor subtype specific. Among these, we have identified 2 HER2+, 
10 ER+, and 17 triple negative specific redundant transcripts. In 
general, HER2+ tumors expressed fewer fusion transcripts (range 4 
to 28/tumor) compared to TN (range11 to 44/tumor). Chromosomal 
distribution patterns were also markedly different among the tumor 
subtypes. For example, ER+ tumors expressed a preponderance of 
redundant fusion transcripts that involve chr1 and 2, whereas TN 
tumors had no fusion transcripts that map to either chromosome. 
Conversely, the predominant locus for TN fusion transcripts was 
chr19, which contains only one HER2+ fusion and no ER+ fusion 
transcripts.
Conclusions: Primary breast tumors express many chimaeric 
transcripts, which we presume to arise primarily from genomic 
rearrangements. The majority of these transcripts are redundant, 
and a subset are tumor subtype specific. These transcripts may mark 
regions of chromosomal instability. HER2+ tumors, in general, appear 
to evidence less chromosomal instability, as inferred from fusion 
transcripts; although some HER2+ tumors appear to be quite unstable. 
TN tumors contain many more redundant fusion transcripts, implying 
increased genomic instability, particularly in chr19. We conclude that 
these fusion transcripts represent a class of heretofore unrecognized 
biomarkers that may be used for sub-classification of breast tumors. 
Some of these transcripts appear to encode proteins that may function 
as tumor-subtype-specific driver mutations and may have potential 
as therapeutic targets in breast cancer.
P3-06-03
Hypodiploidy, 1pter Loss and Inactive X Chromosome Retention 
Are Associated with BRCA1 Somatic or Germline Inactivation in 
Basal-Like Breast Carcinomas: Proposal for a New BRCAness 
Genomic Signature.
Manié E, Popova T, Vincent-Salomon A, Dubois T, Delattre O, Sastre-
Garau X, Stoppa-Lyonnet D, Stern M-H. Institut Curie, Paris, France; 
INSERM, Paris, France; Université Paris-Descartes, Paris, France
Basal-Like Carcinomas (BLCs) are high grade ductal carcinomas 
identified by large scale transcriptomic analyses among carcinomas 
with triple-negative phenotype (ER- PR- HER2-). A particular 
relationship between this phenotype and the BRCA1 breast cancer 
susceptibility gene has been described based on several observations 
including high genomic similarities of sporadic and BRCA1 BLCs. 
BRCA1 mutated patients have been shown to strongly benefit from 
treatments using PARP inhibitors. However, significant benefit of 
this treatment was not demonstrated in sporadic triple-negative breast 
cancers in association to standard chemotherapy in phase III clinical 
trials, which emphasizes the necessity for a better selection of DNA 
repair deficient tumors. The goal of this study was to determine 
whether BRCA1 inactivation leads to particular genomic alterations 
that could be used to identify BRCA1 deficient sporadic BLCs.
Genomic profiling was performed using SNP-arrays (Affymetrix and 
Illumina) and high quality profiles were obtained for 60 BLCs with 
more than 35% of tumor cells. The series contained 28 BRCA1 BLCs 
and 32 sporadic BLCs consisting in 10 sporadic BLCs with BRCA1 
somatic inactivation by promoter methylation (BRCA1-like BLCs) 
and 22 sporadic tumors without BRCA1 methylation (nonBRCA1 
BLCs). Genomic data was mined with GAP methodology (Popova 
et al, Genome Biol 2009), which allows absolute copy-number 
evaluation with DNA content calculation and clarification of Loss 
Of Heterozygosity (LOH) status.
Genomic patterns of BLCs were characterized by frequent and highly 
recurrent allelic losses. Comparison between BRCA1, BRCA1-like and 
nonBRCA1 BLCs confirmed their overall similarity, and identified few 
significant differences enhanced when BRCA1 and BRCA1-like BLCs 
were considered as one group. Firstly, hypodiploidy characterized 
BLCs with BRCA1 germline and/or somatic inactivation. Secondly, 
the 1pter region was found more often lost in BRCA1 and BRCA1-
like BLCs than in nonBRCA1 BLCs. Thirdly, retention of inactive 
X chromosome was a characteristic of BLCs with BRCA1 germline 
and/or somatic inactivation. Finally, a BRCA1ness score based on the 
above described difference is proposed.
In conclusion, despite a strong similarity of genomic patterns in BLCs, 
BRCA1 inactivation leads to few key genomic aberrations which 
constitute a new BRCA1 molecular signature namely hypodiploïdy, 
1pter loss and inactive X chromosome retention. This signature needs 
to be further evaluated in terms of response to PARP inhibitors in 
order to evaluate its capacity to identify patients that will benefit 
from this treatment.
P3-06-04
Sno/miRNA Expression Via Next Generation Sequencing: 
Variation in Patients before and after Treatment.
Banerjee N, Kamalakaran S, Varadan V, Janevski A, Lezon-Geyda 
K, Bossuyt V, Flowers D, Sikov W, Abu-Khalaf M, Rizack T, Harris 
L, Dimitrova N. Philips Research North America, Briarcliff Manor, 
NY; Yale University School of Medicine, New Haven, CT; Brown 
University School of Medicine, Providence, RI
Background: Aberrant expression of small RNA molecules has 
been shown in breast cancer. It is yet unclear if variation exists in 
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small RNA molecule expression in response to treatment. Since next 
generation sequencing offers more globally sensitive detection of sno 
and miRNAs, we performed an RNA-seq study to explore patients 
pre- and post- brief exposure to treatment.
Methods: We sequenced transcriptomes of frozen biopsy samples 
from 8 breast cancer patients enrolled in a clinical trial for neoadjuvant 
therapy using trastuzumab (HER2 positive) or bevacizumab (HER2 
negative) with chemotherapy. Tumor core biopsies were taken before 
and after 10 days of either biologic or nab-paclitaxel treatment and 
stored in OCT compound. Total RNA was extracted and libraries 
were constructed for the 16 samples using TruSeq (Illumina). 
We performed 74bp paired-end sequencing with the Illumina 
GAII platform. Sequences were aligned to the sno/miRNA track 
(containing 928 miRNAs and 413 snoRNAs) in UCSC and read 
counts were determined using Bowtie. We performed differential 
miRNA and snoRNA expression analysis pair-wise in all pre- and 
post-therapy samples. Given that miRNA deregulation relies on their 
protein-coding gene targets, we analyzed the predicted targets of the 
significantly varying miRNAs for functional enrichment.
Results: Each sample had on average 46 million paired-end reads, 
of which on average 70% were mapped to the human genome. 
Overall, we detected 138 miRNAs in at least one sample, with each 
sample expressing 33 miRNAs on average. We detected a total of 11 
miRNAs (7%) that showed significant differential expression with 
treatment. Interestingly, 6 of these miRNAs varied in all patients. 
The predicted targets of these miRNAs were enriched in DNA-
dependent transcription, gene expression, cell proliferation and cell 
communication. Similarly, we detected 202 snoRNAs in at least 
one sample, with each sample expressing 87 snoRNAs on average. 
Of these, we found 21 snoRNAs (10%) to vary significantly upon 
treatment and 6 of these snoRNAs showed expression changes in 
all patients.
Conclusions: These results suggest that variation in sno/miRNA 
expression may play a role in response to treatment. The consistent 
variation of sno/miRNAs in response to treatment suggests shared 
small RNA-mediated mechanisms. If validated, these results suggest 
that next generation sequencing technologies will allow lead to 
improved methods of stratifying, subclassifying and managing 
breast cancer.
P3-06-05
Comparison of Oncotype DX® Recurrence Scores between 
Surgical and Core Biopsy Specimens in Breast Cancer Patients.
Stull TS, Goodwin MC, Anderson JM, Baehner FL, Sing AP, 
Yoshizawa CN, Barrio AV, Frazier TG. The Bryn Mawr Hospital, 
Bryn Mawr, PA; Genomic Health, Inc, Redwood City, CA
Introduction: The Oncotype DX® 21 gene assay is usually performed 
on surgical resection specimens (SRx) for patients (pts) with early 
stage, estrogen receptor positive (ER+) breast cancer to predict the risk 
of recurrence and likelihood of benefit from adjuvant chemotherapy 
(CT) and hormonal therapy (HT). Using the Recurrence Score (RS) 
to aid in making a decision to administer preoperative CT requires 
assaying the core biopsy specimen (CBx). The objective of this study 
is to compare the RS obtained from paired CBx and SRx specimens.
Methods: 25 pts with invasive breast cancer diagnosed by CBx with 
a subsequent Oncotype DX® 21 gene assay performed on the SRx 
were identified. Fixed, paraffin embedded tissue from these paired 
CBx were sent to Genomic Health. The H&E slide from the paired 
SRx sample sent for the RS was used to compare the histology with 
the paired CBx. The RS from the CBx and SRx pairs were examined 
descriptively with scatterplots and Pearson correlation coefficients.
Results: Median age of diagnosis was 64 (range 39-78). Sufficient 
RNA was obtained from all but 1 of the CBx. H&E from CBx and 
SRx were histologically dissimilar for 3 of 24 pairs with RT-PCR 
data. The Pearson correlation for RS between CBx and SRx was 0.83 
(95% CI 0.64, 0.92) for all 24 pairs. The distribution of RS groups 
from CBx was 19 low (RS<18), 3 intermediate (RS 18-30), 2 high 
(RS≥31). The RS group from SRx was unchanged for 22 (92%) pts. 
Two pts switched RS groups, CBx RS 5 to SRx RS 18 and CBx RS 
8 to SRx RS 24; only the latter is clinically meaningful because the 
former straddles the low-intermediate cutpoint. Correlations between 
CBx and SRx for individual single gene scores were 0.84 (95% CI 
0.65, 0.93) for ER, 0.83 (95% CI 0.64, 0.92) for PR, and 0.82 (95% 
CI 0.61, 0.92) for HER2. Similar results were obtained excluding the 
3 histologically dissimilar pairs.
Conclusion: The RS’s obtained from CBx’s were consistently similar 
to the RS’s obtained from the paired SRx. Using an RS obtained 
from a CBx in pts with ER+ disease to make a decision regarding 
neoadjuvant CT or HT is clinically acceptable, thus, giving physicians 
an additional tool to improve pt care and outcomes.
P3-06-06
Comparison of Gene Expression Profiles of Lymph Node Positive 
and Lymph Node Negative ER Positive Breast Tumors in Pre- and 
Postmenopausal Women.
Rapuri PB, Xing L, Brilhart G, Deyarmin B, Kvecher L, Hu H, Hooke 
JA, Shriver CD, Mural RJ. Windber Research Institute, Windber, PA; 
Walter Reed Medical Center, Washington, DC
Background: Breast cancer is the most common female cancer in 
US and is the second leading cause of cancer related death in women. 
Metastases are the primary cause of cancer morbidity and mortality. 
Axillary lymph node (LN) status has long been used as a prognostic 
factor for breast cancer. The molecular mechanisms that control 
LN metastasis remains poorly understood. To better understand the 
various genes and regulatory pathways that drive breast cancer LN 
metastasis, we compared the gene expression profiles between breast 
tumors that have metastasized to the LNs and those which have not 
in pre- and postmenopausal women.
Material and Methods: Tumor cells were isolated from the primary 
tumors (ER+) of postmenopausal node positive (PMNP; N=20), 
postmenopausal node negative (PMNN; N=19), premenopausal 
node positive (PRNP; N=18) and premenopausal node negative 
(PRNN; N=16) women using laser capture microdissection. RNA 
was isolated using the RNAqueous®-micro kit (Ambion, Austin, 
TX). Total RNA was converted to Biotin-labelled aRNA using two 
rounds of amplification with MessageAmp II aRNA amplification kit 
(Applied Biosystems, Foster City, CA). The aRNA concentration was 
determined by Nanodrop 1000 and the quality was assessed with a 
Bioanalyzer. The aRNA was fragmented and hybridized to Human 
Genome U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA). 
Microarray raw data were analyzed using a variety of R programming 
packages for probe density processing, background correction, 
normalization, quality control/quality assessment, and calculation 
of gene expression value, etc. To identify differentially expressed 
genes, Wilcoxon rank sum test with FDR (false discovery rate) control 
was performed for pair-wise comparison between different groups. 
Functional analyses were performed on the identified statistically 
significant differentially expressed genes to search for the functional 
categories and pathways in which they are involved and further 
understand their potential roles in breast cancer metastatic process.
Results: Multivariate data mining (hierarchical clustering analysis and 
principal component analysis, etc) revealed that in postmenopausal 
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women, the node positive and node negative women are well separated 
while this was not the case in premenopausal women. Further analysis 
of the PMNN and PMNP groups to identify differentially expressed 
genes (with at least a 1.5 fold difference) at FDR =0.1 showed that 
232 genes were upregulated and 470 genes were downregulated in 
PMNP vs PMNN groups. Gene function analysis revealed that genes 
down regulated in the PMNP group compared to PMNN are related to 
extracellular matrix, cell adhesion, EGF-like pathway, cytoskeleton 
etc, while the over-expressed genes are related to cell cycle and cell 
division, chromosome condensation, etc.
Discussion: The ability to differentiate lymph node positive cases 
from lymph node negative cases in ER+ breast cancer based 
on transcriptional profiling may have an impact on the clinical 
management of ER+ breast cancer cases. Having transcriptional 
profiles that identify ER+ tumors likely to have poor outcomes would 
suggest more aggressive treatment for such patients.
P3-06-07
Integrated Genomic and Pathway Analysis Reveals Key Pathways 
across Breast Subtypes.
Benz S, Sanborn JZ, Vaske C. Five3 Genomics, LLC, Santa Cruz, CA
Cancer is a disease of genomic perturbations that lead to dysregulation 
of multiple pathways within the cellular system. While common 
pathways are believed to be shared within specific cancer types, 
the mechanisms behind why particular patients respond differently 
to treatment is not well understood. Genomics studies such as The 
Cancer Genome Atlas (TCGA) and Stand Up To Cancer (SU2C) 
attempt to address this issue by collecting large-scale whole-
genome measurements of mRNA expression, DNA copy number, 
and epigenetic features. Common analysis of these measurements 
integrates data across multiple samples to distinguish signal from 
noise. However, serious challenges remain in identifying genomic 
features and pathways significant for prognosis and clinical treatment 
classifications.
We have created the Five3 Analysis Pipeline to streamline discovery 
of individual samples’ mutations, small indels, copy number 
alterations, genome rearrangements, expression changes, and 
resulting pathway activities. This pipeline is capable of processing and 
integrating data from both next generation sequencing and microarray 
platforms in the analysis of single or multiple tumor samples. Our 
sequence analysis corrects for both tumor sample impurity and 
germline variation to accurately identify somatic mutations present 
in the tumor. Our pathway analysis incorporates gene copy number, 
mutations, expression, and promoter methylation on a superimposed 
pathway constructed from several curated pathway databases in a 
sample-specific manner.
By applying this pipeline to the TCGA breast cancer datasets, we 
recapitulate established breast subtypes at a pathway-dependent 
level. For example, basal tumors appear enriched for proliferation 
pathways compared to luminal samples within this cohort. Expanding 
the pathway analysis to include TCGA lung cancer samples, we find 
similar subnetworks activated between basal and squamous lung and 
between luminal and lung adenocarcinomas. This hints at similar 
genomic mechanisms for these subtypes independent of tissue of 
origin. Finally, by analyzing genomic alterations across all breast 
cancers we see mutational clusters in PIK3CA that correspond with 
publicly-available hotspots [1]. As suggested by previous reports 
[2], we find that samples with mutations clustered in exon 10 exhibit 
differential pathway activities relative to those samples with mutations 
clustered in exon 21, independent of subtype and TP53 mutation 
status. These results show the power of this integrated genomic 
platform in elucidating pathway signatures and the need to consider 
cross cancer analyses to identify shared tumorigenic mechanisms that 
may suggest common therapeutic targets.
[1] Forbes, S.A et al. COSMIC: mining complete cancer genomes 
in the Catalogue of Somatic Mutations in Cancer. Nucl. Acids Res. 
(2011) 39: D945-D950
[2] Vasudevan KM et al. AKT-independent signaling downstream of 
oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009 
Jul.;16(1):21–32.
P3-06-08
SCAN-B: An Accelerated Translational Pipeline from Profile to 
Prognosis and Prediction for Individual Breast Cancer Patients.
Loman N, Saal LH, Häkkinen J, Vallon-Christersson J, Ringnér M, 
Hegardt C, Jönsson G, Gruvberger-Saal SK, Kvist A, Reuterswärd 
C, Schulz R, Karlsson A, Jönsson M, Grabau D, Manjer J, Carlson 
J, Malina J, Larsson C, Rydén L, Borg Å. Lund University, Lund, 
Sweden; Skåne University Hospital, Lund, Sweden; Skåne University 
Hospital, Malmö, Sweden
The South Sweden Cancerome Analysis Network - Breast (SCAN-B) 
Initiative is a multidisciplinary network of clinical providers of breast 
cancer (BC) treatment and pre-clinical scientists whose multiyear 
purpose is to 1) prospectively collect and analyze the “-omes” of 
a very large, consecutive, and population-based sample of BCs for 
translational research; 2) utilize this genomic data to develop new 
clinically-relevant biomarker assays; and 3) to build the infrastructure 
for future real-time clinical implementation of resultant biomarkers for 
individualized treatment. Patient enrollment began in the Fall of 2010 
at the seven BC surgical units of the South Sweden Healthcare Region, 
where approximately 1500 new breast cancer diagnoses are treated 
yearly following the guidelines of the South Sweden Breast Cancer 
Group. Currently, tumor and blood samples are being collected at the 
rate of 80-100 patients per month, which represents approximately 
75% of the catchment population. SCAN-B will initially focus on 
tumor transcriptome analysis using mRNA-sequencing on Illumina 
HiSeq 2000 instruments, and in the future multimodal data generated 
from other genomic platforms will also be integrated. Here we present 
initial experiences from this multidisciplinary collaboration including 
descriptions of the clinical routines, specimen handling, laboratory 
processing, mRNA-seq data quality control, short- and long-term 
projects and future directions. We believe large initiatives like 
SCAN-B could significantly reduce the time to discovery, validation, 
and clinical implementation of more powerful diagnostic, prognostic, 
and treatment-predictive tests for breast cancer.
P3-07-01
Are the Findings of ASOCOG Z0011 Applicable to District 
General Hospital Breast Unit – And How Should They Change 
Our Practice?
Olsen SB, Amr B, Omar A, Smith J, Thomson S, Monib S, Lai LM. West 
Hertfordshire NHS Trust, St Albans, Hertfordshire, United Kingdom
Background: There has been considerable debate on the management 
of the axilla in breast cancer patients with lymph node metastasis 
found on sentinel lymph node biopsy (SLNB) following publication 
of the ACOSOG Z0011 study. This study conclude that axillary 
lymph node dissection (ALND) does not add any benefit to overall 
and disease free survival in some patients with positive SLNB. 
However it is not know if the patient characteristics of this study are 
transferable to other settings. A previous UK study has suggested that 
only a minority of patients from an academic specialist centre fit the 
ASOCOG Z0011 criteria and that the patient populations may not be 
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comparable. The aim of our study was to assess the applicability of 
the Z0011 study to our patient population of a large District General 
Hospital in the UK and to what extent it should influence our practice.
Methods: The Z0011 eligibility criteria for inclusion in analysis 
were applied to all patients undergoing SLNB for invasive cancer 
at West Hertfordshire Breast Unit from 2007-2011. These were: 
no neo-adjuvant chemotherapy, clinical T1 and T2 tumours, breast 
conserving surgery followed by whole breast radiotherapy and 1-3 
positive nodes on SLNB. Patent characteristics and results were 
compared using fisher’s exact test.
Results: In our unit a total of 434 patients underwent SNLB of whom 
64(14.7%) met the inclusion criteria of Z0011. Our patient population 
was comparable to that of Z0011 with regards to lymphovascular 
invasion, proportion of patients with micro-metastases and those with 
additional lymph nodes found on completion ALND. Our patients 
had significantly more T2 tumours. The only other statistically 
significant difference was in the proportion of estrogen receptor(ER) 
and progestrogen receptor (PR) positivity.
Table 1
Tumour characteristics Z0011 Our Patients p-value
T1 70.6% (303/436) 43.8% (28/64) P=0.0002
T2 29.4% (126/436) 51.5% (33/64) P=0.0002
ER+/PR+ 61.9%(270/436) 81.3%(52/64) P=0.002
ER-/PR- 14.7%(64/436) 4.7% (3/64) P=0.03
LVI present 25.9% (113/436) 39.1% (25/64) P=0.38
LVI absent 47.7% (208/436) 54.7% (35/64) P=0.38
Micrometastases 44.8%(164/366) 37.5% (24/64) P=0.41
Patients with additional nodes found on ALND 27.3% (97/355) 25.8% (16/64) P=0.65
Conclusion: Only a small proportion (14%) of patients undergoing 
SNLB in our patient population fit the criteria for Z0011. This was a 
higher proportion than in the previous UK study of this type. Similar 
to this study we found the proportion of patients with T2 tumours were 
greater in our patient population compared to Z0011. This is most 
likely a reflection of this unit not being a screening centre and brings 
in to question the international generalisability of Z0011. However 
the only other significant difference in our patients was a lower risk 
profile in terms of hormone rector positivity with more ER/PR positive 
and fewer ER/PR negative patients. The implications of Z0011, will 
in our practice, not make a significant difference to the rate of ANLD. 
We are however considering changing our patient management based 
on the result of Z0011 and this current study of our population, to 
offer no further axillary surgery to patients over 50 with T1 and ER/
PR positive tumours who otherwise fit the Z0011 protocol.
P3-07-02
Prediction of Non-Sentinel Lymph Node Status in Breast 
Cancer Patients with a Micrometastatic Sentinel Lymph Node 
Determined by the One Step Nucleic Acid Amplification (OSNA) 
Assay.
Di Filippo F, Casini B, Gallo E, Terrenato I, Botti C, Mottolese M, 
Pescarmona E, Marandino F, Buglioni S. Regina Elena National 
Cancer Institute, Rome, Italy; Regina Elena National Cancer 
Institute, Italy
Background: Axillary lymph node dissection (ALND) may not be 
necessary in women with breast cancer (BC) who have micrometastasis 
in a sentinel lymph node (SLN), owing to the low risk of non-SLN 
(NSLN) involvement. In our Institute we validated and adopted 
the new molecular diagnostic tool OSNA (One Step Nucleic Acid 
Amplification ) based on the quantitative measurement of Cytokeratin 
19 (CK19) mRNA. The aims of our work in a subgroup of women 
with micrometastatic SLN, were: 1) to correlate the copy numbers of 
CK19 mRNA with the risk of additional positive NSLNs; 2) to assess 
the relationships between the molecular subtype classification based 
on the immunohistochemistry phenotypic patterns and the probability 
of a positive ALND; 3) to verify whether a combination of the new 
above mentioned parameters is able to identify a subgroup of patients 
with a micrometastatic SLN and a negligible risk of positive NSLNs 
in whom ALND may be avoided.
Material and Methods: The intraoperative clinical study was 
conducted on 901 fresh SLNs from 709 consecutive patients with 
clinically node negative BC. The SLN lysates were analyzed by 
OSNA assay. If the CK19 mRNA copy number/mL lysate was less 
than 250 copies/mL, the result was regarded as negative (-); copy 
numbers between 250 and 5000/mL were regarded as micrometastasis 
(+), and copy numbers greater than 5000/mL as macrometastasis 
(++). We analyzed only patients with a micrometastatic SLN. 
Complementary ALND was performed concurrently in case of 
OSNA assay positivity and the probability of having a positive lymph 
node axillary dissection was calculated by the unconditional logistic 
regression model. This series of BC patients were divided into four 
main subtypes taking in account the BC classification as defined by 
a combination of estrogen, progesteron receptors and HER2 status 
evaluated by immunohistochemistry (IHC) and confirmed by FISH 
in case of IHC-HER2 2+.
Results: OSNA positivity for micrometastasis was reported in 91/709 
cases (12,8%).The number of patients with positive ALND was 20 
(22%). The statistical analyses showed that the metastatic involvement 
of NSLNs is associated with SLNs with a high copy numbers (>2000) 
of CK19 mRNA together with luminal B subtype. Otherwise none 
of the luminal A patients with a positive SLN but presenting a copy 
number <1000, had a positive NSLNs.
Conclusions: We showed that biologically-driven analyses may 
be able to build new models with higher performance in terms of 
breast cancer axillary status prediction after positive SLN biopsy 
for micrometastasis. The copy numbers of CK19 mRNA and the 
molecular subtypes are more advantageous than traditional parameters 
because they are not pathologist-dependent and therefore they are 
more reliable and reproducible.
P3-07-03
One-Step Nucleic Acid Amplification (OSNA) for the Diagnosis 
of Sentinel Lymph Nodes of Breast Cancer – Results of the China 
Multicenter Study CBCSG-001c.
Wang YS, Ouyang T, Wu J, Liu YH, Cao XC. Shandong Cancer 
Hospital & Institute, Jinan, Shandong, China; Beijing University 
Cancer Hospital, Beijing, China; Fudan University Cancer Hospital, 
Shanghai, China; Guangdong General Hospital, Guangzhou, 
Guangdong, China; Tianjin Midical University Cancer Hospital, 
Tianjin, China
Background: With the adoption of sentinel lymph node (SLN) biopsy 
as the standard of care, there is an increasing need for the rapid and 
accurate intra-operative diagnosis of SLNs. CBCSG-001c was a 
prospective multicenter trial to validate the One-step nucleic acid 
amplification (OSNA) assay in China. The primary endpoint was the 
concordance rates of intraoperative OSNA assay with the in-depth 
permanent histological analyses based both on cases and SLNs.
Methods: From Feb. to Dec. 2010, 1188 SLNs from 552 breast cancer 
patients were enrolled in the CBCSG-001c study at 5 centers. SLNs 
were cut into alternating ~2mm sections. One half of the sections were 
sampled for H&E, with 4 sections at different intervals. The other half 
was fully tested with the OSNA assay. Predetermined cutoffs were 
calibrated so only metastases >0.2 mm were detected.
Results: The concordance rate was 89.1% (95% CI, 86.3-91.5%), 
sensitivity 87.7% (95% CI, 81.0-92.7%), and specificity 89.6% 
(95% CI, 86.3-92.4%) based on 552 cases, and the concordance 
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rate was 91.4% (95% CI, 89.7-92.9%), sensitivity 83.7% (95% CI, 
77.7-88.6%), and specificity 92.9% (95% CI, 91.1-94.4%) based on 
the 1188 SLNs. This quantitative molecular assessment allows the 
distinction of the size of the metastasis, and the PPV of OSNA [++] 
for macrometastases was 83.2% (95% CI, 75.0- 89.1% ). Discordant 
results were thought to be partly due to the fact that different tissue 
sections were used for OSNA assay and histology, and SLNs with 
ITCs were not considered as histological positive nodes. After 
discordant case investigation, the senstivity of OSNA assay was 
significantly higher than that of intraoprative frozen section and 
touch imprint cyctology.
Discussion: As the largest OSNA study to date, our results, together 
with that of Japan, Germany, and France study, proved the OSNA 
assay based on CK19 mRNA expression to be a reliable and 
standardized tool for the intraoperative detection of SLN metastases 
of breast cancer patients as compared to in-depth permanent histology. 
The high sensitivity of OSNA assay means reducing the risk of second 
operation for ALND, medical care costs and patients anxiety.
P3-07-04
Does Omission of Axillary Dissection after a Positive Sentinel 
Node Biopsy Influence Indication to Adjuvant Chemotherapy in 
Operable Breast Cancer Patients?
Montemurro F, Maggiorotto F, Valabrega G, Kubatzki F, Rossi V, 
Marocco F, Magistris A, Gatti M, Sarotto I, Aglietta M, Ponzone R. 
Fondazione del Piemonte per l’Oncologia/IRCC, Candiolo, Torino, 
Italy
Introduction: Based on the recently published ACSOG Z0011 study 
(JAMA 2011;305:569), axillary dissection (AD) may be avoided 
in breast cancer (BC) patients with a clinically negative axilla 
and a positive sentinel lymph node (SLN) biopsy receiving breast 
conserving surgery (BCS). Because the number of positive axillary 
lymph nodes (ALN) is a widely accepted prognostic marker, we 
evaluated the potential impact of omission of AD on indication to 
adjuvant chemotherapy (ACT).
Patients and methods: Among 1497 patients operated at our Institution 
over 10 years, we identified 321 patients fulfilling the inclusion criteria 
of the ACSOG Z0011 study (BCS plus SLNB, cT1-2, cN0 breast 
cancer and 1 to 2 positive SLN). All patients underwent AD. Each 
case, which was anonymized, was reviewed by our breast team in two 
rounds. In the first round, patient age, histopathology, linfovascular 
invasion, tumor grade, hormone receptor, HER2, and ki67 status 
and number of positive SN nodes (micro and/or macrometastatic) 
were available. In the second round, the information on ALN was 
added. At each round, the panel chose between three indications: 1) 
Recommend ACT; 2) Discuss ACT; 3) No ACT.
Results: SN was micrometastatic in 145 (45%) and macrometastatic in 
176 patients (55%). ALD revealed non-SNs metastases in 96 patients 
(30%). Forty-four of these patients had >3 positive ALN (range 4-24). 
Indications at round 1 and 2 are summarized below.
Changes in adjuvant chemotherapy (ACT) recommendations from Round 1 to Round 2
  Round 2  Totals round 1
 Recommend ACT Discuss ACT No ACT  
 Recommend ACT 172 (97) 5 (3) 0 177
Round 1 Discuss ACT 26 (41) 35 (56) 2 (3) 63
 No ACT 9 (11) 9 (11) 63 (78) 81
Totals round 2  207 49 65 321
p<0.001; number in parentheses indicate row percentages
As a result of the disclosure of the total number of involved ALN, 
a change in the indication occurred in 51 patients (16%). The most 
frequent change was a recommendation to ACT (35 patients, 69% 
of the changes). Among these patients, 9 changed from No-ACT to 
recommend ACT. All except one change in the indication to ACT 
occurred in patients with immunohistochemically defined Luminal A 
and Luminal B/HER2 negative tumors and were mostly towards ACT.
Conclusions: Omission of AD in patients with a positive SLN 
receiving BCS would have altered the indication to ACT in 16% of 
the patients at our Institution. Changes occurred almost exclusively 
in patients with hormone receptor positive/HER2-negative tumors. 
The implications of omission of AD must be taken into account before 
its widespread acceptance, including the possibility of a biologically 
tailored surgical approach.
P3-07-05
Nomogram Incorporating SLN Metastasis Size Provides the 
Most Accurate Prediction of Non-SLN Involvement in Breast 
Cancer Patients.
Gainer SM, Mittendorf EA, Hunt KK, Bassett RL, Yi M, Meric-
Bernstam F, Ross MI, Babiera GV, Kuerer HM, Caudle AS, Hwang 
RF. UT-M.D. Anderson Cancer Center, Houston, TX
Introduction: The finding of metastatic disease in the axillary nodes 
remains an important factor that guides adjuvant therapy decisions in 
breast cancer. The value of completion axillary lymph node dissection 
(ALND) may not be the same in all patients and determining the risk of 
non-SLN involvement can be a guide in surgical decision making. We 
recently developed a nomogram that incorporates the maximum SLN 
metastasis size to predict non-SLN axillary involvement (Mittendorf 
et al., Ann Surgery 2011,in press). The purpose of this study was 
to compare the accuracy of this nomogram to another widely used 
nomogram that does not include SLN metastasis size.
Methods: We queried a prospective breast cancer database for 
patients with clinically negative nodes undergoing sentinel node 
biopsy who did not receive neoadjuvant therapy. We identified 431 
patients with invasive breast cancer treated from 1996 to 2007 who 
had a positive SLN and underwent completion ALND. We evaluated 
clinicopathologic data including histology, multifocality, nuclear 
grade, pathologic tumor size, number of SLNs recovered, number of 
positive SLNs, maximum SLN metastasis size, presence of extranodal 
extension, hormone receptor status, and presence of lymphovascular 
invasion. Data were entered into our nomogram and the nomogram 
that does not include SLN metastasis size. The accuracy of the 2 
nomograms in predicting non-SLN axillary metastasis was compared 
in all patients and in subgroups of patients based on burden of disease 
in the SLN.
Results: For the entire cohort of 431 women with positive SLNs, our 
SLN size nomogram was more accurate in the detection of non-SLN 
disease (area under the receiver operating characteristic curve [AUC] 
78.3% vs. 72.4%, p=0.01). Whether or not SLNs were subjected 
to frozen section did not influence the relative accuracies of the 2 
nomograms. When patients were analyzed by burden of disease in 
the SLNs, our SLN size nomogram was more accurate in predicting 
non-SLN disease in patients with macrometastases in the SLN (AUC 
77.3% vs. 70.3%, p=0.008). There was no significant difference in the 
accuracy of the 2 nomograms for patients with isolated tumor cells 
or micrometastases in the SLNs.
Conclusions: Our nomogram incorporating SLN metastasis size with 
other clinicopathologic factors is the most accurate predictor of the 
risk of non-SLN metastasis in patients with a positive SLN. The SLN 
size nomogram is highly accurate in women with macrometastases, 
who may benefit the most from completion ALND. Using a nomogram 
with SLN metastasis size can provide the most accurate information 
for patient counseling and surgical decision making.
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res; 71(24 Suppl.) December 15, 2011 Cancer Research358s
Accuracy of 2 nomograms in predicting axillary metastasis in non-SLNs in breast cancer patients 
with positive SLNs
 Isolated tumor cells 
(<0.2 mm) (n=13)
Micrometastases 
(0.2-2 mm) 
(n=112)
Macrometastases 
(>2 mm) 
(n=306)
Overall 
(n=431)
AUC for nomogram incorporating 
SLN metastasis size
77.3% 73.3% 77.3% 78.3%
AUC for nomogram not 
incorporating SLN metastasis size
100% 74.7% 70.1% 72.3%
p-value 0.34 0.79 0.008 0.01
P3-07-06
Prognostic Utility of Upfront Nodal Staging Prior to Neoadjuvant 
Chemotherapy: The UAB Experience.
Keene KS, De Los Santos JF, Krontiras H, Hinton B, Meredith R, 
Li Y, Carpenter JT, Bland K, Forero A. University of Alabama at 
Birmingham, Birmingham, AL
Purpose: Controversy exists regarding the prognostic utility of upfront 
lymph node staging in patients receiving neoadjuvant chemotherapy. 
This retrospective study explores whether upfront verses outback 
nodal staging influenced locoregional control and survival endpoints. 
Methods: Between 1999 and 2005 one hundred and fifteen patients 
treated with neoadjuvant chemotherapy at UAB were identified. 
Patient, tumor, and treatment variables were recorded. Timing of 
nodal assessment was based on either surgeon preference or stipulated 
upfront per several clinical protocols. Survival was measured using 
the Kaplan Meier statistics. Univariate and multivariate analyses of 
covariates associated with local-regional control (LRC), progression-
free (PFS) and overall survival (OS) were performed. Results: Mean 
age was 49 years and mean follow-up was 5.8 years. Stage distribution 
was as follows: 40 IIA, 34 IIB, 26 IIIA, 10 IIIB, and 5 IIIC. Definitive 
surgery included breast conservation in 49 patients, total mastectomy 
in 21 and modified radical mastectomy in 44. Seventy-two patients 
had upfront nodal sampling before neoadjuvant therapy, 36 by fine 
needle assessment and the remainder by sentinel node biopsy. Forty-
three patients had their nodal assessment following neoadjuvant 
chemotherapy. Of those with upfront nodal staging: forty nine patients 
had a positive nodal result and 23 had negative findings. In those that 
were sampled at the time of definitive surgery: 21 had positive results, 
21 had a negative result, and 1 patient did not have any nodes in the 
specimen. One hundred five patients had post-operative radiation 
therapy. Overall there was no difference in LRC, PFS or OS outcomes 
between patients that had an upfront nodal staging procedure and 
those that had their nodes sampled at the time of definitive surgery. 
Patients achieving pCR had a non-significant trend towards improved 
overall survival (p=0.12). Final pathologic T, N and group stage 
were statistically significant in determining the progression free, 
p=0.003, 0.011, 0.005 and overall survival, p=0.02, 0.037, and 0.009. 
Lymphovascular space invasion was associated with progression 
free survival on univariate analysis, p=0.0179, but not multivariate 
analysis. Other covariates including age, biologic subtype, grade, type 
of chemotherapy, use of radiation therapy, radiation volume, time to 
complete radiation therapy, and use of hormonal therapy did not affect 
outcomes. Discussion: Upfront as compared with outback lymph node 
staging did not influence locoregional control or survival endpoints. 
Final pathologic stage and not initial clinical stage remains the most 
important prognostic factor associated with survival.
P3-07-07
Effect of Sentinel Lymph Node Biopsy without Axillary Lymph 
Node Dissection on Overall Survival in Patients with T1 or T2 
Node-Positive Breast Cancer: A Report from the Korean Breast 
Cancer Society.
Park HS, Chae BJ, Song BJ, Jung SS, KBCS Investigators. The 
Catholic University of Korea College of Medicine, Seoul, Korea; 
Korean Breast Cancer Society
Introduction: Sentinel lymph node biopsy (SLNB) is accepted as 
an alternative method to axillary lymph node dissection for staging 
axillary lymph node status in clinically node-negative breast cancer. 
Current practical guidelines recommend that axillary lymph node 
dissection (ALND) should be performed in cases with sentinel 
node metastasis, and most of node-positive patients should receive 
adjuvant systemic therapy to reduce locoregional/distant recurrence 
and to improve overall survival irrespective of the number of lymph 
node metastasis. However, patients with ALND are more likely to 
develop lymphedema than those with SLNB alone, and appropriate 
systemic chemotherapy or hormone therapy significantly reduce 
locoregional and distant recurrence in early breast cancer patients. 
For this reason, the previous prospective study, American College of 
Surgeon Oncology Group Z0011 trial, was conducted and it suggested 
that there is no difference in overall survival between node-positive 
patients who received breast conserving treatment with SLNB alone 
and those with ALND after SLNB. This study is aimed to evaluate the 
difference of survival between node-positive patients who underwent 
SLNB alone and those who received ALND after SLNB using the 
Korean Breast Cancer Society registry.
Methods: In 87671 patients with breast cancer in the registry, we 
enrolled 2581 patients who meet the eligible criteria in the study. All 
enrolled patients had T1 or T2 breast cancer, and received mastectomy 
or breast conserving treatment followed by documented adjuvant 
systemic therapy between Jan. 2001 and Apr. 2011. Log-rank test and 
Cox-proportional hazard model were used to access the difference of 
overall survival according to the axillary procedure.
Results: There were 197 patients with SLNB alone and 2384 
patients with ALND after SLNB, respectively. Smaller tumor size, 
lower number of nodal metastasis, and higher proportion of breast 
conserving surgery were shown in patients with SLNB alone than in 
those with ALND after SLNB. There was no significant difference 
in overall survival between 2 groups in the log-rank test. ALND 
after SLNB showed no significant improvement on overall survival 
in Cox-propotional hazard model adjusted by tumor size, number 
of nodal metastasis, and operation type (P=0.78, HR=0.73, 95% 
CI=0.08-6.62).
Conclusion: The current study suggests that ALND after SLNB 
in cases with sentinel lymph node metastasis may not influence 
on the improvement of overall survival and supports the results of 
Z0011 trial. Further validation studies are necessary to expand the 
understanding of the role of performing SLNB alone in patients with 
node-positive breast cancer.
P3-07-08
Accurate Staging of Axillary Lymph Nodes from Breast Cancer 
Patients Using a Novel Molecular Method.
Osako T, Iwase T, Kimura K, Yamashita K, Horii R, Akiyama F. Cancer 
Institute Hospital of Japanese Foundation for Cancer Research, 
Koto-ku, Tokyo, Japan
Background: In breast cancer, the number of axillary lymph node 
metastases is the powerful prognostic factor. However, it is obvious 
that conventional histopathological examinations are non-standardized 
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and limited in their ability to detect metastases accurately due to the 
partial evaluation of a node. This may lead to underestimation of 
nodal staging. The one-step nucleic acid amplification (OSNA) assay 
was developed to overcome this limitation of the histopathological 
examination. This assay can assess the whole lymph node and yields 
semi-quantitative results for the detection of clinically relevant 
nodal metastases by detection and amplification of cytokeratin 19 
mRNA. This assay can classify the nodes into 4 categories, (++), 
(+I), (+), and negative. (++) and (+I) are theoretically regarded 
as macrometastasis and (+) as micrometastasis according to the 
American Joint Committee on Cancer (AJCC) staging system. We 
have shown the OSNA whole node assay detects more sentinel node 
(SN) metastases, particularly micrometastases than 2-mm-section 
frozen-section histology. Thus, we had hypothesized that the OSNA 
assay for non-sentinel nodes (nonSNs) in addition to SNs enables the 
classification of accurate nodal staging for breast cancer patients. In 
the present retrospective cohort study, we compared the performance 
of the OSNA assay with that of routine permanent histology for the 
detection of nonSN metastases among patients with positive SN 
biopsy who have undergone axillary dissection.
Patients and methods: Subjects comprised of consecutive 183 patients 
with clinically and ultrasonographically node-negative pT1-2 breast 
cancer who had undergone axillary dissection after positive SN biopsy 
with the OSNA assay between April 2009 and September 2010. 
Of these, for nonSN evaluation, 64 had single-section permanent 
histology while 119 patients underwent the OSNA whole node assay. 
We compared 1) detection rates of nonSN metastasis, including 
macro- and micrometastases and 2) upstaging rates from SN stage 
after the nonSN assessment according to the 7th AJCC staging system 
between both cohorts. We performed the two-population z test.
Results:
1) NonSNs were found to be positive for metastasis more frequently 
in the OSNA cohort than in the histology cohort (histology 13/64, 
20.3%, 95% CI 11.7-32.6% vs. OSNA 66/119, 55.5%, 95% CI 46.1-
64.5%; P<0.001). We found no significant difference in the frequency 
of macrometastasis in nonSNs (12/64, 18.8%, 95% CI 10.5-30.8% 
vs. 30/119, 25.2%, 95% CI 17.9-34.2%; P=0.42). However, we 
found significant difference in the frequency of micrometastasis in 
nonSNs (1/64, 1.6%, 95% CI; 0.1-9.5% vs. 36/119, 30.3%, 95% CI; 
22.3-39.5%; P<0.001).
2) Total upstaging rates were similar in both cohorts (histology 9/64, 
14.1%, 95% CI 7.0-25.5% vs. OSNA 20/119, 16.8%, 95% CI 10.8-
25.0%; P=0.79).
Conclusion: The OSNA whole node assay detects a far greater 
proportion of nonSN metastases than single-section histology in 
patients with positive SN biopsy. However, in terms of the AJCC 
staging system, upstaging rates from the SN stage were similar in 
both cohorts. Follow-up of the OSNA cohort is required to clarify 
the prognostic implications of this technique; this may lead to the 
establishment of a new breast cancer staging.
P3-07-09
Prediction of Additional Nodal Metastasis in Breast Cancer 
Patients with a Positive Sentinel Node Biopsy: A New Nomogram 
Including HER2 Status.
Ngô C, De Rycke Y, Castellier C, Fourchotte V, Hugonnet F, Hajage 
D, Reyal F, Vincent-Salomon A, Pierga J-Y, Kirova Y, Sastre-Garau 
X, Alran S. Institut Curie, Paris, France; Insitut Curie, Paris, France
Background: The Memorial Sloan Kettering Cancer Center-Breast 
Cancer Nomogram (MSKCC-BCN) predicts additional nodal 
metastasis in patients with positive sentinel lymph node (SLN). This 
statistical tool does not include HER2 status. It has been shown that 
the interaction covariate between estrogen receptor (ER) and HER2 
status was a determinant of SLN positivity. The purpose of our study 
was to determine if the accuracy of MSKCC BCN could be enhanced 
with new variables.
Patients and methods: Our dataset consisted of 2769 consecutive 
patients treated for operable breast cancer with SLN biopsies between 
2006 and 2009. We selected all the patients (n = 588) with a positive 
SLN who underwent a completion axillary lymph node dissection 
(ALND). The MSKCC-BCN was used to calculate the theoretical 
risk of additional nodal metastasis for all patients. The evaluation 
of the MSKCC-BCN was performed with calibration test (Cox 
method) and performance test (Bleeker). Multivariate analysis used 
a logistic regression model. The input was based on the variables 
found significant in the univariate analysis. Interaction covariate 
between ER and HER2 status was included in the model. Our model 
was then analyzed in terms of discrimination (area under the curve) 
and of calibration (Hosmer-Lemeshow test).
Results: Calibration test showed significant differences between 
the probability of additional nodal disease predicted by the 
MSKCC-BCN and the probability observed in our population for 
the following subgroups of patients: histological grade 3 (p= 0.007), 
lymphovascular invasion (p=0.03), multifocality (p=0.04), positive 
ER (p=0.002), micrometastasis in the SLN (p=0.003), isolated tumor 
cells in the SLN (p=0.02 and positive HER2 (p=0.01). Performance 
test showed significant differences for the following variables: 
histological grade (p= 0.02), size of the SLN metastasis (p=0.04) and 
HER2 status (p=0.01). This shows that the MSKCC-BCN is not well 
calibrated and cannot be used for our population. A multivariate model 
to determine the probability of additional nodal metastasis was defined 
with the following variables: pathologic size of the sentinel node 
metastasis, interaction covariate between the ER and HER2 status, 
number of positive SLN and number of SLN removed [Table 1].
Table 1: Multivariate analysis
Significant variable OR CI p
Macrometastasis 1   
Micrometastasis 0.15 [0.08;0.28] <O.OOOO1
Isolated tumor cells 0.16 [0.08;0.32] <0.00001
ER-HER2- 1   
ER-HER2+ 21.97 [2.22;217.76] 0.003
ER+HER2- 5.99 [0.76; 47.17] 0.003
ER+HER2+ 13.47 [1.48;122.76] 0.003
N positive SLN 1.93 [1.32; 2.82] 0.0006
N SLN removed 0.74 [0.64;0.86] 0.00003
This multivariate model resulted in a nomogram tested on the training 
population. It was discriminating with an area under the curve of 0.76 
[0.720-0.808] and well calibrated (Hosmer-Lemeshow test p= 0.51).
Conclusions: We showed that HER2 status and pathologic size of the 
SLN metastasis are determinant to predict additional nodal metastasis 
after a positive SLN. These two variables were included in a new 
nomogram that could help in the decision-making concerning further 
axillary treatment in these patients. Our model has to be validated 
prospectively in external series to confirm its accuracy.
P3-07-10
Sentinel Lymph Node Navigation Surgery Using Combination 
of Indocyanine Green Fluorescence and Blue Dye for Breast 
Cancer Patients.
Takahashi M, Hayashida T, Jinno H, Kitagawa Y. Keio University 
School of Medicine, Tokyo, Shinjuku, Japan
Background: Sentinel lymph node (SLN) biopsy is now widely 
accepted for staging the axilla in breast cancer patients. Several 
methods are presently used to detect SLNs. Combined use of blue dye 
and radiocolloid has previously been described as a superior method 
for detecting SLNs in breast cancer patients, but radiocolloid is not 
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generally available in Japan. SLN detection guided by indocyanine 
green (ICG) fluorescence could emerge as a new and effective method 
for SLN biopsy. The aim of this study was to evaluate SLN biopsy 
using combination of ICG fluorescence and blue dye methods for 
breast cancer patients.
Material and Methods: We enrolled 75 patients with clinically node-
negative breast cancer. An isosulfan blue dye solution (5ml) was 
injected subcutaneously just above the tumor and in the periareolar 
area after the induction of anesthesia. The injection site was massaged 
for five minutes and ICG (2ml) was then injected subcutaneously just 
above the tumor and in the periareolar area before starting the surgical 
procedure. Subcutaneous lymphatic channels draining from the areola 
to the axilla were visualized with a fluorescence imaging system 
(Photodynamic Eye: PDE, Hamamatsu Photonics Corporation, Japan) 
under fluorescence within several minutes. SLNs were dissected under 
direct visualization supported by fluorescence and dye navigation 
and diagnosed by intraoperative frozen section with hematoxylin and 
eosin staining. Any patient with a positive SLN underwent immediate 
axillary lymph node dissection (ALND).
Results: SLNs were detected in all 75 patients. The fluorescence 
imaging identified 2.6 SLNs in 74 (98.7%) of 75 patients. The blue 
dye identified 1.6 SLNs in 68 (90.1%) of 75 patients. Twelve of the 
75 (16.0%) patients had metastatic SLNs and ALND was immediately 
performed. No metastasis revealed in any non-SLN in eight of these 
12 patients. Metastatic SLNs were detected by the ICG fluorescence 
and not by blue dye in four of these 12 patients.
Discussion: The combination of ICG fluorescence and blue dye 
method had two advantages: it could reveal lymph flow on the surface 
before we determined the skin incision line; and it had a high SLN 
detection rate. In hospitals where radioisotopes are unavailable, a 
combination of the two methods would be advantageous.
Mean Number of Sentinel Lymph Nodes and Detection Rate
Detection Method Mean Number Detection Rate
Dye-Positive 1.6 68/75(90.1%)
Fluorescence-Positive 2.6 74/75(98.7%)
Combined Method 2.6 75/75(100%)
P3-07-11
Multicenter Comparative Study between One-Step Nucleic Acid 
Amplification (OSNA) Whole Node Assay and Standard Frozen 
Section Histology: Intraoperative Molecular Assay for Sentinel 
Lymph Node Metastases in Early Breast Cancer Can Avoid a 
Second Surgery.
Espinosa-Bravo M, Ramos T, Aizpurua Gomez M, Sao Avilés A, Peg 
Carmara V, Sancho M, Gónzalez-Orus JM, Xercavins Montosa J, 
Ramos M, Rubio IT. Hospital Universitario Vall d´Hebron, Barcelona, 
Spain; Hospital Universitario de Salamanca, Salamanca, Spain
Studies on intraoperative assessment of sentinel nodes by frozen 
section in breast cancer have reported low sensitivity rates. Recently, 
a molecular-based procedure to detect lymph node metastases, one-
step nucleic acid amplification (OSNA) assay, has been developed. 
OSNA assay can assess a whole lymph node and yields definitive 
semi quantitative results. The aim of this study was to evaluate the 
ability of intraoperative assessment comparing sentinel lymph node 
(SLN) metastases with OSNA assay versus routine H&E frozen 
section (FS) histology.
METHODS:
A cohort of 478 consecutive patients diagnosed in 2010 with early 
breast cancer in two centers was analyzed. Frozen section was 
performed intraoperatively in 228 patients and OSNA assay in 250 
patients. Patient characteristics were evaluated in both groups and 
rates of metastasis detected by both methods were compared.
RESULTS:
Patients and tumor characteristic are summarized in the table.
Patients and tumor characteristic
Characteristics OSNA (n=250) H&E (n=228) p
Age, median (range) 60 (28-90) 59 (29-95) 0.93
Pathology tumor size. Median (range) mm. 18,9 (1-100) 18,6 (2-120) 0.20
Histology    
Ductal 204 188  
DCIS 16 15  
Lobular 17 16  
Other 13 9 0.20
Multifocal 34 29 0.78
Nuclear grade    
Grade 1 60 44  
Grade 2 103 108  
Grade 3 77 68  
Unknown 10 8 0.32
Oestrogen receptor    
Positive 218 203  
Negative 32 25 0.98
Progesterone receptor    
Positive 193 179  
Negative 56 49  
Unknown 1 0 0.28
Her2/neu status    
Positive 25 16  
Negative 219 197  
Unknown 6 15 0.32
Lymphovascular invasion    
Yes 37 24  
No 208 190  
Unknown 5 14 0.27
Ki 67    
> 15 % 78 54  
< = 15 % 163 156  
Unknown 9 18 0.14
A median of 1,95 SLNs were assessed by FS and a median of 2,06 
SLNs by OSNA (p=0.15). Intraoperative histopathological assessment 
detected 67 SLNs metastasis by FS and 107 SLNs metastasis 
by OSNA assay (p=0.07). There were no differences in rates of 
macrometastasis (54 by FS and 74 by OSNA) and micrometastasis (13 
by FS and 33 by OSNA) (p=0.09). When compared the OSNA assay 
with permanent section, 92 SLNs had metastasis by permanent section 
(63 macrometastasis and 29 micrometastasis) with no statistically 
significant differences (p=0.5).
SLNs metastasis were found in 71 patients (31,1 %) by permanent 
section and in 83 (33,2 %) by OSNA assay (p=0.69).
Axillary lymph node dissection (ALND) for metastatic SLN was 
performed in 148 patients, 79 (31,6 %) in OSNA group and 69 (30,2 
%) in the permanent section group (p=0.68). All patients diagnosed 
by OSNA had a complete ALND during the initial surgical procedure. 
On the other hand, ALND was performed in 51 patients (73,9 %) in 
the permanent section in the initial surgery, and ALND was performed 
in a second surgical procedure in18 patients (26 %), due to false 
negative results of the FS (p<0.001).
CONCLUSIONS:
The OSNA assay can detect SLN metastasis as accurately as 
conventional pathology, with no increased detection of positive SLNs. 
Given the definitive pathology of the SLN intraoperatively, the use of 
OSNA can reduce the need for a second surgery in 26 % of patients 
with breast cancer and a positive SLN.
P3-07-12
Value of Preoperative Ultrasound-Guided Axillary Lymph Node 
Biopsy for Preventing Futile Sentinel Node Procedures in Breast 
Cancer: A Systematic Review and Meta-Analysis.
Diepstraten SC, Sever AR, Buckens CF, Veldhuis WB, van den Bosch 
MA, Mali WP, Verkooijen HM. University Medical Center Utrecht, 
Netherlands; Maidstone Hospital, United Kingdom
Purpose: Women affected with invasive breast cancer generally 
undergo sentinel node biopsy (SNB) of the axilla, which is followed 
by axillary dissection if lymph node metastases are found. This 
systematic review and meta-analysis aims to evaluate the utility of 
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preoperative axillary ultrasound-guided needle biopsy in terms of 
staging the axilla and preventing futile SNB.
Methods: We systemically searched Pubmed, Embase and Cochrane 
through March 14, 2011, for studies addressing preoperative 
assessment of axillary lymph node (ALN) status by axillary ultrasound 
and biopsy. Eligible studies had to report on biopsy indication and 
method, and true and false positive and negative outcomes. A pooled 
estimate was calculated for prevalence of futile SNB (defined as the 
proportion of patients needing secondary ALN dissection after a 
negative axillary ultrasound and biopsy) and sensitivity (defined as 
the proportion of patients with ALN involvement detected by axillary 
ultrasound and biopsy).
Results: Twenty-three studies were included which reported on a 
total of 6205 procedures. The pooled prevalence of futile SNB was 
25% (95% CI = 23% to 27%) and the pooled sensitivity was 51% 
(95% CI = 43% to 59%). There was substantial heterogeneity across 
studies for both futile SNB prevalence (I2 = 60.5) and sensitivity (I2 
= 93.3), which could not be explained by between-study differences 
in biopsy technique, inclusion criteria, biopsy indication or study 
design. Sensitivity was increased in studies with a high prevalence 
of axillary lymph node metastases.
Conclusion: Preoperative axillary ultrasound guided biopsy is a 
useful step in the process of axillary staging as around fifty percent 
of breast cancer patients with axillary involvement can be identified 
pre-operatively and are spared a two step surgical intervention. Still, 
one in four women with a US biopsy ‘proven’ negative axilla have 
ALN involvement on SNB and need to undergo completion axillary 
dissection. New techniques may be able to reduce the prevalence of 
futile SNB.
P3-07-13
Validation and Comparison of Models To Predict Nonsentinel 
Lymph Node Metastasis in Chinese Breast Cancer Patients with 
Positive Sentinel Lymph Nodes.
Chen K, Jia W, Zeng Y, Fan M, Su F, Li S. Sun Yat-sen Memorial 
Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Background: Several models for predicting the risk of nonsentinel 
lymph node (NSLN) metastasis in breast cancer patients with positive 
sentinel lymph nodes (SLNs) have been developed. Independent 
validation of these models in different populations is necessary before 
clinical application. This study aimed to validate and compare these 
models in Chinese patients.
Patients and Methods: A total of 159 breast cancer patients with 
positive SLNs treated at our institution were included. Chi-squared 
tests, RP-ROC, CART and multivariate logistic regression were used 
to analyze the risk factors for NSLN involvement in our population. 
ROC curves, calibration plots and false-negative (FN) rates were 
evaluated for 11 reported models. The threshold of each model for 
classifying patients into the low-risk group was adjusted to render 
the FN rate close to 10%.
Results: In total, 81 (50.9%) patients had at least one NSLN 
involvement. Univariate and multivariate analyses revealed that the 
number of negative SLNs (P<0.01, HR=0.63) and the metastasis size 
of the positive SLNs (P<0.01, HR=1.15) independently predicted the 
NSLN status in our population. The Cambridge and Mou models 
outperformed the others, both with AUCs of 0.73. The other models 
performed as follows: the Mayo, Tenon, MDA, MSKCC, Ljubljana, 
SNUH and Louisville models had AUCs of 0.68, 0.66, 0.66, 0.64, 
0.62, 0.61 and 0.60, respectively. The Stanford and Saidi models did 
not present any discriminative capabilities, with AUCs of 0.54 and 
0.50, respectively. The Cambridge, MSKCC and Mayo models were 
well calibrated. The Ljubljana model did not calibrate well.
Table 1, Linear regression for calibration plots(Y=kX+b)
Models k b P-value R-square Hosmer-Lemeshow test P-value
Cambridge 0.78 0.10 <0.01 0.88 0.61
Mayo 0.64 0.18 <0.01 0.65 0.30
MSKCC 0.59 0.22 <0.01 0.60 0.23
Ljubljana 0.32 0.36 >0.05 0.42 0.04
Y=Actual Probability; X= Predictive Probability; Hosmer-Lemeshow test were performed to test the 
null hypothesis that b=0 and K=1.
With adjusted thresholds, the Mayo model outperformed the others 
by classifying the highest proportion of patients (20%) into the low-
risk group. The Cambridge, Mou and MDA models defined 17.0%, 
14.5% and 15.1% of patients as low-risk, respectively.
Table 2
Models Original Threshold Adjusted Threshold Patients under adjusted 
threshold N(%)
FN rate (%)
Mou Score≤14.0 Score≤17.5 23 (14.5) 9.9
Cambridge P≤10.0% P≤16.0% 27 (17.0) 9.9
Mayo P≤10.0% P<25.0% 32 (20.1) 9.9
Tenon Score≤3.5 Score≤2.5 17 (10.7) 4.9
MDA Score≤0.0 Score≤0 24 (15.1) 12.3
MSKCC P≤10.0% P≤10.0% 15 (9.4) 8.6
Ljubljana P≤10.0% P≤8.0% 19 (11.9) 12.3
SNUH Score≤1.5 Score≤0.41 11 (6.9) 4.9
Louisville Score≤1.0 Score≤1.0 0 (0.0) 0.0
Standford P≤10% N/A
Saidi Score≤2 N/A
Conclusion: The Cambridge and Mou models performed well in 
Chinese patients. ROC curves, calibration plots and FN rates should 
be used together for the accurate evaluation of prediction models. 
The analysis of the clinicopathological features of the targeted 
population is critical for the selection of the most appropriate model. 
The models specifically designed for patients with micrometastases 
or macrometastases of SLNs are needed in the future.
P3-07-14
Sensory Disturbance of the Ipsilateral Upper Arm after Breast 
Cancer Surgery with Sentinel Node Biopsy Alone Compared with 
Axillary Dissection – A Prospective Study.
Ohsumi S, Kiyoto S, Takahashi M, Hara F, Takabatake D, Takashima 
S, Aogi K, Shimozuma K. NHO Shikoku Cancer Center, Matsuyama, 
Ehime, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan
Background: Axillary surgery for breast cancer causes several 
postoperative complications including edema of the ipsilateral 
arm and sensory disturbance of the ipsilateral upper arm. Although 
sentinel node biopsy has been considered as a standard procedure 
for node-negative patients, some complications bother patients even 
after it. Although data regarding the quality of life of patients and/or 
subjective and objective assessment of arm morbidity after axillary 
surgery have been reported, to our knowledge, quite a few data have 
been reported on actual examination of sensory disturbance of the 
ipsilateral upper arm after sentinel node biopsy alone. We report 
comparative data regarding the objective and subjective degrees 
of postoperative sensory disturbance of the ipsilateral upper arm 
examined prospectively between sentinel node biopsy alone and 
axillary dissection.
Patients and Methods: A total of 118 patients, who received breast 
cancer surgery with sentinel node biopsy alone (51 patients)(SN 
group) or axillary dissection (67 patients)(AD group) at NHO Shikoku 
Cancer Center, were prospectively evaluated sensory disturbance 
regarding the following: (a) dysesthesia, (b) paresthesia, (c) degree 
of disturbed tactile sensation, (d) degree of disturbed pain sensation, 
(e) ratio of disturbed area of tactile sensation (defined as (A) length of 
disturbed area/(B) total length of upper arm), and (f) ratio of disturbed 
area of pain sensation (defined as A/B). Patients were either asked 
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res; 71(24 Suppl.) December 15, 2011 Cancer Research362s
about the above or examined for them at one month, 6 months and 1 
year, respectively, after surgery. At surgery it was recorded whether or 
not the intercostobrachial nerve(s) were totally preserved in patients 
who underwent axillary dissection. Unpaired t-test, Mann-Whitney 
U-test and Wilcoxon signed rank test were used to test statistical 
significance.
Results: The mean ages at surgery were 54.7 and 53.7 years in the SN 
and AD groups, respectively (P = 0.66). The mean number of biopsied 
lymph nodes in the SN group was 2.4 (range: 1-5). In 22 patients of 
the AD group the intercostobrachial nerves were totally preserved. 
There was no difference in dysesthesia, paresthesia, and the level of 
disturbed pain sensation between the two groups throughout one year 
after surgery. However, the patients in the SN group showed milder 
disturbed tactile sensation at one and 6 months than those in the AD 
group (P = 0.04 and 0.03, respectively). Both the ratios of disturbed 
area of tactile and pain sensation were statistically significantly lower 
in the SN group than in the AD group throughout one year (P = 0.03 ~ 
<0.0001). The mean ratios of disturbed area of those sensations were 
stable in the SN group over the year (0.03-0.05 for both tactile and 
pain sensations, P > 0.12 for any comparison). On the other hand, 
the mean ratios in the AD group became lower from 0.23 to 0.17 for 
tactile sensation and from 0.20 to 0.13 in pain sensation (P = 0.02, 
and 0.05 for tactile and pain sensations, respectively).
Conclusion: Sensory disturbance of the ipsilateral upper arm after 
sentinel node biopsy alone was much milder than after axillary 
dissection throughout the study period.
P3-07-15
Sequential Peri-Areolar and Peri-Tumoural SPECT/CT 
Lymphoscintigraphy Has Identified High Rates of Discordance 
in Both Axillary and Internal Mammary Sentinel Lymph Node 
Mapping.
Noushi F, Spillane A, Gebski V, Snook K, Gillet D, Cooper R, Allwright 
S, Uren R. Sydney University, Sydney, New South Wales, Australia; 
Mater Hospital, Crows Nest, New South Wales, Australia
Introduction:
The release of the MA20 intergroup trial results has confirmed the 
importance of locoregional radiation on local and distant disease 
control and survival. Sentinel lymph node (SLN) evaluation is the gold 
standard for regional lymph node evaluation and radiation oncologists 
continue to utilize the nodal staging to plan adjuvant locoregional 
therapy. Despite over a decade of experience in SLN evaluation there 
persists a common belief that the lymphatic drainage of the whole 
breast is to anteropectoral axillary lymph nodes. Several different 
lymphoscintigraphy injection techniques are in use with claims that 
they all identify the same axillary sentinel nodes. However this is not 
based on a high level of evidence. The evolution of SPECT/ CT has 
led to the accurate anatomic identification of SLN, hence the different 
lymphoscintigraphy techniques can now be directly compared.
Method:
38 patients underwent double sequential lymphoscintigraphy (peri-
areolar followed by peri-tumoural) separated by 1-7 days. Patients 
were referred by 4 surgeons to 3 separate lymphoscintigraphy centres 
with standardisation of tracer substance (99mTc-antimony sulfide 
colloid), lymphoscintigraphy and SPECT/CT evaluation techniques. 
The degree of discordance in sentinel node evaluation was defined as:
•Type 1 - One study demonstrates SLN(s) in a nodal basin [axilla or 
internal mammary chain (IMC)] and the other study demonstrates 
none. 
•Type 2 - Both studies identified SLN(s) in a nodal basin however 
the SLN(s) are all different.
•Type 3 - Both studies identified SLNs in a nodal basin, however 
some SLN(s) are identical and others not.
Results:
SLN Discordance Total n (%) Type 1 Type 2 Type 3
Axilla 9 (24%) 4 (11%) 4 (11%) 1 (3%)
IMC 14 (37%) 13 (34%) 0 1 (3%)
Total (Axilla and/or IMC) 21 (55%) 
Notably 21 patients (55%) had either axilla or IMC lymphoscintigraphy 
discordance. Two patients had both axilla and IMC lymphoscintigraphy 
discordance. 
The majority of discordance was identified in the IMC. In the 
concordant IMC lymphoscintigraphies neither study demonstrated 
IMC SLN. There were no studies that identified identical IMC nodes 
in both PA and PT lymphoscintigraphy.
Discordant axillary drainage was more evident in patients with 
lateral sector tumours compared to IM discordance with medial 
sector tumours.
Conclusions:
Accurate lymphoscintigraphy is the road map to assist a surgeon 
identify lymph node metastases. In turn accurate staging will 
determine appropriate adjuvant therapy decisions particularly regional 
node irradiation. This study demonstrates a high degree of discordance 
between PA and PT lymphoscintigraphy techniques in 55% of patients. 
Inadequate lymphoscintigraphy can result in unrealized false negative 
results, which could impact patient outcomes and clinical trial results.
P3-07-16
The Efficacy of Arm Node Preserving Surgery Using Axillary 
Reverse Mapping for Preventing Lymphedema in Patients with 
Breast Cancer.
Seo YJ, Hwang MJ, Lee JH, Son GT, Choi JE, Bae YK, Kang SH, 
Lee SJ. Yeungnam University College of Medicine, Daegu, Republic 
of Korea
Background: 
Lymphedema affects over 20% of breast cancer patients undergoing 
axillary dissection. Axillary reverse mapping (ARM) technique to 
identify and preserve arm node during sentinel lymph node biopsy 
(SLNB) or axillary lymph node dissection (ALND) was developed 
to prevent lymphedema. The purpose of this study was to investigate 
the location and the metastatic rate of the arm node, and finally to 
evaluate the short term incidence of lymphedema after arm node 
preserving surgery.
Patients and Methods:
From January 2009 to October 2010, 97 breast cancer patients who 
underwent ARM were enrolled. 2.5ml blue dye was injected in 
ipsilateral upper inner arm. After at least 20 minutes after injection, 
SLNB or ALND was performed in the usual manner and blue stained 
arm nodes and/or lymphatics were identified. We checked arm 
circumference at baseline and average of 8.8 months after operation 
in ALND cases and 13.7 months in SLNB cases. Patients were divided 
into two groups, arm node preserved group (70 patients in ALND, 
10 patients in SLNB) and unpreserved group (13 patients in ALND, 
4 patients in SLNB). The difference of arm circumference between 
preoperative and postoperative was checked in these groups.
Results:
The mean number of identified blue stained arm nodes was 1.4±0.6. 
The arm nodes were found in the inferolateral side of axillary and 
thoracodorsal vessels in 57 patients (58.76%), the inferomedial side 
in 37 patients (38.14%), the superolateral side in 2 patients (2.06%), 
and the superomedial side in 1 patient (1.04%). In the majority of 
patients (92%), arm nodes were located between the lower level of 
the axillary vein and just below the second intercostal brachial nerve. 
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In arm node unpreserved group, 2 patients had metastasis in their arm 
node. The one had a common pathway between the arm node and the 
sentinel lymph node. Another did not have a common pathway, but 
had extranodal extension with N3 metastasis. Among ALND patients, 
in arm node preserved group, the difference of arm circumference 
between preoperative and postoperative in ipsilateral and contralateral 
arm was 0.27cm and 0.07cm, respectively, whereas 0.47cm and 
-0.03cm in unpreserved group, and one lymphedema was found after 
6 months. No difference was found between arm node preserved and 
unpreserved group amoung SLNB patients (0.21cm and 0.39cm in in 
preserved group, 0.2cm and 0.02cm in unpreserved group).
Changes in arm circumference
 Arm node No. Circumference change (cm)    Lymphedma
   ipsilateral p-value contralateral p-value  
SLNB removed n=4 0.20±0.46 0.456 0.02±0.73 0.950 no
 preserved n=10 0.21±1.31 0.625 0.39±1.17 0.321 no
ALND removed n=13 0.47±0.85 0.067 -0.03±1.20 0.910 1 case
 preserved n=70 0.27±1.19 0.057 0.07±0.86 0.477 no
SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection
Conclusion:Arm node preserving was possible in all breast cancer 
patients with identifiable arm node, during ALND or SLNB, except for 
those with high surgical N stage, and lymphedema did not developed 
in patient with arm node preserving surgery. Metastasis was not 
found in arm node preserving group in current results, but need to 
be observed in the ongoing progress.
P3-07-17
Optimal Number of Sentinel Lymph Nodes That Could Avoid 
Completion of Axillary Lymph Node Dissection in Operable 
Breast Cancer.
Salmon RJ, de Ricke Y, Falcou MC. Institut Curie, Paris, France
Background: Axillary lymph node dissection (ALND) has been the 
standard of care for breast cancer patients with sentinel lymph node 
(SLN) metastasis. It is now under discussion since the publications 
of ACOZOG Z0011 and NSABP-32. The 1-3% rate of axillary 
recurrence is very low in these studies, whereas the rate of additional 
nodal metastasis after the completion of ALND varies from 15% to 
35%. The purpose of this study was to determine the optimal number 
of nodes to be removed in order to obtain an axilla free of disease 
after initial surgery.
Patients and methods: 4928 consecutive patients treated for breast 
cancer < 2 cm with primary breast surgery with SNB between 2000 and 
2009 were reviewed from the Institut Curie breast cancer prospective 
database. 1165 patients with a positive SLN (macrometastasis, 
micrometastasis and isolated tumor cells) underwent ALND. The 
proportion of patients with positive ALND was analysed according 
to the total number of sentinel lymph nodes biopsied. Results were 
compared with Chi-square test for qualitative variables and with 
Kruskal-Wallis for quantitative variables.
Results: Among the 1165 patients, 308 (26.4%) had a positive ALND. 
Among them, 81.1% of patients had a macrometastasis in the SLN 
versus 45.6% in the 857 patients with negative ALND (p<0.0001); 
10.8% had a micrometastasis versus 31.4% (p<0.001) and 8.1% of 
patients had isolated tumor cells in the SLN versus 23% (p<0.001). 
The proportion of patients with positive ALND decreased with the 
number of sentinel nodes removed (Figure 1), independently of the 
number of positive SLN. Among the 1165 patients, the rate of patients 
with 5 nodes removed or more and with residual disease in the axilla 
was < 1% (n=11). Those patients could have avoided completion 
ALND, representing 3.6% of the total positive ALND that would 
have been neglected.
Conclusions: We showed that patients with positive SLN have a very 
low risk (<1%) of residual disease in the axilla when 5 nodes or more 
have been removed. This number which is a major component of 
nomograms, could be used as a threshold to avoid completion ALND.
P3-07-18
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Long-Term Outcome of Internal Mammary Lymph Node 
Detected by Lymphoscintigraphy in Early Breast Cancer.
Koo MY, Lee JE, Nam SJ, Yang J-H, Lee SK, Kim S, Choi M-Y, Cho 
DH, Kim J, Lee J, Jung SP. Samsung Medical Ceter, Seoul, Korea
Purpose: The purpose of this study is to determine the long-term 
significance of internal mammary lymph node (IMLN) detected by 
lymphoscintigraphy.
Background: IMLN metastasis is an important prognostic indicator 
in breast cancer. However, the necessity of internal mammary sentinel 
lymph node (IMSLN) biopsy for accurate staging, for choosing 
adjuvant treatment, and as a prognostic indicator, has remained 
controversial.
Methods: From January 2001 until December 2006, 525 female 
breast cancer patients underwent radical surgery after preoperative 
lymphatic scintigraphy. We retrospectively analyzed the follow-up 
results, recurrences and deaths of all patients.
Results: There was no significant difference in clinicopathologic 
characteristics between the axilla and the IMLN group. The median 
follow-up period was 118.8 (range, 7-122) months in the axilla group 
and 107.7 (range, 14-108) months in the IMLN group. During the 
median follow-up period, the breast cancer-related death rate in the 
axilla group was 3.6%, which was not significantly different from 
that of the IMLN group (1.3%) (P = 0.484). The five-year survival 
rates (5YRS) did not differ between the two groups (P = 0.306). 
The overall recurrence rate and the locoregional (LR) recurrence 
rate also did not differ between the two groups (P = 0.835 and P = 
0.582, respectively. The recurrence rate of IMLN (both ipsilateral and 
contralateral) metastasis was very low, accounting for 0.5% in the 
axilla group and 1.3% in the IMLN group (P = 0.416).Conclusion: 
The long-term follow up results showed that there was no significant 
difference in both overall outcome and regional recurrence between 
the two groups. Therefore, the necessity of identification of nodal 
basins outside the axilla or the necessity of IMLN sentinel biopsy 
should be reconsidered.
P3-07-20
An Independent Assessment of Seven Nomograms for Predicting 
the Probability of Additional Axillary Nodal Metastasis after 
Positive Sentinel Lymph Node Biopsy in a Cohort of British 
Breast Cancer Population.
Nadeem RM, Gudur LD, Saidan ZA. Lancashire Teaching Hospitals 
NHS Foundation Trust, Chorley, United Kingdom
Background: Axillary lymph node dissection (ALND) is currently 
the recommended procedure in patients with positive sentinel lymph 
node (SLN) biopsy. A significant proportion of patients with positive 
SLNs will not have any additional metastasis in non-sentinel lymph 
nodes (NSLNs). Nomograms could identify a subgroup of patients 
with low risk of further disease in whom completion ALND can be 
avoided. The aim of this study is to assess the accuracy of currently 
available seven nomograms in a cohort of British breast cancer 
population.
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Methods: 138 patients with positive SLNs who underwent completion 
ALND between October 2006-April 2011 were identified. Multiple 
pathological variables including the histological size of the SLNs 
metastasis were analysed. Data was then used to calculate the 
probability of further metastasis in non-SLNs according to the seven 
nomograms that are currently in use: MSKCC, Cambridge, Turkish, 
Stanford, MDACC, Tenon and MOU models.
The area under the receiver-operator characteristic (ROC) curve 
(AUC), 95% confidence intervals, false negative and positive rate 
were calculated for each nomogram. Subgroup analysis includes 
pathological tumour size (< 2 cm and >2 cm) and macro- or 
micrometastasis in SLNs. AUC value > 0.80 has an excellent 
discriminative power.
Results: 56 of 138 patients (41%) had additional metastasis in non-
SLNs.
AUC values with 95% confidence intervals and false negative rate 
are shown in table 1.
table 1 Nomograms with AUC values
Nomograms MSKCC Cambridge Turkish Stanford MDACC Tenon MOU
AUC values 0.68 0.68 0.70 0.69 0.56 0.63 0.74
95% CI 0.59-0.78 0.58-0.77 0.61-0.79 0.60-0.78 0.43-0.69 0.54-0.72 0.65-0.82
False -ive rate 
for ≤ 10% 
Probability
0/3(0%) 2/8(25%) 9/47(19%) 1/5(20%) 2/4(50%) 2/25(8%) 0/12(0%)
46/138(33.3%) had tumour size < 2cm and 18/46( 39 %) had 
additional NSLNs metastasis. AUC values for the subgroups are 
shown in table 2.
table 2 Subgroups analysis
Tumour size ≤ 2 cm MSKCC Cambridge Turkish Stanford MDACC Tenon MOU
AUC values 0.68 0.62 0.69 0.66 0.46 0.71 0.75
Tumour size > 2 cm 92/138(67.3%) had tumour size >2 cm and 38/92( 
41 %) had additional NSLNs metastasis
AUC values 0.71 0.70 0.70 0.76 0.54 0.61 0.77
Macrometastasis  
in SLNs
119/138(86%) had macrometastasis in SLNs and 
55/119( 46.2 %) had additional NSLNs metastasis
AUC values 0.66 0.66 0.68 0.65 0.56 0.57 0.70
Macrometastasis  
in SLNs with  
tumour size > 2 cm
92/138(66.7%) had tumour size>2cm 
with macrometastasis, 37/92(40%) 
had additional NSLNs metastasis.
AUC values 0.70 0.70 0.66 0.72 0.50 0.55 0.74
19/138(14%) who had micrometastasis in SLNs, additional non-
SLNs metastasis was seen in only one patient and AUC values were 
imprecise.
Subgroup analysis identified 6 patients with micrometastasis and 
tumour size < 2 cm, none had additional NSLNs metastasis so AUC 
values cannot be computed. 19/138(14%) who had extracapsular 
extension, additional non-SLNs metastasis was seen in 12/19(63%).
Conclusion: MOU nomogram was more predictive than the other 
nomograms with a better AUC value and false negative rate. 
Subgroup analysis also shows persistently better AUC value for MOU 
nomogram. None of the models were able to achieve an AUC value 
> 0.80 in a cohort of British breast cancer patients.
P3-07-21
Sentinel Lymph Node Metastasis Are More Likely To Develop in 
Triple Positive Breast Cancer Patients without Compromising 
Disease Free Survival.
Rubio IT, Espinosa-Bravo M, Cebrecos I, Sao A, Peg V, Di Cosimo 
S, Cortes J, Xercavins J. Hospital Universitario Vall d´Hebron, 
Barcelona, Spain
Background. Lymph node metastasis are the most significant 
prognostic factor for breast cancer (BC) patients and the use of sentinel 
lymph node biopsy (SLN) has generated an increased detection of 
positive nodes. In the last years, molecular subtypes have provided 
additional information on local recurrence and survival in BC patients. 
The objective of this study is to evaluate the correlation between 
axillary SLN metastasis and molecular subtypes and whether this 
may have prognostic implications.
Methods. A total of 497 patients with clinically node negative T1-T3 
breast cancer underwent SLN biopsy from 2005 to 2009. Patients 
were divided in two groups depending on the timing of SLN biopsy. 
Patients were classified according to ER/PR/Her2 status as (ER/PR/
HER2 + (TP), ER/PR/HER2 – (TN), ER/PR/ + HER2 - and ER/PR - 
HER2 +). For SLN metastasis the following variables were tested in 
univariable and multivariate models: age, tumor grade, tumor type, 
and the combined hormone receptors and HER2.
Results: The SLN was positive in the surgery first group in 127 of 429 
patients ( 29.6 %) while in 27 patients (34.7%) in the neoadjuvant 
group (p = 0.08). Forty patients (8.1%) were classified as TP, 25 
(5.1%) as ER/PR – HER2 +, 364 (73.2%) as ER/PR+ HER2 – and 
68 (13.6%) as TN. Triple positive BC patients were more likely to 
have axillary SLN metastasis compared to other molecular subtypes 
(p < 0.006). Multivariate logistic regression revealed age (< 50 years) 
and TP tumors to be independent predictors of SLN metastasis. Odds 
ratio (OR) for TP vs other molecular subtypes was 3.646 (IC 95% 
1.566-8.488). OR for age < 50 years was 2.353 (IC 95% 1.554-3.559). 
Disease free survival in TP patients tended to be longer compared to 
ER/PR - Her2 + and TN patients.
Conclusions. Her 2 overexpression favours SLN metastasis in ER/PR 
positive tumors over other ER/PR status. Even with increased SLN 
metastasis, TP breast cancer patients do better than TN and ER/PR 
-/Her2 positive patients. Molecular subtype classification may holds 
more potential value in the decision-making process in patients with 
BC than the currently staging system.
P3-07-22
Combined Approach for Staging the Axilla in Breast Cancer 
Patients with Clinically (-)Nodes Versus Sentinel Node Biopsy 
Alone.
Patel RK, Krol VV, Cibull ML, McGrath PC, Fjällskog M-L, 
Pirruccello EA, Szabunio AL, Samayoa LM. University of Kentucky, 
Lexington, KY; Uppsala University, Uppsala, Sweden; VAMC, 
Lexington, KY
Background: Prognostic information and local control for managing 
the majority of clinically node (-) breast cancer patients may be 
achieved by sentinel node biopsy (SNB) alone and/or limited 
axillary dissections (LAD). Currently, 20 - 30% of clinically node (-) 
patients have unnecessary surgery. This study compares the results 
from staging the axilla using SNB alone versus using the combined 
approach shown below.
Methods: Clinically node (-) patients (n=176) were subclassified 
according to their primary tumor histology, axillary ultrasound (US) 
data, and US guided Fine Needle Aspiration (US-FNA) results, as 
follows: Low Risk (LR) for axillary metastasis (n = 62); High Risk 
(HR) with normal axillary US (n = 17); HR with US suggesting 
minimal N1a disease (n = 23); HR with US suggesting N1a disease 
(n = 52); HR with US suggesting N2-3 disease (n = 22). All patients 
with (+) SNB or (+) US-FNA had Axillary Lymph Node Dissections 
(ALND). The number of (+) Sentinel Nodes (SN), Non Sentinel 
Nodes (NSN) and (+) LN after a (+) US-FNA from each patient 
category was correlated with corresponding preoperative data. HR 
patients were defined as having grade II tumors ≥ 1.5 cm and grade 
III tumors > 1.0 cm. US abnormalities in the axilla were interpreted 
as follows: minimal N1a disease equivalent to cortical defects < 5mm 
in 1-3 LN; N1a disease, cortical defects > 5mm in 1-3 LN and N2-3 
disease, complete nodal replacement in ≥ 1 LN. LAD refers to level 
I dissections (1-5 LN).
Results: Three subgroups of patients were identified: Group A, 
patients not requiring ALND (128/176 = 72%); Group B, patients 
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requiring ALND bypassing SNB (22/176 =13%) and Group C, 
patients requiring LAD (26/176 = 15%). Preoperatively these 3 groups 
were categorized as follows: Group A included patients at LR for 
axillary metastasis, HR patients with normal axillary US, HR patients 
with axillary US suggesting minimal N1a disease and HR patients 
with axillary US suggesting N1a disease with (-) US-FNA; Group B 
included HR patients with axillary US suggesting N2-3 disease and (+) 
US-FNA; Group C included HR patients with axillary US suggesting 
N1a disease and (+) US-FNA. The post ALND characteristics for 
these 3 groups are summarized as follows: all Group A patients had 
N1a disease represented by ≤ 2 (+) LN, 94% (17/18) were SN (+) only, 
85% (15/18) with 1 (+) LN and 15% with 2 (+) LN; in Group B, 20 
patients had N2-3 disease and 2 patients had N1a disease, all Group 
B patients had > 2 (+) LN; in group C, 20 patients had N1a disease 
and 2 patients had N2 disease, and 77% had single (+) node disease.
Conclusion: By following this approach a more patient oriented 
method for staging the axilla can be implemented as follows: 1. SNB 
alone for LR patients and for HR patients with axillary US findings 
suggesting no axillary disease, minimal N1a disease and/or N1a 
disease with (-) US-FNA; 2. ALND for HR patients with axillary 
findings suggesting N2-3 disease and a (+) US-FNA; 3. LAD for HR 
patients with US findings suggesting N1a disease and (+) US-FNA. 
This approach would result in a 38% (48/176) reduction in the number 
of SNB and a 30% (22/66) reduction in the number of ALND. This 
translates in to $200,000 (30 - 40%) in procedure-associated savings.
P3-07-23
Intraoperative Molecular Analysis of Sentinel Lymph Nodes 
in Breast Cancer Using One Step Nucleic Acid Amplification 
(OSNA).
Chaudhry A, Massey E, Jenkins M, Calder C, Winters ZE, Rayter Z. 
Bristol Royal Infirmary, Bristol
Introduction: The OSNA method for the intra-operative analysis of 
sentinel lymph nodes (SLNs) in breast cancer has been introduced in 
3 UK centres since 2007. The methodology uses a polymerase chain 
reaction to quantitate CK19, a cytokeratin specific to breast duct 
epithelial cells. OSNA provides “real-time” results on SLNs analysed 
as negative (-) or positive with either micro (+) or macrometastases 
(++).
Method: This is a single-centre prospective pilot study of all patients 
undergoing breast cancer surgery including sentinel node biopsy from 
February 2010 to May 2011. SLN identification was performed using 
a dual localization technique with peri-areolar Patente V blue dye 
and Tc99 radio-active isotope. SLNs were cut into 4 slices labeled 
as A, B, C and D, respectively after the removal of all perinodal fat. 
In all SLNs, slices A and C were processed in OSNA and slices B 
and D underwent histological assessment by H&E staining. Slices 
A and C were prepared for OSNA analysis with the required reagent 
(Lynorhag), followed by centrifugation and homogenization. 
Micro-pipetted samples were processed against control specimens, 
to produce normalized and quantitative curve results. The primary 
outcome measure was to correlate the results of OSNA with 
histopathology for each SLN. A negative SLN resulted in no further 
axillary surgery compared to a level I axillary sampling following 
the presence of micrometastases and a level II dissection following 
the detection of macrometastases. The total duration of OSNA for 
all SLNs was recorded in relation to delays in the completion of the 
intended breast surgery in each patient.
Results: 251 SLNs were analysed in 112 patients (mean age of 55 
years). Comparisons between OSNA and histopathology were made 
in 116 nodes (34 SLNs analysed by OSNA only). SLN positivity 
was evident in 30 nodes (26%) comprising either macrometastases 
(n=13) or micrometastases (n=17). The OSNA sensitivity and 
specificity of was 93% and 89%, respectively. Accounting for a 
tissue allocation bias in the presence of micrometastases only, the 
specificity rose to 94% if these cases were excluded in the analysis. 
There was no correlation between SLN positivity and tumour grade, 
size or receptor status. The time to OSNA results were analysed in 
75 patients undergoing 45 wide local excisions (WLE), of which 18 
were wire localized; 23 mastectomies and 22 SLNB alone. The mean 
time for OSNA was 40.5, 51.8, 54 and 61.5 minutes for 1,2,3, and 
4 sentinel lymph nodes respectively. Operation time was prolonged 
by a median of 20 minutes (range -48 to +65 minutes) WLEs were 
delayed by the greatest time
Exclusions: Nodes that were not available for histological comparison 
i) nodes weighing <0.05g (n=34) were processed whole. ii) 
Departmental agreement from mid March 2011 to process nodes 
whole via OSNA (n=51); 6 had micro or macrometastases.
Conclusion: OSNA prevented staged axillary surgery in 24 (21%) 
of patients. A median time of 20 minutes for the OSNA procedure 
is comparable with acceptable operating times. Current experience 
supports the use of OSNA for each individual whole SLN analysis. 
The pilot data has resulted in a prescribed change in policy to analyse 
the whole SLN using this technique.
P3-07-24
Accuracy and Cost Effectiveness of Frozen Section Examination 
of the Sentinel Lymph Node (SLN) in Ductal Carcinoma In Situ 
(DCIS) of Breast.
Ballehaninna UK, Santoro E, Schaefer SS, Blackwood MM, 
Chamberlain RS. Saint Barnabas Medical Center, Livingston, NJ; 
Maimonides Medical Center, Brooklyn, NY; Saint George’s University 
School of Medicine, West Indies, Grenada; University of Medicine 
and Dentistry of New Jersey, Newark, NJ
Background: SLN biopsy (SLNB) can avoid reoperation for axillary 
staging in DCIS patients upstaged to invasive breast cancer (IBC) 
following resection. Intraoperative frozen section (IFS) examination 
of the SLN is a widely accepted tool for IBC patients in order to 
select candidates for axillary lymph node dissection (ALND), and 
avoid reoperation. Until now, utility of IFS in DCIS patients has not 
been addressed.
Methods: Data from DCIS patients undergoing resection with SLNB 
(2000-11) was analyzed to determine the utility and cost of IFS exam 
and its impact on axillary management. A binomial regression analysis 
was performed to assess factors predictive of IFS positivity and SLN 
metastases (SLNM).
Results: 401 patients (core biopsy, N=276, or excisional biopsy, 
N=125) underwent partial (N=84) or total mastectomy (N=317) 
with SLNB. 77 patients (19.2%) were upstaged to IBC. SLNM 
were identified in 24 patients (5.9%). Immunohistochemistry (IHC) 
positive individual tumor cells (ITCs) was the most common pattern 
of SLNM (N=12, 50%), SLN micrometastasis (SLNmi) was identified 
in 9 patients (37.5%) and macrometastases in 3 patients (12.5%). IFS 
exam was positive in only 5 patients (1.2%) with a sensitivity and 
specificity of 20.8% and 100%. IFS was negative in 396 patients 
(98.7%) yielding a false negative rate (FNR) of 79.2%.
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Table 1: Accuracy of SLN examination methods in DCIS patients (N=401) to identify SLN 
metastasis (N=24)
Method Sensitivity (%) Specificity (%)
Positive  
Predictive  
Value (%)
Negative  
Predictive  
Value (%)
FNR (%)
IFS 20.8% (5/24) 100 % (377/377) 100 % (5/5) 95.2 % (377/396) 79.2% (19/24)
Hematoxylin  
and Eosin
62.5 % (15/24) 100 % (377/377) 100 % (15/15) 97.6% (377/386) 37.5 % (9/24)
Immunohisto- 
chemistry  
(N=398*)
100 % (20/20*) 100 % (20/20*) 100 % (20/20*) 100 % (20/20*) 0
* In 3 patients with SLN macrometastasis, IHC was omitted.
IFS costs $300,480 in DCIS patients of which only $2,970 was 
applicable to IFS positive patients (N=5). 11 of 24 patients with SLNM 
underwent ALND, revealing only 1 patient with further metastasis. 
Presence of IBC or DCIS with micro-invasion, multi-focal/multi-
centricity, and advanced tumor stage were associated with SLNM 
(p<0.05), however no clinico-pathologic variables were predictive 
of IFS positivity.
Table 2: Cost analysis of IFS of SLN in DCIS patients
Procedure/CPT code Cost (US $)
Total charges in US$ (= Number of nodes 
x cost)
IFS/88331 & 88332 $210
IFS + ve = 7 x 210 = $1,470 IFS – ve = 851 x 
210= $178,710 Total= 858 x 210 = $180,180
Operating room charges (mean 
operative time- 20 minutes x 
operating room charges/min)
$15/min or $300/20 
min
Total charges in US$ (= Number of patients 
x cost) IFS +ve = 5 x 300 = $1,500 IFS –ve 
= 396 x 300 = $ 118,800 Total = 401 x 300 = 
$120,300
Total  IFS +ve = $2,970 IFS –ve = $ 297,510 Total 
= $ 300,480
CPT, common procedural terminology code
Conclusions: Most common patterns of SLNM in DCIS (ITCs/
SLNmi) were identified only on routine pathologic assessment. Utility 
of IFS examination in DCIS patients is limited by poor sensitivity, 
high FNR and increased costs. Higher axillary nodal metastases are 
rare and prognostic significance of SLNmi/ITCs in DCIS is unproven. 
IFS examination of SLN in DCIS can be safely omitted and ALND 
should be performed only for SLN macrometastases.
P3-07-25
Sentinel Lymph Node Mapping in Breast Cancer after Primary 
Chemotherapy.
Bonardi S, Andreis D, Allevi G, Aguggini S, Milani M, Generali 
D, Bersiga A, Brizzi MP, Dogliotti L, Berruti A, Bottini A. Azienda 
Ospedaliera Istituti Ospitalieri, Cremona, Italy; Azienda Ospedaliera 
Universitaria San Luigi di Orbassano, Università di Torino, 
Orbassano, Torino, Italy
Background: The High false negativity rate and the possible of 
interference of primary systemic treatment (PST) and biopsy on the 
lymphatic drainage in the breast and axilla are the disadvantages of 
sentinel lymph node biopsy (SNB) after PST. The primary aim of our 
study was to evaluate success rate for identification and isolation of 
sentinel lymph node (SLN) in patients treated with PST. Secondary 
aims were to verify if chemotherapy and biopsy can really alter the 
lymphating drainage, and to identify biological and clinical factors 
that can influence the accuracy of this technique.
Methods: Between June 2000 and April 2007, 176 consecutive 
operable or locally advanced breast cancer patients (T1-4N0-1M0) 
treated with antracyclin-based PST were enrolled in this single 
Institution study . Before performing a surgical biopsy and starting the 
treatment a lymphatic mapping was performed and the skin projection 
of the SLN location was then marked with permanent ink, with the 
aim to verify if the SLN marked did not change after biopsy and PST.
Results: The SLN was removed in 164 patients, with an identification 
rate of 93.2% (95% confidence interval (CI) = 89.4-96.9%). Fifty 
patients (30.5%) had metastatic involvement at SNB, and in 21 
(42.0%) of them the SLN was the only positive node. Nine patients 
(5.5%) had a false negative SLN. The false-negative rate was 15.3% 
(95% CI = 7.1-32.9%). The SNB revealed a sensitivity of 84.7% (95% 
CI = 73.0-96.4%), an accuracy of 94.5% (95% CI = 90.1-99.0%) and 
a negative predictive value of 92.1% (95% CI = 85.8-98.4%). In 163 
patients (99.4%) the SLN marked at baseline was the same removed 
at the end of treatment, while only in 1 case (0.6%) a different SLN 
was identified by the lymphatic mapping performed with radioactive 
colloid. According to clinical and tumor characteristics the rate of 
identification and removal of SNB was higher in patients aged <50 
(95.6%) vs >50 (91.6%), with clinical node negative (95.1%) vs 
positive (88.6%) and with lower grade G2 (98.0%) vs G3 (91.2%). 
False negative rate of SNB was higher in patients aged >50 (17.9%) 
vs <50 (10.0%) and with clinical node negative (17.1%) vs positive 
(12.5%). Lymph node involvement was significantly associated with 
baseline ER positivity (p=0.00595 Chi-square test).
Conclusion: The identification rate, sensitivity and accuracy do not 
differ from other study of SNB after PST. The false-negative rate is 
still high and we are performing analysis to identify biological and 
clinical features that can influence the accuracy of this technique. To 
our knowledge this is the first study with an in vivo demonstration 
that chemotherapy and biopsy do not alter the lymphatic drainage 
of the breast. We are perfoming exploratory analyses to evaluate the 
influence of false-negative rate of SNB on overall survival (OS) and 
progression free survival (PFS).
P3-07-26
How Generalizable Is the Patient Population Enrolled in 
ACOSOG Z11?
Lannin DR, Killelea BK, Grube BJ, Horowitz N, Chagpar AB. Yale 
University School of Medicine, New Haven, CT
Background
The recently published Z11 trial of observation vs. axillary dissection 
for patients with a positive sentinel lymph node showed amazingly 
low axillary recurrence rates in both groups, and has the potential to 
dramatically alter practice. However questions remain about whether 
the Z11 population is representative of the larger population of breast 
cancer patients.
Methods
An institutional database was queried to identify all patients who 
underwent sentinel node biopsy at our breast center from 2004 
to 2010. These cases were retrospectively reviewed to determine 
the percentage of patients who would have met the Z11 eligibility 
requirements, and the demographics and outcomes for this subset 
were compared to those for Z11.
Results
Out of 1215 patients undergoing sentinel node biopsy, 282 (23%) 
had at least one positive sentinel node. However when patients were 
eliminated who had T3 or T4 tumors, more than 2 positive sentinel 
nodes, neo-adjuvant chemotherapy, or who underwent mastectomy, 
only 88 remained who would have been eligible for Z11 (31% of 
those with a positive sentinel node). These patients are compared to 
the Z11 patients in the following table.
Comparison of Z11 trial and our database for T1 - T2 patients with 1 or 2 positive SN’s and no 
neo-adjuvant chemotherapy
 Z11 (n=891) Our lumpectomy (n=88) Our mastectomy (n=86)
Median pt. age 55 57 53
Mean tumor size (cm) 1.7 1.9 2.4
% T2 31% 26% 52%
% micrometastases 41 17 12
% pos non-sn’s* 27 30 45
Total pos nodes*    
1 58% 61% 48%
2-3 27% 18% 29%
4 or more 14% 20% 23%
* for axillary dissection group in Z11
Our lumpectomy patients were generally quite similar to those of Z11 
except ours had a lower percentage of micrometastases and a higher 
percentage of 4 or more positive nodes. As with most other published 
prediction models, the chance of having 4 or more positive nodes 
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in our patients was directly proportional to tumor size and number 
of positive sentinel nodes, and inversely proportional to number of 
negative sentinel nodes.
Conclusions
A relatively small percentage of node positive patients at our 
institution actually met the eligibility requirements for Z11, but this 
subset was similar in most respects to the Z11 population. We have 
developed an algorithm that can be prospectively tested that will allow 
the majority of these patients to forego axillary dissection but that 
will exclude patients most likely to have 4 or more positive nodes.
P3-07-27
ROCK II Expression Can Be a Potential Marker of Non-Sentinel 
Lymph Node Metastasis in Breast Cancer Patients with Sentinel 
Lymph Node Involvement.
Shigematsu H, Taguchi K, Shiotani S, Kawaguchi H, Nishiyama K, 
Ohno S, Okada M. Hiroshima University Hospital, Hiroshima, Japan; 
National Kyushu Cancer Center, Fukuoka, Japan
(Background) It becomes controversy whether axillary lymph node 
dissection is mandatory performed for breast cancer patients with 
positive sentinel lymph nodes (SNs), given that more than half of 
patients with a positive sentinel lymph biopsy have no metastasis in 
non-sentinel lymph nodes (non-SNs). Rho-associated kinase (ROCK) 
is essential part in tumor invasion and metastasis, and its activation is 
reported to be potential marker of lymph node metastasis.
(Purpose) The purpose of this study was to evaluate the expression of 
ROCK II as predictive factor of non-SNs metastasis in breast cancer 
patients with positive SNs.
(Patients and Method) ROCK II protein expression was determined 
using immunohistochemical analysis on formalin-fixed and paraffin-
embedded primary tumor samples composed of 119 SN-positive 
patients who underwent axillary lymph node dissection in National 
Kyushu Cancer Center. ROCK II expression was defined positive 
when there was strong intensity of cytoplasm staining.
(Results) ROCK II expression tended to be strong in invasive area, 
but weak in intraductal component. Of the 119 patients, 35 (29%) 
were determined to be positive for ROCK II expression. Patients 
with ROCK II positive tumor had significantly higher probability of 
non-SNs metastasis compared with patients with ROCK II negative 
tumor (20/35, 57% for positive; 28/84, 33% for negative, p=0.02). In 
multivariate analysis, positive ROCK II expression was significantly 
associated with non-SNs metastasis even after accounting for other 
predictive factors including tumor size, lymphovascular invasion, 
number of SNs metastasis and extra-capsule invasion (positive vs. 
negative, HR 2.6, p=0.04).
Incidence of positive non-SNs in relation to clinicopathological factors in multivariate analysis
Clinicopathological factors number Positive non-SNs (%) P value, multivariate
tumor size   0.47
2cm< 61 34.4  
2cm≥ 58 46.6  
tumor grade   0.06
grade1,2 84 36.9  
grade3 35 48.6  
LVI   0.83
no 41 36.6  
yes 78 42.3  
ER   0.97
positive 94 38.3  
negative 25 48  
HER2   0.17
negative 104 38.5  
positive 15 53.3  
ROCK II expression   0.04
negative 84 33.3  
positive 35 57.1  
size of SLN metastasis   0.17
micrometastatsis 31 19.4  
macrometastasis 88 47.7  
extra capusula invastion   0.002
no 74 28.4  
yes 45 60.0  
number of SLN metastasis   0.006
1 78 29.5  
2≤ 41 61  
(Conclusion) These findings suggest that ROCK II expression can be 
a predictive factor for non-SNs involvement in breast cancer patients 
with SNs metastasis.
P3-07-28
One Step Nucleic Acid Amplification (OSNA) for Intraoperative 
Molecular Detection of Lymph Node Metastases and Micro-
Metastases in Breast Cancer.
Babar MM, Madani R, Jackson P, Irvine T, Layer G, Kissin M. Royal 
Surrey County Hospital, Guildford, SU, United Kingdom; University 
of Surrey, Guildford, SU, United Kingdom
Introduction: Ideally, intraoperative sentinel lymph node analysis in 
breast cancer should be automated, concordant with histopathology 
and practically applicable. One step nucleic acid amplification 
(OSNA), a highly sensitive intraoperative assay of cytokeratin 19 
mRNA, is used for the detection of sentinel lymph node (SLN) 
macro- and micro-metastases in breast cancer. Guildford adopted 
the intraoperative OSNA “live” in December 2008 after undertaking 
a multicentre evaluation of its accuracy and high concordance with 
histopathology and here we present our two year data since its 
introduction.
Methods: Data was collected prospectively from 2008-10. All patients 
eligible for sentinel node biopsy were offered OSNA and operations 
were performed by five consultant breast surgeons. On detection of 
micro-metastasis (+) and positive but inhibited metastases (i+), a level 
1 axillary nodal clearance (ANC) and for a macro-metastasis (++), a 
level 3 ANC was performed.
Results: 471 patients had 999 SLN analysed, median age being 61. All 
except one were females. 72% (n=340) had wide local excision, 26% 
(n=120) underwent mastectomy and 2% (8) SNB alone. Mean tumour 
size was 18.3 mms. 80% (n=371) of the cases were IDC and 55% 
(n=256) had grade II tumour. 34% (n=161/471) had positive SLN who 
had further ANC. Of these, 48% (n=78/161) had macro-metastases, 
37% (n=59/161) had micro-metastases and 15% (n=24/161) had 
positive but inhibited results. 17% (10/59) of the patients with micro-
metastases had positive non-SLN (NSLN), four (4/59, 6.8%) had four 
positive nodes (SLN+NSLN) thus receiving adjuvant radiotherapy. 
8% (2/24) of those with positive but inhibited results and 39% (30/78) 
of those with macro-metastases had positive NSLN.
Conclusion: Over a third of patients had OSNA positive SLN and 
underwent axillary surgery at the same operation. This technique 
eliminates the need for a second operation in sentinel lymph node 
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positive patients and avoids the anxious wait for results in all, 
streamlining the patient’s cancer journey. OSNA upstages patients 
with micro-metastases and long term studies are needed to determine 
the clinical relevance of molecular micro-metastatic disease.
P3-07-29
Validating the Lymph Node Ratio as a Prognostic Indicator 
among South East Asian Breast Cancer Patients.
Saxena N, Hartman M, Bhoo Pathy N, Aziz R, Siew EL, Lee SC, Yip 
CH, Verkooijen HM. National University of Singapore, Singapore, 
Singapore; Faculty of Medicine, University of Malaya, Kuala Lumpur, 
Malaysia; University Medical Center Utrecht, Utrecht, Netherlands; 
National University Cancer Institute, National University Health 
Systems, Singapore, Singapore
Background: Several studies in Caucasian settings have suggested that 
the lymph node ratio (LNR, i.e. the ratio of the number of positive 
nodes to the total number of nodes excised) is a superior prognostic 
indicator for breast cancer as compared to the absolute number 
of nodes involved (pN stage). This study validates the prognostic 
performance of LNR in the South East Asian setting.
Methods: All patients diagnosed with non-metastatic invasive breast 
cancer at the National University Hospital (Singapore) or University 
of Malaya Medical Center (Kuala Lumpur) between 1990 and 2007 
and with information on axillary nodes removed and involved were 
included for analysis (n = 1589). Multivariate Cox regression analysis 
was performed to evaluate the prognostic value of the LNR [low (> 
0 and <0.2), intermediate (0.2 to 0.65) and high risk (>0.65 to 1)] 
and pN staging [pN1, pN2 and pN3] for all cause mortality. Patients 
staged pN0/LNR 0 were excluded from analysis.
Results: According to the LNR classification, 758 patients were 
categorized as low risk, 574 as intermediate risk and 257 as high risk 
LNR. For classic pN staging, 879 were pN1, 447 pN2 and 263 pN3. 
Women in the intermediate risk category (0.2 to 0.65) had a 1.5 fold 
increased risk of death [Adjusted hazard ratio [HRadj] of 1.5 (95%CI, 
1.2 to 1.9]), and women with high risk (>0.65 to 1) LNR had a 3.2 
fold increased risk of death [HRadj of 3.2 (95%CI, 2.6 to 4.1)] as 
compared to the low risk women (>0 and <0.2). Similarly, women 
with pN2 disease had a 1.9 fold increased risk of death [HRadj of 
1.9 (95%CI, 1.5 to 2.4)], and women with pN3 disease had 3.1 fold 
increased risk of death [HRadj 3.1 (95%CI, 2.5 to 3.9)] compared 
to pN1 patients.
Conclusion: Among South East Asian breast cancer patients, both the 
Lymph Node Ratio and the pN Staging system seem to be equally 
good at predicting all cause mortality.
P3-07-30
Applying the Findings of the Z11 Trial to a UK Practice.
Chalmers CR, Mallon EA, Stallard S, Doughty JC, Wilson CR. Western 
Infirmary, Glasgow, Scotland, United Kingdom
Introduction: The finding of a positive sentinel node is currently 
managed by further Level III axillary lymph node clearance (ALNC). 
The rationale behind this approach is that of local disease control, but 
there is little evidence that axillary lymph node clearance results in 
a reduction in axillary recurrence or in mortality. ALNC is however 
associated with increased morbidity (lymphoedema, nerve damage, 
reduced shoulder function) and significantly prolongs hospital stay. 
The Z11 trial suggests that ALNC following positive sentinel node 
biopsy does not result in lower axillary recurrence rates compared 
to the group in whom clearance was not undertaken and has obvious 
implications for evidence-based practice. The Z11 trial has strict 
inclusion criteria (T1/T2 tumour, breast conservation surgery) with 
all patients receiving adjuvant whole breast radiotherapy and systemic 
chemotherapy or endocrine therapy. For patients who do not meet the 
patient population of Z11, such as women undergoing mastectomy, 
the Sloane-Kettering predictive normogram provides an estimate of 
risk for residual axillary disease after positive sentinel node biopsy 
and the estimate of this risk may inform the clinical decision to clear 
the axilla based on individual cancer characteristics.
Methods: Our population comprises both symptomatic and screening 
patients, with an axillary positivity rate of approximately a third. This 
study was undertaken to assess the impact that Z11 would have on 
our practice. Our prospectively maintained records were searched 
for ALNC patients treated between 2003 and 2011. We assessed 
the number of node-positive patients conforming to Z11 criteria 
and the number who demonstrated residual axillary positivity at 
clearance after a positive sentinel node. The axillary recurrence rate 
for this group after ALNC was recorded. We calculated the number 
of clearances that could have been avoided, and extrapolated the 
reduction in morbidity in lymphodema and nerve damage using 
the audited incidence of these complications in our institution. We 
calculated the financial cost saving in terms of theatre usage and 
hospital stay. In addition, we assessed whether the Memorial Sloane 
Kettering predictive normogram is useful in the prediction of residual 
axillary disease for the group of patients excluded from the Z11 cohort.
Results: 1601 patients underwent axillary staging. 65% of our 
patients with node-positive disease were identified pre-operatively 
with ultrasound and biopsy and proceeded directly to ALNC. Our 
overall axillary recurrence rate was low (<1% at 5 years). 26% of 
our patients would not meet the criteria for Z11, predominantly due 
to the requirement for mastectomy. Of those that met the Z11 criteria, 
60% had no further axillary disease at clearance and a further 25% 
demonstrated low volume (1-3 positive nodes) residual disease only. 
The Memorail Sloane Kettering normogram can be used in estimating 
risk of residual axillary disease in patients undergoing mastectomy.
Discussion: Using these criteria nearly 25% of axillary clearances in 
our population of breast cancer patients could be avoided with obvious 
cost savings both in terms of morbidity and finance, considerations 
that are important in planning our service for the future.
P3-07-31
Intra-Operative Assessment of Sentinel Lymph Nodes in Breast 
Cancer with Touch Imprint Cytology (TIC) in 460 Consecutive 
Patients.
Iqbal M, Shetty G, Randhawa S, Sandhu F, Chachlani N, Simon J, 
Harries S, Jones L, Clarke D. Warwick Hospital, Warwick, West 
Midlands, United Kingdom
Background: Sentinel node biopsy (SNB) accurately predicts the 
axillary lymph node status in patients with breast cancer. The sentinel 
lymph node (SLN) is evaluated by routine histology, requiring 3-5 
days for the results and a second operation if the SLN is positive. 
However a second operation can be avoided if a reliable intra-
operative assessment of the SLN was available. The techniques used 
for intra-operative assessment of the SLN include frozen section, 
touch imprint cytology (TIC) and more recently molecular biology 
assays. The aim of this study was to evaluate the accuracy of TIC in 
the assessment of the SLN.
Methods: A prospective study to include 460 patients with breast 
cancer who underwent SNB and had the sentinel node assessed 
intra-operatively with TIC. The SLN was bisected and a touch 
imprint was made on to a slide. The imprint was stained with 
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Giemsa stain. Permanent sections were evaluated with H&E and 
immunohistochemical staining. The TIC results were compared with 
the final histology of the SLN.
Results: 766 SLN’s were harvested from 460 patients (Mean - 1.66). 
Of the 460 patients, TIC was falsely negative in 50(24%) patients. No 
patients had false positive results. Negative predictive value was 87%. 
The accuracy rate was 89%. 94 patients were positive on histology. 
TIC was positive in 44 patients and negative in 50. The sensitivity, 
specificity and positive predictive value of TIC was 47%, 100% 
and 100% respectively. By acting on the results of TIC, 44 patients 
(47%) had an axillary clearance at the primary operation and were 
thus spared a second operation.
Conclusion: TIC in our cohort of 460 patients and 766 sentinel lymph 
nodes had an accuracy rate of 89% and specificity of 100%. Our 
study compares favourably with published literature, confirming that 
TIC is a simple, quick, reliable and reproducible technique that can 
be used for intra operative assessment of the SLN. A sensitivity of 
47% means that about half of the SLN positive patients were spared 
a second operation. We had hoped that with more experience, our 
sensitivity would improve but since this has not been the case we are 
now moving towards molecular biology assays (OSNA) to assess the 
SN intra-operatively.
P3-07-32
The Role of Axillary Ultrasound in the Detection of Metastases 
from Primary Breast Cancers.
Yamashita M, Little E, Fraley J, Hovanessian-Larsen L, Sener SF. 
Keck School of Medicine, University of Southern California, Los 
Angeles, CA
Background: The value of ultrasound (US) in the preoperative 
evaluation of axillary nodes has yet to be completely clarified. 
Preliminary experience with this technique in our institution was 
examined.
Methods: Patients with a radiographic or palpable abnormality of 
the breast had simultaneous breast and axillary US. The exams were 
performed by dedicated breast radiologists using a 12 MHz linear 
array transducer (HDI 5000: Philips Ultrasound). Results were 
reviewed for all patients with invasive cancers who were cN0 and 
had definitive surgical procedures between June 2006 and May 2008. 
Criteria for abnormal lymph nodes were loss of reniform shape, focal 
or diffuse cortical thickening, or eccentric/replaced fatty hilum. US-
guided biopsies were done using a 16g spring-loaded core biopsy 
device (16g MD TECH SuperCore). Patients with positive axillary 
node biopsies bypassed sentinel lymph node biopsy (SLNB) and 
had axillary dissection, whereas those with sonographically normal 
nodes or benign/non-diagnostic biopsy results had SLNB at the time 
of definitive surgery.
Results: Of 128 patients diagnosed with invasive cancer, 23 (18%) 
had abnormal axillary US at the time of initial diagnosis. Biopsies 
were performed in 18 of the 23, of which 12 (67%) were malignant 
and 6 (33%) were benign. Ultrasounds were negative in 105 (82%) 
patients. SLNB was done in 110 patients: 103 with negative US; 4 
patients with abnormal US but negative axillary biopsies; 2 patients 
with abnormal US but no core biopsies; and 1 patient with a positive 
US biopsy. SLNB was negative in 91 (83%) patients and positive 
in 19 (17%). The node-positive status was N1a in 14 patients and 
N1mic in 5. Axillary dissection was done in 32 (25%) of 128 patients, 
comprised of 11 patients with US-guided positive biopsies, 12 with 
positive sentinel nodes, 2 with US-guided negative biopsies, 2 with 
negative ultrasounds, 3 with unbiospied abnormal ultrasounds, and 
2 with a false-negative SLNB. For determining axillary metastases 
with US, sensitivity was 16/31 (52%), specificity was 90/97 (93%), 
positive predictive value was 16/23 (69%), and negative predictive 
value was 90/105 (86%).
Conclusions: US examination was a valuable method of evaluating 
the axilla in newly diagnosed breast cancers. Of 32 patients having 
an axillary dissection, abnormal US eliminated the need for SLNB 
in 17 (53%). Patients with US-guided positive nodes were submitted 
to axillary dissection without SLNB. Therefore, we were unable to 
determine how often US identified an abnormal non-sentinel node, 
thus upstaging the axilla relative to SLNB alone. This question should 
be the topic of further clinical study.
P3-07-33
Are Single Node Metastases More Common in Patients with 
Breast Cancer in the Sentinel Node Era?
Shetty G, Randhawa S, Mohammed I, Harries S, Jones L, Clarke D. 
Warwick Hospital, Warwick, Westmidlands, United Kingdom
Background: The axillary recurrence rate after axillary lymph 
node dissection has been reported as approximately 3%. Since the 
introduction of sentinel node biopsy (SNB), it has become apparent 
that, there is a significant decrease in axillary recurrence, ranging 
from 0.26% to 0.9% in published literature. One of the concerns that 
arises from this data is that, the sentinel node may have been missed 
when routine axillary node clearance were being performed. The aim 
of this study was to compare the results of a cohort of patients who 
had an axillary staging procedure prior to the introduction of SNB 
(axillary clearance) with patients after the introduction of SNB in 
relation to the number who had only one positive node in the axilla.
Methods: From June 2003 to November 2010 data was collected on 
demographics, histopathology and procedure performed. All patients 
with invasive breast cancer prior to April 2005 had an axillary node 
clearance (ANC) with either wide local excision or mastectomy. Since 
April 2005 all patients with invasive breast cancer had a SNB and 
patients with a positive sentinel node (SN) underwent ANC. Patients 
with a negative SNB had no further axillary surgery.
Results: 702 patients had axillary node surgery between June 2003 
and November 2010. 251 patients had axillary node clearance (pre 
SN period) and 451 had SNB (SN period). Average age was 57 years. 
509 patients (156 in pre SNB period and 353 in post SNB period) 
had no nodal metastases. Amongst the 193 node positive patients, 
100 had single node involvement. In the pre SNB period 33 (34.7%) 
patients had single node involvement, compared to 67 (68.3%) 
in SNB period. The histopathological type of cancer did not vary 
significantly between the one node positive, multiple node positive 
and node negative groups.
Conclusion: Our study confirms a significant rise in patients with a 
single node positive in the sentinel node period. This could be due 
to the SLN being “missed” during surgery when an axillary node 
clearance was performed, which would explain the reported higher 
axillary recurrence rates in the pre sentinel node period compared 
to the sentinel node period. Another possibility is that the SN is 
undergoing more detailed histopathological assessment as there are 
fewer number of lymph nodes to be examined.
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P3-07-34
Occult Metastasis in Sentinel Node: Should This Affect the 
Clinical Decision Making? A Systematic Review and Meta-
Analysis.
Valachis A, Nearchou A, Polyzos NP, Lind P, Berqvist J. Mälarsjukhuset, 
Eskilstuna, Sweden; Universitair Ziekenhuis Brussel, Brussels, 
Belgium; Karolinska Institutet, Stockholm, Sweden
Background: The role of occult metastases (micrometastasis or 
isolated tumor cells [ITC]) in sentinel lymph nodes (SLN) remains 
a field of debate and speculation. The purpose of this systematic 
review and meta-analysis was to investigate the prognostic relevance 
of occult metastases in SLN.
Methods: We searched PubMed, without year or language restriction 
through June 2011, for studies on patients with invasive breast cancer 
with micrometastasis or ITC in the SLN and presented Hazard Ratios 
(HR) on Overall Survival (OS) / Disease-Free Survival (DFS) or 
enough data for HR-calculation. We used fixed- or random-effects 
meta-analyses, as appropriate, to calculate pooled estimates of HR.
Results: Fifteen studies were considered eligible. Of those, 3 
studies were excluded due to the lack of data for HR-calculation. 
Both the presence of ITC (5 studies; 1264 patients with ITC) and 
micrometastasis (10 studies; 1093 patients with micrometastasis) 
were associated with worse DFS (pooled HR 1.29, 95% Confidence 
Interval [CI]: 1.09-1.52, P-value = 0.002 for ITC, pooled HR 1.45, 
95% CI: 1.28-1.64, P-value < 0.001 for micrometastasis). No 
significant differences were observed regarding OS neither for the 
presence of ITC (5 studies; 877 patients with ITC; pooled HR 1.20, 
95% CI 0.98-1.46) nor for micrometastasis (8 studies; 1094 patients 
with micrometastasis; pooled HR 1.36, 95% CI: 0.98-1.88).
Conclusion: Based on the current evidence, it seems that the presence 
of occult metastasis in SLN is of prognostic significance in regard 
to DFS. However, the clinical significance of this difference is 
questioned since it cannot be translated into differences in OS. In 
anticipation of randomized trials aimed to evaluating the optimal 
management of each category of tumor burden within SLN, current 
evidence suggest a limited clinical significance of occult metastases 
in SLN.
P3-07-35
Validation of Online Calculators To Predict Non-Sentinel Lymph 
Node Status in Sentinel Lymph Node-Positive Breast Cancer 
Patients.
Tanaka S, Sato N, Fujioka H, Takahashi Y, Kimura K, Iwamoto M. 
Osaka Medical College, Takatsuki, Osaka, Japan
Purpose: Axillary lymph node dissection (ALND) is recommended 
for breast cancer patients with sentinel lymph node (SLN) metastasis, 
but further nodal disease is not always present. Several models exist 
for predicting non-sentinel lymph node (non-SLN) metastasis in 
SLN metastasis. This study evaluated and compared the predictive 
values of the Memorial Sloan-Kettering Cancer Center (MSKCC) 
nomogram and the Stanford nomogram, which were conveniently 
available online, and clarified their usefulness for the micrometastasis 
or isolated tumor cell (ITC) subgroup.
Methods: Data from 89 patients with positive SLN biopsy 
who underwent ALND were used, including 59 patients with 
macrometastasis and 30 with micrometastasis/ITC. The predicted 
probability of non-SLN metastasis was calculated using a 
computerized model from the websites for each nomogram. Results 
were compared using area under the curve (AUC) of the receiver 
operating characteristics curve for each model. False-negative and 
false-positive rates were also calculated.
Results: AUC for the entire population was 0.701 with the MSKCC 
nomogram and 0.756 with the Stanford nomogram. AUCs of 
macrometastasis and micrometastasis/ITC were 0.680 and 0.469 
with the MSKCC nomogram and 0.676 and 0.574 with the Stanford 
nomogram, respectively.
Table 1: Comparison of receiver operating characteristic curves for the 2 nomograms in our data set.
 AUC Standard error 95% CI
Overall population    
NMKCC nomogram 0.701 0.056 0.581-0.799
Stanford nomogram 0.756 0.054 0.636-0.846
Macrometastasis subgroup    
MSKCC nomogram 0.680 0.070 0.532-0.799
Stanford nomogram 0.676 0.071 0.526-0.797
Micrometastasis/ITC subgroup    
MSKCC nomogram 0.469 0.190 0.165-0.798
Stanford nomogram 0.574 0.145 0.296-0.812
AUC, area under the curve; MSKCC, Memorial Sloan-Kettering Cancer Center; ITC, isolated tumor 
cell
Although false-negative cases were not identified, false-positive rates 
were high in both subgroups with these nomograms.
Table 2: False-negative and false-positive rates for non-sentinel lymph node involvement with 
several cut-off values for each nomogram
 Macrometastasis subgroup Micrometastasis/ITC subgroup
Threshold False-negative False-positive False-negative False-positive
MSKCC     
≤ 10% -* 53% (31/59) -* 90% (27/30)
≤ 30% 0% (0/2) 51% (29/57) 0% (0/2) 89% (25/28)
Stanford     
≤ 10% -* 53% (31/59) 0% (0/2) 89% (25/28)
≤ 30% 0% (0/1) 54% (30/56) 0% (0/9) 86% (18/21)
*There was not an applicable case. ITC, isolated tumor cell; MSKCC, Memorial Sloan-Kettering 
Cancer Center
Conclusions: This independent comparison found no significant 
difference between the two nomograms. In our results, these 
nomograms could not reliably predict positive non-SLN in cases 
with SLN micrometastasis/ITC. Further validation in other patient 
populations is needed.
P3-07-36
Predicting Sentinel Lymph Node Metastasis of a Chinese Breast 
Cancer Population: Assessment of an Existing Nomogram and a 
New Predictive Nomogram.
Chen J-Y, Chen J-J, Yang B-L, Liu Z-B, Huang X-Y, Liu G-Y, Han Q-X, 
Yang W-T, Shen Z-Z, Shao Z-M, Wu J. Fudan University Shanghai 
Cancer Center, Shanghai, China
Background: The Memorial Sloan-Kettering Cancer Center (MSKCC) 
developed a nomogram to predict the presence of sentinel lymph node 
(SLN) metastasis in breast cancer patients. In our study, The MSKCC 
nomogram performance for prediction of SLN metastases was 
assessed in Chinese breast cancer population. A new model (Shanghai 
Cancer Center Nomogram, SCC nomogram ) was developed with 
clinically relevant variables and possible advantages.
Methods: Data were collected from 771 patients with successful 
SLN biopsy who were treated during March 2005 to June 2010. 
Touch imprint cytology (TIC) and serial section with H&E staining 
were performed routinely on each sentinel node. 580 SLN biopsy 
procedures from March 2005to November 2009were used as 
training group to validate the MSKCC nomogram and assessed with 
multivariable logistic regression to predict the presence of SLN 
metastasis in breast cancer. The predictive accuracy of MSKCC 
nomogram was assessed by calculating the area under the receiver-
operating characteristic (ROC) curve (AUC). The SCC nomogram 
was created from the logistic regression model. The new model was 
subsequently applied to 191 sequential SLN biopsies from January 
2010 to June 2010 as the validation group.
Results: It was shown that age, tumor size, tumor type, histological 
grade, lymphovascular invasion and neural invasion was correlated 
with the probability of SLN metastasis by univariate analysis 
(P<0.05). By multivariate analysis, tumor size, histological grade and 
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lymphovascular invasion were identified as independent predictors of 
SLN metastasis. The SCC nomogram was then developed with four 
variables associated with SLN metastasis: age, tumor size, histological 
grade and lymphovascular invasion. The new model was accurate and 
discriminating, with AUC of 0.773 when applied to the validation 
group, as compared to the MSKCC nomogram with AUC of 0.754 in 
the modeling group. The trend of actual probability in various decile 
groups was comparable to the predicted probability. For predicted 
probability cut-off points of 7% and 15%, the false-negative rates of 
SCC nomogram were 0% and 8.1%.
Conclusion: As far as we know, this is the first study designed to 
evaluate the MSKCC nomogram and develop a new nomogram in 
Chinese early breast cancer population. Compared to the MSKCC 
nomogram, the SCC nomogram was developed with similar AUC 
but less variables and lower false-negative rates for low-probability 
subgroups. It could provide a more acceptable clinical accessory in 
the preoperative discussion with patients, especially in the very low 
risk of patients. For those patients, the SCC nomogram could be used 
to safely avoid a SLN procedure, thereby reducing postoperative 
morbidity, whereas the rate could be as high as 7% in the literature. 
Although the SCC nomogram that predicts metastasis of breast cancer 
in the sentinel lymph node performed well in Chinese breast cancer 
population, it is imperfect. The SCC nomogram was developed and 
validated in the single instite. The SCC model should be validated in 
different patient groups before it is demonstrated to be reproducible 
and would be applied widely.
P3-07-37
Clinical Characteristics and Treatment of Brazilian Women with 
Breast Cancer at Public and Private Institutions.
Hegg R, Mattar A, Gebrim LH, Emerenciano K, Pinotti M, Perdicaris 
M, van Eyll B, Franke F, Pinczowski H, Freitas, Jr R, Jendiroba D, 
Borges G, Queiroz G, Nascimento YV, Gampel O, Mathias C, Budel 
V, Strepassos E, Delgado G. Perola Byington Hospital, Sao Paulo, SP, 
Brazil; Liga Norte Riograndense; EGIMAJAP; Instituto Santista de 
Oncologia; Instituto do Cancer Arnaldo Vieira de Carvalho; Hospital 
de Caridade de Ijui; Faculdade de Medicina do ABC; Hospital 
das Clinicas de Goiania; Centro Goiano de Oncologia; Clinica 
de Neoplasias Litoral; Hospital Araujo Jorge; Cepon; Hospital do 
Servidor Publico do Estado de Sao Paulo; Nucleo de Oncologia 
da Bahia; Unoversidade Federal do Parana; Hospital Sao Rafael; 
Hospital Santa Lucinda
Background: Breast cancer is the most common type of cancer among 
Brazilian women with almost 50.000 new cases per year. There are 
few data regarding the clinical presentation, treatment and specially 
outcome of this population. Brazilian health system is composed by 
Public institutions (Pu); Private centers (Pr) and some institutions 
that assist both Public and Private patients (PuPr).
Material and Methods: We collected data from 17 cancer centers 
distributed throughout Brazil among Pu; Pr and PuPr centers. 
We’ve analyzed data from 1-clinical characteristics, 2- pathologic 
characteristics and 3-type of treatment received among 2435 patients 
from May 2008 to May 2009.
Results: Mean age at diagnosis was 53 years, with about 30% below 
age 50. Most of the cases were Invasive Ductal Cancer (83%). Stage 
0 was seen in 3.2%, Stage I in 21,8%, Stage II in 46,6%, Stage 3 
in 24,6% and Stage IV in 3,9 %. Clinical Stage III + IV was seen 
in 18,5% of the Pu institutions, only 3,7% of the Pr ones and about 
6,2% among those PuPr. Hormone receptors were positive in 55%. 
Her-2 was overexpressed in 27,3% of the patients, and triple negative 
were seen in 11,6%. Most of the patients were submitted to surgery 
(92,9%). In Pu institutions only 36% of the patients were submitted 
to Breast Conserving Surgery (BCS) and in the Pr institutions 49,4% 
of the patients were submitted to BCS and in the PuPr 47%. Breast 
reconstruction was made in 15,8% and did not differ between Pu 
and Pr institutions. Sentinel node biopsy was done in 30,6% of the 
patients (26,8% of the patients from the Pr institutions and 26,8% of 
the Pu ones and 33% among PuPr). Neoadjuvant treatment was done 
in 21,5% of the patients (Pu=27,2%; Pr=13,9% and PuPr 13,2%). 
Most of this neoadjuvant treatment was chemotherapy (93,8%) and 
only 4,3% was hormonetherapy (HT). 30% of the patients received 
AC, 41% A+taxane and 18,9% FAC/FEC. Besides we have almost 
30% of Her-2 overexpressed only 1,1% of the patients received 
trastuzumab in the neoadjuvant setting. Tamoxifen was used in 
48,3% when neoadjuvant HT was done, and aromatase inhibitor 
(AI) was used in 34,5%. Most of the patients received any kind 
of adjuvant treatment (89,2%). Chemotherapy was done in 76,6% 
and hormonetherapy in 69,8%. When chemotherapy was used the 
preference regiment was FAC/FEC (27,3%), followed by CMF 
(17,5%) and AC (11,9%). Trastuzumab was use in only 5,8% of the 
patients (Pu=6,8%, Pr=18,3% and PuPr 3% among all patients that 
received chemotherapy). In the adjuvant setting, Tamoxifen (TAM) 
was prescribed in 69,8% of the cases (Pu=87,6%, Pr=79,6% and 
PuPr 78,8%), AI in 8,2% (Pu=5,9%, Pr=9,3% and PuPr 13,8%), and 
sequential TAM/AI in 6,6% (Pu=6,1%, Pr=8,3% and PuPr 6,4%). 
About 17% of the patients had metastasis.
Conclusions: There are important differences between the public and 
private institutions in Brazil, the patients from the Pu institutions 
were five times more likely to be diagnosed in stage III or IV, they 
usually receive neoadjuvant treatment, and when surgery was done, 
most of them were treated with radical procedures. Besides the 
overexpression of Her-2 (30%) a minority of the patients received 
treatment with trastuzumab even for the Private centers (high cost 
for a developing country).
P3-07-38
Selective Omission of Blue Dye in Patients Undergoing Sentinel 
Lymph Node Biopsy for Breast Cancer.
Waters JL, Iqbal M, Jones L, Harries S, Clarke D. Warwick Hospital, 
South West Warwickshire Foundation Trust, Warwick, West Midlands, 
United Kingdom
Background: Combined blue dye and radioisotope colloid injection 
with scintigraphy is standard practice for mapping and biopsy of 
sentinel lymph node in breast cancer within the UK. Whilst this 
combination aids sentinel node detection rate, blue dye has a number 
of possible adverse effects including anaphylaxis (reported as 1-3% 
of patients), semi-permanent skin tattooing and staining of bodily 
fluids which may cause distress for the unwary patient. It can also 
cause obscuration of the operating field, making identification and 
dissection of planes more difficult.
Methods: Patients undergoing sentinel lymph node biopsy (SLNB) 
using either a combination of blue dye and radioactive colloid, or 
radioactive colloid alone during a 14 month period were compared 
for identification rate, node harvest number and final positive rate. 
A total of 122 axillary sentinel node biopsies in 121 patients were 
identified. All patients scheduled for sentinel lymph node biopsy 
had intradermal injection of radiocolloid and lymphoscintigram pre-
operatively and were checked for radioactive intensity with gamma 
probe on the table before draping for surgery. Patients with good 
signal proceeded to surgery without blue dye. Those with more than 
3 nodes (n=9), radioisotope skin contamination (n=2), absent signal 
on scintigraphy (n=7) and/or with weak pre-operative radioactive 
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signal (n=22) were given 2 millilitres of patent V dye subdermally 
in the periareolar region. Sentinel node biopsy then proceeded in 
the standard fashion. Data was also collected from the year prior to 
be used as a control group, where the combination of blue dye and 
radioisotope was used for all patients (n=90), and compared with the 
group receiving radioisotope alone.
Results: The rate of identification for single agent and dual agent 
was 100% and 97.5% respectively, with no significant difference in 
mean node harvest using radioisotope alone (1.80) as compared to 
combined technique (1.87 p= 0.88, 95%CI -0.39 to 0.34). There was 
no significant difference in the number of patients with positive nodes 
on final histology when using single agent (13 (14%)) when compared 
to the dual agent technique (10 (25%) p=0.21). There was also no 
difference in the rate or number of node harvest in the group who 
underwent the single agent technique when compared to the control 
group (100% identification, mean harvest 1.84, p=0.77, 95% CI -0.36 
to 0.27), with no difference in node positivity (16 (17%) p=0.68). No 
intra operative adverse reaction was reported in any of the groups.
Discussion: This study has shown no significant difference in the 
localisation rate when selectively omitting blue dye in suitable patients 
compared to the combined technique. This may be due to significant 
operator experience or change in the method of radioisotope injection 
since initial studies were performed. In this study, 86 out of 126 
SLNB proceeded without blue dye, meaning not only a reduction in 
the number of patients with minor adverse effects, but also a potential 
reduction in severe adverse reaction of 68% or 2 patients per year 
within this breast unit.
P3-07-39
Where To Look for Sentinel Lymph Node in Breast Cancer.
Düran A. Klinikum Bayreuth GmbH, Bayreuth, Bayern, Germany
Hypothesis:
The sentinel Lymph node (SLN) is not only the first extra mammary 
point of metastatic spread, it also undergoes reactive changes. 
Sonographically this is evident through an increased width of the 
hypo-echoic cortex of the lymph node. We examined, if it is possible 
to localize SLN on sono-morphological features, if it is sonographic 
detection comparable with the radio nuclide tracer method and if false 
negative rate (FNR) of SLNB can be reduced by ultrsound.
Method:
From 1/2001 to 5/2003, 117 patients with breast cancer where 
prospectively examined for SLN localization using sonography in 
addition to radio nuclide -Tc99m- and/or patent blue-methods. The 
lymph node identified as the SLN in ultrasound was marked using 
a hook-wire. The sonographic parameters used to identify the SLN 
were: The node with the widest hypo echoic cortex, located in the 
caudal axilla and the closest to the glandular tissue and with the 
greatest diameter.
Results:
In all 117 patients, in the region of the caudal axilla, an enlarged, 
reactive, either tumor free or metastatic SLN could be verified. The 
location of the SLN was in all cases on the lateral-caudal thoracic 
wall and consistent with the lymph node group at the lateral border 
of the pectoralis major. The sonographic detection rate of the SLN 
was 86%. 70.6% of the sentinel lymph nodes where affected by 
metastatic spread. In those patients with a pT1a-c-tumor the rate 
of SLN metastatic spread was 20%. The false negative rate (FNR) 
for SLN localization with Tc99m/Blau was 10.6 %. Experience has 
shown that the FNR increases with increasing degree of metastatic 
spread to the SLN. With the addition of sonography of the axilla the 
FNR could be decreased to 3.5%.
Sonographic SLN detection rate: 86% ( n=101/117)
False-negative-rate (Blue/Tc) 10.7% (n=6sln- /56N+)
False-negative-rate (Blue/Tc + Sonography) 3.5% (n=2sln-/56N+)
Conclusions:
The false-negative-rate of detection of suspected lymph nodes can 
be reduced using sonographic localization of the SLN. Sonography 
of the axilla should therefore be an integral part of and standard in 
the sentinel node-biopsy of breast cancer patients.
P3-07-40
Impact of the Sentinel Lymph Node Procedure on the Detection 
of Positive Lymph Nodes in Breast Cancer.
Smeets A, Yoshihara E, Laenen A, Wildiers H, Reynders A, Soens 
J, Paridaens R, Van Ongeval C, Floris G, Moerman P, Neven P, 
Christiaens M-R. University Hospitals Leuven, Leuven, Belgium; 
Katholieke Universiteit Leuven, Leuven, Belgium
Introduction:
The objective of the sentinel lymph node (SLN) procedure in breast 
cancer is to perform an accurate axillary staging and provide good 
local control, while sparing the patients the morbidity of an axillary 
lymph node dissection (ALND). Since its routine clinical use, 
questions have been raised concerning the upstaging of a subgroup 
of node-negative patients and an increase in the overall percentage 
of node-positive patients.
The goal of our study was to investigate the impact of the SLN 
procedure on the detection of positive lymph nodes.
Patients and methods:
We included 1119 consecutive breast cancer patients from one center 
(2007-2009) who underwent primary surgery for a breast cancer 
smaller than 5 cm diameter without clinical involvement of axillary 
lymph nodes. 31 patients had a bilateral breast cancer.
Logistic regression models were used to analyze the effect of various 
predictors on the presence of positive lymph nodes.
First, we fitted univariable models for a number of predictors of which 
the relationship with lymph node involvement was to be expected. 
(multifocality, tumor location in the breast, tumor size, LVI, ER, PR, 
Her-2, tumor grade, age and histologic subtype).
In a second stage, we fitted a multivariable model including the 
procedure (SLN biopsy or ALND) and the predictors that have been 
shown to be related to lymph node involvement in univariable analysis 
or for which this relationship has been suggested in the literature. The 
probability of finding positive lymph nodes was thus calculated in both 
groups correcting for relevant predictors of lymph node involvement.
Results:
The SLN biopsy group includes 830 patients, the ALND group 
320. Tumors in the ALND group are larger (mean 26.65 mm versus 
18.43mm) and more frequently multifocal (24.44% versus 8.19%). 
33% of patients in the ALND group were lymph node positive, 28% 
in the SLN procedure group. Univariable and multivariable analyses 
revealed that LVI, tumor size and multifocality are the most significant 
predictors of lymph node involvement (table 1).
The AUC for the multivariate model is 0.754.
 By comparing ALND en SLN biopsy an odds ratio (OR) of 0.7635 
(95% confidence interval: 0.5334-1.0930) is observed, suggesting 
a higher probability of finding positive lymph nodes with SLN 
procedure. However, the difference between the procedures is not 
significant (p= 0.1404).
Conclusion:
For comparable tumors, the chance of detecting positive lymph nodes 
is not lower when applying SLN procedure compared to ALND. The 
results even point in the direction of a higher detection rate with SLN. 
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However, care should be taken in making this conclusion given a 
non-significant result.
Table 1: Univariable and multivariable analyses
 Univariable Multivariable
 p value p value
ALND versus SLNB 0.0663 0.1404
Age 0.5497 /
Multifocality <0.0001 0.0006
Grade 0.4190 0.3727
Location 0.0027 0.0064
Tumor size <0.0001 <0.0001
LVI <0.0001 <0.0001
IDC 0.6305 0.7130
ILC 0.4873 0.7765
ER 0.0180 0.51998
PR 0.0068 0.1986
Her-2 0.9875 /
P3-07-41
Sentinel Lymph Node Biopsy Is a Reliable Method for Lymph 
Node Evaluation in Neoadjuvant Chemotherapy Treated Breast 
Cancer Patients.
Kaplan R, Qiu Q, Monni S, Swistel A, Shin S. The New York-
Presbyterian Hospital-Weill Cornell Medical Center, New York, NY
Background: Successful sentinel lymph node mapping in breast 
cancer patients treated with neoadjuvant chemotherapy has been 
debated by practicing surgeons due to the potential compromise 
of the lymphatic drainage system after treatment. Furthermore, 
whether clinicopathologic variables associated with sentinel lymph 
node positivity in breast cancer patients differ from similar patients 
who have been treated with neoadjuvant chemotherapy has not been 
well-studied. Materials and Methods: Breast cancer patients who 
received neoadjuvant chemotherapy were identified in our files. A 
similar number of breast cancer patients who did not receive such 
therapy was also selected as a comparison group. Clinicopathologic 
parameters such as age, type of surgical procedure, number of sentinel 
lymph nodes removed and/or positive, number of non-sentinel lymph 
nodes removed and/or positive, tumor size, histologic type/grade, 
presence of lymphovascular invasion, biomarker expression (ER,PR, 
HER-2/neu) and multifocality were recorded for each patient in 
both cohorts. Statistical analysis was performed for each cohort to 
identify variable(s) that correlated with sentinel lymph node positivity. 
Additional analysis was performed by computing the odds ratio of 
sentinel lymph node positivity after adjusting for selected variables. 
Results: Ninety-seven and ninety-three patients who were and were 
not treated with neoadjuvant chemotherapy, respectively, were 
identified. In all patients, successful sentinel lymph node mapping 
was achieved. When these cohorts were separately analyzed, tumor 
size, lymphovascular invasion, and non-sentinel lymph node positivity 
were associated with sentinel lymph node positivity in the cohort 
that did not receive neoadjuvant chemotherapy. In the cohort that 
received therapy, lymphovascular invasion and non-sentinel lymph 
node positivity were associated with sentinel lymph node positivity. 
In addition, after adjusting for tumor size, lymphovascular invasion 
and histologic grade, patients treated with neoadjuvant chemotherapy 
were more likely to have sentinel lymph node positivity than those 
who did not have this treatment (odds ratio: 5.4, 95% CI 2.4, 12.1). 
Conclusions: Successful sentinel lymph node mapping was achieved 
in all ninety-seven breast cancer patients studied. Regardless of 
whether neoadjuvant chemotherapy was administered, the presence 
of lymphovascular invasion and non-sentinel lymph node positivity 
were found to predict sentinel lymph node positivity. By comparing 
two cohorts of breast cancer patients differing only in the use of 
neoadjuvant chemotherapy and adjusting for select variables, those 
in the treated cohort still remained more likely to have a positive 
sentinel lymph node.
P3-07-42
Lymphovascular Invasion Best Correlates with Presence of Nodal 
Metastasis in Sentinel Lymph Node Biopsy.
Absar MS, Adelekan MO, Patel E, Cotterill S. North Manchester 
General Hospital, Manchester, United Kingdom; University of 
Manchester, Manchester, United Kingdom
Background. Sentinel lymph node biopsy (SLNB) biopsy is routinely 
practised for axillary staging with 25-30% having positive SLN. 
Tumour size is the most important parameter taken into consideration 
in decision making in node negative patients with a size cut off for 
4-5cm dependant on different units. Lymphovascular invasion (LVI) 
and Ki-67 a cell-cycle antigen are known important prognostic 
markers along with the tumour grade, oestrogen receptor and herceptin 
receptor status.
Aim. To examine whether lymphovascular invasion, Ki-67 or any 
other factors can be used as a predictor for axillary lymph node 
involvement and hence prognosis.
METHODS. A prospective study of 264 patients with invasive 
breast cancer undergoing SLN biopsy between January 2009 and 
December 2010.
Histopathology reports were reviewed regarding LVI, Ki-67, grade, 
oestrogen, Progesterone and Herceptin receptor and SLN status. 
Stats direct was used to analyse data. Logistic regression was used 
and p-value calculated.
RESULTS. LVI (p value=0.0001) and size(p value=0.0273) were the 
two most significant factors associated with node positivity. Grade 
of tumour had a p-value of 0.0825 and Ki67 had a p-value of 0.5217 
which were not significant.
Factors affecting nodal status
Patient and Tumour factors   p value
Age -0.008564 -0.678984 0.4971
Tumour type 0.041908 0.452277 0.6511
Tumour size 0.041908 2.207519 0.0273
Tumour grade 0.554563 1.736407 0.0825
Lymphovascular invasion 1.545486 3.885225 0.0001
Oestogen receptor 0.015589 0.14465 0.885
Progesteron receptor 0.042683 0.530567 0.5957
Her2 0.034047 0.108314 0.9137
Ki67 -0.006568 -0.64.739 0.5217
DISCUSSION. LVI is the factor which best corelates with presence 
of metastasis in sentinel lymph node. If this information is available 
at the time of decision making, it should be strongly considered and 
pathologists should be encouraged to provide the information. In 
the absence of LVI, size still remains the best predictor of sentinel 
lymph node metastasis pre-operatively although consideration of 
other factors, such as the grade is definitely relevant.
P3-07-43
The Impact of Timing in Sentinel Lymph Node Biopsy in Primary 
Breast Cancer.
Güth U, Schmid SM, Myrick ME, Obermann EC, Viehl CT, Rochlitz 
C, Forrer F. University Hospital Basel, Basel, Switzerland
Background: There is minimal data concerning the impact of timing 
on the radiolabeled colloid marked sentinel lymph node (SLN) 
procedure. Some surgeons believe that the operation should be 
performed as the first case in the morning because a delay could 
theoretically lead to a variation in number of lymph nodes removed; 
there could be a) an artificially higher number due to diffusion of 
the radiolabeled colloid, or b) a lower number due to decay of the 
radiolabeled colloid. We examine the correlation between the number 
of SLN removed and the time of day when the SLN procedure was 
performed.
Methods: Between January 2003 and December 2009, 391 SLN 
procedures were performed in histologically confirmed invasive breast 
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carcinomas at the University Women’s Hospital Basel, Switzerland. 
In line with the procedure defined by the “Swiss Multicenter Sentinel 
Lymph Node Study in Breast Cancer Patients”, each patient underwent 
standard labeling, removal and pathological diagnosis of the SLN. 
In all cases, lymphatic mapping was performed with 99mTc-labeled 
nanocolloid the day before the operation between 2.00 and 3.00 p.m. 
In addition, 2-4 ml of patent blue V was injected 5-10 minutes prior to 
incision. The radiolabeled colloid marked SLN were intraoperatively 
identified by the use of a handheld gamma probe. All samples were 
sent for immediate assessment to the local Institute of Pathology. 
The number of lymph nodes was determined and frozen sections 
were performed.
The timing of the SLN removal can be pinpointed unequivocally in 
all cases, since the pathology report records the arrival of the tissue 
samples for frozen section to the exact minute. In order to analyze the 
correlation between the timing of surgery on the operation day and 
the number of lymph nodes removed, we calculated the minutes from 
the beginning of the operating schedule in the morning (8.00 a.m.) 
until the arrival of the tissue samples in the frozen section laboratory 
(including subtraction of fifteen minutes handling and transport 
time). In order to calculate the association between the timing of the 
operation on the operation day and the number of the SLN removed, 
nonparametric spearman correlation (Spearman-Rho) was used; 
negative values of the coefficient rho indicate a descending trend.
Results: In 391 procedures, 928 SLN (median: 2; range: 1-11) were 
removed. Although blue dye was used in all cases, in the majority 
of cases (50.8%, n=471) the SLN were marked exclusively by 
radiolabeled colloid and only detected by the use of the handheld 
gamma probe. Only in 27 of the 928 SLN (2.9%), did the surgeon 
identify the lymph nodes through the blue coloration alone.
The median time between start of the operation timetable and the SLN 
removal was 150 minutes (range: 25-420). There was a weak negative 
association between timing and the number of SLN removed (Rho=-
0.070; p=0.168), i.e. there was a small, non-significant decrease in 
the number of SLN removed at a later time in the day.
Conclusion: After mapping SLN the previous day by using 
radiolabeled colloid method, the timing on the day of the operation 
has no relevant impact on the number of SLN removed.
P3-07-44
Feasibility of Axillary Reverse Mapping during Sentinel Lymph 
Node Biopsy in Breast Cancer.
Noguchi M, Ohno Y, Nakano Y, Noguchi M, Kosaka T. Kanazawa 
Medical University, Kahoku, Ishikawa, Japan
Background: The axillary reverse mapping (ARM) procedure is based 
on the hypothesis that the lymphatic drainage from the upper arm is 
different from that of the breast. However, the oncologic safety of 
the procedure has not yet been determined.
Methods: The ARM nodes were identified using a fluorescence 
imaging system. Sentinel lymph node (SLN) biopsy was performed 
in patients with clinically uninvolved nodes. If the SLN was positive, 
ALND was performed with removal of ARM nodes. Otherwise, the 
identified ARM nodes were preserved unless they were the same as 
the SLN.
Results: The ARM node was identified in 30 of 91 patients who 
underwent SLN biopsy, and it was the same as the SLN in 23 patients. 
However, in 13 patients with a positive SLN who subsequently 
underwent ALND, ARM nodes were tumor-free when they were not 
the same as the positive SLN.
Conclusions: There are limits to the principle of non-overlap between 
breast and arm nodes. However, it may be feasible to spare ARM 
nodes during ALND in patients with clinically negative nodes.
P3-07-45
Role of SPECT-CT in Detecting Sentinel Lymph Nodes in Patients 
with Ipsilateral Breast Cancer Recurrence and Previous Axillary 
Lymph Node Dissection.
Cordoba O, Perez-Ceresuela F, Roca I, Mendoza C, Cortadellas 
T, Espinosa-Bravo M, Rodriguez J, Peg V, Rubio IT, Xercavins J. 
Hospital Universitari Vall d’Hebron, Barcelona, Spain; Universitat 
Autònoma de Barcelona, Barcelona, Spain
Background: Use of sentinel lymph node dissection in patients with 
ipsilateral breast cancer recurrence and a previous axillary lymph 
node dissection (ALND) is still controversial. Although previous 
reports have showed extra-axillary drainage in 40-60% of patients, 
the clinical significance of this drainage is unknown. SPECT-CT may 
help to localize aberrant sentinel nodes.
Material and Methods: Between 2008 and 2011, SLN were performed 
in 25 patients with ipsilateral breast cancer recurrence and previous 
ALND. The day before surgery 99Tc nanocolloid was injected 
retroareolar in the affected breast and injected intratumorally when the 
recurrence was after a mastectomy. Linfoscintigraphy was obtained in 
all patients and a SPECT-CT was performed in all cases even when 
planar images showed no drainage. During surgery, the sentinel node 
was identified using a gamma probe. During the procedure the surgeon 
decided to remove the sentinel node if it was considered technically 
feasible. The project was IRB approved and all patients signed an 
informed consent.
Results: Records from the previous ALND showed 9 patients with 
positive axillary nodes with a mean of 19 (range 10-35) lymph nodes 
excised. Twenty four patients had undergone a lumpectomy and 1 
patient a mastectomy. After the injection, the SPECT-CT showed at 
least one hot spot in 20 patients, with a mean of 1.8 hot spots (range 
0-5). Hot spots on SPECT-CT were located as follows: in 10 patients 
axillary, 1 subclavicular, 7 internal mammary, 1 intramammary, 1 
mediastinic and 7 patients had a contralateral axillary hot spot. In 4 
patients we don’t found any hot spot on SPECT-CT. After excising 
2 axillary nodes and 1 intrammary node in 3 patients, the pathologist 
didn’t identify any lymph node in the hot spot removed. This are 
considered as false positives (15%). In 4 patients although hot spots 
were identified, sentinel node dissection wasn’t performed because 
it was arguable the benefit for the patients taking into account the 
location and number of hot spots.
Hot spots not removed
Hot spot saw but not removed Other Nodes removed Follow-up (all patients disease free)
1 contralateral axillary and 1 
mediastinic 1 mammary, negative 21 months
3 internal mammary None 20 months
1 internal mammary 1 axillary contralateral, negative 19 months
5 internal mammary None 12 months
All this 4 patients are free of disease and any of them have developed 
recurrences. In 14 (56%) patients all the sentinel nodes were identified 
and removed. Three (3/14 = 21%) patients had positive sentinel 
nodes (1 in the ipsilateral axilla, 1 internal mammary and 1 in the 
contralateral axillary). One patient had 2 positive contralateral axillary 
sentinel nodes so an ALND was performed with no additional positive 
nodes. No surgical complications were observed.
Conclusions: In patients who had a previous ALND who develop a 
breast cancer recurrence, the SPTC-CT might show the exact location 
of aberrant hot spots but, some of the identified as hot spots may not 
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be lymph nodes. We must consider the exact location of the hot spot 
and the likelihood of false positives to avoid additional morbidity 
on the procedure.
P3-07-46
Accuracy of SPIO-Enhanced MR Imaging Alone for the Diagnosis 
of Sentinel Node Metastases in Patients with Breast Cancer.
Motomura K, Nakahara S, Ishitobi M, Komoike Y, Koyama H, Inaji 
H, Horinouchi T, Nakanishi K. Osaka Medical Center for Cancer 
and Cardiovascular Diseases, Osaka, Japan
Background: Superparamagnetic iron oxide (SPIO)-enhanced 
MR imaging has been reported to be promising for the detection 
of metastases in sentinel nodes localized by CT lymphography in 
patients with breast cancer (Motomura, Ann Surg Oncol 2011). The 
current SPIO technique involves imaging before and after contrast 
administration. This study evaluated the accuracy of SPIO-enhanced 
MR imaging alone without unenhanced imaging.
Methods: This study included 120 patients with breast cancer 
demonstrating clinically negative nodes. Sentinel nodes were 
identified by CT lymphography, and MR imaging of the axilla before 
and 18-24 hr after interstitial administration of SPIO was performed. 
A node was considered non-metastatic if it showed a homogenous low 
signal intensity and metastatic if there was an absence of low signal 
intensity either in the entire node or in a focal area on SPIO-enhanced 
MR imaging. The diagnostic accuracy of the SPIO-enhanced imaging 
alone was compared with that of combined unenhanced and SPIO-
enhanced imaging.
Results: The mean number of sentinel nodes identified by 
CT lymphography was 1.2 (range 1-3). Pathologic evaluation 
demonstrated that 28 (23.3%) of 120 patients showed metastasis 
to at least one node. One false negative result was added when 
the evaluation was based solely on SPIO-enhanced MR imaging. 
Consequently, the sensitivity decreased from 84.0% to 80.0% and 
the accuracy decreased from 89.2% to 88.3%, respectively, in the 
SPIO-enhanced MR imaging alone. However, the differences in 
sensitivity and accuracy between SPIO-enhanced MR imaging alone 
and the combined unenhanced and SPIO-enhanced imaging were 
not significant (McNemar’s test; p=1.0). The specificity of enhanced 
imaging alone and that of combined unenhanced and SPIO-enhanced 
imaging were both 90.5%.
Conclusions: A single MR imaging examination performed after 
SPIO administration can be used for accurate diagnosis of sentinel 
node metastases, and thus reduce the time and cost of imaging.
P3-07-47
Validated Nomogram To Predict Sentinel Lymph Node Positivity 
in Breast Cancer Patients.
Kaplan R, Qiu Q, Monni S, D’Alfonso T, Shin SJ. The New York-
Presbyterian Hospital - Weill Cornell Medical College, New York, NY
Background: Sentinel lymph node(SLN) biopsy is commonly 
used to assess axillary lymph node status in breast cancer patients. 
Intraoperative (frozen section) evaluation of SLN may lead to 
immediate axillary dissection if the lymph node is found to be 
positive. In light of the recent outcomes of the Z00011 trial, the use 
of intraoperative evaluation for SLN should diminish since only 
select patients appear to benefit from axillary dissection. We have 
previously reported that tumor size and lymphovascular invasion 
(LVI) strongly predict SLN positivity in a cohort of 350 breast cancer 
patients [Modern Pathology (2011) 24, 30A]. From this test cohort, 
we developed a nomogram which could help identify patients more 
likely to have sentinel lymph node positivity . The aim of this study 
was to validate the efficacy of this nomogram by applying a new, 
non-overlapping cohort of breast cancer patients who had undergone 
sentinel lymph node sampling. Materials and Methods: 93 breast 
cancer patients aged 29-82 (mean:59) who underwent excision (54, 
58%) or mastectomy (39, 42%) with a SLN biopsy were studied. 
Patients who had undergone neoadjuvant chemotherapy were 
excluded. Clinicopathologic parameters such as number of sentinel 
lymph nodes removed and/or positive, number of non-sentinel 
lymph nodes removed and/or positive, tumor size, histologic type/
grade, presence of lymphovascular invasion, biomarker expression 
(ER,PR, HER-2/neu) and multifocality were recorded. Statistical 
analysis was performed to identify which variables correlated with 
SLN positivity in this validation cohort. In addition, the probability of 
SLN positivity for each case was determined by using the nomogram 
and this value was then compared to the patient’s true SLN status. 
Results: When analyzed separately, tumor size (p=0.03) and LVI 
(p=0.01) were variables that were significantly associated with 
SLN positivity in both the test and validation cohorts. Employment 
of the nomogram demonstrated that 60% of patients who were 
predicted to have a positive SLN with at least 0.8 probability were 
truly positive by histologic and immunohistochemical examination. 
Moreover, 89% of patients who were predicted to have a negative 
SLN with at least 0.8 probability were truly negative by histologic 
and immunohistochemical examination. Conclusions: We conclude 
that the utility of this nomogram prior to surgery can help predict 
SLN positivity. This can serve as a complimentary adjunctive tool to 
better select patients who will likely need intraoperative evaluation 
of their sentinel lymph node due to their higher risk of sentinel node 
positivity and thus, benefit from the option of immediate axillary 
dissection at that time.
P3-07-48
Axillary Imaging with Dynamic MRI Following Subcutaneous 
Injection of Superparamagnetic Iron Oxide Nanoparticles.
Douek M, Johnson L, Parikh J, Charles-Eduards G, Hall-Craggs 
M. King’s College London, London, United Kingdom; Guy’ and St 
Thomas’ Hospitals, London, United Kingdom; University College 
Hospital, London, United Kingdom
Background: Surgical axillary staging with sentinel node biopsy in 
clinically node negative patients is standard of care in the management 
of breast cancer. However, sentinel node biopsy is associated with 
morbidity including a 5% risk of lymphoedema. Superparamagnetic 
iron oxide (SPIO) enhanced axillary MRI is a promising novel 
imaging modality that could be used to characterize sentinel nodes 
non-invasively. We evaluated subcutaneous SPIO enhanced axillary 
MRI for pre-operative axillary imaging.
Material and methods: Patients scheduled for sentinel node biopsy 
as part of surgical management of early breast cancer were invited to 
undergo pre-operative axillary MRI. All images were acquired on a 
1.5T scanner using a surface coil. The initial 7 scans were acquired 
on a Siemens Avanto and the later scans on a Achieva MRI scanner 
(Philips, Best, Netherlands). Following a T2-weighted morphological 
scan, patients were injected with 2ml of SPIO (4ml in the final 
3 patients) subcutaneously into the circumareolar margin in the 
upper outer quadrant of the affected breast. Post injection, a slightly 
T2*-weighted dynamic scan was performed (gradient echo, TE = 
1.53ms, TR=2.9ms, flip angle 7 degrees, 3mm slice thickness). In 
addition to the dynamic scan, in 16 patients, a T2 mapping sequence 
was performed at 10minutes and 120 minutes post injection (turbo 
spin echo, 8 equi-spaced TEs from 10 to 80ms, TR=2136ms, 3mm 
slices with an in plane resolution of 1.4x1.4mm). Image analysis was 
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undertaken using Osirix (v3.8, 64-bit). Two consultant radiologists 
experienced at reading breast and axillary MRI reported all scans.
Results: A total of 23 patients underwent axillary MRI with 
subcutaneous SPIO. Of these in 18 patients (78%), uptake of SPIO 
was seen in sentinel nodes and lymphatic tracts. At least 1 sentinel 
node was identified in 17 patients (74%). A total of 106 nodes were 
identified (4.6 ± 1.7 nodes per patient) and of these 40 demonstrated 
a significant drop in signal intensity following SPIO injection (1.7± 
1.3 nodes per patient). All 3 involved nodes were seen to contain a 
metastatic deposit on MRI.
Discussion: Axillary MRI with subcutaneous SPIO injection is a 
robust method for imaging sentinel nodes. The normal node count 
of the axillary basin is lower than expected on histology, suggesting 
that only the larger nodes and those that take up SPIO are visualized 
on MRI.
P3-08-01
Effects of an Integrated Yoga Program on Mood States, Distress, 
Quality of Life, Diurnal Cortisol Rhythms and Natural Killer Cell 
Counts in Metastatic Breast Cancer Survivors.
Gopinath SK, Rao RM, Sanjeevarao VH, Diwakar RB, Basavalingaiah 
AS, Patil S, Raghuram N, Ramarao N, Usharani RM. HCG - BIO 
Super Speciality Centre, Bangalore, Karnataka, India; Swami 
Vivekananda Yoga Anusandhana Samsthana, Bangalore, Karnataka, 
India
Background and objectives: Metastatic breast cancer patients 
experience tremendous psychological distress due to treatment, 
disease and uncertainty of their survival. In this study we evaluated 
the effects of an integrated yoga program versus supportive counseling 
in advanced breast cancer survivors.
Methods: Ninety one Metastatic breast cancer survivors (group mean 
age 50.54 yrs ± 8.53 yrs) registered in hospital based cancer registry 
were recruited if they satisfied selection criteria and gave written 
consent for participation in the study. The study was approved by 
the institutional review board. Subjects were randomized to either 
receive yoga intervention (n=45) or supportive therapy (n=46) 
counseling as a standard of care for 3 months of intervention period. 
Subjects were assessed at baseline and after intervention for mood 
states using hospital anxiety and depression scale, sleep quality 
using Pittsburg Insomnia rating scale, quality of life using EORTC 
Qol C30 for breast and perceived stress using perceived stress scale. 
Saliva samples were collected for three consecutive days at 0600hrs, 
0900hrs and 2100hrs before and after intervention for cortisol 
rhythms using Enzyme Immune Assay kits from Salimetrics and 
blood samples were collected between 0800hrs to 01000hrs for NK 
cell enumeration using flow cytometry. 35 subjects in yoga and 31 
subjects in controls completed the post measures. Data were analyzed 
using both parametric (ANCOVA with respective baseline measure 
as a covariate) and non parametric tests (Mann whitney U test) to 
evaluate effects of intervention on the above outcome measures. 
Data for salivary cortisol data was log transformed, area under the 
curve and cortisol slope computed using linear mixed effects model. 
Results: There was a significant decrease in anxiety (p < 0.001), 
depression (p < 0.001), perceived stress (p = 0.01), fatigue severity 
(p < 0.001) and interference (p < 0.001) in yoga group compared to 
controls post intervention. There was a significant improvement in 
emotional function (p < 0.001), role function (p = 0.03) and cognitive 
function (p < 0.001) and global quality of life (p < 0.001) in yoga 
group compared to controls. There was significant decrease in 0600 
hrs cortisol within the yoga group (p =0.03) alone. There was a 
significant increase in Natural killer cell percent in yoga group (p 
=0.03) compared to controls after intervention. Conclusion: The 
results suggest biobehavioral effects of yoga intervention could 
possibly improve quality of life, reduce psychological distress 
and modulate abnormal cortisol profiles and immune responses in 
metastatic breast cancer patients.
P3-08-02
Evaluating the Impact of Educational Material on Anastrozole 
Treatment Adherence – The Final Results of the ARTEMIS Study.
Nogaret J-M, Coibion M, Neven P, Soepenberg O, Graas M-P, 
Deschamp V, Vanlerberghe T. Jules Bordet Institute, Brussels, 
Belgium; CHC St-Vincent, Rocourt, Belgium; University Hospital 
Leuven, Leuven, Belgium; MariaZiekenhuis, Noord-Limburg, 
Belgium; CHC Saint-Joseph, Liège, Belgium; AstraZeneca Benelux, 
Brussels, Belgium
Rationale: Breast cancer (BC) is the most common cancer in 
European women. Compliance with the prescribed dosing regimen 
is essential for optimal effectiveness of cancer treatment. While 
adjuvant endocrine therapy reduces the risk of BC reoccurrence, 
only limited information is available regarding patient adherence 
to this type of treatment. Electronic monitoring of patients’ dosing 
histories has demonstrated the frequently irregular drug intake of 
patients. The ARTEMIS study (ARimidex Therapy compliance 
Electronic MonitorIng System, NCT00936442) evaluated the impact 
of educational material on the adherence to adjuvant treatment with 
anastrozole (Ax, Arimidex®).
Methods: This randomized (1:1), open-label, parallel-group study 
in 5 centers in Belgium had two treatment groups: GpA-Standard 
Treatment, GpB-Standard Treatment+Education. All patients received 
a 12 month follow-up of Ax treatment according to current clinical 
practice. Patients in GpB also received additional educational material 
on a regular basis (9 mailings). Eligible patients were postmenopausal 
women with hormone sensitive early BC prescribed Ax (<13 weeks 
duration). All patients received Ax (1mg orally/day) in a Medication 
Event Monitoring System (MEMS® AARDEX Ltd) that electronically 
records bottle openings. The 500 ml capacity contained medication 
for 6 months treatment to avoid additional clinical visits to resupply 
medication. The sample size was based on the primary objective: 
adherence to Ax (the daily proportion of patients taking Ax). 
Secondary variables included persistence with Ax (the estimated 
length of time during which the medication is taken), execution of 
the Ax regimen and reasons for treatment discontinuation.
Results: 107 patients (mean age 61.4±9.9 years) were enrolled: 
54 in GpA, 53 in GpB. 16 patients (9 GpA, 7 GpB) discontinued 
prematurely based on the case report form with the MEMS system 
indicating that a further 4 patients (3 GpA, 1 GpB) discontinued. 
Overall, the adherence rate was high and decreased significantly over 
time (p=0.0061). There was no significant difference in adherence 
rate between the two groups (p=0.2358) with the daily average 
probability of correct intake 80.2±4.16% (GpA) and 86.7±4.94% 
(GpB). There was a trend for the persistence rate after 12 months 
to be better in GpB (84.7±5.0%) compared to GpA (77.8±5.7%; 
p=0.0782). An exploratory analysis showed a significant association 
between overall persistence and increasing postmenopausal age 
(Exp(coef)=0.942; p=0.038). The execution of the dosing regimen 
improved over time (p=0.0126) and was similar throughout the study 
for both groups (GpA: 96.5±3.1%, GpB: 94.0±3.1%; p=0.1674). 
Side effects (5 patients, 4.7%) were the most common reason for 
early discontinuation (GpA: 1 patient, GpB: 4 patients) but overall 
side effects were low.
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Conclusion: Educational material by mail did not significantly affect 
patient adherence to anastrozole. Persistence with treatment was 
associated with the post-menopausal age of the women and showed a 
trend for improvement in those receiving educational material. Since 
anastrozole treatment normally lasts 5 years, a longer-term follow-up 
study may provide better insight into the usefulness of MEMS on 
treatment compliance.
P3-08-03
Exercise Increases Soluble Vascular Endothelial Growth Factor 
Receptor-1 (sFlt-1) in the Circulation of Adult Women.
Makey K, Patterson SG, Robinson J, Loftin M, Waddell DE, Miele L, 
Chinchar E, Huang M, Smith AD, Weber M, Gu J-W. University of 
Mississippi Medical Center, Jackson, MS; University of Mississippi, 
Oxford, MS
Background: Physical inactivity increases the risk of several different 
cancers, including breast cancer. Soluble fms-like tyrosine kinase-1 
(sFlt-1) is an extra-cellular Ig-like domain of the VEGF receptor-1 
that is released into the extracellular space and circulation where it 
inhibits the activities of VEGF. Over-expression of sFlt-1 has been 
shown to inhibit ovarian tumor growth in gene therapy experiments. 
The present study tests the hypothesis that exercise can increase sFlt-1 
in the circulation of adult women.
Material and Methods: 63 African American and Caucasian adult 
woman volunteers aged 18-44 were enrolled into a prospective 
exercise study. All the participants walked on a treadmill for 30 
minutes at a moderate intensity (40-60% heart rate reserve), and 
oxygen consumption (VO2) was quantified by utilizing a metabolic 
cart. Blood samples were collected before and immediately after 
exercise. The exercise test was conducted between the first and 
seventh day of the participant’s menstrual cycle. The plasma 
concentrations of sFlt-1, unbound VEGF, and endostatin were 
measured using ELISA kits from R and D Systems.
Results: Plasma levels of sFlt-1 were 67.8±3.7 pg/ml immediately 
after exercise (30 minutes), significantly higher than basal levels of 
54.5±3.3 pg/ml before exercise (P<0.01; n=63). The % increase in 
sFlt-1 levels before and after exercise in adult women was 54%. There 
was no significant difference in the % increase of sFlt-1 levels between 
African American and Caucasian groups (P=0.5334). There was no 
significant difference in plasma levels of endostatin before (92.4±4.4 
ng/ml) and immediately after (93.8±4.4 ng/ml; P=0.8216) exercise. 
The basal plasma levels of unbound VEGF (21.5±4.3 pg/ml) ware 
similar to the plasma levels of VEGF (22.5±4.6 pg/ml; P=0.8652) 
immediately after exercise.
Discussion: We previously reported that plasma levels of sFlt-1 
significantly increased 30 minutes after exercise in adult men, in which 
plasma levels of unbound-VEGF significantly decreased and plasma 
levels of endostatin significantly increased 2 hours after exercise. Until 
now, there has been no data on whether exercise increases plasma 
sFlt-1 levels in women. Our study is the first to show that exercise in 
adult women significantly increases plasma levels of sFlt-1. VEGF 
pathways have both autocrine and paracrine effects for promoting 
breast cancer progression. Previous studies have demonstrated that 
sFlt-1 inhibits the activities of VEGF and suppresses ovarian tumor 
growth in mice. Exercise-induced plasma levels of sFlt-1 could be an 
important clinical biomarker to explore the mechanisms of exercise 
training in reducing breast cancer progression. The sFtl-1 is produced 
in the microvascular and macrovascular endothelial cells that exist 
throughout the skeletal muscle tissues. It is therefore plausible that 
release of sFlt-1 from the skeletal muscles into the circulation might 
be due to exercise-dependent reductions in oxygen tension in the 
skeletal muscle. In future studies, we will determine whether sFlt-1 
can be released directly from the exercised muscle.
P3-08-04
“How Important Is This for Me?” – The Role of Necessity Beliefs 
as Determinants of Breast Cancer Prevention Intentions among 
High-Risk Women.
Verma S, Paquet L, Stacey D, Davis I, Bedard M, Lowry S, Ianni L. 
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Carleton 
University, Ottawa, ON, Canada; University of Ottawa, Ottawa, 
ON, Canada
Background Women at elevated risk for breast cancer (BC) face 
complex risk management decisions. Understanding the determinants 
of pre-counselling risk management intentions would be useful to 
clinicians in helping high-risk women make their decisions. Across 
several medical conditions, the Necessity-Concerns Framework 
(NCF) has emphasized the role of patient’ beliefs about interventions 
offered to them as central to decision-making. In the NCF, beliefs 
are conceptualized as perceived personal need for an intervention 
(necessity) and as concerns about its perceived negative effects. To 
date, the NCF has not been applied to investigate decision-making in the 
high-risk setting. Our objective was to use the NCF to describe the risk 
management beliefs of high-risk women prior to initial consultation. 
The relative importance of BC fear, perceived susceptibility to BC 
and necessity-concerns beliefs in predicting prevention intentions 
was also examined. Methods A survey was sent to patients prior to 
their first risk consultation. BC fear was assessed with Champion 
BC Fear Scale and perceived susceptibility was measured by asking 
women to rate their likelihood of developing BC (0 =definitely will 
not get it to 100=definitely will get it). For each of screening, lifestyle 
modifications, pharmacoprevention (PP) and prophylactic surgery 
(PS), women rated (1=strongly disagree to 5=strongly agree) their 
need for the option (e.g., my health in the future will depend on this 
option, this option will protect me from becoming worse), and its 
negative consequences (e.g. I worry about the long-term effects of 
this option, this option will disrupt my life). Intentions were assessed 
by asking how strongly (1=definitely not to 5=Definitely Yes) they 
intended to adopt each option. The planned sample size is 100 women 
and recruitment is on-going. We report data from 44 women who 
have completed the questionnaire. Results: The majority intended 
to adopt screening (92%) and lifestyle (91%) compared to PP (23%) 
or PS (18%). Screening and lifestyle were associated with stronger 
intentions, higher perceived need, and lower concerns than PP and 
PS (all t-tests, p <0.0001). Hierarchical regression analyses revealed 
that perceived need predicted intentions for each option (all ps < 
0.005, except for screening, p < .1) whereas concern beliefs were 
only correlated with PP intentions (b=-.398, p < .005). Fear of BC 
was related to PP intentions (b=.401, p < .005) and to intentions to 
remain smoke-free (b=-.341, p < .05). Perceived susceptibility did 
not contribute to intentions. Conclusions Our preliminary findings 
are promising and suggest that the NCF is useful for understanding 
decision-making in the high-risk setting. The findings emphasize the 
importance of necessity beliefs in BC risk management decisions. 
For the group as whole, across each risk management option, the 
strongest predictor of intentions was a women’s perception of her 
personal need for the option. Concerns about negative effects and 
BC fear played only a minor role and perceived susceptibility did 
not predict intentions. These observations stress the importance of 
making screening or prevention recommendations hand in hand with 
the individual beliefs and concerns.
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P3-09-01
Change in Carbohydrate Intake and Breast Cancer Prognosis.
Emond JA, Patterson RE, Pierce JP. UCSD Moores Cancer Center, 
La Jolla, CA; San Diego State University, San Diego, CA
Breast tumors over express insulin-like-growth-factor receptors 
(IGF-IR), and levels of expression may be inversely related to tumor 
grade. Dietary factors, particularly carbohydrate intake, may stimulate 
activation of IGF-1R and affect prognosis.
METHODS: Data are from N=2,651 women in the Women’s Healthy 
Eating and Living (WHEL) Dietary Intervention trial, a plant based 
intervention trial that did not have a carbohydrate goal. All women 
were diagnosed with breast cancer within the previous 4 years. 
Carbohydrate dietary intake data were extracted from multiple 24-
hour dietary recalls at study entry and one year, and were compared by 
recurrence status. Time to recurrence was modeled on year-one change 
in carbohydrate intake adjusted for baseline intake, menopausal status, 
and disease, treatment, and study characteristics.
RESULTS: Baseline carbohydrate intake was 233 g/day. Women 
who recurred had a mean increase in carbohydrate intake over the 
first year, compared to those who did not recur (2.3 vs. -2.7 g/day; 
p=0.188). Change in starch intakes accounted for 48% of the change 
in carbohydrate intake (R-squared: 48%; p<0.001). Baseline starch 
intake did not differ by recurrence status (95.8 g/day; p=0.219). Mean 
year-one change in starch intake was -4.1 g/day among women who 
recurred vs. -8.7 g/day among women who did not recur (p=0.015). 
Year-one change in starch intake was independent of the study 
intervention (p=0.326). In the adjusted model, a 5-g/day increase in 
starch related to a 3% increased risk of recurrence (HR=1.03; 95% 
CI 1.01 – 1.06; p=0.017). The increased risk was limited to women 
diagnosed with low grade tumors (Table 1).
Table 1: Adjusted risk of recurrence by year-one change in starch intake.
 Overall Stratified By Primary Tumor Grade
Year-one change, 5g/day  Well/Moderate Differentiation Poor Differentiation
HR (95% CI); p-value
1.03 (1.01-1.06);  
p=0.017
1.05 (1.01-1.09); p=0.007
1.00 (0.96–1.04);  
p=0.981
DISCUSSION: Dietary modifications targeting starch intake warrant 
further investigation as a preventive measure against breast cancer 
recurrence.
P3-09-02
Intermittent Dietary Carbohydrate Restriction Enables Weight 
Loss and Reduces Breast Cancer Risk Biomarkers.
Harvie M, Wright C, Pegington M, Mitchell E, Evans DG, Jebb S, 
Clarke R, Goodacre R, Dunn W, Mattson M, Howell A. University 
Hospital of South Manchester, Manchester, United Kingdom; MRC 
Human Nutrition Research Group, Cambridge, United Kingdom; 
University of Manchester, Manchester, United Kingdom; National 
Institute of Aging, Baltimore
Background: Energy restriction is a potential strategy for breast 
cancer prevention but is difficult to achieve and maintain. We found 
that intermittent energy restriction (2 days strict dieting week) is 
comparable to the standard approach of moderate daily restriction for 
weight loss and marginally better for improving insulin sensitivity, 
but no easier to follow1. In this follow on study we wished to test 
whether 2 novel intermittent low carbohydrate/ low energy diets were 
feasible and easier to follow than a standard daily energy restriction.
Design: Randomised comparison of 3 dietary types over 4 months in 
115 overweight or obese (mean body mass index 31.0 [±5.3 SD] kg/
m2) women at increased risk of breast cancer (lifetime risk > 1 in 6).
Diets:
1. A restricted low carbohydrate diet (RLCD): 650 kcal and <50g 
carbohydrate / day for 2 days per week
2. Ad lib low carbohydrate diet (ALCD): <50g / day for 2 days per 
week with other food types (e.g. protein) ad lib
3. A standard daily restricted Mediterranean diet (DRMD): ~1500kcal 
/ day for 7 days per week
Methods: Weight, anthropometrics, blood markers for breast cancer; 
insulin resistance, oxidative stress markers, leptin, adiponectin, 
lipids, inflammatory markers IGF-1 were assessed at baseline, 1, 3 
and 4 months.
Results: 88/114 completed the study (77%, drop outs 6 RLCD, 8 
ALCD 12 DRMD). Last observation carried forward analyses show 
both intermittent low carbohydrate diets were superior to standard 
daily restriction for reducing weight and body fat: mean (95% 
confidence interval [CI]) change in body fat for RLCD was -4.3 (-5.6 
to -3.0) kg, for ALCD -4.1 (-5.2 to -3.1) kg vs. -2.4 (-3.4 to -1.2) 
kg for DRMD (P value for difference between groups = 0.02). The 
intermittent groups had greater improvement in insulin resistance: 
mean (95% CI) change for RLCD was -22 (-35 to -11) %, ALCD 
-14 (-27 to -5%) % vs. -4 (-16 to 9) % for DRMD (P = 0.02). Other 
biomarkers are being assayed currently.
Conclusion: Greater weight loss, fewer drop outs and greater 
reductions in insulin resistance with the novel intermittent low 
carbohydrate diets indicate that these are alternative approaches for 
energy restriction for potentially reducing risk of breast cancer and 
other diseases.
Reference:
1Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans 
G et al. The effects of intermittent or continuous energy restriction 
on weight loss and metabolic disease risk markers: a randomized trial 
in young overweight women. Int.J Obes (Lond) 35; 714-27, 2011.
This study is funded by the Genesis Breast Cancer Prevention Appeal: 
www.genesisuk.org
P3-09-03
Long-Chain Polyunsaturated Fatty Acid Intake and Its 
Relationship to Long-Chain Polyunsaturated Fatty Acids in 
Serum, Red Blood Cells and Breast Tissue.
Harvey KE, Li S, Carlson SE, Sullivan DK, Klemp JR, Kimler BF, 
Fabian CJ. University of Kansas Medical Center, Kansas City, KS
Background: Long chain omega-3 (n-3) poly unsaturated fatty acids 
(LCPUFA) have anti-inflammatory effects and are able to counteract 
the effects of the pro-inflammatory omega-6 (n-6) fatty acids such 
as arachidonic acid (AA) by substituting for the n-6 fatty acids in 
triglycerides (TG) and phospholipids (PL). Several pre-clinical, 
observational, and case control studies suggest that intake or tissue 
content of n-3 LCPUFA such as eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA), relative to intake or tissue content of 
long chain n-6 fatty acids such as AA may be associated with reduced 
risk of breast cancer. The goal of this study was to determine the 
relationships between dietary intake of fatty acids, tissue levels of 
fatty acids, and breast tissue biomarkers for risk of breast cancer.
Methods: Women (n=74) were recruited from a clinic in which 
women at increased risk for breast cancer had breast tissue acquired 
by random periareolar fine needle aspiration (RPFNA). Breast 
epithelial cells were assessed for cytomorphology and proliferation 
(Ki-67 immunochemistry). Fatty acid dietary intake was assessed with 
the National Cancer Institute Diet History Questionnaire. Plasma, 
erythrocyte, and breast specimens were processed for membrane 
PL and TG and analyzed for individual fatty acids by gas liquid 
chromatography.
Results: Total intake of n-3 PUFA was 1.1 ± 0.5 g/d, and the ratio of 
EPA+DHA:AA was 0.1:1.0 (n=66). Dietary n-3 LCPUFA correlated 
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with n-3 LCPUFA in both plasma and erthyrocyte PL (n=62). Breast 
epithelial cell number, Masood cytomorphology score, and percent 
Ki-67 positive cells were higher in RPFNA specimens which exhibited 
cytologic atypia compared to those which did not (n=74; p<0.001, 
Mann-Whitney Test). Subjects with atypia consumed less dietary n-3 
PUFA (n=66, p=0.020), had lower plasma and erythrocyte PL and 
plasma TG EPA, DHA, total n-3, and EPA+DHA:AA (n=70; p<0.05). 
In breast tissue TG, the ratio of n-3:n-6 was also lower in subjects 
with atypia (n=40; p=0.025).
Conclusions: Overall, women in this high risk cohort consumed very 
low amounts of n-3 LCPUFAs. Dietary intake of n-3 LCPUFA was 
related to levels of n-3 LCPUFA in erythrocyte and plasma PL. Given 
the association of low levels of n-3 fatty acids with cytologic atypia 
(a known risk factor for breast cancer development), an intervention 
to increase n-3 fatty acids and n-3:n-6 ratios has merit and clinical 
trials in high risk women have been initiated.
P3-09-04
Comparative Preventive Efficacy of Aqueous Extracts from 
Lycium Barbarum Bark and Fruit on Estrogen Receptor Positive 
Human Mammary Carcinoma MCF-7 Cells.
Telang NT, Li G, Sepkovic DW, Bradlow LH, Wong GGY, Telang NT. 
Palindrome Liaisons, Montvale, NJ; American Institute for Chinese 
Medicine, New York, NY; Hackensack University Medical Center, 
Hackensack, NJ
Background: Chemotherapy, selective estrogen receptor modulators 
and aromatase inhibitors represent major treatment options for 
estrogen receptor positive (ER+) clinical breast cancer. These 
modalities frequently exhibit acquired tumor resistance and adverse 
systemic toxicity. Natural herbs are increasingly being used in the 
integrative support of breast cancer patients undergoing conventional 
treatment modalities and for prevention purposes. We previously 
reported favorable findings for the fruit of Lycium barbarum (LB), 
known commonly as goji berry, in the prevention for ER+ breast 
cancer (Nutrition & Cancer 61:408-414, 2009). The present study 
compares the preventive efficacy of non-fractionated aqueous extracts 
from the bark of LB (LBB) and the fruit of LB (LBF) on a cell culture 
model for ER + breast cancer.
Material and Methods: The ER+ human mammary carcinoma derived 
MCF-7 cells represented the model. Anchorage dependent growth, 
anchorage independent colony formation and cellular metabolism 
of 17b-estradiol (E2) represented the mechanistic bases for efficacy.
Results: MCF-7 cells grown in serum depleted medium retained 
their responsiveness to E2, exhibiting E2 stimulated promotion of 
anchorage dependent growth and anchorage independent colonies. 
LBB was much more potent than LBF as evidenced by a 95% 
reduction of IC50 from 0.38% for LBF to 0.02% for LBB, and a 
95% reduction of maximum cytostatic concentration (MCC) from 
1% for LBF to 0.05% for LBB. At their respective MCC, LBB 
treatment and LBF treatment produced a 93% and an 89% decrease, 
respectively, in the number of anchorage independent colonies. Also, 
LBB produced a 6.8 fold increase in 2-hydroxyestrone (2-OHE1), 
a 40% decrease in 16a-hydroxyestrone (16a-OHE1) and a 3.7 fold 
increase in estriol (E3) formation. The corresponding values for LBF 
were 3.9, 33 and 10.5. LBB treatment resulted in a 16.3 fold increase 
in 2-OHE1:16a-OHE1 ratio and a 2 fold increase in E3:16a-OHE1 
ratio, while LBF treatment produced a 6.0 fold increase and a 2.9 
fold increase, respectively, in these endocrine biomarkers. These 
data suggest that the preventive efficacy of LBB may predominantly 
be due to up-regulation of the anti-proliferative 2-OHE1 formation, 
while accelerated conversion of the pro-mitogenic 16a-OHE1 to the 
mitogenically inert E3 is the case with LBF.
Discussion: Growth inhibitory profiles of LBB and LBF may in part 
be due to their distinct chemical composition and their complementary 
actions on E2 metabolism. The superior sensitivity of LBB relative 
to LBF, together with its non-toxic nature, suggests the feasibility 
of its use in the prevention of human breast cancer. A prevention 
trial to assess its efficacy and to establish relevant dose schedule 
is warranted. This study validates a mechanism based approach to 
identify and prioritize efficacious herbal extracts for the prevention 
of ER+ breast cancer.
P3-09-05
Understanding the Role of Estrogen in Sex Differences in 
Adipocyte Biology for Cancer Prevention.
Stubbins RE, Holcomb VB, Hong J, Nunez NP. The University of 
Texas at Austin, Austin, TX
Background: Evidence shows that obesity increases the risk and 
mortality of many cancers, specifically breast cancer in post-
menopausal women. Epidemiological studies demonstrate that 
males are at an increased risk for developing obesity, diabetes, and 
cancer compared to females, and after menopause, females mimic 
the males in their susceptibility to the above diseases. Furthermore, 
it has been established that obesity increases systemic and adipose 
tissue inflammation and oxidative stress, which is known to augment 
cancer progression. However, the role of estrogen in regulating 
these metabolic processes in adipose tissue is unclear; therefore, 
our objective is to determine the role of estrogen in adipose tissue 
morphology, inflammation and oxidative stress.
Methods: To determine the role of estrogen in gender differences in 
the susceptibility to obesity we used C57BL/6J mice (15/group): 1) 
males 2) nonovariectomized females 3) ovariectomized females and 
4) ovariectomized females supplemented with estrogen, which were 
randomized to the following diets: 30% calorie-restricted, low-fat or 
high-fat diet. We measured weight gain, percent body fat, abdominal 
adipose tissue, and adipocyte size. Additionally, we assessed markers 
of adipose tissue inflammation, DNA damage, and oxidative stress.
Results: Male mice were more susceptible to obesity than female 
mice. Removal of the ovaries eliminated the protection to obesity 
and estrogen supplementation restored this protection in females. 
In the low-fat and high-fat diet groups, male and ovariectomized 
female mice gained more abdominal adipose tissue due to increased 
adipocyte size compared to nonovariectomized female mice and 
ovariectomized female mice supplemented with estrogen. In the mice 
consuming the high fat diet, the enlarged adipocytes observed in the 
male and ovariectomized female mice were accompanied with crown-
like structures surrounding necrotic adipocytes and F480 positive 
macrophages, suggesting macrophage infiltration. To determine if 
there were sex differences in oxidative stress, we stained adipose 
tissue with gH2AX. Results suggest that nonovariectomized female 
mice and ovariectomized female mice supplemented with estrogen 
have less oxidative stress compared to males and ovariectomized 
females. Additionally, our results show that nonovariectomized 
female and ovariectomized female mice supplemented with estrogen 
had significantly lower CD68, TNFa and iNOS mRNA expression 
levels, but higher catalase mRNA expression levels.
Conclusion: Male mice are more susceptible to the obesogenic effects 
of high fat diets compared to nonovariectomized female mice. In 
ovariectomized females, estrogen supplementation has a protective 
effect against obesity, adipose tissue inflammation and oxidative 
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stress. Our future studies will determine the mechanisms by which 
estrogen protects female mice from adipose tissue inflammation and 
oxidative stress, whether it is a direct or indirect effect. Determining 
the role of estrogen on the above key metabolic processes related 
to obesity is necessary to develop effective strategies for cancer 
prevention specifically in post-menopausal females.
P3-09-06
Changes of Serum Vitamin D According to the Breast Cancer 
Treatment.
Kim HJ, Yi OV, Koh BS, Yu JH, Lee JW, Son BH, Ahn SH. Asan 
Medical Center, Seoul, Korea
Background
Vitamin D deficiency is associated with increased breast cancer risk 
and decreased breast cancer survival. The purpose of this study was to 
determine the effect of breast cancer adjuvant treatment to the vitamin 
D status, as measured by the serum hydroxyvitamin D (25OHD) in 
breast cancer patients.
Patients and Methods
For 589 patients who was diagnosed as a non metastatic breast cancer 
in 2009 at the asan medical center, blood was prospectively analyzed 
in batches for serum 25 OHD level at basal and at 6 and 12month. 
We excluded the patients who took a vitamin D supplementation and 
got a neoadjuvant chemotherapy. Vitamin D sufficiency was defined 
as serum as 30ng/ml or greater, insufficiency as 20 to 29 ng/ml and 
insufficiency as less than 20ng/ml.
Results
At baseline, mean serum 25OHD was greater in summer (April to 
Oct) than Winter(Nov to May ) (28.2ng/ml vs 32.9ng/ml respectively, 
p=0.000). The patients who did not get a chemotherapy and anti-
hormonal therapy as baseline, the patient with chemotherapy showed 
decreased serum 25OHD level than who without chemotherapy in 6 
month but not in 12 month (p=0.003, vs p=0.156 respectively). The 
patients who had taken anti-hormonal therapy showed significant 
increasing serum 25OHD in 6 month and 12 months (p=0.000 both). 
For the patients who got both chemotherapy and anti-hormonal 
therapy, the changes of serum 25OHD level is smaller than the patients 
who got a chemotherapy only.
For the patients who got a chemotherapy, 57% of patients were 
vitamin D sufficient at baseline, but 27% of patients in 6 month and 
49% in 12 month (p=0.001).
Conclusion
Vitamin D status was worsen during chemotherapy but recovered 
after chemotherapy. Anti hormonal therapy make the serum vitamin 
D level increased. The translational research about the effect of 
chemotherapy and anti-hormonal therapy to the vitamin D status 
should be warranted.
P3-10-01
Alternative Dosing Regimens with the EGFr Inhibitors (Gefitinib 
and Lapatinib) in Mammary Cancer Models: Prevention and 
Therapeutic Efficacy.
Lubet RA, Bode AM, Szabo E, Grubbs CJ. National Cancer Institute, 
Bethesda, MD; Hormel Institute, Austin, MN; University of Alabama 
at Birmingham, Birmingham, AL
The EGFR inhibitors are effective in treatment of lung and pancreatic 
cancers (erlotinib, gefitinib) and Neu overexpressing breast cancer 
(lapatinib) in humans; as well as preventing multiple cancers in 
animal models. However, the development of toxicities (Iressa, skin 
rashes; Lapatinib, diarrhea) limit their potential use in prevention; and 
perhaps even in an adjuvant setting. We examined whether alternative 
dosing regimens which might reduce toxicity would still achieve 
preventive and therapeutic efficacy. Female Sprague-Dawley rats 
were administered a single IV dose of methylnitrosourea (MNU) at 
50 days of age. In a prevention study, MNU treated rats administered 
Gefitinib daily (10 mg/kg BW/day, 7x/week) or Gefitinib (70 mg/
kg BW, 1x/week) beginning 5 days after MNU resulted in 94 and 
75% reductions, respectively, in cancer multiplicity. Simultaneous 
measurements of tumor load (number of tumors x tumor weight) 
showed that both regimens resulted in greater than a 90% decrease. 
In the therapeutic study (initiating treatment when animals developed 
a small palpable cancer), both regimens were again highly effective. 
A prevention study was also performed with Lapatinib (75 mg/kg 
BW/day, 7x/week or 525 mg/kg BW, 1x/week). While the daily dose 
reduced cancer multiplicity 90%, the weekly dose caused a 70% 
reduction. Finally, we examined the effects of daily or weekly dosing 
with Iressa (100 mg/kg BW/day, 5x/week or 500 or 250 mg/kg BW, 
1x/week) in an ER- mouse model (using MMTV-Neu; p53+/- mice). 
This study showed that while daily dosing with Iressa decreased tumor 
multiplicity roughly 80%, weekly dosing at either dose caused roughly 
a 50% decrease. These data show that even a significant alteration 
in the dosing of Gefitinib (EGFR 1) or Lapatinib (EGFR 2/1) still 
resulted in a large reduction in mammary cancers. The important 
clinical question will be whether this altered dosing will diminish 
the toxicities associated with these agents. We cannot determine this 
in animal models since, at the effective doses employed, the typical 
toxicities observed in humans are not observed. Supported by NCI 
contract number HHSN261200433001C.
P3-10-02
Gene Expression Changes in Methylnitrosourea (MNU)-Induced 
ER+ Mammary Cancers Following Short-Term Treatment of Rats 
with the Aromatase Inhibitor Vorozole.
Lubet RA, Grubbs CJ, Bode A, You M, Lu Y. National Cancer Institute, 
Bethesda, MD; University of Alabama at Birmingham, Birmingham, 
AL; Hormel Institute, Austin, MN; Medical College of Wisconsin, 
Milwaukee, WI
Aromatase inhibitors have proven to be highly effective in both 
therapy and prevention of ER+ breast cancer. Vorozole (R83842), a 
high affinity competitive inhibitor of aromatase (similar to letrozole 
and anastrozole) showed strong activity in early clinical trials against 
ER+ breast cancer. Furthermore, vorozole was highly effective in 
the prevention and therapy of ER+ cancers in the MNU-mammary 
cancer model (Lubet, et al., Carcinogenesis 19, 1345, 1998). In the 
present study, rats bearing mammary cancers induced by MNU were 
exposed to vorozole (1.25 mg/kg BW/day) for 5 days. Global gene 
expression analysis showed that 162 genes were down-regulated 
and 180 genes up-regulated in cancers treated with vorozole (p < 
0.05 and fold change > 1.5). The genes modulated by vorozole were 
compared with two additional sets of data. First, thirty-two genes and 
a number of pathways exhibited significantly concordant changes 
with aromatase inhibitors both in the animal model and in at least 
three of four published human data sets. In particular, differentially 
expressed genes enriched in the cell cycle pathway that were related 
to chromosome condensation in prometaphase [including Aurora-A, 
Aurora-B, Bub1B, non-SMC condensin I complex, subunit H 
(BRRN1), Condensin, CAP-G, CAP-G/G2, CAP-H/H2, CAP-D2/
D3, CAP-E, TOP2, Cyclin A, Cyclin B, CDK1, Histone H1 and inner 
centromere protein (INCENP)] were downregulated after treatment 
with the aromatase inhibitor. These results appear to be in agreement 
with the strong anti-proliferative effects of aromatase inhibitors in 
both animal and clinical studies. A second comparison was with an 
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in vitro study in which estrogen was removed from MCF-7 cells in 
culture. Decreases in genes related to the E2F1 transcription factor 
were observed. In our study, 13 modulated genes exhibited E2F-1 
binding sites in their promoter regions, and 7 genes contained both ER 
binding and E2F binding sites. We were able to confirm modulation 
of the cell cycle related and E2F-related genes in a large independent 
set of human samples treated with anastrozole. The results on RNA 
changes for Bub 1B, Cyclin A and CDK-1 were verified by employing 
IHC analysis. In summary, gene changes observed in the rat closely 
paralleled gene changes associated with aromatase treatment and 
estrogen withdrawal in humans.
P3-10-03
Bardoxolone (5MeCDDO) Inhibits Cancer Initiation but 
Promotes Progression in Rodent Models of Breast Cancer. What 
Does It Mean for the Antioxidant Response Element (ARE) as a 
Primary Prevention Target?
Lubet RA, Townsend R, Vedell P, Steele VE, Grubbs CJ. National 
Cancer Institute, Bethesda, MD; Washington University School 
of Medicine, Saint Louis, MO; Medical College of Wisconsin, 
Milwaukee, WI; University of Alabama at Birmingham, Birmingham, 
AL
The preventive efficacies of the triterprenoid 5MeCDDO were 
examined in three preclinical models of breast cancer. We initially 
evaluated 5MeCDDO in an ER+ mammary model in which female 
Sprague-Dawley rats were administered MNU, i.v., at 50 days of 
age. 5MeCDDO (27 ppm) was administered in the diet beginning 5 
days after MNU, and continuing for the duration of the study. Doses 
>50 ppm were toxic. 5MeCDDO failed to decrease tumor latency or 
multiplicity and, in fact, increased the size of the cancers which did 
develop. This concentration of 5MeCDDO greatly increased liver 
to body weight ratios. We also examined the preventive efficacy 
of 5MeCDDO (54 and 27 mg/kg diet) in a bitransgenic model 
(MMTV-Neu/p53KO) of ER- mammary cancer. In this model, 
animals develop cancers which overexpress Neu and fail to have a 
mutation in the transmembrane domain of Neu. Similarly to results 
in the MNU model, 5 MeCDDO did not alter either tumor latency 
or multiplicity. The effect of 5MeCDDO was further evaluated in a 
third model in which ER+ tumors were induced by the procarcinogen 
dimethylbenzanthracene (DMBA). DMBA was administered by 
gavage to female Sprague-Dawley rats at 50 days of age. In this 
model (which examines the ability of an agent to alter the activation 
of the carcinogen) the preventive agent was administered beginning 
7 days prior to DMBA and was continued until 7 days post DMBA. 
5,6 Benzoflavone (500 ppm), a positive control, decreased tumor 
multiplicity >90%, while 5MeCDDO (27 or 2.7 ppm) decreased 
multiplicity 65 and 35%, respectively. The efficacy observed in this 
model is in agreement with the ability of the agent to stimulate the 
ARE, and to induce a variety of ARE related genes (e.g., GST PI, 
quinone reductase, etc). Thus, as expected, high induction of the 
ARE was associated with a decrease in DMBA-induced cancer 
initiation, but not a decrease in the progression stage of mammary 
cancer development in three cancer models. This latter finding brings 
into question whether merely measuring induction of the ARE (e.g., 
quinone reductase) is sufficient to imply the general preventive 
efficacy of a given agent or mixture. Supported by NCI contract 
number HHSN261200433001C.
P3-10-04
Halting Early Breast Cancer Progression with Omega-3 Ethyl 
Esters: Altering Tumor Microenvironment in 21T Series Cell 
Lines.
Chen CH, Rhodes ME, Fabian C, Hursting SD, deGraffenried LA. 
University of Texas at Austin, Austin, TX; University of Kansas Cancer 
Center, Kansas City, KS
Observable infiltration of immune cells in stages of early breast 
cancer progression mirrors two recently conceptualized factors of 
carcinogenesis: tumor microenvironment and tumor-promoting 
inflammation.
Clinical studies using immunohistochemical staining for CD45 
in patient-derived breast tissue demonstrate the involvement of 
leukocytes in breast cancer development, but the lack of an appropriate 
in vitro model has hindered molecular studies thus far. However, the 
21T series cell lines effectively mimic breast cancer progression. This 
cell line series was obtained from the same breast cancer patient and 
consists of three
cell lines representing atypical hyperplasia (21PT), ductal carcinoma 
in situ (21NT) and invasive carcinoma (21MT-1). This unique cell 
line series is used in our molecular study of omega-3 ethyl esters as 
breast cancer preventive agents. Preliminary invasion assays have 
described varying degrees of monocyte recruitment according to 
stages of progression. 21PT cells when plated on the bottom chamber 
failed to mobilize monocytes as effectively as 21NT or 21MT-1 and 
the addition of omega-3 ethyl esters suppressed the baseline invasion 
capacity of monocytes by 30%. Epidemiologic studies suggest that 
omega-3 fatty acids can act as potent cancer preventive agents and 
are possibly more potent when used in an ethyl ester form. Based 
on this, we hypothesize that omega-3 ethyl esters may prohibit early 
breast cancer progression through inhibiting immune cell infiltration 
and disrupting the formation of a tumor-promoting inflammatory and 
oxidative microenvironment. Phenotypic studies aim to interrogate 
the effect of omega-3 ethyl esters on tumor microenvironment 
including chemokine secretion and MMP production whereas 
molecular experiments probe into the importance of the Wnt pathway 
as a key player in the transition from ADH to DCIS. This study will 
demonstrate how omega-3 ethyl esters may function as breast cancer 
preventive agents as well as provides a model of study to test the 
efficacy of cancer preventive agents in vitro.
P3-11-01
Effects of Exemestane Therapy on the Lipid Profile of 
Postmenopausal Women with an Elevated Risk of Developing 
Invasive Breast Cancer.
Gatti M, Venzon D, Zujewski J, Korde L, Isaacs C, Cohen P, Warren 
R, Gallagher A, Eng-Wong J. Georgetown University Hospital, 
Washington, DC; National Cancer Institute, National Institutes 
of Health, Bethesda, MD; University of Washington, Seattle, WA; 
Lombardi Comprehensive Cancer Center, Georgetown University 
Hospital, Washington, DC
Background: Aromatase inhibitors are effective for breast cancer 
prevention in postmenopausal women. In the recent MAP.3 
study, exemestane significantly reduced invasive breast cancer 
in postmenopausal women with an elevated risk of developing 
breast cancer. At 35 months follow up there was no increase risk in 
cardiovascular events in this study; however, the effects of exemestane 
use on lipid profiles and cardiovascular health are still unclear.
Methods: We conducted a single-arm phase II trial of exemestane in 
women at increased risk for breast cancer and examined the impact 
of exemestane on lipid profiles. Postmenopausal women at high risk 
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for invasive breast cancer (e.g., Gail Model risk ≥ 1.7, a history of 
lobular neoplasia, atypical ductal hyperplasia, DCIS, or stage I/II 
breast cancer, or BRCA 1/2 mutation) were given exemestane (25 mg 
orally daily) for 2 years. Fasting serum total cholesterol, HDL, LDL, 
triglycerides, and homocysteine were collected at baseline, 3, 12, and 
24 months after initiation of exemestane therapy. Apolipoprotein A 
and B were collected at baseline, 3 and 12 months. Wilcoxon sign 
ranked test was used to analyze if changes from baseline values 
differed from zero. The Hochberg p-value adjustment was used to 
account for multiple hypothesis tests.
Results: Of the 42 women enrolled in the study, 6 dropped out prior 
to completing 1 year and 1 dropped out prior to completing 2 years 
of exemestane therapy. Thirty-one women have completed 2 years 
of exemestane therapy and the remaining 4 are expected to complete 
2 years of therapy by January 2012. On average, participants were 
58.5 years old, mostly Caucasian (n = 37; 84.1%), and had a BMI 
of 29.2 kg/m2. A majority (n = 19) of participants were on lipid-
lowering medications (14 were taking a statin) or taking fish oil 
supplements (n =5) prior to starting on the trial and 1 was started 
on a statin approximately 10 months after starting the trial. There 
were no significant differences in mean lipid values for each of the 
4 assessment points or in the mean change from baseline at 3, 12, 
and 24 months between patients who were taking lipid-lowering 
medications and those were not. In unadjusted analyses, change 
in HDL from baseline was significantly different from zero and 
decreased from baseline at 3, 12 and 24 months (-8.0 mg/dL, -8.5 mg/
dL, and -9.9 mg/dL; All p-values ≤ .001 before and after applying the 
Hochberg adjustment). Total cholesterol also significantly decreased 
from baseline at 3 months (-13.6 mg/dL, p = .002) but was no 
longer significant at 12 and 24 months (-9.6 mg/dL and -11.4 mg/
dL, respectively; p-values = .07). The rest of the lipid panel did not 
significantly change during follow-up.
Discussion: In agreement with previous studies, we found that 
exemestane causes a significant decrease in HDL and total 
cholesterol, while leaving the rest of the lipid panel unchanged. 
Prior studies excluded patients on lipid-lowering medication; half 
of our participants were taking lipid-lowering medication. It is 
notable that both women off and on lipid-lowering medication had 
decreases in HDL. Additional studies are needed to elucidate long-
term cardiovascular outcomes in this high risk but otherwise healthy 
population.
P3-11-02
Changing Paradigms for Breast Cancer Chemoprevention?
Chlebowski RT. Los Angeles Biomedical Research Institute @ 
Harbor-UCLA Medical Center, Torrance, CA
The SERMs tamoxifen and raloxifene are approved for breast cancer 
risk reduction but their acceptance in clinical practice has been poor 
largely related to rare but potentially life threatening side effects 
which requires identification of populations at higher breast cancer 
risk and careful risk benefit discussion (Visvanathan 2009). Recent 
findings from randomized placebo-controlled clinical trials suggest 
potential alternative approaches. In the MAP.3 placebo-controlled trial 
including 4,650 postmenopausal women, exemestane decreased breast 
cancer incidence by 65% (P=0.002) (Goss 2011) with no significant 
difference between groups for fractures, CVD events, other cancers 
or treatment-related deaths. While the median Gail 5-yr risk score of 
participants was 2.3, eligibility factors included age alone (> 60 years) 
regardless of calculated breast cancer risk and accounted for 49% of 
entries. With extended follow-up from the Women’s Health Initiative 
(WHI) randomized, placebo-controlled trial evaluating estrogen 
alone in 10,739 postmenopausal women with prior hysterectomy, 
a statistically significant decrease in breast cancer incidence of 
23% was seen with estrogen use (P=0.02) (LaCroix 2011). Younger 
postmenopausal women (age 50-59 years at entry) randomized to 
estrogen alone had lower risk of myocardial infarction (HR 0.54, 95% 
CI 0.34-0.86) and death (HR 0.73, 95% CI 0.53-1.00). These findings 
contrast to those in the WHI trial evaluating combined estrogen plus 
progestin in 16,608 postmenopausal women with an intact uterus 
where breast cancers were increased 25% (P=0.004) as was breast 
cancer mortality (increased by 96%, P=0.049) (Chlebowski 2010). 
The apparently paradoxical findings that in postmenopausal women 
estrogen addition, as conjugated equine estrogen, lowers breast 
cancer incidence and estrogen reduction, by aromatase inhibitor use, 
also lowers breast cancer incidence are consistent with preclinical 
studies indicating condition dependent change in estrogen influence 
on mammary cancers (Jordan 2011). Major eligibility for the WHI 
trials included anticipated 3-yr survival regardless of breast cancer 
or CVD risk. The findings from the MAP.3 and WHI trials highlight 
the complex relationships between estrogen and breast cancer and 
suggest potential strategies for chronic disease risk reduction in select 
populations of postmenopausal women which may not require formal 
breast cancer risk assessment.
Visvanathan K, Chlebowski RT, et al. J Clin Oncol 2009;27:3235-
3258.
Goss PE, Ingle JN, Ales-Martinez J, Cheung A, Chlebowski RT, et 
al. The NCIC CTG MAP.3 Trial. N Engl J Med 10.1056/NEJMos 
1103507.
Chlebowski RT, Anderson GL, et al. JAMA 2010;304(15):1684-1692.
LaCroix AZ, Chlebowski, RT, et al. JAMA 2011;305(13):1305-14.
Jordan VC, Ford LG. Cancer Prev Res. 4:633-7 (2011).
P3-11-03
A Phase I Trial of D-Limonene in Newly Diagnosed Breast Cancer 
Patients: A Chemoprevention Study.
Lang JE, Miller JA, Nokes BT, LeBeau LG, Delbridge M, Chow H-HS. 
Arizona Cancer Center, University of Arizona, Tucson, AZ
Background: D-limonene (DL) is a highly lipophilic monoterpene 
found naturally in citrus that has been demonstrated in preclinical 
studies to have anticancer properties. Early phase clinical trials 
support the investigation of DL in the chemoprevention of breast 
cancer. We sought to evaluate whether DL and its presumed active 
metabolite perillic acid (PA) would distribute extensively to the breast 
tissue and reach an effective drug concentration. We hypothesized 
that the mechanism of DL is related to the induction of apoptosis in 
cancer cells.
Materials and Methods: We enrolled 40 patients with newly diagnosed 
Stage 0-2 breast cancer to take 2 grams daily of oral DL for 2-6 weeks 
prior to planned surgical intervention. Blood was drawn pre/post 
intervention to assess for toxicity and plasma concentration of DL 
and PA. Adverse effects related or possibly related to the study drug 
were noted. A small piece of breast tissue adjacent to the tumor mass 
was used to measure drug concentration for each patient. DL and PA 
levels in breast tissue were analyzed by gas chromatography and liquid 
chromatography, respectively, in tandem with mass spectrometry. 
Analysis of variance testing was used to determine if DL or PA 
preferentially concentrated in the breast tissue compared to plasma. 
We tested for a possible modulation of the biomarkers estrogen 
receptor (ER), progesterone receptor, HER2, Ki67 or grade pre/post 
treatment by comparing results from the core biopsy to the surgical 
pathology and applying pairwise Student’s T tests. The caspase 3 
and the annexin V assays were performed by plating 10,000 cells 
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per well for the cell lines MCF7, MDA-231, BT474, and T47D and 
separately administering DL and PA acid in serial dilutions in their 
treatment concentration ranges in triplicate and read by microplate.
Results: DL was found to preferentially concentrate in breast tissue 
versus plasma (tissue/plasma concentration ratio (TPCR) of 1297, 
p<0.001) while PA did not concentrate (TPCR of 1.4, p=0.9). 20 
patients (50%) reported Grade 1 eructation, which was the most 
common adverse effect. A slight decrease in white count from a mean 
of 7.1 to 6.6 (p=0.03) and a slight increase in ALT from a mean of 22.5 
to 26.9 (p=0.03) were noted. No other statistically significant changes 
in laboratory values related to serum complete blood count, renal, 
hepatic or other studies were noted. No change in tissue biomarkers 
were noted post-treatment. DL produced a dose dependent increase 
in the apoptotic markers cleaved caspase 3 and annexin V for the 
ER positive cell lines MCF7, BT474, and T47D, however, no such 
response was noted for the triple negative cell line MDA-231. A PA 
dose response trend was noted with the annexin V but not the caspase 
3 assay for each cell line.
Discussion: D-limonene preferentially concentrates in the breast 
tissue and is a candidate chemopreventive agent based on its favorable 
side effect profile. PA does not readily concentrate in the breast 
when administered as oral DL. Our correlative studies establish 
that DL induces apoptosis in ER positive breast cancer cell lines; no 
definite relationship between PA and apoptosis was found. Further 
clinical trials of DL are necessary to establish its potential role as a 
chemopreventive agent in breast cancer.
P3-11-04
A Randomized Phase II Biomarker Study of Atorvastatin in 
Premenopausal Women at Increased Risk for Breast Cancer.
Wood ME, Kingsley F, Ellerton JA, Atkins JN, Grubs SS, Muss 
HB, Garber JE. University of Vermont, Burlington, VT; Cancer 
Consultants, Las Vegas, NV; Southeastern Medical Center, Winston-
Salem, NC; Medical Oncology Hematology Consultants, Newark, 
DE; University of North Carolina Lineberger Comprehensive Cancer 
Center, Chapel Hill, NC; Dana-Farber Cancer Institute, Boston, MA
Statins have been shown in epidemiological and laboratory studies to 
have breast cancer risk reduction properties. We evaluated the effect of 
atorvastatin on breast mammographic density (MD) and other breast 
cancer biomarkers in a small randomized placebo controlled trial.
Methods: Premenopausal women at increased risk for breast cancer 
(due to family history, BRCA positivity, prior biopsy history or 
history of chemoradiotherapy for Hodgkins disease) enrolled after 
signing informed consent and received either 40 mg of atorvastatin or 
placebo daily for 1 year. Biomarker assessment was performed prior 
to initiation and prior to completion of study medication. MD was 
determined using both Breast Imaging Reporting and Data System 
(BI-RADS) and the Visual Analogue Scale (VAS).
Results: 63 women were enrolled between 7/05 – 8/10 in this multi-
institutional trial. 44 have completed study medication and 3 remain 
on study. 25% have withdrawn; 17% of them for toxicity/side effects. 
Of those completing the study; mean age was 47 (range 35-50), 96% 
Caucasian, mean BMI 26.8. 66% had a strong family history (2% 
were BRCA+), 27.7% had ADH/LCIS. We present analysis of MD 
in the first 37 women completing study drug. The two treatment 
groups were well balance for age, BMI, risk factors and baseline 
density. Mean density by VAS was 31.6% at study entry and 32.4% 
at end of treatment. There was no different in change in density 
over time between atorvastatin and placebo using either BIRAD or 
VAS; controlling for BMI did not change results. Futility analysis 
demonstrates low probability of a significant difference between 
treatment groups and the study was closed.
Conclusions: In this multi-institutional randomized prospective 
clinical trial of premenopausal women at increased risk for breast 
cancer we have failed to demonstrate a significant effect of 
atorvastatin on mammographic density. There are several possible 
reasons for this relating to: the study population, method of density 
determination and/or biomarker analyzed. While the primary aim of 
this study (MD) was not met we have shown that biomarker studies 
can be done in a multi-institutional setting. Further biomarker 
evaluation may prove informative.
Funding: This study is sponsored by grants from Breast Cancer 
Research Foundation and Cancer and Leukemia Group B to M. Wood.
P3-11-05
An Efficient Resource To Accelerate Research into the Cause and 
Prevention of Breast Cancer: The Love/Avon Army of Women.
Love SM. Dr. Susan Love Research Foundation, Santa Monica, CA
Background: It is well established that more research into the cause 
and prevention of breast cancer is needed. While many studies are 
done in cell lines and laboratory animals, translation of findings to 
women often falters due to perceived difficulty in recruiting women 
for research. The Dr. Susan Love Research Foundation received a 
grant from the Avon Foundation to form the Love/Avon Army of 
Women (AOW); an on-line recruitment resource launched in 2008, 
designed to partner one million women with the research community 
in an effort to accelerate breast cancer research.
Methods: Researchers submit a proposal to the AOW Scientific 
Advisory Committee. If a study is accepted, a mass e-mail describing 
the study procedures and inclusion/exclusion criteria is sent to the 
entire AOW database. Women sign up at www.armyofwomen.org to 
join and receive AOW e-mails about breast cancer research studies. 
Women self select based on interest and study criteria, and undergo 
a secondary on-line screening before contact information is passed 
on to the researcher for the enrollment process.
Results: Over 356,000 women have signed up, including survivors 
and healthy women, ranging from ages 18 to 100, representing all 
50 US states and 49 countries. To date, the AOW has recruited for 
48 studies, both regional and national, that vary from biomarker and 
circadian rhythm research to psycho-social and quality of life studies. 
With over 54,000 AOW members having participated in the research 
process, this method of recruitment has been found to be effective and 
efficient. The diversity of the AOW members has proved beneficial for 
many studies, such as those needing to enroll racial/ethnic minorities, 
women of varying sexual orientations, or young survivors.
Nine studies were closed to enrollment within the first 48 hours after 
accruing all subjects while others were very quickly over-enrolled by 
5-10%. A urine biomarker study in search of healthy women and breast 
cancer survivors closed within eight hours, after 2,076 women signed 
up, representing a 58% over-enrollment. This overwhelming response 
has led many researchers to seek additional funding to increase their 
statistical significance and accommodate all eligible subjects.
Conclusions: The AOW has proved to be a successful resource for 
scientists to accelerate accrual, expand the number and diversity of 
their subject population and to obtain exactly the type of specimens 
they need when they need it. This partnership between women and 
scientists has revolutionized research and accelerated efforts to 
eradicate breast cancer.
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P3-11-06
A Pilot Study of RPFNA in Overweight and Obese Postmenopausal 
Women.
Korde LA, Grieco VS, Imayama I, Kumai C, Mason C, Duggan CR, 
Wang C-Y, McTiernan A. University of Washington, Seattle, WA; Fred 
Hutchinson Cancer Research Center, Seattle, WA
Background: Random periareolar fine-needle aspiration (RPFNA) 
is a research-based procedure used to obtain breast epithelial cells 
and fluid. Data suggest that atypia in epithelial cells from RPFNA 
specimens is associated with an increased risk of breast cancer, and 
changes in the degree of atypia may be a viable biomarker for response 
to chemopreventive interventions.
Methods: We performed RPFNA on 37 overweight or obese (body 
mass index (BMI≥ 25.0 kg/m2) postmenopausal (50-75 y) women 
enrolled in a randomized clinical trial of Vitamin D vs placebo in 
combination with a lifestyle (diet + exercise)-based weight loss 
program. Eligibility criteria included serum vitamin D concentrations 
10 - 32 ng/mL. The procedure was performed by two trained clinicians 
prior to randomization to assess baseline cell counts and degree 
of atypia. Two areas in the breast (10:00 and 2:00 positions) were 
infiltrated with lidocaine, and 8 to 10 aspirations of cellular material 
were performed using 1.5 inch, 21-gauge needles. The aspirated fluid 
was placed in 9 cc of Cytolyt Thinprep (Hologic Inc.) with 1 cc of 1% 
neutral buffered formalin and slides were prepared according to the 
University of Washington Department of Pathology non-gyn protocol.
Results: Thirty-seven women were included in this analysis. The mean 
age and BMI of study participants was 59.3 years and 32.5 kg/m2, 
respectively. The mean 5-year Gail risk score for study participants 
was 1.96%; 52% of women had a 5-year Gail risk >1.66%. Eight 
participants (21.6%) had >50 cells present on cytology examination. 
One additional participant had 10-50 cells, and one had <10 cells. No 
specimens showed cellular atypia. The remainder of study participants 
had only blood or fibroadipose tissue on cytology specimens. Women 
with epithelial cells present were younger (mean age 55.0 vs. 60.2 
years, p=0.05). There were no significant differences in BMI or Gail 
risk score between those with and without epithelial cells.
Conclusions: RPFNA in our sample of overweight/obese 
postmenopausal women did not yield epithelial cells in a majority 
of participants. Younger age was associated with a greater cell count. 
We are planning further studies to determine whether other markers 
in RPFNA specimens can be used to assess breast tissue changes in 
response to chemopreventive interventions.
P3-11-07
Mammary Gland Biopsy To Examine Surrogate Endpoint 
Biomarkers of Preventive Agent Efficacy.
Heckman-Stoddard B, Lubet RA, Bode AM, Grubbs CJ. National 
Cancer Institute, Bethesda, MD; University of Minnesota, Austin, 
MN; University of AL at Birmingham, Birmingham, AL
Phase II breast cancer prevention trials examine agent activity by 
sampling and imaging the breast through core needle biopsy, fine 
needle aspiration, or imaging (e.g., mammography). The biomarker 
endpoints in normal or at risk breast tissue employed with biopsies 
or fine needle aspirates (e.g., Ki67 or apoptosis) have often not been 
formally validated relative to a tumor endpoint. In this study, we have 
attempted to examine these endpoints in a preclinical model for which 
we have final tumor data. In the methylnitrosourea (MNU)-induced 
rat mammary cancer model, estrogen receptor positive cancers 
develop that are histologically similar to a large majority of human 
tumors. Here we present a protocol for correlating surrogate endpoint 
biomarkers and agent efficacy in the same animal. Biopsy samples 
are taken of the normal mammary gland after MNU treatment, and 
a week later the animals are started on the preventive agent. After 
2 weeks, a second biopsy is taken and the animals are followed for 
tumor development. To test the protocol, we examined surrogate 
endpoints of tamoxifen efficacy at human equivalent dosages (5mg/d 
and 20mg/d). Both doses of tamoxifen prevented the development of 
tumors in the MNU-treated rats. The pre/post biopsy analysis revealed 
a statistically significant reduction in Ki-67 consistent with the clinical 
trial data. Additional biomarkers of apoptosis and the chromosome 
condensation pathway will be presented.
P3-12-01
ROLL Trial – Radio-Guided Occult Lesion Localization Versus 
Wire Guided Localization in Breast Conserving Surgery for Non-
Palpable Breast Cancer: A Multicenter Randomized Controlled 
Trial.
Postma EL, Verkooijen HM, van Esser SE, Hobbelink MG, van der 
Schelling GP, Koelemij R, Witkamp AJ, Contant CM, van Diest PJ, 
Borel Rinkes IH, van den Bosch MA, Mali WP, van Hillegersberg 
R. UMC Utrecht, Utrecht, Netherlands; St. Antonius Ziekenhuis, 
Nieuwegein, Netherlands; Amphia Hospital, Breda, Netherlands; 
Maasstad Hospital, Rotterdam, Netherlands
Background
For the management of non-palpable breast cancer, accurate pre-
operative localization is essential to achieve complete resection 
with acceptable cosmetic results. ROLL takes advantage of the 
intratumorally injected radiotracer, that is already used for the sentinel 
node procedure, to localize the primary tumor during surgery. In a 
multicenter randomized controlled trial, we determined if ROLL is 
superior to the standard of care (i.e. wire guided localization, WGL) 
for preoperative tumor localization.
Methods
Women (>18 yrs.) with histologically proven non-palpable breast 
cancer and eligible for breast conserving treatment (BCT) with 
sentinel node procedure were randomized to ROLL or WGL. Patients 
allocated to ROLL received an intra-tumoral dose of 120 Mbq 
Technetium99 nanocolloid. Guided by a gamma detection probe, the 
surgeon excised the primary tumor and the sentinel node(s). In the 
WGL group, patients received a similar intra-tumoral or periaureolair 
dose of technetium in order to allow sentinel node biopsy. Ultrasound 
or mammography guided insertion of a hooked wire provided surgical 
guidance for excision of the primary tumor. Primary outcome 
measure was the proportion of complete tumor excisions (i.e. with 
negative margins). Furthermore, the proportion of patients requiring 
re-excision was assessed. Data were analyzed according to intention 
to treat analysis.
Results
Three hundred and fourteen patients with 316 invasive breast cancers 
were enrolled. There were no significant differences in proportion 
of complete tumor removal with free margins and re-excision rate; 
complete tumor removal with negative margins was seen in 87.7% 
of patients in the ROLL group versus 87.5% (p=0.97) of patients in 
the WGL group Re-excision was required in 11.7% of patients in the 
ROLL group versus 9.2% (p=0.47) in the WGL group. Incorrect pre-
operative localization (i.e. failure to identify the correct localization 
of the lesion) occurred in 5 (3%) patients in the ROLL group versus 
0 patients in the WGL group (p=0.029). Differences in the volume 
of the excised specimen, duration of the procedure, success rate of 
the sentinel node procedure, surgeons’ preferences and patients’ pain 
perception are currently being analyzed.
Conclusion
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With this multicenter randomized controlled comparison, the first 
of its kind in patients with histologically proven breast cancer, 
we show that ROLL is not superior to WGL in terms of complete 
tumor excision and re-excision rates. Furthermore incorrect lesion 
localization occurred more frequently when applying ROLL. Data on 
long term (6 months) cosmetic results and quality of life (6 weeks, 3 
months, 6 months) are awaited.
P3-12-02
Intra-Operative Margin Assessment of Diffuse Disease with 
MarginProbe™ as an Adjunct to Standard of Care, Results from 
a Randomized Prospective Multi Center Study.
Boolbol SK, Cocilovo C, Tafra L. Beth Israel Medical Center, New 
York, NY; Inova, Alexandria, VA; Anne Arundel Health System, 
Annapolis, MD
Background
The ability to obtain negative margins with a single surgical procedure 
remains a challenge, particularly in patients with diffuse disease such 
as DCIS and lobular pathology. A novel device (MarginProbe, Dune 
Medical Devices, Inc.) is intended to provide surgeons with real 
time, intraoperative detection of cancerous tissues at the margins of 
excised specimens. A study was performed to determine if there was a 
device-associated improvement in complete surgical resection (CSR) 
and therefore a decrease in the rate of patients requiring re-excision 
with these disease types. The current analysis stratified the data based 
on tumor type with a special focus on DCIS patients, patient with a 
DCIS component, and lobular patients.
Methods
All 596 patients underwent breast conservation, with image-guided 
localization, and were randomized in a prospective, international, 
multicenter (n=21) study. Randomization occurred in the operating 
room, following standard lumpectomy procedure, including palpation 
followed by additional cavity resections as indicated. In the device 
arm, MarginProbe was used on each specimen margin and device 
positive readings required additional resections of the cavity. 
Pathologists were blinded to study arm. Re-excision criteria were 
not dictated by the protocol.
A primary endpoint of this study was CSR, defined as the correct 
intraoperative identification and resection (if not skin or fascia) of 
all positive margins on the main lumpectomy specimen. Positive 
lumpectomy specimens were defined as those having at least one 
margin having cancer ≤1mm from the surface. Successful CSR results 
in reduced positive margin rate after lumpectomy.
Results
Results are presented in Table 1. The improvement in CSR was 
significant for all diagnosis types. The decrease in candidates for re-
excision due to failed CSR was significant for all DCIS and mixed 
tumor types.
Table 1
Diagnosis Group
Total 
Patients 
(N)
Patients having 
Successful 
CSR %(N)
p-value
Candidates 
for re-excision 
%(N)
p-value
DCIS Device 83 69% (27/39) P<0.0001 13% (11/83) P=0.0005
 Control 78 17% (6/36)  37% (29/78)  
Mixed (DCIS + Invasive) Device 155 73% (70/96) P<0.0001 16% (25/155) P=0.0004
 Control 179 27% (26/98)  33% (59/179)  
Invasive Lobular Device 26 65% (11/17) P=0.035 19% (5/26) P=0.25
 Control 13 0% (0/5)  38% (5/13)  
Conclusions
Use of the device resulted in significant improvement in CSR and 
therefore a significant decrease in the need for reexcisions. Further 
studies should be conducted to evaluate the use of the device for 
additional patient cohorts, such as patients receiving neoadjuvant 
treatment and patients who have undergone prior breast surgery.
P3-12-03
A Prognostic Index of Ipsilateral Breast Tumor Recurrence 
in Patients Treated with Breast-Conserving Surgery after 
Preoperative Chemotherapy: Validation of M.D. Anderson 
Prognostic Index.
Ohno S, Ohsumi S, Inaji H, Akiyama F, Akashi-Tanaka S, Sato N, 
Takahashi K, Oura S. National Kyushu Cancer Center, Fukuoka, 
Japan; National Shikoku Cancer Center, Matsuyama, Ehime, Japan; 
Osaka Medical Center for Cancer and Cardiovasucular Disease, 
Osaka, Japan; The Cancer Institute of the Japanese Foundation for 
Cancer Research, Tokyo, Tokyo, Japan; National Cancer Center 
Hospital, Tokyo, Tokyo, Japan; Niigata Cacner Center Hospital, 
Niigata, Japan; Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan; 
Wakayama Medical University, Wakayama, Japan
Background: Preoperative chemotherapy (PCT) is widely used 
to increase the possibility of breast-conserving treatment (BCT). 
However, the appropriate indication for BCT after PCT is 
controversial, because the rates of ipsilateral breast tumor recurrence 
(IBTR) may be higher than those reported for BCT when surgery is 
used first. We performed a multicenter retrospective study to evaluate 
factors that were associated with IBTR in patients with BCT after PCT, 
and validated M. D. Anderson Prognostic Index (MDAPI) (Cancer 
2005;103:689-95) using our data set.
Patients and Methods: From eight Japanese hospitals, data were 
extracted on a total of 381 patients with invasive breast cancer (BC) 
who were treated with >3 cycles of PCT followed by breast-conserving 
surgery and irradiation. The rates of IBTR were evaluated by MDAPI 
including clinical N2 or N3 disease, pathologic residual tumor >2 
cm, multifocal pattern of residual disease, and lymphovascular space 
invasion in the specimen. Kaplan-Meier method was used to estimate 
cumulative recurrence rates. Log-rank test and Cox’s proportional 
hazard model were used for statistical analyses.
Results: Median age at diagnosis of the primary tumor was 48 years; 
median size of the primary tumor at diagnosis was 4.0 cm. One 
hundred and forty-six patients received postoperative chemotherapy 
and 211 received postoperative endocrine therapy. At a median 
follow-up period of 50 months, 18 of 381 patients developed IBTR, 
which resulted in 5-year IBTR-free rate of 94.1%. Univariate analyses 
revealed that estrogen receptor (ER) status both before and after 
PCT (positive vs. negative), pathological nodal status after PCT (>4 
vs. 0-3 positive nodes), and pathologically residual invasive tumor 
(>1.8 vs. <1.7 cm) were significantly associated with IBTR (all P < 
0.05). Pathological margin status did not affect IBTR rate (P=0.88). 
Multivariate analysis revealed that significant independent predictors 
of IBTR included ER status after PCT (Hazard Ratio [HR], 0.10; 
P<0.01), size of residual invasive tumor (HR, 5.29; P=0.03), and 
pathological nodal status after PCT (HR, 3.59; P=0.02). The rates 
of IBTR of patients with MDAPI 0-3 were 1.3%, 2.9%, 16.0%, and 
3.6%, respectively. Based on the data of our multivariate analysis, 
ER status after PCT (ER positive;0 and ER negative; 1 was added 
to MDAPI. Total scores of the prognostic index including MDAPI 
and ER status after PCT ranged between 0 and 5. The rates of IBTR 
correlated well with this prognostic index. The 5-year IBTR-free 
survival rates were 0% for 23 patients in score 0, 3.4% for 89 in 
score 1, 3.9% for 51 in score 2, 21.2% for 33 in score 3, and 16.7% 
for 6 in score 4 (P< 0.01).
Conclusion: Our prognostic index (MDAPI plus ER status) would be 
useful for clinical decision making according to surgical procedures 
after PCT. BCT is an appropriate treatment option for patients with 
the low prognostic index (0 to 2). The high risk population with the 
high prognostic index (3 to 5) may benefit from mastectomy.
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Involved Anterior Margins after Breast Conserving Surgery: Is 
Re-Excision Required?
Mullen R, Macaskill EJ, Khalil A, Elseedawy E, Brown DC, Lee AC, 
Purdie C, Jordan L, Thompson AM. Ninewells Hospital, Dundee, 
United Kingdom; Perth Royal Infirmary, Perth, United Kingdom
Background: Complete tumour excision in breast conserving surgery 
(BCS) is critical for successful treatment; involved circumferential 
resection margins are associated with increased disease recurrence. 
However, the importance of an involved anterior margin is less clear. 
The purpose of this study was to audit an aggressive approach to 
involved anterior margins and hence assess whether anterior margin 
re-excision yields clinical benefit.
Material and Methods: A retrospective case note and pathology 
review was performed for all patients who underwent BCS between 
2006 and 2010 through a single cancer centre. An involved margin 
was defined as <1mm clearance of invasive or in situ breast cancer.
Results: 1667 patients underwent BCS for invasive and/or in-situ 
disease, of whom 114 (6.8%) underwent re-excision, most commonly 
for mixed invasive and in-situ pathology. The annual re-excision 
rate rose significantly (p<0.001), with no change in whole tumour 
diameter, specimen weight or specimen volume. A total of 170 
involved margins were identified: most commonly the anterior margin 
(59 margins, 30.6%) followed by the posterior (39 22.9%) or inferior 
(31, 18.3%) margin. Patients with anterior margin involvement were 
more likely to have grade 3 invasive disease (p=0.0323) but less likely 
to have residual disease found at re-excision (2/49 vs. 32/101 margins, 
p=0.0033); there were no differences when in-situ characteristics 
were compared.
Conclusions: Re-excision of involved anterior margins rarely excises 
residual disease and may be unnecessary. Multidisciplinary teams 
should consider whether further therapy for an involved anterior 
margin is required on a patient by patient basis.
P3-12-05
Breast Cancer Recurrence: 2nd Conservative Treatment Versus 
Mastectomy.
Michel V, Houvenaeghel G, Bannier M, Tallet A, Minsat M, 
Lambaudie E, Salem N, Butarelli M, Resbeut M. Paoli Calmettes 
Cancer Institute, Marseille, France
Objectives: Mastectomy (Mt) is considered standard treatment for 
isolated local recurrence (LR) of breast carcinoma. The aim of our 
study was to evaluate a second conservative treatment (defined as 
lumpectomy followed by interstitial brachytherapy (LpIB)) and to 
determine if it compares favorably with the current standard treatment.
Materials and methods: Between January 1981 and December 2009, 
348 patients were treated to the Paoli Calmettes Institute (IPC) for 
an isolated LR : 232 (66,7 %) underwent Mt, 62 (17,8 %) received 
a second radio-surgical conservative treatment (LpIB) and 54 (15,5 
%) a 2nd single surgical treatment (Lp).
We classified each population according to the well known prognosis 
factors.
Then, populations Mt and LpIB were matched taking into account 
these criteria to compare the overall survival (OS), metastasis free 
survival (MFS) and 2nd local recurrence free survival according to 
the treatment delivered.
Results: On 348 reviewed patients, with a median follow-up of 73,3 
months, 65 patients died (42/232 Mt, 8/62 TecCur, 15/54 Tec) and 
100 presented metastasis (64/232 Mt, 15/62 TecCur, 21/54 Tec).
There was no difference in MFS for the 2 groups, LpIB and Mt (80 % 
at 5 years) and the OS was non significantly better in the group LpIB 
compared to the group Mt (90 % and 82 % at 5 years respectively, 
p=0,28), whereas in the LpIB group 17% and 30% presented a relapse 
at 5 years and 10 years respectively.
They subsequently underwent a salvage mastectomy.
Worse results were obtained with lumpectomy alone (OS = 72 % and 
MFS = 68 % at 5 years) compared with 2 other option treatments.
Conclusion: A second conservative treatment for breast cancer 
recurrence, i.e. lumpectomy and interstitial brachytherapy, is possible 
for selected patients, without any negative impact on overall survival, 
nor metastasis free survival.
Keywords:
Local recurrence, interstitial brachytherapy, lumpectomy, conservative 
treatment, mastectomy, overall survival, metastasis free survival, 
breast carcinoma.
P3-13-01
Boost Radiation Therapy Not of Value in Reducing IBTR of 
Invasive or Noninvasive Breast Cancers for Patients with DCIS: 
Results from the NSABP B-24 Trial.
Julian TB, Vicini FA, Costantino JP, Arthur DW, Kidwell KM, Land 
SR, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast 
& Bowel Project, Pittsburgh, PA; Allegheny General Hospital, 
Pittsburgh, PA; Beaumont Health System, Royal Oak, MI; Virginia 
Commonwealth University, Richmond, VA; Graduate School of Public 
Health, University of Pittsburgh, Pittsburgh, PA; Aultman Health 
Foundation, Canton, OH
Background: Whole breast irradiation therapy following lumpectomy 
for invasive breast cancer (IBC) or noninvasive breast cancer (DCIS) 
significantly reduces the risk of local recurrence. Boost radiation 
therapy to the tumor bed has been proven to additionally lower the 
risk of recurrence for IBC. The benefit of boost therapy in patients 
with DCIS is less certain. We carried out a review of the NSABP 
B-24 trial to assess the benefit of boost therapy.
Methods: After lumpectomy and radiation therapy, 1804 women 
with DCIS were randomly assigned to placebo (902) or tamoxifen 
(902). Whole breast irradiation therapy (50 Gy) was mandatory. Boost 
radiation therapy was optional, and boost status was known for 1,569 
patients. Of these, 1392 patients (86.97%) were identified as having 
all data sufficient for multivariate analysis. Of these, 613 received 
boost therapy ranging from 1 Gy -20 Gy, with 81.5% receiving 10 
Gy. Mean time of follow-up was 161 months.
Results: Patients who received boost radiation therapy were more 
likely to be younger (p=0.04), have positive margins (p=0.007), 
and be more likely to have comedo necrosis (p=0.03). Multivariate 
analysis identified only treatment (tamoxifen vs placebo) (HR=0.74, 
95% CI=0.57-0.98, p=0.034), age (≥ 50 verses < 50) (HR=0.47, 95% 
CI=0.36-0.61, p<0.0001), and margin status (positive vs negative) 
(HR: 1.79, 95% CI= 1.31-2.43, p<0.001) as significant predictors for 
ipsilateral breast tumor recurrence (IBTR). Boost had no significant 
effect on IBTR (HR=0.87, 95% CI=0.66-1.15, p=0.33). The lack 
of boost effect applied to both invasive (HR=0.86, 95% CI=0.58-
1.27, p=0.44) and noninvasive IBTR (HR=0.89, 95% CI=0.60-1.33, 
p=0.56).
No interaction was seen between boost and treatment, age, margin 
status, or comedo necrosis.
Conclusion: In NSABP B-24, the addition of boost radiation 
therapy was not found to be of value in reducing IBTR of invasive 
or noninvasive breast cancers for patients with DCIS.
Supported by PHS grants NCI-U10-CA-69651, NCI-U10-CA-12027, 
and NCI P30-CA-14599 from the US NCI and AstraZeneca.
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The Impact of Lymph Node Status on Clinical Outcomes 
Following Accelerated Partial Breast Irradiation.
Shah C, Wilkinson JB, Wallace M, Vicini F. William Beaumont 
Hospital, Royal Oak, MI
Background: Limited data exists on outcomes following accelerated 
partial breast irradiation in node-positive breast cancer patients. The 
purpose of this analysis was to compare clinical outcomes following 
accelerated partial breast irradiation (APBI) between node-negative 
and node-positive early stage breast cancer patients and to identify 
if nodal positivity leads to increased rates of local or axillary failure.
Materials and Methods: 510 patients with early stage breast cancer 
received accelerated partial breast irradiation (APBI) as part of their 
breast conservation therapy between April 1993 and November, 2010. 
Of these, 39 were lymph node positive with 10 patients having N1mi 
disease (median size of mets= 0.82 mm) and 29 patients having N1 
disease (61.5% had one node positive [median size of mets= 2.5 mm], 
30.8% had 2 nodes positive [median size of mets= 8.0 mm], and 
7.7% had 3 nodes positive [median size of mets= 20 mm]). Patient, 
clinical, and pathologic factors were analyzed and compared for the 
node-negative and node-positive cohorts including age, tumor size, 
receptor status, margin status, adjuvant hormonal therapy, adjuvant 
chemotherapy, and length of follow-up. Clinical outcomes were 
analyzed including local recurrence (LR), regional recurrence (RR), 
axillary recurrence (AR), regional-nodal recurrence (RR), distant 
metastases (DM), disease-free survival (DFS), cause-specific survival 
(CSS), and overall survival (OS).
Results: Node-positive patients were younger (p=0.04), had larger 
tumors (p<0.001), and were more likely to receive chemotherapy 
(p<0.001). Median follow up was 5.3 years for node-negative patients 
and 5.9 years for node-positive patients (p=0.06). At 5 years, no 
differences were seen in the 5-year actuarial rates of LR (2.2% v. 2.6%, 
p=0.86), AR (0% v. 0%, p=0.69), DFS (90.0% v. 88.0%, p=0.79), CSS 
(98.0% v. 90.0%, p=0.06), or OS (91.0 v. 84.0%, p=0.65) while higher 
rates of RR (0% v. 6.1%, p<0.001) and DM (2.2% v. 8.9%, p=0.005) 
were noted in node-positive patients. A total of 10 LRs occurred in 
the node-negative patients and 1 LR in the node-positive patients at 
a median of 2.6 and 1.5 years respectively. Both RR that developed 
in node-positive patients were within the supraclavicular fossa at a 
median of 2.8 years. Univariate analysis of LR was performed and age 
(p=0.31), tumor size (p=0.48), ER status (p=0.13), PR status (p=0.34), 
T-stage (p=0.48), chemotherapy (p=0.41), APBI technique (p=0.80), 
and nodal status (p=0.86) were not associated with LR while there 
was a trend for the association of LR with close/positive margins 
(p=0.07), and failure to receive adjuvant hormonal therapy (p=0.06). 
No variables were associated with any type of AR.
Discussion: No difference was seen in the rates of local recurrence or 
axillary failure between node-negative and node-positive following 
APBI with 5-years of follow-up. Increased rates of regional failure 
were noted with APBI in node-positive patients due to supraclavicular 
failures; however, traditional whole breast irradiation techniques 
would not have covered these failures.
P3-13-03
Long-Term Symptoms after Radiotherapy of Supraclavicular 
Lymph Nodes in Breast Cancer Patients.
Lundstedt D, Gustafsson M, Steineck G, Alsadius D, Sundberg A, 
Wilderäng U, Holmberg E, Johansson K-A, Karlsson P. Institute of 
Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 
Gothenburg, Sweden; Institute of Clinical Sciences, Gothenburg, 
Sweden; Karolinska Institute, Stockholm, Sweden
Background and Purpose:
Irradiation of the supraclavicular lymph nodes has historically been 
shown to increase the risk of brachial plexopathy with neurological 
problems in the upper limb. The purpose of this study was to compare 
long-term symptoms after modern radiotherapy (based on 3D dose 
planning) in breast cancer patients with or without irradiation of the 
supraclavicular lymph nodes.
Material and Methods:
We collected information from 814 recurrence free women 
consecutively treated with adjuvant radiotherapy for breast cancer at 
the Sahlgrenska University Hospital in Gothenburg, Sweden, 1999 
to 2004. The women had breast conserving surgery or mastectomy 
with axillary dissection or sentinel node biopsy. The breast area 
was irradiated to 50 Gy in 2.0 Gy fractions. Women with more 
than three lymph node metastases had regional radiotherapy to the 
supraclavicular lymph nodes delivered in 2.0 Gy fractions up to 50 Gy. 
Systemic treatments were given according to regional guidelines. In 
this study the women were classified into three groups depending on if 
they had axillary dissection and regional radiotherapy. The first group 
had both axillary dissection and regional radiotherapy, the second 
group had axillary dissection without regional radiotherapy, and 
the third group had sentinel node biopsy (i.e. no axillary dissection) 
without regional radiotherapy. Three to eight years after radiotherapy, 
the women received a questionnaire asking about paresthesia, pain 
and strength in the upper limb.
Results:
Among women with axillary dissection and regional radiotherapy 
38/192 (19.8%) reported paresthesia in the hand compared to 68/505 
(13.5%) among women with axillary dissection without regional 
radiotherapy; relative risk (RR) 1.47; 95% confidence interval (95% 
CI) 1.02 – 2.11, and compared to 9/112 (8.0%) among women with 
sentinel node biopsy without regional radiotherapy; RR 2.46 (95% 
CI 1.24-4.90). Type of breast surgery, number of examined axillary 
lymph nodes, and chemotherapy had no impact on the occurrence 
of paresthesia. Age was an effect modifier among the women with 
axillary dissection and regional radiotherapy; up to 49 years of age 
26.8% reported paresthesia (RR 2.45; 95% CI 1.05-5.73), between 
50 and 59 years of age 19.7% reported paresthesia (RR 1.81; 95% 
CI 0.73-4.44), and above 59 years of age 10.9% reported paresthesia 
(RR 1.00 Reference). We found no statistically significant differences 
between the groups regarding pain or decreased strength.
Conclusions:
Radiotherapy to the supraclavicular lymph nodes increases the 
occurrence of paresthesia in the hand. The effect was mainly seen 
among younger women. Dose/volume-response analysis regarding 
paresthesia will be presented at the meeting.
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Functional and Cosmetic Outcomes Following Post-Mastectomy 
Irradiation with Tissue Expander/Implant Reconstruction.
Baschnagel A, Shah C, Wilkinson JB, Dekhne N, Margolis J, Arthur 
DW, Vicini F. William Beaumont Hospital, Royal Oak, MI; VCU 
Massey Cancer Center, Richmond, VA
Purpose: To examine the rate of breast reconstruction failure and 
cosmetic outcomes following post-mastectomy radiation therapy 
(PMRT) with temporary tissue expander or implant in place.
Methods and Materials: Ninety-four patients with 95 primary breast 
malignancies underwent mastectomy and immediate tissue expander 
reconstruction followed by PMRT. Ninety tissue expanders and five 
implants were irradiated. All patients received a dose of 5,400 cGy 
given in 180 cGy fractions. Twenty-one patients (22%) received 
tangents alone and seventy-four patients (78%) were treated with 
tangents and a supraclavicular field via a mono-isocentric technique. 
Bolus was used in 91 patients (96%). Eighty-eight patients (93%) 
received chemotherapy and 78 patients (82%) received endocrine 
therapy.
Results: With a median follow up of 22.4 months, nineteen patients 
(20%) developed a reconstruction failure. Ten patients lost their 
tissue expanders with a median time to reconstruction failure of 7 
months (range 3-9 months) while ten patients lost their permanent 
implant with a median time to loss of 19 months (range 9-31 
months) following PMRT. The one and two-year actuarial rate of 
reconstruction failure was 11.2% and 24.9%, respectively. The most 
common cause of failure was infection (37%), followed by skin 
break down (21%), extrusion of expander or implant (16%), fibrosis/
eschar (11%), trauma (11%) and pain (5%). Out of the 19 failures, 
eight patients were salvaged with an autologous flap reconstruction. 
Univariate analysis was performed to examine the association 
between age, chemotherapy, hormonal therapy, smoking status, 
hypertension, diabetes, menopause status, weight and the use of a 
third supraclavicular RT field on reconstruction failure. However no 
risk factors were found to be associated with reconstruction failure. 
In patients who did not have reconstruction failure, good/excellent 
cosmesis was observed in 79% of patients and fair/poor cosmesis 
was observed in 21% of patients.
Conclusions: In our series of women with a high risk of recurrence, 
PMRT with a tissue expander in place followed by a prosthetic implant 
provides good cosmesis in the majority of women with an acceptable 
risk of expander or implant loss.
P3-13-05
Analysis of Heart Dose-Volume Parameters and Cardiac Events 
among Node Positive Breast Cancer (NPBC) Patients Treated with 
Three-Dimensional Conformal Radiation Therapy (3D-CRT).
Bradley J, Prior P, Sparks I, Xiang Q, Santana-Davila R, Walker A, 
Wilson JF, Li XA, White J. Medical College of Wisconsin, Milwaukee, 
WI
Background: 
For NPBC patients the use of regional nodal irradiation (RNI) to the 
supraclavicular, axillary, internal mammary lymph nodes (IMN) in 
addition to the chest wall and/or breast can maximize locoregional 
control and improve overall survival. However, comprehensive RNI 
for breast cancers located on the left side has been linked to late 
cardiac morbidity, potentially lessening the therapeutic benefit of 
treatment. The optimal radiation dose-volume constraints for the 
heart in this setting are not fully understood. We examined NPBC 
patients treated with RNI using 3D-CT based radiation therapy (RT) 
to evaluate cardiac dose and incidence of cardiac events.
Methods: 
Between 2000 and 2007, 150 NPBC patients were treated with RNI 
following lumpectomy or mastectomy using 3D-CRT. In all cases, 
treatment target and normal tissue volumes were delineated on 
treatment CT scans. The heart contour included the ventricles and the 
left atrium. The dose-volume histogram of the cardiac doses delivered 
and the incidence of cardiac events is reported.
Results: 
Median follow-up of surviving patients is 7 (1-10.6) years. Median 
patient age is 50 (27-91). 52.35% are premenopausal, 75.7% estrogen 
receptor positive, 66.3% progesterone receptor positive and 15.92% 
HER-2 positive. Mean positive lymph nodes is 5 (1-29). Extracapsular 
extension is present in 47.31%. Mean microscopic tumor size is 
3.73 (0.1-21) cm. The IMN receive > 40 Gy in 65.5%. 94% had 
chemotherapy, and in 82.3% it was anthracycline-based. At the time 
of RT, 12.2% smoked, 9.5% had diabetes, 32.4% with hypertension, 
and 4.7% with a history of coronary artery disease.
There was 1 (0.7%) right sided patient with cardiac events and 4 
(2.7%) left sided experiencing cardiac events (p = 0.121, Fisher’s 
Exact test). A total of 10 cardiac diagnoses were experienced among 
the 5 patients: coronary artery disease with myocardial infarction (3), 
congestive heart failure (2), cardiomyopathy (2), and arrhythmia (3). 
The median time interval to onset of the events is 2.5 years (0-4.3 
years).
The cardiac doses among 150 patients are as follows: mean V25 is 
5.7, (0.0 - 20.0%), V25 is < 9 % in 74.4% of patients, mean V45 is 
1.8% (0-13.3%), V45 is < 5.5% in 91.8%. The mean maximum point 
dose is 42.8 Gy, and the mean heart dose is 5.6 Gy (0.2-25.3 Gy). The 
mean V25 and V45 in those 5 patients with a cardiac event is 6.7% 
(0.9-11.9%) and 3.7% (0-6.6%), respectively; in the 145 remaining 
patients, 5.7% (0-20.0%) and 1.7% (0-13.3%), respectively. The mean 
heart dose in those with an event is 5.2 Gy (2.4-7.3 Gy) versus 5.6 
Gy (0.2-25.3 Gy) in the remaining patients.
Conclusions: 
The cardiac event rate among these NPBC patients treated with 
RNI and anthracycline-based chemotherapy is low. However, those 
patients with cardiac events have a higher mean V45. No other 
dose-volume relationships are discernible. Additional analysis using 
3DCRT volumes are important to validate these findings and better 
define the dose-volume parameters for cardiac toxicity.
P3-13-06
Cardiovascular Magentic Resonance Imaging and Radiation-
Induced Heart Disease Following Radiotherapy for Breast 
Cancer.
Cutter D, Ferreira V, Basagiannis C, Becher HHH, Correa C, Darby 
S, Francis J, Karamitos T, Lavery B, McGale P, Neubauer S, Newton 
J, Rahimi K, Taylor C. University of Oxford, Oxford, United Kingdom; 
Oxford Cancer Centre, Oxford, United Kingdom
Background
Radiotherapy (RT) forms a vital component of treatment for breast 
cancer, contributing to the increasing number of survivors worldwide. 
It is known from historical cohorts that breast RT increased the risk 
of developing heart disease 10 years or more following treatment. 
It is less certain whether the lower cardiac radiation doses received 
during modern RT still increase cardiac risk. Cardiovascular Magnetic 
Resonance (CMR) imaging has the potential to provide early surrogate 
markers of radiation-induced heart disease that may help predict 
which women will be at increased risk in the future.
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Methods
This is a prospective longitudinal imaging study to evaluate CMR 
findings in a cohort of women receiving adjuvant RT for early breast 
cancer at the Oxford Cancer Centre. The patients undergo CMR 
imaging (with gadolinium enhancement and adenosine stress), 
Doppler echocardiography, blood testing (including BNP and 
troponin), ECG and clinical examination prior to RT, within 72 hours 
of completing RT, and at 3 months, 6 months and 5 years following 
RT. The results of these investigations will be related to cardiac 
radiation exposure estimated using 3D-dosimetric data obtained by 
analysis of CT-based RT planning.
Recruitment and Provisional Results
As of May 2011, 30 women have been recruited. The women had a 
mean age of 57.1 years (range = 42.0 to 63.9). All women had left-
sided cancer and none received adjuvant cytotoxic chemotherapy. 
The mean whole heart dose was 1.47 Gray (range = 0.65 to 4.20), 
the mean left ventricle dose was 2.03 (range = 0.88 to 6.99) and the 
mean left coronary artery dose was 7.55 Gray (range = 1.50 to 24.59).
Preliminary analysis of the first 10 participants showed that all had 
a normal left ventricular ejection fraction at baseline (mean 76%, 
range 60-82%) and immediately following RT (mean reduction 3%, 
p=0.18). None had myocardial oedema as detected by T2-STIR 
imaging or fibrosis and scarring as demonstrated by late gadolinium 
enhancement (LGE).
Conclusion and Future Plans
Preliminary results suggest that the relatively low heart doses received 
by the women undergoing modern CT-planned left breast RT at the 
Oxford Cancer Centre do not result in any cardiovascular abnormality 
detectable by CMR imaging. Further and updated results will be 
available for the San Antonio Breast Cancer Symposium.
Recruitment will continue until at least 20 women have completed 
baseline scans and follow-up scans up to 6 months. At this stage a 
full analysis will be performed including a wider range of CMR 
endpoints including:
- Overall LV systolic function (EF and volumes)
- Regional wall motion analysis
- T2-weighted imaging (oedema)
- T1 and T2 mapping (quantitative T1 and T2 relaxation times)
- Tagged myocardial strain analysis
- Stress perfusion defects (endothelial/microcapillary damage)
- Late gadolinium (LGE) imaging (fibrosis/scarring)
Depending on the results of this analysis, recruitment may be 
expanded to include women with either lower cardiac risk (e.g. 
with right-sided breast cancer) or higher cardiac risk (e.g. receiving 
anthracycline chemotherapy).
P3-13-07
The TARGIT-A Trial Update Confirms No Increase in Local 
Recurrence.
Vaidya JS, Baum M, Wenz F, Bulsara M, Tobias J, Alvarodo M, 
Saunders C, Williams N, Joseph D, On Behalf of the TARGIT Trialists 
Group. University College London, London, United Kingdom; 
University of Heidelberg, Mannheim, United Kingdom; University 
of Notre Dame, Fremantle, United Kingdom; University College 
Hospital and Whittington Hospital, London, United Kingdom; 
School of Surgery, University of Western Australia, London (All), 
United Kingdom; University of San Francisco, London (All), United 
Kingdom; Sir Charles Gairdener Hospital, London (All), United 
Kingdom
Introduction
In June 2010, we published the results of the TARGIT-A trial (1) that 
compared “one-size fits” all radiotherapy (whole breast radiotherapy- 
EBRT group) with risk –adjusted radiotherapy (TARGIT- group: 
single dose TARGeted Intraoperative radioTherapy with additional 
whole breast radiotherapy if adverse prognostic factors were found).
These results showed that the risk of local recurrence in the TARGIT 
group was non-inferior to that of the EBRT group (the difference 
between the two arms was 0.25% at 4 years). We now report the 
results analyzed after further follow up of the total trial cohort without 
unblinding.
Method
As often repeated, unplanned analysis comparing two groups in a 
randomized trial can result in an increased alpha-spent as well as 
carry the risk of a false positive result, we have remained blinded to 
the further recurrences in the trial according to allocated treatment, 
since the original publication in the Lancet. Instead we proposed 
and performed a blinded analysis of the local recurrence rate for the 
whole cohort. We plotted the Kaplan Meier plots and compared the 
estimated 4-year recurrences.
Results
Amongst the 2232 patients randomized, there were 13 recurrences at 
the time of Lancet publication and since then, we have had 8 additional 
recurrences. The number of patients who have completed at least 4 
years of follow up has increased from 420 to 717. We found that the 
4-year Kaplan Meier estimate of local recurrence was 1.08% (95% 
CI 0.59 -1.96) at the time of the Lancet publication and it is 1.09% 
(95% CI 0.65 - 1.85) now.
Conclusion
We found that the overall 4-year recurrence rates of the TARGIT-A 
trial have remained stable with a longer follow up and therefore; it 
is statistically implausible, that one particular arm has a significantly 
higher local recurrence.
References
1. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders 
C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, 
Dewar J, Kraus-Tiefenbacher U, Sutterlin M, Esserman L, Holtveg 
HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, 
Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy 
versus whole breast radiotherapy for breast cancer (TARGIT-A trial): 
an international, prospective, randomised, non-inferiority phase 3 
trial. Lancet 2010;376(9735):91-102.
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P3-13-08
Survival Analysis and Recurrence Patterns in Locally Advanced 
Breast Cancer Following Neoadjuvant Chemotherapy and 
Preoperative Concurrent Chemo Radiotherapy.
Shaw RJ, Lara F, Robles CD, Vilar D. Instituto Nacional de 
Cancerologia, Mexico City, Mexico
Introduction: Although not widely used, preoperative concurrent 
chemo radiotherapy (CCRth) following poor response to neo adjuvant 
chemotherapy (CT) has been recently associated with an improved 
prognosis in patients with locally advanced breast cancer (LABC) and 
high recurrence risk, showing acceptable toxicity profiles, acceptable 
post surgical complication rates and increases in both clinical and 
pathologic response rates and local control rates. The objective of this 
study was to assess disease free survival (DFS), overall survival (OS) 
and patterns of recurrence in a cohort of patients with LABC treated 
with pre operative CCRth following poor response to neo adjuvant CT.
Methods: This longitudinal study included a total of 287 patients 
with LABC treated with pre operative CCRth following poor 
response to neo adjuvant CT between February 2000 and December 
2002. Demographic, clinical/pathologic, therapeutic and follow up 
data were collected from patient charts to determine DFS, OS and 
recurrence patterns.
Results: Stages IIB, IIIA and IIIB accounted for 22.3, 37.6 and 40% 
of the population, respectively. Clinical response rates compared to 
pathologic response rates following anthracyline based CT and CCRth 
were minimal or stable in 16% vs 62.4%, partial in 53 vs 76.3% and 
complete in 30 vs 23.3%. No significant treatment related toxicities 
were identified. Post surgical complications included flap ischemia 
in 16%, partial flap necrosis in 18%, both ischemia and partial flap 
necrosis in 13.2% and partial wound dehiscence in 7.7%. With an 
average follow up of 64.1 + 37.2 months, (0-126.3 months), 36.9% of 
the population relapsed and 55.1% remained disease free. With regard 
to recurrence patterns, 22.6% presented loco regional relapse, 67.7% 
recurred at a distant site and 9.8% showed presented both. Median 
OS was 64.2 months (0-126 months). Five and ten year survival 
probability was shown to be 75% and 60%, respectively.
Conclusions Despite improvements in local control rates and overall 
outcomes with current therapeutic regimens combining chemotherapy, 
surgery, and radiotherapy, 30 to 40% of patients with locally advanced 
breast cancer develop post treatment loco regional recurrence and 
5 year overall survival remains low (50%). Multimodal treatment 
integrating pre operative CCRth is therefore a valid alternative in 
the LABC setting, showing promising results in regard to OS, DFS 
and recurrence rates. Prospective clinical studies to evaluate its use 
are warranted.
P3-13-09
Impact of Estrogen Receptor Negativity on Clinical Outcomes 
Following Accelerated Partial Breast Irradiation.
Wilkinson JB, Baschnagel A, Shah C, Amin M, Nadeau L, Mitchell CK, 
Wallace MF, Chen PY, Grills IS, Martinez AA, Vicini FA. Beaumont 
Cancer Institute, Oakland University William Beaumont School of 
Medicine, Royal Oak, MI
Purpose: To determine the impact of estrogen receptor (ER) negativity 
on clinical outcomes for patients treated with Accelerated Partial 
Breast Irradiation (APBI).
Materials/Methods(s): We evaluated 506 consecutive patients treated 
with interstitial brachytherapy (n=199), balloon-based brachytherapy 
(n=203), and 3D-CRT (n=104). ER negative (ERN) status was 
assigned using the traditional definition of an ER nuclear IHC stain 
< 10%, which corresponds to an Allred/NSABP staining score of < 
2. 63 patients (12.5%) were ER negative and 443 (87.5%) were ER 
positive (ERP). Patient demographics and clinical outcomes (IBTR, 
RNF, DM, DFS, CSS, OS) were analyzed for each group.
Results: The two groups had similar patient characteristics. Tumor 
sizes were slightly larger for the ERN group at 11.9mm vs. 10.7mm, 
although this was not statistically significant (p=0.14). No differences 
were seen in median age (63 vs. 64 years, p=0.36), rate of HER-2/
neu overexpression (83% vs. 91%, p=0.11), or lymph node positivity 
(6% vs. 9%, p=0.55) between the ERN vs. ERP groups, respectively. 
There were an equal distribution of invasive ductal carcinoma (ERN 
n=55, 87%; ERP n=387, 87%) and DCIS (ERN n=8, 13%; ERP n=56, 
13%) patients within each group. The use of chemotherapy (55% 
vs. 15%, p<0.001) and nuclear grade (71% vs. 12%, p<0.001) were 
higher in the ERN vs. ERP cohort. With a mean follow up of 6.1 
years, the 5-year actuarial rates of ipsilateral breast tumor recurrence 
(IBTR), regional nodal failure (RNF), and distant metastasis (DM) 
for the entire cohort were 1.8%, 0.6%, and 3.2%. Although this was 
not statistically significant, ERN patients appear to have an increased 
rate of local failure than patients with ERP histology (4.0% vs. 
1.5%, p=0.13). Rates of RNF and DM were, however, significantly 
higher for the ERN group (RNF: 4.9% ERN vs. 0% ERP, p<0.001; 
DM: 12.1% ERN vs. 2.0% ERP, p<0.001). Although there was no 
difference in overall survival at six years (86% vs. 90%, p=0.67), we 
observed a shorter disease-free survival (86.4% vs. 96.5%, p= 0.01) 
and cause-specific survival (90% vs. 98%, p=0.01) for the ERN vs. 
ERP groups.
Conclusion: The ER negative phenotype of early-stage breast cancer 
may have a decreased rate of locoregional control. We observed 
a higher rate of DM with reduced disease-free and cause-specific 
survival in ER negative cases, emphasizing the importance of 
systemic therapy and careful, long-term follow up for these patients. 
Prospective study of this histologic subtype with a larger cohort of 
patients is needed to substantiate these findings.
P3-13-10
Does Lapatinip Increase Pulmonary Toxicity When Concurrently 
Used with Radiation Therapy? An Experimental Study with 
Wistar-Albino Rats.
Senel Bese N, Yetmen O, Guzel E, Karaca C, Coban I, Elicin O, Suzer 
O. I.U Cerrahpasa Medical Faculty, Istanbul, Turkey
Purpose: Lapatinib (L) is an oral receptor tyrosine kinase inhibitor 
which has shown activity in the treatment of metastatic breast cancer. 
Adjuvant usage of L is being investigated in clinical phase III trials. 
There is no data regarding the side effects of combination of RT and 
L which may be a problem when L is used in the adjuvant setting. 
Lung is the most radiosensitive organ to observe late effects of RT. 
We evaluated if concurrent administration of L has any impact for the 
development of radiation induced pulmonary fibrosis in rats (RIPF).
Material Methods: 40 female Wistar-albino rats (WAR) were divided 
into 4 experimental groups (G). G1 (control) did not receive any 
treatment. G2 (RT) received RT to whole thoracic region. G3 (L) 
received L without RT. G4 (L+RT) received L with RT. A total dose 
of 30 Gy in 10 fractions was given to both lungs with an anterior field 
at 2 cm depth. L equivalent to 1500 mg/day, 60 kg adult dose, were 
calculated according to the mean weight of rats, orally administrated 
with a feeding tube twice daily including the week-ends until WAR 
were sacrificed. WAR were anesthetized and sacrificed 16 weeks after 
RT which was shown to be a sufficient period for the development of 
RIPF in rats. Paraffin sections (5 µm thick) of lungs were stained with 
hematoxylin-eosin and Masson’s trichrome. A comparative analysis 
was performed among 4 groups by scoring the pulmonary injury 
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between 0 and 3 according to the infiltration of inflammatory cells 
into the alveolar spaces, alveolar wall thickening and architectural 
deformation across the entire lung section. Normality distribution 
were tested, then one-way ANOVA followed by post hoc Holm-Sidak 
testing were used.
Results: In G2 inflammatory cell infiltration, fibrosis with damage to 
lung structure and formation of small fibrous masses were observed. 
Alveolar septa was significantly thicker than G1 (p<0.05), which 
revealed totally normal pulmoner structure. G3 showed minimal 
alveolar septal thickening and infiltration of inflammatory cells into 
the alveolar spaces which was not significantly different than G1. 
Histopathological findings in G4 were similar to those in G2 and 
statistically different when compared with the G1 and G3(p<0.05).
Conclusion: Study shows that addition of L to RT does not increase 
RIPF in rats.
P3-13-11
Survival Benefit Associated with Post-Mastectomy Radiation for 
Node-Positive, Intermediate-Risk Breast Cancer Patients: Results 
of a Study from the SEER Registry Data.
Horowitz DP, Ng J, Burri RJ. Columbia University Medical Center-
New York Presbyterian Hosptial, New York, NY
Background: The role of post-mastectomy radiation therapy (PMRT) 
for breast cancer patients with intermediate-risk (1-3 positive nodes) 
disease remains controversial. This Surveillance, Epidemiology, and 
End Results (SEER) study investigated the impact of PMRT in the 
intermediate-risk breast cancer patient population on cause-specific 
survival (CSS) and overall survival (OS). The study also investigated 
the impact of estrogen receptor (ER) status, which has been reported 
in the SEER database since 2004, on the impact of PMRT in this 
patient population on CSS and OS.
Methods: The SEER database was used to identify all breast cancer 
patients who were treated between 2004-2007, who had undergone 
mastectomy, and who had T1-2 tumors and 1-3 pathologically positive 
lymph nodes. The status of radiation therapy, ethnicity, tumor grade, 
TNM stage, year of diagnosis, number of LNs sampled, number of 
LNs positive, and estrogen/progesterone receptor status was recorded. 
Patients missing pathologic or treatment-related information were 
excluded. Statistical analysis for CSS and OS was performed using 
the Kaplan-Meier method and analyzed using the log-rank test. 
Multivariable analysis was performed using the Cox proportional 
hazards regression model. Statistical analyses were performed using 
PASW, version 18.
Results: 10,517 patients were identified, with a median follow-up 
of 21.8 months (range 0-47 months). 2339 patients (22.2%) received 
PMRT. Younger patients, increasing tumor size, increasing tumor 
grade, and ER negative tumors were more likely to receive PMRT. 
PMRT was associated with improved OS, 92.8% (95% CI 91.2-
94.4%) versus 88.7% (95% CI 87.7-89.7%), p < 0.001. However, 
there was no overall CSS benefit to PMRT, p = 0.197. In the subgroup 
with ER positive tumors, PMRT was associated with both improved 
OS, 95.5% (95% CI 93.9-97.1%) versus 91.0% (95% CI 90.0-92.0%), 
p < 0.001, and improved CSS, 97.6% (95% CI 96.6-98.8%) versus 
96.1% (95% CI 95.3-96.9%), p = 0.009. Multivariate analysis showed 
that PMRT was significantly associated with improved survival (HR 
0.744, p = 0.011); increasing age, tumor grade, ER negative tumors, 
increasing tumor stage, and increasing positive nodal ratio were 
associated with increased risk of death.
Conclusion: Patients with intermediate risk breast cancer who 
received PMRT have improved OS compared to those who did not 
receive PMRT. For patients with ER positive tumors, PMRT also 
appears to be associated with improved CSS. Greater consideration 
for post-mastectomy radiation therapy use may be warranted for this 
patient population.
3-Year Cause-Specific Survival
 Survival (%) 95% CI (%) p
Overall   0.197
No PMRT 94.0 93.2-94.8  
PMRT 94.7 93.3-96.1  
ER Positive   0.009
No PMRT 96.1 95.3-96.9  
PMRT 97.6 96.4-98.8  
ER Negative   0.933
No PMRT 86.5 84.0-89.0  
PMRT 86.6 84.2-90.7  
P3-13-12
Electrons for Intraoperative Breast Radiotherapy in Selected 
Patients: Long-Term Results of the Montpellier Phase II Trial.
Lemanski C, Dubois JB, Gutowski M, Gourgou S, Ailleres N, Azria 
D. CRLC Val d’Aurelle, Montpellier, France
Background and purpose: Postoperative whole breast external 
radiotherapy remains the current standard of care for patients with 
early operable breast cancer. In the elderly, the low crude numbers 
of recurrence and the frequency of comorbidities urged teams to 
investigate the feasibility and the results of intraoperative radiotherapy 
(IORT) delivered in one fraction during the surgical procedure.
Material and methods: 94 patients (> 65 years old) accepted to be 
included in this phase II trial according to clinical and histopathology 
criteria and signed the informed consent. Among them, 42 presented 
all the inclusion criteria, namely pT0-1 pN0, non lobular invasive 
unifocal carcinoma, margin ≥ 2 mm (assessed during the surgical 
procedure) and estrogen receptors positivity. All patients were 
operated upon in a dedicated IORT facility (linear accelerator) 
located centrally among six operated rooms. After tumor removal, 
the surgical bed was approximated by sutures to bring the tissue 
within the radiation target volume. The tumor beds were completely 
encompassed by 4 to 6 cm circular fields using flattened applicators 
at a 110 cm distance. One fraction of 21 Gy was prescribed and 
specified at the 90% isodose using electron with energies ranging 
from 6 to 10 MeV. In vivo dosimetry was performed for all patients 
using real-time in vivo semiconductor detectors (PTW) fixed by the 
surgeon within the surgical bed. A 5 year adjuvant hormonotherapy 
was prescribed according to the recommendations.
Primary end-point was the quality index [QI] - ratio between the 
prescribed dose and the in vivo measured dose-. Secondary endpoints 
corresponded to quality of life, local recurrences, cosmetic results, 
specific and overall survival.
Results: Median follow-up is now 54 months [range 12-62]. Median 
age was 72 years [66-80] and median tumor diameter was 10 mm [3-19 
mm]. 36 tumors were grade 1 or 2 and 100 % of the tumors expresses 
estrogen receptors. All patients received the total prescribed dose. 
No external postoperative radiotherapy was delivered. Intraoperative 
dosimetry demonstrated a good accordance between the delivered 
and the prescribed doses for 97% of the 37 evaluable patients. No 
acute grade 2 or greater toxicities were observed. Scores for quality 
of life were collected for all patients and showed no modification 
between pre and posttreatment evaluations. Late cosmetic result 
was good to excellent. All patients are still alive and the 4 year-
disease-free-survival is currently 97%. Two patients recurred: (i) one 
infracentimetric superficial recurrence in the border of the surgical 
bed and close to the skin (at 18 months) (ii) a second primary tumor 
in another quadrant (at 6 months). These two patients underwent 
salvage mastectomy and are free of disease at the time of analysis.
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Conclusion: For a very selected population, these results confirm that 
partial breast IORT with electrons may be considered as an interesting 
alternative to the standard 6-weeks radiotherapy, offering therefore a 
safe one-step procedure treatment.
P3-14-01
Panitumumab in Combination with FEC 100 (5-Fluorouracile, 
Epirubicin, Cyclophosphamide) Followed by Docetaxel (T) in 
Patients with Operable, Triple Negative Breast Cancer (TNBC): 
Final Results of a Multicentre Neoadjuvant Pilot Phase II Study.
Nabholtz J-M, Weber B, Gligorov J, Mouret-Reynier M-A, Tredan 
O, Vanlemmens L, Petit T, Mayer F, Van Praagh-Doreau I, 
Dubray-Longeras P, Nayl B, Ferriere J-P, Jouannaud C, Devaud 
H, Tubiana-Mathieu N, Abrial C, Kwiatkowski F, Planchat E, 
Chalabi N, Penault-Llorca F, Chollet P. Jean Perrin Comprehensive 
Cancer Centre, Clermont-Ferrand, France, Metropolitan; Alexis 
Vautrin Comprehensive Cancer Centre, Vandoeuvre les Nancy, 
France, Metropolitan; Tenon University Hospital, Paris, France, 
Metropolitan; Leon Berard Comprehensive Cancer Centre, Lyon, 
France, Metropolitan; Oscar Lambret Comprehensive Cancer 
Centre, Lille, France, Metropolitan; Paul Strauss Comprehensive 
Cancer Centre, Strasbourg, France, Metropolitan; Georges François 
Leclerc Comprehensive Cancer Centre, Dijon, France, Metropolitan; 
Jean Godinot Comprehensive Cancer Institute, Reims, France, 
Metropolitan; Limoges University Hospital, Limoges, France, 
Metropolitan
Background : Panitumumab is an antibody targeting the epidermal 
growth factor receptor (EGFR) to which a role has been suggested 
in TNBC. Consequently, we evaluated the combination of a standard 
chemotherapy (FEC 100 followed by T) with panitumumab as 
neoadjuvant therapy of oprable TNBC.
Methods : 60 patients with stage II-IIIA disease were prospectively 
included in this multicentre pilot study. Systemic therapy (ST) 
consisted of 4 cycles of FEC 100 (500/100/500 mg/m2) q.3 weeks 
followed by 4 cycles of T (100 mg/m2) q.3 weeks, in combination with 
panitumumab (9 mg/kg) for 8 cycles q.3 weeks. All patients underwent 
surgery at completion of ST. Complete pathologic response (pCR) 
was the primary endpoint (Sataloff/ J Am Coll Surg 1995 ; Chevallier 
: Am J Clin Oncol 1993), with toxicity and biologic ancillary studies 
as secondary endpoints.
Results : Patients characteristics are as follows : mean age 47 [27-
72] ; T2 : 74%, T3 : 26%, (mean tumor size : 40 mm [20-120]) ; N0 
: 65%, N1 : 28% and N2 : 7% ; invasive ductal carcinoma : 96% ; 
Scarff-Bloom-Richardson Grade III : 72%, grade II : 28%. The median 
number of cycles was : FEC 100 : 4 [2-4], T : 4 [0-4], Panitumumab : 
7 [1-8]. Pathological response showed a pCR according to Sataloff’s 
classification of 57.1% [95% IC : 40.7-73.5] and according to 
Chevallier’s classification of 51.4% [95% IC : 34.8-68.0] with an 
overall clinical response rate of 60% (29% CR) [95% IC : 43.8-76.2]. 
Conservative surgery was performed in 79% of cases.
Skin toxicity was the main side-effect : Cutaneous toxicity grade IV 
: 12%, grade III : 26%, grade II : 23%. No ocular complications have 
been reported. Neutropenia grade IV : 23.7% ; febrile neutropenia : 
4.2%. Infection : 0%. Hand-foot syndrome grade III : 4%. Ungueal 
toxicity grade IV : 2.5%, grade II : 25 .5%.
Conclusions : These results suggest that Panitumumab in combination 
with FEC100 followed by T appears efficacious with acceptable 
toxicity in the neoadjuvant therapy of operable TNBC.
P3-14-02
Sequential Versus Upfront Intensified Neoadjuvant Chemotherapy 
in Patients with Large Resectable or Locally Advanced Breast 
Cancer (INTENS), Toxicity Results from a Phase III Study of 
the Dutch Breast Cancer Trialists’ Group (BOOG).
Vriens BE, Van de Vijver KK, Boetes C, van Gastel SM, Wals J, 
Smilde TJ, van Warmerdam LJ, van Laarhoven HW, van Spronsen 
DJ, Borm GF, Tjan-Heijnen VC. Maastricht University Medical 
Centre, Maastricht, Netherlands; Comprehensive Cancer Centre 
the Netherlands, Nijmegen, Netherlands; Atrium Medical Centre, 
Heerlen, Netherlands; Jeroen Bosch Hospital, ‘s Hertogenbosch, 
Netherlands; Catharina-Hospital, Eindhoven, Netherlands; Radboud 
University Nijmegen Medical Centre, Nijmegen, Netherlands; 
Canisius-Wilhelmina Hospital, Nijmegen, Netherlands
Background Taxanes have an established role as (neo-)adjuvant 
treatment of breast cancer. In the present study, we compared 4 AC - 4 
T with 6 cycles of TAC in the neo-adjuvant setting (A=adriamycine, 
C=cyclophosphamide, T=docetaxel). Previously, we reported that 
AC-T resulted in a trend for improved outcome (odds ratio pCR of 
the breast 1.61; 95% CI 0.79-3.33). Now we report the safety data. 
Methods Women presenting with breast cancer, cT2>3cm, cT3, cT4 
and/or cN+, with measurable disease and no prior treatment, age >18 
and <70 years and Karnofsky Score >70% were eligible. Patients were 
randomized to AC (60/600 mg/m2 q3wk x 4 cycles) followed by T 
(100 mg/m2 q3wk x 4 cycles) without primary G-CSF prophylaxis, 
or to TAC (75/50/500 mg/m2 q3wk x 6 cycles) with primary G-CSF 
prophylaxis. If indicated, trastuzumab and/or endocrine therapy were 
given as adjuvant treatment. This present analysis focuses on the 
toxicity profile of the two treatment arms.
Results In total, 201 patients (n=100 AC-T, n=101 TAC) were 
included between February 2006 and April 2009. Baseline 
characteristics (AC-T/TAC) were well balanced. Patients in the AC-T 
arm had more frequently grade 3 / 4 toxicities as compared to the TAC 
arm, respectively in 57% and 28% (p=0.001). Grade 3 / 4 neutropenia 
without fever was more frequently reported with AC-T (35% vs. 4%; 
p=0.001). Grade 3 / 4 febrile neutropenia was also more frequent 
with AC-T (17% versus 5%; p=0.0062) and significantly increased 
during docetaxel treatment after AC. Notably, diarrhea was also more 
frequently seen in the AC-T arm (4% versus 0%, p=0.0423). Other 
grade 3 / 4 toxicities more frequently reported in the AC-T arm were 
neuropathy – sensory (5% vs. 0%; p=0.229) and pain other than 
muscle or bone pain (4% vs. 0%; p=0.0423). There were no grade 3 
/ 4 toxicities more frequently observed in the TAC arm.
Conclusion In the comparison of two taxane-anthracycline-
cyclophosphamide regimens in the neo-adjuvant setting, it is observed 
that the sequential approach with a lower cumulative dose tends to 
have a slightly better efficacy outcome, but at the cost of increased 
grade 3 / 4 toxicity. However, considering the use of primary G-CSF 
prophylaxis in the TAC arm, and the fact that the incidence of febrile 
neutropenia was higher during taxane containing chemotherapy in the 
AC-T arm, the difference might (partly) disappear if primary G-CSF 
prophylaxis would be used in the sequential arm. Primary G-CSF 
prophylaxis may be considered during docetaxel if used sequentially 
after anthracycline-containing chemotherapy.
Support: Unrestricted grants from sanofi-aventis NL BV and Amgen 
BV.
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P3-14-03
ABCB1 Single Nucleotide Polymorphismas a Possible Prognostic 
Factor in Breast Cancer Patients Receiving Docetaxel and 
Doxorubicin Neoadjuvant Chemotherapy on Systemic Treatment.
Kim H-J, Lee K-H, Im S-A, Jang IJ, Yi SJ, Keam B, Kim YJ, Han S-W, 
Oh D-Y, Kim JH, Cho N, Chie EK, Han W, Moon WK, Kim T-Y, Noh 
D-Y, Park IA, Bang Y-J, Ha SW. Seoul National University College of 
Medicine, Seoul, Korea; Cancer Research Institute; Seoul National 
University Bundang Hospital, Seongnam, Korea
Background
Expression of the adenosine triphosphate-binding cassette B1 
(ABCB1) transporter and P-glycoprotein are associated with 
resistance to anticancer drugs. The purpose of this thesis was to 
investigate the role of single nucleotide polymorphism (SNP) in the 
ABCB1 and CYP3A genes in breast cancer patients who were treated 
with neoadjuvant docetaxel and doxorubicin chemotherapy.
Material and Methods
Patients with histologically confirmed breast cancer, Stage II or III, 
referred for neoadjuvant chemotherapy were enrolled. Patients were 
treated with 3 cycles of neoadjuvant and adjuvant chemotherapy with 
docetaxel and doxorubicin. The polymorphisms of ABCB1 (C3435T, 
G2677T/A, and C1236T) were genotyped by polymerase chain 
reaction (PCR) and restriction fragment length polymorphism (RFLP) 
assays. The genotyping of CYP3A was done by the GoldenGate assay 
(Illumina Inc). The correlation of genetic polymorphisms of ABCB1, 
CYP3A, and clinical outcomes was analyzed.
Results
A total of 216 patients were enrolled, and the median age was 44 
years (range 25 - 69 years). The overall radiological response rate 
(RR) was 76.8% while 8.3% of the patients achieved a pathologically 
complete response. After a follow-up duration of 48.8 months, the 
median relapse-free survival (RFS) and overall survival (OS) were 
not reached. ABCB1 3435TT genotype had a longer OS than CT/TT 
genotype (p=0.045) and a trend toward a lower relapse rate (p=0.284) 
although it is statistically insignificant. With univariate analysis of the 
OS, good performance status (PS), invasive ductal carcinoma, initial 
operable stages, estrogen receptor (ER)-positive, non-triple negative, 
and the TT genotype of ABCB1 C3435T were associated with a lower 
risk of death. Multivariate analyses for the OS revealed that PS (HR 
4.670, 95% CI=1.066-10.468; p=0.041), initial clinical stage (HR 
3.198, CI=1.480-6.907; p=0.003), and triple negative phenotype (HR 
3.091, 95% CI=1.245-6.570; p=0.004) were significantly associated 
with the OS. ABCB1 3435TT genotype was also associated with a 
lower risk of death with marginal significance not shown to be an 
independent prognostic factor (HR 0.295 95% CI=0.121-1.122; 
p=0.071). ABCB1 3435TT genotype had a higher AUC than CC/
CT genotype for docetaxel with marginal significance (p =0.054). 
These higher AUCs in the C3435TT genotype was associated with 
increased toxicities of neutropenia (p=0.037) and diarrhea (p=0.017). 
AA (*1/*1)/AG (*1/*3) genotypes of CYP3A5 had a higher AUC 
than GG (*3/*3) for docetaxel with statistical significance (p=0.024). 
However, these higher AUCs of CYP3A5*1 allele carrier did not 
affect the survival and toxicities.
Discussion
This study showed that the genetic polymorphism of ABCB1 
C3435T might be associated with a longer OS and have predictive 
roles after the treatment with the neoadjuvant docetaxel/doxorubicin 
for stage II and III breast cancer. Our results also suggest that the 
prediction of docetaxel toxicity might be possible for ABCB1 C3435T 
polymorphism. Larger prospective studies as well as functional 
studies in human subjects are warranted.
P3-14-04
Assessment of Genomic Prognostic Signatures as Predictors of 
Response to Neoadjuvant Chemotherapy in Patients with Early 
Stage Breast Cancer.
Culakova E, Poniewierski MS, Huang M, Kuderer NM, Ginsburg 
GS, Barry W, Marcom PK, Ready N, Abernethy A, Lyman GH. Duke 
University, Durham, NC
Background: Based on results from randomized clinical trials, 
adjuvant and neoadjuvant chemotherapy (NCT) strategies in early 
stage breast cancer patients (ESBC) achieve comparable long term 
results. Recently, a number of genomic signatures have been reported, 
distinguishing patients with low versus high risk of recurrence. 
While developed primarily as prognostic assays, these classifiers 
have also been proposed to be predictive of benefit from systemic 
chemotherapy. Neoadjuvant studies provide an opportunity to evaluate 
their predictive value for response to NCT.
Methods: A systematic review of gene expression profile studies in 
ESBC patients receiving chemotherapy was conducted. Medline 
search of original research articles of human studies published 
between January 2000 and February 2011 was based on key words 
and MeSH heading terms. Publications presenting outcomes for 
chemotherapy treated patients in groups stratified by multi-gene 
array signatures and utilizing a new independent cohort of patients 
compared to the original development cohort were selected. 
Information from eligible studies was extracted by dual abstraction. 
Reported results were synthesized into combined diagnostic odds ratio 
(DOR) using method of Mantel-Haenszel. This analysis is restricted to 
neoadjuvant studies investigating the association of genomic signature 
prognostic categories with objective tumor response to chemotherapy.
Results: A total of 42 articles were eligible for data abstraction. Out 
of these, 6 publications evaluated response to NCT in good (low 
risk of recurrence) versus poor prognosis groups based on genomic 
prediction. Since two of the studies analyzed the same signature 
on a cohort with large overlap, only 5 studies were included in the 
final analysis, accounting for n=918 patients. Response consisted of 
pathologic complete response (pCR) in 3 studies, pCR or minimal 
residual disease (1 study), and clinical complete response (1 study). 
Prognostic genomic assays included Oncotype DX (1), MammaPrint 
(1), Genomic Grade Index (2) and PAM50 Risk of Relapse Score 
(1). Eight different chemotherapy regimens were utilized. The most 
common drugs were cyclophosphamide, anthracyclines, taxanes, and 
5-fluorouracil. Across all genomic signatures, good prognosis patients, 
as defined by gene expression data, demonstrated consistently low 
rates of response to chemotherapy (median 3%, range 0-12%) 
compared to patients with less favorable prognosis (median 32%, 
range 19-43%). Odds ratio for response in poor versus good prognosis 
patients ranged from 3.9 to 21.7 with combined DOR= 6.6 (95% CI 
3.9-11.3, P<0.0001). No heterogeneity was determined across studies 
(P=0.4). The C-statistic estimating assay discriminatory ability was 
reported in 3 studies ranged from 0.72 to 0.78.
Conclusions: Across all genomic prognostic signatures reported, 
only a very small proportion of patients with signature predicted 
good prognosis achieved complete response to NCT. This suggests 
low sensitivity to chemotherapy among good prognosis patients, 
as determined by the prognostic genomic signatures. This further 
confirms the association between poor prognosis tumors and higher 
responsiveness to chemotherapy.
Funding: NCI: UC2CA14041-01
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Evaluation of Residual Cancer Burden Index (RCBI) as a 
Predictor of Disease Free Survival in a Non-Selected Cohort of 
Breast Cancer Patients Treated in the Neoadjuvant Setting.
Perez-Fidalgo J-A, Martinez M, Ferrer J, Pons V, Burgues O, Bermejo 
B, Furriol J, Eroles P, Lluch A. Hospital Clinico Universitario, 
Valencia, Spain
INTRODUCTION: Pathologic complete response (pCR) is associated 
with long-term survival and is considered as the primary endpoint 
in neoadjuvant trials. Definition of pCR includes patients without 
residual disease of the breast, however the presence of nodal 
metastasis, minimal residual cellularity and residual in situ carcinoma 
were not consistently defined as pCR. These observations, lead 
Symmans et al to construct a new prognostic index, the RCBI, in 
which these important issues were incorporated. RCBI is classified 
into 4 different response subgroups, from RCB-0 or pCR to RCB-
III or absence of response. The aim of our study was to assess the 
prognostic value for recurrence free survival of the RCBI in a cohort of 
unselected breast cancer patients treated in our institution. PATIENTS 
AND METHODS: We performed a retrospective evaluation of 
samples of breast cancer patients treated with neoadjuvant treatment. 
RCBI was assessed by two highly trained pathologists. Patients 
included had a histological diagnosis of breast carcinoma before 
neoadjuvant treatment and were considered candidate for neoadjuvant 
therapy. Clinical variables including date and type of recurrence 
were obtained from clinical records. Prognostic accuracy of RCBI 
index was evaluated by comparison of the Kaplan-Meier survival 
curves of the 4 different groups of response by RCBI. Differences 
were assessed with log-rank. RESULTS: Samples from 70 patients 
treated in the neoadjuvant setting from January 2003 to December 
2006 were included in the analysis. Median age was 54.6 years (range 
31-80), histhologic subtype was ductal carcinoma (87.1%), lobular 
carcinoma (8.5%), and other (4.2%). In biopsy, rate of estrogen 
receptor positive was 72.7%, progesterone receptor positive 62.1%, 
and rate of HER2 overexpression was 26.2%. Neoadjuvant therapy 
administered was anthracycline+taxanes chemotherapy (CT )in 
both sequential or combination schedules in 71.4%, anthracycline-
based CT in 15.7%, and other in 12.9%. Most patients received 
from 6-10 cycles of neoadjuvant CT. 3 patients treated with only 
4 cycles received adjuvant complementary CT. All patients with 
hormone-sensible tumors received adjuvant endocrine therapy and 
20 patients received adjuvant trastuzumab. Number of responses by 
RCB-group was 5 patients (7.1%) with RCB-0, 12 patients (17.1%) 
with RCB-I, 35 (50%) with RCB-II, and 18 (25.7%) with RCB-III. 
With a median follow-up of 41.2 months (range 12.7-120.9 months) 
22 patients (31.4%) have relapsed. Ratio of events/patients in each 
RCB group was 0/5 in RCB-0, 2 /12 in RCB-I, 8/35 in RCB-II and 
15/18 in RCB-III. Differences in recurrence-free survival in each 
group was statistically significant with p=0.0002. CONCLUSIONS: 
Our results suggest that RCBI might be an appropriate prognostic 
tool to predict disease-free survival in a non-selected population of 
breast cancer patients. Further validation of our results with a bigger 
sample size is needed.
P3-14-06
Combined Use of 18F-FDG PET/CT and MRI To Monitor Breast 
Cancer Response during Neoadjuvant Chemotherapy.
Pengel KE, Koolen BB, Vogel W, Valdes Olmos R, Wesseling J, 
Vrancken Peeters M-J, Loo CE, Gilhuijs KG. Netherlands Cancer 
Institute, Amsterdam, Netherlands; Netherlands Cancer Institute, 
Amsterdam; University Medical Centre Utrecht, Utrecht, Netherlands
Background and aim
Contrast-enhanced breast magnetic resonance imaging (MRI) 
is commonly used for the evaluation of the therapeutic effect of 
neoadjuvant chemotherapy (NAC). A recent study demonstrated the 
relevance of breast cancer subtype with regard to the accuracy of MRI 
to predict response during NAC. The role of 18F-fluorodeoxyglucose 
(FDG) positron emission tomography (FDG PET/CT) is under 
investigation, and varying results have been reported. MRI and 
18F-FDG PET/CT, visualize different functional characteristics of the 
tumor (perfusion and glucose metabolism), but it is unclear if they 
complement one another to monitor response to NAC, and whether 
breast cancer subtype plays an independent role.
Method and material
The study group consisted of 65 women with stage II or III breast 
cancer and measurable FDG tumor uptake, who were treated with 
NAC and participated in an ongoing MRI/ FDG PET/CT study. MRI 
and FDG PET/CT scans were acquired prior to and during treatment, 
using prone patient positioning. Written informed consent was 
obtained. Prior to the start of NAC a biopsy was taken and tumors 
were divided into three subtypes, using immunohistochemistry: 
human epidermal growth factor receptor 2 (HER2) amplified (HER2+) 
(N=18), estrogen receptor positive/HER2 non-amplified (ER+/HER2-
) (N=29), and triple negative (TN) tumors (N=18). MRI interpretation 
included lesion morphology at baseline, changes in morphology, 
tumor size, and contrast uptake kinetics (initial and late enhancement). 
At FDG PET/CT the maximum standardized uptake value (SUVmax) 
at baseline and during treatment was obtained. Tumor response 
at pathology was stratified to “incomplete response” (substantial 
presence of vital invasive tumor cells) and “favourable response” 
(complete absence of invasive residual tumor or only a small number 
of scattered tumor cells). Appropriate statistical analyses including 
T-tests, multivariate logistic regression and receiver operating 
characteristic (ROC) curves were employed to indentify factors 
associated with incomplete response at pathology. The following 
imaging and clinical features were candidates for forward feature 
selection in the multivariate analysis: lesion morphology, largest 
tumor diameter, pattern of reduction, absolute and relative change 
in largest tumor diameter at initial and at late enhancement during 
NAC, SUVmax at baseline; absolute and relative change in SUVmax 
during NAC; breast cancer subtype; chemotherapy regimen, and age.
Results
At pathology after NAC, 32 tumors (49 %) showed favourable 
response and 33 (51 %) had residual disease. At multivariate 
analysis, breast cancer subtype, relative change in the diameter of late 
enhancement on MRI and relative change in SUVmax on FDG PET/
CT were independent markers of tumor response at final pathology. 
The area under the ROC curve increased from 0.86 for MRI alone to 
0.94 (p<0.01) in combination with FDG PET/CT and breast cancer 
subtype, yielding 84% sensitivity at 95 % specificity.
Conclusion
MRI and FDG PET/CT show complementary potential to predict 
response during NAC, in addition to breast cancer subtype.
Ackowledgement: This study was supported by the Center for 
Translational Molecular Medicine, project Breast CARE (grant 
03O-104).
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P3-14-07
Relative Risk of Recurrence (RR) over Time in ER Positive and 
Negative T4 Breast Cancer Patients Achieving Less Than pCR 
(<pCR) after Primary Chemotherapy: A Reversal Trend of 
Recurrence beyond 60 Months after Diagnosis.
Ionta MT, Atzori F, Pusceddu V, Notari F, Valle E, Guerzoni D, 
Chiappe A, Marongiu M, Minerba L, Massidda B. University Hospital, 
Cagliari, Italy; Hospital of Oncology Businco, Cagliari, Italy
Background: It is widely assumed that patients (pts) who achieve 
a pCR have a good prognosis and better outcomes compared with 
pts with <pCR, regardless of hormone receptor status. Emerging 
data suggest that achieving < pCR identifies a heterogeneous group 
with different risks of recurrence and death , being ER negative the 
subgroup with the worst prognosis.
Aim of our study was to evaluate the relative risk of recurrence (RR) 
over time in ER-positive (ER+) and ER-negative (ER-) <pCR patients.
Material and Methods: We analyzed 139 consecutive <pCR T4 pts, 
of whom 85 were ER+ (cut-off 10%) and 54 were ER-. Median age 
was 53 y ( range 29-73). Median follow up was 137 months (range 
8-233). All pts received primary anthra-based chemotherapy with or 
without taxanes followed by endocrine therapy for 5 years, if hormone 
receptor positive. We examined the RR of recurrence at 0-24, 25-60, 
61-120 and beyond 120 months (m) interval after diagnosis.
Results: For all 139 pts, the total number of pts with recurrence was 
95 (68%), 54 (63%) in ER+ and 41 (76%) in ER-.tumors. For the 
entire group and both in ER+ and in ER-, the RR of recurrence was 
greatest for the interval between 0-24 months, then decreased rapidly 
in ER- and slowly in ER+ through the 25-120 m interval. For the 0-24 
m and 25-60 m intervals the RR of recurrence was higher for ER- 
pts and after 60 m it crossed and beyond 60 m the RR of recurrence 
was higher in ER+ than in ER- pts. Notably, beyond 120 months we 
observed a little second peak of recurrence, higher in ER+ (7) than in 
ER- (3) pts. Nine of these 10 relapses occurred between 120 to 180 m 
interval, 7 in ER+ (13%) and 2 in ER- (5%) subgroup. In the first 24 
m ER- pts were 86% more likely to relapse compared with ER+, vice 
versa between 61-120 and beyond 120 m intervals, ER- pts were 19% 
and 18% less likely to relapse, respectively, compared with ER+ pts.
Conclusions: The present study confirmed the previous reports which 
showed unfavorable prognosis of the <pCR patients with negative 
ER status, due to their significantly higher relative risk of recurrence 
between 0 to 60 months interval. The ER+ recurrences occurred 
more frequently in late follow-up. A reversal of recurrence between 
ER positive and negative patients beyond 60 months after diagnosis 
was detected. The fact might indicate the importance of long term 
adjuvant hormone therapy for T4 ER positive breast cancer patients 
with <pCR after primary chemotherapy.
 N. (%) 0-24 m (RR) 25-60 m (RR) 61-120 m (RR) >120 m (RR)
Global Relapses/ pts 
at risk
95/139 (68) 52/139 (1.3) 22/136 (0.70) 11/114 (0.50) 10/88 (1.1)
ER+ n.relapses / 54/85 (63) 25/85 (1.02) 14/83 (0.65) 8/66 (0.49) 7/43 (0.69)
ER- n.relapses / 41/54 (76) 27/54 (1.9) 8/53 (0.75) 3/48 (0.40) 3/45 (0.57)
  p=.001 p=.003 p=.009 p=.009
P3-14-08
A Phase II Study of Gemcitabine and Carboplatin (GC) Plus 
Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative 
and BRCA1/2 Mutation-Associated Breast Cancer.
Telli ML, Kurian AW, Jensen KC, Vinayak S, Flaherty P, Lipson JA, 
Wapnir I, Daniel B, Carlson RW, Mills MA, Chang P-J, Schackmann 
E, Rocha C, Sherman B, Blackwood-Chirchir A, Bradley C, Ford 
JM. Stanford University, Stanford, CA; BiPar Sciences, South San 
Francisco, CA
Background: The combination of gemcitabine, platinum and 
inhibition of DNA repair results in synergistic chemosensitivity 
in triple-negative and BRCA1-deficient breast cancer cell lines. 
This study was designed to assess efficacy, safety and predictors of 
response to iniparib, a small molecule whose mechanism of action 
is under investigation, in combination with GC in early-stage triple-
negative and BRCA1/2 mutation-associated BC.
Methods: This single-arm, phase II study (NCT00813956) enrolled 
patients with clinical stage I–IIIA (T ≥1cm by MRI) estrogen 
receptor-negative (≤ 5%), progesterone receptor-negative (≤ 5%), and 
HER2-negative or BRCA1/2 mutation-associated BC. Neoadjuvant 
gemcitabine (1000 mg/m2; IV; D1, 8), carboplatin (AUC 2; IV; D1, 
8), and iniparib (5.6 mg/kg; IV; D1, 4, 8, 11) were given every 21 
days for 4 cycles, until the protocol was amended to increase the 
treatment duration to 6 cycles with enrollment of 36 patients. The 
protocol was further amended to increase the patient number with 
expansion to additional centers. Prior to expansion, reporting of 
interim safety and efficacy results was specified. The primary endpoint 
is pathologic complete response (pCR), defined as the absence of 
invasive carcinoma in the breast and axilla. Pathologic response was 
assessed using the residual cancer burden (RCB) index. Secondary 
endpoints included safety, radiographic response by MRI, breast 
conservation eligibility and correlation of baseline gene expression 
with response.
Results: The pre-expansion cohort consisted of 13 patients assigned to 
4 cycles of treatment and 36 patients assigned to 6 cycles of treatment. 
Among these 49 patients (50 tumors), median tumor size is 35 mm, 
and median age is 48 years. The overall pCR rate is 34% (95% CI 
= 22-48); the pCR rate at 6 cycles is 41% (95% CI = 26-57). RCB 
0/I was observed in 5/13 pts (38%; 95% CI = 18–64) treated with 4 
cycles; 21/37 (57%; 95% CI = 41-71) treated with 6 cycles; and 9/9 
pts (100%) with known BRCA1/2 mutations. Two pts experienced 
disease progression, two locoregional relapse, and three distant 
relapse. Among 45 tumors with Affymetrix-based RNA microarray 
gene expression data, 39/45 (87%) are classified as basal-like, 3/45 
(7%) luminal B, and 3/45 (7%) normal breast-like. Most common 
G3/4 adverse events include neutropenia (31%), anemia (10%), and 
elevated ALT/AST (10%). Alopecia and chemotherapy-induced 
amenorrhea were uncommon. Analyses of secondary endpoints are 
ongoing and will be presented.
Conclusions: Preoperative GC plus iniparib is active in the treatment 
of early-stage triple-negative and BRCA1/2 mutation-associated 
breast cancer.
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A Phase II Preoperative Study of Dasatinib, a Multi-Targeted 
Tyrosine Kinase Inhibitor, in Locally Advanced “Triple-Negative” 
Breast Cancer Patients.
Rimawi MF, Rodriguez AA, Yang WT, Gonzalez-Angulo AM, Nangia 
JR, Wang T, Speers C, Mills G, Hilsenbeck SG, Brown PH, Chang JC. 
Baylor College of Medicine, Houston, TX; The Methodist Hospital, 
Houston, TX; M.D. Anderson Cancer Center, Houston, TX
Background: We previously reported that kinases (Src, Yes-1, cKIT, 
Abl, and EPH4) were druggable in triple negative breast cancer 
(TNBC). In this clinical trial, we sought to translate these findings 
by treating TNBC patients with dasatinib, a multi-targeted kinase 
inhibitor against these targets.
Methods: Women with stage II-III TNBC were eligible. Patients 
received dasatinib at 100 mg daily for 3 to 4 weeks before standard-
of-care definitive surgery and chemotherapy. Biopsies were performed 
at baseline, week 1, and at the time of surgery. A cohort of patients 
had positron emission mammography (PEM; baseline and at 2-3 
weeks of dasatinib therapy). This study was designed to detect an 
increase in clinical response rate from 10% to 25%, using a Simon 
optimal two stage design, with one-sided alpha=5% and power=80%. 
At least 3 responses out of 22 patients were needed to proceed to the 
second stage.
Results: 22 patients were enrolled (Table 1). Median tumor size 
was 7.0 cm (range 2.4-25 cm). Adverse events were modest, mainly 
grade 1-2 (headache: 45%, abnormal LFTs: 55%, GI: 23%, fatigue: 
18%). One patient had a myocardial infarction 24 hours after starting 
dasatinib. Out of 22 patients, 2 (9%) had a clinical partial response 
after 3-4 weeks of therapy, 15 had stable disease (68%), while 5 had 
progressive disease (23%). Of the 8 patients who received paired PEM 
imaging, metabolic responses were observed in 2 patients (25%).
Conclusion: A short course of dasatinib led to clinical responses in 2 
out of 22 patients with TNBC, and the study did not proceed to second 
stage. Since TNBC is a heterogeneous disease, biomarker studies 
including sequencing of candidate genes like B-RAF for inactivating 
mutations might enable selection of those TNBC patients who could 
benefit from dasatinib.
Table 1: Patient Characteristics
  N %
Age    
Median (range) 47 years (28-79)   
Race    
 White 15 68
 Black 7 32
Ethnicity    
 Hispanic 13 59
 Not Hispanic 9 41
Tumor Size    
 ≤ 5cm 7 32
 > 5cm 15 68
Medican (range) 7.0 cm (2.4-25)   
P3-14-10
Early Predictive Value of Non-Responder to Docetaxel in 
Neoadjuvant Chemotherapy in Breast Cancer Using 18F- FDG-
PET.
Hirakata T, Fujisawa T, Yanagita Y, Horikoshi H, Oya N, Akiyoshi 
T, Kinoshita T, Kuwano H. Gunma Prefectural Cancer Center, 
Ota, Gunma, Japan; Tsurugaya Hospital, Isesaki, Gunma, Japan; 
Graduate School of Medicine, Gunma University, Maebashi, Gunma, 
Japan
Background; Clinical response is determined after several cycles 
of chemotherapy by changes in tumor size in imaging procedures 
including ultrasound, MRI or CT. The aim of this prospective study 
was to early detect non-responder to docetaxel (DTX) in neoadjuvant 
chemotherapy using 18F- FDG-PET in patients with breast cancer.
Method; 41 patients were eligible for this study. 37 were assessable 
(4 were not eligible or not evaluable) with Invasive carcinoma 
(T1:10%, T2: 83%). All 37 patients were treated with 4 cycles 
of docetaxel (75mg per square meter) followed by 4 cycles of 
FEC(cyclophosphamide/epirubicin/fluorouracil: 500/75/500 mg 
per square meter) before surgery. 18F-FDG-PET response rate was 
evaluated between before and after the first cycle of DTX. 18F-FDG-
PET images were analyzed by standardized uptake value, SUVmax. 
Clinical response is determined by reduction rate in tumor size with 
MRI (RECIST criteria) between before the first cycle and after the 
fourth cycle of DTX. Pathological response evaluated by core needle 
biopsy after the fourth cycle of DTX.
Result; 18F-FDG-PET response rate after the first cycle of DTX 
showed correlation with tumor size reduction rate with MRI image 
after the fourth cycle of DTX (r=0.746)(P <.001). 0 out of 8 patients 
(0%) revealed cPR with MRI changes in SUV decrease less than 18% 
(P <.001). 8 out of 13 patients (62%) showed cPR (cCR = 0) with 
MRI in SUV decrease over 19 to 44% (P <.001). 9 out of 16 patients 
(56%) were cPR, and 7 out of them (44%) showed cCR with MRI in 
SUV decrease over 45% (P <.001).
Conclusion; Changes of 18F-FDG SUVs in tumors were statistically 
significantly different between responding and nonresponding (P 
<.001). SUV decrease less than 18% after the first cycle indicated 
potential failure to DTX in neoadjuvant chemotherapy.
P3-14-11
Comparison of Two Nomograms To Predict Pathologic Complete 
Response to Neoadjuvant Chemotherapy – Evidence That HER2 
Positive Tumors Need Specific Predictors.
Rouzier R, Frati A, Coutant C, Bezu C, Antoine M, Uzan S, Chopier 
J, Chereau E, Gligorov J. Tenon - APHP, Paris, France
Aim: The purpose of this study was to compare two different 
nomograms to predict pathologic complete response (pCR) to 
preoperative chemotherapy in an independent cohort of 200 patients 
with breast cancer. The first model was the MDACC nomogram 
published in 2005 and the other one was a nomogram based on the 
number of preoperative courses, Ki-67 and steroid hormone receptors 
expression published by Colleoni et al. in 2010
Patients and methods: Data from 200 patients with breast carcinoma 
treated with preoperative chemotherapy and operated at Tenon 
Hospital from 2001 to 2009 were collected. We calculated pCR rate 
predictions with the two nomograms and compare those predictions 
with outcome. Patients received between 4 and 8 course of 
anthracycline/taxanes based chemotherapy. More than 90% of patients 
with HER2 positive tumors received concomitant trastuzumab 
with taxanes. Model performances were quantified with respect to 
discrimination (evaluated by the areas under the receiver operating 
characteristics curves (AUC)) and calibration.
Results: In the entire population, the AUC for the MDACC nomogram 
and the Colleoni nomogram were respectively 0.74 and 0.75. Both 
of them underestimated the pCR rate (p=0.02 and 0.0005). When 
excluding patients treated with trastuzumab, the AUC were 0.78 for 
both of them with no significant difference between the predicted and 
the observed pCR (p=0.14 and 0.15). When analyzing the specific 
population treated with trastuzumab as preoperative treatment, the 
AUC for the MDACC nomogram and the Colleoni nomogram were 
respectively 0.52 and 0.53.
Conclusion: The MDACC and the Colleoni nomograms are accurate 
to predict the probability of pCR after preoperative chemotherapy 
in HER2 negative population but did not correctly predict pCR in 
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HER2 positive patients who received trastuzumab. This suggests 
that response to preoperative chemotherapy including trastuzumab 
is biologically driven and that a specific nomogram or predictor for 
HER2 positive patients has to be developed.
P3-14-12
Local Control of Primary Breast Cancer Treated with Radical 
Radiotherapy Alone after Neoadjuvant Chemotherapy.
Makris A, Li SP, Ravichandran D, Ostler PJ, Pittam M. Mount Vernon 
Cancer Centre, Northwood, Middlesex, United Kingdom; Luton and 
Dunstable, Luton, United Kingdom
Introduction: The aim of this retrospective study was to evaluate 
the local recurrence rates in a cohort of patients who achieved a 
complete clinical response (cCR) to neoadjuvant chemotherapy and 
did not have surgery.
Materials and Methods: 148 women who achieved a cCR to 
neoadjuvant chemotherapy were identified from a prospectively 
maintained database (1995-2011) of 667 patients. 122 patients went on 
to have surgery (either wide local excision or mastectomy) followed 
by radiotherapy. In 26 patients (median age 49, range 35-72 years; 
T2-T4, N0-N3, M0), no surgery was performed but all received radical 
radiotherapy. Surgery was avoided due to either physician or patient 
choice. Recurrence was defined as first relapse of disease, either local 
(ipsilateral breast and/or axilla) or distant.
Results: All 26 patients who avoided surgery had neoadjuvant 
chemotherapy with 20 patients (77%) receiving anthracycline-based 
(FEC, FAC, ECF), 5 (19%) MMM and 1 (4%) CMF chemotherapy. 
The median number of cycles was 6 (range 4-8). Chemotherapy 
was followed by radical external beam radiotherapy to the breast 
+/- supraclavicular fossa and axilla (median dose delivered, 60Gy in 
2Gy fractions). All were identified as operable at diagnosis including 
3 patients who had supraclavicular lymphadenopathy. All 26 patients 
achieved a final cCR in the breast to chemotherapy. 21 patients 
had imaging with mammography and/or ultrasonography to assess 
radiological response at the end of neoadjuvant chemotherapy, of 
which 19 had a complete response and 2, a partial response. After a 
median follow-up of 144 months, 10/26 (38%) patients experienced 
local disease recurrence (2 also had distant recurrence) and 4/26 (15%) 
patients with distant metastases only. Patients with local recurrence 
only, went on to have a mastectomy whilst those with distant disease 
received systemic therapy. There were 10 deaths, 9 of which were 
breast cancer related (33%).
Conclusions: Local recurrence rates were high in patients achieving a 
cCR following neoadjuvant chemotherapy and who avoided surgery. 
Our practice has subsequently changed to include clip insertion and 
surgical excision on completion of chemotherapy. With increasing 
pathologic complete response rates to more active chemotherapy 
schedules (including taxanes +/- herceptin), it is being proposed that 
surgery could be avoided in selected patients. Our study shows that 
caution should be exercised.
P3-14-13
A Prospective Open-Label Randomized Phase II Neoadjuvant 
Study of Non-Pegylated Liposomal Doxorubicin (MYOCET®) 
Plus Cyclophosphamide and Trastuzumab Versus Conventional 
Doxorubicin Plus Cyclophosphamide Alone, Each Followed by 
Docetaxel and Trastuzumab, in HER2-Positive Breast Cancer 
Patients.
Llombart-Cussac A, Pernas-Simon S, Rezai M, Hauschild M, 
Venturini M, Machiels J-P, Paepke S, Luporsi E, Kasiborski F, 
Kayitalire L. Hospital Arnau de Vilanova, Lleida, Spain; L’Hospitalet 
de Llobregat, Barcelona, Spain; Luisenkrankenhaus Düsseldorf, 
Düsseldorf, Germany; Ospedale Sacro Cuore, Negrar (Verona), Italy; 
Cliniques Universitaires St-Luc, Université Catholique de Louvain, 
Brussels, Belgium; Technischen Universität München, München, 
Germany; Centre Alexis Vautrin, Vandoeuvre-Les-Nancy, France; 
Cephalon, Maisons-Alfort, France; Frauenklinik und Brustzentrum 
Rheinfelden, Rheinfelden, Germany
Background: The upfront addition of trastuzumab (Herceptin, H) 
to anthracycline/taxane-based primary chemotherapy significantly 
increases pathological complete response (pCR) in HER2-positive 
breast cancer (BC) patients (pts). However, concerns about the cardiac 
toxicity of concurrent administration of H and standard anthracyclines 
limited its use (Seidman et al 2002, J Clin Oncol 20:1215-21). 
MYOCET® (M) has a better cardiac tolerance profile than standard 
doxorubicin (Adriamycine, A) and might allow to give anthracyclines 
safely in combination with H. We explored the added benefit of early 
and longitudinal exposure to the combination of M with H in early-
stage HER2-positive BC in a phase II multicentric randomized trial.
Methods: Women with stage II or IIIA HER2-positive BC were 
randomized to receive 4 cycles of either M + cyclophosphamide (C) 
+ H (MCH) or AC every 3 weeks (q3w); then followed by 4 cycles 
of docetaxel + H (q3w). The primary endpoint was the pCR rate. 
Secondary endpoints included the overall and cardiac safety (using 
left ventricular ejection fraction [LVEF] and NYHA classification).
Results: Since September 2008, 126 pts with a median age of 51 
and stage II (85 pts) or III (39 pts) BC were randomized: 1 pt did 
not initiate treatment, 12 discontinued treatment prematurely, 21 
were still receiving treatment, 91 had completed treatment and 90 
underwent surgery, as of January 15th 2011. Pathological responses 
are under central review.
In the MCH arm, 1 pt reported a NYHA class II cardiac event and 1 
pt had asymptomatic LVEF decrease down to 42%. In the AC arm, 
2 pts experienced NYHA class II events, 1 pt had LVEF value 17% 
below baseline, and 1 patient had LVEF value 6% below the lower 
normal limit. Mean (±SD) LVEF decrease from baseline to endpoint 
was 0.8% (±6.3) in the MCH arm and 3.8% (±5.8) in the AC arm.
Patients tended to report more grade 3 gastrointestinal (GI) adverse 
event in the MCH arm (8.1% of pts) than in the AC arm (4.8% of 
pts), mainly diarrhea (6.5% of pts in the MCH arm vs 1.6% in the 
AC arm). Other grade 3 GI toxicities were infrequent. Hematological 
toxicity was similar in both arms: 56.4% and 61.9% of pts developed 
grade 3/4 neutropenia, and 16.1% and 14.3% of pts reported febrile 
neutropenia, in the MCH and AC arms respectively. No severe case 
of palmar-plantar erythrodysaestheia syndrome was reported.
Conclusion: The concurrent administration of the non-pegylated 
liposomal doxorubicin MYOCET® and H has an acceptable early 
safety profile that should be confirmed with longer follow-up. 
Pathological response data are pending and will be presented at the 
meeting.
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Increased Prevalence of Low Vitamin D Level in Breast Cancer 
Patients during Neoadjuvant Chemotherapy.
Jacot W, Pouderoux S, Thezenas S, Chapelle A, Romieu G, Lamy P-J. 
CRLC Val d’Aurelle, Montpellier, France
Purpose: Patients with early-stage breast cancer treated with 
neoadjuvant chemotherapy (NCT) are at risk of bone metabolism 
changes, resulting in loss of bone mass. Cancer treatment-induced 
bone loss (CTIBL) increases the risk for skeletal morbidity. 
An understanding of CTIBL is critical for determining the risk, 
identifying which patients may benefit from preventive therapy, and 
for screening patients for early intervention with therapies such as 
bisphosphonates or anti-RANKL therapies. In addition, considering 
the bone metabolism profile in early breast cancer patients, only a 
minority of women had vitamin D levels in the range considered 
sufficient for optimal health. This vitamin D deficiency may be 
associated with poor outcomes in breast cancer. In order to study the 
variation of the bone metabolism markers during NCT, we evaluated 
78 early breast cancer patients homogeneously treated in our centre.
Patients and methods: We studied the serum level of a panel of 
bone metabolism biomarkers (calcium, vitamin D, TRAIL, RANK-
Ligand, Osteoprotegerin (OPG), serum bone trap, serum crosslap and 
DKK1), in a population of 78 early breast cancer patients treated by 
the association of 3 cycles of FEC100 then 4 taxane cycles between 
March 2007 and August 2008. Serum samples were withdrawn before 
the first CT cycle and before surgery. Time course and correlations 
between these biomarkers levels were evaluated. All computations 
were carried out using Stata. Two-sided P-values below 0.05 were 
considered to be statistically significant.
Results: The clinicopathological characteristics of the population 
were classical of a neoadjuvant setting. 23% of the patients achieved 
a pCR. At baseline, 79.5% of the patients presented with vitamin D 
insufficiency (< 30 ng/ml). This proportion increased to nearly all 
the patients before surgery (97.4%, p < 0.0001). The same significant 
decrease in serum levels was found for calcium and RANK-ligand, 
while a significant increase in serum OPG level was noted, resulting 
in an increase of the OPG/RANK-Ligand ratio. Serum calcium and 
vitamin D levels were significantly correlated (Spearman’s coefficient 
= 0.023), while there was a trend (Spearman’s coefficient = 0.1) for 
correlation between serum calcium and RANK-Ligand levels.
Conclusion: To our knowledge, this is the first clinical study 
comprehensively evaluating the changes in bone metabolism during 
early stage breast cancer NCT. In our study, nearly all the patients 
suffered from vitamin D insufficiency by the end of NCT. This 
insufficiency was associated with changes in the calcium / Rank-
Ligand / OPG axis, evocative of a functional regulatory mechanism. 
These results require further analyses in order to define the role of 
pharmacologic modulation of this regulatory mechanism in the bone 
wellbeing of early breast cancer patients. A study evaluating the 
best medical intervention to correct this highly prevalent vitamin D 
insufficiency in this population is ongoing.
P3-14-15
Non-Randomized, Open Label Phase II Trial Evaluating the 
Safety and Efficacy of Taxotere (T) Followed by Myocet (M) 
+ Cyclophosphamide (C) as First-Line Treatment for HER2-
Negative Breast Cancer (BC).
García-Mata J, Calvo L, López R, Ramos M, Castellanos J, Heras 
L. Complexo Hospitalario de Ourense, Ourense, Spain; Complexo 
Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital 
Clínico de Santiago, Santiago de Compostela, A Coruña, Spain; 
Centro Oncológico de Galicia, A Coruña, Spain; Complexo 
Hospitalario Universitario Xeral Cíes, Vigo, Pontevedra, Spain; 
Hospital Sociosanitari de l’Hospitalet, Barcelona, Spain
Background: Breast cancer is the most common malignancy 
in females in Europe and is the most common cause of cancer 
mortality in women, with doxorubicin playing an important role 
in chemotherapy (CT) regimens used in this setting but limited by 
cardiotoxicity. Liposomal encapsulated doxorubicin was designed 
to minimize healthy tissue distribution by altering pharmacokinetics 
thus reducing cardiotoxicity while preserving antitumor efficacy. 
The current study was developed to assess the pathologic complete 
response (pCR), response rate and safety of treatment with taxotere 
(T), non-pegylated liposomal doxorubicin (M) and cyclophosphamide 
(C) in previously untreated patients with BC.
Methods: Patients (pts) with HER2-negative BC receiving 1st-line CT 
were eligible. On Day 1 of each 21-day cycle for a total of 4 cycles, 
pts received T 75 mg/m2 IV, followed sequentially by M 60 mg/m2 and 
C 600 mg/m2 IV every 3 wks for 4 cycles. Breast conserving surgery 
(BCS) was considered if the response was deemed satisfactory, 
otherwise mastectomy was performed and pCR was evaluated. Pts 
must have had LVEF ≥50% at the time of enrolment and had regular 
cardiac evaluation throughout the study (MUGA or ECHO).
Results: A total of 74 pts (50 stages II and 24 IIIA) over a 30-month 
period in six centres were accrued with clinical/pathological responses 
available for 51. The median age was 46 yrs (range 23-75). Histology: 
lobular 7/ductal 67. Grade I/II/III: 6/27/30. ER+/PR+: 43; ER+/
PR-: 13. Triple negative: 18. 50 pts had pre-op CT cycles and were 
subjected to surgery. No clinically significant change in LVEF was 
noticed (Pre-CT LVEF 68.5% [CI95%: 66.7-70.4]; post-CT LVEF 
68.9% [CI95%: 66.0-71.7]).
On an intention to treat analysis, an objective clinical response was 
observed for 38 pts: 6 complete (12%) and 32 partial (63 %). In 
addition, 12 pts (23%) demonstrated stable disease and only one 
progressed (2%).The proportion of patients requiring mastectomy and 
BCS were 14 (28%) and 36 (72%), respectively. On 33 pts with an 
axillary dissection, 25 (76%) had involved nodes. After pathological 
review, 18/50 pts (36 %) were devoid of any tumor cells in both breast 
and lymph nodes according to Miller & Payne’s classification. Median 
number of positive lymph nodes following CT was 3 (IQR 2-6).
All patients were included for toxicity assessment. Grade 3-4 
neutropenia and febrile neutropenia was seen in 23% and 10% pts, 
respectively. Principal non-hematologic grade 3-4 toxicities included 
allergic reaction/hypersensitivity in 6% pts, and asthenia, diarrhoea 
and vomiting in 1%. No pts developed symptomatic CHF. Ten pts 
discontinued treatment: 5 due to taxane-hypersensitivity reaction, 3 
due to disease progression and 2 due to protocol violation.
Conclusions: This multi-centre phase II trial clearly demonstrates 
significant activity (pCR 36%) for neoadjuvant taxane sequentially 
followed by non-pegylated liposomal doxorubicin and 
cyclophosphamide regimen in a HER-2 negative BC population. 
Overall the treatment regimen was well tolerated. Sequential 
T→MC is safe and not associated with changes in LVEF. An updated 
evaluation of efficacy and toxicity profile analysis will be presented.
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P3-14-16
Molecular Phenotype and the Use of HER-2 Targeted Agents 
Influence the Accuracy of Breast MRI after Neoadjuvant 
Chemotherapy.
Moon H-G, Han W, Noh D-Y, Ahn S, Kim J, Shin H, Min J. Seoul 
National University College of Medicine; Dankuk University Hospital
Background: Improved understanding of factors affecting the 
accuracy of breast magnetic resonance imaging (MRI) after 
neoadjuvant systemic therapy (NST) can lead to more tailored use 
of MRI in deciding surgical extent after NST.
Materials and Methods: We analyzed the imaging and clinicopathologic 
data of 463 patients who underwent NST. We aimed to investigate 
whether the molecular subtypes, as well as the use of targeted 
therapies, were associated with changes in the accuracy of MRI 
predicting residual tumor extent.
Results: The accuracy of MRI predicting the residual tumor extent was 
most accurate in triple negative breast cancer and was least accurate 
in Luminal A subtype (Pearson’s correlation coefficient of 0.754 
and 0.531, respectively). Multivariate analysis suggested estrogen 
receptor status as an independent factor influencing the MRI accuracy. 
In HER2-amplified tumors, the use of HER2-targeted agents was 
associated with less accurate MRI prediction. Dual HER2-blockade by 
using trastuzumab and pertuzumab resulted in lowest MRI accuracy 
among the patients treated with HER2-targeted agents.
Conclusion: The accuracy of MRI in predicting residual tumor extent 
was lowest in ER positive tumors treated with NST. In HER2 positive 
tumors, the use of HER2-targeted agents resulted in less accurate 
MRI after NST.
P3-14-17
Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant 
Regimen for HER2-Positive Breast Cancer: The TRAIN Study.
Sonke GS, Mandjes IA, Holtkamp M, Schot M, Oosterkamp HM, 
Wesseling J, Vrancken Peeters M-JT, Rodenhuis S, Linn SC. 
Netherlands Cancer Institute, Amsterdam, Netherlands
Background: Treatment with trastuzumab is highly active in HER2 
positive breast cancer, although cardiotoxicity is a well known side 
effect. The cardiotoxicity of trastuzumab may be aggravated by 
combined treatment with anthracyclines. Consequently, treatment 
with trastuzumab is often delayed pending the administration of 
anthracyclines. Both in vitro and in vivo data suggest that trastuzumab 
synergizes with a range of chemotherapeutic drugs, including taxoid 
drugs and carboplatin. In addition, prolonged pre-operative treatment 
leads to higher pathologic complete remission (pCR) rates. We report 
the results of a fase 2 trial integrating trastuzumab at the start of a 
non-anthracycline containing weekly paclitaxel-carboplatin based 
neo-adjuvant chemotherapy regimen in HER2-positive breast cancer.
Patients and methods: One-hundred patients with stage II or III breast 
cancer, including inflammatory disease, with HER2 overexpression 
(immunohistochemistry and/or in situ hybridization) were treated 
with 24 weekly administrations of paclitaxel 70 mg/m2, carboplatin 
AUC=3 mg.ml-1.min, and trastuzumab 2 mg/kg (loading dose 4 mg/
kg). In cycles 7, 8, 15, 16, 23, and 24 only trastuzumab was given. 
The primary end point was pathologic complete response (pCR) in 
both breast and axilla. The trial was preceded by an initial pilot cohort 
of 55 patients treated with the same regimen.
Results: Final efficacy and safety results of all patients included in 
the phase 2 trial will be reported at the meeting. In the pilot cohort 
of 55 similarly treated patients, 33% had stage II disease, 69% was 
clinically node positive, and 49% was ER and PgR negative. Twenty-
four patients (41%) had a pCR in breast and lymph nodes. pCR in ER 
negative patients was 67%, pCR in ER positive patients was 21%. 
The most commonly reported grade 3/4 toxicities were neutropenia 
(30%) and thrombocytopenia (27%). Dose reduction was required in 
24% of the patients. Grade 3/4 left ventricular systolic dysfunction 
was not observed.
Conclusion: A weekly carboplatin-paclitaxel-trastuzumab neo-
adjuvant regimen is highly active in HER2 positive breast cancer 
with a good safety profile. A subsequent multicenter phase 3 trial will 
compare this regimen to a similar 16 week regimen preceded by 4 
cycles of anthracyclines plus cyclophosphamide.
The study protocol was developed at the joint ECCO-AACR-EORTC-
ESMO Workshop on Methods in Clinical Cancer Research in Flims, 
Switserland.
P3-14-18
Primary Tumor Response to Neoadjuvant Chemotherapy Is 
Significantly Associated with Nodal Pathological Complete 
Response in Breast Cancer Patients with Cytologically Proven 
Axillary Node Metastasis.
Hwang H, Park S, Lee JS, Kim S-I, Park B-W. Yonsei University 
College of Medicine, Seoul, Korea
Background
Axillary node status is the most significant factor for the prediction of 
outcome in breast cancer patients whether they received neoadjuvant 
chemotherapy or not. However, a reliable method to predict nodal 
response to neoadjuvant chemotherapy is not established yet. 
The aim of this study was to identify the predictive factors of 
axillary pathological complete response (pCR) after neoadjuvant 
chemotherapy in breast cancer patients with cytologically proven 
axillary lymph node metastases.
Patients and methods
A total of 123 patients with axillary metastases confirmed by 
ultrasound-guided fine-needle aspiration biopsy were subsequently 
treated with four cycles of anthracycline (60mg/m2) plus 
cyclophosphamide (600mg/m2) followed by doxetaxel (75-100mg/
m2) between August 2008 and March 2011. After neoadjuvant 
chemotherapy, all patients underwent a definite breast surgery 
with complete axillary lymph node dissection. Clinicopathological 
parameters were evaluated using a chi-square test and logistic 
regression model in association with node pCR.
Results
The mean age at diagnosis was 47.9 years in all patients. Eighty-
one (65.9%) patients were preoperative clinical T2 stage, 74 
(60.2%) showed estrogen receptor (ER)-positivity, and 36 (29.3%) 
demonstrated HER2-positivity. A pCR of the axilla and breast was 
determined in 56 (46%) and 40 (31.7%) patients, respectively. 
Breast Pcr rate is significantly associated with age≤50 at diagnosis, 
ER(-),PR(-) and higher Ki-67 proliferation. Axillary pCR rate is 
significantly associated with age at diagnosis of 50 or less, smaller 
primary tumor size at diagnosis, tumor responsiveness to neoadjuvant 
chemotherapy, estrogen hormone receptors-negativity, higher Ki-67 
proliferative index at diagnosis, and subtypes of HER2-enriched or 
triple negative breast cancer. When these factors entered logistic 
regression model, tumor response( SD+PD vs CR+PR: OR 8.603, 
P=0.007), Ki67((-) vs (+): OR 7.157, p=0.009), ER status((+) vs 
(-) :OR 4.943, P=0.036), pre-operation tumor size(>2cm vs ≤2cm 
: OR 5.116, p=0.044), HER2 status( (-) vs (+) : OR 5.029,p=0.046)
remained to be significant for the prediction of axillary pCR, favorable 
nodal response.
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Conclusion
Our study suggests that primary tumor response to neoadjuvant 
chemotherapy is significantly associated with favorable nodal 
response. The factors of tumor and nodal response were similar. There 
are many issues remained to be determined yet.
P3-14-19
Impact of Chemotherapy-Induced Amenorrhea on Response to 
Neoadjuvant Chemotherapy in Breast Cancer.
Ahn SK, Moon HG, Kim JS, You JM, Shin HC, Han W, Noh D-Y. Seoul 
National University Hospital
BACKGROUND: Although chemotherapy and ovarian ablation 
independently improve the outcome of breast cancer, there is 
controversy about the benefit of chemotherapy-induced amenorrhea 
(CIA) in breast cancer. We investigated impact of CIA on response 
to neoadjuvant chemotherapy in breast cancer patients.
METHODS: We reviewed the records of 198 premenopausal 
patients with breast cancer treated with neoadjuvant chemotherapy 
between January 2005 and December 2010. Chemotherapy-induced 
amenorrhea (CIA) was defined as serum FSH level ≥40 IU/L after 
completion of all scheduled neoadjuvant chemotherapy and prior to 
definitive surgery.
RESULTS: Among 198 breast cancer patients, 132 pts (66.7%) 
developed CIA after neoadjuvant chemotherapy. 156 pts (78%) 
underwent DA chemotherapy. The age of CIA patients was older 
than non-CIA patients (41.55±5.55 years vs. 38.27± 6.86 years, 
p=0.001). The incidence of CIA after neoadjuvant chemotherapy was 
significantly higher in responder group (responder vs. nonresponder: 
87 pts (74.4%) vs. 45 pts (55.6%); p=0.006). Additionally, FSH level 
after all scheduled neoadjuvant chemotherapy was significantly 
higher in responder group (FSH 56.41±32.41 IU/L vs. 45.76±30.31 
IU/L; p=0.021). In univariate analysis, CIA (p=0.006) and total 
number of chemotherapy cycle regardless of chemotherapy regimen 
(p=0.04) were significantly associated with tumor response. CIA 
was only independent factor for tumor response after neoadjuvant 
chemotherapy on multivariate analysis (p=0.012).
Multivariate analysis for tumor response in patients with neoadjuvant chemotherapy
Factors Category Odds Ratio 95% CI p-value
CIA Yes vs. No 2.472 1.241-4.924 0.010
Chemo cycle ≤4 vs. >5 0.678 0.336-1.369 0.278
ER Negative vs. Positive 1.583 0.742-0.377 0.235
HG 1&2 vs. 3 1.313 0.650-2.652 0.448
CONCLUSION: CIA after neoadjuvant chemotherapy was 
significantly associated with response to neoadjuvant chemotherapy 
in locally advanced breast cancer.
P3-14-20
Concomitant Taxane-Anthracyclin Regimen for Neoadjuvant 
Chemotherapy of Primary Breast Cancer: Experience from a 
Cohort of 223 Patients Treated in a Single Institution.
Coquan E, Guizard A-V, Heutte N, Bor C, Allouache D, Delcambre 
C, Switsers O, Guilloit J-M, Leiber N, Delozier T, Levy C. François 
Baclesse Cancer Center, Caen, France
Background : Neoadjuvant chemotherapy (NAC) may be an 
alternative to mastectomy for localized breast cancer ineligible 
for breast conservation. The optimal schedule (sequential versus 
concomitant) remains controversial. Based on encouraging results 
of a phase 2 study (Luporsi E. et al, ASCO 2000) a concomitant 
docetaxel (D) and epirubicin (E) neoadjuvant combination is applied 
in neoadjuvant setting in our institution since 2001 for HER2-negative 
patients (pts). The results of this combination are presented, with 
a particular focus on pathological complete response (pCR) and 
conservation rate.
Methods : Between 2001 and 2010, 223 pts received NAC for a T2-
T3 breast cancer initially ineligible for conservative surgery, but with 
hope of breast conservation in case of downstaging by pre-operative 
medical treatment. Six cycles of D (75mg/m²) and E (75mg/m²) 
were administered every 3 weeks before surgery, with prophylactic 
support of G-CSF in order to reduce the risk of febrile neutropenia 
and to maintain the dose-intensity of the NAC. All patients eligible 
for breast conservation after NAC underwent lumpectomy, the others 
were treated by mastectomy. In all cases, an axillary dissection was 
performed. After lumpectomy all patients received radiation therapy, 
after mastectomy RT was limited to high risk of loco-regional relapse. 
Patients with positive hormonal receptors (HR+) received hormonal 
therapy. Results were analyzed in term of breast conservation rate 
(BCR), pathologic response rate (pCR defined as no residual invasive 
tumour in breast and axilla, according to Sataloff’s classification) 
and safety.
Results : Mean age of patients was 49,6 years (range: 26-71). Median 
clinical tumor size was 40mm (range 20-110). Histological subtypes 
were:78,0 % ductal, 15,3 lobular, 1,8 % ductal /lobular and 4,9 % 
other types. SBR grading was: grade I: 14,3 %, grade II: 46,2 %, 
grade III: 33,2 % and 6,3 % unspecified. 77,3 % were HR+, 19,7 % 
of tumours were triple negative (HER2 unknown for 38 cases). A 
breast conservation was achievable for 73,5% of patients, the pCR 
rate was 20,6%. At a median follow up of 48 months, 31 pts relapsed: 
9 pts (4%) experienced a local relapse, 5 regional and 28 distant 
recurrences occured. Additional data about safety and survival will 
be provided for the meeting.
Conclusions : For HER2-negative tumours, 6 cycles of a concomitant 
taxane-anthracyclin pre-operative combination allowed a 20,6% 
pCR rate, slightly lower than obtained with 8 cycles of a sequential 
regimen in several published trials. However breast conservation rate 
was similar with a low risk of local recurrence. According to these 
results, concomitant cytotoxic combination is an acceptable option 
for neoadjuvant treatment of breast cancer.
P3-14-21
Neoadjuvant Therapy Response, Subtype and BRCA Status in 
an Underserved Population.
Tripathy D, Ahmed S, Bahl P, Wang Y, Ji L, Ricker C, Weng Grumley J, 
Liu SV, Sener SF, Klipfel N, Kaur C. University of Southern California, 
Los Angeles, CA
Background: Preoperative (neoadjuvant) chemotherapy is typically 
used for larger operable breast cancer cases, and the degree of 
pathological response correlates with long term outcome. Therapeutic 
response also depends on biological and molecular subtype and is 
increasingly studied in the research setting to identify prognostic 
biomarkers and potential therapeutic targets. Little is known about 
the interactions of neoadjuvant response with biomarker subtypes 
and genetic predisposition in underserved and minority populations.
Methods: IRB approval was obtained to capture demographic, 
clinicopathological and genetic testing data on patients diagnosed with 
invasive breast cancer and treated with preoperative chemotherapy 
and definitive surgery between 2005 and 2010 at Los Angeles County 
Medical Center, which serves a primarily Hispanic and indigent 
population. Treatment followed NCCN guidelines with the exception 
that not all patients with HER2+ disease received trastuzumab. 
Genetic counseling and testing has been available at this center 
since 2007. Pathological complete response (pCR) was defined as no 
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residual invasive disease in breast or nodes. Chi-square or Fisher’s 
Exact test was used to examine associations between pCR and clinical 
factors, and logistic regression analyses were applied to assess each 
variable’s contribution to pCR.
Results: Among 104 patients, of whom 79% were Hispanic, the 
overall pCR rate was 27%. Significantly higher pCR rates were seen 
in age ≥50, clinical N0, HER2+, triple negative, and lumpectomy 
cases. No differences in pCR rate was seen in Hispanics vs. others, 
Grade III vs. I and II or in the 9 BRCA mutations carriers among 45 
tested compared to no mutation or those not tested. Of the 43 patients 
with HER2+ disease, the pCR rate was higher in the 32 patients who 
received trastuzumab (pCR 50.0 vs. 27.3%). Subset pCR rates and 
odds ratios (OR) of achieving pCR are shown below:
pCR Rates and Odds Ratios
Variable N pCR (%) Univariate Multivariate
   OR p-value OR p-value
HER2-neg, ER or PR+ 35 8.6 Ref  Ref  
Triple Negative 26 23.1 3.2 0.31* 4.5 0.075*
HER2+ 43 44.2 8.4 0.002* 15.3 0.001*
       
Age < 50 61 19.7 Ref  N/A
Age ≥ 50 43 37.2 2.4 0.048  
       
Hispanic 82 26.8 Ref  N/A
Non Hispanic 22 27.3 1.02 0.97  
       
BRCA Normal 36 27.8 Ref  N/A
BRCA Mutation 9 11.1 0.331† 0.38  
Not Tested 59 28.8 1.1† 0.62  
       
cT1, T2 25 40.0 Ref  Ref  
Other T 79 22.8 0.44 0.095 0.36 0.10
       
cN0 26 42.3 Ref  N/A
Other N 78 21.8 0.38 0.045  
       
Grade I or II 30 23.3 Ref  N/A
Grade III 74 28.4 1.3 0.6  
       
Mastectomy 88 20.5 Ref  Ref  
Lumpectomy 16 62.5 6.5 0.001 10.4 0.002
†Overall p=0.21; * Overall p=0.001; Ref = reference; N/A = not in multivariate model
Conclusions: In this underserved cohort, with 43% undergoing 
genetic testing, significantly higher pCR rates were seen in HER2+ 
and triple negative and lumpectomy cases, with a trend seen in older 
patients and smaller tumors. There was an unexpected trend of lower 
pCR rate seen in BRCA mutation carriers (pCR OR 0.33), albeit with 
small numbers. No differences were seen in Hispanic cases compared 
to other ethnicities. Further tissue analyses are planned to examine 
established and novel markers and to define exploratory markers 
that could be used for decision-making and target discovery in larger 
datasets within this population.
P3-14-22
Response to Neoadjuvant Chemotherapy in Elderly Patients with 
Locally Advanced Breast Cancer.
Vanderhaegen J, Wildiers H, Christiaens M-R, Smeets A, Leunen K, 
Neven P, Vergote I, Vanlimbergen E, Weltens C, Janssen H, Moerman 
P, Brouckaert O, Brouwers B, Paridaens R. University Hospital 
Gasthuisberg, Leuven, Belgium
Background: Inoperable, locally advanced breast cancer (LABC) 
is common in the elderly. Studies have shown good responses 
with neoadjuvant chemo- and endocrine therapy. However, studies 
targeting the elderly population are rare.
Aim: To assess complete pathological response rate (pCR) following 
neoadjuvant chemotherapy (NACT) and to evaluate the effectiveness 
of this therapeutic option in elderly women with LABC.
Patients: Women (≥70 years) diagnosed at our University Hospital 
with LABC between 1999 and 2010 and treated with neoadjuvant 
chemotherapy. After neoadjuvant systemic treatment pCR was 
assessed if surgery was performed.
Results: 44 women with a mean age of 74.9 (70-93) years were 
included. Most tumors were ductal (IDA 88.6%), of grade 3 (79.5%) 
and hormone-receptor (HR) negative (61.4%). Among the 21 tumors 
(47.7%) that were HER2+ (immunohistochemistry (IHC) 3+ or 2+ 
and FISH+), all but 3 received neoadjuvant Trastuzumab. Only 4 
patients had no surgery (clinical decision or personal choice) while 
the remaining 40 patients underwent either breast-conserving surgery 
(17.5%) or mastectomy (82.5%). 23 patients (52.3%) had pathological 
partial response, 14 patients (31.8%) pCR and 3 patients no response. 
pCR was more frequently achieved in HR-negative (44.4%) than 
in HR- positive patients (11.8%). In both groups HER2 positive 
tumors had better pathological response than HER2 negative tumors. 
After a mean follow-up of 41 months (5-120) 29 patients (65.9%) 
had no evidence of disease, 6 patients (13.6%) had (loco)regional 
recurrence, 12 patients (27.2%) developed metastatic disease and 6 
patients (13.6%) died because of breast cancer. Relapse was more 
frequently seen in patients with a pPR (47.8%) versus patients with 
a pCR (14.3%).
Table 1: Pathological response to NACT
According to  
chemotherapy  
regimen
Anthracycline-
based
Taxane-based with 
Trastuzumab
Taxane-based 
without 
Trastuzumab
Other All
pCR 1/7 (14.3%) 8/17 (47.1%) 5/18 (27.8%) / 14/44 (31.8%)
pPR 3/7 (42.9%) 7/17 (41.2%) 11/18 (61.1%) 2/2 (100%) 23/44 (52.3%)
pSD/NR 2/7 (28.6%) / 1/18 (5.6%) / 3/44 (6.8%)
Not operated 1/7 (14.3%) 2/17 (11.8%) 1/18 (5.6%) / 4/44 (9.1%)
pCR according to  
receptor status HR- HR+ Total   
ER2- 2/12 (16.7%) 1/11 (9.1%) 3/23 (13%)   
HER2+ 10/15 (66.7%) 1/6 (16.7%) 11/21 (52.4%)   
Total 12/27 (44.4%) 2/17 (11.8%) 14/44 (31.8%)   
pCR= pathological complete response; pPR= pathological partial response; SD= stable disease; NR= 
no response
Conclusion: In a selected population of elderly patients with LABC 
and treated with neoadjuvant chemotherapy, a reasonable percentage 
of pCR can be achieved. Concordant with younger populations, this 
percentage is higher in HR-/HER2 positive breast cancer. Neoadjuvant 
chemotherapeutic treatment can thus be as beneficial for the older 
patient as for younger ones. In fit elderly patients, neoadjuvant 
chemotherapy should therefore not be omitted solely on the basis 
of advanced age.
P3-14-23
Response to Neoadjuvant Chemotherapy and Survival in 
Japanese Patients with Triple-Negative Breast Cancer.
Ohtani S, Kochi M, Ito M, Takada S, Matsuura H, Higaki K. 
Hiroshima City Hospital, Hiroshima, Japan
Background: Triple-negative breast cancer (TNBC) is defined by 
the lack of estrogen receptor (ER), progesterone receptor (PgR), 
and human epidermal growth factor receptor 2 (HER2)expression. 
In this study, we compared response to neoadjuvant chemotherapy 
and survival between Japanese patients with TNBC and non-TNBC. 
Patients and Methods: Analysis of a prospectively collected clinical 
database was performed. We analyzed 335 Japanese patients who 
received neoadjuvant chemotherapy at Hiroshima City Hospital for 
stage I-III breast cancer from 2002-2010. Clinical and pathological 
parameters, pathological complete response (pCR) rates, survival 
measurements, and organ specific relapse rates were compared 
between with TNBC and non-TNBC. Results: 21.1% had TNBC. 
Patients with TNBC compared with non-TNBC had not significantly 
higher pCR rate (28% v 19%; p=0.09), similar disease progression-
free survival (DFS) rate (p=0.59), but decreased overall survival 
(OS) rate (p=0.02). TNBC was associated with increased risk for 
visceral metastasis (p<0.0001) and shorter postrecurrence survival 
(p=0.017). If pCR was achieved, patients with TNBC and non-TNBC 
had similar survival. In contrast, patients with residual disease 
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(RD) had worse OS if they had TNBC compared with non-TNBC 
(p=0.01). Conclusion: TNBC patients with pCR after neoadjuvant 
chemotherapy have excellent survival. However, TNBC patients with 
RD have significantly worse survival, compared with non-TNBC 
patients with RD. Japanese patients with TNBC have also similar 
results with those in other ethnic group reported before.
P3-14-24
A Phase II Trial of TS-1 and Docetaxel Followed by 5-FU/
Epirubicin/Cyclophosphamide (FEC) as Preoperative Treatment 
in Women with Stage II/III Breast Cancer.
Hayashida T, Jinno H, Sakata M, Takahashi M, Kitagawa Y. Keio 
University, School of Medicine, Tokyo, Japan
Background: TS-1 is an oral anticancer drug, composed of tegafur, 
gimestat and otastat potassium in a molar ratio of 1:0.4:1, based 
on the biochemical modulation of 5-Fuorouracil. In vivo xenograft 
model showed a synergistic effect of combination chemotherapy with 
TS-1 and docetaxel through down-regulation of dihydropyrimidine 
dehydrogenase (DPD). (Suto et al, Oncology Reports 2006) The 
sequential combination of anthracycline and taxane is a standard of 
care in the preoperative setting, as well as the adjuvant setting. This 
study’s purpose was to determine the efficacy of TS-1 and docetaxel 
followed by fluorouracil/epirubicin/cyclophosphamide (FEC) in the 
preoperative setting.
Patients and Methods: Patients with stage II/III breast cancer received 
4 cycles of TS-1 (TS-1 80 mg/m2 on days 1-14 and docetaxel 40 mg/
m2 on day 1 every 3 weeks), followed by 4 cycles of FEC (fluorouracil 
500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2 on 
day 1 every 3 weeks). The tumor objective response was assessed by 
both caliper and ultrasound. Primary endpoint was the pathological 
complete response (pCR) rate. Secondary endpoints were the clinical 
response rate, adverse drug reactions, and the breast conservation rate.
Results: From November 2009 to December 2010, 39 patients were 
enrolled and 38 patients were assessable for clinical and pathologic 
responses. The overall response rate (caliper) was 81.5% and 
ultrasound response rate was 76.3%. The pCR rate was 13.2% (5/38). 
The breast-conserving rate in patients whose tumor size was 3 cm 
or smaller was 92.9%, and 54.5% of patients whose tumor size was 
larger than 3 cm underwent breast-conserving surgery. The ratio 
of Ki-67 positive cell and progesterone receptor (PgR) status were 
significantly correlated with pCR. Grade 4 neutropenia was observed 
in a patient (2.6%) at the first cycle. The most common grade 3/4 
non-hematologic adverse event was hand-foot syndrome, observed 
in 3 patients (7.9%). One patient (2.6%) showed grade 3 diarrhea.
Conclusions: These results indicate that the sequential combination 
of TS-1 and docetaxel followed by FEC is a well-tolerated, effective 
neoadjuvant treatment for stage II/III breast cancer.
Univariate analysis of factors associated with pCR
 non pCR pCR  
Ki67≥30% 16 5 p=0.049
Ki67<30% 14 0  
PgR (+) 18 0 p=0.019
PgR (-) 14 5  
pCR : pathological complete response, PgR : progesterone receptor
P3-14-25
Neoadjuvant Trastuzumab and Paclitaxel Combination Induces 
a High Rate of Pathological Complete Responses in Locally 
Advanced Breast Cancer by Exploiting Host Antitumor Immunity.
Dolcetti R, Crivellari D, Muraro E, Martorelli D, Miolo G, Lombardi 
D, Massarut S, Perin T, Talamini R, Turchet E, Comaro E, Carbone 
A, Veronesi A. Centro di Riferimento Oncologico, IRCCS; National 
Cancer Institute, Aviano (PN), Italy
Background: A phase II study was performed to assess the role of 
patients’ immune profile in the activity of a trastuzumab-based, non 
anthracycline containing neoadjuvant chemotherapy (NC) regimen 
in locally advanced breast cancer (BC) patients (pts).
Methods: Newly diagnosed T2-3 HER2+ BC pts received a 12 week 
NC with weekly paclitaxel and trastuzumab, which was continued for 
further 12 weeks before surgery in the absence of progression (PRO). 
Further 12 weeks of the same therapy was planned after surgery and 
then trastuzumab alone to 1 year of treatment ± hormonal therapy 
and radiotherapy. In case of PRO, trastuzumab was discontinued 
and anthracyclines were planned. Blood samples were collected 
at diagnosis and every 3 months for 1 year then yearly. The % of 
NK cells, T cells and Treg cells was evaluated by flow cytometry, 
and serum levels of 9 cytokines were assessed by SearchLight 
multiplex array technology. Circulating CD8+ T cells specific 
for a broad spectrum of tumor-associated antigens (Her2, muc-1, 
mammaglobin-A, trag-3, survivin, bcl-xL) were enumerated by IFN-g 
Elispot and in vitro T-mediated, antibody-dependent cell cytotoxicity 
(ADCC) was assessed using patients’ PBMCs.
Results: From July 2006, 34 pts were enrolled, median age 46 yrs 
(range 30-70). Overall objective clinical response rate was 91%, with 
53% of pathological complete responses (pCR) and 38% of partial 
responses. At a median follow-up of 27 months, 4 relapses were 
noted (1 brain, 1 local breast, 2 bone). No cardiotoxicity occurred. 
At diagnosis, pts showed an immune profile similar to that of healthy 
women, whereas higher numbers of Treg cells (p=0.02), NK cells 
(p=0.03), lower T cell numbers (p<0.01) and lower amounts of serum 
IL-2, IL-6, and IL-8 were found in a concomitant control group of 
untreated HER2- pts. Moreover, spontaneous CD8+ T cells specific 
for all 13 HLA-A*0201 epitopes were observed in the whole series, 
with numbers usually higher than those observed in HER2- cases. 
Notably, patients with pCR, unlike those showing partial responses, 
retained high numbers of epitope-specific CD8+ T cells throughout 
the NC treatment, particularly versus survivin and mammaglobin-A 
epitopes. Moreover, pts achieving pCR showed at diagnosis a 
significantly higher efficiency of trastuzumab-mediated ADCC 
compared to pts with partial responses (p=0.05). The treatment also 
induced a progressive increase in the number of NK cells and in the 
efficiency of trastuzumab-mediated ADCC.
Conclusions: NC with paclitaxel and trastuzumab induces high rates 
of pCR with no cardiotoxicity. This clinical efficacy is favoured by 
the retained immunological proficiency of HER2+ pts, who may 
benefit from the immunological synergism between the two drugs. 
In fact, the increased number and activation of NK cells promoted by 
paclitaxel likely favour NK-dependent ADCC responses, known as 
one of trastuzumab’s main mechanisms of action. The possible role 
of trastuzumab-mediated ADCC in preserving event-free survival and 
the involvement of paclitaxel in inducing NK cells’ NF-kB nuclear 
translocation are under evaluation.
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P3-14-26
The Effect of Biologic Subtype in Patients Treated with 
Neoadjuvant Chemotherapy: A UAB Experience.
Keene KS, De Los Santos JF, Meredith R, Hinton B, Li Y, Krontiras 
H, Bland K, Carpenter JT, Forero A. University of Alabama at 
Birmingham, Birmingham, AL
Purpose: Previous studies have suggested that the pre treatment clinical 
stage drives loco-regional recurrence (LRR), distant metastasis (DM) 
and survival in patients treated with neoadjuvant chemotherapy. 
This retrospective analysis was performed to look at the effect of 
biologic subtype on patient outcomes. Methods: Between 1999 and 
2005, 115 patients treated with neoadjuvant chemotherapy, surgery, 
and +/-radiation therapy at UAB were identified. Patient, tumor, 
and treatment characteristics were recorded. Pathologic complete 
response was defined as resolution of both invasive disease and DCIS 
in both the primary and nodal disease. Survival was measured using 
the Kaplan Meier statistics. Univariate and multivariate analyses of 
covariates associated with LRR, DM, progression-free (PFS) and 
overall survival (OS) were performed. Results: The mean age was 49 
years, with a mean follow-up of 5.8 years. Subtype distribution was 
as follows: 52 luminal A, 17 luminal B, 36 triple negative, 9 Her2+ 
and one patient with an unknown biologic subtype. Distribution of 
clinical stage was as follows: 40 IIA, 34 IIB, 26 IIIA, 10 IIIB, and 
5 IIIC. Tumors were down-staged following neoadjuvant therapy as 
follows: 18: pCR, 6: residual DCIS, 17: I, 38: IIA, 11: IIB, 13: IIIA, 
5: IIIB, and 7: IIIC. Pre-treatment clinical stage did not significantly 
influence LRR, DM or progression free and overall survival; however, 
final pathologic T, N and group stage were associated with both 
progression free, p=0.003, 0.011, 0.005 and overall survival, p=0.02, 
0.037, and 0.009. Complete resolution of tumor by mammographic 
or MR imaging to neoadjuvant chemotherapy, was associated with 
an increased overall survival, p=0.0025. Univariate analysis did 
not show a significant effect of biologic subtype, age, grade, use 
of radiation therapy or anti-hormonal therapy. Discussion: In this 
retrospective series, response to chemotherapy and the final pathologic 
stage, representing the volume of residual disease, were important 
predictors of survival. Further study to determine factors predictive 
of chemotherapy response is needed.
P3-14-27
Pegylated Liposomal Doxorubicin (PLD) as Primary Treatment 
in Estrogen Receptor (ER) and HER2 Poor Breast Cancer and 
Risk of Developing Cardiotoxicity or Elderly Patients (pt). Results 
from the Phase II CAPRICE Study.
Gil MJ, Bellet MC, Llombart A, Ojeda B, Manso L, Mesia C, Morales 
S, García-Martinez H, Martínez N, Melé M, Fernández-Ortega A, 
Baselga J. Institut Català d´Oncologia, L´Hospitalet, Barcelona; 
H. Vall d´Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de 
Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales 
Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, 
Spain
Background: Combinations of doxorubicin (DX) and taxanes are 
considered the standard treatment in high risk breast cancer, but 
classical DX is not commonly used in elderly pt or in those with risk 
of developing cardiotoxicity. PLD (Caelyx/Doxil®) is associated with 
less cardiotoxicity. We present a multicentric phase II trial conducted 
by SOLTI group. A combination of PLD and cyclophosphamide (CP) 
followed by paclitaxel (PTX) was tested as primary chemotherapy 
(CT) in pts with stage II-IIIB breast cancer with poor estrogen receptor 
positivity (< 50% positive nuclei) and at least one risk factor of 
developing cardiotoxicity. Our aim was to demonstrate a pathologic 
complete response (pCR) rate similar of prior DX studies without 
cardiac toxicity.
Method: PLD 35 mg/m2 + CP 600 mg/m2 were administered every 
4 weeks (w) for 4 cycles followed by PTX 80 mg/m2 every w for 
12 w. Left ventricular ejection fraction (LVEF), ECG and cardiac 
questionnaire were performed at baseline and 8, 16, 28, 40 w 
thereafter. The primary end point was pCR. Secondary endpoints 
included: cardiac safety, radiological response rate (RRR), breast 
conserving surgery (BCS) rate, toxicity and overall survival at 5 years.
Results: 50 pt were included. Median age: 73 (35-84), 42 pt > 65 
years old; 32 pt (64%) suffer from hypertension and 7 had prior 
cardiac disease. Histological grade III: 36 pts (72%); stage II/III: 
24/26 pt respectively; only 13 pts (26%) were candidate for BCS 
at diagnosis. 46 pt (92%) underwent surgery: BCS 27 (58.6%) and 
mastectomy 19 (41.3%); 4 pt did not proceed to surgery due to serious 
adverse events. In an intent-to-treat analysis pCR rate in breast was 
32% (95% CI 19.5-46.7%), 22% (95% CI 10.5-33.4%) in breast 
and nodes. Among triple negative pt (N=48) pCR was 33.3%. Two 
of seven T4d pt (28.7%) achieved pCR. No significant decrease in 
LVEF was seen: Mean baseline LVEF was 66.6% (52-86), 66.7 
(51-88) after 16w, 62.2 (48-75) after 28w and 64.7 (50-74) after 40 
w. Other toxicities: edema 10%, alopecia 10%, neutropenia 10%, 
stomatitis 8%, neurotoxicity 8%, skin reactions 6%, Hand-Food 
Syndrome 6%. Grade III-V toxicities were reported in 10 patients 
(20%): cardiovascular 3, diarrhea 2, rash 2, lung 2 and neutropenia 
1. Three non-cancer deaths occurred: 1 sudden death in a 82 year’s 
old pt one month after surgery, 1 due to hemorrhagic stroke > 30 
days after completing CT pt with prior cerebrovascular disease , and 
another 84 year’s old due to non-neutropenic pneumonia during CT.
Conclusions: This schedule of primary chemotherapy achieves a 
pCR rate similar to the standard treatment and is feasible in a group 
of patients for whom DX was contraindicated. This strategy enables 
to double the BCS rate. Toxicity was acceptable in a very fragile 
cohort of patients.
P3-14-28
ANZ 0502 NeoGem: A Phase II Trial Evaluating the Efficacy 
and Safety of Epirubicin and Cyclophosphamide Followed by 
Docetaxel with Gemcitabine (+ Trastuzumab If HER2 Positive) 
as Neoadjuvant Chemotherapy for Women with Large Operable 
or Locally Advanced Breast Carcinoma.
McCarthy N, Boyle F, Bull J, Leong E, Simpson A, Kannourakis 
G, Gebski V, Forbes JF, Wilcken N, Lindsay DF, Badger HD. 
Royal Brisbane and Women’s Hospital, Brisbane, Queensland, 
Australia; The Mater Hospital, Sydney, New South Wales, Australia; 
Wellington Hospital, Wellington, New Zealand; Ballarat Oncology 
and Haematology Service, Ballarat, Victoria, Australia; NHMRC 
Clinical Trials Centre, Sydney, New South Wales, Australia; 
University of Newcastle, Newcastle, New South Wales, Australia; 
Calvary Mater Newcastle, Newcastle, New South Wales, Australia; 
Westmead Hospital, Sydney, New South Wales, Australia; Australian 
New Zealand Breast Cancer Trials Group, Newcastle, New South 
Wales, Australia
Background: Neoadjuvant chemotherapy may provide an early 
indication of treatment effect and pathologic complete response 
(pCR) rate is a surrogate measure of disease-free and overall survival. 
Anthracyclines remain an important component of chemotherapy 
regimens for breast cancer (BC), adding a taxane conveys additional 
survival benefit. Gemcitabine (G) has established safety and efficacy 
in metastatic breast cancer (MBC) and combining G with docetaxel 
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(D) shows preclinical synergy but not overlapping toxicities. In MBC, 
efficacy of trastuzumab (T) combined with single agent taxanes 
and G has been demonstrated for tumours that over-express human 
epidermal growth factor receptor 2 (HER2+). NeoGem aimed to 
evaluate the efficacy and safety of neoadjuvant epirubicin (E) and 
cyclophosphamide (C), followed by D and G +/- T (depending on 
HER2 status) in women with large operable or locally advanced BC.
Methods: Eligible patients (pts), ≥18 years, had unilateral, operable 
(at presentation) T2 (≥3cm), T3-4, N0-1, M0 primary BC, no prior 
chemotherapy or hormonal therapy and ECOG status 0-2. All pts 
received E (90mg/m2 i.v.) in combination with C (600mg/m2 i.v.) 
on day 1 q 21 for 4 cycles followed by D (75mg/m2 i.v.) on day 1 
in combination with G (1000mg/m2 i.v.) on days 1 and 8 q 21 for 
4 cycles. HER2+ pts received T (4mg/kg loading then 2mg/kg i.v.) 
concurrent with DG on days 1, 8 and 15 q 21 for 4 cycles. HER2+ 
pts received post-surgical T (6mg/kg) 3 weekly, for a total of one 
year of T therapy. Using a Simon’s 2 stage trial design, the decision 
to proceed to stage 2 followed interim analysis of stage 1. Primary 
endpoint, pCR, was defined as no histologic evidence of invasive 
cancer in the breast. Secondary endpoint, pCRax, was defined as no 
histologic evidence of invasive cancer in the breast and axilla. EC 
followed by DG/DGT was expected to achieve a pCR rate of 35% 
in HER2 negative (HER2-) pts and 40% in HER2+, with the lowest 
limit of therapeutic efficacy being a pCR rate of 22% (HER2-) and 
24% (HER2+). Hence 84 HER2- and 63 HER2+ pts were needed to 
detect significant differences in pCR rates (power 80%, 95% level 
of significance).
Results: Over 32 months 81 pts (63 HER2- and 18 HER2+) were 
enrolled, 78 (96% [61 HER2- and 17 HER2+]) proceeded to surgery. 
Of 78 pts, 21 (27%) achieved pCR and 19 (24%) achieved pCRax. 
Of the 61 HER2- pts, 12 (20% [95% CI: 12%-31%]) achieved pCR 
compared with 9 (53% [95%CI: 31%-74%]) of 17 HER2+ pts. 
Planned chemotherapy was completed by 67 pts (83%), 9 pts (11%) 
discontinued due to adverse events. Thirteen pts (16%) required DG 
dose reductions compared with 7 (8%) pts during EC; 57 (70%) pts 
had ≥ grade 3 neutropenia.
Conclusion: Efficacy in the HER2- cohort did not reach predetermined 
levels of significance (interim analysis); HER2+ recruitment proved 
too slow to continue. High haematological toxicity during DG, 
particularly neutropenia required use of supportive therapy (GCSF). 
Despite relatively small patient numbers, 53% pCR in the HER2+ 
cohort warrants further investigation.
P3-14-29
Neoadjuvant Sunitinib Administered with Weekly Paclitaxel/
Carboplatin in Patients with Locally Advanced Triple-Negative 
Breast Cancer: A Sarah Cannon Research Institute Phase I/II 
Trial.
Yardley DA, Peacock NW, Peyton J, Shipley DL, Spigel S, Barton J, 
Shih KC, Raefsky E, Liggett W, Burris III HA, Hainsworth JD. Sarah 
Cannon Research Institute, Nashville, TN; Tennessee Oncology, 
PLLC, Nashville, TN
Background: Angiogenesis plays a substantial role in breast cancer 
development as well as in triple negative breast cancer (TNBC). 
Sunitinib is an inhibitor of the tyrosine kinase receptors for VEGF, 
platelet-derived growth factor (PDGF), KIT, RET, and fms-like 
tyrosine kinase receptor-3 (FLT3). As monotherapy in heavily 
pretreated breast cancer patients (pts), sunitinib demonstrated a 
response rate of 15% in TNBC (11% of all pts) with stable disease or 
better in 16% of all pts. The combination of paclitaxel and carboplatin 
is ideally suited for further exploration as neoadjuvant chemotherapy 
for TNBC, based on the established preclinical and clinical sensitivity 
of TNBC to these cytotoxic agents. This open label, phase I/II trial 
was designed to evaluate the combination of sunitinib plus paclitaxel 
and carboplatin as neoadjuvant treatment for locally advanced breast 
cancer. The primary objective for the phase I portion was to determine 
the maximum tolerated dose (MTD); these results are presented.
Methods: Women with histologically confirmed invasive triple-
negative adenocarcinoma of the breast, (defined as <10% staining 
by IHC for ER/PR; IHC 0-1+ or FISH negative for HER2), with no 
evidence of metastatic disease and normal LVEF were eligible. All 
pts received sunitinib (days 1-28), paclitaxel (days 1, 8, 15), and 
carboplatin (day 1) in 28-day treatment cycles x6. Following 6 cycles, 
pts had definitive surgery. After ≥2 weeks and evidence of adequate 
wound healing, maintenance sunitinib 25mg PO daily was initiated 
to complete a total of 52 weeks. Three dose levels were evaluated as 
shown in the table below:
Dose Levels Explored
Dose Level No. of Pts Paclitaxel (mg/m2) Carboplatin (AUC) Sunitinib (mg PO)
1 6 70 5 25
2 6 80 5 25
3 3 80 6 25
Doses were escalated in sequential cohorts of pts using standard 
phase I methodology. MTD was defined as the highest dose level 
(DL) producing <1 dose limiting toxicities (DLTs) in a pt cohort. 
The MTD identified in the phase I portion of the study will be used 
in the phase II portion, which will evaluate the efficacy, safety, and 
tolerability of this combination in pts with locally advanced TNBC.
Results: 15 women with TNBC were enrolled between 10/2009 
and 2/2011 [median age 53 years (range: 40-78)]. Due to grade 
3 neutropenia resulting in the inability to deliver cycle 1 day 15 
paclitaxel in the first pt treated at both DLs 1 and 2, these DLs were 
expanded to 6 pts each. No additional cycle 1 DLTs were noted in the 
5 additional pts at either DL. Three pts were accrued to DL 3; there 
were 2 DLTs noted among these pts (grade 3 febrile neutropenia; 
grade 3 neutropenia with cycle 2 day 1 treatment delay). However, 
due to the development of grade 3/4 neutropenia in subsequent 
cycles in 5 of 6 DL 2 pts, resulting in dose delays and requiring 
dose reductions, the MTD of this combination was defined as DL 1 
(paclitaxel 70mg/m2 (Days 1, 8, 15); carboplatin AUC=5 (Day 1); 
sunitinib 25mg PO daily).
Conclusions: The administration of sunitinib with paclitaxel plus 
carboplatin as neoadjuvant therapy is feasible with neutropenia 
defining the MTD of this combination. The phase II portion of this 
study is ongoing.
P3-14-30
Concurrent Celecoxib with FEC Followed by Docetaxel Shows 
Good Responses and Prognosis in a Neoadjuvant Breast Cancer 
Study.
Chow LWC, Tung SY, Ng T-Y, Oh D-Y, Im S-A, Lee M-H, Yip AYS, Toi 
M, Glück S. Organisation for Oncology and Translational Research, 
Hong Kong; UNIMED Medical Institute, Hong Kong; Tuen Mun 
Hospital, Hong Kong; Seoul National University Hospital, Seoul, 
Korea; Soonchunhyang University Hospital, Seoul, Korea; Kyoto 
University, Kyoto, Japan; University of Miami Leonard M. Miller 
School of Medicine, Miami, FL
BACKGROUND: Anthracycline and taxane have been widely 
used as neo-adjuvant therapy(NAT) for breast cancer. Addition 
of COX-2 inhibitors might enhance the anti-cancer effect of 
chemotherapy. This prospective clinical trial studied 5-fluorouracil/
Epirubicin/Cyclophosphamide-Docetaxel(FEC-T) with concurrent 
celecoxib(CXB) as NAT for breast cancer patients(pts). Primary 
endpoints were pathologic complete response(pCR) and clinical 
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response(CR), secondary endpoints were safety and breast 
conservative therapy(BCT) rate. Disease-free survival(DFS) was 
also determined. METHODS: This study accrued 91 pts among 
which 87 pts received FEC(F:500mg/m2; E:100mg/m2; C:500mg/m2) 
followed by T(100mg/m2). In the initial phase, the study randomized 
12 and 11 pts to receive 4 cycles of FEC followed by 4 cycles of T 
with or without concurrent CXB(400mg bid) respectively. Due to 
possible cardiovascular events from COX-2 inhibitors, the study 
protocol was revised to a single arm phase II study which recruited 
another 64 pts who received FEC-T with concurrent CXB at reduced 
dosage(200mg bid). Primary endpoints were compared between pts 
with and without CXB using Fisher’s Exact test. All endpoints and 
survival were evaluated for phase II subjects. RESULTS: Out of 87 
pts, 84 invasive breast cancer pts, age ranged 30-62 (mean: 46±6 
years) and clinically staged IIA (n=48,57.1%), IIB (n=28,33.3%) 
and IIIA (n=8,9.5%), are eligible for comparison between groups 
(CXB+,n=73 / CXB-,n=11). More CRs were observed in CXB+ 
than in CXB- (94.5% vs. 72.7%, p=0.044) but pCR did not show 
statistical difference. In the phase II study, 57/64 pts, including luminal 
A 35(61.4%), luminal B 12(21.1%), HER-2 positive 8(14.0%), and 
triple negative (TPN) 2(3.5%), completed NAT and definitive surgery. 
pCR plus near pCR was observed in 18(31.6%)pts. Excluding TPN 
subtype, pCR (p=0.761) did not but near pCR (p=0.043) differ 
among subtypes. Those with HER-2 amplification had higher near 
pCR than those who did not (6/20 vs. 3/37, p=0.031). Out of 56 pts 
evaluable for CR, 43(75.4%) and 13(22.8%) pts achieved complete 
and partial CR respectively. Over 80% pts received BCT after NAT 
and that 11/14(78.6%) pts who initially were unsuitable for BCT 
with a baseline tumor >5cm became eligible after NAT. At a median 
follow-up of 37 months, 61 pts who completed ≥6 cycles of NAT 
and surgery were followed and 80% of pts are still disease-free. Pts 
responding to the NAT has fewer chance of relapse (p=0.03). Neither 
life-threatening toxicity nor cardiotoxicity was observed. The most 
commonly observed grade 3/4 adverse events included neutropenia 
and leucopenia: 39.1% and 20.3% during FEC, and 16.1% and 12.9% 
during T respectively. Febrile neutropenia was observed in 9.4% pts 
during FEC, but none during T. Less than 40% of pts required G-CSF 
support. Other mild toxicities were manageable. CONCLUSIONS: 
Higher CR was observed in pts receiving neo-adjuvant FEC-T with 
concurrent CXB which appeared well-tolerated and safe. Rate of 
BCT is high after the treatment. Pts with HER-2 amplified breast 
cancer responded better than those who did not. Chance of relapse 
is significantly reduced for NAT responders. Further investigation 
of using COX-2 inhibitors with neo-adjuvant chemotherapy is 
warranted.
P3-14-31
Preoperative Chemotherapy and Bevacizumab for Locally 
Advanced HER-2 Negative Breast Cancer Followed by Prolonged 
Postoperative Bevacizumab for Those with Less Than Complete 
Pathologic Response.
Carpenter JT, Forero A, Falkson CI, Nabell LM, De Los Santos JF, 
Krontiras H, Bland KI, Li Y. University of Alabama at Birmingham, 
Birmingham, AL
We studied patients with locally advanced breast cancer (LABC) to 
evaluate 1) whether adding concurrent bevacizumab to preoperative 
chemotherapy (CT) would increase the pathologic complete 
response (pCR) rate, 2) whether a prolonged postoperative course 
of bevacizumab would prevent or reduce the recurrence rate in 
patients who did experience pCR after preoperative chemotherapy, 
and 3) whether use of pegylated liposomal doxorubicin would prove 
comparably effective to doxorubicin with less toxicity in this setting. 
From 3/08-12/09 32 patients with HER-2 negative operable (LABC) 
received sequential preoperative CT with pegylated liposomal 
doxorubicin 25 mg/M2 every 2 weeks X 3, paclitaxel 175 mg/M2 
every 2 weeks X 3, and cyclophosphamide 60 mg/M2 every 2 weeks 
X 3, all with concurrent bevacizumab 10 mg/kg every 2 weeks. One 
patient’s disease progressed by the end of CT; 1 patient withdrew after 
2 cycles of treatment. All 30 remaining patients had ≥30% shrinkage 
of tumor at the completion of CT. Left ventricular ejection fractions 
on the 31 who completed CT were >55% before and after completing 
CT; no cardiac failure was seen. Grade III toxicities included 
hypertension >150/90 in 7 and palmar-plantar erythrodysesthesia in 
1; other toxicities were grade I or II. No proteinuria was seen. Five 
experienced delayed wound healing after operation. Responses: 
9/32 pCR in breast and axillary nodes (2/15 in ER or PR+, 7/17 
in ER/ PR-), and 3 pCR in breast with ≥1 positive axillary node (2 
ER or PR+, 1 ER/PR-). Hormonal treatment but no further CT was 
given after operation. 20/21 patients with residual invasive cancer in 
breast or nodes started an additional year of bevacizumab 15 mg/kg 
every 3 weeks; 1 never started bevacizumab due to delayed wound 
healing- her disease recurred before starting bevacizumab and she 
died 22 months after diagnosis. All but 6 of these have completed 
the additional year of bevacizumab (1 withdrew early due to the need 
for 2 emergency abdominal operations); 1 experienced recurrence in 
lungs during bevacizumab treatment and subsequently died 24 months 
after starting treatment (ER+). An additional patient with initial pCR 
experienced recurrence in brain, then lung 18 months after starting 
treatment (ER/PR -). With a median followup of 26.5 months since 
diagnosis, 30 of 32 remain alive, 28 of 32 remain free of recurrence, 
and 19 of the 20 who started bevacizumab for less than pCR after 
operation remain free of recurrence. Concurrent bevacizumab did 
not appear to influence the pCR rate from preoperative CT. The pCR 
rate observed using pegylated liposomal doxorubicin is comparable 
to that obtained at UAB with sequential treatment using doxorubicin, 
but is less toxic. Use of bevacizumab after operation in patients with 
LABC who do not experience pCR from preoperative chemotherapy 
may decrease recurrence and appears promising. Further observation 
in this group and further prospective study will be of interest.
Supported by Centocor Ortho Biotech Services and by Genentech
P3-15-01
An Interim Efficacy Analysis of Neoadjuvant Letrozole in the New 
Primary Endocrine-Therapy Origination Study (NEOS/N-SAS 
BC06): A Randomized Study of Adjuvant Endocrine Therapy 
with or without Chemotherapy for Postmenopausal Breast 
Cancer Patients Who Responded to Neoadjuvant Letrozole.
Iwata H, Yamaguchi T, Masuda N, Toyama T, Kashiwaba M, 
Yamamoto Y, Taira N, Saji S, Ohashi Y. Aichi Cancer Center, Nagoya, 
Japan; Tohoku University Graduate School of Medicine, Sendai, 
Japan; NHO Osaka National Hospital, Osaka, Japan; Nagoya City 
University Hospital, Nagoya, Japan; Iwate Medical University, 
Morioka, Japan; Kumamoto University Hospital, Kumamoto, 
Japan; Okayama University Hospital, Okayama, Japan; Saitama 
Medical University International Medical Center, Hidaka, Japan; 
The University of Tokyo, Tokyo, Japan
Background: It has not been established if adjuvant chemotherapy 
is required for patients with intermediate-risk endocrine-responsive 
postmenopausal breast cancer. The NEOS is a randomized controlled 
trial to verify the necessity of adjuvant chemotherapy in patients with 
node-negative, ER-positive, and HER2-negative postmenopausal 
breast cancer who responded to neoadjuvant endocrine therapy. For 
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neoadjuvant letrozole (LET), the protocol specified that an interim 
analysis should be performed to avoid lack of benefit to patients if 
no therapeutic effects, which were anticipated before the start of the 
study, were obtained.
Methods: Patients who complied with the eligibility criteria were 
administered LET preoperatively in weeks 24-28 after primary 
enrollment. Patients evaluated as complete response (CR), partial 
response (PR) or stable disease (SD) underwent secondary enrollment 
and will be divided at random into two arms, an arm given LET for 
4.5-5 years after chemotherapy and another arm given only LET for 
4.5-5 years. Patients evaluated as progressive disease during LET 
treatment will receive discretionary treatment. For neoadjuvant 
LET, the number of patients requiring interim analysis of efficacy 
was calculated as 140 based on the assumption that the threshold 
response rate of CR+PR+SD was 75% and its expected response 
rate was 85% in patients who completed neoadjuvant LET, and that 
the one-sided level of significance was 5% and the statistical power 
was 90%. When the hypothesis that the rate of CR+PR+SD was less 
than 75% was not rejected at a significance level of 5%, the study 
was discontinued and when it was rejected, the study was continued.
Results: As of June 2011, 140 patients in 39 centers had completed 
neoadjuvant LET. The median age was 64 years old (range: 50-75) 
and the median Body Mass Index (BMI) was 23.90 (±3.77). According 
to MRI or CT scan, CR occurred in 2 (1.4%), PR in 57 (40.7%), 
and SD in 59 patients (42.1%). The rate of CR+PR+SD among the 
140 patients was 84.3% (90% confidence interval: 78.6-88.7). In 
ultrasonography, 47 patients (33.6%) showed a decrease in the long 
diameter of 30% or more in a mono-dimensional measurement and 
52 patients (37.1%) showed a decrease in volume of 50% or more 
in a three-dimensional measurement. The neoadjuvant LET effects 
showed no differences in patients with a BMI of less than 20, 20-25, 
and more than 25. No serious adverse events were observed.
Discussion: The rate of patients who achieved CR+PR+SD by 
neoadjuvant LET complied adequately with the continuation criteria 
for the study. We will present the results for 205 patients who could be 
evaluated for efficacy and safety of neoadjuvant LET as of May 2011.
This study was supported by Public Health Research Foundation.
Clinical Trial Registration Information: UMIN (http://www.umin.
ac.jp/), Study ID: 000001090
P3-15-02
The Change of Bone Turnover Markers during Neoadjuvant 
Anastrozole Versus Exemestane: A Randomized Single-Center 
Study.
Jinno H, Shimada K, Takahashi M, Hayashida T, Hirose S, Ikeda T, 
Kitagawa Y. Keio University School of Medicine, Shinjuku, Tokyo, 
Japan; Teikyo University School of Medicine, Itabashi, Tokyo, Japan
Background
Non-steroidal aromatase inhibitors including anastrozole and letrozole 
have been reported to increase the rate of bone turnover, accelerate 
loss of bone, and increase the incidence of fractures. Although 
steroidal inactivator exemestane has similar inhibitory effect on the 
aromatization, animal studies have shown a weak but potentially 
important anabolic effect of exemestane metabolites, which might lead 
to decreased bone resorption. This randomized trial was conducted to 
compare the effect of exemestane and anastorozole on bone turnover 
markers.
Patients and Methods
Fifty-two postmenopausal women with ER-positive, HER2-negative, 
invasive, nonmetastatic, and operable breast cancer were randomly 
assigned to neoadjuvant exemestane (25 mg daily) or anastrozole (1 
mg daily) for 4 months. The primary endpoint was change in bone 
turnover markers including resorption markers urinary and serum 
N-telopeptide (NTX) and the formation markers serum bone alkaline 
phosphatase (BAP). The secondary endpoint was tumor objective 
response (OR) assessed by both caliper and ultrasound. Comparisons 
were also made of breast conservation rate and adverse events.
Results
The changes in serum NTX from baseline to week 16 were not 
statistically different between anastrozole and exemestane . The 
changes in urinary NTX from baseline to week 16 were also not 
statistically different between both groups .BAP did not show any 
significant increase in the exemestane group (10.8%; p=0.21), whereas 
the increase in BAP from baseline to week 16 in the anastrozole 
group was 15.0% and marginally significant (p=0.05). There were 
no significant differences in OR in the intent-to-treat population 
between patients receiving anastrozole or exemestane (45.8% vs. 
39.2%; p=0.63). The OR was similar between the patients with a 
baseline Ki67 index of >15% and <15% in exemestane group (37.5% 
vs. 41.2%; p=0.86). In anastrozole group the OR in patients with 
a baseline Ki67 index of >15% and <15% was 44.4% and 53.8%, 
respectively(p=0.66). Breast conservation rate was similar between 
anastrozole and exemestane (62.5% vs. 67.9%; p=0.68). Treatment 
was well tolerated and much the same for both groups.
Conclusions
There is no significant differences of the change in bone turnover 
markers between anastrozole and exemestane. These results indicate 
exemestane had no anabolic effects which would lead to fewer adverse 
effects on bone.
P3-16-01
Safety Profile and Clinical Activity of Single-Agent BKM120, a 
Pan-Class I PI3K Inhibitor, for the Treatment of Patients with 
Metastatic Breast Carcinoma.
Rodon J, Bendell JC, Abdul Razak AR, Homji N, Trandafir L, 
Quadt C, Graña-Suárez B, Siu LL, Di Tomaso E, Demanse D, 
Massacesi C, Hirawat S, Burris III HA, Baselga J. Vall d’Hebron 
University Hospital, Barcelona, Spain; Sarah Cannon Research 
Institute, Nashville, TN; Princess Margaret Hospital, Toronto, ON, 
Canada; Novartis Pharmaceuticals, Florham Park, NJ; Novartis 
Oncology, Paris, France; Novartis Pharma AG, Basel, Switzerland; 
Novartis Institutes for BioMedical Research Inc, Cambridge, MA; 
Massuchusetts, Boston, MA
Background: Phosphatidylinositol 3-kinase (PI3K) is critical to 
cancer cell growth, survival, and metabolism. BKM120 is an oral 
pan-class I (a, b, g, d) PI3K inhibitor that has demonstrated in vitro 
and in vivo tumor cell growth inhibition in a range of cancer types 
including breast cancer.
Materials and methods: The Phase I study CBKM120X2101 
investigating single-agent daily BKM120 in patients (pts) with 
advanced solid tumors has been recently completed with the 
maximum tolerated dose established at 100 mg/day. Here, we report 
the analysis of metastatic breast carcinoma (MBC) pts enrolled in 
this study.
Results: Overall, 83 pts have enrolled, 21 of whom have MBC. At the 
cut-off date of 25th February 2011, 20 MBC pts were evaluable: 1 pt 
at 80 mg, 1 pt at 150 mg and 18 pts at 100 mg. Patient characteristics 
were as follows: median age 55 years (range 37–71); performance 
status ECOG 0/1/2 for 7/12/1 pts, respectively; visceral disease was 
reported in 16 pts, including liver, 10 pts (50%); lung, 9 pts (45%); 
and pleura, 5 pts (25%); all pts had >3 lines of systemic therapy 
(3–12). The median time from last treatment and study entry was 
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46 days (29–235). The median duration of BKM120 treatment 
administered was 7.5 weeks (1.0–96.4). The most frequent grade 
3 drug-related adverse events (AEs) were: transaminases increase, 
4 pts; psychiatric disorders, 3 pts, consisting of anxiety, affective 
disorder, and mood alteration (1 pt each); diarrhea, 2 pts; fatigue, 
2 pts; and hyperglycemia, 1 pt. The only grade 4 drug-related AE 
was hyperglycemia, reported in 1 pt at 150 mg. Most AEs were 
manageable with treatment interruption and dose reductions. Eighteen 
pts were evaluable for objective tumor response by RECIST. Two 
pts (11%) exhibited partial responses, which were confirmed in a 
triple-negative MBC pt, and unconfirmed in an ER+ HER2– MBC 
pt. For these 2 pts, the treatment duration was 29+ (ongoing) and 6 
months, respectively. An additional 9 pts (50%) had stable disease, 
lasting >4 months in 7 pts (35%).
Conclusions: This preliminary analysis showed that BKM120 
has single-agent activity in heavily pretreated pts with MBC, 
and an acceptable safety profile. Molecular profiling and updated 
pharmacokinetic results will be presented at the meeting.
P3-16-02
Targeting Tumor Initiating Cells with siRNA/Nanotherapy in 
Triple Negative Breast Cancer.
Granados-Principal S, Deng X, Liu D, Chang JC, Shen H, Dave B. 
The Methodist Research Institute, Houston, TX; Baylor College of 
Medicine, Houston, TX
Residual human breast tumor cells after conventional therapies are 
enriched in tumor-initiating cells (TIC) characterized by CD44+/
CD24-/low/lineage- with self-renewal capacities. Our gene expression 
analyses in those cells and in breast cancer cells propagated as 
mammospheres (MSs) reveal an epithelial-mesenchymal-transition 
(EMT) signature (400 genes) mainly found in claudin-low molecular 
subtype human breast tumors. We performed lentiviral shRNA knock-
down of that signature in MS. Critical shRNAs were found to decrease 
the TIC subpopulation. Among those genes, we found STAT3 (signal 
transducer and activator of transcription 3), NTN4 (netrin 4), and 
RPL39L (ribosomal protein L39-like). Here, we used a multiscale 
siRNA delivery system targeting those three genes in order to clarify 
the effect of silencing those genes over the self-renewal capacity on 
MSs with claudin-low features. To this end, duplex small interfering 
RNA (siRNA) against STAT3, NTN4, RPL39L, and scrambled siRNA 
as control, were introduced into neutral nanoliposomes (dioleoyl 
phosphatidylcholine, DOPC), and using mesoporous microscale 
biodegradable silicon particles as carriers. This multistage siRNA 
delivery system has been reported as a good approach for sustained 
gene silencing. Claudin-low-like human breast cancer cell lines 
(SUM159 and BT549) were plated in 24-well ultralow attachment 
plates with mammary epithelial growth medium (MEGM) (5,000 
cells/well). Both cell lines were then treated with 1µg/well/6 wells 
of silicon particles loaded with DOPC nanoliposomes/siRNA. The 
primary MSs were allowed to grow for 3 days. MFs were counted 
by day 3 with a GelCount colony counter (Oxford Optronix, Oxford, 
UK). Mammosphere-Forming Efficiency (MSFE) was calculated 
by dividing the number of MSs by the number of seeded cells. In 
addition, established MSs were serially passaged by dissociation, 
and single cells were replated on fresh 24-well ultra-low attachment 
plates to form secondary mammospheres, which were counted after 
3 days. One-way ANOVA and Tukey test were performed. A p value 
less than 0.05 was considered as significant. Our results show that 
silencing STAT3, NTN4, and RPL39L significantly reduces the MSFE 
in both primary (1%, 0.9%, and 1.7% respectively) (Figure 1) and 
secondary MSs (0.49%, 0.51%, and 0.45% respectively) (Figure 2) 
when compared to the scrambled control (2.4% and 1% respectively) 
in BT549 cells. For SUM159 cells, we did not find any change in 
primary MSs for STAT3 (2.2%) and NTN4 (2.1%), even we found a 
higher percentage of MSFE in those cells treated with RPL39L siRNA 
(3.9%) when compared to the scrambled control (2.1%) (Figure 3). 
Nevertheless, a lesser MSFE were observed in those cells treated with 
STAT3 (0.9%, not significant), NTN4 (0.8%) and RPL39L (0.78%) 
in comparison to control (1.1%) (Figure 4). In conclusion, knocking-
down of EMT-related genes (STAT3, NTN4, and RPL39L) decreases 
significantly the self-renewal capacity in mammospheres derived from 
claudin-low-like human breast tumor cells, being BT549 cells more 
sensitive than SUM159 cells to that silencing with siRNA loaded in 
DOPC nanoliposomes into silicon particles as carriers.
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P3-16-03
Enhancing Anti-IGF Directed Therapeutics by Co-Targeting 
Autophagy.
Oh AS, LaPara K, Yee D. University of Minnesota, Minneapolis, MN
Autophagy (macroautophagy) is a cellular mechanism that maintains 
homeostasis and cell growth by regulating the turnover of damaged 
proteins. Autophagy has a critical role in maintaining cellular 
viability during nutrient starvation and metabolic stress by recycling 
intracellular proteins for nutrient reallocation. Whether the autophagy 
pathway utilized by breast cancer cells has a survival mechanism 
or is a feature of cell death is not fully understood. Since the IGF/
insulin signaling maintains cellular growth, nutrient utilization, and 
survival, increased autophagy or autophagic flux might be induced 
with IGF-I inhibitors as a compensatory survival mechanism. In 
breast cancer cells treated with anti-IGF1R kinase inhibitors, we 
observed an increase in autophagic flux; similar to levels induced 
by nutrient deprivation.
Objective: In this study, we examined whether IGF1R inhibitor 
-induced autophagy is cytoprotective or cytotoxic. If autophagy has 
a protective role in nutrient-depleted conditions it could reduce the 
long term efficacy of IGF1R inhibition by making cells refractory 
to blockade of this signaling system. In this study, we hypothesized 
that blocking autophagy in combination with anti-IGF1R therapies 
(antibodies or small molecules) would further enhance growth 
inhibition in a panel of breast cancer cells types (luminal and basal-
like/triple negative).
Results: We initially examined whether autophagy inhibitors 
(chloroquine or bafilomycin A1) had a differential growth effect on 
breast cancer cells that varied in their sensitivity to IGF1R stimulated 
growth. We found that low-to-moderate IGF growth dependent 
MDA-MB-231 and MDA-MB-435A breast cancer cells were more 
sensitive to chloroquine alone. However, sensitivity to bafilomycin 
A1 differed between breast cancer cell lines compared to chloroquine. 
In conditions of cellular stress when autophagy is normally triggered, 
co-treatment with IGF inhibitor (OSI-906) and chloroquine, increased 
growth inhibition in all breast cancer cell lines. Further, basal-like 
breast cancer cells (i.e. low-to-moderate IGF growth dependent cells) 
had a higher baseline autophagic flux compared to luminal MCF-7L 
breast cancer cells (i.e. highly IGF-I dependent). Using MCF-7L cells 
selected for long-term resistance to IGF1R kinase inhibitor (AEW-
541), we found that these cells were not sensitivite to chloroquine 
or Bafilomycin A1 compared to wild type MCF-7Ls. Inhibiting 
autophagy in combination with anti-IGF therapies could offer benefit 
over single therapy alone if autophagy inhibitors are given together 
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with IGF1R inhibitors, but not in IGF1R inhibitor resistant cancers. 
Additionally, targeting autophagy as a single agent therapy may be 
more beneficial in triple negative breast cancer compared to other 
subtypes of breast cancer.
P3-16-04
A Novel Monoclonal Antibody to Secreted Frizzled Related 
Protein 2 Inhibits Triple Negative Breast Carcinoma Growth 
Rate In Vivo.
Klauber-DeMore N, Fontenot E, Mumper R, Ma P, Rossi E, 
Siamakpour-Reihani S, Bone B, Hilliard E, Ketelsen D, Santos C, 
Patterson C. University of North Carolina at Chapel Hill, Chapel 
Hill, NC
Background: Secreted frizzled related protein 2 (SFRP2) is a 
novel angiogenesis factor expressed in the endothelium of a 
wide variety of human tumors including triple negative breast 
cancer and angiosarcoma. We previously reported generating a 
monoclonal antibody against SFRP2 that inhibits endothelial cell and 
angiosarcoma tube formation in vitro, and decreased tumor volume 
of the SVR angiosarcoma in vivo. The objectives of these studies 
were to determine pharmacokinetic (PK) and pharmacodynamic (PD) 
parameters of the SFRP2 MAb, and evaluate its efficacy in a triple 
negative breast cancer xenograft.
Methods: 125 I-SFRP2 MAb was administered to nude mice i.v. via 
tail vein injections at 0.4 mg/kg, 4 mg/kg, or 10 mg/kg in mice with 
or without tumor. Blood organ, and tumor samples were collected 
at various time points from 5 min to 21 days. Radiolabeled SFRP2 
MAb in serum and tissues was determined using a gamma counter. 
PK parameters were determined based on mean concentration values 
for 3-5 animals per time point. In vivo efficacy study: MDA-MB-231 
human breast cancer xenografts were established in 6-week-old 
female nude mice. Mice were inoculated with 1 x 106 cells s.c.. 
Treatment began on day 16 after tumor inoculation when average 
tumor size was 200 mm3. Animals were randomly assigned (n = 12 
per group) to buffer control, SFRP2 MAb 4 mg/kg iv twice weekly; 
Avastin (Roch) 5 mg/kg iv twice weekly, or IGg control 4 mg/kg 
iv twice weekly. Tumors were harvested when the tumor diameter 
reached 2 cm or at 28 days. Tumor volumes were measured with a 
caliper. Growth rates (percent change per day) were compared with 
the formula ((Final volume- initial volume)/ initial volume) x 100 
/ number of days. Differences in growth rate between treated and 
control were analyzed with a two-tailed t-test.
Results: PK and PD: SFRP2 MAb was long circulating in the blood 
with an average t1/2 in the range of 53-89 hr. In addition, the SFPR2 
MAb was found to preferentially target the tumors versus all other 
organs except for the liver. For example, in tumor bearing mice, the 
blood/tissue ratio on day 14 was smallest in the liver (15:1) and tumor 
(16:1) as compared to all other organs (range: 39:1 to 255:1) proving 
that the tumor was a prime organ for accumulation of the SFRP2 
MAb. The SFPRP2 MAb in tumor bearing and non-tumor bearing 
mice exhibited dose-independent kinetics as a one-way ANOVA 
analysis comparing t1/2 at different dose levels was not statistically 
significant (p=0.2847 and 0.1204, respectively). However, there was 
statistically significant difference in t1/2 of the SFPR2 MAb in tumor-
bearing and non-tumor bearing mice (p=0.0386). Efficacy in triple 
negative breast cancer: There was a 40% decrease in growth rate 
between SFRP2 MAb and control (p=0.03) and a 20% inhibition of 
growth rate between Avastin and control (p=0.40). The IgG negative 
control had no effect on tumor growth.
Conclusion: The SFRP2 MAb was long circulating and the tumor was 
a prime organ for accumulation of the SFRP2 MAb. SFRP2 MAb 
slowed the growth of a human triple negative breast cancer xenograft 
in a tumor model that was not sensitive to Avastin. We conclude that 
SFRP2 is a novel therapeutic target for breast cancer.
P3-16-05
A Phase II Trial Expansion Cohort of the PARP Inhibitor 
Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated 
Metastatic Breast Cancer.
Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Habin K, Qian J, 
Giranda V, Shepherd S, Garber JE, Ellisen LW, Winer EP, Goss PE. 
Massachusetts General Hospital Cancer Center, Boston, MA; Dana 
Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical 
Center, Boston, MA; Harvard Medical School, Boston, MA; Abbott 
Laboratories, Abbott Park, IL
Background: Veliparib (ABT-888) is a novel oral inhibitor of 
Poly (ADP-Ribose) Polymerase (PARP) 1 and 2. Veliparib and 
temozolomide (TMZ) are synergistic in breast cancer xenograft 
models. We recently conducted a phase II study of TMZ and veliparib 
in 41 patients (pts) with metastatic breast cancer (MBC). Activity 
was observed only in pts with known BRCA1 or BRCA2 deleterious 
mutations, with a response rate (RR) of 50% (4/8) and clinical benefit 
rate (CBR) of 62.5%. In order to further evaluate the activity and 
safety of TMZ and veliparib, we enrolled an expansion cohort of 20 
additional patients with BRCA1 or 2 mutations.
Methods: We previously conducted a single arm phase II trial of 
veliparib and TMZ in 41 MBC pts. Eligibility included measurable 
disease, >1 prior MBC therapy and PS ≤ 2. Available archived tumor 
samples were collected. In this expansion cohort, first line therapy for 
MBC and prior PARP inihibitor therapy were allowed, and eligible 
patients were required to have a known deleterious BRCA1 or BRCA2 
mutation identified from prior clinical testing. The dose of veliparib 
in the original cohort was reduced from 40 mg PO BID to 30 mg 
PO BID. In the expansion cohort all patients received veliparib (30 
mg PO BID days 1-7) and TMZ (150mg/m2 PO QD days 1-5) on a 
28 day cycle. RECIST response was evaluated every 2 cycles. The 
primary endpoint was overall response rate. Secondary endpoints 
included PFS, OS, safety and toxicity.
Results: Between June 24, 2010 and Sept 29, 2010, 20 eligible pts 
(median age 42) were enrolled. Baseline characteristics included: 
median PS=0 (range 0-2); 9 BRCA1 carriers, 9 BRCA2 carriers, and 
2 unknown. 17 pts (85%) received prior adjuvant chemotherapy. 9 
patients received a prior platinum chemotherapy. The most common 
grade 3/4 toxicities included thrombocytopenia and neutropenia. 
Best response for the 20 patients evaluable at the time of abstract 
submission includes 3 PR (15%), 6 SD (30%), 11 PD, and a clinical 
benefit rate of 45%. Combined with the initial cohort of 8 known 
carriers from the original 41 patients, the total RR is 25% (7/28) and 
clinical benefit rate of 50% (7 PR, 7 SD). The RR was 40% (6/15) in 
pts without prior platinum treatment, and 9% (1/11) in pts with prior 
platinum treatment. The median PFS for the 20 BRCA carriers was 85 
days, and among patients with prior platinum treatment compared to 
no prior platinum, the median PFS was 70 and 179 days, respectively. 
Three pts remain on study, 1 with a CR for >20 mo.
Discussion: We previously demonstrated that veliparib and TMZ is 
an active combination in BRCA1/2 associated MBC. In this larger 
expansion cohort of 20 additional patients, the combination continued 
to show activity, although the response rate was not as robust as 
previously observed. Differences between the original cohort and the 
expansion cohort may account for some variation in response, such 
as prior platinum or PARP inhibitors therapy, number of lines of prior 
therapy, and the dose of veliparib used (40mg vs 30 mg). These results 
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support further evaluation of this regimen in the BRCA1/2 carrier 
population, and provide the opportunity to evaluate potential factors 
that may predict response or resistance to this regimen.
P3-16-06
Phase II Trial of TS-1 in Combination with Oxaliplatin (SOX) 
in Patients with Metastatic Breast Cancer (MBC) Previously 
Treated with Anthracycline and Taxane Chemotherapy [TORCH] 
[Korean Cancer Study Group (KCSG) BR07-03].
Im S-A, Oh D-Y, Lee KS, Ahn J-H, Shon J, Ahn JS, Kim JH, Han 
SW, Lee MH, Lee KE, Lee K, Kim HJ, Keam B, Kim S-Y, Kim SB, 
Im YH, Ro J, Park H-S. Seoul National University Hospital, Seoul, 
Republic of Korea; National Cancer Center, Republic of Korea; 
Asan Medical Center, Seoul, Republic of Korea; Yonsei University 
College of Medicine, Severance Hospital, Seoul; Samsung Medical 
Center, Seoul, Republic of Korea; Seoul National University Bundang 
Hospital, Seongnam, Republic of Korea; Inha University Hopsital, 
Incheon, Republic of Korea; Ewha Womans University Medical 
Center, Seoul, Republic of Korea; Hanlim University Pyungchon 
Hospital, Pyungchon, Republic of Korea; Kyung Hee University 
Hopital, Seoul, Republic of Korea; Soon Chun Hyang University 
Hospital, Seoul, Republic of Korea
Background: Oxaliplatin, a platinum analogue, is an active drug in 
advanced anthracycline and taxane-pretreated breast cancer patients 
as a single agent and with 5-fluorouracil (5-FU) combination. TS-1 
was developed by the scientific theory of both potentiating antitumor 
activity of 5-FU and reducing gastrointestinal toxicity. This trial was 
performed to evaluate the efficacy and safety of TS-1 in combination 
with oxaliplatin in metastatic breast cancer (MBC) patients previously 
treated with anthracycline and taxane chemotherapy.
Methods: Between October 2007 and October 2009, MBC patients 
were enrolled in this prospective multicenter trial. Eligible criteria 
included age >18 years, at least one measurable lesion, prior treatment 
with anthracycline and taxane chemotherapy, and ECOG Performance 
Status 0–2. TS-1 40 mg/m2 b.i.d. on days 1–14 with oxaliplatin 
130 mg/m2 on day 1 were administered every 3 weeks till disease 
progression. Primary end-point was response rate, and secondary 
end-points were time-to-progression (TTP), overall survival (OS), 
duration of response (DOR) and toxicities. Response was evaluated 
every 6 weeks according to the RECIST criteria v.1.0 and toxicity 
was assessed with NCICTCAE v.3.0.(ClinicalTrials.gov identifier 
NCT00527930).
Results: A total of 87 patients were enrolled. Median age was 48 years 
(range 30-71 years). Nineteen patients (21.8%) had de novo stage IV 
and 68 patients (78.2%) had recurrent disease. Thirty-five patients 
(40.2%) received two-lines of prior chemotherapy in palliative setting. 
Forty-eight patients (55.2%) had ≥ 3 disease sites. Fifty-four patients 
(62.1%) were hormone receptor positive, and 25 patients (28.7%) 
were triple negative. Five patients received prior anti-HER2 therapy. A 
total of 525 cycles were administered (median 6 cycles, range: 1~ 22+ 
cycle). In per-protocol analysis, overall response rate was 38.5% (95% 
CI: 27.7-49.3) (CR 0%, PR 38.5%) and disease control rate (CR, PR, 
and SD) was 67.9% (95% CI: 57.5-78.3). Median TTP, OS, and DOR 
were 6.0 months (95% CI: 5.1-6.9 months), 19.4 months (95% CI: not 
estimated), 6.6 months (95% CI: 3.7-9.6 months), respectively. RR 
was not different by triple negativity (39.1% in TNBC vs. 38.2% in 
non-TNBC, P=0.361). TTP was not different according to the number 
of prior chemotherapy regimens. Reported grade 3 or 4 toxicities 
(per cycle) were neutropenia (10.3%), thrombocytopenia (5.5%), 
diarrhea (1.9%), vomiting (1.9%), and stomatitis (0.2%). There was 
no treatment-related death.
Conclusions: SOX is an effective regimen in anthracycline and taxane 
pretreated MBC patients with manageable toxicities.
P3-16-07
Denosumab in Patients with Breast Cancer and Bone Metastases 
Previously Treated with Zoledronic Acid or Denosumab: Results 
from the 2-Year Open-Label Extension Treatment Phase of a 
Pivotal Phase 3 Study.
Stopeck AT, Lipton A, Martín M, Body J-J, Paterson A, Steger GG, 
Tonkin K, de Boer RH, Fujiwara Y, Yardley D, Jassem J, Takano 
T, Solal-Celigny P, Fan M, Braun A. University of Arizona Cancer 
Center, Tucson, AZ; Penn State Milton S. Hershey Medical Center, 
Hershey, PA; Hospital General Universitario Gregorio Marañón, 
Madrid, Spain; CHU Brugmann, Université Libre de Bruxelles, 
Brussels, Belgium; Tom Baker Cancer Centre, Calgary, AB, Canada; 
Medical University of Vienna, Vienna, Austria; Cross Cancer Institute, 
Edmonton, AB, Canada; Western and Royal Hospitals, Melbourne, 
Australia; National Cancer Center Hospital, Tokyo, Japan; Sarah 
Cannon Research Institute, Nashville, TN; Tennessee Oncology, 
PLLC, Nashville, TN; Medical University of Gdansk, Gdansk, Poland; 
Toranomon Hospital, Tokyo, Japan; Clinique Victor Hugo, Centre 
Jean Bernard, Le Mans, France; Amgen, Inc., Thousand Oaks, CA
Background: Primary results from a phase 3, randomized, double-
blind double-dummy trial showed that compared with zoledronic 
acid (ZA), denosumab reduced the risk of developing a first on-study 
SRE by 18% (hazard ratio, 0.82; 95% CI 0.71 to 0.95; P = 0.01), and 
the risk of multiple SREs by 23% (rate ratio, 0.77; 95% CI 0.66 to 
0.89; P = 0.001) in patients with breast cancer and bone metastases. 
Based on superior efficacy and favorable safety data from the study’s 
primary analysis (Stopeck et al, 2010), all patients who remained on 
treatment were offered open-label denosumab in a prespecified 2-year 
extension treatment phase.
Materials and Methods: A total of 2046 patients with breast cancer 
and bone metastasis were randomized to receive either subcutaneous 
(SC) denosumab 120 mg and intravenous (IV) placebo or IV ZA 4 
mg (adjusted for renal function) and SC placebo Q4W in the double-
blinded treatment phase. Patients who completed the double-blinded 
treatment phase were offered open-label denosumab Q4W for up to 2 
years from the start of the open-label treatment phase. Patients who did 
not participate in the open-label treatment were followed for survival 
every 12 weeks for up to 2 years after their last dose of investigational 
product in the double-blinded treatment phase.
Results: Of the 752 patients who completed the double-blinded 
treatment phase, 667 (89%) patients entered the open-label treatment 
phase: 325 (48.7%) initially randomized to the denosumab group (DD) 
and 342 (51.3%) to the ZA group in the double-blinded treatment 
phase (ZD). Demographics were comparable between groups. The 
total median (Q1, Q3) cumulative denosumab exposure (including 
double-blinded and open-label treatment phases) for DD patients 
was 19.3 months (9.2, 32.2) (range 0.9–59.8 months). Adverse 
events (AEs) were comparable between groups (n = 283/318 [89%] 
for DD patients; n = 303/334 [91%] ZD patients). An additional 20 
patients in the DD group and 18 patients in the ZD group reported 
osteonecrosis of the jaw, resulting in a cumulative incidence of 4.7% 
for DD patients and 3.5% for ZD patients for the entire study duration 
of 5 years. Hypocalcemia AEs during the open-label treatment phase 
were comparable between groups (n = 12 DD; n = 9 ZD). The most 
common AEs were nausea, fatigue, and back pain. Serious AEs were 
reported in 126 (39.6%) DD patients and 133 (39.8%) ZD patients. 
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Overall survival was similar between groups over the entire study: 
median 34.4 months (95% CI 31.5 to 39.3) for DD patients, 34.2 
months (95% CI 31.0 to 37.6) for ZD patients.
Conclusion: A two-year open-label extension treatment phase 
confirmed the long-term safety profile of denosumab in these breast 
cancer patients with bone metastases who continued receiving 
denosumab for up to 5 years or who switched from ZA to denosumab. 
No new safety signals were observed with up to 5 years of monthly 
denosumab therapy.
P3-16-08
A Phase 2, Randomized Open-Label Study of Iniparib, 
Administered Either Weekly or Twice-Weekly in Combination 
with Gemcitabine Plus Carboplatin in Patients with mTNBC.
Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov 
J, Jäger A, Gianni L, Lindeman G, Pham N, Su Y, Gao G, Mery-
Mignard D, Paridaens R, Verweij J. Institut Curie, Paris, Cedex 
05, France; Université de Bordeaux, Bordeaux, INSERM, France; 
Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; 
Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de 
Bruxelles, Brussells, Belgium; Centre Georges François Leclerc, 
Dijon, France; University Hospital Jean Minjoz, Besançon, France; 
University Paris VI, Paris, France; Erasmus University Medical 
Center, Daniel den Hoed Cancer Center, Rotterdam, Netherlands; 
hSR - San Raffaele, Milan, Italy; The Royal Melbourne Hospital and 
The Walter and Eliza Hall Institute of Medical Research, Melbourne, 
Victoria, Australia; Sanofi, Vitry, Paris, France; Sanofi, Great Valley, 
PA; Sanofi, Cambridge, MA; University Hospital Gasthuisberg, 
Catholic University of Leuven, Leuven, Belgium; Erasmus University 
Medical Center, Rotterdam, Netherlands
Background: Iniparib (BSI-201) is an investigational anticancer 
agent whose precise mechanism of action is under active investigation. 
In breast cancer cell lines and xenograft models of triple-negative 
breast cancer (TNBC), iniparib exhibits anti-proliferative activity 
and potentiates the cell cycle effects of some DNA damaging agents. 
In a randomized, open-label phase 2 study in pts with metastatic 
TNBC (mTNBC), iniparib combined with gemcitabine (G) and 
carboplatin (C) (GC) improved efficacy outcomes compared with 
GC alone. A confirmatory phase 3 study with GCI failed to meet 
pre-specified criteria for PFS and OS; however, an exploratory 
subset analysis demonstrated a potential benefit amongst 2nd/3rd line 
pts (O’Shaughnessy et al. ASCO 2011). Here we report results of 
a randomized phase 2 study (NCT01045304) in pts with mTNBC, 
which assesses efficacy and pharmacokinetics (PK) of iniparib 
administered either biw or qw in combination with GC.
Patients and methods: Eligible pts (N=163; median age 49 yrs) had 
documented and measurable TNBC, ECOG PS 0-1, normal organ/
marrow function, and had received ≤2 prior chemotherapy (CT) 
regimens for metastatic disease. Pts were randomized (1:1) to receive 
G (1,000 mg/m2, IV, d 1, 8) plus C (AUC 2, IV, d 1, 8) and iniparib 
either biw (5.6 mg/kg, IV d 1,4,8,11) or qw (11.2 mg/kg, IV d 1,8) 
on a 21 d cycle. Pts were stratified according to prior CT for mTNBC 
(0 vs. 1-2). The primary efficacy endpoint was overall response rate 
(ORR; CR + PR); secondary endpoints included: clinical benefit rate 
(CBR; CR + PR + SD for 24 weeks), PFS, OS and PK.
Results: At the time of analysis, 23% of patients were still on 
treatment. The median number of cycles administered per patient 
was 6 in both arms; exposure to iniparib was identical. Safety data 
are not fully validated. All pts experienced at least 1 treatment 
emergent adverse event (TEAE). Grade (Gr) ≥3 TEAEs occurred in 
94% and 85% of pts in the biw and qw arms, respectively. TEAEs 
Gr ≥3 occurring in ≥5% of pts regardless of relationship to study 
drug (biw vs qw) are as follows: blood and lymphatic 71% vs 67%; 
hepatobiliary 7.5% vs 9.8%; asthenia/fatigue 7.5% vs 11%; GI 
8.8% vs 8.5%; infections 7.5% vs 3.7%; respiratory, thoracic and 
mediastinal 5% vs 8.5%, metabolism and nutrition 4% vs 6%. For 
response data see table.
Response Data
Efficacy Endpoint Iniparib biw Iniparib qw
ITT population + GC (N=81), n (%) + GC (N=82), n (%)
ORR 20 (24.7) 23 (28.0)
CR 1 (1.2) 1 (1.2)
PR 19 (23.5) 22 (26.8)
SD 40 (49.4) 43 (52.4)
CBR 22 (27.2) 28 (34.1)
0 prior chemotherapy
ORR 10 (30.3) 13 (37.1)
CBR 11 (33.3) 17 (48.6)
1-2 prior chemotherapies
ORR 10 (20.8) 10 (21.3)
CBR 11 (22.9) 11 (23.4)
No major difference was observed in drug exposure (based on AUC 
within one cycle) between the two dosing regimens.
Conclusion: Dosing of GCI on a qw schedule produced a similar ORR 
to that obtained with the biw schedule. A comparable safety profile in 
both arms, and consistency with results of previous studies, suggests 
that the weekly combination of GCI may be an appropriate schedule 
for further studies evaluating this combination. OS and PFS data are 
not yet mature; updated efficacy and safety data will be presented.
P3-16-09
Endoxifen, a Newly Developed Breast Cancer Drug, Has Anabolic 
Actions on the Mouse Skeleton.
Hawse JR, Cicek M, Subramaniam M, Pitel KS, Peters KD, Grygo 
SB, Wu X, Evans GL, Iwaniec UT, Turner RT, Ingle JN, Goetz MP, 
Spelsberg TC. Mayo Clinic; Oregon State University
Background: Commonly used endocrine therapies for breast cancer, 
such as aromatase inhibitors in postmenopausal women and tamoxifen 
in premenopausal women, have deleterious effects on bone mineral 
density. Therefore, the identification of novel cancer therapies which 
either maintain or improve bone mass are of clinical need. We have 
recently demonstrated that endoxifen is the most active tamoxifen 
metabolite with regard to inhibiting the growth of ERa+ breast cancer 
cells and these studies have led to the development of endoxifen as 
a novel anti-breast cancer drug for which first-in-human studies are 
now underway. At present, there are no data regarding endoxifen’s 
effects on bone.
Methods: The effects of endoxifen on osteoblast (OB) and 
osteoclast (OC) maturation and gene expression were monitored 
by cell differentiation assays and real-time PCR. Dual-energy 
X-ray absorptiometry (DXA), peripheral Quantitative Computed 
Tomography (pQCT) and micro-Computed Tomography (mCT) were 
used to determine changes in bone density, mass and architecture 
following 45 days of oral endoxifen administration (50mg/kg/day) to 
3-month-old ovariectomized (OVX) C57BL/6 mice relative to vehicle 
control treated animals. Alterations in the numbers and activity of OBs 
and OCs were determined by histomorphometry and serum levels of 
P1NP and CTX-1 respectively.
Results: Endoxifen treatment of mouse derived bone marrow stromal 
cells and human OBs led to significant increases in the expression 
of critical bone marker genes such as Runx2, osterix, osteocalcin, 
osteoprotegerin and alkaline phosphatase in a dose dependent manner. 
Daily administration of endoxifen to OVX mice led to significant 
increases in total body bone mineral density (BMD) (6%) and content 
(BMC) (9%), which was accompanied by a 50% decrease in fat tissue 
mass as determined by DXA. pQCT analysis of the tibial metaphysis 
revealed dramatic increases in BMD (35%) and BMC (20%), as well 
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as trabecular density (52%), cortical content (62%), cortical area 
(60%) and cortical thickness (78%). mCT analysis of the femoral 
metaphysis revealed increases in bone volume/total volume (200%), 
trabecular number (38%) and trabecular thickness (18%), as well as 
decreased trabecular spacing (29%). Interestingly, there was nearly a 
50% increase in the numbers of OCs derived from endoxifen treated 
mice which was associated with elevated expression of OC marker 
genes such as NFATc1, RANK, c-fms and cathepsin-K compared to 
control treated animals. Approximately 4 times as many OBs and 
OCs were observed on the bone surfaces of endoxifen treated mice 
which correlated with nearly 2-fold increases in serum levels of the 
bone formation (P1NP) and resorption (CTX-1) markers.
Conclusions: These data are the first to demonstrate that endoxifen 
has anabolic effects on the mouse skeleton which are similar to that of 
estrogen. Additionally, these data reveal that endoxifen’s mechanism 
of action in bone is different than that reported for tamoxifen and other 
selective estrogen receptor modulators in mice as it increases, rather 
than decreases, bone formation and remodeling. Therefore, the use 
of endoxifen for the treatment of endocrine responsive breast cancer 
may avoid the detrimental skeletal effects of many conventional 
endocrine therapies.
P3-16-10
The Efficacy of Zoledronic Acid in Breast Cancer Adjuvant 
Therapy: A Meta-Analysis of Randomized Controlled Trials.
Lu J, Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z. Fudan 
University Shanghai Cancer Center, Shanghai, China; Shanghai 
Medical College, Fudan University, Shanghai, China
Background: The effect of zoledronic acid in breast cancer adjuvant 
therapy concerning improvement of patient survival has yet to 
be confirmed. We performed a meta-analysis of published and 
unpublished randomized controlled trials with the aim of accurate 
evaluation between clinical outcome and the association of the 
addition of zoledronic acid to adjuvant therapy.
Methods: We searched Pubmed (from 1966 to present) and online 
abstracts from the proceeding Annual Meetings of the American 
Society of Clinical Oncology (ASCO) (years 1992-2010) and online 
abstracts from San Antonio Breast Cancer Symposium (years 2004-
2010). A total of five eligible studies including 3676 subjects and 
3678 controls met our search criteria and were evaluated. Random 
and fixed-effects meta-analytical models were used where indicated, 
and between-study heterogeneity was assessed. The primary study 
endpoints were the DFS. Secondary endpoints were OS, distant 
or loco-regional recurrence free survival and bone metastasis free 
survival.
Results: Compared with the control arm, adjuvant breast cancer 
treatment with zoledronic acid did not significantly improve overall 
survival (OS), disease free survival (DFS), bone metastasis free 
survival, distant and locoregional recurrence free survival. However, 
in the postmenopausal subgroup, the addition of zoledronic acid to 
standard therapy could significantly improve DFS (RR=0.763, 95%CI 
0.658-0.884, p<0.001) and reduce the risk of distant (RR=0.744, 95% 
CI 0.611-0.906, p=0.003) and locoregional recurrence (RR=0.508, 
95% CI 0.340-0.760, p=0.001).
Discussion: Adjuvant zoledronic acid may potentially improve the 
prognosis of postmenopausal patients. Additional studies are needed 
to evaluate the value of adjuvant treatment of zoledronic acid in 
premenopausal couterparts, differing disease stages, and various 
pathological types of breast cancer.
P3-16-11
Prospective Evaluation of Radiation Pneumonitis in Neoadjuvant 
Concurrent Docetaxel and Radiation Therapy for Locally 
Advanced Breast Cancer.
Louie AV, Rodrigues G, Sathya A, Perera F, Ong M, D’Souza D, 
Chambers AF, Brackstone M. London Regional Cancer Program, 
London, ON, Canada
Background: Taxanes are known to have radiosensitizing properties, 
by causing cell arrest in the G2 and M phases of the cell cycle. As 
taxanes have become integrated into routine oncologic use, concerns 
have arisen over the association between taxanes and radiation 
toxicities such as pneumonitis. Pneumonitis has been reported to 
occur both with taxane administration alone or, more commonly, 
with concurrent or sequential radiation. The purpose of this study 
is to evaluate radiation pneumonitis from our institutional phase I/
II protocol of neoadjuvant FEC chemotherapy followed by weekly 
docetaxel concurrent with radiotherapy in the treatment of locally 
advanced breast cancer (LABC).
Materials and Methods: Since August 2009, thirty-two LABC 
patients with stage IIB, IIIA, IIIB, or IIIC invasive breast cancer were 
enrolled to receive protocol based treatment consisting of 3 cycles 
of intravenous (IV) fluorouracil 500 mg/m2, epirubicin 100 mg/m2, 
and cyclophosphamide 500 mg/m2 (FEC) every 3 weeks. Following 
this, weekly IV docetaxel 35 mg/m2 was administered concurrently 
with locoregional external beam radiotherapy to a total dose of 45 
Gy in 25 fractions followed by a boost of 5.4-9 Gy in 3-5 fractions to 
gross residual disease. Adverse events were scored using the National 
Cancer Institute Common Terminology Criteria for Adverse Events 
v3.0. A linear regression model was built used to evaluate potential 
parameters predictive of clinical pneumonitis (grade ≥2).
Results: Of the 32 patients enrolled on this prospective protocol, 
7 were excluded from analysis (n = 6, follow-up < 4 weeks; n = 
1, converted to palliative radiotherapy due to metastatic disease). 
Twenty-five patients remained for analysis. The median age was 48 
years (range 26 to 64). Thirteen patients were treated with intensity 
modulated radiation therapy while 12 were treated using 3D 
conformal radiotherapy. In total 13 patients (52%) experienced clinical 
pneumonitis with 6 of these patients (24%) transiently requiring 
supportive oxygen (grade 3). On linear regression modeling, the use 
of IMRT (p = 0.08), grade 3 skin toxicity (p = 0.08), and baseline 
left ventricular ejection fraction (LVEF, p = 0.05) were potentially 
predictive of symptomatic pneumonitis. Conversely, various heart 
and lung dose-volume histogram parameters, trastuzumab use, bolus 
use, disease laterality, total docetaxel dose, were not predictive of 
symptomatic pneumonitis (p > 0.10). In multivariable modeling, 
the use of IMRT (p = 0.05) and baseline LVEF (0 = 0.03) remained 
predictive of symptomatic pneumonitis.
Conclusion: The use of concurrent weekly docetaxel-based 
chemoradiotherapy in LABC is associated with significant 
symptomatic pneumonitis and may be related to low baseline LVEF 
and the use of IMRT. However, conventional parameters of low 
dose volumes of lung and heart irradiated were not predictive of 
pneumonitis. The relationship of the use of IMRT and taxanes in the 
development of pnemonitis is likely complex and warrants further 
investigation.
P3-16-12
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P3-16-13
Cardiac Safety of Non-Pegylated Liposomal Doxorubicin and 
Docetaxel as 1st Line Treatment in Metastatic HER2 Negative 
Breast Cancer (Myotax Study).
van Warmerdam L, Schiphorst P, Nieboer P, Dercksen M, de Jongh 
F, Schmidt R. Catharina-Ziekenhuis, Eindhoven, Netherlands; 
Streekziekenhuis Koningin Beatrix, Winterswijk, Netherlands; 
Wilhelmina Ziekenhuis, Assen, Netherlands; Maxima MC, Eindhoven, 
Netherlands; Ikazia Ziekenhuis, Rotterdam, Netherlands; Foundation 
BO3, Steenderen, Netherlands
Background : Doxorubicin (DOX) is an effective, but cardiotoxic 
agent in metastatic breast cancer (BC). Incidence of heart failure 
(HF) is 2-4% and increases considerably with cumulative doses over 
450-550 mg/m2. In Myocet® DOX is encapsulated in liposomes. It is 
delivered predominantly to areas with increased capillary permeability 
such as tumors and reduces cardiac exposure. We conducted an open 
non-comparative study to assess cardiac safety of Myocet ® combined 
with docetaxel.
Materials and methods: Females with locally advanced or metastatic 
HER2 negative BC. 6 cycles of Myocet® 60 mg/m2 and docetaxel 
75 mg/m2 q3w as 1st line therapy. Left ventricular ejection fraction 
(LVEF) and disease status were assessed after cycle 2,4 and 6. Primary 
endpoint: signs and symptoms of HF (NYHA III-IV) or LVEF <50% 
and decrease ≥5% (with symptoms) or ≥10% (without symptoms).
Results: 68 patients (pats) were included. Mean (sd;range) age 56,3 y 
(10,2;32-79), mean disease duration 5,5 y (5,1 y;1 mo-19 y), 31 pats 
had anthracyclines (AN) in the past. 49 pats completed all 6 cycles. 
Mean LVEF (%) over time are presented in table 1.
Table 1 - Mean LVEF over time
 All pats (sd;N=) AN pretreated (sd;N=) Not AN pretreated (sd;N=)
Baseline 63,4 (7,2;56) 63,9 (6,8;25) 63,0 (7,5;31)
After cycle 2 60,6 (7.3;56) 59,2 (7,1;25) 61,6 (7,3;31)
After cycle 4 59,8 (7,4;47) 58,3 (8,6;21) 61,0 (6,1;26)
After cycle 6 58,8 (9,2;45) 56,8 (9,2;19) 60,3 (7,0;26)
4 pats (3 AN pretreated) met the LVEF criteria for cardiotoxicity (no 
signs/symptoms of HF) after the 6th cycle. In 3 pats (all AN pretreated) 
a significant drop in LVEF was given as (one of the) reason(s) for 
premature discontinuation, but LVEF criteria for cardiotoxicity were 
not met. 73 grade ≥3 toxicities occurred in 32 pats; most frequent: 
neutropenia (±fever) 19 pats. Premature discontinuations (no. of 
pats): progressive disease 9, cardiotoxicity 3, other toxicity 4, death 
2, other reason 1. In 10 pats the dose of Myocet was reduced. The 
best response was scored for 50 pats with at least 1 measurable lesion: 
CR 4, PR 28, SD 14, PD 4.
Mean LVEF in the entire group decreased during the study from 
63 to 59 (9,2) %. The decrease in the AN pretreated group was 7% 
and in the not pretreated pats 3%. 4 pats met the LVEF criteria for 
cardiotoxicity and 3 others were withdrawn for cardiotoxicity without 
meeting the criteria. 6 of these pats were AN pretreated. None of them 
had signs/symptoms of HF. PR or better was observed in 64% of pats.
Conclusion: Liposomal DOX might provide more cardiac safety 
compared to conventional AN, but pats pretreated with conventional 
AN seem to be more prone to LVEF decrease. No signs or symptoms 
of HF have been observed. The combination of Myocet® and 
docetaxel is efficacious and sufficiently well tolerated and is currently 
investigated in combination with trastuzumab in HER2 positive pats.
P3-16-14
Effect of TG02, a Multikinase Inhibitor, on Triple Negative Breast 
Cancer Cells.
Pandiella A, Ortiz-Ruiz MJ, Burrows F, Ocaña A, Esparis-Ogando A. 
Cancer Research Center, Salamanca, Spain; Hospital Universitario, 
Albacete, Spain; Tragara Pharmaceuticals, San Diego, CA
Background
Breast cancer is the most common neoplasia in women. Formerly, 
we reported that the MAPK Erk5 participates in the proliferation 
of breast cancer cells in vitro, it is overexpressed in the tumours 
of a number of breast cancer patients, and its overexpression is an 
independent prognostic marker for disease-free survival. In addition, 
inhibition of Erk5 sensitized cells to treatments commonly used 
in the breast cancer clinic. Therefore, Erk5 may represent a novel 
therapeutic target in breast cancer. Here we describe the preclinical 
activity of TG02, a novel multi-kinase inhibitor being developed by 
Tragara Pharmaceuticals, in triple negative breast cancer (TNBC). 
TG02 presents a unique kinase inhibitory spectrum, combining Erk5 
inhibitory properties with inhibition of CDKs and certain receptor 
tyrosine kinases.
Material and methods
The action of TG02 on cell proliferation of TNBC cell lines was 
carried out by the MTT-based assay, and its action on cell death 
and cell cycle progression was analyzed by flow cytometry. The 
expression of different kinases and other proteins implicated in 
cell cycle, apoptosis and DNA damage responses were analyzed by 
western blotting. Studies on the action of TG02 in combination with 
chemotherapy were performed in MDAMB231 and HBL100 cells, 
and the potency of the combination was quantitated with the Calcusyn 
software. In vivo studies on the action of TG02 were performed in 
mice xenografted with the TNBC cell line MDA-MB231.
Results
The TNBC cell lines analyzed showed high levels of Erk5 expression, 
and Erk5 was active under resting conditions in some of them. 
TG02 inhibited the kinase activity of Erk5 even though TG02 did 
not affect the Erk5 upstream activating kinase Mek5. TG02 showed 
an inhibitory effect of phosphorylation of residue Thr732 in the 
C-terminal tail of Erk5 without affecting the phosphorylation of the 
activation loop TEY motif. Cell proliferation studies indicated that 
one group of TNBC cells were very sensitive to the action of this 
compound (IC50 ≤100 nM) and another group were more resistant. 
TG02 induced cell cycle arrest at the early G1 and G2 phases of cell 
cycle, and triggered cell death in MDAMB231 (representative cell line 
of the most resistant group), and induced a strong effect of apoptosis 
and a DNA damage response in HCC1187(representative of the 
most sensitive group). In vitro studies indicated that TG02 sensitizes 
TNBC cells to chemotherapy, showing additive or synergistic effects 
depending of the doses. In vivo studies indicated that TG02 exerted 
a strong antitumoral action in mice bearing MDA-MB231-derived 
tumours.
Conclusions
TNBC cells are very sensitive to TG02, both in vitro and in vivo. The 
inhibits the kinase activity of Erk5, which, together with the targeting 
of other kinases, may contribute to the induction of cell cycle arrest 
or apoptosis in response to the compound in TNBC cells. TG02 
synergized with chemotherapy, supporting the possibility of using this 
drug in combination therapy.Taken together, these preclinical studies 
establish the bases for the clinical development of this compound for 
the treatment of TNBC.
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P3-16-15
Phase I Study with Biomarker Evaluation of Neoadjuvant 
Sunitinib in Combination with Exemestane in Post-Menopausal 
Women with Hormone-Sensitive, Her-2 Negative Primary Breast 
Cancer.
Morales S, Gil M, Llombart A, Garcia M, Urruticoechea A, Pernas 
S. University Hospital Arnau de Vilanova, Lleida, Catalu[ntILde]
a, Spain; University Hospital ICO-Duran i Reynals, Barcelona, 
Catalu[ntILde]a, Spain
Background: In preclinical models, oestrogen causes a rapid 
induction of VEGF in mammary tumours leading to tumour 
angiogenesis, tumor growth and cell migration whereas aromatase 
inhibitors (AI) have the opposite effect. Exemestane (E) is an AI, 
effective in metastatic hormone-dependent breast cancer, as well 
as in the adjuvant and neoadjuvant settings. Sunitinib (S) is an oral 
multitargeted tyrosine kinase inhibitor with antiangiogenic activities 
via inhibition of VEGFR, PDGFR, KIT, RET, CSF-1R and FLT-3, and 
direct antitumor activity shown in heavily pretreated subjects with 
advanced breast cancer. The use of antiangiogenic agents at initial 
stages of the disease, when fewer proangiogenic factors are present, 
may result in significantly greater efficacy than using these agents 
at a later stage. Safety profiles of both agents indicate only modest 
toxicity and do not overlap. We hypothesize that since antiangiogenic 
and hormonal agents use different mechanisms of action, combination 
will have additive activity. Regarding (S), continuous dosing (CD) 
at low doses might result in improved efficacy while maintaining 
good tolerability. Methods: This is a phase I study to evaluate the 
safety of (S) in combination with (E) administered for 24 weeks 
(1cycle=4weeks) as neoadjuvant therapy for post-menopausal women 
with newly diagnosed hormone-sensitive, Her-2 negative primary 
breast cancer. We report the results of the first dose escalation part 
of the study intended to determine a safe dose level of (S) that can be 
combined with (E) at conventional fixed dose of 25mg/d. Preliminary 
efficacy data in terms of objective clinical response by WHO criteria 
will also be reported. Results: 18 postmenopausal women with 
ER-positive invasive breast cancer, adequate organ function and 
ECOG 0-1 were enrolled in the study (median age 74, range 57-84) 
to be treated at two dose levels: 25 mg of (E) with either 25mg or 
37.5mg of (S) CD .Two DLTs were identified: grade 3 mucositis at 
level 25mg of (S) and grade 3 asthenia at level 37.5mg of (S). Main 
toxicities were asthenia, leucopenia, mucositis, diarrhea and HBP. 
78% of patients had grade 2 toxicities; 22% had grade 3. There were 
no serious adverse events reported. Median time on treatment with the 
combination was 23 weeks (range 2-24). 16% of patients needed one 
dose reduction of (S), 16% needed two or more and 28% suspended 
(S) administration due to toxicity. 50% of patients completed 24 weeks 
of treatment. None of the patients at 37.5mg (S) level could tolerate 
full doses for the entire treatment period, therefore in our study the 
recommended dosage of (S) that can be safely combined with (E) is 
25mg. Concerning efficacy, 11 out of 18 patients had partial response 
(61%), 6 out of 18 had SD (33%) and only one patient had PD (5%) 
as best response. Conclusion: Safety profile of the combination seems 
to be manageable in most patients. Toxicities were observed mainly 
within the two first cycles. Response rates were similar than those 
previously observed with (E) as monotherapy in the neoadjuvant 
setting. Biomarkers information will be provided.
This study was supported by an Independent Investigator Research 
grant from Pfizer, Inc.
P3-16-16
Overcoming EGFR Resistance Using Dasatinib in Combination 
with Cetuximab and Cisplatin in Triple Negative Breast Cancer 
Cell Lines.
Kim EMH, Gartner E, Choi L, Boerner J. Wayne State University, 
Karmanos Cancer Center, Detroit, MI
Background: Patients presenting with triple negative breast cancers 
(TNBC’s) have a poorer prognosis compared to those with other 
subtypes of breast cancer, and effective therapeutic targets have yet 
to be identified. The majority of TNBC’s overexpress EGFR, however 
studies have demonstrated that EGFR inhibition as a monotherapy is 
ineffective. Interestingly, adding the EGFR inhibitor, cetuximab to 
cisplatin chemotherapy doubled both the response rate and time to 
progression compared with patients only on cisplatin. c-Src tyrosine 
kinase plays a critical role in signal transduction downstream of 
growth factor receptors, and has been found to contribute to the 
resistance of TNBC cell lines through the phosphorylation of EGFR. 
We hypothesize that dasatinib, a c-Src inhibitor, may help overcome 
EGFR resistance and in combination therapy enhance the cytotoxic 
activity.
Material and Methods: A panel of breast cancer cell lines, including 
7 triple negative cell lines, were tested using increasing doses of 
dasatinib (1 nM to 10 µM), cetuximab (1 µg/ml to 100 µg/ml), 
and cisplatin (10 nM to 10 µM) alone and in combination. Growth 
inhibition was determined after 3 days of treatment using the MTT 
colorimetric assay, and apoptosis was assessed through Caspase-3 
activation and TUNEL assays.
Results: All cell lines were generally resistant to cetuximab, with 100 
µg/ml required to decrease cell viability. Two TNBC lines, SUM149 
and SUM229, showed an additional decrease in cell viability with 
dasatinib added to cetuximab, while SUM102 and BT20 cells showed 
an additional decrease in viability using the dasatinib and cisplatin 
combination, compared to single agents. In 4 out of 7 TNBC lines, 
the combination of dasatinib, cisplatin, and cetuximab showed a 
significant decrease in cell viability compared to the combination 
without dasatinib (p-value < 0.02). The decrease in proliferation using 
the combination of dasatinib, cisplatin, and cetuximab was due to an 
increase in apoptosis. In contrast, this combination did not increase 
the loss of cell viability or apoptosis in ER/PR+ and HER2+ breast 
cancer cell lines.
Discussion: Targeting c-Src family kinases with dasatinib may help 
overcome the resistance to EGFR inhibition in triple-negative breast 
cancer. This may have significant clinical implications in treating 
TNBC patients, and hence further investigation into the mechanism 
of this effect is warranted.
P3-16-17
The Identification of Novel Microtubule Stabilizing Taccalonolides.
Risinger AL, Li J, Peng J, Chen Z, Mooberry SL. University of Texas 
Health Science Center, San Antonio, TX; Shanghai Institute of Materia 
Medica, Shanghai, China
Microtubule stabilizing agents, including the taxanes and epothilones, 
are some of the most important drugs used in the treatment of cancer. 
All of the microtubule stabilizers used clinically bind within the 
taxane site on microtubules and work through a similar mechanism 
of action. We have identified a new class of microtubule stabilizers, 
the taccalonolides, from plants of the genus Tacca. The most abundant 
taccalonolides, A and E, are classified as microtubule stabilizers 
due to their ability to disrupt both interphase and mitotic cellular 
microtubules, leading to mitotic arrest and apoptosis. However, 
they are unique from all other microtubule stabilizers in that they do 
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not bind directly to microtubules or stimulate the polymerization of 
tubulin in biochemical preparations. The taccalonolide structure is 
characterized by a highly acetylated pentacyclic steroidal skeleton, 
which is also structurally distinct from all other microtubule targeted 
agents. The unique structure and mechanism of action of the 
taccalonolides, together with their ability to circumvent clinically 
relevant forms of taxane resistance, prompted our efforts to explore 
the structure-activity relationship of this class of molecules. We 
have isolated several novel taccalonolides, designated Z, AA, AB, 
AC, AF and AG, as well as multiple known taccalonolides. Each 
of these taccalonolides exhibited cellular microtubule stabilizing 
activity and antiproliferative actions against breast cancer cells. 
However, profound differences in potencies were noted with IC50 
values ranging from 32 nM to 13 mM. These studies demonstrate that 
microtubule stabilizing activity is a shared trait among this class of 
molecules and that significant structure-activity relationships exist. 
Additionally, in vivo antitumor evaluations of taccalonolides A, E 
and N demonstrate that each of these molecules has activity in vivo 
and that taccalonolide A is the most effective against a syngeneic 
mammary model of breast cancer.
P3-16-18
Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients 
with Previously Treated Metastatic Breast Cancer.
O’Shaughnessy JA, Osborne CRC, Steinberg MA, Holmes FA, Kim 
HS, Kocs DM, Richards PD, Vukelja SJ, Berkowitz N, Buchbinder 
A. Texas Oncology - Baylor Charles A. Sammons Cancer Center, 
Dallas, TX; Virginia Oncology Associates, Norfolk, VA; Texas 
Oncology - Houston Memorial City, Houston, TX; Rocky Mountain 
Cancer Centers, Denver, CO; Texas Oncology - Austin Midtown, 
Austin, TX; Oncology & Hematology Associates of Southwest 
Virginia, Inc., D.B.A. Blue Ridge Cancer Care, Salem, VA; Tyler 
Cancer Center, Tyler, TX; US Oncology; Enzon Pharmaceuticals, 
Inc., Piscataway, NJ
Background: EZN-2208 is a water-soluble PEGylated conjugate of 
SN38 that results in parenteral delivery, increased solubility, higher 
exposure, and longer apparent half-life of SN38, as well as more 
profound deoxyribonucleic acid (DNA) damage and inhibition of 
angiogenesis. EZN-2208 results in prolonged exposure of tumors to 
SN38 via preferential accumulation of EZN-2208 in the tumor and 
prolonged release of SN38 in the blood.
Methods: This trial evaluated EZN-2208 delivered as a 1-h IV 
infusion weekly for 3 wks in 4-wk cycles. The primary objective was 
to determine the overall response rate (RR) in female patients with 
metastatic breast cancer (MBC) who had received prior adjuvant or 
metastatic therapy with either 1) anthracycline and taxane (AT) or 2) 
anthracycline, taxane, and capecitabine (Xeloda®) (ATX). Secondary 
objectives included evaluation of RR based on tumor receptor status, 
duration of response, progression-free survival (PFS), overall survival 
(OS), and safety and toxicity. Response was evaluated using RECIST 
(v1.1).
Results: 148 patients received EZN-2208 in the AT (n=65; median 
age = 56 y [31-84 y]) or ATX (n=83; median age = 55 y [36-83 y]) 
cohorts. All 65 patients in the AT cohort had received 0-2 lines of 
prior cytotoxic therapy for MBC; for the ATX cohort, 31 patients 
(37%) had received 0-2 prior lines of cytotoxic therapy for MBC, 50 
patients (60%) had received 3-4 prior lines, and 2 patients (2%) had 
received 5 prior lines. Preliminary results follow; final data will be 
presented at the meeting. Median (range) cycles of EZN-2208 was 
2.3 (0.3-14) for AT and 2 (0.3-15) for ATX. Best overall response is 
shown in the table. RR (PR+uPR) was 22% for AT and 10% for ATX. 
Median (95% CI) time to progression was 3.8 mo (3.6-7.4) for AT 
and 3.3 mo (1.8-3.7) for ATX. Median (95% CI) duration of response 
was 4.0 mo (3.7-5.6) for AT and 5.2 mo (1.9-..) for ATX. 6-mo PFS 
(95% CI) was 34% (19%-50%) for AT and 19% (9%-29%) for ATX. 
Median PFS (95% CI) was 3.8 mo (2.7-5.6) for AT and 2.9 mo (1.8-
3.7) for ATX. Median OS (95% CI) was 9.1 mo (6.1-12.7) for AT and 
7.9 mo (6.4-12.9) for ATX. Grade 3 or 4 drug-related adverse events 
(>10% of patients in either arm) included neutropenia (43%, 33%), 
diarrhea (11%, 8%), and leukopenia (11%, 6%).
Best Overall Response, N (%)
  AT (N=65) AT (N=83)
Response not yet evaluated  11 5
Not evaluable  8 9
Evaluable  46 69
    
Receptor status    
Patients with any receptor status PR 8 (17) 6 (9)
 uPR* 2 (4) 1 (1)
 SD 26 (57) 36 (52)
 PD 10 (22) 26 (38)
 CBR** 12 (26) 12 (17)
    
Patients with triple-negative breast cancer (TNBC) PR 4 (20) 3 (23)
 SD 11 (55) 5 (38)
 PD 5 (25) 5 (38)
 CBR** 6 (30) 3 (23)
*uPR = unconfirmed partial response; **clinical benefit rate (CBR) = CR+PR or SD >6 months.
Conclusions: EZN-2208 is active in patients with previously treated 
MBC. The activity is similar regardless of ER status and is promising 
in the TNBC population. The safety profile of EZN-2208 is acceptable 
with good tolerability in most patients. Further evaluation of EZN-
2208 in this population is warranted.
P3-17-01
ApoE and Its Receptors (LRP8, VLDLR) Function as Growth 
Signals for Triple-Negative Breast Cancer and Represent a Novel 
Therapeutic Target.
Shiang C, Qi Y, Wang B, Broom B, Pusztai L. UT M.D. Anderson 
Cancer Center
Triple-negative breast cancers (TNBC) lack the expression of 
estrogen, progesterone, and the human epidermal growth factor 
2 receptors and have limited treatment options. We hypothesized 
that genes that are frequently amplified or overexpressed in these 
cancers are functionally important for the growth and survival of 
triple-negative breast cancer.
Materials/Methods: We identified genes overexpressed in TNBC in 
3 different human breast cancer gene expression data sets (n=294, 
n=286, n=198). We assessed the functional importance of the 
consistently overexpressed genes using siRNA screen on 18 breast 
cancer cell lines (10 ER-, 8 ER+) in vitro. We targeted each gene with 
4 different siRNA constructs separately and each experiment was 
performed in triplicate. The genes with the greatest TNBC-specific 
inhibitory effect after siRNA down regulation were selected for further 
mechanistic and signal transduction studies.
Results: 684 genes showed consistent and highly significant 
overexpression in TNBC compared to receptor-positive cancers in 
all 3 data sets. siRNA suppression of 161 of these genes inhibited cell 
growth significantly more in the ER-negative compared to ER-positive 
cells by at least 1 of the 4 siRNAs, 27 genes showed similar effect 
with 2 or more siRNAs and for 2 genes 3 of the 4 siRNAs showed 
preferential growth inhibition in ER-negative cells. These two genes 
were VLDLR (very low-density lipoprotein receptor) and LRP8 
(low density lipoprotein receptor-related protein 8). We validated the 
siRNA screen results and confirmed down regulation of the mRNA 
and protein levels for VLDLR and LRP8 in 4 different ER-negative 
cell lines and showed that siRNA inhibition can be rescued by co-
transfection of the receptor genes. Reanalysis of gene expression 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011415s
December 6-10, 2011 Abstracts: Poster Session 3
data also indicated expression of the LRP8 and VLDLR ligands, 
Reelin or ApoE, in both breast cancer tissues and in cell lines. We 
next demonstrated that exposure to Reelin and ApoE stimulates the 
growth of ER-negative cells in vitro. The stimulatory effect of ApoE 
was isoform dependent ApoE2 (Cys112/Cys158;) has the lowest receptor 
binding affinity and showed no growth stimulation, ApoE3 (Cys112/
Arg158) had modest 50-60% growth stimulation and ApoE4 (Arg112/
Arg158) had the greatest stimulatory effect (300-400%). Suppression 
of the expression of either LRP8 or VLDLR or exposure to RAP 
(an inhibitor of ligand binding to LRP8 and VLDLR) abolished 
this ligand-induced proliferation. ApoE4 stimulation results in the 
transcriptional upregulation of genes involved in proliferation, 
metabolism, and inflammatory signaling pathways. ApoE4 
stimulation increases expression of proteins involved in MAPK/ERK 
pathway, DNA damage repair, and inflammation.
Conclusions: We show that the ApoE – LRP8/VLDLR ligand receptor 
system is overexpressed in human TNBC. We also demonstrated that 
this receptor system mediates a strong growth promoting and survival 
function in TNBC cells in vitro. Interestingly, allelic imbalance 
favoring ApoE4 expression (E3/E4 or E4/E4) has been linked to 
higher risk of developing early onset breast cancer, which is primarily 
TNBC. We propose that inhibitors of LRP8/VLDLR signaling may 
be clinically useful therapeutic or preventive agents for TNBC.
P3-17-02
Targeting the Autophagy Pathway for Drug Resistance of Breast 
Tumor-Initiating Cells.
Zhao H, Li F, Cui K, Sheng J, Landis M, Chang J, Wong S, Dave B. 
The Methodist Hospital Research Institute, Weill Medical College, 
Cornell University, Houston, TX; The Methodist Hospital, Weill 
Medical College, Cornell University, Houston, TX
Background: Our clinical data and experimental evidence reveal that 
the tumor-initiating cells (TICs) in the original tumor are intrinsically 
resistant to conventional chemotherapy and radiation therapy and 
greatly enriched in residual breast cancers after such treatments. 
We have published a gene expression signature of such breast TICs, 
and our pathway analysis on the gene signature suggests that the 
activation of autophagy pathway may be an intrinsic characteristic 
of the TICs. This motivates us to further investigate the role of the 
autophagy pathway in TICs self-maintenance and their resistance 
to hormonal and chemo therapies, as well as their response to TIC-
targeted therapies.
Methods: A collective 84 well-documented autophagy pathway 
genes were used to compare the activation of autophagy pathway 
in different microarray datasets, 1) flow-sorted CD44+/CD24-/low 
cancer cells vs. all other cells (representing 20 patients), and cancer-
derived MSs vs. corresponding primary bulk tumors (representing 
17 patients), 2) before vs. after letrozole and doxetaxel treatments 
(representing 30 patient pairs), 3) before vs. after letrozole treatment 
(representing 176 patient pairs), and 4) before vs. after lapatinib 
treatment (representing 115 patient pairs). We applied the Significance 
Analysis of Microarrays (SAM) algorithm to analyze the expression 
data of 211 normalized probes for the 84 genes. Low-density RTPCR 
array for the 84 genes was used to confirm the differential expressed 
genes on tumor tissues of 18 letrozol treated patient pairs. Two 
human-cancer-in-mouse triple-negative xenograft tumor lines were 
treated with Notch pathway inhibitor alone or in combining with 
docetaxel. The tumor growth, mammosphere formation efficiency, 
and the expression of autophagy marker proteins were evaluated.
Results: Overall, the enrichment analysis of the 84-gene set in all 
the above microarray datasets showed that the autophagy genes 
are significantly enriched in the differential expressed genes. In 
particular, 28 out of the 84 autophagy genes are significantly up-
regulated in the TICs populations while 5 other autophagy genes are 
down-regulated with the false discovery rate (FDR) less than 0.05. 
For the letrozole and doxetaxel treatment microarray analysis, 34 
out of the 84 autophagy genes are significantly up-regulated in the 
after-treatment group (p<0.01), and only 3 out of the 84 autophagy 
genes are down-regulated (FDR<0.05). Interestingly, significantly 
more autophagy genes (15 out of the 84) are down-regulated in the 
after-lapatinib treatment group (p<0.05), and less genes (13 out of 84) 
are up-regulated after lapatinib treatment, thus confirming previous 
observations that lapatinib may affect TICs. We confirmed these 
findings in two human cancer xenograft studies of Notch pathway 
inhibitor (GSI) to target TICs, which showed significantly reduced 
expressions of LC3 and p62, two autophagic markers. In both 
xenograft models, GSI reduced mammosphere formation efficiency 
compared to vehicle control (p<0.05).
Conclusion: Activation of the autophagy pathway in TICs is a 
promising target to combat the drug resistance of breast cancer to 
conventional systemic therapy.
P3-17-03
ADAM17: A Novel Therapeutic Target for Treatment of Triple 
Negative Breast Cancer.
McGowan PM, Mullooly M, Sukor S, Madden S, McDermott E, 
Pierce A, Crown J, O’Donovan N, Duffy MJ. St. Vincent’s University 
Hospital, Dublin, Ireland; University College Dublin Dublin, 
Dublin, Ireland; Dublin City University, Dublin, Ireland; Molecular 
Therapeutics Cancer Ireland, Dublin, Ireland
Background: Due to the absence of ER, PR and HER2, targeted 
therapy is currently unavailable for patients with triple negative 
breast cancer (TNBC). Although TNBC lack overexpression of 
HER2, HER1, or EGFR, signaling is active in at least a subset of 
these cancers. Activation of EGFR is initiated by ADAM17-mediated 
release of ligands such as EGF, TGFa and HB-EGF. The aim of this 
study was to test the hypothesis that inhibition of ADAM17 is a novel 
approach for the treatment of TNBC.
Methods: Gene expression data sets were analyzed for ADAM17 
expression (3,519 samples across 21 datasets incorporating 10 
different microarrays). We used the ADAM17 specific inhibitor, 
WAY-180022 (WAY: Pfizer), the EGFR inhibitor gefitinib and 
5-fluorouracil (5FU) (Sigma Aldrich) to determine their effects on 
the growth of 7 TNBC cell lines (MDA-MB-231, MDA-MB-468, 
SUM159PT, HCC1937, BT20, Hs578t, Hs578i) and 6 non-TNBC 
cell lines (MCF7, T47D, BT474, JIMT-1, SKBR3, MDA-MB-453). 
Growth inhibitory effects were determined by cell counts and by MTT 
cell viability assay (Roche), following 5 days post treatment. Levels 
of TGF alpha were measured by ELISA in conditioned media from 
cells treated with 1µM WAY for 24 hours. Levels of pEGFR were 
also measured by ELISA.
Results: We analyzed expression of ADAM17 across molecular 
subtypes for breast cancer. Levels of ADAM17 mRNA were 
significantly elevated in the basal like subtype (most of which were 
TNBC) compared to luminal A, luminal B or HER2 positive breast 
cancers. In vitro, treatment with WAY-180022 alone resulted in growth 
inhibitory effects ranging from 15 –49% in TNBC cells as determined 
by cell counts. By MTT viability assay, treatment with 1 µM WAY 
resulted in a significant reduction in cell proliferation compared 
to vehicle control in MDA-MB-231 (p = 0.007) cells. Addition of 
WAY to gefitinib resulted in a significant reduction in proliferation 
in MDA-MB-231 cells compared to either gefitinib or WAY alone 
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(p = 0.017 and p = 0.003, respectively). Similarly, addition of WAY 
to 5FU resulted in a significant inhibitory effect compared to 5FU 
alone in MDA-MB-468 (p = 0.007) cells.
Investigating the functional effects of ADAM17 inhibition on breast 
cancer cells, we found that levels of pEGFR were reduced by between 
26 – 57.6% in 5 of 6 lines examined. pEGFR levels were significantly 
reduced in MDA-MB-468 (p = 0.01) and MDA-MB-231 (p = 
0.01) cells. In addition, levels of TGFa were significantly reduced 
following treatment with 1 µM WAY (MDA-MB-468, p = 0.008; 
MDA-MB-231, p = 0.012; HCC1143, p = 0.033; Hs578i8, p = 0.036).
Conclusion: Based on our findings, inhibition of ADAM17 with WAY-
180022 is a potential treatment for patients with TNBC.
Acknowledgement: The authors wish to thank Science Foundation 
Ireland, Strategic Research Cluster award (08/SRC/B1410) to 
Molecular Therapeutics for Cancer Ireland and the Health Research 
Board Clinician Scientist Award (CSA/2007/11) for funding this work.
P3-17-04
CXCR1/2 Regulates Human Breast Cancer Stem Cell Activity Via 
EGFR/HER2-Dependent and -Independent Pathway.
Singh JK, Farnie G, Clarke RB, Bundred NJ. School of Cancer and 
Enabling Sciences, University of Manchester, Paterson Institute 
for Cancer Research, Manchester, United Kingdom; Univeristity 
Hospital of South Manchester, Wythenshawe Hospital, Manchester, 
United Kingdom
Background: Increasing evidence suggests that breast cancers are 
sustained by breast cancer stem cells (CSCs). Interleukin-8 (IL-8) 
via its cognate receptors, CXCR1 and CXCR2, and HER2 regulate 
CSC activity. Cytokine receptors can trans-activate members of 
the epidermal growth factor receptor (EGFR) family in normal and 
malignant tissue. The aims of this study were to determine (1) the 
effect of the IL-8-CXCR1/2 signalling pathway on human breast CSC 
activity, (2) the effect of CXCR1/2 inhibition in combination with 
EGFR/HER-2 inhibition on CSC activity and (3) the interaction of 
CXCR1/2 and EGFR/HER2 in breast cancer.
Methods: Human breast cancer cell lines used were HER2-18 and 
SKBR3 (both HER2 over-expressing). Primary human breast cancer 
cells were extracted from metastatic samples (pleural effusion n=4; 
ascites n=5; local recurrence n=1) and invasive breast cancers (n=1). 
CSC activity was investigated in vitro using the mammosphere 
assay. Mammosphere forming efficiency (MFE) was determined by 
dividing the number of mammospheres >60µm in diameter divided 
by the number of cells seeded and expressed as a percentage. Data 
is represented as mean MFE ± standard error of mean normalised 
to control. Statistical significance (P) was determined using Mann-
Whitney U test (2-tailed). Inhibitors used were SCH563705 (a 
CXCR1/2 inhibitor; 100nM), Lapatinib (an EGFR/HER-2 inhibitor; 
1-10µM) and Gefitinib (an EGFR inhibitor; 1µM).
Results: IL-8 (100ng/ml) increased HER2-18 mean MFE from 
1±0.05% to 1.20±0.04%; 19.5% increase; P=0.0061. This effect 
was reduced by SCH563705 (from 1.20±0.04% to 0.70±0.05; 41.7% 
reduction; P=0.0001) and Lapatinib (from 1.20±0.04% to 0.51±0.04; 
57.5% reduction; P <0.0001). Combination treatment resulted in 
a greater reduction in mean MFE compared to either SCH563705 
(P<0.0001) or Lapatinib (P=0.026).
IL-8 (100ng/ml) increased mean MFE of primary human breast 
cancer cells from 1±0.03% to 1.43±0.06%; 42.9% increase; P<0.0001 
(n=11 patient samples). This effect was reduced by SCH563705 from 
1.43±0.06% to 0.96±0.04%; 32.9% reduction; P<0.0001. In HER2 
over-expressing patient samples (n=4), IL-8-induced increase in 
MFE was reduced by SCH563705 (from 1.43±0.06% to 0.83±0.05; 
42.0% reduction; P<0.0001) and Lapatinib (from 1.43±0.06% to 
0.91±0.05%; 36.4% reduction; P<0.0001). Combination treatment 
resulted in a greater reduction in mean MFE compared to either 
SCH563705 (P=0.0019) or Lapatinib (P<0.0001). In HER2-non-over-
expressing samples (n=6), IL-8-induced increase in MFE was reduced 
by SCH563705 (from 1.45±0.10% to 1.06±0.05; 27.0% decrease; 
P=0.0005) and Lapatinib (from 1.45±0.10% to 1.15±0.07%; 20.7% 
decrease; P=0.0145). Combination treatment had no additional effect.
Western blot analysis of the HER2-18 and SKBR3 cell lines showed 
that IL-8 induced phosphorylation of HER-2, AKT and MAPK within 
10 minutes; these effects were inhibited by Lapatinib and Gefitinib.
Conclusions: IL-8/CXCR1/2 regulates the activity of human breast 
CSCs. Lapatinib inhibited IL-8 signalling suggesting that CXCR1/2 
signal transduction involves an EGFR/HER2-dependent pathway. 
Targeting CXCR1/2 adds to the efficacy of targeting HER2 in HER2-
over-expressing human breast CSCs through inhibition of an EGFR/
HER2-independent pathway.
P3-17-05
Beyond HER2 and Hormonal Agents: The Heat Shock Protein 90 
Inhibitor Ganetespib as a Potential New Breast Cancer Therapy.
Friedland JC, Sang J, Modi S, Bradley R, El-Hariry I, Wada Y, 
Proia DA. Synta Pharmaceuticals, Lexington, MA; Memorial Sloan-
Kettering Cancer Center, New York, NY
Background: Ganetespib is a fully synthetic and selective inhibitor of 
heat shock protein 90 (HSP90), a molecular chaperone recognized as 
a key facilitator of breast cancer initiation, progression and metastasis.
Methods: Preclinical activity of ganetespib across the four major 
breast cancer subtypes and inflammatory breast cancer was assessed 
in vitro and in vivo. Modulation of cell proliferation and viability was 
determined both in monolayer and three-dimensional cultures. HSP90 
client protein expression and activity was monitored by Western blot 
and protein array. To recapitulate clinical dosing, kinetics of client 
protein destabilization were measured following short exposures 
to drug in vitro. Anticancer activity of ganetespib was further 
investigated in vivo using breast cancer xenografts.
Results: Ganetespib displayed potent, low nanomolar activity in 
luminal (A and B), basal (A and B) and inflammatory breast cancer 
cell lines grown as monolayers in vitro. BT-474 (HER2 amplified) 
luminal cells grown as mammospheres in 3D were equally as 
sensitive to ganetespib as those grown in monolayer. In luminal cells, 
ganetespib simultaneously disrupted multiple signaling components 
including the estrogen and progesterone receptor, several receptor 
and non-receptor tyrosine kinases, as well as the MAPK pathway. 
Further, ganetespib effectively inhibited AKT, PDK1 and SGK3 
activity in PIK3CA mutant cells suggesting that HSP90 is essential 
for both AKT-dependent and AKT-independent signaling. Clinically 
relevant exposure times to ganetespib in vitro resulted in potent, 
long term destabilization of HER2. In the basal-like breast cancer 
cell line MDA-MB-231, enriched in CD44+CD24- stem like cells 
that commonly display chemotherapeutic resistance and activated 
JAK2/STAT3 signaling, ganetespib (50 nM) induced significant 
degradation of JAK2 concordant with loss of both tyrosine and 
serine phosphorylation of STAT3, followed by cell death. The potent 
anticancer activity in vitro translated in vivo, where ganetespib was 
effective in modulating breast cancer xenograft growth as a single 
agent in both luminal and basal-like breast cancer models. Finally, 
ganetespib has demonstrated encouraging signs of clinical activity in 
breast cancer patients, including confirmed partial responses in both 
a triple negative breast cancer patient and a HER2 positive breast 
cancer patient.
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Conclusions: Ganetespib is a highly potent HSP90 inhibitor that 
displays preclinical activity in breast cancer due to its ability to 
simultaneously perturb multiple oncogenic signaling pathways.
P3-17-06
Final Results of a Controlled, Randomized 3-Arm Phase II Trial 
of EndoTAG™-1, a Cationic Liposomal Formulation of Paclitaxel 
Targeting Tumor Endothelial Cells, in Advanced Triple-Negative 
Breast Cancer (TNBC).
Awada A, Bondarenko IN, Tarasova O, Bonneterre J, Nowara E, 
Ferrero JM, Bakshi AV, Weidenthaler H, Wilke C, Piccart MJ. Institut 
Jules Bordet, Brussels, Belgium; Dnepropetrovsk State Medical 
Academy, Dnepropetrovsk, Ukraine; Academy of Medical Sciences 
of Ukraine, Kharkov, Ukraine; Centre Oscar Lambret, Lille, France; 
Instytut im. M.Sklodowskiej-Curie, Gliwice, Poland; Centre Antoine 
Lacassagne, Nice, France; Kaushalya Medical Foundation, Thane, 
India; Medigene AG, Martinsried, Germany
Background
EndoTAG™-1 (ET) is an innovative therapy of paclitaxel (P) 
embedded in cationic liposomes displaying antitumor activity by 
targeting negatively charged activated endothelial cells of tumor 
vessels.
Methods
140 patients (pts) with locally relapsed (r) or metastatic (m) centrally 
verified TNBC were randomized to i.v. weekly ET (22mg/m2 ) plus P 
(70mg/m2) (ET+P), biweekly ET alone (44mg/m2) or weekly P (90mg/
m2) in a 2:2:1 ratio. Pts had ≤ 1 prior chemotherapy (CT) for r or m 
disease and ≥ 6 months (mo) after taxane. A cycle (cy) comprised 3 
weeks(w) of therapy and 1 w rest. Pts were treated for a minimum of 
4 cy or until disease progression/unacceptable toxicity.
Primary endpoint was progression-free survival (PFS) rate at week 
16 based on blinded central imaging and local assessment. Secondary 
endpoints included median overall survival (mOS), tumor response 
(RECIST), Quality of Life (QoL) and safety. The study was not 
powered for intergroup comparisons.
Results 
Pts baseline characteristics were overall well distributed. Appr. 80% 
of all pts were treated 1st line for r or m TNBC.
Results of PFS rates at week 16 are shown in table. Based on central 
review, median PFS at week 16 was 4.2 mo for ET+P [95% CI: 3.5-
9.1], 3.4 on ET [2.0-3.8] and 3.7 on P [1.9-6.7]. Antitumor activity 
was highest for ET+P with a clinical benefit rate (complete response 
(CR) + partial response (PR) + stable disease (SD) ≥6 mo at data cut 
off date of week 41) of 53% (26/49 evaluable pts), 31% (15/49) on 
ET and 36% (9/25) on P. The best overall response (CR, PR, SD at 
any time) on ET+P was 80% (39/49), on ET 65% (32/49) and 68% 
(17/25) on P.
Analysis of median OS is shown in table. Analysis of the not 
predefined subgroup (centrally TNBC + ECOG 0/1 + first line 
population) showed an impressive median OS of 17.8 mo for ET+P. 
No differences were reported for QoL. No additional toxicities to those 
known for ET and P were observed except uncomplicated grade 3/4 
neutropenia in the ET + P arm.
 PFS rate at week 16 / 95% confidence intervals
 ET+P ET P
mITT, Central review 59.1% (26/44 pts) /  43.2-73.7
34.2% (13/38 pts) /  
19.6-51.4
48% (12/25 pts) /  
27.8-68.7
mITT, Local review 47.3% (26/55 pts) /  33.7-61.2
29.8% (17/57 pts) /  
18.4-43.4
42.9% (12/28 pts) /  
24.5-62.8
 mOS at cut off date week 41 / 95% confidence intervals
 ET+P ET P
mITT 55 pts, 13.0 mo /  9.3-23.0
57 pts, 11.9 mo /  
7.8-16.3
28 pts, 13.1 mo /  
6.7-23.0
TNBC centrally, ECOG 0/1 
and 1st-line treatment
44 pts, 17.8 mo /  
10.6-na
48 pts, 12.5 mo /  
8.4-19.8
24 pts, 10.1 mo,  
5.9-23.0
Conclusions
At cut-off date week 41, the final analysis demonstrated ET+P as a 
promising combination compared to single agent arms. ET+P was 
well tolerated. These data will be the basis for a confirmatory phase 
III study.
Acknowlegments:
B. Glasschroeder, U. Elsasser
P3-17-07
EGCG, a Green Tea Antioxidant Suppresses Breast Tumor 
Angiogenesis and Growth Via Inhibiting the Activation of HIF-
1a and NFkB, and VEGF Expression.
Makey KL, Tucker KB, Chinchar E, Miele L, Pei I, Thomas EY, Gu 
J-W. University of Mississippi Medical Center, Jackson, MS
Background: Cancer cells are under greater oxidative stress than 
normal cells. Limited studies have showed that epigallocatechin-3-
gallate (EGCG), a green tea antioxidant can afford protection against a 
variety of cancer types. The role of EGCG in breast cancer therapy is 
poorly understood. The present study tests the hypothesis that EGCG 
as an antioxidant can inhibit the activation of HIF-1a and NFkB, 
and VEGF expression, thereby suppressing tumor angiogenesis and 
breast cancer progression.
Material and Methods: 16 eight-wk-old female mice (C57BL/6J) 
were inoculated with 10^6 E0771 (mouse breast cancer) cells in the 
left fourth mammary gland fat pad. 8 mice received EGCG at 50-
100 mg/kg/d in drinking water for 4 weeks. 8 control mice received 
drinking water only. Tumor size was monitored using dial calipers. 
At the end of the experiment, blood samples, tumors, heart and limb 
muscles were collected for measuring VEGF expression using ELISA 
and capillary density (CD) using CD31 immunochemistry. Cultured 
E0771 cells were used for determining the direct effects of EGCG 
on proliferation (3H-thymidine incorporation), migration (Matrigel 
assay), VEGF expression (ELISA), the activation of HIF-1a and 
NFkB (motif binding assays, Active Motif). MCF-7 and MDA-
MB-231 cells were also used for 3H-thymidine incorporation.
Results: Oral EGCG treatment significantly reduced tumor weight 
over the control (0.37±0.15 vs. 1.16±0.30 g; P<0.01), tumor CD 
(109±20 vs. 156±12 capillary #/mm^2; P<0.01), tumor VEGF 
expression (45.72±1.4 vs. 59.03±3.8 pg/mg; P<0.01), respectively. 
EGCG treatment reduced plasma VEGF levels over the control mice 
(26.48±3.76 vs. 40.79±3.5 pg/ml; P<0.01). However, there were no 
differences in the body weight and heart weight between EGCG and 
the control groups. EGCG did not inhibit angiogenesis and VEGF 
expression in the heart and skeletal muscle of mice, compared to the 
control. EGCG at 50 mmol/L significantly inhibited the activation 
of HIF-1a (0.11±0.02 vs. 0.24±0.02; P<0.01) and NFkB (1.15±0.21 
vs. 1.61±0.32; P<0.01) as well as VEGF expression (1752±49 vs. 
2254±91 pg/mg; P<0.01) in cultured E0771 cells, compared to the 
control, respectively. EGCG caused a dose-related inhibition on the 
proliferation and migration in cultured E0771 cells. EGCG also caused 
a dose-related inhibition on the proliferation in cultured MCF-7 and 
MDA-MB-231 cells.
Discussion: These findings support the hypothesis that EGCG, 
a green tea antioxidant, directly targets both tumor cells and 
tumor vasculature, thereby inhibiting tumor growth, proliferation, 
migration, and angiogenesis of breast cancer, which is mediated 
by the inhibition of HIF-1a and NFkB activation as well as VEGF 
expression. Interestingly, oral EGCG treatment has no effects on the 
body weight, heart weight, angiogenesis and VEGF expression in 
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the heart and skeletal muscle of mice. This work will have important 
implications for translating EGCG therapy to human breast cancer 
treatment and prevention.
P3-17-08
Macroautophagy Protects Breast Cancer MCF-7 Cells from 
TAM-Induced Apoptosis Via Mitogen-Activated Protein Kinase 
(MAPK) Pathway.
Hou YF, Ma XY, Liu ZB, Yu SJ, Shao ZM. Cancer Institute, Shanghai, 
China
Tamoxifen (TAM) has been used ubiquitously for endocrine therapy 
for the hormone-sensitive breast cancer. Several studies have revealed 
that tamoxifen treatment induced apoptosis and at the same time 
tamoxifen increased autophagic levels in MCF-7 cells. The previous 
studies attempt to elaborate the significance and mechanism of 
autophagy induced by TAM in breast cancer cells, however, there 
are contradictions among their conclusions, it is still not clear that 
autophagy protects MCF-7 from apoptosis or promotes apoptosis. 
Better understanding of the effect of autophagy induced by TAM 
in breast cancer cells on apoptosis will be of the important clinical 
significance in endocrine therapy for breast cancer.
The present study shows that tamoxifen treatment significantly 
increased autophagic levels by inducing autophagic vacuoles 
formation in MCF-7 cells observed by means of transmission electron 
microscopy and enhancing the expression of autophagy marker, 
icrotubule-associated protein light chain 3 measured by Western 
blot. Our research shows tamoxifen enhanced the phosphorylation 
of MAPKs when inducing autophagy and autophagy decreased 
significantly when kinase inhibitors were separately used to inhibit 
the phosphorylation of ERK, JNK, p38 MAPK. MAPK signal 
transduction pathway was involved in the process of autophagy in 
MCF-7 cells.
To investigate whether Estrogen receptor-a participated in autophagy 
caused by tamoxifen, we constructed Estrogen receptor-a gene 
ESR/1 shRNA expression vector and it could effectively inhibit 
the expression of ER-a in MCF-7 cells. Our research shows that 
autophagy was decreased with the downregulation of ER-a, so we 
conclude that Estrogen receptor-a also involved in autophagy induced 
by tamoxifen in MCF-7 cells.
To find out the specifical role of autophagy in tamoxifen treated 
breast cancer cell MCF-7, we inhibited autophagy producing after 
tamoxifen treatment by pretreating the cells with chloroquine and 
3-methyladenine, both commonly used as autophagy inhibitors. 
Another method for autophagy inhibition was Becline-1 siRNA 
transfection into MCF-7 cells. Than we stained MCF-7 cells with 
anti-Annexin V FITC and PI and examinated apoptotic rate by flow 
cytometer and we also detected activity of caspase7 in MCF-7 cells. 
The results indicate that inhibition of autophagy by the methods 
mentioned induced higher apoptotic level, therefore, autophagy 
protected MCF-7 from apoptosis and inhibiting autophagy may be a 
new strategy to augment the theraputic effect of tamoxifen treatment.
In our study, we induced breast cancer cell MCF-7 resistant to TAM 
in vitro and we found much higher autophagic level in TAM resisitant 
cells compared with TAM not resisitant MCF-7 cells. We draw the 
conclusion that inhibition of autophagy induced by tamoxifen may 
be a new therapy for tamoxifen resisitant breast cancer.
Key words:tamoxifen, breast cancer, autophagy, MCF-7 cells, 
MAPKs, estrogen receptor, inhibition, apoptosis
P3-17-09
Neutralizing the Prolactin Receptor with Therapeutic Antibody 
LFA102: A Novel Approach for the Treatment of Breast Cancer.
Damiano JS, Wasserman E, Rendahl K, Jeffry U, Rediske J, Kakar S, 
Gardner H, Abraham J. Novartis Institutes for BioMedical Research, 
Emeryville, CA; Novartis Pharmaceuticals, Florham Park, NJ; 
Novartis Institutes for BioMedical Research, Cambridge, MA
The prolactin receptor (PRLR) is a class I cytokine receptor required 
for the normal development of the mammary gland and is frequently 
found to be overexpressed in breast tumors. The polypeptide hormone 
prolactin (PRL) has been demonstrated to induce PRLR signaling 
through the Jak/Stat, PI3-kinase/AKT and MAPK pathways, leading 
to cell proliferation and survival. Mammary gland-specific over-
expression of PRL in transgenic mice leads to a higher incidence 
of ER+ and ER- mammary tumors. In addition, the PRLR locus is 
the site of frequent viral integrations in MMTV-induced mammary 
tumors. Elevated serum PRL levels in humans have been correlated 
with an increased risk for breast cancer, especially for ER+ cases, 
implicating a role for this hormone in the development of human 
breast tumors. An analysis of more than 3000 breast tumor specimens 
indicates that PRLR is expressed with high prevalence (60-70% of 
tumors) across all breast cancer subtypes, with a trend towards higher 
expression in ER+ tumors. All of these lines of evidence support the 
hypothesis that targeting the PRL/PRLR axis may be a new approach 
for addressing unmet medical need in breast cancer. LFA102 is a 
Human Engineered™ anti-PRLR antibody of the IgG1 isotype that 
neutralizes the function of PRLR through a non-ligand competitive 
binding interaction. LFA102 blocks PRL-induced signaling and 
proliferation in T47D and MCF7 ER+ human breast cancer cells in 
vitro, and abolishes PRL-induced phosphorylation of Stat5 in T47D 
xenograft tumors in vivo. An examination of disaggregated primary 
human breast tumors ex vivo has indicated that PRL frequently induces 
signaling through Stat5 in the cells and that LFA102 is capable of 
completely antagonizing this signaling. LFA102 also neutralizes rat 
PRLR and the antibody potently regresses PRL-dependent Nb2-C11 
pre-T cell lymphoma tumors in vivo. Preliminary data suggests that 
LFA102 is also capable of inhibiting the growth of carcinogen-induced 
rat mammary tumors. In vitro studies have shown that LFA102 can 
also mediate antibody-dependent cellular cytotoxicity (ADCC) 
and inhibit the PRL-dependent release of the pro-angiogenic factor 
VEGF from breast cancer cells. Thus, there are multiple potential 
mechanisms through which LFA102 could show anti-tumor activity 
in vivo. Preclinical toxicological studies of LFA102 indicate that this 
therapeutic is well tolerated and exhibits a normal pharmacokinetic 
profile in relevant animal species. The safety and pharmacokinetics 
of LFA102 in humans are currently being evaluated in a phase I 
healthy volunteer trial. At the three dose levels explored so far, 
no infusion reactions or severe adverse events related to the drug 
have been reported. Preliminary results suggest that LFA102 has an 
adequate pharmacokinetic profile for further clinical development. 
An assessment of LFA102 in a population of metastatic breast 
cancer patients predicted to have the highest probability of benefit 
is imminent.
P3-17-10
EpCAM as a Target for Chemical Antibodies in Metastatic Breast 
Cancer.
Shigdar SL, Duan W. Deakin University, Geelong, Victoria, Australia
EpCAM is a 40kDa glycoprotein that functions as an adhesion 
molecule in benign epithelium. However, it is over-expressed in 
nearly all carcinomas, including breast carcinomas, and has been 
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implicated in the pathogenesis and progression of cancer. In primary 
breast carcinoma, its over-expression correlates with a diminished 
overall survival in patients with node-positive disease. Indeed, recent 
evidence has shown that EpCAM is expressed at a higher level in 
metastases than in matched primary breast carcinoma. This has led 
to the suggestion that EpCAM over-expression is associated with 
aggressive behaviour, and that it could be considered a promising 
therapeutic target for breast cancer. Several immunotherapy trials are 
ongoing, though there are limitations to their delivery and distribution, 
suggesting a smaller and more effective EpCAM targeting molecule 
is required.
Aptamers, also known as chemical antibodies, are short-stranded 
DNA or RNA molecules and are selected via the systematic evolution 
of ligands by exponential enrichment (SELEX). They are 10 to 20 
times smaller than antibodies and exhibit superb tissue penetration, 
thereby indicating their suitability in cancer targeting. In addition, 
aptamers are more stable, non-immunogenic and non-toxic. Following 
12 rounds of SELEX using EpCAM protein as a target, we generated 
several EpCAM specific RNA aptamers. These were investigated 
using flow cytometry and confocal microscopy for their ability to bind 
to three breast cancer cell lines, MCF-7, T47D and MDA-MB-231. 
Our 19-nt aptamer showed specific binding to all three cell lines. In 
addition, it also showed superior penetration of breast cancer 3-D 
spheroid tumor models, as compared to a control aptamer and negative 
cell lines. This aptamer has also shown efficient internalisation via 
receptor-mediated endocytosis, suggesting it to be a suitable targeting 
moiety for drug delivery to both primary and metastatic tumors. The 
usefulness of this aptamer in clinical applications is being actively 
investigated.
P3-17-11
Dovitinib (TKI258), a Dual Inhibitor of FGFR and VEGFR, 
Induces Tumor Growth Suppression in Xenograft Models of 
Primary Human Breast Cancer.
Shi MM, Linnartz R, Versace R, Graus Porta D, Kay A, Dugan 
M. Novartis Oncology, East Hanover, NJ; Novartis Institutes for 
BioMedical Research, Basel, Switzerland
Introduction: The objective of this study was to evaluate the 
efficacy of dovitinib (TKI258), a small-molecule dual inhibitor of 
fibroblast growth factor receptor (FGFR) and vascular endothelial 
growth factor receptor (VEGFR) in mouse models of human breast 
cancer. Molecular epidemiological studies have implicated that 
FGFR1 and FGFR2 gene amplification plays a critical role in breast 
cancer tumorigenesis. FGFR1 gene amplification correlates with 
gene expression and is associated with poor prognosis in patients 
with estrogen receptor-positive (ER+) tumors. Dual FGFR/VEGFR 
inhibitory activities of dovitinib make it an attractive molecule 
for targeting breast cancer. Experimental Design: Dovitinib was 
evaluated in 3 primary human breast carcinoma xenograft models 
with different histological and molecular profiles: a triple-negative 
breast cancer model (HBCx-15), a HER2+ model (HBCx-5), and an 
ER+ model (HBCx-3). Dovitinib was administered orally at 20- and 
40-mg/kg dose levels (n = 8-10/group), once daily for 21 consecutive 
days. Results: At a dose of 40 mg/kg, dovitinib demonstrated 
strong antitumor efficacy as a single agent, particularly in the ER+ 
HBCx-3 and the HER2+ BCx-5 tumor models (DT/T0 = –26.42% 
and DT/DC = 5.09%, respectively), whereas the response was less 
significant in the triple negative breast cancer HBCx-15 model (DT/
DC = 31.7%). Conclusion: Dovitinib showed significant antitumor 
effect in human breast cancer xenograft mouse models. This study 
provides a strong rationale for clinical investigation of dovitinib in 
patients with advanced breast cancer, particularly in patients with 
ER+ and HER2+ disease.
P3-18-01
cMET Inhibitor and the Inhibition of Growth of Breast Cancer 
Cells in Bone Marrow Matrix Environment.
Ye L, Mason MD, Bramble P, Jiang WG. Cardiff University School 
of Medicine, Cardiff, Wales, United Kingdom; Pfizer Limited, Walton 
Oaks, Surry, United Kingdom
Background: Hepatocyte growth factor (HGF) is a cytokine that has 
a diverse but potential role in cancer including breast cancer. HGF, 
which action is mediated by its specific receptor, cMET, stimulate 
the aggressiveness of cancer cells by increasing the invasiveness and 
cellular migration. HGF is also a potent angiogenic factor. Small 
inhibitors to the HGF receptor are currently investigated in clinical 
trials of various cancers. In solid tumours which have potency of 
bone metastasis, HGF and particularly the HGF receptor, cMET, 
have been found to be particularly over-expressed in tumour cells 
metastasised to bones.
Materials and methods. A panel of breast cancer cell lines were 
used. Cell growth was determined using a colorimetic method. Cell 
adhesion and migration were investigated using a ECIS model. Bone 
matrix proteins were prepared from fresh bones. A small inhibitor to 
human cMET, PF02341066 was used in the present study in all the 
cell models.
Results. Depending on cell types, cancer cells tended to grow at a 
faster rate in bone marrow microenvironment than under normal 
conditions (12% higher for MDA MB 231 cells, for example). While 
PF02341066 have a concentration dependent effect on the growth 
of breast cancer, this effect became more marked when cells were 
growing in the bone marrow matrix. Breast cancer cells migrated 
rapidly in the presence of bone marrow environment, in comparison 
with controls. This was also inhibited by the cMET inhibitor. The 
study further showed that cells over-expressing a molecule linked to 
bone metastasis, namely ALCAM (1,2), responded more vigorously 
to cMET inhibitor in the matrix adhesion and cellular migration.
Conclusions. The present study has shown that the HGF receptor 
inhibitor has an inhibitory effect on breast cancer cells. This is 
particularly so when cells are grown in bone matrix microenvironment. 
It is concluded therefore that inhibitors to the HGF receptor may have 
a particular role in the management of bone metastasis in breast 
cancer.
References: 1. Davies S, Jiang WG. ALCAM, activated leukocyte cell 
adhesion molecule, influences the aggressive nature of breast cancer 
cells, a potential connection to bone metastasis. Anticancer Res. 2010, 
;30(4):1163-8; 2. King JA, et al. Activated leukocyte cell adhesion 
molecule in breast cancer: prognostic indicator. Breast Cancer Res. 
2004;6(5):R478-87
P3-18-02
A Combination of Pathway-Targeted Inhibitor with DNA-Repair 
Inhibitor: Preclinical Efficacy of Zactima and Olaparib in Triple 
Negative Subset of Breast Cancer.
Dey N, Wu H, Sun Y, De P, Leyland-Jones B. Emory University, 
Atlanta, GA
Introduction: Pathway-targeted therapy has not been established 
for the treatment of Triple Negative (TN) subset of breast cancer 
(BC). Despite emerging data supporting the use of polyADP-ribose 
polymerase (PARP) inhibitors, complete and durable responses 
are rare in TNBC and exploration of additional pathway-targeted 
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therapies is needed. The high frequency (72-75%) of EGFR 
expression in TNBCs suggests that loss of BRCA1 may be coupled, 
either directly or indirectly, with EGFR overexpression in breast 
cancer (Van der Groep et al., 2006), and a recent report shows that 
even a partial loss of BRCA1 leads to an overall increase in EGFR 
expression in mammary epithelial cells (Burga et al., 2011). We 
hypothesize that the combined inhibition of growth factor driven 
EGFR pathway (by Zactima, a small molecule kinase inhibitor of 
EGFR and VEGFR-2) and DNA-repair pathway (by Olaparib, PARP 
inhibitor) in the presence of DNA-damaging agent (carboplatin) will 
have anti-proliferative and anti-migratory effects on triple negative 
breast tumor (TNBT) cells.
Methods: The effects of Zactima, Olaparib (single or in combination) 
and carboplatin were studied on: (a) the cell survival/proliferation 
(MTT, SRB, & cell titer-GLO assay), (b) EGF-induced upregulation 
of downstream proliferation markers, (c) the cellular signals for 
apoptosis, (d) fibronectin-directed migration (scratch-assay), (e) the 
vascular mimicry, and (f) the clonogenic survival (3D-ON-TOP assay) 
in different TNBT cell lines.
Results: Our in vitro data show that, (1) Zactima (10 uM) blocked 
EGF-induced phosphorylation of AKT (S473 & T308), S6RP, 
4EBP1 and ERK as early as 1 hr (after the treatment), (2) the range 
of EC50s for Zactima (96 hrs) varied from 5 uM -15 uM (HCC70, 
HCC1937, MDA-MB231, MDA-MB468, BT20), (3) EGFR over-
expressing, PTEN-null, and ATM kinase mutated MDA-MB468 cell 
line exhibited lowest EC50 for Zactima as compared to other TNBT 
cell lines and was found to be the most sensitive cell line to Zactima 
(~ 0.05 uM) when combined with 10 uM fixed dose of Olaparib, (4) 
a combination of Zactima with Olaparib plus carboplatin altered 
an adhesion-dependent cell-survival, increased caspase3 activity 
(expression of cleaved caspase3 and cleaved PARP) time dependently, 
inhibited vascular mimicry (at 6 and 24 hrs), blocked fibronectin-
directed migration (scratch assay, 24 hrs), changed the organization 
of actin-cytoskeleton, and suppressed clonogenic growth in different 
TNBT cells lines.
Conclusion: Zactima alone showed anti-proliferative/pro-apoptotic, 
and anti-migratory effects in TNBT cells. The combination of Zactima 
with Olaparib plus carboplatin was most effective in blocking the 
clonogenic growth of TNBT cells. We are currently pursuing studies 
to, (1) delineate the relationship between the anti-proliferative effects 
(clonogenic assay) of Zactima (alone or in combination) and the status 
of the EGFR/ PI3K pathway using PIK3CA-mutated, PTEN-null and 
EGFR overexpressed TNBT cell lines, and (2) determine the effect 
of Zactima on angiogenesis using HUVEC cells, the results of which 
will be presented in the meeting.
This work was generously supported by AVON foundation.
P3-18-03
In Vitro Potency of mTOR Kinase (TOR1/TOR2) Inhibitor, 
INK128 in ER+ and HER2 Overexpressing Breast Cancer Cells.
De P, Sun Y, Dey N, Leyland-Jones B. Emory University, Atlanta, GA
Background: Persistent activation of the PI3K-AKT-mTOR1/2 
signaling pathway drives aberrant cell growth and proliferation in a 
variety of tumor types including breast tumors. Recent works have 
demonstrated a strong association between mutational activation 
of PIK3CA or loss of function of PTEN and resistance to therapies 
targeted against the ER or HER2 pathway.
Purpose: Since PI3K-AKT-mTOR is one of the major signaling 
pathways responsible for the progression of breast cancer, as well as 
appears to be upregulated during development of the resistance to the 
endocrine and trastuzumab treatment, suppression of this pathway by 
administration of INK128 (mTOR1/2 kinase inhibitor) may therefore 
be efficacious in ER+ and HER2+ breast cancer models.
Experimental Design: To examine this possibility, INK128 
was treated in ER+ (MCF7, BT483, T47D and MDA-MB-415), 
trastuzumab-sensitive HER2+ (BT474), trastuzumab-resistant 
(BT474HR), and PIK3CA mutated/HER2+ breast cancer cells 
(HCC1954 and UACC893). We have tested the effects of INK128 on 
the, (a) cell survival/proliferation, (b) integrin-directed cell migration, 
and small GTP-ase activation, (c) downstream signaling pathways for 
proliferation and apoptosis, and (d) 3D ON-TOP-colony formation.
Results: Treatment of ER+ and HER2+ cell lines with INK128 
in vitro showed that 1) cell lines were sensitive to single agent 
INK128 with 50% inhibitory concentration ranging from 15 nM-
10 µM in ER+ cell lines and 20 nM -50 nM in HER2+ cell lines, 
2) 70-80% anti-proliferative activities were observed on 3D-ON 
TOP colony formation assay in both ER+ and HER2+ cells, 3) 
INK128 dose- and time-dependently blocked downstream effectors 
of mTOR1/2 pathway i.e. p-AKT (at Ser473), p-P70S6K, p-S6 
ribosomal protein, p-4EBP1(interestingly, potent inhibition was 
also observed in cell line resistant to trastuzumab), 4) INK128 also 
blocked AKT phosphorylation at Thr308 (although in lesser extent 
than at Ser473), 5) rapalog-mediated AKT activation was blocked 
when cells were treated with INK128, 6) in ER+ cell lines INK128 
more efficiently blocked p-4EBP1 than rapalog, 7) HER3 expression 
was significantly upregulated following treatment of trastuzumab-
resistant cells (BT474HR) with INK128, and 8) integrin-dependent 
cell migration was significantly abrogated with INK128 in association 
with inhibition of RAC1-GTP.
Conclusion: Our preclinical in vitro data demonstrate that concurrent 
inhibition of mTOR1and mTOR2 is likely to be a more effective 
in both ER+ and HER2+ breast cancer cells than the inhibition of 
mTOR1 alone. We are currently studying the effect of INK128 on 
downstream apoptotic signals in ER+ and HER2+ cell lines, the results 
of which will be presented in the meeting.
INK128 was generously supplied by Inkellikine, San Diego, CA.
P3-18-04
Pathway Guided Selection of Targeted Inhibitors for Breast 
Cancer Treatment.
von Ahsen O, Kim P, Langley E, Hazra S, Lee T, Leesman G, Schneider 
C, Singh S, Krahn T. Bayer Healthcare, Berlin, Germany; Prometheus 
Inc., San Diego, CA
Background: The ability to functionally profile a whole spectrum 
of pathway proteins in tumor may provide valuable information 
about the likelihood of drug response and potential mechanisms for 
drug resistance in breast cancer (BCA) patients. Here we report a 
comprehensive pathway analysis of membrane associated kinases 
such as HER1, HER2, HER3, cMET, IGF1R, PI3K and downstream 
signal transduction proteins including Shc, AKT, ERK, MEK, PDK1, 
PRAS40, p70S6K and eIF4e in breast cancer cell lines and xenografts 
as in response to inhibitors targeting the Her1/Her2 and PI3K/AKT 
and MAPK pathways. For comparison we also analyzed NSCLC 
lines driven by other receptor tyrosine kinases like EGFR and MET.
Methods: Lysates prepared from KPL4 cells and MCF7 cells both 
harboring PIK3CA mutations (with HER2-amplification and low 
level HER2 expression, respectively) treated with 6 inhibitors (an 
allosteric AKT inhibitor, Lapatinib, Regorafenib, MET inhibitor, 
an allosteric MEK inhibitor or PI3K inhibitor) targeting PI3K/AKT 
and MAPK pathways were analyzed for modulations of pathway 
protein phosphorylation using a multiplexed immuno-micorarray. 
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Tissue lysates prepared from KPL4 xenografts treated with AKT 
inhibitor were analyzed for pathway modulation in response to the 
drug treatment. The pathway activation profile shift in response to 
drug treatments in BCA models are compared to other tumor type 
models with diverse oncogenic backgrounds.
Results: The level of phosphorylated AKT (pAKT) was reduced 
when MCF7 cells were treated with AKT inhibitor as well as PI3K 
inhibitor. However, compensatory AKT activation was observed when 
these cells were treated with BRAF or MEK inhibitor. KPL4 cells 
also showed reduction of pAKT when treated with Lapatinib, AKT 
inhibitor or PI3K inhibitor. Compensatory hyper-phosphorylation of 
ERK (pERK) was observed in both cell lines and KPL4 xenografts 
with AKT inhibitor treatment while PI3K inhibition did not induce 
hyper-ERK phosphorylation. Reduction of pERK level was observed 
when both cell lines were treated with MEK inhibitor. Downstream 
analytes like PRAS40 and RPS6 summarize PI3K/AKT pathway 
activity and correlate well with response to treatment whereas eIF4e is 
a good final readout for activity in the RAS/RAF/MEK/ERK pathway. 
Treatment with single agents often even shows adverse profile shift 
through feedback or pathway cross-talk. The comparative analysis 
of pathway modulation in BCA models to other tumor types in 
response to drug treatments revealed several adaptive drug resistance 
mechanism with different oncogenic backgrounds.
Discussion: Evaluation of drug specific pathway modulations in 
cancer cells provided comprehensive information on efficacy of 
specific agents on target protein and pathway inhibition. Multiplexed 
pathway analysis provides valuable information for drug resistance 
mechanisms due to either redundant pathway activation, cross-talk 
or through feedback mechanism and may guide appropriate selection 
of targeted drug-combinations or drug-sequencing in clinical setting. 
For example, the observed increase in ERK phosphorylation due to 
AKT inhibition could be blocked by combination therapy with a 
MEK inhibitor.
P3-18-05
Triple-Negative Breast Cancer: Stem Cells, Cancer and New 
Treatment Strategy.
Yin S, Xu L, Reddy KB. Wayne State University School of Medicine, 
Detroit, MI
Background: Women with triple negative breast cancer (TNBC) 
have a worse prognosis compared with other breast cancer subtypes. 
Hormonal or Herceptin-based therapies were found to be ineffective 
because of the loss of target receptors such as ER, PR and HER-2 
amplification. TNBC has increased recurrence and poor survival, 
despite initial response to neoadjuvant chemotherapy. The aim of this 
study was to determine whether current drug treatment(s) eliminates 
bulk of tumor cells, but it has a minimal effect on cancer stem cells 
(CSCs) leading to tumor recurrence.
Materials and Methods: Cancer stem cells were identified by ALDH-
positive population by fluorescence-activated cell sorting. CSCs 
ability to form mammospheres, are generated in nonadherent and 
nondifferentiated conditions. Apoptosis was assessed using the Cell 
Death Detection ELISAPLUS kit. Xenograft tumor formation was 
evaluated using Nod/Scid mice. Cancer stem cell levels in human 
TNBC and ER+, PR+ and HER2- tumors were obtained by CD44+/
CD24low/- immunohistochemistry.
Results: TNBC tumors express relatively higher levels of cancer 
stem cells compared to ER-positive, PR-positive and HER2-negative 
breast tumors. We studied the effects of PARP inhibitors (AZD2281 
and BSI-201), paclitaxel, docetaxel, cisplatin and cisplatin plus 
TRAIL on CSCs derived from CRL-2335 and MDA-MB-468 TNBC 
cells in vitro. The in vitro data indicates that cisplatin plus TRIAL 
treatment was most effective in eliminating CSCs compared to 
PARP inhibitors, cisplatin, paclitaxel and docetaxel. Treatment with 
cisplatin plus TRAIL also inhibits Wnt-1 signaling and its downstream 
target, b-catenin, phospho b-catenin, cyclin D1, increased apoptosis, 
reduced proliferation and mammosphere formation. Inhibition of 
Wnt-1 by siRNA significantly reduced the ability of CSCs to form 
mammospheres compared to control. However, maximum effect 
was seen in cisplatin plus TRAIL treated cells. The combination of 
cisplatin/TRAIL also inhibited the growth of CRL-2335 Xenografts.
Discussion: We demonstrate for the first time that cisplatin plus 
TRAIL is highly effective in reducing CSCs compared to PARP 
inhibitors, docetaxel or paclitaxel in TNBC cells in vitro. Inhibition of 
Wnt-1 signaling pathways by siRNA or cisplatin plus TRAIL reduces 
cell proliferation and increases apoptosis in CSCs. Taken together the 
data suggests that cisplatin plus TRAIL treatment has the potential 
of providing a new strategy for improving the therapeutic outcome 
in TNBC patients.
P3-18-06
AEZS-131 – A Highly Selective ERK-Inhibitor: Characterization 
and Preclinical Testing in Triple Negative Breast Cancer (TNBC).
Engel JB, Seipelt I, Hönig A, Hahne JC, Teifel M. Medical University 
of Würzburg, Würzburg, Germany; Æterna Zentaris GmbH, 
Frankfurt, Germany
Introduction
Overexpression of MAPK has been detected in 34 % of TNBC and has 
been found to be associated with anthracycline resistance (1). AEZS-
131 is a highly selective orally active ERK1/2-inhibitor, which has 
shown in vivo activity (first in class) in colon cancer. The following 
study explores mode of action and efficacy in models of TNBC.
Study design
AEZS-131 was tested in a kinase panel of 36 STK, 26 TK and 7 PIK 
to check for selectivity. Inhbition of Rsk-phosphorylation (cellular 
substrate of ERK) was evaluated by western blot analysis. Mode of 
action was explored by cell cycle FACS-analysis. Cleavage of PARP 
was explored by Western blot. Cytotoxic efficacy was evaluated in 5 
TNBC, of which 2 had mutations in the MAPK signal transduction 
pathway lines, by MTT assay. Additionally it was explored if 
inhibition of classical apoptosis could abrogate the effect of AEZS-
131.
Results
AEZS-131 selectively inhibited ERK with an IC50<4nM. 
Phosphorylation of Rsk-1 the cellular substrate of ERK was inhibited 
with an IC 50 of 158 nM. AEZS-131 induced cell cycle arrest in 
G1 dose-dependently and cleavage of PARP. EC 50 was 0,739 µM 
for MDA-MB-231 (Ras-mutated), 0,137 µM for MDA-MB-435s 
(B-RAF mutated), 17,5 µM for MDA-MB-468 (PTEN loss), 25 µM 
for HCC 1806. HCC 1937 were not inhibited by the compound. Of 
note, inhibition of classical apoptosis did not alter the cytotoxic effect 
of the compound in MDA-MB-468 and HCC-1806 cells.
Conclusions
AZS-131 was shown to selectively inhibit ERK at low nM 
concentrations and to induce G1-arrest. Accordingly, the cytotoxic 
effect most pronounced in TNBC cell lines with mutations in the 
MAPK pathway. If classical apoptosis is inhibited, cytotoxic effects 
remain unchanged, suggesting that AEZS-131 can also induce non-
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classical forms of programmed cell death. AEZS-131 should be further 
explored in TNBCs with overexpression of MAPK or mutations in 
the MAPK-pathway.
*Æterna Zentaris GmbH, Frankfurt/M, Germany.
(1): MAPK overexpression is associated with anthracycline resistance 
and increased risk for recurrence in patients with triple-negative 
breast cancer.
Eralp Y,Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu 
M, Igci A, Kücücük S, Dincer M, Aydiner A, Topuz E.
Ann Oncol. 2008 Apr;19(4):669-74.
P3-18-07
Multiplex RTK Inhibitor Screening Utilizing a Plate-Based 
Immunoassay with Near-Infrared Detection.
Finkel DJ, James AE, Felix RA, Wegner GJ. R&D Systems Inc., 
Minneapolis, MN; Tocris Bioscience, Bristol, United Kingdom
Receptor-tyrosine kinases (RTKs) are transmembrane proteins that 
have been implicated in various cancers and are considered therapeutic 
targets. The phosphorylation of RTKs on tyrosine residues leads to 
their activation. We have previously used the Proteome Profiler™ 
96 Human Phospho-RTK Antibody Array, a plate-based multiplex 
immunoassay, to determine the phospho-tyrosine profile of RTKs in 
MDA-MB-453 breast cancer cells. Most notably, the ErbB family of 
RTKs were shown to be hyperactivated in this cell line. In this study, 
we use the same multiplex assay to screen a small molecule kinase 
inhibitor library (TOCRIS, Catalog # 3514) to identify inhibitors 
with selectivity towards the ErbB receptors. MDA-MB-453 cells 
were treated with the kinase inhibitor library prior to treatment with 
ligands to stimulate ErbB receptor tyrosine phosphorylation and 
subsequently lysed. The lysates were analyzed with the Proteome 
Profiler 96 Human Phospho-RTK Antibody Array using near-infrared 
fluorescent detection. Ligand-dependent tyrosine phosphorylation 
of all four ErbB receptors was monitored simultaneously and the 
effects of different kinase inhibitors were determined. While several 
known ErbB inhibitors blocked ErbB phosphorylation, our screen 
also identified several inhibitors reported to be selective for other 
kinases that effectively inhibited ErbB activation. The activation of 
ErbB2 was selectively inhibited by NH 125, GF 109203X, SB 202190, 
SB 216763, and ZM 306416 hydrochloride. The results obtained 
with this multiplex assay were confirmed by singleplex ELISA for 
ErbB receptors. Hence, the data collected with our multiplex assay 
provides a rapid method for the analysis of inhibitor effects on a 
defined signaling pathway. This may facilitate a faster identification of 
selective kinase inhibitors that have therapeutic potential for treating 
ErbB-overexpressing cancers.
P4-01-01
Preclinical and Clinical Studies of Estrogen Deprivation Support 
the PDGF/Abl Pathway as a Novel Therapeutic Target for 
Overcoming Resistance.
Weigel MT, Banerjee S, A’Hern R, Arnedos M, Ghazoui Z, Dunbier 
AK, Dowsett M, Martin L-A. Institute of Cancer Research, London, 
United Kingdom; Royal Marsden Hospital, London, United Kingdom
Aim: To determine the relevance of PDGF/Abl signaling pathway 
as a therapeutic target in endocrine resistance in vitro and in vivo.
Rationale: Targeting estrogenic stimulation reduces mortality from 
ER-positive (ER+) breast cancer (BC) but resistance remains a major 
clinical problem. To identify the molecular mechanisms associated 
with resistance to estrogen-deprivation, we previously assessed the 
temporal changes in gene expression during adaptation to long-term 
culture of MCF7 human breast cancer cells in the absence of estradiol 
(E2) (LTED), modeling resistance to an aromatase inhibitor (AI). 
Platelet-derived growth factor (PDGF)/Abl signaling was the top 
adaptive pathway at the point of resistance (p=1.15 E-07), but there 
is limited evidence for it playing a role clinically.
Methods: Gene expression data from postmenopausal women 
with ER+ BC at pre-treatment and at 2-week on-treatment with 
neoadjuvant anastrozole were interrogated. Immunohistochemical 
staining using antibodies against PDGFRa, b and Abl was assessed 
in paired clinical specimen of 45 patients who had received an AI and 
presented progressive disease. Proliferation assays, immunoblots and 
ChIP assays were carried out using either the PDGFR/Abl inhibitor 
nilotinib or siRNA knockdowns in LTED and wild-type MCF7 cells.
Results: In vitro: PDGFRb and Abl expression and phosphorylation 
were elevated in LTED cells. Cell proliferation was decreased in 
LTED cells by siRNA knock-down of either PDGFRb (50% p<0.01), 
Abl (40% p<0.01) or the combination (70% p<0.01). Inhibition of Abl 
activity using nilotinib decreased ER protein levels and suppressed 
ER-mediated transcription by reducing recruitment of AIB1 and CBP 
to the promoter of E-responsive genes TFF1 and GREB1. Clinical: 
Data from 81 patients treated with an AI in the neoadjuvant setting, 
showed increases in PDGFRb gene expression after two weeks 
(1.25 fold, p=0.003). Low PDGFRb at baseline was associated 
with a better response. Of note, paired pre-AI-treatment and relapse 
clinical specimens from a cohort of patients treated in the primary or 
advanced setting revealed increases in tumor protein expression of 
PDGFRa (1.39 fold, p=0.0065), PDGFRb (4.32 fold, p=0.006) and 
Abl (1.8 fold, p=0.001) at the point of relapse. Tumor (T) and stromal 
(S) expression of PDGFRa as well as PDGFRb was significantly 
correlated in pre-treatment and relapse samples (Table 1).
Table 1. PDGFR correlations
 Pre-treatment  Relapse  
 Rs p Rs p
T-PDGFRa vs S-PDGFRa 0.614 (0.377-0.776) <0.001 0.533 (0.298-0.734) <0.001
T-PDGFRb vs S-PDGFRb 0.307 (0.006-0.557) 0.046 0.527 (0.268-0.715) <0.001
High post-treatment tumor and stromal PDGFRb levels were 
associated with a short time to treatment failure (TTF) (T: Rs -0.284, 
p=0.066; S: Rs -0.307, p=0.046). Expression of PDGFRa in relapsing 
tumor specimens was correlated with Abl expression (Rs 0.342, 
p=0.027) and Ki67 levels (Rs 0.39, p=0.01). Furthermore, changes 
in Abl correlated significantly with changes in ER expression (Rs 
0.307, p=0.048).
Discussion: These in vitro and clinical data support a biological 
interaction between PDGF/Abl and ER-signaling and suggest that the 
PDGF signaling pathway warrants clinical evaluation as a therapeutic 
target in endocrine resistant breast cancer.
P4-01-02
Endocrine Resistance: Mechanism, Tumorigenic Capacities, and 
New Therapeutic Strategies.
Morrison GD, Fu X, Ithimakin S, Rimawi MF, Wicha MS, Osborne 
CK, Schiff R. Baylor College of Medicine, Houston, TX; University 
of Michigan, Ann Arbor, MI
Background: Endocrine therapy is the most effective therapies for 
estrogen receptor positive (ER+) breast cancer, but resistance is still a 
major clinical problem. Tumor initiating cells (TICs) in drug resistant 
tumors are believed to be part of the contributing factors for tumor 
relapse. Here we focused on the TICs and how they are related to 
HER2 expression and its downstream factors in acquired endocrine 
resistance models.
Materials and Methods: We have established a panel of endocrine 
resistant cell models through long-term treatment with tamoxifen 
(Tam, 10-7M, >6 months). Resistance to tamoxifen treatment in cells 
(TamR) was confirmed by growth curve assays (Celigo, Cyntellect 
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Inc., San Diego, CA). In vitro mammosphere assays were applied to 
assess the mammosphere forming ability of parental and resistant 
cells. Aldefluor assays (StemCell Technology) were performed to 
measure the aldehyde dehydrogenase (ALDH-1) expressing cell 
population as a marker of TICs. Flow analysis was performed to 
evaluate HER2 expression in the ALDH subpopulations of both 
parental and TamR cells. Immunofluorescence staining was further 
used to detect the expression of ER, HER2, phosphorylated STAT3, 
and b-catenin in sorted ALDH+/- subpopulations.
Results: We found that endocrine resistant cells have a higher 
mammosphere forming ability than their parental counterparts. In 
addition, we showed that the ALDH+ subpopulation was significantly 
upregulated in all TamR derivative lines.
% ALDH+ populations in parental cell lines and their endocrine resistant derivatives
Cell line Parental TamR
MCF7L 1.2±.8 5± 2
ZR75-1 3±1 6±.6
BT483 2.2±.8 12±1.2
T47D .5±.2 39±.5
UACC812 2.2±.4 6.5±2
BT474* 46.4 74.4
Further analysis of the ALDH populations indicated that HER2, as 
well as downstream survival factors such as pSTAT3s727 and b-Catenin, 
are upregulated in the ALDH+ populations as compared to the ALDH- 
population, especially in TamR derivatives.
Discussion: Our data suggest that deregulated HER or other growth 
factor receptor signaling can potentially lead to the enrichment of 
TICs as a potential contributor to endocrine resistance. We will further 
investigate the role and molecular signaling of TICs in endocrine 
resistance of breast cancer, as well as whether and to what extent 
more potent anti-HER inhibitors can improve endocrine sensitivity 
and circumvent resistance.
P4-01-03
Establishment and Characterization of an Endocrine Resistance 
Model In Vitro and In Vivo by Inducible PTEN Knockdown.
Fu X, Shea M, Biswal NC, Mitchell T, Giuliano M, Healy NA, 
Meerbrey KL, Joshi A, Westbrook T, Hilsenbeck SG, Osborne 
CK, Schiff R. Baylor College of Medicine, Houston, TX; National 
University of Ireland, Galway, Ireland
Background: Growth factor receptor and estrogen receptor (ER) 
are two major driving pathways for initiating and sustaining breast 
cancer (BC) development and progression. We have previously shown 
that an inverse correlation exists between the PI3K pathway and 
ER expression/activity in luminal type BCs. High PI3K activation 
signaling correlates to the luminal B subtype of BC with low ER 
expression/activity. However, the involvement of the PI3K pathway 
tumor suppressor PTEN in resistance to endocrine therapy is less 
clear. Here we attempt to develop an experimental system to better 
understand the role of PTEN in this resistance.
Materials and Methods: Two luminal BC cell lines, MCF7L and 
ZR75-B, were stably infected with a lentivirus pINDUCER (Meerbrey 
et al., PNAS, 2011), containing Tet-on responsive shPTEN, turboRFP 
(tRFP) as an inducible tag, and enhanced GFP (eGFP) as a constitutive 
expressed tag for positive cells selection. Immunoblotting of PTEN, 
phosphorylated (p) Akt, pMAPK, pc-Jun, ER, and ER’s downstream 
gene products (PR, IGF-1R) was performed on cells after 6 days of 
doxycycline (Dox) incubation. After pre-starvation for 5 days in 
estrogen deprivation (ED) conditions, the cells -/+ Dox were subjected 
to induction with estrogen (E2) or to endocrine treatment [continued 
ED, tamoxifen (Tam, 10-7M), or fulvestrant (Ful, 10-7M)] in 96-well 
plate format for 9 days. In situ cell cytometry (Celigo, Cyntellect Inc., 
San Diego, CA) was applied to count the cell number by scanning 
the same 96-well plate every other day. Ovariectomized nude mice 
bearing MCF7L-shPTEN xenografts, established in the presence of 
E2 supplementation, were randomized to minus and plus Dox groups, 
with each treatment group continuing E2 or endocrine therapies (ED, 
Tam, or Ful). The in vivo GFP/RFP imaging was performed with a 
home-built cooled and image intensified CCD camera system.
Results: Immunoblot analysis showed a striking loss of PTEN, and 
significant upregulation of pAkt, as well as pMAPK and pc-Jun 
in cells with +Dox. In contrast, levels of ER, PR and IGF1R were 
reduced in cells with +Dox compared to -Dox. In all -Dox groups, 
cell growth was significantly reduced in endocrine treated groups 
compared to the E2 group, whereas +Dox rescued the endocrine 
treatment growth suppression, especially in ED and Tam groups. In 
vivo induction of PTEN shRNA expression was confirmed by RFP 
imaging after feeding the mice with +Dox water. MCF7L-shPTEN 
xenografts randomized to +Dox under ED conditions continued to 
grow over 4 weeks, in contrast to the marked regression of control 
tumors (-Dox) under this endocrine regimen (p<0.05). Comparison 
between plus and minus Dox groups under E2, Tam, or Ful treatment 
is ongoing.
Discussion: These data further support the existence of crosstalk 
between PI3K and ER pathways in luminal type BC. Decreasing 
PTEN levels by shRNA renders the luminal type BC cells de 
novo resistant to endocrine therapy both in vitro and in vivo. The 
pINDUCER PTEN knockdown system combined with live animal 
imaging offers successful real-time, noninvasive tracking of endocrine 
sensitivity by controllably manipulating the level of target gene. 
Combination therapies to overcome endocrine resistance under PTEN 
knockdown conditions are currently underway.
P4-01-04
Effects of CYP2D6 Phenotype and Drug Adherence on Tamoxifen 
Metabolite Levels.
Sousa BA, Nasim S, Cole DE, Wong BY, Hill K, Pritchard KI, Trudeau 
M, Verma S, Dent RA, Petrella T, Gandhi S, Ueng S, Vandenberghe 
U, Romaschin A, Warner E. Sunnybrook Health Sciences Odette 
Cancer Centre, Toronto, ON, Canada; Li Ka Shing Research Institute, 
Biochemistry, Toronto, ON, Canada
Background: Although the activity of cytochrome P450 2D6 
(CYP2D6), the enzyme responsible for conversion of tamoxifen 
(TAM) to its most important active metabolite endoxifen, varies 
significantly with genotype. Routine genotype testing in patients 
on TAM has recently been discouraged. Conflicting results in 
publications regarding the prognostic utility of this test remain 
unexplained. Confounding factors could be lack of predicted 
correlation between CYP2D6 genotype and TAM active metabolites, 
or variability of patient compliance
Methods: Consecutive breast cancer patients on TAM were 
asked to enroll in a study to examine the relationship between 
CYP 2D6 phenotype, patient-reported treatment adherence, and 
TAM metabolites levels. Patients were genotyped for CYP2D6 
polymorphisms using long-range PCR allele-specific amplification 
and single-nucleotide primer extension assay. From the genotypes, 
four phenotype groups were defined: Ultra rapid Metabolizer 
(UM), Extensive Metabolizer (EM), Intermediate Metabolizer (IM) 
and Poor Metabolizer (PM). Plasma was collected after at least 6 
weeks of TAM (20 mg daily). The parent drug TAM, as well as 
4-hydroxy N-desmethyl tamoxifen (endoxifen), 4 hydroxy tamoxifen 
(4OHtam) and N-desmethyl-tamoxifen (NDtam), were determined 
by Liquid Chromatography tandem mass-spectrometry (LC-MS/
MS). Patients also completed a questionnaire about ethinicity, side 
effects, concurrent medications and tamoxifen adherence. Correlation 
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between metabolite/TAM ratio and phenotype was tested by Spearman 
correlation test. Relationship between metabolite levels and adherence 
was tested by Wilcoxon rank sum test. Chi square test was used to 
compare proportions.
Results: Of the 100 patients enrolled there were 62 Caucasians, 25 
Asians, 4 Africans and 6 Unknown. We found a strong correlation 
between ratio of endoxifen/TAM and phenotype (p <.0001) (Table 
1) Over a 2 week period 68 never missed a TAM dose, 25 missed 
1-2 times, 2 missed 3-5 times and 2 > 5times (2 missing data). In 
EM group we found significantly lower levels of TAM (p <.0001), 
NDtam (p=.008), 4OHtam (p=.003) in less adherent patients. A 
trend to decreased levels was also shown for endoxifen (p=.081). No 
associations were found between adherence or phenotype activity 
and side effects.
Table 1.Summary of phenotype and plasma metabolite concentrations
CYP2D6 Phenotype / Metabolite (ng/ml) UM(n=4) EM(n=79) IM(n=12) PM(n=4) p value
Endoxifen 33.3 19.8 10.5 5.1 <.0001
4OHtam 3.9 2.6 2.1 1.9 .001
NDtam 432.7 455.7 634.5 688 .005
TAM 321.2 268.2 269.5 309 .9
Ratio Endoxifen/TAM 0.1 0.07 0.04 0.02 <.0001
Ratio 4OH/TAM 0.001 0.01 0.009 0.01 .08
Ratio NDtam/TAM 1.3 1.7 2.4 2.3 <.0001
Conclusions: Our data suggests the predicted association between 
endoxifen levels and genotype. However, non-adherence may have 
a significant confounding effect. Prospective studies to evaluate 
the prognostic impact of CYP2D6 variants for patients on adjuvant 
tamoxifen should be done but results could be confounded by variable 
drug adherence if this is not measured concurrently.
P4-01-05
The Multikinase Inhibitor Sorafenib Can Overcome Antiestrogen 
Resistance in Patients with Progressive Metastatic Estrogen 
Receptor (ER) Positive Breast Cancer.
Moss J, Black EP, Wang C, Li L, Sloan S, Lye A, Romond E, Weiss 
H, Massarweh S. University of Kentucky and Markey Cancer Center, 
Lexington, KY
Background: Resistance to antiestrogens is a major problem in 
metastatic breast cancer. Preclinical data suggest that growth factor 
signaling and angiogenesis may promote endocrine resistance and 
blocking such pathways may delay resistance.
Methods: We conducted a phase II clinical trial of adding sorafenib, 
a VEGFR and Ras/Raf/MAPK inhibitor, to antiestrogen therapy in 
patients with metastatic ER-positive breast cancer. Patients were 
required to have progressive disease on an anstiestrogen or have 
maximum response with residual measurable disease. A core biopsy 
of accessible breast disease was offered at entry and after 28 days of 
sorafenib. Microarray experiments were performed on frozen tissue 
obtained from 4 paired biopsies using Affymetrix Gene Chip HG-
U133 Plus 2. Data was normalized based on the GCRMA method 
and Expression values of each gene were analyzed based on the 
significant analysis of microarray (SAM) method for paired data. 
Gene set analysis on KEGG pathways was performed using the gene 
set enrichment analysis (GSEA) method, where genes were ranked 
based on the absolute values of their SAM test statistics. Serum was 
collected on day 1 and day 28 for biomarker comparison using ELISA. 
Primary study endpoint was response rate by RECIST criteria after 
3 months of sorafenib and secondary endpoints were safety, time to 
progression (TTP), and biomarker assessment.
Results: Planned sample size was 43 but the study closed after 11 
patients because of slow accrual. Median age was 45 years (Range 
39-72). 7 patients were on tamoxifen, 3 on an aromatase inhibitor, 
and 1 on fulvestrant. Of the 11 patients enrolled, 8 had progressive 
disease (PD) on entry and 3 had confirmed stable disease (SD) 
on antiestrogen alone. One patient with SD at entry discontinued 
sorafenib after 2 weeks because of a grade 3 rash. Of the 10 patients 
evaluable for response, 7 had SD (70%) and 3 had PD. Median 
TTP after adding sorafenib was 182 days (6 months) and in the 8 
patients who entered the study with PD, 5 converted to SD (62%) 
with a median TTP of 192 days (6.4 months). One patient remains 
on treatment after 16 months of enrollment. Most common adverse 
events were rash in 9 patients, weight loss in 8 and hypertension in 
6. Hypophosphatemia was seen in 11 patients, hypokalemia in 9, 
and elevated ALT/AST in 4. The majority of toxicities were grade 1. 
There were 6 grade 3 toxicities; rash, anorexia, hypokalemia, colitis, 
and 2 hypophosphatemia. No grade 4 toxicities occurred. Microarray 
analysis identified 29 enriched pathways with a false discovery rate 
of less than 25%. There was a significant reduction in mean serum 
Transforming growth factor beta (TGF-b) and platelet derived growth 
factor receptor alpha ( PDGFR-a) on day 28 (P values= < 0.0001 and 
0. 0.017, respectively). Tissue and serum biomarker correlates will 
be presented in detail at the meeting.
Conclusions: Sorafenib can overcome resistance to antiestrogens, 
particularly tamoxifen, and may help avoid the routine early use 
of chemotherapy for endocrine resistant disease. Further study of 
strategies to overcome endocrine resistance is warranted to help 
preserve patient quality of life and to investigate mechanisms of 
resistance.
P4-01-06
Global Characterization of the SRC-1 Transcriptome Identifies 
Disintegrin C as an ER-Independent Mediator of Endocrine 
Resistant Breast Cancer.
Bolger JC, McCartan DP, McIlroy M, Byrne C, Fagan A, Xu J, 
O’Gaora P, Hill ADK, Young LS. Royal College of Surgeons in 
Ireland, Dublin, Ireland; University College Dublin, Dublin, Ireland; 
Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, 
TX
Background: The development of breast cancer resistance to 
endocrine therapy results from an increase in cellular plasticity leading 
to the development of a steroid independent tumour. The p160 steroid 
coactivataor protein SRC-1 drives this tumour adaptability. SRC-1 is 
central to the development of the endocrine resistant phenotype and is 
an independent predictor of disease free survival in tamoxifen-treated 
patients. Here, using discovery studies we identify Disintegrin C 
(DC), a multidomain transmembrane glycoprotein as a direct, ER-
independent target of SRC-1.
Methods: SRC-1-ChIP sequencing was performed in endocrine 
resistant (LY2) cells. Microarray experiments were performed on 
LY2 cells transfected with scrambled siRNA or SRC-1 siRNA, +/- 
4-OHT to assess SRC-1-dependent gene expression. Combining the 
ChIP-seq and expression array datasets, a total of 2,065 genes were 
significantly downregulated (p<0.05) following SRC-1 knockdown. 
DC was selected for validation as a potential novel metastatic 
oncogene. DC transcipt levels were measured following knockdown 
and over-expression of SRC-1 and ERa. Mouse xenograft and SRC-
1 knockout models were used to examine DC expression in vivo. 
A TMA comprising 560 patients was stained for DC. Functional 
validation studies were performed using 3D culture and migration 
assays, with transient knockdown of DC and treatment with JC1, an 
inhibitory peptide against DC.
Results: Treatment with 4-OHT significantly increased the number 
of ChIP-enriched intervals identified. The majority of peaks in the 
4-OHT treated sample were close to the transcriptional start site, in 
the promoter, first exon or upstream of the promoter. As a defined 
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ER coactivator, an overlap between ER binding sites and those 
identified for SRC-1 is expected. 43% of high confidence SRC-1 
peaks in 4-OHT-treated LY2 cells contained an ERE binding motif. 
This raises the possibility that, in endocrine resistance, SRC-1 can 
drive transcription independent of ER. Treatment with 4-OHT resulted 
in substantial recruitment of SRC-1 to the DC promoter. In primary 
tumours there was a significant association between transcript levels 
of SRC-1 and DC. Cells derived from mammary tumours of the 
SRC-1-/-/PyMT mouse lacked DC, but there was high expression 
in the wild type PyMT mouse. Knockdown of ERa in LY2 cells did 
not alter DC expression. Knockdown of DC reduced cell migration 
and restored cell differentiation in resistant cells. In xenograft studies 
treatment with 4-OHT increased tumour volume in the resistant 
tumours and induced DC expression. Treatment with recombinant 
JC1 reduced cellular migration in endocrine resistant cells. Kaplan 
Meier estimates of disease free survival show that DC is a strong 
predictor of disease free survival in breast cancer (p<0.0001). SRC-1 
and DC are significant independent predictors of disease recurrence 
(odds ratios 2.18 and 2.4).
Conclusion: Our discovery studies have uncovered a steroid 
independent SRC-1 mediated network in endocrine resistant breast 
cancer. We identified a new SRC-1 target, DC. DC represents a 
rational new therapeutic target with a robust companion biomarker 
for treatment of endocrine resistant tumours.
P4-01-07
Combining Hedgehog Inhibitor, GDC-0449 with Tamoxifen 
Overcomes Tamoxifen-Resistance in In-Vitro and In-Vivo Studies 
of Estrogen-Receptor Positive Breast Cancer.
Majumder S, Lu Y, Teng K-Y, Kaffenberger T, Zhang X, Nuovo G, 
Love RR, Ramaswamy B. The Ohio State University, Columbus, OH; 
International Breast Cancer Research Foundation, Madison, WI
Aims: Approximately 30-40% of patients with estrogen receptor 
positive (ER+) invasive breast cancer relapse despite targeted 
endocrine therapy with tamoxifen. Dependency of ER+ breast tumors 
shifts from estrogen to alternative cell survival mechanisms aberrantly 
activated over time facilitating drug-resistance and survival. We have 
identified Hedgehog (Hhg) signaling pathway as one such alternative 
pathway of survival activated in ER+ tumors that are resistant to 
tamoxifen. We sought to determine if treating such tumors with Hhg 
inhibitor and tamoxifen would improve outcomes.
Methods: Using MCF7 cell lines that are either sensitive (parental) 
or resistant to tamoxifen (4-hydroxy tamoxifen resistant-OHTR) and 
other ER+ cell lines, expression of Hhg markers (SHH, PTCH, SMO, 
GLI1, GLI2 and GLI3) and Hhg targets (SNAIL, MYC, BMI1 and 
FOXM1) was analyzed by Real-time RT-PCR, Western blotting and 
immunocytochemistry. GLI1 transactivation potential was measured 
using 8XGLI-Luciferase reporter plasmid. GLI1 was depleted in 
OHTR and T47D cells using GLI1siRNA. The GLI1 depleted cells 
were exposed to tamoxifen and assessed for i) cell viability by MTT 
assay, ii) extent of apoptosis by TUNEL assay and PARP/Caspase 
cleavage (Western blot), iii) cell cycle profile by flow cytometry 
and iv) presence of tumor initiating cells (TICs) by mammosphere 
formation assay. Effect of GDC-0449, a small molecule inhibitor 
of SMO was tested on OHTR cell induced xenografts in athymic 
nude mice by monitoring tumor growth and distant metastasis. 
Correlation of GLI1 expression in primary breast tumor tissues 
(assessed by immunohistochemistry) and disease-free interval was 
studied in women enrolled on an ongoing clinical trial (OSU 0483) in 
premenopausal women with ER+ breast cancer undergoing adjuvant 
oophorectomy and tamoxifen.
Results: Expression of Hhg signaling molecules and the targets 
are significantly activated in OHTR cells resistant to 0.5 and 1mM 
tamoxifen. Serial passage of the resistant cells in mice resulted in 
aggressive transformation of tumors that micro-metastasized to lung 
and liver. Concurrent increase in Hhg marker expression, TICs and 
acquisition of epithelial mesenchymal transition were observed in the 
cells derived from these tumors. Depletion of GLI1 in OHTR cells 
resulted in reduced proliferation, colony formation and mammosphere 
formation and increased apoptosis in presence of tamoxifen. 
Treatment of OHTR cells with GDC-0449 and tamoxifen inhibited 
cell proliferation in vitro and supressed tumor growth and distant 
metastasis of tamoxifen resistant xenografts in mice. Primary human 
breast tumors expressing higher level of GLI1 demonstrated a trend 
towards increased risk of recurrence (p= 0.08) after tamoxifen therapy.
Conclusions: Our work has demonstrated for the first time that 
activated Hhg signaling is an alternate survival mechanism for 
tamoxifen resistant breast cancer. Furthermore, targeting these tumors 
with a combination of tamoxifen and anti-Hhg therapy inhibited 
tumor growth and development of distant metastases demonstrating 
efficacy of this approach. Clinical trials using this combination in 
patients with advanced ER+ breast cancer are warranted and are 
under development.
P4-01-08
The Role of Ser991 PELP1 Phosphorylation in Therapy 
Resistance and Metastasis of Breast Cancer.
Sareddy GR, Nair BC, Krishnan SR, Gonugunta VK, Vadlamudi RK. 
UTHSCSA, San Antonio, TX
BACKGROUND: Growth factor induced activation of MAPK 
pathway is suggested to play a critical role both in invasive and 
hormone therapy resistant breast cancer via ligand independent 
activation of ERa. Proline Glutamic acid Leucine Rich Protein 
(PELP1) is a well established ER-coregulator that plays a critical 
role in ER’s nuclear and extra-nuclear functions. PELP1 functions 
as a proto-oncogene and deregulation of PELP1 expression is linked 
to increased proliferation, metastasis and therapy resistance. The 
objective of this study is to examine, whether growth factor signaling 
modulates PELP1 mediated ER coactivation functions via MAPK 
pathway.
METHODS: Bioinformatics and phosphopeptide specific antibodies 
were employed in this study. In vitro kinase assays and MAPK 
inhibitors were used to confirm MAPK phosphorylation of PELP1. 
Site directed mutants and ERE reporter gene assays were used to 
demonstrate the significance of MAPK site in PELP1. Growth factor 
and estrogen regulation of PELP1 phosphoryaltion at Ser991 was 
validated in therapy sensitive (MCF7, ZR75) and resistant (MCF-7 
HER2, MCF7-Tam and MCF-7Ca-LTLT cells using PELP1 specific 
phosphoantibody. Breast cancer model cells stably expressing PELP1 
mutant or PELP1 peptides encompassing MAPK phosphorylation 
was used to test the significance of this MAPK site in PELP1 using 
proliferation, migration, and invasion assays. IHC analysis using 
PELP1 phospho antibodies was performed using murine xenograft 
tumors and human breast tumor arrays (TMA).
RESULTS: Growth factors (EGF, Heregulin) induced Ser991 
phosphorylation of PELP1 in murine mammary epithelial cells 
and also in human breast cancer cell lines. Growth factor mediated 
Ser991PELP1 phosphorylation was abrogated by ERK1/2 MAPK 
pathway inhibitors including PD98059 and U0126. In ERE-reporter 
luciferase assays using ZR75 cells, PELP1 (WT) but not the ser991Ala 
mutant of PELP1 corroborated growth factor-ER crosstalk. Therapy 
resistant model cells (MCF-7-Tam, MCF-7-LTLT-ca and MCF-7-
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HER2) exhibited enhanced Ser991PELP1 phosphoryation compared to 
parental MCF7. TAT-Peptide encompassing Ser991 inhibited growth 
factor mediated phosphorylation of PELP1 and revealed a potent 
ability to inhibit the growth of therapy resistant cells. Xenograft 
tumors of hormone therapy model cell lines showed increased 
Ser991PELP1 phosphorylation and enhanced nuclear localization 
compared to hormonal sensitive xenograft tumors. IHC analysis 
of human breast invasive TMA revealed enhanced PELP1 ser991 
phosphorylation in advanced metastatic tumors with prominent 
nuclear/nucleolar localization compared to normal and benign tumors.
CONCLUSIONS: In this study, we identified that growth factor-
MAPK pathway modulate ER coregulator PELP1 functions via 
phosphorylation and demonstrated that Ser991 phosphorylation 
of PELP1 has the potential to govern the growth Factor-ER cross 
talk leading to therapy resistance and metastatic phenotype of 
breast cancer. Peptides encompassing Ser991PELP1 site and Phospho-
antibodies targeting Ser991 represent a novel therapeutic target and 
diagnostic markers in breast cancer. Supported by DOD Fellowship 
W81XWH-09-1-0010 (BCN) and DOD W81XWH-08-1-0604 (RKV)
P4-01-09
Reduced CYBA Expression Leads to the Development of 
Fulvestrant Resistance in a Breast Cancer Cell Line.
Skerry BJO, Ramsahoye BH. The University of Edinburgh, Edinburgh, 
United Kingdom
Background: Acquired resistance to endocrine therapy is an 
important problem in the management of advanced breast cancer. In 
this study we used a cell line model to investigate the evolution of 
fulvestrant resistance. We examined gene expression and promoter 
methylation in estrogen-dependent MCF7 cells and compared two 
derived cell lines, estrogen-hypersensitive LCC1 and fulvestrant-
resistant LCC9, using array technology. Thus we determined 
the epigenetic changes associated with the evolution of estrogen 
independence and fulvestrant resistance, which revealed a role for 
CYBA/p22phox in the acquisition of resistance.
Material and Methods: Estrogen-dependent gene expression was 
measured in MCF7, LCC1 and LCC9 cells using Illumina HT-12 
microarrays. In parallel, differential methylation between MCF7, 
LCC1 and LCC9 cells was examined using Illumina Infinium 
methylation 27 arrays.
Results: Despite marked physiological differences between MCF7, 
LCC1 and LCC9 cells there were few genes which were both 
differentially methylated and differentially expressed. However, 
CYBA was underexpressed in LCC1 (p<10-5) and LCC9 (p<10-
4) and had a methylated promoter in LCC1 (p<10-5) and LCC9 
(p<10-4), with reduced expression correlated to increased estrogen 
independence. This gene codes for the protein p22phox, a critical 
component of membrane NADPH oxidase. We verified expression 
by qRT-PCR and Western blot, and methylation by CpG island 
bisulphite sequencing, demonstrating significant and biologically 
relevant changes. Fulvestrant resistant LCC9 cells exhibited a 20-fold 
reduction in CYBA expression compared to MCF7, corresponding to 
undetectable levels of p22phox. Due to its role in the generation of 
reactive oxygen species (ROS), we investigated the cellular response 
to oxidant damage, finding that LCC9 cells showed reduced sensitivity 
to oxidant damage when compared to MCF7 (p<10-7), in keeping 
with impaired NADPH oxidase function. We then treated MCF7 
cells with a ROS scavenger, N-acetyl cysteine, which reduced their 
sensitivity to fulvestrant (p<10-13). Using siRNA, we knocked down 
CYBA expression, which conferred slight fulvestrant resistance on 
MCF7 cells, mitigating fulvestrant-induced growth arrest (p<10-7).
Discussion: The striking differences in methylation in the CYBA 
promoter and gene expression between these cell lines lead us to 
conclude that the repression of this gene represents an important 
step in the development of fulvestrant resistance. As these cells 
develop estrogen independence and fulvestrant resistance, CYBA/
p22phox levels drop, making the cells more resistant to oxidant 
damage caused by estrogen deprivation and, ultimately, providing 
a selective advantage against fulvestrant-induced growth arrest and 
cell death. CYBA/p22phox may represent a novel druggable target in 
breast cancer, either in the prevention of the acquisition of fulvestrant 
resistance, or the further treatment of resistant tumours.
P4-01-10
The Role of the Steroid Receptor Coactivator SRC1 and Its 
Functional Partner HOXC11 in the Development of Endocrine 
Resistant Breast Cancer.
Walsh CA, McCartan D, Hill ADK, Young LS. Royal College of 
Surgeons in Ireland, Dublin, Ireland
Background: The steroid receptor coactivator; SRC1, has been well 
described in the development of endocrine resistant breast cancer. 
SRC1 associates with clinically aggressive tumours and promotion 
of distant metastasis. It directly interacts with the developmental 
transcription factor, HOXC11 and together they are found to strongly 
predict poor disease-free survival in breast cancer patients (hazard 
ratios: 5.79; P < 0.0001). In this study, we investigate the mechanism 
of SRC1 and HOXC11 action in tumour adaptability and subsequent 
resistance to endocrine therapy.
Materials and Methods: Cells which are resistant to tamoxifen (LY2s) 
have enhanced SRC1 and HOXC11 mRNA and protein expression 
in comparison to their endocrine sensitive parent cells (MCF-7s). 
ChIP-sequencing data for SRC1- and HOXC11- DNA interactions 
in conjunction with DNA microarray and RNA-sequencing data 
identified potential signalling targets at play in the LY2 model 
of endocrine resistance. Real-time analysis and flow cytometry 
confirmed these interactions at a transcriptional and protein level. 
These observations were further confirmed in primary breast cancer 
cultures using flow cytometry.
Results: SRC1 and HOXC11 interactions are driven in tamoxifen 
treated LY2 resistant cells. Combined SRC1 ChIP-sequencing 
and expression array data analysed in conjunction with HOXC11 
ChIP-sequencing and RNA-sequencing data reveal that the SRC1/
HOXC11 transcriptional process can orchestrate the loss of luminal 
cell markers such as ERa, CD24 and PTCH1 whilst concomitantly 
upregulating mediators of tumourigenicity such as CD44 and MSI2. 
Primary breast cancer cultures confirm the loss of CD24 in tamoxifen 
resistant patients. In these patients, loss of CD24 was accompanied 
by loss of steroid receptor expression (ERa and PR) and by a gain 
of the basal marker CD44.
Discussion: Here, we describe a new signalling pathway where SRC1 
and HOXC11 regulate two distinct but complementary mechanisms 
to drive tumour adaptability. Silencing of luminal cell markers and 
a concomitant increase in a basal cell phenotype has the potential to 
alter the survival mechanism of breast cancer cells to evade targeted 
therapy.
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011427s
December 6-10, 2011 Abstracts: Poster Session 4
P4-01-11
Autocrine Human Growth Hormone (hGH) Reduces the 
Sensitivity of Breast Cancer Cells to Treatment with Tamoxifen 
and Fulvestrant.
Perry JK, Chen H, Bougen NM, Liu D-X, Lobie PE. University of 
Auckland, Auckland, New Zealand; National University of Singapore, 
Singapore
Despite recent advances in breast cancer treatment regimes, intrinsic 
or development of resistance to conventional breast cancer therapies 
is still a significant clinical challenge. Expression of growth factors 
by tumour cells has been proposed as one mechanism for developing 
resistance to radiotherapy and chemotherapeutic agents.
The growth hormone/insulin-like growth factor-1 axis is emerging as 
an important mediator of tumour development in human breast cancer. 
Recent studies have demonstrated that humans with growth hormone 
receptor deficiency are protected from developing cancer. Studies 
investigating human growth hormone (hGH) expression in human 
breast cancer have demonstrated that hGH expression is associated 
with specific histopathological features and survival outcomes for 
patients. Increased hGH expression is significantly associated with 
lymph node metastasis, tumour stage, proliferative index, worse 
relapse free survival and reduced overall survival in mammary 
carcinoma. In recent studies we have demonstrated that autocrine hGH 
promotes cell proliferation, cell survival and oncogenicity of human 
mammary carcinoma cells, enhancing anchorage independent cell 
growth, and supporting tumour formation in immunodeficient mice. 
Autocrine hGH also promotes mammary carcinoma cell migration/
invasion and epithelial to mesenchymal transition and tumour 
vascularisation in xenograft studies.
In this study we investigated whether autocrine hGH promotes 
resistance to anti-estrogen therapeutic drugs, sensitivity to tamoxifen 
and fulvestrent using the human breast cancer cell lines MCF-7, T47D 
and BT474. Stable transfection with an expression vector containing 
the hGH gene enhanced MCF-7, T47D and BT474 cell viability, total 
cell number and anchorage independent growth following treatment 
with tamoxifen or fulvestrant when compared to control transfected 
cells. Conversely, treatment of BT474 cells with an hGH receptor 
antagonist (B2036), increased BT474 cell sensitivity to treatment 
with tamoxifen or fulvestrant. Using an estrogen response element 
(ERE) luciferase assay, we observed that autocrine hGH enhanced 
basal estrogen receptor (ER)-mediated transcriptional activity.
Our results demonstrate that forced expression of hGH in mammary 
carcinoma cells enhances ER-mediated signal tranduction and 
promotes resistance to tamoxifen and fulvestrant, while functional 
antagnonism of hGH increased cell sensitivity. Consequently, 
antagonism of the hGH receptor may help maintain sensitivity to 
anti-estrogen therapy and improve the prognosis of patients with 
hormone sensitive breast cancer.
P4-01-12
The Unfolded Protein Response (UPR) and Pro-Survival 
Autophagy Contributes to Antiestrogen Resistance in Breast 
Cancer.
Clarke R, Shajahan AN, Cook KL, Hickman FE, Facey CO. 
Georgetown University, Lombardi Comprehensive Cancer Center, 
Washington, DC
In 2011, most of the 192,000 newly diagnosed cases of invasive 
breast cancer will be estrogen receptor alpha positive (ER+). 
Endocrine therapy, administered as an antiestrogen, e.g., Tamoxifen 
(TAM) or Faslodex (FAS; Fulvestrant; ICI 182,780) or an aromatase 
inhibitor (AI), e.g., Letrozole or Exemestane is the least toxic and 
most effective means to manage the hormone-dependent breast 
cancer in such patients. However, resistance to endocrine therapy 
remains a significant clinical problem. Previously, we have shown 
that antiestrogen resistant breast cancer cells over-express X-Box 
Binding Protein 1 (XBP1), a transcription factor that belongs to the 
basic region/leucine zipper (bZIP) family. XBP1(U) and XBP1(S) 
variants result from an unconventional splicing of the XBP1 
mRNA by IRE1alpha. In the unfolded protein response (UPR), 
endoplasmic reticulum proteins (IRE1alpha, ATF6 and PERK) 
sense cellular stress to regulate the accumulation of unfolded 
proteins. Initially a compensatory mechanism allowing cells to 
recover normal endoplasmic reticulum function, prolonged UPR 
may induce cell death; this is often dependent upon which arm of 
the UPR predominates. XBP1 is an obligate component in both the 
IRE1alpha and ATF6 arms of the UPR. In this study, we show that 
in MCF7/LCC9 [FAS resistant; TAM cross-resistant] cells, there is 
an increase in UPR signaling as detected by increased expression 
of BiP/GRP78. Transient expression of XBP1(S) in MCF7/LCC1 
[antiestrogen sensitive] cells show decreased sensitivity to FAS 
that correlated with increased levels of both basal and FAS-induced 
autophagy as measured by cleaved LC3BII protein fragment, GFP-
LC3 activity, and reduced expression of p62/SQSTM1. Furthermore, 
we show that MCF7/LCC9 cells survive by activating pro-survival 
autophagy through UPR that is regulated by the transcription factor 
c-MYC. An inhibitor of c-MYC, 10058-F4, synergized with FAS 
to inhibit proliferation in MCF7/LCC9 cells by preventing pro-
survival autophagy and increasing apoptosis. Thus, our study shows 
that antiestrogen resistant breast cancer cells evade cell death by 
activating XBP1-mediated UPR that results in c-MYC-mediated 
prosurvival autophagy.
P4-01-13
Biology of Aggressiveness and Tamoxifen Resistance in Hormone 
Receptor-Positive Very Young Age Breast Cancer.
Han W, Ro J, Jung S. Seoul National University Hospital, Seoul, 
Korea; National Cancer Center, Goyang, Kyungi, Korea
It has been known that young breast cancer patients have worse 
outcomes compared with older premenopausal or postmenopausal 
patients. Survival difference between young and older breast cancer 
patients is evident only in hormone receptor positive breast cancer 
regardless of tamoxifen treatment according to our previous report. 
However, the biology of aggressiveness and endocrine resistance of 
breast cancer in very young women is largely unknown. The purpose 
of this study is to find molecular characteristics of hormone receptor 
positive breast cancers of very young age women (<35) compared 
with those of older premenopausal women.
We extracted mRNA from fresh frozen hormone receptor positive 
primary breast cancer tissues of 24 young age breast cancer patients 
(<35 years) and 31 older premenopausal women (40 to 49 years) 
by standard method. All tumor specimens analyzed contained more 
than 50% tumor cells. Hormone receptor status was determined 
by immunohistochemistry (IHC). Gene expression microarray 
experiment was done in the 55 samples using Illumina HumanRef-8 
v3 Expression BeadChip (Illumina, Inc., San Diego, CA). Functional 
and pathway analysis of differentially expressed genes were done 
using DAVID (http://david.abcc.ncifcrf.gov/home.jsp) and Ingenuity 
pathway analysis (IPA, http://www.ingenuity.com). Ki-67 assay 
was done using IHC in 4,957 ER+ breast cancer patients of Seoul 
National University cohort and 1,863 ER+ patients from National 
Cancer Center, Korea.
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res; 71(24 Suppl.) December 15, 2011 Cancer Research428s
355 genes were upregulated (>1.5 fold) and 209 genes were down-
regulated in breast cancer tissues of young age patients (<35) 
compared with those of older patients. In pathway analysis of the 
highly expressed genes in young patients, cell cycle function and 
pathway was significantly activated. The genes of central role in this 
pathway were MYC and CCND1. In IHC assay for 4,957 ER+ Seoul 
National University dataset, the proportion of high Ki-67 expression 
(>=10%) was positively correlated with decreasing age: 26.4%, 
24.0%, 21.3%, 14.8%, 12.0% of women aged <30, 30-34, 35-39, 
40-49, 50-59, respectively (p<0.001). The same correlation pattern 
between younger age and high Ki-67 expression was also seen in 
another 1,863 patient cohort.
In conclusion, we showed that genes involved in cell cycle pathway 
were upregulated in very young age (<35) ER+ breast cancer using 
microarray study. It was validated in large data set using Ki-67 IHC 
assay. High proliferation and fast cell cycle could be a mechanism 
of worse outcome and tamoxifen resistance of ER+ very young age 
breast cancer patients.
P4-01-14
Fulvestrant Regulates Epidermal Growth Factor (EGF) Ligands 
and Induces EGF Receptor Activation in MCF-7 Breast Cancer 
Cells.
Zhang X, Diaz MR, Yee D. University of Minnesota, Minneapolis, MN
Selective Estrogen Receptor Modulators (SERMs) 4 Hydroxy 
Tamoxifen (4-HT) and fulvestrant (fulv) inhibit estrogen receptor a 
(ER) positive breast cancer growth. We have observed that treatment 
(24 to 48 hours) of fulv in MCF-7 cells induced a 190kDa tyrosine 
phosphorylated band, which was blocked by EGFR and HER-2 
tyrosine kinase inhibitors erlotinib and lapatinib. Immunoprecipitation 
showed EGFR, HER-2, and HER-3 were all phosphorylated after fulv 
treatment. 4-HT and estradiol did not cause this phosphorylation. No 
changes in receptor level after fulv treatment were noted. Downstream 
MAPK signaling was also blocked by erlotinib and lapatinib. Fulv 
induced activation of EGFR was ER dependent, since fulv treatment 
in C4-12, an ER negative cell line derived from MCF-7 cells, did 
not induce EGFR activation. Co-treatment with estradiol and fulv 
prevented EGFR activation. To explore the possibility that fulv 
enhanced ligand expression, we collected conditioned media (CM) 
from MCF-7 cells after 48 hours of treatment. pEGFR was lost when 
CM was removed, but recurred within 30 minutes. Cycloheximide 
abolished the ability of fulv to activate EGFR suggesting autorcine 
production of EGFR ligands was induced by fulv. To detect specific 
EGFR ligands, we used qPCR to measure various EGFR ligand 
mRNA levels in MCF-7 and C4-12 cell at 1, 4, 24 and 48 hours after 
fulv treatment. TGF-a and HB-EGF mRNAs were upregulated over 
48 hours, which correlated well with pEGFR activation. 4-HT did 
not affect mRNA levels of these ligands. In contrast, amphiregulin 
(AREG) mRNA levels were substantially reduced 48 hours after 
fulv treatment. A similar trend was seen for AREG mRNA levels in 
4HT treated cells but to a much lesser extent. There was no change 
in any EGFR ligand mRNA levels in ER negative C4-12 cells. These 
qPCR data suggested differential regulation of EGFR ligands by 
fulv treatment contributed to EGFR family member activation and 
was dependent on ER expression. Upon fulv treatment, levels of 
ER were diminished with decreased detection of S167 and S118 ER 
phosphorylation sites. Monolayer cell growth analysis showed that 
while fulv treatment in SFM reduced MCF-7 cell numbers compared 
to control treatment, erlotinib plus fulv significantly reduced cell 
numbers below the level of cells maintained in fulv alone. In 
conclusion, we show that fulv, but not E2 or 4-HT, activates EGFR 
family members accompanied by upregulation of ligands. Since 
SERM resistance has been associated with EGFR family member 
activation, differential control of EGFR ligand gene expression by 
ER may contribute to the development of fulvestrant resistance in 
breast cancer.
P4-01-15
Alteration of Y-box Binding Protein-1 Expression Modifies the 
Response to Endocrine Therapy in Estrogen Receptor Positive 
Breast Cancer.
Ito T, Kamijo S, Izumi H, Kohno K, Ito K-I. Shinshu University School 
of Medicine, Matsumoto, Nagano, Japan; University of Occupational 
& Environmental Health, Kitakyushu, Fukuoka, Japan
Y-box binding protein-1 (YB-1) plays an important role in tumor 
progression and drug resistance. This study examined whether 
YB-1 is involved in the alteration of response to endocrine therapy 
in ER-positive breast cancer cells. MCF7 cells that stably expressed 
YB-1 (MCF7-YB-1) and vector control cells (MCF7-vector) were 
established. These cells were used to analyze the expression of 
the factors related to the ER and growth factor receptor signaling 
pathways, response to the antiestrogens (tamoxifen and fulvestrant), 
and estrogen responsive element (ERE) activity. The effect of knocking 
down endogenous YB-1 expression was tested in wild-type MCF7 
cells. In addition, the expression of the YB-1 and the factors related to 
the ER and growth factor receptor signaling pathways were evaluated 
in the clinical breast cancers treated with preoperative chemotherapy. 
The expression of HER2, AIB1, p-Erk and c-Myc were increased in 
the MCF7-YB-1 cells. In contrast, knocking down of YB-1 decreased 
the expression of these factors, but increased the expression of ERa 
in the wild-type MCF7 cells. Furthermore, sensitivity to antiestrogens 
was decreased in the MCF7-YB-1 in comparison to those in the 
MCF7-vector cells. In the MCF7-YB-1 cells, the expression levels of 
p-Erk and c-Myc were continuously upregulated when the cells were 
treated either with tamoxifen or fulvestrant. The ERE activity was 
decreased in the MCF7-YB-1 cells in comparison to the MCF7-vector 
cells, and the ERE activity of the MCF7-YB-1 cells was inhibited 
by fulvestrant at a lower concentration than that which inhibited the 
ERE activity of the MCF7-vector cells. In the ER-positive clinical 
breast cancers treated with preoperative chemotherapy, significantly 
more of the specimens that showed increased or positive nuclear YB-1 
expression after the chemotherapy were positive for HER2 expression. 
These data suggest that alteration of YB-1 may modify the crosstalk 
between the ER pathway and HER2 pathway in ER-positive breast 
cancer cells, and consequently may alter the response to endocrine 
therapy in these cells.
P4-01-16
The Influence of CYP2D6 Genetic Polymorphisms on Variability 
of Tamoxifen Metabolism in the Lebanese Breast Cancer 
Population.
Tfayli A, Zgheib N, Holail J, Habbal M-Z, Halawi R, El-Saghir N, 
Salem Z. American University of Beirut, Beirut, Lebanon
Introduction The selective estrogen receptor modulator tamoxifen 
is commonly used for the treatment and prevention of breast cancer. 
Tamoxifen needs to be converted by the highly polymorphic 
enzyme, CYP2D6, to its active metabolites (4-hydroxytamoxifen 
and endoxifen) to exert its anti-estrogenic effect. Several clinical 
trials have shown that CYP2D6 poor metabolizers have decreased 
benefit from tamoxifen compared to extensive metabolizers. Large 
ethnic variations have been noticed in the frequency and effect of 
CYP2D6 polymorphisms.
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Objectives To assess for the frequency of CYP2D6*3, *4, *5 
(nonfunctional alleles with *5 being a gene deletion),*41 (reduced 
functional allele) as well as CYP2D6*x N (allele copy number) in 
a sample of Lebanese participants receiving maintenance doses of 
tamoxifen for early stage breast cancer, and to assess the effect of 
these polymorphisms on tamoxifen metabolism in the same subjects.
Methods 111 (median age= 48.7± 8.6years) Lebanese breast cancer 
women were recruited. Blood for isolation of DNA and measurement 
of tamoxifen metabolites was collected. CYP2D6 genotyping was 
performed using real-time PCR. Plasma levels of tamoxifen were 
being measured using HPLC.
Results The allele frequencies of CYP2D6*3, *4, and *41 were 
0.9, 15.9 and 12.1 respectively. 18.9% of patients had more than 
2 CYP2D6 copies and 9% had only 1 copy. Tamoxifen plasma 
concentration didn’t significantly vary among the 4 phenotypic 
groups, although a trend was observed whereby PMs had the highest 
tamoxifen plasma concentrations and UMs had the lowest tamoxifen 
plasma concentrations (Tamoxifen median plasma concentrations 
in µg/L: PM=290, IM=210, EM=190 and UM=170). Furthermore, 
there was a statistically significant variation of Z-tamoxifen plasma 
concentrations among the phenotypic groups when PMs and IMs 
were grouped together: Z-tamoxifen median plasma concentrations 
in µg/L: PM+IM=130, EM=90 and UM=62 (P=0.03).
Conclusion This is the first study in the Middle East that evaluates 
the frequencies of CYP2D6 polymorhisms in a Lebanese breast cancer 
population and the effect of these polymorphisms on tamoxifen 
metabolism. We have shown that CYP2D6 phenotype is significantly 
correlated with Z-tamoxifen levels. PMs and IM group had the highest 
Z-tamoxifen plasma concentrations; in contrast UMs had the lowest 
Z-tamoxifen plasma concentrations. Further recruitment and follow 
up are being performed to assess for the role of these polymorphisms 
in disease outcome.
P4-01-17
TIMP-1 Over-Expression Confers Resistance of MCF-7 Breast 
Cancer Cells to Fulvestrant.
Bjerre CA, Vinther L, Belling K, Schrohl Rasmussen A-S, Li J, Lin X, 
Han Z, Wang J, Bolund L, Jensen V, Nielsen BS, Soekilde R, Gupta 
R, Lademann U, Brünner N, Stenvang J. Faculty of Life Sciences, 
University of Copenhagen, Copenhagen, Denmark; Technical 
University of Denmark, Lyngby, Denmark; Aarhus University, 
Aarhus, Denmark; BGI-Shenzhen, Shenzhen, China; Exiqon A/S, 
Vedbeak, Denmark
Background: Endocrine resistance represents a major challenge in 
the management of estrogen receptor (ER) positive breast cancer. 
Currently no predictive biomarkers for endocrine resistance in ER-
positive breast cancer patients are in clinical use.
In a clinical study, patients with metastatic breast cancer and high 
levels of serum Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) 
had less benefit from endocrine therapy than patients with a lower 
level of serum TIMP-1 [1].
Therefore, we evaluated the association between TIMP-1 and 
response to endocrine therapy using an in vitro approach.
We have previously presented initial results on TIMP-1 and response 
to endocrine therapy [2].
Materials and Methods: MCF-7 cells were stably transfected with 
pcDNA3.1(Hyg)-TIMP-1 plasmid, and a panel of 11 subclones 
with different expression levels of TIMP-1 was generated. 
TIMP-1 expression levels were confirmed using enzyme-linked 
immunosorbent assay (ELISA).
Four subclones with high or low TIMP-1 expression were analyzed for 
the growth response to estrogen, 4-hydroxytamoxifen and fulvestrant. 
These four subclones were analyzed for protein expression by western 
blotting. All subclones were analyzed by whole human genome oligo 
microarrays 4x44K for determination of gene expression levels. Data 
were analyzed using the limma R/Bioconductor package. Paired-end 
Solexa sequencing was applied to selected subclones with high and 
low TIMP-1 levels to identify transcriptomic changes.
Results: High expression of TIMP-1 was associated with resistance 
to fulvestrant, whereas growth response to either estrogen or 
4-hydroxytamoxifen was independent of TIMP-1 expression levels. 
High expression of TIMP-1 protein and mRNA was associated with 
undetectable levels of progesterone receptor (PgR) protein and mRNA 
whereas ER protein and mRNA levels were unaffected by TIMP-1. 
To characterize the potential role of TIMP-1 in estrogen signaling we 
analyzed the expression of reported estrogen-responsive genes and 
no general change was observed. We identified genes that correlated 
positively or negatively to TIMP-1 expression. Among the identified 
genes was PgR, which is a direct target for ER.
Conclusion: Our data suggest that a high expression of TIMP-
1 in vitro is associated with resistance to fulvestrant but not to 
4-hydroxytamoxifen. Estrogen-regulated genes are not generally 
affected by changes in TIMP-1 expression levels and therefore TIMP-
1 appears to affect endocrine resistance through other mechanisms 
than globally regulating ER signaling. However, high expression of 
TIMP-1 is associated with loss of PgR and this may be related to the 
resistance towards fulvestrant.
References:
[1] Lipton, A et al: Serum TIMP-1 and Response to the Aromatase 
Inhibitor Letrozole Versus Tamoxifen in Metastatic Breast Cancer. J 
Clin Oncol; 2008; 26;(16); 2653-8
[2] Effect of TIMP-1 Overexpression on Endocrine Sensitivity of 
MCF-7 ER-positive Human Breast Cancer Cells In Vitro. Cancer 
Res; 2009; 69(24 suppl); abstract nr 2029
P4-01-18
AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine 
Treatment and Reverts the Resistant Phenotype in Hormone 
Receptor-Positive Breast Cancer.
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien 
M, Hilsenbeck SG, Healy N, Mazumdar A, Trivedi MV, Jeselsohn 
R, He HH, Fu X, Gutierrez C, Brown M, Brown PH, Osborne CK, 
Schiff R. Baylor College of Medicine, Houston, TX; Hospital of Prato, 
Prato, Italy; The University of Texas M.D. Anderson Cancer Center, 
Houston, TX; Dana-Farber Cancer Institute and Harvard Medical 
School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth 
Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical 
School, Lebanon, NH; UH College of Pharmacy, Houston, TX
Background: Resistance to endocrine therapy is a major clinical issue. 
The transcription factor AP-1 is a key regulator of cell growth and 
survival as well as a downstream signaling component of several 
pathways deregulated in endocrine-resistant breast cancer. We have 
previously shown that acquired endocrine resistance is associated with 
increased AP-1 activity. AP-1 has also been shown to interact with 
and modulate the ER network and transcriptional program, especially 
under hyperactive growth factor signaling, which is commonly 
associated with endocrine resistance. We hypothesized that interfering 
with AP-1 function would circumvent endocrine resistance possibly 
due to its role in modulating ER transcriptional activity.
Methods and results: We inhibited AP-1 function by a genetic 
approach. We used two different MCF7 clones stably transfected 
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with a Doxycycline (Dox)-inducible dominant-negative (DN) c-Jun 
(MCF7/Tet-Off Tam67 clones 62 and 67) and two vector-alone 
control MCF7 clones. Xenografts of these clones were established 
in ovariectomized nude mice supplemented with estrogen (E2). Mice 
were then randomized to continued E2 supplementation (control) 
or to endocrine therapy with either estrogen deprivation (ED) or 
tamoxifen (Tam), all in the presence or absence of Dox to induce 
the DN c-Jun expression. AP-1 blockade in both MCF7/Tet-Off 
Tam67 clones significantly enhanced sensitivity to Tam by reducing 
time to tumor size halving (p=.014 and p=.006 for clone 62 and 67, 
respectively) and time to complete tumor disappearance (p=.001 
and p=.0034 for clone 62 and 67, respectively). Similar results were 
obtained with ED treatment. In addition, AP-1 blockade significantly 
delayed the onset of Tam resistance by increasing time to tumor size 
doubling (p=.0028). Furthermore, induction of DN c-Jun resulted in a 
dramatic shrinkage of growing tumors after long-term Tam treatment, 
suggesting reversal of endocrine resistance with AP-1 blockade. 
None of the above effects was observed in control clones upon Dox 
removal. Interestingly, no significant effect of AP-1 blockade was 
observed on E2-stimulated tumor growth. IHC analysis showed that 
AP-1 blockade induced tumor response by reducing proliferation (i.e., 
decreased % of Ki67- and phospho-Histone 3-positive cells) and by 
inducing apoptosis (i.e., increased % of cleaved caspase 3/7-positive 
cells). Bioinformatic analyses were conducted to intersect our MCF7 
xenograft/Tam-resistant gene signature and the datasets of genes 
associated with ER DNA-binding sites obtained by whole-genome 
ER cistromic analysis under estrogen or epidermal growth factor 
(EGF) stimulation of MCF7 cells. A significant enrichment of the 
genes associated with the EGF-unique ER DNA-binding sites was 
observed within our Tam-resistant signature (p<2E-16). Remarkably, 
90% of these DNA binding sites harbored an AP-1 motif.
Conclusions: We show that AP-1 blockade increases tumor sensitivity 
and circumvents resistance to endocrine therapy, thus warranting the 
development of AP-1-targeted therapy to improve endocrine treatment 
outcomes. Overall, we suggest that AP-1 is critical in induction of a 
switch in the ER transcriptional program and may be a new hallmark 
of endocrine resistance.
P4-01-19
SRC-1 Expression Is a Prognostic Factor of Breast Cancer-
Specific and Disease-Free Survival in Inflammatory Breast 
Cancer.
Arias-Pulido H, Ahmed RD, Chaher N, Vargas J, Joste N, Lomo 
L, Qualls C, Azziez S, Terki N, Bouzid K, Prossnitz E, Royce M. 
University of New Mexico, Albuquerque, NM; Centre Pierre et Marie 
Curie, Algiers, Algeria
Background: Steroid receptor coactivator (SRC-1 to 3) proteins drive 
nuclear receptor transcriptional activity by modulating transcriptional 
processes such as chromatin modification, transcription initiation, 
chain elongation, and RNA splicing. In patients who display resistance 
to endocrine treatment, SRC-1 has been implicated in the conversion 
of tamoxifen anti-agonist activity to its agonist profile. SRC-1 
expression is a prognostic of DFS in breast cancer, but its role in 
inflammatory breast cancer (IBC) remains unknown.
Materials and Methods: SRC-1 protein levels were measured by 
immunohistochemistry in 103 IBC and 11 normal, non-cancer related 
samples, diagnosed at the Centre Pierre & Marie Curie (Algiers, 
Algeria). Staining results were correlated with protein levels of ER, 
PR, and HER2, and clinico-pathological variables, breast cancer-
specific (BCSS) and disease-free survival (DFS), and response to 
tamoxifen treatment.
Results: SRC-1 was positive in all normal breast tissue, as well as in 
66% of IBC samples. SRC-1 positivity was associated with worse 
OS (P<0.001) and DFS (P=0.004). SRC-1 expression correlated 
with worse BCSS (P=0.011), and marginally with DFS (P=0.046) 
in tamoxifen-treated patients, but strongly with DFS (P=0.007) in 
patients who received no endocrine therapy as indicated by Kaplan-
Meier and log-Rank analyses. Multivariate analysis showed that 
SRC-1 (Hazard Ratios (HR): 5.2; 95%CI: 2.0-13.6; P<0.001) and 
Her2 (HR: 3.1; 95%CI: 1.2-8.1; P=0.02) expression were independent 
prognostic markers of BCSS. SRC-1 (HR: 4.8; 95%CI: 1.9-12.2; 
P<0.001), Her2 (HR: 2.4; 95%CI: 1.0-5.7; P=0.05), and hormone 
treatment (HR: 0.4; 95%CI: 0.2-0.8; P=0.01) were independent 
prognostic markers of DFS.
Discussion: Determining prognosis and predicting response to 
endocrine treatment is of paramount importance in the search for 
personalized treatment. SRC-1 expression predicts worse OS, DFS, 
and, similar to non-IBC, predicts DFS independently of endocrine 
therapy. This study highlights the importance of SRC-1 expression as a 
strong prognosticator of BCSS and disease recurrence in IBC patients.
*Supported by an UICC ICRET Fellowship (ICR/09/043 to Dr. 
Chaher) and by New Mexico State IBC funding (New Mexico Senate 
Bill 532).
P4-01-20
Specific Anti-Proliferative Profile of Endoxifen for MCF-7 Cell 
Compared to 4-OH Tamoxifen.
Saji S, Hirose M, Hayashi S-I, Kuroi K. Saitama Medical University, 
IMC, Saitama, Japan; Tokyo Metropolitan Komagome Hospital, 
Tokyo, Japan; Tohoku University Graduate School of Medicine, 
Sendai, Japan; Kyoto University, Graduate School of Medicine, 
Kyoto, Japan
Background:
Endoxifen and 4-hydroxy tamoxifen are both active metabolites 
of tamoxifen and exert anti-tumor activity for ER+ breast cancer. 
However, only small numbers of paper reported biological profile 
of endoxifen.
Methods:
Cells were incubated with various concentration of endoxifen ( 
(Z)-4-Hydroxy-N-desmethyl Tamoxifen (<10% with (E)-form)) for 
6 days and viability (anti-proliferative index) was assessed by cell 
counting kit-8. For seeking the influence of ERb, two independent 
ERb expressing clones of MCF-7 cells were established by stable 
transfection of ERb vesctor to MCF-7. Western blotting was done 
with ERa, ERb, PgR and HER2 antibodies.
Results:
IC50s of endoxifen for MCF-7 were 100 nM in estradiol (E2) 
deprivation condition and 500 nM in the presence of 1nM E2. These 
are significantly higher than those of 4-OH tamoxifen, which are 10 
nM without E2 and 50 nM with E2, respectively. From the previous 
reports, plasma endoxifen concentrations in breast cancer patients 
were ranged from 20 to 200 nM according to CYP2D6 phenotype. 
Anti-proliferative index of 20 nM endoxifen for MCF-7 was 0.7 
(indicating 30% reduction in proliferative activity), and 200 nM 
endoxifen was 0.5 in the absence of E2. These were 0.95 (20 nM) 
and 0.75 (200nM), respectively, when incubated with 1 nM E2. 
10 nM 4-OH tamoxifen, which is mean concentration in patient 
plasma, showed about 0.6 anti-proliferative index with no regards 
to E2 condition. Without E2, endoxifen reduced ERa expression as 
previously reported, however, endoxifen increased ERa amount in 
the presence of E2 accompanied with decrease of HER-2 expression. 
This alternation of ERa and HER2 expression were identical to those 
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observed using 4-OH tamoxifen. There was a weak tendency that ERb 
expressing MCF-7 clones showed favorable response to endoxifen 
compared to parent MCF-7, but this was not significant.
Conclusion:
Endoxifen is active agent for MCF-7 cell, however, it requires 10-fold 
higher concentration compared to 4-OH tamoxifen to achieve IC 50. 
Difference of anti-proliferative effect between 20 nM and 200 nM of 
endoxifen are relatively small, and it might result in minor difference 
for clinical response, as expected from recent clinical studies of 
CYP2D6. This is the first time to show that endoxifen has opposite 
effect to ERa protein level depending on the presence or absence of 
E2. ERb expression did not enhance activity of endoxifen in contrast 
to previous report.
P4-01-21
An Estrogen-Inducible Transcription Factor FOXP1 Promotes 
Estrogen-Dependent Cell Proliferation of Breast Cancer Cells 
and Is Associated with 5-Year Disease-Free Survival in Patients 
with Tamoxifen-Treated Breast Cancer.
Shigekawa T, Ijichi N, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi 
K, Tsuda H, Osaki A, Saeki T, Inoue S. Tokyo Metropolitan Cancer 
and Infectious Disease Center, Komagome Hospital; Research Center 
for Genomic Medicine, Saitama Medical University; International 
Medical Center, Saitama Medical University; National Cancer Center 
Hospital; National Shikoku Cancer Center; Graduate School of 
Medicine, The University of Tokyo
Estrogen signaling pathways are involved in the growth and 
development of breast tumors through the activation of estrogen 
receptor a (ERa). ERa is expressed in most breast cancers and 
involves in estrogen-dependent proliferation by acting as transcription 
factors activating the expression of target genes. Various coregulators 
and transcription factors are associated with ERa-mediated 
transcriptional control of target genes. Therefore, a comprehensive 
understanding of estrogen signaling pathways in breast cancer is 
required for both treatment and diagnosis of the disease. Forkhead 
box P1 (FOXP1) is a member of the forkhead box transcription 
factor family and has been reported to be associated with various 
types of tumors. Here, we investigated the expression pattern of 
FOXP1 by immunohistochemistry in a series of 133 invasive breast 
cancers and compared it with clinicopathological factors. The 
expression of FOXP1 was detected in nuclei in 89 cases (67%) and 
correlated positively with tumor grade and hormone receptor status, 
including ERa and progesterone receptor (PgR), and negatively with 
pathological tumor size (pT). And in ERa-positive MCF-7 breast 
cancer cells, we demonstrated that FOXP1 mRNA was upregulated 
by estrogen and that ERa recruitment to ER binding sites within the 
FOXP1 gene region identified by ChIP-chip analysis was increased. 
We also demonstrated that proliferation of MCF-7 cells was increased 
by exogenously transfected FOXP1 and decreased by FOXP1-specific 
siRNA. Moreover, in MCF-7 cells, FOXP1 enhanced estrogen 
response element (ERE)-driven transcription. Finally, FOXP1 
immunoreactivity was significantly more elevated in relapse-free 
breast cancer patients treated with tamoxifen than in relapse patients 
treated with it. Taken together, these results suggest that FOXP1 
plays an important role in proliferation of breast cancer cells by 
modulating estrogen signaling and that FOXP1 immunoreactivity 
might be associated with the estrogen dependency of breast cancer 
clinically, which may predict favorable prognosis in the patients 
treated with tamoxifen.
P4-01-22
Cyclin D1 and Its Prognostic Value in Planning of Endocrine 
Therapy for Women of Postmenopausal Age with Breast Cancer.
Skvortsov V, Manikhas A, Manikhas G, Oganesyan A, Raskin G. City 
Clinical Oncology Dispensary, St. Petersburg, Russian Federation; 
Pavlov State Medical University of St. Petersburg, St. Petersburg, 
Russian Federation
Background: Nowadays tamoxifen still remains the primary drug in 
breast cancer endocrine therapy. However, its application is limited 
due to the resistance of tumor cells. The search of adequate biomarkers 
is one of the most actual problems in prognosis of effectiveness 
of tamoxifen adjuvant therapy. The most perspective biomarker is 
cell cycle regulator cyclin D. Besides its central role in cell cycle 
regulation cyclin D1 modulates the estrogen receptors activity and 
can influence on the effectiveness of treatment with antiestrogenes 
and aromatase inhibitors.
The objective of our work was to evaluate the effectiveness of 
tamoxifen in adjuvant therapy of hormone-receptor-positive breast 
cancer in women of postmenopausal age with cyclin D1 expression.
Material and Methods.
To evaluate the effectiveness of tamoxifen adjuvant application in 
women with cyclin D1-positive T1-4N0-3M0 breast cancer we have 
researched 2 retrospective groups of 70 patients that have been on 
regular medical check-up for a period of 5 years or that had previously 
undergone treatment. On the basis of the archive histological material 
we have revealed cyclin D1 in tumor cells.
Results: The expression of cyclin was classified in 4 levels: negative, 
low, moderate and high. Patients with lack of cyclin D1 expression 
or with low quantitative value (according to our data less than 30%) 
have no neoplastic process progression throughout the 5 years of 
tamoxifen adjuvant therapy. These women were both with axillary 
lymph nodes affection and without it (+N; -N). On the contrary, 
women with moderate and high cyclin D1 expression (more than 30%) 
had a relapse of tumor and distant metastasis is prognosed in 5 years 
of observation (p=0,005). Moderate level of cyclin D1 expression was 
observed in 45 (64%) patients and 28 (62%) of them had progression 
with metastasis in bones, 9 (20%) metastasis in soft tissues, 2 (4%) 
metastasis in lungs and 6 (14%) relapse in postoperative scar. High 
expression was revealed in 25 (35%) women and 17 (68 %) of them 
had bone affection, 7 (28%) soft tissue metastasis and 2 (4%) tumor 
relapse in postoperative scar. Lung metastasis were not observed. 
The average period of tumor relapse and progression of neoplastic 
process in patients with cyclin D1-positive breast cancer is 20 months.
Discussion: The results of our work suggest that women with 
hormone-receptor-positive cyclin D1-negative breast cancer on early 
stages have more prolonged non-relapse period during the tamoxifen 
adjuvant therapy. Patients with cyclin D1-positive breast cancer are 
less sensitive to tamoxifen treatment and in adjuvant regime should 
receive therapy with other effective equivalent drugs (aromatase 
inhibitors).
P4-02-01
Bis(2-Ethylhexyl) Phthalate: A Potential Endocrine Disruptor 
Confer Letrozole Insensitivity and Induction of Aromatase 
Activity in Breast Cancer Cells.
Nair HB, Bhaskaran SS, Krishnegowda NK, Tekmal RR, VandeBerg 
JL. Texas Biomedical Research Institute, San Antonio, TX; University 
of Texas Health Science Center, San Antonio, TX
Exposure to endocrine disrupting compounds (EDC’s) is an important 
determinant of mammary gland development and mammary tumor 
pathogenesis. The risk of breast cancer in adulthood is known to 
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be influenced by environmental factors experienced as a fetus. 
Fetal exposure to dietary factors or certain pharmaceuticals and 
environmental chemicals that affect or mimic steroid hormones 
increase predisposition to breast cancer. The mechanisms by which 
EDC’s alter epigenetic programming, differentiation and deregulation 
of ductal branching of mammary glands are poorly understood. A high 
ratio of estrogen receptor a (ERa) to ERb has been recently found 
to be associated with poor prognosis and aggressive disease in breast 
cancer patients. Preliminary studies from our laboratory revealed 
that bis(2-ethylhexyl) phthalate (DEHP) is a possible EDC which 
induces cell proliferation in T47D, MCF7, MCF7/Aro breast cancer 
cells in vitro and confers insensitivity to letrozole, a third generation 
aromatase inhibitor. DEHP increased cell proliferation (MTT assay) in 
a dose dependent manner and was non toxic to T47D, MCF7 and MCF 
7 Aro cells. 1, 10 and 100 nM concentrations of DEHP up regulated 
ERa and down regulated ERb at the mRNA level. Hypermethylation 
in the estrogen receptor beta (ERb) promoter was observed after 
treatment with 1nM DEHP for 24 h, suggesting that DEHP alter 
epigenetic programming through changes in the DNA methylation 
to modify the chromatin structure and change the accessibility of 
DNA to transcription factors. When breast cancer cells were treated 
with letrozole (200nM and DEHP (1nM) together, they survived, 
whereas those treated with letrozole alone did not survive. Aromatase 
mRNA and enzyme levels were higher in the DEHP treated cells 
by comparison with sham control MCF7/Aro cells. Nonmalignant 
MCF-10A breast epithelial cells showed a proliferation advantage 
(MTT assay) by up regulation of ERa as well as aromatase expression 
when treated with 1nM DEHP. Aromatase transgenic mice treated 
with 10mg/Kg b.wt of DEHP over a period of 30 days resulted in the 
excessive ductal branching density and epithelial outgrowth in the 
mammary gland. The present data suggest that dietary accumulation 
of DEHP through plastic food containers, water bottles, etc. may 
contribute to risk of hormone sensitive breast cancer in women and 
chemoinsensitivity and or drug resistance in breast cancer patients.
P4-02-02
The Natural Fetal Estrogen Estetrol (E4), Causes Anti-Estrogenic 
Effects in Women with Endocrine-Responsive Positive Early 
Breast Cancer.
Singer CF, Natter C, Steurer S, Rudas M, Moinfar F, Appels NRCA, 
Visser M, Kubista E, Bennink C. Medical University of Vienna, Wien; 
Medical University of Graz, Wien; Pantarheie Bioscience
Background: Estetrol (E4) is a natural fetal estrogen which exerts 
estrogenic effects on reproductive organs and on the bone, and 
effectively reduces menopausal smyptoms. In contrast to other 
estrogens, however, E4 has estrogen-antagonistic effects on breast 
cancer cell lines in vitro and in the rat DMBA model, which would 
make it a suitable Hormone Replacement Therapy (HRT) in breast 
cancer patients, particularly in women who are being treated with 
aromatase inhibitors.
Patients and Methods: We have investigated the effect of 14 days pre-
operative treatment with 20 mg E4 per day on tumor proliferation, 
apoptosis, ER-receptors, PgR receptor and several endocrine 
parameters in a prospective, randomised, double-blind, placebo-
controlled, neo-adjuvant study in 15 pre- and 14 postmenopausal 
women with estrogen-receptor positive early breast cancer.
Results: Estetrol induced a significant increase of SHBG, a significant 
decrease of FSH in postmenopausal women and no increase of 
gonadotrophins in premenopausal women. Estetrol had no effect 
on Ki67 expression and on apoptosis-related Bax and Bcl-2, but the 
apoptosis index in tumor tissue increased significantly. Systemic 
IGF-1 levels decreased significantly. Surprisingly the intratumoral 
epithelial ER-alpha expression decreased significantly, whereas the 
ER-beta expression showed a trend to increase.
Conclusion: Our data suggest that E4 may be suitable and safe for HRT 
in women with spontaneous or induced menopausal symptoms, since 
apoptosis increases, IGF-1 decreases and no unfavourable effects 
are observed on Ki67, Bax and Bcl-2. The decrease of ER-alpha and 
the increase of ER-beta suggest a mechanism of action, explaining 
why the natural fetal estrogen E4 has estrogen-antagonistic effects 
on breast cancer tissue.
P4-02-03
Biological Functions of Estrogen Receptor-beta and Its Variants 
in Breast Cancer.
Hawse JR, Wu X, Cicek M, Subramaniam M, Negron V, Lingle WL, 
Goetz MP, Spelsberg TC, Ingle JN. Mayo Clinic
Background: The role of estrogen receptor alpha (ERa) in breast 
cancer has been studied extensively; yet, much less is known about 
full-length ERb (ERb1) and even less about its 4 variant forms (ERb2-
5). We have recently implicated a role for ERb1 in sensitizing ERa 
expressing breast cancer cells to anti-estrogens. However, the ability 
of ERb2-5 to modulate ERa and ERb1 activity, and their association 
with cancer development, progression, and response to estradiol (E2) 
and anti-estrogens are not well understood. Here, we provide evidence 
that the presence of ERb variants may be of diagnostic and clinical 
relevance for breast cancer patients and describe the development 
and characterization of a novel, highly specific monoclonal antibody 
(MC10) that is able to detect their expression in tumor biopsies.
Methods: Transient transfection and luciferase assays were used to 
determine the transcriptional activity of ERb2-5 in response to E2 
and anti-estrogens alone or in combination with ERa and ERb1. A 
novel monoclonal antibody targeting all ERb variants (MC10) was 
developed and characterized. The sub-cellular localization of ERb2-5 
was determined via confocal microscopy. Finally, the MC10 antibody 
was used to assess ERb positivity in breast tumors and was compared 
to that of another monoclonal antibody which only detects ERb1.
Results: Unlike ERb1, ERb2-5 do not activate an estrogen response 
element (ERE) in response to E2 and instead, slightly repress the 
activity of this reporter construct. Expression of ERb2-5 does not 
significantly alter the transcriptional activity of ERb1 following 
E2 treatment. However, ERb2, 3 and 5, but not ERb4, significantly 
enhance the E2-induced transcriptional activity of ERa. Interestingly, 
expression of ERb3, 4 and 5, but not ERb2, enhance the ability of anti-
estrogens to block ERa mediated transcriptional activity. Confocal 
microscopy revealed that ERb1 and 2 are almost exclusively localized 
to the cell nucleus. However, ERb3-5 exhibit significant cytoplasmic 
and peri-nuclear localization. Immunohistochemistry of breast cancer 
biopsies using the MC10 antibody revealed multiple staining patterns 
including tumors which exhibit primarily nuclear staining and others 
primarily cytoplasmic, both in the presence and absence of ERa. 
These results are in contrast to the almost exclusive nuclear staining 
obtained on the same tumors with an ERb1-specific antibody.
Conclusions: ERb variants exhibit variable sub-cellular localization 
patterns and can influence the function of ERa, both in response to 
E2 and anti-estrogens. Therefore, the differential expression of ERb 
variants and their cellular localization may influence breast cancer 
progression and/or therapeutic responses. The use of ERb antibodies 
which do not detect all ERb variants, or the use of a single ERb 
antibody which does not discriminate between ERb1 and its variants, 
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is unlikely to reveal the complete biological significance of total ERb 
expression in breast cancer and may in part explain the conflicting 
studies which have been reported for ERb in the field.
P4-02-04
Androgen Receptor (AR) Expression in a Cohort of Patients (pts) 
with Triple Negative Breast Cancer (TNBC).
Gucalp A, Gupta G, Patil S, Wen YH, Akram M, Brogi E, Powell SN, 
Ho AY, Hudis CA, Traina TA. Memorial Sloan-Kettering Cancer 
Center, New York, NY
Background: TNBC, defined by the absence of ER, PR, and HER2, 
is associated with higher risk of recurrence and BC-related mortality, 
earlier age at diagnosis, menarche, and 1st pregnancy, increased 
parity, higher BMI, and African-American/Hispanic race. TNBC is 
a heterogeneous group. Using gene expression analysis, our group 
described a subset of AR+ ER/PR- BC that exhibits androgen-
dependent growth. In vitro studies confirmed the functional role of AR 
and showed that growth could be abrogated by antiandrogens.(Doane 
et al 2006) We translated this work into a phase II trial of bicalutamide 
in pts with AR+ ER/PR- metastatic BC (MBC). (NCT00468715) We 
now describe the prevalence and clinicopathological characteristics 
of AR+TNBC in primary disease in a single-institution retrospective 
cohort.
Methods: We identified 1,032 pts with resectable, TNBC (ER/
PR<1%; HER2<2+/FISH<2.2) who had surgery at MSKCC from 
1998-2006. Exclusion criteria: neoadjuvant chemotherapy, prior 
radiation, inflammatory/MBC. IRB approval was obtained. We 
constructed tissue microarrays (TMA) from 210 primary tumors (> 1 
cm) with each tumor represented by three 0.6mm cores. AR was tested 
with DAKO antibody (Clone AR441; dilution 1:500). TMAs were 
digitized with a Mirax scanner. MetaMorph image analysis software 
was used to quantify the ratio of DAB staining to hematoxylin 
signal. A ratio >1 SD above mean was defined as AR+. AR+ cores 
were manually reviewed; false positives due to core artifact were 
excluded. To evaluate clinicopathological variables and differences 
in recurrence-free survival (RFS) and overall survival (OS) by AR 
status we used chi-square/t-tests and Kaplan-Meier methods/log-rank 
test, respectively.
Results: 169 pts had adequate cores for image analysis/quantification 
of AR. 10% of pts tested AR+ (17/169). Median (med) followup: 
AR+=6 years (yr), AR-=5.6yr. Demographic/clinicopathological 
variables: Table 1 (ages in med yr). Overall med age=54yr (29-84). 
Adjuvant chemotherapy received: AR+ 82%, AR- 87%, p =0.40; 77% 
received anthracycline/taxane-based therapy. Med time to distant 
metastasis (DM)=2.1yr (0.2-6.2yr). We were unable to demonstrate 
a difference in 5yr RFS (69% vs. 77%; p=0.37) or OS (68% vs. 84%; 
p=0.25) between AR+ and AR- TNBC.
Table 1
Variable TNBC p-value
 AR+ N=17 AR- N=152  
T stage    
1 11 68  
2 5 75 0.30
3 0 5  
4 1 4  
N stage    
0 8 87  
1 5 49 0.34
2 2 5  
3 2 11  
Grade    
Intermediate 1 4 0.42
High 15 148  
DM    
N 3 (18%) 26 (17%)  
Visceral 3 25  
Age at diagnosis 57 (34-79) 53 (29-84) 0.17
Age at menarche 13 (10-15) 13 (9-17) 0.31
Menopausal status    
Pre/Peri 5 60 0.42
Post 12 92  
Gestation #    
0 3 15  
1-2 5 62 0.49
≥3 9 75  
Age at 1st pregnancy 22 (16-41) 25 (15-42) 0.57
BMI    
<18.5-24.9 7 59  
25-29.9 5 50 0.96
≥30 5 43  
Family history of ovarian cancer/BC in 1st degree relative 3 31 0.79
Race    
African American/Hispanic 5 30  
White 11 114 0.63
Asian 1 8  
Conclusions: Consistent with our prospective study, AR is expressed 
in ~10% of TNBC tumors in this retrospective cohort. The pts in our 
dataset may be older, postmenopausal, more likely to self-report white 
race and have T1-2/N0-1 BC. No statistically significant differences 
were observed in demographic/clinicopathological variables or 
survival outcomes between AR+ and AR- TNBC. Additional TMA 
data from our database will be presented.
P4-02-05
The Regulation of Artemin Signalling by IGF-1 in Mammary 
Carcinoma Cells.
Yip C, Liu D, Lobie PE, Perry JK. University of Auckland, Auckland, 
New Zealand; National University of Singapore, Singapore
Artemin is a neurotrophic signalling factor which belongs to the 
glial-derived neurotrophic factor (GDNF) family of ligands. Artemin 
acts as a survival, proliferation and migration factor for a number of 
neurological cell types, by signalling through the RET (rearranged 
during transfection) receptor and, in most cases, the GDNF receptor 
(GFR)-a3 co-receptor. Recently, a number of published studies have 
implicated Artemin as a potential oncogene in several cell types, 
including mammary carcinoma cells. Other studies further indicate 
that Artemin may influence cancer progression and tamoxifen 
resistance in some breast cancers. Available clinical data has 
demonstrated that increased Artemin expression is correlated with 
decreased overall patient survival in breast cancer patients and a poor 
outcome in tamoxifen treated breast cancer patients.
Here we investigate interaction between the Artemin and the 
insulin-like growth factor-1 (IGF-1) signal transduction pathways. 
Using mammary carcinoma cell lines, we demonstrate that IGF-1 
treatment increases the endogenous expression of both Artemin and 
its endogenous receptors, RET and GFRa3. Semi-quantitative RT-
PCR assays demonstrated that IGF-1 stimulated mRNA expression 
of Artemin as well as RET and GFRa3 in wild-type MCF-7 and 
ZR-75-1 cells in a time-dependent and dose-dependent manner. The 
same effect was not observed in wild-type T47D cells where IGF-1 
did not increase Artemin mRNA expression.
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We also demonstrated that forced expression of Artemin in MCF-7 
cells consistently enhanced the response of these cells to IGF-1 in 
a number of cell function assays. Forced expression of Artemin 
significantly enhanced IGF-1-mediated stimulation of total cell 
number in MCF-7 cells. Consistent with this, Artemin enhanced 
IGF-1-mediated stimulation of S-phase entry and cell survival. In a 
soft agar assay, forced expression of Artemin also enhanced IGF-1-
mediated stimulation of colony formation. Conversely, depletion of 
Artemin expression using siRNA abrogated the response to IGF-1 
stimulation in MCF-7 cells. Artemin depletion significantly decreased 
IGF-1-stimulated increase in total cell number by decreasing IGF-1-
stimulated cell proliferation and protection from apoptotic cell death. 
In addition, forced expression of Artemin in MCF-7 cells reduced cell 
sensitivity to the IGF-1 receptor small molecule inhibitor, AG1024.
In conclusion, we have demonstrated that IGF-1 increases Artemin 
mRNA and protein expression in the breast cancer cell lines MCF-7 
and ZR-75-1 and have identified potential cross-talk between the 
Artemin and IGF-1 signalling pathways in MCF-7 cells.
P4-02-06
Progesterone Receptor Expression Predicts Poor Outcome in 
Estrogen Receptor Positive, Lymph Node Negative Breast Cancer 
– A Population Based Study.
Purdie CA, Quinlan P, Jordan LB, Ashfield A, Baker L, Dewar JA, 
Thompson AM. Ninewells Hospital & Medical School, Dundee, 
United Kingdom; University of Dundee, Dundee, United Kingdom
Background: Estrogen receptor (ER) positive, lymph node (LN) 
negative breast cancer usually carries a good prognosis; endocrine 
therapy is often the only adjuvant treatment. However, a small 
proportion of such patients do badly (possibly representing those 
with luminal B cancers identified by gene expression profiling). A 
clinically applicable method for identifying this subgroup of poor 
prognosis ER+, LN- patients is required to offer them more intensive 
adjuvant therapy.
Material and methods: A consecutive, unselected series of 1072 new, 
operable breast cancer patients diagnosed between 2000 and 2004 
was studied for ER and progesterone receptor (PR) expression, HER2 
status and standard pathological and demographic parameters. ER 
and PR expression were scored on immunohistochemistry (IHC) 
on preoperative, diagnostic core biopsies using the “Quickscore” 
method. This ensured optimal fixation and tissue processing avoiding 
the variable fixation of resection specimens and the well-described 
sampling error of tissue micro-array (TMA) methodologies. PR 
expression is frequently heterogeneous resulting in false negative 
scores in at least 12% of cases by TMA analysis. HER2 status was 
assessed using IHC with dual color FISH for cases scoring 2+. 
Adjuvant therapy was prescribed using standard protocols; all patients 
with ER+ disease received adjuvant endocrine therapy. Follow up 
data were obtained from the oncology database, and the registrar 
of deaths for the date and cause of death. All deaths not attributable 
to breast cancer were censored at the date of death. Accordingly, 
the primary end-point was breast cancer-specific overall survival. 
Survival analysis was carried out by Kaplan-Meier survival curves 
analysed by the Log-Rank test. Multivariate analysis was carried out 
using Cox’s regression.
Results: Overall, PR- cancers had a worse prognosis than PR+ 
(p<10-12, Hazard Ratio 3.40), even in the ER+ (p=0.006, HR 1.86), 
LN- (p=10-8, HR=5.33) and LN+ (p=10-11, HR=3.26) sub-groups. In 
the ER+ LN- group, the absence of PR expression predicted worse 
prognosis (88% vs 96% 8 year survival, p=0.0003) with a hazard 
ratio of 3.75. This is considerably more significant than Ki67 IHC 
scoring reported for a similar group of patients in other studies (HR 
2.22). Multivariate analysis demonstrated that PR expression was an 
independent prognostic variable second only to LN status and more 
powerful than ER.
Discussion: Patients with ER+, LN-, PR- breast cancers have a 
significantly worse prognosis than those with ER+, LN-, PR+ 
cancers. Unlike Ki67, PR IHC uses a simple, cost effective, standard 
methodology (as for ER) and should identify patients who may 
require chemotherapy in addition to endocrine therapy in this group 
of otherwise good prognosis patients.
P4-02-07
Influence of the Progesterone Receptor on the Prognosis of Breast 
Cancer in Interaction with Other Prognostic Factors.
Salmen JC, Fasching PA, Hepp P, Jueckstock J, Haeberle L, 
Mohrmann S, Beckmann MW, Hartmann A, Wachter DL, Friese K, 
Janni W, Rack B. Frauenklinik der Heinrich-Heine-Universitaet, 
Duesseldorf, Germany; University of California at Los Angeles, 
Los Angeles; LMU Muenchen, Frauenklinik Innenstadt Maistrasse 
11, Muenchen, Germany; Frauenklinik des Universitaetsklinikums 
Erlangen, Erlangen, Germany; Universitaetsklinikum Erlangen, 
Erlangen, Germany
Introduction
The expression of the estrogen receptor (ER) and/or the progesterone 
receptor (PR) is a predictive factor for the response to endocrine 
treatment and to chemotherapy in primary breast cancer. Knowledge 
about the prognostic relevance of the PR is rare and partly 
controversial. Aim of this retrospective study was to analyze the 
prognostic relevance of PR.
Methods
Between 1995 and 2008, data from 5,144 patients with heterogeneously 
treated primary breast cancers have been collected in 3 German 
university hospitals.
The laboratories used immunhistochemical assays for the investigation 
of the ER and PR.
The PR-expression was correlated with patient and tumor 
characteristics.
For each outcome parameter overall survival (OS), distant disease 
free survival (DDFS) and local recurrence free survival (LRFS) cox 
proportional hazad models were built. Furthermore the effect of the 
PR status was analyzed according to tumor subgroups.
Results
PR status was associated with a more favourable OS, DDFS and LRFS 
in the univariate analysis. PR remained an independent prognostic 
factor for OS and DDFS but not for LRFS in the cox proportional 
hazard model.
For OS and DDFS the prognostic effect of PR seemed to be consistent 
among the subgroups and was significant for most of them. Comparing 
subgroups there was a difference between the HR for ER negatives 
and ER positives. In ER negative tumors the prognostic effect of 
the PR seemed to be larger (HR=0.40; 95%CI: 0.25-0.63) than in 
ER positives (HR=0.68; 95%CI: 0.53-0.87). For all other subgroups 
there seemed to be no interaction between PR status and the other 
prognostic factors.
Conclusion
PR positivity results into a similarly favourable prognosis in ER 
negative and ER positive patients. ER positivity alone seems not to 
be sufficient to define a group of patients with the most favourable 
prognosis. On the contrary, patients with ER positive, PR negative 
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tumors have a signicantly deteriorated prognosis and seem to be 
a patient group, which should be investigated concerning drug 
resistance mechanisms.
P4-02-08
Obesity-Induced Aromatase Expression in the Breast 
Microenvironment Promotes Estrogen Receptor Activity 
Independent of Circulating Estradiol Levels.
Bowers LW, Brenner AJ, Li R, Tekmal RR, deGraffenried LA. The 
University of Texas at Austin, Austin, TX; The University of Texas 
Health Science Center at San Antonio, San Antonio, TX
Epidemiological studies indicate that obesity increases the risk of 
postmenopausal breast cancer by approximately 50%. In the past, 
researchers have hypothesized that elevated estrogen synthesis by 
the peripheral adipose tissue may be the principal mediator of breast 
tumorigenesis in this population, which primarily develops estrogen 
receptor alpha (ERa) positive breast cancer. However, obesity is 
also accompanied by an elevation in growth factor and cytokine 
signaling, and these pathways have been linked to tumorigenesis. 
In addition, certain growth factor and cytokine family members can 
promote aromatase expression in both the epithelial and stromal tumor 
compartments. Consequently, we hypothesized that obesity increases 
the risk of postmenopausal breast cancer via elevated aromatase 
expression and/or activity in the local mammary tissue.
To test our hypothesis, we investigated how ERa activity in 
mammary epithelial cells was influenced by adipose stromal cells 
(ASC) cultured under obesity-associated conditions, including high 
cell density and exposure to elevated levels of circulating growth 
factors and cytokines. For the latter condition, sera was obtained 
from postmenopausal women, pooled by BMI category (lean: 18.5-
24.9; obese: ≥30), and applied to the ASC, which were originally 
derived from women undergoing reduction mammoplasty. High 
ASC density was achieved via the protocol previously published 
by Dr. Li. Preliminary data indicated that both elevated cell density 
and sera from obese postmenopausal women induces greater 
aromatase expression in ASC, indicating that multiple factors may 
be contributing to the increased local aromatase expression seen 
with obesity. We are currently exploring the signaling pathways 
responsible for obesity’s upregulation of ASC aromatase expression 
and will present these results at the meeting. Intriguingly, exposure 
to conditioned media from both the high density and obese sera-
exposed ASC enhanced ERa activity in MCF-7 mammary epithelial 
cells, independent from exogenous estradiol but dependent on the 
presence of androgens, suggesting an important role for the aromatase 
enzyme in this observation. To expand on this finding, we plan to 
investigate the effect of ASC conditioned media on different markers 
of cancer aggression, including proliferation and survival, and assess 
the degree to which these effects depend on estradiol. Through further 
examination of obesity’s impact on signaling pathways in both the 
epithelial and stromal tumor compartments, we ultimately hope to 
identify more effective chemopreventive and therapeutic regimens 
for the high-risk obese postmenopausal population.
P4-02-09
Estrogen-Related Receptor a Mediates Insulin-Like Growth 
Factor-I Dependent Migration in Breast Cancer Cells.
Fettig-Anderson LM, Oh AS, Yee D. University of Minnesota, 
Minneapolis, MN
The orphan nuclear estrogen-related receptors (ERR) have homology 
to steroid hormone receptors. Unlike classical steroid hormone 
receptors, ERRs do not have known ligands but are transcriptionally 
activated upon binding to nuclear receptor coregulators such as 
PGC1a, PGC1b, and PPRC1. ERRs regulate energy metabolism 
and are accordingly expressed in tissues that require high energy 
production. ERRs recognize their own ERRE (estrogen-related 
receptor response element) gene promoters, but can also activate 
transcription via ERE (estrogen receptor response element) promoters, 
representing the ability of ERRs to cross participate in ERa regulatory 
pathways in the absence of estrogen. Of the three family members 
(a,b,g), ERRa is the most highly expressed in breast tissue. ERRa 
expression was found to be increased in ERa negative breast cancers 
and associated with poor prognoses. ERRa and its coactivators 
can increase the expression of a critical mediator of breast tumor 
angiogenesis and metastasis, VEGFA. We have previously shown 
that VEGFA is regulated by insulin and IGF receptor activation 
and hypothesized that ERRa may be a mediator of this finding. We 
therefore explored whether ERRa and its coactivators are necessary 
for IGF-I/insulin dependent regulation of VEGFA and cell migration. 
ERRa was expressed in breast cancer cell lines, but no correlation 
was observed with breast cancer subtypes. Reducing endogenous 
ERRa levels by shRNA reduced IGF-I dependent migration in MDA-
MB-231 cells. These results were confirmed using an ERRa specific 
inverse agonist (XCT-790), which also inhibited MDA-MB-231 cell 
migration. Modulating ERRa mRNA levels via shRNA resulted 
in decreased VEGFA mRNA levels in MCF7L cells and increased 
VEGFA mRNA levels in MDA-MB-231 cells, while the inverse 
agonist XCT-790 caused an increase in VEGFA mRNA levels in 
both cell lines. Reducing ERRa levels did not affect the expression 
of the IGF1R, InsR, IRS-1, IRS-2, PI-3K-Akt-mTOR dependent 
signaling pathway. Neither ERRa protein nor mRNA levels were 
modulated by IGF-I or insulin. We conclude that ERRa is important 
for mediating IGF-I dependent migration, but have shown that ERRa 
is not directly regulated by the IGF signaling. We will next explore 
the role of ERRa’s coregulators (PGC1a, PGC1b, and PPRC1) in the 
regulation of VEGFA by the IGF/insulin pathway given their central 
role in regulating ERRa’s function.
P4-02-10
The Relationship between Estrogen Receptor Gene Polymorphism 
and Mammographic Density in Postmenopausal Women.
Baldisserotto FDG, Elias S, Silva IDCG, Nazario ACP. Universidade 
Federal de Sao Paulo - UNIFESP-EPM, Sao Paulo, SP, Brazil
Background Assess the relation between the presence of PVUII 
and XBAI polymorphisms in the estrogen receptor alpha gene and 
mammographic density in postmenopausal women.
Methods For the present analysis, 189 postmenopausal women who 
had never used hormonal therapy and who did not have clinical or 
mammographic features were selected. Based on the ACR-BIRADSâ 
2003 classification, the mammographic density was determined 
by three independent readers (two subjective ratings and one 
computerized – Adobe Photoshop â 7.0 software). Blood samples 
were available to extract DNA according to KIT GFX â protocol. 
PCR-RFLP (Polymerase Chain Reaction – Restriction Fragment 
Length Polymorphism) was then used to identify the polymorphisms.
Results There was a high degree of agreement among the three readers 
to determine the mammographic density (Kappa>0.75). Sixty women 
(32%) had dense breasts and 129 (68%) had non-dense breasts. The 
PVUII polymorphism was found in 132 (69.8%) of 189 women, while 
the XBAI was found in 135 (71.4%) of women. Parity (p=0.02) and 
body mass index (p<0.0001) were associated with mammographic 
density. It was observed that for the XBAI polymorphism, women 
with two mutated alleles were approximately 2.5 times more likely to 
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be classified in dense breasts group (p=0.003) and the presence of both 
wild alleles was associated with fibroglandular tissue replacement 
by fat (p=0.02).
Conclusions There was no significant association of the PVUII 
polymorphism in the estrogen receptor alpha gene with mammographic 
density (p=0.34). However, the XBAI polymorphism was observed at 
a higher mutated homozygous frequency in women with dense breasts 
and there was an increased frequency of wild-type homozygous and 
heterozygous women with fat-replaced breasts (p=0.01).
P4-02-11
Insulin-Like Growth Factor I Promotes Estrogen Receptor 
Positive Breast Cancer Cell Proliferation, in Part, through 
CYP1A1 Signaling.
Rodriguez M, Becker M, Yee D, Potter D. University of Minnesota, 
Minneapolis, MN
Activation of the transmembrane tyrosine kinase insulin-like growth 
factor 1 receptor (IGF-1R) contributes to breast cancer progression. 
Nonetheless, the mechanisms by which the IGF-1R contributes to 
breast cancer progression need to be better characterized to further 
develop therapeutic strategies that target this pathway. It is known 
that cytochrome P450 monooxygenases synthesize metabolites 
from endogenous and exogenous sources that promote breast cancer 
proliferation. Here we propose that activity of the IGF-1R modulates 
the activity of CYP1A1 to promote breast cancer cell proliferation. 
We have found that IGF-IR activation by treatment with IGF1 (5nM 
) for 4hrs induces cytochrome P450 1A1 (CYP1A1) mRNA levels in 
estrogen receptor (ER) positive line T47D-CO, but not ER negative 
line MDA-MB-231. Treatment with IGF1 promotes the proliferation 
of ER positive lines T47D-CO and MCF7. Interestingly, we found 
that treatment with IGF1 only partially compensates the growth-
inhibition induced by CYP1A1 knock down by siRNA, suggesting 
that IGF1 requires CYP1A1 for full promotion of cell growth. 
These preliminary data suggest that IGF-1 signaling functions, in 
part, through CYP1A1 to promote ER positive breast cancer cell 
proliferation. The mechanism of IGF-1 signaling through CYP1A1 
is novel and may represent an effector mechanism for IGF-1. Further 
understanding the role of CYP1A1 downstream of the IGF-1R 
may allow novel approaches for inhibition of breast cancer cell 
proliferation downstream of the IGF-1R.
P4-02-12
Plasma Estradiol Levels and Degree of Estrogen Receptor 
Positivity by Image Analysis in a Large Cohort of Breast Cancer 
Cases: Results from the Nurses’ Health Study.
Collins LC, Frieling GW, Ahern TP, Hu R, Hankinson SE, Tamimi 
RM. Beth Israel Deaconess Medical Center, Boston; Harvard Medical 
School, Boston; Channing Laboratory, Brigham and Women’s 
Hospital, Boston; Harvard School of Public Health, Boston
Background: Breast cancer risk is strongly associated with 
endogenous reproductive hormones. There is also good evidence 
to suggest that endogenous estradiol levels are more strongly 
associated with the development of estrogen receptor (ER) positive 
breast cancers than with ER negative cancers. However, the degree 
of ER positivity in those cancers that develop is not yet established. 
Therefore, we sought to evaluate the proportion and intensity of tumor 
cells demonstrating ER positivity using image analysis in a large 
cohort of breast cancers for which we also had plasma estradiol levels.
Design: Tissue microarray (TMA) sections of breast cancers from 
women enrolled in the Nurses’ Health Study were immunostained 
for ER (1D5, Dako Corporation, Carpinteria, CA). Slides were 
then scanned using the ScanScope slide scanning system (Aperio 
Technologies Inc., Vista, CA) and ER staining was assessed for both 
intensity and percent of nuclei staining positively using a specific 
algorithm, Nuclear v9, which evaluates nuclear size, intensity, 
roundness, curvature, compactness, and elongation. Plasma samples 
were collected prior to the date of diagnosis for all women in the study 
and estradiol levels were determined by radioimmunoassay following 
extraction and celite column chromatography.
Result: Image analysis data for ER was available for 691 breast 
cancers. The mean percent of tumor cell positivity was approximately 
uniformly distributed, with a mean of 44.5%, (median=41.3%, 
max=99.6%). The proportion of tumor cells staining for ER from the 
TMA cores was positively associated with patient age (p<0.0001), 
and postmenopausal status (p=0.008), while inversely associated with 
tumor grade (p<0.0001). Among women with image analysis data for 
ER, plasma estradiol data were also available for 320 postmenopausal 
women. Estrogen receptor positivity (by proportion or intensity) did 
not vary according to plasma estradiol levels (p=0.17).
Mean percent of ER positivity by quintile of plasma estradiol
Quintile of plasma estradiol 
concentration
*Mean estradiol concentration, 
pg/mL (sd)
Percent of tumor nuclei expressing the 
estrogen receptor: mean (sd)
1 4.4 (1.3) 44.6 (31.9)
2 8.4 (3.3) 42.7 (33.7)
3 13.1 (5.4) 55.0 (29.7)
4 19.6 (8.9) 48.4 (29.4)
5 34.0 (19.5) 44.5 (26.8)
*Among post-menopausal women who either never used postmenopausal hormones or were former 
users at the time of their blood draw. Outliers >100pg/ml excluded (n=4).
Conclusion: While high concentrations of plasma estradiol are more 
strongly associated with the development of estrogen receptor positive 
breast cancer versus estrogen receptor negative cancers, the degree 
of estrogen receptor positivity in the breast cancers that develop is 
not influenced by this variable.
P4-03-01
Stat5 Regulates the PI3-Kinase/Akt1 Pathway during Mammary 
Gland Development and Promotes Neoplastic Transformation in 
a Mouse Model for Cowden Syndrome.
Schmidt JW, Sakamoto K, Creamer BA, Leone G, Wagner K-U. 
University of Nebraska Medical Center, Omaha, NE; Ohio State 
University, Columbus, OH
Background: The Jak/Stat pathway responds to extracellular 
signals (i.e. cytokines) to promote physiological responses at the 
transcriptional level. In the developing mammary gland, Jak2/Stat5 
signaling is critical for transducing prolactin signals by promoting 
the proliferation, differentiation, and survival of alveolar epithelial 
cells during pregnancy and lactation. Additionally, hyper-activation of 
Jak2/Stat5 activity has also been shown to cause mammary tumors in 
a number of transgenic models and we have previously shown it plays 
a crucial role in the early neoplastic events of prolactin and ErbB2-
induced tumorigenesis. However, the mechanisms and target genes 
by which Stat5 promotes cell survival and neoplastic transformation 
remain to be elucidated and are the focus of this current study.
Materials and Methods: To assess the functions of Stat5 during 
mammary development, gain-of-function Stat5 was expressed in a 
spatial and temporal manner within the mammary epithelial cells of 
double transgenic females (Wap-rtTA TetO-Stat5S710F model) during 
lactation and involution in a doxycycline (dox)-inducible manner. 
Mammary tissues were collected for histological examination along 
with mRNA, protein, and chromatin immunprecipitation (ChIP) 
analyses. HC11 mouse mammary epithelial cells were infected to 
overexpress wildtype or gain-of-function Stat5, a constitutively active 
prolactin receptor, or combinations of both. Finally, the functional 
cooperation between Stat5 and PI3-kinase/Akt signaling in promoting 
mammary cancer was assessed by expressing hyperactive Stat5 
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specifically within the mammary epithelium of females harboring 
a knock-in PtenG129E mutation found in patients with Cowden 
Syndrome (PtenG129E MMTV-tTA TetO-Stat5S710F model).
Results: Dox-induced expression of active Stat5 during involution 
overrides pro-apoptotic signaling and sustains p-Akt1 levels along 
with expression of the PI3-kinase and Akt1, which are normally 
downregulated at the transcriptional and protein levels during 
involution. ChIP analysis revealed that Stat5 binds two consensus 
sites in the Akt1 promoter during lactation whereas this is lost by 
the second day of involution. Furthermore, Stat5 promotes the 
transcriptional activation of Akt1 through a novel mammary-specific 
promoter and this suggests a mechanism for Stat5 in cell survival both 
in mammary development and breast cancer. Preliminary results also 
suggest that forced expression of active Stat5 in the mammary glands 
of PtenG129E females accelerates the development of mammary 
intraepithelial neoplasia (MIN) lesions predisposed by the loss of 
PI3K/Akt inhibition.
Discussion: In this study we demonstrate that Stat5 regulates PI3-
kinase/Akt1 signaling during mammary gland development and this 
provides a mechanism for enhancing cell survival during lactation 
and for allowing apoptosis through loss of this regulation during 
involution. These findings further suggest that Jak2/Stat5 signaling 
may play an important role in the development of breast cancers 
induced through aberrant PI3-kinase/Akt signaling (i.e. Cowden 
Syndrome) and that targeting Jak2/Stat5 activity might be a suitable 
strategy for prophylactic intervention.
P4-03-02
High Fat Diet-Induced Postmenopausal Obesity Promotes Tumor 
Angiogenesis and Breast Cancer Progression in Age-Relevant 
Ovariectomized Mice.
Gu J-W, Young E, Patterson SG, Makey KL, Huang M, Tucker KB, 
Chinchar E, Miele L. University of Mississippi Medical Center, 
Jackson, MS
Background: Obese postmenopausal women have 50% higher 
risk of breast cancer than non-obese women. The mechanisms 
of postmenopausal obesity-induced breast cancer are poorly 
understood due to lack of the established animal model that mimics 
postmenopausal obesity related to breast cancer progression.
Material and Methods: Using age-relevant C57BL/6 mice, this 
study determined whether postmenopausal obesity increases 
VEGF expression, tumor angiogenesis, and breast tumor growth. 
Ovariectomy (OVX) was performed in 12 sixty week-old female 
mice (life span is about 140 weeks), then followed by a low-fat (5%, 
LF, n=6) or a high-fat (60%, HF, n=6) diet for 12 weeks. In the 8th 
wk of the dietary program, 10^6 E0771 (mouse breast cancer) cells 
were injected in the left fourth mammary gland. Tumor size was 
monitored using dial calipers for 4 wk. Body weights were monitored 
weekly. At the end of the experiment, blood samples, visceral fat, 
and tumors were collected for measuring VEGF expression using 
ELISA and intratumoral microvessel density (IMD) using CD31 
immunochemistry.
Results: Body weight was significantly increased in OVX/HF mice, 
compared to OVX/LF group (55.3±1.7 vs. 41.5±1.5 g; P<0.01). 
There was a two-fold increase in the ratio of visceral fat/BW in OVX/
HF mice, compared to those in OVX/LF group (0.062±0.005 vs. 
0.032±0.003; P<0.01). Postmenopausal obesity significantly increased 
breast tumor weight over the control (4.62±0.63 vs. 1.98±0.27 g; 
P<0.01) and IMD (173±3.7 vs. 139±4.3 IM#/mm^2; P<0.01). Tumor 
VEGF levels were higher in OVX/HF mice, compared to OVX/
LF group (73.3±3.8 vs. 49.5±4.3 pg/mg protein; P<0.01). Plasma 
VEGF levels (69±7.1 vs. 48±3.5 pg/ml) and visceral fat VEGF 
levels (424.4±39.5 vs. 208.5±22.4 pg/mg protein) were significantly 
increased in OVX/HF mice, compared to OVX/LF group, respectively 
(n=6; P<0.01). Interestingly, adipose tissue primary culture showed 
that subcutaneous fat released more VEGF, compared to visceral fat 
(6.77±1.14 vs. 0.94±0.16 pg/mg tissue; n=6; P<0.01). The abdominal 
subcutaneous fat expressed more VEGF proteins than visceral fat in 
OVX/HF mice (692±72 vs. 431±44 pg/mg protein; n=6; P<0.01). 
There was a strong positive linear correlation between increased 
breast tumor weight and visceral fat weight in OVX mice (R2=0.7379; 
N=12; P<0.01). However, there was no significant difference in heart, 
or kidney weight/body weight ratio between postmenopausal obesity 
(OVX/HF) mice and the control mice (OVX/LF).
Discussion: Our observations indicate that ovariectomy plus a high 
fat diet with the inoculation of E0771 (mouse ER+ breast cancer) 
cells in female wild type >60 week old mice can mimic human 
obesity-induced postmenopausal breast cancer. The increased 
tumor angiogenesis in postmenopausal obese mice was correlated 
with increased breast tumor growth, adipose tissue mass, and 
adipokines such as VEGF. These findings support the hypothesis 
that postmenopausal obesity promotes tumor angiogenesis and breast 
cancer progression, possibly through increased adipose tissue mass 
and adipokines such as VEGF that could systemically and locally 
affect breast cancer progression.
P4-03-03
Therapeutic Sensitivities of Mouse Models of Human Breast 
Cancer.
Usary JE, Darr DB, Zhao W, Balletta LD, Aparicio AP, Karginova OA, 
Jordan JL, Perou CM. University of North Carolina, Chapel Hill, NC
Genetically engineered mouse (GEM) models have provided a wealth 
of information regarding the genetic causes of cancer, but their utility 
for preclinical drug evaluation has not been well examined. Here we 
have used three mammary tumor GEM models that represent three 
human breast cancer subtypes and have evaluated their sensitivities 
to chemotherapy and to three biologically targeted agents. We have 
selected three mouse models that resemble human breast cancer 
subtypes based upon common gene expression profiles; Basal-like 
tumors are represented by the C3(1)-T-antigen (C3-TAg) model, 
Luminal B tumors are represented by the MMTV-Neu model, and 
the P53 null transplant T11 line represents the newly described 
Claudin-low breast tumor subtype. On each of these models we 
have tested the therapeutic efficacy of: four chemotherapeutics 
(doxorubicin, carboplatin, paclitaxel, and cyclophosphamide), 
two chemotherapy combinations (carboplatin/paclitaxel and 
doxorubicin/cyclophosphamide), and three biologically targeted 
agents (erlotinib, lapatinib, and ABT-888, alone and combined with 
selected chemotherapies).
The results from individual models were as follows:
The MMTV-Neu tumors were sensitive to the single-agent 
chemotherapeutics carboplatin and cyclophosphamide, and 
cyclophosphamide dramatically increased overall survival of the 
MMTV-Neu mice. The targeted agents lapatinib and erlotinib were 
extremely effective; lapatinib produced a near complete regression in 
every MMTV-Neu mouse tested and both compounds lead to greatly 
increased survival times.
In the Claudin-low T11 line, the tumors were very sensitive to 
cyclophosphamide. Alone and in combination with doxorubicin, 
cyclophosphamide was the only chemotherapeutic able to successfully 
cause tumor regression in this model. None of the biological inhibitors 
were effective as single agents in these mice, nor were they effective 
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in combination with chemotherapeutics other than cyclophosphamide
In the C3-TAg basal-like model, carboplatin alone and in combination 
with other drugs caused volume reduction in some of the tumors. 
Erlotinib was able to cause volume reductions in a third of the treated 
C3-Tag tumors, which revealed a heterogeneity of response within 
this GEM strain. None of the single agent treatments significantly 
increased overall survival in these mice. Those combination 
treatments that were effective showed a range of responses from 
tumor regression to slowed progression.
Finally, we closely examined the heterogeneous responses of the 
C3-Tag tumors to carboplatin/paclitaxel and performed expression 
profiling of sensitive and resistant tumors. We identified a gene 
signature from these treated mouse tumors that was able to predict 
pathological complete response of human patients receiving multi-
agent taxane-containing neoadjuvant chemotherapy regimens. These 
results show that genomically selected GEM models can recapitulate 
findings seen in human tumors (like lapatinib responsiveness in 
HER2+ tumors and carboplatin sensitivity in basal-like tumors) and 
that GEM models can potentially be used to develop biomarkers and 
to test new drug combinations prior to their being tested in humans.
P4-03-04
Identification of Molecular Targets for Cancer-Initiating Cells 
Using a Triple-Negative Breast Cancer Mouse Model.
Kai K, Iwamoto T, Pusztai L, Hortobagyi GN, Saya H, Ueno NT. 
The University of Texas MD Anderson Cancer Center, Houston, TX; 
Institute for Advanced Medical Research, Shinjuku-ku, Tokyo, Japan
Background: Triple-negative breast cancer (TNBC), which is 
negative for estrogen receptor, progesterone receptor, and HER2, 
cannot be targeted with hormonal or anti-HER2 agents and frequently 
relapses. Thus, innovative molecular targeted therapies for TNBC are 
needed. Cancer-initiating cells (CICs) play a crucial role in tumor 
recurrences. TNBC has a much higher proportion of CICs compared 
with the other breast cancer subtypes, reflecting TNBC’s clinical 
aggressiveness. However, qualitative or molecular traits of TNBC 
CICs have not been fully elucidated. We established a TNBC mouse 
model that successfully recapitulated human-like TNBC in vivo 
(SABCS 2010 abstract P1-03-02). We here report the phenotypes and 
molecular features of CICs in our TNBC mouse model. Methods: 
We created this animal model by transferring HRAS(G12V) into 
Ink4a/Arf-knockout (KO) mouse mammary epithelial cells (MECs) 
in vitro and inducing tumors in mammary fat pads of recipient mice. 
The induced TNBCs were digested, and single suspended cells were 
reacted with antibodies to candidate CIC markers CD29, CD24, 
CD44, Sca1, CD61, and CD49f. Expression patterns of the tumor cells 
were analyzed by FACS. Tumor cells were sorted according to their 
expression levels and inoculated into recipient mouse mammary fat 
pads to determine tumor-initiating activity. To analyze the cell-cycle 
status of tumor cells, we stained them with Hoechst 33342 (for DNA 
staining) and pyronin Y (for RNA staining) and analyzed them by 
FACS. The CICs’ genome-wide molecular profiles were determined 
by mouse microarray expression analysis. Results: In FACS and the in 
vivo tumor-initiating assay, the CD49f expression level was the most 
significant for defining tumor-initiating activity. That is, CD49f- tumor 
cells had much higher tumor-initiating activity than did CD49f+ cells 
at 100-cell inoculations (CD49f-, 5 tumors/8 mice; CD49f+, 0/8). We 
hypothesized that tumor initiation by CD49f- cells depends on their 
quiescent profile, which is a trait of CICs. To test this hypothesis, we 
further fractionated CD49f- cells into CD49f- quiescent (CD49f-q) 
cells and CD49f- dividing cells and inoculated these fractions into 
recipient mice. CD49f-q cells had higher tumor-initiating activity 
than that of CD49f- dividing cells. We thus determined that CD49f-q 
cells were CICs in our model. Genome-wide expression patterns for 
CD49f-q cells and CD49f+ cells were compared by paired t test, and 
over- and underexpressed genes in CD49f-q cells were functionally 
annotated by Ingenuity pathway analysis. The top-ranked bioprocess 
of overexpressed genes in CD49f-q cells was hepatic satellite cell 
activation (HSCA), followed by pantothenale and Coenzyme A 
biosynthesis, and HER2 signaling in breast cancer. HSCA is known 
to result in liver fibrosis due to collagen deposits in response to liver 
damage. In CD49f-q cells in our model, collagen family proteins 
and the upstream endothelin-A receptor were overexpressed and 
significantly correlated with HSCA. Conclusion: We identified CICs 
in a mouse TNBC model and revealed their molecular profile. We 
plan to analyze expression of HSCA-associated proteins in human 
TNBC. Our first step is to determine whether endothelin-A receptor 
is a therapeutic target in human TNBC.
P4-03-05
Development of an Inducible Estrogen Receptor Co-Activator 
PELP1 Mammary Tumor Model.
Cortez VA, Newallo D, Chodosh LA, Tekmal RR, Vadlamudi RK. 
The University of Texas Health Science Center at San Antonio, 
San Antonio, TX; University of Pennsylvania School of Medicine, 
Pennsylvania, PA
Despite treatment advances, breast cancer remains the second most 
lethal malignant disease for women worldwide. Given the importance 
of estrogen receptor (ER) and hormone-dependent nature of breast 
cancer, pharmacologic agents were developed to either modulate 
ER functions or reduce circulating estrogens levels. Although 
targeted endocrine therapies significantly reduce mortality in patients 
with estrogen sensitive (ER+) tumors, both de novo and acquired 
resistance limits efficacy. A critical need for identifying more precise 
diagnostic/prognostic biomarkers and novel therapeutic targets 
prompted deeper investigation into ER-coregulatory protein function 
and regulation. ER-coactivator PELP1, mediates both nuclear and 
extra-nuclear estrogen signaling and crosstalk with growth factors. 
PELP1 is deregulated in hormone-driven cancers, associates with 
undifferentiated invasive breast adenocarcinomas and an independent 
prognostic biomarker in assessing clinical outcome of luminal-like 
breast cancer patients. Collectively, several studies suggest PELP1 is 
an ERa coregulator with tumorigenic potential. However, the in vivo 
significance of PELP1 deregulation during initiation and progression 
of breast cancer is unknown. To determine the role of PELP1 over-
expression in mammary tumorigenesis, we generated an inducible 
transgenic murine model. Transgene construct (pTetOPELP1) consists 
of a full-length human PELP1 cDNA linked to luciferase gene reporter 
through an internal ribosomal entry site (IRES). PELP1 transgene 
was purified and microinjected into mouse zygotes to generate 
pTetOPELP1 mice. Founder mice were identified by Southern blot 
analysis, of genomic DNA extracted from tail biopsies, for transgene 
integration through germline transmission. pTetOPELP1 mice were 
breed with mammary gland-specific rtTA mice (MMTVrtTA) to 
produce MMTVrtTA-TetOPELP1 bitransgenic mice. Potential 
founder mice were identified by polymerase chain reaction and breed 
to establish two independent transgenic lines. Transgene expression 
was induced in adult female bitransgenic animals with 200mg/
mL of doxycycline administered in drinking water. Concurrent 
expression and activity of the luciferase gene reporter was detected 
specifically in the mammary gland by in vivo bioluminescence 
imaging, luciferase assay and RT-PCR. Mammary epithelial-specific 
expression of PELP1 was validated by immunohistochemistry 
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and Western blot analysis. PELP1-mediated morphological and 
histological changes were analyzed by examining carmine-stained 
whole mounts and H&E-stained mammary glands sections. Our early 
findings with MMTVrtTA-TetOPELP1 bitransgenic mice (n=30) early 
preneoplastic changes and hyperplasia were evident as early as 12 
weeks and the formation of mammary tumors by 8 months of age 
following PELP1 induction by doxycycline treatment. By utilizing 
the tetracycline-regulatory system, we created a novel, inducible and 
mammary gland-specific PELP1-expressing transgenic model for 
future in vivo studies into molecular mechanisms of PELP1-mediated 
mammary tumorigenesis.
P4-03-06
Development and Comparative Characterization of Metastasis 
in Newly Developed Pre-Clinical Models of Inflammatory Breast 
Cancer.
Chu K, Mu Z, Alpaugh KR, Fernandez S, Freiter EM, Wu H, Zook 
MB, Barsky SH, Cristofanilli M, Robertson FM. The University of 
Texas MD Anderson Cancer Center, Houston, TX; Fox Chase Cancer 
Center, Philadelphia, PA; University of Nevada School of Medicine, 
Reno, NV; Nevada Cancer Institute, Las Vegas, NV
Background: Inflammatory breast cancer (IBC) is the most metastatic 
variant of breast cancer. It is associated with a poor survival rate (40% 
5-year survival) despite appropriate multidisciplinary care. For such 
an aggressive type of cancer, IBC has been understudied, in part due 
to the lack of adequate numbers of cell lines and mouse models that 
recapitulate the human disease. To expand our understanding of IBC, 
we have obtained all of the previously developed and characterized 
IBC cell lines and models including Mary-X, SUM149, SUM190, 
KPL-4, MDA-IBC-3 and have developed two new IBC models, 
designated as FC-IBC01 and FC-IBC02, using tumor cells derived 
from pleural effusion of IBC patients.
Materials and Methods: Each of these IBC cell lines has been 
luciferase (LUC)-tagged, allowing the growth of orthotopic injection 
or subcutaneous implantation to be evaluated by bioluminescent 
imaging (BLI). Alternatively, the LUC-tagged IBC cells can by 
injected via either intra-cardiac or intravenous route of delivery, 
which promotes rapid tumor colonization, resulting in both visceral 
and skeletal metastasis. Growth of IBC tumors can then be monitored 
immediately using BLI, thus eliminating the lag time needed for the 
physical detection of palpable tumors. BLI imaging also allows for 
monitoring of the kinetics and location of development of metastatic 
lesions. Whole transcriptome analysis was performed on IBC cell 
lines and xenograft tissues to define the heterogeneity of IBC as a 
distinct variant of breast cancer
Results: These models have allowed us to identify micro-metastatic 
foci in multiple sites distant from the IBC primary tumor in each 
of these models of IBC and allow the quantitation of anti-tumor 
and anti-metastatic effects of targeted therapeutics as single agents 
as well as the potential synergy of combinations of agents. As an 
example, injection of LUC-tagged IBC cell lines such as SUM149-
Luc, into the left ventricle of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice 
allows the metastatic tumor burden to be monitored longitudinally 
by whole animal BLI, which can be validated at necropsy and by 
immunohistochemical analysis. Whole transcriptome analysis of 
pre-clinical models of IBC reflect the molecular subtypes observed 
in IBC patients, with the majority of IBC models being of the basal 
like, luminal B and Her2 amplified. Discussion: First time analysis 
of known and newly developed pre-clinical models of IBC allows a 
more complete analysis of IBC as a distinct variant of breast cancer. 
Furthermore, these approaches allow rapid evaluation of the promising 
targeted therapeutics identified based on whole transcriptome analysis 
of both IBC patient tumors and pre-clinical models developed from 
IBC patients. We believe that this extensive collection of LUC-tagged 
IBC cell lines is an invaluable tool for IBC research since the cell 
lines encompass the broad spectrum of IBC heterogeneity.
P4-04-01
Identification of a Unique Mammary Cell Type Expressing 
Mesenchymal Markers, but Capable of Multilineage Epithelial 
Differentiation.
Landua JD, Lewis MT. Baylor College of Medicine, Houston, TX
We have identified a previously uncharacterized cell population 
within the epithelial compartment of the post-pubertal mouse 
mammary gland. These cells can be found as singlets or as like 
pairs in both the cap and body cell layer of terminal end buds (TEB) 
of developing ducts, and are ultimately localized in a suprabasal 
position distributed throughout the mature mammary ductal tree. In 
differentiated ducts, these cells typically extend long processes that 
contact multiple surrounding luminal epithelial and myoepithelial 
cells suggesting a function in cell-cell communication. In younger 
animals, identified cells do not express epithelial markers including 
the major cytokeratins (CK) 5, 6, 8, and 14, or E-cadherin, nor do 
they express myoepithelial cell markers such as smooth muscle actin 
or p63. However, in 20 week old non-parous females, these cells 
can give rise to epithelial cell types expressing CK 5, 6, 8, or 14. 
In transplantation assays, epithelial fragment and whole mammary 
gland transplantation did not indicate a major role in regenerative 
growth of mammary ducts. Transplantation of dissociated epithelial 
cells and wound-healing assays are in progress. Taken together, 
these observations suggest that this unique cell population possess 
stem cell-like features in that they are capable of self-renewal, and 
of giving rise to all major differentiated cell types within the mouse 
mammary gland.
P4-04-02
Smoothened Function as a G-Protein Coupled Receptor in 
Mammary Epithelial Cells.
Villanueva H, Visbal AP, Birnbaumer L, Plummer NW, Lewis MT. 
Baylor College of Medicine, Houston, TX; National Institute of 
Environmental Health Sciences, Research Triangle Park, NC
Background: Hedgehog signaling orchestrates many key 
developmental processes, including cell fate determination and tissue 
patterning in the embryo, as well as tissue homeostasis and stem 
cell maintenance in the adult. Aberrant hedgehog signaling has been 
implicated in several cancers including skin, brain, prostate and breast. 
Previous work in our laboratory demonstrated that overexpression of 
activated Smoothened (SMO), a key effector in hedgehog signaling, 
leads to mammary hyperplasia, and is overexpressed in DCIS and 
IBCs.
Consistent with recent data, we now provide evidence that SMO 
signals via Gai proteins in the mouse mammary gland.
Hypothesis: Smoothened promotes mammary gland proliferation 
by functioning as a G-protein coupled receptor(GPCR) and couples 
to one or more members of the PTX-sensitive Gai family of 
heterotrimeric G-protein subunits.
Experimental Design and Methods: Expression of Gai subunit(s) 
was tested by qRT-PCR & immunofluorescence microscopy of 
mammary epithelial cells (MECs) and whole mammary glands from 
SMO and WT mice. We analyzed mammary glands from single Gai 
subunit null mice for developmental abnormalities. Genetic studies 
are underway in which SMO mice are crossed to Gai1, 2 & 3 null mice.
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To elucidate downstream signaling events triggered by SMO 
activation, we are treating SMO derived MECs cultured in a 3D 
matrix and whole gland organ cultures with inhibitors of Gai 
effector molecules and assessing proliferation status. We will also 
employ GTPgS binding assays using primary MECs from SMO 
overexpressing mice to test whether SMO can activate Gai proteins 
in mammary gland epithelium.
Results and Discussion: Treatment of MMTV-Cre dependent SMO 
hyperplasias with pertussis toxin (PTX), a potent inhibitor of Gai 
family of G-protein signaling, significantly attenuates mammary 
gland hyperproliferation. This result supports the hypothesis that 
Smoothened functions as a GPCR interacting with one or more 
members of the Gai family.
We have now found that Gai2 and Gai3 null mice display an increased 
number of terminal end buds and a more completely filled fat pad 
relative to WT control littermates.
Our data suggest that SMO-expressing cells induce proliferation 
of neighboring WT cells and that low-level proliferation in SMO-
expressing cells is not affected by PTX.
qPCR data indicates that Gai1 is the most abundant transcript in 
sorted MECs which overexpress SMO and that the Notch signaling 
pathway may be activated.
While our mechanistic data thus far mostly comprises transcriptional 
analyses coupled with pharmacological inhibition, they offer insight 
as to which pathways may be regulated by SMO activation. Genetic 
crosses between the SMO and Gai null mice should provide evidence 
that these two proteins interact in the developing mammary gland. 
When associated with biochemical data, these studies ought to 
provide functional insight into the mechanism behind SMO-driven 
mammary hyperplasias.
This work offers potential clinical implications towards breast cancer 
treatment as there exist therapeutic agents targeting the hedgehog 
signaling pathway in clinical trials that were developed by solely 
testing their ability to inhibit GLI1/2-mediated transcription. Our 
data identify targets for intervention other than the GLI transcription 
factors.
P4-05-01
Rab25 Alters Cellular Energetics and Growth Signaling during 
Breast Oncogenesis.
Mitra S, Cheng KW, Dennison JB, Mills GB. MD Anderson Cancer 
Center, Houston, TX
Background: Conservation and consumption of cellular energy is 
centrally regulated by growth and metabolism of the whole organism. 
The cancer cell gains autonomy from this regulation to become an 
organism with indeterminate growth potential. Plasma membrane 
receptors including growth factors and nutrient receptors are sensors 
for microenvironmental cues that dictate the intracellular energetic 
pathways to recalibrate ATP production based on available resources. 
So altercations in both growth and metabolic pathways are common 
features of cancers. A unifying component between receptor mediated 
growth signaling and metabolic pathways within a cell could be the 
vesicular trafficking system that imports, transports and exports a 
wide array of cargo from both these pathways.
In fact, derailed endocytosis is a hallmark of cancer. The endocytic 
pathway, as demonstrated by our laboratory, is a frequent target of 
genomic aberrations in cancer, and plays a critical role in maintenance 
of cellular polarity, stem cell fnction, bioenergetics, proliferation, 
motility, invasion, metastasis, apoptosis and autophagy. The Rab 
GTPases along with their effectors are critical regulators of this 
endocytic machinary and can have a huge impact on the cellular 
iterinary of growth and metabolism.
Methods and results : A broad spectrum analysis of distribution of all 
the Rab family members across 52 breast cancer cell lines reflected a 
dichotomous distribution of Rab25, with higher mRNA and protein 
expression in ER+ cell lines. Rab 25 is of immense interest to us 
because of its unique substitution of leucine for glutamine at position 
71which typically decreases the intrinsic GTPase activity, resulting 
in a dominant, constitutively active protein, akin to a transforming 
RAS mutation.
Using high throughput mRNA data analysis, we report that Rab25 and 
its effector Rab Coupling Protein (RCP) are frequently coamplified 
and coordinately elevated in ER +ve breast cancers. Specifically 
in the luminal B subtypes, they are significantly associated with 
a markedly worsened outcome. In vitro, in MCF7 cell line, we 
observe an increased EGFR stability and MAPK signaling in Rab25 
overexpressing stable clones which could be reversed with shRNA 
knockdown of Rab25. Loss of either Rab25 or RCP inhibited survival 
and growth of MCF7 lines under serum free conditions suggesting 
that Rab25 can potentially facilitate growth factor independence 
in cancer cells. Most importantly, we report that Rab25 enhances 
mitochondrial ATP production in breast and ovarian cancer cells 
and significantly reduces acidification of the ECM. Our ongoing 
experiments are directed towards understanding the mechanistic link 
between Rab25 mediated effects on EGFR/pERK signaling and its 
effects on cellular metabolism.
P4-05-02
Early Developmental Exposures to a High Carbohydrate/High 
Fat Diet Affect Glucose Metabolism and Mammary Cancer 
Susceptibility.
Berton TR, Lambertz I, Tian J, Johanning G, Conti C, Fuchs-Young R. 
UT MD Anderson Cancer Center, Smithville, TX; UT MD Anderson 
Cancer Center, Bastrop, TX
Background: The obesity epidemic in the U.S. has substantially 
increased the number of people with altered glucose metabolism. 
Alterations in metabolic programming, resulting from early exposures 
can affect development, metabolism as well as propensity to later 
diseases, including cancer. The Warburg effect describes a mechanism 
by which diet-induced hyperglycemia and hyperinsulinemia can 
contribute to cellular transformation. To investigate the effect of 
a hyperinsulinemia-, hyperglycemia-inducing (HI/HG) diet on 
metabolic programming and susceptibility to mammary cancer, we 
exposed developing mouse pups during three developmental stages: 
gestation, lactation and post-weaning.
Materials and Methods: Female SENCAR mice were fed either 
a mildly restricted, defined, “chow like” control diet (DR) or a HI/
HG, high sucrose/high fat (HS/HF) diet. At 14 weeks, both DR and 
HS/HF fed female mice were bred and the resulting offspring were 
randomized into 8 groups to model all combinations of gestational, 
lactational and post-weaning dietary exposures. Body weights (BW) 
were recorded weekly and Glucose Tolerance Tests (GTTs) were 
conducted on the female offspring at 10-12 weeks of age. Starting at 
7-9 weeks of age, mice received 20 mg/day of DMBA or vehicle by 
daily gavage to induce mammary carcinogenesis.
Results: Animals in the DR/DR/DR (gestational diet/nursing diet/
post-weaning diet) and HS/DR/DR groups had the lowest average BW 
and retained normal response to glucose, while mice in the DR/HS/
HS and HS/HS/HS groups had the highest average BW. Interestingly, 
animals born to DR-fed and nursed by HS/HF mothers and weaned 
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onto a HS/HF diet (DR/HS/HS) were the most glucose intolerant. 
In response to DMBA, animals in the different dietary regimens 
partitioned into high, moderate or low mammary tumor incidence 
groups. Mice fed consistent diets throughout gestation, lactation and 
post-weaning (DR/DR/DR or HS/HS/HS) had intermediate tumor 
incidence. However, mice exposed to DR during gestation and/
or lactation and then switched to a HS/HF diet at weaning had the 
highest tumor incidence and shortest latency. Mice exposed to a HS/
HF diet during gestation and/or lactation and then switched to a DR 
diet at weaning had the fewest mammary tumors and longest latency.
Conclusion: Our data indicate that substantial changes in the type 
and abundance of calories during gestation and/or lactation had 
long-lasting impacts on BW, glucose metabolism, and mammary 
tumorigenesis. Since BW did not consistently correlate with GTT 
results, the effects of dietary manipulation on obesity and glucose 
metabolism appear to be distinguishable. Results also indicate 
that diet-induced changes in the glucose metabolism of the mother 
profoundly affected tumor susceptibility in the exposed female 
offspring. These findings support the contention that rising levels 
of obesity, metabolic syndrome, and diabetes, especially in young 
individuals, may contribute to the increasing incidence of early onset 
breast cancer.
P4-05-03
Mechanism Underlying Metabolic Heterogeneity in Breast 
Cancer Subtypes.
Molina JR, Dennison JB, Zhang F, Mills GB. MD Anderson Cancer 
Center, Houston, TX
Background: Several distinct subtypes of breast cancer (Luminal, 
Basal-like and Her-2+) have been identified by gene expression 
profiling of breast cancers and cell lines. Although much is known 
about the regulation of cell signaling in each breast cancer subtype, 
little is known about subtype-specific energy metabolism and its 
regulation. The majority of cancers, including breast cancer, acquire 
an accelerated metabolic index as part of the transformation process. 
One of the most studied metabolic changes in cancer, referred to as the 
Warburg effect, is the increased uptake of glucose and its conversion 
to lactate; which is released from the cell, thus creating an astringent 
tumor microenvironment with high lactate and low pH. Accumulation 
of lactate in the tumor microenvironment presents cancer cells with 
a potential rich carbon source that could be exploited when the 
preferred nutrient sources, glucose and glutamine, are not abundant 
or available. Thus uptake and conversion of lactate to pyruvate and 
then entry into the TCA cycle and oxidative phosphorylation could 
generate energy that could potentially allow cancer cells to survive 
until other nutrients become available or until the cancer cells can 
invade and migrate toward nutrient rich environments, in other words, 
until they spread locally and metastasize.
Methods and Results: Examination of 59 breast cancer cell lines 
shows differences in expression of numerous proteins and enzymes 
involved in cellular metabolism, including the lactate transporters 
(MCT), the enzyme lactate dehydrogenase (LDH), and glucose 
transporter proteins (GLUT). We found that MCT1 expression is lost 
in the Luminal subtype and correlates with loss of LDHB and the 
regulator and chaperone of MCT1, CD147 (Basigin). Conversely, 
MCT1 is highly expressed in Basal-like and normal cell lines, along 
with CD147 and LDHB. While monocarboxylate transporter proteins 
can transport bi-directionally, MCT1 preferentially transports lactate 
into the cell, while MCT4 transports lactate out of the cell. The loss 
of MCT1 in luminal cells suggests a distinct energy metabolism in 
this subtype versus basal-like cells. The basal-like subtype has been 
further categorized into Basal and Claudin-low subtypes. Claudin-low 
cells express stem-like markers such as CD44+/CD24-, EMT markers 
such as vimentin, and are low expressers of the Claudin proteins. We 
found that MCT1 and CD147 are highly expressed and differentially 
regulated in Claudin-low cell lines as compared to normal cells. We 
have evidence that high lactate (10mM) as a sole energy source delays 
ATP loss and apoptosis in MCT1 expressing cells, but not in luminal 
cell lines that lack MCT1. Thus, claudin-low tumors may benefit 
from local lactate production providing an unexpected energy source.
P4-05-04
Arachidonic Acid-Induced Elevated Expression of 5-Lipoxygenase 
Is Linked to Metastatic Migration of Breast Cancer Cells.
Roy D, De Chatterjee A, Pal R, Roychowdhury S, Das S. University 
of Texas at El Paso, El Paso, TX
Background: In invasive breast cancers, cancerous cells spread 
outside the ducts of the breast and metastasize to lung and other 
tissues. Although the rapid arachidonic acid (AA) metabolism and 
concomitant increase of eicosanoid molecules are involved in the 
proliferation and invasion of breast cancer cells, the exact mechanism 
by which AA metabolites regulate these phenomena are not well 
understood. Here, we show that leukotriene B4 (LTB4), one of the 
metabolites of AA, which is produced by the action of 5-lipoxygenase 
(5-LOX), causes the proliferation and metastatic migration of breast 
cancer cells.
Material and Methods: MDA-MB-231 (invasive breast cancer 
cells) and MCF7 (non-invasive breast cancer cells) were used 
in this study. Briefly, cells were treated with AA (100 mM) and 
nordihydroguaiarectin acid (NDGA, 10 mM), and the secreted 
eicosanoids were characterized by HPLC. Immunofluorescence 
microscopy was performed to elucidate the expression and 
intracellular localization of 5-LOX. The metastatic migration was 
analyzed by wound-healing assays.
Results: Our results suggest that while MDA-MB-231 cells produce 
high levels of PGE2 and PGD2, MCF7 cells synthesize excess HETE 
compounds (HETE5 and HETE8). Interestingly, MDA-MB-231 cells, 
when stimulated with AA, show the increased syntheses of LTB4 
(~3 fold) and decreased PGE2 and PGD2 (~2 fold). In MCF7, on 
the contrary, AA treatment reduced the syntheses of all eicosanoids. 
Furthermore, the expression of 5-LOX in MDA-MB-231 cells 
was also increased by ~2 fold. We observed that AA promotes cell 
migration in MDA-MB-231 cells, which could be blocked by NDGA, 
a generic inhibitor of LOX enzymes. Because LTB4 production and its 
binding with BLT receptors are linked to IL-8 secretion, we measured 
the level of IL-8 synthesized by both MCF7 and MDA-MB-231 cells. 
The results suggest that MDA-MB-231 cells secrete excess IL-8 
(~2 fold) when stimulated with AA, suggesting that LTB4 and IL-8 
interactive pathways are important for cancer metastasis.
Discussion: Our results demonstrate that LTB4 synthesis is linked to 
the metastatic migration of MDA-MB-231 cells, and that it therefore 
should be considered as a target for developing new drugs for the 
treatment of invasive breast cancers.
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P4-05-05
Imaging Mass Spectrometry Based Lipid Metabolites Analysis 
for Breast Cancer.
Ide Y, Nishio T, Hosokawa Y, Matsunuma R, Koizumi K, Ogura 
H, Shiiya N, Setou M. Hamamatsu University School of Medicine, 
Hamamatsu, Japan
Background:
Activation of lipid metabolism is an early event of carcinogenesis 
and a central hallmark of many cancers including breast cancer. 
Recent findings argue that stearoyl CoA desaturase-1 (SCD1), a key 
regulator of the fatty acid (FA) composition and the endoplasmic 
reticulum resident enzyme that converts saturated FA (SFA) into 
monounsaturated FA (MUFA) is a novel regulator of carcinogenesis. 
The distinctive lipids composition of membrane in cancer cells and 
the biological functions of SCD1 , however, still remain uncertain. 
Imaging mass spectrometry (IMS) is a mass spectrometry-based 
analyzing technique that enables visualization of the individual 
molecules without requiring antibodies. It allows comprehensive 
detection of a wide range of biomolecules, such as lipids. We 
attempted to visualize the localization of lipids in breast cancer by 
IMS for better understanding of cancer proliferation.
Materials and methods:
13 specimens were obtained from the primary breast cancer patients. 
All were Japanese woman and aged 41-86 years (mean 61.5y.o.). 
Only one patient received preoperative systematic therapy. 6 were 
estrogen receptor (ER) and/or progesterone receptor (PgR) positive 
and human epidermal growth factor receptor 2 (HER2) negative, 2 
were ER and/or PgR positive and HER2 positive, 2 were both ER 
and PgR negative and HER2 positive and 2 were triple negative.
IMS:
Samples were immediately chilled in liquid Hexan and stored at 
-80°. All specimens were sliced into 10 mm thin sections, mounted 
onto one indium-tin oxide-coated glass slides (Bruker Daltonics) 
and then sprayed by 2,5-Dihydroxybenzoic acid. Matrix assisted 
laser desorption ionization (MALDI) technique was used as a soft 
ionization method. We used time of flight (TOF)/TOF type instrument 
(Ultraflex, Bruker Daltonics) and all the spectrum were acquired 
automatically using Fleximaging software (Bruker Daltonics). Each 
spectral intensity at any mass-to-charge ratio (m/z) was measured at 
16 regions of interest (ROI); 13 ROI were picked up from cancerous 
parts and 3 were from non-cancerous parts. Spectral intensities were 
compared and statistical analysis was performed by Mann Whitney 
test. The software was also used to create two-dimensional ion-
density maps.
Results:
In the cancerous parts of all the 13 specimens, two distinct peaks 
of the molecular ions were detected at m/z 798.5 and 810.5, which 
were not found in the non-cancerous parts. Median intensity of the 
molecular ions at m/z 798.5 and 810.5 were 38.9 and 3.18 in the 
cancerous part, while they were 0.84 and 1.02 in the non-cancerous 
part (p=0.010 and 0.015, respectively). Tandem mass spectrometry 
analysis for these two molecules revealed that they were two kinds 
of phosphatidylcholine (PC), PC (16:0/18:1) and PC (18:0/18:1). 
Localization of the individual PC was visualized by means of IMS, 
which showed that in cancerous part accumulation of PCs containing 
MUFA was more pronounced than those containing SFA only.
Conclusion:
Two kinds of PC containing MUFA were found to highly accumulate 
in cancerous parts, which may suggest involvement of SCD1 in the 
membrane composition regulation and cancer proliferation. Further 
studies may thus be warranted to explore the relation between PC 
localization and the SCD1 expression.
P4-06-01
Withdrawn by Author
P4-06-02
Microscopic Disease in Blood and Bone Marrow Predicts Survival 
in Early Stage Breast Cancer.
Lucci A, Krishnamurthy S, Lodhi A, Bhattacharyya A, Hall C, 
Anderson A, Bedrosian I, Singh B, Kuerer H. University of Texas MD 
Anderson Cancer Center, Houston, TX
Background: Disseminated tumor cells (DTCs) in the bone marrow 
have been identified in 30% of stage I - III breast cancer (BC) patients 
and predict survival. Circulating tumor cells (CTCs) in the blood 
predict outcome in metastatic BC, but their prognostic significance in 
primary BC is unclear. This study determined whether: 1) DTCs and 
CTCs could be identified in significant numbers of non-metastatic BC 
patients and 2) if these cells predict relapse-free (RFS) and overall 
survival (OS).
Methods: Clinical stage I-III BC patients seen at a single tertiary 
cancer center provided informed consent to participate in an IRB-
approved study involving collection of blood (7.5 ml x 2 tubes) and 
bone marrow (10 ml from bilateral iliac crests), and at the time of 
surgery for their primary BC. DTCs were assessed using an anti-
cytokeratin antibody cocktail (MNF 116, CK 8,18, and 19, CAM 
5.2, and AE1/AE3) following ficoll enrichment and cytospin. A 
positive result for DTCs was defined by presence of one or more 
CK-positive cells meeting morphologic criteria for malignancy. CTCs 
were detected using the Cell SearchTM system. A positive result was 
defined as the presence of one or more cells per 7.5 ml blood since 
a threshold for positivity has not been established in non-metastatic 
BC. Statistical analyses used chi-square and Fischer’s exact test.
Results: We prospectively evaluated 313 patients. Mean age was 
53 years, and median follow-up was 32 months. Forty-two percent 
of patients (131) had T1 tumors, 36% (112) T2, 10% (30) T3, and 
13% (40) had T4 disease. Forty-five percent of patients (141/312) 
had positive lymph nodes. DTCs were identified in 29% (91/313) 
and CTCs in 25% (79/313) of all patients. Seven percent (21/313) 
of patients had both DTCs and CTCs. In the overall cohort, 26 (8%) 
patients relapsed and 15 (5%) died. Ten percent (9/91) of DTC positive 
patients died compared to 3% (6/222) of those who did not have DTCs 
(p=0.01). Similarly, 6% (7/79) of those who had CTCs died compared 
to 3% (8/234) of those who did not (p=0.03). Fifteen percent (12/79) 
of CTC positive patents relapsed compared to 6% (14/234, P=0.01) 
of those who were CTC negative. Simultaneous presence of DTCs 
and CTCs was a strong predictor of RFS (log rank p=0.030, HR= 
2.8, 95% C.I. 1.20- 8.10) as well as OS (log rank p=0.026, HR= 3.66, 
95% C.I. 1.03- 13.00) at 2 years. Combined presence of DTCs and 
CTCs was a predictor of outcome and these findings persisted after 
adjusting for variables including hormone receptor status, HER2 
status, primary tumor size, grade, and preoperative lymph node status. 
There was no significant correlation between DTCs and/or CTCs with 
other primary tumor characteristics.
Conclusions: Circulating and disseminated tumor cells can be 
identified in a significant number of non-metastatic breast cancer 
patients. Both CTCs and DTCs predicted outcome, and their combined 
presence was an independent predictor of survival.
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P4-06-03
Multiplex Gene Expression of Disseminated Tumor Cells in 
the Bone Marrow of Breast Cancer Patients Identifies Novel 
Therapeutic Targets.
Aft R, Mudalagiriyappa C, Pillai S, Fleming T, Watson M. Washington 
University, St. Louis, MO
Background: Disseminated tumor cells (DTCs) are detected in the 
bone marrow (BM) of up to 40% of breast cancer patients at the time 
of diagnosis and are an independent prognostic factor for recurrent 
disease. Present techniques for detection of DTC are often laborious, 
and insensitive due to the molecular heterogeneity of the DTCs. We 
have previously optimized and validated a novel, multiplexed gene 
expression technology platform, Nanostring nCounter™ (NC) which 
counts single molecules of RNA, for the multi-marker detection of 
DTCs in BM at a sensitivity of 1 cancer cell per 1 million nucleated 
BM cells. We now validate a 36 gene panel for the detection and 
molecular characterization of DTCs in BM.
Methods: Hybridization probes for 36 genes whose expression are 
associated with breast cancer, metastasis, and/or the cancer stem cell 
phenotype, and which exhibit no or low expression levels in normal 
bone marrow by qRT-PCR were developed for the NC assay. Total 
RNA was isolated from whole BM collected from the right and left 
iliac crest from breast cancer patients and healthy volunteers. 5 ug of 
RNA was analyzed, in duplicate with the NC assay. BM was scored 
positive for expression of an individual gene if expression in duplicate 
samples was 2 standard deviations above mean expression in a set of 
11 independent normal BM samples.
Results: Bilateral BM samples were analyzed prior to any therapy 
from 20 patients: 8 developed metastatic disease within 2-48 months 
(mean of 23 months) after diagnosis, and 12 had no evidence of 
metastatic disease with 3-5 years follow-up. Overall, expression of at 
least one gene in the 36-gene multi-marker panel was detected in 17 
patients (85%). There was excellent correlation between individual 
gene expression in both the right and left iliac crest samples from the 
same patient. Six of the 8 patients (75%) who developed metastatic 
disease had detectable expression of 1-3 genes. Two genes were 
commonly associated with metastatic disease development. 50% (3 
of 6) of the patients who had detectable expression of EBB2 in their 
BM developed metastatic disease, although this did not correlate with 
expression in the corresponding primary tumor from the same patient. 
80% (4 of5) of the patients who expressed the hedgehog pathway 
gene, Ptch1, in their BM developed metastatic disease.
Conclusions: Our data demonstrate the feasibility of using a 36-plex 
NC assay to detect gene expression associated with BM DTCs in 
breast cancer patients. We found expression of 2 targetable genes 
associated with the development of metastatic disease, ERBB2 and 
Ptch1. ERBB2 expression in BM did not correlate with expression 
in the primary tumor. The molecular diversity of gene expression 
observed underscores the need for a multiplexed gene expression 
panel. Ongoing studies are evaluating the clinical utility of this assay 
to detect DTCs relative to existing techniques, for predicting relapse-
free survival, molecular classification, and selecting appropriate 
targeted therapeutics based on BM DTC profiles in breast cancer 
patients.
P4-06-04
Detection of HER2 Gene Amplification in Circulating Tumor 
Cells and Disseminated Tumor Cells by Fluorescence In Situ 
Hybridization Using OncoCEE™.
Krishnamurthy S, Bischoff FZ, Mayer JA, Wong K, Pham T, Kuerer 
HM, Lodhi AK, Bhattacharyya A, Hall CS, Lucci A. University 
of Texas M.D. Anderson Cancer Center, Houston, TX; Biocept 
Laboratories, San Diego, CA
BACKGROUND:
The status of HER2 gene amplification in circulating tumor cells 
(CTCs) and disseminated tumor cells (DTCs) might provide useful 
information for monitoring response to trastuzumab therapy, and 
may provide a basis for consideration of trastuzumab in patients 
with HER2 negative primary tumors who have HER2 positive CTCs 
and/or DTCs. The majority of techniques utilized for detection of 
minimal residual disease are limited in their ability to allow detailed 
phenotypic and genotypic evaluation of the cells. We report the utility 
of a microfluidic platform (OncoCEE™,Biocept, San Diego) for 
detecting HER2 gene amplification in CTCs and DTCs in patients 
with non-metastatic breast cancer.
METHODS:
Peripheral blood (10ml) and bone marrow (BM) (1-2ml) were 
collected from patients with clinical stage I-III breast cancer in acid 
citrate dextrose solution (BD,Franklin Lakes, NJ) and anti-clumping 
reagent (OncoCEE-SureTM). Mononuclear cells were recovered 
using a Percoll density gradient method, incubated with a mixture 
of 10 primary capture antibodies (Abs), introduced into CEETM 
microchannels, stained with fluorescent anti cytokeratin (CK) and 
CD45 abs and finally processed for fluorescence in situ hybridization 
(FISH) using probes specific to centromere 17 (spectrum green) and 
HER2 (spectrum arrange). The ratio of HER2:CEP17 >2.2 in any 
CK+/CD45- and CK-/CD45- cell was regarded as positive for HER2 
gene amplification.
RESULTS:
Peripheral blood and/or BM from 78 patients (65 BM; 70 blood; 57 
matched blood and BM) with T1NO (39), T1N1 (8), T2N0 (12), T2N1 
(2), T2N2 (1), T2N3 (3), T3N0 (2), T3N1 (2), T3N2 (1), T4N0(5), 
T4N1 (3), with HER2+ (n=12) and HER2- (n=58) primary invasive 
breast tumors were studied. The 12 patients with HER2+ primary 
tumors had HER2+ DTCs in 3/12 (25%) and HER2+ CTCs in 1/9 
(11%) cases respectively. HER2+ DTCs and HER2+ CTCs occurred 
in 12/55 (24%) and in 4/63 (6%) of the patients with HER2- primary 
breast tumors. HER2+ CTCs and DTCs occurred simultaneously in 
only 2 patients and in either blood (3) or BM (13) in the remaining 
patients.
CONCLUSION:
1. The cell enrichment and extraction microfluidic technology 
(OncoCEETM) provides a sensitive platform for evaluation of HER2 
gene amplification of CTCs and DTCs.
2. HER2+ primary tumors were associated with either HER2+ CTCs 
or DTCs in 25% of the patients.
3. HER2+ CTCs or DTCs occurred in 28% of patients with HER2- 
primary tumor.
4. Discordant HER2 status was contributed mainly by HER2+ DTCs 
occurring in HER2 - primary tumors.
5. The clinical significance of evaluating the status of HER2 gene 
amplification in CTCs and DTCs in the management of patients with 
breast cancer needs to be evaluated prospectively in larger clinical 
trials.
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Prognostic Impact of Disseminated and Circulating Tumor Cells 
in Patients Treated for Locally Advanced Breast Cancer.
Mathiesen RR, Nesland JM, Renolen A, Løkkevik E, Anker G, 
Østenstad B, Lundgren S, Riisberg T, Mjaaland I, Kvalheim G, 
Lønning PE, Naume B. Oslo University Hospital The Radium 
Hospital, Oslo, Norway; Oslo University Hospital, Oslo, Norway; 
University of Bergen, Bergen, Norway; Haukeland University 
Hospital, Bergen, Norway; St. Olavs University Hospital, Trondheim, 
Norway; Norwegian University of Science and Technology, 
Trondheim, Norway; University Hospital of Northern Norway and 
Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway; 
Stavanger University Hospital, Stavanger, Norway; Oslo University 
Hospital, The Radium Hospital, Oslo, Norway; University of Oslo, 
Oslo, Norway
INTRODUCTION:
Neoadjuvant systemic therapy (NST) in breast cancer patients is 
an established approach to reduce tumor size prior to surgery and 
to assess the clinical effect of therapy on the breast cancer disease. 
The current study was designed to identify primary tumor resistance 
factors to epirubicin and paclitaxel therapy in patients with locally 
advanced breast cancer (Chrisanthar et al PLoSOne 2008 and 2011). 
As a substudy, the incidence of disseminated tumor cells (DTCs) 
and circulating tumor cells (CTCs) before and after therapy, was 
investigated. The aim was to evaluate the prognostic impact of DTCs 
and CTCs as well as to evaluate the effect of NST on DTCs and CTCs.
PATIENTS AND METHODS:
Patients with locally advanced non-inflammatory breast cancer (T3-
4and/or N2) were included in the study. The patients were randomly 
allocated to primary treatment either with epirubicin 90mg/m2 
or paclitaxel 200mg/m2, with cross-over design if no response/
progression, followed by mastectomy and axillary dissection . Bone 
marrow (BM) aspiration and peripheral blood (PB) samples were 
collected before NST (BM1/PB1)(n=230), at the time of surgery 
(BM2/PB2)(n=69; logistic reasons caused reduced sampling) and 12 
months after randomization (BM3/PB3)(n=162). Detection of DTCs/
CTCs was performed by standard immunocytochemical analysis 
of 2x106 mononuclear cells stained for cytokeratin by AE1AE3 
antibodies. Patient outcomes were evaluated over a 10-year follow-
up period. Univariate and multivariable proportional hazards models 
were estimated to assess the prognostic significance of DTC for 
disease-free survival (DFS) and overall survival (OS).
RESULTS:
Before NST (BM1) 21.3% were DTC positive, compared to 15.9% 
and 26.5% at BM2 and BM3, respectively. Of those that both had 
BM1 and BM3 performed, 68% concordance and 22% overlap 
among positive cases was observed. Presence of DTCs in BM3 
predicted reduced DFS (HR 2.2; 95% CI 1.3-3.7; p=0.007) and OS 
(HR 3.0; 95% CI 1.8-5.2; p>0.001). DTC status before NST had no 
impact on outcome. No difference in the results was observed after 
exclusion of patients with limited M1 status at diagnosis (25 and 13 
of those analysed for BM1 and BM3, respectively). The incidence 
of CTCs before NST was 4.9 % compared to 1.4% and 4.3 % at PB2 
and PB3, respectively. Presence of CTC before NST was associated 
with reduced overall survival (HR 2.4; 95% CI 1.2-5.0; p=0.018), 
but CTC status was not significant for DFS or at other time points. 
In the multivariable analysis, DTC status at BM3 remained as a 
prognostic factor for both DFS (HR 2.0; 95% CI 1.1-3.6) and OS 
(HR 2.1; 95% CI 1.04-4.2).
CONCLUSION:
In patients with locally advanced breast cancer, the presence of CTCs 
at the time of diagnosis identified high risk patients. However, the 
sensitivity of the performed CTC analysis was too low for further 
interpretation. Presence of DTCs 12 months after neoadjuvant therapy 
increased the risk for relapse and death. The best clinical utility of 
DTC analysis appears to be as a monitoring tool during follow up, 
in a “window of opportunity” for selection of patients to secondary 
adjuvant treatment intervention within clinical trials.
P4-06-06
Morphological Categories of ICC-Detected CK+ Cells in Bone 
Marrow Have Different Prognostic Impact in Breast Cancer.
Borgen E, Synnestvedt M, Schirmer CB, Schlichting E, Nesland JM, 
Naume B. The Radium Hospital, Oslo University Hospital, Oslo, 
Norway; The Radium Hospital, Oslo University Jospital, Oslo, 
Norway; Ullevål Hospital, Oslo University Hospital, Oslo, Norway; 
University of Oslo, Oslo, Norway
Introduction: Morphological evaluation increases the specificity of 
immunocytochemical analysis (ICC) of disseminated tumor cells 
(DTC) in bone marrow (BM). In the Oslo1 cohort of primary breast 
cancer (BC) patients (pts), ICC-positive cells detected in BM were 
prospectively classified into 4 morphological groups: Tumor cells 
(TC) and un-interpretable cells (UIC, i.e. degenerated/fragmented 
cells), both significantly associated with reduced survival; and 
hematopoietic cells (HC) and questionable HC (Q-HC), not affecting 
outcome (Borgen 1999, Naume 2004). The present study revisits 
these categories, comparing their significance according to therapy 
and tumor subtype.
Materials and methods: Mononuclear cells (MNC) from BM collected 
at surgery of 761 pts were analyzed by standard ICC, including 2x106 
BM MNC stained for cytokeratin by AE1AE3 monoclonal antibodies, 
and corresponding isotype specific negative controls (neg co; 2x106 
BM MNC for most). Cells were classified as TC, UIC, Q-HC or 
HC. Primary tumor analyses included pTpN stage, grade, hormone 
receptor (HR) and HER2. Patients were followed for median 99 
months. Survival analyses were performed by Kaplan Meyer and 
Cox regression analysis.
Results: Frequency of TC in specific test (AE1AE3) was 16.9%, 
UIC 14.0%, Q-HC 23.4% and HC 27.2%. By analyzing the entire 
cohort and numerically correcting for similar cells in neg co, only 
cells classified as TC or UIC predicted systemic relapse. Analysis of 
no adjuvant treated (NO-ADJ; n=390) and adjuvant treated (ADJ; 
n=361) pts separately, revealed that in NO-ADJ pts only those 
harboring Q-HC experienced reduced survival (DDFS: HR 2.2, 95% 
CI 1.2-4.1, p=0.01; BCSS: HR 2.7, 95% CI 1.3-5.5, p=0.006). In ADJ 
pts, only TC and UIC predicted relapse (HR 1.8, 95% CI 1.2-2.9, 
p=0.004) and death (HR 2.0, 95% CI 1.3-3.1, p=0.003). In multivariate 
analysis for NO-ADJ pts, presence of Q-HC by AE1AE3 remained 
significant (DDFS: HR 2.1, 95% CI 1.1-4.1, p=0.031; BCSS: HR 2.4, 
95% CI 1.1-5.1, p=0.024). By subgroup analysis according to HR 
and HER2 (where available), prognostic impact of TC and UIC were 
observed only in HR+/HER2- subgroup (n=538; DDFS:HR 1.9, 95% 
CI 1.2-3.2, p=0.006; BCSS: HR 3.3, 95% CI 1.9-5.6, p›0.001), and not 
in HER2+ (n=80), or triple negative pts (n=117). In contrast, presence 
of Q-HC was associated with worse outcome in triple negative pts 
(n=115; DDFS:HR 2.9, 95% CI 1.4-6.1, p=0.005; BCSS: HR 2.4, 95% 
CI 1.1-5.2, p=0.026), with no significant prognostic impact in the other 
two pts groups. Interestingly, pts habouring ≥ 3 HC in AE1AE3 and 
in neg co together (8.5% of pts), had improved DDFS (HR 0.60, 95% 
CI 0.41-0.88, p=0.008) and BCSS (HR 0.57, CI .036-0.91, p=0.018) 
compared to those with fewer or no HC (p=0.029). Only 4.7% of 
pts with ≥ 3 HC experienced metastasis, versus 20.8% of the other.
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011445s
December 6-10, 2011 Abstracts: Poster Session 4
Conclusion: Morphological DTC subgroups may differ in clinical 
significance according to biology/primary tumor subtype and therapy 
status. This emphasizes the importance of separate analyses of DTC 
categories and further DTC characterization. False positive cells, 
probably in the B-cell lineage, might signify an immune-related 
favorable clinical outcome.
P4-07-01
Circulating Tumor Cells, Disease Recurrence and Survival in 
Newly Diagnosed Breast Cancer.
Franken B, de Groot MR, Terstappen LWMM, Mastboom WJB, 
Van der Palen J, Tibbe AGJ. Medisch Spectrum Twente, Enschede, 
Overijssel, Netherlands; University of Twente, Enschede, Overijssel, 
Netherlands
Background: The presence of circulating tumor cells (CTC) is an 
independent prognostic factor for progression-free survival and 
overall survival (OS) for patients with metastatic breast cancer 
beginning a new line of systemic therapy. The current study was 
undertaken to explore whether the presence of CTC at the time of 
diagnosis was associated with recurrence free survival (RFS) and 
breast cancer related death.
Materials and Methods: In a prospective single center study, CTC 
were enumerated with the CellSearch system in 4 aliquots of 7.5 ml of 
peripheral blood of 504 patients before undergoing surgery for breast 
cancer between September 2003 and January 2009. Four hundred four 
had stage I-III disease and were followed for 6-90 months (median 
48). One hundred had a benign tumor and served as a control group.
Results: In the control group 15 (15%) had >1 CTC / 30 mL of blood. 
In stage I-III patients 76 (19%) had >1 CTC in 30 mL of blood of 
whom 16 (21.1%) developed a recurrence. In 328 patients with 0 CTC 
38 (11.6%) developed a recurrence. Four year RFS was 88.4% for 
favorable CTC and 78.9% for unfavorable CTC (p =0.038). Breast 
cancer related death was 4,3% (14 of 328 patients) for favorable and 
14,5% (11 of 76 patients) for unfavorable CTC (p = 0.001). CTC, 
PR receptor and stage were independent predictors of breast cancer 
related death in multivariate analysis. The corrected odds ratio after 
multivariate analysis for breast cancer related death in patiënts with 
CTC versus patiënts without CTC was 3,47.
Discussion: Presence of CTC in breast cancer patients before 
undergoing surgery with curative intent is associated with an increased 
risk for recurrence and breast cancer related death. This supports 
the notion that the presence of CTC is also important in the primary 
disease setting. In this study the sensitivity of the CellSearch assay was 
increased by a fourfold increase in blood volume and a threshold for 
unfavorable of >1 CTC in 30 mL of blood, which lead to a relatively 
high background in the control group. Thus an increase in specificity 
is desired before initiation of prospective multicenter trials as well as 
a more practical way to process larger blood volumes.
P4-07-02
Detection, Enrichment, Characterization and Propagation 
of Circulating Tumour Cells from Patients with Advanced 
Metastatic Breast Cancer.
Mihalcioiu C, Lian J, Bertos N, Omeroglu A, Sebag M, DiBattista J, 
Li J, Chughtai N, Park M, Kremer R. Royal Victoria Hospital/McGill 
University, Montreal, QC, Canada; McGill University, Montreal, 
QC, Canada
Background: Circulating tumour cells (CTCs) have attracted 
much attention lately due to their potential utility in diagnostic, 
therapeutic and prognostic applications. Characterization of these 
cells may indeed permit more targeted and individualized therapeutic 
approaches, as well as provide a means to monitor treatment response. 
Although detection of CTCs in peripheral blood (PB) is relatively easy 
using current methodologies, characterization of the CTC pool has 
proven more challenging due to their low abundance. Furthermore, 
in-vitro expansion of this elusive cell pool in mammosphere cultures 
has not yet been reported. In order to achieve a more complete 
characterization of CTCs and attempt to obtain live cells in sufficient 
quantity for in vitro expansion, we have used aphaeresis as a means 
to collect a large initial cell fraction from which to enrich CTCs from 
peripheral blood.
Methods: A cohort (n=17) of late stage breast cancer patients were 
first screened using 10ml PB. Peripheral blood mononuclear cells 
(PBMCs) were isolated using a Ficoll gradient and then enriched for 
CTCs by anti-CD45 negative selection using an automated system 
(RoboSep) based on magnetic bead separation. CTCs were detected by 
immunocytochemistry (ICC) for cytokeratin expression and patients 
classified as CTC-positive were selected for the aphaeresis procedure. 
Following collection of aphaeresis material (APM), PBMCs were 
isolated using a Ficoll gradient, enriched by automated anti-CD45 
negative selection and characterized for a variety of markers by ICC, 
immunofluorescence and flow cytometry. CTCs were then cultured 
in serum-free medium as monolayers and suspensions. Recovery at 
the various steps of the isolation process was determined using PB 
from healthy subjects spiked with MCF-7 breast cancer cells and 
processed using the same approach.
Results: Recovery of spiked MCF-7 cells was about 40% after Ficoll 
and magnetic bead separation. Using this negative selection procedure 
17/17 (100%) of subjects tested were positive at screening. Most 
patients (14/17) underwent aphaeresis and a large number (9,600 
to 108,000) of enriched CTCs was recovered from APM in all 
patients tested, either as individual cells or as CTC clusters. Using 
dual immunofluorescence labelling, co-localization of the epithelial 
cell marker CK8 and the chemokine receptor CXCR4 was observed 
within CTCs. Furthermore, over 20% of CTCs were positive for 
both CK8 and ALDH1, indicative of a stem-like phenotype. APM-
derived CTCs from all patients (14/14) could be propagated, both 
as attached cells and in suspension culture. They formed colonies in 
monolayer culture, and clusters in mammosphere culture, indicating 
stem cell-like properties. They replicated for at least three passages 
in mammosphere culture.
Conclusion: Our CTC detection and enrichment method using negative 
selection offers a distinct advantage over current methodologies, 
including collection of clusters, and the ability to grow and expand 
CTCs in serum-free culture conditions. Furthermore, these cells 
demonstrate breast cancer stem cell-like characteristics, the ability 
to replicate for multiple passages as mammospheres in suspensions 
and a metastatic signature.
P4-07-03
Identification of Triple-Negative Primary Breast Cancer 
Xenograft Models with High Numbers of Circulating and 
Disseminated Tumor Cells.
Giuliano M, Christiny PI, Zhang X, Mao S, Contreras A, Lewis MT, 
Rimawi MF, Osborne CK, Schiff R, Trivedi MV. Baylor College of 
Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
Background: Primary breast cancer xenografts, in which tumors 
are grown directly from patients and which maintain their original 
genotype and phenotype, have the potential to facilitate the study of 
tumor biology and progression. These models can also be instrumental 
in the discovery of novel therapeutic targets especially for the 
triple-negative (ER-, PR- and HER2-negative, TN) breast cancer. 
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TN breast cancer is associated with high numbers of circulating 
and disseminated tumor cells (CTCs and DTCs), which predict 
poor outcome in patients and may play a role in tumor progression. 
However, isolation and detection of human CTCs and DTCs in these 
xenograft models have been challenging even with EpCAM-based 
enrichment methods. The goal of this study was to determine if 
CTCs and DTCs could be identified using human pan-CK staining 
in a panel of triple-negative primary breast cancer xenograft lines, 
which could then be employed to study the biology of these cells and 
to test novel therapies.
Methods: We screened 13 stable primary transplantable xenograft 
lines (1-6 mice per line), established by directly transplanting 
ethnically diverse triple-negative tumor samples into the epithelium-
free mammary fat pads of SCID/Beige mice, for the presence of 
CTCs and DTCs. The triple-negative status was maintained in these 
xenograft lines over serial passages. To detect CTCs, peripheral blood 
mononuclear cells (PBMCs) were isolated from the blood collected 
from the inferior vena cava either by Ficoll gradient or RBC lysis, with 
a typical yield of 500,000 PBMCs in 500 ml of blood. Subsequently, 
PBMCs were immunostained for the presence of CTCs, which were 
defined as the cells positive for cytoplasmic human pan-cytokeratin 
staining and nuclear (DAPI/hematoxylin) counter stain. We also 
flushed the femurs and tibias of 7 xenograft lines to harvest bone 
marrow cells (BMCs) for the detection of DTCs using the same 
staining procedure. A xenograft line was considered positive for 
CTCs or DTCs if they were detected in at least 25% of mice. The 
presence of lung metastases was assessed in all the xenograft lines 
by histological examination.
Results: We detected CTCs (range: 1-128/20,000 PBMCs) in 6 out of 
13 xenograft lines (46%) and DTCs (range: 1-21/20,000 BMCs) in 5 
out of 7 (71%) lines. Interestingly, 4 of the 5 DTC-positive lines also 
had detectable CTCs. High numbers of CTCs (>20/20,000 PBMCs) 
were found in 3 xenograft lines, one of which also had high numbers 
of DTCs (>20/20,000 BMCs). No human pan-CK+ cells were detected 
in PBMCs and/or BMCs from 5 control mice without tumors. Among 
13 xenograft lines, lung metastases were found in 5 lines (38%), 
of which 3 had detectable CTCs or DTCs. Of the 3 xenograft lines 
containing high CTCs and/or DTCs, 2 had lung metastases.
Conclusion: In summary, human pan-CK staining can effectively 
detect CTCs and DTCs in isolated PBMCs and BMCs of mice bearing 
triple-negative primary breast cancer xenografts. These xenograft 
lines with detectable CTCs and DTCs may represent a valuable 
preclinical model for detailed characterization of human CTCs and 
DTCs and for the discovery of new therapeutic targets for the triple-
negative breast cancer.
P4-07-04
Nomogram Including Circulating Tumor Cells (CTC) Count 
before and during Chemotherapy for Individual Survival 
Prediction of Metastatic Breast Cancer Patients.
Bidard F-C, Hajage D, Bachelot T, Delaloge S, Brain E, Campone 
M, Wolp-Diniz R, Dieras V, Mathiot C, Asselain B, Pierga J-Y. 
Institut Curie, Paris, France; Centre Leon Berard, Lyon, France; 
Institut Gustave Roussy, Villejuif, France; Institut de Cancérologie 
de l’Ouest, Nantes, France
Background: CTC count before a new line of treatment and CTC 
count early changes under chemotherapy have been reported as an 
independent prognostic marker in metastatic breast cancer in a recent 
pooled analysis in 841 pts (Liu M. ASCO 2011). The aim of this study 
was to build a prognostic tool including CTC and other parameters to 
assesse its predictive value for progression-free survival (PFS) and 
overall survival (OS).
Methods: Data from the IC 2006-04 study were used. This 
prospective multicentre study included 267 metastatic breast cancer 
patients treated by first line chemotherapy with or without targeted 
therapy, in whom appropriate pre-treatment prognostic variables (age, 
performance status, number of metastatic sites, disease-free interval, 
ER, PR and HER2 status, tumor grade, LDH, serum markers, CTC 
count by CellSearch technique before treatment and before cycle 2) 
were available for statistical analysis. We constructed a multivariate 
Cox regression model for PFS and OS prediction. A stepwise selection 
process was applied to achieve the most informative and parsimonious 
models. Performance was measured with the C-index statistic. Internal 
validation was performed using leave-two-out technique.
Results: Four nomograms have been obtained, in two clinical settings: 
at inclusion (before the start of any treatment) taking into account 
the initial CTC count, and during treatment (before cycle 2) taking 
into account CTC changes under treatment. Their accuracy was good 
for PFS and OS prediction, with C-index ranging from 0.72 to 0.88. 
Internal validations allow considering a good accuracy of the models 
in an external population.
Conclusion: These clinically relevant nomograms are a simple tool 
for a personalized prognostic assessment including CTC assessment. 
Validation on independent series of patients are ongoing.
P4-07-05
Comparison of PIK3CA Hot Spot Mutations in the Primary 
Tumor or Metastases with PIK3CA Mutations or PIK3CA Over-
Expression in Circulating Tumor Cells of Metastatic Breast 
Cancer Patients under Sequential Palliative Therapy.
Aktas B, Kasimir-Bauer S, Kasper S, Derks C, Kimmig R, Schuler M, 
Tewes M. West German Cancer Center, University Hospital Essen, 
University of Duisburg-Essen, Essen, Germany
Background: Stem cell like tumor cells have been implied as the 
active source of metastatic spread in primary tumors. To disseminate 
and metastasize, these cells may undergo phenotypic changes, 
known as epithelial-mesenchymal transition (EMT). The PI3K/AKT 
signaling pathway has been identified as one of the most important 
and most frequently mutated pathways involved in these processes. 
Assuming that metastasis requires a dissemination of tumor stem cells 
or tumor cells showing EMT, we studied 174 blood samples of 43 
metastatic breast cancer patients under follow-up of palliative chemo-, 
antibody – or antihormonal therapy for the presence of stemness 
like circulating tumor cells (slCTCs). Further, we correlated these 
data with the occurrence of PIK3CA mutations in slCTCs and with 
the detection of hot spot mutations as well as PTEN loss in primary 
tumors or metastases.
Materials and Methods: All blood samples underwent immunomagnetic 
enrichment using the AdnaTest BreastCancerSelect (AdnaGen AG, 
Germany). RNA was recovered and reverse transcribed for analysis 
using the AdnaTest EMT (multiplex RT-PCR for TWIST, AKT2, 
PI3K), and separately for the stem cell marker ALDH1 applying the 
AdnaTest TumorStemCell. The identification of EMT markers was 
considered positive if at least one of the three markers was detected 
in the sample. The expression of CD34 was analyzed in a subset of 
samples to exclude potential interference of normal hematopoietic 
stem cells. The analysis of PCR products was performed by capillary 
electrophoresis on the Agilent Bioanalyzer 2100. The PIK3CA 
3140 G/A mutation in slCTC-derived cDNA was identified by 
direct sequencing. PIK3CA hot spot mutations in primary tumors or 
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metastases were identified by direct sequencing from microdissected 
FFPE tumor tissue. PTEN loss (as defined as <10% of cells exhibiting 
positive staining) was detected by immunohistochemistry.
Results: During follow up, slCTCs were detected in 23/43 (53%) of 
the patients at least at one time point. ALDH1 was present in 18/43 
(42%) patients, and at least one of the EMT markers was detected in 
22/43 (51%) of the patients with the over-expression of PI3K (87%), 
AKT (96%) and TWIST (22%), respectively. Positivity for both, 
ALDH1 and EMT markers, was found in 15/23 (65%) of the patients. 
So far, analyzing one sample of each slCTC-positive patient during 
follow-up of the disease, there seems to be an occurrence of PIK3CA 
3140 G/A mutation in slCTCs in about 25% of the patients. Examining 
the tissue samples, PTEN loss was found in 3/43 (7%) patients, in 
two of which slCTCs were present. DNA has been extracted from 
the dissected tumor tissues of all patients and is currently analyzed 
for PIK3CA mutations. The results will be available for presentation 
during the SABCS.
Conclusion: This study provides evidence for the presence of therapy-
resistant breast cancer stemness like cells in the blood, possibly 
derived from the tumor or the metastases. Specific PI3K pathway 
inhibitors, alone or in combination therapy, may provide a therapeutic 
strategy for eliminating these cells to improve the prognosis of these 
patients.
P4-07-06
Correlation of Two Analytical Methods for Circulating Tumor 
Cells in Peripheral Blood of Patients with Primary Breast Cancer.
Jaeger BAS, Rack B, Jueckstock J, Salmen J, Ortmann U, Lorenz 
R, Rezai M, Beck T, Schneeweiss A, Zwingers T, Beckmann MW, 
Friese K, Janni W. Klinikum der Ludwig-Maximilians-Universitaet - 
Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, 
Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-Hecker-
Wesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, 
Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; 
University Hospital Heidelberg, Heidelberg, Germany; Estimate, 
Augsburg, Germany; Frauenklinik der Universitaet Erlangen, 
Erlangen, Germany
Background: While the evidence for circulating tumor cells (CTCs) 
as a prognostic marker in metastatic breast cancer has been well 
established, there is still a lack of data in primary disease. In the 
SUCCESS A trial two different techniques for the detection of CTCs 
in early breast cancer were prospectively evaluated.
Material and Methods: SUCCESS A compared FEC-Docetaxel 
vs. FEC-Docetaxel-Gemcitabine and 5 vs. 2 years of treatment with 
zoledronic acid in primary breast cancer patients and node positive 
or high-risk node negative disease. Two different techniques to 
detect CTCs were prospectively evaluated in two consecutive, but 
comparable subgroups of the whole study population.
In 3515 samples the CellSearch® System (Veridex, Warren, USA) 
was used for CTC detection. Immunomagnetic enrichment with 
an EPCAM-antibody was followed by labeling with monoclonal 
antibodies specific for cytokeratin (8, 18, 19) and leukocytes (CD45).
2165 samples were evaluated with a manual immunocytochemistry 
(MICC) protocol. Cytospins were prepared after mononuclear cell 
enrichment based on Oncoquick® centrifugation (greiner bio-
one, Frickenhausen, Germany). Staining was performed with the 
monoclonal pancytokeratin antibody A45-B/B3 (Micromet, Munich, 
Germany) and the APAAP technique. Conventional light field 
microscopy (Axiophot; Zeiss, Oberkochen, Germany) was used for 
the detection of stained cells.
For both methods, the cut-off value for positivity was ≥ 1 CTC. All 
events were evaluated by two independent observers.
Results: CTCs were examined in a total number of 3243 patients 
before and after chemotherapy (CHT). The two subgroups evaluated 
with one or the other method were well-balanced regarding clinical 
parameters as tumor size, grading, lymph node-status, hormone 
receptors and Her2. Furthermore there was no significant correlation 
between the CTC positivity and one of these clinical parameters 
using CellSearch or the MICC, respectively (p > 0,05 using the chi 
square test each time).
Before adjuvant CHT 21.3% (424 out of 1994) and 21.1% (264 out of 
1249) of the patients were found positive for CTCs using CellSearch® 
or the MICC respectively, with a mean CTC level of 5.9 (range: 1 to 
827) and 3.1 (range: 1 to 256).
Immediately after CHT 21.9% (333 out of 1521) and 16.5% (151 out 
of 916) of the patients were positive for CTCs using CellSearch® or 
the MICC. The mean CTC level decreased to 3.0 (range: 1 to 124) 
and 2.1 (range: 1 to 23) in both analytical methods.
Using CellSearch® there was a significant correlation between the 
presence of CTCs before CHT and disease progression (p = 0.0044), 
as well as survival (p = 0.0001), whereas the MICC did not predict 
any of these (p = 0.3143 and p = 0.0801 respectively; the chi-square 
test was used each time).
Conclusion: We found comparable prevalence of CTCs before and 
after adjuvant chemotherapy both with the CellSearch® System or the 
MICC. However, prognostic relevance could only be shown for CTCs 
detected with the CellSearch® System. This may be attributed to the 
high standardization and reproducibility of the automated system, 
as well as the additional CD45 counterstaining. According to our 
findings, the FDA approved CellSearch® System should be used as 
gold standard for CTC detection in future clinical trials.
P4-07-07
Circulating Tumor Cells Predict Survival in Non-Metastatic 
Breast Cancer.
Lucci A, Krishnamurthy S, Bhattacharyya A, Lodhi A, Hall C, Singh B, 
Anderson A, Bedrosian I, Kuerer H. University of Texas MD Anderson 
Cancer Center, Houston, TX
Background: Circulating tumor cells (CTCs) predict outcome in 
metastatic breast cancer (BC), but their prognostic significance in 
non-metastatic BC is unclear. This study determined whether CTCs 
could be identified in non-metastatic BC patients and 2) if CTCs 
predict relapse-free and overall survival.
Methods: Clinical stage I-III BC patients seen at a single tertiary 
cancer center provided informed consent to participate in an IRB-
approved study involving collection of blood (7.5 ml x 2 tubes) before 
systemic therapy and at the time of surgery for their primary BC. CTCs 
were detected using the Cell SearchTM system. A positive result was 
defined as the presence of two or more cells per 7.5 ml blood since 
a threshold for positivity has not been established in primary BC. 
Statistical analyses were done using STATA-IC 11 software.
Results: We prospectively evaluated 291 patients. Mean age was 
54 years, and median follow-up was 30 months. 54% (157) had T1 
tumors, 36%(104) T2, 6% (18) T3, and 4%(12) had T4 disease; 37% 
(107/289) were clinically node-positive (LNs) by axillary ultrasound 
and FNA. Two or more CTCs were identified in 10% (29) patients. 
Seventy-seven percent (225) patients were hormone receptor positive, 
11% (32) were HER2 positive while 16% (48) expressed no receptors. 
Sixteen percent (48) were tumor grade 1, 50% (143) were grade 2 
and 34% (98) were grade 3. Systemic chemotherapy and/or endocrine 
therapy were administered in 80% (233/289) of patients. Sixty-eight 
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percent (167/244) of patients were post-menopausal. Additionally, 
there was no significant correlation between CTCs with primary 
tumor size, lymph node status, estrogen or progesterone receptor 
status, HER2 amplification or tumor grade. Thirty-eight percent 
(6/16) of all relapses occurred in patients with 2 or more CTCs (HR: 
4.48 (95% C.I. 1.61-12.45), Logrank P 0.002) while 40% (4/10) of 
all deaths occurred in patients with 2 or more CTCs (HR: 4.54 (95% 
C.I. 1.27-16.25), Logrank P 0.011).
Conclusions: CTCs were a significant predictor of disease-free and 
overall survival in non-metastatic breast cancer.
P4-07-08
Subsets and Molecular Signatures of Circulating Tumor Cells in 
Breast Cancer Brain Metastasis.
Marchetti D, Zhang L, Wetzel M, Zaidi T, Ridgway L, Schoeber W, 
He W, Groves MD, Katz RL. Baylor College of Medicine, Houston, 
TX; MD Anderson Cancer Center, Houston, TX
Background: Circulating tumor cells (CTCs) represent the “seeds” 
of intractable brain metastatic breast cancer (BMBC); however, 
properties of CTCs targeting the brain remain elusive. For example, 
the FDA-approved CTC platform (CellSearch™, Veridex, LLC) 
detects only CTCs positive for epithelial cell adhesion molecule 
(EpCAM) and cytokeratins (CKs), but is unable to capture any other 
CTC subtypes or analyze biomarkers of brain-homing CTCs. We 
hypothesized that profiling CTCs from BMBC patients might result 
in the identification of brain-colonizing CTC signatures.
Materials and Methods: We employed CellSearch™ and a novel 
technology that uses analysis of specific antigenic markers by 
immunofluorescence, coupled with detecting gene amplification by 
fluorescence in situ hybridization on the same cells; and quantification 
of the signal via automated scanning (FICTION; BioView Duet-3™ 
system).
Results: We established that our approach was feasible by performing 
CTC analyses on peripheral blood mononuclear cells isolated from 
BMBC patients or patients not possessing overt metastatic disease. 
We detected a differential gene amplification for human epidermal 
growth factor receptor1 and 2 (EGFR and HER2, respectively). 
Second, the number of EpCAM-positive CTCs visualized by the 
BioView™ platform was at least three orders of magnitude higher 
than one obtained from CellSearch™ CTC analyses using the same 
specimen. Third, we identified the presence of CTCs positive for 
CKs but negative for EpCAM. Conversely, high levels of pro-
metastatic heparanase, in conjunction with the expression of aldehyde 
dehydrogenase-1 (ALDH1), a known cancer stem-cell marker, were 
detected in CTCs from BMBC patients; with a correlation between 
heparanase, ALDH1, and high EGFR amplification. Finally, extensive 
flow cytometric/FACS analyses validated the presence of CTC subsets 
negative for EpCAM and CD45, a hematolymphoid marker, however 
enriched for heparanase/ALDH1 expression.
Discussion: These findings indicate that the BioView™ platform not 
only captures more EpCAM-positive CTCs than CellSearch™ but 
also allows the detection of novel CTC subtypes possessing varying 
EpCAM levels. Importantly, they suggest that profiling CTC subtypes 
in patients with BMBC can be relevant towards the discovery of 
BMBC founder CTCs. Work is ongoing to further characterize these 
CTC subtypes, and to assess their abilities to metastasize to brain in 
xenotransplantation studies using immunodeficient mice.
P4-07-09
Automated Quantitative Assessment of HER2 Expression of 
Circulating Tumor Cells (CTC) in Metastatic Breast Cancer (IC 
2006-04 Study).
Bidard F-C, Ligthart ST, Decraene C, Bachelot T, Delaloge S, Brain 
E, Campone M, Pierga J-Y, Terstappen LWMM. Institut Curie, Paris, 
France; University of Twente, Enschede, Netherlands; Centre Leon 
Berard, Lyon, France; Institut Gustave Roussy, Villejuif, France; 
Institut de Cancérologie de l’Ouest, Nantes, France
Background: Beyond quantitative CTC analysis for outcome 
assessment, their qualitative analysis could predict drug response 
and resistance. Classification of CTC and quantification of treatment 
targets on CTC can be subjective as they are morphologically 
heterogeneous. Current HER2 fluorescence assessment methods rely 
on a visual comparison between CTC images and external controls 
(cells lines) and are poorly reproducible. We report an automated 
classification and quantification of HER2 expression on CTC in 
a large cohort of metastatic breast cancer (MBC) patients (pts). 
Materials and Methods: CTC enumeration and HER2 assessment 
was performed with the CellSearch® system in pts with MBC 
included in the prospective IC 2006-04 study (Pierga, Ann Oncol 
2011), before first line chemotherapy. The FITC conjugated antibody 
CB11 was used to identify HER2. For quantitative assessment of 
HER2 the breast cancer lines SKBR3 and MCF7 with known HER2 
status were spiked in blood of normal donors and processed with the 
CellSearch system. Digital images of Cytokeratin-PE, DAPI, CD45-
APC, and HER2-FITC from these samples were stored. An algorithm, 
previously developed in prostate cancer (Ligthart, AACR 2011), 
was applied on these images to automate identification of CTC. The 
fluorescence of the HER2 FITC channel for each CTC as well as the 
CD45+, DAPI+ leukocytes contained within each sample were also 
quantified using this algorithm. HER2 fluorescence levels of CTC 
were compared to HER2 status of status of pts. Results: Among 267 
pts included in this study, 103 had at least 1 CTC/7.5 ml and HER2 
fluorescence assessment. In these pts, correlation analysis between 
automated (aCTC) and manual (mCTC) CTC counts showed an 
excellent correlation (R2 =0.978). HER2 fluorescence of CTC, varied 
greatly within and between pts, whereas leukocyte fluorescence 
was more homogeneous. The vast majority of CTC exhibited less 
fluorescence than SKBR3 cells, even in HER2+ pts. Primary tumor 
was HER2+ and HER2- in 36 and 58 pts respectively. Percentage of 
HER2+ CTC was higher in pts with primary HER2+ status.
HER2 status of primary tumor and % of HER2+ CTC
Threshold: % of HER2+ 
CTC within a pt
HER2- pts that are above 
this threshold (%)
HER2+ pts that are above 
this threshold (%) p value
≥20 50 61 NS
≥40 33 47 NS
≥60 9 44 <0.01
≥80 3 33 <0.001
100 2 19 <0.001
the threshold of an automatically identified CTC expressing significantly HER2 was set at the mean 
+1SD of the HER2 staining of the automatically identified leukocytes within each pt sample (internal 
control)
Although a rare event, the presence within a sample of at least 1 CTC 
whose HER2 expression is superior to SKBR3 cells was also strongly 
associated with HER2+ primary tumor (N=15/36 vs. 3/58; p<0.001). 
Conclusion: This study is the first to assess HER2 staining intensity 
in each CTC isolated from a large number of MBC pts. This was 
made possible by the aCTC count that was highly correlated with 
the mCTC count in our cohort and permitted HER2 quantification. 
Our study shows that HER2 staining is highly heterogeneous among 
CTC within each pt. These findings demonstrate the feasibility of real 
time quantitative assessment of treatment targets on CTC and opens 
a path towards personalized treatment.
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P4-07-10
Circulating Tumor Cells in Newly Diagnosed Inflammatory 
Breast Cancer.
Mego M, Giordano A, De Giorgi U, Hsu L, Lucci A, Dawood S, 
Woodward WA, Ueno NT, Valero V, Andreopoulou E, Hortobagyi 
GN, Reuben JM, Cristofanilli M. Comenius University, School of 
Medicine, Bratislava, Slovakia (Slovak Republic); UT MD Anderson 
Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia
Background: Inflammatory breast cancer (IBC) is one of the most 
aggressive forms of breast cancer and is associated with special 
clinical and biological features. Circulating tumor cells (CTC) are 
an independent prognostic factor in metastatic breast cancer for 
progression-free and overall survival. Previously, we showed that 
metastatic IBC patients treated with first and subsequent lines of 
chemotherapy had a lower number of CTC when compared with 
CTC levels of non-IBC patients; hence, the prognostic value of CTC 
in mIBC patients is limited. In the present study, we investigated the 
prognostic value of baseline CTC in newly diagnosed IBC patients.
Patients and methods: This retrospective study included 84 newly 
diagnosed IBC (37 stage III B or C and 47 stage IV) patients treated 
with neoadjuvant therapy or first line chemotherapy between January 
2004 and July 2009 at the MD Anderson Cancer Center. The median 
age was 55 years (range, 23-78). Twenty-four (28.8%) patients were 
HER2 positive, 36 (42.9%) hormone receptor positive and 33 (39.3%) 
were triple receptor negative. CTC were detected and enumerated 
using the CellSearch® system before patients started chemotherapy. 
Progression free survival (PFS) and overall survival (OS) were 
calculated from the date of CTC measurement and estimated by the 
Kaplan-Meier product limit method.
Results: At baseline, 64 (76.2%) patients had at least ≥1 CTC and 29 
(34.5%) ≥5 CTC. Proportions of patients with stage III IBC with ≥1 
CTC and ≥5 CTC were lower than those of newly diagnosed stage 
IV IBC patients (67.6% vs. 86%; p = 0.12 and 24.3% vs. 42.6%; p = 
0.11, respectively). At a median follow up of 22.4 months (range: 4.8 
– 58.3 months), 48 (57.1%) patients experienced disease progression 
and 26 (31.0%) had died. Patients with < 5 CTC had similar PFS (p = 
0.36) and OS (p = 0.80) to those of patients with ≥5 CTC, respectively. 
We investigated the prognostic value of CTC ≥ 1 in stage III IBC 
patients, as well. There was no difference in PFS (p = 0.71) and OS 
(p = 0.15) in patients with CTC = 0 vs. those of patients with CTC ≥ 
1, respectively. Moreover, we correlated CTC levels with prognosis, 
using different CTC threshold, but we observed no correlation 
between baseline CTC and patients’ outcome (Table 1).
Conclusions: CTC can be detected in a large proportion of patients 
with newly diagnosed IBC; however, baseline CTC was not 
prognostic for PFS and OS. Collective dissemination of cancer cells 
via lymphovascular tumor emboli and/or epithelial-mesenchymal 
transition accompanied by inadequate detection of CTC due to lack 
of sensitivity of current assays may account for limited prognostic 
value of CTC in newly diagnosed IBC. Nevertheless, sample size and 
study power could influence study results as well.
Correlation between baseline CTC and prognosis of newly diagnosed IBC patients (N=84)
CTC threshold PFS HR (95% CI) p - value OS HR (95% CI) p - value
0 vs ≥1 0.58 (0.30 - 1.15) 0.17 1.52 (0.54 - 4.27) 0.36
< 2 vs ≥2 0.91 (0.51 - 1.61) 0.74 1.18 (0.53 - 2.59) 0.68
< 3 vs ≥3 0.77 (0.44 - 1.37) 0.36 1.17 (0.54 - 2.52) 0.69
< 4 vs ≥4 0.74 (0.42 - 1.32) 0.28 0.98 (0.45 - 2.12) 0.96
< 5 vs ≥5 0.77 (0.43 - 1.39) 0.36 0.90 (0.41 - 1.98) 0.80
< 10 vs ≥10 0.63 (0.32 - 1.22) 0.12 0.61 (0.26 - 1.44) 0.21
< 50 vs ≥50 0.50 (0.17 - 1.42) 0.07 0.67 (0.19 - 2.30) 0.45
P4-07-11
Circulating Tumor Cells after Neoadjuvant Therapy Predict 
Outcome in Stage I to III Breast Cancer.
Gainer S, Krishnamurthy S, Bhattacharyya A, Lodhi A, Hall C, Kuerer 
H, Bedrosian I, Anderson A, Singh B, Lucci A. The University of Texas 
MD Anderson Cancer Center, Houston, TX
Introduction: Circulating tumor cells (CTCs) predict outcome in 
metastatic breast cancer, but their significance is unclear in non-
metastatic patients. Furthermore, it is unclear if the presence of CTCs 
after completion of neoadjuvant chemotherapy (NACT) predicts 
worse outcome. The purpose of this study was to determine if CTCs 
after NACT predicts worse outcome.
Methods: Clinical stage I-III breast cancer patients seen at a single 
tertiary cancer center provided informed consent to participate in an 
IRB-approved study involving collection of blood (7.5 ml x 2 tubes) at 
the time of surgery for their primary breast cancer. CTCs were detected 
using the Cell SearchTM system. A positive result was defined as the 
presence of one or more cells per 7.5 ml blood since the threshold for 
positivity has not been established in non-metastatic breast cancer. 
Statistical analyses used chi-square and Fischer’s exact test.
Results: One hundred and twenty patients were prospectively enrolled. 
Median age was 50 years and median follow-up was 33 months. Eight 
percent of patients had T1 disease, 35% T2, 18% T3, and 39% T4. 
Fifty-three percent of patients (63/120) had hormone receptor positive 
disease. Thirty-two percent of patients (38/120) were HER-2 positive. 
Thirty percent (36/120) were triple negative. Seventy-eight percent 
(91/120) had lymph node positive disease. Two or more CTCs were 
present in 9% of patients (11/120). Of the 11 patients who died, 3 
had 2 or more CTCs (P=0.08). Of the 20 who relapsed, 6 had 2 or 
more CTCs (P=0.0019).
Conclusions: Presence of two or more CTCs after NACT predicted 
worse relapse free survival in patients with stage I-III breast cancer.
P4-07-12
Identification of p53 Mutation in Whole Genome DNA from Single 
Circulating Tumor Cells (CTCs) and Primary Breast Cancers 
(BC) from Patients (pts) with Metastatic Breast Cancer (MBC).
Yang L, Wang Y, Chu P, Liu Q, Hsieh B, Liu X, Yen Y, Bruce R, Somlo 
G. City of Hope; Palo Alto Research Center
Background: CTCs represent the source of distant metastases, and 
are also implied in the growth/re-growth of primary BC. Molecular/
gene-level characterization of similarities and discordances between 
CTCs and BCs in pts with MBC may provide useful information for 
individualized treatment. Since somatic p53 mutations are frequently 
observed in primary BCs, we set out to assess the feasibility of 
identifying such mutations in CTCs from pts with MBCs, and compare 
the findings with those of the primary BCs from the same pts.
Material and Method: Fiber-optic Array Scanning Technology 
(FAST) was used for identification and location of CTCs on large 
glass substrates. CTCs were identified after blood samples (10 ml) 
from MBC pts were stained to detect CTCs via automated digital 
microscopy by morphology, based on immunofuorescence staining 
for cytokeratin and nucleus, and the absence of CD45. Single CTCs 
from 10 pts with MBC were identified and removed from the glass 
substrates. DNA was extracted, and the whole genome of isolated 
CTCs was amplified by using whole genome amplification method 
(Sigma). P53 mutations in exon 5, exon 6, exon 7 and exon 8 were 
assessed. As comparison, genomic DNA from formalin-fixed and 
paraffin-embedded (FFPE) from primary BCs of the same pts, was 
amplified using the same method.
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Results: p53 mutations were found in 8 out of 10 CTCs, and in 4 out 
of 10 in primary BC samples. Of 8 mutations detected in CTCs, one 
silent mutation and 7 missense mutations were seen. One particular 
point mutation, R181L, previously assessed as functional mutation, 
was observed in 4 out of 8 CTCs. None of the 4 mutations (a silent 
mutation, one missense mutation and two different deletions) detected 
in tumor samples were found in CTCs. We validated that the mutations 
detected in CTCs were not artifacts occurring during genome 
amplification, by comparing p53 mutations between unamplified 
tumor genomic DNA vs. amplified samples.
Conclusion: Whole genome amplification based on extracting DNA 
from single CTCs using FAST, and identification of mutations such as 
those in p53, is feasible. The quantitative and qualitative discordance 
in detecting p53 mutations between CTCs and primary BCs may 
be due to CTCs acquiring new –possibly epithelial-mesenchymal 
transition-like-characteristics with metastatic potential as they evolve 
from the primary tumors or metastatic sites, or, technical issues 
(analyzing FFPE-preserved vs. CTCs, tumor heterogeneity) may 
contribute to our findings. Further assessment of the functionality 
of high frequent functional mutations such as R181L is warranted.
P4-07-13
Prognostic Impact of Circulating Tumor Cells Assessed with the 
Cell Search Assay and Adna Test Breast in Metastatic Breast 
Cancer Patients – The DETECT Study.
Mueller V, Riethdorf S, Rack B, Wolfgang J, Fasching PA, Solomayer 
E, Aktas B, Kasimir-Bauer S, Mury D, Pantel K, Fehm T. University 
Medical Center Hamburg-Eppendorf; LMU Munich; University 
Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander 
University Erlangen Nuremberg, Erlangen; University Medical 
Center Homburg/Saar; University Medical Center Essen; University 
Medical Center Tübingen, All Authors on Behalf of the DETECT 
Study Group
Background: Over the last decade circulating tumor cells (CTC) were 
established as a prognostic factor in breast cancer patients. However, 
there are very limited studies comparing different test methods, 
although several are available.The DETECT trial for metastatic breast 
cancer patients was designed to investiate the prognostic impact of 
CTC. Here, we report on the prognostic relevance of CTC testing 
with different detection methods.
Material and Methods: Patients with primary metastatic breast 
cancer or metastatic recurrence were prospectively enrolled in this 
multicenter trial. CTC were detected using the FDA-approved Cell 
Search® assay applying immunocytochemistry and the RNA-based 
Adna Test Breast Cancer™. After a median follow-up of 11 months 
the first survival data are now presented.
Results: Both methods could be performed in 221 patients. Using 
the CellSearch™ assay 116 of 221 patients were CTC-positive based 
on the cut-off level of 5 cells. Presence of CTC was associated with 
the site of metastatic disease. The OS was 15.4 months in CTC 
positive pts. (95%-CI: 13.5-17.1 mths) compared to 20.4 mths. in 
CTC negative pts. (19.1-21.9 mths. ; p<0.001). In the multivariate 
analysis presence of CTC was the only independent predictor for 
overall survival (HR: 3.4, 95%-CI: 1.7-6.3) including tumorbiological 
factors, menopausal status, number and sites of metastatic disease. 
The progression-free survival was not correlated with CTC status in 
our cohort receiving different types of systemic treatment (p=0.197). 
When the AdnaTest Breast was performed, 88 of 221 (40%) patients 
were CTC positive. Except for HER2 status, no correlation could be 
observed between CTC positivity and any of the clinicopathological 
factors. CTC positivity assessed by the AdnaTest Breast has no impact 
on PFS and OS. A multivariate analysis was therefore not performed.
Conclusions: Currently, several different tests are available for CTC 
detection. Only a few tests have been approved by the FDA and been 
validated in large clinical trials. Therfore, it will be important to 
compare new techniques with the Cell Search assay.
P4-07-14
Circulating Tumor Cells (CTCs) Detection and HER2 Profiling by 
CellSearch® in Non-Metastatic Breast Cancer: An International 
Ring Study To Assess Inter-Reader Variability.
Ignatiadis M, Pierga J-Y, Campion M, Fehm T, Payne R, Rack 
B, Mavroudis D, Riethdorf S, Rothe F, Bessi S, Aura CM, Sandri 
MT, Borgen E, Kraan J, Terstappen LWMM, Piccart M, Sotiriou 
C, Michiels S, Pantel K. Institut Jules Bordet, Brussels, Belgium; 
Institut Curie, Paris, France; Mayo Clinic, Rochester; Universitaets-
Frauenklinik, Tubingen, Germany; Hammersmith Hospital, Imperial 
College, London, United Kingdom; Ludwig-Maximilians-Universitat, 
Munchen, Germany; University of Crete, Crete, Greece; University 
Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hospital 
of Prato, Prato, Italy; Vall d’Hebron, Barcelona, Spain; European 
Institute of Oncology, Milan, Italy; Oslo University Hospital, 
Oslo, Norway; Erasmus Medical Center, Rotterdam, Netherlands; 
University of Twente, Twente, Netherlands
Background: Preliminary results from the Success and Remagus trials 
showed that CTC detection by CellSearch® has adverse prognostic 
value in non-metastatic breast cancer. Moreover, several investigators 
have characterized HER2 expression on CTCs in early breast cancer. 
Since the majority of CTC-positive women with non-metastatic breast 
cancer have only 1 CTC detected / blood volume analyzed, we wanted 
to evaluate the inter-reader variability in this setting. This is a crucial 
step before moving forward with multi-lab/multi-center prospective 
testing of the clinical utility of the CellSearch® technology in non-
metastatic breast cancer.
Methods: Five galleries of CellSearch® images from 3 European 
and one US institution (a total of 307 images) were mailed to 22 
independent readers from 14 European and US academic laboratories 
and 8 readers from two CellSearch® Veridex laboratories in a blinded 
fashion. These images came mainly from studies on CTC and/or 
HER2-positive CTC detection in breast cancer and included healthy 
women (negative controls), women with metastatic (positive controls) 
and non-metastatic disease (Pierga et al SABCS 2010, Pierga et al 
ASCO 2011, Riedthorf et al CCR 2010, Ignatiadis et al PLoS ONE 
2011). Each reader reported the images as either CTC-negative or 
CTC-positive/HER2-negative or CTC-positive/HER2-positive. 
Kappa statistics were used to assess inter-reader agreement. The 8 
Veridex readers were summarized by a majority voting system to 
derive a gold standard in order to compare each independent reader 
using discordance rates.
Results: Kappa statistics showed moderate to good agreement between 
independent readers depending on the gallery evaluated (gallery 1 K: 
0.55, gallery 2 K:0.57 gallery 3 K:0.64, gallery 4 K:0.72, gallery 5 
K:0.85). These differences were attributed to differences in scoring 
difficulty of each gallery. Discordances in CTC-positive vs CTC-
negative events between each reader and the gold standard ranged 
from 2.3%-31.3% with 7 readers showing discordance rates <5%, 
11 readers between 5-10%, 10 readers between 10-14% and only 2 
readers showing discordance rates >14% as compared to the gold 
standard (median discordance rate: 9.3%). Image analysis showed 
that investigators with high discordance rates compared to the Veridex 
gold standard were not always taking into account “morphological 
characteristics” for defining an event as CTC-positive. Discordant 
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results between readers were mainly due to discordance in CTC 
definition and to a lesser extent in the definition of HER2-positivity. 
Indeed, discordances in assigning a CTC-positive event as either 
HER2-negative or HER2-positive ranged from 0.3-13.7% with 19 
readers showing discordance rates <5%, 7 readers between 5-10% 
and 4 readers with discordance rates >10% (median discordance 
rate: 3.9%).
Conclusion: In non-metastatic breast cancer, we observed low 
discordance between most independent readers and the gold standard 
for defining a CellSearch® event as CTC with very few readers 
showing high discordance rates. Concordance can be improved 
through appropriate training and the use of all the tools provided by 
the CellSearch® system for image interpretation.
P4-07-15
Insulin-Like Growth Factor Receptor I (IGFIR) Expression 
in Circulating Tumor Cells (CTCs) of Patients with Early and 
Metastatic Breast Cancer (BC).
Spiliotaki M, Markomanolaki H, Kokotsaki M, Kallergi G, Mavroudis 
D, Georgoulias V, Agelaki S. School of Medicine, University of Crete, 
Heraklion, Crete, Greece; University General Hospital of Heraklion, 
Heraklion, Crete, Greece
Background: Components of the insulin-like growth factor system 
are deregulated and IGFIR overexpression is commonly observed in 
BC, however the expression of the receptor in CTCs of patients with 
BC has not been studied.
Methods: IGFIR expression was assessed in CTCs from 65 patients 
with early and 101 with metastatic breast cancer before the start 
of adjuvant and first-line chemotherapy, respectively. Peripheral 
blood mononuclear cells’ (PBMCs) cytospins were stained with a 
monoclonal A45-B/B3 anti-cytokeratin (CK) antibody and IGFIR 
b-subunit anti-rabbit antibody. IGFIR(+)CK(+) CTCs were detected 
using immunofluorescent microscopy (Ariol system). Phosphorylated 
IGFIR was also evaluated after staining with phospho-IGFIR-b 
(Tyr1131)/Insulin Receptor-b (Tyr1146) antibody.
Results: CK(+) CTCs were detected in 23 (35.3%) patients with early 
and 48.5% with metastatic BC. IGFIR(+) CTCs were identified in 
all (100%) patients with early and in 38 (78%) out of 49 patients 
with metastatic BC (p=0.014). Eighteen (78%) out of 23 patients 
with early disease had exclusively IGFIR(+) CTCs and 5(22%) had 
both IGFIR(+) and IGFIR(-) CTCs. There were no patients in whom 
exclusively IGFIR(-) CTCs were identified. The respective values 
in patients with metastatic disease were 19 (39%), 19 (39%) and 11 
(22%) (p=0.004, compared to early disease). The median percentage 
of the expression of IGFIR(+) and IGFIR(-) CTCs per patient was 
100% (range 25-100) and 0% (range 0-75), in early and 68% (range, 
0-100) and 32% (range 0-100), in metastatic disease, respectively 
(p=0.003). A total of 222 and 386 CTCs were detected in patients 
with early and metastatic disease, respectively. IGFIR expression 
was observed in 84% and 64% of all detected CTCs in adjuvant 
and metastatic patients, respectively (p<0.001). Phosphorylated 
IGFIR has been evaluated in PBMCs’ cytospins from 6 patients 
with adjuvant and 6 with metastatic disease. Interestingly, among 
18 CTCs detected in early BC, all expressed phosphorylated IGFIR, 
whereas, among 34 CTCs identified in metastatic patients, none 
expressed the phosphorylated form of the receptor. The evaluation 
of phosphorylated IGFIR is ongoing and updated results will be 
presented.
Conclusions: IGFIR expression is commonly observed in CTCs of 
patients with BC. IGFIR expression is detected in a higher proportion 
of patients and in a higher proportion of the total number of CTCs 
identified in early compared to metastatic disease. The above 
observations suggest that metastatic progression is associated with 
loss or downregulation of IGFIR expression in breast cancer.
P4-07-16
Development of Circulating Tumor Cell-Endocrine Therapy 
Index in Metastatic Breast Cancer Patients.
Paoletti C, Connelly MC, Chianese DA, Brown ME, Muñiz MC, Rae 
JM, Thomas DG, Hayes DF. University of Michigan Comphrehensive 
Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon 
Valley, PA
Introduction: Only ~ 50% of patients (pts) with estrogen receptor 
(ER) positive metastatic breast cancer (MBC) benefit from endocrine 
therapy (ET). Currently only clinical judgment can be used to identify 
pts with endocrine-refractory MBC, who are better palliated with 
chemotherapy. Circulating Tumor Cells (CTC) are reliably enumerated 
using an automated immunomagnetic system (CellSearch®; Veridex 
LLC). High CTC levels predict rapid progression in pts with MBC. 
We have developed a multi-parameter assay, the CTC-Endocrine 
Therapy Index (CTC-ETI) using CellSearch® that may identify pts 
with ER positive MBC who are unlikely to benefit from ET and may 
be better served with chemotherapy. CTC-ETI scores are assigned 
based on CTC levels coupled with the relative percent and degree of 
marker positivity on the CTC. We report preliminary results from a 
pilot single institutional study.
Methods: CellSearch® has 4 fluorescence channels. Three distinguish 
CTC from WBC (DAPI, anti-cytokeratin, anti-CD45). The 4th 
“empty” channel was used to measure ER, BCL-2, HER-2, and Ki-
67 expression with fluorescent-labeled antibodies. These 4 markers 
reflect sensitivity (ER, BCL-2) or resistance (HER-2, Ki-67) to ET. 
Forty ml of blood was drawn into 4 CellSave® tubes from pts with 
progressive MBC. Whole blood from 4 tubes was pooled and divided 
into 4 different 7.5 ml aliquots of blood, which were processed and 
characterized for CTC counts and each of the four molecular markers 
using the CXC CellSearch® kit.
Results: 21 pts have been accrued to the feasibility study. One patient 
was ineligible. Five of 20 pts had low CTC counts (<5 CTC/7.5ml 
whole blood), and are expected to have a relatively favorable 
prognosis. CTC-ETI was successfully determined in 10 pts (50%): 
2 pts had low, while 3 had intermediate, and 5 had high CTC-ETI. 
Technical difficulties precluded accurate CTC-ETI in the remaining 
5 patients. Of note, expression of the biomarkers among CTC in 
single patients was heterogeneous, suggesting that future iterations 
of the CTC-ETI will have to consider expression variability. Further 
exploratory results regarding associations between CTC-ETI and 
outcomes will be presented.
Conclusions: ER, BCL-2, HER-2, and Ki-67 can be accurately 
determined on CTC using the 4th channel in the CellSearch® system 
to calculate CTC-ETI. We predict that lower CTC-ETI scores (low 
or no CTC, or CTC with high CTC ER and BCL-2 and low CTC 
HER-2 and Ki-67) could be associated with favorable response to 
ET. Successful completion of the feasibility study will lead to a 
prospective trial to determine if high CTC-ETI at baseline predicts 
resistance and rapid progression on ET in women starting a new 
endocrine therapy for MBC.
Supported by Veridex, LLC, Fashion Footwear Charitable Foundation 
of New York/QVC Presents Shoes on Sale ™ (DFH), Associazione 
Sandro Pitigliani and by a studentship from FIRC (CP).
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P4-07-17
Isolation of Highly Pure Circulating Tumor Cells (CTCs) from 
Metastatic Breast Cancer (MBC) Patients for Gene Expression 
Analysis.
Magbanua MJ, Hauranieh L, Pendyala P, Sosa E, Scott J, Rugo H, 
Park J. University of California, San Francisco, CA
Background: The paucity of information regarding the molecular 
nature of CTCs can be largely attributed to the difficulty of isolating 
these rare cells. As such, efforts on RNA profiling of CTCs have been 
limited to studies using immuno-enriched samples containing a high 
background of leukocytes.
Methods: We developed a two-step process: immunomagnetic 
enrichment followed by fluorescence activated cell sorting (IE/FACS) 
to isolate CTCs away from leukocytes and performed expression 
analysis on a limited panel of genes. Magnetic beads coated with 
EpCAM mAb were used to enrich for tumor cells. Enriched samples 
were then subjected to FACS using fluorescently labeled mAbs 
to distinguish tumor cells (EpCAM+) from leukocytes (CD45+) 
during sorting. CTCs and matched leukocytes were isolated from 67 
sequential patients with MBC. Total RNA from isolated 20-50 cells 
was reverse-transcribed into cDNA. Sixty four (64) CTC-related 
genes from previous published reports were chosen for expression 
analysis. cDNA of these genes were pre-amplified and analyzed in 
triplicate via Taqman®-based RT-PCR in a low density array format. 
Statistical analysis of gene expression data was performed using 
Realtime Statminer®.
Results: Unsupervised hierarchical clustering analysis showed 
that CTCs clustered away from the leukocytes. Differential gene 
expression analysis revealed the up-regulation of several genes 
including EPCAM, MUC1, and KRT19 in CTCs (adjusted p <0.05). 
In addition, CTCs showed a significant down-regulation of the 
leukocyte-specific marker PTPRC (CD45) as well as CD44 and VIM, 
markers associated with stem cellness and epithelial to mesenchymal 
transition, respectively.
Discussion: We demonstrate the feasibility of isolation and gene 
expression analysis of CTCs. Molecular profiling confirmed that 
isolated CTCs were highly pure with little or no evidence of leukocyte 
contamination. This approach can serve as a non-invasive source of 
tumor tissue for further molecular characterization of CTCs and for 
monitoring of therapeutic efficacy of targeted therapies in clinical 
trials. This study was supported by CALGB and BCRF.
P4-07-18
Prospective Assessment of Circulating Tumor Cells and Serum 
Markers for PFS Prediction in Metastatic Breast Cancer.
Bidard F-C, Hajage D, Bachelot T, Delaloge S, Brain E, Campone 
M, Cottu P, Beuzeboc P, Mathiot C, Pierga J-Y. Institut Curie, Paris, 
France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, 
Villejuif, France; Centre René Gauducheau, Nantes, France
Purpose: Circulating tumors cells (CTC) have been recently proposed 
as a new dynamic blood marker whose positivity at baseline is a 
prognostic factor and whose changes under treatment are correlated 
with progression-free survival (PFS) in metastatic breast cancer 
patients. However, serum markers levels are also used for the same 
purpose, and no clear comparison as been reported to date.
Patients and methods: The IC 2006-04 enrolled prospectively 267 
metastatic breast cancer patients treated by first line chemotherapy 
and confirmed that CTC levels are an independent prognostic factor 
for PFS and Overall survival (OS). A pre-planned endpoint was to 
compare prospectively the positivity rates and the value of CTC 
(CellSearch®), of serum tumor markers (CEA, CA 15-3, CYFRA 
21.1), and of serum non-tumor markers (LDH, ALP) at baseline and 
under treatment for PFS prediction, independently from the other 
known prognostic factors, using univariate analyses and concordance 
indexes.
Results:
Table 1 shows the incidence of each of the 6 blood markers. Assessing 
all the 6 markers retrieved 90% of patients with at least one elevated 
marker at baseline. Interestingly, a combination of two markers (CA 
15-3 and CYFRA 21.1, often used in lung cancer) retrieved 86% of 
patients with at least one marker elevated at baseline.
All 6 markers were correlated with poor performance status, high 
number of metastatic sites and with each other. Each marker was 
associated, when elevated at baseline, with a significantly shorter 
PFS in univariate anlaysis.
Serum marker changes during treatment, assessed either between 
baseline and week 3 or between baseline and week 6-9, were 
significantly associated with PFS, as reported for CTC. Concordance 
indexes comparison showed no clear superiority of any of the serum 
marker or CTC for PFS prediction.
Conclusion: In the largest prospective CTC study in metastatic breast 
breast cancer, we previously reported that CTC count, but not serum 
markers, is an independent prognostic factor for PFS and overall 
survival. However, for the purpose of PFS prediction by measuring 
blood marker changes during treatment, currently available blood-
derived markers (CTC and serum markers) had globally similar 
performances. Besides CEA and CA 15-3, CYFRA 21.1 is commonly 
elevated in metastatic breast cancer and has a strong prognostic value.
Correlations between elevated markers at baseline
 CA 15-3 
>ULNV
CEA 
>ULNV
CYFRA 21.1 
>ULNV
LDH 
>ULNV
ALP 
>ULNV
CTC >=5 / 
7.5ml
All population at baseline 64% 51% 65% 45% 29% 44%
All population at week 3 66% 46% 34% 43% 28% 17%
All population at week 6-9 64% 40% 27% 49% 22% 13%
ULNV : upper limit of normal value
P4-07-19
Bone Marrow Involvement Is Associated with High Numbers of 
Circulating Tumor Cells in Peripheral Blood of Metastatic Breast 
Cancer Patients.
Grisanti S, Consoli F, Almici C, Bertagna F, Verardi R, Ungari M, 
Amoroso V, Pedersini R, Vassalli L, Montani E, Simoncini EL. Spedali 
Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy
Introduction: Circulating Tumor Cells (CTCs) levels are dynamic 
indicators of prognosis and response to therapy in metastatic breast 
cancer (MBC) patients (pts). CTCs levels have been reported to 
be higher in pts with bone than visceral metastases, respectively. 
However, little is known about CTCs levels in pts with BM 
involvement. We analysed CTC patterns in patients with either 
visceral, bone or BM to test the hypothesis that BM involvement 
would facilitate tumor cells to enter the systemic circulation as CTCs.
Patients and methods: Sites and extension of metastatic disease 
were identified with conventional imaging. Bone metastases were 
diagnosed with either bone scintigraphy or CT-PET and the BM 
involvement was documented histologically by BM biopsy and 
metabolically by CT-PET. A training set of 10 pts was evaluated by 
both BM biopsy and CT-PET to verify the diagnostic performance 
of CT-PET in identifying BM metastases (M+). We found a 100% 
concordance between BM biopsy and CT-PET and we therefore 
used CT-PET for further analyses. The CellSearch System (Veridex 
LLC, Raritan, NJ, USA) was used for the isolation and enumeration 
of CTCs in peripheral blood. The Student’s t-test and the two-way 
ANOVA test were used to compare means of CTCs among patients 
with different metastatic patterns.
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Results: The CTCs mean and median scores of 129 MBC pts were 
analysed. Final analysis focused on 101 pts with bone M+. Thirty-
three pts had bone M+ alone and 68 pts had bone and visceral M+ 
(including lymphnodes, brain, liver and lung/pleura). Number of 
metastatic sites was 1, 2, 3, 4, 5 in 30%, 37%, 25%, 6% and 2% of 
pts, respectively. BM involvement was documented in 27 (27%) of pts 
in the whole series and in 12 (33%) of pts with bone M+ alone. Mean 
CTCs score in the whole series was 392 (0-9993) and the median 
number of CTCs was 20. In the whole series, BM involvement was 
associated with higher mean CTCs scores (1350 vs 42, p .014). In 
pts with bone M+ alone, mean CTCs score was 696 (0-7000) and 
pts with BM involvement had higher mean CTCs scores (1846 vs 
39, p 0.37). Among the different metastatic patterns, the association 
of bone with BM involvement and liver M+ was correlated with the 
highest CTCs numbers. We could not perform comparisons in the 68 
pts with both bone and visceral localizations because of the variety 
of metastatic patterns. However, the two-way ANOVA showed a 
significant influence of BM involvement on mean CTCs scores in 
pts with different metastatic patterns (p >.001).
Conclusions: This work confirms that pts with bone metastases have 
higher numbers of CTCs than pts with visceral metastases. Extensive 
bone disease with BM involvement is characterized by an increase in 
CTCs numbers compared to bone disease without BM involvement. 
Bone marrow metastases are metabolically more active by CT-PET 
and can be accurately detected by metabolic imaging without need 
of BM biopsy. Further studies are ongoing.
P4-07-20
Apoptosis in Circulating Tumor Cells (CTCs) of Early and 
Metastatic Breast Cancer Patients.
Kallergi G, Konstantinidis G, Papadaki M, Agelaki S, Mavroudis D, 
Stournaras C, Georgoulias V. School of Medicine, University of Crete, 
Heraklion, Crete, Greece; University General Hospital of Heraklion, 
Heraklion, Crete, Greece
Background: Metastasis has been associated with the presence of 
circulating (CTCs) and disseminated (DTCs) tumor cells in peripheral 
blood and bone marrow of breast cancer patients, respectively. 
Recent studies have confirmed that the detection of CTCs and DTCs 
represents a strong and independent prognostic factor for decreased 
disease-free and overall survival. However, it is not clear so far 
whether all CTCs are capable to generate metastasis or some of them 
are destined to die. The aim of the present study was to analyze the 
presence of apoptotic CTCs in patients with early and metastatic breast 
cancer. Patients and methods: Double staining immunofluorescent 
(IF) expreriments were performed in peripheral blood mononuclear 
cells (PBMC) cytospins of patients with early (n=23) and metastatic 
breast cancer (n=29), prior to the initiation of adjuvant and first-line 
chemotherapy, respectively. Pancytokeratin A45-B/B3 antibody (as 
a marker of CK-positive cells) was coupled with either M30 (marker 
of apoptotic cells) or Ki67 (marker of proliferating cells) antibodies. 
Apoptotic CTCs were also evaluated using a polycaspase detection 
kit. Results: Significantly lower proportions of apoptotic CTCs were 
detected in metastatic compared to early breast cancer patients using 
the polycaspase kit (3% vs 49%, p=0.0001). These results were 
confirmed with M30 staining (32% vs 67%, in metastatic and early 
disease, respectively, p=0.023). The median percentage of apoptotic 
CTCs per patient was also lower in advanced compared to early 
disease patients (0% vs 100% with the polycaspase kit and 15% vs 
70% with M30 staining). Ki67 positive CTCs were identified in 56% 
of early and metastatic patients, while the ratio of Ki67-positive/
Total CTCs was 15% and 36% respectively. Conclusions: Apoptotic 
CTCs are more commonly observed in early compared to metastatic 
breast cancer, whereas, Ki-67 positive CTCs are more frequently 
encountered in metastatic disease. The differential incidence of 
apoptotic and proliferative CTCs in early and metastatic disease 
is probably related to disease progression. The evaluation of these 
markers in CTCs from patients with breast cancer may provide useful 
prognostic information and could be used to monitor the effectiveness 
of therapy.
P4-07-21
A Comparison of Two Methods for the Detection of Circulating 
Tumor Cells (CTCs) in Patients (pts) with Early and Metastatic 
Breast Cancer (BC): RT-PCR for Cytokeratin (CK) -19 mRNA 
Versus the CellSearch System.
Politaki E, Agelaki S, Apostolaki S, Perraki M, Hatzidaki D, Lianidou 
ES, Mavroudis D, Georgoulias V. University General Hospital of 
Heraklion, Heraklion, Crete, Greece; University of Athens, Athens, 
Greece
Background: Different methods are available for the detection of 
CTCs in pts with BC, however, the variable performance of these 
assays, the heterogeneity of CTCs, and the possible treatment-induced 
alteration of the markers evaluated, imply that no ideal method 
currently exists. We compared the efficiency of two methods to detect 
CTCs in pts with BC.
Patients and Methods: Blood was obtained from 200 pts with early 
and 164 with metastatic BC before the start of adjuvant or first-line 
chemotherapy, respectively. Different aliquots of the same sample 
were evaluated by RT-PCR for CK-19 mRNA and by the CellSearch 
System. Blood samples were available after the end of adjuvant or 
first-line therapy in 99 and 93 pts, respectively. CTCs in 23 and 7.5 ml 
of blood were enumerated by CellSearch, in adjuvant and metastatic 
pts, respectively. Cut-off values of ≥1 and ≥2 CTCs/23 ml and ≥2 
and ≥5 CTCs/7.5 ml were used. Twenty ml of blood were obtained 
for mRNA extraction in all RT-PCR experiments.
Results: In early BC, 18.0% of samples were positive prior to therapy 
by RT-PCR and 37.0% (CTC≥1) and 16.5% (CTC≥2) by CellSearch. 
No significant correlation was shown for the detection of CTCs 
between methods. Overall (positive and negative) concordance was 
62% for CTC≥1 and 73.5% for CTC≥2 (Chi-Square, p=0.161 and 
p=0.307). Post-chemotherapy, the positivity rate was 33.6% (CTC≥1) 
and 18.8% (CTC≥2) by CellSearch and 11.6% by RT-PCR (Spearman, 
R=-0.031, p=0.761). Overall agreement was 60.6% (CTC≥1) and 
71.4% (CTC≥2) (Chi-Square, p=0.771 and p=0.708). In the metastatic 
setting, 37.8% of the samples were positive by RT-PCR, and 50% 
(CTC≥2) or 32.3% (CTC≥5), by CellSearch (Spearman, R=0.373, 
p=0.0001). Overall agreement was 70.0% for CTC≥5 (Chi-Square, 
p=0.0001). Post-chemotherapy, 21% were positive by RT-PCR and 
13.7% and 8.4% by CellSearch for CTC≥2 and ≥5, respectively 
(Spearman, R=0.194, p=0.063). Overall concordance for CTC≥5 
was 79.6% (Chi-Square, p=0.017). Agreement was also observed 
for CTC≥2, pre-and post-chemotherapy (Chi-Square, p=0.0001 
and p=0.010). The concordance rates in the adjuvant and metastatic 
settings are shown in Table 1.
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Table 1: Concordance rates between methods in adjuvant (at CTC≥1) and metastatic (at CTC≥5) 
settings
EARLY DISEASE
Pre-chemo n=200   Post-chemo n=99
 CellSearch (CTC≥1)  CellSearch (CTC≥1)
 Negative (n=126) Positive  
(n=74)
 Negative (n=65) Positive 
(n=34)
RT-PCR n (%) RT-PCR n (%)
Negative (n=164) 107 (53.5) 57 (28.5) Negative (n=86) 56 (56.6) 30 (30.3)
Positive (n=36) 19 (9.5) 17 (8.5) Positive (n=13) 9 (9.1) 4 (4.0)
p=0.161 p=0.771
METASTATIC DISEASE
Pre-chemo n=164 Post-chemo n=93
 CellSearch (CTC≥5)  CellSearch (CTC≥5)
 Negative (n=111) Negative  
(n=53)
 Negative (n=86) Positive  
(n=7)
RT-PCR n (%) RT-PCR n (%)
Negative (n=102) 82 (50.0) 20 (12.2) Negative (n=73) 70 (75.3) 3 (3.2)
Positive (n=62) 29 (17.7) 33 (20.1) Positive (n=20) 16 (17.2) 4 (4.3)
p=0.0001   p=0.017
Conclusions: A high concordance between the two methods was 
detected in metastatic but not in early disease. Patient follow-up will 
determine the clinical relevance of each individual assay or their 
combination in the assessment of patient prognosis.
P4-08-01
Predictive Value of HER2 Serum Levels in Patients Treated 
with Lapatinib or Trastuzumab – A Translational Project in the 
Neoadjuvant “Geparquinto” Trial.
Witzel ID, Loibl S, von Minckwitz G, Abdallah A, Kühn T, Overkamp 
F, Fehm T, Schrader I, Uleer C, Kohls A, Stirnberg S, zu Eulenburg 
C, Untch M, Müller V. University Medical Center Hamburg-
Eppendorf, Hamburg, Germany; German Breast Group, Neu-
Isenburg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; 
University Medical Center Tübingen, Tübingen, Germany; Hospital 
Gelsenkirchen, Gelsenkirchen, Germany; Hospital Esslingen, 
Esslingen, Germany; Oncologianova, Recklinghausen, Germany; 
Gynäko-Onkologische Praxis Hannover, Hannover, Germany; 
Gynäkologische Gemeinschaftspraxis, Hildesheim, Germany; 
Ev. Krankenhaus, Ludwigsfelde-Teltow, Germany; Frauenklinik 
Rheinfelden, Rheinfelden, Germany
Background: Neoadjuvant chemotherapy (NT) has become an 
important approach to assess therapeutic efficacy of new treatment 
strategies. We observed a predictive role of of serum HER2 
(sHER2) with neoadjuvant trastuzumab treatment in the previous 
trial “Geparquattro”. Predictive markers for response to new HER2-
targeted therapies are still lacking. Therefore, we investigated the 
role of sHER2 in the context of trastuzumab and lapatinib treatment.
Methods: The clinical trial Geparquinto incorporated either 
trastuzumab or lapatinib treatment combined with chemotherapy 
for HER2-positive breast cancer patients. Serum samples were taken 
at three different time points: before initiation of NT, after 4 cycles 
of chemotherapy with epirubicin and cyclophophamide and after 
finalization of NT with 4 cycles of docetaxel (pre-surgery). Only 
those patients were included in the analysis with serum available at 
all three time points. sHER2 levels were measured by a commercially 
available ELISA in 159 patients with a HER2-positive primary tumor, 
77 (48%) patients were treated with trastuzumab, 82 (52%) with 
lapatinib. Pathological complete remission (pCR) was defined as no 
microscopic evidence of invasive residual tumor cells in the breast 
and lymph nodes.
Results: Overall pCR rate in this cohort was 28%. sHER2 levels were 
higher in patients with larger tumors (> 5cm, p=0.012) and positive 
nodal status (p=0.001). Higher pre-chemotherapy sHER2 levels 
were associated with higher pCR rates in the entire study cohort (OR 
2.9, 95% CI 1.3-6.7, p=0.012). Additionally, in the lapatinib treated 
patient group, a decrease of serum levels of more than 20% after 4 
cycles of chemotherapy showed a tendency to be associated with 
higher pCR rates (OR 7.7, 95% CI 0.8- 70, p=0.071). In contrast to 
the finding of the previous trial Geparquattro, this was not the case 
in the trastuzumab-treated patient group (p=n.s.).
Conclusion: Results of this study demonstrate pre-chemotherapy 
sHER2 levels to be an independent predictor of response to NT with 
both trastuzumab and lapatinib treatment.
P4-08-02
Estradiol (E2) Mediated Secretion of Vascular Endothelial 
Growth Factor (VEGF) and Stimulation of T-Regulatory Cells 
(T-Regs): Their Role for the Worse Prognosis of Breast Cancer 
(BC) in Premenopause.
Recchia F, Candeloro G, Desideri G, Necozione S, Recchia COC, 
Rea S. Civilian Hospital, Avezzano, AQ, Italy; University, L’Aquila, 
AQ, Italy
Background: E2 plays a key role in all the phases of human 
reproduction, including promotion of uterine basal membrane erosion, 
embryo implantation, placental villi development, and pregnancy 
maintenance. E2 mediates all these functions through the induction 
of VEGF secretion and stimulation of T-Regs with increased tolerance 
for the eterologous embryo. BC might utilize the same pathways for its 
growth and for disease progression: Modulation of VEGF expression 
in BC cells through transcriptional activation and regulation of the 
peripheral development of CD4+CD25+ T-Regs cells. Both VEGF 
and T-Regs are important prognostic factors: In fact high levels of 
VEGF expression are associated with significantly worse survival in 
breast cancer patients, even in sub-groups expected to have a better 
prognosis and T-Regs quantification in breast tumors is valuable for 
assessing disease prognosis and progression. However few clinical 
studies investigated the association between E2, VEGF and T-Regs 
in humans. Objective of this study was to evaluate whether E2 
suppression with an LH-RH analogue was able to down regulate 
VEGF expression, and decrease T-Regs in premenopausal patients 
with high-risk estrogen receptor positive (ER+) and negative (ER-) 
early BC. Material and Methods: From 04-2003 to 10-2008, 100 
premenopausal early BC patients were entered into the study. At 
baseline, in the follicular phase of the menstrual cycle, after surgery, 
plasma E2, VEGF and T-Regs were measured. Measurements 
were repeated every six months. Treatment: LH-RH analogue for 
5 years, chemotherapy tailored to the biological characteristics of 
each patient, radiation therapy, and 5-year hormonal therapy in ER+ 
tumors. Primary end-point was the evaluation of VEGF and T-Regs. 
Secondary end points were progression-free survival (PFS) and 
overall survival (OS). Results: Median age was 43 years (range 26-
45). Median number of positive axillary nodes was 3.3. Eighty-three 
patients were ER+, 17 were ER - and progesterone receptor negative 
(PGR-), 10 were triple negative, 20 were Herb-2 positive. Median KI-
67 was 33% (range 15%-100%). A statistically significant decrease of 
E2,VEGF and T-Regs was observed after 1 and 5 years, in ER+ and 
ER- patients: In particular, VEGF (P<0.001) and T-Regs (P<0.001) 
decreased in 95% of patients that were disease-free. No unexpected 
toxicity of chemotherapy was observed, while hot flashes and G1 
osteopenia occurred after LH-RH analogues administration. After a 
median follow-up of 55 months (range 30-95), 5-year PFS and OS 
rate were 95% and 100%, respectively. Discussion: E2 deprivation 
with an LH-RH analogue is able to decrease plasma VEGF and 
T-Regs levels in premenopausal high risk ER+ and ER- BC patients. 
These data show how E2, through VEGF and T-Regs modulation, 
may be responsible for the worst prognosis that is observed in 
premenopausal BC.
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P4-08-03
Serum Autoantibodies to Breast Cancer Associated Antigens 
Reflect Tumor Biology: An Opportunity for Early Detection & 
Prevention?
Eiermann W, Jackson L, Murray A, Chapman CJ, Peek LJ, 
Widschwendter P, Allen J, Graham H, Robertson JF. Fauenklinik vom 
Roten, Munich, Germany; University of Nottingham, Nottingham, 
United Kingdom; Oncimmune Ltd, Nottingham, United Kingdom; 
Oncimmune LLC, De Soto, KS
Autoantibodies (AABs) are produced as an immune response 
to abnormal (‘non-self’) cancer antigens. Previous studies have 
reported that AABs can be measured in the blood long before 
cancers are presently diagnosed, e.g., up to 4 years before screening 
mammography identified breast cancers and up to 5 years before 
screening CT detected lung cancers. EarlyCDT™-Lung is currently 
available as an aid to early detection of lung cancer in high risk 
patients and measures a panel of seven AABs to general cancer 
antigens and also lung cancer (LC) specific antigens. These AABs 
have previously been reported to be associated with the two main 
types of LC i.e., non-small cell and small cell LC. This study looked 
at AABs to 4 general cancer antigens to evaluate whether their levels 
reflected different biology in primary breast tumors.
Methods
770 patients presented with primary breast cancer to three centers 
(Nottingham, UK n=323; Munich, Germany n=320; Oklahoma, USA 
n=127); the median ages and ranges were 61 (26-82), 61 (20-88) & 
65 (54-84) years, respectively. All had serum samples taken post-
diagnosis and pre-treatment. The tumors were well characterized 
for histological grade, estrogen receptor (ER), progesterone receptor 
(PgR) and HER2 status. Serum samples were tested for AABs to four 
generic cancer antigens(Ags) (p53, SOX2, NY-ESO-1 and Annexin1) 
originally included as part of Oncimmune’s EarlyCDT™-Lung assay. 
The AABs were measured by ELISA on the Oncimmune platform, 
and the EarlyCDT™-Lung cutoffs were used to determine positivity.
Results
131/770 (17%) of primary breast cancers showed elevated AAB levels 
to one or more of the limited panel of four generic antigens. Positivity 
for each AAB was correlated with histological grade, ER, PgR and 
HER2 status. The results, which were similar for each of the three 
centres, were combined, and the results are shown in Table 1 below.
Table 1
 High Grade ER positive PgR positive Her2 positive
p53 8/15 (53%) 6/16 (38%) 4/16 (25%) 10/16 (63%)
NY-ESO-1 17/19 (89%) 7/19 (37%) 7/19 (37%) 3/19 (16%)
SOX2 18/75 (24%) 65/75 (86%) 54/71 (76%) 17/24 (23%)
Annexin 1 9/22 (41%) 17/23 (74%) 13/22 (57%) 4/22 (18%)
p53 AAB positive cancers tended to be hormone receptor negative 
and HER2 positive. NY-ESO-1 positive tumors were almost all higher 
grade with the majority hormone receptor and HER2 negative. SOX2 
positive cancers tended to have a hormone sensitive phenotype (i.e., 
hormone receptor positive and HER2 negative). Annexin 1 positive 
cancers also tended to have a hormone sensitive phenotype as well 
as HER2 negative. The pattern was statistically different for the four 
AABs (p<0.001). The autoantibody profile for ER positive tumours 
was not statistically different from PgR positive tumors.
Conclusions
These data show that specific AABs measured in the serum reflected 
the biology of the breast cancers. Confirmation of this finding could, 
in the future, lead to using immuno-biomarkers such as these to guide 
early therapeutic intervention (e.g. prevention) in a targeted group 
of women.
P4-08-04
Preoperative Thrombin Pathway Activation Identifies Node 
Positive Patients in Early Breast Cancer.
Shaker H, Kirwan C, Landberg G, Bundred NJ. University Hospital 
of South Manchester, Manchester, United Kingdom; Paterson Institute 
for Cancer Research, Manchester, United Kingdom
Activation of the thrombin pathway (TP) is seen in 50% of cancers 
and plays a significant role in promoting metastasis. Cancer-induced 
TP activation is exacerbated by surgery, and this activation may be 
greater in the presence of metastases.
Our aim was to determine if pre-operative plasma d-dimer, a marker 
of TP activation, correlated with the presence of LN metastases in 
early breast cancer. We also examined whether surgery-induced TP 
activation is affected by tumour-associated factors.
Methods 
Plasma d-dimer was measured using automated ELISA pre-operatively 
and at days 1 and 42 following surgery in 103 prospectively recruited 
patients undergoing surgery for early breast cancer(87 invasive,13 
DCIS). D-dimer values were log-transformed and correlated with LN 
metastases, tumour size and grade and hormone receptor status using 
parametric statistical tests.
Results
Median age was 68 years (range 46-82). Mean tumour size was 
14.6 mm (range 7.5-40). Seventy invasive cancer patients had wide 
local excision(WLE) and sentinel node biopsy(SNB) and 17 had 
mastectomy(MX) +/- axillary clearance(ANC).
Twenty-two patients had positive lymph nodes at primary surgery 
(MX 8,WLE 14). Of these 3(14%) were ER-ve and 19(86%) were 
ER+ve.
Mean pre-operative d-dimer was higher (p<0.01) in LN positive 
(704ng/ml, 95% confidence interval, CI, 455-1088) versus LN node 
negative invasive cancers (443ng/ml, CI 304-627) or DCIS (366ng/ml, 
CI 284-471). D-dimer was also higher in patients with lymphovascular 
invasion (612ng/ml, CI 423-886) than in those without (454ng/ml, CI 
385-534) and this approached significance (p=0.084).
Post-operative d-dimer was higher (p<0.05) after MX compared to 
WLE at all timepoints. Following WLE + SNB for invasive cancer, 
post-operative d-dimer rose and was higher at day 1 and day 42 in 
LN positive vs LN negative and in ER negative versus ER positive 
cancers (see table). Repeated measures ANOVA analysis showed that 
the change in d-dimer over time was significantly different between 
subjects according to LN status (p=0.037) or ER status (p=0.015). 
Only one patient in the ER negative group had LN metastases.
There was no association between pre or postoperative d-dimer and 
tumour size, tumour grade or PR status.
Pre and post-operative d-dimer in patients who underwent WLE + SNB
 n
Tumour size  
(mm), mean 
(range)
Pre-op d-dimer (ng/
ml), mean (CI)
Post-op day 1 dimer 
(ng/ml), mean (CI)
Post-op day 42 
dimer (ng/ml), 
mean (CI)
      
LN negative 56 13.0 (2-40) 424 (361-469) 471 (391-568) 525 (424-651)
LN positive 14 15.3 (8-35) 645 (394-1056) 636 (335-1208) 852 (451-1612)
p  0.261**   0.037*
      
ER negative 8 13.9 (2-26) 419(330-534) 867 (146-5132) 632 (330-1211)
ER positive 62 13.4 (7-40) 469(393-561) 474 (405-555) 569 (453-715)
  0.864**   0.015*
* = Repeated measures ANOVA, **=student’s t-test
Conclusion
Pre-operative TP activation and the thrombotic response to surgery 
(as measured by d-dimer) is greater in the presence of LN metastases 
regardless of tumour size.
ER negative cancers (7/8 of which were LN negative) also resulted 
in a greater d-dimer rise, suggesting a difference in the thrombotic 
response to surgery between different cancer phenotypes.
Ongoing work will determine if peri-operative TP activation can act 
as an independent predictor of node status and cancer recurrence.
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P4-08-05
Diagnostic Significance of Exosomal miRNAs in the Plasma of 
Breast Cancer Patients.
Kwong A, Ng EKO, Leung CPH, Chan V, Li R, Wong CLP, Ma ESK. 
The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong 
Sanatorium & Hospital, Hong Kong
Background and Aims: Emerging evidence that microRNAs 
(miRNAs) play an important role in cancer development has 
opened up new opportunities for cancer diagnosis. Recent studies 
demonstrated that released exosomes which contain a subset of both 
cellular mRNA and miRNA could be a useful source of biomarkers 
for cancer detection. Here, we aim to develop a novel biomarker for 
breast cancer diagnosis using exosomal miRNAs in plasma.
Methods: We have developed a rapid and novel isolation protocol 
to enrich tumor-associated exosomes from plasma samples by 
capturing tumor specific surface markers containing exosomes. After 
enrichment, we performed miRNA profiling on four sample sets; (1) 
Ep-CAM marker enriched plasma exosomes of breast cancer patients; 
(2) breast tumors of the same patients; (3) adjacent non-cancerous 
tissues of the same patients; (4) Ep-CAM marker enriched plasma 
exosomes of normal control subjects. Profiling is performed using 
PCR-based array with human microRNA panels that contain more 
than 700 miRNAs.
Results: Our profiling data showed that 15 miRNAs are concordantly 
up-regulated and 13 miRNAs are concordantly down-regulated in 
both plasma exosomes and corresponding tumors. These account for 
~25% (up-regulation) and ~15% (down-regulation) of all miRNAs 
detectable in plasma exosomes. Our findings demonstrate that miRNA 
profile in EpCAM-enriched plasma exosomes from breast cancer 
patients exhibit certain similar pattern to that in the corresponding 
tumors. Based on our profiling results, plasma signatures that 
differentiated breast cancer from control are generated and some 
of the well-known breast cancer related miRNAs such as miR-10b, 
miR-21, miR-155 and miR-145 are included in our panel list. The 
putative miRNA biomarkers are validated on plasma samples from 
an independent cohort from more than 100 cancer patients. Further 
validation of the selected markers is likely to offer an accurate, 
noninvasive and specific diagnostic assay for breast cancer.
Conclusions: These results suggest that exosomal miRNAs in plasma 
may be a novel biomarker for breast cancer diagnosis.
P4-09-01
Identification of Poor Prognosis T1T2N0 Luminal ERBB2-ve 
Breast Carcinomas.
Vincent-Salomon A, Benhamo V, Gravier E, Rigaill G, Robin S, 
Savignoni A, Mariani O, Pierron G, Gentien D, Reyal F, Cottu P, 
Fourquet A, Sastre X, Asselain B, Delattre O. Institut Curie, Paris, 
France
Background: To identify ER+ve ERBB2-ve ductal T1T2N0 
carcinomas associated with a poor prognosis remains challenging. 
We have previously demonstrated that the number of chromosomal 
breakpoints assessed by CGH could be a marker of worse outcome for 
breast carcinomas. Our aim was to validate the CGH based signature 
in a series of luminal ductal and T1T2 N0 carcinoma patients with 
long-term clinical follow-up. Patients and methods : We analyzed 214 
patients treated for an invasive ductal ER+ve ERBB2-ve carcinomas, 
smaller than 30mm. The training set was composed of 109 patients 
(10.9 years of median follow-up; 30 cases associated with a metastatic 
event within less than 4 years/79 control cases with no metastastic 
event at 5 years) and the validation set of 105 patients (10.5 years 
of median follow-up; 30 relapses including contra-lateral breast 
carcinomas, loco-regional relapses and 8 metastatic events). None of 
the patient received adjuvant chemotherapy. 16 received an adjuvant 
hormonotherapy (10 in the training and 6 in the validation groups). 
We genotyped the sample set with the SNP6.0 affymetrix array. After 
RMA normalisation using Genotyping console, segmentation was 
performed according to the Zhang and Siegmund maximum method. 
In the training data set, the number of breakpoints was assessed, 
linked to outcome and the threshold optimising the sensitivity and 
specificity was determined (ROC curve). The threshold prognostic 
value was then tested on the validation series (Kaplan Meier analysis, 
log rank test, determination of relative risk and its confidence interval 
with a Cox model). Results: In the training set, median numbers of 
breakpoints were 7 in cases that experienced a metastatic event after 
more than 5 years and 40.5 in cases that experienced a metastatic 
event in less than 4 years. The threshold (Younden index ) was 34 
breakpoints with a sensitivity of 0.57 and a specificity of 0.94 (AUC: 
0.81[0.71;0.91]). In the validation set, the outcome of patients with 
more than 34 breakpoints was poorer than that of patients with less 
than 34 breakpoints (<34 breakpoints: 19 events in out of 83 patients; 
>34 breakpoints: 11 events out of 22 patients with a median time to 
progression of 108 months; p<0.001 (logrank test); RR: 3.7 [1.73; 
7.92]). In multivariate analysis, the number of breakpoints (>34 
versus <34) remained the only significant parameter for prediction of 
outcome (RR: 3.12, CI[1.33; 7.31], p= 0.009). Histopronostic grade, 
significant in univariate analysis, was not significant in multivariate 
analysis but was correlated with the number of breakpoints. The 
number of breakpoints was statistically significant for prediction 
of metastatic free interval (<34 breakpoints: 4 events in out of 83 
patients; >34 breakpoints: 4 events out of 22 patients with a median 
time to progression of 108 months; p=0.009 (logrank test); RR: 
5.29 [1.32; 21.26]). Conclusion: We demonstated that patients with 
T1T2 (<3cm) N0 ER+Ve ERBB2-ve invasive ductal carcinomas 
harboured a shorter disease free and metastatic free intervals based 
on genomic profiles assessed by SNP6.0 with a threshold of more 
than 34 breakpoints. This new approach to assess prognosis in luminal 
carcinomas is based on a single genomic platform, could allow 
identification of future therapeutic targets.
P4-09-02
G Protein-Coupled Estrogen Receptor 1 Positively Correlates 
with Estrogen Receptor a Expression and Increased Distant 
Disease-Free Survival of Breast Cancer Patients.
Leeb-Lundberg FLM, Sjöström M, Broselid S, Jirström K, Belting M, 
Olde B, Lövgren K, Malmström P, Bendahl P-O, Hartman L, Fernö 
M. Lund University, Lund, Sweden
Background: Endocrine therapy is an important therapeutic choice 
for patients with estrogen receptor (ER)a-positive breast carcinoma 
and functions by blocking proliferative estrogen signalling through 
the classical nuclear ERa. G protein-coupled estrogen receptor 1 
(GPER1) is a novel membrane estrogen receptor responsible for 
unique estrogen responses in vitro and in vivo and that is activated 
by tamoxifen. The aim of this study was to determine the correlation 
of GPER1 with clinicopathological variables and distant disease-free 
survival (DDFS) in breast cancer patients treated with and without 
adjuvant tamoxifen, and whether the prognostic impact is dependent 
on ERa-status.
Mater ia l  and  Methods :  GPER1 was  inves t iga ted  by 
immunohistochemistry in tissue microarrays of breast tumors from 
208 premenopausal node-negative patients (median age 47 years; 
range 30-57), mainly (87%) not subjected to any adjuvant systemic 
treatment, and from 273 stage II patients (median age 63 years; range 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011457s
December 6-10, 2011 Abstracts: Poster Session 4
26-81), all treated with adjuvant tamoxifen for 2 years. Because almost 
90% of the samples had a high percentage (>50%) GPER1-stained 
cells, we decided to evaluate only the staining intensity (negative, 
very weak, weak, moderate, and strong) for this variable. Pearson’s 
c2 test for trend was used for analyzing association between GPER1 
and categorical clinicopathological variables, a test for trend based 
on ranks for association with age and tumor size, and a log-rank test 
for trend for evaluating the impact of GPER1 on DDFS after 5 years 
of follow-up.
Results: GPER1 positively correlated with ERa (P=0.0005 and 
P=0.01, respectively) and progesterone receptor expression (P=0.004 
and P=0.01, respectively) in both the premenopausal and tamoxifen-
treated groups, but not with HER2 expression (P=0.45 and P=0.42, 
respectively). In the premenopausal group, GPER1 negatively 
correlated with tumor size (P=0.02) and positively with age (P=0.003), 
whereas in the tamoxifen group GPER1 did not correlate with either 
tumor size or age. During 5 years of follow up, 64 patients were 
diagnosed with distant recurrences in the tamoxifen group and 34 
patients in the premenopausal group. In univariate analysis, GPER1 
positively correlated with DDFS in the tamoxifen group (P=0.04), 
but non-significantly in the premenopausal group (P=0.08). When 
stratifying for ERa-status, GPER1 was a prognostic factor in the 
ERa-positive subgroup (P=0.02 in tamoxifen group and P=0.08 in 
premenopausal group), but not in the ERa-negative subgroup (P=0.57 
and P=0.95, respectively).
Conclusion: We propose that GPER1 is a prognostic marker for 
increased DDFS in ERa-positive breast cancer. While our results 
suggest that GPER1 is also a tamoxifen-predictive factor, this needs 
to be further studied, ideally in a randomized trial comparing clinical 
outcome for patients treated with and without adjuvant tamoxifen.
P4-09-03
Clinical Significance of HER2+ and Triple-Negative Status in 
Patients with Tumor Size ≤ 1 cm and Node Negative Breast 
Cancer.
Shao T, Boolbol SK, Boachie-Adjei K, Klein P. Beth Israel Medical 
Center, Continuum Cancer Centers of New York, New York, NY
Background: Data regarding the clinical significance of HER2 and 
triple negative status in patients with small node negative tumors is 
limited. Several small case series have suggested an increased risk of 
recurrence in patients with T1abN0M0 HER2+ or triple negative (TN) 
tumors. Conversely, a recent study reported that the recurrence risk 
for T1abN0M0 HER2+ tumors was too low to justify any adjuvant 
chemotherapy or trastuzumab. Therefore it remains unclear who 
among those with small lesions might possibly benefit from more 
aggressive adjuvant therapy.
Methods: We identified all node negative breast cancer patients 
with tumor size ≤ 1 cm diagnosed between 1/1/1995 and 12/21/2008 
through our institutional breast service database. Patients were 
classified according to their receptor status into three groups: 1) 
Hormone receptor (HR)+ (ER or PR positive, HER2 negative); 
2) HER2+ (IHC 3+ or FISH ≥2); and 3) TN (ER, PR, and HER2 
negative). Disease-free survival (DFS) was calculated using Kaplan-
Meier methods. Cox proportional hazards models were used to 
estimate the association between breast cancer subtypes with DFS 
adjusting for patient and disease characteristics.
Results: Among 658 patients with tumor ≤ 1 cm, 494 (75%) of the 
patients were HR+, 109 (17%) were HER2+, and 55 (8%) were TN. 
Two hundred thirty-two tumors were classified as T1a, and 426 were 
classified as T1b. Median age was 58 years (27-92). Median follow-up 
was 3.5 years. The 5-year DFS rates were 97.9%, 95.6%, 93.5% in 
patients with HR+, HER2+, and TN tumors, respectively (p=0.026). 
In multivariate analysis, TN status was associated with worse DFS 
(HR 3.13, 95% CI 1.26-7.73), while HER2+ was not (HR 1.64, 95% 
CI 0.73-3.69). In the HER2+ group, 5-year DFS was also not different 
between patients who received chemotherapy +/- trastuzumab (32%) 
and those who did not (p=0.588). We also analyzed T1aN0 and T1bN0 
patients separately in order to differentiate the sub-populations of 
patients more likely to benefit from systemic adjuvant chemotherapy. 
TN status remains an independent risk factor for worse DFS in T1bN0 
(HR 3.68, 95% CI 1.17-11.6), but not in T1aN0 patients.
Conclusion: TN, but not HER2+ status was associated with worse 
DFS in patients with T1abN0M0 tumors, and adjuvant chemotherapy 
should be considered in TN breast cancer patients who have T1bN0 
tumors.
P4-09-04
Do Decreased CEP17 Signals Indicate the Presence of 
“Monosomy” in Breast Cancer? A Study of HER2 Gene Status 
and HER2 Immunohistochemistry.
Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Duesterhoeft SM, 
Kussick SL, Gown AM. PhenoPath Laboratories, Seattle, WA
Background:
Detection of HER2 gene amplification by fluorescence in-situ 
hybridization (FISH) is one of the key tests predicting clinical 
response of breast cancer to trastuzumab. According to the recent 
ASCO/CAP guidelines for HER2 testing, the tumor is considered 
positive for HER2 gene amplification when the HER2/CEP17 ratio 
is greater than 2.2, negative if less than 1.8, and equivocal if the 
ratio is between 1.8 and 2.2. The need to use CEP17 as reference 
for HER2 assumes that the copy number of CEP17 is equivalent to 
the copy number of chromosome 17. Recent studies, however, have 
shown that this may not be true in cases of increased CEP17 signals 
interpreted as “polysomy”. This study aims to examine the effect 
of decreased CEP17 signals interpreted as “monosomy” on HER2 
protein expression and gene amplification, and to test the hypothesis 
that a subset of these cases may be inappropriately classified as 
amplified or equivocal.
Material and Methods:
59 cases tested in parallel by IHC and FISH were selected based 
on HER2 signals > 2 and CEP17 signals < 1.5. To further examine 
chromosome 17 copy number, FISH mapping studies were performed 
on 5 cases, using probes for SMS, RARA, and TP53 loci which 
are telomeric to the CEP17 and HER2 loci. Chromosome 17 status 
was determined by correlating the mean copy numbers of HER2, 
CEP17, SMS, RARA, and TP53. A gene locus with signal number/
cell between 1.4 and 2.4 was considered consistent with eusomy.
Results:
The 59 cases were divided into three groups based on HER2 signals/
cell. Group 1, comprising 11 cases, had HER2 signals > 4; all were 
amplified with HER2/CEP17 ratios between 3 and 5; 10 of these 11 
cases showed equivocal IHC (2+). Group 2, comprising 17 cases, 
had HER2 signals > 3 and < 4; all were HER2 amplified with HER2/
CEP17 ratios between 2.3 and 3.6, and 15 showed equivocal IHC (2+). 
Group 3, comprising 32 cases, had HER2 signals > 2 and < 3; 19 of 
these showed HER2/CEP17 ratios in the equivocal range (1.8-2.2) 
and 13 were amplified with ratios between 2.3 and 2.8; 25 showed 
equivocal IHC (2+), and 7 were negative by IHC (0,1+). Five cases 
were further tested using FISH probes to alternative chromosome 17 
genes (SMS, RARA, and TP53). The number of CEP17 signals/cell 
of these 5 cases ranged from 1.01 to 1.15 and the HER2 signals/cell 
ranged from 2.05 to 2.84. In these cases when additional probes to 
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chromosome 17 were used as reference genes, 4/5 cases remained 
amplified or equivocal. One case with HER2 signals of 2.05 changed 
from equivocal to negative. 4/5 of these cases showed equivocal 
IHC (2+).
Discussion:
Application of strict ASCO-CAP guidelines on 59 “monosomy” 
cases showed that all were either amplified or equivocal by FISH, 
with the vast majority showing equivocal (2+) IHC. In cases with 
decreased CEP17 signals, most cases remained as “monosomy” using 
the alternative chromosome 17 reference genes. This may be due to 
deletion of the short arm of chromosome 17 or true monosomy of 
chromosome 17. Further studies are warranted on the cases with 2-4 
HER2 signals per cell and “monosomy” in order to permit accurate 
determination of HER2 gene status and appropriate treatment with 
anti-HER2 therapy.
P4-09-05
CA15-3 Adds Prognostic Information in “Luminal” Type Breast 
Cancer – A Single Center Experience Evaluating 700 Patients 
with a Median Follow-Up of 5 Years.
Kantelhardt EJ, Vetter M, Steer S, Ruider T, Holzhausen H-J, Strauß 
H-G, Große R, Thomssen C. GYN/OB, Halle (Saale), Germany; Inst. 
of Pathology, Halle (Saale), Germany
Background: Prognostic markers are essential for the decision about 
individual therapy for patients with newly diagnosed breast cancer. 
Biological meaningful cancer types are revealed by gene expression 
analysis. Steroid hormone receptor (HR) and HER2 status of the 
tumor by immunohistochemistry (IHC) are more easily available and 
predominantly resemble these cancer types. The “luminal” type as HR 
pos. and HER2 neg., the “luminalHER2” type as HR pos. and HER2 
pos., the “HER2” type as HR neg. and HER2 pos. and the “triple neg.” 
type as HER neg. and HER2 neg.. We evaluated preoperative serum 
CA 15-3 and CEA within IHC-cancer types and outcome using our 
own cohort from 1999-2010.
Material and Methods: Since 1999 all patients with breast cancer 
were entered in our tumor registry. Patients were treated by surgery 
and adjuvant therapy according to national guidelines (www.ago-
online.de). Data was entered into SPSS by a specially trained study 
nurse. Follow-up was obtained yearly using our own out-patient 
clinic, information from general practitioners and the general cancer 
registry. Informed consent was taken from the patients at time of 
diagnosis. CA 15-3 and CEA were defined elevated if above 25 U/
ml or 4,6 µg/l respectively.
Results: Preoperative serum CA15-3 available for 1149 patients. 
Patients with elevated results showed a reduced 5year disease-free 
survival (DFS) of 74.4% as compared to 84.7% (p<0.001). CA15-3 
remained an independent prognostic factor in multivariate analysis 
(nodal status, grading, HR). Within HR positive disease, normal 
CA15-3 values predict a significantly better 5years DFS of 89.9% 
compared to 79.7% (p<0.001). No significant difference was seen in 
HR negative patients (5year DFS 57.5% vs 68.4%; p=n.s.). Patients 
with HER2 status available (n=700) were classified into biological 
tumor types by IHC. Significant differences in DFS were seen 
for “luminal” (n=435) tumors only (5year DFS 81.0% vs 91.8% 
(p<0.001). Only trends of differences in DFS were seen in the other 
less frequent tumor types “luminalHER2” (n=90) or “triple neg.” 
(n=112) types. Within the “HER2” (n=63) group no discrimination 
by serum levels of CA15-3 was seen. CEA did not add information 
on prognosis.
Discussion: Decision on adjuvant therapy is increasingly based on 
tumor biology. Particularly, in “luminal” tumors additional prognostic 
information is needed to decide on adjuvant chemotherapy. CA15-3 
may be an easily available, independent marker to identify patients 
with a higher risk of recurrence within this group. Prospective 
validation and comparison to molecular typing is needed.
P4-09-06
The Prognostic Value of Tumour-Stroma Ratio in Triple Negative 
Breast Cancer.
Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven 
EA. Hospital Group Twente, Almelo, Netherlands; Pathology 
Laboratory East Netherlands, Enschede, Netherlands; Medical 
Spectrum Twente, Enschede, Netherlands; Hospital Group Twente, 
Hengelo, Netherlands
Background: Triple-negative cancer constitutes one of the most 
challenging groups of breast cancer given its aggressive clinical 
behaviour, poor outcome and lack of targeted therapy. Until now, 
profiling techniques have not been able to distinguish between patients 
with good and poor outcome. Recent studies suggested an important 
role for stroma in tumour growth and progression. In colorectal-, 
oesophageal- and breast cancer, the tumour-stroma ratio was found 
to be of prognostic value.
Objective: to evaluate the prognostic value of the tumour-stroma ratio 
in triple-negative breast cancer.
Methods: During the period January 2004-2008, 124 consecutive 
triple negative breast cancer patients treated in our hospital were 
retrospective evaluated. Routine Haematoxylin-Eosin (H&E) stained 
histological sections were evaluated by two investigators (kappa 
0.735) for stroma percentage, growth pattern (pushing margin), 
necrosis and amount of lymphocytic infiltrate. Patients with less than 
50% stroma were classified as stroma-low and patients with ≥ 50% 
stroma were classified as stroma-high.
Results: of 124 triple-negative breast cancer patients, 50 (40%) had a 
stroma-high and 74 (60%) had a stroma-low tumour. Survival analysis 
revealed a 5 years relapse free period (RFP) of 85% in the stroma-low 
and 45% in the stroma-high group. Overall survival (OS) was 89% for 
stroma-low and 65% in the patients with a stroma-high tumour. Both 
RFP and OS were significantly worse in patients with stroma-high 
tumours compared to stroma-low. In a multivariate cox-regression 
analysis, tumour stroma remained an independent prognostic variable 
for RFP (HR 2.39; 95% CI 1.07-5.29; p=0.033) and OS (HR 3.00; 95% 
CI 1.08-8.32; 0.034) when corrected for other clinical-pathological 
variables. In addition, tumour-stroma proved to be a strong prognostic 
variable when compared to nodal status, tumour grade and tumour 
size, with respectively a HR of 2.39 (95% CI 1.37-6.26) versus HR 
2.18 (95% CI 1.06-4.48), HR 2.10 (95% CI 0.89-4.91) and HR 0.53 
(95% CI 0.70-3.91) for RFP with comparable numbers for OS.
Conclusion: Tumour-stroma ratio is a strong independent prognostic 
variable in triple-negative breast cancer. It is easy to determine, 
reproducible (kappa 0.735) and can be easily incorporated into routine 
histological examination. This parameter optimizes risk stratification 
and could be target for future therapies.
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P4-09-07
Breast Cancer Outcome by Combined Immunohistochemical ER/
PR/HER2 Receptor Phenotype.
Brouckaert O, Laenen A, Reynders A, Vanderhaegen J, Amant 
F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Weltens 
C, Moerman P, Paridaens R, Wildiers H, Vergote I, Christiaens 
M-R, Neven P. Uz Leuven, Leuven, Vlaams Brabant, Belgium; 
Interuniversity Centre for Biostatistics and Statistical Bioinformatics, 
Hasselt, Limburg, Belgium
Introduction: We previously reported that molecular prognostic 
subgroup classification of operable breast cancers resembles the 
classification based on combined immunohistochemical expression of 
ER, PR and HER-2 receptors. This update represents a larger cohort 
with more detailed follow-up (median 5.5y). Patients and methods: 
A prospective cohort of 4334 breast-cancer patients primary operated 
at our institution between 2000 and 2009. Steroid receptors were 
considered positive for any nuclear staining, HER-2 for strong (3+) 
membrane staining or positive fluorescence in situ hybridization. 
Survival curves were calculated for six predefined breast cancer 
subgroups: ER + PR + HER-2 - (PPN), ER + PR - HER-2 - (PNN), 
ER + PR + HER-2 + (PPP), ER - PR - HER-2 - (NNN), ER - PR - 
HER-2 + (NNP), and ER + PR - HER-2 + (PNP) (figures not allowed 
in abstract). Disease free interval (DFI), distant metastatis free interval 
(DMFI), overall survival (OS) and breast cancer specific survival 
(BCSS) were calculated. A long-rank test was used for testing the null 
hypothesis of no difference between the groups. Results:
Descriptive statistics for subgroups
n,% PPN PNN PNP PPP NNP NNN P-value
All 2926 (69,4) 392 (9,3) 97 (2,3) 201 (4,7) 179 (4,3) 419 (9,9) /
Age at diagnosis 58,2 61,6 56,9 53,4 57,3 56,3 <0,001
Mean NPI 4,2 4,3 4,7 4,9 5,1 4,9 <0,001
NPI low risk 960 (32,8) 104 (26,5) 11 (11,3) 27 (13,4) 10 (5,6) 13 (3,1) <0,0001
NPI 
intermediate 
risk
1283 (43,9) 187 (47,7) 57 (58,8) 99 (49,3) 100 (55,9) 234 (55,9) <0,0001
NPI high risk 477 (16,3) 71 (18,1) 22 (22,7) 69 (34,3) 60 (33,5) 86 (20,5) <0,0001
Grade 1 463 (15,8) 40 (10,2) 0 (0,0) 5 (2,5) 1 (0,56) 0 (0,0) <0,0001
Grade 2 1514 (51,7) 186 (47,5) 26 (26,8) 46 (22,9) 22 (12,3) 25 (6,0) <0,0001
Grade 3 777 (26,6) 137 (35,0) 66 (68,0) 145 (72,1) 150 (83,8) 311 (74,2) <0,0001
Node positive 1128 (38,6) 149 (38,0) 35 (36,1) 97 (48,3) 86 (48,0) 33,9) 0,0022
pT1 1475 (50,4) 182 (46,4) 43 (44,3) 87 (43,3) 77 (43,0) 183 (43,7) 0,0264
pT2 1164 (39,8) 171 (43,6) 48 (49,5) 99 (49,3) 80 (44,7) 204 (48,7) 0,0264
pT3 261 (8,9) 37 (9,4) 4 (4,1) 15 (7,5) 19 (10,6) 29 (6,9) 0,0264
pT4 19 (0,65) 2 (0,5) 1 (1,0) 0 (0,0) 2 (1,1) 2 (0,5) 0,0264
Mastectomy 1171 (40,0) 163 (41,6) 49 (50,5) 95 (47,3) 121 (67,6) 181 (43,2) <0,0001
Axillary lymph 
node dissection 2077 (71,0) 303 (77,3) 74 (76,3) 156 (77,6) 153 (85,5) 325 (77,6) <0,0001
Adjuvant 
endocrine 
therapy
2709 (92,6) 346 (88,3) 79 (81,4) 191 (95,0) 11 (6,15) 19 (4,5) <0,0001
Adjuvant 
radiotherapy 2438 (83,3) 322 (82,14) 86 (88,7) 172 (85,6) 139 (77,7) 86 (88,7) 0,0366
Adjuvant 
chemotherapy 844 (28,9) 134 (34,2) 66 (68) 141 (70,2) 136 (76,0) 302 (72,1) <0,0001
Adjuvant 
endocrine + 
chemotherapy
808 (27,6) 113 (28,9) 51 (52,6) 136 (67,7) 8 (4,5) 8 (1,9) <0,0001
Adjuvant 
trastuzumab - - 51 (52,6) 96 (47,8) 91 (50,8) - 0.7
Breast cancer outcome by receptor phenotype
%, at 5y DFI DMFI BCSS OS
PPN (n=2926) 92,6 94,2 97,5 92,8
PNN (n=392) 88,7 90,6 95,8 91,7
PNP (n=97) 83,2 83,2 90,8 87,7
PPP (n=201) 87,9 92,3 93,9 92,3
NNP (n=179) 78,3 83,5 91,1 88,2
NNN (n=419) 80,7 83,5 87,2 81,9
All (n=4214) 90,0 92,1 95,7 91,3
Log-Rank 
(p-value) <0,0001 <0,0001 <0,0001 <0,0001
Conclusion: Combined receptor expression for ER/PR/HER2 
determines specific breast cancer subtypes with significant different 
clinical behavior. Both predictive and prognostic factors need to be 
considered when interpreting these results.
P4-09-08
Secretory Leukocyte Protease Inhibitor as a Differential 
Diagnostic Biomarker of Tumor Emboli in Inflammatory Breast 
Cancer.
Robertson FM, Ye Z, Chu K, Luo AZ, Wright MC, Jin J, Barsky 
SH, Cristofanilli M, Krishnamurthy S. The University of Texas MD 
Anderson Cancer Center, Houston, TX; University of Nevada School 
of Medicine, Reno, NV; Nevada Cancer Institute, Las Vegas, NV; Fox 
Chase Cancer Center, Philadelphia, PA
Background: Inflammatory breast cancer (IBC) is the most aggressive 
and lethal variant of locally advanced breast cancer. Pathologically, 
IBC is characterized by the presence of nests of cells, defined as 
tumor emboli, that undergo lymphovascular invasion into the skin 
and chest wall and represent the metastatic lesion of IBC. Due to the 
distinct presentation of IBC, it is often misdiagnosed due to a lack 
of defined biomarkers that are specific for tumor emboli in biopsy 
samples of IBC patients. To date, the only validated marker that 
has shown to consistently identify IBC tumor emboli is the surface 
glycoprotein E-cadherin.
Materials and Methods: With the goal of identifying genes specifically 
expressed by IBC tumor emboli, the present studies performed whole 
transcriptome analysis of tumor emboli from skin punch biopsy 
samples from IBC patients and tumor emboli from the Mary-X 
pre-clinical model of IBC which were isolated using laser capture 
microdissection.
Results: Secretory leukocyte peptidase inhibitor (SLPI) was a gene 
identified as being highly expressed by tumor emboli. This gene was 
previously identified as a metastasis related gene, has been reported to 
be associated with poor prognosis in serous ovarian carcinoma and is 
implicated in mediating resistance to paclitaxel. Immunofluorescence 
staining and confocal microscopy revealed that SLPI is a robust 
marker of tumor emboli in skin punch biopsies from IBC patient 
and in Mary-X tumor emboli. SLPI differentially delineates between 
IBC tumor emboli and hair follicles present in the skin, which also 
stain with E-cadherin. An additional marker, Cytokeratin 15 (CK15), 
can be used in combination with SLPI to differentially identify the 
components of the skin that are CK15 positive, and IBC tumor 
emboli that reside within the skin, which are CK15 negative. Use 
of podoplanin antibodies, which stain lymphovascular endothelium, 
demonstrate that IBC tumor emboli that express SLPI protein, are 
completely encircled within the dermal lymphovasculature.
Conclusions: These studies are among the first to identify SLPI 
as a potential biomarker of tumor emboli in skin punch biopsy 
samples from IBC patients and in pre-clinical models of IBC. 
Studies are ongoing to establish the molecular function and role of 
SLPI in mediating the survival and invasion of IBC tumor emboli. 
Collectively, these studies are the first to identify SLPI as a potential 
biomarker of IBC tumor emboli in skin punch biopsy samples. In 
addition to serving as a potential biomarker of tumor emboli, SLPI 
may also serve as a therapeutic target for development of approaches 
to eradicate IBC tumor emboli.
P4-09-09
Expression of c-MET and Phospho c-MET in Breast Cancers by 
Subtype and Its Impact on Survival Outcomes.
Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, 
Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, 
Gonzalez-Angulo AM. MD Anderson Cancer Center, Houston, TX
Background: cMET is a tyrosine-kinase membrane receptor 
and its dysregulation is involved in tumor proliferation, survival, 
angiogenesis, and migration. High levels of cMET have been 
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observed in various tumor types and correlate with adverse outcome. 
The purpose of this study was to evaluate levels of total cMET and 
phospho-cMET (p-cMET) in breast cancer and their impact on 
survival outcomes.
Materials and Methods: We measured quantitative expression of 
cMET and p-cMET in a cohort of 257 breast cancer primary tumor 
samples using reverse phase protein array. The level of cMET/p-cMET 
in each sample was expressed as a log-mean centered value after 
correction for protein loading with the use of the average expression 
levels of > 50 proteins. The regression tree method and Martingale 
residual plots were applied to find the best cutoff point for high and 
low levels of each protein. Linear regression models were used to 
determine if mean expression was different among breast cancer 
subtypes. The Kaplan-Meier method was used to estimate relapse-
free survival (RFS) and overall survival (OS) by cMET and p-cMET 
levels. Cox proportional hazards models were fit to determine the 
association of cMET and p-cMET levels with the risk of recurrence 
and death after adjustment for other patient and disease characteristics.
Results: Median age was 51, (range 23-85) years. There were 140 
(54.5%) hormone receptor (ER/PR)-positive, 53 (20.6%) HER2-
positive, and 64 (24.9%) triple-negative tumors. Using the selected 
cutoffs, a total of 181 (70.4%) and 123 (47.9%) patients had high 
expression of cMET and p-cMET, respectively.
There were no significant differences in the mean expression of 
cMET (P<0.128) and p-cMET (P<0.088) by breast cancer subtype. 
Dichotomized cMET and p-cMET expression was a significant 
prognostic factor of RFS (HR: 0.41, 95% CI: 0.23-0.75, P=0.004, 
and HR: 0.61, 95% CI:0.38-0.96, P=0.033, respectively) and OS 
(HR: 0.31, 95% CI:0.14-0.70, P=0.005, and HR: 0.52, 95% CI:0.29-
0.93, P=0.025, respectively). Within breast cancer subtypes, high 
cMET expression was associated with worse RFS (P=0.02) and OS 
(P=0.01) in ER/PR-positive tumors, and high p-cMET expression was 
associated with worse RFS (P=0.03) and OS (P=0.03) for patients with 
HER2-positive breast cancer. Multivariable model after adjustment 
for patient and tumor characteristics showed that patients with tumors 
with high cMET levels had a significant higher risk of recurrence 
(HR 0.28; 95% CI, 0.36-0.80) and death (HR 0.24; 95% CI, 0.09-
0.65). Similarly, patients with tumors with high p-cMET levels had 
a significant higher risk of recurrence (HR 0.53; 95% CI, 0.29-0.97).
Conclusion: In this cohort of patients, high expression of cMET 
and p-cMET was seen in all subtypes of breast cancer. High levels 
of cMET and p-cMET had a significant impact on breast cancers 
survival outcomes. cMET inhibition may a be promising novel target 
for therapy in breast cancer and deserves investigation.
P4-09-10
Assessment of Circulating Immune Parameters in Patients with 
Metastatic Breast Cancer Improves Survival Prediction.
Tredan O, Manuel M, Chabaud S, Biota C, Bachelot T, Clapisson G, 
Bajard A, Blay J-Y, Caux C, Menetrier-Caux C. Centre Leon Berard, 
Lyon, France
Background: Prediction of survival for metastatic breast cancer 
(MBC) patients (pts) remains a major clinical challenge. Most studies 
proposed prognostic scores based on clinical criteria that are often 
subjective. We already demonstrated that low lymphocyte count is a 
prognostic factor in various pts populations, and we recently showed 
that low CD4 lymphocyte count is a prognostic factor for overall 
survival (OS) in MBC pts. In this study, we evaluate the plasma levels 
of various cytokines and chemokines to improve our immune-based 
prognostic model.
Methods: The first cohort (A) consisted of 39 pts with MBC treated 
with first line chemotherapy between Sep. 04 and Oct. 07. The second 
cohort (B) consisted of 114 pts with MBC who relapsed after at least 
one line of chemotherapy between Dec. 2000 and Nov. 05 and who 
received further chemotherapy. In the cohort A the blood samples were 
drawn before administration of any chemotherapy. In the cohort B 
the samples were drawn after white blood cell recovery. Fresh cells 
have been used for extensive phenotypic analyses. Plasma cytokines 
levels have been measured using commercially available Luminex-
based multiplex kits. Cytokines were clustered into 3 groups based on 
biological pathways, group 1: Th1 response and T-cell proliferation 
(IL-2, IL-7, IL-15, IFNg, IL-12p40, IFNa2, GM-CSF); group 2: Th2 
response (IL-10, IL-13, CCL22), and group 3: inflammatory response 
(IL-1b, IL6, IL-17, TNFa).
Results: In the cohort A: CD4+ T cell levels <450/µL were associated 
with worse OS (HR=2.46 [CI95%=1.21-5.01), p=0.013). In the cohort 
B, 48% of pts had received one previous line of chemotherapy; 
52% had received more than one. CD4+ T cell levels <450/µL were 
also associated with worse OS (HR=1.70 [CI95%=1.04-2.78], 
p=0.036). Analyzing cytokines by clusters, elevation in group 1 (Th1 
response) was associated with poor OS for both cohorts A (HR=1.055 
[CI95%=1.002-1.111), p=0.041) and B (HR=1.12 [CI95%=1.01-
1.24), p=0.032). Conversely, the group 2 (Th2 response) was not 
associated with OS for both cohorts. For the group 3 (inflammatory 
response), the increase of these cytokines values was a prognostic 
factor of OS only for the cohort B (HR=1.10 [CI95%=1.02-1.18), 
p=0.009). In multivariate analysis: in the cohort A, CD4+ T cell 
levels <450/µL (HR=2.45 [CI95%=1.20-5.03), p=0.014) and group 
1 of cytokines (HR=1.055 [CI95%=1.004-1.109), p=0.034) remains 
independent prognostic factors; in the cohort B, poor Performance 
Status (HR=3.10 [CI95%=1.99-4.86), p<0.0001) and group 3 of 
cytokines (HR=1.09 [CI95%=1.01-1.17), p=0.020) were shown to 
be independent prognostic factors.
Conclusions: Combination of PS and biological covariates such as 
lymphocyte CD4+ count or cluster of cytokines is an effective strategy 
to predict survival of pts with MBC receiving first-line chemotherapy 
or subsequent lines. The validation of our immune-based prognostic 
score (combining cytokine levels and immune cell phenotypes) will 
be initiated in a prospective study.
P4-09-11
Kinesin Family Member 2C (KIF2C) Is a New Surrogate 
Prognostic Marker in Breast Cancer (BC).
Abdel-Fatah TMA, Green AR, Lemetre C, Moseley P, Chan S, Ellis IO, 
Balls G. Nottingham University City Hospital NHS Trust, Nottingham, 
United Kingdom; Nottingham University, Nottingham, United 
Kingdom; Nottingham Trent University, Nottingham, United Kingdom
Introduction
Gene expression microarrays, artificial neural network (ANN), tissue 
microarray and immunohistochemistry (IHC) techniques allow for the 
analysis of huge numbers of gene transcripts and their corresponding 
proteins and have been widely applied in predicting clinical outcome.
Methods
1- In this study, we analysed 48,000 gene transcripts of 171 unselected 
series of BC using ANN and pathways analysis to identify genes that 
can be used to predict clinical outcome of BC.
2- The clinic-pathological outcome of candidate genes were validated 
by using IHC in 4 independent primary BC data sets: a) a series of 
379 consecutive high risk BC (NPI>3.4) who treated with surgery 
(S)+ radiotherapy (RT) and did not received neither endocrine (ET) 
nor chemo-therapies (CT), b) A series of 1650 consecutive cases of 
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BC who treated with S + RT and received adjuvant CMF and/or ET 
according to Nottingham prognostic index (NPI), menopausal and 
ER status, c) 250 locally advanced BC treated with anthracycline-
based combination with or without Taxane followed by S + RT and 
d) 145 BC overexpressing HER-2 treated with S + RT followed by 
sequential adjuvant anthracycline combination CT + trastuzumab.
Results
Gene expression analysis
ANN analysis revealed that KIF2C gene was the highest ranked 
gene that predicted clinical outcome and accurately differentiated 
between low and high grade BC based on a 10-fold external cross-
validation analysis with an average classification accuracy of >98%. 
High KIF2C gene expression level was associated with shortest BC 
specific survival (BCSS), disease free (DFS) and distal metastasis 
free survivals (DM-FS); p<0.0001. In univariate analysis, high level 
of KIF2C gene expression was associated with large tumour size, 
higher lymph node stage, negative ER, positive p53 expression and 
HER2 overexpression. However in multivariate analysis, KIF2C gene 
expression level was only statistically associated with histological 
grade (p<00001) and mitosis (p<0.0001). Pathways analysis revealed 
that KIF2C is likely to play a significant role in cytokinesis, cell 
division and cell cycle regulations.
Immunohistochemistry
75% of BC showed overexpression of KIF2C protein. KIF2C 
protein overexpression was associated with unfavourable clinic-
pathological features including high grade, high mitotic index, basal 
like phenotype, triple negative phenotype, HER2 overexpression, 
TOP2A overexpression, p53 mutation, and loss of BRCA1 (adjusted 
p<0.0001).
In univariate analysis, KIF2C protein overexpression was associated 
with patient’s BCSS in both ER+/high risk patients (NPI > 3.4) who 
did not received ET (HR: 3.3, 95% CI: 1.2-9.3, p=0.02) and ER-/
high risk patients who did not received CT (HR: 3.2, 95% CI: 1.1-
8.8, p=0.025).
In 1650 BC series, multivariate Cox regression model including 
validated prognostic factors, confirmed that KIF2C overexpression 
is an independent prognostic factor. KIF2C overexpression showed 
increase in the risk of death (HR: 1.5, 95% CI: 1.1-2.0, p=0.009), 
recurrence (HR: 1.4, 95% CI: 1.1-1.8, p=0.017) and DM (HR: 1.6, 
95% CI: 1.2-2.3, p=0.005).
In conclusion, our findings provide a new insight to a better 
understanding of mammary carcinogenesis and that KIF2C is a 
promising molecular prognostic factor and a potential therapeutic 
target.
P4-09-12
Clinical Validation of Immunohistochemical Signature Predictive 
of Patients’ 8 Year Outcome in Node Negative Breast Carcinomas.
Charpin C, Tavassoli F, Giusiano S, Secq V, Villeret J, Garcia S, 
Lavaut M-N, Bonnier P, Birnbaum D, Iovanna J. INSERM U624 - 
Hopital Nord, Marseille, France; Yale University School of Medicine, 
New Haven; INSERM UMR 891, Marseille, France
Background: Immunohistochemical (IHC) signatures predictive of 
prognosis can be a cost effective alternative to genomic signature 
suitable in clinical practice for patients’ management in early stages 
of breast carcinoma (BrCa) in clinical. IHC procedures are very easy 
to handle in pathology laboratories, since require very few amount 
of formalin fixed tissue samples since assessed on consecutive 4 µm 
thick sections of paraffin embedded tumors fragments validated by 
pathologists’ expertise. We recently reported (C Charpin et al Int J 
Cancer 2009) that standardized IHC assays using high throughput 
densitometry on digitized microscopic images allow to predict an 
adverse outcome of patients with BrCa, provided that identified 
the IHC predictive signatures can be validated in other patients’ 
cohorts. In this regard we have repeated our previously reported IHC 
procedures on 418 series of BrCa (Marseille University) on a second 
series including 303 BrCa diagnosed at Yale University.
Material and Methods: TMA(s) of two cohorts of patients with 
BrCa (418/Marseille University and 303 Yale University) were 
respectively investigated for immunohistochemical expression of 15 
markers, including (i) those of the best signature predictive of patients 
outcome in N- patients in our previous studies and (ii) new markers 
reported in the literature as EMT cells and Stem cells. Monoclonal 
antibodies against HIFa, PI3, pAKT, pmTOR, moesin, P21, 4EBP-
1, P27, Ker 5.6, pMAPKAPK-2, SHARP2, Claudin, ALDH, AF6, 
CD24, IHC was screened using standardized (Ventana Benchmark 
XT) on consecutive 4 µm thick sections of TMAs from both series, 
Quantitative measurements of immunoprecipitates were automatically 
assessed with TRIBVN device, and correlated to 8 year patients’ 
outcome. Logistic regression determined the best combination of 
markers to predict patients’ prognosis and results of the two cohorts 
were compared.
Results: In node negative BrCa the best predictive combination 
of markers signature was HIF-1a, PI3K, Claudin, AF6, pAKT 
independently of ER PR and HER-2 status. When results of logistic 
regression with these markers was compared very similar results 
were obtained with 92.34 % (333/418) of well classified patients in 
the first set (Marseille University series) and 89.8 % (158/176) in the 
second set from Yale University.
Discussion: The results suggest that the new optimal IHC signature 
predictive of prognosis identified in BrCa including HIF-1a, PI3K, 
Claudin, AF6 and pAKT is validated by this study with very similar 
results in two different cohorts of patients.
This validation also suggests (1) that IHC signatures investigated in 
individual patients can be considered as suitable in clinical practice 
offering a cost effective convenient mean to predict patients’ outcome 
at diagnostic time (2) and to select those patients with poor prognosis, 
particularly in N- BrCa subset, requiring more aggressive adjuvant 
therapies, and to avoid useless expensive therapies and their side 
effects in N- patients with favourable prognosis.
P4-09-13
External Validation of Adjuvant! Online Breast Cancer Prognosis 
Tool. Improvement Is Still Needed.
Hajage D, De Rycke Y, Bollet M, Savignoni A, Caly M, Pierga J-Y, 
Horlings HM, Van de Vijver MJ, Vincent-Salomon A, Sigal B, Senechal 
C, Asselain B, Sastre X, Reyal F. Institut Curie, Paris, France; 
Academic Medical Center, Amsterdam, Netherlands
Introduction: AdjuvantOnline is a web-based application designed to 
provide 10 years survival probability patients with breast cancer. Few 
validation studies have underlined some limitations, particularly an 
overestimation of the prognosis among certain subgroups of patients. 
Moreover, several predictors such as HER2 over expression status and 
proliferation markers have not been assessed in Adjuvant! original 
study. We provide the validation of AdjuvantOnline algorithm on 
two breast cancer datasets collected from two large European cancer 
centres, and we determined whether the accuracy of AdjuvantOnline 
is improved by others well known prognostic factors.
Material and Methods: The French data set is composed of 456 
women with early breast cancer, treated at the Institut Curie between 
1995 and 1996. The dutch data set is composed of 295 women less 
that 52 years treated at the Netherlands Cancer Institute between 1984 
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and 1995. Agreement between observation and Adjuvant! prediction 
was checked by testing that the calibration slope was equal to 1. 
Logistic models were performed to evaluate whether risk factors 
adds significant prognostic information, including AdjuvantOnline 
a priori information as an offset.
Results: Ten years survival status was known for 383 patients in 
the French data set and 247 patients in the Dutch data set. Adjuvant! 
prediction was globally well calibrated in the French data set (observed 
survival 86%, predicted survival 85%), but was overestimated in high 
grade, HER2 positive and Ki67 > 20% subgroups. HER2 status, 
Mitotic Index, Ki67 and treatment type were strongly associated 
with 10-year survival, even considering AdjuvantOnline a priori 
information. In the Dutch data set, the overall 10-year survival was 
overestimated by AdjuvantOnline (observed 66%, predicted 79%), 
particularly in patients less than 40 years old.
Conclusion: AdjuvantOnline needs to be updated to adjust 
overoptimistic results in young and high grade patients, and should 
consider candidates, such as Ki67, HER2 and Mitotic Index.
P4-09-14
Differential Expression of the Akt1 Isoform in Mammary Ductal 
Carcinoma.
Sanders AJ, Mansel RE, Jiang WG. Cardiff University School of 
Medicine, Cardiff, United Kingdom
Introduction:
AKT1 is an oncogenic protein and controls numerous cellular 
processes in both normal and cancerous cells. There are three 
isoforms, Akt1 (PKBa), Akt2 (PKBb) and Akt3 (PKBg). Frequently, 
regulation of the Akt pathway is disrupted in cancerous cells and 
interest within the scientific community has focused on the use of 
this pathway in treating cancer. However, recent studies have also 
implicated that Akt1 may act to limit invasive migration of breast 
cancer cells suggesting the potential of this isoform to have both 
pro- and anti- tumorigenic roles. In the current study we examined the 
expression profile of Akt1 in a cohort of ducal carcinoma of the breast.
Methods:
Quantitative transcript analysis was used to assess the expression 
levels of Akt1 in a range of ductal carcinoma of the breast (n=85) 
and normal samples. Expression levels were used in conjunction with 
clinical and pathological data, as well as the clinical outcomes of the 
patients (median follow-up 120 months).
Results:
Expression of Akt1 levels in the mammary ductal carcinoma cohort 
demonstrated a lower level of transcript expression in the lower grade 
and stage cancers. Levels of Akt1 were found to be significantly lower 
in grade 1 ductal breast carcinomas compared to the combined higher 
grade 1 and 2 carcinomas (ductal carcinoma grade 1 median = 3.7 
vs ductal carcinoma grade 2,3 median = 33.6, p = 0.01). In addition 
to this, median transcript levels of Akt1 were found to increase with 
increasing TNM stage of the ductal carcinoma (Median values of Akt1 
in ductal carcinoma TNM 1 = 5.9, TNM 2 = 63.6, TNM 3 = 533 and 
TNM 4 = 13680). This enhanced expression of Akt1 in higher TNM 
stages, compared to TNM stage 1, was found to be significant in 
most cases (TNM1 vs TNM2, p = 0.03; TNM1 vs TNM3, p = 0.15; 
TNM1 vs TNM4, p = 0.03).
Conclusion:
Variable expression of Akt1 was seen throughout the mammary ductal 
carcinoma cohort and correlated with a number of prognostic factors. 
Akt1 transcript levels were found to be significantly reduced in the 
low grade 1 and TNM1 stages when compared to the higher grades 
and TNM stages. Our current data suggests that low levels of Akt1 
may be associated with better clinical patient prognosis in mammary 
ductal carcinoma.
P4-09-15
Clinical and Pathological Predictors of Outcome among Patients 
with Triple Negative Breast Cancer.
Pearlstone DB, Gray M, Garofalo RM, Trapani M, Nyirenda T, 
Hazelwood VA. Hackensack University Medical Center, Hackensack, 
NJ; Stevens Institute of Technology, Hoboken, NJ; John Theurer 
Cancer Center, Hackensack, NJ
Background: Triple negative (TN) breast cancer portends a 
poor prognosis, yet outcomes remain heterogeneous. Specific 
characteristics of individual TN patients that can predict outcome 
compared to non-triple negative (NTN) patients have yet to be well 
defined. Methods: A prospective oncology database at Hackensack 
University Medical Center was queried for all patients with invasive 
breast cancer between 2000 and 2005. Patients with triple negative 
breast cancer were identified and compared to non-triple negative 
patients. Numerical values were compared by Mann-Whitney test; 
categorical values by Chi square/Fisher exact test. Log-rank test 
was used to compare outcome statistics, univariate and multivariate 
analyses were used to identify factors affecting relapse-free survival 
and overall survival. Results: A total of 2,216 patients were identified 
(TN: n=260; NTN: n=1956). There was no difference in race (white 
vs non-white; TN: 82.3% vs NTN: 87.3%) or family history of breast 
cancer (TN: 19.2% vs NTN: 16.8%). TN patients were significantly 
younger (median age; TN: 55.5 vs NTN 57.7; p< .05), had larger 
tumors (mean cm; TN: 3.1 vs NTN: 2.4; p<.05), had higher grade 
tumors (% grade 3; TN:74.6 vs NTN: 26.1; p<.0001), had higher 
proliferation index (>20% nuclei stained for Ki-67; TN: 30.8% 
vs NTN: 6.7%; p<.0001), but were less likely to have lymph node 
metastases at presentation ( TN: 35.7% vs NTN: 48.0%; p < .0001). 
Among node negative patients, overall survival (OS) and disease 
free survival (DFS) were not significantly different between TN and 
NTN. Among node positive patients, both OS and DFS were worse 
for TN patients compared to NTN patients (p < .0008). By univariate 
analysis, age, nodal status, tumor size and tumor grade were all 
independent predictors of DFS, but proliferation rate and TN status 
were not. In a multivariate analysis, however, age, TN status, nodal 
status and tumor size were all significantly associated with DFS. 
Conclusion: Although TN patients have poor outcomes overall, 
among node negative patients, TN status does not affect overall nor 
disease free survival. Among node positive patients, however, TN 
status has a significant impact on outcome. In this analysis, well 
established predictors of outcome, including age, tumor size, tumor 
stage and nodal status were all independent predictors of outcome, 
but TN status and Ki-67 level were not.
P4-09-16
Factors Affecting the Development of Axillary Lymph Node 
Metastases in T1a-T1b Breast Cancers.
Khair TA, Boolbol SK, Boachi-Adjei K, Klein P. Beth Israel Medical 
Center, Continuum Cancer Centers of New York, New York, NY
Background: The presence of axillary nodal metastases is a poor 
prognostic indicator in patients with breast cancer. In the majority 
of patients, axillary nodal involvement correlates with tumor size 
and most commonly in tumors greater that 1 cm. Many series report 
an incidence of axillary nodal metastases in 3-37% of patients with 
tumors less than or equal to 2 cm. The presence of axillary nodal 
metastases will often change the stage of the cancer and role of 
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adjuvant systemic treatment; therefore, it is important to understand 
what features are associated with these small lymph node positive 
tumors. The purpose of this study is to identify characteristics of T1a 
and T1b breast cancers that present with axillary nodal metastasis.
Methods: A retrospective review of a prospective database identified 
878 patients with T1a and T1b breast cancer. Pathologic features 
including tumor grade, hormone receptor status, lymphatic and 
vascular invasion, Her-2 neu status, and tumor histology were 
examined in patients with and without axillary nodal metastases. 
Pearson’s c² test along with stepwise linear regression analysis were 
used to determine which factors were associated with the development 
of axillary nodal metastases.
Results: There were 289 T1a lesions and 589 T1b lesions studied. 
Four independent variables were found to be associated with axillary 
nodal metastases in T1a-T1b breast cancer. As illustrated in Table 1, a 
significant difference was seen in nodal positivity among patients with 
ER negative tumors compared to those with ER positive tumors (p= 
.0000). An increased incidence of nodal positivity was also observed 
among patients with LVI compared with those without LVI (p= .0000). 
A significant difference was observed in nodal positivity among 
patients with perineural invasion compared to those without (p= 
.0006). An increased incidence of nodal positivity was also observed 
among T1a and T1b tumors with a higher histologic grade (p= 0409, 
p= .0001). Of note, when comparing T1a to T1b breast cancers, there 
was no significant difference found among the identified exposure 
variables of interest.
Table 1.
 Node Positive Odds Ratio p value Node Negative Odds Ratio p value
ER Positive 1.00  1.00  
ER Negative 1.84 [CI 1.11, 3.02] .0099 0.540 [CI 0.33, 0.90] .0000
Absence of LVI 1.00  1.00  
Presence of LVI 12.63 [CI 7.21, 22.11] .0000 0.08 [CI 0.05, 0.137] .0000
No Perineural invasion 1.00  1.00  
Perineural Invasion 5.47 [CI 1.84, 16.21] .0006 0.183 [CI 0.06, 0.65] .0006
Histologic Grade 1 1.00  1.00  
Histologic Grade 2 1.72 [CI 1.01, 2.92] .0409 0.58 [CI 0.34, 0.98] .04
Histologic Grade 3 3.07 [CI 1.72, 5.47] .0001 0.33 [CI 0.18, 0.58] .0001
Conclusion: In this series, the overall prevalence of nodal positivity 
in T1a and T1b breast cancer is 12%. An absence of a relationship 
between T1a and T1b cancers with nodal positivity was observed. 
However, the presence of nodal positivity showed a significant 
correlation with ER negativity, LVI, perineural invasion, and higher 
histologic grades.
P4-09-17
Leptin and Adiponectin Expression in Breast Cancer.
Jeong Y-J, Jeong H-Y, Bong J-G, Park S-H, Choi J-H, Oh H-K. School 
of Medicine, Catholic University of Daegu, Daegu, Korea; College 
of Pharmacy, Kyung Hee University, Seoul, Korea
Background: Several adipocytokines, such as leptin, resistin, and 
adiponectin, are associated with obesity and breast cancer. Multiple 
studies have indicated that adipocytokines may significantly influence 
the growth and proliferation of tumors. However, the relationship 
between adipocytokines and breast cancer invasiveness has not been 
investigated in human tissue. The aims of this study were to determine 
the expression of leptin, leptin receptor (ObR), adiponectin and 
adiponectin receptor (AdipoR) in human breast cancer, to evaluate 
their prognostic significance in the breast cancer.
Material and Methods: Specimens from 198 patients with primary 
breast cancer were enrolled, and representative paraffin tumor 
blocks were selected for constructing tissue microarrarys (TMA). 
Immunohistochemical staining for leptin, ObR, adiponectin, and 
AdipoR was performed using TMA, and the clinicopathologic 
characteristics were evaluated from the patient’s medical records.
Results: Stage 0 breast cancer accounted for 41 cases, and 157 cases 
were invasive cancer. A univariate analysis showed that positive rates 
of leptin and ObR expression in the ductal carcinoma in situ (DCIS) 
group were significantly higher than those of the invasive cancer group 
(97.4% vs. 34.0%, p<0.001; 74.4% vs. 29.8%, p<0.001). However, 
positive rates of adiponectin and AdipoR expression in the invasive 
cancer group were significantly higher than those in the DCIS group 
(53.7% vs. 33.3%, p=0.024; 59.9% vs. 26.3%, p<0.001). High leptin 
expression was significantly associated with high Ki-67 expression 
(p=0.016). High adiponectin expression was significantly correlated 
with smaller tumor size (p=0.001). The disease-free survival (DFS) 
and overall survival (OS) rate at 5 years were 89.3% and 96.7%, 
respectively. No difference in DFS and OS was observed based on 
leptin, ObR, adiponectin, AdipoR expression.
Discussion: Previous studies, using serum of breast cancer patients 
or breast cancer cell line, revealed that leptin and ObR may affect 
processes related to cancer initiation and progression, and adiponectin 
has protective effect on tumor progression. However, the precise 
effects of leptin, ObR, adiponectin and AdipoR in breast cancer 
are still unclear. Our results suggest that losses of leptin and ObR 
expression could be associated with invasive cancer, whereas high 
adiponectin and AdipoR expression may be associated with breast 
cancer invasiveness.
P4-09-18
Australian Decision Impact Study: The Impact of Oncotype 
DX Recurrence Score (RS) on Adjuvant Treatment Decisions 
in Hormone Receptor Positive (HR+), Node Negative (N0) and 
Node Positive (N+) Early Stage Breast Cancer (ESBC) in the 
Multidisciplinary Clinic (MDC).
de Boer RH, Baker C, Speakman D, Mann B. Royal Melbourne 
Hospital, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, 
Victoria, Australia; Peter MacCallum Cancer Institue, Melbourne, 
Victoria, Australia; Royal Melbourne and Royal Women’s Hospital, 
Melbourne, Victoria, Australia
Introduction: There has been increasing interest in more accurately 
defining the need for chemotherapy in patients with HR+ ESBC. 
Oncotype DX® has been shown to provide prognostic and predictive 
information beyond traditional histopathological factors. Prior 
clinical impact studies have focused on decisions made by individual 
practitioners. In Australia, the MDC has become the standard forum 
for determining treatment decisions. In this study, we have assessed 
how the RS influences adjuvant systemic treatment decisions in 
the MDC at 4 separate hospitals. Methods: Patients with unifocal 
HR+, HER2-ve ESBC, N0 and N+ (1-3 positive nodes, including 
micrometastases and isolated tumour cells) and no contraindication to 
adjuvant chemotherapy (CTx) or endocrine therapy (H) were eligible. 
A total of 150 patients will be entered. Systemic adjuvant treatment 
recommendations were made and recorded in the MDC, both before 
and after testing with Oncotype DX. The primary endpoint was the 
overall change in the treatment recommendation. Other endpoints 
included confidence in recommendations, assessment of impact of the 
RS, and treatment the patient actually received. Results: Currently, 
RS results on 84 patients are available. Patient age range is 33-82 
years. There are 56 (67%) N0 pts and 28 (33%) N+. Overall, 37 
(44%) women had low, 36 (43%) intermediate and 11 (13%) high 
RS. The RS changed the initial treatment recommendations in 20 
(24%) patients. Of the 34 patients initially recommended CTx+H, 
there was a shift to H alone for 12 (35%), whilst of the 50 patients 
initially recommended H alone, 8 (16%) shifted to CTx+H. A shift 
in treatment recommendations was reported for 8/37 (22%) pts with 
low, 8/36 (22%) with intermediate and 4/11 (36%) with high RS. 
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13/56 (23%) of N0 pts had a change in recommendation, whilst 7/28 
(25%) N+ pts changed (table 1). 5 patients have decided against the 
final MDC recommendations: 3 chose CTx+H after recommendation 
of H (RS of 13,19 and 21 respectively), and 2 declined a CTx+H 
recommendation (RS of 19 and 25). Conclusion: Early results of our 
Australian study suggest an impact of Oncotype DX RS on adjuvant 
treatment decision making in the MDC setting. Updated results on 
the full 150 patients will be presented at the meeting.
Table 1
Nodal Status  N0 (n=56) N1-3 (n=28)
 Pre-RS Rec. CTx + H H alone CTx + H H alone
Post-RS Rec. CTx + H 8 7 14 1
 H alone 6 35 6 7
P4-09-19
PCNA+ Tumor Associated Macrophages Are Associated with 
M1 and M2 Gene Expression, and Confer Poor Prognosis in the 
Absence of Anti-Tumor Immune Environment.
Mukhtar R, Wolf D, Tandon V, Zhu J, Lenburg M, van’t Veer L, 
Campbell MJ, I-SPY Trial Investigators, Esserman LJ. UCSF; Boston 
University
Background
Tumor associated macrophages (TAMs) promote breast tumor 
progression through the production of angiogenic factors, stromal 
breakdown factors, and the suppression of adaptive immunity. TAMs 
are recruited from the circulation to the tumor site, and can undergo a 
spectrum of phenotypic changes, with two contrasting activation states 
described in the literature: the M1 anti-tumoral and M2 pro-tumoral 
phenotypes. We previously identified a population of PCNA+ TAMs 
associated with high grade, hormone receptor (HR) negative tumors 
with poor outcomes. We hypothesized that high PCNA+ TAMs would 
be associated with expression of M2 related genes.
Methods
We used immunohistochemistry to measure PCNA+ TAM levels 
(double positive for PCNA and CD68) in 135 invasive breast cancer 
cases from the I-SPY 1 Trial, a prospective neoadjuvant trial with 
serial core biopsies and gene array data. We developed gene-sets 
representing M1 related, M2 related, and anti-tumoral immune 
response (represented by cytotoxic T cells and MHC Class II) genes 
based on literature review. We compared PCNA+ TAM levels, 
expression of these gene-sets, and outcomes.
Results
Higher than mean PCNA+ TAM counts were associated with 
increasing grade (p < 0.001), HR negativity (p < 0.001), and decreased 
recurrence free survival (RFS, p = 0.05). Among subjects who had a 
pathologic complete response (pCR), there was no difference in RFS 
between those with high versus low PCNA+ TAMs. Among subjects 
without pCR, those with high PCNA+ TAMs had significantly worse 
RFS than those with low PCNA+ TAMs (p = 0.0028). In the 95 
subjects with both PCNA+ TAM results and gene expression arrays 
available, high PCNA+ TAM levels were associated with more 
M1 than M2 related genes. The gene-set representing anti-tumoral 
immune environment was not by itself associated with RFS. However, 
those subjects with both high PCNA+ TAMs and the absence of 
anti-tumoral immune response gene expression had significantly 
worse RFS than those with high PCNA+ TAMs but the presence of 
anti-tumoral immune related genes (p = 0.01).
PCNA+ TAMs are associated with high grade and ER negativity
 High PCNA+ TAMs pvalue
Grade  <0.001
1 14.29%  
2 26.79%  
3 59.72%  
ER status  <0.001
negative 63.93%  
positive 26.76%  
Conclusions
High PCNA+ TAMs had different effects on outcomes depending 
on tumoral immune environment. Instead of being purely M2 
macrophages, PCNA+ TAMs likely represent a heterogeneous 
mixture of TAMs with different polarization states. Additional 
markers are needed to distinguish anti-tumoral from pro-tumoral 
PCNA+ TAMs.
P4-09-20
Expression Profile of Interleukin 17B and the Receptor IL-17BR 
in Clinical Breast Cancer.
Sanders AJ, Mansel RE, Mason MD, Jiang WG. Cardiff University 
School of Medicine, Cardiff, United Kingdom
Introduction:
Interleukin 17B (IL-17B) is a member of the interleukin 17 cytokine 
family. Members of this family have been implicated in conditions 
such as autoimmune diseases and the inflammatory response. 
A number of studies have examined the role of IL17A in cancer 
progression and angiogenesis and shown a variety of functions, both 
pro- and anti- tumorigenic. Currently there is little data on IL-17B and 
the receptor IL-17BR and their involvement in cancer progression. 
The current study looks at the expression profile of IL-17B and IL-
17BR in a clinical breast cancer cohort.
Methods:
The expression profile of IL-17B and IL-17BR was examined in a 
cohort of human normal breast and breast cancer specimens (normal, 
n = 34; tumour, n = 109). IL-17B and IL-17BR transcript expression 
in the samples was analysed using Q-PCR and compared to clinical 
and pathological data.
Results:
Both IL-17B and IL-17BR expression seemed to correlate with NPI 
staging. IL-17B levels were low in patients with NPI-1 or -2 cancers 
(median values 3.1 and 1.1 respectively), with highest levels of IL-
17B being observed in the poorer prognosis NPI-3 group (median 
value 206.9; p = 0.07 NPI-1 vs NPI-3 and p = 0.01 NPI-3 vs NPI-2). 
Similar to this IL17B levels in TNM stage 1 cancers were significantly 
lower than those in higher TNM stages (TNM1 median value = 0.3 vs 
grouped TNM234 median value 10.3, p = 0.03). IL-17BR expression 
also tended to increase with NPI staging (IL-17BR median expression, 
NPI-1 = 0.0, NPI-2 = 0.04 and NPI-3 = 1.59; NPI-1 vs NPI-3 p = 
0.07). Additionally, levels of IL-17BR were found to be significantly 
lower in background tissue compared to cancer tissue (median values 
0.00 vs 0.01 respectively, p = 0.014).
Conclusion:
IL-17BR expression seems to be higher in tumour tissue compared 
to normal background tissue. Additionally, expression of IL-17B 
and IL-17BR both appear to be associated with higher NPI stage, 
particularly in the poor prognostic NPI-3 group. Expression of IL-17B 
seems to be elevated collectively in TNM stage 2, 3 and 4 compared 
to the better prognostic TNM1 stage. Together the data suggests that 
IL-17B and IL-17BR expression may be useful molecules to identify 
poorer prognostic breast cancers in patients.
P4-09-21
A Novel Prognostic Marker for Triple-Negative Breast Cancers.
Wallon UM, Sabol JL, Zemba-Palko V, Carp NZ, Ciocca RM, 
Wojciechowski BS, Prendergast GC. Lankenau Institute for Medical 
Research, Wynnewood, PA; Lankenau Medical Center, Wynnewood, 
PA
BACKGROUND : Triple-negative breast cancers (TNBC) represent 
a highly aggressive form of this disease with few treatment options 
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available. Currently, even the smallest node negative cancers are 
considered by many to warrant treatment with chemotherapy (CTX). 
While many recur early (within 2-3 years), there is a subset of 
long-term survivors illustrating the heterogeneity within this group. 
Here we report our ongoing effort to establish tissue inhibitor of 
metalloproteinase-4 (TIMP-4) as a prognostic marker in all early 
breast cancers a. While the canonical function of TIMPs is to 
inhibit tissue degradation, numerous reports have established that 
TIMPs exert tumor promoting activity. In our prospective study, we 
evaluated TIMP-4 as prognostic marker for TNBC and its role in 
disease progression.
METHODS: Specimens from our retrospective and prospective 
cohorts were assessed by immunohistochemical staining using 
standard techniques and a monoclonal antibody for TIMP-4b in 
accordance with the IRB approved protocol. Staining intensity was 
documented on a scale of 0-3. No data was released to the treating 
physicians at the time of collection. Outcome data from a total of 
240 pts was obtained through tumor registry and clinician practices. 
Staining intensity was then correlated with outcome to calculate 
sensitivity and specificity of the marker. To determine the role of 
TIMP-4 in TNBC cell behavior we have performed microarray 
analyses. The effects of TIMP-4-induced signaling were tested 
using invasion and clonogenic survival assays under normal growth 
conditions and after exposure to gamma radiation.
RESULTS: Elevated TIMP-4 expression identified a high risk 
of relapse and short survival time with 75% sensitivity and 
80% specificity. No discernable differences were noted between 
retrospective and prospective cohorts. Array analyses revealed 
activation of the PI3K/AKT pathway in the presence of TIMP-4. 
Furthermore, elevated TIMP-4 increased the invasive behavior of 
breast cancer cells in Matrigel™-coated invasion chambers and 
reduced sensitivity to gamma irradiation. These effects were reversible 
by addition of either a PI3K inhibitor or an anti-TIMP-4 antibody, 
suggesting their use as potential therapeutic strategies.
CONCLUSIONS : On the basis of these clinical data we suggest that 
TIMP-4 may offer a simple prognostic marker for TNBC patients at 
highest risk. The presence of TIMP-4 identifies a patient population 
likely to recur quickly despite standard CTX treatment. Our research 
suggests that targeted therapy of the PI3K/AKT pathway and/or a 
biological therapeutic approach directed against TIMP-4 may be of 
benefit in this subset of pts and should be explored. Therefore, TIMP-
4 testing of TNBC patients could aid in the selection of a treatment 
regimen to improve survival outcome.
a Liss, M et.al. Am. J. Pathol. 2009
b Donover, P et.al. J. Cell. Biochem. 2010
P4-09-22
Multicenter Quality Assurance Profile Review of Lobular Breast 
Carcinomas Versus the 21 Gene Recurrence Score: Assessment 
of Clinical Relevance.
Dabbs DJ, Hicks D, Tubbs R, Bhargava R, Brufsky A. University of 
Pittsburgh Medical Center, Pittsburgh, PA; University of Rochester 
Medical Center, Rochester, NY; Cleveland Clinic, Cleveland, OH
Introduction
The oncotype dx (ODX) 21 gene recurrence score (RS), was 
intended to predict the 10 year risk of breast cancer recurrence for 
estrogen receptor positive, lymph node negative disease (NEJM 
2004;351:2817-26). The proportions of patients that were reported as 
low, intermediate and high risk were 51%/22%, 27%. This population 
of patients was dominated by ductal carcinomas (DCA), with a 
paucity of classical lobular carcinomas (CLCA), which are ER-rich 
and low grade histology. To date, there is dearth of data regarding the 
relationship of the RS and CLCA, and the clinical relevance regarding 
the ODX RS in CLCA has not been studied.
Methods
As part of quality assurance review at three institutions, the ODX 
RS for all CLCA were reviewed in order to determine the perceived 
clinical relevance of the ODX RS compared to the proportions of RS 
reported (NEJM 2004;351:2817-26).
Results
A total of 219 cases of ODX were performed on CLCA. The low/
intermediate/high risk profile was 58%/40%/2%.
Conclusions (1) The risk profile of ODX for CLCA is very different 
from the original DCA dominant population previously reported. (2) 
If the goal of ODX is to identify candidates for chemotherapy, then 
a high RS is a rare event for CLCA, and as such, the judgment to 
administer chemotherapy to an individual patient would most likely 
depend upon factors other than the ODX, because 98 percent of 
patients are combined low/intermediate risk RS.
P4-09-23
Monitoring Autophosphorylation of Mammalian Target of 
Rapamycin (mTOR) for Histoprognostic Grading of Invasive 
Breast Cancer: Impact on the Reclassification of Patients with 
Grade 2 Tumors Using the Nottingham Grading System.
Sauri-Nadal T, Del Barco S, Vazquez-Martin A, Oliveras-Ferraros 
C, Cufí S, Martin-Castillo B, Lopez-Bonet E, Menendez JA. Catalan 
Institute of Oncology, Girona, Catalonia, Spain; Dr. Josep Trueta 
University Hospital, Girona, Catalonia, Spain
Histological grade is one of the strongest prognostic factors in 
operable breast carcinomas (BC). Although Grade 1 and Grade 3 are 
biologically and clinically distinct tumor entities that clearly separate 
low-risk from high-risk BC patients, 30-60% of BC are classified as 
histological Grade 2, which is associated with an intermediate risk 
of recurrence and is not informative for clinical decision making. 
Previous studies using a 97-gene measure of histological tumor 
grade (i.e. the Genomic Grade Index, GGI) have confirmed GGI’s 
ability to accurately reclassify Grade 2 patients into 2 BC groups with 
high versus low risks of recurrence. However, GGI’s applicability is 
still expensive, technically demanding and is not readily available 
in a routine clinical setting in most hospital laboratories. The 
prognostic abilities of BC gene expression signatures such as GGI 
are due mostly to the detection of proliferation activity. One of the 
strongest, yet simple and well-reproducible proliferation-associated 
prognostic factors is the mitotic activity index (MAI). Here, we 
have tested whether immunohistochemical assessment of MAI by 
assessing the autophosphorylation status of mammalian Target Of 
Rapamycin (mTOR) at Serine 2481 could significantly impact on 
the histopathological classification of Grade 2 BC when using the 
Nottingham Grading System. 1.) We validated the sensitivity of 
phospho-mTORSer2481 (PP-mTOR) labeling in detecting & counting 
mitotic figures and also its usefulness for histoprognostic grading 
in a series of 144 BC biopsies; 2.) we investigated the correlation 
between PP-mTOR MAI and the MAI determined by using an 
antibody selective for the Ser10-phosphorylated Histone H3 (PP-H3), 
a well-recognized mitosis-specific marker. PP-mTOR-labeled mitotic 
figures were easily seen and permitted a quick identification of the 
area of highest mitotic activity, even at low-power magnification. 
Our study showed a statistically significant correlation between 
the subjective mitotic counts obtained by using PP-mTOR labeling 
and those assessed by either standard H&E (r = 0.662) or staining 
with PP-H3 (r = 0.896). PP-mTOR MAI correlated also with tumor 
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proliferative activity as measured with the Ki-67 labeling index (r = 
0.633). Average mitotic counts were significantly higher when using 
labeling with PP-mTOR (range = 0-164 mitotic figures, mean = 17) 
and PP-H3 (0-146, 19) than with the standard H&E protocol (0-60, 
5). When the global histoprognostic score of the Nottingham Grading 
System was re-evaluated on the basis of PP-mTOR staining, there was 
a statistically significant shift from Grade 1 to Grade 2 in 14 cases, 
and from Grade 2 to Grade 3 in 23 cases. Indeed, using PP-mTOR 
MAI instead of standard H&E-determined mitotic counts drastically 
reduced by ~50% the number of Grade 2 tumors while increasing 
~3 times the number of Grade 3 BC. Our findings reveal for the first 
time that immunolabeling with PP-mTORSer2481 constitutes a simple & 
reliable method for quantifying proliferative potential of tumors that 
notably improves Nottingham histoprognostic grading of invasive BC.
P4-09-24
Correlation of Aurora Family Member Expression with Clinical 
Breast Cancer Prognosis.
Annakesavan A, Sanders AJ, Harding KG, Jiang WG. School of 
Medicine, Cardiff University, Cardiff, Wales, United Kingdom
Introduction:
Aurora-A, Aurora-B and Aurora-C are a family of protein kinases 
which have been identified as key regulators of the mitotic cell 
division process. Members of this group have been linked with pro-
tumorigenic effects and have been reported as being up-regulated in 
certain cancers. Our current study examines the expression profile 
of the Aurora-A, Aurora-B and Aurora-C members in a breast cancer 
cohort in relation to a number of predictive factors.
Materials and Methods:
The expression of Aurora-A, Aurora-B and Aurora-C was examined 
in a breast cancer cohort using quantitative real time PCR (normal 
samples n = 34, tumour samples n = 109) and immunhistochemistry 
(IHC). Expression of the aurora members was related to clinical 
parameters such as staging and Nottingham prognostic index (NPI).
Results:
Examination of Aurora-A levels in the breast cancer cohort revealed an 
association of Aurora-A expression with NPI grouping. High levels of 
Aurora-A levels were seen in NPI-1 and NPI-2 stages (NPI-1 median 
= 66.0, NPI-2 median = 64.3), with expression reducing significantly 
at the higher NPI-3 group (NPI-3 median = 20.3; p = 0.029 vs NPI-2 
and p = 0.009 vs NPI-1 respectively). Additionally, Aurora-A levels 
were found to be significantly lower in grade 3 cancers compared 
to grade 1 (median grade 1 = 86.5 vs median grade 3 levels = 52.6, 
p = 0.04). In contrast to this, examination of Aurora-C levels in the 
cohort identified a relatively low level of Aurora-C in NPI-1 and 
NPI-2 group (median values NPI-1 = 88, NPI-2 = 34.4) compared 
to a substantial increase in Aurora-C expression in NPI-3 (median 
value = 1602, p = 0.05 vs NPI-1 and p = 0.06 vs NPI-2). Aurora-B 
expression levels did not exhibit any significant differences within 
the breast cancer cohort.
Conclusions:
Differential expression of Aurora-A, Aurora-B and Aurora-C were 
observed within the breast cancer cohort. Higher Aurora-A expression 
was associated with low NPI groups and grades and potentially with 
better patient prognosis whereas lower levels were seen in the poorer 
prognostic NPI-3 group and higher grades. An opposite trend was seen 
in Aurora-C where lower levels were associated with the NPI-1 and 
NPI-2 groups and significantly higher levels were seen in the NPI-3 
group. Aurora-B levels appeared to have no predictive function. This 
data suggests that together Aurora-A and Aurora-C levels, within a 
patient may be useful for predicting patient outcome.
P4-09-25
Impact of Body Mass Index (BMI) for Clinical Outcomes in 
Japanese Breast Cancer Patients.
Gondou N, Fujita T, Sawaki M, Hattori M, Kondou N, Horio A, Adati 
E, Usio A, Sueta A, Iwata H. Aichi Cancer Hospital; Aichi Cancer 
Center Research Institute
Background:
Obesity is risk factor of breast cancer incidence in postmenopausal 
women including Japanese population. Currently, many clinical trials 
data were shown that obesity may be one of prognostic factors after 
primary treatment in postmenopausal breast cancer patients. However, 
the proportion of obesity is large different between Asain and Western 
populations in all breast cancer patients. There is a little paper about 
relationship between body mass index (BMI) and prognosis after 
surgery in Asian breast cancer population.
Methods:
We conducted retrospective analysis about BMI and outcome after 
primary treatment in Japanese breast cancer patients. We reviewed 
the clinical data (height, weight, BMI, ER status, HER status, and 
outcome) based on our medical reports in our single institution. 
This research object is 1,100 patients with primary breast cancer 
who operated between Jan 2003 and Jan 2006 in our institution. 
Median follow up was 59 months (1-97). All patients are categorized 
into four groups according to BMI. The range of BMI is less than 
18.5 kg/m2,, from 18.5 to 24.9 kg/m2, 25 to 29.9 kg/m2, more than 
30 kg/m2 in underweight, normal, overweight and obesity groups, 
respectively. Patient’s characteristics are well balanced excluding 
age and menopausal status . Nobody is obesity in young women (less 
than 35 years old). The correlation BMI with disease free survival 
(DFS) and overall survival (OS) were statistically analyzed by using 
the Cox hazard model.
Results:
785 (71.3%), 88 (8%), 192 (17.5%), 35 (3.2%) patients were 
categorized into normal, underweight, overweight obesisty groups, 
respectively. Breast cancer recurrences including local and distant 
metastases were occurred in 126 patients (11.5%).66 (6%) patients 
died due to breast cancer recurrence (54 patients) and other disease 
(8 patients). The multivariate hazard ratio (HR) in obesity groups 
was tend to be high compared with normal groups in disease free 
survival and overall survival. HR for OS was 4.30 (95%CI ,1.79-
10.3) in obesity group. However, there are no statistical significant 
differences among four groups. Especially, HR for DFS and OS was 
2.90 (95% CI 1.15-7.30 p=0.024) and 7.05(95%CI 2.38-20.8 P<0.001) 
in obesity group compared with normal group in ER positive patients, 
respectively. However, there are no statistical significant difference 
for DFS and OS among four groups in ER negative patients.
Conclusions:
The proportion of obesity is very lower in Japanese population (3.2%) 
than Western population (about 25-30%). However, obesity might be 
risk factor for DFS and OS in Japanese breast cancer patients with 
ER positive similar with Western countries. The different proportion 
of BMI may be influenced the different overall survival rate in lymph 
node negative breast cancer patients between Japan and Western 
countries. This study is a first report of the association between obesity 
and clinical outcomes in Japanese breast cancer patients. However, 
a number of patients were limited and this study is retrospective 
analyses including heterogeneous subtypes in single institution. A 
large scale cohort study should be conducted based on the clinical 
trial in Japanese population.
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Prognostic Significance of Tissue Inhibitor of Metalloproteinase-1 
(TIMP-1) in Breast Cancer.
Dechaphunkul A, Phukaoloun M, Kanjanapradit K, Graham K, 
Ghosh S, Santos C, Mackey JR. Cross Cancer Institute, University 
of Alberta, Edmonton, AB, Canada; Faculty of Medicine, Prince of 
Songkla University, Hat Yai, Songkhla, Thailand
Background: Despite advances of systemic treatment in breast cancer 
guided by hormonal status and HER2 amplification, new prognostic 
and predictive factors are still warranted to optimize treatments among 
these patients. Tissue Inhibitor of Metalloproteinase-1 (TIMP-1), a 
physiologic inhibitor of Matrix Metalloproteinases (MMPs), can act 
in both pro- and anti-tumoral effects. The prognostic significance 
of TIMP-1 in breast cancer is still controversial. This study aims to 
determine the prognostic significance of TIMP-1 in breast cancer.
Material and Methods: One-hundred and seventy-six primary breast 
cancers from women with early stage disease treated with standard 
adjuvant therapy were analyzed by gene expression microarrays and 
immunohistochemistry for TIMP-1. Immunohistochemical analysis 
was independently reviewed by two pathologists.
Results: At the optimized cut-off point, patients with high TIMP-1 
RNA levels had a significantly shorter time to relapse, with a hazard 
ratio (HR) of 1.6 (p = 0.039), but without significant differences 
in overall survival (HR 1.29, p = 0.37). Although cytoplasmic 
overexpression of TIMP-1 protein was not correlated with early 
relapse (HR 1.2, p = 0.35), high expression was associated with 
shorter overall survival (HR 1.73, p = 0.027). In multivariate analysis, 
when considering stage, histologic grade, hormonal and HER2 status, 
TIMP-1 RNA levels remained independently prognostic for early 
relapse (HR 1.68, p = 0.04).
Discussion: Elevated TIMP-1 RNA levels are independently 
prognostic for early recurrence, whereas protein overexpression of 
TIMP-1 is correlated with short overall survival in primary breast 
cancer.
P4-09-27
Can We Predict the Benefit of the 70-Gene Signature in the Choice 
of Adjuvant Systemic Treatment for ER Positive, HER2 Negative 
Tumors in Daily Practice? A Single Institution Experience.
Torrisi R, Garcia-Etienne CA, Losurdo A, Morenghi E, Di Tommaso 
L, Gatzemeier W, Sagona A, Rossetti C, Eboli M, Rubino A, Barbieri 
E, Andreoli C, Orefice S, Gandini C, Masci G, Santoro A, Tinterri C. 
Humanitas Cancer Center, Milan, Italy
Purpose: Studies have shown that the 70-gene signature 
(MammaPrint®) (MP) may outperform clinicopathological risk 
assessment and may predict the benefit from chemotherapy (CT) in 
patients (pts) with early-stage breast cancer. However, the need of 
fresh tissue and the high cost of the assay limit its use in daily clinical 
practice. We investigated whether 1) tumor clinicopathologic features 
can predict MP risk (high vs. low); 2) MP results could help to make 
decisions for the use of CT in pts with ER positive (ER+ve) breast 
cancer beyond recommendations of known international guidelines 
(NCCN, St. Gallen).
Patients and methods: Women with operable invasive breast cancer 
without evidence of distant disease undergoing surgery at the Breast 
Surgery Department were enrolled into the study. A 3 mm punch 
biopsy of the tumor was obtained from the specimen within the first 
hour after surgery. Samples were shipped to the laboratory in an 
RNA-stabilizing solution and were studied to ensure the presence of 
at least 30% of tumor cells and a customized microarray containing 
70 genes was analyzed as described by the manufacturer.
Results: 124 consecutive pts were enrolled into the study; 106 tumor 
samples were adequate for the microarray. Median age was 53 yrs 
(range 28-83), mean tumor size was 2.3 cm (SD ±1.34), 52.4% pts 
had pN0, 55% of tumors had Ki-67 ≥20% and 36% were poorly 
differentiated. ER were detected in ≥50% of cells in 82% and <1% 
of cells in 15% of tumors, respectively; HER2 was positive in 18% 
of tumors.
As expected, poorly differentiated, ER and PgR negative, HER2 
positive and highly proliferating tumors were more likely to be 
classified as high-MP. We then focused our analysis on ER and PgR 
+ve, HER2 negative tumors and assessed features correlated with 
MP results in this subgroup. Unexpectedly, 31/80 (39%) of these 
tumors were classified as high-MP vs. 49 (61%) low-MP. We found 
that tumor size (T1 vs. T2-T4), poor differentiation (G3 vs G1-2) and 
high proliferation (Ki-67 ≥20%) were significantly associated with 
a high-MP result. In an exploratory multivariate analysis tumor size 
and Ki-67 remained as independent predictors of high-MP result.
At last, when we compared MP risk with recommendations for 
AT from international guidelines we found that in the subgroup of 
candidates for endocrine therapy (ET) in whom the benefit from the 
addition of CT is undetermined, 25/68 pts (37%) were high-MP and 
43 pts (63%) low-MP. When we considered recommendations for AT 
proposed by our multidisciplinary team according to international 
guidelines, 11/25 pts (44%) with high-MP received ET only and 14 
pts (56%) CT + ET, while among 43 pts with low-MP only 9 received 
both CT and ET.
Conclusions: Our study shows that the 70-gene signature was feasible 
in the clinical setting, as 85% of tumor samples were adequate. A 
substantial proportion of ER/PgR+ve, HER2 negative tumors was 
classified as high-MP; within this subgroup, proliferation and tumor 
size independently predicted high-MP results. In 20 pts, MP risk 
would have resulted in discordant recommendations for AT compared 
to those based on standard clinicopathologic features.
P4-09-28
Comparison of Oncotype DX (ODX) and Mammostrat (MS) Risk 
Estimations and Correlations with Histologic Tumor Features in 
Low Grade, ER-Positive Invasive Breast Carcinoma (BC).
Acs G, Kiluk J, Loftus L, Laronga C. Moffitt Cancer Center, Tampa, 
FL; Women’s Pathology Consultants, Ruffolo Hooper & Associates, 
Tampa, FL
Several molecular tests have been developed to estimate risk of 
distant recurrence (RDR) and help clinical decision-making regarding 
adjuvant chemotherapy in early stage BC. The ODX assay is a 21-gene 
expression profile mainly based on expression levels of genes related 
to hormone receptor / HER2 signaling and cell proliferation. MS is an 
immunohistochemistry-based assay measuring the expression of five 
markers thought to play a significant role in BC biology. Although 
both validated tests were shown to stratify patients into groups with 
low, intermediate and high RDR, the tests have not been compared 
head-to-head in the same cohort of patients and little data is available 
regarding their correlation with clinicopathologic tumor features. 
We have previously shown that a proliferative, cellular stroma 
and inflammatory cells associated with tumor cells may account 
for unexpected intermediate/high risk estimations based on ODX 
in low grade BC. In this study we compared the clinicopathologic 
tumor features with risk estimations by ODX and MS in 106 low 
grade ER-positive BC. The histologic features of tumors were 
prospectively determined without knowledge of test results. The 
tumor stroma was evaluated for increased cellularity and presence 
of inflammatory cells. Double immunostain for pancytokeratin and 
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Ki67 was performed to assess cell proliferation in cancer vs stromal/
inflammatory cells. Based on ODX and MS, among the 106 cases 
68, 38 and 0, and 91, 14 and 1 tumors showed low, intermediate and 
high RDR, respectively. Assessment of the concurrence between the 
tests to predict low vs intermediate/high RDR showed a kappa value 
of 0.0541. There was no statistically significant correlation between 
ODX Recurrence Score (RS) and MS risk index values. We found no 
correlation between low vs intermediate/high risk estimation by either 
test and patient age, tumor size, nuclear atypia, mitotic rate, ER and 
HER2 expression levels. BC with intermediate/high RDR by ODX, 
but not by MS, showed significantly lower PR expression, increased 
stromal cellularity and presence of inflammatory cells. Double 
immunostains showed increased proliferation in stromal/inflammatory 
cells compared to cancer cells in cases showing intermediate/high 
RDR by ODX; no such association was seen with regards to MS 
risk estimations. The ratio of Ki67-positive stromal/inflammatory 
vs tumor cells >1 had an area under the curve of 0.8929 (p<0.0001) 
and 0.5026 (p=0.9823) to predict intermediate/high RDR based on 
ODX and MS, respectively. Cases showing intermediate/high RDR 
by ODX but low risk by MS were associated with increased stromal 
cellularity, presence of inflammatory cells and increased numbers of 
Ki-67 positive stromal/inflammatory cells, compared to cases showing 
low risk by both assays. Our results suggest that low grade ER-positive 
BC with increased stromal/inflammatory cell proliferation may show 
an apparent increased RDR as assessed by ODX, which uses RNA 
extracted from a mixture of tumor and stromal/inflammatory cells in 
the assay. MS, which examines cancer cells only (thus, not influenced 
by stromal and inflammatory cells), may provide a better estimation 
of likely tumor behavior in low grade BC.
P4-09-29
A Nomogram To Predict Prognosis in Node-Negative Breast 
Carcinoma.
Mazouni C, Spyratos F, Romain S, Fina F, Bonnier P, Ouafik L, 
Martin P-M. APHM, Marseille, France; Institut Curie - Hôpital René 
Huguenin, Paris, France
Background: Currently, the usefulness of conventional markers for 
breast carcinoma is limited to assess individual outcome. A statistical 
model was developed to improve the prognostic accuracy using 
multiple conventional and emerging prognostic biomarkers.
Methods: A total of 305 node-negative breast carcinomas who 
underwent surgery (+/- radiotherapy) but no adjuvant treatment was 
selected. Putative prognosis factors including age, tumor size, ER, PR, 
SBR grading, urokinase plasminogen activator (uPA), plasminogen 
activator inhibitor type 1 (PAI-1) and thymidine kinase (TK) were 
evaluated. The developed model was internally validated using 
Harrell’s concordance index and calibrated. An external validation 
of the new model is warranted.
Results: Age (p<0.001), PR (p= 0.02), and PAI-1(p=<0.001) were 
included in the Cox regression model predicting overall survival at 
5-years. Internal validation revealed a concordance index of 0.711 
to 0.694 before and after calibration.
Conclusion: A nomogram can be used to predict probability survival 
curves for individual breast cancer patients and the effect of treatment 
options can be evaluated using these models.
P4-09-30
Relationship between DNA Ploidy, Biomarker Expression and 
Molecular Subtypes of Invasive Breast Cancer.
Sarode VR, Rahardja D, Morrison DH, Peng Y, Rao R, Euhus D. 
University of Texas Southwestern Medical Center, Dallas, TX
Background: DNA ploidy has been shown to have prognostic 
significance in patients with breast cancer. Studies in the past have 
mainly utilized flow cytometry (FCM) for measuring DNA ploidy. 
However FCM has several disadvantages, the instrument cannot 
distinguish benign from malignant cells and it cannot be performed 
on small tumor samples. The relationship between DNA ploidy and 
biomarker expression in breast cancer has not been well studied. 
Recently, gene expression analysis has demonstrated distinct subtypes 
of breast cancer. Expression of ER, PR and Her2 by IHC has been used 
as a surrogate tool for the molecular classification of breast cancer.
Aim: To determine the relationship between DNA ploidy, biomarkers 
(ER, PR, HER2, Ki67 and p53) expression and molecular subtypes 
of invasive breast cancer (IBCA) using image analysis.
Design: DNA analysis was performed on Feulgen stained sections 
from the same tumor block used for biomarker analysis. DNA indices 
and ploidy were analyzed using the Autocyte Pathology Workstation 
(Tripath, Burlington, NC). Briefly, a total of 200-300 nuclei were 
collected and mean DNA index reported. DNA index was obtained 
by measuring the optical density of tumor cells in comparison with 
those of the non-neoplastic stromal cells in the sample using the 
latter as the diploid reference (value of 1.0). Tumors were classified 
as diploid (DNA indices of 0.90 to 1.1), aneuploid (DNA indices of 
<0.89 and > 1.1) and multiploid tumors; multiple indices. Patient’s 
age, tumor size, histologic grade, stage, biomarker status and breast 
cancer subtypes were correlated with ploidy status.
Results: Of the 248 cases of IBCA, 176 had aneuploid DNA and 
72 diploid. Aneuploid tumors were predominantly grade 3, 72.1% 
versus 27.9% of diploid (p<0.0001). Tumor ploidy had no significant 
association with age (<40 years) versus older age (>50 years), 
p=0.118. The mean tumor size in aneuploid and diploid tumors was 
4.2 cm and 3.2 cm respectively (p=0.009). Aneuploid tumors were 
frequently ER and PR negative compared to diploid (p<0.0001) with 
a mean ER level of 31.7% compared to 72.2% in diploid tumors 
(p<0.0001). The mean PR level was 17.2% in aneuploid versus 
34.0% in diploid tumors (p=0.0009). The ki67 index was 52.4% 
in aneuploid compared to 29.1% in diploid (p<0.0001). The p53 
expression was 30.3% in aneuploid versus 14.4% in diploid tumors. 
Aneuploid tumors were frequently of advanced T stage compared to 
diploid tumors (p=0.0048). There was no significant association with 
N stage (p=0.734). By multivariate analysis after adjusting for age, 
grade, T and N stage, ER (p=0.0021), PR (p=0.0003), HER2 over-
expression (p= 0.0028), Ki67 (p=0.0383), T stage (p= 0.0172 and 
grade (<0.0001) were significantly associated with aneuploidy. Of 
breast cancer subtypes, Her2 (p<0.0001), triple negative (p<0.0001), 
luminal B subtype (p=0.006) were frequently aneuploid and luminal 
A was frequently diploid (p=0.051).
Conclusion: DNA ploidy measured by image analysis has significant 
association with biomarker expression. Increased DNA content is 
associated with poor prognostic features and aggressive subtypes 
of breast cancer.
P4-09-31
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P4-09-33
The Prognostic Significance of Metaplastic Carcinoma of the 
Breast – A Comprehensive Comparison Study with Common 
Breast Cancers.
Lai H-W, Kuo S-J, Chen D-R, Chen S-T. Changhua Christian Hospital, 
Changhua, Taiwan
Purpose: Metaplastic carcinoma of the breast (MCB) is a rare 
histological subtype of breast cancer with incidence less than 1%. Due 
to its rarity, the clinical characteristics and prognostic significance of 
MCB compared with other common breast cancer, such as infiltrating 
ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC) are 
not clear and controversial between different reports. We performed 
a multi-institutional cases collective comparison study to evaluate 
the clinical characteristics and prognostic status with IDC and ILC.
Materials and methods: Cases of MCB were enrolled from 4 medical 
centers in Taiwan. Forty-five MCB patients combined with 1777 
IDC and 53 ILC patients from cancer registry database of Changhua 
Christian Hospital (CCH) comprised the current study. The patients’ 
demographic data, tumor characteristics and prognosis of MCB were 
analyzed and compared with IDC, and ILC. To further clarify the 
prognostic difference between MCB and IDC, a case control analysis 
was performed to minimize the effect of tumor size, lymph node status 
and other clinicopathologic factors. The disease free survival (DFS) 
and overall survival (OS) between groups were compared.
Results: Compared with IDC, MCB was associated with older age, 
larger tumor size, lesser lymph node positive rate, higher distant 
metastasis, higher tumor grade, lower ER positive tumor, and higher 
triple negative breast cancer subtype (TNBC). Compared with IDC, 
MCB was associated with worse OS (p=0.031), but no difference in 
DFS (p=0.071). While MCB was not statistically different from ILC in 
both DFS and OS (p=0.132 and 0.289, respectively). To eliminate the 
influence of other prognostic factors, 135 cases controlled IDC with 
comparable clinicopathologic parameters were enrolled to compare 
with those 45 MCB patients.
Table 1. Case controlled analysis of IDC and MCB.
Characteristics IDC (N=135) MCB (N=45) P-value
Age (SD) 53.06 (11.15) 55.84 (12.48) 0.1613
T stage (%)   0.4398
1 35 (26.32) 8 (19.51)  
2 76 (57.14) 23 (56.10)  
3-4 22 (16.54) 10 (24.39)  
Lymph node (%)   0.4839
Negative 88 (67.18) 19 (76.00)  
Positive 43 (32.82) 6 (24.00)  
Metastasis (%)   0.5394
Negative 105 (78.36) 31 (73.81)  
Positive 29 (21.64) 11 (26.19)  
Stage (%)   0.9874
1 24 (17.91) 8 (19.05)  
2 73 (54.48) 22 (52.38)  
3 34 (25.37) 11 (26.19)  
4 3 (2.24) 1 (2.38)  
Grade (%)   0.6178
1 2 (1.48) 0 (0.00)  
2 38 (28.15) 7 (20.00)  
3 95 (70.37) 28 (80.00)  
Estrogen receptor (%)   0.5548
Negative 76 (56.30) 27 (61.36)  
Positive 59 (43.70) 17 (38.64)  
Progestrone receptor (%)   0.6346
Negative 70 (51.85) 21 (47.73)  
Positive 65 (48.15) 23 (52.27)  
HER-2 (%)   0.8787
Negative 102 (75.56) 29 (74.36)  
Positive 33 (24.44) 10 (25.64)  
Surgery (%)   0.7813
Lumpectomy 37 (28.03) 13 (30.23)  
Mastectomy 95 (71.97) 30 (69.77)  
Hormonal therapy (%)   0.0763
No 67 (49.63) 28 (65.12)  
Yes 68 (50.37) 15 (34.88)  
Chemotherapy (%)   0.6738
No 30 (22.22) 8 (18.18)  
Yes 105 (77.78) 36 (81.82)  
Radiation therapy (%)   0.3201
No 68 (50.75) 25 (59.52)  
Yes 66 (49.25) 17 (40.48)  
Compared with cases controlled IDC group, the MCB patients 
remained showed poorer OS (p=0.040), but not different in DFS 
(p=0.439).
Conclusion: MCB was associated with poorer OS compared with 
IDC, and this poorer prognosis was related to tumor behavior rather 
than clinicopathologic factors.
P4-09-34
Luminal Infiltrating Lobular Carcinoma of the Breast: Clinical 
and Prognostic Features.
Valdiviezo NI, Vega E, Castañeda C, Flores C, Mendiola CD, Manso 
LM, Dorta M, De Velasco GA, Cortés-Funés H, Ghanem I, Ciruelos 
EM. Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto 
Nacional de Enfermedades Neoplasicas, Lima, Peru
Background:
Infiltrating lobular carcinoma (ILC) and infiltrating ductal carcinoma 
(IDC) are the two most common histologic types of invasive breast 
cancer. Previous studies have demonstrated distinctive clinical 
and biologic characteristics, however some features of ILC are yet 
uncertain like the relationship with the particular subtypes according 
to the gene expression profile.
The purpose of our study is to analyze how the patients with ILC 
differ from IDC regarding of percentage of luminal subtype, the 
tumor factors, treatment and patterns of recurrence.
Patients and Methods:
We assessed 1190 breast cancer patients treated at the Hospital 
Universitario 12 de Octubre between 1995 and 2006 categorized as 
having ILC or IDC pure types.
Results: 
One thousand one hundred ninety tumors were included, being ILC 
223 patients (18, 7%), IDC 967 patients (81, 3%) and 200 patients 
(10%) were luminal HER2+. The current analysis is limited to the 
990 patients classified as luminal HER2-.
Median age was 59, 2 years for ILC and 58, 8 for IDC, with no 
significant differences among the groups. Compared to IDC, 
ILC showed a larger tumor size (≥T3: 15, 2% vs. 4, 8%, p‹0.01), 
lesser nodal involvement (35% vs 42, 7% p 0.048) and lower Ki67 
expression (62, 6% vs. 52, 2% p=0.01). The proportion of luminal A 
subtype was greater in ILC (56, 3% vs. 46, 7% p=0.01). Mastectomy 
was more frequently performed for ILC (61, 2 % vs. 47, 7%, p=0.01).
Regarding systemic therapy, 127(62,4%) ILC patients and 450 (57, 
2%) IDC patients received adjuvant chemotherapy (QT). That was 
anthracycline-based in most cases (47, 2% for ILC and 46,4% for 
IDC). Adjuvant hormonal treatment was prescribed equally among 
both groups (196, 96% ILC and 739, 94% IDC), being the most 
commonly used drug tamoxifen .
With a median follow-up of 94 months, 45 ILC patients (22%) and 
159(20, 2%) IDC relapsed. No differences were observed in DFS 
(p=0, 81) or OS (p=0, 47).
The most frequent metastatic site was bone (33% for ILC and 40, 8% 
for IDC), followed by local relapses (17, 7% for ILC vs. 17% for IDC) 
and liver (15, 5% for ILC vs. 15, 7% for IDC). ILC was associated 
with an increased incidence of peritoneal/mesenteric metastases (8 pts 
17, 7% vs. 1pts 0,6% p‹0.01) and a lower incidence of lung relapses 
(8, 8% vs. 19, 4 % pts p‹0.05).
Conclusion:
Luminal HER2- Infiltrating lobular carcinoma carries distinct 
clinicopathological features. In our study, ILC had similar prognosis 
as IDC.
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Co-Expression of Ki-67 Is Critical for Outcome of Cyclooxygenase-2 
Positive Breast Cancer.
Park S, Koo JS, Lee JS, Hwang H, Ko S, Kim SI, Park B-W. Yonsei 
University College of Medicine, Seoul, Korea
Background: The purpose was to investigate the implications of 
cyclooxygenase-2 (COX-2) and Ki-67 expression on the progression 
and prognosis of breast cancer.
Methods: COX-2 and Ki-67 levels were immunohistochemically 
determined using tissue microarrays of 1,028 breast tumors treated 
between November 1999 and August 2005. COX-2 and Ki-67 
levels were compared by tumor progression and clinicopathological 
parameters were investigated in association with both markers status 
which was divided into 3 subgroups: COX-2(+)/Ki-67(+), COX-2(+)/
Ki-67(-), COX-2(-)/Ki-67(any).
Results: COX-2 expression was significantly higher in intraductal 
carcinoma and progressively decreased in small T1 lesions and 
then in T2-T4 tumors, but Ki-67 was significantly expressed at high 
levels in T2-T4 lesions than in intraductal or T1 carcinomas. COX-
2 expression was positively associated with favorable parameters 
such as older age at diagnosis, smaller size, well-differentiation, 
hormone receptor-positivity, and was inversely associated with 
Ki-67 expression. Among 816 invasive tumors, COX-2 expression 
alone was not related to outcomes. In combination with Ki-67 
expression, however, COX-2(+)/Ki-67(-) tumors were significantly 
associated with favorable characteristics including HER2-negativity 
and demonstrated favorable outcomes. COX-2(+)/Ki-67(+) tumors 
showed unfavorable factors and the worst outcomes. COX-2(-)/
Ki-67(any) subgroup presented intermediate prognosis. Statistical 
significance of COX-2 combined with Ki-67 was maintained in Cox’s 
models adjusting for clinicopathological parameters among not only 
whole population but also ER-positive subgroup.
Conclusions: Our study suggests that COX-2 is expressed in early 
phase of breast cancer development and is associated with favorable 
prognostic markers. But co-expression of high Ki-67 proliferative 
index could indicate an aggressive phenotypic change in COX-2 
positive breast cancer. The mechanisms should be further investigated.
P4-10-01
Tumor Markers Predicting Recurrence Type after a Primary 
Ductal Carcinoma In Situ.
Zhou W, Johansson C, Jirström K, Ringberg A, Blomqvist C, Amini 
R-M, Fjällskog M-L, Wärnberg F. Uppsala University Hospital, 
Uppsala, Sweden; Malmö University Hospital, Malmö, Sweden; 
Lund University, Lund, Sweden; Helsinki University Central Hospital, 
Helsinki, Finland; Uppsala University, Uppsala, Sweden
Background: The risk for recurrence after a primary ductal carcinoma 
in situ (DCIS) is approximately 8% after ten years. If a recurrence 
occurs, the risk of the recurrence being invasive is approximately 50%. 
However, the knowledge of determinants for type of recurrence is 
limited. The purpose of this study was to investigate the predictable 
effect of specific biologic markers on the type recurrence after a 
primary DCIS.
Material and Methods: All women diagnosed with a primary DCIS 
between 1986 and 2004 in Uppsala and Västerås, Sweden were 
included (n=458). We also included all women from the SweDCIS 
Trial with a known recurrence (n=166). TMA blocks were constructed 
and immunohistochemistry (IHC) was used to evaluate the status 
of estrogen receptor (ER), HER2, epidermal growth factor receptor 
(EGFR/HER1), cytokeratin 5/6 (CK 5/6), forkhead box A1 (FOXA1), 
forkhead box C1 (FOXC1), Ki 67, CD 10 and transacting T-cell-
specific transcription factor GATA-3 (GATA-3) in the primary DCIS 
tumors. Logistic regression was employed to calculate the difference 
of expression status of biological markers between groups. Odds 
ratios (ORs) and 95% confidence interval (CI) were calculated, 
with adjustment for age, free margins, surgical type and molecular 
subtype by IHC.
Results: Of the 624 patients, 358 without recurrence were grouped 
as controls. Of the 266 with recurrence, 130 developed an in situ 
recurrence, while the remaining 136 developed invasive recurrence. 
Mastectomy compared to breast conserving surgery (BCS) and free 
margins were associated with less recurrences (OR 0.07, 95% CI 
0.03 – 0.15) and (OR 0.39, 95% CI 0.26 – 0.58). As compared with 
the most common molecular subtype Luminal A, the subtype Luminal 
B had statistically significant higher risk of recurrence (OR 2.01, 95% 
CI 1.12 – 3.59). Higher risk of all recurrences was also observed for 
FOXA1 (OR 3.16, 95% CI 1.48 – 4.74) and FOXC1 (OR 2.39, 95% 
CI 1.39 – 4.09). In the analyses of type of recurrence, ER-negative, 
HER2-positive and EGFR-positive tumors recurred more often as in 
situ; (OR 2.34, 95% CI 1.17 – 4.71), (OR 2.08, 95% CI 1.11 – 3.88) 
and (OR 2.20, 95% CI 1.11 – 4.36). The molecular subtype HER2+ 
was also associated with a lower risk of invasive recurrence (OR 
0.27, 95% CI 0.11 – 0.67).
Conclusion: As expected, mastectomy and free margins were 
associated with a lower risk of recurrence. Molecular subtype Luminal 
B and tumor markers FOXA1 and FOXC1 had a higher risk of 
recurrence. Recurrences after molecular subtype HER2+, ER-negative 
and EGFR-positive DCIS were more often of the in situ type.
P4-10-02
A Meta-Analysis of the Association of Blood Levels of Vitamin-D 
and the Risk of Breast Cancer.
Amir E, Carlsson L, Seruga B, Ocana A, Goodwin PJ. Princess 
Margaret Hospital, Toronto, Canada; Institute of Oncology Ljubljana, 
Ljubljana, Slovenia; Albacete University Hospital, Albacete, Spain; 
Mount Sinai Hospital, Toronto, Canada
Background: A considerable body of literature has examined the 
association of vitamin-D with breast cancer risk and the potential 
role in its prevention. Geographic studies show higher incidence of 
breast cancer in patients residing at high latitudes. Other data linking 
vitamin-D deficiency to breast cancer risk are inconsistent.
Materials and Methods: A literature based meta-analysis was 
conducted. Odds ratios (OR) for breast cancer based on blood levels 
of 25-hydroxy or 1,25-hydroxy vitamin-D were computed and pooled. 
Analysis was conducted separately for studies where blood levels 
were taken before (group A) or after (group B) breast cancer diagnosis.
Results: Thirteen studies were identified. Nine studies were included 
in group A and 4 studies included in group B. For group A, there was 
no significant association between lower vitamin-D levels and breast 
cancer risk (pooled OR = 1.09, 95% confidence intervals 0.99-1.20, 
p=0.08). For group B, there was a highly significant association 
between lower vitamin-D levels and breast cancer (pooled OR = 
2.81, 95% confidence intervals 1.70-4.65, p<0.001). The test for 
interaction between groups was highly significant (p<0.001). When 
all studies were pooled, the OR was 1.38 (95% confidence intervals 
1.13-1.70, p=0.002).
Conclusion: When measured before breast cancer diagnosis, blood 
levels of vitamin-D are not associated with breast cancer risk. 
Breast tumors have been shown to differentially express vitamin-D 
hydroxylase. Therefore, any association of vitamin-D and breast 
cancer in studies measuring blood levels after breast cancer diagnosis 
may be confounded by reverse causation bias.
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P4-10-03
Association between BMI, Physical Activity and Breast Cancer 
Histologic Types.
Nyante SJ, Dallal CM, Gierach GL, Sherman ME, Park Y, Hollenbeck 
AR, Brinton LA. National Cancer Institute, Rockville, MD; AARP, 
Washington, DC
Background: Previous research indicates that certain breast cancer 
risk factor associations vary by histologic tumor type. However, most 
studies have been too small to examine risk factors for uncommon 
histologic types. We examined the association between body mass 
index (BMI), physical activity, and the relative risk of breast cancer 
histologic types in a large prospective cohort study to determine 
whether associations for these risk factors varied by histology.
Methods: This analysis included women in the NIH-AARP Diet and 
Health Cohort Study who were 50 to 71 years old, postmenopausal 
at baseline, and not previously diagnosed with cancer (N=190,348). 
The study cohort was established in 1995-1996 when participants 
completed a baseline questionnaire regarding health and nutritional 
information. BMI (kg/m2) was calculated from self-reported height 
and weight. Daily routine physical activity at work or home was 
derived from a question asking women what best described their 
daily routine at work, or throughout the day if they did not work at 
a job. Choices were mostly sitting with little walking, sitting with a 
fair amount of walking, mostly standing or walking, light lifting or 
climbing stairs/hills, or heavy work/carrying heavy loads. Cancer 
diagnosis and histology were obtained from state cancer registries. 
This analysis includes participant follow-up through December 
31, 2006. After a median 11.2 years of follow-up, 7,631 invasive 
breast cancers were diagnosed: 5,278 ductal, 831 lobular, 640 mixed 
ductal-lobular, 214 mucinous, 132 tubular, and 536 other types. 
Multivariable-adjusted hazard ratios (HRs) and 95% confidence 
intervals (CIs) were estimated using Cox proportional hazards 
regression.
Results: Compared to women with a BMI of 18.5 to 24.9, obese 
women had increased risks of ductal (HR and 95% CI for BMI 30 to 
34.9: 1.24, 1.14 - 1.36; BMI ≥ 35: 1.45, 1.30 - 1.62) and mucinous 
(HR and 95% CI for BMI 30 to 34.9: 1.58, 1.04 - 2.39; BMI ≥ 35: 
1.93, 1.16 - 3.20) cancers. For both histologic types, the relative risk 
increased with increasing BMI (P-trend: ductal P<0.01; mucinous 
P<0.01). Women whose daily activity at work or home consisted of 
mostly standing or walking were at reduced risk of ductal and mixed 
ductal-lobular cancers compared with women who reported mostly 
sitting (HR and 95% CI for ductal: 0.86, 77 - 0.96; mixed-ductal 
lobular: 0.64, 0.48 - 0.86). Women who performed heavy work or 
carried heavy loads were also at a decreased risk of ductal and mixed 
ductal-lobular cancers compared with women reporting mostly sitting 
(HR and 95% CI for ductal: 0.68, 0.52-0.91; mixed ductal-lobular: 
0.18, 0.04-0.72), though there were few mixed ductal-lobular cases 
who reported heavy activity.
Conclusions: High BMI was associated with increased risk of ductal 
and mucinous breast cancers. Women who spent their daily routine 
activity mostly standing or walking or doing heavy work had a reduced 
risk of ductal and mixed ductal-lobular cancers. These differences 
suggest that associations of BMI and physical activity vary by breast 
cancer histologic type in postmenopausal women and may have 
different roles in the etiology of these cancers.
P4-10-04
Automated Breast Cancer Risk Assessment: Identifying High 
Risk Women in the Primary Care Setting.
Ozanne E, Omer Z, Carlson K. University of California, San 
Francisco; Massachusetts General Hospital
Background: Despite the availability of risk assessment tools and risk-
reducing interventions, high risk women are not routinely identified 
in clinical practice, and the few that are, rarely choose interventions 
– often due to misperception of risk. Identification of patients at risk 
needs to begin in the primary care setting, rather than the breast health 
specialty world. To accomplish this, we developed a web-based tool 
that provides automated risk assessment and personalized decision 
support designed for collaborative use between patients and clinicians 
in the primary care setting. We assessed the feasibility and efficacy 
of using this tool in a primary care clinic at an academic hospital to 
identify women at high.
Methods: Women aged 40 to 65 years of age were recruited from 
a schedule of patients attending annual physicals at a primary care 
clinic in an academic hospital. Patients with a history of breast 
cancer, genetic testing, or chemoprevention education were excluded. 
Information used to assess breast cancer risk was gathered from 
medical record review and phone interviews when necessary. Risk 
assessment was performed on all patients using four risk assessment 
models (Gail, Claus, BRCAPRO, and BCSC Density). Patients were 
randomized to view the decision aid either before their appointment or 
with their PCP during their appointment. Prior to each visit, providers 
received a risk report that summarized patient risk and recommended 
referrals. Outcomes were gathered from surveys administered 
to patients before and after appointments, and to providers after 
appointments.
Results: Over 4-months, 98 women were approached to reach the 
enrollment goal of 60 women (61%). 24/60 (40%) patients were 
identified to be high risk for breast cancer using standard high risk 
thresholds. 9/60 (15%) of patients fit criteria for referral to genetic 
counseling, while 15/60 (25%) fit the criteria for referral to a BC 
specialist. Out of the 24 patients who fit the referral criteria, 17 (71%) 
were referred to a high risk clinic by their PCPs. 9/17 (53%) patients 
followed through in scheduling the appointment within 4 months of 
the referral date. The PCPs’ perceptions of these patients’ risk was in 
line with the calculated risk for 21 (88%) of the patients. A discussion 
regarding breast cancer risk reduction occurred with 22/24 (92%) 
of these patients during the visit, while the PCPs chose to use the 
decision aid with only 13/24 (54%) of them. PCP chose to view the 
decision aid during the visit with more high risk patients than average 
risk patients (p=0.04). Use of the DA during the appointment did not 
alter provider satisfaction with visit. A majority of patients thought 
the DA was helpful in making a decision and would recommend it 
to women like them.
Conclusions: Performing personalized risk assessment and use of the 
decision aid in the primary care setting was feasible and acceptable. 
These results suggest risk assessment alone may be enough to 
encourage a discussion about breast cancer risk reduction for some 
providers. This method of risk assessment and decision support 
holds promise in the effort to reduce the incidence and burden of 
breast cancer.
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Improved Breast Cancer Risk Assessment in Biopsied Women 
Using the Polyfactorial Model OncoVue®.
Jupe ER, Pugh TW, Knowlton NS, DeFreese DC. InterGenetics 
Incorporated, Oklahoma City, OK; NSK Statistical Solutions,LLC, 
Choctaw, OK
Background: Regardless of the result, women that have undergone 
a breast biopsy are considered at increased risk due to the clinical 
circumstances leading to the need for the procedure. Both the 
number and outcome of biopsy are considered in the widely used 
Breast Cancer Risk Assessment Tool (BCRAT) also known as the 
Gail model. Accurately estimating individualized risk of developing 
breast cancer is useful for early detection and cancer prevention. 
Although the BCRAT has been demonstrated to accurately estimate 
the number of breast cancers likely to emerge in a population of 
women seeking regular mammography screening, it does not produce 
accurate individualized risk estimates for patient counseling. We have 
simultaneously analyzed gene polymorphism and clinical factor data 
in breast cancer cases and matched controls to develop a polyfactorial 
risk model (OncoVue) to improve estimation of individual risk. In 
three independent patient populations, OncoVue has been shown to 
significantly outperform both the BCRAT and composite risk scores 
produced by combining GWAS SNP risks with the BCRAT. Here we 
have characterized the performance of OncoVue in stratifying risk in 
women that have had one or more breast biopsies.
Materials and Methods: Risk scores were analyzed for participants 
ranging in age from 35 to 89 for a subset of participants that had 
enrolled in a larger case-control study conducted in six distinct 
geographic regions of the United States. The current study focused 
on the analysis of participants that had reported one or more biopsies 
(cases prior to diagnosis/controls at time of enrollment) amounting 
to 1265 Caucasian women (537 cases and 728 controls) in a model 
building set and 303 women in an independent validation set (134 
cases and 169 controls). DNAs were genotyped for 22 SNP variants 
and genotype information was combined with clinical risk factor 
information to calculate the risk scores for the individual participants. 
Clinical factor information was also used to calculate BCRAT risk 
scores. The performance of OncoVue was examined in comparison 
to the BCRAT alone.
Results: For both models, positive likelihood ratios (PLR) were 
calculated as the proportion of patients with breast cancer with an 
elevated lifetime risk estimate (≥20%) divided by the proportion of 
disease-free individuals with an elevated risk estimate. In both the 
model building and validation sets, OncoVue exhibited approximately 
a 2.0-fold improvement compared to the BCRAT in more accurately 
assigning elevated risk estimates to breast cancer cases. In these 
women that are already considered at increased risk because of a 
history of biopsy, the observed level of improved performance of 
OncoVue was similar to that in our previous overall studies.
Conclusions: The OncoVue polyfactorial risk model incorporating 
both genetics and clinical factors improves on individualized breast 
cancer risk estimation compared to the BCRAT which uses only 
clinical factors. The performance in biopsied women further supports 
the potential utility of OncoVue for directing prevention and screening 
decisions.
P4-10-06
Evaluation of BRCAPro Risk Assessment Model in Patients with 
Ductal Carcinoma In Situ.
Muse KI, Elsayegh N, Gutierrez-Barrera AM, Kuerer H, Valero V, 
Litton JK, Hortobagyi GN, Arun BK. UT MD Anderson Cancer 
Center, Houston, TX
Background: The BRCAPRo model is used to predict a patient’s 
likelihood to possess a BRCA1 or BRCA2 gene mutation based 
upon personal and family history. Ductal carcinoma in situ (DCIS) 
is considered a non-invasive condition which can progress to an 
invasive breast cancer if left untreated. Currently, DCIS is not 
specifically accounted for in the BRCAPro model, thereby causing 
DCIS to be weighted in the same manner as an invasive breast 
cancer diagnosis. Historically, a diagnosis of DCIS has been entered 
as having developed into an invasive breast cancer ten years later. 
However, there are no standard guidelines of how DCIS should be 
entered. We sought to determine if there were any differences in 
how DCIS was treated in the BRCAPro model to predict the more 
effective method in calculating the BRCAPro. Methods: Women 
with pure DCIS, who were referred for genetic counseling and 
underwent genetic testing, were included in the study. The likelihood 
of carrying a BRCA mutation was calculated using the BRCAPRO 
model (Version 5.1). Patient characteristics which were entered into 
the BRCAPro model include: tumor markers (estrogen receptor-
ER and progesterone receptor-PR), history of oophorectomy prior 
to diagnosis, family history of 1st and 2nd degree relatives with 
breast and ovarian cancer, race and Ashkenazi Jewish ancestry. Each 
patient’s BRCAPro risk estimate was calculated and compared by 
entering DCIS at the presenting age of diagnosis and by adding 10 
years to the age of diagnosis. Descriptive statistics and a student’s 
t-test were used to compare BRCAPro estimates between the two 
groups. Results: Ninety-five patients with pure DCIS underwent 
genetic counseling and testing. The average age of DCIS diagnosis 
was 45 years (range 26-65). Of the 95 DCIS patients included in 
the study 21% (n=20) tested positive for a BRCA gene mutation (8 
BRCA1 and 12 BRCA2), 77% (n=74) test negative and 0.01% (n=1) 
had a variant of uncertain significance. Overall, DCIS patients who 
tested positive for a BRCA mutation had a higher BRCAPro (40%) 
than patients who tested negative (12%) when presenting age of 
diagnosis was assessed. When 10 years was added, the BRCAPro 
estimate was still higher amongst BRCA positive patients (28%) than 
BRCA negative patients (8%). The mean BRCAPro probability when 
DCIS was entered at presenting age of diagnosis was 18% (0.1-95.4) 
versus 12% (0.1-89.9) when calculated 10 years later. Conclusion: In 
our cohort there was no significant difference in BRCAPro probability 
whether DCIS was entered at the presenting age of diagnosis or 10 
years later (p=0.1). However, future studies are needed to determine 
the most effective method to incorporate DCIS into the BRCAPro 
model in order to determine those individuals who may or may not 
be at increase risk to possess a BRCA gene mutation.
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P4-10-07
Clinico-Pathologic Features of Breast Cancer Patients with 
Primary Metastatic Disease Versus Localized Disease: A 
Multicenter Study.
Barinoff J, Hils R, Bender A, Gross J, Kurz C, Tauchert S, Mann 
E, Schwidde I, Ipsen B, Sawitzki K, Heitz F, Harter P, Traut A, du 
Bois A. Kliniken Essen Mitte, Essen, Germany; Dr.-Horst-Schmidt-
Klinik, Wiesbaden, Germany; Asklepios Klinik, Lich, Germany; Sankt 
Gertrauden-Krankenhaus, Berlin-Wilmersdorf, Germany; Klinikum 
Esslingen, Esslingen am Neckar, Germany; Caritsklinik St. Theresia, 
Saarbrücken, Germany; Universitätsklinikum Gießen und Marburg, 
Standort Marburg, Marburg, Germany; Klinikum Frankfurt Höchst, 
Frankfurt am Main, Germany; Evangelisches Krankenhaus Wesel, 
Wesel, Germany
Objective: Approximately 6% of breast cancer patients present 
with primary metastatic disease (pmBC) at first diagnosis. Clinico-
pathological differences to non-metastatic patients are undetermined.
Methods: Exploratory analysis of patients with pmBC treated in 8 
breast cancer units between 1998 and 2010. Tumor characteristics 
of these patients were compared with non-metastatic breast cancer 
patients (BC) of one breast cancer center who had neither local-
recurrence nor distant metastases during 30 months of follow-
up after first diagnosis. Standard staging in patients with first 
diagnosis of BC included chest X-ray, abdominal ultrasonography 
and bone scan. Molecular subtypes were analyzed and defined by 
immunohistochemical markers (ER, PR, Her2-receptor).
Results: 2.214 patients were included, 1.642 with BC and 572 with 
pmBC, respectively. Patients with pmBC were 7 years older (BC 58 
years of age vs. pmBC 65 years; p=0.000) and were more likely to be 
postmenopausal (74% vs. 83%; p=0.000). Most common localizations 
of distant first metastases were bone (61,5%), liver (24%), lung (21%) 
and non-axillary lymph nodes (12%).
85 (15%) patients with pmBC were diagnosed in stage T1. Factors 
associated with pmBC in multivariate analysis for this group were 
positive lymph node status (OR 3.4; 95%CI 2.3-6.0; p=0.000), 
grading 3 (OR 2.3; 95%CI 1.3-4.0; p=0.003), lobular histology (OR 
2.3; 95%CI 1.2-4.5; p=0,010) and phenotype Luminal B (OR 2.4; 
95%CI 1.25-5.0; p=0.014). 197 (34%) patients with pmBC were 
diagnosed in stage T2; positive lymph node status (OR 4.8; 95%CI 
1.1-3.0; p=0.017) and grading 3 (OR 1.6; 95% CI 1.6-2.3; p=0.019) 
were reported as risk factors for this group. 90 (16%) and 200 
(35%) patients were diagnosed with stages T3 and T4, respectively. 
In T3/4 tumors a positive lymph node status (OR 5.2; 95% CI 2.9-
9.3; p=0.000) and grading 3 (OR 2.2; 95%CI 1.2-3.9; p=0.009) 
could be defined as significant risk factors for distant metastases. 
Postmenopausal status was associated with primary metastases in 
stage T2 (OR 1.8; 95%CI 1.2-2.9; p=0.008) and T3/4 (OR 2.4; 95%CI 
1.2-4.7; p=0.011) but not in T1 tumors (OR 1.3; 95%CI 0.7-2.1; 
p=0.420). There was no association with hormone or Her2 receptor 
status nor with a specific phenotype for T2-4 tumors.
Conclusion: The clinico-pathological features of breast cancer 
patients with or without primary metastases differ. In all stages 
positive lymph node status and higher grading were associated with 
pmBC significantly. Lobular histology was reported as a risk factor 
for T1-2 compared to patients without metastases. This feature was 
not found for T3/4 pmBC. T1 pmBC were likely to be associated 
with luminal B phenotype. T3-4 pmBC have not been associated 
with any phenotype or hormone receptor constellation as risk factor 
for metastases. Tumor biology seems to play a minor role for risk 
of metastases in T3-4 stages compared to patients with T1-tumors. 
Findings from this analysis should be considered in the choice of 
staging methods, especially in stage T1.
P4-10-08
Risk Factor Profiles of Women with DCIS and Invasive Ductal 
Breast Cancers.
Schnabel F, Chun Kim J, Billig J, Cimeno A, Mehta P, Guth A, 
Hochman T, Shapiro R, Hiotis K, Siegel B, Axelrod D. NYU Cancer 
Institute, NYU Langone Medical Center, New York, NY; NYU Langone 
Medical Center, New York, NY
Background
There are well established risk factors for breast cancer, including 
elements of personal and family history. Ductal carcinoma in situ 
(DCIS) and invasive ductal carcinoma (IDC) have long been viewed 
as representing two points on the spectrum of one disease. There is 
limited and conflicting information in the literature regarding risk 
factor profiles for DCIS as compared with IDC. The purpose of this 
study was to investigate the relationship of established risk factors in 
a population of women newly diagnosed with pure DCIS and IDC.
Methods
The Breast Cancer Database at NYU Langone Medical Center was 
queried for women who were diagnosed with pure DCIS and IDC 
from 1/2010-3/2011. Variables of interest included: age, family 
history of breast cancer (FHBC), BRCA1/2 status, age at menarche 
and menopause, parity, age at first birth, breast feeding, body mass 
index (BMI), history of atypical hyperplasia or lobular carcinoma 
in situ (ADH, ALH, LCIS), stage, ER/PR status, and method of 
presentation. Wilcoxon non-parametric tests, Chi-Square tests, and 
Fisher’s Exact Tests were used to evaluate differences among DCIS 
and IDC patients.
Results
Of the 593 women identified in this study, 140 (24%) had pure DCIS 
and 453 (76%) had IDC. The median age at diagnosis was 59 years. 
There were 9 (1.5%) BRCA1/2 mutation carriers. Of these, 7 had 
IDC and 2 had DCIS. The majority of patients with IDC were stage I 
(67%) and ER/PR+ (73%). The majority of patients with DCIS were 
also ER/PR+ (71%). In our cohort, the majority of DCIS (83%) was 
mammographically detected versus 47% of IDC cases. There were 
no statistically significant differences in breast cancer risk factors 
between the two groups.
Table 1: Clinical Characteristics of Study Cohort with DCIS and IDC
VARIABLES DCIS (N=140) IDC (N=453) P-value
AGE (median+range) 58 (34-89) 59 (23-95) 0.14*
FHBC
no 73 (52%) 236 (52%) 0.99^
yes 67 (48%) 217 (48%)  
AGE AT MENARCHE (median+range) 13 (9-19) 13 (8-18) 0.85*
AGE AT MENOPAUSE (median+range) 50 (39-58) 51 (29-63) 0.22*
PARITY
0 41 (29%) 134 (30%) 0.06^
1 30 (21%) 61 (13%)  
≥2 69 (49%) 258 (57%)  
AGE AT 1ST BIRTH 26 (16-41) 26 (16-45) 0.26*
BREAST FEEDING
never 45 (45%) 144 (45%) 0.96^
ever 54 (55%) 175 (55%)  
BMI (median+range) 24.4 (17.3-42.1) 25.3 (16.1-51.5) 0.20*
ADH/ALH
absent 133 (95%) 435 (96%) 0.60^
present 7 (5%) 18 (4%)  
LCIS
absent 135 (96%) 446 (98%) 0.17^^
present 5 (4%) 7 (2%)  
METHOD OF PRESENTATION
palpable finding 7 (5%) 168 (39%) <0.0001^
mammography 110 (83%) 205 (47%)  
ultrasound 5 (4%) 37 (9%)  
MRI 9 (7%) 16 (4%)  
Other 2 (1%) 9 (2%)  
*Wilcoxon Non-Parametric Test, ^Pearson’s Chi-Square, ^^Fisher’s Exact Test
Conclusions
In contrast to some previously published work, the risk factor 
profile in our cohort was similar for patients with IDC and DCIS. 
In this population, the majority of cases of DCIS were detected 
mammographically, underscoring the importance of mammography 
in early detection of breast cancer. There is increasing interest in 
identifying a population of women with DCIS who might never 
progress to invasive disease. Our data suggests that this population 
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is unlikely to be distinguished by its risk factor profile. Genetic and 
molecular characteristics are more likely to provide the criteria by 
which this subgroup of patients is identified.
P4-10-09
Hormone Replacement Therapy: A Benign Breast Disease’s Risk?
Hamy AS, Gronier H, Porcher R, Giacchetti S, Cuvier C, De 
Roquancourt A, Espie M. Saint Louis Hospital, AP HP, Faculté Paris 
VII, Paris, France
Background
Use of hormone replacement therapy (HRT) has been associated with 
increased risk of breast cancer. However relations between use of 
HRT and benign breast lesions remain contradictory (1-3). Our goal 
was to investigate whether HRT and its duration use are associated 
with benign breast lesions.
Materials & Methods
From 2001 to 2007, 2708 patients with a non palpable breast lesion 
were referred to our breast care center. Radiological abnormalities 
were screened either by breast ultrasound mammography, or MRI. Of 
those, 1 329 patients had a biopsy in our Radiology Unit. We focus 
on the postmenopausal women (n=739). Clinical data including HRT 
use extent were reported. Patients with previous history of benign 
breast disease or malignancy were excluded.
Results
The analysis was performed on 739 patients. Biopsies yielded a benign 
result in 414 (56%) of them (fibroadenoma n=71, blunt duct adenosis 
n=94, fibrocystic disease n=92, epithelial hyperplasia n=56, others 
n=101), high risk lesions in 57 (8%) (atypical ductal hyperplasia 
n=28, atypical lobular hyperplasia n=19, lobular carcinoma in situ 
n=10) and malignancy in 268 (36%) (not studied here). For the 471 
patients with benign or high risk breast lesion, the median age was 59 
years, 80% had at least one pregnancy and 27% had a family history 
of breast cancer. Among these 471 patients, 47% of them had used 
an oral contraceptive and 53% of them a HRT, with a mean duration 
of use of 2 years.
The HRT use was not significantly associated with the type of benign 
or high risk breast disease. No association was observed either 
between breast disease and duration of HRT (less or more than 7 
years respectively).Older age was significantly correlated to atypia 
or carcinoma (median age at diagnosis 59 y.o in benign lesions, 60 
y.o in high risk lesions and 62 y.o in malign lesions, with significant 
difference) (p<0,0001).
Results
Lesions Benign Hisgh risk Malign p
Nb of patients 414 57 268  
Age (years) (Q1-Q3) 59 (55-66) 60 (55-64) 62 (57-69) <0.0001
Number of pregnancy (Q1-Q3) 2 (1-2) 1 (0-2) 2 (1-2) 0.078
Breast cancer family history 116 (28%) 18 (31.6%) 82 (30.7%) 0.70
Duration of oral contraceptive use (Q1-Q3) 0 (0-8) 0 (0-8) 0 (0-6) 0.55
Duration of HRT use (Q1-Q3) 1 (0-8) 3 (0-7) 2 (0-9) 0.30
No HRT use 199 (48.1%) 23 (40.4%) 121 (45.1%)  
Duration of HRT less than 7 years 111 (26.8%) 21 (36.8%) 67 (25%)  
Duration of HRT more than 7 years 104 (25.1%) 13 (22.8%) 80 (29.9%)  
Conclusion
In this study of postmenopausal women, HRT and its duration use 
were not associated with the type of benign or high risk breast lesion. 
Although a lack of statistical power may be invoked to explain the 
results, we are called to believe that the magnitude of an effect of 
HRT use is small, if ever it exists.
1. Finkelde DT, Kitchen PR, Hayes PR, McKinlay MR, Henderson 
MA 2001 Symptomatic benign breast disease and hormone 
replacement therapy. Breast 10:127-130
2. Gayet A, Esteve J, Seradour B, Piana L, Jacquemier J 2003 Does 
hormone replacement therapy increase the frequency of breast atypical 
hyperplasia in postmenopausal women? Results from the Bouches 
du Rhone district screening campaign. Eur J Cancer 39:1738-1745
3. Rohan TE, Miller AB 1999 Hormone replacement therapy and 
risk of benign proliferative epithelial disorders of the breast. Eur J 
Cancer Prev 8:123-130
P4-10-10
Breast Cancer Risk Factors among Asian Versus Caucasian 
Women with BRCA1/2 Mutations.
de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, 
McPherson LA, Sharma B, Kardashian A, Schackmann EA, Kingham 
KE, Mills MA, West DW, Ford JM, Kurian AW. Stanford University 
School of Medicine, Stanford, CA; University of Hong Kong Li Ka 
Shing Faculty of Medicine, Hong Kong, China
Background: Prior research suggests that the prevalence and 
penetrance of BRCA1/2 mutations may be different in Asians 
compared with Caucasians. Such differences in penetrance could be 
related to genetic, as well as hormonal, reproductive and lifestyle 
factors.
Methods: Chinese and Caucasian BRCA1/2 mutation carriers were 
recruited from genetics clinics in Hong Kong and California. We 
compared personal and family history of cancer, as well as hormonal, 
reproductive and lifestyle exposures between racial groups. Breast 
density was estimated using BIRADS breast composition categories 
on mammogram. We analyzed DNA samples for single-nucleotide 
polymorphisms (SNPs) that may modify BRCA-associated cancer 
risk, and compared the prevalence between groups. A multivariable 
analysis of potential modifiers of cancer risk is underway.
Results: Forty-two Chinese women from Hong Kong and forty-nine 
Caucasian women from California were enrolled. BRCA1 mutations 
were more common in Caucasian women (63% vs. 43%, P=0.05), 
while BRCA2 mutations were more common among Chinese women 
(57% vs. 33%, P=0.02). More Chinese women had a personal history 
of breast cancer (91% vs. 53%) and ovarian cancer (12% vs. 4%). In 
contrast, significantly more Caucasian women had a family history 
of breast and ovarian cancer. On average, Caucasian women had 
higher parity, breastfed more, had less dense breasts on mammogram, 
and more often underwent prophylactic oophorectomy, all of which 
are protective against breast cancer in the general population. 
However, Caucasian women also consumed more alcohol and had 
higher average BMI. Risk associated alleles in RAD51, MAP3K1 
and TOX3/TNRC9 were more common in Chinese women; risk 
associated alleles in FGFR2 and RASSF1 were similar in frequency 
between groups. Results of the multivariable analysis are pending 
and will be presented.
Discussion: We found notable differences between Chinese and 
Caucasian women in the proportion of BRCA1 versus BRCA2 
mutations, and in the distribution of hormonal, reproductive and 
lifestyle factors, and SNPs associated with breast cancer risk. Such 
variations in risk-modifying factors may contribute to differences 
in BRCA mutation penetrance. Enhanced understanding of racial 
differences in BRCA1/2 mutation epidemiology may inform targeted 
cancer screening and prevention strategies.
P4-10-11
Genetic and Environmental Predictors, Endogenous Hormones 
and Growth Factors and Risk of Estrogen Receptor-Positive 
Breast Cancer in Japanese Women.
Yoshimoto N, Nishiyama T, Toyama T, Takahashi S, Shiraki N, Sugiura 
H, Endo Y, Iwasa M, Fujii Y, Yamashita H. Nagoya City University 
Graduate School of Medical Sciences, Nagoya, Aichi, Japan
The incidence of breast cancer in Japanese women has doubled 
in all age groups over the past two decades. We have recently 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011475s
December 6-10, 2011 Abstracts: Poster Session 4
demonstrated that this marked increase is mostly due to an increase 
in the estrogen receptor (ER)-positive subtype. It is necessary to 
establish risk factors capable of predicting the risk of ER-positive 
breast cancer which will enable the efficient selection of candidates 
for preventive chemotherapy. We analyzed genetic factors, including 
14 single nucleotide polymorphisms (SNPs), environmental risk 
factors (body-mass index (BMI), age at menarche, pregnancy, age 
at first birth, breastfeeding, family history of breast cancer, age at 
menopause, use of hormone replacement therapy, alcohol intake and 
smoking), serum hormones and growth factors (estradiol, testosterone, 
prolactin, insulin-like growth factor 1 (IGF1) and IGF binding protein 
3 (IGFBP3)) and mammographic density in 913 women with breast 
cancer and 278 disease-free controls. To identify important risk 
factors, risk prediction models for ER-positive breast cancer in both 
pre- and postmenopausal women were created by logistic regression 
analysis. In premenopausal women, 1 SNP (CYP19A1-rs10046), age, 
pregnancy, breastfeeding, alcohol intake, serum levels of prolactin, 
testosterone and IGFBP3 were considered to be risk predictors. In 
postmenopausal women, 1 SNP (TP53-rs1042522), age, BMI, age at 
menopause, serum levels of testosterone and IGF1 were identified as 
risk predictors. Risk factors may differ between women of different 
menopausal status, and inclusion of common genetic variants and 
serum hormone measurements as well as environmental factors might 
improve risk assessment models. Further validation studies will clarify 
appropriate risk groups for preventive chemotherapy.
P4-11-01
Bilateral Oophorectomy Is Associated with a Higher Prevalence 
of Arthritis and Lower Bone Mineral Density in Women 40 Years 
and Older.
McCarthy AM, Visvanathan K. Johns Hopkins Bloomberg School 
of Public Health, Baltimore, MD; Johns Hopkins Sidney Kimmel 
Comprehensive Cancer Center, Baltimore, MD
Background: BRCA 1/2 mutation carriers are encouraged to have 
their ovaries removed by age 40 to reduce cancer risk and prolong 
survival. Given the recency of genetic testing, it will be some years 
before robust estimates are available of the long term adverse 
effects. In the meantime data from the general population can help 
inform women and providers about potential adverse effects so that 
preventive strategies can be implemented. Bone loss accelerates 
following natural menopause and oophorectomy before age 45 is 
a known risk factor for osteoporosis. However there is limited data 
quantifying the effects of bilateral oophorectomy on bone mineral 
density (BMD), an early sensitive marker of osteoporosis.
Methods: We evaluated the associations of oophorectomy with 
arthritis and BMD in NHANES III, a nationally representative survey 
conducted 1988-1994. For analysis we included women aged 40 
years and older with no history of cancer who reported a bilateral 
oophorectomy or intact ovaries. Women were asked if a doctor 
told them they had arthritis. Femoral neck BMD was measured by 
dual energy x-ray (DXA). Osteoporosis was defined as BMD (g/
m2) more than 2.5 standard deviations below the mean of white 
women aged 20-29 years. Survey weights were used to account 
for the complex survey design. Odds Ratios (OR) for arthritis and 
osteoporosis were estimated using logistic regression. Oophorectomy 
status was categorized intact ovaries, oophorectomy <45 years, and 
oophorectomy ≥45 years. Multivariate models were adjusted for age 
at interview, race, income, smoking status, education, alcohol, and 
BMI. Analyses were repeated excluding women who reported using 
hormone replacement therapy (HRT).
Results: The sample size was 4039 for the arthritis analysis and 
3660 for the BMD analysis. Women with oophorectomy were more 
likely to report arthritis than women with intact ovaries (45.4% vs. 
32.1% p<0.001).The prevalence was even higher in women with 
oophorectomy <45 years (47.7%). The age-standardized mean 
femoral neck BMD was lower for women reporting oophorectomy 
at <45 years than women with intact ovaries (0.711 vs. 0.743 g/m2 
p=0.017). In multivariate models women with oophorectomy had 
greater odds of arthritis than women with intact ovaries, particularly 
among women with oophorectomy <45 years (OR=1.78 95% CI 
1.31-2.42). The odds of arthritis were even greater after excluding 
HRT users (OR=1.99 95% CI=1.25-3.18). Similarly, women who had 
a prior oophorectomy had greater odds of osteoporosis than women 
with intact ovaries, particularly among women with oophorectomy 
<45 years (OR=1.78 95% CI 1.07-2.97). The odds were increased 
further after excluding HRT users (OR=2.92 95% CI 1.32-6.44).
Conclusions: The prevalence of arthritis and osteoporosis were 
significantly greater in women who reported bilateral oophorectomy. 
Results were most profound among women whose oophorectomy 
was performed before age 45 and among women who never used 
HRT. These results suggest that women who undergo oophorectomy 
for cancer prevention should be closely monitored for osteoporosis 
over the long term.
P4-11-02
Insulin-Like Growth Factor-1 (IGF-1), Insulin-Like Growth 
Factor Binding Protein-3 (IGFBP-3) and Lobule Type among 
Women in the Nurses’ Health Study II (NHS II).
Collins LC, Rice MS, Shen D, Connolly JL, Schnitt SJ, Tamimi RM. 
Beth Israel Deaconess Medical Center and Harvard Medical School; 
Brigham and Women’s Hospital and Harvard School of Public 
Health, Boston
In a previous analysis of women enrolled in NHSII, we found that 
among women diagnosed with benign breast disease (BBD), those 
with predominant type 1/no type 3 lobules were at lower risk of 
subsequent breast cancer compared to women with other lobule 
types. Additionally, studies in animal models suggest that higher 
levels of IGF-1, a polypeptide hormone involved in the proliferation/
differentiation of normal mammary epithelium, may inhibit involution 
of breast lobules. However, the interaction between IGF-1 levels and 
lobule types in determining breast cancer risk has not been previously 
evaluated. Therefore, we examined the association between IGF-1 
levels and lobule type among women with BBD. Methods: We 
conducted a cross-sectional study among 484 women in NHSII with 
biopsy-confirmed BBD between 1993-2001 who had blood samples 
available for determining levels of IGF-1 and IGFBP-3. A pathologist, 
blinded to exposure status, classified lobule type on biopsy slides 
according to the number of acini per lobule (type 1 < 12; type 2~50; 
type 3~80 acini). Lobule type was classified into (1) predominant type 
1/no type 3 lobules or (2) other lobule types. Multivariate logistic 
models were used to assess the associations between plasma IGF-1, 
IGFBP-3, and IGF-1/IGFBP-3 levels with lobule type. Models were 
adjusted for age, IGF-1 batch and additional potential confounders 
in secondary analyses. Results: In univariate analyses, older age at 
biopsy, higher body mass index, postmenopausal status, nulliparity, 
and lower IGF-1 levels were associated with predominant type1/no 
type 3 lobules (p<0.05). In multivariate logistic models adjusting 
for age, higher IGF-1 levels were associated with a decreased risk 
of predominant type 1/no type 3 lobules (OR quartile 4 vs. quartile 
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1 = 0.35, 95%CI: 0.15-0.81). Greater IGF-1/IGFBP-3 ratio was 
also associated with a decreased risk of predominant type1/no type 
3 lobules (OR quartile 4 vs. quartile 1 = 0.24, 95%CI: 0.10-0.57).
IGF-1 to IGFBP-3 Ratio and Lobule Type.
IGF-1 to IGFBP-3 Ratio 
(predominantly Type 
1,no Type 3 / mixed 
lobule)
Quartile 
1 (30/91)
Quartile 2  
(20/101)
Quartile 3 (19/102) Quartile 4 (9/112) p-value
Model 1: Age and batch 1 (Ref) 0.60  (0.30, 1.21) 0.58 (0.28, 1.19) 0.24 (0.10, 0.57) <0.01
Model 2: Model 1 + 
BMI, Menopausal 
Status, Histological 
categories
1 (Ref) 0.74  (0.36, 1.55) 0.73 (0.33, 1.60) 0.34 (0.13, 0.86) 0.07
Model 3: Model 2+ 
parity, alcohol 1 (Ref)
0.79  
(0.38, 1.66) 0.79 (0.36, 1.75) 0.34 (0.13, 0.86) 0.06
Outcome is predominant type 1/no type 3 lobules (complete involution)
These associations persisted, though were slightly attenuated, in 
models adjusting for additional potential confounders. Conclusion: 
Higher IGF-1 levels and greater IGF-1/IGFBP-3 ratios are associated 
with a decreased risk of predominant type 1 lobules/no type 3 lobules 
among women with BBD in the NHSII. Whether this association 
contributes to the mechanism by which IGF-1 confers an elevated 
breast cancer risk requires further investigation.
Acknowledgements: This work was supported by T32 CA09001-35
CA124865, R01 CA050385, and the Breast Cancer Research 
Foundation
P4-11-03
Prognosis of Pregnancy-Associated Breast Cancer: A Meta-
Analysis Involving 39,415 Patients.
Azim, Jr HA, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis 
N, Peccatori FA. Institut Jules Bordet, Brussels, Belgium; European 
Institute of Oncology, Milan, Italy; University of Ioannina, Ioannina, 
Greece
Background: Pregnancy-associated breast cancer (PABC), defined 
as breast cancer diagnosed during pregnancy or one year after is a 
relatively rare disease and hence considerable controversy exists 
regarding its prognosis compared to non-pregnancy-related breast 
cancer.
Methods: Two of the authors independently performed a literature 
search on MEDLINE and Cochrane Library with no date or language 
restrictions. Eligible studies were control-matched, population-based 
and hospital-based studies that have addressed the outcome of patients 
diagnosed during pregnancy or one-year afterwards. The control 
group was defined as patients diagnosed with breast cancer not related 
to pregnancy. The primary and secondary end-points were overall 
and disease-free survival respectively. Pooling of data was done 
using the random effect model. To control for potential differences 
between the two groups in systemic treatment and clinico-pathological 
features (e.g. tumor size, nodal status, ER, etc...) that could affect 
prognosis, we performed a sensitivity analysis by pooling the hazard 
ratios (HRs) of the adjusted multivariate models within each study. 
We also analyzed differences according to time of diagnosis (during 
pregnancy or post-partum), type of study and year of reporting the 
study. Finally, we communicated with the authors of the eligible 
studies to collect unpublished statistics relevant to our analysis to 
further refine our findings.
Results: 29 studies were included in this meta-analysis (2903 
cases and 36, 512 controls). Women diagnosed with PABC had a 
significantly higher risk of death compared to those diagnosed with 
non-pregnancy-related breast cancer (pooled hazard ratio (pHR): 1.47 
[95% CI: 1.30-1.65]). A sensitivity analysis including 11 studies (1222 
PABC cases, 19231 controls) adjusted for differences in tumor size, 
nodal status and systemic treatment showed the same result (pHR: 
1.44 [95% CI: 1.17-1.77]). These findings were consistent in patients 
diagnosed either during pregnancy (pHR: 1.30 [95% CI: 1.01-1.67]) 
or in the post-partum period (pHR: 1.56 [95% CI: 1.08-2.26]) with 
no heterogeneity observed (p=0.43). Sensitivity analyses according 
to the type and year of study showed the same findings. Regarding 
the secondary end-point, only ten studies (531 cases, 1842 controls) 
provided sufficient information to estimate disease-free survival, 
and indeed PABC patients had a higher risk of relapse compared to 
breast cancer controls [pHR: 1.59 (95%CI: 1.23-2.07)]. Collection 
of unpublished data is currently ongoing and further analyses will be 
presented at the meeting.
Conclusion: To the best of our knowledge, this is the largest analysis 
addressing the prognosis of PABC. Our results confirm that PABC is 
independently associated with a worse prognosis whether diagnosis is 
made during pregnancy or in the post-partum period. This underscores 
the possible impact of pregnancy on breast cancer biology. In this 
regard, we are currently interrogating potential biological differences 
between PABC patients and matched breast cancer controls at the 
gene expression level to elucidate the biology of this relatively rare, 
yet very challenging disease.
P4-11-04
Risk of Primary (PBC) and Contralateral Breast Cancer (CBC) 
after Ovarian Cancer (OC) in BRCA1 and BRCA2 Mutation 
Carriers; Implications for Surveillance and Risk Reducing 
Mastectomy.
Seynaeve C, Vencken P, Hooning M, Menke-Pluymers M, Heemskerk-
Gerritsen A, Van Doorn L, Collee M, Jager A, Van Montfort K, 
Burger C, Kriege M. Erasmus MC - Daniel den Hoed Cancer Center, 
Rotterdam, Netherlands
Background
In view of the increased risk of developing breast (BC) cancer, BRCA 
mutation carriers are offered intensive surveillance or risk reducing 
mastectomy (RRM) and/or salpingo-ovariectomy (RRSO). It is 
insufficiently clear how to counsel mutation carriers who have been 
treated for OC, and it may be questioned whether RRM is indicated. 
It is possible that BC risk, both of primary (PBC) and contralateral 
BC (CBC), may be modified by the treatment given for OC mostly 
including surgery and platinum-based chemotherapy. Further, the 
BC risk has to be weighted against the risk of death after OC. So 
far, there are no data available on the PBC or CBC risk after OC in 
BRCA mutation carriers.
Patients and Methods
From the database of the institutional Family Cancer Clinic (FCC), 
we selected BRCA-associated OC patients either without (n= 79, at 
risk of PBC) or with a history of unilateral BC (n=37, at risk of CBC). 
Controls were BRCA mutation carriers without OC, either without 
(n=351) or with a history of unilateral BC (n=294). Follow-up started 
at OC diagnosis, and for controls at date of first visit at the FCC or 
the 35th birthday. Exclusion criteria were: other malignancy besides 
epithelial OC or BC, inadequate follow-up data, bilateral breast cancer 
or mastectomy. Data analyses were performed using t- and chi-squared 
tests, and Kaplan-Meier survival method with death prior to BC as 
competing risk event.
Results 
Only six OC patients (5.1%) did not receive chemotherapy as part of 
primary therapy for OC, five at risk of PBC and one at risk of CBC. 
Chemotherapy schedules were mainly platinum-based (92%). RRSO 
was performed in 45% of the controls.
The risks of PBC at 2, 5, and 10 years in BRCA-associated OC 
patients were 3%, 6% and 11%, respectively, versus 6%, 16% and 
28% in unaffected BRCA mutation carriers (p=0.03). The mortality 
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rate at those time points in the OC group was 13%, 33% and 61%, 
respectively, versus 1%, 2% and 2% in unaffected mutation carriers 
(p<0.001).
In patients with a history of unilateral BC, the risks of CBC at 2, 
5, and 10 years in OC patients were 0%, 7% and 7%, respectively, 
versus 6%, 16% and 34% in the BC patients without OC (p=0.06). 
The mortality rate at similar time points was 19%, 34%, and 55%, 
respectively, in the OC group versus 4%, 11%, and 21% for the non-
OC patients (p<0.001).
Conclusions
The risk of developing a PBC or CBC was much lower in BRCA 
mutation carriers with a history of OC than in mutation carriers 
without OC. Also, since the 10-year mortality rate after ovarian 
cancer was 55-60% and the risk of developing a PBC or CBC at 
the highest was 11% over the same time period, our data suggest 
that intensive breast cancer surveillance strategies for the BRCA-
associated ovarian cancer group might be reconsidered, while risk 
reducing mastectomy is not indicated unless in specific cases requiring 
careful consideration in a multisciplinary setting. Further studies in 
larger groups are warranted.
P4-11-05
Association between Bisphosphonate Use in Metastatic Breast 
Cancer (MBC) and Overall Survival.
Mathew A, Mathew IE, Rosenzweig MQ, Brufsky AM. University of 
Pittsburgh Medical Center; University of Pittsburgh Cancer Institute; 
Magee-Womens Hospital
Background: Pre-clinical studies on bisphosphonates in breast cancer 
have suggested an anti-tumor effect in addition to its bone protective 
role. However, randomized controlled trials of bisphosphonates versus 
placebo have found little evidence of increased overall survival (OS) 
in MBC. We conducted a retrospective single institution cohort study 
of MBC patients to evaluate the association between bisphosphonate 
use and overall survival.
Methods: Baseline demographic and tumor specific data were 
collected on newly diagnosed MBC patients between January 1998 
and December 2009. Other variables included the number and 
sites of each metastasis, use of baseline neoadjuvant and adjuvant 
chemotherapy, and use of hormonal therapy. Bisphosphonate use 
was defined as present if it was administered for a period of at least 
3 months in the metastatic setting. Overall survival was determined 
from the date of diagnosis of first metastatic disease. Survival analysis 
was performed using the Kaplan-Meier method and Cox proportional-
hazards model.
Results: Data were available on 737 patients with MBC, of whom 434 
died during a median follow-up of 2 years; median age was 50.3 years. 
92% of patients were Caucasian; 32% were both ER and PR-negative; 
and 31% were HER2-positive. Over 67% of MBC patients had bone 
metastasis and nearly 80% received bisphosphonates. Multivariate 
analysis found an overall survival benefit for bisphosphonate use, with 
a hazard ratio of 0.63 (95% confidence interval: 0.48-0.84; p<0.002), 
when adjusted for variables with significant effect on survival on 
univariate analysis and other known prognostic variables. These 
variables include age, stage at diagnosis, race, hormone receptor 
status, HER2 status, and number of metastatic sites, presence of 
bone metastasis and the use of adjuvant therapy. The administration 
of adjuvant therapy did not yield a significant survival advantage in 
the analyses.
Conclusion: This retrospective cohort study provides evidence for 
an OS benefit with the use of bisphosphonates in MBC even after 
controlling for other significant prognostic factors.
P4-11-06
Uptake of Selective Estrogen Receptor Modulators and Other 
Breast Cancer Prevention Strategies among High-Risk Women 
Seen in a Breast Center.
Reimers LL, Campbell J, Hershman D, Greenlee H, Terry MB, 
Maurer M, Kalinsky K, Jayasena R, Sandoval R, Alvarez M, Crew 
KD. Columbia University Mailman School of Public Health, New 
York, NY; Columbia University College of Physicians and Surgeons, 
New York, NY; Columbia University, New York, NY
Background: Selective estrogen receptor modulators (SERMs), 
tamoxifen and raloxifene, are FDA-approved for breast cancer (BC) 
risk reduction. However, uptake has been poor in the prevention 
setting, partly due to a lack of knowledge in the medical community 
about BC prevention and public misconceptions about the risks of 
SERMs. We assessed demographic and clinical factors that influence 
SERM uptake among high-risk women seen in an academic breast 
center, where specialized risk counseling is provided by a breast 
surgeon or medical oncologist.
Methods: Potential subjects included high-risk women seen for an 
initial consultation by Breast Surgery or Medical Oncology. Eligibility 
for SERM use included a 5-year Gail risk ≥1.67%, lobular carcinoma 
in situ (LCIS), BRCA mutation carrier, or estrogen receptor (ER)-
positive and/or progesterone receptor (PR)-positive ductal carcinoma 
in situ (DCIS). Demographic and BC risk factor data was collected 
from self-administered questionnaires. Clinical data, including 
prior/current SERM use, was abstracted from medical chart review. 
Differences in distribution of risk factors, between women who ever 
took a SERM and those who did not, were examined using chi-square 
statistics or Fisher’s exact test. Multivariable logistic regression 
models were used to calculate odds ratios (OR) and 95% confidence 
intervals using SERM use as the dependent variable.
Results: Among 247 high-risk women enrolled between March 
2007 and January 2011, median age 51 (17-82); White/Hispanic/
Black/Asian (%): 55/32/7/6. 85% of women were undergoing annual 
mammography, 94% had a breast biopsy, 19% genetic testing, and 
71% Medical Oncology referral. Among 181 (73%) women eligible 
for a SERM, Gail risk ≥1.67%/LCIS/DCIS/BRCA mutation (%): 
35/22/39/3; 83 (46%) ever took a SERM, including 62 on tamoxifen 
and 21 on raloxifene. Early SERM discontinuation was only 7%. 
In multivariable analysis, significant predictors of SERM uptake 
included risk category (DCIS vs. Gail risk ≥1.67%/LCIS/BRCA 
mutation), higher income, higher body mass index (BMI), and referral 
to Medical Oncology. In terms of this high-risk population meeting 
American Cancer Society (ACS) behavioral guidelines for cancer 
prevention, 53% had a BMI <25 kg/m2, 44% consumed ≤1 alcoholic 
beverage per day, and 10% engaged in ≥4 hours of moderate physical 
activity per week; only 3.5% met all 3 recommendations.
Conclusions: Among high-risk women seen at a specialized breast 
center, application of clinical recommendations such as screening 
mammography, genetic testing, and SERM uptake were relatively 
high, suggesting that a comprehensive approach to the management 
of high-risk women is feasible. However, meeting ACS nutrition 
and physical activity guidelines for cancer prevention was limited, 
perhaps due to a lack of reimbursable staff to implement these 
guidelines. Breast cancer risk assessment and available interventions 
for prevention among high-risk women are underutilized in the U.S. 
Future studies should focus on the development and delivery of breast 
cancer prevention strategies.
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Feasibility and Acceptability of Offering Breast Cancer Risk 
Estimation in the Context of the UK National Health Service 
Breast Cancer Screening Programme: A New Paradigm for 
Cancer Prevention.
Evans DGR, Astley S, Stavrinos P, Sahin S, Ingham S, McBurney H, 
Eckersley B, Wilson M, Beetles U, Harvie M, Warren R, Sergeant 
J, Hufton A, Warwick J, Newman W, Buchan I, Cuzick J, Howell 
A. University Hospital of South Manchester, Manchester, United 
Kingdom; University of Manchester, Manchester, United Kingdom; 
Central Manchester Foundation Trust, Manchester, United Kingdom; 
Queen Mary University London, London, United Kingdom
Background: Currently there are no real attempts internationally 
to tailor breast screening programmes to individual risk Methods: 
We have assessed the feasibility of collecting breast cancer risk 
information during routine mammographic screening in the National 
Health Service Breast Screening Programme (NHSBSP) in England, 
in order to consider, ultimately, adapting the screening interval to 
risk of breast cancer and introducing preventive strategies in women 
at high risk. The study Predicting Risk Of Cancer At Screening 
(PROCAS) aims to recruit 60,000 women over 3 years. Results: 
26,000 women (June 8th 2011) have so far given consent to join 
the study. Thirty six percent of the first 20,000 women in nineteen 
screening sites in Manchester consented to enter the study and 
completed a risk factor questionnaire. The median 10 year breast 
cancer risk was 2.65%, with 926 (9.26%) of the first 10,000 women 
having a 10 year risk of ≥5% and 92 (0.92%) having a 10 year 
risk of ≥8% (Tyrer-Cuzick), IQR:1.35. 832 (8.32%) women had a 
mammographic density of 60% or greater (Visual Analogue Scale). 
We collected saliva samples from 1019 women for genetic analysis 
and will extend this to 18% of participants. Of those who agreed to 
participate in the study, 94% indicated that they wished to know their 
breast cancer risk. Women with a 10-year risk of ≥8%, and women 
with a 10-year risk of ≥5% and mammographic density ≥60% were 
invited to attend or be telephoned to be counselled. To date 138 have 
accepted with 135, so far, having received risk counselling. Nineteen 
percent of the high-risk women identified subsequently decided to 
enter a randomised breast cancer prevention study with either a dietary 
or drug intervention (IBIS2, anastrazole vs placebo). Results from 
the first 1,000 women who provided DNA samples suggest that the 
risk information from the 18 validated SNPS may enhance existing 
risk models. Conclusion: This study demonstrates that it is feasible to 
determine individual breast cancer risk and offer women appropriate 
risk-reducing interventions within the context of a population-based 
mammographic screening programme.
P4-11-08
Changes in the Distribution of Loco-Regional and Distant Breast 
Cancer Recurrences over the Last 20 Years: Implications for 
Patient Care and Future Research.
Bouganim N, Clemons M, Amir E. The Ottawa Hospital Cancer 
Center, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, 
ON, Canada
Introduction: Improvements in adjuvant therapy have led to a 
sustained fall in recurrences after early breast cancer. The differential 
reduction of both local-regional and systemic recurrences is poorly 
understood. This study aimed to explore changes in the distribution 
of loco-regional and distant recurrences in clinical trials reported over 
the last 20 years. We also aimed to determine the relative impact of 
adjuvant chemotherapy and endocrine therapy.
Methods: A MEDLINE search for adjuvant, Phase III randomized 
breast cancer clinical studies between January 1990 and March 
2011 was performed. Neo-adjuvant, single agent biologics and 
studies that did not report the proportion of loco-regional and distant 
recurrences were excluded. Change in the frequency of recurrences 
was assessed as the non-parametric correlation between the number 
of loco-regional recurrences (as a proportion of all recurrences) and 
time. Studies were weighted by sample size. Pre-specified subgroup 
analyses were assessed using the interaction test and included type of 
surgery performed, radiotherapy use, menopausal status and type of 
systemic therapy delivered. Definition of local and distant recurrences 
differed between studies. For consistency, loco-regional recurrences 
were classified as recurrences limited to the ipsilateral breast, chest 
wall, axillary, supraclavicular and internal mammary lymph nodes. 
Any other recurrence was defined as distant, with the exception of 
contralateral breast cancer; that was excluded from this analysis.
Results: Fifty-three randomized clinical trials with a total of 86,598 
patients were included in the analysis. Between 1990 and 2011, 
the proportion of loco-regional recurrences has decreased from 
approximately 50% to 10% (Spearman’s rho = -0.40, p<.001). 
There was no interaction between type of surgery (mastectomy 
vs. lumpectomy, p=0.40), adjuvant radiotherapy use (p=0.63) and 
menopausal status (p=0.95) and the correlation of loco-regional 
recurrences and time. Chemotherapy use showed a larger negative 
correlation compared with endocrine therapy (rho = 0.49 vs rho = 
0.24, p=0.008).
Conclusion: Advances in treatment of early breast cancer have 
differentially reduced the proportion of loco-regional recurrences 
compared with distant recurrences. In recent trials, loco-regional 
recurrences account for less than 10-15% of all recurrences. These 
falling event rates may affect patient care, especially when deciding 
on treatments influencing loco-regional control. This change may also 
impact on the design of clinical trials assessing loco-regional therapy 
such as surgery and/or local radiation therapy.
P4-11-09
Polymorphisms Related to Steroid Hormone Concentrations in 
Nipple Aspirate Fluid (NAF).
Lee O, Chatterton RT, Shidfar A, Wang J, Scholtens D, Khan SA. 
Northwestern University, Chicago, IL
Background: The steroid hormone concentrations in NAF are 
variable, and differ significantly from systemic levels. Single 
nucleotide polymorphisms (SNPs) in genes associated with the 
metabolism of estradiol (E2) to 4-hydroxyestradiol (CYP1B1) and 
a transporter of steroid sulfate uptake (SLCO2B1) may partially 
determine the steroid hormone level in NAF, and thereby contribute 
to breast cancer risk. We determined the relationship between SNPs 
of interest and the measured concentrations of sex steroids in NAF.
Methods: Blood samples of 263 women at high risk of breast cancer 
who produced NAF were extracted for gDNA, and 40 ng of gDNA 
was used to determine the presence of the selected SNPs or their 
wild type genes in all subjects by the Taqman Drug Metabolism 
genotyping assays (Applied Biosystems). The concentrations of six 
steroid hormones, estradiol(E2), estrone (E1), progesterone (P4), 
testosterone (T), androstenedione (A4), and dehydroepiandrosterone 
(DHEA), from NAF were measured by immunoassay procedures after 
extraction and purification by High Pressure Liquid Chromatography. 
Comparisons of NAF steroid hormone concentrations were made 
for the polymorphism and wild type groups using the nonparametric 
Mann-Whitney tests (significance p < 0.05, two-tailed).
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Results: 46% of the subjects carried the V432K polymorphism of 
CYP1B1 (rs 1056836, C>G), and 45% of the subjects carried the 
S486F polymorphism of SLCO2B1 (rs 2851069, C>T). All NAF 
hormone concentrations are represented as a median with the quartile 
range (25%, 75%). The NAF P4 levels of the V432K mutation 
carriers of CYP1B1 were significantly lower than those of subjects 
with the wild type alleles: 3.54(1.62, 8.79) ng/mL and 7.65(2.13, 
27.77) ng/mL, respectively (p = 0.002). Those with the S486F 
polymorphism of SLCO2B1 had significantly higher E1 levels than 
the wild type subjects: 0.35(0.14, 1.12) ng/mL and 0.25(0.11, 0.59) 
ng/mL, respectively (p = 0.026) and significantly lower P4 levels: 
3.77(1.71, 11.53) ng/mL and 6.65 (2.34, 22.24) ng/mL, respectively 
(p=0.021). In addition, we found that the women carrying both the 
V432K and S486F mutations had significantly lower P4 levels than 
the women carrying only the S486F mutation: 2.43(1.45, 6.67) ng/mL 
and 6.94(2.13, 26.64) ng/mL (p=0.013). No associations were found 
between the other hormones and these polymorphisms.
Conclusions: The anticipated effects of CYP1B1 in increasing 
clearance of E2 and E1 were not observed. Instead, NAF E1 
concentrations were significantly increased. In subjects with the 
S486F polymorphism of SLCO2B1 the expected decrease in E1 
and E2 in NAF was not observed; nor was the DHEA concentration 
decreased. These expectations were based on the reported lower 
activity of the S486F gene product. The decreased concentrations 
of NAF P4 associated with both polymorphisms are difficult to 
explain. Additional studies are required to understand the observed 
associations, but these findings raise the possibility that low P4 levels 
in NAF may be genetically determined, and suggest the hypothesis 
that this polymorphism may be related to a decreased risk of breast 
cancer.
P4-11-10
Perceptions, Knowledge and Satisfaction with Contralateral 
Prophylactic Mastectomy among Young Women with Breast 
Cancer.
Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, 
Troyan S, Morrow M, Schapira L, Come S, Winer E, Partridge AH. 
Dana- Farber Cancer Institute, Boston, MA; Massachusetts General 
Hospital, Boston, MA; Memorial Sloan-Kettering Cancer Center, 
New York, NY; Beth Isreal Deaconess Medical Center, Boston, MA
Background: There has been an increasing prevalence of contralateral 
prophylactic mastectomy (CPM), particularly among younger women 
with breast cancer. There has been limited research evaluating patient 
preference, knowledge and decision-making regarding this issue.
Methods: We surveyed women who had bilateral mastectomy who 
were enrolled in a multicenter, longitudinal cohort study of women 
diagnosed with breast cancer at age 40 and younger. The CPM survey 
included 23 items on decision making, knowledge, and satisfaction 
with CPM.
Results: Of the 550 patients enrolled as of November 2010, 157 
(28.5%) had bilateral mastectomy, of whom 124 completed the CPM 
survey (response rate 79%). Women with bilateral breast cancer (3) 
or bilateral prophylactic (1) indications for surgery were excluded. 
Median age at diagnosis was 37 years (range 26-40); 26 women 
(21%) reported having a genetic mutation (21 BRCA1 and 5 BRCA2). 
Excluding mutation carriers, women estimated that a median of 10 of 
100 women (range 0-90) would develop contralateral breast cancer in 
the 5 years after unilateral breast cancer treatment and that 5 of 100 
women (range 0 - 98) treated with CPM would develop contralateral 
breast cancer. Eighteen percent of all respondents believed that 
women who undergo bilateral mastectomy live longer. Women were 
asked the importance of potential reasons for undergoing CPM (see 
Table 1). Eighty-two percent of women were “extremely confident” 
in their decision to undergo CPM and 92% would “definitely” still 
choose CPM.
Table 1: Importance of reasons for choosing CPM
 
Extremely/
Very 
Important
Somewhat 
Important
Not at all 
Important
Not Sure Missing
 N (%) N (%) N (%) N (%) N (%)
Decrease chance of CBC 117 (98) 1 (1) 1 (1) - 1 (1)
Peace of mind 113 (94) 5 (4) 1 (1) 1 (1) -
Extend life 111 (93) 3 (3) 6 (5) - -
Feeling at increased risk of CBC 106 (88) 8 (7) 5 (4) 1 (1) -
Prevent metastasis 103 (86) 6 (5) 11 (9) - -
Cosmetic symmetry 71 (59) 32 (27) 17 (14) - -
Worry that screening wouldn’t work 61 (51) 30 (25) 26 (22) 3 (3) -
Strong family history 44 (37) 10 (8) 57 (47) 2 (2) 7 (6)
Follow doctor recommendation 40 (33) 33 (28) 44 (37) - 3 (3)
Cosmetic improvements 35 (29) 29 (24) 53 (44) 3 (3) -
Known genetic mutation 32 (27) 2 (2) 72 (60) 4 (3) 10 (8)
Abnormal mammogram before surgery 18 (15) 6 (5) 82 (68) 5 (4) 9 (8)
Advice from family/friends 17 (14) 40 (33) 61 (51) - 2 (2)
Abnormal MRI before surgery 12 (10) 3 (3) 88 (73) 6 (5) 11 (9)
Abnormal ultrasound before surgery 11 (9) 4 (3) 90 (75) 6 (5) 9 (8)
Cancer in other breast before surgery 10 (8) 1 (1) 94 (78) 5 (4) 10 (8)
Prior radiation to chest 3 (3) 4 (3) 95 (79) 7 (6) 11 (9)
CBC= Contralateral breast cancer. 
Conclusion: Young women with breast cancer have high rates of CPM. 
Many young women who have undergone CPM overestimate the risk 
of contralateral disease and the benefits of CPM, including believing 
that CPM will prevent metastasis and extend life. Interventions to 
counsel young women with early breast cancer to help them make 
optimal surgical treatment decisions are needed.
P4-11-11
Thyroid Disease Is Associated with Breast Cancer: A Meta-
Analysis.
Hardefeldt PJ, Eslick GD, Edirimanne S. The University of Sydney, 
Sydney, NSW, Australia; Nepean Hospital, Penrith, NSW, Australia
Background: The controversial relationship between benign thyroid 
diseases and breast cancer has been investigated for over 50 years. 
Despite extensive population studies, the results as a whole have been 
inconsistent. The purpose of this study was to collate and analyse 
available data, calculating a pooled odds ratio of the risk of breast 
cancer in patients diagnosed with benign thyroid diseases.
Materials and Methods: Studies were obtained from a database search 
of MEDLINE, EMBASE, PubMed, Current Contents and Google 
Scholar with additional cross checking of reference lists. Inclusion 
criteria required a confirmed diagnosis of a benign thyroid disease, 
reporting of an odds ratio or data to calculate an odds ratio (and 95% 
confidence interval) and the use of an internal control group as the 
comparator. Collated data was assessed for heterogeneity and a pooled 
odds ratio calculated. From 276 citations identified in this search, a 
total of 28 studies were identified meeting our inclusion criteria. No 
language restrictions were used in the search or study selection. All 
data were analysed using a random effects model.
Results: There was significant evidence of an increased risk of breast 
cancer in patients with auto-immune thyroiditis, evident in a pooled 
odds ratio (OR) of 2.92 (95% CI: 2.13-4.01). No heterogeneity was 
present (I²=0, p=0.62) and there was no publication bias (p=0.15). In 
addition, the results supported an increased risk associated with the 
presence of anti-thyroid antibodies (OR 2.02, 95% CI: 1.63-2.50) and 
goitre (OR 2.19, 95% CI: 1.44-3.33). Moderate but non-significant 
heterogeneity was present in the analysis of goitre (I²=49.2, p=0.08), 
while the risk of publication bias was not signigicant (p=0.08). In 
the analysis of antibody presence, moderate and non-significant 
heterogeneity was evident (I²=58.3, p=0.08) with no publication bias 
(p=0.07). Subgroup analysis of antibody presence revealed increased 
risk associated with both anti-TPO (OR 2.64, 95% CI: 1.82-3.83) 
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and anti-Tg antibodies (2.71, 95%CI: 1.58-4.69). No heterogeneity 
was present in the analysis of either subgroup evident in an I² index 
of 29.3 (p=.22) and 18.1 (p=0.30), respectively. Publication bias 
was not significant (p=0.53 and 0.17). Quantitative analysis of 
hypothyroidism and hyperthyroidism was not significant, evident in 
pooled odds ratios of 1.56 (95% CI: 0.78-3.12) and 1.56 (95% CI: 
0.84-2.88), respectively. Heterogeneity was high in hypothyroidism 
(I²=80.9, p=0.001) yet minimal in hyperthyroidism (I²=0, p=0.75). 
Publication bias was not significant in either hypothyroidism (p=0.06) 
or hyperthyroidism (p=0.20).
Conclusion: While these results indicate a link between thyroid auto-
immunity and breast cancer, further prospective studies are required 
to definitively prove causality.
P4-11-12
Molecular Phenotype of Breast Cancers in a Large Cohort of 
Young Women According to Time Interval Since Pregnancy.
Collins LC, Gelber S, Marotti JD, Cole K, Kereakoglow S, Ruddy KJ, 
Brachtel EF, Schapira L, Come SE, Borges VF, Schedin PJ, Warner 
E, Winer E, Partridge A. Beth Israel Deaconess Medical Center, 
Boston; Harvard Medical School, Boston; Dana Farber Cancer 
Institute, Boston; Dartmouth-Hitchcock Medical Center, Lebanon, 
Hanover, NH; Brigham and Women’s Hospital, Boston; Massachusetts 
General Hospital, Boston; University of Colorado Cancer Center, 
CO; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
Background: The increase in breast cancer risk during pregnancy and 
post partum is well recognized. The cross-over to protective effect 
does not occur until many years later and varies with age at first birth. 
Recently, a genomic signature specific to the pregnant compared 
with the non-pregnant breast has been identified; this signature 
remains present in the postmenopausal parous breast. Given this, 
we investigated whether time interval since pregnancy affects the 
phenotype of breast cancers arising in young women compared with 
nulliparous women. Methods: We examined molecular phenotype, 
according to histologic grade and biomarker status, in relation to time 
since pregnancy in an ongoing prospective cohort study (n=355) of 
young women (<40yrs) with breast cancer. Medical records were 
reviewed for tumor stage and receptor status. Parity was ascertained 
from questionnaires completed within 9 months of diagnosis. Tumor 
grade was determined by central pathology review. Using tumor grade 
and biomarker expression, cancers were categorized as luminal A 
(ER+ and/or PR+, HER2-, histologic grade 1 or 2); luminal B ( ER+ 
and/or PR+, HER2+, or ER and/or PR+, HER2- and grade 3); HER2 
type (ER-, PR-, HER2+); and triple negative (ER-, PR-, HER2-). 
Results: The median age of the study population is 37 years (range 
17-40). Overall, 80% of women had stage 1 or 2 disease; 67% of 
cancers were ER positive and 32% showed HER2 overexpression. The 
distribution of breast cancer molecular phenotypes by time interval 
since last pregnancy is shown in the table.
Distribution of molecular phenotype by interval between last pregnancy and diagnosis
Molecular Phenotype
Nulliparous 
N=129 (36%)
<= 2 years  
N=51 (14%)
>2-5 years  
N=78 (22%)
>5 years  
N=97 (27%)
Total  
patients 
N=355
Luminal A (ER/PR+, HER2-,  
grade 1 or 2) 52 (40) 13 (25) 20 (26) 33 (34) 118 (33)
Luminal B (ER/PR+, HER2+  
or ER/PR+, HER2-, grade 3)
46 (36) 20 (39) 27 (35) 33 (34) 126 (35)
HER2 type (ER-, PR-, HER2+) 9 (7) 6 (12) 14 (18) 9 (9) 38 (11)
Triple negative 22 (17) 12 (24) 17 (22) 22 (23) 73 (21)
Tumor grade 3 66 (51) 32 (63) 46 (59) 50 (52) 194 (55)
Percents omit missing data
In our large cohort of parous young women, we found no differences 
in the distribution of molecular phenotype according to time interval 
since pregnancy. However, nulliparous young women were more 
likely to develop luminal A cancers compared to parous women 
(40% vs. 29%; unadjusted chi square p-value=0.03) and appeared 
less likely to develop HER2-type and triple negative cancers (7% vs. 
13%, p-value=0.09 and 17% vs. 23%, p-value=0.22 respectively). 
There were no differences in the distribution of luminal B cancers. 
Conclusions: The distribution of molecular phenotypes is similar 
among parous young women regardless of the time interval since 
parturition. Nulliparous young women appear more likely to develop 
luminal A cancers compared to parous women. Whether the difference 
in molecular phenotypes of pregnancy-associated breast cancers vs. 
cancers arising in nulliparous women is due to the effects of genomic 
alteration remains to be investigated. Effects of a prior pregnancy 
appear consistent across a 5-year period, in keeping with the concept 
of genomic alterations identified in the normal pregnant breast and 
thereafter.
P4-11-13
Influence of Two Years of Exemestane on Bone Mineral Density in 
Postmenopausal Women at Increased Risk of Developing Breast 
Cancer; a Companion Study to the NCIC CTG MAP.3 Trial.
Goss PE, Richardson H, Ingle JN, Chlebowski RT, Fabian CJ, Garber 
JE, Sarto GE, Hiltz A, Tu D, Cheung AM. Massachusetts General 
Hospital Cancer Center, Boston, MA; Queen’s University, Kingston, 
ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical 
Research Institute, Torrance, CA; University of Kansas Medical 
Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; 
Center for Women’s Health and Health Research, Madison, WI; 
General Hospital, Toronto, ON, Canada
Background: Exemestane significantly reduced invasive and pre-
invasive breast cancers in postmenopausal women at increased risk for 
breast cancer in the NCIC CTG MAP3 trial with no serious toxicities, 
including excess fractures or osteoporosis.
Purpose: To provide additional information on the effect of 
exemestane on bone loss in women at high risk for breast cancer, 
within a subset of women participating on the NCIC CTG MAP.3B 
study. The primary hypothesis is that exemestane does not induce 
clinically significant bone loss in postmenopausal women at increased 
risk of developing breast cancer at 2 years. The primary objective 
of this companion study is to examine the effect of exemestane on 
lumbar spine and total hip BMD by DEXA at 2 years in women 
participating in the MAP3 trial.
Methods: The MAP.3B bone sub-study registered women from the 
main MAP.3 trial from May 2008 to March 2010. Eligible women had 
to have an acceptable quality BMD scan by DEXA taken within 12 
months prior to randomization to MAP.3. A BMD T-score >-2.0 SD 
(i.e. better than 2 standard deviations below the average peak BMD 
of a young adult woman) was established as the study population cut-
off. A questionnaire including information on height, falls, fractures, 
lifestyle information including physical activity, tobacco and alcohol 
use was completed at baseline, 12 months, 24 months and at last visit. 
Fasting serum for bone biomarkers was collected at 12 months and 
total hip and L1-L4 (postero-anterior) spine BMD were measured 2 
years after randomization on the same Lunar or Hologic scanner. The 
primary objective was to determine differences in hip and spine BMD 
at 2 years. Secondary outcomes include number of skeletal fractures 
and development of osteoporosis 2 years after randomization and 
changes in bone biomarkers at 1 year after randomization. For the 
analysis of the primary endpoints, the upper limit of a one sided 95% 
confidence interval for the difference in mean percentage changes 
between placebo and exemestane will be calculated for the BMD by 
DEXA at each site. We will conclude that exemestane does not induce 
significant bone loss in postmenopausal women at increased risk of 
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developing breast cancer at 2 years when the upper limit is less than 
3% for both sites. Similar confidence interval approach will be used 
to analyze the secondary endpoints.
Results: Between May 2008 and March 2010, 238 postmenopausal 
women were recruited. Median age was 61.8 years, and the majority 
of women were Caucasian (91%), with approximately 20% of the 
participants reporting a recent fall (within past 12 months) and another 
13% reporting a recent fracture prior to randomization. We will report 
results from the primary as well as the secondary endpoints at the 
SABCS meeting.
P4-11-14
Number Needed To Treat (NNT) as a Measure of Incremental 
Drug Benefit: Denosumab vs. Zoledronic Acid for the Prevention 
of Skeletal Related Events (SREs) in Advanced Breast Cancer.
Dranitsaris G, Kaura S. Augmentium Pharma Consulting, Toronto, 
Canada; Novartis Pharmaceuticals, NJ
Background: Intravenous zoledronic acid (ZOL) is the standard of 
care for the prevention of SREs in advanced breast cancer. However, 
monthly subcutaneous denosumab (Dmab) was recently approved 
in the US, as an alternative to ZOL based on the results of a large 
randomized trial which demonstrated a prolongation in median time 
to first SRE (HR = 0.82, p = 0.01) and a 5.8% (p = 0.01) absolute 
reduction in SREs in favour of Dmab over the 34 month study period. 
The challenge for clinicians and payers is how to reconcile the modest 
benefits of Dmab with the cost, which is approximately twice that of 
ZOL. NNT represents the number of patients that need to be treated 
with a new intervention in order to avoid one additional event, and is 
a widely accepted approach used to make sense of numerical results 
from clinical trials. In this analysis, the NNT approach was used to 
assess the incremental benefit of Dmab over ZOL for the prevention 
of SREs in advanced breast cancer.
Methods: The pivotal randomized trial for Dmab vs. ZOL in breast 
cancer (Stopeck, JCO 2010 & US PI 2010) was reviewed. As an 
alternative to ZOL, the NNT with Dmab to avoid any SRE at 12 
and 34 months (trial end) was determined. NNT by type of SRE was 
also estimated. These consisted of pathologic fractures, radiation to 
bone, spinal cord compressions and surgery to bone. The calculated 
NNT represents the incremental benefit provided by Dmab above 
and beyond Zometa therapy.
Results: To avoid a single SRE after 12 months of treatment of 
continuous therapy with Dmab, approximately 36 patients need to be 
treated. To avoid a single fracture and radiation to bone, approximately 
39 and 27 patients need to be treated with Dmab over a 34 month 
period. Dmab was unable to offer any incremental benefit over ZOL 
in terms of avoiding spinal cord compressions or surgery to bone 
after 34 months of treatment.
Discussion: The NNT approach is a simple and effective method to 
express the findings in a clinically meaningful way. In this analysis, 
the incremental benefit of Dmab would only be realized when a 
minimum of 36 patients are treated for 12 months. For the more severe 
skeletal-related events, in terms of clinical and economic burden to 
patients and society, such as spinal cord compression and surgery to 
bone, Dmab did not offer any incremental benefit over ZOL in terms 
of SRE avoidance. This marginal incremental benefit needs to be 
considered alongside the high cost of Dmab.
P4-11-15
Increased Propability of Triple Negative Breast Cancer (TNBC) in 
Premenopausal Patients after Exogenous Hormonal Intake (EHI).
Pistamaltzian NF, Tzavara C, Papadimitriou C, Gyftaki R, 
Tryfonopoulos D, Panopoulos C, Tsoukalas N, Koumakis G, Demiri 
S, Koufopoulos N, Misitzis Y, Apostolikas N, Efremidis A. Agios 
Savvas Cancer Hospital of Athens, Athens, Greece; University of 
Athens, Athens, Greece
Purpose: HRT is a known risk factor for breast cancer (BC) among 
post-menopausal women. Our knowledge in relation to EHI (estrogens 
and/or progestin) and BC among pre-menopausal women is scarce. 
We have studied whether previous EHI influences BC phenotype, 
clinical and pathologic characteristics and correlation with other 
known BC risk factors.
Patients and methods: A prospective analysis (data recorded upon 
patients first presentation) of an electronic database at a tertiary 
cancer centre was performed. Patients’ demographics, risk factors for 
BC (smoking, alcohol use, obesity, family history), clinical profile, 
EHI parameters (duration, cause) and the tumors’ histopathology 
(type, grade,ER/PgR and HER2 by IHC and FISH) were analyzed. 
Premenopausal patients without an EHI history consisted control 
group.
Results: Out of 938 patients treated for BC between 2006 and 2010, 
333(35,5%) were premenopausal and 131(39%) of them reported any 
use of hormones. Median age was identical (43 years,range:20-57) 
among premenopausal patients with and without EHI history. Mean 
duration of use was 28 months (range:1-180). Causes of EHI were 
contraception (35%), pregnancy(17%), menstrual abnormalities(17%) 
and medically assisted fertilization(17%). Smoking, alcohol use and 
obesity didn’t differ among two groups. Family history for BC was 
more common (31, 3% vs. 22,8%, p=0,08)among women with EHI.
No correlation was found among duration of use and the time of 
cancer diagnosis, while the mean time from the cessation of hormones 
to cancer diagnosis was 13 years(range:1-32). Only 18% of breast 
cancers were diagnosed within the first 5 years after exogenous 
hormones cessation.
TNBC was found to be significantly increased among premenopausal 
women with a history for EHI (23,6% vs. 13,4%, p=0,016). This 
increase was independent of the existence of positive family history 
for BC (p=0,61). EHI conferred a twofold increase in the risk for 
a TNBC (OR=1,99 p=0,019). No other clinical or histopathologic 
parameter showed any difference among the two groups.
Conclusion: Prior use of exogenous hormones, for any cause and 
irrespective of the coexistence of other risk factors and family 
history, increases the probability of a triple negative breast cancer 
diagnosis by twofold. Whether this represents a trend of a changing 
epidemiology in the types of BC in prior hormone users vs. non-
users, poses an extremely challenging hypothesis to be verified in 
large epidemiologic studies - given the young age and the treating 
difficulties of this patient population.
P4-11-16
Withdrawn by Author
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Noninferiority (NI) Phase III Trials in Advanced Breast Cancer 
(ABC) over 12 Years.
Saad ED, Militao MS. Dendrix Research, Sao Paulo, Brazil
Background: NI trials have gained increasing importance in 
oncology. The contemporary practice regarding the design features 
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and the results of NI trials have not been formally assessed in ABC.
Methods: We searched PubMed for articles reporting the efficacy 
results of phase III trials on systemic antineoplastic treatments for 
ABC published between 1/1998 and 12/2009 in 11 leading medical 
journals (Ann Oncol, BCRT, BJC, Cancer, CCR, EJC, JCO, JNCI, 
Lancet, Lancet Oncol, and NEJM).
Results: We retrieved 93 reports, 12 of which (13%; 95% CI, 7% – 
22%) had a NI primary hypothesis. Of note, there were no equivalence 
(i.e., two-sided question) studies. There was no significant trend in the 
proportion of NI trials in the two 6-year periods compared (17% vs 
9%; P=0.36). The median (range) sample sizes for NI and superiority 
trials were 404 (160-1354) and 326 (118-907) patients, respectively 
(P=0.32). NI trials enrolled exclusively first-line patients more 
frequently than superiority trials (83% vs 51%; P=0.06). The primary 
endpoint for NI trials was response rate (RR) and progression-free 
survival/time to tumor progression in 8 and 4 cases, respectively. 
Despite their nominally higher number of patients, NI trials were more 
likely than superiority trials to have RR as their primary endpoints 
(67% vs 32%; P=0.03). The NI margin was reported in all trials, 
but justified by authors in only one case. Among trials with RR as 
primary endpoint, the NI margin was 15% in six cases and 25% in 
two. In trials with progression-free survival/time to tumor progression 
as primary endpoints, the lower limit of the confidence interval for 
the hazard ratio to demonstrate NI was always 0.8. Of 12 NI trials, 
9 were positive (i.e., proved NI).
Conclusion: NI trials represent 13% of contemporary phase III 
trials on ABC. Most such trials achieve their primary endpoint. At 
present, NI margins seem to be chosen on historical basis rather than 
on statistical reasoning, and such choice could bear implications on 
trial positivity.
P4-11-18
Mammographic Surveillance in Atypical Hyperplasia of the 
Breast and Subsequent Development of Cancer. A Need for Long 
Term Follow Up.
Koron R, Sridharan U, Mitchell G, Holcombe C. Royal Liverpool 
and Broadgreen University Hospital Trust, Liverpool, Merseyside, 
United Kingdom
Introduction
Atypical hyperplasia of the breast is a known risk factor for breast 
cancer. Despite this risk there are no published guidelines on a 
recommended follow up regime for these patients.
Methods
A retrospective study was carried out on 1920 core biopsy results 
within a major screening breast unit from 2001 to 2005. Patients 
who had a final diagnosis of Atypical Ductal Hyperplasia (ADH), 
Atypical Lobular Hyperplasia (ALH) and Lobular Carcinoma in Situ 
(LCIS) were included.
Information was extracted from multidisciplinary team meeting 
records, departmental data bases, pathology and radiology reports. 
Details of follow up and subsequent cancer diagnosis were noted.
Results
83 patients were diagnosed with ALH, ADH or LCIS from a core 
biopsy. The mean age was 54 years ( range 40-85 years). Seventy six 
(91.6%) of these patients went on to have an excision biopsy. Sixty 
four (77.1%) women have received long term mammographic follow 
up ranging from 5 to 9 years to date. Nineteen patients did not receive 
mammographic surveillance. Of this group 2 patients with LCIS had 
bilateral risk reducing mastectomies and 2 patients died shortly after 
diagnosis with no evidence of breast cancer. Eight patients developed 
breast cancer 3 to 8 years after their initial diagnosis. Of these, four 
patients developed cancer in the same breast that atypia had been 
diagnosed in previously, and four in the contra lateral breast.
Conclusion
12.5 % of patients in the follow up group developed breast cancer 
within 8 years of diagnosis of atypical hyperplasia. A review of the 
literature suggests that in view of the increased risk of subsequent 
breast cancer in this group of women long term follow up is required.
On the basis of these findings we recommend that all patients 
diagnosed with ALH, ADH or LCIS should be entered into an 18 
monthly mammogram surveillance programme for 15 years.
P4-11-19
Healthcare Resource Utilization among Breast Cancer Patients 
with Bone Metastases and Skeletal-Related Events: A Population-
Based Cohort Study in Denmark (1997 - 2009).
Yong M, Christiansen CF, Gammelager H, Sværke C, Chia V, Atchison 
C, Fryzek J. Amgen Inc, Thousand Oaks, CA; Aarhus University 
Hospital, Aarhus, Denmark; Exponent, Alexandria, VA
Background: The healthcare resource utilization (HRU) of breast 
cancer patients who develop bone metastases and skeletal-related 
events (SREs) has not been well-characterized. Our objective was to 
describe the HRU associated with SREs in a large population-based 
cohort of Danish breast cancer patients with bone metastases and 
one or more SRE.
Methods: We identified women diagnosed with incident breast cancer 
from January 1, 1997 through December 31, 2006 using the Danish 
Cancer Registry. We followed this cohort of patients for development 
of subsequent bone metastases and SREs identified through the 
Danish National Registry of Patients through December 31, 2009. 
SREs were defined as pathologic fracture, spinal cord compression, 
and radiation or surgery to bone. Among patients with only one SRE, 
the HRU period, composed of all HRU occurring within a 90-day 
period after the SRE and within a two-week diagnostic period prior 
to the SRE, was assessed. For patients with multiple SREs (each 
one separated by less than 90 days), the HRU period, composed of 
all HRU occurring within a two-week diagnostic period prior to the 
first SRE up until 90 days after the last SRE, was described. Patients 
may have had multiple HRU periods if SREs were separated by more 
than 90 days. The HRU summarized included number of inpatient 
hospitalizations, length of hospitalization stay, outpatient physician 
visits, emergency room visits, and procedures.
Results: We identified 1,148 patients with bone metastases and SREs 
among 38,485 breast cancer patients. The mean age at breast cancer 
diagnosis for those who developed bone metastases and SREs was 59 
years (SD, 13 years) and the majority (72%) of patients had multiple 
SREs during the first HRU period. Approximately 20% to 30% of 
patients with single and multiple SREs, respectively, died within 
the first HRU period. Overall, length of hospitalization was longest 
for patients with spinal cord compression followed by patients with 
pathologic fracture. In general, patients with multiple SREs had higher 
HRU compared to those with a single SRE in the first HRU period, 
particularly in length of hospitalization stay.
Conclusion: SREs secondary to bone metastases are serious events. 
In Denmark, high HRU was observed in all patients with SREs, but 
especially in those with multiple SREs, where increased lengths of 
hospitalization were observed.
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Observational Study of Body Weight Changes and Metabolic 
Syndrome in Breast Cancer Patients Receiving Adjuvant 
Therapy: Characteristics of Dietary Pattern in Korean Breast 
Cancer Patients.
Park JH, Kim S, Kim YN, Kim YJ, Lee K-W, Kim S-W, Kim I, Park 
SY, Park YJ, Choi SH, Kim JH. Seoul National University Bundang 
Hospital, Seongnam
Backgroud: Obesity, postdiagnosis weight gain, and presence of 
metabolic syndrome in breast cancer are reported to adversely affect 
survival among breast cancer survivors. Most of the studies on weight 
gain and metabolic syndrome in breast cancer are from Western 
countries and few information is available on Asian population. We 
designed this prospective observational study to characterize weight 
and metabolic changes during adjuvant treatment in women with early 
breast cancer and to identify factors associated with occurrence of 
metabolic syndrome, focusing on dietary pattern.
Methods: Patients aged 18-75 who underwent curative surgery with 
stage I-III invasive breast cancer were enrolled from 2008 to 2010. We 
measured glucose (FBS), hemoglobin A1c (HbA1c), total cholesterol 
(TC), HDL cholesterol, and triglyceride (TG) level in fasting serum 
samples before starting adjuvant therapy, at 6 months and 12 months 
after enrollment. Body weight, body mass index (BMI), body fat mass, 
and percent body fat at baseline, 6 months, and 12 months were also 
measured. Dietary intake was assessed using valid semi-quantitative 
Food frequency questionnaire (FFQ).
Results: Total of 63 patients were enrolled. Median age of the enrolled 
patients were 48 (range, 25-68), with premenopausal/postmenopausal 
40 (63.5%)/ 23 (36.5%). Fifty (82.0%) and 10 (16.4%) received 
adjuvant chemotherapy followed by hormone therapy and hormone 
therapy alone. Hormone receptor positive (ER+/PR+) and HER2 
positive cancer accounted for 52 (83.9%) and 7 (12.1%). Mean FBS, 
HbA1c, TC, HDL, and TG level was 99.9 mg/dL (range, 83-159), 5.59 
mg/dL (range, 4.8-7.5), 197.4 mg/dL (125-298), 51.9 mg/dL (range, 
30-90), and 119.7 mg/dL (42-371). Mean height, weight, and BMI 
was 158 cm (range, 149-169), 61.7kg (range, 46.2-96.0), and 24.7 
kg/m2 (range, 18.7-35.7), respectively. According to the WHO and 
NIH guidelines for Asian, normal (BMI 18.5-22.9), overweight (BMI 
23-24.9), and obesity (BMI≥25) was 18 (28.6%), 13 (20.6%), and 32 
(50.8%), respectively. Number of patients with metabolic syndrome 
was 18 (34%). Mean BMI (26.1 vs 24.0, p=0.021) and TG (180.6 vs 
92.0, p<0.001) was higher, HDL cholesterol was lower (42.2 vs 57.3, 
p<0.001) in patients with metabolic syndrome. Composition of daily 
calorie intake consisted of 13.5% (range 10.7-21.8) of protein, 6.7% 
(range, 3.3-22.1) of fat, and 70.1% (range, 28.1-79.5) of carbohydrate. 
The presence of metabolic syndrome was associated with a higher 
carbohydrate intake (carbohydrate intake per ideal body weight>6.0) 
(p=0.071). The TG level of patients who indigested high carbohydrate 
was significantly higher (143.8 vs 102.9, p=0.023). The HDL level 
of patients who took high fat diet (>20% of total calorie) was lower 
(45.3 vs 53.5, p=0.045).
Conclusion: In our cohort of Korean breast cancer patients, 34% 
had metabolic syndrome at baseline. Those patients with metabolic 
syndrome consumed higher proportion of carbohydrate, which 
resulted in significantly higher level of TG. Our data suggest that 
composition of calorie intake is different in Asian population 
compared to Western countries, warranting for reappraisal on the 
recommendation on life style modification and diet.
P4-11-21
A Retrospective Analysis of Women at Increased Lifetime Risk 
for Breast Cancer: Referral Patterns to Subspecialty Providers, 
Recommendations and Outcomes.
Ehsani S, Tevaarwerk A, Wilke L, Neuman H, Beckman C, Becker J, 
Stettner A, Strigel R, Szalkucki L, Burkard M, Wisinski KB. University 
of Wisconsin Carbone Cancer Center, Madison, WI
Background: Inheritance of an abnormal BRCA 1/2 gene, a family 
history of breast cancer (BrCa), or a personal history of lobular 
carcinoma in situ (LCIS), atypical hyperplasia, or chest wall 
radiation can significantly increase an individual’s lifetime risk for 
developing BrCa. In 2007, the American Cancer Society (ACS) 
released updated guidelines for screening in women with a lifetime 
risk of BrCa >20-25%. These guidelines added MRI screening to 
annual mammography. The objective of our analysis is to characterize 
patients referred after the release of the 2007 ACS guidelines to 
subspecialty providers specifically for evaluation of BrCa risk and 
analyze subsequent screening and risk reduction recommendations 
in the cohort of patients (pts) with a predicted increased lifetime 
risk for BrCa.
Methods: Pts seen at a single center (University of Wisconsin [UW]) 
between 1/2007-3/2011 by medical, surgical and/or gynecology-
oncology for an increased lifetime risk of BrCa were identified by 
billing codes or evaluation in the UW Breast Cancer Prevention, 
Assessment and Tailored Health Screening (PATHS) Clinic. Pts with a 
personal history of BrCa prior to 1/2007 are excluded. Patients with a 
known genetic predisposition to BrCa, family history of breast cancer, 
or a personal history of LCIS, atypical hyperplasia or chest wall 
radiation are included in this analysis. All charts will be evaluated for 
documentation of the individual’s lifetime risk of BrCa and method 
used for risk-assessment, recommended and performed screening 
tests, concordance with ACS screening guidelines, patient adherence 
to initial and subsequent screening recommendations, and uptake of 
risk reduction strategies. Call-back rates for additional or follow-up 
imaging and/or biopsy following BrCa screening and characteristics 
of all new BrCa diagnoses will be collected.
Results: 240 eligible pts were seen during the study period. 15% of 
pts referred had a known genetic predisposition to BrCa. Most pts 
(75%) were referred for a family history of BrCa. The majority of 
these pts had a predicted lifetime risk of BrCa in excess of 20%, 
with less than 10% of patients being referred having a lifetime risk 
<20%. The remaining pts were referred for a personal history of LCIS, 
atypical hyperplasia or previous radiation to the chest wall. Results 
including subspecialty provider BrCa risk assessment, screening 
and risk-reduction recommendations, patient uptake and adherence, 
outcomes of screening and characteristics of diagnosed BrCa cases 
will be presented.
Conclusion: Pts with a predicted increased lifetime risk for BrCa are 
often evaluated by oncology subspecialty providers. The primary 
factor related to referral is family history of BrCa. The majority 
of patients referred to a subspecialty provider have a calculated 
lifetime risk for BrCa in excess of 20%. This study evaluates provider 
assessment of BrCa risk and subsequent recommendations for 
screening and discussion of risk reduction strategies.
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P4-11-22
Familial History of Cancer among Breast Cancer Women under 
36 yr. in Rio De Janeiro, Brazil.
Koifman S, Ortega GPJ, Koifman RJ. National School of Public 
Health, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, 
RJ, Brazil
Background. Antecedents of familial history of cancer (FHC) have 
been reported as an important feature observed among young women 
with breast cancer (BC). Objective. To explore the distribution of 
FHC in a sample of young women with BC in Brazil. Methods. 
Antecedents of FHC were obtained by a face to face interview carried 
out with 224 BC cases 20-35 yr., and 246 age-frequency matched 
controls, enrolled in a hospital-based case control study carried out 
along 1996-2006 in Rio de Janeiro, Brazil. Unconditional logistic 
regression was performed and BC odds ratios adjusted for age and 
education (adj. OR) were obtained according to FHC characteristics 
(parenthood degree, age of diagnosis and amount of relatives with 
cancer). Results. BC antecedents among 1st degree relatives was 5.4% 
among BC cases and 1.2% of controls (p=0.01). The adj. OR for BC 
among 1st degree relatives was 4.3, 95% CI 1.2-15.8. Comparatively 
to families without BC antecedents, an adj. OR =2.4, 95% CI 1.4-
4.1 was observed for those with 1 reported BC case, and an adj. OR 
= 3.7, 95% CI 1.0 -14.0 for those with 2 or more BC cases (p trend 
=0.0002). A similar trend was verified according to all other cancer 
sites (p-trend < 0.0001). The reported median age of BC diagnosis 
in the 1st generation (proband grand-mothers) was 76 yr., being 45 
yr. at the 2nd generation (proband mothers) , and 38,4 yr. at the 3rd 
(proband sisters). A similar trend along generations was also verified 
for other cancer sites among case relatives, respectively, 69 yr., 58 yr. 
, and 45 yr. The mean age of diagnosis among the cases offspring was 
6.7 yr. (standard deviation, SD = 0.6) and 12.0 yr. (SD = 1.4) among 
the controls descents (p< 0.01). Brain cancer reported among case 
relatives was 6.0 fold higher than among control relatives (3.7 fold 
higher for ovarian cancer, and 3.2 higher for skin cancer). Discussion. 
The observed results reveal that cancer risks among relatives of 
young women with BC are either higher for BC or other selected 
cancer sites. The observed decline along successive generations on 
the age at diagnosis of BC and other tumors is suggestive of recent 
genetic-environmental interaction in the studied sample of young 
women with BC in Brazil.
P4-12-01
The Breast-Activity and Healthy Eating after Diagnosis 
(B-AHEAD) Study – A Randomised Comparison of Weight 
Control Programmes during Adjuvant Treatment.
Harvie M, Pegington M, Bundred N, Campbell A, Wolstenholme J, 
Adams J, Speed S, Morris J, Howell A. Univeristy Hospital of South 
Manchester, Manchester, United Kingdom; University of Dundee, 
United Kingdom; University of Oxford, United Kingdom; University 
of Manchester, United Kingdom; University Hospital of South 
Manchester, United Kingdom
Background: Excess weight at diagnosis and weight gain during 
treatment are linked to increased mortality from breast cancer. Since 
60% of breast cancer patients are overweight at diagnosis and 75% 
gain weight during treatment, weight control should improve outcome 
but the optimal intervention is unknown.
Aim: To compare 3 programmes for weight control after surgery for 
primary breast cancer.
Methods: We have recruited a randomised trial of 2 diet and exercise 
weight control interventions (1. a community based supervised group 
programme, 2. a mail and phone programme) compared to standard 
written advice (control). We are comparing the relative effects of 
the 3 programmes on body weight and composition (by dual energy 
x-ray absorptiometry), cardiovascular risk parameters (lipids, blood 
pressure), a marker of breast cancer prognosis (insulin resistance), 
fitness and quality of life over the first year after diagnosis.
In total 409 women have been randomised (45% of eligible women) 
and 21 women have left the trial (5.1%), 357 have completed the 6 
month assessments, all are due to complete the trial in December 2011.
Results:
Results at 6 months
  
All over- 
weight  
(n = 213)
Chemo- 
therapy  
(n = 73)
No chemo- 
therapy  
(n = 140)
All healthy  
weight  
(n = 144)
Chemo- 
therapy  
(n = 57)
No chemo- 
therapy  
(n = 87)
Weight 
change 
(kg)
Control
-0.5 (-1.6  
to 0.7)
-0.9 (-3.8  
to 1.9)
-0.2 (-1.1  
to 0.7)
1.1 (0.4  
to 1.9)
1.3 (-0.2  
to 2.8)
1.0 (0.2  
to 1.8)
 Mail & phone
-2.1 (-3.1  
to -1.2)
-0.9 (-2.7  
to 0.9)
-2.9 (-4.0  
to -1.7)
-0.1 (-0.9  
to 0.8)
1.1 (-0.5  
to 2.6)
-0.6 (-1.7  
to 0.4)
 Supervised -1.8 (-3.1  to -0.5)
1.2 (-2.0  
to 4.4)
-3.2 (-4.2  
to -2.2)
-0.2 (-1.1  
to 0.7)
0.6 (-1.0  
to 2.2)
-0.8 (-1.8  
to 0.2)
 p 0.089 0.355 0.001 0.038 0.723 0.009
Body fat 
change 
(kg)
Control
-0.5 (-1.2  
to 0.3)
-1.0 (-2.7  
to 0.7)
-0.2 (-0.8  
to 0.5)
0.7 (0.1  
to 1.3)
0.6 (-0.7  
to 1.9)
0.7 (0.0  
to 1.4)
 Mail & phone
-1.7 (-2.4  
to -1.0)
-0.7 (-1.8  
to 0.5)
-2.3 (-3.2  
to -1.5)
-0.3 (-1.0  
to 0.4)
1.1 (-0.1  
to 2.3)
-1.0 (-1.8  
to -0.2)
 Supervised -1.5 (-2.3  to -0.8)
-0.0 (-1.7  
to 1.6)
-2.2 (-3.0  
to -1.5)
-0.4 (-1.0  
to 0.3)
0.5 (-0.7  
to 1.7)
-1.0 (-1.7  
to -0.3)
 p 0.026 0.570 0.001 0.047 0.811 0.001
Mean (95% CI), ANCOVA adjusted for baseline values
Weight and body fat results at 6 months indicate that the low cost 
mail and phone programme is equal to the supervised programme and 
both are significantly superior to written advice, but not in patients 
receiving chemotherapy.
The high uptake and adherence to the trial shows interest and 
motivation of a significant number of cancer patients to make positive 
changes to lifestyle at the time of diagnosis.
The final trial results will be presented at the December meeting.
This abstract presents independent research commissioned by the 
National Institute for Health Research under the Research for Patient 
Benefit programme. The views expressed here are those of the authors 
and not necessarily those of the funding organisations.
P4-12-02
The Association of Anastrozole Adherence and Cognitive Function 
in Breast Cancer.
Sereika SM, Dunbar-Jacob JM, Ryan CM, Adam B, Bender CM. 
University of Pittsburgh, Pittsburgh, PA; University of Pittsburgh 
Medical Center, Pittsburgh, PA
Background: Women with breast cancer experience deterioration 
in cognitive function with adjuvant therapy. Little is known 
about whether declines in cognitive function are associated with 
nonadherence to oral hormonal therapy over time. We investigated 
anastrozole adherence over time and its association with cognitive 
function over the first 12 months of therapy in women with breast 
cancer.
Methods: Using a prospective cohort design, 169 women with early 
stage breast cancer were monitored for 12 months 1) continuously 
for their adherence to anastrozole using electronic event monitoring 
and 2) objectively for cognitive function via a neuropsychological 
battery every 6 months for the first 12 months of hormonal therapy. 
Adherence data were summarized monthly as to the number of doses 
taken as the percentage of prescribed doses taken and the timing of 
doses taken as the percentage of days with correct intake and the 
percentage of doses with correct timing. Six cognitive factors, derived 
via exploratory factor analysis applied to the neuropsychological 
battery, were used for analysis. Data were analyzed using descriptive 
and longitudinal methods.
Results: Participants were white (n=166, 98.2%), well-educated 
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(Mean=15.1 years; SD=2.9, range=10-26) and on average 61.1 
years of age (SD=5.9, range=46-75). Most had stage 1 breast 
cancer (n=123, 72.8%) and were prescribed anastrozole either alone 
(n=110, 65.1%) or immediately after chemotherapy (n=59, 34.9%). 
Initial levels of adherence were fairly high based on number of 
(Mean=89.1, SD=27.1, range=0-111.1) and timing of doses taken 
(Days with correct intake: Mean=86.4, SD=26.8, range=0-100; Doses 
with correct timing: Mean=83.6, SD=29.8, range=0-100); however, 
adherence decreased over the first 12 months of therapy (p<.05) in 
terms of the number of and timing of doses taken and regardless of 
chemotherapy use. Specifically, we found a linear decrease for the 
percentage of prescribed doses taken (linear: t=-2.97, p=.0035); 
however, nonlinear declines were observed for both the percentage of 
days with correct intake (linear: t=-3.33, p=.0011; quadratic: t=2.10, 
p=.0371) and the percentage of doses taken at the correct time (linear: 
t=-3.38, p=.0009; quadratic: t=2.28, p=.0242), suggesting a slowing 
of the rate of decline in adherence related timing of doses for months 
9 through 12. We found that a decrease in executive functioning was 
related to lower percentages of prescribed doses taken (p=.06) and 
doses taken at the correct time (p=.06) from pretreatment to 6 months 
post-anastrozole initiation and even greater evidence (p<.05) from 
pretreatment to 12 months post-anastrozole initiation. From 7 to 12 
months post-anastrozole initiation, we found that a decrease in visual 
learning and memory was related to lower percentages of prescribed 
doses taken (p=.04), days with correct intake (p=.04), and doses taken 
at the correct time (p=.03), while a decrease in attention was related 
to a lower percentage of days with correct intake (p=.04).
Conclusions: These results suggest that breast cancer survivors 
who experience deterioration in cognitive function tend to have 
lower adherence. Efforts should be made to develop interventions 
to compensate for declines in cognitive function and to improve 
anastrozole adherence.
P4-12-03
Post-Diagnosis Weight Gain in Breast Cancer Survivors: When 
Should We Intervene?
Bradshaw PT, Cleveland RJ, Stevens J, Rosamond W, Abrahamson 
PE, Teitelbaum SL, Neugut AI, Gammon MD. University of North 
Carolina at Chapel Hill, Chapel Hill, NC; Mount Sinai School of 
Medicine, New York, NY; Columbia University, New York, NY
Significance. Weight gain after breast cancer diagnosis is common 
and has been linked to poor prognosis. Studies of the etiology and 
longitudinal pattern of post-diagnosis weight gain are limited, yet 
are critical to developing effective prevention strategies to enhance 
survival.. Approach. We investigated the longitudinal pattern and 
determinants of post-diagnosis weight gain among 1,436 breast 
cancer survivors. The population-based cohort included women 
newly diagnosed with a first primary in situ or invasive breast cancer. 
Subjects were interviewed within 6 months of diagnosis and again 
5 years later to ascertain factors related to survival, including self-
reported anthropometric measures. We employed: adjusted random 
effects linear regression to identify factors related to weight change 
during the follow-up; multiple imputation to account for missing 
data; and Wald tests to test for significance of interactions with 
follow-up time.
Results. Average weight gain was 0.74 kilograms (kg) during the 
first year after diagnosis and 2.39 kg at the follow-up interview. 
The strongest predictors of post-diagnosis gain were body size 
characteristics before diagnosis, which varied with time since 
diagnosis. Compared to women with body mass index (BMI, kg/
m2) 18.5-24.9 1 year before diagnosis, those with greater BMI 
were more likely to gain weight during the first year after diagnosis 
[difference in mean yearly increase: BMI 25.0-29.9 vs. 18.5-24.9 
(95% confidence interval): 1.93 kg/year (0.50, 3.37); BMI >=30.0 
vs. 18.5-24.9: 0.47 kg/year (0.24, 0.71)] and after the first year [5.17 
kg/year (3.68, 6.66) and 0.93 kg/year (0.58, 1.28), respectively], 
with the effect greater during the first year (p-interaction: <0.001). 
A pre-diagnosis weight gain of more than 10% since age 20 was 
also associated with post-diagnosis weight gain [during year 1, 
difference in mean yearly increase compared to maintenance within 
3% age 20 weight: 2.32 kg/year (0.59, 4.05); after year 1: 0.53 kg/
year (0.17, 0.89)] with the effect again stronger during the first year 
(p-interaction: 0.02). Modest associations, which varied only slightly 
with time, included: increases in post-diagnosis weight gain with 
chemotherapy, tumor characteristics indicative of poor prognosis, 
and a previous diagnosis of hypertension, blood clots, or diabetes; 
and decreases with increasing recreational physical activity and a 
history of myocardial infarction.
Conclusions. Greater pre-diagnosis BMI and pre-diagnosis adult 
weight gain are strongly related to post-diagnosis weight gain 
among breast cancer survivors. The rate of post-diagnosis weight 
gain appears to be faster during the first year than after, suggesting 
that interventions to prevent post-diagnosis weight gain may be most 
important during the first year after diagnosis, especially among 
women who with BMI >= 25.0 1 year prior to diagnosis.
P4-12-04
Withdrawn by Author
P4-12-05
Impact of the Lifestyle Intervention Study in Adjuvant Treatment 
of Early Breast Cancer (LISA) Weight Loss Intervention upon 
Physical Activity.
Ligibel JA, Segal R, Pond G, Dion M-J, Pritchard KI, Levine M, 
Goodwin PJ. Dana-Farber Cancer Institute, Boston, MA; University 
of Ottawa, Ottawa, ON; McMaster University, Hamilton, ON; 
University of Toronto, Toronto, ON
Observational evidence shows a relationship between obesity and 
poor prognosis in breast cancer (BC). Physical activity (PA) is an 
important component of weight loss and maintenance, but most 
large-scale interventions in BC patients have produced only modest 
improvements in activity. We sought to evaluate changes in PA in 
women participating in LISA, a randomized trial coordinated by the 
Ontario Clinical Oncology Group which was designed to examine 
the impact of a telephone-based weight loss intervention (WLI) upon 
disease free survival in BC patients.
Methods:
Participants were randomized 1:1 to the WLI or educational control 
(EC) group. Eligibility included diagnosis of Stage I-III BC, BMI ≥24 
kg/m2, and treatment with letrozole. The WLI, based on the Diabetes 
Prevention Program, focused on weight reduction through calorie 
restriction and increased physical activity. Delivery involved 19 calls, 
mailings and a participant manual. The PA goal was 150 minutes/
week. PA was measured using the International Physical Activity 
Questionnaire (Short Form) at baseline, 6, 12, and 18 months. Changes 
in time (minutes/week) spent sitting and engaging in moderate, 
vigorous, and walking activities were compared between groups.
Results
338 women were randomized to WLI (n=171) or EC (n=167) from 
20 centers in Canada and the USA. The study was discontinued due 
to loss of funding. The WLI arm lost significantly more weight than 
EC arm, with mean weight loss of 6.1% of body weight vs. 0.6% 
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at 12 months (p<0.001). Activity data are presented in Table 1. At 
baseline, participants were inactive; median vigorous activity was zero 
minutes/week and median time spent sitting was more than 35 hours/
week. WLI participants reported significantly higher participation 
in vigorous, moderate and walking activities, and lower levels of 
sedentary behavior, compared to controls at 6 and 12 months. Higher 
levels of PA were significantly associated with increased weight loss at 
all time periods. Factors associated with increases in activity included 
higher baseline BMI (p=0.014), lower baseline activity (p<0.001) 
and assignment to the WLI arm (p=0.02). Women assigned to WLI 
increased their PA during the intervention period (p=0.017) even after 
adjusting for other significant baseline factors.
Conclusion
Participants in the LISA WLI reported significantly higher levels of 
PA compared with controls. Activity increased most in women who 
were heavier and less active at baseline. Further study of this WLI as 
a potential means to improve BC outcomes is warranted.
Activity Levels (minutes/week)
 Type of Activity Control* Intervention* p-value
Baseline Vigorous 0 (0,40) 0 (0,80) .50
 Moderate 0 (0,120) 30 (0,180) .09
 Walking 145 (60,360) 180 (75,420) .20
 Sitting 2520 (1680-3360) 2100 (1680,3360) .41
 N 167 171  
6 Months Vigorous 0 (0,120) 40 (0,180) .001
 Moderate 60 (0,210) 100 (0,280) .036
 Walking 140 (60,315) 210 (120, 420) .002
 Sitting 2100 (1680,3360) 1680 (1260, 2520) .005
 N 146 151  
12 Months Vigorous 0 (0,150) 30 (0,180) .16
 Moderate 60 (0,240) 120 (40,360) .001
 Walking 180 (60,420) 240 (150,420) .01
 Sitting 2100 (1260,2940) 1680 (1260,2520) .003
 N 140 140  
18 Months Vigorous 0 (0,90) 0 (0,180) .17
 Moderate 100 (0,240) 120 (30,300) .39
 Walking 180 (60,360) 210 (120, 420) .04
 Sitting 2100 (1260,2940) 1890 (1260,2520) .41
 N 113 109  
*Data presented as median (range) 
P4-12-06
Risk Factors for Relative Weight Gain >10% in Breast Cancer 
Survivors: Findings from the SU.VI.MAX Cohort.
Zelek L, Czernichow S, Galan P, Hercberg S. Assistance Publique 
Hôpitaux de Paris, CHU Avicenne, Bobigny, France; INSERM/ U1125 
INRA/CNAM/Université Paris 13, Bobigny, France
Purpose: Since extreme weight gain (EWG, defined as weight gain 
> 10% of baseline body weight) raises risk for recurrence among 
breast cancer survivors (Caan et al. AACR 2011) we undertook 
this study to identify risk factors for EWG after breast cancer. 
Methods: We screened the database of the SU.VI.MAX trial (13017 
pts randomized between low-dose antioxidants and placebo, Arch 
Int Med 2004) to retrieve women with confirmed breast cancer 
occurring after inclusion, and post-cancer follow-up. The following 
data were collected at inclusion and during the study: anthropometric 
measurements, physical activity, tobacco and alcohol consumption, 
level of instruction and socio-economic status, current medications. 
Unlike other breast cancer survivor studies, data have been collected 
prospectively before breast cancer diagnosis. Data management and 
data analysis were performed using SAS software 9.1.3. We also 
screened questionnaires and medical reports to collect data that were 
not recorded in the study database: type of adjuvant therapy (chemo- 
and hormone therapy), use of vitamins and dietary supplements, 
concomitant medications (such as antidepressants, lipid lowering 
agents, thyroid hormones or anti-thyroid drugs), previous use of 
HRT, and whether patients were following a diet plan after breast 
cancer or no.
Results: We identified 176 pts with breast cancer included since 1994 
in the SU.VI.MAX 8-year Cohort Study. Among them, 25% (n=44) 
had weight gain >10% of baseline. The only variable significantly 
correlated with EWG was age at breast cancer diagnosis. Other 
differences, in particular level of physical activity or anthropometric 
measurements, did not reach statistical significance.
Weight gain >10% <10%
Age at diagnosis 52.9±6.2 55.8±6.6
Age at inclusion 47.2±5.7 49.4±6.2
Non smoker 59% 55.6%
Alcohol drinker 68% 59%
Physical activity   
irregular 27.3% 27.9%
walk<1h/d 40.9% 32.6%
walk>1h/d 31.8% 39.5%
No significant differences were seen between patients with EWG 
and others regarding the use of adjuvant chemotherapy (34 v 28%), 
aromatase inhibitors (18 v 22%), or tamoxifen (25 v 21%), previous 
HRT use (44 v 50%) or concomitant drugs including thyroid hormones 
(20 v 17%). A minority of patients was following a diet (16 v 17%) 
but consumption of vitamins or dietary supplements was slightly 
higher in patients without EWG (35 v 50%).
Discussion: Weight gain after breast cancer is a well-known 
phenomenon affecting at various levels half of breast cancer survivors. 
Most recent studies suggest that patients with EWG could have an 
increased recurrence rate. Risk factors for weight gain are still matter 
of debate but the role of adjuvant chemotherapy is widely admitted. 
Our results however indicate that adjuvant therapy does not seem to 
be a major risk factor for EWG. Furthermore, lifestyle and diet do 
not seem to markedly affect the risk of EWG. The only significant 
difference observed in our study is age at diagnosis, suggesting that 
treatment-induced amenorrhea could play a role in some patients. 
Although identification of women at risk remains difficult, thus 
precluding a large proportion of this population from tertiary 
prevention, younger women seem to deserve particular attention.
P4-12-07
Outcomes of a Behavioral Weight Control Intervention among 
Rural Breast Cancer Survivors.
Befort CA, Klemp JR, Austin HL, Krigel S, Sullivan DK, Schmitz 
KH, Perri MG, Fabian CJ. University of Kansas Medical Center; 
University of Pennsylvania; University of Florida
Background: Obese breast cancer survivors have 1.5 to 2.5 fold 
increased risk of recurrence and death compared to their normal 
weight counterparts. Rural women, who comprise over 20% of the 
U.S. population of women, have significantly higher obesity rates 
as well as breast cancer treatment-related disparities. Thus, weight 
control intervention is a key strategy for secondary breast cancer 
prevention in this population. However, access can be challenging in 
the rural setting. Using conference call technology to deliver group-
based intervention is well-suited for rural breast cancer survivors 
because it is easily accessible and provides real-time peer support. The 
purpose of this one-arm treatment study was to examine the impact of 
a 6-month group phone-based behavioral weight control intervention 
on anthropomorphic, diet, physical activity, and psychosocial/quality 
of life outcomes.
Methods: Eligible participants were post-menopausal breast cancer 
survivors (Stage I-IIIc, 3 months to 10 years since surgery, radiation, 
or chemotherapy, < 75 years of age, BMI 27-45 kg/m2) who resided 
in a rural area. The weight control intervention included a reduced 
calorie diet with 2 prepackaged meals and ≥ 5 fruit and vegetables 
servings daily, home-based physical activity gradually increased to 
225 min/week of moderate intensity exercise, weekly self-monitoring 
logs, and weekly 60-minute group phone sessions that addressed 
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behavioral modification and breast cancer survivorship topics. Group 
size ranged from 9 to 13 women. Measures included anthropometrics, 
two 24-hour dietary recall interviews, and questionnaires measuring 
physical activity, fatigue, depression, body image and sexuality, and 
self-efficacy for diet and physical activity behavior change.
Results: Participants (n = 34) were 58.9 ± 7.8 years-old, 3.1 ± 1.6 
years out from treatment, had a baseline BMI of 33.7 ± 4.4 kg/m2, 
and 63% were on anti-hormone therapy. Average sessions attendance 
among all participants, including 3 non-completers, was 90%. Ninety-
one percent of participants (n = 31) attended > 75% of intervention 
sessions and completed post-treatment data collection visits. At 6 
months, significant changes were observed for weight (-12.5 ± 5.8 
kg, 13.9% of baseline weight), waist circumference (-9.4 ± 6.3 cm), 
daily energy intake (-349 ± 550 kcal/day), fruits and vegetables 
(+3.7 ± 4.3 servings/day), percent kcal from fat (-12.6 ± 8.6%), and 
physical activity (+1235 ± 832 kcal/week; all p’s < .001). Significant 
improvements were also seen for Body Image subscales (Strength and 
Health, Social Barriers, Appearance and Sexuality), Depression, and 
Self-Efficacy for diet and physical activity behaviors (all p’s < .05).
Discussion: The intervention produced significant improvements 
in weight, diet, physical activity, and quality of life outcomes that 
compare favorably to the literature. The group phone-based treatment 
delivery approach appears feasible and effective for weight control 
intervention among obese rural breast cancer survivors.
P4-12-08
Five Year Preliminary Outcomes of a Prospective Surveillance 
Model To Reduce Upper Extremity Morbidity Related to Breast 
Cancer Treatment.
Stout NL, Pfalzer L, Levy E, McGarvey C, Gerber L, Springer B, 
Soballe P. National Naval Medical Center; University of Michigan- 
Flint; National Institutes of Health; CLM Consulting; George Mason 
University; Office of the Surgeon General; Naval Hospital San Diego
Background: Early detection and management of physical 
impairments after breast cancer treatment contribute to successful 
functional outcomes and improved quality of life throughout disease 
treatment and survivorship. Assessment of upper extremity (UE) 
morbidity including; shoulder dysfunction, scarring, pain, fatigue and 
lymphedema should be conducted through a prospective surveillance 
model of care to promote early identification of impairments and 
provide intervention while functional limitations are minimal, thereby 
preventing long term loss of function. This report highlights 5-year 
findings related to physical function in patients participating in a 
prospective surveillance model of care.
Methods: A prospective, observational study enrolled women 
with breast cancer at the point of disease diagnosis (n=196) and 
measured UE morbidity, impairments and functional disability 
over a 5 year period. Patient demographics, cancer characteristics, 
measures of UE strength, range of motion (ROM) and limb volume 
were taken pre-operatively and repeated at 1, 3, 6, 9, 12 and 60 
months post-operatively. Subjective assessment of physical activity, 
health status and quality of life were assessed by questionnaire at 
12 and 60 months. 166 subjects completed visits at 1 year and 95 
completed visits at 5 years. All subjects received education regarding 
exercise, risk reduction and advice on return to activity. If physical 
impairments were detected during the study, immediate physical 
therapy intervention was initiated to alleviate the impairment.
Results: The incidence of objective UE impairments at five years 
after treatment was 9% with loss of shoulder ROM, 25% with 
subclinical lymphedema (defined as a > 3% change in limb volume 
from baseline), 5.6% with advanced lymphedema (Stage I or II) and 
27.8% with clinically significant fatigue (defined as > 3 on a visual 
analog scale). Subjectively 8.4% reported feeling moderately or 
severely disabled with their affected arm, 11.1% reported moderate 
to severe difficulty carrying heavy objects, 4.2% reported moderate 
to severe limitations with heavy household chores.
Discussion: This is the first prospective cohort study in the United 
States to specifically monitor physical and functional outcomes to 
5-years post breast cancer treatment. The prospective surveillance 
model of care, conducted by the physical therapist, enabled 
early detection and treatment of breast cancer treatment–related 
impairments resulting in improved long-term function. Long-term 
incidence of UE morbidity after breast cancer treatment has been 
documented in the literature as high as 40-60% with lymphedema and 
up to 60% with fatigue. This study clearly demonstrates the potential 
for substantial reduction in UE dysfunction related to breast cancer 
treatment when using an early identification and intervention model. 
Morbidity such as pain, reduced range of motion, decreased strength 
and sub-clinical lymphedema were detected early and managed 
through the prospective model. These results strongly suggest that 
prospective surveillance monitoring for functional impairments is 
an optimal construct to assure long-term function in women after 
breast cancer treatment.
P4-12-09
Withdrawn by Author
P4-12-10
A Prospective Study of Physical Activity Patterns and Changes in 
Breast Cancer Patients during Active Breast Cancer Treatment.
Kim I-R, Choi E-K, Nam S-J, Lee J, Lee S-K, Yang J, Noh DY, Han 
W, Cho J. Samsung Comprehensive Cancer Center, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 
SurgerySamsung Medical Center, Sungkyunkwan University School 
of Medicine, Seoul, Korea; Konkuk University Medical Center, 
Konkuk University School of Medicine, Seoul, Korea; Seoul National 
University Hospital, Seoul Natioanl University School of Medicine, 
Seoul, Korea; Johns Hopkins Bloomberg School of Public Health, 
Baltimore; Behavior and Society, Johns Hopkins Bloomberg School 
of Public Health, Baltimore
Purpose
Physical activity (PA) has been shown to benefit cancer patients’ 
physical functioning, emotional well-being, and symptom 
management. Moderate PA may reduce the side effects of breast 
cancer treatment and improve quality of life, but most of the studies 
have been conducted after active treatment was completed and there 
is little data on patterns of PA during active treatment. This study aims 
to evaluate patterns and changes in physical activity among breast 
cancer patients during active treatment.
Patients and Methods 
We recruited 411 women with non-metastatic breast cancer between 
July 2010 and Dec 2010 from two major cancer hospitals in Seoul, 
Korea. Trained researchers interviewed participants at enrollment 
(before surgery), and at 2 weeks, 3 months, and 6 months post 
surgery. Intensity and duration of PA were assessed using the 
Minnesota Leisure Time Physical Activity Questionnaire, and energy 
expenditure (the average calories spent per day) was calculated as 
metabolic equivalents (METs). Quality of life (EORTC), fatigue 
(BFI), socio-demographic and clinical characteristics were also 
assessed. After excluding 15 patients with recurrence during follow-
up and 65 patients were lost to follow-up, the final sample size was 
331 patients (80.5%).
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Results
The mean (SD) age and BMI of study participants were 46.4 years 
and 23.3kg/m2 (SD 3.35). 83.7% of women had lumpectomy, and 
70.6% and 85.9% had adjuvant chemotherapy and radiotherapy 
respectively. Breast cancer patients were most likely to spend their 
energy in lifestyle (walking and driving) and leisure (shopping, 
reading, and watching TV) activities but spent little energy in sport 
activities (Table).
Energy Expenditure(Kcal/Day)
Energy expenditure in 
METs/d, Mean (SD)
Baseline 2 weeks Post-surgery
3 months Post-
surgery
6 months Post-
surgery p-value
Lifestyle activities 550.8(32.0) 314.5(39.1) 380.3(42.6) 438.2(54.4) <0.01
Leisure 624.2(13.2) 627.8(17.4) 606.3(19.0) 594.3(24.8) 0.45
Household chores 391.3(20.0) 131.6(18.6) 249.6(20.4) 235.6(26.3) <0.01
Sport 122.5(12.7) 89.3(13.7) 132.2(15.0) 137.0(19.1) 0.01
Total 1674.2(43.7) 1160.3(49.6) 1331.6(54.0) 1398.3(70.3) <0.01
Conclusion
PA declined after the surgery and gradually recovered at 3 and 6 
months post surgery but it did not return to the baseline level. Breast 
cancer patients may need encouragement and support to perform more 
intensive physical activities during active treatment.
*Acknowledgement: The research was accomplished by the support 
from AMOREPACIFIC and Korea Breast Cancer Foundation.
P4-12-11
Myelodysplastic Syndrome Post Primary Breast Cancer 
Treatment: Cases from a Community Cancer Center: 1990-2010.
Kaplan HG, Malmgren JA, Atwood MK. Swedish Cancer Institute, 
Seattle, WA; HealthStat Consulting, Inc., Seattle, WA
Background: Myelodysplastic syndrome (MDS) has not been well 
documented or described post breast cancer (BC) treatment.
Methods: A cohort of all breast cancer patients from 1989 to 2010 
at our institution were followed for incidence of blood disorders of 
any type by our registry system and by linkage to the Surveillance, 
Epidemiology and End Results (SEER) registry for our area. All 
cases of post breast cancer leukemia were reviewed for incidence of 
MDS from a cohort of 9846 cases diagnosed between 1990 and 2010. 
Coding of cases was assigned by the SEER registry using ICD-0 codes 
for type of leukemia from pathology reports. 20 cases of MDS were 
identified and confirmed using SEER coding for MDS and death 
certificate review if applicable. Variables of interest included age, 
race, treatment received, recurrence and treatment for recurrence, time 
interval from breast cancer diagnosis to leukemia diagnosis and time 
from leukemia diagnosis to follow up or death. Cytogenetic studies 
were available on 5 of the 20 patients.
Results: Mean age of the patients was 56 years, range 33-79, with 65% 
< age 65. 90% of the patients were white and 10% Asian. TNM BC 
stage distribution was stage 0=2, stage I=8, stage II=8, and stage III=2. 
MDS was diagnosed at a median time post BC diagnosis of 65 months, 
range 8-205 months including 5 patients treated for recurrence and 
median 47 months, range 8-205 months excluding patients with 
recurrence. Nine patients had initial chemotherapy treatment, two 
without initial adjuvant therapy received chemotherapy for recurrence, 
and 9 received radiation only. Eight of eleven patients who received 
chemotherapy were treated with doxorubicin. All eleven received 
cyclophosphamide. Five of the 20 cases had MDS, not otherwise 
specified (NOS) (9989), 4 cases had MDSàAML, 3 MDS treatment 
related (9987), 3 refractory anemia (RA) (9980), 3 refractory anemia 
with excess blasts (RAEB) (9983), 1 RA with sideroblasts (9982), and 
1 MDS with 5q deletion. Three of the five patients with cytogenetics 
available had chromosome 7 abnormalities and one had 11q21,23. 
Eleven of the 20 patients (55%) died of MDS or MDSàAML with a 
mean survival of 17 months, range 0.5-72 months. Six patients were 
alive at follow up with mean survival 56 months, range 43-89. Two 
of the surviving patients had stem cell transplants. The remaining 
three patients died of other causes with mean survival 66 months, 
range 7-109 months. Mean survival of all patients was 36.26 months, 
range .53-109 months with a significant difference in survival time 
between the patients that died of MDS, those alive at follow up and 
those that died of other causes (F statistic 6.56, p=.008).
Discussion: MDS is a significant complication of breast cancer 
treatment with radiation and/or chemotherapy with a high rate of 
associated mortality.
P4-12-12
Patient-, Illness-, and/or Treatment-Related Baseline Predictors 
of Nonadherence to Oral Hormonal Therapy.
Wickersham KE, Sereika SM, Bender CM. University of Pittsburgh, 
Pittsburgh, PA
Background: Nonadherence to oral hormonal therapy is problematic 
for women with breast cancer. Patient-, illness-, and treatment-
related factors have been associated with nonadherence, but with 
inconsistent findings. Therefore, our aim was to explore predictors 
of nonadherence to hormonal therapy for women with early stage 
breast cancer from the baseline assessment (pre-hormonal therapy) 
to 6 months post-treatment.
Methods: A secondary analysis was performed to explore potential 
patient-, illness-, and treatment-related predictors of nonadherence 
for 198 women enrolled in either: 1) The Anastrozole Use in 
Menopausal Women Study (AIM Study, n=162), or, 2) Predictors 
of Adherence to Hormonal Therapy in Breast Cancer (ONS Study, 
n=36). Nonadherence was defined as the percentage of prescribed 
administrations of hormonal therapy that were not taken during 
the first 6 months of therapy as measured using an electronic 
Drug Exposure Monitor (eDEM) (AARDEX, Ltd.). Chi-square 
tests of independence and Mann-Whitney U tests were performed 
to determine whether data from the two studies could be pooled. 
Descriptive statistics were performed to characterize the sample. 
Multiple linear regression analyses were performed to identify the 
best model in two stages: 1) univariate relationships between each 
candidate predictor variable and the outcome variable (6-month 
nonadherence) were assessed using a cut-off of p=.20; and, 2) 
candidate predictors meeting the criteria were retained for further 
exploration in model-building multiple linear regression analyses 
(stepwise and backward) to determine the predictors of 6-month 
nonadherence summary scores. Candidate predictors were retained 
in the model if they remained associated at p<.10 in the multiple 
linear regression analysis.
Results: Women were 98.3% Caucasian with a mean age 59.1 years 
(SD 7.5) and mean number of years of education of 15.0 (SD 2.9). 
Overall mean nonadherence was 11.6% (13.2% AIM Study, 4.6% 
ONS Study). Chi-square and Mann-Whitney U tests demonstrated 
that the two samples could be pooled, given the data were similar 
on key variables (number of years of education, depression, 
anxiety, fatigue, symptoms, and nonadherence). Both stepwise and 
backward elimination modeling algorithms demonstrated evidence 
of 3 significantly significant variables associated with nonadherence; 
however, the backward elimination model best represented the 
sample (R2=.106, adjusted R2=.086, s=0.28490). Women who worked 
(p=.082), whose primary occupation was clerical or administrative 
(p=.029), had DCIS tumor type (p=.017), or who had higher 
gastrointestinal (GI) symptoms scores (p=.013) were associated 
with nonadherence . The potential for interactions between primary 
occupation, DCIS tumor type, and higher GI symptoms was explored 
and was not significant. In addition, while all tumor types were 
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examined as candidate predictors, participants with DCIS also had 
another tumor to be eligible for the parent studies.
Conclusions: Our study offers insight into potential predictors of 
nonadherence for women participating in one of two cohort studies. 
The findings suggest additional examinations of nonadherence 
concerning work and symptom burden and their relationship to 
nonadherence are indicated.
P4-12-13
A Multi-Center Randomized Controlled Double Blind Trial 
Assessing the Effect of Acupuncture in Reducing Musculoskeletal 
Symptoms in Breast Cancer Patients Taking Aromatase 
Inhibitors: First Interim Analysis.
Bao T, Tarpinian K, Medeiros M, Gould J, Jeter S, Cai L, Tait N, Shetty 
J, Lewis J, Gitten L, Betts K, Hoffman A, Feigenberg S, Chumsri S, 
Armstronge DK, Bardia A, Tan M, Stebbing J, Folkerd E, Dowsett M, 
Singh H, Tkaczuk K, Stearns V. University of Maryland Greenebaum 
Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel 
Comprehensive Cancer Center, Baltimore, MD; Hammersmith 
Hospitals NHS Trust Charing Cross Hospital, London, United 
Kingdom; The Royal Marsden NHS Foundation Trust, London, 
United Kingdom
Background: Aromatase inhibitors (AIs) are recommended as first-line 
adjuvant hormonal therapy in postmenopausal women with hormone-
receptor–positive breast cancer, as monotherapy or sequential therapy 
after tamoxifen. AI-associated musculoskeletal symptoms (AIMSS) 
occur in approximately 50% of women receiving AIs and in some 
may result in discontinuation of treatment. Symptom management 
is essential to ensure that breast cancer patients receive the full 
recommended duration of AI therapy. We conducted a randomized, 
placebo-controlled trial to evaluate the effect of acupuncture on 
AIMSS and report the first interim analysis.
Method: Postmenopausal women with early stage breast cancer, 
experiencing AIMSS, who had not had acupuncture in the year prior 
to the study, were eligible. Patients were randomized to 8 weekly 
acupuncture or sham acupuncture. Health assessment questionnaire 
disability index (HAQ-DI ranging 0-3.0) and pain visual analog scale 
(VAS ranging 0-100) were used to assess clinical musculoskeletal 
disorder severity at weeks 0, 4, 8, and 12 or 24. Change in HAQ-DI 
(DHAQ-DI) and VAS scores (DVAS) from baseline were compared 
between patients receiving acupuncture versus sham acupuncture 
using exact Wilcoxon rank sum test. Serum samples were collected 
for measurements of estrogens and beta endorphin concentrations 
and cytokine profile before and after the intervention to evaluate the 
etiology of AIMSS and the mechanism of acupuncture in treating 
AIMSS.
Results: Between May 2008 and June 2011, 48 patients were 
enrolled, 2 patients were not evaluable due to noncompliance to 
treatment and lost to follow up, 10 were still receiving treatment and 
therefore not evaluable. Thirty-six were evaluable, and were equally 
distributed between the real and sham acupuncture groups. Baseline 
characteristics were balanced between the two groups with regard 
to age, race, and body mass index (BMI) with the exception that 
baseline mean HAQ-DI was higher in the acupuncture group (0.9 
vs 0.55, p=0.04). White/Black/Asian: 26/7/3, Median (range): age: 
61 (45-82); BMI (kg/m2): 31.1 (22.9-59.6). At week 8, both groups 
showed a wide range of DHAQ-DI (DHAQ-DI =HAQ-DIweek8-HAQ-
DIbaseline): from -1.38 to 0.5 in the acupuncture group versus from -1 to 
0.12 in sham acupuncture group. There was no statistically significant 
difference in mean DHAQ-DI between the real and sham acupuncture 
groups (-0.33 vs -0.33, p=0.87). Eleven patients in each group (61%) 
reported decreased HAQ-DI scores, which correlated with improved 
function. There was no difference in mean DVAS between the real and 
sham acupuncture groups (-9.27 vs -13.82, p=0.67). No significant 
side effects were reported. Changes in other time points and in serum 
biomarkers will be presented at the meeting.
Conclusions: The majority of breast cancer patients experiencing 
AIMSS who participated in our study reported a reduced HAQ-DI 
score both from acupuncture and sham acupuncture. We did not 
observe significant differences between responses to real versus sham 
acupuncture after 8 weekly treatments. The study remains open to 
accrual to reach 50 evaluable patients.
P4-12-14
Pilot Study Utilizing Fluorine-18 Fluorodeoxyglucose (F-18 FDG) 
Positron Emission Tomography–Computed Tomography Scan 
(PET-CT Scan) To Investigate Brain Metabolic Changes during 
Treatment in Women with Breast Cancer.
Virani S, Lagos R, Hobbs G, Marano G, Nagaiah G, Abraham J. West 
Virginia University, Morgantown, WV
BACKGROUND: Approximately 25% of the patients undergoing 
chemotherapy develop cognitive changes. Similarly, significant 
neurocognitive changes in verbal memory and executive functioning 
have been reported in patients undergoing endocrine therapy. Though 
extensively studied, specific changes in the brain associated with 
cognitive dysfunction are still not clear. We performed an IRB-
approved retrospective pilot study utilizing brain images from 
standard PET-CT scans in patients being treated for breast cancer. 
Comparison was made between patients initial and follow-up scans 
to look for metabolic changes.
MATERIALS AND METHODS: Thirty nine patients with a diagnosis 
of breast cancer were identified from radiology database of West 
Virginia University Hospitals, who underwent at least two PET-
CT scans during their treatment for breast cancer from 2004-2009. 
Patients with brain metastasis were excluded. NeuroMIM® software 
analysis program was used to compare a comprehensive database of 
physiologic brain anatomy and metabolism with F-18 FDG perfusion 
brain images from the patients. Comparison was made in sixty-three 
defined brain regions. For each patient, two scans at approximately 
twelve month intervals were analyzed. The data sets from initial scans 
were compared with the follow up.
RESULTS: A total of 37 patients received cytotoxic chemotherapy, 
2 patients received only endocrine therapy. Data analysis using the 
signed-rank test shows that the collective Z-score values change 
between the initial and follow up scans. When data analysis is 
applied to the individual brain regions, the Lingual Gyrus (p=0.012) 
and the Angular Gyrus (p=0.056)show statistically significant and 
near significant decreases in brain metabolism respectively. These 
regions are attributed with language, mathematics and cognition. 
Several additional regions such as the fusiform gyrus and the primary 
visual cortex show p-values between 0.05 and 0.10, which indicate 
“trending”. These regions may demonstrate statistically significant 
decrease in metabolism if the sample size is increased.
DISCUSSION: The Lingual and the Angular Gyrus show a 
statistically significant and near significant decrease in glucose 
metabolism respectively, in patients receiving treatment for breast 
cancer. Limitations of this study include lack of baseline brain imaging 
and its clinical correlation with cognitive function. Based upon these 
preliminary findings prospective studies are being planned.
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Cancer Survivor Care: An Evaluation of a Group Visit Model of 
Care for Breast Cancer Survivors at Duke Cancer Center.
Trotter KJ, Schneider S. Duke University Medical Center, Durham, 
NC; Duke University, Duraham, NC
Background: The number of cancer survivors is growing, currently 
with about 2.5 million breast cancer survivors. (ACS, 2010). 
The Institute of Medicine report on survivor care stressed care 
coordination along with attention to survivor concerns as key issues in 
improving follow-up care. Group visits have been shown to improve 
access, health outcomes and health care utilization rates, as well as 
self-management skills.
Purpose: This prospective program evaluation measured patients 
opinions about participation in a group visit clinic.
Methods: A new model of breast cancer survivor care was designed 
and piloted at Duke Cancer Center. Breast cancer survivors who were 
three years post diagnosis attended the clinic together in groups of 
six. An interdisciplinary group visit format in the initial part of the 
appointment provided surveillance, education and support, as well 
as formation of an individualized survivorship care plan to be shared 
with the primary care provider. The first hour included review of their 
personal care plan and a 45-minute facilitated discussion. Afterwards, 
individual visits with the nurse practitioner, and dietitian, physical 
therapist or social worker occurred.
A 22-item questionnaire designed to ascertain opinions regarding 
logistics and the style and function of care delivered is being 
administered to participants. The evaluation tool was approved by 
a panel of experts; pilot tested and has a reading level of 7.8. Data 
collection will be complete July 1, 2011. 103 surveys have been 
collected with a 91% response rate. Preliminary analysis shows 
high satisfaction with the group visit format. What participants liked 
most about the program was sharing with other survivors. 86% of 
participants indicate that they will share the survivorship care plan 
with their PCP. Only 10% responded that they were not sure they 
needed this type of follow up now and expressed that it would be 
more helpful immediately after finishing treatment. Final data will 
be presented. Barriers and facilitators to implementing this type of 
care model will be presented.
Conclusions: The group visit model applied to a breast cancer survivor 
clinic appears feasible and highly satisfactory to participants.
Implications for practice: Group visits can be considered one option 
for survivor care.
P4-13-01
Pain Severity and Analgesic Use Associated with Skeletal-Related 
Events in Patients with Advanced Breast Cancer and Bone 
Metastases.
Fallowfield L, Cleeland CS, Body J-J, Stopeck A, von Moos R, Patrick 
DL, Clemons M, Tonkin K, Masuda N, Lipton A, De Boer R, Salvagni 
S, Tosello Oliveira C, Ying W, Braun A, Cong Z. Cancer Research 
UK, University of Sussex, Brighton, United Kingdom; University of 
Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, 
Université Libre de Bruxelles, Brussels, Belgium; University 
of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital 
Graubünden, Chur, Switzerland; University of Washington, Seattle, 
WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross 
Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, 
Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, 
PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda 
Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle 
do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
Background: Skeletal-related events (SREs), which include 
pathologic fracture (PF), radiation to bone (RB), surgery to bone (SB), 
and spinal cord compression (SCC), occur frequently in patients with 
bone metastases and can lead to debilitating clinical consequences 
such as functional impairment and bone pain. Denosumab (XGEVA®) 
is a fully human monoclonal antibody against RANKL, shown to be 
superior to zoledronic acid (ZA; Zometa®) for the prevention of SREs 
in patients with solid tumors. Denosumab also delayed the onset of 
moderate or severe pain compared with ZA. The pain severity and 
analgesic use associated with each type of SRE were assessed in 
patients with advanced breast cancer and bone metastases.
Methods: Eligible patients received denosumab 120 mg SC or ZA 4 
mg (adjusted for renal function) IV every 4 weeks in a randomized, 
multinational, double-blind, double-dummy trial. Patient-reported 
pain was assessed with the Brief Pain Inventory (BPI; 0 no pain to 10 
severe pain) at baseline (BL) and at each monthly visit. Opioid and 
non-opioid analgesic use was recorded and scored using the Analgesic 
Quantification Algorithm (AQA; 0 no analgesic use to 7 > 600mg oral 
morphine equivalent/day). Data from the two treatment arms were 
pooled for this analysis. Pain and analgesic use were evaluated from 
6 months prior to and 6 months after the first on-study SRE for each 
patient. The comparator group included patients without an SRE and 
was centered at the median time from randomization to first SRE by 
SRE type, with corresponding 12 month assessments. The proportion 
of patients with moderate/severe pain (BPI worst pain score > 4) and 
proportion of patients shifting from no/low analgesic use (AQA ≤ 2) 
at baseline to strong opioid use (AQA ≥ 3) were reported by month 
and by SRE type, and are summarized by mean relative change (%) 
across the time period.
Results: In total, 687 patients with first on-study SRE occurrences 
(PF=450, RB=201, SCC=16, SB=20) were analyzed. A similar 
proportion of patients with and without a PF had moderate/severe 
pain, but a higher proportion of patients with a PF shifted from no/
low analgesic use to strong opioid use (mean relative increase 80%). 
Starting 3 months prior to the event, more patients with RB than those 
without had moderate/severe pain (27% mean relative increase) and 
shifted from no/low analgesic use to strong opioid use (mean relative 
increase 269%). Similar pain and analgesic use patterns were noted 
for patients with SCC (mean relative increase in pain: 63%; in AQA 
shift: 913%). More patients with SB than those without had moderate/
severe pain in the 6 months leading on to SB (mean relative increase 
51%). The difference was attenuated after SB, but during this time 
a much higher proportion of patients with SB shifted from no/mild 
opioid use to strong opioid use (mean relative increase 220%).
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Discussion: SREs are associated with increased pain severity and 
analgesic use in patients with advanced breast cancer and bone 
metastasis. Patterns of pain severity and analgesic use differed by 
SRE type. Effective treatments to prevent SREs can decrease pain 
and the need for treatment with opioid analgesics.
P4-13-02
Hospice Utilization and End of Life Care in Metastatic Breast 
Cancer Patients at a Comprehensive Cancer Center.
O’Connor TL, Ngamphaiboon N, Morris J, Callinan NK, Milch 
RA, Kerr CH, Watroba N, Edge SB. Roswell Park Cancer Institute, 
Buffalo, NY; The Buffalo Center for Hospice and Palliative Care, 
Cheektowaga, NY
Background: Metastatic breast cancer patients have many options 
for therapy and may be at risk for late or absent hospice referrals. 
Previous studies suggest that late referrals to palliative care make 
meaningful improvements in symptoms and quality of life difficult 
to achieve. We examined hospice utilization, status of patients on 
hospice admission, and quality of care documentation in patients 
treated for metastatic breast cancer at Roswell Park Cancer Institute 
(RPCI) from 1999-2010.
Methods: Analysis of breast cancer cases through the RPCI database 
identified 182 cases with deaths resulting from breast cancer eligible 
for services through The Buffalo Center for Hospice and Palliative 
Care (HB) (residence in Erie County, NY). Cases were cross-matched 
to the HB database for information on hospice utilization and 
outcome, and patient symptoms/status on admission to hospice. Date 
of last chemotherapy, opiate use, anxiolytic use, documentation of 
advance directive and palliative care discussion, and place of death 
were collected through chart abstraction.
Results: 182 patients eligible for HB services expired from breast 
cancer during the study period. 122 (67%) utilized hospice services; 
60(33%) did not. 117 patients received chemotherapy as their last 
treatment for metastatic breast cancer; patients referred to hospice 
received their last dose of chemotherapy a median of 31 days (14.1-
47.9) prior to death; non-hospice patients 16 days (0-44.1) p=0.071. 
Patients subsequently admitted to hospice were significantly more 
likely to have a discussion of advance directives by their oncology 
team (30% vs. 5% p=<0.001) and were more likely to die at home 
(56% vs. 8%, p=<0.001). Only 7% of the 60 patients who died without 
a hospice referral had a documented discussion of palliative care as a 
therapeutic option by the oncology team (p<0.001) versus 100% of 
patients referred to hospice. 79% of breast cancer patients not admitted 
to hospice died in an acute care setting. Prior to hospice admission 
or death, 38% (69) patients had documentation of long-acting opiate 
use; 72% (131) were prescribed a short acting opiate, while 29% (52) 
patients were prescribed an anxiolytic. Median length of stay (LOS) 
was 17 days; 14% of patients died within 3 days of admission. Patient 
status on hospice admission is reported in Table 1.
Status on HB admission (n=122)
Age 55 (30-91)
Pain Score
0-1 53 (49%)
2-5 32 (30%)
6-10 23 (21%)
missing 14
Palliative Performance Score (PPS)
10-20 12 (11%)
30-40 63 (59%)
50-60 32 (30%)
missing 15
Understands prognosis 77 (75%)
missing 19
Length of stay (days) 17 (0-746)
# of dependent children
0 76 (72%)
1 16 (15%)
2 5 (5%)
≥ 3 8 (8%)
missing 17
Conclusion: Despite the recognition of the importance of high-quality 
end of life care, including end of life decision-making, advance 
directives, pain and symptom management, and hospice care, 33% 
of metastatic breast cancer patients at our institution died without 
hospice referral. Those patients referred to HB were significantly 
more likely to have an advance directive discussion, and to die at 
home. However, patients referred to HB had a median LOS of 17 
days, and poor PPS. Efforts to enhance discussion of palliative care 
earlier in the treatment of MBC are critical to improved patient care.
P4-13-03
Retrospective Analysis of Palonosetron Compared with Older 
5-HT3 Receptor Antagonists (Ondansetron, Dolasetron, and 
Granisetron) in Preventing Anthracycline-Induced Nausea and 
Vomiting in Breast Cancer Patients from Four Phase 3 Trials.
Rugo HS, Schwartzberg L, Morrow GR, Barbour SY, Ballinari G, 
Thorn MD, Cox D. UCSF Helen Diller Family Comprehensive Cancer 
Center; West Clinic; University of Rochester, School of Medicine and 
Dentistry; Duke University Medical Center; Helsinn Healthcare SA; 
Statistical Resources, Inc; Eisai, Inc.
In patients with breast cancer, the risk of developing chemotherapy-
induced nausea and vomiting (CINV) is particularly high due to 
the common use of highly emetogenic chemotherapy coupled with 
pt-related risk factors including female gender and young age. 
Despite prophylactic antiemetics, controlling CINV is difficult in 
this high risk population, particularly in the delayed phase following 
CT. Palonosetron, a potent 5-HT3 receptor antagonist (RA) with a 
distinctly different pharmacokinetic and receptor binding profile, 
has demonstrated improved CINV protection compared to older 
5-HT3 RAs in phase 3 and 4 clinical trials in a variety of settings 
and tumor types.
We conducted a retrospective subset analysis of pts with breast cancer, 
the majority of whom (89%) received anthracycline combination 
chemotherapy (doxorubicin or epirubicin and cyclophosphamide, 
AC/EC) from four phase 3, randomized, double-blind, parallel 
group studies to assess the comparative effectiveness and safety 
of single IV doses of palonosetron (0.25 or 0.75 mg) versus older 
5HT3-RAs (ondansetron 32 mg, dolasetron 100 mg, and granisetron 
3 mg) in preventing CINV in pts receiving this highly emetogenic 
chemotherapy. The primary efficacy evaluation was for complete 
response (CR), defined as the proportion of patients with no emetic 
episodes & no use of rescue medication during 0-24hrs (acute), >24-
120hrs (delayed), & 0-120hrs (overall) using a logistic regression 
model. A comparative descriptive safety assessment was also 
performed.
A total of 1197 patients with breast cancer were included in this 
analysis (palonosetron n=714; older 5HT3-RAs n=483). Higher CR 
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rates were seen for palonosetron vs. older 5HT3-RAs during the acute 
(63.4% vs 59.4%, p= 0.08), delayed (59.2% vs. 44.9%, p<0.0001) 
and overall (50.7% vs.38.5%, p<0.0001) phases. Rates for CR were 
similarly higher for palonosetron-treated patients in the large subgroup 
of patients receiving AC/EC based chemotherapy. Consistent 
improvements associated with palonosetron were seen for secondary 
endpoints of complete control (CR + no more than mild nausea), no 
emesis, and severity of nausea. The adverse event (AE) profile for 
palonosetron was similar to older 5HT3-RAs, with headache and 
constipation being the most commonly reported treatment-related 
AEs with similar incidences for all 5-HT3 RAs.
This retrospective analysis of patients with breast cancer, including 
a large subgroup receiving anthracycline-based highly emetogenic 
chemotherapy, demonstrated significantly improved CINV prevention 
with palonosetron compared to older 5HT3-RAs, particularly in 
the delayed phase. Safety was comparable. This data has important 
implications for current CINV prevention guidelines.
P4-14-01
Weight-Adjusted Change of Unilateral Arm Volumes for 
Quantification of Lymphedema after Bilateral Breast Surgery.
Miller CL, Specht MC, Ancukiewicz M, Skolny MN, O’Toole J, 
Taghian AG. Massachusetts General Hospital, Boston, MA
Background: Accurate quantification of breast cancer-related 
lymphedema (BCRL) is important for early detection and successful 
management. Arm volume changes after unilateral breast surgery can 
be calculated through relative volume change (RVC) of the affected 
arm using the contralateral arm as a control (Ancukiewicz et al Int 
J Radiat Oncol Biol Phys 79(5):1436-43 2011). However there 
currently exists no accurate method for quantifying arm volume 
changes in patients after bilateral breast surgery. As the number of 
women undergoing bilateral mastectomies continues to increase, 
it is critical to develop a method to quantify arm volume changes 
in this population for detection of lymphedema. Our aim was to 
develop a weight-adjusted formula for unilateral arm volume changes 
independent of the contralateral arm for application in the setting of 
bilateral breast surgery.
Materials and Methods: We analyzed longitudinal measurements 
of arm volumes in 141 unilaterally affected patients undergoing 
screening for BCRL with a perometer at our institution (71 with 
left affected and 70 with right affected arms). Each patient had a 
baseline measurement prior to surgery and at least one post-surgical 
measurement. Median time of follow-up was 27.5 months and median 
standard deviation of longitudinal weight changes within patients 
during follow-up was 3%.
Results: Unilateral arm volume changes of the unaffected arm were 
correlated with weight changes at the last follow-up point (Kendall’s 
tau=.58 and P<.0001). Estimates of slope and intercept for median 
regression line between percent weight change and percent arm 
volume change evaluated for the unaffected arm at last follow-up are, 
respectively, .90 [95% CI] and .009 [95% CI]. Thus, percent weight 
change and percent arm volume change in the unaffected arm have 
an approximately linear relationship, such that the weight adjusted 
change (WAC) of affected unilateral arm volumes can be calculated 
according to the formula WAC=(A2*W1)/(W2*A1) - 1, where A1 
is pre-surgical baseline arm volume on the affected side and A2 is 
post-surgical arm volume on the affected side, and W1, W2 are the 
patient’s weights at these time points. Weight-adjusted change showed 
a strong correlation with RVC (RVC=(A2*U1)/(U2*A1) - 1), where 
A1, A2 are arm volumes on the side of the affected breast, and U1, U2 
are volumes on the contralateral side at these time points (Kendall’s 
tau=.41, P<.0001).
Discussion: Unilateral arm volume changes can be quantified by 
adjusting for weight changes. We propose the weight-adjusted change 
(WAC) formula to calculate unilateral arm volume changes for 
detection and monitoring of BCRL in patients who undergo bilateral 
breast surgery. The validity of such a formula needs to be assessed in 
conjunction with clinically reported lymphedema.
P4-14-02
Risk Factors for Early Lymphoedema Do Not Predict Late 
Development of Lymphoedema.
Kilbreath SL, Beith J, Refshauge KM, Lee M-J, Ward LC. University 
of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, 
Camperdown, NSW, Australia; University of Queensland, St Lucia, 
QLD, Australia
Background: Previously, we investigated whether an upper limb 
8 week exercise program commencing 1 month after surgery was 
associated with higher incidence of LE. As part of that study, we 
investigated the risk factors for development of LE at 12 month 
follow-up, which was equivalent to 15 m post surgery. As LE 
fluctuates during the first year, our secondary aim was to identify 
risk factors for LE at the conclusion of the intervention and at 6 m 
follow-up.
Methods: Women (n=160) were recruited who had undergone 
breast and axillary surgery within the previous month for unilateral 
early stage breast cancer. Potential predictors were measured at 
approximately one month postoperatively after which women were 
randomised to the exercise or control group. Possible predictors of 
LE included age, BMI, side of surgery, treatments for breast cancer, 
physical measures of shoulder range of motion and strength, inter-
limb bioimpedance ratio at each previous measurement occasion 
and the treatment group to which women were randomised. The 
outcome measure for LE was based on the inter-limb impedance 
ratio. Presence of LE was determined using established cut-offs for 
LE. The relationship of each variable to the outcome measures (i.e. 
presence of LE) was assessed using t-tests and correlations. Significant 
variables (P < 0.25) were further examined with a multivariate logistic 
regression model.
Results: At least 10% of women developed LE: following intervention 
(N=15), and at 6m (N=15) and 12 m (N=20) follow-up. Risk factors 
for LE varied across the 3 time points (Table 1). At 12 m follow-up, 
the only significant risk factor was surgery on the non-dominant side. 
In contrast, the risk factors for LE following the intervention were 
allocation to the control group and commencement of taxane-based 
chemotherapy. At 6 m follow-up, risk factors for LE were having LE 
following the intervention and receiving taxane-based chemotherapy.
TABLE 1: Risk factors for development of LE. Results are odds ratios (95% CI) with P values from 
the multivariate analysis.
 Factor Odds Ratio (95% CI) Significance
Following Intervention (3 m 
post-surgery) Age 1.1 (1.0 to 1.2) 0.016
 BMI 1.20 (1.1 to 1.4) 0.009
 Control group 5.6 (1.3 to 24.5) 0.021
 Taxane-based chemotherapy regimen 3.0 (1.2 to 7.5) 0.024
 Inter-limb abduction ROM at baseline 1.1 (1.0 to 1.1) 0.006
6 m Follow-up (9 m post-surgery) Impedance ratio above cut-off following intervention 16.6 (4.2 to 65.6) <0.001
 Taxane based chemotherapy regimen 4.3 (1.3 to 14.0) 0.017
12 m Follow-Up (15 m post-
surgery)
Non-dominant arm is 
affected 11.7 (2.6 to 52.9) 0.001
Conclusion: Fluctuation of LE over the first year is associated with 
different risk factors. For example, fluid accumulation is a common 
side effect of taxanes and it was therefore not surprising that there 
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was a transient increase in LE. However, overall, we speculate that 
the higher risk for LE after 1 year is because of lack of use of the 
non-dominant affected arm. It is use of the upper limb which is likely 
the critical issue in this first year. Exercise was preventative while it 
was being undertaken; we question whether women maintained the 
level of exercise once the intervention concluded.
Acknowledgement: Cancer Council NSW; NBCF Australia
P4-14-03
Support Groups in Breast Cancer: An Evidence Based Assessment 
of 1606 Patients with Concerning Topics for Support Group 
Discussion and Presentation.
Gralla RJ, Morse KD, Rittenberg CN, Petersen JA, Rosen LM, 
Lesser M. Hofstra North Shore - LIJ School of Medicine, New York, 
NY; Nexcura, Seattle, WA; Feinstein Institute for Medical Research, 
Manhasset, NY
Background: Cancer support groups are conducted at most cancer 
centers. Although there is increasing demand among patients and 
families for support groups, little data exist outlining which topics 
patients and caregivers consider as most important for support 
group discussion and presentation. We conducted a large web-based 
anonymous survey to determine preferences of patients and caregivers 
for cancer support groups, including 1606 individuals with breast 
cancer and 3723 with other malignancies.
Methods: The established patient base of NexCura®, a web-based 
information resource, was used to survey registered patients and 
caregivers in this on-line assessment. Participants ranked 26 topics 
on a 5-point Likert scale which evaluated the importance of each 
item. Demographic characteristics, clinical factors, and support group 
content preferences were assessed.
Results: There were 4402 respondents to the invitation to participate, 
and 3723 patients and caregivers elected to participate (85%). 
Characteristics included for all 3723 patients: 70% women, mean age 
58 (range 20-89). For the 1606 patients with breast cancer, 99.8% were 
women, the mean age was 56 (range 27-88); 53% were free of cancer. 
For the whole group, the four most common cancers were breast 45%, 
prostate 15%, lung 6%, and colorectal 5%. 90% of participants were 
patients and 10% were caregivers. 80% of participants rated all 26 
topics. The table below shows rankings by the top 2 categories (the 
percent ranking each topic as “Very Important” or “Important”) of the 
10 highest rated topics (and the rank order for each item) for patients 
with breast cancer and for all patients.
Table 1
TOPICS (Top 10 rated of 26)
BREAST CANCER PATIENTS 
(n=1606):
ALL PATIENTS 
(N=3723):
Cancer treatment choices 94.8% (1) 95.0% (1)
Side effects and their prevention 94.5.% (2) 93.3% (2)
Living with a cancer diagnosis 92.0% (3) 91.3% (3)
Making decisions about care 89.4% (4) 89.9% (4)
Talking with medical professionals 87.8% (5) 88.6% (5)
Dealing with anxiety / depression 87.7% (6) 85.2% (6)
Stress and stress management 87.4% (7) 84.6% (8)
Navigating the health system 87.0% (8) 84.2% (9)
Cancer-related fatigue 86.3% (9) 82.7% (12)
Nutrition, appetite and weight 86.0% (10) 83.1% (10)
Conclusions: 1) This is the largest survey of patients and caregivers 
concerning support groups for patients with breast cancer and for a 
general cancer population. 2) Patients with breast cancer ranked most 
topics similarly to the general cancer population; however, topics 
dealing with fatigue and stress management were somewhat more 
highly ranked by those with breast cancer. 3) Physical, psychological, 
and communication issues were the most highly ranked issues by 
breast cancer patients and families. 4) These results should guide the 
content of support groups to meet the needs of patients and caregivers.
P4-14-04
Tolerance of Docetaxel: Is Obesity a Risk Factor for Toxicity? 
A Pilot Study.
Parent D, Rallet A, Jovenin N, Yazbek G, Cure H, Rey J-B. Institut 
Jean Godinot, Reims, France
Background
Few data are available in the literature regarding chemotherapy dosage 
adjustment in obese patients. Docetaxel is a lipophilic substance, 
highly bound to albumin; obesity might result in an accumulation of 
docetaxel and may lead to a higher rate of toxicity. The objective of 
this study was to assess the tolerance to docetaxel in obese and non 
obese patients, according to their body mass index (BMI).
Methods
A retrospective study was carried out. Patients were divided according 
to their BMI, considering a limit of 30 kg/m². All patients received 
docetaxel (100 mg/m²) as a part of adjuvant chemotherapy for breast 
carcinoma. Toxicity of docetaxel such as neutropenia, hand-foot 
syndrome, mucositis, and neuropathy were assessed in both groups. 
Patients receiving concomitant therapies leading to similar adverse 
events were excluded (e.g. cyclophosphamide, 5-FU, ...). The included 
patients received docetaxel alone or in association with trastuzumab or 
bevacizumab. Qualitative data analysis was performed using Fisher’s 
exact test. Quantitative data were studied using the Student test.
Results
Among the 49 patients, 18 (37%) presented with a BMI > 30 kg/
m². The median age was 53 years-old in the group BMI > 30 and 
55 years-old in the group BMI < 30 (p = 0.9383). The median dose 
intensity delivered was 91% (74-100%) in the group BMI> 30 and 
97.7% (75-100%) in the group BMI < 30 (p = 0.06) . The median 
value for albumin was 75 g/L (59-86 g/L) in the BMI > 30 and 71 
g/L (56-79 g/L) in the BMI < 30 (p = 0.122). Toxicity in both groups 
was as follows:
Table 1 - Docetaxel toxicity according to patients’ BMI
 BMI > 30 kg/m² (n=18) BMI < 30 kg/m² (n=31) p
Neutropenia - n (%) 3 (16.6%) 1 (3.2%) 0.12
Febrile neutropenia - n (%) 4 (22.2%) 2 (6.4%) 0.17
Mucositis - n (%) 4 (22.2%) 0 (0.0%) 0.014 *
Hand-foot syndrome - n (%) 7 (38.8%) 8 (25.8%) 0.35
All toxicities - n (%) 11 (61.1%) 7 (22.6%) 0.013 *
* statistical difference
No neuropathy was observed in both groups.
Conclusions
Obese patients (BMI > 30 kg/m²) presented with more toxicities 
(p = 0.013). Hypoalbuminemia did not represent a risk factor for 
toxicity in this study as patients had normal albumin levels. Obesity 
is a risk factor for toxicity in patients treated with docetaxel. Dosage 
calculation according to body surface area is not suitable for these 
patients. Toxicity in the group BMI < 30 seems to demonstrate greater 
susceptibility to the molecule for these patients.
Further studies will try to identify the different mechanisms of 
toxicity of docetaxel involved obese patients, including the interaction 
between docetaxel and fats. Measures have also to be taken to obtain 
a favorable effectiveness/toxicity balance in obese patients.
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P4-14-05
Chemotherapy-Induced Alopecia, Body Image and Psychological 
Distress in Women with Breast Cancer: A Prospective Study.
Choi E-K, Kim I-R, Nam S-J, Lee J, Yang J, Lee S-K, Noh D-Y, Han 
W, Cho J. Samsung Comprehensive Cancer Center, Samsung Medical 
Center, Sungkyunkwan University School of Medicine; Johns Hopkins 
Bloomberg School of Public Health; Samsung Medical Center, 
Sungkyunkwan University School of Medicine; Konkuk University 
Medical Center, Konkuk University School of Medicine; Seoul 
National University Hospital, Seoul Natioanl University School of 
Medicine
Purpose: While chemotherapy-induced alopecia (CIA) is known 
to be associated with lower quality of life, the longitudinal effect of 
alopecia on body image and distress in unknown. This study examined 
effect of CIA on body image and psychological distress during active 
breast cancer treatment.
Patients and Methods: Between July and Dec 2010, we recruited 
patients with non-metastatic breast cancer who were expected to 
receive adjuvant chemotherapy (N=411) from two cancer hospitals 
in Seoul, Korea. After excluding 15 patients with recurrence and 
65 patients lost to follow-up, the present analysis is based on 331 
patients (80.5%). Participants completed questionnaires on body 
image, quality of life, alopecia distress at enrollment (before surgery), 
before chemotherapy (2 weeks post surgery), during chemotherapy (3 
months post surgery), and after chemotherapy (6 months post surgery). 
Body image and quality of life were assessed by the EORTC QoL 
Questionnaire BR23. Alopecia distress was assessed by the Alopecia 
Distress Scale, which evaluated distress in 4 domains: physical, 
emotional, daily activity, and relationship.
Results: The mean age of the participants was 46.4 (SD 7.91) 
year. 44.9% and 37.6% of them had stage I and II breast cancer, 
respectively. 83.0% of the patients had lumpectomy, and 70.6% and 
85.9% had chemotherapy and radiotherapy, respectively. Patients 
who experienced alopecia had a significantly more negative body 
image and higher distress compared to those who did not experience 
alopecia. Body image rapidly decreased at 3 months post surgery 
coinciding with alopecia, and its effects lasted until 6 months 
post surgery. Moreover, there was a highly statistically significant 
association between more negative body image and higher alopecia 
distress after adjusting for other socio-demographic and clinical 
characteristics. The patterns and changes in body image and distress 
comparing patients with and without alopecia are reported in Table 1.
Variable Control Alopecia P-value
Alopecia distress (range 21 ~84)    
Mean (SD) at baseline 23.8 (8.89) 23.2 (7.34) 0.53
Change from baseline to 2 weeks (95% CI) -2.30 (-4.44, -0.16) -1.43 (-2.80, -0.05)  
Difference in change at 2 weeks (95% CI) reference 0.88 (-1.66, 3.42) 0.50
Change from baseline to 3 mo (95% CI) -1.09 (-3.51, 1.32) 18.53 (17.09, 19.95)  
Difference in change at 3 mo (95% CI) reference 19.62 (16.81, 22.43) <0.01
Change from baseline to 6 mo (95% CI) -2.35 (-5.17, 0.45) 16.68 (14.83, 18.53)  
Difference in change at 6 mo (95% CI) reference 19.04 (15.67, 22.40) <0.01
Body image (range 0~100)    
Mean (SD) at baseline 77.8 (24.06) 80.3 (19.12) 0.28
Change from baseline to 2 weeks (95% CI) -2.46 (-7.14, 2.22) -1.62 (-4.64, 1.40)  
Difference in change at 2 weeks (95% CI) reference 0.84 (-4.73, 6.41) 0.77
Change from baseline to 3 mo (95% CI) -6.86 (-12.27, -1.46) -18.06 (-21.22, -14.90)  
Difference in change at 3 mo (95% CI) reference -11.2 (-17.46, -4.93) <0.01
Change from baseline to 6 mo (95% CI) -3.39 (-9.74, 2.96) -19.39 (-23.56, -15.22)  
Difference in change at 6 mo (95% CI) reference -16.00 (-23.60, -8.41) <0.01
Discussion: Health professionals need to develop clinical pathways 
and education programs to help women with breast cancer manage 
alopecia distress and negative body image during active treatment.
P4-15-01
High Prevalence of Prospective Memory (PM) Impairment in 
Early Breast Cancer (EBC) Survivors within 1 Year of Adjuvant 
Chemotherapy Completion: Novel Findings Concerning Post 
Chemotherapy Cognitive Effects.
Paquet L, Verma S, Collins B, Song X, Wheatley-Price P, Hopkins S, 
Segal R, Dent S, Mirsky D, Goel R, Young V, Clemons M, Keller O, 
Chinneck A, Young R, Bedard M. Carleton University, Ottawa, ON, 
Canada; The Ottawa Hospital Cancer Center, Ottawa, ON, Canada; 
The Ottawa Hospital, Ottawa, ON, Canada
Background Numerous studies have demonstrated that EBC 
survivors report more memory problems than healthy controls. 
However, evidence of impairment on objective tests of memory 
remains inconclusive. Past research has focussed exclusively on 
retrospective memory (remembering information from the past when 
asked to do so), but the complaints of EBC patients appear better 
described as “prospective memory” failures defined as forgetting to 
carry out in the future previously formed intentions. The effective 
performance of many day-to-day activities relies on PM and its 
impairment has negative consequences in everyday life. Despite its 
high ecological relevance, no study has evaluated PM functioning 
in EBC survivors. Consequently, we assessed the prevalence of PM 
impairment among EBC survivors in the year following completion of 
chemotherapy. Methods We undertook a cross sectional quantitative 
case-control study aiming to recruit 80 patients from the Ottawa 
Hospital Regional Cancer Centre and 80 matched healthy controls 
from the community. Patients were within 1 year of having completed 
a first course of chemotherapy. A standardized test of prospective 
memory (Memory for Intention Screening Test) was administered 
to both groups. Following the International Cognition and Cancer 
Task Force recommendation (2008), impairment was defined as a 
score that fell one standard deviation below the mean performance 
of the control group. Standardized measures of depression (CESD), 
anxiety (STAI) and fatigue (Fact-F) were also completed. Results 
Data are available on 36 patients and 18 controls. Age was well 
balanced between the groups (case-control mean age 54y vs. 51y, 
respectively, p=.204). Overall PM impairment was observed in 41% 
of the participants. More importantly, the rate of PM impairment was 
significantly higher in the EBC group than controls (53% vs 17%; 
p < 0.005; odds ratio = 5.588; 95% CI=1.376 to 22.7). Multivariate 
logistic regression showed that PM performance was unaffected by 
age (p=0.459), depression (p=0.358), anxiety (p=0.512) or fatigue 
(p=0.595). Conclusions These preliminary findings provide further 
support for the hypothesis that breast cancer treatment can impair 
cognitive processes and yield new and important insights into the 
type of memory problems experienced by EBC survivors. They 
suggest that a significant proportion of patients exhibit deficits in 
PM, an aspect of memory involved in effective daily functioning. 
Our results also suggest that emotional distress and fatigue do not 
contribute to PM functioning. Further studies in this area should be 
directed at understanding the severity and duration of PM impairment. 
Acknowledging and studying this vexing problem in EBC survivors 
will aid in developing appropriate rehabilitation strategies.
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P4-15-02
Clinical and Epidemiological Correlates of Elevated Distress 
Thermometer Scores in Breast Cancer Patients.
Powers K, Pappas L, Buchmann L, Anderson L, Gauchay L, Rich A, 
Agarwal J. University of Utah, Salt Lake City, UT; Huntsman Cancer 
Institute, Salt Lake City, UT
Objectives: Distress is prevalent in breast cancer patients and can be 
detrimental to quality of life, performance status, treatment adherence, 
and satisfaction with medical care. The National Comprehensive 
Cancer Network (NCCN) developed the Distress Thermometer (DT) 
as a quick and efficient self-assessment tool for screening distress 
in cancer patients. While surveys estimate that between 20-40% of 
patients with cancer have significant levels of distress, fewer than 10% 
are identified and treated. Given time and monetary constraints, it is 
important to refine screening criteria to identify patients with elevated 
risk for distress. In this study, we identify clinical and epidemiological 
factors that are associated with an increased likelihood of elevated 
DT scores (≥4 and ≥7) in breast cancer patients.
Methods: We assessed 229 consecutive female patients with the 
DT at their initial consultation for breast cancer at the Huntsman 
Cancer Hospital between September 2007 and December 2008. The 
DT screening tool measures a global level of distress using a visual 
analogue scale from 0-10 in the shape of a thermometer, with zero 
identified as “No Distress” and ten labeled as “Extreme Distress.” The 
DT screening tool also includes a checklist of common emotional, 
family, physical, practical, and spiritual concerns with instructions 
for the paitent to indicate which of those concerns contributed to the 
distress they experienced within the past week. We chose a score 
≥4 as our cutoff for a positive screen for “distress” and a score ≥7 
as our cutoff for a positive screen for “extreme distress/depression” 
based on previous studies. Variables included in the analyses 
were: age, employment status, race/ethnicity, personal history of 
depression, family history of breast cancer, marital status, estrogen 
and progesterone receptor status, stage of cancer, time since diagnosis, 
and recurrence. Descriptive statistics and logistic regression models 
were used to determine associations between DT and patient data.
Results: Emotional and physical concerns were associated with scores 
≥4 and scores ≥7. Spiritual concerns were significantly associated 
with patients reporting scores ≥7. Patients who were non-Caucasian, 
unemployed, had a prior history of depression, who presented for 
recurrent disease, or who had been recently diagnosed had a higher 
likelihood of scores ≥4 and scores ≥7.
Conclusions: The likelihood of scoring ≥4 and ≥7 on the DT screening 
tool is highest during the first 30 days after receiving a breast cancer 
diagnosis. Four groups of patients should be targeted for aggressive 
screening: patients with a prior diagnosis of depression, patients 
presenting with recurrent disease, unemployed patients, and non-
Caucasian patients. Interventions should address physical, emotional 
and spiritual concerns.
P4-15-03
Patient-Provider Communication and Patient Informational 
Needs for Breast Reconstruction Post-Mastectomy: Results from 
a National Survey.
Ahmed I, Gubin A, Champion L, Harvey A, Amsellem M. The Cancer 
Support Community
For many women, the complexity of processing and learning about 
their breast cancer diagnosis is further complicated by decisions to be 
made about breast reconstruction post-mastectomy. Existing studies 
suggest that these women are provided with information about breast 
reconstruction options of differing depth, breadth, and quality, but 
little is known about how this information is received by the patient 
as well as the value of this information. Guided by Social Cognitive 
Theory, the Cancer Support Community (CSC) conducted a national 
survey in an effort to better understand patients’ information-seeking 
experiences, patient-provider communication, and knowledge about 
breast reconstruction. 840 U.S. women with breast cancer (762 
eligible for breast reconstruction who were then eligible to answer 
survey questions pertaining to their experiences) participated in the 
survey online or by paper-and-pencil at CSC affiliate sites in 2010. 
In addition to demographics, information about their diagnosis, 
treatment, and experience with reconstruction, women rated their 
experience with receiving breast reconstruction information from 
their healthcare professionals as well as their experience searching 
for and receiving information about options and realistic expectations 
for breast reconstruction.
Survey participants came from 46 states, were primarily Caucasian 
(85%), and the mean age at diagnosis was 48.9 years old. Most women 
reported that either a plastic surgeon (73.3%) or a breast surgeon 
(64.0%) had spoken to them about reconstruction, followed by 
oncologist (34.2%) and surgical oncologist (24.8%). Of women whose 
healthcare team had spoken with them about reconstruction, 57.1% 
reported that reconstruction was first discussed at diagnosis. Women 
reported that this information was somewhat (35.1%) or extremely 
(55.5%) useful, though they sought additional information elsewhere. 
Aside from their health care team, most women (60%) sought 
information about reconstruction from other women with breast 
cancer and half sought information from the Internet. Participants 
reported that they would have liked to have had more information 
prior to reconstruction about a variety of topics, including: how 
they would look after reconstruction (34.8% endorsing), how they 
would feel after reconstruction (35.5%), and information about their 
future breast health (25.9%). Open-ended responses suggest many 
patients experience gaps in information with regard to establishing 
realistic expectations about the procedures and outcomes, providing 
comprehensive information at various stages throughout the process, 
and across various treatment options.
Though many participants reported satisfaction with how information 
about reconstruction was provided to them and the quality and scope 
of this information, responses suggest that there is work to be done 
with regard to establishing realistic expectations about the procedures 
and outcomes, providing comprehensive information at various stages 
throughout the process, and across various treatment options.
P4-16-01
Proteomic Analysis of Patient Plasma Identifies Parathyroid 
Hormone Related Protein (PTHrP12-48) as a Potential Biomarker 
of Breast Cancer Bone Metastasis.
Washam CL, Byrum SD, Leitzel K, Suhail AM, Lipton A, Suva LJ. 
Winthrop P. Rockefeller Cancer Institute, University of Arkansas 
for Medical Sciences, Little Rock, AR; Penn State Hershey Cancer 
Institute, Penn State Hershey Medical Center, Hershey, PA; Lebanon 
VA Medical Center, Lebanon, PA
Background: Bone metastasis is a devastating and often incurable 
phase of breast cancer progression that significantly compromises 
patient morbidity and mortality. Despite the well-characterized issues 
associated with tumor progression, there is currently no reliable 
method to detect or predict which patients have or are at increased risk 
for developing bone metastasis. In this study a validated plasma-based 
proteomic profile for the diagnosis of breast cancer bone metastasis 
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was developed and a highly discriminatory protein component of the 
profile identified as a novel fragment of parathyroid hormone related 
protein (PTHrP).
Materials and Methods: Plasma samples were collected from a 
total of 110 breast cancer patients. The training set consisted of 38 
breast cancer patients with clinical evidence of bone metastasis and 
38 with no evidence of a bone metastasis from time of diagnosis 
to clinical outcome. The independent validation cohort consisted 
of 34 breast cancer patients with an unknown bone metastasis 
classification. The training set was analyzed using surface enhanced 
laser desorption time-of-flight mass spectrometry (SELDI-TOF 
MS) and 13 discriminatory protein peaks that contributed to a 
homogeneous partitioning of the training set (n = 76) in multiple 
statistical, bioinformatics, and machine learning modeling scenarios 
were identified and used to construct a RandomForest classifier for 
the detection of breast cancer bone metastasis (sensitivity: 100%, 
specificity: 100%).
Results: The diagnostic profile identified was then independently 
confirmed in a blinded fashion using the validation cohort (sensitivity: 
97%; specificity: 82%). Importantly, the most discriminatory protein 
peak (m/z 4260.92 Da) in the plasma of bone metastasis patients 
was subsequently identified using specific immunodepletion, tryptic 
peptide mapping and peptide sequencing as a unique proteolytic 
PTHrP fragment, PTHrP(12-48). Ongoing studies are determining 
the biogenesis and biological activity of this unique PTHrP peptide.
Discussion: Our discovery of PTHrP(12-48) as a novel plasma 
biomarker of breast cancer bone metastasis validates our plasma 
proteomic approach and provides the first direct evidence for the 
existence of a circulating PTHrP biomarker in breast cancer patient 
plasma that is associated with bone metastasis.
P4-16-02
Problems with Identifying Bone Metastasis-Specific Genes 
without Considering Biological Differences between ER-Positive 
and ER-Negative Breast Cancers.
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Nakamura S, 
Hortobagyi GN, Pusztai L, Symmans F, Ueno NT. The University of 
Texas MD Anderson Cancer Center, Hosuton, TX; The University of 
Texas MD Anderson Cancer Center, Houston, TX; Hospital of Prato 
and Instituto Toscano Tumori, Prato, Italy; Showa University School 
of Medicine, Tokyo, Japan
Background: Bone metastasis-specific genes in breast cancer have 
been reported without considering the significant differences in ER 
status between bone and non-bone metastases. The aims of this study 
were to validate genes that had been reported as bone metastasis-
specific genes using our data set and to identify bone metastasis-
specific genes on the basis of biological differences between ER-
positive and ER-negative breast cancers.
Patients and Methods: We used Affymetrix GeneChip arrays to 
analyze tumor samples obtained from 365 primary invasive breast 
cancer patients who underwent surgery from 1999 to 2008. We 
excluded patients with HER2-positive breast cancer (normalized 
HER2 mRNA expression [probe set 216836_s_at] > 12.54). We 
classified the samples into 3 cohorts according to first metastatic site: 
bone, non-bone, or no metastasis. Differential expression of genes 
between bone and non-bone cohorts that were differentially expressed 
was identified using the Cox proportional hazards model, and gene 
sets was assessed using gene-set analysis.
Results: Of the 365 patients, 34 (9.3%) were included in the bone 
cohort and 32 (8.8%) in the non-bone cohort. Two hundred fourteen 
(58.6%) had ER-positive and 151 (41.4%) had ER-negative breast 
cancer. First, we performed gene-set analysis using 5 gene sets that 
had been reported to be associated with bone metastasis. One gene 
set, which had been detected using an ER-negative breast cancer 
cell line, was validated as predicting bone metastasis in ER-positive 
breast cancer. None of the 5 gene sets predicted bone metastasis 
in ER-negative breast cancer. We then determined the levels of 
individual genes associated with bone metastasis by ER status using 
all 16,712 probe sets filtered by average gene expression level. When 
we analyzed all patients without any stratification by ER status, as 
in previous studies, 592 probe sets were significantly overexpressed 
in the bone cohort compared with the non-bone cohort, with a false 
discovery rate of ≤0.05. However, when we analyzed ER-positive 
and ER-negative breast cancers separately, no genes were found with 
significant differences between bone and non-bone cohorts. Finally, 
we used 2,246 functionally annotated gene sets assembled from Gene 
Ontology to examine possible biological differences between bone 
and non-bone cohorts. In the bone cohort, 151 and 125 gene sets were 
significantly overexpressed in ER-positive and ER-negative breast 
cancers, respectively (P ≤ 0.05). Ppathways related to Cellular growth 
and proliferation, and intracellular and second-messenger signaling 
were overexpressed in ER-positive breast cancer, whereas pathways 
related to nuclear receptor and cytokine signaling were overexpressed 
in ER-negative breast cancer. Most bone-metastasis-related pathways 
were different in ER-positive and ER-negative breast cancers (91.4% 
and 89.6% of the gene sets, respectively).
Discussion: No genes were found that can predict bone metastasis. 
ER-positive and ER-negative breast cancers have different biological 
potentials for bone metastasis. Therefore, we need to assess the 
prediction model of bone metastasis based on the biological features 
for each ER status separately.
P4-16-03
Proof of the Anti-Tumour Effect of Zoledronic Acid (ZA) in Naive 
Bone-Only Metastatic and Locally Advanced Breast Cancer: 
Results from the Biological Window Therapy.
Foroni C, Andreis D, Maldotti M, Cappelletti MR, Generali DG. 
Istituti Ospitalieri di Cremona, Cremona, Italy
Background:
Pre-clinical studies have demonstrated an anti-tumour activity of ZA 
in several cancers. However, the clinical evidence of the ZA anti-
tumour effect is still uncertain. Our study aimed to prove that ZA has 
anti-tumour activity administered alone as a biological window of 
14 days therapy on naïve bone-only metastatic and locally advanced 
breast cancer.
Material and Methods:
27 patients with locally advanced breast cancer (Group 1) and 12 
patients at their first relapse with bone metastasis only (Group 2) 
received 4 mg single dose of ZA before starting with any treatment. 
In Group 1, Ki67 expression was evaluated in tumour specimens 
obtained before and after ZA administration (basal, day 14). In Group 
2, circulating tumour cells (CTCs) were evaluated at baseline, 48 hrs 
and day 14. In Group 1 and 2, the apoptosis and necrosis of tumour 
cells were tested on blood samples by M30 and M65 ELISA assay 
respectively. Parallel, the anti-antitumor activity of ZA, given at the 
dose of 250 mg/mouse every 4 days for 6 cycles, in MDA-Mb-231 
bearing mice was evaluated.
Results:
A significant reduction of Ki67 expression after 14 days (mean, 
25.33% to 21.78%; p=0.035) was observed in Group 1. In Group 
2, we detected a significant reduction of CTC number after 48 hrs 
(median, 16 to 7; p=0.045), followed by a tendency to increase on 
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day 14 (p=0.093). The M30/M65 analysis performed on paired blood 
samples in Group 2 showed after 14 days a significant increase in 
M65 (median, 97 to 112 U/L; p=0.018), more accentuated than the 
concomitant increase in M30 (p=0.308). In MDA-MB-231 bearing 
mice, ZA treatment caused a significant inhibition of tumor growth.
Conclusions:
These results are the first prospective clinical data showing a 
direct anti-tumour effect (either on the tumour or on CTCs) of ZA, 
confirming the in vitro data. By directly affecting the proliferation, 
ZA could have an anti-tumour effect via induction of necrosis, 
suggesting its possible use in combination with conventional 
oncologic treatments of breast cancer.
P4-16-04
An Open-Label, Phase IIa, Non-Randomized Study of 
Radium-223 in Breast Cancer Patients with Bone Dominant 
Disease No Longer Considered Suitable for Endocrine Therapy.
Coleman R, Flamen P, Naume B, Jerusalem G, Garcia C, Piccart 
M, O’Bryan-Tear CG, Aksnes A-K. Weston Park Hospital, Sheffield, 
United Kingdom; Institut Jules Bordet, Brussels, Belgium; Oslo 
University Hospital, Oslo, Norway; CHU Sart Tilman, B35, 
Liege, Belgium; Algeta ASA, Oslo, Norway; Bayer Healthcare 
Pharmaceuticals, Montville, NJ
Background: Radium-223 (Alpharadin™) is a 1st-in-class alpha-
pharmaceutical. It targets bone metastases (mets) with high-energy 
alpha-radiation of extremely short range that spares bone marrow. 
These characteristics generate highly localized radiation zones that 
may inhibit tumor progression and induce pain relief. Radium-223 
has a profound effect on markers of bone metabolism and has shown 
a survival advantage over standard of care in pts with castration-
resistant prostate cancer. The study’s main objective was to investigate 
whether multiple IV injections (inj) of radium-223 have any clinically 
relevant effect on bone markers in metastatic breast cancer (MBC) 
pts with bone dominant disease (BDD). Methods: Study included 
MBC pts with BDD who had progressed (based on imaging or other 
clinically relevant information) on endocrine therapy and were no 
longer considered suitable for endocrine therapy. In this open-label, 
multicenter, single-arm, phase IIa study (EudraCT #2009-012189-30), 
23 pts were scheduled to receive 4 IV inj of radium-223 50 kBq/kg 
every 4 wk. Bone markers were assessed at baseline, prior to every 
treatment, and thereafter at each follow-up visit. Primary efficacy 
endpoint was change in urine levels of NTX (uNTX) and bALP at 
16 wk. Functional imaging with FDG-PET was performed in 20 pts 
at baseline and wk 8 and 16. Symptomatic response was assessed 
using validated questionnaires. Results: Histologic types were ductal 
carcinoma (n=12), lobular carcinoma (n=7), and others (n=2). Median 
interval from diagnosis of breast cancer to 1st relapse was 3 (1, 11) 
years. All except 1 pt received endocrine therapies, and adjuvant 
chemotherapy was given to approximately 60%. 21 of 23 pts were 
treated concurrently with bisphosphonates. 15 of 23 pts received all 
4 inj of radium-223; 4/23 received 3 inj; and 4/23 received 2 inj. Pts 
who received <4 inj had disease progression (bone and visceral mets 
[n=3], visceral mets [n=3]) or withdrawn consent (n=1) and were not 
eligible to continue radium-223. One pt died before 4th inj due to atrial 
fibrillation. Median age was 58 (41, 83) years. Median uNTX levels 
were reduced by 20% (from 36 to 29 nmolBCE/mmol creatinine; 
P=0.03) and 5% (from 36 to 23 nmolBCE/mmol creatinine; P=NS) 
at wk 8 and 16 respectively; 17/23 and 9/13 pts (for whom data 
were available) had a decrease in uNTX at wk 8 and 16 respectively. 
Median bALP levels were reduced by 33% (from 22.1 to 12.1 ng/
mL; P=0.0001) at wk 8 and 33% (from 22.1 to 10.4 ng/mL; P=0.04) 
at wk 16. Bone-ALP levels were reduced in 20/22 pts at wk 8 and 
in 10/12 pts (for whom data were available) at wk 16. Radium-223 
was found to be safe and well tolerated. 3 pts had serious AEs, none 
related to study drug; 1 of them died due to disease progression. 
Functional imaging results, additional bone marker data, and pt-
reported outcomes are being analyzed. Conclusions: Radium-223 
consistently reduced uNTX and bALP during the 16-wk treatment 
period, results observed in addition to bisphosphonate use. Results 
show radium-223 targets the areas of increased bone metabolism 
caused by bone mets. Radium-223 found to be safe and well tolerated, 
confirming highly tolerable SE profile seen in other studies.
P4-16-05
A Randomized Phase 2 Study of a Loading Dose of Ibandronate 
in Patients with Bone Metastases from Breast Cancer.
Ritchie DM, Bray C, Canney P. Beatson West of Scotland Cancer 
Centre, Glasgow, United Kingdom
Bisphosphonates have proven efficacy in reducing skeletal 
complications in metastatic breast cancer. Potent third generation 
bisphosphonates are more effective but the dose limiting toxicity 
is usually renal. Ibandronate is a 3rd generation bisphosphonate 
available in oral and intravenous form which offers many clinical 
advantages in ease of administration and lack of renal toxicity. A 
dose-response effect has been observed between 2mg and 6 mg 
IV doses and there is a single study suggesting that higher dosing 
(4 mg IV daily for 3 days) is tolerable and effective. A steady state 
of oral ibandronate is achieved at 8 days with oral administration 
but time to response is not known. In trials so far, IV ibandronate 
6mgs appears safe. Due to lack of renal toxicity there is potential for 
further escalation of IV ibandronate. The objective of this study was 
to establish if an IV loading dose can improve efficacy and time to 
biochemical response compared to oral standard therapy and to assess 
the safety of a higher IV dose of ibandronate.
Methods and Patients: This was an open randomised phase II 
study conducted on patients with bone metastases from breast 
cancer comparing IV ibandronate 12 mg on day 1 followed by oral 
ibandronate 50 mgs daily (Arm A) with standard oral therapy of 50 
mgs daily from day 1 (Arm B). The primary study end-point was 
the percentage reduction in serum CTX from baseline by day 5 on 
study, secondary end- points were the percentage reduction of bone 
turnover markers including serum CTX from baseline end of week 
8 and percentage reduction in urine NTX from baseline to day 5 
on study and baseline to end of week 1-8. Bone pain was recorded 
by Brief Pain Inventory. Patients had metastatic breast cancer with 
proven bone metastases, no previous treatment with bisphosphonates 
or other bone directed therapy within 6 months and no change in 
systemic therapy within a 3 months preceding trial therapy. Sample 
size of 22 patients in each arm was calculated to give a 90% chance 
detecting a 20% difference in average percentage reduction between 
the IV and oral arms.
Results: Seventeen patients were randomised to each study arm. A 
more rapid change in bone turnover markers was demonstrated in 
patients recieving the 12 mg loading dose of ibandronate. There was a 
15.8% greater reduction of serum CTX in Arm A compared with Arm 
B at day 5, p=0.005. The percentage reduction of serum PINP at day 5 
was also greater in Arm A, p=0.002. Over the 8 week period of study 
there was no overall significant difference in bone turnover markers. 
All patients had pain at study entry, median baseline pain severity 
scores were 3 in study arm and 4 in controls. Average bone pair score 
remained higher in treatment arm B at the end of 8 weeks. There 
were no additional adverse side-effects following administration of 
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12 mg of IV ibandronate and no evidence of additional renal toxicity.
Conclusion: A 12 mg dose of IV ibandronate can be safely 
administered without additional renal toxicity. A rapid reduction 
in bone turnover markers is demonstrated within 5 days of IV 
loading dose of ibandronate. Potential exists for dose escalation of 
ibandronate. The clinical benefit of a more rapid reduction in bone 
turnover markers is unknown.
P4-16-06
Expression Patterns of Receptor Activator of Nuclear Factor-kB 
(RANK) and Src in a Series of Primary Breast Tumors (BT) and 
Bone Metastases (BM) in Patients (pts) with Metastatic Breast 
Cancer (MBC).
Gucalp A, Comen E, Redana S, Evangelista L, Giri DD, Zhang XH, 
Patil S, Akram M, Norton L, Hudis CA, Fornier MN. Memorial Sloan-
Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, 
New York, NY; Piemontese per l’Oncologia - Institute for Cancer 
Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto 
(IOV - IRCCS), Padua, Italy
Background: BM develops in 65-70% of pts with MBC. RANK 
and its ligand (RANK-L) can be critical in the development and 
progression of BM. Src overexpression and deregulation occurs in 
many solid tumors but it has not been fully characterized although 
an association between Src activity defined by a gene expression 
signature and BM particularly in ER+ pts has been described. (Zhang 
XH et al. Cancer Cell. 2009) Our goal was to elucidate the relationship 
between Src and RANK expression in BT and BM in relation to 
estrogen-/progesterone-receptor (ER/PR)/HER2 expression and 
tumor histology (invasive ductal carcinoma (IDC) vs invasive lobular 
carcinoma (ILC)).
Methods: Immunohistochemistry (IHC) for RANK (R&D Systems 
clone 80707) and Src (Cell Applications Inc. Phospho Tyr-416) 
protein expression was performed on archived paraffin embedded BT 
and BM. Scoring: 0=negative, 1+=weak, 2+=intermediate, 3+=strong 
and the percent of positive tumor cells; RANK+ = 2-3+, > 1% of 
cells; Src+ = 1-3+; > 1% of cells. Associations between RANK/Src 
expression and tumor characteristics were assessed using the chi-
square test or McNemar’s test for pairs, as appropriate.
Results: From the MSKCC database, using an IRB-approved waiver 
of consent, we identified 54 pts with MBC who underwent surgical 
biopsy of a metastatic bone lesion at our center between 2005-
2010, and had tissue available for further testing. 17 corresponding 
BT samples were identified. At the time of diagnosis, 43 (79.5%) 
primary tumors were ER or PR (+); 6 (11%) were HER2+; 41 (76%) 
were invasive ductal carcinoma. 87% of BM expressed RANK and 
44% expressed Src. (Table 1) No significant correlation between 
RANK or Src expression in BM and ER/PR/HER2 status of BT was 
observed. A significant correlation between RANK expression and BT 
histology was observed, (p=0.0016): 93% of IDC were RANK (+), in 
comparison to 50% of invasive lobular carcinomas. RANK expression 
was not significantly different between primary tumor and metastatic 
bone samples (p=0.99). There was a borderline significant difference 
in Src expression between primary and metastatic site (p=.06).
Table 1. Tumor Characteristics (n = 54)
Characteristics Number of patients (%)
ER status  
Positive 43 (79.5)
Negative 10 (18.5)
Unknown 1 (2)
PR status  
Positive 40 (74)
Negative 13 (24)
Unknown 1 (2)
HER2 status  
Positive 6 (11)
Negative 46 (85)
Unknown 2 (4)
Histology  
IDC 41 (76)
ILC 8 (15)
Mixed IDC/ILC 4 (7)
Other 1 (2)
Bone Metastases  
RANK expression 47 (87)
Src expression 24 (44)
Primary Tumor  
RANK expression 16 (94)
Src expression 12 (71)
Conclusions: In our cohort, no correlation between RANK or Src 
by IHC and ER/PR/HER2 was identified but RANK expression 
was more common in IDC than ILC. Fidelity was high for RANK 
between primary and metastatic lesions while Src expression may 
possibly vary.
P4-16-07
Breast Cancer Bone Metastasis Prevalence and Survival 
Outcomes: A Quantitative Review of the Literature.
Mitchell ME, Taylor A, Lowe KA, Langeberg W, Alexander D, Kelsh 
M, Body J-J. Exponent; Amgen; CHU Brugmann
Background: Bone metastases are common in breast cancer 
patients and an important cause of morbidity and mortality. This 
review provides the first systematic and quantitative summary of the 
proportion of breast cancer patients with bone metastasis and their 
survival, presented by stage at diagnosis and length of follow-up.
Materials and methods: A literature review was conducted using 
PubMed to identify full-text studies published in English 1999-
2009. Studies were included if they had ≥100 adult patients with 
Stage I-IV breast cancer and were generalizable to the overall breast 
cancer population. The design and intent of included studies varied, 
including clinical trials of bone-targeted therapies and observational 
studies of cancer patients evaluating staging techniques, biomarkers, 
and other factors. To improve homogeneity, studies were grouped by 
stage at diagnosis, whether follow-up for bone metastases occurred, 
and the clinical point at which the proportion of patients with bone 
metastasis was estimated (e.g., at initial staging). Studies reporting 
survival were only included in quantitative summaries if survival was 
measured from the date of bone metastasis diagnosis. With regard to 
clinical trials of bisphosphonates, only proportion and survival data 
from the placebo group were utilized since the goal was to describe 
bone metastasis among patients untreated with bone-targeted therapy. 
Meta-analytic techniques were applied to (1) proportion data using 
random effects models to calculate weighted averages, and (2) 
survival data using an average of reported median survivals. Various 
sensitivity analyses were also conducted.
Results: Nineteen studies were included in our quantitative summary 
of proportion data. At initial staging of breast cancer, 7% (N=2; 95% 
confidence interval [CI]=5-9%) of all patients had bone metastases 
and 69% (N=2; 95% CI=47-85%) of Stage IV patients had bone 
metastases. Among breast cancer patients followed from the diagnosis 
of Stage I-III breast cancer, 10% (N=6; 95% CI=6-15%) had bone 
metastases after a median follow-up <10 years, compared to 24% 
(N=3; 95% CI=19-31%) after a median follow-up >10 years. Twelve 
studies were included in our quantitative summary of survival data. 
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Survival was longer among patients with metastases solely in bone 
(N=7; average median=30 months), compared to patients with bone 
metastases and metastases at other sites (N=5; 23 months) and patients 
with metastases only at sites other than bone (N=3; 9 months). 
Discussion: Significant heterogeneity across studies was observed, 
reflecting the variability in study populations, locations, and other 
factors. Despite this and other limitations (e.g., few studies in some 
categories), this represents the first analysis of the literature to quantify 
the prevalence and survival of bone metastasis in breast cancer. Our 
results indicated that bone is a site of metastasis among more than 50% 
of Stage IV patients at diagnosis of breast cancer. Median survival 
among breast cancer patients with metastases located solely in the 
bone is at least six months longer compared to those with metastases 
at multiple sites (including bone) and sites other than bone.
P4-16-08
Pilot Randomized Trial of De-Escalated (q12 Weekly) Versus 
Standard (q3-4 Weekly) Intravenous Bisphosphonates in Women 
with Low-Risk Bone Metastases from Breast Cancer.
Amir E, Freedman O, Carlsson L, Usmani T, Lee E, Dranitsaris 
G, Clemons M. Princess Margaret Hospital and The University 
of Toronto, Canada; The Ottawa Hospital Cancer Centre and The 
University of Ottawa, Canada
Background: Bone-targeted agent such as bisphosphonates (BPs) 
can reduce skeletal complications from bone metastases but have no 
effect on either disease progression or survival. Despite substantial 
variability in the frequency and severity of skeletal complications, 
patients are empirically treated with BPs at the same dose and schedule 
irrespective of their individual risk.
Materials and Methods: A pilot, randomized, non-inferiority trial 
was conducted. Patients with low-risk bone metastases (serum 
C-telopeptide [CTx] <600ng/L after at least 3 cycles of monthly IV 
BP) were assigned to pamidronate 90mg IV either every 3-4 weeks 
(control) or every 12 weeks (de-escalated). Data on serum CTx and 
bone alkaline phosphatase (BAP), pain scores (brief pain inventory 
[BPI] and functional assessment of cancer therapy-bone pain [FACT-
BP]) were collected at 12 weekly intervals for 48 weeks.
Results: Fifty-four patients were approached, 44 provided consent 
and 38 were eligible for randomization. Median age was 55 (range 
29-77) and mean baseline CTx was 319ng/L (range 10-526). Thirty-
five participants (92%) completed the trial, 2 withdrew consent and 
one participant died. Fourteen control group participants (73.7%) 
and 13 experimental group participants (68.4%) maintained CTx 
in the low risk range (test for two proportions p=0.64). All patients 
not maintaining CTx in the low risk range showed evidence of both 
visceral and bone progression. Compared to the control group, there 
was a trend towards increasing CTx with time in the experimental 
group (p=0.10). There was no significant difference in BAP (p=0.37), 
BPI (p=0.21) or FACT-BP scores (p=0.59) between the two groups. 
Over the 48 week follow-up, two skeletal events were observed in 
each group.
Conclusions: Randomized trials of de-escalated BP therapy in 
women with low-risk bone metastases are feasible. Twelve-weekly 
pamidronate appears non-inferior to 3-4 weekly treatment. Larger 
trials are required to assess whether; 1) increasing CTx levels with 
de-escalated therapy will lead to higher rates of skeletal complications 
and 2) whether BP should be given every 3-4 weeks in patients with 
progressive visceral and bone disease.
P4-16-09
Health Resource Utilization (HRU) Associated with Skeletal-
Related Events (SREs) in Advanced Breast Cancer Patients 
with Bone Metastases: Results from a Prospective Multinational 
Observational Study.
Lüftner D, Lorusso V, Duran I, Hechmati G, Garzon-Rodriguez 
C, Ashcroft J, Bahl A, Ghelani P, Wei R, Thomas E, Hoefeler H. 
Universitätsmedizin Berlin, Berlin, Germany; Oncology Institute ASL, 
Leece, Italy; Centro Integral Oncologico Clara Campal (CIOCC), 
Madrid, Spain; Amgen (Europe) GmbH, Zug, Switzerland; Instituto 
Catalán Oncología ICO-IDIBELL, Barcelona, Spain; Pinderfields 
General Hospital, Wakefield, United Kingdom; University Hospitals 
Bristol, Bristol, United Kingdom; Ovatech Solutions, London, United 
Kingdom; Amgen Inc., So. San Francisco, CA; Forschungszentrum 
Ruhr, Witten, Germany
Background
Patients with advanced breast cancer and bone metastases suffer from 
skeletal complications (SREs, defined as spinal cord compression 
[SCC], surgery to bone [SB], pathologic fracture [PF] or radiation to 
bone [RB]). Planning future resource requirements and estimating the 
value of new treatment options requires prospective data on the health 
resource burden. However, there is a lack of these data in the literature.
Materials and Methods
Patients had bone metastases secondary to advanced breast cancer 
and were eligible to be included in the study if they had: at least one 
SRE within 90 days prior to enrolment; life expectancy >6 months; 
ECOG≤2. HRU (number and length of inpatient hospitalizations, 
outpatient visits, emergency room visits, number of procedures, etc) 
associated with SREs was collected retrospectively for 90 days prior 
to enrolment and prospectively for up to 18-21 months. Attribution of 
HRU to each SRE was determined independently by the investigators. 
This pooled European analysis includes data for breast cancer patients 
from centers in Germany, Italy, Spain and UK.
Results
A total of 223 eligible patients with breast cancer and bone metastases 
were enrolled from the four countries. A total of 118 of 457 SREs 
(25.8%) were associated with inpatient stays with a mean duration 
of 18.2 (SD=15.7) days per inpatient stay (for the total 125 stays; a 
single SRE could contribute multiple hospitalizations). The length of 
inpatient stays varied by facility (i.e., oncology, radiation, surgical) 
and SRE type. The most common SRE requiring hospitalization was 
SB (42 of 54 events [77.8%]) with 45 inpatient stays requiring an 
average length of stay of 15.1 (SD=16.8) days. The least common 
SRE requiring hospitalization, RB (27 of 279 events [9.7%]), was still 
associated with 23 inpatient stays with an average of 16.7 (SD=12.4) 
days per inpatient stay. A total of 342 SREs (74.8%) required an 
outpatient visit and 159 (34.8%) required >5 visits. As expected, RB 
was associated with the highest number of outpatient visits (239 of 
279 [85.7%] SREs). SB and PF were associated with fewer outpatient 
visits with 23 of 54 (42.6%) of 54 SREs and 66 of 105 (62.9%) SREs 
requiring a visit, respectively. 22 of 457 (4.8%) SREs were associated 
with an emergency room visit.
Discussion
SREs can lead to lengthy hospitalizations and numerous outpatient 
visits. Neither pain requiring opioid use nor changes in cancer therapy 
to treat bone pain were reported as SREs, although they may have led 
to additional inpatient and outpatient visits. Thus, HRU estimated in 
this study likely underestimates overall HRU associated with SREs 
in advanced breast cancer patients. Relatively low utilization of 
emergency room visits reported here may be due to emergency care 
provided directly by the specialist oncology unit or the patient visiting 
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a different institution. Preventing SREs in advanced breast cancer 
patients may help to reduce the financial burden to the European 
healthcare systems.
P4-17-01
Trastuzumab Does Not Increase the Incidence of Central Nervous 
System (CNS) Relapses in HER2-Positive Early Breast Cancer: 
The HERA Trial Experience.
Pestalozzi B, Holmes E, Metzger O, de Azambuja E, Hogge L, Scullion 
M, Gelber R, Piccart-Gebhart M, Cameron D. HERA Study Team
Background: Retrospective studies of HER2-positive metastatic 
breast cancer (BC) showed an incidence of CNS metastases of 
21% to 34%. We investigated the incidence and clinical aspects of 
CNS relapse (CNS-R) in patients (pts) enrolled in the HERA trial, a 
prospectively randomized adjuvant trial in node + or high-risk node 
- HER2-positive early BC pts.
Methods: 3401 pts were randomized into the 1-year trastuzumab 
(1yT) or the observation (obs) arms of HERA (Piccart-Gebhart et 
al, 2005, Gianni et al, 2011). The cumulative incidences of first 
disease-free survival (DFS) events in the CNS vs other sites were 
estimated using competing risk analysis. The database of the main 
study had a clinical cut-off date of 9th June 2008. To obtain additional 
information regarding CNS-R (including occurrence of CNS-R after 
first DFS event), a specific CNS-directed questionnaire was sent to 
investigators of pts who were deceased as of July 2009. Information 
collected included the date of CNS-R, whether it was symptomatic, the 
type of CNS-R (brain metastases (BM) or meningeal carcinomatosis 
(MC)), methods of diagnosis, and treatments at the time of CNS-R.
Results: 1yT significantly reduced the risk of other DFS events 
(p=0.000017, Gray’s test), but not of CNS-R (p=0.55) as first event 
(see table). During the first year of follow up, CNS-R accounted for 
15 (14.9%) of the 101 first DFS events in the 1yT arm and 15 (7.7%) 
of the 194 first DFS events in the obs arm. The analysis of baseline 
patient and tumor characteristics associated with CNS-R as first event 
confirmed known risk factors such as young age (<35y), T3 tumor, 
≥ 4 + LN, ER neg, and G3.
First DFS event  Cumulative Incidence of First DFS Events
 Arm 6m 12m 18m 24m 30m 36m
CNS-R 1yT 0.5% 0.9% 1.3% 1.6% 1.9% 2.1%
CNS-R Obs 0.4% 0.9% 1.0% 1.4% 1.5% 1.8%
Other DFS event 1yT 2.2% 5.2% 8.2% 11.8% 14.6% 16.3%
Other DFS event Obs 4.7% 11.0% 14.9% 18.2% 21.0% 22.8%
413 of the 481 questionnaires (85.9%) were returned. 217 of the 413 
deceased pts had a CNS-R diagnosed prior to death (52.5%), with 
more events occurring in the 1yT arm (see table). By contrast, the 
incidence of CNS-R as first DFS event was balanced across the arms.
Event 1yT arm Obs arm Overall
First DFS events in 9 June 2008 dataset    
CNS-R as first DFS event 37 32 69
Other first DFS event 326 421 747
CNS-R events at any time among pts 
deceased as of July 2009 survey
   
Died with CNS-R 88 129 217
Died without CNS-R 98 98 196
Based on the survey data, CNS-R was symptomatic in 189 pts 
(87.1%) with no differences between arms. BM were present in 
211 pts (97.2%), absent in 5 (2.3%), and missing information in 1 
(0.5%). MC was diagnosed in 25 pts (11.5%), absent in 187 (86.2%), 
missing information in 5 (2.3%). Frequencies for BM and MC were 
very similar in both arms.
Conclusion: This retrospective analysis of a prospective large study 
shows more than 50% incidence of clinically diagnosed CNS-R in 
HER2-positive BC pts who have died. CNS-R was symptomatic in 
most pts. CNS-R at any time was less frequent in the 1yT arm (88 vs 
129). There is no evidence that adjuvant trastuzumab increases the 
incidence of CNS-R.
P4-17-02
Whole-Brain Radiation Therapy Plus Concomitant Temozolomide 
for the Treatment of Brain Metastases from Breast Cancer: A 
Randomized Prospective Multicenter Phase II Study.
Kirova YM, Hajage D, Gerber S, Le Scodan R, Pierga J-Y, Bourgier 
C, Campana F, Asselain B, Fourquet A, Levy C. Institut Curie, Paris, 
France; Institut Gustave Roussy, Villejuif, France; Centre François 
Baclesse, France
BACKGROUND: A previously published study of temozolomide 
(TMZ) concurrent with whole-brain radiation therapy (WBRT) 
reported significant improvement in response rates and a nonsignificant 
trend toward improved overall survival compared with WBRT alone 
in patients with brain metastases in different type of tumors. A 
prospective randomized phase II trial of concurrent WBRT and TMZ 
versus WBRT alone was conducted to assess whether the concurrent 
use of WBRT-TMZ resulted in measurable radiological response 
differences at 6 weeks after the treatment in homogeneous population 
of breast cancer (BC) patients.
PATIENTS AND METHODS: In this intent-to-treat study, patients 
with metastatic breast cancer to the brain and not suitable for 
surgery or radio-surgery were enrolled in a randomized prospective 
multicenter phase II study between February 2008 and December 
2010. Patients received temozolomide 75 mg/m(2)/day (days 1-15) 
concurrently with WBRT 30 Gy/10 fractions. Patients were stratified 
by type and metastatic sites. The (MRI) response at 6 weeks was 
the main criteria; response was defined as complete (CR) or partial 
response (PR). Initial and follow-up MRI were realized on a 1.5T 
unit (Siemens) by axial SE-T1 WIs and FLAIR WIs with GdDTA 
injection, EG-3DT1 WIs after GdDTPA. Five target lesions (over 10 
mm greatest diameter) were measured in their 3 dimensions. Non 
measurable lesions were noticed.”The treatment tolerance and clinical 
responses were also evaluated. The study was designed according to 
a modified Fleming two-stage plan based on response hypotheses 
of 30% (H0) versus 50% (H1). Twenty or more responses among 
50 subjects were needed to declare the treatment effective, with risk 
errors alpha 9% and beta 7%.
RESULTS: One hundred metastatic breast cancer patients were 
enrolled in the study, as following: 49 in WBRT-TMZ and 51 in 
WBRT groups. The median age was 55 years [range, 29-79]. The 
median follow-up was 12 weeks [range, 1-94]. There were 15/49 
(31%) partial responses (PR) in WBRT-TMZ and 18/5 1(35%) PR in 
WBRT group. No complete responses were observed. The symptoms 
relief was obtained in 27/49 and 31/51 pts, respectively. The treatment 
tolerance was acceptable in both groups.
CONCLUSION: The benefit of adding TMZ to WBRT was not 
confirmed at 6 weeks. The tolerance was good in both groups. Longer 
follow-up is needed to evaluate the combination of TMZ with WBRT 
in terms of progression free survival.
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P4-17-03
Incidence Rate of Asymptomatic Brain Metastases in Patients 
with HER2+ Metastatic Breast Cancer Screened for EGF111438/
CEREBEL Study.
Pivot X, Hackmann J, Manikhas A, Moore Y, Parikh R, Kothari D, 
Joshi A, Aktan G, Coleman R. University Hospital of Besancon; 
Marien-Hospital; St Petersburg City Clinical Oncology Dispensary; 
GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Uxbridge, 
United Kingdom; Weston Park Hospital
BACKGROUND
Brain metastases constitute a major clinical concern occurring in 28-
43% of women treated for HER2+ metastatic breast cancer (MBC). 
The initial diagnosis of Central Nervous System (CNS) lesion is 
commonly based upon development of neurological symptoms. 
Data to address incidence of CNS lesions in asymptomatic patients 
are rare and not generally reported. EGF111438/CEREBEL study 
requires systematic screening for brain metastases by brain MRI 
and the ineligible patients due to detection of asymptomatic brain 
metastases are reported here.
METHODS
The patients screened for CEREBEL have consented to a multi-centre, 
open-label Phase III study in subjects with HER2+ metastatic breast 
cancer who received prior treatment with anthracyclines or taxanes 
and trastuzumab in the adjuvant or metastatic setting. Eligible 
subjects must not have any history of CNS metastases (including 
leptomeningeal involvement) or have evidence of benign or malignant 
brain tumours and/or clinical evidence of spinal cord metastases at 
baseline. In order to confirm this, subjects must have negative brain 
MRI at baseline as confirmed by independent review (IR). All MRI 
scans of the brain had to be acquired with gadolinium contrast agent 
(T1 only) and 3mm slice thickness without gaps. The primary endpoint 
of CEREBEL is the incidence of CNS lesions as first site of relapse. A 
total of 650 subjects (325 per group) are expected to be randomized 
between capecitabine + trastuzumab versus capecitabine + lapatinib.
RESULTS
The study is currently recruiting with 322 patients enrolled as of 
15.06.2011. At this date, the total number of patients screened 
were 492 and 170 of these patients were screen failures. There are 
15 patients in screening. The percentage of screen failures due to 
asymptomatic brain metastases assessed by investigators was 13.5% 
(23/170). The overall incidence of clinically asymptomatic brain 
metastases assessed by investigators for this study is 4.7% (23/492).
CONCLUSIONS
Around 5% of all screened patients (14% of screen failures) in this 
study who were clinically thought to be free of brain lesions actually 
had brain metastases verified by brain MRI. We therefore conclude 
that screening for occult brain metastases by MRI is important for 
trials with defined CNS endpoints.
P4-17-04
Pharmacokinetic Disposition of PEGylated Liposomal 
Doxorubicin Compared with Non-Liposomal Doxorubicin in an 
Intracranial Breast Cancer Murine Model.
Anders CK, Adamo B, Walsh MD, Karginova O, Darr D, Deal AM, 
Santos C, Bash R, Hanna SK, Carey LA, Miller CR, Sharpless N, 
Zamboni WC. University of North Carolina at Chapel Hill (UNC), 
Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, 
Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel 
Hill, NC; University of Messina, Messina, Italy
Background: Breast cancer brain metastases are an increasingly 
common consequence of advanced breast cancer associated with 
poor prognosis and survival. Systemic therapies capable of crossing 
the blood brain barrier to control both intra- and extracranial disease 
are few. Nanoparticle agents, such as liposomes, achieve a higher 
concentration and prolonged exposure in solid tumors. Liposomal 
formulations of anti-cancer agents have also been shown in 
preclinical and clinical studies to enhance delivery to tumors within 
the brain. We compared the pharmacokinetic (PK) disposition of 
PEGylated liposomal doxorubicin (Doxil®; PLD) with non-liposomal 
doxorubicin (NLD) in an intracranial breast cancer model.
Methods: Athymic (nu/nu) mice (~8wks) were inoculated with MDA-
MB-231-BR (brain subclone) cells expressing luciferase (2×105 cells/
injection) in 5% methylcellulose (5µL) into the right caudate nucleus. 
On day 18, tumor-bearing mice via bioluminescence imaging were 
administered PLD or NLD at 6 mg/kg IV × 1 via tail vein. Mice (n=3) 
were sacrificed at 6 and 24h for PLD and NLD; and 72h for PLD. 
Plasma and intracranial tumor were processed to measure sum total 
doxorubicin via high-performance liquid chromatography (HPLC, 
lower limit of quantification=10 ng/mL). T-tests were used to compare 
means between treatment groups.
Results: Treatment with PLD resulted in higher plasma sum total 
doxorubicin concentrations compared with NLD (Table). PLD was 
detected at 72h in plasma. There were higher intracranial tumor sum 
total doxorubicin concentrations at 6 and 24h for PLD compared with 
NLD; NLD was below limit of quantification (BLQ) at both time 
points. Consistent with the plasma PK of PLD, intracranial tumor sum 
total doxorubicin concentrations for PLD remained elevated at 72h.
Mean ± SD Sum Total Doxorubicin Concentrations
 Time Point
Specimen 6h 24h 72h
 PLD NLD PLD NLD PLD NLD
Plasma  
(ng/mL)
78,691.2 (22,794.2) 17.3 (7.1) 36,646.3 (5,233.3) 14.5 (3.3) 5,909.4 (461.6) -
P value 0.027 0.007 -
Intracranial  
tumor(ng/g)
343.4 (149.8) BLQ 178.6 (22.1) BLQ 131.4 (67.9) -
Conclusions: Liposomal formulations of anti-cancer agents represent 
a promising treatment strategy to treat aggressive breast cancer 
brain metastases due to extended circulation time in plasma and 
higher exposure in intracranial tumor compared with small molecule 
counterparts. In this proof-of-concept preclinical study, PLD exhibits 
both higher and prolonged plasma and intracranial tumor exposure 
compared with NLD. The mechanism of higher intracranial tumor 
exposure with liposomal agents is unknown, however may be due 
to prolonged exposure in plasma, diffusion of encapsulated and/or 
released drug across the blood brain barrier, or enhanced permeation 
and retention effect in tumors. The improved PK profile and tumor 
distribution of PLD compared with NLD in this intracranial BC 
model are hypothesized to translate to improved efficacy and toxicity 
profiles over that of non-liposomal formulations and may represent 
a promising treatment strategy for a disease with limited treatment 
options.
P4-17-05
Brain Metastasis Free Survival (BMFS) Differs between Breast 
Cancer Subtypes.
Bartsch R, Berghoff A, Bago-Horvath Z, DeVries C, Dubsky P, 
Pluschnig U, Rudas M, Rottenfusser A, Fitzal F, Dieckmann K, 
Mader RM, Gnant M, Zielinski CC, Steger GG. Medical University 
of Vienna, Vienna, Austria
BACKGROUND
Brain metastases (BM) are frequently diagnosed in patients (pts) with 
Her2-positive metastatic breast cancer (BC); a rising incidence was 
also reported in triple-negative disease. We hypothesized that pts 
with triple-negative or Her2-positive tumours had shorter BMFS as 
compared to other BC subtypes.
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Therefore, we aimed to compare BMFS in pts with Her2-positive, 
estrogen receptor (ER) positive and triple-negative BC treated at 
the Medical University of Vienna from 1999-2009. In Her2-positive 
tumours, we further investigated the influence of ER co-expression 
on BMFS, as Her2-positive / ER-positive tumours were reported to 
express less aggressive biological properties.
METHODS
BMFS was defined as primary study endpoint and measured as the 
interval from diagnosis of metastatic BC until diagnosis of BM.
A total of 168 pts were identified from a breast cancer database. 34 pts 
were excluded from this analysis as brain was the first site of disease 
progression; hence complete datasets from 134 pts were available (69 
Her2-positive; 33 triple-negative; 32 ER-positive).
Her2 status was analyzed by immunohistochemistry (IHC) and 
reanalyzed by FISH if a score of 2+ was gained. ER was analyzed 
by IHC; ER negative tumours were defined by a cut-off value of 
<10% positively stained tumour cells. BMFS was estimated with the 
Kaplan-Meier product limit method and compared with the log-rank 
test; factors significantly associated with BMFS in the univariate 
analysis were included into a Cox proportional hazard model.
RESULTS
Median BMFS in triple-negative pts was 14 months (m) (95% CI 
12.17-15.83), as compared to 25 m (95% CI 13.37-36.62) in Her2-
positive (p=0.001) and 35 m (95% CI 19.79-50.22) in ER-positive 
pts (p<0.001), respectively.
In Her2-positive pts, prior trastuzumab treatment for metastatic 
disease prolonged median BMFS (29 vs. 11 m; p<0.001); BMFS 
was further improved by trastuzumab in multiple lines (p=0.045) and 
co-positivity for ER and Her2 (30 vs. 15 m; p<0.001).
ER-expression (HR 2.03; 95%CI 1.22-3.36; p<0.05) and prior 
trastuzumab (HR 2.72; 95%CI 1.20-6.17; p=0.017) remained 
independent predictors of longer BMFS in the Cox regression model.
In ER-positive, triple-negative as well as Her2-positive pts, no 
correlation was found between BMFS and factors such as grading, 
histological subtype, stage IV disease at primary diagnosis, disease-
free interval <24 months from primary treatment to diagnosis of 
metastatic disease, presence of visceral metastases, presence of lung 
metastases, and prior capecitabine exposure.
CONCLUSIONS
BMFS in triple-negative disease is significantly shorter as compared 
to Her2-positive or ER-positive tumours, mirroring the aggressiveness 
of this breast cancer subtype. Probably due to improved systemic 
disease control, trastuzumab significantly prolonged BMFS in Her2-
positive pts. Longer BMFS in ER/Her2 co-positive disease reflects 
a less aggressive subtype of Her2-positive breast cancer which is 
less likely to benefit from strategies of BM screening or prevention.
P4-17-06
Prognostic Role of Triple Negative Subtype in Breast Cancer 
Patients with Brain Metastases.
Mathew A, Mathew IE, Rosenzweig MQ, Brufsky AM. University of 
Pittsburgh Medical Center; University of Pittsburgh Cancer Institute; 
Magee-Womens Hospital
Background: Metastatic breast cancer (MBC) patients with brain 
metastases (BM) have a poorer prognosis compared to patients with 
metastases to sites such as bone or other visceral organs. The role 
of breast cancer subtypes such as triple negative (TN) status and 
its relationship with other known prognostic factors have not been 
well delineated in the context of metastatic disease to the brain. We 
conducted a retrospective single institution cohort study of MBC 
patients with BM to evaluate the association between TN subtype 
and overall survival from the diagnosis of BM.
Methods: Baseline demographic and tumor specific data including 
ER, PR and HER2 status were collected on newly diagnosed 
MBC patients between January 1998 and December 2009. Overall 
survival was determined from the date of diagnosis of BM. Survival 
analyses were performed using the Kaplan-Meier method and Cox 
proportional-hazards model.
Results: Data were available on 186 MBC patients with BM, of 
whom 156 died during a median follow-up of 10.2 months from the 
diagnosis of BM; median age was 47.9 years. 91% of patients were 
Caucasian; 25.3% had triple negative disease. Median survival from 
the period of diagnosis of BM in patients with triple negative disease 
was 7 months (Interquartile range, IQR: 3-13) as compared to 11 
months (IQR: 5-22) in patients who were HER2-positive or ER/PR-
positive. Multivariate analysis found a higher risk of death after BM 
for TN disease subtype, with a hazard ratio for death of 2.89 (95% 
confidence interval: 1.89-4.44; p<0.001), when adjusted for variables 
such as age and stage at initial diagnosis of breast cancer, race, the 
number of metastatic sites, and the use of metastatic chemotherapy. 
The administration of metastatic chemotherapy had a significant 
survival benefit in the analyses, with a hazard ratio for death of 0.52 
(95% CI: 0.27-0.99; p=0.048).
Conclusion: This retrospective cohort study in MBC patients with 
BM provides evidence for a greater risk of death in those with TN 
disease as compared to HER2-positive or ER/PR-positive subtypes 
even after adjusting for other prognostic factors.
P4-17-07
The Shifting Landscape of Metastatic Breast Cancer to the CNS.
Quigley MR, Fukui O, Chew B, Bhatia S, Karlovits S. Allegheny 
General Hospital, Pittsburgh, PA
Introduction: Improved survival following the diagnosis of breast 
cancer, in conjunction with new therapies and diagnostics has 
potentially altered the characteristics and course of patients presenting 
with CNS involvement.
Methods: Review of clinical and radiographic records of women 
presenting to a tertiary medical center with the new diagnosis of CNS 
metastatic disease from breast cancer. This was a retrospective review 
from patients identities obtained from two prospective databases
Results: There were 88 women analyzed who were treated over 
the period 1/2003-2/2010, average age 56.9. At the time of initial 
presentation of CNS disease, 68% of patients had multiple brain 
metastases, 17% had a solitary metastasis and 15% had only 
leptomeningeal disease (LMD). The median survival for all patients 
from the time of diagnosis of breast disease was 50.0 months, and 9.7 
months from diagnosis of CNS involvement. The only factor related 
to overall survival was estrogen receptor positive (ER+) pathology 
(57.6 v. 38.2 months, p=.02 log-rank); those related to survival post 
CNS diagnosis were presentation with LMD (p=.004, HR= 3.1, Cox 
regression) and triple negative hormonal/HER2 status (p=.02, HR= 
2.3, Cox regression). Patients with either had a median survival of 
3.1 months (no patients in common). Of the 75 patients who initially 
presented with metastatic brain lesions, 20 (26%) subsequently 
developed LMD in the course of their disease (median 10.4 months), 
following which survival was grim (1.8 months median). Of note 
was that HER2+ status was protective in regard to late development 
of LMD (14.7 vs. 42.3%, p=.03, Chi-square). Symptoms of LMD 
were most commonly lower extremity weakness (14/33), followed 
by cranial nerve deficits (11/33).
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Conclusion: Treatment of patients with metastatic brain disease from 
breast cancer should be tailored to the patient’s hormonal status (as it 
markedly effects survival) and practitioners must be vigilant for the 
development of LMD, especially as it often presents with non-descript 
complaints such as back pain.
P4-17-08
Is Cranial Magnetic Resonance Imaging (MRI) Necessary for 
Staging of Asymptomatic HER2-Positive Breast Cancer Patients?
Kaplan MA, Inal A, Kucukoner M, Urakci Z, Isikdogan A. Dicle 
University, Diyarbakir, Turkey
Background: Breast cancer one of the most common tumors of 
the adults. Approximately 20% to 25% of all breast cancers are 
HER2-positive. It can be assumed that up to 30% of HER2-positive 
metastatic breast cancer (MBC) patients may experience brain 
metastasis during the course of their disease. The aim of this study 
to investigate that whether cranial MR is necessary for staging in 
asymptomatic HER2-positive breast cancer patients.
Material and metods: HER2-positive breast cancer patients without 
symptoms of brain metastasis included in the study. Cranial MRI was 
added to the staging procedures. Subgroup analysis was performed to 
determine risk factors for developing brain metastasis.
Results: Seventy five patients included in the study. Of whom, 71 
were women (94.7%). Median age was 42.5 (22-76). Ten of the 75 
patients (13.3%) had brain metastasis. The distribution rate of brain 
metastasis according to breast cancer stage at diagnosis was: 0% 
for stage I, 9.1% for stage 2, 4.3% for stage 3 and 28.6% for stage 
4 (p=0.027). There was no association between presence of brain 
metastasis and the site of metastasis, estrogen and progesterone 
receptor positivity, grade, histological subgroup, menopausal status 
and gender.
Discussion: Brain metastasis is an important problem for breast 
cancer patients. Treatment strategies may vary in the presence of brain 
metastasis. In our study we found brain metastasis nearly one quarter 
of patients with metastatic HER2-positive breast cancer. Cranial 
MRI imaging can be performed routinely in patient with metastatic 
HER2-positive breast cancer patients.
P4-17-09
Comparative Performances of Prognostic Indexes for Breast 
Cancer Patients Presenting with Brain Metastases.
Braccini A-L, Azria D, Thezenas S, Ferrero J-M, Romieu G, Jacot W. 
CRLC Val d’Aurelle Paul Lamarque, Montpellier, France; Antoine 
Lacassagne Cancer Center, Nice, France
Introduction: Incidence of brain metastases (BM) from breast cancer 
has increased over the past decade, especially for HER2(+) tumours. 
Several scores and prognosis systems have been developed in the brain 
metastases (BM) setting in order to help physicians tailor treatment 
options depending on patient prognosis and to stratify patients 
enrolled in clinical studies. The aim of our study was to compare the 
clinical relevance of the major classifications and existing prognostic 
scores in a population of breast cancer patients affected by BM.
Methods and Materials: In this retrospective study conducted in 
Montpellier and Nice Cancer Centres, we retrospectively reviewed 
the clinical and biological data of 250 patients diagnosed with breast 
cancer BM between 1995 and 2010. Prognostic value and accuracy of 
recursive partitioning analysis (RPA), graded prognostic assessment 
(GPA), basic score for brain metastases (BS-BM) and a clinico-
biological score (BS) developed in phase I study and validated in the 
BM setting were compared.
Results: Median age at BM diagnosis was 55 years-old. Most 
patients (74%) had good performance status (0-1). Brain was the first 
metastatic site in one third of patients (33.6%). In 12.4% of cases, 
no extracerebral metastases were detected at BM diagnosis. Among 
the 250 patients’ tumors, 43.6% overexpressed HER2 receptor and 
25.6% were triple negative (negative estrogen receptor, progesterone 
receptor and HER2 status). After a median follow up of 4.5 years, 
median overall survival from BM diagnosis was 8.9 months (CI 
95%, 6.9-10.3 months). The four scores were able to discriminate 
patients according to their survival. Chi2 tests showed a correlation 
between the different scoring systems. In multivariate analysis, the 
elimination model identified RPA (p = 0.031; hazard ratio, 0.77; 95% 
confidence interval, 0.64-0.91) and BS (p = 0.043; hazard ratio, 0.5; 
95% confidence interval, 0.31-0.80) as the only two independent 
predictors of survival. RPA was the most accurate score in order to 
identify patients with high life expectancy, while RPA and BS were 
the most accurate scores to classify patients with short life expectancy.
Conclusions: In a general unselected population of breast cancer 
affected by BM, RPA seems to be the most useful score. Integration 
of biological parameters in addition of existing clinico-radiological 
scores is promising in order to improve the prognostic determination 
accuracy.
P4-17-10
Insights into Mechanisms Involved in the Accumulation of 
Nanovectors within the Breast Cancer Brain Metastasis.
Yokoi K, Xuewu L, Alexander JF, Fidler IJ, Mauro F, Biana G. The 
Methodist Hospital Research Institute, Houston, TX; M D Anderson 
Cancer Center, Houston, TX
Systemic chemotherapy for brain metastasis of breast cancer 
(BMBC) is considered to be inefficient. It is widely accepted in the 
literature that blood-brain-barrier (BBB) is responsible for clinical 
failures with the conventional chemotherapy. We hypothesized that 
nanovectors, therapeutic carriers with submicron dimensions, can 
be delivered to the brain tissue through a different pathway than 
molecular therapeutics. The objective of this study was to examine 
the accumulation of various intravenously injected nanovectors into 
the brain metastasis of breast and other cancers loci and to explore 
possible mechanisms involved.
Both human (MDAMB231) and mouse (4T1) breast cancer brain 
metastasis were evaluated. We also tested lung (3LL) and colon (CT26) 
originated cancers. Orthotopic brain tumors were produced either by 
intracarotid injection or stereotactic brain injection of cancer cells. 
When the animals became moribund, they were injected intravenously 
with one of the following nanovectors including fluorescently labeled 
PEGylated (100nm) and non-PEGylated (100nm, 250nm, 500nm) 
liposomes, disc-shape silicon particles (600, 1000nm in diameter). The 
accumulation of the nanovectors was compared to an unencapsulated 
fluorescent molecule. The accumulation of the nanovectors in the 
brain tumor tissue was evaluated through live animal imaging (IVIS) 
and immunohistochemical analysis. Immunohistochemical staining 
of endothelial cells and basal membrane markers was performed to 
determine the integrity of the tumor associated vasculature and the 
co-localization of the fluorescent nanovectors/molecules with tumor 
associated vasculature.
Interestingly, we have found that brain metastasis of different tumors 
(originated form breast, lung and colon cancers) possess dissimilar 
accumulation profiles for intravenously administered nanovectors. 
For example when comparing various tumor origins, 4T1 breast 
cancer originated brain tumors enabled the highest accumulation of 
the nanovectors as compared to CT26 and 3LL. On the other hand, 
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free molecule accumulated into the 4T1 brain metastasis model to a 
much lower extend than in nanovector. Finally, the observed brain 
distribution of nanovectors corresponded well with impairment 
in vascular endothelium and basal membrane integrity shown in 
immunohistochemical analysis.
The results of our study point toward a possibility to treat specific 
patients with impaired BBB function with nanovector encapsulated 
chemotherapeutics based on the fact that their transport, accumulation 
and retention in the brain tissue are governed by different biological 
mechanisms, such as Enhanced Permeation and Retention (EPR) 
effect. These studies indicate that it is possible to cross the blood brain 
barrier, thus giving hope to patients with brain metastasis.
P4-17-11
Central Nervous System Involvement and Clinical Outcome, 
Review of 135 Patients, 9-Year Follow Up.
Watanabe J, Ogiya A, Tadokoro Y, Tanaka K, Takahashi K, Uematsu 
T, Mitsuya K. Shizuoka Cancer Center, Shizuoka, Japan; Shizuoka 
Cancer Center
Background: Breast cancer infiltrates into central nervous system 
(CNS) with the incidence of 10-20%. It is commonly accepted 
CNS screening does not contribute to maintain patients’ survival 
in metastatic breast cancer (MBC). We review our MBC cases with 
CNS involvement with the aim of searching prognostic factors and 
evaluating benefits derived from early detection of CNS lesion.
Patients and Methods: From October 2002 to January 2011, 473 MBC 
patients treated at our hospital were reviewed and assessed. CNS 
lesion was found in 133 of 473 (28.5%) mostly by magnetic resonance 
imaging. Receptor statuses in patients with CNS disease were as 
follows; Estrogen receptor-positive 52.4%, HER2-positive 41.1% 
and triple-negative 12.7%. Asymptomatic patient at the diagnosis of 
CNS metastasis, in other words, CNS screening performed case, was 
57.8%. Liver metastasis prior to CNS involvement was observed in 
51.2% of patients.
Results: Within our 9-year follow-up, 122 patients received irradiation 
or operation, and 118 died. While major cause of death was lung or 
liver failure, 23.7% was considered as CNS death. Median overall 
survival from the diagnosis of primary breast cancer, survival from 
the MBC development and survival from CNS involvement were 
1951, 1027 and 321 days respectively. Patients having HER2-
disease showed superior survival after detection of CNS disease 
than HER2-negative patients. (median 514.0 vs 220.0 days, p=0.001) 
Asymptomatic patients, excluding underwent best supportive care 
(BSC), could not receive any survival benefit from early detection 
of CNS lesion. Liver metastasis prior to CNS involvement did not 
affect patients’ survival. Nineteen patients (14.1%), 17 of them were 
asymptomatic, received stereotactic irradiation as an initial treatment 
for CNS lesion, and showed superior survival after CNS event than 
patients received whole brain irradiation, surgery or BSC (median 
670.0 vs 287.0 days, p=0.01).
Conclusion: Our review disclosed superior survival of HER2-disease 
with CNS metastasis. Early detection of CNS metastasis is only 
beneficial to patients when stereotactic irradiation will be suited for.
P4-17-12
Analysis of Predictive and Prognostic Factors for Metastatic 
Breast Cancer Patients with Brain Metastasis Treated by Whole 
Brain Radiotherapy.
Park IH, Lee KS, Shin KH, Ro J. National Cancer Center, Goyang, 
Korea
Background
We addressed the progression free survival of brain metastasis 
(PFS_BM) in metastatic breast cancer (MBC) patients treated by 
whole brain radiotherapy (WBRT) for brain metastasis (BM). In 
addition, we investigated predictive and prognostic factors for the 
PFS_BM and OS_BM.
Patients and methods
A total of 212 patients with BM, treated by WBRT at the National 
Cancer Center between January 2000 and December 2010 were 
reviewed. The PFS_BM was defined as the time interval from the date 
of start of WBRT to the date of a progression of metastatic lesions in 
the brain or death or last follow-up.
Results
The median age of patients was 45 years (range, 22-72 years) and 
the median time to brain metastasis was 12.7 months (range, 0.0-
72.8 months).
Table 1. Patient characteristics (N=212)
Variables No of patients (%)
Age (median, year, range) 45 (22-72)
HR (ER/PgR)  
Positive 50 (23.6%)
Negative 158 (74.5%)
Not known 4 (1.9%)
HER2  
Positive 104 (49.1%)
Negative 104 (49.1%)
Not known 4 (1.9%)
Disease free interval (DFI) < 2yr 118 (55.7%)
ECOG PS  
1-2 189 (89.2%)
3 21 (9.9%)
Not known 2 (0.9%)
No of metastatic lesions in brain  
Single 9 (4.2%)
Oligo (≤ 3) 17 (8.0%)
Multiple (>3) 186 (87.7%)
Maximum LD of metastatic lesions in brain (median, mm, range) 22 (2-85)
Systemic disease status  
At diagnosis 20 (9.4%)
CR 10 (4.7%)
PR 27 (12.7%)
SD 34 (16.0%)
PD 121 (57.1%)
Number of metastatic organs except brain  
0 16 (7.5%)
1-2 86 (40.6%)
≥ 3 110 (51.9%)
Visceral involvement  
Yes 163 (76.9%)
No 49 (23.1%)
Chemotherapy after WBRT  
Yes 152 (71.7%)
No 59 (27.8%)
Not known 1 (0.5%)
LD-long diameter
Of all patients, 50 (23.6%) patients were hormone receptor (HR) 
positive and 104 (49.1%) HER2 positive. Six patients received a 
surgery or a focal radiotherapy for metastatic lesions prior to WBRT. 
Seventy one (33.4%) patients had well controlled extracranial 
systemic disease (CR+PR+SD) when brain metastasis was diagnosed. 
The median survival after BM (OS_BM) was 5.4 months (95% CI, 
4.4-6.4 months) and approximately 14.6% of patients died mainly 
of progressive brain metastasis. The PFS_BM was significantly 
affected by poor performance status (PS ≥3) (P<0.001), uncontrolled 
systemic disease status (P=0.029), disease free interval (DFI) < 2 
years (P=0.011), no chemotherapy after BM (P<0.001), and HER2 
positivity (P=0.002). Of those, poor PS, no chemotherapy after BM, 
and uncontrolled systemic disease status were remained important 
factors on a multivariate analysis. In terms of OS_BM, poor PS 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011505s
December 6-10, 2011 Abstracts: Poster Session 4
(P<0.001), older age (P=0.005), number of systemic metastatic sites 
>3 (P<0.001), uncontrolled systemic disease status (P<0.001), disease 
free interval (DFI) < 2 years (P=0.014), no chemotherapy after BM 
(P<0.001), and visceral involvement (P=0.009) were significant 
factors. Of those, poor PS (P<0.001), uncontrolled systemic disease 
status (P<0.001), and no chemotherapy after BM (P<0.001) were 
important factors for shorter OS_BM when adjusted with other 
factors.
Conclusions
Uncontrolled extracranial systemic disease status, no chemotherapy 
after BM, and poor PS were significant factors for shorter PFS_BM 
and overall survival after brain metastasis.
P4-18-01
Prognostic Role of Tumor and Stromal p16/INK4A in Ductal 
Carcinoma In Situ (DCIS).
Linke SP, Bremer TM, Wärnberg F, Zhou W, Goldstein L, Jirström 
K, Amini R-M. Prelude Corporation, Laguna Hills, CA; Uppsala 
University Hospital, Uppsala, Sweden; PhenoPath Laboratories, 
Seattle, WA; Lund University, Lund, Sweden
Background: DCIS is a pre-invasive breast disease diagnosed 
in ~50,000 women/year in the US. The standard treatment 
recommendation is for mastectomy or breast-conserving surgery 
plus radiotherapy (BCS+RT). However, only ~10% of BCS patients 
avoid recurrence due to RT, and RT provides little or no survival 
benefit. Thus, it is important to stratify patients by risk to help tailor 
treatment to maximize benefit and minimize unnecessary adverse 
effects and costs.
Material and Methods: Tissue microarrays that included tumor cores 
from all women diagnosed with pure DCIS between 1986 and 2004 in 
Uppland and Västmanland, Sweden (n=458) were stained and scored 
for p16/INK4A (clone E6H4) using immunohistochemistry (IHC). 
Semi-quantitative manual scoring was done separately in the tumor 
epithelial cells and peri-tumoral carcinoma-associated fibroblasts 
(CAFs). Based on previous reports, thresholds to define low and high 
p16 levels were set at 25% and 5% positive staining, respectively, 
for the tumor and stromal components. HER2 IHC scoring was 
reported previously. Clinicopathologic characteristics of the set of 
patients for which complete marker data was obtained (n=176) were 
not statistically different than the full set of patients. For survival 
analysis, local ipsilateral DCIS and invasive recurrences, as well as 
lymph node and distant metastases, were included as events (patients 
were censored if they had contralateral breast or other cancers as the 
first event).
Results: Patients were stratified into low and high risk groups using a 
multivariate model incorporating tumor p16, stromal p16, HER2, and 
margin status. Patients treated with BCS only (n=67) had a baseline 
10-year recurrence rate of 31%. The model identified high and low 
risk groups with 10-year recurrence rates of 38% and 7%, respectively 
(hazard ratio=7.1, p=0.009). Similar results were achieved when BCS 
only and BCS+RT patients were combined (n=130). Interestingly, 
all six recurrence events in the set of patients who received full 
mastectomies (n=43) were in the model high risk group.
Discussion: Previous studies have shown mixed results when p16 was 
used as a single marker. Our results suggest a prognostic interaction 
between tumor and stromal p16, as well as HER2, that will form the 
basis of a more comprehensive multi-marker IHC-based prognostic 
panel to assess risk of recurrence in DCIS patients.
P4-18-02
Sentinel Node Biopsy in Extensive Ductal Carcinoma In Situ 
(DCIS) Diagnosed by Vacuum-Assisted Macrobiopsy (VAMB) 
and Treated by Mastectomy: Results of the French Prospective 
Trial CINNAMOME.
Tunon-de-lara C, Giard S, Baron M, Le-Bouedec G, Garbay J-R, 
Blanchot J, Mollard J, Charitansky H, Martin-Françoise S, Michy 
T, Fondrinier E, Butarelli M, Loustalot C, Raout I, Macgrogan 
G. Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, 
Limoges, France
Background: Lymph node evaluation in the management of DCIS 
has been completely abandoned as a result of the documented low 
incidence of nodal metastases (<2%) and the significant morbidity of 
lymph node dissection. However, the risk of occult invasive disease 
exists when the initial diagnosis is performed by vacuum-assisted 
micro biopsy (VAMB). Invasive disease is usually discovered during 
the histological analyses following mastectomy. After mastectomy, the 
only option for patients is complete axillary lymph node dissection 
(ALND). The aim of this study was to evaluate the number of ALND 
that can be avoided by using the sentinel lymph node (SLN) procedure 
to identify patients with invasive disease but no SLN involvement.
Trial design: Patients with extensive microcalcifications on 
mammography and DCIS diagnosed by VAMB treated by mastectomy 
were included in the study. The SLN procedure was performed 
and intraoperative evaluation on frozen sections was carried out. 
If the SLN was positive an ALND was performed during the same 
intervention. If the SLN procedure failed or was negative an ALND 
was not performed. Radiography of the mastectomy specimen was 
performed to assist the pathologist in confirming the DCIS diagnosis, 
to evaluate the size and to determine concordance rates between 
initial VAMB diagnosis and histological analyses. Results: Fourteen 
French cancer centers took part in this protocol over 2 years (May 
2008-December 2010). 228 patients were enrolled, including 197 
DCIS on VAMB. The SLN was identified in 193 cases (98%) but 
one case was not documented at histology leaving 192 valid cases 
for analysis.
Distribution of SLN results and histological lesions found on mastectomy specimens in the series
Initial VAMB result Mastetomy result
Sentinel Lymph Node 
results Treatment outcome
192 DCIS DCIS 116 Positive 2(ALND)
  negatice 114 (no ALND)
 DCIS and micro invasive carcinome 20 positive 4 (ALND)
  negative 16 (ALND avoided)
 DCIS and invasive carcinoma 56 positive 21(ALND)
  negative 35 (ALND avoided)
ALND was not performed for non-invasive disease and negative 
SLN (n=114) and invasive or micro-invasive disease and negative 
SLN (n=51). This meant that ALND was avoided for 67.1% of the 
patients with invasive disease (51/76, 95%CI[56.5-77.7]), or 26.6% 
of patients overall (95%CI [20.3-32.8]), whereas these patients 
would have previously received ALND without the use of the SLN 
procedure. We observed 39.6% (76/192) of discordance between 
VAMB results and definitive results from histology analysis after 
mastectomy across all patients.
Conclusions: SLN is a useful procedure for patients with DCIS 
diagnosed by VAMB treated by mastectomy and presenting 
extensive microcalcifications on mammography. For patients for 
whom microinvasive or invasive carcinoma is later identified on the 
mastectomy specimen, the use of this procedure makes it possible to 
spare over a quarter of them from ALND and the associated morbidity.
Biological analyses are currently underway to determine predictive 
factors of invasive disease associated with DCIS.
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P4-18-03
Basal-Like Phenotype of BRCA Associated Ductal Carcinoma 
In-Situ.
Kristjansdottir K, Laprise J, Scalia-Wilbur J, Simon R, Steinhoff M, 
Legare R. Women and Infants Hospital of RI, Providence, RI
Background: Molecular profiling has identified different subtypes 
of invasive carcinoma. The basal-like tumors represent a subgroup 
that is known for aggressive behavior. The NCCN guidelines 
recommend genetic testing for patients with triple negative breast 
cancer as over 80% of breast cancers in BRCA1 mutation carriers 
are triple negative tumors, and 70% of those fulfill criteria for basal-
like tumors. Ductal carcinoma in-situ (DCIS) is thought to represent 
a non-obligate precursor to invasive breast cancer. Little is known 
about basal-like precursor lesions and their association with germline 
BRCA mutations. The aims of this study were to characterize the 
immunohistochemical phenotype of BRCA associated DCIS and 
evaluate the clinical importance of such lesions.
Material and Methods: We identified 32 cases of DCIS from 28 
women with a known BRCA1/2 mutation, from our genetics database. 
Tumor samples were reviewed to identify areas of DCIS for staining. 
Five micron sections were stained on the Dako Autostainer with 
antibodies to estrogen receptor (ER), progesterone receptor (PR), 
human epidermal growth factor receptor 2 (HER-2), epidermal growth 
factor receptor (EGFR), and CK 5/6.
Results: 44% of the DCIS tumors were from BRCA1 mutation carriers 
and 56% from BRCA2 mutation carriers. 53% of the samples were 
triple negative (staining negative for ER, PR, HER-2) and 69% of 
the triple negative tumors were basal-like tumors (staining positive 
for either EGFR or CK5/6). The basal-like DCIS specimens were all 
high grade, and they all came from BRCA1 positive patients. 71% 
of BRCA1 positive DCIS had basal-like features.
Conclusions: DCIS in BRCA1 mutation carriers shows basal-like 
features that are in line with historical control for invasive carcinomas 
in the same group, suggesting that DCIS is a precursor lesion for 
BRCA1 positive cancer. Although further investigation is needed, 
our data suggest that patients with basal-like DCIS should be offered 
genetic testing.
P4-18-04
Hypofractionated Radiotherapy for Breast Ductal Carcinoma 
In Situ.
Hathout L, Fortin B, Vulpe H, Hijal T, Bahig H, Dubé P, Yassa M. 
Hôpital Maisonneuve-Rosemont, Centre Affilié à l’Université de 
Montréal, Montreal, QC, Canada; McGill University Health Centre, 
The Montreal General Hospital, Montreal, QC, Canada
Background: Conventional radiotherapy at a dose of 50 Gy in 25 
fractions after breast conservative surgery is the standard treatment 
for ductal carcinoma in situ of the breast (DCIS). Hypofractionation 
is an interesting alternative for the treatment of breast cancer, 
providing a less intense treatment scheme for the patient. While the 
hypofractionated regimen of 42.5 Gy in 16 fractions has been shown 
to be equivalent to 50 Gy in 25 in infiltrating ductal carcinoma, 
few studies and no prospective study have reported results using 
hypofractionation in DCIS.
Materials and Methods: In this multicenter collaborative effort, we 
retrospectively reviewed the records of women with a diagnosis of 
DCIS at two Canadian institutions, treated with conservative surgery 
followed by hypofractionated radiotherapy (42.5 Gy in 16 fractions) to 
the whole breast. Tumor, patient and treatment factors were collected. 
Local control was evaluated using the Kaplan Meier method. Curves 
were compared using log rank.
Results: Between 2003 to 2008, 292 patients with DCIS underwent 
conservative surgery followed by hypofractionated radiation in 16 
fractions for a total dose of 42.5 Gy. Treatment delivery was similar 
at both institutions. Mean age at diagnosis was 59 years, with 70 % 
of women being postmenopausal. Nuclear grade was 1-2 in 65 % of 
patients while 28 % had grade 3 tumors. Complete surgical excision 
with negative margins was achieved in 92 % of patients. Radiotherapy 
boost was given to 92 patients (31.5 %) at the discretion of the 
radiation oncologist. After a mean follow up of 3.35 years (range 
1-8 years), 10 patients (3.4 %) had ipsilateral local relapse resulting 
in a disease-free survival (DFS) of 96 % at 4 years. The histology 
at recurrence was DCIS for 8 patients; infiltrative disease for one 
patient and one patient had an unknown histology at recurrence. Age 
was statistically associated with local relapse (DFS 89 % for patients 
under 50 years old vs 97 % for those older than 50, p=0.027). Grade 
was also a significant prognostic factor (DFS 98% for grade 1-2 vs 
91 % for grade 3, p = 0.015). Finally, administration of boost did 
not have an impact on local control (DFS boost 98 % vs 95 % for 
no boost, p=0.44).
Discussion : Hypofractionated radiotherapy (42.5 Gy in 16 fractions) 
provides excellent local control for patients with DCIS undergoing 
breast conservative surgery. This regimen is more convenient to 
both patient and physician since it is less time consuming. Further 
work needs to be done to determine if this regimen is as effective as 
conventional radiotherapy in younger women (age less than 50) and 
those with grade 3 tumors.
P4-18-05
Ductal Carcinoma In Situ with Microinvasion: Clinical and 
Pathological Characteristics, Treatments and Outcomes.
Gandy C, Modesto-Nauleau A, Mery E, Filleron T, Charitansky H, 
Roche H, de Lafontan B. Institut Claudius Regaud, Toulouse, France
Background: Ductal carcinoma in situ with microinvasion (DCISM) is 
a rising rare entity. Because of that and its controversial pathological 
definition, there is a lack of clear recommendations for treatment. The 
purpose of this study was to describe the clinical and pathological 
characteristics, treatments and outcomes of our single institutional 
experience.
Patients and methods: Individual clinical and pathological data were 
collected from 63 women, diagnosed and treated for DCISM at the 
Claudius Regaud Cancer Hospital between January 2000 and April 
2010. All available histological material (45 patients) was reviewed 
by an expert pathologist.
Results: The median age was 56 years (range 34-83). Seven patients 
(11.5%) had a personal history of DCIS, 27 patients (42%) a familial 
history of breast cancer. Fourteen patients (22%) had a clinical sign 
at the diagnosis. Fifty one patients were mammographically detected 
(81%). All the patients underwent surgery, mastectomy for 17 patients 
(27.4%) and conservative surgery for 45 (72.6%). Secondary surgery 
of the breast was required for 21 patients (46.6%) after conservative 
surgery, enlarging surgery (N=13) or mastectomy (N=8). Surgical 
axillary lymph node evaluation was performed on 52 patients 
(82,5%), axillary dissection alone for 10 patients, sentinel node 
biopsy alone for 37 patients and the 2 methods for 5 patients. The 
median size of the DCIS was 16mm (6-80mm) with 37/60 (61.7%) 
grade III Van Nuys classification. The most histological subtype was 
comedo carcinoma (68%). Concerning the 45 reviewed biopsies, the 
size of the microinvasive component was ≤ 1mm for 38 lesions and 
between 1 and 2 mm for 7 lesions. Hormonal receptor status was 
positive for 29 (64.4%), 27 (64.3%) for estrogen receptors and 20 
(44.4%) for progesterone receptors. HER 2 status was performed 
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for 34 patients, among 12 (35%) of them were found overexpressed 
on the microinvasive component. Lymph node invasion was found 
among 2 of the 52 patients (3.8 %) who underwent axillary lymph 
node evaluation. Radiation therapy was delivered to all the patients 
after conservative surgery (n=37)(50 Gy with a 10 Gy boost for 22 
of them) and 2 after mastectomy (chest wall irradiation (50 Gy)). 
Adjuvant hormonotherapy was delivered on 11 patients (18%). 
With a median follow-up of 36,4 months (95%CI=[27.7- 44.16]), 
62 patients are alive at the last follow-up and 58/63 free of disease 
(2 relapses and 3 second cancers).The 3 year disease free survival 
rate was 91.1 (95%CI=[78.1;96.6] ). During follow-up, two local 
relapses occurred on patients treated by mastectomy. One of them 
had local invasive relapse at 43 months and she is still NED after 90 
months. The second patient who had local invasive carcinoma with 
axillary node invasion at 32 months treated by conservative surgery, 
axillary dissection, radiotherapy and chemotherapy, had metastasis 
at 51 months and passed away after 70 months.
Conclusion: Mammographic screening programmes increase the rate 
of small diagnosed tumours, specially DCISM. Despite a priori good 
prognostic outcome, 2 axillary node involvements and 2 delayed 
relapses were observed. So, this kind of presentation deserves better 
evaluation of relapse risk factors to determine adapted adjuvant 
therapies.
P4-18-06
Relationship between Pathological Features, Her2 Protein 
Expression, and HER2 and CEP17 Copy Numbers in DCIS.
Lambein K, Van Bockstal M, Praet M, Denys H, Braems G, Nuyts 
A, Cocquyt V, Pauwels P, Van Den Broecke R, Libbrecht L. Ghent 
University Hospital, Ghent, Belgium; Ghent University, Ghent, 
Belgium
Background
Previous studies in which HER2 status in ductal carcinoma in situ 
(DCIS) was evaluated yielded conflicting results. The reported 
prevalences of HER2 overexpression and amplification vary 
remarkably. These discrepancies might partly be due to differences 
in assessment methods, i.e. FISH or immunohistochemistry (IHC) 
and usage of tissue microarray or whole mount slides. To further 
investigate this issue, we performed both FISH and IHC for HER2, 
evaluated HER2 and CEP17 copy numbers and correlated these data 
with histopathological findings.
Methods
61 DCIS cases were studied, of which 55 pure DCIS and 6 DCIS 
with micro-invasion. Pathological features were evaluated and 
included: architecture, nuclear atypia, necrosis, calcifications, stromal 
inflammation, stromal morphology, extent of lesion, margin width, 
Van Nuys Prognostic Index and Pinder classification. Her2 IHC 
and HER2 dual probe FISH analysis were performed and scored 
according to ASCO/CAP guidelines. HER2/CEP17 ratio and HER2 
and CEP17 copy numbers were separately analysed. IHC for estrogen 
and progesterone receptor (ER and PR) was also performed. Whole 
mount slides were used for all analyses.
Results
15 cases (25%) were scored negative (1+), 10 cases (16%) equivocal 
(2+) and 36 cases (59%) positive (3+) using Her2 IHC. According to 
FISH analysis, 34 of 60 cases (57%) showed HER2 amplification; 
there was insufficient tissue for FISH analysis in one case.
The amplification status of the DCIS lesions correlated with the IHC 
score (p<0,001). 30 of all 34 amplified cases were assigned a 3+ 
IHC score, and remarkably, all these cases showed HER2 clusters 
on FISH analysis (88%).
Amplified lesions showed more frequently nuclear atypia grade 
3 (p=0.0335), extensive comedonecrosis (p=0.002) and stromal 
inflammation (p=0.003). HER2 amplification correlated with the 
presence of micro-invasion (p=0.0218)%. There was no correlation 
with hormone receptor status or other pathological variables.
In the amplified group, high-grade nuclear atypia was associated with 
a higher mean HER2 copy number (p=0.0026) and HER2/CEP17 
ratio (p=0.0356), while this was not the case in the non-amplified 
group. CEP17 copy numbers did not correlate with nuclear atypia.
Conclusions
The correlation between HER2 amplification and adverse pathological 
features, including micro-invasion and the association in amplified 
DCIS between HER2 copy number and high-grade nuclear atypia, 
underscore that HER2 is a driver of DCIS aggressiveness and 
possibly of recurrence in the form of non-invasive cancer. However, 
the prevalence of HER2 overexpression, amplification and cluster 
formation was much higher than in invasive carcinoma, suggesting 
that HER2 might play a less important role in transition from DCIS to 
frankly invasive cancer. Further studies should evaluate non-invasive 
and invasive recurrence of resected DCIS separately.
P4-19-01
Male Breast Cancer According to Tumor Subtype and Race: 
A California Cancer Registry (CCR)-Population Based Study.
Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Hortobagyi 
GN, Giordano SH. The University of Texas, MD Anderson Cancer 
Center; Cancer Prevention Institute of California
Background: Breast cancer in men is a rare disease and accounts 
for 0.6% of all breast cancer cases. Prior reports suggest that male 
breast cancer typically has a ductal histology and is more likely than 
cancers of the female breast to express estrogen and progesterone 
receptors (ER and PR). To our knowledge, there are no population-
based estimates of the rates of Her-2 positive breast cancer or of 
the distribution of breast cancer subtypes in male patients. The 
categorization of breast cancers according to tumor subtype has 
important implications in the prognosis and in the management of 
breast cancer patients. We explored the tumor subtype distribution by 
race/ethnicity in the large, ethnically diverse population of California.
Methods: Retrospective study using the CCR. Participants included 
all male breast cancer patients diagnosed with invasive breast cancer 
between 2005-2009 with known ER, PR and Her2neu status. Among 
the patients with hormone receptor positive (HR+) tumors, survival 
analysis using Kaplan-Meier method was used. Differences in 
probability of survival between groups were compared using log-
rank test.
Results: Six-hundred and seven patients were included. Median age 
at diagnosis was 68 years. Ductal histology was present in 84.7% 
(n=514) of the cases, 51.6% (n=313) of all the tumors were classified 
as grade II. Four hundred and ninety four (81.4%) patients had HR+ 
tumors, defined as ER+ and/or PR+ and Her2neu negative. Ninety 
(14.8%) had Her2neu positive, and 23 (3.8%) had triple receptor 
negative tumors (TN). The majority of patients were white (71%), 
11% were Hispanic, 7.6% black and 10.4% were Asian/Pacific 
Islander/other. The breast cancer tumor subtype varied significantly 
across races/ethnicities (p<.0001). Among non-Hispanic Whites, 
82.6% had HR+, 14.6% had Her-2+, and 2.8% had TN breast cancer. 
For Blacks and Hispanics the distributions were 73.9% HR+, 17.4% 
Her-2+, 8.7% TN and 77.6%, 16.4%, 6.0% respectively. Among HR+ 
patients, blacks and Hispanics were less likely to have PR+ tumors 
compared to whites. The rate of ER+PR- was 6.3% among whites, 
19.6% among blacks and 16.4% among Hispanics (p<0.001). A 
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survival analysis among HR+ patients showed significant differences 
according to race (p=0.018) and stage (p<0.001), with Black patients 
and patients with higher stage disease having poorer outcomes.
Conclusions: In this large cohort of male breast cancer patients, 
the distribution of tumor subtype was different than what has been 
reported in females. Among males, differences in tumor subtype 
exist among different racial/ethnic groups. Blacks were more likely 
to have triple receptor negative tumors and more likely to have 
ER+/PR- tumors than white patients. Among HR+ patients, blacks 
experience the worse survival.
P4-19-02
A Population-Based Study of Contemporary Systemic Therapy 
for Male Breast Cancer.
Bradley KL, Villa D, Speers CH, Woods R, Tyldesley S. British 
Columbia Cancer Agency, Vancouver, BC, Canada
Purpose: To describe the contemporary utilization, effectiveness and 
tolerability of tamoxifen, aromatase inhibitors, and trastuzumab in the 
treatment of early and advanced male breast cancer at a population 
level in British Columbia.
Patients and Methods: Records of 158 consecutive referred cases of 
invasive male breast cancer diagnosed from January 2000 to March 
2010 were analyzed in a population-based cancer program with 
respect to patient and tumour characteristics, usage of endocrine 
agents, toxicity and medication adherence, trastuzumab usage and 
outcome. This group was compared to a population-based random 
sample of 1000 contemporary female breast cancer patients for 
prognostic and demographic factors. Survival outcomes were also 
compared to a cohort of women, matched 2:1 on prognostic and 
treatment factors.
Results: Pathology was most commonly infiltrating ductal carcinoma 
(94.3%) and estrogen-receptor positive (98.7%). Males were older 
(median 69.5 years) compared to women (median 60 years). Stage 
distribution was I (25.3%), II (43.0%), III (24.7%) and IV (7.0%), 
reflecting more advanced presentation compared to female cases 
I (43.9%), II (37.9%), III (12.5%) and IV (5.3%). Tamoxifen was 
prescribed as adjuvant therapy to109 patients, and as palliative 
therapy to 11. Fourteen (11.7%) patients discontinued tamoxifen 
due to toxicity. Aromatase inhibitors were prescribed as adjuvant 
therapy for 16 patients and as palliative therapy for 24; these were 
discontinued due to toxicity in 5 patients (12.5%). Five of 9 patients 
known to over-express Her2 were treated with adjuvant chemotherapy 
with trastuzumab. Overall survival, breast cancer-specific survival 
and progression-free survival at 5 years were 72.4%, 85.5% and 
79.7%, respectively. There was no statistical difference in outcomes 
compared to the matched female cases.
Conclusions: In this large population-based study of contemporary 
systemic therapy for male breast cancer, outcomes appear to be similar 
to those of women with the same diagnosis. Side effect profiles, 
tolerance, adherence and outcomes after tamoxifen, aromatase 
inhibitors and trastuzumab appear to be similar in men compared to 
that described in the literature for women.
P4-19-03
Physical and Psychological Sequelae of Breast Cancer in Men.
Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow 
S, Winer EP, Partridge AH. Dana-Farber Cancer Institute, Boston, 
MA; M.D. Anderson Cancer Center, Houston, TX; Memorial Sloan 
Kettering Cancer Center, New York, NY
Introduction: Little is known about the physical and emotional health 
of men with breast cancer. Information is also lacking regarding 
whether their informational and supportive care needs are being met 
regarding fertility and genetic concerns.
Methods: In an online pilot study recruiting participants through three 
websites focused on male breast cancer, www.outoftheshadowofpink.
com, www.malebreastcancer.org, and www.malebreastcancer.ca, we 
surveyed men with breast cancer about their attitudes, symptoms, 
experiences, and health perceptions. We measured anxiety and 
depression using the Hospitalized Anxiety and Depression Scale 
(HADS), health-related quality of life (QOL) using Functional 
Assessment of Cancer Therapy-Breast (FACT-B), and hormonal 
and sexual symptoms using the Expanded Prostate Cancer Index 
Composite (EPIC) Hormonal and Sexual Scales. We assessed select 
toxicities from therapy and history of genetic and fertility counseling.
Results: Forty-two men responded to this online survey at least in 
part.
Respondent Characteristics, N=42
Median age in years (range) 64 (25-80)
Median time since diagnosis in years (range) 1.8 (0.3-19.4)
Stage  
---0 7%
---1 24%
---2 36%
---3 14%
---4 10%
---Unknown 10%
White 98%
Married or “living as married” 74%
Employed 52%
Financially comfortable (have “money for special things”) 52%
Treatment  
---Received chemotherapy 62%
---On tamoxifen 43%
---On aromatase inhibitor 10%
Results
Genetic Counseling and Testing  
---Referred for genetic counseling or testing 74%
---Had genetic testing for hereditary cancer syndrome 60%
---If tested, found to have a hereditary cancer syndrome 12%
Fertility Issues  
---No biological children at time of survey 24%
---Desired biological children at time of survey 5%
---Informed about fertility risks of treatment 7%
---Stored sperm prior to treatment 2%
Select Symptoms  
---Persistent neuropathy 31%
---Chest wall pain 19%
---Lymphedema 17%
---Heart problem attributed to breast cancer treatment 5%
Distress and Quality of Life  
---Anxious (HADS Anxiety Score >10) 8%
---Depressed (HADS Depression Score >10) 5%
---FACT-B Score (higher=better QOL); Mean (SD) 111.1 (19.9)
---EPIC Hormonal Score (higher=fewer symptoms; Mean (SD) 81.3 (15.5)
---EPIC Sexual Score (higher=better sexual function; Mean (SD) 44.5 (26.3)
---Rated ability to perform sexually over past 4 weeks “very poor” 40%
Conclusions: Men with breast cancer experience substantial 
symptoms in follow-up. Sexual functioning, in particular, may be 
impaired (in men without cancer, mean EPIC Sexual Score is 61.4 
with SD 23.6). Hormonal symptoms are also prevalent (in men 
without cancer, mean EPIC Hormonal Score is 91.7 with SD 9.7). 
We plan to use data from this pilot study to inform a larger study and 
develop targeted interventions to improve sexual functioning and 
reduce symptoms in male breast cancer survivors.
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P4-19-04
Evaluation of Histopathological Parameters in Male Breast 
Cancer Reveals Differences Compared with Female Breast 
Cancer.
Nilsson C, Johansson I, Ahlin C, Thorstenson S, Bergkvist L, Amin 
R-M, Holmqvist M, Hedenfalk I, Fjällskog M-L. Central Hospital of 
Västerås, Västerås, Sweden; Uppsala University, Uppsala, Sweden; 
Lund University, Lund, Sweden; Örebro University Hospital, Örebro, 
Sweden; Linköping University Hospital, Linköping, Sweden; Uppsala, 
Sweden
Purpose: To characterize male breast cancer (MBC) by evaluating 
established histopathological parameters and their prognostic value.
Methods: 197 male patients with invasive breast cancer and available 
paraffin-embedded tumor tissue were retrospectively assessed. 
Patient files were reviewed for clinicopathological data. Tumors 
were re-evaluated for histologic grading on conventional sections. 
Immunohistochemical (IHC) stainings for estrogen receptor (ER), 
progesterone receptor (PgR), human epidermal growth factor receptor 
2 (HER2), silver-enhanced in situ hybridization (SISH), Ki-67, CK5/6 
and epidermal growth factor receptor (EGFR) were performed on 
tissue micro arrays. Data on vital status and cause of death were 
retrieved from the Cause of Death Registry. Cox proportional 
regression models were used for uni- and multivariate analyses.
Results: ER and PgR positivity was demonstrated in 93 and 78 % of 
patients, respectively. Nottingham histologic grade III was seen in 
41% and HER2 positivity in 11% of all patients. Defining molecular 
phenotypes using IHC markers revealed luminal (ER+ and/or PgR+, 
and HER2-) in 83%, luminal/HER2+ (ER+ and/or PgR+, and HER2+) 
in 11%, basal-like (ER-,PgR-,HER2-,EGFR+ and/or CK5/6 +) in 
1%, but no cases of HER2-like or unclassified. Node-positivity (HR 
4.6; 95% CI 1.9-11.4), tumor size > 20 mm (HR 2.3; 95% CI 1.1-
5.0) and ER-negativity (HR 5.2; 95% CI 1.9-14.2) were significant 
risk factors for breast cancer death. Grade, HER2 status, Ki-67, or 
age did not demonstrate independent prognostic information. No 
difference in breast cancer deaths was demonstrated between luminal 
and luminal/HER2.
Conclusion: Male breast cancer tumors seem to be of grade III more 
often than female breast cancer, whereas HER2 expression appears 
equally common. In our study, the most important predictors for breast 
cancer death in male breast cancer were lymph nodes, tumor size 
and ER status. The most common molecular phenotype was luminal.
P4-19-05
A Population-Based Study of Guideline-Based BRCA Screening 
in Male Breast Carcinoma.
Bradley KL, Nuk JE, Chia SK, Villa D, Speers CH, Woods R, Young S, 
Tyldesley S. British Columbia Cancer Agency, Vancouver, BC, Canada
Purpose: The British Columbia Cancer Agency (BCCA) Hereditary 
Cancer Program (HCP) is a publicly funded , centralized program that 
provides BRCA testing to patients with male breast cancer (MBC) 
who meet specified referral criteria (aimed at detecting a mutation in > 
10% of those tested). Criteria include: MBC with Ashkenazi heritage, 
MBC with one other family member with breast or ovarian cancer, 
MBC diagnosed at < 35 years, Bilateral MBC with first diagnosed at 
< 50 year. In this context, the purpose was to study referral patterns 
for hereditary counselling and outcomes of BRCA testing within a 
population-based study of male breast carcinoma.
Patients and Methods: Records of consecutive cases of invasive 
MBC diagnosed from 2000 to 2010 were reviewed. We documented 
any recorded personal and family history of cancer. For those meeting 
the HCP referral criteria we recorded whether a referral was made 
and the outcome of any genetic testing.
Results: Of 158 cases of MBC, 23 (14.6%) patients (21 met referral 
criteria; 2 did not) were seen for genetic counselling, of whom 21 
were offered BRCA1/2 testing, and 19 accepted testing. Of 19 patients 
with BRCA1/2 genetic test results, 3 (16%) had a pathogenic mutation 
identified; one in the BRCA1 gene (c.1387_1390delinsGAAAG) and 
two in the BRCA2 gene (c.755_758delACAG; c.1813dupA). In a 
further 4 cases (21%) an unclassified variant in BRCA1 was identified. 
In the remaining 12 cases (63%), testing was uninformative.
Conclusions: The BRCA1/2 mutation detection rate of 16% is in line 
with the expected rate of >10% using established selection criteria. 
Expanding the criteria at this time to include all male breast cancers 
would be expected to decrease the detection rate below 10% with 
the potential to negatively impact on the publicly-funded and finite 
resources of the Hereditary Cancer Program and Cancer Genetics 
Laboratory.
P4-19-06
Ghrelin Expression Is Associated with Favorable Outcome in 
Male Breast Cancer.
Grönberg M, Nilsson C, Johansson I, Hedenfalk I, Janson ET, 
Fjällskog M-L. Dept. of Medical Sciences, Section of Endocrine 
Oncology, Uppsala, Sweden; Dept. of Oncology, Radiology and 
Clinical Immunology, Uppsala, Sweden; Dept. of Oncology, Clinical 
Sciences, Lund, Sweden; Center for Clinical Research, Västerås, 
Sweden
Background: Expression of the peptide hormones ghrelin and 
obestatin has previously been demonstrated in normal breast as well 
as in breast cancer. Interestingly, ghrelin expression has been shown 
to be associated with longer survival in female patients suffering 
from invasive breast cancer. However, the clinical implications of 
the expression of these peptides in male breast cancer are unclear. 
The aim of this study was to further investigate the role and potential 
clinical value of these peptides in male breast cancer.
Methods: A tissue microarray containing male breast cancer 
specimens from 197 patients was immunostained with antibodies 
directed towards the peptides. The expression of the peptides was 
evaluated and correlated to previously known prognostic factors in 
breast cancer and to the outcome. Cox regression analysis was used 
to assess whether these markers may predict survival of male breast 
cancer patients.
Results: Immunoreactivity for ghrelin and obestatin was observed 
in 81% and 87% of the cases, respectively. No strong correlations 
were found between ghrelin or obestatin expression and other 
known prognostic factors. Only ghrelin expression was significantly 
correlated to breast cancer-specific survival (HR=0.37-0.39, p=0.01-
0.03) in both uni- and multivariate analyses. Reproducibility between 
the two readers was good to very good for both stainings with kappa 
values of 0.65-0.89.
Conclusions: Male breast cancer patients with tumors expressing 
ghrelin had 3 times lower risk for breast cancer death than those 
lacking ghrelin expression. Ghrelin expression is easily assessable 
with good reproducibility using immunohistochemistry. Further 
studies are needed to establish the clinical significance of ghrelin as 
a biomarker in breast cancer.
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P4-20-01
Multicentric Phase II PACS 09/Beverly1 Trial: First Efficacy and 
Safety Results of Neoadjuvant Chemotherapy Combined with 
Bevacizumab in HER2-Negative Patients with Non-Metastatic 
Inflammatory Breast Cancer.
Viens P, Petit T, Dalenc F, Pierga JY, Delozier T, Romieu G, Bonneterre 
J, Ferrero J-M, Kerbrat P, Mouret-Reynier M-A, Bachelot T, Soulie P, 
Lerebours F, Eymard J-C, Deblock M, Lortholary A, Hardy-Bessard 
A-C, Boher J-M, Asselain B, Charafe-Jauffret E, Lemonnier J, 
Martin A-L, Andre F. Institut Paoli Calmettes, Marseille, France; 
Centre Paul Strauss, Strasbourg, France; Institut Claudius Regaud, 
Toulouse, France; Institut Curie, Paris, France; Centre François 
Baclesse, Caen, France; Centre Val d’Aurelle, Montpellier, France; 
Centre Oscar Lambret, Lille, France; Centre Antoine Lacassagne, 
Nice, France; Centre Eugène Marquis, Rennes, France; Centre 
Jean Perrin, Clermont-Ferrand, France; Centre Leon Berard, Lyon, 
France; Centre Paul Papin, Angers, France; Institut Curie, Saint 
Cloud, France; Institut Jean Godinot, Reims, France; Centre Alexis 
Vautrin, Nancy, France; Centre Catherine de Sienne, Nantes, France; 
Clinique Armoricaine, Saint Brieuc, France; R&D Unicancer, Paris, 
France; Institut Gustave Roussy, Villejuif, France
Background: Inflammatory breast cancer (IBC) is a relatively rare 
form of breast cancer. Because this disease exhibits angiogenic 
properties, bevacizumab (BEV) may improves the efficacy of 
neoadjuvant chemotherapy (CT) in IBC.
Methods: Pts with HER2-negative IBC (IHC 0 or 1+ or FISH/CISH-, 
T4d, any N) were included to receive 4 cycles of FEC100 + BEV 15 
mg/kg, d1 q3w, followed by 4 cycles of Docetaxel 100 mg/m2 + BEV 
15 mg/kg q3w. Complete surgery was performed 4–6 weeks after 
the last dose of CT, followed by radiotherapy and endocrine therapy 
for hormone receptor positive (HR+) pts. BEV was re-introduced as 
adjuvant therapy for 10 cycles, giving a total of 18 cycles of BEV. 
The primary endpoint of the PACS09/Beverly1 trial was to evaluate 
the pathologic complete response (pCR; Sataloff classification) rate 
in HER2-negative non-metastatic IBC patients(pts).
Results: Between Jan 2009 and Sep 2010, 101 pts were included 
(100 pts were evaluable). Main baseline characteristics were: median 
age 49 years; postmenopausal status, 39 pts ; SBR 2, 32 pts SBR3 
61 pts, both HR-negative, 55 pts. 85 pts completed neoadjuvant 
therapy according to the protocol, . 90 pts underwent complete 
mastectomy, 4 had a breast-conservative surgery. After neoadjuvant 
treatment, investigator-assessed pCR rate was 27% (18%-36%, CI 
95%). Interestingly, a significantly greater proportion of pCR rate was 
observed in the HR-negative group compared to HR-positive group 
(38% vs 13% respectively; p=0.007). Results from central review 
of pCR are currently in progress. Main Grade 3,4 toxicities were: 
neutropenia (61 pts),febrile neutropenia (36 pts),mucitis (23 pts) 
Neither gr3/4 HTA nor cardiac failure or proteinuria was reported. 
There were no treatment-related deaths.
Conclusions: These data suggest that the use of BEV with neoadjuvant 
CT is active in HER2-negative IBC (pCR rate 27%), with an 
acceptable safety profile. Interestingly, the HR-negative subgroup is 
significantly more responsive than the HR-positive subgroup.
P4-20-02
Inflammatory Breast Cancer (IBC) in the National Comprehensive 
Cancer Network (NCCN): The Disease, the Recurrence Pattern 
and the Outcome.
Lubbe W, Li T, Hughes M, Ottesen R, Cristofanilli M, Weeks J, Wong 
Y-N. Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber 
Cancer Institute, Boston, MA; City of Hope Cancer Center, Duarte, 
CA
Background: Inflammatory breast cancer (IBC) is a unique 
clinicopathologic entity that is characterized by rapid progression 
and aggressive behavior from the onset. The clinical presentation 
consists of erythema, rapid enlargement of the breast, skin ridging, 
and a characteristic peau d’orange appearance of the skin secondary 
to dermal lymphatic tumor involvement. Because of its uncommon 
presentation leading to frequent misdiagnosis, most reports are from 
small single institution series which describe a predictable pattern 
of recurrence in spite of appropriate multidisciplinary treatments. 
We sought to confirm these observations using the large multi-
institutional National Comprehensive Cancer Network (NCCN) 
outcomes database.
Methods: Patients (pts) with newly diagnosed IBC treated between 
1999 and 2009 at 12 participating NCCN institutions were identified. 
The clinical diagnoses of IBC was based on the AJCC definition 
and staged as clinical T4d, N0-3, M0-1. The baseline pathological 
characteristics included histological type, estrogen receptor (ER), 
progesterone-receptor (PR), and HER-2/neu status. Pts were classified 
as receiving multimodality therapy if they received two of the 
following three treatments: surgery (lumpectomy or mastectomy), 
perioperative (neoadjuvant or adjuvant) systemic therapy, or 
perioperative radiation therapy.
Results: We identified a cohort of 673 pts with newly diagnosed IBC 
with a median follow-up of 28.9 months. Of which 195 (29%) had 
metastatic disease at presentation. The median age at presentation was 
52.6 years. Caucasians were 79.4% of the cohort, African American 
9.7%, and 11.0% other ethnic groups. Invasive ductal type comprised 
84% of histologies. Biomarker assessment revealed ER+ (44.7%), 
PR+ (34.3%), and Her2/neu+ (33.4%). LVI was documented in 53.3%. 
Of stage III patients, 75.7% pts received perioperative radiation, 
82% received perioperative systemic therapy and 70.7% underwent 
surgery. All three modalities were received by 64.4% of women. Of 
the stage III pts, 203 recurred. The most frequent sites of recurrence 
for were CNS (20.2%), bone (17.2%), chest wall (13.8%), lung 
(12.3%), liver (11.3%), distant (7.4%) and regional lymph nodes 
(6.9%). With a median of 30 and 20 months of follow-up for stage 
III & IV respectively, the median survival was 66 months (95% CI 
54-107) for stage III pts and 26 months (95% CI: 22-33) for stage IV. 
Among the 82% of stage III pts who received multimodality therapy, 
the 5 year and 10 year OS of 62% and 47%.
Discussion: This is a large retrospective multiinstitutional study that 
confirms the aggressive clinical features, recurrence patterns and 
adverse prognosis of IBC described in previous single institution 
series. Even with aggressive multimodal therapy, the long term 
survival of IBC shorter is than non-IBC. Future investigations are 
needed to address the aggressive biology of IBC to improve diagnosis 
and therapy.
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P4-20-03
T-Cell Cytokine Production Related to Progression of Breast 
Cancer Patients.
Cohen EN, Gao H, Lee B-N, Giordano A, Tin S, Anfossi S, Parker CA, 
Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, 
Ueno NT, Reuben JM. The University of Texas MD Anderson Cancer 
Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; 
The University of Texas Graduate School of Biomedical Sciences at 
Houston, Houston, TX
Background: Impaired immunosurveillance and immune 
dysregulation contribute to the pathogenesis and progression of 
breast cancer (BC). Upon activation, T cells synthesize inflammatory 
cytokines such as TNF-a that can promote or inhibit tumor growth. 
We therefore investigated T-cell cytokine syntheses as a predictor of 
disease progression.
Methods: We recruited 115 BC patients [25 with locally advanced 
breast cancer (LABC), 21 with metastatic breast cancer (MBC), 25 
with non-metastatic inflammatory breast cancer (IBC), and 44 with 
metastatic IBC (mIBC)] and 31 healthy donors (HD) for this ongoing 
study. The tumor phenotype consisted of 69 hormone receptor (HR) 
positive (including 26 patients with HER2 positive disease), 16 HR 
negative but HER2+, 30 triple negative BC (TNBC). To evaluate 
T cell function, peripheral blood mononuclear cells from patients 
and HD were stimulated overnight with immobilized anti-CD3 and 
soluble anti-CD28 antibodies and assessed for the percentage of T 
cells that synthesized cytokines by multi-parameter flow cytometry. 
The associations of T cell cytokine production profile with patient 
progression free survival (PFS) were analyzed by Kaplan Meier Test.
Results: The median follow-up (FU) of 113 evaluable patients was 
14.1 months with a median time to relapse of 10.5 months; 54 patients 
had stable disease (SD) and 59 patients had progression of disease 
(PD). In the entire cohort, on univariate analysis, metastasis, IBC, 
stage, and previous treatment predicted for worse PFS (p< 0.05). In 
non-metastatic patients (LABC+IBC), absolute count of anti-CD3 
activated CD8+ T cells producing IL-17 was significantly higher in 
the SD patients compared with patient with PD (p=0.038), but it did 
not predict PFS (p=0.073). Similarly in metastatic patients, anti-CD3 
activated CD4+ T cells producing TNF-a were significantly higher 
in patients with SD (p=0.025) and was predictive of longer PFS 
(p=0.033). Considering all patients with IBC (IBC + mIBC), although 
patients with PD had significantly fewer (percent and absolute 
number) anti-CD3 activated T cells capable of producing cytokines, 
this immune impairment was mostly related to metastasis and previous 
treatment. However, the percentage of anti-CD3 activated CD8+ 
T cells producing TNF-a was an independent positive prognostic 
indicator of PFS (p=0.002).
Conclusion: Higher than average cytokine syntheses by anti-CD3 
activated T cells are significantly associated with longer PFS. These 
data are consistent with the hypothesis that an adaptive immune 
response can control disease progression.
P4-20-04
Cytokine Synthesis by Activated Dendritic Cells in Relation to 
Disease Progression in Inflammatory Breast Cancer (IBC).
Gao H, Cohen EN, Lee B-N, Giordano A, Tin S, Anfossi S, Parker CA, 
Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, 
Ueno NT, Reuben JM. The University of Texas MD Anderson Cancer 
Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA
Background: Deficiencies in innate and adaptive immune responses 
by plasmacytoid dendritic cells (pDC) and myeloid DC (mDC) have 
been linked to poor clinical outcome in breast cancer (BC) (Treilleux, 
Clin Cancer Res, 2004, PMID 15569976). pDC produce IFN-a 
and pro-inflammatory cytokines that regulate innate and adaptive 
immunity in breast cancer. mDC present in blood and secondary 
lymphoid organs secrete IL-12 and induce inflammatory cytokine 
production by T cells. Therefore, we studied DC activity in the 
peripheral blood and assessed their function with clinical outcome 
in breast cancer patients.
Methods: We recruited 115 BC patients [25 with locally advanced 
non-IBC (LABC), 25 with IBC, 21 with metastatic breast cancer 
(MBC), and 44 with metastatic IBC (mIBC)] and 31 healthy donors 
(HD) for this study. Peripheral blood pDC and mDC were activated 
through toll-like receptor (TLR)-7 to assess IFN-a and IL-10 
production whereas mDC were activated through TLR-8 to assess 
production of IL-12 and TNF-a by multi-parameter flow cytometry. 
Associations between cytokine production by TLR-activated pDC 
and mDC with progression free survival (PFS) and overall survival 
(OS) of patients were analyzed by Kaplan Meier Test.
Results: The median follow-up (FU) of 113 evaluable patients was 
14.1 months with a median time to progression of 10.5 months; 54 
patients had stable disease (SD) and 59 had progression of disease 
(PD). Metastasis, previous treatments, and IBC contributed to shorter 
PFS and OS. Compared to HD, BC patients had significantly fewer 
total DC (p=0.008), mDC (p=0.008), and pDC (p=0.003) per µL. In 
general, the number of TLR-7-activated pDC per µL that produced 
IFN-a(p=0.023) or IL-10 (p=0.027) and the number of TLR-8-
activated mDC per µL that produced IL-12 (p<0.001) or TNF-a 
(p=0,008) were significantly lower in BC patients than in HD. 
However, patients with DC that produced these cytokines above the 
median levels of HD had shorter PFS or OS. In IBC patients, higher 
numbers of TLR-8-activated mDC that produced TNF-a (p=0.025) 
or IL-12 (p=0.003) predicted shorter OS. In mIBC patients, a higher 
number of TLR-7-activated pDC producing IFN-a (p=0.024) or IL-
10 (p=0.034) predicted shorter PFS.
Conclusion: BC patients had significantly fewer pDC and mDC 
in peripheral blood than HD. IBC patients with above average 
numbers of TLR-activated DC capable of producing proinflammatory 
cytokines had a significantly shorter PFS or OS. Disease progression 
in IBC is related to an increased number of activated dendritic cells 
producing inflammatory cytokines.
P4-20-05
Inflammatory Breast Cancer: Comparison of Epidemiology, 
Biology, and Prognosis between Japan and the United States, a 
Hospital-Based Study.
Yamauchi H, Natori A, Hayashi N, Soejima K, Takahashi O, Fukui 
T, Nakamura S, Cristofanilli M, Ueno N. St. Luke’s International 
Hospital, Chuo-ku, Tokyo, Japan; Showa University, Shinagawa-
ku, Tokyo, Japan; Fox Chase Cancer Center, Philadelphia, PA; The 
University of Texas M.D. Anderson Cancer Center, Houston, TX
Background: Inflammatory breast cancer (IBC) is a challenging 
disease characterized by low incidence, rapid progression, and 
poor survival. The epidemiology of IBC has been slow to emerge, 
given that the rarity of IBC makes large prospective clinical trials 
difficult. Compared to non-IBC, well-established features of IBC 
include a younger age of onset and lower frequency of hormone 
receptor positivity. Higher body mass index (BMI) is a purported 
risk factor. Previous reports also suggest that IBC is associated with 
more racial disparities, including incidence and age at diagnosis. 
The epidemiology of IBC in East Asia, however, has not been 
investigated. We performed a comparative study of IBC in Japan 
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versus the United States to determine its epidemiologic and clinical 
features and to evaluate the differences in epidemiological factors 
between the two countries.
Patients and Method: Patients who visited St. Luke’s International 
hospital (SLIH) in Tokyo, Japan and The University of Texas MD 
Anderson Cancer Center (MDA) in Texas, USA between 2003 
and 2009 were identified. Epidemiological and biological data 
were collected from electronic medical records. Patient and tumor 
characteristics were tabulated and stratified by hospital. Kaplan-Meier 
curves were created for survival estimates and log-rank test was used 
for cross-group comparisons. Cox proportional-hazard analysis was 
used to identify a subset of significant prognostic variables that related 
to overall survival.
Result: 34 patients at SLIH and 531 patients at MDA were identified. 
Mean age at diagnosis was 52 years old (range, 32-81, SD, 10.8) and 
50 years old (range, 22-87, SD, 11.6), respectively (P=0.476). Mean 
BMI was 22.9 kg/m2 (range, 17.3-30.5, SD 3.3 ) and 31.0 kg/m2 
(range, 13.6-88.9, SD, 7.8) respectively (P<0.01). Clinical Staging 
was not significantly different; Stage IIIB 38.2%, Stage IIIC 26.5%, 
and Stage IV 32.4% at SLIH versus 48.6%, 23.7%, and 27.3% at 
MDA (P= 0.167). Estrogen receptor (ER) and progesterone receptor 
(PR) negative cases were, respectively, 50.0% and 64.7% at SLIH 
and 50.5% and 64.2% at MDA (ER, P= 0.935; PR, P=0.908). Her-
2 over-expression cases were 38.2% at SLIH and 28.6% at MDA 
(P=0.174). A significant difference in nuclear grade was seen between 
SLIH and MDA: 20.6% at SLIH were Grade 3 versus 68.7% at MDA 
(P<0.01). Median overall survival at SLIH was 3.6 years versus 2.3 
years at MDA (P=0.570). No prognostic factors were associated with 
overall survival.
Conclusion: Though IBC at SLIH differed significantly from IBC 
at MDA by several epidemiologic and biologic factors, there was 
no significant difference in survival. To define the epidemiological, 
prognostic, and risk factors of IBC in Japan, as well as in the world, 
further studies are needed.
P5-01-01
Identification, Validation and Assessment of Transcriptional 
Relevance of a PDGFR-Activation Signature in (Inflammatory) 
Breast Cancer.
Van Laere SJ, Van Golen KL, Joglekar M, Ueno NT, Finetti P, Van 
Dam PA, Viens P, Birnbaum D, Bertucci F, Vermeulen PB, Dirix LY. 
Oncology Center - GH Sint-Augustinus, Wilrijk, Antwerp, Belgium; 
University of Delaware, Newark, DE; The University of Texas MD 
Anderson Cancer Center, Houston, TX; Institut Paoli-Calmettes 
(IPC), Marseille, France; World IBC Consortium; Contributed 
Equally
Introduction. Breast cancer can be divided into several subgroups 
characterized by unique patterns of pathway activation. Platelet-
derived growth factor receptor (PDGFR) signalling has not yet been 
included in this classification scheme, although it has been reported 
to be a potential target for therapy. In this study, we have constructed 
a PDGFR-activation signature and investigated its relevance in breast 
cancer.
Materials and Methods. Sixteen PDGFR-modulated genes were 
identified by intersecting two published PDGFR-modulated gene lists. 
The resulting gene signature was applied onto a publicly available 
gene expression data set of GIST (GSE17743) using principle 
component analysis. The segregation of PDGFR- and KIT-mutated 
GIST samples was investigated using permutation analysis and 
classification sensitivity and specificity were assessed. Using the 
regression coefficients from the first principal component, a PDGFR-
activation score was constructed and applied onto a second data set in 
order to validate the score (GSE1923). Finally, the score was applied 
onto a gene expression data set of 389 breast cancer samples,including 
137 samples from patients with IBC.
Results. Sixteen PDGFR-modulated genes (NR4A1, EGR3, JUNB, 
IER3, TIEG, JUN, BCL3, MYC, NR4A3, PLAU, MCL1, DUSP1, 
DUSP5, DUSP6, SGK, GADD45A) were able to discriminate 
PDGFR-mutated GIST samples from KIT-mutated GIST samples 
with a sensitivity of 75% and a specificity of 85%. Application of the 
PDGFR-activation score onto a data set of control and PDGF-treated 
glioblastoma cells showed a significant increase in the PDGFR-
activation score in the treated condition (P=0.0302). Application 
of the PDGFR-signature onto our series of IBC and nIBC samples 
demonstrated a significant and molecular subtype-independent 
increase in PDGFR-activation in IBC (P=0.0015; FDR=3%). In 
addition, in our series of nIBC samples only, PDGFR-activation was 
associated with decreased DMFS and RFS (P=0.0038 and P=0.0137 
respectively). In fact, PDGFR-activation was an independent 
prognosticator in a multivariate model incorporating the molecular 
subtypes.
Discussion. We identified a gene signature composed of 16 genes able 
to predict PDGFR-activation in tissue samples by gene expression 
analysis. PDGFR-activation is significantly increased in samples from 
patients with IBC, an aggressive form of locally advanced breast 
cancer. In addition, in nIBC, PDGFR-activation is associated with 
DMFS and RFS, independently of the molecular subtypes suggesting 
that PDGFR-activation might add another level of clinically relevant 
heterogeneity in breast cancer.
P5-01-02
Wnt5a Is a Prognostic Biomarker in Estrogen Receptor-Positive 
Premenopausal Breast Cancer.
Sand-Dejmek JT, Ehrnstrom R, Andersson T, Ryden L. Clinical 
Sciences, Skåne University Hospital, Lund University, Malmoe, 
Sweden; Laboratory Medicine, Skåne University Hospital, Lund 
University, Malmoe, Sweden
Background: Wnt proteins belong to a family of secreted growth 
factors, which are involved in a wide range of cellular processes. 
Wnt signaling can be broadly divided into two categories; the 
canonical, ß-catenin-dependent pathway and the non-canonical 
ß-catenin-independent pathway. Wnt5a is a non-canonical signaling 
member of the Wnt family. Studies in two smaller cohorts of breast 
cancer revealed that loss of Wnt5a was associated with early relapse, 
metastatic disease and poor survival. Moreover, reconstitution of 
Wnt5a signalling decreased the migratory capacity and invasiveness 
of cultured breast cancer cells and administration of a Wnt5a-
mimicking peptide was proven to inhibit metastases in a mouse model.
Material and methods: Premenopausal women (n=564) were 
included in a controlled randomised trial and allocated to tamoxifen 
for two years versus no adjuvant treatment. A tumour tissue 
microarrays was constructed and 390/500 samples were evaluable 
for Wnt5a protein expression by immunohistochemistry. Only cases 
with at least 2 evaluable cores were included. Wnt5a levels were 
determined semiquantitatively (scores 0-3). Clinical and pathological 
data such as patient age, histological subtype, pT stage, tumor size, 
pN stage, ER, PR, Ki67 and HER2 status were available. The end-
point was 10 year recurrence-free survival.
Results: Wnt5a protein expression was lost in 158/390 of the analyzed 
tumors and more common in younger (<45 yrs) women (p=0.032). 
Furthermore, loss of Wnt5a was significantly associated with ER 
and PR negativity (p=0.019 and p= 0.033, respectively). Loss of 
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Wnt5a was significantly correlated to poor survival in the whole 
cohort, p=0.02. When analyzing the data according to breast cancer 
subtype, we found that Wnt5a was a strong independent prognostic 
factor in ER+ breast cancer p=0.009, but not in ER- breast cancer 
p=0.8. This was true both in the adjuvantely treated and untreated 
cohorts, verifying that Wnt5a indeed is a true prognostic factor and 
not a predictor of response to therapy.
Discussion: While associated with a better short-time prognosis than 
ER negative tumors, a subset of ER positive breast cancer patients 
are known to experience tumor recurrencies >5 years after primary 
treatment and hence have a dismal prognosis. Those patients need to 
be identified and their tumors targeted with more aggressive treatment 
regimens. We have identified and validated Wnt5a as a prognostic 
biomarker in ER positive breast cancer in premenopausal women. 
Wnt5a signalling could potentially be reconstituted by administration 
of a Wnt5a-mimicking peptide, shown to inhibit metastases in mice, 
thereby offering ER positive premenopausal patients a targeted 
adjuvant therapy that potentially could lower their risk of metastatic 
disease.
P5-01-03
Correlation between Aromatase Expression in Metastatic and 
Primary Breast Cancer.
Ribeiro JM, Luis IV, Correia L, Casimiro S, Fernandes A, Quintela 
A, Mestan J, Ramos M, Costa L. Hospital de Santa Maria, Lisbon, 
Portugal; University of Lisbon, Lisbon; Hospital de Santa Maria, 
Lisbon; Novartis Pharma
Background: Estrogens are the major mitogenic factor in hormone 
dependent breast cancer. In postmenopausal women, estrogen 
production results mainly from extra-glandular conversion of 
androstenedione to estrone. This conversion is catalyzed by the 
enzyme aromatase (Aro). It is known that an higher expression and 
activity of the enzyme Aro is present in primary breast carcinoma 
compared with normal breast tissue. These data may indicate that 
tumors have the ability to produce their own estrogen. However, it is 
not known whether this process can occur at the level of metastasis.
This study aims to determine the expression of aromatase in metastatic 
breast cancer and to analyze its correlation with expression at primary 
tumor and response to aromatase inhibitors (AI).
Material and Methods: We selected 41 patients with metastatic 
breast cancer, followed in the Department of Medical Oncology 
since 1995, undergoing surgery or biopsy of a metastatic lesion in 
the course of the disease (24 liver metastases; 10 bone metastases; 6 
lung metastases; 1 lymph node metastases). For all these patients a 
detailed clinical chart review regarding clinical information (including 
treatment and tumor status) was obtained. Samples (formalin fixed 
and paraffin embedded) were analyzed for aromatase expression by 
immunohistochemistry (IHC), using the anti-aromatase monoclonal 
antibody # 677 (Novartis). Slides were scored considering the 
proportion of immunoreactive cells and intensity of the staining, 
and evaluating separately the epithelial and stromal component. 
The Fisher and log-rank test were used to determine the correlation 
between Aro expression in metastatic tissue and response to AI.
Results: Aromatase was expressed in 51% (21/41) of the samples (13 
liver metastases; 8 bone metastases). The average combined score 
was 130 (10 - 320). The average score was higher in the epithelial 
component versus the stromal component (123 vs. 17.5). There was 
a strong expression of Aro in bone metastases (average combined 
score: 176) compared with other sites.
There was no correlation between Aro expression and estrogen 
receptors expression. In 15 patients, it was also possible to evaluate 
the expression of Aro in the primary tumor. Aro was expressed in 
four cases (36%), with an average combined score of 52.5. The Aro 
expression between the primary tumor and metastasis was concordant 
in nine cases.
Thirty-four patients received AI to treat metastatic disease. The 
median time to progression (TTP) with AI in the entire population 
was 17.8 months. In the group of patients with Aro expression in 
metastasis, the median TTP in AI was 19.5 months, significantly 
higher than that obtained in the group without detectable Aro 
expression: 6.5 months (p = 0.045). The overall survival in the group 
with Aro expression was125 months and the 77 months in patients 
without Aro expression (p = 0.54).
Conclusions: Aromatase is expressed by metastatic tumor cells from 
breast cancer, with a positive and statistically significant correlation 
between its expression in the metastasis and the clinical benefit to IA. 
Its expression was higher in bone metastases compared with other 
sites of metastasis although this difference was not, in our study, 
statistically significant.
P5-01-04
FOXP3 Positive Regulatory T Lymphocytes and Epithelial 
FOXP3 Expression in Synchronous Normal, Ductal Carcinoma 
In Situ and Invasive Cancer of the Breast.
Lal A, Chan L, DeVries S, Chin K, Benz CC, Chen Y-Y, Hwang S, 
Waldman FM. UCSF, SF, CA
Background: FOXP3 expressing regulatory T cells (Tregs) have been 
associated with worse outcome in a number of malignancies, including 
breast cancer. In this study we evaluate the number of FOXP3 
positive T lymphocytes as well as quantitating FOXP3 expression of 
epithelium in synchronous normal, ductal carcinoma in situ (DCIS) 
and invasive ductal carcinoma (IDC) in order to determine whether 
FOXP3 expression increases with cancer progression.
Materials and Methods: 32 cases containing concurrent normal, DCIS 
and IDC lesions of the breast were stained for FOXP3 (e-Bioscience) 
and CD3 (DAKO) using the Envision G/2 Double stain System 
(DAKO). Multiplex stains were separated by imaging using the 
CRi’s Nuance imager. The ratio of colocalized FOXP3 and CD3 
pixels (Treg lymphocytes)/CD3 pixels (all lymphocytes) in adjacent 
stroma was used as a measure of FOXP3 positive Tregs. Epithelial 
FOXP3 expression was quantitated by Image J analysis. A subset of 
the cases (n=13) were also stained by standard immunohistochemistry 
for FOXP3. The number of FOXP3 positive lymphocytes/total 
lymphocytes and the epithelial intensity were scored.
Results: The mean patient age was 52 years. ER, PR and HER2 
positivity in the invasive component was 94%, 84% and 16% 
respectively. One case was triple negative.
The median fraction of FOXP3 lymphocytes increased from normal 
to DCIS to IDC (0.005, 0.019 and 0.030 respectively). Significant 
differences were seen for normal vs. IDC (p=<0.0001) and DCIS 
vs. IDC (p=0.0039). FOXP3 lymphocyte fraction was significantly 
higher in grade 3 compared to grade 1 tumors (p=0.0140). Standard 
immunohistochemistry showed similar results (median value for 
fraction of FOXP3 positive lymphocytes = 0.03, 0.14 and 0.16 
in normal, DCIS and IDC respectively). This was significantly 
different in the normal stroma vs. invasive cancer stroma comparison 
(p=0.017).
For epithelial FOXP3 staining intensity, the median increased 
significantly from normal to DCIS (0.130 to 0.175, p=<0.0001) and 
decreased significantly from DCIS to IDC (0.175 to 0.150, p=0.0181). 
However, FOXP3 epithelial intensity was higher in grade 3 compared 
to grade 1 tumors (p=0.0381). Epithelial FOXP3 expression by 
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standard IHC also showed a similar trend (median H score 100, 150 
and 120, respectively) with a significant increase in the normal vs. 
DCIS comparison (p=0.0090).
FOXP3 lymphocyte count had a positive correlation with FOXP3 
epithelial intensity in the normal and invasive components (Spearman 
r=0.4343, p=0.0130 for normal and Spearman r=0.5456, p=0.0012 
for IDC).
FOXP3 lymphocyte fraction and FOXP3 epithelial intensity did not 
vary significantly with size of invasive tumor, nodal status, or stage 
of disease.
Discussion: FOXP3 is expressed both by tumor infiltrating T 
lymphocytes as well as tumor epithelium. The significant increase in 
FOXP3 T regulatory lymphocytes and FOXP3 epithelial expression 
from normal to invasive cancer suggests a role of FOXP3 in breast 
carcinogenesis and progression. The significant correlation of 
FOXP3-T regulatory lymphocytes and FOXP3 epithelial expression 
in the normal and invasive components suggests expression of one 
may influence the other early in the breast cancer progression pathway.
P5-01-05
Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial 
(CALGB 150007/150012; ACRIN 6657).
Boudreau A, Yau C, Petrillo L, Stemke-Hale K, Mills GB, Gray JW, 
Wolf DM, van ‘t Veer LJ, The I-SPY 1 TRIAL Investigators, Esserman 
LJ. University of California, San Francisco; University of Texas 
MD Anderson Cancer Center; Oregon Health & Science University
Background: Mutations in the catalytic domain of phosphatidylinositol 
3-kinase (PIK3CA) are among the most frequently observed activating 
mutations in breast cancer. We used the I SPY 1 TRIAL, a group of 
biologically and clinically high risk patients molecularly profiled and 
treated with neoadjuvant chemotherapy, to determine the frequency 
of mutations and their relationship to pathologic complete response 
(pCR) and outcomes, within the entire cohort and within subtypes 
defined by growth and hormone receptor (HR) expression.
Methods: Patients enrolled in the I-SPY 1 TRIAL had a tumor size 
≥3.0cm and were administered a doxorubicin-containing regimen, 
followed by a taxane, prior to surgery. Sequenom single nucleotide 
polymorphism (SNP) profiling was performed on breast tumor 
genomic DNA isolated from a subset of patients (n=152). A total 
of 149 SNPs covering 16 genes (including PIK3CA and AKT1/2/3) 
were analyzed. Mutations were tested for association with estrogen 
receptor (ER), progesterone receptor (PgR), and HER2 status, as well 
as pCR, using Fisher’s exact test; associations between mutations 
and recurrence-free survival (RFS) were measured by log-rank tests. 
pCR was defined as no invasive tumor present in either the breast or 
axillary lymph nodes following neoadjuvant treatment.
Results: Of 149 mutations profiled in the cohort, 13 of the SNPs were 
observed. PIK3CA mutations were the most frequently observed in 
the panel (15.1%), followed by AKT1(E17K; 2.7%), CTNNB1(D32; 
1.4%), NRAS(Q61; 0.7%), and FGFR2(N549; 0.7%). Mutations in 
PIK3CA or AKT1 was associated with ER-positivity (p=0.0047) and 
PgR-positivity (p=0.044). Within receptor subtypes, the frequencies 
of PIK3CA/AKT1 mutations were also significantly different 
(HR+HER2-: 27%:(18/68); HER2+ 20% (8/40) [HR+HER2+: 
26%, HR-HER2+: 14%]; HR-HER2-: 0% (0/36), p<0.0008). Unlike 
previous reports (Loi et al, PNAS 2010), no significant association 
between PIK3CA/AKT mutation status and RFS was observed when 
we restricted our analysis to the adjuvant endocrine treated subset 
of the HR+HER2- patients (n=49; log rank p = 0.369). In contrast, 
and similar to cell line reports (Junttila et al, Cancer Cell 2009), 
PIK3CA mutations appears to associate with worse RFS within the 
small subset of trastuzumab treated HER2+ patients (n=22, 13 HR-
HER2+, 9 HR+HER2-; log rank p=0.001), suggesting mutations may 
influence response. Similar analyses of a larger cohort are planned to 
confirm these observations.
Conclusions: Within the I-SPY 1 TRIAL cohort, PIK3CA and AKT1 
mutations are much more frequent in the HR+ and HER2 subsets but 
are not predictive of response to therapy or outcome except potentially 
within the HER2+ subset. The potential link observed between 
activating PIK3CA/AKT mutations and trastuzumab resistance 
merits further investigation, as it may provide a clinical rationale for 
testing PIK3CA mutation status in HER2+ patients and investigating 
combinational therapies targeting this pathway, particularly in the 
HER2+HR+ subset which have an elevated risk for recurrence despite 
pCR and trastuzumab therapy.
P5-01-06
Gene Copy Number and Expression of TYMP and TYMS Are 
Predictive of Outcome in Breast Cancer Patients Treated with 
Capecitabine.
Audet RM, Changyu S, Duchnowska R, Adamowicz K, Zok J, 
Rogowski W, Litwiniuk M, Debska S, Jaworska M, Foszczynska-
Kloda M, Kulma-Kreft M, Zabkowska K, Jassem J, Edgerton S, 
Vang Nielsen K, Thor A, Chang J, Miller K, Sledge GW, Leyland-
Jones B. V M Institut of Research, Montreal, QC, Canada; Medical 
University of Gdansk, Gdansk, Poland; Indiana University School 
of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer 
Center, Indianapolis; Emory University, Atlanta, GA; UC Denver 
School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The 
Methodist Hospital Research Institute, Houston, TX; Military Institute 
of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan 
University of Medical Sciences; Regional Cancer Center, Lodz, MD; 
District Hospital, Wrocław, MD; West Pomeranian Oncology Center, 
Szczecin; Gdynia Oncology Center
Background: The efficacy of the pro-drug capecitabine (C) may be 
affected by the expression of thymidylate synthase (TYMS) and 
thymidine phosphorylase (TYMP), respectively the target and the 
activating enzyme of C, as well as dihydrofolate reductase (DHFR) 
that provides a key intermediate.
Method: In this retrospective study, expression and gene copy number 
(GCN) of the above enzymes were assessed and correlated with 
time-to progression (TTP) and progression-free survival (PFS) of 
adult female patients with pathologically confirmed breast cancer 
and locally advanced or metastatic disease treated with C 1000 mg/
m2 BID days 1-14 of a 21-day cycle. TYMS, TYMP and DHFR GCN 
were scored using custom made FISH probes (Dako, Denmark) in at 
least 60 morphologically intact non-overlapping nuclei. FISH markers 
dichotomized as high/low by the median were correlated with TTP 
and PFS using Cox proportional hazard models in 65, 57 and 24 
patients for TYMS, TYMP and DHFR probes respectively. Gene 
expression was analyzed using the whole genome cDNA-mediated 
annealing, selection extension and ligation (DASL) platform on total 
RNA extracted from FFPE tissue samples and correlated with TTP 
and PFS using Cox models in 75 patients. Correlations between GCN 
and expression were measured using both Pearson’s and Spearman’s 
correlation coefficients.
Results: Our interim results (ASCO 2011) showed that higher TYMS 
GCN was significantly associated with both decreased TTP (HR 1.76, 
95% CI 1.07 to 2.90, p=0.026) and PFS (HR 1.86, 95% CI 1.14 to 
3.04, p=0.036) in the overall patient population. We now observe 1) 
a statistically significant positive correlation between TYMS GCN 
and expression (Pearson 0.26, p=0.049; Spearman 0.25, p=0.056); 
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2) a trend towards worse outcome with higher TYMS expression 
in a) the overall population (TTP-HR 1.23, 95% CI 0.93 to 1.64, 
p=0.148), b) in ER+ patients (TTP-HR 1.46, 95% CI 0.97 to 2.19, 
p=0.07) as well as in c) HER2- patients (TTP-HR 1.17, 95% CI 0.85 
to 1.61, p=0.343), 3) a statistically significant association between 
higher TYMP expression and longer PFS, but not TTP in ER+ and 
HER2- patients (table).
Correlation between TYMP expression and PFS or TTP
 PFS-HR TTP-HR
ER+ (41) 0.10 p=0.041 0.35 p=0.404
ER - (34) 0.22 p=0.074 0.25 p=0.090
HER+ (insuf.) - -
HER- (62) 0.16 p=0.026 0.25 p=0.120
Discussion: Our ASCO 2011 analysis showed that high TYMS GCN 
is predictive of poor outcome in ER+ and HER2- patients, consistent 
with the fact it is the target of C. Here, we show that 1) expression 
of TYMS is significantly correlated with GCN 2) higher TYMS 
expression demonstrates the same trend towards poor outcome in 
ER+ and HER2- patients as in FISH, 3) higher TYMP expression 
is significantly associated with longer PFS in ER+ and HER2- 
patients, consistent with its C activating role. Differential sensitivity 
between FISH and DASL might be explained by the fact that DASL 
is performed in a pool of RNA coming from many cellular types, 
whereas FISH is scored selectively in tumor cells. These findings 
suggest that TYMS and TYMP GCN and expression can be useful 
predictive markers of C sensitivity in human breast cancer.
P5-01-07
Identification of SORBS2 as a Candidate Marker To Predict 
Metastatic Relapse in Breast Cancer.
Alsafadi S, Scott V, Pautier P, Goubar A, Lazar V, Dessen P, Lacroix L, 
Duvillard P, Morice P, André F, Delaloge S. Gustave Roussy Cancer 
Institute, Villejuif, France
Background: Elucidation of promising cancer biomarkers from gene 
expression data can provide important insight into the relationship 
between signaling networks and cancer. SORBS2, sorbin and SH3 
domain containing 2, is a multi-adapter protein involved in signal 
transduction associated to the cytoskeleton and was reported to be 
strongly repressed in pancreatic and cervical cancers.
Methods: With the purpose of identifying genes involved in metastatic 
process, we compared gene expression profiling of 19 invasive ovarian 
cancers and 24 borderline tumors. Prognostic value of the selected 
genes was then tested in a gene expression array database that includes 
1659 patients with early breast cancer (Gyorffy B et al. 2010). Upon 
isolation of SORBS2 as a predictor, its involvement in cell migration 
and tumor progression was investigated in vitro. Small interfering 
RNA targeting SORBS2 was used to downregulate its expression in 
T47D and Hela, two cell lines overexpressing SORBS2. Functional 
effect of siRNA-induced knockdown of SORBS2 on cell viability was 
determined by WST-1 assay and Trypan Blue exclusion test. Effect 
on cell migration was evaluated by wound-healing and transwell 
assays. Western blot analyses were also performed to examine the 
expressions of proteins involved in cell survival, death and migration.
Results: High-throughput analyses of genes that are differentially 
expressed between borderline ovarian tumors and invasive carcinoma 
demonstrated that SORBS2 is significantly downregulated in invasive 
carcinoma (FDR<10e-10). Moreover, SORBS2 loss was a strong 
predictor of relapse in a gene expression array dataset of 1659 patients 
presenting an early breast cancer (HR=0.62, 0.52-0.72, p=6.4e-10). 
In vitro studies showed that SORBS2 specific downregulation 
stimulated cell proliferation, by an average of 40%, in T47D and 
Hela cell lines. SORBS2 knockdown had no effect on either cell 
migration rate or protein expressions of p-FAK and p-Paxillin, 
two focal adhesion proteins which are critical to cell adhesion and 
migration. No significant variations in protein expressions of Akt/
mTOR pro-survival or caspases activation pathways were observed. 
Gene expression profiling before and after SORBS2 dowregulation 
is ongoing in the two cell lines.
Conclusion: This study is the first to provide evidence for an 
antiproliferative activity of SORBS2 with no effect on cell migration 
in breast cancer cells. Our clinical and in vitro data suggest that 
SORBS2 is a candidate marker to predict relapse in patients with early 
breast cancer. Molecular mechanisms mediating the antiproliferative 
effect of SORBS2 are currently being investigated.
P5-01-08
Immunocytochemistry Staining of Estrogen Receptor in 
Circulating Tumor Cells as Compared to Primary Tumor.
Mayer JA, Pham T, Wong KL, Bischoff FZ. Biocept Inc, San Diego, CA
Introduction: Estrogen receptor (ER) status in all breast cancer 
patients is recommended by immunohistochemistry (IHC) and is 
considered standard practice for selection of treatment options. 
However, the analytical sensitivity of IHC in detecting low levels of 
ER is often poor and likely due to methodological variation. Because 
biopsy is not often feasible in all patients presenting with recurrent 
and/or metastatic breast disease, circulating tumor cells (CTCs) offer 
an attractive alternative source of tumor tissue for determining ER 
status and can be monitored more readily to enable a more effective 
course of treatment.
Experimental Design: Twenty ml of peripheral blood was collected 
prospectively from # patients diagnosed with late stage metastatic/
recurrent breast cancer. CTCs were isolated using the microfluidic 
OncoCEETM platform. A cocktail of antibodies was utilized for 
CTC capture and detection with an expanded anti-cytokeratin (CK) 
cocktail mixture and anti-CD45. ER protein expression was assessed 
by immunocytochemistry (ICC) on the cells captured within the 
microchannels and compared to IHC performed on the primary tumor.
Results: CK+/CD45- cells were detected in 23 of 27 cases (85%). 
Among the 23 cases in which CK+ cells were detected, only moderate 
concordance (16/23; 70%) in ER status between primary tumor and 
CTCs was observed.
Conclusions: There is significant heterogeneity between ER protein 
expression in CTCs and primary tumor. ER ICC on CTCs from 
peripheral blood using the OncoCEETM platform is shown to be 
feasible but the comparison likely compromised by lack of tumor 
staging at the time of blood draw. Given that IHC was in some cases 
performed 5-10 years pre-blood draw and that tumors have the 
potential to convert, ER status only moderately correlates to the IHC 
status in the primary tumor. The significance of heterogeneity at the 
ER protein level in CTCs ascertaining to the prognosis and predictive 
response to anti-estrogen therapy needs further evaluation in larger 
prospective clinical trials.
P5-01-09
Differences in Serum Estradiol and Prolactin Concentrations 
in Women Who Yield Nipple Aspiration Fluid and Those Who 
Do Not.
Khan SA, Fought AJ, Scholtens DM, McGathey C, Heinz RE, 
Chatterton RT. Northwestern University, Feinberg School of 
Medicine, Chicago, IL
Introduction: Nipple aspiration fluid, NAF is an important biosample 
for breast cancer research, but its utility is limited by the fact that 
the fraction of NAF-yielders varies from 35% to 90% in various 
studies. NAF yielders (Y) and non-yielders (NY) are known to differ 
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in demographic characteristics, but the systemic endocrine profiles 
of Y and NY populations have not been studied, and may affect the 
generalizability of findings in studies of NAF.
Methods: A subset of participants from an ongoing case-control 
study was included (120 cases, 120 controls). Cases are women 
presenting to the Lynn Sage Breast Center with newly diagnosed 
unilateral breast cancer, and controls are women presenting to the 
Lynn Sage Mammography Center who do not have cancer. NAF 
collection was attempted on all consented subjects; those yielding ≥2 
uL NAF were designated as Y and those yielding <2 uL NAF were 
NY (120 Ys, 120 NYs). Menopausal status, age, race, menstrual cycle 
phase, mammographic density, and serum hormone levels were also 
collected. Differences between Y and NY groups were tested using 
a t-test for age, c2 for race, and Wilcoxon Sum Rank Test for serum 
hormone levels. Mammographic density was quantitated using digital 
or digitized images and the CUMULUS software. Linear regression 
was used to test the relationship between a logged serum hormone 
values and if a patient yielded adjusting for phase of menstrual cycle 
in premenopausal women.
Results: Mean ages of Ys and NYs were not different 51.0 and 52.6, 
respectively (p=0.11). The distribution of Ys by race (Caucasian, 
African American, other), was not different (c2 p=0.58). Median 
serum prolactin concentrations were higher in Ys than NYs for both 
pre- (7.0 and 2.5 ng/ml) and post-menopausal (5.6 and 2.4 ng/ml) 
women, respectively (both p<0.01). Median serum estradiol was 
lower in yielding premenopausal patients only (pre- 90.5 and 64.3 
pg/ml p=0.02; post- p=0.59). Stratifying the premenopausal women 
further into cases and controls, the difference only held for cases and 
not for controls (p=0.02, p=.033). In the premenopausal patients the 
regression models suggested that these relationships for estradiol 
and prolactin remain even after adjusting for phase of the menstrual 
cycle. No differences in Ys versus NYs were found for progesterone, 
follicle stimulating hormone, or sex hormone binding globulin. 
Mammographic density was not different for Ys as compared to 
NYs for pre- (22% and 20%, p=0.83), but was marginally lower for 
post-menopausal Ys versus NYs (11% and 15% density; p=0.07). 
Following stratification of the postmenopausal women into cases 
and controls, the cases who yielded had significantly lower than NYs 
(11% and 19% density, p=0.03), but the control Ys and NYs were not 
different (10% and 11% density, p=0.65).
Conclusion: Pre- and post-menopausal women who yield NAF display 
increased serum prolactin levels, whereas decreased estradiol levels 
were observed in premenopausal NAF Ys. These findings suggest that 
NAF yield has systemic endocrine determinants, with implications for 
biomarker research on NAF samples. Further characterization of Y 
and NY women is important, along with standardization of methods 
of NAF collection, since NAF yield varies widely between studies.
P5-01-10
A Potential New Marker for, and Facilitator of, Hormone 
Independence.
Monaco ME, Wu X, Lee P. NYU School of Medicine, New York, NY; 
VA NY Harbor Healthcare System, New York, NY
Triple negative breast cancers (TNBC) are generally more aggressive 
and have a worse prognosis than cancers that express estrogen (ER), 
progesterone (PGR) and/or human epidermal growth factor receptor 
2 (HER2). Recent data suggests that another hormone receptor, that 
for androgen (AR) may be relevant in terms of further stratifying 
TNBC, with quadruple negative breast cancer (QNBC) having a 
worse prognosis than TNBC. In addition, TNBC vary with respect to 
prognosis and sensitivity to specific treatments, and foreknowledge 
of treatment outcomes has been the goal of numerous studies 
designed to generate predictive gene signatures. Development of 
these signatures involves the use of algorithms that can potentially 
exclude important biomarkers that may appear to be too weakly 
expressed to make the cut-off. We report here that the lipid metabolic 
enzyme, long-chain fatty acyl-CoA synthetase 4 (ACSL4) falls into 
this category of a heretofore-unrecognized biomarker for aggressive 
breast cancer. We have previously reported that ACSL4 expression 
is negatively correlated with the expression of ER and AR in both 
breast cancer cell lines and tumor samples. We now report a positive 
correlation between ACSL4 mRNA expression and QNBC status. 
In two separate studies involving a total of 71 separate breast cancer 
cell lines, values for ACSL4 expression derived from microarray 
data indicated increased expression in QNBC cell lines, p=3.75E-08 
and p=4.59E-08, when compared with cell lines expressing one or 
more receptor biomarkers. An analysis of data derived from 178 
tumor samples indicated a similar correlation, p=2.2E-03. ACSL4 
expression was also correlated with molecular subtype. When breast 
cancer cell lines were classified by subtype, 24 of 26 luminal cell lines 
were negative for ACSL4 expression, 8 of 8 claudin-low cell lines 
were positive for ACSL4 expression, as were 12 of 17 basal-like cell 
lines. Three basal-like cell lines expressed both ACSL4 and HER2. 
Upon further examination, these lines were demonstrated to express 
relatively low levels of other markers that have been suggested to 
correlate with HER2 sensitivity (ESR1, XBP1, FASN, ERBB3), as 
well as to express relatively high levels of markers correlated with 
HER2 resistance (CD44, CAV2).
In order to determine the relationship between ACSL4 expression and 
estrogen independence, ACSL4-negative MCF-7 cells were inducibly 
transfected with ACSL4 cDNA. Induction of ACSL4 resulted in 
abrogation of the proliferation response to estrogen, accompanied by 
a reduction in expression of ER, AR and PGR. In addition, induced 
cells were less sensitive to treatment with tamoxifen, etoposide and 
triacsin C. Information derived from RAF-1-transfected MCF-7 
microarray data suggest that ACSL4 expression can be regulated by 
RAF-1. To further explore this notion, QNBC cells, MDA-MB-231, 
which express high levels of ACSL4, were treated with siRNA for 
RAF-1 and ACSL4 levels monitored by RT-PCR and immunoblot. 
The fall in levels of expression of RAF-1 was accompanied by a 
similar decrease in expression of ACSL4. Reduction of ACSL4, 
however, had no effect on RAF-1 expression.
In summary, these data demonstrate a possible role for ACSL4 as a 
biomarker for prognosis and treatment outcome, as well as a facilitator 
of hormone resistance.
P5-01-11
Small Node-Negative (T1b-cN0) Invasive Hormone Receptor 
(HR)-Positive Breast Cancers: Is There a Population Which Might 
Have Benefit from Adjuvant Chemotherapy?
Park YH, Cho EY, Lee JE, Nam SJ, Yang JH, Ahn JS, Im Y-H. Samsung 
Medical Center
Background: It has been widely accepted that small and node-
negative breast cancers have an excellent prognosis and do not 
generally have clinical benefit from adjuvant chemotherapy. Recently, 
the role of adjuvant chemotherapy for small node negative breast 
cancers has been justified in some high-risk patients, which include 
HER2-positive and triple negative breast cancers. However, the 
question has been raised as to whether there are some patients who 
might have benefit from adjuvant chemotherapy in small node-
negative HR-positive breast cancers. According to the current 2011 
NCCN guideline, 21-gene RT-PCR assay can be considered for tumor 
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size of more than 0.5 cm in HR-positive, HER2-negative cancers. 
In cases of high recurrence score (≥ 31), adjuvant chemotherapy 
in addition to endocrine therapy is recommended as category 2B. 
Because gene array cannot routinely be used in clinical practice 
and has not been validated in prospective randomized trials and the 
usefulness of it still needs to be defined, it would be better if there 
were valuable markers to determine risk for relapse in this setting. 
We hypothesized that there could be a population who might have 
clinical benefit from adjuvant chemotherapy in this small node-
negative HR-positive tumors.
Patients and Methods: We retrospectively analyzed the 
clinicopathologic characteristics and outcomes of 538 postoperative 
HR-positive (ER-positive and/or PgR-positive) T1b-cN0 breast cancer 
patients between 2004 and 2007 at the Samsung Medical Center. We 
performed Cox regression multivariate analysis for relapse using 
variables from univariate analysis by log-rank test for relapse.
Results: The median age at diagnosis was 46 years (range, 22-79). 
During the median 60.5 months of follow-up, the 5-year recurrence 
rate was 5.2%. Anthracycline-based adjuvant chemotherapy was 
administered to 44.8% of the patients. Adjuvant endocrine and 
radiation treatment were administered to 94.6% and 63.7% of the 
patients. There were significant differences according to histologic 
grade (HG), Ki67 index, and age of less than 35 years in univariate 
analyses regarding RFS (p=0.003, p<0.0001, and p=0.003, 
respectively by log-rank test). There was no significant difference 
according to tumor size of subcentimeter (< 1cm) (p=0.826). In Cox 
regression multivariate analysis, high Ki67 index and young age 
of less than 35 years were identified as independent risk factors for 
relapse (p<0.0001 for Ki67 index and 0.015 for young age). The high 
risk patients (n=24, 4.5%) who have high Ki67 index (more than 75%, 
4+) or young age of less than 35 and more than 50% of Ki67 index 
showed better RFS with statistical significance for anthracycline-
containing adjuvant chemotherapy (p=0.029).
Conclusion: A patients’ population may exist who have clinical 
benefit from adjuvant chemotherapy in T1b-cN0 HR-positive breast 
cancer patients. Ki67 index and age are useful as valuable surrogate 
markers to predict recurrence and to have benefit from adjuvant 
chemotherapy in this population.
P5-01-12
Identification of an ATM Activation Subtype in PTEN Mutant 
Breast Tumours.
McCabe N, Walker SM, Goffard N, Wikstrom K, Greenan C, Delaney 
T, McCarthy M, McDyer F, Hill L, Deharo S, Proutski V, Keating K, 
Mullan P, Harkin DP, Kennedy RD. Almac Diagnostics, Craigavon, 
United Kingdom; Queens University Belfast, Belfast, United Kingdom
Background
PTEN is frequently lost in cancer cells through genetic mutation or 
epigenetic silencing. Loss of PTEN function has been widely reported 
to cause up-regulation of the PI3K/AKT signalling pathway resulting 
in increased cell growth, proliferation and survival. More recently 
it has been reported that PTEN null cells demonstrate genomic 
instability through increased ROS and oxidative stress induced DNA 
damage. The aim of this study was to identify a biomarker for PTEN 
status in human breast cancers.
Materials and Methods
A metagene representing ATM activation was generated from public 
cell line data of AT fibroblasts treated with gamma-irradiation. This 
was used to perform hierarchical clustering analysis of a public DNA 
microarray profiling dataset with known PTEN IHC status. The 
metagene was validated in PTEN wildtype and null breast cancer 
cell lines.
Results
We found that PTEN null cells have elevated levels of ROS and 
furthermore activation of the DNA damage signalling kinase, ATM. 
In agreement with this, the ATM metagene signature correlated with 
PTEN mutation in breast cancer tumours. Scoring of PTEN wildtype 
and null breast cancer cell lines using the metagene correlated with 
ATM activation and sensitivity to inhibition of ATM. Furthermore 
we show that inhibition of ATM caused DNA damage, cell cycle 
arrest and apoptosis in PTEN deficient cells suggesting a novel 
therapeutic strategy.
Conclusion
These observations suggest that ATM may represent a therapeutic 
target in PTEN deficient tumours and furthermore ATM activation 
may also be an important biomarker of PTEN mutation or loss in 
breast cancer.
P5-01-13
High Levels of Nuclear Heat Shock Factor 1 (HSF1) Are 
Associated with Poor Prognosis in Breast Cancer: Results from 
the Nurses’ Health Study.
Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, 
Schnitt SJ, Whitesell L, Lindquist S, Tamimi RM, Ince TA. Brigham 
and Women’s Hospital, Boston, MA; Harvard School of Public Health, 
Boston, MA; Dana Farber Cancer Center, Boston, MA; Whitehead 
Institute for Biomedical Sciences, Cambridge, MA; Beth Israel 
Deaconess Medical Center, Boston, MA; University of Miami Miller 
School of Medicine, Miami, FL
Purpose: Heat shock factor 1 (HSF1) is the master transcriptional 
regulator of the cellular response to heat and a wide variety of other 
stressors. We previously reported that HSF1 promotes the survival 
and proliferation of malignant cells. At this time, however, the clinical 
and prognostic significance of HSF1 in cancer is unknown.
Patients and methods: Breast cancer samples from 1,841 participants 
in the Nurses’ Health Study (NHS) were scored for levels of nuclear 
HSF1. Associations of HSF1 status with clinical parameters and 
survival outcomes were investigated by Kaplan-Meier analysis 
and Cox proportional hazard models. The associations were further 
delineated by Kaplan-Meier analysis using publicly available mRNA 
expression data.
Results: Nuclear HSF1 levels were elevated in ~80% of in situ and 
invasive breast carcinomas. In invasive carcinomas, HSF1 expression 
was associated with high histologic grade, larger tumor size, and 
nodal involvement at diagnosis (P<0.0001). Overall, in multivariate 
analysis, high-HSF1 levels were associated with increased breast 
cancer-specific mortality (HR, 1.62; 95% CI, 1.21-2.17). This 
association was seen in the ER-positive population (HR, 2.10; 95% CI, 
1.25-2.47), even in early-stage lymph node negative cases (HR, 1.98; 
95% CI, 1.17-3.33). In public expression profiling data, high-HSF1 
mRNA levels were also associated with an increase in ER-positive 
breast cancer-specific mortality.
Conclusions: Increased HSF1 is associated with reduced survival in 
breast cancer. The findings indicate that HSF1 should be evaluated 
prospectively as an independent prognostic indicator in ER-positive 
breast cancer and that HSF1 may provide a useful therapeutic target.
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P5-01-14
Phosphoproteomic Analysis of TIMP-1 Overexpressing MCF-7 
Human Breast Cancer Cells Reveals Increased Expression and 
Phosphorylation of Topoisomerase Proteins.
Fogh L, Hekmat O, Munk S, Jensen NF, Brünner N, Stenvang J, 
Lademann U, Olsen JV. Faculty of Life Sciences, University of 
Copenhagen, Copenhagen, Denmark; Faculty of Health Science, 
Copenhagen University, Copenhagen, Denmark
Background: Tissue inhibitor of metalloproteinase 1 (TIMP-1) is 
a protein with a potential biological role in drug resistance. Lack 
of TIMP-1 protein either alone (Willemoe et al., Eur J Cancer 
2009) or in combination with Topoisomerase 2A gene aberrations 
has been shown to associate with increased benefit from adjuvant 
treatment with a Topoisomerase 2 inhibitor (epirubicin containing 
combination chemotherapy) while this association was not observed 
in patients treated with a non-Topoisomerase 2 inhibitor combination 
chemotherapy (Ejlertsen et al., JCO 2010).
Aim: To further investigate the molecular mechanisms underlying the 
association between TIMP-1 and epirubicin sensitivity by quantitative 
phosphoproteomics.
Methods: MCF-7 human breast cancer cells were transfected with 
pcDNA3.1(Hyg)-TIMP-1. Among 11 single cell clones, two TIMP-
1 low expressing and two TIMP-1 high expressing clones were 
selected. The clones were labeled by SILAC (stable isotope labeling 
with amino acids in cell culture). Lysates were digested with trypsin 
and fractionated with SCX followed by subsequent enrichment of 
phosphopeptides by TiO2-based chromatography and desalting by 
C18 purification. Total peptides and phosphopeptides were analyzed 
by tandem mass spectrometry and quantified as described (JV Olsen 
et al., Science Signaling 2010). Selected proteins were confirmed 
on Western blots. The sensitivity of the four TIMP-1 cell clones 
was analyzed by treatment of the cells with the following drugs: 
The Topoisomerase 2 inhibitor epirubicin (an anthracycline). The 
Topoisomerase 1 inhibitor SN-38 (the active metabolite of irinotecan, 
a camptothecin analogue) and the combination of these. A specific 
Topoisomerase 2B inhibitor (XK 469, a quinoxaline analogue and 
the DNA crosslinker cisplatin. All experiments were determined with 
an endpoint MTT assay.
Results: The quantitative proteomic analyses confirmed the 
differences in TIMP-1 levels among the four clones. Several proteins 
were consistently found to be upregulated and/or had changed 
phosphorylation levels in the TIMP-1 high cells in two biological 
replicates. Of particular interest was the observation that the 
phosphorylation status and protein levels of Topoisomerase-1, -2A 
and -2B were increased in TIMP-1 high expressing cells compared 
to TIMP-1 low expressing cells. When the four clones were treated 
with specific Topoisomerase inhibitors, the TIMP-1 high expressing 
cells exhibited significantly more resistance to all three inhibitors 
compared to TIMP-1 low expressing cells. When cells were treated 
with a combination of SN-38 and epirubicin, we observed an additive 
but not a synergistic effect. At last, cells were treated with cisplatin 
with no different effect on TIMP-1 high and low expressing cells.
Conclusion and perspectives: The observed upregulation of both 
protein and phosphorylation levels of Topoisomerases in TIMP-1 
high cells may be part of the mechanism by which TIMP-1 confers 
resistance to treatment with Topoisomerase inhibitors in primary 
breast cancer. Further work will include pathway analyses and 
hypothesis testing in clinical material.
P5-01-15
The Functional Role of the Estrogen-Regulated Gene GREB1: 
Characterization of a Novel GREB1 Knockout Mouse Model.
Hnatyszyn HJ, Rodriguez C, Herbert L, Olson R, Lippman ME. 
University of Miami, Miami, FL
Background: Gene regulated in breast cancer 1 (GREB1) was initially 
discovered in breast cancers as an estrogen-regulated gene that 
mediates estrogen-stimulated cell proliferation and is a candidate 
clinical marker for response to endocrine therapy. However, little 
is known of the functional role of GREB1 protein in normal breast 
tissue or breast cancers.
Methods: To address this unknown role, our laboratory designed and 
created a novel Greb1 Knockout Mouse model (C57/bl MEL Greb1 
KO). This constitutive model results in the loss of Greb1 mRNA 
and protein expression in cells where expression of Cre recombinase 
promotes the cleavage of exon 1 and intron 1 of the gene encoding 
Greb1. ROSA26 Cre C57/bl MEL Greb1 KO mice heterozygous for 
the floxed Greb1 allele were crossed to generate experimental litters. 
Initial experiments were designed to evaluate if the complete loss of 
Greb1 expression in offspring homozygous for the floxed Greb1 allele 
was lethal during gestation. Experimental litters were tail clipped and 
genotyped using gDNA and genotype-specific PCR.
Results: Offspring homozygous for the floxed Greb1 allele 
were identified in expected Mendelian ratios with wild type and 
heterozygous siblings. Loss of Greb1 expression was confirmed 
using RT-PCR, in situ hybridization and immunoblotting. Loss of 
both Greb1 alleles was not observed to be lethal during gestation for 
either male or female pups. Preliminary gross observation of these 
homozygous KO mice revealed no overt anatomical differences, 
however, they were 25-30% smaller than their heterozygous and 
wild-type siblings. Breeding experiments are underway to determine 
the fertility of crossbred Greb1 homozygous KO mice. Imaging 
experiments and necropsy with histochemical analysis of tissues will 
reveal any alteration in architecture and function. These findings will 
be summarized in this presentation.
Discussion: As GREB1 has been identified as an estrogen-regulated 
gene involved in breast cancer cell proliferation and a potential 
target for new therapeutic strategies, it is important to understand 
the contribution of GREB1 to the differentiation, development and 
function of normal tissues as well as in breast cancers. Characterization 
of this novel Greb1 KO mouse model will provide answers to these 
functional questions surrounding GREB1.
P5-01-16
The Detection of Circulating CK19 mRNA-Positive Cells in 
the Blood and the Mitotic Index of the Primary Tumor Have 
Independent Prognostic Value in Early Breast Cancer.
Tryfonidis K, Perraki M, Apostolaki S, Kafousi M, Agelaki S, 
Georgoulias V, Stathopoulos EN, Mavroudis D. University General 
Hospital of Heraklion, Heraklion, Crete, Greece; School of Medicine, 
University of Crete, Heraklion, Crete, Greece
Background: Previous studies have shown that the molecular detection 
of CK-19 mRNA in peripheral blood and the mitotic index of primary 
tumor have prognostic value in early breast cancer. The aim of the 
present study was to assess the association between these variables.
Patients and Methods: The primary tumors of 223 operable breast 
cancer patients (92 premenopausal and 131 postmenopausal) were 
evaluated for the mitotic activity index (MAI) classified either as 
<5/10, 6-10/10 and >10/10 or <10/10 and >10/10 mitoses/hpf using 
a standardized protocol as previously reported (Baak JP et al, Breast 
Cancer Res Treat 2009, 115:241-254). Peripheral blood was also 
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collected before the start and after the end of adjuvant chemotherapy 
for detection of CK-19 mRNA-positive cells by RT-PCR as previously 
described (Stathopoulou et al, Clin Cancer Res 2003, 9:5145–5151).
Results: After a median follow-up of 118 months, 75 (33.6%) patients 
have experienced disease relapse and 56 (25.1%) have died of breast 
cancer. MAI was strongly associated with disease-free survival (DFS) 
and overall survival (OS) (p<0.001 for both DFS and OS). Detection 
of CK19 mRNA-positive cells in the peripheral blood before but 
not after adjuvant chemotherapy was marginally associated with 
worse DFS (p=0.055) and OS (p=0.059). There was no correlation 
between MAI and CK19 mRNA detection before chemotherapy. Cox 
regression analysis revealed that both MAI and CK19 mRNA-positive 
cell detection before adjuvant chemotherapy were independent 
variables associated with decreased DFS (p<0.001 and p=0.038, 
respectively) and OS (p<0.001 and p=0.029, respectively). The 
interaction test showed no significant association between MAI and 
detection of CK19 mRNA-positive cells.
Conclusion: MAI of the primary tumor and detection CK-19 mRNA-
positive cells in the blood before the start of adjuvant chemotherapy 
in women with early breast cancer are two independent prognostic 
factors associated with clinical outcome.
P5-01-17
HER2 Amplification in Primary Tumor: A Potential Marker for 
Presence of Circulating Tumor Cells in Inflammatory Breast 
Cancer Patients?
Bhattacharyya A, Krishnamurthy S, Lodhi A, Hall C, Anderson A, 
Jackson S, Ueno N, Bedrosian I, Kuerer H, Lucci A. University of 
Texas MD Anderson Cancer Center, Houston, TX
Background: Inflammatory breast cancer (IBC) is a rare but 
aggressive form of invasive breast cancer accounting for 3-6% of 
all cases and have higher rates of distant recurrence. Circulating 
tumor cells (CTCs) are known to predict outcome in metastatic 
breast cancer (BC) patients, but little is known about their prognostic 
significance in non-metastatic BC. We hypothesized that CTCs can 
be identified in patients with IBCs and may correlate with primary 
tumor characteristics. Methods: All patients had blood samples 
collected at the time of primary surgery. CTCs (per 7.5 ml blood) were 
detected using the Cell Search™ system (Veridex) and were defined 
as nucleated cells lacking CD45 but expressing cytokeratins (CK) 8, 
18, or 19. The presence of ≥ 1 epithelial cells meeting morphologic 
criteria for malignancy was considered a positive result. Statistical 
analyses employed Chi square and Fisher’s exact tests using STATA 
IC 11. Results: We prospectively evaluated 41 IBC patients enrolled 
in an IRB approved protocol undergoing surgery for stage I-III 
breast cancer. Median follow-up was 30 months. Mean age was 52 
years. Thirty five patients (94%) had positive lymph nodes (LNs) 
at presentation, 30 (75%) had high-grade tumors and 20 (53%) had 
lymphovascular invasion. Eleven patients (28%) were ER positive, 
11 (27%) were PR positive and 18 (44%) were HER2 positive. 
IBCs were more likely to be high grade (P<0.0001), ER negative 
(P<0.0001), PR negative (P<0.0001), HER2 positive (P<0.0001), 
High Ki-67 (P= 0.005) and had a BMI of more than 25kg/m2 (P=0.04). 
Eleven (27%) patients were CTC positive. CTCs were more likely 
be found in HER2 positive (8/18; 44%) vs. HER2 negative primary 
tumors (3/20; 15%) [OR= 4.53; 95% C.I. = 1.02-19.52; P= 0.04]. We 
found no statistically significant correlations between primary tumor 
characteristics (ER, PR, LNs, high grade) and presence of CTCs. 
Conclusions: About a quarter of IBC patients had CTCs at the time 
of primary surgery. In these patients HER2 overexpression predicted 
the presence of CTCs. Studies with longer follow-ups is needed to 
determine if CTCs predicted survival.
P5-01-18
Identification of Pax6 as a Human Breast Cancer-Testis Antigen.
Yang M, Wang Y. The First Hospital of Jilin University, Changchun, 
JILin, China; Jilin University, Changchun, JILin, China
Background:
Cancer-testis antigens (CTAs) are specifically expressed in the normal 
testis and various types of cancer cells, but not or expressed with 
very low level in the other normal tissues. CTAs are considered to 
be promising targets for immunotherapy. Little is known on CTAs 
which specifically expressed in breast cancer. Studies show that the 
transcriptional activation by CpG island hypomethylation is believed 
to be an important mechanism of their increased expression.
Objective: 
To find CTAs which specifically expressed in breast cancer; prove 
the increase of its expression in human breast cancer, and explore the 
possibility for it to be developed as target for the immunodiagnosis 
and immunotherapy of breast cancer.
Methods and results
Genomic DNAs were isolated from testis tissue, breast cancer and 
normal breast tissues respectively. To perform CpG island microarray 
assays, genomic DNAs were prepared from 15 paired breast cancer 
biopsies and their normal controls. After obtaining sequence 
information for those clones from the CpG island database, they were 
then used to search for surrounding genes in the gene banks. We found 
several testis specific genes, such as, Pax6, NDRG3 and Synaptojanin 
2. Since the last two genes had been extended investigated, they 
were not the subjects of this study. The Pax6 Gene Was Activated in 
Established and Primary Breast Cancer Cell Lines. First, we examined 
Pax6 gene expression levels in a breast cancer cell line panel that 
included Hs578T, MDA-231, MDA-436, MDA-468, T47D, MCF7 
and MCF7/Adr, by performing RT-PCR where b-actin served as 
control. In addition, the RNAs obtained from normal breast and testis 
tissues were used as negative and positive controls.We found that 
Pax6 was re-expressed in MDA-436, MDA-468, T47D, and MCF7/
Adr. To further test the Pax6 gene’s behavior in primary breast cancer 
cells, we isolated breast cancer epithelial cells from the effusions 
of 8 patients (E4, E5, K151, K259, K473, K573, K596 and K605). 
cRNAs were prepared from those cells and the normal human breast 
cell line (NHBEC) for RT-PCR assays, where cRNAs of paired MCF7 
cells and b-actin served as controls. Results showed that Pax6 was 
expressed in K259, K573, K596 and K605 cells to various degrees. 
Pax6 Was Expressed in a Majority of Breast Cancer Biopsies. To test 
if Pax6 was also expressed in breast cancer tissues, IHC assays were 
carried out using 19 patients’ biopsies where human testes served as 
positive controls. We found that the Pax6 protein existed mainly in 
the cytoplasm of breast cancer cells, but was not detectable in normal 
breast tissue sections.
Conclusion
CpG islands of pax6 promoter region were hypomethylated in human 
breast cancer . The mRNA level of Pax6 in human breast cancer was 
significantly increased contrast to normal breast tissue, contrast to all 
other analyzed normal tissues, suggesting Pax6 is a CTA for breast 
cancer and might be applied as molecular target in immunotherapy 
against human breast cancer.
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P5-01-19
Endothelin-1 Expression in Breast Cancer Tissue, Surrounding 
Stroma, Correlation with Tumor Microvessel Density and Clinical 
Outcome.
Tamkus D, Wiese D, Sikorskii A, Chivu S, Peddi P, Chitneni S. 
Michigan State University (MSU); McLaren Regional Medical 
Center (MRMC)
Background: Endothelin-1 (ET-1) is a peptide which regulates normal 
biological processes such as vascular tone. In addition, endothelin 
signaling pathway is dysregulated in pathophysiological conditions 
such as cancer and fibrosis. It has been shown that endothelin-1 is 
expressed in breast cancer tissue but little is known with regard to 
ET-1 expression in surrounding tumor stroma. In the present study, 
we investigated ET-1 expression in breast tumor cells, surrounding 
stroma, association with tumor microvessel density (MVD) and 
impact on clinical outcome.
Materials and Methods: We conducted a retrospective, multicenter 
study. Patients from 3 medical centers with histologically documented 
stage I-III invasive breast cancer were included in the study. Paraffin 
embedded formalin fixed breast cancer tissue and surrounding stroma 
were evaluated for ET-1 and CD34 (marker for MVD) by IHC. 
ET-1 cytoplasmic expression was scored as positive (3+ by IHC) or 
negative (0, 1+, 2+). Stained vessels by CD34 were counted in five 
consecutive fields at 40 x magnification and their mean was recorded. 
Demographics, clinical data and recurrence free interval (RFI) in 
months were available for statistical analysis.
Results: The study included 92 patients with average age of 55 years 
at diagnosis. Median follow up of patients at the time of analysis was 
72 months. Total of 29 patients experienced disease progression ( 
17 locoregional and 12 distant). Tumor ET-1 expression positively 
correlated with earlier stage: odds ratio (OR) = 22 for stage I and 
OR=20 for stage II as compared with stage III. Positive ET-1 staining 
in tumor was detected in 72.8 % of cases, while ET-1 positive 
expression in stroma was detected only in 6.5% of cases. Interestingly, 
all ET-1 stroma positive tumors were estrogen receptor (ER) positive. 
The means of CD34 were not different according to ET-1 expression 
either in the tumor or stroma. Triple negative breast cancer tumors 
exhibited higher MVD (p=0.0177). In the logistic regression model 
relating ET-1 expression in tumor to clinical variables, ET-1 positive 
tumors showed a trend for the association with higher relapse 
rate (p=0.058). Multivariate analysis suggested that there was no 
significant difference in the recurrence free interval (RFI) between 
the ET-1 positive and ET-1 negative groups (long-rank test p-value 
= 0.71). Survival analysis identified stage as a significant predictor 
of RFI in the Cox proportional hazard model that included ET-1 
expression and other clinical variables.
Conclusions: The significant predictor for ET-1 expression in the 
tumor was early stage. High tumor ET-1 expression was more 
common in patients who experienced breast cancer recurrence. No 
association was found between ET-1 expression and MVD, and 
between ET-1 expression and time to recurrence. Further studies 
with larger sample size are needed to better delineate a role of ET-1 
as prognostic biomarker in early stage breast cancer.
P5-02-01
ErbB4 Ectodomain as a Biomarker and a Potential Therapeutic 
Target for Breast Cancer.
Hollmen M, Liu P, Wildiers H, Reinvall I, Vandorpe T, Smeets A, 
Deraedt K, Vahlberg T, Joensuu H, Leahy D, Schoffski P, Elenius 
K. University of Turku, Turku, Finland; Johns Hopkins University 
School of Medicine, Turku, Finland; University Hospitals Leuven, 
Belgium; University of Turku, Finland; Helsinki University Hospital, 
Helsinki, Finland
ErbB4 function is controversial in breast cancer and influenced 
by alternative splicing of the ERBB4 gene. Here we evaluated 
the cleavable ErbB4 JM-a isoform as a potential drug target and 
biomarker. To address ErbB4 cleavage in breast cancer tissues in 
vivo, extracellular and intracellular cleavage products of ErbB4 
were assessed by ELISA and immunohistochemistry using matched 
serum and tissue samples from a series of 243 breast cancer 
patients. Elevated serum ectodomain level (≥40 ng/mL) and nuclear 
immunoreactivity were present in 21% and 52% of the patients, 
respectively. An elevated serum ErbB4 ectodomain concentration 
was not associated with tumor nuclear immunoreactivity, but was 
significantly associated with the premenopausal status at diagnosis 
(P = 0.04). Estradiol also enhanced ErbB4 cleavage and ErbB4 
cleaving enzyme activity in vitro, supporting a role for estrogen 
signaling in regulation of ErbB4 cleavage. Selective targeting of 
the cleavable ErbB4 JM-a in human breast cancer cells with an 
ErbB4 isoform-specific mAb 1479 inhibited ErbB4 cleavage and 
reduced tumor formation in a mouse xenograft model. Consistent 
with blocking of ErbB4 cleavage, mutagenesis studies and the 3.4 
Å X-ray crystal structure of a complex of the ErbB4 extracellular 
region and the 1479 Fab localized the binding site of mAb 1479 on 
ErbB4 to a region on subdomain IV encompassing JM-a-specific 
residues. These data demonstrate that ErbB4 is cleaved in a subset 
of breast cancer patients, and suggest that the mechanisms by which 
mAb 1479 suppresses breast cancer cell growth involves inhibition 
of ErbB4 cleavage. Serum ErbB4 ectodomain concentration could 
be used as a biomarker to monitor the activity of compounds, such 
as mAb 1479, that target ErbB4 cleavage.
P5-02-02
Divergent Effects of Zoledronate and Denosumab on Cellular 
Interactions between Osteoblasts and Breast Cancer Cells.
Kaiser T, Teufel I, Wallwiener D, Klein G, Fehm T. Medical University 
Hospital of Tuebingen, Tuebingen, Germany; Center for Medical 
Research, University of Tuebingen, Tuebingen, Germany
Background: The development of bone metastases is a multistep 
process that involves interactions between tumor cells and normal 
host components of the bone marrow microenvironment. Emerging 
evidence suggests that the interplay of breast cancer cells with both 
RANKL-expressing osteoblasts, key mediators of osteoclastogenesis, 
and osteoblast-derived extracellular matrix structures is critical to 
the metastatic process. This relationship may contribute to the tumor 
cells’ colonization of bone, invasive behavior, and eventual tumor 
progression. Zoledronate, a nitrogen-containing bisphosphonate 
has demonstrated inhibitory effects on tumor cell adhesion and 
migration. Denosumab, a fully humanized monoclonal antibody 
against receptor activator of nuclear factor-kB ligand (RANKL), 
might also exhibit inhibitory effects on breast cancer cell adhesion 
and migration by neutralizing RANKL. However, despite their 
clinical importance, the mechanisms of zoledronate and denosumab 
in crosstalk between breast cancer cells and osteoblasts still remain 
poorly characterized. 
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Material and Methods: To investigate the influence of zoledronate and 
denosumab on osteoblast-breast cancer cell interactions, cell adhesion 
and migration assays using different breast cancer cell lines (MCF7, 
MDA-MB-231, and SKBR3) were performed.  
Results: Cell-matrix adhesion assays revealed a strong attachment 
of breast cancer cells to several extracellular matrix components 
expressed by osteoblasts. The subsequent incubation of attached 
cells with 100 µM zoledronate for 72 h resulted in a prominent 
reduction of tumor cells’ binding to collagen type I, fibronectin, 
defined laminin isoforms and tenascin-C, whereas incubation with 
10 µg/ml denosumab did not affect the adhesive behavior of breast 
cancer cells. In addition, cell-cell adhesion analyses indicated that 
zoledronate was able to decrease the attachment of breast cancer 
cells to osteoblasts. Furthermore, migration studies using the scratch 
assay and the transwell migration technique clearly showed that the 
conditioned media of osteoblasts (primary osteoblasts as well as 
the osteoblastic cell line CAL72) strongly enhanced the migration 
of the breast cancer cell line MDA-MB-231 compared to the 
conditioned media of osteoclast-like cells, stromal cells and control 
medium, suggesting that exclusively osteoblasts release factors that 
significantly increase tumor cell migration. Interestingly, exposure 
to zoledronate inhibited osteoblast-induced tumor cell migration in 
a concentration-dependent manner. In contrast, denosumab (0.1 – 50 
µg/ml) had no inhibitory effect on the migration of MDA-MB-231 
cells in scratch analysis. However, this agent was found to cause a 
reduction in the number of migrated cells when 10 µg/ml were used 
in transwell assays. 
Discussion: Our data clearly demonstrate that breast cancer cells 
interact with osteoblasts and osteoblast-secreted extracellular 
matrix proteins. The osteoblast-induced breast cancer cell abilities, 
including tumor cell adhesion and migration, were strongly affected 
by zoledronate, but not by denosumab. The influence by zoledronate 
on these interactions provides further insights into the antiresorptive 
effect of this substance on bone metastasis.
P5-02-03
Lipid Raft Disruption by Docosahexaenoic Acid Induces 
Apoptosis in Transformed Human Mammary Luminal Epithelial 
Cells Harboring HER-2 Overexpression.
Ravacci GR, Tharcisio, Junior T, Logullo AF, Torrinhas RS, Brentani 
MM, Waitzberg DL. Medical School, University of São Paulo, São 
Paulo, Brazil; UNIFESP University, São Paulo, Brazil
Background, In HER-2 overexpressing breast cells, HER-2 receptors 
exist on the cell surface as monomers, homodimers and heterodimers 
with EGFR and HER-3. For signal activation and transduction to 
occur, the HER-2 receptors must be located in lipid rafts. Therefore, 
HER-2 overexpression must be accompanied by increased lipid 
rafts on the cell membrane to ensure constant signal transmission. 
Methods, To test this hypothesis, we used HB4a – untransformed 
human mammary epithelial cell strain – and HB4aC5.2 cells – 
HB4a cells co-transfected with ErbB-pJ5E.c-2 (normal full length 
human HER-2 cDNA). We analyzed the lipid rafts, cholesterol and 
fatty acids from cell membrane by confocal microscopy and gas 
chromatography. The proteins associated to HER-2 activity and lipid 
rafts formation, such as Akt, ERK ½ and FASN were analyzed by 
western blotting. To evaluate the lipid rafts importance for HER-2 
signaling, we treated cells with docosahexaenoic acid (DHA) to 
disrupt the lipid rafts. Thereby, all analysis was repeated and cells 
death and apoptosis were analyzed by flow cytometry. Values were 
obtained by the mean and standard deviation of five independent 
experiments and developed in triplicate, by using one-way analysis 
of a variance (ANOVA) test, followed by Bonferroni post-test, to 
identify significant (p<0.05) differences between cell lines and results 
with different concentrations of DHA treatment. Results, HB4aC5.2 
cells have five copies of pJ5E.c-ErbB-2 inserted into their genome and 
express approximately 900 times more HER-2 than HB4a cells. HER-
2 overexpression in HB4aC5.2 cells was accompanied by increased 
lipid rafts in cell membranes, hyperactivation of downstream Akt and 
ERK1/2 proteins, and rate of cell growth increase as compared to 
the HB4a strain. In addition, HER-2 overexpression was associated 
to increased activation of FASN, a key enzyme involved in cellular 
lipogenesis. The final product of FASN activation, palmitate, is used 
to synthesize saturated phospholipids, necessary to form lipid rafts. 
Treatment of HB4aC5.2 cells with DHA, an omega-3 fatty acid, 
disrupted the lipid rafts by its increased incorporation into the cell 
membrane; inhibited HER-2 activation by decreasing Akt, ERK1/2, 
and FASN proteins; and induced apoptosis. The same treatment 
maintained the structure of HB4a cell lipid rafts, accompanied by a 
low percentage of DHA-induced apoptosis. Conclusion, Although 
little is yet known about lipid rafts, our data support the theory that 
disturbances in these micro-domains may represent a useful tool in 
controlling cell signaling triggered by HER-2 receptors and contribute 
to a better understanding of the role of this receptor in HER-2 positive 
breast cancer.
P5-02-04
Disruption of Endothelial Cells Barrier Integrity by Invasive 
Breast Cancer Cells.
Haidari M, Zhang W, Chen Z, Mortazavi A, Dixon R. Texas Heart 
Institute, Houston, TX; The University of Texas Health Science Center 
at Houston, Houston, TX
Despite its critical role in cancer metastasis the molecular mechanisms 
regulating breast cancer cells transendothelial migration are 
poorly understood, but clearly depend on the invasive capacity of 
tumor cells and their ability to breach the endothelial cell barrier. 
Vascular endothelial-cadherin (VE-cadherin) is found specifically 
in the endothelial cell adherens junction and has been implicated 
in playing a fundamental role in controlling the transport across 
the endothelial barrier. Tyrosine phosphorylation of VE-cadherin 
has been implicated in the disruption of endothelial cells adherens 
junctions and diapedesis of metastatic cancer cells. We tested this 
hypothesis that interaction of breast cancer cells with endothelial 
cells initiates the signal transductions that disrupt the endothelium 
barrier integrity. Our studies demonstrated that the attachment of 
MDA-MB-231 human breast cancer cells to Human Umbilical Vein 
Endothelial Cells (HUVECs) leads to tyrosine phosphorylation of VE-
cadherin and the formation of gaps between endothelial cells. These 
were accompanied by activation of two tyrosine kinases, Src and 
proline rich tyrosine kinase (Pyk-2). In addition, immunoprecipitation 
studies indicated that the endothelial cells adherens junction structure 
was disrupted through MDA-MB-231-induced dissociation of VE-
cadherin and b-catenin complex. Activation of RhoA and HRas by 
over expression of constitutively active forms of the genes leads to 
tyrosine phosphorylation of VE-cadherin and Pyk-2 in HUVECs. 
Over expression of dominant negative forms of RhoA, HRas, Raf 
and ERK2 but not Rac1 and Cdc42 attenuated breast cancer cell-
induced tyrosine phosphorylation of VE-cadherin and Pyk-2 in 
HUVECs. Indicating that breast cancer cell-induced VE-cadherin 
tyrosine phosphorylation and disruption of adherens junction in 
endothelial cells is mediated by RhoA and HRas\Raf\MEK\ERK 
signaling cascade. Understanding the precise molecular mechanisms 
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that facilitate breast cancer cells transendothelial migration could 
develop novel therapeutic strategies targeting cancer cell metastasis 
by improving the protective role of endothelial cells.
P5-02-05
Real-Time Subcellular Imaging of Breast Cancer Cell Attachment 
in Blood Vessels Using GFP-Labeled Paxillin in Live Mice.
Suetsugu A, Digman M, Gratton E, Moriwaki H, Saji S, Bouvet 
M, Hoffman RM. AntiCancer Inc., San Diego, CA; University of 
California San Diego, San Diego, CA; Gifu University Graduate 
School of Medicine, Gifu, Japan; University of California Irvine, 
Irvine, CA
Background: Paxillin is involved in the assembly of focal adhesions. 
We wish to visualize paxillin behavior in breast cancer cells in vivo, 
as well as in vitro.
Materials and Methods: Dual-photon confocal microscopy was 
used to image paxillin behavior by linking it to GFP. MDA-MB-231 
human breast cancer cells expressing paxillin-GFP were imaged in 
vitro and in vivo adhering and trafficking in blood vessels in mice. 
106 paxillin-GFP expressing breast cancer cells were injected in the 
epigastric cranialis vein.
Results: In vitro, round breast cancer cells had greater paxillin 
movement than stretched cancer cells as seen by fluorescence 
imaging. Paxillin-GFP breast cancer cells in the epigastric cranialis 
vein were initially rounded and had GFP-expressing protrusions. At 
later timepoints, many paxillin-GFP-expressing breast cancer cells 
stretched. The breast cancer cells then extravasated and subsequently 
grew around the outer surface of the blood vessel after one week. Two 
weeks after injection, paxillin-GFP expressing breast cancer cells were 
imaged migrating along the vessel wall. Most of the paxillin-GFP 
expressing breast cancer cells were stretched and were not mobile. 
With anti-VEGF treatment, paxillin was observed in round structures 
within the cells rather than stretched structures and paxillin movement 
within the cell was arrested.
Discussion: These results demonstrate that breast cancer cells brightly 
expressing paxillin-GFP and two-photon confocal microscopy can 
allow the visualization of the behavior of paxillin within breast cancer 
cells during adhesion and migration along the walls of blood vessels, 
as well as during anti-angiogenesis therapy.
P5-03-01
Cytoplasmic Cyclin E and P-CDK2 Expression in Triple Negative 
Breast Carcinomas Measured by Immunohistochemistry 
Correlates with Poor Outcome.
Biernacka A, Karakas C, Wingate H, Bondy M, Sahin A, Hunt K, 
Khandan K. MD Anderson Cancer Center, Houston, TX
Background: Triple negative breast carcinomas (TNBCs) are 
aggressive malignancies that lack effective therapeutic targets but 
express low molecular isoforms of cyclin E (LMW-E). These LMW-E, 
generated primarily from NH2-terminal elastase cleavage of full 
length cyclin E (EL), preferentially accumulate in the cytoplasm of 
cancer cells. Using a transgenic mouse model system, our laboratory 
has recently shown that cyclin-dependent kinase 2 (CDK2) is required 
for LMW-E-mediated mammary tumorigenesis. These results lead us 
to hypothesize that immunohistochemical cytoplasmic detection of 
LMW-E and phospho-CDK2 in TNBC provides a valuable screening 
tool for those patients most likely to have a poor prognosis who could 
then be treated with anti-CDK2 therapy currently clinically available.
Material and Methods: Tissue micro-arrays from 168 TNBC patients 
were IHC stained for cyclin E and p-CDK2. Cyclin E staining intensity 
and percentage of positivity were evaluated both in the nucleus and 
cytoplasm of cancer cells and four different phenotypes of cyclin E 
were distinguished with respect to predominant nuclear or cytoplasmic 
localization of staining: cyclin E negative, predominantly nuclear, 
both nuclear and cytoplasmic and predominantly cytoplasmic. 
p-CDK2 IHC was achived using an antibody, which recognizes 
phospho-threonine 160 on CDK2. Immunoreactive scores were 
determined by multiplying the intensity with the extent of staining of 
nuclei and cytoplasm. We sought correlations between different cyclin 
E and p-CDK2 expression patterns and disease-free survival (DFS).
Results: Cytoplasmic cyclin E accumulation on IHC of TNBCs 
correlated with poor outcome. Within the median follow up of 7.3 
years tumors with both nuclear and cytoplasmic cyclin E expression 
demonstrated higher recurrence rate compared to entirely negative 
for cyclin E (p=0.0117). In contrast patients with exclusively nuclear 
cyclin E showed only a trend toward decreased DFS compared to 
patients with cyclin E negative tumors (p=0.0896). Furthermore we 
identified the new phenotype of cyclin E immunoreactivity, which is 
characterized by negative nucleus and positive cytoplasmic staining. 
This phenotype was the most significantly associated with poor 
DFS compared to cyclin E negative phenotype (p=0.0026) and as 
the only one distinguished at high risk of early recurrence among 
TNBC patient without axillary nodes involvement (p=0.0105). The 
expression of p-CDK2 was significantly higher in this phenotype than 
the cytoplasmic cyclin E.negative tumors. High p-CDK2 tumors were 
also correlated to worse DFS then p-CDK2 low tumors (P=0.019). 
Lastly, our analyses revealed that tumors positive for both cytoplasmic 
cyclin E and p-CDK2 had higher recurrence rate compared to negative 
for both or positive for one of them (p=0.003).
Discussion: Cytoplasmic cyclin E may help to predict recurrence, 
especially in early stage, node negative TNBCs. We present a new 
concept in assessing cyclin E expression. Poor outcome due to 
TNBCs overexpressing LMW-E provide a rationale to investigate 
the treatment strategies that could specifically target high LMW-E 
tumors. These patients could particularly benefit from treatment with 
CDK2 inhibitors.
P5-03-02
Aurora A Is Closely Linked to an Aggressive Phenotype of Breast 
Cancer.
Yamamoto Y, Ibusuki M, Murakami K, Iwase H. Kumamoto University, 
Graduate School of Medical Sciences, Kumamoto, Japan
(Purpose) Aurora A, a mitotic serine/threonine kinase, is involved 
in important process of mitotic progression. The aim of this study is 
to clarify characteristics of breast cancer with Aurora A expression.
(Methods) We examined, by immunohistochemical analysis, the 
expression of Aurora A in primary invasive breast cancer. We also 
investigated the correlation between expression of Aurora A and 
clinicopathological and biological factors. In addition, we studied 
the prognostic value of Aurora A in breast cancer.
(Results) In 215 cases of invasive cancer examined, Aurora A was 
mainly identified in tumor nuclei. Aurora A expression was detected 
in 67 (31.2%) cases. Expression of Aurora A was correlated with 
tumor size (p=0.002), lymph node metastasis (p=0.002), tumor stage 
(p=0.04) and histological grade (p=0.0031). Aurora A expression was 
also associated with hormone receptor negativity (p=0.0001), and 
increased levels of HER2 (p<0.0028), Ki67 (p<0.0001), HIF-1alpha 
(p<0.0001), VEGF (p=0.007), COX-2 (p=0.002) and p53 (p<0.0001). 
Patients who had increased Aurora A levels in their tumor showed 
shorter disease-free survival (DFS) (p<0.0001) and overall survival 
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(OS) (p=0.0002) than those lacking Aurora A in univariate analysis. 
However, in multivariate analysis of DFS and OS, Aurora A was not 
identified an independent prognostic factor.
(Conclusion) Aurora A expression was significantly correlated 
with tumor burden, poorly differentiation, negativity of hormone 
receptors, tumor cell proliferation, and tumor angiogenesis. These 
findings suggest that Aurora A was closely related with an aggressive 
phenotype in breast cancer.
P5-03-03
Identification of New Substrates for Breast Tumor Specific Low-
Molecular-Weight Cyclin E Cyclin-Dependent-Kinase 2.
Akli S, Duong M, Keyomarsi K. M. D. Anderson Cancer Center, 
University of Texas, Houston, TX
Background: Cyclin E overexpression occurs in 25% of breast cancer 
tumors and is linked to poor prognosis. In tumor cells full length cyclin 
E (FL-E) is processed by an elastase-like protease into low-molecular 
weight isoforms (LMW-E) that are biochemically hyperactive. When 
overexpressed in breast cancer cells, LMW-E induced genomic 
instability and resistance to p21, p27, and antiestrogens. LMW-E 
are tumor specific and are associated with the aggressive triple 
negative breast cancer (TNBC). Transgenic mice overexpressing 
LMW-E had increased incidence of mammary tumors and distant 
metastasis when compared to FL-E. Furthermore, when the role of 
CDK2 in LMW-E mediated mammary tumorigenesis was interrogated 
by crossing LMW-E transgenic mice with CDK2 knock out mice, 
we found that the mice are protected against mammary tumor 
formation. Additionally, treatment of LMW-E transgenic mice with 
roscovitine (a CDK2 inhibitor) delays mammary tumor formation. 
These results indicate that kinase inhibition may have therapeutic 
activity in LMW-E overexpressing tumors as shown in this preclinical 
model. These results lead us to hypothesize that the biological and 
biochemical differences between FL-E and LMW-E may be due to the 
phosphorylation of a distinct set of substrates when complexed with 
CDK2. Our goal is to identify distinct LMW-E/CDK2 substrates on a 
proteome-wide scale that could serve as novel therapeutic targets for 
the treatment of the aggressive LMW-E expressing TNBC.
Material and Methods: We used two different approaches to identify 
LMW-E/CDK2 substrates. 1) We generated an analog sensitive 
CDK2 kinase, (F80A or F80G)-CDK2 to specifically radiolabel its 
substrates in cell extracts followed by their identification by mass 
spectroscopy. 2) We incubated ProtoArrayMicroarrays spotted with 
3000 GST-tagged human protein on high density glass slides either 
with recombinant active FL-E/ CDK2 or LMW-E/ CDK2.
Results: In the first approach, we expressed and purified wild-type 
CDK2 in complex with FL-E or LMW-E and CDK2 (F80A) and 
CDK2 (F80G) from insect cells. Although all 3 CDK2 kinases can 
use ATP to phosphorylate GST-Rb protein, only the F80G mutant 
can use PE-ATP-g-S. In the second approach, we incubated protein 
arrays either with recombinant active FL-E/CDK2 or LMW-E/CDK2 
at a concentration of 50 nM. Our first screen identified a total of 122 
potential substrates to both FL-E/CDK2 or LMW-E/CDK2 kinase 
complexes. We only identified 1 protein that is phosphorylated by 
FL-E/CDK2 significantly more than by LMW-E/CDK2 as compared 
to the 32 potential substrates specific to LMW-E/CDK2 suggesting 
that by losing the N-terminal portion, the LMW-E/CDK2 kinase 
complex is able to specifically interact and phosphorylate novel 
proteins.
Discussion: The identification of new physiological LMW-E/
CDK2 substrates will lead to the development of novel targets for 
therapeutics and the identification of the biological function for the 
treatment of the aggressive LMW-E expressing TNBC.
P5-03-04
Circadian Modulation of Estrogen Receptor alpha Promoter 
Activity.
Villa LM, Santos CS, Cousins S, Finkielstein CV. Virginia Polytechnic 
Institute and State University, Blacksburg, VA
The circadian clock is a molecular mechanism that synchronizes 
environment variations with physiological changes. Disruption of 
the circadian clock has been linked to increased risk in diseases and 
a number of disorders (e.g. jet lag, insomnia, coronary heart disease 
and cancer). Period 2 (PER2), a circadian protein, is at the center of 
the clock’s function. The complete loss of per2 has been shown to 
be common in several types of cancer including breast and ovarian.
Epidemiological studies established a correlation between circadian 
disruption and the development of estrogen dependent tumors. The 
expression of estrogen receptor alpha (ERa) mRNA oscillates in a 
24-hour period and, unlike PER2, ERa peaks during the light phase 
of the day. Because up regulation of ER relates to tumor development, 
defining the mechanisms of ERa expression will contribute to our 
comprehension of cellular proliferation and regulation of normal 
developmental processes. The overall goal of this project is to 
investigate the molecular basis for circadian control of estrogen 
receptor alpha (ERa) transcription.
Transcriptional activation of ERa was measured using a reporter 
system in Chinese Hamster Ovary and MCF-7 cell lines. Data show 
that PER2 influence ERa transcription through a non-canonical 
mechanism independent of its circadian counterparts. Promoter 
analysis using the Alibaba 2.0 suite revealed the presence of various 
putative novel partners. Among them, OCT-1 was found to directly 
interact with Per2, in vitro, and with corresponding response element 
within the ERa promoter. The predicted binding site of OCT-1 is 
267 bps upstream of the promoter. Pull-down assays were used to 
map direct interaction of various PER2 recombinant proteins and 
the DNA-binding domain of OCT-1. Radiolabeled OCT-1 was found 
to bind to the C-terminal end of PER2. Electrophoretic mobility 
shift assays were used to determine direct binding of OCT-1 to the 
promoter. ChIP assay confirmed the recruitment of PER2 to the 
estrogen promoter by OCT-1. Fluorescence anisotropy and surface 
plasmon resonance were employed to establish the binding affinity 
of OCT-1 to the ERa promoter and PER2. OCT-1 was found to have 
a high affinity for the ERa promoter (~10 nM). Furthermore, OCT-1 
recruits PER2 to the estrogen promoter. Preliminary data suggests 
that the transcription factor PER2 might play a role in the regulation 
of the estrogen promoter.
P5-04-01
BP1, a Homeotic Transcription Factor, Indirectly Upregulates 
ER-alpha in ER Positive Cell Lines.
Berg PE, Awate S, Kirolikar SP. The George Washington University, 
Washington, DC
Background: BP1 is a member of the homeobox gene family of 
transcription factors. Our recent studies have shown that BP1 
may play a role in breast cancer cell survival, aggressiveness and 
metastasis. BP1 protein (pBP1) is expressed in 80% of invasive 
ductal breast tumors, including in 57% of ER positive and 89% of 
ER negative tumors. BP1 overexpression results in a more aggressive 
phenotype in breast cancer cells and larger tumors in women with 
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breast cancer. We also observed the presence of mammary tumors in 
mice without estrogen supplementation after injection of MCF7 cells 
overexpressing BP1 compared with unsupplemented mice receiving 
MCF7 cells containing an empty vector. Our goal was to determine 
the pathway by which BP1 might cause this decrease in estrogen 
dependence of MCF7 cells. ER-alpha is a nuclear hormone receptor 
activated by estradiol and is a major target of anti-estrogen therapy. 
It is tightly regulated at the genomic and the non-genomic levels. 
Increased stability of ER-alpha is one mechanism by which cells 
can become ER-alpha independent. One way of altering ER-alpha 
stability is via p300 and BRCA1 since p300 acetylates and stabilizes 
ER-alpha, while BRCA1 destabilizes ER-alpha. We have previously 
shown that BP1 transcriptionally down-regulates BRCA1, suggesting 
that pBP1 may participate in this pathway.
Materials and methods: Protein levels of BRCA1, p300, pS2, pBP1 
and ER-alpha were determined by Western Blot analysis. RNA levels 
were measured by real-time PCR. A ChIP assay was performed to 
confirm binding of pBP1 to the EP300 gene and binding of ER-alpha 
to BP1. MCF7 parental cell lines were treated with 10nM E2 to induce 
the expression of pBP1. Experiments involving effects of siBP1 on 
p300 expression are underway.
Results: Our data demonstrate that MCF7 ER+ cells engineered 
to overexpress BP1 exhibit increased ER-alpha protein, increased 
p300 and decreased BRCA1 protein as compared with control cells 
containing an empty vector and grown under the same conditions. 
Increased ER-alpha levels correlated with increased pS2 expression, 
a known downstream target of ER, demonstrating that there is more 
functional ER-alpha protein in cells overexpressing BP1. ChIP 
assays showed that pBP1 binds in the first intron of EP300-Histone 
acetyltransferase (p300). ChIP assays also showed that ER-alpha 
binds to an estrogen response element (ERE) upstream of the BP1 
gene. MCF7 parental cell lines, when serum starved and treated with 
E2, showed increased BP1 expression compared with cells grown 
in charcoal stripped serum. Thus, BP1 may increase the stability of 
ER-alpha by decreasing BRCA1 and increasing p300.
Conclusions: pBP1 binds and transcriptionally activates p300, 
leading to increased ER-alpha stability, while also partially repressing 
BRCA1. Moreover, ER-alpha, via a feed-forward mechanism, binds 
to the BP1 gene and increases its expression.
P5-04-02
TNBL: An Integrated Knowledge Space of Triple-Negative and 
Basal-Like Breast Cancers.
Zhu J. OmicsHealth LLC, Morris Plains, NJ
Background: To facilitate drug discovery and development in 
triple-negative (TNBC) and basal-like (BLBC) breast cancers, an 
integrated knowledge space was developed through standardizing and 
linking information reported in scientific publications. The tool was 
designed to 1) track and consolidate knowledge around TNBC and 
BLBC; 2) centralize computational resources on molecular profiles, 
disease models, drug effects and clinical outcomes; 3) establish a 
computational platform to facilitate identification of drug targets 
and biomarkers; 4) enable hypothesis generation for novel uses of 
pre-existing compounds including new indications and combinations.
Material and Methods: Querying PubMed with “(basal-like or 
triple-negative) breast cancer” generated 1200 hits. First, text-
mining techniques were employed to filter publications for curation. 
Second, information extracted from biomedical literature and public 
domain databases was standardized with control vocabularies. Third, 
interactions originally presented in natural language were translated 
into a well-structured format according to specific semantic rules 
suited for computational purposes. The concepts and associated 
interactions were captured in a database and could be browsed as 
lists, tables and interactive networks.
Results: Based on the initial assessment of the 1200 abstracts, 500 
papers were selected for further analysis. About 1400 unique concepts 
were extracted and categorized: 1) 600 molecular components such as 
DNA loci, SNP, mRNA, microRNA, protein and complexes; 2) 120 
cellular processes; 3) 100 model systems such as cell lines, xenograft, 
and tissues; 4) 220 compounds and regimens; 5) 180 clinical and 
non-clinical parameters such as survival and chemoresistance; 6) 264 
disease definitions. The most implicated genes in TNBC and BLBC 
were EGFR, BRCA1, TP53, CK5/6, AR, TP63, KRT14, CDH1, 
AKT1, CCND1, VEGF, PTEN, CD44, NFKB1 etc. There were 80 
genes reported related to TNBC and BLBC by more than 3 papers. 
Using the published gene expression datasets of breast cancers, the 
80-gene set proved to be a highly accurate classifier for BLBC and 
non-BLBC. The most researched cellular processes included epithelial 
to mesenchymal transition (EMT), cell migration/metastasis, 
apoptosis, cell proliferation, angiogenesis, beta-catenin/WNT, PI3k/
AKT. The most studied experimental therapies included PARP 
inhibitors, cisplatin, dasatinib, doxorubicin and EGFR inhibitors. 
Concepts and interactions were visualized in networks. For example, 
the EMT network comprised 110 nodes and 162 interactions based 
on 19 references, and the TNBC network contained 514 nodes and 
874 interactions from 217 papers.
Discussion: The number of research papers on TNBC and BLBC are 
growing rapidly with 30-50% increase annually. TNBL provides a 
platform for the research community to standardize scientific findings 
and exchange knowledge efficiently. Through its powerful semantic 
technology and robust visualization capability, it offers integrated and 
comprehensive views of TNBC and BLBC which are not possible 
in the scope of any single research paper. In addition, it facilitates 
high quality hypothesis generation through consolidating up-to-date 
information from all possible sources in a computable format.
P5-04-03
Personalized Cancer Treatment Selection Using Computational 
Signaling Pathway Models.
Verhaegh W, Hatzis P, Clevers H, van de Stolpe A. Philips Research, 
Eindhoven, Netherlands; Hubrecht Institute, Utrecht, Netherlands
Introduction: In clinical oncology, with breast cancer in the front line,
- cancer genome sequencing is entering clinical diagnostics;
- novel drugs target signaling pathways that drive tumor growth;
- metastasized cancer is expected to change into a chronic disease, 
requiring therapy response monitoring and repeated personalized 
choice of targeted therapy.
Hence, there is a need to clinically interpret available genomic data in 
order to diagnose which signaling pathway is driving tumor growth 
in a patient, including the causative mutation, such that appropriate 
targeted drugs can be chosen. Currently available pathway analysis 
tools and databases are not suitable for this.
Companion diagnostics: To address the above need, we are 
developing computational models of signaling pathways, which can 
be used as companion diagnostic tools to translate genomic data into 
meaningful clinical information to enable selection of targeted drugs. 
The aim is to develop such models for the 10 to 20 most relevant 
oncogenic pathways, and use them to predict which one is most likely 
to drive tumor growth in an individual patient, including the probable 
underlying genomic defect.
A model of the Wnt pathway: As a proof of concept, we have built 
a computational model of the Wnt pathway, which is active in colon 
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adenoma and a main player in colon cancer, but also relevant in 
breast cancer. Our first generation model of the Wnt pathway covers 
its transcriptional program, for which we carefully selected a list 
of Wnt target genes. We have modeled this pathway by a Bayesian 
network, which interprets the expression levels of the target genes 
(from Affymetrix U133Plus2.0 arrays), and infers a probability that 
the Wnt pathway is active in a certain patient tumor sample. The 
parameters of the model are partly derived from literature and partly 
fitted on experimental data.
Results: We first fitted a model on data from six pairs of Wnt knock-
down experiments on colon cancer cell line LS174T, and tested it on 
a public set of 32 normal colon samples plus 32 colon adenomas from 
patients (GSE8671). This model perfectly predicted no Wnt activity 
in the normal samples and an active Wnt pathway in the adenomas.
Next, we fitted the model on these 64 patient samples, and tested it 
on a set of 145 normal colon and colon cancer samples from patients 
(GSE20916). The model again predicted no Wnt activity in all 44 
normal samples, and an active Wnt pathway in all cancer samples, 
except for four of the 36 samples from surgically removed colon 
carcinomas, which most likely are the most heterogeneous.
Thirdly, we took the latter model, trained on colon samples, and 
tested it on three breast cancer data sets, one with 51 breast cancer 
cell lines (GSE12777) and two sets of breast cancer samples from 
patients (GSE12276, n = 204; GSE21653, n = 266). Also on this 
different tissue type, our model correctly predicted Wnt activity for 
the few breast cancer cell lines that are known to have an active Wnt 
pathway. For the two patient studies, a significantly higher number 
of samples of the basal subtype were predicted to have an active Wnt 
pathway compared to the other subtypes (Fisher’s exact test: p = 0.021 
for GSE12276; p = 2.7e-5 for GSE21653), in line with increasing 
evidence for Wnt activation in the basal subtype.
P5-05-01
Vitamin D Status in Newly Diagnosed Breast Cancer Patients 
Inversely Correlates with Tumor Size and Moderately Correlates 
with Outcome.
Hatse S, Lambrechts D, Verstuyf M, Smeets A, Brouwers B, Vandorpe 
T, Brouckaert O, Peuteman G, Laenen A, Kriebitzsch C, Dieudonné 
A-S, Paridaens R, Neven P, Christiaens M-R, Bouillon R, Wildiers 
H. Cathologic University of Leuven, Belgium; Catholic University of 
Leuven, Belgium; University Hospitals Leuven, Belgium
Aims: To study the impact of Vitamin D (VitD) status and genetic 
variability in key VitD regulatory genes on patient and breast tumor 
characteristics, and on breast cancer related outcome.
Methods: We examined serum 25-hydroxyvitamin D3 (25OHD) 
levels in a cohort of 1800 early breast cancer patients treated in 
Leuven between 2003 and 2010. Serum was collected at diagnosis 
for all patients; germline DNA from peripheral blood was also 
available for the majority of them. Serum 25OHD was measured by 
radioimmunoassay, and single nucleotide polymorphisms (SNP’s) 
were assessed by Sequenom. Statistical analysis was done by 
multivariable regression models including age, BMI and season and 
by a Cox proportional hazard model for analysis of disease-specific 
survival and disease-free interval.
Results: Lower 25OHD serum levels were significantly correlated 
with larger tumor size (0,4 ng/ml decrease in 25OHD per 1 cm 
increment in tumor size, p=0.0063) but not with lymph node invasion, 
estrogen receptor and HER2 status, or tumor grade. Serum 25ODH 
level was significantly affected by genotypes of rs10741657 and 
rs1993116 (25-hydroxylase; CYP2R1) and of rs222040, rs7041 and 
rs4588 (D-binding protein; DBP), yet its observed association with 
tumor size did not differ between distinct genotypes. Although not 
statistically significant, patients with higher 25OHD levels tended to 
have slightly improved survival. Also, a significant increase in relapse 
risk became apparent after 3 years for patients with 25OHD<30 ng/
mL.
Conclusion: Vitamin D Level in breast cancer patients inversely 
correlates with tumor size and moderately correlates with outcome.
P5-05-02
Phenotypic Plasticity in the Normal Breast.
Sauder CAM, Koziel JE, Choi M, Fox MJ, Badve S, Blosser RJ, 
Mathieson T, Rufenbarger CA, Henry JE, Storniolo AMV, Herbert 
B-S, Clare SE. Indiana University School of Medicine, Indianapolis, 
IN; Susan G. Komen for the Cure® Tissue Bank at the IU Simon 
Cancer Center, Indianapolis, IN; The Catherine Peachy Fund, Inc., 
Warsaw, IN
Background: The cell of origin of metaplastic carcinoma of the breast 
(MCB) is an enigma. MCB comprises less than 4% of all breast 
cancers, and is a member of the subtype of breast cancer referred 
to as Triple Negative Breast Cancer (TNBC). It is aggressive with 
a prognosis worse than that that for invasive ductal carcinoma NOS 
(not otherwise specified), as well as other TNBCs. Identification of 
the histogenesis of MCB is likely to provide clues to its oncogenesis.
Differentiation along non-epithelial lineages is also observed in 
benign lesions of the breast. Adenomyoepitheliomas, thought to 
arise from myoepithelial cells, have been observed to contain areas 
of cartilaginous, sebaceous, squamous, and osseous differentiation.
Methods: Healthy woman volunteers from central Indiana were 
invited to donate breast tissue to the Susan G. Komen for the Cure® 
Tissue Bank at the IU Simon Cancer Center. Starting from the 10 
gauge tissue cores, 28 normal mammary epithelial (HME) and 33 
normal stromal (HMS) cell lines were established using an organoid 
isolation method after digestion with enzymes for 24 hours. The HME 
cell lines were characterized by immunohistochemistry (IHC). Ploidy 
was determined by karyotype and Interphase FISH mapping with 
centromere probes for Chromosomes X and 17. Cellular morphology 
was observed both on two-dimensional and in three-dimensional 
culture systems. The HME cells were subjected to FACS analysis 
using multiple antibodies including CD24, CD44, Muc1, CD49f, 
and EpCAM.
Results: 96.9% of early passage cells are diploid. The HME cells 
express vimentin, CK 5/6, p63, CD 10, CK 18, and HER-1 when 
grown on two dimensional plastic surfaces. Cells placed in the center 
of a sandwich of Matrigel® uniformly form spheres 37mm-325mm 
in diameter. Hematoxylin and eosin staining of the formalin-fixed 
and paraffin-embedded sections of these spheres reveal keratinized 
squamous differentiation. When the cells are grown on Laminin, 
Collagen IV, or Fibronectin surfaces multiple cell types are observed 
including osteoclasts, distinguished by the presence of Tartrate 
Resistant Acid Phospatase; and chondrocytes, confirmed by staining 
with Alcian Blue. Other cells with a spindle-shape and cytoplasmic 
vacuoles turn a dark reddish-brown color when stained with Oil Red 
O, characteristics of adipocytes. In other areas of the culture, the 
cells form a syncitium and they express the protein MyoD, a marker 
of immature muscle. Finally, there are numerous cells with long, 
dendritic processes. These cells express Nestin, a marker of neural 
stem cells; glial fibrillary acidic protein (GFAP), expressed by mature 
astrocytes; and beta-III tubulin produced by differentiated neurons. 
Using FACS, the HME cells were found to be CD49f positive and 
EpCAM negative. Multiple nucleoli were confirmed using anti-
Nucleostemin IHC.
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Conclusions: Phenotypic plasticity is common to all the HME cell 
lines characterized to date. Differentiation into cells of mesodermal 
and ectodermal origin, CD49+/EpCAM- by FACS, and the presence 
of multiple nucleoli suggest that the isolated cells are a multipotent/
stem cell residing in the normal adult breast. These cells, through a 
series of yet to be elucidated events, may be the cells of origin of MCB.
P5-05-03
The Effect of Breastfeeding on Molecular Characteristics of 
Invasive Breast Cancer.
Ellsworth RE, Valente AL, Kane JL, Shriver CD. Henry M. Jackson 
Foundation, Windber, PA; Windber Research Institute, Windber, PA; 
Walter Reed Army Medical Center, Washington, DC
INTRODUCTION: Breastfeeding has been associated with an 
overall decreased risk of developing breast cancer and the protective 
effect of breastfeeding has been associated with decreased risk of 
triple negative and estrogen-responsive breast cancer. Although the 
mechanism by which breastfeeding provides a protective effect is not 
well-defined, physical changes in the mammary epithelium reflecting 
maximal differentiation, may be involved.
METHODS: The database of the Clinical Breast Care Project was 
queried to identify all patients born between 1946 and 1964 (“baby 
boomers”) with invasive breast cancer who had given birth to at least 
one living child. Clinicopathologic characteristics were compared 
between patients who breastfed for at least six cumulative months 
and those who never breastfed using chi-square and Fisher’s exact 
tests. RNA was isolated after laser-microdissection of 24 pairs of 
breastfeeding and non-breastfeeding tumors matched by stage, 
subtype and grade. Gene expression data was generated using HG 
U133A 2.0 microarrays and analyzed using the Partek Genomics Suite 
using a FDR<0.05, 2-fold expression difference to define significance.
RESULTS: Of the 1,008 parous women with invasive breast cancer 
in the database, 325 (33%) breastfed at least 6 months, 165 (16%) 
breastfeed less than 6 months, and 518 (51%) never breastfed. Women 
who breastfed <6 months were not included in additional analyses. 
Age at menarche and first birth and number of children did not 
differ between groups; age at diagnosis was significantly (P<0.0001) 
lower (54.5 years) in women who breastfed compared to those who 
did not (61.0 years). No differences were detected between patients 
who breastfed and those who did not for ethnicity or for any tumor 
characteristics, including tumor stage, grade or size, hormone, HER2 
or lymph node status, or subtype. At the molecular level, however, 21 
probes representing 19 genes were differentially expressed between 
women who breastfed and those who did not. Eleven genes, including 
HAPLN1, had significantly higher and 8 genes, including LGALS7, 
had significantly lower expression in tumors from women who did 
not breastfeed.
CONCLUSIONS: Despite the matching of tumor samples, and lack 
of differences in pathological characteristics between women who 
breastfed ≥6 months and those who did not breastfeed, differentially 
expressed genes were identified between tumors from the two groups. 
Many of the differentially expressed genes have been associated with 
prognosis, especially in ER negative breast tumors. These data suggest 
that breastfeeding does alter the underlying molecular characteristics 
of invasive breast tumors, and may reflect alterations in exposure to 
estrogen levels during breastfeeding.
P5-05-04
Bipshenol-A Modulates Estrogen Receptor Alpha and 
Compromises Tamoxifen-Induced Apoptosis.
Goodson III WH, Luciani MG, Sayeed A, Jaffee I, Moore II DH, 
Dairkee SH. California Pacific Medical Center Research Institute, 
San Francisco, CA; Kimmel Cancer Center, San Francisco, CA; 
California Pacific Medical Center, San Francisco, CA; University 
of California, San Francisco, CA
BACKGROUND: Antiestrogens are important for treatment and 
prevention of breast cancer. Such drugs influence multiple pathways 
involved in regulation of cell survival - including apoptosis. In 
previous work, exposure of human, benign, high-risk donor breast 
epithelial cells (HRBECs) to the xenoestrogen (XE) bisphenol-A 
(BPA) induced gene expression changes predicting disruption of 
apoptotic signaling (Dairkee et al, Cancer Research 2008). Therefore, 
we hypothesized that antiestrogenic, pro-apoptotic effects of 
tamoxifen are likely modulated under the influence of XEs. Because 
the environmental XE , BPA is routinely detected in a large percentage 
of random human blood samples, we employed functional tests to 
determine whether BPA interferes with tamoxifen-induced apoptosis 
in XE-exposed HRBECs.
METHODS: With IRB approval and written informed consent, 
HRBECs were obtained by random periareolar fine needle aspiration 
(RPFNA) from women who were high risk on the basis of personal or 
family history of breast cancer, breast density, or high-risk histology. 
Primary HRBEC cultures were treated for one week with a low 
concentrations of BPA corresponding to levels reported in human body 
fluids. Estrogen Receptor (ER)-a and -b were measured by Western 
blot (n=6). Altered response to tamoxifen toxicity was measured by 
analyzing quantitative changes in the Annexin V-positive apoptotic 
cell population (n=8).
RESULTS: After one-week exposure to BPA, ER-a increased in six 
of six cases, ER-b decreased in 5 of 6 cases, and we observed a 25 
percent reduction in tamoxifen-induced apoptosis. Prior exposure 
to BPA at the high concentration range detected in the human 
population reduced tamoxifen efficacy by 50 percent. There was a 
dose response of evasion of apoptosis to increasing concentrations of 
BPA (P<0.001, two-sided test for slope fixed effect in a linear mixed 
effects regression). Prior exposure to another XE, methylparaben 
(MP), caused a similar dose-dependent decline in tamoxifen-induced 
apoptosis (p<0.001).
CONCLUSION: BPA and MP, in a range of concentrations measured 
in humans, prevent tamoxifen-induced apoptotic cell death. For BPA 
this involves upregulation of ER-a and downregulation of ER-b. 
Because these XEs are widespread in the American population, they 
may play a role in limiting the prophylactic and therapeutic efficacy 
of tamoxifen and other hormone-based therapies.
P5-05-05
Human Papiloma Virus Identification in Intraductal Papilloma 
and Breast Cancer Using Broad-Spectrum Primers.
Balci FL, Bender O, Coskun F, Duzgun AP, Saylam B, Yuney E, Rota 
S, Fidan I, Feldman S, Soran A. Numune Training and Research 
Hospital, Ankara, Turkey; Okmeydani Training and Research 
Hospital, Istanbul, Turkey; Gazi University School of Medicine, 
Turkey; Columbia University College of Physicians and Surgeons, 
New York; University of Pittsburgh, Magee-Womens Hospital, 
Pittsburgh
Background: There is limited data about Human Papiloma Virus 
(HPV) presence in intraductal papilloma, and there are some 
conflicted studies about the effects of HPVs on breast cancer. Most 
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of these studies have methodological pitfalls as well. We conducted 
a retrospective paraffin block study to understand the presence of 
HPV in papilloma and cancer tissues with broad-spectrum primers.
Methods: Twenty seven intraductal papilloma and 18 breast cancer 
patients’ paraffin blocks were obtained from the patients who 
underwent ductoscopy aided papillomectomy or mastectomy. In 
totally 87 histopathological samples, HPV-DNA were identified by 
real time PCR and broad-spectrum genotyping was performed by in 
situ hybridization. The cancer patients were evaluated according to 
the status of Estrojen Reseptor (ER), Progesteron Reseptor (PR) and 
ErbB-2 positivity.
Results: The mean age±SD was 49±16 in papilloma and 52±14 in 
breast cancer patients. We found that 29.6% (8 of 27) of intraductal 
papillomas and 44.4% (8 of 18) of breast cancer paraffin blocks 
had HPV-DNA positivity by PCR in situ hybridization with broad 
spectrum primers. Fifty percent (4 of 8) of HPV-DNA positive 
papillomas had only type 11; in one, only type 6; in one, mixture of 
type 6,11; in one, mixture of type 11, 39; and in one, mixture of type 
11, 39, 82 was detected. Breast cancer lesions had only type 11 of 
HPV-DNA positivity in 62.5% (5 of 8) of cases; in one, mixture of 
type11, 39; in one, mixture of type 11, 82; in one, mixture of type 
6, 11, 39 was detected. In seven HPV-DNA positive cancer patients, 
ER /PR and/or ErbB-2 was positive, but it was only positive in one 
triple negative patient.
Conclusion: HPVs may have a role in developing papilloma and 
breast cancer. Validation of HPVs role in the etiology of breast cancer/
papilloma, require further studies to understand whether the HPVs 
are episomal or integrated during the tumorigenesis.
P5-05-06
Dysregulation in the Transport of Iron and Haem Is Implicated 
in the Aetiopathogenesis of Breast Cancer.
Roe T, Hoar F, Tselepis C. University of Birmingham, Birmingham, 
United Kingdom; City Hospital, Birmingham, United Kingdom
Backround: Mounting evidence implicates iron in the development 
of a number of cancers, including breast. The responsible mechanism 
is poorly understood in breast cancer, although recent work has 
demonstrated irregular expression of various molecular iron 
transporters.
Materials and Methods: Immunohistochemistry on archived 
material was used to evaluate differences in expression of iron 
and haem exporters, importers and storage proteins between breast 
cancer, DCIS and normal breast tissue. The results were corroborated 
by Western blotting and RT-qPCR on protein and RNA samples 
generated from matched normal and cancer specimens collected 
at mastectomy. The ability of benign and malignant breast cells in 
vitro to accumulate excess iron in the presence of exogenous iron/
haem was evaluated with a ferrozine assay. In addition the effect of 
exogenous iron and haem on cell phenotype in vitro was assessed 
in benign and malignant cell lines. Assays utilised included viability 
(MTT), proliferation (BrdU), migration, anchorage-independent 
growth (colony formation) and invasive capacity. These assays were 
then repeated in the presence of iron chelators to investigate their 
potential utility as a therapeutic modality.
Results: Statistically significant increases (p<0.05) were observed 
in expression of the iron importers DCytB, DMT1 and TfR in breast 
cancer relative to normal tissue. Levels of the storage protein ferritin 
were also significantly raised. The iron exporters ferroportin and 
hephaestin were significantly under-expressed in breast cancer, while 
hepcidin (which induces exporter degradation) was over-expressed. 
Levels of the haem importer HCP1 and the exporters BCRP and 
FLVCR were all significantly down-regulated in cancer relative to 
normal.
Both benign and malignant breast cells were capable of importing 
excess iron, although only malignant cells could import excess haem. 
Iron induced increased viability and proliferation in benign cells but 
had no effect on their migratory or invasive capability, or their ability 
to form colonies. Haem had no effect on benign cell phenotype. Iron 
and haem both had significantly positive effects on all these aspects 
of cell phenotype when introduced to malignant breast cells in vitro. 
Iron chelators were capable of abrogating these positive effects.
Discussion: Archived material and prospectively collected matched 
tissue pairs demonstrate that breast cancers exhibit altered expression 
of the proteins involved in transporting iron and haem through the cell. 
In vitro experiments reveal malignant cells to be capable of taking 
up both substances, which both appear to drive a more malignant 
phenotype. These in vitro changes can be reversed through the 
introduction of iron chelators, implying possible efficacy as a novel 
therapy in breast cancer.
P5-05-07
The Msp1 Polymorphism of Cytochrome P-450 CYP1A1 in 
Asymptomatic Women with Breast Cysts.
Fenile R, Nazário A, Facina G. Federal University of São Paulo, São 
Paulo, SP, Brazil; Federal University of São Paulo, Brazil; Federal 
University of Sao Paulo, Brazil
The objective of this study was to determine the prevalence of the 
cystic form of fibrocystic breast changes among women from different 
age groups correlated with the presence of the Msp1 polymorphism 
of cytochrome P-450 CYP1A1. Methods: A retrospective, case-
control study (was carried out with ultrasound examination) was 
performed on 197 women divided into two groups: 44 women with 
cystic breast disease (cases) and 153 women without breast disease 
(controls), the majority Caucasian, aged 41-50 years, having regular 
menstrual cycles, pregnancies and complaining of mastalgia. Genetic 
analyses were carried out by performing polymerase chain reaction 
to detect the Msp1 polymorphism in CYP1A1. Results: Cystic 
breast disease as diagnosed by ultrasound was present in 22% of the 
population studied . In the genetic analysis of CYP1A1, we observed 
the homozygous wild-type genotype in 68.2% of cases and 66% of 
controls. The heterozygous genotype occurred in 31.28% of cases 
and 26.8% of controls. The homozygous mutant genotype was seen 
in zero cases and in 7.2% of controls. There were no statistically 
significant differences in the genotype frequencies observed between 
the case and control groups (p = 0.42). Conclusion: The prevalence 
and the general epidemiological profile of cystic breast disease in 
this group were consistent with the values previously reported the 
literature. There was a higher frequency of heterozygotes in the case 
than in the control group, but this was not true for the homozygote 
mutant genotype. There was no statistically significant association 
detected between the CYP1A1 Msp1 polymorphism and fibrocystic 
breast disease.
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P5-06-01
Gene Expression Analysis of Resistance to Bevacizumab in 
a VEGF-Reinforced Xenograft Model of ER-Positive Breast 
Cancer.
Gökmen-Polar Y, Toroni RA, Goswami C, Sanders KL, Mehta R, 
Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW. 
Indiana University School of Medicine, Indianapolis, IN; University 
of Medicine and Pharmac, La Jolla, CA
Background: Bevacizumab, a monoclonal antibody targeting vascular 
endothelial growth factor (VEGF), had promising therapeutic efficacy 
in breast cancer. However, intrinsic or acquired resistance is common 
in the clinic. To improve our understanding of the underlying 
mechanisms of resistance to bevacizumab (BEV), we report the 
gene expression analysis of resistance to bevacizumab in a VEGF-
overexpressing xenograft model of ER-positive breast cancer.
Methods: We developed a nude mouse xenograft model of resistance 
to anti-VEGF therapy with BEV in which MCF-7 control (ML20) or 
MCF-7 VEGF (MV165) transfectants were implanted in mammary 
fat pads, allowed to grow, then treated with BEV, with collection 
of tumor at early or late time points (while responding (R) to or 
progressing (NR) on anti-VEGF therapy). To elucidate differentially 
expressed gene profiling associated with tumor resistance to BEV, 
we performed whole-genome gene expression analysis (Human WG-
6v2 Expression Beadchips, Illumina) and miRNA profiling (TaqMan 
ArrayHuman MicroRNA A+B Cards Set v3.0, Applied Biosystems). 
Validation of the chosen genes was performed using quantitative 
real-time RT-PCR (qRT-PCR).
Results: Gene expression analysis revealed differentially regulated 
genes in the MV165-NR group compared with the MV165-R group. 
Among the significant genes, Follistatin (FST) and HEY2 were the 
top genes upregulated in NR compared to R by ANOVA. Expression 
of HEY2 is induced by the Notch signaling pathway. Using qRT-
PCR, we validated the expression of FST and Notch in our system. 
FST was significantly decreased (Fold change= -3.2; P=0.03) in the 
R group compared with vehicle in MV165 xenografts. In contrast 
to R group, FST was upregulated significantly (Fold change= 9.3; 
P=0.05) in the NR group. Notch4 displayed increased levels of 
expression in NR group, but it did not reach significance (P=0.23). 
In addition, correlation of mRNA and miRNA profiles showed that 
miRNAs targeting FST and Notch4 were differentially regulated in 
NR group compared to R group in MV165 xenograft tumors. Among 
the miRNAs, TGF-b-induced oncomiR miR-181a is up-regulated in 
NR and targets both FST and Notch4. Other miRNAs that target both 
Notch4 and FST include miR-1, miR-133a, miR-133b, and mir-449b.
Conclusion: Our data serve as a potential mechanistic explanation 
for acquired resistance to bevacizumab. These data may shed 
light on the transitory effect of BEV observed in the E2100 first-
line metastatic breast cancer trial, where VEGF-targeted therapy 
prolongs progression-free survival in metastatic breast cancer without 
improving overall survival.
P5-06-02
Response and Acquired Resistance of BRCA1-Deficient Triple-
Negative Breast Cancer Xenografts to Alkylators or PARP 
Inhibitors.
ter Brugge P, van der Burg E, Kristel P, Boon U, Moutinho Freixas 
C, Esteller M, Hogervorst F, Gevensleben H, Turner N, Wesseling J, 
Jonkers J. Netherlands Cancer Institute, Amsterdam, Netherlands; 
Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, 
Spain; Gene function, Breakthrough breast cancer research centre, 
London, UK
Background. BRCA1 mutated breast tumor cells are defective in 
DNA repair by homologous recombination and therefore especially 
sensitive to treatment with DNA double-strand break (DSB) inducing 
agents, such as alkylators or PARP inhibitors. However, such tumors 
can eventually develop therapy resistance. Understanding therapy 
resistance mechanisms may help in designing treatment strategies 
to overcome therapy resistance.
Methods. We have developed BRCA1-deficient triple-negative breast 
cancer (TNBC) xenograft models by implantating fresh human breast 
tumor pieces and subsequent serial passaging. These models show 
epigenetic loss of BRCA1 due to promoter hypermethylation or genetic 
inactivation of BRCA1 due to a frameshift mutation (c.2210delC) 
resulting in a premature stop codon (p.Thr737LeufsX15). We have 
used these BRCA1-deficient TNBC models to study response and 
acquisition of resistance to alkylating therapy (cisplatin, melphalan) 
and the clinical PARP inhibitor olaparib.
Results. Treated tumors were sensitive to the alkylators cisplatin or 
melphalan or the PARP inhibitor olaparib, in some cases resulting in 
complete remission with no palpable tumor left. However, relapses 
did occur in most cases and repeated treatment of recurrent tumors 
eventually led to aquired resistance.
Since restoration of BRCA1 function has been suggested as a 
mechanism of therapy resistance (Swisher et al., Cancer Res 2008; 
68: 2581), we determined BRCA1 expression in therapy-sensitive 
and -resistant tumors by Western blot analysis. While no full length 
BRCA1 protein could be detected in the therapy-sensitive tumors, 
expression of full length BRCA1 protein was found in the majority 
of cisplatin resistant and olaparib resistant tumors. BRCA1 re-
expression in the therapy-resistant BRCA1-c.2210delC tumors was 
caused by genetic restoration of the reading frame due to reversion 
to the wildtype sequence or additional deletions near the c.2210delC 
mutation. BRCA1-re-expression in the therapy-resistant TNBC 
xenografts with epigenetic loss of BRCA1 was caused either by loss 
of BRCA1 promoter methylation or by complex rearrangements at 
the BRCA1 locus.
Conclusion. Although BRCA1-deficient TNBC xenografts are 
initially very sensitive to alkylating agents and olaparib, resistance 
to treatment develops in almost all treated tumors.This acquired 
resistance is frequently associated with re-expression of BRCA1 due 
to secondary mutations or loss of promoter methylation.
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011529s
December 6-10, 2011 Abstracts: Poster Session 5
P5-06-03
Gene Expression Associated with Breast Cancer Primary and 
Secondary Resistance to Neoadjuvant Chemotherapy.
Fujiki FK, Katayama MLH, Brentani H, Carraro DM, Abreu APS, 
Barros Filho MC, Oliveira CT, Caldeira JRF, Góes JCS, Brentani 
MM, Folgueira MAK. Faculdade de Medicina da Universidade 
de Sao Paulo, Sao Paulo, Brazil; Faculdade de Medicina da USP, 
Sao Paulo, Brazil; Hospital do Cancer A.C. Camargo, Sao Paulo, 
Brazil; Instituto Brasileiro de Controle do Cancer, Sao Paulo, Brazil; 
Hospital do Câncer A.C. Camargo, Sao Paulo, Brazil; Hospital 
Amaral Carvalho, Jau, Sao Paulo, Brazil
In breast cancer, neoadjuvant chemotherapy may provide valuable 
information on tumor resistance mechanisms, as variable degrees 
of tumor response, from pathological complete response until 
progressive disease, may be observed. To have a better insight of the 
resistance process to chemotherapy, we have compared resistant pre 
chemotherapy samples (representing primary or intrinsic resistance) 
and residual post chemotherapy from partially responsive tumors 
(secondary or acquired resistance), by means of their transcriptional 
profile.Tumors from 36 patients submitted to neoadjuvant 
chemotherapy (4 cycles doxorrubicin and cyclophosphamide) were 
collected (12 pre-chemotherapy from primary resistant samples and 
24 post chemotherapy from residual samples) and analyzed by cDNA 
microarray (training set, n=25, 9 resistant; 16 residual) and/or by 
qRT-PCR (technical validation set, n=11, and biological validation 
set, n=11; 8 resistant; 14 residual). In samples from the training 
set analysed using a cDNA microarray platform with 4608 genes 
(Student’s t test; p <0,01; FDR <10), 138 genes were differentially 
expressed between resistant and residual samples, which correctly 
classified tumors in unsupervised hierarchical clustering analysis, with 
high confidence. Genes were mainly involved in regulation of cell 
cycle, regulation of cell growth, cell division, protein modification 
and DNA dependent DNA replication. Among genes involved in cell 
growth and cell division, 12 were selected to be further evaluated, 
using qRT-PCR: MORF4L2, NOTCH2, HTRA1, DLC1, CYR61, 
MLH1, CHFR, CDC16, CDKL1, NOTCH2, HRAS, CDK2, in 
technical and biological validation sets of samples. In the technical 
validation group, a significant positive correlation was observed for 
the expression of five genes (as evaluated by microarray and qRT-PCR, 
Spearman correlation, p<0.05), which were then tested in discriminant 
analysis to detect the best combination to classify resistant and 
residual tumors. The best combinations included all the five selected 
genes, CYR61/DLC1/CDKL1/NOTCH2/HTRA1, as well as three of 
them, CYR61/DLC1/HTRA1, which correctly classified 100% and 
91% of tumors from the technical and biological validation groups 
(100% and 73% in leave one out cross validation, respectively). 
CYR61 was more expressed in residual samples, however no other 
main individual gene expression differences were detected. Our data 
indicate that primary and secondary chemoresistance may present 
some differences, involving mainly cell growth and cell proliferation 
processes. CYR61, a CCN growth factor family member, may 
be synthesized by tumor cells as well as by adjacent fibroblasts, 
exhibiting autocrine and paracrine actions, stimulating proliferation, 
migration and chemoresistance. CYR61 enhanced expression in post 
chemotherapy samples suggests that epithelial stromal interactions 
may be active players in the chemoresistance process, deserving 
more detailed analysis for targeted therapies. Supported by FAPESP.
P5-06-04
Mechanisms of Acquired Resistance to Insulin-Like Growth 
Factor 1 Receptor Inhibitor in MCF-7 Breast Cancer Cell Line.
Ekyalongo RC, Mukohara T, Kataoka Y, Kiyota N, Fujiwara Y, Minami 
H. Kobe University Graduate School of Medicine, Kobe, Japan; Kobe 
University Hospital Cancer Center, Kobe, Japan
Background: No studies have yet clarified the mechanism of acquired 
resistance to insulin-like growth factor-1 receptor (IGF-1R) tyrosine 
kinase inhibitor (TKI). Our previous study of 16 breast cancer 
cell lines found that only MCF-7 expressed high levels of insulin 
receptor substrate (IRS)-1 and was sensitive to the IGF-1R-TKI 
NVP-AEW541.
Material and Methods: We developed a model of acquired resistance 
to NVP-AEW541 by continuously exposing MCF-7 cells to NVP-
AEW541, naming the model MCF-7-NR. To explore the mechanism 
of acquired resistance to NVP-AEW541, the effects of NVP-AEW541 
on cell growth and IGF-1R signaling in MCF-7 and MCF-7-NR cells 
were examined.
Results: With Western blot analysis, we found that MCF-7-NR 
had much lower levels of IRS-1 than parental MCF-7. While 
phosphorylation of Akt was completely inhibited by administration 
of NVP-AEW541 (3 mM) in both cell lines, phosphorylation of S6K 
remained high only in MCF-7-NR. The notion of Akt-independent 
S6K phosphorylation in MCF-7-NR was further supported by the 
fact that cell growth and phosphorylation of S6K was affected by 
administration of the Akt inhibitor perifosine to a lesser degree in 
MCF-7-NR than in MCF-7. Further, the mTOR inhibitor everolimus 
inhibited phosphorylation of S6K and cell growth equally in both 
lines. Screening of MCF-7 and MCF-7-NR lines for phosphorylation 
of 42 receptor tyrosine kinases with and without 3mM NVP-AEW541 
showed that Tyro3 phosphorylation remained high only in MCF-7-NR 
cells. Gene silencing of Tyro3 using siRNA resulted in reduced cell 
growth, decreased phosphorylation of phosphoinositide-dependent 
kinase-1 (PDK-1) and protein kinase C a/bII, reduced expression 
of cyclin D1 in the MCF-7-NR line, with minimal effects evident 
in the MCF-7 line.
Discussion: Findings from our current study support the possibility 
of predicting sensitivity to NVP-AEW541 by measuring IRS-1 
expression, as hypothesized in our previous study. Akt-independent 
activation of mTOR/S6K by an as-yet-undefined mechanism appears 
to induce acquired resistance to NVP-AEW541, and as such mTOR 
inhibitors may have therapeutic value. Tyro3 upregulation and 
migration of control of cellular growth and cyclin D1 expression 
may also induce resistance to NVP-AEW541. Although the validity 
of these findings should be evaluated in further preclinical studies 
and eventually in clinical trials, our observations may lead to 
individualized use of NVP-AEW541 and the development of “back-
up drugs” against tumors that acquire resistance to NVP-AEW541.
P5-06-05
Switching Addictions between HER2 and FGFR2 in HER2-
Positive Breast Tumor Cells: FGFR2 as a Potential Target for 
Salvage after Lapatinib Failure.
Tsurutani J, Azuma K, Sakai K, Aaro T, Nishio K, Nakagawa K. Kinki 
University Faculty of Medicine, Osakasayama, Osaka, Japan
Agents that target HER2 have improved the prognosis of patients 
with HER2-amplified breast cancers. However, patients who initially 
respond to such targeted therapy eventually develop resistance to the 
treatment. We have established a line of lapatinib-resistant breast 
cancer cells (UACC812/LR) by chronic exposure of HER2-amplified 
and lapatinib-sensitive UACC812 cells to the drug. The mechanism 
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by which UACC812/LR acquired resistance to lapatinib was explored 
using comprehensive gene hybridization. The FGFR2 gene in 
UACC812/LR was highly amplified, accompanied by overexpression 
of FGFR2 and reduced expression of HER2, and a cell proliferation 
assay showed that the IC50 of PD173074, a small-molecule inhibitor 
of FGFR tyrosine kinase, was 10,000 times lower in UACC812/LR 
than in the parent cells. PD173074 decreased the phosphorylation of 
FGFR2 and substantially induced apoptosis in UACC812/LR, but not 
in the parent cells. FGFR2 appeared to be a pivotal molecule for the 
survival of UACC812/LR as they became independent of the HER2 
pathway, suggesting that a switch of addiction from the HER2 to the 
FGFR2 pathway enabled cancer cells to become resistant to HER2-
targeted therapy. The present study is the first to implicate FGFR in 
the development of resistance to lapatinib in cancer, and suggests that 
FGFR-targeted therapy might become a promising salvage strategy 
after lapatinib failure in patients with HER2-positive breast cancer.
P5-06-06
The RNA Binding Protein FUS Is a Potential Marker for Breast 
Cancer Progression and Therapy Response.
Brooke GN, Bevan CL, Rudraraju B, Palmieri C. Imperial College 
London, London, United Kingdom
Background: The RNA binding protein FUS is a multifunctional 
protein that has recently been demonstrated to be directed to target 
genes via non-coding RNA, where it represses transcription via 
disruption of the transcriptional complex. We have shown that 
FUS is an important regulator of prostate cancer cell growth; FUS 
over-expression causes G1 arrest, promotes apoptosis and blocks 
proliferation in vitro and in vivo, whereas knock-down increases 
proliferation. This regulation appears to be, at least in part, via 
direct regulation of cyclin D1. Further, analysis of patient samples 
demonstrated that FUS levels are inversely correlated with Gleason 
grade and directly correlated with survival and the presence of 
bone metastases. We hypothesised that FUS is a predictive and/or 
prognostic marker for hormone-dependent cancers. Materials and 
Methods: FUS expression in breast cancer was analysed in silico 
and using Western blotting and immunohistochemistry on a tumour 
microarray. FUS levels were knocked down by siRNA in MCF-
7 cells and chemosensitivity analysed using caspase 3/7 assays. 
Results: Analysis of the Finak dataset (2008) demonstrated that FUS 
expression is significantly lower in breast cancer compared to normal 
breast. Immunohistochemistry revealed that FUS expression is also 
inversely correlated with grade. Importantly, FUS expression was also 
correlated with survival (Kaplan-Meier Plotter); significantly longer 
relapse free survival was seen in patients whose tumours had high 
levels of FUS. FUS expression also appears to correlate with therapy 
response since analysis of the Chang dataset (2003) revealed that 
FUS levels are significantly lower in patients resistant to Docetaxel 
and we found FUS levels to be lower in the tamoxifen resistant 
MCF-7 cell line (MCF-7 TAMR) compared to the parental line. We 
therefore hypothesised that loss of FUS expression may be driving 
therapy failure. In support of this, reducing FUS expression in the 
parental MCF7 line resulted in a significant reduction in docetaxel-
induced Caspase 3/7 activity, suggesting that FUS is a regulator of 
chemosensitivity. Discussion: FUS may be an important regulator 
of breast cancer progression since its levels are inversely correlated 
with grade and directly correlated with relapse free survival. Further, 
lower FUS expression is also correlated with reduced hormone 
therapy and chemo-sensitivity. Since knock-down of FUS reduced 
MCF-7 chemosensitivity, we believe that the observed changes in FUS 
expression are, in part, driving therapy failure and hence propose that 
FUS is a novel target and biomarker for breast cancer.
P5-06-07
The Mechanisms of Autophagy Involved in the Effects of 
Everolimus (RAD001) on Overcoming Multidrug Resistance of 
Breast Cancer Cell Line MCF-7/ADR.
Liu Z-B, Hou YF, Xu W-H, Ling H, Shao Z-M. Breast Cancer Institute, 
Shanghai, China
To investigate the effects of everolimus on overcoming multidrug 
resistance of breast cancer cell line MCF-7/ADR and to explore 
its mechanisms of action. MCF-7 and MCF-7/ADR cells were 
treated with ADM, everolimus alone or by combination at different 
concentrations and different times. Changes of cell morphology were 
observed by microscopy. Apoptosis induced by ADM or everolimus 
were measured by flow cytometry with PI staining and ANNEXIN 
V-FITC staining. Western blot was used to evaluate the expression 
level of apoptosis and autophagy-related molecules. To investigate 
specifically the role of autophagy in everolimus treated breast cancer 
cell lines, we used a siRNA approach, targeting autophagy gene, 
ATG5. The CI for each experimental combination was calculated. 
Dose-dependent inhibition of cell proliferation was observed with 
ADM and everolimus for both 24 and 48h. MCF-7/ADR was resistant 
to ADM. The addition of everolimusdid increase the sensitivity of 
MCF-7/ADM cells to ADM, as indicated by the ID50 by 2.6 fold for 
24h; but for 48h, everolimus is even able to reduce the ID50 of ADM 
much higher to 5-10 times. Thus, inhibition of mTOR does appear 
to restore ADM sensitivity in MCF-7/ADR cells, especially for a 
longer synergistic time (48h). Everolimus alone induced a decrease 
in the phosphorylation of two downstream molecules of mTOR, 
including p70S6K and 4E-BP1, confirming the role of everolimus in 
mTOR signaling regulation, whereas everolimus in combination with 
ADM caused an almost complete suppression of p70S6K and 4E-
BP1 phosphorylation. When cells were exposed to both everolimus 
and ADM for 24h, there was no loss of procaspase-3 nor was there 
a concentration-dependent increase in cleaved caspase protein. On 
the contrary, ADM administration induced the proteolytic cleavage of 
caspase 3, and when ADM was combined with everolimus, a further 
increase in the expression of cleaved caspase 3 was detected in 48h. 
Cells treated with CQ markedly enhanced ADM-induced cell death in 
MCF7/ADR cells in early stage (24h). As observed with immunoblot 
analysis, cotreatment of everolimus and ADM increased expression 
level of ATG5 and LC3-II to -I ratios, also accelerated the rate of 
cell death. That’s why cotreatment with CQ resulted in a rapid drop 
in cell viability with complete cell death observed by CCK-8 test. 
Immunoblot analysis also revealed non significant change of ATG5 
and LC3-II within 48h of everolimus on the base of ADM treatment. 
Silencing ATG5 resulted in a marked downregulation of ATG5 but 
increased the level of proteolytic cleavage of caspase 3 induced by 
ADM alone and cotreatment of everolimus and ADM when cells 
were exposed to both everolimus and ADM for 24h. This result was 
consistent with our finding using the Annexin-V apoptotic assay. For 
48h, the results of proteolytic cleavage of caspase 3 were similar 
as when cells weren’t silenced by ATG5 siRNA. In conclusion, 
autophagy plays bidirectional roles in the mechanisms of tumor cells 
suppression of everolimus combining MCF-7/ADR. Especially in 
late stage, inhibiting autophagy helps to overcoming resistance of 
everolimus and sensitizes cancer cells to ADM-induced apoptosis.
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P5-06-08
Mesenchymal Stem Cells and Carcinoma-Associated Fibroblasts 
Sensitize Breast Cancer Cells in 3D Cultures to Kinase Inhibitors.
Dittmer J, Dittmer A, Oerlecke I, Leyh B, Martens JWM, Thomssen 
C. Clinic for Gynecology University Halle, Germany; Erasmus 
University Medical Center
Background: Bone-derived mesenchymal stem cells (MSCs) are 
attracted to cancer lesions and may differentiate to CAFs. By 
interacting with cancer cells, MSCs and CAFs may promote cancer 
progression and modulate drug sensitivity.
Material and Methods: To analyze ability of MSCs and CAFs to 
modulate drug response, we generated spheroids of MCF-7 or MDA-
MB-231 breast cancer cells in the absence or presence of human (h)
MSCs or hCAFs and tested the susceptibility of the breast cancer cells 
to three different kinase inhibitors (TKI258, RAD001 and RAF265) 
as used in cancer therapy.
Results: While MSCs and CAFs did not affect the response of either 
breast cancer cell line to PDGFR/FGFR/VEGFR inhibitor TKI258, 
they sensitized breast cancer cells to the mTOR inhibitor RAD001. In 
MCF-7 cells, this was accompanied by increased apoptosis. hMSCs 
and to a lesser extent hCAFs also enhanced the cytotoxic effect of 
RAF inhibitor RAF265 on MDA-MB-231 cells. Searching for the 
mechanism that underlies the effect of stromal cells on RAF265 
response we found that stromal cells inhibited RAF265-induced 
increase in ERK1/2 phosphorylation, supported RAF265-dependent 
downregulation of PKCalpha (protein kinase Calpha) and prevented 
RAF265-induced conversion of LC3B, a marker of autophagy. 
To mimic the changes in ERK1/2 phosphorylation and PKCalpha 
expression in response to the stromal cells, we treated cells with 
MEK1 inhibitor U0126 or PKCalpha inhibitor Gö6976, respectively. 
U0126, but not Gö6976, was as effective as hMSCs in sensitizing 
MDA-MB-231 cells to RAF265.
Discussion: Our data suggest that hMSCs and hCAFs increased the 
cytotoxic effect of RAF265 on MDA-MB-231 cells by downregulating 
ERK1/2 phosphorylation. In summary, this study shows that hMSCs 
are able to render breast cancer cells more susceptible to kinase 
inhibitors and that, to the most part, hCAFs to which hMSCs can 
differentiate are able to mimic the drug-sensitizing effects of hMSCs.
P5-06-09
Acquired Sensitivity to TRAIL Mediated Apoptosis in Lapatinib 
Resistant SKBR3 Cells.
Eustace AJ, Browne BC, McDermott M, Gallagher C, Watson W, 
Crown J, O’Donovan N. Dublin City University, Dublin, Ireland; 
University College Dublin, Dublin, Ireland; St. Vincents University 
Hospital, Dublin, Ireland
Introduction
Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor is approved 
for the treatment of trastuzumab-refractory HER2 positive metastatic 
breast cancer. However, not all HER2 positive tumors respond to 
lapatinib and patients who initially respond frequently relapse. 
Understanding the molecular alterations associated with acquisition 
of lapatinib resistance may lead to the identification of targets to 
overcome resistance. Thus, the aim of this study was to examine 
changes in apoptosis in a model of acquired lapatinib resistance.
Methods
SKBR3 cells were treated with 250 nM lapatinib twice weekly for 
6 months to establish the lapatinib resistant cell line SKBR3-L. The 
effects of TNF-related apoptosis-inducing ligand (TRAIL) and tumour 
necrosis factor-a (TNF-a) on cell survival and apoptosis induction 
were examined in SKBR3 and SKBR3-L cells, using the acid 
phosphatase proliferation assay and the terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay. Cleavage of 
poly ADP ribose polymerase (PARP) was used to confirm apoptosis. 
TRAIL-1 and TRAIL-2 receptor expression were measured by flow 
cytometry (FACS).
Results
In SKBR3-L cells, TRAIL treatment (25 ng/ml) significantly inhibited 
cell survival (94.0 ± 12.0 %) compared to the SKBR3 cells (11.0 ± 
2.2 %). Treatment with TNF-a (0.5 ng/ml) also resulted in significant 
inhibition of cell survival (68.2 ± 10.1 %) in SKBR3-L cells compared 
to SKBR3 cells (9.4 ± 9.0 %). TRAIL (25 ng/ml) induced a low level 
of apoptosis in SKBR3 cells (7.0 ± 4.0 %), whereas in SKBR3-L cells, 
TRAIL (25 ng/ml) induced significant apoptosis (54.8 ± 2.6 %, p < 
0.001), as determined by the TUNEL assay. We confirmed by western 
blotting that TRAIL treatment for 72 hours resulted in higher levels 
of PARP cleavage in SKBR3-L cells compared to SKBR3 cells. Both 
western blotting and FACS analysis of TRAIL receptor expression 
showed that neither TRAIL-1 nor TRAIL-2 receptor expression was 
significantly elevated in SKBR3-L cells compared to SKBR3 cells.
Conclusions
SKBR3-L cells, a model of acquired lapatinib resistance, display 
significant sensitivity to TRAIL induced apoptosis compared to the 
parental cell line SKBR3. Thus, targeting TRAIL may represent a 
novel therapeutic strategy to overcome acquired lapatinib resistance.
P5-06-10
Leptin Signaling Impacts Notch and Wnt Crosstalk in Breast 
Cancer.
McGlothen TZ, Gillespie C, Colbert L, Blaylock-Hogans D, Guo S, 
Gonzalez- Perez RR. Morehouse School of Medicine, Atlanta, GA; 
Spelman College, Atlanta, GA
Background: Triple negative breast cancer (TNBC: ER-, PR- and 
Her2/neu-) is an aggressive form of the disease that disproportionately 
affects women of color, has an early onset, and is associated with poor 
survival and a resistance to common therapeutic treatments. We have 
previously demonstrated an association between the adipocytokine 
leptin and Notch signaling pathways in breast cancer. Notch 
participates in a crosstalk relationship with many signaling pathways 
involved in carcinogenesis, including Wnt and leptin, which could in 
turn increase tumor burden and cell survival of MMTV-Wnt1 obese 
mice. We hypothesize that leptin signaling crosstalk with Notch and 
Wnt is instrumental in the development of drug-resistant features 
(increased survival and proliferation) of TNBC.
Objective: The aim of this study was to determine whether leptin 
mediated crosstalk of the Notch and Wnt pathways has a differential 
impact on TNBC compared to ER+ cells.
Materials & Methods: ER+ MCF-7 and TNBC-MDA MB-231 
cells (96-well plate; 1x104 cells/well) were serum deprived for 24 
hours and treated with varying doses of Doxorubicin and Cisplastin 
for 24h in conjunction with pharmacological doses of leptin, leptin 
peptide antagonist (LPrA2), Wnt agonist (Wnt-1) and antagonist 
(Wif-1). Cell proliferation was measured via WST assay. The effect 
of the various treatments on the activation of Wnt (total/pb-catenin), 
Notch (Notch 1-4 and JAG1/Dll-4 and targets survivin/Hey2), and 
leptin (STAT3 and targets VEGF/VEGFR-2) signaling pathways were 
measured using western blot and ELISA. b-Catenin levels were also 
investigated by IHC in DMBA-breast cancer samples from lean and 
DIO (diet-induced obese mice) mice treated with LPrA2. Apoptosis 
was also measured.
Results: Leptin increased the levels of beta-catenin mainly in 
TNBC cells. This leptin-induced effect was also detected in breast 
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tumors from DIO-mice. Interestingly, leptin increased survival (bcl-
2 and Caspase-3 activation)/proliferation (cell number and Cyclin 
D1), expression of Notch and attenuated the detrimental effects of 
Doxorubicin and Cisplastin on breast cancer cells. Wnt-1 had similar 
but less pronounced effects compared to leptin. We also observed 
differences in Notch expression. Moreover, MDA MB-231 cells 
showed decreased response to Wnt1 in the presence of leptin.
Conclusions: Our findings suggest that leptin could play a negative 
role in TNBC by increasing drug-resistance through its crosstalk with 
Wnt and Notch signaling pathways. This may imply that obesity, 
characterized by elevated leptin levels, could negatively affect the 
outcome of TBNC treatment. Taken together, this data supports the 
theory that inhibition of leptin signaling could be a novel way to 
prevent and treat TBNC, particularly in the context of obesity and 
abnormal Wnt and Notch signaling. [This work was supported in part 
by NIH/NCI1SC1CA138658-02; NIH/ARRA/3SC1CA138658-02S1 
and the Georgia Cancer Coalition Distinguished Cancer Scholar 
Award (to RRGP); CREDO (MSCR) 2R25RR017694-06A1 (to 
L.S.C); NIGMS506GM08248 and NCRR 5P20RR11104 (to T.Z.M); 
and facilities and support services at MSM (NIH RR03034 and 1C06 
RR18386)].
P5-06-11
Quercetin-3-Methyl Ether Inhibits Lapatinib-Sensitive and 
Lapatinib-Resistant Breast Cancer Cell Growth by Inducing 
G2/M Arrest and Apoptosis.
Bode AM, Li J, Zhu F, Normanno NE, Ericson ME, Lubet RA. 
University of Minnesota, Austin, MN; INT-Fondazione Pascale, 
Naples, Italy; University of Minnesota, Minneapolis, MN; National 
Cancer Institute, Rockville, MD
Background: Lapatinib, an oral, small-molecule, reversible inhibitor 
of both EGFR and HER2, is highly active in HER2 positive breast 
cancer as a single agent and in combination with other therapeutics. 
However, resistance against lapatinib is an unresolved problem in 
clinical oncology. Recently, interest in the use of natural compounds 
to prevent or treat cancers has gained increasing interest because 
of presumed low toxicity. Quercetin-3-methyl ether, a naturally 
occurring compound present in various plants, has potent anticancer 
activity.
Material and Methods: Quercetin-3-methyl ether was obtained from 
Analyticon Discovery (Potsdam, Germany). Lapatinib-resistant SK-
Br-3 (SK-Br-3-Lap R) cells were isolated in the laboratory of Cell 
Biology and Biotherapy at the Istituto Nazionale dei Tumori, Naples, 
Italy. Parental SK-Br-3 and SK-Br-3-Lap R cells were cultured in 
monolayers at 37 °C in a 5% CO2 incubator in 10% FBS/McCoy 
supplemented with penicillin/streptomycin (100 units/ml; Invitrogen). 
SK-Br-3 Lap R cells were routinely maintained in 1 µM lapatinib. 
Anchorage-dependent and -independent growth and cell cycle were 
assessed in the presence and absence of quercetin-3-methyl ether.
Results: Here, we found that quercetin-3-methyl ether caused in 
a significant growth inhibition of lapatinib-sensitive and -resistant 
breast cancer cells. Western blot data showed that quercetin-3-methyl 
ether had no effect on Akt or MAPKs signaling in resistant cells. 
However, quercetin-3-methyl ether caused a pronounced G2/M 
block mainly through the Chk1-Cdc25c-cyclin B1/Cdk1 pathway in 
lapatinib-sensitive and -resistant cells. In contrast, lapatinib produced 
an accumulation of cells in the G1 phase mediated through cyclin D1, 
but only in lapatinib-sensitive cells. Moreover, quercetin-3-methyl 
ether induced significant apoptosis, accompanied with an increase 
the levels of in cleaved caspase 3, caspase 7 and poly(ADP-ribose) 
polymerase (PARP) in both cell lines.
Conclusion: Overall, these results suggested that quercetin-3-methyl 
ether might be a novel and promising therapeutic agent in lapatinib-
sensitive or -resistant breast cancer patients.
P5-07-01
Novel Alternative Splice Variants of HER2 in Invasive Breast 
Cancer.
Assam EE, Rhodes A, Ladomery M, Harries L, Sohail M. University 
of the West of England, Bristol, Gloucestershire, United Kingdom; 
Royal Devon and Exeter NHS Foundation Trust Hospital, Exeter, 
Devon, United Kingdom; United Hospitals Bristol Foundation Trust, 
Bristol, Gloucestershire, United Kingdom
Background: The Human Epidermal Growth Factor Receptor 2 
(HER2) is an oncogene expressed in 25-30% of invasive breast 
cancers. HER2 shares extensive homology with other members of 
the HER family (HER1, HER3 and HER4), and is constitutively 
active as an homo- and heterodimer. The HER2 gene encodes an 
185kDa transmembrane protein with tyrosine kinase activity. Gene 
amplification or protein expression of HER2 is a predictor of poor 
clinical outcome and decreased survival in women with breast cancer, 
and also indicates a favourable response to Trastuzumab (Herceptin) 
therapy, or a combinational therapy comprising Herceptin plus 
chemotherapy. However, resistance to Trastuzumab remains the case 
in approximately 50% of HER2 amplified/overexpressing tumours. 
Understanding the molecular mechanisms of Trastuzumab resistance 
and identifying more effective therapies, is critical in the treatment 
of patients whose breast cancers express this aggressive disease 
phenotype. In this study, it is postulated that the abnormal generation 
of mRNA splice variants may be responsible for the continued tumour 
growth and progression.
Aims: The aim of this study is to increase our understanding of the 
role of HER-2 splice variants in the development and progression of 
breast cancer. This will inform the development of more sophisticated 
and effective therapies that target specific HER-2 isoforms, rather than 
Herceptin, which targets just the generic wild type HER-2 protein.
Materials and Methods: The entire coding region of HER-2 cDNA 
was PCR amplified using 12 sets of HER-2 specific primers in 
HER-2 positive cell lines (SKOV-3, SKBR-3, MDA-MB-453 and 
MDA-MB-361).
Results: RT-PCR results showed multiple bands in various regions 
of the HER2 mRNA. Sequencing of these bands revealed novel 
alternative splice variants with deletions in exons 13 and 18 of 
the HER2 gene expressed in addition to the wild type HER2. 
Bioinformatic analysis of the deletions revealed a cassette exon 
deletion in exon 13, and a loss of 42 base pairs in the 3’ end of exon 
18 compared to the full length HER2. Both the full length HER2 
sequence and the sequence containing the deletions were translated 
using the ExPASy Translate Tool. This revealed an in-frame deletion 
of 14 amino acids and revealed a novel splice isoform with a deletion 
in the HER2 protein which encompasses the entire ATP binding 
pocket. This was determined by analysis using UniProtKB to identify 
the composition of amino acids for each domain of HER2.
Discussion: Our studies have identified novel splice variants in the 
tyrosine-kinase domain of the HER-2 gene using HER-2 positive cell 
lines. The loss of an ATP binding site in the HER2 gene may lead 
to a less active HER2 isoform which may play a significant role in 
prognosis. Current work is being carried out to study the regulation of 
these splice variants and to study the role of splice factors ASF/SF2 
and SRPK1 in the regulation of HER2 splicing, and to elucidate any 
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significant changes in the HER2 signalling pathways. In addition, the 
expression of these isoforms are currently being investigated in tissues 
from formalin fixed, paraffin embedded and frozen breast tumours.
P5-07-02
Could the Combination of COX-2 Inhibitor and Calcitriol Be a 
New Chemopreventive Approach To Decrease the Incidence of 
Breast Cancer?
Thill M, Cordes T, Fischer D, Hoellen F, Friedrich M, Diedrich K, 
Dittmer C. University Hospital Schleswig-Holstein, Campus Luebeck, 
Luebeck, Germany; Helios Klinikum Krefeld, Krefeld, Germany
Background: COX-2 is a potential molecular prognostic factor 
for breast cancer and 15-hydroxyprostaglandin dehydrogenase 
(15-PGDH) is described as a tumour suppressor in cancer. The 
antiproliferative effects of calcitriol (1,25(OH)2D3) mediated via the 
vitamin D receptor (VDR) render vitamin D a promising target in 
breast cancer therapy.
Material and Methods: The expression of the prostaglandin (PG) 
metabolising enzymes (COX-2, 15-PGDH), the PG receptors, 
the vitamin D metabolising enzymes (1-alpha-hydroxylase, 
24-hydroxylase) and the VDR were determined in benign and 
malignant breast cell lines as well as in normal and malignant 
breast tissue. Measurement of PGE2 and 25(OH)2D3 serum level in 
healthy women and breast cancer patients was performed in winter 
and summertime. Additionally, the influence of calcitriol on cell 
proliferation was determined. In addition we examined the effect of 
calcitriol on the enzyme expression.
Results: We found an inverse correlation between the expression 
of the PG metabolising enzymes with the VDR as well as with the 
vitamin D metabolising enzymes by investigating the tissue samples. 
Moreover, we detected an inverse correlation between the PGE2 and 
25(OH)2D3 serum level in breast cancer patients during wintertime. 
Furthermore the PG receptors were associated with an increased 
carcinogenesis. The breast cell experiments presented a dysregulated 
vitamin D metabolism, especially in the invasive breast cell line. 
Calcitriol showed an antiproliferative effect only in the benign but 
not in the malignant cell lines, and the expression of COX-2 and 
15-hydroxyprostaglandindehydrogenase was influenced by calcitriol 
only in the benign breast cell line.
Conclusions: These results suggest a link between vitamin D and 
PG metabolism and therefore a possible synergism between COX-2 
inhibition and calcitriol in breast cancer cells. For the first time, we 
could show an inverse correlation between the two metabolisms 
in breast cancer on different levels. Thus, the chemopreventive 
combination of calcitriol and/or vitamin D analogue with a COX-2 
inhibitor might decrease the incidence of breast cancer.
P5-07-03
Modulation of Autophagic Activity by Extracellular pH.
Xu T, Su H, Ganapathy S, Yuan Z-M. University of Texas Health 
Science Center at San Antonio, San Antonio, TX
Reprogramming energy metabolism from oxidative phosphorylation 
to aerobic glycolysis, a common feature of human cancer, results in a 
relative acidic tumor microenvironment which is further accentuated 
by hypoxia operating within most tumors. We report that alteration 
of extracellular pH induces marked and rapid changes of autophagic 
activity in a variety of cell lines including mammary non-transformed 
cells and breast cancer cells. Interestingly, acidic and basic conditions 
induce completely opposite effect on autophagy, with its activity 
suppressed at lower pH whereas stimulated at higher pH. Gene 
knockdown experiments indicate that pH induced-autophagy requires 
Beclin 1, Vps34 and ATG5, key components of the autophagy 
pathway. Of note, acidic condition not only inhibits the basal but 
also blocks starvation-induced autophagy activity. Significantly, 
examination of different areas of tumor mass reveals a lower 
autophagic activity within the inner region than the outer region. These 
findings have important implications on the connections between 
autophagy and cancer as well as a wide range of other physiological 
and pathological processes.
P5-07-04
Is a-L-Fucose Overexpressed on Cells of Aggressive Human 
Breast Cancers?
Listinsky JJ, Siegal GP, Listinsky CM. University of Alabama at 
Birmingham, Birmingham, AL; Case Western Reserve University, 
Cleveland, OH
Enzymatic removal of a-L-fucose (fucose) was shown over 20 
years ago to abolish metastases in vivo in a rat model of mammary 
adenocarcinoma [J Cell Biochem 1988; 37: 49-59]. Since that time, 
evidence has accumulated to indicate that fucose is a functional 
effector in human breast cancer; essential for construction of the 
invasive and metastatic phenotypes. In light of these findings, the 
role of fucose in aggressive breast cancers is worthy of further 
investigation.
Our group has modified the method of Wright et al. in order to 
selectively remove cell surface fucose from viable human breast 
cancer cells in vitro. In our experience, a 30 min incubation of 
breast cancer cells with a-L-fucosidase (3.2.1.51) leads to a loss 
of transformative abilities including decreased cancer cell adhesion 
to select extracellular matrix components, decreased invasion into 
complex extracellular matrices, decreased binding by relevant 
antibodies and lectins, and decreased adhesion of cells (rolling) to 
model endothelium under shear stress flow conditions.
From this work we postulated that decisive differences in phenotypic 
and functional properties between treated and control human breast 
cancer cells should be obtainable with currently available models 
of aggressive disease. To that end, we and others have subsequently 
shown that human breast cancer cells express cell surface CD44 which 
carries fucosylated ligands and that its’ defucosylation altered its’ 
malignant phenotype.. Based on these precedents, it is reasonable to 
hypothesize that CD44-enriched breast cancer stem cell populations 
require fucose in order to exert their aggressive behavior. Assays to 
assess the role of fucose in these stem cells are apparent and include a 
battery of tests involving stem cell invasion into extracellular matrices, 
cell binding of antibodies or fucolectins, stem cell aggregation into 
spheroids, colony formation in soft agar, assessment of stem cell 
rolling/adhesion to endothelial cells or purified E-selectin under 
both static or physiological flow conditions and the ability to initiate 
tumors upon inoculation into animal models.
We believe that new insights into aggressive breast cancer cell 
behaviors can be gained through the depletion of cell surface fucose 
from breast cancer cells. Knowledge gained from these studies should 
yield new insights when using current models of human breast cancer 
in vitro and in vivo.
P5-07-05
Hypoxic Mammary Epithelial Cells in Three-Dimensional 
Culture Develop a Cancer-Like Phenotype.
Vaapil M, Helczynska K, Påhlman S, Jögi A. Lund University, Sweden; 
Lund University
Due to inadequate vascularization and tumor cell proliferation solid 
tumors are hypoxic compared to corresponding normal tissues. Tumor 
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hypoxia has been associated with increased metastatic potential and 
worse patient outcome. The hypoxic response is mainly driven by 
the hypoxia inducible transcription factors; HIF -1a and HIF-2a.
We have reported that hypoxia leads to a less differentiated phenotype 
in breast cancer and neuroblastoma, and in the clinic low tumor cell 
differentiation is related to poor prognosis in these diseases. We have 
shown that high levels of HIF-2a protein correlate to distant metastasis 
and poor survival in invasive breast cancer. The aim of the present 
study was to investigate the effect of hypoxia on mammary epithelial 
cell differentiation and epithelial organization. We employed the well-
characterized model of acinar morphogenesis on extra cellular matrix 
substrate. In this model mammary epithelial cells that are cultured 
in three-dimensional culture on a laminin-rich matrix differentiate 
and form acini-like structures with evacuated lumen surrounded by 
polarized palisade cells. We found that hypoxia (1% oxygen) impaired 
the process of acinar morphogenesis and the hypoxic cells failed to 
obtain polarity and that markers of differentiation were affected at 
expression levels as well as cellular localization. The hypoxic cells 
remained proliferative whereas normoxic cells lost Ki-67 expression 
within a week. We found that hypoxia impaired the global histone 
deacetylation that has been shown by others to take place in the 
process of acini formation in mammary epithelial cells. Three days 
post-seeding, during the proliferation stage, both normoxic and 
hypoxic cells stained positive for acetylated histone 4. When the 
normoxic cells went through morphological changes and acinar 
formation, the acetylation of histone 4 was reduced whereas it was 
maintained in the hypoxic cell-clusters at day 10 post-seeding. Thus, 
the hypoxic conditions maintained the epithelial cells in an acetylated 
state, which is generally associated with an open chromatin structure, 
high level of transcription and an undifferentiated stage. These data 
indicate that hypoxia promotes loss of differentiation also at a non-
malignant stage and render the cells a cancer-like phenotype. We are 
currently extending this study in primary cells.
P5-07-06
Effect of Angiotensin-(1-7) and Angiotensin II on T47D Breast 
Cancer Cells in the Proliferation and cAMP Production.
da Silva IDCG, Correa-Noronha SSAA, Noronha SMR, Alecrim C, 
Shimuta SI, Nakaie CR, Gebrim LH, Nazario ACP. UNIFESP, São 
Paulo, SP, Brazil
Angiotensin-(1–7) [Ang(1–7)] is a peptide hormone that produces 
opposite responses to those of the well-characterized peptide 
angiotensin II (Ang II). The main actions of Ang(1-7) and AII occur, 
respectively, via MAS and Angiotensin type 1 receptor (AT1R), 
respectively. Ang (1-7) has blood pressure and proliferative effects 
contrary to those of AngII, exhibits significant antiangiogenic activity 
and may be a novel therapeutic agent for lung cancer treatment 
targeting a specific AT(1-7) receptor (Soto-Pantoja et al., 2009). 
Here, our aim was to evaluate T47D breast cancer cell proliferation 
and cAMP production after treatment with Ang (1–7) and AngII.By 
means of the cyclic AMP (cAMP) competitive enzymeimmunoassay 
system we measured cAMP content of T47D cells. Cell proliferation 
was measured using incorporation of BrdU after Ang (1-7) and AII 
stimulation. Intracellular cAMP increasing drugs like Forskolin (FK) 
and isobutylmethylxanthine (IBMX) were also used to stimulate 
T47D cells.AII inhibited cAMP production (-39%) and A-(1-7) 
increased its formation (48%). Pattern of cAMP production was not 
altered when cells were previously incubated with FK. Results were 
inverted after IBMX incubation. In proliferation, opposite responses 
were observed for Ang II and Ang (1-7), that is, increasing (7.6 times) 
and decreasing (7.5 times) proliferation rates respectively. Also both 
peptides decreased proliferation when cells were stimulated by FK. 
Exactly the opposite happened after IBMX stimulation, both peptides 
increased proliferation. These results suggest that Ang (1-7) inhibits 
growth of T47D cells probably through inhibition of the via RAS/
RAF/MAP quinase, what corroboraties previous findings. On the 
other hand, AngII can induce cell proliferation by an alternative via 
(CREB/ growth factor). Therefore, Ang (1-7) seems to be not only 
a promising target to develop novel lung cancer therapeutic drugs, 
but it also might help to prevent the molecular changes that lead the 
normal breast epithelial cells to cancer initiation.
Financial Support: FAPESP.
P5-07-07
Follistatin Suppresses In Vitro Growth of Breast Cancer Cells 
and Its Reduced Expression in Breast Cancer Associated with 
Poor Differentiation and Prognosis.
Ye L, Mansel RE, Jiang WG. Cardiff University School of Medicine, 
Cardiff, United Kingdom
Background: Bone morphogenetic protein (BMP) belongs to 
TGF-b superfamily, being widely involved in prenatal and postnatal 
development and homeostasis of various tissues and organs. 
BMP signaling has been implicated in tumorigenesis and disease 
progression of certain malignancies. Recent studies demonstrated a 
profound role played Noggin, a BMP antagonist in bone metastasis 
from breast cancer. Current study examined expression of Follistatin, 
another BMP antagonist in a breast cancer cohort, and its relevance 
to pathological and clinical parameters.
Methods: Expression of Follistatin was examined in breast cancer 
tissues (n=93) and normal background tissues (n=30) using 
quantitative real time PCR and immunhistochemistry (IHC). The 
breast tissue samples were collected immediately after surgery. 
The clinical follow-up was routinely performed after surgery. The 
median follow-up period was 120 months (June 2004). Full-length 
human Follistatin coding sequence was cloned into a plasmid 
vector. Following transfection and verification, effect of Follistatin 
overexpression on cell growth was examined using an in vitro growth 
assay.
Results: IHC revealed cytoplamic staining of Follistatin in mammary 
epithelial cells in breast tissues. The staining appeared to be weaker in 
breast cancer, but there was no significant difference in its transcripts 
levels compared with that of normal background tissues. Follistatin 
transcripts were decreased in both moderately differentiated and 
poorly differentiated tumors, p=0.0165 and p=0.0169 in comparison 
with well differentiated tumors respectively. Transcript levels of 
Follistatin in primary tumors tended to be lower in the patients 
with poor prognosis (33.8±14.7) including those patients had local 
recurrence, metastases and died of breast cancer, p=0.09 when 
compared with that of patients remained disease free (117.0±46.0). 
Its expression appeared particularly lower in the patients died of 
the disease (21.8±12.0), p=0.05 v.s. disease free. Over-expression 
of Follistatin exerted inhibitory effect on in vitro growth of MDA-
MB-231 cells.
Conclusions: Decreased expression of Follistatin in primary tumors 
of breast cancer correlates with poorer differentiation and mortality. 
Follistatin suppresses in vitro growth of breast cancer cells. It suggests 
that Follistatin is a negative regulator for tumor growth and disease 
progression of breast cancer.
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P5-08-01
Quantitative Analysis of Strain Ratio of Microcalcification 
Lesions with Surgical Specimen Mammography.
Hung S-H, Chen R-C, Wu Y-T, Chen T, Lin C-H. Taipei City Hospital, 
Taiwan; National Yang- Ming University, Taiwan
Measurement of the strain induced by compression can be useful in 
the diagnosis of breast tumors. Microcalcification (MC) detected by 
mammography could be the only symptom of early breast cancers. 
The purpose of this study was to develop a quantitative method for 
a differential diagnosis of MC lesions based on the strain ratio (SR) 
obtained by applying different breast compression pressure during 
mammography.
Methods: This prospective study was conducted with institutional 
review board approval and the written informed consent was 
obtained. Twenty-five mastectomy specimens (24 for treatment of 
breast cancer and 1 from contralateral prophylactic mastectomy) 
with MCs were examined by digital mammography. There were 
24 malignant MCs (mean size of 18.8 mm) detected in the 24 
separate specimens, including 14 lesions of invasive carcinoma 
and 10 lesions of carcinoma in situ. Five benign MCs (mean size 
of 21.6 mm) were detected, including four lesions which coexisted 
with malignant MCs in the four separate specimens, and one was 
discovered in the prophylactic mastectomy specimen. Each specimen 
experienced four different magnitudes of compression force and the 
corresponding images were acquired for further analysis. Images in 
Digital Imaging and Communications in Medicine format (DICOM) 
were exported into custom software, written in Matlab, to contour 
the region of interest. Stress was defined as the force divided by the 
whole specimen area, and the square root of MC area was calculated 
to represent strain deformation. The SR was the slope of the best-fit 
line through the four points of each lesion. Histology of the MC was 
correlated with SR. Receiver operating characteristic (ROC) curve 
analysis was performed to evaluate the diagnostic performance of SR 
for discrimination between benign and malignant MC.
Results: The SRs were higher in the malignant MC group (139.10 
a.u.) than in the benign MC group (34.09 a.u.; p = 0.024). The SR 
between invasive carcinoma and carcinoma in situ showed no statistic 
significance (127.03 a.u. vs. 156.00 a.u.; p = 0.642). The area under 
the ROC curve for the diagnosis of benign and malignant MC was 
0.825 (95% CI, 0.667 to 0.982).
Conclusion: This study demonstrated that the SR detected by 
mammography showed potential for distinguishing benign from 
malignant MCs. Further in vivo investigations of larger cohorts are 
necessary to validate these results.
P5-08-02
Mammographic Breast Texture Predicts Benign Biopsy Results 
and Composition.
Duewer FW, Kerlikowske K, Tlsty T, Fan B, Parvin B, Ma L, Shepherd 
J. UCSF, San Francisco, CA; LBNL, Berkeley, CA
Purpose: Investigate the relationship between pathology diagnosis, 
biopsy composition, and breast texture measured in digital 
mammogram in women who have had previous benign findings in 
their breast. The long-term goal of this project is to determine whether 
or not global breast texture is associated with tissue composition and 
biopsy results. Such a finding would be of interest because it would 
provide evidence that mammography images contain information 
related to breast biology beyond average density.
Materials and Methods: A total of 124 women who had previously 
received benign biopsies underwent an additional dual-energy/low 
dose full-field digital mammography (DXA) scan of the unaffected 
breast. Three measures of breast density (percent dense area (PD), 
percent fibroglandular volume (%FGV) , absolute fibroglandular 
volume (FGV) from mammogram, 15 biopsy types including apocrine 
metaplasia and non-secretory pituitary adenoma, and four tissue 
compositions (collagen percent area, fat percent area, ductal percent 
area, epithelial percent area) were estimated from biopsies for each 
participant. In addition 45 breast texture features were measured on 
each screening image taken during the dual-energy mammography 
using custom software. Tissue composition at the biopsy location 
was estimated based on the average percent area of stained collagen, 
fat, ductal, and epithelial from up to 3 slides taken from the biopsy. 
Pathology results from the three slides were taken to indicate the 
tissue type.
Results: Neither mammographic percent density, %FGV, nor 
FGV showed significant association with either biopsy type or 
tissue composition. However, some of breast texture features were 
significantly associated with tissue type and tissue composition. The 
strongest associations were found between collagen percent area 
and the neighborhood gray tone difference matrix texture strength 
(R=0.26, P=0.005) and ductal percent area and the gray level 
contrast matrix homogeneity (GLCM HOM) (R=-0.30, P=0.001). 
When classified according to biopsy type, the univariate association 
between ductal percent area and GLCM HOM for apocrine metaplasia 
increased. (R=-0.55, P=0.007)
Conclusion: 10 breast texture features of the unaffected breast were 
significantly associated with local tissue composition and biopsy type. 
Further study will be required to determine whether this association 
is related to masking effects related to breast complexity or changes 
in breast biology driving changes in breast morphology.
CLINICAL RELEVANCE
The use of texture measures as biomarkers of variations in breast 
biology is potentially clinically significant. This work indicates that 
texture measures are associated with some biological outcomes. It 
is possible that this work could be used to improve diagnostic utility 
of computer-aided diagnosis by weighting the probability of various 
benign outcomes according to the measured breast texture.
P5-08-03
How Reader’s Training, Software, and Image Formats Impact 
Percent Dense Area Measures.
Fan B, Duewer F, Wu FF, Kerlikowske K, Vachon C, Shepherd JA. 
University of California San Francisco, San Francisco, CA; Mayo 
Clinic College of Medicine, Rochester, MN
BACKGROUND: Mammographic percent dense area, the percent 
ratio of dense to total breast area in a mammogram, is one of the 
strongest measures of a woman’s risk of breast cancer. However, 
systematic differences have been observed between readers and 
mammography technologies (film and digital) that could cause 
clinically inconsistent associations with risk. The purpose of this study 
was to evaluate inter- and intra-reproducibility of percent dense area 
between readers and between film and digital technologies.
METHODS: One hundred digitized film mammograms were 
randomly selected with 25 films in each of quartile of percent 
density and read by two readers at two different sites (Mayo Clinic 
and UCSF). The readers had extensive experience and were also 
jointly trained at university of Toronto using Cumulus software. After 
training, all films were read twice with at least one year between 
duplicate readings. The Mayo clinic reading used Cumulus while 
UCSF used custom semiautomatic software to estimate total and 
dense tissue area. In addition, digitized films and unprocessed full 
field digital mammograms of the same women were assessed by one 
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reader. The time between the film and digital acquisitions ranged from 
nine to twenty-four months. Interclass correlation coefficient (ICC) 
was calculated for each comparison.
RESULTS: The intra- and inter-observer ICCs, consistency for 
film images, were 0.96 (UCSF) and 0.97 (Mayo), and 0.96 (UCSF 
vs. Mayo). We found ICC between film and digital mammograms 
for percent dense area was 0.88. The digital mammogram had 9% 
significantly higher total breast area and 5% significantly lower 
percent density area compared to film.
CONCLUSIONS: Similarly trained readers had a high reproducibility 
regardless of the software used. Our results suggest centralized reader 
training should enable pooling of film breast density results from 
different clinics. However, pooling film and digital results would 
need careful calibration due to lower measured percent dense areas 
than on film.
P5-08-04
Mammographic Microcalcifications and Breast Cancer 
Tumorigenesis: A Radiologic-Pathologic Analysis.
Naseem M, Murray J, Hilton JF, Han D, Hogeveen S, Heersink 
RL, Muradali D, Simmons C, Bell D, Haq R, Brezden-Masley C. 
St. Michael’s Hospital, Toronto, Canada; University of Toronto, 
Toronto, Canada
Background: Microcalcifications (MCs) are tiny deposits of calcium 
in breast soft tissue. They serve as key diagnostic radiological 
features for localization of malignancy. Approximately 30% of 
early invasive breast cancers have fine, granular MCs detectable on 
mammography; however, their role in breast cancer tumorigenesis 
is currently unknown. The purpose of this study was to investigate 
the relationship between mammographic MCs and breast cancer 
pathology. Methods: A retrospective chart review was performed 
for 882 women treated for breast cancer between 2000-2010 at St. 
Michael’s Hospital. Demographic information (age and menopausal 
status), tumor pathology (size, histology, grade, nodal status and 
lymphovascular invasion), hormonal status (ER and PR), HER-2 
overexpression and presence of MCs were collected for breast cancer 
patients. Chi-square tests were performed for categorical variables 
and t-tests were performed for continuous variables. All tests were 
two-sided and p-values less than 0.05 were considered statistically 
significant. Results: A total of 826 patient charts were included; 
56 (6.4%) patients had metastatic carcinoma and were excluded 
from analysis. Only 37.0% (326/882) of the patients presented with 
mammographic MCs. Patients were more likely to have MCs if they 
were HER-2 positive (51%) as opposed to being HER-2 negative 
(33.4%) (p=0.001). There was a significant association between MCs 
and being perimenopausal with a mean age of 50 (65.2%) (p=0.012). 
Patients with invasive ductal carcinomas (39.7%) were more likely 
to present with MCs than were patients with other tumor histology 
(p=0.001). There was a positive correlation between MCs and tumor 
grade (p=0.051), with grade III tumors (41.85%) presenting with 
the most MCs, followed by grade II (37.95%) and grade I (29.8%). 
There was no significant association between mean age, mean tumor 
size, ER and PR status with the presence of MCs. Conclusion: 
This is the largest study that suggests the appearance of MCs on 
mammograms is strongly associated with HER-2 overexpression, 
invasive ductal carcinoma and perimenopausal status. Since HER-2 
is implicated in mediating aggressive tumor growth and metastasis, 
future studies should investigate the molecular pathways underlying 
HER-2 overexpression and MC development. This would help better 
understand the role of MCs in breast cancer tumorigenesis.
P5-08-05
Withdrawn by Author
P5-08-06
Comparison of Mammographic Density between Ductal 
Carcinoma In Situ and Benign Breast Disease.
Lee JW, Shin EJ, Yi OV, Lee JW, Shin HJ. Asan Medical Center, 
Seoul, Korea
Background:
High breast density is an independent risk factor for breast cancer as 
well as benign breast diseases. However there are few studies about 
breast density of ductal carcinoma in situ (DCIS) and benign breast 
disease(BBD). In this study, we investigated patterns of breast density 
of DCIS and BBD, and comparatively analyzed breast densities of 
DCIS and BBD.
Material and Methods
From 2008 to 2009, 345 patients underwent surgery for DCIS at Asan 
Medical Center, and 295 patients for BBD at 2010. We retrospectively 
reviewed each groups and estimated cranio-caudal view of digital 
mammogram of unaffected breast by computer-assisted thresholding 
methods, using Cumulus 4, version 4.0. For BBD we included atypical 
ductal hyperplasia, fibroadenoma, papilloma(atypical/intraductal), 
phyllodes tumor(benign/borderline), and excluded unavailable 
mammogram(mostly, because of scanned films from outside hospitals 
and previously diagnosed breast cancer).
Results
Mean ages of each group were 46.51 year old in DCIS group and 
41.43 year old in BBD group, and the mean percentage density(PD) 
were 44.89% and 45.27%, respectively.
Mean PD of the BBD group and the DCIS group
 N Mean(%) SD P-value
BBD group 295 45.27 17.26 0.79
DCIS group 345 44.89 18.84  
There was no significant difference between two groups in total 
population(p=0.79). We categorized into two groups according to the 
age, ≥50 and <50, for each DCIS and BBD group. Mean percentage 
density of below 50 year old was 52.92% in DCIS gruop and 49.58% 
in BBD group(p=0.031). Mean percentage density above 50 year old 
was 33.67% in DCIS group and 33.29% In BBD group(p=0.867).
Mean PD of each group in the subgroup aged under 50 and over 50
Disease entity Age Mean PD(%) SD P-value
Benign breast diseases <50 49.58 15.54 0.031
DCIS <50 52.92 16.05  
Benign breast diseases ≥50 33.29 16.20 0.867
DCIS ≥50 33.67 16.62  
Conclusion
The mean values and distribution patterns of PD were similar between 
BBD group and DCIS group. However, in the subgroup aged under 
50, the DCIS group has significantly higher breast density than the 
BBD group. Although the causal association of breast density with 
breast cancer has been relatively well documented, this kind of cross-
sectional study has an inherent limitation. The absolute difference 
between the DCIS group and the BBD group under age 50 (3.34% in 
table2) needs more investigation for its clinical implications.
P5-09-01
Breast Cancer Annual Screening Program Núcleo Mama Porto 
Alegre (NMPOA): Imaging Results after Seven Years.
Caleffi M, Amaral C, Zignani J, Graudenz M, Duarte Filho D. 
Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil
Introduction:The NMPOA cohort started in 2004 with the purpose 
of testing a breast screening model for underserved women in limited 
resource countries. In the city of Porto Alegre (South Brazil with 
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1.5 million population), breast cancer incidence rate is 127/100.000 
(Brazilian NCI,2010) with increasing mortality due to 45% of Stage 
III and IV and no public health care early detection program, it was 
mandatory to test the feasibility of an organized screening program 
for women with very low income and level of education (64% under 
6 years of schooling). In this scenario, there was always a concern of 
over diagnosis that will increase costs (more biopsies and surgeries) 
and under diagnosis by the radiologists involved in the program. We 
present here the results of all breast biopsies performed in this period, 
and its correlation with the attributed BI-RADS classification in order 
to optimize care and costs. Also, this study has a long term proposal 
and other results have been published concerned to the baseline 
profile of the population (Cancer Epidemiol Biomarkers Prev. 2010 
Oct;19(10):2673-9. Epub 2010 Aug 17).
Methods:Since April 2004, 5592 women from 40 to 69 years were 
enrolled in the program and underwent to clinical breast exam and 
annual mammography screening at NMPOA. Initially, lesions were 
classified as B1, B2 or B0. After complementary views or exams, 
B0 was classified as B3, B4 (A, B or C) or B5. B4 and B5 were 
considered positive tests and immediately submitted to biopsy (open 
surgical or ultrasound guided core biopsy). B3 was followed according 
to recommended in BI-RADS fourth edition, and subsequently 
classified as benign (annual follow up) or suspicious findings (biopsy 
performed). The evaluation included histological analysis of breast 
biopsy specimens by two independent pathologists. Predictive 
positive value (PPV), predictive negative value (PNV) and accuracy 
(Acc) were calculated.
Results
BIRADS n(Biopsy) Malign % Benign %
3 37 1 2,7 36 97,3
4(A,B and C) 60 28 46,7 32 53,3
5 33 31 93,9 2 6,1
Results:A total of 259 breast lesions were initially classified as BI-
RADS 0 (recall rate of 2.8%), and further classification of these was: 
166 B3 (64.1%), 60 B4 (23.2%) and 33 B5 (12.7%). Thirty seven B3 
(14.3%) were considered suspicious after 6 months and submitted 
to biopsy. Correlation results of the 130 biopsies performed are 
summarized on [Table1]. PPV of 63.4% (52.8%-73.1%), PNV of 
97.3% (85.8%-99.9%) and an Acc of 73.1% were observed. In this 
sample, 71.7% of BC were ductal invasive carcinoma, 11.7% ductal 
carcinoma in situ, 5% lobular invasive carcinoma and 11.6% were 
other types of neoplasia.
Conclusion:Recall rate is in accordance with the medical audit 
benchmarks recommended of less than 10% published in BI-RADS 
fourth edition. NMPOA is model for limited resource countries 
in breast cancer imaging diagnosis. The radiologists involved in 
the program are classifying breast lesions in accordance with the 
established parameters, with a high accuracy in diagnosis. Even 
though we are dealing with a poorly educated cohort not used to any 
form of screening, our adherence is 57% in 12 months and 71% in 
24 months.
P5-09-02
Reducing Excess Biopsies: Improving Screening through Risk 
Stratification and New Thresholds for Intervention.
Kim DN, Kim J-H, Flowers CI, Elias S, Moore DH, Esserman LJ. 
Athena Breast Health Network, San Francisco, CA; Moffitt Cancer 
Center, Tampa, FL; University Medical Center Utrecht, Utrecht, 
Netherlands; University of California, San Francisco, CA
Background
BI-RADS Category 4 patients have a 2-95% risk for malignancy and 
are generally recommended for breast biopsy with little discrimination 
for risk level or distinction between risk of invasive or in situ disease. 
Our study sought to determine if higher thresholds for biopsy based on 
stratifying for risk and distinguishing between risk of invasive cancer 
and DCIS could reduce biopsy rates and increase cancer-to-biopsy 
yields without missing cancers urgent for resolution.
Methods
108 BI-RADS 4 cases with final outcomes data were evaluated from 
a prospective cohort of 215 consecutive patients seen at a same-
day multidisciplinary breast clinic for women with mammograms 
categorized as BI-RADS 0, 4, or 5 in 2006-07. Final outcomes 
were determined from pathologic diagnosis or two-year follow-up. 
Risk estimates (RE) for DCIS and invasive cancer were collected 
prospectively and re-assessed by a radiologist blinded to outcomes 
and prior reading assessments. Cases were stratified according to the 
risk ranges of the BI-RADS 4 subcategories and risk of invasive or 
in situ disease. Biopsy rates, cancer-to-biopsy yields, and number 
of malignancies missed were calculated for various thresholds for 
intervention.
Results
A ROC curve for invasive cancer risk for the radiologist demonstrated 
a 98.5% level of accuracy (95% confidence interval [CI]: 96.9%, 
100%). 60 cases had some risk for invasive cancer and 48 had some 
risk for DCIS. There were 14 invasive cancer and 11 DCIS outcomes, 
3 of which were high-grade. Pathologic assessment from biopsy or 
surgery was available for 100 patients. The outcomes of 8 cases were 
determined by benign two-year follow-up.
There are several strategies for intervention that improve biopsy yield 
and reduce biopsies for benign disease as shown in Table 1.
Thresholds for Intervention
Biopsy Recommended for: Biopsy Rate
Cancer-
to-Biopsy 
Yield
Invasive Cancers 
Missed
% Invasive Cancers 
Missed
All BI-RADS 4 100% 23% 0 0%
10% ≤ Invasive Cancer RE < 95% 
10% ≤ DCIS RE < 95%
78% 30% 0 0%
10% ≤ Invasive Cancer RE < 95% 
50% ≤ DCIS RE < 95%
48% 39% 1 7%
If cases with RE between 2-10% for DCIS or invasive cancer were 
not biopsied, 23% of biopsies would be avoided and the yield would 
increase to 30%. If cases with invasive cancer RE between 10-95% 
and DCIS RE between 50-95% were biopsied, 52% of biopsies would 
be avoided and the yield would increase to 39%. One invasive ductal 
carcinoma (3 mm, Grade 2) would be missed, although with six-month 
follow-up, this would not be a problem.
Limitations
Small sample size; one radiologist providing RE may not be 
representative of general mammographic assessment.
Conclusion
Setting higher biopsy thresholds for BI-RADS 4 lesions can safely 
reduce biopsy rates and increase biopsy yields. Given evidence 
suggesting that low/intermediate grade DCIS may be overdiagnosed, 
distinguishing between DCIS and invasive cancer risk at screening by 
offering active surveillance as an alternative to biopsy for BI-RADS 
4 lesions suspicious for non-high-grade DCIS may be a promising 
approach for reducing biopsies. This will be prospectively tested in a 
reader study using several radiology readers in a series of 750 cases 
in the Athena Breast Health Network. New biopsy thresholds can be 
set if the results of our study can be validated.
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P5-09-03
Health Literacy Affects Use of Screening Mammography in an 
Underinsured Population.
Komenaka IK, Nodora J, Hsu C-H, Machado L, Klemens AE, Zenuk 
R, Bouton ME, Martinez ME, Weiss BD. Maricopa Medical Center, 
Phoenix, AZ; University of Arizona, Tucson, AZ
Background: In late 2009 significant controversy arose when some 
screening recommendations were changed to advocate screening 
mammography starting at age 50 rather than the long standing 
recommendation of starting at age 40 years. Few would argue, by 
contrast, that patient compliance with screening mammography, 
starting at either 40 years or 50 years, is at optimal levels. National 
data indicate that many more lives would be saved by improving 
compliance with screening recommendations in individuals >50 
than would be saved with screening individuals age 40-50 years. 
The current study was performed to determine if health literacy was 
associated with use of screening mammography in an underinsured 
population.
Methods: Maricopa Medical Center is the county safety net hospital 
in Phoenix, Arizona. 944 patients were seen at the Breast Clinic from 
January 2010 to January 2011. 638 were at least 40 years old and 
therefore candidates for screening mammography. Sociodemographic 
variables were collected. Use of mammography was asked of patients 
and checked by medical records. Health literacy was assessed using 
the Newest Vital Sign (NVS) validated screening instrument, which 
categorizes health literacy on 6-point scale as low health literacy likely 
(0-1 point), low health literacy possible (2-3 points), or health literacy 
adequate (4-6 points). Differences in patient characteristics were 
evaluated based on a Fisher’s exact test for categorical variables and 
one-way ANOVA for continuous variables. Multivariate analysis was 
then performed to determine which patient factors were associated 
with use of screening mammography.
Results: Among women 40 years or older, only 35% used routine 
screening mammography. For women 50 years or older, 38% 
underwent screening mammography. Among women 40 years or 
older and those 50 years or older, significantly more with health 
literacy adequate (NVS 4-6) obtained screening mammography 
than did women in the two lower literacy (NVS 0-1 and 2-3) 
groups (40+: 65% vs. 30% and 30%, p = 0.001. 50+: 65% vs. 33% 
and 37%, p = 0.001). Multivariate analyses adjusted for insurance 
status, employment, white race, Hispanic ethnicity, marital status, 
language, use of alcohol, family history, NVS and education level 
demonstrated that patients with adequate health literacy were more 
likely to use screening mammography (OR 3.66; 95% CI 2.14 – 6.27; 
p < 0.01) than patients in the two lower literacy groups. Similarly, 
uninsured patients were significantly less likely to undergo screening 
mammography (OR 0.57; 95% CI 0.38 – 0.86; p = 0.01) than those 
with insurance. Patients with adequate health literacy and insurance 
were (OR 8.61) more likely to use screening mammography than 
patients who were uninsured and were in the two low literacy groups. 
Patient race, ethnicity, language, employment, income, education 
level, and family history of breast cancer were not associated with 
use of screening mammography in this underinsured, undereducated 
population.
Conclusions: Use of screening mammography was poor in this 
underinsured population. Limited health literacy and lack of insurance 
are risk factors for failure to obtain mammography. Interventions to 
increase use of screening mammography among uninsured patients 
with limited health literacy are needed.
P5-09-04
Predictors of Malignancy and Surgical Outcomes Following 
Indeterminate Core Needle Biopsy in the British Breast Screening 
Programme.
Gillespie HS, Lowry K, Somerville J, McIntosh SA. University of 
Aberdeen., Foresterhill, Aberdeen, Aberdeenshire, Scotland, United 
Kingdom; Belfast City Hospital, Belfast, County Down, United 
Kingdom
Background: The National Health Service Breast Screening 
Programme (NHSBSP) invites women between 50 and 70 years for 
mammography every three years, with abnormal imaging leading 
to further assessment. Core needle biopsy (CNB) is the standard for 
obtaining a definitive pre-operative diagnosis. However a proportion 
of CNBs will be reported as showing indeterminate pathology, with 
uncertain malignant potential. This necessitates surgical diagnostic 
excision biopsy, with attendant potential morbidity, and highlights the 
importance of pre-operative diagnosis. This study aimed to categorise 
the histological lesions prompting B3 classification arising within a 
screening programme, and to quantify the definitive surgical outcomes 
following excision biopsy.
Material and Methods: Data was collected retrospectively from 
January 2000 – December 2010, including demographic details, 
radiological presentation, relevant clinical findings, results of pre-
operative investigations, reports of diagnostic excision biopsy and 
subsequent surgical management. Patients were included if they had a 
B3 CNB result and subsequent excision biopsy, following attendance 
for screening mammography. Primary outcome was classification 
of B3 lesions and positive predictive values (PPV) for malignancy. 
Secondary outcomes were subsequent surgical procedures.
Results: There were 239 B3 lesions, representing 7.1% of all CNB 
carried out within the screening programme. Mean patient age was 
55.6 years, and median lesion size was 14.5 mm (range: 4-25mm). 
Eighty seven lesions (36.4%) were malignant on excision: 28 (11.7%) 
invasive and 52 (21.8%) in situ. Lesion specific PPVs for malignancy 
were as follows: phyllodes tumour 50.0%, atypical ductal hyperplasia 
40.0%, columnar cell lesion 40.0%, papillary lesion 26.7%, lobular 
neoplasia in situ 26.7%, and radial scar/complex sclerosing lesions 
(RS/CSL) 25.9%. The PPV of RS/CSL with atypia was 65.2%, and 
without 25.8%. Of 87 malignant cases, 55 (63.2%) went on to have 
a further surgery. 27 (50.9%) had re-excision of surgical margins, 
10 (18.2%) had a mastectomy, 8 (14.5%) had a wide local excision, 
2 had an axillary biopsy and one patient had a quadrantectomy. 18 
patients had two further operations, the second was most commonly 
an axillary clearance, and 3 patients had three further operations.
Discussion: B3 lesions are heterogeneous in nature, and continue 
to mandate surgical excision, demonstrated by a PPV of 36.4%, the 
highest reported figure in the literature to date. B3 CNB represents 
a significant surgical workload, demonstrated by the fact that 63.2% 
cases go on to have further surgery, and that 8.8% will require 
more than one further operation. Currently there is no pre-operative 
investigation that reliably predicts the likelihood of B3 associated 
malignancy. It has been demonstrated that the use of large volume 
vacuum assisted biopsy can reduce the rate of under diagnosis of both 
in situ and invasive malignancy, and this would clearly reduce the 
requirement for repeated surgery reported in this study.
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P5-09-05
Non-Palpable Lesions Findings in a Breast Cancer Opportunistic 
Screening in South Brazil.
Rockenbach R, Rombaldi RL, Caleffi M. HospitaL Geral, Caxias do 
Sul, Rio Grande do Sul, Brazil; Hospital Moinhos de Vento, Porto 
Alegre, Rio Grande do Sul, Brazil
Introduction: Today breast cancer is a major public health challenge 
in developing countries with increasing mortality rates due to the 
lack of early detection programs and access to care. Mammography 
has been considered the most sensitive test for breast non-palpable 
lesions. The Brazilian National policy recommends mammography 
from age 50 and every two years. This study investigates only 
radiological findings in a set of women seeking for long term breast 
care surveillance. Objectives: To evaluate patients characteristics of 
cases with non-palpable breast lesions.
Material and method: A prospective and transversal study was 
undertaken between March,2009 and April,2010 on 110 women 
with non-palpable breast lesions, diagnosed by mammography or 
ultrasound. Histo-pathological evaluation was performed in core 
biopsy specimen. The following variables were studied: pregnancy, 
parity, menarche, menopause, hormone replacement therapy, breast 
lesion location, tumor size, histopathology findings, mammographic 
and ultrasound classification – BI-Rads.
Results: 23,7% (n=26/110) out of 110 women were diagnosed 
with breast cancer and 76,3% (n=84/110) were diagnosed with 
benign mammary pathology. Mammography, according BIRads 
classification, strongly suggested (p<0,000) the presence of benign 
and malign pathologies. In the breast cancer group, 14 were diagnosed 
with stage 1 (TNM), compared to the official data from INCA where 
stage I is 10% of the cases.
Age range of non-palpable breast lesions (n=110)
 Group 1* (n=26)  Group 2** (n=84)  p***
 nº % nº %  
20-29 years - - 2 2,4 0,651
30-39 years 2 7,7 14 16,7  
40-49 years 9 34,6 29 34,5  
50-59 years 9 25,7 26 31  
> 60 years 6 23,1 13 15,5  
Mean 52+-10,8  49,2+-2  0,153
Group 1 – patients with breast cancer. **Group 2 – patients with benign pathologies. ***p<0,05. 
Conclusion: Mammographic screening reduces mortality by 30% 
after 50 years of age and also provides important benefit (20%) in 
younger women (40-49). Our study showed a cancer detection rate 
of 25,7% and 34,6%, respectively, demonstrating the importance of 
screening also in younger ages. Overall, the rate of biopsy positive was 
very satisfactory (1 out of 4 cases). Among the studied non-palpable 
breast lesions, our findings resulted in 53.8% stage I breast cancers 
(TNM) which reinforces the urgent need of a structured screening 
program in Brazil to save more lives.
Financial support: Avon Institute.
P5-10-01
Metabolic Pharmacodynamic Effect Evidenced by 18FDG-PET 
as a Tool for Early Prediction of Iniparib Efficacy in Metastatic 
Triple Negative Breast Cancer (MTNBC): A Proof of Concept 
Study.
Kerrou K, Gligorov J. Eastern Paris University Hospitals, APHP 
Tenon, Paris, France; Eastern Paris University Hospitals, APHP 
Tenon - APREC, Paris, France
Rationale :
It was hypothesised that Iniparib or 4-iodo-3-nitrobenzamide acts as 
an irreversible inhibitor of PARP1 and possibly other enzymes. It has 
shown successively promising then confusing results in MTNBC in 
combination with chemotherapy. To date, its mechanism of action has 
not been completely elucidated but since 1992, inhibition of glycolysis 
by iniparib and subsequent necrotic cell death has been described.
We hypothesised that early inhibition of glycolysis evidenced by 
in-vivo imaging with 2-((18)F)Fluoro-2-Deoxy-D-Glucose Positron-
Emission Tomography (18FDG-PET) may be a predictor of efficacy 
to iniparib, as it was previously reported for other anticancer drugs.
Objectives :
To detect metabolic pharmacodynamic effect of iniparib plus 
chemotherapy by means of 18FDG PET and proof the concept of 
its use as an early predicitive tool of Iniparib efficacy in MTNBC.
Patients & Methods :
From March to November 2011, 8 pts were included in our institution 
in a randomized phase II study comparing bi-weekly versus weekly 
iniparib treatement in combination with gemcitanine and carboplatin. 
All patients had 18FDG-PET at baseline, at day 7 (D7). The maximum 
value of standardized uptake value (SUVmax) of all measurable 
metastatic lesions was measured and the median SUVmax was 
calculated for all patients at baseline and D7. The metabolic response 
was defined as the percentage of reduction of SUVmax (SUVmax 
Baseline – SUVmax D7) / SUVmax Baseline and the median 
SUVmax response was correlated to RECIST 1.1 response at six 
weeks and to disease-free survival (DFS).
Metabolic response, RECIST1.1 and DFS in the study population
Patient Age median SUVmax response
RECIST1.1 at 
week 6
Best Obtaines response during 
treatment period DFS (days)
1 42 -39.5% PR PR 126
2 57 -51.4% PR CR 433
3 66 -23.4% PR CR 333
4 32 -35.5% PR PR 84
5 41 +3.6% PD PD 49
6 43 -14.5% SD SD 84
7 64 -21.8% SD PR 210
8 38 -36.4% SD PR 204
Disease Free Survival (DFS), Progressive Disease (PD), Stable Disease (SD), Partial Response (PR), 
Complete Response (CR)
Results:
The median decrease in SUVmax of evaluable lesions measured at 
D7 was predictive of RECIST 1.1 response at six weeks and was 
correlated to the best obtained response during the treatment phase. 
Furthermore, it showed a linear correlation with DFS (y = -0,0007x 
- 0,1325; R2 = 0,3402).
Conclusion:
Metabolic pharmacodynamic effect as evidenced by 18FDG PET 
as soon as one week of treatement act as an early predicitive tool of 
Iniparib plus chemotherapy efficacy in MTNBC.
Considering the lack of a predicitive biomarker of response and if 
confirmed on larger study, 18FDG PET could be used as a surrogate 
predictive biomarker is this setting.These results may be considered as 
an in-vivo proof of concept for the inhibition of glycolysis by iniparib.
P5-10-02
Relevance of Magnetic Resonance Imaging To Predict Disease-
Free Survival after Neoadjuvant Chemotherapy of Breast Cancer.
Loo CE, Vrancken Peeters M-JTFD, Wesseling J, Gilhuijs KGA. 
NKI-AVL (Netherlands Cancer Institute - Antoni van Leeuwenhoek 
Hospital), Amsterdam, Netherlands; University Medical Centre 
Utrecht, Utrecht, Netherlands; NKI-AVL, Amsterdam, Netherlands
Purpose:
To explore the relevance of magnetic resonance imaging (MRI) to 
predict disease free survival (DFS) after neoadjuvant chemotherapy 
(NAC) of breast cancer.
Patients and Methods:
Between July 2000 and December 2007, MRI examinations were 
performed in 188 women before, during and after NAC in the context 
of a single-institution review board approved study. Patients were 
consecutively included after informed consent. Interpretation of MRI 
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was revised by an experienced breast MR radiologists and included 
assessment of lesion morphology, changes in morphology, size, and 
contrast uptake kinetics (initial and late enhancement).
MRI features and known prognostic markers of breast cancer 
(age, tumor response at pathology, tumor size at baseline, 
immunohistochemistry-derived breast cancer subtype (triple-
negative; HER2-positive or ER-positive/HER2-negative)) were 
correlated with DFS. Multivariate Cox regression analysis was used 
with forward LR feature selection. Kaplan Meier curves were obtained 
to explore the impact of relevant associations.
Results:
Follow-up data were available of 184 women. The median follow-up 
time was 57,6 months (range 32,4 – 125). In 30 women events were 
found (26 breast cancer related deaths; 29 distant metastasis and 12 
local/regional recurrences).
At multivariate analysis, only breast cancer subtype (p=0.004) and 
largest diameter of late enhancement at MRI after NAC (p=0.006) 
retained prognostic value in favour of response at final pathology, age 
and tumor size at baseline. Cumulative survival at 60 months (kaplan-
meier curves) was 70%, 86.7%, and 89.7% for triple-negatives, 
HER2-positive and ER-positive/HER2-negative subtypes [figure 1], 
respectively, and 88.5%, 81.4 % and 55.1% for absence of washout/ 
plateau after NAC, between 0 and 30 mm washout/plateau, and ≥ 30 
mm washout/plateau, respectively [figure 2].
Conclusions
MRI after NAC in conjunction with breast cancer subtype has 
potential as complementary predictor for DFS. Larger diameters of 
residual late enhancement at MRI after NAC are associated with 
inferior DFS at 60 months.
P5-11-01
The Accuracy of Preoperative Ultrasonography Guided Vacuum-
Assisted Breast Biopsy in Determining Histological Type, ER 
Status, PgR Status, HER2 Status and Ki67 Level in Invasive 
Breast Cancer.
Fujita T, Sawaki M, Hattori M, Kondo N, Horio A, Ushio A, Gondo 
N, Adachi E, Iwata H. Aichi Cancer Center Hospital, Nagoya, Japan
Background: Recently, ultrasonography guided vacuum-assisted 
breast biopsy (US-guided VABB) has been widely used as alternative 
to surgical open biopsy. Enough breast tissue samples obtained by 
US-guided VABB are important because of increasing neoadjuvant 
treatment. Although the information obtained from US-guided 
VABB may be the only information available for determining the 
candidates for neoadjuvant treatment, only few studies evaluated 
the concordance of histological type, estrogen receptor (ER) status, 
progesterone receptor (PgR) status, human epidermal growth factor-2 
(HER2) status, and Ki67 level between US-guided VABB and surgical 
specimen. The aim of this study was to evaluate the accuracy of 
preoperative US-guided VABB.
Materials and Methods: In 439 breast cancer patients without 
neoadjuvant treatment who underwent US-guided VABB and surgical 
resection from April 2004 and March 2011 at Aichi Cancer Center 
hospital, we examined the concordance of Histological type, ER 
status, PgR status, HER2 status, and Ki67 level between US-guided 
VABB and surgical specimen. All the US-guided VABB were 
performed using 11-gauge Mammotome® or 10-gauge VACORA®.
The ER and PgR status were assessed using Allreds scoring system 
by IHC. These statuseswere categorized as positive when the total 
score was more than two. HER2 expression status was tested by IHC 
and FISH. HER2 3+ by IHC, or 2+ and FISH positive were judged 
as HER2 positive. In this study, the Ki67 cut-off level for positivity 
was defined at 20% (Penault-Llorca et al, JCO 2009).
The agreement on histological type, ER status, PgR status, HER2 
status, and Ki67 level were tested using the absolute concordance 
rate and the kappa statistic values.
Results: The concordance rate of histological types between US-
guided VABB and surgical specimens was 93.4% (410 of 439 cases) 
with a Kappa statistic value of 0.82. In 115 cases diagnosed as DCIS 
by US-guided VABB, 28 cases (24.3%) were subsequently diagnosed 
as invasive cancer by surgical specimens. However, among these 
cases, 78.6% (22/28) were T1mic and T1a. And one case (0.3%, 
1/324) diagnosed as invasive cancer by US-guided VABB changed 
DCIS by surgical specimens. The concordance rate of ER, PgR, 
and HER2 status were 96.6% (112/116), 89.5% (102/116), and 
97.4%(113/116), respectively (kappa statistic value of 0.99, 0.76, 
and 0.90). In HER2 status, the concordance rate between US-guided 
VABB and surgical specimens was better than between core needle 
biopsy and surgical specimens (the concordance rate: 88%, kappa 
statistic value: 0.65, Usami et al, Jpn J Clin Oncol 2007).
The agreement of Ki67 level was 85.7% (24/28) with a Kappa statistic 
value of 0.71.
Conclusions: The judgment of histological type, ER status, and 
HER2 status by preoperative US-guided VABB can be used with 
confidence due to determine the treatment strategies according to 
molecular subtype.
P5-11-02
Prediction of Results of MammaPrint’s 70 Gene Signatures by 
Conventional Histopathological and Biological Approaches in 
Patients with Breast Cancer.
Moinfar F, Luschin-Ebengreuth G, Tsybrovskyy O, Regitnig P, 
Mannweiler S, Ratschek M, Bjelic-Radisic V, Pristauz-Telsnigg G, 
Bader A, Seitz G. Medical University of Graz; Sozialstiftung Bamberg
Background: Several studies have shown that MammaPrint’s gene 
signatures allow prognostic stratification of breast cancers that 
is superior to the currently used clinico-pathological risk factors. 
MammaPrint has also been reported to predict chemotherapy 
response. The aim of this study was to find out whether conventional 
histopathological and biological approaches can be used to predict 
MammaPrint results.
Materials and Methods: 96 invasive breast carcinomas were studied 
(of them, 34 cases with positive lymph nodes). For MammaPrint, fresh 
material from breast carcinomas was sent to Agendia (Amsterdam) 
in the provided RNA-laters. Conventional assays included: (i) 
nine histopathologic parameters combined according to a so 
called “Graz Risk Assessment” scheme (“GRA”, see below), (ii) 
immunohistochemistry for MIB-1 (Ki-67) as the “only parameter”, 
(iii) Nottingham Prognostic Index (NPI), (iv) uPA/PAI-1 (Elisa, 
cut-off for uPA: 3 ng/mg, cut-off for PAI-1:14 ng/mg), and (v) flow 
cytometry (either >6% or >10% for SPF). The “GRA” consisted of 
4 “main” factors (high nuclear grade, MIB-1 >20%), Her2/neu pos. 
(immunohistochemistry or FISH), vascular invasion (either lymphatic 
or blood vessels) or lymph node metastasis) and 5 “minor” factors 
(ER neg., PR neg., p53 >10%, tumor necrosis and age > 40 y.o.). 
Tumors were classified as high risk when at least 4 parameters or 2 
“main” factors were present. For MIB-1 scoring, at least 500 cancer 
cells were counted in each case. Different MIB-1 cut-offs (10%, 15%, 
20%, 25%, and 30% or more) were tried. All analyses were performed 
independently and the results of each method were blinded. Overall 
accuracy, sensitivity, specificity, positive predictive value (PPV), 
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and negative predictive value (NPV) of conventional assays were 
calculated. The “best” combination of the assays was evaluated by 
multivariate logistic regression.
Results: Significant association with MammaPrint on univariate 
analysis showed “GRA” (p=8.2e-09), MIB-1 (p=1.1e-08 at 10% 
cut-off), NPI (good vs. moderate + poor prognosis, p=0.001) and 
flow cytometry (p= 0.012 for 10% cut-off and p=0.024 for 6% cut-
off for SPF). uPA/PAI, uPA alone, or PAI alone did not correlate 
with MammaPrint (p-value: 0.22, 0.28, and 0.27, resp.). The overall 
accuracy, sensitivity, specificity, PPV, and NPV of “GRA” were 79%, 
72%, 86%, 83%, and 77%, resp. MIB-1 >10% as “only parameter” 
showed overall accuracy of 78%, sensitivity of 87%, specificity of 
70%, PPV of 73%, and NPV of 85%. With increasing MIB-1 cut-
off, its predictive value dropped continuously. The accuracy of NPI 
and flow cytometry was poor. On multivariate analysis, only “GRA” 
and MIB-1 >10% were significant (p-value: 0.011 and 0.017, resp.).
Conclusion: The overall accuracy of histopathologic and 
immunohistochemical assessment in predicting the results of 
MammaPrint is almost 80% when using “Graz Risk Assessment” 
(“GRA”), closely followed by MIB-1 (at 10% cut-off) with the overall 
accuracy of 78%. By adjusting cut-off values for either MIB-1 or 
“GRA” it might be possible to reliably stratify the vast majority of 
breast cancers into low and high risk groups without MammaPrint, 
whereas MammaPrint would be required only for a minority of 
“uncertain” tumors.
P5-11-03
Real-Time Imaging of Human Breast Tissue with Reflectance 
Confocal Microscopy: Correlation with Routine Pathology.
Fogarty SP, Shiffert MT, Berezowski K, Hartmann D, Cabrera MC, 
Sidawy MK, Furth PA, Liu MC. Georgetown University, Washington, 
DC
Background: Near-infrared reflectance confocal microscopy 
(RCM) allows for immediate noninvasive 3-D optical sectioning of 
opaque objects, such as human tissue, without using the potentially 
destructive staining and fixing methods used with routine pathology. 
Recently, RCM has been used to differentiate between malignant 
and non-malignant dermatologic conditions. We hypothesize that 
this technique can be used to efficiently and reliably evaluate human 
breast tissue for the presence of malignancy without compromising 
the ability to perform routine immunohistochemical (IHC) analyses 
that accompany the diagnosis of invasive breast cancer.
Methods: 45 core needle breast biopsies (12mmx2mm) were collected 
under sonographic guidance. Biopsy specimens were immediately 
placed in phosphate buffered saline, injected with 5% acetic acid to 
enhance reflectivity of the nuclei, and imaged within 5-10 minutes. 
Digital images of the nuclear and cellular morphology from each 
intact specimen were acquired and catalogued within 1 hour of biopsy 
using the VivaCell 5000. Tissue samples were then formalin-fixed 
and sectioned for routine H&E evaluation or IHC assays. A board 
certified pathologist trained on 16 paired RCM images and H&E 
slides was given the blinded test set created from these 45 breast 
biopsies and asked to evaluate the RCM images for the presence of 
carcinoma. Preliminary evaluation was also done on 5 biopsy samples 
with known estrogen receptor (ER) and progesterone receptor (PR) 
status to determine the feasibility of assessing ER/PR on tissue treated 
with acetic acid for RCM.
Results: Routine H&E staining identified invasive carcinoma 10/45 
biopsy samples (9 invasive ductal [IDC], 1 invasive lobular [ILC]); 2 
specimens with IDC also contained ductal carcinoma in situ (DCIS). 
Evaluation of the RCM images led to the same diagnosis of invasive 
carcinoma vs. not in all 45 samples and correctly identified 6/9 IDC 
and 1/1 ILC. RCM correctly identified 1/2 specimens known to 
contain DCIS. RCM misclassified 3 IDC as DCIS (1), ILC (1), or 
lobular carcinoma in situ (1), and 1 DCIS as ILC. With respect to the 
determination of ER/PR status, RCM accurately assessed positivity 
for both receptors in all 5 specimens.
Conclusions: RCM is comparable to standard microscopy for the 
reliable identification of carcinoma, and the ability to evaluate breast 
tissue for malignancy using this technology allows for real-time 
pathology and may negate the need for repeat diagnostic biopsies 
to ensure adequate sampling for diagnosis. Importantly, the ability 
to perform routine IHC for ER/PR status after tissue processing for 
RCM appears to be preserved. Further evaluation applying the existing 
technology to a larger sample size for histopathologic correlation, 
assessment of ER/PR status, and evaluation for HER2 status are 
planned. These encouraging findings support interest in tailoring 
RCM for breast tissue to improve the ability to distinguish between 
invasive vs. in situ disease, and ductal vs. lobular histology.
P5-11-04
A New Immunohistochemistry-Based Assay SBrC5 Classifies 
Invasive Breast Cancer Subtypes – Profiling Five Biomarkers 
in One Single Test.
Liu H, Muralitharan S. Thermo Fisher Scientific, Fremont, CA
Background: Obtaining expression status of estrogen receptor (ER), 
progesterone receptor (PR) and Her2 is essential for guiding treatment 
and predicting outcome for breast cancers. By adding cytokeratin 
5/6 and EGFR to the above mentioned three common biomarkers, 
a five-biomarker breast cancer panel has been validated in previous 
studies for identifying the basal-like subtype with superior prognostic 
values than the triple negative subtype1. The current study aimed to 
evaluate a new immunohistochemical assay, named Subtyping Breast 
Cancers 5-in-1 Assay (abbreviated as SBrC5, or “the assay” in this 
poster), for classifying breast cancer subtypes.
Material and Methods: A cocktail of ER, PR, Her2, cytokeratin 5/ 6 
and EGFR antibodies (SBrC5 Cocktail) and the MultiVision Detection 
Kit (TFS Cat. #: TL-012-MARH) were used in generating the data for 
this poster. The Multivision Detection Kit is a double staining system 
with two visualizing colors, red and blue. The assay was performed 
on a breast cancer tissue microarray containing 75 cases in duplicate. 
Both color and cellular localization of the staining generated from the 
assay was used for the result interpretation. There were three staining 
clusters: 1) Red Nuclei indicated ER or PR positive; 2) Red Membrane 
indicated Her2 expression; and 3) Blue Membrane or Cytoplasm 
indicated EGFR or cytokeratine 5/6 positivity respectively. The same 
breast cancer tissue microarray was also subjected to individual IHC 
tests of ER, PR, Her2, cytokeratin 5/6 and EGFR. The concordance 
between the assay and the individual tests was analyzed.
Results: The assay SBrC5 was found to have excellent effectiveness in 
detecting ER or PR positivity, Her2 over expression, and cytokeratine 
5/6 or EGFR positivity. The concordance for the assay when compared 
to the individual tests for each biomarker were 94.1%, 93.8% and 
92.4% for Her2, combined results of ER and PR, and combined 
results of cytokeratine 5/6 and EGFR respectively. When a similar 
comparison was made, the sensitivity was 87.9%, 94.3% and 73.7%; 
the specificity was 100%, 93.1% and 100%.
Discussion: This study has demonstrated that a single test of the assay 
SBrC5 was able to accomplish the collective task of the individual 
IHC tests of the five-biomarker breast cancer panel. The assay is 
able to provide sufficient information for classifying breast cancer 
subtypes with only a single IHC test. Thus it makes it possible to 
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obtain subtypes information in biopsy settings where the tumor tissue 
obtained is often insufficient for multiple tests required to accomplish 
such task by existing methods.
Reference: Maggie C.U. Cheang, David Voduc, Chris Bajdik, et al. 
Clin Cancer Res March 1, 2008 14; 1368.
P5-11-05
Measurement of Neoadjuvant Chemotherapy Tumor Response 
in Locally Advanced Breast Cancer by Three Methodologies. 
Correlation with Overall Survival.
Garcia-Saenz JA, Romero A, Lopez Garcia-Asenjo JA, Roman JM, 
Moreno A, Fuentes M, Furio V, Pelayo A, Diaz-Rubio E, Caldes T, 
Martin M. Hospital Clinico San Carlos, Madrid, Spain; Hospital 
Principe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital 
Gregorio Marañon, Madrid, Spain
Background: Measurement of residual disease following neoadjuvant 
chemotherapy that accurate predicts long-term survival in locally 
advanced breast cancer (LABC) is an essential requirement for new 
drugs efficacy evaluation. Several methods to assess neoadjuvant 
chemotherapy tumor response have been described. However, to 
our knowledge, agreement between methods and correlation with 
survival in independent prospective cohorts has not been reported.
Patients & Methods: In this study we report neoadjuvant 
chemotherapy tumor response and survival in 151 consecutive 
LABC patients, included in a neoadjuvant clinical trial (http://www.
clinicaltrials.gov; NCT00123929). Patients were randomized to either 
neoadjuvant docetaxel 100 mg/m2 every 21 days or neoadjuvant 
doxorubicin 75mg/m2, every 21 days, for 4 cycles. Following surgery, 
response was established according to three methodologies: the 
measurement of residual breast cancer burden (RBC) as described 
by Symman’s (Symmans WF et al. J Clin Oncol. 2007;25:4414-22), 
Miller and Payne classification (Ogston KN et al. Breast. 2003;12:320-
7) and RECIST criteria. Regarding to Symmans classification we have 
evaluate both RBC index, as a continuous variable, and RBC classes 
as a categorical variable (RBC-0,I,II,III). Kappa Cohen’s coefficient 
(K) was used to test agreement between methods. We assessed the 
correlation between treatment outcome and overall survival (OS) by 
calculating the Harrell’s C- statistic.
Results: Median of follow up was 51.9 months. All three methods 
showed a moderate capacity to classify patients according to OS. 
The C-statistic to predict OS was 0.76 (IC: 0.67- 0.84) for RBC 
index and 0.71 (IC: 0.64-0.78) for RBC classes, 0.68 (IC: 0.58- 
0.78) for RECIST criteria and 0.69 (0.60-0.78) for Miller and Payne 
classification. Interesting, we did not encountered any death events 
within RCB-0 class. No significant differences were found between 
C-statistic when patients were stratified according to therapy. In order 
to assess the agreement between techniques, we grouped categories 1 
and 2 of Miller and Payne classification in 1 category. The agreement 
between Miller and Payne classification and Symmans method was 
very high (K=0.87). In contrast, we found a moderate-fair agreement 
between Miller and Payne classification and RECIST criteria 
(K=0.46) and Symmans method and RECIST criteria (K=0.27).
Conclusion: All three methods predicted fairly well OS. RCB-
0 identified the best outcome group. The agreement between 
methodologies based in pathology analyses was very high. However, 
the agreement falls off when these methodologies were compared 
with RECIST criteria.
P5-11-06
Immunohistochemistry Discordance between Primary and 
Recurrent Tumors in Breat Cancer. Analysis of Potential 
Influence of Technique Bias by Comparing Test-Results under 
Two Different Conditions.
Perez-Fidalgo J-A, Ferrer J, Bosch A, Burgués O, Martinez M, 
Eroles P, Bermejo B, Pons V, Lluch A. Hospital Clinico Universitario, 
Valencia, Spain
Introduction: Discordance in expression of estrogen (ER) or 
progesterone receptors (PgR) and HER2 has been previously 
described in several studies, having this discordance an important 
impact on therapeutic approach or even in survival. However it is 
unclear whether discordance is a reflex of a clonal differentiation to 
a more aggressive biological tumour or the consequence of technical 
biases or inter-explorer variability. We aimed to assess the role of 
technique biases in observed discordance between primary tumour 
(PT) and recurrent tumour (RT) by analyzing discordance in two 
different situations: routine versus optimal conditions.
Patients and methods: We conducted a retrospective study in patients 
(pts) diagnosed with a recurrent breast cancer in the Hospital Clinico 
of Valencia between January 2000 and June 2010. All patients had a 
previous histological diagnose of the PT and all underwent a second 
histological study of the RT. Discordance was assessed in terms of 
hormone-sensibility (HS) (any ER or PgR +) vs hormone-resistance 
(HR) (ER-/PgR -) and triple negativity (TN) (ER-, PgR-, HER2-) 
vs non-TN (any positive). Routine conditions were referred to the 
immunohistochemistry (IHC) assessment of the normal practice on 
the base of which therapeutic decisions were made. Routine conditions 
were performed in the Pathology Department of our institution but PT 
and RT were usually evaluated at different timing and ocasionally by 
different pathologists. In order to assess potential laboratory biases 
we repeated IHC analysis under optimal conditions. For these optimal 
conditions analyses, paired samples from both PT and RT were re-
assessed at the same time and tests were performed in the same way. 
Final determination of the results was made by two highly trained 
pathologists and in case of disagreement in any determination, both 
explorers re-assessed the sample at the same time.
We evaluated discordance between PT and RT under both conditions, 
and the accuracy of determinations in PT or RT between both 
conditions.
Results: 128 paired samples (from 64 different pts) were analysed. 
Median age of the series was 48.5 years (range 27-83). Recurrences 
were loco-regional in 14 pts (21.9%) and distant in 50 pts (78.1%). 
RT tissue was obtained from skin and soft-tissues in 18 pts (28.1%), 
lung in 11 (17.2%), bone in 10 (15.6%), lymph nodes in 10 (15.6%), 
pleura/peritoneum in 9 (14.1%) and liver in 6 (9.4%).
Discordant cases between PT an RT in terms of HS/HR were 30.4% 
in routine conditions and 9.8% in optimal conditions. In terms of 
TN/non-TN were 14.3% in routine vs 8.2% in optimal conditions. 
Accuracy in results HS/HR between routine and optimal conditions 
was 80.7% in PT and 76.0% in RT. In results of TN/non-TN accuracy 
between both conditions was 94.2% in PT and 87.2% in RT.
Conclusions: Results suggest that an important rate of discordance 
observed in routine conditions might be strongly influenced by 
technique biases. However, changes observed in optimal conditions 
with 9.8% discordance in HS/HR and 8.2% in TN/non-TN suggest 
that in a small proportion of tumours, observed discordance might 
be explained by biological mechanisms.
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P5-11-07
Receptor Concordance in Triple-Negative Breast Cancer (TNBC) 
Recurrences.
Killian ME, De Los Santos JF, Forero-Torres A, Krontiras H. 
University of Alabama at Birmingham, Birmingham, AL
Background: The phenotype of TNBC is defined by absence 
of estrogen (ER) and progesterone receptors (PR) and lack of 
amplification of the HER2 oncogene. It is an aggressive form of 
breast cancer, and despite sensitivity to contemporary chemotherapy, 
TNBC have a poorer prognosis than ER positive phenotypes, marked 
by early relapses. This study examines the concordance of receptor 
status in recurrences among patients with TNBC.
Methods: After obtaining IRB approval, we identified patients with 
triple negative breast cancer treated at the University of Alabama at 
Birmingham between 1998 and 2010. Patient and tumor characteristics 
and disease status were recorded. Patients with ER, PR, or HER2 (3+) 
positivity on immunohistochemistry (IHC), or HER2 amplification 
by fluorescence in situ hybridization were excluded. Data regarding 
the receptor status of the recurrence, if known, was documented.
Results: Five hundred and two women with TNBC were diagnosed 
at our institution between 1998 and 2010. Of these patients, 95/502 
(19%) had recurrences. Twenty-seven (28%) were local, 18 (19%) 
were regional, 35 (37%) were distant, and 15 (16%) were both local-
regional and distant. These women ranged in age from 33 to 84 years 
of age. Of the women with a recurrence, 78/95 (82%) had a biopsy 
confirming breast cancer recurrence. Of those biopsied, 33/78 (42%) 
had receptor studies performed, and of these, 30 included data for 
estrogen, progesterone and HER2 receptors. The remaining 3 had only 
IHC for estrogen receptors performed. Twenty-two/thirty (73%) had 
concordance on their biopsy with their initial TNBC status, whereas 
8/30 (27%) women developed a pathologically discordant recurrence.
Conclusion: In this single institution study of TNBC patients, 
approximately one quarter of patients developed a pathologically 
discordant distant recurrence noted at biopsy. It is unclear whether 
patients experiencing a pathologically discordant recurrence differ 
in prognosis from those with concordant recurrences. Further study 
is necessary to evaluate this and determine whether routine biopsy 
based on pathologic discordance rates and outcomes are warranted.
P5-11-08
High Concordance of 5 HER2 In Situ Hybridization Methods 
with Abbott FISH.
Boers JE, Netjes C, Meeuwissen HC, Prinsen C, Bart J, van der Logt 
EMJ, Schuuring E. Isala Klinieken, Zwolle, Netherlands; University 
Medical Center, Groningen, Netherlands
Background: HER2 in situ hybridization (ISH) has become a common 
test in breast cancer. Abbott FISH was used in most clinical studies 
showing the efficacy of anti-HER2 treatment in HER2 positive 
carcinomas. Only reports comparing one or two of newly developed 
ISH assays with Abbott FISH have been published previously. We 
conducted a comprehensive concordance study of 5 ISH methods 
with Abbott FISH in a large series of breast carcinomas.
Methods: Tissue Micro Arrays (TMA) were constructed by taking 
three 0.6 mm tissue cores from formalin-fixed/paraffin-embedded 
tissue-blocks from 402 primary breast carcinomas diagnosed in 2007 
(supported by the Dutch Pathological Society). Up to 384 cases were 
analyzable in the TMA. ISH was performed after ample experience 
with 6 ISH assays. Scoring was performed by two independent 
observers without knowledge of the other ISH data according the 
ASCO-guidelines for HER2-testing. HER2 and chromosome 17 
(Chr17) signals were counted separately, the HER2:Chr17 ratio was 
calculated and considered positive when the ratio was ≥ 2.0 In cases 
with a ratio was between 1.8 and 2.2, additional enumeration was 
performed. The discordant cases were reviewed and scores were 
reassigned on consensus of opinion. Concordance and Cohen’s kappa 
score were calculated.
Results: see table.
Method Analyzable cases HER2 ratio ≥ 2.0 Concordance Kappa score 
FISH, Abbott 372 43 (11,6%) X X
FISH, DAKO 353 41 (11,6%) 99,1% 0,96
FISH, Zytovision 359 46 (12,8%) 99,4% 0,97
single probe SISH, Ventana 359 44 (12,3%) 98,9% 0,95
dual probe SISH, Ventana 373 48 (12,9%) 99,1% 0,96
duoCISH, Zytovision 348 45 (12,9%) 98,0% 0,90
Conclusion: Concordance of 5 HER2 ISH assays with Abbott FISH 
were shown to be 98% or higher. Each of these tests might be used 
for a reliable assessment of HER2 amplification.
P5-11-09
High Concordance for Microarray Based Determination of ER, 
PR and HER2 Receptor Status and Local IHC/FISH Assessment 
Worldwide in 749 Patients.
Wesseling J, Cusumano G, Tinterri C, Sapino A, Zanconati F, Lutke-
Holzik M, Nguygen B, Deck K, Querzoli P, Perin T, Giardina C, 
Seitz G, Guinebretiere J, Barone J, Watanabe T. Netherlands Cancer 
Institute, Amsterdam, Netherlands; CHC, Liege, Belgium; Instituto 
Clinico Humanitas, IRCCS, Rozzano, Italy; Universita di Torino, 
Torino, Italy; Università di Trieste, Trieste, Italy; Medisch Spectrum 
Twente, Enschede, Netherlands; Locg Beach Memorial Health Care, 
Loch Beach, CA; Saddleback Memorial Medical Center, Laguna Hills, 
CA; Instituto di Patologia, Universita di Ferrara, Ferrara, Italy; 
Centro di Riferimento Oncologico, Aviano, Italy; Instituto di Anatomia 
Patologica, Iniverstita degli Studi di Bari, Bari, Italy; Klinikum 
Bamberg, Bamberg, Germany; Centre Rene Huguenin, Saint-Cloud, 
France; Comprehensive Breast Care and Sharp Memorial Hospital, 
San Diego, CA; Hamamatsu Oncology Center, Hamamatsu, Japan
Background
The level of estrogen receptor (ER), progesterone receptor (PR) and 
HER2 expression is predictive for prognosis and/or treatment response 
in breast cancer patients. However, differences in fixation and IHC 
and subjective interpretation can substantially affect the accuracy and 
reproducibility of the results. The commercially available TargetPrint 
test measures the mRNA expression level of ER, PR and HER2 and 
provides high quality second opinion for local IHC/FISH assessment. 
This study compares results from the microarray-based TargetPrint 
with IHC and FISH (for HER2 IHC2+) generated by local standard 
procedures.
Methods
Prospective tumor samples were collected for 749 patients diagnosed 
with breast cancer stage I to IV between February 2008 and January 
2011. The mRNA level of ER, PR and HER2 (TargetPrint) was 
assessed in the Agendia laboratories (Agendia Inc, Irvine, CA; 
Agendia BV, Amsterdam, the Netherlands) in fresh tumor samples 
submitted from 22 hospitals from Europe, New Zealand, Japan and 
US. The results of the IHC/FISH assessments performed according to 
the local standards at the hospitals were compared to the quantitative 
gene expression readouts.
Results
Of the 749 samples, IHC assessment was unknown for 5 ER samples 
and 4 PR samples; FISH was unknown for 24 samples. TargetPrint 
read out was not assessed for HER2 for 11 samples.
Median age of these patients was 61 years. Comparison of IHC and 
gene expression read out by TargetPrint showed a concordance of 
95% for ER; 82% for PR and 91% for HER2.
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In this study, only 4% of all IHC ER positive samples were classified 
negative by microarray. In contrast, 14% of IHC ER negative samples 
were classified positive by microarray. However for HER2, 28% 
of IHC/FISH HER2 positive samples were classified negative by 
microarray and 5% of IHC/FISH HER2 negative samples were 
classified positive by microarray.
Samples with discordant classifications for TargetPrint and local 
assessment are being reviewed in greater detail by a central 
pathologist.
Conclusions
Microarray based readout of ER, PR and HER2 status using 
TargetPrint is highly comparable to local IHC and FISH analysis 
in 749 analyzed samples in various hospitals worldwide. The 
results indicate mRNA expression read out for ER, PR and HER2 
by TargetPrint provides high quality second opinion for local IHC/
FISH assessment.
P5-11-10
Reproducibility and Robustness of the FDA Approved INFORM 
HER2 Dual ISH DNA Probe Cocktail Assay.
Loftin IR, McElhinny AS, Miller R, Garcia C, Bai I, Ranger-Moore 
J, Ostrem J, Padilla M, Grogan T. Ventana Medical Systems, Inc., 
Tucson, AZ
Background: Amplification and/or HER2 overexpression is 
associated with poor clinical outcome for patients with invasive 
breast carcinoma. Determination of HER2 status dictates eligibility 
of patients for trastuzumab (Herceptin) therapy, which has been 
shown to improve prognosis. We present data from the inter-observer 
reproducibility and robustness studies of the FDA approved INFORM 
HER2 Dual ISH DNA Probe Cocktail (HER2 Dual ISH) assay, which 
is an alternative to FISH. The assay is fully automated and is scored 
using light microscopy providing morphological context.
Methods: Ninety-five human invasive breast carcinoma specimens 
(a mix of amplified and non-amplified cases) were stained in a study, 
using the HER2 Dual ISH assay. The slides were enumerated by two 
qualified readers. The same cohort was stained using PathVysion FISH 
and read by one qualified reader.
To verify the robustness of the HER2 Dual ISH assay, customer 
selectable options for factors known to impact the staining quality 
and intensity, which can be varied for troubleshooting, were tested 
on human invasive breast carcinoma cases and xenografts. The slides 
were evaluated by one qualified reader.
For both studies all assay steps were fully automated on a VENTANA 
BenchMark XT automated slide stainer using silver metallographic 
and red colorimetric detections for Dual ISH.
Results: In the inter-observer study the first pass staining success rate 
was >93% for the HER2 Dual ISH assay, while the FISH first pass 
staining success rate was 59%. Some cases were rescued after a second 
attempt, which yielded a second pass staining success rate of 80% for 
FISH and 97% for HER2 Dual ISH. The negative, positive and overall 
agreement rates and 95% confidence intervals for the 61 clinical 
samples of this cohort that were enumerable with both FISH and the 
HER2 Dual ISH assay are 94.7 (75.4-99.1), 95.2 (84.2-98.7), 95.1 
(86.5-98.3) and 89.5 (68.6-97.1), 97.6 (87.7-99.6), 95.1 (86.5-98.3) 
for reader A vs. FISH and reader B vs. FISH respectively. The positive 
and negative agreement rates for the inter-observer reproducibility 
of the HER2 Dual ISH assay were 94.7 and 97.6 %, respectively.
In robustness testing, the recommended staining protocol was shown 
to be effective. All conditions tested resulted in appropriate staining 
(except for mildest cell conditioning and protease options).
Conclusion: The fully automated FDA approved INFORM HER2 
Dual ISH assay is robust, reproducible and concordant with the 
manual FISH assay in determining HER2 status in invasive breast 
carcinoma.
P5-11-11
Automated Quantification Methods Improve the Accuracy of 
PR as an Independent Prognostic Factor in Tamoxifen Treated 
Breast Cancer Patients.
Klimowicz AC, Kornaga EN, Yau A, Pohorelic BK, Petrillo SK, Konno 
M, Magliocco AM. Tom Baker Cancer Centre, Calgary, AB, Canada; 
University of Calgary, Calgary, AB, Canada
Background: Adjuvant endocrine therapy reduces the risk of 
recurrence and death in hormone receptor positive breast cancer 
patients. However, 40-50% of estrogen receptor (ER) positive tumors 
are resistant to endocrine therapy. We have previously shown that 
quantitative measurement of ER protein expression has limited value 
as a prognostic marker in tamoxifen treated patients. The presence 
of progesterone receptor (PR) expression has shown promise as 
prognostic and/or predictive marker for endocrine therapy, including 
adjuvant tamoxifen, but reports are contradictory. Automation of 
scoring methods will improve the accuracy of PR scoring and its 
value as a prognostic factor.
Methods: This retrospective study evaluated breast cancer patients 
treated with adjuvant tamoxifen (n=458) from 1985-2000 at the Tom 
Baker Cancer Centre, Calgary, Canada. Tissue microarrays were 
assembled from formalin fixed paraffin embedded tumor tissue. 
Clinico-pathologic data was obtained from chart review. Five-year 
disease-free survival (DFS) was the primary outcome. DAB-based 
PR staining was used to generate Allred PR scores, as well as to 
generate scores for PR percent area expression and PR integrated 
optical density (PR IOD) using the DAKO ACIS III scanner and image 
analysis software. PR tumor nuclear pixel intensity density scores 
were obtained using fluorescence-based PR staining, scanned and 
quantified with a HistoRx PM2000 scanner and AQUA image analysis 
software. Continuous variables were dichotomized using Xtile.
Results: In our tamoxifen cohort, 5-year DFS was associated with 
tumor grade [HR 4.9(3.5-6.9), p<0.001], tumor size [HR 2.7(1.9-
3.8), p<0.001], lymph node status [HR 5.7(4.0-8.0), p<0.001] and 
ER status [HR 2.4(1.3-4.7), p=0.008]. Low PR was associated with 
significantly worse DFS regardless of the method used to quantify 
its expression. Methods of analysis requiring less subjective input 
had stronger associations between PR expression and outcome. 
The subjective identification of tumor and subjective biomarker 
quantification used in Allred scoring [HR 2.2(1.4-3.3), p<0.001] was 
less effective than ACIS scoring [PR percent area: HR 2.8(1.8-4.3), 
p<0.001; PR IOD: HR 2.9(1.9-4.6), p<0.001], which only requires 
subjective identification of the tumor. All methods were inferior to 
fluorescence-based AQUA scoring [HR 4.2(2.7-6.5), p<0.001], which 
automatically detects the tumor nuclear area using pan-cytokeratin 
and DAPI staining and measures the PR expression within this 
compartment. Multivariate analysis, which included age, tumor 
size, tumor grade, lymph node status, and ER status, confirmed that 
AQUA [HR 3.3(2.0-5.6), p<0.001] was superior to ACIS PR percent 
area [HR 2.3(1.4-3.9), p=0.002] and ACIS PR IOD [HR 2.7(1.6-4.8), 
p<0.001], all of which were superior to Allred scoring [HR 1.2(0.7-
2.1), p=0.511].
Conclusions: We conclude that: 1) PR is an independent prognostic 
marker in our cohort, 2) using less subjective, automated quantitative 
scoring methods improves the value of PR as a prognostic biomarker, 
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3) AQUA appears superior to other automated methods and that 4) the 
incorporation of digital image analysis into practice would improve 
the prognostic value of PR expression in the clinical setting.
P5-11-12
Correlation of Ki67 Expression between Initial Biopsy and 
Surgical Specimen in Untreated Breast Cancer Patients. Does 
Menstrual Cycle Matter?
Torrejón D, Rubio I, Sanchez-Olle G, Peg V, Sansano I, Jimenez 
J, Gomez P, De la Peña L, Di Cosimo S. Vall d’Hebron University 
Hospital, Barcelona, Spain; Solti Breast Cancer Research Group
Background: The measure of proliferative index by Ki67 expression 
is being increasingly used to identify breast cancer subtype and to 
guide treatment decisions. Findings on initial tumor biopsy are in 
some cases, such as for primary systemic treatment, the only data 
available prior to treatment. In addition, results from window studies 
to develop novel anti-tumor agents depends on initial breast cancer 
biopsy findings. This study aims to compare the Ki67 expression on 
initial biopsy with matched primary breast cancer surgical specimens. 
In addtion, we aimed to explore the possible effect of hormonal levels 
- as reflected by menstrual cycle phase - on discordant Ki67 cases.
Material and Methods: A total of 50 random cases were analyzed by 
2 blinded pathologists. Ki67 expression was collected as a continuous 
variable. Tumors were then classified as high - or low-proliferative 
according to a Ki67 value of > or = 15% or < 15%, respectively. 
Sperman Rank test was used to study the correlation between initial 
and surgical biopsies. Data on menstrual cycle phase at the time of 
biopsy and surgery were retrived from medical history of all pre-
menopausal patients.
Results: Baseline patients characteristics are as follows: median 
age 48 (35-56 years), premenopausal 27 (54%), postmenopausal 
23 (46%), invasive ductal carcinoma 38 (76%). A differential 
expression of Ki67 was found in 36 patients (72%), 20 pre- and 16 
post-menopausal. Spearman’s Rank Order correlation did not show 
any significant difference between biopsy and matched surgical 
specimen in terms of Ki67 expression. Indeed, there was a strong 
positive correlation between initial and surgical biopsy, which was 
statistically significant across all patients (rs = .556, P < 0.001), and 
regardless the menopausal status. However, 15% of pre-menopausal 
patients transformed from Ki67 low to high. Therefore, data on 
pre-menopausal patients were analyzed according to the phase 
of menstrual cycle at the timing of initial and surgical biopsies. 
The Spearman’s Rank Order gave no correlation among 14 pre-
menopausal patients with differential menstrual cycle phase at the 
timing of initial biopsy and surgery (rs = .411, P = 0.145).
Conclusions: Initial breast cancer biopsy can be used with high 
confidence for Ki67 determination. However, it should be noted that 
menstrual cycle phase could affect Ki67 expression as women with 
distinct menstrual cycle phase at the time of initial biopsy and final 
surgery do not show concordant results. Prospective evaluation of 
Ki67 expression in premenopausal patients is being planned.
P5-11-13
Rates of Upgrade to Malignancy for 271 Cases of Atypical 
Columnar Cell Hyperplasia Diagnosed by Breast Core Biopsy.
Peres A, Barranger E, Becette V, Boudinet A, Guinebretiere J-M, 
Cherel P. Lariboisiere Hospital, Paris, France; Institut Curie, Saint-
Cloud, France
Purpose: Atypical columnar cell hyperplasia (ACCH) is a borderline 
lesion that might represent an early stage in the development of certain 
low-grade carcinomas in situ (CIS) and invasive cancers. There are no 
guidelines on its management. Our objectives were to determine the 
upgrade to malignancy rate and identify a subpopulation of patients 
that might undergo just mammographic surveillance.
Methods: We retrospectively reviewed the data for 271 ACCH cases 
among 5555 breast core biopsies obtained over a 7-year period (Jan. 
2003 – Jan. 2010). We collated clinical data (age, history of cancer, 
menopausal status), radiological data (lesion type, size, Bi-Rads 
category), technical data (number of biopsies, needle gauge, excision 
quality) and histological data and sought correlations between these 
factors and upgrade rate.
Results: The 271 ACCH comprised 128 cases of pure ACCH, 135 
cases of ACCH + atypical ductal hyperplasia, and 8 cases of ACCH + 
atypical lobular hyperplasia. Overall, 184 patients underwent surgery 
and 46 mammographic surveillance. Surgery detected 34 cases of 
malignancy (23 CIS, 7 invasive cancers, and 4 mixed cases) giving a 
15% upgrade rate. Quality of excision was the only factor associated 
with under-diagnosis.
Conclusion: The presence of ACCH at biopsy warrants surgery.
P5-11-14
Flat Epithelial Atypia of the Breast: A Single Institution 
Experience.
Joh JE, Acs G, Kiluk JV, Laronga C, Khakpour N, Lee MC. H. Lee 
Moffitt Cancer Center & Research Institute, Tampa, FL
Background: Flat epithelial atypia of the breast is a relatively new 
entity of unknown significance. Our objective is to evaluate our 
surgical experience with this diagnosis.
Methods: A single institution database of breast patients from 2005-
2010 was used to identify women who were diagnosed with flat 
epithelial atypia on core biopsy and subsequently underwent surgical 
excision. Patient data regarding history, type and reason for biopsy, 
and associated pathology was collected. Individuals diagnosed with 
flat epithelia atypia and cancer on core biopsies in the same breast 
were excluded.
Results: There were 52 patients who underwent surgical excision 
for the primary diagnosis of flat epithelial atypia. There were 3 (6%) 
patients with a personal history of breast cancer, 14 (27%) patients 
with a family history of breast cancer, and 11 (21%) patients with 
a concurrent new diagnosis of breast cancer in the contralateral 
breast. Core biopsy was recommended in most (81%) cases because 
of suspicious calcifications on mammography. Twenty-eight (54%) 
patients were found to have flat epithelial atypia associated with other 
atypical breast hyperplasia and 24 (46%) had flat epithelial atypia 
as the most significant lesion on core biopsy. In 8 (15%) patients, 
there was a sonographic correlate that was biopsied; 5 had only flat 
epithelial atypia and 3 had flat epithelial atypia associated with other 
atypical hyperplasia. Of the 52 patients there were 4 (8%) patients 
who upstaged to ductal carcinoma in-situ on surgical excision. There 
were no cases of invasive carcinoma. All ductal carcinoma in-situ 
cases were associated with other atypical breast hyperplasia, not flat 
epithelial atypia alone.
Conclusion: Though flat epithelial atypia may be associated with an 
increased risk of breast cancer, surgical excision of pure flat epithelial 
atypia may not be necessary. Larger studies are needed to corroborate 
these findings.
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Should HER-2 Score 0/1+ Breast Cancer Cases Be Retested by 
In-Situ Hybridisation? Results of a Multicenter Retesting Study.
Reiner-Concin AM, Lax S, Regitnig P, Kronberger C, Jasarevic Z, 
Bogner S. Danube Hospital, Vienna, Austria; General Hospital Graz 
West, Graz, Austria; Medical University Graz, Graz, Austria; LKH 
Salzburg, Salzburg, Austria; LHK Feldkirch, Feldkirch, Austria; LKH 
Linz, Linz, Austria
Background: HER-2 status is vital for selection of appropriate therapy 
for breast cancer patients. Accuracy of immunohistochemistry (IHC) 
varies with a major problem of false negative testing. To assess the 
false negative rate retesting by in situ hybridisation was performed 
on a group of primary breast cancers in which according to guidelines 
routine retesting is not recommended.
Material and Methods: 570 breast cancers from 5 pathology 
departments scored 0/1+ by IHC (HercepTest or 4B5-antibody) were 
retested by HER2-Dual-SISH (BDISH) in a central laboratory. CAP/
ASCO guidelines were applied. Cases showing ratios in the amplified 
or equivocal range by BDISH were further analysed by fluorescence 
in situ hybridisation (FISH) using Pathvysion® and ZytoLight® and 
retested centrally by IHC using 4B5 antibody (Ventana).
Results: 25/570 cases (4.38%) were amplified by BDISH, the majority 
with low level amplification (ratios ≤ 3.26). Only two cases showed 
high level ratios (6.35 and 6.48). 17/570 cases (2.98%) showed ratios 
by BDISH in the equivocal range (1.8 – 2.2). 24 amplified and 17 
equivocal cases underwent further retesting. In one case no tumor 
tissue was available for further testing.
On further testing 17/24 (71%) BDISH-amplified cases showed 
IHC scores 2+/3+ and 7/24 (29%) cases showed IHC scores 0/1+. 
Subsequently 3/13 score 2+ cases were amplified by Pathvysion® 
and 9/13 by ZytoLight®. 3/4 score 3+ cases were amplified by both 
FISH assays. In case of amplification ratios of BDISH and both FISH 
assays appeared to be in the same range. Only 2/17 BDISH-equivocal 
carcinomas were confirmed equivocal by Pathvysion® and 6/17 were 
confirmed equivocal by ZytoLight®. All other BDISH-equivocal 
cases were non-amplified by both FISH assays. Discrepant results 
between different methods could partly be caused by interobserver 
variability. This question is currently under investigation. Overall, 
after multistep retesting amplification occurred in only 17 cases 
(2.98%).
Discussion: Amplification is rare in immunohistochemically HER-
2 negative breast carcinomas and occurred predominantly at low 
level in our study. Low level amplification seemed to be diagnosed 
more frequently by BDISH compared with FISH. Since clinical 
data demonstrate a benefit of therapy even in carcinomas with low 
level amplification the identification of these carcinomas might be 
of interest.
Conflicts of Interest: The study was supported by Roche Austria 
GmbH.
P5-11-16
CD44 and CD24 Expression in Ductal Invasive Breast 
Carcinomas, Classified by Molecular Subtypes and Its Association 
with Prognostic Factors.
Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Soares FA, do 
Socorro Maciel M, Brentani MM. Hospital AC Camargo, São Paulo, 
Brazil; Universidade Federal de São Paulo, São Paulo, Brazil; 
Faculdade de Medicina da Universidade de São Paulo, São Paulo, 
Brazil; Hospital A.C. Camargo, São Paulo, Brazil
Backgound: Breast carcinomas (BC) exhibit intra tumoral 
heterogeneity being stratified into several subgroups based in gene 
expression profiles or histochemical biomarkers. It was suggested 
that this heterogeneity is derived in part from the transformation of 
different subsets of cancer stem cells (CSC) in each intrinsic subgroup. 
The presence of CSC can be evidenced by phenotypic analysis of 
CD44 e CD24. This study aimed to identify the CD24 and CD44 
immunophenotypes within invasive ductal breast carcinoma (IDC) 
subgroups defined by immunohistochesmistry markers and determine 
its influence on prognosis as well as its association with the expression 
of Ki67, citokeratins (CK5 and CK18) and claudin-7. Methods: 
Immuno expression of CD44 and CD24 alone or in combination was 
investigated in 95 IDC cases arranged in a tissue microarray (TMA). 
The association with subgroups defined as luminal A and B;HER2 
rich and triple negative, or with the other markers and prognosis 
was analyzed. Results: CD44+/CD24- and CD44-/CD24+ were 
respectively present in 8.4% and 16.8% of the tumors, a lack of both 
proteins was detected in 6.3%, while CD44+/CD24+ was determined 
in 45.3% of the tumors. Although there was no significant correlation 
between subgroups and different phenotypes, the CD44+/CD24- 
phenotype was more common in the basal subgroups but absent 
in HER2 tumors, whereas luminal tumors are enriched in CD44-/
CD24+ and CD44+/CD24+ cells. The frequency of CD44+/CD24- or 
CD44-/CD24+ have not been associated with clinical characteristics 
or biological markers. There was also no significant association of 
these phenotypes with the event free (DFS) and overall survival (OS). 
Single CD44+ was evident in 57.9% and was marginally associated 
to grading and not to any other tumor characteristics, while CD24+ 
was positive in 74.7% of the tumors, showing a significant association 
with ER, PR and Ki67 and a marginal association with CK18 and 
claudin-7. Expression of claudin-7 and Ki67 did not associate with the 
cancer subgroups, while a positive association between CK18 and the 
luminal subgroups was found (p=0.03). CD44+ was not significantly 
associated with OS and DFS whereas CD24+ frequency although 
not significantly associated with OS was associated with a decrease 
in DFS (p=0.07). CK5, CK18 and Ki67 expression had no influence 
in OS or DFS, claudin-7 positive was associated with reduced DFS 
(p=0.05). Conclusions: There was no significant correlation between 
CD44+/CD24- tumor cells frequency and event-free or OS. However, 
a tendency toward a favorable prognosis, was noted. Contrariwise 
the presence of CD44-/CD24+ suggested a worse prognosis. Both 
single CD24 and claudin-7 positivity were associated with reduced 
time of reccurence, suggesting a contribution of these markers to 
aggressiveness. Supported by FAPESP and CNPq.
P5-11-17
Evaluating Tumor Heterogeneity in Immunohistochemistry 
Stained Breast Cancer Tissue.
Potts SJ, Landis N, Eberhard DA, Schmechel SC, Young D, Lange H. 
Flagship Biosciences, Flagstaff, AZ; University of North Carolina, 
Chapel Hill, NC; University of Minnesota, Minneapolis, MN
Context: Quantitative clinical measurement of heterogeneity in 
immunohistochemistry staining would be useful in both evaluating 
patient therapeutic response and identifying underlying issues in 
histopathology laboratory quality control.
Objective: To create a heterogeneity scoring approach (HetMap) that 
allows the visualization of an individual patient’s IHC heterogeneity 
in the context of a population.
Design: We combined HER2 semi-quantitative analysis with the use 
of ecology diversity statistics to evaluate cell-level heterogeneity 
(consistency of protein expression within neighboring cells in a tumor 
nest) and tumor-level heterogeneity (differences of protein expression 
across a tumor as represented by a tissue section). We evaluated the 
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approach on HER2 immunohistochemistry stained breast cancer 
samples, using 200 specimens across two different CLIA laboratories, 
with three pathologists at each laboratory each outlining regions of 
tumor for scoring by automatic cell-based image analysis. HetMap 
was evaluated using three different scoring schemes: HER2 scoring 
according to ASCO/CAP guidelines, H-Score and a new continuous 
HER2 score (HER2cont).
Results: Two definitions of heterogeneity, cell-level and tumor-level, 
provided useful independent measures of heterogeneity. Cell-level 
heterogeneity, reported either as an average or the maximum area 
of heterogeneity across a slide, had low levels of dependency on 
the pathologist choice of region (coefficient of variation of 15%). 
Tumor-level heterogeneity measurements had more dependence on 
the pathologist choice of regions (coefficient of variation of 25%). 
Results were highly similar between the two laboratories, which is 
encouraging for HER2 standardization, as the labs involved different 
pathologists, different specimens, and different standardization 
procedures, although both complied with CLIA/CAP guidelines for 
HER2 testing.
Conclusions: HetMap is a measure of heterogeneity, by which 
pathologists, oncologists, and drug development organizations can 
view cell-level and tumor-level heterogeneity for a patient for a 
given marker in the context of an entire patient cohort. Heterogeneity 
analysis can be a useful means to identify tumors with higher degrees 
of heterogeneity, or to highlight slides that should be rechecked for 
QC issues.
P5-12-01
Aromatase Inhibitor Specific Metastasis Is Driven by the Steroid 
Receptor Coactivator SRC-1.
Theissen SM, McBryan J, Byrne C, Hughes E, Cocchiglia S, Hill AD, 
Young LS. Royal College of Surgeons in Ireland, Dublin 2, Ireland
Aromatase Inhibitors are currently one of the most promising therapies 
of estrogen-receptor positive breast cancer in postmenopausal women. 
Even though many women initially respond to the treatment, 
approximately 30-40% will acquire resistance and relapse within 5 
years. The mechanisms involved in the development of resistance to 
AIs however are poorly understood as long term follow up is only 
now becoming available. To investigate the mechanisms involved in 
AI-specific tumour recurrence, we generated a cell line resistant to 
the AI Letrozole (LetR) and examined a cohort of endocrine treated 
breast cancer patients (n=150). In patients treated with a first-line 
AI (n=89), we found that hormone receptor switching between 
the primary tumour and the resistant metastasis was a common 
feature of disease recurrence. More so, this switch accompanied the 
development of a phenotype displaying an increase in migratory 
capacity and loss of organisation. Both the resistant cell model and AI 
resistant tumour samples expressed high levels of the steroid receptor 
coactivator SRC-1. We also found that the interaction between SRC-
1 and the transcription factor Ets2 was involved in the regulation 
of Myc and MMP9 expression and that SRC-1 was required for 
the aggressive AI resistant phenotype. Expression of SRC-1 in the 
primary and/or recurrent tumour associated with poor disease free 
survival (p=0.01, n=89) in the AI treated population. A significant 
coassociation between SRC-1 and Ets2 in the nucleus of the recurrent 
tissue compared with the matched primary tumour was also observed 
(p=0.0004, n=3). These data describe a novel signaling mechanism 
of AI-specific metastatic progression where SRC-1 utilizes Ets2 to 
promote de-differentiation and migration to drive disease progression.
P5-12-02
Vacuum Assisted Biopsies of Ductal Carcinoma In Situ and 
Concordance with Post-Operative Histology: Implications for 
the Low Risk DCIS Trial.
Soumian S, Down SK, Roked F, Chaudhri S, Francis A. Queen 
Elizabeth Hospital, University Hospitals Birmingham, Birmingham, 
England, United Kingdom
Aim
The enormous increase in the diagnosis of ductal carcinoma in situ 
(DCIS) by the NHS Breast screening has not lead to an expected 
decrease in the incidence of invasive breast cancer. It is not clear 
if all grades of DCIS progress inexorably to invasive cancer if left 
untreated. There is recognition that DCIS is overtreated, ie if left alone 
may not cause harm during the woman’s lifetime. In the absence of 
new clinical trial data, surgery still remains the universal treatment. 
It is known that a higher proportion of patients with screen detected 
DCIS receive mastectomy than those with screen detected invasive 
cancer. Recently a randomized trial called the Low risk DCIS Trial 
has been proposed which intends to specifically compare the current 
treatment of low grade DCIS ie surgery with active monitoring 
using annual mammography. In order to effectively implement this, 
concordance between diagnostic biopsy and excision histology is 
vital and therefore vacuum assisted mammotome biopsy (VAB) and 
a central pathology review of diagnostic biopsy specimens prior to 
randomization will be mandatory. Therefore, in this study, we assessed 
the concordance between diagnostic biopsies performed by VAB 
technique and the post operative histology for DCIS in our institution.
Methods
Retrospective data of all diagnostic breast biopsies specifically using 
the VAB technique with the primary diagnosis of DCIS from year 
2001 to 2010 in our institution was collected. Both screening and 
symptomatic patients were included. Concordance between diagnostic 
histology and post operative excision histology was assessed for high, 
intermediate and low grade DCIS. Demographic details and potential 
factors influencing concordance including number of cores taken and 
lesion size were also collected for analysis.
Results
A total of 161 cases were identified out of which 102 (63%) were of 
high grade, 35 (22%) of intermediate grade and 24 (15%) were of 
low grade histology. In the High grade group, the concordance with 
final histology was 70% (72/102). In this group, the diagnosis was 
upgraded to invasive carcinoma in 21% (21/102). 9% (9/102) were 
downgraded to intermediate or low grade. In the intermediate grade 
group, the concordance with final histology was 66% (23/35). In this 
group, the diagnosis was upgraded to invasive carcinoma in 11% 
(4/35) and to high grade in 17% (6/35). 6% (2/35) were downgraded 
to low grade. In the low grade group, the concordance with final 
histology was 71% (17/24). In this group, the diagnosis was upgraded 
to intermediate grade in 17% (4/24) and invasive carcinoma in 12% 
(3/24). All factors associated with lack of concordance were noted.
Conclusion
Concordance between VAB diagnostic biopsies of high, intermediate 
and low grade DCIS and post operative histology is good in this 
series and is to our knowledge the first to be reported using only 
large volume biopsies by VAB techniques. This audit has identified 
possible factors influencing the lack of concordance and these results 
with concordance data from other UK centres will be used by trial 
pathologists to refine protocols for the Low risk DCIS trial.
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P5-12-03
An Innovative Quantification Method for Tamoxifen and Three 
Metabolites in Formalin-Fixed Paraffin-Embedded Tissues by 
Liquid Chromatography and Tandem Mass Spectrometry.
Magliocco AM, Ng ES, Kangarloo B, Konno M, Paterson A. Tom 
Baker Cancer Centre, Calgary, AB, Canada; University of Calgary, 
Calgary, AB, Canada
Background: Tamoxifen (TAM) has been commonly used as a 
selective estrogen receptor modulator for the treatment and prevention 
of breast cancer. Although this drug is effective in many patients, 
some develop resistant and eventually relapse. Recent studies suggest 
that the cancer recurrence could possibly be due to changes in drug 
metabolism. TAM is metabolized by the cytochrome P450 enzyme 
pathway into several metabolites including 4-hydroxy-tamoxifen 
(4-OH), N-desmethyl-tamoxifen (DMT) and N-desmethyl-4-hydroxy-
tamoxifen (endoxifen). These metabolites have variable potencies 
in suppressing estrogen-dependent breast cancer. Differences 
in metabolism may contribute to the clinical inter-individual 
variability in TAM response. The aim of our study was to provide 
a comprehensive evaluation of TAM and its metabolites through 
quantitative measurement in breast cancer patients to help better 
understand the pharmacological effects of TAM therapy. In the past, 
most methods used to measure the levels of TAM and its metabolites 
were in plasma or fresh/frozen tissue samples. These samples are 
typically not available retrospectively, and their long-term storage is 
expensive and laborious.
Methods: We therefore explored the possibility to utilize formalin-
fixed and paraffin-embedded (FFPE) tissues archived post breast 
surgery for quantification of TAM and its metabolites. Our laboratory 
has developed a rapid, sensitive and specific analytical method using 
liquid chromatography and tandem mass spectrometry (LC-MS/MS) 
for the measurement of TAM and its metabolites in FFPE tissues. The 
FFPE tissues were thin sectioned and deparaffinized by incubating 
twice with xylene for 10 min at room temperature. Sample clean-up 
was carried out subsequently using C2 solid-phase extraction, and 
detection was performed in the multiple-reaction monitoring mode 
with a triple quadrupole mass spectrometer. This method allows 
simultaneous quantification of TAM and three metabolites in FFPE 
tissues with a run time of 12 min.
Results: The assay had good inter- and intra-assay precisions (2-6 
%CV), and was linear over the range of 0.01–5 ng/g for 4-OH and 
endoxifen, and 0.1–50 ng/g for TAM and DMT. The extraction 
recoveries were between 83-88%. The validated method was 
successfully applied to analyze the FFPE tissues obtained from two 
groups of breast cancer patients. Patients were categorized into those 
with tumor recurrence (R) and those without recurrence (NR) after 
at least 2 months of 20 mg/d TAM treatment. Levels of TAM, 4-OH, 
DMT and endoxifen in FFPE tissues were compared between the 
two groups. Our preliminary data show that the ratio of DMT/TAM 
was significantly higher in the R (6.7, n = 13) than the NR patients 
(14.2, n = 9) (p<0.05).
Discussion: The assay described here not only allows accurate 
quantification of TAM and metabolites in FFPE tissues, but also opens 
up an incredible opportunity and new challenges for researchers to 
excavate precious information from FFPE tissues, especially when 
these archival samples represent the only source of biomaterial 
available.
P5-12-04
Genetic Linkage between Acquired and Primary Lymphedema 
Evaluated through Whole Exome Sequencing and NIR 
Fluorescence Lymphatic Imaging.
Sevick-Muraca EM, Gonzalez-Garay ML, Fife CE, Guilliod R, Hall 
O, Marshall MV, Rasmussen JC, Aldrich MB, Darne C, Zhu B, Tan 
I-C, Caskey CT. University of Texas Health Science Center, Houston, 
TX; Memorial Hermann Hospital, Houston, TX
Acquired lymphedema is thought to arise from the damage of the 
lymphatic vasculature that transports excess fluid and macromolecules 
away from tissues for return to the blood vasculature. The onset of 
the cancer acquired disease can occur months to years after lymph 
node dissection and manifests itself as an accumulation of fluid 
and macromolecules in tissues that leads to edema and irresolvable 
swelling. The rare disease of primary lymphedema is identical to 
cancer acquired lymphedema, with the exception that there is no 
trauma or cancer treatment that can be attributed as its cause. Primary 
lymphedema has been attributed to genetic causes since the late 
nineteenth century. Although there are five known genetic causes 
of hereditary or primary lymphedema, the majority of patients with 
lymphedema do not possess mutations in these genes. More recently, 
it has been proposed that a genetic link between cancer acquired 
and primary lymphedema exists. If a genetic susceptibility for 
cancer acquired lymphedema could be found, then we could predict 
which survivors will encounter the disease and could develop new 
therapies which are more effective than the current treatments that 
have remained unchanged for the past 80 years.
In an FDA approved investigational study, we used near-infrared 
(NIR) fluorescence imaging to phenotype the lymphatic architecture 
of subjects with both acquired and primary lymphedema, as well 
as their unaffected family members. We collected blood for DNA 
analyses. NIR fluorescence provided the phenotype of abnormal 
lymphatic function while whole exome sequencing provided the 
genotype. Bioinformatics analyses were then used to identify 
causative genes using cosegregation of familial genotypes using the 
phentotypes found through NIR fluorescence imaging.
The first family analyzed had members with primary and acquired 
lymphedema in which mutations encoding for proteins that participate 
in the HGF/c-MET and PI3K pathways could potentially explain the 
inheritance of lymphedema in this family. The father and affected 
daughters were heterozygous for a de novo SNP HGF in the kringle 
binding domain that interacts with tyrosine kinase receptor c-MET. 
The father had a normal lymphatic phenotype. On the other hand, the 
mother and daughters were heterozygous for the de novo mutation 
of INPPL1 (SHIP-2), adjacent to the SH2 domain of the protein 
that is known to bind to the multifunctional docking site of c-MET 
and associates with proteins in the Rho pathway for cytoskeletal 
reorganization. The daughters possessed both HGF and INPPL1 
mutations and were diagnosed with primary lymphedema while 
the mother, who possessed the INPPL1 mutation, was diagnosed 
at the time of NIR imaging with acquired lymphedema. Analyses 
of remaining families as well as breast cancer related lymphedema 
patients are underway to confirm whether INPPL1 may be a candidate 
susceptibility gene for acquired lymphedema. Supported in parts 
by R01 HL092923 and CA128919, The Texas Star Award, and the 
Cullen Foundation.
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P5-12-05
(In-)Efficiencies in the Preoperative Imaging Evaluation of the 
Medicare Breast Cancer Patient.
Bleicher RJ, Ruth K, Sigurdson ER, Evers K, Wong Y-N, Boraas M, 
Egleston BL. Fox Chase Cancer Center, Philadelphia, PA
Introduction: Breast cancer evaluation requires a combination of 
physical examination and imaging for preoperative diagnosis and 
assessment of surgical treatment options. While imaging remains a 
critical component of that assessment, the burden of patient (pt) return 
visits for imaging is unknown.
Methods: Medicare claims linked to Surveillance Epidemiology 
End Results data were reviewed for women developing breast cancer 
between 1992 and 2005. The preoperative interval was defined as 
the period from the first physician encounter for a breast-related 
diagnosis until therapeutic surgery. Pts without >6 mos of data prior 
to that interval, those having DCIS or Stage IV disease, and those 
having preoperative chemotherapy or radiotherapy were excluded. 
Imaging modality counts exclude image-guidance claims for biopsies.
Results: Among 353,265 Medicare pts developing breast cancer 
between 1992 and 2005, 67,751 women >65 y of age had invasive, 
nonmetastatic breast cancer, and simultaneous breast surgery 
(lumpectomy or mastectomy) with lymph node staging. Median age 
was 75 y and preoperative interval length was 27 d. In the 6 mos 
before the preoperative interval, mammograms (MMGs), breast 
ultrasounds (USs), and breast MRIs were performed exclusive of 
the preoperative interval in 34,192 (50.5%), 16,936 (25.0%), and 
180 (0.3%) pts respectively, while during the preoperative interval, 
MMGs, USs, and MRIs were performed in an additional 30,414 
(44.9%), 17,983 (26.5%), and 1,409 (2.1%) respective pts. Imaging 
was performed on >2 separate dates during the preoperative interval 
in 4.9% of pts in 1992, rising to 19.4% in 2005 (trend, p<0.0001). 
During that interval, there were >2 encounter dates for MMGs 
in 7.0% of pts, rising from 3.9% in 1992 to 8.8% in 2005 (trend, 
p<0.0001); for US, 3.6% overall, rising from 0.2% in 1992 to 6.6% 
in 2005 (trend, p<0.0001). Multiple MRI encounters were rare, 
occurring in 0.2% overall, and increasing to 0.6% in 2005 (trend, 
p<0.0001), while single MRI use increased from <0.1% in 1994 to 
8.3% in 2005 (trend, p<0.0001). In the preoperative interval, use of 
more than one imaging modality on any given date increased from 
4.3% in 1992, to 27.1% in 2005. Among those with imaging, there 
was low correlation between number of imaging dates and number of 
modalities on any given date (rs= 0.13, p<0.0001). MMGs accounted 
for 71.9% of the days where one modality was performed alone, but 
MRI was performed alone 94.1% of the time. The total number of 
imaging dates in the preoperative interval was inversely related to 
age (p<0.0001). Differences in the mean number of imaging dates 
by race and stage were minor and all <0.3 days.
Conclusion: Preoperative Medicare breast imaging claims on multiple 
dates have been increasing substantially since 1992, suggesting that 
the patient’s time burden for such evaluation is increasing. This 
trend is present despite the fact that multiple imaging modalities are 
being performed more frequently on the same date. Efforts to further 
consolidate preoperative breast imaging visits to lower that burden 
should be undertaken where possible in the Medicare population, 
for whom advanced age, in itself, may provide its own challenges.
P5-13-01
Survival Outcome with Bevacizumab: Activation of the 
Phosphatidylinositol-3 Kinase (PI3K) Pathway Due to PIK3CA 
Mutations or PTEN Loss Makes a Difference.
Vidal M, Di Cosimo S, Torrejon D, Saura C, Gómez-Pardo P, Pérez-
Garcia J, Muñoz-Couselo E, Bellet M, Sanchez-Olle G, De Mattos-
Arruda L, Oliveira M, Tabernero J, Baselga J, Cortes J. Vall d’Hebron 
Institute of Oncology, Vall d’Hebron University Hospital, Universitat 
Autònoma de Barcelona, Barcelona, Spain; Massachusetts General 
Hospital Cancer Center. Harvard Medical School, Boston
Background: The PI3K pathway is known to regulate the transcription 
of Vascular Endothelial Growth Factor (VEGF) in endothelial and 
cancer cells. The inhibition of VEGF is the rationale behind the 
development therapy with anti-angiogenics. We investigated the 
activation of PI3K pathway, defined as PTEN loss and/or PIK3CA 
mutations, and the relationship with survival in metastatic breast 
cancer patients treated with the anti-VEGF monoclonal antibody 
bevacizumab.
Patients and methods: Records for patients with HER2 negative 
metastatic breast cancer (MBC), treated with bevacizumab from 
July 2005 to June 2010, and with known PI3K status were reviewed. 
Univariate and multivariate analysis were performed using SPSS 15.0.
Results: A total of 40 patients - 26 with and 14 without PI3K 
activation - were identified. Median age was 47 years (range 27-79). 
Median overall survival (OS) was 41.23 months (CI 95%: 27.29 – 
55.18) and 66.23 months (CI 95%: 61.04 – 71.42) in patients with 
and without PI3K activation, respectively (p=0.04). Among patients 
with PI3K activation, OS was 34.13 months (CI 95%: 22.40 – 45.86) 
and 43.43 months (CI 95%: 26.9 – 59.97) in cases with PIK3CA 
mutations and PTEN loss, respectively. As compared to patients 
without PI3K activation, patients with PI3KCA mutations but not 
patients with PTEN loss showed a significant worse outcome (p=0.006 
and p=0.3, respectively). In the multivariate analysis including grade, 
hormone receptor and Ki67 status, and total lines of treatment, the 
activation of PI3K activation proved to be an independent prognostic 
factor (p=0.03).
Conclusions: The activation of the PI3K pathway is significantly 
associated with decreased OS of MBC patients treated with 
bevacizumab. Prospective evaluation of PI3K activation on VEGF 
signaling with differential implication of PI3KCA and PTEN loss 
is warranted.
P5-13-02
Prediction of Dasatinib Sensitivity of Breast Cancer Based on a 
Novel Tyrosine Kinase-Activity Profiling Assay.
Kawai M, Torikoshi Y, Notoya M, Gohda K, Ueno NT, Ishihara H. 
Sysmex Corporation, Kobe, Hyogo, Japan; The University of Texas 
MD Anderson Cancer Center, Houston, TX
Background: Receptor tyrosine kinases and other membrane-
associated tyrosine kinases are frequently overexpressed, activated, 
or mutated in cancer cells and cause aberrant signal transduction, 
which leads to cellular proliferation, angiogenesis, metastasis, and 
antiapoptosis. Blockage of these signals is considered an efficient 
strategy in cancer therapy, and to date, several tyrosine kinase 
inhibitors (TKIs) and antibody drugs targeting such kinases have been 
developed and are routinely used in clinics. However, the efficacy 
rates of the drugs are, unfortunately, limited. To provide optimum 
care for individual patients, an accurate prediction method for drug 
efficacy is now strongly demanded. Recent studies have shown that 
alteration of multiple kinases is involved in both primary and acquired 
drug resistance. Advantages of multi-targeted TKIs have also been 
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reported. These findings indicate the need for a comprehensive 
evaluation of multiple kinases for predicting drug response. To 
achieve this, we developed a novel method of comprehensively 
profiling kinase activity.
Materials and methods: We characterized the membranous tyrosine 
kinases of breast cancer cell lines using a newly established profiling 
assay. Briefly, crude membrane fractions were prepared and directly 
subjected to the assay with nonspecific substrate (Poly(Glu4-Tyr)). The 
profile of the kinases in the crude membrane fraction was obtained 
by inhibiting the total activity with 13 selected kinds of adenosine 
triphosphate antagonists, independently. The residual activity (RA) 
of membranous kinases was defined as the percentage of activity 
with/without TKI.
Results: Nineteen breast cancer cell lines were classified as “sensitive” 
(n = 6) and “resistant” (n = 13) to dasatinib according to the definition 
in the publication (Cancer Res., 67 2226-38. 2007). The RA of 
tyrosine kinases targeted by different types of TKIs was determined 
by our assay, and we found that two RAs (src inhibitor 1 and PP1) 
showed statistically significant differences between the “sensitive” 
and “resistant” groups (p=0.017, and p=0.002, respectively, Student’s 
t-test). The RA of the two TKIs were also significant predictors for 
dasatinib sensitivity in a receiver operating characteristic curve 
analysis (area under the curve: 0.846 for src inhibitor 1 and 0.910 
for PP1). Since the major target of dasatinib are src family kinases, 
protein expressions of the src family of the cell lines were quantified 
by a Western blotting and compared between the groups. We found 
that the protein expression is not a statistically significant predictor 
of dasatinib sensitivity.
Conclusion: We have shown that a comprehensive tyrosine kinase 
activity profiling assay of cancer cells can predict dasatinib sensitivity. 
We plan to validate this assay prospectively in patients with breast 
cancer who receive dasatinib.
P5-13-03
Correlation of Clinical and Molecular Findings with Pathologic 
Response to Preoperative Lapatinib and Trastuzumab, Separately 
or in Combination, Prior to Neoadjuvant Chemotherapy for 
HER2 Positive Breast Cancer.
Holmes FA, Espina V, Liotta LA, Chang JC, Nagarwala YX, Danso 
M, McIntyre K, Osborne CR, Krekow LK, Gagnon RC, Mahoney 
JM, O’Shaughnessy JA. US Oncology, The Woodlands, TX; Texas 
Oncology, Houston, TX; George Mason University, Manassas, VA; 
The Methodist Hospital, Houston, TX; GlaxoSmithKline Oncology, 
Collegeville, PA; Virginia Oncology Associates, Virginia Beach, VA; 
Texas Oncology Austin, Austin, TX; Baylor Sammons Cancer Center, 
Dallas, TX; Texas Oncology, Bedford, TX; Texas Oncology, Dallas, TX
Background: 15% of curative HER2-positive patients (pts) treated 
with standard trastuzumab (T)-based chemotherapy regimens recur. 
Our prior report (ASCO 2011 #506 using only data from paired 
samples N=49) identified major pathways of resistance: autophagy, 
stem cell, extracellular matrix, and phospho epitopes on FOXO, 
STAT5, EGFR.
Aim: To collect proteomic and microarray data from baseline 
biopsies and identify molecular correlates of pathologic complete 
response (pCR).
Methods: Randomized, open label, phase II. Eligibility: biopsy-
proven HER2 positive stage II, III invasive breast cancer, healthy. 
After informed consent, pt randomized to T or Lapatinib (L) or both 
(T+L) for 2 weeks (wk) then continue same anti-HER2 agent with 
standard chemotherapy (FEC75 IV every 3 wk then Paclitaxel 80 
mg/m2 wk x 12) then surgery. Research biopsy before and 2 wks 
after anti-HER2 agent analyzed by reverse phase protein microarray 
(RPMA) from laser capture microdissected cells, RNA expression 
microarray, and in-vitro stem cell studies. PCR in breast is no invasive 
tumor. ITT is Intent to Treat (all treated pts). Pathways identified 
by analytes (n=42): autophagy (Beclin 1, LC3B, ATG5), stem cell 
(CD44, Mushashi, E-Cadherin, Beta Catenin), extracellular matrix 
(Integrin, MMP). Additional informative analytes: phosphorylated 
HER3, IGFR1.
Results: 100 pts treated: T=33, L=34, T+L=33. % pCR- ITT: 
ER pos/ER neg by arm: T = 40%/67%; L = 21%/50%; T+L = 
58%/50%. Baseline RPMA samples N= 65 (T = 22; L= 25; T+L = 
18). A) Specific analytes contributory to outcome by arm by Random 
Forest analysis: T: Beta Catenin Ser 33/37/Thr 41, EGFR Tyr1045. 
L: MMP14, E-Cadherin, LC3B, Integrin alpha5 B1, Stat 5 Tyr 694, 
IGFR Tyr 1131/1146, Erk Thr 202/Tyr204, NFKB Ser536, FOXO 
Thr24, HER3 Tyr1289. T+L: cerb2, EGFR, Met Tyr1235, CD44, 
E-Cadherin. B) Statistically significant endpoint ratios from network 
analysis that strongly correlate with pCR: T: HER3 Tyr1289/Beclin 
1; PTENser380/ERK Thr202/Tyr204; GSK3B Ser21-9/Stat5 Tyr694; 
p70S6 Thr389/LC3B; p7026 Thr389/MMP9; FOXO Thr24-32/
NFKB Ser536; Beta Catenin Ser 33-37 Thr41/LC3B. L: EGFR 
Tyr1045Beclin1; cerb2/Beclin1; HER3 Tyr1289/Beclin1; PI3K/
FOXO Thr24,32; IRS1 Ser612/Beclin1; Mushashi/IRS1 Ser612. T+L: 
only 4 pts no pCR. C) Microarray analysis confirms the critical role 
of extracellular matrix and autophagy.
Discussion: These findings support the concept that NO-pCR tumors 
can engage a diverse set of strategies to achieve cell survival in the 
face of therapy. The molecular correlates of response found in this 
small, underpowered study provide candidates for future patient 
stratification studies and generate insights for combination therapy.
P5-13-04
Changes in Phosphorylation Status at VEGFR2 and Basal Tumor 
Hypoxic Volume Assessed by Misonidazol (MISO) Positron 
Emission Tomography (PET/CT) as Potential Biomarkers for 
Predicting Response to Bevacizumab in Breast Cancer.
Garcia-Foncilla J, Garcia-Velloso MJ, Dominguez I, Morales S, 
Hernando B, Sanchez R, Alvarez I, Anton A, Illarramendi JJ, De 
Juan A, Martinez P, Lahuerta A, Llombart A, Garcia-Gonzalez M, 
Lao Romera J, Purtolas T, Scherer S, Sabariz Luis, Lopez-Vega JM, 
Galve E, Plazaola A, Boni V. Clinic University of Navarra; Hospital 
Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; 
Hospital Donosti; Hospital Miguel Servet; josejuan.illarr@terra.es; 
Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; 
Roche Basel; Roche Madrid
Background: To evaluate the expression of novel putative biomarkers 
as predictors of benefit from bevacizumab in stage II-III, previously 
untreated breast cancers (BC) patients (pts) in the context of a phase 
II, single-arm, multicenter and prospective clinical trial. To address 
this aim, we examined baseline and induced changes after a single 
bevacizumab administration as potential early predictors of response.
Methods: Pts received a single infusion of bevacizumab (15 mg/ kg) 
(C1) 3 weeks prior to the beginning of neoadjuvant chemotherapy 
consisting in 4 cycles of docetaxel (60 mg/mq), doxorubicin (50 mg/
mq) and bevacizumab (15 mg/ kg) every 21 days (C2-C5) following 
by surgery. Early assessment of tumor changes was performed by 
paired tumor-biopsies and MISO PET/CT before and 14-21 days 
after bevacizumab administration (C1). Biomarker expression was 
assessed by immunohistochemistry (IHC) (Ki67, CD31, CD31/Ki67, 
VEGFR2, pVEGFR2 [Y951]) on formalin-fixed, paraffin-embedded 
tissue before and after bevacizumab infusion (C1). MISO SUV and 
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tumor volume depicted by PET were calculated. Pathological response 
on surgical specimens was assessed according to Miller/Payne 
classification. Pts with tumor reduction >90% were considered as best 
responders (G4-G5) whether tumor reduction <90% were considered 
as no responders. Association between pathological response, IHC 
and MISO biomarkers was analyzed using Mann-Whitney test. 
ROC curve was performed to test sensibility and specificity of the 
biomarker found significantly associated with response and its value 
as independent predictor was tested in the multivariate analysis using 
logistic regression.
Results: This analysis was performed on the training set including 
73 patients (49 yr, range 29-70). Twenty (27%) patients obtained 
best response (G4-G5) whether 50 (68%) were considered as no 
responder (G1-G2-G3). Response was associated with negative 
estrogen receptors expression (p=0.02) and high Ki67 basal and 
after C1 expression (p=0.009 and p=0.01). Six (54%) of triple 
negative tumors were responders (p=0.05). Interestingly, change in 
pVEGFR2 [Y951] staining induced by bevacizumab administration 
and basaline MISO tumor volume was found significantly associated 
with response (p=0.03 and 0.057). Decrease in the phosphorilation 
status of VEGFR2 (Y951) >70% yielded a receiver operating 
characteristic (ROC) curve area of 0.681 (95% CI: 0.536 - 0.825) 
with 84% sensitivity and 95% specificity. The positive and negative 
predictive values for this marker were 60% and 64%, respectively. The 
change in phosphorilation status of VEGFR2p remains a significant 
predictor biomarker of response in multivariate analysis (OR=0.9, 
IC%95 0.96-0.99, p=0.04) after adjusting for clinical-pathological 
characteristics.
Conclusion: These findings underline the potential value of early 
decrease in phosphorilation status of VEGFR2 after bevacizumab 
infusion as predictive biomarker of response to anti-angiogenic 
therapy in breast cancer. Moreover, tumor hypoxic volume obtained 
by MISO might be associated with response. A validation set is 
warranted to confirm these findings.
P5-13-05
Non-Invasive In Vivo 1H Magnetic Resonance Spectroscopy 
(MRS) Monitoring of Breast Tumor Response to IGF1R Targeted 
Therapy.
Sachdev D, Lin JE, Lunzer C, Marjanska M, Garwood M, Yee D. 
University of Minnesota, Minneapolis, MN
Drugs targeting IGF1R are in clinical trials for breast cancer therapy. 
To date no suitable biomarkers of response have been identified for 
this therapy. It is important to select patients with tumors sensitive 
to disruption of IGF1R signaling. In addition, predicting response in 
patients quickly following initial treatment would also assist in the 
development of these strategies. While expression of IGF1R must be 
a minimum requirement for enrolling patients in trials with IGF1R 
agents, the mere expression of IGF1R is not necessarily sufficient 
for IGF-driven biology. We have previously shown that monitoring 
levels of total choline-containing compounds (tCho) non-invasively 
in breast cancer patients with locally advanced breast cancer is a 
useful predictor of response to primary systemic therapy. The tCho 
measured in these studies included choline, phosphocholine (pCho) 
and glycerophosphocholine (GPC). In this study, we examined if 
changes in tCho could be used as a marker of response to anti-IGF1R 
therapy. We tested the effect of two antibodies against IGF1R on 
intratumoral tCho levels in vivo. Mice bearing MCF-7 xenografts 
were subjected to MR imaging (MRI) and spectroscopy (MRS) to 
measure baseline tCho levels. MRI was performed at 4.7 Tesla (200 
mHz) with a transceive surface coil. Single-voxel 1H spectroscopy was 
performed using water suppression and TE-averaging. A fully relaxed, 
unsuppressed water spectrum from the same voxel was acquired 
and tCho signal was referenced against the tissue water signal and 
expressed as mmol/kg water. The next day, mice were treated with 
500 µg of scFv-Fc or phosphate buffered saline, or 800 µg EM164 
or isotype-matched control antibody. 24 hours post-treatment, tCho 
was measured. The percent change in tCho 24h after treatment (% 
tCho24) was determined using the formula 100[(tCho24-tCho0)/
tCho0]. In 9 out 10 mice treated with scFv-Fc, % tCho24 ranged 
from -26 to -81% of baseline levels while in mice treated with PBS 
the change was from 0% to +46%. EM164 treatment also caused 
decrease in tCho levels in 3 out of 3 mice while the control antibody 
did not. tCho was also monitored for a period of 2 weeks during the 
course of treatment with EM164 or control antibody; EM164 caused 
a decrease in tCho with % tCho of -35% while the control antibody 
treated mice showed % tCho of +43% over the two-week treatment. 
To further delineate the precise choline species regulated by IGF 
signaling, MCF-7 cells were treated in vitro with IGF-I for 24h and 
cell extracts subjected to MRS at 14.1 Tesla using a NMR scanner. 
IGF-I enhanced levels of pCho compared to choline and GPC. We 
next investigated if there is a mechanistic link between IGF signaling 
and choline metabolism. MCF-7 cells were treated with IGF-I for 10 
minutes or 24h and levels of choline kinase (ChoK), the rate-limiting 
enzyme that converts choline to pCho and then phosphatidylcholine 
were examined. Surprisingly, IGF-I signaling enhanced ChoK levels. 
Our data show that decrease in tCho could be a surrogate marker of 
early response to anti-IGF1R therapy. Thus, MRS to measure tCho 
levels could be included in the design of clinical trials with such 
reagents to quickly identify patients whose tumors are sensitive to 
inhibition of IGF1R.
P5-13-06
Lipidomic Profile Predicts Pathologic Complete Response to 
Neoadjuvant Weekly Paclitaxel Treatment.
Facina G, Calux NMCT, Silva MFR, Bonetti TCS, Nazario ACP, Silva 
IDCG. Federal University of Sao Paulo, Sao Paulo, Brazil
BACKGROUND: Neoadjuvant chemotherapy is one of the 
main strategies for patients with advanced breast cancer. The 
taxane paclitaxel have an important role in inhibiting microtubule 
polymerization and this mechanism prevents cells from entering 
into the mitotic phase. The therapeutic efficacy and toxicity profile 
of weekly paclitaxel administration have been showed since 90s. 
Lipidomics may be defined as the large-scale study of pathways and 
networks of cellular lipids that is involved in biological systems. In 
the present study our aim was to evaluate the possibility to identify 
a lipidomic signature of good and bad responsers to neoadjuvant 
chemotherapy.
PURPOSE: To analyze and identify the lipid fingerprint in tumor 
biopsy of advanced breast cancer patients who get a complete 
pathologic response (CPR) with weekly paclitaxel treatment and 
compare this with the group who get no response.
MATERIAL AND METHODS: Seventy eight patients with clinical 
stage IIIA breast cancer were selected to receive the neoadjuvant 
treatment with weekly paclitaxel (for a total of 12 doses – 80mg/m2). 
Fifty eight patients completed the treatment purpose. Seven presented 
CPR (Group A) and 5 showed progressions (Group B). The lipids 
were extracted from biopsies and submitted to matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI-MS). MALDI-MS 
spectra were acquired in the positive ion and reflectron modes using 
Synapt Q-ToF mass spectrometers (Waters, Manchester, UK). The 
spectra were acquired in the m/z 700-1200 range. From each spectrum 
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the most intense ions were considered as the starting point of searching 
m/z values which were clearly distinct from noise level in the spectra 
were included in the principal component analysis (PCA).
RESULTS: The PCA analysis of the mass spectra shows that groups 
can be resolved via their MALDI-MS lipid profiles, which suggest 
the patients who presented CPR can present distinct lipid fingerprint 
in the tumor biopsy compared to patients who showed progressions.
CONCLUSION: After genomic and proteomic innovations, it 
turns necessary to explore metabolic processes at the system level. 
Lipidomics is a developing strategy for functional genomics, since 
there is growing evidence that lipids are structural biomolecules, 
which have important function as signal transduction processes, 
second messenger molecules or their precursors. Is possible that 
lipidomic profile of tumor specimen could help us to select the 
patients with advanced breast cancer that might present complete 
pathologic response by weekly paclitaxel treatment. This study will 
be continued to confirm this results and carried the identification of 
the lipids based on earlier studies and MS/MS data using lipidmaps 
and chemspider databases.
P5-13-07
MET and Hepatocyte Growth Factor (HGF) Increased Gene Copy 
Number Is Associated to Trastuzumab Failure in HER2 Positive 
Metastatic Breast Cancer (MBC).
Minuti G, Duchnowska R, Jassem J, Roncalli M, O’Brien T, Fabi 
A, Landi L, Di Marsico R, Biernat W, Czartoryska-Arlukowicz B, 
Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczynska-Kloda M, 
Tempinska-Szalach A, Rossi E, Varella-Garcia M, Cappuzzo F. Istituto 
Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military 
Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, 
Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, 
Italy; Laboratory of Molecular Pathology, University of Colorado 
Cancer Center, Denver, CO; National Cancer Institute Regina Elena, 
Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; 
Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, 
Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria 
Oncology Center, Olsztyn, Poland; West Pomeranian Oncology 
Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA 
Interuniversity Consortium, Bologna, Italy
Background: The ErbB2-targeting monoclonal antibody trastuzumab 
has remarkable efficacy in metastatic breast cancer (MBC) patients 
(pts) with HER2 overexpression or amplification (HER2+), either 
alone or in combination with chemotherapy. However, the response 
rate to trastuzumab is modest and not all pts derive benefit from this 
treatment. Predictive mechanisms of sensitivity and/or resistance 
are largely unknown. Recently, preclinical and limited clinical data 
showed that aberrant MET expression in MBC is a predictor of 
poor prognosis and is involved in trastuzumab resistance. Aim of 
the present study was to investigate whether increased gene copy 
number of MET or its ligand, the hepatocyte growth factor (HGF), 
affect trastuzumab sensitivity.
Patients and Methods: This retrospective study included 130 HER2+ 
MBC pts treated with trastuzumab as monotherapy (N=21) or in 
combination with chemotherapy (N=109). Main inclusion criteria 
were presence of at least one measurable lesion and availability 
of paraffin-embedded tumor tissue from primary cancer. MET and 
HGF gene copy number (GCN) were assessed by fluorescence in 
situ hybridization (FISH). Receiver operating characteristic (ROC) 
analysis was used for identifying the best MET and HGF mean GCN 
cut-off.
Results: In the whole population response rate (RR), including 
complete (CR) and partial response (PR) was 49.2%, disease control 
rate, including CR+PR+ stable disease (SD) was 76.2%, median time 
to progression (TTP) 9.4 months, and median survival (OS) 28.3 
months. MET FISH analysis was successfully performed in all 130 
cases. Median MET mean GCN was 2.96 (range 1.66-8.40), with no 
gene amplification. ROC curve identified a mean of 3.72 MET GCN 
as the optimal cut-off value for discriminating between sensitive 
(CR+PR+SD) and refractory pts (pts with progressive disease [PD] 
at the first disease assessment). MET FISH+ (N=36, mean ≥3.72) had 
a significantly higher PD rate (44.4% versus 16.0%; p=0.001) and a 
significantly shorter TTP (5.7 versus 9.9 months; HR 1.74 95% C.I. 
1.16-2.62; p=0.006) than MET FISH- pts (N=94, mean <3.72). HGF 
GCN was successfully evaluated in 84 pts (64.6%). Median HGF 
mean GCN was 2.80 (range 1.14-6.90). ROC analysis identified a 
cut-off of 3.01 mean HGF GCN as the best discriminating between 
sensitive (CR+PR+SD) and refractory pts. HGF FISH+ (N=33, 
mean ≥ 3.01) had a significantly higher PD rate (30.3% versus 7.8%; 
p=0.007) and a non-significant shorter TTP (9.9 versus 10.5 months, 
HR 1.10 95% C.I. 0.70-1.74, p=0.66).
Conclusions: High GCNs of MET or HGF associate with an increased 
risk of trastuzumab failure in HER2+ MBC. These data support 
a further development of combining anti-HER2 with anti-MET 
strategies in MBC.
P5-13-08
Breast Cancer Index Predicts Likelihood of Breast Conservation 
Surgery after Neoadjuvant Chemotherapy.
Mazouni C, Mathieu M-C, Kesty NC, Zhang Y, Scott V, Schnabel CA, 
Erlander MG, Delaloge S, Andre F. Institut Gustave Roussy, Villejuif, 
France; bioTheranostics, Inc, San Diego, CA
Introduction: Neoadjuvant chemotherapy increases the likelihood 
that breast conservation therapy for breast cancer patients will be 
successful. Breast Cancer Index (BCI), a gene expression assay 
combining HoxB13/IL17BR ratio and Molecular Grade Index (MGI), 
is prognostic for the risk of distant recurrence and overall survival 
in tamoxifen-treated and untreated breast cancer patients. It was 
previously reported that high risk patients, as determined by BCI, had 
a 10-fold greater probability of pathologic complete response (pCR) 
with neoadjuvant chemotherapy than low risk patients. The aim of 
the current study was to examine the relationship between BCI score 
and the use of breast conservation surgery (BCS) following treatment 
with neoadjuvant chemotherapy.
Material and Methods: A total of 145 women (tumor size T1, T2 and 
T3) were treated with neoadjuvant cheomtherapy for stage I-III breast 
cancer. RNA was extracted from FFPE tumor samples and a real-time 
RT-PCR assay was completed to generate a BCI score and risk group 
categorization as previously described (Jerevall et al. Br J Cancer 
2011). The relationship between BCS, BCI and clinicopathological 
factors was examined using univariate and multivariate logistic 
regression.
Results: Of the 145 patients (67% ER+, 54% PR+, 57% >50 y old), 
48 (33.1%) underwent BCS. BCI categorized 62 (43%) of patients 
as low, 50 (34%) as intermediate and 33 (23%) as high risk. The 
rate of BCS for the three BCI risk categories was 15% (low risk), 
48% (intermediate risk) and 45% (high risk). In the low risk group, 
the rate of BCS was 15% corresponding to a NPV of 85%. This is 
consistent with previous data from the same cohort, where the NPV 
of BCI for pCR was 98.4% with only one patient in the low risk group 
achieving pCR. In univariate analysis, pathological tumor size (pT), 
ER, PR, grade and BCI were predictors of BCS. A higher BCI score 
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was associated with higher likelihood of BCS (odds ratio of 3.90; CI: 
1.45-10.49; p=0.0069). In multivariate analysis, pT and BCI remained 
significantly associated with BCS, while ER status was not (p=0.23). 
Results were similar in the subset of patients with T1 and T2 tumors 
(N=97). In this subset, BCI categorized 42% of patients as low, 37% 
as intermediate and 21% as high risk and the rate of BCS was 22%, 
64% and 60%, respectively. In multivariate analysis of this subset, 
only BCI was significantly associated with BCS. In all patients, the 
concordance index based on a model with pT alone was 0.695. When 
BCI was incorporated into the model with pT, the concordance index 
increased to 0.801 (p= 0.0002).
Conclusion: In this study, we have shown that patients with higher 
BCI scores were associated with a higher likelihood of receiving 
BCS after neoadjuvant chemotherapy. Addition of BCI to tumor size 
increased accuracy in predicting likelihood of BCS. BCI along with 
standard pathological factors may improve estimation of individual 
probability of BCS after neoadjuvant chemotherapy. This study 
gives rise to the hypothesis that patients with low BCI should not be 
eligible for neoadjuvant chemotherapy since the likelihood of breast 
conservation is low. Further large confirmatory studies are necessary.
P5-13-09
Correlation of Oncotype  DX Recurrence Scores with 
Pathologic Response Following Neoadjuvant Ixabepilone and 
Cyclophosphamide in Patients with HER2-Negative Breast 
Cancer: A Sarah Cannon Research Institute Phase II Trial.
Yardley DA, Peacock NW, Hendricks C, Huh SY, Ketchum S, Chao C, 
Yoshizawa C, Burris III HA, Hainsworth JD. Sarah Cannon Research 
Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; 
Center for Cancer and Blood Disorders, Bethesda, MD; Providence 
Medical Group, Terre Haute, IN; Mercy Hospital, Portland, ME; 
Genomic Health, Redwood City, CA
Background: Ixabepilone (Ixa) is active in anthracycline and taxane-
refractory metastatic breast cancer as well as in the neoadjuvant setting 
where Ixa yielded a pathologic complete response (pCR) rate of 11%. 
In this study, we evaluated Ixa in combination with cyclophosphamide 
(C) as neoadjuvant treatment for ER+/ER- HER2-negative breast 
cancer. The primary endpoint was pathologic complete response 
(pCR) rate, defined as no residual invasive cancer in breast or lymph 
nodes. The Oncotype DX Breast Cancer Assay, that uses reverse 
transcriptase-polymerase chain reaction (RT-PCR) to assess a panel 
of 21 tumor genes to calculate a score predictive of the likelihood 
of the magnitude of adjuvant chemotherapy benefit, was applied 
to pretreatment and residual disease tumor samples obtained at the 
time of definitive surgery. The likelihood of whether neoadjuvant 
clinical or pathological responses may be predicted by Oncotype DX 
recurrence scores (RS®) was assessed. An interim analysis of the first 
81 patients (pts) was reported at ASCO 2011. The final analysis will 
be presented on all 168 pts.
Methods: Eligible women had locally advanced breast cancer that was 
HER2-negative (IHC 0-1+ or FISH negative), T >2 cm or lymph node 
positive. Pts with inflammatory breast cancer or T1N0 tumors were 
excluded. Pts received Ixa 40mg/m2 with C 600mg/m2 day 1 q21 days 
x6 cycles. Following 6 cycles, had definitive surgery. Postoperative 
locoregional radiation therapy and/or hormonal treatments were at 
discretion of the treating MD per institutional guidelines. Breast core 
biopsy tumor samples were obtained pretreatment and at the time 
of surgery in those pts demonstrating residual disease at surgery. 
Tumor specimens were analyzed using the Oncotype DX RT-PCR 
assay. An interim pretreatment RS assessment in the first 38 pts and 
paired samples in 21 pts was conducted and correlated with clinical 
and pathologic responses.
Results: 168 women enrolled. Baseline characteristics and toxicity 
for the first 118 pts are reported (median age 52 years; 90% invasive 
ductal carcinoma; T2/T3 52%/31%; 42% triple negative). 81 pts have 
undergone surgery. 25 pts discontinued treatment early (toxicity – 
12; disease progression – 8; pt/MD request – 3; pt non-compliance 
- 2).Grade 3/4 toxicity included: neutropenia (65%), leukopenia 
(47%), neuropathy (10%), and febrile neutropenia (7%). Preliminary 
toxicity results with this neoadjuvant treatment have been previously 
reported (Peacock et al, ASCO 2011 Abstract #1066). Oncotype 
DX pretreatment evaluations for the initial 38 pts demonstrated a 
significant logistic regression of pretreatment recurrence score with 
pCR (p = 0.025).
Conclusions: Neoadjuvant therapy with Ixa and cyclophosphamide 
yielded a preliminary pCR rate of 19% (in 81 pts), similar to 
results with other 2-drug combination chemotherapy regimens. 
Preliminary Oncotype DX assessments at baseline indicated that 
baseline recurrence scores may predict pCR rates. These exploratory 
Oncotype DX recurrence scores at baseline and paired with scores 
obtained at the surgery and correlations with pCR will be presented 
for the entire cohort.
P5-13-10
Discordance of Estrogen Receptor and HER-2/neu Status Can 
Be Seen between First and Subsequently Biopsied Metastatic 
Lesions in Breast Cancer.
Lower EE, Kennedy D. Oncology Hematology Care, Cincinnati, OH
Background: We have previously reported discordance between 
primary and first metastasis for both estrogen receptor (ER) and 
HER-2/neu (HER 2) status (Breast Cancer Res Treat 2005;90:65-70 
and Breast Cancer Res Treat 2009;113:301-6). Because biomarker 
status is the primary determinant for targeted therapy, changes in 
biomarkers can impact recommendations for systemic treatment.
Materials and Methods: In order to evaluate the possibility of 
further discordance with the development of additional metastatic 
sites, we examined the ER and HER 2 status of primary and first 
and subsequently biopsied breast cancer metastasis. In most cases, 
the subsequent site of metastasis was the second detected metastasis. 
Pathology reports were reviewed from 65 patients with biopsy proven 
first and additional metastasis; however, immunostain results were 
not available for all three timepoints for all patients. Sites of biopsied 
metastasis included lung, liver, bone, chest wall, and central nervous 
system.
Results: The time between the initial diagnosis and first metastasis 
was 102 (3-676) months [Median (Range)], and the time between 
the first and subsequent metastasis was 60 (6-273) months. For ER, 
there was discordance between the primary lesion and either the first 
or subsequent metastasis in 18 of 65 cases (27.7%). Discordance of 
the ER occurred between the first and subsequent metastasis in 12 
(18%) of cases. Three patterns of ER discordance occurred in these 
12 cases: 4 cases of both primary and first metastasis negative with 
subsequent metastasis positive; 3 cases of primary positive, first 
metastasis negative, and subsequent metastasis positive, and 5 cases 
of primary and first metastasis positive and subsequent metastasis 
negative. For HER 2, discordance was detected between the primary 
and either first or subsequent metastasis in 11 of 36 cases (30.6%). 
Further discordance between the first and subsequent metastatic 
lesions occurred in 8 of 51 (16%) of cases.
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Conclusions: A significant level of discordance for either ER or HER 
2 was detected between first and subsequent metastatic breast cancer 
lesions. For breast cancer patients with new metastasis, consideration 
of reevaluating ER and HER-2/neu status may be worthwhile.
P5-13-11
PTEN and Tau-Protein Expression: Predictive Value of Poor 
Response to Trastuzumab Plus Paclitaxel in Patients with HER2-
Positive Breast Cancer.
Koo DH, Ahn J-H, Yoon DH, Kim S-B, Lee HJ, Kong KY, Son BH, 
Ahn SH, Jung KH. Asan Medical Center, University of Ulsan College 
of Medicine, Seoul, Korea
Backgrounds: Trastuzumab-based chemotherapy has been an active 
treatment in patients (pts) with HER2-positive breast cancer; however, 
primary and secondary resistance has occurred in pts treated with 
trastuzumab (H) alone or in combination with chemotherapy.
Material and Methods: Biomarkers were searched using tissue 
microarrays (TMA) in the HER2-positive breast cancer pts treated 
with H and paclitaxel (P) combination chemotherapy between October 
2004 and August 2010. Tumor blocks of 101 pts were analyzed for 
VEGF, IGF-1R, p-Akt, beta-III tubulin, CD44, Tau-protein, p27 and 
PTEN by immunohistochemical (IHC) analysis. Eight biomarkers 
were assessed to investigate the correlation with the clinical outcomes, 
including response rate (RR), progression free survival (PFS), and 
overall survival (OS).
Results: With a median follow-up duration of 21.7 months (range, 
9.1-55.2 months), 101 pts received H+P chemotherapy in neoadjuvant 
setting (n=36, 35.6%) and recurrent or metastatic setting (n=65, 
64.4%). Median age was 48 (range, 19-83 years), and the majority of 
pts (n=95, 94.1%) had good performance status. Premenopausal pts 
and hormone receptor-negative pts were 48 (47.5%) and 52 (51.5%), 
respectively. The median cycle of H+P chemotherapy was six (range, 
H 1-43; P 1-21). Overall RR was 68.3% (n=69) including complete 
response with 7 pts, and PFS and OS were significantly longer in pts 
responsive to H+P chemotherapy compared with non-responsive 
patients (PFS, p=0.001; OS, p=0.015). Although VEGF, IGF-1R, 
p-Akt, beta-III tubulin, CD44, p27 and PTEN status by IHC were 
not significantly associated with response to H+P chemotherapy, Tau-
protein showed a trend of association without statistical significance 
(RR, 46.2% vs. 71.6%, p=0.066). Among 13 pts with high Tau 
protein expression, 9 pts with both high Tau-protein and low PTEN 
level showed statistically significant lower RR compared with other 
92 pts (22.2% vs. 72.8%; p=0.002). None of the biomarkers was 
related to PFS and OS in pts with recurrent or metastatic disease, 
and to pathologic complete response in pts after H+P chemotherapy 
as neoadjuvant therapy.
Conclusion: Our data showed that both low PTEN level and high Tau-
protein expression were significantly associated with poor response 
to H+P chemotherapy in patients with HER2-positive breast cancer.
P5-13-12
Can the Ki67 Proliferation Index Predict the Oncotype DX 
Recurrence Score in Lymph Node Negative, ER Positive Breast 
Cancer?
Prendergast A, Martin K, Doolan P, Clarke C, Clynes M, Evoy D, 
McDermott E, Crown J, Kennedy S. Dublin City University, Dublin, 
Ireland; Conway Institute of Biomolecular and Biomedical Research, 
University College Dublin, Dublin, Ireland; St. Vincent’s University 
Hospital, Dublin, Ireland
Background Oncotype DX is a 21-gene assay for node-negative, ER 
positive breast cancer. Results are expressed as a Recurrence Score 
(RS). This predicts a low, intermediate or high risk of distant relapse. 
Proliferation-related genes such as Ki67 impact heavily upon the 
calculation of the RS. The assay encompasses several histopathologic 
factors (ER, HER2) and is limited by cost, proprietary nature and turn-
around time. We investigated whether Ki67 proliferation index (PI) 
and routine clinicopathologic parameters could be used to predict RS.
Materials and Methods We obtained clinicopathologic details for 69 
patients (diagnosed 2007-2010) who had RS available. Quantitative 
analysis of Ki67 immunohistochemistry was performed on primary 
tumour. Patients were classified as having a low (≤15%), intermediate 
(16-30%) or high (>30%) Ki67 PI. Risk of recurrence was calculated 
using Adjuvant! Online. Patients with categorized as having a 
poor, moderate, good or excellent prognosis as per the Nottingham 
prognostic index (NPI) and a low, intermediate or high risk of relapse, 
according to the St. Gallen criteria.
Results Mean age at diagnosis was 51.4 years (range: 34-74 years). 
Mean tumour size was 1.9 cm (range: 0.8-4.1cm). Mean Ki67 PI 
was 13.4 % (range 0.2 to 52.6%). RS was low (0-17) in 34 cases, 
intermediate (18-30) in 26 cases and high (>30) in 9 cases. The RS 
was significantly correlated with Ki67 expression (Spearman’s rank 
correlation, r = 0.472, p<0.001). RS was significantly higher in 
patients with a high Ki67 PI, when compared to patients with low and 
intermediate Ki67 PI (Mann Whitney U, p<0.05). RS was significantly 
higher in patients with grade 3 tumours, when compared to patients 
with grade 1 and 2 tumours (Mann Whitney U, p<0.05). Risk of 
recurrence as predicted by Adjuvant! Online, was significantly higher 
in patients with a high RS, when compared to patients with low and 
intermediate RS (Mann Whitney U, p<0.05). RS was significantly 
higher in patients with moderate prognosis, as determined by the 
NPI, when compared to patients classified as having a good/excellent 
prognosis (Mann Whitney U, p<0.05). No patients were classified by 
the NPI as having a poor prognosis. RS was significantly higher in 
patients deemed to be at high risk of relapse by the St. Gallen criteria, 
when compared to patients classified as low and intermediate risk 
(Mann Whitney U, p<0.05). The majority (66.7%) of cases in the 
high RS group had LVI present.
Conclusions This pilot study indicates a trend whereby Ki67 and 
grade will predict whether the Oncotype DX RS is low/intermediate or 
high. Adjuvant! Online, St. Gallen and NPI are also able to distinguish 
patients with a high RS from those with low/intermediate RS. In order 
to verify these findings, we are developing a statistical model using 
these 69 patients as a training set. As there is insufficient follow-up to 
correlate either RS or Ki67 with relapse, a potential test set comprised 
of an additional 50 LN negative, ER positive patients, with an average 
of 13 years follow-up, has been identified. Ki67 analysis of these 
cases is underway to address this issue.
Acknowledgement This work is funded by SFI (SRC award, 08/
SRC/B1410 to MTCI).
P5-13-13
The Role of Topoisomerase IIa in Predicting Sensitivity to 
Anthracyclines in Breast Cancer Patients: A Meta-Analysis of 
Published Literatures.
Lu J, Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z. Shanghai 
Cancer Center, Fudan University, Shanghai, China; Shanghai 
Medical College, Fudan University, Shanghai, China
Topoisomerase IIa is not only a proliferation marker of tumor cells 
but also a target for anthracycline-based chemotherapy. Both in vitro 
and in vivo studies have shown that there was a relationship between 
topo IIa and chemosensitivity to anthracyclines, but the predictive 
role of topo IIa is still controversial in breast cancer patients. A 
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meta-analysis based on published studies was performed with the 
aim of obtaining an accurate evaluation of the association between 
topo IIa and sensitivity to anthracycline-based chemotherapy. A total 
of 13 eligible studies including 2,633 cases and 2,118 controls were 
identified. Topo IIa was associated with sensitivity to anthracyclines 
in locally advanced breast cancer patients who received neoadjuvant 
chemotherapy (RR = 1.93, 95%CI: 1.27-2.94, P=0.002; RR =1.98, 
95%CI: 1.37-2.86, P<0.001). In early breast cancer patients who 
received anthracycline-based adjuvant chemotherapy compared 
with non-taxane-based polychemotherapy, amplification(HR = 0.64, 
95%CI: 0.49-0.83, P=0.001; HR = 0.59, 95% CI: 0.35-1.01, P=0.056) 
or deletion (HR = 0.82, 95%CI: 0.67-1.00, P=0.051; HR =0.58, 
95%CI: 0.35-0.97, P=0.036) of topo IIa was significantly associated 
with better RFS and OS. The subgroup analysis in the early breast 
cancer patients indicated that taxane could be an interference for 
evalutation of the predictive role of topo IIa. In summary, the present 
meta-analysis suggests that topo IIa is a predictive factor for breast 
cancer patients who received anthracycline-based chemotherapy. 
Larger and well-designed prospective studies are required to further 
evaluate the predictive role of topo IIa in clinical practice.
P5-13-14
Drug-Metabolizing Enzyme Polymorphisms and Clinical 
Outcome of Anthracycline-Based Chemotherapy in Chinese Han 
Breast Cancer Patients.
Tang J, Zhao J, Wu J, Ji M, Zhong S. Jiangsu Cancer Hospital, 
Nanjing, Jiangsu, China
Background: Anthracycline is one of the most effective drugs in the 
treatment of breast cancer and many of our most effective treatment 
regimens include anthracycline. Its efficacy can be influenced by 
cellular detoxification mechanisms involving drug metabolism and 
transport pathways. This study aimed to assess whether the functional 
polymorphisms in drug-metabolizing enzymes (MnSOD, CAT and 
GSTs) and transporter MDR1 may predict anthracycline treatment-
related outcomes in Chinese Han breast cancer patients.
Material and methods: Genotyping was performed by allele-specific 
oligonucleotide ligation reaction (MnSOD T47C, CAT C-262T, 
GSTP1 A313G), multiplex PCR (GSTM1 null, GSTT1 null), and 
PCR-RFLP (MDR1 C3435T, G2677T/A and C1236T). Based on 
153 evaluable patients received anthracycline-based neoadjuvant 
chemotherapy for breast cancer , the associations of these genotypes 
or their haplotypes with clinical response and recurrence-free survival 
(RFS) were analyzed.
Results: Of the 153 cases, the patients with GSTP1 313AA genotype 
had inferior response rates relative to those with AG or GG genotype 
(58.4% vs 77.8% or 100.0%; χ2=4.922, P=0.027). Moreover, the 
response rate of the combination of GSTP1 AA with both GSTT1 
present and GSTM1 present was 44%, which was also lower 
comparing with the other groups (70.3%; χ2=6.454, P=0.011). A 
similar result was noticed for MDR1 3435 TT genotype, which had 
a significantly worse chemotherapy response compared with wild-
type C allele carrier (33.3% vs 71.2%; χ2=11.586, P=0.001). Further, 
the response rate of the patients with 3435T-2677T, 3435T-1236T 
or 3435T-2677T-1236T haplotypes was lower than that of the 
patients with the other corresponding haplotypes (P=0.018, 0.011 
and 0.019, respectively), too. Of note, the patients with both the 
adverse genotypes of GSTP1 314AA and MDR 3435TT shown the 
worst treatment efficacy in all (14.3%;χ2=26.33, P=0.000). Mean 
follow-up time of the 149 patients (4 patients lost) was 51 months. 
The recurrence rate in the patients with GSTP1 313AA or/and 
MDR 3435TT in the first three years was 39.0% (41/105), higher 
significantly than those with no adverse genotype [15.9% (7/44); 
OR=0.725, 95%Cl: 0.594-0.885, P=0.006]. Kaplan-Meier survival 
analysis showed that the patients with no adverse genotype were 
associated with reduced hazard of relapse (long-rank test, P<0.01), 
compared to those with 1 or 2 adverse genotypes.
Conclusion: Polymorphisms in GSTs and MDR1 genes may 
help to predict clinical response and RFS of anthracycline-based 
chemotherapy in breast cancer, but further validation is required. 
These results provide support for a polygenic pathway approach for 
assessing the predictive potential of polymorphisms in treatment 
outcomes.
P5-13-15
Proteomic Identification of Predictive Biomarkers of Resistance 
to Neoadjuvant Chemotherapy in Luminal Breast Cancer: A 
Possible Role for 14-3-3 and BID?
Hodgkinson VC, ELFadl D, Agarwal V, Garimella V, Drew PJ, Lind 
MJ, Cawkwell L. University of Hull, Hull, United Kingdom; Castle 
Hill Hospital, Hull, United Kingdom; Hull York Medical School, 
Hull, United Kingdom
Background: Chemotherapy resistance is a major obstacle in 
effective neoadjuvant treatment for oestrogen receptor (ER)-positive 
breast cancer. The ability to predict tumour response would allow 
chemotherapy administration to be directed towards only those 
patients who would benefit, thus maximising treatment efficiency. We 
aimed to identify protein biomarkers associated with chemotherapy 
resistance, using proteomic analysis of fresh ER-positive breast cancer 
samples, and then to perform pilot clinical validation experiments.
Materials and Methods: Chemotherapy resistant and chemotherapy 
sensitive tumour samples were collected from breast cancer patients 
who received standard anthracycline-based neoadjuvant therapy 
consisting of epirubicin with cyclophosphamide followed by 
docetaxel. Comparative proteomics experiments were performed 
using invasive ductal carcinomas which demonstrated ER-positivity 
(luminal subtype). Protein expression was compared between 
chemotherapy resistant and chemotherapy sensitive tumour samples 
using 2-dimensional gel electrophoresis (2-DE) with MALDI-TOF/
TOF mass spectrometry (MS). In addition the Panorama XPRESS 
Profiler725 antibody microarray, containing 725 antibodies from a 
wide variety of cell signalling and apoptosis pathways, was employed 
in the discovery phase. Differentially expressed proteins (DEPs) 
were submitted to Ingenuity Pathway Analysis (IPA) to identify 
any canonical pathway links. A pilot series of archival breast cancer 
samples, from patients treated with neoadjuvant anthracycline-based 
chemotherapy, was used for preliminary clinical validation of putative 
predictive biomarkers.
Results: Five datasets were generated by antibody microarray analysis, 
revealing 41 targets. Of these, 7 DEPs were identified in at least 2 
datasets and these included 14-3-3, BID and Bcl-xL. The top canonical 
pathway matched in IPA was “ERK5 signaling”, which involved 6 
DEPs, including 14-3-3. The “PI3/AKT” pathway also involved 6 
DEPs, including 14-3-3 and Bcl-xL. Three datasets were generated 
using 2-DE with MALDI-TOF/TOF MS, containing over 300 DEPs. 
These included several isoforms of 14-3-3. Differential expression 
of 14-3-3, BID and Bcl-xL was confirmed by immunoblotting in 
samples used for the discovery phase. A pilot clinical validation using 
immunohistochemical analysis of archival breast cancers revealed 
14-3-3 tau and tBID to be significantly associated with chemotherapy 
resistance.
Discussion: We have successfully utilised clinical tumour samples for 
the discovery of putative biomarkers of chemotherapy resistance using 
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two complementary proteomic platforms. We propose a potential role 
for 14-3-3 tau and BID as predictive biomarkers of chemotherapy 
resistance in ER-positive tumours and further validation in a larger 
sample series is now required.
P5-13-16
Reduction in PET Uptake-Value Is an Early Predictor for 
Response to Neoadjuvant Therapy Including Anthracycline and 
Taxane in Stage II-IIIa Breast.
Lao Romera J, Puértolas Hernandez T, Godoy Molias A, Alvarez 
Alejandro M, Madani Perez J, Garcia Mur C, Ubieto MA, Cebollero 
de Miguel A, Artal Cortes A, Anton Torres A. Hospital Universitario 
Miguel Servet, Zaragoza, Spain; Clinica Quirón, Zaragoza, Spain
Background and Aim: Reduction in FDG-PET uptake as response 
predictor after induction chemotherapy for breast cancer has been 
described. Our aim was to determine whether a SUV reduction ≥45% 
in the breast lesion could accurately predict pathological Complete 
Response (pCR).
Material and Method: Stage II-IIIa breast cancer patients (p) with 
primary tumor ≥3cm or positive axilla were included provided 
they were amenable to neoadjuvant chemotherapy with Docetaxel-
Doxorubicin-Cyclophosphamide (TAC). A FDG-PET scan was 
performed on day -1 of the first course and was repeated on day+8 
of the same course. SUV-uptake differences (day 8 minus day -1) 
were correlated to the eventual pathological response according to 
Miller-Payne criteria.
Results: 42p were included. Median age was 45 years (30-66). 11p 
(26.2%) were triple-negative tumors. 2p (4.8%) were Her-2 +. By 
stage, 13p (30.9%) were IIA, 17p (40.4%) IIB and 12p (28.2%) 
IIIA. 23p (54.7%) were N+ (FNAB positive). Median breast-SUV 
on first PET scan was 5.51 (1.3-18.50). 40p (95.2 %) completed the 
scheduled 6 courses. 41p (97.6%) were submitted to surgery. 11p 
(26.2%) achieved a pCR. 40p (95.2%) were evaluable for the primary 
objective. 1p (0.02%) died of disease progression before surgery and 
1p (0.02%) with pCR could not be assessed by PET. 7 out of 14 p 
(50%) with uptake reduction ≥45% with respect to the basal value, 
and 3/ 26p (11.5%) whose reduction was <45% achieved a pCR 
(p=0.007). SUV decrease >45% accurately predicted 7/ 10 pCR 
(70%) that could be assessed.
Conclusions: Our study confirmed the value of PET-SUV reduction 
on day 8th as an early predictor of pCR with neoadjuvant TAC 
chemotherapy.
P5-13-17
Multigene Signature Assays in Patients with Early-Stage Breast 
Cancer (ESBC) Receiving Neoadjuvant Chemotherapy: An NCI-
Funded Systematic Review and Evidence Summary of Predictive 
Performance.
Lyman GH, Culakova E, Poniewierski MS, Huang M, Barry W, 
Ginsburg G, Abernethy A, Marcom PK, Ready N, Kuderer NM. 
Duke University School of Medicine, Durham, NC; Duke University, 
Durham, NC
Background: A comprehensive literature search and evidence 
synthesis of multigene signatures predictive of response to systemic 
chemotherapy in patients with breast cancer was initiated as a part 
of an NCI-funded program on Comparative Effectiveness Research.
Methods: Validation studies were sought of multigene signatures 
for prediction of chemotherapy response (favorable vs unfavorable) 
in ESBC patient cohorts different from those used for signature 
development. Pooled estimates [±95% CI] of assay performance 
for predicting clinical outcome included sensitivity, specificity, 
likelihood ratio, predictive value (PV) and predictive odds ratio 
(POR) utilizing mixed effects models based on the method of Mantel-
Haenszel. Exploratory metaregression analyses on log (POR) were 
also performed. Studies were classified by validation type including 
cell lines to patients, independent internal sample, random split 
sample, or external validation. Evidence for publication bias was 
assessed by Egger’s regression intercept and Begg and Mazumdar’s 
rank correction. Results: Dual-blind review of abstracts identified 
33 studies of neoadjuvant chemotherapy response of which 29 
stratified treatment response by signature classifier category. Classifier 
development was based on tumor response prediction in 20 studies, 
prognosis in 5, and molecular classification in 4. The Table shows 
assay performance measures overall and by study validation type. 
Assay performance based on the POR was positively associated with 
overall study quality (P=.015) and journal impact factor (P=.020). 
However, strong evidence for publication bias was observed based 
on both regression intercept (P<.001) and rank correlation (P=.005). 
No significant differences in assay performance were noted for assays 
originally developed for response prediction (POR=5.3), prognosis 
(POR=6.6) or molecular classification (P=6.9) (P=.770).
Criteria All Cell-Patient External Split Sample Internal
No. Studies 29 3 14 2 10
POR* 5.8[4.5-7.4] 2.9[1.7-5.0] 5.8[4.0-8.4] 6.0[1.5-23.4] 11.1[6.4-19.3]
c-statistic 0.77 - 0.71 - 0.87
Favorable Response 
Group* 43.1% 40.9% 36.8% 46.2% 62.1%
Unfavorable Response 
Group 12.9% 17.1% 10.6% 12.0% 10.6%
*P<.05
Conclusions: While assay performance in predicting response 
to neoadjuvant chemotherapy based on multigene classifiers is 
encouraging, a compelling need exists for greater methodologic 
rigor and standardization of reporting. The predictive performance of 
multigene assay signatures varies with the type of validation sample 
utilized with external validation providing the most conservative 
estimates. No differences were seen for assays developed for 
prediction, prognosis or molecular classification. Considerable 
evidence for publication bias exists reflecting a paucity of smaller 
negative studies. The clinical validity of genomic response prediction 
assays should be evaluated in patient cohorts independent of those 
utilized for signature development. The clinical utility of these assays 
must then be further assessed in comparative effectiveness studies 
compared to commonly utilized clinical and laboratory measures.
Funding: NCI: UC2CA14041-01
P5-13-18
A Study of the Usefulness of Tumor Markers CA 15-3 and TPS in 
Monitoring of Different Subgroups of Metastatic Breast Cancer.
Lindman H, Al-Musawi S, Nilsson G, Yachnin J. Uppsala University, 
Uppsala, Sweden
Background: The sensitivity and specificity of the tumor markers 
cancerantigen 15-3 (CA15-3) and the more seldom used tissue 
polypeptide specific antigen (TPS) for detecting and monitoring 
metastatic breast cancer are relatively well known. However, most 
of the studies in this area were performed before the era of breast 
cancer subtyping and some recent reports have showed differences in 
the sensitivity of CA 15-3 among different subtypes of breast cancer. 
This implies that the usefulness of a tumor marker could vary among 
different subgroups. We performed a retrospective study to find out the 
usefulness of CA 15-3 and TPS in long-term monitoring of metastatic 
breast cancer subgrouped by hormonal and HER2-receptor status.
Patients and methods: CA 15-3 was routinely assessed regularly in 
all patients with metastatic breast cancer since 2003, while TPS was 
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assessed during years 2005 - 2009. In total 142 patients (median age 
60 years, range 22-87) with metastatic breast cancer were identified 
in the local data base and included. The total number of analyzed CA 
15-3 samples were 4232 (mean 30/patient) and TPS 1993 (mean 14/
patient). In each patient the results of the markers were compared with 
disease response and progression during different lines of therapy and 
the patients were grouped based on the ratio of correct tumor marker 
values: “1” (useless) if 0-49% of the values were regarded as true, 
“2” (poor) if 50-74% were true, “3” (good) if 75-94% were true and 
finally “4” (excellent) if 95-100% of the values were considered true. 
If a patient had no elevated values during follow-up, she was reported 
as tumor marker negative: “0”.
Results: In general, the usefulness of CA 15-3 was excellent (4) in 
50% of patients and good (3) in 16% more, compared with only 12% 
and 23% for TPS. Twenty-three percent and 25%, respectively were 
marker negative (0). There was a marked difference in the different 
subgroups. CA 15-3 was very useful (group 3 + 4) in estrogen and 
progesterone receptor positive patients (79%) and hormonal positive 
HER2 positive patients (82%), compared with only 40% in the triple 
negative group and 27% of the patients in the hormonal negative 
HER2 positive group. TPS showed the opposite tendency with less 
value in hormonal positive patients (only 31% in group 3 and 4) 
compared with 40% in triple negative and 45% the hormonal negative 
HER2 positive group. Other factors with strong positive influence of 
the value of the marker were high absolute values, increased value at 
diagnosis of metastatic disease (initial value) and visceral metastases.
Conclusion: Metastatic breast cancer can be well monitored using 
CA 15-3 in about 80% of the cases if the tumor is estrogen or 
progesterone positive. Hormonal receptor negative disease may be 
well monitored with CA 15-3 and/or TPS if there are elevated initial 
values, high absolute values and visceral disease. HER2-status seems 
not to influence the usefulness of CA 15-3 and TPS.
P5-13-19
Borderline Estrogen and Progesterone Receptor Expression and 
Efficacy of Anti-Estrogen Therapy Analyzed by Subpopulation 
Treatment Effect Pattern Plot Analysis.
Luoh S-W, Ramsey B, Park B, Keenan E. Oregon Health and Science 
University, Portland, OR; Portland Veterans Administration Medical 
Center, Portland, OR
Background: The American Society of Clinical Oncology (ASCO) and 
the College of American Pathologists (CAP) recently recommended 
that estrogen receptor (ER) and progesterone receptor (PR) values be 
considered positive in the evaluation of breast cancer specimens if 
there are at least 1% positive tumor nuclei by immunohistochemisty 
(IHC) scoring. This change constitutes a lower cutoff value than 
the 5% or 10% widely used in the past and increases the number of 
patients that can now be treated with anti-estrogen therapy, a therapy 
which carries significant treatment efficacy and a favorable toxicity 
profile. Despite the new recommendation however, it remains unclear 
if patients whose tumors display borderline ER and/or PR expression 
truly benefit from anti-estrogen therapy.
Methods: We examined a total of 608 patient samples from the OHSU 
Knight Cancer Institute Breast Cancer Tissue Repository for which we 
have quantitative ER and PR information and their clinical outcome. 
Of those, 282 patients did not receive any systemic treatment and 165 
received anti-estrogen therapy (the majority tamoxifen). Cytosolic 
steroid hormone receptors were quantitated by conventional steroid 
binding assay and Scatchard plot analysis or by enzyme-linked 
immunoassay system. For immunoassays, human estrogen receptor 
(ER) and progesterone receptor (PR) kits were obtained from Abbott 
Laboratories and assays were conducted according to manufacturer’s 
specification. We performed subpopulation treatment effect pattern 
plot (STEPP) analysis to explore the presence of interaction between 
treatment effects and quantitative ER and PR levels. Clinical outcome 
used in this study includes 5-year overall survival and 5-year breast 
cancer free interval.
Results: Multi-variate analysis finds neither ER nor PR expression 
adjusted by treatment status is associated with either overall survival 
(P= 0.20, median follow up of 63 months) or breast cancer free interval 
(P= 0.82, median follow up of 60 months). For both ER and PR, 
there is no interaction between treatment outcome (5 year survival 
probability) and levels of hormone receptor expression based on 
Kaplan-Meier estimate (P=0.36 and P= 0.65, respectively). Patients 
with borderline ER expression appear to benefit from anti-estrogen 
therapy while patients with borderline PR expression appear to have 
worse outcome with anti-estrogen therapy.
Conclusions: Though descriptive in nature, our STEPP analysis 
provides support for the recommendation by ASCO and CAP to lower 
the cutoff for ER positivity in breast cancer specimens. There is overall 
no interaction between the level of hormone receptor and treatment 
benefit for all patients from low ER to high ER. Therefore, treatment 
will benefit all patients including those with low ER levels. Extending 
hormone therapies to the group of patients whose tumors express 
borderline PR values, however does not seem to confer therapeutic 
benefit. More study is needed to determine the benefits of offering 
anti-estrogen therapy to patients whose tumors express low PR.
P5-13-20
TOP2A Amplification Have Associated with Response to 
Anthracycline-Based Preoperative Chemotherapy in Primary 
Breast Cancer.
Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Zhao L. Cancer Hospital, 
Chinese Academy of Medical Science, Beijing, China
Background: Recent studies have suggested that HER2 gene 
amplification or overexpression have association with sensitivity of 
anthracycline-based chemotherapy. Preclinical studies found that 
TOP2A amplification or deletion only could be detected in HER2 
amplification or over-expressive cases. And TOP2A protein is the 
target of anthracycline. In fact, the value of HER2 for predicting 
response to anthracycline-based chemotherapy in breast cancer may 
be more likely related to the concomitant amplification of the TOP2A 
gene. In this study we studied the association between TOP2A gene 
amplification and response to anthracycline-based preoperative 
chemotherapy. Methods: 309 early and local advanced breast cancer 
cases were enrolled in our study. HER2 proteins were qualitatively 
analysed by IHC, and TOP2A gene alterations were quantified by 
real-time polymerase chain reaction (RT-PCR) in primary tumor core 
biopsies from all HER2 over expressive cases. The enrolled patients 
received an intense dose dense (IDD) (CE, Cyclophosphamide + 
Epirubicin) or conventionally (TE, Paclitaxel+Epirubicin) scheduled 
anthracycline- based preoperative chemotherapy. The tumor was 
evaluated every two cycles. Median time on study for 309 patients 
with follow-up was 38 months. Results: The pCR was 14.3%. HER2 
overexpression was found in 80/309 (25.9%) breast cancer cases, of 
which 61/80 cases have been tested for TOP2A status. 19/80 cases 
have not been tested for TOP2A status because of lacking core biopsies 
tumor tissue after pathological diagnosis. HER2 overexpression was 
associated with a significantly higher pCR rate compared to HER2 
lower expression (27.5% vs. 9.6%, P<0.001). Further analysis was 
carried on and found the significantly higher pCR rate in TOP2A 
co-amplified cases compared to TOP2A deleted or normal cases 
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(56.3% vs. 13.8%, P=0.001). HER2 overexpression was associated 
with a significantly higher pathologic complete response (pCR) rate 
only when TOP2A was co-amplified (56.3% vs. 9.6%, P<0.001), but 
not when deleted or normal (13.8% vs. 9.6%, P=0.183), compared 
to HER2 lower expression tumors. The interaction between HER2 
or TOP2A and anthracycline-based regiment was observed not only 
in IDD but conventionally scheduled preoperative chemotherapy.
Discussion: Previous studies demonstrate that TOP2A gene 
amplification may define a subtype of HER2-positive breast cancer, 
This subtype of breast cancer may be highly sensitive to anthracycline-
based chemotherapy, which may improve progression in HER2 and 
TOP2A co-amplification cases. Howerver, this viewpoint needs 
suppose from preoperative chemotherapy. Using RT-PCR to test 
TOP2A statue from 61 primary breast cancer tumor tissue, we 
demonstrate that TOP2A amplification breast cancer have highly 
sensitive to anthracycline-based preoperative chemotherapy. This 
finding suggests that TOP2A as a predictive marker in breast cancer 
should be included in future studies.
P5-13-21
Japanese Patients with Discordance in Estrogen Receptor between 
Primary Breast Cancer and Recurrent Tumor Have a Poorer 
Outcome.
Tanaka K, Kawaguchi H, Kuba S, Koga C, Nishimura S, Yoshiyama 
T, Ishida M, Nakamura Y, Ohno S. National Kyushu Cancer Center, 
Fukuoka, Japan
Background
Decisions of systemic treatment for recurrent breast cancer are usually 
based on the estrogen receptor (ER), progesterone receptor (PR), and 
HER2 receptor status of the primary tumor. Recently, discordance 
in receptor status between primary and recurrent tumors has been 
reported. The objective of this study was to compare receptor status 
between the primary and recurrent tumor, and to evaluate overall 
survival (OS) after the diagnosis of recurrence between patients with 
discordant and concordant receptor status.
Material and Methods
Patients with recurrent breast cancer treated at National Kyushu 
Cancer Center between January 2004 and May 2011 were reviewed 
retrospectively. Primary and recurrent lesions were analyzed for 
ER and PR by immunohistochemistry (IHC) and HER2 by IHC 
or fluorescence in situ hybridization (FISH). OS in discordant and 
concordant groups for each receptor was estimated by Kaplan-Meier 
method and compared by log-rank test.
Results
Among 283 recurrent breast cancer patients both primary and 
recurrent tumor information for ER, PR, and HER2 was available 
in 69. Among these, recurrent biopsy specimens were obtained from 
locoregional recurrence in 72.5% and from distant metastases in 
27.5%. Discordant rate in receptor status between the primary and 
recurrent tumor was 36.2%. Discordant rate in ER, PR, and HER2 
was 14.4%, 23.1%, and 4.3%, respectively. Two-year OS after the 
diagnosis of recurrence in discordant and concordant ER group 
was 66.7% and 84.7%, respectively. The discordant ER group had 
significantly worse OS than the concordant ER group (P = 0.040). 
There was no significant difference in OS between the discordant and 
concordant PR group (P = 0.950).
Conclusions
Because discordance of receptor status between primary and recurrent 
tumors may exist, tissue confirmation of receptor status of recurrent 
tumor should be considered. Japanese patients with discordant ER 
between primary and recurrent tumor had a poorer outcome.
P5-13-22
Gene Expression Profiles Predict Pathological Complete Response 
to Standard Neoadjuvant Fluorouracil, Doxorubicin, and 
Cyclophosphamide and Paclitaxel with or without Trastuzumab 
in Early Breast Cancer.
Tamura K. National Cancer Center Hospital, Tokyo, Japan
Background: To examine the feasibility of gene expression signature 
as a predictor of pathological complete response (pCR) to sequential 
fluorouracil, doxorubicin, and cyclophosphamide (FEC) and 
weekly paclitaxel (P) with or without trastuzumab (T) neoadjuvant 
chemotherapy.
Materials and Methods: We have conducted consecutive two 
prospective phase II, establishing training and validation sets, with 
similar eligible criteria include, stage IIA-IIIC, chemotherapy-
naïve, measurable disease, age ≥ 20, PS 0/1, and adequate organ 
function. Patients were treated preoperatively with 4 cycles of FEC 
(500/100/500 mg/m2) followed by 12 cycles of weekly P (80 mg/
m2) with or without T (2mg/kg). Patients underwent pretreatment 
fine-needle biopsy for cDNA microarray using Affimetrix Gene 
Chip U133 plus 2.0 arrays with 30,000 differential expressions of 
various genes. We ranked gene probes from training sets according 
to a predictive power concerning pCR by Wilcoxon, and validated 
them using validation sets by SVM.
Results: Between July 2007 and December 2010, 122 patients were 
enrolled in the two consecutive prospective studies (training: 89 pts, 
validation: 33 pts). Median age was 51. PS 0/1: 115/7; Stage IIA/IIB/
IIIA/IIIB/IIIC: 30/57/20/14/1; Histological subtype: ER+HER2- (LA) 
/ ER+HER2+ (LB) / ER-HER2- (TN) / ER-HER2+ (enrich-HER): 
51/18/24/29. All patients have received curable operations. pCR rate 
was 31.1% (LA; 2.0%, LB; 44.4%, TN; 37.5%, enrich-HER; 69.0%). 
104 (85.2%) sufficient mRNA for cDNA microarray from individual 
primary breast cancer tissues fine-needle biopsy are available. As 
reported previously, the breast cancers were classified into a Luminal 
A/B, Basal-like, HER2-enriched, Claudin-low intrinsic subtypes, 
indicating a high quality of the representative method. In HER2 
positive breast cancer, HER2-enriched subtype was a reproductive 
predictive marker. In contrast, In HER2 negative breast cancer, three 
genes (N-myc and STAT interacter, Tryptophanyl-tRNA synthetase, 
and IQCE) and basal-like subtype were validated as the predictors 
of pCR. The three genes were also identified as predictors of pCR in 
the triple negative population.
Conclusions: Specific gene expression profiles predict pCR to 
standard neoadjuvant regimen, especially in triple negative breast 
cancer.
P5-13-23
Individualized Treatment Strategies for HER2-Negative Breast 
Cancer Subtypes.
Ishikawa T, Shimizu D, Yamada A, Sasaki T, Morita S, Tanabe M, 
Kawachi K, Nozawa A, Chishima T, Kimura M, Ichikawa Y, Endo I. 
Yokohama City University Medical Center, Yokohama, Kanagawa, 
Japan; Yokohama City University, Yokohama, Kanagawa, Japan
Background Human epidermal growth factor receptor (HER2)-
negative breast cancers are more heterogeneous than HER2-positive 
cancers, and tailored treatment is therefore required for luminal A 
and triple-negative breast cancer subtypes (LABC and TNBC). We 
therefore examined predictive factors for the efficacy of standard 
chemotherapy in LABC and TNBC subtypes.
Methods A total of 109 LABC and 61 TNBC patients were treated 
with standard neoadjuvant chemotherapy (NAC) consisting of an 
anthracycline and/or taxane. The pathological treatment response 
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and prognosis were examined for each subtype. Expression levels 
of the following factors were examined in association with quasi-
pathological complete response (QpCR): estrogen- and progesterone-
receptor (ER and PgR) status, HER2, nuclear grade, MIB-1, p53, 
topoisomerase IIa (topoIIa), cytokeratin (CK) 5/6 and epidermal 
growth factor (EGFR).
Results QpCR rates in LABC and TNBC were 9.1% (10/109) and 
54.1% (33/61), respectively. In LABC, the expression of PgR tended 
to be inversely associated with pathological response (p=0.087), 
while in TNBC, increased expression of topoIIa (p=0.006) and 
MIB-1 (p=0.018) were identified as predictors of QpCR. TopoIIa 
expression was also significantly associated with pathological 
response in multivariate analysis (p=0.014). The QpCR rate was 
higher in TNBC lacking CK5/6 and/or EGFR expression, defined as 
non-basal subtype (p=0.053).
Conclusions Low expression of PgR may be a possible predictor 
of the efficacy of chemotherapy in LABC, while a high level of 
proliferative activity, indicated by topoIIa and MIB-1, is associated 
with chemosensitivity in TNBC. Further subclassification into basal- 
and non basal-subtypes may also be helpful for the development of 
individualized treatments.
P5-13-24
A Predictive Model of Early Systemic Disease Relapse after 
Standard Adjuvant Therapy for Breast Cancer.
Chen L, Hodskins J, Chokshi S, Croley J, Stevens M, Pasley G, Huller 
K, Reynolds J, Weiss H, Massarweh S. University of Kentucky and 
Markey Cancer Center, Lexington, KY
Background: Early relapse after adjuvant therapy for breast cancer 
is very discouraging and remains a major problem. We sought to 
identify predictors of early relapse risk and build a predictive model 
for relapse using prospectively collected data for patients seen at the 
Markey Cancer Center starting 2007 to date.
Methods: Of the 1098 new patients seen, 814 patients had stage 
I-III disease and were further analyzed for predictors of early 
relapse risk. Univariate analyses were performed for key variables 
including patient age, tumor size, grade, estrogen receptor (ER) status, 
progesterone receptor (PgR) status, and HER2 status. A multivariate 
Cox regression model was built to identify predictors of systemic 
relapse and model-building was performed using step-wise model 
selection to determine candidate models. A risk score was developed 
based on the linear combination of covariates in the final Cox model. 
Time-dependent predictive curves, a newly developed statistical 
methodology, were used to evaluate the predictive accuracy of the 
proposed risk score.
Results: Median patient age was 57 years (Range 25-92) and 88% 
were white. Forty six (46) % had stage I disease, 36% stage II, and 
18% stage III. Median follow up time was 2.3 years. Of this 814 
patient cohort, 708 patients had complete baseline covariate data and 
were used to build the candidate models. The final Cox regression 
model included 5 covariates that were significantly associated with 
risk of early relapse: stage III disease (p = 0.0011), grade III (p = 
0.0028), PgR-negative status (p = 0.0121), HER2-negative status (p = 
0.0305), and node-positive status (p = 0.0360). These five covariates 
were then used to calculate an early recurrence risk score, which is 
the weighted average of these risk factors when present, with the 
weights being the coefficients from the Cox regression model. The 
1-year, 2-year and 3-year predictive curves for this risk score decrease 
considerably, especially for the 2-year and 3-year curves, indicating 
good predictive accuracy of the risk score. The highest risk score 
group, which represents 4.8% of the population, has a 1-year, 2-year 
and 3-year relapse probabilities of 13.0% (95% CI: 4.1%, 27.3%), 
39.4 % (95% CI: 20.1%, 58.3%), and 52.3% (95% CI: 28.5%, 
71.5%), respectively. In comparison, for the overall population, the 
corresponding 1-year, 2-year, and 3-year relapse probabilities were 
only 1.1% (95% CI: 0.5%, 2.1%), 4.2% (95% CI: 2.7%, 6.1%) and 
6.2% (95% CI: 4.2%, 8.6%), respectively.
Conclusions: The developed risk score based on stage, tumor grade, 
PgR, HER2, and node status is highly predictive of early relapse in 
breast cancer patients after standard adjuvant therapy. Our model can 
be used to identify patients with high risk of early disease relapse who 
may otherwise benefit from enrollment on novel adjuvant therapeutic 
trials to improve their outcome.
P5-14-01
Differences in Efficacy by Assessment Method: NCIC CTG 
Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, 
MA.27 Meta-Analysis.
Dong B, Chapman J-AW, Yerushalmi R, Goss PE, Pollak MN, 
Burnell MJ, Bramwell VH, Levine MN, Pritchard KI, Whelan TJ, 
Ingle JN, Parulekar W, Shepherd LE, Gelmon KA. NCIC Clinical 
Trials Group, Queen’s University, Kingston, ON, Canada; Vancouver 
Cancer Centre-BCCA, Vancouver, BC, Canada; Harvard Medical 
School, Boston, MA; McGill University, Montreal, QC, Canada; 
Atlantic Health Sciences Corporation, Saint John, NB, Canada; 
Alberta Cancer Board, Calgary, AB, Canada; McMaster University, 
Hamilton, ON, Canada; University of Toronto, Toronto, ON, Canada; 
Mayo Clinic, Rochester, MN
Background: Based on recent breast cancer literature, we hypothesized 
that there could be substantive differences in apparent efficacy 
estimates using a log-normal (LN) survival model rather than with 
standard Kaplan-Meier (K-M) or Cox model methods. While both 
Cox and LN survival analyses offer greater specification by individual 
patient characteristics, the LN model may more robustly estimate 
survival under model misspecification. Methods: We recently pooled 
data for 5 NCIC CTG primary breast cancer trials: MA.5, MA.12, 
MA.14, MA.21, and MA.27. The total patient count for patients 
who received at least 1 dose of trial therapy is 11,253. Compilation 
included definition of STEEP endpoints (C Hudis, JCO, 2008) and 
standardized factor categorizations. The primary endpoint is Breast 
Cancer Free Interval (BCFI) defined as the time from randomization 
until recurrence: first local invasive or DCIS; regional, or distant; 
contralateral invasive or DCIS; or death from breast cancer. We 
found substantive evidence of non-proportionality for 7 factors 
compiled for the meta-analyses. In this work, we fit multivariate 
Cox and LN models with these 7 factors, lymph node status and 
pathologic T status. We then compare BCFI efficacy estimates for 
patient and tumour characteristics at 1-, 3-, and 5-years obtained with 
K-M, Cox, and LN models. Results: There was evidence that the 
Cox assumption of proportional hazards was violated for 7 factors: 
age, menopausal status, hormone receptor status, anthracycline use, 
chemotherapy use, race, and ECOG performance status. Differences 
between models were intrinsically affected by timing and extent of 
non-proportionality; there was no consistent pattern. In particular, 
investigations to date indicate efficacy estimates with absolute 
differences between K-M, Cox and LN estimates which varied by 
time of assessment: at 1-year 0.0 to 6.7%, at 3-years 0.4 to 18.6%, 
and at 5-years 0.2 to 17.0%. BCFI estimates with the K-M were 
inconsistently closer to those with the LN or Cox model: for K-M 
to Cox at 1-year 0.4 to 5.2%, at 3-years 0.4 to 15%, at 5-years 0.4 
to 14.3%; for K-M to LN at 1-year 0.0 to 6.7%, at 3-years 0.5 to 
18.6%, at 5-years 0.2 to 17.0%; for Cox to LN at 1-year 0.8 to 1.8%, 
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at 3-years 1.9 to 6.0%, at 5-years 0.6 to 5.7%. K-M and Cox models 
have step-wise adjustments at events for K-M and Cox, rather than 
smooth modeling with the LN. Discussion: Even with reasonably 
large population subgroups, there were substantive differences in 
apparent survival (0.0 to 18.6%) between K-M, Cox and LN model 
types. The magnitude of differences in survival estimates was large 
enough to be clinically relevant and warrant further consideration as 
we evaluate new therapies and prognostic/predictive factors. We will 
be statistically investigating framework robustness under differing 
levels of model misspecification.
P5-14-02
Clinicopathologic and Prognostic Difference of Screen Detected 
Breast Cancer Compared with Symptomatic Breast Cancer.
Kim J, Lee SK, Kim S, Koo MY, Choi M-Y, Cho DH, Bae SY, Lee J, 
Jung SP, Lee JE, Yang J-H, Nam SJ. Samsung Medical Center, Seoul, 
Korea; Konkuk University Medical Center, Seoul, Korea
Background: Breast cancer screening program makes it possible to 
detect early cancer, thus to reduce breast cancer mortality. The authors 
studied clinicopathologic characteristics and prognosis of screen 
detected invasive breast cancer compared with symptomatic breast 
cancer. Furthermore, we compared the result according to molecular 
subtypes (luminal A, luminal B, Her2, triple negative), so intended 
to identify the role of screening in each subtypes.
Material and Methods: From January 2002 to June 2008 , 3141 
patients who underwent operation for the treatment of invasive 
ductal carcinoma(NOS) at Samsung medical center were included. 
Among them, 1025 patient were screen detected, 2116 patient were 
symptomatic, out of screening over 2 years. We reviewed the medical 
records retrospectively.
Result: Screen detected breast cancer was associated with older 
patients, smaller tumor size, more hormone receptor- positive, less 
lymph node involvement, lower stage and reduced mortality compared 
with symptomatic breast cancer (P < .001). According to the molecular 
subtype, in luminal A subtype, the result shows better pathologic 
feature and also favorable overall and recur-free survial significantly.
Effect of screen detection on survival (screen detected vs symtomatic)
 Death Recur
 HR (95%CI) p-value HR (95%CI) p-value
Total 1.55 (0.93 to 2.61) 0.095 1.52 (1.08 to 2.14) 0.016
Luminal A 4.31 (1.29 to 14.39) 0.018 1.94 (1.16 to 3.26) 0.007
Luminal B 1.49 (0.28 to 7.99) 0.641 1.574 (0.61 to 4.08) 0.351
Her2+ 0.39 (0.14 to 1.07) 0.390 0.83 (0.38 to 1.81) 0.634
TNBC 1.17 (0.50 to 2.71) 0.717 0.92 (0.50 to 1.71) 0.788
HR : hazard ratio, TNBC : triple negative breast cancer
Conclusion: Compared to symptomatic breast cancer patients, 
screen detected breast cancer patients have favorable pathological 
and molecular characteristics, so better outcomes. According to the 
molecular subtype, only in luminal A subtype, screen detected breast 
cancer shows both overall and disease free survival benefit, and also 
acts as an independent prognostic factor itself. So, screening program 
seems to have a different efficacy depending on the molecular subtype 
of breast cancer
P5-14-03
Genomic Comparison of Paired Primary Breast Carcinomas and 
Macrometastatic Lymph Node Metastases Using Quantitative 
RT-PCR by Oncotype DX: Assessment of the Recurrence Score 
and Quantitative Single Genes.
Boolbol SK, Kirstein L, Harshan M, Klein P, Cohen J-M, Chadha M, 
Baehner FL, Malamud SC. Beth Israel Medical Center, New York, 
NY; Genomic Health Inc., Redwood City, CA
Background: NCCN guidelines now include consideration of the 
21 gene RT-PCR assay in node negative, hormone sensitive breast 
cancers greater than 0.6 cm. Recent data suggests a potential role 
for testing of node positive(N1), hormone sensitive patients as well. 
Currently, no data exists on testing of metastatic lymph nodes. We 
sought to establish the feasibility of Oncotype DX® testing in the 
metastatic lymph nodes and, furthermore, to evaluate the genomic 
concordance between the primary tumor and the nodal deposit. These 
results may further our understanding of tumor heterogeneity and 
biological selectivity in the process of lymph node metastasis and 
ultimately systemic metastases.
Methods: We examined the formalin fixed paraffin embedded 
tumor tissues (FPET) from 100 breast cancer patients from our 
institution’s pathology database with available paired primary tumor 
and macrometastic nodal deposits by Oncotype Dx® testing. Inclusion 
criteria included patients with macrometastatic lymph node disease, 
hormone receptor positive, HER2 negative primary breast cancer. 
The testing laboratory was blinded from the clinical outcomes data 
available on these patients. All FPET samples had H&E slides made 
which were reviewed by board certified surgical breast pathologists 
to determine if there was sufficient invasive tumor and to direct 
dissection of all lymph node samples. The Recurrence Scores and 
quantitative single gene values from the paired samples will be 
examined descriptively with scatterplots and Pearson correlation 
coefficients and reported at the meeting.
Results: All 100 paired specimens were sent for Oncotype DX 
testing. 24 samples were found during standard H&E review to not 
have sufficient tumor for the assay. Of the 176 samples created for 
RNA extraction 173 samples had sufficient RNA for the Oncotype 
DX assay: 85 lymph node and 88 primary breast carcinoma samples. 
Recurrence Scores and quantitative single gene values from the paired 
primary breast carcinoma and lymph node samples will be examined 
descriptively and reported at the meeting.
Conclusion: Previous comparisons of paired primary and metastatic 
samples have used immunohistochemistry and FISH which are 
susceptible to variability in preanalytic variability such as delay to 
fixation, choice of fixative and duration in fixative. This study, using 
quantitative RT-PCR, will be one of the largest comparisons of tumor 
biology in paired samples yet reported in the era of genomic subtyping 
and may have implications for systemic adjuvant treatment.
P5-14-04
RANK Expression in Primary Tumor Tissue at the Time of 
Diagnosis Correlates with Risk of Subsequent Bone Metastases 
in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).
Li J, Moore D, Yau C, Campbell M, Park J, I-SPY-1 TRIAL 
Investigator, Rugo HS. University of California, San Francisco, CA; 
Cancer and Developmental Therapeutics Program, Buck Institute for 
Age Research, Novato, CA
Background: RANK (receptor activator of nuclear factor kappa B) 
is a tumor necrosis factor receptor family protein that is expressed on 
the surface of osteoclasts and critical to bone turnover. RANK is also 
expressed on breast cancer (BC) cells, especially in the metastatic 
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setting. Pre-clinical mouse models have shown that the ligand to 
RANK (RANKL) can induce migration of RANK-expressed tumor 
cells to bone and lung, and that treatment with a RANKL inhibitor can 
reduce BC metastases. ISPY is a multicenter neoadjuvant study with 
well annotated gene expression data. We evaluated RANK expression 
in primary tumor tissues at the time of diagnosis (dx) in patients (pts) 
with BC and correlated expression with risk of subsequent metastases. 
Methods: We evaluated expression of genes in the RANK/RANKL 
pathway in core biopsies at dx, and correlated this data with risk of 
recurrence as well as risk of site specific metastases using the student 
t-test. Results : A total 221 pts were enrolled in this clinical trial, 
all had locally advanced BC (LABC) and received neo-adjuvant 
chemotherapy (96.6% pts received adriamycin + cyclophosphamide-
based regimens), tumor samples were collected at the time of dx by 
core biopsy, and underwent gene array study. Total 38508 genes were 
tested and 149 pts had available gene array data. Average age was 
48.0 yr, pt characteristics are listed in the Table.
Table: Patient Characteristics
Patient Characteristics n (%)
Menopausal Status
Pre-menopausal (n=71, 48%) Post-menopausal (n= 50, 34%) 
Indeterminate (n=28, 19%)
ER Status ER + (n=84, 56%) ER- (n=65, 44%)
Stage Stage I (n=3, 2%) Stage II (n=68, 46%) Stage III (n=64, 43%) 
Inflammatory (n=10, 7%)
Pathology Luminal A/B (n=78, 52% ) Basal (n=47, 32%) Her-2 + (n=27, 18%)
Median follow up was 1260.3 days, range from 175 to 2520 days. 
Thirty-six pts developed recurrent disease; 13 pts developed bone-
dominant metastases (BDM), 15 pts developed non-bone metastases 
(liver, lung, brain, lymph node and contralateral side breast) (NBDM), 
and 8 pts were not evaluable. Median RFS for those with BDM was 
804 days, and for NBDM was 550 days, not significantly different 
(p=0.07). When comparing gene expression in the RANK/RANKL 
pathway, pts who developed BDM had a significantly higher 
expression of RANK (p=0.05) in primary tumor tissues than those 
with NBDM, while there was no difference in RANKL expression 
between the 2 groups. In addition, RANK was also significantly more 
highly expressed in the ER- group than ER+ group (p=0.006) and 
in the basal group compared to the luminal A/B group (p= 0.002). 
Analysis of variance (ANOVA) was then used to adjust clinical 
variability, after adjusting the difference of ER status, pathology 
subtypes, and menopausal status, RANK expression is even more 
significantly correlated with the bone-dominant group (p=0.002). 
Conclusion: Higher RANK expression in primary tumor tissues 
correlates with increased risk of subsequent BDM in pts enrolled 
in iSPY-1 trial. The sample size is small (n=149) and all pts had 
LABC. Our study suggests that targeting RANK/RANKL pathway 
is a promising strategy in preventing BDM in pts with high risk BC, 
further analysis in larger data sets is ongoing.
P5-14-05
Anti-Müllerian Hormone (AMH) Levels in Premenopausal 
Breast Cancer Patients Treated with Adjuvant Chemotherapy – A 
Translational Research Project of the SUCCESS Study.
Neugebauer JK, Rack BK, Kupka M, Dinkel C, Schneeweiss A, 
Schrader I, Tesch H, Rezai M, Söling U, Friese K, Beckmann MW, 
Janni W, Müller V. Ludwig-Maximilians-Universität, Munich, 
Germany; University Hospital Heidelberg, Heidelberg, Germany; 
Henriettenstiftung Hannover, Hannover, Germany; Fachpraxis für 
Onkologie, Frankfurt, Germany; Luisenkrankenhaus Duesseldorf, 
Duesseldorf, Germany; Gemeinschaftspraxis Siehl & Söling, Kassel, 
Germany; University Hospital Erlangen, Erlangen, Germany; 
Heinrich-Heine-Universität, Duesseldorf, Germany; University 
Medical Center, Hamburg-Eppendorf, Germany
Background: Premenopausal women undergoing chemotherapy are 
at risk of premature ovarian failure and long term side-effects caused 
by premature menopause. However, knowledge about the rate of 
ovarian failure and potential markers to evaluate the ovarian reserve 
is limited, especially in the context of modern chemotherapy concepts. 
Therefore, Anti-Müllerian hormone (AMH) was measured at before, 
immediately after and 2 years after chemotherapy in premenopausal 
patients of the SUCCESS study.
Materials and Methods: The German SUCCESS trial is a 
multicenter phase III study comparing FEC-Docetaxel vs. FEC-
Docetaxel+Gemcitabine as adjuvant treatment in patients with node 
positive or high risk node negative primary breast cancer. Blood 
samples were taken prior to and 4 weeks after last cycle of adjuvant 
chemotherapy, as well as after 2 years of follow up. We retrospecitvely 
identified 170 patients stratified premenopausal and aged 40 years or 
younger at trial entry, who received 3cycles of FEC (500/100/500mg/
m2) q3w followed by 3 cycles of docetaxel (100mg/m2) q3w as 
one of the most commonly used chemotherapy regimens in Europe. 
Serum AMH levels were evaluated in a central laboratory by a manual 
immunoassay AMH DSL ELISA (Diagnostic Systems Laboratories, 
Webster, USA).
Results: Median age within this subgroup was 36 years (21-40 years). 
48% of the patients had a tumor stage pT1 and 54% were node 
positive. 69% were hormone receptor positive and 29% Her2 positive. 
Median serum AMH level before adjuvant chemotherapy was 1.32 ng/
ml (range <0.1-11.32). Immediately after chemotherapy AMH levels 
dropped in 96% of the patients below the threshold of detection (<0.1 
ng/ml, range <0.1-3.9ng/ml). No association to classical prognostic 
markers, such as tumor stage, lymph node involvement, etc. was 
observed. After a follow up period of 2 years, serum was available 
from 95 patients. 76% of those patients showed no evidence of ovarian 
function indicated by AMH (<0.1 ng/ml, range <0.1-1.43ng/ml). 
AMH levels prior to and 2 years after chemotherapy were significantly 
correlated with older age, with a reduction of 0.14 ng/ml per life year 
(p=0.0025) and 0.01 ng/ml (p=0.017) respectively. 12 patients (7%) 
received optional gonadotropin-releasing hormone (GnRH) agonists 
during chemotherapy. These patients presented significantly higher 
AMH levels (+ 0.18 ng/ml; p=0.01) 2 years after cytotoxic treatment.
Conclusion: In this retrospective analysis premenopausal patients 
showed a high rate of f ovarian insufficiency reflected by low serum 
AMH levels immediately after cytotoxic treatment and after 2 years 
of follow up. GnRH agonists given as ovarian protectants during 
chemotherapy may have an influence on serum AMH 2 years after 
chemotherapy. Further data from prospective trials with longer follow 
up are needed to evaluate the role of serum AMH as a predictor of 
ovarian failure in breast cancer patients exposed to chemotherapy.
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P5-14-06
Interaction between Stoma and Tumor Characteristics as a New 
Prognostic and Predictive Marker in Breast Carcinomas.
Tagliabue E, Sandri M, Casalini P, Aiello P, Pupa SM, Orlandi 
R, Balsari A, Triulzi T. Fondazione IRCCS- Istituto Nazionale dei 
Tumori, Milan, Italy; University of Milan, Milan, Italy
Background. We recently demonstrated that primary breast tumors 
can be classified based upon extracellular matrix composition (ECM) 
(Bergamaschi et al.) suggesting stroma characteristics could influence 
tumor progression.
Aim of this study is to further investigate the robustness of this 
classification and its impact in tumor progression and response to 
therapy.
Methods. The expression profile of ECM-related genes was analyzed 
by unsupervised hierarchical clustering in 10 independent datasets of 
breast tumors, counting more than 1000 samples and the prognostic 
and predictive value of this signature were evaluated in two datasets 
of not treated patients and in one dataset of neo-adjuvant treated 
patients, respectively.
Results. Only one of ECM subsets (ECM3) showed a homogeneous 
gene pattern that consistently allowed the classification of an 
independent group of tumors in all tested datasets. ECM3 is 
characterized by highly correlated over expression of 34 ECM genes 
encoding mainly structural proteins. From 24 to 38% of cases were 
ECM3-enriched and were mainly estrogen receptor-positive and 
low grade (p<0.0001). The ECM3 showed inconsistent association 
with DMFS in the two data sets of not treated patients, whereas the 
interaction between ECM3 and grade showed strongly and significant 
association with DMFS (HR=5.35, p=0.0012). In particular, 
multivariate analysis of covariates available (size, ER, age and ECM) 
indicated that ECM3 is significantly associated with worse DMFS in 
grade III patients (HR=2.5, p=0.0386), whereas it is slightly correlated 
with better DMFS in grade I-II patients (HR=0.6, p=0.088). It is 
noteworthy that the probability of 10-year DMFS was 90% in ECM3 
versus 74% in non-ECM3 patients in differentiated tumors, and 75% 
in non-ECM3 versus 41 % in ECM3 grade III tumors.
The interaction between ECM3 and grade remained significantly 
associated with DMFS also in ER negative (HR=14.2, p=0.03) and 
ER positive (HR=3.34, p=0.079) subgroups. ECM3, indeed, was 
correlated with good and bad prognosis in differentiated and grade 
III tumors, respectively.
Moreover analysis of a data set of patients treated neoadjuvantly with 
chemotherapy revealed that, among the grade III tumors, pathological 
complete response was reached by 9% of ECM3 versus 74% of 
non-ECM3 tumors (p=0.04). In differentiated tumors no response 
difference was observed according to ECM.
Conclusions. Our results provide evidence that breast carcinoma 
progression and response to therapy are influenced by the interaction 
between tumor and stromal characteristics.
(Partially supported by AIRC).
P5-14-07
Novel Interactions between Immunity and Proliferation in Breast 
Cancer Prognosis.
Nagalla S, Chou JW, Ruiz J, Vaughn JP, Black MA, Miller LD. 
Section on Hematology and Oncology; Department of Biostatistical 
Sciences; Wake Forest University Health Sciences, Winston-Salem, 
NC; Otago School of Medical Sciences, University of Otago, Dunedin, 
New Zealand
Highly proliferative breast tumors are phenotypically and clinically 
heterogeneous and exhibit a significant metastatic tendency. However, 
not all highly proliferative breast cancers will progress to distant 
metastasis, suggesting that other factors may play a role in limiting 
their clinical progression. With an interest in identifying genes that 
predict metastatic capacity of breast cancers in a proliferation-
dependent context, we recently compiled a database of ~2,000 tumor 
expression profiles using microarray data from multiple large breast 
cancer cohorts. We randomized the dataset into training and testing 
sets to allow discovery and validation of novel gene-survival (ie, 
distant metastasis-free survival; DMFS) associations. We employed 
Cox regression analysis to identify genes with statistically significant 
associations with DMFS. Then, we hierarchically clustered the 
expression patterns of the significant genes to identify gene clusters 
lacking correlation with proliferation genes. A large cluster of genes 
with known functions in innate and adaptive immunity emerged. 
Cross referencing these genes to a published microarray dataset 
of pan-leukocyte expression profiles revealed cell type-specific 
structure within the immunity cluster, likely reflective of distinct 
populations of tumor-infiltrating immune cells. Specifically, 3 immune 
gene subclusters identified within the tumors showed predominant 
expression in B-cells, T-cells and natural killer (T/NK) cells, or 
monoctytes and dendritic (M/D) cells. To evaluate the prognostic 
relevance of these immune gene clusters, we averaged the gene 
expression measurements within each cluster to generate “metagenes” 
that could be used to divide breast cancer cases into population tertiles 
based on the low, intermediate and high expression of the immune 
genes. The same was done for a large cluster of proliferation genes 
known to reflect the proliferative capacity of breast cancer cells. 
Strikingly, we found that that prognostic power of the B-cell, T/
NK and M/D metagenes was not consistent among the proliferation 
tertiles, but rather, was exclusively statistically significant in the 
highest proliferation tertile, enriched for basal-like, luminal B and 
HER2+-like tumors. In these tumors, all 3 immune metagenes 
stratified cases into low, intermediate and high risk of recurrence 
with high statistical significance (p<0.0001), wherein the highest 
expression tertile of the immune metagenes corresponded to reduced 
risk of metastatic recurrence (at 5 and 10 years), consistent with a 
long-term anti-metastatic immune response. Comparative analysis of 
the B and T/NK metagenes revealed a highly significant prognostic 
interaction between the two, whereby the low expression tertile of 
either the B-cell or T/NK metagene portends a poor prognosis that 
is not overcome by a high expression tertile of the other. Our results 
suggest that cell type-specific immune signatures in breast cancer can 
predict survival in highly proliferative subtypes of breast cancer, with 
potential to spare some patients from aggressive adjuvant treatment 
while identifying others who will require more than standard of care. 
Furthermore, our results provide novel insight into the important roles 
of T and B cell-mediated immunity in breast cancer progression.
P5-14-08
Impact of  Progesterone Receptor Semiquantitative 
Immunohistochemical Result on Oncotype DX® Recurrence 
Score: A Quality Assurance Study of 1078 Cases.
Bhargava R, Dabbs DJ. Magee-Womens Hospital of UPMC, 
Pittsburgh, PA
Background: The oncotype DX® recurrence score (RS) is 
predominantly dependent on estrogen and progesterone receptor 
content of the tumor, proliferation and HER2 status. We have 
previously shown (Mod Pathol. 2008;21:1255-1261) that 
using a regression equation that incorporates the above along 
with tumor grade components is capable of estimating the RS 
[RS=13.424+5.420 (nuclear grade) +5.538 (mitotic count) –0.045 
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(ER immunohistochemical score) –0.030 (PR immunohistochemical 
score) +9.486 (HER-2/neu)]. Subsequent studies have also shown 
similar findings including a few that suggests an even more important 
role for progesterone receptor. In order to identify the role of semi-
quantitative progesterone receptor immunohistochemical (IHC) result 
in a simplistic manner, we evaluated the PR IHC score (H-score) for 
different categories of RS (low, intermediate, and high) within each 
tumor grade (I, II, III).
Design: As a continuing quality assurance program at our institution, 
all cases sent for oncotype DX® testing that have available tumor 
grade, and RS were included in this study. Hormone receptor results 
at our institution are reported using an H-score like method which 
details the percentage of positive cells showing none, weak, moderate, 
or strong staining. The score is given as the sum of the percent staining 
multiplied by an ordinal value corresponding to the intensity level 
(0=none, 1=weak, 2=moderate, 3=strong). With four intensity levels, 
the resulting score ranges from 0 (no staining in the tumor) to 300 
(diffuse intense staining of the tumor).
Results: A total of 1078 cases were analyzed (see table below).
Relationship between recurrence score and progesterone receptor IHC score within each tumor 
grade category
Tumor Category PR score: median; mean (95% CI)
Grade I and low RS (n=185) 180; 172 (159-185)
Grade I and intermediate RS (n=116) 150; 138 (120-156))
Grade I and high RS (n=7) 0; 34 (-3 to 71)
Grade II and low RS (n=287) 190; 181 (171-191)
Grade II and intermediate RS (n=247) 130; 122 (110-134)
Grade II and high RS (n=67) 40; 69 (49-89)
Grade III and low RS (n=29) 200; 180 (149-211))
Grade III and intermediate RS (n=66) 150; 136 (114-158)
Grade III and high RS (n=74) 50; 76 (58-94)
RS: recurrence score; CI: confidence interval; IHC: immunohistochemical
Conclusions: Within each grade, PR IHC score is inversely related to 
the RS. The dramatic impact of PR IHC score on RS is noteworthy. If 
PR IHC score is combined with traditional histopathologic features 
(nuclear grade, mitotic activity score), and other IHC variables (ER 
IHC score, HER2 status, Ki-67 labeling index), then a tumor’s risk of 
recurrence and need for chemotherapy can be reasonably estimated. 
Oncotype DX® test may not be necessary in more than half of cases 
that are currently sent for testing.
P5-14-09
Malignant Calcification Is an Important Prognostic Factor in 
Women with Invasive Breast Cancer – Suggestion for Regarding 
It as High-Risk Factor in Current Staging and Adjuvant 
Treatment Guidelines.
Ling H, Shao Z-M, Liu Z-B, Xu X-L, Yang W-T, Xu L-H, Gu Y-J. Fudan 
University Shanghai Cancer Center, Shanghai, China
Purpose:
To investigate whether calcification is a prognostic factor for breast 
cancer.
Methods:
A total of 804 patients with invasive breast cancer diagnosed between 
2001 and 2003 were recruited and divided into two groups based 
on whether they had malignant calcification on mammogram. The 
association of calcification with lymph node status, grade, tumor 
size, ER, PR and Her2 status, 8-year disease-free survival (DFS) 
and overall survival (OS) was evaluated. Survival difference was 
analyzed by Kaplan-Meier technique. The relative importance of 
each of the potentially prognostic variables was tested using Cox 
regression analysis.
Results:
The incidence of malignant calcification in all breast cancer was 
41.5%. Compared with tumor without calcification, those with 
calcification had a larger size (2.6cm vs 2.1cm, P=0.000), higher 
axillary lymph node (LN) positive rate (40.1% vs 31.5%, P=0.012), 
more LN involvement (14.8% vs 9.2%, P=0.000), lower ER (54.3% 
vs 65.1%, P=0.002) and PR (42.7% vs 60.6%, P=0.000) expression 
and higher Her2 expression (27.3% vs 14.7%, P=0.000).
The 8-year DFS was lower for patients with calcification than those 
without (89.9% vs. 76.8%, P=0.000). The 8-year OS for tumor with 
calcification was 82.2%, compared with 92.8% for those without 
(P=0.000).
Subgroup analysis showed that the shorter survival and higher relapse 
rate for tumors with calcification could be found in both LN- and 
LN+ patients, also could be found in T1, T2, Grade II, ER+, PR+ 
and Her2- patients.
The existence of calcification, LN stage, tumor size, ER status, and 
grade were significantly associated with survival in univariate analysis. 
Further Cox regression analysis demonstrated that calcification and 
LN stage maintained their prognostic significance in both DFS and 
OS. The hazard ratios of these factors are listed in Table 1.
Hazard Ratios from Multivariate Cox Regression Analysis to DFS & OS
 DFS OS
Calcification P=0.001 P=0.001
no 1 1
yes 1.90 2.16
LN stage P=0.000 P=0.000
N0 1 1
N1 1.75 2.12
N2 3.57 3.98
N3 9.61 11.85
Tumor Size P=0.330 P=0.911
T1 1 1
T2 1.24 1.11
T3 1.73 1.02
ER P=0.150 P=0.040
- 1 1
+ 0.76 0.63
Grade P=0.320 P=0.111
I, II* 1 1
III 1.25 1.48
*Univariate analysis shows there’s no significant difference of survival between Grade I and II
Conclusions:
The existence of calcification is a poor prognostic factor for patients 
with invasive breast cancer. Its prognostic value is only second to LN 
status and is higher than the other factors evaluated, including tumor 
size, grade, and ER, PR status. Thus, breast cancer with calcification 
should be regarded as a high-risk factor when determining cancer 
stage and selecting the adjuvant treatment.
Discussion:
Given the strong prognostic value of calcification revealed in this 
research, the biological mechanism of its formation and related cell 
signal pathway should be investigated. Further adjuvant clinical trial 
should be done to select certain sensitive chemotherapeutic agent 
or regimen. Some biomarkers have been found to have a role in the 
formation of calcification and may be targets for treatment.
P5-14-10
Ethnic Differences in the Association between Tumor Size and 
Lymph Node Status among Breast Cancer Patients in South 
East Asia.
Saxena N, Verkooijen HM, Bhoo Pathy N, Siew EL, Iau P, Lee SC, 
Yip CH, Hartman M. National University of Singapore, Singapore, 
Singapore; University Medical Center Utrecht, Utrecht, Netherlands; 
Julius Center University of Malaya, Kuala Lumpur, Malaysia; 
National University Cancer Institute, National University Health 
Systems, Singapore, Singapore; Faculty of Medicine, University of 
Malaya Medical Center, Kuala Lumpur, Malaysia
Background: South East Asia consists of three major ethnic groups, 
i.e. Chinese, Malays and Indians. Previous work from our breast 
cancer research group showed that Malay ethnicity is an independent 
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predictor of poor survival. In this study we evaluate whether (part of) 
these ethnic survival disparities may be due to ethnic differences in 
the association of tumor size and lymph node involvement.
Methods: We included all patients diagnosed with breast cancer 
at the National University Hospital (Singapore) and University of 
Malaya Medical Center (Kuala Lumpur) between 1990 and 2007, for 
whom information on tumor size and axillary lymph node status was 
available (n = 3805). Ethnic differences in the association between 
tumor size and lymph node involvement were studied and logistic 
regression analysis was performed to determine the independent 
effect of ethnicity on the association of tumor size and lymph node 
involvement.
Results: 1474 patients were categorized as T1 (>0 to 2 cm), 1777 
as T2 (2.1 to 5 cm) and 554 as T3 (>5 cm). Within the small tumor 
size range (>0 to 2 cm) the Malays were significantly more likely to 
present with node positive disease as compared to the other ethnic 
groups (36.9% as compared to 24.5% for Chinese and 25.9% for 
Indians, p value <0.001). Similarly, for tumors measuring 2.1-5 cm, 
Malays were more likely than Chinese and Indians to have lymph 
node involvement (59.5%, 50.2% and 52.1%, respectively p value 
0.016). After adjustment for age, Progesterone Receptor (PR) status, 
grade and treatment received, Malay ethnicity was an independent 
predictor of lymph node involvement, with adjusted Odds Ratio’s of 
1.4 (95% CI 1.0 to 2.1) for T1 tumors and 1.4 (95% CI 1.1 to 1.9) 
for T2 tumors compared to Chinese women.
Conclusion: Malay patients are more likely to present with lymph 
node metastasis especially for the small and midsized tumors as 
compared to the Chinese and Indians. This could reflect differences 
in tumor biology between the three ethnic groups with the Malays 
possibly having more aggressive disease than the others.
P5-14-11
Elevated Serum Ferritin Predicts Reduced Progression-Free 
and Overall Survival in Trastuzumab-Treated Metastatic Breast 
Cancer.
Alkhateeb AA, Connor J, Leitzel K, Ali S, Campbell-Baird C, Evans M, 
Koestler W, Fuchs E-M, Lipton A. The Pennsylvania State University 
Hershey Medical Center, Hershey, PA; Lebanon VA Medical Center, 
Lebanon, PA; Medical University of Vienna, Vienna, Austria
Background: Approximately one-half of HER2-positive breast cancer 
patients will not respond to first-line trastuzumab-containing therapy. 
Since trastuzumab is now used in the HER2-positive adjuvant breast 
cancer setting, trastuzumab resistance will continue to be a vexing 
clinical problem, and better predictive and prognostic biomarkers 
are urgently needed.
One potential biomarker is serum ferritin. Although serum ferritin has 
been used as an indicator of total body iron, a specific functional role 
has not been proposed thus far other than perhaps recycling iron for 
erythropoiesis. Increased serum ferritin levels have been reported in 
breast cancer patients. However, the prevailing paradigm on ferritin 
at the time of these observations did not encourage speculation on its 
role or significance and was dismissed as a non-specific parameter for 
cellular damage. There are now multiple lines of evidence that have 
challenged this traditional paradigm and suggested ferritin to be a 
multi-functional factor involved in key cellular and systemic processes 
including immune regulation, angiogenesis, and iron delivery.
Methods: Pretreatment serum ferritin was measured using an ELISA 
assay in 66 metastatic breast cancer patients before starting first-line 
trastuzumab-containing therapy. Serum ferritin was determined 
using an ELISA from Assaypro, St. Charles, MO. Progression-free 
survival (PFS) and overall survival (OS) were analyzed using the 
Kaplan-Meier method and Cox modeling, with separate analyses 
as continuous serum ferritin, or as dichotomous categorical groups 
using the median pretreatment serum ferritin level as a cut off point. 
To interrogate a functional impact of elevated serum ferritin, we used 
a cell culture model.
Results: When analyzed as dichotomous categorical groups using 
the median pretreatment serum ferritin level as a cut off point, the 
elevated serum ferritin patient cohort had a significantly reduced OS 
(P<0.0001, median OS 12.73 vs. 69.57 months) and PFS (P=0.004, 
8.30 vs. 23.90 months). In the cell culture model, ferritin bound 
to breast cancer cells promoted proliferation and activated AKT 
signaling. These novel observations suggest that the iron storage 
protein ferritin has a signaling role in tumor biology. Since the 
elevation in serum ferritin is unlikely a consequence of a change in 
total body iron, we also examined several possible sources for this 
elevation. Macrophages, but not breast cancer cells, were capable of 
ferritin secretion.
Conclusions: Elevated serum ferritin predicts reduced PFS and overall 
survival in metastatic breast cancer patients treated with first-line 
trastuzumab-containing therapy. The ability of ferritin to activate 
AKT signaling could underlie the trastuzumab resistance in patients. 
Therefore, serum ferritin may not only have predictive value as a 
clinical tool but also has direct functional significance in the treatment 
response, progression and survival of breast cancer patients.
P5-14-12
Bayesian Belief Network Mortality Analysis of a Breast Cancer 
Registry Data Set.
Eberhardt JS, Hyslop T, Mitchell E, Hu H, Rui H. DecisionQ 
Corporation, Washington, DC; Thomas Jefferson University, 
Philadelphia, PA; Windber Research Institute, Windber, PA
Introduction: Bayesian Belief Networks have been used in medicine to 
evaluate clinical data and develop predictive and prognostic models. 
As classification models, they allow us to represent pattern complexity 
beyond what can be accomplished with traditional Kaplan-Meier or 
regression models. We sought to evaluate the use of machine-learned 
Bayesian Belief Networks (ml-BBNs) to develop mortality models 
in breast cancer and to evaluate classification performance for this 
method.
Methods: A set of 2,300 breast bancer cases from a tumor registry 
at Thomas Jefferson University were used to train ml-BBNs. The 
registry set was broken into cohorts for modeling by follow-up times 
of 1 (n=2,202), 2 (n=2,183), 3 (n=2,157), and 5 (n=2,027) years. Each 
cohort was then used to train a ml-BBN and each model was evaluated 
for structure. Variables were recoded into categories: biomarkers (ER, 
PR, Ki67, HER2, p53) as positive or negative; grading, staging, and 
size were broken in categories; while race was recoded into Caucasian 
or African-American. Income and poverty level by census tract were 
also included. Models were evaluated for ability to classify mortality 
(yes/no) within the follow-up period using 10-fold cross-validation 
and Receiver Operating Characteristic curves.
Results: Area Under the Curve (AUC), Positive Predictive Value 
(PPV), and Negative Predictive Value (NPV) were calculated for each 
set of cohort training models and mean values and 95% confidence 
intervals were calculated for mortality (yes/no) within the follow-up 
period. AUCs (and CIs) for 1, 2, 3, and 5 years were: 0.81 (0.70 – 
0.91), 0.74 (0.69 – 0.79), 0.81 (0.77 – 0.86), 0.77 (0.74 – 0.80). PPVs 
for 1, 2, 3, and 5 years were: 12.3% (7.5% – 17.1%), 18.8% (15.4% 
– 22.1%), 18.0% (15.1% – 20.9%), 28.2% (24.7% – 31.7%). NPVs 
for 1, 2, 3, and 5 years were: 99.2% (98.8% – 99.7%), 97.4% (96.9% – 
97.8%), 96.4% (95.1% – 97.7%), 91.7% (89.1% – 94.3%). Predictors 
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of mortality at 1 year were Tumor Stage, at 2 years were Estrogen 
Receptor and Tumor Stage, and at 3 and 5 years were Diagnosis Age, 
Tumor Stage, Estrogen Receptor status, and Ki-67 receptor status.
Discussion / Conclusion: We were able to successfully train ml-
BBNs to estimate mortality using breast cancer registry cohorts. 
Cross-validation showed the models to be robust. The structure of 
the models can inform us how different data elements contribute 
to the estimate of mortality. These models can be used to calculate 
individual probabilities for prognostic guidance given age, staging 
criteria, and biomarkers. Overall 5-year mortality in the study set is 
15.2%, however we can derive subject-specific mortality estimates. 
For example, a 43-year old Stage 3, ER-Negative, Ki-67 Negative 
subject has a 19.9% probability of 5-year mortality, while the same 
subject with positive Ki-67 has a 37.8% probability of mortality. 
Meanwhile, the same probabilities for a 70 year old woman are 67.0% 
and 59.0%, respectively.
Conditional Probability of 5-Year Mortality
Diagnosis Age Stage Estrogen Receptor Ki-67 Receptor 5-Year Mortality
48 or Younger 3 Negative Negative 19.9
48 or Younger 3 Negative Positive 37.8
69 or Older 3 Negative Negative 67.0
69 or Older 3 Negaive Positive 59.0
P5-14-13
Favorable Prognosis in Patients with T1a,b Node-Negative Triple 
Negative Breast Cancers Treated with Multimodality Therapy.
Ho AY, Gupta G, Perez CA, King TA, Patil SM, Rogers KH, Brogi E, 
Morrow M, Hudis C, Traina T, McCormick B, Powell SN, Robson 
ME. Memorial Sloan Kettering Cancer Center, New York, NY
Purpose: To evaluate the clinical characteristics, natural history and 
outcomes in patients with <1cm, node-negative triple negative breast 
cancer (TNBC).
Materials and Methods: After excluding patients who received 
neoadjuvant therapy, 1,022 TNBC patients who received definitive 
breast surgery from 1999 to 2006 were identified from an institutional 
database. Among these, 194 patients had node-negative tumors <1cm 
and comprise the study population. Clinical data was abstracted and 
survival outcomes were analyzed.
Results: Median follow-up time was 71 months (range 2-143). 
Median age at diagnosis was 55.5 years (range 27-84). T stage was 
T1mic in 16 (8.2%), T1a in 49 (25.3%), T1b in 129 (66.5%). The 
majority of tumors were poorly differentiated (N= 142, 73%), lacked 
lymphovascular invasion (N= 170, 87.6%) and were screening-
detected (69%, N=134) . Breast-conserving surgery (BCS) was 
employed in 129 (66.5%) and mastectomy in 65 (33.5%) patients. 
113 (58%) patients received adjuvant chemotherapy and 123 (63%) 
received whole breast radiation. Patients who received chemotherapy 
tended to have more adverse clinical and disease features (younger 
age,T1b, poor tumor grade; all p<0.05). For the entire group, 5 year 
local recurrence-free survival was 96% and distant metastasis-free 
survival was 95%, with no difference in distant relapse rates between 
T1mic/T1a vs. T1b patients (94.5% vs 95.5%, p=0.81 )or by receipt 
of chemotherapy (95.9% vs 94.5%, p=0.63).
Conclusion: Excellent 5-year locoregional and distant control rates 
were achievable in patients with TNBC tumors < 1.0 cm, 58% of 
whom received chemotherapy. These results identify a group of 
TNBC patients with favorable outcomes following early detection 
and multimodality treatment.
P5-14-14
The Presence of a Fibrotic Focus Adds Significant Prognostic 
Information to the Prognostic 76-Gene Relapse Score in Lymph 
Node Negative Breast Cancer.
Van den Eynden GG, Van Laere SJ, Smid M, Martens JW, Foekens 
JA, Vermeulen PB, Dirix LY. Augustinus Hospital, Antwerp, Belgium; 
Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
Introduction: The fibrotic focus (FF) is a practical, easily assessable 
and reproducible integrative histological prognostic parameter in 
breast cancer. Its prognostic value has been shown before (Van den 
Eynden et al. Histopathology 2007). In this study we investigated 
whether the assessment of the FF adds prognostic information to 
the relapse score based on gene expression analysis of 76 genes as 
previously described (Wang et al. Lancet 2005).
Materials and Methods: All patients of 2 previous prognostic breast 
cancer gene expression studies for whom FFPE slides of the tumor 
were available (Wang et al. Lancet 2005 and Yu et al. BMC Cancer 
2007) were selected, leading to a study population of 176 lymph 
node negative breast cancer patients. The presence and size (<1/3 
or >1/3 of tumor area) of a FF were assessed on standard HE slides. 
These data were compared to the 76-gene relapse score, to standard 
clinicopathological variables and to metastasis-free survival.
Results: A small and large FF were found in 31 (17.6%) and 20 
(11.4%) of patients, respectively. In 120 (68.2%) patients there was 
no FF and in 5 patients the presence of a FF could not be assessed due 
to insufficient FFPE material. 64 (36.4%) and 112 (63.6%) patients 
had respectively a good and poor prognostic 76-gene relapse score. 
There was a significant correlation between the presence of a FF 
and a poor 76-gene relapse score, 18 of 20 patients with a large FF 
had a poor relapse score (p = 0.03). Patients with a tumor with a FF 
and especially with a large FF had a significantly reduced metastasis 
free survival (Log rank p<0.001). The same was true for patients 
with a poor 76-gene relapse score (Log rank p<0.001). When only 
patients with a poor relapse score were taken into account, patients 
with a tumor with a large FF had a significantly decreased metastasis-
free survival compared to patients without a FF or with a small 
FF (Log rank p=0.005). In patients with a good relapse score, the 
number of patients with a FF was too small for a separate analysis. 
In a multivariate Cox regression model for metastasis-free survival 
including age, ER and PR status, T stage, the FF and the 76-gene 
relapse score status, the FF (OR 1.5, p=0.02) and the relapse score 
status (OR 3.4, p = 0.001) were significant independent prognostic 
factors. Comparable results were found if the presence of a FF was 
dichotomized in large FF versus no or a small FF.
Conclusion: The assessment of the presence and size of a FF adds 
independent significant prognostic information to the prognostic 
76-gene expression signature, especially in selecting a subgroup of 
patients with a very poor prognosis. Since the assessment of the FF 
is practical, easy, reproducible and cheap it should be considered to 
become part of the standard pathological examination of breast cancer 
resection specimens.
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Prognostic Impact of Chemotherapy-Induced Amenorrhea (CIA) 
in Premenopausal Breast Cancer: A Meta-Analysis of Published 
Literatures.
Lu J, Zhou Q, Yin W. Fudan University Shanghai Cancer Center, 
Shanghai, China
Background: Various studies have reported inconsistent results on 
the prognostic effect of chemotherapy-induced amenorrhea (CIA) 
in premenopausal breast cancer. Therefore, we conducted a meta-
analysis to assess the effect of CIA on prognosis of premenopausal 
women with breast cancer.
Methods: The PubMed database was searched for all relevant studies 
published before March 2011. Relative risks (RRs) were used to 
estimate the association between CIA on various survival outcomes. 
Subgroup analyses were also performed by age, nodal status and 
hormone receptor (HR) status.
Results: With thirteen eligible studies identified, this meta-analysis 
included 5790 cases and 2159 controls. This meta-analysis 
demonstrated that CIA was associated with improved DFS (RR= 
0.39, 95%CI: 0.32~0.47, p<0.001) and OS (RR= 0.30, 95%CI: 
0.21~0.44, p<0.001). In the subgroup analyses, the effect of CIA on 
DFS and OS also existed in HR-positive subjects (for OS, RR= 0.19, 
95%CI: 0.07~0.49, p=0.001; for DFS, RR= 0.47, 95%CI: 0.35~0.63, 
p<0.001) while similar results failed to be observed in HR-negative 
patients (for OS, RR= 0.62, 95%CI: 0.07~5.75, p=0.671; for DFS, 
RR= 1.48, 95%CI: 0.50~4.37, p=0.474). Furthermore, significant 
difference was achieved between women with and without CIA, 
irrespective of age and nodal status .Conclusion: This meta-analysis 
clarifies that CIA might contribute to the improvement of prognosis 
in HR-positive premenopausal breast cancer patients, which is at 
least partially responsible for the benefit of adjuvant chemotherapy 
in premenopausal women through chemical castration.
P5-14-16
Molecular Classification in Primary Breast Cancer and 
Corresponding Lymph Node Metastasis Show Impaired 
Prognostic Profile in the Metastatic Node.
Falck A-K, Ferno M, Bendahl P-O, Rydén L. Clinical Sciences, 
Lund, Sweden
Introduction
The heterogeneity of breast cancer disease has emphasized the need 
to optimize prediction of outcome by molecular classification of 
the primary tumor. Clinical management of primary breast cancer 
is based on biomarkers measured in the primary tumor, whereas 
biomarker analysis in metastatic lymph nodes is not used for clinical 
decision making. Recently, microarray-based expression profiling 
and subsequent immunohistochemical studies have identified 
biologically distinct subtypes using a combination of biomarkers. 
The present study aimed to classify primary breast cancer tumors and 
corresponding lymph node metastases by multiple biomarkers into 
Luminal A, Luminal B, HER2 type and Triple negative phenotype 
and compare outcome.
Material and method
The study is based on a cohort of patients where biomarker expression 
(hormone receptor status (ER, PR), human epidermal growth factor 
receptor 2 (HER2) and Ki67) in primary breast cancer and ipsilateral 
lymph node metastasis recently were reexamined and individually 
related to prognosis. In the present study, 85 patients of the original 
cohort were possible to classify into the four subtypes: Luminal A 
(ER+, PR+/- and Ki67 ≤ 20%), Luminal B (ER+, PR+/-, HER2+/- and 
Ki67 > 20%), HER2- type (ER-, HER2+) and Triple negative (ER-, 
PR-, HER2-). The classifications of primary tumors and corresponding 
lymph node metastases were compared using the McNemar-Bowker 
test of symmetry and the molecular subgroups were related to clinical 
outcome in terms of 5-years distant disease-free survival (DDFS) by 
Cox analysis with luminal A as the reference group.
Results
Primary tumor Lymph node metastasis
 Frequency  
N (%)
HR (95% CI) p-value Frequency N (%) HR (95% CI) p-value
Luminal A 45 (53) 1.0  38 (45) 1.0  
Luminal B 17 (20) 2.8 (0.9-8.4) 0.07 23 (27) 3.1(1.0-9.5) 0.048
HER2-type 11 (13) 4.5 (1.4-14.1) 0.01 11 (13) 7.3 (2.2-23.9) 0.001
Triple negative 12 (14) 5.9 (2.1-16.9) 0.001 13 (15) 4.6 (1.4-15.0) 0.01
In 7 cases (16%) the biomarker classification was discordant 
between the primary tumor and the lymph node metastasis. All of 
the discordant cases shifted to a subtype with a worse prognosis 
according to the lymph node metastasis (p=0.06, Mc Nemar-Bowker 
test of symmetry). When comparing Luminal A to non-Luminal A in 
the primary tumor and the lymph node, the deviation from symmetry 
was significant, p=0.02. DDFS was worse in all subtypes compared 
to the prognosis for Luminal A using Cox analysis in both primary 
tumors and lymph node metastasis.
Conclusion
Our data shows discordance in classification according to a multiple 
molecular phenotype between primary tumors and lymph node 
metastasis in breast cancer patients. The discordant cases were shifted 
from Luminal A to a subtype where survival analysis showed an 
impaired prognosis compared to this subgroup. The finding that the 
molecular phenotype is shifted from a “good” prognostic signature 
in the primary tumor to a “bad” prognostic signature in the metastatic 
node can be of clinical importance for the choice of adjuvant systemic 
therapy in primary breast cancer with lymph node positive disease.
P5-14-17
Stage IV at Presentation – Are HER2 Positive Tumors 
Overrepresented?
Woods R, Yerushalmi R, Speers C, Tydesley S, Gelmon K. BC Cancer 
Agency, Vancouver, BC, Canada
Background: A minority of patients are diagnosed with Stage IV breast 
cancer at presentation. Recent studies (Dawood 2010) have suggested 
a better outcome for de novo vs. recurrent Stage IV but they did not 
account for the variation of molecular subtype. We questioned whether 
HER2 overexpressing tumors were over-represented in de novo Stage 
IV disease, and whether this impacted on survival compared to other 
subtypes. Further, if different subtypes are more likely to present 
with metastatic disease, then this factor may need to be considered 
when developing guidelines for staging. With such considerations in 
mind, the purpose of this study was to determine the breast cancer 
subtypes according to stage. The main hypothesis was that HER2 
positive tumors would be more prevalent in stage IV presentations.
Methods: Using the Breast Cancer Outcomes Unit database from 
the BC Cancer Agency (BCCA), patients referred to the BCCA 
with a new diagnosis of breast cancer between 2005 and 2010 were 
selected. Patients with a previous or synchronous contralateral breast 
cancer, male cases, and patients with referrals for reasons other than 
new disease were excluded. Four subtypes according to available 
markers were defined: ER+/HER2-, ER+/HER2+, ER-/HER2+, and 
ER-/HER2-.
Results: Using these criteria, 485 cases of de novo stage IV disease 
and 10,723 stages I - III cases were extracted. After excluding cases 
with missing data, our final cohort consisted of 10,186 stage I-III 
cases and 425 stage IV cases. Distribution by subtype is presented 
in the Table below.
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T Subtype Distribution by Stage IV or I-III (unknown subtype excluded)
Subtype Stages I - III Stage IV P-value
ER+,HER2- 7405/10186 (72.7%) 254/425 (59.8%)  
ER+, HER2+ 1037/10186 (10.2%) 66/425 (15.5%) <.0001
ER-, HER2- ER-, HER2- 1156/10186 (11.3%)
ER-, HER2- 1156/10186 (11.3%) 
58/425 (13.6%)
 
ER-, HER2+ 588/10186 (5.8%) 47/425 (11.1%)  
Assessment of other patient characteristics for the group of Stage IV 
de novo patients revealed that age (younger for HER+ subgroups), 
site of metastases (more visceral vs. non- visceral for ER-/HER2+ 
and ER-/HER2-) and type of systemic therapy (chemotherapy (CT), 
hormone therapy (HT), trastuzumab (T) or not) were significant. 
Surgery rates for both mastectomy and breast-conserving surgery 
were similar for all subtypes. The ER-/HER2- subtype had the worst 
overall survival (p < 0.001).
Median Overall Survival (OS) in years by Breast Subtype for Stage IV de novo
Subtype Number of Cases Median OS (95% CI)
ER+, HER2- 254 2.7 (2.2, 3.0)
ER+, HER2+ 66 2.6 (2.1, 3.3)
ER-, HER2- 58 0.9 (0.6, 1.2)
ER+, HER2+ 60 1.0 (0.5, 1.4)
Conclusion: Young age and HER2 overexpression is more common 
in stage IV de novo presentations (26.6% of stage IV tumors were 
HER2+ vs. only 16% of stage I-III tumors). This data may be 
important in considering routine staging guidelines at diagnosis to 
ensure correct diagnosis and treatment recommendations.
P5-14-18
Today’s Estrogen Receptor Positive/Her-2-neu Receptor Negative 
Breast Cancer Patients Do Significantly Better Than Yesterday’s 
Estrogen Receptor Positive Breast Cancer Patients.
Madsen EV, Elias SG, Gobardhan PD, van Oort PM, van der Ent FW, 
Nieweg OE, Valdés Olmos RA, Smidt M, van Dalen T. Diakonessenhuis 
Utrecht, Utrecht, Netherlands; University Medical Centre Utrecht, 
Utrecht, Netherlands; The Netherlands Cancer Institute - Antoni 
van Leeuwenhoek Hospital, Amsterdam, Netherlands; Maastricht 
University Medical Centre, Maastricht, Netherlands; Orbis Medical 
Centre, Sittard, Netherlands
Background: Her-2-neu receptor (Her2) positive and triple negative 
breast cancer patients have a poor prognosis. The majority of cancers 
are characterized as estrogen receptor (ER)+/Her2- and these patients 
may now have a better prognosis compared to before the introduction 
of the Her-2-neu receptor.
Material and methods: Since 1997 3424 patients were treated for 
cT1-2N0 breast cancer in three hospitals. Determination of Her2-neu 
status was introduced between 1999 and 2004. Trastuzumab treatment 
has been given routinely since 2005. Survival was evaluated for the 
different groups; ER+/Her2-, ER+/Her2+, ER+/Her2 unknown (status 
not determined).
Results: 2284 patients had ER+/Her2- tumors, 259 had ER+/Her2+ 
tumors and 262 had ER+/Her2 unknown tumors. Systemic treatment 
was given to 48.4%, 71.0% and 43.9% respectively. Estimated 5- 
and 10-year overall survival was 92.0% and 82.2% for ER+/Her2-, 
91.6% and 70.8% ER+/Her2+ and 83.4% and 72.2% for ER+/Her2 
unknown (p < 0.001). The outcome differences between ER+/Her-
2- and ER+/Her-2 unknown tumors remained following adjustment 
for tumor malignancy grade, nodal status and adjuvant systemic 
treatment (OR 0.8: CI 0.72 - 0.88; p<0.001). For patients with ER+/
Her2+ tumors 5 year overall survival was comparable with ER+/
Her2- tumors but 10 year overall survival was comparable with ER+/
Her2 unknown tumors.
Discussion: Patients with ER+/Her2- tumors have a significantly 
better outcome than patients who were classified as ER+ before the 
assessment of Her-2-neu over-expression. Current prognostic models 
do not take this effect into account.
The branching off of the survival curve for patients with ER+/Her2+ 
tumors can be explained by the standard use of trastuzumab during 
the last five years.
P5-14-19
Ipsilateral Breast Tumor Recurrence Prediction with Web-Based 
Normogram in Korea.
Jung SP, Lee SK, Kim S, Koo MY, Choi M-Y, Bae SY, Cho DH, Lee 
J, Kim JK, Yang J-H, Lee JE, Nam SJ. Amsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, Korea; Konkuk 
University Medical Center, Seoul, Korea
Purpose
Ipsilateral Breast Tumor Recurrence(IBTR!) 2.0 is web-based tool 
which predict the ten years risk of local recurrence after breast 
conserving theraphy. This tool integrates seven prognostic factors 
(patient age, margin status, lymphovascular invasion, tumor size, 
tumor grade, use of chemotherapy and hormonal therapy) for local 
recurrence with or without radiation theraphy. To validate IBTR! 2.0 
for Korean breast cancer patients, Samsung Medical Center database 
was used between 1994 and 2001.
Methods
The IBTR! 2.0 nomogram was tested against 358 patients who 
underwent breast conserving surgery with radiation theraphy from 
Samsung Medical Center between 1994 and 2001. The individual 
dadabase which was entered into IBTR! 2.0 computer model generate 
predictive local recurrence rate. The mean predicted and observed 
10-year estimates were compared for the entire cohort and for four 
groups predefined by nomogram-predicted risks: group 1: less than 
3%; group 2: 3% to 5%; group 3: 5% to 10%; and group 4: more 
than 10%.
Results
IBTR! version 2.0 predicted an overall 10-year IBTR estimate of 
5.5% (95% CI, 5.2 to 5.9), while the observed estimate was 7.69% 
(20 IBTR cases in 358 patients, 95% CI, 1.6 to 9.3; P=0.59).
The predicted and observed IBTR estimates were: group 1 ( 2 cases 
in 67 patients): 2.3% versus 2.9%, P=0.53; group 2 ( 2 cases in 124 
patients)): 3.9% versus 4.1%, P=0.18; group 3 (14 cases in 139 
patinets): 7.3% versus 4.8%, P=0.13; and group 4 (2 cases in 28 
patients): 12.15% versus 7.1%, P=0.61.
Conclusion
IBTR! 2.0 is acceptable nomogram for predicting 10 years local 
recurrence using Samsung medical Center database. This nomogram 
showed overestimation in group 3, 4, however did not showed 
statistical differences. This nomogram may assist patient counseling 
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and medical decision making, but prior to using whole Korean 
patients, this model requires validation with multiple Korean sources.
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P5-14-20
Neoadjuvant Chemotherapy (NCT) in 466 Patients for Operable 
Breast Cancer: The Prognostic Value of SBR Grade Variation.
Abrial C, Mouret-Reynier M-A, Wang-Lopez Q, Durando X, Thivat 
E, Raoelfils I, Gimbergues P, Van Praagh-Doreau I, Nabholtz J-M, 
Chollet P, Penault-Llorca F. Jean Perrin Comprehensive Cancer 
Centre, Clermont-Ferrand, France, Metropolitan
Purpose of the study: In a new database harbouring the patients 
of several prospective phase II neoadjuvant trials (fec 50-100, net, 
tncf, taxotere/tncf, taxotere alone), the predictive value of tumour 
factors (SBR grade, RH, Her2, Ki-67 and cycline D1) was studied in 
466 women with stage II-III operable breast cancer treated between 
1991 and 2006.
Patients and methods: Median age of the patients was 48 years [27-
76]. Median diameter of the invasive tumour was 40 mm [10-130]. 
382 (82%) patients had a canalar, 57 (12.2%) a lobular, 14 (3%) a 
mixed or invasive carcinoma, 3 (0.6%) neoplasic cells only and 10 
(2.2%) another carcinoma. Before chemotherapy, 33% were grade III 
SBR. The median number of NCT courses was 6 [1-8] followed by a 
surgery for 98%, a radiotherapy for 93%, an adjuvant chemotherapy 
(20%) and/or a hormonotherapy (56%).
Results: Overall response rate was 73% (18% complete). The 
complete pathological response (pCR) rate was 17.2% according to 
Chevallier’s classification. On 455 patients operated, 324 (71%) had 
a conservative surgery. On 390 patients with an axillary dissection, 
195 (50%) had involved nodes (median number : 2 [1-20]). After a 
median follow-up of 135 months, DFS and actuarial survival at 120 
months were 61.9% and 73%, respectively.
After chemotherapy, we found a significant variation for SBR grade 
: there was five fold more patients for whom we observed a down 
grading of the SBR grade (grade 2/3 to grade 1) than up grading 
(grade 1 to grade 2/3), p=6.1.10-6. For patients in objective response, 
we observed a significant decrease of SBR grade (p=1.7.10-3).
Moreover, the variation of SBR grade was also pronostic. Indeed, the 
disesase-free survival for patients who presented a SBR down grading 
after chemotherapy was significantly better (p=0.031) compared to 
patients for whom SBR grade remained stable or was in up grading. 
There was a tendancy for overall survival (p=0.15).
Conclusion: Down grading of SBR grade appears linked to 
response and so may constitute a parameter of better prognostic. 
At the opposite, up grading of SBR grade is an adverse prognostic 
factor. To conclude, it is interesting to emphasize that SBR grade 
variations can be assessed when patients are not in pCR, ie plays a 
complementary role.
P5-14-21
Predicting the Status of the Axillary Lymph Nodes in 1300 
Consecutive Patients with Early Breast Cancer Treated in a 
Single Institution.
Yoshihara E, Smeets A, Laenen A, Reynders A, Wildiers H, Soens 
J, Paridaens R, Van Ongeval C, Floris G, Moerman P, Neven P, 
Christiaens M-R. Catholic University of Leuven, Leuven, Belgium; 
University Hospitals Leuven, Leuven, Belgium
Purpose. Lymph node involvement is the most important prognostic 
factor in breast cancer. It is a multifactorial event determined by 
tumour and patient characteristics. Several predictors of axillary 
lymph node metastasis (ALNM) in breast cancer have been described. 
The purpose of this study was to determine clinical and pathological 
factors predictive for ALNM in patients with early breast cancer and 
to build a model to portend lymph node involvement.
Methods. We evaluated 1300 consecutive patients surgically treated 
in our institution (2007-2009) for cT1-T2 invasive breast cancer. 
The patient and tumour characteristics evaluated included: age at 
diagnosis, number of foci, histologic grade, location, tumour size, 
histologic subtype, lymphovascular invasion (LVI), estrogen-receptor 
(ER), progesterone-receptor (PR) and Her2 status. Univariate and 
multivariate analyses were performed. Factors significantly associated 
with lymph node metastasis by univariate analysis and histologic 
subtype were included in the multivariate model. We validated our 
model with the same 1300 patients on the basis of a multivariable 
logistic regression model containing the variables, using a correction 
factor.
Results. By univariate analysis, the incidence of ALNM was 
significantly higher in patients with a tumour with LVI (P < 0.0001), 
larger tumours (P < 0.0001), tumours with a higher histologic grade 
(P < 0.0001), tumours located retroareolar or lateral in the breast (P < 
0.0001), tumours with multiple foci (P = 0.0002) and in patients who 
underwent an axillary lymph node dissection. We found no effect of 
ER/PR nor HER-2 status.
Univariate analyses.
Variable OddsRatio (95% CI) P value
Age 1.0010 (0.9921 - 1.0100) 0.8259
Number of foci 1.3980 (1.1738 - 1.6651) 0.0002
Histologic grade   
Overall effect  < 0.0001
Tumour location   
Overall effect  < 0.0001
Tumour size 1.0567 (1.0457 - 1.0679) < 0.0001
Histologic subtype   
Overall effect  0.5738
Lymphovascular invasion   
Present vs. absent 8.6468 (6.4149 - 11.6552) < 0.0001
Estrogen-receptor status   
Positive vs. negative 1.2638 (0.9288 - 1.7195) 0.1362
Progesterone-receptor status   
Positive vs. negative 1.0440 (0.8065 - 1.3515) 0.7435
Her-2   
Positive vs. negative 0.7318 (0.1833 - 2.9213) 0.6584
Procedure   
ALND vs. SLNB 2.9405 (2.3311 – 3.7093) < 0.0001
By multivariate analysis, lymph node involvement was significantly 
associated with the presence of lymphovascular invasion (P < 0.0001), 
larger tumour size (P < 0.0001), axillary lymph node dissection (P 
= 0.0003), retroareolar and lateral tumour location in the breast (P = 
0.0019) and the presence of multiple foci (P = 0.0155).
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Multivariate analyses
Variable P value
Number of foci 0.0139
Histologic grade 0.6110
Tumour location 0.0022
Tumour size <.0001
Invasive ductal carcinoma 0.9363
Invasive lobular carcinoma 0.6864
Lymphovascular invasion <.0001
Procedure 0.0003
The discrimination of the model, calculated by the area under the 
curve (AUC), was 0.778.
Conclusions. LVI and tumour size emerged as most powerful 
independent predictors of ALNM. A model with an AUC of 0.50 
is equivalent to the toss of a coin, a model with an AUC > 0.70 
is considered as good. In conclusion, our result is not perfect 
in discrimination which raises further questions. It is clear that 
underlying mechanisms of ALNM remain to be elucidated.
P5-14-22
Prospect ive  Observat ional  Study To Descr ibe  the 
Clinicopathological and Biological Characteristics and the 
Management of Metastatic Breast Cancer Patients Who 
Experienced Complete or Partial Remission or Disease 
Stabilization during at Least 3 Years.
Zamora P, Pérez-Carrión R, Manso L, Crespo C, Mendiola C, Alvarez-
López I, Margeli M, Bayo-Calero JL, González-Farre X, Santaballa 
A, Ciruelos EM, Afonso R, Lao J, Catalán G, Álvarez-Gallego JV, 
Miramón-López J, Salvador-Bofill FJ, Ruiz-Borrego M. Hospital La 
Paz, Madrid, Spain; Hospital Quirón, Madrid, Spain; Hospital 12 
de Octubre, Madrid, Spain; Hospital Ramón y Cajal, Madrid, Spain; 
Hospital Donostia, San Sebastián, Spain; Hospital Germans Trias 
i Pujol, Badalona, Spain; Hospital Juan Ramón Jiménez, Huelva, 
Spain; Hospital Clinic de Barcelona, Barcelona, Spain; Hospital 
La Fe, Valencia, Spain; Hospital Nuestra Señora de la Candelaria, 
Santa Cruz de Tenerife, Spain; Hospital Miguel Servet, Zaragoza, 
Spain; Hospital Son Llàtzer, Mallorca, Spain; Complejo Hospitalario 
de Zamora, Zamora, Spain; Hospital Serranía de Ronda, Ronda, 
Spain; Hospital Virgen de Valme, Sevilla, Spain; Hospital Virgen 
del Rocío, Sevilla, Spain
Background: Trastuzumab has shown an improvement in survival 
outcomes among patients with HER2+ metastatic breast cancer 
(MBC). Identification of pathological, clinical factors and tumor 
genetic profile that may predict long-term remission has become a 
key-issue. We aimed to describe the clinicopathological and biological 
characteristics of MBC patients who experienced complete response 
(CR), partial response (PR), or stable disease (SD) during at least 3 
years and their management in routine clinical practice.
Methods: Multicenter, observational, cross-sectional study. Data were 
collected from women with HER2+ MBC treated with a trastuzumab-
based regimen who maintained a partial or complete remission or 
disease stabilization beyond 3 years. The interim results from the 
first 65 patients evaluated are presented.
Results: Median age: 59 (52-70) years. Metastatic disease was 
diagnosed after a median of 23.5 (1.6-48.8) months since primary 
tumor diagnosis. The predominant tumor type was ductal carcinoma 
(89.2%) and 47% showed histological grade III. Mean tumor size: 
3.6±2.2cm (anatomical pathology), 5.1±2.8cm (imaging studies). 
Hormonal status: Progesterone receptor positive 46% and estrogen 
receptor positive 43%. Most common metastatic sites: lung (23%), 
liver (17%) and bone (14%). Overexpression of HER2 was assessed 
by IHC in 97% of patients, of whom 94% were HER2+ (3+) and 
17% had FISH+ HER2 status. Tumor was positive for p53 and Ki67 
in 23% and 41.5%, respectively. Surgery was performed on 83% of 
patients, of which 73% underwent radical mastectomy; 96% had 
their axillary nodes removed. Surgery of metastases was performed 
on 7.8%. First line chemotherapy was received by 91% with the 
most frequent schemes being paclitaxel (24%), vinorelbine (15%) 
and paclitaxel/carboplatine (14%). First line hormonal therapy and 
radiotherapy was used in 45% and 12%, respectively. All patients 
received first line trastuzumab, administered on a weekly schedule 
in 51%. Trastuzumab was used in combination in most of patients 
(89.2%) with a median number of cycles of 18 (7.0-41.5) and during 
a median of 53.3±25 months. 66% of patients achieved a CR, 21% 
PR and 13% had SD. Median time since trastuzumab was initiated 
to CR, PR or SD was 5 (4-7) months. Median duration of CR, PR or 
SD was 56 (44.5-78.0) months. Trastuzumab was maintained beyond 
CR, PR or SD in 99% during a median of 46.5 (35-67) months. 75% 
of patients continue on treatment with trastuzumab. Only 2 patients 
discontinued trastuzumab due to toxicity. At the time of the analysis, 
19% had progressed, 57% were alive and free of disease and among 
patients on treatment (93%), 54% were on trastuzumab. Cardiac 
toxicity was the most common toxicity (36%) among those suffering 
at least one (22%).
Conclusions: The preliminary findings support that trastuzumab 
provides a substantial long-term survival benefit with a manageable 
safety profile in HER2+ MBC patients. This study adds to the evidence 
that there may be benefit in continuing trastuzumab after achieving 
remission or disease stabilization. Final results will be presented in 
the forthcoming congress.
P5-14-23
Clinical Outcomes of Different Subtypes Detected by 
Immunohistochemistry of Early Invasive Breast Cancers in a 
Monoinstitutional Series.
Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, 
Aldovini D, Dipasquale M, Galligioni E. S Chiara Hospital, Trento; 
FBK, Trento; S. Chiara Hospital, Trento
Background: Early invasive breast cancer (EIBC) is an heterogeneous 
disease. Immunohistochemical (IHC) markers can be used to classify 
tumors in different biological subtypes with different clinical behavior.
Purpose: The aim of our study was to evaluate survival outcomes 
for patients (pts) with different subtypes of EIBC as classified using 
four ICH markers (ER, PR, HER2 and Ki67).
Methods: We evaluated data from 3403 consecutive cases of EIBC 
treated from 1995 to 2008 and classified as: luminal A (positive ER 
and PR, negative HER2 and Ki67< 14%), luminal B (positive ER 
and/or PR, negative HER2 and Ki67>14%), luminal C (positive ER 
and/or PR, positive HER2, any Ki67), HER2+ (negative ER and 
PR, positive HER2, any ki67), triple negative (negative ER and PR, 
negative HER2, any ki67). Log-rank test and Kaplan-Meyer estimator 
were performed to evaluate the impact of ICH subtypes on overall 
survival (OS), Event Free Survival (EFS) and their correlation with 
other known prognostic factors such as N, G, Size, Age.
Results: We identified 917 luminal A (26.9%) , 1731 luminal B 
(50.9%) , 279 (8.2%) luminal C, 183 HER2 + (5.4%) and 293 
triple negative (8.6%). Median age was 61 years. Luminal A was 
more frequently (p<0.001) associated with older age, smaller size, 
negative axilla involvement, low grading. Observed events (relapses, 
contralateral and second tumors) were: 54 in luminal A (6%), 215 in 
luminal B (16%) , 40 in luminal C (14%), 42 in HER2+ (23%) and 
59 in triple negative (20%). Disease free interval (DFI) was shorter in 
luminal C, HER2 and TN (median DFI: 30, 26 and 19 months) than 
in Luminal A and B (median DFI: 51 and 41 month). Luminal A and 
B presented more bony and less visceral recurrences than luminal C, 
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HER2 and triple negative tumors. At median follow up of 51 months 
EFS was 94.1% in luminal A, 87.5% in luminal B, 85.5% in luminal C, 
76.8% in HER2+ and 79.7% in triple negative. Corresponding OS was 
95.3% in luminal A, 89% in luminal B, 89.2% in luminal C, 80.9% in 
HER2+, 81.9% in triple negative. Different subtypes EFS according 
to nodal status, grading, tumor size and age, was reported in table 1.
Subtypes EFS by N, G, size and age
 Luminal A (%) Luminal B (%) Luminal C (%) HER2+ (%) Triple  negative (%) p
Total 94.1 87.5 85.5 76.8 79.7 <0.001
N0 95.5 91.5 92.8 86.2 88.7 0.007
N+ 91.3 81.8 75.2 66.3 66.1 <0.001
G1 96.2 89.6 83.3 100.0 81.8 0.09
G2 92.6 89.5 87.4 81.5 83.7 0.195
G3 92.2 83.1 86.3 74.8 79.1 0.02
T1 95.6 91.5 90.7 81.6 86.8 <0.001
T2 88.9 83.4 79.3 72.5 75.9 0.013
T3-4 91.3 73.2 76.5 72.7 55.2 0.015
Age < 40 90.5 75.9 75.9 57.9 83.3 0.013
Age 40-55 93.8 88.4 83.5 79.6 76.3 <0.001
Age > 55 94.3 87.8 88.8 78.8 81.3 <0.001
Table 1 
Considering only Luminal subtypes, Luminal B and C were 
significantly associated with poor EFS vs Luminal A EIBCs in both 
N0 (p=0.046) and N+ pts (p<0.001), in T1 (p=0.013) and T2 (p=0.03) 
pts, in pts older than 40 years (p=0.002).
Conclusions: Luminal A showed better prognosis in term of EFS and 
OS than other subtypes regardless other prognostic factors as clinical 
features (age) and tumor extent (T and N).
P5-14-24
The Long Term Prognostic Impact of Real-Time Quantitative 
RT-PCR Detection of Cytokeratin 19 mRNA in Preoperative Bone 
Marrow Aspirates of Early Breast Cancer Patients.
Punie K, Wynendaele W, Clement P, Paridaens R, Christiaens M-R, 
Jacobs B, Wildiers H. University Hospitals Gasthuisberg, Leuven, 
Belgium; Catholic University Leuven, Leuven, Belgium
Purpose: Several studies have evaluated the prognostic effect of 
bone marrow micrometastases at the time of surgery in early breast 
cancer, but few studies have long term outcome data. We report here 
a cohort with more than ten years follow-up.
Materials and methods: 131 patients with primary operable invasive 
breast cancer were enrolled in the protocol from February 1998 to 
September 1999. Bone marrow aspirates, obtained from the iliac crest 
or the sternum, were analyzed with real-time quantitative reverse-
transcription polymerase chain reaction (RT-PCR) for the presence 
of cytokeratin 19 (CK19) mRNA. All patients received standard 
therapy and follow-up. After a median follow-up of 133 months, data 
about disease recurrence (invasive disease free survival, IDFS) and 
survival (breast cancer specific survival (BCSS) and overall survival 
(OS)) were collected. A control group consisted of archived cDNA 
samples from 38 patients with hematological malignant antecedents 
in complete remission and without known gene arrangements. The 
upper limit of the 95% confidence interval of the level of CK19 
positive cells is this group was used as cut-off (260 cytokeratin 19+ 
cells / 5 x 106 leucocytes) to determine bone marrow status in breast 
cancer patients.
Results: 69 bone marrow samples from breast cancer patients (52,7 
%) were considered CK19 positive. IDFS was 60.9 % and 79 % 
for CK19+ and CK19- patients, respectively (log-rank p-value = 
0,036). When CK19 was evaluated as a continuous variable, IDFS 
also correlated significantly with the level of CK19 mRNA in bone 
marrow aspirates (p-value = 0,019). Except for lymph node status 
(ANOVA linear regression p-value = 0.022), there was no significant 
correlation between the level of CK19+ cells in the bone marrow and 
classical prognostic factors (pathological tumor stage, tumor size, 
differentiation grade, hormonal receptor status).
In multivariate Cox-regression analysis correcting for tumor 
size, differentiation grade, lymph node status, hormone receptor 
status, tumor stage and treatment modalities (surgical procedure, 
chemotherapy, radiotherapy and antihormonal therapy), the CK19 
bone marrow status still was a significant predictor of IDFS. (p-value 
= 0.042)
Differences in BCSS (78 % of CK19 + patients and 84 % of CK19 
- patients) and OS (75 % in CK 19 + patients and 74 % in CK 19 - 
patients) were not statistically significant. (log rank p-values 0.087 
and 0.883, respectively).
Conclusion: This study demonstrates the long term (>ten years) 
prognostic effect of CK19 mRNA detection with RT-PCR in the bone 
marrow of operable breast cancer patients.
P5-14-25
Disease Presentation, Treatment, and Outcome in Young and 
Elderly Women with Breast Cancer.
Yu E, Yu D, Godette K, Mister D, Torres M. Emory University, 
Atlanta, GA
Aim: To determine the influence of age on disease presentation, 
treatment, and outcome in breast cancer patients who are not routinely 
screened by mammography, women younger than 40 and women 
older than 69 years.
Methods: The records of 272 breast cancer patients who presented 
to the Emory University Department of Radiation Oncology 
between 1997 and 2010 were reviewed. We excluded women with 
inflammatory or Stage IV breast cancer and those diagnosed between 
the ages of 40 and 69. We compared presentation, staging, treatment, 
and outcomes in women younger than 40 with those older than 69.
Results: The median age of the young and older patient groups were 
31 (range 16-40) and 76 years (range 70-91), respectively. Young 
women more often presented with a symptomatic breast mass than 
older women whose cancers were more frequently detected on 
screening mammography (p<.001). Young women were less likely 
than older women to present with significant co-morbidities including 
hypertension, diabetes, or cardiac disease (2% vs 76%, p<.001). A 
higher proportion of young women had high grade (50% vs 25%), T2/
T3 tumors (69% vs 26%), and node positive disease (50% vs 23%) 
(p<.001 for all comparisons) than older women. Also, more young 
women had triple negative (25% vs 12.5%, p=.048) or HER2 positive 
breast cancers (34.4% vs. 18.3%, p=.02). Regarding treatment, older 
patients were less likely to undergo surgical axillary nodal staging 
(72% vs. 88%, p<.04) or chemotherapy (23% vs 84%, p<.001). 
Among women treated with chemotherapy, older women more often 
received a non-anthracycline based regimen (82% vs 7% of young 
patients, p<.001). Following neoadjuvant chemotherapy, significantly 
more young women had a complete pathological response (23% vs 
13% in older women, p<.03). Fifty-two percent of young women 
received mastectomy versus 14% of older women (p<.001). In part 
due to their low rates of breast conserving surgery, younger women 
trended toward less radiation treatment (81% vs 90% in older women, 
p=.12). Among estrogen receptor positive patients, more young 
women received adjuvant endocrine therapy than older women 
(91.4% vs 72%, p=.05). The median follow-up period for the entire 
group was 38 months (range 1-160). At 3 years, young women were 
more likely to recur locoregionally (10% vs. 2%, p=.06) and distantly 
(16% vs 5%, p=.04) than older women, though both groups had 
comparable breast cancer-specific (96% vs 96%, p=0.2) and overall 
survival (96% vs 93%, p=.3). On multivariate analysis, old age was 
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011571s
December 6-10, 2011 Abstracts: Poster Session 5
a significant predictor of poorer overall survival (p=.05), whereas 
initial tumor size and nodal status were independent predictors of 
breast cancer recurrence (p<.05).
Discussion: Our data suggest that young women present with more 
advanced stage tumors than older patients and are subsequently treated 
with more aggressive surgery and systemic treatments, including 
chemotherapy and endocrine therapy. In spite of this, young women 
are more likely to develop breast cancer recurrence largely due to 
their higher T and N stages at diagnosis. Select women less than the 
age of 40 may benefit from screening and early detection of their 
breast cancers. Regardless, future studies aimed at developing better 
systemic treatments for younger breast cancer patients are warranted.
P5-14-26
Results from a Prospective Clinical Study on the Impact of 
Oncotype DX on Adjuvant Treatment Decision Making in a 
Cohort of 142 UK Patients.
Holt S, Bertelli G, Brinkworth E, Durrani S, Jones S, Khawaja S, 
Laggner U, Moe M, Pudney D, Pitcher S, Rolles M, Sharaiha Y, 
Whelan S. Prince Philip Hospital, Llanelli, Carmarthenshire, United 
Kingdom; Singleton Hospital, Swansea, West Glamorgan, United 
Kingdom; Bronglais Hospital, Aberystwyth, Ceredigion, United 
Kingdom
Objectives: International guidelines support the use of the Oncotype 
DX derived Recurrence Score (RS) to provide additional prognostic 
and predictive information in early breast cancer but experience in 
the UK is limited. In our prospective study we evaluate this test for 
the NHS and its impact on costs (subject of a separate abstract) and 
treatment recommendations by UK oncologists.
Methods: 150 tests were made available to consecutive patients 
with ER+, pN0, pN1itc or pN1mic early breast cancer who had 
no contraindication to adjuvant chemotherapy (CT) and who 
would accept CT + hormone therapy (HT) if recommended. CT 
recommendations of oncologists based on Adjuvant! Online figures 
were recorded at an initial consultation. Eligible patients were 
consented to Oncotype DX testing and review arranged once the 
result was available. After a second consultation a final decision on 
adjuvant therapy was recorded.
Results: Analysis is based on 142 patients. (150 tests performed, 3 
failed to give a result, 3 repeated tests giving a result on the second 
block, one bilateral and one test stopped because the patient withdrew 
from the study). Initial treatment recommendations changed in 38 
(26.8%) cases. Of the patients initially recommended CT + HT (total 
57 patients), 26 (45.6%) patients were spared chemotherapy after 
review with the RS. Of the 85 patients initially recommended HT 
only 12 (14.1%) were changed to HT + CT.
Decision impact of Oncotype DX testing
DECISION Patient Number % of Patients % Change
HT only unchanged 73 51.41%  
HT only changed to HT+CT 12 8.45% 14.11%
    
CT+HT unchanged 31 21.83%  
CT+HT changed to HT only 26 18.31% 45.61%
Further analysis shows that Grade, estrogen receptor status by 
immunohistochemistry (ER by IHC) and progesterone receptor by 
immunohistochemistry (PR by IHC) are correlated to RS but in our 
cohort age, size and node status were not. (Spearman rank correlation 
for grade is 0.05, 95%, Cl 0.36 to 0.61; for ER by IHC is -0.36, Cl -0.49 
to -0.20; and for PR by IHC is -0.49, 95%, Cl -0.60 to -0.35). Apart 
from HER2 positive patients who are already recognized to return a 
high RS, further analysis of our series shows no clear combination 
of currently available prognostic factors that would predict RS and 
therefore reliably avoid testing of any subset of patients.
Conclusion: The results of our study suggest that Oncotype DX is 
applicable and feasible to perform in UK patients with a reduction in 
the use of adjuvant chemotherapy consistent with findings of reported 
studies. RS added prognostic information beyond information 
provided by Adjuvant!
P5-14-27
Prognostic Factors of Node-Negative, High Risk and 1-3 Positive 
Lymph Nodes Breast Cancer by Intrinsic Subtype in Patients with 
Adjuvant Chemotherapy.
Kojima Y, Hashimoto K, Harano K, Shimizu C, Yunokawa M, 
Yonemori K, Tamura K, Katsumata N, Ando M, Kinoshita T, Fujiwara 
Y. National Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuo-Ku, 
Japan
Purpose: St. Gallen 2007 categorized high risk, node-negative breast 
cancer (HNBC) and 1-3 lymph nodes positive BC (LNBC) without 
HER2 overexpression as intermediate risk. We hypothesized that triple 
negative BC (TNBC) and hormone-receptor positive without HER2 
overexpression (H-BC) in intermediate risk have different prognostic 
factor in patients with adjuvant chemotherapy (AdC).
Methods: We examined disease-free survival (PFS) and overall 
survival (OS) of TNBC and H-BC with regard to potential prognostic 
factors. All the patients included in this study were categorized 
intermediate risk by St.Gallen 2007 and received AdC.
Results: A total of 470 patients were identified; H-BC (n=360) and 
TNBC (n=110). Age (<35) was significantly associated with DFS in 
TNBC while it was not in H-BC (p=0.0.1 and p=0.63, respectively). 
Tumor size (>2cm) and tumor grade related to DFS in H-BC but not 
in TNBC. Tumor grade was not associated with DFS in both H-BC 
and TNBC (p=0.64 and p=0.91, respectively). Lymph node metastasis 
was a significant factor of DFS only for H-BC (p=0.009 and p=0.19).
Conclusions: In TNBC, age was only a significant factor associated 
with DFS while in H-BC, lymph node status and tumor size rather 
age related to DFS.
P5-15-01
Words Matter: Influence of DCIS Diagnosis Terminology on 
Patient Treatment Decisions.
Omer Z, Hwang ES, Esserman LJ, Ozanne EM. University of 
California, San Francisco; Massachusetts General Hospital
Background: Treatment of ductal carcinoma in-situ (DCIS) poses 
significant challenges. Although retrospective studies suggest that 
most cases of low grade DCIS will never progress to invasive disease, 
it remains difficult to accurately identify those patients at greatest 
risk. In this situation where many diagnosed tumors could follow 
an indolent course for the patient’s lifetime, both systemic therapy 
and watchful waiting could be reasonable options, similar to those 
currently offered to patients with early prostate cancer. One strategy 
that has been suggested to reduce overtreatment is to use terms other 
than “ductal carcinoma in situ” when explaining a diagnosis of DCIS 
to a patient. In the current study, we have investigated the effect of 
terminology on women’s stated treatment preference for DCIS.
Methods: Women 40-65 years of age were recruited from a database 
of volunteers at an academic hospital. Subjects with a personal history 
of breast cancer were excluded. Endpoints were gathered from a 
web-based survey. Each subject was presented with three different 
scenarios, each of which used a different terminology for DCIS: 
non-invasive breast cancer, breast lesion, and abnormal cells. The 
scenarios included a detailed explanation of the risks and benefits of 
three treatment options: surgery, systemic treatment only and active 
surveillance. After reading each scenario, the subject was asked to 
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choose among the treatment options and to explain her choice.
Results: 187 subjects completed the survey. More women chose active 
surveillance when DCIS was described using the terms “abnormal 
cells” or “breast lesion” than using the term “non-invasive cancer” 
(Table 1) . The majority of women (97/187, 52%) changed their 
treatment preference when a different term was used to describe 
DCIS. Of the 97 women who changed their treatment preference, 47 
(48%) chose surgery when the term “non-invasive cancer” was used 
to describe DCIS, but chose a less invasive treatment when “cancer” 
was not used in the diagnosis. Of 90 people who did not change their 
treatment preference, 39 (43%) chose active surveillance.
Among the three treatments, the percent of women who chose surgery 
was the highest (84/187; 46%) when the term “non-invasive cancer” 
was used. 47/84 (56%) of the women who chose surgery when 
using the term “non-invasive breast cancer” changed their treatment 
preference when a different term was used. 36/84 (43%) switched 
to active surveillance while 11/84 (13%) switched to medication.
Conclusion: These results support that the specific terminology used to 
explain a diagnosis of DCIS influences patients’ treatment preference. 
Moreover, we found that women may entertain treatment preferences 
other than surgery for DCIS when the tradeoffs of each choice are 
clearly explained. Avoiding the word “cancer” in the diagnosis may 
offer a strategy that reduces fear-based treatment decisions and may 
reduce the burden of overtreatment for DCIS.
 Terminology used to describe the diagnosis
Participant choices: Non-invasive breast 
cancer Number (%)
Breast Lesion Number 
(%)
Abnormal Cells 
Number (%)
Total (n=187)    
Surgery 84 (46) 60 (32) 58 (31)
Medication 38 (21) 31 (17) 44 (24)
Active Surveillance 62 (33) 95 (51) 85 (45)
P5-15-02
Patients’ Views about How Oncologists Should Explain Prognosis 
in Advanced Cancer.
Kiely BE, McCaughan G, Christodoulou S, Tattersall MHN, Beale 
P, Grimison P, Stockler MR. University of Sydney, Sydney, NSW, 
Australia; Royal Prince Alfred and Concord Hospitals, Sydney, 
NSW, Australia
Background: Many women with advanced breast cancer want 
information about their life expectancy. Understanding the type 
of information patients want will help oncologists improve their 
discussions about prognosis. We sought the attitudes of women 
previously diagnosed with breast cancer to using three scenarios for 
survival (best case, worst case and most likely) to explain prognosis 
to people with advanced cancer.
Methods: Members of the Breast Cancer Network Australia 
(BCNA) review and survey group and oncology clinic attendees 
with a previous breast cancer diagnosis were invited to complete a 
questionnaire describing two options for explaining prognosis to a 
hypothetical patient with incurable cancer who wanted prognostic 
information: providing either 3 scenarios for survival or just the 
median survival time. Associations between respondent attitudes and 
their demographic and tumour characteristics were explored.
Results: Characteristics of the 254 BCNA respondents and the 
68 outpatient respondents respectively were: median age 56 years 
and 54 years; median years since breast cancer diagnosis 6 and 3; 
college/university educated 70% and 34%; self-report of cancer 
spread beyond the lymph nodes 10% and 26%. Significantly more 
respondents agreed that explaining 3 scenarios (vs just the median 
survival time) would: be easy to understand (92% v 71%), be helpful 
(94% v 63%), convey hope (68% v 36%), reassure (56% v 30%) 
and help family members (92% v 65%), with all p-values <0.001. 
The proportions of respondents agreeing that each of the 3 scenarios 
should be presented were: best case 92%, worst case 84% and most 
likely 93%. Although 53% agreed the worst case scenario on its own 
was likely to upset people, only 31% agreed that explaining all 3 
scenarios together was likely to upset people. When asked how they 
would prefer information about their own prognosis, 92% wanted 
all 3 scenarios, either with (49%) or without (43%) the estimated 
median survival. Most respondents (88%) agreed it would be helpful 
to receive a printed summary of the scenarios for survival. No 
differences were seen between the BCNA respondents and breast 
cancer outpatients for attitudes to presenting all 3 scenarios; however, 
BCNA respondents were significantly less likely than breast cancer 
outpatients to agree that the median survival was helpful, reassuring 
or easy to understand. Women with more education were more likely 
to agree that presenting all 3 scenarios would be helpful (95% v 
87%, p=0.04). Age, year of diagnosis, relationship status and extent 
of disease were not significantly associated with particular attitudes.
Conclusion: Most respondents judged presentation of best case, 
worst case and most likely scenarios preferable, more helpful and 
more reassuring than presentation of just the median survival time 
when oncologists explain prognosis to people with advanced cancer.
P5-15-03
Development of a Patient Decision Aid for Women 70 Years 
and Older with Stage I, Hormonally Sensitive, Breast Cancer 
Considering Adjuvant Treatment Post-Lumpectomy.
Szumacher E, Wong J, D’Alimonte L, Angus J, Paszat L, Metcalfe K, 
Whelan T, Llewellyn-Thomas H. Odette Cancer Centre, Sunnybrook 
Health Sciences Centre, Toronto, ON, Canada; University of Toronto, 
Toronto, ON, Canada; Education Independent Consultant, Toronto, 
ON; Juravinski Cancer Centre, Hamilton, ON, Canada; Women’s 
College Research Institute, Toronto, ON, Canada; Dartmouth Medical 
School, Lebanon, NH
Background: Decision Aids (DA) are developed with the intent to 
support people in making specific and deliberate choices by improving 
information transfer about different outcomes . Previous research has 
shown that DAs can increase patient knowledge regarding treatment 
options, reduce decisional conflict, and increase patient satisfaction 
with the decision-making process. However, no DAs have been 
developed to help older breast cancer patients decide whether or 
not to undergo adjuvant RT. We developed and tested a DA for 
older women with stage I,ER/PR positive breast cancer considering 
adjuvant treatment post-lumpectomy and we examined its impact on 
treatment decision-making process.
Methods and Materials: A DA was developed and evaluated in three 
steps following the Ottawa Decision Aid Framework: 1) Needs 
assessment (N=16); 2) Pilot I, to examine the DA’s acceptability 
(N=12); and 3) Pilot II, a pre-test post-test (N=38) with older women 
with ER/PR responsive breast cancer post-lumpectomy who were 
receiving adjuvant RT. Measures included questionnaires to assess 
patient’s satisfaction with the DA, patients’ self-reported decisional 
conflict (DC), level of distress, treatment-related knowledge, and 
choice predisposition
Results: The DA is a booklet that details each adjuvant treatment 
option’s benefits, risks and side-effects tailored to their clinical 
profile; includes a value clarification exercise; and steps to guide 
them towards their own treatment decision. All women felt the DA 
was helpful and informative. Compared with baseline scores, patients 
had a statistically significant (p < .05) reduction in DC (adjusted 
mean difference [AMD], -7.18; 95% confidence interval [CI], 
-13.50 to 12.59); increased clarity of the treatment benefits and risks 
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(AMD, -10.86, CI, -20.33 to 21.49; and improved general treatment 
knowledge (AMD, 8.99, CI, 2.88 to 10.28) after using the DA. General 
trends were also reported in patient’s choice predisposition scores 
suggesting potential differences in treatment decision after DA use.
Discussion: This study provides evidence that this DA may be a 
helpful educational tool for this group of women. The quality of care 
for older breast cancer patients may be enhanced by using a tailored 
DA to help the patient be informed of their treatment options and to 
prepare for decision-making.
P5-15-04
Withdrawn by Author 
P5-15-05
Impact of Breast Specialized Physician Consultation on Surgical 
Decision Making for Breast Cancer and Decision Conflict in 
Women with Hereditary Breast Cancer Risk.
Boughey JC, Hoskin TL, Williams CI, Hartmann LC, Allers TM, 
Degnim AC, Frost M. Mayo Clinic, Rochester, MN
Background: Women with hereditary breast cancer risk, who develop 
breast cancer, face complex surgical decisions related to their breast 
cancer and risk to their contralateral breast. The aim of this study 
was to prospectively evaluate the factors influencing decision making 
in these women and degree of decision conflict before and after 
consultation with breast specialized physicians (BSP).
Methods: Women with hereditary breast cancer risk and recently 
diagnosed with unilateral breast cancer were enrolled in a prospective 
decision making questionnaire study. Questionnaires were completed 
prior to their initial breast clinic visit and after consultation with a 
breast clinic physician, nurse educator and a breast surgeon.
Results: 68 women completed both questionnaires. Mean age was 52 
(range 27-84). Prior to meeting with BSP, 10 (15%) women reported 
having made a decision for the cancer side and 18 (26%) reported 
being close to deciding. Of the 20 who expressed a surgical preference 
prior to consultation, 5 (25%) changed their decision after meeting 
with the BSP [1 to mastectomy (MTX), 4 to breast conservation 
(BC)]. After consultation with BSP, 65 (96%) reported having made 
a decision (BC in 29 (45%), MTX in 35 (54%), unspecified in one). 
The most commonly cited reasons influencing surgical choice were 
doctor’s advice (79%), family history of breast cancer (74%) and 
worrisome findings on biopsy (50%).
Prior to meeting with BSP, 9 (13%) women reported having made 
a decision regarding screening and/or risk-reducing options for the 
contralateral breast and another 11 (16%) reported being close to a 
decision. The choices in these 20 women were screening only in 10 
(50%), contralateral prophylactic MTX (CPM) in 3 (15%), CPM 
and oophorectomy in 2 (10%), other combinations of options in 4, 
and unspecified in 1. After meeting with the BSP, 49 (72%) reported 
having made a decision regarding the contralateral breast; this 
decision was for screening only in 21 (43%), CPM only in 9 (18%), 
screening plus tamoxifen in 7 (14%), CPM and oophorectomy in 2 
(4%), other combinations of options in 8, and unspecified in 2. The 
most commonly cited reasons for choices on the contralateral side 
were: family history (81%), doctor’s advice (78%), and worrisome 
findings on biopsy (43%); only 25% cited psychological or emotional 
reasons.
For both the cancer and contralateral sides, decisional conflict was 
significantly lower after meeting with BSP than prior to meeting 
with BSP.
Decision-conflict scale total scores (possible range 0-100; higher scores indicate more decisional 
conflict) summarized for each side and compared between timepoints
 N Mean (SD) prior to meeting BSP Mean (SD) after meeting BSP p-value
Cancer side 58 45.8 (17.6) 11.6 (10.9) 0.0001
Contralateral side 63 44.2 (20.7) 19.2 (17.2) 0.0001
Conclusion: The BSP consult and family history have the greatest 
influence on decision making among women with hereditary risk 
diagnosed with breast cancer. After consultation most women felt 
they had made decisions for both the cancer and contralateral sides 
and reported significantly lower decision conflict compared to prior 
to the consultation.
P5-16-01
Are We Going To Be Able To Train Future Surgeons How To 
Perform Axillary Lymph Node Dissection?
Betambeau N, Chan C. Cheltenham General Hospital, Cheltenham, 
Gloucestershire, United Kingdom
Background: Axillary lymph node dissection (ALND) has been 
performed regularly by surgeons for several decades. The sentinel 
lymph node era has led to a reduction in ALND procedures 
as node negative women are now spared further surgery and 
morbidity. Following the publication of the ACOSOG Z0011 trial, 
it is conceivable that completion ALND (cALND) may be rendered 
unnecessary for many women who have breast conserving surgery 
and have 1 to 2 positive sentinel lymph node disease. If there is a 
substantial drop in ALND procedures, this may impact on our ability 
to train surgeons in the future.
Material and Methods: We retrospectively reviewed the breast cancer 
practice for 2 consultant surgeons in a busy UK centre. In this centre 
all patients with a positive diagnosis of invasive breast cancer had pre-
operative axillary ultrasound scanning (USS) and needle biopsy (fine 
needle aspiration or core biopsy) if enlarged or suspicious axillary 
lymph nodes were seen. Hence sentinel lymph node biopsy (SLNB) 
was only performed on patients with both clinically and radiologically 
negative axillary lymph nodes.
Results: In 2009 and 2010 the 2 consultants treated a total of 255 
patients with invasive breast cancer. Thirty one patients (12.2%) had 
positive axillary lymph disease identified by USS and axillary needle 
biopsy; these women were treated with ALND. The remaining 224 
patients had clinically and radiologically negative axillary lymph 
nodes and proceeded to SLNB. Of these, 58 patients had at least one 
positive sentinel lymph node (25.9%) and proceeded to cALND; 39 
women had breast conserving surgery and 19 women had mastectomy. 
If our centre were to adopt a policy of observation only in those 
women having breast conserving surgery and whom had no more than 
2 positive sentinel lymph nodes (as per ACOSOG Z0011 trial), then 
33 fewer ALND would have been performed. This would leave a new 
total of 56 ALND procedures being performed over a 2 year period in 
women with pre-operatively identified positive axillary lymph nodes, 
those undergoing mastectomy and those women with 3 or greater 
positive sentinel lymph nodes on SLNB. On our service we have 2 
residents which would result in a maximum number of 14 ALND 
procedures per year that each resident may be trained to perform. 
It is likely that the actual number will be less due to commitments 
away from the elective operating room, such as emergency duties and 
annual leave etc. Is this an adequate number of ALND procedures for 
a resident to gain competence in the technique?
Discussion: The training of surgical residents is competence based 
and if our centre is representative of most centres treating breast 
cancers in the UK, will the teaching of ALND procedures be limited 
to specialist, ultra-high volume centres if the ACOSOG Z0011 trial 
findings are to be adopted?
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The Impact of Educational Materials on Compliance and 
Persistence with Adjuvant Aromatase Inhibitors: 2 Year Follow-
Up and Final Results from the CARIATIDE Study.
Neven P, Markopoulos C, Tanner MME, Marty ME, Kreienberg 
R, Atkins L, Franquet AA, Serin D, Gulcelik MA, Deschamp V. 
University Hospitals Leuven, Leuven, Belgium; Medical School 
University of Athens, Athens, Greece; Tampere University Hospital, 
Tampere, Finland; Saint Louis University Hospital, Paris, France; 
University of Ulm, Ulm, Bade-Wurttemberg, Germany; University 
College London, London, United Kingdom; IDDI (International 
Drug Development Institute), Louvain-la-Neuve (Ottignies), Belgium; 
Institut St. Catherine, Avignon, France; Ankara Oncology Hospital, 
Ankara, Turkey; AstraZeneca, Brussels, Belgium
Rationale
Understanding and effectively addressing the factors that affect patient 
compliance with adjuvant aromatase inhibitors (AI) is required in 
order for patients to obtain maximum benefit from treatment. The 
CARIATIDE study sought to determine whether the provision of 
educational materials (EM) could improve compliance and persistence 
with adjuvant AI. At 1-y follow-up (FU), there was no improvement 
in overall compliance with AI therapy, compliance with initial AI or 
persistence rates when EM were provided. Final results from the 2-y 
FU are presented here.
Methods
This 2-y, global observational study (NCT00681122) randomized 
2758 patients, across 18 countries, to Group A: Standard Therapy 
or Group B: Standard Therapy + EM. The EM were developed 
in collaboration with patient advocates, and consisted of a range 
of information on breast cancer-related topics. Compliance rate 
with adjuvant AI medication was the primary endpoint. Secondary 
endpoints included persistence rate after 1 and 2y, and reasons for, and 
time to, discontinuation of AI therapy. Compliance rate was defined 
as the proportion of patients being ‘compliant’ with the adjuvant AI 
medication; switching from AI therapy to tamoxifen would result in 
a non-compliance score at time of switching. For compliance with 
initial adjuvant AI medication, switching to another AI or hormone 
therapy would result in a non-compliance score. A patient was 
considered a ‘persistent’ user if they did not switch AI medication, 
AI medication was uninterrupted and there was no discontinuation 
of the AI medication during the second year. Patients’ compliance 
and behavior were evaluated using compliance questionnaires, EM 
feedback and validated questionnaires (EORTC IN-PATSAT32, 
GHQ-12, FACT-ES).
Results
Of the 2758 patients randomized at study initiation, 2242 were 
available for analysis at 2-y FU. The results confirmed those obtained 
at 1-y FU. No statistically significant difference in compliance with 
AI therapy was observed between Group A and Group B (82% and 
82%, respectively, p=0.9926). Compliance with initial AI was 81% 
in Group A and 80% in Group B (p=0.5541), with persistence rates of 
90% and 88%, respectively (p=0.2425). Of the proportion of patients 
who had compliance data for both years (Group A n=1118; Group B 
n=1111) 72% were compliant for the whole 2-y FU period. Across 
the full 2-y FU, AI treatment discontinuation rates of 8% and 9% 
were observed in Group A and B, respectively, with discontinuation 
most frequently attributed to AI-related side effects. Analysis showed 
that no specific baseline demographic characteristics were associated 
with compliance behavior. Compliance rates differed widely between 
countries.
Conclusions
At 2-y FU, EM were not found to improve overall patient compliance, 
compliance with initial AI, or persistence with therapy. In total, 72% of 
patients were compliant across the full 2-y FU. AI-related side effects 
remained the most frequent cause of AI treatment discontinuation 
across the full FU period. The 2-y CARIATIDE data confirm the 
1-y findings.
P5-16-03
The Breast Cancer Novela, Se Valiente…Son Tus Senos, an 
Innovative Tool To Educate Latina Women about Breast Cancer.
Febus-Sampayo I, Mota R, Yaker A. SHARE: Self-Help for Women 
with Breast or Ovarian Cancer, New York, NY
Background: The Hispanic population is the fastest growing 
population and largest minority group in the United States. Breast 
cancer remains the leading cause of cancer death among latina 
women in part because they are more frequently diagnosed at a later 
stage than non-Hispanic whites. Critical information about early 
detection, diagnosis and treatment options is often inaccessible 
due to cultural and language barriers. There is a need to reach the 
Hispanic community in new and compelling ways. The purpose of 
this initiative was to reach diverse Spanish speaking communities, 
particularly in New York City, with information about breast health 
and breast cancer that was culturally-sensitive, language appropriate, 
scientifically and medically accurate and, most importantly, relevant 
to the lives of the people in the community.
Methods: Latina breast cancer survivors and non-survivors from 
diverse Hispanic communities were identified and three 8 person focus 
groups, two for non-survivors and one for survivors, were organized 
to explore breast cancer-related issues relevant to these communities. 
The women’s personal stories and common issues and experiences as 
well as medical information reviewed by a medical advisory group, 
formed the basis for the development of a breast cancer novela. The 
novela is a popular Spanish-language comic book style publication 
widely distributed in the Hispanic communities. The breast cancer 
novela used the real life stories of the women to address barriers to 
accessing health care and empower women in Hispanic communities. 
A distribution plan was developed and a curriculum created for in-
person educational seminars at community organizations. Surveys 
prior to and following the educational intervention were conducted.
Results: We distributed over 25,000 novelas in Spanish to 478 sites 
within New York City and to 89 other sites throughout the U.S. We 
printed and distributed 2500 copies of an English version of the 
novela at the request of health providers. Attendees at a launch event 
helped identify distribution sites and educational seminar venues. 
Peer facilitators conducted these seminars, with the novela as the 
primary communication tool. The content of the workshops included 
information about breast health, risk, early detection, myths and 
realities about a diagnosis, managing relationships, survivorship and 
resources. To date, 17 seminars have been conducted and attended by 
more than 330 attendees. Results of the surveys as well as detailed 
information describing the distribution sites of the novela and 
feedback we received about its impact, will be presented at SABCS
Discussion: Se Valiente…Son Tus Senos, is an innovative educational 
tool that conveys information about breast health, breast cancer 
detection, diagnosis, treatment and survivorship that is personal, 
relevant, compelling and accessible. The breast cancer novela serves 
as a vehicle to change information levels and increase women’s 
knowledge and to provide health providers with insights that enable 
them to treat members of Spanish-speaking communities in a 
culturally competent manner.
www.aacrjournals.org Cancer Res; 71(24 Suppl.) December 15, 2011575s
December 6-10, 2011 Abstracts: Poster Session 5
P5-17-01
Evaluation of Psychosocial Distress in Main Care-Givers of 
Patients with Metastatic Breast Cancer Who Receive Treatment 
in a Community Based Oncology Group Practice.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, 
Mergenthaler U, Thomalla J, van Roye C, Köppler H. Hematology/
Oncology Group Practice, Koblenz, Germany; Institute for Health 
Care Research in Oncology, Koblenz, Germany
Introduction: It is well-known that people who care for patients 
with a metastatic carcinoma are exposed to an above-average level 
of psychosocial distress. No data are available concerning the distress 
of main care-givers of female patients with metastatic breast cancer, 
who are treated in a community based oncology group practice.
Methods: Standardized cross-sectional survey of main care-givers 
and patients with metastatic breast cancer who were treated in a 
community based oncology group practice in Germany between 
04/2010-03/2011. Psychosocial distress of the patients and their 
main care-givers were evaluated using the German versions of the 
Distress Thermometer (DT) and the Problem List (PL). In addition 
anxiety and depression of the main care-givers were assessed using 
the Hospital Anxiety and Depression Scale (HADS-D).
Results: 83 female patients with a median age of 65 (41-93) were 
interviewed. 6% did not have a main care-giver, 7% indicated that 
they needed no support, 48% reported one main care-giver and 39% 
several. Partners (60%), children (47%), siblings (11%) and friends 
(10%) were the most important care-givers. 47% of patients preferred 
visiting the practice in companion with their care-givers. The patients’ 
median score on the DT was 5 (0-10), with 34% scoring above cut-off 
(> 5) for psychosocial distress.
52 main care-givers (61% male, 39% female) with a median age of 
57.5 (41-86) were interviewed. The relationships to the patients were 
as follows: partners 62%, children 27%, mothers, siblings and friends 
each with 4%. The main care-givers themselves were supported by 
partners (54%), children (21%) friends (17%) and siblings (8%), 23% 
did not receive any support. The median score on the DT was 5 (0-
10), with 44% scoring above cut-off (> 5) for psychosocial distress. 
According to the HADS-D 37% (cut-off ≥ 8) of the care-givers 
reported anxiety, with a mean score of 6.6 (0-14). 15% could be 
regarded as depressed (cut-off ≥ 8), with a mean score of 4.1 (0-15).
Conclusions: The main care-givers are distressed even more than the 
patients themselves. 37% of care-givers reported anxiety; depression 
can be observed too, but less frequently in 15%. Both issues should 
be addressed by healthcare professionals.
P5-17-02
Associations between Breast Cancer Patients’ Satisfaction with 
Nursing Staff and Hospital Characteristics, Results of a German 
Multicenter Study.
Wuerstlein R, Kowalski C, Diener S, Krebs S, Pfaff H, Harbeck N. 
University Hospital Cologne, CIO, Köln, Germany
Background: Only few studies have investigated the association 
between breast center characteristics such as teaching status, number 
of patients, whether clinical trials are conducted, or whether breast 
care nurses are employed and patients’ perceptions of care.
Objective: The aim of the study was to determine whether or not 
the satisfaction of newly-diagnosed breast cancer patients with 
nursing staff correlates with hospital characteristics after adjusting 
for relevant patient characteristics. The study is part of a national 
process-identifying project focusing on breast cancer of the MAGS 
NRW (Ministry of work, health and social affairs, North Rhine 
Westfalia, Germany).
Methods: Multilevel regression analysis was applied combining 
data from newly-diagnosed breast cancer patients (n= 3733) on 
patient characteristics and satisfaction with nursing staff and data on 
characteristics of the hospitals (n= 93 breast centers in Germany) in 
which patients were treated. Patients’ perspectives were measured for 
six month using the Cologne Patient Questionnaire for Breast Cancer 
(CPQ-BC), the other informations and hospital characteristics were 
collected by medical personnel.
Results: Full data of 2945 patients from 81 hospitals were analysed in 
the multilevel logistic regression model. The odds for patients being 
satisfied with nursing staff were significantly higher in hospitals which 
employed breast care nurses at the time of the survey. At the patient 
level, patients were significantly more likely to be satisfied with 
nursing staff if they were native speakers, and with higher self-rated 
health. Cross-level interaction analysis suggested that higher patient 
satisfaction resulting from employing breast care nurses was largely 
limited to native speaking patients. Other hospital characteristics 
were not significantly associated with the perception of nursing 
staff (teaching hospital, required number of surgeries, clinical trial 
participation).
Conclusions: The results demonstrate that patient satisfaction with 
nursing staff is higher if breast care nurses are employed in the treating 
hospital. Further work will focus on the description of the breast care 
nurses work as it is interpreted individually in every breast center. 
However, only the satisfaction of native speakers was significantly 
higher when breast care nurses were employed.
Implications for Practice: Findings suggest that hospitals should 
invest in employing specialist nurses. Special attention should be 
paid to the care of non-native speaking patients.
P5-17-03
The Association between Breast Cancer Related Lymphedema’s 
Risk Factors and Likelihood of Edema Progression.
Skolny MN, Miller CL, O’Toole J, Sadek B, Ancukiewicz M, Taghain 
AG. Massachusetts General Hospital, Boston, MA
Purpose/Objective(s): Breast cancer related lymphedema (BCRL) is 
one of the most feared long term side effects of treatment. Although 
emergence of the sentinel lymph node biopsy (SLNB) has decreased 
the rate of BCRL, it continues to be an issue for this population. The 
goal of this study is to evaluate the prognostic risk factors for BCRL 
development and progression based on longitudinal prospective limb 
volume (LV) measurements and associated surgical, radiation and 
medical oncology factors.
Materials/Methods: Since 2005 newly diagnosed breast cancer (BC) 
patients were prospectively screen via perometery (Pero-System). 
For this analysis patients were required to have undergone at least 
four measurements and have at least 24 months of follow up to 
allow for adequate time for LE development. Bilateral pre-operative 
volume measurements of the upper extremity were compared to post- 
operative measurements and at 4 to 6 month intervals to assess for 
limb volume changes. At each time point (tx), relative volume change 
(RVC) of the treated arm was calculated using volume ratios of treated 
(T) to non-treated (N) side compared to the pre-operative baseline (t1) 
(RVC=(Ttx/Ntx)/(Tt1/Nt1)-1) as described in Ancukiewicz et al 2010. 
Our institution utilizes >5% RVC as an indicator of lymphedema. For 
this analysis, mild lymphedema was classified as a RVC of 5-9.9% and 
moderate lymphedema was classified as a RVC ≥ 10%. A univariate 
analysis was performed to identify risk factors and likelihood to LE 
progression.
Results: In a cohort of 415 women, 14.4 %(60) and 6.7% (28) 
developed mild and moderate BCRL, respectively. Twenty percent 
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(14) and 75 %(21) of patients in the mild and moderate cohorts, 
respectively, had a persistent edema that was documented at a least 2 
consecutive data points. Eighty percent (56) and 25% (7) of patients 
that had a documented incidence of an elevated RVC had returned 
below an RVC<5% and their subsequent visits. Based on Kendall’s 
Tau P-value of <0.0001 persistent edemas were associated with 
axillary lymph node dissection (ALND), number of lymph nodes 
removed, axillary fields and dose of radiation.
Conclusion: Breast cancer related lymphedema is a feared long term 
side effects and negatively impacts the physical and psychological 
aspects of an individual’s life. A condition that is considered 
manageable but not curable, it is essential providers identify high 
risk individuals. Establishing a a lymphedema screening program 
may identify early lymphedema which could be potentially be treated 
successfully.
P5-17-04
Association between Breast Cancer and Osteoporosis among 
Women 85 Years or Older.
Okanami Y, Honma N, Arai T, Sawabe M, Maeda I, Takagi M, Younes 
M, Takubo K. St. Marianna University School of Medicine, Kawasaki, 
Kanagawa, Japan; Tokyo Metropolitan Institute of Gerontology; 
Baylor College of Medicine
Background: The pathogenesis of breast cancer in very elderly women 
is of interest, because estrogen levels are likely to be extremely low 
during the development of the disease. Estrogens have opposing 
effects on the pathogenesis of breast cancer and osteoporosis. In an 
effort to understand the significance of estrogens in the pathogenesis 
of breast cancer in this group, we examined the association between 
breast cancer and osteoporosis in women at least 85 years old, 
taking body mass index (BMI) and hormone receptors status into 
consideration.
Methods:Clinical records of consecutive elderly women (≥ 85 y/o) 
who underwent breast cancer surgery at Tokyo Metropolitan Geriatric 
Hospital (BC) and control women of the same age group (Cont) were 
reviewed; osteoporosis and BMI status in both groups were recorded 
and compared. The status of estrogen receptor (ER) and progesterone 
receptor (PR) of breast cancers was examined immunohistochemically 
and compared between BC with and without osteoporosis (BC-OP 
and BC-nonOP, respectively).
Results:Frequency of osteoporosis was significantly lower among 
BC than Cont. There was no difference in BMI measured after 85 
y/o between BC and Cont; however, percentage of women, whose 
BMI measured when they were in their sixties or seventies was ≥ 
20% higher than BMI measured when they were 85 y/o or older, was 
significantly higher among BC than Cont (31% and 2%, respectively. 
P = 0.0001). ER positivity of breast cancer did not differ between 
BC-OP and BC-nonOP, whereas PR positivity was significantly higher 
among BC-nonOP than BC-OP (P = 0.0359).
Discussion:The inverse relationship between the incidence of breast 
cancer and osteoporosis suggests an important role for estrogens in 
the pathogenesis of breast cancer in the very elderly women. Our 
finding that one third of BC had ≥ 20% higher BMI when they were 
in their sixties or seventies suggests they may also had elevated 
serum estrogens during these earlier years, because increased BMI 
has been reported to be associated with increased serum estrogens 
in postmenopausal women. Expression of PR is regulated by 
estrogen-ER signaling, and PR positivity is considered to reflect 
the effectiveness of estrogen-ER pathway. Significant difference 
of PR positivity between BC-nonOP and BC-OP suggests the more 
importance of estrogens in BC-nonOP than BC-OP.
Conclusion:Estrogens seem to play an important role in the 
pathogenesis of breast cancers in very elderly women, especially 
without osteoporosis. With increasing aging population in developed 
countries, those findings may have implications for breast cancer 
prevention in this age group.
P5-17-05
24 Months Follow-Up Results from PACT (Patient’s Anastrozole 
Compliance to Therapy Programme), a Non-Interventional 
Study Evaluating the Influence of a Standardized Information 
Service on Compliance in Postmenopausal Women with Early 
Breast Cancer.
Lueck H-J, Hadji P, Harbeck N, Jackisch C, Blettner M, Zaun S, 
Windemuth-Kieselbach C, Beck T, Köhler U, Schmitt D, Kreienberg R. 
Gyn-Oncological Practice, Hannover, Germany; Phillips-University, 
Marburg, Germany; Breast Center, University of Cologne, Cologne, 
Germany; City Womens Hospital Offenbach, Offenbach, Germany; 
Institute of Medical Biostatistics, University, Mainz, Germany; 
AstraZeneca Germany, Wedel, Germany; Alcedis GmbH, Germany; 
Hospital Rosenheim, Rosenheim, Germany; Hospital St. Georg, 
Leipzig, Germany; Consulting Doctor-Patient Communication, 
Radolfzell, Germany; University Womens’ Hospital, Ulm, Germany
Introduction: According to recent retrospective studies, compliance 
to adjuvant endocrine therapy for early breast cancer (EBC) may 
drop to below 70% after one year and to as low as 50% by year 4. 
PACT aimed to increase treatment adherence in postmenopausal 
women taking an adjuvant aromatase inhibitor via a standardized 
information service (educational arm). Yet, after 12 months, 
there was no difference in compliance between the standard and 
educational arm (reported at this meeting 2010). Methods: PACT is 
a prospective, randomised, two-arm parallel-group study in Germany, 
sponsored by AstraZeneca (NCT00555867). Postmenopausal women 
on anastrozole for hormone-receptor positive (HR+) EBC were 
randomized to routine clinical care alone or to receive additional 
standardized information (educational arm) at nine times over the first 
12 months of adjuvant therapy. Primary endpoints were compliance 
and persistence rates in the educational versus routine arm after 12 
months. Secondary endpoints included longer follow-up, reasons 
for non-compliance, influence of baseline characteristics , and 
clinical outcome parameters (DSF, OS). Compliance was evaluated 
via patient questionnaires, prescription data and physician recall. 
Per protocol compliance was analysed only for patients with full 
documentation both by patients and physicians. Persistence was 
defined as the duration of time from initiation to discontinuation 
of therapy (Cramer et al 2007) and measured by prescription data. 
Results: PACT enrolled 4,923 female patients at 109 breast centres 
and 1,361 registered specialist practices from all regions in Germany. 
4,397 patients were evaluable for baseline characteristics. 2,707 
patients were evaluable for the primary endpoint (full documentation 
on tablet intake both by patients and physicians). No difference in 
compliance could be shown between the standard (88.2%) and the 
educational arm (88.3%) at 12 months (p=0.92, Fisher’s exact test). 
Persistence rates were 40.3% for the standard arm and 43.0% for the 
educational arm, respectively (p=0.17, Fisher’s exact test). At 24 
months, data from 1539 patients was available for analysis compliance 
per protocol. Compliance rates were 88.7% (educational arm) and 
87% (standard arm; p=0.29). Persistence again much lower at 41.1% 
and 42.1% (p=0.68). Variables influencing compliance were regular 
attendance to follow-up visits, participation in a cancer rehabilitation 
program, number of co-morbidities and current employment status. 
Persistence was influenced by factors such as tumour stage, joint pain 
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and cancer rehab program participation. Conclusion: The addition of 
standardized information materials to standard clinical care did not 
lead to a significant increase in compliance or persistence rates at 12 
or 24 months. With 4,923 women included, the PACT study represents 
the largest prospective study to evaluate the influence of educational 
material as well as baseline demographic and histopathological 
characteristics on the compliance and persistence to adjuvant 
endocrine therapy in postmenopausal patients with HR+ EBC.
P5-17-06
Pilot Study of a Questionnaire To Assess Impact of a Breast 
Cancer Diagnosis in Young Women on Their Relationship with 
Their Mothers.
Ali A, Fergus K, Wright F, Pritchard K, Kiss A, Warner E. Sunnybrook 
Health Sciences Centre, Toronto, ON, Canada
Background: Breast cancer in young women (≤ 40) is associated with 
greater morbidity, both physical and psychological, and mortality than 
in older women. For women in their 20s and 30s we would expect 
the mother daughter relationship to be uniquely impacted by breast 
cancer. However, no study has apparently looked at the effects of a 
breast cancer diagnosis in this situation. We completed a pilot study 
to assess the clarity, content and sensitivity of a questionnaire that 
will be used in a comprehensive assessment of this relationship in 
young women with breast cancer. Methods: A questionnaire with 
a mixture of Likert and open-ended items was developed after a 
literature review, obtaining input from an interdisciplinary panel of 
experts in psychology, medical oncology, research methodology, and 
breast cancer, and informal interviews with 3 young breast cancer 
survivors. Topics covered include demographics, nature of the mother-
daughter relationship pre and post diagnosis and sources of support 
to daughters and mothers. Ten breast cancer survivors (≤ age 40 at 
diagnosis and > 36 months after their diagnosis) were asked to assess 
the questionnaire. Results: Ten patients, median age 37 years (range 
31-52), participated in the pilot study. The average time to complete 
the questionnaire was about 30 minutes. No questions were reported 
to be upsetting. All but 1 patient indicated that the questionnaire was 
clear. The questionnaire was modified based on patient feedback. The 
number of items was reduced from 51 to 38. Items concerning, for 
example, nature of the mother-daughter relationship during childhood 
or teenage years, and openness to discussing personal gynecological 
matters prior to breast cancer diagnosis were ultimately excluded. A 
question inquiring about the most difficult issues the daughter faced 
after diagnosis was added. Some questions were changed from open 
ended format to relevant tick box options after reaching response 
item saturation during the pilot phase. Of the 10 patients, 8 felt close 
to their mothers in the year prior to their diagnosis. Seven patients 
reported turning to their mothers for support when they first learned 
of the diagnosis, and 4 stated their mother was the first person they 
turned to. All 10 felt their mothers were emotionally and practically 
supportive. Five indicated that their relationship got closer post-
diagnosis. One patient reported that her mother was not coping, 
and 3 indicated that their mothers did not have adequate support. 
Many patients felt that health care providers could help mothers 
by being empathetic, providing information, and linking mothers 
with supports. Discussion: The mother-daughter relationship is an 
important source of support for young breast cancer survivors. Our 
questionnaire will be used in 100 women ≤ age 40 and within 3 years 
of diagnosis to further study the impact of breast cancer in a young 
woman on the mother-daughter relationship and to determine whether 
any intervention targeted to the mothers (eg. information or support 
groups) might be helpful.
P5-17-07
HER2+ Metastatic Breast Cancer Patient Experiences on 
Treatment in the Biologic Era: Findings from a Community 
Web-Based Survey.
Mayer M, Doan JF, Lang K, Hurvitz SA, Lalla D, Woodward RM, 
Brammer MG, Menzin J, Tripathy D. AdvancedBC.org; Genentech, 
Inc., South San Francisco, CA; Boston Health Economics, Waltham, 
MA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, 
CA; USC/Norris Comprehensive Cancer Center, Los Angeles, CA
Background: HER2-directed biologic therapy is part of recommended 
treatment for women with HER2+ metastatic breast cancer (MBC). 
However, little is known regarding the quality of life (QoL) experience 
and symptom burden in these women outside of clinical trials.
Methods: This one-time, web-based survey was conducted with 6 
independent U.S. breast cancer support groups. Respondents were 
required to be female, aged 18+ with HER2+ MBC, and to have 
received active treatment in the past month outside of a clinical trial. 
Data were collected on demographic, clinical, employment, QoL 
(Rotterdam Symptom Checklist and EQ-5D), and other measures. 
Survey responses were stratified by active treatment (biologic alone, 
biologic in combination with other therapy, no biologic) and number 
of months since diagnosis of MBC.
Results: Of 337 possible respondents, 185 women with HER2+ MBC 
completed the survey. The majority were aged 45-59 years (53.5%), 
white (94.6%), living with a spouse or partner (74.6%), and had at 
least some college education (93.5%). Most (64.9%) reported bone as 
a site of metastasis, followed by liver (36.2%), lung (31.9%), and brain 
(21.6%). During the prior month, 60 respondents (32.4%) had received 
biologic therapy only (trastuzumab, lapatinib and/or bevacizumab), 93 
(50.3%) received biologic with another treatment, 21 (11.4%) received 
no biologic and 11 (5.9%) did not report a specific active treatment. 
Demographic and clinical characteristics were similar across therapy 
groups, with some geographic variation. Overall, the tumor receptor 
status was ER+/PR+ for 43.2% of respondents. Mean months since 
MBC diagnosis ranged from 46 among those taking a biologic with 
another treatment to 60 for those taking biologics only. Average 
Rotterdam subscale scores indicate that psychological symptoms 
caused the greatest impairment (mean= 67.8 of 100, where 100 is 
best), followed by physical symptoms (74.1) and activity limitations 
(87.3). There were no clinically meaningful (≥8 point) differences 
across biologic groups, with the greatest difference between the 
biologic with other therapy (73.5) and biologic-only (80.8) groups for 
“overall evaluation of life.” The average EQ-5D utility index score 
was 0.8 (1.0 is perfect health), with minimal variation across therapy 
groups. Most respondents reported no problems with mobility (62-
77%) or self-care (≥90% across groups). However, pain/discomfort 
and anxiety/depression were problematic for more than 50% of all 
respondents, and were most commonly reported among the biologic 
plus other treatment group (61.3% and 51.6% respectively, P<.05 
for differences in usual activity problems). Rotterdam and EQ-5D 
dimension scores indicated less impairment with more time since 
MBC diagnosis, particularly for EQ-5D mobility, self-care, usual 
activities, and pain/discomfort. Pain and mobility scores for those 
diagnosed 72+ months ago were significantly better than for those 
diagnosed 0-17 months ago (both P<.05).
Conclusions: This community survey of women with HER2+ MBC 
provides valuable insight into treatment, quality of life and symptom 
burden. Pain and psychological issues continue to be challenges for 
this population.
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The Value of Progression-Free Survival from the Patient 
Perspective: An Online Survey of Women with Metastatic Breast 
Cancer in the United States.
Hurvitz SA, Mathias SD, Doan JF, Crosby RD. UCLA School 
of Medicine/Translational Oncology Research International, 
Los Angeles, CA; Health Outcomes Solutions, Winter Park, FL; 
Genentech, Inc., South San Francisco, CA
Background: While PFS indicates the period of time a patient’s’ 
disease does not progress, there is debate about the relative value of 
longer PFS in the absence of a meaningful difference in OS. However, 
there are no known published reports about the value of PFS from 
the patient’s perspective.
Material and Methods: This was a 2 -part project consisting of 
instrument development (via focus groups) and cross-sectional 
administration to 2 groups of women, those who had vs. those 
who had not experienced disease progression. Based on input from 
19 women with MBC in the US, we developed an MBC-specific 
questionnaire (MBC-P). The questionnaire focuses on unique aspects 
relevant to MBC patients including concerns about the future, social 
isolation, fear, activity limitations, mental health, social functioning, 
and activity limitations. The MBC-P also presented descriptions 
of two hypothetical treatments: Treatment X, associated with 12 
mos of PFS and Treatment Y with 16 mos of PFS, which had the 
same side effect profile. Respondents were asked to state which 
treatment was associated with better overall quality of life (O-QOL), 
physical functioning (PF), emotional well being (EWB), and which 
treatment was preferred. We compared mean scores at the item level 
for respondents based on progression status. One final aspect of the 
questionnaire asked respondents to rate (on a 0 - 100 scale) O-QOL, 
PF, EWB at the time of initial breast cancer (BC) diagnosis, MBC 
diagnosis, and MBC progression (if applicable). Ethics approval 
was obtained.
Results: 282 women completed the survey [mean age: 50 yrs 
(range: 21-80)]; 56% had experienced progressive disease. Women 
whose disease had progressed were more likely (p < 0.05) to report 
putting their life on hold, worrying about there not being a treatment 
that will work, feeling less confident about their treatment, and 
experiencing greater limitations in recreational or physical activities 
and accomplishing things/tasks. For the hypothetical descriptions, 
no differences emerged based on progression status. Despite being 
told that side effects and OS were the same for both scenarios, 
significantly more women responded that treatment Y (vs. treatment 
X) would result in better QOL, physical functioning, and emotional 
well being. Additionally, 88% of respondents preferred treatment Y 
over treatment X. Ratings for different stages of disease on O-QOL, 
PF and EWB were lowest the first time a woman was told her MBC 
had progressed and highest when told she had responded to treatment 
(O-QOL: 58 vs. 77; PF: 61 vs. 71; EWB: 51 vs. 77).
Discussion: The MBC-P questionnaire was developed with input from 
women with MBC and is a useful tool to evaluate the value of PFS 
from the patient’s perspective. Women with MBC whose cancer had 
progressed were more limited in areas pertaining to treatment and 
activity limitations compared to women who had not experienced 
progression. Surprisingly, even when told that side effects and OS 
were similar, women rated O-QOL, PF, and EWB as being better 
for a hypothetical drug that provided 4 additional months of PFS. 
Results should be confirmed with a larger, more diverse sample of 
MBC patients and eventually in a prospective study.
P5-18-01
No Effect of Adjuvant Chemotherapy in Postmenopausal Patients 
with Invasive Lobular (Mixed) Breast Cancer.
Truin W, Voogd A, Vreugdenhil G, Van der Heiden-van der Loo 
M, Siesling S, Roumen R. Maxima Medical Centre, Veldhoven, 
Netherlands; Maastricht University, Maastricht, Netherlands; 
Comprehensive Cancer Centre, Utrecht, Netherlands; Comprehensive 
Cancer Centre, Enschede, Netherlands
Background: Although the literature is clear concerning the lack 
of response of invasive lobular breast cancer to neoadjuvant 
chemotherapy, no studies exist on the effectiveness of the adjuvant 
use of chemotherapy in these patients, as compared to those with 
ductal and mixed type lobular cancer.
Methods: All women with primary non-metastatic invasive ductal or 
(mixed type) lobular breast cancer, aged 50 to 69 years, diagnosed in 
the period 1995 to 2008 and treated with surgery, were selected from 
the Netherlands Cancer Registry and followed until January 1, 2010. 
Patients were divided in two groups: those who received adjuvant 
hormonal therapy only versus those receiving hormonal therapy in 
combination with adjuvant chemotherapy. Cox proportional hazards 
analyses were carried out to determine the impact of chemotherapy in 
addition to hormonal treatment, for each histological entity separately.
Results: In total 19,609 patients had ductal cancer, 3,685 had pure 
lobular cancer and 1,391 had mixed type lobular cancer. The patient 
groups were comparable with respect to the use of adjuvant systemic 
treatment. The 10-year survival of patients with ductal cancer treated 
with hormonal therapy alone was 69%, compared to 74% for those 
treated with hormonal therapy and chemotherapy (P<.0001). For 
patients with lobular cancer, the 10-year survival rate was 68% after 
hormonal treatment alone and 66% after hormonal therapy with 
chemotherapy (P=.45). The hazard ratio for death among the patients 
with ductal cancer receiving chemotherapy in addition to hormonal 
treatment was 0.70 (95% CI, 0.64-0.76, p<0.0001), as compared to 
those receiving hormonal treatment alone. In patients with pure or 
mixed type lobular cancer, however, the hazard ratio’s were 1.00 
(95% CI, 0.82-1.21, p=0.97) and 0.98 (95% CI, 0.70-1.33, p=0.83), 
respectively. A statistically significant interaction was observed 
between the use of adjuvant chemotherapy and histological tumor 
type.
Conclusions: Adjuvant chemotherapy confers no additional beneficial 
effects in postmenopausal patients with pure or mixed type lobular 
breast cancer receiving hormonal therapy.
P5-18-02
A Population Level Assessment of Emergency Room Visits and 
Hospitalizations for Women Undergoing Adjuvant Chemotherapy 
for Early Breast Cancer.
Enright KA, Trudeau M, Yun L, Grunfeld E, Krzyzanowska M. Peel 
Regional Cancer Centre, Credit Valley Hospital, Mississauga, ON, 
Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; 
Institute for Clinical Evaluative Science, Toronto, ON, Canada; 
University of Toronto, Toronto, ON, Canada; Cancer Care Ontario, 
Toronto, ON, Canada; Princess Margaret Hospital, Toronto, ON, 
Canada
Background: Adjuvant chemotherapy is considered the standard of 
care for women with lymph node positive and high risk lymph node 
negative breast cancer. While the acute toxicities of chemotherapy are 
well documented in clinical trials, the frequency of serious treatment 
related toxicities of adjuvant chemotherapy in the general population 
is not well described. We undertook a population based assessment 
of the frequency of serious treatment related toxicity in women 
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undergoing adjuvant chemotherapy for early breast cancer (EBC).
Methods: All incident EBC patients diagnosed between January 2007 
and December 2008 in Ontario, Canada were identified from the 
Ontario Cancer Registry. Patient records were linked deterministically 
to multiple provincial administrative health care databases to provide 
comprehensive medical follow-up. Exclusion criteria were set to 
exclude patients on chemotherapy for advanced breast cancer. Any 
patient with who received at least 1 cycle of adjuvant chemotherapy 
was included in the analysis. Serious toxicities resulting in emergency 
room (ER) visits or hospitalizations occurring between the start date 
of chemotherapy and 30 days after the last dose of chemotherapy 
were identified. Logistic regression models were used to identify the 
impact of chemotherapy regimen, age, comorbidity and duration on 
therapy on the likelihood of experiencing serious toxicity.
Results: Of the 3090 women identified in our cohort, 1440 (46.6%) 
experienced at least 1 serious toxicity resulting in an ER visit during 
their adjuvant treatment. Of the ER visits, the majority (1107, 87%) 
were attributable to treatment related toxicities. Febrile neutropenia 
(FN) was the most common treatment related toxicity occurring in 
27.1% of patients in the cohort. Docetaxel containing regimens were 
associated with a significantly higher rate of ER visits and FN (54.6%, 
34.6%) compared with paclitaxel (38.0%, 17.9%), or anthracycline 
alone (epirubicin 45.8%, 23.8%; doxorubicin 32.8%, 15.4%). Table 
1 displays the impact of clinical and patient factors on multivariable 
analysis.
Multivariable analysis for serious toxicity on adjuvant chemotherapy in EBC
 Any Acute Care Contact Hospitalization for Febrile Neutropenia
 OR 95% CI OR 95% CI
Regimen Type     
Anthracycline + paclitaxel 1.31 1.01 -1.71* 1.35 0.97 – 1.88
Anthracycline + docetaxel 2.58 2.12 – 3.13† 3.18 2.50 – 4.04 †
Epirubicin Alone 1.57 1.13 – 2.12** 1.60 1.08 – 2.38*
Doxorubicin Alone 1.00 Ref 1.00 Ref
Age (y) 1.00 0.99 – 1.02 1.00 0.99 – 1.01
Income Quintile(lowest to highest)     
Q1 1.32 1.04 – 1.64* 1.22 0.94 – 1.60
Q2 1.07 0.85 – 1.34 1.08 0.84 – 1.40
Q3 1.15 0.92 – 1.44 1.23 0.96- 1.57
Q4 0.93 0.75 – 1.63 0.89 0.69 – 1.14
Q5 1.00 Ref 1.00 Ref
Charlson Comorbidity 1.59 1.18- 2.14** 1.38 1.00 – 1.89*
Trastuzumab Use 1.09 0.90 – 1.32 1.00 0.81 -1.24
Duration on chemotherapy 1.04 1.02 – 1.05 † 1.03 1.02 – 1.05 †
* P < 0.05; **P < 0.01; † P <0.0001
Conclusion: Serious toxicities are a common in women undergoing 
adjuvant chemotherapy for EBC and result in significant acute health 
care utilization.
P5-18-03
First Interim Toxicity Analysis of the Randomized Phase III WSG 
Plan B Trial Comparing 4xEC-4xDoc Versus 6xTC in Breast 
Cancer Patients with HER2 Negative Breast Cancer (BC).
Nitz U, Gluz O, Krepe H, Liedtke B, Aktas B, Henschen S, Pollmanns 
A, Krabisch P, Zuna I, Shak S, Thomsseen C, Harbeck N. West 
German Study Group, Moenchengladbach, Germany; Breast Centre 
Niederrhein/Bethesda Hospital, Moenchengladbach, Germany; 
Bethesda Hospital, Wuppertal, Germany; Medizinishce Hochschule, 
Hannover, Germany; Evangelical Hospital, Bergisch Gladbach, 
Germany; University Hospital, Essen, Germany; Johanniter Hospital, 
Stendal, Germany; Evangelical Hospital, Oberhausen, Germany; 
City Hospital Chemnitz, Chemnitz, Germany; Genomic Health Inc, 
Redwood City, Germany; University Hospital Halle/Saale, Halle/
Saale, Germany; University Hospital Cologne, Cologne, Germany
Background: Anthracycline-taxane based adjuvant chemotherapy 
(cht) is considered standard in node-positive and high-risk node-
negative BC. However, retrospective analyses suggest that in HER2- 
BC, benefit from anthracyclines may not outweigh acute and long 
term toxicities. Recurrence Score (RS) identifies patients who are not 
candidates for cht based on their low relapse risk, as well as minimal, 
if any, benefit of cht. The WSG Plan B trial investigates anthracycline-
free cht in HER2- BC and is the first trial in Europe prospectively 
incorporating RS for decision making regarding adjuvant cht in both 
N0 and N+ BC.
Methods: Plan B trial randomizes HER2- BC patients with high-risk 
N0 (at least one risk factor: >pT2; negative HR status; G2-3; age 
<35 years old; high uPA/PAI-1) or N+ disease to 6xTC (Docetaxel 
75Cyclophosphomide600) vs. 4xEC (Epirubicin90Cyclophosphomide600)-
4xDocetaxel100. G-CSF prophylaxis is recommended according to 
current ASCO guidelines. The statistical design previews n=2.448 
randomized to cht; patients with HR+ BC, N0-3 and a RS <11 receive 
endocrine therapy only.
Results:
From April 2009 to June 2011, 3037 patients have been recruited 
and 2296 randomized (TC/EC-Doc: 1146/1150; age <65 years old: 
900/911; >65 years old: 246/239). From the patients with HR+ disease 
(n=2368) 18% had a RS 0-11, 61% a RS 12-25 and 21% a RS > 25. 
In patients with 0-3 positive LN and RS of 0-11 (n=329) who opted 
for no cht 257 are in the observational arm. In the group with an 
intermediate risk (RS 12-25) 14% drop outs before start of cht have 
been reported. In 1172 fully monitored patients 22 toxicity-related 
therapy stops have been reported in the TC and 34 in the EC-Doc 
arm (p=0.12).
614 serious adverse events (SAE) have been reported (299 TC vs. 
315 EC-Doc). There is no difference in patients <65 years old (TC 
vs. EC-Doc: 218/218), but slightly more SAE’s in patients >65 years 
old treated by EC-Doc (97 vs. 81, p=0.13).
The most frequent SAEs were: leucopenia, febrile neutropenia (TC/
EC-Doc:37 (3.3%)/31 (2.7%), n.s.), infections and heart/vascular 
events (TC/EC-Doc 29/40, n.s.). In patients >65 years old, there is a 
trend towards more febrile neutropenia (13 vs. 5; p=0.06) in the TC, 
and more severe mucositis/diarrhea/nausea (3 vs. 15; p=0.007) and 
heart/vascular events (5 vs. 14; p=0.06) in the EC-Doc arm.
There were 5 therapy related deaths (TC 5 (0.4%)/EC-Doc 0, p=0.03); 
3 in patients <65 years, 2 in patients >65 years (4 due to sepsis, 1 
due to cardiac failure).
Detailed data on relationship between the protocol specified, RS-
guided treatment assignment and toxicity, and use of G-CSF support 
will be updated for the meeting.
Conclusions: The Plan-B trial is one of the largest randomized 
phase III trials currently evaluating anthracycline-free adjuvant cht 
in HER2- BC. The cht administered within the study was generally 
well tolerated, but higher number of treatment-related deaths has 
been observed within the TC arm. The short term toxicity profile 
seems be different between both study arms, particularly in patients 
> 65 years old. On the basis of prognosis as determined by RS, cht 
has been spared after a shared decision process in a substantial group 
of patients.
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Safety Profile of Ixabepilone as Adjuvant Treatment for Poor 
Prognosis Early Breast Cancer: First Results of the Unicancer-
PACS 08 Trial.
Campone M, Spielmann M, Wildiers H, Cottu P, Kerbrat P, Levy 
C, Mayer F, Bachelot T, Winston T, Eymard J-C, Uwer L, Machiels 
J-P, Verhoeven D, Jaubert D, Facchini T, Orfeuvre H, Canon J-L, 
Asselain B, Roca L, Lacroix Triki M, Martin AL, Roche H. Centre 
René Gauducheau, Nantes, France; Institut Gustave Roussy, Villejuif, 
France; Katholike Universiteit, Leuven, Belgium; Institut Curie, 
Paris, France; Centre Eugène Marquis, Rennes, France; Centre 
François Baclesse, Caen, France; Centre Georges-François Leclerc, 
Dijon, France; Centre Léon Bérard, Lyon, France; Mayo Clinic 
Florida, Jacksonville; Institut Jean Godinot, Reims, France; Centre 
Alexis Vautrin, Nancy, France; UCL Cliniques Universitaires SAINT-
LUC, Bruxelles, Belgium; AZ Klina Oncology, Brasschaat, Belgium; 
Clinique Tivoli, Bordeaux, France; Polyclinique de Courlancy, 
Reims, France; Centre Hospitalier de Fleyriat, Bourg en Bresse, 
France; Grand Hopital de Charleroi, Charleroi, Belgium; Centre Val 
d’Aurelle, Montpellier, France; Institut Claudius Regaud, Toulouse, 
France; R&D Unicancer, Paris, France
Purpose: PACS 01 trial demonstrated that the sequential adjuvant 
chemotherapy with FEC100 followed by docetaxel (D) significantly 
improves disease-free and overall survival in node-positive(N+) 
early breast cancer (BC). However, Triple negative (TN) and ER+/
PR-/HER2- subgroups are significantly associated to a worse 
prognosis even after adjunction of D. As Ixabepilone (Ixa) has notable 
preclinical and clinical activity in these subgroups, the PACS 08 trial 
aims to compare standard FEC100-D regimen to 3 cycles of FEC100 
followed by 3 cycles of Ixa. We report the preliminary results of the 
toxicity profile.
Patients and methods: Patients (pts) had localized resectable unilateral 
ER-/PR-/HER2- or ER+/PR-/HER2- BC. Main inclusion criteria 
were: age<70 years, normal cardiac, hepatic, haematological and renal 
functions. Arm A: pts received 3 cycles of FEC100 (F and C, each 
at 500 mg/m2, E 100 mg/m2, every 3 weeks) followed by 3 cycles 
of D (100 mg/m2 every 3 weeks); Arm B, Ixa 40 mg/m2 replaced D. 
Radiotherapy was mandatory after conservative surgery and endocrine 
therapy was given to ER+ pts. A 5% absolute difference in disease-
free survival at 5 years is the main statistical end-point.
Results: Between October 2007 and September 2010, 762 pts with 
TNBC or ER+/PR-/HER2- BC were enrolled. Recruitment was 
interrupted due to BMS decision to stop Ixa development in adjuvant 
setting. Main pts characteristics were well balanced between the 2 
arms: median age 53 years, postmenopausal 57.8%, conservative 
surgery 68.4%, node positive 59.5%. A total of 755 pts were evaluable 
for safety. Treatment was completed for 93.4% and 86.1% of pts in 
arms A and B, respectively. During FEC100 sequence, toxicities were 
well balanced between the two arms. From cycle 4, whereas Gr3/4 
sensory neurotoxicity (12pts; 3.5%) and thrombopenia (7pts; 2%) 
were reported in Ixa arm, none of these toxicities was reported in 
the D arm (p0.001). There were significantly more Gr3/4 neutropenia 
on day 21 in Ixa arm (13pts, 6.6% vs 4pts, 1.9%; p<]0.005). No 
significant difference was observed for febrile neutropenia. Fewer 
cutaneous toxicities were observed in Ixa arm (2pts, 0.6% vs 10pts, 
2.6%; p<0.05). No significant difference was observed neither for 
motor neurotoxicity or hepatic function between two arms. More pts 
discontinued treatment in Ixa arm compared to D arm (49pts (13%) 
vs 26pts (7%), p<0.05). Main reasons were Gr3/4 haematological 
adverse events (AE) and Gr3/4 neurotoxicities for Ixa arm and due to 
GR3/4 haematological AE for D arm. One non expected Gr4 bullous 
dermatitis was reported during the first Ixa cycle. 2 deaths due to septic 
shock occured in Ixa arm (both at cycle 4 for a 56- and a 66-year-old 
woman). However, according to the IDMC no obvious precipitating 
factor questioning the Ixa arm was identified.
Conclusion: Our results indicate that D arm is more often associated 
to significant haematological toxicities, whereas both neurotoxicities 
and haematological toxicities are reported in the Ixa arm. Although 
significantly more pts discontinued treatment due to adverse events 
in Ixa arm compared to D arm, Ixa may still represent a promising 
therapeutic option for pts in the adjuvant setting especially for poor 
prognosis BC.
P5-18-05
Incidence of Febrile Neutropenia in Patients Treated with 
Docetaxel and Cyclophosphamide (TC) for Adjuvant Breast 
Cancer.
Yee J, Chan J, Fehrenbacher L, Fredriks D, Chen D, Wong W, Colley 
D. Kaiser Permanente, Northern California; Kaiser Permanente, 
Northwest
Background: Adjuvant docetaxel with cyclophosphamide (TC) 
chemotherapy use in the community is common based on its improved 
disease outcomes compared to doxorubicin with cyclophosphamide 
(AC) treatment, lack of cardiac toxicity associated with anthracyclines, 
and perceived low incidence of febrile neutropenia (FN). In the pivotal 
trial of AC versus TC, the incidence of FN in breast cancer patients 
who received TC treatment was 4% in patients under 65 years and 
8% in patients greater than 65 years. Growth factors (CSF) were not 
used in the trial, but antibiotics were used significantly. FN rates of 
11.6% to 50% have been reported in multiple small studies, prompting 
warnings that primary prophylaxis with growth factor should be used. 
The true incidence of FN in community based patients may be higher 
than in the original clinical trial population as non-trial patients may 
have risk factors known to increase the risk for chemotherapy-induced 
FN, including increased age or other comorbid conditions. We wanted 
to know the incidence of FN in patients receiving TC chemotherapy 
who were not given primary prophylaxis with CSF.
Methods: Using our electronic medical record system, a retrospective 
review of patients starting TC for breast cancer in 2010 at Kaiser 
Permanente Northern California was included. Patients had 
started a four or six cycle regimen of docetaxel 75 mg/m2 and 
cyclophosphamide 600 mg/m2 every 21 days. Patients were stratified 
into two groups: (1) CSF primary prophylaxis given with the first 
cycle versus (2) no CSF primary prophylaxis given with the first 
cycle. CSF prophylaxis was given by physician choice. FN episodes 
were defined with a clinical diagnosis code for FN from emergency 
department visits or hospitalizations. The primary outcome was the 
incidence of TC-induced FN in patients who did not receive CSF 
primary prophylaxis with the first cycle of treatment.
Results: 332 patients with a mean age of 57.9 years (range 30.5 to 
83.6 years) were included. Of these, 204 (61.4%) did not receive 
primary CSF prophylaxis (mean age 57.4 years, range 30.5 to 83.6 
years), and 128 (38.6%) received primary CSF prophylaxis (mean age 
58.5 years, range 36.6 to 82.4 years). The incidence of FN during any 
cycle was 24.5% (50/204) in those who did not receive primary CSF 
prophylaxis and 8.6% (11/128) in those who did (p=0.0003). Patients 
were hospitalized for FN for a total of 174 days (mean 3.2 days, 
range 1 to 13 days). Mean days hospitalized were 3.2 in each group. 
We will present risk factors associated with the development of FN.
Conclusion: In the largest population based report to date, we report 
the incidence of febrile neutropenia to be 24.5% in patients not 
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receiving primary CSF prophylaxis. The rate is higher than originally 
reported for TC. Primary prophylaxis with CSF should be considered 
when treating this patient population with TC chemotherapy. Further 
analysis, including risk factor assessment, will be presented.
P5-18-06
Taxanes and Cyclophosphamide Are Equally Effective in Breast 
Cancer: A Meta-Analysis of Ten Phase III Trials in Early and 
Advanced Disease.
Vriens BE, Lobbezoo DJ, Voogd AC, Veeck J, Tjan-Heijnen VC. 
Maastricht University Medical Centre, Maastricht, Netherlands; 
Maxima Medical Centre, Eindhoven, Netherlands
Background Overall taxanes did not improve survival in metastatic 
breast cancer trials (n=10 trials), whereas they do so in (neo-)adjuvant 
breast cancer trials (n=28 trials). We also noticed that in a substantial 
number of ‘negative’ metastatic trials, taxane-regimens were used 
without cyclophosphamide. To further explore this, we compared the 
outcome of studies in early and advanced breast cancer with a similar 
design, that is all studies substituting taxanes for cyclophosphamide.
Methods We identified 10 phase III taxane-based chemotherapy trials 
in early and advanced disease, in which taxanes were used instead of 
cyclophosphamide. They all compared a regimen of an anthracycline 
combined with a taxane versus an anthracycline combined with 
cyclophosphamide, i.e., AT versus AC. A pooled analysis was 
performed using the Review Manager software (RevMan 5) provided 
by the Cochrane Collaboration.
Results In total, 5 studies in advanced disease, 2 studies in neo-
adjuvant, and 3 studies in adjuvant disease setting were included 
and analyzed for their primary endpoint. In metastatic breast cancer 
studies, the hazard ratio of overall survival was 1.03 (95% CI 0.92 to 
1.15) for taxanes as compared to cyclophosphamide. Also, studies on 
early breast cancer with a similar design showed no improvement for 
taxanes, resulting in an odds ratio for pCR of 0.91 (95% CI 0.57 to 
1.43) in the neo-adjuvant setting and a hazard ratio for 5-year disease-
free survival of 0.96 (95% CI 0.84 to 1.09) in the adjuvant setting.
Conclusion Re-assessment of studies of drugs both assessed in 
metastatic and early breast cancer provides a new tool for improved 
understanding. This meta-analysis shows that cyclophosphamide in 
breast cancer patients is equally effective as taxanes, and thus should 
be considered of pivotal importance in the treatment of metastatic 
and early breast cancer. Full appreciation of its relevance will prevent 
replacement of cyclophosphamide in future trials or in daily practice.
Funding: Netherlands Organization for Health Research and 
Development (ZonMw 80-82500-98-10901)
P5-18-07
Presence of Disseminated Tumor Cells after Adjuvant 
Chemotherapy in Breast Cancer and Disseminated Tumor Cells 
Monitoring during Secondary Adjuvant Treatment.
Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg 
T, Kersten C, Mjaaland I, Vindi L, Schirmer CB, Nesland JM, Naume 
B. Oslo University Hospital, The Radium Hospital, Oslo, Norway; 
Oslo University Hospital, Ullevål, Oslo, Norway; Hospital Innlandet, 
Gjøvik, Norway; University Hospital Northern Norway, Tromsø, 
Norway; Sørlandet Hospital Kristiansand, Kristiansand, Norway; 
Stavanger University Hospital, Stavanger, Norway; Ålesund Hospital, 
Ålesund, Norway; University of Oslo, Norway
Introduction: Detection of disseminated tumor cells (DTC) after 
completion of systemic adjuvant treatment is a strong predictor of 
early systemic relapse and death. This analysis can discover early 
failure of a chosen adjuvant systemic treatment. In this study, we 
wanted to evaluate the value of DTC detection in bone marrow (BM) 
as a surrogate marker for response to docetaxel rescue treatment, to 
predict the effect of this treatment. Further, we wanted to compare 
disease free survival between patients treated with docetaxel resulting 
in eradication of DTC after treatment and patients treated with 
docetaxel where DTC persists after treatment. The follow up of the 
study is still ongoing. Here, we present the preliminary descriptive 
data from the study.
Materials and Methods: A total of 1128 pts with node positive or high 
risk node negative disease (T1c/T2GII-IIIN0) was enrolled in the 
period from October 2003 to May 2008. All patients had completed 
primary surgery and received 6 cycles of adjuvant antracycline 
containing chemotherapy. The first BM aspiration was performed 8-12 
weeks after termination of adjuvant chemotherapy (BM1). A second 
BM aspiration was performed 6 months later (BM2). The processing 
of BM and DTC analysis (by ICC) were performed as previsously 
described (Wiedswang G et al, J Clin Oncol 2003). If BM2 was 
positive (+) for DTC, the patient was treated with docetaxel (3qw, 6 
courses) Docetaxel-treated patients were reexamined at the inclusion 
hospital with new BM analysis at approximately 1 month (BM3) and 
13 months (BM4) after the last docetaxel infusion.
Results: Of 997 patients with conclusive DTC results for both BM1 
and BM2, 83 patients (8.3%) were BM1 positive and 78 (7.8%) 
BM2 positive. Among the BM1+ patients, 15 (18.1%) were BM2+. 
The concordance between BM1 and BM2 were 87%. Of the patients 
positive at one or both time points, the concordance was 10% (15/146). 
The BM1 was not significantly associated with primary tumor 
characteristics (although borderline significance for Grade and ER 
status), whereas for BM2, DTC+ patients had increased frequency of 
node positive disease and pN2-3 stage (p=0.001, chi-square), and were 
positively associated with lobular carcinoma (p=0.01, chi-square). 
At BM1 24.7% of the DTC+ patients had >1 DTC, and 9.9% had 
≥3 DTC. For BM2, 48.2% had >1 DTC, and 25.7% had ≥3 DTC. 
For patients with positive BM2 receiving docetaxel, the BM3 turned 
DTC negative in 55 of 66 evaluable cases (83.3%), and 48 of 59 were 
negative in BM4 (81.4%). Of 67 patients with a conclusive BM result 
at either BM3 or BM4, 12 were BM positive. Of 16 patients with ≥3 
DTC before docetaxel treatment, only 4 patients were positive after 
treatment (25%).
Conclusions: DTC status after adjuvant antracycline containing 
chemotherapy changes during the first 9 months of FU, with increased 
DTC positivity among patients with pN+ disease and lobular 
carcinomas. After docetaxel rescue treatment, the majority of patients 
experience disappearance of the DTCs. The clinical significance 
of these results awaits mature FU data, but the present results may 
indicate possibility for eradication of residual disease by alternative 
chemotherapy.
P5-18-08
A Comparative Effectiveness Analysis of Trastuzumab Persistence 
between Two Adjuvant Breast Cancer Treatment Regimens 
among US Health Plan Enrollees.
Lalla D, Pelletier EM, Goodman S, Brammer M, Schabert VF. 
Genentech Inc., South San Francisco, CA; IMS Consulting Group, 
Watertown, MA; IMS Consulting Group, Woodland Hills, CA
Background: Approved US indications for trastuzumab include 
adjuvant treatment of HER2-overexpressing breast cancer in 
anthracycline-based (ACTH) or non-anthracycline-based (TCH) 
regimens. The objective of this study was to compare trastuzumab 
persistence across adjuvant breast cancer treatment regimens for US 
health plan enrollees.
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Materials and Methods: This retrospective cohort study using the 
IMS LifeLinkTM Health Plan Claims Database included adjuvant breast 
cancer patients, defined as those with a mastectomy or lumpectomy 
and a primary breast cancer diagnosis (index diagnosis) from 1/1/2006 
to 12/31/2008. Additional inclusion criteria were: aged ≥18 years; a 
second primary breast cancer diagnosis ≤90 days of the first; no other 
primary or secondary neoplasms ≤180 days before or ≤90 days after 
the index diagnosis; a first trastuzumab claim (index claim) and ≥1 
carboplatin, cyclophosphamide, taxane, or anthracycline claim ≤210 
days of the index diagnosis; and no trastuzumab claim before the 
index diagnosis. Regimens were classified as ACTH (doxorubicin, 
cyclophosphamide, a taxane, trastuzumab) or TCH (docetaxel, 
carboplatin, trastuzumab) from therapies observed after the index 
claim. Trastuzumab persistence (days from the index claim to earliest 
of trastuzumab discontinuation, a new malignant neoplasm, end of 
plan enrollment, 360 days after the index claim, or end of available 
data) was reported for patients with ≥2 trastuzumab claims and 
compared across regimens using the Kaplan-Meier estimator and 
Cox proportional hazards models.
Results: 550 breast cancer patients met all study criteria (291 ACTH, 
259 TCH, 46 unassigned); patients receiving TCH were older (median 
52 vs. 50 years; P=0.018). For years 2006-2008, the annual share of 
the cohort initiating ACTH decreased from 69.3% to 35.2%; patients 
initiating TCH increased from 26.7% to 56.5%. Patients receiving 
ACTH were treated with trastuzumab for fewer days (mean=256, 
median=334) versus patients on TCH (mean=282, median 344, 
P=0.018). Fewer patients on ACTH remained on trastuzumab at 
day 90 (83% vs. 91%), day 180 (71% vs. 79%), day 270 (61% vs. 
72%), and day 360 (20% vs. 26%). Compared to patients on TCH, 
patients on ACTH continued to be treated with trastuzumab for a 
shorter duration post-index after adjusting for age, region, plan type, 
prescriber specialty, and comorbidities (HR=0.77, 95% CI [0.63, 
0.95]; P=0.016).
Discussion: The share of adjuvant breast cancer patients initiating 
TCH increased from 2006 to 2008, while use of ACTH decreased 
over the same time period, and patients treated with TCH remained 
on trastuzumab for a longer period of time. From a clinical standpoint, 
patients derive maximum benefit from their medications when they are 
persistent long-term, which can lead to economic benefits with regards 
to lower overall healthcare costs. Further analyses will evaluate 
whether adjuvant breast cancer regimens differ in weight-adjusted 
cumulative trastuzumab doses received during therapy.
P5-18-09
The Incidence of Febrile Neutropenia in the First Course of 
Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with 
or without Pegfilgrastim.
Jones S, Paul D, Sedlacek S, Vukelja S, Wilks ST, Stokoe C, Osborne 
CR, Krekow L, McIntyre K, Holmes FA, Guerra L, Zhan F, Asmar 
L, O’Shaughnessy J, Blum JL. US Oncology, The Woodlands, TX; 
Baylor-Sammons Cancer Center, Baylor University, Dallas, TX; 
Rocky Mountain Cancer Center, Denver, CO; Texas Oncology-Tyler, 
Tyler, TX; Cancer Care Centers of South Texas, San Antonio, TX; 
Texas Oncology, Plano, TX; Breast Cancer Center of North Texas, 
Bedford, TX; Texas Oncology-Dallas Presbyterian Hospital, Dallas, 
TX; Texas Oncology-Houston Memorial City, Houston, TX
Background: In our original doxorubicin-cyclophosphamide/
docetaxel-cyclophosphamide (AC/TC) adjuvant study (JCO 27: 
1177-1183, 2009), we reported an incidence of febrile neutropenia 
(FN) of 5% (8% in women ≥65 years) with the TC regimen without 
prophylactic WBC growth factors but with a recommendation for 
prophylactic antibiotics. There is a paucity of data on the incidence 
of FN with the TC regimen aside from this clinical trial. Because we 
have been conducting a randomized adjuvant study of TC compared 
to other regimens, we used this opportunity to analyze the incidence 
of FN during the first course of chemotherapy with TC in the first 
cohort of randomized patients (US Oncology Network study 06090). 
The prophylactic use of WBC growth factors was at the investigator’s 
discretion.
Patients and Methods: The study included 1298 patients entered 
between May 2007 and May 2009. Of these, 649 were included in 
the TC arm. Median age was 54 years (range 27-71), 75.5% were 
Caucasian, 561 (86.4%) were in PS 0 at baseline, and about half 
were node negative. Eight patients did not receive study treatment 
for various reasons. Among the 641 patients who received TC; 213 
(33.3%) received pegfilgrastim, 48 (7.5%) received filgrastim and 
were not included in this analysis, and 380 (59.2%) patients did not 
receive either during the first cycle. Thus, this analysis focused on 
593 women who did or did not receive prophylactic pegfilgrastim 
in cycle 1.
Results: All patients with a reported adverse event of FN or with a 
reported AE of fever with some degree of neutropenia (in order to 
capture all possible cases of FN) during the first cycle of TC were 
identified [Table 1]. FN and fever + neutropenia occurred in a total of 
6 (2.8%) patients who received pegfilgrastim and 36 (9.5%) patients 
who did not. A comparison of age, race, performance status and stage 
of disease between these 2 groups revealed that they were similar. The 
213 patients who received pegfilgrastim were slightly older (median 
56 years, range 27-71) compared to those who did not (median 53 
years, range 30-71).
Table 1. FN and Fever+Neutropenia During Cycle 1
Adverse Event Pegfilgrastim
 Yes No
 n=213 (%) n=380 (%)
FN 4 (1.9) 26 (6.8)
Fever+Neutropenia 2 (0.9) 10 (2.6)
Totals 6 (2.8) 36 (9.5)
During all 6 cycles, 41 patients reported FN, and 30 (73%) of these 
patients experienced FN during cycle 1.
Conclusion: Among 593 women who received TC as adjuvant 
chemotherapy, the incidence of FN during the first cycle was under 
10% whether or not the patients received prophylactic pegfilgrastim.
P5-18-10
Utilisation of Primary and Secondary G-CSF Prophylaxis Enables 
Optimal Dose Delivery of Standard Adjuvant Chemotherapy 
in Early Breast Cancer: Results of 1655 Patients from a Single 
Institution.
Chan A, McGregor S. Mount Hospital, Perth, WA, Australia
Background: Chemotherapy for early breast cancer (EBC) confers 
significant survival advantages. However, myelosuppression is a 
common cause of chemotherapy dose reduction that may subsequently 
compromise survival benefits. Primary prophylaxis (PG) with 
granulocyte-colony stimulating factor (G) is indicated for TAC 
regimen, but rates of grade 3/4 neutropenia (G3/4N) associated with 
other adjuvant regimens in a non-trial setting are not well documented. 
Optimal use of G will likely enable planned dose delivery, leading to 
optimal BC outcomes. This retrospective study reports dose delivery 
outcome with judicious use of G in a single institution.
Methods: Consecutive patients (pts) with EBC who received 
chemotherapy at Mount Hospital from January 1999 - December 2010 
were included. Data was collected prospectively for pt characteristics, 
regimen given and neutropenic complications. Only pts who 
received a minimum of 1 cycle of chemotherapy were included. PG 
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was only available in pts receiving TAC after 1/4/2007; Secondary 
G prophylaxis (SG) was given for G3/4N in first cycle, febrile 
neutropenia (FN) or delay in neutrophil recovery (DN). Primary 
outcome measure was dose delivery defined as relative dose intensity 
(RDI - fraction of dose per unit of time of standard regimen) and 
fraction planned dose received (PDR). Secondary endpoints included 
EBC outcome and incidence of haematological malignancies.
Results: Over the 12-yr period, 1655 pts (62% node positive) with 
mean age of 51yr (24-88yr) were included. Chemotherapy given 
- n(%): Non-anthracycline(A)/taxane(T) 63(3.8); A 671(40.5); AT 
666(40.2); T-only 255(15.4). Overall 64% of pts received G: PG given 
for TAC in 167(10); SG was given for first cycle G3/4N 677(41), 
FN 87(5) - 89% during first cycle, DN 109(7). Mean RDI and PDR 
was 0.97 v 0.95 and 0.98 v 0.97 for pts who received G and did not, 
respectively. Amongst pts aged < or ≥65yr, rate of G use and >85% 
PDR were comparable (65% v 66%; and 4% v 6%, respectively). 
Five cases of myelodysplasia or acute leukaemia were reported (4 pts 
received G) - 0.37% v 0.17% of pts having G or not, respectively. All 
cases received an anthracycline with cyclophosphamide. At median 
follow-up of 44.9 months [Q1: 25.1- Q3: 69.6], DFS was 88.9% and 
OS 92.6%. PDR <85% occurred in 5% pts, with OS of 78% v 93% 
if pts received < or ≥85%, respectively.
Discussion: Significant rates of myelosuppression occur with 
regimens commonly used in the community. These regimens are not 
associated with FN rates >20% and thus PG is not advised. Routine 
monitoring of first-cycle neutrophil nadir enabled the identification of 
those pts at high risk of developing further neutropenic complications 
and consequent need for dose reduction or delay. Utilisation of G in 
these high risk pts enabled a high RDI to be delivered, comparable 
to pts who did not experience significant myelosuppression. Further, 
pts who did not develop significant first cycle myelosuppression 
were largely spared the need for G. In this manner, concerns 
regarding haematological toxicity and costs associated with G use 
are minimised.
P5-18-11
Incidence of Chemotherapy Dose Reductions and Dose Delays, 
and Reduced Chemotherapy Dose Intensity in Early Stage Breast 
Cancer.
Weycker D, Edelsberg J, Kartashov A, Barron R, Lyman G. Policy 
Analysis Inc. (PAI), Brookline, MA; Amgen Inc., Thousand Oaks, CA; 
Duke University, Durham, NC
Background: Chemotherapy is widely used to treat early stage 
breast cancer (ESBC). Dose reductions and dose delays--e.g., due to 
advanced age or severe/febrile neutropenia--are generally believed 
to increase risk of disease progression and reduce survival. Little is 
known about incidence of chemotherapy dose reductions and dose 
delays among women with ESBC in clinical practice.
Methods: This study employed a retrospective cohort design and 
electronic medical records from over 60 community oncology clinics 
in more than 20 states (2004-2010). Study population included 
adult women who received myelosuppressive chemotherapy for 
ESBC (stages I-IIIA). For each such woman, each unique cycle 
of chemotherapy within their first observed course was identified. 
Incidences of chemotherapy dose delays (≥7 days for any drug in 
≥1 cycles), chemotherapy dose reductions (≥15% for any drug in ≥1 
cycles), and low relative chemotherapy dose intensity (<85% over 
the course) -- relative to physician-reported planned chemotherapy 
administration -- were descriptively analyzed for the seven most 
frequently observed regimens among subjects.
Results: 2,350 women received seven most frequently observed 
regimens (80% of study population); mean age -- across regimens -- 
ranged from 51-56 years, and 31-94% received primary prophylaxis 
against severe/febrile neutropenia with a colony-stimulating factor. 
Incidence of dose reductions ranged from 17-48%, and dose delays, 
from 24-45%. Overall mean relative dose intensity (RDI) ranged from 
80%-99%, and 17-50% of subjects received RDI <85%; mean RDI 
among those with low RDI ranged from 40%-67%.
 AC (n=418)
Dose- 
Dense AC 
(n=107)
AC->T 
(n=123)
Dose-Dense 
AC->T 
(n=645)
TAC 
(n=321)
TC (n=592)
TCH 
(n=144)
Patient 
Characteristics
       
Age, mean (SD) 53.7 (10.1) 53.5 (10.7) 55.4 (12.1) 52.5 (10.4) 51.2 (9.5) 56.2 (10.6) 54.2 (11.1)
1° Prophylaxis, % 48.1 93.5 30.9 90.9 82.2 58.1 50.7
Chemotherapy        
Reduc. ≥15%, 
% (SE)
17.2 (2.0) 27.1 (4.3) 48.0 (4.5) 29.6 (1.8) 23.1 (2.6) 21.3 (1.8) 47.2 (4.3)
Delay ≥7d, % (SE) 24.4 (2.2) 35.5 (4.5) 44.7 (4.5) 42.5 (1.9) 34.0 (2.8) 26.4 (1.9) 40.3 (4.3)
RDI, mean (SE) 99.9 (1.4) 89.0 (2.4) 79.5 (2.2) 89.3 (1.4) 86.5 (1.7) 88.5 (1.2) 79.8 (2.6)
RDI <85%, % (SE) 17.0 (2.0) 31.8 (4.4) 49.6 (4.5) 29.0 (1.8) 26.5 (2.7) 21.6 (1.8) 44.4 (4.3)
RDI*, mean (SE) 53.3 (2.6) 61.4 (3.4) 52.9 (2.8) 67.3 (2.1) 43.7 (2.4) 39.6 (2.0) 52.5 (3.4)
AC: doxorubicin (60 mg/m2) / cyclophosphamide (600 mg/m2) -- Q3 x 4 cycles / Q2 x 4 cycles (dose dense) 
AC->T: doxorubicin (60 mg/m2) / cyclophosphamide (600 mg/m2) -> paclitaxel (175 mg/m2) / docetaxel 
(100 mg/m2) -- Q3 x 4 cycles -> Q3 x 4 cycles / Q2 x 4 cycles -> Q2 x 4 cycles (dose dense) TAC: docetaxel 
(75 mg/m2) / doxorubicin (50 mg/m2) / cyclophosphamide (500 mg/m2) -- Q3 x 6 weeks TC: docetaxel (75 
mg/m2) / cyclophosphamide (600 mg/m2) -- Q3 x 4 weeks TCH: docetaxel (75 mg/m2) / carboplatin (360 
mg/m2) -- Q3 x 6 weeks *Among patients with RDI <85%
Discussion: Chemotherapy dose delays and dose reductions are 
common in ESBC, among those receiving dose-dense as well as 
conventional regimens.
P5-18-12
Perception, Practice and Toxicity of Adjuvant Treatment of 
HER2+ Breast Cancer in Wisconsin.
Rocque GB, Onitilo AA, Engel JM, Pettke EN, Boshoven AM, Zhang 
S, Kim KM, Rishi S, Waack B, Wisinski KB, Tevaarwerk AJ, Burkard 
ME. University of Wisconsin Carbone Cancer Center, Madison, WI; 
The Marshfield Clinic, Weston, WI; University of Wisconsin School 
of Medicine and Public Health, Madison, WI
INTRODUCTION: Multiple trastuzumab-containing (neo)adjuvant 
regimens are used for HER2+ BrCa, but the experience with these 
regimens in routine practice is not reported. Some oncologists select 
TCH based on BCIRG 006, whereas others prefer anthracycline-based 
therapy. We evaluated whether oncologists’ perceptions of these 
regimens match clinical experience.
METHODS: We surveyed 151 Wisconsin (WI) oncologists regarding 
factors impacting selection of TCH versus AC-TH; 65 (42%) 
responded. At the same time, we reviewed 200 cases of HER2+ BrCa 
treated with adjuvant trastuzumab from 2003 to 2010 at the University 
of Wisconsin Carbone Cancer Center (UW) and the Marshfield Clinic. 
We collected baseline patient and tumor characteristics, regimen 
administered, and toxicities as assessed by lab values, cardiac ejection 
fraction (EF), hospitalizations, dose reductions/delays, and ability to 
complete therapy.
RESULTS: Two-thirds of surveyed oncologists prefer anthracycline-
based therapy over TCH. Of oncologists preferring TCH, 20 of 23 had 
been in practice for >10 years. Oncologists perceived that AC-TH and 
TCH were equally likely to be completed. The majority of physicians 
select therapy based on patient age and stage, with a preference for 
AC-TH for node-positive disease and TCH for early stage (T1a-bN0) 
tumors. Despite BCIRG 006 remaining unpublished at the time of 
the survey, peer-review publication was cited as the most important 
factor in selecting this regimen. Although use of granulocyte colony 
stimulating factor (GCSF) in BCIRG 006 has not reported, 50% of 
oncologists indicated routine use with cycle 1 of TCH.
Of the 200 cases reviewed, 114 women received AC-TH, 48 women 
received TCH, and 38 had other regimens. The median age was 53 
years old, 52% had node positive disease. Acute toxicity trended 
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higher with TCH. For example, there were fewer dose modifications/
delays for AC-TH than TCH (31% vs. 46%, p=0.07). This may have 
been due to common use of GCSF with AC-TH (77% vs. 33% use 
with TCH). Neutropenic fever (NF) was higher with TCH, reaching 
25% incidence when administered without GCSF. However, NF did 
not occur in the 8 TCH patients who received cycle 1 GCSF. There 
was no correlation between NF and patient age. The incidence of 
left ventricular EF decline leading to cessation of trastuzumab was 
similar for both regimens (19.4% AC-TH vs. 14.6% TCH; p = 0.64). 
Trastuzumab was completed as planned in 70% of patients. Although 
EF decline was most common explanation, 13% of early trastuzumab 
discontinuations occurred for other reasons.
CONCLUSION: TCH and AC-TH are the most commonly 
administered adjuvant regimens for WI women with HER2+ BrCa. 
Amongst WI oncologists, TCH is perceived as safer, but is less 
likely to be recommended for node-positive BrCa. This retrospective 
analysis suggests that acute myelosuppression is greater for TCH, 
with a significant rate of NF. Per ASCO guidelines, these data suggest 
GCSF should be used routinely with TCH due to high rate of FN. 
We were intrigued that oncologists who have been in practice longer 
are more likely to choose TCH. The reasons for this are unclear, but 
are perhaps related to prior experience with long-term cardiotoxicity 
with AC-TH.
P5-18-13
Adjuvant Chemotherapy with Vinorelbine+5FU or Capecitabine 
in Poor Responders to Neoadjuvant EC- Docetaxel Chemotherapy 
(NAC) for Locally Advanced Breast Cancers.
Giacchetti S, Hajage D, Pierga J-Y, Delaloge S, Brain E, Tembo O, 
Sigal B, Mathieu M-C, Bertheau P, Guinebretiere J-M, Asselain B, 
Marty M. Hôpital Saint Louis, Paris, France; Institut Curie, Paris, 
France; Institut Gustave Roussy, Villejuif, France
Background: Post-operative chemotherapy in poor responders after 
NAC is questionable. We evaluated the use of adjuvant Vinorelbin 
(NVB) + continuous infusion 5FU or Capecitabine (Cap) in women 
with poor pathological response to preoperative sequential Epirubicin 
Cyclophosphamide- Docetaxel.(ECT)
Materials and methods: From May 2004 till October 2007, 340 
patients (pts) with stage II or III breast adenocarcinoma received 
neoadjuvant ECT +/- Traztuzumab (HER2+), +/- Celecoxib (HER2 
negative) in a randomized phase II trial (Pierga, 2010). 53 patients 
(15.5 %) had pathological complete response (no infiltrative or in 
situ carcinoma in the breast and lymph nodes). Eleven pts were 
not operated. 276 pts had grade 3-4 Chevallier residual disease. 
These poor responders could be optionally offered post surgery 
chemotherapy (NVB+5-FU or Cap)+/- Traztuzumab.This regimen 
started concomitantly with post-operative RT. All positive hormonal 
receptors received hormonotherapy. We attempted to evaluate DFS 
according to post operative CT in the 276 pts. To take into account 
the differences between populations, treated and untreated patients 
were matched (1:1) according to variables with a significant difference 
between the two groups, analyses were adjusted with all other 
prognostic factors.
Results: Out of 276 pts with 3-4 chevallier’s grade after NAC, 198 
pts did not receive any CT (group A), 78 received adjuvant CT (group 
B): NVB + 5-FU (FUN: N=41) or Cap (N=17) + Traztuzumab (21pts, 
11 FUN and 10 CapNVB), 28 pts HER2+ in the group A receive 
Traztuzumab alone after surgery. The main characteristics of these 
patients differed for the initial lymph nodes status (N0: 15 (19 %) 
in group A vs 88 (44 %) in group B, p = <0.0001 and the number of 
positive lymph nodes after surgery (mean: 4.39 vs 1.95, p = 0.0004 
respectively in groups A and B).
With a median follow up of 38.9 months, 63/276 pts (22.8 %) recurred, 
44 (22 %) in the group A and 19 (24.3 %) in the group B. DFS for 
the 276 pts is 95% at 12 months (m) and 86% at 24 m, 95% and 87% 
in group A and 96% and 83% in group B . (logrank test : p= 0.63).
We matched the 2 groups (124 pts; 62 /group) according to initial 
lymph nodes status, local response (Chevallier grade 3 or 4) and pN 
status after NAC. Characteristics of this matched population were 
similar except for more ER negative in chemo group, 19 pts (30.6 %) 
and 9 pts (14.5 %) in non chemo arm. In this population, 27 events 
occurred, with 13 in the chemo group and 14 in the non chemo’one. 
Treatment effect was non significant in univariate analysis (p = 0.93). 
In multivariate analysis adjusted for initial tumor size (TNM), age, 
molecular status (hormonal receptor and HER2 status), histological 
grade, initial lymph node status, histological response after NAC, 
treatment effect was non significant (Hazard Ratio = 1 IC95% [0.38 ; 
2.67], p = 0.99). There was no difference in treatment effect according 
to molecular status (test for interaction p = 0.30).This multivariate 
analysis was also completed in the 276 pts with similar results.
Conclusion: In poor responders patients after Anthracyclins-
Taxanes NAC, adjuvant chemotherapy with Vinorelbine- 5-FU or 
Capecitabine- did not appear to prolong DFS.
P5-19-01
Final Results of a Three-Arm Randomised Phase II Study of 
Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and 
Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in 
Patients with Metastatic Breast Cancer Previously Treated with 
Anthracyclines.
Campone M, Dobrovolskaya N, Tjulandin S, Chen S-C, Fourie S, 
Mefti F, Konstantinova M, Lefresne F, Meheust N, Jassem J. Institut de 
Cancérologie de l’Ouest/René Gauducheau, Saint Herblain, Nantes 
Cedex, France; Russian Research Center of Roentgenoradiology, 
Moscow, Russian Federation; Russian Oncological Research Center, 
Moscow, Russian Federation; Chang Gung Memorial Hospital, 
Taipei, Taiwan; Wilmed Park Oncology, Klerksdorp, South Africa; 
Centre René Huguenin, Saint-Cloud, France; Moscow Regional 
Oncology Dispensary, Moscow, Russian Federation; Institut de 
Recherche Pierre Fabre, Boulogne, France; Medical University of 
Gdansk, Gdansk, Poland
Purpose: Owing to the increasing number of patients treated with 
anthracycline-based adjuvant chemotherapy, there is a need for new 
effective and tolerable non-anthracycline based regimens in metastatic 
breast cancer.
Patients and methods: Patients with HER2-negative metastatic breast 
cancer previously treated with anthracyclines in (neo) adjuvant setting 
were randomised to fully oral 3-weekly cycles of the combination 
of oral vinorelbine with capecitabine (V+C), to the same drugs 
alternating every 3 cycles (V⇔C), or to the combination of docetaxel 
and capecitabine (D+C). V was given at 80 mg/m2 (after the first 
cycle at 60 mg/m2) on days 1 and 8 in the V+C arm and weekly in 
the V⇔C arm, C at 1,000 mg/m2 bid from days 1 to 14, and D on 
day 1 at 75 mg/m2. The primary endpoint was disease control rate 
(CR+PR+NC ≥ 3 months). 
Results: A total of 139 patients were randomly assigned to V+C 
(44 patients), V⇔C (47 patients) and D+C (48 patients). After an 
independent review, the disease control rate in the intent-to-treat 
population in the V+C, V⇔ and D+C arms [95% CI] was 70.5% 
[54.8-83.2], 37.0% [23.2-52.5] and 70.8% [55.9-83.1]. The response 
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rate was 31.8% [18.6-47.6], 8.7% [2.4-20.8] and 35.4% [22.2-50.5], 
respectively. The median duration of progression-free survival in 
the V+C, V⇔C and D+C arms [95% CI] was 7.2 months [5.3-8.9], 
3.4 months [2.6-5.6] and 8.9 months [7.2-12.0]; the median overall 
survival [95% CI] was 22.2 [18.8; 29.9], 19.4 [12.5; 35.4] and 24.2 
[14.2; 38.5] months, respectively. Lower efficacy observed in the 
sequential arm could be due to higher prevalence of patients with 
visceral disease in this arm (91.3% in comparison to 65.9% in V+C 
and 64.6% in D+C arm). Combinations of V+C or D+C showed 
similar efficacy and a different toxicity profile; V+C induced less 
neutropenia, infection, hand-foot syndrome, fatigue/asthenia and 
alopecia, whereas D+C- less gastrointestinal toxicity.
Conclusions: V+C combination constitutes a valuable fully oral 
alternative option to D+C in patients with metastatic breast cancer 
previously treated with anthracyclines in (neo)adjuvant setting, while 
offering the advantages of an all-oral treatment.
P5-19-02
Comparison of the Incidence of Peripheral Neuropathy with 
Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer 
Patients: A Randomized Phase II Study.
Vahdat L, Gopalakrishna P, Garcia AA, Vogel C, Pellegrino C, 
Lindquist D, Iannotti N. Weill Cornell Medical College, New York, 
NY; Eisai, Inc., Woodcliff Lake, NJ; University of Southern California 
Keck School of Medicine, Los Angeles, CA; Sylvester Comprehensive 
Cancer Center, University of Miami, Miller School of Medicine, 
Deerfield Beach, FL; Montefiore Medical Center, New York, NY; 
US Oncology, Sedona, AZ; Hematology-Oncology Associates of the 
Treasure Coast, Port Saint Lucie, FL 
Background: Peripheral neuropathy (PN) is a common toxicity 
and treatment limiting factor in heavily pretreated patients (pts) 
with metastatic breast cancer (MBC). Consequently, tolerability is 
important when choosing treatment. Eribulin mesylate has recently 
been approved in the US for patients with MBC who have previously 
received at least two chemotherapeutic regimens for metastatic disease 
including an anthracycline and a taxane. Eribulin was associated with 
a 34.6% incidence of PN (7.8% grade 3; 0.4% grade 4), however, over 
half of pts experiencing grade 3/4 PN continued eribulin. Ixabepilone 
(IXA) is frequently used in late-line MBC pts and registration studies 
reported an overall PN incidence of 63% (14-21% grade 3/4). We 
sought to define incidence of PN of eribulin and IXA in a late-line 
setting since indirect comparisons suggest eribulin may have a more 
favorable neurotoxicity profile compared with IXA.
Methods: This randomized, two-arm, multicenter, open-label, phase 
II study stratified pts by pre-existing neuropathy (grade 0 or 1) and 
number of prior chemotherapy (CT) regimens (≤3 or >3). 104 pts 
with locally recurrent or MBC, who had received at least one prior 
cytotoxic CT, including a taxane for MBC were randomized to receive 
eribulin mesylate (n=52; 1.4 mg/m2 2- to 5-min IV on Days 1 and 8 
of a 21-day cycle) or IXA (n=52; 40 mg/m2 as a 3 h IV infusion on 
Day 1 of a 21-day cycle). The primary objective was to compare the 
incidence of neuropathic adverse events. Secondary objectives were: 
1) to compare the severity of neuropathy using CTCAE grading, a 
patient-reported neurotoxicity questionnaire (SRNQ), and vibration 
sensitivity (VS); 2) to evaluate efficacy as measured by objective 
response rate (ORR), clinical benefit rate (CBR), disease control rate 
(DCR), and progression-free survival (PFS); and 3) to evaluate safety.
Results: Of 51 eribulin and 50 IXA pts who received treatment, 
eribulin-treated pts experienced a trend towards less PN and 
treatment-emergent neuropathy (TEN) than IXA-treated pts (31.4% 
vs 44.0%, p=0.1632; and 33.3% vs 48.0%, p=0.1284, respectively). 
The incidence of grade ≥3 neuropathy was 9.8% and 22% for eribulin 
and IXA, respectively. Time to onset of severe neuropathy was earlier 
for IXA relative to eribulin (4.8 vs 9.9 weeks, respectively); by cycle 
4, 44% of subjects receiving IXA experienced TEN compared with 
24% on eribulin. SRNQ and VS results will be analyzed separately. 
Treatment-emergent adverse events (TEAEs) and serious TEAEs 
were comparable (98% and 96%; 37% and 34% in eribulin- and 
IXA-treated subjects, respectively). Eribulin-treated pts experienced 
less discontinuation of treatment due to neuropathy (3.9% vs 18%) or 
TEAEs in general (11.8% vs 32.0%) relative to IXA pts. The efficacy 
data for eribulin vs IXA was 15.4% vs 5.8% for ORR, 26.9% vs 
19.2% for CBR, 67.3% vs 55.8% for DCR, and 104 days vs 95 days 
for median PFS, respectively.
Conclusions: Although the difference in overall incidence of PN 
and TEN was not significant for eribulin vs IXA, eribulin tended 
to show less PN and TEN. Eribulin also had less severe and longer 
time to development of grade 3/4 PN and fewer discontinuations 
due to toxicity.
Support: Eisai Inc.
P5-19-03
Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-
Line Treatment of Metastatic Breast Cancer (MBC): Overall 
Survival and Safety Analysis of a Randomized Phase II Trial.
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas 
GM, Clawson A, Bhar P. Northwestern University, Chicago, IL; 
Leningrad Regional Oncology Center, Russian Federation; Yaroslavl 
Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation; 
City Oncology Hospital, Moscow, Russian Federation; St. Petersburg 
Oncology Center, St. Petersburg, Russian Federation; Celgene 
Corporation, Summit, NJ
Background: We previously reported the results of a phase II study 
evaluating the efficacy and safety of 3 different dosing regimens of ab-
pac and docetaxel for the first-line treatment (Tx) of MBC (Gradishar 
et al. J Clin Oncol. 2009;27:3611-3619). Here, we report final overall 
survival (OS) and an analysis of safety and associated dose reductions 
(DRs). Methods: Patients (pts; N = 300) with previously untreated 
MBC were randomized to 1 of 4 Tx arms (table). A step-down 
statistical approach was used for pairwise comparisons of Tx arms. 
The trial was powered for antitumor activity and safety. Results: Tx 
arm C produced the longest OS (33.8 months) with an 11.6-month 
longer median OS vs arm B (HR 0.575; P = .008) and a 7.2-month 
longer median OS vs arm D (HR 0.688; P not statistically significant). 
OS data were consistent with previously reported investigator 
assessment of overall response rates and progression-free survival. 
Grade (gr) 4 neutropenia (np) was significantly less frequent in the 
ab-pac arms vs. the docetaxel arm (5-9% vs. 75%; P < .001). Febrile 
np occurred in 1% of each ab-pac arm vs 8% in the docetaxel arm. 
Rates of gr 3 sensory neuropathy (SN) were 21%, 9%, 22% and 12%, 
respectively, in arms A-D (P = .083). No gr 4 SN occurred. Median 
time to improvement to ≤ gr 2 SN was 20-22 days in the ab-pac arms 
vs 41 days in the docetaxel arm. Gr 3 fatigue occurred in 5, 0, 4, and 
19% of pts in arms A-D, respectively. In arm C, best response was 
observed at cycle 2, whereas DRs due to toxicity occurred later, at 
cycle 4 (table). The percentage of pts dose reduced due to ≥ 1 Tx-
related toxicity were 18%, 17%, 47%, and 28% in arms A-D. The 
median cycles at which DRs occurred were 7, 5, 4, and 3, respectively. 
Np and SN were the most common toxicities leading to DRs.
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AB-Pac 300 
mg/m2 q3w 
(n=76) A
AB-Pac 100 
mg/m2 qw 3/4 
(n=76) B
AB-Pac 150 
mg/m2 qw 3/4 
(n=74) C
Docetaxel 100 
mg/m2 q3w 
(n=74) D
Overall P HR
ORRa, n % 35 (46) 48 (63) 55 (74) 29 (39) < 0.001 -
Cycle of best responsea, 
median 4 (3,21) 2 (2,8) 2 (2,15) 5 (2,18) <0.001
b -
PFS in monthsc, median 10.9 7.5 14.6 7.8
0.008; C vs B: 
.001; C vs D: 
.012
-
OS in months, median 27.7 22.2 33.8 26.6 Overall: 0.047; 
C vs Bd: .008
C vs D: 
.688 C vs 
B: .575
Cycle of DR, median 7 (2,13) 5 (2,13) 4 (1,19) 3 (2,13) - -
Patients with > 1 
toxicity leading to DRe, 
n (%)
14 (18) 13 (17) 35 (47) 21 (28) - -
Np, n (%) 2 (3) 8 (11) 20 (27) 8 (11) - -
SN, n (%) 9 (12) 4 (5) 11 (15) 1 (1) - -
Febrile Np, n (%) 0 1 (1) 1 (1) 6 (8) - -
Other, n(%) 4 (5) 1 (1) 5 (7) 7 (9) - -
q3w, every 3 weeks; qw 3/4, first 3 out of 4 weeks. aInvestigator assessment of overall response rate (complete 
response + partial response) bBased on Kruskal-Wallis test cInvestigator assessed dBy log-rank test eThe most 
common toxicities that led to DR are listed.
Conclusion: Ab-Pac 150 mg/m2 qw3/4 resulted in a 33.8-month OS, 
a longer OS than historically achieved with taxane monotherapy in 
MBC. Within the 150 mg/m2 ab-pac arm, best response occurred at 
cycle 2, whereas DRs due to toxicities occurred at later cycles. These 
data indicate that dosing ab-pac at 150 mg/m2 on a qw3/4 schedule 
may allow pts to achieve a clinical response before emergence of 
dose-limiting adverse events.
P5-19-04
Results of a Randomized Phase II Study Demonstrate Benefit of 
Platinum-Based Regimen in the First-Line Treatment of Triple 
Negative Breast Cancer (TNBC).
Fan Y, Xu BH, Yuan P, Wang JY, Ma F, Ding XY, Zhang P, Li Q, Cai RG. 
Cancer Institute & Hospital, Chinese Academy of Medical Sciences 
& Peking Union Medical College, Beijing, China
Background: It is supposed that triple negative breast cancer (TNBC) 
may be more sensitive to DNA damage agents such as platinum. This 
study was designed to compare platinum-based regimen (docetaxel 
plus cisplatin) with non-platinum-based regimen (docetaxel plus 
capecitabine) in the first-line treatment of advanced triple negative 
breast cancer patients.
Patients and Methods: This was a single-institution, randomized 
phase II clinical trial. Eligible TNBC women with first relapse or 
metastasis who had measurable disease were randomized (1:1) to 
receive either TP regimen (docetaxel 75mg/m2 plus cisplatin 75mg/
m2 intravenous infusion day 1) or TX regimen (docetaxel 75mg/m2 
intravenous infusion day 1 plus capecitabine 1000mg/m2 bid, two 
weeks on, one week off) every 3 weeks for up to 6 cycles, until disease 
progression, unacceptable toxicity or patient consent withdrawal. The 
primary endpoint was objective response rate (ORR) and secondary 
endpoints included progression free survival (PFS), overall survival 
(OS) and safety profile. To detect a difference of 0.35 in response rate 
between groups with a power of 80% and 2-sided significance level 
at 0.05, there should be at least 26 patients in each group. As of Jun 
1st, 2011, 53 patients had been randomized and evaluated.
Results: After a median follow-up of 24 months, the results showed 
much higher response rate in TP group than TX group although the 
clinical benefit rate was not significantly different. PFS was more 
than doubled in TP group compared with TX group. Overall survival 
was also statistically improved. G3/4 vomiting was merely observed 
in 3 patients from TP group. On the contrary, only patients in TX 
group (5/26) reported G2/3 Hand-Foot Syndrome. No differences 
were found in hematological and other non-hematological toxicities.
 TP arm TX arm Hazard Ratio  
 (n=27) (n=26) (95%CI) P value
ORR(%) 59.3 15.4  0.001
CBR(%) 77.8 61.5  0.135
Median PFS, months 10.9 4.8 0.29(0.14-0.57) <0.001
Median OS, months 32.8 21.5 0.41(0.18-0.92) 0.027
Conclusions: Although it is a small sample size phase II study, it 
strongly suggested that cisplatin-contained TP regimen improved 
patient outcome, as measured by ORR, CBR, PFS and OS, compared 
with non-cisplatin-based TX regimen in the first-line treatment of 
advanced TNBC patients. This is the first prospective study to show 
superiority of cisplatin over capecitabine in TNBC. Together with 
additional ongoing clinical trials comparing platinum with other 
chemotherapeutic agents in various settings, the role of platinum in 
TNBC can be further elucidated.
P5-19-05
Age-Related Changes in the Pharmacokinetics (pK), Response, 
and Toxicity of Weekly nab-Paclitaxel in Patients with Metastatic 
Breast Cancer (MBC).
Hurria A, Synold T, Blanchard S, Wong C, Mortimer J, Luu T, Chung 
C, Ramani R, Katheria V, Hansen K, Jayani R, Brown J, Williams B, 
Rotter A, Somlo G. City of Hope, Duarte, CA
Background: Although cancer is a disease of aging, few studies 
have evaluated the association between patient age and the pK or 
pharmacodynamics (pD) of cancer therapeutics. The goals of this 
study were 1) to evaluate the age-related changes in the pK and pD 
of weekly nab-paclitaxel in patients with MBC; 2) to determine 
response rate; and 3) to explore the relationship of age with pK and pD 
parameters (i.e., dose reductions, dose delays and grade > 3 toxicities).
Patients and Methods: Forty patients with MBC, receiving 1st or 2nd 
line chemotherapy, entered an IRB approved protocol to evaluate the 
age-related changes in the pK of weekly nab-paclitaxel administered 
at 100 mg/m2 IV for 3 weeks followed by a 1-week break. Patients 
were accrued from 4 age strata <50, 50-60, 60-70, and >70 years of 
age. Blood samples were collected for pK analysis with the first dose 
of nab-paclitaxel. Response was assessed every 2 cycles. Toxicity 
was graded using the NCI Common Toxicity Criteria for Adverse 
Events (v 3.0) and was adjudicated as attributable to nab-paclitaxel 
if it was possibly, probably, or definitely related. Linear regression 
analysis was used to examine the strength of the relationship between 
patient age and natural logarithm of 24 hour area under the curve 
(AUC). Two-sided two-sample t-tests were used to assess if there 
was a difference in mean age based on the presence of pD variables 
(i.e., dose reductions, dose delays and grade > 3 toxicities). The 
significance level was set to 0.05.
Results: Of the 40 patients who entered the study, 39 (98%) were 
evaluable with a mean age of 60 (SD=13.4; min=30; max=81). 
Patients were accrued in the following age cohorts: <50 (n= 10; 26%), 
50-60 (n= 5; 13%), 60-70 (n= 15; 38%), and >70 (n= 9; 23%) years 
of age. The median number of courses completed was 4 (min=1, 
max=21). The response rate was: 0% (n=0) CR, 31% (n=12) PR, 
38% (n=15) SD. Grade 3 toxicity was experienced by 26% (n=10). 
We observed 8% (n=3) grade 3 hematological toxicities [neutrophils 
(n=1; 3%), leukocytes (n=2; 5%)] and 18% (n=7) grade 3 non-
hematological toxicities [nausea and hypophosphatemia (n=1; 3%), 
diarrhea and infection without neutropenia (n=1; 3%), fatigue (n=2; 
5%), hyponatremia (n=1; 3%), and infections without neutropenia 
(n=2; 5%)]. There were no cases of grade 4 or 5 toxicity. Grade 2 
sensory neuropathy was experienced by 8% (n=3; no cases in the 
70+ age cohort). Dose reductions or course delays were experienced 
by 62% (n=24) and 21% (n=8), respectively. There was a borderline 
significant positive association between age and natural logarithm of 
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total nab-paclitaxel 24 hour AUC (coef=.01; se=.006; p=0.055; n=36). 
There were no differences in the mean ages based on the presence of 
grade 3 or higher toxicity (p =0.75), need for dose reductions (p=0.48), 
or need for dose delays (p=0.61).
Discussion: There is a borderline statistically significant relationship 
between age and 24 hour AUC but no differences in mean age based 
on pD variables (i.e., dose reductions, dose delays and grade > 3 
toxicities) were identified. The treatment is well-tolerated across all 
age groups.
P5-19-06
Highly Effective of Gemcitabine and Cisplatin (GP) as First-Line 
Combination Therapy in Patients with Triple-Negative Metastatic 
Breast Cancer: Final Report of a Phase II Trial.
Wang Z, Hu X, Wang B, Wang L, Zhang J, Wang H, Liu G, Hu Z, Wu 
J, Shao Z. Cancer Hospital of Fudan University, Shanghai Medical 
College, Shanghai, China
Background: Triple-negative breast cancer (TNBC) contributes to 
poor prognosis and there is no established standard chemotherapy this 
subtype of patients. It has been postulated that related cancers would 
confer sensitivity to certain cytotoxic agents like cisplatin. Cisplatin 
and gemcitabine have single-agent activity in metastatic breast cancer 
and preclinical data support synergy of the combination. The objective 
of this study was to evaluate doublet with gemcitabine/Cisplatin (GP) 
as first-line therapy in patients with metastatic TNBC.
Material and Methods: This is a prospective single-institutional, 
open-label, phase II trial. The primary endpoint was progression free 
survival (PFS). Eligible subjects were aging from 18 to 75 years old, 
with no prior chemotherpay for MBC, with tumors negative for ER, 
PR or HER2, with at least one measurable disease according to the 
RECIST criteria, with ECOG PS of 0-1, and with adequate organ 
function. All patients received 21-day cycles of gemcitabine 1,000mg/
m2 on days 1 and 8 and cisplatin 25 mg/m2 on days 1 through 3. 
Treatment was continued until disease progression or unacceptable 
toxicity or up to 8 cycles. (ClinicalTrials.gov number, NCT00601159)
Results: A median age was 49 years (range: 29-74 years). 58 
patients had received neo/adjuvant chemotherapy (53 patients with 
anthracycline and/or taxane). The median number of treatment cycles 
was six (range: 2-8 cycles). In 64 assessable patients, we observed 10 
complete response (CR; 15.6%), 30 partial responses (PR; 46.9%), 
17 patients (26.6%) with stable disease (SD), and 7 patients (10.9%) 
with progressive disease, for an overall response rate of 62.5% (95% 
CI, 50.3% to 74.7%).. The median PFS was 7.7 months (95% CI, 
6.0 to 9.4). With a median follow-up time of 28 months, the median 
overall survival was 19.1 months (95% CI, 12.5 to 25.7). Grade 3 or 4 
toxicities were neutropenia 42.2%, thrombocytopenia 29.7%, anemia 
18.8%, nausea/vomiting 15.6%, fatigue 14.1%, constipation 3%, 
sensory neuropathy 1.6%, 2 patients developed febrile neutropenia. 
The chemotherapy doses were reduced in 13.3% (6 pts) because of 
toxicity. There were no treatment-related deaths.
Conclusion: Significant activity and favorable toxicity profile of GP 
regimen as first-line chemotherapy in patients with metastatic TNBC. 
It provided a basis for considering GP for further evaluation in phase 
III trials for women with metastatic TNBC in China. (ClinicalTrials.
gov number, NCT01287624)
P5-19-07
The Effects of ABCC2 and SLCO1B3 Single Nucleotide 
Polymorphisms on Docetaxel-Induced Leukopenia in Breast 
Cancer Patients.
Chen J, Wu LJ, Shen P, Yu LF, Huang S. The First Affiliated 
Hospital,College of Medicine, Zhejiang University, Hangzhou, 
Zhejiang, China
Purpose Docetaxel-based combination treatment has known to be 
effective for breast cancer. Genotyping of ABCC2 and SLCO1B3 
were demonstrated determining the risk of docetaxel-induced 
leucopenia in other ethnic . We designed this phase II trial to evaluate 
single nucleotide polymorphisms (SNPs) of the two genes association 
with docetaxel haematological toxicity in chemonaive breast cancer 
patients of chinese population.
Patients and Methods We selected 45 breast cancer patients who 
received docetaxel combination chemotherapy, Genomic DNA 
was isolated from peripheral blood and detected polymorphisms in 
ABCC2 and SLCO1B3.
Results All patients were evaluated for toxicity. 28 patients 
developed with grade 3 or 4 leukopenia, and 17 with grade 1 or 2 
in nadir leukocyte from cycle 1 baseline. The combined analysis 
indicated a significant association of 9383C/G in ABCC2 (P = 0.002) 
and 5676A/G in SLCO1B3 (P = 0.005) with docetaxel induced 
leukopenia.Patients homozygous for the variant allele (GG) of 
SLCO1B3 5676A/G had significantly higher leukopenia compared 
to patients with AA/AG genotypes(P <0.05). Similar trend was 
observed for ABCC2 (9383C/G) with heterozygotes (CG) having 
the highest percentage decrease compared to those with CC/GG 
genotypes(P = 0.06).
Conclusion The study indicating that SNPs in ABCC2 and SLCO1B3 
may predict the risk of leukopenia induced by docetaxel chemotherapy 
in china breast cancer patients.
P5-19-08
Pooled Analysis of Individual Patient Data from Capecitabine 
Monotherapy Clinical Trials in Anthracycline-/Taxane-Pretreated 
Locally Advanced or Metastatic Breast Cancer (LA/MBC).
Blum JL, Barrios CH, Feldman N, Verma S, McKenna E, Lee S, Scotto 
N, Gralow J. Baylor Sammons Cancer Center, Texas Oncology, US 
Oncology, Dallas, TX; PUCRS School of Medicine, Porto Alegre, 
Brazil; Olive View-UCLA Medical Center, Sylmar, CA; Sunnybrook 
Oddette Cancer Centre, University of Toronto, Toronto, ON, Canada; 
Hoffmann-La Roche Inc., San Francisco, CA; F. Hoffmann-La Roche 
Ltd, Basel, Switzerland; University of Washington, Seattle, WA
Background: Capecitabine (C) has shown efficacy as monotherapy 
in anthracycline (A)-/taxane (T)-pretreated LA/MBC in phase II/
III trials. Since its approval, the treatment landscape in MBC has 
evolved, and C has served as the combination partner and/or active 
comparator in trials of novel agents in pretreated MBC. This pooled 
analysis of clinical trial data, spanning a 12-yr period, assessed the 
efficacy and safety of C across treatment lines and the impact of 
disease characteristics on clinical outcomes with C.
Methods: Individual patient (pt) data were pooled from 7 clinical 
trials conducted by Roche/GNE from Feb 1996–Jun 2008 where C 
monotherapy was the test/control regimen for pts with LA/MBC 
with/without prior A/T therapy. Analyses were performed on an ITT 
basis. Univariate and multivariate regression analyses assessed the 
impact of pt/disease characteristics and prior therapy on outcomes.
Results: Data from 805 pts enrolled to intermittent C monotherapy 
were analyzed: 268 in the 1st-line metastatic setting; 537 in the 
≥2nd-line metastatic setting (table).
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 AV02119 AV03694* AV03693* SO14697 SO14799 SO15179 NO15542
Therapy line ≥2nd 1st 2nd ≥2nd 1st 2nd ≥2nd
Regimen C vs  
C+Bev
CTx (A, T or C) 
+ placebo vs CTx 
(A, T or C) + Bev
CTx (T, C or 
G) + placebo vs 
CTx (T, C or G) 
+ Bev
C
C vs  
CMF
C (two  
doses)  
vs P
C
Pts enrolled 
to C 
monotherapy, 
n
230 206 47 163 62 22† 75
Pts treated 
with C 
monotherapy, 
n
215 201 46 162 61 22† 74
C daily dose, 
mg/m²
2,500 2,000 2,000 2,510 2,510 2,510 2,510
*C cohort only; no data on CTx-related AEs collected, lower C starting dose used; †Only pts in the C 
2,510mg/m² arm. CTx = chemotherapy; Bev = bevacizumab; G = gemcitabine; P = paclitaxel
Median age: 55 yrs (range 23–90). Most pts were Caucasian (81%) 
with ECOG PS of 0 (55%). Baseline demographics were balanced 
across treatment lines. Data on A/T treatment history were available 
for 719 pts; 557 pts received prior A/T therapy, 176 were A-refractory, 
234 T-refractory and 154 A- and T-refractory. Pooled overall response 
rate (ORR) was 21.0% (1.7% complete; 19.3% partial). ORR was 
25.0% and 19.0% for pts treated in the 1st- and ≥2nd-line settings 
(OR 0.70, 95% CI: 0.5–1.0; p=0.0486). Median PFS was 126.9 days 
(95% CI: 119–132) in the pooled analysis, and significantly longer 
in pts receiving 1st- vs ≥2nd-line C: 150.0 vs 112.0 days (HR 1.45, 
95% CI: 1.23–1.71; p<0.0001). Pooled median OS was 482.1 days 
(95% CI: 438–516). Significantly longer median OS was seen in pts 
receiving 1st- vs ≥2nd-line C: 666.0 vs 396.0 days (HR 1.98, 95% CI: 
1.62–2.41; p<0.0001). 62 pts (8%) withdrew due to C-related AEs, 
which were severe in 4% of pts and life threatening in 2%. AEs of 
special interest occurred in 489 pts (63%); these were severe in 24% 
of pts and life threatening in 2%. Gastrointestinal disorders were 
most frequent (417 pts [53%]), and were severe or life threatening 
in 13% and 1% of pts.
Conclusions: This pooled analysis of pt data (n=805) revealed 
significantly longer ORR/survival in pts receiving 1st- vs ≥2nd-line 
C for A-/T-pretreated MBC. Univariate and multivariate analyses 
are ongoing; results will be presented. Safety data were in-line with 
findings from phase III trials of C in MBC.
P5-19-09
Phase II Trial of Ixabepilone Plus Carboplatin in Patients with 
Metastatic Breast Cancer: The ECLIPSE Study.
Osborne C, Challagalla JD, Fanning SR, Eisenbeis CF, Holmes 
FA, Monaghan GG, Neubauer MA, Rabe AC, Raja V, Robbins 
GJ, Taboada C, Vukelja SJ, Wilks ST, Wang Y, Brown J-A, Asmar 
L, O’Shaughnessy J. US Oncology, The Woodlands, TX; Baylor-
Sammons Cancer Center, Dallas, TX; Texas Oncology, Witchita Falls, 
KS; Cancer Centers of The Carolinas, Greenville, SC; Cancer Centers 
of North Carolina, Raleigh, NC; Texas Oncology-Houston Memorial 
City, Houston, TX; Kansas City Cancer Center, Kansas City, MO; 
Kansas City Cancer Center-Southwest, Overland Park, KS; Kansas 
City Cancer Center, Kansas City, KS; Florida Cancer Institute-New 
Hope, New Port Richey, FL; Texas Oncology-Methodist Charlton 
Cancer Center, Dallas, TX; Texas Oncology-Tyler, Tyler, TX; Cancer 
Centers of South Texas, San Antonio, TX
Introduction: Ixabepilone adds to the antitumor effectiveness of 
capecitabine in both ER+ and triple negative (TN) breast cancer. 
Ixabepilone has antitumor activity in taxane-refractory patients, and 
novel combinations are needed in this poor prognosis population. 
Carboplatin combined with gemcitabine or paclitaxel has activity in 
metastatic breast cancer; there is also demonstrated activity of the 
gemcitabine/carboplatin combination in the ER+ versus TN subsets. 
A Phase I study of ixabepilone + carboplatin in solid tumor patients 
demonstrated the safety of this combination.1 We conducted a Phase 
II trial of ixabepilone + carboplatin at the doses and schedule used 
in the Phase I trial to determine its effectiveness in hormone receptor 
positive (HR+) and TN patients.
Methods: This was a Phase II, open label, nonrandomized parallel, 
noncomparative study of 2 groups. Patients could have received up 
to 2 lines of treatment for metastatic disease. All patients received 
ixabepilone 20 mg/m2 on Days 1 and 8 and carboplatin AUC=2.5 on 
Days 1 and 8 of each 21-day cycle. Patients were stratified as either 
(HR+) (n=50) or (TN) ER-/PR-/HER2- (n=53). Patients received 
drug until PD or intolerable toxicity. Patients continued treatment for 
as long as they responded (CR, PR, or SD). The primary objective 
was to evaluate objective response rate (ORR). Secondary objectives 
included evaluation of clinical benefit rate (CBR) defined as ORR 
(CR+PR)+SD≥6 months, progression-free survival (PFS), overall 
survival (OS), duration of responses, and toxicity.
Results: Based on preliminary data, 96 patients (55 [57.3%] HR+ 
and 40 [41.7%] TN) received study treatment, with 1 patient found 
ineligible. Median age was 55.2 years; all were females; baseline 
PS of 0/1/2 was 50/44/2; stage at diagnosis I/II/III/IV/unknown was 
12/38/23/21/2, respectively. PR was 26.3% overall. There were no 
CRs. CBR overall was 41.1% (39), 52.7% (29) for HR+ patients, 
and 25.6% (10) for TN patients. Median PFS was 7.6 months, and 
median OS was 12.7 months. The median time to response and 
duration of response in patients achieving a PR was 1.7 and 6.5 
months, respectively. Grade 3/4 hematological toxicities included 
49% neutropenia, 10.4% anemia, and 4.2% thrombocytopenia. The 
most common grade 3/4 non-hematologic toxicities included fatigue 
(8.3%), nausea (6.3%), neuropathy (6.3%), vomiting (5.2%), and 
dehydration (5.2%). Of 32 deaths during the study, one was due to 
neutropenic sepsis, and 25 were due to PD.
Conclusion: The combination of ixabepilone plus carboplatin 
was a tolerable and active regimen for both HR+ and TN breast 
cancer. In general, it had expected hematologic and manageable 
non-hematological toxicities. Further follow-up of the remaining 12 
patients still on treatment is ongoing.
1. Plummer R, et al. Clin Cancer Res. 2008 Dec 15;14(24):8288-8294.
P5-19-10
Correlation of Response of Weekly Paclitaxel and Paraplatin as 
First Line Treatment of Metastatic Breast Cancer with p53 Status.
El-Sadda W, Magdy M, Abdel-Halim I, Abdel-Wahab A. Mansoura 
University Hospital, Mansoura, Egypt
Background
Paclitaxel is one of the most active drugs in metastatic breast cancer. 
Weekly paclitaxel seems less toxic & more efficient compared with 
paclitaxel every 3 weeks (possibly because of the proapoptotic 
and antiangiogenic activity), the dose intensity is quiet higher with 
tolerable toxicity. The sensitivity of tumors overexpressing p53 to 
paclitaxel is a matter of debate.
The purpose of study is to evaluate weekly paclitaxel and paraplatin 
in patients with metastatic breast cancer in terms of response rate, 
toxicity profile, relation of response to p53 status, progression free 
survival & overall survival.
Patients & Methods:
Between September 2006 & September 2008, 60 patients with 
measurable metastatic breast cancer after adjuvant anthracycline 
treatment, WHO PS <2, adequate renal, liver & bone marrow function. 
Patients received no prior chemotherapy for metastasis. Pathology 
specimens were evaluated for p53 status by immunohistochemistry 
(IHC). All patients received weekly paclitaxel 80 mg/m2 D1, D8, D15 
(one hour IV infusion) and paraplatin AUC 5 D1 (IV infusion over 
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half an hour) every 4 weeks for six cycles. Response was assessed 
every 2 cycles, patients showed an objective response (CR, PR or 
SD) had continued to 8 cycles.
Results: All patients were evaluable for response, toxicity & survival. 
Median age was 50 years range (42-64 years), median WHO PS 0. 
Main metastatic sites were lung 40%, liver 30%, LN 20%, Skin 12% 
& bone 50%. Forty percent of patients had one metastatic site, 40% 
had 2 metastatic sites and 20% had > 2 metastatic sites.
The total number of cycles delivered was 466 with a median of 7 
cycles / patient with no dose reduction. The overall response rate 
was 65% (CR 25%, PR 40%), SD 27% & PD 8%. Overexpression 
of p53 was found in 18 (30%) of the 60 studied patients, four of them 
showed only PR, compared to 30 patients having normal p53 status 
responded to treatment including 15 CRs. Overexpression of p53 
had a significant negative impact on response to treatment (p=0.01).
No grade 4 toxicity G2 anemia 15%, G3 neutropenia observed in 
13.3%, G2 neuropathy occurred in 15%. Median time to progression 
& median survival were 18.5 & 28 months respectively.
Conclusion:
The overall response rate achieved with weekly paclitaxel plus 
paraplatin is among the highest in metastatic breast cancer. However, 
the poor response rate seen in patients with p53 overexpression 
suggests the use of other combinations that may help to improve 
the outcome.
P5-19-11
Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with 
Metastatic Breast Cancer.
Schwartzberg L, Rubin P, Patnaik A, Itri L, Olson AL, Seidman AD. 
The West Clinic, Memphis, TN; The Moses H. Cone Regional Cancer 
Center, Greensboro, NC; START Center - South Texas Accelerated 
Research Therapeutics, San Antonio, TX; Genta Incorporated, 
Berkeley Heights, NJ; Memorial Sloan-Kettering Cancer Center, 
New York, NY
Background: Parenteral taxanes (docetaxel, paclitaxel) are among 
the most active agents in treating metastatic breast cancer (MBC). 
However, their use is limited by inherent or acquired multidrug 
resistance, hypersensitivity, and neurotoxicity. Tesetaxel is an 
advanced-generation, orally available taxane that is formulated as a 
capsule for oral administration and has a long terminal half-life in 
plasma (~180 hrs). Unlike standard taxanes, tesetaxel is not a substrate 
for P-glycoprotein (P-gp), a major cause of taxane resistance. The 
drug is highly concentrated in cells that overexpress P-gp. In taxane-
resistant breast cancer xenografts (DU4475), tesetaxel induced a 
94% reduction in tumor size, substantially exceeding the activity of 
docetaxel and paclitaxel (46% and 26%, respectively). Neurotoxicity 
was also substantially lower with tesetaxel compared with equi-
myelotoxic doses of docetaxel. Among more than 350 patients (pts), 
there have been no occurrences of hypersensitivity reactions. An initial 
phase 2 study as 2nd-line therapy for pts with MBC who progressed 
after multidrug anthracycline-containing regimens showed a 38% 
partial response (PR) rate using tesetaxel Q3 wks at a dose of 27-35 
mg/m2. We conducted a Phase 2, open-label, multicenter study of 
the efficacy and safety of tesetaxel as first-line therapy in women 
with MBC.
Methods: Eligible pts have Stage IV, HER2-negative MBC; ECOG 
PS 0-1; and adequate organ function. No prior chemotherapy is 
allowed (other than 1 regimen in the adjuvant setting). Tesetaxel 
was administered orally Q3 wks at a starting dose of 27 mg/m2 with 
escalation to 35 mg/m2 as tolerated. No premedication for potential 
hypersensitivity was used. RECIST response rate was the primary 
endpoint. A Simon min-max two-stage design was used with a target 
response rate of 30% in 25 pts.
Results: To date, 20 women have been enrolled and treated. The 
median age was 62 years (range, 45-78). Time from diagnosis was > 
4 years in 5 pts and ≤ 4 years in 6; MBC was newly diagnosed in the 
remaining 9. Hormone receptor status was triple negative in 5 pts at 
diagnosis and 10 at the time of metastasis. The most common sites of 
metastasis were lung (13 pts) and bone (9). Prior treatment included 
hormonal therapy in 13 pts, adjuvant chemotherapy in 16 (most 
commonly, ACT), and radiotherapy in 9. Of 11 pts currently evaluable 
for response, PR was achieved in 6 (55%), with confirmation of 
response in 4 and an ongoing PR in 1 of the 2 pts with an unconfirmed 
PR. SD was observed in 2 and disease progression in 3. Neutropenia 
was the most common adverse event, affecting 50% of pts; Grade 3-4 
occurrences were observed most often after escalation of the tesetaxel 
dose to 35 mg/m2. Single occurrences (Grade 1) of neuropathy and nail 
changes were reported. There were no occurrences of hypersensitivity.
Conclusions: Tesetaxel overcomes multiple disadvantages of 
standard parenteral taxanes and is highly active in 1st- and 2nd-line 
MBC. To date, overall response rates in these settings are 55% and 
38%, respectively. In view of this, we have amended the trial to expand 
the initial cohort. Potential schedule-dependency will be examined 
in a future cohort with a newly developed weekly-times-3 schedule. 
Updated results in both cohorts will be presented.
P5-19-12
Integration of Capecitabine Monotherapy with Capecitabine 
Combination Therapy in Metastatic Breast Cancer Patients: 
First Report on Safety and Efficacy of Single Agent Capecitabine 
Maintenance Study.
Xu B, Wang J, Yuan P, Ma F, Li Q, Zhang P, Fan Y, Li Q. Cancer 
Hospital Chinese Academy of Medical Sciences, Beijing, China
Background: Giving the high degree of efficacy and safety profile, 
Docetaxel/Paclitaxel in combination with Capecitabine are indicated as 
1st line standard chemotherapy for anthracycline pretreated or resistant 
metastatic breast cancer (MBC) patients. Maintenance chemotherapy 
is chemotherapy administered to patients without progression after an 
initial chemotherapy, generally as 1st line treatment. Unfortunately, no 
clinical studies has prospectively evaluated the efficacy and safety of 
capecitabine single agent maintenance in MBC. Methods: Previously 
untreated patients with metastatic breast cancer (MBC) were randomly 
assigned to receive Capecitabine 1,000 mg/m2 orally twice daily on 
day 1-14 , Vinorbine 25 mg/m2 on day 1 and 8 (NX) in 21-day cycle or 
Capecitabine 1,000 mg/m2 orally twice daily on day 1-14, Docetaxel 
75 mg/m2 on day 1 (TX), in 21-day cycle. The primary endpoint was 
to compare progression free survival (PFS), second endpoints were 
safety profiles (NCI-CTC 3.0), overall survival and response rate. 
During Initial study treatment, 21 days as one cycle and 6-8 cycles 
are required; Patients who were responding (complete or partial), or 
whose diseases were stable followed by Capecitabine: 1,000 mg/m2 
PO twice daily (day 1-14) 21 days as one cycle until progression or 
unacceptable toxicity. This was designed as a non-inferiority study. 
The efficacy analysis was based on the intent-to-treat population 
(all patients randomized and received at least one dose of test drug). 
Safety was assessed on the safety population who received at least 
one dose of study medication. Results: Ninety one women were 
enrolled in fourteen months. Fifty six patients were treated with TX 
and 35 with NX . The median PFS was 7 (NX)versus 9 months(NX)
(P=0.1888). According to RECIST criteria, similar objective response 
rates [19(54.2%) on TX versus 28(50%) on NX, P= 0.158] and similar 
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clinical benefit (CR+PR+SD) [29(82.9%) on TX versus 48(85.7%) on 
NX, P=0.216] were achieved. The main adverse events included grade 
3-4 neutropenia (40.0% versus 30.4%; P=0.115), hand-foot syndrome 
(2.8% versus 12.5%; P=0.096) , grade 2-3 gastrointestinal adverse 
events (37.2% versus 19.7%; P=0.037), myalgia and arthralgia 
(2.9% versus 5.4%; P=0.363), with NX and TX, respectively. 2.8% 
versus 12.5% were discontinued treatment for toxicity with NX and 
TX(P=0.092).. Numbers of patients transferred into maintenance 
treatment with Capecitabine were 22(70.9%) versus 36(64.3%) in 
NX and TX arm respectively. 13.6% versus 13.9%(P=0.303) of the 
patients were discontinued treatment for toxicity with NX and TX 
respectively. The main toxicity in maintenance phase was grade 2-3 
hand-foot syndrome. The median cycles of maintenance treatment 
was 4 cycles, 4 patients received Capecitabine maintenance treatment 
for more than 12 cycles. Discussion: There are few clinical study to 
compare the two regimens, especially with Capecitabine maintenance 
treatment. Our preliminary study found that NX and TX regimen have 
similar efficacy but different toxicity. Both regimen can be used as 
front-line treatment of MBC.
P5-19-13
A Randomized Phase II Trial of First-Line Metastatic Breast 
Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound 
Paclitaxel (ab-pac) Given Weekly at 150 mg/m2.
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas 
GM, Clawson A, Bhar P. Northwestern University Feinberg School 
of Medicine, Chicago, IL; Leningrad Regional Oncology Center, 
Russian Federation; Yaroslavl Regional Clinical Oncology Hospital, 
Yaroslavl, Russian Federation; City Oncology Hospital, Russian 
Federation; St. Petersburg City Oncology Center, St. Petersburg, 
Russian Federation; Celgene Corporation, Summit, NJ
Background: We previously reported the results of a phase II study 
evaluating the efficacy and safety of 3 different dosing regimens of 
ab-pac and docetaxel for the first-line treatment of MBC (Gradishar 
et al. J ClinOncol. 2009;27:3611). Here we report outcomes for a 
subset of patients (pts) during treatment with ab-pac at 150 mg/m2 
weekly for the first 3 weeks of a 4-week schedule (qw 3/4). Methods: 
Patients (N = 300) with previously untreated MBC were randomized 
to 1 of 4 treatment arms: arm A, ab-pac at 300 mg/m2 q3w; arm B, 
ab-pac at 100 mg/m2 qw 3/4; arm C, ab-pac at 150 mg/m2 qw 3/4; 
arm D, docetaxel at 100 mg/m2 q3w. A step-down statistical approach 
was used for pairwise comparisons of treatment groups. The trial was 
powered for antitumor activity and safety. Results: Treatment arm 
C produced the longest overall survival (OS) (33.8 months) with an 
11.6-month longer median OS vs arm B (22.2 months, HR 0.575; P 
= .008) and a 7.2-month longer median OS vs arm D (26.6 months, 
HR 0.688; P not statistically significant). Median OS in arm A was 
27.7 months. These OS data were consistent with previously published 
overall response rates (ORR) and progression-free survival (PFS). 
Forty-seven percent of pts in arm C required dose reduction due to 
toxicity, including 27% due to neutropenia (np), 15% due to sensory 
neuropathy (SN), 3% due to allergy/immunology, 1% due to febrile 
np, and 1% due to ulceration of the skin. The median OS for the subset 
of pts requiring DRs in arm C was comparable to pts not dose reduced: 
35.2 and 31.8, respectively. Pts who were dose reduced in arm C 
received a median of 2 additional cycles of treatment compared with 
those without DRs: 10 (range 2 – 27) vs 8 (range 1 – 27). Investigator 
assessed ORR and PFS were numerically higher in pts dose reduced 
vs those not reduced. Baseline characteristics were similar between 
pts requiring DRs vs not.
 Ab-pac 150 mg/m2 qw 3/4
 Baseline Characteristics Pts Dose Reduced n = 35 Pts Not Dose Reduced n = 39
Age, mean (years) 54 53
< 65 years, % 86 87
Postmenopausal, % 60 82
ECOG PS 0, % 40 26
ECOG PS 1, % 60 62
ECOG PS 2, % 0 13
Stage III/IV at primary diagnosis, % 60 59
Visceral metastases 74 85
 Clinical Outcome 
ORRa, % (95% CI) 80 (67-93) 69 (55-84)
PFSa in months, median 14.8 12.8
OS in months, median 35.2 31.8
Pts on secondary therapies, n (%) 31 (89) 26 (67)
 Safety 
Sensory neuropathy, n (%)b 12 (34) 4 (10)
Neutropenia, n (%) Grade 3 18 (51) 8 (24)
Neutropenia, n (%) Grade 4 1 (3) 6 (18)
qw 3/4, first 3 out of 4 weeks; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology 
Group performance status. aInvestigator assessed. bAll grade 3, no grade 4.
Conclusion: Pts in the ab-pac 150 mg/m2qw 3/4 arm who were dose 
reduced achieved a similar OS compared to patients who were not 
dose reduced. No clear trends in baseline characteristics emerged to 
predict the requirement for dose reduction in the 150 mg/m2 ab-pac 
arm. The ab-pac 150 mg/m2 qw 3/4 dosing regimen provided a survival 
advantage in this phase II trial in first-line MBC and dose reductions 
could be used to manage toxicities and prolong treatment duration 
without compromising efficacy.
P5-19-14
Platinum-Based Chemotherapy in Triple-Negative Breast Cancer.
Villarreal-Garza C, Bouganim N, Khalaf D, Clemons M, Kassam F, 
Enright K, Verma S, Myers J, Dent R. Sunnybrook Odette Cancer 
Centre, Toronto, ON, Canada; The Ottawa Hospital Cancer Centre, 
Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, 
Canada; Credit Valley Hospital, Mississauga, ON, Canada
Background: There is increasing evidence that DNA repair defects 
characteristic of BRCA1-related cancers and triple negative breast 
cancer (TNBC) confer sensitivity to certain chemotherapeutic agents, 
such as platinums. However, prospective and retrospective studies 
comparing the efficacy of these agents versus conventional treatment 
in TNBC are lacking. The aim of this study was to evaluate the 
efficacy of platinum-based chemotherapy (PBC) in metastatic TNBC 
in terms of median duration of treatment and overall-survival (OS) 
and compare it to patients treated with conventional chemotherapy.
Methods: We performed a retrospective chart review of patients with 
metastatic TNBC who received PBC from January 2007 to June 2010 
treated at the Sunnybrook Odette Cancer Center and the Ottawa 
Hospital Cancer Centre. This cohort was compared to a control group 
that included metastatic TNBC treated with conventional agents that 
included anthracyclines, taxanes, capecitabine, and vinorelbine.
Results: A total of 166 metastatic TNBC patients were analyzed: 60 
treated with PBC and 106 managed with conventional treatment. 
Median age at diagnosis was 48 years and distant disease-free interval 
was 26 months (m) for both groups. Patients on both groups had 
multiple sites of metastases at diagnosis of recurrence than a single 
site of metastasis (69% for both groups). Of the 60 patients treated 
with PBC, 90% received a combination regimen, most commonly 
weekly cisplatin plus gemcitabine in 37% of patients and cisplatin 
plus vinorelbine in 17% of patients. The median number of cycles 
delivered was 4 (1-24). 33% received the PBC as first-line treatment, 
38% as second-line, 18% as third-line, 7% as fourth line, and 3% 
as fifth-line. Only 8 patients (5%) discontinued PBC secondary to 
toxicity. The median time on treatment in first, second and third-line 
therapy was longer for the PBC group compared to the conventional 
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group (5 vs. 2 m, p=0.108; 5 vs. 2 m, p=0.01; and 4 vs. 1 m, p=0.026). 
Patients treated with PBC had a longer OS compared to those managed 
conventionally (16 vs. 10 m, p=0.039).
Conclusions:
PBC appears to improve clinical outcomes in patients with metastatic 
TNBC compared to those treated with conventional chemotherapy 
regimens. Although this is a retrospective study with its obvious 
limitations, it adds to the growing body of literature, suggesting the 
benefit of PBC in TNBC. Prospective trials are needed to confirm 
its benefit in order to integrate it as part of the routine management 
of these patients.
P5-20-01
Patient Valuation of Reduced Risk of Side Effects during 
Treatment for Metastatic Breast Cancer.
Lalla D, McLaughlin T, Brammer M, Bramley T, Bare A, Carlton 
R. Genentech Inc., S San Francisco, CA; Xcenda, Palm Harbor, FL
Background: Chemotherapy treatment for metastatic breast cancer 
(MBC) has shown significant benefits in survival for breast cancer 
patients. However, chemotherapy is associated with several side 
effects that have a significant impact on patients’ quality of life. The 
objective of this analysis was to quantify the value patients with MBC 
place on reduced risk of treatment side effects.
Methods: A willingness to pay (WTP) survey was developed to 
assess metastatic breast cancer patients’ willingness to pay for a 
reduction in the risk of breast cancer treatment side effects. The 
survey assessed patients’ WTP for a 25%, 50% and 100% reduction 
in the risk of all side effects. Patients were also asked to select the 
side effect they would pay the most to avoid. Additionally, the survey 
collected demographic information such as treatment regimen, age, 
race/ethnicity, region, employment status, and insurance type.
Results: The survey was completed by 202 metastatic breast cancer 
patients. Most survey respondents were white (94%), married (62%), 
and over the age of 51 (78%). Most patients were covered by private 
insurance (67%) or Medicare (24%). Of the 58% of respondents who 
remembered paying out of pocket for their last treatment, the average 
out of pocket payment was $459. Survey respondents were willing to 
pay an extra $1,886, $3,837 and $7,794 for a 25%, 50% and 100% 
reduction in the risk of all side effects, respectively. Hair loss (28%), 
pain (17%) and nausea (15%) were selected most often as the side 
effect respondents would pay the most to avoid.
Discussion: Chemotherapy for MBC is associated with several 
adverse events that patients would like to avoid or reduce such as 
hair loss, pain, nausea and neutropenia. This analysis demonstrates 
patients with MBC place a significant value on reducing the risk of 
side effects and are willing to pay 4.2 times for a treatment devoid 
of side effects as compared to a treatment with a 25% reduction in 
the risk of treatment side effects.
P5-20-02
N-Terminal Pro-Brain B-Type Natriuretic Peptide (nt-pro-BNP) 
before and during Treatment with Trastuzumab Allows Early 
Detection of Cardiotoxicity in Breast Cancer Patients.
Blancas I, Carrillo J, Legerén M, Delgado M, Jurado JM, Zarcos 
I, Villaescusa A, Gómez FJ, Moreno E, García-Puche JL. Hospital 
Clínico San Cecilio, Granada, Spain; University of Granada, 
Granada, Spain
Background: The treatment with Trastuzumab (T) is associated with 
a certain degree of cardiotoxicity. This study sought to evaluate the 
level of nt-pro-BNP as a possible marker of cardiotoxicity so accurate 
as the value of left ventricular ejection fraction (LVEF)
Patients and methods: Forty patients with breast cancer treated with 
T were prospectively measured LVFE with echocardiography and 
nt-pro-BNP level before and every 3 months during T treatment. 
Median age: 50years(27;70). Received T as adjuvant treatment: 
82.5% of the patients and 17.5% for metastatic disease.Patients with 
previous chemotherapy: 13(32.5%)neoadjuvant, 23(57.5%)adjuvant 
and 7(17.5%) for metastastic disease. Patients with previous treatment 
with anthracyclines: 12(30%)neoadjuvant, 21(52.5%)adjuvant and 
2(5%)for metastatic disease(one patient had received anthracyclines 
too during adjuvant treatment).None received anthracyclines and T 
concomitant. Chi-square analyzed the correlation of high pathological 
level of nt-pro-BNP (values over the normal range,adjusted by the 
patient age) and a significative decrease of LVEF (more than 10% 
when LVEF >50% or more than 5% when LVEF< 50%)
Results: A decrease in LVEF was observed in 6 patients(15%) and 
pathological high levels of nt-pro-BNP in 7(17.5%).Two patients(5%) 
presented cardiac insufficiency with clinical symptoms, in both 
nt-pro-BNP was higher than 600pg/ml and LVEF lower than 40%.
In the other patients the decreases of LVEF(never were<40%) or 
high levels of nt-proBNP(never were>600pg/ml)were not related 
to any clinical symptoms. Chi-square analysis showed a correlation 
between pathological high levels of nt-pro-BNP and significative 
decrease of LVEF (p=0.001), The estimated risk of a false negative 
nt-pro-BNP result (nt-pro-BNP normal value and significative LVEF 
decrease) was 2.735% (95 % confidence interval: 0.878 to 8.522 %) 
and the estimated risk of a false positive nt-pro-BNP result (nt-pro-
BNP pathological value and no significative LVEF decrease) was 
0.132%(95% confidence interval: 0.39 to 0.448%)
Conclusion:The level of nt-pro-BNP is a possible marker of 
cardiotoxicity so accurate as the value of LVEF in patients with breast 
cancer treated with T.
P5-20-03
Personalizing Supportive Care: A Clinical Prediction Model for 
Neutropenic Complications in Patients with Early-Stage Breast 
Cancer (ESBC) Receiving Intermediate Risk Chemotherapy.
Kuderer NM, Culakova E, Poniewierski MS, Crawford J, Dale D, 
Lyman GH. Duke University, Durham, NC; University of Washington, 
Seattle, WA
Background: Neutropenic complications including severe and febrile 
neutropenia (FN) represent major dose-limiting toxicities of cancer 
chemotherapy. A general risk model for neutropenic complications 
across major solid tumors has been developed and validated (Lyman 
et al. Cancer 2011). Current guidelines recommend consideration of 
primary prophylaxis with a colony-stimulating factor (CSF) in patients 
at >20% risk of FN. The decision for primary CSF prophylaxis in 
patients on intermediate risk chemotherapy (10-20%) is based on 
physician assessment of individual patient risk factors for FN. This 
study assesses the ability of this general FN risk model to identify 
ESBC patients on intermediate risk chemotherapy who are at a 
personal high risk for developing a neutropenic complication.
Methods: A prospective cohort study accrued 4458 consenting patients 
starting a new chemotherapy regimen at 115 randomly selected 
community oncology practices throughout the United States from 
2002-2006. The risk of severe or febrile neutropenia (SNFN) in cycle 
1 and across 4 cycles was estimated [±95% CI] utilizing logistic 
regression analysis and adjusting for key clinical factors including 
among others: age, prior chemotherapy, abnormal hepatic or renal 
function, low pretreatment white blood count, immunosuppressive 
medications, CSF prophylaxis, and planned relative dose intensity 
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as well as major chemotherapeutic agents. The cumulative risk of 
FN across 4 cycles was also estimated by the product limit method 
of Kaplan and Meier.
Results: Among 1224 patients with ESBC, 822 received intermediate 
risk chemotherapy based on National Comprehensive Cancer Network 
guidelines. Among these patients, cycle 1 SNFN occurred in 37%, 
at least one episode of FN over 4 cycles of chemotherapy in 17%, 
with 15% receiving primary CSF prophylaxis. The predicted risk of 
cycle 1 SNFN ranged from 1%-79%, with mean (median) risk of 
33.8% (39.0%). Model performance was good with a c-statistic of 
0.73 [0.69-0.76]. Based on this general FN risk model, cycle 1 SNFN 
occurred in 47% of predicted high risk ESBC patients [42 - 52%] 
compared to 13% [8-17%] of low risk patients. One or more FN 
events over 4 cycles occurred in 20% [17-24%] of predicted high 
risk versus 10% [6-14%] in low risk patients. The cumulative risk 
of FN by Kaplan-Meier estimation was 23% in high risk and 10% in 
low risk patients. Model sensitivity and specificity for FN were 83% 
and 33%, respectively. The majority of SNFN (76%) and FN (58%) 
events among high risk patients occurred in cycle 1. 50% of high 
risk patients who did not receive primary CSF prophylaxis went on 
to receive CSF during subsequent cycles.
Conclusions: Based on good test performance characteristics, this 
clinical FN prediction model also identifies ESBC patients receiving 
intermediate risk chemotherapy at high personal risk for FN (FN 
>20%) over the first 4 cycles of chemotherapy. Half of predicted high 
risk patients without primary CSF prophylaxis will be given CSF in 
subsequent cycles after the occurrence of a neutropenic complication. 
This also confirms previous clinical trial findings that the majority of 
febrile neutropenic events occur in the first cycle.
P5-20-04
Is Primary Prophylaxis with G-CSF Indicated for Adjuvant TC or 
FEC-D Chemotherapy? A Systematic Review and Meta-Analyses.
Younis T, Rayson D, Thompson K. Dalhousie University at the Queen 
Elizabeth II Health Sciences Centre, Halifax, NS, Canada
Background: Adjuvant chemotherapeutic regimens incorporating 
docetaxel, including TC (taxotere 75 mg/m2; cyclophosphamide 
600 mg/m2 q 3 weekly for 4 cycles) and FEC-D (5-flurouracil 500 
mg/m2; epirubicin 100 mg/m2; cyclophosphamide 500 mg/m2 q 3 
weekly for 3 cycles followed by docetaxel 100 mg/m2 q 3 weekly for 
3 cycles), appear to be associated with rates of febrile neutropenia 
(FN) in routine clinical practice that are higher than those reported 
in the pivotal clinical trials (7-33% vs. 11% & 18-35% vs. 5%, 
respectively). Although primary prophylaxis with G-CSF (granulocyte 
colony-stimulating factor) is indicated for chemotherapeutic 
regimens associated with rates of FN > 20%, the variable FN rates 
reported with TC and FEC-D outside of clinical trials have precluded 
definitive recommendations for G-CSF primary prophylaxis in most 
jurisdictions. A systematic review and meta-analysis was therefore 
conducted to assess; i) FN rates associated with TC and FEC-D 
without and with G-CSF primary prophylaxis outside of clinical trial 
settings, and ii) the potential impact of G-CSF prophylaxis on FN 
prevention. Methods: A PubMed search was conducted and major 
conference abstracts were reviewed up to June 15th 2011 to identify all 
English language reports of FN rates associated with adjuvant TC or 
FEC-D outside of clinical trial settings. FN rates with and/or without 
G-CSF prophylaxis were abstracted, and LOS (length of stay in 
hospital) and mortality following FN were noted. Summary incidences 
and odds ratios (OR) with 95% confidence intervals (95%CI) were 
calculated using random- and fixed-effects models. Results: A total of 
902 patients treated with TC (average age 55 years, range 27-84, 19% 
≥ 65 years) and 1342 treated with FEC-D (average age 52 years, range 
24-78, 9% ≥ 65 years) from 13 and 9 relevant studies respectively, 
were included. Overall FN rates of 17% (range: 7-33%) and 24% 
(range: 18-35%) were reported for TC and FEC-D, with an average 
primary G-CSF utilization rate of 47% and 30%, respectively. For 
TC, the pooled random-effects meta-analysis estimates of FN rates 
were 7% (95%CI: 5-10%) with primary G-CSF and 29% (95%CI: 
24-35%) without G-CSF (OR=0.17, 95%CI: 0.09-0.33). For FEC-D, 
the FN rates were 9% (95%CI: 4-19%) with and 31% (95%CI: 27-
35%) without primary prophylaxis (OR=0.22, 95%CI: 0.09-0.56). For 
FEC-D, 50% of the FN events occurred during the 1st D cycle and 65% 
overall occurred during D treatments. Older age (≥ 65 years) did not 
appear to correlate with higher FN rates. Breakthrough FN occurred 
in 5% across both regimens despite G-CSF secondary prophylaxis. FN 
was associated with 3.7 and 4.0 LOS days and 0% and 2% mortality 
during TC and FEC-D, respectively. Conclusions: TC and FEC-D 
without G-CSF are associated with unacceptably high FN rates in 
routine clinical practice. Primary prophylaxis with G-CSF should be 
considered for adjuvant TC chemotherapy, and for the D-component 
of FEC-D regimen, irrespective of patient age.
P5-20-05
Peripheral Blood Transcriptomics and Doxorubicin Cardiotoxicity.
Todorova VK, Beggs ML, Dhakal IB, Hennings LJ, Makhoul I, 
Klimberg VS. University of Arkansas for Medical Sciences, Little 
Rock, AR
Background: Doxorubicin (DOX) cardiotoxicity is dose-dependent 
and unpredictable. Currently, the clinical methods used for detection 
of pre-symptomatic DOX-induced cardiotoxicity show low diagnostic 
sensitivity and identify the existing cardiomyopathy rather than 
prevent it. It has been reported that DOX cardiomyopathy can occur at 
low doses, suggesting the presence of increased phenotypic sensitivity 
by some individuals. Studies have found specific gene expression 
signatures of circulating blood cells in response to physiological and 
pathological changes, suggesting that they can be used as biosensors 
for diagnostic purposes. This study aimed to characterize the 
peripheral blood mononuclear cells (PBMC) gene expression profile 
associated with DOX-induced cardiotoxicity with an ultimate goal 
to identify biomarkers for early prediction of DOX cardiotoxicity.
Materials and Methods. Twenty Sprague Dawley rats were 
randomized into 2 groups: DOX-treated (n=12) and controls (n=8). 
DOX-treated rats received a single intraperitoneal dose of 12 mg/
kg DOX (similar to 65mg/m2 for humans) and the controls were 
injected with saline. All rats were sacrificed 48 hours after DOX 
administration and blood, and samples from the heart left ventricle 
(LV) were collected. Histopathological alterations were evaluated 
microscopically. RNAs was isolated from cardiac LV and PBMCs. 
Cardiac and PBMC genome-wide expression profiling were 
performed using Illumina Rat Ref-12 BeadChip microarrays. For 
statistical analysis the raw data were log2 transformed and median 
normalized. The differential analysis per gene was performed using 
a 2-sample (control vs. DOX-treated) Student’s t-test. Statistical 
significance was set at false discovery rate (FDR)<0.05. Differentially 
expressed genes were mapped to known metabolic/signaling pathways 
using MetaCore GENEGO software.
Results. A total of 1406 transcripts were differentially expressed in 
the hearts (247 upregulated and 1159 downregulated) and 1526 in 
PBMCs (271 upregulated and 1255 downregulated) between DOX-
treated rats and control rats. Of these 1237 genes (92%) were similarly 
differentially regulated (179 upregulated and 1058 downregulated) 
both in the hearts and PBMCs. Fifty metabolic/signaling pathways 
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were significantly affected by DOX-treatment. The top ten of 
these include oxidative phosphorylation; cell proliferation and 
differentiation; TGF, WNT and cytoskeletal remodeling; insulin 
signaling; cell adhesion; regulation of amino acid metabolism, 
cytoskeleton remodeling, PI3K/AKt signaling and CCR5 signaling 
in macrophages and T lymphocytes.
Discussion: The results from this study showed that PBMC gene 
expression profile reflected a similar pattern in the hearts of rats 
treated with DOX and provide a novel and important information 
about the feasibility of the PBMC as a surrogate marker for DOX 
cardiotoxicity. The data obtained lay a foundation for further clinical 
studies to identify the cardiotoxicity risk, predict DOX-treatment 
response and ultimately to allow the anti-cancer therapy to be tailored 
to individual patients.
P5-20-06
Survival in Women with Breast Cancer Who Used or Did Not Use 
Scalp Cooling in the Neoadjuvant/Adjuvant Setting.
Lemieux J, Perron L, Provencher L, Brisson J, Amireault C, 
Blanchette C, Maunsell E. Centre de Recherche FRSQ du CHA 
Universitaire de Québec, Quebec City, QC, Canada; Hôpital du Saint-
Sacrement, Quebec City, QC, Canada; Université Laval, Quebec City, 
QC, Canada; Institut Nationale de Santé Publique, Quebec City, QC, 
Canada; Université de Montréal, Montreal, QC, Canada
Background: Scalp cooling can prevent chemotherapy-induced 
alopecia. Success varies according to the type of chemotherapy. A 
controversy exists regarding the use of scalp cooling because of the 
lack of safety data. No data are available regarding the impact on 
survival.
Purpose: To compare overall survival in women who used or did not 
use scalp cooling in the neoadjuvant/adjuvant setting.
Method: The survival of women treated in a specialized breast 
cancer centre (the Centre des Maladies du Sein Deschênes-Fabia) in 
Quebec City who all used scalp cooling was compared to that of a 
population-based random sample of women treated in other regions of 
the province of Quebec (Canada) where scalp cooling is not available. 
Cox proportional hazard models were used.
Results: Overall, survival was comparable (and possibly better 
although not at a conventionally statistically significant level: HR 
= 0.80, 95 % CI : 0.63-1.01, p=0.06) among the 553 women who 
used scalp cooling compared to the 817 who did not. An interaction 
was found between scalp cooling and treatment in the adjuvant vs. 
neoadjuvant setting (p-interaction=0.015). In the adjuvant setting 
(n=485 scalp cooling and 740 no scalp cooling), the crude HR (in 
favour of scalp cooling) was 0.66 (95% CI: 0.50-0.87, p=0.003). In 
the neoadjuvant setting (n=68 scalp cooling and 77 no scalp cooling), 
the HR was 1.40 (95% CI: 0.84-2.33, p=0.2). No interaction was 
found with stage.
Conclusion: This is the first study to compare survival of women 
who used scalp cooling to that of women who did not. Scalp cooling 
to prevent chemotherapy-induced alopecia had no negative effect on 
survival in women with breast cancer who used it.
P5-20-07
Estimation of Febrile Neutropenia in Women Receiving Docetaxel 
Plus Cyclophosphamide as Adjuvant Therapy for Early Stage 
Breast Cancer: A Retrospective Analysis.
Bordoni RE, Haislip ST, Gilmore JW, Sharpe J, Abella E, Choi MR. 
Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand 
Oaks, CA
Background: US Oncology Trial 9735 (Jones S, et al. JCO. 
2006;24:5381-5387) established the docetaxel plus cyclophosphamide 
(TC) regimen as an effective adjuvant therapy for early stage breast 
cancer (ESBC). This trial did not specifically evaluate the incidence 
of febrile neutropenia (FN) as a study endpoint, but rates of 4%–8% 
were reported. Prophylactic granulocyte colony-stimulating factor 
(G-CSF) support was not allowed; reactive G-CSF support overall 
was not reported. Subsequent reports in the community setting 
have indicated FN rates of 25%–50% without G-CSF support and 
0%–6.3% with G-CSF support (Table 1). To better determine the 
incidence of FN among ESBC patients treated with TC, we performed 
a retrospective clinical data review from the electronic medical record 
(EMR) database of Georgia Cancer Specialists, a large community 
oncology practice.
Methods: EMR data were captured between January 2006 and March 
2010. Eligibility included women ≥ 18 years old with ESBC (stage 
I–IIIA) who completed ≥ 1 cycle of TC. The study time period was 
from the first dose of chemotherapy (CTX) to 6 weeks after the last 
dose of CTX, death, or loss to follow-up. The primary endpoint was 
the incidence of FN. Other endpoints included the incidence of severe 
(grade 3/4) neutropenia, neutropenia-related hospitalizations, G-CSF 
use, relative dose intensity (RDI), and dose delays and reductions.
Results: Data from 662 patients were included in the analysis. Median 
age was 55 (range: 25–81) years. 40% of patients were white. The 
median number of CTX cycles received was 4 (range: 1–6). Most 
patients (91%) received G-CSF support; 73% as primary prophylaxis. 
See Table 2 for additional results.
Conclusions: This is the largest retrospective, community-based study 
to evaluate the incidence of FN in ESBC patients treated with TC. 
The observed FN rate of 5% (with 91% of patients receiving G-CSF) 
is consistent with other published reports using TC (Table 1). Our 
results suggest that TC is a taxane regimen with clinically significant 
myelosuppression (similar to other commonly used regimens in 
ESBC, such as TAC [NCCN Guidelines v2.2011]) and that the use 
of G-CSF support should always be considered.
Table 1.
 Soong D, et al. JCO. 
2009;27:e101-2.
Myers R, et 
al. SABCS. 
2009.
Vandenberg T, et al.  
Curr Oncol.  
2010;17:2-3.
Chan A, et al. 
Support Care Cancer. 
2011;19:497-504.
 (N = 12) (N = 86) (N = 39) (N = 159)
FN with G-CSF Not reported 2% 0% 6.3%
FN without G-CSF 50% 37% 46% 25%
Table 2.
N = 662
n (%)
FN overall/cycle 1 31 (5) / 22 (3)
Grade 3/4 neutropenia overall/cycle 1 282 (43) / 182 (27)
Neutropenia-related hospitalizations 25 (4)
G-CSF use  
 Overall 604 (91)
 Primary prophylaxis 486 (73)
 Secondary prophylaxis 57 (9)
 Treatment/salvage 61 (9)
Completed ≥4 cycles of CTX 556/632* (88)
RDI ≥85% 532/599*† (89)
Dose delays (interval > 28 days) 24/632* (4)
Dose reductions (≥ 20%) 28/632* (4)
*30 patients who had modifications to the TC regimen after the 1st cycle were excluded. †33 patients 
who did not complete 4 cycles of TC by the study cut-off date were excluded. RDI was calculated 
over cycles 1–4.
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P5-20-08
Multicenter Results of Scalp Cooling To Prevent Chemotherapy-
Induced Alopecia in 1500 Breast Cancer Patients.
van den Hurk C, Peerbooms M, Komen M, Nortier H, Breed W. 
Comprehensive Cancer Centre South (IKZ), Eindhoven, Netherlands; 
Medical Centre Alkmaar, Alkmaar, Netherlands; Leiden University 
Medical Centre, Leiden, Netherlands
Background
Chemotherapy-induced alopecia (CIA) is a frequent occurring side 
effect of cancer treatment that has high psychological impact on many 
patients and their relatives. CIA may be prevented by scalp cooling.
Methods
Breast cancer patients who received scalp cooling could participate 
in this registration study from 2006 and onwards. Nurses and patients 
completed questionnaires. Scalp cooling was performed using 
the Paxman PSC1 or PSC2 system and was considered satisfying 
when patients did not wear a wig or head cover. Logistic regression 
analyses will be used to examine determinants of the scalp cooling 
result, including age, type /length /thickness /chemical manipulation 
(dyeing, waving, colouring) of hair, type/dose of chemotherapy, 
cytostatic infusion time, post-infusion cooling time, dampening hair 
or use of conditioner before scalp cooling and previous treatment 
with chemotherapy.
Results
The use of scalp cooling increased from 4 hospitals in 2005 to 60 
out of 100 Dutch hospitals in 2011. The registration comprised about 
1500 scalp cooled breast cancer patients of whom 79% were treated 
in the adjuvant setting. Overall, patients’ satisfaction with the result 
of scalp cooling was 50%, but varied for different chemotherapy 
schemes and dosages from 8% in docetaxel 75 mg/m2, doxorubicin 
50 mg/m2, cyclophosphamide 500 mg/m2 (TAC) to 81% in paclitaxel 
70-90 mg/m2. The results of the regression analyses will be presented 
at the conference.
Discussion
Scalp cooling is effective in most commonly used chemotherapy 
regimens for breast cancer patients. Therefore, scalp cooling should 
be offered more often. Efficacy depends on the type and dose of 
chemotherapy. Other factors influencing the result have never been 
studied in multivariate analyses before. Scalp cooling is ineffective in 
patients treated with a combination of a taxane and an anthracyclin. 
The frequent use of scalp cooling in the adjuvant setting indicates 
minimal fear for an increased incidence of scalp skin metastases after 
scalp cooling in breast cancer patients. Multicenter registration of 
results improves information for medical professionals and patients 
and will lead to more frequent use of scalp cooling and improvement 
of the method.
P5-21-01
A Renewable Tissue Resource of Phenotypically Stable Human 
Breast Cancer Xenografts for Preclinical Studies.
Zhang X, Dobrolecki LE, Lai Q, Landis MD, Wong H, Tsimelzon A, 
Claerhout S, Contreras A, Gutierrez C, Huang J, Wu M-F, Pavlick 
AC, Froehlich AM, Hilsenbeck SG, Mills GB, Wiechmann L, Petrovic 
I, Rimawi MF, Schiff R, Chang JC, Lewis MT. Baylor College of 
Medicine, Houston, TX; The University of Texas MD Anderson Cancer 
Center, Houston, TX
Introduction
Translational breast cancer research is hampered severely by 
difficulties in obtaining and studying primary human breast tissue, 
and by the lack of in vivo preclinical models that accurately reflect 
patient tumor biology. These limitations are due, in part, to the fact 
that traditional immunocompromised mouse models are not generally 
permissive for growth. We sought to circumvent some of these 
limitations by transplanting and growing human mammary tumors 
in the mammary fat pad of SCID/Beige immunocompromised mice 
in the absence of exogenous human fibroblasts.
Aims and Methods
To establish a set of stable human breast cancer xenografts for 
preclinical studies. Human breast cancer biopsies were received, 
minced into small fragments and then transplanted directly into 
“cleared” fat pads of recipient SCID/Beige immunocompromised 
mice. Transplanted fat pads were checked weekly. After initial tumor 
was palpated and harvested, tumor fragments were transplanted into 
new SCID/Beige hosts for subsequent transplant generations. Serial 
immunohistochemical evaluations were performed to confirm human 
origin and biomarker status. Analytical flow cytometry for evaluating 
expression of proposed “cancer stem cell” markers, and gene and 
protein expression analysis were carried out on all stable lines.
Results and Conclusions
Xenograft lines were established directly from breast cancer patient 
samples, without intervening culture in vitro, using the epithelium-
free mammary fat pad as the transplantation site. Of the conditions 
tested, xenograft take rate was highest in the presence of a low-dose 
estradiol pellet without exogenous human fibroblasts. Thirty six 
stably transplantable xenograft lines representing 27 patients were 
established, using pre-treatment, mid-treatment, and/or post-treatment 
samples. Most patients yielding xenografts were “triple-negative” 
(ER-PR-HER2-) (n=21), we were able to establish lines from three 
ER-PR-HER2+ patients, one ER+PR+HER2-, one ER+PR-HER2- 
and one “triple-positive” (ER+PR+HER2+) patients. Serially 
passaged xenografts show phenotypic consistency with the tumor 
of origin at the histopathology level, and remarkable stability across 
multiple transplant generations at both the genomic, transcriptomic, 
and proteomic levels. Of 27 lines evaluated fully, thirteen xenografts 
showed metastasis to the mouse lung. These models thus serve as a 
renewable, quality-controlled tissue resource, and should prove useful 
for preclinical evaluation of experimental therapeutics.
P5-21-02
The Susan G. Komen for the Cure® Tissue Bank at the IU 
Simon Cancer Center: The Source for Normal Breast Tissue 
and Biospecimens.
Clare SE, Mathieson T, Henry JE, Zhang H, Way ES, Ridley KE, Badve 
S, Herbert B-S, Rufenbarger CA, Storniolo AMV. Indiana University 
School of Medicine, Indianapolis, IN
Background: Our efforts to prevent and treat breast cancer are 
significantly impeded by a lack of knowledge of the biology and 
developmental genetics of the normal mammary gland. This 
ignorance has been the consequence of the lack of access to richly 
annotated, high quality normal breast specimens. The Susan G. 
Komen for the Cure® Tissue Bank at the IU Simon Cancer Center 
(KTB) was established expressly to remedy this deficiency. The 
KTB is a repository of specimens from volunteer donors with no 
clinical evidence of breast malignancy. The Bank’s mission is to 
make available specimens that will enable an understanding of the 
developmental biology of the normal breast, to provide insight into 
breast oncogenesis, and to provide a normal control for breast cancer 
research. The purpose of this presentation is to increase the awareness 
of this unique and rich research resource and to actively solicit the 
use of its specimens.
Methods: The KTB has been prospectively banking fresh frozen 
breast tissue since mid-2006. Coincident with the tissue donation 
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two tubes of blood are obtained, which are processed for lymphocyte 
DNA, serum and plasma. These specimens are richly annotated with 
detailed information regarding the donors’ reproductive history, 
medical history, family history, and medications. Standard Operating 
Procedures have been constructed so as to control, limit and identify 
potential sources of bias. All of this information is recorded in an 
Oracle-based, searchable database.
Results: As of June 2011, the KTB and its predecessor bank, Mary 
Ellen’s Bank, have available fresh frozen breast tissue (10 gauge 
cores) from 1469 donors; formalin-fixed, paraffin-embedded tissue 
from 1055; DNA from 7507; serum from 2382; and plasma from 3771 
donors. The KTB has also established 28 epithelial and 33 stromal 
cell lines from the cores; 4 of the epithelial cell lines have been 
immortalized using hTERT. Donors range in age from 18-86 years of 
age. 9% of donors to the KTB describe themselves as Hispanic/Latino. 
5.2% of donors are Black or African-American. Using the Gail Risk 
Model, there is a bimodal distribution of life-time breast cancer risk 
among the donors: the largest peak is at 10% and a smaller one at 18%.
Conclusions: The KTB is a unique and invaluable research resource 
which is now open for business and accessible to researchers across 
the globe. We encourage researchers to avail themselves of this unique 
tissue resource and to also acquaint themselves with other sources 
of healthy breast tissue, i.e., the Love/Avon Army of Women [http://
www.armyofwomen.org/].
P5-21-03
The Breast Cancer Campaign Tissue Bank.
Jones L, Chelala C, Ellis I, Ekbote U, Green A, Hanby A, Jordan L, 
Purdie C, Quinlan P, Speirs V. Barts Cancer Institute, London, United 
Kingdom; University of Nottingham, Nottingham, United Kingdom; 
University of Leeds, Leeds, United Kingdom; University of Dundee, 
Dundee, United Kingdom
The breast cancer research community has recognised that access to 
a source of carefully collected well-annotated human breast tissue is 
essential for translational research. Research institutions often face 
barriers in gaining access to this resource as collections typically 
have restrictive access policies or an over burdensome application 
process. This was formally recognised by around 50 prominent breast 
cancer researchers through a Gap Analysis conducted in London, UK 
in 20061. As a direct result of this report, 4 leading UK centres (Barts 
Cancer Institute, the Universities of Dundee, Leeds and Nottingham) 
with multi disciplinary expertise in pathology, basic science, 
bioinformatics and computer science have collaborated with a leading 
breast cancer charity to form the Breast Cancer Campaign Tissue Bank 
(BCCTB; http://www.breastcancercampaigntissuebank.org). BCCTB 
is a unique resource of biological materials and supportive clinical 
data, efficiently and ethically collected from patients with breast 
cancer, to provide researchers with high quality, relevant materials, 
helping to raise the standard of breast cancer research and facilitating 
the co-ordinated translation of scientific findings into the clinical 
setting. A wide range of biological materials are banked, including 
fresh frozen tumour and surrounding tissue, isolated purified cell 
populations (which can be provided for culture or DNA/RNA/protein 
extraction), whole blood and serum samples, as well as formalin-fixed 
paraffin-embedded material. Specialised collections are also available 
through the Bank on a collaborative basis. BCCTB has a centralised 
IT system allowing efficient tracking of samples and recording of raw 
data from studies, and providing a user-friendly web-based search 
portal to view material available. A purpose-built Bioinformatics 
platform allows mining breast cancer literature data from multiple 
sources and integrating different types of -omics and clinical data 
alongside publically relevant annotations from a growing number of 
biological resources such as NCBI, Ensembl, UniProt and Reactome. 
This platform is also fully interoperable with the International Cancer 
Genome Consortium (ICGC) and can be automatically cross-queried 
from the ICGC data portal which allows direct cross-comparison 
of experimental findings generated from the ICGC breast cancer 
projects with literature-derived information stored in our portal. 
Together this results in the highly efficient and co-ordinated use 
of samples, reducing duplication of effort and facilitating data 
mining and analysis. As science is constantly evolving we have an 
inbuilt R&D program, including cell immortalisation, investigating 
improved sample storage and collection methods and on-going IT 
development, all of which will ensure the bank remains cutting-edge. 
Tissue is released following review by a Tissue Access Committee 
comprising clinical and non-clinical breast cancer researchers and 
patient advocates. Direct interaction with end users ensures the 
materials and data supplied meets the researcher needs. Currently 
BCCTB is accepting applications from UK based researchers with 
projects funded by Breast Cancer Campaign. It will launch to the 
wider breast cancer community in the next 18 months.
1Thompson A et al., Breast Cancer Research 2008, 10:R26.
P5-21-04
Patient Attitudes towards Undergoing Additional Breast Biopsy 
for Research Purposes.
Naim FM, Ballinger R, McLauchlan R, Hadjiminas DJ, Hogben K, 
Palmieri C, Cleator SJ. Royal Free Hospital, Royal Free Hampstead 
NHS Trust, London, United Kingdom; Brighton and Sussex Medical 
School, Brighton, United Kingdom; Charing Cross Hospital, Imperial 
NHS Healthcare Trust, London, United Kingdom
Background: Acquisition of additional breast tissue for research 
has become integral to breast oncology research but no data exists 
regarding patient attitudes to additional, non-diagnostic biopsies. 
Baseline research biopsies may be obtained as part of the diagnostic 
process as extra passage(s) of the needle through a ‘generic consent’ 
process, or as an additional biopsy event after carcinoma diagnosis 
has been confirmed and eligibility for a specific study has been 
established. This study sought to explore patient perspectives to such 
biopsies. Patients and Methods: Patients attending breast clinics 
were recruited to complete a questionnaire prior to their consultation 
(and any interaction with researchers or clinicians seeking consent 
for research biopsies) which examined willingness to undergo an 
extra fine needle aspirate (FNA) and/or core needle biopsy (CNB) for 
research either at time of the diagnostic biopsy (B1) or after diagnosis 
(B2). Descriptions of FNA and CNB procedures were supplied to 
those with no prior experience. Patient perspectives towards donating 
surplus tissue left over from a diagnostic procedure and/or surgery for 
storage for future research was also explored. Results: 100 patients 
were recruited, 42% with a prior history of breast carcinoma, 23% 
with family history of breast carcinoma and 65%/ 42% with previous 
experience of CNB/ FNA respectively for either benign or malignant 
disease. Willingness to undergo additional biopsy was greater for 
the B1 than the B2 time point, but equivalent for CNB and FNA 
(willingness CNB B1 50% vs B2 26%, willingness FNA B1 50% vs 
B2 29%). A statistically significant increase in willingness to undergo 
CNB and FNA at B1 and/or B2 was seen in association with prior 
diagnosis of breast cancer, family history of breast cancer, previous 
visit to breast clinic and prior experience of breast biopsy. Reasons 
for willingness or unwillingness were recorded. 83% of patients 
expressed a willingness to allow surplus tissue to be stored in a bio-
bank for future research.
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Conclusions: When asked by questionnaire prior to clinic 
consultation, additional research biopsy was much more acceptable 
if undertaken at time of initial diagnostic biopsy rather than at a later 
time point. Acceptability was equivalent for CNB and FNA. Previous 
experience of biopsy, previous attendance to breast clinic, a prior 
history of breast cancer or family history of breast cancer increased 
acceptability suggesting that willingness is increased with knowledge 
of the biopsy procedure.
P5-22-01
Feasibility and Patient Safety of Serial Biopsies (bx) in Metastatic 
HER2-Positive Breast Cancer (BC) To Evaluate Alterations in 
Molecular Biomarkers (BM): Preliminary Results of SHERsig 
(Study of HER2 Signature in Metastatic Breast Cancer) a 
Prospective Phase II Study.
Chan A, Chan S, Price D, Bergh J, Lluch A, Redfern A, Chirgwin J, 
Lidbrink E, Dhadda A, Lopéz-Vega J, Lindman H, Beith J, Baron-
Hay S, Kiermaier A, Herbst F, Ellis I. Mount Medical Centre, Perth, 
Australia; Nottingham City Hospital, Nottingham, United Kingdom; 
Karolinska Institutet and University Hospital, Stockholm, Sweden; 
Hospital Clínico Universitario de Valencia, Valencia, Spain; Royal 
Perth Hospital, Perth, Australia; Eastern Health Melbourne, 
Australia; Scarborough Hospital, Scarborough, United Kingdom; 
Hospital Universitario Marques de Valdecilla, Santander, Spain; 
Uppsala University Hospital, Uppsala, Sweden; Royal Prince Alfred 
Hospital, Camperdown, Australia; Royal North Shore Hospital, St 
Leonards, Australia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; 
Nottingham University Hospitals, Nottingham, United Kingdom
Background: The use of trastuzumab (H)-based therapy for HER2-
positive BC has significantly altered outcomes. Yet up to 64% of 
metastatic patients (pts) fail to respond (Robert JCO 2006) and 
most pts will progress within 24-42 months (m) following an initial 
response for metastatic disease. Preclinical data suggest several in 
vitro resistance mechanisms but confirmatory in vivo data are lacking, 
preventing optimal personalized care. This ongoing proof-of-concept 
study examines serial bx in pts with HER2-positive metastatic BC in 
order to assess BM profiles across multiple lines of treatment.
Methods: Key eligibility criteria include: centrally confirmed HER2 
status, minimum of 1 disease site considered suitable for serial bx, 
normal coagulation profile and cardiac function, prior adjuvant/
neoadjuvant taxane and H completed ≥12 m and ≥6 m respectively, 
ECOG ≤2. Pts receive q3wk H with clinician choice of taxane 
(docetaxel 75-100 mg/m2 q21, paclitaxel 80 mg/m2 weekly or 175 
mg/m2 q21 [TH]). At the time of progressive disease, pts receive 
capecitabine (X) and H. Two core bx and 1 optional fine needle 
aspirate are performed at the following times: baseline (after 3 weeks 
[w] of TH), at 6 w, at time of first progression prior to XH, and at 
the time of progression on XH. Tumor assessments are performed at 
6 w, then 9 w intervals, with cardiac assessment every 6 m. Primary 
endpoint aims to explore and potentially define BM signatures that 
could alter during HER2-targeted therapy and predict for decreased 
or increased sensitivity to H-based treatment. Secondary endpoints 
include bx safety, ORR and TTP. At time of baseline bx, pts have the 
option to complete a pt satisfaction questionnaire.
Results: Between August 2009 and June 2011, 58 pts were screened; 
29 enrolled. The other 29 pts were screen failures, with 3 pts (5%) 
specifically declining entry due to the requirement for serial bx. 
Median age is 53 y (range 37-86), with 9 and 20 pts having recurrent 
or de novo metastatic disease. Eight pts received adjuvant systemic 
treatment, including H in 4 pts. Baseline bx performed in the breast, 
n (%): 15 (52), bone: 6 (21), liver: 4 (14), and lymph nodes: 4 (14); 
14 and 27 pts underwent bx at 3 and 6 w respectively. After a median 
of 34 w of treatment 11 pts progressed on TH and 7 pts underwent 
planned bx. There were 12 SAEs, none related to bx. Most AEs were 
grade 1/2 (95%) with 3% grade 3 and 1 death due to intercurrent 
illness. From a total of 43 bx, 12 (27%) grade 1/2 AEs (hematoma 2, 
transient hypotension 2, mild pain 8) were reported, with resolution 
in all instances. Fifteen pts consented to the pt satisfaction substudy.
Conclusions: Preliminary results of the first reported serial bx study 
in metastatic BC demonstrated 95% pt acceptance of this approach. 
Evaluation of BM profiles will be conducted following planned 
recruitment of 50 pts. To date, the feasibility and safety of obtaining 
serial bx in metastatic BC is supported by the current safety profile 
and patient uptake. Updated recruitment data will be presented.
P5-23-01
The Impact of Primary Tumor Resection on the Survival of 
Patients with Stage IV Breast Cancer According to Molecular 
Subtype.
Ahn SK, Moon H-G, Kim JS, You JM, Shin HC, Han W, Noh D-Y. 
Seoul National University Hospital
Purpose: The main treatment for stage IV breast cancer is currently 
systemic therapy. Surgical resection of the primary tumor is usually 
done for treating the tumor-related complications. Recent studies 
have suggested that surgery may improve the long-term survival 
of stage IV breast cancer patients. We evaluated the impact of the 
primary surgical resection site on the survival of stage IV breast cancer 
patients according to molecular subtype using nationwide Korean 
breast cancer registry data.
Methods: We analyzed the records of the stage IV breast cancer 
patients from Korean Central Cancer Registry (KCCR) between 1999 
and 2008. We used clinical assays to distinguish luminal A (HR+/
HER2-, n=290), luminal B (HR+/HER2+, n=154), Basal-like (HR-/
HER2-, n=107) and HER2 (HR-/HER2+, n=145). The clinical and 
tumor characteristics, the type of treatments and the overall survival 
were compared between the surgically versus nonsurgically treated 
patients according to molecular subtype.
Results: Of the 1091 identified patients, 719 (65.9%) received surgical 
excision of their primary tumor and 372 (34.1%) did not. The mean 
survival was 86 months versus 43 months for the surgically treated 
patients vs. the patients without surgery, respectively (p<0.001). On 
a multivariate analysis with using the Cox model and after adjusting 
for tumor size, visceral metastases, the number of metastatic sites 
and bone only metastases, surgery was an independent factor for 
improved survival in patients with luminal A type (Hazard Ratio, 
0.505; 95% Confidence Interval, 0.265-0.962, p=0.038) but not in 
those with luminal B (p=0.192), basal-like (p=0.128) and HER2 
subtype (p=0.114).Conclusion: Surgical resection of the primary 
tumor in stage IV breast cancer patients was independently associated 
with improved survival only in luminal A subtype.
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P5-23-02
Clinicopathological Features of Young Patients Age <35 Years 
with Breast Cancer in Japan.
Kataoka A, Tokunaga E, Masuda N, Shien T, Ohno S, Kinoshita T, 
Shimizu C. Breast Surgery Clinic, Minato-ku, Tokyo, Japan; Kyushu 
University Hospital, Fukuoka City, Fukuoka, Japan; National 
Hospital Organization Osaka National Hospital, Osaka City, Osaka, 
Japan; Okayama University Hospital, Okayama City, Okayama, 
Japan; National Hospital Organization Kyushu Cancer Center, 
Fukuoka City, Fukuoka, Japan; National Cancer Center Hospital, 
Chuo-ku, Tokyo, Japan; The Japanese Breast Cancer Society (JBCS) 
Study Group on Breast Cancer in Young Women
Background: The aim of this study is to clarify clinicopathological 
features of breast cancer in young women.
Materials and methods: Clinicopathological characteristics were 
compared between young (<35) patients and non-young (>35) patients 
among 109,617 records of JBCS database registered from 2004 to 
2009, and overall survival (10-yr OS) were calculated among 146,690 
records from 1975 to 2000 with 8.6 years of median follow up period.
Results: Clinicopathological factors of 2,982 young patients (2.7%) 
were compared with 106,295 non-young patients. Young patients had 
more familial history of breast cancer, more subjective symptom, less 
bilateral tumor, lower BMI, larger tumor, more inflammatory breast 
cancer, more positive node, less ER-positive, more HER2-positive, 
more triple-negative tumor, and more advanced TNM-stage.
Comparison of clinicopathological factors between young and non-young patients with breast 
cancer
factors young patients (<35) 
n=2,982
non-young patients 
(>=35) n=106,295
p-value
have a family history of breast cancer 12.4% 9.4% <0.0001
have a subjective symptom 83.2% 67.3% <0.0001
bilateral breast cancer 2.6% 7.2% <0.0001
BMI<18 11.4% 5.2% <0.0001
BMI >25 10.4% 22.8% <0.0001
tumor size (mean) 2.9cm 2.5cm <0.0001
lymph node metastais 35.2% 31.2% <0.0001
inflammatory breast 1.1% 0.6% <0.0001
ER-positive 72.7% 76.9% <0.0001
HER2- positive 18.2% 15.8% <0.0001
triple-negative 16.3% 12.2% <0.0001
TNM Stage I 42.4% 50.1% <0.0001
TNM Stage II 43.9% 39.8% <0.0001
TNM Stage III 10.4% 7.7% <0.0001
TNM Stage IV 3.3% 2.4% <0.0001
Young patients were received more neoadjuvant chemotherapy and 
breast conserving therapy (BCT), compared with non-young patients.
Comparison of treatments between young and non-young patients with breast cancer
treatments young patients 
(<35) n=2,982
non-young patients (>=35) 
n=106,295
p-value
neoadjuvant therapy 24.7% 11.3% <0.0001
neo-chemotherapy 97.1% 89.8% <0.0001
neo-endocrine therapy 15.7% 16.9% 0.4085
neo-targeted therapy 11.9% 11.0% 0.4488
neo-radiation therapy 1.2% 1.1% 0.7402
surgery 98.6% 98.8% 0.2604
BCT 62.7% 57.0% <0.0001
mastectomy 35.0% 41.9% <0.0001
Adjuvant therapy 79.1% 80.6% 0.006
adj-chemotherapy 55.5% 41.5% <0.0001
adj-endocrine therapy 76.2% 81.2% <0.0001
adj-targeted therapy 9.6% 5.8% <0.0001
adj-radiation therapy 62.0% 50.9% <0.0001
Eighty-percent of patients were received adjuvant therapy, among 
them, treatment rate of chemotherapy, molecular targeted therapy 
and radiation therapy was significantly higher in young patients 
than non-young patients. There was significant difference in 10-yr 
OS between young and non-young patients with Stage I-IIIA disease 
(Stage I 80% vs. 90%, IIA 78% vs. 85%, IIB 67% vs. 78%, IIIA 42% 
vs. 64%), but not with Stage IIIB and IIIC. Advanced TNM stage, 
lymph node metastasis and ER-negative tumor were significantly 
poorer prognostic factors for young patients by univariate analysis. 
Approximately 9% of young patients were at pregnancy at the time 
of diagnosis had more advanced disease and worse prognosis.
Conclusions: We conclude that young patients with breast cancer 
have an advanced or an endocrine-unresponsive tumor and have 
unfavorable outcome. Advocacy for awareness of breast cancer to 
young women and development of new targeted therapy against 
advanced, HER2-positve and triple-negative tumor are important to 
improve the survival of young patients with breast cancer.
P5-23-03
Breast Cancer in Elderly Treatment Algorithm – A New Approach 
To Optimize the Management of Breast Cancer in Older Patients.
Tahir M, Pretorius R, Robinson T, Walker R, Stotter A. University 
Hospitals of Leicester NHS Trust, Leicester, United Kingdom
Background: Elderly patients have been receiving a sub-standard 
treatment for early breast cancer when compared to younger age 
group patients. A higher percentage of them are being treated with 
primary endocrine therapy (PET) based on the premise that they may 
not survive surgery or live long enough to benefit from it. In clinical 
practice, however, there is no validated assessment in place to assess 
their surgical risk or estimate their life expectancy. This study aimed 
to optimize the treatment of early breast cancer in older patients using 
comprehensive geriatric assessment (CGA). It tested the hypothesis 
that CGA could be used to predict 2-year survival in older breast 
cancer patients. Based on that a treatment algorithm was devised 
which could be used to recommend whether PET or surgery plus 
endocrine treatment would be best indicated in individual patients.
Methods: The study included women >70 years of age with early 
breast cancer, seen in a dedicated Leicester clinic between 04/2005 
and 04/2007. All patients had comprehensive assessment including 
documentation of co-morbidities, Mini-mental state examination 
(MMSe), Geriatric depression score (GDS), Activities of daily living 
(ADL), Instrumental activities of daily living (IADL) and American 
society of anesthesiologist score (ASA). Analysis was performed to 
find components of the CGA that were helpful in predicting 2-year 
survival in these patients.
Results: 123 patients were included; age range was 70-94 (median-82). 
Twenty-two patients died within 2-years. Logistic regression 
analysis found MMSe, ADL, and ASA score to have an independent 
association with 2-year survival. A statistically significant correlation 
(p-value 0.000) was found between the dichotomized combined-score 
of these components and 2-year survival. Breast Cancer in Elderly 
Treatment Algorithm (BCETA) was devised using the scores of 
these three components. Patients who scored one or higher (high-
risk group), were found to have <48% two-year survival; those, who 
scored zero (low-risk group), have >86% chance of two-year survival. 
The overall accuracy for the algorithm was 81%.
Conclusion: Breast Cancer in Elderly Treatment Algorithm is a new 
and systematic approach to optimize the management of breast cancer 
in elderly patients. It is helpful in identifying high-risk patients with 
expected short-survival who may benefit from PET, if their cancer 
is hormone receptor positive. Patients with predicted longer life 
expectancy (low-risk) may be recommended standard treatment. A 
prospective study is ongoing at Leicester research clinic to validate 
the results.
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BREAST CANCER IN ELDERLY TREATMENT ALGORITHM
Name:
Hospital No: DOB:
Address: Diagnosis:
COMPREHENSIVE GERIATRIC ASSESSMENT
Mini-Mental State examination  
MMS score BCETA score
20-30 0
0-19 1
Activities of Daily living/Barthel index  
ADL score BCETA score
12-20 0
0-11 1
American Society of Anesthesiologists Scale  
ASA score BCETA score
1-3 0
4 1
TOTAL BCETA SCORE
Total BCETA score 2 year survival Recommended treatment
0 87% Surgery plus ET
1-3 <48% PET
P5-23-04
Gonadotrophin-Releasing Hormone Analogues for Ovarian 
Function Preservation in Women with Premenopausal Breast 
Cancer Undergoing Adjuvant Chemotherapy: A Systematic 
Review and Meta-Analysis.
Cruz MRS, Motta E, Silva EMK, Bernardo SG, Atallah AN. Hospital 
Sao Jose, Sao Paulo, Brazil; Universidade Federal de Sao Paulo, 
Sao Paulo, Brazil
Background: Breast cancer, the most common female malignancy, 
is also the most frequent tumor in women of reproductive age. 
Young women with breast cancer usually present adverse prognostic 
features and higher rates of recurrence when compared with their 
older counterparts. Adjuvant chemotherapy is usually recommended 
for this group of patients and premature ovarian failure (POF) is a 
potential complication.
Material and Methods: We conducted a systematic search in 
MEDLINE, EMBASE, Cochrane Systematic Reviews databases 
and ClinicalTrials.gov from their inception until June 2011. The 
search was conducted to include published peer-reviewed studies 
on the issue of fertility preservation in women with breast cancer 
undergoing adjuvant chemotherapy. The search terms were tailored 
individually for each database to include the following Medical 
Subject Headings (MeSH) and text words: gonadotropin releasing 
hormone, breast neoplasms, drug therapy, premature ovarian failure 
and fertility. No language restriction was applied. We also searched 
for additional studies by reviewing the reference lists of retrieved 
articles, and studies presented in abstract form were also located in this 
manner. The main outcomes were return of spontaneous menstruation, 
ovulation and pregnancy rate.
Results: We found 8 RCTs that met the inclusion criteria. Data were 
extracted from 3 RCTs. Data were only available for resumption 
of ovulation. There were no data available for markers of ovarian 
function, rate of ovulation and pregnancy. The rate of women with 
spontaneous menstruation demonstrated a statistically significant 
difference in favor of the use of GnRH-a (OR 3.11;95% CI, 2.04–472).
Discussion: Use of GnRH concomitant to adjuvant chemotherapy in 
premenopausal breast cancer women aiming to reduce rates of POF 
has been subject of controversy during the last decade. Evidence 
from recently presented RCTs suggests there is a benefit of GnRH 
for ovarian function protection in this setting.
P5-23-05
Withdrawn by Author
P5-23-06
Monitoring of Quality Indicators Should Lead to Quality 
Measures. A Dynamic Clinical Pathway for the Treatment of 
Patients with Early Breast Cancer Is a Tool for Better Cancer 
Care: Implementation and Prospective Analysis between 2002-
2010.
van Dam PA, Verheyden G, Trinh BX, VanderMussele H, Wuyts H, 
Verkinderen L, Hauspy J, Vermeulen P, Dirix LY. Sint Augustinus 
Hospital, Wilrijk, Antwerp, Belgium
Aim: To describe the effects of the development, implementation and 
prospective systematic evaluation and adaptation of a clinical care 
pathway for the management of patients with early breast cancer 
between 2002 and 2010) in a single breast unit.
Materials and methods: In 2002 a clinical pathway was developed by 
the multidisciplinary breast team of the Sint Augustinus Hospital for 
de diagnosis and treatment of patients with operable breast cancer. 
Performance measurements were documented systematically by care 
providers using an order communication, planning and result reporting 
system. Annual analysis of predefined clinical outcome measures and 
indicators was performed. Based on these data and evidence based 
guidelines the pathway was regularly adapted to improve patient care.
Results: The annual number of patients included in the pathway (289 
vs 390, p 0.01) ), proportion of patients with Tis-T1 tumors (42% vs 
58 %, p 0.01), negative lymph nodes (44% vs 58%, p < 0.01)) and 
no metastases at diagnosis ( 91.5% vs 95.9%) has risen significantly 
between 2002 and 2010. Histological subtypes remained the same. 
The average length of hospital stay (7.0 days vs 4.1 days, p 0.01) 
nearly halved and the proportion of breast conserving surgery (BCS) 
(43% vs 57%), preoperative guide wire localization (14% vs 27%) 
for impalpable lesions and use of sentinel node biopsy (0% vs 49%) 
increased significantly (p 0.01). Evolution of quality indicators defined 
by Eusoma (www.eusomadb.org/indicators.htm) between 2002 and 
2010 shows a significant improvement of cancer care: proportion 
of positive of preoperative histologic diagnosis (59.7% vs 88.4%, p 
0.001), more then 9 lymph nodes removed when axillary clearance 
performed (85.6 vs 91.4%, p< 0.04), BCS for invasive carcinoma 
up to 3 cm (62.0% vs 82.6%, p 0.016), BCS for DCIS up to 20 mm 
(43.8% vs 78.6%, p 0.016), hormone therapy in endocrine sensitive 
tumor (84.8% vs 97.4%, p 0.002), adjuvant chemotherapy in ER 
negative (PT1c or N+) invasive carcinoma (72% vs 95.6% p 0.028), 
proportion of second surgery (25% vs 10%, p 0.001) and clear 
margins after last operation (95% vs 99%, p 0.02). All mandatory 
EUSOMA requirements were fulfilled in 2010. Patient satisfaction 
improved significantly over the years (13/19 measured parameters 
p <0.05 between 2002-2010). Progression free 4 year survival was 
significantly higher for all patients, for T1 tumors only and for T2-T4 
tumors only, treated in 2006-2008 compared to 1999-2002 and 2003-
2005 (respectively p 0.006, p 0.05, p 0.06). Overall 4 year survival 
of the entire M0 population treated in 2006-2008 was significantly 
better (p 0.05)
Conclusion: Although the patient characteristics changed over the 
years due to better screening, this clinical pathway for the treatment 
of patients operable breast cancer proved to be an important tool to 
improve the quality of patient care and patient satisfaction. Better 
adherence to guidelines and constant feedback of treatment data to 
the breast team contributes to a superior patient outcome. Measuring 
quality indicators proved useful to develop quality measures 
improving patient care.
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P5-23-07
Treatment Strategy of Locally Advanced Breast Cancer in Sub 
Group (T3N1M0, T4bN1M0) in Developing Countries.
Gupta AK, Kaushal M. Mahatma Gandhi Memorial Medical College 
and Maharaja Yashwantrao Hospital, Indore, Madhya Pradesh, India
With the recent advances in modern day chemotherapy and hormonal 
therapy for locally advanced breast cancer [stage III, T3 N1 and 
T4bN1], most of the oncologist around the globe now prefer to give 
neoadjuvent chemotherapy and, or hormonal therapy followed by 
surgery in the treatment of these cases.
Randomized research have also shown that this strategy provides 
‘pathological complete resolution’ as compared to surgery and then 
adjuvant chemotherapy in terms of decreasing in size of tumar, 
decrease in vascularity of tumor mass and micrometastasis . Some 
author believes that this improve the overall survival duration of 
patients.
This protocol is widely accepted but ….
BUT WHAT IF YOU LOSE YOUR PATIENT ON FOLLOWUP…
Especially in the developing countries of south east asian region 
and African continent, where there is poor socioeconomic status and 
lack of education among common people. The patient gets frustrated 
after first few doses of neoadjuvent therapy, due to side effects of 
chemotherapy and don’t consider chemotherapy as a treatment 
compare to surgery. Thus the patient loses faith in treatment strategy 
itself and go untraceable after one or two sessions of the therapy.
The government of developing countries lack resources in terms 
of manpower and money for satisfactory completion of treatment 
making the above condition even worse. In our study we followed 
230 patients of locally advanced breast cancer in subgroup of stage III 
[T3 N1, T4bN1] and divided them into two plans on random basis .
In first plan we approached with the surgical management followed 
by adjuvant chemotherapy & counseled the patients for completion 
of chemotherapy . This plan was shown to 115 patients, out of which 
100 patients provided good acceptance & completed the course of 
chemotherapy. There were 15 patients who remained untraceable 
after surgery.
On the other hand in the 2 group the patients were counseled for 
neoadjuvent chemotherapy and then surgery in next stage. In this 
group 115 patients were introduced, out of which 60 patients were lost 
on follow up after 2-3 sessions. The majority of patients complained 
about the side effects of chemotherapy and financial reasons and 
did not come back. Rest of the patients completed the whole course.
With no doubt about the result of the treatment, the second group has 
equivocal survival advantages in terms of morbidity and mortality, 
but we lost more than half of the patients of second group before 
completion of treatment .
Primarily the acceptance of surgical treatment is more in developing 
countries, as it is quite more feasible for government and even 
economical for common people. Thus we prefer the strategy of surgery 
followed by adjuvant chemo/hormonal therapy in locally advanced 
breast cancer [stage III T3N1, T4bN1 ] especially in developing 
countries like India.
THE MOTTO OF THIS STRATEGY IS TO PROVIDE BENEFIT OF 
COMPLETE TREATMENT TO THE PATIENT THAN TO LOSE 
THE PATIENT COMPLETELY BEFORE TREATMENT.
OT1-01-01
Prospective Clinical Trial Evaluating Efficacy of Zoledronic 
Acid (ZA) Prophylaxis for Prevention of Aromatase Inhibitor 
Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial.
Bardia A, Blackford A, Jeter S, Tarpinian K, Fetting JF, Miller 
R, Slater S, Henry NL, Giles J, Stearns V. Johns Hopkins Kimmel 
Cancer Center, Baltimore, MD; University of Michigan, Ann Arbor, 
MI; Columbia University, New York City, NY
Brief background: Aromatase inhibitor associated musculoskeletal 
symptoms (AIMSS) occur in approximately 50% of patients receiving 
AIs (Henry 08). However, interventions to prevent or treat AIMSS 
have not been established. In a retrospective study (Muslimani 09), 
patients receiving bisphosphonates along with AIs were less likely to 
report AIMSS compared to those not taking bisphosphonates (35% 
vs. 60%). However, the efficacy of bisphosphonates in reducing 
incidence of AIMSS has not been studied prospectively, so it cannot 
be recommended for routine clinical practice.
Trial design: We are conducting a single arm, phase II clinical trial 
of 4 mg intravenous zoledronic acid (ZA) given at baseline and at 
6 months, in combination with letrozole 2.5 mg daily for one year. 
Development of AIMSS will be assessed using the standardized 
Health Assessment Questionnaire (HAQ-DI) and pain Visual Analog 
Scale (VAS) at baseline,1, 3, 6, and 12 months. Secondary endpoints 
include mammographic breast density (when intact contralateral 
breast), bone mineral density, bone turnover metabolites, circulating 
inflammatory markers, and patient reported quality of life measures. 
Prevalence of AIMSS will be compared to historical controls from a 
recently completed multi-institutional study designated Exemestane 
and Letrozole Pharmacogenetics (ELPh trial, ClinicalTrials.gov 
#NCT00228956). The current study has the same eligibility criteria, 
method and intervals of outcome assessment, and AI medication, as 
the ELPh trial, ensuring that the two cohorts are comparable.
Eligibility criteria: Postmenopausal women who have completed 
local therapy and chemotherapy for hormone receptor positive DCIS 
or stage I-III breast cancer and who are scheduled to receive adjuvant 
AI. Prior tamoxifen therapy is permitted.
Specific aims:
1. Percentage of women experiencing AIMSS at 1, 3, 6, and 12 months 
after initiation of ZA and letrozole, as compared to historical controls.
2. Change in bone mineral density and breast density between baseline 
and 12 months for those receiving ZA and letrozole, as compared to 
historical controls.
3. Change in bone turnover markers and inflammatory markers 
between baseline and 1, 3, 6 and 12 months for those receiving ZA 
and letrozole, as compared to historical controls.
Statistical methods: Allowing for a 20% dropout rate, a total sample 
size of 59 patients yields 80% power to detect reduction in AIMSS 
incidence from 50% to 30% with a two sided type I error rate of 5%. 
The rates of AIMSS and other endpoints at each time point and across 
all time points between controls and patients will be compared with 
a logistic regression model that adjusts for potential confounding 
variables and include random effects as appropriate to account for 
correlation between outcomes in the same patient.
Present accrual and target accrual: The Johns Hopkins Institutional 
Review Board approved the study and it opened to accrual in January 
2011. Since that time, 12 participants have signed consent and started 
therapy, and 2 have completed the 3 month evaluation.
Funding: Trial supported by BCRF. ZA and letrozole kindly supplied 
by Novartis.
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OT1-01-02
A Multicentre Study Assessing 12-Weekly Intravenous 
Bisphosphonate Therapy in Women with Low Risk Bone 
Metastases from Breast Cancer – The TRIUMPH Trial.
Bouganim N, Hilton J, Vandermeer L, Hopkins S, Spencer P, Robbins 
D, Amir E, Dent S, Milano C, Ooi D, Dranitsaris G, Clemons M. 
The Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess 
Margaret Hospital, Toronto, ON, Canada; The Ottawa Hospital, 
Ottawa, ON, Canada
Background: Metastatic bone disease is a major cause of morbidity 
and mortality for breast cancer patients. Bisphosphonates (BP) have 
been shown to significantly delay the onset and frequency of skeletal 
related events (SREs), improve pain control and overall quality of 
life. Most patients receive intravenous BP every 3-4 weeks regardless 
of their individual risk for a SRE. This “one size fits all” strategy 
could expose those patients at a relatively low risk of SREs to an 
increased chance of adverse drug effects, as well as to the financial 
and quality of life burden of multiple visits to the cancer centre for 
treatments. This study aimed to assess whether IV BP can be safely 
given at reduced frequency.
Methods: The primary objective of this study is to demonstrate in 
women with biochemically defined low-risk bone metastases that 
the administration of IV BP every 12 weeks is sufficient to maintain 
biochemical stability for one year. Eligibility criteria include; bone 
metastases from breast cancer, have received at least three months 
of regular 3-4 weekly IV BP, satisfactory renal function, adequate 
dental health, no systemic treatment change or recent SRE within 
4 weeks of study entry. Low risk disease will be defined as serum 
CTx levels <600 ng/L Biochemical failure is defined as CTx levels 
>600 ng/L measured at predefined time points (6, 12, 24, 36 and 
48th). Secondary objectives are to evaluate the palliative benefit 
of 12-weekly IV BP therapy as reflected by occurrence of SREs, 
analgesic use, self-reported pain using the validated BP and FACT-BP 
questionnaires. Sample size was calculated at 68 patients. Given the 
small sample size, nonparametric Bootstrapping will be employed 
to calculate point estimates, standard deviations and 95% confidence 
intervals (CIs). An exploratory multivariable analysis will also be 
undertaken to determine baseline factors that were associated with 
patient’s maintaining their telopeptide levels in the low risk range.
Conclusion: TRIUMPH opened in October 2010 and as of June 
2011, has quickly accrued 54/68 patients (79%). This trial has the 
potential to allow lower risk women to receive less frequent dosing of 
bisphosphonates, thus improving their quality of life with less cancer 
center visits and reducing their chance of drug induced adverse events.
OT1-01-03
A Phase 3 Randomized, Double-Blind, Placebo-Controlled 
Multicenter Study Comparing Denosumab with Placebo as 
Adjuvant Treatment for Women with Early-Stage Breast Cancer 
Who Are at High Risk of Disease Recurrence (D-CARE).
Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martín M, Braun 
A, Ke C, Maniar T, Braun S, Dansey R, Coleman RE. Massachusetts 
General Hospital Cancer Center, Boston, MA; PUCRS School of 
Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, 
Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital 
Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; 
Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, 
Sheffield, United Kingdom
Background: Bone is a common site of distant recurrence in women 
with early-stage breast cancer. Cancer cells are thought to stimulate 
osteoclast-mediated bone resorption, which releases growth factors 
and cytokines that promote tumor growth. RANK Ligand (RANKL) 
is the key mediator of osteoclast-induced bone destruction. In 
preclinical studies, RANKL inhibition reduced the incidence of bone 
and lung metastases, suppressed tumor progression, and prolonged 
survival of tumor-bearing mice. Effects were additive with hormonal, 
chemotherapy, or targeted therapies. Denosumab is a fully human 
monoclonal antibody against RANKL, approved in the U.S. for the 
prevention of skeletal-related events in patients with bone metastases 
from solid tumors. In patients with castrate-resistant prostate cancer, 
denosumab significantly improved bone metastasis-free survival 
(BMFS) compared to placebo. The D-CARE trial evaluates BMFS 
effects of denosumab in women with stage II or III breast cancer.
Methods: Women with node-positive or locally advanced (T3 or T4) 
disease, and known hormone and HER-2 receptor status are eligible. 
Standard-of-care adjuvant or neoadjuvant chemo-, endocrine, or HER-
2 targeted therapy, alone or in combination must be planned with 
curative intent. Women with a prior history of breast cancer (other 
than ductal carcinoma in situ [DCIS] or lobular carcinoma in situ 
[LCIS]) or distant metastasis, oral bisphosphonate (BP) use within 1 
year or any intravenous BP use are excluded. Patients are randomized 
1:1 to receive denosumab 120 mg or placebo subcutaneously 
monthly for 6 mos, then every 3 mos, for a total of 5 yrs treatment. 
All patients receive vitamin D (≥ 400 IU) and calcium (≥ 500 mg) 
supplements. Primary endpoint of this event-driven trial is BMFS. 
Secondary endpoints include disease-free (DFS) and overall survival. 
The study is powered for both, BMFS and DFS. Safety, quality of 
life assessments and biomarkers are additional endpoints. The trial, 
sponsored by Amgen Inc. and registered with the ClinicalTrials.gov 
identifier NCT01077154 began enrolling patients in June 2010.
PG and DF are supported in part by the Avon Foundation, NY.
OT1-01-04
NEO-ZOTAC: A Phase III Randomized Trial with Neoadjuvant 
Chemotherapy (TAC) with or without Zoledronic Acid for 
Patients with HER2-Negative Large Resectable or Locally 
Advanced Breast Cancer.
van de Ven S, Nortier JWR, Liefers GJ, ten Tije A, Kessels LW, van 
Laarhoven HWM, van Warmerdam LJC, Vriens B, van den Bosch 
J, van Meershoek-Klein Kranenbarg E, van Leeuwen E, Kroep JR. 
Leiden University Medical Center, Leiden, Netherlands; Amphia 
Hospital, Breda, Netherlands; Deventer Hospital, Deventer, 
Netherlands; University Medical Center St. Radboud Nijmegen, 
Nijmegen, Netherlands; Catharina Hospital, Eindhoven, Netherlands; 
Academic Hospital Maastricht, Maastricht, Netherlands; Albert 
Schweitzer Hospital, Dordrecht, Netherlands; BOOG Study Center, 
Amsterdam, Netherlands
Background: The role of bisphosphonates (BPs) when added to the 
(neo) adjuvant treatment of breast cancer is still unknown. Adding the 
most potent BP zoledronic acid to neoadjuvant chemotherapy may 
lead to an improved clinical and pathological response in patients 
with breast cancer.
Trial design: After randomization, patients will be treated in arm 
A (experimental) or arm B (control group). Arm A: 6x TAC q 3 
weeks with zoledronic acid; Doxorubicin 50 mg/m² i.v. followed by 
Cyclophosphamide 500 mg/m2 i.v. and Docetaxel 75 mg/m² i.v. on day 
1, Pegylated G-CSF 6 mg once per cycle s.c on day 2, zoledronic acid 
4 mg i.v in 15 minutes within 24 hours after infusion of chemotherapy. 
Arm B: 6x TAC q 3 weeks; Doxorubicin 50 mg/m² i.v. followed by 
Cyclophosphamide 500 mg/m2 i.v. and Docetaxel 75 mg/m² i.v. on 
day 1, Pegylated G-CSF 6 mg once per cycle s.c on day 2.
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Eligibility criteria: Main inclusion criteria are large resectable or 
locally advanced breast cancer (T2,T3,T4, every N, M0), measurable 
disease, histological proven HER2-negative breast cancer, age ≥18 
years, WHO 0-2, adequate bone marrow-, renal- and liver function, 
written informed consent. Main exclusion criteria are evidence of 
distant metastases (M1), history of breast cancer, prior breast surgery, 
prior chemotherapy or radiation therapy, previous malignancy within 
5 years, prior bisphosphonate usage, peripheral neuropathy > grade 
2, current active dental problems.
Study endpoints: The primary endpoint of this study is the pathologic 
complete response (pCR) rate to neoadjuvant chemotherapy with or 
without zoledronic acid at surgery. Secondary endpoints are clinical 
response (RECIST 1.1), ER/PR and HER2 heterogeneity in core 
biopsy vs. operation specimen, toxicity, disease free survival and 
overall survival.
Optional side studies include fluorescent imaging (SoftScan®), 
changes in bone biochemical markers and the insulin-like growth 
factor (IGF) pathway, circulating tumor cells (CTC’s) and circulating 
endothelial cells (CEC’s), the false-negative rate of the sentinel 
node biopsy after neoadjuvant chemotherapy, single nucleotide 
polymorphisms (SNPs) and Ki-67, apoptotic index and IGF pathway 
in core biopsy and operation specimen.
Statistical Methods: This study is designed as a randomized, open-
label, multi centre phase III trial. It is anticipated that using a 5% 
significance level based on the two-sided Fisher’s exact test with a 
power of 80%, a total number of 250 patients (125 patients in each 
arm) are needed to show an improvement of the pCR rates from 17% 
in arm B to 34% in the experimental arm A. Randomization will be 
done according to the Pocock’s minimization technique stratified 
by cT-classification, cN-classification and estrogen receptor status. 
The primary endpoint will be analyzed using the Cochran-Mantel-
Haenszel test.
An interim efficacy analysis (analyzing pCR) after 100 operated 
patients is planned.
Accrual: Patients are currently being included from 27 centers in the 
Netherlands. Presently (16th June 2011) a total number of 116 patients 
have been included since start of the study (July 2010). The expected 
end of accrual of 250 patients will be the last quarter of 2012.
OT1-02-01
Phase II Neoadjuvant Trial of Anthracycline Based Regimens 
Followed by a Combination with Nanoparticle Almumin-Bound 
Paclitaxel and Trastuzumab in Patients with Operable T2-3,N0-
1,Her2 Positive Breast Cancer.
Iwamoto M, Takahashi Y, Kimura K, Tanaka S, Uchiyama K. 
OsakaMedical College, Osaka, Japan
Background: Anthracycline and taxane have been widely used and 
studied in neoadjuvant setting for treatment of locally advanced 
breast cancer. Various regimens have explored the addition of 
newer agents to determine safety and efficacy, and pathological 
complete response(pCR) has been demonstrated to be associated 
with favorable overall survival in primary breast cancer. In addition, 
Three year median follow-up data of the TECHNO Trial revealed 
that the neoadjuvant combination of trastuzumab and chemotherapy 
resulted in a high chance for a pCR. We conducted a clinical Phase 
II neoadjuvant trial of Anthracycline based regimens(EC,AC,FEC) 
followed by a combination with nanoparticle albumin-bound 
Paclitaxel and Trastuzumab in patients with operable T2-3,N0-1,Her2 
positive breast cancer.
Patients and Methods: The study is designed to evaluate EC or AC 
or FEC followed a combination of nanoparticle almumin-bound 
Paclitaxel and Trastuzumab as neoadjuvant therapy in patients 
with Her2 positive locally advanced(T2-3,N0-1) breast cancer. 
Patients are treated with neoadjuvant EC(Epirubicin 90 mg/m2, 
Cyclophosphamide 600 mg/m2) or AC(Doxorubicin 90 mg/m2 , 
Cyclophosphamide 600 mg/m2) or FEC(Fluorouracil 500mg/m2, 
Epirubicin 100 mg/m2 , Cyclophosphamide 500 mg/m2 ) q21d x 
4, follosed by a combination with nanoparticle almumin-bound 
Paclitaxel(260 mg/m2 ) and Trastuzumab q21d x 4.
Patients undergo surgery 4-6 weeks later from completing 
chemotherapy. pCR, the primary endpoint is defined as no evidence 
of invasive tumors in the final surgical sample both in the breast and 
axillary lymph nodes. Secondary endpoints include objective clinical 
response rate, disease-free interval, overall survival, rate of breast 
concerving surgery, and the safety of the treatment.
OT1-02-02
HALT MBC: HER2 Suppression with the Addition of Lapatinib 
to Trastuzumab in HER2-Positive Metastatic Breast Cancer 
(LPT112515).
Lin N, Danso M, David A, Muscato J, Ellis C, DeSilvio M, Garofalo 
A, Nagarwala Y, Winer E. Dana-Farber Cancer Institute; Virginia 
Oncology Associates; Augusta Oncology Associates; Missouri Cancer 
Associates; GlaxoSmithKline
Background 
Lapatinib in combination with trastuzumab enhanced anti-tumor 
activity in HER2-positive breast cancer (BC) preclinical models. In 
patients (pts) with trastuzumab-treated, HER2-positive metastatic 
(M) BC, treatment with the combination was associated with longer 
progression-free (PFS) and overall survival (OS) compared with 
lapatinib alone. In pts with stage II/III BC, preoperative treatment 
with the combination plus paclitaxel resulted in significantly higher 
pathological complete response rates compared with paclitaxel 
combined with either agent alone. This evidence supports the concept 
of dual HER2 blockade as a treatment strategy for HER2-positive 
BC. This present study is designed to evaluate whether the addition 
of lapatinib improves PFS among women with HER2-positive MBC 
receiving trastuzumab as maintenance therapy.
Trial Design
In this open-label, Phase III study, pts are stratified by line of treatment 
(first/second) and hormone receptor status (positive/negative) then 
randomized 1:1 to receive maintenance treatment with either lapatinib 
(1000mg once daily, continuously) in combination with trastuzumab 
(6mg/kg once every 3 weeks [Q3W]) or trastuzumab (6mg/kg Q3W) 
alone. Pts will receive study treatment until disease progression, death, 
discontinuation due to adverse events or other reasons.
Eligibility Criteria
Pts with HER2-positive MBC who have completed 12-24 weeks of 
first- or second-line treatment with trastuzumab plus chemotherapy 
and have objective response or stable disease. Pts with stable brain 
metastasis are eligible if entering the study on second-line treatment.
Specific Aims
The primary objective is to compare PFS of lapatinib in combination 
with trastuzumab to trastuzumab as continued HER2 suppression 
therapy. Secondary objectives are to evaluate OS, clinical benefit 
rate, safety and tolerability.
Statistical Methods
Efficacy endpoints will be analyzed in the intent to treat population. 
A total of 193 PFS events from 280 randomized pts will be required 
to detect a 50% increase in median PFS in pts who receive lapatinib 
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plus trastuzumab compared with trastuzumab (median PFS time is 
27 versus 18 weeks, respectively); hazard ratio of 0.67 with an 80% 
power and a 1-sided type I error of 0.025.
Present and Target Accrual
Sixteen of the target 280 pts have been randomized. The trial is 
currently open for accrual in the United States and Canada.
OT1-02-03
EGF114299: Safety and Efficacy of an Aromatase Inhibitor (AI) 
in Combination with Lapatinib (L), Trastuzumab (T) or Both 
for the Treatment of Hormone Receptor-Positive (HR+), HER2+ 
Metastatic Breast Cancer (MBC).
Johnston S, Leigh M, Florance A, Wroblewski S, Gradishar W. Royal 
Marsden NHS Foundation Trust & Institute of Cancer Research; 
GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Research 
Triangle Park, NC; Northwestern University
Background: Data from the L plus letrozole (EGF30008) and the 
Trastuzumab and Anastrozole Directed Against ER-Positive HER2-
Positive Mammary Carcinoma (TaNDEM) studies demonstrated that 
HER2 targeted and endocrine therapy (ET) is a better strategy than ET 
alone. In EGF30008, progression-free survival (PFS) in the HER2+ 
population was statistically significantly longer in the letrozole plus 
L group compared with the letrozole plus placebo group. The HR was 
0.71 (95% CI: 0.53-0.96; stratified log rank P=.019). Median PFS 
was 35.4 weeks in the letrozole plus L group compared with 13.0 
weeks in the letrozole plus placebo group.
The present study (EGF114299) is a phase III, open-label, multicenter 
trial designed to evaluate benefit in overall survival (OS) provided by 
L/T/AI and L/AI, in pts with HR+/HER2+ MBC who have received 
neo-/adjuvant T and ET. It will also provide further data on dual HER2 
suppression in an attempt to prevent acquired endocrine resistance.
Trial Design: Pts will be randomized to 1 of 3 treatment arms: L 1000 
mg po QD plus T (loading dose of 8 mg/kg followed by maintenance 
with 6 mg/kg IV q3w plus an AI po QD); T plus an AI; or L 1500 
mg po QD plus an AI). Choices of AI include letrozole, anastrozole, 
or exemestane.
Eligibility Criteria: HR+ (ER and/or PgR) and HER2+ Stage IV MBC 
pts are to be enrolled. Pts must have received neo-/adjuvant T and 
ET, and are treatment naive for MBC.
Specific Aims: The primary objective is to evaluate OS of L/T/AI as 
compared with T/AI. The secondary objectives are to assess: OS in 
T/AI vs L/AI and T/L/AI vs L/AI; PFS; overall response rate; clinical 
benefit rate; safety and tolerability; and QoL relative to baseline.
A 4-year recruitment is anticipated. More than 200 centers across 25 
countries are planned; approximately 50 centers are currently open 
for enrollment.
Statistical Methods: The study is powered to detect a 42% 
improvement in the risk of death (HR=0.70) in all pts receiving L/T/
AI (median 28.5 months) compared with T/AI (median 20 months). 
The hypothesis will be tested using a 1-sided test for superiority with 
a=0.025 with a power of 80%.
Present and Target Accrual: One (1) of 525 pts has been randomized.
The majority of eligible pts may reside in countries where T is 
commercially available and reimbursable, particularly North America 
and Western Europe. Patients who have participated in previous neo-/
adjuvant trials including a T regimen are eligible, provided they meet 
all other inclusion criteria.
The study is currently recruiting pts, with an anticipated target accrual 
of 525 patients by March 2016.
OT1-02-04
Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of 
Breast Cancer: APHINITY (BIG 4-11/BO25126/TOC4939g).
von Minckwitz G, Baselga J, Bradbury I, de Azambuja E, Scullion 
MJ, Ross G, Saini KS, Piccart-Gebhart M. German Breast Group, 
Neu-Isenburg, Germany; Massachusetts General Hospital, Boston; 
Frontier Science and Technology Research Foundation, Scotland; 
BrEAST Data Center, Jules Bordet Institute, Brussels, Belgium; 
Roche, Welwyn Garden City, United Kingdom; Breast International 
Group Headquarters, Brussels, Belgium; Breast International Group, 
Brussels, Belgium
Background: Approximately 20% of breast cancer (BC) patients 
(pts) have HER2-positive tumors. While the adjuvant use of the 
anti-HER2 humanized monoclonal antibody trastuzumab (T) has 
been shown to improve disease-free (DFS) and overall survival 
(OS), not all pts treated with this agent benefit from this therapy. 
Pertuzumab (P) is a humanized monoclonal antibody that inhibits 
HER2 dimerization and induces ADCC with a complementary 
mechanism of action to T. In HER2-positiveadvanced BC, T and P 
is active in pts who have progressed to T. In the neoadjuvant setting, 
T and P in combination with chemotherapy (CT) nearly doubled 
the pathological complete response rate compared to either T or 
P administered in combination with CT (45.8% vs 29% vs 24%, 
respectively). Therefore, comprehensive HER2 blockade with two 
anti-HER2 monoclonal antibodies warrants further investigation in 
the adjuvant setting.
Trial Design: APHINITY is a prospective, randomized, multicenter, 
double-blind, placebo-controlled study in pts with HER2-positive 
primary BC who have had an excision of their tumor. Pts will be 
randomized to one of 2 arms (1:1 ratio). The investigational arm will 
comprise of a course of adjuvant CT (investigators choice) consisting 
of either an anthracycline-taxane or taxane-platin containing regimens 
and T and P for 1 year. The comparator arm will consist of the same 
adjuvant CT backbone with T and placebo for 1 year.
Major Eligibility Criteria:
1. Non-metastatic primary BC histologically confirmed and 
adequately excised
2. Node-positive or node-negative: for patients with node-positive 
disease (pN ≥1), any pT except T0; for patients with node-negative 
disease (pN0), tumor size must be >1.0 cm OR for tumor size between 
>0.5 cm and ≤1.0 cm, at least one of the following features will be 
required: histologic grade 3 OR negative for ER and PgR OR age 
<35 years
3. The interval between definitive surgery for BC and randomization 
must be at least 3 weeks but no more than 7 weeks
4. Baseline LVEF ≥55%
5. HER2-positive BC confirmed by a central laboratory and defined as: 
IHC 3+ in >10% immunoreactive cells OR HER2 gene amplification 
by in situ hybridization [ISH] (ratio of HER2 gene signals to 
centromere 17 signals ≥2)
Aims: The primary objective is to compare invasive disease-free 
survival (IDFS) between both treatment arms. Secondary objectives 
include comparing IDFS including second non-BC, DFS, OS, 
recurrence-free interval (RFI), distant RFI, cardiac safety, overall 
safety and health-related quality of life in the two treatment arms.
Statistical Methods: Pts will be stratified based on nodal status, type 
of adjuvant CT regimen, hormone receptor status and geographical 
region. The study is designed to have an 80% power to test the null 
hypothesis of no true difference in risk of an IDFS event (HR = 1) 
versus the alternative hypothesis of a difference (HR = 0.75) in hazard 
rates with a 5%, 2-sided significance level.
Target accrual: 3806; Present accrual: Start Q4 2011
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OT1-02-05
A Phase III Clinical Trial Comparing Trastuzumab Given 
Concurrently with Radiation Therapy to Radiation Therapy 
(RT) Alone for Women with HER2-Positive DCIS Resected by 
Lumpectomy: NSABP B-43.
Julian TB, Anderson SJ, Cobleigh MA, Siziopikou KP, Arthur DW, 
Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Chu L, Leasure NC, 
Atkins JN, Polikoff J, Seay TE, McCaskill-Stevens W, Rabinovitch 
R, Wolmark N. National Surgical Breast & Bowel Project (NSABP, 
Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA; 
University of Pittsburgh Graduate School of Public Health and 
NSABP Biostatistical Center, Pittsburgh, PA; Rush University 
Medical Center, Chicago, IL; Northwestern University Feinberg 
School of Medicine, Chicago, IL; Virginia Commonwealth University, 
Richmond, VA; Aultman Health Foundation, Canton, OH; Colorado 
Cancer Research Program, Denver, CO; Iowa Oncology Research 
Association, Des Moines, IA; Florida Cancer Specialists, Sarasota, 
FL; Reading Regional Cancer Center, West Reading, PA; SCCC-
CCOP, Goldsboro, NC; Kaiser Permanente Southern California, San 
Diego, CA; Atlanta Regional Community Clinical Oncology Program, 
Atlanta, GA; National Cancer Institute, Rockville, MD; University 
of Colorado, Aurora, CO
Background: Because a substantial portion of DCIS is ER negative 
and overexpresses HER2, therapy targeting this protein is a promising 
strategy for HER2-overexpressing DCIS.
Preclinical studies have shown that trastuzumab (T) boosts the 
effectiveness of RT in xenograft models and in cell lines with 
no detrimental effect on irradiated HER2-normal cells. Studies 
correlating clinical response with molecular markers in T-treated 
patients show that apoptosis occurs within 1 wk of starting single-
agent T, with little effect on proliferation. Shorter duration treatments 
with this agent require investigation. Adjuvant trials using T during 
breast irradiation have already provided ample safety evidence.
Will T administered during WBI improve lumpectomy + WBI results 
in women with HER2-positive DCIS? This trial will allow us to 
better understand the biology of breast cancer and its prevention 
and will extend the benefits of breast-conserving surgery for women 
with DCIS.
Trial Design: Post lumpectomy for DCIS without evidence of an 
invasive component, a central review of each patient’s pure DCIS 
lesion is carried out for HER2 by IHC analysis. If the HER2 is 2+, 
FISH analysis is done, and patients whose tumors are HER2 3+ or 
FISH positive can be randomly assigned to receive 2 doses of T 3 
wk apart during WBI or to receive WBI alone.
Eligibility criteria: Women 18 years or older with an ECOG status 
of 0 or 1 who have undergone a margin-clear lumpectomy for DCIS 
and whose tumors are clinically or pathologically node negative are 
eligible. DCIS must be HER2 positive by central testing. ER and/or 
PR status must be known before random assignment.
Specific aims: The primary aim is to determine if T given concurrently 
with WBI is more beneficial in preventing IBC recurrence, ipsilateral 
skin cancer recurrence, or ipsilateral DCIS compared with WBI alone 
for HER2-positive DCIS resected by lumpectomy. Secondary aims are 
to compare the possible benefit of T given during WBI to that of WBI 
alone in preventing regional or distant recurrence and contralateral 
invasive or DCIS breast cancer. B-43 will determine if invasive or 
DCIS DFS, recurrence-free interval, and OS can be improved with 
the addition of T to WBI. The effects of T on ovarian function in 
premenopausal women will also be assessed.
Statistical methods and accrual: Our design calls for accrual of 2000 
patients during a 7.9-year period. As of May 31, 2011, 578 patients 
have been entered. A definitive analysis of primary endpoints will be 
performed when 163 ipsilateral breast cancer events occur (7.5 and 
8 years after protocol initiation). This number of events affords 80% 
power to detect a hazard reduction of 36%, from 1.73 ipsilateral breast 
cancer events per 100 patient-years to 1.11 events per 100 patient-
years. The 36% observed reduction in the hazard of IIBCR-SCR-DCIS 
on the T arm is based on a projection of 40% hazard reduction if the 
compliance were perfect, with a 10% noncompliance rate.
Supported by PHS grants NCI-U10-CA-69651, NCI-U10-CA-12027, 
and NCI P30-CA-14599 from the US NCI and Genentech, Inc.
OT1-02-06
DETECT III – A Multicenter, Randomized, Phase III Study To 
Compare Standard Therapy Alone Versus Standard Therapy Plus 
Lapatinib in Patients with Initially HER2-Negative Metastatic 
Breast Cancer and HER2-Positive Circulating Tumor Cells.
Melcher CA, Janni W, Ortmann U, Jäger B, Rack B, Müller V, 
Schneeweiss A, Pantel K, Solomayer E-F, Fehm T. University Hospital 
Duesseldorf, Duesseldorf, Germany; University Hospital Munich, 
Munich, Germany; National Center for Tumor Diseases Heidelberg, 
Heidelberg, Germany; University Hospital Hamburg, Hamburg, 
Germany; University Hospital Homburg, Homburg/Saar, Germany; 
University Hospital Tuebingen, Tuebingen, Germany; University 
Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany
Background
In breast cancer patients, HER2 status may change over the course 
of the disease. Approximately 20-30 % of initially HER2-negative 
patients have HER2-positive metastasis (Zidan et al. 2005, Tewes 
et al. 2009). Re-evaluation of HER2 status on metastatic tissue is 
warranted, but not always possible, especially during the course 
of therapy. Determining HER2 status on circulating tumor cells is 
one option for re-evaluating HER2 status at the time metastasis is 
diagnosed as described in our previous study DETECT I (Fehm et al. 
2010). However, at present it is unclear if therapy based on the HER2 
status of CTC offers a clinical benefit for patients.
Therefore, the study DETECT III aims to assess whether lapatinib, 
as one of the HER2-targeted therapies, in initially HER2-negative 
breast cancer patients with HER2-positive CTC is effective at the 
time of distant disease.
Trial Design
DETECT III is a prospective, multicenter, randomized, open-label, 
two arm phase III study. As only half of the patients with HER2-
negative MBC will be CTC-positive and approx. 32% will exhibit 
HER2-positive CTCs a screening of about 1420 patients will be 
needed. Approx. 228 patients will be enrolled in the study and 
randomized 1:1 to one of the following regimens Arm A (n=114): 
Standard Treatment, Arm B (n=114): Standard Treatment plus 
Lapatinib.
Planned duration of individual study participation 
•Max. duration of randomized treatment period: 12 months
•Max. follow-up period: 24 months
Main eligibility criteria
1. Metastatic breast cancer
2. HER2-negative primary tumor tissue and/or biopsies from 
metastatic sites or locoregional recurrences
3. Evidence of HER2-positive CTCs
4. Indication for a standard chemo- or endocrine therapy whose 
combination with lapatinib is either approved or has been investigated 
in prior clinical trials
5. Tumor evaluation within 6 weeks before randomization
6. ≥ 1 lesion that can be accurately measured according to RECIST
7. LVEF ≥ 50
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Specific aims
Objective
The objective of the trial is to prove the clinical efficacy of lapatinib in 
patients with metastasizing breast cancer who exhibit HER2-positive 
circulating tumor cells (CTC) although the primary tumor tissue and/
or biopsies from metastatic sites were investigated for HER2 status 
and showed HER2-negativity.
Primary endpoint:
•Progression free survival
Secondary endpoints:
•Overall response rate
•Clinical benefit rate
•Overall survival
•Dynamic of CTC
•Quality of life
•Safety and tolerability of lapatinib
Statistical methods
The primary endpoint will be analyzed by Kaplan-Meier method 
using the logrank test in order to compare the PFS distributions of 
the two arms.
Efficacy, toxicity and other event rates are calculated, providing 
confidence intervals. In case of comparison between patient groups, 
these rates will be analyzed by Fisher’s exact test or x² test. The Kaplan 
Meier analysis for all event related data will be carried out overall for 
the whole patient population. Furthermore a Cox regression analysis 
will be done using the following covariates
•Hormone receptor status (positive/negative)
•Number of prior chemotherapy lines for metastatic disease
•Prior endocrine therapy for metastatic disease
•Endocrine treatment vs. cytotoxic treatment
•One metastatic site vs. multiple metastatic sites
•Bone metastases vs. no bone involvement
•Performance status (0 / > 0)
OT1-02-07
NSABP B-47: A Randomized Phase III Trial of Adjuvant 
Therapy Comparing Chemotherapy Alone (Six Cycles of 
Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin 
Plus Cyclophosphamide Followed by Weekly Paclitaxel) to 
Chemotherapy Plus Trastuzumab in Women with Node-Positive 
or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
Fehrenbacher L, Jeong J-H, Rastogi P, Geyer CE, Paik S, Ganz 
PA, Land SR, Costantino JP, Swain SM, Mamounas EP, Wolmark 
N. National Surgical Adjuvant Breast and Bowel Project (NSABP) 
Operations and Biostatistical Centers; Kaiser Permanente, Northern 
California; University of Pittsburgh Graduate School of Public 
Health; University of Pittsburgh Cancer Institute, University of 
Pittsburgh School of Medicine; Allegheny General Hospital; Jonsson 
Comprehensive Cancer Center at UCLA; Washington Cancer 
Institute, Washington Hospital Center; Aultman Health Foundation
Adjuvant studies utilizing trastuzumab in early HER2+ breast 
cancer demonstrated a large reduction in recurrence and death. Post-
enrollment central testing showed HER2 non-amplified participants 
derived similar benefit. Among HER2-amplified patients, multiple 
studies showed no effect on benefit by degree of amplification. 
Extensive testing including blinded external review confirmed the 
non-amplified nature of the HER2 normal group. Detailed relevant 
background and confirmatory studies will be provided. As a result 
of these findings, NSABP study B-47, sponsored by the NCI, was 
activated January 2011. The study is NCI central IRB approved, open 
in the CTSU, and endorsed by SWOG as of April 2011.
Study: Selection of one of the two chemotherapy regimens is by 
physician choice: The non-anthracycline regimen is TC (docetaxel 
75 mg/m2, cyclophosphamide 600 mg/m2) administered IV every 
3 weeks for 6 cycles; the anthracycline regimen is AC followed 
by WP (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/
m2 administered IV either every 3 weeks or every 2 weeks [per 
investigator discretion] for 4 cycles followed by paclitaxel 80 mg/
m2 IV weekly for 12 doses). Patients will be randomly assigned 
to receive chemotherapy with or without trastuzumab therapy. For 
patients receiving the TC chemotherapy regimen, trastuzumab will 
be given every 3 weeks during and following chemotherapy until 1 
year after the first trastuzumab dose (8 mg/kg loading dose; 6 mg/
kg for the remaining doses). For patients receiving the AC followed 
by WP chemotherapy regimen, trastuzumab will begin with the first 
dose of weekly paclitaxel and will be given weekly for 12 doses 
(4 mg/kg loading dose; 2 mg/kg for the remaining weekly doses). 
Following completion of WP, trastuzumab therapy will continue with 
6 mg/kg doses given every 3 weeks for a total of 1 year. Patients 
will also receive adjuvant radiation therapy and endocrine therapy, 
as clinically indicated.
Detailed menstrual history, concurrent medications, weight changes, 
and biomarkers (estrogen, stress, inflammation status) will be 
collected throughout the study. Collection of circulating tumor cells 
as an ancillary study is planned.
Eligibility: Eligibility includes: node positive or high risk node 
negative female breast cancer patients; HER2 IHC 1+ or 2+ scores, 
but non amplified by FISH; normal cardiac, renal, and liver function. 
Detailed eligibility will be provided.
Statistical: The primary aim is to determine whether the addition 
of trastuzumab to chemotherapy improves invasive disease-free 
survival (IDFS).
3260 patients will be enrolled to provide statistical power of 0.9 to 
detect a 33% reduction in the hazard rate of IDFS using a one-sided 
alpha level of 0.025. Projected accrual time is approximately 3 years.
Progress: Protocol was activated in January 2011. First patient was 
entered in February 2011. As of June 16, 2011, 115 of 3260 patients 
have been enrolled. Supported by NCI U10-12027, -37377, 69651, 
69974, and Genentech, Inc.
OT1-02-08
The PERSEPHONE Trial: Duration of Trastuzumab with 
Chemotherapy in Women with HER2 Positive Early Breast 
Cancer. Changing the Randomisation Point To Address Potential 
Barriers to Recruitment.
Earl HM, Loi S, Vallier A-L, Hiller L, Ogburn-Storey E, Higgins 
H, Dunn J. Addenbrooke’s Hospital, Cambridge, United Kingdom; 
University of Warwick, Coventry, United Kingdom
Background: Persephone is a phase III randomised controlled trial 
comparing six months of trastuzumab (9 doses) to the standard 12 
month duration (18 doses) in patients with HER2 positive early 
breast cancer in respect of disease free survival, safety and cost-
effectiveness. The trial opened to recruitment in October 2007 but 
soon showed that meeting recruitment targets was challenging, 
reaching only 20-30 patients per month. A key issue seemed to be 
the mandatory requirement to randomise before patients started 
trastuzumab treatment. Successful accrual of patients in the PHARE 
trial, a Persephone sister study, run by the National Institute for 
Cancer, Paris had not incorporated this criteria.
Method: In September 2009, following accrual of 316 patients, 
this potential barrier to recruitment was addressed by a major 
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protocol amendment which relaxed the eligibility criteria to allow 
randomisation of patients who had received up to 9 doses of 
trastuzumab.
Results: To date, 1334 patients have been randomised into 
PERSEPHONE. After the amendment, monthly recruitment increased 
to 40-50 patients and, more recently, to 60-70 patients. Of the 1018 
patients recruited since September 2009, 450 (44%) patients had 
received at least 1 dose of trastuzumab pre-randomisation (see Table).
Number of trastuzumab doses received pre-randomisation in 1018 patients.
Number of trastuzumab doses received pre randomisation N %
0 557 55%
1 142 14%
2 74 7%
3 67 7%
4 42 4%
5 32 3%
6 27 2.5%
7 27 2.5%
8 20 2%
9 19 2%
Unknown 11 1%
Retrospective collection of pre-randomisation trastuzumab dose and 
toxicity information has proved successful, allowing analyses of dose 
intensity, toxicity and compliance to be carried out on all patients.
Conclusion: Relaxing the eligibility criteria has considerably 
improved recruitment into the PERSEPHONE trial without 
compromising the important endpoints the trial sets out to assess.
OT1-02-09
A Phase II Randomized Trial of Lapatinib with Either Vinorelbine 
or Capecitabine as First- and Second-Line Therapy for HER2-
Overexpressing Metastatic Breast Cancer.
Janni W, Pikiel J, Sarosiek T, Karaszewska B, Papadimitriou CA, 
Schwedler K, Alavarez Gallego J, Caruso M, Herve RA, Lau MR, 
Williams LS, Briggs K, Sapunar FJ. Heinrich-Heine-Universität; 
Wojewódzkie Centrum Onkologii; Centrum Medyczne Ostrobramska; 
Przychodnia Lekarska KOMED; Alexandra Hospital; Johann-
Wolfgang-Goethe-Universität; Hospital Provinval de Zamora; 
Humanitas Centro Catanese di Oncologia; Centre Médical Clarval; 
GlaxoSmithKline
Background: Lapatinib, a dual kinase inhibitor of epidermal 
growth factor receptor (EGFR) and the human epidermal growth 
factor receptor-2 (HER2/ErbB2), is approved for the treatment of 
HER2-overexpressing (HER2+) metastatic breast cancer (MBC) 
in combination with capecitabine following progression after 
trastuzumab, anthracyclines, and taxanes. Vinorelbine is an important 
chemotherapy option in MBC, and multiple phase II trials in 
combination with trastuzumab have been conducted.
Methods: This randomized, open-label, multicenter, phase II study 
(VITAL, LAP112620, NCT01013740) is evaluating the efficacy and 
safety of lapatinib with either vinorelbine or capecitabine in women 
with HER2+ MBC. A total of 105 stage IV breast cancer patients with 
disease progression who have received ≤1 chemotherapy regimen in 
the metastatic setting with an ECOG performance status of ≤1 are 
randomized 2:1 to either: lapatinib 1250 mg orally once daily (QD) 
continuously plus vinorelbine 20 mg/m2 intravenously on days 1 and 
8 every third week; or lapatinib 1250 mg orally QD continuously plus 
capecitabine 2000 mg/m2/d orally in 2 doses 12 hours apart on days 
1 to 14 every third week. Following progression in the randomized 
phase, patients will be given the option to cross over to the other 
arm. The primary endpoint is progression-free survival and will be 
analyzed with a descriptive intent since the study is not powered to 
detect differences between treatment arms. Secondary endpoints 
include overall response rate, overall survival, duration of response, 
time to response, and clinical benefit rate.
The study is currently recruiting in 8 countries in Europe (Bulgaria, 
France, Germany, Greece, Italy, Poland, Serbia, Spain) and 2 in Latin 
America (Chile, Mexico).
Funding Source: GlaxoSmithKline
OT1-02-10
Phase I-II Study of HER2 Vaccination with Poly(I) • Poly(C12U) 
(Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer 
Patients.
Higgins DM, Childs J, Parker S, Guthrie KA, Disis ML, Salazar LG. 
University of Washington, Seattle, WA; Fred Hutchinson Cancer 
Research Center, Seattle, WA
Background: Despite improved response rates and overall survival, 
many HER2+ breast cancer (BC) patients have disease relapse 
suggesting residual microscopic disease. HER2 vaccines given with 
adjuvants that can enhance, sustain, and skew antigen immunogenicity 
toward a Th1 phenotype could induce robust tumor-specific Th1 
immunity resulting in immunologic eradication of residual tumor 
cells and potentially prevent relapse. One such adjuvant is Ampligen 
which is highly selective as a TLR-3 agonist. Our pre-clinical studies 
show a dose effect in the tumor prevention efficacy of Ampligen when 
given as an adjuvant with vaccines. We hypothesize HER2 peptide 
vaccination given with standard adjuvant 100mcg GMCSF and 
Ampligen can induce a higher incidence and magnitude of protective 
HER2-specific Th1 immunity than with GMCSF alone.
Trial design: Phase I-II randomized 2-stage HER2 vaccine study. 
Stage I will enroll 40 patients (10/arm) into one of 4 Ampligen 
dose arms (4, 20, 79, or 495 mcg + HER2 vaccine). The Ampligen 
“maximum biologic dose” (MBD), the dose with the highest 
incidence/magnitude of immune response and lowest incidence of 
toxicity will be defined. Stage II will enroll 48 patients (24/arm) 
receiving Ampligen MBD + HER2 vaccine + GMCSF or HER2 
vaccine + GMCSF to evaluate if Ampligen MBD increases the 
incidence and magnitude of immunity vs HER2 vaccine + GMCSF 
alone. Patients will be enrolled sequentially and randomized equally 
into all arms via a permuted block design. Patients will receive 3 
monthly vaccines. Toxicity and immune response will be assessed.
Aims: 1) To evaluate toxicity and define the MBD of Ampligen as 
an adjuvant with HER2 vaccination 2) determine if Ampligen MBD 
when combined with GMCSF as adjuvant and HER2 vaccination 
increases incidence/magnitude of HER2 Th1 immunity compared 
to standard GMCSF alone.
Eligibility criteria: Stage II--IV HER2+ BC patients who: 1) have 
completed definitive standard treatment, and in clinical remission 
2) 14 days post chemotherapy and steroids 3) have adequate blood 
counts 4) are off trastuzumab 5) have no active autoimmune disease.
Statistical methods: In aim 1, we expect mild toxicity between the 
4 dose arms, thus lack of efficacy based on incidence of immune 
response will be evaluated. Six responses must be observed within 
a dose arm to move forward based on historical 60% response rate 
(RR) with standard GMCSF (probability of continuing if true RR 
is 40% and 70% is 0.17, 0.85, respectively). In aim 2, 24 patients/
arm provides 80% power to detect 40% difference in incidence of 
immune response between the 2 groups (Pearson chi-square test, 
two-sided alpha of 0.05) and 82% power to assess a 0.85 SD unit 
difference in change between control and MBD, based on a 2-sample 
t-test (p=0.05) and effect size defined as the difference in the means 
divided by the common SD. Incidences of HER2 Th1 immunity 
will be compared across treatment arms via Pearson chi-square test; 
magnitude of immune response will be compared across groups via 
linear regression model.
CTRC-AACR San Antonio Breast Cancer Symposium
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Study Accrual: Target accrual is 88 patients: Stage 1 (n=40) and 
Stage II (n=48). There has been no accrual at this time.
OT1-02-11
MotHER: A Registry Developed for Women with Breast Cancer 
Who Have Received Trastuzumab within 6 Months Prior to 
Conception or during Pregnancy.
Brown VD, Andrews EB, Wang LI, Chu LK, Trudeau C, Keppler-
Noreuil KM. Kendle International, Wilmington, NC; RTI International, 
Research Triangle Park, NC; Genentech, South San Francisco, CA; 
Univ. of Iowa Hospital and Clinics, Iowa City, IA
Background: Trastuzumab is a humanized monoclonal antibody that 
targets HER2, a protein that is overexpressed in approximately 20% 
of patients with breast cancer (BC). Trastuzumab is approved for the 
treatment of HER2-positive BC in both the metastatic and adjuvant 
settings, and is classified as US Food and Drug Administration 
(FDA) Pregnancy Category D, which indicates evidence of fetal 
harm, but benefit may outweigh risk. In the postmarketing setting, 
oligohydramnios has been reported in patients who received 
trastuzumab during pregnancy either alone, or in combination with 
chemotherapy. As a result, this registry was requested by the FDA and 
was established as part of a post-marketing commitment.
Study Design: MotHER uses a prospective, observational cohort 
design to evaluate the outcomes of pregnancies in women exposed to 
trastuzumab within 6 months prior to conception or during pregnancy. 
Women are followed until pregnancy outcome is known; infants 
are followed through the first year of life. Medical information is 
primarily collected from the patient’s healthcare providers (HCPs) 
(ob/gyn, oncologist, pediatrician). Using a standardized recording 
and coding system, information collected on potential defects noted 
at birth or during the pediatric follow-up period is evaluated and 
classified by a birth defect evaluator/clinical geneticist.
Eligibility Criteria: Enrollment is voluntary and must be initiated 
by the patient before the pregnancy outcome. Enrollment may be 
suggested by an HCP. A verbal informed consent process is used. 
Patients with known prenatal testing results may enroll; however, 
to reduce the potential for bias, patients with knowledge of prenatal 
testing results (either normal or abnormal) will be analyzed as a 
separate subset.
Aims: The aim of this study is to evaluate the effects of trastuzumab 
therapy on pregnancy outcome in women who were administered 
trastuzumab while pregnant. The MotHER registry is the first 
prospective cohort study to be established for investigating the effects 
of a targeted cancer therapy on pregnancy outcome. The greatest 
challenge for this registry is to enroll a sufficient number of patients 
from the relatively small population of trastuzumab-exposed women 
who become pregnant.
Analysis Methods: Primary outcome measures are the occurrences 
of oligohydramnios, live births, fetal deaths/stillbirths (≥20 weeks 
gestation), and fetal/infant major malformations, deformations, 
disruptions or functional deficits. Secondary outcomes include 
pre-term births, elective terminations, miscarriages, fetal growth 
abnormalities, and pregnancy or delivery complications. The sample 
size has not been pre-specified. The study is descriptive: event 
proportions and associated confidence intervals will be calculated; 
statistical testing is inappropriate.
Accrual: This registry was activated in December 2008 and will accrue 
in the US over a 10-year period. As of June 20, 2011, 5 patients had 
been enrolled.
Contact Information: Patient and HCP awareness of the registry and 
willingness to participate are crucial to its ultimate success.
OT1-02-12
Early Detection of Cardiotoxicity by Advanced Cardiac Imaging 
and a Novel Biomarker in Breast Cancer Patients Undergoing 
Chemotherapy.
Marfatia R, Inyangetor D, Decena K, Kumar S, Alluri N, Yang 
C, Hager D, Fellows D, Runowicz CD, Kaloudis E, Liang BT, 
Tannenbaum S, Avelar E. University of Connecticut Health Center, 
Farmington, CT
Background
The survival rate of breast cancer patients has increased due to 
improvements in cancer treatment. However, many survivors develop 
irreversible or reversible cardiotoxicity associated with anthracycline 
or trastuzumab therapy, respectively. To detect cardiac damage, the 
currently accepted method is to measure left ventricular ejection 
fraction (LVEF) by echocardiography, which lacks the sensitivity to 
predict early cardiac dysfunction.
Early identification of cardiotoxicity is essential to cancer survivors, as 
development of cardiomyopathy carries a worse outcome independent 
of cancer prognosis. Currently, there are no accepted guidelines for the 
early detection of myocardial injury. The use of cardiac biomarkers 
and more sensitive echocardiographic techniques have expanded 
options for monitoring, but have yet to reach a consensus.
Hence, our study will evaluate the potential predictive value of novel 
cardiac biomarkers and advanced echocardiographic and cardiac 
magnetic resonance imaging (CMR) techniques to detect subclinical 
myocardial damage. Our findings may be applicable for monitoring 
new antineoplastic agents during food and drug administration (FDA) 
clinical trials.
Trial Design
Prospective cohort study with internal control of 20 patients newly 
diagnosed with breast cancer. The trial will assess endpoints at 
baseline, 2 weeks after initiation of therapy, and 2 weeks and 6 months 
after chemotherapy completion.
1. Primary Endpoint
a. Decline in left ventricular ejection fraction assessed by CMR and 
3D-echo not detected by conventional methods
b. Presence of either myocardial fibrosis or edema detected by CMR
c. Changes in myocardial deformation detected by echo or CMR strain
d. Increase in cardiac biomarkers (Serum caspase-3 p17 peptide, 
Troponin I, B-type natriuretic peptide) and possible correlation with 
imaging parameters
2. Secondary Endpoint
a. Development New York Heart Association class 1 to 4 symptoms
b. Decrease in LVEF of ≥5% to ≤50% with or without symptoms
Eligibility Criteria
Inclusion Criteria:
1. Newly diagnosed stage I, II, or III breast cancer
2. Age between 18 and 75 years old.
3. Treatment with trastuzumab or anthracycline-based chemotherapy
Exclusion Criteria:
1. History of cardiovascular disease
2. Pacemaker
3. History of mediastinal radiotherapy
4. Creatinine clearance <30 ml/min
5. Serum bilirubin >2.0 mg/dl, ALT and AST > 100 U/l)
6. Hypertension, uncontrolled >140/90
7. LVEF <55% per 2-D echocardiogram
8. Claustrophobia
Specific Aims
1. Detect early myocardial injury.
2. Evaluate early predictors of left ventricular dysfunction.
3. Evaluate timing of monitoring during or post treatment
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Statistical Method
This is a pilot study and 20 patients are required to reach statistical 
significance with 85% power. All values will be analyzed as mean±SD 
or n (%). Categorical indicators will be analyzed using nonparametric 
statistics such as Cochran’s Q. Changes in imaging and biomarker 
parameters will be assessed using analysis of variance, while 
correlation between the two will be assessed using mixed models 
appropriate for binary outcome. Significance will be accepted at p 
≤0.05 for all tests.
Present accrual and target accrual
Nine subjects are enrolled with a goal of 20.
Contact for people interested in trial:
1. Dr. Erick Avelar, eavelar@uchc.edu
2. Dr. Susan Tannenbaum, stannenbaum@uchc.edu
OT1-02-13
Cardiac Biomarkers on Trastuzumab (Cabot Trial): Determining 
the Cardiac Biomarker Profile in Breast Cancer Patients 
Receiving Adjuvant Trastuzumab Therapy.
Kumar VNC, Kavsak P, Rask S, Mukherjee SD, Ellis P, Dhesy-
Thind B. Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; 
Juravinski Hospital, Hamilton, ON, Canada; Juravinski Cancer 
Centre, Hamilton, ON, Canada
Background: Trastuzumab is a humanized anti-HER2 monoclonal 
antibody that has demonstrated a 50% reduction in the risk of HER2+ 
breast cancer recurrence. This benefit is at the risk of possible cardiac 
dysfunction. Detecting trastuzumab-related cardiotoxicity based on 
physical examination and assessment of left ventricular ejection 
fraction (LVEF) by serial echocardiography or multi gated acquisition 
(MUGA) scan, has low diagnostic sensitivity and low predictive 
power in detecting subclinical myocardial injury. There is interest in 
developing simple, non-invasive, and cost-effective tools for early 
identification of trastuzumab-related cardiotoxicity. Use of easily 
detectible cardiac biomarkers in blood, such as cardiac troponins 
(cTnT and cTnI) and natriuretic peptides (NPs), are being evaluated. 
Kavsak et al. have studied a high-sensitivity cTn (hs-cTn) assay 
that is 10-fold more sensitive, and may be able to identify evolving 
injury earlier when compared to the conventional cTn assays. B-type 
natriuretic peptide (BNP) has been established as an indicator for heart 
failure. Pro-BNP is secreted from the cardiac ventricles in response 
to increased pressure and volume and is divided into NT-pro-BNP 
and BNP. The longer half-life of NT-proBNP may make it a more 
accurate predictor of ventricular stress. Trial design: This is a pilot 
single institution, prospective cohort study of 25 patients. Breast 
cancer patients will be seen at the Juravinski Cancer Centre, Hamilton, 
Canada. Biomarkers will be collected at baseline, then days 1 and 2 of 
every 21 day cycle for the first 3 months, then every 42 days for the 
next 3 months. LVEF will be measured at baseline and then every 3 
months while on trastuzumab. Eligibility criteria: Patients with stage 
I-III, HER2 positive (3+ by immunohistochemistry or FISH+) breast 
cancer receiving adjuvant trastuzumab therapy. Patients who have 
received prior trastuzumab therapy or are unable to provide informed 
consent will be excluded. Specific aims: To determine the biological 
profile of cardiac biomarkers – cTnT, hs-cTn, and NT-proBNP – in 
patients on adjuvant trastuzumab; and, to determine if elevations 
in these biomarkers correlate with LVEF. Statistical methods: A 
convenient sample size of 25 patients will be entered into this pilot 
study. The minimum of 20 patients is a requirement by the Clinical 
Laboratory Standards Institute (CLSI) to formally accept existing 
reference ranges for the cardiac biomarkers to be used in the HER2 
breast cancer population (National Committee for Clinical Laboratory 
Standards (NCCLS)). Present accrual and target accrual: 8 patients 
have enrolled to date.
OT1-03-01
A Randomized Phase III Clinical Trial of Standard Adjuvant 
Endocrine Therapy +/- Chemotherapy in Patients (pts) with 1-3 
Positive Nodes, Hormone Receptor (HR)-Positive and HER2-
Negative Breast Cancer with Recurrence Score (RS) of 25 or 
Less: SWOG S1007.
Gonzalez-Angulo AM, Barlow WE, Gralow JR, Meric-Bernstam 
F, Hayes DF, Moinpour CM, Ramsey SD, Schott AF, Sparks DB, 
Albain KS, Hortobagyi GN. MD Anderson Cancer Center, Houston, 
TX; Cancer Research And Biostatistics, Seattle, WA; Seattle Cancer 
Care Alliance/University of Washington, Seattle, WA; University of 
Michigan, Ann Arbor, MI; Fred Hutchinson Cancer Research Ctr, 
Seattle, WA; University of Michigan and SWOG, Ann Arbor, MI; 
SWOG, San Antonio, TX; Loyola Univ Chicago Stritch School of 
Medicine, Maywood, IL
Background: Multi-gene tumor assays have provided clinically 
useful prognostic information for pts with HR receptor and node-
positive breast cancer. The 21-gene RS was shown to be prognostic 
for pts treated with tamoxifen alone, and exploratory studies 
suggested that it may be predictive of benefit from chemotherapy. In 
retrospective analyses from SWOG S8814, pts with low RS appeared 
to get no benefit from adjuvant CAF chemotherapy, while those with 
higher RS did. These retrospective data require validation, especially 
since more modern chemotherapy might be more effective than the 
regimen used in S8814.
Specific Aims/Trial Design: In January 2011, SWOG activated a phase 
III randomized clinical trial (registration number NCT01272037) to 
test the efficacy of using modern chemotherapy regimens in node 
positive pts with low RS, whose prognosis is still moderately poor 
but may not benefit from adjuvant chemotherapy based on tumor 
biology predicted by the RS value. The trial is similar to the Tailor 
RX study, but focuses on a node-positive population with low and 
intermediate RS.
Eligibility Criteria: Pts with 1 to 3 positive lymph nodes, HR-
positive and HER2-negative invasive breast cancer with RS ≤ 25 
are eligible for randomization. Pts will be informed of their RS. 
Target and Present Accrual: Approximately 9400 patients will 
be screened to randomize 4000, stratified by RS (0-13 vs. 14-25), 
menopausal status, and axillary surgery (sentinel node vs. complete 
dissection); 46 are presently registered. Statistical Methods: The trial 
is powered to find a significant interaction of treatment assignment 
and the continuous RS value and, subsequently, derive a cut point 
for using the assay to guide treatment decisions. Pts who consent to 
screening are required to consent to banking of the tumor tissue and 
blood for further studies. Patient Reported Outcomes will be collected 
pre, post-screening and post-randomization. The study also has a 
cost-effectiveness analysis.
Funding: Supported in part by National Cancer Institute grants 
CA32102 & CA38926, and in part by the Susan G. Komen for 
the Cure® Research Program, and the Breast Cancer Research 
Foundation.
CTRC-AACR San Antonio Breast Cancer Symposium
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OT1-03-02
SAFIR01: A Molecular Screening Trial for Metastatic Breast 
Cancer Patients.
Andre F, Peletekian C, Jimenez M, Ferrero JM, Delaloge S, Roman 
Roman S, Dessen P, Bonnefoi H. Gustave Roussy Institute; Unicancer; 
Curie Institute; Bergonie Institute; Centre antoine lacassagne, Nice, 
France
Background: High number of new drugs are targeting molecular 
alterations that occur in a few number of patients. Molecular screening 
that consists in the assessment of single molecular alteration during 
the screening phase of the therapeutic trial is not suitable. Indeed, 
this modality of screening is associated with a high rate of screen 
failure due to the low incidence of the molecular alteration. In order 
to optimize molecular screening, we have launched a clinical trial 
that aims at performing array CGH and hot spot mutations in patients 
with metastatic breast cancer.
Patients and Methods. The trial plans to include 400 patients with 
metastatic breast cancer and included the first patient in may 2011. 
This trial is being sponsored by French federation of Cancer centers 
(UNICANCER) and involves 20 centers. Biopsy is being performed 
on metastatic site. Both frozen and FFPE samples are obtained. DNA 
extraction is being performed in the investigation center after control 
for the % of cancer cells. Array CGH and PIK3CA/AKT mutations 
(SANGE method) are being performed in four genomic platforms. 
A pilot study that included 106 patients has shown the feasibility of 
such technologies in the context of daily practice. Data from array 
CGH are being sent to a bioinformatician who forward the results on 
both pre-selected targets, DNA instability and some targets of interest 
selected based on log2(ratio) and function. Recommendations for 
trials are then being sent to each investigator. There is no limitation 
for previous lines and it is recommended to perform biopsy in patients 
who do not present progressive disease. This trial is being funded by 
French NCI (750 000 euros)
Conclusion: SAFIR01 is a trial that aims at using high throughput 
technologies in order to drive patients with molecular alterations to 
specific therapeutic trials. Further amendments are being planned 
including implementation of high throughput sequencing and 
performance of functional testing. Further trial will compare this high 
throughput approach to standard methods for target identification.
OT1-03-03
Effect of Tamoxifen Therapy on Inhibition of Tumor Suppressor 
p53 by Estrogen Receptor.
Kulkarni S, Fetterly GJ, Morrison CD, Adjei AA, Andrews C, Edge 
SP, Mukhopadhyay UK, Swetzig WM, Das GM. Roswell Park Cancer 
Institute, Buffalo, NY
Background: A large number of patients with estrogen receptor 
(ER)-positive tumors are resistant to tamoxifen (TAM). Although 
several plausible reasons for such resistance have been suggested, 
the mechanisms remain unclear. ER mediates effects of estrogen by 
promoting proliferation of breast cancer cells. Tumor suppressor 
protein p53 guards against tumorigenesis by preventing proliferation 
of cells with genomic damage. Dr. Das’s laboratory previously 
reported that ER binds and functionally suppresses wild type p53 in 
human breast cancer cells and xenograft tumor tissue, and TAM is 
capable of inhibiting this interaction. We hypothesize that relieving 
suppression of wild type p53 by ER could be an important mechanism 
underlying TAM action in breast cancer. To test this hypothesis, we 
have initiated a pilot randomized clinical trial of 50 women with 
newly diagnosed ERa-positive breast cancer.
Specific Aims: 1) To investigate the effect of a short pre-surgical 
intervention with TAM on the ER-p53 interaction in ER-positive, p53 
wild type breast tumors and 2) To confirm the wild type status of p53 
and analyze the functional status of the p53 pathway by monitoring 
expression of selected p53 target genes in tumors that have and have 
not been treated with TAM.
Trial design: A randomized clinical trial in the pre-surgical setting 
was proposed with either TAM 20mg for four weeks vs. no 
intervention. Patients randomized to the TAM arm will undergo 
multiple pharmacokinetic and phamacodynamic measurements of 
TAM metabolites and genotyping for common polymorphisms of 
TAM metabolism genes, CYP2D6 and CYP3A4/5. Fresh tumor 
tissue will be harvested from all patients at the time of surgery 
for analysis of ER-p53 protein interaction using tissue chromatin 
immunoprecipitation (tissue ChIP) assay. p53 gene status will be 
determined by sequencing. RNA and protein expression of ER, p53, 
and a selected group of ER and p53 target genes in the diagnostic 
core biopsy and surgical specimens will be analyzed by quantitative 
real-time PCR (qRTPCR) and immunohistochemistry (IHC). TAM 
metabolites will also be measured in the tumor and the surrounding 
benign tissue.
Eligibility criteria: Women greater or equal to eighteen years of age 
diagnosed with ER-positive invasive breast cancer (approximately 
1cm in size) who will undergo primary surgical excision for their 
initial therapy are eligible. Women must not be pregnant, be on current 
hormonal therapy, or have a history of hypercoagulable syndrome or 
prior arterial or venous thrombosis.
Statistical methods: Descriptive statistics such as frequencies and 
relative frequencies will be computed for all categorical variables. 
Numeric variables will be summarized using simple descriptive 
statistics such as mean, standard deviation, and quartiles. Ninety-
five percent confidence intervals will be computed. ChIP data will 
be subjected to Fisher’s Exact Test. IHC date will be analyzed by 
Wilcoxon-Mann-Whitney test.
Present accrual and target accrual: We have accrued 17 patients to 
date and plan to accrue a total of 50 patients, 25 in each arm.
OT2-01-01
International Breast Cancer Study Group (IBCSG) Trial 22-
00: Low-Dose Cytotoxics as Maintenance “Anti-Angiogenesis 
Treatment” Following Adjuvant Induction Chemotherapy for 
Patients with ER-Negative and PgR-Negative Breast Cancer.
Colleoni M. International Breast Cancer Study Group
Background
Patients with endocrine responsive disease benefit from five years of 
endocrine therapy after chemotherapy, but for patients with endocrine 
non-responsive disease there is no evidence of benefit of extending 
treatment beyond a standard duration (three to six months). The low-
dose maintenance chemotherapy (metronomic cyclophosphamide and 
methotrexate (CM) given orally) regimen being tested in this trial was 
developed in advanced disease and resulted in tumor shrinkage even 
in heavily pretreated patients. The mechanism of this effect might be 
through anti-angiogenesis or by interference with progression of the 
stromal structure of metastases.
Trial Design
This randomized phase III trial compares 12 months of CM 
Maintenance chemotherapy (CMM) (cyclophosphamide 50/mg/day 
orally continuously for 1 year; methotrexate 2.5 mg/twice a day orally 
days 1 and 2 of every week for 1 year) vs. no CMM, following breast 
cancer surgery and standard induction chemotherapy. Stratification 
factors: institution, menopausal status, induction regimen. Concurrent 
trastuzumab is permitted for patients with HER2-positive disease.
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Major Eligibility Criteria
-Histologically proven primary breast cancer
-Both estrogen and progesterone receptor status negative (<10% of 
tumor cells positive by IHC)
-Known HER2 status
-Approved induction chemotherapy must begin within 8 weeks after 
definitive surgery
-Pathological axillary staging
-Pre-randomization Quality of Life Forms completed
Specific Aim
To evaluate the efficacy of a low-dose chemotherapy regimen, 
hypothesized to have anti-angiogenic activity, administered following 
a standard chemotherapy program, in patients whose tumors are not 
endocrine therapy-responsive.
Statistical Methods
The primary analysis population will be intention-to-treat (all 
randomized patients). The primary endpoint, disease-free survival 
(DFS), will be compared between treatment arms using a two-sided 
stratified logrank test with an alpha level of 0.05.
Based on results from ER-negative populations in other IBCSG 
trials, we assume that the overall five-year disease-free survival for 
the group receiving induction chemotherapy alone will be 70%. Due 
to a relatively high non-adherence rate (14% of 398 early patients 
randomized to CMM did not start CM), the original sample size of 
900 was increased to 1080 (October 2010), and the target number of 
events from 256 to 307. With this revision detection of a true hazard 
ratio of 0.70 will be achieved with a power of 72% despite a 15% 
non-adherence rate in the CMM group.
Present and Target Accrual
Target: 1080 patients. Present: 967 (as of June 1, 2011).
Related Research
Serum Substudy for 170 patients will evaluate differences from 
baseline to 18 months post baseline in serum VEGF, VCAM-1 and 
NRP protein values.
Patient self-reported quality-of-life assessments are collected at 
baseline and months 9, 12, 18, 24 for all patients.
Central pathology review of histology, grade, ER, PgR, Her2, and 
Ki-67 for all patients is ongoing.
OT2-01-02
First-Line Bevacizumab in Combination with Capecitabine or 
Paclitaxel for HER2-Negative Locally Recurrent or Metastatic 
Breast Cancer (LR/MBC): A Randomized Phase III Trial.
Beslija S, Brodowicz T, Greil R, Inbar MJ, Kahán Z, Kaufman B, 
Lang I, Steger GG, Stemmer SM, Zielinski C, Zvirbule Z, The CECOG 
TURANDOT Trialists. Institute of Oncology, Sarajevo, Bosnia 
and Herzegovina; Medical University of Vienna, Vienna, Austria; 
University Hospital Salzburg, Salzburg, Austria; Tel Aviv Sourasky 
Medical Centre, Tel Aviv, Israel; University of Szeged, Szeged, 
Hungary; Sheba Medical Center, Tel Hashomer, Israel; National 
Institute of Oncology, Budapest, Hungary; Rabin Medical Center, 
Petah Tikva, Israel; Riga Eastern Clinical University Hospital, 
Riga, Latvia
Background: A number of phase III studies have shown significant 
progression-free survival (PFS) benefits with the combination of 
bevacizumab (Bev) and either first-line capecitabine (X) or taxane 
therapy in LR/MBC. The ongoing open-label, randomized, phase 
III CECOG-sponsored TURANDOT study (CECOG/BC.1.3.005) is 
investigating the efficacy and safety of first-line Bev plus paclitaxel 
(P) versus Bev plus X in this setting.
Materials and methods: Eligible patients (pts) are aged ≥18 years 
with HER2-negative, chemonaïve LR/MBC, an ECOG performance 
status of 0–2 and a life expectancy >12 weeks. Prior chemotherapy 
and concomitant hormonal therapy for LR/MBC are not permitted, 
but prior (neo)adjuvant chemotherapy is allowed if completed ≥6 
months before randomization or ≥12 months if taxane based. Pts are 
randomized to receive Bev 10mg/kg days 1, 15 plus P 90mg/m2 days 
1, 8, 15, q28d (Arm A) or Bev 15mg/kg day 1 plus X 1,000mg/m2 
bid days 1–14, q21d (Arm B) until disease progression, unacceptable 
toxicity or withdrawal of consent. The primary objective is to 
demonstrate non-inferiority in overall survival (OS) with Bev plus 
P versus Bev plus X (upper limit ≤1.33 for the two-sided confidence 
interval for hazard ratio [HR]). Secondary objectives are: comparison 
of overall response rate (RECIST criteria); PFS; time to response; 
duration of response; time to treatment failure; safety (CTCAE version 
3); and quality of life (EORTC QLQ-30). The recruitment target 
is 560 pts. A sample size of 490 pts in the per-protocol population 
will be required to provide 80% power to reject the null hypothesis 
of inferiority at a one-sided significance level of 0.025, assuming a 
24-month median OS with Bev plus P and an alternative hypothesis 
of HR=1. Data cut-off for adverse event reports was 12 Apr 2010. 
Interim and final efficacy analyses will be triggered after 175 and 
389 events, respectively.
Results: Recruitment to the study began in Sep 2008 and was 
completed in Aug 2010, with 561 pts randomized. Follow-up is 
ongoing.
Conclusions: TURANDOT is the first study to examine the efficacy 
and safety of Bev plus P versus Bev plus X as first-line treatment for 
pts with LR/MBC.
OT2-01-03
Eribulin in Women with Locally Advanced Breast Cancer Who 
Do Not Achieve Pathologic Complete Response (pCR) Following 
Neoadjuvant Chemotherapy: A Sarah Cannon Research Institute 
Phase II Trial.
Yardley DA, Peacock NW, Hainsworth JD, Burris III HA. Sarah 
Cannon Research Institute, Nashville, TN; Tennessee Oncology, 
PLLC, Nashville, TN
Background: Little evidence currently exists to support the use of 
further therapy for women with localized breast cancer who do not 
achieve pathologic complete response (pCR) after treatment with 
standard neoadjuvant chemotherapy. Eribulin is a novel inhibitor 
of microtubule formation via induction of irreversible cell cycle 
arrest at G2/M. It retains in vitro activity against cancer cells that 
are paclitaxel-resistant due to b tubulin mutations, and induces less 
neuropathy in mice when compared with paclitaxel. Eribulin mesylate 
was recently approved by the FDA for the treatment of patients with 
metastatic breast cancer (MBC) who have previously received ≥2 
chemotherapeutic regimens for the treatment of metastatic disease. 
Prior therapy should have included an anthracycline and a taxane in 
either the adjuvant or metastatic setting.
Study Objectives: This phase II trial is designed to assess the efficacy 
of eribulin mesylate in women with localized breast cancer who do 
not achieve pCR following standard neoadjuvant chemotherapy (+ 
trastuzumab in HER2-positive tumors). The primary endpoint is 
2-year disease-free survival (DFS). The secondary goal of this trial 
is to assess the feasibility of the administration of 6 post-operative 
cycles of eribulin in patients (pts) who have received neoadjuvant 
chemotherapy.
Eligibility: Women aged ≥18 years with a histological diagnosis 
of invasive breast cancer (T1-3, N1-2, M0) who have received 
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≥4 cycles of anthracycline and/or taxane containing neoadjuvant 
chemotherapy regimen (+trastuzumab in HER2-positive tumors) are 
eligible. Pts must have failed to achieve a pCR following neoadjuvant 
treatment (i.e. residual invasive breast cancer (>5mm) in the breast 
or lymph nodes at surgery [ypT1b-T4, N1-N2, M0]). Additional 
eligibility criteria include: ECOG performance status of 0-1; adequate 
hematologic, hepatic and renal function. Pts with nonhealed surgical 
wounds, known or active cardiovascular disease, QTc interval > 480 
msecs, chronic use of QTc prolonging drugs, as well as previous breast 
cancer diagnosis <3 years prior to trial entry, are excluded.
Trial Design: Pts are stratified into three cohorts according to HER2 
and hormone receptor status as follows: triple-negative (Cohort 
A, n=54), hormone-receptor positive/HER2-negative (Cohort B, 
n=42) and HER2-positive (Cohort C, n=52). All pts receive eribulin 
mesylate 1.4mg/m2 IV on days 1&8 of each 21–day treatment cycle 
for 6 cycles. Pts with HER2-postive tumors also receive trastuzumab 
6mg/kg IV day 1 of each cycle. Locoregional radiotherapy and/or 
adjuvant hormonal therapy (Cohort B only) will be administered 
per institutional guidelines. With standard neoadjuvant therapy, 
the approximate 2-year DFS of pts who do not achieve pCR are as 
follows: triple-negative, 40%; hormone-receptor-positive/HER2-
negative, 80%; and HER2-positive, 60%. For a one-sided test of 
hypothesis at alpha = 0.10 and power = 0.80, the required numbers 
of evaluable patients treated in each cohort are 49, 38, and 47, 
respectively, to demonstrate improvement in treatment outcome in 
these groups of at-risk pts.
The trial is currently enrolling and has an accrual goal of 148 patients.
OT2-01-04
Cardiac Safety of Anthracycline-Containing Adjuvant 
Chemotherapy of Early Breast Cancer: OSCAR/ABC Ongoing, 
Observational, Multicentric Study.
Ricevuto E, Cocciolone V, Zilli M, Scognamiglio MT, Pistilli B, Di 
Menna G, Mancini M, Cannita K, Adinolfi MI, Ferrandina MG, 
Pancotti A, Recchia F, Latini L, Ficorella C, Iacobelli S. San Salvatore 
Hospital, University of L’Aquila, L’Aquila, Italy; SS. Annunziata 
Hospital and G. Bernabeo Hospital, University G. D’Annunzio, 
Chieti, Italy; Ospedale Civile of Macerata, Macerata, Italy; F. 
Renzetti Hospital, Lanciano, Chieti, Italy; Catholic University of the 
Sacred Heart, Rome, Campobasso, Italy; Mazzini Hospital, Teramo, 
Italy; Ospedale Civile of Avezzano, Avezzano, L’AquILa, Italy
BACKGROUND: Among the different chemotherapeutic options 
available for adjuvant treatment of early breast cancer (EBC), 
anthracycline-containing regimens represent prevalent choices. 
OSCAR/ABC is an observational, prospectic, multicentric study 
aimed at evaluating, in the clinical practice, the relevance of cardiac 
dysfunction and congestive heart failure (CHF) associated to “free 
choice”, anthracycline-containing adjuvant regimens and to identify 
patients at increased cardiac risk. PATIENTS AND METHODS: 
patients candidate to receive adjuvant anthracycline-containing 
chemotherapy, will be enrolled in the study. Data on demographic and 
clinical characteristics of patients (age, cardio-vascular comorbidity) 
tumor features (TNM, histotype, ER and PgR status, Ki67, and HER2 
status), type of adjuvant regimen and tolerability of treatment will be 
collected and centrally registered at the Consorzio Interuniversitario 
Nazionale per la Bio-Oncologia (CINBO) using e-CRFs. Data on type, 
sites and doses of radiotherapy performed will be collected, to evaluate 
the possible impact on cardiac function. Primary aim of the study is 
to evaluate the prevalence of cardiac dysfunction and CHF among the 
whole population enrolled, particularly according to risk criteria and 
type of administered chemotherapy. Cardiac dysfunction is defined 
as limiting cardio-vascular toxicity (≥ Grade 3 dyspnea, arrhytmia, 
hypertension) and/or asymptomatic LVEF reduction ≥20% (if >50% 
at the baseline) or ≥10% (if ≤50% at baseline); CHF is defined as 
clinical diagnosis and/or symptomatic LVEF reduction ≥20% (if 
>50% at the baseline) or ≥10% (if ≤50% at baseline). Assessment 
of cardiac risk involves the evaluation of age (< vs ≥ 65 years), 
cardio-vascular comorbidities (requiring treatment or not) and Left-
Ventricular Ejection Fraction LVEF (> vs ≤ 55%) at diagnosis. Clinical 
and instrumental cardiac evaluation (ECG, Ecocardiography) will be 
performed at study entry, on-treatment and up to 5 years thereafter. 
Secondary objective of the study is to evaluate the clinical properness 
of different adjuvant anthracyclines-containing chemotherapy options, 
with regard to prevalence of therapeutic regimens, safety, efficacy 
(DFS and OS) and costs analysis. Cardiac safety and general toxicity 
on-treatment will be evaluated according to NCI criteria. The expected 
enrollment is 1,200 patients in 36 months. From September 2010 to 
May 2011, 7 of the 13 Centers involved in the study are active, with 
65 enrolled patients.
OT2-02-01
The SOLE Trial: International Breast Cancer Study Group 
(IBCSG 35-07) and Breast International Group (BIG 1-07) Study 
of Letrozole Extension.
Colleoni M. SOLE Collaborative Group and International Breast 
Cancer Study Group
Background
The SOLE trial tests the hypothesis that treatment-free intervals 
during the course of five years of extended adjuvant letrozole will 
improve disease-free survival (DFS). The hypothesis is based on the 
observation in animal models that intermittent letrozole withdrawal 
will permit some estrogenic stimulation which makes residual 
resistant disease susceptible to letrozole reintroduction.
Trial Design
Randomized, Phase III trial comparing 5 years of continuous letrozole 
vs. 5 years of intermittent letrozole. The intermittent group receives 
letrozole daily for the first 9 months (followed by a 3-month gap) 
years 1-4, and 12 months year 5. Stratification factors are institution 
and prior endocrine therapy (SERM, AI or both).
Major Eligibility Criteria
-Postmenopausal
-Disease-free
-Received 4-6 years of prior adjuvant endocrine therapy (SERM 
and/or AI)
-Randomized within 12 months of last dose of prior endocrine therapy
-Endocrine-responsive breast cancer at diagnosis
-Node-positive breast cancer at diagnosis
Specific Aim
To compare continuous and intermittent letrozole given for a five year 
period for postmenopausal women who are disease-free following 
4-6 years of prior adjuvant endocrine therapy with SERM(s) and/or 
AI(s) for endocrine-responsive node-positive operable breast cancer.
Statistical Methods
The primary analysis will be undertaken with the intention-to-treat 
population of all randomized patients. The primary endpoint DFS 
will be compared between treatment arms using a two-sided stratified 
logrank test with an overall experiment-wise alpha level equal to at 
most 0.05.
For the eligible population of patients with node positive disease at 
initial diagnosis, we assume 90% of patients who receive continuous 
extended letrozole will be alive and disease-free at 4 years from 
randomization (based on results of MA.17). The sample size was 
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determined to provide 80% power to detect a 20% reduction in the 
risk of an event defining DFS associated with intermittent letrozole 
compared with continuous letrozole (hazard ratio = 0.80; increase 
in 4-year DFS from 90% to 91.917%) using a two-sided 0.05 level 
test of significance.
Present and Target Accrual
Target: 4800; Present: 2655 (June 1, 2011)
Related Research
The SOLE-EST Substudy focuses on the changes in estrogen 
levels that occur on letrozole and during the three month treatment 
gap without letrozole; and relationships between changes in patient-
reported musculoskeletal symptoms, grip strength and QL. The target 
accrual goal is 100 patients (75 intermittent and 25 continuous).
The SOLE Quality of Life Substudycompares differences in patient-
reported symptoms and QL between continuous letrozole for 5 years 
and intermittent letrozole over a 2-year period. The target accrual 
goal is 834 patients.
Central Pathology Review for all patients of histology, grade, ER, 
PgR, HER2, and Ki-67 is ongoing.
Contact Information
The SOLE trial is a worldwide collaboration among cooperative 
groups and large institutions primarily through the Breast International 
Group (BIG).
OT2-03-01
Incidence of Mastalgia as a Presenting Complaint in Iranian 
Population with Regard to Age, BMI, Education, Residency 
(City or Rural), State of Marriage and Compare with Western 
Countries.
Razavi S. Private Breast Clinic, Esfahan, Islamic Republic of Iran
As it is has usually been stated , breast pain (mastalgia) is among 
the most common (or the commonest) cause of women referring to a 
breast clinic .The incidence has been reported in different ranges ,and 
some studies (e.g. Canadian groups) have stated that mastalgia has 
its lowest incidence in middle east (compared to western countries).
Based on this information ,I have recently planned a study to 
investigate this issue.
To evaluate this data, I planned a questionnaire for every new 
patient coming to my breast clinic randomly. Every questionnaire 
was double checked & if still incomplete, was completed by phone 
communication.
The only inclusion criteria were to be a new patient. In this way over 
550 questioners were completed during over 4 months. The aim is 
to find if there is any statistical difference in incidence rate and if 
there is any, evaluate any demographic difference that can be a cause.
OT2-03-02
Prospective Neo-Adjuvant Registry Trial Linking MammaPrint, 
Subtyping and Treatment Response: Neoadjuvant Breast Registry 
– Symphony Trial (NBRST).
Whitworth P, Beitsch P, Gittleman M, Akbari S. Nashville Breast 
Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast 
Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, 
VA
Background
MammaPrint is performed on a diagnostic multi-gene array featuring 
>4,500 genes. This platform enables additional gene expression 
profiles to be analyzed simultaneously on one tumor specimen. 
BluePrint, an eighty gene Molecular Subtyping Profile, discriminates 
between three distinctive subtypes; Basal-type, Luminal-type, and 
ERBB2 (HER2)-type. Studies have shown marked differences 
in response to neo-adjuvant treatment in groups stratified by 
MammaPrint and BluePrint.
Trial design
A prospective observational, case-only study linking MammaPrint, 
BluePrint, TargetPrint, TheraPrint (together referred to as the 
Symphony suite) and possible additional profiles of interest to neo-
adjuvant treatment response and Distant Metastases Free Survival 
(DMFS) and Relapse Free Survival (RFS).
20-30 institutions in the US will be invited to contribute clinical 
patient data from enrolled patients after a MammaPrint, TargetPrint, 
BluePrint and TheraPrint (Symphony suite) has been successfully 
performed and the patient has started neo-adjuvant therapy. Treatment 
is at the discretion of the physician, adhering to NCCN approved 
regimens or a recognized alternative.
Eligibility criteria
· Women with histologically proven breast cancer, who have started 
or are scheduled to start neo-adjuvant chemotherapy therapy or 
neo-adjuvant hormone therapy, after successful Symphony suite 
assessment
· Age 18-90
· Written informed consent
· No excisional biopsy or axillary dissection
· No confirmed distant metastatic disease
· No prior therapy for the treatment of breast cancer
Scope
The scope of this registry study is to measure chemosensitivity as 
defined by pCR (primary endpoint), or endocrine sensitivity as defined 
by partial response, (a primary endpoint for neo-adjuvant endocrine 
therapy and a secondary endpoint for neoadjuvant chemotherapy), 
metastasis-free survival and relapse-free survival (secondary 
endpoints) in molecular subgroups, determined by the MammaPrint 
and BluePrint; as well as correlation to Targetprint and Theraprint 
read outs in addition to investigating novel response profiles.
Statistical methods
The response rate and corresponding confidence intervals will be 
presented as a proportion of all patients enrolled. The confidence 
intervals will be calculated using the normal approximation to the 
binomial distribution. Comparison of response rates between different 
molecular subgroups will be conducted using Pearson Chi-square test. 
Correlation of chemosensitivity and endocrine sensitivity (as defined 
by pCR) to TheraPrint will be determined using Pearson correlation 
and linear fit models.
Kaplan-Meier curves for RFS and DMFS will be calculated for 
different molecular subgroups.
Present accrual and target accrual 
The target accrual is to enroll approximately 500 patients in 4 years.
OT2-03-03
Spectroscopic Feature of Breast Cancer.
Ogura H, Yamashita D, Nasu H, Hosokawa Y, Koizumi K, Yamaki E, 
Yoshimoto K, Suzuki T, Ueda Y, Oda M, Yamashita Y, Sakahara H. 
Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, 
Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
Objectives: To examine optical properties of breast cancer by time-
resolved spectroscopy.
Materials and Methods: We irradiated a pulsed laser of 760, 800, and 
830 nm wave-length lights at multiple sites of both breasts including 
the site just above the cancer and detected the light transmitted through 
the breast with TRS-20SH (Hamamatsu Photonics K.K.). Absorption 
coefficient (ma), reduced scattering coefficient (ms’), total hemoglobin 
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(tHb), and oxygen saturation (SO2) of the breast were calculated by 
photon diffusion equation. The clinical trial started in January 2007. A 
total of one hundred nine breast cancer patients participated in the trial 
and written informed consent were obtained from all of the patients.
Results: In 800 nm wave-length, absorption coefficient (ma) of breast 
cancer tissue was significantly high, compared with contra-lateral 
normal breast (cancer:0.0677± 0.0293, normal breast;0.0479± 0.0161, 
p<0.001).
Table1
 ma (/cm)  ms’ (/cm)  
 cancer normal breast  cancer normal breast  
760nm 0.076 0.0554 p<0.001 9.499 9.718 p=0.20
800nm 0.0677 0.0479 p<0.001 9.07 9.348 p=0.10
830nm 0.0823 0.0594 p<0.001 8.972 9.194 p=0.17
Absorption coefficient (ma) and reduced scattering coefficient (ms’)of cancer / normal breast
The result was the same in 760, and 830 nm. There was no difference 
in reduced scattering coefficient (ms’) between breast cancer tissue 
and contra-lateral normal breast (800 nm cancer:9.070±1.217, normal 
breast;9.348±1.243, p=0.10). The tHb of breast cancer tissue was 
significantly high, compared with normal breast (cancer:31.0± 14.7, 
normal breast;21.0±8.2, p<0.001). There was no difference in oxygen 
saturation (SO2) between breast cancer tissue and contra-lateral 
normal breast (cancer:72.8±4.1, normal breast;73.8±4.5, p=0.08).
Table2
 cancer normal breast  
tHb (mM) 31.0±14.7 21.0±8.2 p<0.001
SO2(%) 72.8±4.1 73.8±4.5 p=0.08
tHb and SO2 of cancer/normal breast
Conclusion: Absorption coefficient (ma) and tHb increased in breast 
cancer, whereas reduced scattering coefficient (ms’) did not.
OT2-03-04
A Trial Model for the Future in the Search for Personalised 
Medicine – The UK POETIC and EPHOS-B Perioperative Trials 
Experience.
Bliss JM, Robison LE, Webster-Smith MF, Emson MA, Kilburn LS, 
Smith IE, Robertson J, Dowsett M, Bundred NJ, Cameron DA, Vidya 
R, Horgan K, Evans AA, Kokan JS, Pinhel I, A’Hern R, On Behalf 
of the POETIC & EPHOS-B Trialists. Institute of Cancer Research, 
Sutton, London, United Kingdom; Royal Marsden Hospital, London, 
United Kingdom; Nottingham University Hospitals, Nottingham, 
United Kingdom; Royal Marsden Hospital and Breakthrough Breast 
Cancer Centre, London, United Kingdom; Wythenshawe Hospital, 
Manchester, United Kingdom; Western General Hospital, Edinburgh, 
United Kingdom; Stafford Hospital, Stafford, United Kingdom; 
Leeds General Infirmary, Leeds, United Kingdom; Poole Hospital, 
Poole, United Kingdom; Macclesfield District General Hospital, 
Macclesfield, United Kingdom
Background: Perioperative therapy offers the opportunity to measure 
biological response to treatment in the primary tumor in early breast 
cancer (EBC), enhancing prospects for personalised medicine. 
Perioperative trials form an expanding component of the UK national 
breast cancer trials portfolio. Unlike traditional neoadjuvant studies, 
activity dovetails around timelines for standard treatment with no 
planned delay to primary surgery. Tissue samples collected prior to 
randomisation (baseline) & again at surgery address key biological 
endpoints & are essential for perioperative studies.
Methods: As the UK’s largest perioperative trial, POETIC (ER+ve 
postmenopausal EBC, +/- aromatase inhibitor therapy, biomarker & 
disease outcome) aims to recruit 4000 patients from 100+ centres. 
EPHOS-B (HER2+ve EBC, +/- lapatinib or trastuzumab) focuses 
on biomarker endpoints & aims to recruit 250 patients. Barriers to 
recruitment included 1) integration of research protocols into busy 
breast surgical clinics, extending a clinical trials culture across a 
multidisciplinary breast diagnostic team, & ensuring appropriate 
GCP training, 2) satisfying requirements for storing research tissue, 
3) complying with government cancer wait times, 4) obtaining 
biomarker results within required timelines 5) ensuring completeness 
& quality of tissue samples. Additional challenges for EPHOS-B 
include managing requirements for scheduling of oncological therapy 
(e.g. trastuzumab) in pre-operative setting, delivery of such therapy 
outside the randomising hospital & rapid access to cardiac screening 
before randomisation.
Results: The following strategies were developed to overcome 
barriers 1) increasing collaborative working at sites & adopting a 
pragmatic approach to type of tissue required. Centres choose to 
provide both FFPE tissue & tissue in RNA-later, or FFPE tissue only; 
2) working with national regulators to agree interpretation of current 
legislation in designation of when tissue is “in transit” (enabling it 
to reside outside a tissue bank) & “research” tissue (where transfer 
to a tissue bank is required); 3) agreement with government that 
procedures integral to perioperative trials comply with cancer wait 
times; 4) promoting reorganisation of site processes for obtaining 
essential biomarker results; 5) pilot lab work to inform site guidance 
on tissue collection procedures to ensure quality of samples received. 
A tracking database allows completeness of tissue samples to be 
monitored. Work to improve timelines for HER2 testing in EPHOS-B 
is ongoing, & challenges of delivering anti-HER2 therapy in this 
setting have been addressed.
Conclusions: Assessment of biological response to therapy in 
the primary tumor in EBC within national trials is feasible. Many 
barriers faced by POETIC have been overcome, & with recruitment 
now 100+ patients per month, newer centres benefit from earlier 
experience. Lessons learnt in POETIC apply to EPHOS-B, allowing 
investigators to focus on resolving more challenging issues specific 
to that trial. In many centres both trials have been important drivers 
in improving timeliness of molecular testing & therefore benefited the 
patient pathway in general as well as securing high quality trial data.
OT2-03-05
Evaluation of the Prevalence and Prognostic Significance of 
VEGF165b in Breast Cancer Patients Compared to Healthy 
Women.
Guenthner-Biller MM, Rademacher A, Mayr D, Engelstädter V, Friese 
K, Jeschke U, Rack B. Ludwig-Maximilians-University, Munich, 
Bavaria, Germany
Background: VEGF165b mRNA was first isolated in 2002 by RT-PCR 
out of renal cortex tissue which resulted in a shorter PCR product 
than predicted from previously identified isoforms. This isoform was 
subsequently identified and cloned in both primary epithelial cells 
as well as in stable immortalized podocyte cell lines. Because of the 
nature of this splice variant and its distal splicing of the 3’-untranslated 
region of the VEGF mRNA, most previously investigated expression 
studies will not have distinguished VEGF165b form other isoforms. This 
may explain some of the data that does not show clear relationships 
between VEGF expression and angiogenesis. Moreover recent studies 
showing that VEGF-neutralizing antibodies could be more effective 
by targeting the proangiogenic splice variants rather than a pan-VEGF 
strategy. There has been only limited in vitro data regarding the role 
of VEGF165b but no in vivo data regarding the level of expression of 
VEGF165b in breast cancer or its possible correlation with disease 
progression.
Trial design: This is a monocentric observational cohort study with 
the primary objective to estimate the prevalence of VEGF165b in breast 
cancer patients compared to healthy controls and correlate it with 
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existing clinical data. There are two groups of patients included in 
this study; patients with newly diagnosed breast cancer and healthy 
volunteers.
Eligibility criteria: The eligibility criteria for the breast cancer group 
are newly diagnosed ductal, lobular or inflammatory breast cancer at 
stage I-IV, no prior treatment, above 18 years of age. The eligibility 
criteria for the healthy volunteers are healthy women with no history 
of cancer with no current medical therapies and above 18 years of age.
Specific aims: The primary objective of this trial is to estimate 
the prevalence of VEGF165b in breast cancer patients and healthy 
volunteers. The secondary objective is the correlation of VEGF165b 
with clinical characteristics over time.
Statistical method: The statistical analysis being used in this study 
will be primarily descriptive with the calculation of mean and median 
and confidence intervals. The difference in distribution of the values 
will be examined in a one way variant analysis. We will also correlate 
results from different biospecimens and correlate the prevalence of 
variant presence or absence.
Material and methods: The samples will be analysed using a specific 
ELISA as well as immunohistochemistry. The accuracy and sensitivity 
of the available ELISA are of utmost importance in this setting. Bates 
et al have done previous work evaluating the ELISA used in this 
study and have shown that it underestimates the value for VEGF165b 
but that it is specific for VEGF165b. Since we will rather look at 
individual variation over the course of time, it will not have an effect 
regarding the expected results but it prohibits a direct comparison of 
the measured levels of VEGF165 to VEGF165b if they are not corrected 
for this lack in sensitivity.
OT2-03-06
ACRIN 6698 MR Imaging Biomarkers for Assessment of Breast 
Cancer Response to Neoadjuvant Chemotherapy: A Sub-Study 
of the I-SPY 2 TRIAL (Investigation of Serial Studies To Predict 
Your Therapeutic Response with Imaging And moLecular 
Analysis).
Hylton NM, Partridge SC, Rosen M, Kim E, L’Heureux DZ, Esseman 
L. University of California at San Francisco, San Francisco, CA; 
University of Washington, Seattle, WA; Hospital of the University of 
Pennsylvania, Philadelphia, PA; Brown University, Providence, RI; 
American College of Radiology Imaging Network, Philadelphia, PA
Background: Functional MRI techniques may be utilized for 
characterizing breast tumors and measuring response to neoadjuvant 
chemotherapy (NAC). Dynamic contrast enhanced (DCE) MRI is the 
most common functional breast MRI technique. Fitting DCE MRI data 
to an appropriate pharmacokinetic model allows noninvasive, in vivo 
measurement of physiological parameters related to tissue perfusion, 
microvascular permeability, and extracellular/extravascular volume 
fraction. Diffusion weighted imaging (DWI) MRI is an alternative 
technique that measures the mobility of water molecules in vivo and 
is sensitive to tissue characteristics such as cell density, membrane 
permeability, and microstructure. DWI provides complementary 
information to DCE MRI about tumor biology and has shown promise 
for early prediction of response. The master ISPY2 multi-center 
study is a process targeting the rapid, focused clinical development 
of paired oncologic therapies and biomarkers. Its framework is an 
adaptive phase II clinical trial design in the neoadjuvant setting for 
women with locally advanced breast cancer. As a sub-study, ACRIN 
6698 will combine both DCE and DWI MRI data to generate novel 
imaging biomarkers that correlate with treatment response. The 
two studies will provide a rich data set that can be used to elucidate 
molecular pathways and tumor responses to novel investigational 
drugs with standard chemotherapy. Trial design: ACRIN 6698 will 
perform advanced DCE and DWI MR imaging as part of the I-SPY 
TRIAL. The ISPY 2 adaptive therapy design will use different tumor 
biomarker assays to identify patients with high risk of recurrence. 
Patients will receive NAC doublet chemotherapy and trastuzumab 
(if Her2+). Patients will be randomized and stratified into different 
arms receiving investigational agents of different drug classes. ACRIN 
6698 patients will receive four advanced MRI exams (both DCE and 
DWI) at baseline, early therapy, mid therapy and prior to surgery. 
Specific aims: The primary aim will determine if the % change in 
tumor apparent diffusion coefficient (ADC) measured on DWI from 
baseline to early treatment timepoint is predictive of pathologic 
complete response (pCR). The secondary aim will determine if the 
combined measurement of percentage change in tumor ADC on DWI, 
and percentage change in tumor volume and peak signal enhancement 
ratio (SER) on DCE MRI is predictive of pCR. Statistical methods: 
Receiver operating characteristic (ROC) curve and corresponding area 
under the ROC curves (AUC) for the individual marker, % change 
in tumor ADC, and % change in tumor volume and peak SER, will 
be estimated. Linear score of the 3 markers will be derived by fitting 
the multivariate logistic regression model, where the outcome is a 
binary variable for pCR and the predictors are the 3 measurements. 
The ROC curve for the derived linear score will be constructed and 
its AUC value will be estimated. Target accrual: ACRIN 6698 is 
open to ISPY 2 sites. The target accrual is 200 of ISPY 2’s planned 
enrollment of 800 participants.
OT2-03-07
Withdrawn by Author
OT2-04-01
A Randomized Phase II Trial of Vitamin D vs Placebo in 
Premenopausal Women: CALGB 70806.
Wood ME, Kingsley F, Ambaye AB, Yee L, Jung S-H, Marshall 
JR, Paskett E. University of Vermont, Burlington, VT; Ohio State 
University; Roswell Park Cancer Institute; Duke University
Background: Chemoprevention studies are long and expensive. 
Gaining information about the feasibility of an agent using biomarker 
endpoints can save money and ensure that only the most promising 
agents move forward. There is strong evidence to suggest breast 
cancer prevention properties for vitamin D. The safety and tolerability 
of this agent makes it a perfect candidate for a chemopreventive agent. 
This clinical trial will evaluate the effect of vitamin d on several breast 
cancer; providing important information regarding the feasibility of 
a larger chemoprevention study using cancer development as the 
endpoint. Successful completion of this study will also validate this 
design of biomarker testing of potential chemoprevention agents 
within a cooperative group setting and add to data validating these 
specific biomarkers.
Methods: This is a randomized placebo controlled trial of one year 
of 2000 units of vitamin D (cholecalciferol) for premenopausal 
women (≥ 35 years) with increased breast density. The primary aim 
of this study is to evaluate the effect of vitamin D on breast density. 
Secondary aims include evaluation of vitamin D effects on IGF1 
and markers of cellular proliferation (Ki-67 and atypia). In addition 
3 methods of density analysis (Breast Imaging Reporting and Data 
System (BI-RADS), Visual Analogue Scale (VAS), and the Boyd 
method) will be compared. For the primary endpoint of change 
in mammographic density we will have an 87% power to detect a 
standardized effect size (difference in means divided by standard 
deviation) of 0.4 in change of mammographic density between 
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two arms. The target effect size is 2.64%.This study was activated 
10/15/2010 and has been opened at 75 sites with 15 patients enrolled. 
Target accrual is 250.
Funding: This study is sponsored by the NCI and CALGB.
OT2-04-02
Metformin for Breast Cancer Prevention: A Pilot Study.
Ledgerwood MM, Ojeda-Fournier H, Patterson R, Hasteh F, Andre 
MP, Cadmus L, Blair S. University of California, San Diego, CA
Background: There is a body of accumulating evidence connecting 
metformin, a biguanide derivative which reduces hepatic 
gluconeogensis and improves skeletal muscle insulin sensitivity, to 
reduced breast cancer risk. This, in addition to a well established drug 
safety record among diabetics and non-diabetics, has provoked an 
interest in further study of metformin’s effects on breast cancer risk 
indicators. In our study, we examine the effects of metformin on breast 
density and proliferative cell marker Ki67, both indicators of breast 
cancer risk. This is a small observational pilot study to determine the 
feasibility of subject recruitment, data collection through fine-needle 
aspiration, and breast density measurement.
Trial Design: Recruitment of 10 breast surgery patients with high risk 
histology to: 1. Undergo peri-areolar fine needle aspiration (RPFNA) 
used to collect breast cells for analysis of proliferative marker Ki67. 
2. Breast density assessment by a) mammography (the standard 
method) and b) whole-breast ultrasound (an innovative method 
recently developed at UCSD).
Each subject will undergo a single view mammogram, whole-breast 
ultrasound, and intra-operative RPFNA. No drug or therapeutic 
intervention will take place in this pilot study.
Eligibility: Female undergoing excisional high risk breast surgery.
Specific Aims: Aim 1. To determine the feasibility of recruiting 
high risk breast surgery patients to an observational study involving 
RPFNA, mammography, and whole-breast ultrasound. Aim 2. 
a) To compare mammography and whole-breast ultrasound for 
measurement of breast density. b) To examine potential for detecting 
biomarkers of cell proliferation through RPFNA.
Statistical Method: Breast density will be determined by the ratio 
of fibroglandular tissue to fat measured on mammogram and WBU. 
Cell proliferation will be assessed by the percentage of positivity for 
biomarker Ki67 in breast ductal cells.
Accrual and target accrual: Five of ten breast excisional high risk 
breast surgery subjects have been accrued at this time.
OT2-04-03
Uptake of a Randomized Breast Cancer Prevention Trial 
Comparing Letrozole to Placebo in BRCA1/2 Mutations Carriers: 
The FNCLCC ONCO-03/LIBER Trial.
Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker JP, 
Chabbert Buffet N, Lemonnier J, Roca L, Mijonnet S, Baudry 
K, Martin AL. University Hospital CHU Arnaud de Villeneuve, 
Montpellier, France; Centre Léon Bérard, Lyon and Université de 
Lyon 1; CNRS; UMR 5558, Villeurbanne, France; Centre Francois 
Baclesse, Caen, France; Institut Gustave Roussy, Villejuif; Centre 
Paul Strauss, Strasbourg; AP HP Hôpital Tenon; Fédération 
Nationale Française des Centres de Lutte Contre le Cancer
Background: Women with germline BRCA1or BRCA2 (BRCA1/2) 
mutations are an extreme risk population for developing breast cancer, 
with a life-time risk of 56-80%. Prophylactic mastectomy provides a 
valid option to reduce such risk, but it considerably affects the quality 
of life. Medical prevention by aromatase inhibitor that has been 
recently shown to have preventive effect may thus be an alternative. 
LIBER is an ongoing, double-blind, randomized phase III trial to 
evaluate the efficacy of five-years letrozole versus placebo to decrease 
breast cancer incidence in post-menopausal BRCA1/2 mutation 
carriers (NCT00673335). We present data on the uptake of this trial.
Methods: To evaluate theoretical feasibility, we compared inclusion 
criteria of women in the LIBER trial (n=113) to characteristics of 
women entered in the prospective ongoing national GENEPSO cohort 
(n=1505). Uptake was evaluated through a survey sent to all active 
centres, with responses obtained from 17 of the 20 (85%) centres.
Results: According to characteristics of the women included in 
GENEPSO cohort (n=1505) and the survey, approximately one 
third of BRCA1/2 mutation carriers are eligible for this study. From 
november 2009 to may 2010, 534 women eligible from chart review 
have been informed by mail of the trial and were invited to an oral 
information by participating centres. Of them, 44% of women came 
to the dedicated medical visit. Uptake of drug prevention trial was 
32 % of orally informed women and 15 % of overall eligible women. 
Main reasons of refusal were: potential side effects, probability to 
receive the placebo and lack of support from the women’s physicians. 
Prior prophylactic oophorectomy and history ofprevious unilateral 
breast cancer were more frequent in women enrolled in the ONCO-
03/LIBER trial than in the French cohort (93% versus 60% and 50 
% versus 39 %, respectively), suggesting a higher motivation for 
medical prevention in these subgroups of patients.
Conclusion: One third of women with a BRCA1/2 mutation are 
eligible to the ONCO-03/LIBER prevention trial. 32 % of orally 
informed women and, only 15% of overall eligible women entered 
the trial. To reach accrual objective (n=308), a greater information 
of the trial should be offered to women with BRCA1/2 mutation and 
the trial has been proposed to other countries.
OT2-05-01
An Open-Label Positron Emission Tomography Study To 
Investigate and Quantify Brain and Tumor Penetration 
of Carbon-11-Labeled Lapatinib in Patients with HER2-
Overexpressing Advanced or Metastatic Breast Cancer.
Coombes RC, Reise JA, Lau MR, Carme SC, Searle GE, Huiban M, 
Burgess P, Noibi S, Koch K, Sapunar F, Saleem A. Imperial College; 
GlaxoSmithKline Oncology; GlaxoSmithKline Clincial Imaging 
Centre
Background: Patients with HER2-overexpressing (HER2+) breast 
cancer tend to develop visceral metastases. About a third will develop 
brain metastases in the course of their disease. Several anticancer 
agents including trastuzumab are not believed to readily cross the 
blood-brain barrier (BBB); therefore, central nervous system (CNS) 
disease progression is emerging as an important clinical problem 
in this patient population. Although preclinical data indicate that 
lapatinib brain concentrations are low in healthy animals, probably 
due to the BBB efflux transporters, observations from clinical studies 
suggest lapatinib treatment might be associated with reduced CNS 
tumor growth. One hypothesis is that disruption of the BBB by 
tumors circumvents the usual protective function of transporters. 
Alternatively, inhibition of efflux transporters by lapatinib enhances 
its own accumulation with repeat dosing. The role of lapatinib in 
prevention of brain metastases is currently being explored in a phase 
III trial, EGF 111438 (CEREBEL).
Methods: To directly assess if lapatinib penetrates the brain and 
brain metastases, an open-label non-randomized study using 
carbon-11–labeled [11C] lapatinib is enrolling patients with HER2+ 
metastatic breast cancer. A minimum of 10 patients with an ECOG 
of <3 are grouped into 2 cohorts: with at least one 1-cm diameter 
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brain metastasis or without brain metastases. Two positron emission 
tomography (PET) scans will be performed in each patient following 
intravenous administration of a microdose of [11C] lapatinib: in 
lapatinib-naïve patients and at steady-state lapatinib, after treatment 
with unlabelled oral lapatinib 1500 mg once daily for 8 days. [11C] 
lapatinib time-activity curves will be generated for normal brain 
and brain metastases, the PET volume of distribution in the brain 
calculated and penetration of [11C] lapatinib into the brain quantified. 
Analysis of brain PET data is explorative as [11C] lapatinib is a 
new tracer. Therefore, this study investigates both the difference in 
lapatinib brain penetration between patients with and without brain 
metastases, as well as the effect of low and high concentrations of 
lapatinib on the BBB efflux system.
The study is currently recruiting in one center in the United Kingdom.
OT2-05-02
ACRIN 6691 Monitoring and Predicting Breast Cancer 
Neoadjuvant Chemotherapy Response Using Diffuse Optical 
Spectroscopic Imaging (DOSI).
Tromberg BJ, L’Heureux DZ, Mankoff DA, Zhang Z, Cerussi A, 
Mehta R, Carpenter PM, Butler JA, Hylton NM, Kaufman P, Pogue 
BW, Paulsen K, Yodh AG, Boas D, Isakoff S. University of California, 
Irvine, CA; American College of Radiology Imaging Network, 
Philadelphia, PA; University of Washington, Seattle, WA; Brown 
University, Providence, RI; University of California at San Fransisco, 
San Fransisco, CA; Dartmouth University, Lebanon, NH; University 
of Pennsylvania, Philadelphia, PA; Massachusetts General Hospital, 
Charlestown, MA; Massachusetts General Hospital, Boston, MA
Background: Imaging technologies monitoring and predicting breast 
cancer response to neoadjuvant chemotherapy (NAC) are of increasing 
interest. The utility of conventional imaging approaches varies and 
identifies the need for alternate functional imaging strategies. The use 
of model-based photon migration methods to quantitatively separate 
light absorption from scattering in multiply-scattering tissues is a type 
of near-infrared spectroscopy (NIRS) broadly referred to as diffuse 
optical spectroscopy (DOS) [Bevilacqua,et al. Applied Optics, 2000; 
Jakubowski,et al., J of Applied Optics, 2009]. DOSI is a promising 
experimental technology that allows patients undergoing NAC to be 
followed with a “no significant risk” device meeting Food and Drug 
Administration criteria for exempt status. The current design is a 
mobile device which offers increased accessibility and is relatively 
simple to perform and interpret, as compared to mammography, 
magnetic resonance imaging, and positron emission tomography. Due 
to its size and portability, DOSI is a low barrier-to-access technology, 
creating new opportunities for patients to receive personalized 
treatment and for physicians to gain new insight into response 
mechanisms. The long-term goal is to provide oncologists with a 
relatively simple, risk-free bedside tool that can be used to help inform 
medical decisions on chemotherapy regimen, duration, and timing 
of surgery, thereby maximizing therapeutic response and minimizing 
unnecessary toxicity. Trial design: In this phase I/II prospective single 
arm study, patients will receive SOC NAC at five (5) NCI Network 
for Translational Research in Optical Imaging (NTROI) clinical sites 
with identical DOSI instruments and procedures. Patients will receive 
four DOSI exams: at baseline before chemotherapy, at early therapy 
5-10 days after NAC initiation, at mid therapy, and at post therapy 
prior to surgery. The protocol will evaluate a harmonized DOSI 
technology platform that has been standardized for NAC monitoring. 
Eligibility: Women who have been diagnosed with breast cancer, 
have had confirmation by pre-treatment biopsy, and are scheduled to 
receive NAC followed by surgery are eligible for this trial. Specific 
aims: The primary aim of this clinical trial is to determine whether 
the baseline to mid-therapy changes in the DOSI measurement of the 
quantitative tumor tissue optical index can predict final pathologic 
complete response in patients with breast cancer undergoing NAC. 
The secondary aims investigate the correlation between additional 
DOSI quantitative measurements of tumor biochemical composition 
obtained at other timepoints, the full range of pathologic response 
(i.e. complete, partial, and non-response), and any corresponding 
imaging measurements. Statistical methods: Logistic regression 
models will be used to study the relationships between pathological 
complete response and percent change in tissue optical index tumor 
to normal ratio at different imaging time points. Study size: A total 
of sixty (60) patients will be enrolled in this imaging study. Currently, 
one patient has accrued.
OT2-05-03
ACRIN 6688 Phase II Study of Fluorine-18 3’-Deoxy-3’ 
Fluorothymidine (FLT) in Invasive Breast Cancer.
Jolles PJ, Kostakoglu L, Bear HD, Idowu MO, Kurdziel K, Shankar 
L, Mankoff DA, Duan F, L’Heureux DZ. Virginia Commonwealth 
University, Richmond, VA; Mount Sinai School of Medicine, New 
York, NY; National Cancer Institute, Bethesda, MD; University 
of Washington, Seattle, WA; Brown University, Providence, RI; 
American College of Radiology Imaging Network, Philadelphia, PA
Background: Neoadjuvant chemotherapy (NAC) prior to surgery 
provides enhanced options for locoregional management and has 
become an integral component of primary breast cancer management. 
Initial tumor response in patients receiving NAC is generally 
determined at therapy completion. This evaluation is determined by 
either the presence/absence of palpable tumor as a clinical response 
and/or presence/absence of invasive tumor cells in the breast and nodes 
as a pathological response. The ability to evaluate the effectiveness of 
neoadjuvant therapy early during treatment would be of significant 
importance. FDG PET imaging has been shown to be predictive of 
subsequent tumor response, but the tendency of FDG to accumulate 
in inflammatory tissues can complicate image interpretation. MRI 
changes have also been touted as predictors of response. Preliminary 
data suggest that early FLT PET is better able to predict response 
to therapy, as FLT uptake has been shown to correlate with cellular 
proliferation, and does not significantly accumulate in inflammatory 
tissue (Kenny et al, Eur J Nucl Med Mol Imaging 2007:1339-1347). 
The analysis of these data may provide a better understanding of 
early treatment response and improve the clinical management of 
breast cancer in the future. Trial design and eligibility: In this 
phase II multi-institutional study, breast cancer patients with locally 
advanced disease with a tumor size ≥2cm (measured on imaging or 
estimated by physical exam) are eligible. Participants will receive 
standard of care NAC at their respective institutions. Participants 
will have 3 FLT imaging sessions to evaluate therapy response: 
at baseline, early-treatment (5-10 days after initiating treatment), 
and post-treatment prior to surgery. Specific aims: The primary 
objective is to correlate the percentage change in the standardized 
uptake value between baseline and early therapy FLT in the primary 
tumor with pathologic response. Correlatively, FLT PET parameters 
will be compared with proliferative indices from the initial biopsy 
and residual tumor surgical samples using Ki-67 staining, mitotic 
index, and residual cancer burden. Potential safety issues and the 
physiologic effects associated with FLT administration will also be 
evaluated. Statistical methods: To evaluate the relationship between 
an uptake parameter and pathologic complete response, a ROC curve 
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will be estimated and the area under the curve, along with its 95% 
confidence interval, will be determined. Accrual: Currently, 45/67 
patients have accrued to the study.
OT2-05-04
ACRIN PA 4006: Comparison of Full-Field Digital Mammography 
with Digital Breast Tomosynthesis Image Acquisition in Relation 
to Screening Call-Back Rate.
Conant EF, Maidment A, Copit D, Olson CB, Heckel ML, Gatsonis 
C. Hospital of the University of Pennsylvania, Philadelphia, PA; 
Albert Einstein Medical Center, Philadelphia, PA; American College 
of Radiology Imaging Network, Philadelphia, PA; Brown University, 
Providence, RI
Background: With competing parameters of specificity and 
sensitivity, breast cancer screening must limit both missed cancers 
and false-positive call-backs (with potential to biopsy) to reduce cost 
and unnecessary anxiety to patients. Full-field digital mammography 
(FFDM) has been shown to provide improved sensitivity over 
analog mammography in the detection of breast cancers, particularly 
in women with dense breasts. Unfortunately, call-back rates for 
both digital and analog screening mammography have similar, 
elevated rates of approximately 10% (E. Pisano et al, NEJM, 2005). 
Incorporation of digital breast tomosynthesis (DBT), a novel 3-D 
reconstruction of multiple low-dose digital mammographic images, 
may reduce the number of call-back visits needed by providing many 
of the benefits of diagnostic imaging at screening. This study will 
assess variations in DBT image acquisition while limiting radiation 
dose to women with varying breast sizes and densities, to define 
parameters to be used in a larger national screening tomosynthesis 
trial. Eligibility: Asymptomatic women 25 years and older with 
no breast cancer history are eligible for Group A or B (see below). 
Pregnant women, women unable to tolerate compression of the breast 
associated with mammography, women with implants, and women 
with breasts too large for DBT are excluded from participation. Trial 
design/target accrual: This multicenter trial uses Hologic digital 
mammography units at two institutions in Philadelphia, Pennsylvania. 
The timing of the study-related imaging visits are segregated into 
two cohorts, screening (Group A) and diagnostic (Group B). Group 
A comprises 500 women who will undergo both FFDM and DBT 
at screening. Initial independent interpretations of the FFDM and 
DBT from local readers will determine call back. Enriched Group B 
comprises 50 women who have been informed of abnormal findings 
from a FFDM screening within 30 days of enrollment. They will be 
recruited prior to their diagnostic imaging and consent to DBT of 
both breasts as part of their diagnostic imaging. Participants from 
both Groups will be followed or biopsied as recommended by their 
treating physician. Follow up includes medical record review and 
images collection at approximately 1-year. Follow-up data may be 
collected up to 18 months. Specific aims and statistical methods: 
ACRIN PA 4006 will evaluate the specificity of 2-D FFDM versus 
a combination of 2-D and 3-D tomosynthesis imaging in breast 
cancer screening. Specificity will be measured by the participant 
call-back rate by each modality. Sensitivity and specificity by 
lesion-type characteristics, especially focused on DBT assessment 
of calcifications, will be compared.Current accrual:  Currently, the 
trial accrual has reached 259 of 550.
OT2-05-05
Phase I/II Study of Adoptive T Cell Therapy Following In Vivo 
Priming with a HER2 Peptide-Based Vaccine in Patients with 
Stage IV Breast Cancer.
Parker SL, Higgins DM, Childs JS, Dang Y, Guthrie KA, Disis ML, 
Salazar LG, Coveler A. University of Washington, Seattle, WA; Fred 
Hutchinson Cancer Research Center, Seattle, WA
Background: Adoptive T cell therapy has evolved from preclinical 
setting to a potentially feasible treatment strategy for advanced breast 
cancer (BC). However, the ability to expand tumor antigen specific 
T cells ex vivo has been one of the major hurdles that has limited 
clinical translation of adoptive T cell therapy. Tumor specific T cells 
are rare in unprimed patients and generating large bulk cultures from 
rare precursor frequencies is difficult. We have found immunizing 
HER2+ patients to increase tumor specific T cell precursor frequencies 
to the levels of a vaccinated foreign antigen markedly improves the 
ability to generate large numbers of tumor specific T cells in vitro. 
We hypothesize that T cell expansion strategies that are facilitated 
by prior immunization will be clinically useful in the treatment of 
advanced BC.
Design: A Phase I/II non-randomized, single arm study. Priming with 
a HER2 ICD vaccine will be performed at 1 week intervals for a total 
of 3 vaccines. Patients will undergo leukapheresis 2 weeks after the 
3rd vaccine to collect PBMC for T cell expansion. Patients will be 
pre-treated with cyclophosphamide 24 hours prior to 1st T cell infusion 
and then receive up to 3 dose-escalating infusions of T cells given 
7-10 days apart. Three HER2 vaccine booster immunizations will then 
be administered at 1, 2, and 4 months after the final T cell infusion. 
Follow-up for persistent and continued immunity will then ensue.
Aims: To evaluate the safety of infusing escalating doses of HER2 
specific T cells into patients with advanced HER2+ BC using ex vivo 
expanded autologous T cells, to investigate to what extent HER2 
specific T cell immunity can be boosted or generated in individuals 
after infusion of HER2 specific T cells, to evaluate how long T cell 
immune augmentation persists in vivo after adoptive transfer of HER2 
specific T cells and subsequent booster immunizations.
Criteria: Patients with HER2+ Stage IV BC who: have been 
maximally treated and not achieved a complete remission, have stable 
or slowly progressive disease, HER2+, and have adequate LVEF.
Statistical Methods: Toxicity will be determined by chemical and 
clinical parameters evaluated at various time points. If the true 
probability of a DLT is 0.11, then the probability of observing 0 DLT’s 
in 20 patients is 0.097. If the true probability of a DLT is 0.18, then the 
probability of observing ≤1 DLT’s in 20 patients is 0.102, and if the 
true probability of a DLT is 0.27, then the probability of observing ≤2 
DLT’s in 20 patients is 0.064. Therefore, with low observed rates of 
DLT (≤10%), we can be reasonably confident (~90%) with 20 patients 
that the true DLT rate is < 0.27. Immunologic response, defined as the 
successful boosting of precursor frequency with infusion of HER2-
specific T cells, will be evaluated by assessing the change in T cell 
level from baseline. To assess the durability of the T cell response, we 
are primarily interested in estimating the proportion of patients whose 
T cells persist at a level the same or greater as the level after the final 
T cell infusion as long as 6 months following the final booster vaccine.
Accrual: Target=20/Actual=14
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OT2-05-06
ACOSOG Z11101/ACRIN 6694: Effect of Preoperative Breast 
MRI on Surgical Outcomes, Costs and Quality of Life of Women 
with Breast Cancer.
Bedrosian I, Suman VJ, Yao K, Shih Y-CT, Yen TWF, Comstock C, 
Newstead G, Birdwell R, Kim E, L’Heureux DZ, Gatsonis C. MD 
Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; 
University of Chicago, Evanston, IL; University of Chicago, Chicago, 
IL; Medical College of Wisconsin, Milwaukee, WI; Memorial Sloan-
Kettering Cancer Center, New York City, NY; Harvard Medical 
School, Boston, MA; Brown University, Providence, RI; American 
College of Radiology Imaging Network, Philadelphia, PA
Background: Surgical planning and local-regional treatment of 
breast cancer relies on accurate assessment of disease extent including 
the primary tumor size and the presence/absence of multiple tumor 
foci. As a staging modality for breast cancer, MRI has shown high 
sensitivity for detection of additional foci of diseases within the 
index breast. However, the impact of preoperative breast MRI on 
reducing re-excision rates and improving local control is less clear. 
Data from the COMICE trial in the UK suggested that routine use of 
pre-operative breast MRI did not alter rates of re-excision; however 
issues have been raised about the lack of quality standards for the 
MR imaging that may have resulted in the negative results of this 
trial. Retrospective data suggest that local recurrence is not impacted 
by use of breast MRI. In concert with data showing no improvement 
in clinical outcomes of breast cancer patients, concerns have been 
raised that routine use of preoperative breast MRI is associated with 
increased rates of mastectomy and delays to surgery. Therefore, 
the application of MRI for preoperative surgical staging remains 
controversial. In order to address this ongoing controversy, a joint 
effort has been launched by ACOSOG and ACRIN for a prospective 
clinical trial focused on evaluating the impact of preoperative breast 
MRI on clinically relevant patient outcomes. An important part of this 
collaboration is implementation of standards of how MRI findings 
should be clinically managed and used to direct localization methods 
and surgical planning, thereby creating guidelines for subsequent 
patient intervention. Trial design/eligibility criteria: A prospective 
multicenter trial will include women eligible for BCT by standard 
criteria and randomized between current standard of care, clinical 
examination and mammography (+/- ultrasound) and the same plus 
preoperative breast MRI. The study will focus on women at the highest 
risk of local recurrence: ER/PR/HER-2 negative (triple negative) 
and HER-2 amplified breast cancers. Specific aims: To compare 
the rates of local recurrence following breast conserving therapy in 
a cohort randomized to preoperative staging with mammography 
or mammography plus breast MRI. Additionally, a comparison of 
rates of re-operation, time to local recurrence, survival outcomes, 
contralateral breast cancer rates, rates of multicentric disease and 
other secondary aims will be performed. Costs and quality of life 
measures will also be investigated. Statistical methods: A stratified 
logrank test and Cox partial likelihood score test will be used to assess 
whether the distribution of LR times differs with respect to diagnostic 
work-up approach having adjusted for tumor stage. Cox modeling 
with the Cox partial likelihood score test will be used to examine 
the strength of association between these time to event distributions 
and such additional potential prognostic factors as menopausal 
status, chemotherapy, radiation therapy, ER, PR, number of positive 
lymph nodes, HER-2/neu expression, Nottingham grade, and Ki-67 
expression. Target Accrual: 556 patients
OT2-06-01
A Phase III Randomized Multicentric French Study To Evaluate 
the Impact of a Localized 16-Gy Boost after Conservative 
Surgery and a 50-Gy Whole-Breast Irradiation in Breast Ductal 
Carcinoma In Situ (The BONBIS Trial).
Azria D, Cowen D, De La Lande B, Bourgier C, Latorzeff I, Leblanc-
Onfroy M, Douadi-Gaci Z, Pradier O, Peignaux K, Levy C, Ellis 
S, Lecouillard I, Racadot S, Bontemps P, Benyoucef A, Lagarde P, 
Laharie-Mineur H, Cretin J, Marchal C, Serin D, Lemanski C. CRLC 
Val d’Aurelle, Montpellier, France; AP-HM, Marseille, France; 
Centre Rene Huguenin, Saint Cloud, France; IGR, Villejuif, France; 
Groupe ONCORAD, Toulouse, France; Centre Rene Gauducheau, 
Nantes, France; Centre Catherine de Sienne, Nantes, France; CHU 
Brest, Brest, France; CRLC G-F Leclerc, Dijon, France; CRLC 
François Baclesse, Caen, France; Centre Catalan d’Oncologie, 
Perpignan, France; CRLC Eugene Marquis, Rennes, France; Centre 
Leon Berard, Lyon, France; CHU Besancon, Besancon, France; 
Centre Henri Becquerel, Rouen, France; Institut Bergonie, Bordeaux, 
France; Clinique Tivoli, Bordeaux, France; Clinique Valdegour, 
Nimes, France; Centre Alexis Vautrin, Vandoeuvre les Nancy, France; 
Institut Sainte Catherine, Avignon, France
Background: Ductal carcinoma in situ is defined as breast cancer 
confined to the ducts of the breast without evidence of penetration of 
the basement membrane. Local treatment quality represents one of the 
most prognostic factors as half of recurrences are invasive diseases. 
The main goal of adjuvant radiotherapy after conservative surgery 
is to decrease local recurrences and to permit breast conservation 
with low treatment-induced sequelae. Several randomized trials 
have established the impact of 50 Gy to the whole breast (WB) 
in terms of local control. Nevertheless, no randomized trial is still 
available concerning the role of the boost in this disease. The phase 
III randomized trial “BONBIS” is elaborated to evaluate the impact 
of a 16-Gy boost after 50 Gy delivered to the whole breast in 25 
fractions and 33 days.
Methods: A total of 1950 patients DCIS breast cancer patients are 
planned to be enrolled in this trial. Patients will receive the following 
treatment: (A) WB radiotherapy of 50 Gy in 25 fractions vs. (B) WB 
radiotherapy of 50 Gy in 25 fractions plus a localized 16-Gy boost in 8 
fractions. The primary endpoint is local-relapse free survival (LRFS). 
This trial is designed to detect an expected rate in control arm of 
7% and 4 % in experimental arm. With 90% power and a=0.05, 137 
events are necessary to achieve the main goal. An interim analysis 
is planned after 50% of observed event. Stratifications are made 
based on recognized prognostic factors: age, hormonal treatment, 
differentiation, circumstance of diagnosis, surgical margin, centre.
Secondary endpoints are relapse free survival, overall survival, acute 
and late toxicities, cosmetic results, and quality of life. Translational 
researches are also planned to identify intrinsic radiosensitivity of 
normal tissues (radiation-induced apoptosis assay, genome-wide 
association study) but also predictive models of tumor recurrences. 
Inclusions have started in November 2008 and are not so far than 
the planned estimation.
This trial is granted by the French National Cancer Institute (PHRC 
2008) and supported by the French National Society of Radiation 
Oncology (SFRO).
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OT2-06-02
A Randomized Phase III Study of Conventional Whole Breast 
Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women 
with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413.
Julian TB, Costantino JP, Vicini FA, White JR, Cecchini RS, Winter 
KA, Arthur DW, Kuske R, Rabinovitch R, Parda DS, Mamounas 
EP, Curran, Jr WJ, Wolmark N. National Surgical Adjuvant Breast 
& Bowel Project (NSABP), Pittsburgh, PA; Allegheny General 
Hospital, Pittsburgh, PA; NSABP Biostatistical Center, Pittsburgh, 
PA; University of Pittsburgh Graduate School of Public Health, 
Pittsburgh, PA; Beaumont Health System, Royal Oak, MI; Radiation 
Therapy Oncology Group (RTOG), Philadelphia, PA; Medical 
College of Wisconsin, Milwaukee, WI; Virginia Commonwealth 
University, Richmond, VA; Arizona Breast Cancer Specialists, 
Scottsdale, AZ; University of Colorado Denver, Aurora, CO; Aultman 
Health Foundation, Canton, OH; Emory University, Atlanta, GA
Background: Breast-conserving therapy (BCT) with WBI is an 
accepted option in the treatment of most patients with stage 1 or 
2 breast cancer, but not all eligible patients utilize it. This may 
be because of age, length of time required for WBI treatment and 
availability of this method, and burden of care. There is a large body 
of mature phase I and II data, and some preliminary phase III data, 
that relate to the replacement of WBI after lumpectomy with PBI 
delivered in 4-5 days and restricted to the region of the tumor bed. 
Can an acceptable outcome be achieved with radiation therapy (RT) 
delivered only to the region of the tumor?
Trial design: For the administration of WBI, we are using standard 
techniques delivered over 5-7 weeks as outlined in the B-39/0413 
protocol. For the adminsitration of PBI, we are using high-dose-
rate multi-catheter brachytherapy, high-dose-rate single-entry 
intracavitary brachytherapy (MammoSite®, MammoSite® ML, 
Contura™ MLB, and SAVI®), and 3D conformal external beam 
RT. PBI is given twice a day, at least 6 hours apart, on 5 treatment 
days over a period of 5-10 days. The technique selected depends 
on technical considerations, radiation oncology facility technique 
credentialing, and patient preference. Before random assignment, 
patients must have a planning CT. Those randomized to WBI receive 
chemotherapy, if applicable, before their RT. Those randomized to 
PBI receive RT before chemotherapy, if applicable. All treatment sites 
must pass a rigorous QA and QC process for PBI before and during 
the duration of the study. We are using a QOL program to assess 
cosmesis, fatigue, symptoms, and perceived convenience of care.
Eligibility criteria: Patients must have stage 0 or stage 1 or 2 IBC 
with no evidence of metastatic disease. Tumor size must be 3 cm or 
less. Women must have undergone a lumpectomy with the margins of 
the resected specimen histologically free of cancer, including DCIS. 
Patients must have no more than 3 positive axillary nodes. Accrual 
is open to all premenopausal women and to postmenopausal women 
who have IBC that is ER/PR negative or node positive. Patients are 
stratified according to disease stage, menopausal status, hormone 
receptor status, and intention to receive chemotherapy. Following 
stratification, patients are randomly assigned to receive WBI or PBI.
Specific aims: The primary endpoint is the comparison of those 
receiving PBI and WBI for the diagnosis of in-breast tumor recurrence 
(IBTR). The study will also compare women receiving PBI and WBI 
for overall survival, recurrence-free survival, and distant disease-free 
survival. QOL aims are related to cosmesis, fatigue, treatment-related 
symptoms, and perceived convenience of care.
Statistical analysis and accrual: PBI and WBI will be declared 
equivalent if the estimated relative risk of IBTR falls between 0.86 
and 1.17. Analysis will occur after 175 IBTRs are diagnosed. At the 
end of May 2011, accrual was 3962 of 4300 patients.
Supported by PHS grants NCI-U10-CA-69651, NCI-U10-CA-12027, 
and NCI P30-CA-14599 from the US NCI.
OT2-07-01
Pasireotide Long Acting Release (LAR) in Breast Cancer Patients 
To Prevent Lymphocele after Mastectomy and Axillary Node 
Dissection: A Randomized, Multicenter, Phase II Study.
Chereau E, Uzan C, Bezu C, Mazouni C, Ballester M, Gouy S, 
Rimareix F, Garbay J-R, Daraï E, Uzan S, Coutant C, Rouzier R. 
Tenon - APHP, Paris, France; Institut Gustave Roussy, Villejuif, 
France
Background: Lymphocele is the principal post-operative morbidity 
following axillary node dissection. According to the literature, 
incidence can vary from 4 to 89%.
Encouraging results in terms of reducing postoperative lymphoceles 
as well as drainage duration and volume using octreotide have been 
recorded recently. A new molecule, namely pasireotide, developed 
by Novartis Pharma AG, Basle Switzerland, is a somatostatin analog 
possessing high binding affinity to 4 of the 5 somatostatin receptors.
Trial design: We are performing a prospective, randomized 1:1, double 
blind, multicenter trial against placebo with a Bayesian design.
Eligibility criteria: any female patient scheduled for breast surgery 
with mastectomy and axillary node dissection indicated at the pre-
surgical stage.
Specific aims : The purpose of this trial is to assess the efficacy of a 
single pre-surgical injection of pasireotide LAR 60 mg im in reducing 
the postoperative incidence of symptomatic lymphoceles following 
mastectomy with axillary node dissection for breast cancer. Patients 
are followed up for 4 weeks
Statistical methods: The statistical analysis will be carried out 
sequentially after observing the principal criterion (i.e. success is 
defined as a total volume of lymphocele following single or repeated 
aspiration ≤ 60 cc in the 28 days following surgery or a routine 
aspiration volume on the 28th day ≤ 120cc) of each patient included 
for each randomization group, with or without treatment.
It involves estimating the probability of a response in each group 
using a Bayesian design based on a beta-binomial model. With the 
Bayesian approach, the response rate in each group (pi) is considered 
as a random variable, with a priori density focused on the anticipated 
response rate of 80% in the group receiving treatment and 60% in 
the non-treatment group, which will be sequentially updated as the 
observations are made according to a so-called a posteriori law.
Present accrual and target accrual: The sample size consists of a total 
of 90 patients with 45 patients in the active treatment group and 45 
patients in the placebo one. To date more than 50% of the patients 
have been included.
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OT2-07-02
SWOG S0927: A Randomized Double Blind Placebo-Controlled 
Trial of Omega-3-Fatty Acid for the Control of Aromatase 
Inhibitor (AI)-Induced Musculoskeletal Pain in Women with 
Early Stage Breast Cancer.
Hershman DL, Unger JM, Crew KD, Moinpour CM, Minasian LM, 
Hansen L, Lew DL, Kaberle K, Wade JL, Meyskens FL. Columbia 
University, New York, NY; SWOG, Seattle, WA; National Cancer 
Institute, Bethesda, MD; Legacy Good Samaritan Hosp & MC, 
Portland, OR; SWOG, San Antonio, TX; Cancer Care Specialists 
of Illinois, Decatur, IL; University of California, Irvine, Orange 
County, CA
Background: Despite the well-proven efficacy of aromatase 
inhibitors(AIs) for the treatment of hormone-sensitive breast cancer, a 
significant number of women suffer from musculoskeletal side-effects 
which can result in early discontinuation of this important medication. 
Given the proposed anti-inflammatory effects of omega-3-fatty acid 
and the paucity of therapeutic options for AI-induced arthralgia, it 
is therefore reasonable to test the efficacy of omega-3-fatty acid in 
women with breast cancer who have developed moderate to severe 
joint symptoms after initiating AIs.
Specific aims: To assess if omega-3-fatty acid as compared to placebo 
causes a reduction in worst joint pain/stiffness in women with AI-
associated arthralgias at 12weeks as measured by the modified Brief 
Pain Inventory (BPI). Additional measures will include the WOMAC, 
M-SACRAH, FACT-ES and global rating of change, which will be 
assessed at baseline, 6, 12 and 24 weeks. We will evaluate fasting 
lipids, hormone levels, serum inflammatory markers (TNF, IL2, 
CRP), and markers of joint destruction (CTX-II) at baseline, 12 and 
24 weeks.
Eligibility criteria:Pts. must have histologically-confirmed stages I-III 
breast cancer, with no evidence of metastatic disease and undergone 
definitive breast cancer surgery. Pts must be post-menopausal and 
currently be taking a third-generation AI –anastrazole(Arimidex®), 
letrozole (Femara®), or exemestane (Aromasin®) for at least the 
previous 90 days prior to registration with plans to continue for at 
least an additional 180 days after registration.The patient must have a 
worse joint pain/stiffness score of 5 or greater on the 10-point scale of 
the BPI which started or increased after initiation of AI. Pts must not 
have taken omega-3-fatty acid supplements within the past 3 months 
prior to registration.Pts will be randomized to receive 6 capsules 
daily (at 1,000 mg each; ~600mg combination of ethyl esters EPA/
DHA) of omega-3-fattyacid or matching placebo daily for 24 weeks.
Statistical methods:We stipulate an alpha=.05 two-sided test, with 
an estimated 5% non-adherenceand 20% dropout rate at the primary 
endpoint evaluation time of 12 weeks after randomization. For a two 
point difference in worst joint pain/stiffness and a 3.5 point SD at 12 
weeks, 222 eligible patients would be required for 90% power under 
a two-arm normal design.To allow ineligibility rate of 10%, 246 total 
pts will be enrolled.The study should be activated September 2011.
Funding: Supported by National Cancer Institute grant CA037429
OT3-01-01
Randomized Phase II Study of Fulvestrant Versus Fulvestrant 
Plus Bortezomib in Postmenopausal Women with Estrogen 
Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant 
Metastatic Breast Cancer (MBC): New York Cancer Consortium 
Trial P8457.
Adelson KB, Raptis G, Sparano J, Germain D. Mount Sinai School of 
Medicine, New York, NY; Albert Einstein Cancer Center, Bronx, NY
Background: Bortezomib ia proteasome inhibitor that enhances 
fulvestrant-mediated aggregation of the ER in the cytoplasm without 
blocking ER degradation in the nucleus in ER+ human breast cancer 
cell lines, thereby promoting cytoplasmic ER aggresomes which 
activate a sustained unfolded protein response leading to apoptotic cell 
death; the combination also induces tumor regression in a tamoxifen 
resistant T47D-cyclin D1 xenograft model more effectively than either 
agent alone (Clin Cancer Res 2011; 17: 2292-2300).
Hypothesis: We hpothesize that the combination of fulvestrant and 
bortezomib will be more effective than fulvestrant alone in ER+, 
AI-resistant MBC.
Trial design: This is an open-label randomized phase II design in 
which patients with MBC are randomized to receive fulvestrant 
alone (500 mg IM day -14, day +1, and day +14 during cycle 1, then 
500 mg every 4 weeks on day +1 during cycle 2 and thereafter) or in 
combination with bortezomib (1.6 mg/m2 IV days +1, +8, +15 every 
cycle). Stratification factors for randomization include performance 
status (ECOG 0 vs. 1-2), measurable disease (yes vs. no), and prior 
chemotherapy for MBC (yes vs. no). Patients who progress on 
fulvestrant alone may cross over to the combination.
Eligibility criteria: Postmenopausal women with ER+, Her2-negative, 
MBC who have progressive disease during AI therapy for metastatic 
disease, or relapse while receiving adjuvant AI therapy. Up to one 
prior chemotherapy regimen for metastatic disease is permitted.
Specific aims:
Primary Objective: To determine if the addition of bortezomib to 
fulvestrant significantly improves median progression-free survival 
(PFS), defined as the time from cycle 1, day 1 of therapy until disease 
progression or death from any cause.
Secondary Objectives: To determine: (1) adverse event rates in both 
arms, (2) the clinical benefit rate (CBR – objective response [by 
RECIST 1.1] and/or progression free at 24 weeks), (3) the objective 
response and CBR after crossover from fulvestrant to fulvestrant 
plus bortezomib.
Translational Objectives: To perform an exploratory analysis of the 
effects of the combination on intratumoral nuclear/cytoplasmic ER 
ratio, unfolded protein response (BiP), apoptotis (cleaved caspase 3, 
Bcl-2 phospho JNK.)
Statistical methods: he median PFS for patients receiving fulvestrant 
alone is expected to be approximately 5.4 months based upon patients 
with AI-resistant disease enrolled on the CONFIRM trial ( J Clin 
Oncol 2010; 28: 4594-4600). The trial is designed to detect a 70% 
improved in median PFS to 9.0 months (alpha=0.10, beta =0.10), 
which will require 59 eligible patients in each arm.
Present accrual and target accrual: 24/118
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OT3-01-02
Imatinib Mesylate in Combination with Vinorelbine for Patients 
with Metastatic Breast Cancer – An Ongoing Phase I/II Clinical 
Trial.
Mundhenke C, Schem C, Bauerschlag DO, Weigel MT, Hilpert F, 
Eidtmann H, Tiemann K, Muth M, May C, Hanson S, Jonat W, Maass 
N. Kiel University, Kiel, SH, Germany; RWTH Aachen, Aachen, NRW, 
Germany; Novartis Pharma, Nuremberg, Bavaria, Germany; Institut 
fuer Haematopathologie Hamburg, Hamburg, HH, Germany
Background: Imatinib mesylate is a tyrosine kinase inhibitor which 
originally had been developed to block pathognomonic bcr-abl 
oncoprotein in chronic myeloic leukemia. It is also an inhibitor of the 
receptor tyrosine kinases of platelet-derived growth factor (PDGF) 
and stem cell factor (SCF), c-Kit, and abl. Therefore it also inhibits 
PDGF- and SCF-mediated cellular events, as tumor cell proliferation 
in solid tumors. Additionally, inhibition of PDGF- b-receptor relieves 
tumor hypertension in solid tumors and thereby helps to deliver higher 
concentrations of cytotoxic drugs into the tumor cell. Vinorelbine is a 
semisynthetic vincaalcaloid with antitumor activity. As a single agent 
and as a combination partner of other cytotoxic drugs, it has proven 
good tolerability and high effectiveness in treatment of patients with 
metastatic breast cancer (MBC). This study was designed to evaluate 
the feasability of the combination of imatinib mesylate and the 
cytotoxic drug of vinorelbine in different concentrations in patients 
with advanced and MBC.
Study design: This is a prospective open-label, single arm phase I/
II study combining 400 mg Imatinib Mesylate p.o. daily (amended 
from 600 mg) with an escalating dose of vinorelbine i.v. weekly for 
patients with locally advanced or metastatic breast cancer.
Patients must have tumors expressing PDGF-receptor-a and/ or -b 
and/or c-kit and have received pretreatment with an anthracyclin 
containing regimen. Main study endpoints are feasibility and 
tolerability of this novel combination. In addition to the total toxicity 
and the incidences of hematological and non-hematological toxicity of 
grade 3 and 4, the clinical activity together with the clinical response 
rate and the time to disease progression will be evaluated.The quality 
of life is examined during the whole course of treatment.
Recruitment started for level one with 10 mg/m² vinorelbine and 
proceeds to the next higher levels 15, 20 and 25 mg/m². Each dose 
level will be filled with at least five patients. Patients of one dose level 
will be followed for a minimum of 28 days during therapy, before 
enrolment of patients for the next dose level can start. For translational 
research multiple skin biopsies will be taken (skin wounding assays). 
When feasible tumor-biopsies are taken before and during therapy. 
Expression of tyrosine kinase receptors (c-kit and PDGF-receptor) 
will be correlated with treatment response.
Present accrual and target accrual: 33 patients have been enrolled 
into the study. Dose levels I-III have been fully recruited. In dose 
level IV two patients with visceral metastasis are ongoing on study 
medication. Safety and clinical data will be available after the last 
patient discontinues study treatment.
Information on the study protocol, the translational subprotocol 
and details on c-kit and PDGF-receptor expression analysis will be 
presented at the meeting.
OT3-01-03
Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in 
Patients with Operable Invasive Breast Cancer: New York Cancer 
Consortium Trial P8740.
Kalinsky K, Sparano JA, Kim M, Crew KD, Maurer MA, Taback B, 
Feldman SM, Hibshoosh H, Wiechmann LS, Adelson KB, Hershman 
DL. Columbia University Medical Center, New York, NY; Albert 
Einstein College of Medicine, New York, NY; Mount Sinai School of 
Medicine, New York, NY
Background: To serve as a bridge between pre-clinical and early 
clinical testing, pre-surgical studies are being designed to expose 
patients to a limited duration of an anti-cancer agent before launching 
a lengthy clinical trial program. In this model, modulation of 
predictive tissue and serum biomarkers are assessed. At Columbia 
University, we have completed 3 pre-surgical studies. The PI3K/
Akt signaling pathway is an important signaling pathway in breast 
cancer (BC). The first allosteric Akt inhibitor to enter clinical 
development, MK-2206 is well-tolerated and has demonstrated 
anti-cancer properties in pre-clinical and early-phase clinical studies. 
The purpose of this study (NCI P8740) is to determine the effects 
of MK-2206 on women with newly diagnosed BC between breast 
biopsy and surgery. Trial Design: Patients (n=30) will receive 2 doses 
of weekly MK-2206 (200 mg): first dose at day -9 and second at day 
-2 from surgery. This drug administration consistency will decrease 
the potential for noise in detecting true biomarker response. This 
time period was selected based upon the pharmacokinetic profile of 
weekly MK-2206. The main eligibility criteria for this open-label pre-
surgical trial include operable, clinical stage I (at least T1c) to IIIC 
invasive BC. Patients not considered for neoadjuvant chemotherapy 
are eligible. Specific Aims: Our hypothesis is that MK-2206 will 
decrease phospho-AktSer473 in tumor tissue after 2 weekly doses. 
To maintain sample quality and ensure that phospho-Akt evaluated on 
formalin-fixed paraffin-embedded (FFPE) tissue is comparable across 
samples (given the 20 minute half life of AKT), all samples will be 
processed rapidly by a standardized protocol. Secondary objectives 
include the following in FFPE: modulation of downstream PI3K/
Akt pathway signaling [immunohistochemistry and reverse phase-
protein microarray analysis (RPPA)]; change in tumor proliferation 
(Ki-67 staining); and exploration of whether PI3K/Akt signaling 
change depends upon tumor genetics (PIK3CA mutation or PTEN 
loss) or expression (Hormone Receptor/HER2 status). Pre- and post-
MK-2206 blood will be collected for phospho-expression analysis 
in peripheral blood mononuclear cells (RPPA and western blotting). 
Statistical Methods: With the expectation that 20% of the matched 
pre- and post-treatment tissue samples will not be analyzable, we 
will enroll 30 patients to ensure that matched tumor samples from 24 
patients are available for our primary analysis. A sample size of 24 
patients will yield greater than 90% power to detect a difference in 
the mean score between pre-and-post treatment samples of 60 units, 
paired t-test (2-sided, 0.05 significance level). This trial was recently 
activated by the NCI and currently ready to accrue patients. Patients 
will be enrolled and treated at affiliated institutions in the New York 
Cancer Consortium.
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OT3-01-04
TANIA: A Randomized Phase III Trial Evaluating Continued 
and Reintroduced Bevacizumab (BEV) in Patients Previously 
Treated with 1st-Line BEV for Locally Recurrent/Metastatic 
Breast Cancer (LR/mBC).
von Minckwitz G, Cortés J, Gligorov J, Marschner NW, Puglisi 
F, Vrdoljak E, Duenne A-A, Zielinski C. German Breast Group, 
GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d’Hebron 
University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, 
France; Outpatient Cancer Centre, Freiburg, Germany; University 
Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; 
F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University 
of Vienna, Vienna, Austria
Background: BEV has repeatedly demonstrated improvements 
in progression-free survival (PFS) in randomized phase III trials, 
providing benefit in the 1st- and 2nd-line settings when combined 
with chemotherapy versus chemotherapy alone. However, the role 
of BEV in BEV-pretreated LR/mBC is unclear. The TANIA trial 
(MO22998) was initiated to address this question.
Trial design: TANIA is an open-label randomized multicenter phase 
III trial. Eligible patients are aged ≥18 years with HER2-negative LR/
mBC that has progressed during or after ≥12 weeks of 1st-line BEV 
combined with chemotherapy for LR/mBC. Maintenance therapy with 
BEV and/or endocrine therapy before study enrollment is permitted. 
Patients who have previously received anti-angiogenic therapy other 
than BEV in the 1st-line LR/mBC setting are not eligible. BEV-
specific exclusion criteria are similar to previous randomized trials (eg 
inadequately controlled hypertension; history of nephrotic syndrome, 
hypertensive crisis, gastrointestinal perforation, or grade 3/4 venous 
thromboembolism; significant vascular disease). All patients must 
provide written informed consent. After stratification according to 
hormone receptor status, time to 1st progression (<6 vs ≥6 months), 
choice of chemotherapy (taxane vs non-taxane vs vinorelbine), and 
LDH level (≤1.5 vs >1.5 × upper normal limit), eligible patients are 
randomized 1:1 to 2nd-line treatment with either standard single-agent 
chemotherapy alone (arm 1) or standard single-agent chemotherapy 
combined with BEV (15 mg/kg q3w or 10 mg/kg q2w, depending 
on the chosen chemotherapy regimen; arm 2). 2nd-line therapy 
is continued until disease progression, unacceptable toxicity, or 
patient withdrawal. At progression, patients in arm 1 receive 3rd-line 
chemotherapy without BEV (ie no crossover permitted) and those in 
arm 2 receive 3rd-line chemotherapy in combination with BEV (unless 
prevented by unacceptable toxicity). Maintenance endocrine therapy 
is permitted in both arms (in combination with BEV in arm 2). At 3rd 
progression, BEV is permitted in all patients. The primary objective is 
to determine the therapeutic benefit of continued or reintroduced BEV 
in combination with 2nd-line chemotherapy for patients previously 
treated with 1st-line BEV plus chemotherapy, determined by the 
duration of PFS from the time of randomization to 2nd progression 
(or death). Additional objectives include evaluation of the interval 
between 2nd and 3rd progression, the interval between randomization 
and 3rd progression, PFS in stratified subgroups, overall response 
rate to 2nd-line therapy, overall survival (OS), 1-year OS rate, safety, 
quality of life (FACT-B and EQ-5D), and translational research. The 
sample size of 488 patients is calculated assuming median PFS of 7 
months in arm 1, a hazard ratio of 0.75, a recruitment period of 30 
months, and a 5% dropout rate (ie 439 eligible patients), providing 
80% power at two-sided a=0.05. As of 15th June 2011, 23 patients 
have been enrolled. The primary analysis is planned after 384 patients 
have shown progression on 2nd-line therapy.
OT3-01-05
PARP Inhibition after Preoperative Chemotherapy in Patients 
with Triple-Negative Breast Cancer (TNBC) or Known BRCA 
1/2 Mutations: Hoosier Oncology Group BRE09-146.
Miller KD, Perkins SM, Badve SS, Sledge GW, Schneider BP. Indiana 
University Melvin and Bren Simon Cancer Center
Background: Based on recently reported I-SPY trial, TNBC patients 
who had residual disease category II or III had 2-year disease free 
survival (DFS) of only ~40% (J Clin Oncol 2009;27:18s). Currently, 
no standard systemic therapy exists for this high-risk group. It 
represents a real opportunity to explore the potential impact of 
novel therapies. Recent laboratory and early clinical studies (Nature 
2005;434:913) identified a unique sensitivity to DNA-damaging 
chemotherapy and PARP inhibition. We initiated a randomized 
phase II trial of DNA-damaging chemotherapy (cisplatin) or PARP-
inhibition + cisplatin in TNBC patients with substantial residual 
invasive disease after standard anthracycline and/or taxane containing 
neoadjuvant chemotherapy. Methods: To ensure a high-risk 
population, patients must have residual disease category 0-2 based 
on the Miller-Payne classification system, residual cancer burden 
classification II or III, residual lymph node involvement, or at least 
2 cm of residual invasive disease in the breast. After completion of 
standard radiation therapy (when indicated), patients are randomized 
1:1 to cisplatin (75 mg/M2 IV Day 1 every 3 weeks x 4 cycles) alone 
or in combination with PARP inhibition (PF-01367338 - 24 mg IV D1, 
2, 3 of each 3 week cycle with a single dose escalation to 30 mg in 
the absence of significant toxicity in cycle 1 followed by maintenance 
PARP inhibition weekly x 24 weeks). The primary objective is 
2-year DFS. To detect an improvement in 2-year DFS from 40% 
with cisplatin alone to 63.2% in the cisplatin + PF-01367338 arm 
(corresponding to HR=0.5), with 80% power using a one-side log-rank 
test with 0.10 level of significance, 102 patients are required in the 
primary analysis. Secondary objectives include safety, 1-year DFS, 
overall survival, and biomarkers of tumor recurrence, resistance to 
chemotherapy and/or PARP inhibition. Two dose escalation safety 
cohorts (N=13) were completed without dose limiting toxicity; the 
randomized portion began enrolment in 11/2010 has enrolled 20 
patients as of 05/2011.
OT3-01-06
A Phase 2 Study Investigating the Safety, Efficacy and Surrogate 
Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat 
(MS-275) in Patients with Advanced Breast Cancer.
Connolly RM, Jankowitz RC, Andreopoulou E, Allred JB, Jeter SC, 
Zorzi J, Adam BM, Espinoza-Delgado I, Baylin SB, Zahnow CA, Ahuja 
N, Davidson NE, Stearns V. Sidney Kimmel Comprehensive Cancer 
Center at Johns Hopkins University, Baltimore, MD; University of 
Pittsburgh Cancer Institute, Pittsburgh, PA; Albert Einstein College 
of Medicine, Montefiore Medical Center, New York, NY; Mayo Clinic, 
Rochester, MN; National Cancer Institute, Bethesda, MD
Background:
Epigenetic alterations in the genome, including abnormal DNA 
methylation and histone hypoacetylation, initiate and promote 
cancerous changes via several mechanisms, including inactivation of 
tumor suppressor genes. Preclinical investigations in breast cancer 
suggest that use of epigenetic modifiers results in re-expression 
of aberrantly silenced genes and proteins that represent important 
therapeutic targets (e.g. estrogen receptor alpha, ER). Combination 
therapy with a DNA methyltransferase inhibitor (DNMTI) and a 
histone deacetylase inhibitor (HDACI) has yielded superior ER re-
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expression and greater restoration of tamoxifen responsiveness than 
with HDACI alone. We hypothesize that clinically tolerable doses of 
the DNMTI 5-azacitidine (5-AZA) and the HDACI entinostat may 
not only effect changes in DNA methylation and gene expression, 
but also yield objective disease responses in women with advanced 
breast cancer.
Trial design:
This multicenter phase II study (NCT01349959) is enrolling patients 
with advanced human epidermal growth factor receptor 2 (HER2)-
negative breast cancer with triple negative (ER/progesterone receptor 
[PR]/HER2-negative, Cohort A) or hormone-resistant (Cohort B) 
disease. Patients will receive 5-AZA 40 mg/m2 subcutaneously days 
1-5 and 8-10 and entinostat 7 mg orally days 3 and 10 every 28 days. 
Because of the potential for re-expression of the ER with epigenetic 
agents, patients will be offered continuation of 5-AZA and entinostat 
at progression with the addition of hormonal therapy (investigator 
discretion). Mandatory tumor biopsies will be performed at baseline 
and after 8 weeks of therapy to evaluate correlative biomarkers.
Eligibility Criteria:
Eligible patients must be ≥ 18 years, have measurable locally 
advanced/metastatic triple-negative (at least one prior chemotherapy 
received adjuvant/metastatic setting) or hormone-resistant (must have 
received two prior hormonal agents and one prior chemotherapy) 
disease, adequate organ function and ECOG PS ≤ 2.
Specific Aims:
1. Objective response rate (ORR) by RECIST 1.1 criteria.
2. Safety and tolerability
3. Progression-free survival, overall survival and clinical benefit rate.
4. Safety and toxicity data, feasibility and response rate where 
hormonal therapy is added to the combination under investigation at 
the time of progressive disease.
5. Pharmacokinetics, cytidine deaminase, changes from baseline 
of candidate gene methylation and expression in circulating 
deoxyribonucleic acid (DNA) and malignant tissue.
Statistical Methods:
Using a two-stage three-outcome design to assess the efficacy of the 
combination, a maximum of 30 patients (requiring 27 evaluable) will 
be accrued to each cohort unless undue toxicity is encountered for 
a maximum sample size of 60 patients. The study design tests the 
null hypothesis that the ORR is at most 5% against the alternative 
hypothesis that it is at least 20% with a type I error of 4% and power 
of 90%.
Present and Targeted Accrual:
This study has just opened to patient enrollment. We anticipate a 
rapid accrual of 60 patients within 1 year.br](Funding from Stand 
Up to Cancer and CTEP).
OT3-01-07
The BEACON Study (BrEAst Cancer Outcomes with NKTR-
102): A Phase 3 Open-Label, Randomized, Multicenter Study 
of NKTR-102 Versus Treatment of Physician’s Choice (TPC) in 
Patients (pts) with Locally Recurrent or Metastatic Breast Cancer 
(MBC) Previously Treated with an Anthracycline, a Taxane, and 
Capecitabine (ATC).
Awada A, Leung ACF, Zhao C, Hannah AL, Perez EA. Universite 
Libre de Bruxelles, Brussels, Belgium; Nektar Therapeutics, San 
Francisco, CA; Mayo Clinic, Jacksonville, FL
Background: NKTR-102 is a next-generation topoisomerase I 
inhibitor-polymer conjugate with a markedly reduced Cmax and a 
continuous exposure profile compared to irinotecan. A phase 2 trial 
of single-agent NKTR-102 compared a dose of 145 mg/m2 every 
2w or every 3w in 3rd-line MBC (Awada et al, ASCO 2011). Overall 
the ORR was 29% (including 3% CR) with the prior ATC subset 
demonstrating an ORR of 31%. Dosing every 3w was better tolerated; 
in this arm, median PFS equaled 5.3m and median OS equaled 
13.1m. Trial Design: NKTR-102 will be compared to TPC in an 
open-label, randomized, parallel, two arm multicenter Phase 3 pivotal 
study in pts with previously treated locally recurrent or metastatic 
breast cancer. Key Entry Criteria: Adult females, with ECOG 0 
or 1 with adequate liver, kidney and marrow function. All patients 
must have received prior therapy with an anthracycline (in neo/
adjuvant or metastatic setting or both), a taxane (in neo/adjuvant or 
metastatic setting or both) and capecitabine (in neo/adjuvant or locally 
advanced/metastatic setting or both) unless not medically appropriate 
or explicitly contraindicated for the patient. All chemotherapy- and 
radiation-related toxicities must have resolved to ≤ Grade 1, except 
for stable sensory neuropathy ≤ Grade 2 and alopecia. Pts with brain 
metastases may be eligible, if stable for prior 4 weeks without steroids. 
Pts with Grade ≥ 2 pre-existing diarrhea or receiving chronic anti-
diarrheal supportive care are not eligible. Statistical Methods: The 
primary efficacy endpoint is OS. Secondary endpoints include ORR 
by RECIST v1.1 and PFS. Pts will be randomized 1:1 to NKTR-102 
given IV at 145 mg/m2 over 90-min every 21 days or TPC. Patients 
randomized to TPC will receive single agent chemotherapy, limited 
to choice of one of the following 5 agents: eribulin, ixabepilone, 
vinorelbine, gemcitabine, or a taxane. The investigator must decide 
which agent will be given to the patient prior to randomization. Pts 
will be stratified by geographical region and disease characteristics. 
Target Accrual: Approximately 840 patients (420 pts per treatment 
arm) will be randomized in order to obtain 615 deaths (alpha = 0.05; 
power 90% with one interim analysis scheduled when 50% of the 
deaths have occurred). PK sampling will be performed in a subset 
of pts and blood and/or tumor samples are planned for potential 
predictive markers of response and toxicity. Enrollment is expected 
to remain open until the end of 2013.
OT3-01-08
Phase II Study of S-1 Combined with Cisplatin in the First-Line 
Treatment of Triple Negative Breast Cancer.
Fan Y, Xu BH. Cancer Hospital & Institute,Chinese Academy of 
Medical Sciences & Peking Union Medical College, Beijing, China
Rationale: There is no standard choice of first-line treatment for triple 
negative breast cancer (TNBC). It is supposed that TNBC may be 
more sensitive to DNA damage agents such as platinum but resistant 
to cell cycle specific agents including taxanes and 5-fluorouracil. 
Currently these hypotheses are under investigation in several ongoing 
clinical trials. S-1 is an orally administered fluorinated pyrimidine 
with high activity in non-small-cell lung cancer and gastric cancer. 
Recently single agent S-1 has been reported to be effective in 
capecitabine-resistant metastatic breast cancer with a response rate 
of 27.8% and median TTP of 6.2 months. So it is intriguing to find 
whether S-1 plus cisplatin would be a valuable regimen in TNBC 
patients with limited choices of management.
Design: This is a prospective, single-arm phase II study. Eligible 
patients are treated first with S-1( 80mg/m2, 2 weeks on and 1 week 
off) and cisplatin (75mg/m2 intravenously day1) every 3 weeks as 
a cycle for up to 6 cycles, until disease progression, unacceptable 
toxicity or patient consent withdrawal. If no PD was observed 
after 6 cycles, patients can remain on S-1 until disease progression, 
unacceptable toxicity or patient consent withdrawal.
Eligibility: Major inclusion criteria includes: 1. histologically 
confirmed triple negative breast cancer; 2. advanced patients without 
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prior treatment for locally recurrent or metastatic disease; 3. patients 
must have received anthracyclines and taxanes in neo/adjuvant 
setting; 4. at least one measurable disease according to RECIST 1.1; 
5. adequate organ function within acceptable range.
Endpoints: The primary endpoint is objective response rate (ORR) and 
secondary endpoints include progression free survival (PFS), overall 
survival (OS) and safety profile. Exploratory biomarks will be studied 
for TS and DPD enzyme expression and genotyping.
Statistical considerations: The expected response rate is around 50% 
based on the literature, and the null hypothesis is based on a response 
rate no greater than 30%. According to Simon’s two stage phase II 
design with errors of 0.05 and 0.20 respectively, a minimum of 15 
patients would be required in the first stage and totally 46 patients after 
the second stage. Since a non-compliance rate of 10% is expected, 
we plan to enroll a total of 50 patients.
Recruitment: Currently it has just been initiated with 1 patient still on 
screening. The target accrual, as stated above, is 50 patients.
OT3-01-09
Phase 3 Trial Comparing Capecitabine in Combination with 
SorafenIb or Placebo for Treatment of Locally Advanced or 
Metastatic HER2-Negative Breast Cancer (RESILIENCE).
Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar 
WJ. Massachusetts General Hospital Cancer Center; West Clinic; 
Bayer HealthCare Pharmaceuticals; Feinberg School of Medicine, 
Northwestern University
Sorafenib (SOR) is an oral multikinase inhibitor with antiangiogenic 
and antiproliferative activity. SOR is currently indicated for renal cell 
and hepatocellular carcinoma, with indications in other tumor types 
being explored. In a double-blind, randomized phase 2b screening 
trial (SOLTI-0701) in patients with advanced HER2-negative breast 
cancer (BC), the addition of SOR to capecitabine (CAP) showed 
a statistically significant improvement in the primary endpoint of 
progression-free survival (PFS) compared with placebo (PL)+CAP 
(median 6.4 vs 4.1 mo; hazard ratio=0.58; 1-sided P=0.0006). The 
combination was tolerable. Grade 3/4 adverse events were comparable 
between treatment arms with the exception of grade 3 hand-foot 
skin reaction/syndrome (HFSR/HFS) (44% in SOR+CAP vs 14% in 
PL+CAP). The SOLTI-0701 results indicate a potential role for the 
oral combination of SOR+CAP in the treatment of BC and support 
a phase 3 trial.
Design: RESILIENCE is an ongoing multinational, double-blind, 
PL-controlled, randomized phase 3 trial designed to assess SOR+CAP 
as a first- or second-line therapy in advanced HER2-negative BC. 
Eligibility criteria include: ≥18 years of age; ≤1 prior chemotherapy 
regimen for advanced BC; and resistant to/failed taxane and 
anthracycline or no indication for further anthracycline treatment. 
Prior hormonal or radiation therapy is allowed, but prior use of VEGF 
inhibitors is not. Patients with significant cardiovascular disease or 
active brain metastases are not eligible. Patients are stratified by 
hormone receptor status, geographic region, and prior chemotherapy 
for advanced BC and randomized (1:1) to CAP (1000 mg/m2 po twice 
daily [BID], days 1–14 of a 21-day cycle) in combination with SOR 
(po BID, days 1–21, total dose 600 mg/day) or matching PL. CAP 
and SOR/PL doses can be escalated to 2500 mg/m2 per day and 800 
mg/day, respectively, as tolerated. The protocol outlines strategies 
to manage toxicities with dose interruption and reduction. Dose 
re-escalation after reduction is allowed for SOR/PL (per protocol 
guidance) but not for capecitabine. Guidelines are provided for 
prophylactic and symptomatic treatment of HFSR/HFS. Radiographic 
assessment is every 6 wk for the first 36 wk, and every 9 wk thereafter. 
The primary endpoint is PFS. Assuming a 1-sided alpha of 0.005 
and a power of 98.9%, the sample size is estimated at ~519 patients, 
with primary analysis planned after 363 events. Secondary endpoints 
include overall survival, time to progression, overall response rate 
(RECIST 1.1 criteria), duration of response, and safety. In addition, 
patient reported outcomes will be assessed, and the trial will include 
an exploratory analysis of biomarkers. Enrollment began in Nov 
2010. The trial is registered at ClinicalTrials.gov (NCT01234337).
Conclusions: RESILIENCE will provide definitive PFS data for 
SOR+CAP as a first- or second-line therapy in HER2-negative locally 
advanced or metastatic BC. The phase 3 design and improved dosing 
guidance since SOLTI-0701 will better characterize the benefit-to-risk 
profile of this regimen.
OT3-01-10
Withdrawn by Author
OT3-01-11
A Randomized, Phase II Multicenter, Double-Blind, Placebo-
Controlled Trial Evaluating MetMAb and/or Bevacizumab in 
Combination with Weekly Paclitaxel in Patients with Metastatic 
Triple-Negative Breast Cancer.
Daniel BR, Campone M, Dieras V, Ervin T, Yu W, Paton VE, Xia Q, 
Peterson A. Chattanooga Oncology Hematology Associates - SCRI, 
Chattanooga, TN; Centre Rene Gauducheau, Nantes-Saint Herblain, 
France; Institute Curie, Paris, France; Florida Cancer Specialists, 
Englewood, FL; Genentech Inc., South San Francisco, CA
Background: Dysregulation of the HGF/Met pathway has been 
associated with tumorigenesis in many malignancies, including the 
basal sub-type of triple-negative breast cancer. MetMAb (RG3638) is 
a recombinant, humanized, monovalent monoclonal antibody directed 
against Met. By binding to the extracellular domain of Met, MetMAb 
selectively blocks ligand binding and subsequent activation by HGF.
Pre-clinical data support the efficacy of combining MetMAb with 
numerous chemotherapy agents and with targeted agents including 
bevacizumab and erlotinib. In clinic, MetMAb has been generally well 
tolerated as a single agent (Phase I), in combination with bevacizumab 
(Phase Ib) and with bevacizumab in a dose escalation/expansion study 
(Phase Ib)1 as well as in combination with erlotinib in patients with 
previously treated NSCLC2. The combination of MetMAb + erlotinib 
in NSCLC demonstrated significant benefit in both PFS and OS in 
patients with Met diagnostic positive tumors whereas those patients 
with Met diagnostic negative tumors demonstrated a detrimental 
effect in both PFS and OS. The most commonly reported adverse 
events associated with MetMAb are peripheral edema and fatigue.
Methods: This clinical trial is a randomized three-arm Phase II 
study in patients with triple-negative metastatic breast cancer, which 
makes up the majority of basal sub-type breast cancer. Patients will 
be randomized (1:1:1) to either paclitaxel + bevacizumab + placebo; 
paclitaxel + placebo + MetMAb; or paclitaxel + bevacizumab + 
MetMAb. The primary endpoint of this study is PFS in all patients and 
by Met diagnostic status. Secondary endpoints include an evaluation 
of OS, ORR, safety, and pharmacokinetics. To date, 11 patients have 
been enrolled, and 10 patients have been treated.
Primary and secondary analyses will include all randomized patients, 
with patients analyzed according to the treatment arm to which they 
were assigned. Kaplan-Meier methodology will be used to estimate 
the median PFS for each treatment arm. An estimate of the HR with 
95% CI will be determined using a Cox regression model with an 
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indicator variable for the MetMAb-containing arm. Safety will be 
assessed through summaries of adverse events and will include all 
patients who receive any amount of study treatment.
This study remains open for accrual; further details on the trial can 
be found on the ClinicalTrials.gov website under NCT01186991.
1. Moss et al, In: Proceedings of the 102nd Annual Meeting of the 
American Association for Cancer Research; 2011 Apr 2-6; Orlando, 
FL; AACR 2011 (abstr 4717).
2. Spigel et al, J Clin Oncol 29:2011 (suppl; abstr 7505).
OT3-01-12
Withdrawn by Author
OT3-01-13
Phase One Trial of Combined Temsirolimus, Erlotinib, and 
Cisplatin in Advanced Solid Tumors.
Maurer M, Kalinsky K, Crew K, Jayasena R, Forman J, Lau Y-K, 
Shaw J, Parsons R, Hershman D. Columbia University, New York, NY
Background: A large subset of triple negative breast cancers (TNBC) 
are driven in part by a combination of activated growth factor signaling 
and downstream constitutive activation of the PI3K pathway. One 
therapeutic strategy is to target each driver simultaneously, requiring 
an understanding of drug interactions and combined toxicities. There 
is a strong correlation between loss of PTEN and both expression of 
EGFR and mutation of p53 in a subset of TNBC. Single agent trials 
targeting EGFR in breast cancer have been a disappointment likely, 
in part, due to constitutive downstream activation of PI3K, AKT and 
mTOR signaling, mainly through loss of PTEN expression. Preclinical 
studies have demonstrated 1) that resistance to EGFR-targeted therapy 
in the setting of an activated PI3K pathway can be overcome with 
rapamycin (which inhibits the TORC1 mTOR complex), and 2) that 
a subset of TNBC cells with p53 mutations are particularly sensitive 
to the DNA damaging agent cisplatin due to their high expression 
of p63 and p73. We have hypothesized that targeting the EGFR, 
PTEN and DNA damage pathways simultaneously with the rapalog 
temsirolimus, the EGFR inhibitor erlotinib, and cisplatin will provide 
therapeutic benefit in a definable subset of TNBC patients.
Design: Single institution phase one dose escalation trial of combined 
temsirolimus, erlotinib, and cisplatin in advanced solid tumor patients. 
Cisplatin and temsirolimus are given on day 1 and day 8 of 21 day 
cycles and erlotinib is taken daily without interruption. Patients are 
dose escalated using a standard 3+3 design. Cisplatin is given at a 
fixed dose of 30 mg/m2. Erlotinib was started at 100 mg and will be 
escalated to 150 mg. Temsirolimus was started at 15 mg, and after 
erlotinib escalation, will be escalated to 25 mg. The objectives of 
the study are: 1) characterize toxicity of the regimen and establish 
combined maximal tolerated dosing, 2) measure drug target inhibition 
by assessing EGFR, AKT, and mTOR activation in serial assessments 
of peripheral blood mononuclear cells and skin biopsies, 3) measure 
the pharmacokinetics of all three drugs in combination, and 4) 
exploratory assessment of molecular measures of PTEN, EGFR, and 
p53 status, and markers of activated downstream pathways in patient’s 
archived pathology specimens to assess feasibility of identifying 
candidate biomarkers in future trials involving patients with TNBC. 
Eligibility criteria include one prior treatment for advanced disease, 
ECOG PS=0-1, measurable or non-measurable disease, available 
archived tumor sample, non-smoking, normal renal function, and 
lack of concurrent use of strong CYP3A4 inhibitors or inducers. 
Because of significant rash encountered in prior combination trials 
of EGFR and TORC1 inhibitors, a prophylactic oral doxycycline 
strategy supported by randomized trials is being employed. Current 
accrual is 6 out of a possible 18 patients.
OT3-01-14
N0937: Phase II Trial of Brostallicin and Cisplatin in Patients 
with Metastatic Triple Negative Breast Cancer.
Moreno-Aspitia A, Rowland KM, Liu H, Hillman DW, Stella PJ, 
Perez EA. Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, 
MN; Carle Cancer Center, Urbana, IL; St. Joseph Mercy Cancer 
Center, Ypsilanti, MI
Background: Tumors that are negative for estrogen and progesterone 
receptors and do not over express HER2 are referred as “triple 
negative” breast cancer (TNBC). These tumors are characterized 
by unique molecular profiles on gene expression arrays, aggressive 
behavior with a high recurrence rate, an increased risk of visceral 
metastases, poor prognosis and lack of targeted therapies. Brostallicin 
is a novel synthetic compound from the class of DNA minor groove 
binding (MGB) anti-cancer agents. It retains activity in cancer cells 
resistant to alkylating agents, topoisomerase I inhibitors and is fully 
active against DNA-mismatch repair deficient tumor cells. Cells 
expressing relatively high glutathione/glutathione S-transferase 
(GSH/GST) levels are more susceptible to brostallicin antitumor 
efficacy. Cisplatin administration increases expression of GST in 
tumor cells leading to an increased anti-tumor efficacy of brostallicin.
Trial design: Single-stage phase II study - based on the effects 
of cisplatin on GSH/GST levels in preclinical models, the most 
reasonable sequence to explore was cisplatin on Day 1 followed by 
brostallicin on Day 2 repeated every 21 days.
Eligibility criteria: Women or men ≥18 years of age with confirmed 
adenocarcinoma of the breast with clinical evidence of measurable 
metastatic disease and triple negative subtype according to current 
ASCO CAP guidelines [ER/PR ≤1%; HER2 negative), who received 
0-4 prior chemotherapy regimens in the metastatic setting; with 
adequate hematologic, renal and hepatic functions; and no active 
CNS metastases.
Aims: To study the efficacy of the novel drug, brostallicin, as 
well as to serve as proof of concept of its mechanism of action in 
TNBC. The primary endpoint is to evaluate clinical efficacy of the 
combination of brostallicin and cisplatin in the treatment of patients 
with metastatic TNBC, as measured by progression-free survival 
(PFS) at 3 months with 89% power (0.10 significance level) to detect 
an absolute difference of 20%. Secondary endpoints include ORR by 
RECIST, duration of response, 6-month PFS, overall survival (OS) 
and adverse event profile. Tertiary endpoints include assessment of 1) 
GSH levels prior to the administration of cisplatin and of brostallicin; 
and 2) the prevalence of BCRA-1 mutation by IHC in the primary 
or metastatic tumor.
Statistical methods: The largest 3-month PFS proportion where the 
proposed treatment regimen would be considered ineffective in this 
population was estimated at 35% based on the median PFS of 60 
days in patients with metastatic TNBC enrolled in the N0234 trial 
(erlotinib and gemcitabine as 1st/2nd line), and the smallest 3-month 
PFS success proportion that may warrant subsequent studies with the 
proposed regimen in this patient population was estimated at 55%. 
The interim analysis will be reported when the 20th eligible patient 
has been followed for 3 months.
Present accrual and target accrual: 21 patients have been accrued 
at the time of abstract submission (June 2011). Target accrual is 42 
evaluable patients.
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OT3-01-15
Phase III Trial Evaluating the Addition of Bevacizumab to 
Endocrine Therapy as First-Line Treatment for Advanced Breast 
Cancer: The LEA Study.
De la Haba-Rodriguez JR, von Minckwitz G, Martín M, Morales S, 
Crespo C, Guerrero A, Anton-Torres A, Gil M, Muñoz M, Carrasco 
E, Rodríguez-Martin C, Porras I, Aktas B, Schoenegg W, Tio J, Mehta 
K, Loibl S, On Behalf of GEICAM and GBG. University Reina Sofia 
Hospital, Córdoba, Spain; German Breast Group, Neu-Isenberg, 
Germany; Universitario Gregorio Marañón, Spain; Hospital Ararnu 
de Vilanova de Lleida, Spain; Hospital Universitario Ramón y 
Cajal, Spain; Instituto Valenciano de Oncologia, Spain; Miguel 
Servet University Hospital, Spain; Institut Catala d’Oncologia, 
Spain; Provincial Hospital Clinic, Barcelona, Spain; GEICAM 
Headquarters, Madrid, Spain; University Hospital, Essen, Germany; 
Praxis Dr Schnoenegg, Berlin, Germany; Universitaetsklinikum 
Muenster, Germany
Background: Retrospective clinical data suggest that high 
vascular endothelial growth factor (VEGF) levels in breast tumors 
are associated with a decreased response to endocrine therapy. 
We designed the randomized phase III LEA study of first-line 
bevacizumab in combination with endocrine therapy, to address 
the hypothesis that anti-VEGF treatment can prevent resistance to 
endocrine therapy in patients with advanced breast cancer sensitive 
to such treatment.
Methods: Postmenopausal patients with evaluable locally recurrent or 
metastatic breast cancer, HER2-negative- and estrogen receptor (ER)- 
and/or progesterone receptor (PgR)-positive disease, and eligible to 
receive hormonal treatment are candidates for this study. Patients 
are randomized to receive letrozole 2.5mg daily or fulvestrant, 
250mg every 4 weeks (Arm A) or the same hormonal therapy plus 
bevacizumab 15mg/kg every 3 weeks (Arm B). The primary objective 
is to compare progression-free survival (PFS) between the treatment 
arms. Secondary endpoints are overall survival, time to treatment 
failure, overall response rate, response duration, clinical benefit rate 
and safety. In total, 344 patients (172 in each treatment arm) will be 
needed to detect a hazard ratio of 0.69 (corresponding to a median 
PFS of 9 months in Arm A and 13 months in Arm B) with a power of 
80% and a two-tailed log-rank test at 0.05. With an expected drop-out 
rate of 10%, 378 patients will be included. Efficacy analysis will be 
triggered after 270 events.
Results: Recruitment began in November 2007. To date, 348 patients 
have been included in the study in Spain (n=244) and Germany 
(n=104). We anticipate completing recruitment by September 2011. 
Baseline characteristics of the first 334 randomized patients are 
shown in the table.
 Arm A (n=166) Arm B (n=168)
ECOG performance status, %
 0 71.1 72.8
 1 28.3 26.6
 2 0.6 0.6
Hormone receptor status, %
 ER+/PgR+ 71.1 79.4
 ER+/PgR- 24.1 17.1
 ER-/PgR+ 0.6 2.9
 ER+/PgR unknown 4.2 0.6
Histological type, %
 Ductal 74.4 74.7
 Lobular 16.5 16.9
 Mixed 1.8 3.6
 Other 7.3 4.8
Tumor grade, %
 G1 11.7 13.9
 G2 51.5 48.8
 G3 17.8 18.1
 GX 19.0 19.3
Stage at randomization, %
 Locally recurrent 3.6 3.6
 Metastatic 96.4 96.4
Disease sites, %
 Visceral 11.4 18.1
 Soft tissue 9.2 10.7
 Bone 65.0 63.1
 Other 14.3 8.1
Conclusions: LEA is the first study to explore the use of an anti-
angiogenic drug in combination with endocrine therapy in the context 
of a phase III study.
OT3-01-16
A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab 
(DALO) in Estrogen Receptor Positive (ER+) Breast Cancer.
Lu BD, Blum JL, Cortes J, Rugo HS, Swanton C, Eaton L, Song Y, 
Zhang T, Ebbinghaus SW, Baselga J. Merck Research Laboratories, 
Kenilworth, NJ; Texas Oncology, US Oncology, Dallas, TX; Vall 
D’Hebron University Hospital, Barcelona, Spain; UCSF Hellen 
Diller Family Comprehensive Cancer Center, San Francisco, CA; The 
Royal Marsend Hospital, Sutton, United Kingdom; Merck Research 
Laboratories, North Wales, PA; Merck Research Laboratories, 
Boston, MA; Massachusetts General Hospital, Boston, MA
Background: Activation of the PI3K/AKT/mTOR pathway is common 
in breast cancer. Preclinical studies indicate that the dual inhibition 
of IGFR and mTOR may be additive or synergistic and abrogates 
the feedback activation of AKT due to rapamycin analog mTOR 
inhibitors. A phase 1 study of the mTOR inhibitor RIDA and the 
anti-IGFR antibody DALO demonstrated that the combination was 
feasible and well-tolerated at doses that were nearly those used for the 
two single agents and with dose limiting toxicity of stomatitis, similar 
to RIDA as monotherapy. A preliminary signal of anti-tumor activity, 
including partial responses and prolonged progression free survival, 
was observed in ER+ breast cancer, especially in high proliferation 
tumors. This observation is supported by data from tumor profiling 
and preclinical data suggesting that ER+ high proliferation breast 
cancer may be responsive to the RIDA-DALO combination. Methods: 
This is a two-part, adaptive design study intended to first test the 
combination of RIDA-DALO against a standard agent, exemestane, 
for ER+ positive breast cancer that has progressed after aromatase 
inhibitors. The trial is a multi-center, international, randomized study 
with PFS as the primary endpoint. Patients (pts) are stratified into 
high and low proliferation strata based on baseline Ki67, and the low 
proliferation stratum is capped to ensure adequate enrollment of high 
proliferation pts. If Part A shows a PFS benefit for RIDA-DALO, 
Part B is intended to show the PFS benefit of the combination over 
the single agents by comparing RIDA-DALO to RIDA and DALO. 
Part B will be further adapted based on whether the PFS benefit in 
Part A is observed in all-comers or the high proliferation subset. 
Tumor tissue is collected for molecular profiling and analysis of 
intrinsic subtype, with an efficacy analysis based on classification 
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of tumors using the genomic grade index (GGI) as an exploratory 
objective. This trial design is intended to establish proof of concept 
that RIDA-DALO can prolong PFS in ER+ breast cancer in all-comers 
or a high proliferation subset by Ki67, while efficiently addressing 
the development of two investigational agents in combination and 
leading to a two-arm Phase 3 design.
OT3-01-17
Randomized, Double-Blind, Placebo-Controlled Phase II 
Trial of Low-Dose Metronomic Cyclophosphamide Alone or 
in Combination with Veliparib (ABT-888) in Chemotherapy-
Resistant ER and/or PR-Positive, HER2/neu-Negative Metastatic 
Breast Cancer: New York Cancer Consortium Trial P8853.
Andreopoulou E, Chen AP, Zujewski JA, Kalinsky K, Vahdat L, Raptis 
G, Hershman D, Novic Y, Muggia F, Sparano J. Albert Einstein 
College of Medicine/Montefiore Medical Center, Bronx, NY; National 
Cancer Institute, Bethesda, MD; Columbia University Medical 
Center, New York, NY; Weill Cornell Medical College, New York, NY; 
Mount Sinai School of Medicine, New York, NY; New York University 
Langone Medical Center, New York, NY
Background: Veliparib is an orally available, small molecule inhibitor 
of poly(ADP-ribose) polymerase (PARP). PARP is an essential 
nuclear enzyme that plays a role in recognition of DNA damage and 
facilitation of DNA repair. PARP inhibitors potentiate the cytotoxicity 
of DNA-damaging agents, including cyclophosphamide (C). The 
rationale for the proposed trial is as follows: (1) low-dose, continuous 
metronomic C (50 mp PO daily) has activity in refractory metastatic 
breast cancer (MBC), (2) PARP is induced by DNA damaging agents, 
(3) PARP expression is comparable in ER-positive and ER-negative 
disease, (4) some ER-positive breast cancers exhibit defective 
homologous recombination pathway repair genes (eg, RAD51 and 
XRCC3), (5) the PARP inhibitor iniparib appears to be more effective 
when used in chemotherapy resistant disease. Taken together, these 
findings suggest that veliparib-C combination may be more effective 
than metronomic C alone in chemotherapy resistant MBC.
Trial design: A randomized Phase II trial design 1:1. S. Blocked 
randomization will be performed at all participating sites. Patients 
are randomized to oral C (50mg PO daily) plus either veliparib (60mg 
PO daily) or matching placebo.
Eligibility criteria:(1) ER- and or PR-positive, HER2-negative 
MBC, (2) ECOG PS 0-1, (3) at least 2 prior chemotherapy regimens 
for MBC, including a taxane and capecitabine. 4) at least 1 line of 
endocrine therapy for metastatic disease (includes relapse while 
receiving endocrine therapy).
Specific aims: Primary: To determine if the addition of veliparib 
to metronomic dose C improves median progression free survival 
(PFS) compared with C alone in patients with ER and/or PR-positive, 
Her2-negative MBC who progressed on at least two lines of prior 
chemotherapy and one line of prior endocrine therapy.
Secondary: 1)To determine if the addition veliparib to C chemotherapy 
improves a) response rate b) clinical benefit rate (defined as objective 
response plus stable disease for at least 24 weeks from day +1) 2)
Survival in patients treated with C alone and C plus veliparib. 3)
Adverse event profile in patients treated with C alone and C plus 
veliparib .
Translational: Exploratory analyses will evaluate whether the 
macroH2A1.1 and PARP1 expression status in archival paraffin, 
or veliparib-induced PAR downregulation in peripheral blood 
mononuclear cells, is predictive of benefit from veliparib.
Statistical methods: The primary endpoint is PFS, and the trial is 
powered to detect an increase in median PFS from 3 to 6 months 
(alpha=0.10, beta=0.10), which will require enrollment of 62 eligible 
patients over 12 months.
Enrollment: The study is active and open to enrollment.
Clinical trials.gov NCT01351909
OT3-01-18
Combination Immunotherapy with Trastuzumab and the HER2 
Vaccine E75 in Low and Intermediate HER2-Expressing Breast 
Cancer Patients To Prevent Recurrence.
Sears AK, Clifton GT, Vreeland TJ, Hale DF, Ponniah S, Mittendorf 
EA, Peoples GE. Brooke Army Medical Center, Ft. Sam Houston, 
TX; Uniformed Services University of the Health Sciences, USMCI, 
Bethesda, MD; UT M.D. Anderson Cancer Center, Houston, TX
Background: In a phase II trial, the HER2-derived E75 vaccine 
administered with the immunoadjuvant GM-CSF has been shown to 
reduce breast cancer recurrence in the adjuvant setting, with a greater 
benefit seen in patients with low levels of HER2 expression (IHC 1+ 
or 2+). There has also been recent suggestion that patients with low 
HER2 expression may also benefit from trastuzumab. Preclinical 
testing of the combination of trastuzumab and the E75 vaccine has 
shown a synergism with combinational therapy. Finally, from our 
phase II trials of cytotoxic T cell-eliciting peptide vaccines, sequential 
treatment with trastuzumab and HER2 vaccination has resulted in 
no recurrences in 30 patients with a median follow-up of 48 months. 
Based on these results, we have designed a trial to evaluate the ability 
of the combination of trastuzumab and the E75 vaccine to prevent 
breast cancer recurrence.
Trial Design: This study will be a multi-center, prospective, 
randomized, single-blinded, phase II trial evaluating trastuzumab 
+ E75+GM-CSF (immunoadjuvant) vs. trastuzumab + GM-CSF 
alone (no E75) in the adjuvant setting in breast cancer patients. 
Eligible patients include node positive (or node negative if negative 
for both ER and PR) disease-free breast cancer patients with low or 
intermediate levels of HER2 expression (IHC 1+ or 2+) and adequate 
cardiac function (LVEF >50%). Patients must be HLA-A2 /A3+ (E75 
is HLA-A2/A3-restricted). Patients will be enrolled after completing 
standard of care multi-modal therapy and randomized between the 
two treatment arms with stratification by HER2 expression (1+ or 2+) 
and nodal status (N0, N1, N2, or N3). Vaccinations (E75+GM-CSF 
or GM-CSF alone) will be administered as six monthly intradermal 
inoculations concurrently with trastuzumab therapy. The primary 
efficacy endpoint is to compare disease-free survival (DFS) between 
treatment arms at 24 months. Secondary objectives will include 
evaluation of cardiac toxicity from combination therapy (periodic 
cardiac assessment with MUGA or ECHO), DFS at 36 months, and 
immunologic responses to vaccination. From previously published 
experience with trastuzumab, we expect a recurrence rate of 15% 
in trastuzumab (plus GM-CSF) treated patients and anticipate that 
the combination of trastuzumab with E75+GM-CSF will reduce this 
recurrence rate to 5%. In order to show a statistical difference between 
these recurrence rates, we plan to enroll 150 patients per treatment 
arm (300 total) with a type I error rate of 5% and 80% power to detect 
the primary endpoint. Trial accrual is anticipated to begin in January 
2012, with a two year period of enrollment followed by a three year 
follow-up period.
Conclusion: We hypothesize that combination adjuvant 
immunotherapy with trastuzumab and E75 vaccination will result 
in a greater reduction in breast cancer recurrence than trastuzumab 
therapy alone and have designed a multi-center, prospective, 
randomized, single-blinded, phase II trial evaluating the efficacy of 
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this immunotherapy combination.Contact Information: This trial is 
sponsored by Genentech and RXi Pharmaceuticals through the Henry 
M. Jackson Foundation.
OT3-01-19
Phase II Study of Topical Imiquimod and Weekly Abraxane for 
the Treatment of Breast Cancer Cutaneous Metastases.
Higgins DM, Childs J, Parker S, Disis ML, Salazar LG. University 
of Washington, Seattle, WA
Background: Breast cancer (BC) cutaneous lesions present as local 
chest wall recurrence or as isolated sites of metastatic disease. The 
treatment of cutaneous lesions is challenging and includes chest 
wall resection, local radiation therapy, and/or salvage chemotherapy 
which is not curative, associated with significant morbidity, and 
results in overall response rates of 20-30%. Thus, investigation of 
novel treatment strategies is warranted. This study incorporates 
multimodality treatment with topical imiquimod, a TLR-7agonist 
which generates an immune signal similar to that of pathogenic 
bacteria and Abraxane, a conventional systemic chemotherapy with 
potential immunostimulatory effects. Combined, these two agents 
provide local and systemic strategies which are potentially synergistic; 
and more effective than as single-agents in treating and controlling 
cutaneous disease.
Trial design: A Phase II single arm, non-randomized study. Patients 
will be sequentially enrolled and receive a maximum of 3 treatment 
cycles. A treatment cycle consists of topical imiquimod daily to target 
lesions for 4 days/week for 4 weeks in addition to Abraxane on Days 
1, 8, and 15 every 28 days. Toxicity will be evaluated weekly during 
treatment then monthly for four months. Defined lesions are assessed 
at baseline and monthly. Skin biopsies are obtained pre and post 
treatment for histologic analysis and RT-PCR analysis of a 7 IFN-
related gene signature previously associated with tumor inhibition. 
Immunity to BC antigens and serum TGF-b levels are also evaluated.
Aims: To evaluate the safety and anti-tumor effects of 
chemoimmunotherapy with topical imiquimod and Abraxane.
Eligibility criteria: Patients with progressive or relapsed BC after 
standard therapy who 1) have measurable cutaneous metastatic 
lesions, 2) are at least 7 days from last chemotherapy, 30 days 
from local radiotherapy and/or systemic steroids, 3) have adequate 
blood counts and 4) no history of active autoimmune disease. 
Bisphosphonates, trastuzumab, and/or hormonal therapy is allowed.
Statistical methods: Antitumor activity of target lesions will be 
assessed per modified WHO criteria. Complete response (CR)-
complete clearance of lesions; Partial response (PR) ≥ 50% decrease 
in lesion size; Stable disease (SD) < 50% decrease in lesion size; 
Progressive disease (PD) increase in ≥ 25% lesion size). Historical 
overall response rates (ORR) with second and third line salvage 
chemotherapy range from 20-30%, with CR rates less than 2%. Based 
on these numbers, an ORR of 50% or a CR rate of 10% will be used 
as benchmarks for success (i.e., ≥8 responses or ≥2 CRs among 15 
patients (observed ORR of ≥ 53% or observed CR rate of ≥ 13%) to 
consider the treatment worthy of further study. As a measure of the 
precision of the estimate of ORR achievable with 15 patients, if the 
response rate is 60%, we will be 80% confident that the observed 
RR is within 0.16 of the true RR with 15 patients treated. Toxicity 
will be evaluated by CTCAE v. 3.0 and descriptive statistics will 
be used to summarize changes from baseline and for reporting of 
immunological parameters.
Accrual: 10 patients received treatment with a target accrual of 15.
OT3-02-01
A 1-Year Prospective Longitudinal Study of the Role of 
Psychosocial Factors in Adherence to Adjuvant Endocrine 
Therapy in Early Breast Cancer.
Song X, Verma S, Dent S, Clemons M, Graham N, Bedard M, Paquet L. 
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Carleton 
University, Ottawa, ON, Canada
Background: Extensive evidence suggests that endocrine therapy 
(ET) and adherence to adjuvant ET directly impacts on disease-
free and overall survival in women with hormone receptor positive 
(HR+) early stage breast cancer (EBC). Despite this, adherence to 
ET is suboptimal, with 35%-50% of patients discontinuing therapy 
earlier than recommended. Interventions to improve adherence are 
lacking, due in part to a poor understanding of the modifiable risk 
factors influencing adherence. Virtually all authors have focused 
on educational needs of patients and side effect management of ET 
but there remains a paucity of data on how potentially modifiable 
psychosocial factors present at outset of treatment initiation influence 
adherence. We believe that a better understanding of these factors 
may lead to interventions which enable women to adhere to long term 
life-saving therapies. This study aims to identify such factors guided 
by the Common-Sense Model of Self-Regulation which proposes that 
cognitive, emotional, coping and interpersonal factors are modifiable 
determinants of adherence.
Study Design: The study is a single centre prospective longitudinal 
quantitative study. Women diagnosed with HR+ EBC for which 
endocrine therapy is intended will be enrolled. Participants will 
complete questionnaires prior to initiating ET, then at 3, 6 and 12 
months. The predictor variables are: 1) modifiable factors including 
illness and treatment cognitions, self-efficacy in coping with side 
effects anticipated or experienced, fear of breast cancer recurrence, 
trait anxiety, patient-physician interaction, 2) treatment-induced 
toxicities and 3) clinical factors including ET, chemotherapy, 
radiation, cancer stage and menopausal status. The outcome variable 
is adherence measured at each assessment post-treatment initiation 
with pill counts and participants’self-report.
Inclusion criteria: 1.Histologically proven Stage I, II, IIIa EBC; 2. 
Treatment with ET (tamoxifen or an aromatase inhibitor).
Specific Aims: To evaluate the impact on adherence to ET by 1) 
potentially modifiable psychosocial factors 2) side effects and 3) 
clinical factors.
Statistical Method: Adherence responses will be transformed into 
dummy coded variables (0=take ET as prescribed; 1=does not take 
ET as prescribed). For each assessment, several separate univariate 
logistic regressions will be conducted with demographic (age, 
education, work and marital status, ethnicity), cognitive (illness 
and treatment perception), emotional (fear of recurrence and 
anxiety), coping (self-efficacy), and patient-physician relationship 
(role preference, trust and satisfaction), severity of side effects 
and clinical factors, as independent predictors of adherence. Only 
predictors which are significant at the 0.25 level will be entered in 
subsequent hierarchical multiple regression models to identify the 
main determinants of adherence.
Accrual: Expected study accrual is 200 over 12-18 months. Accrual 
started in May of 2011 and 36 patients have been accrued to the study.
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OT3-02-02
Yoga Compared to Exercise as a Therapeutic Intervention during 
(Neo)adjuvant Chemotherapy in Women with Stage I-III Breast 
Cancer.
Wiedemann F, Büssing A, Halle M, Kiechle M, Kohls N, Ostermann 
T, Sattler D, Ettl J. Technische Universität München, Munich, 
Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis 
Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-
Universität München, Bad Tölz, Germany
Background: Psychological and physical distress is high in breast 
cancer patients receiving neoadjuvant or adjuvant chemotherapy. The 
patients’ability to cope with this distress has an impact on treatment 
variables, i.e. deliverable chemotherapy dose, tolerabilty of side 
effects, and finaly treatment completion rate. Exercise intervention 
studies have shown physiological and psychological benefits when 
undertaken during cancer treatment. There is also evidence that mind/
body interventions such as yoga are useful to manage treatment-
related symptoms and anxiety in breast cancer patients. Considering 
the specific theoretical background of mind/body interventions this 
ongoing trial aims to elucidate the different effects of yoga and 
conventional exercise on physical and psychological factors in breast 
cancer patients undergoing neoadjuvant or adjuvant chemotherapy.
Trial design: Longitudinal data collection within an open, prospective, 
randomized trial using standardized questionnaires about inner 
correspondence and peacefulness with practices (ICPH), health-
related quality of life (EORTC QLC C-30), fatigue (Cancer Fatigue 
Scale, CFS-D), mindfulness (Freiburg Mindfulness Inventory, FMI), 
spiritual/religious attitudes and disease coping (SpREUK), and 
life satisfaction (Brief Multidimensional Life Satisfaction Scale, 
BMLSS). Patients with newly diagnosed stage I-III breast cancer 
undergoing neoadjuvant or adjuvant chemotherapy are randomly 
assigned to receive yoga or conventional exercise on a 1:1 ratio. The 
yoga intervention consists of a weekly 60-minute Iyengar-Yoga group-
session together with individual home-based, selfcontained 20-minute 
sessions twice a week. The conventional exercise intervention consists 
of a weekly 60-minute physiotherapy exercise session together with 
individual home-based, selfcontained 20-minute sessions twice a 
week. Data assessments via questionnaires are done at baseline, right 
after the 12-week intervention period and 2 months after the end of 
intervention. Statistical analysis includes analysis of variance with 
all collected parameters and analysis of correlation between ICPH 
and above parameters. For statistical power 1-b=0.8 and twosided 
probability of error a=0.05 the target accrual is 120 patients. Patient 
accrual within two breast care units started in April 2011 with 12 
patients being on study to date (2011, June 21). Planned period of 
accrual is 20 months.
OT3-02-03
Patient Empowerment by Group Medical Consultations in 
the Follow-Up of Breast Cancer Survivors and Surveillance of 
Women with a BRCA Mutation.
van Laarhoven HWM, Prins JB, Schlooz MS, Besselink RM, 
Bögemann L, van Koolwijk MPA, Hoogerbrugge N, Visser A. Radboud 
University Nijmegen Medical Centre, Nijmegen, Netherlands
Background: During usual follow-up care for breast cancer patients 
only little time is left for psychosocial support, while most patients 
experience several complaints, which may increase levels of distress 
or effect the quality of life. BRCA mutation carriers have a 40-80% 
life-time risk of developing breast cancer. They have a complex choice 
to make between yearly breast cancer surveillance or prophylactic 
mastectomy. Both options show increased survival rates.
To fulfill the needs for psychosocial support and information we have 
introduced group medical consultations (GMCs). A GMC provides 
individual medical visits conducted within a group. This 90 minute 
group-visit with 8-12 patients gives patients the opportunity to spend 
more time with their clinician and a behavioral health professional 
and learn from other patients experiencing similar topics. However, it 
should be noted that group sessions may increase fear in some patients.
Trial design: This multicenter randomized controlled trial will assess 
the effect of GMCs compared to individual visits for patients in the 
follow-up after breast cancer and for women with a BRCA mutation. 
The intervention group will participate in a GMC once, while the 
control group will have usual care.
Eligibility criteria: Inclusion criteria for the follow-up of breast 
cancer patients are: histologically proven breast cancer; age ≥18 
years; primary treatment completed maximally 5 years ago. For 
BRCA mutation carriers inclusion criteria are: carrier of a BRCA1 
or BRCA2 mutation; diagnosed maximally 2 years ago; age ≥25 
years. Exclusion criteria for both groups are: currently involved in a 
diagnostic work-up because of a suspicion of breast cancer; metastatic 
breast cancer; current psychiatric disorder; insufficient command 
of the Dutch language. A history of prophylactic mastectomy is an 
exclusion criteria only for BRCA mutation carriers.
Study endpoint: Primary outcomes in this study are empowerment 
and psychological distress. In addition, the effects on cancer worry, 
information needs and information giving, self-examination of the 
breasts, treatment compliance, patient satisfaction, quality of life and 
costs of care (secondary outcome measures) will be studied.
Statistical methods: To assess a clinically relevant effect of GMCs on 
psychological distress with a power of 80%, a two-side significance of 
5%, and a standard deviation of 45, 80 patients need to be included in 
each group. Randomization will take place per patient in blocks of 16 
patients. Differences between baseline and post-test between the two 
groups will be compared by using ANCOVA for primary outcomes 
and ANOVA or mixed model for secondary analysis.
Accrual: Patients are currently being recruited at the Radboud 
University Nijmegen Medical Center. In the future other centers in the 
Netherlands will participate. Presently (21th june 2011) a total number 
of 37 patients have been included since start of the study (april 2011). 
The expected end of accrual of 320 patients will be December 2012.
OT3-02-04
TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant 
Bevacizumab, Metronomic Chemotherapy (CM), Diet and 
Exercise after Preoperative Chemotherapy for Breast Cancer.
Mayer EL, Ligibel JA, Burstein HJ, Peppercorn JM, Miller KD, Carey 
LA, Dickler MN, Mayer IA, Forero A, Eng-Wong J, Pletcher PJ, Ryabin 
N, Gelman R, Wolff AC, Winer EP. Dana-Farber Cancer Institute, 
Boston, MA; Duke University Medical Center, Durham, NC; Indiana 
University Melvin and Bren Simon Cancer Center, Indianapolis, IN; 
University of North Carolina at Chapel Hill, Durham, NC; Memorial 
Sloan-Kettering Cancer Center, New York, NY; Vanderbilt University, 
Nashville, TN; University of Alabama, Birmingham, AL; Georgetown 
University Lombardi Comprehensive Cancer Center, Washington, 
DC; Hoosier Oncology Group, Indianapolis, IN; Johns Hopkins 
Kimmel Cancer Center, Baltimore, MD
Background
Patients (pts) with residual breast cancer after neoadjuvant 
chemotherapy are at increased risk of recurrence; no proven risk-
reduction strategies exist, supporting exploration of novel therapies 
in the post-preoperative setting. Bevacizumab (B) combined with 
chemotherapy is active in metastatic disease; ongoing studies are 
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exploring the efficacy of adjuvant combination chemotherapy and 
B. DFCI 05-055 (Mayer et al, ASCO 2007, 2008) demonstrated 
the feasibility of 1 year B after preoperative chemotherapy. Also, 
increasing data support risk reduction through lifestyle interventions 
(Segal, Ligibel et al, ASCO 2011). The ABCDE trial was designed to 
evaluate extended adjuvant B in a high risk post-preoperative cohort, 
and also assess the contribution of exercise to a dietary intervention.
Eligibility Criteria
Eligible pts have HER2- breast cancer and have received preoperative 
anthracycline and/or taxane-based chemotherapy with residual 
invasive disease at surgery. Acceptable stages include: triple 
negative if preop stages I-III, or ER+/PR+ if stage III preop or IIB 
postop. Acceptable organ function and standard B exclusions apply. 
Registration must occur between 28-180 days after last surgery.
Specific Aims
Primary endpoint is recurrence-free survival at a median follow-
up of 6 years. Secondary endpoints include B pharmacogenomics, 
evaluation of the impact of exercise on quality of life and biomarkers 
associated with recurrence, and prospective examination of cardiac 
toxicity. Residual tissue-based predictors of outcome will be 
extensively explored, including PAM50, Ki67, and VEGF hypoxia 
signature.
Methods
This is a 2 x 2 randomized study with a first randomization to 6 months 
(mo) B 15 mg/kg every 3 weeks (wks) plus 6 mo CM (C 50 mg daily, 
M 2.5 mg twice daily days 1, 2 each wk), followed by 2.5 years B 15 
mg/kg every 6-8 wks, versus observation. A second randomization 
is to a 1 year telephone-based lifestyle intervention, offering dietary 
modification alone, or in combination with a structured exercise 
program.
Statistical Methods and Accrual
Total sample size is 660 pts within the Translational Breast Cancer 
Research Consortium. Overall power is 0.80 to detect a hazard ratio 
of 0.59-0.68, depending on pt population. Accrual initiated early 2011 
and is expected to continue for the next 36 months.
Conclusions
Patients with residual disease after preoperative chemotherapy 
are at high risk of recurrence and have unmet medical needs. To 
our knowledge, this is the only trial testing a prolonged but less 
intensive adjuvant B schedule in this clinical setting. Results of this 
study could have critical implications for the management of this 
patient population and for the design of future clinical trials with 
anti-angiogenic agents.
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